NULL__:__100050__:__AARSKOG SYNDROME, AUTOSOMAL DOMINANT__:____:__
Percent__:__100070__:__AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 1; AAA1__:__ANEURYSM, ABDOMINAL AORTIC; AAA;; ABDOMINAL AORTIC ANEURYSM__:__
Number Sign__:__100100__:__PRUNE BELLY SYNDROME; PBS__:__ABDOMINAL MUSCLES, ABSENCE OF, WITH URINARY TRACT ABNORMALITY AND CRYPTORCHIDISM;; EAGLE-BARRETT SYNDROME; EGBRS__:__
NULL__:__100200__:__ABDUCENS PALSY__:____:__
Number Sign__:__100300__:__ADAMS-OLIVER SYNDROME 1; AOS1__:__AOS;; ABSENCE DEFECT OF LIMBS, SCALP, AND SKULL;; CONGENITAL SCALP DEFECTS WITH DISTAL LIMB REDUCTION ANOMALIES;; APLASIA CUTIS CONGENITA WITH TERMINAL TRANSVERSE LIMB DEFECTS__:__APLASIA CUTIS CONGENITA, CONGENITAL HEART DEFECT, AND FRONTONASAL CYSTS, INCLUDED
Caret__:__100500__:__MOVED TO 200150__:____:__
Percent__:__100600__:__ACANTHOSIS NIGRICANS__:____:__
Asterisk__:__100640__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A1; ALDH1A1__:__ALDEHYDE DEHYDROGENASE 1; ALDH1;; ACETALDEHYDE DEHYDROGENASE 1;; ALDH, LIVER CYTOSOLIC;; RETINAL DEHYDROGENASE 1; RALDH1__:__
Plus__:__100650__:__ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2__:__ALDEHYDE DEHYDROGENASE 2;; ALDH, LIVER MITOCHONDRIAL;; ACETALDEHYDE DEHYDROGENASE 2__:__SUBLINGUAL NITROGLYCERIN, SUSCEPTIBILITY TO POOR RESPONSE TO, INCLUDED;; ALDH2/HMGIC FUSION GENE, INCLUDED;; ESOPHAGEAL CANCER, ALCOHOL-RELATED, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__100660__:__ALDEHYDE DEHYDROGENASE, FAMILY 3, SUBFAMILY A, MEMBER 1; ALDH3A1__:__ALDEHYDE DEHYDROGENASE 3; ALDH3;; ACETALDEHYDE DEHYDROGENASE 3;; ALDH, STOMACH TYPE__:__
Asterisk__:__100670__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER B1; ALDH1B1__:__ALDEHYDE DEHYDROGENASE 5; ALDH5;; ACETALDEHYDE DEHYDROGENASE 5__:__
NULL__:__100675__:__ACETAMINOPHEN METABOLISM__:____:__
Asterisk__:__100678__:__ACETYL-CoA ACETYLTRANSFERASE 2; ACAT2__:__ACETOCOENZYME A ACETYLTRANSFERASE 2;; ACETOACETYL-CoA THIOLASE, CYTOSOLIC__:__
Caret__:__100680__:__MOVED TO 100740__:____:__
Asterisk__:__100690__:__CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1__:__CHRNA;; ACETYLCHOLINE RECEPTOR, MUSCLE, ALPHA SUBUNIT; ACHRA__:__
NULL__:__100700__:__ACHARD SYNDROME__:____:__
Asterisk__:__100710__:__CHOLINERGIC RECEPTOR, NICOTINIC, BETA POLYPEPTIDE 1; CHRNB1__:__CHRNB;; ACETYLCHOLINE RECEPTOR, MUSCLE, BETA SUBUNIT; ACHRB__:__
Asterisk__:__100720__:__CHOLINERGIC RECEPTOR, NICOTINIC, DELTA POLYPEPTIDE; CHRND__:__ACETYLCHOLINE RECEPTOR, MUSCLE, DELTA SUBUNIT; ACHRD__:__
Asterisk__:__100725__:__CHOLINERGIC RECEPTOR, NICOTINIC, EPSILON POLYPEPTIDE; CHRNE__:__ACETYLCHOLINE RECEPTOR, MUSCLE, EPSILON SUBUNIT; ACHRE__:__
Asterisk__:__100730__:__CHOLINERGIC RECEPTOR, NICOTINIC, GAMMA POLYPEPTIDE; CHRNG__:__ACETYLCHOLINE RECEPTOR, MUSCLE, GAMMA SUBUNIT; ACHRG__:__
Caret__:__100735__:__MOVED TO 142445__:____:__
Asterisk__:__100740__:__ACETYLCHOLINESTERASE; ACHE__:__ACETYLCHOLINE ACETYLHYDROLASE;; YT__:__
Asterisk__:__100790__:__ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG OF, 1; ASCL1__:__MAMMALIAN ACHAETE-SCUTE HOMOLOG 1; MASH1;; HUMAN ACHAETE-SCUTE HOMOLOG 1; HASH1__:__
Number Sign__:__100800__:__ACHONDROPLASIA; ACH__:____:__
Percent__:__100820__:__ACHOO SYNDROME__:__AUTOSOMAL DOMINANT COMPELLING HELIOOPHTHALMIC OUTBURST SYNDROME;; PHOTIC SNEEZE REFLEX;; SNEEZING FROM LIGHT EXPOSURE;; PEROUTKA SNEEZE__:__
Asterisk__:__100850__:__ACONITASE, MITOCHONDRIAL; ACO2__:__ACONM__:__
Asterisk__:__100880__:__ACONITASE 1, SOLUBLE; ACO1__:__ACONITATE HYDRATASE, SOLUBLE;; ACONITASE, SOLUBLE; ACONS;; IRON-RESPONSIVE ELEMENT-BINDING PROTEIN 1; IREB1;; IRE-BINDING PROTEIN 1; IREBP1; IREBP;; IRON REGULATORY PROTEIN 1; IRP1__:__
Caret__:__100900__:__MOVED TO 100880__:____:__
Number Sign__:__101000__:__NEUROFIBROMATOSIS, TYPE II; NF2__:__NEUROFIBROMATOSIS, CENTRAL TYPE;; ACOUSTIC SCHWANNOMAS, BILATERAL;; BILATERAL ACOUSTIC NEUROFIBROMATOSIS; BANF;; ACOUSTIC NEURINOMA, BILATERAL; ACN__:__
NULL__:__101120__:__ACROCEPHALOPOLYSYNDACTYLY TYPE III__:__ACPS III;; ACPS WITH LEG HYPOPLASIA;; SAKATI-NYHAN SYNDROME__:__
Number Sign__:__101200__:__APERT SYNDROME__:__ACROCEPHALOSYNDACTYLY, TYPE I; ACS1;; ACS I__:__APERT-CROUZON DISEASE, INCLUDED;; ACROCEPHALOSYNDACTYLY, TYPE II, INCLUDED;; ACS II, INCLUDED;; VOGT CEPHALODACTYLY, INCLUDED
Number Sign__:__101400__:__SAETHRE-CHOTZEN SYNDROME; SCS__:__ACROCEPHALOSYNDACTYLY, TYPE III; ACS3;; ACS III;; CHOTZEN SYNDROME;; ACROCEPHALY, SKULL ASYMMETRY, AND MILD SYNDACTYLY__:__SAETHRE-CHOTZEN SYNDROME WITH EYELID ANOMALIES, INCLUDED;; BLEPHAROPHIMOSIS, EPICANTHUS INVERSUS, AND PTOSIS 3, FORMERLY, INCLUDED; BPES3, FORMERLY, INCLUDED
Number Sign__:__101600__:__PFEIFFER SYNDROME__:__ACROCEPHALOSYNDACTYLY, TYPE V; ACS5;; ACS V;; NOACK SYNDROME__:__CRANIOFACIAL-SKELETAL-DERMATOLOGIC DYSPLASIA, INCLUDED
Number Sign__:__101800__:__ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS1__:__ADOHR__:__
NULL__:__101805__:__ACROFACIAL DYSOSTOSIS, CATANIA TYPE__:__AFD, CATANIA TYPE__:__
NULL__:__101840__:__ACROKERATODERMA, HEREDITARY PAPULOTRANSLUCENT__:____:__
Percent__:__101850__:__PALMOPLANTAR KERATODERMA, PUNCTATE TYPE III; PPKP3__:__ACROKERATOELASTOIDOSIS; AKE;; COLLAGENOUS PLAQUES OF HANDS AND FEET__:__
Number Sign__:__101900__:__ACROKERATOSIS VERRUCIFORMIS; AKV__:__HOPF DISEASE__:__
NULL__:__102000__:__ACROLEUKOPATHY, SYMMETRIC__:____:__
Percent__:__102100__:__ACROMEGALOID CHANGES, CUTIS VERTICIS GYRATA, AND CORNEAL LEUKOMA__:__ROSENTHAL-KLOEPFER SYNDROME__:__
Percent__:__102150__:__ACROMEGALOID FACIAL APPEARANCE SYNDROME__:__AFA SYNDROME;; THICK LIPS AND ORAL MUCOSA__:__
Number Sign__:__102200__:__PITUITARY ADENOMA 1, MULTIPLE TYPES; PITA1__:__SOMATOTROPINOMA, FAMILIAL ISOLATED; FIS;; ISOLATED FAMILIAL SOMATOTROPINOMA; IFS;; SOMATOTROPHINOMA, FAMILIAL;; ACROMEGALY DUE TO PITUITARY ADENOMA 1;; PAGH1__:__PITUITARY ADENOMA PREDISPOSITION, INCLUDED; PAP, INCLUDED;; PITUITARY ADENOMA, FAMILIAL ISOLATED, INCLUDED; FIPA, INCLUDED
Percent__:__102300__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 1; RLS1__:__ACROMELALGIA, HEREDITARY;; EKBOM SYNDROME__:__
Percent__:__102350__:__ACROMIAL DIMPLES__:__SUPRASPINOUS FOSSAE, CONGENITAL__:__
Number Sign__:__102370__:__ACROMICRIC DYSPLASIA; ACMICD__:____:__
NULL__:__102400__:__ACROOSTEOLYSIS__:____:__
Asterisk__:__102480__:__ACROSIN; ACR__:____:__PROACROSIN, INCLUDED;; PREPROACROSIN, INCLUDED
Caret__:__102490__:__MOVED TO 607323__:____:__
Number Sign__:__102500__:__HAJDU-CHENEY SYNDROME; HJCYS__:__ACROOSTEOLYSIS WITH OSTEOPOROSIS AND CHANGES IN SKULL AND MANDIBLE;; CHENEY SYNDROME;; ARTHRODENTOOSTEODYSPLASIA;; SERPENTINE FIBULA-POLYCYSTIC KIDNEY SYNDROME; SFPKS__:__
Percent__:__102510__:__ACROPECTOROVERTEBRAL DYSPLASIA; ACRPV__:__F SYNDROME__:__
NULL__:__102520__:__ACRORENAL SYNDROME__:____:__
Asterisk__:__102525__:__ACROSOMAL VESICLE PROTEIN 1; ACRV1__:__SP-10 PROTEIN__:__
Number Sign__:__102530__:__SPERMATOGENIC FAILURE 6; SPGF6__:__GLOBOZOOSPERMIA;; ROUND-HEADED SPERMATOZOA;; SPERMATOZOA, ROUND-HEADED;; ACROSOME MALFORMATION OF SPERMATOZOA__:__
Asterisk__:__102540__:__ACTIN, ALPHA, CARDIAC MUSCLE; ACTC1__:__ACTC;; SMOOTH MUSCLE ACTIN;; ACTIN, ALPHA__:__
Asterisk__:__102545__:__ACTIN, GAMMA-2, SMOOTH MUSCLE, ENTERIC; ACTG2__:__ACTSG;; ACTE;; ACTIN, ALPHA-3, FORMERLY; ACTA3, FORMERLY__:__
Caret__:__102550__:__MOVED TO 102630__:____:__
Asterisk__:__102560__:__ACTIN, GAMMA-1; ACTG1__:__ACTIN, GAMMA; ACTG;; CYTOSKELETAL GAMMA-ACTIN;; ACTIN, CYTOPLASMIC, 2__:__
Asterisk__:__102565__:__FILAMIN C; FLNC__:__FILAMIN, GAMMA;; FILAMIN 2; FLN2;; ACTIN-BINDING PROTEIN 280, AUTOSOMAL FORM; ABP280A;; ABPA;; ACTIN-BINDING PROTEIN-LIKE; ABPL__:__
Caret__:__102570__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__102573__:__ACTININ, ALPHA-2; ACTN2__:____:__
Asterisk__:__102574__:__ACTININ, ALPHA-3; ACTN3__:____:__
Asterisk__:__102575__:__ACTININ, ALPHA-1; ACTN1__:____:__
Asterisk__:__102576__:__ACTIVIN A RECEPTOR, TYPE I; ACVR1__:__ACTIVIN A RECEPTOR, TYPE II-LIKE KINASE 2; ACVRLK2;; ACTIVIN RECEPTOR-LIKE KINASE 2; ALK2__:__
Asterisk__:__102577__:__REPLICATION FACTOR C, SUBUNIT 4; RFC4__:__ACTIVATOR 1, 37-KD SUBUNIT;; REPLICATION FACTOR C, 37-KD SUBUNIT;; RFC2, YEAST, HOMOLOG OF__:__
Asterisk__:__102578__:__ACUTE PROMYELOCYTIC LEUKEMIA, INDUCER OF; PML__:__MYL__:__PML/RARA FUSION GENE, INCLUDED
Asterisk__:__102579__:__REPLICATION FACTOR C, SUBUNIT 1; RFC1__:__ACTIVATOR 1, 140-KD SUBUNIT;; REPLICATION FACTOR C, 140-KD SUBUNIT; RFC140;; RFC__:__
Asterisk__:__102581__:__ACTIVIN A RECEPTOR, TYPE IIA; ACVR2A__:__ACVR2__:__
Asterisk__:__102582__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; STAT3__:__ACUTE-PHASE RESPONSE FACTOR; APRF__:__
NULL__:__102590__:__ACYLASE, COBALT-ACTIVATED__:____:__
Asterisk__:__102593__:__ACYLOXYACYL HYDROLASE; AOAH__:____:__
Asterisk__:__102595__:__ACYLPHOSPHATASE 2, MUSCLE TYPE; ACYP2__:__ACYLPHOSPHATASE, MUSCLE; ACYP__:__
Asterisk__:__102600__:__ADENINE PHOSPHORIBOSYLTRANSFERASE; APRT__:____:__
Asterisk__:__102610__:__ACTIN, ALPHA, SKELETAL MUSCLE 1; ACTA1__:__ASMA__:__
Asterisk__:__102620__:__ACTIN, ALPHA-2, SMOOTH MUSCLE, AORTA; ACTA2__:__ACTIN, ALPHA, SMOOTH MUSCLE, AORTIC; ACTSA;; ACTIN, VASCULAR SMOOTH MUSCLE__:__
Asterisk__:__102630__:__ACTIN, BETA; ACTB__:__BETA-ACTIN;; ACTIN, CYTOPLASMIC, 1__:__
Caret__:__102640__:__MOVED TO 102630__:____:__
Asterisk__:__102642__:__STEROL O-ACYLTRANSFERASE 1; SOAT1__:__SOAT;; ACYL-CoA:CHOLESTEROL ACYLTRANSFERASE; ACACT;; ACAT1;; STEROL ACYLTRANSFERASE__:__
Asterisk__:__102645__:__ACYLPEPTIDE HYDROLASE; APH__:__N-ACYLAMINOACYLPEPTIDE HYDROLASE; APEH__:__
NULL__:__102650__:__ADACTYLIA, UNILATERAL__:__TERMINAL TRANSVERSE DEFECTS OF HAND, UNILATERAL__:__
NULL__:__102660__:__ADAMANTINOMA OF LONG BONES__:____:__
Asterisk__:__102670__:__MUCOSAL VASCULAR ADDRESSIN CELL ADHESION MOLECULE 1; MADCAM1__:__ADDRESSIN, MUCOSAL;; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; MACAM1__:__
Asterisk__:__102680__:__ADDUCIN 1; ADD1__:__ADDUCIN, ALPHA__:__
Asterisk__:__102681__:__ADDUCIN 2; ADD2__:__ADDUCIN, BETA__:__
NULL__:__102699__:__ADENO-ASSOCIATED VIRUS INTEGRATION SITE 1; AAVS1__:____:__
Number Sign__:__102700__:__SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY__:__SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET__:__SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED
Caret__:__102710__:__MOVED TO 102720__:____:__
Asterisk__:__102720__:__DIPEPTIDYL PEPTIDASE IV; DPP4__:__DIPEPTIDYL PEPTIDASE, INTESTINAL;; ADENOSINE DEAMINASE COMPLEXING PROTEIN 2; ADCP2;; T-CELL ACTIVATION ANTIGEN CD26; CD26__:__
NULL__:__102730__:__ADENOSINE DEAMINASE, ELEVATED, HEMOLYTIC ANEMIA DUE TO__:____:__
Asterisk__:__102750__:__ADENOSINE KINASE; ADK__:____:__
Asterisk__:__102770__:__ADENOSINE MONOPHOSPHATE DEAMINASE 1; AMPD1__:__AMP DEAMINASE;; MYOADENYLATE DEAMINASE__:__
Asterisk__:__102771__:__ADENOSINE MONOPHOSPHATE DEAMINASE 2; AMPD2__:____:__
Asterisk__:__102772__:__ADENOSINE MONOPHOSPHATE DEAMINASE 3; AMPD3__:____:__
Asterisk__:__102775__:__ADENOSINE A1 RECEPTOR; ADORA1__:__RDC7__:__
Asterisk__:__102776__:__ADENOSINE A2A RECEPTOR; ADORA2A__:__A2AR;; ADORA2;; RDC8__:__
Asterisk__:__102777__:__ADENOSINE A2 RECEPTOR-LIKE; ADORA2L1__:__ADORA2B-LIKE;; ADORA2L__:__
Percent__:__102800__:__ADENOSINE TRIPHOSPHATASE DEFICIENCY, ANEMIA DUE TO__:____:__
Number Sign__:__102900__:__ADENOSINE TRIPHOSPHATE, ELEVATED, OF ERYTHROCYTES__:__PYRUVATE KINASE HYPERACTIVITY__:__
Asterisk__:__102910__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, BETA SUBUNIT; ATP5F1B__:__ATP5B;; MITOCHONDRIAL ATP SYNTHASE, BETA SUBUNIT; ATPMB;; ATPSB__:__
Caret__:__102920__:__REMOVED FROM DATABASE__:____:__
Caret__:__102930__:__REMOVED FROM DATABASE__:____:__
Caret__:__102940__:__REMOVED FROM DATABASE__:____:__
Caret__:__102970__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__102980__:__ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 1; ADCYAP1__:__PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PACAP__:__PACAP38, INCLUDED;; PACAP27, INCLUDED;; PACAP-RELATED PEPTIDE, INCLUDED; PRP, INCLUDED
Asterisk__:__102981__:__ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 1, RECEPTOR FOR; ADCYAP1R1__:__PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE RECEPTOR, TYPE I;; PACAP RECEPTOR, TYPE I;; PAC1__:__
Caret__:__102990__:__MOVED TO 145600__:____:__
Asterisk__:__103000__:__ADENYLATE KINASE 1; AK1__:__ADENYLATE KINASE, SOLUBLE__:__
Asterisk__:__103020__:__ADENYLATE KINASE 2; AK2__:__ADENYLATE KINASE, MITOCHONDRIAL MYOKINASE__:__
Asterisk__:__103030__:__ADENYLATE KINASE 3-LIKE 1; AK3L1__:__AK4, MOUSE, HOMOLOG OF; AK4;; ADENYLATE KINASE 3, FORMERLY; AK3, FORMERLY__:__
Number Sign__:__103050__:__ADENYLOSUCCINASE DEFICIENCY; ADSLD__:__ADENYLOSUCCINATE LYASE DEFICIENCY;; ADSL DEFICIENCY__:__
Asterisk__:__103060__:__ADENYLOSUCCINATE SYNTHETASE; ADSS__:__Ade(-)H, COMPLEMENT OF; ADEH__:__
Asterisk__:__103070__:__ADENYLATE CYCLASE 8; ADCY8__:__ADCY8;; ADENYLYL CYCLASE, BRAIN, TYPE I;; ADENYLATE CYCLASE 3, FORMERLY; ADCY3, FORMERLY__:__
Asterisk__:__103071__:__ADENYLATE CYCLASE 2; ADCY2__:__ADENYLYL CYCLASE 2;; ADENYLYL CYCLASE, BRAIN, TYPE II__:__
Asterisk__:__103072__:__ADENYLATE CYCLASE 1; ADCY1__:__ADENYLYL CYCLASE 1;; ADENYLYL CYCLASE, FETAL BRAIN, TYPE I__:__
Number Sign__:__103100__:__ADIE PUPIL__:__ADIE SYNDROME;; POORLY REACTING PUPILS__:__HOLMES-ADIE SYNDROME, INCLUDED
Asterisk__:__103180__:__ADP-RIBOSYLATION FACTOR 1; ARF1__:____:__
Asterisk__:__103188__:__ADP-RIBOSYLATION FACTOR 5; ARF5__:____:__
Asterisk__:__103190__:__ADP-RIBOSYLATION FACTOR 3; ARF3__:____:__
Asterisk__:__103195__:__PERILIPIN 2; PLIN2__:__ADIPOSE DIFFERENTIATION-RELATED PROTEIN; ADRP;; ADIPOPHILIN__:__
Percent__:__103200__:__ADIPOSIS DOLOROSA__:__DERCUM DISEASE__:__
Asterisk__:__103220__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ADENINE NUCLEOTIDE TRANSLOCATOR), MEMBER 4; SLC25A4__:__ADENINE NUCLEOTIDE TRANSLOCATOR 1; ANT1;; ADP/ATP TRANSLOCATOR OF SKELETAL MUSCLE; ANT;; ADP/ATP TRANSLOCASE 1;; ADP/ATP CARRIER 1; AAC1__:__
NULL__:__103230__:__ADRENOCORTICAL HYPOFUNCTION, CHRONIC PRIMARY CONGENITAL__:__ADDISON DISEASE, CONGENITAL__:__
Asterisk__:__103260__:__FERREDOXIN 1; FDX1__:__ADRENODOXIN; ADX__:__
Asterisk__:__103270__:__FERREDOXIN REDUCTASE; FDXR__:__FERREDOXIN:NADP(+) REDUCTASE;; ADRENODOXIN REDUCTASE; ADXR__:__
Asterisk__:__103275__:__ADRENOMEDULLIN; ADM__:____:__
Asterisk__:__103280__:__H19, IMPRINTED MATERNALLY EXPRESSED NONCODING TRANSCRIPT; H19__:__LONG INTERGENIC NONCODING RNA H19;; lincRNA H19;; ADULT SKELETAL MUSCLE GENE; ASM;; ASM1__:__
Number Sign__:__103285__:__ADULT SYNDROME__:__ACRO-DERMATO-UNGUAL-LACRIMAL-TOOTH SYNDROME__:__
Percent__:__103300__:__HYPOGLOSSIA-HYPODACTYLIA__:__PEROMELIA WITH MICROGNATHISM;; OROMANDIBULAR LIMB HYPOPLASIA;; AGLOSSIA-ADACTYLIA__:__HANHART SYNDROME, INCLUDED
Asterisk__:__103320__:__AGRIN; AGRN__:____:__
Caret__:__103321__:__MOVED TO 128239__:____:__
Asterisk__:__103390__:__AHNAK NUCLEOPROTEIN; AHNAK__:__DESMOYOKIN__:__
NULL__:__103400__:__AINHUM__:____:__
Percent__:__103420__:__ALACRIMA, CONGENITAL, AUTOSOMAL DOMINANT__:__ALACRIMIA CONGENITA, AUTOSOMAL DOMINANT__:__
Number Sign__:__103470__:__ALBINISM, OCULAR, WITH SENSORINEURAL DEAFNESS__:__WAARDENBURG SYNDROME, TYPE 2, WITH OCULAR ALBINISM, AUTOSOMAL RECESSIVE; WS2-OA__:__
Number Sign__:__103500__:__TIETZ ALBINISM-DEAFNESS SYNDROME; TADS__:__TIETZ SYNDROME;; ALBINISM-DEAFNESS OF TIETZ;; HYPOPIGMENTATION/DEAFNESS OF TIETZ__:__
Number Sign__:__103580__:__PSEUDOHYPOPARATHYROIDISM, TYPE IA; PHP1A__:__PHP IA;; ALBRIGHT HEREDITARY OSTEODYSTROPHY WITH MULTIPLE HORMONE RESISTANCE__:__
Caret__:__103581__:__MOVED TO 103580__:____:__
Asterisk__:__103600__:__ALBUMIN; ALB__:____:__
Asterisk__:__103700__:__ALCOHOL DEHYDROGENASE 1A, CLASS I, ALPHA POLYPEPTIDE; ADH1A__:__ALCOHOL DEHYDROGENASE 1; ADH1;; ADH, ALPHA SUBUNIT__:__
Asterisk__:__103710__:__ALCOHOL DEHYDROGENASE 5, CHI POLYPEPTIDE; ADH5__:__ALCOHOL DEHYDROGENASE, CHI ISOZYME;; ADH, CLASS III; ADHX;; FORMALDEHYDE DEHYDROGENASE; FDH;; FORMALDEHYDE DEHYDROGENASE, GLUTATHIONE-DEPENDENT;; S-NITROSOGLUTATHIONE REDUCTASE; GSNOR__:__
Asterisk__:__103720__:__ALCOHOL DEHYDROGENASE 1B, CLASS I, BETA POLYPEPTIDE; ADH1B__:__ALCOHOL DEHYDROGENASE 2; ADH2;; ADH, BETA SUBUNIT__:__
Asterisk__:__103730__:__ALCOHOL DEHYDROGENASE 1C, GAMMA POLYPEPTIDE; ADH1C__:__ALCOHOL DEHYDROGENASE 3; ADH3;; ADH, GAMMA SUBUNIT__:__
Asterisk__:__103735__:__ALCOHOL DEHYDROGENASE 6; ADH6__:____:__
Asterisk__:__103740__:__ALCOHOL DEHYDROGENASE 4; ADH4__:__ALCOHOL DEHYDROGENASE, PI ISOZYME;; ADH, CLASS II__:__
Number Sign__:__103780__:__ALCOHOL DEPENDENCE__:__ALCOHOLISM__:__ALCOHOL DEPENDENCE, PROTECTION AGAINST, INCLUDED;; AERODIGESTIVE TRACT CANCER, SQUAMOUS CELL, ALCOHOL-RELATED, PROTECTION AGAINST, INCLUDED
Caret__:__103800__:__MOVED TO 253200 AND 258870__:____:__
Asterisk__:__103830__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER A1; AKR1A1__:__ALDEHYDE REDUCTASE; ALR__:__
Asterisk__:__103850__:__ALDOLASE A, FRUCTOSE-BISPHOSPHATE; ALDOA__:__FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE A;; ALDOLASE A; ALDA;; ALDOLASE 1;; FRUCTOALDOLASE A__:__
Asterisk__:__103870__:__ALDOLASE C, FRUCTOSE-BISPHOSPHATE; ALDOC__:__ALDOLASE 3;; FRUCTOALDOLASE C; ALDC__:__
Asterisk__:__103880__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER B1; AKR1B1__:__ALDOSE REDUCTASE; AR;; ALDEHYDE REDUCTASE 1; ALDR1__:__
Asterisk__:__103890__:__ALDOSE REDUCTASE M; ARM__:____:__
Number Sign__:__103900__:__HYPERALDOSTERONISM, FAMILIAL, TYPE I; HALD1__:__GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; GRA;; FH I;; GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM; GSH;; ALDOSTERONISM, SENSITIVE TO DEXAMETHASONE;; ACTH-DEPENDENT HYPERALDOSTERONISM SYNDROME__:__
NULL__:__103920__:__ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS, FAMILIAL__:____:__
Asterisk__:__103950__:__ALPHA-2-MACROGLOBULIN; A2M__:__MACROGLOBULIN, ALPHA-2__:__
Percent__:__104000__:__ALOPECIA AREATA 1; AA1__:____:__ALOPECIA UNIVERSALIS, INCLUDED; AU, INCLUDED
Number Sign__:__104100__:__PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 1; PPKCA1__:__PPKCA, STEVANOVIC TYPE;; KERATODERMA-HYPOTRICHOSIS-LEUKONYCHIA TOTALIS SYNDROME__:__
NULL__:__104110__:__ALOPECIA, FAMILIAL FOCAL; ALPF__:____:__
Percent__:__104130__:__ALOPECIA, PSYCHOMOTOR EPILEPSY, PYORRHEA, AND MENTAL SUBNORMALITY__:__SHOKEIR SYNDROME__:__
Asterisk__:__104145__:__AFAMIN; AFM__:__ALPHA-ALBUMIN; ALBA; ALB2__:__
Asterisk__:__104150__:__ALPHA-FETOPROTEIN; AFP__:____:__
Asterisk__:__104155__:__ZINC FINGER HOMEOBOX 3; ZFHX3__:__AT MOTIF-BINDING FACTOR 1; ATBF1;; AT-BINDING TRANSCRIPTION FACTOR 1;; ALPHA-FETOPROTEIN ENHANCER-BINDING PROTEIN__:__
Asterisk__:__104160__:__GLUCOSIDASE, ALPHA, NEUTRAL AB; GANAB__:__ALPHA-GLUCOSIDASE, NEUTRAL, AB FORM;; GLUCOSIDASE II, ALPHA SUBUNIT__:__
Asterisk__:__104170__:__N-ACETYL-ALPHA-D-GALACTOSAMINIDASE; NAGA__:__ALPHA-GALACTOSIDASE B; GALB__:__
Asterisk__:__104175__:__GLYCOPROTEIN, ALPHA-GALACTOSYLTRANSFERASE 1 PSEUDOGENE; GGTA1P__:__GGTA1;; ALPHA-1,3-GALACTOSYLTRANSFERASE__:__
Asterisk__:__104180__:__GLUCOSIDASE, ALPHA, NEUTRAL C; GANC__:__ALPHA-GLUCOSIDASE C, NEUTRAL__:__
Number Sign__:__104200__:__ALPORT SYNDROME, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__104210__:__ALPHA-2A-ADRENERGIC RECEPTOR; ADRA2A__:__ADRAR;; ALPHA-2-ADRENERGIC RECEPTOR, PLATELET TYPE;; ADRENOCEPTOR, ALPHA-2A; ADRA2__:__
Asterisk__:__104219__:__ALPHA-1D-ADRENERGIC RECEPTOR; ADRA1D__:__ALPHA-1A-ADRENERGIC RECEPTOR, FORMERLY; ADRA1A, FORMERLY__:__
Asterisk__:__104220__:__ALPHA-1B-ADRENERGIC RECEPTOR; ADRA1B__:__ALPHA-1-ADRENERGIC RECEPTOR; ADRA1__:__
Asterisk__:__104221__:__ALPHA-1A-ADRENERGIC RECEPTOR; ADRA1A__:__ALPHA-1C-ADRENERGIC RECEPTOR, FORMERLY; ADRA1C, FORMERLY__:__
Caret__:__104222__:__MOVED TO 104219__:____:__
Asterisk__:__104225__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-ASSOCIATED PROTEIN 1; LRPAP1__:__ALPHA-2-MACROGLOBULIN RECEPTOR-ASSOCIATED PROTEIN; A2RAP; MRAP; RAP__:__
Asterisk__:__104230__:__FUCOSYLTRANSFERASE 4; FUT4__:__ALPHA-3-FUCOSYLTRANSFERASE; FCT3A__:__
Asterisk__:__104240__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 4; ST3GAL4__:__SIALYLTRANSFERASE 4C; SIAT4C;; ALPHA-3-N-ACETYLNEURAMINYLTRANSFERASE;; CMP-N-ACETYLNEURAMINATE-BETA-GALACTOSIDASE ALPHA-2,3-SIALYLTRANSFERASE;; CGS23;; NANTA3;; ST3O/N__:__
Plus__:__104250__:__ALPHA-2C-ADRENERGIC RECEPTOR; ADRA2C__:__ALPHA-2-ADRENERGIC RECEPTOR, RENAL TYPE__:__CONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF, INCLUDED
Asterisk__:__104260__:__ALPHA-2B-ADRENERGIC RECEPTOR; ADRA2B__:__ALPHA-2-ADRENERGIC RECEPTOR-LIKE 1;; ADRA2L1__:__
Number Sign__:__104290__:__ALTERNATING HEMIPLEGIA OF CHILDHOOD 1; AHC1__:____:__
Number Sign__:__104300__:__ALZHEIMER DISEASE; AD__:__PRESENILE AND SENILE DEMENTIA__:__ALZHEIMER DISEASE, FAMILIAL, 1, INCLUDED; AD1, INCLUDED;; ALZHEIMER DISEASE, EARLY-ONSET, WITH CEREBRAL AMYLOID ANGIOPATHY, INCLUDED;; ALZHEIMER DISEASE, PROTECTION AGAINST, INCLUDED
Number Sign__:__104310__:__ALZHEIMER DISEASE 2; AD2__:__ALZHEIMER DISEASE 2, LATE-ONSET;; ALZHEIMER DISEASE ASSOCIATED WITH APOE4__:__
Asterisk__:__104311__:__PRESENILIN 1; PSEN1__:__PS1;; S182__:__
NULL__:__104350__:__AMASTIA, BILATERAL, WITH URETERAL TRIPLICATION AND DYSMORPHISM__:____:__
NULL__:__104400__:__AMELIA AND TERMINAL TRANSVERSE HEMIMELIA__:____:__
Number Sign__:__104500__:__AMELOGENESIS IMPERFECTA, TYPE IB; AI1B__:__AMELOGENESIS IMPERFECTA, HYPOPLASTIC LOCAL, AUTOSOMAL DOMINANT;; AIH2;; ENAMEL HYPOPLASIA, HEREDITARY LOCALIZED__:__
Number Sign__:__104510__:__AMELOGENESIS IMPERFECTA, TYPE IV; AI4__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION-HYPOPLASTIC TYPE, WITH TAURODONTISM; AIHHT__:__
Number Sign__:__104530__:__AMELOGENESIS IMPERFECTA, TYPE IA; AI1A__:__AMELOGENESIS IMPERFECTA, HYPOPLASTIC TYPE IA__:__
Percent__:__104570__:__AMELOONYCHOHYPOHIDROTIC SYNDROME__:____:__
NULL__:__104600__:__AMENORRHEA-GALACTORRHEA SYNDROME__:____:__
Asterisk__:__104610__:__AMILORIDE-BINDING PROTEIN 1; ABP1__:__ABP;; DIAMINE OXIDASE; DAO;; DAO1__:__
Asterisk__:__104613__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 6A; CCT6A__:__CCT6;; T-COMPLEX HOMOLOG TCP20; TCP20;; HISTIDINE TRANSPORT REGULATOR 3; HTR3;; AMINO ACID TRANSPORT DEFECT-COMPLEMENTING__:__
Asterisk__:__104614__:__SOLUTE CARRIER FAMILY 3 (CYSTINE, DIBASIC, AND NEUTRAL AMINO ACID TRANSPORTER), MEMBER 1; SLC3A1__:__AMINO ACID TRANSPORTER 1; ATR1;; D2H;; RBAT__:__
Asterisk__:__104615__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 1; SLC7A1__:__AMINO ACID TRANSPORTER, CATIONIC 1; ATRC1;; CATIONIC AMINO ACID TRANSPORTER 1; CAT1__:__
Asterisk__:__104620__:__AMINOACYLASE 1; ACY1__:__N-ACYL-L-AMINO ACID AMIDOHYDROLASE;; ACYLASE__:__
Asterisk__:__104640__:__AMPHIREGULIN; AREG__:__SCHWANNOMA-DERIVED GROWTH FACTOR; SDGF__:__
Asterisk__:__104650__:__AMYLASE, PANCREATIC, A; AMY2A__:____:__
Asterisk__:__104660__:__AMYLASE, PANCREATIC, B; AMY2B__:____:__
Asterisk__:__104700__:__AMYLASE, SALIVARY, A; AMY1A__:__AMYLASE, SALIVARY; AMY1__:__
Asterisk__:__104701__:__AMYLASE, SALIVARY, B; AMY1B__:____:__
Asterisk__:__104702__:__AMYLASE, SALIVARY, C; AMY1C__:____:__
Caret__:__104740__:__MOVED TO 602414__:____:__
Asterisk__:__104750__:__SERUM AMYLOID A1; SAA1__:__AMYLOID A, SERUM; SAA__:__
Asterisk__:__104751__:__SERUM AMYLOID A2; SAA2__:__AMYLOID A, SERUM, 2__:__
Asterisk__:__104752__:__SERUM AMYLOID A4; SAA4__:__AMYLOID A, SERUM, 4;; SERUM AMYLOID A4, CONSTITUTIVE__:__
Asterisk__:__104760__:__AMYLOID BETA A4 PRECURSOR PROTEIN; APP__:__AMYLOID OF AGING AND ALZHEIMER DISEASE; AAA;; CEREBRAL VASCULAR AMYLOID PEPTIDE; CVAP;; PROTEASE NEXIN II; PN2__:__
Asterisk__:__104770__:__AMYLOID P COMPONENT, SERUM; APCS__:__SERUM AMYLOID P; SAP;; PENTRAXIN 2, SHORT; PTX2__:__
Asterisk__:__104775__:__AMYLOID BETA A4 PRECURSOR-LIKE PROTEIN 1; APLP1__:__AMYLOID PRECURSOR-LIKE PROTEIN 1;; AMYLOID PRECURSOR-LIKE PROTEIN; APLP__:__
Asterisk__:__104776__:__AMYLOID BETA A4 PRECURSOR-LIKE PROTEIN 2; APLP2__:__AMYLOID PRECURSOR-LIKE PROTEIN 2;; CDEI-BINDING PROTEIN; CDEBP;; SPERM MEMBRANE PROTEIN__:__
Number Sign__:__105120__:__AMYLOIDOSIS, FINNISH TYPE__:__AMYLOIDOSIS V;; AMYLOIDOSIS, MERETOJA TYPE;; AMYLOID CRANIAL NEUROPATHY WITH LATTICE CORNEAL DYSTROPHY;; AMYLOIDOSIS DUE TO MUTANT GELSOLIN__:__CEREBRAL AMYLOID ANGIOPATHY, GSN-RELATED, INCLUDED;; CORNEAL DYSTROPHY, LATTICE TYPE II, INCLUDED; LCD2, INCLUDED;; LATTICE CORNEAL DYSTROPHY, TYPE II, INCLUDED
Number Sign__:__105150__:__CEREBRAL AMYLOID ANGIOPATHY, CST3-RELATED__:__AMYLOIDOSIS, CEREBROARTERIAL, ICELANDIC TYPE;; AMYLOIDOSIS VI;; HEREDITARY CEREBRAL HEMORRHAGE WITH AMYLOIDOSIS; HCHWA;; CEREBRAL HEMORRHAGE, HEREDITARY, WITH AMYLOIDOSIS__:__
Number Sign__:__105200__:__AMYLOIDOSIS, FAMILIAL VISCERAL__:__AMYLOIDOSIS VIII;; OSTERTAG TYPE AMYLOIDOSIS;; GERMAN TYPE AMYLOIDOSIS;; AMYLOIDOSIS, FAMILIAL RENAL;; AMYLOIDOSIS, SYSTEMIC NONNEUROPATHIC__:__
Number Sign__:__105210__:__AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED__:__HEREDITARY AMYLOIDOSIS, TRANSTHYRETIN-RELATED;; TRANSTHYRETIN AMYLOIDOSIS;; AMYLOID POLYNEUROPATHY, FAMILIAL; FAP__:__AMYLOIDOSIS, LEPTOMENINGEAL, TRANSTHYRETIN-RELATED, INCLUDED;; AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED, INCLUDED
Number Sign__:__105250__:__AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 1; PLCA1__:__AMYLOIDOSIS, PRIMARY CUTANEOUS, 1; PCA1;; PCA;; LICHEN AMYLOIDOSIS, FAMILIAL;; AMYLOIDOSIS IX;; AMYLOIDOSIS, FAMILIAL CUTANEOUS LICHEN__:__
NULL__:__105300__:__AMYOTROPHIC DYSTONIC PARAPLEGIA__:____:__
Number Sign__:__105400__:__AMYOTROPHIC LATERAL SCLEROSIS 1; ALS1__:__AMYOTROPHIC LATERAL SCLEROSIS 1, FAMILIAL; FALS;; AMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL DOMINANT__:__AMYOTROPHIC LATERAL SCLEROSIS 1, AUTOSOMAL RECESSIVE, INCLUDED;; AMYOTROPHIC LATERAL SCLEROSIS, SPORADIC, INCLUDED
Number Sign__:__105500__:__AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX 1__:__AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX OF GUAM;; GUAM DISEASE;; ALS-PDC__:__
Number Sign__:__105550__:__FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 1; FTDALS1__:__FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS; FTDALS;; FRONTOTEMPORAL DEMENTIA AND/OR MOTOR NEURON DISEASE; FTDMND;; AMYOTROPHIC LATERAL SCLEROSIS AND/OR FRONTOTEMPORAL DEMENTIA; ALSFTD__:__
NULL__:__105563__:__ANAL SPHINCTER DYSPLASIA; ASDP__:____:__
NULL__:__105565__:__ANAL SPHINCTER MYOPATHY, INTERNAL__:__PROCTALGIA FUGAX DUE TO ANAL SPHINCTER MYOPATHY__:__
NULL__:__105570__:__ANDROSTENONE, ABILITY TO SMELL__:____:__
NULL__:__105580__:__ANAL CANAL CARCINOMA__:____:__CLOACOGENIC CARCINOMA, INCLUDED
Asterisk__:__105590__:__ANAPLASTIC LYMPHOMA KINASE; ALK__:____:__ALK/EML4 FUSION GENE, INCLUDED;; ALK/NPM1 FUSION GENE, INCLUDED;; ALK/RNF213 FUSION GENE, INCLUDED;; ALK/CARS FUSION GENE, INCLUDED;; ALK/CLTC FUSION GENE, INCLUDED
Percent__:__105600__:__ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE III; CDAN3__:__DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE III;; CDA III;; ANEMIA WITH MULTINUCLEATED ERYTHROBLASTS;; ERYTHRORETICULOSIS, HEREDITARY BENIGN__:__
Number Sign__:__105650__:__DIAMOND-BLACKFAN ANEMIA 1; DBA1__:__DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME__:__
Percent__:__105800__:__ANEURYSM, INTRACRANIAL BERRY, 1; ANIB1__:__ANEURYSMAL SUBARACHNOID HEMORRHAGE, FAMILIAL__:__
NULL__:__105805__:__ANEURYSM OF INTERVENTRICULAR SEPTUM__:____:__
Number Sign__:__105830__:__ANGELMAN SYNDROME; AS__:__HAPPY PUPPET SYNDROME, FORMERLY__:__ANGELMAN SYNDROME CHROMOSOME REGION, INCLUDED; ANCR, INCLUDED
NULL__:__105835__:__ANGEL-SHAPED PHALANGOEPIPHYSEAL DYSPLASIA; ASPED__:____:__
Asterisk__:__105850__:__ANGIOGENIN; ANG__:__RIBONUCLEASE A FAMILY, 5; RNASE5__:__
NULL__:__106050__:__ANGIOMA SERPIGINOSUM, AUTOSOMAL DOMINANT__:____:__
Percent__:__106070__:__ANGIOMA, HEREDITARY NEUROCUTANEOUS__:____:__SPINAL ARTERIAL VENOUS MALFORMATIONS WITH CUTANEOUS HEMANGIOMAS, INCLUDED;; HEMANGIOMATOSIS, DISSEMINATED, INCLUDED
Number Sign__:__106100__:__ANGIOEDEMA, HEREDITARY, TYPE I; HAE1__:__ANGIONEUROTIC EDEMA, HEREDITARY; HANE;; C1 ESTERASE INHIBITOR, DEFICIENCY OF__:__ANGIOEDEMA, HEREDITARY, TYPE II, INCLUDED; HAE2, INCLUDED
Plus__:__106150__:__ANGIOTENSINOGEN; AGT__:__SERPINA8__:__IgA NEPHROPATHY, PROGRESSION TO RENAL FAILURE IN, SUSCEPTIBILITY TO, INCLUDED;; ANGIOTENSIN I, INCLUDED;; ANGIOTENSIN II, INCLUDED
Caret__:__106160__:__MOVED TO 106165__:____:__
Asterisk__:__106165__:__ANGIOTENSIN RECEPTOR 1; AGTR1__:__ANGIOTENSIN II RECEPTOR, VASCULAR TYPE 1; AT2R1;; ANGIOTENSIN RECEPTOR 1A; AGTR1A;; AT1R__:__ANGIOTENSIN RECEPTOR 1B, INCLUDED; AGTR1B, INCLUDED
Plus__:__106180__:__ANGIOTENSIN I-CONVERTING ENZYME; ACE__:__ACE1;; DIPEPTIDYL CARBOXYPEPTIDASE 1; DCP1;; KININASE II__:__ANGIOTENSIN I-CONVERTING ENZYME, PLASMA LEVEL OF, INCLUDED;; ANGIOTENSIN I-CONVERTING ENZYME, BENIGN SERUM INCREASE, INCLUDED;; IgA NEPHROPATHY, PROGRESSION TO RENAL FAILURE IN, SUSCEPTIBILITY TO, INCLUDED;; ANGIOTENSIN I-CONVERTING ENZYME, TESTICULAR, INCLUDED
Number Sign__:__106190__:__ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS; ANHD__:__DANN-EPSTEIN-SOHAR SYNDROME__:__
Asterisk__:__106195__:__SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 3; SLC4A3__:__SLC2C;; ANION EXCHANGER 3; AE3;; ANION EXCHANGER, NEURONAL__:__
Caret__:__106200__:__MOVED TO 106210__:____:__
Number Sign__:__106210__:__ANIRIDIA 1; AN1__:__AN;; ANIRIDIA II, FORMERLY; AN2, FORMERLY__:__CATARACT, CONGENITAL, WITH LATE-ONSET CORNEAL DYSTROPHY, INCLUDED
NULL__:__106220__:__ANIRIDIA AND ABSENT PATELLA__:____:__
NULL__:__106230__:__ANIRIDIA, MICROCORNEA, AND SPONTANEOUSLY REABSORBED CATARACT__:____:__
NULL__:__106240__:__ANISOCORIA__:____:__
NULL__:__106250__:__ANKYLOBLEPHARON FILIFORME ADNATUM AND CLEFT PALATE; AFA__:____:__
Number Sign__:__106260__:__ANKYLOBLEPHARON-ECTODERMAL DEFECTS-CLEFT LIP/PALATE; AEC__:__AEC SYNDROME;; HAY-WELLS SYNDROME__:__
NULL__:__106280__:__ANKYLOGLOSSIA__:__'TONGUE-TIE'__:__
Number Sign__:__106300__:__SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1; SPDA1__:__ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO;; MARIE-STRUMPELL SPONDYLITIS;; BECHTEREW SYNDROME__:__
NULL__:__106400__:__ANKYLOSING VERTEBRAL HYPEROSTOSIS WITH TYLOSIS__:____:__DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS, INCLUDED; DISH, INCLUDED
Asterisk__:__106410__:__ANKYRIN 2; ANK2__:__ANKYRIN, NONERYTHROID;; ANKYRIN, BRAIN;; ANKYRIN, NEURONAL;; ANKYRIN-B__:__
Asterisk__:__106490__:__ANNEXIN A3; ANXA3__:__ANNEXIN III; ANX3;; LIPOCORTIN III__:__
Asterisk__:__106491__:__ANNEXIN A4; ANXA4__:__ANNEXIN IV; ANX4;; PLACENTAL ANTICOAGULANT PROTEIN II;; ZYMOGEN GRANULE MEMBRANE-ASSOCIATED PROTEIN, 36-KD; ZAP36__:__
NULL__:__106500__:__ANNULAR ERYTHEMA__:____:__
Number Sign__:__106600__:__TOOTH AGENESIS, SELECTIVE, 1; STHAG1__:__HYPODONTIA/OLIGODONTIA 1; HYD1;; SECOND PREMOLARS AND THIRD MOLARS, ABSENCE OF;; TOOTH AGENESIS, FAMILIAL__:__TOOTH AGENESIS, SELECTIVE, WITH OROFACIAL CLEFT, INCLUDED;; HYPODONTIA/OLIGODONTIA WITH OROFACIAL CLEFT, INCLUDED
Percent__:__106700__:__TOTAL ANOMALOUS PULMONARY VENOUS RETURN 1; TAPVR1__:__ANOMALOUS PULMONARY VENOUS RETURN; APVR;; SCIMITAR SYNDROME;; SCIMITAR ANOMALY__:__
NULL__:__106750__:__ANONYCHIA WITH FLEXURAL PIGMENTATION__:____:__
NULL__:__106900__:__ANONYCHIA-ECTRODACTYLY__:____:__
NULL__:__106990__:__ANONYCHIA-ONYCHODYSTROPHY WITH BRACHYDACTYLY TYPE B AND ECTRODACTYLY__:____:__
Percent__:__106995__:__ANONYCHIA-ONYCHODYSTROPHY WITH HYPOPLASIA OR ABSENCE OF DISTAL PHALANGES__:__COOKS SYNDROME__:__
Percent__:__107000__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 6; NDNC6__:__ANONYCHIA/HYPONYCHIA AND ONYCHODYSTROPHY;; ANONYCHIA, PARTIAL__:__
Percent__:__107100__:__ANORECTAL ANOMALIES__:____:__
Percent__:__107200__:__ANOSMIA, ISOLATED CONGENITAL; ANIC__:__ANOSMIA, CONGENITAL__:__
Caret__:__107240__:__MOVED TO 116930__:____:__
Number Sign__:__107250__:__ANTERIOR SEGMENT DYSGENESIS 1; ASGD1__:__ANTERIOR SEGMENT MESENCHYMAL DYSGENESIS; ASMD;; ANTERIOR SEGMENT OCULAR DYSGENESIS; ASOD__:__
Caret__:__107253__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__107254__:__ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY 30.2A8; MIC12__:__LEUKOCYTE ANTIGEN MIC12__:__
Asterisk__:__107257__:__ANTIGEN MSK3 IDENTIFIED BY MONOCLONAL ANTIBODY M68; MSK3__:____:__
Asterisk__:__107260__:__ANTIGEN MSK41 IDENTIFIED BY MONOCLONAL ANTIBODY E3; MSK41__:____:__
Asterisk__:__107265__:__CD19 ANTIGEN; CD19__:__B-LYMPHOCYTE ANTIGEN CD19__:__
Asterisk__:__107266__:__CD22 ANTIGEN; CD22__:__B-CELL ANTIGEN CD22;; SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 2; SIGLEC2__:__
Asterisk__:__107269__:__CD44 ANTIGEN; CD44__:__HERMES ANTIGEN;; Pgp1;; MDU3;; INLU-RELATED p80 GLYCOPROTEIN__:__
Asterisk__:__107270__:__CD38 ANTIGEN; CD38__:__ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE;; ECTO-NICOTINAMIDE ADENINE DINUCLEOTIDE GLYCOHYDROLASE__:__
Asterisk__:__107271__:__CD59 ANTIGEN; CD59__:__PROTECTIN;; HUMAN LEUKOCYTE ANTIGEN MIC11; MIC11;; SURFACE ANTIGEN RECOGNIZED BY MONOCLONAL ANTIBODY 16.3A5__:__
Asterisk__:__107272__:__CD72 ANTIGEN; CD72__:__LYB2, MOUSE, HOMOLOG OF; LYB2__:__
Asterisk__:__107273__:__CD69 ANTIGEN; CD69__:__EARLY T-CELL ACTIVATION ANTIGEN p60__:__
Asterisk__:__107280__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 3; SERPINA3__:__ALPHA-1-ANTICHYMOTRYPSIN; AACT;; ANTICHYMOTRYPSIN, ALPHA-1; ACT__:__
Asterisk__:__107285__:__SECRETORY LEUKOCYTE PROTEASE INHIBITOR; SLPI__:__ANTILEUKOPROTEASE;; HUMAN SEMINAL PROTEINASE INHIBITOR; HUSI__:__
Percent__:__107290__:__ANTIPYRINE METABOLISM__:____:__
Asterisk__:__107300__:__SERPIN PEPTIDASE INHIBITOR, CLADE C (ANTITHROMBIN), MEMBER 1; SERPINC1__:__ANTITHROMBIN III; AT3;; ANTITHROMBIN;; HEPARIN COFACTOR I__:__
Asterisk__:__107310__:__SOLUTE CARRIER FAMILY 9, MEMBER 1; SLC9A1__:__ANTIPORTER, SODIUM-HYDROGEN ION, AMILORIDE-SENSITIVE; APNH;; SODIUM/HYDROGEN EXCHANGER 1; NHE1;; Na+/H+ ANTIPORTER__:__
NULL__:__107320__:__ANTIPHOSPHOLIPID SYNDROME, FAMILIAL__:__LUPUS ANTICOAGULANT, FAMILIAL__:__
Asterisk__:__107323__:__ALDEHYDE DEHYDROGENASE 7 FAMILY, MEMBER A1; ALDH7A1__:__ANTIQUITIN; ATQ1;; ALPHA AMINO-ADIPIC SEMIALDEHYDE DEHYDROGENASE;; ALPHA-AASA DEHYDROGENASE;; AASA DEHYDROGENASE__:__
Asterisk__:__107325__:__CD3-EPSILON-ASSOCIATED PROTEIN; CD3EAP__:__CD3 ANTIGEN, EPSILON-ASSOCIATED PROTEIN;; ANTISENSE ERCC1; ASE1;; POLYMERASE I-ASSOCIATED FACTOR, 49-KD, MOUSE, HOMOLOG OF; PAF49__:__
Asterisk__:__107400__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 1; SERPINA1__:__ALPHA-1-ANTITRYPSIN; AAT;; PROTEASE INHIBITOR 1; PI;; PI1;; ANTI-ELASTASE;; ANTITRYPSIN__:__
NULL__:__107410__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 2, PSEUDOGENE; SERPINA2P__:__PROTEASE INHIBITOR 1-LIKE; PIL;; ANTITRYPSIN-RELATED PROTEIN; ATR;; ALPHA-1-ANTITRYPSIN-RELATED GENE SEQUENCE; ARGS;; SERPINA2__:__
NULL__:__107440__:__ANTIVIRAL STATE REPRESSOR, REGULATOR OF; AVRR__:____:__
Asterisk__:__107450__:__INTERFERON-ALPHA, -BETA, AND -OMEGA RECEPTOR 1; IFNAR1__:__IFNAR;; ANTIVIRAL PROTEIN, ALPHA-TYPE; AVP;; ANTIVIRAL PROTEIN, BETA-TYPE;; INTERFERON-ALPHA RECEPTOR;; IFRC INTERFERON-BETA RECEPTOR; IFNBR__:__
Caret__:__107460__:__MOVED TO 107450__:____:__
Asterisk__:__107470__:__INTERFERON-GAMMA RECEPTOR 1; IFNGR1__:__AVP, TYPE II;; ANTIVIRAL PROTEIN, TYPE II;; IMMUNE INTERFERON RECEPTOR 1;; CD119 ANTIGEN; CD119__:__
Number Sign__:__107480__:__TOWNES-BROCKS SYNDROME 1; TBS1__:__RENAL-EAR-ANAL-RADIAL SYNDROME;; REAR SYNDROME;; ANUS, IMPERFORATE, WITH HAND, FOOT, AND EAR ANOMALIES;; DEAFNESS, SENSORINEURAL, WITH IMPERFORATE ANUS AND THUMB ANOMALIES__:__TOWNES-BROCKS-BRANCHIOOTORENAL-LIKE SYNDROME, INCLUDED
NULL__:__107500__:__AORTIC ARCH ANOMALY WITH PECULIAR FACIES AND MENTAL RETARDATION__:____:__
NULL__:__107550__:__AORTIC ARCH INTERRUPTION, FACIAL PALSY, AND RETINAL COLOBOMA__:____:__
Asterisk__:__107580__:__TRANSCRIPTION FACTOR AP2-ALPHA; TFAP2A__:__AP2;; ACTIVATING ENHANCER-BINDING PROTEIN 2-ALPHA;; AP2 TRANSCRIPTION FACTOR; AP2TF;; TFAP2__:__
Number Sign__:__107600__:__APLASIA CUTIS CONGENITA, NONSYNDROMIC; ACC__:__CONGENITAL DEFECT OF SKULL AND SCALP;; SCALP DEFECT, CONGENITAL__:__
Caret__:__107601__:__MOVED TO 100300__:____:__
NULL__:__107640__:__APNEA, CENTRAL SLEEP__:____:__
Percent__:__107650__:__APNEA, OBSTRUCTIVE SLEEP__:__OSA;; OBSTRUCTIVE SLEEP APNEA SYNDROME; OSAS;; SLEEP APNEA/HYPOPNEA SYNDROME; SAHS; OSAHS__:__
Plus__:__107670__:__APOLIPOPROTEIN A-II; APOA2__:____:__APOLIPOPROTEIN A-II DEFICIENCY, INCLUDED
Plus__:__107680__:__APOLIPOPROTEIN A-I; APOA1__:__APOLIPOPROTEIN OF HIGH DENSITY LIPOPROTEIN__:__APOA1 DEFICIENCY, INCLUDED;; APOA1/APOC3 FUSION GENE, INCLUDED
Asterisk__:__107690__:__APOLIPOPROTEIN A-IV; APOA4__:____:__
NULL__:__107700__:__APPENDICITIS, PRONENESS TO__:____:__
Asterisk__:__107710__:__APOLIPOPROTEIN C-I; APOC1__:____:__
Asterisk__:__107720__:__APOLIPOPROTEIN C-III; APOC3__:____:__APOC3/APOA1 FUSION GENE, INCLUDED
Plus__:__107730__:__APOLIPOPROTEIN B; APOB__:____:__APOB100, INCLUDED;; APOB48, INCLUDED;; APOLIPOPROTEIN B ALLOTYPES, INCLUDED;; Ag LIPOPROTEIN TYPES, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED
Asterisk__:__107740__:__APOLIPOPROTEIN D; APOD__:____:__
Asterisk__:__107741__:__APOLIPOPROTEIN E; APOE__:____:__
Asterisk__:__107748__:__APEX NUCLEASE 1; APEX1__:__APURINIC ENDONUCLEASE; APE; APE1;; HUMAN APURINIC ENDONUCLEASE 1; HAP1;; APURINIC/APYRIMIDINIC EXONUCLEASE;; REDOX FACTOR 1; REF1__:__
Number Sign__:__107750__:__ARBITRARY RESTRICTION POLYMORPHISM 1__:__ANONYMOUS RESTRICTION POLYMORPHISM 1; ARP1;; RESTRICTION FRAGMENT LENGTH POLYMORPHISM 14A;; RFLP-14A;; ARP-14A; D14S1__:__
Asterisk__:__107760__:__APOLIPOPROTEIN F; APOF__:__LIPID TRANSFER INHIBITOR PROTEIN; LTIP__:__
Asterisk__:__107770__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1; LRP1__:__LIPOPROTEIN RECEPTOR-RELATED PROTEIN; LRP;; ALPHA-2-MACROGLOBULIN RECEPTOR; A2MR;; APOLIPOPROTEIN RECEPTOR; APR;; APOLIPOPROTEIN E RECEPTOR; APOER;; CD91;; CED1, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__107773__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 2; NR2F2__:__TRANSCRIPTION FACTOR COUP 2; TFCOUP2;; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; COUPTFII;; APOLIPOPROTEIN REGULATORY PROTEIN I; ARP1__:__
Asterisk__:__107776__:__AQUAPORIN 1; AQP1__:__AQUAPORIN-CHIP;; AQP-CHIP;; CHANNEL-LIKE INTEGRAL MEMBRANE PROTEIN, 28-KD; CHIP28__:__
Asterisk__:__107777__:__AQUAPORIN 2; AQP2__:__AQUAPORIN-CD__:__
NULL__:__107800__:__ARCUS CORNEAE__:__CORNEAL ARCUS;; ARCUS SENILIS__:__
Asterisk__:__107820__:__ARGINYL-tRNA SYNTHETASE; RARS__:__ARGINYL-tRNA SYNTHETASE 1; RARS1;; ARGINYL-tRNA SYNTHETASE, CYTOPLASMIC__:__
Asterisk__:__107830__:__ARGINASE 2; ARG2__:____:__
Caret__:__107840__:__MOVED TO 215700__:____:__
NULL__:__107850__:__ARM FOLDING PREFERENCE__:____:__
NULL__:__107900__:__ARMS, MALFORMATION OF__:____:__
Asterisk__:__107910__:__CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1; CYP19A1__:__CYTOCHROME P450, SUBFAMILY XIX; CYP19;; AROMATASE; ARO__:__CYP19A1/CGNL1 FUSION GENE, INCLUDED;; CYP19A1/TMOD3 FUSION GENE, INCLUDED;; CYP19A1/TRPM7 FUSION GENE, INCLUDED
NULL__:__107920__:__AROMATIC ALPHA-KETO ACID REDUCTASE__:__ALPHA-KETO ACID REDUCTASE; KAR__:__
Asterisk__:__107930__:__DOPA DECARBOXYLASE; DDC__:__AROMATIC L-AMINO ACID DECARBOXYLASE; AADC__:__
Asterisk__:__107940__:__ARRESTIN, BETA, 1; ARRB1__:__BETA-ARRESTIN 1; ARB1__:__
Asterisk__:__107941__:__ARRESTIN, BETA, 2; ARRB2__:__BETA-ARRESTIN 2; ARB2;; BARR2__:__
Caret__:__107950__:__MOVED TO 138800__:____:__
Number Sign__:__107970__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 1; ARVC1__:__UHL ANOMALY, INCLUDED;; CARDIOMYOPATHY, RIGHT VENTRICULAR DILATED, INCLUDED
NULL__:__108000__:__ARTERIES, ANOMALIES OF__:____:__
Number Sign__:__108010__:__ARTERIOVENOUS MALFORMATIONS OF THE BRAIN__:__BAVM;; CEREBRAL ARTERIOVENOUS MALFORMATIONS__:__INTRACRANIAL HEMORRHAGE IN BRAIN ARTERIOVENOUS MALFORMATIONS, SUSCEPTIBILITY TO, INCLUDED
NULL__:__108050__:__ARTERITIS, FAMILIAL GRANULOMATOUS, WITH JUVENILE POLYARTHRITIS__:____:__
NULL__:__108100__:__ARTHRITIS, SACROILIAC__:____:__
Caret__:__108110__:__MOVED TO 108120__:____:__
Number Sign__:__108120__:__ARTHROGRYPOSIS, DISTAL, TYPE 1A; DA1A__:__ARTHROGRYPOSIS, DISTAL, TYPE 1; DA1;; ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE I; AMCD1__:__
Caret__:__108130__:__MOVED TO 601680__:____:__
Caret__:__108140__:__MOVED TO 601680__:____:__
Number Sign__:__108145__:__ARTHROGRYPOSIS, DISTAL, TYPE 5; DA5__:__ARTHROGRYPOSIS WITH OCULOMOTOR LIMITATION AND ELECTRORETINAL ABNORMALITIES;; OCULOMELIC AMYOPLASIA;; ARTHROGRYPOSIS, DISTAL, TYPE IIB; DAIIB__:__
NULL__:__108200__:__ARTHROGRYPOSIS, DISTAL, TYPE 6; DA6__:__ARTHROGRYPOSIS AND SENSORINEURAL DEAFNESS__:__
Number Sign__:__108300__:__STICKLER SYNDROME, TYPE I; STL1__:__STICKLER SYNDROME, VITREOUS TYPE 1;; STICKLER SYNDROME, MEMBRANOUS VITREOUS TYPE;; ARTHROOPHTHALMOPATHY, HEREDITARY PROGRESSIVE; AOM__:__
NULL__:__108320__:__ARTICHOKE, MODIFICATION OF TASTE BY__:____:__
Asterisk__:__108330__:__CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1A1__:__CYTOCHROME P450, AROMATIC COMPOUND-INDUCIBLE;; ARYL HYDROCARBON HYDROXYLASE; AHH;; FLAVOPROTEIN-LINKED MONOOXYGENASE;; CYTOCHROME P1-450, DIOXIN-INDUCIBLE;; CYTOCHROME P1-450, INDUCIBLE BY 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN;; TCDD-INDUCIBLE CYTOCHROME P1-450; P450DX;; POLYCYCLIC AROMATIC COMPOUND-INDUCIBLE P450__:__
Percent__:__108340__:__ARYL HYDROCARBON HYDROXYLASE INDUCIBILITY__:__AHH INDUCIBILITY; AHHI__:__
Asterisk__:__108345__:__N-ACETYLTRANSFERASE 1; NAT1__:__ARYLAMIDE ACETYLASE 1; AAC1;; ARYLAMINE N-ACETYLTRANSFERASE 1;; ACETYL-CoA:ARYLAMINE N-ACETYLTRANSFERASE__:__
Asterisk__:__108355__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2; GRB2__:__ASH PROTEIN;; ABUNDANT SRC HOMOLOGY__:__
Asterisk__:__108360__:__ASIALOGLYCOPROTEIN RECEPTOR 1; ASGR1__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER H1; CLEC4H1__:__
Asterisk__:__108361__:__ASIALOGLYCOPROTEIN RECEPTOR 2; ASGR2__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER H2; CLEC4H2__:__
Asterisk__:__108370__:__ASPARAGINE SYNTHETASE; ASNS__:__HUMAN COMPLEMENT FOR HAMSTER TEMPERATURE-SENSITIVE MUTANT ts11__:__
Percent__:__108390__:__ASPARAGUS, SPECIFIC SMELL HYPERSENSITIVITY__:____:__
Caret__:__108400__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__108410__:__ASPARAGINYL-tRNA SYNTHETASE; NARS__:__ASNRS__:__
Percent__:__108420__:__SPERMATOGENIC FAILURE 2; SPGF2__:__ASPERMIOGENESIS FACTOR; ASG__:__
NULL__:__108450__:__ASYMMETRIC SHORT STATURE SYNDROME__:____:__
Number Sign__:__108500__:__EPISODIC ATAXIA, TYPE 2; EA2__:__ATAXIA, EPISODIC, WITH NYSTAGMUS;; EPISODIC ATAXIA, NYSTAGMUS-ASSOCIATED;; CEREBELLOPATHY, HEREDITARY PAROXYSMAL;; ATAXIA, FAMILIAL PAROXYSMAL;; ACETAZOLAMIDE-RESPONSIVE HEREDITARY PAROXYSMAL CEREBELLAR ATAXIA; APCA;; CEREBELLAR ATAXIA, PAROXYSMAL, ACETAZOLAMIDE-RESPONSIVE; CAPA__:__
Number Sign__:__108600__:__SPASTIC ATAXIA 1, AUTOSOMAL DOMINANT; SPAX1__:____:__
Percent__:__108650__:__SPASTIC ATAXIA 7, AUTOSOMAL DOMINANT; SPAX7__:__SPASTIC ATAXIA WITH CONGENITAL MIOSIS;; MIOSIS, CONGENITAL, WITH SPASTIC ATAXIA__:__
NULL__:__108700__:__ATAXIA WITH FASCICULATIONS__:____:__
Number Sign__:__108720__:__ATELOSTEOGENESIS, TYPE I; AO1__:__AOI;; GIANT CELL CHONDRODYSPLASIA;; SPONDYLOHUMEROFEMORAL HYPOPLASIA__:__
Number Sign__:__108721__:__ATELOSTEOGENESIS, TYPE III; AO3__:__AOIII__:__
Percent__:__108725__:__ATHEROSCLEROSIS SUSCEPTIBILITY; ATHS__:__ATHEROGENIC LIPOPROTEIN PHENOTYPE; ALP__:__
Asterisk__:__108728__:__ATP CITRATE LYASE; ACLY__:__CLATP;; ATPCL;; ACL__:__
Asterisk__:__108729__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, GAMMA SUBUNIT 1; ATP5F1C__:__ATP5C1;; ATP5C;; MITOCHONDRIAL ATP SYNTHASE, GAMMA SUBUNIT 1__:__
Asterisk__:__108730__:__ATPase, Ca(2+)-TRANSPORTING, FAST-TWITCH 1; ATP2A1__:__SARCOPLASMIC RETICULUM Ca(2+)-ATPase 1; SERCA1__:__SERCA1 TRUNCATED ISOFORM, INCLUDED; S1T, INCLUDED
Asterisk__:__108731__:__ATPase, Ca(2+)-TRANSPORTING, PLASMA MEMBRANE, 1; ATP2B1__:__PLASMA MEMBRANE Ca(2+)-ATPase, TYPE 1; PMCA1__:__
Asterisk__:__108732__:__ATPase, Ca(2+)-TRANSPORTING, PLASMA MEMBRANE, 4; ATP2B4__:__PLASMA MEMBRANE Ca(2+)-ATPase, TYPE 4; PMCA4;; ATP2B2, FORMERLY__:__
Asterisk__:__108733__:__ATPase, Ca(2+)-TRANSPORTING, PLASMA MEMBRANE, 2; ATP2B2__:__PLASMA MEMBRANE Ca(2+)-ATPase, TYPE 2; PMCA2__:__
Asterisk__:__108740__:__ATPase, Ca(2+)-TRANSPORTING, SLOW-TWITCH; ATP2A2__:__ATP2B;; SARCOPLASMIC RETICULUM Ca(2+)-ATPase 2; SERCA2__:__
Asterisk__:__108745__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 16-KD, V0 SUBUNIT C; ATP6V0C__:__ATPase, H+ TRANSPORTING, LYSOSOMAL; ATP6L;; VACUOLAR PROTON PUMP, SUBUNIT C; VPPC__:__
Asterisk__:__108746__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 31-KD, V1 SUBUNIT E, ISOFORM 1; ATP6V1E1__:__ATP6V1E;; ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT E; ATP6E;; VACUOLAR PROTON PUMP, 31-KD SUBUNIT;; ATP6E2; E2__:__
Percent__:__108760__:__ATRESIA OF EXTERNAL AUDITORY CANAL AND CONDUCTIVE DEAFNESS__:____:__
Number Sign__:__108770__:__ATRIAL STANDSTILL 1; ATRST1__:__ATRIAL CARDIOMYOPATHY WITH HEART BLOCK;; CARDIOMYOPATHY, FAMILIAL, WITH CONDUCTION DISTURBANCE__:__
Asterisk__:__108780__:__NATRIURETIC PEPTIDE PRECURSOR A; NPPA__:__ATRIAL NATRIURETIC POLYPEPTIDES; ANP;; CARDIONATRIN;; ATRIONATRIURETIC FACTOR;; ATRIAL NATRIURETIC FACTOR; ANF;; PRONATRIODILATIN; PND;; ATRIOPEPTIN__:__
Percent__:__108800__:__ATRIAL SEPTAL DEFECT 1; ASD1__:__ASD__:__ATRIAL SEPTAL DEFECT, PRIMUM TYPE, INCLUDED;; ASD I, INCLUDED;; ATRIAL SEPTAL DEFECT, SECUNDUM TYPE, INCLUDED;; ASD II, INCLUDED
Number Sign__:__108900__:__ATRIAL SEPTAL DEFECT 7 WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTION DEFECTS; ASD7__:__ASD WITH OR WITHOUT ATRIOVENTRICULAR CONDUCTION DEFECTS__:__
NULL__:__108950__:__ATRIAL TACHYARRHYTHMIA WITH SHORT PR INTERVAL__:____:__
Asterisk__:__108960__:__NATRIURETIC PEPTIDE RECEPTOR A/GUANYLATE CYCLASE A; NPR1__:__ATRIAL NATRIURETIC PEPTIDE RECEPTOR, TYPE A; ANPRA; NPRA;; ATRIONATRIURETIC PEPTIDE RECEPTOR, TYPE A;; GUANYLYL CYCLASE 2A; GUC2A__:__
Asterisk__:__108961__:__NATRIURETIC PEPTIDE RECEPTOR 2; NPR2__:__GUANYLATE CYCLASE B; GCB;; GUC2B; GUCY2B;; ATRIAL NATRIURETIC PEPTIDE RECEPTOR, TYPE B; ANPRB;; ATRIONATRIURETIC PEPTIDE RECEPTOR, TYPE B; NPRB;; ANPB RECEPTOR__:__
Asterisk__:__108962__:__NATRIURETIC PEPTIDE RECEPTOR C; NPR3__:__ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR; ANPRC;; ATRIONATRIURETIC PEPTIDE RECEPTOR, TYPE C__:__
Caret__:__108970__:__MOVED TO 120520__:____:__
Percent__:__108980__:__PR INTERVAL, VARIATION IN__:__ATRIOVENTRICULAR CONDUCTION TIME, VARIATION IN__:__
Number Sign__:__108985__:__SVEINSSON CHORIORETINAL ATROPHY; SCRA__:__ATROPHIA AREATA; AA;; PERIPAPILLARY CHORIORETINAL DEGENERATION, ICELANDIC TYPE;; HELICOIDAL PERIPAPILLARY CHORIORETINAL DEGENERATION; HPCD__:__
Asterisk__:__108990__:__ATTACHED CELL ANTIGEN 28.3.7; MIC7__:____:__
Percent__:__109000__:__AURICULOOSTEODYSPLASIA__:____:__
NULL__:__109050__:__AUROCEPHALOSYNDACTYLY__:__AURALCEPHALOSYNDACTYLY__:__
Asterisk__:__109090__:__SJOGREN SYNDROME ANTIGEN B; SSB__:__AUTOANTIGEN La;; La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 3; LARP3__:__
Asterisk__:__109091__:__CALRETICULIN; CALR__:__CRT;; AUTOANTIGEN Ro; RO;; COMPLEMENT COMPONENT C1q RECEPTOR; CC1QR__:__
Asterisk__:__109092__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 21; TRIM21__:__SJOGREN SYNDROME ANTIGEN A1; SSA1;; SICCA SYNDROME ANTIGEN A; SSA;; AUTOANTIGEN Ro/SSA, 52-KD; RO52__:__
Number Sign__:__109100__:__AUTOIMMUNE DISEASE__:____:__
Asterisk__:__109110__:__AUTONOMOUSLY REPLICATING SEQUENCE 1__:__ARS1__:__
NULL__:__109120__:__AXENFELD-RIEGER ANOMALY WITH PARTIALLY ABSENT EYE MUSCLES, DISTINCTIVE FACE, HYDROCEPHALY, AND SKELETAL ABNORMALITIES__:__DE HAUWERE SYNDROME;; IRIS DYSPLASIA WITH OCULAR HYPERTELORISM, PSYCHOMOTOR RETARDATION, AND SENSORINEURAL DEAFNESS__:__
NULL__:__109130__:__AXIAL OSTEOMALACIA__:____:__
Asterisk__:__109135__:__AXL RECEPTOR TYROSINE KINASE; AXL__:__ONCOGENE AXL;; AXL TRANSFORMING GENE__:__
Number Sign__:__109150__:__MACHADO-JOSEPH DISEASE; MJD__:__SPINOCEREBELLAR ATAXIA 3; SCA3;; SPINOCEREBELLAR ATROPHY III;; AZOREAN NEUROLOGIC DISEASE;; SPINOPONTINE ATROPHY;; NIGROSPINODENTATAL DEGENERATION__:__
Percent__:__109160__:__AZOTEMIA, FAMILIAL__:____:__
Asterisk__:__109170__:__LEUKOCYTE-SPECIFIC TRANSCRIPT 1; LST1__:__B144 PROTEIN;; D6S49E__:__
NULL__:__109180__:__BABOON M7 VIRUS INTEGRATION SITE; BEVI__:____:__
Asterisk__:__109190__:__SOLUTE CARRIER FAMILY 1 (NEUTRAL AMINO ACID TRANSPORTER), MEMBER 5; SLC1A5__:__NEUTRAL AMINO ACID TRANSPORTER-LIKE PROTEIN;; BABOON M7 VIRUS RECEPTOR; M7V1; M7VS1;; RD114 VIRUS RECEPTOR; RDRC;; RD114 SENSITIVITY__:__
Asterisk__:__109195__:__BACTERICIDAL PERMEABILITY-INCREASING PROTEIN; BPI__:____:__
Percent__:__109200__:__ALOPECIA, ANDROGENETIC, 1; AGA1__:__ANDROGENETIC ALOPECIA; AGA__:__BALDNESS, MALE PATTERN, INCLUDED; MPB, INCLUDED
Plus__:__109270__:__SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1; SLC4A1__:__BAND 3 OF RED CELL MEMBRANE; BND3;; ERYTHROCYTE MEMBRANE PROTEIN BAND 3; EMPB3;; ERYTHROID PROTEIN BAND 3; EPB3;; ANION EXCHANGE PROTEIN 1; AE1__:__ACANTHOCYTOSIS, ONE FORM OF, INCLUDED
Asterisk__:__109280__:__SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 2; SLC4A2__:__ANION EXCHANGER, NONERYTHROID; AE2;; ERYTHROCYTE MEMBRANE PROTEIN BAND 3-LIKE 1; EPB3L1;; BAND 3-LIKE PROTEIN; BND3L;; NONERYTHROID BAND 3; NBND3;; HKB3__:__
NULL__:__109300__:__BANKI SYNDROME__:____:__
Percent__:__109350__:__GASTROESOPHAGEAL REFLUX; GER__:__GASTROESOPHAGEAL REFLUX DISEASE; GERD;; GASTROESOPHAGEAL REFLUX, PEDIATRIC__:__
Caret__:__109390__:__MOVED TO 301845__:____:__
Number Sign__:__109400__:__BASAL CELL NEVUS SYNDROME; BCNS__:__GORLIN SYNDROME;; GORLIN-GOLTZ SYNDROME;; NEVOID BASAL CELL CARCINOMA SYNDROME; NBCCS;; MULTIPLE BASAL CELL NEVI, ODONTOGENIC KERATOCYSTS, AND SKELETAL ANOMALIES__:__
Asterisk__:__109480__:__BASIGIN; BSG__:__TCSF;; EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER; EMMPRIN;; M6 LEUKOCYTE ACTIVATION ANTIGEN; M6;; CD147 ANTIGEN; CD147__:__
Percent__:__109500__:__BASILAR IMPRESSION, PRIMARY__:____:__
Asterisk__:__109530__:__CD48 ANTIGEN; CD48__:__B-CELL ACTIVATION MARKER; BCM1; BLAST1;; SLAM FAMILY, MEMBER 2; SLAMF2__:__
Asterisk__:__109535__:__CD40 ANTIGEN; CD40__:__B CELL-ASSOCIATED MOLECULE CD40;; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 5; TNFRSF5__:__
NULL__:__109540__:__B-CELL GROWTH FACTOR; BCGF__:__B-CELL GROWTH FACTOR 1; BCGF1__:__
Percent__:__109543__:__LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 2__:__CLLS2;; B-CELL MALIGNANCY, LOW-GRADE;; DISRUPTED IN B-CELL MALIGNANCY; DBM;; LEUKEMIA, CHRONIC LYMPHOCYTIC, B-CELL; BCLL__:__
Asterisk__:__109545__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 17; TNFRSF17__:__B-CELL MATURATION FACTOR; BCMA; BCM__:__
Asterisk__:__109560__:__B-CELL LEUKEMIA/LYMPHOMA 3; BCL3__:__BCL4, FORMERLY__:__
Asterisk__:__109565__:__B-CELL LYMPHOMA 6; BCL6__:__ZINC FINGER PROTEIN 51; ZNF51;; LYMPHOMA-ASSOCIATED ZINC FINGER GENE ON CHROMOSOME 3; LAZ3__:__BCL6/H4FM FUSION GENE, INCLUDED;; BCL6/IKAROS FUSION GENE, INCLUDED;; BCL6/LCP1 FUSION GENE, INCLUDED;; BCL6/IL21R FUSION GENE, INCLUDED
Asterisk__:__109580__:__B-CELL TRANSLOCATION GENE 1; BTG1__:____:__
NULL__:__109600__:__BEETURIA__:__BETACYANINURIA__:__
Asterisk__:__109610__:__TRANSLOCATOR PROTEIN, 18-KD; TSPO__:__BENZODIAZEPINE RECEPTOR, PERIPHERAL; BZRP; PBR;; BENZODIAZEPINE PERIPHERAL BINDING SITE; PBS; BPBS;; ISOQUINOLINE CARBOXAMIDE-BINDING PROTEIN__:__
Plus__:__109630__:__BETA-1-ADRENERGIC RECEPTOR; ADRB1__:__ADRB1R;; B1AR__:__CONGESTIVE HEART FAILURE AND BETA-BLOCKER RESPONSE, MODIFIER OF, INCLUDED
Asterisk__:__109635__:__G PROTEIN-COUPLED RECEPTOR KINASE 2; GRK2__:__BETA-ADRENERGIC RECEPTOR KINASE 1; ADRBK1;; BARK1;; BETA-ARK1__:__
Asterisk__:__109636__:__BETA-ADRENERGIC RECEPTOR KINASE 2; ADRBK2__:__BARK2;; GRK3__:__
Asterisk__:__109640__:__BETA-GLYCEROL PHOSPHATASE; GPB__:____:__
Percent__:__109650__:__BEHCET SYNDROME__:__BEHCET DISEASE; BD__:__
Percent__:__109660__:__BETA-AMINO ACIDS, RENAL TRANSPORT OF; AABT__:__TAURINE RENAL REABSORPTION__:__
NULL__:__109670__:__BETA-ADRENERGIC STIMULATION, RESPONSE TO; BAS__:____:__
Asterisk__:__109675__:__ST6 BETA-GALACTOSAMIDE ALPHA-2,6-SIALYLTRANSFERASE 1; ST6GAL1__:__ST6GALI;; SIALYLTRANSFERASE 1; SIAT1;; ST6N__:__
Asterisk__:__109684__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE I; HSD17B1__:__17-BETA-HSD I;; ESTRADIOL 17-BETA-DEHYDROGENASE II; EDH17B2__:__
Asterisk__:__109685__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE II; HSD17B2__:__17-BETA-HSD II__:__
Plus__:__109690__:__BETA-2-ADRENERGIC RECEPTOR; ADRB2__:__BETA-ADRENERGIC RECEPTOR; ADRBR;; BETA-2-ADRENOCEPTOR; BAR; B2AR;; ADRB2R__:__BETA-2-ADRENORECEPTOR AGONIST, REDUCED RESPONSE TO, INCLUDED
Asterisk__:__109691__:__BETA-3-ADRENERGIC RECEPTOR; ADRB3__:____:__
Asterisk__:__109700__:__BETA-2-MICROGLOBULIN; B2M__:____:__
Asterisk__:__109710__:__BETA-2-MICROGLOBULIN REGULATOR; B2MR__:____:__
Asterisk__:__109715__:__3-BETA-HYDROXYSTEROID DEHYDROGENASE 1; HSD3B1__:__3-BETA-HYDROXYSTEROID DEHYDROGENASE/DELTA-ISOMERASE, TYPE I;; 3-BETA-HSD, PLACENTAL TYPE__:__
Percent__:__109720__:__BILIARY CIRRHOSIS, PRIMARY, 1; PBC1__:__PBC__:__
Number Sign__:__109730__:__AORTIC VALVE DISEASE 1; AOVD1__:__AORTIC VALVE DISEASE;; BICUSPID AORTIC VALVE; BAV;; AORTIC VALVE, BICUSPID;; AORTIC VALVE, CALCIFICATION OF;; AORTIC STENOSIS, CALCIFIC__:__
NULL__:__109740__:__BIFID NOSE, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__109750__:__BILIVERDIN REDUCTASE A; BLVRA__:__BILIVERDIN IX-ALPHA REDUCTASE;; BVR;; BLVR;; BVRA__:__
Asterisk__:__109760__:__5-HYDROXYTRYPTAMINE RECEPTOR 1A; HTR1A__:__SEROTONIN 5-HT-1A RECEPTOR;; BETA-2-ADRENERGIC RECEPTOR-LIKE PROTEIN G-21__:__
Asterisk__:__109770__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 1; CEACAM1__:__BILIARY GLYCOPROTEIN; BGP;; BILIARY GLYCOPROTEIN 1; BGP1;; CD66 ANTIGEN; CD66__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE PSEUDOGENES, INCLUDED;; CEACAMPS, INCLUDED
Asterisk__:__109780__:__BKM DNA__:__BANDED KRAIT MINOR SATELLITE DNA; BKMA1__:__BKMA2, INCLUDED
Number Sign__:__109800__:__BLADDER CANCER__:____:__
NULL__:__109820__:__BLADDER DIVERTICULUM__:____:__
NULL__:__109900__:__BLEPHAROCHALASIS AND DOUBLE LIP__:__ASCHER SYNDROME__:__
NULL__:__110000__:__BLEPHAROCHALASIS, SUPERIOR__:____:__
NULL__:__110050__:__BLEPHARONASOFACIAL MALFORMATION SYNDROME__:__PASHAYAN SYNDROME__:__
Number Sign__:__110100__:__BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPES__:____:__BPES, TYPE I, INCLUDED;; BPES WITH OVARIAN FAILURE, INCLUDED;; BPES, TYPE II, INCLUDED;; BPES WITHOUT OVARIAN FAILURE, INCLUDED;; BPES WITH DUANE RETRACTION SYNDROME, INCLUDED
NULL__:__110150__:__BLEPHAROPTOSIS, MYOPIA, AND ECTOPIA LENTIS__:____:__
NULL__:__110250__:__BLOOD GROUP--ABO SUPPRESSOR__:____:__
Asterisk__:__110300__:__ABO GLYCOSYLTRANSFERASE; ABO__:__ABO HISTO-BLOOD GROUP GLYCOSYLTRANSFERASES__:__TRANSFERASE A, ALPHA 1-3-N-ACETYLGALACTOSAMINYLTRANSFERASE, INCLUDED;; TRANSFERASE B, ALPHA 1-3-GALACTOSYLTRANSFERASE, INCLUDED
NULL__:__110310__:__BLOOD GROUP--ABH ANTIGEN, TYPE 2__:____:__
Percent__:__110350__:__BLOOD GROUP--AHONEN; AN__:____:__
Number Sign__:__110450__:__BLOOD GROUP, COLTON SYSTEM; CO__:__COLTON BLOOD GROUP SYSTEM__:__COLTON-NULL PHENOTYPE, INCLUDED
Number Sign__:__110500__:__BLOOD GROUP, DIEGO SYSTEM; DI__:__DIEGO BLOOD GROUP SYSTEM__:__
Asterisk__:__110600__:__ADP-RIBOSYLTRANSFERASE 4; ART4__:__DOK1__:__
Number Sign__:__110700__:__BLOOD GROUP, DUFFY SYSTEM; FY__:__DUFFY BLOOD GROUP SYSTEM__:__PLASMODIUM VIVAX, RESISTANCE TO, INCLUDED
NULL__:__110720__:__BLOOD GROUP--En__:____:__
Asterisk__:__110750__:__GLYCOPHORIN C; GYPC__:__GPC;; SIALOGLYCOPROTEIN, BETA__:__GLYCOPHORIN D, INCLUDED; GYPD, INCLUDED; GPD, INCLUDED;; SIALOGLYCOPROTEIN, GAMMA, INCLUDED
Number Sign__:__110800__:__BLOOD GROUP, I SYSTEM; Ii__:__I BLOOD GROUP SYSTEM;; Ii BLOOD GROUP SYSTEM__:__ADULT i PHENOTYPE, INCLUDED
Number Sign__:__110900__:__BLOOD GROUP--KELL SYSTEM; KEL__:__BLOOD GROUP--KELL-CELLANO SYSTEM__:__KELL-NULL, INCLUDED;; K(0), INCLUDED;; Ko, INCLUDED
Number Sign__:__111000__:__BLOOD GROUP, KIDD SYSTEM; JK__:__KIDD BLOOD GROUP SYSTEM__:__
Plus__:__111100__:__FUCOSYLTRANSFERASE 3; FUT3__:__LEWIS ENZYME__:__BLOOD GROUP--LEWIS SYSTEM, INCLUDED; Le, INCLUDED;; Les, INCLUDED
Percent__:__111130__:__BLOOD GROUP--LKE; LKE__:__BLOOD GROUP--LUKE, FORMERLY__:__
Number Sign__:__111150__:__BLOOD GROUP--LUTHERAN INHIBITOR; INLU__:__DOMINANT LU (a-b-) PHENOTYPE__:__
Number Sign__:__111200__:__BLOOD GROUP--LUTHERAN SYSTEM; LU__:____:__AUBERGER SYSTEM, INCLUDED; AU, INCLUDED
Number Sign__:__111250__:__BLOOD GROUP SYSTEM, LANDSTEINER-WIENER; LW__:__LANDSTEINER-WIENER BLOOD GROUP SYSTEM__:__
Number Sign__:__111300__:__BLOOD GROUP, MN; MN__:__MN BLOOD GROUP__:__BLOOD GROUP, MNSs SYSTEM, INCLUDED;; MNSs BLOOD GROUP SYSTEM, INCLUDED;; MNS BLOOD GROUP SYSTED, INCLUDED
NULL__:__111360__:__BLOOD GROUP--NEWFOUNDLAND; NFLD__:____:__
Number Sign__:__111380__:__BLOOD GROUP--OK; OK__:____:__
Number Sign__:__111400__:__BLOOD GROUP, P1PK SYSTEM__:____:__P(1) PHENOTYPE, INCLUDED;; P(2) PHENOTYPE, INCLUDED;; P1(k) PHENOTYPE, INCLUDED;; P2(k) PHENOTYPE, INCLUDED;; p PHENOTYPE, INCLUDED;; NOR POLYAGGLUTINATION SYNDROME, INCLUDED
Caret__:__111410__:__MOVED TO 111400__:____:__
Number Sign__:__111500__:__BLOOD GROUP--PRIVATE SYSTEMS__:__ANTIGENIC DETERMINANTS OF LOW FREQUENCY IN THE POPULATION__:__
Number Sign__:__111600__:__BLOOD GROUP, LANGEREIS SYSTEM; LAN__:____:__
Number Sign__:__111620__:__RADIN BLOOD GROUP ANTIGEN; RD__:__BLOOD GROUP--RADIN ANTIGEN__:__
Asterisk__:__111680__:__RHESUS BLOOD GROUP, D ANTIGEN; RHD__:__BLOOD GROUP--RHESUS SYSTEM D POLYPEPTIDE__:__
Caret__:__111690__:__MOVED TO 111700__:____:__
Asterisk__:__111700__:__RHESUS BLOOD GROUP, CcEe ANTIGENS; RHCE__:__BLOOD GROUP--RHESUS SYSTEM Cc/Ee POLYPEPTIDE;; RHC;; RHE__:__
Asterisk__:__111730__:__BETA-1,4-N-ACETYL-GALACTOSAMINYLTRANSFERASE 2; B4GALNT2__:__GALGT2;; CT-GalNAc TRANSFERASE__:__
Number Sign__:__111740__:__BLOOD GROUP, Ss; Ss__:__Ss BLOOD GROUP__:__
Number Sign__:__111750__:__BLOOD GROUP--SCIANNA SYSTEM; SC__:__SCIANNA BLOOD GROUP__:__
Percent__:__111800__:__BLOOD GROUP--STOLTZFUS SYSTEM; Sf__:____:__
Percent__:__112000__:__BLOOD GROUP--Ul SYSTEM; UL__:____:__
Number Sign__:__112010__:__BLOOD GROUP--WALDNER TYPE; WD__:__WALDNER BLOOD GROUP ANTIGEN__:__
Number Sign__:__112050__:__BLOOD GROUP--WRIGHT ANTIGEN; WR__:__WRIGHT BLOOD GROUP ANTIGEN__:__
Number Sign__:__112100__:__YT BLOOD GROUP ANTIGEN__:__CARTWRIGHT ANTIGEN__:__
Percent__:__112200__:__BLUE RUBBER BLEB NEVUS__:__BEAN SYNDROME__:__
Asterisk__:__112203__:__CD80 ANTIGEN; CD80__:__CD28 ANTIGEN LIGAND 1; CD28LG1;; B-LYMPHOCYTE ACTIVATION ANTIGEN B7-1; LAB7;; B71 ANTIGEN__:__
Asterisk__:__112205__:__CD79A ANTIGEN; CD79A__:__IMMUNOGLOBULIN-ASSOCIATED ALPHA; IGA;; B LYMPHOCYTE-SPECIFIC MB1 PROTEIN; MB1;; MEMBRANE-BOUND IMMUNOGLOBULIN IgM-ALPHA__:__
Asterisk__:__112210__:__MEMBRANE-SPANNING 4 DOMAINS, SUBFAMILY A, MEMBER 1; MS4A1__:__B-LYMPHOCYTE SURFACE ANTIGEN B1; B1;; CD20__:__
Number Sign__:__112240__:__COLE-CARPENTER SYNDROME 1; CLCRP1__:__BONE FRAGILITY WITH CRANIOSYNOSTOSIS, OCULAR PROPTOSIS, HYDROCEPHALUS, AND DISTINCTIVE FACIAL FEATURES__:__
Number Sign__:__112250__:__DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS HISTIOCYTOMA; DMSMFH__:__BONE DYSPLASIA WITH MEDULLARY FIBROSARCOMA; BDMF;; BONE DYSPLASIA WITH MALIGNANT FIBROUS HISTIOCYTOMA;; MYOPATHY, LIMB-GIRDLE, WITH BONE FRAGILITY__:__
Asterisk__:__112260__:__GAMMA-CARBOXYGLUTAMIC ACID PROTEIN, BONE; BGLAP__:__BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN;; BONE Gla PROTEIN; BGP;; OSTEOCALCIN; OC__:__
Asterisk__:__112261__:__BONE MORPHOGENETIC PROTEIN 2; BMP2__:__BONE MORPHOGENETIC PROTEIN 2A; BMP2A__:__REGULATORY ELEMENT, CIS-ACTING, ENHANCER, 110 KB DOWNSTREAM OF BMP2, INCLUDED; RECE-BMP2, INCLUDED
Asterisk__:__112262__:__BONE MORPHOGENETIC PROTEIN 4; BMP4__:__BONE MORPHOGENETIC PROTEIN 2B; BMP2B;; BMP2B1__:__
Asterisk__:__112263__:__BONE MORPHOGENETIC PROTEIN 3; BMP3__:__OSTEOGENIN__:__
Asterisk__:__112264__:__BONE MORPHOGENETIC PROTEIN 1; BMP1__:__TOLLOID, DROSOPHILA, HOMOLOG OF; TLD;; PROCOLLAGEN C-PROTEINASE__:__
Asterisk__:__112265__:__BONE MORPHOGENETIC PROTEIN 5; BMP5__:____:__
Asterisk__:__112266__:__BONE MORPHOGENETIC PROTEIN 6; BMP6__:__VG1-RELATED SEQUENCE; VGR1__:__
Asterisk__:__112267__:__BONE MORPHOGENETIC PROTEIN 7; BMP7__:__OSTEOGENIC PROTEIN 1; OP1__:__
NULL__:__112270__:__BONE PAIN, PERIODIC__:____:__
Percent__:__112300__:__BOOK SYNDROME__:__PHC SYNDROME__:__
Number Sign__:__112310__:__BOOMERANG DYSPLASIA__:____:__
Percent__:__112350__:__WEISMANN-NETTER SYNDROME; WNS__:__BOWING OF LEGS, ANTERIOR, WITH DWARFISM;; TOXOPACHYOSTEOSE DIAPHYSAIRE TIBIO-PERONIERE__:__
NULL__:__112370__:__BRACHMANN-DE LANGE-LIKE FACIAL CHANGES WITH MICROCEPHALY, METATARSUS ADDUCTUS, AND DEVELOPMENTAL DELAY__:____:__
Number Sign__:__112410__:__HYPERTENSION AND BRACHYDACTYLY SYNDROME; HTNB__:__BRACHYDACTYLY WITH HYPERTENSION;; BRACHYDACTYLY, TYPE E, WITH SHORT STATURE AND HYPERTENSION;; BILGINTURAN SYNDROME__:__
NULL__:__112430__:__LONG-THUMB BRACHYDACTYLY SYNDROME__:__BRACHYDACTYLY, LONG-THUMB TYPE__:__
Percent__:__112440__:__BRACHYDACTYLY, COMBINED B AND E TYPES__:__PITT-WILLIAMS BRACHYDACTYLY;; BRACHYDACTYLY, BALLARD TYPE__:__
NULL__:__112450__:__BRACHYDACTYLY, PREAXIAL, WITH HALLUX VARUS AND THUMB ABDUCTION__:__CHRISTIAN BRACHYDACTYLY__:__
Number Sign__:__112500__:__BRACHYDACTYLY, TYPE A1; BDA1__:__FARABEE-TYPE BRACHYDACTYLY__:__
Number Sign__:__112600__:__BRACHYDACTYLY, TYPE A2; BDA2__:__BRACHYMESOPHALANGY II;; MOHR-WRIEDT TYPE BRACHYDACTYLY__:__
Percent__:__112700__:__BRACHYDACTYLY, TYPE A3; BDA3__:__BRACHYMESOPHALANGY V;; BRACHYDACTYLY-CLINODACTYLY__:__
Percent__:__112800__:__BRACHYDACTYLY, TYPE A4; BDA4__:__BRACHYMESOPHALANGY II AND V;; TEMTAMY TYPE BRACHYDACTYLY__:__
Caret__:__112900__:__MOVED TO 112800__:____:__
NULL__:__112910__:__OSEBOLD-REMONDINI SYNDROME__:__BRACHYMESOPHALANGY WITH MESOMELIC SHORT LIMBS AND CARPAL AND TARSAL OSSEOUS ABNORMALITIES;; BRACHYDACTYLY, TYPE A6; BDA6__:__
Number Sign__:__113000__:__BRACHYDACTYLY, TYPE B1; BDB1__:__BRACHYDACTYLY, TYPE B; BDB__:__
Number Sign__:__113100__:__BRACHYDACTYLY, TYPE C; BDC__:__BRACHYDACTYLY, HAWS TYPE__:__
Number Sign__:__113200__:__BRACHYDACTYLY, TYPE D; BDD__:__STUB THUMB__:__
Number Sign__:__113300__:__BRACHYDACTYLY, TYPE E1; BDE1__:__BRACHYDACTYLY, TYPE E; BDE__:__
NULL__:__113301__:__BRACHYDACTYLY, TYPE E, WITH ATRIAL SEPTAL DEFECT, TYPE II__:____:__
NULL__:__113310__:__BRACHYDACTYLY-ECTRODACTYLY WITH FIBULAR APLASIA OR HYPOPLASIA__:____:__
NULL__:__113400__:__BRACHYDACTYLY-NYSTAGMUS-CEREBELLAR ATAXIA__:____:__
NULL__:__113450__:__BRACHYDACTYLY-DISTAL SYMPHALANGISM SYNDROME__:____:__
NULL__:__113470__:__BRACHYMESOMELIA-RENAL SYNDROME__:____:__
NULL__:__113475__:__BRACHYMETATARSUS IV__:__METATARSUS IV, SHORT;; TOE, FOURTH, SHORT__:__
NULL__:__113477__:__BRACHYMORPHISM-ONYCHODYSPLASIA-DYSPHALANGISM SYNDROME__:__BOD SYNDROME__:__
NULL__:__113480__:__BRACHYTELEPHALANGY WITH CHARACTERISTIC FACIES AND KALLMANN SYNDROME__:____:__
Number Sign__:__113500__:__BRACHYOLMIA TYPE 3; BCYM3__:__BRACHYOLMIA, AUTOSOMAL DOMINANT;; BRACHYRACHIA__:__
Asterisk__:__113503__:__BRADYKININ RECEPTOR B2; BDKRB2__:__BRADYKININ RECEPTOR 2; BKR2__:__
Asterisk__:__113505__:__BRAIN-DERIVED NEUROTROPHIC FACTOR; BDNF__:____:__
Asterisk__:__113508__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, ETA ISOFORM; YWHAH__:__BRAIN PROTEIN 14-3-3, ETA ISOFORM;; TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN 1; YWHA1;; 14-3-3-ETA__:__
Asterisk__:__113510__:__BRAIN-SPECIFIC PROTEIN Pc-1__:__DUARTE BRAIN-SPECIFIC PROTEIN__:__
Asterisk__:__113520__:__BRANCHED-CHAIN AMINOTRANSFERASE 1; BCAT1__:__BCT1;; PLACENTAL PROTEIN 18; PP18__:__P3, INCLUDED
Asterisk__:__113530__:__BRANCHED-CHAIN AMINOTRANSFERASE 2; BCAT2__:__BCT2__:__
NULL__:__113600__:__BRANCHIAL CLEFT ANOMALIES__:____:__BRANCHIAL CYSTS, INCLUDED
NULL__:__113610__:__BRANCHIAL MYOCLONUS WITH SPASTIC PARAPARESIS AND CEREBELLAR ATAXIA__:____:__
Number Sign__:__113620__:__BRANCHIOOCULOFACIAL SYNDROME; BOFS__:__BOF SYNDROME;; BRANCHIAL CLEFTS WITH CHARACTERISTIC FACIES, GROWTH RETARDATION, IMPERFORATE NASOLACRIMAL DUCT, AND PREMATURE AGING;; HEMANGIOMATOUS BRANCHIAL CLEFTS-LIP PSEUDOCLEFT SYNDROME;; LIP PSEUDOCLEFT-HEMANGIOMATOUS BRANCHIAL CYST SYNDROME__:__
Caret__:__113630__:__MOVED TO 151410__:____:__
Caret__:__113640__:__MOVED TO 151410__:____:__
Number Sign__:__113650__:__BRANCHIOOTORENAL SYNDROME 1; BOR1__:__BRANCHIOOTORENAL DYSPLASIA;; MELNICK-FRASER SYNDROME__:__
Caret__:__113660__:__MOVED TO 151410__:____:__
Percent__:__113670__:__HYPERTROPHY OF THE BREAST, JUVENILE; JHB__:__GIGANTOMASTIA, JUVENILE__:__
Percent__:__113700__:__BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 1; BNAH1__:__AMASTIA;; ATHELIA;; AMAZIA__:__
Asterisk__:__113703__:__RIBOSOMAL PROTEIN L13; RPL13__:__BREAST BASIC CONSERVED GENE 1; BBC1;; D16S444E__:__
Asterisk__:__113705__:__BREAST CANCER 1 GENE; BRCA1__:____:__
Asterisk__:__113710__:__TREFOIL FACTOR 1; TFF1__:__BREAST CANCER ESTROGEN-INDUCIBLE SEQUENCE; BCEI;; GASTROINTESTINAL TREFOIL PROTEIN pS2; pS2__:__
Asterisk__:__113720__:__BREAST CANCER-ASSOCIATED DF3 ANTIGEN__:____:__
NULL__:__113721__:__BREAST CANCER-RELATED REGULATOR OF TP53__:__BCPR;; BREAST CANCER SUPPRESSOR__:__
Asterisk__:__113725__:__POU DOMAIN, CLASS 4, TRANSCRIPTION FACTOR 2; POU4F2__:__POU-DOMAIN TRANSCRIPTION FACTOR BRN3B; BRN3B;; BRN3.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__113730__:__UNCOUPLING PROTEIN 1; UCP1__:__UCP;; BROWN ADIPOSE TISSUE UNCOUPLING PROTEIN;; THERMOGENIN__:__
Number Sign__:__113750__:__ALBINISM, OCULOCUTANEOUS, TYPE VI; OCA6__:____:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 4, INCLUDED; SHEP4, INCLUDED;; SKIN/HAIR/EYE PIGMENTATION 4, FAIR/DARK SKIN, INCLUDED
Number Sign__:__113800__:__EPIDERMOLYTIC HYPERKERATOSIS; EHK__:__BULLOUS ERYTHRODERMA ICHTHYOSIFORMIS CONGENITA OF BROCQ;; BULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; BCIE;; BULLOUS ICHTHYOSIFORM ERYTHRODERMA; BIE;; EPIDERMOLYTIC ICHTHYOSIS__:__EPIDERMOLYTIC HYPERKERATOSIS, LATE-ONSET, INCLUDED
Asterisk__:__113810__:__DYSTONIN; DST__:__DYSTONIA MUSCULORUM, MOUSE, HOMOLOG OF; DMH; DT;; BULLOUS PEMPHIGOID ANTIGEN 1; BPAG1;; BP240__:__
Asterisk__:__113811__:__COLLAGEN, TYPE XVII, ALPHA-1; COL17A1__:__BULLOUS PEMPHIGOID ANTIGEN 2; BPAG2;; BP180__:__
Number Sign__:__113900__:__PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA; PFHB1A__:__PFHBIA;; HEART BLOCK, PROGRESSIVE FAMILIAL, TYPE I; PFHBI;; LENEGRE-LEV DISEASE;; CARDIAC CONDUCTION DEFECT, PROGRESSIVE; PCCD;; BUNDLE BRANCH BLOCK;; HEREDITARY BUNDLE BRANCH SYSTEM DEFECT; HBBD__:__HEART BLOCK, NONPROGRESSIVE, INCLUDED;; CARDIAC CONDUCTION DEFECT, NONPROGRESSIVE, INCLUDED
Percent__:__113950__:__BUNDLE BRANCH BLOCK, FAMILIAL ISOLATED COMPLETE RIGHT__:____:__
Asterisk__:__113955__:__BUNGAROTOXIN, ALPHA, RECEPTOR FOR; BGTXR__:____:__
NULL__:__113960__:__BUTYRYLESTERASE 1__:____:__
Number Sign__:__113970__:__BURKITT LYMPHOMA; BL__:____:__
Asterisk__:__113995__:__COMPLEMENT COMPONENT 5a RECEPTOR 1; C5AR1__:__COMPLEMENT COMPONENT 5 RECEPTOR 1; C5R1;; C5a ANAPHYLATOXIN RECEPTOR; C5AR;; CD88 ANTIGEN; CD88__:__
Number Sign__:__114000__:__CAFFEY DISEASE__:__INFANTILE CORTICAL HYPEROSTOSIS__:__
Asterisk__:__114010__:__CARBAMOYL PHOSPHATE SYNTHETASE/ASPARTATE TRANSCARBAMOYLASE/DIHYDROOROTASE; CAD__:__CAD TRIFUNCTIONAL PROTEIN;; CPSase/ATCase/DHOase__:__
Asterisk__:__114019__:__CADHERIN 15; CDH15__:__CADHERIN, MUSCLE;; M-CADHERIN; MCAD;; CDHM;; CDH14, FORMERLY;; CDH3, FORMERLY__:__
Asterisk__:__114020__:__CADHERIN 2; CDH2__:__CADHERIN, NEURONAL;; N-CADHERIN; NCAD;; CALCIUM-DEPENDENT ADHESION PROTEIN, NEURONAL; CDHN__:__
Asterisk__:__114021__:__CADHERIN 3; CDH3__:__CADHERIN, PLACENTAL;; P-CADHERIN; PCAD;; CALCIUM-DEPENDENT ADHESION PROTEIN, PLACENTAL;; CDHP__:__
Asterisk__:__114025__:__CATENIN, ALPHA-2; CTNNA2__:__ALPHA-N-CATENIN;; CADHERIN-ASSOCIATED PROTEIN, RELATED; CAPR__:__
NULL__:__114030__:__CAFE-AU-LAIT SPOTS, MULTIPLE__:____:__
Asterisk__:__114050__:__CALBINDIN 1; CALB1__:__CALB;; CALBINDIN, 28-KD__:__
Asterisk__:__114051__:__CALBINDIN 2; CALB2__:__CALBINDIN, 29-KD;; CALBINDIN D29K;; CALRETININ__:__
NULL__:__114065__:__CALCIFIC AORTIC DISEASE WITH IMMUNOLOGIC ABNORMALITIES, FAMILIAL__:____:__
Asterisk__:__114070__:__ANNEXIN A6; ANXA6__:__ANNEXIN VI; ANX6;; CALCIUM-BINDING PROTEIN p68;; CALELECTRIN__:__
Asterisk__:__114078__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II-ALPHA; CAMK2A__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IIA__:__
Asterisk__:__114080__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IV; CAMK4__:__BRAIN Ca(2+)/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV__:__
Asterisk__:__114085__:__S100 CALCIUM-BINDING PROTEIN A10; S100A10__:__CALPACTIN I, LIGHT CHAIN; CAL1L;; CALPACTIN I, p11 SUBUNIT; CLP11;; ANNEXIN II LIGAND; ANX2LG;; ANNEXIN II, LIGHT CHAIN;; p11__:__
Asterisk__:__114090__:__CALPASTATIN; CAST__:____:__
Percent__:__114100__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, CHILDHOOD-ONSET__:__IBGC, CHILDHOOD-ONSET;; STRIOPALLIDODENTATE CALCINOSIS, BILATERAL, CHILDHOOD-ONSET;; CEREBRAL CALCIFICATION, NONARTERIOSCLEROTIC, IDIOPATHIC, CHILDHOOD-ONSET__:__
Asterisk__:__114105__:__PROTEIN PHOSPHATASE 3, CATALYTIC SUBUNIT, ALPHA ISOFORM; PPP3CA__:__CALCINEURIN A; CALNA; CANA;; CALCINEURIN A1; CALNA1;; CALCINEURIN A-ALPHA;; CNA-ALPHA;; PROTEIN PHOSPHATASE 2B, CATALYTIC SUBUNIT, ALPHA ISOFORM, FORMERLY; PPP2B, FORMERLY__:__
Asterisk__:__114106__:__PROTEIN PHOSPHATASE 3, CATALYTIC SUBUNIT, BETA ISOFORM; PPP3CB__:__CALCINEURIN A-BETA;; CNA-BETA;; CALCINEURIN A2; CALNA2;; CALCINEURIN B, FORMERLY; CALNB, FORMERLY;; PROTEIN PHOSPHATASE 2B, CATALYTIC SUBUNIT, BETA ISOFORM, FORMERLY__:__
Asterisk__:__114107__:__PROTEIN PHOSPHATASE 3, CATALYTIC SUBUNIT, GAMMA ISOFORM; PPP3CC__:__CALCINEURIN A3; CALNA3;; CALCINEURIN A-GAMMA;; CALCINEURIN, TESTIS-SPECIFIC CATALYTIC SUBUNIT;; PROTEIN PHOSPHATASE 2B, CATALYTIC SUBUNIT, GAMMA ISOFORM, FORMERLY__:__
Asterisk__:__114110__:__S100 CALCIUM-BINDING PROTEIN A6; S100A6__:__CALCYCLIN; CACY__:__
Caret__:__114120__:__MOVED TO 211900__:____:__
Asterisk__:__114130__:__CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA; CALCA__:__CALCITONIN; CALC1; CT__:__CALCITONIN GENE-RELATED PEPTIDE, INCLUDED; CGRP, INCLUDED;; KATACALCIN, INCLUDED
Asterisk__:__114131__:__CALCITONIN RECEPTOR; CALCR__:__CTR; CTR1__:__
Percent__:__114140__:__CALLOSITIES, HEREDITARY PAINFUL__:__CALLOSITIES, PAINFUL PLANTAR__:__
Percent__:__114150__:__CAMPTOBRACHYDACTYLY__:____:__
Asterisk__:__114160__:__CALCITONIN-RELATED POLYPEPTIDE, BETA; CALCB__:__CALCITONIN GENE-RELATED PEPTIDE-2; CGRP2; CALC2__:__
Asterisk__:__114170__:__CALPAIN, SMALL SUBUNIT 1; CAPNS1__:__CALPAIN 4; CAPN4;; CANPS;; CALCIUM-DEPENDENT PROTEASE, SMALL SUBUNIT; CDPS__:__
Asterisk__:__114180__:__CALMODULIN 1; CALM1__:__PHOSPHORYLASE KINASE, DELTA SUBUNIT; PHKD__:__
Caret__:__114181__:__MOVED TO 114180__:____:__
Asterisk__:__114182__:__CALMODULIN 2; CALM2__:__PHKD2__:__
Asterisk__:__114183__:__CALMODULIN 3; CALM3__:__PHKD3__:__
Asterisk__:__114184__:__CALMODULIN-LIKE 3; CALML3__:__CALMODULIN-LIKE PROTEIN; CLP__:__
Asterisk__:__114190__:__CALCITONIN RECEPTOR-LIKE GENE; CALCRL__:__CALCITONIN RECEPTOR-LIKE RECEPTOR; CRLR;; CALCITONIN GENE-RELATED PEPTIDE RECEPTOR; CGRPR__:__
Percent__:__114200__:__CAMPTODACTYLY 1; CAMPD1__:__CAMPTODACTYLY AND KNUCKLE PADS__:__STREBLODACTYLY, INCLUDED
Asterisk__:__114204__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-2/DELTA SUBUNIT 1; CACNA2D1__:__CALCIUM CHANNEL, L TYPE, ALPHA-2 POLYPEPTIDE; CACNL2A;; CALCIUM CHANNEL, ALPHA-2/DELTA SUBUNIT__:__
Asterisk__:__114205__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1C SUBUNIT; CACNA1C__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 1, CARDIAC MUSCLE; CACNL1A1;; CCHL1A1;; CaV1.2;; CALCIUM CHANNEL, CARDIAC DIHYDROPYRIDINE-SENSITIVE, ALPHA-1 SUBUNIT;; DHPR, ALPHA-1 SUBUNIT;; CACH2__:__
Asterisk__:__114206__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1D SUBUNIT; CACNA1D__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 2; CACNL1A2;; CALCIUM CHANNEL, NEUROENDOCRINE/BRAIN-TYPE, ALPHA-1 SUBUNIT__:__
Asterisk__:__114207__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA-1 SUBUNIT; CACNB1__:__CALCIUM CHANNEL, L TYPE, BETA-1 POLYPEPTIDE; CACNLB1;; CALCIUM CHANNEL, NEURONAL DIHYDROPYRIDINE-SENSITIVE, BETA SUBUNIT; CCHLB;; CCHLB1__:__
Asterisk__:__114208__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1S SUBUNIT; CACNA1S__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 3, SKELETAL MUSCLE; CACNL1A3;; CCHL1A3;; CALCIUM CHANNEL, SKELETAL MUSCLE DIHYDROPYRIDINE-SENSITIVE, ALPHA-1 SUBUNIT;; CaV.1__:__
Asterisk__:__114209__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-1 SUBUNIT; CACNG1__:__CALCIUM CHANNEL, L TYPE, GAMMA POLYPEPTIDE; CACNLG;; CALCIUM CHANNEL, NEURONAL DIHYDROPYRIDINE-SENSITIVE, GAMMA SUBUNIT__:__
Asterisk__:__114210__:__S100 CALCIUM-BINDING PROTEIN A4; S100A4__:__CALCIUM PLACENTAL PROTEIN; CAPL;; FIBROBLAST-SPECIFIC PROTEIN 1; FSP1__:__
Asterisk__:__114212__:__CALCYPHOSINE; CAPS__:____:__
Asterisk__:__114213__:__CALDESMON 1; CALD1__:__CDM__:__
Asterisk__:__114217__:__CALNEXIN; CANX__:__CNX__:__
Asterisk__:__114220__:__CALPAIN 1; CAPN1__:__CALPAIN, LARGE POLYPEPTIDE L1;; CALPAIN I, LARGE SUBUNIT; CANPL1;; CALCIUM-ACTIVATED NEUTRAL PROTEASE 1, CATALYTIC SUBUNIT; CANP1;; CALCIUM-ACTIVATED NEUTRAL PROTEASE, MU, LARGE SUBUNIT;; MU-CANP, LARGE SUBUNIT;; CALPAIN, MU, LARGE SUBUNIT;; MU-CALPAIN, LARGE SUBUNIT;; MU-CAPN, LARGE SUBUNIT__:__
Asterisk__:__114230__:__CALPAIN 2; CAPN2__:__CALPAIN, LARGE POLYPEPTIDE L2;; CALPAIN II, LARGE SUBUNIT; CANPL2;; CALCIUM-ACTIVATED NEUTRAL PROTEASE 2, CATALYTIC SUBUNIT; CANP2__:__
Asterisk__:__114240__:__CALPAIN 3; CAPN3__:__CALPAIN, LARGE POLYPEPTIDE L3;; CALPAIN III, LARGE SUBUNIT; CANPL3;; CALCIUM-ACTIVATED NEUTRAL PROTEASE 3, MUSCLE-SPECIFIC, LARGE SUBUNIT; CANP3;; p94__:__
Asterisk__:__114250__:__CALSEQUESTRIN 1; CASQ1__:__CASQ;; CALSEQUESTRIN, FAST-TWITCH, SKELETAL MUSCLE;; CALMITINE;; CALSEQUESTRIN, CELL__:__
Asterisk__:__114251__:__CALSEQUESTRIN 2; CASQ2__:__CALSEQUESTRIN, FAST-TWITCH, CARDIAC MUSCLE__:__
Caret__:__114260__:__MOVED TO 300006__:____:__
Asterisk__:__114280__:__CAMPATH-1 ANTIGEN; CDW52__:____:__
Number Sign__:__114290__:__CAMPOMELIC DYSPLASIA__:__CMPD;; CMD1; CMPD1;; CMPD1/SRA1__:__CAMPOMELIC DYSPLASIA WITH AUTOSOMAL SEX REVERSAL, INCLUDED;; ACAMPOMELIC CAMPOMELIC DYSPLASIA, INCLUDED;; ACAMPOMELIC CAMPOMELIC DYSPLASIA WITH AUTOSOMAL SEX REVERSAL, INCLUDED;; CAMPTOMELIC DYSPLASIA, INCLUDED
Number Sign__:__114300__:__ARTHROGRYPOSIS, DISTAL, TYPE 3; DA3__:__GORDON SYNDROME;; ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE IIA;; CAMPTODACTYLY, CLEFT PALATE, AND CLUBFOOT__:__
Asterisk__:__114350__:__NUCLEOPORIN, 214-KD; NUP214__:__CAIN GENE; CAN;; D9S46E__:__NUP214/DEK FUSION GENE, INCLUDED;; NUP214/ABL1 FUSION GENE, INCLUDED
Caret__:__114400__:__MOVED TO 120435__:____:__
NULL__:__114450__:__CANCER, FAMILIAL, WITH IN VITRO RADIORESISTANCE__:____:__
Number Sign__:__114480__:__BREAST CANCER__:__BREAST CANCER, FAMILIAL__:__BREAST CANCER, FAMILIAL MALE, INCLUDED
Number Sign__:__114500__:__COLORECTAL CANCER; CRC__:__COLON CANCER__:__
Number Sign__:__114550__:__HEPATOCELLULAR CARCINOMA__:__HCC;; CANCER, HEPATOCELLULAR;; LIVER CANCER;; LIVER CELL CARCINOMA; LCC;; HEPATOMA__:__HEPATOBLASTOMA, INCLUDED;; HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION, INCLUDED
Percent__:__114580__:__CANDIDIASIS, FAMILIAL, 1; CANDF1__:__CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT, WITH OR WITHOUT THYROID DISEASE;; CMCT__:__
Percent__:__114600__:__CANINE TEETH, ABSENCE OF UPPER PERMANENT__:____:__
Asterisk__:__114610__:__CANNABINOID RECEPTOR 1; CNR1__:__CB1 RECEPTOR; CB1; CB1R__:__
NULL__:__114620__:__CRANIOFACIOFRONTODIGITAL SYNDROME__:__CANTU CRANIOFACIOFRONTODIGITAL SYNDROME__:__
NULL__:__114650__:__CAR FACTOR DEFICIENCY__:____:__
NULL__:__114700__:__CARABELLI ANOMALY OF MAXILLARY MOLAR TEETH__:____:__
Asterisk__:__114750__:__CARBONIC ANHYDRASE III; CA3__:__CA III;; CARBONIC ANHYDRASE, MUSCLE-SPECIFIC;; CARBONIC ANHYDRASE C__:__
Asterisk__:__114760__:__CARBONIC ANHYDRASE IV; CA4__:__CA IV__:__
Asterisk__:__114761__:__CARBONIC ANHYDRASE VA; CA5A__:__CARBONIC ANHYDRASE, MITOCHONDRIAL;; CARBONIC ANHYDRASE 5; CA5;; CA V;; CA VA__:__
Asterisk__:__114770__:__CARBONIC ANHYDRASE VII; CA7__:__CA VII__:__
Asterisk__:__114780__:__CARBONIC ANHYDRASE VI; CA6__:__CA VI;; CARBONIC ANHYDRASE, SECRETED;; GUSTIN__:__
Asterisk__:__114800__:__CARBONIC ANHYDRASE I; CA1__:__CA I;; CARBONIC ANHYDRASE A;; CARBONIC ANHYDRASE B, FORMERLY__:__
Asterisk__:__114815__:__CARBONIC ANHYDRASE VIII; CA8__:__CA VIII;; CARBONIC ANHYDRASE-RELATED POLYPEPTIDE; CARP;; CARBONIC ANHYDRASE-LIKE SEQUENCE; CALS__:__
Asterisk__:__114830__:__CARBONYL REDUCTASE 1; CBR1__:__CARBONYL REDUCTASE; CBR__:__
Asterisk__:__114835__:__CARBOXYLESTERASE 1; CES1__:__SERINE ESTERASE 1; SES1;; CARBOXYLESTERASE, LIVER;; TRIACYLGLYCEROL HYDROLASE; TGH;; CARBOXYLESTERASE 2, FORMERLY; CES2, FORMERLY;; CHOLESTEROL ESTER HYDROLASE, NEUTRAL, MACROPHAGE-DERIVED; CEH__:__
Caret__:__114836__:__MOVED TO 114835__:____:__
Asterisk__:__114840__:__CARBOXYL-ESTER LIPASE; CEL__:__CARBOXYL-ESTER HYDROLASE;; CHOLESTEROL ESTERASE;; LYSOPHOSPHOLIPASE;; BILE SALT-STIMULATED LIPASE; BSSL;; BILE SALT-DEPENDENT LIPASE; BSDL__:__BILE SALT-DEPENDENT LIPASE, ONCOFETAL ISOFORM, INCLUDED;; FETOACINAR PANCREATIC PROTEIN, INCLUDED; FAPP, INCLUDED; FAP, INCLUDED;; CARBOXYL-ESTER LIPASE-LIKE, INCLUDED; CELL, INCLUDED
Caret__:__114841__:__MOVED TO 114840__:____:__
Asterisk__:__114850__:__CARBOXYPEPTIDASE A1; CPA1__:__CPA;; PROCARBOXYPEPTIDASE A1, PANCREATIC__:__
Asterisk__:__114851__:__CARBOXYPEPTIDASE A3, MAST CELL; CPA3__:__MC-CPA__:__
Asterisk__:__114852__:__CARBOXYPEPTIDASE B1, TISSUE; CPB1__:__CARBOXYPEPTIDASE B, PANCREATIC;; PROCARBOXYPEPTIDASE B, PANCREATIC; PCPB;; PANCREAS-SPECIFIC PROTEIN; PASP__:__
Asterisk__:__114855__:__CARBOXYPEPTIDASE E; CPE__:__CARBOXYPEPTIDASE H__:__
Asterisk__:__114860__:__CARBOXYPEPTIDASE M; CPM__:____:__
Asterisk__:__114890__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 5; CEACAM5__:__CARCINOEMBRYONIC ANTIGEN; CEA__:__
Percent__:__114900__:__CARCINOID TUMORS, INTESTINAL__:____:__
NULL__:__115000__:__CARDIAC ARRHYTHMIA__:__EXTRASYSTOLES__:__
Number Sign__:__115080__:__CARDIAC CONDUCTION DEFECT__:____:__SUDDEN CARDIAC DEATH, INCLUDED; SCD, INCLUDED;; FAMILIAL SUDDEN DEATH, INCLUDED
Number Sign__:__115150__:__CARDIOFACIOCUTANEOUS SYNDROME 1; CFC1__:__CFC SYNDROME;; CFCS__:__
Number Sign__:__115195__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 2; CMH2__:____:__
Number Sign__:__115196__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 3; CMH3__:____:__
Number Sign__:__115197__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4; CMH4__:____:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 4, SUSCEPTIBILITY TO, INCLUDED
Caret__:__115198__:__MOVED TO 192600 AND 115197__:____:__
Number Sign__:__115200__:__CARDIOMYOPATHY, DILATED, 1A; CMD1A__:__CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT 1; CDCD1;; CARDIOMYOPATHY, IDIOPATHIC DILATED;; CARDIOMYOPATHY, FAMILIAL IDIOPATHIC;; CARDIOMYOPATHY, CONGESTIVE__:__
Number Sign__:__115210__:__CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 1; RCM1__:__RCM__:__
NULL__:__115250__:__COLLAGENOMA, FAMILIAL CUTANEOUS__:____:__
Number Sign__:__115300__:__HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL DOMINANT; HCVAD__:____:__CAROTENOIDS, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1, INCLUDED
Number Sign__:__115310__:__PARAGANGLIOMAS 4; PGL4__:__CAROTID BODY TUMORS AND MULTIPLE EXTRAADRENAL PHEOCHROMOCYTOMAS;; PHEOCHROMOCYTOMA, EXTRAADRENAL, AND CERVICAL PARAGANGLIOMA;; PARAGANGLIOMAS, HEREDITARY EXTRAADRENAL;; PHEOCHROMOCYTOMA, FAMILIAL EXTRAADRENAL;; PARAGANGLIOMA, FAMILIAL MALIGNANT__:__
NULL__:__115400__:__CARPAL DISPLACEMENT__:__CARPAL BOSSING__:__
Number Sign__:__115430__:__CARPAL TUNNEL SYNDROME; CTS1__:__CTS;; AMYOTROPHY, THENAR, OF CARPAL ORIGIN__:__
Asterisk__:__115435__:__HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 1; HAPLN1__:__CARTILAGE LINK PROTEIN; CRTL1__:__
Asterisk__:__115437__:__MATRILIN 1; MATN1__:__CARTILAGE MATRIX PROTEIN; CRTM; CMP__:__
Asterisk__:__115440__:__CASEIN KINASE II, ALPHA-1; CSNK2A1__:__CASEIN KINASE II, ALPHA SUBUNIT; CK2A1__:__
Asterisk__:__115441__:__CASEIN KINASE II, BETA; CSNK2B__:__CASEIN KINASE II, BETA SUBUNIT; CK2B;; PHOSVITIN__:__
Asterisk__:__115442__:__CASEIN KINASE II, ALPHA-2; CSNK2A2__:__CASEIN KINASE II, ALPHA-PRIME SUBUNIT; CK2A2__:__
Asterisk__:__115450__:__CASEIN, ALPHA; CSN1__:__CASA__:__CASEIN, ALPHA-S1, INCLUDED
Asterisk__:__115460__:__CASEIN, BETA; CSN2__:__CASB__:__
Number Sign__:__115470__:__CAT EYE SYNDROME; CES__:__SCHMID-FRACCARO SYNDROME;; CHROMOSOME 22 PARTIAL TETRASOMY;; INV DUP(22)(q11)__:__
Asterisk__:__115500__:__CATALASE; CAT__:____:__
Asterisk__:__115501__:__TYROSINASE-RELATED PROTEIN 1; TYRP1__:__TYRP; TRP;; CATALASE B; CATB; CAS2;; GLYCOPROTEIN 75; GP75;; b-PROTEIN__:__
NULL__:__115645__:__CATARACT, ABERRANT ORAL FRENULA, AND GROWTH RETARDATION__:____:__
Percent__:__115650__:__CATARACT 32, MULTIPLE TYPES; CTRCT32__:__CATARACT, ANTERIOR POLAR, 1; CTAA1;; CATARACT, ANTERIOR POLAR; CAP;; CATARACT, POSTERIOR POLAR, 5; CTPP5__:__
Percent__:__115660__:__CATARACT 7; CTRCT7__:__CATARACT 7, CERULEAN TYPE;; CATARACT, CONGENITAL, CERULEAN TYPE, 1; CCA1__:__
Percent__:__115665__:__CATARACT 8, MULTIPLE TYPES; CTRCT8__:__CATARACT, CONGENITAL, VOLKMANN TYPE; CCV__:__
Number Sign__:__115700__:__CATARACT 4, MULTIPLE TYPES; CTRCT4__:__CATARACT 4, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, CRYSTALLINE ACULEIFORM; CACA;; CATARACT, CONGENITAL, CERULEAN TYPE, 3; CCA3;; CATARACT, NONNUCLEAR POLYMORPHIC CONGENITAL; PCC;; CATARACT, PUNCTATE, PROGRESSIVE JUVENILE-ONSET__:__
Percent__:__115800__:__CATARACT 29; CTRCT29__:__CATARACT 29, CORALLIFORM__:__
Number Sign__:__115900__:__CATARACT 42; CTRCT42__:____:__
Number Sign__:__116100__:__CATARACT 20, MULTIPLE TYPES; CTRCT20__:____:__
Caret__:__116150__:__MOVED TO 116200 AND 107250__:____:__
Number Sign__:__116200__:__CATARACT 1, MULTIPLE TYPES; CTRCT1__:__CATARACT 1, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, DUFFY-LINKED;; CATARACT, ZONULAR PULVERULENT, 1; CZP1; CZP; CAE1__:__
Number Sign__:__116300__:__CATARACT 30, MULTIPLE TYPES; CTRCT30__:____:__
Number Sign__:__116400__:__CATARACT 41; CTRCT41__:__CATARACT 41, CONGENITAL NUCLEAR TYPE__:__
Number Sign__:__116600__:__CATARACT 6, MULTIPLE TYPES; CTRCT6__:__CATARACT, POSTERIOR POLAR, 1; CTPP1;; CATARACT, AGE-RELATED CORTICAL, 2; ARCC2__:__
Number Sign__:__116700__:__CATARACT 13 WITH ADULT i PHENOTYPE; CTRCT13__:____:__
Plus__:__116790__:__CATECHOL-O-METHYLTRANSFERASE; COMT__:____:__CATECHOL-O-METHYLTRANSFERASE ACTIVITY, LOW, IN RED CELLS, INCLUDED
Number Sign__:__116800__:__CATARACT 5, MULTIPLE TYPES; CTRCT5__:__CATARACT, LAMELLAR;; CATARACT, MARNER TYPE; CAM; CTM__:__
Asterisk__:__116805__:__CATENIN, ALPHA-1; CTNNA1__:__ALPHA-E-CATENIN;; CADHERIN-ASSOCIATED PROTEIN__:__
Asterisk__:__116806__:__CATENIN, BETA-1; CTNNB1__:__CADHERIN-ASSOCIATED PROTEIN, BETA; CTNNB__:__
Asterisk__:__116810__:__CATHEPSIN B; CTSB__:__CATB;; AMYLOID PRECURSOR PROTEIN SECRETASE;; APP SECRETASE; APPS__:__REGULATORY ELEMENT, CIS-ACTING, ENHANCER, UPSTREAM OF CTSB, INCLUDED
Asterisk__:__116820__:__CATHEPSIN H; CTSH__:____:__
Asterisk__:__116830__:__CATHEPSIN G; CTSG__:__CATG__:__
Asterisk__:__116831__:__GRANZYME H; GZMH__:__CATHEPSIN G-LIKE 2; CTSGL2;; CGL2__:__
Asterisk__:__116840__:__CATHEPSIN D; CTSD__:____:__
Asterisk__:__116845__:__CATHEPSIN S; CTSS__:____:__
NULL__:__116850__:__CATATRICHY__:__FORELOCK__:__
Number Sign__:__116860__:__CEREBRAL CAVERNOUS MALFORMATIONS; CCM__:__CAVERNOUS ANGIOMA, FAMILIAL;; CAVERNOUS ANGIOMATOUS MALFORMATIONS; CAM;; CEREBRAL CAPILLARY MALFORMATIONS__:__CEREBRAL CAVERNOUS MALFORMATIONS 1, INCLUDED; CCM1, INCLUDED;; CAVERNOUS MALFORMATIONS OF CNS AND RETINA, INCLUDED;; HYPERKERATOTIC CUTANEOUS CAPILLARY-VENOUS MALFORMATIONS ASSOCIATED WITH CEREBRAL CAPILLARY MALFORMATIONS, INCLUDED
NULL__:__116870__:__CELIAC ARTERY STENOSIS FROM COMPRESSION BY MEDIAN ARCUATE LIGAMENT OF DIAPHRAGM__:____:__
Asterisk__:__116880__:__CATHEPSIN L; CTSL__:__MAJOR EXCRETED PROTEIN; MEP;; CATL__:__
Asterisk__:__116890__:__CATHEPSIN E; CTSE__:__CATE__:__
Asterisk__:__116896__:__CUT-LIKE HOMEOBOX 1; CUX1__:__CUT, DROSOPHILA, HOMOLOG OF, 1;; CUT-LIKE 1; CUTL1;; CCAAT DISPLACEMENT PROTEIN; CDP; CDP1;; CUX; CUX1__:__CDP/CUT ALTERNATIVELY SPLICED PRODUCT, INCLUDED; CASP, INCLUDED
Asterisk__:__116897__:__CCAAT/ENHANCER-BINDING PROTEIN, ALPHA; CEBPA__:__C/EBP-ALPHA;; CEBP__:__
Asterisk__:__116898__:__CCAAT/ENHANCER-BINDING PROTEIN, DELTA; CEBPD__:__C/EBP-DELTA;; CRP3__:__
Asterisk__:__116899__:__CYCLIN-DEPENDENT KINASE INHIBITOR 1A; CDKN1A__:__CDKN1;; CDK-INTERACTING PROTEIN 1; CIP1;; WILDTYPE p53-ACTIVATED FRAGMENT 1; WAF1;; p21__:__
Asterisk__:__116900__:__CDC28 PROTEIN KINASE 1B; CKS1B__:__CDC2-ASSOCIATED PROTEIN CKS1; CKS1__:__
Asterisk__:__116901__:__CDC2-ASSOCIATED PROTEIN CKS2; CKS2__:____:__
Number Sign__:__116920__:__LEUKOCYTE ADHESION DEFICIENCY, TYPE I; LAD__:__LAD1;; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 1 IMMUNODEFICIENCY;; LFA1 IMMUNODEFICIENCY__:__
Asterisk__:__116930__:__CELL ADHESION MOLECULE, NEURAL, 1; NCAM1__:__CD56;; ANTIGEN MSK39 IDENTIFIED BY MONOCLONAL ANTIBODY 5.1H11; MSK39__:__
Caret__:__116935__:__MOVED TO 602783__:____:__
Asterisk__:__116940__:__CYCLIN-DEPENDENT KINASE 1; CDK1__:__CELL DIVISION CYCLE 2, G1 TO S AND G2 TO M; CDC2;; CELL CYCLE CONTROLLER CDC2;; p34(CDC2)__:__
Asterisk__:__116945__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 2; MCM2__:__MINICHROMOSOME MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, 2;; MITOTIN;; CELL DIVISION CYCLE-LIKE 1; CDCL1;; NUCLEAR PROTEIN BM28; BM28__:__
Asterisk__:__116946__:__CELL DIVISION CYCLE 27; CDC27__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 3; APC3__:__
Asterisk__:__116947__:__CELL DIVISION CYCLE 25A; CDC25A__:____:__
Asterisk__:__116948__:__CELL DIVISION CYCLE 34, S. CEREVISIAE, HOMOLOG OF; CDC34__:__UBIQUITIN-CONJUGATING ENZYME CDC34;; UBC3; UBCH3;; UBIQUITIN-CONJUGATING ENZYME E2R 1; UBE2R1__:__
Asterisk__:__116949__:__CELL DIVISION CYCLE 25B; CDC25B__:____:__
NULL__:__116950__:__TEMPERATURE-SENSITIVE AF8 COMPLEMENT; AF8T__:__CELL CYCLE CONTROLLER, G1__:__
Asterisk__:__116951__:__CYCLIN-DEPENDENT KINASE 11A; CDK11A__:__CELL DIVISION CYCLE 2-LIKE 2; CDC2L2;; PITSLRE A__:__
Asterisk__:__116952__:__CELL DIVISION CYCLE 42; CDC42__:__GTP-BINDING PROTEIN, 25-KD; G25K__:__
Asterisk__:__116953__:__CYCLIN-DEPENDENT KINASE 2; CDK2__:__CELL DIVISION KINASE 2;; p33(CDK2)__:__
Caret__:__116954__:__MOVED TO 120920__:____:__
Asterisk__:__116955__:__CCHC-TYPE ZINC FINGER NUCLEIC ACID-BINDING PROTEIN; CNBP__:__ZINC FINGER PROTEIN 9; ZNF9;; CELLULAR RETROVIRAL NUCLEIC ACID-BINDING PROTEIN 1; CNBP1__:__
Asterisk__:__116957__:__RETINOBLASTOMA-LIKE 1; RBL1__:__CELLULAR PROTEIN p107; CP107; p107__:__
Asterisk__:__116960__:__MORTALITY FACTOR 4; MORF4__:__SENESCENCE-RELATED, CELLULAR, 1; SEN1;; CELLULAR SENESCENCE 1;; CELL SENESCENCE-RELATED GENE, COMPLEMENTATION GROUP B; CSR__:__
Number Sign__:__117000__:__CENTRAL CORE DISEASE OF MUSCLE; CCD__:__CCO__:__MINICORE MYOPATHY, MODERATE, WITH HAND INVOLVEMENT, INCLUDED;; MULTICORE MYOPATHY, MODERATE, WITH HAND INVOLVEMENT, INCLUDED;; MULTIMINICORE DISEASE, MODERATE, WITH HAND INVOLVEMENT, INCLUDED;; NEUROMUSCULAR DISEASE, CONGENITAL, WITH UNIFORM TYPE 1 FIBER, INCLUDED; CNMDU1, INCLUDED
Percent__:__117100__:__CENTRALOPATHIC EPILEPSY__:__CENTROTEMPORAL EPILEPSY; ECT;; TEMPORAL-CENTRAL FOCAL EPILEPSY;; BENIGN ROLANDIC EPILEPSY;; BENIGN EPILEPSY OF CHILDHOOD WITH CENTROTEMPORAL SPIKES; BECTS__:__
Asterisk__:__117139__:__CENTROMERIC PROTEIN A; CENPA__:____:__
Asterisk__:__117140__:__CENTROMERIC PROTEIN B; CENPB__:____:__
Asterisk__:__117141__:__CENTROMERIC PROTEIN C1; CENPC1__:____:__CENTROMERIC PROTEIN C1 PSEUDOGENE, INCLUDED; CENPC2, INCLUDED
Asterisk__:__117142__:__CENTROMERIC PROTEIN D; CENPD__:____:__
Asterisk__:__117143__:__CENTROMERIC PROTEIN E; CENPE__:__KINESIN FAMILY MEMBER 10; KIF10__:__
Caret__:__117200__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__117210__:__SPINOCEREBELLAR ATAXIA 31; SCA31__:__SPINOCEREBELLAR ATAXIA, 16q22-LINKED__:__
Number Sign__:__117300__:__CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 2__:__DEMENTIA, FAMILIAL DANISH; FDD;; FAMILIAL DANISH DEMENTIA;; CEREBELLAR ATAXIA, CATARACT, DEAFNESS, AND DEMENTIA OR PSYCHOSIS;; HEREDOPATHIA OPHTHALMOOTOENCEPHALICA; HOOE__:__
Asterisk__:__117340__:__CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 2; CDR2__:__CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN, 62-KD; CDR62__:__
Caret__:__117350__:__MOVED TO 183090__:____:__
Number Sign__:__117360__:__SPINOCEREBELLAR ATAXIA 29; SCA29__:__CEREBELLAR ATAXIA, CONGENITAL NONPROGRESSIVE, AUTOSOMAL DOMINANT; CNPCA;; CEREBELLAR VERMIS APLASIA;; APLASIA OF CEREBELLAR VERMIS; ACV__:__
Caret__:__117400__:__MOVED TO 164400 AND 117210__:____:__
Number Sign__:__117550__:__SOTOS SYNDROME 1; SOTOS1__:__SOTOS SYNDROME;; CEREBRAL GIGANTISM;; CHROMOSOME 5q35 DELETION SYNDROME__:__
NULL__:__117600__:__CEREBRAL SARCOMA__:____:__
Number Sign__:__117650__:__CEREBROCOSTOMANDIBULAR SYNDROME; CCMS__:__RIB GAP DEFECTS WITH MICROGNATHIA__:__
Asterisk__:__117700__:__CERULOPLASMIN; CP__:__FERROXIDASE__:__
Number Sign__:__117800__:__APOCRINE GLAND SECRETION, VARIATION IN__:__EAR WAX, WET/DRY; EWWD;; WET WAX; WW;; CERUMEN, VARIATION IN;; AXILLARY ODOR, VARIATION IN;; COLOSTRUM SECRETION, VARIATION IN__:__
NULL__:__117850__:__CERVICAL HYPERTRICHOSIS WITH UNDERLYING KYPHOSCOLIOSIS__:__HYPERTRICHOSIS, POSTERIOR CERVICAL, WITH UNDERLYING KYPHOSCOLIOSIS__:__
NULL__:__117900__:__CERVICAL RIB__:____:__
NULL__:__118000__:__CERVICAL VERTEBRAL BRIDGE__:____:__
NULL__:__118005__:__CERVICAL VERTEBRAL DYSPLASIA__:____:__
Number Sign__:__118100__:__KLIPPEL-FEIL SYNDROME 1, AUTOSOMAL DOMINANT; KFS1__:__KFS;; CERVICAL VERTEBRAL FUSION, AUTOSOMAL DOMINANT__:__
Caret__:__118150__:__MOVED TO 107776__:____:__
Asterisk__:__118190__:__HEAT-SHOCK 60-KD PROTEIN 1; HSPD1__:__HSP60;; CHAPERONIN, 60-KD; CPN60;; GroEL, E. COLI, HOMOLOG OF__:__
Number Sign__:__118200__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1B; CMT1B__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY I; HMSN I;; HEREDITARY MOTOR AND SENSORY NEUROPATHY IB; HMSN IB;; HMSN1;; HMSN1B;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1B;; CHARCOT-MARIE-TOOTH DISEASE, SLOW NERVE CONDUCTION TYPE, LINKED TO DUFFY;; PERONEAL MUSCULAR ATROPHY;; CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDED MYELIN SHEATHS, TYPE 1B__:__
Number Sign__:__118210__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A1; CMT2A1__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2A1;; CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2A1;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2A1;; HEREDITARY MOTOR AND SENSORY NEUROPATHY IIA1;; HMSN IIA1;; HMSN2A1__:__
Number Sign__:__118220__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1A; CMT1A__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY IA; HMSN IA;; HMSN1A;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1A;; CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDED MYELIN SHEATHS, TYPE 1A__:__
NULL__:__118230__:__CHARCOT-MARIE-TOOTH DISEASE, GUADALAJARA NEURONAL TYPE__:____:__
Number Sign__:__118300__:__CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS__:__CHARCOT-MARIE-TOOTH NEUROPATHY AND DEAFNESS, AUTOSOMAL DOMINANT;; CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1E; CMT1E__:__
NULL__:__118301__:__CHARCOT-MARIE-TOOTH DISEASE WITH PTOSIS AND PARKINSONISM__:____:__
NULL__:__118330__:__CHEILITIS GLANDULARIS__:____:__
NULL__:__118350__:__CHEMODECTOMA, INTRAABDOMINAL, WITH CUTANEOUS ANGIOLIPOMAS__:____:__
Number Sign__:__118400__:__CHERUBISM__:__CRBM__:__
Percent__:__118420__:__CHIARI MALFORMATION TYPE I__:__CM1__:__CHIARI MALFORMATION TYPE I WITH SYRINGOMYELIA, INCLUDED;; CM1 WITH SYRINGOMYELIA, INCLUDED
Asterisk__:__118423__:__CHIMERIN 1; CHN1__:__N-CHIMERIN; CHN;; CHIMERIN, ALPHA-1;; GTPase-ACTIVATING PROTEIN, RHO, 2; ARHGAP2;; RHO GTPase-ACTIVATING PROTEIN 2; RHOGAP2__:__CHIMERIN, ALPHA-2, INCLUDED
Asterisk__:__118425__:__CHLORIDE CHANNEL 1, SKELETAL MUSCLE; CLCN1__:__CHLORIDE CHANNEL, MUSCLE; CLC1__:__
NULL__:__118430__:__CHLORPROPAMIDE-ALCOHOL FLUSHING; CPAF__:____:__
Asterisk__:__118440__:__CHOLECYSTOKININ; CCK__:____:__
Asterisk__:__118444__:__CHOLECYSTOKININ A RECEPTOR; CCKAR__:____:__
Asterisk__:__118445__:__CHOLECYSTOKININ B RECEPTOR; CCKBR__:__GASTRIN RECEPTOR; GASR__:__
Number Sign__:__118450__:__ALAGILLE SYNDROME 1; ALGS1__:__ALAGILLE SYNDROME; ALGS;; ALAGILLE-WATSON SYNDROME; AWS;; CHOLESTASIS WITH PERIPHERAL PULMONARY STENOSIS;; ARTERIOHEPATIC DYSPLASIA; AHD;; HEPATIC DUCTULAR HYPOPLASIA, SYNDROMATIC__:__
Asterisk__:__118455__:__CYTOCHROME P450, SUBFAMILY VIIA, POLYPEPTIDE 1; CYP7A1__:__CYP7;; CHOLESTEROL 7-ALPHA-HYDROXYLASE;; CHOLESTEROL 7-ALPHA-MONOOXYGENASE__:__
Asterisk__:__118457__:__CHOLESTEROL CRYSTALLIZATION INHIBITOR; CCI__:____:__
Asterisk__:__118470__:__CHOLESTERYL ESTER TRANSFER PROTEIN, PLASMA; CETP__:__LIPID TRANSFER PROTEIN I__:__
Caret__:__118480__:__MOVED TO 134634__:____:__
Asterisk__:__118485__:__CYTOCHROME P450, SUBFAMILY XIA, POLYPEPTIDE 1; CYP11A1__:__CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME;; CYTOCHROME P450 SIDE-CHAIN CLEAVAGE ENZYME;; CYTOCHROME P450SCC;; CYTOCHROME P450C11A1;; CYP11A__:__
Asterisk__:__118490__:__CHOLINE ACETYLTRANSFERASE; CHAT__:____:__
Asterisk__:__118491__:__CHOLINE KINASE, ALPHA; CHKA__:__CHK;; CKI, YEAST, HUMAN COMPLEMENT OF__:__
Asterisk__:__118493__:__CHOLINERGIC RECEPTOR, MUSCARINIC, 2; CHRM2__:__ACETYLCHOLINE RECEPTOR, MUSCARINIC, 2__:__
Asterisk__:__118494__:__CHOLINERGIC RECEPTOR, MUSCARINIC, 3; CHRM3__:__ACETYLCHOLINE RECEPTOR, MUSCARINIC, 3__:__
Asterisk__:__118495__:__CHOLINERGIC RECEPTOR, MUSCARINIC, 4; CHRM4__:__ACETYLCHOLINE RECEPTOR, MUSCARINIC, 4__:__
Asterisk__:__118496__:__CHOLINERGIC RECEPTOR, MUSCARINIC, 5; CHRM5__:__ACETYLCHOLINE RECEPTOR, MUSCARINIC, 5__:__
Asterisk__:__118502__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 2; CHRNA2__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-2 SUBUNIT__:__
Asterisk__:__118503__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 3; CHRNA3__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-3 SUBUNIT__:__
Asterisk__:__118504__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 4; CHRNA4__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-4 SUBUNIT__:__
Asterisk__:__118505__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 5; CHRNA5__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-5 SUBUNIT__:__
Asterisk__:__118507__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, BETA POLYPEPTIDE 2; CHRNB2__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, BETA-2 SUBUNIT__:__
Asterisk__:__118508__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, BETA POLYPEPTIDE 3; CHRNB3__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, BETA-3 SUBUNIT__:__
Asterisk__:__118509__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, BETA POLYPEPTIDE 4; CHRNB4__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, BETA-4 SUBUNIT__:__
Asterisk__:__118510__:__CHOLINERGIC RECEPTOR, MUSCARINIC, 1; CHRM1__:__ACETYLCHOLINE RECEPTOR, MUSCARINIC, 1__:__
Asterisk__:__118511__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 7; CHRNA7__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-7 SUBUNIT__:__
Number Sign__:__118600__:__CHONDROCALCINOSIS 2; CCAL2__:__CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD__:__
NULL__:__118610__:__CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION__:__FAMILIAL APATITE DISEASE__:__
NULL__:__118650__:__CHONDRODYSPLASIA PUNCTATA, AUTOSOMAL DOMINANT__:____:__CHONDRODYSPLASIA PUNCTATA DUE TO VITAMIN K DEFICIENCY, INCLUDED;; CHONDRODYSPLASIA PUNCTATA DUE TO WARFARIN TERATOGENICITY, INCLUDED
Percent__:__118651__:__CHONDRODYSPLASIA PUNCTATA, TIBIA-METACARPAL TYPE__:__CHONDRODYSPLASIA PUNCTATA, MT TYPE__:__
Asterisk__:__118661__:__VERSICAN; VCAN__:__CHONDROITIN SULFATE PROTEOGLYCAN 2; CSPG2;; CHONDROITIN SULFATE PROTEOGLYCAN CORE PROTEIN, CARTILAGE__:__
NULL__:__118670__:__CHONDRONECTIN__:____:__
Number Sign__:__118700__:__CHOREA, BENIGN HEREDITARY; BHC__:__BCH;; HEREDITARY PROGRESSIVE CHOREA WITHOUT DEMENTIA__:__
NULL__:__118750__:__CHOREOATHETOSIS, FAMILIAL INVERTED__:__INFANTILE CHOREOATHETOSIS OF FISHER__:__
Number Sign__:__118800__:__PAROXYSMAL NONKINESIGENIC DYSKINESIA 1; PNKD1__:__PAROXYSMAL DYSTONIC CHOREOATHETOSIS; PDC;; CHOREOATHETOSIS, FAMILIAL PAROXYSMAL; FPD1;; MOUNT-REBACK SYNDROME;; CHOREOATHETOSIS, NONKINESIGENIC;; DYSTONIA 8; DYT8__:__
Asterisk__:__118820__:__CHORIONIC SOMATOMAMMOTROPIN HORMONE 2; CSH2__:__CHORIONIC SOMATOMAMMOTROPIN B; CSB__:__
Asterisk__:__118825__:__CHM-LIKE; CHML__:__RAB ESCORT PROTEIN 2; REP2__:__
Percent__:__118830__:__CHYLOMICRONEMIA, FAMILIAL, DUE TO CIRCULATING INHIBITOR OF LIPOPROTEIN LIPASE__:__HYPERLIPOPROTEINEMIA, TYPE IC__:__
Percent__:__118840__:__CHROMATE RESISTANCE; CHR__:____:__
Asterisk__:__118850__:__CHORIONIC GONADOTROPIN, ALPHA CHAIN; CGA__:__GLYCOPROTEIN HORMONES, ALPHA CHAIN;; FOLLICLE-STIMULATING HORMONE, ALPHA CHAIN; FSHA;; LUTEINIZING HORMONE, ALPHA CHAIN; LHA;; THYROID-STIMULATING HORMONE, ALPHA CHAIN; TSHA;; THYROTROPIN, ALPHA CHAIN__:__
Asterisk__:__118860__:__CHORIONIC GONADOTROPIN, BETA CHAIN; CGB__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 3; CGB3__:__
NULL__:__118865__:__CHOROIDAL OSTEOMA, BILATERAL__:____:__
Asterisk__:__118870__:__CHROMOSOMAL PROTEIN, NONHISTONE 1; NHCP1__:____:__
Asterisk__:__118880__:__CHROMOSOMAL PROTEIN, NONHISTONE 2; NHCP2__:____:__
Asterisk__:__118888__:__CHYMOTRYPSIN-LIKE PROTEASE; CTRL__:__CTRL1__:__
Asterisk__:__118890__:__CHYMOTRYPSINOGEN B1; CTRB1__:__CHYMOTRYPSINOGEN B; CTRB;; CHYMOTRYPSINOGEN A;; ALPHA-CHYMOTRYPSINOGEN__:__
NULL__:__118900__:__CIRRHOSIS, FAMILIAL__:____:__
Asterisk__:__118910__:__CHROMOGRANIN A; CHGA__:__CGA;; SECRETORY PROTEIN I__:__PARATHYROID SECRETORY PROTEIN, INCLUDED; PSP, INCLUDED;; PANCREASTATIN, INCLUDED;; CHROMOSTATIN, INCLUDED;; CATESTATIN, INCLUDED
Asterisk__:__118920__:__CHROMOGRANIN B; CHGB__:__SECRETOGRANIN I; SCG1__:__
Asterisk__:__118930__:__SECRETOGRANIN II; SCG2__:__CHROMOGRANIN C; CHGC__:__SECRETONEURIN, INCLUDED; SN, INCLUDED
Asterisk__:__118938__:__CHYMASE 1; CMA1__:__CHYMASE, MAST CELL;; CHYMASE, HEART; CYH__:__
Caret__:__118940__:__MOVED TO 118938__:____:__
NULL__:__118943__:__CHYMOSIN PSEUDOGENE; CYMP__:____:__PROCHYMOSIN, INCLUDED
Asterisk__:__118945__:__CILIARY NEUROTROPHIC FACTOR; CNTF__:____:__
Asterisk__:__118946__:__CILIARY NEUROTROPHIC FACTOR RECEPTOR; CNTFR__:__CNTFR-ALPHA__:__
Asterisk__:__118950__:__CITRATE SYNTHASE, MITOCHONDRIAL; CS__:____:__
Caret__:__118953__:__MOVED TO 192020__:____:__
Asterisk__:__118955__:__CLATHRIN, HEAVY POLYPEPTIDE; CLTC__:__CLATHRIN HEAVY CHAIN; CHC__:__CLTC/TFE3 FUSION GENE, INCLUDED;; CLTC/ALK FUSION GENE, INCLUDED
Asterisk__:__118960__:__CLATHRIN, LIGHT POLYPEPTIDE A; CLTA__:__LCA__:__
Asterisk__:__118970__:__CLATHRIN, LIGHT POLYPEPTIDE B; CLTB__:__LCB__:__
NULL__:__118980__:__CLAVICLE, PSEUDARTHROSIS OF, CONGENITAL__:____:__
Asterisk__:__118990__:__SPERM-SPECIFIC ANTIGEN 2; SSFA2__:__CLEAVAGE SIGNAL 1; CS1;; KRAS-INDUCED ACTIN-INTERACTING PROTEIN; KRAP__:__
Percent__:__119000__:__CLEFT CHIN__:__CHIN DIMPLE__:__
Percent__:__119100__:__SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 1; SHFLD1__:__SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY; SHFLD;; CLEFT HAND AND ABSENT TIBIA;; APLASIA OF TIBIA WITH ECTRODACTYLY;; TIBIAL APLASIA WITH SPLIT-HAND/SPLIT-FOOT DEFORMITY;; ECTRODACTYLY WITH APLASIA OF LONG BONES__:__
Number Sign__:__119300__:__VAN DER WOUDE SYNDROME 1; VWS1__:__VDWS;; LIP-PIT SYNDROME; LPS; PIT;; CLEFT LIP AND/OR PALATE WITH MUCOUS CYSTS OF LOWER LIP__:__
Number Sign__:__119500__:__POPLITEAL PTERYGIUM SYNDROME; PPS__:__CLEFT LIP/PALATE, PARAMEDIAN MUCOUS CYSTS OF THE LOWER LIP, POPLITEAL PTERYGIUM, DIGITAL AND GENITAL ANOMALIES;; FACIOGENITOPOPLITEAL SYNDROME__:__
Percent__:__119530__:__OROFACIAL CLEFT 1; OFC1__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 1;; OROFACIAL CLEFT, NONSYNDROMIC; OFC;; CLEFT LIP/PALATE, NONSYNDROMIC__:__
Percent__:__119540__:__CLEFT PALATE, ISOLATED; CPI__:__CLEFT PALATE; CP__:__
Percent__:__119550__:__SYNGNATHIA__:__CLEFT PALATE-LATERAL SYNECHIA SYNDROME;; CPLS SYNDROME__:__
NULL__:__119570__:__CLEFT SOFT PALATE__:____:__
Number Sign__:__119580__:__BLEPHAROCHEILODONTIC SYNDROME 1; BCDS1__:__BLEPHAROCHEILODONTIC SYNDROME; BCDS;; BCD SYNDROME;; CLEFTING, ECTROPION, AND CONICAL TEETH;; ECTROPION, INFERIOR, WITH CLEFT LIP AND/OR PALATE;; ELSCHNIG SYNDROME;; LAGOPHTHALMIA WITH BILATERAL CLEFT LIP AND PALATE__:__
Number Sign__:__119600__:__CLEIDOCRANIAL DYSPLASIA; CCD__:__CLEIDOCRANIAL DYSOSTOSIS; CLCD__:__CLEIDOCRANIAL DYSPLASIA, FORME FRUSTE, WITH BRACHYDACTYLY, INCLUDED;; CLEIDOCRANIAL DYSPLASIA, FORME FRUSTE, DENTAL ANOMALIES ONLY, INCLUDED
NULL__:__119650__:__CLEIDORHIZOMELIC SYNDROME__:____:__
Number Sign__:__119800__:__CLUBFOOT, CONGENITAL, WITH OR WITHOUT DEFICIENCY OF LONG BONES AND/OR MIRROR-IMAGE POLYDACTYLY; CCF__:____:__
Number Sign__:__119900__:__DIGITAL CLUBBING, ISOLATED CONGENITAL__:__CLUBBING OF DIGITS;; ACROPACHY, HEREDITARY__:__
Percent__:__119915__:__CLUSTER HEADACHE, FAMILIAL__:____:__
NULL__:__120000__:__COARCTATION OF AORTA__:____:__
NULL__:__120040__:__COCHLEOSACCULAR DEGENERATION WITH PROGRESSIVE CATARACTS__:____:__
Percent__:__120050__:__COXSACKIEVIRUS B3 SUSCEPTIBILITY; CXB3S__:__CB3S__:__
Asterisk__:__120070__:__COLLAGEN, TYPE IV, ALPHA-3; COL4A3__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-3 CHAIN__:__TUMSTATIN, INCLUDED;; GOODPASTURE ANTIGEN, INCLUDED
Number Sign__:__120080__:__COLCHICINE RESISTANCE__:__COLCHICINE SENSITIVITY; CLCS__:__
Asterisk__:__120090__:__COLLAGEN, TYPE IV, ALPHA-2; COL4A2__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-2 CHAIN__:__
Number Sign__:__120100__:__FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 1; FCAS1__:__FCAS;; COLD HYPERSENSITIVITY;; COLD-INDUCED AUTOINFLAMMATORY SYNDROME, FAMILIAL;; COLD URTICARIA, FAMILIAL; FCU;; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 1; CAPS1__:__
Asterisk__:__120105__:__COLIPASE, PANCREATIC; CLPS__:____:__
Asterisk__:__120110__:__COLLAGEN, TYPE X, ALPHA-1; COL10A1__:____:__
Asterisk__:__120120__:__COLLAGEN, TYPE VII, ALPHA-1; COL7A1__:__LONG-CHAIN COLLAGEN;; LC COLLAGEN__:__
Asterisk__:__120130__:__COLLAGEN, TYPE IV, ALPHA-1; COL4A1__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-1 CHAIN__:__ARRESTEN, INCLUDED
Asterisk__:__120131__:__COLLAGEN, TYPE IV, ALPHA-4; COL4A4__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-4 CHAIN__:__
Plus__:__120140__:__COLLAGEN, TYPE II, ALPHA-1; COL2A1__:__COLLAGEN, TYPE II;; COLLAGEN OF CARTILAGE__:__CHONDROCALCIN, INCLUDED;; VITREORETINOPATHY WITH PHALANGEAL EPIPHYSEAL DYSPLASIA, INCLUDED
Plus__:__120150__:__COLLAGEN, TYPE I, ALPHA-1; COL1A1__:__COLLAGEN OF SKIN, TENDON, AND BONE, ALPHA-1 CHAIN__:__COL1A1/PDGFB FUSION GENE, INCLUDED;; OI/EDS COMBINED SYNDROME, INCLUDED
Asterisk__:__120160__:__COLLAGEN, TYPE I, ALPHA-2; COL1A2__:__COLLAGEN OF SKIN, TENDON, AND BONE, ALPHA-2 CHAIN__:__
Asterisk__:__120165__:__COLLAGEN, TYPE XIX, ALPHA-1; COL19A1__:__COLLAGEN, TYPE IX-LIKE; COL9A1L__:__
Caret__:__120170__:__MOVED TO 120190__:____:__
Asterisk__:__120180__:__COLLAGEN, TYPE III, ALPHA-1; COL3A1__:__COLLAGEN, FETAL;; COLLAGEN, BLOOD VESSEL__:__
Asterisk__:__120190__:__COLLAGEN, TYPE V, ALPHA-2; COL5A2__:__AB COLLAGEN__:__
Number Sign__:__120200__:__COLOBOMA, OCULAR, AUTOSOMAL DOMINANT__:__COLOBOMA, UVEORETINAL;; COLOBOMA OF IRIS, CHOROID, AND RETINA; COI__:__
Asterisk__:__120210__:__COLLAGEN, TYPE IX, ALPHA-1; COL9A1__:__COLLAGEN, CARTILAGE-SPECIFIC SHORT;; ALPHA-1(IX) COLLAGEN CHAIN;; CARTILAGE-SPECIFIC SHORT COLLAGEN__:__
Asterisk__:__120215__:__COLLAGEN, TYPE V, ALPHA-1; COL5A1__:____:__
Asterisk__:__120216__:__COLLAGEN, TYPE V, ALPHA-3; COL5A3__:____:__
Asterisk__:__120220__:__COLLAGEN, TYPE VI, ALPHA-1; COL6A1__:__COLLAGEN, INTIMAL;; SHORT-CHAIN COLLAGEN__:__
Asterisk__:__120240__:__COLLAGEN, TYPE VI, ALPHA-2; COL6A2__:____:__
Asterisk__:__120250__:__COLLAGEN, TYPE VI, ALPHA-3; COL6A3__:____:__
Asterisk__:__120251__:__COLLAGEN, TYPE VIII, ALPHA-1; COL8A1__:____:__
Asterisk__:__120252__:__COLLAGEN, TYPE VIII, ALPHA-2; COL8A2__:____:__
Asterisk__:__120260__:__COLLAGEN, TYPE IX, ALPHA-2; COL9A2__:____:__
Asterisk__:__120270__:__COLLAGEN, TYPE IX, ALPHA-3; COL9A3__:____:__
Asterisk__:__120280__:__COLLAGEN, TYPE XI, ALPHA-1; COL11A1__:____:__
Asterisk__:__120290__:__COLLAGEN, TYPE XI, ALPHA-2; COL11A2__:____:__
Percent__:__120300__:__COLOBOMA OF MACULA__:__AGENESIS OF MACULA__:__
Caret__:__120310__:__MOVED TO 120140__:____:__
Asterisk__:__120320__:__COLLAGEN, TYPE XII, ALPHA-1; COL12A1__:____:__
Caret__:__120321__:__MOVED TO 120320__:____:__
Asterisk__:__120324__:__COLLAGEN, TYPE XIV, ALPHA-1; COL14A1__:__UNDULIN; UND__:__
Asterisk__:__120325__:__COLLAGEN, TYPE XV, ALPHA-1; COL15A1__:____:__
Asterisk__:__120326__:__COLLAGEN, TYPE XVI, ALPHA-1; COL16A1__:____:__
Caret__:__120327__:__MOVED TO 113811__:____:__
Asterisk__:__120328__:__COLLAGEN, TYPE XVIII, ALPHA-1; COL18A1__:____:__ENDOSTATIN, INCLUDED
Number Sign__:__120330__:__PAPILLORENAL SYNDROME; PAPRS__:__RENAL-COLOBOMA SYNDROME;; OPTIC NERVE COLOBOMA WITH RENAL DISEASE;; COLOBOMA OF OPTIC NERVE WITH RENAL DISEASE;; OPTIC COLOBOMA, VESICOURETERAL REFLUX, AND RENAL ANOMALIES;; RENAL-COLOBOMA SYNDROME WITH MACULAR ABNORMALITIES;; CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT WITH OR WITHOUT OCULAR ABNORMALITIES;; CAKUT WITH OR WITHOUT OCULAR ABNORMALITIES__:__
Asterisk__:__120340__:__COLLAGEN, TYPE I, ALPHA, RECEPTOR; COL1AR__:__COLLAGEN RECEPTOR; COLR__:__
Asterisk__:__120350__:__COLLAGEN, TYPE XIII, ALPHA-1; COL13A1__:____:__
Asterisk__:__120353__:__MATRIX METALLOPROTEINASE 1; MMP1__:__COLLAGENASE, FIBROBLAST; CLG; CLGN;; COLLAGENASE, INTERSTITIAL__:__
Asterisk__:__120355__:__MATRIX METALLOPROTEINASE 8; MMP8__:__COLLAGENASE I, NEUTROPHIL; CLG1__:__
Asterisk__:__120360__:__MATRIX METALLOPROTEINASE 2; MMP2__:__COLLAGENASE TYPE IV-A; CLG4A;; COLLAGENASE TYPE IV, 72-KD;; GELATINASE, 72-KD;; GELATINASE A;; GELATINASE, NEUTROPHIL__:__
Asterisk__:__120361__:__MATRIX METALLOPROTEINASE 9; MMP9__:__COLLAGENASE TYPE IV-B; CLG4B;; COLLAGENASE TYPE IV, 92-KD;; COLLAGENASE TYPE V;; GELATINASE, 92-KD;; GELATINASE B; GELB__:__
NULL__:__120400__:__COLOBOMA OF MACULA WITH TYPE B BRACHYDACTYLY__:__APICAL DYSTROPHY;; SORSBY SYNDROME__:__
Asterisk__:__120420__:__COLONY-STIMULATING FACTOR 1; CSF1__:__COLONY-STIMULATING FACTOR, MACROPHAGE-SPECIFIC; MCSF__:__
Number Sign__:__120430__:__COLOBOMA OF OPTIC NERVE__:____:__OPTIC NERVE HEAD PITS, BILATERAL CONGENITAL, INCLUDED;; MORNING GLORY DISC ANOMALY, INCLUDED
Number Sign__:__120433__:__COLOBOMA, OCULAR, WITH OR WITHOUT HEARING IMPAIRMENT, CLEFT LIP/PALATE, AND/OR MENTAL RETARDATION; COB1__:____:__
Number Sign__:__120435__:__LYNCH SYNDROME I__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 1; HNPCC1;; COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1; FCC1;; COCA1__:__LYNCH SYNDROME II, INCLUDED
Asterisk__:__120436__:__MutL, E. COLI, HOMOLOG OF, 1; MLH1__:____:__
NULL__:__120440__:__COLONIC VARICES WITHOUT PORTAL HYPERTENSION__:____:__
Percent__:__120450__:__COMEDONES, FAMILIAL DYSKERATOTIC__:____:__
Caret__:__120460__:__MOVED TO 191170__:____:__
Asterisk__:__120470__:__DCC NETRIN 1 RECEPTOR; DCC__:__NETRIN RECEPTOR DCC;; DELETED IN COLORECTAL CARCINOMA;; COLORECTAL CANCER-RELATED CHROMOSOME SEQUENCE 18; CRC18;; CRCR1__:__
NULL__:__120500__:__COMMISSURAL LIP PITS__:____:__
Percent__:__120502__:__BRANCHIOOTIC SYNDROME 2__:__BO SYNDROME 2; BOS2__:__
Asterisk__:__120520__:__MEMBRANE METALLOENDOPEPTIDASE; MME__:__COMMON ACUTE LYMPHOCYTIC LEUKEMIA ANTIGEN; CALLA;; CD10;; NEPRILYSIN;; NEUTRAL ENDOPEPTIDASE, MEMBRANE-ASSOCIATED; NEP;; ENKEPHALINASE;; ATRIOPEPTIDASE__:__
Asterisk__:__120550__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, A CHAIN; C1QA__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, ALPHA POLYPEPTIDE;; COMPLEMENT COMPONENT C1q, A CHAIN;; SERUM C1q__:__
Asterisk__:__120560__:__COMPLEMENT COMPONENT C1q, FIBROBLAST TYPE__:____:__
Asterisk__:__120570__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, B CHAIN; C1QB__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, BETA POLYPEPTIDE;; COMPLEMENT COMPONENT C1q, B CHAIN__:__
Asterisk__:__120575__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, C CHAIN; C1QC__:__COMPLEMENT COMPONENT C1q, C CHAIN;; COMPLEMENT COMPONENT 1, q SUBCOMPONENT, GAMMA POLYPEPTIDE; C1QG__:__
Asterisk__:__120577__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT, RECEPTOR 1; C1QR1__:__CD93 ANTIGEN; CD93;; COMPLEMENT COMPONENT 1q RECEPTOR; C1QR;; COLLECTIN RECEPTOR__:__
Asterisk__:__120580__:__COMPLEMENT COMPONENT 1, s SUBCOMPONENT; C1S__:__COMPLEMENT COMPONENT C1s__:__
Asterisk__:__120620__:__COMPLEMENT COMPONENT RECEPTOR 1; CR1__:__COMPLEMENT COMPONENT 3b/4b RECEPTOR;; C3-BINDING PROTEIN;; C3BR;; C4BR;; CD35__:__
Asterisk__:__120650__:__COMPLEMENT COMPONENT RECEPTOR 2; CR2__:__COMPLEMENT COMPONENT 3d RECEPTOR; C3DR;; EPSTEIN-BARR VIRUS RECEPTOR;; EBV RECEPTOR;; CD21__:__
Asterisk__:__120700__:__COMPLEMENT COMPONENT 3; C3__:____:__C3a, INCLUDED;; C3b, INCLUDED;; C3c, INCLUDED;; C3d, INCLUDED;; ACYLATION-STIMULATING PROTEIN, INCLUDED; ASP, INCLUDED
Number Sign__:__120790__:__COMPLEMENT COMPONENT 4, PARTIAL DEFICIENCY OF__:____:__
Asterisk__:__120810__:__COMPLEMENT COMPONENT 4A; C4A__:__COMPLEMENT COMPONENT 4S; C4S;; ACIDIC C4;; C4, RODGERS FORM;; SLP, MOUSE, HOMOLOG OF; SLP__:__
Asterisk__:__120820__:__COMPLEMENT COMPONENT 4B; C4B__:__COMPLEMENT COMPONENT 4F; C4F;; BASIC C4;; C4, CHIDO FORM__:__
Asterisk__:__120830__:__COMPLEMENT COMPONENT 4-BINDING PROTEIN, ALPHA; C4BPA__:__C4b RECEPTOR; C4BP__:__COMPLEMENT COMPONENT 4-BINDING PROTEIN, ALPHA-LIKE 1, INCLUDED; C4BPAL1, INCLUDED
Asterisk__:__120831__:__COMPLEMENT COMPONENT 4-BINDING PROTEIN, BETA CHAIN; C4BPB__:____:__
Caret__:__120832__:__MOVED TO 120830__:____:__
Asterisk__:__120900__:__COMPLEMENT COMPONENT 5; C5__:____:__
Asterisk__:__120920__:__CD46 ANTIGEN; CD46__:__TROPHOBLAST-LYMPHOCYTE CROSS-REACTIVE ANTIGEN; TLX;; MEMBRANE COFACTOR PROTEIN; MCP;; COMPLEMENT MEMBRANE COFACTOR PROTEIN;; ANTIGEN DEFINED BY MONOCLONAL ANTIBODY TRA-2-10; MIC10__:__
Asterisk__:__120930__:__COMPLEMENT COMPONENT 8, GAMMA SUBUNIT; C8G__:__C8C__:__
Asterisk__:__120940__:__COMPLEMENT COMPONENT 9; C9__:____:__
Asterisk__:__120950__:__COMPLEMENT COMPONENT 8, ALPHA SUBUNIT; C8A__:__C8 ALPHA__:__
Asterisk__:__120960__:__COMPLEMENT COMPONENT 8, BETA SUBUNIT; C8B__:__COMPLEMENT COMPONENT C8B;; C8 BETA__:__
Number Sign__:__120970__:__CONE-ROD DYSTROPHY 2; CORD2__:__CONE-ROD DYSTROPHY; CORD;; CONE-ROD RETINAL DYSTROPHY; CRD; CRD2;; RETINAL CONE-ROD DYSTROPHY; RCRD2__:__
Asterisk__:__120980__:__INTEGRIN, ALPHA-M; ITGAM__:__COMPLEMENT RECEPTOR TYPE 3, ALPHA SUBUNIT; CR3A;; Mac1, ALPHA SUBUNIT; MAC1A;; Mo1, ALPHA SUBUNIT; MO1A;; CD11B__:__
Caret__:__121000__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__121009__:__CONNECTIVE TISSUE GROWTH FACTOR; CTGF__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 8; IGFBP8;; CCN2__:__
Asterisk__:__121010__:__PRO-PLATELET BASIC PROTEIN; PPBP__:__CXC CHEMOKINE LIGAND 7; CXCL7;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 7; SCYB7__:__PLATELET BASIC PROTEIN, INCLUDED; PBP, INCLUDED;; CONNECTIVE TISSUE-ACTIVATING PEPTIDE III, INCLUDED; CTAP3, INCLUDED;; BETA-THROMBOGLOBULIN, INCLUDED; TGB, INCLUDED;; THROMBOGLOBULIN, BETA-1, INCLUDED; TGB1, INCLUDED;; NEUTROPHIL-ACTIVATING PEPTIDE 2, INCLUDED; NAP2, INCLUDED;; THROMBOCIDIN 1, INCLUDED; TC1, INCLUDED;; THROMBOCIDIN 2, INCLUDED; TC2, INCLUDED
Asterisk__:__121011__:__GAP JUNCTION PROTEIN, BETA-2; GJB2__:__GAP JUNCTION PROTEIN, 26-KD;; CONNEXIN 26; CX26__:__
Asterisk__:__121012__:__GAP JUNCTION PROTEIN, ALPHA-4; GJA4__:__GAP JUNCTION PROTEIN, 37-KD;; CONNEXIN 37; CX37__:__
Asterisk__:__121013__:__GAP JUNCTION PROTEIN, ALPHA-5; GJA5__:__GAP JUNCTION PROTEIN, 40-KD;; CONNEXIN 40; CX40__:__
Asterisk__:__121014__:__GAP JUNCTION PROTEIN, ALPHA-1; GJA1__:__GAP JUNCTION PROTEIN, 43-KD;; CONNEXIN 43; CX43;; HEART CONNEXIN__:__
Asterisk__:__121015__:__GAP JUNCTION PROTEIN, ALPHA-3; GJA3__:__GAP JUNCTION PROTEIN, 46-KD;; CONNEXIN 46; CX46__:__
Caret__:__121020__:__MOVED TO 160120__:____:__
Number Sign__:__121050__:__ARTHROGRYPOSIS, DISTAL, TYPE 9; DA9__:__BEALS SYNDROME;; CONTRACTURAL ARACHNODACTYLY, CONGENITAL; CCA__:__
NULL__:__121070__:__ARTHROGRYPOSIS, DISTAL, TYPE 2E__:__CONTRACTURES OF FINGERS AND JAW__:__
Number Sign__:__121200__:__SEIZURES, BENIGN FAMILIAL NEONATAL, 1; BFNS1__:____:__EPILEPSY, BENIGN NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED;; SEIZURES, BENIGN FAMILIAL NEONATAL, 1, AND/OR MYOKYMIA, INCLUDED
Number Sign__:__121201__:__SEIZURES, BENIGN FAMILIAL NEONATAL, 2; BFNS2__:__CONVULSIONS, BENIGN FAMILIAL NEONATAL, 2; BFNC2__:__
Percent__:__121210__:__FEBRILE SEIZURES, FAMILIAL, 1; FEB1__:__CONVULSIONS, FAMILIAL FEBRILE, 1__:__
Caret__:__121250__:__MOVED TO 300088__:____:__
NULL__:__121270__:__COPPER DEFICIENCY, FAMILIAL BENIGN__:____:__
Number Sign__:__121300__:__COPROPORPHYRIA, HEREDITARY; HCP__:__COPROPORPHYRINOGEN OXIDASE DEFICIENCY;; CPOX DEFICIENCY;; CPO DEFICIENCY;; CPX DEFICIENCY__:__HARDEROPORPHYRIA, INCLUDED
NULL__:__121350__:__CORACOCLAVICULAR JOINT, ANOMALOUS__:____:__
Asterisk__:__121360__:__CORE-BINDING FACTOR, BETA SUBUNIT; CBFB__:__POLYOMAVIRUS ENHANCER-BINDING PROTEIN 2-BETA; PEBP2B__:__CBFB/MYH11 FUSION GENE, INCLUDED
Percent__:__121390__:__CORNEA GUTTATA WITH ANTERIOR POLAR CATARACTS__:____:__
Percent__:__121400__:__CORNEA PLANA 1, AUTOSOMAL DOMINANT; CNA1__:____:__
NULL__:__121450__:__CORNEAL DEGENERATION, RIBBONLIKE, WITH DEAFNESS__:__BAND KERATOPATHY WITH DEAFNESS__:__
Caret__:__121700__:__MOVED TO 122000__:____:__
Number Sign__:__121800__:__SCHNYDER CORNEAL DYSTROPHY; SCCD__:__CORNEAL DYSTROPHY, SCHNYDER;; SCHNYDER CRYSTALLINE CORNEAL DYSTROPHY;; CORNEAL DYSTROPHY, CRYSTALLINE, OF SCHNYDER__:__
Number Sign__:__121820__:__CORNEAL DYSTROPHY, EPITHELIAL BASEMENT MEMBRANE; EBMD__:__CORNEAL DYSTROPHY, ANTERIOR BASEMENT MEMBRANE;; COGAN CORNEAL DYSTROPHY;; CORNEAL DYSTROPHY, MAP-DOT-FINGERPRINT TYPE;; CORNEAL DYSTROPHY, MICROCYSTIC__:__
Number Sign__:__121850__:__CORNEAL DYSTROPHY, FLECK__:__CFD;; FLECK CORNEAL DYSTROPHY; FCD;; CORNEAL DYSTROPHY, FRANCOIS-NEETENS SPECKLED OR FLECKED__:__
Number Sign__:__121900__:__CORNEAL DYSTROPHY, GROENOUW TYPE I; CDGG1__:__GRANULAR CORNEAL DYSTROPHY, TYPE I; GCD1;; CORNEAL DYSTROPHY, PUNCTATE OR NODULAR__:__
Number Sign__:__122000__:__CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 1; PPCD1__:__POSTERIOR POLYMORPHOUS CORNEAL DYSTROPHY; PPCD;; CORNEAL DYSTROPHY, HEREDITARY POLYMORPHOUS POSTERIOR;; MAUMENEE CORNEAL DYSTROPHY;; CORNEAL ENDOTHELIAL DYSTROPHY 1, AUTOSOMAL DOMINANT, FORMERLY; CHED1, FORMERLY__:__
Number Sign__:__122100__:__CORNEAL DYSTROPHY, MEESMANN; MECD__:__CORNEAL DYSTROPHY, MEESMANN EPITHELIAL;; MEESMANN CORNEAL DYSTROPHY;; CORNEAL DYSTROPHY, JUVENILE EPITHELIAL, OF MEESMANN__:__
Number Sign__:__122200__:__CORNEAL DYSTROPHY, LATTICE TYPE I; LCD1__:__LCD;; LATTICE CORNEAL DYSTROPHY, TYPE I;; CDL1__:__
Number Sign__:__122400__:__EPITHELIAL RECURRENT EROSION DYSTROPHY; ERED__:__CORNEAL EROSIONS, RECURRING HEREDITARY__:__
NULL__:__122430__:__CORNEAL HYPESTHESIA WITH RETINAL ABNORMALITIES, SENSORINEURAL DEAFNESS, UNUSUAL FACIES, PERSISTENT DUCTUS ARTERIOSUS, AND MENTAL RETARDATION__:__RAMOS-ARROYO SYNDROME__:__
NULL__:__122440__:__CORNEODERMATOOSSEOUS SYNDROME__:__CDO SYNDROME;; CORNEAL DYSTROPHY, EPITHELIAL, WITH SKIN AND SKELETAL CHANGES__:__
Percent__:__122450__:__CORNEAL HYPESTHESIA, FAMILIAL__:__TRIGEMINAL ANESTHESIA, FAMILIAL__:__
NULL__:__122455__:__CORONARY ARTERY DISSECTION, SPONTANEOUS__:____:__
Percent__:__122460__:__HUMAN CORONAVIRUS SENSITIVITY; HCVS__:__CORONAVIRUS 229E SUSCEPTIBILITY; CVS__:__
Number Sign__:__122470__:__CORNELIA DE LANGE SYNDROME 1; CDLS1__:__CDL; CDLS;; TYPUS DEGENERATIVUS AMSTELODAMENSIS;; DE LANGE SYNDROME;; BRACHMANN-DE LANGE SYNDROME; BDLS__:__
Caret__:__122480__:__MOVED TO 166740__:____:__
Asterisk__:__122500__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 6; SERPINA6__:__CORTICOSTEROID-BINDING GLOBULIN; CBG;; TRANSCORTIN__:__
NULL__:__122550__:__CORTICOSTERONE SIDE-CHAIN ISOMERASE; CSCI__:____:__
Asterisk__:__122559__:__CORTICOTROPIN-RELEASING HORMONE-BINDING PROTEIN; CRHBP__:__CORTICOTROPIN-RELEASING FACTOR-BINDING PROTEIN; CRFBP__:__
Asterisk__:__122560__:__CORTICOTROPIN-RELEASING HORMONE; CRH__:__CORTICOTROPIN-RELEASING FACTOR; CRF__:__
Asterisk__:__122561__:__CORTICOTROPIN-RELEASING HORMONE RECEPTOR 1; CRHR1__:__CORTICOTROPIN-RELEASING FACTOR RECEPTOR; CRFR1;; CORTICOTROPIN-RELEASING HORMONE RECEPTOR; CRHR__:__
NULL__:__122580__:__COSTOCORACOID LIGAMENT, CONGENITALLY SHORT__:____:__
Number Sign__:__122600__:__SPONDYLOCOSTAL DYSOSTOSIS 5; SCDO5__:__SCOLIOSIS, CONGENITAL, WITH OR WITHOUT RIB ANOMALIES;; SPONDYLOCOSTAL DYSPLASIA;; SPONDYLOTHORACIC DYSOSTOSIS;; COSTOVERTEBRAL SEGMENTATION ANOMALIES__:__
Number Sign__:__122700__:__COUMARIN RESISTANCE__:__COUMARIN, POOR METABOLISM OF;; WARFARIN RESISTANCE__:__COUMARIN SENSITIVITY, INCLUDED;; WARFARIN SENSITIVITY, INCLUDED
Plus__:__122720__:__CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 6; CYP2A6__:__COUMARIN 7-HYDROXYLASE;; CYTOCHROME P450, PHENOBARBITAL-INDUCIBLE; P450PB;; CYP2A3, FORMERLY__:__TEGAFUR, POOR METABOLISM OF, INCLUDED
Percent__:__122750__:__COXA VARA__:____:__
NULL__:__122780__:__COXOAURICULAR SYNDROME__:____:__
NULL__:__122850__:__CRANIOACROFACIAL SYNDROME__:____:__
Number Sign__:__122860__:__CRANIODIAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CDD__:____:__
Number Sign__:__122880__:__CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS__:____:__
NULL__:__122900__:__CRANIOFACIAL DYSOSTOSIS WITH DIAPHYSEAL HYPERPLASIA__:__OSTEOSCLEROSIS, STANESCU TYPE__:__
Caret__:__122920__:__MOVED TO 304110__:____:__
Number Sign__:__123000__:__CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; CMDD__:__CMD;; CRANIOMETAPHYSEAL DYSPLASIA, JACKSON TYPE; CMDJ__:__
NULL__:__123050__:__CRANIORHINY__:____:__
Number Sign__:__123100__:__CRANIOSYNOSTOSIS 1; CRS1__:__CRS;; CRANIOSTENOSIS__:__
Asterisk__:__123101__:__MUSCLE SEGMENT HOMEOBOX, DROSOPHILA, HOMOLOG OF, 2; MSX2__:__MSH, DROSOPHILA, HOMOLOG OF, 2__:__
Number Sign__:__123150__:__JACKSON-WEISS SYNDROME; JWS__:__CRANIOSYNOSTOSIS, MIDFACIAL HYPOPLASIA, AND FOOT ABNORMALITIES__:__
Percent__:__123155__:__HYDROCEPHALUS, AUTOSOMAL DOMINANT; HDCPH1__:____:__
Asterisk__:__123260__:__C-REACTIVE PROTEIN, PENTRAXIN-RELATED; CRP__:__PENTRAXIN 1, SHORT; PTX1__:__
NULL__:__123270__:__CREATINE KINASE, BRAIN TYPE, ECTOPIC EXPRESSION OF; CKBE__:____:__
Asterisk__:__123280__:__CREATINE KINASE, BRAIN TYPE; CKB__:__BRAIN CREATINE KINASE; BCK__:__
Asterisk__:__123290__:__CREATINE KINASE, MITOCHONDRIAL 1B; CKMT1B__:__CREATINE KINASE, UBIQUITOUS MITOCHONDRIAL; UMTCK;; MTCK, UBIQUITOUS;; MTCK, PLACENTAL;; CREATINE KINASE, MITOCHONDRIAL 1, CENTROMERIC COPY;; CKMT1, CENTROMERIC COPY;; CREATINE KINASE, MITOCHONDRIAL 1, FORMERLY; CKMT1, FORMERLY__:__
Asterisk__:__123295__:__CREATINE KINASE, MITOCHONDRIAL 2; CKMT2__:__CREATINE KINASE, SARCOMERIC MITOCHONDRIAL; CKMTS__:__
Asterisk__:__123310__:__CREATINE KINASE, MUSCLE TYPE; CKM__:__CKMM__:__
Number Sign__:__123320__:__CREATINE PHOSPHOKINASE, ELEVATED SERUM__:__CPK, ELEVATED SERUM;; HYPERCKEMIA, IDIOPATHIC__:__
Number Sign__:__123400__:__CREUTZFELDT-JAKOB DISEASE; CJD__:__CREUTZFELDT-JAKOB DISEASE, FAMILIAL__:__CREUTZFELDT-JAKOB DISEASE, SPORADIC, INCLUDED; sCJD, INCLUDED;; CREUTZFELDT-JAKOB DISEASE, VARIANT, INCLUDED; vCJD, INCLUDED;; CREUTZFELDT-JAKOB DISEASE, HEIDENHAIN VARIANT, INCLUDED
Number Sign__:__123450__:__CRI-DU-CHAT SYNDROME__:__CAT CRY SYNDROME;; CHROMOSOME 5p DELETION SYNDROME__:__
Number Sign__:__123500__:__CROUZON SYNDROME__:__CRANIOFACIAL DYSOSTOSIS, TYPE I; CFD1;; CROUZON CRANIOFACIAL DYSOSTOSIS__:__
NULL__:__123540__:__CRYOFIBRINOGENEMIA, FAMILIAL PRIMARY__:____:__
Percent__:__123550__:__CRYOGLOBULINEMIA, FAMILIAL MIXED__:__MELTZER SYNDROME__:__
Caret__:__123555__:__MOVED TO 125220__:____:__
NULL__:__123557__:__CRYPTOTIA, FAMILIAL__:____:__
NULL__:__123560__:__CRYPTOMICROTIA-BRACHYDACTYLY SYNDROME__:____:__
Percent__:__123570__:__CRYPTOPHTHALMOS, UNILATERAL OR BILATERAL, ISOLATED__:__ANKYLOBLEPHARON, SIMPLE;; CRYPTOPHTHALMOS WITH MICROPHTHALMIA AND PETERS ANOMALY__:__
Asterisk__:__123580__:__CRYSTALLIN, ALPHA-A; CRYAA__:__CRYSTALLIN, ALPHA-1; CRYA1;; HEAT-SHOCK PROTEIN BETA-4; HSPB4__:__
Asterisk__:__123590__:__CRYSTALLIN, ALPHA-B; CRYAB__:__CRYSTALLIN, ALPHA-2; CRYA2;; HEAT-SHOCK PROTEIN BETA-5; HSPB5__:__
Asterisk__:__123610__:__CRYSTALLIN, BETA-A1; CRYBA1__:__CRYSTALLIN, BETA-1; CRYB1;; CRYSTALLIN, BETA-A1/A3__:__
Asterisk__:__123620__:__CRYSTALLIN, BETA-B2; CRYBB2__:__CRYSTALLIN, BETA-2; CRYB2__:__CRYBB2P1, INCLUDED
Asterisk__:__123630__:__CRYSTALLIN, BETA-B3; CRYBB3__:__CRYSTALLIN, BETA-3; CRYB3__:__
Asterisk__:__123631__:__CRYSTALLIN, BETA-A4; CRYBA4__:____:__
Asterisk__:__123660__:__CRYSTALLIN, GAMMA-A; CRYGA__:__CRYSTALLIN, GAMMA-1; CRYG1__:__CRYSTALLIN, GAMMA-E PSEUDOGENE 1, INCLUDED; CRYGEP1, INCLUDED;; CRYG5, INCLUDED
Asterisk__:__123670__:__CRYSTALLIN, GAMMA-B; CRYGB__:__CRYSTALLIN, GAMMA-2; CRYG2__:__
Asterisk__:__123680__:__CRYSTALLIN, GAMMA-C; CRYGC__:__CRYSTALLIN, GAMMA-3; CRYG3__:__
Asterisk__:__123690__:__CRYSTALLIN, GAMMA-D; CRYGD__:__CRYSTALLIN, GAMMA-4; CRYG4__:__
Asterisk__:__123691__:__CRYSTALLIN, ZETA; CRYZ__:__QUINONE OXIDOREDUCTASE__:__
Asterisk__:__123695__:__PHOSPHATE CYTIDYLYLTRANSFERASE 1, CHOLINE, ALPHA ISOFORM; PCYT1A__:__PHOSPHATE CYTIDYLYLTRANSFERASE 1, CHOLINE; PCYT1;; CYTIDYLYLTRANSFERASE, CTP-PHOSPHOCHOLINE; CTPCT;; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE;; CCT-ALPHA__:__
Number Sign__:__123700__:__CUTIS LAXA, AUTOSOMAL DOMINANT 1; ADCL1__:____:__
Caret__:__123710__:__MOVED TO 123660__:____:__
Caret__:__123720__:__MOVED TO 123660__:____:__
Asterisk__:__123730__:__CRYSTALLIN, GAMMA-S; CRYGS__:__CRYSTALLIN, GAMMA-8; CRYG8__:__
Asterisk__:__123740__:__CRYSTALLIN, MU; CRYM__:____:__
Number Sign__:__123790__:__BEARE-STEVENSON CUTIS GYRATA SYNDROME; BSTVS__:__BEARE-STEVENSON SYNDROME;; CUTIS GYRATA SYNDROME OF BEARE AND STEVENSON__:__
Asterisk__:__123803__:__ACTIVATING TRANSCRIPTION FACTOR 1; ATF1__:__cAMP-DEPENDENT TRANSCRIPTION FACTOR 1__:__ATF1/EWS FUSION GENE, INCLUDED;; ATF1/FUS FUSION GENE, INCLUDED
Asterisk__:__123805__:__PHOSPHODIESTERASE 3A, cGMP-INHIBITED; PDE3A__:__cAMP PHOSPHODIESTERASE, MYOCARDIAL cGMP-INHIBITED__:__
Asterisk__:__123810__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 1; CREB1__:__CREB__:__CREB/EWS FUSION GENE, INCLUDED
Asterisk__:__123811__:__ACTIVATING TRANSCRIPTION FACTOR 2; ATF2__:__CREBP1;; cAMP RESPONSE ELEMENT-BINDING PROTEIN 2, FORMERLY; CREB2, FORMERLY__:__
Asterisk__:__123812__:__cAMP RESPONSE ELEMENT MODULATOR; CREM__:____:__INDUCIBLE cAMP EARLY REPRESSOR, INCLUDED; ICER, INCLUDED
Asterisk__:__123825__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, ALPHA-1; CNGA1__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, PHOTORECEPTOR, cGMP-GATED, 1; CNCG1;; CNCG;; RETINAL ROD cGMP-GATED CHANNEL, ALPHA SUBUNIT__:__
Asterisk__:__123828__:__CYCLIN-DEPENDENT KINASE 3; CDK3__:__CELL DIVISION KINASE 3__:__
Asterisk__:__123829__:__CYCLIN-DEPENDENT KINASE 4; CDK4__:__CELL DIVISION KINASE 4;; PSK-J3__:__
Asterisk__:__123830__:__CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CNP__:__CNP1;; 2-PRIME,3-PRIME CYCLIC NUCLEOTIDE 3-PRIME PHOSPHOHYDROLASE__:__
Asterisk__:__123831__:__CYCLIN-DEPENDENT KINASE 5; CDK5__:__CELL DIVISION KINASE 5;; PSSALRE__:__
Asterisk__:__123832__:__CYCLIN-DEPENDENT KINASE INHIBITOR 3; CDKN3__:__CYCLIN-DEPENDENT KINASE INTERACTOR 1; CDI1__:__
Asterisk__:__123833__:__CYCLIN D2; CCND2__:____:__
Asterisk__:__123834__:__CYCLIN D3; CCND3__:____:__
Asterisk__:__123835__:__CYCLIN A2; CCNA2__:__CYCLIN A; CCNA__:__
Asterisk__:__123836__:__CYCLIN B1; CCNB1__:__CYCLIN B; CCNB__:__
Asterisk__:__123837__:__CYCLIN E1; CCNE1__:__CYCLIN E; CCNE__:__
Asterisk__:__123838__:__CYCLIN C; CCNC__:____:__
Caret__:__123839__:__MOVED TO 600262__:____:__
Asterisk__:__123840__:__PEPTIDYL-PROLYL ISOMERASE A; PPIA__:__CYCLOPHILIN A; CYPA;; CYPH__:__
Asterisk__:__123841__:__PEPTIDYL-PROLYL ISOMERASE B; PPIB__:__CYCLOPHILIN B; CYPB__:__
Asterisk__:__123842__:__PEPTIDYL-PROLYL ISOMERASE C; PPIC__:__CYCLOPHILIN C; CYPC__:__
Caret__:__123850__:__MOVED TO 132700__:____:__
NULL__:__123853__:__CYPRUS FACIAL NEUROMUSCULOSKELETAL SYNDROME__:____:__
Asterisk__:__123855__:__CYSTATIN 1; CST1__:__CYSTATIN SN__:__
Asterisk__:__123856__:__CYSTATIN 2; CST2__:__CYSTATIN SA__:__
Asterisk__:__123857__:__CYSTATIN 4; CST4__:__CYSTATIN S__:__
Asterisk__:__123858__:__CYSTATIN 5; CST5__:__CYSTATIN D__:__
Asterisk__:__123859__:__CYSTEINYL-tRNA SYNTHETASE; CARS__:__CYSRS__:__CARS/ALK FUSION GENE, INCLUDED
Asterisk__:__123860__:__CYTIDINE 5-PRIME TRIPHOSPHATE SYNTHETASE 1; CTPS1__:__CTPS;; CTP SYNTHETASE;; CTP SYNTHASE__:__
Asterisk__:__123864__:__CYTOCHROME c OXIDASE, SUBUNIT 4I1; COX4I1__:__CYTOCHROME c OXIDASE, SUBUNIT IV, ISOFORM 1;; CYTOCHROME c OXIDASE, SUBUNIT IV; COX4__:__
Asterisk__:__123866__:__CYTOCHROME c OXIDASE, SUBUNIT 5B; COX5B__:__CYTOCHROME c OXIDASE, SUBUNIT Vb__:__
Asterisk__:__123870__:__CYTOCHROME c OXIDASE, SUBUNIT 8A; COX8A__:__CYTOCHROME c OXIDASE, SUBUNIT VIII, A__:__
Asterisk__:__123875__:__CYSTEINE-RICH INTESTINAL PROTEIN 1; CRIP1__:__CYSTEINE-RICH INTESTINAL PROTEIN; CRIP;; CYSTEINE-RICH HEART PROTEIN; CRHP__:__
Asterisk__:__123876__:__CYSTEINE- AND GLYCINE-RICH PROTEIN 1; CSRP1__:__CYSTEINE-RICH PROTEIN 1; CRP1;; CYSTEINE-RICH PROTEIN; CSRP; CRP__:__
NULL__:__123880__:__CYSTIC ANGIOMATOSIS OF BONE, DIFFUSE__:__GORHAM-STOUT DISEASE; GSD;; OSTEOLYSIS, MASSIVE__:__
Asterisk__:__123885__:__S100 CALCIUM-BINDING PROTEIN A8; S100A8__:__CYSTIC FIBROSIS ANTIGEN; CFAG;; CALGRANULIN A; CAGA; CGLA;; MYELOID-RELATED PROTEIN 8; MRP8__:__S100A8/S100A9 COMPLEX, INCLUDED;; CALPROTECTIN, INCLUDED
Asterisk__:__123886__:__S100 CALCIUM-BINDING PROTEIN A9; S100A9__:__CYSTIC FIBROSIS ANTIGEN B;; CALGRANULIN B; CAGB; CGLB;; MYELOID-RELATED PROTEIN 14; MRP14__:__S100A9/S100A8 COMPLEX, INCLUDED;; CALPROTECTIN, INCLUDED
Asterisk__:__123889__:__INTERLEUKIN 10 RECEPTOR, BETA; IL10RB__:__IL10R2;; CYTOKINE RECEPTOR FAMILY II, MEMBER 4; CRFB4__:__
Asterisk__:__123890__:__CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4; CTLA4__:__CD152__:__CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4, SOLUBLE ISOFORM, INCLUDED
Asterisk__:__123900__:__EZRIN; EZR__:__VILLIN 2; VIL2;; CYTOVILLIN; CVIL; CVL__:__
Asterisk__:__123910__:__GRANZYME B; GZMB__:__CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED SERINE ESTERASE 1; CTLA1;; GRANZYME 2;; PROTEASE, SERINE, B; CSPB;; CATHEPSIN G-LIKE 1; CGL1__:__
Asterisk__:__123920__:__CYTIDINE DEAMINASE; CDA__:____:__
Asterisk__:__123930__:__CYTOCHROME P450, SUBFAMILY IIB, POLYPEPTIDE 6; CYP2B6__:__CYTOCHROME P450, PHENOBARBITAL-INDUCIBLE__:__
Asterisk__:__123940__:__KERATIN 4, TYPE II; KRT4__:__K4;; KB4;; CYTOKERATIN 4; CYK4; CK4__:__
Caret__:__123950__:__MOVED TO 250790__:____:__
Caret__:__123960__:__MOVED TO 122720__:____:__
Asterisk__:__123970__:__CYTOCHROME C, SOMATIC; CYCS__:__CYTOCHROME C; CYC__:__
Asterisk__:__123980__:__CYTOCHROME C1; CYC1__:____:__
Asterisk__:__123995__:__CYTOCHROME c OXIDASE, SUBUNIT 7A1; COX7A1__:__CYTOCHROME c OXIDASE, SUBUNIT VIIa, POLYPEPTIDE 1;; CYTOCHROME c OXIDASE, SUBUNIT VIIa, MUSCLE ISOFORM; COX7AM__:__
Asterisk__:__123996__:__CYTOCHROME c OXIDASE, SUBUNIT 7A2; COX7A2__:__CYTOCHROME c OXIDASE, SUBUNIT VIIa, POLYPEPTIDE 2;; CYTOCHROME c OXIDASE, SUBUNIT VIIa, LIVER ISOFORM 1;; COX7AL; COX7AL1__:__
NULL__:__123997__:__CYTOCHROME c OXIDASE, SUBUNIT 7A2, PSEUDOGENE 2; COX7A2P2__:__CYTOCHROME c OXIDASE, SUBUNIT VIIa, POLYPEPTIDE 3; COX7A3;; CYTOCHROME c OXIDASE, SUBUNIT VIIa, LIVER ISOFORM 2; COX7AL2__:__
Number Sign__:__124000__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 1; MC3DN1__:____:__
Asterisk__:__124010__:__CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 4; CYP3A4__:__CYP3; CYP3A;; P450, FAMILY III;; P450-III, STEROID-INDUCIBLE;; GLUCOCORTICOID-INDUCIBLE P450; P450C3;; CYTOCHROME P450PCN1;; NIFEDIPINE OXIDASE__:__
Asterisk__:__124015__:__CYTOCHROME P450 OXIDOREDUCTASE; POR__:__CYTOCHROME P450 REDUCTASE__:__
Asterisk__:__124020__:__CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19__:__MEPHENYTOIN 4-PRIME-HYDROXYLASE;; P450C2C;; CYP2C__:__
Asterisk__:__124030__:__CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6__:__CPD6;; P450DB1;; DEBRISOQUINE 4-HYDROXYLASE__:__
Asterisk__:__124040__:__CYTOCHROME P450, SUBFAMILY IIE; CYP2E1__:__P450C2E;; ETHANOL-INDUCIBLE P450__:__
Asterisk__:__124050__:__D-AMINO ACID OXIDASE; DAO__:__DAMOX;; DAAO__:__
Plus__:__124060__:__CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 2; CYP1A2__:__CYTOCHROME P-450, AROMATIC COMPOUND-INDUCIBLE;; DIOXIN-INDUCIBLE P3-450__:__PHENACETIN METABOLISM, DEFECT IN, INCLUDED;; PHENACETIN O-DEETHYLASE, DEFICIENCY OF, INCLUDED
Asterisk__:__124070__:__CYTOCHROME P450, SUBFAMILY IIF, POLYPEPTIDE 1; CYP2F1__:____:__
Asterisk__:__124075__:__CYTOCHROME P450, SUBFAMILY IVB, MEMBER 1; CYP4B1__:____:__
Asterisk__:__124080__:__CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 2; CYP11B2__:__STEROID 11/18-BETA-HYDROXYLASE;; STEROID 18-OXIDASE;; ALDOSTERONE SYNTHASE; ALDOS__:__CORTICOSTERONE METHYLOXIDASE I, INCLUDED;; CMO I, INCLUDED;; CORTICOSTERONE METHYLOXIDASE II, INCLUDED;; CMO II, INCLUDED;; ALDOSTERONE TO RENIN RATIO, INCREASED, INCLUDED
Asterisk__:__124089__:__CYTOCHROME c OXIDASE, SUBUNIT 6B1; COX6B1__:__CYTOCHROME c OXIDASE, SUBUNIT VIb, POLYPEPTIDE 1;; CYTOCHROME c OXIDASE, SUBUNIT VIb; COX6B__:__
Asterisk__:__124090__:__CYTOCHROME c OXIDASE, SUBUNIT 6C; COX6C__:__CYTOCHROME c OXIDASE, SUBUNIT VIc__:__COX6C/HMGIC FUSION GENE, INCLUDED
Asterisk__:__124092__:__INTERLEUKIN 10; IL10__:__CYTOKINE SYNTHESIS INHIBITORY FACTOR; CSIF__:__
Asterisk__:__124095__:__CYTOPLASMIC TYROSINE KINASE; CSK__:__c-SRC TYROSINE KINASE__:__
Asterisk__:__124097__:__D SITE OF ALBUMIN PROMOTER-BINDING PROTEIN; DBP__:__DABP;; TRANSCRIPTION FACTOR DBP__:__
NULL__:__124100__:__DANUBIAN ENDEMIC FAMILIAL NEPHROPATHY__:__DEFN;; BALKAN ENDEMIC NEPHROPATHY; BEN;; NEPHROPATHIA EPIDEMICA__:__
Number Sign__:__124200__:__DARIER-WHITE DISEASE; DAR__:__KERATOSIS FOLLICULARIS;; DARIER DISEASE; DD__:__DARIER DISEASE, ACRAL HEMORRHAGIC TYPE, INCLUDED;; DARIER DISEASE, SEGMENTAL, INCLUDED
Percent__:__124300__:__DARWINIAN TUBERCLE OF PINNA__:__DARWINIAN POINT OF PINNA__:__DARWINIAN NOTCH, INCLUDED
NULL__:__124400__:__DARWINIAN TUBERCLE OF PINNA__:____:__
Asterisk__:__124450__:__D-ASPARTATE OXIDASE; DDO__:__DASOX__:__
Number Sign__:__124480__:__DEAFNESS, CONGENITAL, WITH ONYCHODYSTROPHY, AUTOSOMAL DOMINANT; DDOD__:__DDOD SYNDROME__:__
NULL__:__124490__:__DEAFNESS, CONDUCTIVE STAPEDIAL, WITH EAR MALFORMATION AND FACIAL PALSY__:____:__
Number Sign__:__124500__:__VOHWINKEL SYNDROME; VOWNKL__:__DEAFNESS, CONGENITAL, WITH KERATOPACHYDERMIA AND CONSTRICTIONS OF FINGERS AND TOES;; MUTILATING KERATODERMA;; KERATODERMA HEREDITARIUM MUTILANS; KHM__:__
Caret__:__124580__:__REMOVED FROM DATABASE__:____:__
Percent__:__124700__:__DEAFNESS, MID-TONE NEURAL__:____:__
Caret__:__124800__:__MOVED TO 600994__:____:__
Number Sign__:__124900__:__DEAFNESS, AUTOSOMAL DOMINANT 1; DFNA1__:__KONIGSMARK SYNDROME;; DEAFNESS, AUTOSOMAL DOMINANT 1, WITH OR WITHOUT THROMBOCYTOPENIA__:__
Caret__:__124910__:__MOVED TO 124900__:____:__
NULL__:__124950__:__DEAFNESS, SENSORINEURAL, WITH PERIPHERAL NEUROPATHY AND ARTERIAL DISEASE__:____:__
NULL__:__125000__:__DEAFNESS, UNILATERAL__:____:__
NULL__:__125050__:__DEAFNESS WITH ANHIDROTIC ECTODERMAL DYSPLASIA__:____:__
Caret__:__125100__:__MOVED TO 602588__:____:__
Asterisk__:__125220__:__DEFENSIN, ALPHA, 1; DEFA1__:__DEFENSIN 1; DEF1;; HUMAN NEUTROPHIL PEPTIDE 1; HNP1;; MYELOID-RELATED SEQUENCE; MRS__:__DEFENSIN, ALPHA, 2, INCLUDED; DEFA2, INCLUDED;; HUMAN NEUTROPHIL PEPTIDE 2, INCLUDED; HNP2, INCLUDED;; CRYPTDIN, INCLUDED;; RETROCYCLIN, INCLUDED
NULL__:__125230__:__DEAFNESS-CRANIOFACIAL SYNDROME__:____:__
Asterisk__:__125240__:__CD55 ANTIGEN; CD55__:__DECAY-ACCELERATING FACTOR FOR COMPLEMENT; DAF__:__
Number Sign__:__125250__:__OPTIC ATROPHY WITH OR WITHOUT DEAFNESS, OPHTHALMOPLEGIA, MYOPATHY, ATAXIA, AND NEUROPATHY__:__DOMINANT OPTIC ATROPHY PLUS SYNDROME; DOA+__:__
Asterisk__:__125255__:__DECORIN; DCN__:__DERMATAN SULFATE PROTEOGLYCAN 2; DSPG2;; PROTEOGLYCAN II;; PG II;; PG40__:__
Percent__:__125260__:__DEFECTIVE INTERFERING PARTICLE INDUCTION, CONTROL OF__:__DIPI, CONTROL OF;; HOMOLOGOUS VIRAL INTERFERENCE;; VESICULAR STOMATITIS VIRUS DEFECTIVE INTERFERING PARTICLE REPRESSOR; VDI__:__
Asterisk__:__125263__:__SULFOTRANSFERASE FAMILY 2A, DEHYDROEPIANDROSTERONE-PREFERRING, MEMBER 1; SULT2A1__:__SULFOTRANSFERASE, DEHYDROEPIANDROSTERONE-PREFERRING; STD;; DHEA SULFOTRANSFERASE; DHEAST;; DEHYDROEPIANDROSTERONE SULFOTRANSFERASE__:__
Asterisk__:__125264__:__DEK ONCOGENE; DEK__:__D6S231E__:__DEK/NUP214 FUSION GENE, INCLUDED
Asterisk__:__125265__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 5; REEP5__:__DELETED IN POLYPOSIS 1; DP1;; TB2;; D5S346;; YOP1, S. CEREVISIAE, HOMOLOG OF; YOP1;; CHROMOSOME 5 OPEN READING FRAME 18; C5ORF18__:__
Asterisk__:__125270__:__DELTA-AMINOLEVULINATE DEHYDRATASE; ALAD__:__ALADH;; PORPHOBILINOGEN SYNTHASE; PBGS__:__
NULL__:__125280__:__DENS EVAGINATUS__:____:__
Asterisk__:__125290__:__DELTA-AMINOLEVULINATE SYNTHASE 1; ALAS1__:__ALAS;; ALAS, HOUSEKEEPING TYPE; ALASH__:__
NULL__:__125300__:__DENS IN DENTE AND PALATAL INVAGINATIONS__:____:__
Asterisk__:__125305__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.9; EPB49__:__DEMATIN__:__
Number Sign__:__125310__:__CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY, TYPE 1; CADASIL1__:__CADASIL;; DEMENTIA, HEREDITARY MULTI-INFARCT TYPE;; CASIL__:__
NULL__:__125320__:__DEMENTIA/PARKINSONISM WITH NON-ALZHEIMER AMYLOID PLAQUES__:____:__
Number Sign__:__125350__:__FAILURE OF TOOTH ERUPTION, PRIMARY; PFE__:__PRIMARY FAILURE OF ERUPTION, NONSYNDROMIC;; PRIMARY RETENTION OF TEETH;; UNERUPTED SECOND PRIMARY MOLAR;; POSTERIOR OPENBITE MALOCCLUSION, FAMILIAL;; DENTAL NONERUPTION__:__
Number Sign__:__125370__:__DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA__:__MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA__:__
Number Sign__:__125400__:__DENTIN DYSPLASIA, TYPE I; DTDP1__:__DENTIN DYSPLASIA, SHIELDS TYPE I;; ROOTLESS TEETH;; RADICULAR DENTIN DYSPLASIA__:__DENTIN DYSPLASIA, TYPE I, WITH EXTREME MICRODONTIA AND MISSHAPEN TEETH, INCLUDED
Number Sign__:__125420__:__DENTIN DYSPLASIA, TYPE II; DTDP2__:__DENTIN DYSPLASIA, SHIELDS TYPE II;; CORONAL DENTIN DYSPLASIA;; ANOMALOUS DYSPLASIA OF DENTIN;; PULPAL DYSPLASIA;; PULP STONES__:__
Percent__:__125440__:__DENTIN DYSPLASIA WITH SCLEROTIC BONES__:____:__
Asterisk__:__125450__:__DEOXYCYTIDINE KINASE; DCK__:____:__
NULL__:__125460__:__DEOXYRIBOSE-5-PHOSPHATE ALDOLASE DEFICIENCY__:____:__
Percent__:__125480__:__MAJOR AFFECTIVE DISORDER 1; MAFD1__:__MANIC-DEPRESSIVE PSYCHOSIS; MD1;; BIPOLAR AFFECTIVE DISORDER; BPAD;; MANIC-DEPRESSIVE PSYCHOSIS, AUTOSOMAL__:__
Asterisk__:__125485__:__DENTIN SIALOPHOSPHOPROTEIN; DSPP__:____:__DENTIN PHOSPHOPROTEIN, INCLUDED; DPP, INCLUDED;; DENTIN PHOSPHOPHORYN, INCLUDED;; DENTIN SIALOPROTEIN, INCLUDED; DSP, INCLUDED
Number Sign__:__125490__:__DENTINOGENESIS IMPERFECTA 1; DGI1__:__OPALESCENT DENTIN;; DENTINOGENESIS IMPERFECTA WITHOUT OSTEOGENESIS IMPERFECTA;; OPALESCENT TEETH WITHOUT OSTEOGENESIS IMPERFECTA;; DENTINOGENESIS IMPERFECTA, SHIELDS TYPE II;; DGI-II;; CAPDEPONT TEETH__:__
Number Sign__:__125500__:__DENTINOGENESIS IMPERFECTA, SHIELDS TYPE III__:__DGI-III;; BRANDYWINE TYPE DENTINOGENESIS IMPERFECTA__:__
Asterisk__:__125505__:__DEOXYRIBONUCLEASE I; DNASE1__:__DNase I, LYSOSOMAL; DNL1__:__
Caret__:__125510__:__REMOVED FROM DATABASE__:____:__
Percent__:__125520__:__CAYLER CARDIOFACIAL SYNDROME__:__DEPRESSOR ANGULI ORIS MUSCLE, HYPOPLASIA OF;; ASYMMETRIC CRYING FACIES; ACF;; FACIAL PARESIS, PARTIAL, UNILATERAL__:__
NULL__:__125530__:__DERMAL RIDGES, NELSON SYNDROME__:____:__
Percent__:__125540__:__DERMAL RIDGES, PATTERNLESS__:____:__
Percent__:__125550__:__DERMAL RIDGES-OFF-THE-END; ROES__:__RIDGES-OFF-THE-END SYNDROME__:__
NULL__:__125570__:__DERMATOGLYPHICS--ARCH ON ANY DIGIT__:____:__
NULL__:__125580__:__DERMATOGLYPHICS--FINGER RIDGE COUNT__:____:__
Percent__:__125590__:__DERMATOGLYPHICS--FINGERPRINT PATTERN__:____:__
Number Sign__:__125595__:__DERMATOPATHIA PIGMENTOSA RETICULARIS; DPR__:____:__
Asterisk__:__125597__:__DERMATOPONTIN; DPT__:____:__
NULL__:__125600__:__DERMATOSIS PAPULOSA NIGRA__:____:__
Number Sign__:__125630__:__VIBRATORY URTICARIA; VBU__:__DERMODISTORTIVE URTICARIA; DDU;; VIBRATORY ANGIOEDEMA__:__
NULL__:__125635__:__DERMOGRAPHISM, FAMILIAL__:__DERMATOGRAPHISM, FAMILIAL__:__
Percent__:__125640__:__DERMOODONTODYSPLASIA__:__ECTODERMAL DYSPLASIA, HAIR-NAIL-TOOTH TYPE__:__
Asterisk__:__125643__:__DESMOCOLLIN 1; DSC1__:____:__
Asterisk__:__125645__:__DESMOCOLLIN 2; DSC2__:__DESMOCOLLIN 3, FORMERLY; DSC3, FORMERLY;; DESMOSOMAL GLYCOPROTEIN II/III; DG2/3; DG2__:__
Asterisk__:__125647__:__DESMOPLAKIN; DSP__:____:__DESMOPLAKIN I, INCLUDED; DSPI, INCLUDED;; DESMOPLAKIN II, INCLUDED; DSPII, INCLUDED
Caret__:__125650__:__MOVED TO 606418__:____:__
Asterisk__:__125660__:__DESMIN; DES__:____:__
Asterisk__:__125670__:__DESMOGLEIN 1; DSG1__:__PEMPHIGUS FOLIACEUS ANTIGEN; PFA__:__
Asterisk__:__125671__:__DESMOGLEIN 2; DSG2__:__HUMAN DESMOGLEIN COLON; HDGC__:__
Number Sign__:__125700__:__DIABETES INSIPIDUS, NEUROHYPOPHYSEAL__:__DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE__:__
Number Sign__:__125800__:__DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL__:__DIABETES INSIPIDUS, NEPHROGENIC, TYPE II__:__
Number Sign__:__125850__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1__:__MODY, TYPE 1;; MILD JUVENILE DIABETES MELLITUS__:__
Number Sign__:__125851__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 2; MODY2__:__MODY, TYPE 2;; MODY, GLUCOKINASE-RELATED__:__
Number Sign__:__125852__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 2__:__INSULIN-DEPENDENT DIABETES MELLITUS 2; IDDM2__:__
Number Sign__:__125853__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM__:__DIABETES MELLITUS, TYPE II; T2D;; NONINSULIN-DEPENDENT DIABETES MELLITUS;; MATURITY-ONSET DIABETES__:__INSULIN RESISTANCE, SUSCEPTIBILITY TO, INCLUDED;; DIABETES MELLITUS, TYPE 2, PROTECTION AGAINST, INCLUDED
Asterisk__:__125855__:__DIACYLGLYCEROL KINASE, ALPHA, 80-KD; DGKA__:__DIACYLGLYCEROL KINASE, ALPHA; DAGK1;; DAGK, 80-KD;; DGK-ALPHA__:__
Plus__:__125860__:__NAD(P)H DEHYDROGENASE, QUINONE 1; NQO1__:__NAD(P)H:MENADIONE OXIDOREDUCTASE 1, DIOXIN-INDUCIBLE 1; NMOR1;; DIAPHORASE 4; DIA4;; DT DIAPHORASE; DTD__:__BENZENE TOXICITY, SUSCEPTIBILITY TO, INCLUDED;; LEUKEMIA, POST-CHEMOTHERAPY, SUSCEPTIBILITY TO, INCLUDED;; BREAST CANCER, POST-CHEMOTHERAPY SURVIVAL IN, INCLUDED
Caret__:__125870__:__MOVED TO 600941__:____:__
Asterisk__:__125880__:__DIAPHORASE 3; DIA3__:__SPERM DIAPHORASE;; GONADAL DIAPHORASE__:__
NULL__:__125890__:__DIARRHEA, GLUCOSE-STIMULATED SECRETORY, WITH COMMON VARIABLE IMMUNODEFICIENCY__:____:__
NULL__:__125900__:__DIASTEMA, DENTAL MEDIAL__:____:__
Asterisk__:__125950__:__DIAZEPAM BINDING INHIBITOR; DBI__:__ACYL-CoA BINDING PROTEIN; ACBP;; CHOLECYSTOKININ-RELEASING PEPTIDE, TRYPSIN-SENSITIVE__:__
Percent__:__126050__:__DIGITOTALAR DYSMORPHISM__:__ULNAR DRIFT, HEREDITARY__:__
Asterisk__:__126060__:__DIHYDROFOLATE REDUCTASE; DHFR__:____:__DIHYDROFOLATE REDUCTASE PSEUDOGENES, INCLUDED;; DHFR PSEUDOGENES, INCLUDED
Caret__:__126061__:__MOVED TO 126060__:____:__
Asterisk__:__126063__:__DIHYDROLIPOAMIDE S-SUCCINYLTRANSFERASE; DLST__:__ALPHA-KETOGLUTARATE DEHYDROGENASE COMPLEX, E2 COMPONENT__:__
Asterisk__:__126064__:__DIHYDROOROTATE DEHYDROGENASE; DHODH__:__DHOdehase;; URA1, YEAST, HUMAN COMPLEMENT OF__:__
Asterisk__:__126065__:__CYTOCHROME P450, FAMILY 24, SUBFAMILY A, POLYPEPTIDE 1; CYP24A1__:__CYTOCHROME P450, SUBFAMILY XXIV; CYP24;; 1,25-DIHYDROXYVITAMIN D3 24-HYDROXYLASE;; VITAMIN D 24-HYDROXYLASE__:__
Percent__:__126070__:__DILUTION, PIGMENTARY__:__ALBINOIDISM, OCULOCUTANEOUS, AUTOSOMAL DOMINANT;; ALBINISM, PARTIAL;; HYPOPIGMENTATION__:__
Asterisk__:__126090__:__PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE 1; PCBD1__:__PCBD;; DIMERIZATION COFACTOR OF HEPATIC NUCLEAR FACTOR 1-ALPHA; DCOH__:__
NULL__:__126100__:__DIMPLES, FACIAL__:__CHEEK DIMPLES;; SMILING DIMPLES__:__
Asterisk__:__126110__:__ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; ARNT__:__DIOXIN RECEPTOR, NUCLEAR TRANSLOCATOR;; HYPOXIA-INDUCIBLE FACTOR 1, BETA SUBUNIT; HIF1B;; HIF1-BETA;; TANGO__:__ARNT/TEL FUSION GENE, INCLUDED
Caret__:__126140__:__MOVED TO 102720__:____:__
Asterisk__:__126141__:__DIPEPTIDYL PEPTIDASE VI; DPP6__:__DIPEPTIDYL PEPTIDASE IV-RELATED PROTEIN;; DPPX__:__
Asterisk__:__126150__:__HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HBEGF__:__HEPARIN-BINDING EGF;; HEGFL;; DIPHTHERIA TOXIN RECEPTOR; DTR__:__
NULL__:__126180__:__DISCRIMINATION, TWO-POINT, REDUCTION IN__:__SENSORY DISCRIMINATION__:__
NULL__:__126190__:__DISPROPORTIONATE SHORT STATURE WITH PTOSIS AND VALVULAR HEART LESIONS__:____:__
Number Sign__:__126200__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO; MS__:__DISSEMINATED SCLEROSIS__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 1, INCLUDED; MS1, INCLUDED
NULL__:__126250__:__DISTAL OSTEOSCLEROSIS__:__OSTEOSCLEROSIS, DISTAL__:__
Asterisk__:__126255__:__DISTAL-LESS HOMEOBOX 2; DLX2__:__TES1__:__
Percent__:__126300__:__DISTICHIASIS__:__EYELASHES, TWO ROWS OF__:__
NULL__:__126320__:__DISTICHIASIS WITH CONGENITAL ANOMALIES OF THE HEART AND PERIPHERAL VASCULATURE__:____:__
Asterisk__:__126330__:__DNA, CYTOPLASMIC-MEMBRANE; DNCM__:__cmDNA__:__
Asterisk__:__126335__:__GROWTH ARREST- AND DNA DAMAGE-INDUCIBLE GENE GADD45, ALPHA; GADD45A__:__DNA DAMAGE-INDUCIBLE TRANSCRIPT 1; DDIT1;; DNA DAMAGE-INDUCIBLE GENE GADD45; GADD45__:__
Asterisk__:__126337__:__DNA DAMAGE-INDUCIBLE TRANSCRIPT 3; DDIT3__:__C/EBP-HOMOLOGOUS PROTEIN; CHOP;; GROWTH ARREST- AND DNA DAMAGE-INDUCIBLE GENE GADD153; GADD153__:__CHOP/FUS FUSION GENE, INCLUDED;; CHOP/EWS FUSION GENE, INCLUDED
Asterisk__:__126340__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 2; ERCC2__:__DNA REPAIR DEFECT EM9 OF CHINESE HAMSTER OVARY CELLS, COMPLEMENTATION OF; EM9;; XPD GENE; XPD__:__
Asterisk__:__126350__:__DEOXYRIBONUCLEASE II, LYSOSOMAL; DNASE2__:__DNase II, LYSOSOMAL; DNL2__:__
NULL__:__126370__:__DNA, SATELLITE, III; HS3; D1Z1__:____:__
Asterisk__:__126375__:__DNA METHYLTRANSFERASE 1; DNMT1__:__DNA METHYLTRANSFERASE; DNMT;; DNA CYTOSINE-5-METHYLTRANSFERASE; MCMT;; CXXC FINGER PROTEIN 9; CXXC9__:__
Asterisk__:__126380__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 1; ERCC1__:__DNA REPAIR DEFECT UV-20 OF CHINESE HAMSTER OVARY CELLS, COMPLEMENTATION OF; UV20__:__
NULL__:__126390__:__DNA, LOW-REPETITIVE SEQUENCES OF__:__REPETITIVE SEQUENCE DNA__:__
Asterisk__:__126391__:__LIGASE I, DNA, ATP-DEPENDENT; LIG1__:__DNA LIGASE I__:__
NULL__:__126410__:__DNA, SATELLITE, ALPHA TYPE__:____:__
Asterisk__:__126420__:__TOPOISOMERASE, DNA, I; TOP1__:____:__TOP1/NUP98 FUSION GENE, INCLUDED
Asterisk__:__126430__:__TOPOISOMERASE, DNA, II, ALPHA; TOP2A__:__DNA TOPOISOMERASE II; TOP2__:__
Asterisk__:__126431__:__TOPOISOMERASE, DNA, II, BETA; TOP2B__:____:__
Caret__:__126440__:__REMOVED FROM DATABASE__:____:__
Caret__:__126448__:__MOVED TO 126453__:____:__
Asterisk__:__126449__:__DOPAMINE RECEPTOR D1; DRD1__:__DOPAMINE RECEPTOR D1A; DRD1A__:__
Asterisk__:__126450__:__DOPAMINE RECEPTOR D2; DRD2__:__D2R__:__
Asterisk__:__126451__:__DOPAMINE RECEPTOR D3; DRD3__:____:__
Asterisk__:__126452__:__DOPAMINE RECEPTOR D4; DRD4__:__D4DR__:__
Asterisk__:__126453__:__DOPAMINE RECEPTOR D5; DRD5__:__DOPAMINE RECEPTOR D1B; DRD1B__:__
Asterisk__:__126455__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, DOPAMINE), MEMBER 3; SLC6A3__:__DOPAMINE TRANSPORTER; DAT;; DAT1__:__
NULL__:__126500__:__DOUBLE NAIL FOR FIFTH TOE__:____:__
Percent__:__126550__:__DOUGHNUT LESIONS OF SKULL, FAMILIAL__:____:__
Number Sign__:__126600__:__DOYNE HONEYCOMB RETINAL DYSTROPHY; DHRD__:__DOYNE HONEYCOMB DEGENERATION OF RETINA; DHD__:__MALATTIA LEVENTINESE, INCLUDED; MLVT, INCLUDED;; DRUSEN, RADIAL, AUTOSOMAL DOMINANT, INCLUDED
Asterisk__:__126650__:__SOLUTE CARRIER FAMILY 26, MEMBER 3; SLC26A3__:__DOWNREGULATED IN ADENOMA; DRA__:__
Asterisk__:__126660__:__DREBRIN E; DBN1__:____:__
Number Sign__:__126700__:__BASAL LAMINAR DRUSEN__:__DRUSEN OF BRUCH MEMBRANE;; DRUSEN, CUTICULAR;; DRUSEN, EARLY ADULT-ONSET, GROUPED__:__
Percent__:__126800__:__DUANE RETRACTION SYNDROME 1; DURS1__:__DRS;; DUANE SYNDROME; DUS;; DUANE ANOMALY;; RETRACTION SYNDROME__:__
Caret__:__126830__:__MOVED TO 169100__:____:__
NULL__:__126840__:__DUODENAL ULCER DUE TO ANTRAL G-CELL HYPERFUNCTION__:____:__
Percent__:__126850__:__DUODENAL ULCER, HYPERPEPSINOGENEMIC I__:____:__
Percent__:__126900__:__DUPUYTREN CONTRACTURE__:____:__DUPUYTREN CONTRACTURE 1, INCLUDED; DUPC1, INCLUDED;; PLANTAR FIBROMAS, INCLUDED;; PLANTAR FIBROMATOSIS, FAMILIAL, INCLUDED
NULL__:__126950__:__DWARFISM WITH TALL VERTEBRAE__:____:__
Number Sign__:__127000__:__KENNY-CAFFEY SYNDROME, TYPE 2; KCS2__:__DWARFISM, CORTICAL THICKENING OF TUBULAR BONES, AND TRANSIENT HYPOCALCEMIA;; KENNY SYNDROME__:__
NULL__:__127100__:__DWARFISM, LEVI TYPE__:__SNUB-NOSED TYPE OF DWARFISM__:__
NULL__:__127200__:__DWARFISM WITH STIFF JOINTS AND OCULAR ABNORMALITIES__:__MOORE-FEDERMAN SYNDROME__:__
Number Sign__:__127300__:__LERI-WEILL DYSCHONDROSTEOSIS; LWD__:__DYSCHONDROSTEOSIS; DCO__:__MADELUNG DEFORMITY, INCLUDED
NULL__:__127350__:__DYSCHONDROSTEOSIS AND NEPHRITIS__:____:__
Number Sign__:__127400__:__DYSCHROMATOSIS SYMMETRICA HEREDITARIA; DSH__:__DYSCHROMATOSIS SYMMETRICA HEREDITARIA 1; DSH1;; RETICULATE ACROPIGMENTATION OF DOHI; RAD;; SYMMETRIC DYSCHROMATOSIS OF THE EXTREMITIES__:__
Percent__:__127500__:__DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 1; DUH1__:____:__
Number Sign__:__127550__:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 1; DKCA1__:__DYSKERATOSIS CONGENITA, SCOGGINS TYPE__:__
Percent__:__127600__:__DYSKERATOSIS, HEREDITARY BENIGN INTRAEPITHELIAL; HBID__:__DKBI__:__
Number Sign__:__127700__:__DYSLEXIA, SUSCEPTIBILITY TO, 1; DYX1__:__WORD-BLINDNESS, CONGENITAL;; READING DISABILITY, SPECIFIC, 1__:__DYSLEXIA, SUSCEPTIBILITY TO, 4, INCLUDED; DYX4, INCLUDED;; DYSLEXIA, SUSCEPTIBILITY TO, 7, INCLUDED; DYX7, INCLUDED
Number Sign__:__127750__:__DEMENTIA, LEWY BODY; DLB__:__LEWY BODY DEMENTIA;; DIFFUSE LEWY BODY DISEASE__:__DIFFUSE LEWY BODY DISEASE WITH GAZE PALSY, INCLUDED;; LEWY BODY VARIANT OF ALZHEIMER DISEASE, INCLUDED
NULL__:__127800__:__DYSPLASIA EPIPHYSEALIS HEMIMELICA__:__TREVOR DISEASE__:__
NULL__:__127820__:__DYSPLASIA EPIPHYSEALIS HEMIMELICA WITH CHONDROMAS AND OSTEOCHONDROMAS__:__OSTEOCHONDROMATOSIS, DOMINANT CARPOTARSAL__:__
Percent__:__128000__:__DYSTELEPHALANGY__:__KIRNER DEFORMITY__:__
Number Sign__:__128100__:__DYSTONIA 1, TORSION, AUTOSOMAL DOMINANT; DYT1__:__DYSTONIA MUSCULORUM DEFORMANS 1;; EARLY-ONSET TORSION DYSTONIA; EOTD__:__
Number Sign__:__128101__:__DYSTONIA 4, TORSION, AUTOSOMAL DOMINANT; DYT4__:__WHISPERING DYSPHONIA, HEREDITARY;; DYSTONIA MUSCULORUM DEFORMANS 4__:__
Number Sign__:__128200__:__EPISODIC KINESIGENIC DYSKINESIA 1; EKD1__:__PAROXYSMAL KINESIGENIC CHOREOATHETOSIS; PKC;; PAROXYSMAL KINESIGENIC DYSKINESIA; PKD;; DYSTONIA, FAMILIAL PAROXYSMAL;; DYSTONIA 10; DYT10__:__
Number Sign__:__128230__:__DYSTONIA, DOPA-RESPONSIVE; DRD__:__DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT__:__
Number Sign__:__128235__:__DYSTONIA 12; DYT12__:__DYSTONIA-PARKINSONISM, RAPID-ONSET; RDP__:__
Asterisk__:__128239__:__DYSTROPHIN-ASSOCIATED GLYCOPROTEIN 1; DAG1__:__DAG;; DYSTROGLYCAN, ALPHA;; AGRIN RECEPTOR; AGRNR__:__DYSTROGLYCAN, BETA, INCLUDED
Asterisk__:__128240__:__UTROPHIN; UTRN__:__DYSTROPHIN-LIKE PROTEIN; DMDL;; DYSTROPHIN-RELATED PROTEIN 1; DRP1;; DRP__:__
Asterisk__:__128260__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE E; SNRPE__:__E PROTEIN OF SMALL NUCLEAR RIBONUCLEOPROTEIN COMPLEXES__:__
NULL__:__128290__:__EAR ANTITRAGUS, TAG AT BASE OF__:____:__
NULL__:__128300__:__EAR EXOSTOSES__:__EXOSTOSES OF EXTERNAL AUDITORY CANAL__:__
NULL__:__128400__:__EAR FLARE__:____:__
NULL__:__128500__:__EAR FOLDING__:____:__
Percent__:__128600__:__EAR MALFORMATION__:__CUP EAR__:__
Percent__:__128700__:__PREAURICULAR FISTULAE, CONGENITAL__:__PAFC;; EAR PITS__:__
NULL__:__128710__:__EAR PITS, POSTERIOR HELICAL__:__POSTERIOR HELICAL EAR PITS; PHEP__:__EARLOBE INDENTATIONS, POSTERIOR, INCLUDED
NULL__:__128800__:__EAR WITHOUT HELIX__:____:__
NULL__:__128900__:__EARLOBE ATTACHMENT, ATTACHED VS UNATTACHED__:____:__
NULL__:__128950__:__EARLOBE CREASE__:____:__
Percent__:__128980__:__EARLOBES, THICKENED, WITH CONDUCTIVE DEAFNESS FROM INCUDOSTAPEDIAL ABNORMALITIES__:____:__
Asterisk__:__128990__:__EARLY GROWTH RESPONSE 1; EGR1__:__KROX24;; NERVE GROWTH FACTOR-INDUCED CLONE A; NGFIA;; ZIF268__:__
Asterisk__:__128992__:__EARLY GROWTH RESPONSE 4; EGR4__:__NERVE GROWTH FACTOR-INDUCED CLONE C; NGFIC__:__
NULL__:__129000__:__EARRING HOLES, NATURAL__:__EARLOBE SINUSES__:__
Asterisk__:__129010__:__EARLY GROWTH RESPONSE 2; EGR2__:__KROX20__:__
NULL__:__129100__:__EARS, ABILITY TO MOVE__:____:__
Percent__:__129150__:__ECHO VIRUS 11 SENSITIVITY; E11S__:____:__
Asterisk__:__129190__:__ECTO-5-PRIME NUCLEOTIDASE; NT5E__:__E5NT; ENT; NTE;; NUCLEOTIDASE, ECTO-5-PRIME; NT5;; CD73__:__
Number Sign__:__129200__:__BASAN SYNDROME__:__ADERMATOGLYPHIA WITH CONGENITAL FACIAL MILIA AND ACRAL BLISTERS, DIGITAL CONTRACTURES, AND NAIL ABNORMALITIES;; ECTODERMAL DYSPLASIA, ABSENT DERMATOGLYPHIC PATTERN, CHANGES IN NAILS, AND SIMIAN CREASE__:__
Number Sign__:__129400__:__RAPP-HODGKIN SYNDROME; RHS__:__ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH CLEFT LIP/PALATE__:__
Number Sign__:__129490__:__ECTODERMAL DYSPLASIA 10A, HYPOHIDROTIC/HAIR/NAIL TYPE, AUTOSOMAL DOMINANT; ECTD10A__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC, AUTOSOMAL DOMINANT; HED__:__
Number Sign__:__129500__:__CLOUSTON SYNDROME__:__ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE; ECTD2;; ECTODERMAL DYSPLASIA, HIDROTIC, AUTOSOMAL DOMINANT;; CLOUSTON HIDROTIC ECTODERMAL DYSPLASIA;; ECTODERMAL DYSPLASIA, HIDROTIC, 2, FORMERLY; HED2, FORMERLY__:__
NULL__:__129510__:__ECTODERMAL DYSPLASIA, TRICHOODONTOONYCHIAL TYPE__:____:__
NULL__:__129540__:__ECTODERMAL DYSPLASIA SYNDROME WITH DISTINCTIVE FACIAL APPEARANCE AND PREAXIAL POLYDACTYLY OF FEET__:____:__
NULL__:__129550__:__ECTODERMAL DYSPLASIA WITH ADRENAL CYST__:____:__
Number Sign__:__129600__:__ECTOPIA LENTIS 1, ISOLATED, AUTOSOMAL DOMINANT; ECTOL1__:____:__
NULL__:__129750__:__ECTOPIA PUPILLAE__:____:__
NULL__:__129810__:__ECTRODACTYLY AND ECTODERMAL DYSPLASIA WITHOUT CLEFT LIP/PALATE__:__EEC SYNDROME WITHOUT CLEFT LIP/PALATE__:__
NULL__:__129830__:__ECTRODACTYLY-CLEFT PALATE SYNDROME__:__ECP SYNDROME__:__
NULL__:__129840__:__EDEMA, FAMILIAL IDIOPATHIC, PREPUBERTAL__:____:__
Number Sign__:__129850__:__EDINBURGH MALFORMATION SYNDROME__:____:__
Percent__:__129900__:__ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 1; EEC1__:__EEC;; EEC SYNDROME 1__:__
NULL__:__129905__:__EGASYN__:__ESTERASE 22; ES22__:__
Number Sign__:__130000__:__EHLERS-DANLOS SYNDROME, CLASSIC TYPE, 1; EDSCL1__:__EHLERS-DANLOS SYNDROME, TYPE I, FORMERLY; EDS1, FORMERLY;; EHLERS-DANLOS SYNDROME, SEVERE CLASSIC TYPE, FORMERLY;; EDS I, FORMERLY;; EHLERS-DANLOS SYNDROME, GRAVIS TYPE, FORMERLY__:__
Number Sign__:__130010__:__EHLERS-DANLOS SYNDROME, CLASSIC TYPE, 2; EDSCL2__:__EHLERS-DANLOS SYNDROME, TYPE II, FORMERLY; EDS2, FORMERLY;; EHLERS DANLOS SYNDROME, MILD CLASSIC TYPE, FORMERLY;; EDS II, FORMERLY;; EHLERS DANLOS SYNDROME, MITIS TYPE, FORMERLY__:__
Percent__:__130020__:__EHLERS-DANLOS SYNDROME, HYPERMOBILITY TYPE; EDSHMB__:__EHLERS-DANLOS SYNDROME, TYPE III; EDS3;; EDS III;; BENIGN HYPERMOBILITY SYNDROME__:__
Number Sign__:__130050__:__EHLERS-DANLOS SYNDROME, VASCULAR TYPE; EDSVASC__:__EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT; EDS4;; EDS IV;; EHLERS-DANLOS SYNDROME, ARTERIAL TYPE;; EHLERS-DANLOS SYNDROME, ECCHYMOTIC TYPE;; EHLERS-DANLOS SYNDROME, SACK-BARABAS TYPE__:__
Number Sign__:__130060__:__EHLERS-DANLOS SYNDROME, ARTHROCHALASIA TYPE, 1; EDSARTH1__:__EHLERS-DANLOS SYNDROME, TYPE VIIA, AUTOSOMAL DOMINANT; EDS7A;; EDS VIIA;; ARTHROCHALASIS MULTIPLEX CONGENITA;; EDS VII, MUTANT PROCOLLAGEN TYPE__:__
Number Sign__:__130070__:__EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 1; EDSSPD1__:__EHLERS-DANLOS SYNDROME WITH SHORT STATURE AND LIMB ANOMALIES; EDSSLA;; PROTEODERMATAN SULFATE, DEFECTIVE BIOSYNTHESIS OF;; PDS, DEFECTIVE BIOSYNTHESIS OF;; DERMATAN SULFATE PROTEOGLYCAN;; XYLOSYLPROTEIN 4-BETA-GALACTOSYLTRANSFERASE DEFICIENCY;; XGPT DEFICIENCY;; GALACTOSYLTRANSFERASE I DEFICIENCY;; EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 1, FORMERLY; EDSP1, FORMERLY__:__
Number Sign__:__130080__:__EHLERS-DANLOS SYNDROME, PERIODONTAL TYPE, 1; EDSPD1__:__EHLERS-DANLOS SYNDROME, TYPE VIII; EDS8;; EDS VIII;; EHLERS-DANLOS SYNDROME, PERIODONTITIS TYPE;; EHLERS-DANLOS SYNDROME, PERIODONTOSIS TYPE__:__
NULL__:__130090__:__EHLERS-DANLOS SYNDROME, AUTOSOMAL DOMINANT, TYPE UNSPECIFIED__:__EDS, UNSPECIFIED TYPE;; EHLERS-DANLOS SYNDROME, FRIEDMAN-HARROD TYPE__:__
NULL__:__130100__:__ELASTOSIS PERFORANS SERPIGINOSA; EPS__:__ELASTOMA INTRAPAPILLARE PERFORANS VERRUCIFORMIS;; MIESCHER ELASTOMA__:__
Asterisk__:__130120__:__CHYMOTRYPSIN-LIKE ELASTASE FAMILY, MEMBER 1; CELA1__:__ELASTASE 1; ELA1;; ELASTASE, PANCREATIC, FORMERLY__:__
Asterisk__:__130130__:__ELASTASE, NEUTROPHIL-EXPRESSED; ELANE__:__ELASTASE 2; ELA2;; ELASTASE, NEUTROPHIL; NE;; HNE;; ELASTASE, LEUKOCYTE;; HLE;; MEDULLASIN;; PROTEASE, SERINE, BONE MARROW__:__
Asterisk__:__130135__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 1; SERPINB1__:__PROTEASE INHIBITOR 2, MONOCYTE/NEUTROPHIL DERIVED; ELANH2;; ELASTASE INHIBITOR, MONOCYTE/NEUTROPHIL; EI__:__
Asterisk__:__130160__:__ELASTIN; ELN__:____:__
Percent__:__130180__:__ELECTROENCEPHALOGRAM, LOW-VOLTAGE__:__EEG, LOW-VOLTAGE; EEGL;; ELECTROENCEPHALOGRAPHIC VARIANT PATTERN 1; EEGV1__:__
Percent__:__130190__:__ELECTROENCEPHALOGRAPHIC PATTERN, BETA FREQUENCY, QUANTITATIVE TRAIT LOCUS; EEGBQTL__:____:__
NULL__:__130200__:__ELECTROENCEPHALOGRAPHIC PECULIARITY: 14 AND 6 PER SEC. POSITIVE SPIKE PHENOMENON__:____:__
NULL__:__130300__:__ELECTROENCEPHALOGRAPHIC PECULIARITY: FRONTO-PRECENTRAL BETA WAVE GROUPS__:____:__
NULL__:__130400__:__ELECTROENCEPHALOGRAPHIC PECULIARITY: OCCIPITAL SLOW BETA WAVES__:____:__
Asterisk__:__130410__:__ELECTRON TRANSFER FLAVOPROTEIN, BETA POLYPEPTIDE; ETFB__:____:__
Asterisk__:__130500__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1; EPB41__:__PROTEIN 4.1, RED BLOOD CELL TYPE; 4.1R;; EL1 GENE__:__
Asterisk__:__130590__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, ALPHA-1; EEF1A1__:__ELONGATION FACTOR 1, ALPHA-1;; ELONGATION FACTOR 1, ALPHA; EF1A; EEF1A__:__CERVICAL CANCER SUPPRESSOR 3 ISOFORM, INCLUDED; CCS3, INCLUDED
Caret__:__130591__:__MOVED TO 600655__:____:__
Asterisk__:__130592__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, DELTA; EEF1D__:__ELONGATION FACTOR 1, DELTA; EF1D;; GUANINE NUCLEOTIDE EXCHANGE PROTEIN__:__
Asterisk__:__130593__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, GAMMA; EEF1G__:__ELONGATION FACTOR 1, GAMMA; EF1G;; EEF1B-GAMMA__:__
Number Sign__:__130600__:__ELLIPTOCYTOSIS 2; EL2__:__ELLIPTOCYTOSIS, RHESUS-UNLINKED TYPE__:__
Asterisk__:__130610__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 2; EEF2__:__ELONGATION FACTOR 2; EF2;; POLYPEPTIDYL-tRNA TRANSLOCASE__:__
Asterisk__:__130620__:__RIBOSOMAL PROTEIN S14; RPS14__:__EMETINE RESISTANCE GENE; EMTB__:__
Number Sign__:__130650__:__BECKWITH-WIEDEMANN SYNDROME; BWS__:__EXOMPHALOS-MACROGLOSSIA-GIGANTISM SYNDROME;; EMG SYNDROME;; WIEDEMANN-BECKWITH SYNDROME; WBS__:__BECKWITH-WIEDEMANN SYNDROME CHROMOSOME REGION, INCLUDED; BWCR, INCLUDED
Asterisk__:__130660__:__ELASTIN MICROFIBRIL INTERFACER 1; EMILIN1__:__ELASTIN MICROFIBRIL INTERFACE-LOCATED PROTEIN; EMILIN__:__
NULL__:__130700__:__EMPHYSEMA, HEREDITARY PULMONARY__:____:__
NULL__:__130710__:__EMPHYSEMA, CONGENITAL LOBAR; CLE__:____:__
Number Sign__:__130720__:__LATERAL MENINGOCELE SYNDROME; LMNS__:__LMS;; LEHMAN SYNDROME__:__
Number Sign__:__130900__:__AMELOGENESIS IMPERFECTA, TYPE IIIA; AI3A__:__AMELOGENESIS IMPERFECTA, TYPE III; AI3;; AMELOGENESIS IMPERFECTA, HYPOCALCIFICATION TYPE, AUTOSOMAL DOMINANT; ADHCAI;; AMELOGENESIS IMPERFECTA, HYPOMINERALIZATION TYPE__:__
NULL__:__130950__:__ENCEPHALOPATHY, RECURRENT, OF CHILDHOOD__:____:__
Number Sign__:__131100__:__MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1__:__MEN I;; ENDOCRINE ADENOMATOSIS, MULTIPLE;; MEA I;; WERMER SYNDROME__:__MEN1 SOMATIC MUTATIONS, INCLUDED
Asterisk__:__131150__:__ENDOGENOUS RETROVIRAL SEQUENCE 1; ERV1__:____:__
Asterisk__:__131170__:__ENDOGENOUS RETROVIRAL SEQUENCE 3; ERV3__:__HUMAN PROVIRUS-LINKED KRUPPEL; HPLK__:__
Asterisk__:__131180__:__ENDOGENOUS RETROVIRAL POL-LIKE SEQUENCE-2; ERPL2__:____:__
Asterisk__:__131190__:__ENDOGENOUS RETROVIRAL POL-LIKE SEQUENCE-1; ERPL1__:__ONCOGENE HLM2__:__
Asterisk__:__131195__:__ENDOGLIN; ENG__:__CD105__:__
Percent__:__131200__:__ENDOMETRIOSIS, SUSCEPTIBILITY TO, 1__:__ENDO1__:__
Asterisk__:__131210__:__SELECTIN E; SELE__:__E-SELECTIN;; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ELAM1;; ELAM__:__
Asterisk__:__131220__:__FIBROBLAST GROWTH FACTOR 1; FGF1__:__ENDOTHELIAL CELL GROWTH FACTOR; ECGF;; HEPARIN-BINDING GROWTH FACTOR 1; HBGF1;; FIBROBLAST GROWTH FACTOR, ACIDIC; FGFA; AFGF__:__ENDOTHELIAL CELL GROWTH FACTOR, ALPHA, INCLUDED; ECGFA, INCLUDED;; ENDOTHELIAL CELL GROWTH FACTOR, BETA, INCLUDED; ECGFB, INCLUDED
Asterisk__:__131222__:__THYMIDINE PHOSPHORYLASE; TYMP__:__TP;; ENDOTHELIAL CELL GROWTH FACTOR, PLATELET-DERIVED; ECGF; ECGF1;; PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PDECGF;; GLIOSTATIN__:__
Asterisk__:__131230__:__ANNEXIN A5; ANXA5__:__ANNEXIN V; ANX5;; ENDONEXIN II; ENX2;; PLACENTAL ANTICOAGULANT PROTEIN I;; VASCULAR ANTICOAGULANT-ALPHA;; LIPOCORTIN V;; PLACENTAL PROTEIN 4; PP4;; ANCHORIN CII__:__
Asterisk__:__131235__:__KDEL ENDOPLASMIC RETICULUM PROTEIN RETENTION RECEPTOR 1; KDELR1__:__ERD2, S. CEREVISIAE, HOMOLOG OF; ERD2;; HDEL RECEPTOR, S. CEREVISIAE, HOMOLOG OF__:__
Plus__:__131240__:__ENDOTHELIN 1; EDN1__:__ET1__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 7, INCLUDED; HDLCQ7, INCLUDED;; PREPROENDOTHELIN 1, INCLUDED
Asterisk__:__131241__:__ENDOTHELIN 2; EDN2__:__ET2__:__
Asterisk__:__131242__:__ENDOTHELIN 3; EDN3__:__ET3__:__
Asterisk__:__131243__:__ENDOTHELIN RECEPTOR, TYPE A; EDNRA__:__ENDOTHELIN RECEPTOR, ET1-SPECIFIC TYPE; ETA;; ETRA__:__
Asterisk__:__131244__:__ENDOTHELIN RECEPTOR, TYPE B; EDNRB__:__ENDOTHELIN RECEPTOR, NONSELECTIVE TYPE; ETB;; ETRB; ETBR__:__
Asterisk__:__131290__:__ENGRAILED 1; EN1__:____:__
Number Sign__:__131300__:__CAMURATI-ENGELMANN DISEASE; CAEND__:__CED;; ENGELMANN DISEASE;; DIAPHYSEAL DYSPLASIA 1, PROGRESSIVE; DPD1;; PROGRESSIVE DIAPHYSEAL DYSPLASIA; PDD__:__
Asterisk__:__131310__:__ENGRAILED 2; EN2__:____:__
Asterisk__:__131320__:__GATA-BINDING PROTEIN 3; GATA3__:__ENHANCER-BINDING PROTEIN GATA3__:__
Asterisk__:__131330__:__PROENKEPHALIN; PENK__:__ENKEPHALIN A;; PREPROENKEPHALIN A__:__
Asterisk__:__131340__:__PRODYNORPHIN; PDYN__:__ENKEPHALIN B;; PREPROENKEPHALIN B__:__
Asterisk__:__131360__:__ENOLASE 2; ENO2__:__ENOLASE, GAMMA;; ENOLASE, NEURON-SPECIFIC; NSE__:__
Asterisk__:__131370__:__ENOLASE 3; ENO3__:__ENOLASE, BETA;; ENOLASE, MUSCLE-SPECIFIC; MSE__:__
NULL__:__131375__:__ENOLASE, SPERM SPECIFIC; ENO4__:____:__
Asterisk__:__131390__:__NIDOGEN 1; NID1__:__NIDOGEN; NID;; ENTACTIN__:__
Asterisk__:__131398__:__RIBONUCLEASE, RNase A FAMILY, 3; RNASE3__:__RNS3;; EOSINOPHIL CATIONIC PROTEIN; ECP__:__
Asterisk__:__131399__:__EOSINOPHIL PEROXIDASE; EPX__:____:__
Percent__:__131400__:__EOSINOPHILIA, FAMILIAL__:__EOS__:__
Asterisk__:__131410__:__RIBONUCLEASE, RNase A FAMILY, 2; RNASE2__:__RNS2;; EOSINOPHIL-DERIVED NEUROTOXIN; EDN__:__
NULL__:__131430__:__EOSINOPHILOPENIA__:__EOSINOPHIL APLASIA__:__
Number Sign__:__131440__:__MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA__:__MPE; EMP;; EOSINOPHILS, MALIGNANT PROLIFERATION OF__:__
Caret__:__131445__:__MOVED TO 137800__:____:__
NULL__:__131450__:__EPIBLEPHARON OF LOWER LID__:____:__
NULL__:__131460__:__EPIBLEPHARON OF UPPER LID__:____:__
Percent__:__131500__:__EPICANTHUS__:____:__
Asterisk__:__131530__:__EPIDERMAL GROWTH FACTOR; EGF__:__UROGASTRONE; URG__:__
Asterisk__:__131550__:__EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR__:__V-ERB-B AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG;; ONCOGENE ERBB;; ERBB1;; HER1;; SPECIES ANTIGEN 7; SA7__:__EGFR/SEPT14 FUSION GENE, INCLUDED
Asterisk__:__131560__:__FLOTILLIN 2; FLOT2__:__EPIDERMAL SURFACE ANTIGEN 1; ESA1;; MEMBRANE COMPONENT, CHROMOSOME 17, SURFACE MARKER 1; M17S1__:__
NULL__:__131600__:__EPIDERMOID CYSTS__:____:__
Number Sign__:__131705__:__TRANSIENT BULLOUS DERMOLYSIS OF THE NEWBORN; TBDN__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, NEONATAL FORM;; DYSTROPHIC EPIDERMOLYSIS BULLOSA, NEONATAL__:__
Number Sign__:__131750__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT; DDEB__:__DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT;; EPIDERMOLYSIS BULLOSA DYSTROPHICA, COCKAYNE-TOURAINE TYPE; EBDCT;; EPIDERMOLYSIS BULLOSA DYSTROPHICA, PASINI TYPE;; ALBOPAPULOID DOMINANT DYSTROPHIC EPIDERMOLYSIS BULLOSA; EBDD__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA WITH SUBCORNEAL CLEAVAGE, INCLUDED; EBDSC, INCLUDED
Number Sign__:__131760__:__EPIDERMOLYSIS BULLOSA SIMPLEX, DOWLING-MEARA TYPE; EBSDM__:__EPIDERMOLYSIS BULLOSA HERPETIFORMIS, DOWLING-MEARA TYPE;; EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED SEVERE__:__
Number Sign__:__131800__:__EPIDERMOLYSIS BULLOSA SIMPLEX, LOCALIZED__:__EPIDERMOLYSIS BULLOSA SIMPLEX, WEBER-COCKAYNE TYPE;; EPIDERMOLYSIS BULLOSA OF HANDS AND FEET;; EBS, ACRAL FORM__:__
Number Sign__:__131850__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, PRETIBIAL__:__DYSTROPHIC EPIDERMOLYSIS BULLOSA, PRETIBIAL;; DEB, PRETIBIAL;; EPIDERMOLYSIS BULLOSA, PRETIBIAL__:__
NULL__:__131880__:__EPIDERMOLYSIS BULLOSA WITH DEFICIENCY OF GALACTOSYLHYDROXYLYSYL GLUCOSYLTRANSFERASE__:____:__
Number Sign__:__131900__:__EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED__:__EBS, GENERALIZED;; EPIDERMOLYSIS BULLOSA SIMPLEX, KOEBNER TYPE__:__
Number Sign__:__131950__:__EPIDERMOLYSIS BULLOSA SIMPLEX, OGNA TYPE; EBSOG__:____:__
Number Sign__:__131960__:__EPIDERMOLYSIS BULLOSA SIMPLEX WITH MOTTLED PIGMENTATION; EBSMP__:__SPECKLED HYPERPIGMENTATION WITH PUNCTATE PALMOPLANTAR KERATOSES AND CHILDHOOD BLISTERING__:__
Number Sign__:__132000__:__EPIDERMOLYSIS BULLOSA WITH CONGENITAL LOCALIZED ABSENCE OF SKIN AND DEFORMITY OF NAILS__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, BART TYPE__:__
NULL__:__132090__:__EPILEPSY, BENIGN OCCIPITAL; BOE__:____:__
Percent__:__132100__:__PHOTOPAROXYSMAL RESPONSE 1; PPR1__:__PPR;; PHOTOSENSITIVITY;; PHOTOCONVULSIVE REACTION;; EPILEPSY, PHOTOGENIC__:__
NULL__:__132300__:__EPILEPSY, READING__:____:__
Asterisk__:__132350__:__SYNTAXIN 2; STX2__:__EPIMORPHIN; EPIM;; SYNTAXIN 2A; STX2A;; SYNTAXIN 2B; STX2B;; SYNTAXIN 2C; STX2C__:__
Number Sign__:__132400__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 1; EDM1__:__MULTIPLE EPIPHYSEAL DYSPLASIA, COMP-RELATED__:__EPIPHYSEAL DYSPLASIA, FAIRBANK TYPE, INCLUDED;; EPIPHYSEAL DYSPLASIA, RIBBING TYPE, INCLUDED
Number Sign__:__132450__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MYOPIA AND CONDUCTIVE DEAFNESS; EDMMD__:____:__
NULL__:__132500__:__EPISTAXIS, HEREDITARY__:____:__
Number Sign__:__132600__:__PILOMATRIXOMA__:__PILOMATRICOMA; PTR;; EPITHELIOMA CALCIFICANS OF MALHERBE__:__
Number Sign__:__132700__:__CYLINDROMATOSIS, FAMILIAL__:__ANCELL-SPIEGLER CYLINDROMAS;; 'TURBAN TUMOR' SYNDROME;; CYLINDROMAS, DERMAL ECCRINE__:__
Number Sign__:__132800__:__MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO; MSSE__:__FERGUSON-SMITH-TYPE EPITHELIOMA;; ESS1, FORMERLY__:__
Asterisk__:__132810__:__EPOXIDE HYDROLASE 1, MICROSOMAL; EPHX1__:__EPOXIDE HYDROLASE; EPHX;; EPOXIDE HYDROLASE, MICROSOMAL XENOBIOTIC; EPOX__:__
Asterisk__:__132811__:__EPOXIDE HYDROLASE 2, CYTOSOLIC; EPHX2__:____:__
NULL__:__132850__:__EPSTEIN-BARR VIRUS INSERTION SITE 1; EBVS1__:__EPSTEIN-BARR VIRUS INTEGRATION SITE__:__
Caret__:__132860__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__132880__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 6; NR2F6__:__V-ERB-A AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG-LIKE 2; ERBAL2;; ERBA-RELATED 2; EAR2__:__
Asterisk__:__132890__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 1; NR2F1__:__TRANSCRIPTION FACTOR COUP 1; TFCOUP1;; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; COUPTFI; COUPTF1;; ERBA-RELATED 3; EAR3;; V-ERB-A AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG-LIKE 3; ERBAL3__:__
Number Sign__:__132900__:__AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4__:__FAA4;; AORTIC ANEURYSM/AORTIC DISSECTION AND PATENT DUCTUS ARTERIOSUS__:__
NULL__:__132990__:__ERYTHEMA NODOSUM, FAMILIAL__:____:__
Percent__:__133000__:__ERYTHEMA PALMARE HEREDITARIUM__:____:__
Number Sign__:__133020__:__ERYTHERMALGIA, PRIMARY__:__ERYTHROMELALGIA, PRIMARY;; ERYTHROMELALGIA, FAMILIAL__:__NEUROPATHY, SMALL FIBER, INCLUDED; SFNP, INCLUDED
Asterisk__:__133090__:__STOMATIN; STOM__:__ERYTHROCYTE SURFACE PROTEIN BAND 7.2; EPB72;; ERYTHROCYTE BAND 7 INTEGRAL MEMBRANE PROTEIN; BND7__:__
Number Sign__:__133100__:__ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1__:__POLYCYTHEMIA, PRIMARY FAMILIAL AND CONGENITAL; PFCP;; ERYTHROCYTOSIS, AUTOSOMAL DOMINANT BENIGN__:__
Asterisk__:__133170__:__ERYTHROPOIETIN; EPO__:__EP__:__
Asterisk__:__133171__:__ERYTHROPOIETIN RECEPTOR; EPOR__:____:__
Number Sign__:__133180__:__ERYTHROLEUKEMIA, FAMILIAL, SUSCEPTIBILITY TO; FERLK__:__DI GUGLIELMO DISEASE, FAMILIAL;; LEUKEMIA, ACUTE MYELOGENOUS, M6__:__
Number Sign__:__133190__:__SPINOCEREBELLAR ATAXIA 34; SCA34__:__ERYTHROKERATODERMIA WITH ATAXIA__:__
Number Sign__:__133200__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1; EKVP1__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA; EKVP;; ERYTHROKERATODERMIA VARIABILIS; EKV;; ERYTHROKERATODERMIA, PROGRESSIVE SYMMETRIC; PSEK;; ERYTHROKERATODERMIA FIGURATA, CONGENITAL FAMILIAL, IN PLAQUES;; ERYTHROKERATODERMIA VARIABILIS WITH ERYTHEMA GYRATUM REPENS__:__GREITHER DISEASE, INCLUDED;; KERATOSIS PALMOPLANTARIS TRANSGREDIENS ET PROGREDIENS, INCLUDED
Asterisk__:__133220__:__ESTERASE A4; ESA4__:____:__
Asterisk__:__133230__:__ESTERASE A-5; ESA5__:__ACETYLESTERASE, ADULT BRAIN__:__ACETYLESTERASE, FETAL BRAIN, INCLUDED;; ESA7, INCLUDED
Number Sign__:__133239__:__ESOPHAGEAL CANCER__:____:__ESOPHAGEAL SQUAMOUS CELL CARCINOMA, SUSCEPTIBILITY TO, INCLUDED;; ESCC, SUSCEPTIBILITY TO, INCLUDED;; AERODIGESTIVE TRACT CANCER, SUSCEPTIBILITY TO, INCLUDED;; GASTRIC CARDIA ADENOCARCINOMA, SUSCEPTIBILITY TO, INCLUDED
NULL__:__133240__:__ESOPHAGEAL RING, LOWER__:____:__
Caret__:__133250__:__MOVED TO 172460__:____:__
NULL__:__133260__:__ESTERASE B; ESB__:____:__
NULL__:__133270__:__ESTERASE C; ESC__:____:__
Asterisk__:__133280__:__ESTERASE D; ESD__:____:__S-FORMYLGLUTATHIONE HYDROLASE, INCLUDED; FGH, INCLUDED
Asterisk__:__133290__:__ESTERASE B3; ESB3__:____:__
NULL__:__133300__:__ESTERASE ES-2, REGULATOR FOR__:____:__
Caret__:__133420__:__MOVED TO 113710__:____:__
Plus__:__133430__:__ESTROGEN RECEPTOR 1; ESR1__:__ESTROGEN RECEPTOR; ESR; ER;; ESTROGEN RECEPTOR, ALPHA; ESRA__:__HDL CHOLESTEROL, AUGMENTED RESPONSE OF, TO HORMONE REPLACEMENT, INCLUDED;; ATHEROSCLEROSIS, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__133435__:__RUNT-RELATED TRANSCRIPTION FACTOR 1, TRANSLOCATED TO, 1; RUNX1T1__:__RUNX1, TRANSLOCATED TO, 1;; ACUTE MYELOGENOUS LEUKEMIA 1 TRANSLOCATION 1, CYCLIN-D RELATED; AML1T1;; ETO GENE; ETO;; MYELOID TRANSLOCATION GENE ON 8q22; MTG8;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 2; ZMYND2;; CORE-BINDING FACTOR, ALPHA SUBUNIT 2, TRANSLOCATED TO, 1; CBFA2T1__:__ETO/AML FUSION GENE, INCLUDED
Asterisk__:__133440__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E; EIF4E__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E FAMILY, MEMBER 1; EIF4E1;; EIF4E FAMILY, MEMBER 1;; EIF4E-LIKE 1; EIF4EL1;; MESSENGER RNA CAP-BINDING PROTEIN EIF4E__:__
Asterisk__:__133450__:__EWING SARCOMA BREAKPOINT REGION 1; EWSR1__:__EWS GENE; EWS__:__EWS/FLI1 FUSION GENE, INCLUDED;; EWS/ERG FUSION GENE, INCLUDED;; EWS/WT1 FUSION GENE, INCLUDED;; EWS/ATF1 FUSION GENE, INCLUDED;; EWS/FEV FUSION GENE, INCLUDED;; EWS/ZNF278 FUSION GENE, INCLUDED;; EWS/CREB1 FUSION GENE, INCLUDED;; EWS/NR4A3 FUSION GENE, INCLUDED;; EWS/POU5F1 FUSION GENE, INCLUDED;; EWS/ETV1 FUSION GENE, INCLUDED;; EWS/ETV4 FUSION GENE, INCLUDED;; EWS/UQCRH FUSION GENE, INCLUDED
Percent__:__133500__:__EXCHONDROSIS OF PINNA, POSTERIOR__:__EAR BUMP__:__
Asterisk__:__133510__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 3; ERCC3__:__XPB GENE; XPB__:__
Asterisk__:__133520__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 4; ERCC4__:__XPF GENE__:__
Asterisk__:__133530__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 5; ERCC5__:__ERCM2;; UV DAMAGE, EXCISION REPAIR OF, UV-135; UVDR;; RAD2, YEAST, HOMOLOG OF;; XERODERMA PIGMENTOSUM, GROUP G CORRECTING PROTEIN; XPGC;; XPG GENE; XPG__:__
Asterisk__:__133535__:__EXCISION REPAIR, COMPLEMENTING DEFECTIVE, IN MOUSE CELLS; ERCM1__:____:__
Number Sign__:__133540__:__COCKAYNE SYNDROME B; CSB__:____:__
Asterisk__:__133550__:__SOLUTE CARRIER FAMILY 1 (NEURONAL/EPITHELIAL HIGH AFFINITY GLUTAMATE TRANSPORTER), MEMBER 1; SLC1A1__:__EXCITATORY AMINO ACID CARRIER 1; EAAC1;; EAAT3;; GLUTAMATE TRANSPORTER, HIGH AFFINITY__:__
NULL__:__133600__:__EXOSTOSES OF HEEL__:____:__
NULL__:__133690__:__EXOSTOSES WITH ANETODERMIA AND BRACHYDACTYLY, TYPE E__:____:__
Number Sign__:__133700__:__EXOSTOSES, MULTIPLE, TYPE I__:__EXT; EXT1;; MULTIPLE CARTILAGINOUS EXOSTOSES;; DIAPHYSEAL ACLASIS;; MULTIPLE OSTEOCHONDROMAS;; OSTEOCHONDROMATOSIS__:__
Number Sign__:__133701__:__EXOSTOSES, MULTIPLE, TYPE II__:__EXT2__:__
NULL__:__133705__:__EXTERNAL AUDITORY CANAL, BILATERAL ATRESIA OF, WITH CONGENITAL VERTICAL TALUS__:__RASMUSSEN SYNDROME__:__
Caret__:__133710__:__REMOVED FROM DATABASE__:____:__
Caret__:__133730__:__REMOVED FROM DATABASE__:____:__
Caret__:__133740__:__REMOVED FROM DATABASE__:____:__
NULL__:__133750__:__EXTRASYSTOLES, MULTIFORM VENTRICULAR, WITH SHORT STATURE, HYPERPIGMENTATION AND MICROCEPHALY__:____:__
Number Sign__:__133780__:__EXUDATIVE VITREORETINOPATHY 1; EVR1__:__EXUDATIVE VITREORETINOPATHY, FAMILIAL, AUTOSOMAL DOMINANT;; FEVR, AUTOSOMAL DOMINANT;; CRISWICK-SCHEPENS SYNDROME__:__RETINOPATHY OF PREMATURITY, INCLUDED; ROP, INCLUDED
NULL__:__133800__:__EYEBROW, WHORL IN__:____:__
NULL__:__133900__:__HEMIFACIAL HYPERPLASIA__:__HEMIFACIAL HYPERTROPHY;; FACIAL HEMIHYPERTROPHY;; FACIAL ASYMMETRY__:__
NULL__:__134000__:__FACIAL HYPERTRICHOSIS__:____:__
Caret__:__134100__:__MOVED TO 601471__:____:__
Percent__:__134200__:__FACIAL PALSY, FAMILIAL RECURRENT PERIPHERAL__:____:__
NULL__:__134300__:__FACIAL SPASM__:____:__
Asterisk__:__134350__:__COMPLEMENT FACTOR D; CFD__:__FACTOR D; DF;; ADIPSIN; ADN__:__
Asterisk__:__134370__:__COMPLEMENT FACTOR H; CFH__:__H FACTOR 1; HF1;; FACTOR H; HF__:__FACTOR H-LIKE 1, INCLUDED; FHL1, INCLUDED;; COMPLEMENT FACTOR H-LIKE 1, INCLUDED; CFHL1, INCLUDED
Asterisk__:__134371__:__COMPLEMENT FACTOR H-RELATED 1; CFHR1__:__FACTOR H-RELATED GENE 1; FHR1;; H FACTOR-LIKE 1; HFL1__:__
Asterisk__:__134390__:__COAGULATION FACTOR III; F3__:__TISSUE FACTOR; TF;; TISSUE THROMBOPLASTIN__:__
NULL__:__134400__:__FACTOR V EXCESS WITH SPONTANEOUS THROMBOSIS__:__THROMBOPHILIA WITH ELEVATED FACTOR V;; PROACCELERIN EXCESS__:__
NULL__:__134430__:__FACTOR VII AND FACTOR VIII, COMBINED DEFICIENCY OF__:__FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY IV; FMFD IV;; MULTIPLE COAGULATION FACTOR DEFICIENCY IV; MCFD4__:__
Caret__:__134450__:__MOVED TO 613878__:____:__
NULL__:__134500__:__FACTOR VIII DEFICIENCY__:__AUTOSOMAL HEMOPHILIA A__:__
NULL__:__134510__:__FACTOR VIII AND FACTOR IX, COMBINED DEFICIENCY OF; F8F9D__:__FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY II; FMFD II__:__
NULL__:__134520__:__FACTORS VIII, IX AND XI, COMBINED DEFICIENCY OF__:__FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY V; FMFD V;; MULTIPLE COAGULATION FACTOR DEFICIENCY V; MCFD5__:__
Caret__:__134530__:__MOVED TO 227600__:____:__
NULL__:__134540__:__FACTOR IX AND FACTOR XI, COMBINED DEFICIENCY OF__:__FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY VI; FMFD VI;; MULTIPLE COAGULATION FACTOR DEFICIENCY VI; MCFD6__:__
Asterisk__:__134570__:__FACTOR XIII, A1 SUBUNIT; F13A1__:__F13A;; FIBRIN STABILIZING FACTOR, A SUBUNIT;; FSF, A SUBUNIT;; FIBRINOLIGASE;; TRANSGLUTAMINASE, PLASMA__:__
Asterisk__:__134580__:__FACTOR XIII, B SUBUNIT; F13B__:__FIBRIN STABILIZING FACTOR, B SUBUNIT;; FSF, B SUBUNIT__:__
Percent__:__134600__:__FANCONI RENOTUBULAR SYNDROME 1; FRTS1__:__FANCONI RENOTUBULAR SYNDROME; FRTS;; RENAL FANCONI SYNDROME; RFS;; ADULT FANCONI SYNDROME;; FANCONI SYNDROME WITHOUT CYSTINOSIS;; LUDER-SHELDON SYNDROME__:__
Number Sign__:__134610__:__FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL DOMINANT__:__FMF, AUTOSOMAL DOMINANT__:__
Asterisk__:__134629__:__FARNESYL DIPHOSPHATE SYNTHASE; FDPS__:__FARNESYLPYROPHOSPHATE SYNTHETASE; FPS__:__
Caret__:__134631__:__MOVED TO 134629__:____:__
Caret__:__134632__:__MOVED TO 134629__:____:__
Caret__:__134633__:__MOVED TO 134629__:____:__
Caret__:__134634__:__MOVED TO 134629__:____:__
Asterisk__:__134635__:__FARNESYLTRANSFERASE, CAAX BOX, ALPHA; FNTA__:__PROTEIN GERANYLGERANYLTRANSFERASE TYPE I, ALPHA SUBUNIT; PGGT1A__:__
Asterisk__:__134636__:__FARNESYLTRANSFERASE, CAAX BOX, BETA; FNTB__:____:__
Asterisk__:__134637__:__FAS CELL SURFACE DEATH RECEPTOR; FAS__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 6; TNFRSF6;; APOPTOSIS ANTIGEN 1; APT1;; FAS ANTIGEN;; SURFACE ANTIGEN APO1; APO1;; CD95__:__
Asterisk__:__134638__:__FAS LIGAND; FASLG__:__FASL;; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 6; TNFSF6;; APOPTOSIS ANTIGEN LIGAND 1; APT1LG1;; APOPTOSIS ANTIGEN LIGAND;; CD95 LIGAND; CD95L;; CD178 ANTIGEN; CD178__:__
Asterisk__:__134640__:__FATTY ACID-BINDING PROTEIN 2; FABP2__:__FATTY ACID-BINDING PROTEIN, INTESTINAL__:__
Asterisk__:__134650__:__FATTY ACID-BINDING PROTEIN 1; FABP1__:__FATTY ACID-BINDING PROTEIN, LIVER; FABPL;; Z PROTEIN__:__
Asterisk__:__134651__:__FATTY ACID-BINDING PROTEIN 3; FABP3__:__FATTY ACID-BINDING PROTEIN, MUSCLE AND HEART;; FATTY ACID-BINDING PROTEIN, SKELETAL MUSCLE;; MAMMARY-DERIVED GROWTH INHIBITOR; MDGI__:__
Asterisk__:__134660__:__GLUTATHIONE S-TRANSFERASE, PI; GSTP1__:__GLUTATHIONE S-TRANSFERASE 3; GST3;; GST, CLASS PI;; FATTY ACID ETHYL ESTER SYNTHASE III, MYOCARDIAL; FAEES3__:__GLUTATHIONE S-TRANSFERASE PI PSEUDOGENE, INCLUDED; GSTPP, INCLUDED
Asterisk__:__134690__:__FAU GENE; FAU__:__FBR-MuSV ASSOCIATED UBIQUITOUSLY EXPRESSED GENE__:__
Caret__:__134700__:__MOVED TO 300908__:____:__
NULL__:__134720__:__FECUNDITY GENE, BOOROOLA, OF SHEEP, HOMOLOG OF__:__FECB__:__
NULL__:__134750__:__FELTY SYNDROME__:____:__
Asterisk__:__134770__:__FERRITIN HEAVY CHAIN 1; FTH1__:__FTH;; FHC;; FTHL6__:__
NULL__:__134780__:__FEMORAL-FACIAL SYNDROME; FFS__:__FEMORAL HYPOPLASIA-UNUSUAL FACIES SYNDROME; FHUFS__:__
Asterisk__:__134790__:__FERRITIN LIGHT CHAIN; FTL__:____:__
Asterisk__:__134795__:__FIBRILLARIN; FBL__:__FLRN__:__
Asterisk__:__134797__:__FIBRILLIN 1; FBN1__:__FIBRILLIN; FBN__:__
Asterisk__:__134820__:__FIBRINOGEN, A ALPHA POLYPEPTIDE; FGA__:__FIBRINOGEN--ALPHA POLYPEPTIDE CHAIN__:__
Asterisk__:__134830__:__FIBRINOGEN, B BETA POLYPEPTIDE; FGB__:__FIBRINOGEN--BETA POLYPEPTIDE CHAIN__:__
Asterisk__:__134850__:__FIBRINOGEN, G GAMMA POLYPEPTIDE; FGG__:__FIBRINOGEN--GAMMA POLYPEPTIDE CHAIN__:__
NULL__:__134900__:__FIBRINOLYTIC DEFECT__:____:__
Asterisk__:__134920__:__FIBROBLAST GROWTH FACTOR 2; FGF2__:__FIBROBLAST GROWTH FACTOR, BASIC; FGFB; BFGF__:__
Asterisk__:__134921__:__FIBROBLAST GROWTH FACTOR 6; FGF6__:__HST2 ONCOGENE__:__
Asterisk__:__134934__:__FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3__:____:__FGFR3/TACC3 FUSION GENE, INCLUDED
Asterisk__:__134935__:__FIBROBLAST GROWTH FACTOR RECEPTOR 4; FGFR4__:__TYROSINE KINASE RELATED TO FIBROBLAST GROWTH FACTOR RECEPTOR; TKF__:__
Caret__:__135000__:__MOVED TO 178500__:____:__
Number Sign__:__135100__:__FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP__:____:__
Number Sign__:__135150__:__BIRT-HOGG-DUBE SYNDROME; BHD__:__HORNSTEIN-KNICKENBERG SYNDROME;; FIBROFOLLICULOMAS WITH TRICHODISCOMAS AND ACROCHORDONS__:__
Number Sign__:__135290__:__DESMOID DISEASE, HEREDITARY__:__FIBROMATOSIS, FAMILIAL INFILTRATIVE; FIF__:__DESMOID TUMOR CAUSED BY SOMATIC MUTATION, INCLUDED
Number Sign__:__135300__:__FIBROMATOSIS, GINGIVAL, 1; GINGF1__:__GINGF;; GGF1;; FIBROMATOSIS, GINGIVAL, HEREDITARY; HGF__:__
Number Sign__:__135400__:__HYPERTRICHOSIS, CONGENITAL GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA; HTC3__:__FIBROMATOSIS, GINGIVAL, WITH HYPERTRICHOSIS;; CHROMOSOME 17q24.2-q24.3 DELETION SYNDROME;; CHROMOSOME 17q24.2-q24.3 DUPLICATION SYNDROME;; MICRODELETION 17q24.2-q24.3 SYNDROME;; MICRODUPLICATION 17q24.2-q24.3 SYNDROME;; HYPERTRICHOSIS TERMINALIS, GENERALIZED, WITH OR WITHOUT GINGIVAL HYPERPLASIA__:__
Number Sign__:__135500__:__ZIMMERMANN-LABAND SYNDROME 1; ZLS1__:__LABAND SYNDROME;; FIBROMATOSIS, GINGIVAL, WITH ABNORMAL FINGERS, FINGERNAILS, NOSE, AND EARS, AND SPLENOMEGALY__:__
Percent__:__135550__:__FIBROMATOSIS, GINGIVAL, WITH PROGRESSIVE DEAFNESS__:__GINGIVAL FIBROMATOSIS WITH SENSORINEURAL HEARING LOSS; GFD;; JONES SYNDROME__:__
NULL__:__135580__:__FIBROMUSCULAR DYSPLASIA; FMDA__:__FIBROMUSCULAR DYSPLASIA OF ARTERIES;; FMD__:__
Asterisk__:__135600__:__FIBRONECTIN 1; FN1__:__FN;; LARGE, EXTERNAL, TRANSFORMATION-SENSITIVE PROTEIN; LETS__:__
NULL__:__135610__:__FIBRONECTIN-LIKE 2; FNL2__:____:__
Asterisk__:__135620__:__INTEGRIN, ALPHA-5; ITGA5__:__FIBRONECTIN RECEPTOR, ALPHA SUBUNIT; FNRA;; VERY LATE ACTIVATION PROTEIN 5, ALPHA SUBUNIT; VLA5A__:__
Asterisk__:__135630__:__INTEGRIN, BETA-1; ITGB1__:__GLYCOPROTEIN IIa;; GP IIa;; FIBRONECTIN RECEPTOR, BETA SUBUNIT; FNRB;; VERY LATE ACTIVATION PROTEIN, BETA POLYPEPTIDE;; VLA-BETA; VLAB;; CD29__:__
Caret__:__135631__:__MOVED TO 135630__:____:__
Number Sign__:__135700__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 1; CFEOM1__:__OPHTHALMOPLEGIA, CONGENITAL;; BLEPHAROPTOSIS WITH ABSENT EYE MOVEMENTS;; FEOM1 LOCUS__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3B, INCLUDED; CFEOM3B, INCLUDED
Number Sign__:__135750__:__LAURIN-SANDROW SYNDROME; LSS__:__SANDROW SYNDROME;; MIRROR HANDS AND FEET WITH NASAL DEFECTS;; TETRAMELIC MIRROR-IMAGE POLYDACTYLY; TMIP;; MIRROR-IMAGE POLYDACTYLY; MIP;; FIBULA AND ULNA, DUPLICATION OF, WITH ABSENCE OF TIBIA AND RADIUS__:__LAURIN-SANDROW SYNDROME, SEGMENTAL, INCLUDED
NULL__:__135800__:__FIBULA, RECURRENT DISLOCATION OF HEAD OF__:____:__
Asterisk__:__135820__:__FIBULIN 1; FBLN1__:____:__
Asterisk__:__135821__:__FIBULIN 2; FBLN2__:____:__
Number Sign__:__135900__:__COFFIN-SIRIS SYNDROME 1; CSS1__:__COFFIN-SIRIS SYNDROME; CSS;; FIFTH DIGIT SYNDROME;; MENTAL RETARDATION, AUTOSOMAL DOMINANT 12; MRD12__:__
Asterisk__:__135940__:__FILAGGRIN; FLG__:____:__PROFILAGGRIN, INCLUDED
NULL__:__135950__:__FINGER LOCKING, RECURRENT, WITH INTRAUTERINE GROWTH RETARDATION AND PROPORTIONATE SHORT STATURE__:____:__
Number Sign__:__136000__:__ADERMATOGLYPHIA; ADERM__:__FINGERPRINTS, ABSENCE OF__:__
NULL__:__136100__:__FINGERS, RELATIVE LENGTH OF__:__2D:4D FINGER-LENGTH RATIO__:__
Number Sign__:__136120__:__FISH-EYE DISEASE; FED__:__DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY__:__
Asterisk__:__136130__:__FLAVIN-CONTAINING MONOOXYGENASE 1; FMO1__:__FMO, FETAL LIVER__:__
Asterisk__:__136131__:__FLAVIN-CONTAINING MONOOXYGENASE 4; FMO4__:__FLAVIN-CONTAINING MONOOXYGENASE 2, FORMERLY; FMO2, FORMERLY;; FMO, ADULT LIVER FORM;; TRIMETHYLAMINE OXYGENASE;; TMA OXYGENASE__:__
Asterisk__:__136132__:__FLAVIN-CONTAINING MONOOXYGENASE 3; FMO3__:____:__
Number Sign__:__136140__:__FLOATING-HARBOR SYNDROME; FLHS__:____:__
NULL__:__136150__:__FLOOD FACTOR DEFICIENCY__:____:__
NULL__:__136200__:__FLUSHING OF EARS AND SOMNOLENCE__:____:__
Percent__:__136300__:__FLYNN-AIRD SYNDROME__:____:__
Asterisk__:__136350__:__FIBROBLAST GROWTH FACTOR RECEPTOR 1; FGFR1__:__FMS-LIKE TYROSINE KINASE 2; FLT2;; FMS-LIKE GENE; FLG__:__FGFR1/BCR FUSION GENE, INCLUDED;; FGFR1/FGFR1OP2 FUSION GENE, INCLUDED;; FGFR1/ZNF198 FUSION GENE, INCLUDED;; FGFR1/TACC1 FUSION GENE, INCLUDED
Asterisk__:__136351__:__FMS-RELATED TYROSINE KINASE 3; FLT3__:__STEM CELL TYROSINE KINASE 1; STK1;; FLK2__:__
Asterisk__:__136352__:__FMS-LIKE TYROSINE KINASE 4; FLT4__:__VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3; VEGFR3__:__
NULL__:__136400__:__FOCAL EPITHELIAL HYPERPLASIA OF THE ORAL MUCOSA__:____:__
Asterisk__:__136425__:__FOLATE RECEPTOR 2, FETAL; FOLR2__:__FOLATE-BINDING PROTEIN, PLACENTAL;; FOLATE RECEPTOR, BETA__:__
Asterisk__:__136430__:__FOLATE RECEPTOR 1, ADULT; FOLR1__:__FOLATE-BINDING PROTEIN, ADULT; FBP;; FOLATE RECEPTOR; FOLR;; FOLATE RECEPTOR, ALPHA;; OVARIAN CANCER-ASSOCIATED ANTIGEN; MOv18__:__
Asterisk__:__136435__:__FOLLICLE-STIMULATING HORMONE RECEPTOR; FSHR__:__FSH RECEPTOR__:__
Asterisk__:__136440__:__3-KETODIHYDROSPHINGOSINE REDUCTASE; KDSR__:__FOLLICULAR LYMPHOMA VARIANT TRANSLOCATION 1; FVT1;; FOLLICULAR-VARIANT-TRANSLOCATION GENE__:__
Asterisk__:__136470__:__FOLLISTATIN; FST__:____:__
NULL__:__136480__:__FOURTH CRANIAL NERVE PALSY, FAMILIAL CONGENITAL__:__TROCHLEAR NERVE PALSY, FAMILIAL CONGENITAL;; SUPERIOR OBLIQUE OCULOMOTOR PALSY, FAMILIAL CONGENITAL;; STRABISMUS FROM SUPERIOR OBLIQUE PALSY__:__
Caret__:__136490__:__MOVED TO 103710__:____:__
Percent__:__136500__:__FOCAL FACIAL DERMAL DYSPLASIA 1, BRAUER TYPE; FFDD1__:__BRAUER SYNDROME;; HEREDITARY SYMMETRICAL APLASTIC NEVI OF TEMPLES;; BITEMPORAL APLASIA CUTIS CONGENITA__:__
Asterisk__:__136510__:__FOLYLPOLYGLUTAMATE SYNTHETASE; FPGS__:____:__
Asterisk__:__136515__:__FOS-LIKE ANTIGEN 1; FOSL1__:__FOS-RELATED ANTIGEN 1; FRA1__:__
Number Sign__:__136520__:__FOVEAL HYPOPLASIA 1; FVH1__:__FOVEAL HYPOPLASIA 1 WITH OR WITHOUT ANTERIOR SEGMENT ANOMALIES AND/OR CATARACT__:__
Asterisk__:__136530__:__FOLLICLE-STIMULATING HORMONE, BETA POLYPEPTIDE; FSHB__:__FOLLITROPIN, BETA CHAIN__:__
Asterisk__:__136533__:__FORKHEAD BOX O1A; FOXO1A__:__FOXO1;; FORKHEAD IN RHABDOMYOSARCOMA; FKHR;; FORKHEAD, DROSOPHILA, HOMOLOG OF, IN RHABDOMYOSARCOMA__:__FKHR/PAX7 FUSION GENE, INCLUDED;; FKHR/PAX3 FUSION GENE, INCLUDED
Asterisk__:__136535__:__FORMIN 1; FMN1__:__FORMIN; FMN;; LIMB DEFORMITY, MOUSE, HOMOLOG OF; LD__:__
Asterisk__:__136537__:__FORMYL PEPTIDE RECEPTOR 1; FPR1__:__FMLP RECEPTOR;; N-FORMYLPEPTIDE RECEPTOR__:__
Asterisk__:__136538__:__FORMYL PEPTIDE RECEPTOR 2; FPR2__:__FORMYL PEPTIDE RECEPTOR-LIKE 1; FPRL1;; FORMYL PEPTIDE RECEPTOR HOMOLOG 1; FPRH1;; HM63;; LIPOXIN A4 RECEPTOR; ALXR; LXA4R__:__
Asterisk__:__136539__:__FORMYL PEPTIDE RECEPTOR 3; FPR3__:__FORMYL PEPTIDE RECEPTOR-LIKE 2; FPRL2;; FORMYL PEPTIDE RECEPTOR HOMOLOG 2; FPRH2__:__
Number Sign__:__136540__:__FRAGILE SITE 10q23__:____:__
Number Sign__:__136550__:__MACULAR DYSTROPHY, RETINAL, 1, NORTH CAROLINA TYPE; MCDR1__:__NORTH CAROLINA MACULAR DYSTROPHY; NCMD;; CENTRAL AREOLAR PIGMENT EPITHELIAL DYSTROPHY; CAPED;; RETINAL PIGMENT EPITHELIAL DYSTROPHY, CENTRAL;; FOVEAL DYSTROPHY, PROGRESSIVE, FORMERLY__:__
Caret__:__136560__:__MOVED TO 616109__:____:__
Number Sign__:__136570__:__CHROMOSOME 16p12.1 DELETION SYNDROME, 520-KB__:____:__FRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(p12.1), INCLUDED; FRA16E, INCLUDED;; FRAGILE SITE 16p12, INCLUDED
Number Sign__:__136580__:__FRAGILE SITE, DISTAMYCIN A TYPE, RARE, FRA(16)(q22.1); FRA16B__:__FRAGILE SITE 16q22__:__
Number Sign__:__136590__:__FRAGILE SITE 20p11__:____:__
NULL__:__136600__:__FRIEDREICH ATAXIA, SO-CALLED, WITH OPTIC ATROPHY AND SENSORINEURAL DEAFNESS__:____:__
Caret__:__136610__:__MOVED TO 601464__:____:__
Number Sign__:__136620__:__FRAGILE SITE 10q25; FRA10B__:__BrdU-DEPENDENT FRAGILE SITE__:__
Number Sign__:__136630__:__MENTAL RETARDATION, FRA12A TYPE__:____:__
Number Sign__:__136640__:__FRAGILE SITE 9q32__:____:__
Caret__:__136650__:__MOVED TO 601153__:____:__
Number Sign__:__136660__:__FRAGILE SITE 17p12__:____:__
Caret__:__136670__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__136680__:__FRASIER SYNDROME__:____:__
Caret__:__136750__:__MOVED TO 164770__:____:__
Number Sign__:__136760__:__FRONTONASAL DYSPLASIA 1; FND1__:__FRONTORHINY;; FRONTONASAL DYSPLASIA; FND;; FRONTONASAL MALFORMATION; FNM;; MEDIAN FACIAL CLEFT SYNDROME__:__
Caret__:__136770__:__MOVED TO 164770__:____:__
Number Sign__:__136800__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 1; FECD1__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, EARLY-ONSET__:__
Asterisk__:__136820__:__FUCOSIDASE, ALPHA-L, 2; FUCA2__:__ALPHA-L-FUCOSIDASE 2;; FUCOSIDASE, ALPHA-L, PLASMA__:__
NULL__:__136830__:__FUCOSIDASE REGULATOR__:__ALPHA-L-FUCOSIDASE REGULATOR; FUCT__:__
Asterisk__:__136835__:__FUCOSYLTRANSFERASE 5; FUT5__:__ALPHA-3-FUCOSYLTRANSFERASE, PLASMA TYPE__:__
Asterisk__:__136836__:__FUCOSYLTRANSFERASE 6; FUT6__:____:__
Asterisk__:__136840__:__FULL-LENGTH RETROVIRAL SEQUENCE 1; FRV1__:____:__
Asterisk__:__136850__:__FUMARATE HYDRATASE; FH__:__FUMARASE__:__FUMARATE HYDRATASE, CYTOSOLIC, INCLUDED; FH1, INCLUDED;; FUMARATE HYDRATASE, MITOCHONDRIAL, INCLUDED; FH2, INCLUDED
Asterisk__:__136870__:__FULL-LENGTH RETROVIRAL SEQUENCE 2; FRV2__:____:__
Number Sign__:__136880__:__FUNDUS ALBIPUNCTATUS__:____:__RETINITIS PUNCTATA ALBESCENS, INCLUDED
Asterisk__:__136890__:__FULL-LENGTH RETROVIRAL SEQUENCE 3; FRV3__:____:__
Number Sign__:__136900__:__SORSBY FUNDUS DYSTROPHY; SFD__:__FUNDUS DYSTROPHY, PSEUDOINFLAMMATORY, OF SORSBY;; MACULAR DYSTROPHY, HEMORRHAGIC__:__
Asterisk__:__136950__:__FURIN, PAIRED BASIC AMINO ACID CLEAVING ENZYME; FURIN__:__PAIRED BASIC AMINO ACID CLEAVING ENZYME; PACE;; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 3; PCSK3;; SPC1__:__
NULL__:__137000__:__FUTCHER LINE__:____:__
Asterisk__:__137010__:__F9 EMBRYONIC ANTIGEN; FEA__:____:__
Asterisk__:__137020__:__TISSUE-SPECIFIC TRANSPLANTATION ANTIGEN 3; TSTA3__:__GDP-KETO-6-DEOXYMANNOSE 3,5-EPIMERASE, 4-REDUCTASE;; RED CELL NADP(H)-BINDING PROTEIN;; FX__:__
Asterisk__:__137025__:__FYN ONCOGENE RELATED TO SRC, FGR, YES; FYN__:__FYN TYROSINE KINASE PROTOONCOGENE;; SRC-LIKE KINASE; SLK;; SYN__:__
Asterisk__:__137026__:__G PROTEIN-COUPLED RECEPTOR KINASE 4; GRK4__:__GPRK4;; G PROTEIN-COUPLED RECEPTOR KINASE 2-LIKE; GPRK2L__:__
Asterisk__:__137028__:__GALACTOKINASE 2; GALK2__:__GK2__:__
Asterisk__:__137030__:__GALACTOSE MUTAROTASE; GALM__:__ALDOSE 1-EPIMERASE;; GALACTOSE ENZYME ACTIVATOR; GLAT;; GAL PLUS ACTIVATOR__:__
Caret__:__137033__:__MOVED TO 153619__:____:__
Asterisk__:__137035__:__GALANIN; GAL__:__GALN; GLNN__:__
NULL__:__137040__:__GALLBLADDER, AGENESIS OF__:____:__
NULL__:__137050__:__GAMMA-A-GLOBULIN, DEFECT IN ASSEMBLY OF__:__IMMUNOGLOBULIN A, DEFECT IN ASSEMBLY OF;; IgA, DEFECT IN ASSEMBLY OF__:__
Asterisk__:__137060__:__BETA-1,4-GALACTOSYLTRANSFERASE 1; B4GALT1__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 1;; GTB;; GALACTOSYLTRANSFERASE 1; GT1;; GLYCOPROTEIN 4-BETA-GALACTOSYLTRANSFERASE 2; GGTB2__:__LACTOSE SYNTHETASE, INCLUDED
Caret__:__137061__:__MOVED TO 137060__:____:__
Asterisk__:__137070__:__FUSED IN SARCOMA; FUS__:__FUSION, DERIVED FROM 12-16 TRANSLOCATION, MALIGNANT LIPOSARCOMA;; TRANSLOCATED IN LIPOSARCOMA; TLS__:__FUS/ATF1 FUSION GENE, INCLUDED;; FUS/CHOP FUSION GENE, INCLUDED;; FUS/ERG FUSION GENE, INCLUDED;; FUS/CREB3L2 FUSION GENE, INCLUDED
Percent__:__137100__:__IMMUNOGLOBULIN A DEFICIENCY 1; IGAD1__:__IMMUNOGLOBULIN A, SELECTIVE DEFICIENCY OF;; IgA, SELECTIVE DEFICIENCY OF;; GAMMA-A-GLOBULIN, SELECTIVE DEFICIENCY OF__:__
NULL__:__137130__:__GASTRIC SNEEZING__:__STOMACH SNEEZE REFLEX__:__
Asterisk__:__137140__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-2; GABRA2__:__GABA-A RECEPTOR, ALPHA-2 POLYPEPTIDE__:__
Asterisk__:__137141__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-4; GABRA4__:__GABA-A RECEPTOR, ALPHA-4 POLYPEPTIDE__:__
Asterisk__:__137142__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-5; GABRA5__:__GABA-A RECEPTOR, ALPHA-5 POLYPEPTIDE__:__
Asterisk__:__137143__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-6; GABRA6__:__GABA-A RECEPTOR, ALPHA-6 POLYPEPTIDE__:__
Asterisk__:__137150__:__4-AMINOBUTYRATE AMINOTRANSFERASE; ABAT__:__GAMMA-AMINOBUTYRATE TRANSAMINASE; GABAT;; GABA-TRANSFERASE;; GABA-TRANSAMINASE__:__
Asterisk__:__137160__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-1; GABRA1__:__GABA-A RECEPTOR, ALPHA-1 POLYPEPTIDE__:__
Asterisk__:__137161__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, RHO-1; GABRR1__:__GABA-C RECEPTOR, RHO-1 SUBUNIT__:__
Asterisk__:__137162__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, RHO-2; GABRR2__:__GABA-C RECEPTOR, RHO-2 SUBUNIT__:__
Asterisk__:__137163__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, DELTA; GABRD__:__GABA-A RECEPTOR, DELTA POLYPEPTIDE__:__
Asterisk__:__137164__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, GAMMA-2; GABRG2__:__GABA-A RECEPTOR, GAMMA-2 POLYPEPTIDE__:__
Asterisk__:__137165__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), MEMBER 1; SLC6A1__:__GAMMA-AMINOBUTYRIC ACID TRANSPORTER;; GABA TRANSPORTER; GABATR;; GABATHG__:__
Asterisk__:__137166__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, GAMMA-1; GABRG1__:__GABA-A RECEPTOR, GAMMA-1 POLYPEPTIDE__:__
Asterisk__:__137167__:__GAMMA-GLUTAMYL CARBOXYLASE; GGCX__:____:__
Asterisk__:__137168__:__GAMMA-GLUTAMYLTRANSFERASE 5; GGT5__:__GAMMA-GLUTAMYLTRANSFERASE-LIKE ACTIVITY 1; GGTLA1;; GAMMA-GLUTAMYL TRANSPEPTIDASE-RELATED ENZYME; GGTREL;; GAMMA-GLUTAMYL CLEAVING ENZYME;; GAMMA-GLUTAMYL LEUKOTRIENASE; GGL__:__
Asterisk__:__137170__:__GAMMA-GLUTAMYL CYCLOTRANSFERASE; GGCT__:__GLUTAMYLCYCLOTRANSFERASE, GAMMA; GCTG;; CHROMOSOME 7 OPEN READING FRAME 24; C7ORF24;; CYTOCHROME c-RELEASING FACTOR, 21-KD; CRF21__:__
Asterisk__:__137181__:__GAMMA-GLUTAMYLTRANSFERASE 2; GGT2__:____:__
Asterisk__:__137190__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, BETA-1; GABRB1__:__GABA-A RECEPTOR, BETA-1 POLYPEPTIDE__:__
Asterisk__:__137192__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, BETA-3; GABRB3__:__GABA-A RECEPTOR, BETA-3 POLYPEPTIDE__:__
Number Sign__:__137200__:__NEUROMYOTONIA AND AXONAL NEUROPATHY, AUTOSOMAL RECESSIVE; NMAN__:__GAMSTORP-WOHLFART SYNDROME;; MYOKYMIA, MYOTONIA, AND MUSCLE WASTING__:__
Asterisk__:__137207__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 32; LRRC32__:__GLYCOPROTEIN A REPETITIONS PREDOMINANT; GARP;; D11S833E__:__
NULL__:__137210__:__GASTRIC VOLVULUS, INTRATHORACIC__:____:__
Number Sign__:__137215__:__GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC__:__GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC;; GASTRIC CANCER, FAMILIAL DIFFUSE__:__BREAST CANCER, LOBULAR, INCLUDED; LBC, INCLUDED;; GASTRIC CANCER, FAMILIAL DIFFUSE, AND CLEFT LIP WITH OR WITHOUT CLEFT PALATE, INCLUDED
Asterisk__:__137216__:__ATPase, H+,K+ EXCHANGING, ALPHA SUBUNIT; ATP4A__:__GASTRIC HYDROGEN-POTASSIUM ATPase, ALPHA;; ATP6A, FORMERLY__:__
Asterisk__:__137217__:__ATPase, H+,K+ EXCHANGING, BETA POLYPEPTIDE; ATP4B__:__GASTRIC HYDROGEN-POTASSIUM ATPase, BETA__:__
NULL__:__137220__:__GASTRIC JUICE PEPTIDES__:____:__
Asterisk__:__137240__:__GASTRIC INHIBITORY POLYPEPTIDE; GIP__:__GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE__:__
Plus__:__137241__:__GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GIPR__:__INSULINOTROPIC POLYPEPTIDE RECEPTOR, GLUCOSE-DEPENDENT__:__PLASMA GLUCOSE, 2-HOUR, QUANTITATIVE TRAIT LOCUS 2, INCLUDED; PGQTL2, INCLUDED
Number Sign__:__137245__:__LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TYPE__:__MALT LYMPHOMA;; GASTRIC LYMPHOMA, PRIMARY__:__
Asterisk__:__137250__:__GASTRIN; GAS__:____:__
Asterisk__:__137260__:__GASTRIN-RELEASING PEPTIDE; GRP__:__GASTRIN-RELEASING POLYPEPTIDE;; BOMBESIN; BN__:__
NULL__:__137270__:__GASTROCUTANEOUS SYNDROME__:__PEPTIC ULCER/HIATAL HERNIA, MULTIPLE LENTIGINES/CAFE-AU-LAIT SPOTS, HYPERTELORISM, MYOPIA__:__
NULL__:__137280__:__GASTRITIS, FAMILIAL GIANT HYPERTROPHIC__:__MENETRIER DISEASE__:__
Asterisk__:__137290__:__TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TACSTD2__:__MEMBRANE COMPONENT, CHROMOSOME 1, SURFACE MARKER 1; M1S1;; GASTROINTESTINAL TUMOR-ASSOCIATED ANTIGEN 1, 40-KD GLYCOPROTEIN; GA733-1;; GA733__:__
Asterisk__:__137295__:__GATA-BINDING PROTEIN 2; GATA2__:____:__
Asterisk__:__137350__:__GELSOLIN; GSN__:____:__
Caret__:__137357__:__MOVED TO 194072__:____:__
Percent__:__137360__:__GENOCHONDROMATOSIS__:____:__
NULL__:__137370__:__GENU VALGUM, ST. HELENA FAMILIAL__:__GENU VALGUM, HEREDITARY PUBERTAL__:__
NULL__:__137400__:__GEOGRAPHIC AND FISSURED TONGUE__:____:__GLOSSITIS, BENIGN MIGRATORY, INCLUDED;; SCROTAL TONGUE, INCLUDED;; LINGUA PLICATA, INCLUDED
Number Sign__:__137440__:__GERSTMANN-STRAUSSLER DISEASE; GSD__:__ENCEPHALOPATHY, SUBACUTE SPONGIFORM, GERSTMANN-STRAUSSLER TYPE;; GERSTMANN-STRAUSSLER-SCHEINKER DISEASE; GSS;; CEREBELLAR ATAXIA, PROGRESSIVE DEMENTIA, AND AMYLOID DEPOSITS IN CNS;; AMYLOIDOSIS, CEREBRAL, WITH SPONGIFORM ENCEPHALOPATHY;; PRION DEMENTIA__:__CEREBRAL AMYLOID ANGIOPATHY, PRNP-RELATED, INCLUDED
Percent__:__137500__:__GIANT NEUTROPHIL LEUKOCYTES__:____:__
Number Sign__:__137550__:__MELANOCYTIC NEVUS SYNDROME, CONGENITAL; CMNS__:__GIANT PIGMENTED HAIRY NEVUS; GPHN;; GIANT CONGENITAL PIGMENTED NEVUS;; PIGMENTED MOLES__:__NEVUS SPILUS, INCLUDED;; SPITZ NEVUS, INCLUDED
Caret__:__137560__:__MOVED TO 155100__:____:__
Asterisk__:__137570__:__SOLUTE CARRIER FAMILY 20 (PHOSPHATE TRANSPORTER), MEMBER 1; SLC20A1__:__GIBBON APE LEUKEMIA VIRUS RECEPTOR 1; GLVR1;; PHOSPHATE TRANSPORTER 1; PIT1__:__
Percent__:__137575__:__GIGANTIFORM CEMENTOMA, FAMILIAL__:__CEMENTOMAS, FAMILIAL MULTIPLE;; CEMENTAL DYSPLASIA, PERIAPICAL__:__
Number Sign__:__137580__:__GILLES DE LA TOURETTE SYNDROME; GTS__:__TOURETTE SYNDROME; TS;; TOURETTE DISORDER__:__CHRONIC MOTOR TICS, INCLUDED
Number Sign__:__137600__:__ANTERIOR SEGMENT DYSGENESIS 4; ASGD4__:__IRIDOGONIODYSGENESIS, TYPE 2; IRID2;; IRIDOGONIODYSGENESIS SYNDROME; IGDS;; IRIS HYPOPLASIA WITH EARLY-ONSET GLAUCOMA, AUTOSOMAL DOMINANT; IHGA__:__
NULL__:__137700__:__GLAUCOMA WITH ELEVATED EPISCLERAL VENOUS PRESSURE__:____:__
Number Sign__:__137750__:__GLAUCOMA 1, OPEN ANGLE, A; GLC1A__:__GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 1; JOAG1__:__GLAUCOMA 1, OPEN ANGLE, L, INCLUDED; GLC1L, INCLUDED
Number Sign__:__137760__:__GLAUCOMA, PRIMARY OPEN ANGLE; POAG__:____:__GLAUCOMA 1, OPEN ANGLE, E, INCLUDED; GLC1E, INCLUDED;; GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET, INCLUDED
NULL__:__137763__:__GLAUCOMA AND SLEEP APNEA__:____:__
Caret__:__137765__:__MOVED TO 608328__:____:__
Asterisk__:__137780__:__GLIAL FIBRILLARY ACIDIC PROTEIN; GFAP__:____:__
Number Sign__:__137800__:__GLIOMA SUSCEPTIBILITY 1; GLM1__:____:__GLIOMA OF BRAIN, FAMILIAL, INCLUDED; GLM, INCLUDED;; GLIOBLASTOMA MULTIFORME, INCLUDED; GBM, INCLUDED;; ASTROCYTOMA, INCLUDED;; OLIGODENDROGLIOMA, INCLUDED;; EPENDYMOMA, INCLUDED;; SUBEPENDYMOMA, INCLUDED
NULL__:__137900__:__GLOBULIN ANOMALY INVOLVING BETA (2A)-GLOBULIN__:____:__
Number Sign__:__137920__:__RENAL CYSTS AND DIABETES SYNDROME; RCAD__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 5; MODY5;; HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, ATYPICAL;; FJHN, ATYPICAL;; GLOMERULOCYSTIC KIDNEY DISEASE, HYPOPLASTIC TYPE;; GLOMERULOCYSTIC KIDNEY, FAMILIAL HYPOPLASTIC;; CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT WITH DIABETES;; CAKUT WITH DIABETES__:__
Number Sign__:__137940__:__HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA-RENAL DEFECT SYNDROME; HLTRS__:__GLOMERULONEPHRITIS WITH SPARSE HAIR AND TELANGIECTASES;; TELANGIECTATIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS__:__
Percent__:__137950__:__GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 1; GFND1__:__GLOMERULOPATHY WITH GIANT FIBRILLAR DEPOSITS;; LOBULAR GLOMERULOPATHY, FAMILIAL__:__
Asterisk__:__137960__:__MPV17, MOUSE, HOMOLOG OF; MPV17__:____:__
Number Sign__:__138000__:__GLOMUVENOUS MALFORMATIONS; GVM__:__VENOUS MALFORMATIONS WITH GLOMUS CELLS; VMGLOM;; GLOMUS TUMORS, MULTIPLE;; GLOMANGIOMAS, MULTIPLE__:__
Asterisk__:__138030__:__GLUCAGON; GCG__:____:__GLUCAGON-LIKE PEPTIDE 1, INCLUDED; GLP1, INCLUDED;; GLUCAGON-LIKE PEPTIDE 2, INCLUDED; GLP2, INCLUDED
Asterisk__:__138032__:__GLUCAGON-LIKE PEPTIDE 1 RECEPTOR; GLP1R__:__GLP1 RECEPTOR__:__
Asterisk__:__138033__:__GLUCAGON RECEPTOR; GCGR__:____:__
Caret__:__138035__:__MOVED TO 230800__:____:__
Asterisk__:__138040__:__NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, MEMBER 1; NR3C1__:__GLUCOCORTICOID RECEPTOR; GCCR; GR;; GCR; GRL__:__
NULL__:__138060__:__GLUCOCORTICOID RECEPTOR-LIKE 1; GRLL1__:__GCRL;; GLUCOCORTICOID RECEPTOR 2; GCR2__:__
NULL__:__138070__:__GLUCOGLYCINURIA__:____:__
Asterisk__:__138079__:__GLUCOKINASE; GCK__:__GK; GLK;; HEXOKINASE 4; HK4;; LIVER GLUCOKINASE; LGLK__:__
Asterisk__:__138090__:__HEXOSE-6-PHOSPHATE DEHYDROGENASE; H6PD__:__GLUCOSE DEHYDROGENASE; GDH;; GDH/6PGL ENDOPLASMIC BIFUNCTIONAL PROTEIN;; HEXOSE-6-PHOSPHATE DEHYDROGENASE PRECURSOR;; GLUCOSE-6-PHOSPHATE DEHYDROGENASE, SALIVARY;; G6PD, H FORM; G6PDH;; GLUCOSE 1-DEHYDROGENASE__:__
Caret__:__138100__:__MOVED TO 138090__:____:__
NULL__:__138110__:__GLUCOSE-6-PHOSPHATE DEHYDROGENASE-LIKE; G6PDL__:____:__
Asterisk__:__138120__:__HEAT-SHOCK 70-KD PROTEIN 5; HSPA5__:__GLUCOSE-REGULATED PROTEIN, 78-KD; GRP78;; IMMUNOGLOBULIN HEAVY CHAIN-BINDING PROTEIN; BIP__:__
Asterisk__:__138130__:__GLUTAMATE DEHYDROGENASE 1; GLUD1__:__GLUD;; GDH__:__
Asterisk__:__138140__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 1; SLC2A1__:__GLUCOSE TRANSPORTER 1; GLUT; GLUT1;; ERYTHROCYTE/HEPATOMA GLUCOSE TRANSPORTER;; HUMAN T-CELL LEUKEMIA VIRUS RECEPTOR; HTLVR;; HTLV-1 AND HTLV-2 RECEPTOR__:__
Asterisk__:__138150__:__GLUTAMATE OXALOACETATE TRANSAMINASE, MITOCHONDRIAL; GOT2__:__ASPARTATE AMINOTRANSFERASE, MITOCHONDRIAL__:__
Asterisk__:__138160__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 2; SLC2A2__:__GLUCOSE TRANSPORTER 2; GLUT2;; GLUCOSE TRANSPORTER, LIVER/ISLET__:__
Asterisk__:__138170__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 3; SLC2A3__:__GLUCOSE TRANSPORTER 3; GLUT3;; GLUCOSE TRANSPORTER, FETAL SKELETAL MUSCLE__:__SOLUTE CARRIER FAMILY 2, MEMBER 3 PSEUDOGENE, INCLUDED; SLC2A3P, INCLUDED;; GLUCOSE TRANSPORTER 3 PSEUDOGENE 1, INCLUDED; GLUT3P1, INCLUDED
Asterisk__:__138180__:__GLUTAMATE OXALOACETATE TRANSAMINASE, SOLUBLE; GOT1__:__ASPARTATE AMINOTRANSFERASE, CYTOSOLIC; AST__:__
Asterisk__:__138190__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 4; SLC2A4__:__GLUCOSE TRANSPORTER 4; GLUT4;; GLUCOSE TRANSPORTER, INSULIN-RESPONSIVE__:__
Asterisk__:__138200__:__GLUTAMATE PYRUVATE TRANSAMINASE; GPT__:__GLUTAMATE PYRUVATE TRANSAMINASE, SOLUBLE RED CELL; GPT1;; GLUTAMATE PYRUVATE TRANSAMINASE, SOLUBLE LIVER;; ALANINE AMINOTRANSFERASE 1; AAT1; ALT1;; ALANINE AMINOTRANSFERASE, SOLUBLE__:__
Asterisk__:__138210__:__GLUTAMATE PYRUVATE TRANSAMINASE 2; GPT2__:__GLUTAMATE PYRUVATE TRANSAMINASE, MITOCHONDRIAL;; ALANINE AMINOTRANSFERASE 2; ALT2__:__
Caret__:__138220__:__MOVED TO 138200__:____:__
Asterisk__:__138230__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE/FRUCTOSE TRANSPORTER), MEMBER 5; SLC2A5__:__GLUCOSE TRANSPORTER 5; GLUT5;; GLUCOSE TRANSPORTER, KIDNEY__:__
Caret__:__138240__:__MOVED TO 138170__:____:__
Asterisk__:__138243__:__GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 3; GRIK3__:__GLUTAMATE RECEPTOR 7; GLUR7; GLR7__:__
Asterisk__:__138244__:__GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 2; GRIK2__:__GLUTAMATE RECEPTOR 6; GLR6; GLUR6__:__
Asterisk__:__138245__:__GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 1; GRIK1__:__GLUTAMATE RECEPTOR 5; GLR5; GLUR5__:__
Asterisk__:__138246__:__GLUTAMATE RECEPTOR, IONOTROPIC, AMPA 4; GRIA4__:__GLUTAMATE RECEPTOR 4; GLUR4;; GLURD__:__
Asterisk__:__138247__:__GLUTAMATE RECEPTOR, IONOTROPIC, AMPA 2; GRIA2__:__GLUTAMATE RECEPTOR 2; GLUR2;; GLURB__:__
Asterisk__:__138248__:__GLUTAMATE RECEPTOR, IONOTROPIC, AMPA 1; GRIA1__:__GLUTAMATE RECEPTOR 1; GLUR1;; GLURA__:__
Asterisk__:__138249__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 1; GRIN1__:__N-METHYL-D-ASPARTATE RECEPTOR CHANNEL, SUBUNIT ZETA-1; NMDAR1;; NR1__:__
Asterisk__:__138250__:__ALDEHYDE DEHYDROGENASE 18 FAMILY, MEMBER A1; ALDH18A1__:__1-PYRROLINE-5-CARBOXYLATE SYNTHETASE; PYCS;; P5CS;; GLUTAMATE GAMMA-SEMIALDEHYDE SYNTHETASE; GSAS__:__
Asterisk__:__138251__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, ASSOCIATED PROTEIN; GRINA__:__N-METHYL-D-ASPARTATE RECEPTOR-ASSOCIATED PROTEIN 1; NMDARA1;; N-METHYL-D-ASPARTATE RECEPTOR, GLUTAMATE-BINDING SUBUNIT;; GLUTAMATE RECEPTOR, NMDA SUBTYPE, GLUTAMATE-BINDING SUBUNIT__:__
Asterisk__:__138252__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 2B; GRIN2B__:__N-METHYL-D-ASPARTATE RECEPTOR CHANNEL, SUBUNIT EPSILON-2; NMDAR2B;; NR2B__:__
Asterisk__:__138253__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 2A; GRIN2A__:__N-METHYL-D-ASPARTATE RECEPTOR CHANNEL, SUBUNIT EPSILON-1; NMDAR2A;; NR2A__:__
Asterisk__:__138254__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 2C; GRIN2C__:__N-METHYL-D-ASPARTATE RECEPTOR CHANNEL, SUBUNIT EPSILON-3; NMDAR2C;; NR2C__:__
Caret__:__138270__:__MOVED TO 138385__:____:__
Asterisk__:__138275__:__GLUTAMATE DECARBOXYLASE 2; GAD2__:__GLUTAMIC ACID DECARBOXYLASE 2;; GLUTAMATE DECARBOXYLASE, PANCREATIC ISLET AND BRAIN, 65-KD; GAD65__:__
Caret__:__138276__:__MOVED TO 605363__:____:__
NULL__:__138277__:__GLUTAMIC ACID DECARBOXYLASE, BRAIN, MEMBRANE FORM__:____:__
Asterisk__:__138280__:__GLUTAMINASE; GLS__:__GLUTAMINASE, PHOSPHATE-ACTIVATED;; GLUTAMINASE, PLATELET;; KIAA0838__:__
Asterisk__:__138290__:__GLUTAMATE-AMMONIA LIGASE; GLUL__:__GLUTAMINE SYNTHETASE; GLNS__:__GLUTAMATE-AMMONIA LIGASE-LIKE 1, INCLUDED; GLULL1, INCLUDED;; GLUTAMATE-AMMONIA LIGASE-LIKE 2, INCLUDED; GLULL2, INCLUDED;; GLUTAMATE-AMMONIA LIGASE-LIKE 3, INCLUDED; GLULL3, INCLUDED
Asterisk__:__138292__:__GLUTAMINE:FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE 1; GFPT1__:__GFAT1;; GFAT__:__GFPT1L, INCLUDED
Asterisk__:__138295__:__GLUTAMYL-PROLYL-tRNA SYNTHETASE; EPRS__:__GLU-PRO-tRNA SYNTHETASE; GLUPRORS;; PROLYL-tRNA SYNTHETASE; PARS__:__
Asterisk__:__138297__:__GLUTAMYL AMINOPEPTIDASE; ENPEP__:__AMINOPEPTIDASE A; APA;; GP160__:__
Plus__:__138300__:__GLUTATHIONE REDUCTASE; GSR__:____:__GLUTATHIONE REDUCTASE, HEMOLYTIC ANEMIA DUE TO DEFICIENCY OF, IN RED CELLS, INCLUDED
Asterisk__:__138319__:__GLUTATHIONE PEROXIDASE 2; GPX2__:__GLUTATHIONE PEROXIDASE, GASTROINTESTINAL__:__
Asterisk__:__138320__:__GLUTATHIONE PEROXIDASE 1; GPX1__:____:__
Asterisk__:__138321__:__GLUTATHIONE PEROXIDASE 3; GPX3__:__GLUTATHIONE PEROXIDASE, PLASMA__:__
Asterisk__:__138322__:__GLUTATHIONE PEROXIDASE 4; GPX4__:__PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PHGPX__:__
Asterisk__:__138330__:__GLUTATHIONE S-TRANSFERASE, MICROSOMAL, 1; MGST1__:__GLUTATHIONE S-TRANSFERASE 12; GST12__:__
Asterisk__:__138333__:__GLUTATHIONE S-TRANSFERASE, MU-4; GSTM4__:__GLUTATHIONE S-TRANSFERASE M4__:__
Caret__:__138335__:__MOVED TO 138370__:____:__
NULL__:__138340__:__GLUTATHIONE TRANSFERASE ACTIVITY TOWARD TRANS-STILBENE OXIDE__:__TRANS-STILBENE OXIDE GLUTATHIONE TRANSFERASE ACTIVITY__:__
Asterisk__:__138350__:__GLUTATHIONE S-TRANSFERASE, MU-1; GSTM1__:__GLUTATHIONE S-TRANSFERASE M1;; GLUTATHIONE TRANSFERASE, CLASS MU, 1;; GST1;; LIVER AND FIBROBLAST GST1__:__
Asterisk__:__138359__:__GLUTATHIONE S-TRANSFERASE, ALPHA-1; GSTA1__:__GLUTATHIONE S-TRANSFERASE A1;; GST, CLASS ALPHA, 1__:__
Asterisk__:__138360__:__GLUTATHIONE S-TRANSFERASE, ALPHA-2; GSTA2__:__GLUTATHIONE S-TRANSFERASE A2;; GLUTATHIONE S-TRANSFERASE 2; GST2;; LIVER GST2;; GST, CLASS ALPHA, 2__:__
Caret__:__138370__:__MOVED TO 134660__:____:__
Asterisk__:__138380__:__GLUTATHIONE S-TRANSFERASE, MU-2; GSTM2__:__GLUTATHIONE S-TRANSFERASE 4; GST4;; GLUTATHIONE S-TRANSFERASE M2;; GST, MUSCLE; GSTM__:__
Asterisk__:__138385__:__GLUTATHIONE S-TRANSFERASE, MU-5; GSTM5__:__GLUTATHIONE S-TRANSFERASE M5;; GLUTATHIONE S-TRANSFERASE, CLASS MU, 5__:__
Asterisk__:__138390__:__GLUTATHIONE S-TRANSFERASE, MU-3; GSTM3__:__GLUTATHIONE S-TRANSFERASE M3;; BRAIN GST; GSTB;; GLUTATHIONE S-TRANSFERASE 5; GST5__:__
Caret__:__138391__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__138400__:__GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GAPDH__:__GAPD; G3PD;; OCT1 COACTIVATOR IN S PHASE, 38-KD COMPONENT;; OCAS, p38 COMPONENT__:__
Asterisk__:__138420__:__GLYCEROL-3-PHOSPHATE DEHYDROGENASE 1; GPD1__:__GLYCEROPHOSPHATE DEHYDROGENASE;; GLYCEROL-3-PHOSPHATE DEHYDROGENASE, CYTOSOLIC__:__
Asterisk__:__138430__:__GLYCEROL-3-PHOSPHATE DEHYDROGENASE 2; GPD2__:__GLYCEROPHOSPHATE DEHYDROGENASE-2 Ca(2+)-RESPONSIVE MITOCHONDRIAL FAD-LINKED;; GPD, MITOCHONDRIAL; GPDM;; GDH2__:__
Asterisk__:__138440__:__PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE/PHOSPHORIBOSYLGLYCINAMIDE SYNTHETASE/PHOSPHORIBOSYLAMINOIMIDAZOLE SYNTHETASE; GART__:____:__GLYCINAMIDE PHOSPHORIBOSYLTRANSFERASE, INCLUDED;; GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE, INCLUDED; GARS, INCLUDED;; GLYCINAMIDE PHOSPHORIBOSYL SYNTHETASE, INCLUDED;; GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE, INCLUDED; GARTF, INCLUDED;; PHOSPHORIBOSYLGLYCINAMIDE SYNTHETASE, INCLUDED; PRGS, INCLUDED;; PHOSPHORIBOSYLAMINOIMIDAZOLE SYNTHETASE, INCLUDED; PAIS, INCLUDED;; AIRS, INCLUDED;; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE, INCLUDED; PGFT, INCLUDED
Asterisk__:__138450__:__SERINE HYDROXYMETHYLTRANSFERASE, MITOCHONDRIAL; SHMT2__:__GLYCINE AUXOTROPH A, HUMAN COMPLEMENT FOR HAMSTER; GLY A+__:__
Asterisk__:__138470__:__COMPLEMENT FACTOR B; CFB__:__FACTOR B; FB;; PROPERDIN FACTOR B; BF;; FACTOR B, PROPERDIN;; C3 PROACTIVATOR;; C3 PROACCELERATOR;; GLYCINE-RICH BETA-GLYCOPROTEIN; GBG__:__
Asterisk__:__138480__:__GLYCINE B COMPLEMENTING; GLYB__:__GLYCINE AUXOTROPH B, HUMAN COMPLEMENT OF HAMSTER;; GLY B+__:__
Asterisk__:__138491__:__GLYCINE RECEPTOR, ALPHA-1 SUBUNIT; GLRA1__:____:__
Asterisk__:__138492__:__GLYCINE RECEPTOR, BETA SUBUNIT; GLRB__:____:__
Number Sign__:__138500__:__HYPERGLYCINURIA__:__GLYCINURIA WITH OR WITHOUT OXALATE UROLITHIASIS;; GLYCINURIA WITH OR WITHOUT OXALATE NEPHROLITHIASIS;; IMINOGLYCINURIA TYPE II__:__
Asterisk__:__138550__:__GLYCOGEN PHOSPHORYLASE, BRAIN TYPE; PYGB__:____:__
Asterisk__:__138570__:__GLYCOGEN SYNTHASE 1; GYS1__:__GLYCOGEN SYNTHASE, MUSCLE;; GYS__:__
Asterisk__:__138571__:__GLYCOGEN SYNTHASE 2; GYS2__:__GLYCOGEN SYNTHASE, LIVER;; LIVER GLYCOGEN SYNTHASE__:__
Asterisk__:__138590__:__GLYCOPHORIN E; GYPE__:__GPE__:__
Asterisk__:__138600__:__OROSOMUCOID 1; ORM1__:__ORM;; GLYCOPROTEIN, ALPHA-1-ACID, OF SERUM;; ALPHA-1-ACID GLYCOPROTEIN;; ALPHA-1-AGP; AGP1__:__
Asterisk__:__138610__:__OROSOMUCOID 2; ORM2__:__GLYCOPROTEIN, ALPHA-1-ACID, OF SERUM, TYPE 2;; ALPHA-1-ACID GLYCOPROTEIN, TYPE 2; AGP2__:__
Asterisk__:__138670__:__ALPHA-1-B-GLYCOPROTEIN; A1BG__:__GAB;; A1B;; ABG__:__
Asterisk__:__138680__:__ALPHA-2-HS-GLYCOPROTEIN; AHSG__:__A2HS; AHS; HSGA;; FETUIN, MOUSE, HOMOLOG OF;; FETUIN A; FETUA__:__
Asterisk__:__138700__:__APOLIPOPROTEIN H; APOH__:__GLYCOPROTEIN I, BETA-2; B2GP1;; GLYCOPROTEIN 1, BETA-2;; BG__:__
NULL__:__138710__:__GLYCOPROTEIN, RENAL__:____:__
Asterisk__:__138720__:__GLYCOPROTEIN Ib, PLATELET, BETA POLYPEPTIDE; GP1BB__:__PLATELET GLYCOPROTEIN Ib, BETA POLYPEPTIDE;; GP Ib, BETA SUBUNIT__:__
Asterisk__:__138750__:__GLYOXALASE I; GLO1__:____:__
Asterisk__:__138760__:__HYDROXYACYL GLUTATHIONE HYDROLASE; HAGH__:__GLYOXALASE II; GLO2__:__
NULL__:__138770__:__GMS SYNDROME__:__GONIODYSGENESIS--MENTAL RETARDATION--SHORT STATURE SYNDROME__:__
NULL__:__138790__:__GOITER, MULTINODULAR, CYSTIC RENAL DISEASE, AND DIGITAL ANOMALIES__:__MULTINODULAR GOITER/CYSTIC RENAL DISEASE/DIGITAL ANOMALIES;; MNG/CRD/DA__:__
Number Sign__:__138800__:__GOITER, MULTINODULAR 1, WITH OR WITHOUT SERTOLI-LEYDIG CELL TUMORS; MNG1__:__GOITER, NONTOXIC, WITH INTRATHYROIDAL CALCIFICATION;; MULTINODULAR GOITER, ADOLESCENT;; EUTHYROID GOITER;; SIMPLE GOITER__:__
Asterisk__:__138850__:__GONADOTROPIN-RELEASING HORMONE RECEPTOR; GNRHR__:__GNRHR1;; GRHR;; LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR; LHRHR__:__
Asterisk__:__138890__:__GOOSECOID HOMEOBOX; GSC__:____:__
Number Sign__:__138900__:__URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 1; UAQTL1__:__GOUT SUSCEPTIBILITY 1; GOUT1__:__
NULL__:__138920__:__GRANDDAD SYNDROME__:__GROWTH RETARDATION, AGED FACIES, NORMAL DEVELOPMENT, DECREASED SUBCUTANEOUS FAT, AUTOSOMAL DOMINANT INHERITANCE__:__
NULL__:__138930__:__GRANT SYNDROME__:____:__
Asterisk__:__138945__:__GRANULIN PRECURSOR; GRN__:__PROGRANULIN; PGRN;; EPITHELIN PRECURSOR;; PROEPITHELIN; PEPI;; GRANULIN-EPITHELIN PRECURSOR; GEP;; PC CELL-DERIVED GROWTH FACTOR; PCDGF;; ACROGRANIN;; GLYCOPROTEIN, 88-KD; GP88__:__GRANULINS, INCLUDED;; EPITHELINS, INCLUDED
Asterisk__:__138960__:__COLONY-STIMULATING FACTOR 2; CSF2__:__GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GMCSF__:__
Asterisk__:__138965__:__CHEMOKINE, CXC MOTIF, LIGAND 6; CXCL6__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 6; SCYB6;; GRANULOCYTE CHEMOTACTIC PROTEIN 2; GCP2__:__
Asterisk__:__138970__:__COLONY-STIMULATING FACTOR 3; CSF3__:__GRANULOCYTE COLONY-STIMULATING FACTOR; GCSF__:__
Asterisk__:__138971__:__COLONY-STIMULATING FACTOR 3 RECEPTOR, GRANULOCYTE; CSF3R__:__GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR; GCSFR__:__
Asterisk__:__138972__:__CCAAT/ENHANCER-BINDING PROTEIN, GAMMA; CEBPG__:__C/EBP-GAMMA;; GRANULOCYTE COLONY-STIMULATING FACTOR PROMOTER ELEMENT 1-BINDING PROTEIN; GPE1BP;; GPE1-BINDING PROTEIN__:__
Asterisk__:__138981__:__GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR, BETA; CSF2RB__:__INTERLEUKIN 5 RECEPTOR, BETA; IL5RB;; INTERLEUKIN 3 RECEPTOR, BETA; IL3RB;; COMMON BETA CHAIN;; BETA-C__:__
NULL__:__138990__:__GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL DOMINANT TYPE__:____:__
NULL__:__139000__:__GRANULOSIS RUBRA NASI__:____:__
Asterisk__:__139080__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, GRAVES DISEASE AUTOANTIGEN), MEMBER 16; SLC25A16__:__GRAVES DISEASE AUTOANTIGEN; GDA;; D10S105E__:__
Number Sign__:__139090__:__GRAY PLATELET SYNDROME; GPS__:__BLEEDING DISORDER, PLATELET-TYPE, 4; BDPLT4;; PLATELET ALPHA-GRANULE DEFICIENCY__:__
Percent__:__139100__:__GRAYING OF HAIR, PRECOCIOUS__:__WHITE HAIR, PREMATURE__:__
Asterisk__:__139110__:__CHEMOKINE, CXC MOTIF, LIGAND 2; CXCL2__:__GRO2 ONCOGENE; GRO2;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 2; SCYB2;; MACROPHAGE INFLAMMATORY PROTEIN 2; MIP2;; GRO PROTEIN, BETA; GROB;; MIP2-ALPHA; MIP2A__:__
Asterisk__:__139111__:__CHEMOKINE, CXC MOTIF, LIGAND 3; CXCL3__:__GRO3 ONCOGENE; GRO3;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B; MEMBER 3; SCYB3;; GRO PROTEIN, GAMMA; GROG;; MACROPHAGE INFLAMMATORY PROTEIN-2-BETA; MIP2B__:__
Asterisk__:__139130__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-3; GNB3__:____:__
Asterisk__:__139139__:__NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; NR4A1__:__HORMONE RECEPTOR; HMR;; GROWTH FACTOR INDUCIBLE NUCLEAR PROTEIN N10; NP10;; GROWTH FACTOR RESPONSE PROTEIN 1; GFRP1;; NAK1;; NUCLEAR HORMONE RECEPTOR TR3; TR3;; NUR77, MOUSE, HOMOLOG OF; NUR77;; NGFIB__:__
Caret__:__139145__:__MOVED TO 139139__:____:__
Asterisk__:__139150__:__RAS p21 PROTEIN ACTIVATOR 1; RASA1__:__GUANOSINE TRIPHOSPHATASE-ACTIVATING PROTEIN;; GTPase-ACTIVATING PROTEIN; GAP;; p120 RASGAP__:__
Asterisk__:__139160__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA Z POLYPEPTIDE; GNAZ__:____:__
Asterisk__:__139180__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING, POLYPEPTIDE 2 PSEUDOGENE 1; GNAI2P1__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING, POLYPEPTIDE-h; GNAIH;; GUANINE NUCLEOTIDE-BINDING PROTEIN, POLYPEPTIDE 2A; GNAI2A;; GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING, POLYPEPTIDE-2-LIKE; GNAI2L__:__
Asterisk__:__139185__:__GROWTH ARREST-SPECIFIC 1; GAS1__:____:__
Asterisk__:__139190__:__GROWTH HORMONE-RELEASING HORMONE; GHRH__:__SOMATOCRININ;; GROWTH HORMONE-RELEASING FACTOR; GHRF__:__
Asterisk__:__139191__:__GROWTH HORMONE-RELEASING HORMONE RECEPTOR; GHRHR__:__GROWTH HORMONE-RELEASING FACTOR RECEPTOR; GHRFR__:__
Asterisk__:__139200__:__GROUP-SPECIFIC COMPONENT; GC__:__VITAMIN D-BINDING PROTEIN; DBP; VDBP;; VITAMIN D-BINDING ALPHA-GLOBULIN; VDBG__:__
Number Sign__:__139210__:__MYHRE SYNDROME; MYHRS__:__GROWTH-MENTAL DEFICIENCY SYNDROME OF MYHRE;; LARYNGOTRACHEAL STENOSIS, ARTHROPATHY, PROGNATHISM, AND SHORT STATURE; LAPS SYNDROME__:__
Caret__:__139220__:__REMOVED FROM DATABASE__:____:__
Caret__:__139230__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__139240__:__GROWTH HORMONE 2; GH2__:__GROWTH HORMONE, VARIANT; GHV;; GROWTH HORMONE, PLACENTAL; GH2;; GROWTH HORMONE-LIKE; GHL__:__
Asterisk__:__139250__:__GROWTH HORMONE 1; GH1__:__GH;; GROWTH HORMONE, NORMAL; GHN;; GROWTH HORMONE, PITUITARY__:__
Asterisk__:__139255__:__METALLOTHIONEIN 3; MT3__:__METALLOTHIONEIN III;; GROWTH INHIBITORY FACTOR, BRAIN; GIFB;; GROWTH INHIBITORY FACTOR, NEUROTROPHIC; GRIF__:__
Asterisk__:__139259__:__G1- TO S-PHASE TRANSITION 1; GSPT1__:__GST1, YEAST, HOMOLOG OF; GST1;; PEPTIDE CHAIN RELEASE FACTOR 3A; ERF3A;; ETF3A__:__
Asterisk__:__139260__:__GUANINE DEAMINASE; GDA__:__GUANASE;; CYTOPLASMIC PSD95 INTERACTOR; CYPIN__:__
Asterisk__:__139265__:__GUANOSINE MONOPHOSPHATE REDUCTASE; GMPR__:__GUANOSINE MONOPHOSPHATE REDUCTASE 1; GMPR1;; GMP REDUCTASE__:__
Asterisk__:__139270__:__GUANYLATE KINASE 1; GUK1__:__GMP KINASE; GMK;; ATP:GMP PHOSPHOTRANSFERASE__:__
NULL__:__139280__:__GUANYLATE KINASE 2; GUK2__:____:__
NULL__:__139290__:__GUANYLATE KINASE 3; GUK3__:____:__
Number Sign__:__139300__:__AROMATASE EXCESS SYNDROME; AEXS__:__AROMATASE ACTIVITY, INCREASED__:__GYNECOMASTIA, FAMILIAL, DUE TO INCREASED AROMATASE ACTIVITY, INCLUDED;; GYNECOMASTIA, HEREDITARY, INCLUDED
Asterisk__:__139310__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING ACTIVITY POLYPEPTIDE 1; GNAI1__:__G PROTEIN, ALPHA-INHIBITING 1; Gi;; INHIBITORY G PROTEIN;; ADENYLATE CYCLASE INHIBITORY PROTEIN__:__
Asterisk__:__139311__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-ACTIVATING ACTIVITY POLYPEPTIDE O; GNAO1__:__Go, ALPHA SUBUNIT;; GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-'OTHER'; GNAO;; G-ALPHA-o__:__
Asterisk__:__139312__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-ACTIVATING ACTIVITY POLYPEPTIDE, OLFACTORY TYPE; GNAL__:__G-ALPHA-OLF__:__
Asterisk__:__139313__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11; GNA11__:____:__
Asterisk__:__139314__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-15; GNA15__:__GNA16, FORMERLY__:__
Asterisk__:__139320__:__GNAS COMPLEX LOCUS; GNAS__:__GNAS1 GENE, FORMERLY; GNAS1, FORMERLY__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-STIMULATING ACTIVITY POLYPEPTIDE 1, INCLUDED; GNAS1, INCLUDED;; Gs, ALPHA SUBUNIT, INCLUDED;; STIMULATORY G PROTEIN, INCLUDED;; ADENYLATE CYCLASE STIMULATORY PROTEIN, ALPHA SUBUNIT, INCLUDED;; SECRETOGRANIN VI, INCLUDED;; NEUROENDOCRINE SECRETORY PROTEIN 55, INCLUDED; NESP55, INCLUDED;; XL-ALPHA-S, INCLUDED; XLAS, INCLUDED;; A/B TRANSCRIPT, INCLUDED;; ALTERNATIVE GENE PRODUCT ENCODED BY THE XL EXON, INCLUDED; ALEX, INCLUDED
Asterisk__:__139330__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-TRANSDUCING ACTIVITY POLYPEPTIDE 1; GNAT1__:__G PROTEIN, ALPHA-TRANSDUCING 1;; TRANSDUCIN, ROD-SPECIFIC, ALPHA POLYPEPTIDE__:__
Asterisk__:__139340__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-TRANSDUCING ACTIVITY POLYPEPTIDE 2; GNAT2__:__G PROTEIN, ALPHA-TRANSDUCING 2;; TRANSDUCIN, CONE-SPECIFIC, ALPHA POLYPEPTIDE__:__
Asterisk__:__139350__:__KERATIN 1, TYPE II; KRT1__:__K1;; KB1;; CYTOKERATIN 1; CK1__:__
Asterisk__:__139360__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING ACTIVITY POLYPEPTIDE 2; GNAI2__:__G PROTEIN, ALPHA-INHIBITING 2B; GNAI2B__:__
Asterisk__:__139370__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-INHIBITING ACTIVITY POLYPEPTIDE 3; GNAI3__:__G PROTEIN, ALPHA-INHIBITING 3__:__
Asterisk__:__139380__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-1; GNB1__:__TRANSDUCIN, BETA POLYPEPTIDE__:__
Asterisk__:__139390__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-2; GNB2__:____:__
Asterisk__:__139391__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-TRANSDUCING ACTIVITY POLYPEPTIDE 2; GNGT2__:____:__
Asterisk__:__139392__:__GUANYLATE CYCLASE ACTIVATOR 2A; GUCA2A__:__GUCA2;; GUANYLIN;; GUANYLIN 2, INTESTINAL__:__
Number Sign__:__139393__:__GUILLAIN-BARRE SYNDROME, FAMILIAL; GBS__:__POLYNEUROPATHY, INFLAMMATORY DEMYELINATING, ACUTE; AIDP__:__POLYNEUROPATHY, INFLAMMATORY DEMYELINATING, CHRONIC, INCLUDED; CIDP, INCLUDED
Asterisk__:__139395__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-TRANSDUCING ACTIVITY POLYPEPTIDE 3; GNAT3__:__GUSTDUCIN, ALPHA POLYPEPTIDE;; GDCA;; GUSTATORY G PROTEIN__:__
Asterisk__:__139396__:__GUANYLATE CYCLASE 1, SOLUBLE, ALPHA-3; GUCY1A3__:__GUANYLYL CYCLASE, SOLUBLE, ALPHA-3; GUCA3;; GUANYLATE CYCLASE, SOLUBLE, ALPHA-1; GUCY1A1;; GUANYLYL CYCLASE, NITRIC OXIDE-SENSITIVE, ALPHA-1 SUBUNIT;; NITRIC OXIDE-SENSITIVE GUANYLYL CYCLASE, ALPHA-1 SUBUNIT;; NOGC, ALPHA-1 SUBUNIT__:__
Asterisk__:__139397__:__GUANYLATE CYCLASE 1, SOLUBLE, BETA-3; GUCY1B3__:__GUANYLYL CYCLASE, SOLUBLE, BETA-3; GUCB3;; GUANYLATE CYCLASE, SOLUBLE, BETA-1; GUCY1B1;; GUANYLYL CYCLASE, NITRIC OXIDE-SENSITIVE, BETA-1 SUBUNIT;; NITRIC OXIDE-SENSITIVE GUANYLYL CYCLASE, BETA-1 SUBUNIT;; NOGC, BETA-1 SUBUNIT__:__
NULL__:__139400__:__HAIR WHORL__:__COWLICK; CROWN__:__DOUBLE HAIR WHORL, INCLUDED
Percent__:__139450__:__HAIR MORPHOLOGY 2; HRM2__:__CURLY HAIR;; HAIR CURVATURE, VARIATION IN__:__
NULL__:__139500__:__HAIRY EARS__:__HYPERTRICHOSIS PINNAE AURIS__:__
Percent__:__139600__:__HAIRY ELBOWS__:__HYPERTRICHOSIS CUBITI__:__
Asterisk__:__139605__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 1; HES1__:__HAIRY, DROSOPHILA, HOMOLOG OF; HRY__:__
NULL__:__139630__:__HAIRY NOSE TIP__:____:__
Percent__:__139650__:__HAIRY PALMS AND SOLES__:__CIRCUMSCRIBED HAIRY DYSEMBRYOPLASIA OF PALMS__:__
NULL__:__139750__:__HAND AND FOOT DEFORMITY WITH FLAT FACIES__:____:__
NULL__:__139800__:__HAND CLASPING PATTERN__:____:__
Percent__:__139900__:__HAND SKILL, RELATIVE; HSR__:__HANDEDNESS__:__
Number Sign__:__140000__:__HAND-FOOT-GENITAL SYNDROME; HFG__:__HAND-FOOT-UTERUS SYNDROME; HFU__:__
Asterisk__:__140050__:__GRANZYME A; GZMA__:__HANUKAH FACTOR SERINE PROTEASE; HFSP;; CYTOLYTIC T CELL- AND NATURAL KILLER CELL-SPECIFIC TRYPSIN-LIKE SERINE PROTEASE;; CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED SERINE ESTERASE 3; CTLA3__:__
Caret__:__140090__:__MOVED TO 189903__:____:__
Asterisk__:__140100__:__HAPTOGLOBIN; HP__:____:__HAPTOGLOBIN, ALPHA POLYPEPTIDE, INCLUDED;; HAPTOGLOBIN, BETA POLYPEPTIDE, INCLUDED;; Bp, INCLUDED
Asterisk__:__140210__:__HAPTOGLOBIN-RELATED PROTEIN GENE; HPR__:____:__
Percent__:__140300__:__HASHIMOTO THYROIDITIS__:__HT;; HASHIMOTO STRUMA;; HYPOTHYROIDISM, AUTOIMMUNE__:__THYROID AUTOANTIBODIES, INCLUDED
Caret__:__140340__:__MOVED TO 125370__:____:__
Number Sign__:__140350__:__HAWKINSINURIA__:____:__
Percent__:__140400__:__PROGRESSIVE FAMILIAL HEART BLOCK, TYPE II; PFHB2__:__PFHBII__:__
NULL__:__140450__:__HEART-HAND SYNDROME, SPANISH TYPE__:____:__
NULL__:__140500__:__HEART, MALFORMATION OF__:____:__
Asterisk__:__140550__:__HEAT-SHOCK 70-KD PROTEIN 1A; HSPA1A__:__HEAT-SHOCK 70-KD PROTEIN 1; HSPA1;; HEAT-SHOCK PROTEIN, 70-KD, 1;; HSP70-1;; HSP70-1A;; HSP72;; HEAT-SHOCK 70-KD PROTEIN, INDUCIBLE; HSP70I__:__
Asterisk__:__140555__:__HEAT-SHOCK 70-KD PROTEIN 6; HSPA6__:__HSP70B-PRIME__:__
Asterisk__:__140556__:__HEAT-SHOCK 70-KD PROTEIN 7; HSPA7__:__HSP70B__:__
Asterisk__:__140559__:__HEAT-SHOCK 70-KD PROTEIN-LIKE 1; HSPA1L__:__HEAT-SHOCK PROTEIN, 70-KD, HOMOLOGOUS;; HSP70-HOM;; HSP70-1L;; HSP70T__:__
Asterisk__:__140560__:__HEAT-SHOCK 70-KD PROTEIN 2; HSPA2__:__HEAT-SHOCK PROTEIN, 70-KD, 2;; HSP70-2;; HEAT-SHOCK PROTEIN, 70-KD, 3;; HSP70-3__:__
Caret__:__140570__:__MOVED TO 140550__:____:__
Asterisk__:__140571__:__HEAT-SHOCK PROTEIN, 90-KD, ALPHA, CLASS A, MEMBER 1; HSP90AA1__:__HEAT-SHOCK 90-KD PROTEIN 1, ALPHA, FORMERLY; HSPCA, FORMERLY;; HSPC1;; HSP90A;; HSP89-ALPHA; HSP89A;; HEAT-SHOCK 90-KD PROTEIN 1, ALPHA-LIKE 4; HSPCAL4;; LIPOPOLYSACCHARIDE-ASSOCIATED PROTEIN 2; LAP2;; LPS-ASSOCIATED PROTEIN 2__:__
Asterisk__:__140572__:__HEAT-SHOCK PROTEIN, 90-KD, ALPHA, CLASS B, MEMBER 1; HSP90AB1__:__HEAT-SHOCK 90-KD PROTEIN 1, BETA, FORMERLY; HSPCB, FORMERLY;; HSPC2;; HSP90B__:__
Caret__:__140573__:__MOVED TO 140571__:____:__
Caret__:__140574__:__MOVED TO 140571__:____:__
Asterisk__:__140575__:__HEAT-SHOCK PROTEIN, 90-KD, ALPHA, CLASS A, MEMBER 2; HSP90AA2__:__HEAT-SHOCK 90-KD PROTEIN 1, ALPHA-LIKE 3, FORMERLY; HSPCAL3, FORMERLY__:__
Caret__:__140576__:__MOVED TO 140571__:____:__
Asterisk__:__140580__:__HEAT-SHOCK TRANSCRIPTION FACTOR 1; HSF1__:__HEAT-SHOCK FACTOR 1__:__
Asterisk__:__140581__:__HEAT-SHOCK TRANSCRIPTION FACTOR 2; HSF2__:__HEAT-SHOCK FACTOR 2__:__
Number Sign__:__140600__:__OSTEOARTHRITIS SUSCEPTIBILITY 2; OS2__:__OSTEOARTHRITIS OF DISTAL INTERPHALANGEAL JOINTS;; OADIP;; DIPOA;; HAND OSTEOARTHRITIS; HOA__:__HEBERDEN NODES, INCLUDED
Number Sign__:__140700__:__HEINZ BODY ANEMIAS__:____:__
Asterisk__:__140750__:__SUPPRESSOR OF TUMORIGENICITY 5; ST5__:__HELA TUMOR SUPPRESSION; HTS1__:__
NULL__:__140850__:__HEMANGIOMAS, CAVERNOUS, OF FACE AND SUPRAUMBILICAL MIDLINE RAPHE__:__RAPHE, SUPRAUMBILICAL MIDLINE, WITH CAVERNOUS FACIAL HEMANGIOMAS;; STERNAL NONUNION WITH SUPRAUMBILICAL RAPHE__:__
NULL__:__140900__:__HEMANGIOMAS OF SMALL INTESTINE__:____:__
NULL__:__141000__:__HEMANGIOMA-THROMBOCYTOPENIA SYNDROME__:__KASABACH-MERRITT SYNDROME; KMS__:__
Asterisk__:__141180__:__HEMATOPOIETIC PROTEIN HEM-1; HEM1__:____:__
Number Sign__:__141200__:__HEMATURIA, BENIGN FAMILIAL; BFH__:__THIN-BASEMENT-MEMBRANE NEPHROPATHY;; THIN MEMBRANE NEPHROPATHY; TMN__:__
Asterisk__:__141250__:__HEME OXYGENASE 1; HMOX1__:__HEMOXYGENASE 1; HO1;; HEAT SHOCK PROTEIN, 32-KD; HSP32__:__
Asterisk__:__141251__:__HEME OXYGENASE 2; HMOX2__:__HEMOXYGENASE 2__:__
Percent__:__141300__:__HEMIFACIAL ATROPHY, PROGRESSIVE; HFA__:__PARRY-ROMBERG SYNDROME__:__
Percent__:__141350__:__HEMIFACIAL HYPERPLASIA WITH STRABISMUS__:__BENCZE SYNDROME__:__
Percent__:__141400__:__HEMIFACIAL MICROSOMIA WITH RADIAL DEFECTS__:__GOLDENHAR SYNDROME WITH IPSILATERAL RADIAL DEFECT;; OCULOAURICULOVERTEBRAL SPECTRUM WITH RADIAL DEFECT;; OAVS WITH RADIAL DEFECT__:__
NULL__:__141405__:__HEMIFACIAL SPASM, FAMILIAL__:____:__
Number Sign__:__141500__:__MIGRAINE, FAMILIAL HEMIPLEGIC, 1; FHM1__:__FHM;; MHP1__:__MIGRAINE, FAMILIAL HEMIPLEGIC 1, WITH PROGRESSIVE CEREBELLAR ATAXIA, INCLUDED;; MIGRAINE, SPORADIC HEMIPLEGIC, INCLUDED
NULL__:__141700__:__HEMOLYTIC POIKILOCYTIC ANEMIA DUE TO REDUCED ANKYRIN BINDING SITES__:____:__
Number Sign__:__141749__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1__:__HEMOGLOBIN F, HEREDITARY PERSISTENCE OF; HPFH;; HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, HB GENE CLUSTER-RELATED__:__DELTA-BETA THALASSEMIA, INCLUDED
Number Sign__:__141750__:__ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, CHROMOSOME 16-RELATED__:__ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, DELETION-TYPE;; ATR-16 SYNDROME;; ATR, DELETION-TYPE;; HEMOGLOBIN H-RELATED MENTAL RETARDATION; HBHR;; MENTAL RETARDATION WITH HEMOGLOBIN H;; CHROMOSOME 16p DELETION SYNDROME__:__
Asterisk__:__141800__:__HEMOGLOBIN--ALPHA LOCUS 1; HBA1__:__3-PRIME ALPHA-GLOBIN GENE;; MINOR ALPHA-GLOBIN LOCUS__:__
Asterisk__:__141850__:__HEMOGLOBIN--ALPHA LOCUS 2; HBA2__:__5-PRIME ALPHA-GLOBIN GENE;; ALPHA-GLOBIN LOCUS, SECOND;; MAJOR ALPHA-GLOBIN LOCUS__:__
Asterisk__:__141860__:__HEMOGLOBIN--ALPHA LOCUS 3__:__ALPHA-GLOBIN LOCUS, THIRD__:__
Asterisk__:__141900__:__HEMOGLOBIN--BETA LOCUS; HBB__:____:__
Caret__:__141940__:__MOVED TO 141900__:____:__
Asterisk__:__142000__:__HEMOGLOBIN--DELTA LOCUS; HBD__:____:__
Asterisk__:__142100__:__HEMOGLOBIN--EPSILON LOCUS; HBE1__:____:__
Asterisk__:__142200__:__HEMOGLOBIN, GAMMA A; HBG1__:__HEMOGLOBIN--GAMMA LOCUS, 136 ALANINE__:__
Asterisk__:__142210__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER D; HIST1H1D__:__HISTONE GENE CLUSTER 1, H1D;; HIST1 ClUSTER, H1D;; H1D;; H1.3;; H1 HISTONE FAMILY, MEMBER 3, FORMERLY; H1F3, FORMERLY__:__
Asterisk__:__142220__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER E; HIST1H1E__:__HISTONE GENE CLUSTER 1, H1E;; HIST1 CLUSTER, H1E;; H1E;; H1.4;; H1 HISTONE FAMILY, MEMBER 4, FORMERLY; H1F4, FORMERLY__:__
Asterisk__:__142230__:__HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34; CD34__:____:__
Asterisk__:__142240__:__HEMOGLOBIN--THETA-1 LOCUS; HBQ1__:____:__
Asterisk__:__142250__:__HEMOGLOBIN, GAMMA G; HBG2__:__HEMOGLOBIN--GAMMA LOCUS, 136 GLYCINE__:__
Caret__:__142270__:__MOVED TO 142200__:____:__
Asterisk__:__142290__:__HEMOPEXIN; HPX__:____:__
Caret__:__142300__:__MOVED TO 142310__:____:__
Number Sign__:__142309__:__HEMOGLOBIN--VARIANTS FOR WHICH THE CHAIN CARRYING THE MUTATION IS UNKNOWN OR UNCERTAIN__:____:__
Asterisk__:__142310__:__HEMOGLOBIN--ZETA LOCUS; HBZ__:__HEMOGLOBIN ZETA;; 5-PRIME ZETA LOCUS;; HEMOGLOBIN ZETA-2, FORMERLY; HBZ2, FORMERLY__:__
Number Sign__:__142330__:__HEPATIC ADENOMAS, FAMILIAL__:__LIVER CELL ADENOMAS, FAMILIAL__:__
Caret__:__142333__:__MOVED TO 114550__:____:__
Percent__:__142335__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5; HBFQTL5__:____:__
Percent__:__142340__:__DIAPHRAGMATIC HERNIA, CONGENITAL__:__DIH;; HERNIA, CONGENITAL DIAPHRAGMATIC; HCD; CDH;; DIAPHRAGMATIC DEFECT, CONGENITAL;; DIAPHRAGM, UNILATERAL AGENESIS OF;; HEMIDIAPHRAGM, AGENESIS OF__:__DIAPHRAGMATIC HERNIA 1, INCLUDED; DIH1, INCLUDED;; DIAPHRAGM, COMPLETE AGENESIS OF, INCLUDED
NULL__:__142350__:__HERNIA, DOUBLE INGUINAL__:____:__
Asterisk__:__142360__:__HEPARIN COFACTOR II; HCF2__:__LEUSERPIN 2; LS2;; SERPIND1__:__
Asterisk__:__142370__:__HEMOPOIETIC CELL KINASE; HCK__:____:__
Caret__:__142380__:__MOVED TO 114550__:____:__
Asterisk__:__142385__:__HEPATIC LEUKEMIA FACTOR; HLF__:____:__HLF/E2A FUSION GENE, INCLUDED
Asterisk__:__142390__:__HEPATIC PROTEIN; HEP10__:____:__
Number Sign__:__142395__:__HEPATITIS B VACCINE, RESPONSE TO__:__HBV VACCINE, RESPONSE TO__:__
Percent__:__142400__:__HERNIA, HIATUS__:__HIATAL HERNIA__:__
Asterisk__:__142408__:__MACROPHAGE STIMULATING 1; MST1__:__HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN; HGFL;; MACROPHAGE STIMULATING PROTEIN; MSP__:__
Asterisk__:__142409__:__HEPATOCYTE GROWTH FACTOR; HGF__:__SCATTER FACTOR; SF;; LUNG FIBROBLAST-DERIVED MITOGEN;; HEPATOPOIETIN A__:__
Asterisk__:__142410__:__HNF1 HOMEOBOX A; HNF1A__:__TRANSCRIPTION FACTOR 1; TCF1;; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA;; HEPATOCYTE NUCLEAR FACTOR 1; HNF1;; HEPATIC NUCLEAR FACTOR-1-ALPHA;; ALBUMIN PROXIMAL FACTOR__:__
Caret__:__142420__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__142440__:__HEPSIN; HPN__:__TRANSMEMBRANE PROTEASE, SERINE 1; TMPRSS1__:__
Asterisk__:__142445__:__NEUREGULIN 1; NRG1__:__HEREGULIN, ALPHA; HGL; HRGA;; NEU DIFFERENTIATION FACTOR; NDF;; ACETYLCHOLINE RECEPTOR-INDUCING ACTIVITY, CHICK, HOMOLOG OF; ARIA__:__GLIAL GROWTH FACTOR 2, INCLUDED; GGF2, INCLUDED;; SENSORY AND MOTOR NEURON-DERIVED FACTOR, INCLUDED; SMDF, INCLUDED
Caret__:__142450__:__MOVED TO 600644__:____:__
Asterisk__:__142460__:__SYNDECAN 2; SDC2__:__SYND2;; HEPARAN SULFATE PROTEOGLYCAN; HSPG;; HSPG1;; FIBROGLYCAN__:__
Asterisk__:__142461__:__HEPARAN SULFATE PROTEOGLYCAN OF BASEMENT MEMBRANE; HSPG2__:__PERLECAN; PLC__:__
Percent__:__142470__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HBFQTL2__:____:__
NULL__:__142500__:__HETEROCHROMIA IRIDIS__:____:__
Caret__:__142510__:__MOVED TO 300049__:____:__
Caret__:__142550__:__MOVED TO 142600__:____:__
Asterisk__:__142560__:__DEAD BOX POLYPEPTIDE 39B; DDX39B__:__HLA-B-ASSOCIATED TRANSCRIPT 1; BAT1;; U2AF65-ASSOCIATED PROTEIN, 56-KD; UAP56;; D6S81E__:__
Asterisk__:__142570__:__HEXOKINASE 3; HK3__:__HEXOKINASE, WHITE CELL__:__
Asterisk__:__142580__:__PROLINE-RICH COILED-COIL PROTEIN 2A; PRRC2A__:__HLA-B-ASSOCIATED TRANSCRIPT 2; BAT2;; D6S51E__:__
Asterisk__:__142590__:__BCL2-ASSOCIATED ATHANOGENE 6; BAG6__:__SCYTHE, XENOPUS, HOMOLOG OF;; HLA-B-ASSOCIATED TRANSCRIPT 3; BAT3;; D6S52E__:__
Asterisk__:__142600__:__HEXOKINASE 1; HK1__:____:__
Asterisk__:__142610__:__G-PATCH DOMAIN- AND ANKYRIN REPEATS-CONTAINING PROTEIN 1; GPANK1__:__HLA-B-ASSOCIATED TRANSCRIPT 4; BAT4;; D6S54E__:__
Asterisk__:__142620__:__ABHYDROLASE DOMAIN-CONTAINING 16A; ABHD16A__:__HLA-B-ASSOCIATED TRANSCRIPT 5; BAT5;; D6S82E__:__
Asterisk__:__142622__:__HIPPOCALCIN; HPCA__:____:__
Number Sign__:__142623__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1__:__HIRSCHSPRUNG DISEASE; HSCR;; AGANGLIONIC MEGACOLON;; MEGACOLON, AGANGLIONIC; MGC__:__HIRSCHSPRUNG DISEASE, PROTECTION AGAINST, INCLUDED
NULL__:__142625__:__HIRSUTISM, SKELETAL DYSPLASIA, AND MENTAL RETARDATION__:____:__
NULL__:__142630__:__HISTIOCYTOSIS, PROGRESSIVE MUCINOUS__:____:__
Asterisk__:__142640__:__HISTIDINE-RICH GLYCOPROTEIN; HRG__:__HRGP__:__
NULL__:__142660__:__HEXOSAMINIDASE C; HEXC__:____:__
Number Sign__:__142669__:__BEUKES HIP DYSPLASIA; BHD__:__HIP DYSPLASIA, BEUKES TYPE;; BEUKES FAMILIAL HIP DYSPLASIA; BFHD;; OSTEOARTHROPATHY, PREMATURE DEGENERATIVE, OF HIP__:__
Number Sign__:__142680__:__PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT__:__FPF;; HIBERNIAN FEVER, FAMILIAL; FHF;; FAMILIAL HIBERNIAN FEVER;; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME; TRAPS;; TNF RECEPTOR-ASSOCIATED PERIODIC SYNDROME__:__
Number Sign__:__142690__:__ACNE INVERSA, FAMILIAL, 1; ACNINV1__:__ACNE INVERSA, FAMILIAL;; HIDRADENITIS SUPPURATIVA, FAMILIAL__:__
Asterisk__:__142695__:__HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN; HDLBP__:__VIGILIN; VGL__:__
Percent__:__142700__:__DEVELOPMENTAL DYSPLASIA OF THE HIP 1; DDH1__:__HIP DYSPLASIA, DEVELOPMENTAL; DDH;; HIP DYSPLASIA, CONGENITAL; CDH;; ACETABULAR DYSPLASIA__:__
Asterisk__:__142701__:__HISTATIN 1; HTN1__:__HIS1__:__PAROTID BASIC PROTEIN, POST-, INCLUDED;; POST-PB PROTEIN, INCLUDED; PPB, INCLUDED
Asterisk__:__142702__:__HISTATIN 3; HTN3__:__HISTATIN 2; HTN2; HIS2__:__HISTATIN 5, INCLUDED; HTN5, INCLUDED;; PB, INCLUDED
Asterisk__:__142703__:__HISTAMINE RECEPTOR H2; HRH2__:____:__
Asterisk__:__142704__:__HISTIDINE DECARBOXYLASE; HDC__:____:__
Asterisk__:__142705__:__HISTIDINE-RICH CALCIUM-BINDING PROTEIN; HRC__:____:__
Asterisk__:__142708__:__H1 HISTONE FAMILY, MEMBER 0; H1F0__:__H1.0;; H1-0 HISTONE;; H1FV__:__
Asterisk__:__142709__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER A; HIST1H1A__:__HISTONE GENE CLUSTER 1, H1A;; HIST1 CLUSTER, H1A;; H1A;; H1.1;; H1 HISTONE FAMILY, MEMBER 1, FORMERLY; H1F1, FORMERLY__:__
Asterisk__:__142710__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER C; HIST1H1C__:__HISTONE GENE CLUSTER 1, H1C;; HIST1 CLUSTER, H1C;; H1C;; H1.2;; H1 HISTONE FAMILY, MEMBER 2, FORMERLY; H1F2; FORMERLY__:__
Asterisk__:__142711__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER B; HIST1H1B__:__HISTONE GENE CLUSTER 1, H1B;; HIST1 CLUSTER, H1B;; H1B;; H1.5;; H1 HISTONE FAMILY, MEMBER 5, FORMERLY; H1F5, FORMERLY__:__
Asterisk__:__142712__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, MEMBER T; HIST1H1T__:__HISTONE GENE CLUSTER 1, H1 HISTONE FAMILY, TESTIS-SPECIFIC MEMBER;; HISTONE GENE CLUSTER 1, H1T;; HIST1 CLUSTER, H1T;; H1T;; H1.T;; H1 HISTONE, TESTIS-SPECIFIC;; H1 HISTONE FAMILY, MEMBER T, FORMERLY; H1FT, FORMERLY__:__
Asterisk__:__142720__:__HISTONE GENE CLUSTER 2, H2A HISTONE FAMILY, MEMBER A3; HIST2H2AA3__:__HISTONE GENE CLUSTER 2, H2AA3;; HIST2 CLUSTER, H2AA3;; H2A HISTONE FAMILY, MEMBER O; H2AFO;; H2A/O;; H2A.2;; HIST2H2AA__:__
NULL__:__142730__:__HISTIOCYTIC DERMATOARTHRITIS__:____:__
Asterisk__:__142750__:__HISTONE GENE CLUSTER 2, H4 HISTONE FAMILY, MEMBER A; HIST2H4A__:__HISTONE GENE CLUSTER 2, H4A;; HIST2 CLUSTER, H4A;; HIST2H4;; H4 HISTONE FAMILY, MEMBER N; H4FN;; H4 HISTONE, FAMILY 2; H4F2__:__
Caret__:__142760__:__MOVED TO 142720__:____:__
Asterisk__:__142763__:__H2A HISTONE FAMILY, MEMBER Z; H2AFZ__:__H2AZ HISTONE;; H2AZ__:__
Asterisk__:__142765__:__REGULATORY FACTOR X, 2; RFX2__:__HLA CLASS II REGULATORY FACTOR RFX2__:__
NULL__:__142770__:__HLA MODIFIER__:____:__
Asterisk__:__142780__:__HISTONE GENE CLUSTER 2, H3 HISTONE FAMILY, MEMBER C; HIST2H3C__:__HISTONE GENE CLUSTER 2, H3C;; HIST2 CLUSTER, H3C;; H3 HISTONE, FAMILY 2; H3F2;; H3 HISTONE FAMILY, MEMBER N; H3FN;; H3 HISTONE FAMILY, MEMBER M; H3FM;; H3/M;; H3.2__:__
Asterisk__:__142790__:__CD74 ANTIGEN; CD74__:__INVARIANT POLYPEPTIDE OF MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II ANTIGEN-ASSOCIATED;; HLA-DR-GAMMA; DHLAG; HLADG;; Ia-GAMMA;; Ia-ASSOCIATED INVARIANT CHAIN;; HISTOCOMPATIBILITY: CLASS II ANTIGENS, GAMMA CHAIN OF;; INVARIANT CHAIN; II__:__
Asterisk__:__142795__:__HLA-8 HISTOCOMPATIBILITY TYPE; HLA8__:____:__
Asterisk__:__142800__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, A; HLA-A__:__HLA-A HISTOCOMPATIBILITY TYPE__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, H PSEUDOGENE, INCLUDED; HLA-H, INCLUDED;; MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, J PSEUDOGENE, INCLUDED; HLA-J, INCLUDED
Asterisk__:__142810__:__HISTIDYL-tRNA SYNTHETASE; HARS__:__HRS;; HISRS__:__
Plus__:__142830__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, B; HLA-B__:__HLA-B HISTOCOMPATIBILITY TYPE__:__ABACAVIR HYPERSENSITIVITY, SUSCEPTIBILITY TO, INCLUDED;; SYNOVITIS, CHRONIC, SUSCEPTIBILITY TO, INCLUDED;; DRUG-INDUCED LIVER INJURY DUE TO FLUCLOXACILLIN, INCLUDED
Asterisk__:__142840__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, C; HLA-C__:__HLA-C HISTOCOMPATIBILITY TYPE__:__
Caret__:__142850__:__MOVED TO 142860__:____:__
Asterisk__:__142855__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DM ALPHA; HLA-DMA__:__HLA-DM HISTOCOMPATIBILITY TYPE, ALPHA CHAIN;; HLADM;; RING6__:__
Asterisk__:__142856__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DM BETA; HLA-DMB__:__HLA-DM HISTOCOMPATIBILITY TYPE, BETA CHAIN;; HLADMB;; RING7__:__
Asterisk__:__142857__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DR BETA-1; HLA-DRB1__:____:__
Asterisk__:__142858__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DP BETA-1; HLA-DPB1__:__HLA-DP HISTOCOMPATIBILITY TYPE, BETA-1 SUBUNIT__:__
Asterisk__:__142860__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DR ALPHA; HLA-DRA__:__HLA-DRA1;; HLA-DR HISTOCOMPATIBILITY TYPE;; HLA-D HISTOCOMPATIBILITY TYPE__:__
Caret__:__142870__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__142871__:__HLA-G HISTOCOMPATIBILITY ANTIGEN, CLASS I; HLA-G__:__HLA-6.0; HLA60;; T-CELL A LOCUS; TCA__:__
Asterisk__:__142880__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DP ALPHA-1; HLA-DPA1__:__HLA-DP;; HLA-SB HISTOCOMPATIBILITY TYPE; HLA-SB__:__
Asterisk__:__142890__:__HLA-MT HISTOCOMPATIBILITY TYPE; HLA-MT__:____:__
Number Sign__:__142900__:__HOLT-ORAM SYNDROME; HOS__:__HOS1;; HEART-HAND SYNDROME;; ATRIODIGITAL DYSPLASIA__:__
Plus__:__142910__:__3-HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE; HMGCR__:__HMG-CoA REDUCTASE__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 3, INCLUDED; LDLCQ3, INCLUDED;; STATINS, ATTENUATED CHOLESTEROL LOWERING BY, INCLUDED
Asterisk__:__142920__:__HLA-DO HISTOCOMPATIBILITY TYPE; HLA-DO__:____:__
Caret__:__142925__:__MOVED TO 142800__:____:__
Asterisk__:__142930__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DN ALPHA; HLA-DNA__:__HLA-DZ HISTOCOMPATIBILITY TYPE; HLADZ__:__
Asterisk__:__142940__:__3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE 1; HMGCS1__:__3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE, SOLUBLE;; HMG-CoA SYNTHASE, CYTOSOLIC; HMGCS__:__
Number Sign__:__142945__:__HOLOPROSENCEPHALY 3; HPE3__:__HLP3__:__
Number Sign__:__142946__:__HOLOPROSENCEPHALY 4; HPE4__:____:__
Asterisk__:__142950__:__HOMEOBOX A7; HOXA7__:__HOMEOBOX 1A; HOX1A;; Hox-1.1, MOUSE, HOMOLOG OF;; Antp, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__142951__:__HOMEOBOX A6; HOXA6__:__HOMEOBOX 1B; HOX1B;; Hox-1.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__142952__:__HOMEOBOX A5; HOXA5__:__HOMEOBOX 1C; HOX1C;; Hox-1.3, MOUSE, HOMOLOG OF__:__
Asterisk__:__142953__:__HOMEOBOX A4; HOXA4__:__HOMEOBOX 1D; HOX1D;; Hox-1.4, MOUSE, HOMOLOG OF;; Dfd, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__142954__:__HOMEOBOX A3; HOXA3__:__HOMEOBOX 1E; HOX1E;; Hox-1.5, MOUSE, HOMOLOG OF__:__
Asterisk__:__142955__:__HOMEOBOX A1; HOXA1__:__HOMEOBOX 1F; HOX1F;; Hox-1.6, MOUSE, HOMOLOG OF;; lab, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__142956__:__HOMEOBOX A9; HOXA9__:__HOMEOBOX 1G; HOX1G;; Hox-1.7, MOUSE, HOMOLOG OF;; Abd-B, DROSOPHILA, HOMOLOG OF__:__HOXA9/NUP98 FUSION GENE, INCLUDED;; HOXA9/MSI2 FUSION GENE, INCLUDED
Asterisk__:__142957__:__HOMEOBOX A10; HOXA10__:__HOMEOBOX 1H; HOX1H__:__
Asterisk__:__142958__:__HOMEOBOX A11; HOXA11__:__HOMEOBOX 1I; HOX1I__:__
Asterisk__:__142959__:__HOMEOBOX A13; HOXA13__:__HOMEOBOX 1J; HOX1J__:__
Asterisk__:__142960__:__HOMEOBOX B5; HOXB5__:__HOMEOBOX 2A; HOX2A;; Hox2.1, MOUSE, HOMOLOG OF__:__
Asterisk__:__142961__:__HOMEOBOX B6; HOXB6__:__HOMEOBOX 2B; HOX2B;; Hox-2.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__142962__:__HOMEOBOX B7; HOXB7__:__HOMEOBOX 2C; HOX2C;; Hox-2.3, MOUSE, HOMOLOG OF__:__
Asterisk__:__142963__:__HOMEOBOX B8; HOXB8__:__HOMEOBOX 2D; HOX2D;; Hox-2.4, MOUSE, HOMOLOG OF__:__
Asterisk__:__142964__:__HOMEOBOX B9; HOXB9__:__HOMEOBOX 2E; HOX2E;; Hox-2.5, MOUSE, HOMOLOG OF__:__
Asterisk__:__142965__:__HOMEOBOX B4; HOXB4__:__HOMEOBOX 2F; HOX2F;; Hox-2.6, MOUSE, HOMOLOG OF__:__
Asterisk__:__142966__:__HOMEOBOX B3; HOXB3__:__HOMEOBOX 2G; HOX2G;; Hox-2.7, MOUSE, HOMOLOG OF__:__
Asterisk__:__142967__:__HOMEOBOX B2; HOXB2__:__HOMEOBOX 2H; HOX2H;; Hox-2.8, MOUSE, HOMOLOG OF__:__
Asterisk__:__142968__:__HOMEOBOX B1; HOXB1__:__HOMEOBOX 2I; HOX2I;; Hox-2.9, MOUSE, HOMOLOG OF__:__
Asterisk__:__142970__:__HOMEOBOX C8; HOXC8__:__HOMEOBOX 3A; HOX3A;; Hox-3.1, MOUSE, HOMOLOG OF__:__
Asterisk__:__142971__:__HOMEOBOX C9; HOXC9__:__HOMEOBOX 3B; HOX3B;; Hox-3.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__142972__:__HOMEOBOX C6; HOXC6__:__HOMEOBOX 3C; HOX3C;; Hox-6.1, MOUSE, HOMOLOG OF__:__
Asterisk__:__142973__:__HOMEOBOX C5; HOXC5__:__HOMEOBOX 3D; HOX3D;; Hox-6.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__142974__:__HOMEOBOX C4; HOXC4__:__HOMEOBOX 3E; HOX3E__:__
Asterisk__:__142975__:__HOMEOBOX C12; HOXC12__:__HOMEOBOX 3F; HOX3F__:__
Asterisk__:__142976__:__HOMEOBOX C13; HOXC13__:__HOMEOBOX 3G; HOX3G__:__HOXC13/NUP98 FUSION GENE, INCLUDED
Asterisk__:__142980__:__HOMEOBOX D3; HOXD3__:__HOMEOBOX 4A; HOX4A;; Hox-4.1, MOUSE, HOMOLOG OF__:__
Asterisk__:__142981__:__HOMEOBOX D4; HOXD4__:__HOMEOBOX 4B; HOX4B;; Hox-4.2, MOUSE, HOMOLOG OF;; HOMEOBOX X__:__
Asterisk__:__142982__:__HOMEOBOX D9; HOXD9__:__HOMEOBOX 4C; HOX4C;; Hox-4.3, MOUSE, HOMOLOG OF__:__
Asterisk__:__142983__:__MUSCLE SEGMENT HOMEOBOX, DROSOPHILA, HOMOLOG OF, 1; MSX1__:__MSH, DROSOPHILA, HOMOLOG OF, 1;; HOMEOBOX 7; HOX7__:__
Asterisk__:__142984__:__HOMEOBOX D10; HOXD10__:__HOMEOBOX 4D; HOX4D;; Hox-4.4, MOUSE, HOMOLOG OF__:__
Asterisk__:__142985__:__HOMEOBOX D8; HOXD8__:__HOMEOBOX 4E; HOX4E;; Hox-4.5, MOUSE, HOMOLOG OF__:__
Asterisk__:__142986__:__HOMEOBOX D11; HOXD11__:__HOMEOBOX 4F; HOX4F;; Hox-4.6, MOUSE, HOMOLOG OF__:__HOXD11/NUP98 FUSION GENE, INCLUDED
Asterisk__:__142987__:__HOMEOBOX D1; HOXD1__:__HOMEOBOX 4G; HOX4G;; Hox-4.7, MOUSE, HOMOLOG OF__:__
Asterisk__:__142988__:__HOMEOBOX D12; HOXD12__:__HOMEOBOX 4H; HOX4H__:__
Asterisk__:__142989__:__HOMEOBOX D13; HOXD13__:__HOMEOBOX 4I; HOX4I__:__
Caret__:__142990__:__MOVED TO 142981__:____:__
Asterisk__:__142991__:__EVEN-SKIPPED HOMEOBOX 2; EVX2__:__HOMEOBOX EVX-2__:__
Asterisk__:__142992__:__H6 FAMILY HOMEOBOX 1; HMX1__:__HOMEOBOX GENE H6; H6;; NKX5.3__:__
Asterisk__:__142993__:__VISUAL SYSTEM HOMEOBOX 2; VSX2__:__HOMEOBOX 10; HOX10;; CEH10 HOMEODOMAIN-CONTAINING HOMOLOG; CHX10__:__
Asterisk__:__142994__:__MOTOR NEURON AND PANCREAS HOMEOBOX 1; MNX1__:__HOMEOBOX GENE HB9; HLXB9;; HB9__:__
Asterisk__:__142995__:__H.20-LIKE HOMEOBOX 1; HLX1__:__H.20, DROSOPHILA, HOMOLOG OF;; HOMEOBOX GENE HB24__:__
Asterisk__:__142996__:__EVEN-SKIPPED HOMEOBOX 1; EVX1__:__HOMEOBOX EVX-1__:__
Percent__:__143000__:__HORNER SYNDROME, CONGENITAL__:____:__
Asterisk__:__143010__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, E; HLA-E__:__HLAE;; HLA-E HISTOCOMPATIBILITY TYPE;; HLA-6.2;; QA1, MOUSE, HOMOLOG OF; QA1__:__
NULL__:__143020__:__HPA I RECOGNITION POLYMORPHISM, BETA-GLOBIN-RELATED; HPA1__:__RESTRICTION FRAGMENT LENGTH POLYMORPHISM, SICKLE CELL ANEMIA-RELATED__:__
Asterisk__:__143023__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 7; RASSF7__:__CHROMOSOME 11 OPEN READING FRAME 13; C11ORF13;; HRAS1-RELATED CLUSTER 1; HRC1__:__
Asterisk__:__143024__:__GUANINE NUCLEOTIDE-BINDING PROTEIN-LIKE 1; GNL1__:__HSR1 GTP-BINDING PROTEIN; HSR1__:__
Asterisk__:__143025__:__HTLV-RELATED ENDOGENOUS SEQUENCE 1; HRES1__:____:__
Asterisk__:__143030__:__CD9 ANTIGEN; CD9__:__LEUKOCYTE ANTIGEN MIC3; MIC3;; ANTIGEN DEFINED BY MONOCLONAL ANTIBODY 602-29__:__
Asterisk__:__143040__:__ANTIGEN DEFINED BY MONOCLONAL ANTIBODY F10.44.2__:__HUMAN LEUKOCYTE ANTIGEN MIC4; MIC4__:__
NULL__:__143050__:__HUMERORADIAL SYNOSTOSIS__:____:__
Asterisk__:__143054__:__HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENHANCER-BINDING PROTEIN 2; HIVEP2__:__ZAS FAMILY, MEMBER 2; ZAS2;; MAJOR HISTOCOMPATIBILITY COMPLEX-BINDING PROTEIN 2; MBP2;; SCHNURRI, DROSOPHILA, HOMOLOG OF, 2; SHN2;; SCHNURRI 2;; MIBP1__:__
Asterisk__:__143055__:__CYCLIN T1; CCNT1__:__CYCLIN T; CCNT;; CYCLIN C-RELATED PROTEIN;; CDK9-ASSOCIATED C-TYPE CYCLIN__:__
Asterisk__:__143060__:__HUMAN LEUKOCYTE ANTIGEN MIC6; MIC6__:__ANTIGEN DEFINED BY MONOCLONAL ANTIBODY H207__:__
Caret__:__143065__:__MOVED TO 107271__:____:__
Caret__:__143070__:__REMOVED FROM DATABASE__:____:__
Caret__:__143080__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__143089__:__HUMAN T-CELL LEUKEMIA VIRUS ENHANCER FACTOR; HTLF__:____:__
Caret__:__143090__:__MOVED TO 138140__:____:__
Number Sign__:__143095__:__SPONDYLOEPIPHYSEAL DYSPLASIA WITH CONGENITAL JOINT DISLOCATIONS; SEDCJD__:__HUMEROSPINAL DYSOSTOSIS; HSD;; SPONDYLOEPIPHYSEAL DYSPLASIA, OMANI TYPE;; CHONDRODYSPLASIA WITH MULTIPLE DISLOCATIONS; CDMD__:__
Number Sign__:__143100__:__HUNTINGTON DISEASE; HD__:__HUNTINGTON CHOREA__:__
Asterisk__:__143110__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, F; HLA-F__:__HLA-F HISTOCOMPATIBILITY TYPE;; cda12 CLASS I GENE;; HLA-CDA12;; HLA-5.4__:__
Caret__:__143150__:__MOVED TO 426000__:____:__
Asterisk__:__143170__:__MALE-ENHANCED ANTIGEN 1; MEA1__:__MEA__:__
Number Sign__:__143200__:__WAGNER VITREORETINOPATHY; WGVRP__:__EROSIVE VITREORETINOPATHY; ERVR;; WAGNER VITREORETINAL DEGENERATION;; HYALOIDEORETINAL DEGENERATION OF WAGNER;; WAGNER SYNDROME 1; WGN1__:__
Number Sign__:__143400__:__CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 2; CAKUT2__:__URETEROPELVIC JUNCTION OBSTRUCTION; UPJO;; PELVIURETERIC JUNCTION OBSTRUCTION; PUJO;; HYDRONEPHROSIS DUE TO PUJO;; MULTICYSTIC RENAL DYSPLASIA, BILATERAL; MCRD__:__
Asterisk__:__143450__:__HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, BETA SUBUNIT; HADHB__:__TRIFUNCTIONAL PROTEIN, BETA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, BETA SUBUNIT;; ECHB__:__
NULL__:__143460__:__5-HYDROXYTRYPTAMINE OXYGENASE REGULATOR; HTOR__:____:__
Number Sign__:__143465__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER; ADHD__:__HYPERACTIVITY OF CHILDHOOD__:__
Number Sign__:__143470__:__HYPERALPHALIPOPROTEINEMIA 1; HALP1__:__CHOLESTEROL ESTER TRANSFER PROTEIN DEFICIENCY;; CETP DEFICIENCY__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 10, INCLUDED;; HDLCQ10, INCLUDED
Number Sign__:__143500__:__GILBERT SYNDROME__:__HYPERBILIRUBINEMIA, GILBERT TYPE; HBLRG;; HYPERBILIRUBINEMIA, ARIAS TYPE;; HYPERBILIRUBINEMIA I__:__
Percent__:__143850__:__ORTHOSTATIC HYPOTENSIVE DISORDER, STREETEN TYPE__:__OHDS;; ORTHOSTATIC HYPOTENSIVE DISORDER;; HYPERBRADYKININISM__:__
Number Sign__:__143860__:__HYPERCHLORHIDROSIS, ISOLATED; HYCHL__:____:__
Number Sign__:__143870__:__HYPERCALCIURIA, ABSORPTIVE, 2; HCA2__:__HYPERCALCIURIA, FAMILIAL IDIOPATHIC__:__
Number Sign__:__143880__:__HYPERCALCEMIA, INFANTILE, 1; HCINF1__:__HYPERCALCEMIA, IDIOPATHIC, OF INFANCY__:__
Number Sign__:__143890__:__HYPERCHOLESTEROLEMIA, FAMILIAL__:__FHC; FH;; HYPERLIPOPROTEINEMIA, TYPE II;; HYPERLIPOPROTEINEMIA, TYPE IIA;; HYPER-LOW-DENSITY-LIPOPROTEINEMIA;; HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL;; LDL RECEPTOR DISORDER__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2, INCLUDED; LDLCQ2, INCLUDED
Number Sign__:__144010__:__HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, TYPE B__:__APOLIPOPROTEIN B-100, FAMILIAL LIGAND-DEFECTIVE;; HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LIGAND-DEFECTIVE APOLIPOPROTEIN B;; APOLIPOPROTEIN B-100, FAMILIAL DEFECTIVE__:__
NULL__:__144020__:__HYPERCHOLESTEROLEMIA SUPPRESSOR__:____:__
NULL__:__144050__:__HYPERHEPARINEMIA__:____:__
NULL__:__144100__:__HYPERHIDROSIS, GUSTATORY; HYPRG__:__GUSTATORY SWEATING;; FREY SYNDROME;; AURICULOTEMPORAL NERVE SYNDROME__:__
Percent__:__144110__:__HYPERHIDROSIS PALMARIS ET PLANTARIS; HYPRPP__:__HYPERHIDROSIS, PRIMARY PALMAR__:__
NULL__:__144120__:__HYPERIMMUNOGLOBULIN G1(A1) SYNDROME__:____:__
Percent__:__144150__:__HYPERKERATOSIS LENTICULARIS PERSTANS; HLP__:__FLEGEL DISEASE__:__
NULL__:__144190__:__HYPERKERATOSIS-HYPERPIGMENTATION SYNDROME__:____:__
Number Sign__:__144200__:__PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC; EPPK__:__PPKE;; KERATODERMA, EPIDERMOLYTIC PALMOPLANTAR;; PALMOPLANTAR KERATODERMA, VORNER TYPE;; HYPERKERATOSIS, LOCALIZED EPIDERMOLYTIC;; KERATOSIS PALMARIS ET PLANTARIS FAMILIARIS;; TYLOSIS;; KERATOSIS OF GREITHER__:__PALMOPLANTAR KERATODERMA, EPIDERMOLYTIC, WITH KNUCKLE PADS, INCLUDED
Number Sign__:__144250__:__HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL__:__FAMILIAL COMBINED HYPERLIPIDEMIA__:__
NULL__:__144300__:__HYPERLIPOPROTEINEMIA, TYPE II, AND DEAFNESS__:____:__
Caret__:__144400__:__MOVED TO 143890__:____:__
NULL__:__144600__:__HYPERLIPOPROTEINEMIA, TYPE IV__:__CARBOHYDRATE-INDUCIBLE HYPERLIPEMIA__:__
Number Sign__:__144650__:__HYPERLIPOPROTEINEMIA, TYPE V__:__HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED__:__
Number Sign__:__144700__:__RENAL CELL CARCINOMA, NONPAPILLARY; RCC__:__HYPERNEPHROMA;; ADENOCARCINOMA OF KIDNEY__:__NONPAPILLARY RENAL CARCINOMA 1 LOCUS, INCLUDED; NRC1, INCLUDED
Number Sign__:__144750__:__ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL DOMINANT__:__HYPEROSTOSIS CORTICALIS GENERALISATA, BENIGN FORM OF WORTH, WITH TORUS PALATINUS;; OSTEOSCLEROSIS, AUTOSOMAL DOMINANT__:__
Number Sign__:__144755__:__HYPEROSTOSIS CRANIALIS INTERNA; HCIN__:____:__
NULL__:__144800__:__HYPEROSTOSIS FRONTALIS INTERNA__:__MORGAGNI-STEWART-MOREL SYNDROME__:__
Number Sign__:__145000__:__HYPERPARATHYROIDISM 1; HRPT1__:__HYPERPARATHYROIDISM, FAMILIAL ISOLATED PRIMARY; FIHP__:__PARATHYROID ADENOMA, FAMILIAL, INCLUDED
Number Sign__:__145001__:__HYPERPARATHYROIDISM 2 WITH JAW TUMORS; HRPT2__:__HYPERPARATHYROIDISM, FAMILIAL PRIMARY, WITH MULTIPLE OSSIFYING JAW FIBROMAS;; HYPERPARATHYROIDISM-JAW TUMOR SYNDROME, HEREDITARY; HPT-JT__:__PARATHYROID ADENOMATOSIS, FAMILIAL CYSTIC, INCLUDED
Percent__:__145100__:__HYPERPIGMENTATION OF EYELIDS__:____:__
NULL__:__145200__:__HYPERPIGMENTATION OF FULDAUER AND KUIJPERS__:____:__
Number Sign__:__145250__:__HYPERPIGMENTATION WITH OR WITHOUT HYPOPIGMENTATION, FAMILIAL PROGRESSIVE; FPHH__:__MELANOSIS UNIVERSALIS HEREDITARIA; MUH;; HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 2, FORMERLY; FPH2, FORMERLY__:__
Percent__:__145260__:__PSEUDOHYPOALDOSTERONISM, TYPE IIA; PHA2A__:__HYPERPOTASSEMIA AND HYPERTENSION, FAMILIAL;; HYPERTENSIVE HYPERKALEMIA, FAMILIAL;; GORDON HYPERKALEMIA-HYPERTENSION SYNDROME__:__
NULL__:__145270__:__HYPERPROGLUCAGONEMIA__:__GLUCAGON, LARGE MOLECULAR WEIGHT SPECIES OF__:__
NULL__:__145290__:__HYPERREFLEXIA; HRX__:____:__
NULL__:__145295__:__HYPERSECRETION OF ADRENAL ANDROGENS, FAMILIAL__:____:__
NULL__:__145300__:__HYPERSENSITIVITY PNEUMONITIS, FAMILIAL__:____:__
NULL__:__145350__:__HYPERTAURINURIC CARDIOMYOPATHY__:____:__
Percent__:__145400__:__HYPERTELORISM__:____:__
Number Sign__:__145410__:__OPITZ GBBB SYNDROME, TYPE II; GBBB2__:__OPITZ GBBB SYNDROME, AUTOSOMAL DOMINANT;; HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS;; G SYNDROME;; HYPOSPADIAS-DYSPHAGIA SYNDROME;; OPITZ-FRIAS SYNDROME;; OPITZ-G SYNDROME, TYPE II; OGS2;; TELECANTHUS WITH ASSOCIATED ABNORMALITIES;; BBB SYNDROME;; HYPERTELORISM-HYPOSPADIAS SYNDROME;; TELECANTHUS-HYPOSPADIAS SYNDROME;; OPITZ BBBG SYNDROME;; GBBB SYNDROME;; OPITZ OCULOGENITOLARYNGEAL SYNDROME, TYPE II;; CHROMOSOME 22q11.2 DELETION SYNDROME, OPITZ PHENOTYPE__:__
Number Sign__:__145420__:__HYPERTELORISM, TEEBI TYPE; TBHS__:__BRACHYCEPHALOFRONTONASAL DYSPLASIA__:__
Number Sign__:__145500__:__HYPERTENSION, ESSENTIAL__:__EHT__:__
Asterisk__:__145505__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 3; ACSM3__:__SA, RAT, HOMOLOG OF; SA; SAH__:__
NULL__:__145590__:__HYPERTHERMIA, CUTANEOUS, WITH HEADACHES AND NAUSEA__:__FARMER SYNDROME__:__
Number Sign__:__145600__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1__:__MHS;; HYPERTHERMIA OF ANESTHESIA;; HYPERPYREXIA, MALIGNANT; MH__:__KING SYNDROME, INCLUDED;; KING-DENBOROUGH SYNDROME, INCLUDED
Number Sign__:__145650__:__THYROID HORMONE RESISTANCE, SELECTIVE PITUITARY; PRTH__:__HYPERTHYROIDISM, FAMILIAL, DUE TO INAPPROPRIATE THYROTROPIN SECRETION__:__
Number Sign__:__145680__:__HYPERTHYROXINEMIA, DYSTRANSTHYRETINEMIC; DTTRH__:__HYPERTHYROXINEMIA, DYSPREALBUMINEMIC;; DYSTRANSTHYRETINEMIC EUTHYROIDAL HYPERTHYROXINEMIA;; EUTHRYROIDAL HYPERTHYROXINEMIA 2__:__
Percent__:__145700__:__HYPERTRICHOSIS LANUGINOSA CONGENITA__:__HYPERTRICHOSIS UNIVERSALIS__:__
Percent__:__145701__:__HYPERTRICHOSIS UNIVERSALIS CONGENITA, AMBRAS TYPE; HTC1__:__AMBRAS SYNDROME;; HYPERTRICHOSIS, CONGENITAL GENERALIZED__:__
Number Sign__:__145750__:__HYPERTRIGLYCERIDEMIA, FAMILIAL__:____:__
Percent__:__145800__:__HYPERTROPHIA MUSCULORUM VERA__:____:__
Number Sign__:__145900__:__HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS__:__DEJERINE-SOTTAS SYNDROME; DSS;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 3; CMT3;; HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE III; HMSN3;; DEJERINE-SOTTAS NEUROPATHY; DSN__:__
Number Sign__:__145980__:__HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1__:__HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN__:__HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED
Number Sign__:__145981__:__HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2__:__FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II__:__
Number Sign__:__146000__:__HYPOCHONDROPLASIA; HCH__:____:__
Number Sign__:__146110__:__HYPOGONADOTROPIC HYPOGONADISM 7 WITH OR WITHOUT ANOSMIA; HH7__:__HYPOGONADISM, ISOLATED HYPOGONADOTROPIC;; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; IHH__:__
Caret__:__146150__:__MOVED TO 300337__:____:__
NULL__:__146160__:__HYPOMELIA WITH MULLERIAN DUCT ANOMALIES__:__LIMB-UTERUS SYNDROME__:__
Number Sign__:__146200__:__HYPOPARATHYROIDISM, FAMILIAL ISOLATED; FIH__:__HYPOPARATHYROIDISM, AUTOSOMAL DOMINANT__:__HYPOPARATHYROIDISM, AUTOSOMAL RECESSIVE, INCLUDED
Number Sign__:__146255__:__HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; HDR__:__HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA SYNDROME; HDRS;; BARAKAT SYNDROME;; NEPHROSIS, NERVE DEAFNESS, AND HYPOPARATHYROIDISM__:__
Number Sign__:__146300__:__HYPOPHOSPHATASIA, ADULT__:__HYPOPHOSPHATASIA, MILD__:__ODONTOHYPOPHOSPHATASIA, INCLUDED
Percent__:__146350__:__HYPOPHOSPHATEMIC BONE DISEASE; HBD__:____:__
Number Sign__:__146390__:__CHROMOSOME 18p DELETION SYNDROME__:__18p- SYNDROME__:__
Caret__:__146400__:__MOVED TO 125400__:____:__
Percent__:__146450__:__HYPOSPADIAS 3, AUTOSOMAL; HYSP3__:____:__
Number Sign__:__146500__:__MULTIPLE SYSTEM ATROPHY 1, SUSCEPTIBILITY TO; MSA1__:__MSA1, SUSCEPTIBILITY TO__:__AUTONOMIC FAILURE, PURE, INCLUDED;; HYPOTENSION, ORTHOSTATIC, INCLUDED
Number Sign__:__146510__:__PALLISTER-HALL SYNDROME; PHS__:__HYPOTHALAMIC HAMARTOBLASTOMA, HYPOPITUITARISM, IMPERFORATE ANUS, AND POSTAXIAL POLYDACTYLY__:__
Number Sign__:__146520__:__HYPOTRICHOSIS 2; HYPT2__:__HYPOTRICHOSIS SIMPLEX OF THE SCALP 1; HTSS1;; HTSS;; HYPOTRICHOSIS, SPANISH TYPE__:__
Caret__:__146530__:__MOVED TO 301845__:____:__
Number Sign__:__146550__:__HYPOTRICHOSIS 4; HYPT4__:__MARIE UNNA HEREDITARY HYPOTRICHOSIS 1; MUHH1;; HYPOTRICHOSIS, MARIE UNNA TYPE, 1__:__
NULL__:__146580__:__HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE SUPPRESSOR__:____:__
Number Sign__:__146590__:__ICHTHYOSIS HYSTRIX, CURTH-MACKLIN TYPE; IHCM__:____:__
NULL__:__146600__:__ICHTHYOSIS HYSTRIX GRAVIOR__:__ICHTHYOSIS, LAMBERT TYPE;; PORCUPINE MAN__:__
Asterisk__:__146630__:__INTERCELLULAR ADHESION MOLECULE 2; ICAM2__:____:__
Asterisk__:__146631__:__INTERCELLULAR ADHESION MOLECULE 3; ICAM3__:____:__
Asterisk__:__146640__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 2; ITIH2__:____:__
Asterisk__:__146650__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 3; ITIH3__:____:__
Asterisk__:__146660__:__INTERLEUKIN 7; IL7__:____:__
Asterisk__:__146661__:__INTERLEUKIN 7 RECEPTOR; IL7R__:__INTERLEUKIN 7 RECEPTOR-ALPHA;; IL7R-ALPHA; IL7RA;; CD127__:__
Asterisk__:__146680__:__INSULIN-DEGRADING ENZYME; IDE__:__INSULYSIN;; INSULINASE__:__
Asterisk__:__146690__:__IMP DEHYDROGENASE 1; IMPDH1__:__INOSINE-5-PRIME-MONOPHOSPHATE DEHYDROGENASE, TYPE I; IMPD1;; IMPD__:__IMP DEHYDROGENASE-LIKE 1, INCLUDED; IMPDHL1, INCLUDED
Asterisk__:__146691__:__IMP DEHYDROGENASE 2; IMPDH2__:__INOSINE-5-PRIME-MONOPHOSPHATE DEHYDROGENASE, TYPE II; IMPD2; IMPDHII__:__
Caret__:__146692__:__MOVED TO 146690__:____:__
Number Sign__:__146700__:__ICHTHYOSIS VULGARIS__:__ICHTHYOSIS SIMPLEX__:__
Asterisk__:__146710__:__INTERLEUKIN 2 RECEPTOR, BETA; IL2RB__:__CD122 ANTIGEN; CD122__:__
NULL__:__146720__:__ICHTHYOSIS--CHEEK--EYEBROW SYNDROME__:__ICE SYNDROME__:__
Asterisk__:__146730__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 1; IGFBP1__:__IBP1;; PLACENTAL PROTEIN 12;; IGF-BP25__:__
Asterisk__:__146731__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2; IGFBP2__:__IBP2;; IGF-BP53__:__
Asterisk__:__146732__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 3; IGFBP3__:__IBP3__:__
Asterisk__:__146733__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 4; IGFBP4__:__IBP4__:__
Asterisk__:__146734__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 5; IGFBP5__:__IBP5__:__
Asterisk__:__146735__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 6; IGFBP6__:__IBP6__:__
Asterisk__:__146738__:__INSULIN-LIKE 3; INSL3__:__INSULIN-LIKE PEPTIDE, LEYDIG CELL-SPECIFIC;; RELAXIN-LIKE FACTOR; RLF__:__
Asterisk__:__146740__:__Fc FRAGMENT OF IgG, LOW AFFINITY IIIa, RECEPTOR FOR; FCGR3A__:__IMMUNOGLOBULIN G Fc RECEPTOR III-2;; FCRIII-2;; CD16A__:__
NULL__:__146750__:__ICHTHYOSIS, LAMELLAR, AUTOSOMAL DOMINANT__:__LAMELLAR ICHTHYOSIS, AUTOSOMAL DOMINANT__:__
Asterisk__:__146760__:__Fc FRAGMENT OF IgG, HIGH AFFINITY Ia, RECEPTOR FOR; FCGR1A__:__IMMUNOGLOBULIN G Fc RECEPTOR I; IGFR1;; CD64__:__
Asterisk__:__146770__:__IMMUNOGLOBULIN LAMBDA-LIKE POLYPEPTIDE 1; IGLL1__:__IGLL;; IMMUNOGLOBULIN OMEGA POLYPEPTIDE CHAIN; IGO;; LAMBDA-5, MOUSE, HOMOLOG OF;; IGL5, MOUSE, HOMOLOG OF__:__
Caret__:__146771__:__MOVED TO 146770__:____:__
Asterisk__:__146780__:__IMMUNOGLOBULIN KAPPA DELETING ELEMENT; IGKDEL__:____:__
Asterisk__:__146790__:__Fc FRAGMENT OF IgG, LOW AFFINITY IIa, RECEPTOR FOR; FCGR2A__:__FCG2;; IMMUNOGLOBULIN G Fc RECEPTOR II; FcGR; IGFR2;; CDw32;; CD32__:__
Number Sign__:__146800__:__ICHTHYOSIS BULLOSA OF SIEMENS; IBS__:__ICHTHYOSIS, BULLOUS TYPE__:__ICHTHYOSIS EXFOLIATIVA, INCLUDED
NULL__:__146810__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRPHEGAL; IPHEG__:____:__
NULL__:__146820__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRGAT; IGAT__:____:__
NULL__:__146830__:__IMMUNE DEFICIENCY, FAMILIAL VARIABLE__:____:__
NULL__:__146840__:__IMMUNODEFICIENCY WITH DEFECTIVE LEUKOCYTE AND LYMPHOCYTE FUNCTION AND WITH RESPONSE TO HISTAMINE-1 ANTAGONIST__:____:__
NULL__:__146850__:__IMMUNE SUPPRESSION; IS__:__STREPTOCOCCAL CELL WALL ANTIGEN, SUPPRESSION OF IMMUNE RESPONSE TO; ISSCW;; ISCW__:__
Asterisk__:__146880__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DQ ALPHA-1; HLA-DQA1__:__HLA-DQA;; HLADC HISTOCOMPATIBILITY TYPE; HLA-DQ__:__IMMUNE RESPONSE ANTIGENS HIa, INCLUDED;; DC1, INCLUDED
Asterisk__:__146900__:__IgA CONSTANT HEAVY CHAIN 1; IGHA1__:__IMMUNOGLOBULIN Am1__:__
Asterisk__:__146910__:__IMMUNOGLOBULIN HEAVY CHAIN DIVERSITY GENE CLUSTER; IGHD@__:__IGHD GENE CLUSTER; IGHD;; IGD1;; IGHDY1__:__
Asterisk__:__146920__:__ADENOSINE DEAMINASE, RNA-SPECIFIC; ADAR__:__ADENOSINE DEAMINASE, RNA-SPECIFIC, 1; ADAR1;; DOUBLE-STRANDED RNA-SPECIFIC ADENOSINE DEAMINASE; DSRAD; DRADA;; INTERFERON-INDUCED PROTEIN 4; IFI4;; G1P1__:__
Asterisk__:__146928__:__CHEMOKINE, CXC MOTIF, RECEPTOR 2; CXCR2__:__INTERLEUKIN 8 RECEPTOR, BETA; IL8RB;; INTERLEUKIN 8 RECEPTOR, TYPE 2; IL8R2__:__
Asterisk__:__146929__:__CHEMOKINE, CXC MOTIF, RECEPTOR 1; CXCR1__:__INTERLEUKIN 8 RECEPTOR, ALPHA; IL8RA;; INTERLEUKIN 8 RECEPTOR, TYPE 1; IL8R1__:__
Asterisk__:__146930__:__INTERLEUKIN 8; IL8__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 8; SCYB8;; MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC FACTOR;; NEUTROPHIL-ACTIVATING PEPTIDE 1; NAP1;; GRANULOCYTE CHEMOTACTIC PROTEIN 1; GCP1;; CHEMOKINE, CXC MOTIF, LIGAND 8; CXCL8__:__
Asterisk__:__146931__:__INTERLEUKIN 9; IL9__:__T-CELL/MAST CELL GROWTH FACTOR P40__:__
Caret__:__146932__:__MOVED TO 300007__:____:__
Asterisk__:__146933__:__INTERLEUKIN 10 RECEPTOR, ALPHA; IL10RA__:__INTERLEUKIN 10 RECEPTOR; IL10R;; IL10R1__:__
Caret__:__146940__:__MOVED TO 147220__:____:__
NULL__:__146950__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRHGAL; IHG__:____:__
NULL__:__146960__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRTGAL; ITG__:____:__
Asterisk__:__146970__:__IMMUNOGLOBULIN KAPPA LIGHT CHAIN JOINING GENE CLUSTER; IGKJ@__:__IGKJ GENE CLUSTER; IGKJ__:__
Asterisk__:__146980__:__IMMUNOGLOBULIN KAPPA LIGHT CHAIN VARIABLE GENE CLUSTER; IGKV@__:__IGKV GENE CLUSTER; IGKV__:__
NULL__:__146990__:__IMMUNOGLOBULIN HEAVY CHAIN DIVERSITY REGION 2; IGHDY2__:__IGD2__:__
Asterisk__:__147000__:__IgA CONSTANT HEAVY CHAIN 2; IGHA2__:__IMMUNOGLOBULIN Am2__:__
Asterisk__:__147010__:__IMMUNOGLOBULIN HEAVY CHAIN JOINING GENE CLUSTER; IGHJ@__:__IGHJ GENE CLUSTER; IGHJ__:__
Asterisk__:__147020__:__IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION MU; IGHM__:__IMMUNOGLOBULIN HEAVY CHAIN MU CONSTANT REGION;; IgM HEAVY CHAIN CONSTANT REGION__:__
Asterisk__:__147040__:__INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 2; IFIT2__:__INTERFERON-INDUCED PROTEIN 54; IFI54;; G10P2__:__
Asterisk__:__147045__:__Fc FRAGMENT OF IgA, RECEPTOR FOR; FCAR__:__IMMUNOGLOBULIN A Fc RECEPTOR IG;; CD89__:__
Number Sign__:__147050__:__IgE RESPONSIVENESS, ATOPIC; IGER__:__IMMUNOGLOBULIN E, BASIC LEVEL OF, IN SERUM;; IgE, LEVEL OF; IGEL;; IgE RESPONSE UNDERLYING ALLERGIC ASTHMA AND RHINITIS__:__IgE, ELEVATED LEVEL OF, INCLUDED;; ATOPY, SUSCEPTIBILITY TO, INCLUDED;; ATOPIC HYPERSENSITIVITY, INCLUDED
Number Sign__:__147060__:__HYPER-IgE RECURRENT INFECTION SYNDROME 1, AUTOSOMAL DOMINANT; HIES1__:__HYPER-IgE SYNDROME, AUTOSOMAL DOMINANT;; HIES, AUTOSOMAL DOMINANT;; JOB SYNDROME__:__
Percent__:__147061__:__IMMUNOGLOBULIN E CONCENTRATION, SERUM; IGES__:____:__
Asterisk__:__147070__:__IMMUNOGLOBULIN HEAVY CHAIN VARIABLE GENE CLUSTER; IGHV@__:__IGHV GENE CLUSTER; IGHV__:__
NULL__:__147080__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRGLPHE 1; IGLP1__:____:__
NULL__:__147090__:__IMMUNE RESPONSE TO SYNTHETIC POLYPEPTIDE--IRGLPHE 2; IGLP2__:____:__
Asterisk__:__147100__:__IgG HEAVY CHAIN LOCUS; IGHG1__:__IMMUNOGLOBULIN Gm1__:__IGHG1/CCND1 FUSION GENE, INCLUDED;; IGHG1/LHX4 FUSION GENE, INCLUDED
Asterisk__:__147110__:__IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION GAMMA-2; IGHG2__:__IMMUNOGLOBULIN HEAVY CHAIN GAMMA-2 CONSTANT REGION;; IgG2 HEAVY CHAIN CONSTANT REGION;; IMMUNOGLOBULIN Gm2__:__
Asterisk__:__147120__:__IMMUNOGLOBULIN Gm3; IGHG3__:____:__
Asterisk__:__147130__:__IMMUNOGLOBULIN Gm4; IGHG4__:____:__
Asterisk__:__147138__:__MEMBRANE-SPANNING 4 DOMAINS, SUBFAMILY A, MEMBER 2; MS4A2__:__Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, BETA SUBUNIT; FCER1B;; IMMUNOGLOBULIN E RECEPTOR, HIGH AFFINITY, BETA POLYPEPTIDE;; Fc IgE RECEPTOR, BETA CHAIN;; IMMUNOGLOBULIN E REGULATOR; IGHER; IGER__:__
Asterisk__:__147139__:__Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, GAMMA SUBUNIT; FCER1G__:__IMMUNOGLOBULIN E RECEPTOR, HIGH AFFINITY, OF MAST CELLS, GAMMA POLYPEPTIDE;; Fc IgE RECEPTOR, GAMMA CHAIN; FCRG;; Fc RECEPTOR, COMMON GAMMA CHAIN__:__
Asterisk__:__147140__:__Fc FRAGMENT OF IgE, HIGH AFFINITY I, RECEPTOR FOR, ALPHA SUBUNIT; FCER1A__:__IMMUNOGLOBULIN E RECEPTOR, HIGH AFFINITY, OF MAST CELLS, ALPHA POLYPEPTIDE;; Fc IgE RECEPTOR, ALPHA CHAIN__:__
Asterisk__:__147141__:__TRANSCRIPTION FACTOR 3; TCF3__:__IMMUNOGLOBULIN ENHANCER-BINDING FACTORS E12/E47; E2A;; IMMUNOGLOBULIN TRANSCRIPTION FACTOR 1; ITF1;; VITAMIN D RECEPTOR-INTERACTING REPRESSOR; VDIR;; NEGATIVE VITAMIN D RESPONSE ELEMENT-BINDING PROTEIN__:__E2A/HLF FUSION GENE, INCLUDED;; E2A/PBX1 FUSION GENE, INCLUDED;; E2A/TFPT FUSION GENE, INCLUDED
Asterisk__:__147150__:__MYXOVIRUS RESISTANCE 1, MOUSE, HOMOLOG OF; MX1__:__INTERFERON-INDUCIBLE PROTEIN p78; IFI78;; MxA__:__
Caret__:__147160__:__MOVED TO 147180__:____:__
Asterisk__:__147170__:__IMMUNOGLOBULIN: HEAVY DELTA CHAIN; IGHD__:____:__
Asterisk__:__147180__:__IMMUNOGLOBULIN: HEAVY EPSILON CHAIN; IGHE__:__IMMUNOGLOBULIN EPSILON; IgE__:__IMMUNOGLOBULIN: HEAVY EPSILON CHAIN PSEUDOGENE 1, INCLUDED; IGHEP1, INCLUDED;; IMMUNOGLOBULIN: HEAVY EPSILON CHAIN PSEUDOGENE 2, INCLUDED; IGHEP2, INCLUDED;; V(KAPPA) PSEUDOGENES, INCLUDED
Asterisk__:__147183__:__RECOMBINATION SIGNAL-BINDING PROTEIN FOR IMMUNOGLOBULIN KAPPA J REGION; RBPJ__:__RECOMBINATION SIGNAL-BINDING PROTEIN SUPPRESSOR OF HAIRLESS, DROSOPHILA, HOMOLOG OF; RBPSUH;; IMMUNOGLOBULIN KAPPA J REGION RECOMBINATION SIGNAL-BINDING PROTEIN 1; IGKJRB1;; RECOMBINATION SIGNAL-BINDING PROTEIN 1 FOR J-KAPPA; RBPJK; RBPJ;; C PROMOTER-BINDING FACTOR 1; CBF1__:__
Asterisk__:__147185__:__IMMUNOGLOBULIN KAPPA VARIABLE 1/OR2-108; IGKV1OR2108__:__IMMUNOGLOBULIN KAPPA ORPHON 1; IGO1;; IMMUNOGLOBULIN TRANSPOSED ELEMENT 1__:__
Asterisk__:__147200__:__IMMUNOGLOBULIN KAPPA LIGHT CHAIN CONSTANT REGION; IGKC__:__IMMUNOGLOBULIN KM;; IMMUNOGLOBULIN InV__:__
Caret__:__147210__:__MOVED TO 147180__:____:__
Asterisk__:__147220__:__IMMUNOGLOBULIN LAMBDA CONSTANT REGION 1; IGLC1__:__IGLC;; IMMUNOGLOBULIN: LAMBDA LIGHT CHAIN__:__
Asterisk__:__147230__:__IMMUNOGLOBULIN LAMBDA LIGHT CHAIN JOINING GENE CLUSTER; IGLJ@__:__IGLJ GENE CLUSTER; IGLJ__:__
Asterisk__:__147240__:__IMMUNOGLOBULIN LAMBDA LIGHT CHAIN VARIABLE GENE CLUSTER; IGLV@__:__IGLV GENE CLUSTER; IGLV__:__
Asterisk__:__147245__:__CD79B ANTIGEN; CD79B__:__IMMUNOGLOBULIN-ASSOCIATED BETA; IGB;; IMMUNOGLOBULIN-ASSOCIATED B29 PROTEIN; B29__:__
Number Sign__:__147250__:__SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR; SMMCI__:__INCISORS, FUSED;; FUSED INCISORS;; SINGLE UPPER CENTRAL INCISOR;; SINGLE CENTRAL MAXILLARY INCISOR__:__SOLITARY MEDIAN MAXILLARY CENTRAL INCISOR SYNDROME, INCLUDED;; SMMCI SYNDROME, INCLUDED
NULL__:__147251__:__INCISORS, FUSED MANDIBULAR__:__'DOUBLE TOOTH'__:__
NULL__:__147260__:__IMMUNOGLOBULIN SWITCH SEQUENCES__:__S SEQUENCES__:__IMMUNOGLOBULIN-INDEPENDENT SWITCH SEQUENCES, INCLUDED
Asterisk__:__147263__:__INOSITOL POLYPHOSPHATE-1-PHOSPHATASE; INPP1__:____:__
Asterisk__:__147264__:__INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 75-KD; INPP5B__:____:__
Asterisk__:__147265__:__INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR, TYPE 1; ITPR1__:__IP3R;; IP3R1__:__
Asterisk__:__147267__:__INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR, TYPE 3; ITPR3__:__IP3R3__:__
Asterisk__:__147270__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 1; ITIH1__:__IATIH;; ITIH__:__
Asterisk__:__147280__:__INSULIN-LIKE GROWTH FACTOR II RECEPTOR; IGF2R__:__MANNOSE 6-PHOSPHATE RECEPTOR, CATION-INDEPENDENT; MPRI;; CIMPR__:__
Asterisk__:__147290__:__INHIBIN, BETA A; INHBA__:__INHIBIN, BETA-1;; FOLLICLE-STIMULATING HORMONE-RELEASING PROTEIN; FRP;; FSH-RELEASING PROTEIN;; FSH-RELEASING FACTOR;; ERYTHROID DIFFERENTIATION FACTOR; EDF__:__ACTIVIN A, INCLUDED;; ACTIVIN A-B, INCLUDED;; ACTIVIN BETA-A, INCLUDED
NULL__:__147300__:__INCISORS, LONG UPPER CENTRAL__:____:__
Asterisk__:__147310__:__CHEMOKINE, CXC MOTIF, LIGAND 10; CXCL10__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 10; SCYB10;; INTERFERON-GAMMA-INDUCIBLE PROTEIN 10; IP10; INP10;; INTERFERON-GAMMA-INDUCED FACTOR;; MOB1, MOUSE, HOMOLOG OF__:__
NULL__:__147320__:__INSULIN RECEPTORS, FAMILIAL INCREASE IN__:____:__
NULL__:__147330__:__INCISORS, LOWER CENTRAL, ABSENCE OF__:____:__
NULL__:__147350__:__INCISORS, ROTATION OF UPPER CENTRAL__:____:__
Asterisk__:__147360__:__INVOLUCRIN; IVL__:____:__
Asterisk__:__147370__:__INSULIN-LIKE GROWTH FACTOR I RECEPTOR; IGF1R__:____:__
Asterisk__:__147380__:__INHIBIN, ALPHA; INHA__:____:__
Asterisk__:__147390__:__INHIBIN, BETA B; INHBB__:__INHIBIN, BETA-2__:__ACTIVIN BETA-B, INCLUDED;; ACTIVIN B, INCLUDED
Percent__:__147400__:__INCISORS, SHOVEL-SHAPED__:__SINODONTY__:__
Caret__:__147410__:__REMOVED FROM DATABASE__:____:__
Caret__:__147420__:__MOVED TO 601419__:____:__
Percent__:__147421__:__INCLUSION BODY MYOSITIS__:__IBM__:__
Number Sign__:__147430__:__MARSILI SYNDROME; MARSIS__:__INSENSITIVITY TO PAIN, CONGENITAL, AUTOSOMAL DOMINANT;; CONGENITAL ANALGESIA, AUTOSOMAL DOMINANT__:__
Asterisk__:__147435__:__INDOLEAMINE 2,3-DIOXYGENASE; IDO1__:__INDO;; IDO__:__
Asterisk__:__147440__:__INSULIN-LIKE GROWTH FACTOR I; IGF1__:__IGF I;; SOMATOMEDIN C__:__
Asterisk__:__147450__:__SUPEROXIDE DISMUTASE 1; SOD1__:__SUPEROXIDE DISMUTASE, CYTOSOLIC;; SUPEROXIDE DISMUTASE, SOLUBLE;; SOD, SOLUBLE;; SUPEROXIDE DISMUTASE, COPPER-ZINC;; INDOPHENOL OXIDASE A; IPOA__:__
Asterisk__:__147460__:__SUPEROXIDE DISMUTASE 2; SOD2__:__SUPEROXIDE DISMUTASE, MITOCHONDRIAL;; INDOPHENOL OXIDASE B; IPO-B;; MANGANESE SUPEROXIDE DISMUTASE; MNSOD__:__
Asterisk__:__147470__:__INSULIN-LIKE GROWTH FACTOR II; IGF2__:__SOMATOMEDIN A__:__
Number Sign__:__147480__:__CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY, 1; ICP1__:__CHOLESTASIS, PREGNANCY-RELATED, 1__:__
Asterisk__:__147485__:__INTRACISTERNAL A PARTICLE-PROMOTED POLYPEPTIDE; IPP__:____:__
Caret__:__147490__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__147510__:__INSULIN-RELATED DNA POLYMORPHISM; IRDN__:__INSULIN-LINKED POLYMORPHIC REGION; ILPR;; INSULIN MINISATELLITE;; INS VNTR;; INSULIN-RELATED VNTR__:__
Asterisk__:__147520__:__INOSINE TRIPHOSPHATASE; ITPA__:__INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE__:__
Asterisk__:__147521__:__INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE A; ITPKA__:____:__
Asterisk__:__147522__:__INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE B; ITPKB__:____:__
NULL__:__147530__:__INSENSITIVITY TO PAIN WITH HYPERPLASTIC MYELINOPATHY__:____:__
NULL__:__147540__:__INSECT STINGS, HYPERSENSITIVITY TO__:____:__
Plus__:__147545__:__INSULIN RECEPTOR SUBSTRATE 1; IRS1__:____:__CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__147553__:__INTERFERON, OMEGA-1; IFNW1__:__IFN-ALPHA-LIKE__:__INTERFERON, OMEGA-2, PSEUDOGENE, INCLUDED; IFNWP2, INCLUDED
Caret__:__147554__:__MOVED TO 147553__:____:__
Asterisk__:__147556__:__INTEGRIN, ALPHA-6; ITGA6__:__CD49F__:__
Asterisk__:__147557__:__INTEGRIN, BETA-4; ITGB4__:____:__
Asterisk__:__147558__:__INTEGRIN, BETA-6; ITGB6__:____:__
Asterisk__:__147559__:__INTEGRIN, BETA-7; ITGB7__:____:__
NULL__:__147560__:__INTERFERON ANTIVIRAL DEPRESSOR__:____:__
Asterisk__:__147561__:__INTEGRIN, BETA-5; ITGB5__:____:__
Asterisk__:__147562__:__INTERFERON, ALPHA-2; IFNA2__:____:__
Asterisk__:__147563__:__INTEGRIN-BINDING SIALOPROTEIN; IBSP__:__BONE SIALOPROTEIN II;; BONE SIALOPROTEIN; BSP;; SIALOPROTEIN, BONE__:__
Asterisk__:__147564__:__INTERFERON, ALPHA-4; IFNA4__:____:__
Asterisk__:__147565__:__INTERFERON, ALPHA-5; IFNA5__:____:__
Asterisk__:__147566__:__INTERFERON, ALPHA-6; IFNA6__:____:__
Asterisk__:__147567__:__INTERFERON, ALPHA-7; IFNA7__:____:__
Asterisk__:__147568__:__INTERFERON, ALPHA-8; IFNA8__:____:__
Asterisk__:__147569__:__INTERFERON-GAMMA RECEPTOR 2; IFNGR2__:__IFGR2;; INTERFERON-GAMMA TRANSDUCER 1; IFNGT1;; INTERFERON-GAMMA RECEPTOR, ACCESSORY FACTOR FOR__:__
Asterisk__:__147570__:__INTERFERON, GAMMA; IFNG__:__IFG;; IFN, IMMUNE; IFI__:__
Asterisk__:__147571__:__UBIQUITIN-LIKE MODIFIER ISG15; ISG15__:__INTERFERON-INDUCED PROTEIN IFI-15K; G1P2;; INTERFERON-INDUCED PROTEIN 15; IFI15__:__
Asterisk__:__147572__:__INTERFERON-ALPHA-INDUCIBLE PROTEIN 6; IFI6__:__INTERFERON-INDUCED PROTEIN IFI-6-16; IFI616;; G1P3__:__
Asterisk__:__147573__:__INTERFERON PRODUCTION REGULATOR; IFNR__:__INTERFERON-GAMMA-RESPONSIVE INDUCER OF CLASS II MHC ANTIGENS; IFNGM; IFNGM2__:__
Asterisk__:__147574__:__INTERFERON REGULATORY FACTOR 9; IRF9__:__INTERFERON-STIMULATED TRANSCRIPTION FACTOR 3, GAMMA; ISGF3G;; ISGF3-GAMMA;; p48__:__INTERFERON-STIMULATED GENE FACTOR 3, INCLUDED; ISGF3, INCLUDED
Asterisk__:__147575__:__INTERFERON REGULATORY FACTOR 1; IRF1__:____:__
Asterisk__:__147576__:__INTERFERON REGULATORY FACTOR 2; IRF2__:____:__
Asterisk__:__147577__:__INTERFERON, ALPHA-10; IFNA10__:____:__
Asterisk__:__147578__:__INTERFERON, ALPHA-13; IFNA13__:____:__
Asterisk__:__147579__:__INTERFERON, ALPHA-14; IFNA14__:__LEUKOCYTE INTERFERON 2H; LEIF2H__:__
Asterisk__:__147580__:__INTERFERON, ALPHA-16; IFNA16__:____:__
Caret__:__147581__:__MOVED TO 100880__:____:__
Asterisk__:__147582__:__IRON-RESPONSIVE ELEMENT-BINDING PROTEIN 2; IREB2__:__IRE-BINDING PROTEIN 2; IRP2__:__
Asterisk__:__147583__:__INTERFERON, ALPHA-17; IFNA17__:__INTERFERON A; INFA;; LEUKOCYTE INTERFERON 2C1; LEIF2C1__:__
Asterisk__:__147584__:__INTERFERON, ALPHA-21; IFNA21__:____:__
Caret__:__147585__:__MOVED TO 147660__:____:__
Asterisk__:__147586__:__INTERFERON-GAMMA-INDUCIBLE PROTEIN 16; IFI16__:____:__
Caret__:__147590__:__MOVED TO 109120__:____:__
NULL__:__147610__:__IRIS PIGMENT LAYER, CLEAVAGE OF__:____:__
Asterisk__:__147620__:__INTERLEUKIN 6; IL6__:__INTERFERON, BETA-2; IFNB2;; B-CELL DIFFERENTIATION FACTOR;; B-CELL STIMULATORY FACTOR 2; BSF2;; HEPATOCYTE STIMULATORY FACTOR; HSF;; HYBRIDOMA GROWTH FACTOR; HGF__:__
Asterisk__:__147625__:__ISLET CELL AUTOANTIGEN 1; ICA1__:__ISLET CELL AUTOANTIGEN, 69-KD; ICA69__:__
Number Sign__:__147630__:__INSULINOMATOSIS AND DIABETES MELLITUS; INSDM__:__ISLET CELL ADENOMATOSIS__:__
Asterisk__:__147640__:__INTERFERON, BETA-1; IFNB1__:__INTERFERON, FIBROBLAST; IFF;; IFN, FIBROBLAST;; BETA-INTERFERON; IFB; IFNB__:__
Asterisk__:__147650__:__ISOCITRATE DEHYDROGENASE 2; IDH2__:__ISOCITRATE DEHYDROGENASE, NADP(+)-SPECIFIC, MITOCHONDRIAL; IDPM__:__
Asterisk__:__147660__:__INTERFERON, ALPHA-1; IFNA1__:__INTERFERON, LEUKOCYTIC;; ALPHA-INTERFERON; IFN; IFNA;; IFN-ALPHA;; IFN, LEUKOCYTE; IFL__:__INTERFERON, ALPHA, PSEUDOGENE 22, INCLUDED; IFNAP22, INCLUDED
Asterisk__:__147670__:__INSULIN RECEPTOR; INSR__:____:__
Asterisk__:__147671__:__INSULIN RECEPTOR-RELATED RECEPTOR; INSRR__:__IRR__:__
Asterisk__:__147678__:__CASPASE 1, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP1__:__INTERLEUKIN 1-BETA CONVERTASE; IL1BC;; IL1B-CONVERTASE;; IL1B-CONVERTING ENZYME; ICE__:__
Asterisk__:__147679__:__INTERLEUKIN 1 RECEPTOR ANTAGONIST; IL1RN__:__IL1RA__:__
Asterisk__:__147680__:__INTERLEUKIN 2; IL2__:__T-CELL GROWTH FACTOR; TCGF__:__
Asterisk__:__147681__:__INTERLEUKIN 11; IL11__:____:__
Asterisk__:__147683__:__INTERLEUKIN 13; IL13__:____:__
Caret__:__147684__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__147685__:__FORKHEAD BOX K2; FOXK2__:__INTERLEUKIN ENHANCER-BINDING FACTOR 1; ILF1;; ILF__:__
Caret__:__147686__:__MOVED TO 300119__:____:__
Asterisk__:__147690__:__INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 1; IFIT1__:__INTERFERON-INDUCED PROTEIN 56; IFI56;; INTERFERON-INDUCED PROTEIN IFI-56K; G10P1;; INTERFERON-INDUCIBLE mRNA 561; RNM561;; ISG56;; C56__:__
Asterisk__:__147700__:__ISOCITRATE DEHYDROGENASE 1; IDH1__:__ISOCITRATE DEHYDROGENASE, NADP(+)-SPECIFIC, SOLUBLE;; PEROXISOMAL ISOCITRATE DEHYDROGENASE; PICD;; ISOCITRATE DEHYDROGENASE, NADP(+)-DEPENDENT, CYTOSOLIC; IDPC; ICDC__:__
NULL__:__147710__:__INTUSSUSCEPTION__:____:__
Asterisk__:__147720__:__INTERLEUKIN 1-BETA; IL1B__:__IL1-BETA__:__
Asterisk__:__147730__:__INTERLEUKIN 2 RECEPTOR, ALPHA; IL2RA__:__IL2 RECEPTOR; IL2R;; IL2R, ALPHA CHAIN;; T-CELL GROWTH FACTOR RECEPTOR; TCGFR;; TAC ANTIGEN;; CD25__:__
Asterisk__:__147740__:__INTERLEUKIN 3; IL3__:__MULTI-CSF__:__
Number Sign__:__147750__:__IVIC SYNDROME__:__RADIAL RAY DEFECTS, HEARING IMPAIRMENT, EXTERNAL OPHTHALMOPLEGIA, AND THROMBOCYTOPENIA;; OCULOOTORADIAL SYNDROME; OORS__:__
Asterisk__:__147760__:__INTERLEUKIN 1-ALPHA; IL1A__:__IL1-ALPHA__:__
Percent__:__147770__:__JOHNSON NEUROECTODERMAL SYNDROME__:__JOHNSON-MCMILLIN SYNDROME; JMS;; ALOPECIA-ANOSMIA-DEAFNESS-HYPOGONADISM SYNDROME;; AADH SYNDROME__:__
Asterisk__:__147780__:__INTERLEUKIN 4; IL4__:__B-CELL STIMULATORY FACTOR 1; BSF1__:__
Asterisk__:__147781__:__INTERLEUKIN 4 RECEPTOR; IL4R__:__INTERLEUKIN 4 RECEPTOR, ALPHA; IL4RA__:__
Asterisk__:__147790__:__IMMUNOGLOBULIN J POLYPEPTIDE, LINKER PROTEIN FOR IMMUNOGLOBULIN ALPHA AND MU POLYPEPTIDES; IGJ__:__IGCJ;; J CHAIN; JCH__:__
Number Sign__:__147791__:__JACOBSEN SYNDROME; JBS__:__CHROMOSOME 11q DELETION SYNDROME;; PARTIAL 11q MONOSOMY SYNDROME__:__
Asterisk__:__147795__:__JANUS KINASE 1; JAK1__:____:__
Asterisk__:__147796__:__JANUS KINASE 2; JAK2__:____:__JAK2/ETV6 FUSION GENE, INCLUDED
Percent__:__147800__:__AASE-SMITH SYNDROME I__:__AASE-SMITH SYNDROME;; JOINT CONTRACTURES WITH OTHER ABNORMALITIES__:__
Asterisk__:__147810__:__INTERLEUKIN 1 RECEPTOR, TYPE I; IL1R1__:__INTERLEUKIN 1 RECEPTOR, ALPHA, TYPE I; IL1RA;; INTERLEUKIN 1 RECEPTOR; IL1R__:__
Asterisk__:__147811__:__INTERLEUKIN 1 RECEPTOR, TYPE II; IL1R2__:__INTERLEUKIN 1 RECEPTOR, BETA, TYPE II; IL1RB__:__
NULL__:__147820__:__INTERNAL CAROTID ARTERY, SPONTANEOUS DISSECTION OF__:____:__
Asterisk__:__147830__:__T-CELL TUMOR INVASION AND METASTASIS 1; TTIM1__:__INVASION AND METASTASIS FACTORS ON CHROMOSOME 7; INM7;; INVASION-INDUCING LOCUS__:__
Asterisk__:__147840__:__INTERCELLULAR ADHESION MOLECULE 1; ICAM1__:__CD54;; SURFACE ANTIGEN OF ACTIVATED B CELLS, BB2; BB2;; ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY BB2__:__
Asterisk__:__147850__:__INTERLEUKIN 5; IL5__:__EOSINOPHIL DIFFERENTIATION FACTOR; EDF__:__
Asterisk__:__147851__:__INTERLEUKIN 5 RECEPTOR, ALPHA; IL5RA__:__IL5R__:__
NULL__:__147860__:__INTERFERON, BETA-3; IFNB3__:____:__
Asterisk__:__147870__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 2; WNT2__:__ONCOGENE INT1-LIKE 1; INT1L1;; INT1-RELATED PROTEIN; IRP__:__
Asterisk__:__147880__:__INTERLEUKIN 6 RECEPTOR; IL6R__:__INTERLEUKIN 6 RECEPTOR, ALPHA; IL6RA;; CD126__:__
Asterisk__:__147890__:__MYXOVIRUS RESISTANCE 2, MOUSE, HOMOLOG OF; MX2__:__INTERFERON-INDUCIBLE PROTEIN p78, SECOND LOCUS;; MxB__:__
Number Sign__:__147891__:__ISCHIOCOXOPODOPATELLAR SYNDROME; ICPPS__:__SMALL PATELLA SYNDROME; SPS;; PATELLA APLASIA, COXA VARA, AND TARSAL SYNOSTOSIS;; ISCHIOPATELLAR DYSPLASIA;; COXOPODOPATELLAR SYNDROME;; SCOTT-TAOR SYNDROME__:__
Asterisk__:__147892__:__DEIODINASE, IODOTHYRONINE, TYPE I; DIO1__:__THYROXINE DEIODINASE, TYPE I; TXDI1__:__
Percent__:__147900__:__JOINT LAXITY, FAMILIAL__:__FAMILIAL JOINT INSTABILITY SYNDROME;; ARTICULAR HYPERMOBILITY SYNDROME;; EHLERS-DANLOS SYNDROME, TYPE XI, FORMERLY;; EDS XI, FORMERLY;; EDS11, FORMERLY__:__
Asterisk__:__147910__:__KALLIKREIN 1; KLK1__:__KALLIKREIN, RENAL/PANCREATIC/SALIVARY; KLKR;; KALLIKREIN, TISSUE__:__
Number Sign__:__147920__:__KABUKI SYNDROME 1; KABUK1__:__KABUKI SYNDROME;; KABUKI MAKE-UP SYNDROME; KMS;; NIIKAWA-KUROKI SYNDROME__:__
Asterisk__:__147935__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 4; SERPINA4__:__KALLISTATIN; KST;; TISSUE KALLIKREIN INHIBITOR;; PROTEASE INHIBITOR 4; PI4__:__
Asterisk__:__147940__:__ISLET AMYLOID POLYPEPTIDE; IAPP__:__IAP;; AMYLIN;; DIABETES-ASSOCIATED PEPTIDE; DAP__:__
Number Sign__:__147950__:__HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA; HH2__:__KALLMANN SYNDROME 2; KAL2__:__
Asterisk__:__147960__:__KALLIKREIN-RELATED PEPTIDASE 2; KLK2__:__KALLIKREIN 2;; KALLIKREIN, GLANDULAR;; KALLIKREIN, PROSTATIC__:__
Number Sign__:__148000__:__KAPOSI SARCOMA, SUSCEPTIBILITY TO__:__MULTIPLE IDIOPATHIC PIGMENTED HEMANGIOSARCOMA, SUSCEPTIBILITY TO__:__MULTICENTRIC CASTLEMAN DISEASE, SUSCEPTIBILITY TO, INCLUDED; MCD, INCLUDED
Asterisk__:__148020__:__KERATIN 19; KRT19__:__K19;; KERATIN, TYPE I, 40-KD__:__
Asterisk__:__148021__:__KERATIN ASSOCIATED PROTEIN 5-9; KRTAP5-9__:__KERATIN, CUTICLE, ULTRAHIGH-SULFUR, 1; KRN1__:__
Asterisk__:__148022__:__KERATIN-ASSOCIATED PROTEIN 5-1; KRTAP5-1__:__KERATIN, CUTICLE, ULTRAHIGH-SULFUR, 1-LIKE; KRN1L__:__
Asterisk__:__148030__:__KERATIN 15, TYPE I; KRT15__:__K15;; KA15;; CYTOKERATIN 15__:__
Asterisk__:__148040__:__KERATIN 5, TYPE II; KRT5__:__K5;; KB5__:__
Asterisk__:__148041__:__KERATIN 6A, TYPE II; KRT6A__:__KERATIN, EPIDERMAL TYPE II, K6A; K6A;; KB6__:__
Asterisk__:__148042__:__KERATIN 6B, TYPE II; KRT6B__:__KERATIN, EPIDERMAL TYPE II, K6B; K6B;; CYTOKERATIN 6B; CK6B;; KB10__:__
Asterisk__:__148043__:__KERATIN 3, TYPE II; KRT3__:__K3;; KB3;; CYTOKERATIN 3; CK3__:__
Number Sign__:__148050__:__KBG SYNDROME; KBGS__:__MACRODONTIA, MENTAL RETARDATION, CHARACTERISTIC FACIES, SHORT STATURE, AND SKELETAL ANOMALIES__:__
Asterisk__:__148059__:__KERATIN 7, TYPE II; KRT7__:__K7;; KB7;; KERATIN, SIMPLE EPITHELIAL;; KERATIN, TYPE II, CYTOSKELETAL, 7; K2C7;; SARCOLECTIN; SCL__:__
Asterisk__:__148060__:__KERATIN 8, TYPE II; KRT8__:__K8;; KB8 CYTOKERATIN 8; CK8; CYK8__:__
Asterisk__:__148065__:__KERATIN 13, TYPE I; KRT13__:__K13;; KA13;; CYTOKERATIN 13; CK13__:__
Asterisk__:__148066__:__KERATIN 14, TYPE I; KRT14__:__K14;; KA14__:__
Asterisk__:__148067__:__KERATIN 16, TYPE I; KRT16__:__K16;; KA16__:__
Asterisk__:__148069__:__KERATIN 17, TYPE I; KRT17__:__K17;; KA17;; CYTOKERATIN 17; CK17__:__
Asterisk__:__148070__:__KERATIN 18, TYPE I; KRT18__:__K18;; KA18;; CYTOKERATIN 18; CYK18; CK18__:__
Asterisk__:__148080__:__KERATIN 10, TYPE I; KRT10__:__K10;; KA10__:__
Percent__:__148100__:__KELOID FORMATION__:____:__
Asterisk__:__148180__:__FIBROBLAST GROWTH FACTOR 7; FGF7__:__KERATINOCYTE GROWTH FACTOR; KGF__:__
Caret__:__148181__:__MOVED TO 176943__:____:__
Number Sign__:__148190__:__KERATITIS, HEREDITARY__:____:__
Number Sign__:__148200__:__KERATOENDOTHELIITIS FUGAX HEREDITARIA; KEFH__:__KERATITIS FUGAX HEREDITARIA__:__
Number Sign__:__148210__:__KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL DOMINANT__:__KID SYNDROME, AUTOSOMAL DOMINANT__:__
Number Sign__:__148300__:__KERATOCONUS 1; KTCN1__:____:__
Number Sign__:__148350__:__KERATODERMA, PALMOPLANTAR, WITH DEAFNESS__:____:__
NULL__:__148360__:__KERATODERMA, PALMOPLANTAR, WITH NAIL DYSTROPHY AND HEREDITARY MOTOR-SENSORY NEUROPATHY__:__AXONAL NEUROPATHY WITH PALMOPLANTAR KERATODERMA;; CHARCOT-MARIE-TOOTH DISEASE WITH PALMOPLANTAR KERATODERMA AND NAIL DYSTROPHY__:__
Number Sign__:__148370__:__KERATOLYTIC WINTER ERYTHEMA; KWE__:__OUDTSHOORN SKIN DISEASE__:__
NULL__:__148390__:__KERATOSIS, FAMILIAL ACTINIC__:____:__
Number Sign__:__148500__:__TYLOSIS WITH ESOPHAGEAL CANCER; TOC__:__PALMOPLANTAR KERATODERMA WITH ESOPHAGEAL CANCER;; KERATOSIS PALMARIS ET PLANTARIS WITH ESOPHAGEAL CANCER__:__
NULL__:__148520__:__KERATOSIS PALMARIS ET PLANTARIS WITH CLINODACTYLY__:____:__
Number Sign__:__148600__:__PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IA; PPKP1A__:__PALMOPLANTAR KERATODERMA, PUNCTATE TYPE I; PPKP1;; KPPP1;; KERATODERMIA PALMOPLANTARIS PAPULOSA, BUSCHKE-FISCHER-BRAUER TYPE;; KERATOSIS PALMOPLANTARIS PAPULOSA__:__
Number Sign__:__148700__:__PALMOPLANTAR KERATODERMA I, STRIATE, FOCAL, OR DIFFUSE; PPKS1__:__KERATOSIS PALMOPLANTARIS STRIATA I;; STRIATE PALMOPLANTAR KERATODERMA I; SPPK1;; KERATODERMA, PALMOPLANTAR, STRIATE FORM I; KPPS1__:__
Percent__:__148730__:__KERATOSIS, FOCAL PALMOPLANTAR AND GINGIVAL__:__FOCAL PALMOPLANTAR AND GINGIVAL HYPERKERATOSIS SYNDROME__:__
Asterisk__:__148750__:__KINASE-LIKE PROTEIN G7P1; G7P1__:____:__
Asterisk__:__148760__:__KINESIN FAMILY MEMBER 11; KIF11__:__KINESIN-LIKE 1; KNSL1;; KINESIN, HEAVY CHAIN;; EG5, XENOPUS, HOMOLOG OF; EG5;; THYROID HORMONE RECEPTOR-INTERACTING PROTEIN 5; TRIP5__:__
NULL__:__148800__:__KLEEBLATTSCHAEDEL__:__CLOVERLEAF SKULL;; KLEEBLATTSCHADEL__:__
Number Sign__:__148820__:__WAARDENBURG SYNDROME, TYPE 3; WS3__:__WAARDENBURG SYNDROME WITH UPPER LIMB ANOMALIES;; WAARDENBURG SYNDROME, TYPE III;; KLEIN-WAARDENBURG SYNDROME__:__
Percent__:__148840__:__KLEINE-LEVIN HIBERNATION SYNDROME__:__KLEINE-LEVIN SYNDROME__:__
Caret__:__148860__:__MOVED TO 601076__:____:__
Caret__:__148870__:__MOVED TO 118100__:____:__
Caret__:__148900__:__MOVED TO 118100__:____:__
Percent__:__149000__:__KLIPPEL-TRENAUNAY-WEBER SYNDROME__:__KTW SYNDROME;; KLIPPEL-TRENAUNAY SYNDROME; KTS;; ANGIOOSTEOHYPERTROPHY SYNDROME__:__
Number Sign__:__149100__:__KNUCKLE PADS__:____:__
Number Sign__:__149200__:__KNUCKLE PADS, LEUKONYCHIA, AND SENSORINEURAL DEAFNESS__:__BART-PUMPHREY SYNDROME__:__
Percent__:__149300__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 2; NDNC2__:__KOILONYCHIA, HEREDITARY;; SPOON NAILS__:__KOILONYCHIA WITH LEUKONYCHIA, INCLUDED
Number Sign__:__149400__:__HYPEREKPLEXIA 1; HKPX1__:__STARTLE DISEASE, FAMILIAL;; STARTLE REACTION, EXAGGERATED;; EXAGGERATED STARTLE REACTION;; STHE;; STIFF-BABY SYNDROME;; STIFF-MAN SYNDROME, CONGENITAL;; STIFF-PERSON SYNDROME, CONGENITAL;; KOK DISEASE__:__
NULL__:__149500__:__KYRLE DISEASE__:____:__
NULL__:__149600__:__LABIA MINORA, INCOMPLETE ADHESION OF__:____:__
Number Sign__:__149700__:__LACRIMAL DUCT DEFECT; LCDD__:__NASOLACRIMAL DUCT OBSTRUCTION;; LACRIMAL PUNCTA, ABSENCE OF__:__
Number Sign__:__149730__:__LACRIMOAURICULODENTODIGITAL SYNDROME; LADD__:__LADD SYNDROME;; LEVY-HOLLISTER SYNDROME__:__
Asterisk__:__149750__:__LACTALBUMIN, ALPHA; LALBA__:____:__
Asterisk__:__150000__:__LACTATE DEHYDROGENASE A; LDHA__:__LDH, SUBUNIT M__:__
Asterisk__:__150100__:__LACTATE DEHYDROGENASE B; LDHB__:__LDH, SUBUNIT H__:__
Asterisk__:__150150__:__LACTATE DEHYDROGENASE C; LDHC__:__LDH, TESTICULAR FORM; LDHX__:__
Caret__:__150160__:__MOVED TO 150000__:____:__
NULL__:__150170__:__LACTIC ACIDOSIS, CHRONIC ADULT FORM__:____:__
Asterisk__:__150200__:__CHORIONIC SOMATOMAMMOTROPIN HORMONE 1; CSH1__:__CHORIONIC SOMATOMAMMOTROPIN A; CSA; CSMT;; LACTOGEN, PLACENTAL; PL__:__
Asterisk__:__150205__:__LACTOPEROXIDASE; LPO__:____:__
Asterisk__:__150210__:__LACTOTRANSFERRIN; LTF__:__LACTOFERRIN; LF__:__
Caret__:__150220__:__MOVED TO 223000__:____:__
Number Sign__:__150230__:__TRICHORHINOPHALANGEAL SYNDROME, TYPE II; TRPS2__:__LANGER-GIEDION SYNDROME; LGS;; CHROMOSOME 8q24.1 DELETION SYNDROME__:__
Asterisk__:__150240__:__LAMININ, BETA-1; LAMB1__:____:__
Number Sign__:__150250__:__LARSEN SYNDROME; LRS__:____:__
Percent__:__150260__:__LARYNGEAL ABDUCTOR PARALYSIS__:__LABD;; GERHARDT SYNDROME;; VOCAL CORD DYSFUNCTION, FAMILIAL__:__
Percent__:__150270__:__LARYNGEAL ADDUCTOR PARALYSIS; LAP__:__VOCAL CORD DYSFUNCTION, ADDUCTOR TYPE__:__
NULL__:__150280__:__LARYNGOMALACIA__:____:__
Asterisk__:__150290__:__LAMININ, GAMMA-1; LAMC1__:__LAMININ B2, FORMERLY; LAMB2, FORMERLY__:__
Asterisk__:__150292__:__LAMININ, GAMMA-2; LAMC2__:__LAMININ B2 POLYPEPTIDE, TRUNCATED;; LAMB2, TRUNCATED; LAMB2T;; KALININ;; LAMININ, NICEIN, BETA-2; LAMNB2;; LAMININ 5, GAMMA-2 SUBUNIT;; LAM5, GAMMA-2 SUBUNIT__:__
NULL__:__150300__:__LARYNX, CONGENITAL PARTIAL ATRESIA OF__:____:__
Asterisk__:__150310__:__LAMININ, BETA-3; LAMB3__:__LAMININ B3;; LAMININ 5, BETA-3 SUBUNIT;; LAM5, BETA-3 SUBUNIT__:__
Asterisk__:__150320__:__LAMININ, ALPHA-1; LAMA1__:__LAMININ A; LAMA__:__
Asterisk__:__150325__:__LAMININ, BETA-2; LAMB2__:__LAMININ S; LAMS__:__
Asterisk__:__150330__:__LAMIN A/C; LMNA__:____:__LAMIN A, INCLUDED;; LAMIN C, INCLUDED; LMNC, INCLUDED;; PRELAMIN A, INCLUDED;; PROGERIN, INCLUDED
Asterisk__:__150340__:__LAMIN B1; LMNB1__:__LMNB__:__
Asterisk__:__150341__:__LAMIN B2; LMNB2__:____:__
NULL__:__150360__:__LARYNGEAL WEB, FAMILIAL__:__GLOTTIC WEB, CONGENITAL ANTERIOR;; SUBGLOTTIC WEB;; SUBGLOTTIC BAR__:__
Asterisk__:__150370__:__RIBOSOMAL PROTEIN SA; RPSA__:__LAMININ RECEPTOR 1; LAMR1;; LAMBR;; LAMININ RECEPTOR, 67-KD; 67LR__:__
Asterisk__:__150390__:__LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 1; LTBP1__:____:__
Number Sign__:__150400__:__TOOTH AGENESIS, SELECTIVE, 4; STHAG4__:__TOOTH AGENESIS, SELECTIVE, 4, WITH OR WITHOUT ECTODERMAL DYSPLASIA;; LATERAL INCISORS, ABSENCE OF;; LATERAL INCISORS, PEGGED OR MISSING;; SUCCEDANEOUS TEETH, AGENESIS OF__:__
NULL__:__150500__:__LATTICE DEGENERATION OF RETINA LEADING TO RETINAL DETACHMENT__:____:__
NULL__:__150550__:__LAZY LEUKOCYTE SYNDROME__:____:__
Asterisk__:__150570__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 1; LGALS1__:__GALECTIN 1; GAL1__:__
Asterisk__:__150571__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 2; LGALS2__:__GALECTIN 2__:__
NULL__:__150590__:__LEG ULCERS, FAMILIAL, OF JUVENILE ONSET__:____:__
Number Sign__:__150600__:__LEGG-CALVE-PERTHES DISEASE; LCPD__:__LCP;; LEGG-PERTHES DISEASE;; PERTHES DISEASE__:__
Number Sign__:__150699__:__LEIOMYOMA, UTERINE; UL__:____:__
NULL__:__150700__:__LEIOMYOMA OF VULVA AND ESOPHAGUS__:__LEIOMYOMATOSIS, ESOPHAGOGASTRIC AND VULVAR__:__
Number Sign__:__150800__:__HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC__:__MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATA 1, WITH OR WITHOUT RENAL CELL CARCINOMA; MCUL1;; LEIOMYOMATOSIS AND RENAL CELL CANCER, HEREDITARY; LRCC;; LEIOMYOMA, MULTIPLE CUTANEOUS; MCL__:__
NULL__:__150900__:__LENTIGINES__:____:__
NULL__:__151000__:__LENTIGINOSIS, CENTROFACIAL NEURODYSRAPHIC__:__LENTIGINOSIS, TOURAINE TYPE__:__
Percent__:__151001__:__LENTIGINOSIS, INHERITED PATTERNED__:__LENTIGINOSIS, GENERALIZED;; LENTIGINOSIS PROFUSA;; LENTIGINOSIS, DIFFUSE__:__
Asterisk__:__151020__:__LENTIL AGGLUTININ BINDING__:__LCH RECEPTOR__:__
Number Sign__:__151050__:__LENZ-MAJEWSKI HYPEROSTOTIC DWARFISM; LMHD__:__LENZ-MAJEWSKI SYNDROME__:__
Number Sign__:__151100__:__LEOPARD SYNDROME 1; LPRD1__:__LENTIGINOSIS, CARDIOMYOPATHIC;; MULTIPLE LENTIGINES SYNDROME__:__
Number Sign__:__151200__:__CHROMOSOME 8q22.1 DUPLICATION SYNDROME__:__LERI PLEONOSTEOSIS__:__
Number Sign__:__151210__:__PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, TORRANCE TYPE; PLSDT__:__LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, TORRANCE TYPE;; THANATOPHORIC DYSPLASIA, TORRANCE VARIANT__:__PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, LUTON TYPE, INCLUDED; PLSDL, INCLUDED;; THANATOPHORIC DYSPLASIA, LUTON VARIANT, INCLUDED
Asterisk__:__151250__:__LETHAL ANTIGEN--A1; AL-A1__:__SPECIES ANTIGEN 11-1; SA11-1; S1; MER1__:__E7-ASSOCIATED CELL-SURFACE ANTIGEN, INCLUDED
Asterisk__:__151290__:__BETA-1,3-GLUCURONYLTRANSFERASE 1; B3GAT1__:__GLUCURONOSYLTRANSFERASE P; GLCATP__:__
Asterisk__:__151300__:__LEUCYL-CYSTINYL AMINOPEPTIDASE; LNPEP__:__LEUCINE AMINOPEPTIDASE OF PLACENTA;; OXYTOCINASE;; INSULIN-RESPONSIVE AMINOPEPTIDASE, MOUSE, HOMOLOG OF; IRAP__:__
Asterisk__:__151310__:__LEUCINE TRANSPORT, HIGH; LEUT__:__HIGH L-LEUCINE TRANSPORT; HTL__:__
Asterisk__:__151350__:__LEUCYL-tRNA SYNTHETASE; LARS__:__LRS;; LARS1;; LEUS;; RNTLS__:__
NULL__:__151380__:__LEUKEMIA, ACUTE MONOCYTIC__:____:__
Asterisk__:__151385__:__RUNT-RELATED TRANSCRIPTION FACTOR 1; RUNX1__:__ACUTE MYELOID LEUKEMIA 1 GENE; AML1;; CORE-BINDING FACTOR, RUNT DOMAIN, ALPHA SUBUNIT 2; CBFA2;; PEBP2-ALPHA-B; PEBP2AB__:__AML1/TEL FUSION GENE, INCLUDED;; AML1/MDS1 FUSION GENE, INCLUDED;; AML1/ETO FUSION GENE, INCLUDED;; AML1/MDS1/EAI1 FUSION GENE, INCLUDED; AME, INCLUDED;; AML1/FOG2 FUSION GENE, INCLUDED;; RUNX1/YTHDF2 FUSION GENE, INCLUDED;; RUNX1/SH3D19 FUSION GENE, INCLUDED;; RUNX1/ZNF687 FUSION GENE, INCLUDED
Caret__:__151390__:__MOVED TO 180385__:____:__
Number Sign__:__151400__:__LEUKEMIA, CHRONIC LYMPHOCYTIC; CLL__:__LEUKEMIA, CHRONIC LYMPHATIC__:__
Asterisk__:__151410__:__BREAKPOINT CLUSTER REGION; BCR__:__BCR1__:__BCR/ABL FUSION GENE, INCLUDED;; BCR/FGFR1 FUSION GENE, INCLUDED;; BCR/PDGFRA FUSION GENE, INCLUDED
Plus__:__151430__:__B-CELL CLL/LYMPHOMA 2; BCL2__:__ONCOGENE B-CELL LEUKEMIA 2__:__LEUKEMIA/LYMPHOMA, B-CELL, 2, INCLUDED
Asterisk__:__151440__:__LYMPHOBLASTIC LEUKEMIA-DERIVED SEQUENCE 1; LYL1__:____:__
Asterisk__:__151441__:__LEUKEMIA/LYMPHOMA, CHRONIC B-CELL, 5; BCL5__:__B-CELL LEUKEMIA/LYMPHOMA 5;; BCL3, FORMERLY__:__
Asterisk__:__151442__:__STATHMIN 1; STMN1__:__STATHMIN; SMN;; LEUKEMIA-ASSOCIATED PHOSPHOPROTEIN p18; LAP18;; METABLASTIN;; OP18__:__
Asterisk__:__151443__:__LEUKEMIA INHIBITORY FACTOR RECEPTOR; LIFR__:____:__
Asterisk__:__151445__:__Fc FRAGMENT OF IgE, LOW AFFINITY II, RECEPTOR FOR; FCER2__:__LEUKOCYTE ANTIGEN CD23; CD23;; IgE-BINDING FACTOR; IGEBF;; IMMUNOGLOBULIN E RECEPTOR, LOW AFFINITY II;; IgE RECEPTOR, LYMPHOCYTE;; C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER J; CLEC4J__:__
NULL__:__151450__:__LEUKOCYTE ANTIGEN GROUP FIVE; LAG5__:__GRANULOCYTE ANTIGEN 5__:__
Asterisk__:__151460__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, C; PTPRC__:__LEUKOCYTE-COMMON ANTIGEN; LCA;; T200 GLYCOPROTEIN;; CD45;; CD45R;; Ly5, HOMOLOG OF;; B220__:__
Caret__:__151465__:__MOVED TO 162643__:____:__
NULL__:__151500__:__LEUKOCYTE NUCLEAR APPENDAGES, HEREDITARY PREVALENCE OF__:____:__
Asterisk__:__151510__:__INTEGRIN, ALPHA-X; ITGAX__:__LEUKOCYTE SURFACE ANTIGEN p150,95, ALPHA SUBUNIT;; LEU M5, ALPHA SUBUNIT;; MYELOID MEMBRANE ANTIGEN, ALPHA SUBUNIT;; CD11C__:__
Asterisk__:__151520__:__LEUKOCYTE TYROSINE KINASE; LTK__:__PROTEIN TYROSINE KINASE-1; TYK1__:__
Asterisk__:__151523__:__LEUKOCYTE SURFACE ANTIGEN CD37; CD37__:____:__
Asterisk__:__151525__:__LEUKOCYTE SURFACE ANTIGEN CD53; CD53__:__ANTIGEN MOX44 IDENTIFIED BY MONOCLONAL ANTIBODY MRC-OX44; MOX44__:__
Asterisk__:__151530__:__ALANYL AMINOPEPTIDASE; ANPEP__:__AMINOPEPTIDASE N; PEPN;; CD13 ANTIGEN; CD13;; LEUKOCYTE SURFACE ANTIGEN GP150; GP150__:__
Caret__:__151540__:__MOVED TO 600623__:____:__
Caret__:__151550__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__151570__:__LEUKOTRIENE A4 HYDROLASE; LTA4H__:____:__
Caret__:__151580__:__MOVED TO 142360__:____:__
NULL__:__151590__:__LICHEN SCLEROSUS ET ATROPHICUS; LSA__:____:__
Number Sign__:__151600__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3; NDNC3__:__LEUKONYCHIA TOTALIS AND/OR PARTIALIS;; PORCELAIN NAILS__:__LEUKONYCHIA STRIATUS, INCLUDED;; LEUKONYCHIA PUNCTATA, INCLUDED
NULL__:__151610__:__LEVATOR-MEDIAL RECTUS SYNKINESIS__:__OCULOMOTOR-LEVATOR SYNKINESIS__:__
NULL__:__151620__:__LICHEN PLANUS, FAMILIAL__:____:__
Number Sign__:__151623__:__LI-FRAUMENI SYNDROME; LFS__:__SARCOMA FAMILY SYNDROME OF LI AND FRAUMENI;; SBLA SYNDROME__:__LI-FRAUMENI-LIKE SYNDROME, INCLUDED; LFL, INCLUDED
Asterisk__:__151625__:__LIGATIN; LGTN__:____:__
Asterisk__:__151626__:__LINE RETROTRANSPOSABLE ELEMENT 1; LRE1__:__LINE-1.2 RETROTRANSPOSABLE ELEMENT; L1.2__:__
Asterisk__:__151627__:__LINKIN__:____:__
Asterisk__:__151628__:__LINE RETROTRANSPOSABLE ELEMENT 2; LRE2__:____:__
Percent__:__151630__:__LIP, MEDIAN NODULE OF UPPER__:____:__
NULL__:__151640__:__LIP, HAMARTOMATOUS__:__ENLARGEMENT OF LOWER LIP__:__
Number Sign__:__151660__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2__:__FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES__:__
Asterisk__:__151670__:__LIPASE, HEPATIC; LIPC__:__LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL__:__
Asterisk__:__151675__:__LIPOCALIN 1; LCN1__:__LIPOCALIN, TEAR;; PREALBUMIN, TEAR;; PROTEIN MIGRATING FASTER THAN ALBUMIN;; VON EBNER GLAND PROTEIN;; VEG PROTEIN; VEGP__:__
Caret__:__151680__:__MOVED TO 269880__:____:__
Asterisk__:__151690__:__ANNEXIN A1; ANXA1__:__ANNEXIN I; ANX1;; LIPOCORTIN I; LPC1;; CALPACTIN II__:__
NULL__:__151700__:__LIPOMA OF THE CONJUNCTIVA__:____:__
Caret__:__151710__:__MOVED TO 151740__:____:__
Caret__:__151720__:__MOVED TO 151740__:____:__
Caret__:__151730__:__MOVED TO 151740__:____:__
Asterisk__:__151740__:__ANNEXIN A2; ANXA2__:__ANNEXIN II; ANX2;; ANNEXIN II, HEAVY CHAIN;; LIPOCORTIN II; LPC2; LIP2__:__ANNEXIN II PSEUDOGENE 1, INCLUDED; ANX2P1, INCLUDED;; ANX2P2, INCLUDED;; ANX2P3, INCLUDED
Asterisk__:__151750__:__LIPASE, HORMONE-SENSITIVE; LIPE__:__HSL__:__
NULL__:__151800__:__LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL__:__LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC__:__
Percent__:__151900__:__LIPOMATOSIS, MULTIPLE__:__LIPOMATOSIS, FAMILIAL MULTIPLE; FML;; LIPOMA; LIPO__:__
Asterisk__:__151990__:__LIPOPOLYSACCHARIDE-BINDING PROTEIN; LBP__:__LPS-BINDING PROTEIN__:__
Percent__:__152100__:__LIPOPROTEIN TYPES--Ld SYSTEM__:____:__
Plus__:__152200__:__APOLIPOPROTEIN(a); LPA__:____:__LIPOPROTEIN(a), INCLUDED; Lp(a), INCLUDED;; LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA, INCLUDED;; SINKING PRE-BETA-LIPOPROTEIN, INCLUDED; SPB, INCLUDED;; LIPOPROTEIN(a) DEFICIENCY, CONGENITAL, INCLUDED;; Lp(a) DEFICIENCY, CONGENITAL, INCLUDED;; CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED
NULL__:__152300__:__LIPOPROTEIN TYPES--Lt SYSTEM__:____:__
Asterisk__:__152310__:__TISSUE FACTOR PATHWAY INHIBITOR; TFPI__:__EXTRINSIC PATHWAY INHIBITOR; EPI;; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; LACI;; TFPI1__:__
Asterisk__:__152390__:__ARACHIDONATE 5-LIPOXYGENASE; ALOX5__:__5-LIPOXYGENASE; LOG5; 5-LO__:__
Asterisk__:__152391__:__ARACHIDONATE 12-OXIDOREDUCTASE; ALOX12__:__12-LIPOXYGENASE; LOG12;; 12LO__:__
Asterisk__:__152392__:__ARACHIDONATE 15-LIPOXYGENASE; ALOX15__:__15-LIPOXYGENASE, RETICULOCYTE ARACHIDONATE__:__
NULL__:__152400__:__LIPOPROTEIN, VARIANT OF BETA__:__BETA-LIPOPROTEIN, DOUBLE__:__
NULL__:__152420__:__LITHIUM TRANSPORT__:____:__
Asterisk__:__152422__:__LOCUS CONTROL REGION, ALPHA__:__LCR-ALPHA; LCRA__:__
Caret__:__152423__:__MOVED TO 192090__:____:__
Asterisk__:__152424__:__LOCUS CONTROL REGION, BETA__:__LCR-BETA; LCRB__:__
Asterisk__:__152425__:__ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 1; ACSL1__:__FATTY ACID CoA LIGASE, LONG CHAIN 2; FACL2;; LONG CHAIN ACYL-CoA SYNTHETASE 2; LACS2;; PALMITOYL-CoA LIGASE 2;; FATTY ACID CoA LIGASE, LONG CHAIN 1; FACL1;; LONG CHAIN ACYL-CoA SYNTHETASE; LACS;; ACYL-CoA SYNTHETASE 1; ACS1;; PALMITOYL-CoA LIGASE 1__:__
Caret__:__152426__:__MOVED TO 152425__:____:__
Asterisk__:__152427__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 2; KCNH2__:__HUMAN ETHER-A-GO-GO-RELATED GENE; HERG;; ETHER-A-GO-GO-RELATED GENE, HUMAN;; ERG1;; KV11.1__:__
Percent__:__152430__:__LONGEVITY 1__:____:__
Asterisk__:__152445__:__LORICRIN; LOR__:____:__EPIDERMAL DIFFERENTIATION COMPLEX, INCLUDED; EDC, INCLUDED
NULL__:__152450__:__LOW DENSITY LIPOPROTEIN, VARIATION IN MOLECULAR WEIGHT OF__:____:__
Caret__:__152460__:__MOVED TO 137950__:____:__
NULL__:__152550__:__LUMBAR STENOSIS, FAMILIAL__:____:__
NULL__:__152600__:__LUNULAE OF FINGERNAILS__:____:__
Asterisk__:__152690__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 6; XRCC6__:__THYROID AUTOANTIGEN, 70-KD; G22P1;; Ku ANTIGEN, 70-KD SUBUNIT; Ku70;; LUPUS AUTOANTIGEN p70;; THYROID-LUPUS AUTOANTIGEN; TLAA__:__
Number Sign__:__152700__:__SYSTEMIC LUPUS ERYTHEMATOSUS; SLE__:____:__EXCESS LYMPHOCYTE LOW MOLECULAR WEIGHT DNA, INCLUDED;; EXCESS LMW-DNA, INCLUDED
Asterisk__:__152760__:__GONADOTROPIN-RELEASING HORMONE 1; GNRH1__:__GNRH;; LUTEINIZING HORMONE-RELEASING HORMONE; LHRH__:__PROLACTIN RELEASE-INHIBITING FACTOR, INCLUDED; PIF, INCLUDED
Caret__:__152761__:__MOVED TO 138850__:____:__
Asterisk__:__152780__:__LUTEINIZING HORMONE, BETA POLYPEPTIDE; LHB__:__LUTROPIN, BETA CHAIN;; INTERSTITIAL CELL STIMULATING HORMONE, BETA CHAIN;; CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 4; CGB4__:__
Asterisk__:__152790__:__LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR; LHCGR__:__LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; LCGR;; LUTEINIZING HORMONE RECEPTOR; LHR;; GONADOTROPIN RECEPTOR__:__
Percent__:__152800__:__LYMPHANGIECTASIA, INTESTINAL__:____:__
NULL__:__152900__:__LYMPHEDEMA AND CEREBRAL ARTERIOVENOUS ANOMALY__:____:__
Number Sign__:__152950__:__MICROCEPHALY WITH OR WITHOUT CHORIORETINOPATHY, LYMPHEDEMA, OR MENTAL RETARDATION; MCLMR__:__MICROCEPHALY, LYMPHEDEMA, CHORIORETINAL DYSPLASIA SYNDROME;; MLCRD SYNDROME;; MICROCEPHALY AND CHORIORETINOPATHY WITH OR WITHOUT MENTAL RETARDATION, AUTOSOMAL DOMINANT;; CDMMR SYNDROME;; LYMPHEDEMA, MICROCEPHALY, CHORIORETINOPATHY SYNDROME;; LYMPHEDEMA AND RETINAL FOLDS WITH MICROCEPHALY AND MICROPHTHALMOS__:__
Caret__:__153000__:__MOVED TO 153400__:____:__
Number Sign__:__153100__:__LYMPHATIC MALFORMATION 1; LMPHM1__:__NONNE-MILROY LYMPHEDEMA;; MILROY DISEASE;; LYMPHEDEMA, EARLY-ONSET;; PRIMARY CONGENITAL LYMPHEDEMA; PCL;; LYMPHEDEMA, HEREDITARY, TYPE I, FORMERLY;; LYMPHEDEMA, HEREDITARY, IA, FORMERLY; LMPH1A, FORMERLY__:__
Percent__:__153200__:__LYMPHATIC MALFORMATION 5; LMPHM5__:__MEIGE DISEASE;; MEIGE LYMPHEDEMA;; LYMPHEDEMA, LATE-ONSET;; LYMPHEDEMA PRAECOX;; LYMPHEDEMA, HEREDITARY, II, FORMERLY; LMPH2, FORMERLY__:__
Asterisk__:__153240__:__SELECTIN L; SELL__:__L-SELECTIN;; LYMPHOCYTE ADHESION MOLECULE 1; LYAM1; LAM1;; LEU8;; CD62 ANTIGEN LIGAND; CD62L__:__
Asterisk__:__153243__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 8; TNFRSF8__:__LYMPHOID ACTIVATION ANTIGEN CD30; CD30__:__
Plus__:__153245__:__LYMPHOID ENHANCER-BINDING FACTOR 1; LEF1__:__TRANSCRIPTION FACTOR, T CELL-SPECIFIC, 1, ALPHA;; TCF1-ALPHA__:__SEBACEOUS TUMORS, SOMATIC, INCLUDED
NULL__:__153280__:__LYMPHOCYTE CYTOSOL POLYPEPTIDE, 40-KD__:__LC40P;; LCP40__:__
NULL__:__153290__:__LYMPHOCYTE CYTOSOL POLYPEPTIDE, 49-KD__:__LC49P;; LCP49__:__
Percent__:__153300__:__YELLOW NAIL SYNDROME__:__YNS;; LYMPHEDEMA AND YELLOW NAILS__:__
Asterisk__:__153310__:__CHARCOT-LEYDEN CRYSTAL PROTEIN; CLC__:__LYSOPHOSPHOLIPASE OF EOSINOPHIL;; GALECTIN 10; LGALS10__:__
Asterisk__:__153330__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 1; LAMP1__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN A; LAMPA;; LYSOSOMAL MEMBRANE GLYCOPROTEIN, 120-KD; LGP120;; CD107A__:__
Caret__:__153335__:__MOVED TO 182284__:____:__
Asterisk__:__153337__:__LYMPHOCYTE ACTIVATION GENE 3; LAG3__:__CD223 ANTIGEN; CD223__:__
Asterisk__:__153340__:__LYMPHOCYTE ANTIGEN CD5; CD5__:__Ly1, MOUSE, HOMOLOG OF;; T1;; LEU1__:__
Caret__:__153360__:__MOVED TO 300257__:____:__
Asterisk__:__153370__:__INTEGRIN, ALPHA-L; ITGAL__:__LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN, TYPE 1, ALPHA SUBUNIT; LFA1A;; CD11A__:__
Asterisk__:__153380__:__LYMPHOCYTE CYTOSOL POLYPEPTIDE, 20-KD__:__CP20;; LCP20__:__
Asterisk__:__153390__:__LYMPHOCYTE-SPECIFIC PROTEIN-TYROSINE KINASE; LCK__:__ONCOGENE LCK;; p56(LCK)__:__
Number Sign__:__153400__:__LYMPHEDEMA-DISTICHIASIS SYNDROME; LPHDST__:__LYMPHEDEMA WITH DISTICHIASIS__:__LYMPHEDEMA-DISTICHIASIS SYNDROME WITH RENAL DISEASE AND DIABETES MELLITUS, INCLUDED
Asterisk__:__153420__:__CD58 MOLECULE; CD58__:__LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN, TYPE 3; LFA3__:__
Asterisk__:__153430__:__LYMPHOCYTE CYTOSOLIC PROTEIN 1; LCP1__:__LYMPHOCYTE CYTOSOL POLYPEPTIDE, 64-KD; LC64P; CP64;; L-PLASTIN; LPL;; PLASTIN 2; PLS2__:__
Asterisk__:__153432__:__LYMPHOCYTE-SPECIFIC PROTEIN;  LSP1__:__pp52__:__
Asterisk__:__153435__:__LYMPHOKINE-ACTIVATED KILLER CELL LIGAND; LAKL__:____:__
Asterisk__:__153440__:__LYMPHOTOXIN-ALPHA; LTA__:__LYMPHOTOXIN-A;; TUMOR NECROSIS FACTOR, BETA; TNFB;; TNF, LYMPHOCYTE-DERIVED__:__
Asterisk__:__153450__:__LYSOZYME; LYZ__:____:__
Asterisk__:__153454__:__PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE; PLOD1__:__LYSYL HYDROXYLASE; LLH; LH;; LYSYL HYDROXYLASE 1; LH1;; LYSINE HYDROXYLASE__:__
Asterisk__:__153455__:__LYSYL OXIDASE; LOX__:____:__
Asterisk__:__153456__:__LYSYL OXIDASE-LIKE 1; LOXL1__:__LOXL__:__
Caret__:__153460__:__MOVED TO 232600__:____:__
NULL__:__153470__:__MACROCEPHALY, BENIGN FAMILIAL__:__COLE-HUGHES SYNDROME__:__
Caret__:__153480__:__MOVED TO 158350__:____:__
Number Sign__:__153550__:__CHROMOSOME 5q DELETION SYNDROME__:__5q- SYNDROME;; MACROCYTIC ANEMIA, REFRACTORY, DUE TO 5q DELETION; MAR__:__MEGAKARYOCYTES, UNILOBULAR NUCLEATED, INCLUDED
Percent__:__153600__:__MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 1; WM1__:____:__MACROGLOBULINEMIA, WALDENSTROM, SOMATIC, INCLUDED
Asterisk__:__153615__:__CAPPING PROTEIN, GELSOLIN-LIKE; CAPG__:__MACROPHAGE CAPPING PROTEIN; MCP__:__
Asterisk__:__153618__:__MANNOSE RECEPTOR, C-TYPE, 1; MRC1__:__MACROPHAGE MANNOSE RECEPTOR; MMR; MR;; CD206__:__
Asterisk__:__153619__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3; LGALS3__:__MACROPHAGE GALACTOSE-SPECIFIC LECTIN; MAC2;; GALACTOSIDE-BINDING PROTEIN; GALBP;; GALECTIN 3; GAL3__:__GALECTIN 3 INTERNAL GENE, INCLUDED; GALIG, INCLUDED
Asterisk__:__153620__:__MACROPHAGE MIGRATION INHIBITORY FACTOR; MIF__:__MMIF__:__
Asterisk__:__153622__:__MACROPHAGE SCAVENGER RECEPTOR; MSR1__:__SCAVENGER RECEPTOR CLASS A, MEMBER 1; SCARA1;; SRA__:__
Percent__:__153630__:__MACROGLOSSIA__:____:__
Asterisk__:__153634__:__MACROPHAGE ANTIGEN CD68; CD68__:__MACROSIALIN__:__
Caret__:__153640__:__MOVED TO 155100__:____:__
Caret__:__153650__:__MOVED TO 155100__:____:__
Number Sign__:__153670__:__BERNARD-SOULIER SYNDROME, TYPE A2, AUTOSOMAL DOMINANT; BSSA2__:____:__
Number Sign__:__153700__:__MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2__:__VITELLIFORM MACULAR DYSTROPHY, EARLY-ONSET;; VITELLIFORM MACULAR DYSTROPHY, JUVENILE-ONSET;; BEST MACULAR DYSTROPHY; BMD;; MACULAR DEGENERATION, POLYMORPHIC VITELLINE;; BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL__:__
Number Sign__:__153800__:__MACULAR DEGENERATION, AGE-RELATED, 2; ARMD2__:__MACULOPATHY, AGE-RELATED, 2;; MACULAR DEGENERATION, SENILE__:__
Percent__:__153840__:__MACULAR DYSTROPHY, VITELLIFORM, 1; VMD1__:__MACULAR DYSTROPHY, ATYPICAL VITELLIFORM__:__
Caret__:__153860__:__MOVED TO 169150__:____:__
Percent__:__153870__:__MACULAR DYSTROPHY, CONCENTRIC ANNULAR__:__MCDCA;; MACULAR DYSTROPHY, BENIGN CONCENTRIC ANNULAR; BCAMD__:__
Percent__:__153880__:__MACULAR DYSTROPHY, DOMINANT CYSTOID; DCMD__:__CYSTOID MACULAR DYSTROPHY; CYMD;; MACULAR EDEMA, CYSTOID;; MDDC__:__
NULL__:__153890__:__MACULAR DYSTROPHY, FENESTRATED SHEEN TYPE__:____:__
Caret__:__153900__:__MOVED TO 600110__:____:__
Caret__:__154000__:__MOVED TO 145250__:____:__
Number Sign__:__154020__:__HYPOMAGNESEMIA 2, RENAL; HOMG2__:__MAGNESIUM WASTING, RENAL;; MAGNESIUM LOSS, ISOLATED RENAL__:__
Asterisk__:__154030__:__NUCLEASE-SENSITIVE ELEMENT-BINDING PROTEIN 1; NSEP1__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, Y BOX-BINDING PROTEIN 1; YB1;; YBX1;; DNA-BINDING PROTEIN B; DBPB__:__
Asterisk__:__154040__:__RD RNA-BINDING PROTEIN; RDBP__:__MAJOR HISTOCOMPATIBILITY COMPLEX GENE RD; RD;; NEGATIVE ELONGATION FACTOR POLYPEPTIDE E; NELFE__:__
Asterisk__:__154045__:__LENS INTRINSIC MEMBRANE PROTEIN 2, 19-KD; LIM2__:__MP19;; MP17__:__
Asterisk__:__154050__:__MAJOR INTRINSIC PROTEIN OF LENS FIBER; MIP__:__MP26;; MIP26;; LIM1;; AQUAPORIN 0; AQP0__:__
Asterisk__:__154100__:__MALATE DEHYDROGENASE, MITOCHONDRIAL; MDH2__:____:__
Asterisk__:__154200__:__MALATE DEHYDROGENASE, SOLUBLE; MDH1__:__MALATE DEHYDROGENASE, CYTOPLASMIC__:__
Number Sign__:__154230__:__46,XY SEX REVERSAL 4; SRXY4__:__46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, WITH 9p24.3 DELETION;; CHROMOSOME 9p24.3 DELETION SYNDROME__:__
Asterisk__:__154235__:__MALE GERM CELL-ASSOCIATED KINASE; MAK__:____:__
Asterisk__:__154250__:__MALIC ENZYME 1; ME1__:__MALIC ENZYME, NADP(+)-DEPENDENT, CYTOSOLIC;; MALIC ENZYME, SOLUBLE; MES;; MALATE DEHYDROGENASE, NADP(+)-DEPENDENT, SOLUBLE__:__
Asterisk__:__154270__:__MALIC ENZYME 2; ME2__:__MALIC ENZYME, NAD(+)-DEPENDENT, MITOCHONDRIAL__:__
Percent__:__154275__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2__:__MHS2__:__
Percent__:__154276__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3__:__MHS3__:__
Asterisk__:__154280__:__SUPPRESSOR OF ANCHORAGE INDEPENDENCE 1; SAI1__:__TRANSFORMATION SUPPRESSOR 1; TFS1;; NEOPLASTIC TRANSFORMATION, SUPPRESSION OF;; MALIGNANT TRANSFORMATION SUPPRESSION 1; MTS1__:__
NULL__:__154300__:__MALOCCLUSION DUE TO PROTUBERANT UPPER FRONT TEETH__:____:__
Asterisk__:__154360__:__MALTASE-GLUCOAMYLASE; MGAM__:__MGA__:__
Asterisk__:__154365__:__PROTEASOME 26S SUBUNIT, ATPase, 2; PSMC2__:__MAMMALIAN SUPPRESSOR OF sgv-1 OF YEAST; MSS1;; PROTEASE 26S, SUBUNIT 7; S7__:__
NULL__:__154370__:__MAMMASTATIN__:____:__
Number Sign__:__154400__:__ACROFACIAL DYSOSTOSIS 1, NAGER TYPE; AFD1__:__MANDIBULOFACIAL DYSOSTOSIS, TREACHER COLLINS TYPE, WITH LIMB ANOMALIES;; NAGER ACROFACIAL DYSOSTOSIS;; AFD, NAGER TYPE;; NAGER SYNDROME__:__
Number Sign__:__154500__:__TREACHER COLLINS SYNDROME 1; TCS1__:__TREACHER COLLINS-FRANCESCHETTI SYNDROME; TCOF;; TREACHER COLLINS SYNDROME; TCS;; MANDIBULOFACIAL DYSOSTOSIS; MFD1__:__
Asterisk__:__154540__:__MANNOSE 6-PHOSPHATE RECEPTOR, CATION-DEPENDENT; M6PR__:__CDMPR;; SMALL MANNOSE 6-PHOSPHATE RECEPTOR; SMPR__:__
Asterisk__:__154545__:__LECTIN, MANNOSE-BINDING, SOLUBLE, 2; MBL2__:__MANNOSE-BINDING LECTIN; MBL;; MANNOSE-BINDING PROTEIN, SERUM; MBP1;; MANNAN-BINDING PROTEIN;; COLLECTIN 1; COLEC1__:__
Asterisk__:__154550__:__MANNOSEPHOSPHATE ISOMERASE; MPI__:__PHOSPHOMANNOSE ISOMERASE 1; PMI1; PMI__:__
Percent__:__154570__:__MANNOSE 6-PHOSPHATE RECEPTOR RECOGNITION DEFECT, LEBANESE TYPE__:__PHOSPHODIESTER GLYCOSIDE DEFICIENCY__:__
Asterisk__:__154580__:__MANNOSIDASE, ALPHA, CLASS 2C, MEMBER 1; MAN2C1__:__MANNOSIDASE, ALPHA A, CYTOPLASMIC; MANA__:__
Asterisk__:__154582__:__MANNOSIDASE, ALPHA, CLASS 2A, MEMBER 1; MAN2A1__:__MANNOSIDASE, ALPHA, II; MANA2__:__
NULL__:__154600__:__MARCUS GUNN PHENOMENON__:__JAW-WINKING;; MAXILLOPALPEBRAL SYNKINESIS__:__
Number Sign__:__154700__:__MARFAN SYNDROME; MFS__:__MARFAN SYNDROME, TYPE I; MFS1__:__
Caret__:__154705__:__MOVED TO 610380__:____:__
NULL__:__154750__:__MARFANOID HYPERMOBILITY SYNDROME__:____:__
Number Sign__:__154780__:__MARSHALL SYNDROME; MRSHS__:____:__
Asterisk__:__154790__:__PROTEASE INHIBITOR 5; PI5__:__SERPIN FAMILY B, MEMBER 5; SERPINB5;; MASPIN__:__
Number Sign__:__154800__:__MASTOCYTOSIS, CUTANEOUS; MASTC__:__URTICARIA PIGMENTOSA;; MASTOCYTOSIS, MACULOPAPULAR CUTANEOUS;; MASTOCYTOSIS, DIFFUSE CUTANEOUS__:__MASTOCYTOSIS, SYSTEMIC, INCLUDED; MASTSYS, INCLUDED;; MASTOCYTOSIS, INDOLENT, INCLUDED;; MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC DISORDER, INCLUDED;; MAST CELL LEUKEMIA, INCLUDED
NULL__:__154850__:__MASTICATORY MUSCLES, HYPERTROPHY OF__:__MASSETER MUSCLE HYPERTROPHY__:__
Asterisk__:__154870__:__MATRIX GAMMA-CARBOXYGLUTAMIC ACID; MGP__:__GAMMA-CARBOXYGLUTAMIC ACID PROTEIN, MATRIX;; MATRIX Gla PROTEIN; MGLAP__:__
Asterisk__:__154950__:__MAX PROTEIN; MAX__:__MYC-ASSOCIATED FACTOR X__:__
Percent__:__155000__:__MAXILLOFACIAL DYSOSTOSIS__:____:__
Percent__:__155050__:__MAXILLONASAL DYSPLASIA, BINDER TYPE__:__BINDER SYNDROME__:__
Number Sign__:__155100__:__MACROTHROMBOCYTOPENIA AND GRANULOCYTE INCLUSIONS WITH OR WITHOUT NEPHRITIS OR SENSORINEURAL HEARING LOSS; MATINS__:__BLEEDING DISORDER, PLATELET-TYPE, 6; BDPLT6;; MAY-HEGGLIN ANOMALY; MHA;; DOHLE LEUKOCYTE INCLUSIONS WITH GIANT PLATELETS;; MACROTHROMBOCYTOPENIA WITH LEUKOCYTE INCLUSIONS;; GIANT PLATELET SYNDROME WITH THROMBOCYTOPENIA;; SEBASTIAN SYNDROME; SBS;; SEBASTIAN PLATELET SYNDROME;; MACROTHROMBOCYTOPENIA WITH DISPERSED LEUKOCYTIC INCLUSIONS;; EPSTEIN SYNDROME; EPSTNS;; MACROTHROMBOCYTOPENIA, NEPHRITIS, AND DEAFNESS;; MACROTHROMBOCYTOPENIA, NEPHRITIS, DEAFNESS, AND LEUKOCYTE INCLUSIONS;; FECHTNER SYNDROME; FTNS;; MACROTHROMBOCYTOPENIA AND PROGRESSIVE SENSORINEURAL DEAFNESS;; ALPORT SYNDROME WITH MACROTHROMBOCYTOPENIA, FORMERLY; APSM, FORMERLY__:__
Asterisk__:__155120__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 11; ADAM11__:__METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN; MDC__:__
NULL__:__155140__:__MECKEL DIVERTICULUM__:____:__
Percent__:__155145__:__CLEFT, MEDIAN, OF UPPER LIP WITH POLYPS OF FACIAL SKIN AND NASAL MUCOSA__:__PAI SYNDROME__:__
NULL__:__155150__:__MEDIAN-ULNAR NERVE COMMUNICATIONS__:__MARTIN-GRUBER MEDIAN-ULNAR ANASTOMOSIS__:__
NULL__:__155200__:__MEDIOSTERNAL DEPIGMENTATION LINE__:____:__
Number Sign__:__155240__:__THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC__:__FMTC;; MTC1__:__
Caret__:__155250__:__MOVED TO 130130__:____:__
Number Sign__:__155255__:__MEDULLOBLASTOMA; MDB__:____:__MEDULLOBLASTOMA, DESMOPLASTIC, INCLUDED;; MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY, INCLUDED; MBEN, INCLUDED
Number Sign__:__155310__:__VISCERAL MYOPATHY; VSCM__:__MEGACYSTIS-MICROCOLON-INTESTINAL HYPOPERISTALSIS SYNDROME; MMIH;; INFANTILE VISCERAL MYOPATHY;; MEGADUODENUM AND/OR MEGACYSTIS;; BERDON SYNDROME;; PSEUDOOBSTRUCTION, IDIOPATHIC INTESTINAL__:__
Percent__:__155350__:__MEGALENCEPHALY, AUTOSOMAL DOMINANT__:____:__
Number Sign__:__155500__:__MACRODACTYLY__:__MEGALODACTYLY__:__
Asterisk__:__155540__:__MELANOCORTIN 3 RECEPTOR; MC3R__:__MC3 RECEPTOR__:__
Asterisk__:__155541__:__MELANOCORTIN 4 RECEPTOR; MC4R__:__MCR RECEPTOR__:__
Asterisk__:__155550__:__SILVER, MOUSE, HOMOLOG OF; SILV__:__MELANOCYTE PROTEIN 17; PMEL17;; PREMELANOSOMAL PROTEIN; PMEL;; GP100;; ME20__:__
Asterisk__:__155555__:__MELANOCORTIN 1 RECEPTOR; MC1R__:__MELANOCYTE-STIMULATING HORMONE RECEPTOR; MSHR;; MELANOTROPIN RECEPTOR__:__
Percent__:__155600__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 1; CMM1__:__MELANOMA, CUTANEOUS MALIGNANT; CMM;; MELANOMA, MALIGNANT;; FAMILIAL ATYPICAL MOLE-MALIGNANT MELANOMA SYNDROME; FAMMM;; MELANOMA, FAMILIAL; MLM;; DYSPLASTIC NEVUS SYNDROME, HEREDITARY; DNS;; B-K MOLE SYNDROME__:__
Number Sign__:__155601__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 2; CMM2__:____:__
NULL__:__155700__:__MELANOMA, MALIGNANT FAMILIAL INTRAOCULAR__:____:__
Number Sign__:__155720__:__MELANOMA, UVEAL__:____:__
Asterisk__:__155730__:__CHEMOKINE, CXC MOTIF, LIGAND 1; CXCL1__:__GRO1 ONCOGENE; GRO1;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 1; SCYB1;; GRO PROTEIN, ALPHA; GROA;; MELANOMA GROWTH STIMULATORY ACTIVITY, ALPHA; MGSA;; KERATINOCYTE-DERIVED CHEMOKINE, MOUSE, HOMOLOG OF; KC__:__
Asterisk__:__155735__:__MELANOMA ADHESION MOLECULE; MCAM__:__MELANOMA-ASSOCIATED GLYCOPROTEIN MUC18; MUC18;; CD146;; GICERIN, CHICKEN, HOMOLOG OF__:__
Asterisk__:__155740__:__CD63 ANTIGEN; CD63__:__MELANOMA-ASSOCIATED ANTIGEN MLA1; MLA1;; MELANOMA-ASSOCIATED ANTIGEN ME491;; GRANULOPHYSIN__:__
Caret__:__155741__:__MOVED TO 600186__:____:__
Asterisk__:__155750__:__MELANOMA-ASSOCIATED ANTIGEN p97; MFI2__:__p97 MELANOMA ANTIGEN; MAP97;; MELANOTRANSFERRIN__:__
Number Sign__:__155755__:__MELANOMA-ASTROCYTOMA SYNDROME__:__MELANOMA AND NEURAL SYSTEM TUMOR SYNDROME__:__
Asterisk__:__155760__:__AGGRECAN; ACAN__:__AGGRECAN 1; AGC1;; AGCAN;; CHONDROITIN SULFATE PROTEOGLYCAN CORE PROTEIN 1; CSPG1__:__
NULL__:__155770__:__MELANOMA TUMOR ANTIGEN GP90__:__CLASS 1 UNIQUE TUMOR ANTIGEN OF MELANOMA; GP90__:__
Caret__:__155800__:__MOVED TO 145250__:____:__
Percent__:__155900__:__MELKERSSON-ROSENTHAL SYNDROME__:__MROS; MRS;; MELKERSSON SYNDROME__:__
Percent__:__155950__:__MELORHEOSTOSIS, ISOLATED__:__MEL__:__
Caret__:__155960__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__155970__:__MEMBRANE GLYCOPROTEIN MRC OX-2; MOX2__:__OX2;; CD200__:__
Caret__:__155975__:__MOVED TO 112205__:____:__
Percent__:__155980__:__MEMBRANOUS CRANIAL OSSIFICATION, DELAYED__:____:__
NULL__:__156000__:__MENIERE DISEASE__:____:__
Asterisk__:__156100__:__MN1 GENE; MN1__:__MENINGIOMA CHROMOSOME REGION 1; MGCR1__:__MN1/TEL FUSION GENE, INCLUDED
NULL__:__156190__:__MENTAL AND GROWTH RETARDATION WITH AMBLYOPIA__:____:__
Number Sign__:__156200__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 1; MRD1__:____:__CHROMOSOME 2q23.1 DELETION SYNDROME, INCLUDED
NULL__:__156220__:__MERALGIA PARAESTHETICA, FAMILIAL__:____:__
Asterisk__:__156225__:__LAMININ, ALPHA-2; LAMA2__:__LAMININ 2, HEAVY CHAIN__:__MEROSIN, INCLUDED;; LAMININ 2, INCLUDED;; LAMININ M, INCLUDED; LAMM, INCLUDED
Percent__:__156230__:__MESOMELIC DWARFISM OF HYPOPLASTIC TIBIA AND RADIUS TYPE__:____:__
Percent__:__156232__:__MESOMELIC DYSPLASIA, KANTAPUTRA TYPE; MMDK__:__MDK;; MESOMELIC DYSPLASIA WITH ANKLE, CARPAL, AND TARSAL SYNOSTOSIS;; MESOMELIC DYSPLASIA, THAI TYPE__:__
Number Sign__:__156240__:__MESOTHELIOMA, MALIGNANT; MESOM__:____:__
Number Sign__:__156250__:__METACHONDROMATOSIS; METCDS__:____:__
NULL__:__156300__:__METACHROMASIA OF FIBROBLASTS__:____:__
NULL__:__156310__:__METACHROMATIC LEUKODYSTROPHY, ADULT-ONSET, WITH NORMAL ARYLSULFATASE A__:____:__
Caret__:__156340__:__MOVED TO 156360__:____:__
Asterisk__:__156349__:__METALLOTHIONEIN 1B; MT1B__:__METALLOTHIONEIN IB__:__
Asterisk__:__156350__:__METALLOTHIONEIN 1A; MT1A__:__METALLOTHIONEIN IA__:__
Asterisk__:__156351__:__METALLOTHIONEIN 1E; MT1E__:__METALLOTHIONEIN IE__:__
Asterisk__:__156352__:__METALLOTHIONEIN 1F; MT1F__:__METALLOTHIONEIN IF__:__
Asterisk__:__156353__:__METALLOTHIONEIN 1G; MT1G__:__METALLOTHIONEIN IG__:__
Asterisk__:__156354__:__METALLOTHIONEIN 1H; MT1H__:__METALLOTHIONEIN IH__:__
Asterisk__:__156355__:__METALLOTHIONEIN 1I; MT1I__:__METALLOTHIONEIN I-I__:__
Asterisk__:__156356__:__METALLOTHIONEIN 1J; MT1J__:__METALLOTHIONEIN IJ__:__
Asterisk__:__156357__:__METALLOTHIONEIN 1K; MT1K__:__METALLOTHIONEIN IK__:__
Asterisk__:__156358__:__METALLOTHIONEIN 1L; MT1L__:__METALLOTHIONEIN IL__:__
Asterisk__:__156359__:__METALLOTHIONEIN 1X; MT1X__:__METALLOTHIONEIN IX__:__
Asterisk__:__156360__:__METALLOTHIONEIN 2A; MT2A__:__METALLOTHIONEIN II; MT2__:__METALLOTHIONEIN II PROCESSED PSEUDOGENE, INCLUDED; MT2P1, INCLUDED
Number Sign__:__156400__:__METAPHYSEAL CHONDRODYSPLASIA, JANSEN TYPE; MCDJ__:__METAPHYSEAL CHONDRODYSPLASIA, MURK JANSEN TYPE__:__
Asterisk__:__156490__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 1; NME1__:__NONMETASTATIC CELLS 1, PROTEIN EXPRESSED IN;; METASTASIS INHIBITION FACTOR NM23;; NONMETASTATIC PROTEIN 23; NM23;; NONMETASTATIC PROTEIN 23, HOMOLOG 1; NM23H1;; NUCLEOSIDE DIPHOSPHATE KINASE-A; NDPKA;; GZMA-ACTIVATED DNase; GAAD;; AWD, DROSOPHILA, HOMOLOG OF; AWD__:__NM23H1B, INCLUDED;; NM23 LONG VARIANT, INCLUDED; NM23LV, INCLUDED;; NME1-NME2 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__156491__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 2; NME2__:__NONMETASTATIC CELLS 2, PROTEIN EXPRESSED IN;; METASTASIS INHIBITION FACTOR NM23B;; NONMETASTATIC PROTEIN 23B; NM23B;; NONMETASTATIC PROTEIN 23, HOMOLOG 2; NM23H2;; NUCLEOSIDE DIPHOSPHATE KINASE-B; NDPKB__:__
Number Sign__:__156500__:__METAPHYSEAL CHONDRODYSPLASIA, SCHMID TYPE; MCDS__:__SPONDYLOMETAPHYSEAL DYSPLASIA, JAPANESE TYPE__:__
Number Sign__:__156510__:__METAPHYSEAL DYSPLASIA WITH MAXILLARY HYPOPLASIA WITH OR WITHOUT BRACHYDACTYLY; MDMHB__:____:__
Percent__:__156520__:__METATARSUS VARUS, TYPE I__:____:__
Number Sign__:__156530__:__METATROPIC DYSPLASIA__:__METATROPIC DWARFISM__:__
Asterisk__:__156535__:__METHYL-CpG-BINDING DOMAIN PROTEIN 1; MBD1__:__PROTEIN CONTAINING METHYL-CpG-BINDING DOMAIN 1; PCM1;; CXXC FINGER PROTEIN 3; CXXC3__:__METHYL-CpG-BINDING PROTEIN 1 COMPLEX, INCLUDED;; MECP1 COMPLEX, INCLUDED
Caret__:__156536__:__MOVED TO 600113__:____:__
Asterisk__:__156540__:__METHYLTHIOADENOSINE PHOSPHORYLASE; MTAP__:__MeSAdo PHOSPHORYLASE; MSAP__:__
Number Sign__:__156550__:__KNIEST DYSPLASIA__:____:__
Asterisk__:__156560__:__METHIONYL-tRNA SYNTHETASE; MARS__:__MTRNS;; METRS;; METHIONINE tRNA LIGASE__:__
Asterisk__:__156565__:__N-METHYLPURINE DNA GLYCOSYLASE; MPG__:__METHYLADENINE DNA GLYCOSYLASE; MDG;; 3-METHYLADENINE DNA GLYCOSYLASE;; 3MeAde DNA GLYCOSYLASE;; 3-ALKYLADENINE DNA GLYCOSYLASE; AAG;; ALKYLPURINE DNA N-GLYCOSYLASE; APNG__:__
Asterisk__:__156569__:__METHYLGUANINE-DNA METHYLTRANSFERASE; MGMT__:____:__
Asterisk__:__156570__:__5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; MTR__:__TETRAHYDROPTEROYLGLUTAMATE METHYLTRANSFERASE;; METHIONINE SYNTHASE; MS__:__
Caret__:__156575__:__MOVED TO 600682__:____:__
Percent__:__156580__:__MICROCEPHALY, AUTOSOMAL DOMINANT__:____:__
Caret__:__156590__:__MOVED TO 152950__:____:__
Number Sign__:__156600__:__MICROCORIA, CONGENITAL__:__CHROMOSOME 13q32 DELETION SYNDROME;; MCOR;; MIOSIS, CONGENITAL__:__
Number Sign__:__156610__:__SKIN CREASES, CONGENITAL SYMMETRIC CIRCUMFERENTIAL, 1; CSCSC1__:__SKIN CREASES, MULTIPLE BENIGN RING-SHAPED, OF LIMBS;; CIRCUMFERENTIAL SKIN CREASES, KUNZE TYPE;; MICHELIN TIRE BABY SYNDROME__:__
NULL__:__156620__:__MICROCEPHALY-DEAFNESS SYNDROME__:____:__
NULL__:__156700__:__MICROCORNEA, GLAUCOMA, AND ABSENT FRONTAL SINUSES__:____:__
Asterisk__:__156790__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 2; MFAP2__:__MICROFIBRIL-ASSOCIATED GLYCOPROTEIN; MAGP;; MAGP1__:__
NULL__:__156810__:__MICROGASTRIA-LIMB REDUCTION DEFECTS ASSOCIATION; MLRD__:____:__
NULL__:__156830__:__MICROMELIC BONE DYSPLASIA WITH CLOVERLEAF SKULL__:____:__
Asterisk__:__156845__:__MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITF__:__MICROPHTHALMIA, MOUSE, HOMOLOG OF; MI__:__
Percent__:__156850__:__MICROPHTHALMIA, ISOLATED, WITH CATARACT 1; MCOPCT1__:__CATARACT, CONGENITAL, WITH MICROPHTHALMIA; CATM__:__
NULL__:__156900__:__MICROPHTHALMIA, ISOLATED, WITH CORECTOPIA; MCOPCR__:__MICROPHTHALMIA AND CORECTOPIA;; MICROPHTHALMIA WITH MYOPIA AND CORECTOPIA__:__
Caret__:__157100__:__MOVED TO 193220__:____:__
Asterisk__:__157129__:__MICROTUBULE-ASSOCIATED PROTEIN 1B; MAP1B__:__FUTSCH, DROSOPHILA, HOMOLOG OF; FUTSCH__:__
Asterisk__:__157130__:__MICROTUBULE-ASSOCIATED PROTEIN 2; MAP2__:__MAP, DENDRITE-SPECIFIC__:__
Asterisk__:__157132__:__MICROTUBULE-ASSOCIATED PROTEIN 4; MAP4__:____:__
Asterisk__:__157140__:__MICROTUBULE-ASSOCIATED PROTEIN TAU; MAPT__:__MTBT1__:__
Asterisk__:__157145__:__MICROSEMINOPROTEIN, BETA; MSMB__:__MSPB__:__
Asterisk__:__157147__:__MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MTTP__:__MTP;; MTP, LARGE SUBUNIT__:__
NULL__:__157150__:__MICROSPHEROPHAKIA WITH HERNIA__:____:__
NULL__:__157151__:__MICROSPHEROPHAKIA-METAPHYSEAL DYSPLASIA__:____:__
Caret__:__157160__:__MOVED TO 157140__:____:__
Number Sign__:__157170__:__HOLOPROSENCEPHALY 2; HPE2__:____:__
NULL__:__157200__:__MIDPHALANGEAL HAIR__:__MIDDIGITAL HAIR__:__
Percent__:__157300__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1__:__MGR1;; MGAU; MA;; MIGRAINE__:__
Percent__:__157400__:__MILIA, MULTIPLE ERUPTIVE; MEM__:____:__
Caret__:__157500__:__MOVED TO 173310__:____:__
Caret__:__157550__:__MOVED TO 117000__:____:__
Asterisk__:__157560__:__MINISATELLITE 33.6__:__MS336;; D1S111__:__
Asterisk__:__157570__:__MINISATELLITE 33.15__:__MS3315;; D7S437__:__
Number Sign__:__157600__:__MIRROR MOVEMENTS 1; MRMV1__:__MIRROR MOVEMENTS 1 AND/OR AGENESIS OF THE CORPUS CALLOSUM;; MIRROR MOVEMENTS, CONGENITAL;; BIMANUAL SYNERGIA__:__
Number Sign__:__157640__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1__:__
Caret__:__157650__:__MOVED TO 500002__:____:__
Asterisk__:__157655__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 1; NDUFS1__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 75-KD SUBUNIT__:__
Asterisk__:__157660__:__MITOCHONDRIAL RNA-PROCESSING ENDORIBONUCLEASE, RNA COMPONENT OF; RMRP__:__LONG NONCODING RNA RMRP;; lncRNA RMRP;; RMRPR__:__
Caret__:__157670__:__MOVED TO 600438__:____:__
Asterisk__:__157680__:__CELL DIVISION CYCLE 25C; CDC25C__:__MITOSIS INDUCER CDC25; CDC25__:__
Percent__:__157700__:__MITRAL VALVE PROLAPSE 1; MVP1__:__MITRAL VALVE PROLAPSE, MYXOMATOUS 1; MMVP1;; MYXOMATOUS MITRAL VALVE PROLAPSE 1;; MITRAL VALVE PROLAPSE, FAMILIAL; MVP PROLAPSED MITRAL VALVE; PMV;; MITRAL REGURGITATION, FAMILIAL;; FLOPPY MITRAL VALVE;; BARLOW SYNDROME;; MYXOMATOUS VALVULAR DISEASE, FAMILIAL;; CLICK-MURMUR SYNDROME__:__
Number Sign__:__157800__:__CARDIOSPONDYLOCARPOFACIAL SYNDROME; CSCF__:__MITRAL REGURGITATION, CONDUCTIVE DEAFNESS, AND FUSION OF CERVICAL VERTEBRAE AND OF CARPAL AND TARSAL BONES__:__
Caret__:__157860__:__MOVED TO 142860__:____:__
Percent__:__157900__:__MOEBIUS SYNDROME; MBS__:__MOBIUS SYNDROME; MBS;; MOEBIUS SEQUENCE__:__
Caret__:__157910__:__MOVED TO 157900__:____:__
Caret__:__157920__:__MOVED TO 309845__:____:__
Percent__:__157950__:__PERMANENT MOLARS, SECONDARY RETENTION OF__:__ANKYLOSIS OF TEETH;; DENTAL ANKYLOSIS;; MOLAR I REINCLUSION__:__
NULL__:__157960__:__MOLONEY LEUKEMIA VIRUS INTEGRATION SITE 2, MOUSE, HOMOLOG OF; MLVI2__:____:__
Asterisk__:__157970__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 7; PSMD7__:__MOLONEY LEUKEMIA VIRUS 34 PROVIRAL INTEGRATION SITE GENE, MOUSE, HOMOLOG OF; MOV34;; RPN8__:__
Caret__:__157975__:__MOVED TO 172411__:____:__
NULL__:__157980__:__MOMO SYNDROME__:__MACROSOMIA, OBESITY, MACROCEPHALY, AND OCULAR ABNORMALITIES__:__
Number Sign__:__158000__:__MONILETHRIX; MNLIX__:____:__
Caret__:__158020__:__MOVED TO 600182__:____:__
NULL__:__158030__:__ANTIGEN DEFINED BY MONOCLONAL ANTIBODY AJ9__:__MSK1__:__
NULL__:__158040__:__ANTIGEN DEFINED BY MONOCLONAL ANTIBODY T87__:__MSK2__:__
NULL__:__158050__:__MONKEY RED BLOOD CELL RECEPTOR; MRBC__:__B-CELL RECEPTOR FOR MONKEY RED BLOOD CELLS__:__
Asterisk__:__158070__:__SOLUTE CARRIER FAMILY 3 (ACTIVATOR OF DIBASIC AND NEUTRAL AMINO ACID TRANSPORT), MEMBER 2; SLC3A2__:__MDU1;; ANTIGEN DEFINED BY MONOCLONAL ANTIBODY 4F2, HEAVY CHAIN;; 4F2 HEAVY CHAIN; 4F2HC;; CD98 HEAVY CHAIN; CD98; CD98HC__:__MONOCLONAL ANTIBODY 44D7, INCLUDED
NULL__:__158100__:__MONOPHALANGY OF GREAT TOE__:____:__
Plus__:__158105__:__CHEMOKINE, CC MOTIF, LIGAND 2; CCL2__:__SMALL INDUCIBLE CYTOKINE A2; SCYA2;; MONOCYTE CHEMOTACTIC PROTEIN 1; MCP1;; MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR; MCAF__:__CORONARY ARTERY DISEASE, MODIFIER OF, INCLUDED;; CORONARY ARTERY DISEASE, DEVELOPMENT OF, IN HIV, INCLUDED
Asterisk__:__158106__:__CHEMOKINE, CC MOTIF, LIGAND 7; CCL7__:__SMALL INDUCIBLE CYTOKINE A7; SCYA7;; MONOCYTE CHEMOTACTIC PROTEIN 3; MCP3__:__
Asterisk__:__158120__:__MONOCYTE DIFFERENTIATION ANTIGEN CD14; CD14__:__MYELOID CELL-SPECIFIC LEUCINE-RICH GLYCOPROTEIN__:__
Caret__:__158130__:__MOVED TO 158105__:____:__
Caret__:__158150__:__MOVED TO 172250__:____:__
Number Sign__:__158170__:__CHROMOSOME 9p DELETION SYNDROME__:__MONOSOMY 9p SYNDROME__:__
NULL__:__158250__:__NONDISJUNCTION__:__MOSAICISM, CHROMOSOMAL;; MIXOPLOIDY, FAMILIAL__:__
Asterisk__:__158270__:__MOTILIN; MLN__:____:__
NULL__:__158280__:__MOTION SICKNESS__:____:__
Number Sign__:__158300__:__ARTHROGRYPOSIS, DISTAL, TYPE 7; DA7__:__TRISMUS-PSEUDOCAMPTODACTYLY SYNDROME;; MOUTH, INABILITY TO OPEN COMPLETELY, AND SHORT FINGER-FLEXOR TENDONS;; HECHT SYNDROME__:__
Percent__:__158310__:__MUCOEPITHELIAL DYSPLASIA, HEREDITARY__:__HMD__:__
Number Sign__:__158320__:__MUIR-TORRE SYNDROME; MRTES__:__CUTANEOUS SEBACEOUS NEOPLASMS AND KERATOACANTHOMAS, MULTIPLE, WITH GASTROINTESTINAL AND OTHER CARCINOMAS__:__
Number Sign__:__158330__:__MULLERIAN APLASIA AND HYPERANDROGENISM__:__MULLERIAN DUCT FAILURE AND HYPERANDROGENISM__:__
Asterisk__:__158340__:__MUCIN 1, TRANSMEMBRANE; MUC1__:__MUCIN 1, URINARY;; PEANUT-REACTIVE URINARY MUCIN; PUM;; MUCIN, TUMOR-ASSOCIATED EPITHELIAL;; POLYMORPHIC EPITHELIAL MUCIN; PEM;; EPITHELIAL MEMBRANE ANTIGEN; EMA__:__
Asterisk__:__158343__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 1; ABCC1__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MRP1;; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN; MRP__:__
NULL__:__158345__:__MULTIPLE EXOSTOSES WITH SPASTIC TETRAPARESIS__:____:__
Number Sign__:__158350__:__COWDEN SYNDROME 1; CWS1__:__CS; CD;; MULTIPLE HAMARTOMA SYNDROME; MHAM;; PTEN HAMARTOMA TUMOR SYNDROME; PHTS;; PTEN HAMARTOMA TUMOR SYNDROME WITH GRANULAR CELL TUMOR;; BANNAYAN-RILEY-RUVALCABA SYNDROME; BBRS;; BANNAYAN-ZONANA SYNDROME; BZS;; RILEY-SMITH SYNDROME;; RUVALCABA-MYHRE-SMITH SYNDROME; RMSS;; MACROCEPHALY, PSEUDOPAPILLEDEMA, AND MULTIPLE HEMANGIOMATA;; MACROCEPHALY, MULTIPLE LIPOMAS, AND HEMANGIOMATA__:__LHERMITTE-DUCLOS DISEASE, INCLUDED; LDD, INCLUDED;; DYSPLASTIC GANGLIOCYTOMA OF THE CEREBELLUM, INCLUDED;; CEREBELLOPARENCHYMAL DISORDER VI, INCLUDED; CPD6, INCLUDED;; CEREBELLAR GRANULE CELL HYPERTROPHY AND MEGALENCEPHALY, INCLUDED;; PROTEUS-LIKE SYNDROME, INCLUDED
Asterisk__:__158370__:__MUCIN 2, INTESTINAL; MUC2__:____:__
Asterisk__:__158371__:__MUCIN 3A, INTESTINAL; MUC3A__:__MUCIN 3, INTESTINAL; MUC3__:__
Asterisk__:__158372__:__MUCIN 4, TRACHEOBRONCHIAL; MUC4__:____:__
Asterisk__:__158373__:__MUCIN 5, SUBTYPES A AND C, TRACHEOBRONCHIAL; MUC5AC__:__MUC5;; MUCIN 5, TRACHEOBRONCHIAL/GASTRIC__:__
Asterisk__:__158374__:__MUCIN 6, GASTRIC; MUC6__:____:__
Asterisk__:__158375__:__MUCIN 7, SALIVARY; MUC7__:__MUCIN, SALIVARY, LOW MOLECULAR WEIGHT__:__
Asterisk__:__158378__:__SOLUTE CARRIER FAMILY 20 (PHOSPHATE TRANSPORTER), MEMBER 2; SLC20A2__:__PHOSPHATE TRANSPORTER, SODIUM-DEPENDENT, 2; PIT2;; GIBBON APE LEUKEMIA RETROVIRUS RECEPTOR 2; GLVR2;; MURINE LEUKEMIA VIRUS, AMPHOTROPIC, RECEPTOR FOR; MLVAR;; RECEPTOR FOR AMPHOTROPIC MURINE RETROVIRUS; RAM1__:__
Asterisk__:__158380__:__ECOTROPIC VIRAL INTEGRATION SITE 2A; EVI2A__:__MURINE MYELOID LEUKEMIA-ASSOCIATED GENE EVI2A, MOUSE, HOMOLOG OF;; MURINE MYELOID LEUKEMIA-ASSOCIATED GENE EVI2, MOUSE, HOMOLOG OF; EVI2;; EVDA__:__
Asterisk__:__158381__:__ECOTROPIC VIRAL INTEGRATION SITE 2B; EVI2B__:__MURINE MYELOID LEUKEMIA-ASSOCIATED GENE EVI2B, MOUSE, HOMOLOG OF;; EVDB__:__
Percent__:__158400__:__MUSCLE CRAMPS, FAMILIAL__:____:__
Percent__:__158500__:__MUSCULAR ATROPHY, ATAXIA, RETINITIS PIGMENTOSA, AND DIABETES MELLITUS__:____:__
Number Sign__:__158580__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA; HMN7A__:__HMN VIIA;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIA;; DHMN7A;; DHMNVP;; SPINAL MUSCULAR ATROPHY, DISTAL, WITH VOCAL CORD PARALYSIS;; HARPER-YOUNG MYOPATHY__:__
Number Sign__:__158590__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; HMN2A__:__HMN IIA;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIA; DHMN2A;; SPINAL MUSCULAR ATROPHY, DISTAL, ADULT, AUTOSOMAL DOMINANT, IIA;; CHARCOT-MARIE-TOOTH DISEASE, SPINAL, IIA__:__
Number Sign__:__158600__:__SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMAL DOMINANT; SMALED1__:__SMA-LED;; SPINAL MUSCULAR ATROPHY, CHILDHOOD, PROXIMAL, AUTOSOMAL DOMINANT;; SPINAL MUSCULAR ATROPHY, JUVENILE, PROXIMAL, AUTOSOMAL DOMINANT;; KUGELBERG-WELANDER SYNDROME, AUTOSOMAL DOMINANT__:__
NULL__:__158650__:__MUSCULAR ATROPHY, MALIGNANT NEUROGENIC__:____:__
Caret__:__158700__:__MOVED TO 105400__:____:__
NULL__:__158800__:__MUSCULAR DYSTROPHY, BARNES TYPE__:____:__
Number Sign__:__158810__:__BETHLEM MYOPATHY 1; BTHLM1__:__BETHLEM MYOPATHY;; MYOPATHY, BENIGN CONGENITAL, WITH CONTRACTURES;; MUSCULAR DYSTROPHY, BENIGN CONGENITAL;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 5; LGMDD5__:__
Number Sign__:__158900__:__FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1__:__MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1;; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FSHD; FMD;; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1A; FSHD1A;; LANDOUZY-DEJERINE MUSCULAR DYSTROPHY__:__FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY, INFANTILE, INCLUDED;; FACIOSCAPULOHUMERAL DYSTROPHY WITH SENSORINEURAL HEARING LOSS AND TORTUOSITY OF RETINAL ARTERIOLES, INCLUDED
Number Sign__:__158901__:__FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; FSHD2__:__FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2, DIGENIC;; FSHD2, DIGENIC;; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 2;; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL, TYPE 1B; FSHD1B__:__
Caret__:__159000__:__MOVED TO 609200__:____:__
Caret__:__159001__:__MOVED TO 181350__:____:__
Percent__:__159050__:__MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC, WITH INTERNALIZED CAPILLARIES__:____:__
NULL__:__159100__:__MUSCULAR HYPOPLASIA, CONGENITAL UNIVERSAL, OF KRABBE__:____:__
Percent__:__159300__:__MUSICAL PERFECT PITCH__:__ABSOLUTE PITCH; AP__:__
Asterisk__:__159350__:__MUTATED IN COLORECTAL CANCERS; MCC__:____:__
NULL__:__159400__:__MYASTHENIA, LIMB-GIRDLE, AUTOIMMUNE__:__MYASTHENIA GRAVIS, LIMB-GIRDLE__:__
Asterisk__:__159405__:__V-MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG-LIKE 1; MYBL1__:__MYB-RELATED GENE AMYB__:__
NULL__:__159410__:__MYDRIATIC RESPONSE TO PHARMACOLOGIC AGENTS__:____:__
NULL__:__159420__:__MYDRIASIS, CONGENITAL__:____:__
Asterisk__:__159430__:__MYELIN BASIC PROTEIN; MBP__:__MYELIN A1 PROTEIN, BASIC;; MYELIN MEMBRANE ENCEPHALITOGENIC PROTEIN__:__HEMOPOIETIC MBP, INCLUDED; HMBP, INCLUDED
Asterisk__:__159440__:__MYELIN PROTEIN ZERO; MPZ__:__MYELIN GLYCOPROTEIN P-ZERO; P0;; MYELIN PROTEIN, PERIPHERAL; MPP__:__
Caret__:__159455__:__MOVED TO 170715__:____:__
Asterisk__:__159460__:__MYELIN-ASSOCIATED GLYCOPROTEIN; MAG__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 4A; SIGLEC4A__:__
Asterisk__:__159465__:__MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MOG__:____:__
NULL__:__159500__:__MYELINATED OPTIC NERVE FIBERS__:____:__
Asterisk__:__159530__:__MYELOPROLIFERATIVE LEUKEMIA VIRUS ONCOGENE; MPL__:__THROMBOPOIETIN RECEPTOR; TPOR;; MYELOPROLIFERATIVE LEUKEMIA VIRUS, MOUSE, HOMOLOG OF; MPLV__:__
Asterisk__:__159540__:__LEUKEMIA-INHIBITORY FACTOR; LIF__:__CHOLINERGIC DIFFERENTIATION FACTOR;; D-FACTOR__:__
Number Sign__:__159550__:__ATAXIA-PANCYTOPENIA SYNDROME; ATXPC__:__MYELOCEREBELLAR DISORDER__:__
Asterisk__:__159552__:__MYELOID CELL LEUKEMIA SEQUENCE 1; MCL1__:____:__MYELOID CELL LEUKEMIA 1, LONG ISOFORM, INCLUDED; MCL1L, INCLUDED;; MYELOID CELL LEUKEMIA 1, SHORT ISOFORM, INCLUDED; MCL1S, INCLUDED
Asterisk__:__159553__:__MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN; MNDA__:____:__
Plus__:__159555__:__LYSINE-SPECIFIC METHYLTRANSFERASE 2A; KMT2A__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA GENE; MLL; MLL1;; TRITHORAX, DROSOPHILA, HOMOLOG OF; TRX1;; HRX;; MYELOID/LYMPHOID LEUKEMIA GENE;; MIXED LINEAGE LEUKEMIA GENE;; ALL1 GENE; ALL1;; CXXC FINGER PROTEIN 7; CXXC7__:__MIXED LINEAGE LEUKEMIA, INCLUDED;; MLL/AF4 FUSION GENE, INCLUDED;; MLL/ENL FUSION GENE, INCLUDED;; MLL/AF9 FUSION GENE, INCLUDED;; MLL/GMPS FUSION GENE, INCLUDED;; MLL/FBP17 FUSION GENE, INCLUDED;; MLL/LPP FUSION GENE, INCLUDED;; MLL/GPH FUSION GENE, INCLUDED;; MLL/PNUTL1 FUSION GENE, INCLUDED;; MLL/CDK6 FUSION GENE, INCLUDED;; MLL/LASP1 FUSION GENE, INCLUDED;; MLL/GRAF FUSION GENE, INCLUDED;; MLL/ABI1 FUSION GENE, INCLUDED;; MLL/LAF4 FUSION GENE, INCLUDED;; MLL/CBL FUSION GENE, INCLUDED;; MLL/LARG FUSION GENE, INCLUDED;; MLL/AF10 FUSION GENE, INCLUDED;; MLL/AF15q14 FUSION GENE, INCLUDED;; MLL/AF6 FUSION GENE, INCLUDED;; MLL/CIP29 FUSION GENE, INCLUDED;; MLL/SEPT6 FUSION GENE, INCLUDED;; MLL/MAML2 FUSION GENE, INCLUDED;; MLL/KIAA1524 FUSION GENE, INCLUDED
Asterisk__:__159556__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 1; MLLT1__:__MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 1;; ELEVEN-NINETEEN LEUKEMIA GENE; ENL__:__ENL/MLL FUSION GENE, INCLUDED
Asterisk__:__159557__:__AF4/FMR2 FAMILY, MEMBER 1; AFF1__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 2; MLLT2;; MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 2;; ALL1-FUSED GENE FROM CHROMOSOME 4; AF4__:__
Asterisk__:__159558__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 3; MLLT3__:__MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 3;; ALL1-FUSED GENE FROM CHROMOSOME 9; AF9__:__
Asterisk__:__159559__:__AFADIN; AFDN__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 4; MLLT4;; MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 4;; ALL1-FUSED GENE FROM CHROMOSOME 6; AF6;; CANOE, DROSOPHILA, HOMOLOG OF__:__AF6/MLL FUSION GENE, INCLUDED
NULL__:__159580__:__MYELOPATHY, HTLV-1-ASSOCIATED; HAM__:__FAMILIAL SPASTIC PARAPARESIS, HTLV-1-ASSOCIATED__:__
Asterisk__:__159590__:__CD33 ANTIGEN; CD33__:__MYELOID DIFFERENTIATION ANTIGEN CD33;; SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 3; SIGLEC3;; p67__:__
Percent__:__159595__:__MYELOPROLIFERATIVE SYNDROME, TRANSIENT__:__MST;; LEUKEMIA, TRANSIENT;; TRANSIENT ABNORMAL MYELOPOIESIS; TAM__:__
Percent__:__159600__:__MYOCLONIC EPILEPSY, HARTUNG TYPE__:____:__
NULL__:__159700__:__MYOCLONUS AND ATAXIA__:__RAMSAY HUNT SYNDROME__:__
NULL__:__159800__:__MYOCLONUS, CEREBELLAR ATAXIA, AND DEAFNESS__:____:__
Number Sign__:__159900__:__DYSTONIA 11, MYOCLONIC; DYT11__:__MYOCLONUS-DYSTONIA SYNDROME;; MYOCLONIC DYSTONIA;; DYSTONIA, ALCOHOL-RESPONSIVE;; MYOCLONUS, HEREDITARY ESSENTIAL__:__
Number Sign__:__159950__:__SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY; SMAPME__:__MYOCLONUS, HEREDITARY, WITH PROGRESSIVE DISTAL MUSCULAR ATROPHY__:__
Asterisk__:__159970__:__MYOGENIC DIFFERENTIATION ANTIGEN 1; MYOD1__:__MYOD;; MYOGENIC FACTOR 3; MYF3__:__
Asterisk__:__159980__:__MYOGENIN; MYOG__:__MYOGENIC FACTOR 4; MYF4__:__
Asterisk__:__159990__:__MYOGENIC FACTOR 5; MYF5__:____:__
Asterisk__:__159991__:__MYOGENIC FACTOR 6; MYF6__:__MUSCLE REGULATORY FACTOR 4; MRF4;; HERCULIN__:__
Asterisk__:__160000__:__MYOGLOBIN; MB__:____:__
Percent__:__160010__:__MYOGLOBINURIA, AUTOSOMAL DOMINANT__:____:__
Caret__:__160100__:__MOVED TO 160120__:____:__
Number Sign__:__160120__:__EPISODIC ATAXIA, TYPE 1; EA1__:__EPISODIC ATAXIA WITH MYOKYMIA; EAM;; ATAXIA, EPISODIC, WITH MYOKYMIA; AEM; AEMK;; PAROXYSMAL ATAXIA WITH NEUROMYOTONIA, HEREDITARY;; MYOKYMIA WITH PERIODIC ATAXIA__:__MYOKYMIA 1, INCLUDED;; CONTINUOUS MUSCLE FIBER ACTIVITY, HEREDITARY, INCLUDED;; ISAACS-MERTENS SYNDROME, INCLUDED;; MYOKYMIA 1 WITH OR WITHOUT HYPOMAGNESEMIA, INCLUDED
Number Sign__:__160150__:__MYOPATHY, CENTRONUCLEAR, 1; CNM1__:__MYOPATHY, CENTRONUCLEAR, AUTOSOMAL DOMINANT;; MYOTUBULAR MYOPATHY, AUTOSOMAL DOMINANT__:__
Caret__:__160200__:__MOVED TO 161800__:____:__
Percent__:__160300__:__MYOPATHY, DISTAL, INFANTILE-ONSET__:____:__
Number Sign__:__160500__:__MYOPATHY, DISTAL, 1; MPD1__:__MYOPATHY, LATE DISTAL HEREDITARY;; LAING DISTAL MYOPATHY;; MYOPATHY, DISTAL, EARLY-ONSET, AUTOSOMAL DOMINANT__:__
Caret__:__160550__:__MOVED TO 157640__:____:__
Number Sign__:__160565__:__MYOPATHY, TUBULAR AGGREGATE, 1; TAM1__:__MYOPATHY, TUBULAR AGGREGATE; TAM;; TUBULAR AGGREGATE MYOPATHY__:__
NULL__:__160570__:__MYOPATHY WITH STORAGE OF GLYCOPROTEINS AND GLYCOSAMINOGLYCANS__:____:__
Percent__:__160700__:__MYOPIA 2, AUTOSOMAL DOMINANT; MYP2__:____:__
Asterisk__:__160710__:__MYOSIN, HEAVY CHAIN 6, CARDIAC MUSCLE, ALPHA; MYH6__:__MYH, CARDIAC; MYHC;; MYOSIN, CARDIAC, HEAVY CHAIN, ALPHA; MYHCA__:__
Asterisk__:__160720__:__MYOSIN, HEAVY CHAIN 3, SKELETAL MUSCLE, EMBRYONIC; MYH3__:__MYOSIN, SKELETAL, HEAVY CHAIN, EMBRYONIC 1; MYHSE1;; MYHC-EMB__:__
Asterisk__:__160730__:__MYOSIN, HEAVY CHAIN 1, SKELETAL MUSCLE, ADULT; MYH1__:__MYOSIN, SKELETAL, HEAVY CHAIN, ADULT 1; MYHSA1;; MYOSIN, HEAVY CHAIN, IIx/d;; MYH2X/D;; MYHC2X/D;; MYHC IIx/d;; MHC IIx/d__:__
Asterisk__:__160740__:__MYOSIN, HEAVY CHAIN 2, SKELETAL MUSCLE, ADULT; MYH2__:__MYOSIN, SKELETAL, HEAVY CHAIN, ADULT 2; MYHSA2;; MYOSIN, HEAVY CHAIN, IIa; MYHC2A; MYH2A;; MYHC IIa;; MHC IIa__:__
Asterisk__:__160741__:__MYOSIN, HEAVY CHAIN 8, SKELETAL MUSCLE, PERINATAL; MYH8__:__MYOSIN, HEAVY CHAIN, PERINATAL;; MYHC-PERI;; MYHC-PN__:__
Asterisk__:__160742__:__MYOSIN, HEAVY CHAIN 4, SKELETAL MUSCLE; MYH4__:__MYOSIN, SKELETAL MUSCLE, HEAVY CHAIN;; MYOSIN, HEAVY CHAIN, IIb; MYHC2B; MYH2B;; MYHC IIb;; MHC IIb__:__
Asterisk__:__160745__:__MYOSIN, HEAVY CHAIN 11, SMOOTH MUSCLE; MYH11__:__MYOSIN, SMOOTH MUSCLE, HEAVY CHAIN 11; SMHC;; SMOOTH MUSCLE MYOSIN HEAVY CHAIN; SMMHC__:__MYH11/CBFB FUSION GENE, INCLUDED
Percent__:__160750__:__MYOSITIS__:__MYOPATHY, FAMILIAL IDIOPATHIC INFLAMMATORY; IIM__:__
Asterisk__:__160760__:__MYOSIN, HEAVY CHAIN 7, CARDIAC MUSCLE, BETA; MYH7__:__MYOSIN, CARDIAC, HEAVY CHAIN, BETA; MYHCB__:__
Asterisk__:__160770__:__MYOSIN, LIGHT CHAIN 4, ALKALI, ATRIAL, EMBRYONIC; MYL4__:__EMBRYONIC/ATRIAL MYOSIN ALKALI LIGHT CHAIN;; MYOSIN, ATRIAL/FETAL MUSCLE, LIGHT CHAIN__:__
Asterisk__:__160775__:__MYOSIN, HEAVY CHAIN 9, NONMUSCLE; MYH9__:__CELLULAR MYOSIN HEAVY CHAIN, TYPE A;; MYOSIN, HEAVY CHAIN, NONMUSCLE, TYPE A; NMMHCA;; NONMUSCLE MYOSIN IIA;; NMHC IIA__:__
Asterisk__:__160776__:__MYOSIN, HEAVY CHAIN 10, NONMUSCLE; MYH10__:__CELLULAR MYOSIN HEAVY CHAIN, TYPE B;; MYOSIN, HEAVY CHAIN, NONMUSCLE, TYPE B; NMMHCB;; NONMUSCLE MYOSIN IIB;; NMHC IIB__:__
Asterisk__:__160777__:__MYOSIN VA; MYO5A__:__MYO5;; MYOSIN, HEAVY CHAIN 12; MYH12;; MYOXIN;; DILUTE, MOUSE, HOMOLOG OF__:__
Asterisk__:__160780__:__MYOSIN, LIGHT POLYPEPTIDE 1, ALKALI, SKELETAL, FAST; MYL1__:__MYOSIN, LIGHT CHAIN, FAST SKELETAL__:__
Asterisk__:__160781__:__MYOSIN, LIGHT CHAIN 2, REGULATORY, CARDIAC, SLOW; MYL2__:__MLC2;; REGULATORY LIGHT CHAIN OF MYOSIN;; RLC OF MYOSIN;; MYOSIN, LIGHT CHAIN, REGULATORY VENTRICULAR__:__
Asterisk__:__160782__:__MYOSIN, LIGHT CHAIN 5, REGULATORY; MYL5__:____:__
Asterisk__:__160790__:__MYOSIN, LIGHT CHAIN 3, ALKALI, VENTRICULAR, SKELETAL, SLOW; MYL3__:__ESSENTIAL LIGHT CHAIN OF MYOSIN;; ELC OF MYOSIN;; MYOSIN, LIGHT CHAIN 1, SLOW, B; MLC1SB;; MYOSIN, LIGHT CHAIN 1, VENTRICULAR; MLC1V__:__
Asterisk__:__160793__:__MYOSIN-BINDING PROTEIN C, FAST TYPE; MYBPC2__:__MYBPCF__:__
Asterisk__:__160794__:__MYOSIN-BINDING PROTEIN C, SLOW TYPE; MYBPC1__:__MYBPCS__:__
Asterisk__:__160795__:__MYOSIN-BINDING PROTEIN H; MYBPH__:__MYOSIN-BINDING PROTEIN, 86-KD__:__
Number Sign__:__160800__:__MYOTONIA CONGENITA, AUTOSOMAL DOMINANT__:__THOMSEN DISEASE; THD__:__MYOTONIA LEVIOR, INCLUDED
Number Sign__:__160900__:__MYOTONIC DYSTROPHY 1; DM1__:__DYSTROPHIA MYOTONICA 1;; DYSTROPHIA MYOTONICA; DM;; STEINERT DISEASE__:__
Number Sign__:__160980__:__CARNEY COMPLEX, TYPE 1; CNC1__:__CARNEY MYXOMA-ENDOCRINE COMPLEX;; CARNEY SYNDROME; CAR;; MYXOMA, SPOTTY PIGMENTATION, AND ENDOCRINE OVERACTIVITY;; NAME SYNDROME;; LAMB SYNDROME__:__
NULL__:__160990__:__MYOTONIC MYOPATHY WITH CYLINDRICAL SPIRALS__:____:__
Asterisk__:__160993__:__N-MYRISTOYLTRANSFERASE 1; NMT1__:__MYRISTOYL-CoA:PROTEIN N-MYRISTOYLTRANSFERASE; NMT__:__
Asterisk__:__160994__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN M; HNRNPM__:__HNRPM;; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN M4; HNRNPM4; HNRPM4;; N-ACETYLGLUCOSAMINE RECEPTOR 1, FORMERLY; NAGR1, FORMERLY__:__
Asterisk__:__160995__:__ALPHA-1,3-MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT1__:__GlcNAc-T I;; N-ACETYLGLUCOSAMINYLTRANSFERASE I;; MGAT;; UDP-N-ACETYLGLUCOSAMINE:ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE I; GLCT1__:__
Asterisk__:__160998__:__NAD(P)H DEHYDROGENASE, QUINONE 2; NQO2__:__NAD(P)H:MENADIONE OXIDOREDUCTASE 1, DIOXIN-INDUCIBLE 2; NMOR2__:__
Number Sign__:__161000__:__NAEGELI-FRANCESCHETTI-JADASSOHN SYNDROME; NFJS__:__NAEGELI SYNDROME;; NFJ SYNDROME__:__
Asterisk__:__161015__:__NADH-UBIQUINONE OXIDOREDUCTASE FLAVOPROTEIN 1; NDUFV1__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 51-KD SUBUNIT;; UQOR1__:__
Percent__:__161050__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 1; NDNC1__:__TWENTY-NAIL DYSTROPHY;; ONYCHODYSTROPHY TOTALIS, ISOLATED__:__NAIL GROWTH, INCLUDED
NULL__:__161070__:__NAIL HIGH-SULFUR PROTEIN__:____:__
NULL__:__161080__:__NAIL LOW-SULFUR PROTEIN__:____:__
NULL__:__161100__:__NAILBEDS, PIGMENTATION OF__:____:__
Number Sign__:__161200__:__NAIL-PATELLA SYNDROME; NPS__:__NPS1;; ONYCHOOSTEODYSPLASIA;; TURNER-KIESER SYNDROME;; FONG DISEASE__:__
Number Sign__:__161400__:__NARCOLEPSY 1; NRCLP1__:__NARCOLEPTIC SYNDROME 1__:__CATAPLEXY, INCLUDED
NULL__:__161470__:__NASAL ALAR COLLAPSE, BILATERAL__:____:__
NULL__:__161480__:__NASAL BONES, ABSENCE OF__:____:__
Percent__:__161500__:__NASAL GROOVE, FAMILIAL TRANSVERSE__:____:__
NULL__:__161530__:__NASAL HYPERPIGMENTATION, FAMILIAL TRANSVERSE__:____:__
Percent__:__161550__:__NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 2; NPCA2__:____:__
Asterisk__:__161555__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY C, MEMBER 1; KLRC1__:__NATURAL KILLER CELL LECTIN; NKG2__:__NKG2A, INCLUDED;; NKG2B, INCLUDED
Asterisk__:__161560__:__INTERLEUKIN 12A; IL12A__:__IL12, p35 SUBUNIT;; CYTOTOXIC LYMPHOCYTE MATURATION FACTOR; CLMF;; NATURAL KILLER CELL STIMULATORY FACTOR, 35-KD SUBUNIT; NKSF1;; IL35, p35 SUBUNIT__:__
Asterisk__:__161561__:__INTERLEUKIN 12B; IL12B__:__IL12, SUBUNIT p40;; INTERLEUKIN 23, p40 SUBUNIT;; CYTOTOXIC LYMPHOCYTE MATURATION FACTOR 2; CLMF2;; NATURAL KILLER CELL STIMULATORY FACTOR, 40-KD SUBUNIT; NKSF2__:__
Asterisk__:__161565__:__NATURAL KILLER CELL TRIGGERING RECEPTOR; NKTR__:__NATURAL KILLER TUMOR RECOGNITION SEQUENCE__:__
NULL__:__161600__:__NAVICULAR BONE, ACCESSORY__:____:__
Asterisk__:__161650__:__NEBULIN; NEB__:____:__
NULL__:__161700__:__NECROTIZING ENCEPHALOMYELOPATHY, SUBACUTE, OF LEIGH, ADULT__:__LEIGH SYNDROME, ADULT__:__
Number Sign__:__161800__:__NEMALINE MYOPATHY 3; NEM3__:____:__MYOPATHY, ACTIN, CONGENITAL, WITH EXCESS OF THIN MYOFILAMENTS, INCLUDED;; NEMALINE MYOPATHY 3, WITH INTRANUCLEAR RODS, INCLUDED;; MYOPATHY, ACTIN, CONGENITAL, WITH CORES, INCLUDED
Percent__:__161900__:__RENAL FAILURE, PROGRESSIVE, WITH HYPERTENSION; RFH1__:__NEPHROPATHY, FAMILIAL;; NEPHRITIS, FAMILIAL, WITHOUT DEAFNESS OR OCULAR DEFECT;; RENAL FAILURE, ADULT-ONSET; AORF__:__
Percent__:__161950__:__IgA NEPHROPATHY, SUSCEPTIBILITY TO, 1; IGAN1__:__IGAN;; NEPHRITIS, IgA TYPE;; BERGER DISEASE__:__
Number Sign__:__162000__:__HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1__:__HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE__:__
Asterisk__:__162010__:__NERVE GROWTH FACTOR RECEPTOR; NGFR__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 16; TNFRSF16;; p75(NTR);; CD271__:__
NULL__:__162020__:__NERVE GROWTH FACTOR, ALPHA SUBUNIT; NGFA__:____:__
Asterisk__:__162030__:__NERVE GROWTH FACTOR; NGF__:__NERVE GROWTH FACTOR, BETA SUBUNIT; NGFB__:__
Caret__:__162040__:__MOVED TO 147960__:____:__
Asterisk__:__162060__:__GROWTH-ASSOCIATED PROTEIN 43; GAP43__:__NEUROMODULIN;; NERVE GROWTH-RELATED PEPTIDE GAP43__:__
Asterisk__:__162080__:__NEURAL RETINA LEUCINE ZIPPER; NRL__:__NEURAL RETINA-SPECIFIC GENE;; D14S46E__:__
Number Sign__:__162091__:__SCHWANNOMATOSIS 1; SWNTS1__:__NEURILEMMOMATOSIS, CONGENITAL CUTANEOUS__:__
Asterisk__:__162095__:__PLEIOTROPHIN; PTN__:__NEURITE OUTGROWTH-PROMOTING FACTOR, HEPARIN-BINDING;; NEURITE GROWTH-PROMOTING FACTOR 1; NEGF1;; HEPARIN-BINDING GROWTH FACTOR 8; HBGF8__:__
Asterisk__:__162096__:__MIDKINE; MDK__:__MIDGESTATION AND KIDNEY PROTEIN; MK;; NEURITE GROWTH-PROMOTING FACTOR 2, FORMERLY; NEGF2, FORMERLY__:__
Number Sign__:__162100__:__AMYOTROPHY, HEREDITARY NEURALGIC; HNA__:__NEURITIS WITH BRACHIAL PREDILECTION; NAPB;; BRACHIAL PLEXUS NEUROPATHY, HEREDITARY;; AMYOTROPHY, HEREDITARY NEURALGIC, WITH PREDILECTION FOR BRACHIAL PLEXUS__:__
Asterisk__:__162150__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 1; PCSK1__:__NEUROENDOCRINE CONVERTASE 1; NEC1;; PROPROTEIN CONVERTASE 1; PC1;; PROHORMONE CONVERTASE 1;; PROHORMONE CONVERTASE 3; PC3__:__
Asterisk__:__162151__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 2; PCSK2__:__PROPROTEIN CONVERTASE PC2; PC2;; NEUROENDOCRINE CONVERTASE 2; NEC2__:__
Number Sign__:__162200__:__NEUROFIBROMATOSIS, TYPE I; NF1__:__NEUROFIBROMATOSIS, PERIPHERAL TYPE;; VON RECKLINGHAUSEN DISEASE__:__
Number Sign__:__162210__:__NEUROFIBROMATOSIS, FAMILIAL SPINAL__:__FSNF__:__
Caret__:__162220__:__MOVED TO 162200 AND 606764__:____:__
Asterisk__:__162230__:__NEUROFILAMENT PROTEIN, HEAVY POLYPEPTIDE; NEFH__:__NFH__:__
NULL__:__162240__:__NEUROFIBROMATOSIS-PHEOCHROMOCYTOMA-DUODENAL CARCINOID SYNDROME__:__NPDC SYNDROME;; DUODENAL CARCINOID SYNDROME__:__
Asterisk__:__162250__:__NEUROFILAMENT PROTEIN, MEDIUM POLYPEPTIDE; NEFM__:__NEUROFILAMENT 3; NEF3;; NFM__:__
NULL__:__162260__:__NEUROFIBROMATOSIS, TYPE III, MIXED CENTRAL AND PERIPHERAL; NF3A__:__NEUROFIBROMATOSIS, TYPE III, OF RICCARDI;; NF III; NF3;; NEUROFIBROMATOSIS, TYPE III, RICCARDI TYPE__:__NEUROFIBROMAS, PALMAR CUTANEOUS, INCLUDED
NULL__:__162270__:__NEUROFIBROMATOSIS, TYPE IV, OF RICCARDI; NF4__:__NEUROFIBROMATOSIS, VARIANT FORM(S) OF;; NF IV;; NEUROFIBROMATOSIS, ATYPICAL__:__
Asterisk__:__162280__:__NEUROFILAMENT PROTEIN, LIGHT POLYPEPTIDE; NEFL__:__NEUROFILAMENT PROTEIN, LIGHT CHAIN; NFL;; NF68__:__
Number Sign__:__162300__:__MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B__:__MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY__:__MUCOSAL NEUROMA SYNDROME, INCLUDED
Asterisk__:__162320__:__TACHYKININ 1; TAC1__:__TACHYKININ 2, FORMERLY; TAC2, FORMERLY__:__NEUROKININ A, INCLUDED; NKNA, INCLUDED;; NEUROKININ 2, INCLUDED; NK2, INCLUDED;; SUBSTANCE P, INCLUDED;; NEUROMEDIN L, INCLUDED;; NEUROPEPTIDE K, INCLUDED;; SUBSTANCE K, FORMERLY, INCLUDED
Asterisk__:__162321__:__TACHYKININ RECEPTOR 2; TACR2__:__NEUROKININ A RECEPTOR; NKNAR;; NEUROKININ 2 RECEPTOR; NK2R;; SUBSTANCE K RECEPTOR__:__
Asterisk__:__162323__:__TACHYKININ RECEPTOR 1; TACR1__:__NEUROKININ 1 RECEPTOR; NK1R;; SUBSTANCE P RECEPTOR__:__
Asterisk__:__162330__:__TACHYKININ 3; TAC3__:__NEUROKININ B; NKB;; NEUROMEDIN K;; NKNB;; TACHYKININ 2, MOUSE, HOMOLOG OF; TAC2__:__
Asterisk__:__162332__:__TACHYKININ RECEPTOR 3; TACR3__:__NEUROKININ 3 RECEPTOR; NK3R;; NEUROKININ B RECEPTOR__:__
Asterisk__:__162340__:__NEUROMEDIN B; NMB__:____:__
Asterisk__:__162341__:__NEUROMEDIN B RECEPTOR; NMBR__:____:__
Number Sign__:__162350__:__CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B__:__KUFS DISEASE, AUTOSOMAL DOMINANT;; CEROID LIPOFUSCINOSIS, NEURONAL, PARRY TYPE__:__
Asterisk__:__162360__:__NESCIENT HELIX LOOP HELIX 1; NHLH1__:__NSCL;; HEN1__:__
Asterisk__:__162361__:__NESCIENT HELIX LOOP HELIX 2; NHLH2__:__NEURONAL SCL-LIKE PROTEIN 2; NSCL2;; HEN2__:__
Percent__:__162370__:__NEUROPATHY, CONGENITAL, WITH ARTHROGRYPOSIS MULTIPLEX__:____:__
Caret__:__162375__:__MOVED TO 118200__:____:__
NULL__:__162380__:__NEUROPATHY, HEREDITARY SENSORIMOTOR, WITH UPPER MOTOR NEURON, VISUAL PATHWAY AND AUTONOMIC DISTURBANCE__:____:__
Number Sign__:__162400__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IA; HSAN1A__:__HSAN IA;; HSAN1;; NEUROPATHY, HEREDITARY SENSORY, TYPE IA; HSN1A;; HSN IA;; NEUROPATHY, HEREDITARY SENSORY RADICULAR, AUTOSOMAL DOMINANT, TYPE 1A__:__
Number Sign__:__162500__:__NEUROPATHY, HEREDITARY, WITH LIABILITY TO PRESSURE PALSIES; HNPP__:__POLYNEUROPATHY, FAMILIAL RECURRENT;; TOMACULOUS NEUROPATHY__:__
NULL__:__162600__:__NEUROPATHY, WITH PARAPROTEIN IN SERUM, CEREBROSPINAL FLUID AND URINE__:____:__
Asterisk__:__162640__:__NEUROPEPTIDE Y; NPY__:__Y NEUROPEPTIDE__:__
Asterisk__:__162641__:__NEUROPEPTIDE Y RECEPTOR Y1; NPY1R__:__NPYR__:__
Asterisk__:__162642__:__NEUROPEPTIDE Y RECEPTOR Y2; NPY2R__:____:__
Asterisk__:__162643__:__CHEMOKINE, CXC MOTIF, RECEPTOR 4; CXCR4__:__NEUROPEPTIDE Y RECEPTOR Y3; NPY3R;; FUSIN;; D2S201E;; LEUKOCYTE-DERIVED SEVEN-TRANSMEMBRANE-DOMAIN RECEPTOR; LESTR;; SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR, SPLEEN;; HM89;; LIPOPOLYSACCHARIDE-ASSOCIATED PROTEIN 3; LAP3;; LPS-ASSOCIATED PROTEIN 3__:__
Asterisk__:__162650__:__NEUROTENSIN; NTS__:____:__
Asterisk__:__162651__:__NEUROTENSIN RECEPTOR 1; NTSR1__:____:__
Asterisk__:__162660__:__NEUROTROPHIN 3; NTF3__:__NEUROTROPHIC FACTOR 3; NT3__:__
Caret__:__162661__:__MOVED TO 162662__:____:__
Asterisk__:__162662__:__NEUROTROPHIN 4; NTF4__:__NEUROTROPHIN 5; NTF5;; NEUROTROPHIN 4/5;; NEUROTROPHIC FACTOR 5; NT5;; NEUROTROPHIC FACTOR 4; NT4__:__
Percent__:__162700__:__NEUTROPENIA, CHRONIC FAMILIAL__:__LEUKOPENIA, BENIGN FAMILIAL__:__
Number Sign__:__162800__:__CYCLIC NEUTROPENIA__:__CYCLIC HEMATOPOIESIS__:__
Asterisk__:__162815__:__NEUTROPHIL AZUROCIDIN; NAZC__:__AZUROCIDIN; AZU1;; CATIONIC ANTIMICROBIAL PROTEIN-37; CAP37__:__
Percent__:__162820__:__NEUTROPHIL MIGRATION; NM__:__NEUTROPHIL CHEMOTACTIC RESPONSE; NCR__:__
Number Sign__:__162830__:__NEUTROPHILIA, HEREDITARY__:____:__
Asterisk__:__162860__:__CD177 ANTIGEN; CD177__:__NEUTROPHIL-SPECIFIC ANTIGEN 1; NB1;; PRV1;; HNA2A__:__
Caret__:__162870__:__MOVED TO 146740__:____:__
NULL__:__162880__:__NEUTROPHIL-SPECIFIC ANTIGEN: ND1__:____:__
Asterisk__:__162890__:__NEUTROPHIL-SPECIFIC ANTIGEN: NE1__:____:__
Number Sign__:__162900__:__NEVUS, EPIDERMAL__:__NEVUS, KERATINOCYTIC, NONEPIDERMOLYTIC__:__NEVUS SEBACEOUS, INCLUDED;; NEVUS, WOOLLY HAIR, INCLUDED
Number Sign__:__163000__:__CAPILLARY MALFORMATIONS, CONGENITAL; CMC__:__NEVI FLAMMEI, FAMILIAL MULTIPLE;; PORT-WINE STAIN;; CAPILLARY MALFORMATIONS; CMAL__:__
NULL__:__163050__:__NEVUS ANEMICUS__:____:__
Percent__:__163100__:__NEVUS FLAMMEUS OF NAPE OF NECK__:__UNNA NEVUS;; ERYTHEMA NUCHAE__:__
Number Sign__:__163200__:__SCHIMMELPENNING-FEUERSTEIN-MIMS SYNDROME; SFM__:__SFM SYNDROME;; LINEAR SEBACEOUS NEVUS SYNDROME;; SEBACEOUS NEVUS SYNDROME, LINEAR;; JADASSOHN NEVUS PHAKOMATOSIS; JNP;; NEVUS SEBACEUS OF JADASSOHN;; ORGANOID NEVUS PHAKOMATOSIS;; EPIDERMAL NEVUS SYNDROME, FORMERLY__:__
Asterisk__:__163260__:__NUCLEAR FACTOR ERYTHROID 2-LIKE 1; NFE2L1__:__NFE2-RELATED TRANSCRIPTION FACTOR;; NFE2-RELATED FACTOR 1; NRF1;; TRANSCRIPTION FACTOR 11; TCF11__:__
Percent__:__163400__:__NIEVERGELT SYNDROME__:__MESOMELIC DYSPLASIA, NIEVERGELT TYPE__:__
Number Sign__:__163500__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 2; CSNBAD2__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, RAMBUSCH TYPE__:__
NULL__:__163600__:__NIPPLES INVERTED__:__MAMMILLAE INVERTITAE__:__
Percent__:__163700__:__NIPPLES, SUPERNUMERARY__:__ACCESSORY NIPPLES;; POLYMASTIA;; POLYTHELIA, FAMILIAL__:__
Caret__:__163728__:__MOVED TO 163730__:____:__
Plus__:__163729__:__NITRIC OXIDE SYNTHASE 3; NOS3__:__NITRIC OXIDE SYNTHASE, ENDOTHELIAL; ENOS__:__CORONARY ARTERY SPASM 1, SUSCEPTIBILITY TO, INCLUDED;; ALZHEIMER DISEASE, LATE-ONSET, SUSCEPTIBILITY TO, INCLUDED;; HYPERTENSION, PREGNANCY-INDUCED, SUSCEPTIBILITY TO, INCLUDED;; HYPERTENSION RESISTANT TO CONVENTIONAL THERAPY, INCLUDED
Asterisk__:__163730__:__NITRIC OXIDE SYNTHASE 2A; NOS2A__:__NOS2;; NOS2A, INDUCIBLE, HEPATOCYTE;; NITRIC OXIDE SYNTHASE, INDUCIBLE; INOS;; NITRIC OXIDE SYNTHASE, MACROPHAGE__:__
Asterisk__:__163731__:__NITRIC OXIDE SYNTHASE 1; NOS1__:____:__NITRIC OXIDE SYNTHASE, NEURONAL, INCLUDED;; NITRIC OXIDE SYNTHASE, PENILE NEURONAL, INCLUDED; PNNOS, INCLUDED
Number Sign__:__163800__:__SICK SINUS SYNDROME 2; SSS2__:__SICK SINUS SYNDROME 2 WITH OR WITHOUT CARDIAC NONCOMPACTION AND/OR ASCENDING AORTA DILATION;; ATRIAL FIBRILLATION WITH BRADYARRHYTHMIA;; SINUS NODE DISEASE, FAMILIAL, AUTOSOMAL DOMINANT;; SINUS BRADYCARDIA SYNDROME, FAMILIAL, AUTOSOMAL DOMINANT__:__
NULL__:__163850__:__NODULI CUTANEI, MULTIPLE, WITH URINARY TRACT ABNORMALITIES__:____:__
Asterisk__:__163890__:__SYNUCLEIN, ALPHA; SNCA__:__NON-A-BETA COMPONENT OF ALZHEIMER DISEASE AMYLOID, PRECURSOR OF; NACP;; NON-A4 COMPONENT OF AMYLOID, PRECURSOR OF__:__
Caret__:__163900__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__163905__:__HIGH MOBILITY GROUP BOX 1; HMGB1__:__HIGH MOBILITY GROUP PROTEIN 1; HMG1;; CHROMOSOMAL PROTEIN, NONHISTONE, HMG1;; NONHISTONE CHROMOSOMAL PROTEIN HMG1;; AMPHOTERIN__:__
Asterisk__:__163906__:__HIGH MOBILITY GROUP BOX 2; HMGB2__:__HIGH MOBILITY GROUP PROTEIN 2; HMG2;; CHROMOSOMAL PROTEIN, NONHISTONE, HMG2;; NONHISTONE CHROMOSOMAL PROTEIN HMG2__:__
Asterisk__:__163910__:__HIGH MOBILITY GROUP NUCLEOSOMAL BINDING PROTEIN 2; HMGN2__:__HIGH MOBILITY GROUP PROTEIN 17; HMG17;; CHROMOSOMAL PROTEIN, NONHISTONE, HMG17;; NONHISTONE CHROMOSOMAL PROTEIN HMG17__:__
Asterisk__:__163920__:__HIGH MOBILITY GROUP NUCLEOSOMAL BINDING PROTEIN 1; HMGN1__:__HIGH MOBILITY GROUP PROTEIN 14; HMG14;; CHROMOSOMAL PROTEIN, NONHISTONE, HMG14;; NONHISTONE CHROMOSOMAL PROTEIN HMG14__:__
Number Sign__:__163950__:__NOONAN SYNDROME 1; NS1__:__NOONAN SYNDROME;; MALE TURNER SYNDROME;; FEMALE PSEUDO-TURNER SYNDROME;; TURNER PHENOTYPE WITH NORMAL KARYOTYPE__:__PTERYGIUM COLLI SYNDROME, INCLUDED
Caret__:__163955__:__MOVED TO 163950 AND 610733__:____:__
Asterisk__:__163970__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, NORADRENALINE), MEMBER 2; SLC6A2__:__NEUROTRANSMITTER TRANSPORTER, NORADRENALINE; NAT1;; NOREPINEPHRINE TRANSPORTER PROTEIN 1; NET; NET1__:__
Asterisk__:__163980__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 6; CEACAM6__:__NONSPECIFIC CROSSREACTING ANTIGEN; NCA;; NORMAL CROSSREACTING ANTIGEN;; CEA-LIKE PROTEIN; CEAL__:__
NULL__:__164000__:__NOSE, ANOMALOUS SHAPE OF__:__POTATO NOSE__:__
Asterisk__:__164005__:__NUCLEAR FACTOR I/X; NFIX__:__NUCLEAR FACTOR I, X-TYPE;; CCAAT-BINDING TRANSCRIPTION FACTOR;; NF1A__:__
Asterisk__:__164008__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ALPHA; NFKBIA__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR; NFKBI;; NUCLEAR FACTOR KAPPA-B INHIBITOR;; INHIBITOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS, ALPHA;; I-KAPPA-B-ALPHA; IKBA__:__
Asterisk__:__164009__:__NUCLEAR MITOTIC APPARATUS PROTEIN 1; NUMA1__:____:__NUMA1/RARA FUSION GENE, INCLUDED
Asterisk__:__164010__:__CHMP FAMILY, MEMBER 1A; CHMP1A__:__CHROMATIN-MODIFYING PROTEIN 1A;; CHARGED MULTIVESICULAR BODY PROTEIN 1A;; CHMP1;; PROCOLLAGEN, TYPE III, N-ENDOPEPTIDASE; PCOLN3;; METALLOPROTEASE 1; PRSM1;; METALLOPROTEASE, 33-KD__:__
Asterisk__:__164011__:__NUCLEAR FACTOR KAPPA-B, SUBUNIT 1; NFKB1__:__TRANSCRIPTION FACTOR NFKB1;; NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS 1__:__NFKB p105, INCLUDED;; NFKB p50, INCLUDED
Asterisk__:__164012__:__NUCLEAR FACTOR KAPPA-B, SUBUNIT 2; NFKB2__:__TRANSCRIPTION FACTOR NFKB2;; NFKB, p52/p100 SUBUNIT;; NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS 2;; ONCOGENE LYT 10; LYT10;; LYMPHOCYTE TRANSLOCATION CHROMOSOME 10__:__NFKB, p100 SUBUNIT, INCLUDED;; NFKB, p52 SUBUNIT, INCLUDED
Asterisk__:__164013__:__NUCLEAR FACTOR RELATED TO KAPPA-B BINDING PROTEIN; NFRKB__:____:__
Asterisk__:__164014__:__V-REL AVIAN RETICULOENDOTHELIOSIS VIRAL ONCOGENE HOMOLOG A; RELA__:__NUCLEAR FACTOR KAPPA-B, SUBUNIT 3; NFKB3;; TRANSCRIPTION FACTOR NFKB3;; NFKB, p65 SUBUNIT;; NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS 3__:__RELA/C11ORF95 FUSION GENE, INCLUDED
Asterisk__:__164015__:__MATRIN 3; MATR3__:____:__
Caret__:__164016__:__MOVED TO 600489__:____:__
Asterisk__:__164017__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HNRNPA1__:__HNRPA1;; NUCLEAR RIBONUCLEOPROTEIN PARTICLE A1 PROTEIN__:__
Caret__:__164018__:__MOVED TO 600124__:____:__
Caret__:__164019__:__MOVED TO 600124__:____:__
Asterisk__:__164020__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN C; HNRNPC__:__HNRPC__:__NUCLEAR RIBONUCLEOPROTEIN PARTICLE C1 PROTEIN, INCLUDED;; NUCLEAR RIBONUCLEOPROTEIN PARTICLE C2 PROTEIN, INCLUDED
Asterisk__:__164021__:__NUCLEAR RIBONUCLEOPROTEIN PARTICLE L PROTEIN__:____:__
Caret__:__164022__:__MOVED TO 300199__:____:__
Asterisk__:__164031__:__NUCLEOLAR PROTEIN 1; NOL1__:__NUCLEOLAR ANTIGEN p120; p120;; PROLIFERATING CELL NUCLEOLAR PROTEIN P120__:__
Asterisk__:__164035__:__NUCLEOLIN; NCL__:__C23__:__
Asterisk__:__164040__:__NUCLEOPHOSMIN/NUCLEOPLASMIN FAMILY, MEMBER 1; NPM1__:__NUCLEOPHOSMIN; NPM;; NUCLEOLAR PHOSPHOPROTEIN B23;; NUMATRIN__:__NPM1/ALK FUSION GENE, INCLUDED
Asterisk__:__164050__:__PURINE NUCLEOSIDE PHOSPHORYLASE; PNP__:__NUCLEOSIDE PHOSPHORYLASE; NP;; PURINE-NUCLEOSIDE:ORTHOPHOSPHATE RIBOSYLTRANSFERASE__:__
Asterisk__:__164060__:__NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1; NAP1L1__:__NAP1; NAP1L;; NAPI-RELATED PROTEIN; NRP;; NUCLEOSOME ASSEMBLY PROTEIN I-RELATED PROTEIN__:__
Percent__:__164100__:__NYSTAGMUS 2, CONGENITAL, AUTOSOMAL DOMINANT; NYS2__:__NYSTAGMUS, CONGENITAL MOTOR, 2__:__
Percent__:__164150__:__NYSTAGMUS, HEREDITARY VERTICAL__:____:__
Asterisk__:__164160__:__LEPTIN; LEP__:__OBESE, MOUSE, HOMOLOG OF; OB__:__
Percent__:__164170__:__NYSTAGMUS, VOLUNTARY__:____:__
Asterisk__:__164175__:__POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 1; POU2F1__:__OTF, LYMPHOID-SPECIFIC, 1; OTF1;; OCTAMER-BINDING TRANSCRIPTION FACTOR 1; OCT1__:__
Asterisk__:__164176__:__POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 2; POU2F2__:__OTF, LYMPHOID-SPECIFIC, 2; OTF2;; OCTAMER-BINDING TRANSCRIPTION FACTOR 2; OCT2__:__
Asterisk__:__164177__:__POU DOMAIN, CLASS 5, TRANSCRIPTION FACTOR 1; POU5F1__:__OCTAMER-BINDING TRANSCRIPTION FACTOR 3; OCT3; OTF3;; OCTAMER-BINDING TRANSCRIPTION FACTOR 4; OCT4; OTF4__:__POU5F1/EWS FUSION GENE, INCLUDED
NULL__:__164180__:__OCULOCEREBROCUTANEOUS SYNDROME__:__OCCS;; ORBITAL CYST WITH CEREBRAL AND FOCAL DERMAL MALFORMATIONS;; DELLEMAN SYNDROME__:__
NULL__:__164185__:__OCULAR CICATRICIAL PEMPHIGOID; OCP__:____:__
NULL__:__164190__:__OCULAR DOMINANCE__:____:__
Number Sign__:__164200__:__OCULODENTODIGITAL DYSPLASIA; ODDD__:__ODD SYNDROME;; OCULODENTOOSSEOUS DYSPLASIA; ODOD__:__
Percent__:__164210__:__HEMIFACIAL MICROSOMIA; HFM__:__OCULOAURICULOVERTEBRAL SPECTRUM; OAVS;; GOLDENHAR SYNDROME;; OCULOAURICULOVERTEBRAL DYSPLASIA;; OAV DYSPLASIA;; FACIOAURICULOVERTEBRAL SEQUENCE;; FAV SEQUENCE__:__
Percent__:__164220__:__SCHILBACH-ROTT SYNDROME__:__OCULAR HYPOTELORISM, SUBMUCOSAL CLEFT PALATE, AND HYPOSPADIAS;; CLEFT PALATE, HYPOTELORISM, AND HYPOSPADIAS;; BLEPHAROFACIOSKELETAL SYNDROME; BRSS__:__
Number Sign__:__164230__:__OBSESSIVE-COMPULSIVE DISORDER; OCD__:____:__
Number Sign__:__164280__:__FEINGOLD SYNDROME 1; FGLDS1__:__FEINGOLD SYNDROME;; OCULODIGITOESOPHAGODUODENAL SYNDROME; ODED;; ODED SYNDROME;; MICROCEPHALY-OCULO-DIGITO-ESOPHAGEAL-DUODENAL SYNDROME; MODED;; DIGITAL ANOMALIES WITH SHORT PALPEBRAL FISSURES AND ATRESIA OF ESOPHAGUS OR DUODENUM;; MICROCEPHALY, MENTAL RETARDATION, AND TRACHEOESOPHAGEAL FISTULA SYNDROME;; MMT SYNDROME;; MICROCEPHALY AND DIGITAL ABNORMALITIES WITH NORMAL INTELLIGENCE__:__
Number Sign__:__164300__:__OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD__:__MUSCULAR DYSTROPHY, OCULOPHARYNGEAL__:__
Percent__:__164310__:__OCULOPHARYNGODISTAL MYOPATHY; OPDM__:__FACIOOCULOLARYNGOPHARYNGEAL MYOPATHY WITH DISTAL AND RESPIRATORY INVOLVEMENT; FOLP-DR__:__
Asterisk__:__164320__:__ODORANT-BINDING PROTEIN 2A; OBP2A__:__ODORANT-BINDING PROTEIN; OBP__:__
NULL__:__164330__:__ODONTOMA-DYSPHAGIA SYNDROME__:____:__
Asterisk__:__164340__:__OLFACTORY MARKER PROTEIN; OMP__:____:__
Asterisk__:__164342__:__OLFACTORY RECEPTOR, FAMILY 1, SUBFAMILY D, MEMBER 2; OR1D2__:__OLFACTORY RECEPTOR 1; OLFR1;; TESTICULAR ODORANT RECEPTOR OR17-4; OR17-4__:__
Asterisk__:__164343__:__EARLY B-CELL FACTOR 1; EBF1__:__EBF;; OLFACTORY NEURONAL TRANSCRIPTION FACTOR 1; OLF1;; COLLIER/OLF1/EBF TRANSCRIPTION FACTOR 1; COE1__:__
Asterisk__:__164345__:__OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; OMG__:__OMGP__:__
Asterisk__:__164350__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE 1; OAS1__:__2-PRIME,5-PRIME-OLIGOISOADENYLATE SYNTHETASE; OIAS;; 2-PRIME,5-PRIME-A SYNTHETASE__:__
Asterisk__:__164360__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, ALPHA SUBUNIT 1; ATP5F1A__:__ATP5A;; ATP5A1;; MITOCHONDRIAL ATP SYNTHETASE; ATPM;; MITOCHONDRIAL ATP SYNTHETASE, OLIGOMYCIN-RESISTANT; OMR;; MODIFIER OF MIN 2, MOUSE, HOMOLOG OF; MOM2__:__
Number Sign__:__164400__:__SPINOCEREBELLAR ATAXIA 1; SCA1__:__SPINOCEREBELLAR ATROPHY I;; OLIVOPONTOCEREBELLAR ATROPHY I; OPCA1;; OPCA I;; CEREBELLOPARENCHYMAL DISORDER I; CPD1;; MENZEL TYPE OPCA;; OLIVOPONTOCEREBELLAR ATROPHY IV; OPCA4;; OPCA IV;; SCHUT-HAYMAKER TYPE OPCA__:__
Number Sign__:__164500__:__SPINOCEREBELLAR ATAXIA 7; SCA7__:__OLIVOPONTOCEREBELLAR ATROPHY III; OPCA3;; OPCA III;; OPCA WITH RETINAL DEGENERATION;; OPCA WITH MACULAR DEGENERATION AND EXTERNAL OPHTHALMOPLEGIA;; AUTOSOMAL DOMINANT CEREBELLAR ATAXIA, TYPE II;; ADCA, TYPE II__:__
Caret__:__164600__:__MOVED TO 164400__:____:__
NULL__:__164680__:__ONYCHOGRYPOSIS, PEDAL, WITH KERATOSIS PLANTARIS AND COARSE HAIR__:____:__
Asterisk__:__164690__:__V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ABL2__:__ONCOGENE ABL2;; ONCOGENE ABLL;; ABELSON-RELATED GENE; ARG;; ONCOGENE ARG__:__ABL2/ETV6 FUSION GENE, INCLUDED
NULL__:__164700__:__OLIVOPONTOCEREBELLAR ATROPHY V; OPCA V__:__OPCA WITH DEMENTIA AND EXTRAPYRAMIDAL SIGNS__:__
Caret__:__164710__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__164720__:__V-ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG 1; ETS1__:__ONCOGENE ETS1;; ETS1 ONCOGENE__:__
Asterisk__:__164730__:__V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1; AKT1__:__ONCOGENE AKT1;; PROTEIN KINASE B-ALPHA;; PKB-ALPHA;; RAC SERINE/THREONINE PROTEIN KINASE__:__
Asterisk__:__164731__:__V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 2; AKT2__:__ONCOGENE AKT2;; PROTEIN KINASE B, BETA; PKBB;; PKB-BETA__:__
Asterisk__:__164740__:__V-ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG 2; ETS2__:__ONCOGENE ETS2;; ETS2 ONCOGENE;; ETS2 INTRONIC TRANSCRIPT; ETS2IT1__:__
Percent__:__164745__:__OMODYSPLASIA 2; OMOD2__:__OMODYSPLASIA, AUTOSOMAL DOMINANT__:__
Number Sign__:__164750__:__OMPHALOCELE, AUTOSOMAL__:__CHROMOSOME 1p31 DUPLICATION SYNDROME__:__
Asterisk__:__164755__:__VIRAL INTEGRATION SITE 1; VIS1__:__HIS1__:__
Caret__:__164756__:__MOVED TO 164755__:____:__
Asterisk__:__164757__:__V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; BRAF__:__ONCOGENE BRAF;; BRAF1;; RAFB1__:__BRAF/AKAP9 FUSION GENE, INCLUDED;; BRAF/KIAA1549 FUSION GENE, INCLUDED
Caret__:__164759__:__MOVED TO 167000__:____:__
Asterisk__:__164760__:__V-RAF-1 MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; RAF1__:__ONCOGENE RAF1;; TRANSFORMING REPLICATION-DEFECTIVE MURINE RETROVIRUS 3611-MSV;; ONCOGENE MIL;; CRAF__:__RAF1/SRGAP3 FUSION GENE, INCLUDED
Asterisk__:__164761__:__REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET__:__RET PROTOONCOGENE__:__RET/ELKS FUSION GENE, INCLUDED
Asterisk__:__164762__:__V-CRK AVIAN SARCOMA VIRUS CT10 ONCOGENE HOMOLOG; CRK__:__ONCOGENE CRK;; CRKII__:__
Asterisk__:__164765__:__CORTACTIN; CTTN__:__ONCOGENE EMS1; EMS1__:__
Asterisk__:__164770__:__COLONY-STIMULATING FACTOR 1 RECEPTOR; CSF1R__:__MCSFR;; ONCOGENE FMS; FMS;; c-FMS;; CD115 ANTIGEN; CD115;; V-FMS MCDONOUGH FELINE SARCOMA VIRAL ONCOGENE HOMOLOG, FORMERLY__:__
Asterisk__:__164772__:__V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG B; FOSB__:__ONCOGENE FOSB;; GOSB__:__DELTA-FOSB, INCLUDED
Asterisk__:__164780__:__V-SKI AVIAN SARCOMA VIRAL ONCOGENE HOMOLOG; SKI__:__ONCOGENE SK, CHICKEN VIRAL;; SK ONCOGENE; SKI__:__
Asterisk__:__164785__:__MOUSE DOUBLE MINUTE 2 HOMOLOG; MDM2__:__p53-BINDING PROTEIN MDM2;; ONCOPROTEIN MDM2;; HDM2__:__
Asterisk__:__164790__:__NEUROBLASTOMA RAS VIRAL ONCOGENE HOMOLOG; NRAS__:__ONCOGENE NRAS; NRAS1__:__
Asterisk__:__164795__:__ONCOMODULIN; OCM__:__PARVALBUMIN, BETA__:__
Percent__:__164800__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 5; NDNC5__:__ONYCHOLYSIS, PARTIAL, WITH SCLERONYCHIA;; ONYCHOLYSIS, HEREDITARY DISTAL__:__
Asterisk__:__164810__:__V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG; FOS__:__ONCOGENE FOS;; FBJ OSTEOSARCOMA VIRUS__:__
Asterisk__:__164820__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 1; WNT1__:__ONCOGENE INT1; INT1__:__MOUSE MAMMARY TUMOR VIRUS INTEGRATION SITE 1, INCLUDED
Caret__:__164830__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__164831__:__LEUKEMIA VIRAL BMI-1 ONCOGENE, MOUSE, HOMOLOG OF; BMI1__:____:__
Asterisk__:__164840__:__V-MYC AVIAN MYELOCYTOMATOSIS VIRAL-RELATED ONCOGENE, NEUROBLASTOMA-DERIVED; MYCN__:__ONCOGENE NMYC;; NMYC ONCOGENE;; AVIAN MYELOCYTOMATOSIS VIRAL-RELATED ONCOGENE, NEUROBLASTOMA-DERIVED;; NEUROBLASTOMA MYC ONCOGENE__:__
Asterisk__:__164850__:__V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG, LUNG CARCINOMA-DERIVED; MYCL__:__V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG 1, LUNG CARCINOMA-DERIVED; MYCL1;; AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG 1, LUNG CARCINOMA-DERIVED;; ONCOGENE LMYC;; MYC-RELATED GENE FROM LUNG CANCER__:__
Asterisk__:__164860__:__MET PROTOONCOGENE; MET__:__ONCOGENE MET;; HEPATOCYTE GROWTH FACTOR RECEPTOR; HGFR__:__
Asterisk__:__164865__:__V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG-LIKE 1; MYCLK1__:__ONCOGENE MYC-LIKE-1;; AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG LIKE-1__:__
Asterisk__:__164870__:__V-ERB-B2 AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ERBB2__:__ONCOGENE ERBB2;; ONCOGENE NGL, NEUROBLASTOMA- OR GLIOBLASTOMA-DERIVED; NGL;; NEU;; TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER2; TKR1;; HER2__:__HERSTATIN, INCLUDED
Asterisk__:__164873__:__ETS VARIANT GENE 3; ETV3__:__ONCOGENE PE1; PE1;; MITOGENIC ETS TRANSCRIPTIONAL SUPPRESSOR; METS__:__
Asterisk__:__164874__:__FORKHEAD BOX G1; FOXG1__:__FORKHEAD BOX G1B; FOXG1B;; FORKHEAD-LIKE 1; FKHL1;; ONCOGENE QIN;; BRAIN FACTOR 1; BF1__:__
Asterisk__:__164875__:__VAV1 ONCOGENE; VAV1__:__ONCOGENE VAV;; ONCOGENE VAV1__:__
Asterisk__:__164880__:__V-YES-1 YAMAGUCHI SARCOMA VIRAL ONCOGENE; YES1__:__ONCOGENE YES1;; YAMAGUCHI SARCOMA ONCOGENE__:__
Caret__:__164891__:__MOVED TO 164757__:____:__
Percent__:__164900__:__OPHTHALMOMANDIBULOMELIC DYSPLASIA__:__OMM SYNDROME__:__
Caret__:__164905__:__MOVED TO 600326__:____:__
Asterisk__:__164910__:__V-REL AVIAN RETICULOENDOTHELIOSIS VIRAL ONCOGENE HOMOLOG; REL__:__ONCOGENE REL;; C-REL__:__
Asterisk__:__164920__:__V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG; KIT__:__KIT ONCOGENE;; MAST CELL GROWTH FACTOR RECEPTOR;; STEM CELL FACTOR RECEPTOR; SCFR__:__
Asterisk__:__164940__:__GARDNER-RASHEED FELINE SARCOMA VIRAL ONCOGENE HOMOLOG; FGR__:__ONCOGENE FGR;; FGR ONCOGENE;; SRC2 ONCOGENE, FORMERLY__:__
Asterisk__:__164950__:__FIBROBLAST GROWTH FACTOR 3; FGF3__:__ONCOGENE INT2; INT2;; V-INT2 MURINE MAMMARY TUMOR VIRUS INTEGRATION SITE ONCOGENE HOMOLOG__:__MOUSE MAMMARY TUMOR VIRUS INTEGRATION SITE 2, INCLUDED
Asterisk__:__164951__:__NOTCH, DROSOPHILA, HOMOLOG OF, 4; NOTCH4__:__ONCOGENE INT3; INT3;; NOTCH, DROSOPHILA, HOMOLOG OF, 3, FORMERLY; NOTCH3, FORMERLY__:__MOUSE MAMMARY TUMOR VIRUS INTEGRATION SITE 3, INCLUDED
Asterisk__:__164953__:__ONCOGENE LIPOSARCOMA; LPSA__:__D19S381E__:__
Asterisk__:__164958__:__NEPHROBLASTOMA OVEREXPRESSED GENE; NOV__:__ONCOGENE NOV;; CCN3__:__
Asterisk__:__164960__:__ONCOGENE PIM 1; PIM1__:__SERINE/THREONINE PROTEIN KINASE PIM1;; PIM__:__
Caret__:__164970__:__MOVED TO 191315 AND 191030__:____:__
Asterisk__:__164975__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5A; WNT5A__:__ONCOGENE WNT5A__:__
Asterisk__:__164980__:__FIBROBLAST GROWTH FACTOR 4; FGF4__:__HEPARIN SECRETORY TRANSFORMING PROTEIN 1; HSTF1;; ONCOGENE HST;; HUMAN STOMACH CANCER, TRANSFORMING FACTOR FROM;; FGF-RELATED ONCOGENE;; KAPOSI SARCOMA ONCOGENE; KFGF__:__
Percent__:__165000__:__OPHTHALMOPLEGIA, FAMILIAL STATIC__:__EXTERNAL OPHTHALMOPLEGIA, NONPROGRESSIVE, CONGENITAL HEREDITARY__:__
Caret__:__165010__:__MOVED TO 164710__:____:__
Asterisk__:__165020__:__V-ROS AVIAN UR2 SARCOMA VIRUS ONCOGENE HOMOLOG 1; ROS1__:__ONCOGENE ROS; ROS;; MCF3__:__ROS1/FIG FUSION GENE, INCLUDED
Asterisk__:__165040__:__RAS-ASSOCIATED PROTEIN RAB8A; RAB8A__:__RAS-ASSOCIATED PROTEIN RAB8; RAB8;; ONCOGENE MEL; MEL__:__
Asterisk__:__165060__:__TRANSFER RNA SELENOCYSTEINE 1; TRNAU1__:__tRNA SELENOCYSTEINE 1;; tRNA PHOSPHOSERINE; TRSP;; OPAL SUPPRESSOR PHOSPHOSERINE tRNA__:__
Asterisk__:__165070__:__FMS-RELATED TYROSINE KINASE 1; FLT1__:__ONCOGENE FLT; FLT;; VASCULAR ENDOTHELIAL GROWTH FACTOR/VASCULAR PERMEABILITY FACTOR RECEPTOR;; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; VEGFR1__:__
Asterisk__:__165080__:__V-ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG; ERG__:__ONCOGENE ERG;; ETS-RELATED GENE__:__ERG1, INCLUDED;; ERG2, INCLUDED;; ERG/TMPRSS2 FUSION GENE, INCLUDED;; ERG/EWS FUSION GENE, INCLUDED;; ERG/FUS FUSION GENE, INCLUDED
Asterisk__:__165090__:__RELATED RAS VIRAL ONCOGENE HOMOLOG; RRAS__:__ONCOGENE RRAS__:__
Asterisk__:__165095__:__ONCOSTATIN M; OSM__:____:__
NULL__:__165098__:__OPHTHALMOPLEGIA, FAMILIAL TOTAL, WITH IRIS TRANSILLUMINATION__:____:__
Asterisk__:__165110__:__S13 AVIAN ERYTHROBLASTOSIS ONCOGENE HOMOLOG; SEA__:__ONCOGENE SEA__:__
Asterisk__:__165120__:__V-YES-1 YAMAGUCHI SARCOMA VIRAL RELATED ONCOGENE HOMOLOG; LYN__:__ONCOGENE LYN__:__
Asterisk__:__165140__:__ONCOGENE PVT1; PVT1__:__MYC ACTIVATOR__:__
NULL__:__165150__:__OPHTHALMOPLEGIA, PROGRESSIVE, WITH SCROTAL TONGUE AND MENTAL DEFICIENCY__:____:__
Asterisk__:__165160__:__V-JUN AVIAN SARCOMA VIRUS 17 ONCOGENE HOMOLOG; JUN__:__ONCOGENE JUN__:__ACTIVATOR PROTEIN 1, INCLUDED; AP1, INCLUDED;; ENHANCER-BINDING PROTEIN AP1, INCLUDED
Asterisk__:__165161__:__ONCOGENE JUN-B; JUNB__:____:__
Asterisk__:__165162__:__ONCOGENE JUN-D; JUND__:____:__
Asterisk__:__165170__:__SPLEEN FOCUS FORMING VIRUS PROVIRAL INTEGRATION ONCOGENE SPI1; SPI1__:__ONCOGENE SPI1;; SFFV VIRUS-INDUCED MURINE ERYTHROLEUKEMIA ONCOGENE, MOUSE, HOMOLOG OF;; HEMATOPOIETIC TRANSCRIPTION FACTOR PU.1__:__
Asterisk__:__165180__:__MAS1 ONCOGENE; MAS1__:__MAS__:__
Asterisk__:__165190__:__FIBROBLAST GROWTH FACTOR 5; FGF5__:____:__
Asterisk__:__165195__:__OPIOID RECEPTOR, DELTA-1; OPRD1__:__OPRD__:__
Asterisk__:__165196__:__OPIOID RECEPTOR, KAPPA-1; OPRK1__:__OPRK__:__
NULL__:__165199__:__OPTIC ATROPHY, HEARING LOSS, AND PERIPHERAL NEUROPATHY, AUTOSOMAL DOMINANT__:____:__
NULL__:__165200__:__OPTIC ATROPHY WITH DEMYELINATING DISEASE OF CNS__:____:__
NULL__:__165210__:__ONCOGENE BMYC; BMYC__:____:__
Asterisk__:__165215__:__MDS1 AND EVI1 COMPLEX LOCUS; MECOM__:__ECOTROPIC VIRAL INTEGRATION SITE 1; EVI1;; ONCOGENE EVI1;; MYELOID LEUKEMIA-ASSOCIATED GENE EVI1, MOUSE, HOMOLOG OF__:__EVI1/GR6 FUSION GENE, INCLUDED;; EVI1/RBPH1 FUSION GENE, INCLUDED
Asterisk__:__165220__:__GLIOMA-ASSOCIATED ONCOGENE HOMOLOG; GLI1__:__ONCOGENE GLI; GLI__:__
Asterisk__:__165230__:__GLI-KRUPPEL FAMILY MEMBER 2; GLI2__:__ONCOGENE GLI2__:__
Asterisk__:__165240__:__GLI-KRUPPEL FAMILY MEMBER 3; GLI3__:__ONCOGENE GLI3__:__
Asterisk__:__165250__:__GLI-KRUPPEL FAMILY MEMBER HKR1; HKR1__:__ONCOGENE HKR1__:__
Asterisk__:__165260__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 22; ZSCAN22__:__GLI-KRUPPEL FAMILY MEMBER HKR2; HKR2;; ONCOGENE HKR2__:__
Asterisk__:__165270__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 48; ZBTB48__:__GLI-KRUPPEL FAMILY MEMBER HKR3; HKR3;; ONCOGENE HKR3;; TELOMERIC ZINC FINGER-ASSOCIATED PROTEIN; TZAP__:__
Asterisk__:__165280__:__GLI-KRUPPEL FAMILY MEMBER 4; GLI4__:__ONCOGENE GLI4;; ONCOGENE HKR4__:__
NULL__:__165290__:__ONCOGENE RMYC; RMYC__:____:__
Number Sign__:__165300__:__OPTIC ATROPHY 3, AUTOSOMAL DOMINANT; OPA3__:__OPTIC ATROPHY AND CATARACT, AUTOSOMAL DOMINANT__:__
Asterisk__:__165320__:__LIVER CANCER ONCOGENE; LCO__:__ONCOGENE LCA__:__
Asterisk__:__165330__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 3; WNT3__:__ONCOGENE INT4; INT4__:__MOUSE MAMMARY TUMOR VIRUS INTEGRATION SITE 4, INCLUDED
Asterisk__:__165340__:__SKI-LIKE; SKIL__:__ONCOGENE SNO; SNO__:__
Caret__:__165350__:__MOVED TO 311040__:____:__
Asterisk__:__165360__:__CAS-BR-M MURINE ECOTROPIC RETROVIRAL TRANSFORMING SEQUENCE HOMOLOG; CBL__:__CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE;; C-CBL;; ONCOGENE CBL;; ONCOGENE CBL2;; RNF55__:__CBL/MLL FUSION GENE, INCLUDED
Asterisk__:__165370__:__RAS HOMOLOG GENE FAMILY, MEMBER B; RHOB__:__APLYSIA RAS-RELATED HOMOLOG 6; ARH6;; ARHB;; ONCOGENE RHO H6; RHOH6__:__
Asterisk__:__165380__:__RAS HOMOLOG GENE FAMILY, MEMBER C; RHOC__:__APLYSIA RAS-RELATED HOMOLOG 9; ARH9;; ARHC;; ONCOGENE RHO H9; RHOH9__:__
Asterisk__:__165390__:__RAS HOMOLOG GENE FAMILY, MEMBER A; RHOA__:__APLYSIA RAS-RELATED HOMOLOG 12; ARH12;; ARHA;; ONCOGENE RHO H12; RHOH12; RHO12__:__
Caret__:__165490__:__MOVED TO 165500__:____:__
Number Sign__:__165500__:__OPTIC ATROPHY 1; OPA1__:__OPTIC ATROPHY, JUVENILE;; KJER-TYPE OPTIC ATROPHY;; OPTIC ATROPHY, KJER TYPE; OAK__:__
NULL__:__165510__:__OPTIC ATROPHY WITH NEGATIVE ELECTRORETINOGRAMS__:____:__
Number Sign__:__165550__:__OPTIC NERVE HYPOPLASIA, BILATERAL__:____:__OPTIC NERVE APLASIA, BILATERAL, INCLUDED
NULL__:__165590__:__OROFACIODIGITAL SYNDROME X; OFD10__:__OFDS X;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE X;; OROFACIODIGITAL SYNDROME WITH FIBULAR APLASIA;; ORAL-FACIAL-DIGITAL SYNDROME WITH FIBULAR APLASIA__:__
NULL__:__165600__:__ORBITAL MARGIN, HYPOPLASIA OF__:____:__
Caret__:__165630__:__MOVED TO 163200__:____:__
Caret__:__165635__:__MOVED TO 258870__:____:__
Asterisk__:__165640__:__ORNITHINE DECARBOXYLASE 1; ODC1__:____:__ORNITHINE DECARBOXYLASE PSEUDOGENE, INCLUDED; ODCP, INCLUDED;; ORNITHINE DECARBOXYLASE 2, INCLUDED; ODC2, INCLUDED
Caret__:__165650__:__MOVED TO 165640__:____:__
Percent__:__165660__:__OSLAM SYNDROME__:__OSTEOSARCOMA, LIMB ANOMALIES, AND MACROCYTOSIS;; OSTEOSARCOMA, LIMB ANOMALIES, AND ERYTHROID MACROCYTOSIS WITH MEGALOBLASTIC MARROW__:__
NULL__:__165670__:__OSSIFIED EAR CARTILAGES__:____:__
NULL__:__165680__:__OSSICULAR MALFORMATIONS, FAMILIAL__:____:__
Percent__:__165700__:__THIEMANN DISEASE__:__THIEMANN EPIPHYSEAL DISEASE;; OSTEOARTHROPATHY OF FINGERS, FAMILIAL__:__
Number Sign__:__165720__:__OSTEOARTHRITIS SUSCEPTIBILITY 1; OS1__:__OA;; OSTEOARTHROSIS;; OSTEOARTHRITIS OF HIP, FEMALE-SPECIFIC, SUSCEPTIBILITY TO__:__
Number Sign__:__165800__:__SHORT STATURE AND ADVANCED BONE AGE, WITH OR WITHOUT EARLY-ONSET OSTEOARTHRITIS AND/OR OSTEOCHONDRITIS DISSECANS; SSOAOD__:__OSTEOCHONDRITIS DISSECANS, SHORT STATURE, AND EARLY-ONSET OSTEOARTHRITIS; OD__:__
Percent__:__166000__:__ENCHONDROMATOSIS, MULTIPLE, OLLIER TYPE__:__OLLIER DISEASE;; OSTEOCHONDROMATOSIS;; DYSCHONDROPLASIA__:__
Number Sign__:__166200__:__OSTEOGENESIS IMPERFECTA, TYPE I; OI1__:__OI, TYPE I;; OSTEOGENESIS IMPERFECTA TARDA;; OSTEOGENESIS IMPERFECTA WITH BLUE SCLERAE__:__
Number Sign__:__166210__:__OSTEOGENESIS IMPERFECTA, TYPE II; OI2__:__OI, TYPE II;; OSTEOGENESIS IMPERFECTA CONGENITA, PERINATAL LETHAL FORM;; OSTEOGENESIS IMPERFECTA CONGENITA; OIC;; VROLIK TYPE OF OSTEOGENESIS IMPERFECTA__:__
Number Sign__:__166220__:__OSTEOGENESIS IMPERFECTA, TYPE IV; OI4__:__OI, TYPE IV;; OSTEOGENESIS IMPERFECTA WITH NORMAL SCLERAE__:__
NULL__:__166230__:__OSTEOGENESIS IMPERFECTA WITH OPALESCENT TEETH, BLUE SCLERAE AND WORMIAN BONES, BUT WITHOUT FRACTURES__:____:__
Caret__:__166240__:__MOVED TO 166200__:____:__
Number Sign__:__166250__:__OSTEOGLOPHONIC DYSPLASIA; OGD__:__OSTEOGLOPHONIC DWARFISM__:__
Number Sign__:__166260__:__GNATHODIAPHYSEAL DYSPLASIA; GDD__:__OSTEOGENESIS IMPERFECTA WITH UNUSUAL SKELETAL LESIONS;; GNATHODIAPHYSEAL SCLEROSIS__:__
Number Sign__:__166300__:__MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO__:__OSTEOLYSIS, HEREDITARY, OF CARPAL BONES WITH OR WITHOUT NEPHROPATHY;; MULTICENTRIC OSTEOLYSIS, AUTOSOMAL DOMINANT__:__
Number Sign__:__166350__:__OSSEOUS HETEROPLASIA, PROGRESSIVE; POH__:__ECTOPIC OSSIFICATION, FAMILIAL;; OSTEOMA CUTIS__:__
NULL__:__166400__:__OSTEOMAS OF MANDIBLE__:____:__
NULL__:__166450__:__OSTEOMESOPYKNOSIS__:__AXIAL OSTEOSCLEROSIS__:__
Asterisk__:__166490__:__SECRETED PHOSPHOPROTEIN 1; SPP1__:__OSTEOPONTIN; OPN;; BONE SIALOPROTEIN;; URINARY STONE PROTEIN;; EARLY T LYMPHOCYTE ACTIVATION 1; ETA1__:__
Caret__:__166500__:__MOVED TO 300373__:____:__
Number Sign__:__166600__:__OSTEOPETROSIS, AUTOSOMAL DOMINANT 2; OPTA2__:__OSTEOPETROSIS, AUTOSOMAL DOMINANT, TYPE II;; MARBLE BONES, AUTOSOMAL DOMINANT;; OSTEOSCLEROSIS FRAGILIS GENERALISATA;; ALBERS-SCHONBERG DISEASE, AUTOSOMAL DOMINANT__:__
Number Sign__:__166700__:__BUSCHKE-OLLENDORFF SYNDROME; BOS__:__DERMATOOSTEOPOIKILOSIS;; DERMATOFIBROSIS, DISSEMINATED, WITH OSTEOPOIKILOSIS;; DERMATOFIBROSIS LENTICULARIS DISSEMINATA WITH OSTEOPOIKILOSIS;; OSTEOPATHIA CONDENSANS DISSEMINATA__:__OSTEOPOIKILOSIS, ISOLATED, INCLUDED;; DERMATOFIBROSIS LENTICULARIS DISSEMINATA, ISOLATED, INCLUDED;; OSTEOPOIKILOSIS WITH MELORHEOSTOSIS, INCLUDED
NULL__:__166705__:__OSTEOPOIKILOSIS AND DACRYOCYSTITIS__:____:__
Number Sign__:__166710__:__OSTEOPOROSIS__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS; BMND;; OSTEOPOROSIS, POSTMENOPAUSAL;; OSTEOPOROSIS, INVOLUTIONAL__:__FRACTURE, HIP, SUSCEPTIBILITY TO, INCLUDED
Caret__:__166720__:__MOVED TO 130720__:____:__
NULL__:__166740__:__OSTEOSCLEROSIS WITH ICHTHYOSIS AND FRACTURES__:__CORTICAL THICKENING OF LONG BONES WITH BOWING AND ICHTHYOSIS__:__
Number Sign__:__166750__:__OTODENTAL DYSPLASIA__:__CHROMOSOME 11q13 DELETION SYNDROME;; OTODENTAL SYNDROME__:__OTODENTAL SYNDROME WITH COLOBOMA, INCLUDED;; OCULOOTODENTAL SYNDROME, INCLUDED
Number Sign__:__166760__:__OTITIS MEDIA, SUSCEPTIBILITY TO; OMS__:__OTITIS MEDIA, CHRONIC/RECURRENT;; COME/ROM__:__
Number Sign__:__166780__:__OTOFACIOCERVICAL SYNDROME 1; OTFCS__:__OFC; OFC1__:__
Percent__:__166800__:__OTOSCLEROSIS 1; OTSC1__:__OTS__:__
Number Sign__:__166900__:__OVALOCYTOSIS, SOUTHEAST ASIAN; SAO__:__OVALOCYTOSIS, MALAYSIAN-MELANESIAN-FILIPINO TYPE;; ELLIPTOCYTOSIS 4; EL4;; ELLIPTOCYTOSIS, STOMATOCYTIC HEREDITARY;; HE, STOMATOCYTIC__:__
NULL__:__166910__:__OVALOCYTOSIS, HEREDITARY HEMOLYTIC, WITH DEFECTIVE ERYTHROPOIESIS__:____:__
Asterisk__:__166945__:__NEIGHBOR OF BRCA1 GENE 1; NBR1__:__MEMBRANE COMPONENT, CHROMOSOME 17, SURFACE MARKER 2; M17S2__:__
NULL__:__166950__:__TERATOMA, OVARIAN__:__DERMOID CYST, OVARIAN__:__
NULL__:__166970__:__OVARIAN FIBROMATA__:____:__
NULL__:__166990__:__OSTEOCHONDRODYSPLASIA, RHIZOMELIC, WITH CALLOSAL AGENESIS, THROMBOCYTOPENIA, HYDROCEPHALUS, AND HYPERTENSION__:____:__
Number Sign__:__167000__:__OVARIAN CANCER__:____:__OVARIAN CANCER, EPITHELIAL, INCLUDED
Number Sign__:__167030__:__NEPHROLITHIASIS, CALCIUM OXALATE; CAON__:__KIDNEY STONES;; UROLITHIASIS, CALCIUM OXALATE__:__
Asterisk__:__167040__:__OXYSTEROL-BINDING PROTEIN; OSBP__:__OSBP1__:__
Asterisk__:__167050__:__OXYTOCIN; OXT__:__OXYTOCIN--NEUROPHYSIN I;; OT__:__NEUROPHYSIN I, INCLUDED;; PREPROOXYTOCIN, INCLUDED
Asterisk__:__167055__:__OXYTOCIN RECEPTOR; OXTR__:__OTR__:__
Percent__:__167100__:__HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL DOMINANT; PHOAD__:__PHO, AUTOSOMAL DOMINANT;; PACHYDERMOPERIOSTOSIS, AUTOSOMAL DOMINANT;; PDP, AUTOSOMAL DOMINANT__:__
Number Sign__:__167200__:__PACHYONYCHIA CONGENITA 1; PC1__:__PACHYONYCHIA CONGENITA, JADASSOHN-LEWANDOWSKY TYPE, FORMERLY;; JADASSOHN-LEWANDOWSKY SYNDROME, FORMERLY__:__
Number Sign__:__167210__:__PACHYONYCHIA CONGENITA 2; PC2__:__PACHYONYCHIA CONGENITA, JACKSON-LAWLER TYPE, FORMERLY__:__
NULL__:__167220__:__PACMAN DYSPLASIA__:__EPIPHYSEAL STIPPLING WITH OSTEOCLASTIC HYPERPLASIA__:__
Number Sign__:__167250__:__PAGET DISEASE OF BONE 3; PDB3__:____:__
NULL__:__167300__:__PAGET DISEASE, EXTRAMAMMARY__:____:__
Number Sign__:__167320__:__INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 1; IBMPFD1__:__MULTISYSTEM PROTEINOPATHY 1; MSP1;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, WITH PAGET DISEASE OF BONE;; PAGETOID AMYOTROPHIC LATERAL SCLEROSIS;; PAGETOID NEUROSKELETAL SYNDROME;; LOWER MOTOR NEURON DEGENERATION WITH PAGET-LIKE BONE DISEASE__:__
Number Sign__:__167400__:__PAROXYSMAL EXTREME PAIN DISORDER__:__PEXPD; PEPD;; PAIN, SUBMANDIBULAR, OCULAR, AND RECTAL, WITH FLUSHING;; RECTAL PAIN, FAMILIAL__:__
Asterisk__:__167405__:__PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 6; PCSK6__:__PAIRED BASIC AMINO ACID CLEAVING ENZYME 4; PACE4;; SPC4__:__
Asterisk__:__167409__:__PAIRED BOX GENE 2; PAX2__:____:__
Asterisk__:__167410__:__PAIRED BOX GENE 7; PAX7__:__PAIRED DOMAIN GENE HuP1; HUP1__:__PAX7/FKHR FUSION GENE, INCLUDED
Asterisk__:__167411__:__PAIRED BOX GENE 1; PAX1__:__PAIRED DOMAIN GENE HuP48; HUP48__:__
Asterisk__:__167413__:__PAIRED BOX GENE 4; PAX4__:__PAIRED DOMAIN GENE 4__:__
Asterisk__:__167414__:__PAIRED BOX GENE 5; PAX5__:__PAIRED DOMAIN GENE 5;; B-CELL LINEAGE-SPECIFIC ACTIVATOR PROTEIN; BSAP__:__
Asterisk__:__167415__:__PAIRED BOX GENE 8; PAX8__:__PAIRED DOMAIN GENE 8__:__PAX8/PPARG FUSION GENE, INCLUDED
Asterisk__:__167416__:__PAIRED BOX GENE 9; PAX9__:__PAIRED DOMAIN GENE 9__:__
Asterisk__:__167420__:__PAIRED-RELATED HOMEOBOX GENE 1; PRRX1__:__PRX1;; PAIRED MESODERM HOMEOBOX 1; PMX1;; PHOX1__:__
Percent__:__167500__:__PALATOPHARYNGEAL INCOMPETENCE__:__VELOPHARYNGEAL INCOMPETENCE; VPI;; VELOPHARYNGEAL INSUFFICIENCY__:__
NULL__:__167600__:__PALMARIS LONGUS MUSCLE, ABSENCE OF__:____:__
NULL__:__167700__:__PALMOMENTAL REFLEX__:____:__
Percent__:__167730__:__NASOPALPEBRAL LIPOMA-COLOBOMA SYNDROME; NPLCS__:__PALPEBRAL COLOBOMA-LIPOMA SYNDROME__:__
NULL__:__167750__:__PANCREAS, ANNULAR__:____:__
NULL__:__167755__:__PANCREAS, DORSAL, AGENESIS OF__:____:__
Asterisk__:__167770__:__REGENERATING ISLET-DERIVED 1-ALPHA; REG1A__:__REGENERATING ISLET-DERIVED, RAT, HOMOLOG OF; REG;; LITHOSTATHINE;; PANCREATIC STONE PROTEIN, SECRETORY; PSPS__:__
Asterisk__:__167771__:__REGENERATING ISLET-DERIVED 1-BETA; REG1B__:__REG I-BETA;; REGENERATING ISLET-DERIVED, RAT, HOMOLOG-LIKE; REGL;; PANCREATIC STONE PROTEIN, SECRETORY, 2; PSPS2__:__
Asterisk__:__167780__:__PANCREATIC POLYPEPTIDE/PANCREATIC ICOSAPEPTIDE; PPY__:__PNP__:__
Asterisk__:__167790__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 1; SPINK1__:__PANCREATIC SECRETORY TRYPSIN INHIBITOR; PSTI;; TUMOR-ASSOCIATED TRYPSIN INHIBITOR; TATI__:__
Number Sign__:__167800__:__PANCREATITIS, HEREDITARY; PCTT__:__HPC;; HP;; PANCREATITIS, CHRONIC__:__PANCREATITIS, CHRONIC, SUSCEPTIBILITY TO, INCLUDED;; PANCREATITIS, CALCIFIC, INCLUDED;; PANCREATITIS, CHRONIC, PROTECTION AGAINST, INCLUDED
Asterisk__:__167805__:__REGENERATING ISLET-DERIVED 3-ALPHA; REG3A__:__PANCREATITIS-ASSOCIATED PROTEIN; PAP;; PAP1;; ISLET NEOGENESIS-ASSOCIATED PROTEIN; INGAP__:__
NULL__:__167850__:__PANCYTOPENIA AND OCCLUSIVE VASCULAR DISEASE__:____:__
Percent__:__167870__:__PANIC DISORDER 1; PAND1__:__PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 13q-RELATED__:__PANIC DISORDER WITH BLADDER CONDITIONS, INCLUDED;; PANIC DISORDER WITH JOINT LAXITY, INCLUDED
Percent__:__167900__:__PAPILLOMATOSIS, CONFLUENT AND RETICULATED; CARP__:__PAPILLOMATOSIS, RETICULATED AND CONFLUENT, OF GOUGEROT AND CARTEAUD;; PAPILLOMATOSIS, FAMILIAL CUTANEOUS__:__
NULL__:__167950__:__PAPILLOMATOSIS, FLORID, OF NIPPLE__:____:__
NULL__:__167959__:__HUMAN PAPILLOMAVIRUS TYPE 18 INTEGRATION SITE 1; HPV18I1__:__PAPILLOMAVIRUS TYPE 18 INTEGRATION SITE 1__:__
NULL__:__167960__:__HUMAN PAPILLOMAVIRUS TYPE 18 INTEGRATION SITE 2; HPV18I2__:__PAPILLOMAVIRUS TYPE 18 INTEGRATION SITE 2__:__
Number Sign__:__168000__:__PARAGANGLIOMAS 1; PGL1__:__PARAGANGLIOMAS, FAMILIAL, 1;; PARAGANGLIOMATA; PGL;; GLOMUS TUMORS, FAMILIAL, 1;; CHEMODECTOMAS;; CAROTID BODY TUMORS; CBT1;; GLOMUS JUGULARE TUMORS;; PARAGANGLIOMA, CAROTID BODY;; PARAGANGLIOMAS, FAMILIAL NONCHROMAFFIN, 1__:__PARAGANGLIOMAS WITH SENSORINEURAL HEARING LOSS, INCLUDED
NULL__:__168100__:__PARALYSIS AGITANS, JUVENILE, OF HUNT__:__PARKINSON DISEASE, JUVENILE, OF HUNT__:__
NULL__:__168200__:__PARAMOLAR TUBERCLE OF BOLK__:__BOLK CUSP__:__
Number Sign__:__168300__:__PARAMYOTONIA CONGENITA OF VON EULENBURG; PMC__:__PARALYSIS PERIODICA PARAMYOTONICA__:__PARAMYOTONIA CONGENITA WITHOUT COLD PARALYSIS, INCLUDED
Caret__:__168350__:__MOVED TO 168300__:____:__
Asterisk__:__168360__:__EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA, HOMOLOG-LIKE 4; ELAVL4__:__HU-ANTIGEN D; HUD;; PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN; PNEM__:__
Number Sign__:__168400__:__PARASTREMMATIC DWARFISM__:____:__
Asterisk__:__168440__:__PARATHYMOSIN; PTMS__:____:__
Asterisk__:__168450__:__PARATHYROID HORMONE; PTH__:__PARATHYRIN;; PARATHORMONE__:__
Caret__:__168460__:__MOVED TO 145001__:____:__
Asterisk__:__168461__:__CYCLIN D1; CCND1__:__PARATHYROID ADENOMATOSIS 1; PRAD1;; B-CELL CLL/LYMPHOMA 1; BCL1;; B-CELL LEUKEMIA 1__:__CCND1/IGHG1 FUSION GENE, INCLUDED;; CCND1/PTH FUSION GENE, INCLUDED;; CCND1/IGLC1 FUSION GENE, INCLUDED;; CCND1/FSTL3 FUSION GENE, INCLUDED
Asterisk__:__168468__:__PARATHYROID HORMONE 1 RECEPTOR; PTH1R__:__PARATHYROID HORMONE RECEPTOR 1; PTHR1;; PTH RECEPTOR; PTHR;; PARATHYROID HORMONE/PARATHYROID HORMONE-RELATED PROTEIN RECEPTOR;; PTH/PTHRP RECEPTOR__:__
Asterisk__:__168470__:__PARATHYROID HORMONE-LIKE HORMONE; PTHLH__:__PARATHYROID HORMONE-RELATED PROTEIN; PTHRP;; PTH-RELATED PROTEIN;; PTHR, FORMERLY__:__
Number Sign__:__168500__:__PARIETAL FORAMINA 1; PFM1__:__PFM;; PARIETAL FORAMINA, SYMMETRIC;; FORAMINA PARIETALIA PERMAGNA; FPP;; CATLIN MARKS;; CRANIUM BIFIDUM OCCULTUM;; CRANIUM BIFIDUM, HEREDITARY__:__
Number Sign__:__168550__:__PARIETAL FORAMINA WITH CLEIDOCRANIAL DYSPLASIA; PFMCCD__:__CLEIDOCRANIAL DYSPLASIA WITH PARIETAL FORAMINA__:__
Number Sign__:__168600__:__PARKINSON DISEASE, LATE-ONSET; PD__:__PARK__:__
Number Sign__:__168601__:__PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1__:__PARKINSON DISEASE 1, AUTOSOMAL DOMINANT LEWY BODY__:__ATYPICAL PARKINSON DISEASE, INCLUDED
Number Sign__:__168605__:__PERRY SYNDROME__:__PARKINSONISM WITH ALVEOLAR HYPOVENTILATION AND MENTAL DEPRESSION__:__
Caret__:__168610__:__MOVED TO 600274__:____:__
NULL__:__168710__:__PAROTID PROLINE-RICH SALIVARY PROTEIN Pc__:____:__
Asterisk__:__168730__:__PROLINE-RICH PROTEIN, HaeIII SUBFAMILY, 1; PRH1__:__PAROTID ACIDIC PROTEIN; Pa;; ACIDIC SALIVARY PROLINE-RICH PROTEIN, HaeIII TYPE, 1__:__PAROTID ISOELECTRIC FOCUSING VARIANT PROTEIN, INCLUDED; PIF, INCLUDED;; PAROTID DOUBLE-BAND PROTEIN, INCLUDED; Db, INCLUDED
Asterisk__:__168790__:__PROLINE-RICH PROTEIN, HaeIII SUBFAMILY, 2; PRH2__:__PAROTID PROLINE-RICH PROTEIN; Pr;; ACIDIC SALIVARY PROLINE-RICH PROTEIN, HaeIII TYPE, 2__:__
NULL__:__168800__:__PAROTIDOMEGALY, HEREDITARY BILATERAL__:____:__
Asterisk__:__168810__:__PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 2; PRB2__:__PAROTID SALIVARY PROTEIN SIZE VARIANT; Ps;; BASIC SALIVARY PROLINE-RICH PROTEIN, BstNI TYPE, 2__:__CON1, INCLUDED
Plus__:__168820__:__PARAOXONASE 1; PON1__:__PON;; PARAOXONASE, PLASMA;; ARYLESTERASE;; ESTERASE A; ESA__:__PON1 ENZYME ACTIVITY, VARIATION IN, INCLUDED;; ORGANOPHOSPHATE POISONING, SUSCEPTIBILITY TO, INCLUDED;; CORONARY ARTERY DISEASE, SUSCEPTIBILITY TO, INCLUDED;; CORONARY ARTERY SPASM 2, SUSCEPTIBILITY TO, INCLUDED
NULL__:__168830__:__PASSOVOY FACTOR DEFECT__:____:__
Asterisk__:__168840__:__PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 3; PRB3__:__PAROTID SALIVARY GLYCOPROTEIN; G1;; BASIC SALIVARY PROLINE-RICH PROTEIN, BstNI TYPE, 3__:__
Caret__:__168850__:__MOVED TO 147891__:____:__
Percent__:__168860__:__PATELLA APLASIA-HYPOPLASIA; PTLAH__:____:__
NULL__:__168885__:__PAROXYSMAL TONIC UPGAZE, BENIGN CHILDHOOD, WITH ATAXIA__:____:__
Asterisk__:__168890__:__PARVALBUMIN; PVALB__:____:__
Percent__:__168900__:__PATELLA, CHONDROMALACIA OF__:____:__
Percent__:__169000__:__PATELLA, FAMILIAL RECURRENT DISLOCATION OF__:____:__
Number Sign__:__169100__:__CHAR SYNDROME; CHAR__:__PATENT DUCTUS ARTERIOSUS WITH FACIAL DYSMORPHISM AND ABNORMAL FIFTH DIGITS__:__
Number Sign__:__169150__:__MACULAR DYSTROPHY, PATTERNED, 1; MDPT1__:__PATTERNED DYSTROPHY OF RETINAL PIGMENT EPITHELIUM;; MACULAR DYSTROPHY, BUTTERFLY-SHAPED PIGMENTARY;; BUTTERFLY DYSTROPHY OF RETINAL PIGMENT EPITHELIUM__:__
NULL__:__169170__:__PATTERSON PSEUDOLEPRECHAUNISM SYNDROME__:____:__
Asterisk__:__169190__:__CYCLIN-DEPENDENT KINASE 18; CDK18__:__PCTAIRE PROTEIN KINASE 3; PCTK3;; PCTAIRE3__:__
NULL__:__169200__:__PECHET FACTOR DEFICIENCY__:__DYNIA FACTOR DEFICIENCY__:__
NULL__:__169300__:__PECTUS EXCAVATUM__:__FUNNEL CHEST__:__
Number Sign__:__169400__:__PELGER-HUET ANOMALY; PHA__:____:__
Number Sign__:__169500__:__LEUKODYSTROPHY, DEMYELINATING, ADULT-ONSET, AUTOSOMAL DOMINANT; ADLD__:__PELIZAEUS-MERZBACHER DISEASE, AUTOSOMAL DOMINANT OR LATE-ONSET TYPE, FORMERLY__:__
Percent__:__169545__:__PELVIC LIPOMATOSIS WITH CROSSED RENAL ECTOPIA__:____:__
NULL__:__169550__:__PELVIS-SHOULDER DYSPLASIA__:__KOSENOW SYNDROME;; SCAPULOILIAC DYSOSTOSIS__:__
Number Sign__:__169600__:__BENIGN CHRONIC PEMPHIGUS; BCPM__:__PEMPHIGUS, BENIGN FAMILIAL;; HAILEY-HAILEY DISEASE; HHD__:__
NULL__:__169610__:__PEMPHIGUS VULGARIS, FAMILIAL__:____:__
Asterisk__:__169615__:__DESMOGLEIN 3; DSG3__:__PEMPHIGUS VULGARIS ANTIGEN; PVA__:__
Asterisk__:__169700__:__PEPSINOGEN; PG__:__PEPSINOGEN A; PGA;; PEPSINOGEN, GROUP I;; UROPEPSINOGEN, GROUP A__:__
NULL__:__169710__:__PEPSINOGEN 3, GROUP I; PGA3__:__PEPSINOGEN I--SECOND LOCUS__:__
Asterisk__:__169720__:__PEPSINOGEN 4, GROUP I; PGA4__:____:__
Asterisk__:__169730__:__PEPSINOGEN 5, GROUP I; PGA5__:____:__
Asterisk__:__169740__:__PROGASTRICSIN; PGC__:__PEPSINOGEN C GASTRICSIN;; PEPSINOGEN, GROUP II__:__
Asterisk__:__169800__:__PEPTIDASE A; PEPA__:__CARNOSINASE 2; CN2;; CNDP2;; NONSPECIFIC DIPEPTIDASE, CYTOSOLIC;; CARNOSINASE, TISSUE__:__
Asterisk__:__169900__:__PEPTIDASE B; PEPB__:____:__
Asterisk__:__170000__:__PEPTIDASE C; PEPC__:____:__
Number Sign__:__170100__:__PROLIDASE DEFICIENCY__:____:__
Asterisk__:__170200__:__PEPTIDASE E; PEPE__:____:__
Asterisk__:__170250__:__LEUCINE AMINOPEPTIDASE 3; LAP3__:__PEPTIDASE S; PEPS__:__
Asterisk__:__170260__:__TRANSPORTER, ATP-BINDING CASSETTE, MAJOR HISTOCOMPATIBILITY COMPLEX, 1; TAP1__:__TRANSPORTER, ABC, MHC, 1;; ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 2; ABCB2;; ATP-BINDING CASSETTE TRANSPORTER, MAJOR HISTOCOMPATIBILITY COMPLEX, 1;; ABC TRANSPORTER, MHC, 1;; PEPTIDE TRANSPORTER PSF1;; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;; PEPTIDE SUPPLY FACTOR 1; PSF1;; ANTIGEN PEPTIDE TRANSPORTER 1; APT1;; RING4__:__
Asterisk__:__170261__:__TRANSPORTER, ATP-BINDING CASSETTE, MAJOR HISTOCOMPATIBILITY COMPLEX, 2; TAP2__:__TRANSPORTER, ABC, MHC, 2;; ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 3; ABCB3;; ATP-BINDING CASSETTE TRANSPORTER, MAJOR HISTOCOMPATIBILITY COMPLEX, 2;; ABC TRANSPORTER, MHC, 2;; RING11;; PEPTIDE SUPPLY FACTOR 2; PSF2;; PEPTIDE TRANSPORTER PSF2;; ANTIGEN PEPTIDE TRANSPORTER 2; APT2__:__
Asterisk__:__170270__:__PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE; PAM__:____:__
Asterisk__:__170280__:__PERFORIN 1; PRF1__:__PFN1;; PORE-FORMING PROTEIN; PFP__:__
Asterisk__:__170285__:__NUCLEOPORIN, 85-KD; NUP85__:__NUCLEOPORIN, 75-KD; NUP75;; FLJ12549;; FROUNT;; PERICENTRIN, FORMERLY; PCNT, FORMERLY__:__
Asterisk__:__170290__:__PERILIPIN 1; PLIN1__:__PLIN__:__
Caret__:__170300__:__MOVED TO 142680__:____:__
Number Sign__:__170390__:__ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS__:__ANDERSEN SYNDROME;; LONG QT SYNDROME 7; LQT7;; ANDERSEN-TAWIL SYNDROME; ATS;; PERIODIC PARALYSIS, POTASSIUM-SENSITIVE CARDIODYSRHYTHMIC TYPE__:__
Number Sign__:__170400__:__HYPOKALEMIC PERIODIC PARALYSIS, TYPE 1; HOKPP1__:__HYPOKALEMIC PERIODIC PARALYSIS; HOKPP__:__
Number Sign__:__170500__:__HYPERKALEMIC PERIODIC PARALYSIS; HYPP__:__ADYNAMIA EPISODICA HEREDITARIA WITH OR WITHOUT MYOTONIA;; GAMSTORP DISEASE__:__NORMOKALEMIC PERIODIC PARALYSIS, POTASSIUM-SENSITIVE, INCLUDED
NULL__:__170600__:__NORMOKALEMIC PERIODIC PARALYSIS__:____:__
Number Sign__:__170650__:__PERIODONTITIS, AGGRESSIVE, 1__:__PERIODONTITIS, JUVENILE; JPD; JP;; PERIODONTITIS, PREPUBERTAL; PPP__:__
NULL__:__170700__:__PERIPHERAL DYSOSTOSIS__:____:__
Asterisk__:__170710__:__PERIPHERIN; PRPH__:____:__
Asterisk__:__170715__:__PERIPHERAL MYELIN PROTEIN 2; PMP2__:__MYELIN P2 PROTEIN; MP2__:__
NULL__:__170900__:__PERNICIOUS ANEMIA__:____:__
Caret__:__170950__:__REMOVED FROM DATABASE__:____:__
NULL__:__170980__:__PERONEAL NERVE, ACCESSORY DEEP__:____:__
NULL__:__170990__:__PEROXIDASE, SALIVARY; SAPX__:____:__
Asterisk__:__170993__:__PEROXISOME BIOGENESIS FACTOR 2; PEX2__:__PEROXISOMAL MEMBRANE PROTEIN 3; PXMP3;; PEROXISOMAL MEMBRANE PROTEIN, 35-KD; PMP35;; PEROXISOMAL ASSEMBLY FACTOR 1; PAF1;; PEROXIN 2__:__
Asterisk__:__170995__:__ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 3; ABCD3__:__PEROXISOMAL MEMBRANE PROTEIN 1; PXMP1;; PEROXISOMAL MEMBRANE PROTEIN, 70-KD; PMP70__:__
Plus__:__170998__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA; PPARA__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PPAR__:__HYPERAPOBETALIPOPROTEINEMIA, SUSCEPTIBILITY TO, INCLUDED
Percent__:__171000__:__PEYRONIE DISEASE__:____:__
Asterisk__:__171050__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 1; ABCB1__:__P-GLYCOPROTEIN 1; PGY1;; MULTIDRUG RESISTANCE 1; MDR1;; GP170;; DOXORUBICIN RESISTANCE__:__
Asterisk__:__171060__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 4; ABCB4__:__P-GLYCOPROTEIN 3; PGY3;; MULTIDRUG RESISTANCE 3; MDR3__:__
NULL__:__171100__:__PHAGOCYTOSIS, PLASMA-RELATED DEFECT IN__:____:__
Asterisk__:__171150__:__SULFOTRANSFERASE FAMILY 1A, CYTOSOLIC, PHENOL-PREFERRING, MEMBER 1; SULT1A1__:__SULFOTRANSFERASE, PHENOL-PREFERRING 1; STP1;; PHENOL SULFOTRANSFERASE, THERMOSTABLE FORM; STP;; ST1A3;; PHENOL SULFOTRANSFERASE; PPST__:__
Asterisk__:__171190__:__PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PNMT__:__PENT__:__
Number Sign__:__171200__:__THIOUREA TASTING; THIOT__:____:__PHENYLTHIOCARBAMIDE TASTING, INCLUDED;; PTC TASTING, INCLUDED;; PROPYLTHIOURACIL TASTING, INCLUDED;; PROP TASTING, INCLUDED
Number Sign__:__171300__:__PHEOCHROMOCYTOMA__:__PHEOCHROMOCYTOMA, SUSCEPTIBILITY TO__:__
Caret__:__171350__:__MOVED TO 115310__:____:__
Number Sign__:__171400__:__MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A__:__PHEOCHROMOCYTOMA AND AMYLOID-PRODUCING MEDULLARY THYROID CARCINOMA;; PTC SYNDROME;; SIPPLE SYNDROME__:__THYROID CARCINOMA, FAMILIAL MEDULLARY, INCLUDED
NULL__:__171420__:__PHEOCHROMOCYTOMA--ISLET CELL TUMOR SYNDROME__:____:__
NULL__:__171450__:__PHLEBECTASIA OF LIPS__:____:__
NULL__:__171480__:__PHOCOMELIA-ECTRODACTYLY, EAR MALFORMATION, DEAFNESS, AND SINUS ARRHYTHMIA__:__FACIOAURICULORADIAL DYSPLASIA__:__
Asterisk__:__171490__:__PHOSDUCIN; PDC__:____:__
Asterisk__:__171500__:__ACID PHOSPHATASE 1, SOLUBLE; ACP1__:__PHOSPHATASE, ACID, OF ERYTHROCYTE__:__
Asterisk__:__171640__:__PHOSPHATASE, ACID, TYPE 5, TARTRATE-RESISTANT; ACP5__:__TARTRATE-RESISTANT ACID PHOSPHATASE; TRAP__:__
Asterisk__:__171650__:__ACID PHOSPHATASE 2, LYSOSOMAL; ACP2__:__PHOSPHATASE, ACID, OF TISSUES;; LYSOSOMAL ACID PHOSPHATASE;; ACP2--BETA POLYPEPTIDE__:__
NULL__:__171660__:__PHOSPHATASE, ACID, OF TISSUES__:__LYSOSOMAL ACID PHOSPHATASE;; ACP3--ALPHA POLYPEPTIDE__:__
Caret__:__171700__:__REMOVED FROM DATABASE__:____:__
Percent__:__171720__:__ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1__:__ALPQTL1;; ALKALINE PHOSPHATASE, ELEVATED SERUM;; HYPERPHOSPHATASEMIA, BENIGN FAMILIAL__:__
Asterisk__:__171740__:__ALKALINE PHOSPHATASE, INTESTINAL; ALPI__:__IAP__:__
Asterisk__:__171750__:__ALKALINE PHOSPHATASE, INTESTINAL, FETAL FORM__:__ALPIF__:__
Asterisk__:__171760__:__ALKALINE PHOSPHATASE, LIVER; ALPL__:__ALKALINE PHOSPHATASE, LIVER/BONE/KIDNEY TYPE;; ALKALINE PHOSPHATASE, TISSUE-NONSPECIFIC; TNSALP; TNAP__:__
Asterisk__:__171790__:__PHOSPHATASE, PROSTATE-SPECIFIC ACID; ACPP__:__PROSTATIC ACID PHOSPHATASE; PAP__:__
Asterisk__:__171800__:__ALKALINE PHOSPHATASE, PLACENTAL; ALPP__:__PLAP; PALP;; REGAN ISOZYME__:__SECRETED ALKALINE PHOSPHATASE, INCLUDED; SEAP, INCLUDED;; ALKALINE PHOSPHATASE, SECRETED, INCLUDED
Asterisk__:__171810__:__ALKALINE PHOSPHATASE, PLACENTAL-LIKE 2; ALPPL2__:__ALKALINE PHOSPHATASE, GERM CELL; ALPG; GCAP;; ALKALINE PHOSPHATASE, TESTICULAR AND THYMUS;; NAGAO ISOENZYME__:__
Asterisk__:__171820__:__PHOSPHATASE, SALIVARY ACID, A; SACP; ACPS__:____:__
Asterisk__:__171830__:__PHOSPHATASE, SALIVARY ACID, B__:____:__
Asterisk__:__171833__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 1; PIK3R1__:__PHOSPHATIDYLINOSITOL 3-KINASE-ASSOCIATED p85-ALPHA; GRB1;; PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT, 85-KD, ALPHA;; p85-ALPHA__:__
Asterisk__:__171834__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, ALPHA; PIK3CA__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, ALPHA;; p110-ALPHA;; PI3K-ALPHA;; PIK3-ALPHA__:__
Asterisk__:__171835__:__6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 2; PFKFB2__:__PFKFB, CARDIAC__:__
Asterisk__:__171840__:__PHOSPHOFRUCTOKINASE, PLATELET TYPE; PFKP__:__PFK, PLATELET TYPE;; PFK, FIBROBLAST TYPE; PFKF__:__
Caret__:__171850__:__MOVED TO 171860 AND 610681__:____:__
Asterisk__:__171860__:__PHOSPHOFRUCTOKINASE, LIVER TYPE; PFKL__:__PFK, LIVER TYPE__:__
Caret__:__171880__:__MOVED TO 610681__:____:__
Asterisk__:__171885__:__PHOSPHODIESTERASE 7A, cAMP-SPECIFIC, HIGH AFFINITY; PDE7A__:__PDE1/PDE2, YEAST, HUMAN COMPLEMENT OF; HCP1__:__
Asterisk__:__171890__:__PHOSPHODIESTERASE 1A; PDE1A__:__HCAM1__:__
Asterisk__:__171891__:__PHOSPHODIESTERASE 1B; PDE1B__:__PDE1B1__:__
Asterisk__:__171900__:__PHOSPHOGLUCOMUTASE 1; PGM1__:____:__
Asterisk__:__172000__:__PHOSPHOGLUCOMUTASE 2; PGM2__:____:__
Asterisk__:__172100__:__PHOSPHOGLUCOMUTASE 3; PGM3__:__N-ACETYLGLUCOSAMINE-PHOSPHATE MUTASE 1; AGM1__:__
NULL__:__172110__:__PHOSPHOGLUCOMUTASE 4__:__PGM4;; MILK PGM__:__
Percent__:__172150__:__6-PHOSPHOGLUCONOLACTONASE DEFICIENCY__:__PGLS DEFICIENCY;; 6PGL DEFICIENCY__:__
Asterisk__:__172200__:__6-PHOSPHOGLUCONATE DEHYDROGENASE, ERYTHROCYTE; PGD__:__PGD, ERYTHROCYTE; 6PGD__:__
Asterisk__:__172250__:__PHOSPHOGLYCERATE MUTASE 1; PGAM1__:__PHOSPHOGLYCERATE MUTASE A; PGAMA;; PHOSPHOGLYCERATE MUTASE, BRAIN; PGAMB__:__
Asterisk__:__172270__:__PHOSPHOGLYCERATE KINASE 2; PGK2__:__PHOSPHOGLYCERATE KINASE OF SPERMATOZOA; PGKB;; PGK, TESTICULAR__:__
Asterisk__:__172280__:__PHOSPHOGLYCOLATE PHOSPHATASE; PGP__:____:__
NULL__:__172290__:__PHOSPHOGLYCOPROTEIN 1; PGP1__:____:__
Caret__:__172300__:__MOVED TO 171860__:____:__
Asterisk__:__172400__:__GLUCOSE-6-PHOSPHATE ISOMERASE; GPI__:__GLUCOSE PHOSPHATE ISOMERASE;; PHOSPHOHEXOSE ISOMERASE; PHI;; PHOSPHOGLUCOSE ISOMERASE; PGI;; AUTOCRINE MOTILITY FACTOR; AMF;; NEUROLEUKIN; NLK__:__
Asterisk__:__172405__:__PHOSPHOLAMBAN; PLN__:____:__
Asterisk__:__172410__:__PHOSPHOLIPASE A2, GROUP IB; PLA2G1B__:__PHOSPHOLIPASE A2, PANCREATIC;; PHOSPHOLIPASE A2 POLYPEPTIDE A; PLA2A;; PLA2__:__
Asterisk__:__172411__:__PHOSPHOLIPASE A2, GROUP IIA; PLA2G2A__:__PHOSPHOLIPASE A2, SYNOVIAL; PLA2S; PLAS1;; PHOSPHOLIPASE A2 POLYPEPTIDE B; PLA2B;; MODIFIER OF MIN-1, MOUSE, HOMOLOG OF; MOM1__:__
Asterisk__:__172420__:__PHOSPHOLIPASE C, GAMMA-1; PLCG1__:__PLC1;; PHOSPHOLIPASE C-148; PLC148__:__
Plus__:__172425__:__PHOSPHOLIPID TRANSFER PROTEIN; PLTP__:__LIPID TRANSFER PROTEIN II__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 9, INCLUDED; HDLCQ9, INCLUDED
Asterisk__:__172430__:__ENOLASE 1; ENO1__:__ENOLASE, ALPHA;; PHOSPHOPYRUVATE HYDRATASE; PPH__:__CRYSTALLIN, TAU, INCLUDED;; ENOLASE, NONNEURONAL, INCLUDED; NNE, INCLUDED
Asterisk__:__172439__:__PHOSPHORIBOSYLAMINOIMIDAZOLE CARBOXYLASE; PAICS__:__AIR CARBOXYLASE; AIRC;; SAICAR SYNTHETASE__:__
Asterisk__:__172450__:__PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; PPAT__:__GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; GPAT__:__
Asterisk__:__172460__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE 1; MTHFD1__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE/METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE/FORMYLTETRAHYDROFOLATE SYNTHETASE, NADP(+)-DEPENDENT;; CYCLOHYDROLASE/FORMYLTETRAHYDROFOLATE SYNTHETASE, NADP(+)-DEPENDENT;; C1-TETRAHYDROFOLATE SYNTHASE, CYTOPLASMIC;; C1-THF-SYNTHASE__:__
Asterisk__:__172470__:__PHOSPHORYLASE KINASE, MUSCLE, GAMMA-1; PHKG1__:____:__
Asterisk__:__172471__:__PHOSPHORYLASE KINASE, TESTIS/LIVER, GAMMA-2; PHKG2__:____:__
Asterisk__:__172480__:__PHOSPHOSERINE PHOSPHATASE; PSPH__:__PSP__:__
Asterisk__:__172490__:__PHOSPHORYLASE KINASE, BETA SUBUNIT; PHKB__:____:__
NULL__:__172500__:__PHOTOMYOCLONUS, DIABETES MELLITUS, DEAFNESS, NEPHROPATHY, AND CEREBRAL DYSFUNCTION__:__HERRMANN SYNDROME__:__
Number Sign__:__172700__:__PICK DISEASE OF BRAIN__:__LOBAR ATROPHY OF BRAIN;; DEMENTIA WITH LOBAR ATROPHY AND NEURONAL CYTOPLASMIC INCLUSIONS__:__
Number Sign__:__172800__:__PIEBALD TRAIT; PBT__:__PIEBALDISM__:__
NULL__:__172850__:__PIEBALD TRAIT WITH NEUROLOGIC DEFECTS__:____:__
Asterisk__:__172860__:__SERPIN PEPTIDASE INHIBITOR, CLADE F, MEMBER 1; SERPINF1__:__PIGMENT EPITHELIUM-DERIVED FACTOR; PEDF__:__
Number Sign__:__172870__:__PIGMENTED PARAVENOUS CHORIORETINAL ATROPHY; PPCRA__:____:__
NULL__:__172880__:__PIERRE ROBIN SYNDROME AND OLIGODACTYLY__:__ROBIN SEQUENCE AND OLIGODACTYLY__:__
Percent__:__172900__:__PIGMENTED PURPURIC ERUPTION__:____:__
NULL__:__173000__:__PILONIDAL SINUS__:____:__
Number Sign__:__173100__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE II; IGHD2__:__IGHD II;; GROWTH HORMONE DEFICIENCY, ISOLATED, AUTOSOMAL DOMINANT;; PITUITARY DWARFISM DUE TO ISOLATED GROWTH HORMONE DEFICIENCY, AUTOSOMAL DOMINANT__:__
Asterisk__:__173110__:__POU DOMAIN, CLASS 1, TRANSCRIPTION FACTOR 1; POU1F1__:__PITUITARY-SPECIFIC TRANSCRIPTION FACTOR 1; PIT1;; GROWTH HORMONE FACTOR 1; GHF1__:__
Asterisk__:__173120__:__SECRETORY GRANULE NEUROENDOCRINE PROTEIN 1; SGNE1__:__PITUITARY POLYPEPTIDE 7B2; P7B2;; SECRETOGRANIN V__:__
Number Sign__:__173200__:__PITYRIASIS RUBRA PILARIS; PRP__:____:__
Asterisk__:__173310__:__PROGESTAGEN-ASSOCIATED ENDOMETRIAL PROTEIN; PAEP__:__PROGESTAGEN-DEPENDENT ENDOMETRIAL PROTEIN;; PREGNANCY-ASSOCIATED ENDOMETRIAL ALPHA-2-GLOBULIN;; PLACENTAL PROTEIN 14; PP14;; GLYCODELIN-A; GdA;; GLYCODELIN-S; GdS__:__BETA-LACTOGLOBULIN, INCLUDED
Asterisk__:__173320__:__RIBONUCLEASE/ANGIOGENIN INHIBITOR 1; RNH1__:__RNH;; RIBONUCLEASE INHIBITOR; RI;; PLACENTAL RIBONUCLEASE INHIBITOR; PRI;; CYTOSOLIC RIBONUCLEASE INHIBITOR; CRI__:__
Asterisk__:__173321__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 6; SERPINB6__:__PROTEASE INHIBITOR 6; PI6;; PLACENTAL THROMBIN INHIBITOR; PTI;; SPI3, MOUSE, HOMOLOG OF; SPI3__:__
Asterisk__:__173325__:__JUNCTION PLAKOGLOBIN; JUP__:__PLAKOGLOBIN; PKGB;; DESMOPLAKIN III; DP3;; DP III;; CATENIN, GAMMA__:__
Asterisk__:__173335__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1; ENPP1__:__PHOSPHODIESTERASE I/NUCLEOTIDE PYROPHOSPHATASE 1; PDNP1;; PLASMA CELL MEMBRANE GLYCOPROTEIN PC-1; PC1;; PCA1;; MEMBRANE COMPONENT, CHROMOSOME 6, SURFACE MARKER 1; M6S1;; LY41, MOUSE, HOMOLOG OF;; ALKALINE PHOSPHODIESTERASE I;; NUCLEOTIDE PYROPHOSPHATASE; NPPS__:__
Asterisk__:__173340__:__PLASMINOGEN-LIKE B1; PLGLB1__:__PLASMINOGEN-RELATED GENE B; PRGB__:__
Asterisk__:__173350__:__PLASMINOGEN; PLG__:____:__ANGIOSTATIN, INCLUDED;; MICROPLASMIN, INCLUDED
Asterisk__:__173360__:__SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1; SERPINE1__:__PLASMINOGEN ACTIVATOR INHIBITOR 1; PAI1;; ENDOTHELIAL PLASMINOGEN ACTIVATOR INHIBITOR__:__
Asterisk__:__173370__:__PLASMINOGEN ACTIVATOR, TISSUE; PLAT__:__TPA__:__
Asterisk__:__173390__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 2; SERPINB2__:__PLASMINOGEN ACTIVATOR INHIBITOR, TYPE 2; PAI2;; PLANH2;; MONOCYTE ARGININE-SERPIN;; MONOCYTE-DERIVED PLASMINOGEN ACTIVATOR INHIBITOR;; UROKINASE INHIBITOR__:__
Asterisk__:__173391__:__PLASMINOGEN ACTIVATOR RECEPTOR, UROKINASE-TYPE; PLAUR__:__UPA RECEPTOR; UPAR;; CD87 ANTIGEN; CD87__:__
Asterisk__:__173393__:__PLATELET-ACTIVATING FACTOR RECEPTOR; PTAFR__:__PAFR__:__
NULL__:__173395__:__PLATELET ADENYLATE CYCLASE ACTIVITY__:____:__
NULL__:__173400__:__PLATELET AGGREGATION, SPONTANEOUS__:____:__
Asterisk__:__173410__:__PLATELET-DERIVED GROWTH FACTOR RECEPTOR, BETA; PDGFRB__:__PDGFR;; PDGFR1__:__PDGFRB/ETV6 FUSION GENE, INCLUDED;; PDGFRB/D10S170 FUSION GENE, INCLUDED;; PDGFRB/RABPT5 FUSION GENE, INCLUDED;; PDGFRB/HIP1 FUSION GENE, INCLUDED;; PDGFRB/MYO18A FUSION GENE, INCLUDED
NULL__:__173420__:__PLATELET DISORDER, UNDEFINED__:____:__
Asterisk__:__173430__:__PLATELET-DERIVED GROWTH FACTOR, ALPHA POLYPEPTIDE; PDGFA__:__PLATELET-DERIVED GROWTH FACTOR, A CHAIN__:__
Asterisk__:__173445__:__PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1; PECAM1__:__CD31__:__
NULL__:__173450__:__PLATELET FACTOR 3 DEFICIENCY__:____:__
Asterisk__:__173460__:__PLATELET FACTOR 4; PF4__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 4; SCYB4;; CHEMOKINE, CXC MOTIF, LIGAND 4; CXCL4__:__
Asterisk__:__173461__:__PLATELET FACTOR 4, VARIANT 1; PF4V1__:__PLATELET FACTOR 4-ALTERNATE; PF4A;; PF4-ALT;; CXCL4-LIKE 1; CXCL4L1;; CXCL4 VARIANT 1; CXCL4V1__:__
Asterisk__:__173470__:__INTEGRIN, BETA-3; ITGB3__:__PLATELET GLYCOPROTEIN IIIa; GP3A;; GP IIIa;; PLATELET FIBRINOGEN RECEPTOR, BETA SUBUNIT;; CD61__:__
Asterisk__:__173490__:__PLATELET-DERIVED GROWTH FACTOR RECEPTOR, ALPHA; PDGFRA__:__PDGFR2__:__PDGFRA/BCR FUSION GENE, INCLUDED;; PDGFRA/FIP1L1 FUSION GENE, INCLUDED
Percent__:__173500__:__PLATELET GROUPS--Ko SYSTEM; HPA-2__:____:__SIB(a), INCLUDED
Asterisk__:__173510__:__CD36 ANTIGEN; CD36__:__LEUKOCYTE DIFFERENTIATION ANTIGEN CD36;; PLATELET GLYCOPROTEIN IV; GP4;; GLYCOPROTEIN IIIb; GP3B;; GP IIIb;; THROMBOSPONDIN RECEPTOR;; COLLAGEN RECEPTOR, PLATELET;; FATTY ACID TRANSLOCASE; FAT__:__
Asterisk__:__173511__:__GLYCOPROTEIN V, PLATELET; GP5__:__PLATELET GLYCOPROTEIN V;; GP V__:__
Asterisk__:__173515__:__GLYCOPROTEIN IX, PLATELET; GP9__:__PLATELET GLYCOPROTEIN IX;; GP IX__:__
Percent__:__173540__:__PLATELET GROUPS--Pl(E) SYSTEM__:____:__
NULL__:__173560__:__PLATELET MEMBRANE FLUIDITY; PMF__:____:__
Asterisk__:__173570__:__PLECKSTRIN; PLEK__:__PLATELET P47;; PLATELET AND LEUKOCYTE C KINASE SUBSTRATE__:__
NULL__:__173580__:__PLATELET RESPONSIVENESS TO ADRENALINE, DEPRESSED__:____:__
NULL__:__173590__:__PLATELET SIGNAL PROCESSING DEFECT__:____:__
Number Sign__:__173600__:__PNEUMOTHORAX, PRIMARY SPONTANEOUS__:__PSP__:__
Asterisk__:__173610__:__SELECTIN P; SELP__:__PLATELET ALPHA-GRANULE MEMBRANE PROTEIN;; CD62;; GRANULOCYTE MEMBRANE PROTEIN; GRMP;; GMP140;; P-SELECTIN__:__
Number Sign__:__173650__:__KINDLER SYNDROME; KNDLRS__:__POIKILODERMA, HEREDITARY ACROKERATOTIC;; BULLOUS ACROKERATOTIC POIKILODERMA OF KINDLER AND WEARY;; POIKILODERMA, CONGENITAL, WITH BULLAE, WEARY TYPE__:__
NULL__:__173700__:__POIKILODERMA, HEREDITARY SCLEROSING__:____:__
Caret__:__173750__:__MOVED TO 173800 AND 157900__:____:__
Percent__:__173800__:__POLAND SYNDROME__:__POLAND SYNDACTYLY;; POLAND ANOMALY;; POLAND SEQUENCE__:__PECTORALIS MUSCLE, ABSENCE OF, INCLUDED
Asterisk__:__173850__:__POLIOVIRUS RECEPTOR; PVR__:__PVS;; CD155;; NECTIN-LIKE PROTEIN 5; NECL5__:__
Caret__:__173865__:__MOVED TO 604680__:____:__
Asterisk__:__173870__:__POLY(ADP-RIBOSE) POLYMERASE 1; PARP1__:__POLY(ADP-RIBOSE) POLYMERASE; PPOL; PARP;; POLY(ADP-RIBOSE) SYNTHETASE;; ADP-RIBOSYLTRANSFERASE; ADPRT;; ADPRT1__:__
Caret__:__173871__:__MOVED TO 173870__:____:__
Asterisk__:__173880__:__POLYMERIC IMMUNOGLOBULIN RECEPTOR; PIGR__:__POLY-Ig RECEPTOR;; TRANSMEMBRANE SECRETORY COMPONENT__:__
Number Sign__:__173900__:__POLYCYSTIC KIDNEY DISEASE 1 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD1__:__POLYCYSTIC KIDNEY DISEASE, ADULT; ADPKD;; POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE I; APKD1;; POTTER TYPE III POLYCYSTIC KIDNEY DISEASE, FORMERLY__:__
Asterisk__:__173910__:__POLYCYSTIN 2; PKD2__:__PKD2 GENE;; PC2;; TRPP2__:__
Number Sign__:__174000__:__MEDULLARY CYSTIC KIDNEY DISEASE 1; MCKD1__:__MCKD;; MEDULLARY CYSTIC KIDNEY DISEASE, AUTOSOMAL DOMINANT; ADMCKD1;; POLYCYSTIC KIDNEYS, MEDULLARY TYPE__:__
Number Sign__:__174050__:__POLYCYSTIC LIVER DISEASE 1 WITH OR WITHOUT KIDNEY CYSTS; PCLD1__:____:__
Caret__:__174100__:__MOVED TO 192350__:____:__
Number Sign__:__174200__:__POLYDACTYLY, POSTAXIAL, TYPE A1; PAPA1__:__POSTAXIAL POLYDACTYLY, TYPE A; PAPA;; POLYDACTYLY, POSTAXIAL__:__POSTAXIAL POLYDACTYLY, TYPE B, INCLUDED; PAPB, INCLUDED
Number Sign__:__174300__:__OROFACIODIGITAL SYNDROME V; OFD5__:__OFDS V;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE V;; OROFACIODIGITAL SYNDROME, THURSTON TYPE;; THURSTON SYNDROME;; POLYDACTYLY, POSTAXIAL, WITH MEDIAN CLEFT OF UPPER LIP__:__
NULL__:__174310__:__POLYDACTYLY, POSTAXIAL, WITH PROGRESSIVE MYOPIA__:__POLYDACTYLY-MYOPIA SYNDROME; PMS__:__
Percent__:__174400__:__POLYDACTYLY, PREAXIAL I__:__THUMB POLYDACTYLY__:__THENAR HYPOPLASIA, INCLUDED;; FROMONT ANOMALY, INCLUDED
Number Sign__:__174500__:__POLYDACTYLY, PREAXIAL II; PPD2__:__POLYDACTYLY OF TRIPHALANGEAL THUMB;; TRIPHALANGEAL THUMB-POLYDACTYLY SYNDROME__:__TRIPHALANGEAL THUMB WITH POLYSYNDACTYLY, INCLUDED;; TRIPHALANGEAL THUMB-POLYSYNDACTYLY SYNDROME, INCLUDED;; TPT-PS SYNDROME, INCLUDED;; TRIPHALANGEAL THUMB, INCLUDED; TPT, INCLUDED
Percent__:__174600__:__POLYDACTYLY, PREAXIAL III__:__INDEX FINGER POLYDACTYLY__:__
Number Sign__:__174700__:__POLYDACTYLY, PREAXIAL IV__:__POLYSYNDACTYLY, UNCOMPLICATED__:__CROSSED POLYDACTYLY, TYPE I, INCLUDED; CP1, INCLUDED
NULL__:__174750__:__POLYKARYOCYTOSIS INDUCER; FUSE__:____:__
Asterisk__:__174760__:__POLYMERASE, DNA, BETA; POLB__:____:__
Asterisk__:__174761__:__POLYMERASE (DNA-DIRECTED), DELTA 1, CATALYTIC SUBUNIT; POLD1__:__POLYMERASE, DNA, DELTA; POLD__:__
Asterisk__:__174762__:__POLYMERASE, DNA, EPSILON; POLE__:__POLYMERASE, DNA, EPSILON-1; POLE1__:__
Asterisk__:__174763__:__POLYMERASE, DNA, GAMMA; POLG__:__POLYMERASE, DNA, GAMMA-1; POLG1;; POLG, CATALYTIC SUBUNIT;; POLG-ALPHA; POLGA__:__
Percent__:__174770__:__ACTINIC PRURIGO__:__POLYMORPHIC LIGHT ERUPTION, HEREDITARY; HPLE__:__JUVENILE SPRING ERUPTION OF EARS, INCLUDED
Number Sign__:__174800__:__MCCUNE-ALBRIGHT SYNDROME; MAS__:__ALBRIGHT SYNDROME__:__POLYOSTOTIC FIBROUS DYSPLASIA, INCLUDED; PFD, INCLUDED; POFD, INCLUDED
Number Sign__:__174810__:__FAMILIAL EXPANSILE OSTEOLYSIS; FEO__:__POLYOSTOTIC OSTEOLYTIC DYSPLASIA, HEREDITARY EXPANSILE; HEPOD;; MCCABE DISEASE;; EXPANSILE OSTEOLYSIS, FAMILIAL; EOF__:__
Asterisk__:__174880__:__LYMPHOCYTE CYTOSOL POLYPEPTIDE, 100-KD__:__LCP100;; CP100;; POLYPEPTIDE OF LYMPHOCYTE CYTOSOL, 100-KD; P0TLC100__:__
Number Sign__:__174900__:__JUVENILE POLYPOSIS SYNDROME; JPS__:__POLYPOSIS, JUVENILE INTESTINAL; PJI;; JUVENILE INTESTINAL POLYPOSIS; JIP;; POLYPOSIS, FAMILIAL, OF ENTIRE GASTROINTESTINAL TRACT__:__JUVENILE POLYPOSIS OF STOMACH, INCLUDED;; JUVENILE POLYPOSIS COLI, INCLUDED
Caret__:__175000__:__MOVED TO 174900__:____:__
Percent__:__175020__:__POLYPOSIS, GASTRIC__:____:__
Number Sign__:__175050__:__JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME; JPHT__:__JP/HHT SYNDROME;; JUVENILE POLYPOSIS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA;; JPS/HHT;; TELANGIECTASIA, HEREDITARY HEMORRHAGIC, WITH JUVENILE POLYPOSIS COLI;; POLYPOSIS, GENERALIZED JUVENILE, WITH PULMONARY ARTERIOVENOUS MALFORMATION__:__
Number Sign__:__175100__:__FAMILIAL ADENOMATOUS POLYPOSIS 1; FAP1__:__ADENOMATOUS POLYPOSIS OF THE COLON; APC;; FAMILIAL POLYPOSIS OF THE COLON; FPC;; POLYPOSIS, ADENOMATOUS INTESTINAL__:__GARDNER SYNDROME, INCLUDED; GS, INCLUDED;; BRAIN TUMOR-POLYPOSIS SYNDROME 2, INCLUDED; BTPS2, INCLUDED;; FAMILIAL ADENOMATOUS POLYPOSIS, ATTENUATED, INCLUDED; AFAP, INCLUDED;; ADENOMATOUS POLYPOSIS COLI, ATTENUATED, INCLUDED; AAPC, INCLUDED
Number Sign__:__175200__:__PEUTZ-JEGHERS SYNDROME; PJS__:__POLYPOSIS, HAMARTOMATOUS INTESTINAL;; POLYPS-AND-SPOTS SYNDROME__:__
NULL__:__175400__:__POLYPOSIS, INTESTINAL, SCATTERED AND DISCRETE__:__POLYPS, SCATTERED, DISCRETE INTESTINAL__:__
NULL__:__175450__:__POLYPOSIS, INTESTINAL, WITH MULTIPLE EXOSTOSES__:____:__
NULL__:__175500__:__POLYPOSIS, SKIN PIGMENTATION, ALOPECIA, AND FINGERNAIL CHANGES__:__CRONKHITE-CANADA SYNDROME__:__
NULL__:__175505__:__POLYPOSIS OF GASTRIC FUNDUS WITHOUT POLYPOSIS COLI__:__FUNDIC GLAND POLYPOSIS__:__
NULL__:__175510__:__POLYPS, MULTIPLE AND RECURRENT INFLAMMATORY FIBROID, GASTROINTESTINAL__:____:__
Percent__:__175690__:__POLYSYNDACTYLY, CROSSED__:____:__
Number Sign__:__175700__:__GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS__:__POLYSYNDACTYLY WITH PECULIAR SKULL SHAPE__:__
NULL__:__175750__:__POPLITEAL CYST__:__BAKER CYST__:__
Number Sign__:__175780__:__PORENCEPHALY 1; POREN1__:__HEMIPLEGIA, INFANTILE, WITH PORENCEPHALY PORENCEPHALY, TYPE 1; T1P;; PORENCEPHALY, TYPE 1, AUTOSOMAL DOMINANT; ADT1P__:__
Number Sign__:__175800__:__POROKERATOSIS 1, MULTIPLE TYPES; POROK1__:__POROKERATOSIS OF MIBELLI__:__
Percent__:__175850__:__POROKERATOSIS 2, PALMAR, PLANTAR, AND DISSEMINATED TYPE; POROK2__:__POROKERATOSIS, PALMAR, PLANTAR, AND DISSEMINATED; PPPD;; POROKERATOSIS, PALMAR, PLANTAR, AND DISSEMINATED, 1; PPPD1;; POROKERATOSIS PLANTARIS PALMARIS ET DISSEMINATA;; POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA__:__
Percent__:__175860__:__PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II; PPKP2__:__POROKERATOSIS PUNCTATA PALMARIS ET PLANTARIS; PPPP__:__
Number Sign__:__175900__:__POROKERATOSIS 3, MULTIPLE TYPES; POROK3__:__POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 1; DSAP1__:__
Number Sign__:__176000__:__PORPHYRIA, ACUTE INTERMITTENT; AIP__:__PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY__:__PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED
Caret__:__176010__:__MOVED TO 176000__:____:__
NULL__:__176090__:__PORPHYRIA CUTANEA TARDA, TYPE I__:__PCT, TYPE I;; PCT, 'SPORADIC' TYPE__:__
Number Sign__:__176100__:__PORPHYRIA CUTANEA TARDA__:__PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY__:__PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED
Number Sign__:__176200__:__PORPHYRIA VARIEGATA__:__VARIEGATE PORPHYRIA; VP;; PORPHYRIA, SOUTH AFRICAN TYPE;; PROTOPORPHYRINOGEN OXIDASE DEFICIENCY;; PPOX DEFICIENCY__:__VARIEGATE PORPHYRIA, HOMOZYGOUS VARIANT, INCLUDED
NULL__:__176240__:__POSTAXIAL OLIGODACTYLY, TETRAMELIC__:____:__
NULL__:__176250__:__POSTERIOR COLUMN ATAXIA__:__BIEMOND ATAXIA__:__
Asterisk__:__176256__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 2; KCNC2__:____:__
Asterisk__:__176257__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 6; KCNA6__:__HBK2__:__
Asterisk__:__176258__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 1; KCNC1__:__KV3.1;; NGK2__:__
Asterisk__:__176260__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 1; KCNA1__:__MK1, MOUSE, HOMOLOG OF;; KV1.1__:__
Asterisk__:__176261__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 1; KCNE1__:__ISK;; MINIMAL POTASSIUM ION CHANNEL; MINK__:__
Asterisk__:__176262__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 2; KCNA2__:__MK2, MOUSE, HOMOLOG OF;; KV1.2__:__
Asterisk__:__176263__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 3; KCNA3__:__MK3, MOUSE, HOMOLOG OF;; POTASSIUM CHANNEL 3; PCN3;; KV1.3__:__
Asterisk__:__176264__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 3; KCNC3__:____:__
Asterisk__:__176265__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 4; KCNC4__:____:__
Asterisk__:__176266__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 4; KCNA4__:__POTASSIUM CHANNEL, FETAL SKELETAL MUSCLE;; POTASSIUM CHANNEL, TYPE A;; POTASSIUM CHANNEL, RAPIDLY INACTIVATING;; POTASSIUM CHANNEL, CARDIAC;; POTASSIUM CHANNEL 2; PCN2;; HK1__:__
Asterisk__:__176267__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 5; KCNA5__:__POTASSIUM CHANNEL 1; PCN1;; POTASSIUM CHANNEL, INSULINOMA AND ISLET CELL;; HCK1;; HK2__:__
Asterisk__:__176268__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 7; KCNA7__:____:__
Caret__:__176269__:__MOVED TO 176266__:____:__
Number Sign__:__176270__:__PRADER-WILLI SYNDROME; PWS__:__PRADER-LABHART-WILLI SYNDROME__:__PRADER-WILLI SYNDROME CHROMOSOME REGION, INCLUDED; PWCR, INCLUDED;; PRADER-WILLI-LIKE SYNDROME ASSOCIATED WITH CHROMOSOME 6, INCLUDED
Asterisk__:__176290__:__DELTA, DROSOPHILA, HOMOLOG-LIKE 1; DLK1__:__PREADIPOCYTE FACTOR 1; PREF1;; FETAL ANTIGEN 1; FA1;; pG2__:__
Asterisk__:__176300__:__TRANSTHYRETIN; TTR__:__PREALBUMIN, THYROXINE-BINDING; TBPA;; PALB__:__
Number Sign__:__176305__:__PREAXIAL DEFICIENCY, POSTAXIAL POLYDACTYLY, AND HYPOSPADIAS__:__GUTTMACHER SYNDROME__:__
Asterisk__:__176310__:__PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 1; PBX1__:____:__PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR PSEUDOGENE 1, INCLUDED; PBXP1, INCLUDED;; PBX1/E2A FUSION GENE, INCLUDED
Asterisk__:__176311__:__PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 2; PBX2__:__HOMEOBOX 12; HOX12__:__
Asterisk__:__176312__:__PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 3; PBX3__:____:__
Asterisk__:__176385__:__PREGNANCY-ASSOCIATED PLASMA PROTEIN A; PAPPA__:__IGFBP4 PROTEASE;; DIFFERENTIALLY EXPRESSED IN PLACENTA 1; DIPLA1__:__
Asterisk__:__176390__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 1; PSG1__:__PSBG1;; PSGGA;; B1G1__:__
Asterisk__:__176391__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 2; PSG2__:__PSBG2;; PSGGB__:__
Asterisk__:__176392__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 3; PSG3__:____:__
Asterisk__:__176393__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 4; PSG4__:____:__
Asterisk__:__176394__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 5; PSG5__:____:__
Asterisk__:__176395__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 6; PSG6__:____:__
Asterisk__:__176396__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 7; PSG7__:____:__
Asterisk__:__176397__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 8; PSG8__:____:__
Asterisk__:__176398__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 9; PSG9__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 11, FORMERLY; PSG11, FORMERLY__:__
Asterisk__:__176399__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 10; PSG10__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 12, FORMERLY; PSG12, FORMERLY__:__
Number Sign__:__176400__:__PRECOCIOUS PUBERTY, CENTRAL, 1; CPPB1__:____:__
Asterisk__:__176401__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 11; PSG11__:__PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN 13, FORMERLY; PSG13, FORMERLY__:__
Number Sign__:__176410__:__PRECOCIOUS PUBERTY, MALE-LIMITED__:__SEXUAL PRECOCITY, FAMILIAL, GONADOTROPIN-INDEPENDENT;; TESTOTOXICOSIS, FAMILIAL__:__LEYDIG CELL ADENOMA, SOMATIC, WITH MALE-LIMITED PRECOCIOUS PUBERTY, INCLUDED
Asterisk__:__176420__:__PREGNANCY ZONE PROTEIN; PZP__:__COMPLEMENT COMPONENT 3- AND PREGNANCY ZONE PROTEIN-LIKE ALPHA-2-MACROGLOBULIN DOMAIN-CONTAINING PROTEIN 6; CPAMD6;; C3- AND PZP-LIKE ALPHA-2-MACROGLOBULIN DOMAIN-CONTAINING PROTEIN 6__:__
Number Sign__:__176430__:__PREMATURE CHROMATID SEPARATION TRAIT; PCS__:__TOTAL PREMATURE CHROMATID SEPARATION TRAIT__:__
Caret__:__176440__:__MOVED TO 311360__:____:__
Number Sign__:__176450__:__CURRARINO SYNDROME__:__CURRARINO TRIAD__:__SACRAL AGENESIS SYNDROME, INCLUDED;; SACRAL AGENESIS, HEREDITARY, WITH PRESACRAL MASS, ANTERIOR MENINGOCELE, AND/OR TERATOMA, AND ANORECTAL MALFORMATION, INCLUDED;; SCRA1, INCLUDED
Number Sign__:__176500__:__CEREBRAL AMYLOID ANGIOPATHY, ITM2B-RELATED, 1__:__DEMENTIA, FAMILIAL BRITISH; FBD;; PRESENILE DEMENTIA WITH SPASTIC ATAXIA;; CEREBRAL AMYLOID ANGIOPATHY, BRITISH TYPE__:__
Asterisk__:__176590__:__PROFILIN 2; PFN2__:____:__
NULL__:__176600__:__PRESENILE DEMENTIA, KRAEPELIN TYPE__:____:__
Asterisk__:__176610__:__PROFILIN 1; PFN1__:____:__
NULL__:__176620__:__PRIAPISM, FAMILIAL IDIOPATHIC__:____:__
NULL__:__176630__:__PRIMARY RELEASE DISORDER OF PLATELETS__:____:__
Asterisk__:__176635__:__PRIMASE POLYPEPTIDE 1; PRIM1__:__PRIMASE, p49 SUBUNIT;; PRIMASE, p48 SUBUNIT__:__
Asterisk__:__176636__:__PRIMASE POLYPEPTIDE 2A; PRIM2A__:__PRIM2;; PRIMASE, p58 SUBUNIT__:__
Asterisk__:__176640__:__PRION PROTEIN; PRNP__:__PRP;; PRION-RELATED PROTEIN; PRIP__:__
Number Sign__:__176670__:__HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS__:__PROGERIA__:__PROGERIA SYNDROME, CHILDHOOD-ONSET, INCLUDED
Caret__:__176680__:__MOVED TO 142880__:____:__
Percent__:__176690__:__PROGEROID SHORT STATURE WITH PIGMENTED NEVI__:__MULVIHILL-SMITH SYNDROME__:__
Percent__:__176700__:__PROGNATHISM, MANDIBULAR__:__'HABSBURG JAW';; 'HAPSBURG JAW'__:__
Asterisk__:__176705__:__PROHIBITIN; PHB__:__PHB1__:__
Asterisk__:__176710__:__PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, ISOFORM 1; P4HA1__:__PROLYL 4-HYDROXYLASE, ALPHA-1 SUBUNIT;; PROLYL 4-HYDROXYLASE, ALPHA SUBUNIT; P4HA__:__
Asterisk__:__176720__:__PROLACTIN-INDUCIBLE PROTEIN; PIP__:__GROSS CYSTIC DISEASE FLUID PROTEIN;; GCDFP-15__:__
Asterisk__:__176730__:__INSULIN; INS__:__PROINSULIN__:__INS-IGF2 SPLICED READ-THROUGH TRANSCRIPTS, INCLUDED; INSIGF, INCLUDED
Asterisk__:__176740__:__PROLIFERATING CELL NUCLEAR ANTIGEN; PCNA__:__DNA POLYMERASE DELTA AUXILIARY PROTEIN__:__
Asterisk__:__176741__:__PROLIFERATION-RELATED Ki-67 ANTIGEN; MKI67__:__ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY Ki-67; KIA;; KI67__:__
Asterisk__:__176760__:__PROLACTIN; PRL__:____:__
Asterisk__:__176761__:__PROLACTIN RECEPTOR; PRLR__:____:__
Asterisk__:__176763__:__PEROXIREDOXIN 1; PRDX1__:__PRXI;; PROLIFERATION-ASSOCIATED GENE A; PAGA;; NATURAL KILLER-ENHANCING FACTOR A; NKEFA__:__
NULL__:__176770__:__PROLINE-NEGATIVE AUXOTROPH OF HAMSTER, COMPLEMENTATION OF; PROA__:____:__
Percent__:__176780__:__PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO__:__PROLAPSE OF VAGINA AND RECTUM;; RECTAL PROLAPSE;; VAGINAL PROLAPSE__:__PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 1, INCLUDED; PVOP1, INCLUDED
Asterisk__:__176785__:__PROLYLCARBOXYPEPTIDASE; PRCP__:__PCP;; ANGIOTENSINASE C__:__
Asterisk__:__176790__:__PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, BETA SUBUNIT; P4HB__:__PROLYL 4-HYDROXYLASE, BETA SUBUNIT;; PHDB; PROHB; PO4HB;; DISULFIDE ISOMERASE; DSI;; PROTEIN DISULFIDE ISOMERASE/OXIDOREDUCTASE; PDI;; PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 1; PDIA1;; THYROID HORMONE-BINDING PROTEIN p55, CELLULAR;; GLUTATHIONE-INSULIN TRANSHYDROGENASE; GIT__:__
Asterisk__:__176793__:__PRO-MELANIN-CONCENTRATING HORMONE-LIKE 1, PSEUDOGENE; PMCHL1__:____:__
Asterisk__:__176794__:__PRO-MELANIN-CONCENTRATING HORMONE-LIKE 2, PSEUDOGENE; PMCHL2__:____:__
Asterisk__:__176795__:__PRO-MELANIN-CONCENTRATING HORMONE; PMCH__:__MELANIN-CONCENTRATING HORMONE; MCH__:__
Asterisk__:__176797__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 16; ZBTB16__:__ZINC FINGER PROTEIN 145; ZNF145;; PROMYELOCYTIC LEUKEMIA ZINC FINGER; PLZF__:__PLZF/RARA FUSION GENE, INCLUDED
NULL__:__176800__:__PRONATION-SUPINATION OF THE FOREARM, IMPAIRMENT OF__:____:__
Asterisk__:__176801__:__PROSAPOSIN; PSAP__:__SPHINGOLIPID ACTIVATOR PROTEIN 1, FORMERLY; SAP1, FORMERLY;; SPHINGOLIPID ACTIVATOR PROTEIN 2, FORMERLY; SAP2, FORMERLY__:__SAPOSIN A, INCLUDED; SAPA, INCLUDED;; SAPOSIN B, INCLUDED; SAPB, INCLUDED;; SAPOSIN C, INCLUDED; SAPC, INCLUDED;; SAPOSIN D, INCLUDED; SAPD, INCLUDED
Asterisk__:__176802__:__PROSTAGLANDIN E RECEPTOR 1, EP1 SUBTYPE; PTGER1__:____:__
Asterisk__:__176803__:__PROSTAGLANDIN D2 SYNTHASE, BRAIN; PTGDS__:__PGD2 SYNTHASE; PGDS2; PDS;; BETA-TRACE;; LIPOCALIN-TYPE PROSTAGLANDIN D SYNTHASE; LPGDS;; PROSTAGLANDIN D SYNTHASE, LIPOCALIN-TYPE__:__
Asterisk__:__176804__:__PROSTAGLANDIN E RECEPTOR 2, EP2 SUBTYPE; PTGER2__:____:__
Asterisk__:__176805__:__PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1; PTGS1__:__CYCLOOXYGENASE 1; COX1;; PROSTAGLANDIN G/H SYNTHASE 1; PGHS1__:__CYCLOOXYGENASE 3, INCLUDED; COX3, INCLUDED;; PARTIAL COX1 PROTEINS, INCLUDED; PCOX1, INCLUDED
Asterisk__:__176806__:__PROSTAGLANDIN E RECEPTOR 3, EP3 SUBTYPE; PTGER3__:____:__
Number Sign__:__176807__:__PROSTATE CANCER__:____:__
Asterisk__:__176820__:__KALLIKREIN-RELATED PEPTIDASE 3; KLK3__:__KALLIKREIN 3;; ANTIGEN, PROSTATE-SPECIFIC; APS;; PROSTATE-SPECIFIC ANTIGEN; PSA__:__
Asterisk__:__176830__:__PROOPIOMELANOCORTIN; POMC__:__POC;; PRO-ACTH-ENDORPHIN__:__MELANOTROPIN, INCLUDED;; MELANOCYTE-STIMULATING HORMONE, INCLUDED;; LIPOTROPIN, INCLUDED
Asterisk__:__176842__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 2; PSMA2__:__HC3;; PSC2__:__
Asterisk__:__176843__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 3; PSMA3__:__HC8;; PSC3__:__
Asterisk__:__176844__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 5; PSMA5__:__PROTEASOME COMPONENT 5; PSC5;; PROTEASOME SUBUNIT ZETA__:__
Asterisk__:__176845__:__PROTEASOME COMPONENT 8; PSC8__:____:__
Asterisk__:__176846__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 4; PSMA4__:__PROTEASOME COMPONENT 9; PSC9;; HC9__:__
Asterisk__:__176847__:__PROTEASOME SUBUNIT, BETA-TYPE, 10; PSMB10__:__PROTEASOME SUBUNIT MECL1;; PROTEASOME SUBUNIT BETA-2I__:__
Asterisk__:__176851__:__PROTEIN CARBOXYL METHYLTRANSFERASE 1; PCMT1__:__L-ISOASPARTYL/D-ASPARTYL PROTEIN METHYLTRANSFERASE__:__
Number Sign__:__176860__:__THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT; THPH3__:__PROTEIN C DEFICIENCY, AUTOSOMAL DOMINANT;; PROC DEFICIENCY, AUTOSOMAL DOMINANT__:__PROTEIN C DEFICIENCY, ACQUIRED, INCLUDED
Asterisk__:__176870__:__ALPHA-1 MICROGLOBULIN/BIKUNIN PRECURSOR; AMBP__:__ALPHA-1 MICROGLOBULIN; A1M;; PROTEIN HC; HCP;; COMPLEX-FORMING GLYCOPROTEIN HETEROGENEOUS IN CHARGE__:__INTER-ALPHA-TRYPSIN INHIBITOR, LIGHT CHAIN, INCLUDED; ITIL, INCLUDED; IATIL, INCLUDED;; BIKUNIN, INCLUDED;; URINARY TRYPSIN INHIBITOR, INCLUDED; UTI, INCLUDED
Asterisk__:__176871__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 2; EIF2AK2__:__PROTEIN KINASE, INTERFERON-INDUCIBLE DOUBLE-STRANDED RNA-ACTIVATED; PRKR;; PKR;; p68 KINASE__:__
Asterisk__:__176872__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1; MAP2K1__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 1; PRKMK1;; MKK1; MAPKK1;; MAPK/ERK KINASE 1; MEK1__:__
Asterisk__:__176873__:__CYCLIN-DEPENDENT KINASE 11B; CDK11B__:__CELL DIVISION CYCLE 2-LIKE 1; CDC2L1;; PROTEIN KINASE p58; PK58; p58;; CDC-RELATED PROTEIN KINASE p58;; PITSLRE B;; CDK11__:__
Caret__:__176874__:__MOVED TO 114085__:____:__
Asterisk__:__176875__:__PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA ISOFORM; PPP1CA__:__PROTEIN PHOSPHATASE 1, ALPHA SUBUNIT; PPP1A__:__
Asterisk__:__176876__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 11; PTPN11__:__PROTEIN-TYROSINE PHOSPHATASE 2C; PTP2C;; TYROSINE PHOSPHATASE SHP2; SHP2__:__
Asterisk__:__176877__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 3; PTPN3__:__PTPH1__:__
Asterisk__:__176878__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 4; PTPN4__:__PROTEIN-TYROSINE PHOSPHATASE, MEGAKARYOCYTE; PTPMEG; PTPMEG1;; MEGAKARYOCYTE PHOSPHATASE__:__
Asterisk__:__176879__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 5; PTPN5__:__PTPN, STRIATUM-ENRICHED; STEP__:__
Asterisk__:__176880__:__PROTEIN S; PROS1__:__PROTEIN S, ALPHA; PSA__:__PROTEIN S PSEUDOGENE, INCLUDED; PROSP, INCLUDED;; PROTEIN S, BETA, INCLUDED; PSB, INCLUDED;; PROS2, INCLUDED
Asterisk__:__176882__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, BETA; PTPRB__:__VASCULAR ENDOTHELIAL PROTEIN-TYROSINE PHOSPHATASE; VEPTP__:__
Asterisk__:__176883__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 6; PTPN6__:__PROTEIN-TYROSINE PHOSPHATASE 1C; PTP1C;; TYROSINE PHOSPHATASE SHP1; SHP1;; HEMATOPOIETIC CELL PHOSPHATASE; HCPH__:__
Asterisk__:__176884__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, ALPHA; PTPRA__:__PTP-ALPHA; PTPA;; RPTPase-ALPHA;; LCA-RELATED PHOSPHATASE; LRP__:__
Asterisk__:__176885__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 1; PTPN1__:__PROTEIN PHOSPHOTYROSYLPHOSPHATASE 1B; PTP1B;; PROTEIN-TYROSINE PHOSPHATASE, PLACENTAL__:__
Asterisk__:__176886__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, GAMMA; PTPRG__:__PROTEIN-TYROSINE PHOSPHATASE GAMMA; PTPG__:__
Asterisk__:__176887__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 2; PTPN2__:__PROTEIN-TYROSINE PHOSPHATASE, T-CELL; PTPT__:__
Asterisk__:__176888__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, MU; PTPRM__:__PROTEIN-TYROSINE PHOSPHATASE RECEPTOR-LIKE 1; PTPRL1__:__
Asterisk__:__176889__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 7; PTPN7__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, STRESS-INDUCED; PTPNI__:__
Asterisk__:__176891__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, ZETA-1; PTPRZ1__:__PTPRZ;; PTP-ZETA; PTPZ;; RPTP-BETA; RPTPB__:__
Asterisk__:__176892__:__PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, BETA; PRKACB__:__PROTEIN KINASE A, C-BETA SUBUNIT__:__
Asterisk__:__176893__:__PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, GAMMA; PRKACG__:__PROTEIN KINASE A, C-GAMMA SUBUNIT__:__
Asterisk__:__176894__:__PROTEIN KINASE, cGMP-DEPENDENT, REGULATORY, TYPE I; PRKG1__:__cGMP-DEPENDENT PROTEIN KINASE, TYPE I, BETA; cGKI-BETA;; PRKGR1B__:__cGMP-DEPENDENT PROTEIN KINASE, TYPE I, ALPHA, INCLUDED;; cGKI-ALPHA, INCLUDED
Asterisk__:__176895__:__PROTEIN Z; PROZ__:__PZ;; VITAMIN K-DEPENDENT PLASMA GLYCOPROTEIN__:__
NULL__:__176900__:__PROTEOLYTIC CAPACITY OF PLASMA__:____:__
Asterisk__:__176910__:__PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE II, ALPHA; PRKAR2A__:__PROTEIN KINASE A, RII-ALPHA SUBUNIT__:__
Asterisk__:__176911__:__PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE I, BETA; PRKAR1B__:__PROTEIN KINASE A, RI-BETA SUBUNIT;; PRKAR1__:__
Asterisk__:__176912__:__PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE II, BETA; PRKAR2B__:__PROTEIN KINASE A, RII-BETA SUBUNIT;; PRKAR2__:__
Asterisk__:__176914__:__PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, GAMMA ISOFORM; PPP1CC__:__PROTEIN PHOSPHATASE 1, GAMMA SUBUNIT; PPP1G__:__
Asterisk__:__176915__:__PROTEIN PHOSPHATASE 2, CATALYTIC SUBUNIT, ALPHA ISOFORM; PPP2CA__:__PROTEIN PHOSPHATASE 2A, CATALYTIC SUBUNIT, ALPHA ISOFORM; PP2CA__:__
Asterisk__:__176916__:__PROTEIN PHOSPHATASE 2, CATALYTIC SUBUNIT, BETA ISOFORM; PPP2CB__:__PROTEIN PHOSPHATASE 2A, CATALYTIC SUBUNIT, BETA ISOFORM;; PP2CB__:__
Number Sign__:__176920__:__PROTEUS SYNDROME__:__GIGANTISM, PARTIAL, OF HANDS AND FEET, NEVI, HEMIHYPERTROPHY, AND MACROCEPHALY__:__ELATTOPROTEUS SYNDROME, INCLUDED
Asterisk__:__176930__:__COAGULATION FACTOR II; F2__:__THROMBIN;; PROTHROMBIN;; FACTOR II__:__
Asterisk__:__176940__:__S100 CALCIUM-BINDING PROTEIN A1; S100A1__:__S100-ALPHA; S100A__:__
Asterisk__:__176941__:__TYROSINE KINASE 2; TYK2__:____:__
Asterisk__:__176942__:__FPS/FES-RELATED TYROSINE KINASE; FER__:__PROTEIN-TYROSINE KINASE 3; TYK3__:__
Asterisk__:__176943__:__FIBROBLAST GROWTH FACTOR RECEPTOR 2; FGFR2__:__FGF RECEPTOR;; PROTEIN TYROSINE KINASE, RECEPTOR-LIKE, 14; TK14__:__KERATINOCYTE GROWTH FACTOR RECEPTOR, INCLUDED; KGFR, INCLUDED;; BEK, MOUSE, HOMOLOG OF, INCLUDED;; FIBROBLAST GROWTH FACTOR RECEPTOR BEK, INCLUDED
Caret__:__176944__:__MOVED TO 134935__:____:__
Asterisk__:__176945__:__EPHRIN RECEPTOR EphA8; EPHA8__:__EPH- AND ELK-RELATED KINASE; EEK;; PROTEIN TYROSINE KINASE EEK;; HEK3__:__
Asterisk__:__176946__:__EPHRIN RECEPTOR EphA2; EPHA2__:__EPITHELIAL CELL RECEPTOR PROTEIN-TYROSINE KINASE; ECK__:__
Asterisk__:__176947__:__ZETA-CHAIN-ASSOCIATED PROTEIN KINASE; ZAP70__:__SYK-RELATED TYROSINE KINASE; SRK;; PROTEIN TYROSINE KINASE ZAP70;; ZETA-ASSOCIATED PROTEIN, 70-KD__:__
Asterisk__:__176948__:__MITOGEN-ACTIVATED PROTEIN KINASE 1; MAPK1__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 1; PRKM1;; PROTEIN KINASE, MITOGEN-ACTIVATED, 2; PRKM2;; EXTRACELLULAR SIGNAL-REGULATED KINASE 2; ERK2;; PROTEIN TYROSINE KINASE ERK2;; p42MAPK__:__
Asterisk__:__176949__:__MITOGEN-ACTIVATED PROTEIN KINASE 4; MAPK4__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 4; PRKM4;; PROTEIN-TYROSINE KINASE ERK3-RELATED;; ERK3-RELATED;; p63MAPK__:__
Caret__:__176950__:__MOVED TO 262890__:____:__
Asterisk__:__176960__:__PROTEIN KINASE C, ALPHA; PRKCA__:__PKCA__:__
Asterisk__:__176970__:__PROTEIN KINASE C, BETA; PRKCB__:__PRKCB1;; PKCB__:__PRKCB2, INCLUDED
Asterisk__:__176975__:__PROTEIN KINASE C, EPSILON; PRKCE__:__PKCE__:__
Asterisk__:__176977__:__PROTEIN KINASE C, DELTA; PRKCD__:__PKCD__:__
Asterisk__:__176980__:__PROTEIN KINASE C, GAMMA; PRKCG__:__PKCC; PKCG__:__
Asterisk__:__176981__:__RECEPTOR FOR ACTIVATED PROTEIN KINASE C, 1; RACK1__:__PROTEIN KINASE C, RECEPTOR FOR ACTIVATED, 1;; GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-2-LIKE 1; GNB2L1__:__
Asterisk__:__176982__:__PROTEIN KINASE C, ZETA FORM; PRKCZ__:__PKC2;; PKC-ZETA__:__PKM-ZETA, INCLUDED
Asterisk__:__176990__:__S100 CALCIUM-BINDING PROTEIN, BETA; S100B__:____:__
Asterisk__:__176991__:__S100 CALCIUM-BINDING PROTEIN A5; S100A5__:__S100D__:__
Asterisk__:__176992__:__S100 CALCIUM-BINDING PROTEIN A3; S100A3__:__S100E__:__
Asterisk__:__176993__:__S100 CALCIUM-BINDING PROTEIN A2; S100A2__:__S100L__:__
Number Sign__:__177000__:__PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1__:__PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY__:__
Asterisk__:__177010__:__SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 2; SERPINE2__:__PROTEASE INHIBITOR 7; PI7;; GLIAL-DERIVED NEURITE PROMOTING FACTOR;; PROTEASE NEXIN I; PN1;; GLIAL-DERIVED NEXIN 1__:__
Asterisk__:__177015__:__PROTEIN SERINE KINASE H1; PSKH1__:____:__
Asterisk__:__177020__:__PROTEINASE 3; PRTN3__:__PR3;; MYELOBLASTIN; MBT;; P29;; AZUROPHIL GRANULE PROTEIN 7; AGP7;; SERINE PROTEINASE, NEUTROPHIL WEGENER AUTOANTIGEN__:__
Caret__:__177030__:__MOVED TO 176880__:____:__
Asterisk__:__177040__:__SERGLYCIN; SRGN__:__PROTEOGLYCAN 1; PRG1; PRG;; PLATELET PROTEOGLYCAN PROTEIN CORE; PPG;; PROTEOGLYCAN PROTEIN CORE FOR MAST CELL SECRETORY GRANULE__:__
Asterisk__:__177045__:__PROTEASOME SUBUNIT, BETA-TYPE, 9; PSMB9__:__LARGE MULTIFUNCTIONAL PROTEASE 2; LMP2;; PROTEASOME-RELATED GENE 2;; RING12;; PROTEASOME SUBUNIT BETA-1I__:__
Asterisk__:__177046__:__PROTEASOME SUBUNIT, BETA-TYPE, 8; PSMB8__:__LARGE MULTIFUNCTIONAL PROTEASE 7; LMP7;; PROTEASOME-RELATED GENE 7;; RING10;; PROTEASOME SUBUNIT BETA-5I__:__
Percent__:__177050__:__PROTRUSIO ACETABULI__:____:__
Asterisk__:__177060__:__PROTEIN KINASE C SUBSTRATE, 80-KD, HEAVY CHAIN; PRKCSH__:__G19P1;; GLUCOSIDASE II, BETA SUBUNIT__:__HEPATOCYSTIN, INCLUDED
Asterisk__:__177061__:__MYRISTOYLATED ALANINE-RICH PROTEIN KINASE C SUBSTRATE; MARCKS__:__MAC; MACS;; PROTEIN KINASE C SUBSTRATE, 80-KD, LIGHT CHAIN; PRKCSL__:__
Asterisk__:__177070__:__PROTEIN 4.2, ERYTHROCYTIC; EPB42__:____:__
Asterisk__:__177075__:__V-MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG; MAF__:__PROTOONCOGENE MAF__:__
NULL__:__177100__:__PRURITUS, HEREDITARY LOCALIZED__:____:__
Caret__:__177150__:__MOVED TO 177170__:____:__
Number Sign__:__177170__:__PSEUDOACHONDROPLASIA; PSACH__:__PSEUDOACHONDROPLASTIC DYSPLASIA;; SPONDYLOEPIPHYSEAL DYSPLASIA, PSEUDOACHONDROPLASTIC__:__
Number Sign__:__177200__:__LIDDLE SYNDROME 1; LIDLS1__:__LIDDLE SYNDROME; LIDLS;; PSEUDOALDOSTERONISM;; PSEUDOHYPERALDOSTERONISM__:__
NULL__:__177300__:__PSEUDOARTHROGRYPOSIS__:__HEREDITARY CONGENITAL RIGIDITY OF ELBOWS AND KNEES;; ANKYLOSIS AT ELBOW AND KNEE__:__
NULL__:__177350__:__PSEUDOATROPHODERMA COLLI__:____:__
Asterisk__:__177400__:__BUTYRYLCHOLINESTERASE; BCHE__:__PSEUDOCHOLINESTERASE E1; CHE1;; ACYLCHOLINE ACYLHYDROLASE__:__
Caret__:__177500__:__MOVED TO 177400__:____:__
NULL__:__177600__:__PSEUDOCHOLINESTERASE, INCREASE IN PLASMA LEVEL OF__:____:__
Number Sign__:__177650__:__EXFOLIATION SYNDROME; XFS__:__EXFOLIATION GLAUCOMA; XFG;; PSEUDOEXFOLIATION GLAUCOMA; PEXG;; PSEUDOEXFOLIATION OF THE LENS;; PSEUDOEXFOLIATION SYNDROME; PEXS__:__
Number Sign__:__177700__:__GLAUCOMA 1, OPEN ANGLE, P; GLC1P__:____:__
Caret__:__177720__:__MOVED TO 194380__:____:__
Number Sign__:__177735__:__PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL DOMINANT; PHA1A__:__PHA I, AUTOSOMAL DOMINANT__:__
Percent__:__177750__:__PSEUDOMONILETHRIX__:____:__
NULL__:__177800__:__PSEUDOPAPILLEDEMA__:____:__
Number Sign__:__177820__:__PSEUDO-VON WILLEBRAND DISEASE; VWDP__:__BLEEDING DISORDER, PLATELET-TYPE, 3; BDPLT3;; VON WILLEBRAND DISEASE, PLATELET-TYPE__:__
Number Sign__:__177850__:__PSEUDOXANTHOMA ELASTICUM, FORME FRUSTE__:____:__PSEUDOXANTHOMA ELASTICUM, HETEROZYGOUS, INCLUDED
Caret__:__177860__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__177900__:__PSORIASIS 1, SUSCEPTIBILITY TO; PSORS1__:____:__
Number Sign__:__177980__:__PTERYGIA, MENTAL RETARDATION, AND DISTINCTIVE CRANIOFACIAL FEATURES__:__HASPESLAGH SYNDROME__:__
NULL__:__177990__:__PTERYGIUM COLLI, ISOLATED__:____:__
NULL__:__178000__:__PTERYGIUM OF CONJUNCTIVA AND CORNEA__:____:__
Number Sign__:__178110__:__ARTHROGRYPOSIS, DISTAL, TYPE 8; DA8__:__MULTIPLE PTERYGIUM SYNDROME, AUTOSOMAL DOMINANT;; PTERYGIUM SYNDROME, MULTIPLE, AUTOSOMAL DOMINANT__:__
Percent__:__178200__:__PTERYGIUM, ANTECUBITAL__:____:__
Percent__:__178300__:__PTOSIS, HEREDITARY CONGENITAL 1; PTOS1__:____:__
NULL__:__178330__:__PTOSIS, STRABISMUS, AND ECTOPIC PUPILS__:____:__
Percent__:__178350__:__PUBIC BONE DYSPLASIA__:____:__
NULL__:__178370__:__PULMONARY ATRESIA WITH VENTRICULAR SEPTAL DEFECT__:____:__
NULL__:__178400__:__PULMONARY EDEMA OF MOUNTAINEERS, SUSCEPTIBILITY TO__:__HIGH ALTITUDE PULMONARY HYPERTENSION; HAPH__:__
Number Sign__:__178500__:__PULMONARY FIBROSIS, IDIOPATHIC; IPF__:__IDIOPATHIC PULMONARY FIBROSIS, FAMILIAL;; FIBROSING ALVEOLITIS, CRYPTOGENIC;; FIBROCYSTIC PULMONARY DYSPLASIA;; INTERSTITIAL PNEUMONITIS, USUAL; UIP__:__HAMMAN-RICH DISEASE, INCLUDED
NULL__:__178550__:__PULMONARY HEMOSIDEROSIS__:____:__
Number Sign__:__178600__:__PULMONARY HYPERTENSION, PRIMARY, 1; PPH1__:__PHT;; PULMONARY ARTERIAL HYPERTENSION; PAH__:__PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED, INCLUDED;; PULMONARY HYPERTENSION, PRIMARY, FENFLURAMINE-ASSOCIATED, INCLUDED;; PULMONARY HYPERTENSION, PRIMARY, 1, WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA, INCLUDED;; PPH1 WITH HHT, INCLUDED
NULL__:__178610__:__PULMONARY NODULAR LYMPHOID HYPERPLASIA, FAMILIAL__:____:__
Asterisk__:__178620__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN C; SFTPC__:__SURFACTANT-ASSOCIATED PROTEIN, PULMONARY, 2; SFTP2;; PULMONARY SURFACTANT APOPROTEIN PSP-C; SPC;; PSP-C;; SURFACTANT PROTEOLIPID SPL-pVal;; PULMONARY SURFACTANT PROTEIN SP5__:__
Asterisk__:__178630__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN A1; SFTPA1__:__PULMONARY SURFACTANT APOPROTEIN PSP-A; PSAP;; SURFACTANT-ASSOCIATED PROTEIN, PULMONARY 1; SFTP1;; PULMONARY SURFACTANT-ASSOCIATED PROTEIN, 35-KD; PSPA; SPA; SPA1;; COLLECTIN 4; COLEC4__:__
Asterisk__:__178635__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN D; SFTPD__:__PULMONARY SURFACTANT APOPROTEIN PSP-D;; PSP-D SURFACTANT PROTEIN D; SP-D;; SURFACTANT-ASSOCIATED PROTEIN, PULMONARY 4; SFTP4;; COLLECTIN 7; COLEC7__:__
Asterisk__:__178640__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN B; SFTPB__:__SURFACTANT-ASSOCIATED PROTEIN, PULMONARY, 3; SFTP3;; PULMONARY SURFACTANT APOPROTEIN PSP-B; SPB;; PSP-B;; PULMONARY SURFACTANT-ASSOCIATED PROTEIN, 18-KD__:__
Asterisk__:__178642__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN A2; SFTPA2__:__PULMONARY SURFACTANT PROTEIN AII; SPAII; SPA2;; COLLECTIN 5; COLEC5__:__
NULL__:__178650__:__PULMONIC STENOSIS, ATRIAL SEPTAL DEFECT, AND UNIQUE ELECTROCARDIOGRAPHIC ABNORMALITIES__:__CIUFFO SYNDROME__:__
NULL__:__178651__:__PULMONIC STENOSIS AND DEAFNESS__:____:__
NULL__:__178800__:__PUPIL, EGG-SHAPED__:____:__
NULL__:__178900__:__PUPILLARY MEMBRANE, PERSISTENCE OF__:____:__
Asterisk__:__178990__:__MATRIX METALLOPROTEINASE 7; MMP7__:__MATRILYSIN, UTERINE;; PUTATIVE METALLOPROTEINASE I; PUMP1__:__
NULL__:__178995__:__PRURITIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY; PUPPP__:__POLYMORPHIC ERUPTION OF PREGNANCY__:__
NULL__:__179000__:__PURPURA SIMPLEX__:____:__
Percent__:__179010__:__PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 1; IHPS1__:__PYLORIC STENOSIS, INFANTILE;; PYLORIC STENOSIS, INFANTILE HYPERTROPHIC; IHPS__:__
Asterisk__:__179020__:__PYRIDOXAL KINASE; PDXK__:__PYRIDOXINE KINASE; PNK;; PKH;; VITAMIN B6 KINASE__:__
Asterisk__:__179030__:__PYROPHOSPHATASE, INORGANIC, 1; PPA1__:__PP__:__
Asterisk__:__179035__:__PYRROLINE-5-CARBOXYLATE REDUCTASE 1; PYCR1__:__PRO3, YEAST, HUMAN COMPLEMENT OF__:__
Caret__:__179040__:__MOVED TO 179050__:____:__
Asterisk__:__179050__:__PYRUVATE KINASE, MUSCLE; PKM__:__PYRUVATE KINASE 3; PK3;; OPA-INTERACTING PROTEIN 3; OIP3;; THYROID HORMONE-BINDING PROTEIN, CYTOSOLIC; THBP1__:__PYRUVATE KINASE, MUSCLE, 1, INCLUDED; PKM1, INCLUDED;; PYRUVATE KINASE, MUSCLE, 2, INCLUDED; PKM2, INCLUDED
Asterisk__:__179060__:__PYRUVATE DEHYDROGENASE, BETA POLYPEPTIDE; PDHB__:__PYRUVATE DEHYDROGENASE COMPLEX, E1 BETA POLYPEPTIDE; PHE1B__:__
Asterisk__:__179061__:__PYRUVATE DEHYDROGENASE, ALPHA-2; PDHA2__:__PYRUVATE DEHYDROGENASE, E1-ALPHA POLYPEPTIDE, TESTIS-SPECIFIC__:__
Asterisk__:__179080__:__RAB GERANYLGERANYL TRANSFERASE, BETA SUBUNIT; RABGGTB__:__RAB GERANYLGERANYLTRANSFERASE, BETA COMPONENT;; GG TRANSFERASE, COMPONENT B; GGTB__:__
Caret__:__179090__:__MOVED TO 164730__:____:__
Asterisk__:__179095__:__UBIQUITIN-CONJUGATING ENZYME E2B; UBE2B__:__RAD6, YEAST, HOMOLOG OF, TYPE B; RAD6B;; HHR6B__:__
Percent__:__179200__:__RADIAL HEADS, POSTERIOR DISLOCATION OF__:____:__
NULL__:__179250__:__RADIAL HYPOPLASIA, TRIPHALANGEAL THUMBS, HYPOSPADIAS, AND MAXILLARY DIASTEMA__:____:__
NULL__:__179270__:__RADIAL RAY HYPOPLASIA WITH CHOANAL ATRESIA__:____:__
NULL__:__179280__:__RADIAL-RENAL SYNDROME__:____:__
NULL__:__179300__:__RADIOULNAR SYNOSTOSIS__:____:__
NULL__:__179400__:__RADIUS, APLASIA OF, WITH CLEFT LIP/PALATE__:____:__
Asterisk__:__179410__:__RADIXIN; RDX__:____:__
NULL__:__179450__:__RAGWEED SENSITIVITY__:____:__
Asterisk__:__179490__:__RAS-ASSOCIATED PROTEIN RAB3A; RAB3A__:____:__
NULL__:__179500__:__RAINDROP HYPOPIGMENTATION__:____:__
Asterisk__:__179502__:__RAP1, GTPase-GDP DISSOCIATION STIMULATOR 1; RAP1GDS1__:__GTPase-GDP DISSOCIATION STIMULATOR, RAP1, 1;; GDP-DISSOCIATION STIMULATOR 1; GDS1;; SMGGDS__:__RAP1GDS1/NUP98 FUSION GENE, INCLUDED
Asterisk__:__179503__:__RAS-RELATED ASSOCIATED WITH DIABETES; RRAD__:__RAS GENE ASSOCIATED WITH DIABETES; RAD__:__RAD POLYMORPHISM 1, INCLUDED; RAD1, INCLUDED
Asterisk__:__179505__:__RAS HOMOLOG GENE FAMILY, MEMBER G; RHOG__:__RAS HOMOLOG GENE G;; ARHG__:__
Asterisk__:__179508__:__RAS-ASSOCIATED PROTEIN RAB1; RAB1__:__RAB1A__:__
Asterisk__:__179509__:__RAS-ASSOCIATED PROTEIN RAB2; RAB2__:__RAB2A__:__
Asterisk__:__179510__:__RAS-ASSOCIATED PROTEIN RAB3B; RAB3B__:____:__
Asterisk__:__179511__:__RAS-ASSOCIATED PROTEIN RAB4A; RAB4A__:__RAB4__:__
Asterisk__:__179512__:__RAS-ASSOCIATED PROTEIN RAB5A; RAB5A__:__RAB5__:__
Asterisk__:__179513__:__RAS-ASSOCIATED PROTEIN RAB6A; RAB6A__:__RAS-ASSOCIATED PROTEIN RAB6; RAB6__:__
Asterisk__:__179514__:__RAS-ASSOCIATED PROTEIN RAB5B; RAB5B__:____:__
Asterisk__:__179520__:__RAS-RELATED PROTEIN 1A; RAP1A__:__KREV1__:__
Asterisk__:__179530__:__RAS-RELATED PROTEIN RAP1B; RAP1B__:____:__
Asterisk__:__179540__:__RAS-RELATED PROTEIN 2A; RAP2A__:__RAP2;; KREV__:__
Asterisk__:__179541__:__RAS-RELATED PROTEIN 2B; RAP2B__:____:__
Asterisk__:__179550__:__V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG A; RALA__:__RAS-LIKE PROTEIN; RAL__:__
Asterisk__:__179551__:__V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG B; RALB__:__RAS-LIKE PROTEIN B__:__
Asterisk__:__179555__:__RAS SUPPRESSOR PROTEIN 1; RSU1__:____:__
Asterisk__:__179590__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F; PTPRF__:__RECEPTOR-LINKED PROTEIN-TYROSINE PHOSPHATASE LAR;; LEUKOCYTE ANTIGEN-RELATED TYROSINE PHOSPHATASE; LAR__:__
Percent__:__179600__:__RAYNAUD DISEASE__:__COLD FINGERS, HEREDITARY__:__
Asterisk__:__179605__:__PERIPHERIN 2, MOUSE, HOMOLOG OF; PRPH2__:__RDS, MOUSE, HOMOLOG OF; RDS;; PERIPHERIN, PHOTORECEPTOR TYPE;; RETINAL DEGENERATION, SLOW, MOUSE, HOMOLOG OF__:__
Asterisk__:__179610__:__EPHRIN RECEPTOR EphA1; EPHA1__:__ONCOGENE EPH;; RECEPTOR TYROSINE KINASE EPH;; EPH TYROSINE KINASE/ERYTHROPOIETIN-PRODUCING HEPATOMA AMPLIFIED SEQUENCE; EPHT;; EPH TYROSINE KINASE 1; EPHT1__:__
Asterisk__:__179611__:__EPHRIN RECEPTOR EphA3; EPHA3__:__HUMAN EMBRYO KINASE; HEK;; RECEPTOR TYROSINE KINASE HEK;; EPH-LIKE TYROSINE KINASE 1; ETK1;; HEK4;; TYRO4__:__
Number Sign__:__179613__:__RECOMBINANT CHROMOSOME 8 SYNDROME__:__REC8 SYNDROME;; CHROMOSOME 8q22.1-qter DUPLICATION AND 8pter-p23.1 DELETION;; SAN LUIS VALLEY SYNDROME__:__
Asterisk__:__179615__:__RECOMBINATION-ACTIVATING GENE 1; RAG1__:____:__
Asterisk__:__179616__:__RECOMBINATION-ACTIVATING GENE 2; RAG2__:____:__
Asterisk__:__179617__:__RAD51, S. CEREVISIAE, HOMOLOG OF; RAD51__:__RAD51, S. CEREVISIAE, HOMOLOG OF, A; RAD51A;; RECOMBINATION PROTEIN A; RECA;; RECA, E. COLI, HOMOLOG OF__:__
Asterisk__:__179618__:__RECOVERIN; RCV1__:__CANCER-ASSOCIATED RETINOPATHY PROTEIN;; CAR PROTEIN__:__
Number Sign__:__179620__:__RAPH BLOOD GROUP SYSTEM__:__MER2 BLOOD CELL ANTIGEN EXPRESSION; MER2__:__
Percent__:__179650__:__RED CELL PERMEABILITY DEFECT__:__ELLIPTOCYTOSIS WITH TRANSVERSE SLITLIKE CHANGES__:__
Percent__:__179700__:__RED CELL PHOSPHOLIPID DEFECT WITH HEMOLYSIS__:__HIGH RED CELL PHOSPHATIDYLCHOLINE HEMOLYTIC ANEMIA; HPCHA;; PHOSPHATIDYLCHOLINE RED CELL MEMBRANE DISORDER;; LEAKY RED CELL SYNDROME__:__
Asterisk__:__179710__:__REGULATOR OF CHROMOSOME CONDENSATION 1; RCC1__:__CHROMOSOME CONDENSATION 1; CHC1__:__
Caret__:__179715__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__179730__:__RELAXIN 1; RLN1__:__RELAXIN H1; RLXH1__:__
Asterisk__:__179740__:__RELAXIN 2; RLN2__:__RELAXIN H2; RLXH2;; RELAXIN, OVARIAN, OF PREGNANCY__:__
Asterisk__:__179755__:__PAPILLARY RENAL CELL CARCINOMA TRANSLOCATION-ASSOCIATED GENE; PRCC__:____:__PRCC/TFE3 FUSION GENE, INCLUDED
Caret__:__179760__:__MOVED TO 144700__:____:__
Caret__:__179770__:__MOVED TO 144700__:____:__
Asterisk__:__179780__:__DIPEPTIDASE 1; DPEP1__:__DIPEPTIDASE 1, RENAL;; RENAL DIPEPTIDASE; RDP;; DEHYDROPEPTIDASE I;; MICROSOMAL DIPEPTIDASE; MDP;; MEMBRANE-BOUND DIPEPTIDASE 1; MBD1__:__
Number Sign__:__179800__:__RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL DOMINANT__:__RTA, DISTAL TYPE, AUTOSOMAL DOMINANT;; RENAL TUBULAR ACIDOSIS I;; RTA, CLASSIC TYPE;; RTA, GRADIENT TYPE__:__
Asterisk__:__179820__:__RENIN; REN__:____:__
NULL__:__179830__:__RENAL TUBULAR ACIDOSIS, PROXIMAL__:__RENAL TUBULAR ACIDOSIS II;; RTA, PROXIMAL TYPE;; RTA, RATE TYPE__:__
Asterisk__:__179835__:__REPLICATION PROTEIN A1, 70-KD; RPA1__:__RPA70;; REPA1__:__
Asterisk__:__179836__:__REPLICATION PROTEIN A2, 32-KD; RPA2__:__RPA32;; REPA2__:__
Asterisk__:__179837__:__REPLICATION PROTEIN A3, 14-KD; RPA3__:__RPA14;; REPA3__:__
Asterisk__:__179838__:__CAP-GLY DOMAIN-CONTAINING LINKER PROTEIN 1; CLIP1__:__RESTIN; RSN;; REED-STERNBERG MICROTUBULE-ASSOCIATED PROTEIN;; CYTOPLASMIC LINKER 1; CYLN1;; CYTOPLASMIC LINKER PROTEIN 170; CLIP170__:__
NULL__:__179840__:__RETICULAR DYSTROPHY OF RETINAL PIGMENT EPITHELIUM__:____:__
Number Sign__:__179850__:__DOWLING-DEGOS DISEASE 1; DDD1__:__DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES__:__
Percent__:__179900__:__RETINAL APLASIA__:__AMAUROSIS CONGENITA__:__
Number Sign__:__180000__:__RETINAL ARTERIES, TORTUOSITY OF; RATOR__:__RETINAL HEMORRHAGE WITH VASCULAR TORTUOSITY__:__
Percent__:__180020__:__RETINAL CONE DYSTROPHY 1; RCD1__:__RETINAL CONE DEGENERATION;; CONE DYSTROPHY, AUTOSOMAL DOMINANT__:__
Asterisk__:__180040__:__RETINAL DEGENERATION 3, MOUSE, HOMOLOG OF; RD3__:__CHROMOSOME 1 OPEN READING FRAME 36; C1ORF36__:__
Percent__:__180050__:__RETINAL DETACHMENT__:____:__
Caret__:__180060__:__MOVED TO 152950__:____:__
Asterisk__:__180069__:__RETINOID ISOMEROHYDROLASE RPE65; RPE65__:____:__
Caret__:__180070__:__MOVED TO 221900__:____:__
Asterisk__:__180071__:__PHOSPHODIESTERASE 6A, cGMP-SPECIFIC, ROD, ALPHA; PDE6A__:__RETINAL ROD PHOTORECEPTOR cGMP PHOSPHODIESTERASE, ALPHA SUBUNIT; PDEA__:__
Asterisk__:__180072__:__PHOSPHODIESTERASE 6B, cGMP-SPECIFIC, ROD, BETA; PDE6B__:__RETINAL ROD PHOTORECEPTOR cGMP PHOSPHODIESTERASE, BETA SUBUNIT; PDEB;; RD, MOUSE, HOMOLOG OF;; RD1, MOUSE, HOMOLOG OF__:__
Asterisk__:__180073__:__PHOSPHODIESTERASE 6G, cGMP-SPECIFIC, ROD, GAMMA; PDE6G__:__RETINAL ROD PHOTORECEPTOR cGMP PHOSPHODIESTERASE, GAMMA SUBUNIT; PDEG__:__
NULL__:__180080__:__RETINAL VENOUS BEADING__:____:__
Asterisk__:__180090__:__RETINALDEHYDE-BINDING PROTEIN 1; RLBP1__:__CELLULAR RETINALDEHYDE-BINDING PROTEIN; CRALBP__:__
Number Sign__:__180100__:__RETINITIS PIGMENTOSA 1; RP1__:____:__
Caret__:__180102__:__MOVED TO 180380__:____:__
Caret__:__180103__:__MOVED TO 500004__:____:__
Number Sign__:__180104__:__RETINITIS PIGMENTOSA 9; RP9__:____:__
Number Sign__:__180105__:__RETINITIS PIGMENTOSA 10; RP10__:____:__
Asterisk__:__180190__:__RETINOIC ACID RECEPTOR, GAMMA; RARG__:____:__RARG/NUP98 FUSION GENE, INCLUDED
Number Sign__:__180200__:__RETINOBLASTOMA; RB1__:__RB__:__
Asterisk__:__180201__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 4A; ARID4A__:__ARID-CONTAINING PROTEIN 4A;; RETINOBLASTOMA-BINDING PROTEIN 1; RBP1; RBBP1__:__
Asterisk__:__180202__:__LYSINE-SPECIFIC DEMETHYLASE 5A; KDM5A__:__JUMONJI, AT-RICH INTERACTIVE DOMAIN 1A; JARID1A;; RETINOBLASTOMA-BINDING PROTEIN 2; RBP2; RBBP2__:__
Asterisk__:__180203__:__RETINOBLASTOMA-LIKE 2; RBL2__:__RETINOBLASTOMA-RELATED GENE RB2; RB2;; p130__:__
NULL__:__180210__:__RETINOPATHY, PERICENTRAL PIGMENTARY, DOMINANT__:____:__
Asterisk__:__180220__:__RETINOIC ACID RECEPTOR, BETA; RARB__:__RAR, BETA FORM;; HEPATITIS B VIRUS ACTIVATED PROTEIN, HAP;; HBV-ACTIVATED PROTEIN;; RAR-EPSILON__:__
Asterisk__:__180230__:__RETINOIC ACID-BINDING PROTEIN, CELLULAR, TYPE I; CRABP1__:__CRABP;; RETINOIC ACID-BINDING PROTEIN 5; RBP5__:__
Asterisk__:__180231__:__RETINOIC ACID-BINDING PROTEIN, CELLULAR, TYPE II; CRABP2__:____:__
Asterisk__:__180240__:__RETINOIC ACID RECEPTOR, ALPHA; RARA__:__RAR, ALPHA FORM__:__ACUTE PROMYELOCYTIC LEUKEMIA BREAKPOINT CLUSTER REGION, INCLUDED;; RARA/PML FUSION GENE, INCLUDED;; RARA/PLZF FUSION GENE, INCLUDED;; RARA/NUMA1 FUSION GENE, INCLUDED;; RARA/PRKAR1A FUSION GENE, INCLUDED
Asterisk__:__180245__:__RETINOID X RECEPTOR, ALPHA; RXRA__:____:__
Asterisk__:__180246__:__RETINOID X RECEPTOR, BETA; RXRB__:____:__
Asterisk__:__180247__:__RETINOID X RECEPTOR, GAMMA; RXRG__:__RXRC__:__
Asterisk__:__180250__:__RETINOL-BINDING PROTEIN 4; RBP4__:__RETINOL-BINDING PROTEIN, PLASMA__:__
Asterisk__:__180260__:__RETINOL-BINDING PROTEIN 1; RBP1__:__RETINOL-BINDING PROTEIN, CELLULAR; RBPC;; CELLULAR RETINOL-BINDING PROTEIN; CRBP;; CELLULAR RETINOL-BINDING PROTEIN 1; CRBP1;; CRBPI__:__
NULL__:__180270__:__RETINOSCHISIS, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__180280__:__RETINOL-BINDING PROTEIN 2; RBP2__:__RETINOL-BINDING PROTEIN, CELLULAR, 2; RBPC2;; CELLULAR RETINOL-BINDING PROTEIN 2; CRBP2;; CRBPII__:__
Asterisk__:__180290__:__RETINOL-BINDING PROTEIN 3; RBP3__:__RETINOL-BINDING PROTEIN, INTERSTITIAL; RBPI;; INTERSTITIAL RETINOL-BINDING PROTEIN; IRBP__:__
Number Sign__:__180295__:__RHABDOMYOSARCOMA, EMBRYONAL, 2; RMSE2__:____:__
Asterisk__:__180297__:__RHESUS BLOOD GROUP-ASSOCIATED GLYCOPROTEIN; RHAG__:__RHESUS ASSOCIATED POLYPEPTIDE, 50-KD; RH50A;; RH2__:__
Number Sign__:__180300__:__RHEUMATOID ARTHRITIS; RA__:__RHEUMATOID ARTHRITIS, SUSCEPTIBILITY TO__:__
Caret__:__180330__:__REMOVED FROM DATABASE__:____:__
NULL__:__180350__:__RHEUMATOID NODULOSIS__:____:__
NULL__:__180360__:__RHINY__:____:__
Asterisk__:__180370__:__THIOSULFATE SULFURTRANSFERASE; TST__:__RHODANESE; RDS__:__
Asterisk__:__180380__:__RHODOPSIN; RHO__:__OPSIN 2; OPN2__:__
Asterisk__:__180381__:__G PROTEIN-COUPLED RECEPTOR KINASE 1; GRK1__:__GPRK1;; RHODOPSIN KINASE; RHOK;; RK__:__
Asterisk__:__180385__:__LIM DOMAIN ONLY 2; LMO2__:__RHOMBOTIN 2; RBTN2;; RHOMBOTIN-LIKE 1; RBTNL1; RHOM2;; T-CELL TRANSLOCATION GENE 2; TTG2__:__
Asterisk__:__180386__:__LIM DOMAIN ONLY 3; LMO3__:__RHOMBOTIN-LIKE-2; RBTNL2;; RHOMBOTIN 3; RBTN3; RHOM3__:__
Asterisk__:__180390__:__RIBONUCLEOTIDE REDUCTASE, M2 SUBUNIT; RRM2__:__RIBONUCLEOTIDE REDUCTASE, SMALL SUBUNIT;; RIBONUCLEOTIDE REDUCTASE, R2 SUBUNIT; R2__:__
Asterisk__:__180410__:__RIBONUCLEOTIDE REDUCTASE, M1 SUBUNIT; RRM1__:__RIBONUCLEOTIDE REDUCTASE, LARGE SUBUNIT;; RIBONUCLEOTIDE REDUCTASE, R1 SUBUNIT; R1__:__
Asterisk__:__180420__:__RNA, 5S RIBOSOMAL, GENE CLUSTER 1; RN5S1@__:__5S rRNA CLUSTER 1__:__
Asterisk__:__180430__:__RIBOSE 5-PHOSPHATE ISOMERASE A; RPIA__:__RPI__:__
Asterisk__:__180435__:__RIBONUCLEASE L; RNASEL__:__RIBONUCLEASE 4; RNS4;; RIBONUCLEASE, 2-5A-DEPENDENT, INTERFERON-INDUCED;; INTERFERON-INDUCED 2-5A-DEPENDENT RNase__:__
Asterisk__:__180440__:__RIBONUCLEASE, RNase A FAMILY, 1; RNASE1__:__RIBONUCLEASE, PANCREATIC;; RNS1;; RIB1__:__
Asterisk__:__180450__:__RIBOSOMAL RNA 1; RNR1__:____:__
Asterisk__:__180451__:__RIBOSOMAL RNA 2; RNR2__:____:__
Asterisk__:__180452__:__RIBOSOMAL RNA 3; RNR3__:____:__
Asterisk__:__180453__:__RIBOSOMAL RNA 4; RNR4__:____:__
Asterisk__:__180454__:__RIBOSOMAL RNA 5; RNR5__:____:__
Asterisk__:__180460__:__RIBOSOMAL PROTEIN S6; RPS6__:____:__
Caret__:__180461__:__MOVED TO 180472__:____:__
Caret__:__180462__:__MOVED TO 180472__:____:__
Asterisk__:__180463__:__RIBOSOMAL PROTEIN S20A; RPS20A__:____:__
Asterisk__:__180464__:__RIBOSOMAL PROTEIN S20B; RPS20B__:____:__
Asterisk__:__180465__:__RIBOSOMAL PROTEIN S25; RPS25__:____:__
Asterisk__:__180466__:__RIBOSOMAL PROTEIN L19; RPL19__:____:__
Asterisk__:__180467__:__RIBOSOMAL PROTEIN L30; RPL30__:____:__
Asterisk__:__180468__:__RIBOSOMAL PROTEIN L35A; RPL35A__:____:__
Asterisk__:__180469__:__RIBOSOMAL PROTEIN L36A-LIKE; RPL36AL__:__RIBOSOMAL PROTEIN L36A; RPL36A__:__
Asterisk__:__180470__:__RIBOPHORIN I; RPN1__:__RBPH1__:__RBPH1/EVI1 FUSION GENE, INCLUDED
Asterisk__:__180471__:__RIBOSOMAL PROTEIN S11; RPS11__:____:__
Asterisk__:__180472__:__RIBOSOMAL PROTEIN S17; RPS17__:____:__RIBOSOMAL PROTEIN S17a-LIKE 1, INCLUDED; RPS17L1, INCLUDED;; RIBOSOMAL PROTEIN S17a, INCLUDED; RPS17A, INCLUDED;; RIBOSOMAL PROTEIN S17b-LIKE 2, INCLUDED; RPS17L2, INCLUDED;; RIBOSOMAL PROTEIN S17b, INCLUDED; RPS17B, INCLUDED
Asterisk__:__180473__:__RIBOSOMAL PROTEIN S18; RPS18__:____:__
Asterisk__:__180474__:__RIBOSOMAL PROTEIN L22; RPL22__:__EPSTEIN-BARR ASSOCIATED PROTEIN; EAP__:__
Asterisk__:__180475__:__RIBOSOMAL PROTEIN L12; RPL12__:____:__
Asterisk__:__180476__:__RIBOSOMAL PROTEIN S13; RPS13__:____:__
Asterisk__:__180477__:__RIBOSOMAL PROTEIN S21; RPS21__:____:__
Asterisk__:__180478__:__RIBOSOMAL PROTEIN S3a; RPS3A__:____:__
Asterisk__:__180479__:__RIBOSOMAL PROTEIN L4; RPL4__:____:__
Asterisk__:__180480__:__RIBULOSE 5-PHOSPHATE 3-EPIMERASE; RPE__:____:__
Asterisk__:__180490__:__RIBOPHORIN II; RPN2__:____:__
Number Sign__:__180500__:__AXENFELD-RIEGER SYNDROME, TYPE 1; RIEG1__:__RIEGER SYNDROME, TYPE 1;; RIEG;; RGS__:__
Asterisk__:__180510__:__RIBOSOMAL PHOSPHOPROTEIN, LARGE, P0; RPLP0__:__RIBOSOMAL PHOSPHOPROTEIN, ACIDIC, P0__:__
Asterisk__:__180520__:__RIBOSOMAL PHOSPHOPROTEIN, LARGE, P1; RPLP1__:__RIBOSOMAL PHOSPHOPROTEIN, ACIDIC, P1__:__
Asterisk__:__180530__:__RIBOSOMAL PHOSPHOPROTEIN, LARGE, P2; RPLP2__:__RIBOSOMAL PHOSPHOPROTEIN, ACIDIC, P2__:__
Asterisk__:__180535__:__RIBOSOMAL PROTEIN S15; RPS15__:__RAT INSULINOMA GENE HOMOLOG; RIG__:__
Caret__:__180540__:__MOVED TO 131410__:____:__
Number Sign__:__180550__:__RING DERMOID OF CORNEA; RDC__:____:__
Percent__:__180600__:__RINGED HAIR__:__PILI ANNULATI__:__
Asterisk__:__180610__:__REARRANGED LMYC FUSION; RLF__:__RLF PROTEIN INVOLVED IN ACTIVATION OF LMYC__:__
Asterisk__:__180620__:__TRANSFER RNA METHIONINE 2; TRNAM2__:__tRNA METHIONINE INITIATOR 2; TRNAMI2;; RNA, TRANSFER, METHIONINE INITIATOR, 2; RNTMI2__:__
Asterisk__:__180621__:__TRANSFER RNA METHIONINE 1; TRNAM1__:__TRANSFER RNA METHIONINE INITIATOR 1;; TRMI1 tRNA METHIONINE INITIATOR 1;; RNA, INITIATOR METHIONINE TRANSFER, 1; RNTMI1__:__
Asterisk__:__180630__:__DEAD/H BOX 5; DDX5__:__RNA HELICASE, 68-KD;; HELICASE, RNA, NUCLEAR 1; HLR1;; G17P1;; NUCLEAR ANTIGEN, 68-KD; p68;; RNA-DEPENDENT ATPase__:__
Asterisk__:__180640__:__TRANSFER RNA GLUTAMIC ACID; TRNAE1__:__TRNE;; tRNA GLUTAMIC ACID; TRE__:__
Asterisk__:__180645__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 73A; SNORA73A__:__RNA, U17A SMALL NUCLEOLAR; RNU17A;; snoRNA, U17A;; RNA, SMALL NUCLEOLAR E1; RNE1__:__
Asterisk__:__180646__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 62; SNORA62__:__RNA, U108 SMALL NUCLEOLAR; RNU108;; RNA, E2 SMALL NUCLEOLAR; RNE2;; snoRNA, E2__:__
Asterisk__:__180647__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 63; SNORA63__:__RNA, U107 SMALL NUCLEOLAR; RNU107;; RNA, E3 SMALL NUCLEOLAR; RNE3;; snoRNA, E3__:__
Asterisk__:__180660__:__POLYMERASE II, RNA, SUBUNIT A; POLR2A__:__RPB1, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 220-KD SUBUNIT;; RNA POLYMERASE II, LARGE SUBUNIT; RPO2; RPOL2; POLR2__:__
Asterisk__:__180661__:__POLYMERASE II, RNA, SUBUNIT B; POLR2B__:__RPB2, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 140-KD SUBUNIT;; RNA POLYMERASE II, SECOND LARGEST SUBUNIT__:__
Asterisk__:__180662__:__POLYMERASE II, RNA, SUBUNIT I; POLR2I__:__RPB9, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 14.5-KD SUBUNIT__:__
Asterisk__:__180663__:__POLYMERASE II, RNA, SUBUNIT C; POLR2C__:__RPB3, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 33-KD SUBUNIT__:__
Asterisk__:__180664__:__POLYMERASE II, RNA, SUBUNIT E; POLR2E__:__RPB5, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 25-KD SUBUNIT__:__
Asterisk__:__180670__:__RNA POLYMERASE III TRANSCRIPTIONAL UNITS__:____:__
Asterisk__:__180680__:__RNA, U1A SMALL NUCLEAR; RNU1A__:__snRNA, U1A;; RNA, U1 SMALL NUCLEAR; RNU1__:__
Asterisk__:__180690__:__RNA, U2 SMALL NUCLEAR, 1; RNU2-1__:__snRNA, U2 RNA, U2 SMALL NUCLEAR, FORMERLY; RNU2, FORMERLY__:__
Asterisk__:__180691__:__RNA, U5A SMALL NUCLEAR; RNU5A__:__snRNA, U5A;; RNA, U5 SMALL NUCLEAR; RNU5__:__
Asterisk__:__180692__:__RNA, U6 SMALL NUCLEAR, 1; RNU6-1__:__RNA, U6 SMALL NUCLEAR; RNU6;; snRNA, U6A;; RNA, U6A SMALL NUCLEAR, FORMERLY; RNU6A, FORMERLY__:__
Number Sign__:__180700__:__ROBINOW SYNDROME, AUTOSOMAL DOMINANT 1; DRS1__:__ROBINOW DWARFISM;; FETAL FACE SYNDROME;; ACRAL DYSOSTOSIS WITH FACIAL AND GENITAL ABNORMALITIES__:__
Asterisk__:__180710__:__SMALL NUCLEOLAR RNA, C/D BOX, 3A; SNORD3A__:__RNA, U3 SMALL NUCLEOLAR; RNU3;; snoRNA, U3__:__
Caret__:__180720__:__MOVED TO 180680__:____:__
Asterisk__:__180721__:__ROD OUTER SEGMENT PROTEIN 1; ROM1__:__ROSP1__:__
NULL__:__180730__:__ROMBO SYNDROME__:____:__
Asterisk__:__180740__:__SMALL NUCLEAR RIBONUCLEOPROTEIN, U1 SUBUNIT, 70-KD; SNRNP70__:__SNRP70;; RNA, U1 SMALL NUCLEAR, ASSOCIATED PROTEIN; U1RNP; U1AP;; RIBONUCLEOPROTEIN U1, SMALL NUCLEAR; RPU1;; RIBONUCLEOPROTEIN U1, SMALL NUCLEAR, 70-KD; U170K;; RNP ANTIGEN__:__
Number Sign__:__180750__:__ROBINOW-SORAUF SYNDROME__:__CRANIOSYNOSTOSIS-BIFID HALLUX SYNDROME;; ACROCEPHALOSYNDACTYLY, ROBINOW-SORAUF TYPE__:__
Number Sign__:__180800__:__ROUSSY-LEVY HEREDITARY AREFLEXIC DYSTASIA__:__ROUSSY-LEVY SYNDROME__:__
Caret__:__180840__:__MOVED TO 601625__:____:__
Number Sign__:__180849__:__RUBINSTEIN-TAYBI SYNDROME 1; RSTS1__:__RSTS;; RUBINSTEIN SYNDROME;; BROAD THUMBS AND GREAT TOES, CHARACTERISTIC FACIES, AND MENTAL RETARDATION;; BROAD THUMB-HALLUX SYNDROME__:__
Caret__:__180850__:__MOVED TO 180849__:____:__
Number Sign__:__180860__:__SILVER-RUSSELL SYNDROME; SRS__:__RUSSELL-SILVER SYNDROME; RSS;; SILVER-RUSSELL DWARFISM__:__
NULL__:__180870__:__RUVALCABA SYNDROME__:____:__
Percent__:__180900__:__RUTHERFURD SYNDROME__:__CORNEAL DYSTROPHY WITH GUM HYPERTROPHY;; GINGIVAL HYPERTROPHY WITH CORNEAL DYSTROPHY__:__
Asterisk__:__180901__:__RYANODINE RECEPTOR 1; RYR1__:__RYANODINE RECEPTOR, SKELETAL MUSCLE; RYDR;; SKELETAL MUSCLE RYANODINE RECEPTOR; SKRR;; SARCOPLASMIC RETICULUM CALCIUM RELEASE CHANNEL__:__
Asterisk__:__180902__:__RYANODINE RECEPTOR 2; RYR2__:__RYANODINE RECEPTOR, CARDIAC__:__
Asterisk__:__180903__:__RYANODINE RECEPTOR 3; RYR3__:__RYANODINE RECEPTOR, BRAIN__:__
Asterisk__:__180910__:__SALIVARY ESTERASE__:____:__
Number Sign__:__180920__:__APLASIA OF LACRIMAL AND SALIVARY GLANDS; ALSG__:____:__SALIVARY GLANDS, ABSENCE OF, INCLUDED;; PAROTID APLASIA OR HYPOPLASIA, INCLUDED
Caret__:__180930__:__REMOVED FROM DATABASE__:____:__
Caret__:__180940__:__REMOVED FROM DATABASE__:____:__
Percent__:__180950__:__SALIVARY SUBSTANCE, CLOSTRIDIUM BOTULINUM TYPE__:____:__
Asterisk__:__180960__:__S-ADENOSYLHOMOCYSTEINE HYDROLASE; AHCY__:__SAHH__:__
Asterisk__:__180980__:__S-ADENOSYLMETHIONINE DECARBOXYLASE; AMD1__:__AMD__:__
Asterisk__:__180989__:__PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 1; PRB1__:__BASIC SALIVARY PROLINE-RICH PROTEIN, BstNI TYPE, 1__:__SALIVARY PROTEIN Pe, INCLUDED;; PAROTID MIDDLE BAND PROTEIN, INCLUDED; Pm, INCLUDED;; PmF, INCLUDED;; PmS, INCLUDED;; CON2, INCLUDED
Asterisk__:__180990__:__PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 4; PRB4__:__BASIC SALIVARY PROLINE-RICH PROTEIN, BstNI TYPE, 4__:__SALIVARY PROTEIN Po, INCLUDED
Number Sign__:__181000__:__SARCOIDOSIS, SUSCEPTIBILITY TO, 1; SS1__:__SARCOIDOSIS;; BOECK SARCOID__:__
NULL__:__181010__:__SALIVARY DUCT CALCULI__:__PAROTID DUCT CALCULI;; SUBMANDIBULAR DUCT CALCULI__:__
Number Sign__:__181030__:__SALIVARY GLAND ADENOMA, PLEOMORPHIC__:__SGPA;; PSA__:__
Asterisk__:__181031__:__S-ANTIGEN; SAG__:__ARRESTIN;; S-ARRESTIN;; ROD ARRESTIN__:__
Asterisk__:__181035__:__TETRASPANIN 31; TSPAN31__:__SARCOMA AMPLIFIED SEQUENCE; SAS__:__
NULL__:__181180__:__SAY SYNDROME__:__CLEFT PALATE, MICROCEPHALY, LARGE EARS, AND SHORT STATURE__:__
NULL__:__181200__:__SC(1) TRAIT OF SALIVA__:____:__
NULL__:__181250__:__SCALP DEFECTS AND POSTAXIAL POLYDACTYLY__:____:__
Number Sign__:__181270__:__SCALP-EAR-NIPPLE SYNDROME; SENS__:__FINLAY-MARKS SYNDROME;; SEN SYNDROME__:__
NULL__:__181300__:__SCAPULA, CONTOUR OF VERTEBRAL BORDER OF__:____:__
Number Sign__:__181350__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT; EDMD2__:__EMD2;; EMERY-DREIFUSS MUSCULAR DYSTROPHY, AUTOSOMAL DOMINANT;; SCAPULOILIOPERONEAL ATROPHY WITH CARDIOPATHY;; MUSCULAR DYSTROPHY WITH EARLY CONTRACTURES AND CARDIOMYOPATHY, AUTOSOMAL DOMINANT;; HAUPTMANN-THANNHAUSER MUSCULAR DYSTROPHY;; CARDIOMYOPATHY, DILATED, WITH QUADRICEPS MYOPATHY;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B, FORMERLY; LGMD1B, FORMERLY;; MUSCULAR DYSTROPHY, PROXIMAL, TYPE 1B, FORMERLY__:__
Number Sign__:__181400__:__SCAPULOPERONEAL SYNDROME, NEUROGENIC, KAESER TYPE; SCPNK__:__KAESER SYNDROME;; STARK-KAESER SYNDROME;; SCAPULOPERONEAL SYNDROME, NEUROGENIC TYPE, OF KAESER__:__
Number Sign__:__181405__:__SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY; SPSMA__:__AMYOTROPHY, NEUROGENIC SCAPULOPERONEAL, NEW ENGLAND TYPE__:__
Number Sign__:__181430__:__SCAPULOPERONEAL MYOPATHY, MYH7-RELATED; SPMM__:__SCAPULOPERONEAL MUSCULAR DYSTROPHY; SPMD;; SCAPULOPERONEAL SYNDROME, MYOPATHIC TYPE__:__
Percent__:__181440__:__SCHEUERMANN DISEASE__:__SCHEUERMANN JUVENILE KYPHOSIS;; SPINAL OSTEOCHONDROSIS__:__
Number Sign__:__181450__:__ULNAR-MAMMARY SYNDROME; UMS__:__PALLISTER ULNAR-MAMMARY SYNDROME;; SCHINZEL SYNDROME__:__
Percent__:__181460__:__SCHISTOSOMA MANSONI INFECTION, SUSCEPTIBILITY/RESISTANCE TO__:__SCHISTOSOMA MANSONI, INTENSITY OF INFECTION BY; SM1__:__
Number Sign__:__181500__:__SCHIZOPHRENIA; SCZD__:__SCHIZOPHRENIA WITH OR WITHOUT AN AFFECTIVE DISORDER__:__
Percent__:__181510__:__SCHIZOPHRENIA 1; SCZD1__:__SCHIZOPHRENIA 1 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 5-RELATED__:__
Caret__:__181515__:__MOVED TO 300977__:____:__
Caret__:__181520__:__MOVED TO 104640__:____:__
Asterisk__:__181590__:__SCL/TAL1-INTERRUPTING LOCUS; STIL__:__SCL-INTERRUPTING LOCUS; SIL__:__
Percent__:__181600__:__HURIEZ SYNDROME; HRZ__:__SCLEROTYLOSIS;; SCLEROATROPHIC AND KERATOTIC DERMATOSIS OF LIMBS__:__
NULL__:__181700__:__SCLEROCORNEA, AUTOSOMAL DOMINANT__:____:__
Percent__:__181750__:__SCLERODERMA, FAMILIAL PROGRESSIVE__:__SYSTEMIC SCLEROSIS, SUSCEPTIBILITY TO__:__CREST SYNDROME, INCLUDED
Percent__:__181800__:__SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 1; IS1__:__ADOLESCENT ISOLATED SCOLIOSIS; AIS;; ADOLESCENT IDIOPATHIC SCOLIOSIS__:__
Number Sign__:__182000__:__KERATOSIS, SEBORRHEIC__:____:__
Asterisk__:__182090__:__SIMIAN SARCOMA-ASSOCIATED VIRUS-1/GIBBON APE LEUKEMIA VIRUS; SSAV1__:__GLV__:__
Asterisk__:__182098__:__SECRETIN RECEPTOR; SCTR__:____:__
Asterisk__:__182099__:__SECRETIN; SCT__:____:__
Asterisk__:__182100__:__FUCOSYLTRANSFERASE 2; FUT2__:__SECRETOR FACTOR; Se;; SEC2__:__
Asterisk__:__182115__:__CYTOHESIN 1; CYTH1__:__PLECKSTRIN HOMOLOGY, SEC7, AND COILED-COIL DOMAINS PROTEIN 1; PSCD1;; SEC7, YEAST, HOMOLOG OF; SEC7;; D17S811E__:__
Asterisk__:__182120__:__SECRETED PROTEIN, ACIDIC, CYSTEINE-RICH; SPARC__:__OSTEONECTIN; ON;; BM40__:__
Asterisk__:__182125__:__SEPIAPTERIN REDUCTASE; SPR__:____:__
Asterisk__:__182128__:__SERINE DEHYDRATASE; SDS__:__SDH__:__
Asterisk__:__182131__:__5-HYDROXYTRYPTAMINE RECEPTOR 1B; HTR1B__:__SEROTONIN 5-HT-1B RECEPTOR;; SEROTONIN 5-HT-1D-BETA RECEPTOR;; 5-HYDROXYTRYPTAMINE-1D-BETA RECEPTOR; HTR1DB__:__
Asterisk__:__182132__:__5-HYDROXYTRYPTAMINE RECEPTOR 1E; HTR1E__:__SEROTONIN 5-HT-1E RECEPTOR__:__
Asterisk__:__182133__:__5-HYDROXYTRYPTAMINE RECEPTOR 1D; HTR1D__:__SEROTONIN 5-HT-1D RECEPTOR;; 5-HYDROXYTRYPTAMINE RECEPTOR 1D-ALPHA; HTR1DA;; RDC4__:__
Asterisk__:__182134__:__5-HYDROXYTRYPTAMINE RECEPTOR 1F; HTR1F__:__5-HYDROXYTRYPTAMINE-1E-LIKE RECEPTOR; HTR1EL;; SEROTONIN 5-HT-1F RECEPTOR;; SEROTONIN 5-HT-1E-LIKE RECEPTOR;; MR77__:__
Asterisk__:__182135__:__5-HYDROXYTRYPTAMINE RECEPTOR 2A; HTR2A__:__SEROTONIN 5-HT-2A RECEPTOR;; SEROTONIN 5-HT-2 RECEPTOR, FORMERLY; HTR2, FORMERLY__:__
Asterisk__:__182137__:__5-HYDROXYTRYPTAMINE RECEPTOR 7; HTR7__:__SEROTONIN 5-HT-7 RECEPTOR__:__
Asterisk__:__182138__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, SEROTONIN), MEMBER 4; SLC6A4__:__SEROTONIN TRANSPORTER; SERT;; 5-HYDROXYTRYPTAMINE TRANSPORTER; 5-HTT;; HTT__:__
Asterisk__:__182139__:__5-HYDROXYTRYPTAMINE RECEPTOR 3A; HTR3A__:__5-HYDROXYTRYPTAMINE RECEPTOR 3; HTR3;; SEROTONIN 5-HT-3 RECEPTOR__:__
Asterisk__:__182140__:__SEMENOGELIN I; SEMG1__:__SEMENOGELIN; SEMG;; CANCER/TESTIS ANTIGEN 103__:__
Asterisk__:__182141__:__SEMENOGELIN II; SEMG2__:____:__
Caret__:__182143__:__MOVED TO 177040__:____:__
Asterisk__:__182144__:__SERINE HYDROXYMETHYLTRANSFERASE, CYTOSOLIC; SHMT1__:____:__
Asterisk__:__182145__:__SERUM PROTEIN POLYMORPHISM M-158__:__SPPM-158__:__
NULL__:__182150__:__SIMOSA CRANIOFACIAL SYNDROME__:____:__
Asterisk__:__182160__:__SIALOPHORIN; SPN__:__LEUKOSIALIN; LSN;; LEUKOCYTE LARGE SIALOGLYCOPROTEIN;; CD43;; GPL115__:__
Number Sign__:__182170__:__ANEMIA, SIDEROBLASTIC, 4; SIDBA4__:____:__
Asterisk__:__182175__:__SIGNAL RECOGNITION PARTICLE, 19-KD; SRP19__:____:__
Asterisk__:__182180__:__SIGNAL RECOGNITION PARTICLE RECEPTOR, ALPHA SUBUNIT; SRPRA__:__SIGNAL RECOGNITION PARTICLE RECEPTOR; SRPR;; DOCKING PROTEIN; DP__:__
NULL__:__182190__:__SINUS NODE DISEASE AND MYOPIA__:__SICK SINUS SYNDROME AND MYOPIA;; SSS-MYOPIA SYNDROME__:__
NULL__:__182200__:__SELLA TURCICA, BRIDGED__:____:__
Caret__:__182203__:__MOVED TO 162643__:____:__
Asterisk__:__182205__:__SEX HORMONE-BINDING GLOBULIN; SHBG__:__ANDROGEN-BINDING PROTEIN; ABP;; TESTOSTERONE-BINDING BETA-GLOBULIN; TEBG__:__
NULL__:__182210__:__SHPRINTZEN OMPHALOCELE SYNDROME__:__OMPHALOCELE WITH HYPOPLASIA OF PHARYNX AND LARYNX, LEARNING DISABILITY, DYSMORPHIC FACIES, AND SCOLIOSIS;; PHARYNX AND LARYNX HYPOPLASIA WITH OMPHALOCELE__:__
Number Sign__:__182212__:__SHPRINTZEN-GOLDBERG CRANIOSYNOSTOSIS SYNDROME; SGS__:__CRANIOSYNOSTOSIS WITH ARACHNODACTYLY AND ABDOMINAL HERNIAS;; MARFANOID DISORDER WITH CRANIOSYNOSTOSIS, TYPE I;; MARFANOID CRANIOSYNOSTOSIS SYNDROME__:__
NULL__:__182220__:__SISTER CHROMATID EXCHANGE, FREQUENCY OF__:__SCE, FREQUENCY OF__:__
Number Sign__:__182230__:__SEPTOOPTIC DYSPLASIA__:__DE MORSIER SYNDROME__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 5, INCLUDED; CPHD5, INCLUDED;; GROWTH HORMONE DEFICIENCY WITH PITUITARY ANOMALIES, INCLUDED
Number Sign__:__182250__:__SINGLETON-MERTEN SYNDROME 1; SGMRT1__:____:__
NULL__:__182255__:__SKELETAL DYSPLASIA WITH DELAYED EPIPHYSEAL AND CARPAL BONE OSSIFICATION__:____:__
Asterisk__:__182257__:__PROTEINASE INHIBITOR 3; PI3__:__SKIN-DERIVED ANTILEUKOPROTEINASE; SKALP;; ANTILEUKOPROTEINASE, SKIN-DERIVED;; ELAFIN;; ELASTASE-SPECIFIC INHIBITOR; ESI;; TRAPPIN 2__:__
NULL__:__182260__:__SLIPPED FEMORAL CAPITAL EPIPHYSES__:__EPIPHYSIOLYSIS CAPITIS FEMORIS__:__
Asterisk__:__182265__:__SMALL PROLINE-RICH PROTEIN 1A; SPRR1A__:____:__
Asterisk__:__182266__:__SMALL PROLINE-RICH PROTEIN 1B; SPRR1B__:__CORNIFIN__:__
Asterisk__:__182267__:__SMALL PROLINE-RICH PROTEIN 2A; SPRR2A__:____:__
Asterisk__:__182268__:__SMALL PROLINE-RICH PROTEIN 2B; SPRR2B__:____:__
NULL__:__182269__:__SMALL PROLINE-RICH PROTEIN 2C, PSEUDOGENE; SPRR2C__:____:__
NULL__:__182270__:__KETONE COMPOUNDS, ABILITY TO SMELL__:____:__
Asterisk__:__182271__:__SMALL PROLINE-RICH PROTEIN 3; SPRR3__:____:__
Asterisk__:__182279__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE N; SNRPN__:__SMN__:__SNRPN UPSTREAM READING FRAME, INCLUDED; SNURF, INCLUDED
Percent__:__182280__:__SMALL CELL CANCER OF THE LUNG__:__SCLC1;; SCLC; SCCL__:__
Asterisk__:__182281__:__CHEMOKINE, CC MOTIF, LIGAND 1; CCL1__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 1; SCYA1;; SMALL INDUCIBLE CYTOKINE A1;; INFLAMMATORY CYTOKINE I-309; I309__:__
Asterisk__:__182282__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDES B AND B1; SNRPB__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDES B AND B-PRIME__:__
Asterisk__:__182283__:__CHEMOKINE, CC MOTIF, LIGAND 3; CCL3__:__SMALL INDUCIBLE CYTOKINE A3; SCYA3;; MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA; MIP1A;; LD78-ALPHA__:__
Asterisk__:__182284__:__CHEMOKINE, CC MOTIF, LIGAND 4; CCL4__:__SMALL INDUCIBLE CYTOKINE A4; SCYA4;; MACROPHAGE INFLAMMATORY PROTEIN 1-BETA; MIP1B;; MIP1B1;; IMMUNE ACTIVATION 2; ACT2;; AT744.1__:__
Asterisk__:__182285__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE A; SNRPA__:____:__
Number Sign__:__182290__:__SMITH-MAGENIS SYNDROME; SMS__:__CHROMOSOME 17p11.2 DELETION SYNDROME__:__SMITH-MAGENIS SYNDROME CHROMOSOME REGION, INCLUDED; SMCR, INCLUDED
Asterisk__:__182305__:__SOLUTE CARRIER FAMILY 8 (SODIUM-CALCIUM EXCHANGER), MEMBER A1; SLC8A1__:__SODIUM-CALCIUM EXCHANGER 1; NCX1__:__
Asterisk__:__182307__:__SOLUTE CARRIER FAMILY 9, MEMBER 3; SLC9A3__:__SODIUM/HYDROGEN EXCHANGER 3; NHE3;; SODIUM/HYDROGEN EXCHANGER, APICAL EPITHELIAL__:__
Asterisk__:__182308__:__SOLUTE CARRIER FAMILY 17 (ORGANIC ANION COTRANSPORTER), MEMBER 1; SLC17A1__:__SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 1;; SODIUM-PHOSPHATE TRANSPORT 1, KIDNEY; NPT1;; RENAL SODIUM-PHOSPHATE TRANSPORT PROTEIN 1__:__
Asterisk__:__182309__:__SOLUTE CARRIER FAMILY 34 (TYPE II SODIUM/PHOSPHATE COTRANSPORTER), MEMBER 1; SLC34A1__:__SOLUTE CARRIER FAMILY 17, MEMBER 2, FORMERLY; SLC17A2, FORMERLY;; SODIUM/PHOSPHATE TRANSPORT 2, KIDNEY; NPT2;; RENAL SODIUM/PHOSPHATE TRANSPORT PROTEIN 2;; NaPi3__:__
Asterisk__:__182310__:__ATPase, Na+/K+ TRANSPORTING, ALPHA-1 POLYPEPTIDE; ATP1A1__:__SODIUM-POTASSIUM-ATPase, ALPHA-1 POLYPEPTIDE;; Na,K-ATPase, ALPHA-A CATALYTIC POLYPEPTIDE__:__
Asterisk__:__182330__:__ATPase, Na+/K+ TRANSPORTING, BETA-1 POLYPEPTIDE; ATP1B1__:__Na,K-ATPase BETA-1 POLYPEPTIDE__:__
Asterisk__:__182331__:__ATPase, Na+/K+ TRANSPORTING, BETA-2 POLYPEPTIDE; ATP1B2__:__Na,K-ATPase BETA-2 POLYPEPTIDE;; ADHESION MOLECULE ON GLIA; AMOG__:__
Asterisk__:__182340__:__ATPase, Na+/K+ TRANSPORTING, ALPHA-2 POLYPEPTIDE; ATP1A2__:__SODIUM-POTASSIUM-ATPase, ALPHA-2 POLYPEPTIDE;; Na,K-ATPase, ALPHA-A(+) CATALYTIC POLYPEPTIDE;; Na,K-ATPase, ALPHA-B POLYPEPTIDE__:__
Asterisk__:__182350__:__ATPase, Na+/K+ TRANSPORTING, ALPHA-3 POLYPEPTIDE; ATP1A3__:__SODIUM-POTASSIUM-ATPase, ALPHA-3 POLYPEPTIDE;; ATPase, Na+/K+, ALPHA III__:__
Asterisk__:__182360__:__ATPase, H+/K+ TRANSPORTING, NONGASTRIC, ALPHA POLYPEPTIDE; ATP12A__:__HYDROGEN/POTASSIUM-EXCHANGING ATPase 12A;; ATPase, Na+/K+ TRANSPORTING, ALPHA POLYPEPTIDE-LIKE 1; ATP1AL1;; SODIUM/POTASSIUM-ATPase, ALPHA POLYPEPTIDE-LIKE__:__
Caret__:__182370__:__MOVED TO 182330__:____:__
Asterisk__:__182380__:__SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 1; SLC5A1__:__SODIUM-GLUCOSE TRANSPORTER 1; SGLT1;; SODIUM-GLUCOSE COTRANSPORTER, INTESTINAL;; NA+/GLUCOSE COTRANSPORTER, HIGH AFFINITY; NAGT__:__
Asterisk__:__182381__:__SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 2; SLC5A2__:__SODIUM-GLUCOSE TRANSPORTER 2; SGLT2;; SODIUM-GLUCOSE COTRANSPORTER, RENAL;; SODIUM-GLUCOSE COTRANSPORTER, KIDNEY LOW AFFINITY__:__
Asterisk__:__182389__:__SODIUM CHANNEL, NEURONAL TYPE I, ALPHA SUBUNIT; SCN1A__:__SODIUM CHANNEL, BRAIN TYPE I, ALPHA SUBUNIT; NAC1;; NAV1.1__:__
Asterisk__:__182390__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE II, ALPHA SUBUNIT; SCN2A__:__SODIUM CHANNEL, BRAIN TYPE II, ALPHA SUBUNIT; NAC2;; NAV1.2;; SODIUM CHANNEL, NEURONAL TYPE II, ALPHA SUBUNIT-1, FORMERLY; SCN2A1, FORMERLY__:__
Asterisk__:__182391__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE III, ALPHA SUBUNIT; SCN3A__:__SODIUM CHANNEL, NEURONAL TYPE III, ALPHA SUBUNIT;; SODIUM CHANNEL, BRAIN TYPE III, ALPHA SUBUNIT; NAC3;; NAV1.3__:__
Asterisk__:__182392__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE VII, ALPHA SUBUNIT; SCN7A__:__SODIUM CHANNEL, NEURONAL TYPE VI, ALPHA SUBUNIT;; SODIUM CHANNEL, VOLTAGE-GATED, TYPE VI, ALPHA SUBUNIT; SCN6A__:__
Asterisk__:__182396__:__SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID COTRANSPORTER FAMILY), MEMBER 1; SLC10A1__:__SODIUM/TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; NTCP;; SODIUM/TAUROCHOLATE COTRANSPORTING POLYPEPTIDE, HEPATIC; NTCP1__:__
NULL__:__182400__:__SOMATOMEDIN, EMBRYONIC__:____:__
Number Sign__:__182410__:__SNEDDON SYNDROME__:__LIVEDO RETICULARIS AND CEREBROVASCULAR ACCIDENTS__:__
Asterisk__:__182450__:__SOMATOSTATIN; SST__:__SMST;; GROWTH HORMONE INHIBITORY HORMONE; GHIH__:__SOMATOSTATIN 28, INCLUDED;; SOMATOSTATIN 14, INCLUDED;; NEURONOSTATIN, INCLUDED
Asterisk__:__182451__:__SOMATOSTATIN RECEPTOR 1; SSTR1__:____:__
Asterisk__:__182452__:__SOMATOSTATIN RECEPTOR 2; SSTR2__:____:__
Asterisk__:__182453__:__SOMATOSTATIN RECEPTOR 3; SSTR3__:____:__
Asterisk__:__182454__:__SOMATOSTATIN RECEPTOR 4; SSTR4__:____:__
Plus__:__182455__:__SOMATOSTATIN RECEPTOR 5; SSTR5__:____:__SOMATOSTATIN ANALOG, RESISTANCE TO, INCLUDED
Asterisk__:__182465__:__SON DNA-BINDING PROTEIN; SON__:____:__
Asterisk__:__182500__:__SORBITOL DEHYDROGENASE; SORD__:__SORBITOL DEHYDROGENASE 1; SORD1__:__SORBITOL DEHYDROGENASE 2, INCLUDED; SORD2, INCLUDED
Asterisk__:__182520__:__SORCIN; SRI__:__MULTIDRUG-RESISTANCE COMPLEX, CLASS 4;; MDR COMPLEX, CLASS 4__:__
Asterisk__:__182530__:__SON OF SEVENLESS, DROSOPHILA, HOMOLOG 1; SOS1__:__SOS1 GUANINE NUCLEOTIDE EXCHANGE FACTOR__:__
Asterisk__:__182590__:__TREFOIL FACTOR 2; TFF2__:__SPASMOLYTIC PROTEIN 1; SP; SML1__:__
Number Sign__:__182600__:__SPASTIC PARAPLEGIA 3, AUTOSOMAL DOMINANT; SPG3A__:__SPG3;; STRUMPELL DISEASE;; FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 1; FSP1__:__
Number Sign__:__182601__:__SPASTIC PARAPLEGIA 4, AUTOSOMAL DOMINANT; SPG4__:__FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 2; FSP2__:__
NULL__:__182610__:__SPASTIC PARAPLEGIA, EPILEPSY, AND MENTAL RETARDATION; SPEMR__:____:__
NULL__:__182690__:__SPASTIC PARAPLEGIA, SENSORINEURAL DEAFNESS, MENTAL RETARDATION, AND PROGRESSIVE NEPHROPATHY__:____:__
Caret__:__182700__:__MOVED TO 270685__:____:__
Asterisk__:__182790__:__SPECTRIN, BETA, NONERYTHROCYTIC, 1; SPTBN1__:__SPECTRIN, NONERYTHROID, BETA SUBUNIT; SPTB2;; BETA-SPECTRIN, GENERAL FORM;; BETA-G SPECTRIN;; FODRIN, BETA;; EMBRYONIC LIVER BETA-FODRIN; ELF;; SPECTRIN, BETA-II__:__
NULL__:__182800__:__SPASTIC PARAPLEGIA WITH ASSOCIATED EXTRAPYRAMIDAL SIGNS__:____:__
Asterisk__:__182810__:__SPECTRIN, ALPHA, NONERYTHROCYTIC 1; SPTAN1__:__SPECTRIN, NONERYTHROID, ALPHA SUBUNIT; NEAS;; SPECTRIN, ALPHA-II;; FODRIN, ALPHA__:__
NULL__:__182815__:__SPASTIC PARAPLEGIA WITH NEUROPATHY AND POIKILODERMA__:____:__
NULL__:__182820__:__SPASTIC PARAPLEGIA WITH PRECOCIOUS PUBERTY__:__PRECOCIOUS PUBERTY WITH SPASTIC PARAPLEGIA__:__
NULL__:__182830__:__SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND DEMENTIA__:____:__
Asterisk__:__182860__:__SPECTRIN, ALPHA, ERYTHROCYTIC 1; SPTA1__:____:__
Asterisk__:__182870__:__SPECTRIN, BETA, ERYTHROCYTIC; SPTB__:__SPECTRIN, BETA-I__:__
NULL__:__182875__:__SPEECH DEVELOPMENT, DELAYED, WITH FACIAL ASYMMETRY, STRABISMUS, AND TRANSVERSE EARLOBE CREASE__:____:__
Asterisk__:__182878__:__OUTER DENSE FIBER OF SPERM TAILS 1; ODF1__:__OUTER DENSE FIBER OF SPERM TAILS, 27-KD; ODF27;; SPERM OUTER DENSE FIBER; SODF__:__
Caret__:__182879__:__MOVED TO 104776__:____:__
Asterisk__:__182880__:__SPERM PROTAMINE P1; PRM1__:____:__
NULL__:__182882__:__SPERM PROTAMINE P4; PRM4__:____:__
Asterisk__:__182888__:__ZONA PELLUCIDA GLYCOPROTEIN 2; ZP2__:__SPERM RECEPTOR, SECONDARY__:__
Asterisk__:__182889__:__ZONA PELLUCIDA GLYCOPROTEIN 3; ZP3__:__ZONA PELLUCIDA GLYCOPROTEIN 3A; ZP3A;; SPERM RECEPTOR__:__ZONA PELLUCIDA GLYCOPROTEIN 3B, INCLUDED; ZP3B, INCLUDED
Asterisk__:__182890__:__SPERM PROTAMINE P2; PRM2__:____:__
Asterisk__:__182891__:__SPERMIDINE SYNTHASE; SRM__:__SPS1__:__
Caret__:__182892__:__MOVED TO 300105__:____:__
Number Sign__:__182900__:__SPHEROCYTOSIS, TYPE 1; SPH1__:__SPHEROCYTOSIS, HEREDITARY, 1; HS1;; SPH; HS__:__
Number Sign__:__182920__:__MYOPATHY, SPHEROID BODY__:____:__
Caret__:__182930__:__MOVED TO 167800__:____:__
Number Sign__:__182940__:__NEURAL TUBE DEFECTS, SUSCEPTIBILITY TO; NTD__:____:__SPINA BIFIDA, INCLUDED
Percent__:__182950__:__SPINAL ARACHNOIDITIS__:____:__
Percent__:__182960__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1__:__HMN I;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE I; DHMN1;; SPINAL MUSCULAR ATROPHY, DISTAL, JUVENILE, AUTOSOMAL DOMINANT, I;; CHARCOT-MARIE-TOOTH DISEASE, SPINAL, I__:__
Percent__:__182970__:__SPINAL MUSCULAR ATROPHY, FACIOSCAPULOHUMERAL TYPE__:__FSHSMA__:__
Number Sign__:__182980__:__SPINAL MUSCULAR ATROPHY, LATE-ONSET, FINKEL TYPE; SMAFK__:__FINKEL LATE-ADULT TYPE SMA;; SPINAL MUSCULAR ATROPHY, PROXIMAL, ADULT, AUTOSOMAL DOMINANT__:__
NULL__:__182990__:__SPINAL INTRADURAL ARACHNOID CYSTS__:____:__
Caret__:__183000__:__MOVED TO 137440__:____:__
NULL__:__183020__:__SPINAL MUSCULAR ATROPHY, SEGMENTAL__:____:__
Percent__:__183050__:__SPINOCEREBELLAR ATAXIA WITH RIGIDITY AND PERIPHERAL NEUROPATHY__:____:__
Caret__:__183085__:__MOVED TO 109150__:____:__
Number Sign__:__183086__:__SPINOCEREBELLAR ATAXIA 6; SCA6__:____:__
Number Sign__:__183090__:__SPINOCEREBELLAR ATAXIA 2; SCA2__:__SPINOCEREBELLAR ATROPHY II;; OLIVOPONTOCEREBELLAR ATROPHY, HOLGUIN TYPE;; OLIVOPONTOCEREBELLAR ATROPHY II; OPCA2;; SPINOCEREBELLAR ATAXIA, CUBAN TYPE;; CEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS;; WADIA-SWAMI SYNDROME;; SPINOCEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS; SDSEM__:__AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 13, INCLUDED; ALS13, INCLUDED
NULL__:__183100__:__SPINOCEREBELLAR ATROPHY WITH PUPILLARY PARALYSIS__:____:__
Caret__:__183250__:__REMOVED FROM DATABASE__:____:__
NULL__:__183300__:__SPLENOGONADAL FUSION WITH LIMB DEFECTS AND MICROGNATHIA__:__SPLENOGONADAL FUSION LIMB DEFECT SYNDROME;; SGFLD SYNDROME__:__
NULL__:__183350__:__SPLENOMEGALY SYNDROME WITH SPLENIC GERMINAL CENTER HYPOPLASIA AND REDUCED CIRCULATING T HELPER CELLS__:____:__
NULL__:__183400__:__SPLIT LOWER LIP__:____:__
NULL__:__183500__:__SPLIT-HAND AND SPLIT-FOOT WITH HYPODONTIA__:____:__
Number Sign__:__183600__:__SPLIT-HAND/FOOT MALFORMATION 1; SHFM1__:__SPLIT-HAND/FOOT MALFORMATION 1 WITH OR WITHOUT DEAFNESS;; SPLIT-HAND/FOOT DEFORMITY 1; SHFD1; SHSF1;; SPLIT-HAND DEFORMITY;; ECTRODACTYLY; ECD__:__
NULL__:__183700__:__SPLIT-FOOT DEFORMITY WITH MANDIBULOFACIAL DYSOSTOSIS__:__PATTERSON-STEVENSON-FONTAINE SYNDROME__:__
NULL__:__183800__:__SPLIT-HAND WITH CONGENITAL NYSTAGMUS, FUNDAL CHANGES, AND CATARACTS__:__NYSTAGMUS-SPLIT HAND SYNDROME;; KARSCH-NEUGEBAUER SYNDROME; KNS__:__
NULL__:__183802__:__SPLIT-HAND WITH OBSTRUCTIVE UROPATHY, SPINA BIFIDA, AND DIAPHRAGMATIC DEFECTS__:____:__
Percent__:__183840__:__SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 2; SPDA2__:____:__
NULL__:__183849__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH HYPOTRICHOSIS__:__WHYTE SYNDROME__:__
NULL__:__183850__:__SPONDYLOEPIPHYSEAL DYSPLASIA WITH PUNCTATE CORNEAL DYSTROPHY__:____:__
Number Sign__:__183900__:__SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA; SEDC__:__SED CONGENITA;; SPONDYLOEPIPHYSEAL DYSPLASIA, CONGENITAL TYPE__:__
NULL__:__184000__:__SPONDYLOEPIPHYSEAL DYSPLASIA, MYOPIA, AND SENSORINEURAL DEAFNESS__:____:__
Number Sign__:__184095__:__SPONDYLOEPIPHYSEAL DYSPLASIA, MAROTEAUX TYPE__:__SED, MAROTEAUX TYPE;; PSEUDO-MORQUIO SYNDROME, TYPE 2__:__
Percent__:__184100__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL DOMINANT__:____:__
Percent__:__184200__:__SPONDYLOLISTHESIS__:____:__
Number Sign__:__184250__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, STRUDWICK TYPE; SEMDSTWK__:__SEMD, STRUDWICK TYPE;; SPONDYLOMETAEPIPHYSEAL DYSPLASIA CONGENITA, STRUDWICK TYPE;; SMED, STRUDWICK TYPE;; SMED, TYPE I;; STRUDWICK SYNDROME;; DAPPLED METAPHYSIS SYNDROME;; SPONDYLOMETAPHYSEAL DYSPLASIA; SMD;; SEMDC__:__
Number Sign__:__184252__:__SPONDYLOMETAPHYSEAL DYSPLASIA, KOZLOWSKI TYPE; SMDK__:__SMD, KOZLOWSKI TYPE__:__
NULL__:__184253__:__SPONDYLOMETAPHYSEAL DYSPLASIA, ALGERIAN TYPE__:__SPONDYLOMETAPHYSEAL DYSPLASIA, SCHMIDT TYPE;; SPONDYLOMETAPHYSEAL DYSPLASIA WITH SEVERE GENU VALGUM__:__
Number Sign__:__184255__:__SPONDYLOMETAPHYSEAL DYSPLASIA, CORNER FRACTURE TYPE; SMDCF__:__SPONDYLOMETAPHYSEAL DYSPLASIA, SUTCLIFFE TYPE__:__
NULL__:__184260__:__SPONDYLOMETAPHYSEAL DYSPLASIA WITH DENTINOGENESIS IMPERFECTA__:__GOLDBLATT SYNDROME;; ODONTOCHONDRODYSPLASIA; ODCD__:__
NULL__:__184300__:__SPONDYLOSIS, CERVICAL__:____:__
Percent__:__184400__:__SPRENGEL DEFORMITY__:__HIGH SCAPULA__:__
Asterisk__:__184420__:__FARNESYLDIPHOSPHATE FARNESYLTRANSFERASE 1; FDFT1__:__SQUALENE SYNTHASE__:__
Asterisk__:__184429__:__SRY-BOX 2; SOX2__:__SRY-RELATED HMG-BOX GENE 2__:__
Asterisk__:__184430__:__SRY-BOX 4; SOX4__:__SRY-RELATED HMG-BOX GENE 4;; ECOTROPIC VIRAL INTEGRATION SITE 16; EVI16__:__
Number Sign__:__184450__:__STUTTERING, FAMILIAL PERSISTENT, 1; STUT1__:__STAMMERING__:__
Number Sign__:__184460__:__STAPES ANKYLOSIS WITH BROAD THUMBS AND TOES__:__ANKYLOSIS OF STAPES, HYPEROPIA, BROAD THUMBS, BROAD FIRST TOES, AND SYNDACTYLY;; TEUNISSEN-CREMERS SYNDROME;; STAPES ANKYLOSIS SYNDROME WITHOUT SYMPHALANGISM__:__
Asterisk__:__184470__:__STATHERIN; STATH__:__STR__:__
Number Sign__:__184500__:__STEATOCYSTOMA MULTIPLEX__:__SEBACEOUS CYSTS, MULTIPLE__:__
NULL__:__184510__:__STEATOCYSTOMA MULTIPLEX WITH NATAL TEETH__:____:__
Asterisk__:__184600__:__CYSTATIN A; CSTA__:__STEFIN A; STFA;; STF1__:__
Caret__:__184601__:__MOVED TO 601145__:____:__
Percent__:__184700__:__POLYCYSTIC OVARY SYNDROME 1; PCOS1__:__PCO1; PCO;; PCOS;; STEIN-LEVENTHAL SYNDROME;; HYPERANDROGENEMIA__:__
NULL__:__184705__:__STEINFELD SYNDROME__:____:__
Asterisk__:__184745__:__KIT LIGAND; KITLG__:__KL; KITL;; MAST CELL GROWTH FACTOR; MGF;; MGF STEM CELL FACTOR; SCF;; STEEL, MOUSE, HOMOLOG OF;; STEEL FACTOR; SF__:__
Caret__:__184747__:__MOVED TO 136351__:____:__
Asterisk__:__184753__:__STEROID 5-ALPHA-REDUCTASE 1; SRD5A1__:____:__
Caret__:__184754__:__MOVED TO 201910__:____:__
Asterisk__:__184755__:__STEROL CARRIER PROTEIN 2; SCP2__:__STEROL CARRIER PROTEIN X; SCPX__:__
Asterisk__:__184756__:__STEROL REGULATORY ELEMENT-BINDING TRANSCRIPTION FACTOR 1; SREBF1__:__STEROL REGULATORY ELEMENT-BINDING PROTEIN 1; SREBP1__:__
Asterisk__:__184757__:__NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 1; NR5A1__:__FUSHI TARAZU FACTOR, DROSOPHILA, HOMOLOG 1; FTZF1; FTZ1;; STEROIDOGENIC FACTOR 1; SF1;; ADRENAL 4 BINDING PROTEIN; AD4BP__:__
NULL__:__184800__:__STERNUM, PREMATURE OBLITERATION OF SUTURES OF__:____:__
Number Sign__:__184840__:__OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT; OSMEDA__:__OSMED, HETEROZYGOUS;; WEISSENBACHER-ZWEYMULLER SYNDROME; WZS;; PIERRE ROBIN SYNDROME WITH FETAL CHONDRODYSPLASIA STICKLER SYNDROME, NONOCULAR TYPE, FORMERLY;; STICKLER SYNDROME, TYPE III, FORMERLY; STL3, FORMERLY__:__
Percent__:__184850__:__STIFF-PERSON SYNDROME; SPS__:__STIFF-MAN SYNDROME;; STIFF-TRUNK SYNDROME__:__PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY, INCLUDED; PERM, INCLUDED; PER, INCLUDED
Number Sign__:__184900__:__STIFF SKIN SYNDROME; SSKS__:____:__
Number Sign__:__185000__:__OVERHYDRATED HEREDITARY STOMATOCYTOSIS; OHST__:__OHS;; POTASSIUM-SODIUM DISORDER OF ERYTHROCYTE__:__
Caret__:__185010__:__MOVED TO 194380__:____:__
Number Sign__:__185020__:__CRYOHYDROCYTOSIS; CHC__:__STOMATOCYTOSIS, COLD-SENSITIVE__:__
Percent__:__185050__:__STORAGE POOL PLATELET DISEASE__:____:__
NULL__:__185069__:__STORM SYNDROME__:____:__
Number Sign__:__185070__:__STORMORKEN SYNDROME; STRMK__:__THROMBOCYTOPATHY, ASPLENIA, AND MIOSIS;; YORK PLATELET SYNDROME; YPS__:__
Percent__:__185100__:__STRABISMUS, SUSCEPTIBILITY TO__:____:__STRABISMUS, SUSCEPTIBILITY TO, 1, INCLUDED; STBMS1, INCLUDED
NULL__:__185120__:__STRATTON-PARKER SYNDROME__:__GROWTH HORMONE DEFICIENCY WITH WORMIAN BONES, CARDIAC ANOMALY, AND BRACHYCAMPTODACTYLY__:__
Percent__:__185200__:__STRIAE DISTENSAE, FAMILIAL__:____:__
Asterisk__:__185250__:__MATRIX METALLOPROTEINASE 3; MMP3__:__STROMELYSIN I; STMY1; STR1; SL1;; TRANSIN__:__
Asterisk__:__185260__:__MATRIX METALLOPROTEINASE 10; MMP10__:__STROMELYSIN II; STMY2; ST2; SL2__:__
Asterisk__:__185261__:__MATRIX METALLOPROTEINASE 11; MMP11__:__STROMELYSIN III; STMY3__:__
Number Sign__:__185300__:__STURGE-WEBER SYNDROME; SWS__:____:__
Caret__:__185400__:__MOVED TO 150360__:____:__
Asterisk__:__185430__:__CLUSTERIN; CLU__:__SULFATED GLYCOPROTEIN 2; SGP2;; APOLIPOPROTEIN J; APOJ;; COMPLEMENT-ASSOCIATED PROTEIN SP-40,40;; COMPLEMENT LYSIS INHIBITOR; CLI;; TESTOSTERONE-REPRESSED PROSTATE MESSAGE 2; TRPM2__:__
Asterisk__:__185440__:__SUPPRESSOR OF TUMORIGENICITY 2; ST2__:____:__
Caret__:__185450__:__REMOVED FROM DATABASE__:____:__
NULL__:__185460__:__SULFHEMOGLOBINEMIA, CONGENITAL__:____:__
Asterisk__:__185470__:__SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT B, IRON SULFUR PROTEIN; SDHB__:__SUCCINATE DEHYDROGENASE 2, S. CEREVISIAE, HOMOLOG OF;; SDH2, HOMOLOG OF__:__
NULL__:__185480__:__SUPRABULBAR PARESIS, CONGENITAL__:__WORSTER-DROUGHT SYNDROME__:__
Asterisk__:__185490__:__SUPEROXIDE DISMUTASE 3; SOD3__:__SUPEROXIDE DISMUTASE, EXTRACELLULAR;; EC-SOD__:__SUPEROXIDE DISMUTASE, ELEVATED EXTRACELLULAR, INCLUDED
Number Sign__:__185500__:__SUPRAVALVULAR AORTIC STENOSIS; SVAS__:__SUPRAVALVAR AORTIC STENOSIS, EISENBERG TYPE__:__
Asterisk__:__185510__:__SURFACE ANTIGEN 5; S5__:____:__
Asterisk__:__185520__:__SURFACE ANTIGEN 6; S6__:____:__
Asterisk__:__185535__:__EPITHELIAL CELLULAR ADHESION MOLECULE; EPCAM__:__TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 1; TACSTD1;; ANTIGEN DEFINED BY MONOCLONAL ANTIBODY AUAI; MIC18;; MEMBRANE COMPONENT, CHROMOSOME 4, SURFACE MARKER 1; M4S1;; GASTROINTESTINAL TUMOR-ASSOCIATED ANTIGEN 2, 35-KD GLYCOPROTEIN;; GA733-2__:__
NULL__:__185540__:__SURFACE ANTIGEN, GLYCOPROTEIN 75__:__SURFACE GLYCOPROTEIN 75; SGP75__:__
Asterisk__:__185560__:__SURFACE ANTIGEN 8; S8__:____:__
Asterisk__:__185570__:__SURFACE ANTIGEN 17; SA17__:__S9__:__
Asterisk__:__185580__:__SURFACE ANTIGEN 22; S13__:____:__
Asterisk__:__185590__:__SURFACE ANTIGEN 21; S14__:____:__
Caret__:__185595__:__REMOVED FROM DATABASE__:____:__
NULL__:__185600__:__SYMPHALANGISM OF TOES__:____:__
Asterisk__:__185605__:__SYNAPTOTAGMIN 1; SYT1__:__p65__:__
NULL__:__185610__:__SURFACE POLYPEPTIDES, ANONYMOUS__:__SPA2;; SPA5__:__
Asterisk__:__185620__:__SURFEIT 1; SURF1__:____:__
Asterisk__:__185630__:__SURFEIT 2; SURF2__:____:__
Asterisk__:__185640__:__RIBOSOMAL PROTEIN L7a; RPL7A__:__SURFEIT 3; SURF3__:__
Asterisk__:__185641__:__MEDIATOR COMPLEX SUBUNIT 22; MED22__:__SURFEIT 5; SURF5__:__
Asterisk__:__185642__:__SURFEIT 6; SURF6__:____:__
NULL__:__185650__:__SYMPHALANGISM, C. S. LEWIS TYPE__:__THUMBS, STIFF__:__
Asterisk__:__185660__:__SURFEIT 4; SURF4__:__ERV29, S. CEREVISIAE, HOMOLOG OF; ERV29__:__
Percent__:__185700__:__SYMPHALANGISM, DISTAL__:__SYM2__:__
NULL__:__185750__:__SYMPHALANGISM WITH MULTIPLE ANOMALIES OF HANDS AND FEET__:____:__
Number Sign__:__185800__:__SYMPHALANGISM, PROXIMAL, 1A; SYM1A__:__SYM1;; CUSHING SYMPHALANGISM;; HEREDITARY ABSENCE OF THE PROXIMAL INTERPHALANGEAL JOINTS__:__
Asterisk__:__185860__:__SYNAPTIC VESICLE GLYCOPROTEIN 2A; SV2A__:__SYNAPTIC VESICLE GLYCOPROTEIN 2; SV2__:__
Asterisk__:__185861__:__SYNAPTIC VESICLE GLYCOPROTEIN 2B; SV2B__:__KIAA0735__:__
Asterisk__:__185880__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 1; VAMP1__:__SYNAPTOBREVIN 1; SYB1__:__
Asterisk__:__185881__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 2; VAMP2__:__SYNAPTOBREVIN 2; SYB2__:__
Number Sign__:__185900__:__CHROMOSOME 2q35 DUPLICATION SYNDROME__:__SYNDACTYLY, TYPE I; SDTY1;; SD1;; ZYGODACTYLY__:__CRANIOSYNOSTOSIS, PHILADELPHIA TYPE, INCLUDED
Number Sign__:__186000__:__SYNPOLYDACTYLY 1; SPD1__:__SYNDACTYLY, TYPE II; SDTY2__:__
Number Sign__:__186100__:__SYNDACTYLY, TYPE III__:__SDTY3;; RING AND LITTLE FINGER SYNDACTYLY;; SYNDACTYLY OF FINGERS IV AND V__:__
Number Sign__:__186200__:__SYNDACTYLY, TYPE IV; SDTY4__:__HAAS TYPE SYNDACTYLY;; POLYSYNDACTYLY, HAAS TYPE;; SD4__:__
Number Sign__:__186300__:__SYNDACTYLY, TYPE V; SDTY5__:__SYNDACTYLY WITH METACARPAL AND METATARSAL FUSION__:__
Percent__:__186350__:__SYNDACTYLY-POLYDACTYLY-EARLOBE SYNDROME__:__SPEL SYNDROME__:__
Asterisk__:__186355__:__SYNDECAN 1; SDC1__:__SYND1;; SYNDECAN; SDC;; CD138 ANTIGEN; CD138__:__
Asterisk__:__186357__:__SYNDECAN 3; SDC3__:__SYND3;; SYNDECAN, NEURAL TYPE;; N-SYNDECAN; SDCN__:__
Asterisk__:__186360__:__ANNEXIN A7; ANXA7__:__ANNEXIN VII; ANX7;; SYNEXIN; SNX__:__
Percent__:__186400__:__SYNOSTOSES, TARSAL, CARPAL, AND DIGITAL__:__CALCANEONAVICULAR COALITION__:__
Number Sign__:__186500__:__MULTIPLE SYNOSTOSES SYNDROME 1; SYNS1__:__SYNOSTOSES, MULTIPLE, WITH BRACHYDACTYLY;; SYMPHALANGISM-BRACHYDACTYLY SYNDROME;; WL SYNDROME;; DEAFNESS-SYMPHALANGISM SYNDROME OF HERRMANN;; FACIOAUDIOSYMPHALANGISM SYNDROME__:__
Number Sign__:__186550__:__LIEBENBERG SYNDROME; LBNBG__:__SYNOSTOSIS, CARPAL, WITH DYSPLASTIC ELBOW JOINTS AND BRACHYDACTYLY;; BRACHYDACTYLY WITH JOINT DYSPLASIA__:__
Number Sign__:__186570__:__TARSAL-CARPAL COALITION SYNDROME; TCC__:____:__SYNOSTOSIS OF TALUS AND CALCANEUS WITH SHORT STATURE, INCLUDED
NULL__:__186575__:__SYNOVIAL CHONDROMATOSIS, FAMILIAL, WITH DWARFISM__:____:__
Number Sign__:__186580__:__BLAU SYNDROME; BLAUS__:__SARCOIDOSIS, EARLY-ONSET; EOS;; GRANULOMATOSIS, FAMILIAL JUVENILE SYSTEMIC;; ARTHROCUTANEOUVEAL GRANULOMATOSIS; ACUG;; JABS SYNDROME;; GRANULOMATOUS INFLAMMATORY ARTHRITIS, DERMATITIS, AND UVEITIS, FAMILIAL;; GRANULOMATOSIS, FAMILIAL, BLAU TYPE__:__
Asterisk__:__186590__:__SYNTAXIN 1A; STX1A__:__SYNTAXIN 1; STX1;; SYNTAXIN, BRAIN;; p35-1__:__
Asterisk__:__186591__:__SYNTAXIN 4; STX4__:__STX4A;; SYNTAXIN, PLACENTAL;; p35-2__:__
NULL__:__186600__:__SYRINGOMAS, MULTIPLE__:____:__
Caret__:__186690__:__REMOVED FROM DATABASE__:____:__
Percent__:__186700__:__SYRINGOMYELIA, NONCOMMUNICATING ISOLATED__:____:__
Asterisk__:__186710__:__T-CELL ACTIVATION ANTIGEN p250; TP250__:____:__
Asterisk__:__186711__:__CD27 ANTIGEN; CD27__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7; TNFRSF7;; T-CELL ACTIVATION ANTIGEN S152; S152__:__
Asterisk__:__186720__:__CD6 ANTIGEN; CD6__:__T-CELL DIFFERENTIATION ANTIGEN CD6__:__
Asterisk__:__186730__:__CD8 ANTIGEN, BETA POLYPEPTIDE; CD8B__:__T-CELL GLYCOPROTEIN CD8B;; CD8B1__:__
Asterisk__:__186740__:__CD3 ANTIGEN, GAMMA SUBUNIT; CD3G__:__CD3-GAMMA;; T-CELL ANTIGEN RECEPTOR COMPLEX, GAMMA SUBUNIT OF T3; T3G__:__
Asterisk__:__186745__:__TALIN 1; TLN1__:__TALIN; TLN__:__
NULL__:__186750__:__TALONAVICULAR COALITION__:____:__
Asterisk__:__186760__:__ANTIGEN CD28; CD28__:__T-CELL ANTIGEN CD28;; Tp44__:__
Asterisk__:__186770__:__T-CELL LEUKEMIA, HOMEOBOX 1; TLX1__:__HOMEOBOX 11; HOX11;; T-CELL LEUKEMIA 3 GENE; TCL3__:__
Asterisk__:__186780__:__CD247 ANTIGEN; CD247__:__CD3 ANTIGEN, ZETA SUBUNIT; CD3Z;; CD3-ZETA;; T-CELL ANTIGEN RECEPTOR COMPLEX, ZETA SUBUNIT OF CD3; TCRZ__:__
Asterisk__:__186790__:__CD3 ANTIGEN, DELTA SUBUNIT; CD3D__:__CD3-DELTA;; T-CELL ANTIGEN RECEPTOR COMPLEX, DELTA SUBUNIT OF T3; T3D;; OKT3, DELTA CHAIN__:__
Asterisk__:__186810__:__T-CELL RECEPTOR DELTA CHAIN CONSTANT REGION; TRDC__:____:__
Asterisk__:__186820__:__T-CELL ANTIGEN CD7; CD7__:__Tp41__:__
Asterisk__:__186830__:__CD3 ANTIGEN, EPSILON SUBUNIT; CD3E__:__CD3-EPSILON;; T-CELL ANTIGEN RECEPTOR COMPLEX, EPSILON SUBUNIT OF T3; T3E; TCRE__:__
Asterisk__:__186845__:__CD81 ANTIGEN; CD81__:__TARGET OF ANTIPROLIFERATIVE ANTIBODY 1; TAPA1__:__
Percent__:__186850__:__TARSAL COALITION__:__TARSAL FUSION__:__
Asterisk__:__186852__:__PROTEASOME 26S SUBUNIT, ATPase, 3; PSMC3__:__TAT-BINDING PROTEIN 1; TBP1__:__
Asterisk__:__186854__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, TAURINE), MEMBER 6; SLC6A6__:__TAURINE TRANSPORTER; TAUT__:__
Asterisk__:__186855__:__T-CELL ACUTE LYMPHOCYTIC LEUKEMIA 2; TAL2__:____:__
Asterisk__:__186860__:__T-CELL LEUKEMIA/LYMPHOMA 4; TCL4__:____:__
Asterisk__:__186880__:__T-CELL RECEPTOR ALPHA CHAIN CONSTANT REGION; TRAC__:____:__
Percent__:__186890__:__TEAR PROTEIN, ANODAL__:____:__
Asterisk__:__186910__:__CD8 ANTIGEN, ALPHA POLYPEPTIDE; CD8A__:__p32;; OKT8 T-CELL ANTIGEN;; T8 T-CELL ANTIGEN; CD8__:__T-CELL ANTIGEN LEU2, INCLUDED; LEU2, INCLUDED;; LEU2 T-LYMPHOCYTE ANTIGEN, INCLUDED
Caret__:__186920__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__186921__:__LIM DOMAIN ONLY 1; LMO1__:__RHOMBOTIN 1; RBTN1;; RHOMBOSINE; RHOM1;; T-CELL TRANSLOCATION GENE 1; TTG1__:__
Asterisk__:__186930__:__T-CELL RECEPTOR BETA CHAIN CONSTANT REGION 1; TRBC1__:____:__
Asterisk__:__186940__:__CD4 ANTIGEN; CD4__:__T-CELL ANTIGEN T4/LEU3__:__
Asterisk__:__186945__:__FK506-BINDING PROTEIN 1A; FKBP1A__:__FK506-BINDING PROTEIN 1; FKBP1;; FK506-BINDING PROTEIN, 12-KD; FKBP12;; FK506-BINDING PROTEIN, T-CELL, 12-KD;; CALSTABIN 1__:__
Asterisk__:__186946__:__FK506-BINDING PROTEIN 2; FKBP2__:__FK506-BINDING PROTEIN, T-CELL, 13-KD; FKBP13__:__
Asterisk__:__186947__:__FK506-BINDING PROTEIN 3; FKBP3__:__FK506-BINDING PROTEIN, T-CELL, 25-KD; FKBP25__:__
NULL__:__186950__:__T-CELL SUBGROUPS, NON-HLA-LINKED__:____:__
Asterisk__:__186960__:__T-CELL LEUKEMIA/LYMPHOMA 1A; TCL1A__:__TCL1;; LYMPHOMA/LEUKEMIA, T-CELL__:__
Asterisk__:__186970__:__T-CELL RECEPTOR GAMMA CHAIN CONSTANT REGION 1; TRGC1__:____:__
Asterisk__:__186973__:__IL2-INDUCIBLE T-CELL KINASE; ITK__:__TYROSINE KINASE EXPRESSED MAINLY IN T CELLS; EMT;; T-CELL ITK/TSK TYROSINE KINASE, MOUSE, HOMOLOG OF__:__
Asterisk__:__186975__:__T COMPLEX-ASSOCIATED TESTIS-EXPRESSED 1; TCTE1__:____:__
Asterisk__:__186977__:__T COMPLEX-ASSOCIATED TESTIS-EXPRESSED 3; TCTE3__:____:__
Asterisk__:__186980__:__T-COMPLEX 1; TCP1__:__T-COMPLEX HOMOLOG TCP1__:__
Asterisk__:__186982__:__T-COMPLEX HOMOLOG TCP11; TCP11__:____:__
Asterisk__:__186990__:__T-LYMPHOCYTE SURFACE CD2 ANTIGEN; CD2__:__T11;; SHEEP ERYTHROCYTE RECEPTOR; SRBC__:__
Percent__:__187000__:__TEETH, ODD SHAPES OF__:____:__LOBODONTIA, INCLUDED;; CONICAL TEETH, MULTIPLE, INCLUDED
Caret__:__187010__:__MOVED TO 187011__:____:__
Asterisk__:__187011__:__CHEMOKINE, CC MOTIF, LIGAND 5; CCL5__:__SMALL INDUCIBLE CYTOKINE A5; SCYA5;; REGULATED UPON ACTIVATION, NORMALLY T-EXPRESSED, AND PRESUMABLY SECRETED; RANTES;; T CELL-SPECIFIC RANTES;; T CELL-SPECIFIC PROTEIN p228; TCP228__:__
Asterisk__:__187020__:__T-COMPLEX 10; TCP10__:__TCP10A__:__
NULL__:__187030__:__T-COMPLEX LOCUS TCP10B; TCP10B__:____:__
Asterisk__:__187040__:__T-CELL ACUTE LYMPHOCYTIC LEUKEMIA 1; TAL1__:__STEM CELL LEUKEMIA HEMATOPOIETIC TRANSCRIPTION FACTOR; SCL;; T-CELL LEUKEMIA/LYMPHOMA 5; TCL5__:__
NULL__:__187050__:__TEETH PRESENT AT BIRTH__:__NATAL TEETH__:__
NULL__:__187100__:__TEETH, SUPERNUMERARY__:____:__
Percent__:__187260__:__TELANGIECTASIA, HEREDITARY BENIGN__:__HBT;; TELANGIECTASIA, GENERALIZED ESSENTIAL__:__
Asterisk__:__187270__:__TELOMERASE REVERSE TRANSCRIPTASE; TERT__:__TELOMERASE CATALYTIC SUBUNIT; TCS1;; EST2__:__
Asterisk__:__187280__:__POLYMERASE III, RNA, SUBUNIT D; POLR3D__:__TEMPERATURE SENSITIVITY COMPLEMENTATION, CELL CYCLE SPECIFIC, tsBN51; BN51T;; TSBN51__:__
NULL__:__187290__:__TEMPERATURE SENSITIVITY COMPLEMENTATION, CELL CYCLE SPECIFIC, H142; H142T__:____:__
Number Sign__:__187300__:__TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 1; HHT1__:__HHT;; TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER;; OSLER-RENDU-WEBER DISEASE;; ORW DISEASE__:__
NULL__:__187310__:__TEMPERATURE SENSITIVITY COMPLEMENTATION, CELL CYCLE SPECIFIC, K12__:__ts COMPLEMENTING, K12; K12T__:__
NULL__:__187320__:__TEMPERATURE SENSITIVITY COMPLEMENTATION, CELL CYCLE SPECIFIC, ts13; TS13__:____:__
NULL__:__187330__:__TEMPERATURE SENSITIVITY COMPLEMENTATION, CELL CYCLE SPECIFIC, ts546; TS546__:____:__
NULL__:__187340__:__TEMPERATURE-SENSITIVE LETHAL MUTATION__:____:__
NULL__:__187350__:__TELECANTHUS__:____:__
NULL__:__187360__:__TEMPORAL ARTERITIS__:__GIANT CELL ARTERITIS; GCA;; CRANIAL ARTERITIS;; POLYMYALGIA RHEUMATICA__:__
Percent__:__187370__:__ARTHROGRYPOSIS, DISTAL, TYPE 10; DA10__:__CONGENITAL PLANTAR CONTRACTURES;; TENDO CALCANEUS, SHORT__:__
Asterisk__:__187380__:__TENASCIN C; TNC__:__TENASCIN; TN;; CYTOTACTIN;; HEXABRACHION; HXB__:__
NULL__:__187390__:__TENDONS, EXTENSOR, OF FINGERS, ANOMALOUS INSERTION OF__:____:__
Plus__:__187395__:__TERATOCARCINOMA-DERIVED GROWTH FACTOR 1; TDGF1__:__CRIPTO GROWTH FACTOR; CRGF__:__FOREBRAIN DEFECTS, INCLUDED
NULL__:__187400__:__TESTICULAR TORSION__:__TORSION OF TESTICULAR CORD__:__
Asterisk__:__187410__:__DEOXYNUCLEOTIDYLTRANSFERASE, TERMINAL; DNTT__:__TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE; TDT;; TERMINAL TRANSFERASE__:__
Asterisk__:__187430__:__CYSTEINE-RICH SECRETORY PROTEIN 2; CRISP2__:__TESTIS-SPECIFIC PROTEIN 1; TPX1;; TSP1__:__
Caret__:__187450__:__MOVED TO 182205__:____:__
Number Sign__:__187500__:__TETRALOGY OF FALLOT; TOF__:____:__
NULL__:__187501__:__TETRALOGY OF FALLOT AND GLAUCOMA__:____:__
NULL__:__187510__:__TETRAMELIC MONODACTYLY__:____:__
Asterisk__:__187520__:__TETRANECTIN; TNA__:____:__
NULL__:__187550__:__THALASSEMIA, BETA+, SILENT ALLELE__:____:__
Number Sign__:__187600__:__THANATOPHORIC DYSPLASIA, TYPE I; TD1__:__THANATOPHORIC DYSPLASIA; TD;; THANATOPHORIC DWARFISM;; PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE;; LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE__:__
Number Sign__:__187601__:__THANATOPHORIC DYSPLASIA, TYPE II; TD2__:__THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL;; THANATOPHORIC DYSPLASIA WITH KLEEBLATTSCHAEDEL;; CLOVERLEAF SKULL WITH THANATOPHORIC DWARFISM__:__
Percent__:__187650__:__THEOPHYLLINE BIOTRANSFORMATION__:____:__
Asterisk__:__187680__:__THIOPURINE S-METHYLTRANSFERASE; TPMT__:____:__
Asterisk__:__187700__:__THIOREDOXIN; TXN__:__TRX;; TRX1__:__
NULL__:__187750__:__THORACIC DYSOSTOSIS, ISOLATED__:____:__
NULL__:__187760__:__THORACOLARYNGOPELVIC DYSPLASIA; TLPD__:__BARNES SYNDROME__:__
NULL__:__187770__:__THORACOPELVIC DYSOSTOSIS__:____:__
Asterisk__:__187790__:__THREONYL-tRNA SYNTHETASE; TARS__:__THRRS__:__
Number Sign__:__187800__:__BLEEDING DISORDER, PLATELET-TYPE, 16; BDPLT16__:__GLANZMANN THROMBASTHENIA, AUTOSOMAL DOMINANT;; THROMBASTHENIA OF GLANZMANN AND NAEGELI, AUTOSOMAL DOMINANT__:__
Number Sign__:__187900__:__BLEEDING DISORDER, PLATELET-TYPE, 17; BDPLT17__:__THROMBASTHENIA-THROMBOCYTOPENIA, HEREDITARY__:__
Asterisk__:__187930__:__COAGULATION FACTOR II RECEPTOR; F2R__:__CF2R;; THROMBIN RECEPTOR; TR;; PROTEASE-ACTIVATED RECEPTOR 1; PAR1__:__
NULL__:__187940__:__THROMBOCYTE B; THB__:____:__
Number Sign__:__187950__:__THROMBOCYTHEMIA 1; THCYT1__:__THROMBOCYTOSIS 1__:__
Number Sign__:__188000__:__THROMBOCYTOPENIA 2; THC2__:__THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 2__:__
NULL__:__188020__:__THROMBOCYTOPENIA, CYCLIC__:____:__
Number Sign__:__188025__:__THROMBOCYTOPENIA, PARIS-TROUSSEAU TYPE; TCPT__:__CHROMOSOME 11q23 DELETION SYNDROME__:__
NULL__:__188030__:__THROMBOCYTOPENIC PURPURA, AUTOIMMUNE; AITP__:__IMMUNE THROMBOCYTOPENIC PURPURA; ITP;; IDIOPATHIC THROMBOCYTOPENIC PURPURA__:__
Asterisk__:__188035__:__PRO-PLATELET BASIC PROTEIN-LIKE 1; PPBPL1__:__THROMBOGLOBULIN, BETA-2; TGB2__:__
Asterisk__:__188040__:__THROMBOMODULIN; THBD__:__THRM;; CD141 ANTIGEN; CD141__:__
Number Sign__:__188050__:__THROMBOPHILIA DUE TO THROMBIN DEFECT; THPH1__:__THROMBOPHILIA DUE TO FACTOR 2 DEFECT;; VENOUS THROMBOSIS;; VENOUS THROMBOEMBOLISM__:__THROMBOSIS, PROTECTION AGAINST, INCLUDED
Number Sign__:__188055__:__THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2__:__ACTIVATED PROTEIN C RESISTANCE;; APC RESISTANCE;; THROMBOPHILIA DUE TO DEFICIENCY OF ACTIVATED PROTEIN C COFACTOR;; PROC COFACTOR DEFICIENCY;; PCCF DEFICIENCY;; THROMBOPHILIA V__:__THROMBOPHILIA DUE TO FACTOR V LEIDEN, INCLUDED
Asterisk__:__188060__:__THROMBOSPONDIN I; THBS1__:__TSP1__:__
Asterisk__:__188061__:__THROMBOSPONDIN II; THBS2__:__TSP2__:__
Asterisk__:__188062__:__THROMBOSPONDIN III; THBS3__:____:__
Asterisk__:__188070__:__THROMBOXANE A2 RECEPTOR, PLATELET; TBXA2R__:____:__
NULL__:__188100__:__THUMB DEFORMITY__:____:__
NULL__:__188150__:__THUMB DEFORMITY AND ALOPECIA__:____:__
Caret__:__188200__:__MOVED TO 107000__:____:__
NULL__:__188201__:__THUMBS, STIFF, WITH BRACHYDACTYLY TYPE A1 AND DEVELOPMENTAL DELAY__:____:__
Asterisk__:__188230__:__THY-1 T-CELL ANTIGEN; THY1__:__THETA ANTIGEN;; CD90 ANTIGEN; CD90__:__
Asterisk__:__188250__:__THYMIDINE KINASE, MITOCHONDRIAL; TK2__:____:__
Asterisk__:__188300__:__THYMIDINE KINASE, SOLUBLE; TK1__:____:__
Asterisk__:__188340__:__THYMOCYTE ANTIGEN CD1C; CD1C__:__BDCA1__:__
Asterisk__:__188345__:__DEOXYTHYMIDYLATE KINASE; DTYMK__:__THYMIDYLATE KINASE; TYMK;; CDC8__:__
Asterisk__:__188350__:__THYMIDYLATE SYNTHETASE; TYMS__:__THYMIDYLATE SYNTHASE; TS; TMS;; dTMP SYNTHASE__:__
Asterisk__:__188360__:__THYMOCYTE ANTIGEN CD1B; CD1B__:____:__
Asterisk__:__188370__:__THYMOCYTE ANTIGEN CD1A; CD1A__:__CD1__:__
Asterisk__:__188380__:__THYMOPOIETIN; TMPO__:__TP;; LAMINA-ASSOCIATED POLYPEPTIDE 2; LAP2__:__
Asterisk__:__188390__:__PROTHYMOSIN, ALPHA; PTMA__:__THYMOSIN, ALPHA__:__
Caret__:__188395__:__MOVED TO 300159__:____:__
Asterisk__:__188399__:__THYMOSIN, BETA-10; TMSB10__:____:__
Number Sign__:__188400__:__DIGEORGE SYNDROME; DGS__:__CHROMOSOME 22q11.2 DELETION SYNDROME;; HYPOPLASIA OF THYMUS AND PARATHYROIDS;; THIRD AND FOURTH PHARYNGEAL POUCH SYNDROME__:__DIGEORGE SYNDROME CHROMOSOME REGION, INCLUDED; DGCR, INCLUDED;; TAKAO VCF SYNDROME, INCLUDED;; CATCH22, INCLUDED
Asterisk__:__188410__:__THYMOCYTE ANTIGEN CD1D; CD1D__:____:__
Asterisk__:__188411__:__THYMOCYTE ANTIGEN CD1E; CD1E__:____:__
Asterisk__:__188450__:__THYROGLOBULIN; TG__:____:__
NULL__:__188455__:__THYROGLOSSAL DUCT CYST, FAMILIAL__:____:__
Number Sign__:__188470__:__THYROID CANCER, NONMEDULLARY, 2; NMTC2__:____:__
Caret__:__188530__:__MOVED TO 118850__:____:__
Asterisk__:__188540__:__THYROID-STIMULATING HORMONE, BETA CHAIN; TSHB__:__THYROTROPIN, BETA CHAIN;; TSH-BETA__:__
Plus__:__188545__:__THYROTROPIN-RELEASING HORMONE RECEPTOR; TRHR__:____:__THYROTROPIN-RELEASING HORMONE RESISTANCE, GENERALIZED, INCLUDED
Number Sign__:__188550__:__THYROID CANCER, NONMEDULLARY, 1; NMTC1__:__PAPILLARY CARCINOMA OF THYROID; PACT; PTC; TPC;; FAMILIAL NONMEDULLARY THYROID CANCER, PAPILLARY;; NONMEDULLARY THYROID CARCINOMA, PAPILLARY__:__
Caret__:__188555__:__MOVED TO 179050__:____:__
NULL__:__188560__:__THYROID HORMONE PLASMA MEMBRANE TRANSPORT DEFECT__:__HYPERTHYROXINEMIA, EUMETABOLIC, DUE TO T4 PLASMA MEMBRANE TRANSPORT;; DEFECT;; THYROID HORMONE RESISTANCE DUE TO T4 PLASMA MEMBRANE TRANSPORT DEFECT__:__
Number Sign__:__188570__:__THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL DOMINANT; GRTH__:__GTHR;; THYROID HORMONE UNRESPONSIVENESS;; HYPERTHYROXINEMIA, FAMILIAL EUTHYROID, SECONDARY TO PITUITARY AND PERIPHERAL RESISTANCE TO THYROID HORMONES__:__
Number Sign__:__188580__:__THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 1; TTPP1__:____:__
Caret__:__188590__:__MOVED TO 190120__:____:__
Asterisk__:__188595__:__THYROTROPH EMBRYONIC FACTOR; TEF__:____:__
Caret__:__188600__:__MOVED TO 314200__:____:__
NULL__:__188700__:__BLOUNT DISEASE, INFANTILE__:__OSTEOCHONDROSIS DEFORMANS TIBIAE, INFANTILE;; TIBIA VARA, INFANTILE__:__
Number Sign__:__188740__:__TIBIA, HYPOPLASIA OR APLASIA OF, WITH POLYDACTYLY; THYP__:__TIBIAL HEMIMELIA-POLYDACTYLY-TRIPHALANGEAL THUMBS WITH FIBULAR DIMELIA__:__
Caret__:__188770__:__MOVED TO 188740__:____:__
Percent__:__188800__:__TIBIAL TORSION, BILATERAL MEDIAL__:____:__
Asterisk__:__188825__:__TISSUE INHIBITOR OF METALLOPROTEINASE 2; TIMP2__:____:__
Asterisk__:__188826__:__TISSUE INHIBITOR OF METALLOPROTEINASE 3; TIMP3__:____:__
Asterisk__:__188830__:__PROTEIN KINASE, cAMP-DEPENDENT, REGULATORY, TYPE I, ALPHA; PRKAR1A__:__PROTEIN KINASE A, RI-ALPHA SUBUNIT;; TISSUE-SPECIFIC EXTINGUISHER 1; TSE1__:__PRKAR1A/RARA FUSION GENE, INCLUDED;; PTC2 CHIMERIC ONCOGENE, INCLUDED
Asterisk__:__188840__:__TITIN; TTN__:__CONNECTIN__:__
NULL__:__188850__:__TL ANTIGEN__:__THYMUS LEUKEMIA ANTIGEN; TLA;; HISTOCOMPATIBILITY 2, T-REGION LOCUS 18; H2-T18__:__
Asterisk__:__188855__:__GRANULYSIN; GNLY__:__T-LYMPHOCYTE ACTIVATION GENE 519; TLA519;; D2S69E;; NKG5__:__
Asterisk__:__188860__:__MYELIN AND LYMPHOCYTE PROTEIN; MAL__:__T-LYMPHOCYTE MATURATION-ASSOCIATED PROTEIN;; T-CELL DIFFERENTIATION PROTEIN__:__
Number Sign__:__188890__:__TOBACCO ADDICTION, SUSCEPTIBILITY TO__:__CIGARETTE HABITUATION, SUSCEPTIBILITY TO;; SMOKING HABIT, SUSCEPTIBILITY TO;; NICOTINE DEPENDENCE, SUSCEPTIBILITY TO;; NICOTINE ADDICTION, SUSCEPTIBILITY TO;; NICOTINE DEPENDENCE, PROTECTION AGAINST__:__
NULL__:__189000__:__TOE, FIFTH, NUMBER OF PHALANGES IN__:____:__
NULL__:__189100__:__TOE, MISSHAPEN__:____:__
NULL__:__189150__:__TOE, ROTATED FIFTH__:____:__
NULL__:__189200__:__TOES, RELATIVE LENGTH OF FIRST AND SECOND__:____:__
NULL__:__189230__:__TOES, SPACE BETWEEN FIRST AND SECOND__:____:__
NULL__:__189300__:__TONGUE CURLING, FOLDING, OR ROLLING__:____:__CLOVERLEAF TONGUE, INCLUDED;; TREFOIL TONGUE, INCLUDED
NULL__:__189490__:__MALPOSITION OF TEETH WITH OR WITHOUT HYPODONTIA/OLIGODONTIA__:__ECTOPIC ERUPTION OF TEETH__:__
Number Sign__:__189500__:__WITKOP SYNDROME__:__ECTODERMAL DYSPLASIA 3, WITKOP TYPE; ECTD3;; ECTODERMAL DYSPLASIA 3, TOOTH/NAIL TYPE;; NAIL DYSPLASIA WITH HYPODONTIA;; TOOTH-AND-NAIL SYNDROME; TNS__:__
NULL__:__189600__:__TORTICOLLIS__:____:__
Percent__:__189700__:__TORUS PALATINUS AND TORUS MANDIBULARIS__:____:__
Percent__:__189800__:__PREECLAMPSIA/ECLAMPSIA 1; PEE1__:__PREG1;; PEE;; TOXEMIA OF PREGNANCY__:__HYPERTENSION, PREGNANCY-INDUCED, INCLUDED;; HEMOLYSIS, ELEVATED LIVER ENZYMES, AND LOW PLATELET COUNT, INCLUDED; HELLP, INCLUDED
Asterisk__:__189880__:__TRANSFER RNA ASPARAGINE 1; TRNAN1__:__tRNA ASPARAGINE 1; TRN1;; TRN__:__
Asterisk__:__189889__:__TRANSCRIPTION FACTOR CP2; TFCP2__:__ALPHA-GLOBIN TRANSCRIPTION FACTOR CP2;; LATE SV40 FACTOR; LSF__:__LBP1C, INCLUDED;; LBP1D, INCLUDED
Asterisk__:__189890__:__TRANSFER RNA ASPARAGINE-LIKE; TRNL__:____:__
Asterisk__:__189901__:__TRANSCRIPTION FACTOR 9; TCF9__:__TRANSCRIPTIONAL REPRESSOR GCF__:__
Asterisk__:__189902__:__TRANSCRIPTION FACTOR DP1; TFDP1__:__E2F DIMERIZATION PARTNER 1; DP1;; TRANSCRIPTION FACTOR, SEQUENCE-SPECIFIC, DRTF1__:__
Asterisk__:__189903__:__NUCLEAR TRANSCRIPTION FACTOR Y, ALPHA; NFYA__:__TRANSCRIPTION FACTOR NF-Y, A SUBUNIT;; NUCLEAR FACTOR BINDING TO Y BOX OF HLA GENES;; HAP2 CCAAT-BINDING PROTEIN__:__
Asterisk__:__189904__:__NUCLEAR TRANSCRIPTION FACTOR Y, BETA; NFYB__:__TRANSCRIPTION FACTOR NF-Y, B SUBUNIT__:__
Asterisk__:__189905__:__TRANSCOBALAMIN I; TCN1__:__TC I;; TC1;; HAPTOCORRIN;; VITAMIN B12-BINDING PROTEIN 1;; COBALOPHILIN;; B12-BINDING ALPHA-GLOBULIN__:__
Asterisk__:__189906__:__TRANSCRIPTION FACTOR Sp1; SP1__:__SPECIFICITY PROTEIN 1__:__
Asterisk__:__189907__:__HNF1 HOMEOBOX B; HNF1B__:__TRANSCRIPTION FACTOR 2; TCF2;; TRANSCRIPTION FACTOR, LIVER-SPECIFIC, 3;; HEPATOCYTE NUCLEAR FACTOR-1-BETA;; HEPATIC NUCLEAR FACTOR-1-BETA;; HEPATOCYTE NUCLEAR FACTOR 2; HNF2__:__
Asterisk__:__189908__:__TRANSCRIPTION FACTOR 7; TCF7__:__TRANSCRIPTION FACTOR, T CELL-SPECIFIC, 1;; T CELL FACTOR 1; TCF1__:__
Asterisk__:__189909__:__ZINC FINGER E BOX-BINDING HOMEOBOX 1; ZEB1__:__TRANSCRIPTION FACTOR 8; TCF8;; T-LYMPHOCYTE-SPECIFIC INTERLEUKIN 2 INHIBITOR;; DELTA-EF1;; NIL2A__:__
Asterisk__:__189910__:__TRANSFER RNA SERINE (AGA) 2-4; TRS-AGA2-4__:__TRANSFER RNA SERINE 2; TRNAS2;; tRNA SERINE 2; TRS2;; tRNA-SER; TRNS__:__
Asterisk__:__189911__:__TRANSFER RNA GLYCINE 1; TRNAG1__:__TRANSFER RNA GLYCINE-CCC-1; TRG1__:__
Asterisk__:__189912__:__TRANSFER RNA PROLINE (TGG) 3-5; TRP-TGG3-5__:__TRANSFER RNA PROLINE 3; TRNAP3;; TRP3__:__
Asterisk__:__189913__:__TRANSFER RNA THREONINE (TGT) 6-1; TRT-TGT6-1__:__TRANSFER RNA THREONINE 1; TRNAT1;; TRT1__:__
Asterisk__:__189918__:__TRANSFER RNA LYSINE (TTT) 3-4; TRK-TTT3-4__:__TRANSFER RNA LYSINE 1; TRNAK1;; tRNA LYSINE 1; TRK1;; tRNA LYSINE 1 (UUU)__:__
Asterisk__:__189919__:__TRANSFER RNA GLUTAMINE 1; TRNAQ1__:__tRNA GLUTAMINE 1; TRQ1__:__
Asterisk__:__189920__:__TRANSFER RNA LEUCINE 2; TRNAL2__:__tRNA LEUCINE 2; TRL2__:__
Asterisk__:__189921__:__TRANSFER RNA VALINE (AAC) 1-4; TRV-AAC1-4__:__TRANSFER RNA VALINE 1; TRNAV1;; tRNA VALINE 1; TRV1__:__
Asterisk__:__189923__:__TRANSFER RNA GLUTAMINE 2; TRNAQ2__:__tRNA GLUTAMINE 2; TRQ2__:__
Asterisk__:__189930__:__TRANSFER RNA PROLINE 1; TRNAP1__:__tRNA PROLINE 1; TRP1__:__
Asterisk__:__189931__:__TRANSFER RNA PROLINE 2; TRNAP2__:__tRNA PROLINE 2; TRP2__:__
Asterisk__:__189932__:__TRANSFER RNA LEUCINE (AAG) 2-1; TRL-AAG2-1__:__TRANSFER RNA LEUCINE 1; TRNAL1;; tRNA LEUCINE 1; TRL1__:__
Asterisk__:__189933__:__TRANSFER RNA THREONINE 2; TRNAT2__:__tRNA THREONINE 2; TRT2__:__
Asterisk__:__189940__:__TRANSLOCATED PROMOTER REGION; TPR__:__TUMOR POTENTIATING REGION__:__
NULL__:__189960__:__TRACHEOESOPHAGEAL FISTULA WITH OR WITHOUT ESOPHAGEAL ATRESIA__:__ESOPHAGEAL ATRESIA WITH OR WITHOUT TRACHEOESOPHAGEAL FISTULA__:__
NULL__:__189961__:__TRACHEOPATHIA OSTEOPLASTICA__:__TRACHEOBRONCHOPATHIA OSTEOCHONDROPLASTICA__:__
Asterisk__:__189962__:__GENERAL TRANSCRIPTION FACTOR IIE, POLYPEPTIDE 1; GTF2E1__:__TRANSCRIPTION FACTOR IIE, ALPHA SUBUNIT;; TFIIE, ALPHA SUBUNIT; TF2E1__:__
Asterisk__:__189963__:__GENERAL TRANSCRIPTION FACTOR IIB; GTF2B__:__RNA POLYMERASE II TRANSCRIPTION FACTOR IIB; TFIIB; TF2B;; TRANSCRIPTION FACTOR IIB__:__
Asterisk__:__189964__:__GENERAL TRANSCRIPTION FACTOR IIE, POLYPEPTIDE 2; GTF2E2__:__TRANSCRIPTION FACTOR IIE, BETA SUBUNIT;; TFIIE, BETA SUBUNIT; TF2E2__:__
Asterisk__:__189965__:__CCAAT/ENHANCER-BINDING PROTEIN, BETA; CEBPB__:__C/EBP-BETA;; INTERLEUKIN 6-DEPENDENT DNA-BINDING PROTEIN; IL6DBP;; LIVER ACTIVATOR PROTEIN; LAP;; LIVER-ENRICHED TRANSCRIPTIONAL ACTIVATOR PROTEIN;; TRANSCRIPTION FACTOR 5; TCF5;; NFIL6__:__
Asterisk__:__189967__:__TEA DOMAIN FAMILY MEMBER 1; TEAD1__:__TRANSCRIPTION FACTOR 13; TCF13;; TRANSCRIPTIONAL ENHANCER FACTOR 1; TEF1__:__
Asterisk__:__189968__:__GENERAL TRANSCRIPTION FACTOR IIF, POLYPEPTIDE 1, 74-KD; GTF2F1__:__TRANSCRIPTION FACTOR IIF, ALPHA SUBUNIT;; TFIIF ALPHA;; TF2F1;; RAP74__:__
Asterisk__:__189969__:__GENERAL TRANSCRIPTION FACTOR IIF, POLYPEPTIDE 2, 30-KD; GTF2F2__:__TRANSCRIPTION FACTOR IIF, BETA SUBUNIT; TF2F2;; TFIIF BETA;; RAP30__:__
Asterisk__:__189970__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-TRANSDUCING ACTIVITY POLYPEPTIDE 1; GNGT1__:__TRANSDUCIN, GAMMA POLYPEPTIDE__:__
Asterisk__:__189971__:__E2F TRANSCRIPTION FACTOR 1; E2F1__:__TRANSCRIPTION FACTOR E2F;; RETINOBLASTOMA-BINDING PROTEIN 3; RBP3;; RETINOBLASTOMA-ASSOCIATED PROTEIN 1; RBAP1__:__
Asterisk__:__189972__:__GENERAL TRANSCRIPTION FACTOR IIH, POLYPEPTIDE 1; GTF2H1__:__GTF2H, 62-KD SUBUNIT;; TRANSCRIPTION FACTOR IIH, 62-KD SUBUNIT;; TFIIH, 62-KD SUBUNIT;; TFB1__:__
Asterisk__:__189973__:__E74-LIKE FACTOR 1; ELF1__:__ETS-RELATED TRANSCRIPTION FACTOR ELF1__:__
Caret__:__189974__:__MOVED TO 139380__:____:__
Asterisk__:__189980__:__ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; ABL1__:__TRANSFORMATION GENE: ONCOGENE ABL;; ABELSON STRAIN OF MURINE LEUKEMIA VIRUS; ABL__:__ABL1/BCR FUSION GENE, INCLUDED;; ABL1/NUP214 FUSION GENE, INCLUDED
Asterisk__:__189990__:__V-MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG; MYB__:__ONCOGENE MYB;; AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG;; ONCOGENE AMV__:__
Asterisk__:__190000__:__TRANSFERRIN; TF__:____:__
Asterisk__:__190010__:__TRANSFERRIN RECEPTOR; TFRC__:__TRANSFERRIN RECEPTOR 1; TFR1;; TFR;; TRFR;; CD71__:__
Asterisk__:__190020__:__V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG; HRAS__:__HRAS1;; HARVEY MURINE SARCOMA VIRUS ONCOGENE; RASH1;; p21(RAS);; p21;; TRANSFORMATION GENE: ONCOGENE HAMSV__:__
Asterisk__:__190030__:__V-FES FELINE SARCOMA VIRAL/V-FPS FUJINAMI AVIAN SARCOMA VIRAL ONCOGENE HOMOLOG; FES__:__ONCOGENE FES;; FELINE SARCOMA VIRUS;; FPS__:__
Asterisk__:__190040__:__PLATELET-DERIVED GROWTH FACTOR, BETA POLYPEPTIDE; PDGFB__:__V-SIS PLATELET-DERIVED GROWTH FACTOR, BETA POLYPEPTIDE;; PLATELET-DERIVED GROWTH FACTOR, B CHAIN;; PDGF, B CHAIN;; PDGF2;; ONCOGENE SIS;; SIMIAN SARCOMA VIRAL ONCOGENE HOMOLOG; SSV__:__PDGFB/COL1A1 FUSION GENE, INCLUDED
Asterisk__:__190060__:__V-MOS MOLONEY MURINE SARCOMA VIRAL ONCOGENE HOMOLOG; MOS__:__MOLONEY MURINE SARCOMA VIRUS; MSV;; ONCOGENE MOS__:__
Asterisk__:__190070__:__V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG; KRAS__:__ONCOGENE KRAS2; KRAS2;; KIRSTEN MURINE SARCOMA VIRUS 2; RASK2;; C-KRAS__:__V-KI-RAS1 PSEUDOGENE, INCLUDED; KRAS1P, INCLUDED;; ONCOGENE KRAS1, INCLUDED; KRAS1, INCLUDED;; KIRSTEN RAS1, INCLUDED; RASK1, INCLUDED
Asterisk__:__190080__:__V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG; MYC__:__ONCOGENE MYC;; AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG;; PROTOONCOGENE HOMOLOGOUS TO MYELOCYTOMATOSIS VIRUS__:__
Asterisk__:__190090__:__V-SRC AVIAN SARCOMA (SCHMIDT-RUPPIN A-2) VIRAL ONCOGENE; SRC__:__ONCOGENE SRC;; PROTOONCOGENE SRC;; SRC ONCOGENE;; AVIAN SARCOMA VIRUS; ASV__:__
Percent__:__190100__:__GENIOSPASM 1; GSM1__:__TREMBLING CHIN__:__
Caret__:__190110__:__MOVED TO 190070__:____:__
Asterisk__:__190120__:__THYROID HORMONE RECEPTOR, ALPHA-1; THRA__:__THYROID HORMONE RECEPTOR, CENTRAL NERVOUS SYSTEM FORM; THRA1;; ERBA-ALPHA;; ONCOGENE ERBA; ERBA;; ERBA-RELATED 7; EAR7;; V-ERB-A AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; ERBA1__:__THYROID HORMONE RECEPTOR, ALPHA-2, INCLUDED; THRA2, INCLUDED;; THYROID HORMONE RECEPTOR, ALPHA-3, INCLUDED; THRA3, INCLUDED
Asterisk__:__190151__:__V-ERB-B2 AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 3; ERBB3__:__ONCOGENE ERBB3;; TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3; HER3__:__
Asterisk__:__190160__:__THYROID HORMONE RECEPTOR, BETA; THRB__:__V-ERB-A AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; ERBA2;; ONCOGENE ERBA2;; ERBA-BETA__:__
Asterisk__:__190170__:__TRANSFORMING GROWTH FACTOR, ALPHA; TGFA__:____:__
Asterisk__:__190180__:__TRANSFORMING GROWTH FACTOR, BETA-1; TGFB1__:__TGF-BETA; TGFB__:__
Asterisk__:__190181__:__TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE I; TGFBR1__:__ACTIVIN RECEPTOR-LIKE KINASE 5; ALK5__:__
Asterisk__:__190182__:__TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE II; TGFBR2__:____:__
Caret__:__190190__:__MOVED TO 154280__:____:__
Asterisk__:__190195__:__TRANSGLUTAMINASE 1; TGM1__:__TRANSGLUTAMINASE, KERATINOCYTE; TGK;; TRANSGLUTAMINASE, EPIDERMAL TYPE I__:__
Asterisk__:__190196__:__TRANSGLUTAMINASE 2; TGM2__:__TRANSGLUTAMINASE, TISSUE;; TRANSGLUTAMINASE C; TGC;; GUANINE NUCLEOTIDE-BINDING PROTEIN, H POLYPEPTIDE; GNAH;; G PROTEIN, ALPHA SUBUNIT, Gh CLASS;; G-ALPHA-h__:__
Asterisk__:__190197__:__CONTACTIN 2; CNTN2__:__TRANSIENTLY-EXPRESSED AXONAL GLYCOPROTEIN; TAX1;; TAG1, RAT, HOMOLOG OF;; AXONIN 1__:__
Asterisk__:__190198__:__NOTCH, DROSOPHILA, HOMOLOG OF, 1; NOTCH1__:__TRANSLOCATION-ASSOCIATED NOTCH HOMOLOG; TAN1__:__
NULL__:__190200__:__TREMOR OF INTENTION, ATAXIA, AND LIPOFUSCINOSIS__:____:__
Asterisk__:__190220__:__TRANSFORMING GROWTH FACTOR, BETA-2; TGFB2__:____:__
Asterisk__:__190230__:__TRANSFORMING GROWTH FACTOR, BETA-3; TGFB3__:____:__
Asterisk__:__190231__:__TRANSITION PROTEIN 1; TNP1__:__TP1__:__
Asterisk__:__190232__:__TRANSITION PROTEIN 2; TNP2__:____:__
Number Sign__:__190300__:__TREMOR, HEREDITARY ESSENTIAL, 1; ETM1__:__TREMOR, FAMILIAL ESSENTIAL, 1; FET1__:__
Percent__:__190310__:__TREMOR, NYSTAGMUS, AND DUODENAL ULCER__:____:__
Asterisk__:__190315__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, CITRATE TRANSPORTER), MEMBER 1; SLC25A1__:__SOLUTE CARRIER FAMILY 20, MEMBER 3, FORMERLY; SLC20A3, FORMERLY;; TRICARBOXYLATE TRANSPORT PROTEIN, MITOCHONDRIAL;; CITRATE TRANSPORT PROTEIN; CTP;; SCHEGGIA, DROSOPHILA, HOMOLOG OF; SEA__:__
Number Sign__:__190320__:__TRICHODENTOOSSEOUS SYNDROME; TDO__:__TDO SYNDROME__:__
Number Sign__:__190330__:__TRICHOMEGALY; TCMGLY__:__EYELASHES, LONG__:__
Percent__:__190340__:__DISCOID FIBROMAS, FAMILIAL MULTIPLE; FMDF__:__TRICHODISCOMAS, FAMILIAL MULTIPLE__:__
NULL__:__190345__:__TRICHOEPITHELIOMAS, MULTIPLE DESMOPLASTIC__:____:__
Number Sign__:__190350__:__TRICHORHINOPHALANGEAL SYNDROME, TYPE I; TRPS1__:__TRPS I__:__
Number Sign__:__190351__:__TRICHORHINOPHALANGEAL SYNDROME, TYPE III; TRPS3__:__SUGIO-KAJII SYNDROME__:__
NULL__:__190360__:__TRICHODYSPLASIA-XERODERMA__:____:__
Asterisk__:__190370__:__TRICHOHYALIN; TCHH__:__THH;; THL;; TRHY__:__
NULL__:__190400__:__TRIGEMINAL NEURALGIA__:__TIC DOULOUREUX__:__
NULL__:__190410__:__TRIGGER THUMB__:____:__
NULL__:__190420__:__TRIGLYCERIDE STORAGE DISEASE, TYPE I__:____:__
NULL__:__190430__:__TRIGLYCERIDE STORAGE DISEASE, TYPE II__:____:__
Number Sign__:__190440__:__TRIGONOCEPHALY 1; TRIGNO1__:__CRANIOSYNOSTOSIS, METOPIC__:__
NULL__:__190445__:__TRIIODOTHYRONINE RECEPTOR AUXILIARY PROTEIN; TRAP__:____:__
Asterisk__:__190450__:__TRIOSEPHOSPHATE ISOMERASE 1; TPI1__:__TPI__:__
Asterisk__:__190470__:__TRIPEPTIDYL PEPTIDASE II; TPP2__:____:__
NULL__:__190500__:__TRIPHALANGEAL THUMB WITH DOUBLE PHALANGES__:____:__
Percent__:__190600__:__TRIPHALANGEAL THUMB, NONOPPOSABLE__:____:__
Caret__:__190605__:__MOVED TO 174500__:____:__
NULL__:__190650__:__TRIPHALANGEAL THUMBS AND DISLOCATION OF PATELLA__:____:__
Percent__:__190680__:__TRIPHALANGEAL THUMBS WITH BRACHYECTRODACTYLY__:____:__
Number Sign__:__190685__:__DOWN SYNDROME__:__TRISOMY 21__:__DOWN SYNDROME CHROMOSOME REGION, INCLUDED; DCR, INCLUDED;; DOWN SYNDROME CRITICAL REGION, INCLUDED; DSCR, INCLUDED;; TRANSIENT MYELOPROLIFERATIVE DISORDER OF DOWN SYNDROME, INCLUDED;; LEUKEMIA, MEGAKARYOBLASTIC, OF DOWN SYNDROME, INCLUDED
Asterisk__:__190700__:__ZINC FINGER PROTEIN 36, MOUSE, HOMOLOG OF; ZFP36__:__TRISTETRAPROLIN; TTP__:__
NULL__:__190800__:__TRISTICHIASIS__:__EYELASHES, THREE ROWS OF__:__
Number Sign__:__190900__:__TRITANOPIA__:__COLORBLINDNESS, TRITANOPIC;; BLUE COLORBLINDNESS;; COLORBLINDNESS, TRITAN; CBT__:__
Asterisk__:__190920__:__TROPHOBLAST GLYCOPROTEIN; TPBG__:__M6P1__:__
Asterisk__:__190930__:__TROPOMODULIN; TMOD__:__E-TROPOMODULIN; ETMOD__:__
Asterisk__:__190940__:__ENDOGENOUS RETROVIRAL SEQUENCE, TRUNCATED 1; ERVT1__:__TRUNCATED ENDOGENOUS RETROVIRAL SEQUENCE 1; TRV1__:__
Asterisk__:__190950__:__ENDOGENOUS RETROVIRAL SEQUENCE, TRUNCATED 2; ERVT2__:__TRUNCATED ENDOGENOUS RETROVIRAL SEQUENCE 2; TRV2__:__
Asterisk__:__190960__:__ENDOGENOUS RETROVIRAL SEQUENCE, TRUNCATED 3; ERVT3__:__TRUNCATED ENDOGENOUS RETROVIRAL SEQUENCE 3; TRV3__:__
Asterisk__:__190970__:__ENDOGENOUS RETROVIRAL SEQUENCE, TRUNCATED 4; ERVT4__:__TRUNCATED ENDOGENOUS RETROVIRAL SEQUENCE 4; TRV4__:__
Asterisk__:__190980__:__ENDOGENOUS RETROVIRAL SEQUENCE, TRUNCATED 5; ERVT5__:__TRUNCATED ENDOGENOUS RETROVIRAL SEQUENCE 5; TRV5__:__
Asterisk__:__190990__:__TROPOMYOSIN 2; TPM2__:__TROPOMYOSIN, SKELETAL MUSCLE BETA; TMSB__:__
NULL__:__191000__:__TROCHLEA OF THE HUMERUS, APLASIA OF__:____:__
Asterisk__:__191010__:__TROPOMYOSIN 1; TPM1__:__TROPOMYOSIN, SKELETAL MUSCLE ALPHA; TMSA__:__
Caret__:__191020__:__MOVED TO 120920__:____:__
Asterisk__:__191030__:__TROPOMYOSIN 3; TPM3__:__ALPHA-TROPOMYOSIN 3;; ALPHA-TROPOMYOSIN, SLOW SKELETAL__:__TRK ONCOGENE, INCLUDED;; TPM3/NTRK1 FUSION GENE, INCLUDED
Asterisk__:__191039__:__TROPONIN C, FAST; TNNC2__:__TROPONIN C, FAST SKELETAL__:__
Asterisk__:__191040__:__TROPONIN C, SLOW; TNNC1__:__TROPONIN C, SLOW-TWITCH SKELETAL MUSCLE;; TROPONIN C, CARDIAC; TNC__:__
Asterisk__:__191041__:__TROPONIN T1, SKELETAL, SLOW; TNNT1__:__TROPONIN T__:__
Asterisk__:__191042__:__TROPONIN I, SLOW-TWITCH SKELETAL MUSCLE ISOFORM; TNNI1__:____:__
Asterisk__:__191043__:__TROPONIN I, FAST-TWITCH SKELETAL MUSCLE ISOFORM; TNNI2__:____:__
Asterisk__:__191044__:__TROPONIN I, CARDIAC; TNNI3__:__TROPONIN I, CARDIAC MUSCLE ISOFORM__:__
Asterisk__:__191045__:__TROPONIN T2, CARDIAC; TNNT2__:____:__
Asterisk__:__191050__:__TRYPTOPHANYL-tRNA SYNTHETASE; WARS__:__TRYPTOPHANYL-tRNA SYNTHETASE, CYTOPLASMIC;; TRPRS;; IFP53__:__
Asterisk__:__191060__:__TRYPTOPHAN HYDROXYLASE 1; TPH1__:__TPH__:__
Asterisk__:__191070__:__TRYPTOPHAN 2,3-DIOXYGENASE; TDO2__:__TRYPTOPHAN OXYGENASE; TRPO__:__
Asterisk__:__191080__:__TRYPTASE, ALPHA/BETA-1; TPSAB1__:__MAST CELL PROTEASE 7; MCP7__:__TRYPTASE, ALPHA, INCLUDED;; TRYPTASE, ALPHA-I, INCLUDED;; TRYPTASE, ALPHA-II, INCLUDED;; TRYPTASE I, INCLUDED;; TRYPTASE, BETA-I, INCLUDED
Asterisk__:__191081__:__TRYPTASE, BETA-2; TPSB2__:__TRYPTASE, BETA;; TRYPTASE II;; TRYPTASE, BETA-II;; MAST CELL PROTEASE 6; MCP6__:__TRYPTASE III, INCLUDED;; TRYPTASE, BETA-III, INCLUDED
Caret__:__191090__:__MOVED TO 191100__:____:__
Caret__:__191091__:__MOVED TO 191100__:____:__
Asterisk__:__191092__:__TSC2 GENE; TSC2__:__TUBERIN;; TSC4 GENE, FORMERLY; TSC4, FORMERLY__:__
Number Sign__:__191100__:__TUBEROUS SCLEROSIS 1; TSC1__:__TUBEROUS SCLEROSIS COMPLEX; TSC;; TUBEROSE SCLEROSIS; TS__:__
Asterisk__:__191110__:__TUBULIN, ALPHA-4A; TUBA4A__:__TUBULIN, ALPHA-1; TUBA1;; TUBULIN, ALPHA, TESTIS-SPECIFIC;; H2-ALPHA__:__
Asterisk__:__191120__:__TUBULIN, ALPHA-LIKE 1; TUBAL1__:__H-ALPHA-44__:__
Asterisk__:__191130__:__TUBULIN, BETA; TUBB__:__TUBULIN, BETA, CLASS I;; TUBB5;; M40__:__
Asterisk__:__191135__:__TUBULIN, GAMMA-1; TUBG1__:__TUBG;; TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 1; TUBGCP1__:__
NULL__:__191150__:__TUFTSIN DEFICIENCY__:____:__
Asterisk__:__191155__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 1; TM4SF1__:__TUMOR-ASSOCIATED ANTIGEN L6; TAAL6;; MEMBRANE COMPONENT, CHROMOSOME 3, SURFACE MARKER 1; M3S1__:__
Asterisk__:__191160__:__TUMOR NECROSIS FACTOR; TNF__:__TUMOR NECROSIS FACTOR, ALPHA; TNFA;; CACHECTIN;; TNF, MONOCYTE-DERIVED;; TNF, MACROPHAGE-DERIVED__:__
Asterisk__:__191161__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 1; TNFAIP1__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN, ENDOTHELIAL__:__
Asterisk__:__191163__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 3; TNFAIP3__:__A20;; OTU DOMAIN-CONTAINING PROTEIN 7C; OTUD7C__:__
Asterisk__:__191164__:__EPHRIN A1; EFNA1__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 1; EPLG1;; TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 4; TNFAIP4;; LIGAND OF EPH-RELATED KINASE 1; LERK1;; EFL1__:__
Asterisk__:__191170__:__TUMOR PROTEIN p53; TP53__:__P53;; TRANSFORMATION-RELATED PROTEIN 53; TRP53__:__
Asterisk__:__191175__:__HEAT-SHOCK PROTEIN, 90-KD, BETA, 1; HSP90B1__:__TUMOR REJECTION ANTIGEN 1;; TRA1;; STRESS-INDUCIBLE TUMOR REJECTION ANTIGEN GP96;; GLUCOSE-REGULATED PROTEIN, 94-KD; GRP94__:__
Percent__:__191181__:__SUPPRESSOR OF TUMORIGENICITY 3; ST3__:__TUMOR-SUPPRESSOR GENE, HELA CELL TYPE; TSHL;; CERVICAL CARCINOMA, TUMOR-SUPPRESSOR GENE INVOLVED IN; CCTS__:__
Asterisk__:__191190__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 1A; TNFRSF1A__:__TUMOR NECROSIS FACTOR RECEPTOR 1; TNFR1;; TUMOR NECROSIS FACTOR-ALPHA RECEPTOR; TNFAR;; TNFR, 55-KD;; TNFR, 60-KD__:__
Asterisk__:__191191__:__TUMOR NECROSIS FACTOR RECEPTOR SUBFAMILY, MEMBER 1B; TNFRSF1B__:__TUMOR NECROSIS FACTOR RECEPTOR 2; TNFR2;; TUMOR NECROSIS FACTOR, BETA RECEPTOR; TNFBR;; TNFR, 75-KD;; TNFR, 80-KD__:__
Asterisk__:__191195__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 8; MAP3K8__:__TUMOR PROGRESSION LOCUS 2; TPL2;; CANCER OSAKA THYROID ONCOGENE; COT;; ONCOGENE COT;; EWING SARCOMA TRANSFORMANT; EST__:__
Percent__:__191200__:__TUNE DEAFNESS__:__DYSMELODIA;; AMUSIA, CONGENITAL;; TONE DEAFNESS__:__
NULL__:__191250__:__TWINNING DUE TO SUPERFETATION__:__SUPERFETATION TWINNING__:__
NULL__:__191270__:__TYROSINASE-LIKE; TYRL__:__TYROSINASE-RELATED SEGMENT__:__
Asterisk__:__191275__:__DOPACHROME TAUTOMERASE; DCT__:__TYROSINASE-RELATED PROTEIN 2; TYRP2__:__
Asterisk__:__191290__:__TYROSINE HYDROXYLASE; TH__:____:__
Asterisk__:__191305__:__TYROSINE KINASE, B-LYMPHOCYTE SPECIFIC; BLK__:____:__
Asterisk__:__191306__:__KINASE INSERT DOMAIN RECEPTOR; KDR__:__TYROSINE KINASE GROWTH FACTOR RECEPTOR;; FLK1, MOUSE, HOMOLOG OF; FLK1;; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR;; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; VEGFR2__:__
Caret__:__191309__:__MOVED TO 190151__:____:__
Asterisk__:__191311__:__DISCOIDIN DOMAIN RECEPTOR FAMILY, MEMBER 2; DDR2__:__NEUROTROPHIC TYROSINE KINASE RECEPTOR-RELATED 3; NTRKR3;; TYROSINE KINASE RECEPTOR RELATED TO NEUROTROPHIC TRK; TKT__:__
Asterisk__:__191315__:__NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 1; NTRK1__:__TYROSINE KINASE RECEPTOR; TRK;; TYROSINE KINASE RECEPTOR A; TRKA__:__TRK ONCOGENE, INCLUDED;; NTRK1/TPM3 FUSION GENE, INCLUDED;; NTRK1/TFG FUSION GENE, INCLUDED
Asterisk__:__191316__:__NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 3; NTRK3__:__TYROSINE KINASE RECEPTOR C; TRKC;; NEUROTROPHIN 3 RECEPTOR__:__NTRK3/ETV6 FUSION GENE, INCLUDED
Asterisk__:__191317__:__U2 SMALL NUCLEAR RNA AUXILIARY FACTOR 1; U2AF1__:__U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, 35-KD SUBUNIT; U2AF35__:__
Asterisk__:__191318__:__U2 SMALL NUCLEAR RNA AUXILIARY FACTOR 2; U2AF2__:__U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, 65-KD SUBUNIT; U2AF65__:__
Caret__:__191320__:__MOVED TO 191339__:____:__
Asterisk__:__191321__:__UBIQUITIN A-52-RESIDUE RIBOSOMAL PROTEIN FUSION PRODUCT; UBA52__:__HUMAN UBIQUITIN CARBOXYL EXTENSION PROTEIN, 52-RESIDUE; HUBCEP52;; UBCEP, 52-AMINO ACID; CEP52;; RIBOSOMAL PROTEIN L40; RPL40__:__
Asterisk__:__191325__:__UBIQUITIN-ACTIVATING ENZYME 7; UBE7__:__UBIQUITIN-ACTIVATING ENZYME E1-LIKE; UBE1L__:__
Asterisk__:__191327__:__UBIQUINOL-CYTOCHROME c REDUCTASE, RIESKE IRON-SULFUR; UQCRFS1__:____:__
Asterisk__:__191328__:__UBIQUINOL-CYTOCHROME c REDUCTASE CORE PROTEIN I; UQCRC1__:__CYTOCHROME bc1__:__
Asterisk__:__191329__:__UBIQUINOL-CYTOCHROME c REDUCTASE CORE PROTEIN II; UQCRC2__:____:__
Asterisk__:__191330__:__UBIQUINOL-CYTOCHROME c REDUCTASE-BINDING PROTEIN; UQCRB__:__UBIQUINONE-BINDING PROTEIN; UQBC;; UQPC__:__
Asterisk__:__191339__:__UBIQUITIN B; UBB__:__POLYUBIQUITIN B__:__
Asterisk__:__191340__:__UBIQUITIN C; UBC__:__POLYUBIQUITIN__:__
Asterisk__:__191342__:__UBIQUITIN CARBOXYL-TERMINAL ESTERASE L1; UCHL1__:__UBIQUITIN C-TERMINAL HYDROLASE, NEURON-SPECIFIC;; PGP9.5__:__
Asterisk__:__191343__:__RIBOSOMAL PROTEIN S27a; RPS27A__:__UBIQUITIN A-80-RESIDUE RIBOSOMAL PROTEIN FUSION PRODUCT; UBA80;; HUMAN UBIQUITIN CARBOXYL EXTENSION PROTEIN, 80-RESIDUE; HUBCEP80; CEP80;; UBIQUITIN CARBOXYL EXTENSION PROTEIN 1; UBCEP1__:__
Caret__:__191344__:__MOVED TO 191321__:____:__
Asterisk__:__191350__:__DOLICHYL-PHOSPHATE N-ACETYLGLUCOSAMINE PHOSPHOTRANSFERASE; DPAGT1__:__UDP-GlcNAc:DOLICHYL-PHOSPHATE N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE;; DPAGT2;; GlcNAc-1-P TRANSFERASE__:__
Percent__:__191390__:__INFLAMMATORY BOWEL DISEASE 11; IBD11__:____:__
NULL__:__191400__:__ULNA AND FIBULA, HYPOPLASIA OF__:__MESOMELIC DWARFISM OF HYPOPLASTIC ULNA AND FIBULA TYPE;; REINHARDT-PFEIFFER MESOMELIC DYSPLASIA__:__
NULL__:__191420__:__ULNA METAPHYSEAL DYSPLASIA SYNDROME__:__METAPHYSEAL CHONDRODYSPLASIA, ROSENBERG TYPE__:__
Percent__:__191440__:__ULNAR HYPOPLASIA__:__UPPER LIMB MESOMELIC DYSPLASIA__:__
Number Sign__:__191480__:__UNCOMBABLE HAIR SYNDROME 1; UHS1__:__UNCOMBABLE HAIR SYNDROME; UHS;; PILI TRIANGULI ET CANALICULI__:__
NULL__:__191482__:__UNCOMBABLE HAIR, RETINAL PIGMENTARY DYSTROPHY, DENTAL ANOMALIES, AND BRACHYDACTYLY__:__BORK SYNDROME__:__
Percent__:__191500__:__UNDRITZ ANOMALY__:__HYPERSEGMENTATION OF NUCLEI OF POLYMORPHONUCLEAR LEUKOCYTES__:__
Asterisk__:__191510__:__COLD-SHOCK DOMAIN-CONTAINING E1, RNA-BINDING; CSDE1__:__GENE UPSTREAM OF NRAS;; UNR;; D1S155E__:__
Percent__:__191520__:__UPINGTON DISEASE__:__PERTHES-LIKE HIP DISEASE, ENCHONDROMATA, AND ECCHONDROMATA__:__
Asterisk__:__191523__:__UPSTREAM TRANSCRIPTION FACTOR 1; USF1__:__UPSTREAM STIMULATORY FACTOR 1;; MAJOR LATE TRANSCRIPTION FACTOR; MLTF__:__
Asterisk__:__191525__:__URACIL-DNA GLYCOSYLASE; UNG__:__DNA GLYCOSYLASE, URACIL; DGU__:__URACIL-DNA GLYCOSYLASE, MITOCHONDRIAL ISOFORM, INCLUDED; UDG1M, INCLUDED;; UNG1, INCLUDED;; UDG1, INCLUDED;; URACIL-DNA GLYCOSYLASE, NUCLEAR ISOFORM, INCLUDED; UDG1N, INCLUDED;; UNG2, INCLUDED;; UDG1A, INCLUDED
Percent__:__191530__:__URATE-BINDING GLOBULIN, DECREASE IN__:____:__
NULL__:__191540__:__URATE OXIDASE, PSEUDOGENE; UOX__:__URICASE__:__
Percent__:__191550__:__URETER, BIFID OR DOUBLE__:____:__
NULL__:__191600__:__URETER, CANCER OF__:____:__
NULL__:__191650__:__URETEROCELE__:____:__
NULL__:__191700__:__UROLITHIASIS, URIC ACID, AUTOSOMAL DOMINANT__:__NEPHROLITHIASIS, URIC ACID, AUTOSOMAL DOMINANT__:__
Asterisk__:__191710__:__CYTIDINE MONOPHOSPHATE (UMP-CMP) KINASE 1, CYTOSOLIC; CMPK1__:__CYTIDINE MONOPHOSPHATE KINASE; CMPK;; CYTIDYLATE KINASE; CMK;; URIDINE MONOPHOSPHATE/CYTIDINE MONOPHOSPHATE KINASE;; UMP/CMP KINASE;; UMP/CMPK;; URIDINE MONOPHOSPHATE KINASE; UMPK; UMK__:__
Asterisk__:__191720__:__5-PRIME,3-PRIME-NUCLEOTIDASE, CYTOSOLIC; NT5C__:__PYRIMIDINE 5-PRIME NUCLEOTIDASE 2; P5N2;; URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE 2; UMPH2;; DEOXYRIBONUCLEOTIDASE, CYTOSOLIC, 1; DNT1__:__
Asterisk__:__191730__:__URIDINE PHOSPHORYLASE 1; UPP1__:____:__
Asterisk__:__191740__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1;; URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1; UGT1;; UDP-GLYCOSYLTRANSFERASE 1;; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE, BILIRUBIN;; BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A GENE COMPLEX, INCLUDED; UGT1A, INCLUDED;; UGT1A GENE COMPLEX, INCLUDED
Caret__:__191741__:__MOVED TO 191740__:____:__
Caret__:__191742__:__MOVED TO 600067 AND 191740__:____:__
Caret__:__191743__:__MOVED TO 191742__:____:__
Caret__:__191750__:__MOVED TO 191760__:____:__
Asterisk__:__191760__:__URIDYL DIPHOSPHATE GLUCOSE PYROPHOSPHORYLASE 2; UGP2__:__UGPP2;; UDPG;; UGP1__:__
NULL__:__191800__:__URINARY BLADDER, ATONY OF__:____:__
Caret__:__191810__:__MOVED TO 131530__:____:__
Number Sign__:__191830__:__RENAL HYPODYSPLASIA/APLASIA 1; RHDA1__:__RENAL ADYSPLASIA;; RENAL AGENESIS;; RENAL APLASIA;; HEREDITARY RENAL APLASIA; HRA__:__
Asterisk__:__191840__:__PLASMINOGEN ACTIVATOR, URINARY; PLAU__:__UPA;; UROKINASE; URK__:__
Asterisk__:__191845__:__UROMODULIN; UMOD__:__TAMM-HORSFALL GLYCOPROTEIN; THP; THGP__:__
NULL__:__191850__:__URTICARIA, AQUAGENIC__:____:__
Number Sign__:__191900__:__MUCKLE-WELLS SYNDROME; MWS__:__URTICARIA-DEAFNESS-AMYLOIDOSIS SYNDROME;; UDA SYNDROME;; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 2; CAPS2__:__
NULL__:__191950__:__URTICARIA, FAMILIAL LOCALIZED HEAT__:____:__
NULL__:__192000__:__UTERINE ANOMALIES__:____:__
Asterisk__:__192020__:__SECRETOGLOBIN, FAMILY 1A, MEMBER 1; SCGB1A1__:__UTEROGLOBIN; UGB;; BLASTOKININ;; CLARA CELL SECRETORY PROTEIN; CCSP;; CLARA CELL-SPECIFIC 10-KD PROTEIN; CC10; CC10KD;; CLARA CELL-SPECIFIC 16-KD PROTEIN; CC16__:__
NULL__:__192050__:__UTERUS BICORNIS BICOLLIS WITH PARTIAL VAGINAL SEPTUM AND UNILATERAL HEMATOCOLPOS WITH IPSILATERAL RENAL AGENESIS__:____:__
Caret__:__192070__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__192090__:__CADHERIN 1; CDH1__:__CADHERIN, EPITHELIAL;; E-CADHERIN; CDHE; ECAD;; UVOMORULIN; UVO;; CALCIUM-DEPENDENT ADHESION PROTEIN, EPITHELIAL;; LIVER CELL ADHESION MOLECULE; LCAM__:__
NULL__:__192100__:__UVULA, BIFID__:__UVULA, CLEFT__:__
Asterisk__:__192130__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A1; ATP6V0A1__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, NONCATALYTIC ACCESSORY PROTEIN 1A; ATP6N1A;; ATP6N1;; VACUOLAR PROTON PUMP, SUBUNIT 1; VPP1__:__
Asterisk__:__192132__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 56/58-KD, V1 SUBUNIT B, ISOFORM 1; ATP6V1B1__:__ATP6B1;; VACUOLAR PROTON PUMP, SUBUNIT 3; VPP3__:__
Asterisk__:__192150__:__VALYL-tRNA SYNTHETASE; VARS__:__VALYL-tRNA SYNTHETASE 1; VARS1;; G7A;; VALRS;; VARS2, FORMERLY__:__
NULL__:__192200__:__VARICOSE VEINS__:____:__
Asterisk__:__192225__:__VASCULAR CELL ADHESION MOLECULE 1; VCAM1__:____:__
Asterisk__:__192240__:__VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA__:__VEGF__:__
NULL__:__192300__:__VASCULAR HELIX OF UMBILICAL CORD__:____:__
NULL__:__192310__:__VASCULITIS, LYMPHOCYTIC, NODULAR__:____:__
Number Sign__:__192315__:__VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL__:__CEREBRORETINAL VASCULOPATHY, HEREDITARY; CRV;; RETINOPATHY, VASCULAR, WITH CEREBRAL AND RENAL INVOLVEMENT AND RAYNAUD AND MIGRAINE PHENOMENA__:__
Asterisk__:__192320__:__VASOACTIVE INTESTINAL PEPTIDE; VIP__:____:__PHM27, INCLUDED
Asterisk__:__192321__:__VASOACTIVE INTESTINAL PEPTIDE RECEPTOR 1; VIPR1__:__VIP RECEPTOR, TYPE I; VIPR;; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE RECEPTOR, TYPE II;; PACAP RECEPTOR, TYPE II;; HVR1__:__
Asterisk__:__192340__:__ARGININE VASOPRESSIN; AVP__:__ARVP;; VASOPRESSIN-NEUROPHYSIN II;; ANTIDIURETIC HORMONE; ADH__:__NEUROPHYSIN II, INCLUDED; NPII, INCLUDED
Percent__:__192350__:__VATER/VACTERL ASSOCIATION__:____:__
NULL__:__192400__:__VEINS, PATTERN OF, ON ANTERIOR THORAX__:____:__
Number Sign__:__192430__:__VELOCARDIOFACIAL SYNDROME__:__CHROMOSOME 22q11.2 DELETION SYNDROME;; VCF SYNDROME; VCFS;; SHPRINTZEN VCF SYNDROME__:__
NULL__:__192445__:__VENTRICULAR EXTRASYSTOLES WITH SYNCOPE, PERODACTYLY, AND ROBIN SEQUENCE__:____:__
Caret__:__192450__:__MOVED TO 603829__:____:__
Number Sign__:__192500__:__LONG QT SYNDROME 1; LQT1__:__WARD-ROMANO SYNDROME; WRS;; ROMANO-WARD SYNDROME; RWS;; VENTRICULAR FIBRILLATION WITH PROLONGED QT INTERVAL__:__LONG QT SYNDROME 1/2, DIGENIC, INCLUDED; LQT1/2, DIGENIC, INCLUDED;; LONG QT SYNDROME 1, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__192600__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 1; CMH1__:__CMH;; VENTRICULAR HYPERTROPHY, HEREDITARY;; ASYMMETRIC SEPTAL HYPERTROPHY; ASH;; HYPERTROPHIC SUBAORTIC STENOSIS, IDIOPATHIC__:__
Number Sign__:__192605__:__VENTRICULAR TACHYCARDIA, FAMILIAL__:__VENTRICULAR TACHYCARDIA, FAMILIAL POLYMORPHIC__:__
NULL__:__192700__:__VENULAR INSUFFICIENCY, SYSTEMIC__:____:__
NULL__:__192800__:__VERTEBRAL FUSION, POSTERIOR LUMBOSACRAL, WITH BLEPHAROPTOSIS__:____:__
Percent__:__192900__:__VERTEBRAL HYPOPLASIA WITH LUMBAR KYPHOSIS__:____:__
Number Sign__:__192950__:__VERTICAL TALUS, CONGENITAL; CVT__:__ROCKER-BOTTOM FOOT;; PES VALGUS, CONGENITAL CONVEX__:__
Asterisk__:__192968__:__INTEGRIN, ALPHA-1; ITGA1__:__VERY LATE ACTIVATION PROTEIN 1; VLA1__:__
Caret__:__192972__:__MOVED TO 192975__:____:__
Asterisk__:__192974__:__INTEGRIN, ALPHA-2; ITGA2__:__VERY LATE ACTIVATION PROTEIN 2 RECEPTOR, ALPHA-2 SUBUNIT;; VLA2 RECEPTOR, ALPHA-2 SUBUNIT; VLAA2;; CD49B;; GLYCOPROTEIN Ia;; GP Ia__:__
Asterisk__:__192975__:__INTEGRIN, ALPHA-4; ITGA4__:__VERY LATE ACTIVATION PROTEIN 4 RECEPTOR, ALPHA-4 SUBUNIT;; VLA4 RECEPTOR, ALPHA-4 SUBUNIT;; CD49D__:__
Asterisk__:__192977__:__VERY LOW DENSITY LIPOPROTEIN RECEPTOR; VLDLR__:____:__
Percent__:__193000__:__VESICOURETERAL REFLUX 1; VUR1__:__VUR__:__
Asterisk__:__193001__:__SOLUTE CARRIER FAMILY 18 (VESICULAR MONOAMINE), MEMBER 2; SLC18A2__:__VESICULAR AMINE TRANSPORTER 2; VAT2;; VESICULAR MONOAMINE TRANSPORTER 2; VMAT2;; SYNAPTIC VESICLE MONOAMINE TRANSPORTER, BRAIN; SVMT;; SYNAPTIC VESICLE AMINE TRANSPORTER, BRAIN; SVAT__:__
Asterisk__:__193002__:__SOLUTE CARRIER FAMILY 18 (VESICULAR MONOAMINE), MEMBER 1; SLC18A1__:__VESICULAR AMINE TRANSPORTER 1; VAT1;; VESICULAR MONOAMINE TRANSPORTER 1; VMAT1;; ADRENAL CHROMAFFIN GRANULE AMINE TRANSPORTER; CGAT__:__
Percent__:__193003__:__NYSTAGMUS 4, CONGENITAL, AUTOSOMAL DOMINANT; NYS4__:__VESTIBULOCEREBELLAR DISORDER WITH PREDOMINANT OCULAR SIGNS__:__
NULL__:__193005__:__VESTIBULOCOCHLEAR DYSFUNCTION, PROGRESSIVE__:____:__
Percent__:__193007__:__VERTIGO, BENIGN RECURRENT; BRV__:__VERTIGO, BENIGN PAROXYSMAL POSITIONAL; BPPV;; VESTIBULOPATHY, FAMILIAL__:__VERTIGO, BENIGN RECURRENT, 1, INCLUDED; BRV1, INCLUDED
Caret__:__193010__:__MOVED TO 112266__:____:__
Asterisk__:__193040__:__VILLIN; VIL__:__VILLIN 1; VIL1__:__
Caret__:__193050__:__MOVED TO 125630__:____:__
Asterisk__:__193060__:__VIMENTIN; VIM__:____:__
Asterisk__:__193065__:__VINCULIN; VCL__:____:__METAVINCULIN, INCLUDED
Asterisk__:__193067__:__FRIEND LEUKEMIA VIRUS INTEGRATION 1; FLI1__:__VIRAL INTEGRATION REGION FLI1, MOUSE, HOMOLOG OF__:__EWING SARCOMA BREAKPOINT REGION 2, INCLUDED; EWSR2, INCLUDED;; FLI1/EWS FUSION GENE, INCLUDED
NULL__:__193070__:__VIRUS RD114 RNA COMPLEMENTARITY__:____:__
Percent__:__193090__:__TRANSCOBALAMIN I DEFICIENCY__:__TCN1 DEFICIENCY;; COBALAMIN PSEUDODEFICIENCY DUE TO TRANSCOBALAMIN DEFICIENCY;; COBALAMIN R BINDER PROTEIN DEFICIENCY__:__TRANSCOBALAMIN I DEFICIENCY WITH LACTOFERRIN DEFICIENCY, INCLUDED;; R BINDER DEFICIENCY WITH LACTOFERRIN DEFICIENCY, INCLUDED
Number Sign__:__193100__:__HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL DOMINANT; ADHR__:__VITAMIN D-RESISTANT RICKETS, AUTOSOMAL DOMINANT;; HYPOPHOSPHATEMIA, AUTOSOMAL DOMINANT__:__
Asterisk__:__193190__:__VITRONECTIN; VTN__:__SERUM SPREADING FACTOR;; COMPLEMENT S-PROTEIN;; SOMATOMEDIN B__:__
Percent__:__193200__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 6; VAMAS6__:____:__
Asterisk__:__193210__:__INTEGRIN, ALPHA-V; ITGAV__:__VITRONECTIN RECEPTOR, ALPHA POLYPEPTIDE; VNRA;; CD51__:__
Number Sign__:__193220__:__VITREORETINOCHOROIDOPATHY; VRCP__:__VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT; ADVIRC;; VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT;; VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOS__:__MICROCORNEA, ROD-CONE DYSTROPHY, CATARACT, AND POSTERIOR STAPHYLOMA, INCLUDED; MRCS, INCLUDED
Number Sign__:__193230__:__VITREORETINAL DEGENERATION, SNOWFLAKE TYPE; SVD__:__SNOWFLAKE VITREORETINAL DEGENERATION__:__
Number Sign__:__193235__:__VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY; VRNI__:__PROLIFERATIVE VITREORETINOPATHY; PVR;; VITREORETINOPATHY, NEOVASCULAR INFLAMMATORY, AUTOSOMAL DOMINANT; ADNIV__:__
NULL__:__193240__:__VOCAL CORD PARALYSIS AND PTOSIS__:____:__
Asterisk__:__193245__:__VOLTAGE-DEPENDENT ANION CHANNEL 2; VDAC2__:____:__
Percent__:__193250__:__VOLVULUS OF MIDGUT__:__INTESTINAL MALROTATION, FAMILIAL__:__
Caret__:__193290__:__MOVED TO 151675__:____:__
Number Sign__:__193300__:__VON HIPPEL-LINDAU SYNDROME; VHL__:____:__VON HIPPEL-LINDAU SYNDROME, MODIFIERS OF, INCLUDED
Number Sign__:__193400__:__VON WILLEBRAND DISEASE, TYPE 1; VWD1__:__VON WILLEBRAND DISEASE, TYPE I;; VWD, TYPE 1__:__
NULL__:__193450__:__VULVOVAGINITIS, ALLERGIC SEMINAL__:____:__
Number Sign__:__193500__:__WAARDENBURG SYNDROME, TYPE 1; WS1__:__WAARDENBURG SYNDROME WITH DYSTOPIA CANTHORUM__:__
Number Sign__:__193510__:__WAARDENBURG SYNDROME, TYPE 2A; WS2A__:__WAARDENBURG SYNDROME, TYPE IIA;; WAARDENBURG SYNDROME WITHOUT DYSTOPIA CANTHORUM;; WS2__:__
Number Sign__:__193520__:__WATSON SYNDROME; WTSN__:__PULMONIC STENOSIS WITH CAFE-AU-LAIT SPOTS;; CAFE-AU-LAIT SPOTS WITH PULMONIC STENOSIS__:__
Asterisk__:__193525__:__WEE1, S. POMBE, HOMOLOG OF; WEE1__:__WEE1 TYROSINE KINASE;; WEE1, SOMATIC; WEE1A__:__
Number Sign__:__193530__:__WEYERS ACROFACIAL DYSOSTOSIS; WAD__:__ACRODENTAL DYSOSTOSIS OF WEYERS;; CURRY-HALL SYNDROME__:__
Number Sign__:__193670__:__WHIM SYNDROME; WHIMS__:__WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS SYNDROME__:__
Caret__:__193675__:__REMOVED FROM DATABASE__:____:__
Caret__:__193680__:__MOVED TO 128101__:____:__
Number Sign__:__193700__:__ARTHROGRYPOSIS, DISTAL, TYPE 2A; DA2A__:__FREEMAN-SHELDON SYNDROME; FSS;; WHISTLING FACE-WINDMILL VANE HAND SYNDROME;; CRANIOCARPOTARSAL DYSTROPHY;; CRANIOCARPOTARSAL DYSPLASIA__:__
Number Sign__:__193900__:__WHITE SPONGE NEVUS 1; WSN1__:__WHITE SPONGE NEVUS OF CANNON;; LEUKOKERATOSIS, HEREDITARY MUCOSAL__:__
NULL__:__194000__:__WIDOW'S PEAK__:____:__
Number Sign__:__194050__:__WILLIAMS-BEUREN SYNDROME; WBS__:__CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB;; WILLIAMS SYNDROME; WMS; WS__:__
Number Sign__:__194070__:__WILMS TUMOR 1; WT1__:__NEPHROBLASTOMA__:__
Number Sign__:__194071__:__WILMS TUMOR 2; WT2__:____:__
Number Sign__:__194072__:__WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, AND MENTAL RETARDATION SYNDROME; WAGR__:__WAGR SYNDROME;; CHROMOSOME 11p13 DELETION SYNDROME__:__
Number Sign__:__194080__:__DENYS-DRASH SYNDROME; DDS__:__DRASH SYNDROME;; WILMS TUMOR AND PSEUDO- OR TRUE HERMAPHRODITISM;; NEPHROPATHY, WILMS TUMOR, AND GENITAL ANOMALIES__:__
Percent__:__194090__:__WILMS TUMOR 3; WT3__:____:__
Caret__:__194100__:__MOVED TO 106600__:____:__
Number Sign__:__194190__:__WOLF-HIRSCHHORN SYNDROME; WHS__:__CHROMOSOME 4p16.3 DELETION SYNDROME;; PITT-ROGERS-DANKS SYNDROME; PRDS;; PITT SYNDROME;; WITTWER SYNDROME__:__
Number Sign__:__194200__:__WOLFF-PARKINSON-WHITE SYNDROME__:__WPW SYNDROME__:__PREEXCITATION SYNDROME, INCLUDED;; ACCESSORY ATRIOVENTRICULAR PATHWAYS, INCLUDED
Number Sign__:__194300__:__WOOLLY HAIR, AUTOSOMAL DOMINANT; ADWH__:____:__
NULL__:__194320__:__WORONETS TRAIT__:____:__
Percent__:__194350__:__WT LIMB-BLOOD SYNDROME__:____:__
Asterisk__:__194355__:__X BOX-BINDING PROTEIN 1; XBP1__:__X BOX-BINDING PROTEIN 2; XBP2__:__
Asterisk__:__194360__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 1; XRCC1__:__X-RAY REPAIR CROSS-COMPLEMENTING 1__:__
Asterisk__:__194363__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 4; XRCC4__:____:__
Asterisk__:__194364__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 5; XRCC5__:__Ku ANTIGEN, 80-KD SUBUNIT; Ku80;; Ku86__:__
NULL__:__194370__:__X-RAY SENSITIVITY; XRS__:____:__
Number Sign__:__194380__:__DEHYDRATED HEREDITARY STOMATOCYTOSIS 1 WITH OR WITHOUT PSEUDOHYPERKALEMIA AND/OR PERINATAL EDEMA; DHS1__:__DEHYDRATED HEREDITARY STOMATOCYTOSIS; DHS;; XEROCYTOSIS, HEREDITARY;; DESICCYTOSIS, HEREDITARY;; PSEUDOHYPERKALEMIA, FAMILIAL, 1, DUE TO RED CELL LEAK; PSHK1;; PSEUDOHYPERKALEMIA EDINBURGH__:__
NULL__:__194400__:__XERODERMA PIGMENTOSUM, AUTOSOMAL DOMINANT, MILD__:____:__
Asterisk__:__194450__:__YEAST FACTOR__:____:__
Asterisk__:__194460__:__ALPHA-2-GLYCOPROTEIN, ZINC; AZGP1__:__ZINC-ALPHA-2-GLYCOPROTEIN; ZAG; ZA2G__:__
Percent__:__194470__:__ZINC, ELEVATED PLASMA__:__ALBUMIN BINDING OF ZINC, ELEVATED;; HYPERZINCEMIA, FAMILIAL DYSALBUMINEMIC__:__HYPERZINCEMIA AND HYPERCALPROTECTINEMIA, INCLUDED
Asterisk__:__194480__:__ZINC FINGER PROTEIN 3, MOUSE, HOMOLOG OF; ZFP3__:____:__
Asterisk__:__194490__:__ZINC FINGER PROTEIN 1; ZNF1__:____:__
Asterisk__:__194500__:__ZINC FINGER PROTEIN 2; ZNF2__:____:__
Asterisk__:__194510__:__ZINC FINGER PROTEIN 3; ZNF3__:____:__
Caret__:__194520__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__194521__:__ZINC FINGER PROTEIN 33A; ZNF33A__:__ZINC FINGER AND ZAK-ASSOCIATED PROTEIN WITH KRAB DOMAIN; ZZAPK;; KIAA0065;; ZINC FINGER PROTEIN 11A; ZNF11A;; ZNF11;; KOX2__:__
Asterisk__:__194522__:__ZINC FINGER PROTEIN 33B; ZNF33B__:__ZINC FINGER PROTEIN 11B; ZNF11B__:__
Asterisk__:__194524__:__ZINC FINGER PROTEIN 18; ZNF18__:__KOX11__:__
Asterisk__:__194525__:__ZINC FINGER PROTEIN 19; ZNF19__:__KOX12__:__
Asterisk__:__194526__:__ZINC FINGER PROTEIN 34; ZNF34__:__KOX32__:__
Asterisk__:__194527__:__ZINC FINGER PROTEIN 23; ZNF23__:__ZINC FINGER PROTEIN 359; ZNF359__:__
Asterisk__:__194528__:__ZINC FINGER PROTEIN 25; ZNF25__:__KOX19__:__
Asterisk__:__194529__:__ZINC FINGER PROTEIN 22; ZNF22__:__KOX15__:__
Caret__:__194530__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__194531__:__ZINC FINGER PROTEIN 7; ZNF7__:__KOX4__:__
Asterisk__:__194532__:__ZINC FINGER PROTEIN 8; ZNF8__:____:__
Asterisk__:__194533__:__ZINC FINGER PROTEIN 35; ZNF35__:__ZINC FINGER PROTEIN HF.10; HF10__:__
Asterisk__:__194534__:__ZINC FINGER PROTEIN 24; ZNF24__:__KOX17;; ZNF191__:__
Asterisk__:__194535__:__ZINC FINGER PROTEIN 29; ZNF29__:__KOX26__:__
Asterisk__:__194536__:__ZINC FINGER PROTEIN 12; ZNF12__:__KOX3__:__
Asterisk__:__194537__:__ZINC FINGER PROTEIN 26; ZNF26__:__KOX20__:__
Asterisk__:__194538__:__ZINC FINGER PROTEIN 10; ZNF10__:__KOX1__:__
Asterisk__:__194539__:__ZINC FINGER PROTEIN 32; ZNF32__:____:__
Asterisk__:__194540__:__HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENHANCER-BINDING PROTEIN 1; HIVEP1__:__ZINC FINGER PROTEIN 40; ZNF40;; MAJOR HISTOCOMPATIBILITY COMPLEX-BINDING PROTEIN 1; MBP1;; POSITIVE REGULATORY DOMAIN II-BINDING FACTOR 1; PRDIIBF1;; ZAS FAMILY, MEMBER 1; ZAS1__:__
Asterisk__:__194541__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 25; ZBTB25__:__ZINC FINGER PROTEIN KUP; KUP;; ZINC FINGER PROTEIN 46, FORMERLY; ZNF46, FORMERLY__:__
Asterisk__:__194542__:__ZINC FINGER PROTEIN 44; ZNF44__:__KOX7__:__
Asterisk__:__194543__:__ZINC FINGER PROTEIN 69; ZNF69__:____:__
Asterisk__:__194544__:__ZINC FINGER PROTEIN 70; ZNF70__:____:__
Asterisk__:__194545__:__ZINC FINGER PROTEIN 71; ZNF71__:__ENDOTHELIAL ZINC FINGER PROTEIN INDUCED BY TNF-ALPHA; EZFIT__:__
Asterisk__:__194546__:__ZINC FINGER PROTEIN 72; ZNF72__:____:__
Asterisk__:__194547__:__ZINC FINGER PROTEIN 73; ZNF73__:____:__
Asterisk__:__194548__:__ZINC FINGER PROTEIN 74; ZNF74__:____:__
Asterisk__:__194549__:__ZINC FINGER PROTEIN 76; ZNF76__:__D6S229E__:__
Asterisk__:__194550__:__MYELOID ZINC FINGER GENE 1; MZF1__:__ZINC FINGER PROTEIN 42; ZNF42;; ZINC FINGER, MYELOID, RETINOIC ACID-RESPONSIVE;; MZF1B__:__
Asterisk__:__194551__:__ZINC FINGER PROTEIN 77; ZNF77__:____:__
Asterisk__:__194552__:__ZINC FINGER PROTEIN 79; ZNF79__:____:__
Asterisk__:__194553__:__ZINC FINGER PROTEIN 80; ZNF80__:____:__
Asterisk__:__194554__:__ZINC FINGER PROTEIN 45; ZNF45__:__ZINC FINGER PROTEIN 13; ZNF13;; KOX5__:__
Asterisk__:__194555__:__ZINC FINGER PROTEIN 224; ZNF224__:__KOX22__:__ZINC FINGER PROTEIN 255, INCLUDED; ZNF255, INCLUDED;; BONE MARROW ZINC FINGER PROTEIN 2, INCLUDED; BMZF2, INCLUDED
Asterisk__:__194556__:__ZINC FINGER PROTEIN 14; ZNF14__:__KOX6__:__
Asterisk__:__194557__:__ZINC FINGER PROTEIN 20; ZNF20__:__KOX13__:__
Asterisk__:__194558__:__ZINC FINGER PROTEIN 83; ZNF83__:____:__
Asterisk__:__194624__:__ZINC FINGER PROTEIN 117; ZNF117__:____:__
Asterisk__:__194628__:__ZINC FINGER PROTEIN 121; ZNF121__:____:__
Asterisk__:__194630__:__ZINC FINGER PROTEIN 123; ZNF123__:____:__
Asterisk__:__194631__:__ZINC FINGER PROTEIN 124; ZNF124__:____:__
Asterisk__:__194632__:__ZINC FINGER PROTEIN 125; ZNF125__:____:__
Asterisk__:__194633__:__ZINC FINGER PROTEIN 126; ZNF126__:____:__
Asterisk__:__194648__:__ZINC FINGER PROTEIN 141; ZNF141__:____:__
Asterisk__:__195000__:__ZONA PELLUCIDA GLYCOPROTEIN 1; ZP1__:____:__
Caret__:__195002__:__MOVED TO 182889__:____:__
Number Sign__:__200100__:__ABETALIPOPROTEINEMIA; ABL__:__ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY__:__
Number Sign__:__200110__:__ABLEPHARON-MACROSTOMIA SYNDROME; AMS__:____:__
NULL__:__200130__:__ABSENT EYEBROWS AND EYELASHES WITH MENTAL RETARDATION__:__PSEUDOPROGERIA SYNDROME__:__
Number Sign__:__200150__:__CHOREOACANTHOCYTOSIS; CHAC__:__LEVINE-CRITCHLEY SYNDROME;; ACANTHOCYTOSIS WITH NEUROLOGIC DISORDER;; NEUROACANTHOCYTOSIS;; CHOREA-ACANTHOCYTOSIS__:__
NULL__:__200170__:__ACANTHOSIS NIGRICANS WITH MUSCLE CRAMPS AND ACRAL ENLARGEMENT__:____:__
NULL__:__200300__:__ACETOPHENETIDIN SENSITIVITY__:____:__
Asterisk__:__200350__:__ACETYL-CoA CARBOXYLASE-ALPHA; ACACA__:__ACCA;; ACETYL-CoA CARBOXYLASE 1; ACC1__:__
Percent__:__200400__:__ACHALASIA, FAMILIAL ESOPHAGEAL__:____:__
Caret__:__200440__:__MOVED TO 231550__:____:__
NULL__:__200450__:__ACHALASIA-MICROCEPHALY SYNDROME__:____:__
Number Sign__:__200500__:__ACHEIROPODY; ACHP__:__ACHEIROPODIA;; ACHEIROPODY, BRAZILIAN TYPE__:__
Number Sign__:__200600__:__ACHONDROGENESIS, TYPE IA; ACG1A__:__ACHONDROGENESIS, HOUSTON-HARRIS TYPE__:__
Number Sign__:__200610__:__ACHONDROGENESIS, TYPE II; ACG2__:__ACHONDROGENESIS, LANGER-SALDINO TYPE;; CHONDROGENESIS IMPERFECTA;; ACHONDROGENESIS, TYPE IB, FORMERLY__:__HYPOCHONDROGENESIS, INCLUDED
Number Sign__:__200700__:__CHONDRODYSPLASIA, GREBE TYPE__:__ACHONDROGENESIS, BRAZILIAN;; GREBE CHONDRODYSPLASIA;; GREBE DYSPLASIA;; ACROMESOMELIC DYSPLASIA, GREBE TYPE; AMDG;; ACHONDROGENESIS, TYPE II, FORMERLY__:__
Caret__:__200710__:__MOVED TO 200610__:____:__
Caret__:__200720__:__MOVED TO 200610__:____:__
NULL__:__200900__:__SHORT-LIMB SKELETAL DYSPLASIA WITH SEVERE COMBINED IMMUNODEFICIENCY__:__SLSD WITH SCID;; ACHONDROPLASIA, SO-CALLED, AND SEVERE COMBINED IMMUNODEFICIENCY__:__
Caret__:__200930__:__REMOVED FROM DATABASE__:____:__
NULL__:__200950__:__ACID PHOSPHATASE DEFICIENCY__:____:__
NULL__:__200970__:__ACKERMAN SYNDROME__:__MOLAR ROOTS, PYRAMIDAL, WITH JUVENILE GLAUCOMA AND UNUSUAL UPPER LIP;; GLAUCOMA, JUVENILE, WITH UNUSUAL UPPER LIP AND DENTAL ROOTS__:__
NULL__:__200980__:__ACRORENAL-MANDIBULAR SYNDROME__:__ACRORENAL-UTERINE-MANDIBULAR SYNDROME; ARUMS;; SPLIT-HAND AND SPLIT-FOOT WITH MANDIBULAR HYPOPLASIA__:__
Number Sign__:__200990__:__ACROCALLOSAL SYNDROME; ACLS__:__HALLUX DUPLICATION, POSTAXIAL POLYDACTYLY, AND ABSENCE OF CORPUS CALLOSUM;; SCHINZEL ACROCALLOSAL SYNDROME__:__JOUBERT SYNDROME 12, INCLUDED; JBTS12, INCLUDED;; JOUBERT SYNDROME 12/15, DIGENIC, INCLUDED
NULL__:__200995__:__ACROCEPHALOPOLYDACTYLOUS DYSPLASIA__:__ELEJALDE SYNDROME__:__
Number Sign__:__201000__:__CARPENTER SYNDROME 1; CRPT1__:__CARPENTER SYNDROME;; ACROCEPHALOPOLYSYNDACTYLY TYPE II;; ACPS II__:__
NULL__:__201020__:__ACROCEPHALOPOLYSYNDACTYLY TYPE IV__:__ACPS IV;; GOODMAN SYNDROME__:__
NULL__:__201050__:__ACROCRANIOFACIAL DYSOSTOSIS__:____:__
Number Sign__:__201100__:__ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ__:____:__
Percent__:__201170__:__ACROFACIAL DYSOSTOSIS SYNDROME OF RODRIGUEZ__:__RODRIGUEZ LETHAL ACROFACIAL DYSOSTOSIS SYNDROME__:__
NULL__:__201180__:__ACROFRONTOFACIONASAL DYSOSTOSIS 1__:__AFFN DYSOSTOSIS 1; AFFND1;; POLYSYNDACTYLY, POSTAXIAL, FRONTONASAL DYSOSTOSIS, AND CLEFT LIP/PALATE;; CLEFT LIP/PALATE WITH FRONTONASAL DYSOSTOSIS AND POSTAXIAL POLYSYNDACTYLY__:__
Caret__:__201181__:__MOVED TO 239710__:____:__
NULL__:__201200__:__ACROGERIA, GOTTRON TYPE__:__METAGERIA;; ACROMETAGERIA__:__
Number Sign__:__201250__:__ACROMESOMELIC DYSPLASIA, HUNTER-THOMPSON TYPE; AMDH__:__ACROMESOMELIC DWARFISM__:__
Number Sign__:__201300__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIA; HSAN2A__:__HSAN IIA;; NEUROPATHY, HEREDITARY SENSORY, TYPE IIA; HSN2A;; HSN IIA;; ACROOSTEOLYSIS, NEUROGENIC;; ACROOSTEOLYSIS, GIACCAI TYPE;; NEUROPATHY, HEREDITARY SENSORY RADICULAR, AUTOSOMAL RECESSIVE;; MORVAN DISEASE;; NEUROPATHY, PROGRESSIVE SENSORY, OF CHILDREN;; NEUROPATHY, CONGENITAL SENSORY__:__
NULL__:__201310__:__ACRORENAL SYNDROME, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__201400__:__ACTH DEFICIENCY, ISOLATED; IAD__:__ADRENOCORTICOTROPIC HORMONE DEFICIENCY__:__
Number Sign__:__201450__:__ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF; ACADMD__:__ACADM DEFICIENCY;; MCAD DEFICIENCY;; MCADH DEFICIENCY;; CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY__:__
Caret__:__201460__:__MOVED TO 201475__:____:__
Number Sign__:__201470__:__ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF; ACADSD__:__ACADS DEFICIENCY;; LIPID-STORAGE MYOPATHY SECONDARY TO SHORT-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY;; SCADH DEFICIENCY;; SCAD DEFICIENCY__:__
Number Sign__:__201475__:__ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF; ACADVLD__:__VLCAD DEFICIENCY__:__
Percent__:__201550__:__ADDUCTED THUMBS SYNDROME__:____:__
Number Sign__:__201710__:__LIPOID CONGENITAL ADRENAL HYPERPLASIA; LCAH__:__ADRENAL HYPERPLASIA I;; LIPOID HYPERPLASIA, CONGENITAL, OF ADRENAL CORTEX WITH MALE PSEUDOHERMAPHRODITISM__:__
Number Sign__:__201750__:__ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS; ABS1__:____:__
Number Sign__:__201810__:__ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY__:__ADRENAL HYPERPLASIA II;; 3-BETA-HSD DEFICIENCY; HSDB__:__
Number Sign__:__201910__:__ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY__:__ADRENAL HYPERPLASIA III;; 21-HYDROXYLASE DEFICIENCY;; CYP21 DEFICIENCY;; CONGENITAL ADRENAL HYPERPLASIA 1; CAH1__:__HYPERANDROGENISM, NONCLASSIC TYPE, DUE TO 21-HYDROXYLASE DEFICIENCY, INCLUDED
Number Sign__:__202010__:__ADRENAL HYPERPLASIA, CONGENITAL, DUE TO STEROID 11-BETA-HYDROXYLASE DEFICIENCY__:__ADRENAL HYPERPLASIA IV;; STEROID 11-BETA-HYDROXYLASE DEFICIENCY;; 11-BETA-HYDROXYLASE DEFICIENCY;; ADRENAL HYPERPLASIA, HYPERTENSIVE FORM;; P450C11B1 DEFICIENCY__:__
Number Sign__:__202110__:__ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY__:__ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY__:__17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED
NULL__:__202150__:__ADRENAL HYPOPLASIA, CONGENITAL, WITH ABSENT PITUITARY LUTEINIZING HORMONE__:____:__
NULL__:__202155__:__ADRENAL HYPOPLASIA, CYTOMEGALIC TYPE__:____:__
Number Sign__:__202200__:__GLUCOCORTICOID DEFICIENCY 1; GCCD1__:__FAMILIAL GLUCOCORTICOID DEFICIENCY 1; FGD1;; ADRENAL UNRESPONSIVENESS TO ACTH;; ACTH RESISTANCE__:__
Number Sign__:__202300__:__ADRENOCORTICAL CARCINOMA, HEREDITARY; ADCC__:____:__ADRENOCORTICAL CARCINOMA, PEDIATRIC, INCLUDED
NULL__:__202355__:__ADRENOCORTICAL UNRESPONSIVENESS TO ACTH WITH POSTRECEPTOR DEFECT__:__FAMILIAL GLUCOCORTICOID DEFICIENCY DUE TO DEFECT DISTAL TO ACTH RECEPTOR__:__
Number Sign__:__202370__:__PEROXISOME BIOGENESIS DISORDER 2B; PBD2B__:____:__
Number Sign__:__202400__:__AFIBRINOGENEMIA, CONGENITAL__:____:__HYPOFIBRINOGENEMIA, CONGENITAL, INCLUDED
Caret__:__202500__:__MOVED TO 600899 AND 601457__:____:__
NULL__:__202550__:__AGANGLIONOSIS, TOTAL INTESTINAL__:____:__
NULL__:__202600__:__AGENESIS OF CEREBRAL WHITE MATTER__:____:__
Number Sign__:__202650__:__AGNATHIA-OTOCEPHALY COMPLEX; AGOTC__:__DYSGNATHIA COMPLEX AGNATHIA-HOLOPROSENCEPHALY;; HOLOPROSENCEPHALY-AGNATHIA;; OTOCEPHALY__:__
NULL__:__202660__:__PAGOD SYNDROME__:__AGONADISM WITH MULTIPLE INTERNAL MALFORMATIONS__:__
Number Sign__:__202700__:__NEUTROPENIA, SEVERE CONGENITAL, 1, AUTOSOMAL DOMINANT; SCN1__:____:__
NULL__:__202900__:__ALANINURIA WITH MICROCEPHALY, DWARFISM, ENAMEL HYPOPLASIA, AND DIABETES MELLITUS__:__STIMMLER SYNDROME__:__
NULL__:__203000__:__FRONTONASAL DYSPLASIA WITH ALAR CLEFTS__:__ALAR-NASAL CARTILAGES, COLOBOMA OF, WITH TELECANTHUS__:__
Number Sign__:__203100__:__ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A__:__OCULOCUTANEOUS ALBINISM, TYPE I; OCA1;; ALBINISM I;; OCULOCUTANEOUS ALBINISM, TYROSINASE-NEGATIVE; ATN__:__
Number Sign__:__203200__:__ALBINISM, OCULOCUTANEOUS, TYPE II; OCA2__:__OCULOCUTANEOUS ALBINISM, TYPE II;; OCULOCUTANEOUS ALBINISM, TYROSINASE-POSITIVE;; ALBINISM II__:__ALBINISM, BROWN OCULOCUTANEOUS, INCLUDED; BOCA, INCLUDED;; BROWN OCULOCUTANEOUS ALBINISM, INCLUDED
Caret__:__203280__:__MOVED TO 606952__:____:__
Caret__:__203285__:__MOVED TO 608233__:____:__
Number Sign__:__203290__:__ALBINISM, OCULOCUTANEOUS, TYPE III; OCA3__:__OCULOCUTANEOUS ALBINISM, TYPE III;; ALBINISM III;; RUFOUS OCULOCUTANEOUS ALBINISM; ROCA;; XANTHISM__:__
Number Sign__:__203300__:__HERMANSKY-PUDLAK SYNDROME 1; HPS1__:__ALBINISM WITH HEMORRHAGIC DIATHESIS AND PIGMENTED RETICULOENDOTHELIAL CELLS;; DELTA STORAGE POOL DISEASE__:__
Caret__:__203310__:__MOVED TO 203200__:____:__
Percent__:__203330__:__PSEUDOHYPOPARATHYROIDISM, TYPE II; PHP2__:__PHP II__:__
NULL__:__203340__:__ALBINISM-MICROCEPHALY-DIGITAL ANOMALIES SYNDROME__:__MICROCEPHALY-ALBINISM-DIGITAL ANOMALIES SYNDROME__:__
Number Sign__:__203400__:__CORTICOSTERONE METHYLOXIDASE TYPE I DEFICIENCY__:__CMO I DEFICIENCY;; ALDOSTERONE DEFICIENCY I;; HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 1; FHHA1A;; ALDOSTERONE DEFICIENCY DUE TO DEFECT IN STEROID 18-HYDROXYLASE;; 18-HYDROXYLASE DEFICIENCY;; STEROID 18-HYDROXYLASE DEFICIENCY__:__
Number Sign__:__203450__:__ALEXANDER DISEASE; ALXDRD__:____:__
Number Sign__:__203500__:__ALKAPTONURIA; AKU__:__HOMOGENTISIC ACID OXIDASE DEFICIENCY__:__
NULL__:__203550__:__ALOPECIA-CONTRACTURES-DWARFISM MENTAL RETARDATION SYNDROME__:__ACD MENTAL RETARDATION SYNDROME__:__
NULL__:__203600__:__ALOPECIA-EPILEPSY-OLIGOPHRENIA SYNDROME OF MOYNAHAN__:__MOYNAHAN ALOPECIA SYNDROME__:__
Number Sign__:__203650__:__ALOPECIA-MENTAL RETARDATION SYNDROME 1; APMR1__:__APMR;; AMR SYNDROME__:__
Number Sign__:__203655__:__ALOPECIA UNIVERSALIS CONGENITA; ALUNC__:__ATRICHIA, GENERALIZED__:__
Number Sign__:__203700__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A__:__ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC__:__
Percent__:__203740__:__ALPHA-KETOGLUTARATE DEHYDROGENASE DEFICIENCY__:__ALPHA-KGD DEFICIENCY;; 2-KETOGLUTARATE DEHYDROGENASE DEFICIENCY;; OXOGLUTARIC ACIDURIA__:__
Number Sign__:__203750__:__ALPHA-METHYLACETOACETIC ACIDURIA__:__2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY__:__
NULL__:__203760__:__ALPHA-2-DEFICIENT COLLAGEN DISEASE__:__MEIGEL DISEASE__:__
Number Sign__:__203780__:__ALPORT SYNDROME, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__203800__:__ALSTROM SYNDROME; ALMS__:__ALSS__:__
Number Sign__:__204000__:__LEBER CONGENITAL AMAUROSIS 1; LCA1__:__AMAUROSIS CONGENITA OF LEBER I;; LCA;; RETINAL BLINDNESS, CONGENITAL; CRB__:__
Number Sign__:__204100__:__LEBER CONGENITAL AMAUROSIS 2; LCA2__:__AMAUROSIS CONGENITA OF LEBER II__:__
NULL__:__204110__:__AMAUROSIS CONGENITA, CONE-ROD TYPE, WITH CONGENITAL HYPERTRICHOSIS__:____:__
Number Sign__:__204200__:__CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3__:__NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE__:__
Number Sign__:__204300__:__CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE; CLN4A__:____:__
Caret__:__204400__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__204500__:__CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2__:__CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE__:__NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED
Caret__:__204600__:__MOVED TO 204500__:____:__
Number Sign__:__204650__:__AMELOGENESIS IMPERFECTA, TYPE IC; AI1C__:__AMELOGENESIS IMPERFECTA, LOCAL HYPOPLASTIC TYPE, AUTOSOMAL RECESSIVE;; AMELOGENESIS IMPERFECTA, HYPOPLASTIC, WITH OR WITHOUT OPENBITE MALOCCLUSION, AUTOSOMAL RECESSIVE__:__
Number Sign__:__204690__:__AMELOGENESIS IMPERFECTA, TYPE IG; AI1G__:__ENAMEL-RENAL SYNDROME; ERS;; ENAMEL-RENAL-GINGIVAL SYNDROME;; AMELOGENESIS IMPERFECTA, HYPOPLASTIC, WITH NEPHROCALCINOSIS;; AMELOGENESIS IMPERFECTA AND GINGIVAL FIBROMATOSIS SYNDROME; AIGFS__:__
Number Sign__:__204700__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA1; AI2A1__:__AMELOGENESIS IMPERFECTA, PIGMENTED HYPOMATURATION TYPE, 1__:__
NULL__:__204730__:__AMINO ACIDURIA WITH MENTAL DEFICIENCY, DWARFISM, MUSCULAR DYSTROPHY, OSTEOPOROSIS, AND ACIDOSIS__:____:__
Number Sign__:__204750__:__2-AMINOADIPIC 2-OXOADIPIC ACIDURIA; AMOXAD__:____:__
Percent__:__204800__:__AMOBARBITAL, DEFICIENT N-HYDROXYLATION OF__:____:__
NULL__:__204850__:__AMYLOIDOSIS OF GINGIVA AND CONJUNCTIVA, WITH MENTAL RETARDATION__:____:__
Number Sign__:__204870__:__CORNEAL DYSTROPHY, GELATINOUS DROP-LIKE; GDLD__:__CDGDL;; AMYLOIDOSIS, CORNEAL;; AMYLOID CORNEAL DYSTROPHY, JAPANESE TYPE;; CORNEAL DYSTROPHY, LATTICE TYPE III;; LATTICE CORNEAL DYSTROPHY, TYPE III__:__
NULL__:__204900__:__AMYLOIDOSIS, CUTANEOUS BULLOUS__:____:__
NULL__:__205000__:__AMYOTONIA CONGENITA__:__OPPENHEIM DISEASE__:__
Number Sign__:__205100__:__AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2__:__ALS, JUVENILE; ALSJ__:__
Percent__:__205200__:__AMYOTROPHIC LATERAL SCLEROSIS, JUVENILE, WITH DEMENTIA__:__ALS-DEMENTIA COMPLEX__:__
NULL__:__205250__:__AMYOTROPHIC LATERAL SCLEROSIS WITH POLYGLUCOSAN BODIES__:____:__
Number Sign__:__205400__:__TANGIER DISEASE; TGD__:__HIGH DENSITY LIPOPROTEIN DEFICIENCY, TYPE 1; HDLDT1;; HIGH DENSITY LIPOPROTEIN DEFICIENCY, TANGIER TYPE;; ANALPHALIPOPROTEINEMIA__:__
Caret__:__205600__:__MOVED TO 105650__:____:__
NULL__:__205700__:__ANEMIA, AUTOIMMUNE HEMOLYTIC__:____:__
Caret__:__205900__:__MOVED TO 105650__:____:__
Number Sign__:__205950__:__ANEMIA, SIDEROBLASTIC, 2, PYRIDOXINE-REFRACTORY; SIDBA2__:____:__
NULL__:__206000__:__ANEMIA, SIDEROBLASTIC, PYRIDOXINE-RESPONSIVE, AUTOSOMAL RECESSIVE__:__ANEMIA, CONGENITAL SIDEROBLASTIC, B6-RESPONSIVE__:__
Number Sign__:__206100__:__ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 1; AHMIO1__:____:__
Number Sign__:__206200__:__IRON-REFRACTORY IRON DEFICIENCY ANEMIA; IRIDA__:__ANEMIA, HYPOCHROMIC MICROCYTIC, WITH DEFECT IN IRON METABOLISM;; IRON-HANDLING DISORDER, HEREDITARY;; PSEUDO-IRON-DEFICIENCY ANEMIA__:__
NULL__:__206300__:__ANEMIA, NONSPHEROCYTIC HEMOLYTIC, ASSOCIATED WITH ABNORMALITY OF RED CELL MEMBRANE__:____:__
NULL__:__206400__:__ANEMIA, NONSPHEROCYTIC HEMOLYTIC, POSSIBLY DUE TO DEFECT IN PORPHYRIN METABOLISM__:____:__
Number Sign__:__206500__:__ANENCEPHALY; ANPH__:____:__
NULL__:__206550__:__ANGIOLIPOMATOSIS, FAMILIAL__:__ANGIOLIPOMA MICROTHROMBOTICUM__:__
Percent__:__206570__:__ANGIOMATOSIS, DIFFUSE CORTICOMENINGEAL, OF DIVRY AND VAN BOGAERT__:__DIVRY-VAN BOGAERT SYNDROME__:__
NULL__:__206600__:__ANHIDROSIS, FAMILIAL GENERALIZED, WITH ABNORMAL OR ABSENT SWEAT GLANDS__:____:__
Number Sign__:__206700__:__GILLESPIE SYNDROME; GLSP__:__ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL RETARDATION__:__
NULL__:__206750__:__ANIRIDIA, PARTIAL, WITH UNILATERAL RENAL AGENESIS AND PSYCHOMOTOR RETARDATION__:____:__
Percent__:__206780__:__ANODONTIA OF PERMANENT DENTITION__:__TEETH, PERMANENT, ABSENCE OF__:__
Number Sign__:__206800__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4; NDNC4__:__ANONYCHIA/HYPONYCHIA CONGENITA;; ANONYCHIA TOTALIS__:__
Number Sign__:__206900__:__MICROPHTHALMIA, SYNDROMIC 3; MCOPS3__:__MICROPHTHALMIA AND ESOPHAGEAL ATRESIA SYNDROME;; ANOPHTHALMIA, CLINICAL, WITH ASSOCIATED ANOMALIES;; ANOPHTHALMIA-ESOPHAGEAL-GENITAL SYNDROME;; AEG SYNDROME__:__OPTIC NERVE HYPOPLASIA AND ABNORMALITIES OF THE CENTRAL NERVOUS SYSTEM, INCLUDED
Number Sign__:__206920__:__MICROPHTHALMIA WITH LIMB ANOMALIES; MLA__:__WAARDENBURG ANOPHTHALMIA SYNDROME;; ANOPHTHALMIA-SYNDACTYLY;; OPHTHALMOACROMELIC SYNDROME; OAS__:__
NULL__:__207000__:__ANOSMIA FOR ISOBUTYRIC ACID__:____:__
NULL__:__207300__:__ANTITHROMBIN, FAMILIAL HEMORRHAGIC DIATHESIS DUE TO__:____:__
Number Sign__:__207410__:__ANTLEY-BIXLER SYNDROME WITHOUT GENITAL ANOMALIES OR DISORDERED STEROIDOGENESIS; ABS2__:__TRAPEZOIDOCEPHALY-SYNOSTOSIS SYNDROME;; MULTISYNOSTOTIC OSTEODYSGENESIS WITH LONG BONE FRACTURES;; OSTEODYSGENESIS, MULTISYNOSTOTIC, WITH FRACTURES__:__
NULL__:__207500__:__ANUS, IMPERFORATE__:____:__
NULL__:__207600__:__TAKAYASU ARTERITIS__:__AORTIC ARCH SYNDROME;; YOUNG FEMALE ARTERITIS;; PULSELESS DISEASE__:__
NULL__:__207620__:__APHALANGY WITH HEMIVERTEBRAE__:____:__
Caret__:__207700__:__MOVED TO 107600__:____:__
NULL__:__207720__:__APNEA, CENTRAL SLEEP__:__SLEEP APNEA, LETHAL CENTRAL__:__
NULL__:__207731__:__APLASIA CUTIS CONGENITA WITH INTESTINAL LYMPHANGIECTASIA__:__ACC WITH INTESTINAL LYMPHANGIECTASIA__:__
NULL__:__207740__:__APLASIA OF EXTENSOR MUSCLES OF FINGERS, UNILATERAL, WITH GENERALIZED POLYNEUROPATHY__:____:__
Number Sign__:__207750__:__APOLIPOPROTEIN C-II DEFICIENCY__:__HYPERLIPOPROTEINEMIA, TYPE IB;; C-II ANAPOLIPOPROTEINEMIA;; APOC2 DEFICIENCY__:__
Caret__:__207765__:__MOVED TO 218030__:____:__
NULL__:__207770__:__APROSENCEPHALY SYNDROME__:__XK SYNDROME;; GARCIA-LURIE SYNDROME__:__
NULL__:__207780__:__AREDYLD__:__ACRORENAL FIELD DEFECT, ECTODERMAL DYSPLASIA, AND LIPOATROPHIC DIABETES__:__
NULL__:__207790__:__ARACHNOID CYSTS, INTRACRANIAL__:____:__
Number Sign__:__207800__:__ARGININEMIA__:__ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY__:__
Number Sign__:__207900__:__ARGININOSUCCINIC ACIDURIA__:__ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY__:__
Percent__:__207950__:__CHIARI MALFORMATION TYPE II__:__CM2;; ARNOLD-CHIARI MALFORMATION__:__
Number Sign__:__208000__:__ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1__:__GACI;; IDIOPATHIC INFANTILE ARTERIAL CALCIFICATION; IIAC;; ARTERIAL CALCIFICATION, IDIOPATHIC INFANTILE;; ARTERIOPATHY, OCCLUSIVE INFANTILE__:__CORONARY SCLEROSIS, MEDIAL, OF INFANCY, INCLUDED
Number Sign__:__208050__:__ARTERIAL TORTUOSITY SYNDROME; ATS__:__ARTERIAL TORTUOSITY__:__
Percent__:__208060__:__ARTERIOSCLEROSIS, SEVERE JUVENILE__:____:__
NULL__:__208080__:__ARTHROGRYPOSIS, DISTAL, WITH HYPOPITUITARISM, MENTAL RETARDATION, AND FACIAL ANOMALIES__:____:__
NULL__:__208081__:__ARTHROGRYPOSIS, DISTAL, WITH MENTAL RETARDATION AND CHARACTERISTIC FACIES__:____:__
Number Sign__:__208085__:__ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 1; ARCS1__:__ARC SYNDROME; ARCS__:__
Number Sign__:__208100__:__ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC TYPE; AMCN__:__AMC, NEUROGENIC TYPE__:__
Caret__:__208110__:__MOVED TO 208155__:____:__
Number Sign__:__208150__:__FETAL AKINESIA DEFORMATION SEQUENCE; FADS__:__PENA-SHOKEIR SYNDROME, TYPE I;; FETAL AKINESIA SEQUENCE;; ARTHROGRYPOSIS MULTIPLEX CONGENITA WITH PULMONARY HYPOPLASIA__:__
NULL__:__208155__:__ILLUM SYNDROME__:__ARTHROGRYPOSIS, WHISTLING FACE, AND DEVELOPMENTAL RETARDATION__:__
NULL__:__208158__:__ARTHROGRYPOSIS WITH HYPERKERATOSIS__:____:__
Caret__:__208200__:__MOVED TO 259450__:____:__
Number Sign__:__208230__:__ARTHROPATHY, PROGRESSIVE PSEUDORHEUMATOID, OF CHILDHOOD; PPAC__:__PROGRESSIVE PSEUDORHEUMATOID ARTHROPATHY OF CHILDHOOD;; SPONDYLOEPIPHYSEAL DYSPLASIA TARDA WITH PROGRESSIVE ARTHROPATHY; SEDT-PA;; PROGRESSIVE PSEUDORHEUMATOID DYSPLASIA; PPD__:__
Number Sign__:__208250__:__CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS SYNDROME; CACP__:__ARTHROPATHY-CAMPTODACTYLY SYNDROME;; HYPERTROPHIC SYNOVITIS, CONGENITAL FAMILIAL;; JACOBS SYNDROME;; FIBROSING SEROSITIS, FAMILIAL;; PERICARDITIS-ARTHROPATHY-CAMPTODACTYLY SYNDROME;; PAC SYNDROME;; CAMPTODACTYLY-ARTHROPATHY-PERICARDITIS SYNDROME;; CAP SYNDROME__:__
NULL__:__208300__:__ASCITES, CHYLOUS__:____:__
Number Sign__:__208400__:__ASPARTYLGLUCOSAMINURIA; AGU__:__GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA__:__
Percent__:__208500__:__SHORT-RIB THORACIC DYSPLASIA 1 WITH OR WITHOUT POLYDACTYLY; SRTD1__:__ASPHYXIATING THORACIC DYSTROPHY 1; ATD1;; JEUNE SYNDROME;; THORACIC-PELVIC-PHALANGEAL DYSTROPHY__:__
Number Sign__:__208530__:__RIGHT ATRIAL ISOMERISM; RAI__:__RIGHT ISOMERISM;; ASPLENIA WITH CARDIOVASCULAR ANOMALIES;; IVEMARK SYNDROME__:__POLYSPLENIA SYNDROME, INCLUDED;; POLYASPLENIA, INCLUDED;; HETEROTAXY, VISCEROATRIAL, AUTOSOMAL RECESSIVE, INCLUDED;; VAH, AUTOSOMAL RECESSIVE, INCLUDED
Number Sign__:__208540__:__RENAL-HEPATIC-PANCREATIC DYSPLASIA 1; RHPD1__:__RHPD__:__
Number Sign__:__208550__:__ASTHMA, NASAL POLYPS, AND ASPIRIN INTOLERANCE__:__ASA TRIAD__:__ASTHMA, ASPIRIN-INDUCED, SUSCEPTIBILITY TO, INCLUDED;; ASTHMA AND NASAL POLYPS, INCLUDED
NULL__:__208600__:__ASTHMA, SHORT STATURE, AND ELEVATED IgA__:____:__
NULL__:__208700__:__ATAXIA WITH MYOCLONIC EPILEPSY AND PRESENILE DEMENTIA__:____:__
Percent__:__208750__:__ATAXIA, DEAFNESS, AND CARDIOMYOPATHY__:____:__
Caret__:__208800__:__MOVED TO 312170__:____:__
NULL__:__208850__:__ATAXIA-DEAFNESS-RETARDATION SYNDROME__:__ADR SYNDROME__:__
NULL__:__208870__:__ATAXIA-MICROCEPHALY-CATARACT SYNDROME__:__AMC SYNDROME__:__
Number Sign__:__208900__:__ATAXIA-TELANGIECTASIA; AT__:__AT1;; LOUIS-BAR SYNDROME__:__AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED
Caret__:__208905__:__MOVED TO 208900__:____:__
NULL__:__208910__:__ATAXIA-TELANGIECTASIA WITH GENERALIZED SKIN PIGMENTATION AND EARLY DEATH__:____:__
Number Sign__:__208920__:__ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH__:__ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA;; ATAXIA-OCULOMOTOR APRAXIA 1; AOA1;; ATAXIA-TELANGIECTASIA-LIKE SYNDROME;; CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HA__:__ATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED
Caret__:__209000__:__MOVED TO 613179__:____:__
NULL__:__209010__:__ATHEROSCLEROSIS, PREMATURE, WITH DEAFNESS, NEPHROPATHY, DIABETES MELLITUS, PHOTOMYOCLONUS, AND DEGENERATIVE NEUROLOGIC DISEASE__:____:__
NULL__:__209050__:__ATHROMBIA, ESSENTIAL__:____:__
Percent__:__209100__:__ATONIC-ASTATIC SYNDROME OF FOERSTER__:____:__
Number Sign__:__209300__:__ATRANSFERRINEMIA__:__HYPOTRANSFERRINEMIA, FAMILIAL__:__TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED
Caret__:__209400__:__MOVED TO 600309__:____:__
Number Sign__:__209500__:__ATRICHIA WITH PAPULAR LESIONS; APL__:__PAPULAR ATRICHIA__:__
NULL__:__209600__:__ATRIOVENTRICULAR DISSOCIATION__:__A-V DISSOCIATION__:__
Percent__:__209700__:__ATROPHODERMA VERMICULATA; AVA__:__FOLLICULITIS ULERYTHEMATOSA RETICULATA;; ATROPHODERMIA VERMICULATA;; HONEYCOMB ATROPHY;; ATROPHODERMIA RETICULATA SYMMETRICA FACIEI__:__
Caret__:__209750__:__MOVED TO 209950__:____:__
NULL__:__209770__:__AURAL ATRESIA, MULTIPLE CONGENITAL ANOMALIES, AND MENTAL RETARDATION__:____:__
NULL__:__209800__:__AUSTRALIA ANTIGEN__:____:__
Percent__:__209850__:__AUTISM__:__AUTISTIC DISORDER__:__AUTISM, SUSCEPTIBILITY TO, 1, INCLUDED; AUTS1, INCLUDED;; AUTISM SPECTRUM DISORDER, INCLUDED; ASD, INCLUDED
Number Sign__:__209880__:__CENTRAL HYPOVENTILATION SYNDROME, CONGENITAL; CCHS__:__AUTONOMIC CONTROL, CONGENITAL FAILURE OF;; ONDINE CURSE, CONGENITAL__:__ONDINE-HIRSCHSPRUNG DISEASE, INCLUDED; OHD, INCLUDED;; CCHS WITH HIRSCHSPRUNG DISEASE, INCLUDED;; HADDAD SYNDROME, INCLUDED
Number Sign__:__209885__:__BARBER-SAY SYNDROME; BBRSAY__:__BSS;; HYPERTRICHOSIS, ATROPHIC SKIN, ECTROPION, AND MACROSTOMIA__:__
Number Sign__:__209900__:__BARDET-BIEDL SYNDROME 1; BBS1__:____:__
Asterisk__:__209901__:__BBS1 GENE; BBS1__:____:__
Number Sign__:__209920__:__BARE LYMPHOCYTE SYNDROME, TYPE II__:__BLS, TYPE II;; BARE LYMPHOCYTE SYNDROME; BLS;; SEVERE COMBINED IMMUNODEFICIENCY, HLA CLASS II-NEGATIVE;; SCID, HLA CLASS II-NEGATIVE__:__BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP A, INCLUDED;; BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP B, INCLUDED;; BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP C, INCLUDED;; BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP D, INCLUDED;; BARE LYMPHOCYTE SYNDROME, TYPE II, COMPLEMENTATION GROUP E, INCLUDED
Caret__:__209930__:__MOVED TO 241200__:____:__
Number Sign__:__209950__:__IMMUNODEFICIENCY 27A; IMD27A__:__IMMUNODEFICIENCY 27A, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE;; IFNGR1 DEFICIENCY, AUTOSOMAL RECESSIVE__:__
NULL__:__209970__:__BEEMER LETHAL MALFORMATION SYNDROME__:__HYDROCEPHALUS, CARDIAC MALFORMATION, DENSE BONES, ETC.__:__
Number Sign__:__210000__:__BEHR SYNDROME; BEHRS__:__OPTIC ATROPHY, INFANTILE HEREDITARY, WITH NEUROLOGIC ABNORMALITIES__:__
NULL__:__210050__:__BERRY ANEURYSM, CIRRHOSIS, PULMONARY EMPHYSEMA, AND CEREBRAL CALCIFICATION__:__CEREBRAL ANEURYSM-CIRRHOSIS SYNDROME__:__
Number Sign__:__210100__:__BETA-AMINOISOBUTYRIC ACIDURIA; BAIBA__:__BETA-AMINOISOBUTYRIC ACID, URINARY EXCRETION OF;; BAIB URINARY EXCRETION;; HYPER-BETA-AMINOISOBUTYRIC ACIDURIA__:__
Number Sign__:__210200__:__3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D__:__MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I__:__
Number Sign__:__210210__:__3-METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY; MCC2D__:__MCC2 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA II;; METHYLCROTONYLGLYCINURIA, TYPE II__:__
Number Sign__:__210250__:__SITOSTEROLEMIA__:__STSL;; PHYTOSTEROLEMIA__:__MACROTHROMBOCYTOPENIA/STOMATOCYTOSIS, MEDITERRANEAN, INCLUDED
Caret__:__210300__:__MOVED TO 201300__:____:__
NULL__:__210350__:__BIEMOND SYNDROME II__:____:__
Number Sign__:__210370__:__BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD__:__BIETTI CRYSTALLINE DYSTROPHY;; BIETTI TAPETORETINAL DEGENERATION WITH MARGINAL CORNEAL DYSTROPHY__:__
NULL__:__210400__:__BIFID NOSE, AUTOSOMAL RECESSIVE__:__MEDIAN FISSURE OF NOSE;; NOSE, MEDIAN CLEFT OF__:__
Caret__:__210450__:__MOVED TO 607765__:____:__
Percent__:__210500__:__BILIARY ATRESIA, EXTRAHEPATIC; EHBA__:____:__
NULL__:__210550__:__BILIARY MALFORMATION WITH RENAL TUBULAR INSUFFICIENCY__:__CHOLESTATIC JAUNDICE AND RENAL TUBULAR INSUFFICIENCY__:__
Number Sign__:__210600__:__SECKEL SYNDROME 1; SCKL1__:__SCKL;; SECKEL-TYPE DWARFISM;; NANOCEPHALIC DWARFISM;; MICROCEPHALIC PRIMORDIAL DWARFISM I;; BIRD-HEADED DWARFISM__:__
NULL__:__210700__:__MICROCEPHALIC PRIMORDIAL DWARFISM, MONTREAL TYPE__:__BIRD-HEADED DWARFISM, MONTREAL TYPE__:__
Number Sign__:__210710__:__MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I; MOPD1__:__MOPD I; MOPD;; OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE I;; BRACHYMELIC PRIMORDIAL DWARFISM;; TAYBI-LINDER SYNDROME; TALS;; CEPHALOSKELETAL DYSPLASIA;; LOW-BIRTH-WEIGHT DWARFISM WITH SKELETAL DYSPLASIA__:__
Number Sign__:__210720__:__MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II; MOPD2__:__MOPD II;; OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE II__:__
Percent__:__210730__:__MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III__:__MOPD III; MOPD3;; OSTEODYSPLASTIC PRIMORDIAL DWARFISM, TYPE III;; MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, CAROLINE CRACHAMI TYPE;; MOPD, CAROLINE CRACHAMI TYPE;; MICROCEPHALIC OSTEODYSPLASTIC PRIMORDIAL DWARFISM, SICILIAN FAIRY TYPE;; MOPD, SICILIAN FAIRY TYPE__:__
NULL__:__210740__:__BANGSTAD SYNDROME__:__BIRD-HEADED DWARFISM WITH PROGRESSIVE ATAXIA, INSULIN-RESISTANT DIABETES, GOITER, AND PRIMARY GONADAL INSUFFICIENCY__:__
Percent__:__210745__:__BLEPHAROPHIMOSIS WITH PTOSIS, SYNDACTYLY, AND SHORT STATURE__:____:__
Number Sign__:__210750__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 6; SHEP6__:__SKIN/HAIR/EYE PIGMENTATION 6, BLOND/BROWN HAIR;; SKIN/HAIR/EYE PIGMENTATION 6, BLUE/GREEN EYES__:__
Number Sign__:__210900__:__BLOOM SYNDROME; BLM__:__BS; BLS;; MICROCEPHALY, GROWTH RESTRICTION, AND INCREASED SISTER CHROMATID EXCHANGE 1; MGRISCE1__:__
NULL__:__211000__:__BLUE DIAPER SYNDROME__:__HYPERCALCEMIA, FAMILIAL, WITH NEPHROCALCINOSIS AND INDICANURIA__:__
Asterisk__:__211100__:__FUCOSYLTRANSFERASE 1; FUT1__:__H ANTIGEN;; Hh__:__
NULL__:__211120__:__BONE DYSPLASIA, LETHAL, HOLMGREN TYPE__:____:__
Caret__:__211170__:__MOVED TO 249420__:____:__
Number Sign__:__211180__:__BOWEN-CONRADI SYNDROME; BWCNS__:__BOWEN HUTTERITE SYNDROME, FORMERLY__:__
NULL__:__211200__:__BOWEN SYNDROME OF MULTIPLE MALFORMATIONS__:____:__
Percent__:__211350__:__KYPHOMELIC DYSPLASIA__:__BOWING, CONGENITAL, WITH SHORT BONES__:__
NULL__:__211355__:__BOWING OF LONG BONES, ASYMMETRIC AND SYMMETRIC__:____:__
NULL__:__211369__:__BRACHYDACTYLY, TYPE A2, WITH MICROCEPHALY__:____:__
NULL__:__211370__:__BRACHYMETAPODY-ANODONTIA-HYPOTRICHOSIS-ALBINOIDISM__:__ANODONTIA-HYPOTRICHOSIS SYNDROME;; OCULOOSTEOCUTANEOUS SYNDROME__:__
Number Sign__:__211380__:__ELSAHY-WATERS SYNDROME; ESWS__:__BRACHIOSKELETOGENITAL SYNDROME;; BSG SYNDROME;; HYPOSPADIAS, HYPERTELORISM, UPPER LID COLOBOMA, AND MIXED-TYPE HEARING LOSS__:__
Percent__:__211390__:__SABINAS BRITTLE HAIR SYNDROME__:__BRITTLE HAIR AND MENTAL DEFICIT__:__
Number Sign__:__211400__:__BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 1; BESC1__:__CYSTIC FIBROSIS-LIKE SYNDROME__:__
Caret__:__211410__:__MOVED TO 114450__:____:__
Caret__:__211420__:__REMOVED FROM DATABASE__:____:__
NULL__:__211450__:__BRONCHOMALACIA__:__WILLIAMS-CAMPBELL SYNDROME__:__
NULL__:__211480__:__BUERGER DISEASE__:__THROMBOANGIITIS OBLITERANS__:__
Number Sign__:__211500__:__FAZIO-LONDE DISEASE__:__BULBAR PALSY, PROGRESSIVE, OF CHILDHOOD__:__
Number Sign__:__211530__:__BROWN-VIALETTO-VAN LAERE SYNDROME 1; BVVLS1__:__BULBAR PALSY, PROGRESSIVE, WITH SENSORINEURAL DEAFNESS;; PONTOBULBAR PALSY WITH DEAFNESS__:__
Caret__:__211550__:__MOVED TO 113900__:____:__
Number Sign__:__211600__:__CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 1; PFIC1__:__BYLER DISEASE__:__
Number Sign__:__211750__:__C SYNDROME__:__OPITZ TRIGONOCEPHALY SYNDROME;; TRIGONOCEPHALY SYNDROME__:__
NULL__:__211770__:__CAHMR SYNDROME__:__CATARACT, HYPERTRICHOSIS, MENTAL RETARDATION SYNDROME__:__
Number Sign__:__211800__:__CALCIFICATION OF JOINTS AND ARTERIES; CALJA__:__ARTERIAL CALCIFICATION DUE TO DEFICIENCY OF CD73; ACDC__:__
Percent__:__211890__:__CAMPOMELIA, CUMMING TYPE__:__CERVICAL LYMPHOCELE WITH BOWED LONG BONES;; CUMMING SYNDROME__:__
Number Sign__:__211900__:__TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 1; HFTC1__:__TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL; HFTC;; CALCINOSIS, TUMORAL, WITH HYPERPHOSPHATEMIA;; TUMORAL CALCINOSIS, PRIMARY HYPERPHOSPHATEMIC; PHPTC;; LIPOCALCINOGRANULOMATOSIS;; TEUTSCHLAENDER DISEASE, FAMILIAL;; MORBUS TEUTSCHLAENDER;; HYPEROSTOSIS-HYPERPHOSPHATEMIA SYNDROME; HHS;; HYPEROSTOSIS WITH HYPERPHOSPHATEMIA;; CORTICAL HYPEROSTOSIS WITH HYPERPHOSPHATEMIA__:__
NULL__:__211910__:__CAMPTODACTYLY SYNDROME, GUADALAJARA, TYPE I; GCS1__:__FACIOTHORACOSKELETAL SYNDROME; FTSS__:__
NULL__:__211920__:__CAMPTODACTYLY SYNDROME, GUADALAJARA, TYPE II__:____:__
NULL__:__211930__:__CAMPTODACTYLY WITH FIBROUS TISSUE HYPERPLASIA AND SKELETAL DYSPLASIA__:____:__
Percent__:__211960__:__CAMPTODACTYLY WITH MUSCULAR HYPOPLASIA, SKELETAL DYSPLASIA, AND ABNORMAL PALMAR CREASES__:__TEL HASHOMER CAMPTODACTYLY SYNDROME__:__
NULL__:__211965__:__CAMPTODACTYLY-ICHTHYOSIS SYNDROME__:____:__
Caret__:__211970__:__MOVED TO 114290__:____:__
Number Sign__:__211980__:__LUNG CANCER__:____:__ALVEOLAR CELL CARCINOMA, INCLUDED;; ADENOCARCINOMA OF LUNG, INCLUDED;; NONSMALL CELL LUNG CANCER, INCLUDED;; LUNG CANCER, PROTECTION AGAINST, INCLUDED
NULL__:__211990__:__CAMPTOMELIC SYNDROME, LONG-LIMB TYPE__:__CAMPOMELIC SYNDROME, LONG-LIMB TYPE__:__
Number Sign__:__212050__:__CANDIDIASIS, FAMILIAL, 2; CANDF2__:__CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL RECESSIVE;; CARD9 IMMUNODEFICIENCY__:__
NULL__:__212060__:__CARBIMAZOLE SENSITIVITY__:____:__
Number Sign__:__212065__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ia; CDG1A__:__CDG Ia; CDGIa;; JAEKEN SYNDROME;; PHOSPHOMANNOMUTASE 2 DEFICIENCY;; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE Ia, FORMERLY__:__
Number Sign__:__212066__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A__:__CDG IIa; CDGIIa;; ALKURAYA SYNDROME;; MENTAL RETARDATION, GROWTH RETARDATION, PROMINENT COLUMELLA, AND OPEN MOUTH;; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE II, FORMERLY; CDGS2, FORMERLY__:__
NULL__:__212067__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE I/IIx__:__CDG-x__:__
Number Sign__:__212070__:__CARBOXYPEPTIDASE N DEFICIENCY__:____:__
NULL__:__212080__:__CARDIAC LIPIDOSIS, FAMILIAL__:____:__
NULL__:__212090__:__CARDIAC SEPTAL DEFECTS WITH COARCTATION OF THE AORTA__:____:__
Number Sign__:__212093__:__CARDIAC VALVULAR DEFECT, DEVELOPMENTAL; CVDD__:____:__
NULL__:__212100__:__CARDIOAUDITORY SYNDROME OF SANCHEZ CASCOS__:____:__
Caret__:__212110__:__MOVED TO 611880__:____:__
Number Sign__:__212112__:__CARDIOMYOPATHY, DILATED, WITH HYPERGONADOTROPIC HYPOGONADISM__:__MALOUF SYNDROME;; CARDIOMYOPATHY, CONGESTIVE, WITH HYPERGONADOTROPIC HYPOGONADISM;; CARDIOMYOPATHY, DILATED, WITH PREMATURE OVARIAN FAILURE;; CARDIOMYOPATHY WITH PRIMARY TESTICULAR FAILURE;; NAJJAR SYNDROME;; GENITAL ANOMALY WITH CARDIOMYOPATHY;; CARDIOGENITAL SYNDROME__:__
Caret__:__212120__:__MOVED TO 212112__:____:__
Percent__:__212130__:__CARDIOMYOPATHY ASSOCIATED WITH MYOPATHY AND SUDDEN DEATH__:____:__
NULL__:__212135__:__CARDIOSKELETAL SYNDROME, KUWAITI TYPE__:____:__
Number Sign__:__212138__:__CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD__:__CACT DEFICIENCY__:__
Number Sign__:__212140__:__CARNITINE DEFICIENCY, SYSTEMIC PRIMARY; CDSP__:__SYSTEMIC CARNITINE DEFICIENCY; SCD;; CARNITINE DEFICIENCY, SYSTEMIC, DUE TO DEFECT IN RENAL REABSORPTION OF CARNITINE;; CARNITINE DEFICIENCY, PRIMARY;; CARNITINE TRANSPORTER, PLASMA-MEMBRANE, DEFICIENCY OF;; CARNITINE UPTAKE DEFECT; CUD__:__
Percent__:__212160__:__CARNITINE DEFICIENCY, MYOPATHIC__:____:__
Percent__:__212200__:__CARNOSINEMIA__:__CARNOSINASE DEFICIENCY__:__
Number Sign__:__212350__:__SENGERS SYNDROME__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 10 (CARDIOMYOPATHIC TYPE); MTDPS10;; CARDIOMYOPATHY AND CATARACT__:__
NULL__:__212360__:__PALMOPLANTAR KERATODERMA AND CONGENITAL ALOPECIA 2; PPKCA2__:__PPKCA, WALLIS TYPE;; CATARACT-ALOPECIA-SCLERODACTYLY SYNDROME; CASS__:__
Percent__:__212400__:__CATARACT AND CONGENITAL ICHTHYOSIS__:____:__
Number Sign__:__212500__:__CATARACT 46, JUVENILE-ONSET; CTRCT46__:__CATARACT, JUVENILE, HUTTERITE TYPE__:__
NULL__:__212540__:__CATARACT, MICROCEPHALY, FAILURE TO THRIVE, KYPHOSCOLIOSIS SYNDROME__:__CAMFAK SYNDROME__:__CATARACT, MICROCEPHALY, ARTHROGRYPOSIS, KYPHOSIS SYNDROME, INCLUDED;; CAMAK SYNDROME, INCLUDED
Number Sign__:__212550__:__OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY; ODRMD__:____:__
Caret__:__212600__:__REMOVED FROM DATABASE__:____:__
Caret__:__212700__:__REMOVED FROM DATABASE__:____:__
NULL__:__212710__:__CATARACT-ATAXIA-DEAFNESS-RETARDATION SYNDROME__:__POLYNEUROPATHY-CATARACT-DEAFNESS SYNDROME__:__
Number Sign__:__212720__:__MARTSOLF SYNDROME__:__CATARACT-MENTAL RETARDATION-HYPOGONADISM__:__
Number Sign__:__212750__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 1; CELIAC1__:__CELIAC SPRUE, SUSCEPTIBILITY TO, 1;; GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 1__:__
Number Sign__:__212780__:__CENANI-LENZ SYNDACTYLY SYNDROME; CLSS__:__CENANI SYNDACTYLISM;; CENANI-LENZ SYNDACTYLY;; SYNDACTYLY, TYPE VII__:__
Percent__:__212790__:__PREMATURE CENTROMERE DIVISION; PCD__:__X-CHROMOSOME CENTROMERE PECULIARITY__:__
NULL__:__212800__:__CEPHALIN LIPIDOSIS__:____:__
NULL__:__212835__:__CEREBELLAR ATAXIA AND ECTODERMAL DYSPLASIA__:____:__
Number Sign__:__212840__:__GORDON HOLMES SYNDROME; GDHS__:__CEREBELLAR ATAXIA AND HYPOGONADOTROPIC HYPOGONADISM; CAHH;; LUTEINIZING HORMONE-RELEASING HORMONE, DEFICIENCY OF, WITH ATAXIA;; LHRH DEFICIENCY AND ATAXIA__:__
NULL__:__212850__:__CEREBELLAR ATAXIA AND NEUROSENSORY DEAFNESS__:____:__
NULL__:__212890__:__CEREBELLAR ATAXIA, BENIGN, WITH THERMOANALGESIA__:__CEREBELLAR ATAXIA WITH LOSS OF PAIN AND TEMPERATURE SENSATION__:__
Percent__:__212895__:__CEREBELLAR ATAXIA, EARLY-ONSET, WITH RETAINED TENDON REFLEXES; EOCA__:____:__
Caret__:__212900__:__MOVED TO 258450__:____:__
Caret__:__212905__:__MOVED TO 606854__:____:__
Percent__:__213000__:__CEREBELLAR HYPOPLASIA__:____:__
NULL__:__213002__:__CEREBELLAR HYPOPLASIA WITH ENDOSTEAL SCLEROSIS__:____:__
NULL__:__213010__:__CEREBELLAR VERMIS APLASIA WITH ASSOCIATED FEATURES SUGGESTING SMITH-LEMLI-OPITZ SYNDROME AND MECKEL SYNDROME__:____:__
Percent__:__213100__:__CEREBELLOPARENCHYMAL DISORDER II; CPD2__:__CPD, LATE-ONSET RECESSIVE TYPE__:__
Number Sign__:__213200__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 2; SCAR2__:__CEREBELLAR HYPOPLASIA, NONPROGRESSIVE NORMAN TYPE;; CEREBELLAR GRANULAR CELL HYPOPLASIA AND MENTAL RETARDATION, CONGENITAL;; CEREBELLOPARENCHYMAL DISORDER III; CPD3;; CPD III__:__
Number Sign__:__213300__:__JOUBERT SYNDROME 1; JBTS1__:__JOUBERT SYNDROME; JBTS;; JOUBERT-BOLTSHAUSER SYNDROME;; CEREBELLOPARENCHYMAL DISORDER IV; CPD4;; CEREBELLOOCULORENAL SYNDROME 1; CORS1__:__
NULL__:__213400__:__CEREBELLOPARENCHYMAL DISORDER V; CPD5__:__SPINODENTATE ATROPHY;; DYSSYNERGIA CEREBELLARIS MYOCLONICA OF HUNT__:__
NULL__:__213500__:__CEREBRAL ANGIOPATHY, DYSPHORIC__:____:__
Number Sign__:__213600__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 1; IBGC1__:__STRIOPALLIDODENTATE CALCINOSIS, BILATERAL; BSPDC;; STRIOPALLIDODENTATE CALCINOSIS, AUTOSOMAL DOMINANT, ADULT-ONSET;; CEREBRAL CALCIFICATION, NONARTERIOSCLEROTIC, IDIOPATHIC, ADULT-ONSET;; FERROCALCINOSIS, CEREBROVASCULAR;; FAHR DISEASE, FAMILIAL, FORMERLY;; BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 3, FORMERLY; IBGC3, FORMERLY__:__
Number Sign__:__213700__:__CEREBROTENDINOUS XANTHOMATOSIS; CTX__:__CEREBRAL CHOLESTERINOSIS__:__
NULL__:__213820__:__CEREBRAL MALFORMATION, SEIZURES, HYPERTRICHOSIS, AND OVERLAPPING FINGERS__:____:__
NULL__:__213900__:__CEREBRAL SCLEROSIS SIMILAR TO PELIZAEUS-MERZBACHER DISEASE__:____:__
NULL__:__213950__:__CEREBROCORTICAL DEGENERATION OF INFANCY__:____:__
Number Sign__:__213980__:__CRANIOFACIAL DYSMORPHISM, SKELETAL ANOMALIES, AND MENTAL RETARDATION SYNDROME; CFSMR__:__CEREBROFACIOTHORACIC DYSPLASIA__:__
Number Sign__:__214100__:__PEROXISOME BIOGENESIS DISORDER 1A (ZELLWEGER); PBD1A__:__ZS; ZWS;; CEREBROHEPATORENAL SYNDROME; CHR__:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 1, INCLUDED; CG1, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP E, INCLUDED; CGE, INCLUDED
Number Sign__:__214110__:__PEROXISOME BIOGENESIS DISORDER 2A (ZELLWEGER); PBD2A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 2, INCLUDED; CG2, INCLUDED
Number Sign__:__214150__:__CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1__:__COFS SYNDROME; COFS;; PENA-SHOKEIR SYNDROME, TYPE II__:__
NULL__:__214200__:__CEROID STORAGE DISEASE__:__LIPOFUSCIN STORAGE DISEASE__:__
NULL__:__214290__:__CERVICAL VERTEBRAE, AGENESIS OF__:____:__
Number Sign__:__214300__:__KLIPPEL-FEIL SYNDROME 2, AUTOSOMAL RECESSIVE; KFS2__:__KFS, AUTOSOMAL RECESSIVE;; CERVICAL VERTEBRAL FUSION, AUTOSOMAL RECESSIVE__:__
Number Sign__:__214350__:__CHAND SYNDROME; CHANDS__:__CURLY HAIR-ANKYLOBLEPHARON-NAIL DYSPLASIA SYNDROME__:__
Percent__:__214370__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH DEAFNESS, MENTAL RETARDATION, AND ABSENT SENSORY LARGE MYELINATED FIBERS__:__CHARCOT-MARIE-TOOTH DISEASE AND DEAFNESS;; DEAFNESS WITH CHARCOT-MARIE-TOOTH DISEASE__:__
Caret__:__214380__:__MOVED TO 606002__:____:__
Number Sign__:__214400__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A; CMT4A__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4A;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4A__:__
Number Sign__:__214450__:__GRISCELLI SYNDROME, TYPE 1; GS1__:__GRISCELLI SYNDROME WITH NEUROLOGIC IMPAIRMENT;; PARTIAL ALBINISM AND PRIMARY NEUROLOGIC DISEASE WITHOUT HEMOPHAGOCYTIC SYNDROME;; GRISCELLI SYNDROME, CUTANEOUS AND NEUROLOGIC TYPE__:__
Number Sign__:__214500__:__CHEDIAK-HIGASHI SYNDROME; CHS__:____:__
Number Sign__:__214700__:__DIARRHEA 1, SECRETORY CHLORIDE, CONGENITAL; DIAR1__:__CHLORIDE DIARRHEA, CONGENITAL, FINNISH TYPE;; CHLORIDORRHEA, CONGENITAL__:__
Number Sign__:__214800__:__CHARGE SYNDROME__:__CHARGE ASSOCIATION--COLOBOMA, HEART ANOMALY, CHOANAL ATRESIA, RETARDATION, GENITAL AND EAR ANOMALIES;; HALL-HITTNER SYNDROME; HHS__:__
Percent__:__214900__:__CHOLESTASIS-LYMPHEDEMA SYNDROME__:__CHLS;; AAGENAES SYNDROME;; LYMPHEDEMA-CHOLESTASIS SYNDROME; LCS; LCS1__:__
Number Sign__:__214950__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4; CBAS4__:__CHOLESTASIS, INTRAHEPATIC, WITH DEFECTIVE CONVERSION OF TRIHYDROXYCOPROSTANIC ACID TO CHOLIC ACID;; TRIHYDROXYCOPROSTANIC ACID IN BILE__:__
NULL__:__214980__:__CHOLESTASIS WITH GALLSTONE, ATAXIA, AND VISUAL DISTURBANCE__:____:__
NULL__:__215030__:__CHOLESTEROL PNEUMONIA__:____:__
Number Sign__:__215045__:__CHONDRODYSPLASIA, BLOMSTRAND TYPE; BOCD__:____:__
NULL__:__215050__:__CHONDRODYSPLASIA CALCIFICANS METAPHYSEALIS__:____:__
Number Sign__:__215100__:__RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 1; RCDP1__:__PEROXISOME BIOGENESIS DISORDER 9; PBD9;; CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC FORM; CDPR;; CHONDRODYSTROPHIA CALCIFICANS PUNCTATA__:__
NULL__:__215105__:__CHONDRODYSPLASIA PUNCTATA SYNDROME__:____:__
Number Sign__:__215140__:__GREENBERG DYSPLASIA; GRBGD__:__HYDROPS-ECTOPIC CALCIFICATION-MOTH-EATEN SKELETAL DYSPLASIA;; HEM SKELETAL DYSPLASIA;; MOTH-EATEN SKELETAL DYSPLASIA;; CHONDRODYSTROPHY, HYDROPIC AND PRENATALLY LETHAL TYPE__:__
Number Sign__:__215150__:__OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; OSMEDB__:__OSMED;; CHONDRODYSTROPHY WITH SENSORINEURAL DEAFNESS;; NANCE-INSLEY SYNDROME;; NANCE-SWEENEY CHONDRODYSPLASIA;; WEISSENBACHER-ZWEYMULLER SYNDROME, FORMERLY; WZS, FORMERLY__:__
NULL__:__215250__:__CHONDROITIN-6-SULFATURIA, DEFECTIVE CELLULAR IMMUNITY, NEPHROTIC SYNDROME__:____:__
Number Sign__:__215300__:__CHONDROSARCOMA__:____:__
Number Sign__:__215400__:__CHORDOMA, SUSCEPTIBILITY TO; CHDM__:____:__
NULL__:__215450__:__CHOREA, BENIGN FAMILIAL__:____:__
Number Sign__:__215470__:__BOUCHER-NEUHAUSER SYNDROME; BNHS__:__SPINOCEREBELLAR ATAXIA, HYPOGONADOTROPIC HYPOGONADISM, AND CHORIORETINAL DYSTROPHY__:__
NULL__:__215480__:__CHOROID PLEXUS CALCIFICATION AND MENTAL RETARDATION__:____:__
Number Sign__:__215500__:__CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 1; CACD1__:__CHOROIDAL DYSTROPHY, CENTRAL AREOLAR; CACD;; CHOROIDAL SCLEROSIS__:__
NULL__:__215510__:__CHROMOSOMAL INSTABILITY WITH TISSUE-SPECIFIC RADIOSENSITIVITY__:____:__
NULL__:__215518__:__CILIARY DISCOORDINATION DUE TO RANDOM CILIARY ORIENTATION__:__RUTLAND CILIARY DISORIENTATION SYNDROME__:__
Percent__:__215520__:__CILIARY DYSKINESIA WITH TRANSPOSITION OF CILIARY MICROTUBULES__:____:__
NULL__:__215550__:__CIRCUMVALLATE PLACENTA SYNDROME__:____:__
Number Sign__:__215600__:__CIRRHOSIS, FAMILIAL__:____:__CIRRHOSIS, FAMILIAL, WITH PULMONARY HYPERTENSION, INCLUDED;; INDIAN CHILDHOOD CIRRHOSIS, INCLUDED; ICC, INCLUDED;; SEN SYNDROME, INCLUDED;; COPPER-OVERLOAD CIRRHOSIS, INCLUDED;; ENDEMIC TYROLEAN INFANTILE CIRRHOSIS, INCLUDED; ETIC, INCLUDED;; COPPER TOXICOSIS, IDIOPATHIC, INCLUDED; ICT, INCLUDED;; CIRRHOSIS, CRYPTOGENIC, INCLUDED;; CIRRHOSIS, NONCRYPTOGENIC, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__215700__:__CITRULLINEMIA, CLASSIC__:__CITRULLINEMIA, TYPE I; CTLN1;; CITRULLINURIA;; ARGININOSUCCINATE SYNTHETASE DEFICIENCY;; ASS DEFICIENCY__:__
NULL__:__215720__:__CITRULLINE TRANSPORT DEFECT__:____:__
NULL__:__215800__:__CLEFT LARYNX, POSTERIOR__:____:__STRIDOR, CONGENITAL, INCLUDED
NULL__:__215850__:__CLEFT-LIMB-HEART MALFORMATION SYNDROME__:__CLH SYNDROME__:__
NULL__:__216100__:__CLEFT LIP/PALATE WITH ABNORMAL THUMBS AND MICROCEPHALY__:__OROCRANIODIGITAL SYNDROME;; JUBERG-HAYWARD SYNDROME; JHS__:__
NULL__:__216300__:__CLEFT PALATE, DEAFNESS, AND OLIGODONTIA__:____:__
NULL__:__216330__:__CLEIDOCRANIAL DYSPLASIA, RECESSIVE FORM__:____:__
Number Sign__:__216340__:__YUNIS-VARON SYNDROME; YVS__:__CLEIDOCRANIAL DYSPLASIA WITH MICROGNATHIA, ABSENT THUMBS, AND DISTAL APHALANGIA__:__
Number Sign__:__216360__:__COACH SYNDROME__:__CEREBELLAR VERMIS HYPO/APLASIA, OLIGOPHRENIA, CONGENITAL ATAXIA, OCULAR COLOBOMA, AND HEPATIC FIBROSIS;; JOUBERT SYNDROME WITH CONGENITAL HEPATIC FIBROSIS__:__
Number Sign__:__216400__:__COCKAYNE SYNDROME A; CSA__:____:__
Caret__:__216411__:__MOVED TO 216400__:____:__
Number Sign__:__216550__:__COHEN SYNDROME; COH1__:__COH;; HYPOTONIA, OBESITY, AND PROMINENT INCISORS;; PEPPER SYNDROME;; CHS1, FORMERLY__:__
Percent__:__216700__:__COLLAGENOSIS, FAMILIAL REACTIVE PERFORATING; RPC__:____:__
NULL__:__216800__:__COLOBOMA OF MACULA AND SKELETAL ANOMALIES__:____:__
Number Sign__:__216820__:__COLOBOMA, OCULAR, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__216900__:__ACHROMATOPSIA 2; ACHM2__:__COLORBLINDNESS, TOTAL;; ROD MONOCHROMATISM 2;; ROD MONOCHROMACY 2; RMCH2__:__
NULL__:__216920__:__COMBINED INFLAMMATORY AND IMMUNOLOGIC DEFECT__:____:__
Percent__:__216950__:__COMPLEMENT COMPONENT C1r/C1s DEFICIENCY__:__C1r/C1s DEFICIENCY__:__
Number Sign__:__217000__:__COMPLEMENT COMPONENT 2 DEFICIENCY; C2D__:__C2 DEFICIENCY__:__
Asterisk__:__217030__:__COMPLEMENT FACTOR I; CFI__:__COMPLEMENT COMPONENT I;; FACTOR I; FI;; C3b INACTIVATOR__:__
Asterisk__:__217050__:__COMPLEMENT COMPONENT 6; C6__:____:__
Asterisk__:__217070__:__COMPLEMENT COMPONENT 7; C7__:____:__
Number Sign__:__217080__:__JALILI SYNDROME__:__CONE-ROD DYSTROPHY AND AMELOGENESIS IMPERFECTA__:__
Number Sign__:__217085__:__CONGENITAL HEART DEFECTS, HAMARTOMAS OF TONGUE, AND POLYSYNDACTYLY; CHDTHP__:____:__
Number Sign__:__217090__:__PLASMINOGEN DEFICIENCY, TYPE I__:____:__LIGNEOUS CONJUNCTIVITIS, INCLUDED;; DYSPLASMINOGENEMIA, INCLUDED;; PLASMINOGEN DEFICIENCY, TYPE II, INCLUDED
Number Sign__:__217095__:__CONOTRUNCAL HEART MALFORMATIONS; CTHM__:____:__TRUNCUS ARTERIOSUS COMMUNIS, INCLUDED;; CONOTRUNCAL ANOMALY FACE SYNDROME, INCLUDED; CAFS, INCLUDED;; DOUBLE-OUTLET RIGHT VENTRICLE, INCLUDED; DORV, INCLUDED;; PERSISTENT TRUNCUS ARTERIOSUS, INCLUDED; PTA, INCLUDED;; INTERRUPTED AORTIC ARCH, INCLUDED
Percent__:__217100__:__CONSTRICTING BANDS, CONGENITAL__:__AMNIOTIC BAND SEQUENCE; ABS;; STREETER ANOMALY__:__ADAM COMPLEX, INCLUDED;; TERMINAL TRANSVERSE DEFECTS OF ARM, INCLUDED;; AMPUTATION, CONGENITAL, INCLUDED
NULL__:__217150__:__CONTRACTURES, CONGENITAL, TORTICOLLIS, AND MALIGNANT HYPERTHERMIA__:____:__
NULL__:__217200__:__CONVULSIVE DISORDER, FAMILIAL, WITH PRENATAL OR EARLY ONSET__:____:__
Number Sign__:__217300__:__CORNEA PLANA 2, AUTOSOMAL RECESSIVE; CNA2__:____:__
Number Sign__:__217400__:__CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS; CDPD__:__CDPD1;; CORNEAL DYSTROPHY AND SENSORINEURAL DEAFNESS;; HARBOYAN SYNDROME__:__
Percent__:__217500__:__CORNEAL DYSTROPHY, BAND-SHAPED__:__BAND KERATOPATHY__:__
NULL__:__217520__:__CORNEAL DEGENERATION, BAND-SHAPED SPHEROID__:____:__
NULL__:__217600__:__CENTRAL CLOUDY DYSTROPHY OF FRANCOIS; CCDF__:__CORNEAL DYSTROPHY, CENTRAL TYPE__:__
Number Sign__:__217700__:__CORNEAL ENDOTHELIAL DYSTROPHY; CHED__:__CORNEAL DYSTROPHY, CONGENITAL HEREDITARY ENDOTHELIAL;; CONGENITAL HEREDITARY ENDOTHELIAL DYSTROPHY OF CORNEA;; CORNEAL ENDOTHELIAL DYSTROPHY 2, AUTOSOMAL RECESSIVE, FORMERLY; CHED2, FORMERLY__:__
Number Sign__:__217800__:__MACULAR DYSTROPHY, CORNEAL; MCD__:__CORNEAL DYSTROPHY, MACULAR TYPE;; GROENOUW TYPE II CORNEAL DYSTROPHY;; MACULAR CORNEAL DYSTROPHY, TYPE I;; MCDC1, FORMERLY__:__MACULAR CORNEAL DYSTROPHY, TYPE II, INCLUDED
Percent__:__217980__:__CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND ROBIN SEQUENCE__:__TORIELLO-CAREY SYNDROME__:__
Percent__:__217990__:__CORPUS CALLOSUM, AGENESIS OF__:__ACC__:__
Number Sign__:__218000__:__AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN__:__CHARLEVOIX DISEASE;; ANDERMANN SYNDROME;; POLYNEUROPATHY, SENSORIMOTOR, WITH OR WITHOUT AGENESIS OF THE CORPUS CALLOSUM;; CORPUS CALLOSUM, AGENESIS OF, WITH NEURONOPATHY__:__
NULL__:__218010__:__CORTICAL BLINDNESS, RETARDATION, AND POSTAXIAL POLYDACTYLY__:____:__
Number Sign__:__218030__:__APPARENT MINERALOCORTICOID EXCESS; AME__:__AME1;; CORTISOL 11-BETA-KETOREDUCTASE DEFICIENCY__:__
Number Sign__:__218040__:__COSTELLO SYNDROME; CSTLO__:__FACIOCUTANEOSKELETAL SYNDROME;; FCS SYNDROME__:__MYOPATHY, CONGENITAL, WITH EXCESS OF MUSCLE SPINDLES, INCLUDED; CMEMS, INCLUDED
NULL__:__218050__:__CRAMPS, FAMILIAL ADOLESCENT__:____:__
NULL__:__218090__:__CRANE-HEISE SYNDROME__:__CLEFT LIP/PALATE, AGENESIS OF CLAVICLES AND CERVICAL VERTEBRAE, AND TALIPES EQUINOVARUS__:__
Percent__:__218100__:__CRANIAL NERVES, CONGENITAL PARESIS OF__:____:__
NULL__:__218200__:__CRANIAL NERVES, RECURRENT PARESIS OF__:____:__
NULL__:__218300__:__CRANIODIAPHYSEAL DYSPLASIA; CDD__:____:__
Number Sign__:__218330__:__CRANIOECTODERMAL DYSPLASIA 1; CED1__:__SENSENBRENNER SYNDROME;; LEVIN SYNDROME I__:__
Number Sign__:__218340__:__TEMTAMY SYNDROME; TEMTYS__:__MENTAL RETARDATION WITH OR WITHOUT CRANIOFACIAL DYSMORPHISM, OCULAR COLOBOMA, OR ABNORMAL CORPUS CALLOSUM__:__
NULL__:__218350__:__CRANIOFACIAL DYSSYNOSTOSIS WITH SHORT STATURE__:__BILATERAL LAMBDOID AND SAGITTAL SYNOSTOSIS; BLSS__:__
Number Sign__:__218400__:__CRANIOMETAPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE; CMDR__:____:__
NULL__:__218450__:__CRANIOSTENOSIS, SAGITTAL, WITH CONGENITAL HEART DISEASE, MENTAL DEFICIENCY, AND MANDIBULAR ANKYLOSIS__:__PFEIFFER CARDIOCRANIAL SYNDROME__:__
Caret__:__218455__:__MOVED TO 251200__:____:__
Caret__:__218500__:__MOVED TO 123100 AND 123150__:____:__
NULL__:__218530__:__CRANIOSYNOSTOSIS WITH ANOMALIES OF THE CRANIAL BASE AND DIGITS__:____:__
NULL__:__218550__:__CRANIOSYNOSTOSIS WITH FIBULAR APLASIA__:____:__
Number Sign__:__218600__:__BALLER-GEROLD SYNDROME; BGS__:__CRANIOSYNOSTOSIS WITH RADIAL DEFECTS;; CRANIOSYNOSTOSIS-RADIAL APLASIA SYNDROME__:__
NULL__:__218649__:__CRANIOSYNOSTOSIS-MENTAL RETARDATION SYNDROME OF LIN AND GETTIG__:____:__
NULL__:__218650__:__CRANIOSYNOSTOSIS-MENTAL RETARDATION-CLEFTING SYNDROME__:____:__
NULL__:__218670__:__CRANIOTELENCEPHALIC DYSPLASIA__:____:__
Number Sign__:__218700__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 2; CHNG2__:__THYROID DYSGENESIS;; THYROID AGENESIS;; THYROID HYPOPLASIA;; THYROID, ECTOPIC;; HYPOTHYROIDISM, CONGENITAL, DUE TO THYROID DYSGENESIS;; HYPOTHYROIDISM, ATHYREOTIC;; ATHYREOTIC HYPOTHYROIDISM;; RESISTANCE TO THYROTROPIN; RTSH;; THYROTROPIN RESISTANCE__:__
Number Sign__:__218800__:__CRIGLER-NAJJAR SYNDROME, TYPE I__:__HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME__:__
Percent__:__218900__:__CROME SYNDROME__:____:__
Number Sign__:__219000__:__FRASER SYNDROME 1; FRASRS1__:__FRASER SYNDROME;; CRYPTOPHTHALMOS WITH OTHER MALFORMATIONS;; CRYPTOPHTHALMOS-SYNDACTYLY SYNDROME__:__
Number Sign__:__219050__:__CRYPTORCHIDISM, UNILATERAL OR BILATERAL__:__UNDESCENDED TESTIS__:__
NULL__:__219070__:__CURVED NAIL OF FOURTH TOE__:__CLAW-LIKE FINGERS AND TOES__:__
Number Sign__:__219080__:__ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; AIMAH1__:__ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA;; ADRENOCORTICOTROPIC HORMONE-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA;; CORTICOTROPIN-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA;; CUSHING SYNDROME, ADRENAL, DUE TO AIMAH__:__
Number Sign__:__219090__:__PITUITARY ADENOMA 4, ACTH-SECRETING; PITA4__:__CUSHING DISEASE, PITUITARY__:__
NULL__:__219095__:__CUTANEOUS PHOTOSENSITIVITY AND COLITIS, LETHAL__:____:__
Number Sign__:__219100__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IA; ARCL1A__:__ARCL1;; CUTIS LAXA, AUTOSOMAL RECESSIVE__:__
Number Sign__:__219150__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIA; ARCL3A__:__DE BARSY SYNDROME A;; CUTIS LAXA, CORNEAL CLOUDING, AND MENTAL RETARDATION;; PROGEROID SYNDROME OF DE BARSY__:__
Number Sign__:__219200__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIA; ARCL2A__:__ARCL2;; CUTIS LAXA WITH CONGENITAL DISORDER OF GLYCOSYLATION;; CUTIS LAXA WITH GROWTH AND DEVELOPMENTAL DELAY;; CUTIS LAXA, DEBRE TYPE;; CUTIS LAXA WITH BONE DYSTROPHY;; CUTIS LAXA WITH JOINT LAXITY AND RETARDED DEVELOPMENT__:__
NULL__:__219250__:__CUTIS MARMORATA TELANGIECTATICA CONGENITA; CMTC__:____:__
NULL__:__219300__:__CUTIS VERTICIS GYRATA AND MENTAL RETARDATION; CVG/MR__:____:__
NULL__:__219400__:__CYANOSIS AND HEPATIC DISEASE__:____:__
Number Sign__:__219500__:__CYSTATHIONINURIA__:__CYSTATHIONASE DEFICIENCY__:__
NULL__:__219550__:__CYSTEINE PEPTIDURIA__:____:__
NULL__:__219600__:__CYSTIC DISEASE OF LUNG__:____:__
Number Sign__:__219700__:__CYSTIC FIBROSIS; CF__:__MUCOVISCIDOSIS__:__
NULL__:__219721__:__CYSTIC FIBROSIS WITH HELICOBACTER PYLORI GASTRITIS, MEGALOBLASTIC ANEMIA, AND MENTAL RETARDATION__:____:__
Number Sign__:__219730__:__VENTRICULOMEGALY WITH CYSTIC KIDNEY DISEASE; VMCKD__:____:__
Number Sign__:__219750__:__CYSTINOSIS, ADULT NONNEPHROPATHIC__:__CYSTINOSIS, OCULAR NONNEPHROPATHIC;; CYSTINOSIS, BENIGN NONNEPHROPATHIC__:__
Number Sign__:__219800__:__CYSTINOSIS, NEPHROPATHIC; CTNS__:__LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF__:__CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED
Number Sign__:__219900__:__CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC TYPE__:__CYSTINOSIS, INTERMEDIATE__:__
Number Sign__:__220100__:__CYSTINURIA__:__CSNU;; CYSTINURIA, TYPE I, FORMERLY; CSNU1, FORMERLY;; CYSTINURIA, TYPE II, FORMERLY;; CYSTINURIA, TYPE III, FORMERLY; CSNU3, FORMERLY;; CYSTINURIA, TYPE NON-I, FORMERLY__:__CYSTINURIA, TYPE A, INCLUDED;; CYSTINURIA, TYPE B, INCLUDED;; CYSTINURIA, TYPE A/B, INCLUDED
Number Sign__:__220110__:__MITOCHONDRIAL COMPLEX IV DEFICIENCY__:__CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY__:__
Number Sign__:__220111__:__LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC__:__CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE__:__
Number Sign__:__220120__:__D-GLYCERIC ACIDURIA__:__D-GLYCERIC ACIDEMIA;; GLYCERATE KINASE DEFICIENCY__:__
Number Sign__:__220150__:__HYPOURICEMIA, RENAL, 1; RHUC1__:__DALMATIAN HYPOURICEMIA;; RENAL HYPOURICEMIA__:__
Percent__:__220200__:__DANDY-WALKER SYNDROME; DWS__:____:__DANDY-WALKER MALFORMATION, INCLUDED; DWM, INCLUDED
Number Sign__:__220210__:__RITSCHER-SCHINZEL SYNDROME 1; RTSC1__:__CRANIOCEREBELLOCARDIAC DYSPLASIA;; 3C SYNDROME;; DANDY-WALKER-LIKE MALFORMATION WITH ATRIOVENTRICULAR SEPTAL DEFECT__:__
NULL__:__220219__:__DANDY-WALKER MALFORMATION WITH MENTAL RETARDATION, MACROCEPHALY, MYOPIA, AND BRACHYTELEPHALANGY__:____:__
NULL__:__220220__:__DANDY-WALKER MALFORMATION WITH POSTAXIAL POLYDACTYLY__:__DWM WITH POSTAXIAL POLYDACTYLY;; PIERQUIN SYNDROME__:__
Number Sign__:__220290__:__DEAFNESS, AUTOSOMAL RECESSIVE 1A; DFNB1A__:____:__DEAFNESS, DIGENIC, GJB2/GJB6, INCLUDED;; DEAFNESS, DIGENIC, GJB2/GJB3, INCLUDED
NULL__:__220300__:__DEAFNESS, CONGENITAL, AND FAMILIAL MYOCLONIC EPILEPSY__:____:__
Number Sign__:__220400__:__JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1__:__DEAFNESS, CONGENITAL, AND FUNCTIONAL HEART DISEASE;; PROLONGED QT INTERVAL IN EKG AND SUDDEN DEATH;; CARDIOAUDITORY SYNDROME OF JERVELL AND LANGE-NIELSEN;; SURDO-CARDIAC SYNDROME__:__
Number Sign__:__220500__:__DEAFNESS, ONYCHODYSTROPHY, OSTEODYSTROPHY, MENTAL RETARDATION, AND SEIZURES SYNDROME; DOORS__:__DOOR SYNDROME;; DIGITORENOCEREBRAL SYNDROME;; DRC SYNDROME;; BRACHYDACTYLY DUE TO ABSENCE OF DISTAL PHALANGES;; ERONEN SYNDROME__:__
Number Sign__:__220600__:__SPLIT-HAND/FOOT MALFORMATION 1 WITH SENSORINEURAL HEARING LOSS, AUTOSOMAL RECESSIVE; SHFM1D__:__DEAFNESS, CONGENITAL, WITH SPLIT HANDS AND FEET__:__
Caret__:__220700__:__MOVED TO 220290__:____:__
Caret__:__220800__:__MOVED TO 220700__:____:__
NULL__:__220900__:__DEAFNESS, CONGENITAL, WITH TOTAL ALBINISM__:____:__
Caret__:__221000__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__221200__:__DEAFNESS AND MYOPIA; DFNMYP__:____:__
Percent__:__221300__:__DEAFNESS, CONDUCTIVE, WITH MALFORMED EXTERNAL EAR__:____:__
NULL__:__221320__:__DEAFNESS, CONDUCTIVE, WITH PTOSIS AND SKELETAL ANOMALIES__:____:__
Percent__:__221350__:__DEAFNESS, CONGENITAL, WITH VITILIGO AND ACHALASIA__:____:__
NULL__:__221400__:__DEAFNESS, NERVE TYPE, WITH MESENTERIC DIVERTICULA OF SMALL BOWEL AND PROGRESSIVE SENSORY NEUROPATHY__:__GROLL-HIRSCHOWITZ SYNDROME__:__
NULL__:__221500__:__DEAFNESS, NEURAL, CONGENITAL MODERATE__:____:__
Caret__:__221600__:__MOVED TO 220290__:____:__
Caret__:__221650__:__MOVED TO 220290__:____:__
NULL__:__221700__:__DEAFNESS, NEURAL, WITH ATYPICAL ATOPIC DERMATITIS__:____:__
NULL__:__221740__:__DEAFNESS-OLIGODONTIA SYNDROME__:____:__
NULL__:__221745__:__DEAFNESS, SENSORINEURAL, AUTOSOMAL-MITOCHONDRIAL TYPE__:____:__
Number Sign__:__221750__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 3; CPHD3__:__PITUITARY HORMONE DEFICIENCY, COMBINED, WITH RIGID CERVICAL SPINE;; DEAFNESS, SENSORINEURAL, WITH PITUITARY DWARFISM__:__
NULL__:__221760__:__DERMATOGLYPHICS--PALMAR TRIRADIUS d, ABSENCE OF__:____:__
Number Sign__:__221770__:__POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY 1; PLOSL1__:__PLOSL;; NASU-HAKOLA DISEASE; NHD;; PRESENILE DEMENTIA WITH BONE CYSTS;; DEMENTIA, PREFRONTAL, WITH BONE CYSTS;; DEMENTIA, PROGRESSIVE, WITH LIPOMEMBRANOUS POLYCYSTIC OSTEODYSPLASIA;; BRAIN-BONE-FAT DISEASE__:__
NULL__:__221780__:__DERMATOGLYPHICS--HYPOTHENAR RADIAL ARCH__:____:__
NULL__:__221790__:__DERMATOLEUKODYSTROPHY__:____:__
Percent__:__221800__:__DERMOCHONDROCORNEAL DYSTROPHY__:__FRANCOIS SYNDROME__:__
NULL__:__221810__:__DERMATOOSTEOLYSIS, KIRGHIZIAN TYPE__:__KIRGHIZIAN DERMATOOSTEOLYSIS__:__
Number Sign__:__221820__:__LEUKOENCEPHALOPATHY, HEREDITARY DIFFUSE, WITH SPHEROIDS; HDLS__:__LEUKOENCEPHALOPATHY, ADULT-ONSET, WITH AXONAL SPHEROIDS AND PIGMENTED GLIA; ALSP;; LEUKOENCEPHALOPATHY WITH NEUROAXONAL SPHEROIDS, AUTOSOMAL DOMINANT;; GLIOSIS, FAMILIAL PROGRESSIVE SUBCORTICAL; GPSC;; DEMENTIA, FAMILIAL, NEUMANN TYPE;; SUBCORTICAL GLIOSIS OF NEUMANN__:__
Number Sign__:__221900__:__PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL RECESSIVE; PHPVAR__:__RETINAL NONATTACHMENT, NONSYNDROMIC CONGENITAL; RNANC; NCRNA;; RETINAL NONATTACHMENT AND FALCIFORM DETACHMENT;; PERSISTENT FETAL VASCULATURE__:__
NULL__:__221950__:__DEXTROCARDIA WITH UNUSUAL FACIES AND MICROPHTHALMIA__:____:__
NULL__:__221995__:__DIABETES INSIPIDUS, NEPHROGENIC, WITH MENTAL RETARDATION AND INTRACEREBRAL CALCIFICATION__:____:__
Caret__:__222000__:__MOVED TO 125800__:____:__
Percent__:__222100__:__DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM__:__DIABETES MELLITUS, TYPE I;; JUVENILE-ONSET DIABETES; JOD__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 1, INCLUDED; IDDM1, INCLUDED;; INSULIN-DEPENDENT DIABETES MELLITUS 1, INCLUDED
Number Sign__:__222300__:__WOLFRAM SYNDROME 1; WFS1__:__WFS;; DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS; DIDMOAD__:__
NULL__:__222350__:__DIAMINOPENTANURIA__:__CYSTINE-LYSINURIA__:__
Percent__:__222400__:__DIAPHRAGMATIC HERNIA 2; DIH2__:____:__
Number Sign__:__222448__:__DONNAI-BARROW SYNDROME__:__FACIOOCULOACOUSTICORENAL SYNDROME;; DBS/FOAR SYNDROME;; DIAPHRAGMATIC HERNIA, EXOMPHALOS, ABSENT CORPUS CALLOSUM, HYPERTELORISM, MYOPIA, SENSORINEURAL DEAFNESS, AND PROTEINURIA__:__
Number Sign__:__222470__:__TRICHOHEPATOENTERIC SYNDROME 1; THES1__:__THE SYNDROME;; DIARRHEA, SYNDROMIC;; DIARRHEA, FATAL INFANTILE, WITH TRICHORRHEXIS NODOSA__:__
NULL__:__222500__:__DIASTEMATOMYELIA__:____:__
Number Sign__:__222600__:__DIASTROPHIC DYSPLASIA; DTD__:__DD__:__DIASTROPHIC DYSPLASIA, BROAD BONE-PLATYSPONDYLIC VARIANT, INCLUDED
Percent__:__222690__:__DIBASIC AMINO ACIDURIA I__:____:__
Number Sign__:__222700__:__LYSINURIC PROTEIN INTOLERANCE; LPI__:__DIBASIC AMINO ACIDURIA II__:__
Number Sign__:__222730__:__DICARBOXYLIC AMINOACIDURIA; DCBXA__:__GLUTAMATE-ASPARTATE TRANSPORT DEFECT__:__
Asterisk__:__222745__:__2,4-DIENOYL-CoA REDUCTASE 1, MITOCHONDRIAL; DECR1__:____:__
Number Sign__:__222748__:__DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD__:__DIHYDROPYRIMIDINURIA;; DPYS DEFICIENCY;; DPH DEFICIENCY__:__
Caret__:__222760__:__MOVED TO 220500__:____:__
Number Sign__:__222765__:__RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2__:__DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY;; DHAPAT DEFICIENCY;; GLYCERONEPHOSPHATE O-ACYLTRANSFERASE DEFICIENCY;; GNPAT DEFICIENCY;; PEROXISOMAL DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY;; CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC, DUE TO DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE DEFICIENCY__:__
Number Sign__:__222800__:__BISPHOSPHOGLYCERATE MUTASE DEFICIENCY__:__BISPHOSPHOGLYCEROMUTASE DEFICIENCY;; BPGM DEFICIENCY;; DIPHOSPHOGLYCERATE MUTASE DEFICIENCY OF ERYTHROCYTE;; DPGM DEFICIENCY__:__
Number Sign__:__222900__:__SUCRASE-ISOMALTASE DEFICIENCY, CONGENITAL; CSID__:__DISACCHARIDE INTOLERANCE I;; SUCROSE-ISOMALTOSE MALABSORPTION, CONGENITAL;; SUCROSE INTOLERANCE, CONGENITAL;; SI DEFICIENCY__:__
Number Sign__:__223000__:__LACTASE DEFICIENCY, CONGENITAL__:__ALACTASIA, CONGENITAL;; DISACCHARIDE INTOLERANCE II__:__
Number Sign__:__223100__:__LACTOSE INTOLERANCE, ADULT TYPE__:__HYPOLACTASIA, ADULT TYPE;; ADULT LACTASE DEFICIENCY;; DISACCHARIDE INTOLERANCE III__:__LACTASE PERSISTENCE, INCLUDED
Percent__:__223200__:__DISORGANIZATION, MOUSE, HOMOLOG OF__:__DS__:__
NULL__:__223300__:__DISSEMINATED SCLEROSIS WITH NARCOLEPSY__:____:__
NULL__:__223320__:__DIVERTICULOSIS, SMALL-INTESTINAL__:____:__
NULL__:__223330__:__DIVERTICULOSIS OF BOWEL, HERNIA, AND RETINAL DETACHMENT__:____:__
NULL__:__223340__:__DK PHOCOMELIA SYNDROME__:__PHOCOMELIA, THROMBOCYTOPENIA, ENCEPHALOCELE, UROGENITAL MALFORMATIONS;; VON VOSS-CHERSTVOY SYNDROME__:__
NULL__:__223350__:__DOHLE BODIES AND LEUKEMIA__:____:__
Number Sign__:__223360__:__ORTHOSTATIC HYPOTENSION 1; ORTHYP1__:__DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL;; NOREPINEPHRINE DEFICIENCY;; NORADRENALINE DEFICIENCY__:__
Percent__:__223370__:__DUBOWITZ SYNDROME__:____:__
NULL__:__223380__:__DOPAMINE BETA-HYDROXYLASE, PLASMA, THERMOLABILITY OF__:____:__
NULL__:__223400__:__DUODENAL ATRESIA__:____:__
NULL__:__223500__:__DWARFISM, LOW-BIRTH-WEIGHT TYPE, WITH UNRESPONSIVENESS TO GROWTH HORMONE__:____:__
NULL__:__223540__:__DWARFISM, MENTAL RETARDATION, AND EYE ABNORMALITY__:__MOLLICA SYNDROME__:__
NULL__:__223550__:__DWARFISM, PROPORTIONATE, WITH HIP DISLOCATION__:____:__
Caret__:__223600__:__MOVED TO 127100__:____:__
Caret__:__223610__:__MOVED TO 228900__:____:__
Number Sign__:__223800__:__DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC__:____:__
Number Sign__:__223900__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE III; HSAN3__:__HSAN III;; DYSAUTONOMIA, FAMILIAL; DYS; FD;; RILEY-DAY SYNDROME__:__
NULL__:__224000__:__DYSAUTONOMIA-LIKE DISORDER__:____:__
Number Sign__:__224050__:__CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 1; CAMRQ1__:__CEREBELLAR HYPOPLASIA, VLDLR-ASSOCIATED;; CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDAL LOCOMOTION 1;; CEREBELLAR ATAXIA, CONGENITAL, AND MENTAL RETARDATION, AUTOSOMAL RECESSIVE;; DYSEQUILIBRIUM SYNDROME; DES__:__
Number Sign__:__224100__:__ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE II; CDAN2__:__DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE II;; CDA II;; DYSERYTHROPOIETIC ANEMIA, HEMPAS TYPE;; HEREDITARY ERYTHROBLASTIC MULTINUCLEARITY WITH POSITIVE ACIDIFIED-SERUM TEST; HEMPAS__:__
Number Sign__:__224120__:__ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A__:__DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I__:__
Caret__:__224200__:__MOVED TO 229200__:____:__
Number Sign__:__224230__:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 1; DKCB1__:____:__
NULL__:__224250__:__DYSMYELINATION WITH JAUNDICE__:____:__
Percent__:__224300__:__DYSOSTEOSCLEROSIS__:____:__
Percent__:__224400__:__DYSSEGMENTAL DYSPLASIA, ROLLAND-DESBUQUOIS TYPE; DDRD__:__DYSSEGMENTAL DWARFISM, ROLLAND-DESBUQUOIS TYPE;; ANISOSPONDYLIC CAMPTOMICROMELIC DWARFISM, ROLLAND-DESBUQUOIS TYPE__:__
Number Sign__:__224410__:__DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER TYPE; DDSH__:__DYSSEGMENTAL DWARFISM, SILVERMAN-HANDMAKER TYPE;; ANISOSPONDYLIC CAMPTOMICROMELIC DWARFISM, SILVERMAN-HANDMAKER TYPE__:__
Number Sign__:__224500__:__DYSTONIA 2, TORSION, AUTOSOMAL RECESSIVE; DYT2__:__DYSTONIA MUSCULORUM DEFORMANS 2__:__
NULL__:__224550__:__DYSTONIA WITH RINGBINDEN__:____:__
Caret__:__224570__:__MOVED TO 500001__:____:__
Caret__:__224600__:__MOVED TO 128200__:____:__
Number Sign__:__224690__:__MEIER-GORLIN SYNDROME 1; MGORS1__:__EAR, PATELLA, SHORT STATURE SYNDROME; EPS;; MICROTIA, ABSENT PATELLAE, MICROGNATHIA SYNDROME;; MEIER-GORLIN SYNDROME__:__
NULL__:__224700__:__EBSTEIN ANOMALY__:____:__
Number Sign__:__224750__:__SCHOPF-SCHULZ-PASSARGE SYNDROME; SSPS__:__KERATOSIS PALMOPLANTARIS WITH CYSTIC EYELIDS, HYPODONTIA, AND HYPOTRICHOSIS;; ECCRINE TUMORS WITH ECTODERMAL DYSPLASIA__:__
NULL__:__224800__:__ECTODERMAL DYSPLASIA AND NEUROSENSORY DEAFNESS__:____:__
Number Sign__:__224900__:__ECTODERMAL DYSPLASIA 10B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL RECESSIVE; ECTD10B__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC; HED;; ECTODERMAL DYSPLASIA, ANHIDROTIC; EDA__:__
Percent__:__225000__:__ROSSELLI-GULIENETTI SYNDROME__:____:__
NULL__:__225040__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH HYPOTHYROIDISM AND AGENESIS OF THE CORPUS CALLOSUM__:____:__
NULL__:__225050__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH HYPOTHYROIDISM AND CILIARY DYSKINESIA__:__HEDH SYNDROME__:__
Number Sign__:__225060__:__CLEFT LIP/PALATE-ECTODERMAL DYSPLASIA SYNDROME; CLPED1__:__ZLOTOGORA-OGUR SYNDROME;; ECTODERMAL DYSPLASIA, MARGARITA ISLAND TYPE;; ECTODERMAL DYSPLASIA, TYPE 4; ED4;; ECTODERMAL DYSPLASIA, CLEFT LIP AND PALATE, MENTAL RETARDATION, AND SYNDACTYLY__:__OROFACIAL CLEFT 7, INCLUDED; OFC7, INCLUDED;; CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 7, INCLUDED
Number Sign__:__225100__:__ECTOPIA LENTIS 2, ISOLATED, AUTOSOMAL RECESSIVE; ECTOL2__:____:__
Number Sign__:__225200__:__ECTOPIA LENTIS ET PUPILLAE__:__ECTOPIA LENTIS WITH ECTOPIA OF PUPIL__:__
Number Sign__:__225250__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 5; CHNG5__:____:__
Number Sign__:__225280__:__ECTODERMAL DYSPLASIA, ECTRODACTYLY, AND MACULAR DYSTROPHY SYNDROME; EEMS__:__EEM SYNDROME__:__
NULL__:__225290__:__ECTRODACTYLY-POLYDACTYLY__:____:__
Number Sign__:__225300__:__SPLIT-HAND/FOOT MALFORMATION 6; SHFM6__:__ECTRODACTYLY, AUTOSOMAL RECESSIVE__:__
NULL__:__225310__:__EHLERS-DANLOS SYNDROME WITH PLATELET DYSFUNCTION FROM FIBRONECTIN ABNORMALITY__:__FN ABNORMALITY;; EHLERS-DANLOS SYNDROME, TYPE X;; EDS X; EDS10;; EHLERS-DANLOS SYNDROME, DYSFIBRONECTINEMIC TYPE__:__
Number Sign__:__225320__:__EHLERS-DANLOS SYNDROME, CARDIAC VALVULAR TYPE; EDSCV__:____:__
Caret__:__225350__:__MOVED TO 130050__:____:__
Caret__:__225360__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__225400__:__EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 1; EDSKSCL1__:__EHLERS-DANLOS SYNDROME, TYPE VI; EDS6;; EDS VI;; EHLERS-DANLOS SYNDROME, OCULAR-SCOLIOTIC TYPE;; NEVO SYNDROME;; EHLERS-DANLOS SYNDROME, TYPE VIA, FORMERLY; EDS6A, FORMERLY__:__
Number Sign__:__225410__:__EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS TYPE; EDSDERMS__:__DERMATOSPARAXIS;; EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL RECESSIVE;; EDS VIIC;; EDS7C__:__
Caret__:__225450__:__MOVED TO 182860__:____:__
Number Sign__:__225500__:__ELLIS-VAN CREVELD SYNDROME; EVC__:__CHONDROECTODERMAL DYSPLASIA;; MESOECTODERMAL DYSPLASIA__:__
NULL__:__225700__:__ENCEPHALOMALACIA, MULTILOCULAR__:____:__
NULL__:__225740__:__ENCEPHALOPATHY, AXONAL, WITH NECROTIZING MYOPATHY, CARDIOMYOPATHY, AND CATARACTS__:__LYON SYNDROME__:__
Number Sign__:__225750__:__AICARDI-GOUTIERES SYNDROME 1; AGS1__:__AGS;; ENCEPHALOPATHY, FAMILIAL INFANTILE, WITH INTRACRANIAL CALCIFICATION AND CHRONIC CEREBROSPINAL FLUID LYMPHOCYTOSIS;; CREE ENCEPHALITIS;; PSEUDOTOXOPLASMOSIS SYNDROME__:__AICARDI-GOUTIERES SYNDROME 1, AUTOSOMAL DOMINANT, INCLUDED
Number Sign__:__225753__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 4; PCH4__:__ENCEPHALOPATHY, FATAL INFANTILE, WITH OLIVOPONTOCEREBELLAR HYPOPLASIA__:__
NULL__:__225755__:__ENCEPHALOPATHY WITH INTRACRANIAL CALCIFICATION, GROWTH HORMONE DEFICIENCY, MICROCEPHALY, AND RETINAL DEGENERATION__:____:__
Number Sign__:__225790__:__PROLIFERATIVE VASCULOPATHY AND HYDRANENCEPHALY-HYDROCEPHALY SYNDROME; PVHH__:__HYDRANENCEPHALY, FOWLER TYPE;; FOWLER SYNDROME;; HYDROCEPHALY/HYDRANENCEPHALY DUE TO CEREBRAL VASCULOPATHY;; ENCEPHALOCLASTIC PROLIFERATIVE VASCULOPATHY; EPV__:__
Caret__:__225795__:__MOVED TO 166000__:____:__
NULL__:__226000__:__ENDOCARDIAL FIBROELASTOSIS; EFE__:____:__
NULL__:__226100__:__ENDOCARDIAL FIBROELASTOSIS AND COARCTATION OF ABDOMINAL AORTA__:____:__
NULL__:__226110__:__ENDOTHELIAL DYSTROPHY, CONGENITAL HEREDITARY, WITH NAIL HYPOPLASIA__:____:__
NULL__:__226150__:__ENTEROCOLITIS__:____:__
Number Sign__:__226200__:__ENTEROKINASE DEFICIENCY__:__ENTEROPEPTIDASE DEFICIENCY__:__
Number Sign__:__226300__:__COMPLEMENT HYPERACTIVATION, ANGIOPATHIC THROMBOSIS, AND PROTEIN-LOSING ENTEROPATHY; CHAPLE__:____:__
NULL__:__226350__:__EOSINOPHILIC FASCIITIS__:____:__
Number Sign__:__226400__:__EPIDERMODYSPLASIA VERRUCIFORMIS 1; EV1__:__EPIDERMODYSPLASIA VERRUCIFORMIS; EV__:__
NULL__:__226440__:__EPIDERMOLYSIS BULLOSA, LATE-ONSET LOCALIZED JUNCTIONAL, WITH MENTAL RETARDATION__:____:__
Caret__:__226450__:__MOVED TO 226600 AND 226650__:____:__
Percent__:__226500__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA NEUROTROPHICA__:__EPIDERMOLYSIS BULLOSA WITH CONGENITAL DEAFNESS;; EPIDERMOLYSIS BULLOSA PROGRESSIVA, RECESSIVE; EBR3__:__
Number Sign__:__226600__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE; RDEB__:__DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL RECESSIVE;; EPIDERMOLYSIS BULLOSA DYSTROPHICA, HALLOPEAU-SIEMENS TYPE; EBR1;; EPIDERMOLYSIS BULLOSA DYSTROPHICA, GENERALIZED SEVERE, AUTOSOMAL RECESSIVE__:__EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE, LOCALISATA VARIANT, INCLUDED;; EPIDERMOLYSIS BULLOSA DYSTROPHICA INVERSA, AUTOSOMAL RECESSIVE, INCLUDED
Number Sign__:__226650__:__EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ TYPE__:__EPIDERMOLYSIS BULLOSA JUNCTIONALIS, NON-HERLITZ TYPE;; EPIDERMOLYSIS BULLOSA JUNCTIONALIS, PROGRESSIVE;; EPIDERMOLYSIS BULLOSA JUNCTIONALIS, SEVERE NONLETHAL;; EPIDERMOLYSIS BULLOSA JUNCTIONALIS, DISENTIS TYPE;; EPIDERMOLYSIS BULLOSA, GENERALIZED ATROPHIC BENIGN; GABEB__:__EPIDERMOLYSIS BULLOSA, JUNCTIONAL, LOCALISATA VARIANT, INCLUDED;; JUNCTIONAL EPIDERMOLYSIS BULLOSA INVERSA, INCLUDED;; JEB-I, INCLUDED
Number Sign__:__226670__:__EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY; EBSMD__:__EPIDERMOLYSIS BULLOSA SIMPLEX AND LIMB-GIRDLE MUSCULAR DYSTROPHY;; MD-EBS; MDEBS__:__
Number Sign__:__226700__:__EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ TYPE__:__EPIDERMOLYSIS BULLOSA JUNCTIONALIS, HERLITZ TYPE;; JEB-HERLITZ TYPE;; EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ-PEARSON TYPE;; HERLITZ-PEARSON-TYPE EPIDERMOLYSIS BULLOSA;; EPIDERMOLYSIS BULLOSA LETALIS__:__
Number Sign__:__226730__:__EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA__:__EPIDERMOLYSIS BULLOSA, JUNCTIONAL, WITH PYLORIC ATRESIA;; JUNCTIONAL EPIDERMOLYSIS BULLOSA WITH PYLORIC ATRESIA;; JEB-PA;; EPIDERMOLYSIS BULLOSA, JUNCTIONAL, WITH PYLORIC ATRESIA AND APLASIA CUTIS CONGENITA;; EB-PA-ACC;; CARMI SYNDROME;; APLASIA CUTIS CONGENITA WITH GASTROINTESTINAL ATRESIA__:__
NULL__:__226735__:__EPIDERMOLYSIS BULLOSA WITH DIAPHRAGMATIC HERNIA__:____:__
Number Sign__:__226750__:__KOHLSCHUTTER-TONZ SYNDROME; KTZS__:__EPILEPSY AND YELLOW TEETH;; EPILEPSY, DEMENTIA, AND AMELOGENESIS IMPERFECTA;; KOHLSCHUTTER SYNDROME__:__
NULL__:__226800__:__EPILEPSY, PHOTOGENIC, WITH SPASTIC DIPLEGIA AND MENTAL RETARDATION__:____:__
NULL__:__226810__:__EPILEPSY WITH BILATERAL OCCIPITAL CALCIFICATIONS__:____:__
NULL__:__226850__:__EPILEPSY-TELANGIECTASIA__:____:__
Number Sign__:__226900__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 4; EDM4__:__MULTIPLE EPIPHYSEAL DYSPLASIA, AUTOSOMAL RECESSIVE;; MULTIPLE EPIPHYSEAL DYSPLASIA WITH CLUBFOOT;; MULTIPLE EPIPHYSEAL DYSPLASIA WITH BILAYERED PATELLAE__:__
NULL__:__226950__:__EPIPHYSEAL DYSPLASIA OF FEMORAL HEAD, MYOPIA, AND DEAFNESS__:____:__
Percent__:__226960__:__EPIPHYSEAL DYSPLASIA, MICROCEPHALY, AND NYSTAGMUS__:__LOWRY-WOOD SYNDROME; LWS__:__
Number Sign__:__226980__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS__:__MED-IDDM SYNDROME;; IDDM-MED SYNDROME;; WOLCOTT-RALLISON SYNDROME__:__
NULL__:__226985__:__EPITHELIAL SQUAMOUS DYSPLASIA, KERATINIZING DESQUAMATIVE, OF URINARY TRACT__:____:__
Number Sign__:__226990__:__IMMUNODEFICIENCY 32B; IMD32B__:__IMMUNODEFICIENCY 32B, MONOCYTE, DENDRITIC CELL, AND NATURAL KILLER CELL DEFICIENCY, AUTOSOMAL RECESSIVE;; IRF8 DEFICIENCY, AUTOSOMAL RECESSIVE;; EPSTEIN-BARR VIRUS, SUSCEPTIBILITY TO CHRONIC INFECTION BY__:__
NULL__:__227000__:__ERYTHEMA OF ACRAL REGIONS__:____:__
NULL__:__227010__:__ERMINE PHENOTYPE__:__PIGMENTARY DISORDER WITH HEARING LOSS__:__BLACK LOCKS WITH ALBINISM AND DEAFNESS SYNDROME, INCLUDED; BADS, INCLUDED
Percent__:__227050__:__TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD; TEC__:__ERYTHROBLASTOPENIA, TRANSIENT__:__
Percent__:__227090__:__ERYTHRODERMA, LETHAL CONGENITAL__:____:__
Caret__:__227100__:__MOVED TO 120900__:____:__
Percent__:__227150__:__ETHANOLAMINOSIS__:__ETHANOLAMINE KINASE DEFICIENCY__:__
Caret__:__227200__:__MOVED TO 614841__:____:__
NULL__:__227210__:__EYEBROWS, DUPLICATION OF, WITH STRETCHABLE SKIN AND SYNDACTYLY__:____:__
Number Sign__:__227220__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 1; SHEP1__:__SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES;; SKIN/HAIR/EYE PIGMENTATION 1, BLUE/BROWN EYES;; SKIN/HAIR/EYE PIGMENTATION 1, BLOND/BROWN HAIR;; EYE COLOR, BROWN/BLUE;; EYE COLOR, BLUE/NONBLUE;; EYE COLOR 3; EYCL3;; BROWN EYE COLOR 2; BEY2;; HAIR COLOR 3; HCL3__:__
Number Sign__:__227240__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 5; SHEP5__:__SKIN/HAIR/EYE PIGMENTATION 5, BLACK/NONBLACK HAIR;; SKIN/HAIR/EYE PIGMENTATION 5, DARK/LIGHT EYES;; SKIN/HAIR/EYE PIGMENTATION 5, DARK/FAIR SKIN__:__
NULL__:__227250__:__FACIAL ABNORMALITIES, KYPHOSCOLIOSIS, AND MENTAL RETARDATION__:____:__
NULL__:__227255__:__FACIAL DYSMORPHISM WITH MULTIPLE MALFORMATIONS__:____:__
Number Sign__:__227260__:__FOCAL FACIAL DERMAL DYSPLASIA 3, SETLEIS TYPE; FFDD3__:__SETLEIS SYNDROME;; BITEMPORAL FORCEPS MARKS SYNDROME;; FACIAL ECTODERMAL DYSPLASIA;; FOCAL FACIAL DERMAL DYSPLASIA, TYPE II, FORMERLY__:__
NULL__:__227270__:__FACIOCARDIOMELIC DYSPLASIA, LETHAL__:____:__
NULL__:__227280__:__FACIOCARDIORENAL SYNDROME__:__EASTMAN-BIXLER SYNDROME__:__
Caret__:__227290__:__MOVED TO 222448__:____:__
Caret__:__227295__:__MOVED TO 211910__:____:__
Number Sign__:__227300__:__FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 1; F5F8D1__:__FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY I; FMFD1;; FMFD I;; MULTIPLE COAGULATION FACTOR DEFICIENCY I; MCFD1__:__
NULL__:__227310__:__FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, WITH NORMAL PROTEIN C AND PROTEIN C INHIBITOR__:____:__
NULL__:__227320__:__FACIOTHORACOGENITAL SYNDROME__:____:__
Percent__:__227330__:__FACIODIGITOGENITAL SYNDROME, AUTOSOMAL RECESSIVE__:__AARSKOG-LIKE SYNDROME;; KUWAIT TYPE FACIODIGITOGENITAL SYNDROME__:__
Number Sign__:__227400__:__FACTOR V DEFICIENCY__:__PARAHEMOPHILIA;; OWREN PARAHEMOPHILIA;; LABILE FACTOR DEFICIENCY__:__
Number Sign__:__227500__:__FACTOR VII DEFICIENCY__:__F7 DEFICIENCY;; HYPOPROCONVERTINEMIA__:__
Number Sign__:__227600__:__FACTOR X DEFICIENCY__:__F10 DEFICIENCY;; STUART-PROWER FACTOR DEFICIENCY__:__
Number Sign__:__227645__:__FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC__:__FACC; FAC;; FANCONI PANCYTOPENIA, TYPE 3; FA3__:__
Number Sign__:__227646__:__FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2__:__FAD2;; FANCONI ANEMIA, COMPLEMENTATION GROUP D; FANCD; FACD;; FANCONI PANCYTOPENIA, TYPE 4; FA4__:__
Number Sign__:__227650__:__FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA__:__FANCONI ANEMIA; FA__:__FANCONI ANEMIA, ESTREN-DAMESHEK VARIANT, INCLUDED;; ESTREN-DAMESHEK VARIANT OF FANCONI ANEMIA, INCLUDED;; ESTREN-DAMESHEK VARIANT OF FANCONI PANCYTOPENIA, INCLUDED
Caret__:__227660__:__MOVED TO 300514__:____:__
Caret__:__227700__:__MOVED TO 134600__:____:__
Caret__:__227800__:__MOVED TO 134600__:____:__
Number Sign__:__227810__:__FANCONI-BICKEL SYNDROME; FBS__:__HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI__:__
NULL__:__227850__:__FANCONI-LIKE SYNDROME__:____:__
Number Sign__:__228000__:__FARBER LIPOGRANULOMATOSIS; FRBRL__:__FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY__:__
NULL__:__228020__:__FASCIAL DYSTROPHY, CONGENITAL__:____:__
Percent__:__228100__:__VISCERAL STEATOSIS, CONGENITAL__:__FATTY LIVER DISEASE, CONGENITAL;; FATTY METAMORPHOSIS OF VISCERA;; STEATOSIS OF LIVER;; WHITE LIVER DISEASE__:__
NULL__:__228200__:__FEMUR-FIBULA-ULNA SYNDROME__:__FFU SYNDROME__:__
Percent__:__228250__:__FEMUR, UNILATERAL BIFID, WITH MONODACTYLOUS ECTRODACTYLY__:__GOLLOP-WOLFGANG COMPLEX; GWC__:__
Number Sign__:__228300__:__HYPOGONADOTROPIC HYPOGONADISM 23 WITHOUT ANOSMIA; HH23__:__PASQUALINI SYNDROME;; FERTILE EUNUCH SYNDROME__:__
NULL__:__228355__:__FETAL IODINE DEFICIENCY DISORDER; FIDD__:__ENDEMIC CRETINISM__:__
NULL__:__228400__:__FEVER, FAMILIAL LIFELONG PERSISTENT__:____:__
Number Sign__:__228520__:__FIBROCHONDROGENESIS 1; FBCG1__:____:__
Number Sign__:__228550__:__MYOFIBROMATOSIS, INFANTILE, 1; IMF1__:__MYOFIBROMATOSIS, JUVENILE;; FIBROMATOSIS, CONGENITAL GENERALIZED; CGF__:__
NULL__:__228560__:__FIBROMATOSIS, GINGIVAL, WITH DISTINCTIVE FACIES__:____:__
Number Sign__:__228600__:__HYALINE FIBROMATOSIS SYNDROME; HFS__:__HYALINOSIS, SYSTEMIC__:__
NULL__:__228800__:__FIBROSCLEROSIS, MULTIFOCAL__:__MEDIASTINAL FIBROSIS, FAMILIAL;; RETROPERITONEAL FIBROSIS, FAMILIAL__:__
Number Sign__:__228900__:__FIBULAR HYPOPLASIA AND COMPLEX BRACHYDACTYLY__:__DU PAN SYNDROME__:__
Number Sign__:__228930__:__FIBULAR APLASIA OR HYPOPLASIA, FEMORAL BOWING AND POLY-, SYN-, AND OLIGODACTYLY__:__FUHRMANN SYNDROME__:__
NULL__:__228940__:__FIBULOULNAR APLASIA OR HYPOPLASIA WITH RENAL ABNORMALITIES__:____:__
Number Sign__:__228960__:__HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY__:__HMWK DEFICIENCY;; KININOGEN DEFICIENCY, HIGH MOLECULAR WEIGHT;; FITZGERALD TRAIT__:__KININOGEN DEFICIENCY, TOTAL, INCLUDED;; KININOGEN DEFICIENCY, HIGH MOLECULAR WEIGHT AND LOW MOLECULAR WEIGHT, INCLUDED;; FLAUJEAC TRAIT, INCLUDED;; WILLIAMS TRAIT, INCLUDED
Number Sign__:__228980__:__FLECK RETINA, FAMILIAL BENIGN; FRFB__:____:__
NULL__:__228990__:__FLECK RETINA OF KANDORI__:____:__
Asterisk__:__229000__:__KALLIKREIN B, PLASMA, 1; KLKB1__:__PREKALLIKREIN; PKK;; FLETCHER FACTOR;; KLK3, FORMERLY__:__
NULL__:__229045__:__FOCAL EPITHELIAL HYPERPLASIA, ORAL__:__FEH, ORAL;; HECK DISEASE__:__
Number Sign__:__229050__:__FOLATE MALABSORPTION, HEREDITARY__:____:__
Number Sign__:__229070__:__HYPOGONADOTROPIC HYPOGONADISM 24 WITHOUT ANOSMIA; HH24__:__FOLLICLE-STIMULATING HORMONE DEFICIENCY, ISOLATED__:__
Number Sign__:__229100__:__GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY__:__FORMIMINOTRANSFERASE DEFICIENCY;; FORMIMINOGLUTAMIC ACIDURIA;; FIGLU-URIA__:__
Percent__:__229120__:__FOUNTAIN SYNDROME__:__MENTAL RETARDATION, SENSORINEURAL DEAFNESS, SKELETAL ABNORMALITIES, AND COARSE FACE WITH FULL LIPS__:__
Caret__:__229150__:__MOVED TO 300624__:____:__
Number Sign__:__229200__:__BRITTLE CORNEA SYNDROME 1; BCS1__:__FRAGILITAS OCULI WITH JOINT HYPEREXTENSIBILITY;; CORNEAL FRAGILITY, KERATOGLOBUS, BLUE SCLERAE, JOINT HYPEREXTENSIBILITY;; DYSGENESIS MESODERMALIS CORNEAE ET SCLERAE;; EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY__:__
NULL__:__229230__:__FRASER-LIKE SYNDROME__:__FUSED EYELIDS, AIRWAY ANOMALIES, OVARIAN CYSTS, AND DIGITAL ANOMALIES__:__
NULL__:__229250__:__FREESIA FLOWERS, INABILITY TO SMELL__:____:__
Number Sign__:__229300__:__FRIEDREICH ATAXIA 1; FRDA__:__FRDA1;; FA__:__FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED
NULL__:__229310__:__FRIEDREICH ATAXIA AND CONGENITAL GLAUCOMA__:____:__
Percent__:__229400__:__FRONTOFACIONASAL DYSPLASIA__:__FFND;; FRONTOFACIONASAL DYSOSTOSIS__:__
Percent__:__229500__:__FRUCTOSE AND GALACTOSE INTOLERANCE__:____:__
Number Sign__:__229600__:__FRUCTOSE INTOLERANCE, HEREDITARY__:__FRUCTOSEMIA;; FRUCTOSE-1-PHOSPHATE ALDOLASE DEFICIENCY;; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE B DEFICIENCY;; ALDOLASE B DEFICIENCY;; ALDOB DEFICIENCY__:__
NULL__:__229650__:__FRUCTOSE UTILIZATION__:____:__
Number Sign__:__229700__:__FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D__:____:__
Number Sign__:__229800__:__FRUCTOSURIA, ESSENTIAL__:__HEPATIC FRUCTOKINASE DEFICIENCY;; KETOHEXOKINASE DEFICIENCY__:__
Percent__:__229850__:__FRYNS SYNDROME; FRNS__:__DIAPHRAGMATIC HERNIA, ABNORMAL FACE, AND DISTAL LIMB ANOMALIES__:__
Caret__:__229900__:__MOVED TO 258870__:____:__
Caret__:__229950__:__MOVED TO 136820__:____:__
Number Sign__:__230000__:__FUCOSIDOSIS__:__ALPHA-L-FUCOSIDASE DEFICIENCY__:__
Number Sign__:__230200__:__GALACTOKINASE DEFICIENCY__:__GALK DEFICIENCY;; GALACTOSEMIA II__:__
NULL__:__230300__:__GALACTORRHEA__:____:__
Number Sign__:__230350__:__GALACTOSE EPIMERASE DEFICIENCY__:__GALE DEFICIENCY;; GALACTOSEMIA III;; UDP-GALACTOSE-4-EPIMERASE DEFICIENCY__:__
Number Sign__:__230400__:__GALACTOSEMIA__:__GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY;; GALT DEFICIENCY;; GALACTOSEMIA, CLASSIC__:__GALACTOSEMIA, DUARTE VARIANT, INCLUDED
Caret__:__230430__:__MOVED TO 300622__:____:__
Number Sign__:__230450__:__GAMMA-GLUTAMYLCYSTEINE SYNTHETASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO__:____:__
Number Sign__:__230500__:__GM1-GANGLIOSIDOSIS, TYPE I__:__GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I;; GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1;; BETA-GALACTOSIDASE-1 DEFICIENCY;; GLB1 DEFICIENCY__:__GM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED
Number Sign__:__230600__:__GM1-GANGLIOSIDOSIS, TYPE II__:__GANGLIOSIDOSIS, GENERALIZED GM1, JUVENILE TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 2__:__GANGLIOSIDOSIS, GENERALIZED GM1, LATE-INFANTILE TYPE, INCLUDED
Number Sign__:__230650__:__GM1-GANGLIOSIDOSIS, TYPE III__:__GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3__:__
Caret__:__230700__:__MOVED TO 272800__:____:__
Caret__:__230710__:__MOVED TO 272800__:____:__
Number Sign__:__230740__:__GAPO SYNDROME; GAPOS__:__GROWTH RETARDATION, ALOPECIA, PSEUDOANODONTIA, AND OPTIC ATROPHY__:__
NULL__:__230750__:__GASTROSCHISIS__:____:__ABDOMINAL WALL DEFECTS, INCLUDED
Number Sign__:__230800__:__GAUCHER DISEASE, TYPE I__:__GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY__:__
Number Sign__:__230900__:__GAUCHER DISEASE, TYPE II__:__GD II;; GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE__:__
Number Sign__:__231000__:__GAUCHER DISEASE, TYPE III__:__GD III;; GAUCHER DISEASE, SUBACUTE NEURONOPATHIC TYPE;; GAUCHER DISEASE, CHRONIC NEURONOPATHIC TYPE;; GAUCHER DISEASE, JUVENILE AND ADULT, CEREBRAL__:__GAUCHER DISEASE, TYPE IIIA, INCLUDED;; GAUCHER DISEASE, TYPE IIIB, INCLUDED;; GAUCHER DISEASE, NORRBOTTNIAN TYPE, INCLUDED
Number Sign__:__231005__:__GAUCHER DISEASE, TYPE IIIC__:____:__
Number Sign__:__231050__:__GELEOPHYSIC DYSPLASIA 1; GPHYSD1__:____:__
NULL__:__231060__:__GENITOPALATOCARDIAC SYNDROME__:__GARDNER-SILENGO-WACHTEL SYNDROME;; MALE PSEUDOHERMAPHRODITISM WITH MICROGNATHIA, CLEFT PALATE, AND CONOTRUNCAL CARDIAC DEFECT__:__
Number Sign__:__231070__:__GERODERMA OSTEODYSPLASTICUM; GO__:__GERODERMIA OSTEODYSPLASTICA;; WALT DISNEY DWARFISM__:__
NULL__:__231080__:__GERMAN SYNDROME__:____:__
Number Sign__:__231090__:__HYDATIDIFORM MOLE, RECURRENT, 1; HYDM1__:__HYDATIDIFORM MOLE; HYDM;; HYDATIDIFORM MOLE, COMPLETE; CHM;; GESTATIONAL TROPHOBLASTIC DISEASE__:__
Number Sign__:__231095__:__GHOSAL HEMATODIAPHYSEAL DYSPLASIA; GHDD__:__GHOSAL SYNDROME__:__
NULL__:__231100__:__HEMOCHROMATOSIS, NEONATAL__:__NH;; NHC;; ALLOIMMUNE HEPATITIS, CONGENITAL;; NEONATAL HEPATITIS, FORMERLY;; GIANT CELL HEPATITIS, FORMERLY__:__
Number Sign__:__231200__:__BERNARD-SOULIER SYNDROME; BSS__:__BLEEDING DISORDER, PLATELET-TYPE, 1; BDPLT1;; PLATELET GLYCOPROTEIN Ib DEFICIENCY;; GLYCOPROTEIN Ib, PLATELET, DEFICIENCY OF;; VON WILLEBRAND FACTOR RECEPTOR DEFICIENCY__:__BERNARD-SOULIER SYNDROME, TYPE A1, INCLUDED;; BERNARD-SOULIER SYNDROME, TYPE B, INCLUDED;; BERNARD-SOULIER SYNDROME, TYPE C, INCLUDED
Number Sign__:__231300__:__GLAUCOMA 3, PRIMARY CONGENITAL, A; GLC3A__:__GLAUCOMA, CONGENITAL; GLC3;; BUPHTHALMOS__:__GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET, INCLUDED;; GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, INCLUDED
Caret__:__231400__:__REMOVED FROM DATABASE__:____:__
Caret__:__231500__:__MOVED TO 231300__:____:__
Caret__:__231520__:__MOVED TO 273750__:____:__
Number Sign__:__231530__:__3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY__:__HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY__:__
Number Sign__:__231550__:__ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAAS__:__TRIPLE-A SYNDROME;; ALACRIMA-ACHALASIA-ADRENAL INSUFFICIENCY NEUROLOGIC DISORDER;; GLUCOCORTICOID DEFICIENCY AND ACHALASIA;; ALLGROVE SYNDROME;; ADDISONIAN-ACHALASIA SYNDROME;; HYPOADRENALISM WITH ACHALASIA;; ALACRIMA-ACHALASIA-ADDISONIANISM;; ACTH-RESISTANT ADRENAL INSUFFICIENCY, ACHALASIA AND ALACRIMA__:__ACHALASIA-ALACRIMA SYNDROME, INCLUDED
Caret__:__231610__:__REMOVED FROM DATABASE__:____:__
NULL__:__231630__:__MONOSODIUM GLUTAMATE SENSITIVITY__:__CHINESE RESTAURANT SYNDROME__:__
Number Sign__:__231670__:__GLUTARIC ACIDEMIA I; GA1__:__GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY__:__
Asterisk__:__231675__:__ELECTRON TRANSFER FLAVOPROTEIN DEHYDROGENASE; ETFDH__:__ELECTRON TRANSFER FLAVOPROTEIN:UBIQUINONE OXIDOREDUCTASE; ETFQO__:__
Number Sign__:__231680__:__MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD__:__GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA__:__GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED
Number Sign__:__231690__:__GLUTARIC ACIDURIA III; GA3__:__GA III;; GLUTARYL-CoA OXIDASE DEFICIENCY__:__
Number Sign__:__231900__:__GLUTATHIONE SYNTHETASE DEFICIENCY OF ERYTHROCYTES, HEMOLYTIC ANEMIA DUE TO; GSSDE__:____:__
Number Sign__:__231950__:__GLUTATHIONURIA__:__GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY__:__
NULL__:__231970__:__GLUTEAL MUSCLES, ABSENCE OF__:____:__
Asterisk__:__232000__:__PROPIONYL-CoA CARBOXYLASE, ALPHA SUBUNIT; PCCA__:__pccA COMPLEMENTATION GROUP__:__
Asterisk__:__232050__:__PROPIONYL-CoA CARBOXYLASE, BETA SUBUNIT; PCCB__:__pccBC COMPLEMENTATION GROUP__:__
Number Sign__:__232200__:__GLYCOGEN STORAGE DISEASE Ia; GSD1A__:__GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS__:__
Caret__:__232210__:__MOVED TO 232200__:____:__
Number Sign__:__232220__:__GLYCOGEN STORAGE DISEASE Ib; GSD1B__:__GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT__:__
Number Sign__:__232240__:__GLYCOGEN STORAGE DISEASE Ic; GSD1C__:__GSD Ic__:__GLYCOGEN STORAGE DISEASE Id, INCLUDED; GSD1D, INCLUDED
Number Sign__:__232300__:__GLYCOGEN STORAGE DISEASE II; GSD2__:__GSD II; ACID ALPHA-GLUCOSIDASE DEFICIENCY;; GAA DEFICIENCY;; POMPE DISEASE;; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM;; CARDIOMEGALIA GLYCOGENICA DIFFUSA;; ACID MALTASE DEFICIENCY; AMD;; ALPHA-1,4-GLUCOSIDASE DEFICIENCY__:__
Caret__:__232330__:__MOVED TO 300257__:____:__
Number Sign__:__232400__:__GLYCOGEN STORAGE DISEASE III; GSD3__:__FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY__:__GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED
Number Sign__:__232500__:__GLYCOGEN STORAGE DISEASE IV; GSD4__:__GSD IV;; GLYCOGEN BRANCHING ENZYME DEFICIENCY;; GBE1 DEFICIENCY;; ANDERSEN DISEASE;; BRANCHER DEFICIENCY;; GLYCOGENOSIS IV;; AMYLOPECTINOSIS;; CIRRHOSIS, FAMILIAL, WITH DEPOSITION OF ABNORMAL GLYCOGEN__:__GSD IV, CLASSIC HEPATIC, INCLUDED;; GSD IV, NONPROGRESSIVE HEPATIC, INCLUDED;; GSD IV, NEUROMUSCULAR FORM, FATAL PERINATAL, INCLUDED;; GSD IV, NEUROMUSCULAR FORM, CONGENITAL, INCLUDED;; GSD IV, NEUROMUSCULAR FORM, CHILDHOOD, INCLUDED;; GSD IV, NEUROMUSCULAR FORM, ADULT, WITH ISOLATED MYOPATHY, INCLUDED
Number Sign__:__232600__:__GLYCOGEN STORAGE DISEASE V; GSD5__:__GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY__:__
Number Sign__:__232700__:__GLYCOGEN STORAGE DISEASE VI; GSD6__:__GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER__:__
Number Sign__:__232800__:__GLYCOGEN STORAGE DISEASE VII; GSD7__:__GSD VII;; MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY;; PFKM DEFICIENCY;; TARUI DISEASE__:__
NULL__:__232900__:__GLYCOPROTEIN STORAGE DISEASE__:____:__
Number Sign__:__233100__:__RENAL GLUCOSURIA; GLYS__:__GLYS1;; GLYCOSURIA, RENAL__:__
NULL__:__233270__:__GOMBO SYNDROME__:__GROWTH RETARDATION, OCULAR ABNORMALITIES, MICROCEPHALY, BRACHYDACTYLY, AND OLIGOPHRENIA__:__
Number Sign__:__233300__:__OVARIAN DYSGENESIS 1; ODG1__:__OVARIAN DYSGENESIS, HYPERGONADOTROPIC, AUTOSOMAL RECESSIVE;; OVARIAN DYSGENESIS, HYPERGONADOTROPIC, WITH NORMAL KARYOTYPE;; GONADAL DYSGENESIS, XX TYPE;; XX GONADAL DYSGENESIS; XXGD;; OVARIAN FAILURE, HYPERGONADOTROPIC__:__
Number Sign__:__233400__:__PERRAULT SYNDROME 1; PRLTS1__:__OVARIAN DYSGENESIS WITH SENSORINEURAL DEAFNESS;; GONADAL DYSGENESIS, XX TYPE, WITH DEAFNESS__:__
Number Sign__:__233420__:__46,XY SEX REVERSAL 7; SRXY7__:__46,XY SEX REVERSAL, PARTIAL OR COMPLETE, DHH-RELATED;; 46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, DHH-RELATED;; GONADAL DYSGENESIS, XY, MALE-LIMITED; GDXYM__:__
NULL__:__233430__:__GONADAL DYSGENESIS, XY TYPE, WITH ASSOCIATED ANOMALIES__:____:__
NULL__:__233450__:__GOODPASTURE SYNDROME__:____:__
Caret__:__233500__:__MOVED TO 612289__:____:__
Number Sign__:__233600__:__IMMUNODEFICIENCY 59 AND HYPOGLYCEMIA; IMD59__:__GRANULOCYTOPENIA WITH IMMUNOGLOBULIN ABNORMALITY__:__
Number Sign__:__233650__:__COMBINED CELLULAR AND HUMORAL IMMUNE DEFECTS WITH GRANULOMAS; CCHIDG__:____:__
NULL__:__233670__:__GRANULOMATOUS DISEASE WITH DEFECT IN NEUTROPHIL CHEMOTAXIS__:____:__
Number Sign__:__233690__:__GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-NEGATIVE__:__CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-NEGATIVE;; CGD DUE TO DEFICIENCY OF THE ALPHA SUBUNIT OF CYTOCHROME b;; CYBA DEFICIENCY__:__
Number Sign__:__233700__:__GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE I; CDG1__:__CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE I;; GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF1 DEFICIENCY;; NEUTROPHIL CYTOSOL FACTOR 1, DEFICIENCY OF;; NCF1, DEFICIENCY OF;; SOLUBLE OXIDASE COMPONENT II, DEFICIENCY OF;; SOC2, DEFICIENCY OF;; p47-PHOX, DEFICIENCY OF__:__
Number Sign__:__233710__:__GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE II; CDG2__:__CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE II;; GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF2 DEFICIENCY;; NEUTROPHIL CYTOSOL FACTOR 2, DEFICIENCY OF;; NCF2, DEFICIENCY OF;; p67-PHOX, DEFICIENCY OF__:__
NULL__:__233800__:__GROUPED PIGMENTATION OF THE RETINA__:__GROUPED PIGMENTATION OF RETINAL PIGMENT EPITHELIUM;; GROUPED PIGMENTATION OF THE MACULA__:__
NULL__:__233805__:__GROWTH FACTORS, COMBINED DEFECT OF__:__INSULIN, INSULIN-LIKE GROWTH FACTOR I, AND EPIDERMAL GROWTH FACTOR DEFICIENCY;; WERNER-LIKE SYNDROME DUE TO COMBINED GROWTH FACTOR DEFICIENCY__:__
NULL__:__233810__:__GROWTH RETARDATION, SMALL AND PUFFY HANDS AND FEET, AND ECZEMA__:____:__
Number Sign__:__233910__:__HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B__:__HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY__:__DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED
Number Sign__:__234000__:__FACTOR XII DEFICIENCY__:__F12 DEFICIENCY;; HAGEMAN FACTOR DEFICIENCY;; HAF DEFICIENCY__:__
NULL__:__234030__:__HAIR DEFECT WITH PHOTOSENSITIVITY AND MENTAL RETARDATION__:____:__
Number Sign__:__234050__:__TRICHOTHIODYSTROPHY 4, NONPHOTOSENSITIVE; TTD4__:__TRICHOTHIODYSTROPHY, NONPHOTOSENSITIVE 1; TTDN1;; AMISH BRITTLE HAIR BRAIN SYNDROME; ABHS;; HAIR-BRAIN SYNDROME;; BIDS SYNDROME;; POLLITT SYNDROME;; TRICHOTHIODYSTROPHY-NEUROCUTANEOUS SYNDROME__:__
Percent__:__234100__:__HALLERMANN-STREIFF SYNDROME; HSS__:__FRANCOIS DYSCEPHALIC SYNDROME__:__
Number Sign__:__234200__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1__:__PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PKAN;; PKAN NEUROAXONAL DYSTROPHY, JUVENILE-ONSET;; HALLERVORDEN-SPATZ DISEASE__:__
NULL__:__234250__:__HALL-RIGGS MENTAL RETARDATION SYNDROME__:____:__
NULL__:__234280__:__HALLUX VARUS AND PREAXIAL POLYSYNDACTYLY__:____:__
NULL__:__234300__:__HALO NEVI__:__LEUKODERMA ACQUISITUM CENTRIFUGUM OF SUTTON__:__
NULL__:__234350__:__HALOTHANE HEPATITIS__:____:__
Number Sign__:__234500__:__HARTNUP DISORDER; HND__:__HARTNUP DISEASE__:__
Number Sign__:__234580__:__HEIMLER SYNDROME 1; HMLR1__:__HEARING LOSS, SENSORINEURAL, WITH ENAMEL HYPOPLASIA AND NAIL DEFECTS;; PEROXISOME BIOGENESIS DISORDER 1C; PBD1C__:__
NULL__:__234700__:__HEART BLOCK, CONGENITAL__:____:__
NULL__:__234750__:__HEART, MALFORMATION OF__:____:__
NULL__:__234800__:__HEMANGIOMATOSIS, CUTANEOUS, WITH ASSOCIATED FEATURES__:____:__
Number Sign__:__234810__:__PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2__:__HEMANGIOMATOSIS, FAMILIAL PULMONARY CAPILLARY__:__
NULL__:__234820__:__HEMANGIOPERICYTOMA, MALIGNANT__:____:__
Percent__:__235000__:__HEMIHYPERPLASIA, ISOLATED; IH__:__HEMIHYPERPLASIA; HHP;; HEMIHYPERTROPHY, ISOLATED__:__HEMI-3 SYNDROME, INCLUDED
Number Sign__:__235200__:__HEMOCHROMATOSIS, TYPE 1; HFE1__:__HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH__:__
Percent__:__235255__:__MULLERIAN DERIVATIVES, PERSISTENCE OF, WITH LYMPHANGIECTASIA AND POSTAXIAL POLYDACTYLY__:__URIOSTE SYNDROME__:__
Caret__:__235360__:__MOVED TO 219100__:____:__
NULL__:__235370__:__HEMOLYTIC ANEMIA WITH THERMAL SENSITIVITY OF RED CELLS__:____:__
Number Sign__:__235400__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1; AHUS1__:__AHUS, SUSCEPTIBILITY TO, 1__:__HEMOLYTIC UREMIC SYNDROME, TYPICAL, INCLUDED
NULL__:__235500__:__HEMOSIDEROSIS, PULMONARY, WITH DEFICIENCY OF GAMMA-A GLOBULIN__:____:__
Number Sign__:__235510__:__HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1; HKLLS1__:__HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME;; LYMPHATIC DYSPLASIA, GENERALIZED__:__
Number Sign__:__235550__:__HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI__:____:__
Number Sign__:__235555__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2__:__CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY__:__
Caret__:__235600__:__MOVED TO 400045__:____:__
Number Sign__:__235700__:__HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO HEXOKINASE DEFICIENCY__:____:__
Number Sign__:__235730__:__MOWAT-WILSON SYNDROME; MOWS__:__MICROCEPHALY, MENTAL RETARDATION, AND DISTINCT FACIAL FEATURES, WITH OR WITHOUT HIRSCHSPRUNG DISEASE;; HIRSCHSPRUNG DISEASE-MENTAL RETARDATION SYNDROME__:__
Caret__:__235735__:__MOVED TO 277580__:____:__
NULL__:__235740__:__HIRSCHSPRUNG DISEASE WITH POLYDACTYLY, RENAL AGENESIS, AND DEAFNESS__:____:__
NULL__:__235750__:__HIRSCHSPRUNG DISEASE WITH ULNAR POLYDACTYLY, POLYSYNDACTYLY OF BIG TOES, AND VENTRICULAR SEPTAL DEFECT__:____:__
NULL__:__235760__:__HIRSCHSPRUNG DISEASE WITH HYPOPLASTIC NAILS AND DYSMORPHIC FACIAL FEATURES__:____:__
Number Sign__:__235800__:__HISTIDINEMIA__:__HISTIDINE AMMONIA-LYASE DEFICIENCY;; HAL DEFICIENCY;; HISTIDASE DEFICIENCY;; HIS DEFICIENCY__:__
Percent__:__235830__:__HISTIDINURIA DUE TO A RENAL TUBULAR DEFECT__:____:__
Percent__:__235900__:__HISTIOCYTOSIS, FAMILIAL LIPOCHROME__:____:__
Number Sign__:__236000__:__LYMPHOMA, HODGKIN, CLASSIC; CHL__:__HODGKIN DISEASE__:__
Percent__:__236100__:__HOLOPROSENCEPHALY 1; HPE1__:__HOLOPROSENCEPHALY, FAMILIAL ALOBAR;; HPE, FAMILIAL; HPEC;; ARHINENCEPHALY;; CYCLOPIA;; DEMYER SEQUENCE__:__
NULL__:__236110__:__HOLZGREVE SYNDROME__:____:__
NULL__:__236130__:__HOMOCARNOSINOSIS__:__HOMOCARNOSINASE DEFICIENCY__:__
Number Sign__:__236200__:__HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY__:__HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY__:__HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED
Number Sign__:__236250__:__HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE REDUCTASE ACTIVITY__:__METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY;; MTHFR DEFICIENCY__:__MTHFR DEFICIENCY, THERMOLABILE TYPE, INCLUDED
Number Sign__:__236270__:__HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE__:__HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblE COMPLEMENTATION TYPE;; VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE;; METHYLCOBALAMIN DEFICIENCY, cblE TYPE__:__
NULL__:__236300__:__HOOFT DISEASE__:____:__
Percent__:__236400__:__HUMERORADIAL SYNOSTOSIS__:____:__HUMERORADIAL/MULTIPLE SYNOSTOSIS SYNDROME, INCLUDED
NULL__:__236410__:__HUMERORADIAL SYNOSTOSIS WITH CRANIOFACIAL ANOMALIES__:____:__
NULL__:__236450__:__HUTTERITE CEREBROOSTEONEPHRODYSPLASIA SYNDROME__:__COND;; CEREBROOSTEONEPHOSIS SYNDROME__:__
Caret__:__236490__:__MOVED TO 228600__:____:__
Number Sign__:__236500__:__MULTINUCLEATED NEURONS, ANHYDRAMNIOS, RENAL DYSPLASIA, CEREBELLAR HYPOPLASIA, AND HYDRANENCEPHALY; MARCH__:__HYDRANENCEPHALY WITH RENAL APLASIA-DYSPLASIA__:__
Number Sign__:__236600__:__HYDROCEPHALUS, CONGENITAL, 1; HYC1__:__HYDROCEPHALY;; VENTRICULOMEGALY;; HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1, FORMERLY__:__
NULL__:__236635__:__HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS__:__AQUEDUCTAL STENOSIS__:__
NULL__:__236640__:__HYDROCEPHALUS WITH ASSOCIATED MALFORMATIONS__:____:__
NULL__:__236660__:__HYDROCEPHALUS, TALL STATURE, JOINT LAXITY, AND KYPHOSCOLIOSIS__:____:__
Number Sign__:__236670__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT1-RELATED;; HYDROCEPHALUS, AGYRIA, AND RETINAL DYSPLASIA;; HARD SYNDROME;; CEREBROOCULAR DYSPLASIA-MUSCULAR DYSTROPHY SYNDROME;; COD-MD SYNDROME__:__
Number Sign__:__236680__:__HYDROLETHALUS SYNDROME 1; HLS1__:____:__
NULL__:__236690__:__HYDROCEPHALUS, NORMAL-PRESSURE__:____:__
Number Sign__:__236700__:__MCKUSICK-KAUFMAN SYNDROME; MKKS__:__HYDROMETROCOLPOS SYNDROME;; HYDROMETROCOLPOS, POSTAXIAL POLYDACTYLY, AND CONGENITAL HEART MALFORMATION; HMCS;; KAUFMAN-MCKUSICK SYNDROME__:__
Number Sign__:__236730__:__UROFACIAL SYNDROME 1; UFS1__:__UROFACIAL SYNDROME; UFS;; OCHOA SYNDROME;; HYDRONEPHROSIS WITH PECULIAR FACIAL EXPRESSION;; INVERTED SMILE AND OCCULT NEUROPATHIC BLADDER;; FACIAL PALSY, PARTIAL, WITH URINARY ABNORMALITIES__:__
Number Sign__:__236750__:__HYDROPS FETALIS, NONIMMUNE; NIHF__:____:__HYDROPS FETALIS, ALPHA-THALASSEMIA-RELATED, INCLUDED;; HEMOGLOBIN H HYDROPS FETALIS SYNDROME, INCLUDED
Number Sign__:__236792__:__L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA__:__L-2-HYDROXYGLUTARIC ACIDEMIA__:__
Percent__:__236795__:__3-HYDROXYISOBUTYRIC ACIDURIA__:____:__
Number Sign__:__236800__:__HYDROXYKYNURENINURIA__:__XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL__:__
Percent__:__236900__:__HYDROXYLYSINURIA__:____:__
NULL__:__237000__:__HYDROXYPROLINEMIA__:__4-HYDROXY-L-PROLINE OXIDASE DEFICIENCY__:__
NULL__:__237100__:__HYMEN, IMPERFORATE__:____:__
Number Sign__:__237300__:__CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO__:__CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY__:__
Number Sign__:__237310__:__N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY; NAGSD__:__HYPERAMMONEMIA DUE TO N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY;; N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY;; NAGS DEFICIENCY__:__
NULL__:__237400__:__HYPER-BETA-ALANINEMIA__:__HYPERALANINEMIA__:__
Number Sign__:__237450__:__HYPERBILIRUBINEMIA, ROTOR TYPE; HBLRR__:__ROTOR SYNDROME__:__
Number Sign__:__237500__:__DUBIN-JOHNSON SYNDROME; DJS__:__HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II__:__
NULL__:__237550__:__HYPERBILIRUBINEMIA, CONJUGATED, TYPE III__:____:__
Percent__:__237800__:__HYPERBILIRUBINEMIA, SHUNT, PRIMARY; PSHB__:____:__
Number Sign__:__237900__:__HYPERBILIRUBINEMIA, TRANSIENT FAMILIAL NEONATAL; HBLRTFN__:__LUCEY-DRISCOLL SYNDROME__:__BREAST MILK JAUNDICE, INCLUDED
Caret__:__238200__:__MOVED TO 220100__:____:__
Asterisk__:__238300__:__GLYCINE DECARBOXYLASE; GLDC__:__GLYCINE CLEAVAGE SYSTEM P PROTEIN; GCSP;; GLYCINE DEHYDROGENASE__:__
Asterisk__:__238310__:__AMINOMETHYLTRANSFERASE; AMT__:__GLYCINE CLEAVAGE SYSTEM T PROTEIN; GCST__:__
Number Sign__:__238320__:__LEYDIG CELL HYPOPLASIA, TYPE I__:__LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM;; HYPERGONADOTROPIC HYPOGONADISM, MALE, DUE TO LHCGR DEFECT;; LEYDIG CELL HYPOPLASIA, COMPLETE;; LEYDIG CELL AGENESIS__:__LEYDIG CELL HYPOPLASIA, TYPE II, INCLUDED;; LEYDIG CELL HYPOPLASIA, PARTIAL, INCLUDED;; LUTEINIZING HORMONE RESISTANCE, FEMALE, INCLUDED
Asterisk__:__238330__:__GLYCINE CLEAVAGE SYSTEM H PROTEIN; GCSH__:____:__
Asterisk__:__238331__:__DIHYDROLIPOAMIDE DEHYDROGENASE; DLD__:__PYRUVATE DEHYDROGENASE COMPONENT E3; PHE3; E3;; BRANCHED CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX, E3 COMPONENT;; LIPOAMIDE REDUCTASE;; LIPOAMIDE DEHYDROGENASE; LAD; LADH;; LIPOYL DEHYDROGENASE;; DIHYDROLIPOYL DEHYDROGENASE;; DIAPHORASE;; GLYCINE CLEAVAGE SYSTEM L PROTEIN; GCSL__:__
NULL__:__238340__:__HYPERLEUCINE-ISOLEUCINEMIA__:____:__
NULL__:__238350__:__HYPERLEXIA__:__COMPULSIVE READING;; PRECOCIOUS READING__:__
Caret__:__238400__:__MOVED TO 144650__:____:__
Caret__:__238500__:__MOVED TO 144650__:____:__
Number Sign__:__238600__:__HYPERLIPOPROTEINEMIA, TYPE I__:__LIPOPROTEIN LIPASE DEFICIENCY;; LPL DEFICIENCY;; HYPERCHYLOMICRONEMIA, FAMILIAL;; HYPERLIPEMIA, IDIOPATHIC, BURGER-GRUTZ TYPE;; HYPERLIPEMIA, ESSENTIAL FAMILIAL;; LIPASE D DEFICIENCY;; LIPD DEFICIENCY;; HYPERLIPOPROTEINEMIA, TYPE IA;; CHYLOMICRONEMIA, FAMILIAL__:__
Number Sign__:__238700__:__HYPERLYSINEMIA, TYPE I__:__LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY__:__
NULL__:__238710__:__HYPERLYSINEMIA DUE TO DEFECT IN LYSINE TRANSPORT INTO MITOCHONDRIA__:____:__
NULL__:__238750__:__HYPERLYSINURIA WITH HYPERAMMONEMIA__:__HYPERLYSINEMIA, PERIODIC__:__
NULL__:__238800__:__HYPERMETABOLISM DUE TO DEFECT IN MITOCHONDRIA__:____:__
NULL__:__238950__:__HYPEROPIA, HIGH__:____:__
Number Sign__:__238970__:__HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME__:__HHH SYNDROME; HHHS; HHH;; ORNITHINE TRANSLOCASE DEFICIENCY__:__
Number Sign__:__239000__:__PAGET DISEASE OF BONE 5, JUVENILE-ONSET; PDB5__:__JUVENILE PAGET DISEASE; JPD;; HYPEROSTOSIS CORTICALIS DEFORMANS JUVENILIS;; HYPERPHOSPHATASIA, FAMILIAL IDIOPATHIC;; HYPERPHOSPHATASEMIA, CHRONIC CONGENITAL IDIOPATHIC;; OSTEOECTASIA, FAMILIAL__:__
Number Sign__:__239100__:__VAN BUCHEM DISEASE; VBCH__:__HYPEROSTOSIS CORTICALIS GENERALISATA;; HYPERPHOSPHATASEMIA TARDA;; ENDOSTEAL HYPEROSTOSIS, AUTOSOMAL RECESSIVE__:__
NULL__:__239199__:__HYPERPARATHYROIDISM, NEONATAL SELF-LIMITED PRIMARY, WITH HYPERCALCIURIA__:____:__
Number Sign__:__239200__:__HYPERPARATHYROIDISM, NEONATAL SEVERE; NSHPT__:__NSPH; NHPT;; HYPERPARATHYROIDISM, NEONATAL SEVERE PRIMARY__:__
Number Sign__:__239300__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 1; HPMRS1__:__MABRY SYNDROME;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 2; GPIBD2__:__
NULL__:__239350__:__HYPERPHOSPHATEMIA, POLYURIA, AND SEIZURES__:____:__
Caret__:__239400__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__239500__:__HYPERPROLINEMIA, TYPE I; HYRPRO1__:__HPI;; PROLINE OXIDASE DEFICIENCY__:__
Number Sign__:__239510__:__HYPERPROLINEMIA, TYPE II; HYRPRO2__:__HPII;; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE DEFICIENCY__:__
NULL__:__239710__:__ACROFRONTOFACIONASAL DYSOSTOSIS 2__:__AFFN DYSOSTOSIS 2; AFFND2;; ACROFRONTOFACIONASAL DYSOSTOSIS WITH GENITOURINARY ANOMALIES;; NAGUIB-RICHIERI-COSTA SYNDROME;; HYPERTELORISM, HYPOSPADIAS, AND POLYSYNDACTYLY SYNDROME__:__
NULL__:__239711__:__HYPERTELORISM AND TETRALOGY OF FALLOT__:____:__
Percent__:__239800__:__HYPERTELORISM, MICROTIA, FACIAL CLEFTING SYNDROME__:__HMC SYNDROME__:__
NULL__:__239840__:__HYPERTRICHOSIS, CONGENITAL ANTERIOR CERVICAL, WITH PERIPHERAL SENSORY AND MOTOR NEUROPATHY__:____:__
Number Sign__:__239850__:__CANTU SYNDROME__:__HYPERTRICHOTIC OSTEOCHONDRODYSPLASIA__:__
NULL__:__239900__:__HYPERTROPHIC NEUROPATHY AND CATARACT__:____:__
NULL__:__240000__:__HYPERURICEMIA, INFANTILE, WITH ABNORMAL BEHAVIOR AND NORMAL HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE__:____:__
Caret__:__240100__:__REMOVED FROM DATABASE__:____:__
NULL__:__240150__:__HYPERVITAMINOSIS A, SUSCEPTIBILITY TO__:____:__
Percent__:__240200__:__HYPOADRENOCORTICISM, FAMILIAL__:__ADRENAL HYPOPLASIA;; ADRENAL APLASIA;; ADDISON DISEASE__:__
Number Sign__:__240300__:__AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE I, WITH OR WITHOUT REVERSIBLE METAPHYSEAL DYSPLASIA; APS1__:__APS I;; AUTOIMMUNE POLYENDOCRINOPATHY-CANDIDIASIS-ECTODERMAL DYSTROPHY; APECED;; AUTOIMMUNE POLYGLANDULAR SYNDROME, TYPE I;; POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE I;; PGA I;; HYPOADRENOCORTICISM WITH HYPOPARATHYROIDISM AND SUPERFICIAL MONILIASIS__:__AUTOIMMUNE POLYENDOCRINOPATHY SYNDROME, TYPE I, AUTOSOMAL DOMINANT, INCLUDED;; POLYGLANDULAR DEFICIENCY SYNDROME, PERSIAN-JEWISH TYPE, INCLUDED
NULL__:__240400__:__HYPOASCORBEMIA__:__SCURVY;; VITAMIN C, INABILITY TO SYNTHESIZE__:__L-GULONOLACTONE OXIDASE PSEUDOGENE, INCLUDED; GULOP, INCLUDED;; L-GULONOLACTONE OXIDASE, NONFUNCTIONAL, INCLUDED;; GULO, NONFUNCTIONAL, INCLUDED
Number Sign__:__240500__:__IMMUNODEFICIENCY, COMMON VARIABLE, 2; CVID2__:__ANTIBODY DEFICIENCY DUE TO TACI DEFECT;; HYPOGAMMAGLOBULINEMIA DUE TO TACI DEFICIENCY__:__
Number Sign__:__240600__:__GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A__:__GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0__:__
Number Sign__:__240800__:__HYPOGLYCEMIA, LEUCINE-INDUCED; LIH__:__LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY__:__
Number Sign__:__240900__:__HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY; HIHGHH__:____:__
NULL__:__240950__:__HYPOGONADISM-CATARACT SYNDROME__:__CATARACTS AND TESTICULAR FAILURE__:__
NULL__:__241000__:__HYPOGONADISM WITH LOW-GRADE MENTAL DEFICIENCY AND MICROCEPHALY__:____:__
Number Sign__:__241080__:__WOODHOUSE-SAKATI SYNDROME__:__HYPOGONADISM, ALOPECIA, DIABETES MELLITUS, MENTAL RETARDATION, DEAFNESS, AND EXTRAPYRAMIDAL SYNDROME;; EXTRAPYRAMIDAL DISORDER, PROGRESSIVE, WITH PRIMARY HYPOGONADISM, MENTAL RETARDATION, AND ALOPECIA__:__
Percent__:__241090__:__HYPERGONADOTROPIC HYPOGONADISM AND PARTIAL ALOPECIA__:____:__
NULL__:__241100__:__HYPOGONADISM, MALE__:____:__HYPOGONADISM AND TESTICULAR ATROPHY, INCLUDED
NULL__:__241120__:__HYPOHIDROSIS WITH ABNORMAL PALMAR DERMAL RIDGES__:__SWEAT GLAND HYPOPLASIA__:__
Percent__:__241150__:__HYPOKALEMIC ALKALOSIS, FAMILIAL, WITH SPECIFIC RENAL TUBULOPATHY__:__HYPOKALEMIA, FAMILIAL;; GULLNER SYNDROME__:__
Number Sign__:__241200__:__BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2__:__HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 2, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 2__:__
Percent__:__241310__:__HYPOMANDIBULAR FACIOCRANIAL DYSOSTOSIS__:____:__
Caret__:__241400__:__MOVED TO 146200__:____:__
Number Sign__:__241410__:__HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRDS__:__HYPOPARATHYROIDISM WITH SHORT STATURE, MENTAL RETARDATION, AND SEIZURES;; SANJAD-SAKATI SYNDROME;; HYPOPARATHYROIDISM, CONGENITAL, ASSOCIATED WITH DYSMORPHISM, GROWTH RETARDATION, AND DEVELOPMENTAL DELAY__:__
Number Sign__:__241500__:__HYPOPHOSPHATASIA, INFANTILE__:__HOPS;; PHOSPHOETHANOLAMINURIA__:__HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED
Number Sign__:__241510__:__HYPOPHOSPHATASIA, CHILDHOOD__:____:__
NULL__:__241519__:__HYPOPHOSPHATEMIA, RENAL, WITH INTRACEREBRAL CALCIFICATIONS__:____:__
Number Sign__:__241520__:__HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 1; ARHR1__:__ARHR;; HYPOPHOSPHATEMIA, AUTOSOMAL RECESSIVE; ARHP__:__
Number Sign__:__241530__:__HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA, HEREDITARY; HHRH__:__HYPERCALCIURIC RICKETS__:__
NULL__:__241540__:__HYPOPITUITARISM, CONGENITAL, WITH CENTRAL DIABETES INSIPIDUS__:____:__
Number Sign__:__241550__:__HYPOPLASTIC LEFT HEART SYNDROME 1; HLHS1__:__HLHS__:__
Number Sign__:__241600__:__IMMUNODEFICIENCY 43; IMD43__:__BETA-2-MICROGLOBULIN DEFICIENCY;; B2M DEFICIENCY;; HYPOPROTEINEMIA, HYPERCATABOLIC__:__
Caret__:__241750__:__MOVED TO 146450__:____:__
NULL__:__241760__:__HYPOSPADIAS-MENTAL RETARDATION SYNDROME__:____:__
NULL__:__241800__:__HYPOTHALAMIC HAMARTOMAS__:____:__CONGENITAL HYPOTHALAMIC HAMARTOMA SYNDROME, INCLUDED; CHHS, INCLUDED
Number Sign__:__241850__:__HYPOTHYROIDISM, THYROIDAL OR ATHYROIDAL, WITH SPIKY HAIR AND CLEFT PALATE__:__BAMFORTH-LAZARUS SYNDROME__:__
Caret__:__241900__:__MOVED TO 203655__:____:__
NULL__:__242050__:__HYPOURICEMIA, HYPERCALCINURIA, AND DECREASED BONE DENSITY__:____:__
Number Sign__:__242100__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 2; ARCI2__:__COLLODION BABY, SELF-HEALING;; ICHTHYOSIFORM ERYTHRODERMA, NONBULLOUS CONGENITAL, 1, FORMERLY; NCIE1, FORMERLY;; ICHTHYOSIFORM ERYTHRODERMA, BROCQ CONGENITAL, NONBULLOUS FORM, FORMERLY__:__
NULL__:__242150__:__ICHTHYOSIFORM ERYTHRODERMA, CORNEAL INVOLVEMENT, AND DEAFNESS__:__KERATITIS-ICHTHYOSIS-DEAFNESS SYNDROME, AUTOSOMAL RECESSIVE;; KID SYNDROME, AUTOSOMAL RECESSIVE;; DESMONS SYNDROME__:__
Caret__:__242170__:__MOVED TO 601675__:____:__
Number Sign__:__242300__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1; ARCI1__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 1, WITH BATHING SUIT DISTRIBUTION;; COLLODION BABY, SELF-HEALING; SHCB;; ICHTHYOSIS CONGENITA;; LAMELLAR EXFOLIATION OF NEWBORN;; DESQUAMATION OF NEWBORN;; COLLODION FETUS;; ICHTHYOSIS CONGENITA II; ICR2;; ICHTHYOSIS, LAMELLAR, 1, FORMERLY; LI1, FORMERLY__:__
NULL__:__242400__:__ICHTHYOSIS CONGENITA WITH BILIARY ATRESIA__:____:__
Number Sign__:__242500__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4B; ARCI4B__:__ICHTHYOSIS CONGENITA, HARLEQUIN FETUS TYPE;; HARLEQUIN ICHTHYOSIS; HI;; 'HARLEQUIN FETUS'__:__
NULL__:__242510__:__ICHTHYOSIS WITH ALOPECIA, ECLABIUM, ECTROPION, AND MENTAL RETARDATION__:____:__
NULL__:__242520__:__ICHTHYOSIS, HEPATOSPLENOMEGALY, AND CEREBELLAR DEGENERATION__:____:__
NULL__:__242530__:__ICHTHYOSIS, MENTAL RETARDATION, DWARFISM, AND RENAL IMPAIRMENT__:____:__
NULL__:__242550__:__ICHTHYOSIS, SPLIT HAIRS, AND AMINO ACIDURIA__:____:__
Number Sign__:__242600__:__IMINOGLYCINURIA__:____:__
Caret__:__242650__:__MOVED TO 244400__:____:__
Percent__:__242670__:__CILIARY DYSKINESIA WITH DEFECTIVE RADIAL SPOKES__:__IMMOTILE CILIA SYNDROME DUE TO DEFECTIVE RADIAL SPOKES__:__
NULL__:__242680__:__CILIARY DYSKINESIA WITH EXCESSIVELY LONG CILIA__:__IMMOTILE CILIA SYNDROME DUE TO EXCESSIVELY LONG CILIA__:__
Percent__:__242700__:__IMMUNE DEFECT DUE TO ABSENCE OF THYMUS__:__T-LYMPHOCYTE DEFICIENCY;; NEZELOF SYNDROME;; THYMIC APLASIA__:__
Caret__:__242800__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__242840__:__VICI SYNDROME; VICIS__:__IMMUNODEFICIENCY WITH CLEFT LIP/PALATE, CATARACT, HYPOPIGMENTATION, AND ABSENT CORPUS CALLOSUM__:__
NULL__:__242850__:__IMMUNE DEFICIENCY DISEASE__:____:__
Number Sign__:__242860__:__IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 1; ICF1__:__IMMUNE DEFICIENCY, VARIABLE, WITH CENTROMERIC INSTABILITY OF CHROMOSOMES 1, 9, AND 16;; CENTROMERIC INSTABILITY, IMMUNODEFICIENCY SYNDROME; CIID;; IMMUNODEFICIENCY SYNDROME, VARIABLE__:__
NULL__:__242870__:__IMMUNODEFICIENCY, PARTIAL COMBINED, WITH ABSENCE OF HLA DETERMINANTS AND BETA-2-MICROGLOBULIN FROM LYMPHOCYTES__:____:__
NULL__:__242880__:__IMMUNOERYTHROMYELOID HYPOPLASIA__:____:__
NULL__:__242890__:__IMMUNOGLOBULIN D LEVEL IN PLASMA, LOW__:____:__
Number Sign__:__242900__:__SCHIMKE IMMUNOOSSEOUS DYSPLASIA; SIOD__:__IMMUNOOSSEOUS DYSPLASIA, SCHIMKE TYPE__:__
Number Sign__:__243000__:__INDIFFERENCE TO PAIN, CONGENITAL, AUTOSOMAL RECESSIVE; CIP__:__INSENSITIVITY TO PAIN, CHANNELOPATHY-ASSOCIATED;; CONGENITAL ANALGESIA, AUTOSOMAL RECESSIVE;; ASYMBOLIA FOR PAIN__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IID, INCLUDED; HSAN2D, INCLUDED
NULL__:__243050__:__INDOLYLACROYL GLYCINURIA WITH MENTAL RETARDATION__:____:__
Number Sign__:__243060__:__SPERMATOGENIC FAILURE 5; SPGF5__:__MALE INFERTILITY WITH LARGE-HEADED, MULTIFLAGELLAR, POLYPLOID SPERMATOZOA;; INFERTILITY ASSOCIATED WITH MULTITAILED SPERMATOZOA AND EXCESSIVE DNA__:__
NULL__:__243080__:__INOSINE PHOSPHORYLASE DEFICIENCY, IMMUNE DEFECT DUE TO__:____:__
Caret__:__243095__:__MOVED TO 270450__:____:__
NULL__:__243100__:__INTERNAL CAROTID ARTERIES, HYPOPLASIA OF__:____:__
NULL__:__243110__:__IMMUNODEFICIENCY WITH DEFECTIVE T-CELL RESPONSE TO INTERLEUKIN 1__:__INTERLEUKIN 1, DEFECTIVE T-CELL RESPONSE TO__:__
Number Sign__:__243150__:__GASTROINTESTINAL DEFECTS AND IMMUNODEFICIENCY SYNDROME; GIDID__:__INTESTINAL ATRESIA, MULTIPLE AND/OR INFLAMMATORY BOWEL DISEASE WITH OR WITHOUT IMMUNODEFICIENCY;; INTESTINAL ATRESIA, MULTIPLE; MINAT;; FAMILIAL INTESTINAL POLYATRESIA SYNDROME; FIPA__:__
Percent__:__243180__:__VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE__:__INTESTINAL PSEUDOOBSTRUCTION DUE TO NEURONAL DISEASE;; ARGYROPHIL MYENTERIC PLEXUS, DEFICIENCY OF;; PSEUDOOBSTRUCTION, CHRONIC IDIOPATHIC INTESTINAL, NEURONAL TYPE__:__NEURONAL INTESTINAL DYSPLASIA, TYPE A, INCLUDED;; NID A, INCLUDED
NULL__:__243185__:__INTESTINAL PSEUDOOBSTRUCTION WITH PATENT DUCTUS ARTERIOSUS AND NATAL TEETH__:____:__
NULL__:__243200__:__INTRACRANIAL HYPERTENSION, IDIOPATHIC__:__PSEUDOTUMOR CEREBRI__:__
Number Sign__:__243300__:__CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 1; BRIC1__:__SUMMERSKILL SYNDROME__:__
Asterisk__:__243305__:__INVERSIN; INVS__:__INVERSION OF EMBRYONIC TURNING; INV;; NEPHROCYSTIN 2; NPHP2__:__
Number Sign__:__243310__:__BARAITSER-WINTER SYNDROME 1; BRWS1__:__IRIS COLOBOMA WITH PTOSIS, HYPERTELORISM, AND MENTAL RETARDATION;; FRYNS-AFTIMOS SYNDROME;; PACHYGYRIA, MENTAL RETARDATION, EPILEPSY, AND CHARACTERISTIC FACIES;; CEREBROOCULOFACIAL LYMPHATIC SYNDROME; COFLS;; MENTAL RETARDATION WITH EPILEPSY AND CHARACTERISTIC FACIES;; CEREBROFRONTOFACIAL SYNDROME;; CHROMOSOME 7p22 DELETION SYNDROME__:__
NULL__:__243320__:__INTRINSIC FACTOR AND R BINDER, COMBINED CONGENITAL DEFICIENCY OF__:____:__
Caret__:__243340__:__MOVED TO 242860__:____:__
Number Sign__:__243400__:__ACETYLATION, SLOW__:__SLOW ACETYLATOR PHENOTYPE;; ISONIAZID INACTIVATION, SLOW;; INH INACTIVATION, SLOW__:__ACETYLATION, FAST, INCLUDED;; FAST ACETYLATOR PHENOTYPE, INCLUDED;; INH INACTIVATION, FAST, INCLUDED
NULL__:__243440__:__ISOTRETINOIN EMBRYOPATHY-LIKE SYNDROME__:__MICROTIA-AORTIC ARCH SYNDROME__:__
NULL__:__243450__:__ISOVALERIC ACID, INABILITY TO SMELL__:____:__
Number Sign__:__243500__:__ISOVALERIC ACIDEMIA; IVA__:__ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY__:__
Percent__:__243600__:__JEJUNAL ATRESIA__:__APPLE PEEL SYNDROME;; APPLE PEEL SMALL BOWEL SYNDROME; APSB__:__
Number Sign__:__243605__:__STROMME SYNDROME; STROMS__:__JEJUNAL ATRESIA WITH MICROCEPHALY AND OCULAR ANOMALIES;; APPLE PEEL SYNDROME WITH MICROCEPHALY AND OCULAR ANOMALIES;; CILIARY DYSKINESIA, PRIMARY, 31, FORMERLY; CILD31, FORMERLY__:__
Number Sign__:__243700__:__HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE; HIES2__:__HYPER-IgE SYNDROME, AUTOSOMAL RECESSIVE;; HIES, AUTOSOMAL RECESSIVE__:__
Number Sign__:__243800__:__JOHANSON-BLIZZARD SYNDROME; JBS__:__NASAL ALAR HYPOPLASIA, HYPOTHYROIDISM, PANCREATIC ACHYLIA, AND CONGENITAL DEAFNESS__:__
Percent__:__243910__:__ARIMA SYNDROME__:__DEKABAN-ARIMA SYNDROME;; JOUBERT SYNDROME WITH BILATERAL CHORIORETINAL COLOBOMA;; COLOBOMA, CHORIORETINAL, WITH CEREBELLAR VERMIS APLASIA;; CEREBROOCULOHEPATORENAL SYNDROME__:__
NULL__:__244100__:__JUMPING FRENCHMEN OF MAINE__:____:__
Number Sign__:__244200__:__HYPOGONADOTROPIC HYPOGONADISM 3 WITH OR WITHOUT ANOSMIA; HH3__:____:__
Percent__:__244300__:__KAPUR-TORIELLO SYNDROME__:__LONG COLUMELLA WITH CLEFT LIP/PALATE AND EYE, HEART, AND INTESTINAL ANOMALIES__:__
Number Sign__:__244400__:__CILIARY DYSKINESIA, PRIMARY, 1; CILD1__:__PCD;; CILIARY DYSKINESIA, PRIMARY, 1, WITH OR WITHOUT SITUS INVERSUS;; IMMOTILE CILIA SYNDROME; ICS;; POLYNESIAN BRONCHIECTASIS__:__KARTAGENER SYNDROME, INCLUDED;; DEXTROCARDIA, BRONCHIECTASIS, AND SINUSITIS, INCLUDED;; SIEWERT SYNDROME, INCLUDED
Number Sign__:__244450__:__KAUFMAN OCULOCEREBROFACIAL SYNDROME; KOS__:__BLEPHAROPHIMOSIS-PTOSIS-INTELLECTUAL DISABILITY SYNDROME; BPIDS__:__
Number Sign__:__244460__:__KENNY-CAFFEY SYNDROME, TYPE 1; KCS1__:__KCS;; KENNY-CAFFEY SYNDROME, AUTOSOMAL RECESSIVE__:__
Caret__:__244500__:__MOVED TO 148300__:____:__
NULL__:__244510__:__KERATOCONUS AND CONGENITAL HIP DYSPLASIA__:____:__
NULL__:__244600__:__KERATOCONUS POSTICUS CIRCUMSCRIPTUS; KPC__:____:__KPC WITH ASSOCIATED MALFORMATIONS, INCLUDED
NULL__:__244850__:__PALMOPLANTAR KERATODERMA, NORRBOTTEN RECESSIVE TYPE; PPKNR__:____:__
Number Sign__:__245000__:__PAPILLON-LEFEVRE SYNDROME; PALS__:__PLS;; KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA__:__
Number Sign__:__245010__:__HAIM-MUNK SYNDROME; HMS__:__KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER__:__
Number Sign__:__245050__:__SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE DEFICIENCY; SCOTD__:__SCOT DEFICIENCY;; SUCCINYL-CoA:3-KETOACID CoA-TRANSFERASE DEFICIENCY;; SUCCINYL-CoA:ACETOACETATE TRANSFERASE DEFICIENCY;; KETOACIDOSIS DUE TO SCOT DEFICIENCY__:__
Percent__:__245100__:__RICHARDS-RUNDLE SYNDROME; RRNS__:__ATAXIA-DEAFNESS-MENTAL RETARDATION SYNDROME__:__
NULL__:__245130__:__KETOADIPICACIDURIA__:____:__
Number Sign__:__245150__:__KEUTEL SYNDROME; KTLS__:__PULMONIC STENOSIS, BRACHYTELEPHALANGISM, AND CALCIFICATION OF CARTILAGES__:__
NULL__:__245160__:__KNIEST-LIKE DYSPLASIA WITH PURSED LIPS AND ECTOPIA LENTIS__:__BURTON SYNDROME__:__
NULL__:__245180__:__KIFAFA SEIZURE DISORDER__:____:__
NULL__:__245190__:__KNIEST-LIKE DYSPLASIA, LETHAL__:____:__
Number Sign__:__245200__:__KRABBE DISEASE__:__GLOBOID CELL LEUKODYSTROPHY; GLD; GCL;; GLOBOID CELL LEUKOENCEPHALOPATHY;; GALACTOSYLCERAMIDE BETA-GALACTOSIDASE DEFICIENCY;; GALACTOCEREBROSIDASE DEFICIENCY;; GALC DEFICIENCY__:__
Caret__:__245210__:__MOVED TO 192430 AND 188400__:____:__
Number Sign__:__245300__:__KURU, SUSCEPTIBILITY TO__:____:__
Number Sign__:__245340__:__ERYTHROCYTE LACTATE TRANSPORTER DEFECT__:__LACTATE TRANSPORTER DEFECT, MYOPATHY DUE TO__:__
Number Sign__:__245348__:__PYRUVATE DEHYDROGENASE E2 DEFICIENCY; PDHDD__:__LACTIC ACIDEMIA DUE TO DEFECT OF E2 LIPOYL TRANSACETYLASE OF THE PYRUVATE DEHYDROGENASE COMPLEX__:__
Number Sign__:__245349__:__PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY; PDHXD__:__LACTIC ACIDEMIA DUE TO DEFECT IN LIPOYL-CONTAINING COMPONENT X OF THE PYRUVATE DEHYDROGENASE COMPLEX__:__
Number Sign__:__245400__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 9 (ENCEPHALOMYOPATHIC TYPE WITH METHYLMALONIC ACIDURIA); MTDPS9__:__LACTIC ACIDOSIS, FATAL INFANTILE, FORMERLY__:__
NULL__:__245450__:__LACTIC ACIDURIA DUE TO D-LACTIC ACID__:____:__
Number Sign__:__245480__:__SPECIFIC GRANULE DEFICIENCY 1; SGD1__:__LACTOFERRIN-DEFICIENT NEUTROPHILS;; NEUTROPHIL LACTOFERRIN DEFICIENCY__:__
Caret__:__245500__:__REMOVED FROM DATABASE__:____:__
NULL__:__245550__:__LAMBERT SYNDROME__:__BRANCHIAL DYSPLASIA, CLUBFOOT, INGUINAL HERNIA, AND BILIARY ATRESIA__:__
NULL__:__245552__:__LAMBOTTE SYNDROME__:__MICROCEPHALY, HOLOPROSENCEPHALY, AND INTRAUTERINE GROWTH RETARDATION__:__
Number Sign__:__245570__:__EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT MENTAL RETARDATION; FESD__:__APHASIA, ACQUIRED, WITH EPILEPSY__:__LANDAU-KLEFFNER SYNDROME, INCLUDED; LKS, INCLUDED;; CONTINUOUS SPIKE AND WAVES DURING SLOW-WAVE SLEEP SYNDROME, INCLUDED; CSWS, INCLUDED; CSWSS, INCLUDED;; ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, AUTOSOMAL DOMINANT, INCLUDED; RESDAD, INCLUDED; ADRESD, INCLUDED;; BENIGN EPILEPSY OF CHILDHOOD WITH CENTROTEMPORAL SPIKES, INCLUDED; BECTS, INCLUDED
Number Sign__:__245590__:__GROWTH HORMONE INSENSITIVITY WITH IMMUNODEFICIENCY__:__LARON SYNDROME DUE TO POSTRECEPTOR DEFECT;; GROWTH HORMONE INSENSITIVITY DUE TO POSTRECEPTOR DEFECT__:__
Number Sign__:__245600__:__MULTIPLE JOINT DISLOCATIONS, SHORT STATURE, AND CRANIOFACIAL DYSMORPHISM WITH OR WITHOUT CONGENITAL HEART DEFECTS; JDSCD__:__LARSEN SYNDROME, AUTOSOMAL RECESSIVE, FORMERLY__:__
NULL__:__245650__:__LARSEN-LIKE SYNDROME, LETHAL TYPE__:____:__
Number Sign__:__245660__:__LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS__:__LOGIC SYNDROME__:__
Number Sign__:__245800__:__LAURENCE-MOON SYNDROME; LNMS__:____:__
Number Sign__:__245900__:__LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY__:__LCAT DEFICIENCY;; NORUM DISEASE__:__
Percent__:__246000__:__LEG, ABSENCE DEFORMITY OF, WITH CONGENITAL CATARACT__:____:__
Number Sign__:__246200__:__DONOHUE SYNDROME__:__LEPRECHAUNISM__:__INSULIN RECEPTOR, DEFECT IN, INCLUDED
Number Sign__:__246300__:__LEPROSY, SUSCEPTIBILITY TO, 3; LPRS3__:____:__
Percent__:__246400__:__LETTERER-SIWE DISEASE__:__L-S DISEASE; LESD;; HISTIOCYTOSIS X, ACUTE DISSEMINATED__:__
Number Sign__:__246450__:__3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD__:__HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA__:__
NULL__:__246470__:__LEUKEMIA, ACUTE MYELOCYTIC, WITH POLYPOSIS COLI AND COLON CANCER__:____:__
Caret__:__246490__:__MOVED TO 266265__:____:__
NULL__:__246500__:__LEUKOMELANODERMA, INFANTILISM, MENTAL RETARDATION, HYPODONTIA, HYPOTRICHOSIS__:____:__
Asterisk__:__246530__:__LEUKOTRIENE C4 SYNTHASE; LTC4S__:____:__
NULL__:__246550__:__LICHTENSTEIN SYNDROME__:____:__
NULL__:__246555__:__LIMB DEFECTS, DISTAL TRANSVERSE, WITH MENTAL RETARDATION AND SPASTICITY__:____:__
Number Sign__:__246560__:__SPLIT-HAND/FOOT MALFORMATION 3; SHFM3__:__SHSF3;; LIMB DEFICIENCIES, DISTAL, WITH MICROGNATHIA;; CHROMOSOME 10q24 DUPLICATION SYNDROME__:__
NULL__:__246570__:__FIBULAR APLASIA, TIBIAL CAMPOMELIA, AND OLIGOSYNDACTYLY SYNDROME__:__FATCO SYNDROME__:__
Asterisk__:__246600__:__PANCREATIC LIPASE; PNLIP__:__PL;; LIPASE, PANCREATIC__:__
Number Sign__:__246650__:__LIPASE DEFICIENCY, COMBINED__:__LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY__:__
Number Sign__:__246700__:__CHYLOMICRON RETENTION DISEASE; CMRD__:__ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS__:__
Caret__:__246800__:__MOVED TO 257220__:____:__
Number Sign__:__246900__:__DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD__:__DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III__:__
Number Sign__:__247100__:__LIPOID PROTEINOSIS OF URBACH AND WIETHE__:__LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE__:__
NULL__:__247150__:__LIP PRINTS__:____:__
Number Sign__:__247200__:__MILLER-DIEKER LISSENCEPHALY SYNDROME; MDLS__:__MDS__:__CHROMOSOME 17p13.3 DELETION SYNDROME, INCLUDED;; MILLER-DIEKER SYNDROME CHROMOSOME REGION, INCLUDED; MDCR, INCLUDED
Caret__:__247400__:__MOVED TO 210710__:____:__
NULL__:__247410__:__LYMPHEDEMA-HYPOPARATHYROIDISM SYNDROME__:__HYPOPARATHYROIDISM-LYMPHEDEMA SYNDROME__:__
Number Sign__:__247420__:__LUTHERAN NULL__:__RECESSIVE LU (a-b-) PHENOTYPE__:__
NULL__:__247430__:__LYMPHOBLASTIC TRANSFORMATION, INHIBITION OF__:____:__
Caret__:__247440__:__MOVED TO 153100 AND 616843__:____:__
NULL__:__247450__:__LYMPHOBLASTIC TRANSFORMATION, INTRINSIC DEFECT IN__:____:__
NULL__:__247610__:__LYMPHOID INTERSTITIAL PNEUMONIA; LIP__:____:__
NULL__:__247630__:__LYMPHOID SYSTEM DETERIORATION, PROGRESSIVE__:____:__
NULL__:__247640__:__LYMPHOBLASTIC LEUKEMIA, ACUTE, WITH LYMPHOMATOUS FEATURES; LALL__:__LYMPHOMATOUS ALL__:__
NULL__:__247650__:__LYMPHOKINE DEFICIENCY__:____:__
Percent__:__247800__:__LYMPHOPENIC HYPERGAMMAGLOBULINEMIA, ANTIBODY DEFICIENCY, AUTOIMMUNE HEMOLYTIC ANEMIA, AND GLOMERULONEPHRITIS__:____:__
Caret__:__247900__:__MOVED TO 238700__:____:__
NULL__:__247950__:__LYSINE MALABSORPTION SYNDROME__:____:__
Asterisk__:__247980__:__LIPASE B, LYSOSOMAL ACID; LIPB__:__LYSOSOMAL ACID LIPASE-B__:__
NULL__:__247990__:__MACDERMOT-WINTER SYNDROME__:____:__
Number Sign__:__248000__:__MACROCEPHALY/MEGALENCEPHALY SYNDROME, AUTOSOMAL RECESSIVE; MGCPH__:____:__
NULL__:__248010__:__MACROEPIPHYSEAL DYSPLASIA WITH OSTEOPOROSIS, WRINKLED SKIN, AND AGED APPEARANCE__:____:__
NULL__:__248100__:__MACROSOMIA ADIPOSA CONGENITA__:____:__
NULL__:__248110__:__MACROSOMIA WITH MICROPHTHALMIA, LETHAL__:____:__
Number Sign__:__248190__:__HYPOMAGNESEMIA 5, RENAL, WITH OR WITHOUT OCULAR INVOLVEMENT; HOMG5__:__HYPOMAGNESEMIA, RENAL, WITH OCULAR INVOLVEMENT;; HYPOMAGNESEMIA, FAMILIAL, WITH HYPERCALCIURIA, NEPHROCALCINOSIS, AND SEVERE OCULAR INVOLVEMENT;; FHHNC WITH SEVERE OCULAR INVOLVEMENT;; MACULAR COLOBOMA, BILATERAL, WITH HYPERCALCIURIA__:__
Number Sign__:__248200__:__STARGARDT DISEASE 1; STGD1__:__STGD;; MACULAR DEGENERATION, JUVENILE;; MACULAR DYSTROPHY WITH FLECKS, TYPE 1__:__FUNDUS FLAVIMACULATUS, INCLUDED; FFM, INCLUDED;; RETINAL DYSTROPHY, EARLY-ONSET SEVERE, INCLUDED
Number Sign__:__248250__:__HYPOMAGNESEMIA 3, RENAL; HOMG3__:__HYPOMAGNESEMIA, PRIMARY, DUE TO DEFECT IN RENAL TUBULAR TRANSPORT OF MAGNESIUM;; HYPOMAGNESEMIA, ISOLATED RENAL;; HYPOMAGNESEMIA, FAMILIAL, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS__:__HYPERCALCIURIA, CHILDHOOD, SELF-LIMITING, INCLUDED
NULL__:__248260__:__MAGNESIUM, ELEVATED RED CELL__:____:__
Number Sign__:__248300__:__MAL DE MELEDA; MDM__:__MELEDA DISEASE;; KERATOSIS PALMOPLANTARIS TRANSGREDIENS OF SIEMENS__:__
Percent__:__248310__:__PLASMODIUM FALCIPARUM BLOOD INFECTION LEVEL__:__PFBI;; PLASMODIUM FALCIPARUM PARASITEMIA__:__
Number Sign__:__248340__:__3MC SYNDROME 3; 3MC3__:__FACIAL CLEFTING SYNDROME, GYPSY TYPE;; MALPUECH FACIAL CLEFTING SYNDROME, FORMERLY__:__
NULL__:__248350__:__MALOCCLUSION AND SHORT STATURE__:____:__
Number Sign__:__248360__:__MALONYL-CoA DECARBOXYLASE DEFICIENCY__:____:__
Number Sign__:__248370__:__MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY; MADA__:__LIPODYSTROPHY, TYPE A, ASSOCIATED WITH MANDIBULOACRAL DYSPLASIA;; CRANIOMANDIBULAR DERMATODYSOSTOSIS__:__MANDIBULOACRAL DYSPLASIA WITH TYPE A LIPODYSTROPHY, ATYPICAL, INCLUDED
Number Sign__:__248390__:__TREACHER COLLINS SYNDROME 3; TCS3__:__MANDIBULOFACIAL DYSOSTOSIS, TREACHER COLLINS TYPE, AUTOSOMAL RECESSIVE__:__
NULL__:__248400__:__MANDIBULOFACIAL DYSOSTOSIS WITH MENTAL RETARDATION__:____:__
Number Sign__:__248450__:__MANITOBA OCULOTRICHOANAL SYNDROME; MOTA__:__MARLES SYNDROME__:__
Number Sign__:__248500__:__MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA__:__ALPHA-MANNOSIDOSIS;; LYSOSOMAL ALPHA-D-MANNOSIDASE DEFICIENCY;; ALPHA-MANNOSIDASE B DEFICIENCY__:__
Number Sign__:__248510__:__MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB__:__BETA-MANNOSIDOSIS;; LYSOSOMAL BETA-MANNOSIDASE DEFICIENCY;; BETA-MANNOSIDASE DEFICIENCY__:__
Number Sign__:__248600__:__MAPLE SYRUP URINE DISEASE; MSUD__:__BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY__:__MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED
Asterisk__:__248610__:__DIHYDROLIPOAMIDE BRANCHED-CHAIN TRANSACYLASE; DBT__:__BRANCHED-CHAIN ACYLTRANSFERASE, E2 COMPONENT; BCATE2;; BRANCHED-CHAIN KETO ACID DEHYDROGENASE COMPLEX, E2 COMPONENT__:__
Asterisk__:__248611__:__BRANCHED-CHAIN KETO ACID DEHYDROGENASE E1, BETA POLYPEPTIDE; BCKDHB__:__E1B__:__
Number Sign__:__248700__:__MARDEN-WALKER SYNDROME; MWKS__:__MWS__:__
Caret__:__248750__:__MOVED TO 154700__:____:__
NULL__:__248760__:__MARFANOID HABITUS WITH MICROCEPHALY AND GLOMERULONEPHRITIS__:____:__
NULL__:__248770__:__MARFANOID MENTAL RETARDATION SYNDROME, AUTOSOMAL__:____:__
Number Sign__:__248800__:__MARINESCO-SJOGREN SYNDROME; MSS__:____:__
Caret__:__248810__:__MOVED TO 248800__:____:__
Number Sign__:__248900__:__MAST SYNDROME__:__SPASTIC PARAPLEGIA 21, AUTOSOMAL RECESSIVE; SPG21__:__
NULL__:__248910__:__CUTANEOUS MASTOCYTOSIS, CONDUCTIVE HEARING LOSS AND MICROTIA__:____:__
NULL__:__248950__:__MCDONOUGH SYNDROME__:____:__
Number Sign__:__249000__:__MECKEL SYNDROME, TYPE 1; MKS1__:__MECKEL-GRUBER SYNDROME, TYPE 1;; MECKEL SYNDROME; MKS;; MES;; DYSENCEPHALIA SPLANCHNOCYSTICA;; GRUBER SYNDROME;; MECKEL-GRUBER SYNDROME__:__
Number Sign__:__249100__:__FAMILIAL MEDITERRANEAN FEVER; FMF__:__FAMILIAL MEDITERRANEAN FEVER, AUTOSOMAL RECESSIVE;; POLYSEROSITIS, RECURRENT;; POLYSEROSITIS, FAMILIAL PAROXYSMAL__:__
Caret__:__249210__:__MOVED TO 155310__:____:__
NULL__:__249230__:__MEGAEPIPHYSEAL DWARFISM__:____:__
NULL__:__249240__:__MEGALENCEPHALY WITH DYSMYELINATION__:__MEGALENCEPHALY WITH DIFFUSE WHITE MATTER HYPODENSITY__:__
Number Sign__:__249270__:__THIAMINE-RESPONSIVE MEGALOBLASTIC ANEMIA SYNDROME; TRMA__:__THIAMINE METABOLISM DYSFUNCTION SYNDROME 1 (MEGALOBLASTIC ANEMIA, DIABETES MELLITUS, AND DEAFNESS TYPE); THMD1;; MEGALOBLASTIC ANEMIA, THIAMINE-RESPONSIVE, WITH DIABETES MELLITUS AND SENSORINEURAL DEAFNESS;; ROGERS SYNDROME;; THIAMINE-RESPONSIVE ANEMIA SYNDROME;; THIAMINE-RESPONSIVE MYELODYSPLASIA__:__
NULL__:__249300__:__MEGALOCORNEA__:____:__
Percent__:__249310__:__MEGALOCORNEA-MENTAL RETARDATION SYNDROME__:__MMR SYNDROME;; NEUHAUSER SYNDROME__:__
Number Sign__:__249400__:__MELANOSIS, NEUROCUTANEOUS; NCMS__:__NEUROMELANOSIS__:__
Number Sign__:__249420__:__FRANK-TER HAAR SYNDROME; FTHS__:__TER HAAR SYNDROME;; BORRONE DERMATOCARDIOSKELETAL SYNDROME;; MELNICK-NEEDLES SYNDROME, AUTOSOMAL RECESSIVE, FORMERLY__:__
Number Sign__:__249500__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 1; MRT1__:____:__
NULL__:__249599__:__MENTAL RETARDATION SYNDROME, BELGIAN TYPE__:____:__
NULL__:__249600__:__MENTAL RETARDATION SYNDROME, MIETENS-WEBER TYPE__:__MIETENS-WEBER SYNDROME__:__
Percent__:__249620__:__OHDO SYNDROME__:__OHDO BLEPHAROPHIMOSIS SYNDROME;; MENTAL RETARDATION, CONGENITAL HEART DISEASE, BLEPHAROPHIMOSIS, BLEPHAROPTOSIS, AND HYPOPLASTIC TEETH__:__
NULL__:__249630__:__MENTAL RETARDATION, BUENOS AIRES TYPE__:__MUTCHINICK SYNDROME__:__
Percent__:__249650__:__MERCAPTOLACTATE-CYSTEINE DISULFIDURIA; MCDU__:__DISULFIDURIA, MIXED__:__
NULL__:__249660__:__MESANGIAL SCLEROSIS, DIFFUSE RENAL, WITH OCULAR ABNORMALITIES__:____:__
NULL__:__249670__:__MESOAXIAL HEXADACTYLY AND CARDIAC MALFORMATION__:__MEXICAN CARDIOMELIC DYSPLASIA__:__
Number Sign__:__249700__:__LANGER MESOMELIC DYSPLASIA; LMD__:__DYSCHONDROSTEOSIS, HOMOZYGOUS;; MESOMELIC DWARFISM OF THE HYPOPLASTIC ULNA, FIBULA, AND MANDIBLE TYPE__:__
NULL__:__249710__:__MESOMELIC LIMB SHORTENING AND BOWING__:____:__
Caret__:__249800__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__249900__:__METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY__:__METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATOR DEFICIENCY;; SAPOSIN B DEFICIENCY__:__
Number Sign__:__250100__:__METACHROMATIC LEUKODYSTROPHY; MLD__:__METACHROMATIC LEUKOENCEPHALOPATHY;; CEREBRAL SCLEROSIS, DIFFUSE, METACHROMATIC FORM;; SULFATIDE LIPIDOSIS;; ARYLSULFATASE A DEFICIENCY;; ARSA DEFICIENCY;; CEREBROSIDE SULFATASE DEFICIENCY__:__PSEUDOARYLSULFATASE A DEFICIENCY, INCLUDED;; METACHROMATIC LEUKODYSTROPHY, LATE INFANTILE, INCLUDED;; METACHROMATIC LEUKODYSTROPHY, JUVENILE, INCLUDED;; METACHROMATIC LEUKODYSTROPHY, ADULT, INCLUDED
Percent__:__250215__:__METAPHYSEAL ACROSCYPHODYSPLASIA__:__WEDGE-SHAPED EPIPHYSES OF KNEES;; CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES OF KNEES WITH BRACHYDACTYLY__:__
Number Sign__:__250220__:__SPONDYLOMETAPHYSEAL DYSPLASIA, SEDAGHATIAN TYPE; SMDS__:__SEDAGHATIAN CHONDRODYSPLASIA;; METAPHYSEAL CHONDRODYSPLASIA, CONGENITAL LETHAL__:__
NULL__:__250230__:__METAPHYSEAL CHONDRODYSPLASIA, KAITILA TYPE__:____:__
Number Sign__:__250250__:__CARTILAGE-HAIR HYPOPLASIA; CHH__:__METAPHYSEAL CHONDRODYSPLASIA, MCKUSICK TYPE__:__
NULL__:__250300__:__METAPHYSEAL CHONDRODYSPLASIA, PENA TYPE__:____:__
Number Sign__:__250400__:__METAPHYSEAL DYSPLASIA, SPAHR TYPE; MDST__:__METAPHYSEAL CHONDRODYSPLASIA, SPAHR TYPE__:__
Number Sign__:__250410__:__RETINITIS PIGMENTOSA WITH OR WITHOUT SKELETAL ANOMALIES; RPSKA__:__METAPHYSEAL CHONDRODYSPLASIA WITH RETINITIS PIGMENTOSA__:__
NULL__:__250420__:__METAPHYSEAL DYSOSTOSIS, MENTAL RETARDATION, AND CONDUCTIVE DEAFNESS__:____:__
NULL__:__250450__:__METAPHYSEAL DYSPLASIA, ANETODERMA, AND OPTIC ATROPHY__:____:__
Number Sign__:__250460__:__METAPHYSEAL DYSPLASIA WITHOUT HYPOTRICHOSIS; MDWH__:__CARTILAGE-HAIR HYPOPLASIA-LIKE SKELETAL DYSPLASIA WITHOUT HYPOTRICHOSIS OR IMMUNODEFICIENCY;; CARTILAGE-HAIR HYPOPLASIA VARIANT, SKELETAL MANIFESTATIONS ONLY; CHHV__:__
NULL__:__250500__:__METAPHYSEAL MODELING ABNORMALITY, SKIN LESIONS, AND SPASTIC PARAPLEGIA__:____:__
Caret__:__250600__:__MOVED TO 156530__:____:__
Number Sign__:__250620__:__3-HYDROXYISOBUTYRYL-CoA HYDROLASE DEFICIENCY; HIBCHD__:__BETA-HYDROXYISOBUTYRYL CoA DEACYLASE DEFICIENCY;; HIBCH DEFICIENCY;; METHACRYLIC ACIDURIA;; METHACRYLIC ACID TOXICITY;; VALINE METABOLIC DEFECT__:__
NULL__:__250650__:__METHANE PRODUCTION__:____:__
NULL__:__250700__:__METHEMOGLOBIN REDUCTASE DEFICIENCY__:__NADPH-DEPENDENT METHEMOGLOBIN REDUCTASE DEFICIENCY;; TPNH-METHEMOGLOBIN REDUCTASE DEFICIENCY__:__
Number Sign__:__250790__:__METHEMOGLOBINEMIA AND AMBIGUOUS GENITALIA; METAG__:__ISOLATED 17,20-LYASE DEFICIENCY, PURE;; METHEMOGLOBINEMIA TYPE IV, FORMERLY;; METHEMOGLOBINEMIA DUE TO DEFICIENCY OF CYTOCHROME b5, FORMERLY__:__
Number Sign__:__250800__:__METHEMOGLOBINEMIA DUE TO DEFICIENCY OF METHEMOGLOBIN REDUCTASE__:__NADH-DEPENDENT METHEMOGLOBIN REDUCTASE DEFICIENCY;; NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY;; METHEMOGLOBINEMIA, CONGENITAL, AUTOSOMAL RECESSIVE__:__METHEMOGLOBINEMIA, TYPE I, INCLUDED;; METHEMOGLOBINEMIA, TYPE II, INCLUDED;; NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY, TYPE I, INCLUDED;; NADH-CYTOCHROME b5 REDUCTASE DEFICIENCY, TYPE II, INCLUDED
Number Sign__:__250850__:__METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY__:__MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT__:__
Percent__:__250900__:__METHIONINE MALABSORPTION SYNDROME__:__SMITH-STRANG DISEASE;; OASTHOUSE URINE DISEASE__:__
Number Sign__:__250940__:__HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG__:__HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY__:__
Number Sign__:__250950__:__3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1__:__MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY__:__
NULL__:__250951__:__3-METHYLGLUTACONIC ACIDURIA, TYPE IV; MGCA4__:__MGA, TYPE IV; MGA4__:__
Number Sign__:__251000__:__METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY__:__METHYLMALONIC ACIDEMIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY MMA DUE TO MCM DEFICIENCY;; METHYLMALONIC ACIDURIA, mut TYPE__:__METHYLMALONIC ACIDURIA, mut(0) TYPE, INCLUDED;; METHYLMALONIC ACIDURIA, mut(-) TYPE, INCLUDED
Number Sign__:__251100__:__METHYLMALONIC ACIDURIA, cblA TYPE__:__METHYLMALONIC ACIDEMIA, cblA TYPE;; METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESIS OF ADENOSYLCOBALAMIN, cblA TYPE__:__
Number Sign__:__251110__:__METHYLMALONIC ACIDURIA, cblB TYPE__:__METHYLMALONIC ACIDEMIA, cblB TYPE;; METHYLMALONIC ACIDURIA, VITAMIN B12-RESPONSIVE, DUE TO DEFECT IN SYNTHESIS OF ADENOSYLCOBALAMIN, cblB TYPE__:__
Number Sign__:__251120__:__METHYLMALONYL-CoA EPIMERASE DEFICIENCY__:__METHYLMALONYL-CoA RACEMASE DEFICIENCY;; METHYLMALONIC ACIDURIA III, FORMERLY__:__METHYLMALONYL-CoA EPIMERASE DEFICIENCY WITH SEPIAPTERIN REDUCTASE DEFICIENCY, INCLUDED
Asterisk__:__251170__:__MEVALONATE KINASE; MVK__:____:__
NULL__:__251190__:__MICROCEPHALIC PRIMORDIAL DWARFISM, TORIELLO TYPE__:____:__
Number Sign__:__251200__:__MICROCEPHALY 1, PRIMARY, AUTOSOMAL RECESSIVE; MCPH1__:__PREMATURE CHROMOSOME CONDENSATION WITH MICROCEPHALY AND MENTAL RETARDATION;; PREMATURE CHROMOSOME CONDENSATION SYNDROME;; PCC SYNDROME__:__
NULL__:__251220__:__MICROCEPHALY-CARDIOMYOPATHY__:____:__
Number Sign__:__251230__:__MICROCEPHALY-MICROMELIA SYNDROME; MIMIS__:____:__
NULL__:__251240__:__MICROCEPHALY WITH CHEMOTACTIC DEFECT AND TRANSIENT HYPOGAMMAGLOBULINEMIA__:____:__
NULL__:__251250__:__MICROCEPHALY WITH CERVICAL SPINE FUSION ANOMALIES__:____:__
Number Sign__:__251255__:__JAWAD SYNDROME; JWDS__:__KELLY SYNDROME;; MICROCEPHALY WITH MENTAL RETARDATION AND DIGITAL ANOMALIES__:__
Number Sign__:__251260__:__NIJMEGEN BREAKAGE SYNDROME; NBS__:__ATAXIA-TELANGIECTASIA VARIANT V1; AT-V1;; MICROCEPHALY WITH NORMAL INTELLIGENCE, IMMUNODEFICIENCY, AND LYMPHORETICULAR MALIGNANCIES;; SEEMANOVA SYNDROME II;; NONSYNDROMAL MICROCEPHALY, AUTOSOMAL RECESSIVE, WITH NORMAL INTELLIGENCE;; IMMUNODEFICIENCY, MICROCEPHALY, AND CHROMOSOMAL INSTABILITY__:__BERLIN BREAKAGE SYNDROME, INCLUDED; BBS, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT V2, INCLUDED; AT-V2, INCLUDED
Number Sign__:__251270__:__MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 1; MCCRP1__:____:__
Number Sign__:__251280__:__MICROCEPHALY, SEIZURES, SPASTICITY, AND BRAIN CALCIFICATIONS; MISSBC__:____:__
Number Sign__:__251290__:__PSEUDO-TORCH SYNDROME 1; PTORCH1__:__PSEUDO-TORCH SYNDROME; BAND-LIKE CALCIFICATION WITH SIMPLIFIED GYRATION AND POLYMICROGYRIA; BLCPMG__:__
Number Sign__:__251300__:__GALLOWAY-MOWAT SYNDROME 1; GAMOS1__:__MICROCEPHALY, HIATAL HERNIA, AND NEPHROTIC SYNDROME;; GALLOWAY SYNDROME;; NEPHROSIS-NEURONAL DYSMIGRATION SYNDROME;; NEPHROSIS-MICROCEPHALY SYNDROME;; CEREBELLAR ATAXIA WITH MENTAL RETARDATION, OPTIC ATROPHY, AND SKIN ABNORMALITIES; CAMOS;; SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 5, FORMERLY; SCAR5, FORMERLY__:__
NULL__:__251400__:__MICROCOLON__:____:__
Number Sign__:__251450__:__DESBUQUOIS DYSPLASIA 1; DBQD1__:__DESBUQUOIS SYNDROME;; MICROMELIC DWARFISM WITH VERTEBRAL AND METAPHYSEAL ABNORMALITIES AND ADVANCED CARPOTARSAL OSSIFICATION__:__DESBUQUOIS DYSPLASIA, KIM VARIANT, INCLUDED
Caret__:__251455__:__MOVED TO 258315__:____:__
Caret__:__251500__:__MOVED TO 600118__:____:__
NULL__:__251505__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 4; MCOPCB4__:__MICROPHTHALMIA WITH COLOBOMATOUS CYST__:__
Percent__:__251600__:__MICROPHTHALMIA, ISOLATED 1; MCOP1__:__MCOP;; ANOPHTHALMIA, CLINICAL, ISOLATED;; MICROPHTHALMOS, AUTOSOMAL RECESSIVE__:__
NULL__:__251700__:__MICROPHTHALMIA WITH HYPEROPIA, RETINAL DEGENERATION, MACROPHAKIA, AND DENTAL ANOMALIES__:____:__
Number Sign__:__251750__:__MICROSPHEROPHAKIA AND/OR MEGALOCORNEA, WITH ECTOPIA LENTIS AND WITH OR WITHOUT SECONDARY GLAUCOMA; MSPKA__:____:__
Percent__:__251800__:__MICROTIA WITH MEATAL ATRESIA AND CONDUCTIVE DEAFNESS__:____:__
Number Sign__:__251850__:__DIARRHEA 2, WITH MICROVILLUS ATROPHY; DIAR2__:__MICROVILLUS INCLUSION DISEASE; MVID;; MICROVILLUS ATROPHY, CONGENITAL;; DAVIDSON DISEASE;; CONGENITAL FAMILIAL PROTRACTED DIARRHEA WITH ENTEROCYTE BRUSH-BORDER ABNORMALITIES;; INTRACTABLE DIARRHEA OF INFANCY__:__
Number Sign__:__251880__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 3 (HEPATOCEREBRAL TYPE); MTDPS3__:____:__
Caret__:__251890__:__MOVED TO 143450__:____:__
NULL__:__251900__:__MITOCHONDRIAL MYOPATHY__:____:__
NULL__:__251945__:__MITOCHONDRIAL MYOPATHY WITH A DEFECT IN MITOCHONDRIAL-PROTEIN TRANSPORT__:____:__
Number Sign__:__251950__:__MITOCHONDRIAL MYOPATHY WITH LACTIC ACIDOSIS; MMLA__:____:__
Number Sign__:__252010__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 1; MC1DN1__:__MITOCHONDRIAL COMPLEX I DEFICIENCY;; NADH:Q(1) OXIDOREDUCTASE DEFICIENCY;; NADH-COENZYME Q REDUCTASE DEFICIENCY;; MITOCHONDRIAL NADH DEHYDROGENASE COMPONENT OF COMPLEX I, DEFICIENCY OF__:__
Number Sign__:__252011__:__MITOCHONDRIAL COMPLEX II DEFICIENCY__:__SUCCINATE CoQ REDUCTASE DEFICIENCY__:__
Caret__:__252030__:__REMOVED FROM DATABASE__:____:__
Percent__:__252100__:__MOHR SYNDROME__:__OROFACIODIGITAL SYNDROME II; OFD2;; OFDS II;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE II__:__
Number Sign__:__252150__:__MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP A; MOCODA__:__SULFITE OXIDASE, XANTHINE DEHYDROGENASE, AND ALDEHYDE OXIDASE, COMBINED DEFICIENCY OF__:__
Number Sign__:__252160__:__MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP B; MOCODB__:____:__
Caret__:__252200__:__MOVED TO 158000 AND 607903__:____:__
NULL__:__252250__:__MONOCYTE CHEMOTACTIC DISORDER__:____:__
Number Sign__:__252270__:__MONOSOMY 7 OF BONE MARROW__:__MYELODYSPLASIA AND LEUKEMIA SYNDROME WITH MONOSOMY 7; MLSM7;; CHROMOSOME 7q DELETION__:__
NULL__:__252300__:__MORQUIO SYNDROME C__:__MORQUIO SYNDROME, NONKERATOSULFATE-EXCRETING TYPE__:__
NULL__:__252320__:__MOTOR NEUROPATHY, PERIPHERAL, WITH DYSAUTONOMIA__:____:__
Percent__:__252350__:__MOYAMOYA DISEASE 1; MYMY1__:__MOYAMOYA DISEASE; MYMY;; SPONTANEOUS OCCLUSION OF THE CIRCLE OF WILLIS__:__
Number Sign__:__252500__:__MUCOLIPIDOSIS II ALPHA/BETA__:__MUCOLIPIDOSIS II; ML II;; ML II ALPHA/BETA;; I-CELL DISEASE; ICD__:__
Number Sign__:__252600__:__MUCOLIPIDOSIS III ALPHA/BETA__:__ML III ALPHA/BETA;; MUCOLIPIDOSIS IIIA; ML IIIA;; MUCOLIPIDOSIS III;; ML III;; PSEUDO-HURLER POLYDYSTROPHY__:__MUCOLIPIDOSIS III ALPHA/BETA, ATYPICAL, INCLUDED
Number Sign__:__252605__:__MUCOLIPIDOSIS III GAMMA__:__ML III GAMMA;; MUCOLIPIDOSIS III, COMPLEMENTATION GROUP C;; MUCOLIPIDOSIS IIIC;; ML IIIC;; MUCOLIPIDOSIS III, IRANIAN VARIANT FORM;; MUCOLIPIDOSIS III, VARIANT FORM__:__
Number Sign__:__252650__:__MUCOLIPIDOSIS IV; ML4__:__ML IV;; SIALOLIPIDOSIS__:__
Number Sign__:__252700__:__MUCOPOLYSACCHARIDOSES, UNCLASSIFIED TYPES__:____:__
Asterisk__:__252800__:__ALPHA-L-IDURONIDASE; IDUA__:__IDURONIDASE, ALPHA-L__:__
Number Sign__:__252900__:__MUCOPOLYSACCHARIDOSIS, TYPE IIIA; MPS3A__:__MPS IIIA;; SANFILIPPO SYNDROME A;; HEPARAN SULFATE SULFATASE DEFICIENCY;; SULFAMIDASE DEFICIENCY__:__
Number Sign__:__252920__:__MUCOPOLYSACCHARIDOSIS, TYPE IIIB; MPS3B__:__MPS IIIB;; SANFILIPPO SYNDROME B;; N-ACETYL-ALPHA-D-GLUCOSAMINIDASE DEFICIENCY;; NAGLU DEFICIENCY__:__
Number Sign__:__252930__:__MUCOPOLYSACCHARIDOSIS, TYPE IIIC; MPS3C__:__MPS IIIC;; SANFILIPPO SYNDROME C;; ACETYL-CoA:ALPHA-GLUCOSAMINIDE N-ACETYLTRANSFERASE DEFICIENCY__:__
Number Sign__:__252940__:__MUCOPOLYSACCHARIDOSIS, TYPE IIID; MPS3D__:__MPS IIID;; SANFILIPPO SYNDROME D;; N-ACETYLGLUCOSAMINE-6-SULFATASE DEFICIENCY__:__
Number Sign__:__253000__:__MUCOPOLYSACCHARIDOSIS, TYPE IVA; MPS4A__:__MORQUIO SYNDROME A;; MPS IVA;; MORQUIO A DISEASE;; GALACTOSAMINE-6-SULFATASE DEFICIENCY;; GALNS DEFICIENCY__:__
Number Sign__:__253010__:__MUCOPOLYSACCHARIDOSIS, TYPE IVB; MPS4B__:__MORQUIO SYNDROME B;; MPS IVB__:__
Number Sign__:__253200__:__MUCOPOLYSACCHARIDOSIS, TYPE VI; MPS6__:__MPS VI;; MAROTEAUX-LAMY SYNDROME;; ARYLSULFATASE B DEFICIENCY;; ARSB DEFICIENCY;; N-ACETYLGALACTOSAMINE-4-SULFATASE DEFICIENCY__:__
Number Sign__:__253220__:__MUCOPOLYSACCHARIDOSIS, TYPE VII; MPS7__:__MPS VII;; SLY SYNDROME;; BETA-GLUCURONIDASE DEFICIENCY;; GUSB DEFICIENCY__:__
Caret__:__253230__:__MOVED TO 601492__:____:__
Percent__:__253240__:__MUCUS INSPISSATION OF RESPIRATORY TRACT__:____:__
Number Sign__:__253250__:__MULIBREY NANISM__:__MUSCLE-LIVER-BRAIN-EYE NANISM;; PERICARDIAL CONSTRICTION AND GROWTH FAILURE;; PERHEENTUPA SYNDROME__:__
Number Sign__:__253260__:__BIOTINIDASE DEFICIENCY__:__BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET__:__
Number Sign__:__253270__:__HOLOCARBOXYLASE SYNTHETASE DEFICIENCY__:__HLCS DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, NEONATAL FORM;; MULTIPLE CARBOXYLASE DEFICIENCY, EARLY ONSET__:__
Number Sign__:__253280__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED__:__
Number Sign__:__253290__:__MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE; LMPS__:__PTERYGIUM SYNDROME, MULTIPLE, LETHAL TYPE__:__
Number Sign__:__253300__:__SPINAL MUSCULAR ATROPHY, TYPE I; SMA1__:__SMA I;; SMA, INFANTILE ACUTE FORM;; MUSCULAR ATROPHY, INFANTILE;; WERDNIG-HOFFMANN DISEASE__:__
Number Sign__:__253310__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1__:__LCCS;; MULTIPLE CONTRACTURE SYNDROME, FINNISH TYPE__:__
NULL__:__253320__:__MULTICORE MYOPATHY WITH MENTAL RETARDATION, SHORT STATURE, AND HYPOGONADOTROPIC HYPOGONADISM__:__CHUDLEY SYNDROME__:__
Number Sign__:__253400__:__SPINAL MUSCULAR ATROPHY, TYPE III; SMA3__:__SMA III;; MUSCULAR ATROPHY, JUVENILE;; KUGELBERG-WELANDER SYNDROME; KWS;; SPINAL MUSCULAR ATROPHY, MILD CHILDHOOD AND ADOLESCENT FORM__:__
Caret__:__253500__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__253550__:__SPINAL MUSCULAR ATROPHY, TYPE II; SMA2__:__SMA II;; MUSCULAR ATROPHY, SPINAL, INTERMEDIATE TYPE;; MUSCULAR ATROPHY, SPINAL, INFANTILE CHRONIC FORM__:__
NULL__:__253590__:__MUSCULAR DYSTROPHY, ADULT-ONSET, WITH LEUKOENCEPHALOPATHY__:____:__
Number Sign__:__253600__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY__:__MYOSITIS, EOSINOPHILIC, INCLUDED
Number Sign__:__253601__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 3; LGMD3__:__
Number Sign__:__253700__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 5; LGMDR5__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C;; MUSCULAR DYSTROPHY, DUCHENNE-LIKE;; DUCHENNE-LIKE MUSCULAR DYSTROPHY, AUTOSOMAL RECESSIVE, TYPE 1; DMDA1;; DMDA;; ADHALIN DEFICIENCY, SECONDARY;; SARCOGLYCAN, GAMMA, DEFICIENCY OF;; SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, NORTH AFRICAN TYPE; SCARMD;; MAGHREBIAN MYOPATHY__:__
Number Sign__:__253800__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4__:__FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED__:__
Caret__:__253850__:__MOVED TO 602771__:____:__
Percent__:__253900__:__MUSCULAR DYSTROPHY, CONGENITAL, PRODUCING ARTHROGRYPOSIS__:____:__
NULL__:__254000__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH INFANTILE CATARACT AND HYPOGONADISM__:____:__
Number Sign__:__254090__:__ULLRICH CONGENITAL MUSCULAR DYSTROPHY 1; UCMD1__:__ULLRICH CONGENITAL MUSCULAR DYSTROPHY; UCMD;; MUSCULAR DYSTROPHY, SCLEROATONIC;; ULLRICH DISEASE;; ULLRICH SCLEROATONIC MUSCULAR DYSTROPHY;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 22; LGMDR22__:__
NULL__:__254100__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH RAPID PROGRESSION__:____:__
Number Sign__:__254110__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 8; LGMDR8__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2H; LGMD2H;; MUSCULAR DYSTROPHY, HUTTERITE TYPE;; SARCOTUBULAR MYOPATHY__:__
NULL__:__254120__:__MUSCULAR HYPERTONIA, LETHAL__:____:__
Number Sign__:__254130__:__MIYOSHI MUSCULAR DYSTROPHY 1; MMD1__:__MIYOSHI MYOPATHY;; MUSCULAR DYSTROPHY, DISTAL, LATE-ONSET, AUTOSOMAL RECESSIVE__:__
Percent__:__254150__:__MUSK, INABILITY TO SMELL__:____:__
NULL__:__254190__:__MYASTHENIA, CONGENITAL, REFRACTORY TO ACETYLCHOLINESTERASE INHIBITORS__:____:__
Caret__:__254195__:__MOVED TO 608931__:____:__
NULL__:__254200__:__MYASTHENIA GRAVIS; MG__:____:__
Number Sign__:__254210__:__MYASTHENIC SYNDROME, CONGENITAL, 6, PRESYNAPTIC; CMS6__:__MYASTHENIC SYNDROME, PRESYNAPTIC, CONGENITAL, ASSOCIATED WITH EPISODIC APNEA; CMSEA;; CONGENITAL MYASTHENIC SYNDROME TYPE Ia2, FORMERLY; CMS1A2, FORMERLY;; CMS Ia2, FORMERLY;; MYASTHENIA, FAMILIAL INFANTILE, FORMERLY; FIM, FORMERLY;; MYASTHENIA GRAVIS, FAMILIAL INFANTILE, 2, FORMERLY; FIMG2, FORMERLY__:__
Number Sign__:__254300__:__MYASTHENIC SYNDROME, CONGENITAL, 10; CMS10__:__MYASTHENIA, LIMB-GIRDLE, FAMILIAL, FORMERLY; LGM, FORMERLY;; CONGENITAL MYASTHENIC SYNDROME TYPE Ib, FORMERLY; CMS1B, FORMERLY;; CMS Ib, FORMERLY;; MYASTHENIC MYOPATHY, FORMERLY__:__
NULL__:__254400__:__MYCOSIS FUNGOIDES__:____:__
Number Sign__:__254450__:__MYELOFIBROSIS__:____:__MYELOFIBROSIS WITH MYELOID METAPLASIA, INCLUDED; MMM, INCLUDED
Number Sign__:__254500__:__MYELOMA, MULTIPLE__:____:__AMYLOIDOSIS, SYSTEMIC, INCLUDED; AL, INCLUDED;; AL AMYLOIDOSIS, INCLUDED
Number Sign__:__254600__:__MYELOPEROXIDASE DEFICIENCY; MPOD__:__MPO DEFICIENCY__:__
NULL__:__254700__:__MYELOPROLIFERATIVE DISEASE, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__254770__:__EPILEPSY, MYOCLONIC JUVENILE; EJM__:__MYOCLONIC EPILEPSY, JUVENILE; JME;; PETIT MAL, IMPULSIVE;; JANZ SYNDROME__:__MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 1, INCLUDED; EJM1, INCLUDED
Number Sign__:__254780__:__MYOCLONIC EPILEPSY OF LAFORA__:__MELF;; LAFORA DISEASE;; LAFORA BODY DISEASE; LBD;; EPILEPSY, PROGRESSIVE MYOCLONIC, 2A; EPM2A;; EPM2__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 2B, INCLUDED; EPM2B, INCLUDED
Number Sign__:__254800__:__MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG__:__ULD;; EPILEPSY, PROGRESSIVE MYOCLONIC, 1A; EPM1A;; EPILEPSY, PROGRESSIVE MYOCLONIC, 1; EPM1;; PROGRESSIVE MYOCLONIC EPILEPSY; PME;; BALTIC MYOCLONIC EPILEPSY__:__
Number Sign__:__254900__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 4, WITH OR WITHOUT RENAL FAILURE; EPM4__:__ACTION MYOCLONUS-RENAL FAILURE SYNDROME; AMRF;; MYOCLONUS-NEPHROPATHY SYNDROME__:__
Number Sign__:__254940__:__CAREY-FINEMAN-ZITER SYNDROME; CFZS__:__MYOPATHY, CONGENITAL NONPROGRESSIVE, WITH MOEBIUS SEQUENCE AND ROBIN SEQUENCE__:__
NULL__:__254950__:__MYOPATHY, GRANULOVACUOLAR LOBULAR, WITH ELECTRICAL MYOTONIA__:____:__
NULL__:__254960__:__MYOPATHY DUE TO MALATE-ASPARTATE SHUTTLE DEFECT__:____:__
Number Sign__:__255100__:__LIPID STORAGE MYOPATHY DUE TO FLAVIN ADENINE DINUCLEOTIDE SYNTHETASE DEFICIENCY; LSMFLAD__:____:__
Number Sign__:__255110__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC, STRESS-INDUCED__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, MYOPATHIC;; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ADULT-ONSET;; CPT II DEFICIENCY, MYOPATHIC;; CPT2 DEFICIENCY, LATE-ONSET__:__
Number Sign__:__255120__:__CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY__:__CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I__:__
Number Sign__:__255125__:__MYOPATHY WITH LACTIC ACIDOSIS, HEREDITARY; HML__:__MYOPATHY WITH EXERCISE INTOLERANCE, SWEDISH TYPE;; MYOPATHY WITH DEFICIENCY OF SUCCINATE DEHYDROGENASE AND ACONITASE;; MYOGLOBINURIA DUE TO ABNORMAL GLYCOLYSIS__:__
NULL__:__255140__:__MYOPATHY WITH GIANT ABNORMAL MITOCHONDRIA__:____:__
Number Sign__:__255160__:__MYOPATHY, MYOSIN STORAGE, AUTOSOMAL RECESSIVE; MSMB__:__MYOPATHY, HYALINE BODY, AUTOSOMAL RECESSIVE__:__
Caret__:__255170__:__MOVED TO 603280__:____:__
Number Sign__:__255200__:__MYOPATHY, CENTRONUCLEAR, 2; CNM2__:__MYOPATHY, CENTRONUCLEAR, AUTOSOMAL RECESSIVE;; MYOTUBULAR MYOPATHY, AUTOSOMAL RECESSIVE__:__
Percent__:__255300__:__MYOPATHY, CONGENITAL__:__BATTEN-TURNER CONGENITAL MYOPATHY__:__
Number Sign__:__255310__:__MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION; CFTD__:__FIBER-TYPE DISPROPORTION MYOPATHY, CONGENITAL; CFTDM__:__
Number Sign__:__255320__:__MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA__:__MINICORE MYOPATHY;; MULTICORE MYOPATHY;; MULTIMINICORE MYOPATHY MULTICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA;; MULTIMINICORE DISEASE WITH EXTERNAL OPHTHALMOPLEGIA__:__
Percent__:__255500__:__MYOPIA 18, AUTOSOMAL RECESSIVE; MYP18__:____:__
Number Sign__:__255600__:__MYOSCLEROSIS, AUTOSOMAL RECESSIVE__:__MYOPATHY, MYOSCLEROTIC;; MYOSCLEROSIS, CONGENITAL, OF LOWENTHAL__:__
Number Sign__:__255700__:__MYOTONIA CONGENITA, AUTOSOMAL RECESSIVE__:__BECKER DISEASE;; MYOTONIA, GENERALIZED__:__
NULL__:__255710__:__MYOTONIA WITH SKELETAL ABNORMALITIES AND MENTAL RETARDATION__:____:__
Number Sign__:__255800__:__SCHWARTZ-JAMPEL SYNDROME, TYPE 1; SJS1__:__SCHWARTZ-JAMPEL SYNDROME; SJS;; MYOTONIC MYOPATHY, DWARFISM, CHONDRODYSTROPHY, AND OCULAR AND FACIAL ABNORMALITIES;; SCHWARTZ-JAMPEL-ABERFELD SYNDROME;; SJA SYNDROME;; CHONDRODYSTROPHIC MYOTONIA__:__
NULL__:__255900__:__MYXEDEMA__:____:__
Number Sign__:__255960__:__MYXOMA, INTRACARDIAC__:__ATRIAL MYXOMA, FAMILIAL__:__
Percent__:__255980__:__NASODIGITOACOUSTIC SYNDROME__:__KEIPERT SYNDROME__:__
NULL__:__255990__:__NATHALIE SYNDROME__:____:__
Number Sign__:__255995__:__MYOPATHY, CONGENITAL, BAILEY-BLOCH; MYPBB__:__NATIVE AMERICAN MYOPATHY; NAM;; MYOPATHY, CONGENITAL, WITH MYOPATHIC FACIES, SCOLIOSIS, AND MALIGNANT HYPERTHERMIA__:__
Number Sign__:__256000__:__LEIGH SYNDROME; LS__:__NECROTIZING ENCEPHALOPATHY, INFANTILE SUBACUTE, OF LEIGH; SNE__:__LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX I DEFICIENCY, INCLUDED;; LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX II DEFICIENCY, INCLUDED;; LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX III DEFICIENCY, INCLUDED;; LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX IV DEFICIENCY, INCLUDED;; LEIGH SYNDROME DUE TO MITOCHONDRIAL COMPLEX V DEFICIENCY, INCLUDED
NULL__:__256020__:__NAIL-PATELLA-LIKE RENAL DISEASE__:__GLOMERULAR BASEMENT MEMBRANE DISEASE, NAIL-PATELLA SYNDROME TYPE__:__
Number Sign__:__256030__:__NEMALINE MYOPATHY 2; NEM2__:____:__
Number Sign__:__256040__:__PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1; PRAAS1__:__CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE SYNDROME; CANDLE;; NAKAJO-NISHIMURA SYNDROME; NKJO;; JOINT CONTRACTURES, MUSCULAR ATROPHY, MICROCYTIC ANEMIA, AND PANNICULITIS-INDUCED LIPODYSTROPHY;; JMP SYNDROME;; AUTOINFLAMMATION, LIPODYSTROPHY, AND DERMATOSIS SYNDROME; ALDD__:__PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 1, DIGENIC, INCLUDED
Number Sign__:__256050__:__ATELOSTEOGENESIS, TYPE II; AO2__:__AOII;; NEONATAL OSSEOUS DYSPLASIA I__:__DE LA CHAPELLE DYSPLASIA, INCLUDED; DLCD, INCLUDED
Number Sign__:__256100__:__NEPHRONOPHTHISIS 1; NPHP1__:__NEPHRONOPHTHISIS, FAMILIAL JUVENILE;; NPH1__:__
NULL__:__256120__:__NEPHROPATHY, DEAFNESS, AND HYPERPARATHYROIDISM__:____:__
NULL__:__256150__:__NEPHROSIALIDOSIS__:____:__
NULL__:__256200__:__NEPHROSIS WITH DEAFNESS AND URINARY TRACT AND DIGITAL MALFORMATIONS__:____:__
Number Sign__:__256300__:__NEPHROTIC SYNDROME, TYPE 1; NPHS1__:__FINNISH CONGENITAL NEPHROSIS; CNF;; NEPHROTIC SYNDROME, CONGENITAL__:__
Caret__:__256340__:__MOVED TO 146255__:____:__
Caret__:__256350__:__MOVED TO 600995__:____:__
Number Sign__:__256370__:__NEPHROTIC SYNDROME, TYPE 4; NPHS4__:____:__
Number Sign__:__256450__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 1; HHF1__:__PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHHI;; HYPOGLYCEMIA, HYPERINSULINEMIC, OF INFANCY;; HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA;; NESIDIOBLASTOSIS OF PANCREAS;; HYPERINSULINISM, FAMILIAL, WITH PANCREATIC NESIDIOBLASTOSIS;; HYPERINSULINISM, CONGENITAL__:__
Number Sign__:__256500__:__NETHERTON SYNDROME; NETH__:__ERYTHRODERMA, ICHTHYOSIFORM, WITH HYPOTRICHOSIS AND HYPER-IgE;; NS;; NETHERTON DISEASE;; COMEL-NETHERTON SYNDROME__:__
Number Sign__:__256520__:__NEU-LAXOVA SYNDROME 1; NLS1__:__NEU-LAXOVA SYNDROME; NLS__:__
Number Sign__:__256540__:__GALACTOSIALIDOSIS; GSL__:__GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY__:__
Number Sign__:__256550__:__NEURAMINIDASE DEFICIENCY__:__SIALIDOSIS, TYPE II;; MUCOLIPIDOSIS I;; ML I;; LIPOMUCOPOLYSACCHARIDOSIS;; SIALIDASE DEFICIENCY;; GLYCOPROTEIN NEURAMINIDASE DEFICIENCY;; NEUG DEFICIENCY;; NEURAMINIDASE 1 DEFICIENCY;; NEU DEFICIENCY;; NEU1 DEFICIENCY__:__SIALIDOSIS, TYPE I, INCLUDED;; CHERRY RED SPOT--MYOCLONUS SYNDROME, INCLUDED;; MYOCLONUS--CHERRY RED SPOT SYNDROME, INCLUDED
Number Sign__:__256600__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A__:__NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE__:__
NULL__:__256690__:__NEUROFACIODIGITORENAL SYNDROME__:__NFDR SYNDROME__:__
Number Sign__:__256700__:__NEUROBLASTOMA, SUSCEPTIBILITY TO__:____:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 1, INCLUDED; NBLST1, INCLUDED
Number Sign__:__256710__:__ELEJALDE DISEASE__:__NEUROECTODERMAL MELANOLYSOSOMAL DISEASE__:__
NULL__:__256720__:__NEUROLOGIC DISEASE, INFANTILE MULTISYSTEM, WITH OSSEOUS FRAGILITY__:____:__
Number Sign__:__256730__:__CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1__:__CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET__:__NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED
Number Sign__:__256731__:__CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5__:__CEROID LIPOFUSCINOSIS, NEURONAL, 5, VARIABLE AGE AT ONSET__:__NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, FINNISH VARIANT, INCLUDED;; FINNISH vLINCL, INCLUDED
Number Sign__:__256800__:__INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA__:__NEUROPATHY, CONGENITAL SENSORY, WITH ANHIDROSIS;; HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY IV; HSAN4;; HSAN IV;; FAMILIAL DYSAUTONOMIA, TYPE II__:__
Number Sign__:__256810__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 6 (HEPATOCEREBRAL TYPE); MTDPS6__:__NAVAJO NEUROHEPATOPATHY; NNH;; NAVAJO NEUROPATHY; NN__:__NAVAJO FAMILIAL NEUROGENIC ARTHROPATHY, INCLUDED
Number Sign__:__256840__:__NEUROPATHY, HEREDITARY SENSORY, WITH SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__256850__:__GIANT AXONAL NEUROPATHY 1, AUTOSOMAL RECESSIVE; GAN1__:__GAN__:__
Caret__:__256851__:__MOVED TO 256850__:____:__
Percent__:__256855__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, WITH EXCESSIVE MYELIN FOLDING COMPLEX, AUTOSOMAL RECESSIVE__:__HMSN WITH EXCESSIVE MYELIN OUTFOLDING, AUTOSOMAL RECESSIVE;; CHARCOT-MARIE-TOOTH DISEASE WITH EXCESSIVE MYELIN FOLDING, AUTOSOMAL RECESSIVE__:__
NULL__:__256860__:__NEUROPATHY, HEREDITARY SENSORY, ATYPICAL__:____:__
NULL__:__256870__:__NEUROPATHY, PAINFUL__:____:__
NULL__:__257000__:__NEUROVISCERAL STORAGE DISEASE WITH CURVILINEAR BODIES__:____:__
Caret__:__257050__:__MOVED TO 257220__:____:__
NULL__:__257100__:__NEUTROPENIA, LETHAL CONGENITAL, WITH EOSINOPHILIA__:____:__
Percent__:__257150__:__NEUTROPHIL ACTIN DYSFUNCTION; NAD__:____:__
Number Sign__:__257200__:__NIEMANN-PICK DISEASE, TYPE A__:__SPHINGOMYELIN LIPIDOSIS;; SPHINGOMYELINASE DEFICIENCY__:__NIEMANN-PICK DISEASE, INTERMEDIATE, PROTRACTED NEUROVISCERAL, INCLUDED
Number Sign__:__257220__:__NIEMANN-PICK DISEASE, TYPE C1; NPC1__:__NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA__:__NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED
Caret__:__257250__:__MOVED TO 257220__:____:__
Number Sign__:__257270__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B; CSNB1B__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, COMPLETE, AUTOSOMAL RECESSIVE;; CSNB, COMPLETE, AUTOSOMAL RECESSIVE__:__
Number Sign__:__257300__:__MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 1; MVA1__:__MVA SYNDROME__:__
Number Sign__:__257320__:__LISSENCEPHALY 2; LIS2__:__LISSENCEPHALY SYNDROME, NORMAN-ROBERTS TYPE;; NORMAN-ROBERTS SYNDROME__:__
NULL__:__257350__:__NUCHAL BLEB, FAMILIAL__:__CYSTIC HYGROMA, FETAL; FCH__:__
NULL__:__257400__:__NYSTAGMUS, CONGENITAL, AUTOSOMAL RECESSIVE__:____:__
NULL__:__257500__:__OBESITY-HYPOVENTILATION SYNDROME__:__PICKWICKIAN SYNDROME__:__
Percent__:__257550__:__OCULAR MOTOR APRAXIA__:__OCULOMOTOR APRAXIA, COGAN TYPE; COMA;; SACCADE INITIATION FAILURE, CONGENITAL__:__
Percent__:__257600__:__OCULAR MYOPATHY WITH CURARE SENSITIVITY__:____:__
NULL__:__257790__:__OCULOCEREBRAL HYPOPIGMENTATION SYNDROME OF PREUS__:____:__
Percent__:__257800__:__OCULOCEREBRAL SYNDROME WITH HYPOPIGMENTATION__:__CROSS SYNDROME;; KRAMER SYNDROME__:__
Number Sign__:__257850__:__OCULODENTODIGITAL DYSPLASIA, AUTOSOMAL RECESSIVE__:__ODDD, AUTOSOMAL RECESSIVE;; OCULODENTOOSSEOUS DYSPLASIA, AUTOSOMAL RECESSIVE;; ODOD, AUTOSOMAL RECESSIVE__:__
Percent__:__257910__:__OCULOPALATOCEREBRAL SYNDROME__:__OCULOPALATOCEREBRAL DWARFISM;; OPC DWARFISM__:__
Number Sign__:__257920__:__3MC SYNDROME 1; 3MC1__:__OCULOPALATOSKELETAL SYNDROME;; CRANIOSYNOSTOSIS WITH LID ANOMALIES;; MICHELS SYNDROME, FORMERLY__:__
Caret__:__257950__:__MOVED TO 164300__:____:__
NULL__:__257960__:__OCULOTRICHODYSPLASIA; OTD__:____:__
Percent__:__257970__:__OCULORENOCEREBELLAR SYNDROME__:__ORC SYNDROME__:__
Number Sign__:__257980__:__ODONTOONYCHODERMAL DYSPLASIA; OODD__:____:__
NULL__:__258040__:__OEIS COMPLEX__:__OMPHALOCELE-EXSTROPHY-IMPERFORATE ANUS-SPINAL DEFECTS__:__
Number Sign__:__258100__:__OGUCHI DISEASE 1__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, OGUCHI TYPE 1; CSNBO1__:__
Caret__:__258120__:__MOVED TO 271245__:____:__
Percent__:__258150__:__SPERMATOGENIC FAILURE 1; SPGF1__:__OLIGOSYNAPTIC INFERTILITY;; OLIGOCHIASMATIC INFERTILITY__:__
NULL__:__258200__:__OLIVER SYNDROME__:__POSTAXIAL POLYDACTYLY AND MENTAL RETARDATION__:__
Percent__:__258300__:__OLIVOPONTOCEREBELLAR ATROPHY II, AUTOSOMAL RECESSIVE__:__OPCA II, FICKLER-WINKLER TYPE__:__
Number Sign__:__258315__:__OMODYSPLASIA 1; OMOD1__:__OMODYSPLASIA, GENERALIZED FORM;; OMODYSPLASIA, AUTOSOMAL RECESSIVE;; MICROMELIC DYSPLASIA, CONGENITAL, WITH DISLOCATION OF RADIUS__:__
NULL__:__258320__:__OMPHALOCELE-CLEFT PALATE SYNDROME, LETHAL__:__CLEFT PALATE-OMPHALOCELE SYNDROME, LETHAL__:__
Percent__:__258360__:__ONYCHOTRICHODYSPLASIA AND NEUTROPENIA__:____:__
Percent__:__258400__:__OPHTHALMOPLEGIA TOTALIS WITH PTOSIS AND MIOSIS__:____:__
Number Sign__:__258450__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1__:__
NULL__:__258470__:__OPHTHALMOPLEGIC NEUROMUSCULAR DISORDER WITH ABNORMAL MITOCHONDRIA__:____:__
Number Sign__:__258480__:__OPSISMODYSPLASIA; OPSMD__:____:__
Percent__:__258500__:__OPTIC ATROPHY 6; OPA6__:__OPTIC ATROPHY, CONGENITAL OR EARLY INFANTILE, AUTOSOMAL RECESSIVE__:__
Number Sign__:__258501__:__3-METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3__:__MGA, TYPE III; MGA3;; OPTIC ATROPHY PLUS SYNDROME;; OPTIC ATROPHY, INFANTILE, WITH CHOREA AND SPASTIC PARAPLEGIA;; IRAQI-JEWISH 'OPTIC ATROPHY PLUS';; COSTEFF SYNDROME;; OPTIC ATROPHY 3, AUTOSOMAL RECESSIVE;; OPA3, AUTOSOMAL RECESSIVE__:__
NULL__:__258650__:__OPTIC ATROPHY, HEARING LOSS, AND PERIPHERAL NEUROPATHY, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__258660__:__NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY, SUSCEPTIBILITY TO__:__NAION, SUSCEPTIBILITY TO;; OPTIC NEUROPATHY, ANTERIOR ISCHEMIC, SUSCEPTIBILITY TO__:__
Percent__:__258700__:__OPTICOCOCHLEODENTATE DEGENERATION__:____:__
NULL__:__258800__:__ORAL SENSIBILITY, DISTURBANCE OF__:____:__
NULL__:__258840__:__ORAL AND DIGITAL ANOMALIES WITH ICHTHYOSIS__:____:__
Percent__:__258850__:__OROFACIODIGITAL SYNDROME III; OFD3__:__OFDS III;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE III;; SUGARMAN SYNDROME__:__
Number Sign__:__258860__:__OROFACIODIGITAL SYNDROME IV; OFD4__:__OFDS IV;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE IV;; OFD SYNDROME WITH TIBIAL DEFECTS;; MOHR-MAJEWSKI SYNDROME;; OFD SYNDROME, BARAITSER-BURN TYPE;; BARAITSER-BURN SYNDROME__:__
Percent__:__258865__:__OROFACIODIGITAL SYNDROME IX; OFD9__:__OFDS IX;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE IX;; ORAL-FACIAL-DIGITAL SYNDROME WITH RETINAL ABNORMALITIES;; OROFACIODIGITAL SYNDROME WITH RETINAL ABNORMALITIES__:__
Number Sign__:__258870__:__GYRATE ATROPHY OF CHOROID AND RETINA; GACR__:__HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY__:__
Number Sign__:__258900__:__OROTIC ACIDURIA__:__OROTIC ACIDURIA I;; OROTATE PHOSPHORIBOSYLTRANSFERASE AND OROTIDYLIC DECARBOXYLASE DEFICIENCY;; OPRT AND ODC DEFICIENCY;; OROTIDYLIC PYROPHOSPHORYLASE AND OROTIDYLIC DECARBOXYLASE DEFICIENCY;; URIDINE MONOPHOSPHATE SYNTHASE DEFICIENCY;; UMP SYNTHASE DEFICIENCY;; UMPS DEFICIENCY__:__OROTIC ACIDURIA WITHOUT MEGALOBLASTIC ANEMIA, INCLUDED; OAWA, INCLUDED
Caret__:__258920__:__MOVED TO 258900__:____:__
Number Sign__:__259050__:__PRIMROSE SYNDROME; PRIMS__:__OSSIFIED EAR CARTILAGES WITH MENTAL DEFICIENCY, MUSCLE WASTING, AND BONY CHANGES__:__
Number Sign__:__259100__:__HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 1; PHOAR1__:__PHO, AUTOSOMAL RECESSIVE;; PACHYDERMOPERIOSTOSIS, AUTOSOMAL RECESSIVE;; PDP, AUTOSOMAL RECESSIVE;; TOURAINE-SOLENTE-GOLE SYNDROME__:__CRANIOOSTEOARTHROPATHY, INCLUDED; COA, INCLUDED;; FAMILIAL IDIOPATHIC OSTEOARTHROPATHY OF CHILDHOOD, INCLUDED;; CURRARINO IDIOPATHIC OSTEOARTHROPATHY, INCLUDED; CIO, INCLUDED
NULL__:__259200__:__BLOUNT DISEASE, ADOLESCENT__:__OSTEOCHONDROSIS DEFORMANS TIBIAE, ADOLESCENT;; TIBIA VARA, ADOLESCENT__:__
Percent__:__259250__:__OSTEODYSPLASIA, FAMILIAL, ANDERSON TYPE__:____:__
NULL__:__259270__:__OSTEODYSPLASTY, PRECOCIOUS, OF DANKS, MAYNE, AND KOZLOWSKI__:____:__
Caret__:__259400__:__MOVED TO 166210__:____:__
NULL__:__259410__:__OSTEOGENESIS IMPERFECTA CONGENITA, MICROCEPHALY, AND CATARACTS__:____:__
Number Sign__:__259420__:__OSTEOGENESIS IMPERFECTA, TYPE III; OI3__:__OI, TYPE III;; OSTEOGENESIS IMPERFECTA, PROGRESSIVELY DEFORMING, WITH NORMAL SCLERAE__:__
Number Sign__:__259440__:__OSTEOGENESIS IMPERFECTA, TYPE IX; OI9__:__OI, TYPE IX__:__
Number Sign__:__259450__:__BRUCK SYNDROME 1; BRKS1__:__KUSKOKWIM DISEASE;; ARTHROGRYPOSIS-LIKE DISORDER__:__
Number Sign__:__259500__:__OSTEOGENIC SARCOMA__:__OSTEOSARCOMA; OSRC__:__
NULL__:__259550__:__OSTEOID OSTEOMA__:____:__
Number Sign__:__259600__:__MULTICENTRIC OSTEOLYSIS, NODULOSIS, AND ARTHROPATHY; MONA__:__TORG SYNDROME;; NODULOSIS-ARTHROPATHY-OSTEOLYSIS SYNDROME;; NAO SYNDROME;; AL-AQEEL SEWAIRI SYNDROME;; OSTEOLYSIS, HEREDITARY MULTICENTRIC;; TORG-WINCHESTER SYNDROME, FORMERLY__:__
NULL__:__259610__:__OSTEOLYSIS SYNDROME, RECESSIVE__:__OSTEOLYSIS, DISTAL, WITH SHORT STATURE, MENTAL RETARDATION, AND CHARACTERISTIC FACIAL APPEARANCE__:__
NULL__:__259650__:__OSTEOMA OF MIDDLE EAR__:____:__
NULL__:__259660__:__OSTEOMALACIA, SCLEROSING, WITH CEREBRAL CALCIFICATION__:____:__
NULL__:__259680__:__CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CRMO__:__OSTEOMYELITIS, CHRONIC MULTIFOCAL; CMO__:__
NULL__:__259690__:__OSTEOPENIA AND SPARSE HAIR__:____:__
Number Sign__:__259700__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 1; OPTB1__:__OSTEOPETROSIS, INFANTILE MALIGNANT 1;; MARBLE BONES, AUTOSOMAL RECESSIVE;; ALBERS-SCHONBERG DISEASE, AUTOSOMAL RECESSIVE__:__
Number Sign__:__259710__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 2; OPTB2__:__OSTEOPETROSIS, OSTEOCLAST-POOR;; OSTEOPETROSIS, MILD AUTOSOMAL RECESSIVE FORM__:__
Number Sign__:__259720__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 5; OPTB5__:__OSTEOPETROSIS, INFANTILE MALIGNANT 3__:__
Number Sign__:__259730__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 3; OPTB3__:__OSTEOPETROSIS WITH RENAL TUBULAR ACIDOSIS;; CARBONIC ANHYDRASE II DEFICIENCY;; GUIBAUD-VAINSEL SYNDROME;; MARBLE BRAIN DISEASE__:__
NULL__:__259750__:__OSTEOPOROSIS, JUVENILE__:__IDIOPATHIC JUVENILE OSTEOPOROSIS; IJO__:__
Number Sign__:__259770__:__OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG__:__OPS;; OSTEOGENESIS IMPERFECTA, OCULAR FORM__:__
Number Sign__:__259775__:__RAINE SYNDROME; RNS__:__OSTEOSCLEROTIC BONE DYSPLASIA, LETHAL__:__
Percent__:__259780__:__OTOONYCHOPERONEAL SYNDROME__:____:__
Number Sign__:__259900__:__HYPEROXALURIA, PRIMARY, TYPE I; HP1__:__OXALOSIS I;; GLYCOLIC ACIDURIA;; ALANINE-GLYOXYLATE AMINOTRANSFERASE DEFICIENCY;; PEROXISOMAL ALANINE:GLYOXYLATE AMINOTRANSFERASE DEFICIENCY;; HEPATIC AGT DEFICIENCY;; SERINE:PYRUVATE AMINOTRANSFERASE DEFICIENCY__:__
Number Sign__:__260000__:__HYPEROXALURIA, PRIMARY, TYPE II; HP2__:__OXALOSIS II;; GLYCERIC ACIDURIA;; GLYOXYLATE REDUCTASE/HYDROXYPYRUVATE REDUCTASE DEFICIENCY;; D-GLYCERATE DEHYDROGENASE DEFICIENCY__:__
Number Sign__:__260005__:__5-OXOPROLINASE DEFICIENCY; OPLAHD__:__OXOPROLINURIA DUE TO 5-OXOPROLINASE DEFICIENCY__:__
NULL__:__260100__:__PA POLYMORPHISM OF ALPHA-2-GLOBULIN__:__ALPHA-2-GLOBULIN POLYMORPHISM PA__:__
NULL__:__260130__:__PACHYONYCHIA CONGENITA, AUTOSOMAL RECESSIVE__:____:__
NULL__:__260150__:__PALANT CLEFT PALATE SYNDROME__:____:__
NULL__:__260200__:__PALLIDAL DEGENERATION, PROGRESSIVE, WITH RETINITIS PIGMENTOSA__:____:__
Number Sign__:__260300__:__PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK15__:__PARKINSONIAN-PYRAMIDAL SYNDROME; PKPS;; PALLIDOPYRAMIDAL SYNDROME;; PALLIDO-PYRAMIDAL SYNDROME__:__
Number Sign__:__260350__:__PANCREATIC CANCER__:__PANCREATIC CARCINOMA;; PANCREATIC ACINAR CARCINOMA__:__
Number Sign__:__260370__:__PANCREATIC AGENESIS 1; PAGEN1__:__PAGEN;; PANCREATIC HYPOPLASIA, CONGENITAL__:__
Number Sign__:__260400__:__SHWACHMAN-DIAMOND SYNDROME 1; SDS1__:__SHWACHMAN-DIAMOND SYNDROME; SDS;; PANCREATIC INSUFFICIENCY AND BONE MARROW DYSFUNCTION;; SHWACHMAN-BODIAN SYNDROME;; LIPOMATOSIS OF PANCREAS, CONGENITAL__:__
NULL__:__260450__:__PANCREATIC INSUFFICIENCY, COMBINED EXOCRINE__:____:__
NULL__:__260470__:__PANENCEPHALITIS, SUBACUTE SCLEROSING__:__SUBACUTE SCLEROSING PANENCEPHALITIS; SSPE__:__
NULL__:__260480__:__PANCREATITIS, SCLEROSING CHOLANGITIS, AND SICCA COMPLEX__:____:__
Caret__:__260490__:__MOVED TO 174800__:____:__
Number Sign__:__260500__:__PAPILLOMA OF CHOROID PLEXUS; CPP__:__CHOROID PLEXUS PAPILLOMA__:__CHOROID PLEXUS CARCINOMA, INCLUDED; CPC, INCLUDED
NULL__:__260530__:__PARANA HARD-SKIN SYNDROME__:____:__
Number Sign__:__260540__:__PARKINSON-DEMENTIA SYNDROME__:____:__SUPRANUCLEAR PALSY, PROGRESSIVE, 1, ATYPICAL, INCLUDED;; STEELE-RICHARDSON-OLSZEWSKI SYNDROME, ATYPICAL, INCLUDED
NULL__:__260555__:__PARTINGTON-ANDERSON SYNDROME__:____:__
Number Sign__:__260565__:__PEHO SYNDROME; PEHO__:__PROGRESSIVE ENCEPHALOPATHY WITH EDEMA, HYPSARRHYTHMIA, AND OPTIC ATROPHY;; INFANTILE CEREBELLOOPTIC ATROPHY__:__
NULL__:__260570__:__PELGER-HUET-LIKE ANOMALY AND EPISODIC FEVER WITH ABDOMINAL PAIN__:____:__
Number Sign__:__260600__:__LEUKODYSTROPHY, HYPOMYELINATING, 3; HLD3__:____:__
NULL__:__260650__:__PELLAGRA-LIKE SYNDROME__:____:__
Number Sign__:__260660__:__COUSIN SYNDROME__:__CRANIOFACIAL DYSMORPHISM, HYPOPLASIA OF SCAPULA AND PELVIS, AND SHORT STATURE;; PELVISCAPULAR DYSPLASIA__:__
Number Sign__:__260800__:__PENTOSURIA; PNTSU__:__L-XYLULOSURIA;; XYLITOL DEHYDROGENASE DEFICIENCY;; L-XYLULOSE REDUCTASE DEFICIENCY__:__
NULL__:__260900__:__PERICARDIAL EFFUSION, CHRONIC__:__CHOLESTEROL PERICARDITIS__:__
NULL__:__260910__:__PERIFOLLICULITIS CAPITIS ABSCEDENS ET SUFFODIENS, FAMILIAL__:__DISSECTING CELLULITIS OF THE SCALP__:__
Number Sign__:__260920__:__HYPER-IgD SYNDROME; HIDS__:__HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE__:__
NULL__:__260950__:__PERIODONTITIS, CHRONIC__:__PERIODONTITIS, ADULT__:__
NULL__:__260970__:__PERIPHERAL NEUROPATHY, ATAXIA, FOCAL NECROTIZING ENCEPHALOPATHY, AND SPONGY DEGENERATION OF BRAIN__:____:__
Caret__:__260980__:__MOVED TO 300388__:____:__
Number Sign__:__261000__:__INTRINSIC FACTOR DEFICIENCY; IFD__:__PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR__:__
Number Sign__:__261100__:__MEGALOBLASTIC ANEMIA 1__:__MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF__:__
NULL__:__261400__:__PERONEUS TERTIUS MUSCLE, ABSENCE OF__:____:__
Number Sign__:__261500__:__EOSINOPHIL PEROXIDASE DEFICIENCY; EPXD__:__EOSINOPHIL PEROXIDASE DEFICIENCY, PARTIAL;; PEROXIDASE AND PHOSPHOLIPID DEFICIENCY IN EOSINOPHILS;; PRESENTEY ANOMALY__:__
Caret__:__261510__:__MOVED TO 261515__:____:__
Number Sign__:__261515__:__D-BIFUNCTIONAL PROTEIN DEFICIENCY__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY;; DBP DEFICIENCY;; PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY;; PBFE DEFICIENCY__:__
Number Sign__:__261540__:__PETERS-PLUS SYNDROME__:__KRAUSE-KIVLIN SYNDROME;; PETERS ANOMALY WITH SHORT-LIMB DWARFISM__:__
Number Sign__:__261550__:__PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I AND II; PMDS__:__PSEUDOHERMAPHRODITISM, MALE INTERNAL;; HERNIA UTERI INGUINALE;; PERSISTENT OVIDUCT SYNDROME;; FEMALE GENITAL DUCTS IN OTHERWISE NORMAL MALE__:__
NULL__:__261560__:__PFEIFFER-PALM-TELLER SYNDROME__:__PPT SYNDROME;; SHORT STATURE, UNIQUE FACIES, ENAMEL HYPOPLASIA, PROGRESSIVE JOINT STIFFNESS, AND HIGH-PITCHED VOICE__:__
NULL__:__261575__:__PHAVER SYNDROME__:____:__
NULL__:__261590__:__PHENFORMIN 4-HYDROXYLATION__:____:__
Number Sign__:__261600__:__PHENYLKETONURIA; PKU__:__PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE__:__HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED
Number Sign__:__261630__:__HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C__:__HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY__:__
Number Sign__:__261640__:__HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A__:__HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY__:__HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED
Percent__:__261650__:__PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, MITOCHONDRIAL; PCKDM__:__PCK2 DEFICIENCY;; PEPCK2 DEFICIENCY__:__
Caret__:__261660__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__261670__:__GLYCOGEN STORAGE DISEASE X; GSD10__:__GSD X;; PHOSPHOGLYCERATE MUTASE, MUSCLE, DEFICIENCY OF;; MYOPATHY DUE TO PHOSPHOGLYCERATE MUTASE DEFICIENCY;; PGAMM DEFICIENCY__:__
Number Sign__:__261680__:__PHOSPHOENOLPYRUVATE CARBOXYKINASE DEFICIENCY, CYTOSOLIC; PCKDC__:__PCK1 DEFICIENCY, CYTOSOLIC;; PEPCK DEFICIENCY, CYTOSOLIC__:__
Number Sign__:__261740__:__GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL__:__PHOSPHORYLASE KINASE DEFICIENCY OF HEART;; GLYCOGEN STORAGE DISEASE OF HEART__:__
Number Sign__:__261750__:__GLYCOGEN STORAGE DISEASE IXb; GSD9B__:__GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE__:__
Percent__:__261800__:__PIERRE ROBIN SYNDROME; PRBNS__:__GLOSSOPTOSIS, MICROGNATHIA, AND CLEFT PALATE;; PIERRE ROBIN SEQUENCE__:__
Percent__:__261900__:__PILI TORTI, EARLY-ONSET__:__PILI TORTI, RONCHESE TYPE;; TWISTED HAIR__:__
NULL__:__261990__:__PILI TORTI AND DEVELOPMENTAL DELAY__:____:__
Number Sign__:__262000__:__BJORNSTAD SYNDROME; BJS__:__PILI TORTI AND NERVE DEAFNESS;; PTD__:__
NULL__:__262020__:__PILODENTAL DYSPLASIA WITH REFRACTIVE ERRORS__:__TRICHODENTAL DYSPLASIA WITH HYPEROPIA__:__
Number Sign__:__262190__:__PINEAL HYPERPLASIA, INSULIN-RESISTANT DIABETES MELLITUS, AND SOMATIC ABNORMALITIES__:__RABSON-MENDENHALL SYNDROME;; MENDENHALL SYNDROME__:__
Number Sign__:__262300__:__ACHROMATOPSIA 3; ACHM3__:__PINGELAPESE BLINDNESS;; TOTAL COLORBLINDNESS WITH MYOPIA;; ACHROMATOPSIA WITH MYOPIA;; ACHM1, FORMERLY;; ROD MONOCHROMATISM 1, FORMERLY;; ROD MONOCHROMACY 1, FORMERLY; RMCH1, FORMERLY__:__
Caret__:__262350__:__MOVED TO 194190__:____:__
Number Sign__:__262400__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IA; IGHD1A__:__IGHD IA;; GROWTH HORMONE DEFICIENCY, ISOLATED, AUTOSOMAL RECESSIVE;; ILLIG-TYPE GROWTH HORMONE DEFICIENCY;; PRIMORDIAL DWARFISM;; SEXUAL ATELEIOTIC DWARFISM;; PITUITARY DWARFISM I__:__
Number Sign__:__262500__:__LARON SYNDROME__:__GROWTH HORMONE INSENSITIVITY SYNDROME;; PITUITARY DWARFISM II;; GROWTH HORMONE RECEPTOR DEFICIENCY__:__
Number Sign__:__262600__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 2; CPHD2__:__PANHYPOPITUITARISM;; ATELIOTIC DWARFISM WITH HYPOGONADISM;; PITUITARY DWARFISM III;; HANHART DWARFISM__:__
Number Sign__:__262650__:__KOWARSKI SYNDROME__:__BIODEFECTIVE GROWTH HORMONE;; PITUITARY DWARFISM WITH NORMAL IMMUNOREACTIVE GROWTH HORMONE AND LOW SOMATOMEDIN__:__
Number Sign__:__262700__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 4; CPHD4__:__PITUITARY HORMONE DEFICIENCY, COMBINED, WITH OR WITHOUT CEREBELLAR DEFECTS;; SHORT STATURE, PITUITARY AND CEREBELLAR DEFECTS, AND SMALL SELLA TURCICA__:__
NULL__:__262710__:__PITUITARY DWARFISM WITH LARGE SELLA TURCICA__:____:__
Caret__:__262780__:__MOVED TO 107910__:____:__
NULL__:__262800__:__PLASMA CLOT RETRACTION FACTOR, DEFICIENCY OF__:____:__
Number Sign__:__262850__:__ALPHA-2-PLASMIN INHIBITOR DEFICIENCY__:__ANTIPLASMIN DEFICIENCY;; PLASMIN INHIBITOR DEFICIENCY__:__
NULL__:__262875__:__PLATELET PROSTACYCLIN RECEPTOR DEFECT__:__VIENNA-HIETZING DEFECT__:__
Number Sign__:__262890__:__SCOTT SYNDROME; SCTS__:__BLEEDING DISORDER, PLATELET-TYPE, 7; BDPLT7;; BLEEDING ABNORMALITY DUE TO DEFICIENCY OF PLATELET BINDING OF FACTOR X;; PROTHROMBIN CONVERSION DEFECT, FAMILIAL;; PROTHROMBIN CONSUMPTION DEFICIENCY;; PROTHROMBIN CONSUMPTION INHIBITOR, FAMILIAL__:__
NULL__:__262900__:__PLEOCONIAL MYOPATHY WITH SALT CRAVING__:____:__
Percent__:__263000__:__INTERSTITIAL PNEUMONITIS, DESQUAMATIVE, FAMILIAL; DIP__:__PNEUMONITIS, DESQUAMATIVE INTERSTITIAL, FAMILIAL;; PNEUMONIA, DESQUAMATIVE INTERSTITIAL, FAMILIAL;; INTERSTITIAL LUNG DISEASE, DESQUAMATIVE;; ILD, DESQUAMATIVE__:__
NULL__:__263100__:__POLYCYSTIC KIDNEY, CATARACT, AND CONGENITAL BLINDNESS__:____:__
Number Sign__:__263200__:__POLYCYSTIC KIDNEY DISEASE 4 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD4__:__POLYCYSTIC KIDNEY DISEASE 4 WITH OR WITHOUT HEPATIC DISEASE;; POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE; ARPKD;; POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1; PKHD1;; POLYCYSTIC KIDNEY DISEASE, INFANTILE, TYPE I;; PKD3, FORMERLY__:__HEPATIC FIBROSIS, CONGENITAL, INCLUDED
Number Sign__:__263210__:__GILLESSEN-KAESBACH-NISHIMURA SYNDROME; GIKANIS__:__POLYCYSTIC KIDNEY DISEASE, AUTOSOMAL RECESSIVE, WITH MICROBRACHYCEPHALY, HYPERTELORISM, AND BRACHYMELIA__:__
Number Sign__:__263300__:__POLYCYTHEMIA VERA; PV__:__POLYCYTHEMIA RUBRA VERA; PRV__:__
Number Sign__:__263400__:__ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2__:__ERYTHROCYTOSIS, AUTOSOMAL RECESSIVE BENIGN;; POLYCYTHEMIA, VHL-DEPENDENT;; POLYCYTHEMIA, CHUVASH TYPE__:__
Percent__:__263450__:__POLYDACTYLY, POSTAXIAL, TYPE A5; PAPA5__:____:__
Caret__:__263510__:__MOVED TO 613091__:____:__
Number Sign__:__263520__:__SHORT-RIB THORACIC DYSPLASIA 6 WITH OR WITHOUT POLYDACTYLY; SRTD6__:__SHORT RIB-POLYDACTYLY SYNDROME, TYPE II;; SRPS, TYPE II;; MAJEWSKI SYNDROME;; SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA; SRPS2A;; POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE II__:__
Caret__:__263530__:__MOVED TO 613091__:____:__
NULL__:__263540__:__POLYDACTYLY, POSTAXIAL, WITH DENTAL AND VERTEBRAL ANOMALIES__:____:__
NULL__:__263550__:__POLYMYOCLONUS, INFANTILE__:____:__
Caret__:__263560__:__MOVED TO 214400__:____:__
Number Sign__:__263570__:__POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN__:__POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD__:__
NULL__:__263600__:__POLYSACCHARIDE, STORAGE OF UNUSUAL__:____:__
NULL__:__263610__:__POLYHYDRAMNIOS, CHRONIC IDIOPATHIC__:__LACTOGEN RECEPTOR DEFECT OF CHORION__:__
Caret__:__263620__:__MOVED TO 240300__:____:__
Percent__:__263630__:__POLYSYNDACTYLY WITH CARDIAC MALFORMATION__:__BONNEAU SYNDROME__:__
Number Sign__:__263650__:__BARTSOCAS-PAPAS SYNDROME; BPS__:__POPLITEAL PTERYGIUM SYNDROME, LETHAL TYPE;; PTERYGIUM, POPLITEAL, LETHAL TYPE;; MULTIPLE PTERYGIUM SYNDROME, ASLAN TYPE__:__
Number Sign__:__263700__:__PORPHYRIA, CONGENITAL ERYTHROPOIETIC__:__CEP;; GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY__:__
Number Sign__:__263750__:__POSTAXIAL ACROFACIAL DYSOSTOSIS; POADS__:__MILLER SYNDROME;; GENEE-WIEDEMANN SYNDROME__:__
Number Sign__:__263800__:__GITELMAN SYNDROME; GTLMNS__:__HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION__:__
NULL__:__264010__:__PRADER-WILLI HABITUS, OSTEOPENIA, AND CAMPTODACTYLY__:__URBAN-ROGERS-MEYER SYNDROME__:__
NULL__:__264050__:__PRENATAL BOWING__:____:__
NULL__:__264060__:__PREPAPILLARY VASCULAR LOOPS__:__PRERETINAL VASCULAR LOOPS__:__
Number Sign__:__264070__:__HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D__:__HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY__:__
NULL__:__264080__:__PROGESTERONE RESISTANCE__:__PSEUDOCORPUS LUTEUM INSUFFICIENCY__:__
Percent__:__264090__:__PROGEROID SYNDROME, NEONATAL__:__WIEDEMANN-RAUTENSTRAUCH SYNDROME__:__
NULL__:__264110__:__PROLACTIN DEFICIENCY, ISOLATED__:____:__
NULL__:__264120__:__PROLACTIN DEFICIENCY WITH OBESITY AND ENLARGED TESTES__:__PRL DEFICIENCY WITH OBESITY AND ENLARGED TESTES__:__
NULL__:__264140__:__PRUNE BELLY SYNDROME WITH PULMONIC STENOSIS, MENTAL RETARDATION, AND DEAFNESS__:____:__
Caret__:__264150__:__MOVED TO 177170__:____:__
Caret__:__264160__:__MOVED TO 177170__:____:__
NULL__:__264180__:__PSEUDODIASTROPHIC DYSPLASIA__:____:__
Caret__:__264200__:__MOVED TO 221900__:____:__
Percent__:__264270__:__PSEUDOHERMAPHRODITISM, FEMALE, WITH SKELETAL ANOMALIES__:____:__
Number Sign__:__264300__:__17-BETA HYDROXYSTEROID DEHYDROGENASE III DEFICIENCY__:__17-KETOSTEROID REDUCTASE DEFICIENCY OF TESTIS;; 17-KSR DEFICIENCY;; NEUTRAL 17-BETA-HYDROXYSTEROID OXIDOREDUCTASE DEFICIENCY;; PSEUDOHERMAPHRODITISM, MALE, WITH GYNECOMASTIA__:__POLYCYSTIC OVARY SYNDROME DUE TO 17-KETOSTEROID REDUCTASE DEFICIENCY, INCLUDED
Number Sign__:__264350__:__PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B__:__PHA I, AUTOSOMAL RECESSIVE__:__
NULL__:__264420__:__FUNDUS DYSTROPHY, PSEUDOINFLAMMATORY, RECESSIVE FORM__:__PFD, LAVIA TYPE;; PFD, FINNISH TYPE__:__
Caret__:__264450__:__MOVED TO 190685__:____:__
Number Sign__:__264470__:__PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY__:__STRAIGHT-CHAIN ACYL-CoA OXIDASE DEFICIENCY;; PSEUDONEONATAL ADRENOLEUKODYSTROPHY__:__
NULL__:__264475__:__PSEUDOPAPILLEDEMA, OCULAR HYPOTELORISM, BLEPHAROPHIMOSIS, AND HAND ANOMALIES__:__ACROOTOOCULAR SYNDROME;; AOO SYNDROME__:__
NULL__:__264480__:__PSEUDOTRISOMY 13 SYNDROME__:__HOLOPROSENCEPHALY-POLYDACTYLY SYNDROME__:__
NULL__:__264500__:__PSEUDOURIDINURIA AND MENTAL DEFECT__:____:__
Number Sign__:__264600__:__PSEUDOVAGINAL PERINEOSCROTAL HYPOSPADIAS; PPSH__:__MALE PSEUDOHERMAPHRODITISM DUE TO 5-ALPHA-REDUCTASE DEFICIENCY;; FAMILIAL INCOMPLETE MALE PSEUDOHERMAPHRODITISM, TYPE 2__:__MICROPENIS, INCLUDED
Number Sign__:__264700__:__VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1A; VDDR1A__:__VITAMIN D-DEPENDENT RICKETS, TYPE 1A;; 1-ALPHA, 25-HYDROXYVITAMIN D3 DEFICIENCY, SELECTIVE;; 25-HYDROXYCHOLECALCIFEROL-1-HYDROXYLASE DEFICIENCY;; 1-ALPHA-HYDROXYLASE DEFICIENCY;; VITAMIN D DEPENDENCY, TYPE 1; VDD1;; PSEUDOVITAMIN D-DEFICIENCY RICKETS, TYPE IA; PDDR1A;; PDDR IA__:__
Number Sign__:__264800__:__PSEUDOXANTHOMA ELASTICUM; PXE__:__GRONBLAD-STRANDBERG SYNDROME__:__PSEUDOXANTHOMA ELASTICUM, MODIFIER OF SEVERITY OF, INCLUDED;; PXE, MODIFIER OF SEVERITY OF, INCLUDED
Caret__:__264810__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__264900__:__COAGULATION FACTOR XI; F11__:__FACTOR XI__:__
Number Sign__:__265000__:__MULTIPLE PTERYGIUM SYNDROME, ESCOBAR VARIANT; EVMPS__:__ESCOBAR SYNDROME;; MULTIPLE PTERYGIUM SYNDROME, NONLETHAL TYPE;; PTERYGIUM SYNDROME;; MULTIPLE PTERYGIUM SYNDROME;; PTERYGIUM COLLI SYNDROME;; PTERYGIUM UNIVERSALE__:__
Number Sign__:__265050__:__3MC SYNDROME 2; 3MC2__:__PTOSIS OF EYELIDS WITH DIASTASIS RECTI AND HIP DYSPLASIA;; OCULO-SKELETAL-ABDOMINAL SYNDROME;; OSA SYNDROME;; CARNEVALE SYNDROME, FORMERLY__:__
Number Sign__:__265100__:__PULMONARY ALVEOLAR MICROLITHIASIS__:____:__
Number Sign__:__265120__:__SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1__:__PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 1;; INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN B DEFICIENCY;; INTERSTITIAL LUNG DISEASE, NONSPECIFIC, DUE TO SURFACTANT PROTEIN B DEFICIENCY__:__
NULL__:__265140__:__PULMONARY ARTERIOVENOUS FISTULAS__:____:__
NULL__:__265150__:__PULMONARY ATRESIA WITH INTACT VENTRICULAR SEPTUM__:____:__
NULL__:__265200__:__PULMONARY BULLAE CAUSING PNEUMOTHORAX__:____:__
Percent__:__265300__:__LYMPHANGIECTASIA, PULMONARY, CONGENITAL; CPL__:__LYMPHANGIOMATOSIS, PULMONARY;; PULMONARY CYSTIC LYMPHANGIECTASIS__:__
Number Sign__:__265380__:__ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS; ACDMPV__:__ALVEOLAR CAPILLARY DYSPLASIA WITH MISALIGNMENT OF PULMONARY VEINS AND OTHER CONGENITAL ANOMALIES__:__
NULL__:__265400__:__PULMONARY HYPERTENSION, PRIMARY, AUTOSOMAL RECESSIVE__:____:__
NULL__:__265430__:__LUNG AGENESIS__:__PULMONARY HYPOPLASIA, PRIMARY__:__
Number Sign__:__265450__:__PULMONARY VENOOCCLUSIVE DISEASE 1, AUTOSOMAL DOMINANT; PVOD1__:__PVOD__:__
NULL__:__265500__:__PULMONIC STENOSIS__:____:__
NULL__:__265600__:__PULMONIC STENOSIS AND CONGENITAL NEPHROSIS__:____:__
Number Sign__:__265800__:__PYCNODYSOSTOSIS__:__PYKNODYSOSTOSIS; PKND;; PYCD__:__
Percent__:__265850__:__PYGMY__:__PYGMY, AFRICAN__:__
NULL__:__265880__:__PYKNOACHONDROGENESIS__:____:__
Number Sign__:__265900__:__PYLE DISEASE; PYL__:__METAPHYSEAL DYSPLASIA__:__
Percent__:__265950__:__PYLORIC ATRESIA__:____:__
Number Sign__:__266100__:__EPILEPSY, PYRIDOXINE-DEPENDENT; EPD__:__PYRIDOXINE-DEPENDENT EPILEPSY; PDE;; PYRIDOXINE DEPENDENCY WITH SEIZURES;; AASA DEHYDROGENASE DEFICIENCY__:__
Number Sign__:__266120__:__URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO__:__HEMOLYTIC ANEMIA DUE TO UMPH1 DEFICIENCY;; PYRIMIDINE 5-PRIME NUCLEOTIDASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO;; HEMOLYTIC ANEMIA DUE TO P5N DEFICIENCY;; P5N DEFICIENCY;; UMPH1 DEFICIENCY__:__
Number Sign__:__266130__:__GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD__:__5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA__:__
Number Sign__:__266140__:__PYROPOIKILOCYTOSIS, HEREDITARY; HPP__:____:__
Number Sign__:__266150__:__PYRUVATE CARBOXYLASE DEFICIENCY__:__PC DEFICIENCY;; ATAXIA WITH LACTIC ACIDOSIS II;; LEIGH NECROTIZING ENCEPHALOPATHY DUE TO PYRUVATE CARBOXYLASE DEFICIENCY;; LEIGH SYNDROME DUE TO PYRUVATE CARBOXYLASE DEFICIENCY__:__
Number Sign__:__266200__:__PYRUVATE KINASE DEFICIENCY OF RED CELLS__:__PYRUVATE KINASE DEFICIENCY OF ERYTHROCYTE;; PK DEFICIENCY__:__
Percent__:__266250__:__RADICULONEUROPATHY, FATAL NEONATAL__:____:__
NULL__:__266255__:__RADIOULNAR SYNOSTOSIS, UNILATERAL, WITH DEVELOPMENTAL RETARDATION AND HYPOTONIA__:____:__
Number Sign__:__266265__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C__:__CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS__:__
NULL__:__266270__:__RAMON SYNDROME__:__CHERUBISM, GINGIVAL FIBROMATOSIS, EPILEPSY, MENTAL DEFICIENCY, HYPERTRICHOSIS, AND STUNTED GROWTH__:__
Number Sign__:__266280__:__RAPADILINO SYNDROME__:____:__
Number Sign__:__266300__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2__:__RED HAIR COLOR; RHC;; BLOND HAIR/FAIR SKIN;; RHA;; HAIR COLOR 2; HCL2__:__UV-INDUCED SKIN DAMAGE, SUSCEPTIBILITY TO, INCLUDED
Percent__:__266350__:__RED SKIN PIGMENT ANOMALY OF NEW GUINEA__:____:__
NULL__:__266400__:__REESE RETINAL DYSPLASIA__:____:__
Number Sign__:__266500__:__REFSUM DISEASE, CLASSIC__:__REFSUM DISEASE, ADULT, 1;; PHYTANIC ACID OXIDASE DEFICIENCY;; HEREDOPATHIA ATACTICA POLYNEURITIFORMIS;; HEREDITARY MOTOR AND SENSORY NEUROPATHY IV; HMSN4;; HMSN IV__:__
Number Sign__:__266510__:__PEROXISOME BIOGENESIS DISORDER 3B; PBD3B__:____:__
Number Sign__:__266600__:__INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 1; IBD1__:____:__REGIONAL ENTERITIS, INCLUDED;; CROHN DISEASE, INCLUDED;; ULCERATIVE COLITIS, INCLUDED;; CROHN DISEASE-ASSOCIATED GROWTH FAILURE, SUSCEPTIBILITY TO, INCLUDED
NULL__:__266810__:__RENAL AND MULLERIAN DUCT HYPOPLASIA__:____:__
Number Sign__:__266900__:__SENIOR-LOKEN SYNDROME 1; SLSN1__:__SENIOR-LOKEN SYNDROME;; LOKEN-SENIOR SYNDROME;; RENAL-RETINAL SYNDROME;; JUVENILE NEPHRONOPHTHISIS WITH LEBER AMAUROSIS;; RENAL DYSPLASIA AND RETINAL APLASIA__:__
NULL__:__266910__:__RENAL DYSPLASIA-LIMB DEFECTS SYNDROME__:__RL SYNDROME__:__
Number Sign__:__266920__:__SHORT-RIB THORACIC DYSPLASIA 9 WITH OR WITHOUT POLYDACTYLY; SRTD9__:__MAINZER-SALDINO SYNDROME; MZSDS;; CONORENAL SYNDROME;; RENAL DYSPLASIA, RETINAL PIGMENTARY DYSTROPHY, CEREBELLAR ATAXIA, AND SKELETAL DYSPLASIA__:__
Number Sign__:__267000__:__PERLMAN SYNDROME; PRLMNS__:__RENAL HAMARTOMAS, NEPHROBLASTOMATOSIS, AND FETAL GIGANTISM;; NEPHROBLASTOMATOSIS, FETAL ASCITES, MACROSOMIA, AND WILMS TUMOR__:__
Number Sign__:__267010__:__MECKEL SYNDROME, TYPE 7; MKS7__:__RENAL-HEPATIC-PANCREATIC DYSPLASIA WITH DANDY-WALKER CYST;; GOLDSTON SYNDROME__:__
NULL__:__267200__:__RENAL TUBULAR ACIDOSIS III__:__RTA, DISLOCATION TYPE;; RTA, BICARBONATE-WASTING TYPE__:__
Number Sign__:__267300__:__RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS__:__RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVE DEAFNESS;; RENAL TUBULAR ACIDOSIS WITH PROGRESSIVE NERVE DEAFNESS;; RTA WITH PROGRESSIVE NERVE DEAFNESS__:__
NULL__:__267400__:__RENAL, GENITAL, AND MIDDLE EAR ANOMALIES__:____:__
Number Sign__:__267430__:__RENAL TUBULAR DYSGENESIS; RTD__:__PRIMITIVE RENAL TUBULE SYNDROME__:__RENAL TUBULAR DYSGENESIS WITH CHOANAL ATRESIA AND ATHELIA, INCLUDED
NULL__:__267450__:__RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS__:__RDS OF PREMATURITY;; HYALINE MEMBRANE DISEASE, FORMERLY__:__
NULL__:__267480__:__RESPIRATORY UNDERRESPONSIVENESS TO HYPOXIA AND HYPERCAPNIA__:____:__
Number Sign__:__267500__:__RETICULAR DYSGENESIS__:__RETICULAR DYSGENESIA;; CONGENITAL ALEUKIA;; SEVERE COMBINED IMMUNODEFICIENCY WITH LEUKOPENIA;; DE VAAL DISEASE;; HEMATOPOIETIC HYPOPLASIA, GENERALIZED;; ALEUKOCYTOSIS__:__
Percent__:__267700__:__HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 1; FHL1__:__HPLH1;; HLH1;; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL; FHL; FHLH; HPLH;; RETICULOSIS, FAMILIAL HISTIOCYTIC;; HEMOPHAGOCYTIC RETICULOSIS, FAMILIAL;; ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL; FEL__:__
NULL__:__267730__:__RETICULUM CELL SARCOMA__:____:__
NULL__:__267740__:__RETINAL DEGENERATION AND EPILEPSY__:____:__
Number Sign__:__267750__:__KNOBLOCH SYNDROME 1; KNO1__:__KNO;; RETINAL DETACHMENT AND OCCIPITAL ENCEPHALOCELE__:__
NULL__:__267760__:__RETINAL DEGENERATION WITH NANOPHTHALMOS, CYSTIC MACULAR DEGENERATION, AND ANGLE CLOSURE GLAUCOMA__:____:__
NULL__:__267800__:__RETINAL DYSTROPHY, RETICULAR PIGMENTARY, OF POSTERIOR POLE__:____:__
NULL__:__267900__:__RETINAL TELANGIECTASIA AND HYPOGAMMAGLOBULINEMIA__:____:__
Number Sign__:__268000__:__RETINITIS PIGMENTOSA; RP__:____:__
NULL__:__268010__:__RETINITIS PIGMENTOSA INVERSA WITH DEAFNESS__:____:__
NULL__:__268020__:__RETINITIS PIGMENTOSA, DEAFNESS, MENTAL RETARDATION, AND HYPOGONADISM__:__INSULIN-RESISTANT DIABETES WITH ACANTHOSIS NIGRICANS, HYPOGONADISM, PIGMENTARY RETINOPATHY, DEAFNESS, AND MENTAL RETARDATION__:__
NULL__:__268025__:__RETINITIS PIGMENTOSA, LATE-ADULT ONSET__:__RETINITIS PIGMENTOSA, 'SENILE'__:__
Caret__:__268030__:__MOVED TO 600105__:____:__
NULL__:__268040__:__RETINOHEPATOENDOCRINOLOGIC SYNDROME__:__RHE SYNDROME__:__
NULL__:__268050__:__RETINOPATHY, PIGMENTARY, AND MENTAL RETARDATION__:__MIRHOSSEINI-HOLMES-WALTON SYNDROME__:__
NULL__:__268060__:__RETINOPATHY, PERICENTRAL PIGMENTARY, AUTOSOMAL RECESSIVE__:__RETINITIS PIGMENTOSA, PERICENTRAL__:__
Percent__:__268080__:__RETINOSCHISIS OF FOVEA__:____:__
Number Sign__:__268100__:__ENHANCED S-CONE SYNDROME; ESCS__:____:__GOLDMANN-FAVRE SYNDROME, INCLUDED;; RETINOSCHISIS WITH EARLY HEMERALOPIA, INCLUDED;; FAVRE HYALOIDEORETINAL DEGENERATION, INCLUDED
Number Sign__:__268130__:__REVESZ SYNDROME__:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 5; DKCA5;; EXUDATIVE RETINOPATHY WITH BONE MARROW FAILURE__:__
Number Sign__:__268150__:__RH-NULL, REGULATOR TYPE; RHNR__:__RH-NULL HEMOLYTIC ANEMIA, REGULATOR TYPE;; RH-NULL DISEASE, REGULATOR TYPE__:__RH-MOD, INCLUDED;; RH DEFICIENCY SYNDROME, INCLUDED
Number Sign__:__268200__:__MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE__:__MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT__:__
Number Sign__:__268210__:__RHABDOMYOSARCOMA, EMBRYONAL, 1; RMSE1__:__RHABDOMYOSARCOMA 1; RMS1;; RHABDOMYOSARCOMA CHROMOSOMAL REGION; RMSCR__:__
Number Sign__:__268220__:__RHABDOMYOSARCOMA 2; RMS2__:__RHABDOMYOSARCOMA, ALVEOLAR; RMSA__:__
NULL__:__268240__:__RHEUMATIC FEVER-RELATED ANTIGEN__:____:__RHEUMATIC FEVER, ACUTE, SUSCEPTIBILITY TO, INCLUDED
NULL__:__268250__:__RHIZOMELIC SYNDROME__:__RHIZOMELIC DYSPLASIA, FAMILIAL__:__
Number Sign__:__268300__:__ROBERTS SYNDROME; RBS__:__LONG BONE DEFICIENCIES ASSOCIATED WITH CLEFT LIP-PALATE__:__
Number Sign__:__268305__:__ROBIN SEQUENCE WITH CLEFT MANDIBLE AND LIMB ANOMALIES__:__RICHIERI-COSTA-PEREIRA SYNDROME; RCPS__:__
Number Sign__:__268310__:__ROBINOW SYNDROME, AUTOSOMAL RECESSIVE; RRS__:__COSTOVERTEBRAL SEGMENTATION DEFECT WITH MESOMELIA, FORMERLY;; COVESDEM SYNDROME, FORMERLY__:__ROBINOW SYNDROME, AUTOSOMAL RECESSIVE, WITH APLASIA/HYPOPLASIA OF PHALANGES AND METACARPALS/METATARSALS, INCLUDED;; ROBINOW SYNDROME, AUTOSOMAL RECESSIVE, WITH BRACHY-SYN-POLYDACTYLY, INCLUDED
NULL__:__268315__:__ROD-CONE DYSTROPHY, SENSORINEURAL DEAFNESS, AND FANCONI-TYPE RENAL DYSFUNCTION__:____:__
NULL__:__268320__:__RODRIGUES BLINDNESS__:__MICROPHTHALMIA, MICROCORNEA, AND SCLEROCORNEA WITH SHORT STATURE AND HAIR AND DENTAL ABNORMALITIES__:__
Number Sign__:__268400__:__ROTHMUND-THOMSON SYNDROME; RTS__:__POIKILODERMA ATROPHICANS AND CATARACT__:__
NULL__:__268500__:__ROWLEY-ROSENBERG SYNDROME__:__GROWTH RETARDATION, PULMONARY HYPERTENSION, AND AMINO ACIDURIA__:__
NULL__:__268650__:__RUDIGER SYNDROME__:____:__
Caret__:__268670__:__MOVED TO 270400__:____:__
Percent__:__268700__:__SACCHAROPINURIA__:__HYPERLYSINEMIA, TYPE II;; SACCHAROPINE DEHYDROGENASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY__:__
Number Sign__:__268800__:__SANDHOFF DISEASE__:__GM2-GANGLIOSIDOSIS, TYPE II;; HEXOSAMINIDASES A AND B DEFICIENCY__:__SANDHOFF DISEASE, ADULT TYPE, INCLUDED;; SANDHOFF DISEASE, JUVENILE TYPE, INCLUDED;; SANDHOFF DISEASE, INFANTILE TYPE, INCLUDED
Percent__:__268850__:__RICHIERI-COSTA/GUION-ALMEIDA SYNDROME__:__SHORT STATURE, MENTAL RETARDATION, EYE ANOMALIES, AND CLEFT LIP/PALATE;; SAO PAULO MCA/MR SYNDROME__:__
Number Sign__:__268900__:__SARCOSINEMIA; SARCOS__:__HYPERSARCOSINEMIA;; SARCOSINE DEHYDROGENASE COMPLEX DEFICIENCY;; SARDH DEFICIENCY; SARDHD;; SARD DEFICIENCY__:__
Caret__:__268950__:__MOVED TO 254110__:____:__
Number Sign__:__269000__:__SC PHOCOMELIA SYNDROME__:__SC PSEUDOTHALIDOMIDE SYNDROME__:__
Number Sign__:__269150__:__SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME__:__SGS__:__
Number Sign__:__269160__:__SCHIZENCEPHALY__:____:__
Percent__:__269200__:__AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II; APS2__:__SCHMIDT SYNDROME;; DIABETES MELLITUS, ADDISON DISEASE, MYXEDEMA;; POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE II;; PGA II;; POLYENDOCRINE AUTOIMMUNE SYNDROME, TYPE II;; APS II__:__
Number Sign__:__269250__:__SCHNECKENBECKEN DYSPLASIA; SHNKND__:__CHONDRODYSPLASIA, LETHAL NEONATAL, WITH SNAIL-LIKE PELVIS__:__
Percent__:__269300__:__CRANIOMETADIAPHYSEAL DYSPLASIA; CRMDD__:____:__
Number Sign__:__269400__:__ANTERIOR SEGMENT DYSGENESIS 7; ASGD7__:__CORNEAL OPACIFICATION WITH OTHER OCULAR ANOMALIES; COPOA;; SCLEROCORNEA WITH OTHER OCULAR ANOMALIES__:__
Number Sign__:__269500__:__SCLEROSTEOSIS 1; SOST1__:__SOST;; CORTICAL HYPEROSTOSIS WITH SYNDACTYLY__:__
Number Sign__:__269600__:__SEA-BLUE HISTIOCYTE DISEASE__:__SEA-BLUE HISTIOCYTOSIS;; HISTIOCYTOSIS, SEA-BLUE__:__
NULL__:__269630__:__SECOND METATARSAL-METACARPAL SYNDROME__:____:__
NULL__:__269650__:__SECRETORY COMPONENT DEFICIENCY__:__IgA DEFICIENCY, SECRETORY__:__
Number Sign__:__269700__:__LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 2; CGL2__:__BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 2;; SEIP SYNDROME;; BERARDINELLI SYNDROME;; LIPODYSTROPHY, TOTAL, AND ACROMEGALOID GIGANTISM;; LIPOATROPHIC DIABETES, CONGENITAL;; LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 2;; BRUNZELL SYNDROME, BSCL2-RELATED__:__
NULL__:__269720__:__SEIZURES, BENIGN FAMILIAL NEONATAL, AUTOSOMAL RECESSIVE__:__BFNS, AUTOSOMAL RECESSIVE;; CONVULSIONS, BENIGN FAMILIAL NEONATAL, AUTOSOMAL RECESSIVE;; EPILEPSY, BENIGN FAMILIAL NEONATAL, AUTOSOMAL RECESSIVE__:__
NULL__:__269800__:__SENILE PLAQUE FORMATION__:____:__
Number Sign__:__269840__:__IMMUNODEFICIENCY 48; IMD48__:__SELECTIVE T-CELL DEFECT; STCD__:__
Percent__:__269860__:__SHORT-RIB THORACIC DYSPLASIA 12; SRTD12__:__SHORT RIB-POLYDACTYLY SYNDROME, TYPE IV; SRPS4;; SRPS IV;; BEEMER-LANGER SYNDROME;; SHORT RIB SYNDROME, BEEMER TYPE__:__
NULL__:__269870__:__SHORT STATURE-OBESITY SYNDROME; SSOS__:____:__
Number Sign__:__269880__:__SHORT SYNDROME__:__SHORT STATURE, HYPEREXTENSIBILITY, HERNIA, OCULAR DEPRESSION, RIEGER ANOMALY, AND TEETHING DELAY;; LIPODYSTROPHY, PARTIAL, WITH RIEGER ANOMALY AND SHORT STATURE__:__
Number Sign__:__269920__:__INFANTILE SIALIC ACID STORAGE DISEASE; ISSD__:__SIALURIA, INFANTILE FORM;; N-ACETYLNEURAMINIC ACID STORAGE DISEASE;; NANA STORAGE DISEASE; NSD__:__
Number Sign__:__269921__:__SIALURIA__:__SIALURIA, FRENCH TYPE__:__
Caret__:__269950__:__MOVED TO 206000__:____:__
Caret__:__270050__:__MOVED TO 180860__:____:__
Number Sign__:__270100__:__HETEROTAXY, VISCERAL, 5, AUTOSOMAL; HTX5__:__SITUS INVERSUS VISCERUM; SIV__:__
Percent__:__270150__:__SJOGREN SYNDROME__:__SICCA SYNDROME__:__
Number Sign__:__270200__:__SJOGREN-LARSSON SYNDROME; SLS__:__ICHTHYOSIS, SPASTIC NEUROLOGIC DISORDER, AND OLIGOPHRENIA;; FATTY ALCOHOL:NAD+ OXIDOREDUCTASE DEFICIENCY;; FATTY ALDEHYDE DEHYDROGENASE DEFICIENCY;; FALDH DEFICIENCY__:__
NULL__:__270220__:__SJOGREN-LARSSON-LIKE ICHTHYOSIS WITHOUT CNS OR EYE INVOLVEMENT__:__ICHTHYOSIS, SJOGREN-LARSSON-LIKE, WITHOUT CNS OR EYE INVOLVEMENT__:__
Caret__:__270230__:__MOVED TO 187600__:____:__
Caret__:__270240__:__MOVED TO 268400__:____:__
Number Sign__:__270300__:__PEELING SKIN SYNDROME 1; PSS1__:__PSS;; SKIN PEELING, FAMILIAL CONTINUOUS GENERALIZED;; KERATOLYSIS EXFOLIATIVA CONGENITA;; DECIDUOUS SKIN__:__
NULL__:__270350__:__ANOSMIA FOR BUTYL MERCAPTAN__:__SKUNK N-BUTYL MERCAPTAN, INABILITY TO SMELL__:__
Number Sign__:__270400__:__SMITH-LEMLI-OPITZ SYNDROME; SLOS__:__SLO SYNDROME;; RSH SYNDROME;; RUTLEDGE LETHAL MULTIPLE CONGENITAL ANOMALY SYNDROME;; POLYDACTYLY, SEX REVERSAL, RENAL HYPOPLASIA, AND UNILOBAR LUNG;; LETHAL ACRODYSGENITAL SYNDROME__:__
Number Sign__:__270420__:__DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, WITH OR WITHOUT OTHER CONGENITAL ANOMALIES; DIAR3__:__SODIUM DIARRHEA, CONGENITAL; CSD;; DIARRHEA 3, SECRETORY SODIUM, CONGENITAL, SYNDROMIC__:__
NULL__:__270425__:__SODIUM-POTASSIUM-ATPase ACTIVITY OF RED CELL__:__SODIUM PUMP SITES, NUMBER OF__:__
Number Sign__:__270450__:__INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO; IGF1RES__:__SOMATOMEDIN, END-ORGAN INSENSITIVITY TO;; SOMATOMEDIN-C, RESISTANCE TO;; IGF-I RESISTANCE__:__INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO, DUE TO INCREASED BINDING PROTEIN, INCLUDED
NULL__:__270460__:__SONODA SYNDROME__:__ROUND FACE WITH DEPRESSED NASAL BRIDGE AND SMALL MOUTH, CONGENITAL HEART DEFECT, AND RETARDED DEVELOPMENT__:__
NULL__:__270500__:__ATAXIA, SPASTIC, CHILDHOOD-ONSET, AUTOSOMAL RECESSIVE, WITH OPTIC ATROPHY AND MENTAL RETARDATION__:____:__
Number Sign__:__270550__:__SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY TYPE; SACS__:__SPASTIC ATAXIA 6, AUTOSOMAL RECESSIVE; SPAX6;; CHARLEVOIX-SAGUENAY SPASTIC ATAXIA;; AUTOSOMAL RECESSIVE SPASTIC ATAXIA OF CHARLEVOIX-SAGUENAY; ARSACS__:__
Percent__:__270600__:__SPASTIC DIPLEGIA AND MENTAL RETARDATION__:__SPASTIC DIPLEGIA, INFANTILE TYPE__:__
Caret__:__270680__:__MOVED TO 270750__:____:__
Number Sign__:__270685__:__SPASTIC PARAPLEGIA 17, AUTOSOMAL DOMINANT; SPG17__:__SPASTIC PARAPLEGIA WITH AMYOTROPHY OF HANDS AND FEET;; SILVER SYNDROME;; SILVER SPASTIC PARAPLEGIA SYNDROME__:__
Number Sign__:__270700__:__SPASTIC PARAPLEGIA 15, AUTOSOMAL RECESSIVE; SPG15__:__SPASTIC PARAPLEGIA AND RETINAL DEGENERATION;; KJELLIN SYNDROME__:__
Caret__:__270710__:__MOVED TO 270550, 190350, AND 616944__:____:__
Number Sign__:__270750__:__SPASTIC PARAPLEGIA 23; SPG23__:__SPASTIC PARAPLEGIA WITH PIGMENTARY ABNORMALITIES;; SPASTIC PARAPARESIS, VITILIGO, PREMATURE GRAYING, CHARACTERISTIC FACIES;; LISON SYNDROME__:__
Number Sign__:__270800__:__SPASTIC PARAPLEGIA 5A, AUTOSOMAL RECESSIVE; SPG5A__:____:__
NULL__:__270805__:__SPASTIC PARAPLEGIA WITH MYOCLONIC EPILEPSY__:____:__
NULL__:__270850__:__SPASTIC PARESIS, GLAUCOMA, AND MENTAL RETARDATION__:____:__
NULL__:__270900__:__SPASTIC PSEUDOSCLEROSIS__:__DISSEMINATED ENCEPHALOMYELOPATHY;; CORTICOPALLIDODEGENERATION__:__
NULL__:__270950__:__SPASTIC QUADRIPLEGIA, RETINITIS PIGMENTOSA, AND MENTAL RETARDATION__:____:__
Number Sign__:__270960__:__SPERMATOGENIC FAILURE 4; SPGF4__:__AZOOSPERMIA DUE TO PERTURBATIONS OF MEIOSIS;; AZOOSPERMIA WITH MATURATION ARREST;; SPERMATOGENESIS ARREST__:__PREGNANCY LOSS, RECURRENT, 4, INCLUDED; RPRGL4, INCLUDED
Number Sign__:__270970__:__SPHEROCYTOSIS, TYPE 3; SPH3__:__SPHEROCYTOSIS, HEREDITARY, 3; HS3__:__
Caret__:__271100__:__MOVED TO 153400__:____:__
NULL__:__271109__:__SPINAL MUSCULAR ATROPHY WITH MENTAL RETARDATION__:____:__
NULL__:__271110__:__SPINAL MUSCULAR ATROPHY WITH MICROCEPHALY AND MENTAL SUBNORMALITY__:____:__
Caret__:__271120__:__MOVED TO 182960__:____:__
Number Sign__:__271150__:__SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4__:__SPINAL MUSCULAR ATROPHY, ADULT FORM;; SPINAL MUSCULAR ATROPHY, PROXIMAL, ADULT, AUTOSOMAL RECESSIVE__:__
NULL__:__271200__:__SPINAL MUSCULAR ATROPHY, RYUKYUAN TYPE__:____:__
NULL__:__271220__:__SPINAL MUSCULAR ATROPHY, SCAPULOPERONEAL__:____:__
NULL__:__271225__:__SPINAL MUSCULAR ATROPHY, TYPE I, WITH CONGENITAL BONE FRACTURES__:____:__
Number Sign__:__271245__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7__:__SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY__:__
Percent__:__271250__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 3; SCAR3__:__SPINOCEREBELLAR ATAXIA WITH BLINDNESS AND DEAFNESS; SCABD__:__
NULL__:__271270__:__SPINOCEREBELLAR ATAXIA WITH DYSMORPHISM__:____:__
NULL__:__271310__:__SPINOCEREBELLAR DEGENERATION AND CORNEAL DYSTROPHY__:__CORNEAL-CEREBELLAR SYNDROME;; CORNEAL DYSTROPHY WITH SPINOCEREBELLAR DEGENERATION__:__
NULL__:__271320__:__SPINOCEREBELLAR DEGENERATION WITH MACULAR CORNEAL DYSTROPHY, CONGENITAL CATARACTS, AND MYOPIA__:__BEDOUIN SPASTIC ATAXIA SYNDROME__:__
NULL__:__271322__:__SPINOCEREBELLAR DEGENERATION WITH SLOW EYE MOVEMENTS; SDSEM__:____:__
Number Sign__:__271400__:__ASPLENIA, ISOLATED CONGENITAL; ICAS__:__HYPOSPLENIA, ISOLATED CONGENITAL;; SPLENIC HYPOPLASIA;; ASPLENIA, FAMILIAL__:__
NULL__:__271500__:__SPLENOPORTAL VASCULAR ANOMALIES__:____:__
Percent__:__271510__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SPONASTRIME TYPE__:__SPONDYLAR AND NASAL ALTERATIONS WITH STRIATED METAPHYSES;; SPONASTRIME DYSPLASIA;; SHORT-LIMB DWARFISM WITH SADDLE NOSE, SPINAL ALTERATIONS, AND METAPHYSEAL STRIATION__:__
NULL__:__271520__:__SPONDYLOCOSTAL DYSOSTOSIS WITH ANAL ATRESIA AND UROGENITAL ANOMALIES__:__CASAMASSIMA-MORTON-NANCE SYNDROME;; CMN SYNDROME__:__
Percent__:__271530__:__BRACHYOLMIA TYPE 1, HOBAEK TYPE; BCYM1A__:__BRACHYOLMIA, RECESSIVE TYPE OF HOBAEK;; SPONDYLODYSPLASIA WITH PURE BRACHYOLMIA__:__
Caret__:__271550__:__MOVED TO 607944__:____:__
Percent__:__271600__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE__:____:__
NULL__:__271620__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA WITH MENTAL RETARDATION__:__SEDT WITH MENTAL RETARDATION__:__
Percent__:__271630__:__BRACHYOLMIA TYPE 1, TOLEDO TYPE; BCYM1B__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, TOLEDO TYPE;; SED, CHONDROITIN SULFATE TYPE;; PAPS-CHONDROITIN SULFATE SULFOTRANSFERASE DEFICIENCY__:__
Number Sign__:__271640__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 1, WITH OR WITHOUT FRACTURES; SEMDJL1__:__SEMDJL__:__
Percent__:__271650__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, IRAPA TYPE; SEMDIT__:____:__
Number Sign__:__271665__:__SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE__:__SMED-SL;; SMED, SHORT LIMB-HAND TYPE;; SMED, TYPE II;; SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-ABNORMAL CALCIFICATION TYPE;; SMED, SHORT LIMB-ABNORMAL CALCIFICATION TYPE;; SMED-SL/AC__:__
Number Sign__:__271700__:__SPONDYLOPERIPHERAL DYSPLASIA__:__SPONDYLOPERIPHERAL DYSPLASIA WITH SHORT ULNA__:__
Number Sign__:__271900__:__CANAVAN DISEASE__:__CANAVAN-VAN BOGAERT-BERTRAND DISEASE;; SPONGY DEGENERATION OF CENTRAL NERVOUS SYSTEM;; ASPARTOACYLASE DEFICIENCY;; ASPA DEFICIENCY;; ASP DEFICIENCY;; AMINOACYLASE 2 DEFICIENCY;; ACY2 DEFICIENCY__:__
Number Sign__:__271930__:__STRIATONIGRAL DEGENERATION, INFANTILE; SNDI__:__INFANTILE BILATERAL STRIATAL NECROSIS; IBSN;; BILATERAL STRIATAL NECROSIS, INFANTILE;; STRIATAL DEGENERATION, FAMILIAL__:__
NULL__:__271950__:__SUBAORTIC STENOSIS, MEMBRANOUS__:____:__
NULL__:__271960__:__SUBAORTIC STENOSIS--SHORT STATURE SYNDROME__:__ONAT SYNDROME__:__
Number Sign__:__271980__:__SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD__:__SSADH DEFICIENCY;; 4-HYDROXYBUTYRIC ACIDURIA;; GABA METABOLIC DEFECT;; GAMMA-HYDROXYBUTYRIC ACIDURIA__:__
NULL__:__272000__:__SUCROSURIA, HIATUS HERNIA AND MENTAL RETARDATION__:____:__
NULL__:__272100__:__SUDANOPHILIC CEREBRAL SCLEROSIS__:__SCHILDER DISEASE__:__
Number Sign__:__272120__:__SUDDEN INFANT DEATH SYNDROME__:__SIDS__:__
NULL__:__272150__:__SUGARMAN BRACHYDACTYLY__:__BRACHYDACTYLY WITH MAJOR PROXIMAL PHALANGEAL SHORTENING__:__
Number Sign__:__272200__:__MULTIPLE SULFATASE DEFICIENCY; MSD__:__MUCOSULFATIDOSIS;; SULFATIDOSIS, JUVENILE, AUSTIN TYPE__:__
Number Sign__:__272300__:__SULFITE OXIDASE DEFICIENCY, ISOLATED; ISOD__:__SULFOCYSTEINURIA__:__
NULL__:__272350__:__SUMMITT SYNDROME__:____:__
Percent__:__272370__:__SUSCEPTIBILITY TO LYSIS BY ALLOREACTIVE NATURAL KILLER CELLS; EC1__:__NATURAL KILLER CELL SUSCEPTIBILITY 1; NKS1__:__
Number Sign__:__272430__:__CRISPONI/COLD-INDUCED SWEATING SYNDROME 1; CISS1__:__CRISPONI SYNDROME;; SOHAR-CRISPONI SYNDROME;; MUSCLE CONTRACTIONS, TETANOFORM, WITH CHARACTERISTIC FACE, CAMPTODACTYLY, HYPERTHERMIA, AND SUDDEN DEATH__:__
Number Sign__:__272440__:__FILIPPI SYNDROME; FLPIS__:__SYNDACTYLY, TYPE I, WITH MICROCEPHALY AND MENTAL RETARDATION;; SCOTT CRANIODIGITAL SYNDROME WITH MENTAL RETARDATION__:__
NULL__:__272450__:__SYNDESMODYSPLASIC DWARFISM__:____:__
Number Sign__:__272460__:__SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME; SCT__:__SPONDYLOCARPOTARSAL SYNDROME;; SYNSPONDYLISM, CONGENITAL;; VERTEBRAL FUSION WITH CARPAL COALITION;; SCOLIOSIS, CONGENITAL, WITH UNILATERAL UNSEGMENTED BAR__:__
Caret__:__272480__:__MOVED TO 186700__:____:__
Caret__:__272500__:__MOVED TO 269700__:____:__
Caret__:__272550__:__MOVED TO 138500__:____:__
NULL__:__272600__:__TAPETORETINAL DEGENERATION WITH ATAXIA__:____:__
NULL__:__272620__:__TARDIVE DYSKINESIA__:____:__
Percent__:__272650__:__TATSUMI FACTOR DEFICIENCY__:____:__
NULL__:__272700__:__TAURODONTISM__:____:__
Number Sign__:__272750__:__GM2-GANGLIOSIDOSIS, AB VARIANT__:__HEXOSAMINIDASE ACTIVATOR DEFICIENCY;; GM2 ACTIVATOR DEFICIENCY;; AB VARIANT GM2-GANGLIOSIDOSIS;; TAY-SACHS DISEASE, AB VARIANT__:__
Number Sign__:__272800__:__TAY-SACHS DISEASE; TSD__:__GM2-GANGLIOSIDOSIS, TYPE I;; B VARIANT GM2-GANGLIOSIDOSIS;; HEXOSAMINIDASE A DEFICIENCY;; HEXA DEFICIENCY__:__TAY-SACHS DISEASE, JUVENILE, INCLUDED;; HEXOSAMINIDASE A DEFICIENCY, ADULT TYPE, INCLUDED;; GM2-GANGLIOSIDOSIS, ADULT CHRONIC TYPE, INCLUDED;; GM2-GANGLIOSIDOSIS, VARIANT B1, INCLUDED;; TAY-SACHS DISEASE, VARIANT B1, INCLUDED;; TAY-SACHS DISEASE, PSEUDO-AB VARIANT, INCLUDED
NULL__:__272950__:__TEEBI-SHALTOUT SYNDROME; TBSH__:__CRANIOFACIAL ANOMALIES, ABNORMAL HAIR, CAMPTODACTYLY, AND CAUDAL APPENDAGE__:__
NULL__:__272980__:__TEETH, CONGENITAL ABSENCE OF, WITH TAURODONTIA AND SPARSE HAIR__:__TAURODONTIA, ABSENT TEETH, AND SPARSE HAIR__:__
NULL__:__273000__:__TEETH, FUSED__:____:__
NULL__:__273050__:__TEETH, NONERUPTION OF, WITH MAXILLARY HYPOPLASIA AND GENU VALGUM__:____:__
NULL__:__273120__:__TERATOMA, PINEAL__:____:__
NULL__:__273150__:__TESTES, RUDIMENTARY__:____:__
Percent__:__273250__:__TESTICULAR REGRESSION SYNDROME; TRS__:__TESTICULAR REGRESSION, EMBRYONIC;; XY GONADAL AGENESIS SYNDROME;; ANORCHIA, FAMILIAL__:__
Number Sign__:__273300__:__TESTICULAR GERM CELL TUMOR; TGCT__:__MALE GERM CELL TUMOR; MGCT__:__SEMINOMA, INCLUDED;; NONSEMINOMATOUS GERM CELL TUMORS, INCLUDED;; TERATOMA, TESTICULAR, INCLUDED;; EMBRYONAL CELL CARCINOMA, INCLUDED;; ENDODERMAL SINUS TUMOR, INCLUDED;; SPERMATOCYTIC SEMINOMA, INCLUDED
Caret__:__273350__:__MOVED TO 154230__:____:__
NULL__:__273390__:__TETRAAMELIA WITH ECTODERMAL DYSPLASIA AND LACRIMAL DUCT ABNORMALITIES__:____:__
Number Sign__:__273395__:__TETRAAMELIA SYNDROME 1; TETAMS1__:__TETRAAMELIA SYNDROME, AUTOSOMAL RECESSIVE__:__
NULL__:__273400__:__TETRAMELIC DEFICIENCIES, ECTODERMAL DYSPLASIA, DEFORMED EARS, AND OTHER ABNORMALITIES__:__ODONTOTRICHOMELIC SYNDROME__:__
NULL__:__273490__:__THALAMIC DEGENERATION, SYMMETRIC INFANTILE__:____:__
NULL__:__273600__:__THALIDOMIDE SUSCEPTIBILITY__:____:__
NULL__:__273680__:__THANATOPHORIC DYSPLASIA, GLASGOW VARIANT__:__NEONATALLY LETHAL SHORT-LIMB SKELETAL DYSPLASIA, GLASGOW TYPE__:__
NULL__:__273730__:__THORACIC DYSPLASIA-HYDROCEPHALUS SYNDROME__:____:__
NULL__:__273740__:__THORACOMELIC DYSPLASIA__:__'THORACO-LIMB' DYSPLASIA__:__
Number Sign__:__273750__:__THREE M SYNDROME 1; 3M1__:__3M SYNDROME;; LE MERRER SYNDROME;; DOLICHOSPONDYLIC DYSPLASIA;; GLOOMY FACE SYNDROME__:__YAKUT SHORT STATURE SYNDROME, INCLUDED
NULL__:__273770__:__THREONINEMIA__:__HYPERTHREONINEMIA__:__
Number Sign__:__273800__:__GLANZMANN THROMBASTHENIA; GT__:__BLEEDING DISORDER, PLATELET-TYPE, 2; BDPLT2;; THROMBASTHENIA OF GLANZMANN AND NAEGELI;; PLATELET GLYCOPROTEIN IIb-IIIa DEFICIENCY;; GP IIb-IIIa COMPLEX, DEFICIENCY OF;; PLATELET FIBRINOGEN RECEPTOR, DEFICIENCY OF;; GLYCOPROTEIN COMPLEX IIb-IIIa, DEFICIENCY OF__:__
Number Sign__:__273900__:__THROMBOCYTOPENIA 3; THC3__:__THROMBOCYTOPENIA, AUTOSOMAL RECESSIVE, 3__:__
Number Sign__:__274000__:__THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME; TAR__:__TAR SYNDROME;; CHROMOSOME 1q21.1 DELETION SYNDROME, 200-KB__:__
Number Sign__:__274150__:__THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP__:__MICROANGIOPATHIC HEMOLYTIC ANEMIA;; THROMBOTIC MICROANGIOPATHY, FAMILIAL;; UPSHAW-SCHULMAN SYNDROME; USS;; SCHULMAN-UPSHAW SYNDROME;; UPSHAW FACTOR, DEFICIENCY OF;; MICROANGIOPATHIC HEMOLYTIC ANEMIA, CONGENITAL;; THROMBOTIC THROMBOCYTOPENIC PURPURA, FAMILIAL__:__
Asterisk__:__274180__:__THROMBOXANE A SYNTHASE 1; TBXAS1__:__THROMBOXANE A SYNTHASE, PLATELET;; CYTOCHROME P450, SUBFAMILY V; CYP5;; CYP5A1__:__
Percent__:__274190__:__THUMB AGENESIS, SHORT STATURE, AND IMMUNODEFICIENCY__:____:__
NULL__:__274200__:__THUMB, DISTAL HYPEREXTENSIBILITY OF__:____:__
NULL__:__274205__:__THUMB, HYPOPLASTIC, WITH CHOROID COLOBOMA, POORLY DEVELOPED ANTIHELIX, AND DEAFNESS__:____:__
NULL__:__274210__:__THYMIC APLASIA WITH FETAL DEATH__:____:__
NULL__:__274230__:__THYMOMA, FAMILIAL__:__THYMIC NEOPLASIA__:__
NULL__:__274240__:__THYROCEREBRORETINAL SYNDROME__:____:__
Caret__:__274260__:__MOVED TO 274230__:____:__
NULL__:__274265__:__THYMIC-RENAL-ANAL-LUNG DYSPLASIA__:____:__
Number Sign__:__274270__:__DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY__:__DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL__:__5-FLUOROURACIL TOXICITY, INCLUDED
Number Sign__:__274300__:__THYROID HORMONE RESISTANCE, GENERALIZED, AUTOSOMAL RECESSIVE; GRTH__:__GTHR;; THYROID HORMONE UNRESPONSIVENESS;; REFETOFF SYNDROME__:__
Number Sign__:__274400__:__THYROID DYSHORMONOGENESIS 1; TDH1__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 1;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 1;; IODINE ACCUMULATION, TRANSPORT, OR TRAPPING DEFECT__:__
Number Sign__:__274500__:__THYROID DYSHORMONOGENESIS 2A; TDH2A__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2A;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2A;; IODIDE PEROXIDASE DEFICIENCY;; THYROID PEROXIDASE DEFICIENCY__:__
Number Sign__:__274600__:__PENDRED SYNDROME; PDS__:__DEAFNESS WITH GOITER;; GOITER-DEAFNESS SYNDROME;; THYROID DYSHORMONOGENESIS 2B; TDH2B;; THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B__:__
Number Sign__:__274700__:__THYROID DYSHORMONOGENESIS 3; TDH3__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 3;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 3__:__
Number Sign__:__274800__:__THYROID DYSHORMONOGENESIS 4; TDH4__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 4;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 4;; IODOTYROSINE DEHALOGENASE DEFICIENCY;; DEIODINASE DEFICIENCY__:__
Number Sign__:__274900__:__THYROID DYSHORMONOGENESIS 5; TDH5__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 5;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 5__:__
Percent__:__275000__:__GRAVES DISEASE, SUSCEPTIBILITY TO, 1; GRD1__:__GRD;; THYROTOXICOSIS;; HYPERTHYROIDISM, AUTOIMMUNE__:__
Number Sign__:__275100__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4__:__THYROTROPIN DEFICIENCY, ISOLATED;; THYROID-STIMULATING HORMONE DEFICIENCY;; TSH DEFICIENCY;; PITUITARY CRETINISM__:__THYROTROPIN, BIOLOGICALLY INACTIVE, INCLUDED
Percent__:__275120__:__THYROTROPIN-RELEASING HORMONE DEFICIENCY__:__TRH DEFICIENCY;; HYPOTHALAMIC HYPOTHYROIDISM__:__
NULL__:__275190__:__TIGLIC ACIDEMIA__:____:__
Number Sign__:__275200__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 1; CHNG1__:__THYROTROPIN RESISTANCE;; THYROID-STIMULATING HORMONE, RESISTANCE TO; RTSH;; TSH RESISTANCE;; HYPOTHYROIDISM, NONAUTOIMMUNE;; HYPOTHYROIDISM, CONGENITAL, DUE TO TSH RESISTANCE;; HYPOTHYROIDISM DUE TO UNRESPONSIVENESS TO THYROTROPIN__:__
Number Sign__:__275210__:__RESTRICTIVE DERMOPATHY, LETHAL__:__TIGHT SKIN CONTRACTURE SYNDROME, LETHAL;; HYPERKERATOSIS-CONTRACTURE SYNDROME;; FETAL HYPOKINESIA SEQUENCE DUE TO RESTRICTIVE DERMOPATHY__:__
NULL__:__275220__:__TIBIAL HEMIMELIA__:__THM;; TIBIA, ABSENCE OF__:__
NULL__:__275230__:__TIBIA, ABSENCE OF, WITH CONGENITAL DEAFNESS__:____:__
NULL__:__275240__:__TINEA IMBRICATA, SUSCEPTIBILITY TO__:____:__
Percent__:__275250__:__TONGUE, PIGMENTED FUNGIFORM PAPILLAE OF__:____:__
NULL__:__275300__:__TRACHEOBRONCHOMEGALY__:____:__
Number Sign__:__275350__:__TRANSCOBALAMIN II DEFICIENCY__:__TC II DEFICIENCY;; TCN2 DEFICIENCY__:__
Number Sign__:__275355__:__SQUAMOUS CELL CARCINOMA, HEAD AND NECK; HNSCC__:____:__
Asterisk__:__275360__:__TREHALASE; TREH__:__ALPHA,ALPHA-TREHALOSE-1-D-GLUCOHYDROLASE__:__
Percent__:__275370__:__TRICARBOXYLIC ACID CYCLE, DEFECT OF__:____:__
Number Sign__:__275400__:__OLIVER-MCFARLANE SYNDROME; OMCS__:__TRICHOMEGALY WITH MENTAL RETARDATION, DWARFISM, AND PIGMENTARY DEGENERATION OF RETINA;; EYELASHES, LONG, WITH MENTAL RETARDATION__:__
NULL__:__275450__:__TRICHOODONTOONYCHIAL DYSPLASIA WITH BONE DEFICIENCY__:____:__
Caret__:__275500__:__MOVED TO 190350__:____:__
Caret__:__275550__:__MOVED TO 234050__:____:__
NULL__:__275595__:__TRIGONOBRACHYCEPHALY, BULBOUS BIFID NOSE, MICROGNATHIA, AND ABNORMALITIES OF THE HANDS AND FEET__:____:__
Caret__:__275600__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__275630__:__CHANARIN-DORFMAN SYNDROME; CDS__:__NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION__:__
Caret__:__275650__:__MOVED TO 214950__:____:__
Number Sign__:__275900__:__SPASTIC PARAPLEGIA 20, AUTOSOMAL RECESSIVE; SPG20__:__TROYER SYNDROME;; SPASTIC PARAPARESIS, CHILDHOOD-ONSET, WITH DISTAL MUSCLE WASTING;; SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, TROYER TYPE__:__
Asterisk__:__276000__:__PROTEASE, SERINE, 1; PRSS1__:__TRYPSINOGEN 1; TRY1;; TRYPSINOGEN, CATIONIC__:__TRYPSIN 1, INCLUDED
Percent__:__276100__:__TRYPTOPHANURIA WITH DWARFISM__:____:__
NULL__:__276200__:__T-SUBSTANCE ANOMALY__:____:__
Number Sign__:__276300__:__MISMATCH REPAIR CANCER SYNDROME; MMRCS__:__CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME; CMMRDS;; MISMATCH REPAIR DEFICIENCY;; MMR DEFICIENCY;; CHILDHOOD CANCER SYNDROME;; BRAIN TUMOR-POLYPOSIS SYNDROME 1; BTPS1;; BTP1 SYNDROME;; TURCOT SYNDROME__:__
Percent__:__276400__:__TWINNING, DIZYGOTIC__:____:__OVARIAN RESPONSE TO FSH STIMULATION, INCLUDED
NULL__:__276410__:__TWINNING, MONOZYGOTIC__:____:__
Caret__:__276500__:__MOVED TO 276710__:____:__
Number Sign__:__276600__:__TYROSINEMIA, TYPE II; TYRSN2__:__RICHNER-HANHART SYNDROME;; TYROSINE AMINOTRANSFERASE DEFICIENCY;; TAT DEFICIENCY;; TYROSINE TRANSAMINASE DEFICIENCY;; KERATOSIS PALMOPLANTARIS WITH CORNEAL DYSTROPHY;; OREGON TYPE TYROSINEMIA;; TYROSINOSIS, OCULOCUTANEOUS TYPE__:__
Number Sign__:__276700__:__TYROSINEMIA, TYPE I; TYRSN1__:__HEPATORENAL TYROSINEMIA;; FUMARYLACETOACETASE DEFICIENCY;; FAH DEFICIENCY__:__
Number Sign__:__276710__:__TYROSINEMIA, TYPE III; TYRSN3__:__4-HYDROXYPHENYLPYRUVIC ACID OXIDASE DEFICIENCY;; 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE DEFICIENCY__:__
NULL__:__276800__:__TYROSINOSIS__:____:__
Number Sign__:__276820__:__ULNA AND FIBULA, ABSENCE OF, WITH SEVERE LIMB DEFICIENCY__:__LIMB/PELVIS-HYPOPLASIA/APLASIA SYNDROME; LPHAS;; AL-AWADI/RAAS-ROTHSCHILD SYNDROME; AARRS;; SCHINZEL PHOCOMELIA SYNDROME__:__
NULL__:__276821__:__ULNAR HYPOPLASIA WITH MENTAL RETARDATION__:__MESOMELIA OF THE UPPER LIMBS, ANONYCHIA CONGENITA, CLUBFEET, AND MENTAL RETARDATION__:__
NULL__:__276822__:__ULNAR AGENESIS AND ENDOCARDIAL FIBROELASTOSIS__:____:__
Caret__:__276850__:__MOVED TO 274150__:____:__
Number Sign__:__276880__:__UROCANASE DEFICIENCY; UROCD__:____:__
Number Sign__:__276900__:__USHER SYNDROME, TYPE I; USH1__:__US1;; RETINITIS PIGMENTOSA AND CONGENITAL DEAFNESS__:__USHER SYNDROME, TYPE IB, INCLUDED; USH1B, INCLUDED;; USHER SYNDROME, TYPE IA, FORMERLY, INCLUDED; USH1A, FORMERLY, INCLUDED;; USHER SYNDROME, TYPE I, FRENCH VARIETY, FORMERLY, INCLUDED
Number Sign__:__276901__:__USHER SYNDROME, TYPE IIA; USH2A__:____:__
Number Sign__:__276902__:__USHER SYNDROME, TYPE IIIA; USH3A__:__USHER SYNDROME, TYPE III; USH3__:__
Asterisk__:__276903__:__MYOSIN VIIA; MYO7A__:__MYOSIN, UNCONVENTIONAL, FAMILY VII, MEMBER A; MYU7A__:__
Number Sign__:__276904__:__USHER SYNDROME, TYPE IC; USH1C__:__USHER SYNDROME, TYPE I, ACADIAN VARIETY__:__
Caret__:__276905__:__MOVED TO 605472__:____:__
Percent__:__276950__:__VACTERL ASSOCIATION WITH HYDROCEPHALUS__:__VACTERL-H__:__VATER ASSOCIATION WITH HYDROCEPHALUS, INCLUDED;; VATER ASSOCIATION WITH MACROCEPHALY AND VENTRICULOMEGALY, INCLUDED
Percent__:__277000__:__MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME__:__MRKH SYNDROME;; MULLERIAN APLASIA/DYSGENESIS;; VON MAYER-ROKITANSKY-KUSTER ANOMALY;; MRKH ANOMALY;; MRK ANOMALY;; UTERUS BIPARTITUS SOLIDUS RUDIMENTARIUS CUM VAGINA SOLIDA;; CONGENITAL ABSENCE OF UTERUS AND VAGINA; CAUV__:__UROGENITAL ADYSPLASIA, INCLUDED
Percent__:__277100__:__VALINEMIA__:__VALINE TRANSAMINASE DEFICIENCY;; HYPERVALINEMIA__:__
Percent__:__277150__:__VAN BOGAERT-HOZAY SYNDROME__:____:__
Number Sign__:__277170__:__OROFACIODIGITAL SYNDROME VI; OFD6__:__ORAL-FACIAL-DIGITAL SYNDROME, TYPE VI;; OFDS VI;; VARADI-PAPP SYNDROME;; VARADI SYNDROME;; POLYDACTYLY, CLEFT LIP/PALATE OR LINGUAL LUMP, AND PSYCHOMOTOR RETARDATION__:__
NULL__:__277175__:__VASCULAR HYALINOSIS__:____:__
Number Sign__:__277180__:__VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF; CBAVD__:__CAVD__:__
NULL__:__277200__:__RIGHT VENTRICULAR HYPOPLASIA, ISOLATED__:__IRVH__:__
Number Sign__:__277300__:__SPONDYLOCOSTAL DYSOSTOSIS 1, AUTOSOMAL RECESSIVE; SCDO1__:__VERTEBRAL ANOMALIES;; JARCHO-LEVIN SYNDROME;; SPONDYLOTHORACIC DYSPLASIA;; COSTOVERTEBRAL DYSPLASIA;; SPONDYLOTHORACIC DYSOSTOSIS__:__
Percent__:__277320__:__VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPLEGIA__:__INTESTINAL PSEUDOOBSTRUCTION WITH EXTERNAL OPHTHALMOPLEGIA;; MUSCULAR DYSTROPHY, OCULOGASTROINTESTINAL__:__
Percent__:__277350__:__HYPERCAROTENEMIA AND VITAMIN A DEFICIENCY, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__277380__:__METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblF TYPE; MAHCF__:__METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblF TYPE;; METHYLMALONIC ACIDURIA DUE TO VITAMIN B12-RELEASE DEFECT;; VITAMIN B12 LYSOSOMAL RELEASE DEFECT;; COBALAMIN, DEFECT IN LYSOSOMAL RELEASE OF;; VITAMIN B12 STORAGE DISEASE;; COBALAMIN F DISEASE; cblF__:__
Number Sign__:__277400__:__METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC__:__METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE__:__METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED
Number Sign__:__277410__:__METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD__:__METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblD TYPE;; METHYLMALONIC ACIDURIA, cblH TYPE, FORMERLY;; METHYLMALONIC ACIDEMIA, cblH TYPE, FORMERLY__:__HOMOCYSTINURIA, cblD TYPE, VARIANT 1, INCLUDED;; METHYLMALONIC ACIDURIA, cblD TYPE, VARIANT 2, INCLUDED
Caret__:__277420__:__MOVED TO 277440__:____:__
Number Sign__:__277440__:__VITAMIN D-DEPENDENT RICKETS, TYPE 2A; VDDR2A__:__VITAMIN D-DEPENDENT RICKETS, TYPE 2A, WITH OR WITHOUT ALOPECIA;; RICKETS, HEREDITARY VITAMIN D-RESISTANT; HVDRR;; GENERALIZED RESISTANCE TO 1,25-DIHYDROXYVITAMIN D;; VITAMIN D-RESISTANT RICKETS WITH END-ORGAN UNRESPONSIVENESS TO 1,25-DIHYDROXYCHOLECALCIFEROL;; PSEUDOVITAMIN D-DEFICIENCY, TYPE IIA;; PDDR IIA;; HYPOCALCEMIC VITAMIN D-RESISTANT RICKETS;; RICKETS-ALOPECIA SYNDROME__:__
Number Sign__:__277450__:__VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 1; VKCFD1__:__VKCFD;; VITAMIN K-DEPENDENT COAGULATION DEFECT;; FAMILIAL MULTIPLE COAGULATION FACTOR DEFICIENCY III;; FMFD III;; MULTIPLE COAGULATION FACTOR DEFICIENCY III; MCFD3;; FACTORS II, VII, IX, AND X, COMBINED DEFICIENCY OF;; GLUTAMIC ACID, DEFICIENT GAMMA-CARBOXYLATION OF__:__
Number Sign__:__277460__:__VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED__:__ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA__:__
NULL__:__277465__:__VITILIGO, PROGRESSIVE, WITH MENTAL RETARDATION AND URETHRAL DUPLICATION__:____:__
Number Sign__:__277470__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2A; PCH2A__:__PCH2;; PONTOCEREBELLAR HYPOPLASIA WITH PROGRESSIVE CEREBRAL ATROPHY;; VOLENDAM NEURODEGENERATIVE DISEASE__:__
Number Sign__:__277480__:__VON WILLEBRAND DISEASE, TYPE 3; VWD3__:__VON WILLEBRAND DISEASE, TYPE III;; VWD, TYPE 3__:__
Number Sign__:__277580__:__WAARDENBURG SYNDROME, TYPE 4A; WS4A__:__WAARDENBURG SYNDROME, TYPE IVA;; WAARDENBURG SYNDROME WITH HIRSCHSPRUNG DISEASE, TYPE 4A;; WAARDENBURG-SHAH SYNDROME;; SHAH-WAARDENBURG SYNDROME;; WS4__:__
Number Sign__:__277590__:__WEAVER SYNDROME; WVS__:__WEAVER-SMITH SYNDROME; WSS__:__WEAVER-LIKE SYNDROME, INCLUDED
Number Sign__:__277600__:__WEILL-MARCHESANI SYNDROME 1; WMS1__:__WEILL-MARCHESANI SYNDROME, AUTOSOMAL RECESSIVE;; SPHEROPHAKIA-BRACHYMORPHIA SYNDROME;; MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL__:__
Caret__:__277610__:__MOVED TO 184840__:____:__
Number Sign__:__277700__:__WERNER SYNDROME; WRN__:____:__
Percent__:__277720__:__WHISTLING FACE SYNDROME, RECESSIVE FORM__:____:__
Percent__:__277730__:__WERNICKE-KORSAKOFF SYNDROME__:__TRANSKETOLASE DEFECT;; ALCOHOL-INDUCED ENCEPHALOPATHY__:__
NULL__:__277740__:__WHITE FORELOCK WITH MALFORMATIONS__:____:__
Number Sign__:__277900__:__WILSON DISEASE__:__WND; WD;; HEPATOLENTICULAR DEGENERATION__:__
Number Sign__:__277950__:__WINCHESTER SYNDROME; WNCHRS__:____:__
Caret__:__277970__:__MOVED TO 614493__:____:__
NULL__:__277990__:__WOLFF MENTAL RETARDATION SYNDROME__:____:__
Number Sign__:__278000__:__LYSOSOMAL ACID LIPASE DEFICIENCY__:__CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY__:__WOLMAN DISEASE, INCLUDED
NULL__:__278100__:__WOLMAN DISEASE WITH HYPOLIPOPROTEINEMIA AND ACANTHOCYTOSIS__:____:__
Number Sign__:__278150__:__HYPOTRICHOSIS 8; HYPT8__:__HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 3; LAH3__:__WOOLLY HAIR, AUTOSOMAL RECESSIVE 1, WITH OR WITHOUT HYPOTRICHOSIS, INCLUDED; ARWH1, INCLUDED
NULL__:__278200__:__WOOLLY HAIR, HYPOTRICHOSIS, EVERTED LOWER LIP, AND OUTSTANDING EARS__:__SALAMON SYNDROME__:__
Caret__:__278205__:__MOVED TO 601214__:____:__
Number Sign__:__278250__:__WRINKLY SKIN SYNDROME; WSS__:____:__
Number Sign__:__278300__:__XANTHINURIA, TYPE I; XAN1__:__XANTHINE DEHYDROGENASE DEFICIENCY;; XDH DEFICIENCY;; XANTHINE OXIDASE DEFICIENCY__:__
Caret__:__278400__:__MOVED TO 203290__:____:__
Caret__:__278600__:__MOVED TO 236800__:____:__
Number Sign__:__278700__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA__:__XP, GROUP A;; XERODERMA PIGMENTOSUM I; XP1__:__
Number Sign__:__278720__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC__:__XPCC;; XP, GROUP C;; XERODERMA PIGMENTOSUM III; XP3__:__
Number Sign__:__278730__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD__:__XP, GROUP D; XPDC;; XERODERMA PIGMENTOSUM IV;; XP4 XERODERMA PIGMENTOSUM VIII, FORMERLY; XP8, FORMERLY;; XP, GROUP H, FORMERLY; XPH, FORMERLY__:__
Number Sign__:__278740__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E__:__XPE;; XP, GROUP E;; XERODERMA PIGMENTOSUM V; XP5__:__
Number Sign__:__278750__:__XERODERMA PIGMENTOSUM, VARIANT TYPE; XPV__:__XERODERMA PIGMENTOSUM WITH NORMAL DNA REPAIR RATES;; PHOTOSENSITIVITY WITH DEFECTIVE DNA SYNTHESIS__:__
Number Sign__:__278760__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF__:__XP, GROUP F;; XERODERMA PIGMENTOSUM VI; XP6__:__XERODERMA PIGMENTOSUM, TYPE F/COCKAYNE SYNDROME, INCLUDED; XPF/CS, INCLUDED
Number Sign__:__278780__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG__:__XP, GROUP G; XPGC;; XERODERMA PIGMENTOSUM VII; XP7__:__XERODERMA PIGMENTOSUM, TYPE G/COCKAYNE SYNDROME, INCLUDED; XPG/CS, INCLUDED
Number Sign__:__278800__:__DE SANCTIS-CACCHIONE SYNDROME__:____:__
Caret__:__278810__:__MOVED TO 278720__:____:__
Number Sign__:__278850__:__46,XX SEX REVERSAL 2; SRXX2__:__CHROMOSOME 17q24 DUPLICATION SYNDROME__:__
NULL__:__278900__:__XYLOSIDASE DEFICIENCY__:____:__
Percent__:__279000__:__YOUNG SYNDROME__:__AZOOSPERMIA, OBSTRUCTIVE, AND CHRONIC SINOPULMONARY INFECTIONS;; SINUSITIS-INFERTILITY SYNDROME;; BARRY-PERKINS-YOUNG SYNDROME__:__
Number Sign__:__280000__:__COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, MENTAL RETARDATION, AND EAR ANOMALIES SYNDROME; CHIME__:__CHIME SYNDROME;; ZUNICH NEUROECTODERMAL SYNDROME;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 5; GPIBD5__:__
Number Sign__:__300000__:__OPITZ GBBB SYNDROME, TYPE I; GBBB1__:__OPITZ GBBB SYNDROME, X-LINKED;; OPITZ SYNDROME; OS;; OPITZ SYNDROME, X-LINKED; OSX;; OPITZ-G SYNDROME, TYPE I; OGS1;; OPITZ BBBG SYNDROME, TYPE I; BBBG1;; HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS;; HYPERTELORISM-HYPOSPADIAS SYNDROME;; TELECANTHUS-HYPOSPADIAS SYNDROME__:__
Percent__:__300001__:__ICHTHYOSIS, X-LINKED, WITHOUT STEROID SULFATASE DEFICIENCY__:____:__
Asterisk__:__300002__:__ARYLSULFATASE D; ARSD__:____:__
Asterisk__:__300003__:__ARYLSULFATASE F; ARSF__:____:__
Number Sign__:__300004__:__CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA__:__ACC WITH ABNORMAL GENITALIA;; PROUD SYNDROME__:__
Asterisk__:__300005__:__METHYL-CpG-BINDING PROTEIN 2; MECP2__:____:__
Asterisk__:__300006__:__CENTRIN 2; CETN2__:__CENTRIN, EF-HAND PROTEIN, 2;; CALTRACTIN; CALT__:__
Asterisk__:__300007__:__INTERLEUKIN 9 RECEPTOR; IL9R__:____:__
Asterisk__:__300008__:__CHLORIDE CHANNEL 5; CLCN5__:__CHLORIDE CHANNEL, VOLTAGE-GATED, K2; CLCK2;; CLC5__:__
Number Sign__:__300009__:__DENT DISEASE 1__:__NEPHROLITHIASIS, HYPERCALCIURIC, X-LINKED;; UROLITHIASIS, HYPERCALCIURIC, X-LINKED;; NEPHROLITHIASIS 2; NPHL2__:__
Asterisk__:__300010__:__A-11 GENE; A11__:__DXS435E__:__
Asterisk__:__300011__:__ATPase, Cu(2+)-TRANSPORTING, ALPHA POLYPEPTIDE; ATP7A__:____:__
Asterisk__:__300012__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 1; SMARCA1__:__SUCROSE NONFERMENTING, YEAST, HOMOLOG-LIKE 1; SNF2L1;; SNF2-LIKE 1__:__
Asterisk__:__300013__:__N-ALPHA-ACETYLTRANSFERASE 10, NatA CATALYTIC SUBUNIT; NAA10__:__ARD1 N-ACETYLTRANSFERASE, S. CEREVISIAE, HOMOLOG OF, A; ARD1A;; ARREST-DEFECTIVE PROTEIN 1; ARD1;; TE2__:__
Asterisk__:__300014__:__ATPase, Ca(2+)-TRANSPORTING, PLASMA MEMBRANE, 3; ATP2B3__:__PLASMA MEMBRANE Ca(2+)-ATPase, TYPE 3; PMCA3__:__
Asterisk__:__300015__:__ACETYLSEROTONIN METHYLTRANSFERASE, X-CHROMOSOMAL; ASMT__:__HYDROXYINDOLE-O-METHYLTRANSFERASE, X-CHROMOSOMAL; HIOMT__:__
Asterisk__:__300016__:__MELANOMA ANTIGEN, FAMILY A, 1; MAGEA1__:__MELANOMA-ASSOCIATED ANTIGEN 1; MAGE1;; MELANOMA-ASSOCIATED ANTIGEN MZ2-E__:__
Asterisk__:__300017__:__FILAMIN A; FLNA__:__FILAMIN, ALPHA;; FILAMIN 1; FLN1;; FLN;; ACTIN-BINDING PROTEIN 280; ABP280__:__
Number Sign__:__300018__:__46,XY SEX REVERSAL 2; SRXY2__:__46,XY SEX REVERSAL, DAX1-RELATED;; DOSAGE-SENSITIVE SEX REVERSAL; DSS__:__
Asterisk__:__300019__:__HOST CELL FACTOR C1; HCFC1__:__HCF1;; VP16 ACCESSORY PROTEIN__:__
Caret__:__300020__:__MOVED TO 102610__:____:__
Caret__:__300021__:__MOVED TO 301830__:____:__
Asterisk__:__300022__:__PLEXIN A3; PLXNA3__:__PLEXIN 4; PLXN4;; TRANSMEMBRANE PROTEIN SEX; SEX__:__
Asterisk__:__300023__:__RHO GTPase-ACTIVATING PROTEIN 4; ARHGAP4__:__RHO GAP HEMATOPOIETIC PROTEIN C1; RGC1;; GTPase-ACTIVATING PROTEIN, RHO, 4; RHOGAP4__:__
Asterisk__:__300024__:__ZINC FINGER PROTEIN 157; ZNF157__:____:__
Asterisk__:__300025__:__CAUDAL-TYPE HOMEOBOX TRANSCRIPTION FACTOR 4; CDX4__:____:__
Asterisk__:__300026__:__NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 2; NAP1L2__:__BRAIN SPECIFIC GENE BPX; BPX__:__
Asterisk__:__300027__:__RNA-BINDING MOTIF PROTEIN 3; RBM3__:____:__
Asterisk__:__300028__:__ZINC FINGER-, CCCH DOMAIN-, AND RNA-BINDING MOTIF-CONTAINING SERINE/ARGININE-RICH PROTEIN 2; ZRSR2__:__U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, SMALL SUBUNIT 2; U2AF1RS2__:__
Number Sign__:__300029__:__RETINITIS PIGMENTOSA 3; RP3__:__RETINITIS PIGMENTOSA 15; RP15;; CONE-ROD DEGENERATION, X-LINKED;; CHOROIDORETINAL DEGENERATION WITH RETINAL REFLEX IN HETEROZYGOUS WOMEN__:__
Percent__:__300030__:__DEAFNESS, X-LINKED 3; DFNX3__:__DEAFNESS, X-LINKED 4, CONGENITAL SENSORINEURAL; DFN4__:__
Asterisk__:__300031__:__FAMILY WITH SEQUENCE SIMILARITY 11, MEMBER A; FAM11A__:____:__FRAGILE SITE, FOLIC ACID TYPE, FRA(X)(q28) F, INCLUDED; FRAXF, INCLUDED
Asterisk__:__300032__:__ATR-X GENE; ATRX__:__HELICASE 2, X-LINKED; XH2;; X-LINKED NUCLEAR PROTEIN GENE; XNP__:__
Asterisk__:__300033__:__FORKHEAD BOX O4; FOXO4__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 7; MLLT7;; MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 7;; ALL1-FUSED GENE FROM X CHROMOSOME; AFX1__:__
Asterisk__:__300034__:__ANGIOTENSIN II RECEPTOR, TYPE 2; AGTR2__:____:__
Asterisk__:__300035__:__EPHRIN B1; EFNB1__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 2; EPLG2;; LIGAND OF EPH-RELATED KINASE 2; LERK2;; EFL3;; ELK LIGAND; ELKL__:__
Asterisk__:__300036__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, CREATINE), MEMBER 8; SLC6A8__:__CREATINE TRANSPORTER; CT1; CRTR; CRT__:__
Asterisk__:__300037__:__GLYPICAN 3; GPC3__:__OCI-5, RAT, HOMOLOG OF__:__
Asterisk__:__300038__:__PYRIMIDINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 4; P2RY4__:__P2Y4;; NUCLEOTIDE RECEPTOR, URIDINE; NRU; UNR__:__
Asterisk__:__300039__:__POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 4; POU3F4__:__BRAIN-4; BRN4__:__
Asterisk__:__300040__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 1A; SMC1A__:__SMC1-ALPHA;; STRUCTURAL MAINTENANCE OF CHROMOSOMES 1-LIKE 1; SMC1L1;; SMC1;; DXS423E;; KIAA0178__:__
Asterisk__:__300041__:__GUANYLATE CYCLASE 2F, RETINAL; GUCY2F__:__GUANYLYL CYCLASE 2F, RETINAL;; GC-F;; RETGC2__:__
NULL__:__300042__:__ALOPECIA, CONGENITAL; ALPC__:____:__
Caret__:__300043__:__MOVED TO 611663__:____:__
Asterisk__:__300044__:__TRANSKETOLASE-LIKE 1; TKTL1__:__TRANSKETOLASE 2; TKT2;; TRANSKETOLASE-RELATED GENE; TKR__:__
Caret__:__300045__:__MOVED TO 602081__:____:__
Percent__:__300046__:__MENTAL RETARDATION, X-LINKED 23; MRX23__:____:__
Percent__:__300047__:__MENTAL RETARDATION, X-LINKED 20; MRX20__:____:__
Number Sign__:__300048__:__INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED__:__IPOX;; CONGENITAL IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION; CIIP;; CIIP, X-LINKED; CIIPX;; INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT__:__CONGENITAL SHORT BOWEL SYNDROME, X-LINKED, INCLUDED
Number Sign__:__300049__:__PERIVENTRICULAR NODULAR HETEROTOPIA 1; PVNH1__:__HETEROTOPIA, PERIVENTRICULAR, X-LINKED DOMINANT;; HETEROTOPIA, FAMILIAL NODULAR;; NODULAR HETEROTOPIA, BILATERAL PERIVENTRICULAR; NHBP; BPNH;; HETEROTOPIA, PERIVENTRICULAR, EHLERS-DANLOS VARIANT;; PERIVENTRICULAR NODULAR HETEROTOPIA 4, FORMERLY; PVNH4, FORMERLY__:__HETEROTOPIA, PERIVENTRICULAR NODULAR, WITH FRONTOMETAPHYSEAL DYSPLASIA, INCLUDED
Asterisk__:__300050__:__UBIQUITIN-SPECIFIC PROTEASE 11; USP11__:__UBIQUITIN CARBOXYL-TERMINAL HYDROLASE, X-LINKED; UHX1__:__
Asterisk__:__300051__:__GLYCOPROTEIN M6B; GPM6B__:__NEURONAL MEMBRANE GLYCOPROTEIN M6B__:__
Asterisk__:__300052__:__DYSTROPHIN-RELATED PROTEIN 2; DRP2__:____:__
Asterisk__:__300053__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 7: VAMP7__:__SYNAPTOBREVIN-LIKE 1; SYBL1;; TETANUS NEUROTOXIN-INSENSITIVE VAMP; TIVAMP__:__
NULL__:__300054__:__BODY LENGTH, MOUSE, HUMAN HOMOLOG__:____:__
Number Sign__:__300055__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13__:__MENTAL RETARDATION, X-LINKED 79; MRX79;; MENTAL RETARDATION, X-LINKED 16; MRX16;; MENTAL RETARDATION, X-LINKED, WITH SPASTICITY;; MENTAL RETARDATION WITH PSYCHOSIS, PYRAMIDAL SIGNS, AND MACROORCHIDISM; PPMX__:__
Asterisk__:__300056__:__HOLOCYTOCHROME C SYNTHASE; HCCS__:____:__
Caret__:__300057__:__MOVED TO 601324__:____:__
Caret__:__300058__:__MOVED TO 300446__:____:__
Asterisk__:__300059__:__TRANSMEMBRANE PROTEIN 187; TMEM187__:__CHROMOSOME X OPEN READING FRAME 12; CXORF12;; DXS9878E;; ITBA1 GENE__:__
Asterisk__:__300060__:__L ANTIGEN FAMILY, MEMBER 3; LAGE3__:__ITBA2 GENE;; DXS9879E__:__
Asterisk__:__300061__:__ZINC FINGER, MYM-TYPE 3; ZMYM3__:__ZINC FINGER PROTEIN 261; ZNF261;; DXS6673E__:__
Percent__:__300062__:__MENTAL RETARDATION, X-LINKED 14; MRX14__:____:__
Caret__:__300063__:__MOVED TO 304930__:____:__
NULL__:__300064__:__MENTAL RETARDATION, X-LINKED, WITH CRANIOFACIAL DYSMORPHISM__:__MENTAL RETARDATION, X-LINKED, HYDE-FORSTER TYPE__:__
Asterisk__:__300065__:__CENTROMERIC PROTEIN I; CENPI__:__FSH PRIMARY RESPONSE, RAT, HOMOLOG OF, 1; FSHPRH1;; LEUCINE-RICH PRIMARY RESPONSE GENE 1; LRPR1;; MIS6__:__
Number Sign__:__300066__:__DEAFNESS, X-LINKED 4; DFNX4__:__DEAFNESS, X-LINKED 6, PROGRESSIVE; DFN6;; DEAFNESS, NONSYNDROMIC SENSORINEURAL PROGRESSIVE 6__:__
Number Sign__:__300067__:__LISSENCEPHALY, X-LINKED, 1; LISX1__:__XLIS;; LISSENCEPHALY AND AGENESIS OF CORPUS CALLOSUM__:__SUBCORTICAL LAMINAR HETEROTOPIA, X-LINKED, INCLUDED; SCLH, INCLUDED;; SUBCORTICAL BAND HETEROTOPIA, X-LINKED, INCLUDED; SBH, INCLUDED;; DOUBLE CORTEX SYNDROME, INCLUDED;; DC SYNDROME, INCLUDED
Number Sign__:__300068__:__ANDROGEN INSENSITIVITY SYNDROME; AIS__:__TESTICULAR FEMINIZATION SYNDROME; TFM;; ANDROGEN RECEPTOR DEFICIENCY;; AR DEFICIENCY;; DIHYDROTESTOSTERONE RECEPTOR DEFICIENCY;; DHTR DEFICIENCY__:__
Caret__:__300069__:__MOVED TO 302060__:____:__
Asterisk__:__300070__:__FIBROBLAST GROWTH FACTOR 13; FGF13__:__FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 2; FHF2__:__
Number Sign__:__300071__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A; CSNB2A__:__CSNB, INCOMPLETE, X-LINKED;; NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2; CSNB2__:__
Asterisk__:__300072__:__UBIQUITIN-SPECIFIC PROTEASE 9, X-LINKED; USP9X__:__DROSOPHILA FAT FACETS-RELATED, X-LINKED; DFFRX;; FAM__:__
NULL__:__300073__:__FETAL AKINESIA SYNDROME, X-LINKED__:____:__
Asterisk__:__300074__:__X CHROMOSOME-CONTROLLING ELEMENT; XCE__:__X INACTIVATION INTERGENIC TRANSCRIPTION ELEMENT; XITE;; XCA__:__
Asterisk__:__300075__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 3; RPS6KA3__:__RIBOSOMAL S6 KINASE 2; RSK2;; MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 1B; MAPKAPK1B;; MAPKAP KINASE 1B;; ISPK1__:__
Percent__:__300076__:__IMMUNONEUROLOGIC DISORDER, X-LINKED__:__WOODS-BLACK-NORBURY SYNDROME__:__
Caret__:__300077__:__MOVED TO 300419__:____:__
Asterisk__:__300078__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 1; NDUFA1__:__MWFE, B. TAURUS, HOMOLOG OF__:__
Asterisk__:__300079__:__INHIBITOR OF APOPTOSIS, X-LINKED; XIAP__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 4; BIRC4;; APOPTOSIS INHIBITOR 3; API3;; IAP-LIKE PROTEIN; ILP;; MAMMALIAN IAP HOMOLOG A; MIHA__:__
Asterisk__:__300080__:__RNA-BINDING MOTIF PROTEIN 10; RBM10__:__RNA-BINDING PROTEIN S1-1, RAT, HOMOLOG OF;; DXS8237E__:__
Asterisk__:__300081__:__DEOXYRIBONUCLEASE I-LIKE 1; DNASE1L1__:__DNase I, LYSOSOMAL-LIKE; DNL1L;; DNase I-LIKE, MUSCLE-SPECIFIC__:__
Percent__:__300082__:__COGNITIVE FUNCTION 1, SOCIAL; CGF1__:__SOCIAL COGNITION__:__
Asterisk__:__300083__:__PROTEIN KINASE, X-LINKED; PRKX__:__PROTEIN KINASE PKX1; PKX1__:__
Asterisk__:__300084__:__NON-POU DOMAIN-CONTAINING OCTAMER-BINDING PROTEIN; NONO__:__NUCLEAR RNA-BINDING PROTEIN, 54-KD; NRB54;; p54NRB;; p54(NRB)__:__NONO/TFE3 FUSION GENE, INCLUDED
Percent__:__300085__:__CONE-ROD DYSTROPHY, X-LINKED, 2; CORDX2__:__CONE DYSTROPHY 2, X-LINKED; COD2__:__
Asterisk__:__300086__:__LYSOPHOSPHATIDIC ACID RECEPTOR 4; LPAR4__:__LPA4;; P2Y5-LIKE RECEPTOR;; PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 9; P2RY9; P2Y9;; G PROTEIN-COUPLED RECEPTOR 23; GPR23__:__
Number Sign__:__300087__:__X INACTIVATION, FAMILIAL SKEWED, 1; SXI1__:____:__
Number Sign__:__300088__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 9; EIEE9__:__EPILEPSY, FEMALE-RESTRICTED, WITH MENTAL RETARDATION; EFMR;; JUBERG-HELLMAN SYNDROME__:__
Asterisk__:__300089__:__ISOCITRATE DEHYDROGENASE 3, GAMMA SUBUNIT; IDH3G__:__ISOCITRATE DEHYDROGENASE, NAD(+)-SPECIFIC, MITOCHONDRIAL, GAMMA SUBUNIT__:__
Asterisk__:__300090__:__SIGNAL SEQUENCE RECEPTOR, DELTA; SSR4__:__TRANSLOCON-ASSOCIATED PROTEIN, DELTA SUBUNIT; TRAPD__:__
Asterisk__:__300091__:__FOS-INDUCED GROWTH FACTOR; FIGF__:__VASCULAR ENDOTHELIAL GROWTH FACTOR D; VEGFD__:__
Asterisk__:__300092__:__TESTIS-EXPRESSED GENE 28; TEX28__:__CHROMOSOME X OPEN READING FRAME 2; CXORF2__:__
Asterisk__:__300093__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, EPSILON; GABRE__:__GABA-A RECEPTOR, EPSILON POLYPEPTIDE__:__
Caret__:__300094__:__MOVED TO 600539__:____:__
Asterisk__:__300095__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 2; SLC16A2__:__MONOCARBOXYLATE TRANSPORTER 8; MCT8;; X-LINKED PEST-CONTAINING TRANSPORTER; XPCT;; DXS128E__:__
Asterisk__:__300096__:__TETRASPANIN 7; TSPAN7__:__MEMBRANE COMPONENT, X CHROMOSOME, SURFACE MARKER 1; MXS1;; TRANSMEMBRANE PROTEIN A15;; TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 2; TM4SF2__:__
Asterisk__:__300097__:__MELANOMA ANTIGEN, FAMILY B, 1; MAGEB1__:__MAGE-LIKE GENE ON Xp; MAGEL1;; DSS/AHC CRITICAL INTERVAL GENE, FROM MAGE SUPERFAMILY, 10; DAM10__:__
Asterisk__:__300098__:__MELANOMA ANTIGEN, FAMILY B, 2; MAGEB2__:__DSS/AHC CRITICAL INTERVAL GENE, FROM MAGE SUPERFAMILY, 6; DAM6__:__
Caret__:__300099__:__MOVED TO 300097__:____:__
Number Sign__:__300100__:__ADRENOLEUKODYSTROPHY; ALD__:__ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY__:__ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED
Asterisk__:__300101__:__BONE MARROW KINASE, X-LINKED; BMX__:__PROTEIN TYROSINE KINASE BMX__:__
Asterisk__:__300102__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 4; PNPLA4__:__GS2 GENE; GS2;; PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT, ETA;; IPLA2-ETA;; DXS1283E__:__
Asterisk__:__300103__:__SHROOM FAMILY MEMBER 2; SHROOM2__:__APICAL PROTEIN OF XENOPUS-LIKE; APXL__:__
Asterisk__:__300104__:__GDP DISSOCIATION INHIBITOR 1; GDI1__:__RAB GDP-DISSOCIATION INHIBITOR, ALPHA; RABGDIA;; RAB GDI-ALPHA;; RHOGDI;; OLIGOPHRENIN 2; OPHN2__:__
Asterisk__:__300105__:__SPERMINE SYNTHASE; SMS__:____:__
Number Sign__:__300106__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, X-LINKED; SEMDX__:__SEMD, X-LINKED__:__
Asterisk__:__300107__:__BOMBESIN-LIKE RECEPTOR 3; BRS3__:__BOMBESIN RECEPTOR SUBTYPE 3__:__
Asterisk__:__300108__:__DIAPHANOUS, DROSOPHILA, HOMOLOG OF, 2; DIAPH2__:__DIA;; DIA2__:__
Asterisk__:__300109__:__PROTEIN PHOSPHATASE, EF-HAND CALCIUM-BINDING DOMAIN 1; PPEF1__:__PROTEIN PHOSPHATASE, SERINE/THREONINE TYPE, WITH EF-HAND MOTIFS__:__
Asterisk__:__300110__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-1F SUBUNIT; CACNA1F__:____:__
Asterisk__:__300111__:__PRICKLE, DROSOPHILA, HOMOLOG OF, 3; PRICKLE3__:__PRICKLE-LIKE 3;; LIM DOMAIN ONLY 6; LMO6__:__
Asterisk__:__300112__:__PROTEOLIPID PROTEIN 2; PLP2__:__PROTEOLIPID PROTEIN, COLONIC EPITHELIUM-ENRICHED;; DIFFERENTIATION-DEPENDENT PROTEIN A4; A4__:__
NULL__:__300113__:__X-LINKED B CELL SURFACE ANTIGEN, MOUSE, HOMOLOG-LIKE 1; XLRL__:____:__
Number Sign__:__300114__:__RAYNAUD-CLAES SYNDROME; MRXSRC__:__MENTAL RETARDATION, X-LINKED 49; MRX49;; MENTAL RETARDATION, X-LINKED 15; MRX15__:__
Percent__:__300115__:__MENTAL RETARDATION, X-LINKED 50; MRX50__:____:__
Asterisk__:__300116__:__MATURE T-CELL PROLIFERATION 1; MTCP1__:__C6.1B;; p13__:__
Asterisk__:__300117__:__NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 3; NAP1L3__:____:__
Asterisk__:__300118__:__RHO GTPase-ACTIVATING PROTEIN 6; ARHGAP6__:__GTPase-ACTIVATING PROTEIN, RHO, 6; RHOGAP6__:__
Asterisk__:__300119__:__INTERLEUKIN 13 RECEPTOR, ALPHA-1; IL13RA1__:__INTERLEUKIN 13 RECEPTOR, ALPHA; IL13RA;; NR4, MOUSE, HOMOLOG OF__:__
Asterisk__:__300120__:__MASTERMIND-LIKE DOMAIN-CONTAINING PROTEIN 1; MAMLD1__:__CHROMOSOME X OPEN READING FRAME 6; CXORF6;; F18 GENE; F18__:__
Asterisk__:__300121__:__DOUBLECORTIN; DCX__:__DBCN__:__
Caret__:__300122__:__MOVED TO 300000__:____:__
Number Sign__:__300123__:__MENTAL RETARDATION, X-LINKED, WITH PANHYPOPITUITARISM__:____:__MENTAL RETARDATION, X-LINKED, WITH ISOLATED GROWTH HORMONE DEFICIENCY, INCLUDED; MRGH, INCLUDED
Asterisk__:__300124__:__GTP-BINDING PROTEIN 6; GTPBP6__:__PSEUDOAUTOSOMAL GTP-BINDING PROTEIN-LIKE; PGPL__:__
Percent__:__300125__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 2__:__MGR2;; MFTS__:__
Asterisk__:__300126__:__DYSKERIN; DKC1__:__NOPP140-ASSOCIATED PROTEIN, 57-KD; NAP57__:__
Asterisk__:__300127__:__OLIGOPHRENIN 1; OPHN1__:__OPN1__:__
Asterisk__:__300128__:__LYSINE-SPECIFIC DEMETHYLASE 6A; KDM6A__:__UBIQUITOUSLY TRANSCRIBED TETRATRICOPEPTIDE REPEAT GENE ON X CHROMOSOME; UTX__:__
NULL__:__300129__:__HEMATOPOIETIC STEM CELL KINETICS, CONTROL OF__:____:__
Asterisk__:__300130__:__INTERLEUKIN 13 RECEPTOR, ALPHA-2; IL13RA2__:____:__
Asterisk__:__300131__:__PLASTIN 3; PLS3__:__T-PLASTIN__:__
Asterisk__:__300132__:__TROPHININ; TRO__:__MELANOMA ANTIGEN, FAMILY D, 3; MAGED3__:__
Asterisk__:__300133__:__VON HIPPEL-LINDAU BINDING PROTEIN 1; VBP1__:__PREFOLDIN 3; PFDN3__:__
Asterisk__:__300134__:__DUAL-SPECIFICITY PHOSPHATASE 9; DUSP9__:__MAP KINASE PHOSPHATASE 4; MKP4__:__
Asterisk__:__300135__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 7; ABCB7__:__ATP-BINDING CASSETTE 7; ABC7;; ATP-BINDING CASSETTE TRANSPORTER 7;; ABC TRANSPORTER 7__:__
Percent__:__300136__:__DIABETES MELLITUS, INSULIN-DEPENDENT, X-LINKED, SUSCEPTIBILITY TO__:__IDDMX;; INSULIN-DEPENDENT DIABETES MELLITUS, X-LINKED, SUSCEPTIBILITY TO__:__
Asterisk__:__300137__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 1; IGSF1__:__IMMUNOGLOBULIN-LIKE DOMAIN-CONTAINING 1; IGDC1;; INHIBIN-BINDING PROTEIN; INHBP__:__
Asterisk__:__300138__:__CHLORIDE INTRACELLULAR CHANNEL 2; CLIC2__:__XAP121__:__
Asterisk__:__300139__:__IMMUNOGLOBULIN-BINDING PROTEIN 1; IGBP1__:__PROTEIN PHOSPHATASE 2A, REGULATORY SUBUNIT ALPHA-4;; ALPHA-4__:__
Caret__:__300140__:__MOVED TO 600655__:____:__
Caret__:__300141__:__MOVED TO 612725__:____:__
Asterisk__:__300142__:__p21 PROTEIN-ACTIVATED KINASE 3; PAK3__:__p21 CDC42/RAC1-ACTIVATED KINASE 3;; OLIGOPHRENIN 3; OPHN3__:__
Number Sign__:__300143__:__MENTAL RETARDATION, X-LINKED 21; MRX21__:__MENTAL RETARDATION, X-LINKED 34; MRX34__:__
Asterisk__:__300144__:__GLUTAMATE DEHYDROGENASE 2; GLUD2__:____:__
Asterisk__:__300145__:__X-PROLYL AMINOPEPTIDASE 2; XPNPEP2__:__X-PROLYL AMINOPEPTIDASE, MEMBRANE-BOUND;; AMINOPEPTIDASE P, 2; APP2__:__
Asterisk__:__300146__:__CALPAIN 6; CAPN6__:____:__
Percent__:__300147__:__PROSTATE CANCER, HEREDITARY, X-LINKED 1; HPCX1__:__PROSTATE CANCER SUSCEPTIBILITY, X-LINKED; PCSX__:__
Number Sign__:__300148__:__MEHMO SYNDROME; MEHMO__:__MENTAL RETARDATION, EPILEPTIC SEIZURES, HYPOGONADISM AND HYPOGENITALISM, MICROCEPHALY, AND OBESITY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 20; MRXS20;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 25; MRXS25;; MENTAL RETARDATION, X-LINKED, SYNDROMIC, BORCK TYPE; MRXSBRK__:__
Asterisk__:__300149__:__CBP/p300-INTERACTING TRANSACTIVATOR WITH GLU/ASP-RICH C-TERMINAL DOMAIN, 1; CITED1__:__MELANOCYTE-SPECIFIC GENE 1; MSG1__:__
Asterisk__:__300150__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ADENINE NUCLEOTIDE TRANSLOCATOR), MEMBER A5; SLC25A5__:__ADENINE NUCLEOTIDE TRANSLOCATOR 2; ANT2;; ADP/ATP TRANSLOCATOR OF FIBROBLASTS;; ADP/ATP TRANSLOCASE 2;; ADP/ATP CARRIER 2; AAC2__:__
Asterisk__:__300151__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ADENINE NUCLEOTIDE TRANSLOCATOR), MEMBER A6; SLC25A6__:__ADENINE NUCLEOTIDE TRANSLOCATOR 3; ANT3;; ADP/ATP TRANSLOCATOR OF LIVER;; ADP/ATP TRANSLOCASE 3;; ADP/ATP CARRIER 3; AAC3__:__
Asterisk__:__300152__:__MELANOMA ANTIGEN, FAMILY B, 3; MAGEB3__:____:__
Asterisk__:__300153__:__MELANOMA ANTIGEN, FAMILY B, 4; MAGEB4__:____:__
Asterisk__:__300154__:__ESX1-LIKE PROTEIN; ESX1L__:__EXTRAEMBRYONIC, SPERMATOGENESIS, HOMEOBOX 1-LIKE PROTEIN;; ESX1-RELATED PROTEIN 1; ESXR1__:__
Percent__:__300155__:__RETINITIS PIGMENTOSA 24; RP24__:____:__
Asterisk__:__300156__:__CANCER/TESTIS ANTIGEN 1B; CTAG1B__:__CANCER/TESTIS ANTIGEN 1; CTAG1;; CTAG;; NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1; NYESO1;; LAGE2;; LAGE2B;; LAGE2, TELOMERIC COPY__:__
Asterisk__:__300157__:__ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 4; ACSL4__:__FATTY ACID CoA LIGASE, LONG CHAIN 4; FACL4;; ACYL-CoA SYNTHETASE 4; ACS4__:__
Percent__:__300158__:__ARTHROGRYPOSIS, CONGENITAL, LOWER LIMB, X-LINKED; ACLLX__:__ARTHROGRYPOSIS, X-LINKED, TYPE V, FORMERLY; AMCX5, FORMERLY__:__
Asterisk__:__300159__:__THYMOSIN, BETA-4, X CHROMOSOME; TMSB4X__:__THYMOSIN, BETA-4; TMSB4;; TB4X;; PROTHYMOSIN BETA-4; PTMB4__:__
Asterisk__:__300160__:__DEAD/H BOX 3, X-LINKED; DDX3X__:__DDX3;; DBX__:__
Asterisk__:__300161__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 3; EIF2S3__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2, GAMMA; EIF2G__:__
Asterisk__:__300162__:__ACETYLSEROTONIN METHYLTRANSFERASE-LIKE; ASMTL__:__ACETYLSEROTONIN METHYLTRANSFERASE-LIKE, X-LINKED; ASMTLX__:__
Asterisk__:__300163__:__FOUR-AND-A-HALF LIM DOMAINS 1; FHL1__:__SLIM1;; FHL1A;; KYOT, MOUSE, HOMOLOG OF__:__FHL1B, INCLUDED;; SLIMMER, INCLUDED;; FHL1C, INCLUDED
Asterisk__:__300164__:__INACTIVATION ESCAPE 1; INE1__:____:__
Asterisk__:__300165__:__INACTIVATION ESCAPE 2; INE2__:____:__
Number Sign__:__300166__:__MICROPHTHALMIA, SYNDROMIC 2; MCOPS2__:__OCULOFACIOCARDIODENTAL SYNDROME;; OFCD SYNDROME;; MICROPHTHALMIA, CATARACTS, RADICULOMEGALY, AND SEPTAL HEART DEFECTS;; ANOP2, FORMERLY;; MAA2, FORMERLY__:__
Asterisk__:__300167__:__HEPHAESTIN; HEPH__:____:__
Asterisk__:__300168__:__GLYPICAN 4; GPC4__:____:__
Asterisk__:__300169__:__APOPTOSIS-INDUCING FACTOR, MITOCHONDRIA-ASSOCIATED, 1; AIFM1__:__APOPTOSIS-INDUCING FACTOR; AIF;; PROGRAMMED CELL DEATH 8; PDCD8__:__
Asterisk__:__300170__:__OFD1 GENE; OFD1__:__CHROMOSOME X OPEN READING FRAME 5; CXORF5__:__
Asterisk__:__300171__:__MYOTUBULARIN-RELATED PROTEIN 1; MTMR1__:____:__
Asterisk__:__300172__:__CALCIUM/CALMODULIN-DEPENDENT SERINE PROTEIN KINASE; CASK__:__VERTEBRATE LIN2 HOMOLOG; LIN2;; CAMGUK, DROSOPHILA, HOMOLOG OF; CMG__:__
Asterisk__:__300173__:__MELANOMA ANTIGEN, FAMILY A, 2; MAGEA2__:__MAGEA2A;; MAGE2__:__
Asterisk__:__300174__:__MELANOMA ANTIGEN, FAMILY A, 3; MAGEA3__:__MAGE3__:__
Asterisk__:__300175__:__MELANOMA ANTIGEN, FAMILY A, 4; MAGEA4__:__MAGE4;; MAGE4a;; MAGE4b__:__
Asterisk__:__300176__:__MELANOMA ANTIGEN, FAMILY A, 6; MAGEA6__:__MAGE6__:__
Asterisk__:__300177__:__MELANOMA ANTIGEN, FAMILY A, 12; MAGEA12__:__MAGE12__:__
Asterisk__:__300178__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 1; ZBED1__:__BED-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 1;; AC-LIKE TRANSPOSABLE ELEMENT; ALTE;; TRAMP;; DREF, DROSOPHILA, HOMOLOG OF; DREF;; KIAA0785__:__
Percent__:__300179__:__X INACTIVATION, FAMILIAL SKEWED, 2; SXI2__:____:__
Asterisk__:__300180__:__ARYLSULFATASE E; ARSE__:____:__
Asterisk__:__300181__:__X INACTIVATION-SPECIFIC TRANSCRIPT-ANTISENSE; TSIX__:__XIST-ANTISENSE__:__
Asterisk__:__300182__:__MEDIATOR COMPLEX SUBUNIT 14; MED14__:__COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 2; CRSP2;; CRSP, 150-KD SUBUNIT; CRSP150;; CHROMOSOME X OPEN READING FRAME 4; CXORF4;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN; TRAP170;; EXLM1;; RGR1__:__
Caret__:__300183__:__MOVED TO 302060__:____:__
NULL__:__300184__:__HYPOTONIA, CONGENITAL NYSTAGMUS, ATAXIA, AND ABNORMAL AUDITORY BRAINSTEM RESPONSES__:____:__
Asterisk__:__300185__:__A-KINASE ANCHOR PROTEIN 4; AKAP4__:__A-KINASE ANCHOR PROTEIN, 82-KD; AKAP82;; TESTIS-SPECIFIC GENE HI; HI;; FSC1, MOUSE, HOMOLOG OF__:__
Asterisk__:__300186__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 1A, X-LINKED; EIF1AX__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 1A; EIF1A;; EUKARYOTIC TRANSLATION INITIATION FACTOR 4C; EIF4C__:__
Asterisk__:__300187__:__SUSHI REPEAT-CONTAINING PROTEIN, X-LINKED; SRPX__:__SRPX1;; ETX1__:__
Asterisk__:__300188__:__MEDIATOR COMPLEX SUBUNIT 12; MED12__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 12, S. CEREVISIAE, HOMOLOG OF;; TRINUCLEOTIDE REPEAT-CONTAINING GENE 11; TNRC11;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 230-KD SUBUNIT; TRAP230;; HUMAN OPPOSITE PAIRED GENE; HOPA;; KIAA0192__:__
Asterisk__:__300189__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 3; DLG3__:__NEUROENDOCRINE DLG; NEDLG;; SYNAPSE-ASSOCIATED PROTEIN 102; SAP102__:__
Asterisk__:__300190__:__SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH PROTEIN-LIKE PROTEIN; SH3BGRL__:__SH3BGR-LIKE PROTEIN__:__
Asterisk__:__300191__:__TETRASPANIN 6; TSPAN6__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 6; TM4SF6__:__
Asterisk__:__300192__:__SARCOMA, SYNOVIAL, X BREAKPOINT 2; SSX2__:__SARCOMA, SYNOVIAL, X-CHROMOSOME-RELATED 2__:__SSX2-SYT FUSION GENE, INCLUDED
Asterisk__:__300193__:__HIGH MOBILITY GROUP BOX 3; HMGB3__:__HIGH MOBILITY GROUP PROTEIN 4; HMG4;; NONHISTONE CHROMOSOMAL PROTEIN HMG4;; CHROMOSOMAL PROTEIN, NONHISTONE, HMG4;; HMG2A__:__
Number Sign__:__300194__:__AMME COMPLEX__:__ALPORT SYNDROME, MENTAL RETARDATION, MIDFACE HYPOPLASIA, AND ELLIPTOCYTOSIS;; ATS-MR;; CHROMOSOME Xq22.3 TELOMERIC DELETION SYNDROME__:__
Asterisk__:__300195__:__AMME CHROMOSOME REGION GENE 1; AMMECR1__:____:__
Asterisk__:__300196__:__TRANSDUCIN-BETA-LIKE 1, X-LINKED; TBL1X__:__TRANSDUCIN-BETA-LIKE 1; TBL1;; EBI, DROSOPHILA, HOMOLOG OF; EBI__:__
Asterisk__:__300197__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, ACCESSORY PROTEIN 1; ATP6AP1__:__ATP6IP1;; ATP6S1;; VACUOLAR ATPase SUBUNIT 1; VATPS1;; Ac45__:__
Asterisk__:__300198__:__GLYCOGENIN 2; GYG2__:__GN2__:__
Asterisk__:__300199__:__RNA-BINDING MOTIF PROTEIN, X CHROMOSOME; RBMX__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN G; HNRNPG__:__RNA-BINDING MOTIF PROTEIN, X CHROMOSOME, RETROGENE, INCLUDED; RBMXRT, INCLUDED;; RNA-BINDING MOTIF PROTEIN, X CHROMOSOME, PSEUDOGENE 1, INCLUDED; RBMXP1, INCLUDED
Number Sign__:__300200__:__ADRENAL HYPOPLASIA, CONGENITAL; AHC__:__ADRENAL HYPOPLASIA, CONGENITAL, WITH HYPOGONADOTROPIC HYPOGONADISM; AHCH;; ADDISON DISEASE, X-LINKED; AHX;; AHC WITH HHG;; CYTOMEGALIC ADRENOCORTICAL HYPOPLASIA;; AHC WITH ISOLATED GONADOTROPIN DEFICIENCY__:__
Asterisk__:__300201__:__CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYSLTR1__:__CYSLT1;; CYSLT1R__:__
Asterisk__:__300202__:__TRACKING PROTEIN PARTICLE COMPLEX, SUBUNIT 2; TRAPPC2__:__SEDLIN; SEDL__:__
Asterisk__:__300203__:__CYCLIN-DEPENDENT KINASE-LIKE 5; CDKL5__:__SERINE/THREONINE PROTEIN KINASE 9; STK9__:__
Asterisk__:__300204__:__MIDLINE 2; MID2__:__MIDIN 2__:__
Asterisk__:__300205__:__EMOPAMIL-BINDING PROTEIN; EBP__:__3-BETA-HYDROXYSTEROID-DELTA-8,DELTA-7 ISOMERASE__:__
Asterisk__:__300206__:__INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN-LIKE 1; IL1RAPL1__:__INTERLEUKIN 1 RECEPTOR 8; IL1R8__:__IL1RAPL1/DMD FUSION GENE, INCLUDED
Asterisk__:__300207__:__G PROTEIN-COUPLED RECEPTOR 50; GPR50__:__H9__:__
Asterisk__:__300208__:__SEX COMB ON MIDLEG, DROSOPHILA, HOMOLOG-LIKE 2; SCML2__:____:__
Number Sign__:__300209__:__SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 2; SGBS2__:____:__
Number Sign__:__300210__:__MENTAL RETARDATION, X-LINKED 58; MRX58__:____:__
Percent__:__300211__:__EPISODIC MUSCLE WEAKNESS, X-LINKED; EMWX__:____:__
Asterisk__:__300212__:__REGUCALCIN; RGN__:__SENESCENCE MARKER PROTEIN 30; SMP30__:__
Asterisk__:__300213__:__CAAX BOX PROTEIN 1; CXX1__:____:__
Asterisk__:__300214__:__PLEXIN B3; PLXNB3__:__PLEXIN 6; PLXN6__:__
Number Sign__:__300215__:__LISSENCEPHALY, X-LINKED, 2; LISX2__:__LISSENCEPHALY, X-LINKED, WITH AMBIGUOUS GENITALIA; XLAG;; XLISG__:__HYDRANENCEPHALY AND ABNORMAL GENITALIA, INCLUDED
NULL__:__300216__:__COATS DISEASE__:__RETINAL TELANGIECTASIS__:__
Asterisk__:__300217__:__RETINOIC ACID-INDUCED 2; RAI2__:____:__
Percent__:__300218__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 7; MRXS7__:__AHMAD X-LINKED MENTAL RETARDATION SYNDROME__:__
Number Sign__:__300219__:__MYOTUBULAR MYOPATHY WITH ABNORMAL GENITAL DEVELOPMENT__:____:__
Caret__:__300220__:__MOVED TO 300438__:____:__
Percent__:__300221__:__LYMPHOMA, HODGKIN, X-LINKED PSEUDOAUTOSOMAL__:__HODGKIN DISEASE, X-LINKED PSEUDOAUTOSOMAL__:__
Asterisk__:__300222__:__INTEGRAL MEMBRANE PROTEIN 2A; ITM2A__:__E25A__:__
Asterisk__:__300223__:__MELANOMA ANTIGEN, FAMILY C, 1; MAGEC1__:____:__
Asterisk__:__300224__:__MELANOMA ANTIGEN, FAMILY D, 1; MAGED1__:__NEUROTROPHIN RECEPTOR-INTERACTING MAGE HOMOLOG; NRAGE;; DLXIN1__:__
Asterisk__:__300225__:__NADPH OXIDASE 1; NOX1__:__NADPH OXIDASE HOMOLOG 1; NOH1;; MITOGENIC OXIDASE 1; MOX1;; GP91-2__:__
Asterisk__:__300226__:__SMALL MUSCLE PROTEIN, X-LINKED; SMPX__:__CHISEL, MOUSE, HOMOLOG OF; CSL__:__
Asterisk__:__300227__:__SEX COMB ON MIDLEG, DROSOPHILA, HOMOLOG-LIKE 1; SCML1__:____:__
Percent__:__300228__:__TESTICULAR GERM CELL TUMOR 1; TGCT1__:____:__
Asterisk__:__300229__:__VARIABLY CHARGED, X CHROMOSOME; VCX__:__VCX1;; VARIABLY CHARGED, X CHROMOSOME, WITH 10 REPEATS; VCX10R;; VARIABLY CHARGED, X CHROMOSOME, B1; VCXB1__:__
Asterisk__:__300230__:__CARBONIC ANHYDRASE VB, MITOCHONDRIAL; CA5B__:__CA VB__:__
Asterisk__:__300231__:__SOLUTE CARRIER FAMILY 9, MEMBER 6; SLC9A6__:__SODIUM/HYDROGEN EXCHANGER 6; NHE6__:__
NULL__:__300232__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, X-LINKED, WITH MENTAL DETERIORATION__:__SEMD, X-LINKED, WITH MENTAL DETERIORATION__:__
NULL__:__300233__:__RADIOULNAR SYNOSTOSIS, RADIAL RAY ABNORMALITIES, AND SEVERE MALFORMATIONS IN THE MALE__:____:__
Asterisk__:__300234__:__UBIQUITOUSLY EXPRESSED TRANSCRIPT; UXT__:____:__
Asterisk__:__300235__:__ZINC FINGER-ENCODING GENE, X-LINKED, DUPLICATED, A; ZXDA__:____:__
Asterisk__:__300236__:__ZINC FINGER-ENCODING GENE, X-LINKED, DUPLICATED, B; ZXDB__:____:__
Asterisk__:__300237__:__TRANSCRIPTION ELONGATION FACTOR A-LIKE 1; TCEAL1__:__TCEA-LIKE 1;; p21;; SII-RELATED GENE; SIIR__:__
Number Sign__:__300238__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 11; MRXS11__:__SHASHI X-LINKED MENTAL RETARDATION SYNDROME; SMRXS;; MENTAL RETARDATION, X-LINKED, SHASHI TYPE__:__
Asterisk__:__300239__:__EPIDERMAL GROWTH FACTOR-LIKE 6; EGFL6__:__EGF-LIKE 6;; MAM- AND EGF-CONTAINING GENE; MAEG__:__
Caret__:__300240__:__MOVED TO 305000__:____:__
Asterisk__:__300241__:__G PROTEIN-COUPLED RECEPTOR 34; GPR34__:____:__
Asterisk__:__300242__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, BRAIN), MEMBER 14; SLC25A14__:__BRAIN MITOCHONDRIAL CARRIER PROTEIN 1; BMCP1;; UNCOUPLING PROTEIN 5; UCP5__:__
Number Sign__:__300243__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHRISTIANSON TYPE; MRXSCH__:__ANGELMAN-LIKE SYNDROME, X-LINKED;; MENTAL RETARDATION, MICROCEPHALY, EPILEPSY, AND ATAXIA SYNDROME__:__
Number Sign__:__300244__:__TERMINAL OSSEOUS DYSPLASIA; TOD__:__TERMINAL OSSEOUS DYSPLASIA AND PIGMENTARY DEFECTS; TODPD;; ODPD;; OSSEOUS DYSPLASIA, DIGITAL, WITH FACIAL PIGMENTARY DEFECTS AND MULTIPLE FRENULA; ODPF;; ODPF SYNDROME__:__
Percent__:__300245__:__PTOSIS, HEREDITARY CONGENITAL 2__:__PTOS2;; PTOSIS, X-LINKED; PTOSX__:__
Asterisk__:__300246__:__PROTOCADHERIN 11, X-LINKED; PCDH11X__:__PROTOCADHERIN, X CHROMOSOME; PCDHX;; PROTOCADHERIN 11, FORMERLY; PCDH11, FORMERLY__:__
Asterisk__:__300247__:__BONE MORPHOGENETIC PROTEIN 15; BMP15__:__GROWTH/DIFFERENTIATION FACTOR 9B; GDF9B__:__
Asterisk__:__300248__:__INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, KINASE OF, GAMMA; IKBKG__:__NF-KAPPA-B ESSENTIAL MODULATOR; NEMO;; IKK-GAMMA;; FIP3__:__
Asterisk__:__300249__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 17, YEAST, HOMOLOG OF, B; TIMM17B__:__TIM17B__:__
Caret__:__300250__:__MOVED TO 202200__:____:__
Caret__:__300251__:__MOVED TO 605875__:____:__
Asterisk__:__300252__:__PEPTIDYL-PROLYL CIS/TRANS ISOMERASE, NIMA-INTERACTING, 4; PIN4__:__PARVULIN 14; PAR14;; EPVH__:__
Asterisk__:__300253__:__G PROTEIN-COUPLED RECEPTOR 173; GPR173__:__SUPERCONSERVED RECEPTOR EXPRESSED IN BRAIN 3; SREB3__:__
Asterisk__:__300254__:__SUPPRESSOR OF VARIEGATION 3-9, DROSOPHILA, HOMOLOG OF, 1; SUV39H1__:__SU(VAR)3-9, DROSOPHILA, HOMOLOG OF, 1__:__
Asterisk__:__300255__:__O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE; OGT__:__UDP-N-ACETYLGLUCOSAMINE:POLYPEPTIDE BETA-N-ACETYLGLUCOSAMINYL TRANSFERASE;; GlcNAc TRANSFERASE__:__
Asterisk__:__300256__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE X; HSD17B10__:__HSD10;; HYDROXYACYL-CoA DEHYDROGENASE II; HADH2;; 3-HYDROXYACYL-CoA DEHYDROGENASE II;; AMYLOID BETA-BINDING POLYPEPTIDE ERAB; ERAB;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE; MHBD;; AMYLOID BETA-BINDING ALCOHOL DEHYDROGENASE; ABAD;; 3-HYDROXYACYL-CoA DEHYDROGENASE, SHORT CHAIN; SCHAD;; MITOCHONDRIAL RIBONUCLEASE P PROTEIN 2; MRPP2__:__
Number Sign__:__300257__:__DANON DISEASE__:__VACUOLAR CARDIOMYOPATHY AND MYOPATHY, X-LINKED;; PSEUDOGLYCOGENOSIS II;; ANTOPOL DISEASE;; LYSOSOMAL GLYCOGEN STORAGE DISEASE WITHOUT ACID MALTASE DEFICIENCY, FORMERLY;; GLYCOGEN STORAGE DISEASE IIb; GSD2B, FORMERLY;; GSD IIb, FORMERLY__:__
Caret__:__300258__:__MOVED TO 616651__:____:__
NULL__:__300259__:__MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, X-LINKED__:__MTBSX__:__
Number Sign__:__300260__:__LUBS X-LINKED MENTAL RETARDATION SYNDROME; MRXSL__:__MECP2 DUPLICATION SYNDROME;; MENTAL RETARDATION, X-LINKED, SYNDROMIC, LUBS TYPE;; MENTAL RETARDATION, X-LINKED, WITH RECURRENT RESPIRATORY INFECTIONS__:__
Percent__:__300261__:__ARMFIELD X-LINKED MENTAL RETARDATION SYNDROME; MRXSA__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARMFIELD TYPE__:__
Percent__:__300262__:__ABIDI X-LINKED MENTAL RETARDATION SYNDROME; MRXSAB__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, ABIDI TYPE__:__
Number Sign__:__300263__:__SIDERIUS X-LINKED MENTAL RETARDATION SYNDROME; MRXSSD__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, SIDERIUS TYPE;; SIDERIUS-HAMEL SYNDROME__:__
Asterisk__:__300264__:__UBIQUILIN 2; UBQLN2__:__PLIC2, MOUSE, HOMOLOG OF; PLIC2;; CHAP1__:__
Asterisk__:__300265__:__ZIC FAMILY, MEMBER 3; ZIC3__:__ZINC FINGER PROTEIN OF CEREBELLUM 3;; HTX1__:__
Percent__:__300266__:__SPASTIC PARAPLEGIA 16, X-LINKED; SPG16__:____:__
Asterisk__:__300267__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 6; ARHGEF6__:__PAK-INTERACTING EXCHANGE FACTOR, ALPHA; PIXA;; ALPHA-PIX;; COOL2__:__
Caret__:__300268__:__MOVED TO 610618__:____:__
Asterisk__:__300269__:__HISTONE DEACETYLASE 8; HDAC8__:____:__
NULL__:__300270__:__ADRENOMYODYSTROPHY__:____:__
Number Sign__:__300271__:__MENTAL RETARDATION, X-LINKED 72; MRX72__:____:__
Asterisk__:__300272__:__HISTONE DEACETYLASE 6; HDAC6__:__KIAA0901__:__
Percent__:__300273__:__GOITER, MULTINODULAR 2; MNG2__:____:__
Caret__:__300274__:__MOVED TO 300068__:____:__
Asterisk__:__300275__:__NAD(P)H STEROID DEHYDROGENASE-LIKE PROTEIN; NSDHL__:____:__
Asterisk__:__300276__:__ECTODYSPLASIN A2 RECEPTOR; EDA2R__:__ECTODYSPLASIN RECEPTOR, X-LINKED; XEDAR;; ECTODYSPLASIN A2 ISOFORM RECEPTOR;; EDA-A2 RECEPTOR;; EDA-A2R__:__
Asterisk__:__300277__:__INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN-LIKE 2; IL1RAPL2__:__INTERLEUKIN 1 RECEPTOR 9; IL1R9__:__
Asterisk__:__300278__:__NYCTALOPIN; NYX__:____:__
Caret__:__300279__:__MOVED TO 300260__:____:__
Number Sign__:__300280__:__URUGUAY FACIOCARDIOMUSCULOSKELETAL SYNDROME; FCMSU__:__FCMS;; FACIOCARDIOMUSCULOSKELETAL SYNDROME, URUGUAY TYPE__:__
Asterisk__:__300281__:__POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 1; KCND1__:__Kv4.1__:__
Asterisk__:__300282__:__ECTO-NOX DISULFIDE-THIOL EXCHANGER 2; ENOX2__:__CYTOSOLIC OVARIAN CARCINOMA ANTIGEN 1; COVA1__:__
Asterisk__:__300283__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 1; IRAK1__:__IRAK__:__
Asterisk__:__300284__:__RAS-ASSOCIATED PROTEIN RAB9; RAB9__:____:__
Asterisk__:__300285__:__RAS-ASSOCIATED PROTEIN 9B; RAB9B__:__RAS-ASSOCIATED PROTEIN RAB9-LIKE; RAB9L__:__
Asterisk__:__300286__:__KRUPPEL-LIKE FACTOR 8; KLF8__:__ZINC FINGER PROTEIN 741; ZNF741;; BASIC KRUPPEL-LIKE FACTOR 3; BKLF3__:__
Asterisk__:__300287__:__P ANTIGEN FAMILY, MEMBER 4; PAGE4__:__PROSTATE-ASSOCIATED GENE 4;; G ANTIGEN, FAMILY C, 1; GAGEC1;; GAGE9;; JM27;; PROSTATE-ASSOCIATED GENE 1, FORMERLY; PAGE1, FORMERLY__:__
Asterisk__:__300288__:__P ANTIGEN FAMILY, MEMBER 1; PAGE1__:__PROSTATE-ASSOCIATED GENE 1;; G ANTIGEN, FAMILY B, 1; GAGEB1__:__
Asterisk__:__300289__:__X ANTIGEN FAMILY, MEMBER 1D; XAGE1D__:__XAGE1;; G ANTIGEN, FAMILY D, 2; GAGED2__:__
Caret__:__300290__:__MOVED TO 614732__:____:__
Number Sign__:__300291__:__ECTODERMAL DYSPLASIA AND IMMUNODEFICIENCY 1; EDAID1__:__ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNE DEFICIENCY;; ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY; HEDID;; HYPER-IgM IMMUNODEFICIENCY, X-LINKED, WITH HYPOHIDROTIC ECTODERMAL DYSPLASIA; XHMED__:__
Asterisk__:__300292__:__FORKHEAD BOX P3; FOXP3__:__SCURFIN;; JM2__:__
Caret__:__300293__:__MOVED TO 301410__:____:__
Asterisk__:__300294__:__MEMBRANE-BOUND TRANSCRIPTION FACTOR PROTEASE, SITE 2; MBTPS2__:__SITE-2 PROTEASE; S2P__:__
Asterisk__:__300295__:__ONCOGENE PIM2; PIM2__:__SERINE/THREONINE PROTEIN KINASE PIM2__:__
Asterisk__:__300296__:__PLACENTA-SPECIFIC GENE 1; PLAC1__:____:__
Asterisk__:__300297__:__APELIN; APLN__:__APJ RECEPTOR LIGAND__:__
Asterisk__:__300298__:__UPF3, YEAST, HOMOLOG OF, B; UPF3B__:__REGULATOR OF NONSENSE TRANSCRIPTS 3B; RENT3B;; UPF3X__:__
Number Sign__:__300299__:__NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX__:__XLN__:__
Asterisk__:__300300__:__BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK__:__AGAMMAGLOBULINEMIA TYROSINE KINASE; ATK;; B-CELL PROGENITOR KINASE; BPK__:__
Number Sign__:__300301__:__ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNODEFICIENCY, OSTEOPETROSIS, AND LYMPHEDEMA; OLEDAID__:____:__
Asterisk__:__300302__:__DYNEIN, LIGHT CHAIN, TCTEX TYPE, 3; DYNLT3__:__T COMPLEX-ASSOCIATED TESTIS-EXPRESSED 1-LIKE; TCTE1L__:__
Asterisk__:__300303__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 6; RPS6KA6__:__RIBOSOMAL S6 KINASE 4; RSK4__:__
Asterisk__:__300304__:__CULLIN 4B; CUL4B__:__KIAA0695__:__
Asterisk__:__300305__:__SPERM PROTEIN ASSOCIATED WITH THE NUCLEUS, X CHROMOSOME, FAMILY MEMBER A1; SPANXA1__:__SPANX;; SPANX FAMILY, MEMBER A1__:__
Percent__:__300306__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 11; BMIQ11__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__300307__:__T-BOX 22; TBX22__:____:__
Asterisk__:__300308__:__FERRITIN HEAVY POLYPEPTIDE-LIKE 17; FTHL17__:____:__
Asterisk__:__300309__:__UBIQUITIN-SPECIFIC PROTEASE 26; USP26__:____:__
Percent__:__300310__:__AGAMMAGLOBULINEMIA, X-LINKED, TYPE 2; AGMX2__:__XLA2__:__
Asterisk__:__300311__:__TESTIS-EXPRESSED GENE 11; TEX11__:____:__
Asterisk__:__300312__:__TESTIS-EXPRESSED GENE 13A; TEX13A__:____:__
Asterisk__:__300313__:__TESTIS-EXPRESSED GENE 13B; TEX13B__:____:__
Asterisk__:__300314__:__TAF7-LIKE RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 50-KD; TAF7L__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR Q; TAF2Q__:__
Asterisk__:__300315__:__NUCLEAR RNA EXPORT FACTOR 2; NXF2__:____:__
Asterisk__:__300316__:__NUCLEAR RNA EXPORT FACTOR 3; NXF3__:____:__
Asterisk__:__300317__:__RALBP1-ASSOCIATED EPS DOMAIN-CONTAINING PROTEIN 2; REPS2__:__PARTNER OF RALBP1; POB1__:__
Asterisk__:__300318__:__NUCLEAR RNA EXPORT FACTOR 4; NXF4__:____:__
Asterisk__:__300319__:__NUCLEAR RNA EXPORT FACTOR 5; NXF5__:____:__
Asterisk__:__300320__:__NTF2-LIKE EXPORT FACTOR 2; NXT2__:____:__
Number Sign__:__300321__:__FG SYNDROME 2; FGS2__:____:__
Number Sign__:__300322__:__LESCH-NYHAN SYNDROME; LNS__:__HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE__:__HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED
Number Sign__:__300323__:__KELLEY-SEEGMILLER SYNDROME__:__GOUT, HPRT-RELATED;; HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY, PARTIAL;; HPRT DEFICIENCY, PARTIAL;; HPRT1 DEFICIENCY, PARTIAL__:__
Percent__:__300324__:__MENTAL RETARDATION, X-LINKED 53; MRX53__:____:__
Asterisk__:__300325__:__SYNOVIAL SARCOMA, X BREAKPOINT 3; SSX3__:____:__
Asterisk__:__300326__:__SYNOVIAL SARCOMA, X BREAKPOINT 4; SSX4__:____:__
Asterisk__:__300327__:__SYNOVIAL SARCOMA, X BREAKPOINT 5; SSX5__:____:__
Asterisk__:__300328__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED FAMILY, MEMBER 1-LIKE; KCNE1L__:__KCNE5__:__
Asterisk__:__300329__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 33; ZBTB33__:__KAISO GENE; KAISO__:__
Asterisk__:__300330__:__SPANX FAMILY, MEMBER C; SPANXC__:__SPERM PROTEIN ASSOCIATED WITH THE NUCLEUS, X CHROMOSOME, FAMILY MEMBER C;; CTP11__:__
Percent__:__300331__:__THROMBOCYTHEMIA, X-LINKED; THCYTX__:__THROMBOCYTOSIS, X-LINKED__:__
Asterisk__:__300332__:__INTEGRIN, BETA-1, BINDING PROTEIN OF, 2; ITGB1BP2__:__MELUSIN__:__
Asterisk__:__300333__:__RAS-ASSOCIATED PROTEIN RAB33A; RAB33A__:____:__
Asterisk__:__300334__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 5; TRPC5__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 5;; TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 5; TRP5__:__
Asterisk__:__300335__:__ANGIOTENSIN I-CONVERTING ENZYME 2; ACE2__:__ACEH__:__
Asterisk__:__300336__:__NEUROLIGIN 3; NLGN3__:____:__
Number Sign__:__300337__:__HYPOMELANOSIS OF ITO; HMI__:__INCONTINENTIA PIGMENTI ACHROMIANS; IPA;; ITO HYPOMELANOSIS; ITO;; INCONTINENTIA PIGMENTI, TYPE I, FORMERLY; IP1, FORMERLY__:__
Asterisk__:__300338__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, ALPHA-2; CNGA2__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, OLFACTORY, 2; CNG2;; OCNC1, MOUSE, HOMOLOG OF; OCNC1__:__
Asterisk__:__300339__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, BETA; PPP2R3B__:__PROTEIN PHOSPHATASE 2A, REGULATORY SUBUNIT, 48-KD; PR48__:__
Asterisk__:__300340__:__MELANOMA ANTIGEN, FAMILY A, 5; MAGEA5__:__MAGE5__:__
Asterisk__:__300341__:__MELANOMA ANTIGEN, FAMILY A, 8; MAGEA8__:__MAGE8__:__
Asterisk__:__300342__:__MELANOMA ANTIGEN, FAMILY A, 9; MAGEA9__:__MAGE9__:__
Asterisk__:__300343__:__MELANOMA ANTIGEN, FAMILY A, 10; MAGEA10__:__MAGE10__:__
Asterisk__:__300344__:__MELANOMA ANTIGEN, FAMILY A, 11; MAGEA11__:__MAGE11__:__
Percent__:__300345__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 1; MCOPCB1__:__MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 1__:__
Asterisk__:__300346__:__HIV-1 TAT STIMULATORY FACTOR 1; HTATSF1__:__TATSF1__:__
Asterisk__:__300347__:__EARLY LYMPHOID ACTIVATION GENE__:__EPAG__:__
Asterisk__:__300348__:__KELCH-LIKE 4; KLHL4__:____:__
Asterisk__:__300349__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, THETA; GABRQ__:__GABA-A RECEPTOR, THETA POLYPEPTIDE__:__
Asterisk__:__300350__:__CHORDIN-LIKE 1; CHRDL1__:__VENTROPTIN; VOPT__:__
Percent__:__300351__:__GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 1__:__GRDX1__:__GRAVES DISEASE, SUSCEPTIBILITY TO, X-LINKED 2, INCLUDED; GRDX2, INCLUDED
Number Sign__:__300352__:__CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1__:__CREATINE DEFICIENCY SYNDROME, X-LINKED;; CREATINE TRANSPORTER DEFECT;; MENTAL RETARDATION, X-LINKED, WITH SEIZURES, SHORT STATURE, AND MIDFACE HYPOPLASIA;; MENTAL RETARDATION, X-LINKED, WITH CREATINE TRANSPORT DEFICIENCY__:__
Asterisk__:__300353__:__V-SET AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 4; VSIG4__:__IMMUNOGLOBULIN SUPERFAMILY PROTEIN Z39IG; Z39IG;; COMPLEMENT RECEPTOR OF THE IMMUNOGLOBULIN SUPERFAMILY; CRIG__:__
Number Sign__:__300354__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, CABEZAS TYPE; MRXSC__:__CABEZAS SYNDROME;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 15; MRXS15;; MENTAL RETARDATION, X-LINKED, WITH SHORT STATURE, HYPOGONADISM, AND ABNORMAL GAIT;; MENTAL RETARDATION, X-LINKED, WITH SHORT STATURE; MRSS__:__
Percent__:__300355__:__MENTAL RETARDATION, X-LINKED 73; MRX73__:____:__
Asterisk__:__300356__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 8, YEAST, HOMOLOG OF, A; TIMM8A__:__DEAFNESS/DYSTONIA PEPTIDE; DDP;; DEAFNESS/DYSTONIA PEPTIDE 1; DDP1;; DFN1, FORMERLY__:__
Asterisk__:__300357__:__CYTOKINE RECEPTOR-LIKE FACTOR 2; CRLF2__:__CRL2;; THYMIC STROMAL LYMPHOPOIETIN RECEPTOR; TSLPR__:__CRLF2/P2RY8 FUSION GENE, INCLUDED
Asterisk__:__300358__:__PROTEIN KINASE, LYSINE-DEFICIENT 3; WNK3__:__PRKWNK3;; KIAA1566__:__
Asterisk__:__300359__:__SARCOMA ANTIGEN 1; SAGE1__:__SAGE__:__
Caret__:__300360__:__MOVED TO 300354__:____:__
Asterisk__:__300361__:__NERVE GROWTH FACTOR RECEPTOR-ASSOCIATED PROTEIN 1; NGFRAP1__:__NGFR-ASSOCIATED PROTEIN 1;; p75(NTR)-ASSOCIATED CELL DEATH EXECUTOR; NADE;; BRAIN-EXPRESSED X-LINKED GENE 3; BEX3__:__
Asterisk__:__300362__:__ARMADILLO REPEAT CONTAINING, X-LINKED 1; ARMCX3__:__ARM PROTEIN LOST IN EPITHELIAL CANCERS, X CHROMOSOME, 1; ALEX1__:__
Asterisk__:__300363__:__ARMADILLO REPEAT CONTAINING, X-LINKED 2; ARMCX2__:__ARM PROTEIN LOST IN EPITHELIAL CANCERS, X CHROMOSOME, 2; ALEX2;; KIAA0512__:__
Asterisk__:__300364__:__ARMADILLO REPEAT CONTAINING, X-LINKED 3; ARMCX3__:__ARM PROTEIN LOST IN EPITHELIAL CANCERS, X CHROMOSOME, 3; ALEX3__:__
Asterisk__:__300365__:__TOLL-LIKE RECEPTOR 7; TLR7__:____:__
Asterisk__:__300366__:__TOLL-LIKE RECEPTOR 8; TLR8__:____:__
Number Sign__:__300367__:__THROMBOCYTOPENIA, X-LINKED, WITH OR WITHOUT DYSERYTHROPOIETIC ANEMIA; XLTDA__:____:__
Asterisk__:__300368__:__SOLUTE CARRIER FAMILY 9, MEMBER 7; SLC9A7__:__SODIUM/HYDROGEN EXCHANGER 7; NHE7__:__
Asterisk__:__300369__:__ACIDIC REPEAT-CONTAINING GENE; ACRC__:____:__
Asterisk__:__300370__:__3-PRIME REPAIR EXONUCLEASE 2; TREX2__:____:__
Asterisk__:__300371__:__ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 1; ABCD1__:__ADRENOLEUKODYSTROPHY PROTEIN; ALDP__:__
Percent__:__300372__:__MENTAL RETARDATION, X-LINKED 42; MRX42__:____:__
Number Sign__:__300373__:__OSTEOPATHIA STRIATA WITH CRANIAL SCLEROSIS; OSCS__:__HYPEROSTOSIS GENERALISATA WITH STRIATIONS__:__
Asterisk__:__300374__:__SH3-DOMAIN KINASE-BINDING PROTEIN 1; SH3KBP1__:__CBL-INTERACTING PROTEIN, 85-KD; CIN85__:__
Asterisk__:__300375__:__CARBOHYDRATE SULFOTRANSFERASE 7; CHST7__:__CHONDROITIN 6-SULFOTRANSFERASE 2; C6ST2__:__
Number Sign__:__300376__:__MUSCULAR DYSTROPHY, BECKER TYPE; BMD__:__BECKER MUSCULAR DYSTROPHY;; MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, BECKER TYPE__:__
Asterisk__:__300377__:__DYSTROPHIN; DMD__:____:__APO-DYSTROPHIN 1, INCLUDED
Percent__:__300378__:__RADIAL RAY DEFICIENCY, X-LINKED__:__RRDX__:__
Asterisk__:__300379__:__RING FINGER PROTEIN, LIM DOMAIN-INTERACTING; RLIM__:__RING FINGER PROTEIN 12; RNF12;; RING ZINC FINGER PROTEIN NY-REN-43 ANTIGEN__:__
Asterisk__:__300380__:__CYTIDINE 5-PRIME TRIPHOSPHATE SYNTHETASE 2; CTPS2__:__CTP SYNTHETASE 2;; CTP SYNTHASE 2__:__
Asterisk__:__300381__:__ZINC FINGER PROTEIN 185; ZNF185__:____:__
Asterisk__:__300382__:__ARISTALESS-RELATED HOMEOBOX, X-LINKED; ARX__:____:__
Asterisk__:__300383__:__COMPLEMENT FACTOR PROPERDIN; CFP__:__PROPERDIN P FACTOR, COMPLEMENT; PFC;; PROPERDIN;; FACTOR P__:__
Asterisk__:__300384__:__EMERIN; EMD__:__STA__:__
Asterisk__:__300385__:__NUCLEOSOMAL BINDING PROTEIN 1; NSBP1__:____:__
Asterisk__:__300386__:__CD40 LIGAND; CD40LG__:__CD40 ANTIGEN LIGAND; CD40L;; CD154;; TNF-RELATED ACTIVATION PROTEIN; TRAP;; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 5; TNFSF5;; GP39__:__
Number Sign__:__300387__:__MENTAL RETARDATION, X-LINKED 63; MRX63__:__MENTAL RETARDATION, X-LINKED 68; MRX68__:__
Percent__:__300388__:__POLYMICROGYRIA, BILATERAL PERISYLVIAN, X-LINKED; BPPX__:__PMGX;; BPP;; PERISYLVIAN SYNDROME, CONGENITAL BILATERAL; CBPS__:__
Caret__:__300389__:__MOVED TO 300029__:____:__
Asterisk__:__300390__:__CHM GENE; CHM__:__RAB ESCORT PROTEIN 1; REP1;; RAB GERANYLGERANYLTRANSFERASE, COMPONENT A;; RAB GG TRANSFERASE;; GGTA__:__
Asterisk__:__300391__:__AMELOGENIN; AMELX__:__ALGN;; AMG;; AMGL__:__
Asterisk__:__300392__:__WAS GENE; WAS__:__WAS PROTEIN; WASP__:__
Asterisk__:__300393__:__G PROTEIN-COUPLED RECEPTOR 101; GPR101__:__GPCR101__:__
Asterisk__:__300394__:__TAFAZZIN; TAZ__:__G4.5__:__
Asterisk__:__300395__:__THO COMPLEX, SUBUNIT 2; THOC2__:__THO2, YEAST, HOMOLOG OF; THO2__:__
Asterisk__:__300396__:__CANCER/TESTIS ANTIGEN 2; CTAG2__:__LAGE1;; CTL-RECOGNIZED ANTIGEN ON MELANOMA; CAMEL__:__
Caret__:__300397__:__MOVED TO 300352__:____:__
Asterisk__:__300398__:__B-CELL RECEPTOR-ASSOCIATED PROTEIN 31; BCAP31__:__BAP31;; DXS1357E__:__
Asterisk__:__300399__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 1, INHIBITOR OF: PCSK1N__:__PROSAAS__:__
Number Sign__:__300400__:__SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED; SCIDX1__:__SEVERE COMBINED IMMUNODEFICIENCY, X-LINKED, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE;; SCIDX; XSCID;; SCID, X-LINKED;; IMMUNODEFICIENCY 4; IMD4__:__
Asterisk__:__300401__:__PROTEOLIPID PROTEIN 1; PLP1__:__PROTEOLIPID PROTEIN, MYELIN; PLP;; LIPOPHILIN__:__DM20, INCLUDED
Asterisk__:__300402__:__LEUCINE ZIPPER, DOWNREGULATED IN CANCER 1; LDOC1__:____:__
Asterisk__:__300403__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 11; NDUFB11__:__NADH DEHYDROGENASE 1 BETA SUBCOMPLEX, 11 NEURONAL PROTEIN, 17.3-KD;; p17.3__:__
Caret__:__300404__:__MOVED TO 308205__:____:__
Asterisk__:__300405__:__RAS-ASSOCIATED PROTEIN RAB40A-LIKE; RAB40AL__:__RAS-LIKE GTPase GENE; RLGP__:__
Percent__:__300406__:__FG SYNDROME 3; FGS3__:____:__
Asterisk__:__300407__:__POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 5; PABPC5__:__POLYADENYLATE-BINDING PROTEIN 5; PABP5;; POLY(A)-BINDING PROTEIN 5__:__
Asterisk__:__300408__:__GRIP1-ASSOCIATED PROTEIN 1; GRIPAP1__:__GRASP1;; KIAA1167__:__
Asterisk__:__300409__:__MORTALITY FACTOR 4-LIKE PROTEIN 2; MORF4L2__:__MORF4-LIKE PROTEIN 2;; MORF-RELATED GENE X; MRGX;; KIAA0026__:__
Asterisk__:__300410__:__ANGIOMOTIN; AMOT__:__KIAA1071__:__
Asterisk__:__300411__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCED FACTOR 2-LIKE, X-LINKED; TGIF2LX__:__TGIFLX__:__
Caret__:__300412__:__MOVED TO 300166__:____:__
Asterisk__:__300413__:__MUSCLEBLIND-LIKE SPLICING REGULATOR 3; MBNL3__:__MUSCLEBLIND-LIKE PROTEIN 3;; MUSCLEBLIND-LIKE PROTEIN, X-LINKED; MBXL__:__
Asterisk__:__300414__:__PHD FINGER PROTEIN 6; PHF6__:____:__
Asterisk__:__300415__:__MYOTUBULARIN; MTM1__:____:__
Asterisk__:__300416__:__X ANTIGEN FAMILY, MEMBER 2; XAGE2__:__G ANTIGEN, FAMILY D, 3; GAGED3__:__
Asterisk__:__300417__:__G PROTEIN-COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1; GPRASP1__:__GASP1;; G PROTEIN-COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN; GASP;; KIAA0443__:__
Asterisk__:__300418__:__G1- TO S-PHASE TRANSITION 2; GSPT2__:__GST2, YEAST, HOMOLOG OF; GST2;; PEPTIDE CHAIN RELEASE FACTOR 3B; ERF3B__:__
Number Sign__:__300419__:__MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT SEIZURES, ARX-RELATED; MRXARX__:__MENTAL RETARDATION, X-LINKED 29; MRX29;; MENTAL RETARDATION, X-LINKED 32; MRX32;; MENTAL RETARDATION, X-LINKED 33; MRX33;; MENTAL RETARDATION, X-LINKED 38; MRX38;; MENTAL RETARDATION, X-LINKED 43; MRX43;; MENTAL RETARDATION, X-LINKED 54; MRX54;; MENTAL RETARDATION, X-LINKED 76; MRX76;; MENTAL RETARDATION, X-LINKED 87; MRX87__:__
Asterisk__:__300420__:__PRAJA 1; PJA1__:____:__
Caret__:__300421__:__MOVED TO 194190__:____:__
Number Sign__:__300422__:__FG SYNDROME 4; FGS4__:____:__MENTAL RETARDATION, X-LINKED, WITH OR WITHOUT NYSTAGMUS, INCLUDED
Number Sign__:__300423__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, HEDERA TYPE; MRXSH__:__MENTAL RETARDATION, X-LINKED, WITH EPILEPSY; MRXE__:__
Number Sign__:__300424__:__RETINITIS PIGMENTOSA 23; RP23__:____:__
Number Sign__:__300425__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 1; AUTSX1__:____:__
Caret__:__300426__:__MOVED TO 300143__:____:__
Asterisk__:__300427__:__NEUROLIGIN 4; NLGN4__:__NL4;; KIAA1260__:__
Percent__:__300428__:__MENTAL RETARDATION, X-LINKED 2; MRX2__:____:__
Asterisk__:__300429__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 9; ARHGEF9__:__PEM2;; COLLYBISTIN;; KIAA0424__:__
Caret__:__300430__:__MOVED TO 300419__:____:__
NULL__:__300431__:__ATKIN-FLAITZ SYNDROME__:__ATKIN SYNDROME__:__
Caret__:__300432__:__MOVED TO 308350__:____:__
Percent__:__300433__:__MENTAL RETARDATION, X-LINKED 81; MRX81__:____:__
Number Sign__:__300434__:__STOCCO DOS SANTOS X-LINKED MENTAL RETARDATION SYNDROME; SDSX__:__MENTAL RETARDATION, X-LINKED, STOCCO DOS SANTOS TYPE__:__
Asterisk__:__300435__:__PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PGRMC1__:____:__
Percent__:__300436__:__MENTAL RETARDATION, X-LINKED 46; MRX46__:____:__
Asterisk__:__300437__:__EMBRYONIC STEM CELL-EXPRESSED RAS; ERAS__:__V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG 2; HRAS2;; V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG PSEUDOGENE, FORMERLY; HRASP, FORMERLY__:__
Number Sign__:__300438__:__HSD10 MITOCHONDRIAL DISEASE; HSD10MD__:__HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR__:__
Asterisk__:__300439__:__RING FINGER PROTEIN 128; RNF128__:__GENE RELATED TO ANERGY IN LYMPHOCYTES; GRAIL__:__
Asterisk__:__300440__:__NFKB-REPRESSING FACTOR; NKRF__:__NRF;; NUCLEAR FACTOR KAPPA-B-REPRESSING FACTOR;; ITBA4__:__
Asterisk__:__300441__:__SH3 PROTEIN EXPRESSED IN LYMPHOCYTES__:__SLY;; HEMATOPOIETIC ADAPTOR CONTAINING SH3 AND SAM DOMAINS 2; HACS2;; CHROMOSOME X OPEN READING FRAME 9; CXORF9__:__
Caret__:__300442__:__MOVED TO 311900__:____:__
Asterisk__:__300443__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 3; SLC7A3__:__CATIONIC AMINO ACID TRANSPORTER 3; CAT3__:__
Asterisk__:__300444__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 14; SLC6A14__:__AMINO ACID TRANSPORTER B(0+);; ATB(0+)__:__
Asterisk__:__300445__:__H2A HISTONE FAMILY, MEMBER B3; H2AFB3__:__H2A HISTONE FAMILY, MEMBER B; H2AFB;; H2A HISTONE, BARR BODY-DEFICIENT; H2ABBD__:__
Asterisk__:__300446__:__RHOX HOMEOBOX FAMILY, MEMBER 1; RHOXF1__:__OVARY-, TESTIS-, AND EPIDIDYMIS-EXPRESSED GENE; OTEX;; HOMEOBOX PROTEIN, PEPP SUBFAMILY, 1; PEPP1__:__
Asterisk__:__300447__:__RHOX HOMEOBOX FAMILY, MEMBER 2; RHOXF2__:__HOMEOBOX PROTEIN, PEPP SUBFAMILY, 2; PEPP2__:__
Number Sign__:__300448__:__ALPHA-THALASSEMIA MYELODYSPLASIA SYNDROME; ATMDS__:__HEMOGLOBIN H DISEASE, ACQUIRED__:__
Caret__:__300449__:__MOVED TO 300448__:____:__
Asterisk__:__300450__:__FETAL AND ADULT TESTIS-EXPRESSED GENE 1; FATE1__:__FATE__:__
Asterisk__:__300451__:__ECTODYSPLASIN A; EDA__:__ECTODYSPLASIN;; EDA1 GENE;; ED1 GENE; ED1__:__ECTODYSPLASIN A1 ISOFORM, INCLUDED;; EDA-A1, INCLUDED;; ECTODYSPLASIN A2 ISOFORM, INCLUDED;; EDA-A2, INCLUDED
Asterisk__:__300452__:__INHIBITOR OF GROWTH, X-LINKED; INGX__:__INHIBITOR OF GROWTH 2, FORMERLY; ING2, FORMERLY__:__
Asterisk__:__300453__:__FAMILY WITH SEQUENCE SIMILARITY 50, MEMBER A; FAM50A__:__XAP5 GENE;; DXS9928E;; HXC26;; 9F__:__
Percent__:__300454__:__MENTAL RETARDATION, X-LINKED 77; MRX77__:____:__
Number Sign__:__300455__:__RETINITIS PIGMENTOSA, X-LINKED, AND SINORESPIRATORY INFECTIONS, WITH OR WITHOUT DEAFNESS__:____:__
Asterisk__:__300456__:__CYCLIN B3; CCNB3__:____:__CCNB3/BCOR FUSION GENE, INCLUDED
Asterisk__:__300457__:__NHS GENE; NHS__:____:__
Caret__:__300458__:__MOVED TO 300055__:____:__
Asterisk__:__300459__:__TENOMODULIN; TNMD__:__TEM;; CHONDROMODULIN I-LIKE; CHM1L;; CHM1-LIKE__:__
Asterisk__:__300460__:__PROTOCADHERIN 19; PCDH19__:__KIAA1313__:__
Asterisk__:__300461__:__ORNITHINE CARBAMOYLTRANSFERASE; OTC__:__ORNITHINE TRANSCARBAMYLASE__:__
Asterisk__:__300462__:__A-KINASE ANCHOR PROTEIN 14; AKAP14__:__A-KINASE ANCHOR PROTEIN, 28-KD; AKAP28__:__
Asterisk__:__300463__:__POLYGLUTAMINE-BINDING PROTEIN 1; PQBP1__:__NUCLEAR PROTEIN CONTAINING A WW DOMAIN, 38-KD; NPW38__:__
Percent__:__300464__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 3__:__CHDS3__:__
Caret__:__300465__:__MOVED TO 301040__:____:__
Asterisk__:__300466__:__MELANOMA ANTIGEN, FAMILY B, 5; MAGEB5__:____:__
Asterisk__:__300467__:__MELANOMA ANTIGEN, FAMILY B, 6; MAGEB6__:____:__
Asterisk__:__300468__:__MELANOMA ANTIGEN, FAMILY C, 2; MAGEC2__:__CANCER-TESTIS ANTIGEN 10; CT10;; HCA587;; MELANOMA ANTIGEN, FAMILY E, 1, FORMERLY; MAGEE1, FORMERLY__:__
Asterisk__:__300469__:__MELANOMA ANTIGEN, FAMILY C, 3; MAGEC3__:____:__
Asterisk__:__300470__:__MELANOMA ANTIGEN, FAMILY D, 2; MAGED2__:__MAGED__:__
Percent__:__300471__:__CUBITUS VALGUS WITH MENTAL RETARDATION AND UNUSUAL FACIES__:____:__
Number Sign__:__300472__:__CORPUS CALLOSUM, AGENESIS OF, WITH MENTAL RETARDATION, OCULAR COLOBOMA, AND MICROGNATHIA__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 28; MRXS28__:__
Asterisk__:__300473__:__NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 1; NR0B1__:__DSS-AHC CRITICAL REGION ON THE X CHROMOSOME 1, GENE 1; DAX1__:__
Asterisk__:__300474__:__GLYCEROL KINASE; GK__:__ATP:GLYCEROL PHOSPHOTRANSFERASE__:__
Number Sign__:__300475__:__DEAFNESS, DYSTONIA, AND CEREBRAL HYPOMYELINATION; DDCH__:____:__CONTIGUOUS ABCD1/DXS1375E DELETION SYNDROME, INCLUDED; CADDS, INCLUDED
Number Sign__:__300476__:__CONE-ROD DYSTROPHY, X-LINKED, 3; CORDX3__:____:__
Asterisk__:__300477__:__FAMILY WITH SEQUENCE SIMILARITY 9, MEMBER A; FAM9A__:____:__
Asterisk__:__300478__:__FAMILY WITH SEQUENCE SIMILARITY 9, MEMBER B; FAM9B__:____:__
Asterisk__:__300479__:__FAMILY WITH SEQUENCE SIMILARITY 9, MEMBER C; FAM9C__:____:__
Asterisk__:__300480__:__TAK1-BINDING PROTEIN 3; TAB3__:__TGF-BETA-ACTIVATED KINASE 1/MAP3K7-BINDING PROTEIN 3;; TAK1/MAP3K7-BINDING PROTEIN 3;; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7-INTERACTING PROTEIN 3; MAP3K7IP3;; NF-KAPPA-B-ACTIVATING PROTEIN 1; NAP1__:__
Asterisk__:__300481__:__CYTOCHROME b(-245), BETA SUBUNIT; CYBB__:__CYTOCHROME b(558), BETA SUBUNIT;; p91-PHOX;; NADPH OXIDASE 2; NOX2;; GP91-1__:__
Asterisk__:__300482__:__GRB2-ASSOCIATED BINDING PROTEIN 3; GAB3__:____:__
Caret__:__300483__:__MOVED TO 300031__:____:__
Percent__:__300484__:__OROFACIODIGITAL SYNDROME VIII; OFD8__:__OFDS VIII;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE VIII;; ORAL-FACIAL-DIGITAL SYNDROME WITH HYPOPLASTIC EPIGLOTTIS;; EDWARDS SYNDROME__:__
Asterisk__:__300485__:__BCL6 COREPRESSOR; BCOR__:__KIAA1575__:__BCOR/CCNB3 FUSION GENE, INCLUDED
Number Sign__:__300486__:__MENTAL RETARDATION, X-LINKED, WITH CEREBELLAR HYPOPLASIA AND DISTINCTIVE FACIAL APPEARANCE__:__MENTAL RETARDATION, X-LINKED 60, FORMERLY; MRX60, FORMERLY__:__
Asterisk__:__300487__:__ACTIN-RELATED PROTEIN T1; ACTRT1__:__ARPT1__:__
Percent__:__300488__:__MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENOQ1__:____:__
Number Sign__:__300489__:__SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED 3; SMAX3__:__SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED RECESSIVE;; DSMAX__:__
Asterisk__:__300490__:__SH2 DOMAIN PROTEIN 1A; SH2D1A__:__SIGNALING LYMPHOCYTE ACTIVATION MOLECULE-ASSOCIATED PROTEIN;; SLAM-ASSOCIATED PROTEIN; SAP__:__
Number Sign__:__300491__:__EPILEPSY, X-LINKED, WITH VARIABLE LEARNING DISABILITIES AND BEHAVIOR DISORDERS__:____:__
Asterisk__:__300492__:__FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER A; FAM3A__:____:__
Asterisk__:__300493__:__SPERM PROTEIN ASSOCIATED WITH THE NUCLEUS, X CHROMOSOME, FAMILY MEMBER A2; SPANXA2__:____:__
Number Sign__:__300494__:__ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1; ASPGX1__:____:__
Number Sign__:__300495__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 2; AUTSX2__:____:__MENTAL RETARDATION, X-LINKED, INCLUDED
Number Sign__:__300496__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3__:____:__
Number Sign__:__300497__:__ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2; ASPGX2__:____:__
Percent__:__300498__:__MENTAL RETARDATION, X-LINKED 45; MRX45__:____:__
Asterisk__:__300499__:__FTSJ HOMOLOG 1; FTSJ1__:__SPB1, S. CEREVISIAE, HOMOLOG OF;; JM23__:__
Number Sign__:__300500__:__ALBINISM, OCULAR, TYPE I; OA1__:__NETTLESHIP-FALLS TYPE OCULAR ALBINISM__:__
Caret__:__300501__:__MOVED TO 309549__:____:__
Asterisk__:__300502__:__PYRUVATE DEHYDROGENASE, ALPHA-1; PDHA1__:__PYRUVATE DEHYDROGENASE COMPLEX, E1-ALPHA POLYPEPTIDE 1; PHE1A;; PDHCE1A;; PDHA__:__
Caret__:__300503__:__MOVED TO 300419__:____:__
Percent__:__300504__:__MENTAL RETARDATION, X-LINKED 52; MRX52__:____:__
Percent__:__300505__:__MENTAL RETARDATION, X-LINKED 84; MRX84__:____:__
Asterisk__:__300506__:__TSC22 DOMAIN FAMILY, MEMBER 3; TSC22D3__:__DELTA SLEEP-INDUCING PEPTIDE, IMMUNOREACTOR; DSIPI;; GLUCOCORTICOID-INDUCED LEUCINE ZIPPER; GILZ__:__
Asterisk__:__300507__:__H2B HISTONE FAMILY, MEMBER W, TESTIS-SPECIFIC; H2BFWT__:____:__
Asterisk__:__300508__:__UTP14, S. CEREVISIAE, HOMOLOG OF, A; UTP14A__:__NY-CO-16__:__
Percent__:__300509__:__DYSLEXIA, SUSCEPTIBILITY TO, 9; DYX9__:____:__
Number Sign__:__300510__:__OVARIAN DYSGENESIS 2; ODG2__:__OVARIAN DYSGENESIS, HYPERGONADOTROPIC, X-LINKED;; OVARIAN FAILURE, HYPERGONADOTROPIC, DUE TO OVARIAN DYSGENESIS__:__PREMATURE OVARIAN FAILURE 4, INCLUDED; POF4, INCLUDED
Number Sign__:__300511__:__PREMATURE OVARIAN FAILURE 2A; POF2A__:____:__
Asterisk__:__300512__:__WD REPEAT-CONTAINING PROTEIN 13; WDR13__:____:__
Asterisk__:__300513__:__G PROTEIN-COUPLED RECEPTOR 119; GPR119__:__G PROTEIN-COUPLED RECEPTOR 2; GPCR2__:__
Number Sign__:__300514__:__FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB__:__FACB;; FANCONI PANCYTOPENIA, TYPE 2; FA2__:__
Asterisk__:__300515__:__FANCB GENE; FANCB__:__FANCONI ANEMIA-ASSOCIATED POLYPEPTIDE, 95-KD; FAAP95;; FAAP90;; FLJ34064__:__
Asterisk__:__300516__:__ATPase, CLASS VI, TYPE 11C; ATP11C__:__ATPase IQ; ATPIQ;; ATPase IG; ATPIG__:__
Asterisk__:__300517__:__SPINDLIN FAMILY, MEMBER 2__:__SPIN2;; SPIN2, TELOMERIC COPY__:__
Percent__:__300518__:__MENTAL RETARDATION, X-LINKED 82; MRX82__:____:__
Percent__:__300519__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, MARTIN-PROBST TYPE; MRXSMP__:__MARTIN-PROBST DEAFNESS-MENTAL RETARDATION SYNDROME__:__
Asterisk__:__300520__:__CLAUDIN 2; CLDN2__:____:__
Asterisk__:__300521__:__KINESIN FAMILY MEMBER 4A; KIF4A__:__KIF4__:__
Asterisk__:__300522__:__IQ MOTIF- AND SEC7 DOMAIN-CONTAINING PROTEIN 2; IQSEC2__:__KIAA0522__:__
Number Sign__:__300523__:__ALLAN-HERNDON-DUDLEY SYNDROME; AHDS__:__ALLAN-HERNDON SYNDROME;; MONOCARBOXYLATE TRANSPORTER 8 DEFICIENCY;; TRIIODOTHYRONINE RESISTANCE;; T3 RESISTANCE;; MENTAL RETARDATION, X-LINKED, WITH HYPOTONIA;; MENTAL RETARDATION AND MUSCULAR ATROPHY__:__
Asterisk__:__300524__:__NEURITE EXTENSION AND MIGRATION FACTOR; NEXMIF__:__KIAA2022__:__
Asterisk__:__300525__:__PYRIMIDINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 8; P2RY8__:__P2Y8__:__P2RY8/CRLF2 FUSION GENE, INCLUDED
Asterisk__:__300526__:__WD REPEAT-CONTAINING PROTEIN 45; WDR45__:__WD40 REPEAT PROTEIN INTERACTING WITH PHOSPHOINOSITIDES 4; WIPI4__:__
Asterisk__:__300527__:__NUDIX HYDROLASE 10; NUDT10__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 10;; NUDIX MOTIF 10;; DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE 3, ALPHA; DIPP3A;; DIPP3-ALPHA;; APS2__:__
Asterisk__:__300528__:__NUDIX HYDROLASE 11; NUDT11__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 11;; NUDIX MOTIF 11;; DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE 3, BETA; DIPP3B;; DIPP3-BETA;; APS1__:__
Asterisk__:__300529__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 10; P2RY10__:__P2Y10__:__
Caret__:__300530__:__MOVED TO 611775__:____:__
Asterisk__:__300531__:__SPROUTY, DROSOPHILA, HOMOLOG OF, 3; SPRY3__:____:__
Asterisk__:__300532__:__VARIABLY CHARGED, X CHROMOSOME, 2; VCX2__:__VARIABLY CHARGED, X CHROMOSOME, WITH 2 REPEATS; VCX2R;; VARIABLY CHARGED, X CHROMOSOME, B; VCXB__:__
Asterisk__:__300533__:__VARIABLY CHARGED, X CHROMOSOME, 3A; VCX3A__:__VARIABLY CHARGED, X CHROMOSOME, WITH 8 REPEATS; VCX8R;; VARIABLY CHARGED, X CHROMOSOME, A; VCXA__:__
Number Sign__:__300534__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, CLAES-JENSEN TYPE; MRXSCJ__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, JARID1C-RELATED; MRXSJ__:__
Asterisk__:__300535__:__OCRL GENE; OCRL__:__OCRL1__:__
Percent__:__300536__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 4; BMND4__:____:__
Caret__:__300537__:__MOVED TO 300049__:____:__
Asterisk__:__300538__:__ARGININE VASOPRESSIN RECEPTOR 2; AVPR2__:__ANTIDIURETIC HORMONE RECEPTOR; ADHR;; VASOPRESSIN V2 RECEPTOR; V2R__:__
Number Sign__:__300539__:__NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS; NSIAD__:____:__
Asterisk__:__300540__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 7; HAUS7__:__UCHL5-INTERACTING PROTEIN; UCHL5IP;; UCH37-INTERACTING PROTEIN 1; UIP1__:__
Asterisk__:__300541__:__SARCOMA, SYNOVIAL, X BREAKPOINT 6; SSX6__:____:__
Asterisk__:__300542__:__SARCOMA, SYNOVIAL, X BREAKPOINT 7; SSX7__:____:__
Asterisk__:__300543__:__SARCOMA, SYNOVIAL, X BREAKPOINT 8; SSX8__:____:__
Asterisk__:__300544__:__SARCOMA, SYNOVIAL, X BREAKPOINT 9; SSX9__:____:__
Asterisk__:__300545__:__HEPARAN SULFATE 6-O-SULFOTRANSFERASE 2; HS6ST2__:____:__
Asterisk__:__300546__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 1; FGD1__:____:__
Asterisk__:__300547__:__MST3- AND SOK1-RELATED KINASE__:__MASK;; MAMMALIAN STERILE 20-LIKE 4; MST4__:__
Asterisk__:__300548__:__MELANOMA ANTIGEN, FAMILY H, 1; MAGEH1__:__MAGEH__:__
Asterisk__:__300549__:__MELANOMA ANTIGEN, FAMILY A, 2B; MAGEA2B__:____:__
Asterisk__:__300550__:__PHOSPHATE-REGULATING ENDOPEPTIDASE HOMOLOG, X-LINKED; PHEX__:__PEX__:__
Caret__:__300551__:__MOVED TO 309530__:____:__
Asterisk__:__300552__:__MIDLINE 1; MID1__:__MIDLINE 1 RING FINGER GENE;; MIDIN;; FINGER ON X AND Y, MOUSE, HOMOLOG OF; FXY__:__
Asterisk__:__300553__:__BROMODOMAIN- AND WD REPEAT-CONTAINING PROTEIN 3; BRWD3__:____:__
Number Sign__:__300554__:__HYPOPHOSPHATEMIC RICKETS, X-LINKED RECESSIVE__:____:__
Number Sign__:__300555__:__DENT DISEASE 2__:____:__
Asterisk__:__300556__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, ACCESSORY PROTEIN 2; ATP6AP2__:__M8-9, BOVINE, HOMOLOG OF;; ATP6M8-9;; RENIN RECEPTOR__:__
Percent__:__300557__:__PARKINSON DISEASE 12; PARK12__:__PARKINSON DISEASE, X-LINKED__:__
Number Sign__:__300558__:__MENTAL RETARDATION, X-LINKED 30; MRX30__:__MENTAL RETARDATION, X-LINKED 47; MRX47__:__
Number Sign__:__300559__:__GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D__:__GSD IXd;; MUSCLE PHOSPHORYLASE KINASE DEFICIENCY;; MUSCLE GLYCOGENOSIS, X-LINKED__:__
Asterisk__:__300560__:__PHD FINGER PROTEIN 8; PHF8__:__ZINC FINGER PROTEIN 422; ZNF422;; KIAA1111__:__
Asterisk__:__300561__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 2; SLITRK2__:__CHROMOSOME X OPEN READING FRAME 2; CXORF2;; CHROMOSOME X OPEN READING FRAME 1; CXORF1;; TRANSMEMBRANE PROTEIN 257; TMEM257;; KIAA1854__:__
Asterisk__:__300562__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 4; SLITRK4__:____:__
Caret__:__300563__:__MOVED TO 311070__:____:__
Asterisk__:__300564__:__TSPY-LIKE 2; TSPYL2__:__CELL DIVISION AUTOANTIGEN 1; CDA1;; DIFFERENTIALLY EXPRESSED NUCLEOLAR TGFB1 TARGET; DENTT;; CASK-INTERACTING NUCLEOSOME ASSEMBLY PROTEIN; CINAP__:__
Caret__:__300565__:__MOVED TO 300561__:____:__
Asterisk__:__300566__:__LHFP-LIKE PROTEIN 1; LHFPL1__:____:__
Asterisk__:__300567__:__PHOSPHOGLYCERATE MUTASE FAMILY MEMBER 4; PGAM4__:__PHOSPHOGLYCERATE MUTASE FAMILY 3; PGAM3__:__
Asterisk__:__300568__:__MICRO RNA 221; MIR221__:__miRNA221;; MIRN221__:__
Asterisk__:__300569__:__MICRO RNA 222; MIR222__:__miRNA222;; MIRN222__:__
Asterisk__:__300570__:__TRANSCRIPTION FACTOR YY2; YY2__:__ZNF631__:__
Caret__:__300571__:__MOVED TO 615465__:____:__
Asterisk__:__300572__:__ADHESION G PROTEIN-COUPLED RECEPTOR G2; ADGRG2__:__G PROTEIN-COUPLED RECEPTOR 64; GPR64;; G PROTEIN-COUPLED RECEPTOR, EPIDIDYMIS-SPECIFIC;; HUMAN EPIDIDYMIS-SPECIFIC PROTEIN 6; HE6__:__
Asterisk__:__300573__:__ZINC FINGER PROTEIN 674; ZNF674__:____:__
Asterisk__:__300574__:__CHEMOKINE, CXC MOTIF, RECEPTOR 3; CXCR3__:__G PROTEIN-COUPLED RECEPTOR 9; GPR9;; CD183 ANTIGEN; CD183__:__
Asterisk__:__300575__:__RIPPLY1, ZEBRAFISH, HOMOLOG OF; RIPPLY1__:__LOC92129__:__
Asterisk__:__300576__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 15; ZDHHC15__:____:__
Number Sign__:__300577__:__MENTAL RETARDATION, X-LINKED 91; MRX91__:____:__
Number Sign__:__300578__:__CHROMOSOME Xp11.3 DELETION SYNDROME__:__MENTAL RETARDATION, X-LINKED, WITH RETINITIS PIGMENTOSA__:__
Asterisk__:__300579__:__SHROOM FAMILY MEMBER 4; SHROOM4__:__KIAA1202__:__
Percent__:__300580__:__MYOPATHY, CONGENITAL, WITH FIBER-TYPE DISPROPORTION, X-LINKED; CFTDX__:____:__
Percent__:__300581__:__FG SYNDROME 5; FGS5__:____:__
Number Sign__:__300582__:__SHORT STATURE, IDIOPATHIC, X-LINKED; ISS__:____:__
Asterisk__:__300583__:__VESTIGIAL-LIKE 1; VGLL1__:__VGL1;; TONDU; TDU__:__
Number Sign__:__300584__:__IMMUNODEFICIENCY WITHOUT ANHIDROTIC ECTODERMAL DYSPLASIA__:__IMMUNODEFICIENCY, ISOLATED;; IMMUNODEFICIENCY, PURE__:__
Asterisk__:__300585__:__ZINC FINGER PROTEIN 673; ZNF673__:__FLJ20344__:__
Asterisk__:__300586__:__ARYLSULFATASE H; ARSH__:____:__
Asterisk__:__300587__:__MALIGNANT T-CELL AMPLIFIED SEQUENCE 1; MCTS1__:__MCT1__:__
Asterisk__:__300588__:__TENEURIN TRANSMEMBRANE PROTEIN 1; TENM1__:__ODZ, DROSOPHILA, HOMOLOG OF, 1; ODZ1;; TENASCIN M1; TNM1;; TENEURIN 1__:__
Percent__:__300589__:__NYSTAGMUS 5, CONGENITAL, X-LINKED; NYS5__:____:__
Number Sign__:__300590__:__CORNELIA DE LANGE SYNDROME 2; CDLS2__:__CORNELIA DE LANGE SYNDROME, X-LINKED;; CDLS, X-LINKED__:__
Percent__:__300591__:__STATURE QUANTITATIVE TRAIT LOCUS 6; STQTL6__:____:__
Asterisk__:__300592__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A11; CT47A11__:__CT47.11;; LOC255313__:__
Asterisk__:__300593__:__SPERM ACROSOME-ASSOCIATED PROTEIN 5; SPACA5__:__LOC389852__:__
Asterisk__:__300594__:__G ANTIGEN 1; GAGE1__:____:__
Asterisk__:__300595__:__G ANTIGEN 2C; GAGE2C__:__GAGE2__:__
Asterisk__:__300596__:__G ANTIGEN 3; GAGE3__:____:__
Asterisk__:__300597__:__G ANTIGEN 4; GAGE4__:____:__
Asterisk__:__300598__:__G ANTIGEN 5; GAGE5__:____:__
Asterisk__:__300599__:__G ANTIGEN 6; GAGE6__:____:__
Number Sign__:__300600__:__ALAND ISLAND EYE DISEASE; AIED__:__FORSIUS-ERIKSSON TYPE OCULAR ALBINISM__:__
Asterisk__:__300601__:__G ANTIGEN 7; GAGE7__:____:__
NULL__:__300602__:__CLARK-BARAITSER SYNDROME__:__BARAITSER SYNDROME__:__
Asterisk__:__300603__:__POF1B GENE; POF1B__:__FLJ22792;; ACTIN-BINDING PROTEIN, 34-KD__:__
Number Sign__:__300604__:__PREMATURE OVARIAN FAILURE 2B; POF2B__:____:__
Percent__:__300605__:__RETINITIS PIGMENTOSA 34; RP34__:____:__
Caret__:__300606__:__MOVED TO 313500__:____:__
Number Sign__:__300607__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 8; EIEE8__:__HYPEREKPLEXIA AND EPILEPSY__:__
Asterisk__:__300608__:__DACHSHUND, DROSOPHILA, HOMOLOG OF, 2; DACH2__:____:__
Asterisk__:__300609__:__MALE-SPECIFIC LETHAL 3, DROSOPHILA, HOMOLOG OF; MSL3__:__MALE-SPECIFIC LETHAL 3-LIKE 1; MSL3L1;; DROSOPHILA MSL3-LIKE 1__:__
Asterisk__:__300610__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H2; HNRNPH2__:__HNRPH2;; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H-PRIME__:__
Asterisk__:__300611__:__C1GALT1-SPECIFIC CHAPERONE 1; C1GALT1C1__:__CORE 1 BETA-3-GALACTOSYLTRANSFERASE-SPECIFIC MOLECULAR CHAPERONE;; COSMC;; C1GALT2__:__
Percent__:__300612__:__BROOKS-WISNIEWSKI-BROWN SYNDROME__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, BROOKS-WISNIEWSKI-BROWN TYPE; MRXSBWB__:__
Percent__:__300613__:__MYOPIA 13, X-LINKED; MYP13__:____:__
Number Sign__:__300614__:__DEAFNESS, X-LINKED 5; DFNX5__:__AUDITORY NEUROPATHY, X-LINKED, 1, WITH PERIPHERAL SENSORY NEUROPATHY; AUNX1__:__
Number Sign__:__300615__:__BRUNNER SYNDROME; BRNRS__:____:__ANTISOCIAL BEHAVIOR, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__300616__:__LEUCINE ZIPPER PROTEIN 4; LUZP4__:__HOM-TES-85__:__
Asterisk__:__300617__:__BRCA1/BRCA2-CONTAINING COMPLEX, SUBUNIT 3; BRCC3__:__C6.1A;; BRCC36__:__
Asterisk__:__300618__:__PHD FINGER PROTEIN 16; PHF16__:__JADE3;; KIAA0215__:__
Percent__:__300619__:__CATARACT, ATAXIA, SHORT STATURE, AND MENTAL RETARDATION__:__CASM SYNDROME__:__
Asterisk__:__300620__:__V-SET AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 1; VSIG1__:__GLYCOPROTEIN A34; GPA34__:__
Asterisk__:__300621__:__DXF34 GENE__:__DXF34;; SPINDLIN FAMILY, MEMBER 2, CENTROMERIC COPY;; SPIN2, CENTROMERIC COPY__:__
Number Sign__:__300622__:__TN POLYAGGLUTINATION SYNDROME; TNPS__:__GALACTOSYLTRANSFERASE DEFICIENCY__:__
Number Sign__:__300623__:__FRAGILE X TREMOR/ATAXIA SYNDROME; FXTAS__:____:__
Number Sign__:__300624__:__FRAGILE X SYNDROME; FXS__:__FRAGILE X MENTAL RETARDATION SYNDROME;; MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28;; X-LINKED MENTAL RETARDATION AND MACROORCHIDISM;; MARKER X SYNDROME;; MARTIN-BELL SYNDROME__:__
Asterisk__:__300625__:__KITA-KYUSHU LUNG CANCER ANTIGEN 1__:__KKLC1;; CHROMOSOME X OPEN READING FRAME 61; CXORF61__:__
Asterisk__:__300626__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 11; ASB11__:____:__
Asterisk__:__300627__:__ZINC FINGER PROTEIN 449; ZNF449__:__ZSCAN19__:__
Asterisk__:__300628__:__FERM DOMAIN-CONTAINING PROTEIN 7; FRMD7__:____:__
Asterisk__:__300629__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, SIGMA-2 SUBUNIT; AP1S2__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, SMALL 1-LIKE;; CLATHRIN ADAPTOR COMPLEX AP1, SIGMA-1B SUBUNIT__:__
Caret__:__300630__:__MOVED TO 304340__:____:__
Asterisk__:__300631__:__TRANSMEMBRANE PROTEIN 27; TMEM27__:__COLLECTRIN;; NX17__:__
Asterisk__:__300632__:__PDZ DOMAIN-CONTAINING 11; PDZD11__:__ATPase-INTERACTING PDZ PROTEIN; AIPP1;; PLASMA MEMBRANE CALCIUM ATPase-INTERACTING SINGLE PDZ PROTEIN; PISP;; PMCA-INTERACTING SINGLE PDZ PROTEIN__:__
Number Sign__:__300633__:__HYPOSPADIAS 1, X-LINKED; HYSP1__:____:__
Asterisk__:__300634__:__PDZ DOMAIN-CONTAINING 4; PDZD4__:__PDZK4;; PDZRN4L;; KIAA1444;; LU1__:__
Number Sign__:__300635__:__LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 2; XLP2__:__XIAP DEFICIENCY__:__
Number Sign__:__300636__:__IMMUNODEFICIENCY 33; IMD33__:__IMMUNODEFICIENCY 33, MYCOBACTERIOSIS, X-LINKED;; ATYPICAL MYCOBACTERIOSIS, FAMILIAL, X-LINKED 1; AMCBX1__:__
Asterisk__:__300637__:__G ANTIGEN 12I; GAGE12I__:__GAGE7B__:__
Asterisk__:__300638__:__G ANTIGEN 8; GAGE8__:____:__
Caret__:__300639__:__MOVED TO 300354__:____:__
Number Sign__:__300640__:__INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2; IPD2__:____:__
Asterisk__:__300641__:__SOLUTE CARRIER FAMILY 25, MEMBER 43; SLC25A43__:____:__
Asterisk__:__300642__:__SUSHI REPEAT-CONTAINING PROTEIN, X-LINKED, 2; SRPX2__:__SUSHI REPEAT PROTEIN UPREGULATED IN LEUKEMIA; SRPUL__:__
Number Sign__:__300643__:__ROLANDIC EPILEPSY, MENTAL RETARDATION, AND SPEECH DYSPRAXIA, X-LINKED; RESDX__:____:__
Asterisk__:__300644__:__GALACTOSIDASE, ALPHA; GLA__:__ALPHA-GALACTOSIDASE A; GALA__:__
Number Sign__:__300645__:__IMMUNODEFICIENCY 34; IMD34__:__IMMUNODEFICIENCY 34, MYCOBACTERIOSIS, X-LINKED;; ATYPICAL MYCOBACTERIOSIS, FAMILIAL, X-LINKED 2; AMCBX2__:__
Asterisk__:__300646__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 9; ZDHHC9__:__DHHC DOMAIN-CONTAINING PROTEIN 9; DHHC9__:__
Asterisk__:__300647__:__APC MEMBRANE RECRUITMENT PROTEIN 1; AMER1__:__WTX;; FAMILY WITH SEQUENCE SIMILARITY 123, MEMBER B; FAM123B__:__
Asterisk__:__300648__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A1; CT45A1__:__CANCER/TESTIS ANTIGEN 45, MEMBER 1; CT45.1__:__
Asterisk__:__300649__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 5; SLC38A5__:__TRANSPORT SYSTEM N, PROTEIN 2; SN2__:__
NULL__:__300650__:__ALBINISM, OCULAR, WITH LATE-ONSET SENSORINEURAL DEAFNESS; OASD__:__OCULAR ALBINISM WITH SENSORINEURAL DEAFNESS;; DEAFNESS AND OCULAR ALBINISM__:__
Asterisk__:__300651__:__PORCUPINE, DROSOPHILA, HOMOLOG OF; PORCN__:__PORC__:__
Percent__:__300652__:__ANGIOMA SERPIGINOSUM, X-LINKED__:____:__
Number Sign__:__300653__:__PHOSPHOGLYCERATE KINASE 1 DEFICIENCY__:__PGK1 DEFICIENCY__:__
Asterisk__:__300654__:__FATTY ACID AMIDE HYDROLASE 2; FAAH2__:____:__
Asterisk__:__300655__:__KELCH-LIKE 13; KLHL13__:__KIAA1309__:__
Asterisk__:__300656__:__URACIL PHOSPHORIBOSYLTRANSFERASE, S. CEREVISIAE, HOMOLOG OF; UPRT__:____:__
Asterisk__:__300657__:__CANCER/TESTIS ANTIGEN 1A; CTAG1A__:__LAGE2A;; LAGE2, CENTROMERIC COPY__:__
Asterisk__:__300658__:__NDP GENE; NDP__:__NORRIN__:__
Number Sign__:__300659__:__MENTAL RETARDATION, X-LINKED 93; MRX93__:__MENTAL RETARDATION, X-LINKED, WITH MACROCEPHALY__:__
Percent__:__300660__:__LEUKOENCEPHALOPATHY WITH METAPHYSEAL CHONDRODYSPLASIA; LKMCD__:____:__
Number Sign__:__300661__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY__:__PRPS1 SUPERACTIVITY__:__GOUT, PRPS-RELATED, INCLUDED
Asterisk__:__300662__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 11; SNORA11__:__snoRNA, U107__:__
Asterisk__:__300663__:__AUTOPHAGY 4, S. CEREVISIAE, HOMOLOG OF, A; ATG4A__:__APG4, S. CEREVISIAE, HOMOLOG OF, A; APG4A;; AUTOPHAGIN 2;; AUTL2__:__
Asterisk__:__300664__:__SPANX FAMILY, MEMBER N1; SPANXN1__:____:__
Asterisk__:__300665__:__SPANX FAMILY, MEMBER N2; SPANXN2__:____:__
Asterisk__:__300666__:__SPANX FAMILY, MEMBER N3; SPANXN3__:____:__
Asterisk__:__300667__:__SPANX FAMILY, MEMBER N4; SPANXN4__:____:__
Asterisk__:__300668__:__SPANX FAMILY, MEMBER N5; SPANXN5__:____:__
Asterisk__:__300669__:__SPANX FAMILY, MEMBER B1; SPANXB1__:__SPERM PROTEIN ASSOCIATED WITH THE NUCLEUS, X CHROMOSOME, FAMILY MEMBER B1;; SPANXB__:__
Asterisk__:__300670__:__SPANX FAMILY, MEMBER D; SPANXD__:____:__
Asterisk__:__300671__:__SPANX FAMILY, MEMBER E; SPANXE__:____:__
Number Sign__:__300672__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2; EIEE2__:__INFANTILE SPASM SYNDROME, X-LINKED 2; ISSX2__:__
Number Sign__:__300673__:__ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS__:____:__
Asterisk__:__300674__:__MOTILE SPERM DOMAIN-CONTAINING PROTEIN 1; MOSPD1__:____:__
Asterisk__:__300675__:__PARANEOPLASTIC MA ANTIGEN 3; PNMA3__:__PARANEOPLASTIC ANTIGEN MA3; MA3__:__
Number Sign__:__300676__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 14; MRXS14__:____:__
Asterisk__:__300677__:__CHROMOSOME X OPEN READING FRAME 15; CXORF15__:__TAXILIN, GAMMA;; FACTOR INHIBITING ATF4-MEDIATED TRANSCRIPTION; FIAT__:__
Asterisk__:__300678__:__DUAL-SPECIFICITY PHOSPHATASE 21; DUSP21__:__LMWDSP21__:__
Number Sign__:__300679__:__CHROMOSOME Xp21 DELETION SYNDROME__:__COMPLEX GLYCEROL KINASE DEFICIENCY__:__
Asterisk__:__300680__:__PREGNANCY-UPREGULATED, NONUBIQUITOUS, CAM KINASE; PNCK__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I-BETA; CAMK1B;; BSTK3, MOUSE, HOMOLOG OF__:__
Asterisk__:__300681__:__DEDICATOR OF CYTOKINESIS 11; DOCK11__:__ACTIVATED CDC42-ASSOCIATED GUANINE NUCLEOTIDE EXCHANGE FACTOR; ACG;; ZIZIMIN 2; ZIZ2__:__
Asterisk__:__300682__:__MICRO RNA 424; MIR424__:__miRNA424;; MIRN424__:__MICRO RNA 322, INCLUDED; MIR322, INCLUDED;; miRNA322, INCLUDED;; MIRN322, INCLUDED
Asterisk__:__300683__:__SEPTIN 6; SEPT6__:__SEP2, DROSOPHILA, HOMOLOG OF; SEP2;; KIAA0128__:__SEPT6/MLL FUSION GENE, INCLUDED
Asterisk__:__300684__:__X KELL BLOOD GROUP PRECURSOR-RELATED, X-LINKED; XKRX__:__MEMBRANE PROTEIN XPLAC; XPLAC;; XKR2;; XRG2__:__
Asterisk__:__300685__:__PROLINE-RICH GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 3; PRRG3__:__PROLINE-RICH GLA PROTEIN 3; PRGP3;; TRANSMEMBRANE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 3; TMG3__:__
Asterisk__:__300686__:__MICRO RNA 448; MIR448__:__miRNA448;; MIRN448__:__
Asterisk__:__300687__:__ERCC6-LIKE; ERCC6L__:__PIK1-INTERACTING CHECKPOINT HELICASE; PICH__:__
Asterisk__:__300688__:__BCL6 COREPRESSOR-LIKE 1; BCORL1__:____:__
Asterisk__:__300689__:__START DOMAIN-CONTAINING PROTEIN 8; STARD8__:__DELETED IN LIVER CANCER 3; DLC3;; STARTGAP3;; KIAA0189__:__
Asterisk__:__300690__:__BRAIN-EXPRESSED X-LINKED GENE 1; BEX1__:____:__
Asterisk__:__300691__:__BRAIN-EXPRESSED X-LINKED GENE 2; BEX2__:____:__
Asterisk__:__300692__:__BEX FAMILY MEMBER 4; BEX4__:__BRAIN-EXPRESSED X-LINKED GENE 4;; BRAIN-EXPRESSED X-LINKED GENE-LIKE 1; BEXL1__:__
Asterisk__:__300693__:__BEX FAMILY MEMBER 5; BEX5__:__BRAIN-EXPRESSED X-LINKED GENE 5;; NGFRAP1-LIKE 1; NGFRAP1L1__:__
Asterisk__:__300694__:__MICRO RNA 223; MIR223__:__miRNA223;; MIRN223__:__
Number Sign__:__300695__:__SCAPULOPERONEAL MYOPATHY, X-LINKED DOMINANT; SPM__:__SCAPULOPERONEAL MYOPATHY, FHL1-RELATED__:__
Number Sign__:__300696__:__MYOPATHY, X-LINKED, WITH POSTURAL MUSCLE ATROPHY; XMPMA__:____:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 6, X-LINKED, INCLUDED; EDMD6, INCLUDED
Asterisk__:__300697__:__HECT, UBA, AND WWE DOMAINS-CONTAINING PROTEIN 1; HUWE1__:__UPSTREAM REGULATORY ELEMENT-BINDING PROTEIN 1; UREB1;; URE-BINDING PROTEIN 1;; LASU1;; KIAA0312__:__
Asterisk__:__300698__:__TRANSMEMBRANE PROTEIN 47; TMEM47__:__BRAIN CELL MEMBRANE PROTEIN 1; BCMP1__:__
Number Sign__:__300699__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, WU TYPE; MRXSW__:__MENTAL RETARDATION, X-LINKED 94; MRX94;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 29; MRXS29__:__
Percent__:__300700__:__ALBINISM-DEAFNESS SYNDROME; ADFN__:__ALDS__:__
Asterisk__:__300701__:__ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 12; ZCCHC12__:__SMAD-INTERACTING ZINC FINGER PROTEIN 1; SIZN1__:__
Asterisk__:__300702__:__MELANOMA ANTIGEN, FAMILY D, 4; MAGED4__:__MAGEE1;; KIAA1859__:__
Percent__:__300703__:__SPINOCEREBELLAR ATAXIA, X-LINKED 5; SCAX5__:____:__
Percent__:__300704__:__PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2__:____:__
Number Sign__:__300705__:__CHROMOSOME Xp11.22 DUPLICATION SYNDROME__:__MENTAL RETARDATION, X-LINKED 17; MRX17;; MENTAL RETARDATION, X-LINKED 31; MRX31__:__
Number Sign__:__300706__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST__:__MENTAL RETARDATION AND MACROCEPHALY SYNDROME__:__
Number Sign__:__300707__:__TOE SYNDACTYLY, TELECANTHUS, AND ANOGENITAL AND RENAL MALFORMATIONS; STAR__:__STAR SYNDROME;; SYNDACTYLY WITH RENAL AND ANOGENITAL MALFORMATIONS__:__
Asterisk__:__300708__:__FAMILY WITH SEQUENCE SIMILARITY 58, MEMBER A; FAM58A__:____:__
Percent__:__300709__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 9; MRXS9__:____:__
Percent__:__300710__:__ALOPECIA, ANDROGENETIC, 2; AGA2__:____:__
Percent__:__300711__:__PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 4; IHPS4__:____:__
Percent__:__300712__:__CRANIOFACIOSKELETAL SYNDROME__:____:__
Asterisk__:__300713__:__OTU DOMAIN-CONTAINING PROTEIN 5; OTUD5__:__DUBA__:__
Asterisk__:__300714__:__OTU DOMAIN-CONTAINING PROTEIN 6A; OTUD6A__:__DUBA2;; HIN6 PROTEASE__:__
Asterisk__:__300715__:__MAGNESIUM TRANSPORTER 1; MAGT1__:__IAP__:__
Percent__:__300716__:__MENTAL RETARDATION, X-LINKED 95; MRX95__:____:__
Number Sign__:__300717__:__REDUCING BODY MYOPATHY, X-LINKED 1A, SEVERE, WITH INFANTILE OR EARLY CHILDHOOD ONSET; RBMX1A__:____:__
Number Sign__:__300718__:__REDUCING BODY MYOPATHY, X-LINKED 1B, WITH LATE CHILDHOOD OR ADULT ONSET; RBMX1B__:____:__
Percent__:__300719__:__DEAFNESS, CATARACT, RETINITIS PIGMENTOSA, AND SPERM ABNORMALITIES__:____:__
Asterisk__:__300720__:__G ANTIGEN 2A; GAGE2A__:____:__
Asterisk__:__300721__:__MICRO RNA LET7F2; MIRLET7F2__:__LET7, C. ELEGANS, HOMOLOG OF, F2; LET7F2;; miRNA LET7F2;; MIRNLET7F2__:__
Asterisk__:__300722__:__MICRO RNA 19B2; MIR19B2__:__miRNA19B2;; MIRN19B2__:__
Asterisk__:__300723__:__SYNAPTOTAGMIN-LIKE 4; SYTL4__:__GRANUPHILIN__:__
Asterisk__:__300724__:__CONNECTOR ENHANCER OF KINASE SUPPRESSOR OF RAS 2; CNKSR2__:__CONNECTOR ENHANCER OF KSR 2;; CNK, DROSOPHILA, HOMOLOG OF, 2; CNK2;; KIAA0902__:__
Asterisk__:__300725__:__RAS-RELATED GTP-BINDING PROTEIN B; RRAGB__:__RAGB__:__
Asterisk__:__300726__:__G ANTIGEN 2B; GAGE2B__:____:__
Asterisk__:__300727__:__G ANTIGEN 12C; GAGE12C__:____:__
Asterisk__:__300728__:__G ANTIGEN 12D; GAGE12D__:____:__
Asterisk__:__300729__:__G ANTIGEN 12E; GAGE12E__:____:__
Asterisk__:__300730__:__G ANTIGEN 12F; GAGE12F__:____:__
Asterisk__:__300731__:__G ANTIGEN 12G; GAGE12G__:____:__
Asterisk__:__300732__:__G ANTIGEN 12H; GAGE12H__:____:__
Asterisk__:__300733__:__G ANTIGEN 12J; GAGE12J__:____:__
Asterisk__:__300734__:__G ANTIGEN 13; GAGE13__:____:__
Asterisk__:__300735__:__G ANTIGEN 2D; GAGE2D__:____:__
Asterisk__:__300736__:__G ANTIGEN 2E; GAGE2E__:____:__
Asterisk__:__300737__:__G ANTIGEN 10; GAGE10__:____:__
Asterisk__:__300738__:__P ANTIGEN FAMILY, MEMBER 2; PAGE2__:__PROSTATE-ASSOCIATED GENE 2;; GAGEC2__:__
Asterisk__:__300739__:__P ANTIGEN FAMILY, MEMBER 3; PAGE3__:__PROSTATE-ASSOCIATED GENE 3;; GAGED1__:__
Asterisk__:__300740__:__X ANTIGEN FAMILY, MEMBER 3; XAGE3__:__PLACENTA-SPECIFIC 6; PLAC6__:__
Asterisk__:__300741__:__FAMILY WITH SEQUENCE SIMILARITY 120, MEMBER C; FAM120C__:__CHROMOSOME X OPEN READING FRAME 17; CXORF17__:__
Asterisk__:__300742__:__X ANTIGEN FAMILY, MEMBER 1A; XAGE1A__:____:__
Asterisk__:__300743__:__X ANTIGEN FAMILY, MEMBER 1B; XAGE1B__:____:__
Asterisk__:__300744__:__X ANTIGEN FAMILY, MEMBER 1C; XAGE1C__:____:__
Asterisk__:__300745__:__X ANTIGEN FAMILY, MEMBER 1E; XAGE1E__:____:__
Asterisk__:__300746__:__COAGULATION FACTOR IX; F9__:__FACTOR IX;; PLASMA THROMBOPLASTIN COMPONENT; PTC__:__
Asterisk__:__300747__:__STEROID SULFATASE; STS__:__ARYLSULFATASE C; ARSC;; ESTRONE SULFATASE__:__STEROID SULFATASE, ISOZYME S, INCLUDED
Asterisk__:__300748__:__G PROTEIN-COUPLED RECEPTOR 82; GPR82__:____:__
Number Sign__:__300749__:__MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA; MICPCH__:__MICPCH SYNDROME;; MENTAL RETARDATION, X-LINKED, SYNDROMIC, NAJM TYPE; MRXSNA__:__
Percent__:__300750__:__SPASTIC PARAPLEGIA 34, X-LINKED; SPG34__:____:__
Number Sign__:__300751__:__ANEMIA, SIDEROBLASTIC, 1; SIDBA1__:__ANEMIA, SIDEROBLASTIC, X-LINKED; XLSA;; ANEMIA, HYPOCHROMIC; ANH1;; ANEMIA, HEREDITARY SIDEROBLASTIC;; HEREDITARY IRON-LOADING ANEMIA__:__
Number Sign__:__300752__:__PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED; XLEPP__:__PROTOPORPHYRIA, ERYTHROPOIETIC, X-LINKED DOMINANT; XLDPP;; ERYTHROHEPATIC PROTOPORPHYRIA, X-LINKED__:__
Asterisk__:__300753__:__APOLIPOPROTEIN O; APOO__:__MY025;; FAMILY WITH SEQUENCE SIMILARITY 121B; FAM121B;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 26-KD SUBUNIT; MIC26;; MICOS COMPLEX, 26-KD SUBUNIT__:__
Asterisk__:__300754__:__TAF9B RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 31-KD; TAF9B__:__TAF9L;; TAFII31L__:__
Number Sign__:__300755__:__AGAMMAGLOBULINEMIA, X-LINKED; XLA__:__BRUTON-TYPE AGAMMAGLOBULINEMIA;; AGAMMAGLOBULINEMIA, X-LINKED, TYPE 1; AGMX1;; IMMUNODEFICIENCY 1; IMD1__:__HYPOGAMMAGLOBULINEMIA, X-LINKED, INCLUDED
Percent__:__300756__:__ALZHEIMER DISEASE 16; AD16__:____:__
Asterisk__:__300757__:__RP2 GENE; RP2__:____:__
Number Sign__:__300758__:__HYPOSPADIAS 2, X-LINKED; HYSP2__:____:__
Asterisk__:__300759__:__MELANOMA ANTIGEN, FAMILY E, 1; MAGEE1__:__DYSTROBREVIN-ASSOCIATED MAGE PROTEIN; DAMAGE;; KIAA1587__:__
Asterisk__:__300760__:__MELANOMA ANTIGEN, FAMILY E, 2; MAGEE2__:____:__
Asterisk__:__300761__:__MELANOMA ANTIGEN, FAMILY B, 10; MAGEB10__:____:__
Asterisk__:__300762__:__MELANOMA ANTIGEN, FAMILY B, 16; MAGEB16__:____:__
Asterisk__:__300763__:__MELANOMA ANTIGEN, FAMILY B, 17; MAGEB17__:____:__
Asterisk__:__300764__:__MELANOMA ANTIGEN, FAMILY A, 9B; MAGEA9B__:____:__
Asterisk__:__300765__:__MELANOMA ANTIGEN, FAMILY D, 4B; MAGED4B__:____:__
Asterisk__:__300766__:__NFKB-ACTIVATING PROTEIN; NKAP__:____:__
Asterisk__:__300767__:__REPLICATION PROTEIN A4; RPA4__:__RPA2, HOMOLOG OF;; REPLICATION PROTEIN A COMPLEX, 34-KD SUBUNIT, HOMOLOG OF__:__
Asterisk__:__300768__:__CYLICIN 1; CYLC1__:____:__
Asterisk__:__300769__:__MICRO RNA 224; MIR224__:__MIRN224;; miRNA224__:__
Number Sign__:__300770__:__SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 4; SMDP4__:__PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 4;; PAP DUE TO CSF2RA DEFICIENCY;; CSF2RA DEFICIENCY__:__
Asterisk__:__300771__:__TRANSCRIPTION ELONGATION FACTOR A-LIKE 7; TCEAL7__:____:__
Asterisk__:__300772__:__TRANSCRIPTION FACTOR DP FAMILY, MEMBER 3; TFDP3__:__HEPATOCELLULAR CARCINOMA ANTIGEN 661; HCA661;; CANCER/TESTIS ANTIGEN 30; CT30;; E2F-LIKE;; DP4__:__
Asterisk__:__300773__:__APEX NUCLEASE (APURINIC/APYRIMIDINIC ENDONUCLEASE) 2; APEX2__:__APE2;; XTH2;; APURINIC/APYRIMIDINIC ENDONUCLEASE LIKE-2; APEXL2;; APEX NUCLEASE-LIKE 2__:__
Asterisk__:__300774__:__RAS-ASSOCIATED PROTEIN RAB39B; RAB39B__:____:__
Asterisk__:__300775__:__E74-LIKE FACTOR 4; ELF4__:__MYELOID ELF1-LIKE FACTOR; MEF__:__
Asterisk__:__300776__:__ALG13, S. CEREVISIAE, HOMOLOG OF; ALG13__:__ASPARAGINE-LINKED GLYCOSYLATION 13, S. CEREVISIAE, HOMOLOG OF;; GLYCOSYLTRANSFERASE 28 DOMAIN-CONTAINING 1; GLT28D1__:__
Asterisk__:__300777__:__EPSILON-TRIMETHYLLYSINE HYDROXYLASE; TMLHE__:__TMLH;; BUTYROBETAINE-GAMMA,2-OXOGLUTARATE DIOXYGENASE 2; BBOX2__:__
Percent__:__300778__:__CORNEAL DYSTROPHY, LISCH EPITHELIAL; LECD__:__LISCH EPITHELIAL CORNEAL DYSTROPHY;; BAND-SHAPED AND WHORLED MICROCYSTIC CORNEAL EPITHELIAL DYSTROPHY__:__
Percent__:__300779__:__CORNEAL DYSTROPHY, ENDOTHELIAL, X-LINKED; XECD__:__ENDOTHELIAL CORNEAL DYSTROPHY, X-LINKED__:__
Asterisk__:__300780__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A1; CT47A1__:__CT47.1__:__
Asterisk__:__300781__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A2; CT47A2__:__CT47.2__:__
Asterisk__:__300782__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A3; CT47A3__:__CT47.3__:__
Asterisk__:__300783__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A4; CT47A4__:__CT47.4__:__
Asterisk__:__300784__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A5; CT47A5__:__CT47.5__:__
Asterisk__:__300785__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A6; CT47A6__:__CT47.6__:__
Asterisk__:__300786__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A7; CT47A7__:__CT47.7__:__
Asterisk__:__300787__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A8; CT47A8__:__CT47.8__:__
Asterisk__:__300788__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A9; CT47A9__:__CT47.9__:__
Asterisk__:__300789__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER A10; CT47A10__:__CT47.10__:__
Asterisk__:__300790__:__CANCER/TESTIS ANTIGEN FAMILY 47, MEMBER B1; CT47B1__:__CT47A13;; CT47.13__:__
Asterisk__:__300791__:__NIK-RELATED KINASE; NRK__:__NIK-LIKE EMBRYO-SPECIFIC KINASE; NESK__:__
Asterisk__:__300792__:__MICRO RNA 106A; MIR106A__:__miRNA106A;; MIRN106A__:__
Asterisk__:__300793__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A2; CT45A2__:__CANCER/TESTIS ANTIGEN 45, MEMBER 2; CT45.2__:__
Asterisk__:__300794__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A3; CT45A3__:__CANCER/TESTIS ANTIGEN 45, MEMBER 3; CT45.3__:__
Asterisk__:__300795__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A4; CT45A4__:__CANCER/TESTIS ANTIGEN 45, MEMBER 4; CT45.4__:__
Asterisk__:__300796__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A5; CT45A5__:__CANCER/TESTIS ANTIGEN 45, MEMBER 5; CT45.5__:__
Asterisk__:__300797__:__CANCER/TESTIS ANTIGEN FAMILY 45, MEMBER A6; CT45A6__:__CANCER/TESTIS ANTIGEN 45, MEMBER 6; CT45.6__:__
Asterisk__:__300798__:__PHOSPHORYLASE KINASE, LIVER, ALPHA-2 SUBUNIT; PHKA2__:____:__
Number Sign__:__300799__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, RAYMOND TYPE; MRXSR__:____:__
Caret__:__300800__:__MOVED TO 103580__:____:__
Number Sign__:__300801__:__CHROMOSOME Xp11.23-p11.22 DUPLICATION SYNDROME__:____:__
Number Sign__:__300802__:__MENTAL RETARDATION, X-LINKED 96; MRX96__:____:__
Number Sign__:__300803__:__MENTAL RETARDATION, X-LINKED 97; MRX97__:__MENTAL RETARDATION, X-LINKED 65; MRX65;; MRXZ__:__
Number Sign__:__300804__:__JOUBERT SYNDROME 10; JBTS10__:____:__
Asterisk__:__300805__:__FMR1 ANTISENSE RNA 1; FMR1AS1__:__ANTISENSE FMR1 GENE; ASFMR1;; FMR1 GENE, ANTISENSE__:__
Asterisk__:__300806__:__AF4/FMR2 FAMILY, MEMBER 2; AFF2__:__FMR2 GENE; FMR2__:__FRAGILE SITE, FOLIC ACID TYPE, RARE, FRA(X)(q28) E, INCLUDED; FRAXE, INCLUDED
Number Sign__:__300807__:__THROMBOPHILIA, X-LINKED, DUE TO FACTOR IX DEFECT; THPH8__:____:__DEEP VENOUS THROMBOSIS, PROTECTION AGAINST, INCLUDED
Asterisk__:__300808__:__G PROTEIN-COUPLED RECEPTOR 143; GPR143__:__OA1 GENE__:__
Percent__:__300809__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 15; SLEB15__:____:__
Asterisk__:__300810__:__MICRO RNA 98; MIR98__:__miRNA98;; MIRN98__:__
Asterisk__:__300811__:__MICRO RNA 105-1; MIR105-1__:__miRNA105-1;; MIRN105-1__:__
Asterisk__:__300812__:__MICRO RNA 105-2; MIR105-2__:__miRNA105-2;; MIRN105-2__:__
NULL__:__300813__:__SARCOMA, SYNOVIAL__:____:__
Number Sign__:__300814__:__NYSTAGMUS 6, CONGENITAL, X-LINKED; NYS6__:____:__
Number Sign__:__300815__:__CHROMOSOME Xq28 DUPLICATION SYNDROME__:____:__
Number Sign__:__300816__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 6; COXPD6__:__ENCEPHALOMYOPATHY, MITOCHONDRIAL, X-LINKED__:__
Asterisk__:__300817__:__EF-HAND DOMAIN (C-TERMINAL)-CONTAINING PROTEIN 2; EFHC2__:__EF-HAND DOMAIN-CONTAINING PROTEIN 2__:__
Number Sign__:__300818__:__PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1__:____:__
Asterisk__:__300819__:__ZINC FINGER PROTEIN 630; ZNF630__:____:__
Asterisk__:__300820__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 15; MAP3K15__:__APOPTOSIS SIGNAL-REGULATING KINASE 3; ASK3__:__
Asterisk__:__300821__:__OPSIN 1, MEDIUM-WAVE-SENSITIVE; OPN1MW__:__GREEN CONE PIGMENT; GCP__:__
Asterisk__:__300822__:__OPSIN 1, LONG-WAVE-SENSITIVE; OPN1LW__:__RED CONE PIGMENT; RCP__:__
Asterisk__:__300823__:__IDURONATE 2-SULFATASE; IDS__:____:__
Asterisk__:__300824__:__OPN1LW AND OPN1MW GENES, CONTROLLER OF__:__OPSIN LOCUS CONTROL REGION;; LOCUS CONTROL REGION, RED AND GREEN PHOTOPIGMENT GENES;; RED AND GREEN PIGMENT GENES, CONTROLLER OF__:__
Asterisk__:__300825__:__RETINOBLASTOMA-BINDING PROTEIN 7; RBBP7__:____:__
Asterisk__:__300826__:__STROMAL ANTIGEN 2; STAG2__:__COHESIN SUBUNIT SA2__:__
Asterisk__:__300827__:__FIBROBLAST GROWTH FACTOR 16; FGF16__:____:__
Asterisk__:__300828__:__PATCHED DOMAIN-CONTAINING PROTEIN 1; PTCHD1__:____:__
Percent__:__300829__:__CARDIOMYOPATHY, FATAL FETAL, DUE TO MYOCARDIAL CALCIFICATION__:____:__
Number Sign__:__300830__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 4; AUTSX4__:__CHROMOSOME Xp22 DELETION SYNDROME__:__
Number Sign__:__300831__:__CK SYNDROME__:__MENTAL RETARDATION, X-LINKED, WITH THIN BODY HABITUS AND CORTICAL MALFORMATION__:__
Asterisk__:__300832__:__JUST PROXIMAL TO XIST; JPX__:__NONCODING RNA 183; NCRNA00183;; ENOX__:__
Number Sign__:__300833__:__46,XX SEX REVERSAL 3; SRXX3__:__CHROMOSOME Xq26 DUPLICATION SYNDROME;; 46,XX SEX REVERSAL, SOX3-RELATED__:__CHROMOSOME Xq26 DELETION SYNDROME, INCLUDED
Number Sign__:__300834__:__MACULAR DEGENERATION, X-LINKED ATROPHIC__:____:__
Number Sign__:__300835__:__ANEMIA, X-LINKED, WITH OR WITHOUT NEUTROPENIA AND/OR PLATELET ABNORMALITIES; XLANP__:____:__
Asterisk__:__300836__:__KAL1 GENE; KAL1__:__KALLMANN SYNDROME INTERVAL GENE 1; KALIG1;; ADHESION MOLECULE-LIKE, X-LINKED; ADMLX;; ANOSMIN 1__:__
Asterisk__:__300837__:__DIACYLGLYCEROL KINASE, KAPPA, 142-KD; DGKK__:____:__
Asterisk__:__300838__:__FERM AND PDZ DOMAINS-CONTAINING PROTEIN 4; FRMPD4__:__PSD95-INTERACTING REGULATOR OF SPINE MORPHOGENESIS; PRESO;; KIAA0316__:__
Asterisk__:__300839__:__RETINOSCHISIN; RS1__:____:__
Asterisk__:__300840__:__PRA1 DOMAIN FAMILY, MEMBER 2; PRAF2__:__JM4__:__
Asterisk__:__300841__:__COAGULATION FACTOR VIII; F8__:__FACTOR VIII;; COAGULATION FACTOR VIIIC, PROCOAGULANT COMPONENT; F8C__:__
Number Sign__:__300842__:__MCLEOD SYNDROME; MCLDS__:__MCLEOD PHENOTYPE;; NEUROACANTHOCYTOSIS, MCLEOD TYPE__:__MCLEOD SYNDROME WITH CHRONIC GRANULOMATOUS DISEASE, INCLUDED
Percent__:__300843__:__BORNHOLM EYE DISEASE; BED__:__MYOPIA, HIGH, WITH NONPROGRESSIVE CONE DYSFUNCTION__:__
Number Sign__:__300844__:__MENTAL RETARDATION, X-LINKED 19; MRX19__:____:__
Number Sign__:__300845__:__MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC HYPOGONADISM, AND FACIAL DYSMORPHISM; MYMY4__:__CHROMOSOME Xq28 DELETION SYNDROME, 3.4-KB;; SYNDROMIC MOYAMOYA DISEASE__:__
Asterisk__:__300846__:__CD99 ANTIGEN-LIKE 2; CD99L2__:__CD99B__:__
Number Sign__:__300847__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 5; AUTSX5__:____:__
Percent__:__300848__:__MENTAL RETARDATION, X-LINKED 89; MRX89__:____:__
Number Sign__:__300849__:__MENTAL RETARDATION, X-LINKED 41; MRX41__:__MENTAL RETARDATION, X-LINKED 48; MRX48__:__
Number Sign__:__300850__:__MENTAL RETARDATION, X-LINKED 90; MRX90__:____:__
Percent__:__300851__:__MENTAL RETARDATION, X-LINKED 92; MRX92__:____:__
Percent__:__300852__:__MENTAL RETARDATION, X-LINKED 88; MRX88__:____:__
Number Sign__:__300853__:__IMMUNODEFICIENCY, X-LINKED, WITH MAGNESIUM DEFECT, EPSTEIN-BARR VIRUS INFECTION, AND NEOPLASIA; XMEN__:____:__
Number Sign__:__300854__:__RENAL CELL CARCINOMA, Xp11-ASSOCIATED; RCCX1__:____:__
Number Sign__:__300855__:__OGDEN SYNDROME; OGDNS__:__N-TERMINAL ACETYLTRANSFERASE DEFICIENCY; NATD__:__
Percent__:__300856__:__HYPOSPADIAS 4, X-LINKED, SUSCEPTIBILITY TO; HYSP4__:____:__
Number Sign__:__300857__:__AMYOTROPHIC LATERAL SCLEROSIS 15 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS15__:____:__
Percent__:__300858__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 17; MRXS17__:__MENTAL RETARDATION, X-LINKED, WITH ALACRIMA AND ACHALASIA__:__
Asterisk__:__300859__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 22; CCDC22__:____:__
Number Sign__:__300860__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, NASCIMENTO TYPE; MRXSN__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 30; MRXS30__:__
Percent__:__300861__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, CHUDLEY-SCHWARTZ TYPE; MRXSCS__:__MENTAL RETARDATION, X-LINKED, WITH SEIZURES, HYPOGAMMAGLOBULINEMIA, AND GAIT DISTURBANCE__:__
Asterisk__:__300862__:__ACYL-CoA THIOESTERASE 9; ACOT9__:__MITOCHONDRIAL ACYL-CoA THIOESTERASE, 48-KD; MTACT48__:__
Number Sign__:__300863__:__CHONDRODYSPLASIA WITH PLATYSPONDYLY, DISTINCTIVE BRACHYDACTYLY, HYDROCEPHALY, AND MICROPHTHALMIA__:____:__
NULL__:__300864__:__CEREBRAL-CEREBELLAR-COLOBOMA SYNDROME, X-LINKED__:____:__
Asterisk__:__300865__:__MICRO RNA 503; MIR503__:__miRNA503__:__
Asterisk__:__300866__:__MICRO RNA 510; MIR510__:__miRNA510__:__
Number Sign__:__300867__:__KABUKI SYNDROME 2; KABUK2__:____:__
Number Sign__:__300868__:__MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 20; EIEE20;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 4; GPIBD4__:__
Number Sign__:__300869__:__CHROMOSOME Xq27.3-q28 DUPLICATION SYNDROME__:____:__
Percent__:__300870__:__ANEURYSM, INTRACRANIAL BERRY, 5; ANIB5__:____:__
Asterisk__:__300871__:__FUN14 DOMAIN-CONTAINING PROTEIN 1; FUNDC1__:____:__
Number Sign__:__300872__:__AUTISM, SUSCEPTIBILITY TO, X-LINKED 6; AUTSX6__:__EPSILON-TRIMETHYLLYSINE HYDROXYLASE DEFICIENCY; TMLHED__:__
Asterisk__:__300873__:__GUANINE NUCLEOTIDE-BINDING PROTEIN-LIKE 3-LIKE PROTEIN; GNL3L__:__GNL3-LIKE PROTEIN__:__
Asterisk__:__300874__:__MICRO RNA 508; MIR508__:__miRNA508;; MIRN508__:__
Asterisk__:__300875__:__MICRO RNA 509-1; MIR509-1__:__miRNA509-1;; MIRN509-1;; MICRO RNA 509; MIR509__:__
Asterisk__:__300876__:__MICRO RNA 509-3; MIR509-3__:__miRNA509-3;; MIRN509-3__:__
Asterisk__:__300877__:__MICRO RNA 506; MIR506__:__miRNA506;; MIRN506__:__
Asterisk__:__300878__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR C1; DMRTC1__:____:__
Asterisk__:__300879__:__XG GLYCOPROTEIN; XG__:__PBDX__:__
Asterisk__:__300880__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 10; PSMD10__:__p28;; GANKYRIN;; p28(GANK)__:__
Percent__:__300881__:__BARATELA-SCOTT SYNDROME__:____:__
Number Sign__:__300882__:__CORNELIA DE LANGE SYNDROME 5; CDLS5__:____:__
Asterisk__:__300883__:__SORTING NEXIN 12; SNX12__:____:__
Number Sign__:__300884__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 36; EIEE36__:____:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Is, INCLUDED; CDG1S, INCLUDED;; CDG Is, INCLUDED; CDGIs, INCLUDED
Asterisk__:__300885__:__CYTOCHROME c OXIDASE, SUBUNIT 7B; COX7B__:__CYTOCHROME c OXIDASE, SUBUNIT VIIb__:__
Number Sign__:__300886__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 32; MRXS32__:____:__
Number Sign__:__300887__:__LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 2; LSDMCA2__:__APLASIA CUTIS CONGENITA, RETICULOLINEAR, WITH MICROCEPHALY, FACIAL DYSMORPHISM, AND OTHER CONGENITAL ANOMALIES; APLCC__:__
Number Sign__:__300888__:__HYPOTHYROIDISM, CENTRAL, AND TESTICULAR ENLARGEMENT; CHTE__:____:__
Asterisk__:__300889__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12B; ZC3H12B__:__MCP1-INDUCED PROTEIN 2; MCPIP2__:__
Asterisk__:__300890__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 9; ASB9__:____:__
Asterisk__:__300891__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 12; ASB12__:____:__
Asterisk__:__300892__:__LONG INTERGENIC NONCODING RNA 850; LINC00850__:__KUCG1__:__
Asterisk__:__300893__:__MICRO RNA 502; MIR502__:__miRNA502__:__
Number Sign__:__300894__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 5; NBIA5__:__BETA-PROPELLER PROTEIN-ASSOCIATED NEURODEGENERATION; BPAN;; STATIC ENCEPHALOPATHY OF CHILDHOOD WITH NEURODEGENERATION IN ADULTHOOD; SENDA__:__
Number Sign__:__300895__:__OHDO SYNDROME, X-LINKED; OHDOX__:__BLEPHAROPHIMOSIS-MENTAL RETARDATION SYNDROME, MAAT-KIEVIT-BRUNNER TYPE__:__
Number Sign__:__300896__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm; CDG2M__:__CDG IIm; CDGIIm;; EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22; EIEE22__:__
Asterisk__:__300897__:__ZINC FINGER C4H2 DOMAIN-CONTAINING PROTEIN; ZC4H2__:__KIAA1166__:__
Asterisk__:__300898__:__CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 1, ANTISENSE; CDR1AS__:__CDR1 ANTISENSE TRANSCRIPT;; CIRCULAR RNA SPONGE FOR MIR7; CIRS7__:__
Asterisk__:__300899__:__RIBOSOMAL PROTEIN L39; RPL39__:____:__
Caret__:__300900__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__300901__:__X-ACTIVE-SPECIFIC NONCODING TRANSCRIPT; XACT__:__ACTIVE X CHROMOSOME-COATING TRANSCRIPT, NONCODING;; X-ACTIVE-COATING TRANSCRIPT;; LONG INTERGENIC NONCODING RNA XACT;; lincRNA XACT__:__
Asterisk__:__300902__:__RIBOSOMAL PROTEIN L36A; RPL36A__:__RPL44, YEAST, HOMOLOG OF; RPL44__:__
Asterisk__:__300903__:__G PROTEIN-COUPLED RECEPTOR 174; GPR174__:__GPCR17__:__
Asterisk__:__300904__:__INSULIN RECEPTOR SUBSTRATE 4; IRS4__:____:__
Number Sign__:__300905__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6__:__CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED DOMINANT, 6__:__
Asterisk__:__300906__:__PYRUVATE DEHYDROGENASE KINASE, ISOENZYME 3; PDK3__:____:__
Asterisk__:__300907__:__CLEAVAGE STIMULATION FACTOR, 3-PRIME PRE-RNA, SUBUNIT 2, 64-KD; CSTF2__:__CSTF64__:__
Number Sign__:__300908__:__ANEMIA, NONSPHEROCYTIC HEMOLYTIC, DUE TO G6PD DEFICIENCY__:__FAVISM, SUSCEPTIBILITY TO__:__
Number Sign__:__300909__:__ANGIOEDEMA INDUCED BY ACE INHIBITORS, SUSCEPTIBILITY TO; AEACEI__:____:__
Number Sign__:__300910__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18; BMND18__:__OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES, SUSCEPTIBILITY TO__:__
Number Sign__:__300911__:__PARKINSONISM WITH SPASTICITY, X-LINKED; XPDS__:____:__
Number Sign__:__300912__:__MENTAL RETARDATION, X-LINKED 98; MRX98__:____:__
Asterisk__:__300913__:__VMA21, S. CEREVISIAE, HOMOLOG OF; VMA21__:____:__
Number Sign__:__300914__:__DEAFNESS, X-LINKED 6; DFNX6__:____:__
Number Sign__:__300915__:__MICROPHTHALMIA, SYNDROMIC 13; MCOPS13__:__MAINE MICROPHTHALMOS;; COLOBOMATOUS MICROPHTHALMIA WITH MICROCEPHALY, SHORT STATURE, AND PSYCHOMOTOR RETARDATION__:__
Asterisk__:__300916__:__PARANEOPLASTIC MA ANTIGEN FAMILY, MEMBER 5; PNMA5__:__PARANEOPLASTIC ANTIGEN-LIKE PROTEIN 5;; KIAA1934__:__
Asterisk__:__300917__:__PARANEOPLASTIC MA ANTIGEN FAMILY, MEMBER 6A; PNMA6A__:__PARANEOPLASTIC ANTIGEN-LIKE PROTEIN 6A;; PNMA6__:__
Number Sign__:__300918__:__PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTIC PLAQUES, X-LINKED__:__OLMSTED SYNDROME, X-LINKED; OLMSX__:__
Number Sign__:__300919__:__MENTAL RETARDATION, X-LINKED 99; MRX99__:____:__
Asterisk__:__300920__:__ATAXIN 3-LIKE; ATXN3L__:____:__
Asterisk__:__300921__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 9; BHLHB9__:__p60 TRANSCRIPTION REGULATOR PROTEIN; p60TRP;; KIAA1701__:__
Asterisk__:__300922__:__CYSTEINE-RICH HYDROPHOBIC DOMAIN PROTEIN 1; CHIC1__:__BRAIN X-LINKED GENE; BRX__:__
Number Sign__:__300923__:__MENTAL RETARDATION, X-LINKED 100; MRX100__:____:__
Asterisk__:__300924__:__ACYL-CoA WAX ALCOHOL ACYLTRANSFERASE 1; AWAT1__:__DIACYL-GLYCEROL ACYLTRANSFERASE 2; DGA2__:__
Asterisk__:__300925__:__ACYL-CoA WAX ALCOHOL ACYLTRANSFERASE 2; AWAT2__:__WAX SYNTHASE;; DIACYLGLYCEROL O-ACYLTRANSFERASE CANDIDATE 4; DC4;; MFAT__:__
Asterisk__:__300926__:__DIACYLGLYCEROL O-ACYLTRANSFERASE 2-LIKE 6; DGAT2L6__:__DIACYLGLYCEROL O-ACYLTRANSFERASE CANDIDATE 3; DC3__:__
Asterisk__:__300927__:__PEROXIREDOXIN 4; PRDX4__:__ANTIOXIDANT ENZYME 372; AOE372__:__
Number Sign__:__300928__:__MENTAL RETARDATION, X-LINKED 101; MRX101__:____:__
Asterisk__:__300929__:__MICRO RNA 718; MIR718__:__miRNA718__:__
Asterisk__:__300930__:__MAP7 DOMAIN-CONTAINING PROTEIN 3; MAP7D3__:__MDP3__:__
Asterisk__:__300931__:__PIRIN; PIR__:____:__
Number Sign__:__300932__:__THYROXINE-BINDING GLOBULIN QUANTITATIVE TRAIT LOCUS; TBGQTL__:____:__
Asterisk__:__300933__:__PIH1 DOMAIN-CONTAINING PROTEIN 3; PIH1D3__:____:__
Number Sign__:__300934__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iy; CDG1Y__:__CDG IY; CDGIy__:__
Asterisk__:__300935__:__PROLINE-RICH GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 1; PRRG1__:__PROLINE-RICH GLA PROTEIN 1; PRGP1__:__
Asterisk__:__300936__:__FTX TRANSCRIPT, XIST REGULATOR, NONCODING; FTX__:__GENE 5-PRIME TO XIST;; LONG INTERGENIC NONCODING RNA 182; LINC00182;; lincRNA 182__:__
Asterisk__:__300937__:__RHO GTPase-ACTIVATING PROTEIN 36; ARHGAP36__:____:__
Asterisk__:__300938__:__MATRIX REMODELING-ASSOCIATED PROTEIN 5; MXRA5__:__ADLICAN__:__
Asterisk__:__300939__:__THYMOSIN, BETA-15A; TMSB15A__:____:__
Asterisk__:__300940__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN-CONTAINING PROTEIN 2; GDPD2__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 3; GDE3__:__
Asterisk__:__300941__:__SOLUTE CARRIER FAMILY 25, MEMBER 53; SLC25A53__:__MITOCHONDRIAL CARRIER TRIPLE REPEAT 6; MCART6__:__
Number Sign__:__300942__:__CHROMOSOME Xq26.3 DUPLICATION SYNDROME__:__CHROMOSOME Xq26 MICRODUPLICATION SYNDROME;; X-LINKED ACROGIGANTISM; XLAG__:__
Number Sign__:__300943__:__PITUITARY ADENOMA 2, GROWTH HORMONE-SECRETING; PITA2__:__ACROMEGALY DUE TO PITUITARY ADENOMA 2;; ACROMEGALY, X-LINKED__:__
Asterisk__:__300944__:__CSAG FAMILY, MEMBER 1; CSAG1__:__CHONDROSARCOMA-ASSOCIATED GENE; CSAGE__:__
Asterisk__:__300945__:__TSR2, 20S rRNA ACCUMULATION, S. CEREVISIAE, HOMOLOG OF; TSR2__:__WGG MOTIF-CONTAINING PROTEIN 1; WGG1__:__
Number Sign__:__300946__:__DIAMOND-BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA14__:____:__
Asterisk__:__300947__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 120; CCDC120__:____:__
Asterisk__:__300948__:__PHOSPHATE CYTIDYLYLTRANSFERASE 1, CHOLINE, BETA ISOFORM; PCYT1B__:__CCT-BETA__:__
Asterisk__:__300949__:__FORKHEAD BOX R2; FOXR2__:__FORKHEAD BOX N6; FOXN6__:__
Asterisk__:__300950__:__MICRO RNA 20B; MIR20B__:__miRNA20B__:__
Asterisk__:__300951__:__RING FINGER PROTEIN 113A; RNF113A__:__ZINC FINGER PROTEIN 183; ZNF183__:__
Number Sign__:__300952__:__LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 3; LSDMCA3__:__LINEAR SKIN DEFECTS WITH CARDIOMYOPATHY AND OTHER CONGENITAL ANOMALIES__:__
Number Sign__:__300953__:__TRICHOTHIODYSTROPHY 5, NONPHOTOSENSITIVE; TTD5__:____:__
Asterisk__:__300954__:__CHROMOSOME X OPEN READING FRAME 40A; CXORF40A__:__ENDOTHELIAL-OVEREXPRESSED LIPOPOLYSACCHARIDE-ASSOCIATED FACTOR 1; EOLA1__:__
Asterisk__:__300955__:__APOLIPOPROTEIN O-LIKE; APOOL__:__FAMILY WITH SEQUENCE SIMILARITY 121A; FAM121A;; CHROMOSOME X OPEN READING FRAME 33; CXORF33;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 27-KD SUBUNIT; MIC27;; MICOS COMPLEX, 27-KD SUBUNIT__:__
Asterisk__:__300956__:__BRAF PSEUDOGENE 1; BRAFP1__:__LONG NONCODING RNA BRAFP1;; lncRNA BRAFP1__:__
Number Sign__:__300957__:__MENTAL RETARDATION, X-LINKED 12; MRX12__:__MENTAL RETARDATION, X-LINKED 35; MRX35__:__
Number Sign__:__300958__:__MENTAL RETARDATION, X-LINKED 102; MRX102__:____:__
Asterisk__:__300959__:__CHROMOSOME X OPEN READING FRAME 36; CXORF36__:__DIA1-RELATED PROTEIN; DIA1R__:__
Number Sign__:__300960__:__MEND SYNDROME; MEND__:__MALE EBP DISORDER WITH NEUROLOGIC DEFECTS__:__
Asterisk__:__300961__:__MID1-INTERACTING PROTEIN 1; MID1IP1__:__MIG12__:__
Asterisk__:__300962__:__GEM-ASSOCIATED PROTEIN 8; GEMIN8__:__FAMILY WITH SEQUENCE SIMILARITY 51, MEMBER A1; FAM51A1__:__
Number Sign__:__300963__:__RITSCHER-SCHINZEL SYNDROME 2; RTSC2__:____:__
Asterisk__:__300964__:__LAS1-LIKE RIBOSOME BIOGENESIS FACTOR; LAS1L__:__LAS1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__300965__:__RETROTRANSPOSON GAG DOMAIN-CONTAINING PROTEIN 1; RGAG1__:__MAMMALIAN RETROTRANSPOSON-DERIVED GENE 9; MART9; MAR9;; KIAA1318__:__
Number Sign__:__300966__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 33; MRXS33__:____:__
Number Sign__:__300967__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 34; MRXS34__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, MIRCSOF-LANGOUET TYPE; MRXSML__:__
Number Sign__:__300968__:__MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED; MRXS99F__:____:__
Asterisk__:__300969__:__G PROTEIN-COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 2; GPRASP2__:__GASP2__:__
Asterisk__:__300970__:__MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 4; MORC4__:__ZINC FINGER CW DOMAIN PROTEIN 4: ZCW4;; ZINC FINGER CW DOMAIN- AND COILED-COIL DOMAIN-CONTAINING PROTEIN 2; ZCWCC2__:__
Number Sign__:__300971__:__BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5__:____:__
Number Sign__:__300972__:__IMMUNODEFICIENCY 47; IMD47__:__IMMUNODEFICIENCY AND HEPATOPATHY WITH OR WITHOUT NEUROLOGIC FEATURES__:__
Asterisk__:__300973__:__RHOX HOMEOBOX FAMILY MEMBER 1, PSEUDOGENE 1; RHOXF1P1__:__lncRHOXF1__:__
Asterisk__:__300974__:__PHOSPHOLIPASE C, PHOSPHATIDYLINOSITOL-SPECIFIC, X DOMAIN-CONTAINING PROTEIN 1; PLCXD1__:__PIPLC X DOMAIN-CONTAINING PROTEIN 1__:__
Asterisk__:__300975__:__UBIQUITIN-SPECIFIC PROTEASE 27, X-LINKED; USP27X__:__USP27;; USP22-LIKE; USP22L__:__
Asterisk__:__300976__:__FAMILY WITH SEQUENCE SIMILARITY 46, MEMBER D; FAM46D__:____:__
Percent__:__300977__:__SCHOLTE SYNDROME; SHLTS__:__EARLY BALDING, PATELLA LUXATION, ACROMICRIA, AND HYPOGONADISM__:__
Number Sign__:__300978__:__TONNE-KALSCHEUER SYNDROME; TOKAS__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH OR WITHOUT HAND AND FOOT ANOMALIES, GENITAL ANOMALIES, OR CONGENITAL DIAPHRAGMATIC HERNIA;; MENTAL RETARDATION, X-LINKED 61; MRX61__:__
Number Sign__:__300979__:__Xq25 DUPLICATION SYNDROME__:____:__Xq25 TRIPLICATION SYNDROME, INCLUDED
Asterisk__:__300980__:__KELCH-LIKE 15; KLHL15__:__KIAA1677__:__
Asterisk__:__300981__:__VARIABLY CHARGED, X CHROMOSOME, 3B; VCX3B__:__VARIABLY CHARGED, X CHROMOSOME, C; VCXC__:__
Number Sign__:__300982__:__MENTAL RETARDATION, X-LINKED 103; MRX103__:____:__
Number Sign__:__300983__:__MENTAL RETARDATION, X-LINKED 104; MRX104__:____:__
Number Sign__:__300984__:__MENTAL RETARDATION, X-LINKED 105; MRX105__:____:__
Number Sign__:__300985__:__VAS DEFERENS, CONGENITAL BILATERAL APLASIA OF, X-LINKED; CBAVDX__:____:__
Number Sign__:__300986__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, BAIN TYPE; MRXSB__:____:__
Caret__:__300987__:__MOVED TO 300148__:____:__
Number Sign__:__300988__:__IMMUNODEFICIENCY 50; IMD50__:__IMMUNODEFICIENCY 50, X-LINKED RECESSIVE__:__
Number Sign__:__300989__:__MEESTER-LOEYS SYNDROME; MRLS__:____:__
Number Sign__:__300990__:__MIDFACE HYPOPLASIA, HEARING IMPAIRMENT, ELLIPTOCYTOSIS, AND NEPHROCALCINOSIS; MFHIEN__:____:__
Number Sign__:__300991__:__CILIARY DYSKINESIA, PRIMARY, 36, X-LINKED; CILD36__:__CILIARY DYSKINESIA, PRIMARY, 36, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__300992__:__NEGATIVE REGULATOR OF P-BODY ASSOCIATION; NBDY__:__LONG INTERGENIC NONCODING RNA 1420; LINC01420;; NONANNOTATED P-BODY-DISSOCIATING POLYPEPTIDE; NOBODY__:__
Asterisk__:__300993__:__PAS DOMAIN-CONTAINING REPRESSOR 1; PASD1__:__CANCER-TESTIS ANTIGEN 63; CT63;; OXTES1__:__
Asterisk__:__300994__:__HIGHLY DIVERGENT HOMEOBOX; HDX__:__CHROMOSOME X OPEN READING FRAME 43; CXORF43__:__
Asterisk__:__300995__:__KIAA1210 GENE; KIAA1210__:____:__
Asterisk__:__300996__:__YIP1 DOMAIN FAMILY, MEMBER 6; YIPF6__:____:__
Number Sign__:__300997__:__MENTAL RETARDATION, X-LINKED 106; MRX106__:____:__
Number Sign__:__300998__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, 35; MRXS35__:____:__
Asterisk__:__300999__:__FUNCTIONAL INTERGENIC REPEATING RNA ELEMENT; FIRRE__:__LONG INTERGENIC NONCODING RNA 1200; LINC01200__:__
Number Sign__:__301000__:__WISKOTT-ALDRICH SYNDROME; WAS__:__WISKOTT-ALDRICH SYNDROME 1; WAS1;; ALDRICH SYNDROME;; ECZEMA-THROMBOCYTOPENIA-IMMUNODEFICIENCY SYNDROME;; IMMUNODEFICIENCY 2; IMD2__:__
Asterisk__:__301001__:__DXZ4-ASSOCIATED NONCODING TRANSCRIPT 1, PROXIMAL; DANT1__:____:__
Asterisk__:__301002__:__PROTEIN KINASE, SERINE/ARGININE-SPECIFIC, 3; SRPK3__:__PROTEIN KINASE, ARGININE/SERINE-RICH SPLICING FACTOR, 3;; SRSF PROTEIN KINASE 3; SRPK3;; MUSCLE-SPECIFIC SERINE KINASE 1; MSSK1;; STK23__:__
Asterisk__:__301003__:__G-PATCH DOMAIN AND KOW MOTIFS; GPKOW__:__G-PATCH DOMAIN-CONTAINING PROTEIN 5; GPATCH5; GPATC5__:__
Asterisk__:__301004__:__DXZ4-ASSOCIATED NONCODING TRANSCRIPT 2, DISTAL; DANT2__:____:__
Asterisk__:__301005__:__FERM- AND PDZ DOMAIN-CONTAINING PROTEIN 3; FRMPD3__:__KIAA1817__:__
Number Sign__:__301006__:__GALLOWAY-MOWAT SYNDROME 2, X-LINKED; GAMOS2__:____:__
Asterisk__:__301007__:__ZINC FINGER, MATRIN-TYPE 1; ZMAT1__:__KIAA1789__:__
Number Sign__:__301008__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, HOUGE TYPE; MRXSHG__:____:__
Asterisk__:__301009__:__P ANTIGEN FAMILY, MEMBER 5; PAGE5__:__PROSTATE-ASSOCIATED GENE 5;; CANCER-TESTIS ANTIGEN 16; CT16;; G ANTIGEN FAMILY E, MEMBER 1; GAGEE1__:__
Number Sign__:__301010__:__MYOPIA 26, X-LINKED, FEMALE-LIMITED; MYP26__:____:__
Asterisk__:__301011__:__THYMOSIN, BETA-15B; TMSB15B__:____:__
Asterisk__:__301012__:__CHROMOSOME X OPEN READING FRAME 56; CXORF56__:____:__
Number Sign__:__301013__:__MENTAL RETARDATION, X-LINKED 107; MRX107__:____:__
Number Sign__:__301014__:__OSTEOGENESIS IMPERFECTA, TYPE XIX; OI19__:____:__
Number Sign__:__301015__:__HEMOLYTIC ANEMIA, CONGENITAL, X-LINKED__:____:__
Asterisk__:__301016__:__RAS-RELATED PROTEIN 2C; RAP2C__:____:__
Asterisk__:__301017__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 2C; PPP1R2C__:__PPP1R2 FAMILY, MEMBER C;; PROTEIN PHOSPHATASE 1 INHIBITOR 4; I4;; PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 2, PSEUDOGENE 9, FORMERLY; PPP1R2P9, FORMERLY__:__
Number Sign__:__301018__:__DEAFNESS, X-LINKED 7; DFNX7__:____:__
Asterisk__:__301019__:__KDM5C ADJACENT TRANSCRIPT, NONCODING; KANTR__:__LONG INTERGENIC NONCODING TRANSCRIPT KANTR;; lincRNA KANTR;; LONG INTERGENIC NONCODING TRANSCRIPT 1155; LINC01155;; lincRNA SPASM__:__
Number Sign__:__301020__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 12; MC1DN12__:____:__
Number Sign__:__301021__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 30; MC1DN30__:____:__
Number Sign__:__301040__:__ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, X-LINKED; ATRX__:__ALPHA-THALASSEMIA/MENTAL RETARDATION SYNDROME, NONDELETION TYPE;; ATR-X SYNDROME;; ATR, NONDELETION TYPE__:__
Number Sign__:__301050__:__ALPORT SYNDROME, X-LINKED; ATS__:__NEPHROPATHY AND DEAFNESS, X-LINKED__:__
Caret__:__301090__:__MOVED TO 273395__:____:__
Caret__:__301100__:__MOVED TO 301200__:____:__
Number Sign__:__301200__:__AMELOGENESIS IMPERFECTA, TYPE IE; AI1E__:__AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 1;; AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, WITH SNOW-CAPPED TEETH;; AMELOGENESIS IMPERFECTA, X-LINKED 1; AIH1;; ENAMEL HYPOPLASIA, X-LINKED__:__
Percent__:__301201__:__AMELOGENESIS IMPERFECTA, HYPOPLASTIC/HYPOMATURATION, X-LINKED 2__:__AMELOGENESIS IMPERFECTA 3, HYPOPLASTIC TYPE, FORMERLY; AIH3, FORMERLY;; ENAMEL HYPOPLASIA, X-LINKED__:__
Number Sign__:__301220__:__PIGMENTARY DISORDER, RETICULATE, WITH SYSTEMIC MANIFESTATIONS, X-LINKED; PDR__:__XLPDR__:__
Asterisk__:__301300__:__DELTA-AMINOLEVULINATE SYNTHASE 2; ALAS2__:__ALAS, ERYTHROID; ALASE;; 5-AMINOLEVULINATE SYNTHASE, ERYTHROID-SPECIFIC__:__
Number Sign__:__301310__:__ANEMIA, SIDEROBLASTIC, AND SPINOCEREBELLAR ATAXIA; ASAT__:____:__
NULL__:__301410__:__NEURAL TUBE DEFECTS, X-LINKED__:____:__SPINA BIFIDA, X-LINKED, INCLUDED
Number Sign__:__301500__:__FABRY DISEASE__:__ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY__:__FABRY DISEASE, CARDIAC VARIANT, INCLUDED
Percent__:__301590__:__MICROPHTHALMIA, SYNDROMIC 4; MCOPS4__:__MICROPHTHALMIA WITH ANKYLOBLEPHARON AND MENTAL RETARDATION;; ANOP1, FORMERLY__:__
NULL__:__301700__:__ANOSMIA__:____:__
Asterisk__:__301770__:__ARRESTIN 3, RETINAL; ARR3__:__X-ARRESTIN; ARRX;; CONE ARRESTIN;; ARRESTIN 4; ARR4__:__
Asterisk__:__301780__:__ARYLSULFATASE C, ISOZYME F; ARSC2__:__ARSC, f FORM__:__
NULL__:__301790__:__SPINOCEREBELLAR ATAXIA, X-LINKED 3__:__SCAX3;; ATAXIA-DEAFNESS SYNDROME, X-LINKED__:__
NULL__:__301800__:__ANUS, IMPERFORATE__:____:__
Caret__:__301810__:__MOVED TO 215700__:____:__
NULL__:__301815__:__ARTHROGRYPOSIS, ECTODERMAL DYSPLASIA, CLEFT LIP/PALATE, AND DEVELOPMENTAL DELAY__:____:__
Caret__:__301820__:__MOVED TO 208085__:____:__
Number Sign__:__301830__:__SPINAL MUSCULAR ATROPHY, X-LINKED 2; SMAX2__:__SPINAL MUSCULAR ATROPHY, X-LINKED LETHAL INFANTILE;; SPINAL MUSCULAR ATROPHY, INFANTILE X-LINKED; XLSMA;; ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, X-LINKED;; AMC, DISTAL, X-LINKED;; ARTHROGRYPOSIS, X-LINKED, TYPE I; AMCX1__:__
Number Sign__:__301835__:__ARTS SYNDROME; ARTS__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18__:__
NULL__:__301840__:__SPINOCEREBELLAR ATAXIA, X-LINKED 4__:__SCAX4;; ATAXIA-DEMENTIA SYNDROME, X-LINKED__:__
Percent__:__301845__:__BAZEX SYNDROME; BZX__:__BAZEX-DUPRE-CHRISTOL SYNDROME; BDCS;; FOLLICULAR ATROPHODERMA AND BASAL CELL CARCINOMAS__:__
NULL__:__301850__:__TUBULIN, BETA__:____:__
Asterisk__:__301870__:__BIGLYCAN; BGN__:__PROTEOGLYCAN I; PGI__:__
Caret__:__301880__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__301900__:__BORJESON-FORSSMAN-LEHMANN SYNDROME; BFLS__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, BORJESON-FORSSMAN-LEHMANN TYPE; MRXSBFL;; BORJESON SYNDROME; BORJ;; MENTAL RETARDATION, EPILEPSY, AND ENDOCRINE DISORDERS__:__
NULL__:__301940__:__BRACHYDACTYLY, MONONEN TYPE__:__THUMBS AND GREAT TOES, SHORT AND ABDUCTED__:__
NULL__:__301950__:__BRANCHIAL ARCH SYNDROME, X-LINKED__:__MANDIBULOFACIAL DYSOSTOSIS, TORIELLO TYPE__:__
Percent__:__302000__:__BULLOUS DYSTROPHY, HEREDITARY MACULAR TYPE__:__EPIDERMOLYSIS BULLOSA, MACULAR TYPE; EBM__:__
Asterisk__:__302020__:__S100 CALCIUM-BINDING PROTEIN G; S100G__:__CALBINDIN 3; CALB3;; VITAMIN D-DEPENDENT CALCIUM-BINDING PROTEIN; CABP9K; CABP1;; CALBINDIN D9K__:__
Percent__:__302030__:__CALVARIAL HYPEROSTOSIS__:____:__
Number Sign__:__302045__:__CARDIOMYOPATHY, DILATED, 3B; CMD3B__:__CARDIOMYOPATHY, DILATED, X-LINKED; XLCM__:__
Number Sign__:__302060__:__BARTH SYNDROME; BTHS__:__CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2__:__
Number Sign__:__302200__:__CATARACT 40; CTRCT40__:__CATARACT 40 WITH OR WITHOUT MICROCORNEA;; CATARACT, CONGENITAL, X-LINKED; CXN;; CATARACT, CONGENITAL TOTAL, WITH POSTERIOR SUTURAL OPACITIES IN HETEROZYGOTES; CCT__:__
Caret__:__302300__:__MOVED TO 302200__:____:__
Number Sign__:__302350__:__NANCE-HORAN SYNDROME; NHS__:__CATARACT-DENTAL SYNDROME;; CATARACT, X-LINKED, WITH HUTCHINSONIAN TEETH;; MESIODENS-CATARACT SYNDROME__:__
Caret__:__302380__:__MOVED TO 616145__:____:__
NULL__:__302400__:__CENTRAL INCISORS, ABSENCE OF__:____:__
Number Sign__:__302500__:__SPINOCEREBELLAR ATAXIA, X-LINKED 1; SCAX1__:__OLIVOPONTOCEREBELLAR ATROPHY, X-LINKED;; OPCA, X-LINKED; OPCAX__:__
NULL__:__302600__:__SPINOCEREBELLAR ATAXIA, X-LINKED 2__:__SCAX2;; CEREBELLAR ATAXIA WITH EXTRAPYRAMIDAL INVOLVEMENT, EARLY-ONSET__:__
Asterisk__:__302650__:__CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 1; CDR1__:__CDR;; CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN, 34-KD; CDR34__:__
NULL__:__302700__:__CEREBRAL SCLEROSIS, DIFFUSE, SCHOLZ TYPE__:____:__
Number Sign__:__302800__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1__:__CMTX;; CHARCOT-MARIE-TOOTH PERONEAL MUSCULAR ATROPHY, X-LINKED;; HEREDITARY MOTOR AND SENSORY NEUROPATHY, X-LINKED;; HMSN, X-LINKED;; CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED, 1;; CMT2, FORMERLY__:__
Percent__:__302801__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 2; CMTX2__:__CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 2__:__
Percent__:__302802__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 3; CMTX3__:__CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 3__:__
NULL__:__302803__:__CHARCOT-MARIE-TOOTH PERONEAL MUSCULAR ATROPHY, X-LINKED, WITH APLASIA CUTIS CONGENITA__:____:__
NULL__:__302900__:__CHARCOT-MARIE-TOOTH PERONEAL MUSCULAR ATROPHY AND FRIEDREICH ATAXIA, COMBINED__:____:__
Number Sign__:__302905__:__ABRUZZO-ERICKSON SYNDROME; ABERS__:__CHARGE-LIKE SYNDROME, X-LINKED__:__
Asterisk__:__302910__:__CHLORIDE CHANNEL 4; CLCN4__:__CHLORIDE CHANNEL, VOLTAGE-GATED, 4__:__
Caret__:__302920__:__MOVED TO 305425__:____:__
Caret__:__302940__:__MOVED TO 302950__:____:__
Number Sign__:__302950__:__CHONDRODYSPLASIA PUNCTATA 1, X-LINKED RECESSIVE; CDPX1__:__CPXR;; CHONDRODYSPLASIA PUNCTATA, BRACHYTELEPHALANGIC__:__
Number Sign__:__302960__:__CHONDRODYSPLASIA PUNCTATA 2, X-LINKED DOMINANT; CDPX2__:__CDPXD; CPXD;; CONRADI-HUNERMANN SYNDROME;; HAPPLE SYNDROME;; CONRADI-HUNERMANN-HAPPLE SYNDROME__:__
Number Sign__:__303100__:__CHOROIDEREMIA; CHM__:__TAPETOCHOROIDAL DYSTROPHY, PROGRESSIVE; TCD__:__CHOROIDAL SCLEROSIS, INCLUDED
Number Sign__:__303110__:__CHOROIDEREMIA, DEAFNESS, AND MENTAL RETARDATION__:__CHROMOSOME Xq21 DELETION SYNDROME__:__
Number Sign__:__303350__:__MASA SYNDROME__:__MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS;; SPASTIC PARAPLEGIA 1, X-LINKED; SPG1;; CLASPED THUMB AND MENTAL RETARDATION;; THUMB, CONGENITAL CLASPED, WITH MENTAL RETARDATION;; ADDUCTED THUMB WITH MENTAL RETARDATION;; GAREIS-MASON SYNDROME;; CRASH SYNDROME__:__
Number Sign__:__303400__:__CLEFT PALATE WITH OR WITHOUT ANKYLOGLOSSIA, X-LINKED; CPX__:____:__
Number Sign__:__303600__:__COFFIN-LOWRY SYNDROME; CLS__:____:__
Asterisk__:__303630__:__COLLAGEN, TYPE IV, ALPHA-5; COL4A5__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-5 CHAIN__:__
Asterisk__:__303631__:__COLLAGEN, TYPE IV, ALPHA-6; COL4A6__:__COLLAGEN OF BASEMENT MEMBRANE, ALPHA-6__:__
NULL__:__303650__:__COLONIC ATRESIA__:____:__
Number Sign__:__303700__:__BLUE CONE MONOCHROMACY; BCM__:__BLUE CONE MONOCHROMATISM;; COLORBLINDNESS, BLUE-MONO-CONE-MONOCHROMATIC TYPE; CBBM__:__CONE DYSTROPHY 5, X-LINKED, INCLUDED; COD5, INCLUDED
Number Sign__:__303800__:__COLORBLINDNESS, PARTIAL, DEUTAN SERIES; CBD__:__DEUTAN COLORBLINDNESS; DCB;; DEUTERANOPIA;; GREEN COLORBLINDNESS__:__DEUTERANOMALY, INCLUDED
Number Sign__:__303900__:__COLORBLINDNESS, PARTIAL, PROTAN SERIES; CBP__:__PROTANOPIA;; RED COLORBLINDNESS__:__PROTANOMALY, INCLUDED
Caret__:__304000__:__MOVED TO 613522__:____:__
Number Sign__:__304020__:__CONE-ROD DYSTROPHY, X-LINKED, 1; CORDX1__:____:__CONE DYSTROPHY 1, X-LINKED, INCLUDED; COD1, INCLUDED
NULL__:__304030__:__CONE DYSTROPHY, X-LINKED, WITH TAPETAL-LIKE SHEEN__:____:__
Asterisk__:__304040__:__GAP JUNCTION PROTEIN, BETA-1; GJB1__:__GAP JUNCTION PROTEIN, 32-KD;; CONNEXIN 32; CX32;; LIVER CONNEXIN__:__
Percent__:__304050__:__AICARDI SYNDROME; AIC__:__CORPUS CALLOSUM, AGENESIS OF, WITH CHORIORETINAL ABNORMALITY__:__
Number Sign__:__304100__:__CORPUS CALLOSUM, PARTIAL AGENESIS OF, X-LINKED__:____:__
Number Sign__:__304110__:__CRANIOFRONTONASAL SYNDROME; CFNS__:__CRANIOFRONTONASAL DYSPLASIA; CFND;; CRANIOFRONTONASAL DYSOSTOSIS__:__
Number Sign__:__304120__:__OTOPALATODIGITAL SYNDROME, TYPE II; OPD2__:__OPD II SYNDROME;; OPD SYNDROME 2;; CRANIOORODIGITAL SYNDROME;; FACIOPALATOOSSEOUS SYNDROME; FPO__:__
Number Sign__:__304150__:__OCCIPITAL HORN SYNDROME; OHS__:__CUTIS LAXA, X-LINKED, FORMERLY;; EHLERS-DANLOS SYNDROME, OCCIPITAL HORN TYPE, FORMERLY;; EDS IX, FORMERLY;; EDS9, FORMERLY__:__
NULL__:__304200__:__CUTIS VERTICIS GYRATA, THYROID APLASIA, AND MENTAL RETARDATION__:____:__
NULL__:__304300__:__CYANIDE, INABILITY TO SMELL__:____:__
Number Sign__:__304340__:__PETTIGREW SYNDROME; PGS__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 5; MRXS5;; MENTAL RETARDATION, X-LINKED, WITH DANDY-WALKER MALFORMATION, BASAL GANGLIA DISEASE, AND SEIZURES;; MENTAL RETARDATION, X-LINKED, SYNDROMIC, FRIED TYPE; MRXSF;; MENTAL RETARDATION, X-LINKED 59; MRX59;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 21; MRXS21__:__
NULL__:__304350__:__DEAFNESS-HYPOGONADISM SYNDROME__:__DHS__:__
Number Sign__:__304400__:__DEAFNESS, X-LINKED 2; DFNX2__:__DEAFNESS, CONDUCTIVE, WITH STAPES FIXATION;; DEAFNESS 3, CONDUCTIVE, WITH STAPES FIXATION; DFN3;; PERILYMPHATIC GUSHER-DEAFNESS SYNDROME;; DEAFNESS, MIXED, WITH PERILYMPHATIC GUSHER;; NANCE DEAFNESS;; SENSORINEURAL DEAFNESS, PROFOUND, WITH OR WITHOUT A CONDUCTIVE COMPONENT, ASSOCIATED WITH A UNIQUE DEVELOPMENTAL ABNORMALITY OF THE EAR__:__
Number Sign__:__304500__:__DEAFNESS, X-LINKED 1; DFNX1__:__DEAFNESS, X-LINKED 2, SENSORINEURAL CONGENITAL; DFN2__:__
Caret__:__304590__:__MOVED TO 304500__:____:__
Caret__:__304600__:__MOVED TO 304590__:____:__
Number Sign__:__304700__:__MOHR-TRANEBJAERG SYNDROME; MTS__:__DYSTONIA-DEAFNESS SYNDROME; DDS;; DEAFNESS-DYSTONIA-OPTIC ATROPHY SYNDROME; DDP;; DEAFNESS SYNDROME, PROGRESSIVE, WITH BLINDNESS, DYSTONIA, FRACTURES, AND MENTAL DEFICIENCY;; OPTICOACOUSTIC NERVE ATROPHY WITH DEMENTIA;; JENSEN SYNDROME__:__
Percent__:__304730__:__DERMOIDS OF CORNEA; CND__:____:__
Caret__:__304750__:__MOVED TO 306955__:____:__
Number Sign__:__304790__:__IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED; IPEX__:__X-LINKED AUTOIMMUNITY-ALLERGIC DYSREGULATION SYNDROME; XLAAD;; IDDM-SECRETORY DIARRHEA SYNDROME; DMSD;; AUTOIMMUNITY-IMMUNODEFICIENCY SYNDROME, X-LINKED;; DIARRHEA, POLYENDOCRINOPATHY, FATAL INFECTION SYNDROME, X-LINKED;; ENTEROPATHY, AUTOIMMUNE, WITH HEMOLYTIC ANEMIA AND POLYENDOCRINOPATHY;; POLYENDOCRINOPATHY, IMMUNE DYSFUNCTION, AND DIARRHEA, X-LINKED; XPID;; DIABETES MELLITUS, CONGENITAL INSULIN-DEPENDENT, WITH FATAL SECRETORY DIARRHEA;; IMMUNODEFICIENCY, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED, FORMERLY__:__ISLETS OF LANGERHANS, ABSENCE OF, INCLUDED
Number Sign__:__304800__:__DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED__:__NDI;; DIABETES INSIPIDUS, NEPHROGENIC, TYPE I__:__
NULL__:__304900__:__DIABETES INSIPIDUS, NEUROHYPOPHYSEAL TYPE__:____:__
Caret__:__304930__:__MOVED TO 304790__:____:__
NULL__:__304950__:__DYGGVE-MELCHIOR-CLAUSEN SYNDROME, X-LINKED__:____:__
Caret__:__304990__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__305000__:__DYSKERATOSIS CONGENITA, X-LINKED; DKCX__:__ZINSSER-COLE-ENGMAN SYNDROME__:__HOYERAAL-HREIDARSSON SYNDROME, INCLUDED; HHS, INCLUDED;; CEREBELLAR HYPOPLASIA WITH PANCYTOPENIA, INCLUDED;; GROWTH RETARDATION, PRENATAL, WITH PROGRESSIVE PANCYTOPENIA AND CEREBELLAR HYPOPLASIA, INCLUDED
Caret__:__305050__:__MOVED TO 304700__:____:__
Number Sign__:__305100__:__ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC, X-LINKED; XHED__:__ECTODERMAL DYSPLASIA 1, HYPOHIDROTIC/HAIR/TOOTH TYPE, X-LINKED; ECTD1;; XLHED;; ECTODERMAL DYSPLASIA, ANHIDROTIC, X-LINKED; EDA;; EDA1;; ECTODERMAL DYSPLASIA, HYPOHIDROTIC, 1; HED1;; ECTODERMAL DYSPLASIA 1; ED1;; CHRIST-SIEMENS-TOURAINE SYNDROME;; CST SYNDROME__:__
Percent__:__305200__:__EHLERS-DANLOS SYNDROME, TYPE V__:__EDS5;; EDS V__:__
Caret__:__305300__:__MOVED TO 302060__:____:__
NULL__:__305350__:__EPIDERMODYSPLASIA VERRUCIFORMIS, X-LINKED; EDVX; EDV2__:____:__
Asterisk__:__305360__:__MEMBRANE PROTEIN, PALMITOYLATED 1; MPP1__:__ERYTHROCYTE MEMBRANE PROTEIN p55; EMP55;; PALMITOYLATED ERYTHROCYTE MEMBRANE PROTEIN; PEMP__:__
Asterisk__:__305370__:__TISSUE INHIBITOR OF METALLOPROTEINASE 1; TIMP1__:__TIMP;; ERYTHROID POTENTIATING ACTIVITY; EPA;; COLLAGENASE INHIBITOR, HUMAN; HCI__:__
Asterisk__:__305371__:__GATA-BINDING PROTEIN 1; GATA1__:__ERYTHROID TRANSCRIPTION FACTOR 1; ERYF1;; GLOBIN TRANSCRIPTION FACTOR 1; GF1;; TRANSCRIPTION FACTOR GATA1__:__
Number Sign__:__305390__:__EXUDATIVE VITREORETINOPATHY 2, X-LINKED; EVR2__:__EXUDATIVE VITREORETINOPATHY, FAMILIAL, 2;; EVRX;; FEVR, X-LINKED; FEVRX__:__
Number Sign__:__305400__:__AARSKOG-SCOTT SYNDROME; AAS__:__FACIOGENITAL DYSPLASIA; FGDY;; FACIODIGITOGENITAL SYNDROME;; AARSKOG SYNDROME, X-LINKED__:__FACIOGENITAL DYSPLASIA WITH ATTENTION DEFICIT-HYPERACTIVITY DISORDER, INCLUDED;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 16, INCLUDED; MRXS16, INCLUDED
Asterisk__:__305423__:__FACTOR VIII-ASSOCIATED GENE 1; F8A__:__DXS522E;; HAP40__:__
Asterisk__:__305424__:__FACTOR VIII-ASSOCIATED GENE 2__:__F8B;; DXS1253E__:__
Caret__:__305425__:__MOVED TO 134629__:____:__
Percent__:__305435__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HBFQTL3__:__F-CELL PRODUCTION, X-LINKED; FCPX;; HETEROCELLULAR HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, SWISS TYPE;; HPFH, SWISS TYPE__:__
Number Sign__:__305450__:__OPITZ-KAVEGGIA SYNDROME; OKS__:__FG SYNDROME 1; FGS1;; FG SYNDROME; FGS;; MENTAL RETARDATION, LARGE HEAD, IMPERFORATE ANUS, CONGENITAL HYPOTONIA, AND PARTIAL AGENESIS OF CORPUS CALLOSUM;; KELLER SYNDROME__:__
NULL__:__305550__:__FINGERPRINT BODY MYOPATHY__:____:__
Number Sign__:__305600__:__FOCAL DERMAL HYPOPLASIA; FDH__:__FODH; DHOF;; GOLTZ SYNDROME;; GOLTZ-GORLIN SYNDROME__:__
Number Sign__:__305620__:__FRONTOMETAPHYSEAL DYSPLASIA 1; FMD1__:__FMD__:__
Caret__:__305645__:__MOVED TO 136760__:____:__
Caret__:__305650__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__305660__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-3; GABRA3__:__GABA-A RECEPTOR, ALPHA-3 POLYPEPTIDE__:__
Asterisk__:__305670__:__GASTRIN-RELEASING PEPTIDE RECEPTOR; GRPR__:____:__
NULL__:__305690__:__GENITOURINARY TRACT ANOMALIES__:____:__
NULL__:__305700__:__SPERMATOGENIC FAILURE, X-LINKED, 1; SPGFX1__:__SERTOLI CELL-ONLY SYNDROME;; GERMINAL CELL APLASIA;; DEL CASTILLO SYNDROME__:__
NULL__:__305800__:__MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, X-LINKED__:__MESANGIOCAPILLARY GLOMERULONEPHRITIS, X-LINKED__:__
Asterisk__:__305900__:__GLUCOSE-6-PHOSPHATE DEHYDROGENASE; G6PD__:____:__
Caret__:__305910__:__MOVED TO 138130__:____:__
Asterisk__:__305915__:__GLUTAMATE RECEPTOR, IONOTROPIC, AMPA 3; GRIA3__:__GLUTAMATE RECEPTOR 3; GLUR3;; GLURC__:__
NULL__:__305920__:__GLUTAMYL RIBOSE-5-PHOSPHATE STORAGE DISEASE__:__ADP-RIBOSE PROTEIN HYDROLASE DEFICIENCY__:__
Caret__:__305980__:__MOVED TO 138140__:____:__
Asterisk__:__305990__:__GLYCINE RECEPTOR, ALPHA-2 SUBUNIT; GLRA2__:____:__
Number Sign__:__306000__:__GLYCOGEN STORAGE DISEASE IXa1; GSD9A1__:__LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY__:__GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED
Caret__:__306100__:__MOVED TO 400044__:____:__
Caret__:__306190__:__MOVED TO 300200__:____:__
Asterisk__:__306250__:__COLONY-STIMULATING FACTOR 2 RECEPTOR, ALPHA; CSF2RA__:__GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR, LOW AFFINITY, ALPHA SUBUNIT; GMCSFR__:__
NULL__:__306300__:__GRANULOMAS, CONGENITAL CEREBRAL__:____:__
Number Sign__:__306400__:__GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CDGX__:__CGD;; CYTOCHROME b-NEGATIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED;; CHRONIC GRANULOMATOUS DISEASE, X-LINKED__:__CYTOCHROME b-POSITIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, INCLUDED;; GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, VARIANT, INCLUDED;; CHRONIC GRANULOMATOUS DISEASE, ATYPICAL, INCLUDED
Asterisk__:__306480__:__HALOACID DEHALOGENASE-LIKE HYDROLASE DOMAIN-CONTAINING 1A; HDHD1A__:__DXF68S1E;; GS1 GENE__:__
Caret__:__306500__:__MOVED TO 312300__:____:__
Caret__:__306600__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__306700__:__HEMOPHILIA A; HEMA__:__HEMOPHILIA, CLASSIC__:__
NULL__:__306800__:__HEMOPHILIA A WITH VASCULAR ABNORMALITY__:____:__
Number Sign__:__306900__:__HEMOPHILIA B; HEMB__:__CHRISTMAS DISEASE;; FACTOR IX DEFICIENCY;; F9 DEFICIENCY;; PLASMA THROMBOPLASTIN COMPONENT DEFICIENCY__:__HEMOPHILIA B(M), INCLUDED;; HEMOPHILIA B LEYDEN, INCLUDED
NULL__:__306930__:__HEMOPOIETIC PROLIFERATION__:____:__
NULL__:__306950__:__HERNIA, ANTERIOR DIAPHRAGMATIC__:____:__
Number Sign__:__306955__:__HETEROTAXY, VISCERAL, 1, X-LINKED; HTX1__:__DEXTROCARDIA WITH OTHER CARDIAC MALFORMATIONS;; LATERALITY, X-LINKED;; SITUS INVERSUS, COMPLEX CARDIAC DEFECTS, AND SPLENIC DEFECTS, X-LINKED__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 1, X-LINKED, INCLUDED; CHTD1, INCLUDED
Percent__:__306960__:__HHHH SYNDROME__:__HEREDITARY HEMIHYPOTROPHY HEMIPARESIS HEMIATHETOSIS SYNDROME__:__
Caret__:__306970__:__MOVED TO 426000__:____:__
NULL__:__306980__:__HIRSCHSPRUNG DISEASE WITH TYPE D BRACHYDACTYLY__:____:__
NULL__:__306990__:__HOLOPROSENCEPHALY WITH FETAL AKINESIA/HYPOKINESIA SEQUENCE__:____:__
NULL__:__306995__:__HOMOSEXUALITY 1; HMS1__:__SEXUAL ORIENTATION, MALE__:__
Number Sign__:__307000__:__HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS__:__HSAS1;; HYDROCEPHALUS, X-LINKED; HYCX;; AQUEDUCTAL STENOSIS, X-LINKED; XLAS__:__HYDROCEPHALUS, X-LINKED, WITH CONGENITAL IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION, INCLUDED
NULL__:__307010__:__HYDROCEPHALUS WITH CEREBELLAR AGENESIS__:____:__
Number Sign__:__307030__:__GLYCEROL KINASE DEFICIENCY; GKD__:__GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA__:__
Number Sign__:__307150__:__HYPERTRICHOSIS, CONGENITAL GENERALIZED; HTC2__:__CHROMOSOME Xq27.1 INTERCHROMOSOMAL INSERTION SYNDROME;; CGH;; HCG__:__
Number Sign__:__307200__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE III, WITH AGAMMAGLOBULINEMIA; IGHD3__:__IGHD III;; GROWTH HORMONE DEFICIENCY WITH HYPOGAMMAGLOBULINEMIA, X-LINKED;; HYPOGAMMAGLOBULINEMIA AND ISOLATED GROWTH HORMONE DEFICIENCY, X-LINKED;; AGAMMAGLOBULINEMIA AND ISOLATED GROWTH HORMONE DEFICIENCY, X-LINKED;; FLEISHER SYNDROME__:__
Caret__:__307300__:__MOVED TO 312300__:____:__
NULL__:__307500__:__HYPOGONADISM, MALE, WITH MENTAL RETARDATION AND SKELETAL ANOMALIES__:____:__
Caret__:__307600__:__MOVED TO 602014__:____:__
Percent__:__307700__:__HYPOPARATHYROIDISM, X-LINKED; HYPX__:__PARATHYROID GLANDS, AGENESIS OF__:__
Number Sign__:__307800__:__HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; XLHR__:__HYPOPHOSPHATEMIA, X-LINKED; XLH;; HYP;; VITAMIN D-RESISTANT RICKETS, X-LINKED;; HYPOPHOSPHATEMIC VITAMIN D-RESISTANT RICKETS; HPDR__:__
Caret__:__307810__:__MOVED TO 307800 AND 300550__:____:__
NULL__:__307830__:__HYPOURICEMIA, FAMILIAL RENAL, DUE TO TUBULAR HYPERSECRETION__:____:__
Asterisk__:__308000__:__HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1; HPRT1__:__HPRT;; HGPRT__:__
Number Sign__:__308050__:__CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS__:__CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS__:__
Number Sign__:__308100__:__ICHTHYOSIS, X-LINKED; XLI__:__STEROID SULFATASE DEFICIENCY;; STS DEFICIENCY;; PLACENTAL STEROID SULFATASE DEFICIENCY;; STEROID SULFATASE DEFICIENCY DISEASE; SSDD__:__ICHTHYOSIS, X-LINKED, COMPLICATED, INCLUDED
NULL__:__308200__:__ICHTHYOSIS AND MALE HYPOGONADISM__:____:__RUD SYNDROME, INCLUDED;; RUDS, INCLUDED
Number Sign__:__308205__:__IFAP SYNDROME WITH OR WITHOUT BRESHECK SYNDROME__:__ICHTHYOSIS FOLLICULARIS, ATRICHIA, AND PHOTOPHOBIA WITH OR WITHOUT BRAIN ANOMALIES, RETARDATION, ECTODERMAL DYSPLASIA, SKELETAL MALFORMATIONS, HIRSCHSPRUNG DISEASE, EAR/EYE ANOMALIES, CLEFT PALATE/CRYPTORCHIDISM, AND KIDNEY DYSPLASIA/HYPOPLASIA__:__
Caret__:__308210__:__REMOVED FROM DATABASE__:____:__
NULL__:__308220__:__IMMUNODEFICIENCY, X-LINKED, WITH DEFICIENCY OF 115,000 DALTON SURFACE GLYCOPROTEIN__:__GPL115 DEFICIENCY__:__
Number Sign__:__308230__:__IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1; HIGM1__:__HYPER-IgM IMMUNODEFICIENCY, X-LINKED; XHIM;; HYPER-IgM SYNDROME 1;; HYPER-IgM SYNDROME; HIGM; IHIS;; IMMUNODEFICIENCY 3; IMD3__:__
Number Sign__:__308240__:__LYMPHOPROLIFERATIVE SYNDROME, X-LINKED, 1; XLP1__:__XLP;; LYMPHOPROLIFERATIVE DISEASE, X-LINKED; XLPD;; LYP;; DUNCAN DISEASE;; EPSTEIN-BARR VIRUS INFECTION, FAMILIAL FATAL;; EBV INFECTION, SEVERE, SUSCEPTIBILITY TO; EBVS;; INFECTIOUS MONONUCLEOSIS, SEVERE, SUSCEPTIBILITY TO;; IMMUNODEFICIENCY, X-LINKED PROGRESSIVE COMBINED VARIABLE;; IMMUNODEFICIENCY 5; IMD5;; PURTILO SYNDROME__:__
Percent__:__308250__:__IMMUNOGLOBULIN M, LEVEL OF__:____:__
Percent__:__308280__:__IMPACTED TEETH, MULTIPLE__:____:__
NULL__:__308290__:__IMPRINTING GENE RELATED TO RETINOBLASTOMA__:____:__
Number Sign__:__308300__:__INCONTINENTIA PIGMENTI; IP__:__INCONTINENTIA PIGMENTI, FAMILIAL MALE-LETHAL TYPE;; BLOCH-SULZBERGER SYNDROME;; INCONTINENTIA PIGMENTI, TYPE II, FORMERLY; IP2, FORMERLY__:__
Caret__:__308310__:__MOVED TO 308300__:____:__
Number Sign__:__308350__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1; EIEE1__:__INFANTILE SPASM SYNDROME, X-LINKED 1; ISSX1;; WEST SYNDROME, X-LINKED;; OHTAHARA SYNDROME, X-LINKED;; INFANTILE EPILEPTIC-DYSKINETIC ENCEPHALOPATHY;; XMESID__:__
Caret__:__308370__:__MOVED TO 312300__:____:__
Asterisk__:__308380__:__INTERLEUKIN 2 RECEPTOR, GAMMA; IL2RG__:__INTERLEUKIN RECEPTOR, COMMON GAMMA CHAIN;; INTERLEUKIN RECEPTOR, GAMMA-C;; CD132 ANTIGEN; CD132__:__
Asterisk__:__308385__:__INTERLEUKIN 3 RECEPTOR, ALPHA; IL3RA__:__CD123 ANTIGEN; CD123__:__
Caret__:__308400__:__REMOVED FROM DATABASE__:____:__
NULL__:__308500__:__IRIS HYPOPLASIA WITH GLAUCOMA; IHG__:____:__
NULL__:__308600__:__JAUNDICE, FAMILIAL OBSTRUCTIVE, OF INFANCY__:____:__
Number Sign__:__308700__:__HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA; HH1__:__KALLMANN SYNDROME 1; KAL1;; KMS;; HYPOGONADOTROPIC HYPOGONADISM AND ANOSMIA; HHA;; DYSPLASIA OLFACTOGENITALIS OF DE MORSIER;; ANOSMIC HYPOGONADISM__:__
NULL__:__308750__:__KALLMANN SYNDROME WITH SPASTIC PARAPLEGIA__:__SPASTIC PARAPLEGIA-KALLMANN SYNDROME__:__
Number Sign__:__308800__:__KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, X-LINKED; KFSDX__:__KERATOSIS FOLLICULARIS SPINULOSA DECALVANS CUM OPHIASI__:__
NULL__:__308830__:__KERATOSIS FOLLICULARIS, DWARFISM, AND CEREBRAL ATROPHY__:____:__
Asterisk__:__308840__:__L1 CELL ADHESION MOLECULE; L1CAM__:__MIC5;; NEURAL CELL ADHESION MOLECULE L1; CAML1__:__
NULL__:__308850__:__LARYNGEAL ABDUCTOR PARALYSIS__:__VOCAL CORD DYSFUNCTION, FAMILIAL;; PLOTT SYNDROME__:__
Percent__:__308905__:__LEBER OPTIC ATROPHY, SUSCEPTIBILITY TO__:__LOAS;; LEBER HEREDITARY OPTIC NEUROPATHY, MODIFIER OF;; LHON, MODIFIER OF__:__
Caret__:__308930__:__MOVED TO 312170__:____:__
Number Sign__:__308940__:__LEIOMYOMATOSIS, DIFFUSE, WITH ALPORT SYNDROME; DL-ATS__:__LEIOMYOMATOSIS, ESOPHAGEAL AND VULVAL, WITH NEPHROPATHY;; ALPORT SYNDROME AND DIFFUSE LEIOMYOMATOSIS; ATS-DL;; CHROMOSOME Xq22.3 CENTROMERIC DELETION SYNDROME__:__
NULL__:__308950__:__LESCH-NYHAN PHENOTYPE WITH NORMAL HGPRT__:____:__
NULL__:__308960__:__LEUKEMIA, ACUTE, ?X-LINKED__:____:__
Caret__:__308980__:__MOVED TO 151660__:____:__
Number Sign__:__308990__:__PROTEINURIA, LOW MOLECULAR WEIGHT, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS__:____:__
Number Sign__:__309000__:__LOWE OCULOCEREBRORENAL SYNDROME; OCRL__:__OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY__:__
NULL__:__309050__:__LUTHERAN SUPPRESSOR, X-LINKED; XS__:__LUXS__:__
Asterisk__:__309060__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 2; LAMP2__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN B; LAMPB;; LYSOSOMAL MEMBRANE GLYCOPROTEIN, 110-KD; LGP110;; CD107B__:__
Percent__:__309100__:__MACULAR DYSTROPHY, X-LINKED__:____:__
Number Sign__:__309120__:__SPERMATOGENIC FAILURE, X-LINKED, 2; SPGFX2__:__MALE INFERTILITY FROM DEFECT IN MEIOSIS__:__
Caret__:__309150__:__MOVED TO 614279__:____:__
Percent__:__309200__:__MAJOR AFFECTIVE DISORDER 2; MAFD2__:__MANIC-DEPRESSIVE ILLNESS; MDI;; MANIC-DEPRESSIVE PSYCHOSIS, X-LINKED; MDX;; BIPOLAR AFFECTIVE DISORDER; BPAD__:__
Number Sign__:__309300__:__MEGALOCORNEA; MGC1__:__MGCN__:__
Number Sign__:__309350__:__MELNICK-NEEDLES SYNDROME; MNS__:__MELNICK-NEEDLES OSTEODYSPLASTY;; OSTEODYSPLASTY OF MELNICK AND NEEDLES__:__
Number Sign__:__309400__:__MENKES DISEASE__:__MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE__:__
Caret__:__309470__:__MOVED TO 309500__:____:__
NULL__:__309480__:__MENTAL RETARDATION AND PSORIASIS__:____:__
Caret__:__309490__:__MOVED TO 309580__:____:__
Number Sign__:__309500__:__RENPENNING SYNDROME 1; RENS1__:__MENTAL RETARDATION, X-LINKED, RENPENNING TYPE;; SUTHERLAND-HAAN X-LINKED MENTAL RETARDATION SYNDROME; SHS;; GOLABI-ITO-HALL SYNDROME;; MENTAL RETARDATION, X-LINKED, WITH SPASTIC DIPLEGIA;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 3; MRXS3;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 8; MRXS8;; MENTAL RETARDATION, X-LINKED 55; MRX55__:__
Number Sign__:__309510__:__PARTINGTON X-LINKED MENTAL RETARDATION SYNDROME; PRTS__:__PARTINGTON SYNDROME;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 1; MRXS1;; MENTAL RETARDATION, X-LINKED, WITH DYSTONIC MOVEMENTS, ATAXIA, AND SEIZURES;; MENTAL RETARDATION, X-LINKED 36; MRX36__:__
Number Sign__:__309520__:__LUJAN-FRYNS SYNDROME__:__MENTAL RETARDATION, X-LINKED, WITH MARFANOID HABITUS__:__
Number Sign__:__309530__:__MENTAL RETARDATION, X-LINKED 1; MRX1__:__MRX;; MENTAL RETARDATION, X-LINKED 18; MRX18;; MENTAL RETARDATION, X-LINKED 78; MRX78__:__
Caret__:__309540__:__MOVED TO 309548__:____:__
Number Sign__:__309541__:__METHYLMALONIC ACIDEMIA AND HOMOCYSTEINEMIA, cblX TYPE__:__MENTAL RETARDATION, X-LINKED 3; MRX3__:__
Percent__:__309545__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 12; MRXS12__:____:__
Number Sign__:__309548__:__MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH FRAGILE SITE FRAXE__:__FRAXE MENTAL RETARDATION SYNDROME__:__
Number Sign__:__309549__:__MENTAL RETARDATION, X-LINKED 9; MRX9__:__MENTAL RETARDATION, X-LINKED 44; MRX44__:__
Asterisk__:__309550__:__FMR1 GENE; FMR1__:__FRAGILE X MENTAL RETARDATION PROTEIN; FMRP__:__FRAGILE SITE, FOLIC ACID TYPE, RARE, fraXq27.3, INCLUDED; FRAXA, INCLUDED
Percent__:__309555__:__MENTAL RETARDATION WITH OPTIC ATROPHY, DEAFNESS, AND SEIZURES__:__GUSTAVSON SYNDROME; GUST__:__
Percent__:__309560__:__MENTAL RETARDATION WITH SPASTIC PARAPLEGIA AND PALMOPLANTAR HYPERKERATOSIS__:____:__
Number Sign__:__309580__:__MENTAL RETARDATION-HYPOTONIC FACIES SYNDROME, X-LINKED, 1; MRXHF1__:__SMITH-FINEMAN-MYERS SYNDROME 1; SFM1;; SFMS;; XLMR-HYPOTONIC FACIES SYNDROME;; CARPENTER-WAZIRI SYNDROME;; CHUDLEY-LOWRY SYNDROME;; JUBERG-MARSIDI SYNDROME; JMS;; HOLMES-GANG SYNDROME;; MENTAL RETARDATION, X-LINKED, WITH GROWTH RETARDATION, DEAFNESS, AND MICROGENITALISM__:__
Number Sign__:__309583__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR__:__SNYDER-ROBINSON MENTAL RETARDATION SYNDROME; SRS__:__
Number Sign__:__309585__:__WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 6; MRXS6;; MENTAL RETARDATION, X-LINKED, WITH GYNECOMASTIA AND OBESITY__:__
Caret__:__309590__:__MOVED TO 309580__:____:__
Caret__:__309600__:__MOVED TO 300523__:____:__
Caret__:__309605__:__MOVED TO 314580__:____:__
Percent__:__309610__:__PRIETO X-LINKED MENTAL RETARDATION SYNDROME; PRS__:__MENTAL RETARDATION, X-LINKED, SYNDROMIC 2; MRXS2;; MENTAL RETARDATION, X-LINKED, WITH DYSMORPHISM AND CEREBRAL ATROPHY__:__
Percent__:__309620__:__MENTAL RETARDATION, SKELETAL DYSPLASIA, AND ABDUCENS PALSY; MRSD__:__CHRISTIAN SYNDROME; CHRS__:__
Number Sign__:__309630__:__METACARPAL 4-5 FUSION; MF4__:____:__
NULL__:__309640__:__MENTAL RETARDATION WITH SPASTIC PARAPLEGIA__:____:__
Caret__:__309645__:__MOVED TO 602111__:____:__
Caret__:__309660__:__MOVED TO 300257__:____:__
Caret__:__309700__:__MOVED TO 310600__:____:__
Number Sign__:__309800__:__MICROPHTHALMIA, SYNDROMIC 1; MCOPS1__:__LENZ MICROPHTHALMIA SYNDROME;; LENZ DYSPLASIA;; MAA, FORMERLY__:__
Number Sign__:__309801__:__LINEAR SKIN DEFECTS WITH MULTIPLE CONGENITAL ANOMALIES 1; LSDMCA1__:__MICROPHTHALMIA, SYNDROMIC 7; MCOPS7;; MICROPHTHALMIA WITH LINEAR SKIN DEFECTS; MLS;; MICROPHTHALMIA, DERMAL APLASIA, AND SCLEROCORNEA;; MIDAS SYNDROME__:__
NULL__:__309840__:__MODIFIER, X-LINKED, FOR NEUROFUNCTIONAL DEFECTS__:__TOURETTE SYNDROME, MODIFIER OF__:__
Asterisk__:__309845__:__MOESIN; MSN__:__MEMBRANE-ORGANIZING EXTENSION SPIKE PROTEIN__:__
Asterisk__:__309850__:__MONOAMINE OXIDASE A; MAOA__:__AMINE OXIDASE (FLAVIN-CONTAINING) A__:__
Asterisk__:__309860__:__MONOAMINE OXIDASE B; MAOB__:__MAO, PLATELET;; MAO, BRAIN;; AMINE OXIDASE (FLAVIN-CONTAINING) B__:__
Number Sign__:__309900__:__MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2__:__MPS II;; HUNTER SYNDROME;; IDURONATE 2-SULFATASE DEFICIENCY;; IDS DEFICIENCY;; SULFOIDURONATE SULFATASE DEFICIENCY;; SIDS DEFICIENCY__:__
NULL__:__309930__:__MUSCULAR DYSTROPHY, CARDIAC TYPE__:____:__
NULL__:__309950__:__MUSCULAR DYSTROPHY, HEMIZYGOUS LETHAL TYPE__:____:__
NULL__:__310000__:__MUSCULAR DYSTROPHY, MABRY TYPE__:____:__
NULL__:__310095__:__MUSCULAR DYSTROPHY, PROGRESSIVE PECTORODORSAL__:__MUSCULAR DYSTROPHY, PROGRESSIVE, INVOLVING SHOULDER GIRDLE AND BACK__:__
Number Sign__:__310200__:__MUSCULAR DYSTROPHY, DUCHENNE TYPE; DMD__:__DUCHENNE MUSCULAR DYSTROPHY;; MUSCULAR DYSTROPHY, PSEUDOHYPERTROPHIC PROGRESSIVE, DUCHENNE TYPE__:__
Number Sign__:__310300__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1__:__EMD1;; MUSCULAR DYSTROPHY, TARDIVE, DREIFUSS-EMERY TYPE, WITH CONTRACTURES;; SCAPULOPERONEAL SYNDROME, X-LINKED, FORMERLY;; HUMEROPERONEAL NEUROMUSCULAR DISEASE, FORMERLY__:__
Caret__:__310305__:__MOVED TO 601415__:____:__
Asterisk__:__310310__:__MYCL-RELATED PROCESSED GENE; MYCL2__:____:__
NULL__:__310350__:__MYELOLYMPHATIC INSUFFICIENCY__:__PELGER-LIKE ANOMALY WITH LEUKOPENIA AND SUSCEPTIBILITY TO INFECTIONS__:__
NULL__:__310370__:__MYOCLONIC EPILEPSY, PROGRESSIVE__:____:__
Number Sign__:__310400__:__MYOPATHY, CENTRONUCLEAR, X-LINKED; CNMX__:__MYOTUBULAR MYOPATHY, X-LINKED; MTMX; XLMTM;; MYOTUBULAR MYOPATHY 1; MTM1__:__
Number Sign__:__310440__:__MYOPATHY, X-LINKED, WITH EXCESSIVE AUTOPHAGY; MEAX__:__XMEA__:__
Caret__:__310450__:__MOVED TO 159000__:____:__
Percent__:__310460__:__MYOPIA 1, X-LINKED; MYP1__:____:__
NULL__:__310465__:__N SYNDROME; NSX__:____:__
Number Sign__:__310468__:__NEPHROLITHIASIS, X-LINKED RECESSIVE, WITH RENAL FAILURE; XRN__:__NEPHROLITHIASIS, X-LINKED RECESSIVE, TYPE 1;; UROLITHIASIS, X-LINKED RECESSIVE, TYPE 1;; NEPHROLITHIASIS 1; NPHL1__:__
NULL__:__310470__:__NEUROPATHY, HEREDITARY SENSORY, X-LINKED__:____:__
Number Sign__:__310490__:__COWCHOCK SYNDROME; COWCK__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 4; CMTX4;; CHARCOT-MARIE-TOOTH DISEASE WITH DEAFNESS AND MENTAL RETARDATION;; NEUROPATHY, AXONAL MOTOR-SENSORY, WITH DEAFNESS AND MENTAL RETARDATION; NAMSD;; NADMR__:__
Number Sign__:__310500__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A__:__CSNB, COMPLETE, X-LINKED;; NIGHT BLINDNESS, CONGENITAL STATIONARY, WITH MYOPIA;; HEMERALOPIA-MYOPIA;; MYOPIA-NIGHT BLINDNESS; NBM1__:__NYCTALOPIA, INCLUDED
Number Sign__:__310600__:__NORRIE DISEASE; ND__:__ATROPHIA BULBORUM HEREDITARIA;; EPISKOPI BLINDNESS__:__
NULL__:__310650__:__NUCLEAR RIBONUCLEIC ACID; nRNA__:____:__
Number Sign__:__310700__:__NYSTAGMUS 1, CONGENITAL, X-LINKED; NYS1__:__NYSTAGMUS, CONGENITAL MOTOR, 1;; NYSTAGMUS 1, INFANTILE, X-LINKED;; NYSTAGMUS, INFANTILE IDIOPATHIC, FORMERLY; IIN, FORMERLY__:__NYSTAGMUS, INFANTILE PERIODIC ALTERNATING, X-LINKED, INCLUDED; XIPAN, INCLUDED;; XLPAN, INCLUDED
NULL__:__310800__:__NYSTAGMUS, MYOCLONIC__:____:__
NULL__:__310900__:__OCCIPITAL HAIR, WHITE LOCK OF__:____:__
NULL__:__310980__:__OMPHALOCELE, X-LINKED__:____:__
Caret__:__310990__:__MOVED TO 190020__:____:__
Percent__:__311000__:__OPHTHALMOPLEGIA, EXTERNAL, AND MYOPIA; OPEM__:__MYOPIA-OPHTHALMOPLEGIA SYNDROME__:__
Asterisk__:__311010__:__V-RAF MURINE SARCOMA 3611 VIRAL ONCOGENE HOMOLOG 1; ARAF1__:__ONCOGENE ARAF1;; RAFA1;; ONCOGENE PKS2__:__
Caret__:__311020__:__MOVED TO 311010__:____:__
Asterisk__:__311030__:__MCF.2 CELL LINE-DERIVED TRANSFORMING SEQUENCE; MCF2__:__ONCOGENE MCF2;; ONCOGENE DBL; DBL__:__
Asterisk__:__311040__:__ELK1, MEMBER OF ETS ONCOGENE FAMILY; ELK1__:__ONCOGENE ELK1__:__ELK2, MEMBER OF ETS ONCOGENE FAMILY, PSEUDOGENE 1, INCLUDED
Percent__:__311050__:__OPTIC ATROPHY 2; OPA2__:__OPTIC ATROPHY, X-LINKED;; OPTIC ATROPHY, NON-LEBER TYPE, WITH EARLY ONSET__:__
Number Sign__:__311070__:__CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5__:__OPTIC ATROPHY, POLYNEUROPATHY, AND DEAFNESS;; ROSENBERG-CHUTORIAN SYNDROME;; CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 5__:__
NULL__:__311100__:__OPTIC ATROPHY--SPASTIC PARAPLEGIA SYNDROME__:____:__
Caret__:__311150__:__MOVED TO 304700__:____:__
Number Sign__:__311200__:__OROFACIODIGITAL SYNDROME I; OFD1__:__ORAL-FACIAL-DIGITAL SYNDROME, TYPE I;; OFDS I;; PAPILLON-LEAGE AND PSAUME SYNDROME__:__
Asterisk__:__311240__:__TBC1 DOMAIN FAMILY, MEMBER 25; TBC1D25__:__ORNITHINE AMINOTRANSFERASE-LIKE 1; OATL1__:__
Caret__:__311241__:__MOVED TO 258870__:____:__
Number Sign__:__311250__:__ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO__:__ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY;; OTC DEFICIENCY__:__VALPROATE SENSITIVITY, INCLUDED
Caret__:__311280__:__MOVED TO 300373__:____:__
Number Sign__:__311300__:__OTOPALATODIGITAL SYNDROME, TYPE I; OPD1__:__OPD I SYNDROME;; OPD SYNDROME 1__:__OTOPALATODIGITAL SPECTRUM DISORDER, INCLUDED;; FRONTOOTOPALATODIGITAL OSTEODYSPLASIA, INCLUDED
NULL__:__311350__:__OUABAIN RESISTANCE; OUBR__:____:__
Number Sign__:__311360__:__PREMATURE OVARIAN FAILURE 1; POF1__:__PREMATURE OVARIAN FAILURE, X-LINKED; POFX;; HYPERGONADOTROPIC OVARIAN FAILURE, X-LINKED;; OVARIAN FAILURE, PREMATURE; POF;; PRIMARY OVARIAN INSUFFICIENCY, FRAGILE X-ASSOCIATED;; FRAGILE X PREMATURE OVARIAN FAILURE__:__
NULL__:__311400__:__PAINE SYNDROME__:__MICROCEPHALY WITH SPASTIC DIPLEGIA__:__SEEMANOVA SYNDROME I, INCLUDED
NULL__:__311450__:__PALLISTER W SYNDROME__:__W SYNDROME__:__
Number Sign__:__311510__:__WAISMAN SYNDROME; WSMN__:__PARKINSONISM, EARLY-ONSET, WITH MENTAL RETARDATION;; BASAL GANGLION DISORDER WITH MENTAL RETARDATION; BGMR;; WSN__:__
Asterisk__:__311550__:__CYCLIN-DEPENDENT KINASE 16; CDK16__:__PCTAIRE PROTEIN KINASE 1; PCTK1;; PCTAIRE1__:__
Caret__:__311601__:__MOVED TO 312080__:____:__
Caret__:__311700__:__REMOVED FROM DATABASE__:____:__
Caret__:__311750__:__MOVED TO 170650__:____:__
Asterisk__:__311770__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS A PROTEIN; PIGA__:____:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS A PROTEIN, PSEUDOGENE 1, INCLUDED; PIGAP1, INCLUDED; PIGAP, INCLUDED
Asterisk__:__311790__:__6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 1; PFKFB1__:__PFKFB, LIVER;; PFRX__:__
Asterisk__:__311800__:__PHOSPHOGLYCERATE KINASE 1; PGK1__:__3-PHOSPHOGLYCEROKINASE;; PGKA__:__PHOSPHOGLYCERATE KINASE 1 PSEUDOGENE 1, INCLUDED; PGK1P1, INCLUDED;; PHOSPHOGLYCERATE KINASE 1 PSEUDOGENE 2, INCLUDED; PGK1P2, INCLUDED
Caret__:__311810__:__MOVED TO 311800__:____:__
Asterisk__:__311850__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE I; PRPS1__:____:__
Asterisk__:__311860__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE II; PRPS2__:____:__
Asterisk__:__311870__:__PHOSPHORYLASE KINASE, MUSCLE, ALPHA-1 SUBUNIT; PHKA1__:____:__
NULL__:__311895__:__PIERRE ROBIN SEQUENCE WITH FACIAL AND DIGITAL ANOMALIES__:____:__
Number Sign__:__311900__:__TARP SYNDROME; TARPS__:__TALIPES EQUINOVARUS, ATRIAL SEPTAL DEFECT, ROBIN SEQUENCE, AND PERSISTENCE OF LEFT SUPERIOR VENA CAVA;; PIERRE ROBIN SYNDROME WITH CONGENITAL HEART MALFORMATION AND CLUBFOOT__:__
Number Sign__:__312000__:__PANHYPOPITUITARISM, X-LINKED; PHPX__:__PITUITARY DWARFISM IV, FORMERLY__:__
Caret__:__312030__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__312040__:__POLYMERASE, DNA, ALPHA-1; POLA1__:__POLA DNA POLYMERASE-ALPHA, p180 SUBUNIT__:__
Number Sign__:__312060__:__PROPERDIN DEFICIENCY, X-LINKED; CFPD__:__PROPERDIN P FACTOR DEFICIENCY; PFD;; COMPLEMENT FACTOR PROPERDIN DEFICIENCY;; PROPERDIN DEFICIENCY, TYPE I__:__PROPERDIN DEFICIENCY, TYPE II, INCLUDED;; PROPERDIN DEFICIENCY, TYPE III, INCLUDED
Asterisk__:__312070__:__UBIQUITIN-LIKE 4A; UBL4A__:__UBL4;; GDX;; DXS254E__:__
Number Sign__:__312080__:__PELIZAEUS-MERZBACHER DISEASE; PMD__:__LEUKODYSTROPHY, HYPOMYELINATING, 1; HLD1__:__
Asterisk__:__312090__:__SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID COTRANSPORTER FAMILY) MEMBER 3; SLC10A3__:__PROTEIN P3__:__
Asterisk__:__312095__:__A-KINASE ANCHOR PROTEIN 17A; AKAP17A__:__SPLICING FACTOR, ARGININE/SERINE-RICH, 17A; SFRS17A;; PSEUDOAUTOSOMAL GENE XE7;; DXYS155E__:__
Caret__:__312100__:__MOVED TO 312300__:____:__
Percent__:__312150__:__MULTIPLE PTERYGIUM SYNDROME, X-LINKED__:__PTERYGIUM SYNDROME, MULTIPLE, X-LINKED__:__
Number Sign__:__312170__:__PYRUVATE DEHYDROGENASE E1-ALPHA DEFICIENCY; PDHAD__:__PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY;; PYRUVATE DECARBOXYLASE DEFICIENCY;; ATAXIA, INTERMITTENT, WITH ABNORMAL PYRUVATE METABOLISM;; PDH DEFICIENCY;; ATAXIA, INTERMITTENT, WITH PYRUVATE DEHYDROGENASE DEFICIENCY;; ATAXIA WITH LACTIC ACIDOSIS I__:__LACTIC ACIDEMIA, THIAMINE-RESPONSIVE, INCLUDED
Asterisk__:__312173__:__RIBOSOMAL PROTEIN L10; RPL10__:__QM GENE__:__
Asterisk__:__312180__:__UBIQUITIN-CONJUGATING ENZYME E2A; UBE2A__:__RAD6, YEAST, HOMOLOG OF, TYPE A; RAD6A;; HHR6A__:__
NULL__:__312190__:__RADIAL APLASIA, X-LINKED__:__RADIAL APLASIA AND ANOGENITAL ANOMALIES__:__
NULL__:__312200__:__RADIAL LOOP, PLAIN, ON RIGHT INDEX FINGER__:____:__
NULL__:__312210__:__RADIATION SENSITIVITY OF NATURAL KILLER ACTIVITY__:__X-RAY NK SENSITIVITY; XNKS__:__
Number Sign__:__312300__:__ANDROGEN INSENSITIVITY, PARTIAL; PAIS__:__REIFENSTEIN SYNDROME;; ANDROGEN INSENSITIVITY, PARTIAL, WITH OR WITHOUT BREAST CANCER;; FAMILIAL INCOMPLETE MALE PSEUDOHERMAPHRODITISM, TYPE 1__:__
Caret__:__312390__:__MOVED TO 314310__:____:__
Caret__:__312400__:__MOVED TO 604278__:____:__
Asterisk__:__312420__:__RENIN-BINDING PROTEIN; RENBP__:____:__
Caret__:__312450__:__MOVED TO 252010__:____:__
Percent__:__312500__:__RETICULOENDOTHELIOSIS, X-LINKED__:____:__
Caret__:__312530__:__REMOVED FROM DATABASE__:____:__
NULL__:__312550__:__RETINAL DYSPLASIA, PRIMARY; PRD__:____:__
Number Sign__:__312600__:__RETINITIS PIGMENTOSA 2; RP2__:____:__
Asterisk__:__312610__:__RETINITIS PIGMENTOSA GTPase REGULATOR; RPGR__:____:__
Percent__:__312612__:__RETINITIS PIGMENTOSA 6; RP6__:__RETINITIS PIGMENTOSA, X-LINKED RECESSIVE, 6__:__
Number Sign__:__312700__:__RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1__:__XLRS1;; RS__:__
Number Sign__:__312750__:__RETT SYNDROME; RTT__:__RTS;; AUTISM, DEMENTIA, ATAXIA, AND LOSS OF PURPOSEFUL HAND USE__:__RETT SYNDROME, ZAPPELLA VARIANT, INCLUDED;; RETT SYNDROME, PRESERVED SPEECH VARIANT, INCLUDED;; RETT SYNDROME, ATYPICAL, INCLUDED
Asterisk__:__312760__:__RIBOSOMAL PROTEIN S4, X-LINKED; RPS4X__:__SINGLE-COPY ABUNDANT mRNA; SCAR;; CELL CYCLE GENE 2; CCG2__:__
NULL__:__312780__:__RUSSELL-SILVER SYNDROME, X-LINKED__:__RUSSELL-SILVER-LIKE SYNDROME WITH SKIN PIGMENTATION;; PARTINGTON SYNDROME__:__
Caret__:__312800__:__MOVED TO 600145__:____:__
Asterisk__:__312820__:__SARCOMA, SYNOVIAL, X BREAKPOINT 1; SSX1__:__SARCOMA, SYNOVIAL, X-CHROMOSOME-RELATED 1;; SSRC__:__SSX1-SYT FUSION GENE, INCLUDED
NULL__:__312830__:__SCARF SYNDROME__:__SKELETAL ABNORMALITIES, CUTIS LAXA, CRANIOSTENOSIS, AMBIGUOUS GENITALIA, RETARDATION, AND FACIAL ABNORMALITIES__:__
NULL__:__312840__:__SCHIMKE X-LINKED MENTAL RETARDATION SYNDROME__:__CHOREOATHETOSIS WITH MENTAL RETARDATION, X-LINKED__:__
Caret__:__312860__:__MOVED TO 272440__:____:__
Asterisk__:__312861__:__5-HYDROXYTRYPTAMINE RECEPTOR 2C; HTR2C__:__SEROTONIN 5-HT-2C RECEPTOR;; SEROTONIN 5-HT-1C RECEPTOR, FORMERLY; HTR1C, FORMERLY__:__
Number Sign__:__312863__:__COMBINED IMMUNODEFICIENCY, X-LINKED; CIDX__:__XCID;; IMMUNODEFICIENCY 6; IMD6__:__
Asterisk__:__312865__:__SHORT STATURE HOMEOBOX; SHOX__:__PSEUDOAUTOSOMAL HOMEOBOX-CONTAINING OSTEOGENIC GENE; PHOG__:__
Number Sign__:__312870__:__SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1; SGBS1__:__SGBS;; BULLDOG SYNDROME;; DYSPLASIA GIGANTISM SYNDROME, X-LINKED; DGSX;; GOLABI-ROSEN SYNDROME;; SIMPSON DYSMORPHIA SYNDROME; SDYS__:__
Caret__:__312890__:__MOVED TO 312920__:____:__
Caret__:__312900__:__MOVED TO 303350__:____:__
NULL__:__312910__:__SPASTIC PARAPARESIS AND DEAFNESS__:____:__
Number Sign__:__312920__:__SPASTIC PARAPLEGIA 2, X-LINKED; SPG2__:__SPPX2__:__
Percent__:__313000__:__SPATIAL VISUALIZATION, APTITUDE FOR__:__VISUOSPATIAL/PERCEPTUAL ABILITIES; VSPA__:__TURNER SYNDROME-ASSOCIATED NEUROCOGNITIVE PHENOTYPE, INCLUDED
Asterisk__:__313020__:__SPERMIDINE/SPERMINE N(1)-ACETYLTRANSFERASE 1; SAT1__:__SSAT;; SSAT1__:__
Caret__:__313100__:__MOVED TO 605041__:____:__
Number Sign__:__313200__:__SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1; SMAX1__:__SPINAL AND BULBAR MUSCULAR ATROPHY; SBMA;; KENNEDY DISEASE; KD;; KENNEDY SPINAL AND BULBAR MUSCULAR ATROPHY;; BULBOSPINAL MUSCULAR ATROPHY, X-LINKED;; BULBOSPINAL NEURONOPATHY, X-LINKED RECESSIVE; XBSN__:__
Percent__:__313350__:__SPLIT-HAND/FOOT MALFORMATION 2; SHFM2__:__SPLIT-HAND/SPLIT-FOOT ANOMALY, X-LINKED;; SPLIT-HAND/FOOT DEFORMITY 2; SHFD2;; SHSF2__:__
Number Sign__:__313400__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, X-LINKED; SEDT__:__SED TARDA, X-LINKED;; SPONDYLOEPIPHYSEAL DYSPLASIA, LATE__:__
Percent__:__313420__:__SPONDYLOMETAPHYSEAL DYSPLASIA, X-LINKED__:__SPONDYLOMETAPHYSEAL DYSPLASIA, RICHMOND TYPE__:__
Asterisk__:__313430__:__SRY-BOX 3; SOX3__:__SRY-RELATED HMG-BOX GENE 3__:__
Asterisk__:__313440__:__SYNAPSIN I; SYN1__:__BRAIN PROTEIN 4.1__:__
Caret__:__313450__:__REMOVED FROM DATABASE__:____:__
Caret__:__313460__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__313470__:__CD99 ANTIGEN, X CHROMOSOME; CD99__:__MIC2 SURFACE ANTIGEN, X CHROMOSOME; MIC2X;; CELL SURFACE ANTIGEN 12E7, X CHROMOSOME;; E2 ANTIGEN, X CHROMOSOME;; CELL SURFACE ANTIGEN HBA-71, X CHROMOSOME; HBA71;; CELL SURFACE ANTIGEN O13, X CHROMOSOME;; MSK5X__:__
Asterisk__:__313475__:__SYNAPTOPHYSIN; SYP__:____:__
NULL__:__313480__:__TaqI POLYMORPHISM; TAQ1__:____:__
NULL__:__313490__:__TAURODONTISM, MICRODONTIA, AND DENS INVAGINATUS__:____:__
Number Sign__:__313500__:__TOOTH AGENESIS, SELECTIVE, X-LINKED, 1; STHAGX1__:__HYPODONTIA/OLIGODONTIA, X-LINKED, 1__:__
Caret__:__313550__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__313650__:__TAF1 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 250-KD; TAF1__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1;; TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2A; TAF2A;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 250-KD; TAFII250;; CELL CYCLE, G1 PHASE DEFECT; CCG1;; CELL CYCLE GENE 1;; CELL CYCLE BLOCK, G1-TO-S; CCGS;; BA2R__:__TRANSCRIPTION FACTOR IID, INCLUDED; TFIID, INCLUDED; TF2D, INCLUDED;; TATA-BINDING PROTEIN-CONTAINING COMPLEX, INCLUDED
Caret__:__313680__:__MOVED TO 187395__:____:__
Asterisk__:__313700__:__ANDROGEN RECEPTOR; AR__:__DIHYDROTESTOSTERONE RECEPTOR; DHTR;; NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, MEMBER 4; NR3C4__:__
Percent__:__313850__:__THORACOABDOMINAL SYNDROME; THAS__:__TAS__:__MIDLINE DEFECTS, X-LINKED, INCLUDED;; PENTALOGY OF CANTRELL, INCLUDED
Number Sign__:__313900__:__THROMBOCYTOPENIA 1; THC1__:__THC;; THROMBOCYTOPENIA, X-LINKED; XLT;; THROMBOCYTOPENIA, X-LINKED, 1__:__THROMBOCYTOPENIA, X-LINKED, INTERMITTENT, INCLUDED
NULL__:__314000__:__THROMBOCYTOPENIA WITH ELEVATED SERUM IgA AND RENAL DISEASE__:____:__
Number Sign__:__314050__:__THROMBOCYTOPENIA WITH BETA-THALASSEMIA, X-LINKED; XLTT__:__THROMBOCYTOPENIA, PLATELET DYSFUNCTION, HEMOLYSIS, AND IMBALANCED GLOBIN SYNTHESIS__:__
NULL__:__314100__:__THUMBS, CONGENITAL CLASPED__:__ADDUCTED THUMBS SYNDROME__:__
Asterisk__:__314200__:__THYROXINE-BINDING GLOBULIN OF SERUM; TBG__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 7; SERPINA7;; T4-BINDING GLOBULIN;; TBG, SERUM__:__
NULL__:__314240__:__TOOTH SIZE__:____:__
Number Sign__:__314250__:__DYSTONIA 3, TORSION, X-LINKED; DYT3__:__DYSTONIA-PARKINSONISM, X-LINKED; XDP;; TORSION DYSTONIA-PARKINSONISM, FILIPINO TYPE__:__
Percent__:__314300__:__TORTICOLLIS, KELOIDS, CRYPTORCHIDISM, AND RENAL DYSPLASIA; TKCR__:__TKC;; TKCR SYNDROME;; GOEMINNE SYNDROME__:__
Asterisk__:__314310__:__TRANSCRIPTION FACTOR FOR IMMUNOGLOBULIN HEAVY-CHAIN ENHANCER 3; TFE3__:____:__TFE3/ASPSCR1 FUSION GENE, INCLUDED;; TFE3/PRCC FUSION GENE, INCLUDED;; TFE3/SFPQ FUSION GENE, INCLUDED;; TFE3/CLTC FUSION GENE, INCLUDED
NULL__:__314320__:__TRIGONOCEPHALY WITH SHORT STATURE AND DEVELOPMENTAL DELAY__:____:__
Caret__:__314350__:__REMOVED FROM DATABASE__:____:__
NULL__:__314360__:__ULNAR HYPOPLASIA WITH LOBSTER-CLAW DEFORMITY OF FEET__:____:__
Asterisk__:__314370__:__UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 1; UBA1__:__UBIQUITIN-ACTIVATING ENZYME 1; UBE1;; BN75 TEMPERATURE SENSITIVITY COMPLEMENTING; GXP1__:__TEMPERATURE-SENSITIVE MUTATION, MOUSE, COMPLEMENTATION OF, INCLUDED;; tsA1S9, INCLUDED;; A1S9T, INCLUDED;; A1S9, INCLUDED
Asterisk__:__314375__:__SOLUTE CARRIER FAMILY 35 (UDP-GALACTOSE TRANSPORTER), MEMBER 2; SLC35A2__:__UDP-GALACTOSE TRANSLOCATOR; UGALT__:__UDP-GALACTOSE TRANSPORTER, ISOFORM 1, INCLUDED; UGT1, INCLUDED;; UDP-GALACTOSE TRANSPORTER, ISOFORM 2, INCLUDED; UGT2, INCLUDED
Percent__:__314380__:__UNIQUE GREEN PHENOMENON__:____:__
Number Sign__:__314390__:__VACTERL ASSOCIATION, X-LINKED, WITH OR WITHOUT HYDROCEPHALUS; VACTERLX__:__VACTERL-H, X-LINKED__:__
Number Sign__:__314400__:__CARDIAC VALVULAR DYSPLASIA, X-LINKED; CVD1__:__VALVULAR HEART DISEASE, CONGENITAL;; MYXOMATOUS VALVULAR DYSTROPHY, X-LINKED; XMVD__:__
Percent__:__314500__:__VAN DEN BOSCH SYNDROME__:____:__
NULL__:__314550__:__VESICOURETERAL REFLUX, X-LINKED; VURX__:____:__
Caret__:__314555__:__MOVED TO 604492__:____:__
NULL__:__314560__:__VON WILLEBRAND DISEASE, X-LINKED FORM__:____:__
NULL__:__314570__:__WIDOW'S PEAK SYNDROME__:__WIDOW'S PEAK, PTOSIS, AND SKELETAL ANOMALIES__:__
Number Sign__:__314580__:__WIEACKER-WOLFF SYNDROME; WRWF__:__WIEACKER SYNDROME;; CONTRACTURES OF FEET, MUSCLE ATROPHY, AND OCULOMOTOR APRAXIA;; APRAXIA, OCULOMOTOR, WITH CONGENITAL CONTRACTURES AND MUSCLE ATROPHY;; MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME; MCS;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 4; MRXS4;; MENTAL RETARDATION, X-LINKED, WITH CONGENITAL CONTRACTURES AND LOW FINGERTIP ARCHES__:__
Percent__:__314600__:__WILDERVANCK SYNDROME__:__CERVICOOCULOACOUSTIC SYNDROME__:__
Asterisk__:__314670__:__X INACTIVATION-SPECIFIC TRANSCRIPT; XIST__:____:__X INACTIVATION CENTER, INCLUDED; XIC, INCLUDED
Asterisk__:__314690__:__LYSINE-SPECIFIC DEMETHYLASE 5C; KDM5C__:__JUMONJI, AT-RICH INTERACTIVE DOMAIN 1C; JARID1C;; SELECTED cDNA ON X, MOUSE, HOMOLOG OF; SMCX;; XE169;; DXS1272E__:__
NULL__:__314700__:__BLOOD GROUP, XG SYSTEM; XG__:__XG BLOOD GROUP SYSTEM__:__
Percent__:__314705__:__XG REGULATOR; XGR__:__XG AND MIC2 EXPRESSION ON ERYTHROCYTES__:__
NULL__:__314800__:__XH ANTIGEN__:____:__
Asterisk__:__314850__:__KELL BLOOD GROUP PROTEIN, MCLEOD SYNDROME-ASSOCIATED; XK__:__KELL BLOOD GROUP PRECURSOR;; XK LOCUS;; PRECURSOR SUBSTANCE, KELL BLOOD GROUP; KX;; KELL COMPLEX, 37-KD COMPONENT__:__
Percent__:__314900__:__XM SYSTEM__:____:__
Caret__:__314920__:__REMOVED FROM DATABASE__:____:__
Caret__:__314940__:__REMOVED FROM DATABASE__:____:__
Caret__:__314960__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__314980__:__ZINC FINGER PROTEIN, X-LINKED; ZFX__:____:__
Asterisk__:__314990__:__ZINC FINGER PROTEIN 711; ZNF711__:__ZINC FINGER PROTEIN 6; ZNF6;; CMPX1__:__
Asterisk__:__314993__:__ZINC FINGER PROTEIN 182; ZNF182__:__ZINC FINGER PROTEIN 21; ZNF21__:__
Asterisk__:__314995__:__ZINC FINGER PROTEIN 41; ZNF41__:____:__
Asterisk__:__314997__:__ZINC FINGER PROTEIN 75D; ZNF75D__:__ZINC FINGER PROTEIN 75; ZNF75__:__
Asterisk__:__314998__:__ZINC FINGER PROTEIN 81; ZNF81__:____:__
Caret__:__315000__:__MOVED TO 302200__:____:__
Caret__:__400000__:__REMOVED FROM DATABASE__:____:__
Caret__:__400001__:__MOVED TO 426000__:____:__
Caret__:__400002__:__MOVED TO 314700__:____:__
Asterisk__:__400003__:__DELETED IN AZOOSPERMIA; DAZ__:__DAZ1__:__DELETED IN AZOOSPERMIA 4, INCLUDED; DAZ4, INCLUDED
Percent__:__400004__:__RETINITIS PIGMENTOSA, Y-LINKED; RPY__:____:__
Asterisk__:__400005__:__UBIQUITIN-SPECIFIC PROTEASE 9, Y CHROMOSOME; USP9Y__:__DROSOPHILA FAT FACETS-RELATED, Y-LINKED; DFFRY__:__
Asterisk__:__400006__:__RNA-BINDING MOTIF PROTEIN, Y CHROMOSOME, FAMILY 1, MEMBER A1; RBMY1A1__:__RBMY;; RNA-BINDING MOTIF PROTEIN 1; RBM1;; RNA-BINDING MOTIF PROTEIN 2; RBM2;; Y CHROMOSOME RNA RECOGNITION MOTIF 1; YRRM1;; Y CHROMOSOME RNA RECOGNITION MOTIF 2; YRRM2__:__
Caret__:__400007__:__MOVED TO 400006__:____:__
Asterisk__:__400008__:__PROTEIN KINASE, Y-LINKED; PRKY__:____:__
Asterisk__:__400009__:__UBIQUITOUSLY TRANSCRIBED TETRATRICOPEPTIDE REPEAT GENE ON Y CHROMOSOME; UTY__:__UTY1;; LYSINE-SPECIFIC DEMETHYLASE 6C; KDM6C__:__
Asterisk__:__400010__:__DEAD/H BOX 3, Y-LINKED; DDX3Y__:__DBY__:__
Asterisk__:__400011__:__ACETYLSEROTONIN METHYLTRANSFERASE-LIKE, Y-LINKED__:__ASMTLY__:__
Asterisk__:__400012__:__VARIABLY CHARGED, Y CHROMOSOME; VCY__:__VCY1;; BASIC PROTEIN, Y CHROMOSOME, 1; BPY1__:__
Asterisk__:__400013__:__BASIC PROTEIN, Y CHROMOSOME, 2; BPY2__:__BPY2A;; VARIABLY CHARGED, Y CHROMOSOME, 2; VCY2;; VCY2A__:__
Asterisk__:__400014__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 1A, Y-LINKED; EIF1AY__:____:__
Asterisk__:__400015__:__XK-RELATED PROTEIN ON Y CHROMOSOME__:__XKRY__:__
Asterisk__:__400016__:__CHROMODOMAIN PROTEIN, Y CHROMOSOME, 1; CDY1__:__CDY__:__
Asterisk__:__400017__:__THYMOSIN, BETA-4, Y CHROMOSOME; TMSB4Y__:__TB4Y__:__
Asterisk__:__400018__:__CHROMODOMAIN PROTEIN, Y CHROMOSOME, 2; CDY2__:____:__
Asterisk__:__400019__:__PTPBL-RELATED GENE ON Y; PRY__:__PTPBL-RELATED GENE ON Y, 1; PRY1;; PTPN13-LIKE, Y-LINKED; PTPN13LY__:__
Asterisk__:__400020__:__SHORT STATURE HOMEOBOX, Y-LINKED; SHOXY__:____:__
Percent__:__400021__:__LYMPHOMA, HODGKIN, Y-LINKED PSEUDOAUTOSOMAL__:__HODGKIN DISEASE, Y-LINKED PSEUDOAUTOSOMAL__:__
Asterisk__:__400022__:__PROTOCADHERIN 11, Y-LINKED; PCDH11Y__:__PROTOCADHERIN, Y CHROMOSOME; PCDHY;; PROTOCADHERIN 22, FORMERLY; PCDH22, FORMERLY__:__
Asterisk__:__400023__:__CYTOKINE RECEPTOR-LIKE FACTOR 2, Y-LINKED; CRLF2Y__:____:__
Caret__:__400024__:__MOVED TO 415000__:____:__
Asterisk__:__400025__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCED FACTOR 2-LIKE, Y-LINKED; TGIF2LY__:__TGIFLY__:__
Asterisk__:__400026__:__DELETED IN AZOOSPERMIA 2; DAZ2__:____:__
Asterisk__:__400027__:__DELETED IN AZOOSPERMIA 3; DAZ3__:____:__
Asterisk__:__400028__:__NEUROLIGIN 4, Y-LINKED; NLGN4Y__:__KIAA0951__:__
Asterisk__:__400029__:__HEAT-SHOCK TRANSCRIPTION FACTOR, Y-LINKED; HSFY__:____:__
Asterisk__:__400030__:__RIBOSOMAL PROTEIN S4, Y-LINKED, 2; RPS4Y2__:____:__
Asterisk__:__400031__:__CHROMOSOME Y OPEN READING FRAME 15A; CYORF15A__:____:__
Asterisk__:__400032__:__CHROMOSOME Y OPEN READING FRAME 15B; CYORF15B__:____:__
Asterisk__:__400033__:__TRANSDUCIN-BETA-LIKE 1, Y-LINKED; TBL1Y__:____:__
Asterisk__:__400034__:__CHONDROITIN SULFATE PROTEOGLYCAN 4 PSEUDOGENE 1, Y-LINKED; CSPG4P1Y__:__CHONDROITIN SULFATE PROTEOGLYCAN 4-LIKE, Y-LINKED; CSPG4LY;; CSPG4-LIKE, Y-LINKED__:__
Asterisk__:__400035__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 2-LIKE, Y-LINKED; GOLGA2LY__:__GOLGA2-LIKE, Y-LINKED__:__
Asterisk__:__400036__:__TESTIS-SPECIFIC TRANSCRIPT, Y-LINKED, 3; TTTY3__:____:__
Asterisk__:__400037__:__TESTIS-SPECIFIC TRANSCRIPT, Y-LINKED, 4; TTTY4__:____:__
Asterisk__:__400038__:__TESTIS-SPECIFIC TRANSCRIPT, Y-LINKED, 5; TTTY5__:____:__
Asterisk__:__400039__:__TESTIS-SPECIFIC TRANSCRIPT, Y-LINKED, 6; TTTY6__:____:__
Asterisk__:__400040__:__TESTIS-SPECIFIC TRANSCRIPT, Y-LINKED, 17; TTTY17__:____:__
Asterisk__:__400041__:__PTPBL-RELATED GENE ON Y, 2; PRY2__:__PTPN13-LIKE GENE, Y-LINKED, 2;; PTPN13-LIKE GENE, Y-LINKED, CENTROMERIC__:__
Number Sign__:__400042__:__SPERMATOGENIC FAILURE, Y-LINKED, 1; SPGFY1__:__SERTOLI CELL-ONLY SYNDROME, Y-LINKED;; SERTOLI CELL-ONLY SYNDROME, TYPE I__:__SERTOLI CELL-ONLY SYNDROME, TYPE II, INCLUDED;; HYPOSPERMATOGENESIS, INCLUDED;; INCOMPLETE SERTOLI CELL-ONLY SYNDROME, INCLUDED
Percent__:__400043__:__DEAFNESS, Y-LINKED 1; DFNY1__:____:__
Number Sign__:__400044__:__46,XY SEX REVERSAL 1; SRXY1__:__46,XY SEX REVERSAL, SRY-RELATED;; 46,XY GONADAL DYSGENESIS, COMPLETE, SRY-RELATED__:__46,XY TRUE HERMAPHRODITISM, SRY-RELATED, INCLUDED;; TESTIS-DETERMINING FACTOR, X-CHROMOSOMAL, FORMERLY, INCLUDED; TDFX, FORMERLY, INCLUDED;; SEX-REVERSING LOCUS ON X, FORMERLY, INCLUDED; SRVX, FORMERLY, INCLUDED
Number Sign__:__400045__:__46,XX SEX REVERSAL 1; SRXX1__:__46,XX SEX REVERSAL, SRY-POSITIVE;; XX MALE, SRY-POSITIVE;; 46,XX TESTICULAR DISORDER OF SEX DEVELOPMENT;; 46,XX GONADAL DYSGENESIS, COMPLETE, SRY-POSITIVE__:__46,XX TRUE HERMAPHRODITISM, SRY-POSITIVE, INCLUDED;; OVOTESTICULAR DISORDER OF SEX DEVELOPMENT, INCLUDED;; OVOTESTICULAR DSD, INCLUDED
Asterisk__:__400046__:__PHOSPHOLIPASE C, PHOSPHATIDYLINOSITOL-SPECIFIC, X DOMAIN-CONTAINING PROTEIN 1, Y-LINKED__:__PLCXD1Y;; PIPLC X DOMAIN-CONTAINING PROTEIN 1, Y-LINKED__:__
Asterisk__:__402500__:__ACETYLSEROTONIN METHYLTRANSFERASE, Y-CHROMOSOMAL; ASMT__:__ASMTY;; HYDROXYINDOLE-O-METHYLTRANSFERASE, Y-CHROMOSOMAL; HIOMTY__:__
Asterisk__:__403000__:__ADENINE NUCLEOTIDE TRANSLOCATOR 3, Y-CHROMOSOMAL; ANT3Y__:____:__
Asterisk__:__410000__:__AMELOGENIN, Y-CHROMOSOMAL; AMELY__:__AMGY;; AMELOGENIN-LIKE; AMGL__:__
Number Sign__:__415000__:__SPERMATOGENIC FAILURE, Y-LINKED, 2; SPGFY2__:__SPERMATOGENIC FAILURE, NONOBSTRUCTIVE, Y-LINKED;; AZOOSPERMIA, NONOBSTRUCTIVE, Y-LINKED;; OLIGOZOOSPERMIA, NONOBSTRUCTIVE, Y-LINKED;; OLIGOSPERMIA, NONOBSTRUCTIVE, Y-LINKED;; SPERMATOGENIC ARREST, Y-LINKED__:__AZOOSPERMIA FACTOR REGIONS, INCLUDED;; AZF REGIONS, INCLUDED
Caret__:__424000__:__REMOVED FROM DATABASE__:____:__
NULL__:__424500__:__GONADOBLASTOMA; GBY__:____:__
Asterisk__:__425000__:__GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR, ALPHA SUBUNIT, Y-CHROMOSOMAL; CSF2RY__:____:__
NULL__:__425500__:__HAIRY EARS, Y-LINKED__:__HYPERTRICHOSIS PINNAE AURIS, Y-LINKED__:__
Asterisk__:__426000__:__LYSINE-SPECIFIC DEMETHYLASE 5D; KDM5D__:__JUMONJI, AT-RICH INTERACTIVE DOMAIN 1D; JARID1D;; SELECTED cDNA ON Y, MOUSE, HOMOLOG OF; SMCY;; HISTOCOMPATIBILITY Y ANTIGEN; HY; HYA;; H-Y ANTIGEN__:__
Asterisk__:__430000__:__INTERLEUKIN 3 RECEPTOR, Y-CHROMOSOMAL; IL3RA__:__IL3RY;; IL3RAY__:__
Asterisk__:__450000__:__CD99 ANTIGEN, Y CHROMOSOME__:__MIC2 SURFACE ANTIGEN, Y CHROMOSOME; MIC2Y;; CELL SURFACE ANTIGEN 12E7, Y CHROMOSOME;; CELL SURFACE ANTIGEN HBA-71, Y CHROMOSOME; HBA71;; E2 ANTIGEN, Y CHROMOSOME;; CELL SURFACE ANTIGEN O13, Y CHROMOSOME__:__
Asterisk__:__465000__:__A-KINASE ANCHOR PROTEIN 17A, Y-CHROMOSOMAL; AKAP17A__:__SPLICING FACTOR, ARGININE/SERINE RICH, 17A, Y-CHROMOSOMAL; SFRS17A;; PSEUDOAUTOSOMAL GENE XE7, Y-CHROMOSOMAL; XE7Y__:__
Asterisk__:__470000__:__RIBOSOMAL PROTEIN S4, Y-LINKED, 1; RPS4Y1__:____:__
Percent__:__475000__:__GROWTH CONTROL, Y-CHROMOSOME INFLUENCED; GCY__:__STATURE; STA;; TOOTH SIZE; TS; TSY__:__
Asterisk__:__480000__:__SEX-DETERMINING REGION Y; SRY__:__TESTIS-DETERMINING FACTOR; TDF;; TESTIS-DETERMINING FACTOR ON Y; TDY__:__
Asterisk__:__480100__:__TESTIS-SPECIFIC PROTEIN, Y-LINKED, 1; TSPY1__:__TSPY__:__
Caret__:__488000__:__MOVED TO 475000__:____:__
NULL__:__489000__:__UBIQUITIN-ACTIVATING ENZYME, Y-LINKED__:__UBE1Y__:__
Asterisk__:__489500__:__XG REGULATOR; XGR__:__XG AND MIC2 EXPRESSION ON ERYTHROCYTES__:__
Asterisk__:__490000__:__ZINC FINGER PROTEIN, Y-LINKED; ZFY__:____:__
Number Sign__:__500000__:__CARDIOMYOPATHY, INFANTILE HISTIOCYTOID__:__CARDIOMYOPATHY, INFANTILE XANTHOMATOUS;; CARDIOMYOPATHY, FOCAL LIPID;; CARDIOMYOPATHY, ONCOCYTIC;; FOAMY MYOCARDIAL TRANSFORMATION OF INFANCY__:__
Number Sign__:__500001__:__LEBER OPTIC ATROPHY AND DYSTONIA__:__LEBER HEREDITARY OPTIC NEUROPATHY WITH DYSTONIA; LDYT;; DYSTONIA, FAMILIAL, WITH VISUAL FAILURE AND STRIATAL LUCENCIES;; MARSDEN SYNDROME__:__
Number Sign__:__500002__:__MITOCHONDRIAL MYOPATHY WITH DIABETES__:__MITOCHONDRIAL MYOPATHY, LIPID TYPE__:__
Number Sign__:__500003__:__STRIATONIGRAL DEGENERATION, INFANTILE, MITOCHONDRIAL__:__BILATERAL STRIATAL NECROSIS, INFANTILE, MITOCHONDRIAL;; INFANTILE BILATERAL STRIATAL NECROSIS, MITOCHONDRIAL__:__
Number Sign__:__500004__:__RETINITIS PIGMENTOSA-DEAFNESS SYNDROME__:__RETINITIS PIGMENTOSA 8, FORMERLY; RP8, FORMERLY;; RETINITIS PIGMENTOSA 21, FORMERLY; RP21, FORMERLY__:__
Number Sign__:__500005__:__HYPOMAGNESEMIA, HYPERTENSION, AND HYPERCHOLESTEROLEMIA, MITOCHONDRIAL__:____:__
Number Sign__:__500006__:__CARDIOMYOPATHY, INFANTILE HYPERTROPHIC__:____:__
Number Sign__:__500007__:__CYCLIC VOMITING SYNDROME; CVS__:____:__CYCLIC VOMITING SYNDROME WITH NEUROMUSCULAR DISEASE, INCLUDED;; CYCLIC VOMITING SYNDROME-PLUS, INCLUDED;; CVS-PLUS, INCLUDED
Number Sign__:__500008__:__DEAFNESS, NONSYNDROMIC SENSORINEURAL, MITOCHONDRIAL__:____:__
Number Sign__:__500009__:__MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT; MMIT__:__MITOCHONDRIAL MYOPATHY, INFANTILE, TRANSIENT, DUE TO RESPIRATORY CHAIN DEFICIENCY;; COX DEFICIENCY MYOPATHY, INFANTILE, TRANSIENT;; RESPIRATORY CHAIN DEFICIENCY, INFANTILE, TRANSIENT__:__
Number Sign__:__500010__:__ATAXIA AND POLYNEUROPATHY, ADULT-ONSET__:____:__
Number Sign__:__500011__:__MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 3; MLASA3__:____:__
Number Sign__:__500014__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, MITOCHONDRIAL TYPE 1; MC1DM1__:____:__
Number Sign__:__502000__:__AGING__:____:__
Number Sign__:__502500__:__ALZHEIMER DISEASE, SUSCEPTIBILITY TO, MITOCHONDRIAL__:____:__
Caret__:__510000__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__515000__:__CHLORAMPHENICOL TOXICITY__:__ANEMIA, CHLORAMPHENICOL-INDUCED__:__CHLORAMPHENICOL RESISTANCE, INCLUDED
Asterisk__:__516000__:__COMPLEX I, SUBUNIT ND1; MTND1__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND1;; NADH DEHYDROGENASE, SUBUNIT 1__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, MITOCHONDRIAL TYPE 3, INCLUDED; MC1DM3, INCLUDED
Asterisk__:__516001__:__COMPLEX I, SUBUNIT ND2; MTND2__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND2;; NADH DEHYDROGENASE, SUBUNIT 2__:__
Asterisk__:__516002__:__COMPLEX I, SUBUNIT ND3; MTND3__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND3;; NADH DEHYDROGENASE, SUBUNIT 3__:__
Asterisk__:__516003__:__COMPLEX I, SUBUNIT ND4; MTND4__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND4;; NADH DEHYDROGENASE, SUBUNIT 4__:__
Asterisk__:__516004__:__COMPLEX I, SUBUNIT ND4L; MTND4L__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND4L;; NADH DEHYDROGENASE, SUBUNIT 4L__:__
Asterisk__:__516005__:__COMPLEX I, SUBUNIT ND5; MTND5__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND5;; NADH DEHYDROGENASE, SUBUNIT 5__:__
Asterisk__:__516006__:__COMPLEX I, SUBUNIT ND6; MTND6__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT ND6;; NADH DEHYDROGENASE, SUBUNIT 6__:__
Asterisk__:__516020__:__CYTOCHROME b OF COMPLEX III; MTCYB__:__COMPLEX III, CYTOCHROME b SUBUNIT;; UBIQUINONE-CYTOCHROME c OXIDOREDUCTASE, CYTOCHROME b SUBUNIT__:__
Asterisk__:__516030__:__COMPLEX IV, CYTOCHROME c OXIDASE SUBUNIT I; MTCO1__:__CYTOCHROME c OXIDASE I; CO1; COX1__:__
Asterisk__:__516040__:__COMPLEX IV, CYTOCHROME c OXIDASE SUBUNIT II; MTCO2__:__CYTOCHROME c OXIDASE II; COII; COX2__:__
Asterisk__:__516050__:__CYTOCHROME c OXIDASE III; MTCO3__:__COMPLEX IV, CYTOCHROME c OXIDASE SUBUNIT III; COIII__:__
Plus__:__516060__:__ATP SYNTHASE 6; MTATP6__:__COMPLEX V, ATP SYNTHASE, SUBUNIT ATPase 6; ATP6__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, MITOCHONDRIAL TYPE 1, INCLUDED; MC5DM1, INCLUDED
Plus__:__516070__:__ATP SYNTHASE 8; MTATP8__:__COMPLEX V, ATP SYNTHASE, SUBUNIT ATPase 8; ATP8__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, MITOCHONDRIAL TYPE 2, INCLUDED; MC5DM2, INCLUDED;; BRAIN PSEUDOATROPHY, REVERSIBLE, VALPROATE-INDUCED, SUSCEPTIBILITY TO, INCLUDED;; CARDIOMYOPATHY, APICAL HYPERTROPHIC, AND NEUROPATHY, INCLUDED
Number Sign__:__520000__:__DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD__:__DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS__:__
Number Sign__:__520100__:__DIARRHEA, CHRONIC, WITH VILLOUS ATROPHY__:____:__
Number Sign__:__530000__:__KEARNS-SAYRE SYNDROME; KSS__:__OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS__:__
Number Sign__:__535000__:__LEBER OPTIC ATROPHY__:__LEBER HEREDITARY OPTIC NEUROPATHY; LHON__:__
Number Sign__:__540000__:__MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS__:__MELAS SYNDROME__:__
Number Sign__:__545000__:__MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF__:__MERRF SYNDROME__:__
Caret__:__550000__:__MOVED TO 157640__:____:__
Number Sign__:__550500__:__MYOGLOBINURIA, RECURRENT__:____:__
Caret__:__550900__:__MOVED TO 603041__:____:__
Number Sign__:__551000__:__MITOCHONDRIAL MYOPATHY, LETHAL, INFANTILE; LIMM__:____:__
Number Sign__:__551200__:__NEPHROPATHY, CHRONIC TUBULOINTERSTITIAL__:____:__
Number Sign__:__551500__:__NEUROPATHY, ATAXIA, AND RETINITIS PIGMENTOSA__:__NARP SYNDROME__:__
Number Sign__:__553000__:__ONCOCYTOMA__:____:__
Caret__:__555000__:__MOVED TO 607313__:____:__
Number Sign__:__556500__:__PARKINSON DISEASE, MITOCHONDRIAL__:____:__
Number Sign__:__557000__:__PEARSON MARROW-PANCREAS SYNDROME__:__SIDEROBLASTIC ANEMIA WITH MARROW CELL VACUOLIZATION AND EXOCRINE PANCREATIC DYSFUNCTION__:__
Number Sign__:__560000__:__RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA__:____:__
Asterisk__:__561000__:__RIBOSOMAL RNA, MITOCHONDRIAL, 12S; MTRNR1__:__rRNA, 12S, MITOCHONDRIAL__:__
Asterisk__:__561010__:__RIBOSOMAL RNA, MITOCHONDRIAL, 16S; MTRNR2__:__rRNA, 16S, MITOCHONDRIAL__:__HUMANIN, INCLUDED; HN, INCLUDED;; HUMANIN, MITOCHONDRIAL, INCLUDED;; HNM, INCLUDED
Number Sign__:__580000__:__DEAFNESS, AMINOGLYCOSIDE-INDUCED__:__DEAFNESS, STREPTOMYCIN-INDUCED;; STREPTOMYCIN OTOTOXICITY__:__
Asterisk__:__590000__:__TRANSFER RNA, MITOCHONDRIAL, ALANINE; MTTA__:__tRNA-ALA, MITOCHONDRIAL__:__
Asterisk__:__590005__:__TRANSFER RNA, MITOCHONDRIAL, ARGININE; MTTR__:__tRNA-ARG, MITOCHONDRIAL__:__
Asterisk__:__590010__:__TRANSFER RNA, MITOCHONDRIAL, ASPARAGINE; MTTN__:__tRNA-ASN, MITOCHONDRIAL__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, MITOCHONDRIAL TYPE 2, INCLUDED; MC1DM2, INCLUDED
Asterisk__:__590015__:__TRANSFER RNA, MITOCHONDRIAL, ASPARTIC ACID; MTTD__:__tRNA-ASP, MITOCHONDRIAL__:__
Asterisk__:__590020__:__TRANSFER RNA, MITOCHONDRIAL, CYSTEINE; MTTC__:__tRNA-CYS, MITOCHONDRIAL__:__
Asterisk__:__590025__:__TRANSFER RNA, MITOCHONDRIAL, GLUTAMIC ACID; MTTE__:__tRNA-GLU, MITOCHONDRIAL__:__
Asterisk__:__590030__:__TRANSFER RNA, MITOCHONDRIAL, GLUTAMINE; MTTQ__:__tRNA-GLN, MITOCHONDRIAL__:__
Asterisk__:__590035__:__TRANSFER RNA, MITOCHONDRIAL, GLYCINE; MTTG__:__tRNA-GLY, MITOCHONDRIAL__:__
Asterisk__:__590040__:__TRANSFER RNA, MITOCHONDRIAL, HISTIDINE; MTTH__:__tRNA-HIS, MITOCHONDRIAL__:__
Asterisk__:__590045__:__TRANSFER RNA, MITOCHONDRIAL, ISOLEUCINE; MTTI__:__tRNA-ILE, MITOCHONDRIAL__:__
Asterisk__:__590050__:__TRANSFER RNA, MITOCHONDRIAL, LEUCINE, 1; MTTL1__:__tRNA-LEU, MITOCHONDRIAL, 1__:__
Asterisk__:__590055__:__TRANSFER RNA, MITOCHONDRIAL, LEUCINE, 2; MTTL2__:__tRNA-LEU, MITOCHONDRIAL, 2__:__
Asterisk__:__590060__:__TRANSFER RNA, MITOCHONDRIAL, LYSINE; MTTK__:__tRNA-LYS, MITOCHONDRIAL__:__
Asterisk__:__590065__:__TRANSFER RNA, MITOCHONDRIAL, METHIONINE; MTTM__:__tRNA-MET, MITOCHONDRIAL__:__
Asterisk__:__590070__:__TRANSFER RNA, MITOCHONDRIAL, PHENYLALANINE; MTTF__:__tRNA-PHE, MITOCHONDRIAL__:__
Asterisk__:__590075__:__TRANSFER RNA, MITOCHONDRIAL, PROLINE; MTTP__:__tRNA-PRO, MITOCHONDRIAL__:__
Asterisk__:__590080__:__TRANSFER RNA, MITOCHONDRIAL, SERINE, 1; MTTS1__:__tRNA-SER, MITOCHONDRIAL, 1__:__
Asterisk__:__590085__:__TRANSFER RNA, MITOCHONDRIAL, SERINE, 2; MTTS2__:__tRNA-SER, MITOCHONDRIAL, 2__:__
Asterisk__:__590090__:__TRANSFER RNA, MITOCHONDRIAL, THREONINE; MTTT__:__tRNA-THR, MITOCHONDRIAL__:__
Asterisk__:__590095__:__TRANSFER RNA, MITOCHONDRIAL, TRYPTOPHAN; MTTW__:__tRNA-TRP, MITOCHONDRIAL__:__
Asterisk__:__590100__:__TRANSFER RNA, MITOCHONDRIAL, TYROSINE; MTTY__:__tRNA-TYR, MITOCHONDRIAL__:__
Asterisk__:__590105__:__TRANSFER RNA, MITOCHONDRIAL, VALINE; MTTV__:__tRNA-VAL, MITOCHONDRIAL__:__
Number Sign__:__598500__:__WOLFRAM SYNDROME, MITOCHONDRIAL FORM__:__DIABETES INSIPIDUS AND MELLITUS WITH OPTIC ATROPHY AND DEAFNESS, MITOCHONDRIAL FORM;; DIDMOAD SYNDROME, MITOCHONDRIAL FORM__:__
NULL__:__600000__:__SPONDYLOCAMPTODACTYLY__:__CAMPTODACTYLY WITH CERVICAL PLATYSPONDYLY__:__
Number Sign__:__600001__:__HEART DEFECTS, CONGENITAL, AND OTHER CONGENITAL ANOMALIES; HDCA__:__PANCREATIC HYPOPLASIA, CONGENITAL, WITH DIABETES MELLITUS AND CONGENITAL HEART DISEASE;; PANCREATIC AGENESIS AND CONGENITAL HEART DEFECTS; PACHD__:__
Number Sign__:__600002__:__EIKEN SYNDROME__:__EIKEN SKELETAL DYSPLASIA;; BONE MODELING DEFECT OF HANDS AND FEET__:__
Asterisk__:__600003__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA-2 SUBUNIT; CACNB2__:__Ca(V) BETA-2; CAVB2;; MYASTHENIC SYNDROME ANTIGEN B; MYSB;; LAMBERT-EATON MYASTHENIC SYNDROME ANTIGEN__:__
Asterisk__:__600004__:__EPHRIN RECEPTOR EphA5; EPHA5__:__HEK7;; EPH HOMOLOGY KINASE 1, RAT, HOMOLOG OF;; EHK1, RAT, HOMOLOG OF;; BSK, MOUSE, HOMOLOG OF;; TYRO4__:__
Asterisk__:__600005__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, TRANSACTIVATOR; MHC2TA__:__MHC CLASS II TRANSACTIVATOR;; CLASS II TRANSACTIVATOR; C2TA; CIITA__:__
Asterisk__:__600006__:__REGULATORY FACTOR X, 1; RFX1__:____:__
Asterisk__:__600007__:__FMS-RELATED TYROSINE KINASE 3 LIGAND; FLT3LG__:__FLT3 LIGAND; FL; FLT3L__:__
Asterisk__:__600008__:__NICOTINAMIDE N-METHYLTRANSFERASE; NNMT__:____:__
Asterisk__:__600009__:__INTERFERON-ALPHA-INDUCIBLE PROTEIN 27; IFI27__:__INTERFERON-STIMULATED GENE 12; ISG12;; ISG12A__:__
Asterisk__:__600010__:__INSULINOMA-ASSOCIATED 1; INSM1__:__IA1__:__
Asterisk__:__600011__:__EPHRIN RECEPTOR EphB4; EPHB4__:__HEPATOMA TRANSMEMBRANE KINASE; HTK;; MYK, MOUSE, HOMOLOG OF; MYK1;; TYRO11__:__
Asterisk__:__600012__:__UBIQUITIN-CONJUGATING ENZYME E2L 1; UBE2L1__:__UBIQUITIN-CONJUGATING ENZYME L-UBC; UBCL;; UBC4, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__600013__:__TRANSCRIPTION FACTOR YY1; YY1__:__YIN YANG 1__:__
Asterisk__:__600014__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 2; SMARCA2__:__SUCROSE NONFERMENTING, YEAST, HOMOLOG-LIKE 2; SNF2L2;; SNF2-LIKE 2;; SNF2/SWI2, YEAST, HOMOLOG OF;; BRM, DROSOPHILA, HOMOLOG OF; BRM__:__
Caret__:__600015__:__MOVED TO 106165__:____:__
Asterisk__:__600016__:__CONTACTIN 1; CNTN1__:____:__
Asterisk__:__600017__:__SYNDECAN 4; SDC4__:__SYND4;; RYUDOCAN;; AMPHIGLYCAN__:__
Asterisk__:__600018__:__OPIOID RECEPTOR, MU-1; OPRM1__:__OPRM;; MU OPIOID RECEPTOR; MOR;; MOR1__:__
Asterisk__:__600019__:__CYTOCHROME b561; CYB561__:____:__
Asterisk__:__600020__:__MAX-INTERACTING PROTEIN 1; MXI1__:____:__
Asterisk__:__600021__:__MAX DIMERIZATION PROTEIN 1; MXD1__:__MAD1;; BHLHC58__:__
Asterisk__:__600022__:__PROSTAGLANDIN I2 RECEPTOR; PTGIR__:__PROSTANOID IP RECEPTOR; PRIPR;; PROSTACYCLIN RECEPTOR__:__
Asterisk__:__600023__:__CADHERIN 11; CDH11__:__CADHERIN, OSTEOBLAST;; OB-CADHERIN; CDHOB__:__
Asterisk__:__600024__:__LAMIN B RECEPTOR; LBR__:__LMN2R__:__
Asterisk__:__600025__:__KINESIN LIGHT CHAIN 1; KLC1__:__KINESIN 2; KNS2;; KNS2A;; KLC__:__
Asterisk__:__600026__:__SYNTROPHIN, BETA-1; SNTB1__:__SNT2B1;; DYSTROPHIN-ASSOCIATED PROTEIN, BASIC A1; A1B;; DAPA1B__:__
Asterisk__:__600027__:__SYNTROPHIN, BETA-2; SNTB2__:__SNT2B2;; SYNTROPHIN-LIKE; SNTL__:__
Asterisk__:__600028__:__DISTAL-LESS HOMEOBOX 5; DLX5__:____:__
Asterisk__:__600029__:__DISTAL-LESS HOMEOBOX 1; DLX1__:____:__
Asterisk__:__600030__:__DISTAL-LESS HOMEOBOX 6; DLX6__:____:__
Asterisk__:__600031__:__CHITINASE 1; CHIT1__:__CHITINASE, MACROPHAGE; CHIT;; CHITOTRIOSIDASE;; METHYLUMBELLIFERYL-TETRA-N-ACETYLCHITOTETRAOSIDE HYDROLASE__:__
Caret__:__600032__:__MOVED TO 182455__:____:__
Asterisk__:__600033__:__TISSUE FACTOR PATHWAY INHIBITOR 2; TFPI2__:__PLACENTAL PROTEIN 5; PP5;; RETINAL PIGMENT EPITHELIUM CELL FACTOR 1; REF1__:__
Asterisk__:__600034__:__EMPTY SPIRACLES, DROSOPHILA, HOMOLOG OF, 1; EMX1__:____:__
Asterisk__:__600035__:__EMPTY SPIRACLES, DROSOPHILA, 2, HOMOLOG OF; EMX2__:____:__
Asterisk__:__600036__:__ORTHODENTICLE, DROSOPHILA, HOMOLOG OF, 1; OTX1__:____:__
Asterisk__:__600037__:__ORTHODENTICLE, DROSOPHILA, HOMOLOG OF, 2; OTX2__:____:__
Asterisk__:__600038__:__MEGAKARYOCTYE-ASSOCIATED TYROSINE KINASE; MATK__:__HEMATOPOIETIC CONSENSUS TYROSINE-LACKING KINASE; HYL;; CSK-TYPE PROTEIN TYROSINE KINASE; CTK__:__
Asterisk__:__600039__:__BCL2-LIKE 1; BCL2L1__:__BCL2-RELATED GENE; BCLX__:__BCL2-RELATED PROTEIN, LONG ISOFORM, INCLUDED; BCLXL, INCLUDED;; BCL2-RELATED PROTEIN, SHORT ISOFORM, INCLUDED; BCLXS, INCLUDED
Asterisk__:__600040__:__BCL2-ASSOCIATED X PROTEIN; BAX__:____:__
Asterisk__:__600041__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 2; P2RY2__:__PURINOCEPTOR P2Y2; P2Y2; P2Y2R;; P2U NUCLEOTIDE RECEPTOR; P2UR__:__
Asterisk__:__600042__:__MELANOCORTIN 5 RECEPTOR; MC5R__:__MC5 RECEPTOR__:__
Asterisk__:__600043__:__SULFOTRANSFERASE FAMILY 1E, ESTROGEN-PREFERRING, MEMBER 1; SULT1E1__:__SULFOTRANSFERASE, ESTROGEN-PREFERRING; STE;; ESTROGEN SULFOTRANSFERASE, LIVER; EST__:__ARYL SULFOTRANSFERASE, INCLUDED
Asterisk__:__600044__:__THROMBOPOIETIN; THPO__:__TPO;; MYELOPROLIFERATIVE LEUKEMIA VIRUS ONCOGENE LIGAND;; MPL LIGAND;; MEGAKARYOCYTE COLONY-STIMULATING FACTOR; MKCSF;; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MGDF__:__
Asterisk__:__600045__:__DNA DAMAGE-BINDING PROTEIN 1; DDB1__:__DDB, p127 SUBUNIT__:__
Plus__:__600046__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1; ABCA1__:__ATP-BINDING CASSETTE 1; ABC1;; ATP-BINDING CASSETTE TRANSPORTER 1;; ABC TRANSPORTER 1;; CHOLESTEROL EFFLUX REGULATORY PROTEIN; CERP__:__CORONARY HEART DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA, PROTECTION AGAINST, INCLUDED;; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED
Asterisk__:__600047__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 2; ABCA2__:__ATP-BINDING CASSETTE 2; ABC2;; ATP-BINDING CASSETTE TRANSPORTER 2;; ABC TRANSPORTER 2;; KIAA1062__:__
Caret__:__600048__:__MOVED TO 114480__:____:__
Asterisk__:__600049__:__MDS1 GENE; MDS1__:____:__MDS1/AML1 FUSION GENE, INCLUDED
Asterisk__:__600050__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11; MAP3K11__:__MIXED-LINEAGE PROTEIN KINASE 3; MLK3;; PROTEIN-TYROSINE KINASE PTK1; PTK1__:__
Asterisk__:__600051__:__EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; EPS15__:__ALL1-FUSED GENE FROM CHROMOSOME 1; AF1P__:__
Asterisk__:__600052__:__APELIN RECEPTOR; APLNR__:__APJ PUTATIVE RECEPTOR PROTEIN RELATED TO ANGIOTENSIN RECEPTOR; APJR;; ANGIOTENSIN RECEPTOR-LIKE 1; AGTRL1__:__
Asterisk__:__600053__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, ALPHA-3; CNGA3__:__CONE PHOTORECEPTOR cGMP-GATED CHANNEL;; CYCLIC NUCLEOTIDE-GATED CHANNEL, OLFACTORY, 3; CNG3__:__
Caret__:__600054__:__MOVED TO 300338__:____:__
Caret__:__600055__:__MOVED TO 426000__:____:__
Caret__:__600056__:__MOVED TO 314690__:____:__
Percent__:__600057__:__EXSTROPHY OF BLADDER__:____:__BLADDER EXSTROPHY AND EPISPADIAS COMPLEX, INCLUDED; BEEC, INCLUDED
Asterisk__:__600058__:__PROTEIN TYROSINE KINASE TXK; TXK__:__RESTING LYMPHOCYTE KINASE; RLK__:__
Number Sign__:__600059__:__RETINITIS PIGMENTOSA 13; RP13__:____:__
Number Sign__:__600060__:__DEAFNESS, AUTOSOMAL RECESSIVE 2; DFNB2__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 2; NSRD2__:__
Asterisk__:__600061__:__RAD23, YEAST, HOMOLOG OF, A; RAD23A__:__HHR23A__:__
Asterisk__:__600062__:__RAD23, YEAST, HOMOLOG OF, B; RAD23B__:__HHR23B;; HR23B__:__
Asterisk__:__600063__:__TROVE DOMAIN FAMILY, MEMBER 2; TROVE2__:__AUTOANTIGEN Ro/SSA, 60-KD; RO60;; SJOGREN SYNDROME ANTIGEN A2; SSA2__:__
Asterisk__:__600064__:__KERATIN-ASSOCIATED PROTEIN 11-1; KRTAP11-1__:__HAIR FOLLICLE-SPECIFIC GENE 1; HACL1__:__
Asterisk__:__600065__:__INTEGRIN, BETA-2; ITGB2__:__LEUKOCYTE CELL ADHESION MOLECULE CD18; CD18__:__LEUKOCYTE-ASSOCIATED ANTIGENS CD18/11A, CD18/11B, CD18/11C, INCLUDED
Asterisk__:__600066__:__EPHRIN RECEPTOR EphA6; EPHA6__:__HEK12;; EPH HOMOLOGY KINASE 2, RAT, HOMOLOG OF;; EHK2, RAT, HOMOLOG OF__:__
Asterisk__:__600067__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B4; UGT2B4__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B4;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B4;; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B11, FORMERLY;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B11, FORMERLY; UGT2B11, FORMERLY__:__
Asterisk__:__600068__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B7; UGT2B7__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B7;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B7;; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B9;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B9; UGT2B9__:__
Asterisk__:__600069__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B15; UGT2B15__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B15;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B15;; URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B8;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B8; UGT2B8__:__
Asterisk__:__600070__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B10; UGT2B10__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B10;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B10__:__
Caret__:__600071__:__MOVED TO 600067__:____:__
Number Sign__:__600072__:__FATAL FAMILIAL INSOMNIA; FFI__:__INSOMNIA, FATAL FAMILIAL__:__
Asterisk__:__600073__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 2; LRP2__:__GLYCOPROTEIN 330;; MEGALIN__:__
Asterisk__:__600074__:__CD24 ANTIGEN; CD24__:____:__
Asterisk__:__600075__:__TATA BOX-BINDING PROTEIN; TBP__:__SCA17 GENE__:__
Asterisk__:__600076__:__TENSIN 1; TNS1__:__TENSIN; TNS__:__
Caret__:__600077__:__MOVED TO 224750__:____:__
Caret__:__600078__:__MOVED TO 300012__:____:__
Asterisk__:__600079__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 12; PTPN12__:__PROTEIN-TYROSINE PHOSPHATASE G1; PTPG1;; PTP-PEST__:__
NULL__:__600080__:__MYELOCYTIC LEUKEMIA-LIKE SYNDROME, FAMILIAL, CHRONIC__:__CML-LIKE SYNDROME, FAMILIAL__:__
Number Sign__:__600081__:__VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B; VDDR1B__:__VITAMIN D-DEPENDENT RICKETS, TYPE 1B;; 25-HYDROXYVITAMIN D3 DEFICIENCY, SELECTIVE;; PSEUDOVITAMIN D3 DEFICIENCY RICKETS DUE TO 25-HYDROXYLASE DEFICIENCY__:__
Percent__:__600082__:__PROSTATIC HYPERPLASIA, BENIGN; BPH__:____:__
Caret__:__600083__:__MOVED TO 300144__:____:__
NULL__:__600084__:__MACROCYTOSIS, FAMILIAL__:____:__
Asterisk__:__600085__:__PROTEIN-TYROSINE KINASE SYK; SYK__:__SPLEEN TYROSINE KINASE__:__
Asterisk__:__600086__:__ALCOHOL DEHYDROGENASE 7; ADH7__:__ADH, CLASS IV__:__
Asterisk__:__600087__:__TUFTELIN; TUFT1__:____:__
Caret__:__600088__:__MOVED TO 113810__:____:__
NULL__:__600089__:__PANCREATIC BETA CELL AGENESIS WITH NEONATAL DIABETES MELLITUS__:____:__
Caret__:__600090__:__MOVED TO 300013__:____:__
Caret__:__600091__:__MOVED TO 158600__:____:__
NULL__:__600092__:__CHONDRODYSPLASIA-PSEUDOHERMAPHRODITISM SYNDROME__:____:__
NULL__:__600093__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA WITH CHARACTERISTIC FACIES__:____:__
Caret__:__600094__:__MOVED TO 300095__:____:__
Caret__:__600095__:__MOVED TO 246560__:____:__
NULL__:__600096__:__PUERTO RICAN INFANT HYPOTONIA SYNDROME__:____:__
Caret__:__600097__:__MOVED TO 300106__:____:__
Asterisk__:__600098__:__RELATED RAS VIRAL ONCOGENE HOMOLOG 2; RRAS2__:__ONCOGENE RRAS2;; TERATOCARCINOMA ONCOGENE TC21; TC21__:__
Caret__:__600099__:__MOVED TO 246530__:____:__
Caret__:__600100__:__MOVED TO 601792__:____:__
Number Sign__:__600101__:__DEAFNESS, AUTOSOMAL DOMINANT 2A; DFNA2A__:____:__
Caret__:__600102__:__MOVED TO 300067__:____:__
Asterisk__:__600103__:__SYNAPTOTAGMIN 4; SYT4__:____:__
Asterisk__:__600104__:__SYNAPTOTAGMIN 2; SYT2__:____:__
Number Sign__:__600105__:__RETINITIS PIGMENTOSA 12; RP12__:__RETINITIS PIGMENTOSA WITH OR WITHOUT PARAARTERIOLAR PRESERVATION OF RETINAL PIGMENT EPITHELIUM;; RP WITH OR WITHOUT PRESERVED PARAARTERIOLE RETINAL PIGMENT EPITHELIUM;; RP WITH OR WITHOUT PPRPE__:__
Asterisk__:__600106__:__INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 40-KD; INPP5A__:____:__
Caret__:__600107__:__MOVED TO 300014__:____:__
Asterisk__:__600108__:__MATRIX METALLOPROTEINASE 13; MMP13__:__COLLAGENASE 3; CLG3__:__
Caret__:__600109__:__MOVED TO 602668__:____:__
Number Sign__:__600110__:__STARGARDT DISEASE 3; STGD3__:__MACULAR DYSTROPHY WITH FLECKS, TYPE 3;; STARGARDT-LIKE MACULAR DYSTROPHY, AUTOSOMAL DOMINANT__:__
Asterisk__:__600111__:__SOLUTE CARRIER FAMILY 1 (GLIAL HIGH AFFINITY GLUTAMATE TRANSPORTER), MEMBER 3; SLC1A3__:__EXCITATORY AMINO ACID TRANSPORTER 1; EAAT1;; GLIAL HIGH AFFINITY GLUTAMATE TRANSPORTER;; GLUTAMATE/ASPARTATE TRANSPORTER, HIGH AFFINITY, SODIUM-DEPENDENT; GLAST1;; GLAST__:__
Asterisk__:__600112__:__DYNEIN, CYTOPLASMIC 1, HEAVY CHAIN 1; DYNC1H1__:__DNCH1;; DYNEIN, CYTOPLASMIC-LIKE; DNCL; DNECL;; DYNEIN HEAVY POLYPEPTIDE, CYTOPLASMIC; DHC1; DHC1A;; DNCHC1__:__
Caret__:__600113__:__MOVED TO 300005__:____:__
Asterisk__:__600114__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 3; CCT3__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 3;; CCT-GAMMA; CCTG;; TCP1 RING COMPLEX, POLYPEPTIDE 5; TRIC5__:__
Caret__:__600115__:__MOVED TO 163260__:____:__
Number Sign__:__600116__:__PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE; PARK2__:__PARKINSON DISEASE, JUVENILE, AUTOSOMAL RECESSIVE; PDJ;; PARKINSONISM, EARLY-ONSET, WITH DIURNAL FLUCTUATION; EPDF__:__
NULL__:__600117__:__DYSPHASIA, FAMILIAL DEVELOPMENTAL__:____:__
Number Sign__:__600118__:__WARBURG MICRO SYNDROME 1; WARBM1__:__MICRO SYNDROME__:__
Asterisk__:__600119__:__SARCOGLYCAN, ALPHA; SGCA__:__ADHALIN; ADL;; DYSTROGLYCAN 2; DAG2;; DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 50-KD;; 50-DAG__:__
Caret__:__600120__:__MOVED TO 186100__:____:__
Number Sign__:__600121__:__RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 3; RCDP3__:__ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE DEFICIENCY;; ALKYLGLYCERONE-PHOSPHATE SYNTHASE DEFICIENCY;; AGPS DEFICIENCY__:__
NULL__:__600122__:__MALE PSEUDOHERMAPHRODITISM/MENTAL RETARDATION SYNDROME, VERLOES TYPE__:__VERLOES SYNDROME__:__
NULL__:__600123__:__ATRIOVENTRICULAR SEPTAL DEFECT WITH BLEPHAROPHIMOSIS AND ANAL AND RADIAL DEFECTS__:____:__
Asterisk__:__600124__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2/B1; HNRNPA2B1__:__HNRPA2B1__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2, INCLUDED; HNRPA2, INCLUDED;; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1, INCLUDED; HNRPB1, INCLUDED
Caret__:__600125__:__MOVED TO 126065__:____:__
Asterisk__:__600126__:__PHOSPHODIESTERASE 4A, cAMP-SPECIFIC; PDE4A__:__DUNCE-LIKE PHOSPHODIESTERASE E2, FORMERLY; DPDE2, FORMERLY__:__
Asterisk__:__600127__:__PHOSPHODIESTERASE 4B, cAMP-SPECIFIC; PDE4B__:__DUNCE-LIKE PHOSPHODIESTERASE E4, FORMERLY; DPDE4, FORMERLY__:__
Asterisk__:__600128__:__PHOSPHODIESTERASE 4C, cAMP-SPECIFIC; PDE4C__:__DUNCE-LIKE PHOSPHODIESTERASE E1, FORMERLY; DPDE1, FORMERLY__:__
Asterisk__:__600129__:__PHOSPHODIESTERASE 4D, cAMP-SPECIFIC; PDE4D__:__DUNCE-LIKE PHOSPHODIESTERASE E3, FORMERLY; DPDE3, FORMERLY__:__
Asterisk__:__600130__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE 1; APOBEC1__:__BEDP__:__
Percent__:__600131__:__EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 1; ECA1__:____:__
Number Sign__:__600132__:__RETINITIS PIGMENTOSA 14; RP14__:____:__
Asterisk__:__600133__:__LAMININ, ALPHA-4; LAMA4__:__LAMA3, FORMERLY__:__
Caret__:__600134__:__MOVED TO 605158__:____:__
Asterisk__:__600135__:__CORTEXIN 1; CTXN1__:__CTXN__:__
Asterisk__:__600136__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9; MAP3K9__:__MIXED-LINEAGE KINASE 1; MLK1__:__
Asterisk__:__600137__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 10; MAP3K10__:__MIXED-LINEAGE KINASE 2; MLK2;; MKN28 KINASE;; SERINE/THREONINE KINASE, MKN28-DERIVED, NONRECEPTOR-TYPE; MST__:__
Number Sign__:__600138__:__RETINITIS PIGMENTOSA 11; RP11__:____:__
Caret__:__600139__:__MOVED TO 137800__:____:__
Asterisk__:__600140__:__CREB-BINDING PROTEIN; CREBBP__:__CBP__:__CBP/MOZ FUSION GENE, INCLUDED
Asterisk__:__600141__:__HEAT-SHOCK 10-KD PROTEIN; HSPE1__:__CHAPERONIN 10 HOMOLOG;; cpn10 HOMOLOG;; GroES HOMOLOG; GroES;; HSP10__:__
Number Sign__:__600142__:__CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY; CARASIL__:__MAEDA SYNDROME;; SUBCORTICAL VASCULAR ENCEPHALOPATHY, PROGRESSIVE;; CEREBROVASCULAR DISEASE WITH THIN SKIN, ALOPECIA, AND DISC DISEASE__:__
Number Sign__:__600143__:__CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8__:____:__
Asterisk__:__600144__:__INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR, TYPE 2; ITPR2__:____:__
Number Sign__:__600145__:__SACRAL DEFECT WITH ANTERIOR MENINGOCELE__:__SDAM__:__CAUDAL DYSGENESIS SYNDROME, INCLUDED;; CAUDAL REGRESSION SYNDROME, INCLUDED;; SACRAL AGENESIS, INCLUDED;; SIRENOMELIA, INCLUDED
Caret__:__600146__:__MOVED TO 270800__:____:__
Asterisk__:__600147__:__MESENCHYME HOMEOBOX 1; MEOX1__:__MOX1 DIVERGED HOMEOBOX GENE;; MOX1, MOUSE, HOMOLOG OF__:__
NULL__:__600148__:__GLYCEROL KINASE 2; GK2__:__GLYCEROL KINASE, TESTICULAR, TYPE A; GKTA;; GLYCEROL KINASE PSEUDOGENE 2; GKP2__:__
NULL__:__600149__:__GLYCEROL KINASE 3 PSEUDOGENE; GK3P__:__GLYCEROL KINASE, TESTICULAR, TYPE B; GKTB;; GKP3__:__
Asterisk__:__600150__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, SUBFAMILY M, ALPHA MEMBER 1; KCNMA1__:__SLOWPOKE, DROSOPHILA, HOMOLOG OF; SLO;; SLO1;; SLO-ALPHA resulting in__:__
Number Sign__:__600151__:__BARDET-BIEDL SYNDROME 3; BBS3__:____:__
Asterisk__:__600152__:__SEC13-LIKE PROTEIN 1; SEC13L1__:__SEC13, YEAST, HOMOLOG OF; SEC13;; SEC13-RELATED PROTEIN; SEC13R;; D3S1231E__:__
Asterisk__:__600153__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS F PROTEIN; PIGF__:____:__
Asterisk__:__600154__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS H PROTEIN; PIGH__:____:__
Number Sign__:__600155__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2; HSCR2__:____:__
Percent__:__600156__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 5; HSCR5__:____:__
Asterisk__:__600157__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, BETA-1 SUBUNIT; AP1B1__:__ADAPTIN, BETA-1; ADTB1;; ADAPTIN, BETA-PRIME;; BETA-ADAPTIN-MENINGIOMA GENE ON CHROMOSOME 22; BAM22__:__
Caret__:__600158__:__MOVED TO 251290__:____:__
NULL__:__600159__:__PTERYGIUM COLLI AND MENTAL RETARDATION WITH FACIAL AND DIGITAL ANOMALIES__:____:__
Asterisk__:__600160__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2A; CDKN2A__:__CDKN2;; CDK4 INHIBITOR;; MULTIPLE TUMOR SUPPRESSOR 1; MTS1;; TP16;; p16(INK4);; p16(INK4A)__:__p14(ARF), INCLUDED;; p12, INCLUDED;; p16-GAMMA, INCLUDED
Asterisk__:__600161__:__PRADER-WILLI/ANGELMAN REGION RNA 1; PWAR1__:__PAR1;; D15S227E__:__
Asterisk__:__600162__:__PRADER-WILLI/ANGELMAN REGION RNA 5; PWAR5__:__PAR5;; D15S226E__:__
Asterisk__:__600163__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE V, ALPHA SUBUNIT; SCN5A__:__NAV1.5__:__
Asterisk__:__600164__:__GTP-BINDING MITOGEN-INDUCED T-CELL PROTEIN; GEM__:__KINASE-INDUCIBLE RAS-LIKE PROTEIN; KIR__:__
Percent__:__600165__:__NANOPHTHALMOS 1; NNO1__:__NANOPHTHALMIA 1;; NANOPHTHALMOS, AUTOSOMAL DOMINANT;; NANOPHTHALMOS WITH HIGH HYPEROPIA AND ANGLE-CLOSURE GLAUCOMA;; MICROPHTHALMOS, SIMPLE, AUTOSOMAL DOMINANT__:__
NULL__:__600166__:__HYPERPARATHYROIDISM, PRIMARY, CAUSED BY WATER CLEAR CELL HYPERPLASIA__:____:__
Asterisk__:__600167__:__HISTAMINE RECEPTOR H1; HRH1__:__BPHS, MOUSE, HOMOLOG OF;; H1R__:__
Asterisk__:__600168__:__MACROPHAGE STIMULATING 1 RECEPTOR; MST1R__:__RON PROTEIN TYROSINE KINASE; RON;; MACROPHAGE STIMULATING PROTEIN RECEPTOR;; MSP RECEPTOR__:__
Asterisk__:__600169__:__MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I CHAIN-RELATED GENE A; MICA__:____:__
Asterisk__:__600170__:__AQUAPORIN 3; AQP3__:____:__
NULL__:__600171__:__GONADAL AGENESIS__:____:__
Asterisk__:__600172__:__METAL-REGULATORY TRANSCRIPTION FACTOR 1; MTF1__:____:__
Asterisk__:__600173__:__JANUS KINASE 3; JAK3__:__JANUS KINASE, LEUKOCYTE; JAKL;; LJAK__:__
Asterisk__:__600174__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, ALPHA; PITPNA__:__PITPN__:__
Number Sign__:__600175__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; HMN8__:__NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIII; DHMN8;; SPINAL MUSCULAR ATROPHY, DISTAL, CONGENITAL NONPROGRESSIVE;; SPINAL MUSCULAR ATROPHY, CONGENITAL BENIGN, WITH CONTRACTURES__:__
Percent__:__600176__:__PACHYGYRIA WITH MENTAL RETARDATION, SEIZURES, AND ARACHNOID CYSTS__:__PACHYGYRIA WITH MENTAL RETARDATION AND SEIZURES__:__
Caret__:__600177__:__MOVED TO 300102__:____:__
Asterisk__:__600178__:__MICROTUBULE-ASSOCIATED PROTEIN 1A; MAP1A__:__MTAP1A__:__
Asterisk__:__600179__:__GUANYLATE CYCLASE 2D, MEMBRANE; GUCY2D__:__GUC2D;; GUANYLATE CYCLASE 2D, RETINAL;; GUCY2E, MOUSE, HOMOLOG OF;; ROD OUTER SEGMENT MEMBRANE GUANYLATE CYCLASE; ROSGC;; RETGC;; RETGC1__:__
Caret__:__600180__:__MOVED TO 108355__:____:__
Asterisk__:__600181__:__LIPOCALIN 2; LCN2__:__NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN; NGAL;; ONCOGENIC LIPOCALIN 24P3;; UTEROCALIN__:__
Asterisk__:__600182__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 5; SLC7A5__:__MEMBRANE PROTEIN E16; E16; MPE16;; L-TYPE AMINO ACID TRANSPORTER 1; LAT1;; ANTIGEN DEFINED BY MONOCLONAL ANTIBODY 4F2, LIGHT CHAIN; 4F2LC;; D16S469E__:__
Asterisk__:__600183__:__DUAL-SPECIFICITY PHOSPHATASE 3; DUSP3__:__VH1-RELATED PHOSPHATASE; VHR;; VACCINIA VIRUS PHOSPHATASE VH1-RELATED__:__
Asterisk__:__600184__:__CARNITINE ACETYLTRANSFERASE; CRAT__:__CAT1__:__
Asterisk__:__600185__:__BRCA2 GENE; BRCA2__:__FANCD1 GENE; FANCD1__:__
Caret__:__600186__:__MOVED TO 300016__:____:__
Asterisk__:__600187__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 5A; EIF5A__:__EIF5A1__:__
Asterisk__:__600188__:__AMINO-TERMINAL ENHANCER OF SPLIT; AES__:__GROUCHO-RELATED GENE 5; GRG5__:__
Asterisk__:__600189__:__TRANSDUCIN-LIKE ENHANCER OF SPLIT 1; TLE1__:__ENHANCER OF SPLIT GROUCHO 1; ESG1;; GROUCHO-RELATED GENE 1; GRG1__:__
Asterisk__:__600190__:__TRANSDUCIN-LIKE ENHANCER OF SPLIT 3; TLE3__:__ENHANCER OF SPLIT GROUCHO 3; ESG3__:__
Caret__:__600191__:__MOVED TO 300018__:____:__
Asterisk__:__600192__:__SYNOVIAL SARCOMA TRANSLOCATION, CHROMOSOME 18; SS18__:__SYNOVIAL SARCOMA, TRANSLOCATED TO X CHROMOSOME; SSXT;; SYT__:__SYT/SSX1 FUSION GENE, INCLUDED;; SYT/SSX2 FUSION GENE, INCLUDED
Percent__:__600193__:__WAARDENBURG SYNDROME, TYPE 2B; WS2B__:__WAARDENBURG SYNDROME, TYPE IIB__:__
Asterisk__:__600194__:__KERATIN 2, TYPE II; KRT2__:__K2;; KB2;; KERATIN 2A; KRT2A;; KERATIN 2e; KRT2E__:__
Number Sign__:__600195__:__VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM__:__VMCM1__:__
Caret__:__600196__:__MOVED TO 300019__:____:__
Asterisk__:__600197__:__V-MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE FAMILY, PROTEIN K; MAFK__:__NUCLEAR FACTOR ERYTHROID 2, UBIQUITOUS SUBUNIT; NFE2U;; NFE2, 18-KD SUBUNIT;; p18__:__
Caret__:__600198__:__MOVED TO 163260__:____:__
Caret__:__600199__:__MOVED TO 300021__:____:__
Caret__:__600200__:__MOVED TO 133440__:____:__
Asterisk__:__600201__:__AGOUTI SIGNALING PROTEIN; ASIP__:__ASP;; AGOUTI, MOUSE, HOMOLOG OF; AGTI__:__
Percent__:__600202__:__DYSLEXIA, SUSCEPTIBILITY TO, 2; DYX2__:__READING DISABILITY, SPECIFIC, 2__:__
Caret__:__600203__:__MOVED TO 300030__:____:__
Number Sign__:__600204__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 2; EDM2__:____:__
Caret__:__600205__:__MOVED TO 107748__:____:__
Asterisk__:__600206__:__EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 8; EPS8__:____:__
Asterisk__:__600207__:__HIPPOCALCIN-LIKE 1; HPCAL1__:____:__
Caret__:__600208__:__MOVED TO 155100__:____:__
Percent__:__600209__:__EXOSTOSES, MULTIPLE, TYPE III; EXT3__:____:__
Asterisk__:__600210__:__RUNT-RELATED TRANSCRIPTION FACTOR 3; RUNX3__:__CORE-BINDING FACTOR, RUNT DOMAIN, ALPHA SUBUNIT 3; CBFA3;; AML2 GENE; AML2;; PEBP2-ALPHA-C; PEBP2AC__:__
Asterisk__:__600211__:__RUNT-RELATED TRANSCRIPTION FACTOR 2; RUNX2__:__CORE-BINDING FACTOR, RUNT DOMAIN, ALPHA SUBUNIT 1; CBFA1;; AML3 GENE; AML3;; PEBP2-ALPHA-A;; OSF2__:__
Asterisk__:__600212__:__FATTY ACID SYNTHASE; FASN__:____:__
Caret__:__600213__:__MOVED TO 176310__:____:__
Asterisk__:__600214__:__ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGER__:__RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; RAGE__:__
Asterisk__:__600215__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 1; MFAP1__:____:__
Caret__:__600216__:__MOVED TO 400002__:____:__
Caret__:__600217__:__MOVED TO 601545__:____:__
Caret__:__600218__:__MOVED TO 600068__:____:__
Caret__:__600219__:__MOVED TO 600069__:____:__
Asterisk__:__600220__:__PHOSPHOLIPASE C, GAMMA-2; PLCG2__:__PHOSPHOLIPASE C, PHOSPHATIDYLINOSITOL-SPECIFIC__:__
Asterisk__:__600221__:__TEK TYROSINE KINASE, ENDOTHELIAL; TEK__:__PROTEIN RECEPTOR TYROSINE KINASE, EPITHELIAL-SPECIFIC, TIE-2; TIE2__:__
Asterisk__:__600222__:__TYROSINE KINASE WITH IMMUNOGLOBULIN AND EGF FACTOR HOMOLOGY DOMAINS 1; TIE1__:__PROTEIN RECEPTOR TYROSINE KINASE TIE 1;; TIE__:__
Percent__:__600223__:__SPINOCEREBELLAR ATAXIA 4; SCA4__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL DOMINANT, WITH SENSORY AXONAL NEUROPATHY__:__
Number Sign__:__600224__:__SPINOCEREBELLAR ATAXIA 5; SCA5__:____:__
Asterisk__:__600225__:__GTP CYCLOHYDROLASE I; GCH1__:____:__
Caret__:__600226__:__MOVED TO 300031__:____:__
Asterisk__:__600227__:__CYCLIN F; CCNF__:__F-BOX ONLY PROTEIN 1; FBXO1; FBX1__:__
Asterisk__:__600228__:__SODIUM CHANNEL, NONVOLTAGE-GATED 1, ALPHA SUBUNIT; SCNN1A__:__SCNN1;; SODIUM CHANNEL, EPITHELIAL, ALPHA SUBUNIT; SCNEA__:__
Asterisk__:__600229__:__SOLUTE CARRIER FAMILY 1 (GLUTAMATE/NEUTRAL AMINO ACID TRANSPORTER), MEMBER 4; SLC1A4__:__NEUTRAL AMINO ACID TRANSPORTER; ASCT1__:__
Asterisk__:__600230__:__PHOSPHOLIPASE C, BETA-3; PLCB3__:____:__
Number Sign__:__600231__:__PALMOPLANTAR KERATODERMA, BOTHNIAN TYPE; PPKB__:____:__
Asterisk__:__600232__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, BETA-2; GABRB2__:__GABA-A RECEPTOR, BETA-2 POLYPEPTIDE__:__
Asterisk__:__600233__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, GAMMA-3; GABRG3__:__GABA-A RECEPTOR, GAMMA-3 POLYPEPTIDE__:__
Asterisk__:__600234__:__3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE 2; HMGCS2__:__3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE, MITOCHONDRIAL;; HMG-CoA SYNTHASE, MITOCHONDRIAL;; MITOCHONDRIAL HMG-CoA SYNTHASE__:__
Asterisk__:__600235__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE I, BETA SUBUNIT; SCN1B__:____:__
Asterisk__:__600236__:__CENTROMERIC PROTEIN F; CENPF__:__MITOSIN__:__
Asterisk__:__600237__:__HISTONE CELL CYCLE REGULATION DEFECTIVE, S. CEREVISIAE, HOMOLOG OF, A; HIRA__:__HIR, S. CEREVISIAE, HOMOLOG OF, A;; TUP-LIKE ENHANCER OF SPLIT 1; TUPLE1;; DIGEORGE SYNDROME CRITICAL REGION GENE 1; DGCR1__:__
Asterisk__:__600238__:__TRANSGLUTAMINASE 3; TGM3__:__TRANSGLUTAMINASE E; TGE__:__
Asterisk__:__600239__:__G PROTEIN-COUPLED RECEPTOR 1; GPR1__:____:__
Asterisk__:__600240__:__CHEMOKINE (C-C) RECEPTOR 10; CCR10__:__G PROTEIN-COUPLED RECEPTOR 2; GPR2__:__
Asterisk__:__600241__:__G PROTEIN-COUPLED RECEPTOR 3; GPR3__:__ADENYLATE CYCLASE CONSTITUTIVE ACTIVATOR; ACCA__:__
Asterisk__:__600242__:__CHEMOKINE, CC MOTIF, RECEPTOR 7; CCR7__:__EPSTEIN-BARR VIRUS-INDUCED GENE 1; EBI1;; CMKBR7__:__
Asterisk__:__600243__:__DEFENDER AGAINST CELL DEATH 1; DAD1__:____:__
Asterisk__:__600244__:__PROGRAMMED CELL DEATH 1; PDCD1__:__PD1;; CD279 ANTIGEN; CD279__:__
Asterisk__:__600245__:__FIBROMODULIN; FMOD__:____:__
Asterisk__:__600246__:__ELK4, ETS-DOMAIN PROTEIN; ELK4__:__SRF ACCESSORY PROTEIN 1; SAP1__:__
Asterisk__:__600247__:__ELK3, ETS-DOMAIN PROTEIN; ELK3__:__SRF ACCESSORY PROTEIN 2; SAP2;; ETS-RELATED PROTEIN; ERP;; NET__:__
Caret__:__600248__:__MOVED TO 300009__:____:__
Asterisk__:__600249__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER L1; ALDH1L1__:__10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; FTHFD;; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE, CYTOSOLIC;; CYTOSOLIC 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE__:__
Asterisk__:__600250__:__CHEMOKINE, C MOTIF, LIGAND 1; XCL1__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY C, MEMBER 1; SCYC1;; SINGLE CYSTEINE MOTIF 1; SCM1;; SINGLE CYSTEINE MOTIF 1A; SCM1A;; LYMPHOTACTIN; LTN__:__
Number Sign__:__600251__:__FACIAL CLEFTING, OBLIQUE, 1; OBLFC1__:__OCULOMAXILLOFACIAL DYSPLASIA WITH OBLIQUE FACIAL CLEFTS__:__
NULL__:__600252__:__LOWRY-MACLEAN SYNDROME__:____:__
Asterisk__:__600253__:__ARYL HYDROCARBON RECEPTOR; AHR__:____:__
Caret__:__600254__:__MOVED TO 300032__:____:__
Caret__:__600255__:__MOVED TO 400000__:____:__
Caret__:__600256__:__MOVED TO 123155__:____:__
Number Sign__:__600257__:__CHROMOSOME 8q12.1-q21.2 DELETION SYNDROME__:__BOR-DUANE HYDROCEPHALUS CONTIGUOUS GENE SYNDROME__:__
Asterisk__:__600258__:__POSTMEIOTIC SEGREGATION INCREASED, S. CEREVISIAE, 1; PMS1__:__MISMATCH REPAIR GENE PMSL1; PMSL1__:__
Asterisk__:__600259__:__POSTMEIOTIC SEGREGATION INCREASED, S. CEREVISIAE, 2; PMS2__:__MISMATCH REPAIR GENE PMSL2; PMSL2__:__
Caret__:__600260__:__MOVED TO 300008__:____:__
Caret__:__600261__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__600262__:__PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 2; PTGS2__:__CYCLOOXYGENASE 2; COX2;; PROSTAGLANDIN G/H SYNTHASE 2; PGHS2;; PHS II;; GLUCOCORTICOID-REGULATED INFLAMMATORY PROSTAGLANDIN G/H SYNTHASE; GRIPGHS__:__
Number Sign__:__600263__:__HELICOBACTER PYLORI INFECTION, SUSCEPTIBILITY TO__:____:__
Asterisk__:__600264__:__ARGININE VASOPRESSIN RECEPTOR 1B; AVPR1B__:__ANTIDIURETIC HORMONE, RECEPTOR FOR, V1B;; VASOPRESSIN V1B RECEPTOR;; PITUITARY VASOPRESSIN RECEPTOR 3; AVPR3__:__
Caret__:__600265__:__MOVED TO 300033__:____:__
Asterisk__:__600266__:__SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT METAL ION TRANSPORTER), MEMBER 1; SLC11A1__:__NATURAL RESISTANCE-ASSOCIATED MACROPHAGE PROTEIN 1; NRAMP1; NRAMP__:__
Asterisk__:__600267__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 13; PTPN13__:__PROTEIN-TYROSINE PHOSPHATASE PTPL1;; FAS-ASSOCIATED PROTEIN-TYROSINE PHOSPHATASE 1; FAP1__:__
Percent__:__600268__:__OCULOECTODERMAL SYNDROME; OES__:__APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS__:__
NULL__:__600269__:__SHORT TARSUS WITH ABSENCE OF LOWER EYELASHES; STALE__:____:__
Asterisk__:__600270__:__PROCOLLAGEN C-ENDOPEPTIDASE ENHANCER; PCOLCE__:__PROCOLLAGEN, TYPE I, COOH-TERMINAL PROTEINASE ENHANCER__:__
Asterisk__:__600271__:__DESMOCOLLIN 3; DSC3__:__DESMOCOLLIN 4; DSC4__:__
Asterisk__:__600272__:__COILIN; COIL__:__COILIN p80; CLN80__:__
Number Sign__:__600273__:__POLYCYSTIC KIDNEY DISEASE, INFANTILE SEVERE, WITH TUBEROUS SCLEROSIS; PKDTS__:__CHROMOSOME 16p13.3 DELETION SYNDROME, DISTAL;; TUBEROUS SCLEROSIS/POLYCYSTIC KIDNEY DISEASE CONTIGUOUS GENE SYNDROME__:__
Number Sign__:__600274__:__FRONTOTEMPORAL DEMENTIA; FTD__:__FRONTOTEMPORAL LOBAR DEGENERATION WITH TAU INCLUSIONS;; FTLD WITH TAU INCLUSIONS;; DEMENTIA, FRONTOTEMPORAL, WITH PARKINSONISM;; FRONTOTEMPORAL DEMENTIA WITH PARKINSONISM;; FRONTOTEMPORAL LOBE DEMENTIA; FLDEM;; FTDP17;; MULTIPLE SYSTEM TAUOPATHY WITH PRESENILE DEMENTIA; MSTD;; DISINHIBITION-DEMENTIA-PARKINSONISM-AMYOTROPHY COMPLEX; DDPAC;; WILHELMSEN-LYNCH DISEASE; WLD;; PALLIDOPONTONIGRAL DEGENERATION; PPND__:__PICK COMPLEX, INCLUDED
Asterisk__:__600275__:__NOTCH, DROSOPHILA, HOMOLOG OF, 2; NOTCH2__:____:__
Asterisk__:__600276__:__NOTCH, DROSOPHILA, HOMOLOG OF, 3; NOTCH3__:____:__
Asterisk__:__600277__:__INHIBITOR OF DNA BINDING 3; ID3__:__HEIR1__:__
Asterisk__:__600278__:__RAP1, GTPase-ACTIVATING PROTEIN 1; RAP1GA1__:__GTPase-ACTIVATING PROTEIN, RAP1, 1; RAP1GAP__:__
Asterisk__:__600279__:__PEROXISOME BIOGENESIS FACTOR 19; PEX19__:__PEROXISOMAL FARNESYLATED PROTEIN; PXF;; HOUSEKEEPING GENE, 33-KD; HK33;; HOUSEKEEPING GENE 33;; PEROXIN 19;; D1S2223E__:__
Asterisk__:__600280__:__NUCLEOTIDE-BINDING PROTEIN 1; NUBP1__:__NBP;; NBP35__:__
Asterisk__:__600281__:__HEPATOCYTE NUCLEAR FACTOR 4-ALPHA; HNF4A__:__HNF4-ALPHA;; HEPATOCYTE NUCLEAR FACTOR 4; HNF4;; TRANSCRIPTION FACTOR 14, HEPATIC NUCLEAR FACTOR; TCF14__:__
Asterisk__:__600282__:__GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 4; GRIK4__:__KA1__:__
Asterisk__:__600283__:__GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 5; GRIK5__:__KA2__:__
Asterisk__:__600284__:__ELONGATION FACTOR RNA POLYMERASE II; ELL__:__ELEVEN NINETEEN LYSINE-RICH LEUKEMIA GENE__:__
Asterisk__:__600285__:__EUKARYOTIC TRANSLATION TERMINATION FACTOR 1; ETF1__:__RELEASE FACTOR 1; RF1;; ERF1__:__
Asterisk__:__600286__:__PHOSPHATIDYLINOSITOL 4-KINASE, CATALYTIC, ALPHA; PI4KA__:__PIK4CA;; PI4K-ALPHA;; PHOSPHATIDYLINOSITOL 4-KINASE, TYPE III, ALPHA;; PI4KIII-ALPHA__:__
Asterisk__:__600287__:__GLYCYL-tRNA SYNTHETASE; GARS__:____:__
Asterisk__:__600288__:__FORKHEAD BOX A2; FOXA2__:__HEPATOCYTE NUCLEAR FACTOR 3-BETA; HNF3B__:__
Asterisk__:__600289__:__MITOGEN-ACTIVATED PROTEIN KINASE 14; MAPK14__:__CYTOKINE-SUPPRESSIVE ANTIINFLAMMATORY DRUG-BINDING PROTEIN 1; CSBP1;; CSAID-BINDING PROTEIN 1;; STRESS-ACTIVATED PROTEIN KINASE 2A; SAPK2A;; p38 MAP KINASE; p38;; p38-ALPHA;; MXI2__:__CYTOKINE-SUPPRESSIVE ANTIINFLAMMATORY DRUG-BINDING PROTEIN 2, INCLUDED; CSBP2, INCLUDED;; CSAID-BINDING PROTEIN 2, INCLUDED
Caret__:__600290__:__MOVED TO 600289__:____:__
Asterisk__:__600291__:__ADENYLATE CYCLASE 3; ADCY3__:__ADENYLYL CYCLASE 3;; KIAA0511__:__
Asterisk__:__600292__:__ADENYLATE CYCLASE 4; ADCY4__:__ADENYLYL CYCLASE 4__:__
Asterisk__:__600293__:__ADENYLATE CYCLASE 5; ADCY5__:__ADENYLYL CYCLASE 5__:__
Asterisk__:__600294__:__ADENYLATE CYCLASE 6; ADCY6__:__ADENYLYL CYCLASE 6__:__
Asterisk__:__600295__:__NATRIURETIC PEPTIDE PRECURSOR B; NPPB__:__BNP;; NATRIURETIC PEPTIDE, BRAIN TYPE__:__
Asterisk__:__600296__:__NATRIURETIC PEPTIDE PRECURSOR C; NPPC__:__NATRIURETIC PEPTIDE, TYPE C; CNP__:__
Asterisk__:__600297__:__CAUDAL-TYPE HOMEOBOX TRANSCRIPTION FACTOR 2; CDX2__:__CAUDAL-TYPE HOMEOBOX TRANSCRIPTION FACTOR 3; CDX3;; INSULIN-REGULATING TRANSCRIPTION FACTOR CDX3__:__
Asterisk__:__600298__:__LIM HOMEOBOX TRANSCRIPTION FACTOR 1, ALPHA; LMX1A__:__LIM HOMEOBOX TRANSCRIPTION FACTOR 1; LMX1;; LMX1.1;; INSULIN-REGULATING TRANSCRIPTION FACTOR LMX1__:__
Asterisk__:__600299__:__PERICENTRIOLAR MATERIAL 1; PCM1__:____:__PCM1/RET FUSION GENE, INCLUDED
Asterisk__:__600300__:__SOLUTE CARRIER FAMILY 1 (GLIAL HIGH AFFINITY GLUTAMATE TRANSPORTER), MEMBER 2; SLC1A2__:__EXCITATORY AMINO ACID TRANSPORTER 2; EAAT2;; GLUTAMATE TRANSPORTER 1; GLT1__:__EAAT2b, INCLUDED;; GLT1A, INCLUDED;; GLT1B, INCLUDED
Asterisk__:__600301__:__ACYL-CoA DEHYDROGENASE, SHORT/BRANCHED CHAIN; ACADSB__:__SBCAD;; 2-METHYLBUTYRYL-CoA DEHYDROGENASE__:__
NULL__:__600302__:__FRYNS MACROCEPHALY__:__MACROCEPHALY WITH SPASTIC PARAPLEGIA AND DISTINCTIVE CRANIOFACIAL APPEARANCE__:__
Asterisk__:__600303__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; RAPGEF1__:__GUANINE NUCLEOTIDE-RELEASING FACTOR 2; GRF2;; CRK SH3-BINDING GNRP; C3G__:__
Caret__:__600304__:__MOVED TO 170400__:____:__
Asterisk__:__600305__:__ENOYL-CoA DELTA ISOMERASE 1; ECI1__:__DODECENOYL-CoA DELTA ISOMERASE; DCI;; 3,2-TRANS-ENOYL-CoA ISOMERASE;; DELTA-3-DELTA-2-ENOYL-CoA ISOMERASE__:__
Asterisk__:__600306__:__PROTEASOME SUBUNIT, BETA-TYPE, 5; PSMB5__:__PROTEASOME SUBUNIT X;; PSX LARGE MULTIFUNCTIONAL PROTEASE X; LMPX;; PROTEASOME SUBUNIT BETA-5__:__
Asterisk__:__600307__:__PROTEASOME SUBUNIT, BETA-TYPE, 6; PSMB6__:__PROTEASOME SUBUNIT DELTA;; PROTEASOME SUBUNIT Y;; PSY LARGE MULTIFUNCTIONAL PROTEASE Y; LMPY;; PROTEASOME SUBUNIT BETA-1__:__
Asterisk__:__600308__:__AQUAPORIN 4; AQP4__:__MERCURIAL-INSENSITIVE WATER CHANNEL; MIWC__:__
Number Sign__:__600309__:__ATRIOVENTRICULAR SEPTAL DEFECT 3; AVSD3__:____:__
Asterisk__:__600310__:__CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMP__:__THROMBOSPONDIN V; THBS5__:__
Asterisk__:__600311__:__GRANZYME M; GZMM__:__LYMPHOCYTE MET-ASE 1;; PROTEASE, SERINE, NATURAL KILLER CELL, MET-ASE__:__
Asterisk__:__600312__:__NUDIX HYDROLASE 1; NUDT1__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 1;; NUDIX MOTIF 1;; MutT HOMOLOG 1; MTH1;; 8-OXO-7,8-DIHYDROGUANOSINE TRIPHOSPHATASE__:__
Caret__:__600313__:__MOVED TO 600535__:____:__
Asterisk__:__600314__:__SH2 DOMAIN-CONTAINING ADAPTOR PROTEIN B; SHB__:__SHB ADAPTOR PROTEIN__:__
Asterisk__:__600315__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 4; TNFRSF4__:__TAX-TRANSCRIPTIONALLY ACTIVATED GLYCOPROTEIN 1 RECEPTOR; TXGP1L;; OX40 ANTIGEN;; LYMPHOID ACTIVATION ANTIGEN ACT35; ACT35;; CD134__:__
Number Sign__:__600316__:__DEAFNESS, AUTOSOMAL RECESSIVE 3; DFNB3__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 3; NSRD3__:__
Asterisk__:__600317__:__TROPOMYOSIN 4; TPM4__:____:__
Percent__:__600318__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 3; IDDM3__:__INSULIN-DEPENDENT DIABETES MELLITUS 3__:__
Percent__:__600319__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 4; IDDM4__:__INSULIN-DEPENDENT DIABETES MELLITUS 4__:__
Number Sign__:__600320__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 5; IDDM5__:__INSULIN-DEPENDENT DIABETES MELLITUS 5__:__
Percent__:__600321__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 7; IDDM7__:__INSULIN-DEPENDENT DIABETES MELLITUS 7__:__
Asterisk__:__600322__:__SYNAPTOSOMAL-ASSOCIATED PROTEIN, 25-KD; SNAP25__:__SNAP__:__
Asterisk__:__600323__:__REGULATOR OF G PROTEIN SIGNALING 1; RGS1__:__IMMEDIATE-EARLY RESPONSE 1, B-CELL SPECIFIC; IER1;; 1R20;; BL34__:__
Asterisk__:__600324__:__CHEMOKINE, CXC MOTIF, LIGAND 5; CXCL5__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 5; SCYB5;; NEUTROPHIL-ACTIVATING PEPTIDE ENA-78; ENA78;; LIPOPOLYSACCHARIDE-INDUCED CXC CHEMOKINE; LIX__:__
Percent__:__600325__:__AMINOPTERIN SYNDROME SINE AMINOPTERIN; ASSA__:__PSEUDOAMINOPTERIN SYNDROME__:__
Asterisk__:__600326__:__DEAD/H BOX 6; DDX6__:__RNA HELICASE, 54-KD; p54;; HELICASE, RNA, NUCLEAR 2; HLR2;; ONCOGENE RCK__:__
Asterisk__:__600327__:__SYNAPTOTAGMIN 3; SYT3__:____:__
Asterisk__:__600328__:__MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 6; MLLT6__:__ALL1-FUSED GENE FROM CHROMOSOME 17; AF17__:__
NULL__:__600329__:__OSTEOPETROSIS AND INFANTILE NEUROAXONAL DYSTROPHY__:____:__
Caret__:__600330__:__MOVED TO 102500__:____:__
NULL__:__600331__:__PARC SYNDROME__:__POIKILODERMA, ALOPECIA, RETROGNATHISM, AND CLEFT PALATE__:__
Percent__:__600332__:__RIPPLING MUSCLE DISEASE 1; RMD1__:____:__
NULL__:__600333__:__MOTOR NEURON DISEASE WITH DEMENTIA AND OPHTHALMOPLEGIA__:____:__
Number Sign__:__600334__:__TIBIAL MUSCULAR DYSTROPHY, TARDIVE; TMD__:__TARDIVE TIBIAL MUSCULAR DYSTROPHY;; UDD MYOPATHY__:__
NULL__:__600335__:__SUCCINIC ACIDEMIA__:____:__
Asterisk__:__600336__:__SOLUTE CARRIER FAMILY 18 (VESICULAR ACETYLCHOLINE), MEMBER 3; SLC18A3__:__VESICULAR ACETYLCHOLINE TRANSPORTER; VACHT__:__
Asterisk__:__600337__:__BRADYKININ RECEPTOR B1; BDKRB1__:__BRADYKININ RECEPTOR 1; BKR1;; B1R__:__
Asterisk__:__600338__:__ARYLACETAMIDE DEACETYLASE; AADAC__:__DAC__:__
Asterisk__:__600339__:__HEPATOMA-DERIVED GROWTH FACTOR; HDGF__:____:__
Asterisk__:__600340__:__PLASMA MEMBRANE PROTEOLIPID; PLLP__:__PLASMOLIPIN; PMLP;; TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 11; TM4SF11__:__
Asterisk__:__600341__:__TYRO3 PROTEIN TYROSINE KINASE; TYRO3__:__PROTEIN TYROSINE KINASE 3__:__
Asterisk__:__600342__:__G PROTEIN-COUPLED RECEPTOR, RETINAL; RGR__:__RPE-RETINAL G PROTEIN-COUPLED RECEPTOR__:__
Percent__:__600343__:__PAROTID SALIVARY GLANDS, POLYCYSTIC DYSGENETIC DISEASE OF; PDDP__:____:__
Caret__:__600344__:__MOVED TO 300058__:____:__
Asterisk__:__600345__:__BETACELLULIN; BTC__:____:__
Asterisk__:__600346__:__POLYCOMB GROUP RING FINGER PROTEIN 2; PCGF2__:__MEL18;; ZINC FINGER PROTEIN 144; ZNF144__:__
Asterisk__:__600347__:__BREVICAN; BCAN__:__BRAIN-ENRICHED HYALURONAN-BINDING; BEHAB; CHONDROITIN SULFATE PROTEOGLYCAN 7; CSPG7__:__
Number Sign__:__600348__:__BAND HETEROTOPIA; BH__:____:__
Asterisk__:__600349__:__INHIBITOR OF DNA BINDING 1; ID1__:__INHIBITOR OF DIFFERENTIATION 1__:__
Caret__:__600350__:__MOVED TO 300034__:____:__
NULL__:__600351__:__ENTEROPATHY, FAMILIAL, WITH VILLOUS EDEMA AND IMMUNOGLOBULIN G2 DEFICIENCY__:____:__
Caret__:__600352__:__MOVED TO 112205__:____:__
Asterisk__:__600353__:__S100 CALCIUM-BINDING PROTEIN A7; S100A7__:__PSORIASIN; PSOR1__:__
Asterisk__:__600354__:__SURVIVAL OF MOTOR NEURON 1; SMN1__:__SURVIVAL OF MOTOR NEURON, TELOMERIC COPY; SMNT;; SMN;; T-BCD541__:__
Asterisk__:__600355__:__NEURONAL APOPTOSIS INHIBITORY PROTEIN; NAIP__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 1; BIRC1__:__
NULL__:__600356__:__PACHYDERMODACTYLY, FAMILIAL__:____:__
Asterisk__:__600357__:__RIBOSOMAL PROTEIN S8; RPS8__:____:__
Asterisk__:__600358__:__GUANINE MONOPHOSPHATE SYNTHETASE; GMPS__:__GMP SYNTHETASE__:__GMPS/MLL FUSION GENE, INCLUDED
Asterisk__:__600359__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 1; KCNJ1__:__RENAL OUTER-MEDULLARY POTASSIUM CHANNEL; ROMK; ROMK1;; KIR1.1__:__
Percent__:__600360__:__APLASIA CUTIS CONGENITA OF LIMBS, AUTOSOMAL RECESSIVE__:____:__
Percent__:__600361__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY V__:__HMSN V;; HMSN5;; PERONEAL MUSCULAR ATROPHY WITH PYRAMIDAL FEATURES, AUTOSOMAL DOMINANT;; CHARCOT-MARIE-TOOTH DISEASE WITH PYRAMIDAL FEATURES, AUTOSOMAL DOMINANT;; CHARCOT-MARIE-TOOTH NEUROPATHY WITH PYRAMIDAL FEATURES, AUTOSOMAL DOMINANT;; CMT WITH PYRAMIDAL FEATURES__:__
Asterisk__:__600362__:__FLIGHTLESS I, DROSOPHILA, HOMOLOG OF; FLII__:__FLI__:__
Number Sign__:__600363__:__SPASTIC PARAPLEGIA 6, AUTOSOMAL DOMINANT; SPG6__:__FAMILIAL SPASTIC PARAPLEGIA, AUTOSOMAL DOMINANT, 3; FSP3__:__
Asterisk__:__600364__:__GUANYLATE CYCLASE ACTIVATOR 1A; GUCA1A__:__GUANYLATE CYCLASE-ACTIVATING PROTEIN, PHOTORECEPTOR 1; GCAP1;; GUANYLIN 1, RETINA; GUCA1__:__
Asterisk__:__600365__:__ACTIVE BCR-RELATED GENE; ABR__:____:__
Asterisk__:__600366__:__ISL LIM HOMEOBOX 1; ISL1__:__ISL1 TRANSCRIPTION FACTOR, LIM/HOMEODOMAIN;; ISLET1__:__
Asterisk__:__600367__:__CLEAVAGE STIMULATION FACTOR, 3-PRIME PRE-RNA, SUBUNIT 3, 77-KD; CSTF3__:__CSTF, 77-KD SUBUNIT; CSTF77__:__
Caret__:__600368__:__MOVED TO 300907__:____:__
Asterisk__:__600369__:__CLEAVAGE STIMULATION FACTOR, 3-PRIME PRE-RNA, SUBUNIT 1, 50-KD; CSTF1__:____:__
Asterisk__:__600370__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER), MEMBER 3; SLC25A3__:__PHOSPHATE CARRIER, MITOCHONDRIAL; PHC__:__
Caret__:__600371__:__MOVED TO 142695__:____:__
Asterisk__:__600372__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 1; NEDD1__:____:__
Number Sign__:__600373__:__CODAS SYNDROME__:__CEREBRAL, OCULAR, DENTAL, AURICULAR, AND SKELETAL ANOMALIES SYNDROME__:__
Asterisk__:__600374__:__BBS4 GENE; BBS4__:____:__
Asterisk__:__600375__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 2; XRCC2__:____:__
Number Sign__:__600376__:__TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 2; HHT2__:____:__PULMONARY ARTERIAL HYPERTENSION, HEREDITARY HEMORRHAGIC TELANGIECTASIA-RELATED, INCLUDED
Asterisk__:__600377__:__GALANIN RECEPTOR 1; GALR1__:__GALNR; GALNR1;; GALANIN RECEPTOR 1, BRAIN__:__
Asterisk__:__600378__:__INNER MEMBRANE PROTEIN, MITOCHONDRIAL; IMMT__:__MITOFILIN;; HEART MUSCLE PROTEIN; HMP;; MITOCHONDRIAL INNER MEMBRANE ORGANIZING SYSTEM PROTEIN 2; MINOS2;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 60-KD SUBUNIT; MIC60;; MICOS COMPLEX, 60-KD SUBUNIT__:__
Asterisk__:__600379__:__MYELIN TRANSCRIPTION FACTOR 1; MYT1__:__PROTEOLIPID PROTEIN-BINDING PROTEIN; PLPB1__:__
Asterisk__:__600380__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 2; NR1H2__:__UBIQUITOUSLY EXPRESSED NUCLEAR RECEPTOR; UNR;; NER;; LX RECEPTOR BETA; LXRB__:__
Asterisk__:__600381__:__KINECTIN; KTN1__:__CG1 ANTIGEN; CG1__:__
Asterisk__:__600382__:__MYC PROMOTER-BINDING PROTEIN__:__IRLB__:__
Number Sign__:__600383__:__MESOMELIA-SYNOSTOSES SYNDROME__:__CHROMOSOME 8q13 DELETION SYNDROME;; MESOMELIC DYSPLASIA WITH ACRAL SYNOSTOSES, VERLOES-DAVID-PFEIFFER TYPE;; MESOMELIC DYSPLASIA, SYNDROMIC__:__
Percent__:__600384__:__APHALANGIA, PARTIAL, WITH SYNDACTYLY AND DUPLICATION OF METATARSAL IV__:____:__
Asterisk__:__600385__:__ADENYLATE CYCLASE 7; ADCY7__:__ADENYLYL CYCLASE 7__:__
Asterisk__:__600386__:__INHIBITOR OF DNA BINDING 2; ID2__:__INHIBITOR OF DIFFERENTIATION 2__:__
Asterisk__:__600387__:__BONE MARROW STROMAL CELL ANTIGEN 1; BST1__:__CD157__:__
Asterisk__:__600388__:__MEPRIN, ALPHA SUBUNIT; MEP1A__:____:__
Asterisk__:__600389__:__MEPRIN, BETA SUBUNIT; MEP1B__:____:__
Asterisk__:__600390__:__UPSTREAM TRANSCRIPTION FACTOR 2, FOS-INTERACTING; USF2__:__UPSTREAM STIMULATORY FACTOR 2;; FOS-INTERACTING PROTEIN; FIP__:__
Asterisk__:__600391__:__GLUCOSAMINYL (N-ACETYL) TRANSFERASE 1, CORE 2; GCNT1__:__BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE 1__:__
Asterisk__:__600392__:__RAD52, YEAST, HOMOLOG OF; RAD52__:____:__
Asterisk__:__600393__:__FLAP STRUCTURE-SPECIFIC ENDONUCLEASE 1; FEN1__:__MATURATION FACTOR 1; MF1__:__
Caret__:__600394__:__MOVED TO 300036__:____:__
Asterisk__:__600395__:__GLYPICAN 1; GPC1__:____:__
Asterisk__:__600396__:__DEAH BOX POLYPEPTIDE 8; DHX8__:__DEAD/H BOX 8; DDX8;; PRP22, S. CEREVISIAE, HOMOLOG OF;; RNA HELICASE 1; HRH1__:__
Asterisk__:__600397__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAB-RELATED SUBFAMILY, MEMBER 1; KCNB1__:__KV2.1__:__
Asterisk__:__600398__:__ZINC FINGER PROTEIN 160; ZNF160__:____:__
Percent__:__600399__:__PECTUS EXCAVATUM, MACROCEPHALY, SHORT STATURE, AND DYSPLASTIC NAILS__:____:__
Asterisk__:__600400__:__PROLYL ENDOPEPTIDASE; PREP__:__PROLYL OLIGOPEPTIDASE__:__
Caret__:__600401__:__MOVED TO 600247__:____:__
Caret__:__600402__:__MOVED TO 300035__:____:__
Asterisk__:__600403__:__FIBROBLAST ACTIVATION PROTEIN, ALPHA; FAP__:__FAPA;; SEPRASE__:__
Asterisk__:__600404__:__REPLICATION FACTOR C, SUBUNIT 2; RFC2__:__RFC, 40-KD SUBUNIT;; RFC4, YEAST, HOMOLOG OF__:__
Asterisk__:__600405__:__REPLICATION FACTOR C, SUBUNIT 3; RFC3__:__RFC, 38-KD SUBUNIT;; RFC5, YEAST, HOMOLOG OF__:__
Caret__:__600406__:__MOVED TO 102577__:____:__
Asterisk__:__600407__:__REPLICATION FACTOR C, SUBUNIT 5; RFC5__:__RFC, 36.5-KD SUBUNIT;; RFC3, YEAST, HOMOLOG OF__:__
Asterisk__:__600408__:__DISCOIDIN DOMAIN RECEPTOR FAMILY, MEMBER 1; DDR1__:__NEUROEPITHELIAL TYROSINE KINASE; NEP;; RECEPTOR TYROSINE KINASE NEP;; EPITHELIAL DISCOIDIN DOMAIN RECEPTOR 1; EDDR1;; EPITHELIAL-SPECIFIC RECEPTOR KINASE;; NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 4; NTRK4;; TYROSINE KINASE RECEPTOR E; TRKE;; PTK3, MOUSE, HOMOLOG OF;; DISCOIDIN DOMAIN RECEPTOR; DDR;; CELL ADHESION KINASE; CAK;; RECEPTOR TYROSINE KINASE 6; RTK6__:__
Asterisk__:__600409__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-DELTA; PPARD__:__NUCLEAR HORMONE RECEPTOR 1; NUC1;; NUCI GENE; NUCI;; PPAR-BETA; PPARB__:__
Asterisk__:__600410__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 6; TNFAIP6__:__TUMOR NECROSIS FACTOR-STIMULATED GENE 6; TSG6__:__
Asterisk__:__600411__:__GUANYLATE-BINDING PROTEIN 1, INTERFERON-INDUCIBLE, 67-KD; GBP1__:____:__
Asterisk__:__600412__:__GUANYLATE-BINDING PROTEIN 2, INTERFERON-INDUCIBLE; GBP2__:__GUANYLATE-BINDING PROTEIN 1, MOUSE, HOMOLOG OF; GBP1__:__
Asterisk__:__600413__:__GUANYLATE-BINDING PROTEIN 3; GBP3__:____:__
Asterisk__:__600414__:__PEROXISOME BIOGENESIS FACTOR 5; PEX5__:__PEROXISOME RECEPTOR 1; PXR1;; PEROXIN 5;; PTS1 RECEPTOR; PTS1R__:__
Asterisk__:__600415__:__TOCOPHEROL TRANSFER PROTEIN, ALPHA; TTPA__:__TTP1;; ALPHA-TOCOPHEROL TRANSFER PROTEIN; ATTP;; ALPHA-TTP__:__
NULL__:__600416__:__MUSCULAR DYSTROPHY, SCAPULOHUMERAL__:____:__
Asterisk__:__600417__:__5-PRIME-NUCLEOTIDASE, CYTOSOLIC II; NT5C2__:__NUCLEOTIDASE, 5-PRIME, CYTOSOLIC II;; NUCLEOTIDASE, 5-PRIME, TYPE B; NT5B;; PURINE 5-PRIME-NUCLEOTIDASE; PNT5__:__
Asterisk__:__600418__:__AMPHIPHYSIN; AMPH__:__AMPHIPHYSIN I__:__
NULL__:__600419__:__ANGIOKERATOMA CORPORIS DIFFUSUM WITH ARTERIOVENOUS FISTULAS__:____:__
Caret__:__600420__:__MOVED TO 300039__:____:__
Asterisk__:__600421__:__GLYCINE RECEPTOR, ALPHA-3 SUBUNIT; GLRA3__:____:__
Asterisk__:__600422__:__FATTY ACID-BINDING PROTEIN 6; FABP6__:__FATTY ACID-BINDING PROTEIN, ILEAL;; ILEAL LIPID-BINDING PROTEIN; ILLBP; ILBP;; GASTROTROPIN;; INTESTINAL BILE ACID-BINDING PROTEIN; IBABP__:__
Asterisk__:__600423__:__ENDOTHELIN-CONVERTING ENZYME 1; ECE1__:__ECE__:__
Asterisk__:__600424__:__SOLUTE CARRIER FAMILY 19 (FOLATE TRANSPORTER), MEMBER 1; SLC19A1__:__FOLATE TRANSPORTER; FOLT;; REDUCED FOLATE CARRIER 1; RFC1;; INTESTINAL FOLATE CARRIER 1; IFC1__:__
Caret__:__600425__:__MOVED TO 189902__:____:__
Asterisk__:__600426__:__E2F TRANSCRIPTION FACTOR 2; E2F2__:____:__
Asterisk__:__600427__:__E2F TRANSCRIPTION FACTOR 3; E2F3__:____:__
Asterisk__:__600428__:__VAV2 ONCOGENE; VAV2__:__ONCOGENE VAV2__:__
Asterisk__:__600429__:__GLUCOSAMINYL (N-ACETYL) TRANSFERASE 2, I-BRANCHING ENZYME; GCNT2__:__BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE 2;; DEVELOPMENTAL I ANTIGEN;; I-BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; IGNT__:__
Number Sign__:__600430__:__CHROMOSOME 2q37 DELETION SYNDROME__:__ALBRIGHT HEREDITARY OSTEODYSTROPHY-LIKE SYNDROME;; BRACHYDACTYLY-MENTAL RETARDATION SYNDROME; BDMR__:__
Asterisk__:__600431__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2B; CDKN2B__:__MULTIPLE TUMOR SUPPRESSOR 2;; MTS2;; p15(INK4B);; TP15;; CDK4B INHIBITOR__:__
Asterisk__:__600432__:__PRECEREBELLIN 1; CBLN1__:__PRECEREBELLIN;; CEREBELLIN PRECURSOR__:__CEREBELLIN, INCLUDED
Asterisk__:__600433__:__PRECEREBELLIN 2; CBLN2__:____:__
Asterisk__:__600434__:__FATTY ACID-BINDING PROTEIN 4; FABP4__:__FATTY ACID-BINDING PROTEIN, ADIPOCYTE;; ADIPOCYTE PROTEIN AP2__:__
Asterisk__:__600435__:__CARDIOTROPHIN 1; CTF1__:__CT1__:__
Asterisk__:__600436__:__GLUTATHIONE S-TRANSFERASE, THETA-1; GSTT1__:____:__
Asterisk__:__600437__:__GLUTATHIONE S-TRANSFERASE, THETA-2; GSTT2__:____:__
Asterisk__:__600438__:__TRANSCRIPTION FACTOR A, MITOCHONDRIAL; TFAM__:__TCF6;; TRANSCRIPTION FACTOR 6-LIKE 2; TCF6L2__:__TRANSCRIPTION FACTOR 6-LIKE 1, INCLUDED; TCF6L1, INCLUDED;; TRANSCRIPTION FACTOR 6-LIKE 3, INCLUDED; TCF6L3, INCLUDED;; MITOCHONDRIAL TRANSCRIPTION FACTOR 1, INCLUDED; MTTF1, INCLUDED
Asterisk__:__600439__:__SINGLE-STRANDED DNA-BINDING PROTEIN 1; SSBP1__:__SSBP;; SENSOR OF SINGLE-STRANDED DNA COMPLEX, SUBUNIT B1; SOSSB1;; SOSS COMPLEX, SUBUNIT B1__:__
Asterisk__:__600440__:__ENDONUCLEASE G, MITOCHONDRIAL; ENDOG__:____:__
Asterisk__:__600441__:__GROWTH ARREST-SPECIFIC 6; GAS6__:__AXL RECEPTOR TYROSINE KINASE LIGAND; AXLLG;; AXL STIMULATORY FACTOR; AXSF__:__
Asterisk__:__600442__:__AQUAPORIN 5; AQP5__:____:__
Asterisk__:__600443__:__GLUTAREDOXIN; GLRX__:__GRX;; THIOLTRANSFERASE__:__
Asterisk__:__600444__:__SOLUTE CARRIER FAMILY 5 (INOSITOL TRANSPORTER), MEMBER 3; SLC5A3__:__SODIUM/MYOINOSITOL COTRANSPORTER;; SMIT__:__
Asterisk__:__600445__:__ADENOSINE A3 RECEPTOR; ADORA3__:__A3 ADENOSINE RECEPTOR; A3AR__:__
Asterisk__:__600446__:__ADENOSINE A2B RECEPTOR; ADORA2B__:__A2BR__:__
Asterisk__:__600447__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12; MAP3K12__:__ZIPPER PROTEIN KINASE; ZPK;; DUAL LEUCINE ZIPPER KINASE; DLK;; PROTEIN KINASE MUK__:__
Asterisk__:__600448__:__PROTEIN KINASE C, THETA; PRKCQ__:____:__
Asterisk__:__600449__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER 1; AKR1C1__:__DIHYDRODIOL DEHYDROGENASE, TYPE I; DDH1; DD1;; ALDO-KETO REDUCTASE C; HAKRC__:__
Asterisk__:__600450__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER C2; AKR1C2__:__DIHYDRODIOL DEHYDROGENASE, TYPE II; DDH2; DD2;; ALDO-KETO REDUCTASE D; HAKRD;; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE, TYPE III__:__
Asterisk__:__600451__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER C4; AKR1C4__:__CHLORDECONE REDUCTASE; CHDR; CDR;; ALDO-KETO REDUCTASE A; HAKRA;; DIHYDRODIOL DEHYDROGENASE 4; DD4;; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE, TYPE I__:__
Caret__:__600452__:__MOVED TO 600408__:____:__
Asterisk__:__600453__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 25; TRIM25__:__ZINC FINGER PROTEIN 147; ZNF147;; ESTROGEN-RESPONSIVE FINGER PROTEIN; EFP__:__
Asterisk__:__600454__:__RIBOSOMAL PROTEIN S3; RPS3__:____:__
Asterisk__:__600455__:__RNA, U15A SMALL NUCLEOLAR; RNU15A__:__snoRNA, U15A__:__
Asterisk__:__600456__:__NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 2; NTRK2__:__TYROSINE KINASE RECEPTOR B; TRKB__:__
NULL__:__600457__:__HYPERTRICHOSIS, ANTERIOR CERVICAL__:____:__
NULL__:__600458__:__ADENOMYOSIS__:____:__
NULL__:__600459__:__ARTERIAL DISSECTION WITH LENTIGINOSIS__:____:__
NULL__:__600460__:__CLEFT PALATE, CARDIAC DEFECT, GENITAL ANOMALIES, AND ECTRODACTYLY__:__CCGE;; ACROCARDIOFACIAL SYNDROME; ACFS__:__
NULL__:__600461__:__HEMOLYTIC ANEMIA, LETHAL CONGENITAL NONSPHEROCYTIC, WITH GENITAL AND OTHER ABNORMALITIES__:____:__
Number Sign__:__600462__:__MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 1; MLASA1__:__MITOCHONDRIAL MYOPATHY AND SIDEROBLASTIC ANEMIA__:__
Asterisk__:__600463__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A3; ALDH1A3__:__ALDEHYDE DEHYDROGENASE 6; ALDH6;; ACETALDEHYDE DEHYDROGENASE 6;; RETINALDEHYDE DEHYDROGENASE 3; RALDH3__:__
Asterisk__:__600464__:__ADP-RIBOSYLATION FACTOR 6; ARF6__:____:__
Asterisk__:__600465__:__ANKYRIN 3; ANK3__:__ANKYRIN-G__:__
Asterisk__:__600466__:__ALDEHYDE DEHYDROGENASE 3 FAMILY, MEMBER B1; ALDH3B1__:__ALDEHYDE DEHYDROGENASE 7; ALDH7;; ACETALDEHYDE DEHYDROGENASE 7__:__
Percent__:__600467__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4__:__MHS4__:__
Caret__:__600468__:__MOVED TO 300011__:____:__
Asterisk__:__600469__:__NUCLEAR CAP-BINDING PROTEIN 1; NCBP1__:__NUCLEAR CAP-BINDING PROTEIN, 80-KD;; NCBP;; CBP80__:__
Asterisk__:__600470__:__ZIC FAMILY, MEMBER 1; ZIC1__:__ZINC FINGER PROTEIN OF CEREBELLUM 1;; ZIC__:__
Asterisk__:__600471__:__DEFENSIN, ALPHA, 6; DEFA6__:__DEFENSIN 6; DEF6__:__
Asterisk__:__600472__:__DEFENSIN, ALPHA, 5; DEFA5__:__DEFENSIN 5; DEF5; HD5__:__
Asterisk__:__600473__:__PURINE-RICH ELEMENT-BINDING PROTEIN A; PURA__:__PUR-ALPHA__:__
Asterisk__:__600474__:__CATHELICIDIN ANTIMICROBIAL PEPTIDE; CAMP__:__CATIONIC ANTIMICROBIAL PROTEIN, 18-KD; CAP18;; CRAMP, MOUSE, HOMOLOG OF; CRAMP__:__LL37, INCLUDED;; PEPTIDE ANTIBIOTIC, PR-39, PORCINE, HOMOLOG OF, INCLUDED; FALL39, INCLUDED
Asterisk__:__600475__:__TAF10 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 30-KD; TAF10__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2H; TAF2H;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 30-KD; TAFII30;; TAF2A, FORMERLY__:__
Caret__:__600476__:__MOVED TO 300040__:____:__
Asterisk__:__600477__:__SOLUTE CARRIER FAMILY 9, MEMBER 5; SLC9A5__:__SODIUM/HYDROGEN EXCHANGER 5; NHE5__:__
Asterisk__:__600478__:__SUPERKILLER VIRALICIDIC ACTIVITY 2, S. CEREVISIAE, HOMOLOG-LIKE; SKIV2L__:__SKI2, S. CEREVISIAE, HOMOLOG OF; SKI2;; SKI2W__:__
Caret__:__600479__:__MOVED TO 120324__:____:__
Asterisk__:__600480__:__TRANSCRIPTION FACTOR 12; TCF12__:__HELIX-LOOP-HELIX TRANSCRIPTION FACTOR 4; HTF4__:__TCF12/NR4A3 FUSION GENE, INCLUDED
Asterisk__:__600481__:__STEROL REGULATORY ELEMENT-BINDING TRANSCRIPTION FACTOR 2; SREBF2__:__STEROL REGULATORY ELEMENT-BINDING PROTEIN 2; SREBP2__:__
Caret__:__600482__:__MOVED TO 300116__:____:__
Asterisk__:__600483__:__FIBROBLAST GROWTH FACTOR 8; FGF8__:__ANDROGEN-INDUCED GROWTH FACTOR; AIGF__:__
Caret__:__600484__:__MOVED TO 300002__:____:__
Caret__:__600485__:__MOVED TO 300003__:____:__
Caret__:__600486__:__MOVED TO 300076__:____:__
Asterisk__:__600487__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 4; PCSK4__:__PROPROTEIN CONVERTASE PC4__:__
Asterisk__:__600488__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 5; PCSK5__:__PROPROTEIN CONVERTASE PC5__:__
Asterisk__:__600489__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC, CALCINEURIN-DEPENDENT 1; NFATC1__:__NFAT TRANSCRIPTION COMPLEX, CYTOSOLIC COMPONENT; NFATC;; NFAT2__:__
Asterisk__:__600490__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC, CALCINEURIN-DEPENDENT 2; NFATC2__:__NFAT1;; NUCLEAR FACTOR OF ACTIVATED T CELLS, PREEXISTING COMPONENT; NFATP;; NFAT TRANSCRIPTION COMPLEX, PREEXISTING COMPONENT__:__
Asterisk__:__600491__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 3; MFAP3__:____:__
Asterisk__:__600492__:__NUCLEAR FACTOR ERYTHROID 2-LIKE 2; NFE2L2__:__NFE2-RELATED FACTOR 2; NRF2;; NFE2-RELATED TRANSCRIPTION FACTOR 2__:__
Asterisk__:__600493__:__ADHESION G PROTEIN-COUPLED RECEPTOR E1; ADGRE1__:__EGF-LIKE MODULE-CONTAINING, MUCIN-LIKE HORMONE RECEPTOR 1; EMR1__:__
Asterisk__:__600494__:__POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 2; POU3F2__:__POUF3;; BRN2, MOUSE, HOMOLOG OF; BRN2;; OCTAMER BINDING TRANSCRIPTION FACTOR 7; OCT7;; N-OCT-3 GENE__:__
Asterisk__:__600495__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4-GAMMA, 1; EIF4G1__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4G; EIF4G;; EIF4-GAMMA;; EIF4GI__:__
Number Sign__:__600496__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 3; MODY3__:__MODY, TYPE 3__:__
Asterisk__:__600497__:__PROTEIN KINASE, AMP-ACTIVATED, CATALYTIC, ALPHA-2; PRKAA2__:__AMP-ACTIVATED PROTEIN KINASE, CATALYTIC, ALPHA-2;; AMPK-ALPHA-2__:__
Caret__:__600498__:__MOVED TO 313470__:____:__
Caret__:__600499__:__REMOVED FROM DATABASE__:____:__
Caret__:__600500__:__MOVED TO 600758__:____:__
Number Sign__:__600501__:__ABCD SYNDROME; ABCDS__:__ALBINISM, BLACK LOCK, CELL MIGRATION DISORDER OF THE NEUROCYTES OF THE GUT, AND DEAFNESS__:__
Asterisk__:__600502__:__IMMUNOGLOBULIN MU-BINDING PROTEIN 2; IGHMBP2__:__CARDIAC TRANSCRIPTION FACTOR 1; CATF1;; SMUBP2__:__
Asterisk__:__600503__:__SUB1, S. CEREVISIAE, HOMOLOG OF; SUB1__:__ACTIVATED RNA POLYMERASE II TRANSCRIPTION COFACTOR 4; PC4;; p15__:__
Asterisk__:__600504__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 4; KCNJ4__:__HIPPOCAMPAL INWARD RECTIFIER POTASSIUM CHANNEL; HIR; HRK1__:__
Asterisk__:__600505__:__CASEIN KINASE I, ALPHA-1; CSNK1A1__:__CK1-ALPHA;; CK1__:__
Caret__:__600506__:__MOVED TO 604286__:____:__
Caret__:__600507__:__MOVED TO 601177__:____:__
Asterisk__:__600508__:__NCK ADAPTOR PROTEIN 1; NCK1__:__NCK;; NCK-ALPHA;; MELANOMA NCK PROTEIN__:__
Asterisk__:__600509__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 8; ABCC8__:__SULFONYLUREA RECEPTOR; SUR;; SUR1;; SULFONYLUREA RECEPTOR, BETA CELL HIGH AFFINITY__:__
Percent__:__600510__:__GLAUCOMA-RELATED PIGMENT DISPERSION SYNDROME; GPDS1__:__GLAUCOMA, PIGMENT-DISPERSION TYPE;; PIGMENT DISPERSION SYNDROME; PDS__:__
Percent__:__600511__:__SCHIZOPHRENIA 3; SCZD3__:__SCHIZOPHRENIA 3 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 6-RELATED__:__
Number Sign__:__600512__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 1; ETL1__:__EPILEPSY, LATERAL TEMPORAL LOBE, AUTOSOMAL DOMINANT; ADLTE;; EPILEPSY, PARTIAL, WITH AUDITORY FEATURES; ADPEAF__:__
Number Sign__:__600513__:__EPILEPSY, NOCTURNAL FRONTAL LOBE, 1; ENFL1__:____:__
Asterisk__:__600514__:__REELIN; RELN__:__RL__:__
Asterisk__:__600515__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 12; P2RY12__:__PURINORECEPTOR P2Y12; P2Y12;; PLATELET ADP RECEPTOR__:__
Asterisk__:__600516__:__BCL2 ANTAGONIST KILLER 1; BAK1__:__BAK;; BCL2L7__:__BAK-LIKE, INCLUDED
Asterisk__:__600517__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 3; SERPINB3__:__SQUAMOUS CELL CARCINOMA ANTIGEN 1; SCCA1__:__
Asterisk__:__600518__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 4; SERPINB4__:__SQUAMOUS CELL CARCINOMA ANTIGEN 2; SCCA2;; LEUPIN__:__
Asterisk__:__600519__:__GENERAL TRANSCRIPTION FACTOR IIA, GAMMA SUBUNIT; GTF2A2__:__TRANSCRIPTION FACTOR IIA, 2; TF2A2__:__
Asterisk__:__600520__:__GENERAL TRANSCRIPTION FACTOR IIA, ALPHA/BETA SUBUNITS; GTF2A1__:__TRANSCRIPTION FACTOR IIA, 1; TF2A1__:__
Asterisk__:__600521__:__MANNAN-BINDING LECTIN SERINE PROTEASE 1; MASP1__:__MASP;; COMPLEMENT-ACTIVATING COMPONENT OF Ra-REACTIVE FACTOR; CRARF__:__
Plus__:__600522__:__PHOSPHOLIPASE A2, GROUP IVA; PLA2G4A__:__PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, ALPHA;; CPLA2-ALPHA__:__PHOSPHOLIPASE A2, GROUP IVA, DEFICIENCY OF, INCLUDED
Asterisk__:__600523__:__SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT METAL ION TRANSPORTER), MEMBER 2; SLC11A2__:__NATURAL RESISTANCE-ASSOCIATED MACROPHAGE PROTEIN 2; NRAMP2;; DIVALENT CATION TRANSPORTER 1; DCT1;; DIVALENT METAL TRANSPORTER 1; DMT1__:__
Asterisk__:__600524__:__RYK RECEPTOR-LIKE TYROSINE KINASE; RYK__:__RYK1__:__
Asterisk__:__600525__:__DISTAL-LESS HOMEOBOX 3; DLX3__:____:__
Asterisk__:__600526__:__MAP/MICROTUBULE AFFINITY-REGULATING KINASE 2; MARK2__:__ELKL MOTIF KINASE; EMK1;; PAR1, C. ELEGANS, HOMOLOG OF, B; PAR1B__:__
Asterisk__:__600527__:__EPHRIN B2; EFNB2__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 5; EPLG5;; LIGAND OF EPH-RELATED KINASE 5; LERK5;; HTK LIGAND; HTKL__:__
Asterisk__:__600528__:__CARNITINE PALMITOYLTRANSFERASE I, LIVER; CPT1A__:__CPT IA;; CPT I, LIVER;; CPT1__:__
Asterisk__:__600529__:__AU-SPECIFIC RNA-BINDING PROTEIN; AUH__:__3-METHYLGLUTACONYL-CoA HYDRATASE__:__
Asterisk__:__600530__:__SOLUTE CARRIER FAMILY 9, MEMBER 2; SLC9A2__:__SODIUM/HYDROGEN EXCHANGER 2; NHE2__:__
Asterisk__:__600531__:__SOLUTE CARRIER FAMILY 9, MEMBER 4; SLC9A4__:__SODIUM/HYDROGEN EXCHANGER 4; NHE4__:__
Asterisk__:__600532__:__NADH-UBIQUINONE OXIDOREDUCTASE FLAVOPROTEIN 2; NDUFV2__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 24-KD SUBUNIT__:__
Asterisk__:__600533__:__VANG-LIKE 2; VANGL2__:__LOOP-TAIL-ASSOCIATED PROTEIN; LTAP;; LOOP-TAIL PROTEIN 1; LPP1;; VAN GOGH, DROSOPHILA, HOMOLOG OF, 2;; STRABISMUS, DROSOPHILA, HOMOLOG OF, 1; STBM1; STB1;; LOOP-TAIL, MOUSE, HOMOLOG OF;; KIAA1215__:__
Asterisk__:__600534__:__BONE MARROW STROMAL CELL ANTIGEN 2; BST2__:__TETHERIN;; CD317 ANTIGEN; CD317__:__
Asterisk__:__600535__:__MESENCHYME HOMEOBOX 2; MEOX2__:__MOX2 DIVERGED HOMEOBOX GENE;; MOX2, MOUSE, HOMOLOG OF;; GROWTH ARREST-SPECIFIC HOMEOBOX; GAX__:__
Asterisk__:__600536__:__INTEGRIN, ALPHA-7; ITGA7__:____:__
Asterisk__:__600537__:__RECQ PROTEIN-LIKE; RECQL__:__DNA HELICASE, RECQ-LIKE, TYPE 1; RECQL1__:__
Asterisk__:__600538__:__PEROXIREDOXIN 2; PRDX2__:__PRX2;; PEROXIDE REDUCTASE, THIOREDOXIN-DEPENDENT; TDPX1; TPX1;; NATURAL KILLER-ENHANCING FACTOR B; NKEFB__:__
Asterisk__:__600539__:__PROTEIN KINASE C, IOTA FORM; PRKCI__:__PROTEIN KINASE C, LAMBDA/IOTA;; PKC-LAMBDA/IOTA;; PRKC-LAMBDA/IOTA__:__
Asterisk__:__600540__:__TRANSCRIPTION FACTOR Sp4; SP4__:__HF1B__:__
Asterisk__:__600541__:__ETS VARIANT GENE 1; ETV1__:__ETS TRANSLOCATION VARIANT 1;; ER81, MOUSE, HOMOLOG OF__:__ETV1/TMPRSS2 FUSION GENE, INCLUDED;; ETV1/EWS FUSION GENE, INCLUDED
Asterisk__:__600542__:__NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 3; NR4A3__:__CHONDROSARCOMA, MYXOID EXTRASKELETAL, FUSED TO EWS; CSMF;; CHN;; NEURON-DERIVED ORPHAN RECEPTOR 1; NOR1;; MITOGEN-INDUCED NUCLEAR ORPHAN RECEPTOR; MINOR__:__NR4A3/EWS FUSION GENE, INCLUDED;; NR4A3/RBP56 FUSION GENE, INCLUDED;; NR4A3/TCF12 FUSION GENE, INCLUDED
Asterisk__:__600543__:__V-ERB-B2 AVIAN ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 4; ERBB4__:__ONCOGENE ERBB4;; TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER4__:__
Asterisk__:__600544__:__SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 1; SLC15A1__:__HYDROGEN ION/PEPTIDE COTRANSPORTER, INTESTINAL; HPEPT1__:__
Caret__:__600545__:__MOVED TO 300240__:____:__
NULL__:__600546__:__INTRAUTERINE GROWTH RETARDATION WITH INCREASED MITOMYCIN C SENSITIVITY__:____:__
Asterisk__:__600547__:__CYSTEINE CONJUGATE BETA-LYASE 1; CCBL1__:__BETA-LYASE, KIDNEY;; KYNURENINE AMINOTRANSFERASE I; KAT1__:__
Asterisk__:__600548__:__HEAT-SHOCK 70-KD PROTEIN 9; HSPA9__:__HSPA9B;; MORTALIN;; MORTALIN 2; MOT2;; MORTALIN, PERINUCLEAR;; GLUCOSE-REGULATED PROTEIN, 75-KD; GRP75__:__
Asterisk__:__600549__:__IK CYTOKINE, DOWNREGULATOR OF HLA II; IK__:__CYTOKINE IK;; IK FACTOR;; RED__:__
Asterisk__:__600550__:__CATHEPSIN O; CTSO__:____:__
Asterisk__:__600551__:__G PROTEIN-COUPLED RECEPTOR 4; GPR4__:____:__
Asterisk__:__600552__:__CHEMOKINE, C MOTIF, RECEPTOR 1; XCR1__:__CCXCR1;; G PROTEIN-COUPLED RECEPTOR 5; GPR5;; XC CHEMOKINE RECEPTOR 1; XCR1;; LYMPHOTACTIN RECEPTOR__:__
Asterisk__:__600553__:__G PROTEIN-COUPLED RECEPTOR 6; GPR6__:____:__
Asterisk__:__600554__:__INTERLEUKIN 15; IL15__:____:__
Asterisk__:__600555__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1; STAT1__:____:__
Asterisk__:__600556__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 2; STAT2__:____:__
Caret__:__600557__:__MOVED TO 102582__:____:__
Asterisk__:__600558__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 4; STAT4__:____:__
NULL__:__600559__:__HYDROCEPHALUS, ENDOCARDIAL FIBROELASTOSIS, AND CATARACTS__:__HEC SYNDROME__:__
Asterisk__:__600560__:__SHC TRANSFORMING PROTEIN 1; SHC1__:__SHC PROTEIN A; SHCA__:__p46, INCLUDED;; p52, INCLUDED;; p66, INCLUDED
NULL__:__600561__:__SPONDYLOEPIPHYSEAL DYSPLASIA WITH ATLANTOAXIAL INSTABILITY__:____:__
Asterisk__:__600562__:__CADHERIN 12; CDH12__:__N-CADHERIN 2;; CADHERIN, NEURONAL, 2;; BR-CADHERIN; CDHB__:__
Asterisk__:__600563__:__PROSTAGLANDIN F RECEPTOR; PTGFR__:__PROSTAGLANDIN RECEPTOR F(2-ALPHA)__:__
Asterisk__:__600564__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 4; ITIH4__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN-LIKE, 1; ITIHL1;; INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN-RELATED PROTEIN; IHRP;; PLASMA KALLIKREIN-SENSITIVE GLYCOPROTEIN 120; PK120__:__
Asterisk__:__600565__:__NEUREXIN I; NRXN1__:____:__
Asterisk__:__600566__:__NEUREXIN II; NRXN2__:____:__
Asterisk__:__600567__:__NEUREXIN III; NRXN3__:____:__
Asterisk__:__600568__:__NEUROLIGIN 1; NLGN1__:__NL1__:__
Caret__:__600569__:__MOVED TO 300103__:____:__
Asterisk__:__600570__:__CHLORIDE CHANNEL 2; CLCN2__:__CLC2__:__
Asterisk__:__600571__:__RE1-SILENCING TRANSCRIPTION FACTOR; REST__:__NEURON-RESTRICTIVE SILENCER FACTOR; NRSF__:__
Asterisk__:__600572__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 7; SRSF7__:__SERINE/ARGININE-RICH SPLICING FACTOR 7;; SPLICING FACTOR, ARGININE/SERINE-RICH, 7; SFRS7__:__
Asterisk__:__600573__:__TAF7 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 55-KD; TAF7__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2F; TAF2F;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 55-KD; TAFII55__:__
Asterisk__:__600574__:__LEUCINE ZIPPER-LIKE TRANSCRIPTIONAL REGULATOR 1; LZTR1__:____:__
Asterisk__:__600575__:__TRANSLIN; TSN__:__RECOMBINATION HOTSPOT-ASSOCIATED FACTOR 1; RCHF1;; TESTIS-BRAIN RNA-BINDING PROTEIN; TBRBP__:__
Asterisk__:__600576__:__GATA-BINDING PROTEIN 4; GATA4__:____:__
Asterisk__:__600577__:__LIM HOMEOBOX GENE 3; LHX3__:__LIM3__:__
Asterisk__:__600578__:__OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY H, MEMBER 3; OR2H3__:__OLFACTORY RECEPTOR 2; OLFR2__:__
Asterisk__:__600579__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, O; PTPRO__:__GLOMERULAR EPITHELIAL PROTEIN 1; GLEPP1;; PROTEIN TYROSINE PHOSPHATASE PTP-U2; PTPU2__:__
Asterisk__:__600580__:__CHLORIDE CHANNEL 3; CLCN3__:__CLC3__:__
Asterisk__:__600581__:__INHIBITOR OF DNA BINDING 4; ID4__:__IDB4__:__
Asterisk__:__600582__:__ASPARTATE BETA-HYDROXYLASE; ASPH__:__ASPARTYL/ASPARAGINYL-BETA-HYDROXYLASE; HAAH;; BAH__:__JUNCTIN, INCLUDED;; JUNCTATE, INCLUDED;; HUMBUG, INCLUDED
Asterisk__:__600583__:__TEC PROTEIN TYROSINE KINASE; TEC__:____:__
Asterisk__:__600584__:__NK2 HOMEOBOX 5; NKX2-5__:__NK2, DROSOPHILA, HOMOLOG OF, E; NKX2E;; CARDIAC-SPECIFIC HOMEOBOX 1; CSX1;; CSX;; NKX2.5, MOUSE, HOMOLOG OF__:__
Asterisk__:__600585__:__TRANSGLUTAMINASE 4; TGM4__:__TRANSGLUTAMINASE P; TGP;; TRANSGLUTAMINASE, PROSTATE__:__
Asterisk__:__600586__:__EPITHELIAL CELL TRANSFORMING SEQUENCE 2 ONCOGENE; ECT2__:__ONCOGENE ECT2__:__
Asterisk__:__600587__:__POM121/ZP3 FUSION PROTEIN; POMZP3__:__POMZP3 FUSION PROTEIN__:__
Caret__:__600588__:__MOVED TO 188025__:____:__
Asterisk__:__600589__:__SERUM RESPONSE FACTOR; SRF__:__C-FOS SERUM RESPONSE ELEMENT-BINDING FACTOR__:__
Asterisk__:__600590__:__PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, BETA ISOFORM; PPP1CB__:__PROTEIN PHOSPHATASE 1-BETA;; PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, DELTA ISOFORM; PPP1CD;; PROTEIN PHOSPHATASE 1-DELTA__:__
Asterisk__:__600591__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, POLYPEPTIDE 1; SNAPC1__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, 43-KD SUBUNIT; SNAP43;; PSE-BINDING TRANSCRIPTION FACTOR, GAMMA;; PTF-GAMMA__:__
Asterisk__:__600592__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 7; MCM7__:__MINICHROMOSOME MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, 7;; CDC47, S. CEREVISIAE, HOMOLOG OF; CDC47;; MCM2, FORMERLY__:__
Percent__:__600593__:__CRANIOSYNOSTOSIS, ADELAIDE TYPE; CRSA__:____:__
Asterisk__:__600594__:__DIGEORGE SYNDROME CRITICAL REGION GENE 2; DGCR2__:__INTEGRAL MEMBRANE PROTEIN DELETED IN DIGEORGE SYNDROME; IDD__:__
Asterisk__:__600595__:__INTRAFLAGELLAR TRANSPORT 88, CHLAMYDOMONAS, HOMOLOG OF; IFT88__:__TG737, MOUSE, HOMOLOG OF; TG737;; POLARIS, MOUSE, HOMOLOG OF;; TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 10; TTC10;; DAF19, C. ELEGANS, HOMOLOG OF; DAF19;; D13S1056E__:__
Asterisk__:__600596__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 4; MFAP4__:____:__
Asterisk__:__600597__:__PHOSPHOLIPASE C-LIKE 1; PLCL1__:__PHOSPHOLIPASE C DELETED IN LUNG CARCINOMA; PLCL;; PHOSPHOLIPASE C-RELATED CATALYTICALLY INACTIVE PROTEIN 1; PRIP1__:__
NULL__:__600598__:__SETTING-SUN PHENOMENON, FAMILIAL BENIGN__:____:__
Asterisk__:__600599__:__KRUPPEL-LIKE FACTOR 1; KLF1__:__ERYTHROID KRUPPEL-LIKE FACTOR; EKLF__:__
Asterisk__:__600600__:__EPHRIN RECEPTOR EphB1; EPHB1__:__NEURONALLY EXPRESSED EPH-RELATED TYROSINE KINASE; NET;; EPH TYROSINE KINASE 2; EPHT2;; HEK6;; ELK__:__
Caret__:__600601__:__MOVED TO 600289__:____:__
Caret__:__600602__:__MOVED TO 300083__:____:__
Caret__:__600603__:__MOVED TO 300071__:____:__
Caret__:__600604__:__MOVED TO 600376__:____:__
Asterisk__:__600605__:__METAXIN 1; MTX1__:__MTX;; MTXN__:__
Caret__:__600606__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__600607__:__VACUOLAR PROTEIN SORTING 72, YEAST, HOMOLOG OF; VPS72__:__TRANSCRIPTION FACTOR-LIKE 1; TCFL1;; TRANSFORMATION SUPPRESSOR GENE YL-1; YL1__:__
Asterisk__:__600608__:__PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, ISOFORM 2; P4HA2__:__PROLYL 4-HYDROXYLASE, ALPHA-2 SUBUNIT__:__
Asterisk__:__600609__:__GA-BINDING PROTEIN TRANSCRIPTION FACTOR, ALPHA SUBUNIT; GABPA__:__GABP-ALPHA;; NUCLEAR RESPIRATORY FACTOR 2, ALPHA SUBUNIT; NRF2A;; ADENOVIRUS E4 GENE TRANSCRIPTION FACTOR, 60-KD SUBUNIT;; E4TF1-60__:__
Asterisk__:__600610__:__GA-BINDING PROTEIN TRANSCRIPTION FACTOR, BETA SUBUNIT; GABPB__:____:__GA-BINDING PROTEIN TRANSCRIPTION FACTOR, BETA SUBUNIT 1, INCLUDED; GABPB1, INCLUDED;; GABP-BETA, INCLUDED;; NUCLEAR RESPIRATORY FACTOR 2, BETA SUBUNIT 1, INCLUDED; NRF2B1, INCLUDED;; NUCLEAR RESPIRATORY FACTOR 2, BETA SUBUNIT 2, INCLUDED; NRF2B2, INCLUDED;; ADENOVIRUS E4 GENE TRANSCRIPTION FACTOR 1, 53-KD SUBUNIT, INCLUDED;; E4TF1-53, INCLUDED;; GA-BINDING PROTEIN TRANSCRIPTION FACTOR, BETA SUBUNIT 2, INCLUDED; GABPB2, INCLUDED;; GABP-GAMMA, INCLUDED;; NUCLEAR RESPIRATORY FACTOR 2, GAMMA SUBUNIT 1, INCLUDED; NRF2G1, INCLUDED;; NUCLEAR RESPIRATORY FACTOR 2, GAMMA SUBUNIT 2, INCLUDED; NRF2G2, INCLUDED;; ADENOVIRUS E4 GENE TRANSCRIPTION FACTOR 1, 47-KD SUBUNIT, INCLUDED;; E4TF1-47, INCLUDED
Asterisk__:__600611__:__FK506-BINDING PROTEIN 4; FKBP4__:__T-CELL FK506-BINDING PROTEIN, 59-KD; FKBP59; FKBP52__:__
Caret__:__600612__:__MOVED TO 300101__:____:__
Asterisk__:__600613__:__NEUROBLASTOMA CANDIDATE REGION, SUPPRESSION OF TUMORIGENICITY 1; NBL1__:__DIFFERENTIAL SCREENING-SELECTED GENE ABERRANT IN NEUROBLASTOMA; DAN;; D1S1733E;; N03__:__
Asterisk__:__600614__:__S100 CALCIUM-BINDING PROTEIN P; S100P__:____:__
Asterisk__:__600615__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 7; LGALS7__:__GALECTIN 7; GAL7__:__
Asterisk__:__600616__:__LUMICAN; LUM__:__LDC__:__
Asterisk__:__600617__:__STEROIDOGENIC ACUTE REGULATORY PROTEIN; STAR__:__START DOMAIN-CONTAINING PROTEIN 1; STARD1__:__
Asterisk__:__600618__:__ETS VARIANT GENE 6; ETV6__:__TRANSLOCATION, ETS, LEUKEMIA; TEL;; TEL1 ONCOGENE__:__ETV6/PDGFRB FUSION GENE, INCLUDED;; ETV6/MN1 FUSION GENE, INCLUDED;; ETV6/AML1 FUSION GENE, INCLUDED;; ETV6/ARNT FUSION GENE, INCLUDED;; ETV6/MDS2 FUSION GENE, INCLUDED;; ETV6/ABL2 FUSION GENE, INCLUDED;; ETV6/PER1 FUSION GENE, INCLUDED;; ETV6/NTRK3 FUSION GENE, INCLUDED;; ETV6/ACS2 FUSION GENE, INCLUDED;; ETV6/BTL FUSION GENE, INCLUDED;; ETV6/JAK2 FUSION GENE, INCLUDED;; ETV6/RUNX1 FUSION GENE, INCLUDED
Caret__:__600619__:__MOVED TO 300097__:____:__
Asterisk__:__600620__:__FK506-BINDING PROTEIN 1B; FKBP1B__:__FK506-BINDING PROTEIN 1-LIKE; FKBP1L;; FK506-BINDING PROTEIN, 12.6-KD; FKBP12.6;; CALSTABIN 2__:__
Asterisk__:__600621__:__STATHMIN-LIKE 2; STMN2__:__SUPERIOR CERVICAL GANGLIA, NEURAL SPECIFIC, 10; SCGN10;; SUPERIOR CERVICAL GANGLION 10; SCG10;; NEURONAL GROWTH-ASSOCIATED PROTEIN SCG10__:__
Caret__:__600622__:__MOVED TO 300069__:____:__
Asterisk__:__600623__:__CD82 ANTIGEN; CD82__:__KANGAI 1; KAI1;; PROSTATE CANCER ANTIMETASTASIS GENE KAI1;; LEUKOCYTE SURFACE ANTIGEN R2; SAR2;; SUPPRESSOR OF TUMORIGENICITY 6; ST6;; R2 LEUKOCYTE ANTIGEN__:__
Percent__:__600624__:__CONE-ROD DYSTROPHY 1; CORD1__:__CRD1__:__
Number Sign__:__600625__:__OROFACIAL CLEFT 11; OFC11__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 11__:__CLEFT LIP, CONGENITAL HEALED, INCLUDED;; CONGENITAL HEALED CLEFT LIP, INCLUDED; CHCL, INCLUDED
Asterisk__:__600626__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING PROTEIN; LGALS3BP__:__MAC2-BINDING PROTEIN; MAC2BP;; SERUM PROTEIN 90K; 90K;; L3 ANTIGEN__:__
Number Sign__:__600627__:__HYPERTRYPTOPHANEMIA; HYPTRP__:__HYPERTRYPTOPHANEMIA, FAMILIAL__:__
NULL__:__600628__:__LOOSE ANAGEN HAIR SYNDROME__:____:__
Asterisk__:__600629__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DO BETA; HLA-DOB__:__HLA-DO HISTOCOMPATIBILITY TYPE, BETA CHAIN__:__
Number Sign__:__600630__:__UV-SENSITIVE SYNDROME 1; UVSS1__:____:__
Percent__:__600631__:__ENURESIS, NOCTURNAL, 1; ENUR1__:__BEDWETTING__:__
Asterisk__:__600632__:__OPIOID-BINDING PROTEIN/CELL ADHESION MOLECULE-LIKE; OPCML__:__OPIOID-BINDING CELL ADHESION MOLECULE;; OBCAM;; IGLON1__:__
Asterisk__:__600633__:__TREFOIL FACTOR 3; TFF3__:__INTESTINAL TREFOIL FACTOR; ITF__:__
Number Sign__:__600634__:__PITUITARY ADENOMA, PROLACTIN-SECRETING__:__PROLACTINOMA, FAMILIAL__:__
Asterisk__:__600635__:__NK2 HOMEOBOX 1; NKX2-1__:__THYROID TRANSCRIPTION FACTOR 1; TITF1;; TTF1;; THYROID NUCLEAR FACTOR;; NK2, DROSOPHILA, HOMOLOG OF, A; NKX2A;; NK2.1, MOUSE, HOMOLOG OF;; THYROID-SPECIFIC ENHANCER-BINDING PROTEIN; TEBP__:__
Asterisk__:__600636__:__CASPASE 3, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP3__:__PARP CLEAVAGE PROTEASE;; APOPAIN;; CPP32;; YAMA__:__
Asterisk__:__600637__:__SOLUTE CARRIER FAMILY 1 (HIGH AFFINITY ASPARTATE/GLUTAMATE TRANSPORTER), MEMBER 6; SLC1A6__:__EXCITATORY AMINO ACID TRANSPORTER 4; EAAT4__:__
Number Sign__:__600638__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3A, WITH OR WITHOUT EXTRAOCULAR INVOLVEMENT; CFEOM3A__:__FEOM3 LOCUS__:__
Asterisk__:__600639__:__CASPASE 2, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP2__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 2; NEDD2;; ICE AND CED3 HOMOLOG 1; ICH1__:__
Caret__:__600640__:__MOVED TO 311770__:____:__
Asterisk__:__600641__:__SULFOTRANSFERASE FAMILY 1A, CYTOSOLIC, PHENOL-PREFERRING, MEMBER 3; SULT1A3__:__SULFOTRANSFERASE, MONOAMINE-PREFERRING; STM__:__
Asterisk__:__600642__:__MYOSIN IG; MYO1G__:__MINOR HISTOCOMPATIBILITY ANTIGEN HA-2; HA2;; HLA-HA2;; D6S207E__:__
NULL__:__600643__:__CAROLI DISEASE, ISOLATED__:____:__
Asterisk__:__600644__:__NECTIN 1; NECTIN1__:__POLIOVIRUS RECEPTOR-LIKE 1; PVRL1;; HERPESVIRUS ENTRY MEDIATOR C; HVEC;; POLIOVIRUS RECEPTOR-RELATED 1; PVRR1;; PVRR; PRR__:__
Caret__:__600645__:__MOVED TO 600579__:____:__
Asterisk__:__600646__:__PROTEIN C RECEPTOR; PROCR__:__ENDOTHELIAL PROTEIN C RECEPTOR; EPCR;; CELL CYCLE, CENTROSOME-ASSOCIATED PROTEIN; CCCA;; CCD41__:__
Asterisk__:__600647__:__H6 FAMILY HOMEOBOX 2; HMX2__:__HOMEOBOX GENE H6-LIKE; H6L;; NKX5.2__:__
Caret__:__600648__:__MOVED TO 113800__:____:__
Number Sign__:__600649__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY WITH HYPOKETOTIC HYPOGLYCEMIA;; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, HEPATOCARDIOMUSCULAR;; CPT II DEFICIENCY, HEPATIC;; CPT2 DEFICIENCY, INFANTILE__:__
Asterisk__:__600650__:__CARNITINE PALMITOYLTRANSFERASE II; CPT2__:__CPT II__:__
Number Sign__:__600651__:__FRAGILE SITE 11B; FRA11B__:____:__
Number Sign__:__600652__:__DEAFNESS, AUTOSOMAL DOMINANT 4A; DFNA4A__:__DEAFNESS, AUTOSOMAL DOMINANT 4; DFNA4__:__
Caret__:__600653__:__MOVED TO 600381__:____:__
Asterisk__:__600654__:__PROTEASOME ACTIVATOR SUBUNIT 1; PSME1__:__PROTEASOME ACTIVATOR 28-ALPHA;; PA28-ALPHA; PA28A;; INTERFERON-GAMMA-INDUCIBLE PROTEIN 5111; IFI5111;; MCP ACTIVATOR, 29-KD SUBUNIT__:__
Asterisk__:__600655__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, BETA-2; EEF1B2__:__ELONGATION FACTOR 1, BETA-2A;; ELONGATION FACTOR 1, BETA; EF1B__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, BETA-1, PSEUDOGENE, INCLUDED; EEF1B1, INCLUDED; EEF1B2P1, INCLUDED;; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, BETA-3, PSEUDOGENE, INCLUDED; EEF1B3, INCLUDED; EEF1B2P2, INCLUDED;; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, BETA-4, PSEUDOGENE, INCLUDED; EEF1B4, INCLUDED; EEF1B2P3, INCLUDED
Caret__:__600656__:__MOVED TO 600655__:____:__
Caret__:__600657__:__MOVED TO 300140__:____:__
Asterisk__:__600658__:__PROTEIN PHOSPHATASE 5, CATALYTIC SUBUNIT; PPP5C__:__PP5__:__
Asterisk__:__600659__:__E2F TRANSCRIPTION FACTOR 4; E2F4__:____:__
Asterisk__:__600660__:__MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE A; MEF2A__:____:__
Asterisk__:__600661__:__MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE B; MEF2B__:____:__
Asterisk__:__600662__:__MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE C; MEF2C__:____:__
Asterisk__:__600663__:__MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE D; MEF2D__:____:__
Asterisk__:__600664__:__CONSERVED HELIX-LOOP-HELIX UBIQUITOUS KINASE; CHUK__:__INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, KINASE OF, ALPHA; IKBKA;; NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, KINASE OF, ALPHA; NFKBIKA;; I-KAPPA-B KINASE-ALPHA;; IKK-ALPHA; IKKA;; I-KAPPA-B KINASE 1; IKK1__:__
Asterisk__:__600665__:__MELATONIN RECEPTOR 1A; MTNR1A__:__MT1__:__
Number Sign__:__600666__:__POLYCYSTIC KIDNEY DISEASE 3 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD3__:__POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE III; APKD3__:__
Asterisk__:__600667__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 2; FZD2__:____:__
Percent__:__600668__:__CHONDROCALCINOSIS 1; CCAL1__:__CHONDROCALCINOSIS WITH EARLY-ONSET OSTEOARTHRITIS__:__
Percent__:__600669__:__EPILEPSY, IDIOPATHIC GENERALIZED; EIG__:__IDIOPATHIC GENERALIZED EPILEPSY; IGE__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 1, INCLUDED; EIG1, INCLUDED;; EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 8, INCLUDED
NULL__:__600670__:__VARICELLA, SEVERE RECURRENT__:____:__
Caret__:__600671__:__MOVED TO 600594__:____:__
Caret__:__600672__:__MOVED TO 300025__:____:__
Asterisk__:__600673__:__UPSTREAM BINDING TRANSCRIPTION FACTOR (RNA POLYMERASE I); UBTF__:__UPSTREAM BINDING FACTOR; UBF__:__
Percent__:__600674__:__MICROTIA-ANOTIA__:____:__
Asterisk__:__600675__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 3; XRCC3__:__X-RAY REPAIR CROSS-COMPLEMENTING PROTEIN 3__:__
Asterisk__:__600676__:__CATR TUMORIGENIC CONVERSION 1; CATR1__:____:__
Caret__:__600677__:__MOVED TO 300192__:____:__
Asterisk__:__600678__:__MutS, E. COLI, HOMOLOG OF, 6; MSH6__:__G/T MISMATCH-BINDING PROTEIN; GTBP__:__
NULL__:__600679__:__DERMOID CYSTS, FAMILIAL FRONTONASAL__:____:__
Caret__:__600680__:__MOVED TO 256730__:____:__
Asterisk__:__600681__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 2; KCNJ2__:__HHIRK1;; IRK1;; KIR2.1__:__
Asterisk__:__600682__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 1; SLC16A1__:__MONOCARBOXYLATE TRANSPORTER 1; MCT1__:__
Caret__:__600683__:__MOVED TO 109190__:____:__
Asterisk__:__600684__:__T-LYMPHOCYTE SURFACE ANTIGEN LY-9; LY9__:__CD229;; SLAM FAMILY, MEMBER 3; SLAMF3__:__
Asterisk__:__600685__:__KARYOPHERIN ALPHA-2; KPNA2__:__RECOMBINATION-ACTIVATING GENE COHORT 1; RCH1;; SRP1-ALPHA;; IMPORTIN ALPHA-1;; QIP2__:__
Asterisk__:__600686__:__KARYOPHERIN ALPHA-1; KPNA1__:__SUPPRESSOR OF RNA POLYMERASE I MUTATION, S. CEREVISIAE, HOMOLOG OF; SRP1;; RECOMBINATION ACTIVATING GENE COHORT 2; RCH2;; IMPORTIN ALPHA-5__:__
Asterisk__:__600687__:__T-CELL LYMPHOMA INVASION AND METASTASIS 1; TIAM1__:____:__
Asterisk__:__600688__:__CARBOXYPEPTIDASE A2, PANCREATIC; CPA2__:__PROCARBOXYPEPTIDASE A2, PANCREATIC__:__
Caret__:__600689__:__MOVED TO 300096__:____:__
Asterisk__:__600690__:__T-CELL LEUKEMIA TRANSLOCATION-ASSOCIATED GENE; TCTA__:____:__
Asterisk__:__600691__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 1; SLC27A1__:__LONG CHAIN FATTY ACID TRANSPORT PROTEIN; FATP;; FATTY ACID TRANSPORT PROTEIN 1; FATP1;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 4; ACSVL4__:__
Asterisk__:__600692__:__TROPONIN T3, FAST SKELETAL; TNNT3__:____:__
Asterisk__:__600693__:__POLYPYRIMIDINE TRACT-BINDING PROTEIN 1; PTBP1__:__PTB;; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE I;; HNRNPI__:__
Asterisk__:__600694__:__INTERLEUKIN 6 SIGNAL TRANSDUCER; IL6ST__:__GP130 TRANSDUCER CHAIN; GP130__:__
Caret__:__600695__:__MOVED TO 601434__:____:__
Asterisk__:__600696__:__ENOYL-CoA HYDRATASE 1, PEROXISOMAL; ECH1__:__DELTA-3,5-DELTA-2,4-DIENOYL CoA ISOMERASE__:__
Asterisk__:__600697__:__RETINOBLASTOMA-BINDING PROTEIN 5; RBBP5__:__RETINOBLASTOMA-BINDING PROTEIN RBQ3;; RBQ3__:__
Asterisk__:__600698__:__HIGH MOBILITY GROUP AT-HOOK 2; HMGA2__:__HIGH MOBILITY GROUP PROTEIN I-C; HMGIC;; HIGH MOBILITY GROUP PROTEIN HMGIC BREAKPOINT ASSOCIATED WITH BENIGN LIPOMA; BABL;; LIPO__:__HMGIC/LPP FUSION GENE, INCLUDED;; HMGIC/LHFP FUSION GENE, INCLUDED;; HMGIC/RAD51L1 FUSION GENE, INCLUDED;; HMGIC/HEI10 FUSION GENE, INCLUDED;; HMGIC/ALDH2 FUSION GENE, INCLUDED;; HMGIC/COX6C FUSION GENE, INCLUDED
Caret__:__600699__:__MOVED TO 400003__:____:__
Asterisk__:__600700__:__LIM DOMAIN-CONTAINING PREFERRED TRANSLOCATION PARTNER IN LIPOMA; LPP__:__LIPOMA-PREFERRED PARTNER__:__LPP/MLL FUSION GENE, INCLUDED;; LPP/HMGIC FUSION GENE, INCLUDED
Asterisk__:__600701__:__HIGH MOBILITY GROUP AT-HOOK 1; HMGA1__:__HMGIY;; HIGH MOBILITY GROUP PROTEIN Ia; HMGA1A;; HIGH MOBILITY GROUP PROTEIN I__:__HIGH MOBILITY GROUP PROTEIN Ib, INCLUDED; HMGA1B, INCLUDED;; HIGH MOBILITY GROUP PROTEIN Y, INCLUDED; HMGIY, INCLUDED;; HIGH MOBILITY GROUP PROTEIN Ic, INCLUDED; HMGA1C, INCLUDED
Asterisk__:__600702__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE VIII, ALPHA SUBUNIT; SCN8A__:__NAV1.6__:__
Asterisk__:__600703__:__RIBOSOMAL PROTEIN S1-LIKE; RPS1L__:____:__
Caret__:__600704__:__MOVED TO 300047__:____:__
NULL__:__600705__:__SATOYOSHI SYNDROME__:__KOMURAGAERI DISEASE;; MUSCLE SPASMS, INTERMITTENT, WITH ALOPECIA, DIARRHEA, AND SKELETAL ABNORMALITIES__:__
NULL__:__600706__:__PROXIMAL MYOPATHY WITH FOCAL DEPLETION OF MITOCHONDRIA__:____:__
Asterisk__:__600707__:__SIGNAL RECOGNITION PARTICLE, 9-KD; SRP9__:__Alu RNA BINDING PROTEIN, 9-KD SUBUNIT; ALURBP__:__
Asterisk__:__600708__:__SIGNAL RECOGNITION PARTICLE, 14-KD; SRP14__:__Alu RNA-BINDING PROTEIN, 14-KD SUBUNIT; ALURBP__:__
Asterisk__:__600709__:__ISOLEUCYL-tRNA SYNTHETASE; IARS__:__ILRS;; ILERS__:__
Caret__:__600710__:__MOVED TO 600564__:____:__
Asterisk__:__600711__:__ETS VARIANT GENE 4; ETV4__:__ETS TRANSLOCATION VARIANT 4;; E1A ENHANCER BINDING PROTEIN; E1AF__:__ETV4/EWS FUSION GENE, INCLUDED
Asterisk__:__600712__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; HNRNPK__:__HNRPK__:__
Asterisk__:__600713__:__11-BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE I; HSD11B1__:__HSD11L__:__
Asterisk__:__600714__:__DUAL-SPECIFICITY PHOSPHATASE 1; DUSP1__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 10; PTPN10;; CL100;; MAP KINASE PHOSPHATASE 1; MKP1__:__
Asterisk__:__600715__:__THROMBOSPONDIN IV; THBS4__:____:__
Asterisk__:__600716__:__PROTEIN TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 22; PTPN22__:__PEST-DOMAIN PHOSPHATASE; PEP;; LYMPHOID PHOSPHATASE; LYP;; PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE 8, FORMERLY; PTPN8, FORMERLY__:__
Caret__:__600717__:__MOVED TO 120165__:____:__
Caret__:__600718__:__MOVED TO 185535__:____:__
Asterisk__:__600719__:__NITRIC OXIDE SYNTHASE 2B; NOS2B__:____:__
Asterisk__:__600720__:__NITRIC OXIDE SYNTHASE 2C; NOS2C__:____:__
Number Sign__:__600721__:__D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1__:__D2HGA__:__
Asterisk__:__600722__:__PALMITOYL-PROTEIN THIOESTERASE 1; PPT1__:__PALMITOYL-PROTEIN THIOESTERASE; PPT__:__
Asterisk__:__600723__:__MEMBRANE PROTEIN, PALMITOYLATED 2; MPP2__:__DISCS LARGE A, DROSOPHILA, HOMOLOG OF;; DLG-A TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF;; DISCS LARGE, HOMOLOG 2, FORMERLY; DLG2, FORMERLY__:__
Asterisk__:__600724__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, BETA-1; CNGB1__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, PHOTORECEPTOR, cGMP-GATED, 2; CNCG2;; CYCLIC NUCLEOTIDE-GATED CHANNEL, PHOTORECEPTOR, cGMP-GATED, 3-LIKE; CNCG3L;; GLUTAMIC ACID-RICH PROTEIN 1; GAR1; GARP;; RETINAL ROD cGMP-GATED CHANNEL, BETA SUBUNIT;; RETINAL ROD cGMP-GATED CHANNEL, GAMMA SUBUNIT__:__
Asterisk__:__600725__:__SONIC HEDGEHOG; SHH__:____:__
Asterisk__:__600726__:__INDIAN HEDGEHOG; IHH__:____:__
Asterisk__:__600727__:__NUCLEAR FACTOR I/A; NFIA__:__TRANSCRIPTION FACTOR NFIA;; KIAA1439__:__
Asterisk__:__600728__:__NUCLEAR FACTOR I/B; NFIB__:__TRANSCRIPTION FACTOR NFIB__:__
Asterisk__:__600729__:__NUCLEAR FACTOR I/C; NFIC__:__TRANSCRIPTION FACTOR NFIC;; CTF__:__
Asterisk__:__600730__:__NEUROPEPTIDES B AND W RECEPTOR 1; NPBWR1__:__NPB AND NPW RECEPTOR 1;; G PROTEIN-COUPLED RECEPTOR 7; GPR7;; OPIOID-SOMATOSTATIN-LIKE RECEPTOR 7__:__
Asterisk__:__600731__:__G PROTEIN-COUPLED RECEPTOR 8; GPR8__:__OPIOID-SOMATOSTATIN-LIKE RECEPTOR 8__:__
Asterisk__:__600732__:__ADP-RIBOSYLATION FACTOR-LIKE 4D; ARL4D__:__ADP-RIBOSYLATION FACTOR 4-LIKE; ARF4L__:__
Asterisk__:__600733__:__PANCREAS/DUODENUM HOMEOBOX PROTEIN 1; PDX1__:__PANCREATIC AND DUODENAL HOMEOBOX 1;; INSULIN PROMOTER FACTOR 1; IPF1;; HOMEODOMAIN TRANSCRIPTION FACTOR IPF1;; SOMATOSTATIN TRANSCRIPTION FACTOR 1; STF1;; IDX1__:__
Asterisk__:__600734__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 5; KCNJ5__:__CARDIAC INWARD RECTIFIER; CIR;; G PROTEIN-ACTIVATED INWARDLY RECTIFYING POTASSIUM CHANNEL 4; GIRK4;; INWARDLY RECTIFYING POTASSIUM CHANNEL KIR3.4;; KATP1__:__
Asterisk__:__600735__:__INTERFERON-INDUCED PROTEIN 35; IFI35__:__INTERFERON-INDUCIBLE PROTEIN, 35-KD; IFP35__:__
NULL__:__600736__:__VELOFACIOSKELETAL SYNDROME__:____:__
Caret__:__600737__:__MOVED TO 605820__:____:__
Asterisk__:__600738__:__SELECTIN P LIGAND; SELPLG__:__P-SELECTIN GLYCOPROTEIN LIGAND;; PSGL1__:__
Asterisk__:__600739__:__SHC-LIKE PROTEIN; SHCL1__:____:__
Number Sign__:__600740__:__HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3__:__FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE__:__
Caret__:__600741__:__MOVED TO 176636__:____:__
Asterisk__:__600742__:__TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE III; TGFBR3__:__BETA-GLYCAN__:__
Asterisk__:__600743__:__TRANSCRIPTION FACTOR AP4; TFAP4__:____:__
Asterisk__:__600744__:__T-CELL TRANSCRIPTION FACTOR EB; TFEB__:__TCFEB__:__TFEB/ALPHA FUSION GENE, INCLUDED
Asterisk__:__600745__:__APOLIPOPROTEIN C-IV; APOC4__:____:__
Asterisk__:__600746__:__CAUDAL-TYPE HOMEOBOX TRANSCRIPTION FACTOR 1; CDX1__:____:__
Asterisk__:__600747__:__T-BOX 2; TBX2__:____:__
Asterisk__:__600748__:__TRANSMEMBRANE BAX INHIBITOR MOTIF-CONTAINING PROTEIN 6; TMBIM6__:__BAX INHIBITOR 1; BI1;; TESTIS-ENHANCED GENE TRANSCRIPT; TEGT__:__
Asterisk__:__600749__:__CCAAT/ENHANCER-BINDING PROTEIN, EPSILON; CEBPE__:__C/EBP-EPSILON;; CRP1__:__
Asterisk__:__600750__:__PENTRAXIN II, NEURONAL; NPTX2__:__NP2;; NEURONAL ACTIVITY-REGULATED PENTRAXIN; NARP__:__
Asterisk__:__600751__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 1; SIGLEC1__:__SIALOADHESIN; SN;; CD169__:__
Asterisk__:__600752__:__G PROTEIN-COUPLED RECEPTOR 12; GPR12__:____:__
Asterisk__:__600753__:__GOLGI APPARATUS PROTEIN 1; GLG1__:__GOLGI SIALOGLYCOPROTEIN MG-160;; E-SELECTIN LIGAND 1, MOUSE, HOMOLOG OF; ESL1__:__
Asterisk__:__600754__:__MATRIX METALLOPROTEINASE 14; MMP14__:__MATRIX METALLOPROTEINASE 14, MEMBRANE-TYPE;; MEMBRANE-TYPE MATRIX METALLOPROTEINASE 1;; MT1-MMP__:__
Asterisk__:__600755__:__SYNAPSIN II; SYN2__:____:__
Asterisk__:__600756__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-PRIME; PPP2R4__:__PROTEIN PHOSPHATASE 2A, REGULATORY SUBUNIT B-PRIME;; PHOSPHOTYROSYL PHOSPHATASE ACTIVATOR; PTPA;; PR53__:__
Percent__:__600757__:__OROFACIAL CLEFT 3; OFC3__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 3__:__
Asterisk__:__600758__:__PROTEIN-TYROSINE KINASE, CYTOPLASMIC; PTK2__:__FOCAL ADHESION KINASE; FAK;; FOCAL ADHESION KINASE 1; FAK1__:__
Asterisk__:__600759__:__PRESENILIN 2; PSEN2__:__PS2;; STM2__:__
Asterisk__:__600760__:__SODIUM CHANNEL, NONVOLTAGE-GATED 1, BETA SUBUNIT; SCNN1B__:__SODIUM CHANNEL, EPITHELIAL, BETA SUBUNIT; SCNEB__:__
Asterisk__:__600761__:__SODIUM CHANNEL, NONVOLTAGE-GATED 1, GAMMA SUBUNIT; SCNN1G__:__SODIUM CHANNEL, EPITHELIAL, GAMMA SUBUNIT; SCNEG__:__
Asterisk__:__600762__:__HUMAN PAPILLOMAVIRUS E5 CENTRAL SEQUENCE-LIKE 1; HPVC1__:__PAPILLOMAVIRUS E5-LIKE PROTEIN; PE5L__:__
Asterisk__:__600763__:__TUMOR PROTEIN, TRANSLATIONALLY-CONTROLLED 1; TPT1__:__TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TCTP;; HISTAMINE-RELEASING FACTOR, IMMUNOGLOBULIN E-DEPENDENT; HRF__:__
Asterisk__:__600764__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I-RELATED; MR1__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I-LIKE SEQUENCE; HLALS;; MHC-RELATED PROTEIN 1__:__
Caret__:__600765__:__MOVED TO 600137__:____:__
Caret__:__600766__:__MOVED TO 300104__:____:__
Asterisk__:__600767__:__GDP-DISSOCIATION INHIBITOR 2; GDI2__:__RAB GDP-DISSOCIATION INHIBITOR, BETA; RABGDIB;; RAB GDI-BETA__:__
Asterisk__:__600768__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 9; PTPN9__:____:__
Asterisk__:__600769__:__TETRASPANIN 8; TSPAN8__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 3; TM4SF3;; TUMOR ASSOCIATED ANTIGEN CO-029__:__
Asterisk__:__600770__:__MUCIN 5, SUBTYPE B, TRACHEOBRONCHIAL; MUC5B__:__MUC5__:__
Percent__:__600771__:__DWARFISM, FAMILIAL, WITH MUSCLE SPASMS__:____:__
Asterisk__:__600772__:__TAF11 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 28-KD; TAF11__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2I;; TAF2I TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 28-KD; TAFII28__:__
Asterisk__:__600773__:__TAF12 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 20-KD; TAF12__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2J; TAF2J;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 20-KD; TAFII20__:__
Asterisk__:__600774__:__TAF13 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 18-KD; TAF13__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2K; TAF2K;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 18-KD; TAFII18__:__
Number Sign__:__600775__:__CRANIOSYNOSTOSIS 4; CRS4__:____:__
NULL__:__600776__:__FRYNS MICROPHTHALMIA SYNDROME__:__MICROPHTHALMIA WITH FACIAL CLEFTING;; ANOPHTHALMIA-PLUS SYNDROME__:__
Asterisk__:__600777__:__TRANSCRIPTION TERMINATION FACTOR, RNA POLYMERASE I; TTF1__:____:__
Asterisk__:__600778__:__CYCLIN-DEPENDENT KINASE INHIBITOR 1B; CDKN1B__:__p27(KIP1);; KIP1__:__
Caret__:__600779__:__MOVED TO 164874__:____:__
Caret__:__600780__:__MOVED TO 241410__:____:__
Asterisk__:__600781__:__PEPTIDE YY; PYY__:____:__
Asterisk__:__600782__:__SYNAPTOTAGMIN 5; SYT5__:____:__
Asterisk__:__600783__:__HISTIDYL-tRNA SYNTHETASE 2; HARS2__:__HISTIDYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL HISRS;; HISTIDYL-tRNA SYNTHETASE-LIKE; HARSL;; HARS-RELATED GENE; HARSR;; HO3__:__
Asterisk__:__600784__:__GRANZYME K; GZMK__:__TRYPTASE II; TRYP2;; GRANZYME 3__:__
Percent__:__600785__:__VITAMIN D-DEPENDENT RICKETS, TYPE 2B, WITH NORMAL VITAMIN D RECEPTOR; VDDR2B__:____:__
Asterisk__:__600786__:__ELONGIN A; ELOA__:__TRANSCRIPTION ELONGATION FACTOR B, POLYPEPTIDE 3; TCEB3;; TCEB3A;; ELONGIN A1;; ELONGIN, 110-KD SUBUNIT__:__
Asterisk__:__600787__:__ELONGIN B; ELOB__:__TRANSCRIPTION ELONGATION FACTOR B, POLYPEPTIDE 2; TCEB2;; ELONGIN, 18-KD SUBUNIT__:__
Asterisk__:__600788__:__ELONGIN C; ELOC__:__TRANSCRIPTION ELONGATION FACTOR B, POLYPEPTIDE 1; TCEB1;; ELONGIN, 15-KD SUBUNIT__:__
Asterisk__:__600789__:__RIBOSOMAL PROTEIN L23-LIKE; RPL23L__:__L23 MITOCHONDRIAL-RELATED PROTEIN; L23MRP; MRPL23__:__
Percent__:__600790__:__CHORIORETINAL ATROPHY, PROGRESSIVE BIFOCAL__:__CRAPB;; PROGRESSIVE BIFOCAL CHORIORETINAL ATROPHY; PBCRA__:__
Number Sign__:__600791__:__DEAFNESS, AUTOSOMAL RECESSIVE 4, WITH ENLARGED VESTIBULAR AQUEDUCT; DFNB4__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 4; NSRD4;; DILATED VESTIBULAR AQUEDUCT; DVA__:__
Percent__:__600792__:__DEAFNESS, AUTOSOMAL RECESSIVE 5; DFNB5__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 5; NSRD5__:__
Caret__:__600793__:__MOVED TO 300081__:____:__
Number Sign__:__600794__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; HMN5A__:__HMN VA;; NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V; HMN5;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA; DHMN5A;; DHMN VA;; SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA; DSMAVA;; SPINAL MUSCULAR ATROPHY, DISTAL, TYPE V; DSMAV;; SPINAL MUSCULAR ATROPHY, DISTAL, WITH UPPER LIMB PREDOMINANCE__:__
Number Sign__:__600795__:__FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED; FTD3__:__DMT1; DEM;; DEMENTIA, FAMILIAL NONSPECIFIC__:__
Asterisk__:__600796__:__SPLICING FACTOR 3A, SUBUNIT 2; SF3A2__:__SF3A, 66-KD SUBUNIT; SF3A66;; SPLICEOSOME-ASSOCIATED PROTEIN, 62-KD; SAP62__:__
Asterisk__:__600797__:__INSULIN RECEPTOR SUBSTRATE 2; IRS2__:____:__
Asterisk__:__600798__:__NECTIN 2; NECTIN2__:__POLIOVIRUS RECEPTOR-LIKE 2; PVRL2;; HERPESVIRUS ENTRY MEDIATOR B; HVEB;; POLIOVIRUS RECEPTOR-RELATED 2; PVRR2; PRR2;; CD112 ANTIGEN; CD112;; NECTIN 2__:__
Asterisk__:__600799__:__BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE II; BMPR2__:____:__
Asterisk__:__600800__:__NGFIA-BINDING PROTEIN; NAB1__:__EGR1-BINDING PROTEIN 1__:__
NULL__:__600801__:__ISOPROTERENOL-MEDIATED VASODILATATION__:____:__
Number Sign__:__600802__:__SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE__:__SCID, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-NEGATIVE__:__
Number Sign__:__600803__:__GALLBLADDER DISEASE 1; GBD1__:__CHOLELITHIASIS, LOW PHOSPHOLIPID-ASSOCIATED; LPAC__:__
Asterisk__:__600804__:__MELATONIN RECEPTOR 1B; MTNR1B__:__MEL1B;; MT2__:__
Asterisk__:__600805__:__LAMININ, ALPHA-3; LAMA3__:__LAMININ A3;; LAMININ 5, ALPHA-3 SUBUNIT;; LAM5, ALPHA-3 SUBUNIT;; EPILIGRIN, 170-KD SUBUNIT;; BM600__:__
Asterisk__:__600806__:__CALPONIN 1; CNN1__:__CALPONIN, BASIC, SMOOTH MUSCLE;; CALPONIN H1, MOUSE, HOMOLOG OF;; SMOOTH MUSCLE-CELL CALPONIN; SMCC__:__
Number Sign__:__600807__:__ASTHMA, SUSCEPTIBILITY TO__:__ASTHMA, BRONCHIAL;; ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO__:__ASTHMA, PROTECTION AGAINST, INCLUDED;; ASTHMA, DIMINISHED RESPONSE TO ANTILEUKOTRIENE TREATMENT IN, INCLUDED
Percent__:__600808__:__ENURESIS, NOCTURNAL, 2; ENUR2__:____:__
Caret__:__600809__:__MOVED TO 132890__:____:__
Asterisk__:__600810__:__PHOSPHOLIPASE C, BETA-4; PLCB4__:__PLC-BETA-4__:__
Asterisk__:__600811__:__DNA DAMAGE-BINDING PROTEIN 2; DDB2__:__DDB, p48 SUBUNIT__:__
Asterisk__:__600812__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 1; SRSF1__:__SERINE/ARGININE-RICH SPLICING FACTOR 1;; SPLICING FACTOR, ARGININE/SERINE-RICH, 1; SFRS1;; ALTERNATIVE SPLICING FACTOR; ASF;; SPLICING FACTOR 2; SF2;; SPLICING FACTOR, ARGININE/SERINE-RICH, 30-KD, A; SRp30a__:__
Asterisk__:__600813__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 2; SRSF2__:__SERINE/ARGININE-RICH SPLICING FACTOR 2;; SPLICING FACTOR SC35; SC35;; SPLICING FACTOR, ARGININE/SERINE-RICH, 30-KD, B; SRp30b;; SPLICING FACTOR, ARGININE/SERINE-RICH, 2; SFRS2__:__
Asterisk__:__600814__:__MEIOTIC RECOMBINATION 11, S. CEREVISIAE, HOMOLOG OF, A; MRE11A__:__MRE11__:__
Asterisk__:__600815__:__POLYMERASE (DNA-DIRECTED), DELTA 2, REGULATORY SUBUNIT; POLD2__:__DNA POLYMERASE, DELTA 2, SMALL SUBUNIT__:__
Asterisk__:__600816__:__HEAT-SHOCK 70-KD PROTEIN 8; HSPA8__:__HEAT-SHOCK COGNATE PROTEIN, 71-KD; HSC71;; HSP73;; HSC70;; HEAT-SHOCK 70-KD PROTEIN 10, FORMERLY; HSPA10, FORMERLY;; LIPOPOLYSACCHARIDE-ASSOCIATED PROTEIN 1; LAP1;; LPS-ASSOCIATED PROTEIN 1__:__
Asterisk__:__600817__:__VISININ-LIKE 1; VSNL1__:__VILIP;; VILIP1__:__
Asterisk__:__600818__:__TRANSGELIN; TAGLN__:__SM22-ALPHA; SM22__:__
Asterisk__:__600819__:__FMR1 AUTOSOMAL HOMOLOG 1; FXR1__:__FRAGILE X-RELATED PROTEIN 1; FXR1P;; FRAGILE X MENTAL RETARDATION, AUTOSOMAL HOMOLOG 1__:__
Asterisk__:__600820__:__ARCHAIN 1; ARCN1__:__COATOMER PROTEIN COMPLEX, SUBUNIT DELTA; COPD;; COP, DELTA__:__
Asterisk__:__600821__:__ARGININE VASOPRESSIN RECEPTOR 1A; AVPR1A__:____:__
Asterisk__:__600822__:__TAF9 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 32-KD; TAF9__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2G; TAF2G;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 32-KD; TAFII32;; TAFII31__:__
Asterisk__:__600823__:__PROTEASE, SERINE, 8; PRSS8__:__PROSTASIN__:__
Asterisk__:__600824__:__CYSTEINE- AND GLYCINE-RICH PROTEIN 3; CSRP3__:__CYSTEINE-RICH PROTEIN 3; CRP3;; LIM DOMAIN PROTEIN, CARDIAC;; CLP LIM DOMAIN PROTEIN, MUSCLE; MLP__:__
Asterisk__:__600825__:__RAR-RELATED ORPHAN RECEPTOR A; RORA__:__RAR-RELATED ORPHAN RECEPTOR ALPHA;; RZR-ALPHA; RZRA;; RETINOIC ACID-BINDING RECEPTOR ALPHA__:__
Asterisk__:__600826__:__CHONDROITIN SULFATE PROTEOGLYCAN 3; CSPG3__:__NEUROCAN; NCAN__:__
Asterisk__:__600827__:__PHOSPHODIESTERASE 6C, cGMP-SPECIFIC, CONE, ALPHA-PRIME; PDE6C__:__PDEA2__:__
Asterisk__:__600828__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, O SUBUNIT; ATP5O__:__MITOCHONDRIAL ATP SYNTHASE, O SUBUNIT;; OLIGOMYCIN SENSITIVITY-CONFERRING PROTEIN; OSCP__:__
Asterisk__:__600829__:__INOSITOL POLYPHOSPHATE PHOSPHATASE-LIKE 1; INPPL1__:__SH2-CONTAINING INOSITOL PHOSPHATASE 2; SHIP2__:__
Asterisk__:__600830__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 26; TRIM26__:__ACID FINGER PROTEIN; AFP;; ZINC FINGER PROTEIN 173, FORMERLY; ZNF173, FORMERLY__:__
Asterisk__:__600831__:__DEATH-ASSOCIATED PROTEIN KINASE 1; DAPK1__:__DAPK__:__
Asterisk__:__600832__:__ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER A; ANP32A__:__PUTATIVE HUMAN HLA CLASS II-ASSOCIATED PROTEIN; PHAP1;; PHAP I;; LEUCINE-RICH ACIDIC NUCLEAR PROTEIN; LANP__:__
Asterisk__:__600833__:__SUPPRESSOR OF TUMORIGENICITY 7; ST7__:__TSG7;; RAY1;; FAM4A1__:__
Asterisk__:__600834__:__ZINC FINGER PROTEIN 165; ZNF165__:__LD65__:__
Asterisk__:__600835__:__CHEMOKINE, CXC MOTIF, LIGAND 12; CXCL12__:__STROMAL CELL-DERIVED FACTOR 1; SDF1;; PRE-B CELL GROWTH-STIMULATING FACTOR; PBSF__:__
Asterisk__:__600836__:__CRYSTALLIN, BETA-A2; CRYBA2__:____:__
Asterisk__:__600837__:__GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GDNF__:____:__
Asterisk__:__600838__:__FORKHEAD BOX N1; FOXN1__:__WINGED HELIX NUDE; WHN__:__
Asterisk__:__600839__:__SOLUTE CARRIER FAMILY 12 (SODIUM/POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 1; SLC12A1__:__SODIUM-POTASSIUM-CHLORIDE TRANSPORTER 2; NKCC2__:__
Asterisk__:__600840__:__SOLUTE CARRIER FAMILY 12 (SODIUM/POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 2; SLC12A2__:__SODIUM-POTASSIUM-CHLORIDE TRANSPORTER 1; NKCC1;; NA-K-CL COTRANSPORTER, BUMETANIDE-SENSITIVE; BSC__:__
NULL__:__600841__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA-1-LIKE 14; EEF1A1L14__:__PROSTATIC CARCINOMA TUMOR-INDUCING GENE 1; PTI1__:__
Asterisk__:__600842__:__GLUCOKINASE REGULATORY PROTEIN; GCKR__:__GKRP__:__
Asterisk__:__600843__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 3; P2RX3__:__PURINOCEPTOR P2X3; P2X3;; P2X RECEPTOR, SUBUNIT 3__:__
Asterisk__:__600844__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 2; P2RX2__:__P2X RECEPTOR, SUBUNIT 2; P2X2__:__
Asterisk__:__600845__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 1; P2RX1__:__PURINOCEPTOR P2X1; P2X1;; P2X RECEPTOR, SUBUNIT 1__:__
Asterisk__:__600846__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 4; P2RX4__:__PURINOCEPTOR P2X4; P2X4; P2X4R;; P2X RECEPTOR, SUBUNIT 4__:__
Caret__:__600847__:__MOVED TO 600695__:____:__
Asterisk__:__600848__:__NUCLEAR RECEPTOR COREPRESSOR 2; NCOR2__:__SILENCING MEDIATOR FOR RETINOID AND THYROID HORMONE RECEPTORS; SMRT__:__
Asterisk__:__600849__:__NUCLEAR RECEPTOR COREPRESSOR 1; NCOR1__:____:__
Number Sign__:__600850__:__SCHIZOPHRENIA 4; SCZD4__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 22q11-RELATED__:__
NULL__:__600851__:__MITOCHONDRIAL IMPORT-STIMULATING FACTOR__:__MSF__:__
Number Sign__:__600852__:__RETINITIS PIGMENTOSA 17; RP17__:____:__
Asterisk__:__600853__:__N-DEACETYLASE/N-SULFOTRANSFERASE 1; NDST1__:__HEPARAN GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE 1;; HEPARAN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE; HSST__:__
Caret__:__600854__:__MOVED TO 600877__:____:__
Asterisk__:__600855__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1A; DYRK1A__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1; DYRK1;; DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE; DYRK;; MNB PROTEIN KINASE, SERINE/THREONINE-SPECIFIC;; MINIBRAIN, DROSOPHILA, HOMOLOG OF; MNB; MNBH__:__
Asterisk__:__600856__:__CYCLIN-DEPENDENT KINASE INHIBITOR 1C; CDKN1C__:__p57(KIP2);; KIP2__:__
Asterisk__:__600857__:__SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT A, FLAVOPROTEIN; SDHA__:__SUCCINATE DEHYDROGENASE 1, S. CEREVISIAE, HOMOLOG OF;; SDH1, HOMOLOG OF__:__
Number Sign__:__600858__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 6; CMH6__:____:__
Asterisk__:__600859__:__AMINOACYL tRNA SYNTHETASE COMPLEX-INTERACTING MULTIFUNCTIONAL PROTEIN 2; AIMP2__:__JTV1 GENE;; tRNA SYNTHETASE COFACTOR p38; p38__:__
Asterisk__:__600860__:__GENERAL TRANSCRIPTION FACTOR IIIA; GTF3A__:__TFIIIA__:__
Asterisk__:__600861__:__REGULATOR OF G PROTEIN SIGNALING 2; RGS2__:__BASIC HELIX-LOOP-HELIX PHOSPHOPROTEIN G0S8__:__
Asterisk__:__600862__:__ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN WITH FG REPEATS 1; AGFG1__:__ARFGAP WITH FG REPEATS 1;; HIV-1 REV-BINDING PROTEIN; HRB;; REV-INTERACTING PROTEIN; RIP;; REV/REX ACTIVATION DOMAIN-BINDING PROTEIN; RAB__:__
Asterisk__:__600863__:__CASEIN KINASE I, EPSILON; CSNK1E__:__DOUBLETIME, DROSOPHILA, HOMOLOG OF; DBT__:__
Asterisk__:__600864__:__CASEIN KINASE I, DELTA; CSNK1D__:____:__
Asterisk__:__600865__:__RETICULON 1; RTN1__:__NEUROENDOCRINE-SPECIFIC PROTEIN; NSP__:__
Asterisk__:__600866__:__PROGRAMMED CELL DEATH 2; PDCD2__:__ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 7; ZMYND7__:__
Asterisk__:__600867__:__SIGNAL SEQUENCE RECEPTOR, BETA; SSR2__:__TRANSLOCON-ASSOCIATED PROTEIN, BETA;; TRAP-BETA__:__
Asterisk__:__600868__:__SIGNAL SEQUENCE RECEPTOR, ALPHA; SSR1__:__TRANSLOCON-ASSOCIATED PROTEIN, ALPHA SUBUNIT;; TRAP-ALPHA; TRAPA__:__
Asterisk__:__600869__:__G PROTEIN-COUPLED RECEPTOR KINASE 6; GRK6__:__GPRK6__:__
Asterisk__:__600870__:__G PROTEIN-COUPLED RECEPTOR KINASE 5; GRK5__:__GPRK5__:__
Asterisk__:__600871__:__GROWTH FACTOR-INDEPENDENT 1; GFI1__:__ZNF163__:__
Caret__:__600872__:__MOVED TO 300113__:____:__
Asterisk__:__600873__:__CHITOBIASE, DI-N-ACETYL-; CTBS__:__CHITOBIASE, LYSOSOMAL; CTB__:__
Asterisk__:__600874__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-5; GNG5__:__G PROTEIN GAMMA-5 SUBUNIT__:__
Asterisk__:__600875__:__ACYLPHOSPHATASE, ERYTHROCYTE; ACYP1__:__ACYPE__:__
Asterisk__:__600876__:__SYNTAXIN 3; STX3__:__STX3A__:__
Asterisk__:__600877__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 6; KCNJ6__:__GIRK2;; POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 7, FORMERLY; KCNJ7, FORMERLY__:__
Caret__:__600878__:__MOVED TO 601296__:____:__
Asterisk__:__600879__:__NUCLEAR RESPIRATORY FACTOR 1; NRF1__:__ALPHA-PAL__:__
Number Sign__:__600880__:__BUDD-CHIARI SYNDROME; BDCHS__:____:__MEMBRANOUS OBSTRUCTION OF INFERIOR VENA CAVA, INCLUDED; MOVC, INCLUDED
Number Sign__:__600881__:__CATARACT 10, MULTIPLE TYPES; CTRCT10__:__CATARACT, CONGENITAL ZONULAR, WITH SUTURAL OPACITIES; CCZS__:__
Number Sign__:__600882__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B__:__CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2B;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B;; HEREDITARY MOTOR AND SENSORY NEUROPATHY IIB; HMSN IIB;; HMSN2B__:__
Percent__:__600883__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 8; IDDM8__:__INSULIN-DEPENDENT DIABETES MELLITUS 8__:__
Percent__:__600884__:__CARDIOMYOPATHY, DILATED, 1B; CMD1B__:__CARDIOMYOPATHY, FAMILIAL DILATED, 1; CMPD1;; CARDIOMYOPATHY, FAMILIAL DILATED; FDC__:__
Caret__:__600885__:__MOVED TO 251260__:____:__
Number Sign__:__600886__:__HYPERFERRITINEMIA WITH OR WITHOUT CATARACT; HRFTC__:__HYPERFERRITINEMIA-CATARACT SYNDROME;; HYPERFERRITINEMIA, HEREDITARY, WITH CONGENITAL CATARACTS; HHCS__:__
Asterisk__:__600887__:__MutS, E. COLI, HOMOLOG OF, 3; MSH3__:__MISMATCH REPAIR PROTEIN 1; MRP1;; DIVERGENT UPSTREAM PROTEIN; DUP__:__
Asterisk__:__600888__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 5; ARHGEF5__:__TRANSFORMING IMMORTALIZED MAMMARY; TIM;; ONCOGENE TIM__:__
Asterisk__:__600889__:__COMPLEMENT FACTOR H-RELATED 2; CFHR2__:__FACTOR H-RELATED GENE 2; FHR2;; H FACTOR-LIKE 3; HFL3;; CFHL2__:__
Asterisk__:__600890__:__HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA__:__TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA__:__
Caret__:__600891__:__MOVED TO 300098__:____:__
Asterisk__:__600892__:__SINGLE-MINDED, DROSOPHILA, HOMOLOG OF, 2; SIM2__:__SIM__:__
Caret__:__600893__:__MOVED TO 300099__:____:__
Caret__:__600894__:__MOVED TO 300574__:____:__
Asterisk__:__600895__:__PROLACTIN-RELEASING HORMONE RECEPTOR; PRLHR__:__PRLH RECEPTOR;; PROLACTIN-RELEASING PEPTIDE RECEPTOR; PRRPR;; G PROTEIN-COUPLED RECEPTOR 10; GPR10;; GR3__:__
Asterisk__:__600896__:__G PROTEIN-COUPLED RECEPTOR 14; GPR14__:__UROTENSIN RECEPTOR; UTR;; UROTENSIN II RECEPTOR; UTR2__:__
Asterisk__:__600897__:__GAP JUNCTION PROTEIN, ALPHA-8; GJA8__:__GAP JUNCTION PROTEIN, 50-KD;; CONNEXIN 50; CX50;; LENS INTRINSIC MEMBRANE PROTEIN MP70; MP70__:__
Asterisk__:__600898__:__SRY-BOX 11; SOX11__:__SRY-RELATED HMG-BOX GENE 11__:__
Asterisk__:__600899__:__PROTEIN KINASE, DNA-ACTIVATED, CATALYTIC SUBUNIT; PRKDC__:__DNA-DEPENDENT PROTEIN KINASE, CATALYTIC SUBUNIT; DNPK1;; p350;; DNA-PKcs;; DNA-DEPENDENT PROTEIN KINASE; DNAPK;; HYPERRADIOSENSITIVITY COMPLEMENTING 1, MOUSE, HOMOLOG OF; HYRC1__:__
Asterisk__:__600900__:__SARCOGLYCAN, BETA; SGCB__:__DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 43-KD__:__
Number Sign__:__600901__:__FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE__:__FACE__:__
Asterisk__:__600902__:__SELENOPHOSPHATE SYNTHETASE 1; SEPHS1__:__SPS1__:__
NULL__:__600903__:__WISKOTT-ALDRICH SYNDROME, AUTOSOMAL DOMINANT FORM__:____:__
Asterisk__:__600904__:__ASTROTACTIN 1; ASTN1__:__ASTROTACTIN; ASTN__:__
Caret__:__600905__:__MOVED TO 600600__:____:__
NULL__:__600906__:__ECTODERMAL DYSPLASIA WITH MENTAL RETARDATION AND SYNDACTYLY__:____:__
NULL__:__600907__:__ENAMEL HYPOPLASIA, CATARACTS, AND AQUEDUCTAL STENOSIS__:____:__
NULL__:__600908__:__KENNERKNECHT SYNDROME__:__AGONADISM, 46,XY, WITH MENTAL RETARDATION, SHORT STATURE, RETARDED BONE AGE, AND MULTIPLE EXTRAGENITAL MALFORMATIONS__:__
Asterisk__:__600909__:__LANOSTEROL SYNTHASE; LSS__:__2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE; OSC__:__
Asterisk__:__600910__:__INSULIN-LIKE 4; INSL4__:__EARLY PLACENTA INSULIN-LIKE PEPTIDE; EPIL;; PLACENTIN__:__
Asterisk__:__600911__:__METALLOPHOSPHOESTERASE DOMAIN-CONTAINING PROTEIN 2; MPPED2__:__CHROMOSOME 11 OPEN READING FRAME 8; C11ORF8;; FETAL BRAIN PROTEIN 239;; D11S302E__:__
Asterisk__:__600912__:__TRANSCRIPTION FACTOR 19; TCF19__:__SC1__:__
Caret__:__600913__:__MOVED TO 602055__:____:__
Asterisk__:__600914__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 5; SRSF5__:__SERINE/ARGININE-RICH SPLICING FACTOR 5;; SPLICING FACTOR, ARGININE/SERINE-RICH, 5; SFRS5;; SPLICING FACTOR, ARGININE/SERINE-RICH, 40-KD; SRp40__:__
Asterisk__:__600915__:__NESTIN; NES__:____:__
Asterisk__:__600916__:__INOSITOL POLYPHOSPHATE-4-PHOSPHATASE, TYPE I, 107-KD; INPP4A__:__INPP4__:__
Asterisk__:__600917__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 3A; PPP1R3A__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 3; PPP1R3;; PROTEIN PHOSPHATASE 1, GLYCOGEN-ASSOCIATED REGULATORY SUBUNIT; PP1G;; PROTEIN PHOSPHATASE 1, GLYCOGEN-TARGETING SUBUNIT, MUSCLE; GM__:__
Caret__:__600918__:__MOVED TO 220100__:____:__
Number Sign__:__600919__:__CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED__:__ANKYRIN-B SYNDROME__:__LONG QT SYNDROME 4, INCLUDED; LQT4, INCLUDED
Number Sign__:__600920__:__VAN DEN ENDE-GUPTA SYNDROME; VDEGS__:__MARDEN-WALKER-LIKE SYNDROME WITHOUT PSYCHOMOTOR RETARDATION;; BLEPHAROPHIMOSIS, ARACHNODACTYLY, AND CONGENITAL CONTRACTURES__:__
Asterisk__:__600921__:__FIBROBLAST GROWTH FACTOR 9; FGF9__:__GLIA-ACTIVATING FACTOR; GAF__:__
Asterisk__:__600922__:__MYOSIN LIGHT CHAIN KINASE; MYLK__:__MYOSIN LIGHT POLYPEPTIDE KINASE; MLCK__:__KINASE-RELATED PROTEIN, INCLUDED; KRP, INCLUDED;; TELOKIN, INCLUDED
Asterisk__:__600923__:__PROTOPORPHYRINOGEN OXIDASE; PPOX__:____:__
Asterisk__:__600924__:__GROWTH FACTOR, ERV1-LIKE; GFER__:__ERV1, S. CEREVISIAE, HOMOLOG OF; HERV1;; AUGMENTER OF LIVER REGENERATION; ALR__:__
Asterisk__:__600925__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, J; PTPRJ__:__DEP1;; PROTEIN-TYROSINE PHOSPHATASE, ETA;; SUSCEPTIBILITY TO COLON CANCER 1, MOUSE, HOMOLOG OF; SCC1;; CD148__:__
Asterisk__:__600926__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, EPSILON; PTPRE__:____:__
Asterisk__:__600927__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2D; CDKN2D__:__p19(INK4D)__:__
Asterisk__:__600928__:__NITROGEN PERMEASE REGULATOR-LIKE 3; NPRL3__:__CHROMOSOME 16 OPEN READING FRAME 35; C16ORF35;; CONSERVED GENE TELOMERIC TO ALPHA GLOBIN CLUSTER__:__
Asterisk__:__600929__:__CRYSTALLIN, BETA-B1; CRYBB1__:____:__
Asterisk__:__600930__:__SPERM ADHESION MOLECULE 1; SPAM1__:__PH20__:__
NULL__:__600931__:__PROTOCADHERIN 3__:__PCDH3__:__
Asterisk__:__600932__:__POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 9; KCNJ9__:__G PROTEIN-COUPLED INWARD RECTIFIER POTASSIUM CHANNEL; GIRK3__:__
Asterisk__:__600933__:__COAGULATION FACTOR II RECEPTOR-LIKE 1; F2RL1__:__G PROTEIN-COUPLED RECEPTOR 11; GPR11;; PROTEINASE-ACTIVATED RECEPTOR 2; PAR2;; PROTEASE-ACTIVATED RECEPTOR 2__:__
Asterisk__:__600934__:__FOLATE HYDROLASE 1; FOLH1__:__FOLH;; GLUTAMATE CARBOXYPEPTIDASE II; GCP2;; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; PSM; PSMA;; N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE 1; NAALAD1;; NAALADase I__:__
Asterisk__:__600935__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 8; KCNJ8__:__INWARDLY RECTIFYING POTASSIUM CHANNEL Kir6.1__:__
Asterisk__:__600936__:__HYALURONAN-MEDIATED MOTILITY RECEPTOR; HMMR__:__RHAMM__:__
Asterisk__:__600937__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 11; KCNJ11__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, BIR SUBUNIT;; BETA-CELL INWARD RECTIFIER SUBUNIT; BIR;; INWARDLY RECTIFYING POTASSIUM CHANNEL Kir6.2__:__
Asterisk__:__600938__:__RETINOBLASTOMA-BINDING PROTEIN 6; RBBP6__:__p53-ASSOCIATED CELLULAR PROTEIN, TESTIS-DERIVED; PACT;; P2PR;; SNAMA, DROSOPHILA, HOMOLOG OF; SNAMA__:__
Asterisk__:__600939__:__INTERLEUKIN 11 RECEPTOR, ALPHA; IL11RA__:____:__IL11RA/GALT SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__600940__:__LIGASE III, DNA, ATP-DEPENDENT; LIG3__:__DNA LIGASE III__:__
Asterisk__:__600941__:__BILIVERDIN REDUCTASE B; BLVRB__:__BVRB;; NADPH-FLAVIN REDUCTASE; FLR;; METHEMOGLOBIN REDUCTASE;; NADPH REDUCTASE__:__
Caret__:__600942__:__MOVED TO 600943__:____:__
Asterisk__:__600943__:__SERPIN PEPTIDASE INHIBITOR, CLADE H, MEMBER 1; SERPINH1__:__COLLAGEN-BINDING PROTEIN 2; CBP2;; COLLIGIN 2;; SERPINH2;; HEAT-SHOCK PROTEIN 47; HSP47;; RHEUMATOID ARTHRITIS ANTIGEN-A47; RA-A47__:__CBP1, INCLUDED
Asterisk__:__600944__:__DEOXYHYPUSINE SYNTHASE; DHPS__:____:__
Asterisk__:__600945__:__UROCORTIN; UCN__:__UROTENSIN I__:__
Asterisk__:__600946__:__GROWTH HORMONE RECEPTOR; GHR__:____:__GROWTH HORMONE-BINDING PROTEIN, INCLUDED; GHBP, INCLUDED
Asterisk__:__600947__:__HUNTINGTIN-ASSOCIATED PROTEIN 1; HAP1__:__HAP2;; NEUROAN 1__:__
Asterisk__:__600948__:__MYELIN-ASSOCIATED OLIGODENDROCYTE BASIC PROTEIN; MOBP__:____:__
Asterisk__:__600949__:__IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION-2__:__IGV2; IGHV2__:__
Asterisk__:__600950__:__ARYLALKYLAMINE N-ACETYLTRANSFERASE; AANAT__:__SEROTONIN N-ACETYLTRANSFERASE; SNAT__:__
Asterisk__:__600951__:__TELOMERIC REPEAT-BINDING FACTOR 1; TERF1__:__TRF1;; TRF;; PIN2__:__
NULL__:__600952__:__TRANSSEXUALITY__:____:__
Asterisk__:__600953__:__INTERLEUKIN 18; IL18__:__INTERFERON-GAMMA-INDUCING FACTOR; IGIF__:__
Asterisk__:__600954__:__DEATH-ASSOCIATED PROTEIN; DAP__:__DAP1__:__
Number Sign__:__600955__:__PROPROTEIN CONVERTASE 1/3 DEFICIENCY__:__OBESITY AND ENDOCRINOPATHY DUE TO IMPAIRED PROCESSING OF PROHORMONES__:__
Asterisk__:__600956__:__ANTI-MULLERIAN HORMONE TYPE II RECEPTOR; AMHR2__:__ANTI-MULLERIAN HORMONE RECEPTOR; AMHR;; MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR; MISR2__:__
Asterisk__:__600957__:__ANTI-MULLERIAN HORMONE; AMH__:__MULLERIAN-INHIBITING SUBSTANCE; MIS;; MULLERIAN-INHIBITING FACTOR; MIF__:__
Asterisk__:__600958__:__MYOSIN-BINDING PROTEIN C, CARDIAC; MYBPC3__:____:__
Asterisk__:__600959__:__COATOMER PROTEIN COMPLEX, SUBUNIT BETA 1; COPB1__:__COATOMER PROTEIN COMPLEX, SUBUNIT BETA; COPB;; BETA COAT PROTEIN__:__
Asterisk__:__600960__:__SET NUCLEAR PROTOONCOGENE; SET__:__SET TRANSLOCATION, MYELOID LEUKEMIA-ASSOCIATED;; INHIBITOR OF GZMA-ACTIVATED DNase; IGAAD;; TAFI-BETA__:__
Caret__:__600961__:__MOVED TO 601498__:____:__
Number Sign__:__600962__:__PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC; NEPPK__:__PPKNE;; NONEPIDERMOLYTIC PALMOPLANTAR KERATODERMA;; KERATODERMA, NONEPIDERMOLYTIC PALMOPLANTAR;; TYLOSIS__:__
Asterisk__:__600963__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 5; SIX5__:__DM LOCUS-ASSOCIATED HOMEODOMAIN PROTEIN; DMAHP__:__
Caret__:__600964__:__MOVED TO 266500__:____:__
Number Sign__:__600965__:__DEAFNESS, AUTOSOMAL DOMINANT 6; DFNA6__:__DEAFNESS, AUTOSOMAL DOMINANT 14; DFNA14;; DEAFNESS, AUTOSOMAL DOMINANT 38; DFNA38__:__
Asterisk__:__600966__:__LETHAL GIANT LARVAE, DROSOPHILA, HOMOLOG OF, 1; LLGL1__:__LLGL;; HUGL1;; DLG4, FORMERLY__:__
Asterisk__:__600967__:__E2F TRANSCRIPTION FACTOR 5; E2F5__:____:__
Asterisk__:__600968__:__SOLUTE CARRIER FAMILY 12 (SODIUM/CHLORIDE TRANSPORTER), MEMBER 3; SLC12A3__:__SODIUM-CHLORIDE COTRANSPORTER, THIAZIDE-SENSITIVE; NCCT;; THIAZIDE-SENSITIVE NA-CL COTRANSPORTER; TSC;; SODIUM-CHLORIDE COTRANSPORTER; NCC__:__
Number Sign__:__600969__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 3; EDM3__:____:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 3, WITH MYOPATHY, INCLUDED
Asterisk__:__600970__:__MYOSIN VI; MYO6__:____:__
Number Sign__:__600971__:__DEAFNESS, AUTOSOMAL RECESSIVE 6; DFNB6__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 6; NSRD6__:__
Number Sign__:__600972__:__ACHONDROGENESIS, TYPE IB; ACG1B__:__ACHONDROGENESIS, FRACCARO TYPE__:__
Caret__:__600973__:__MOVED TO 600308__:____:__
Number Sign__:__600974__:__DEAFNESS, AUTOSOMAL RECESSIVE 7; DFNB7__:__DEAFNESS, AUTOSOMAL RECESSIVE 11; DFNB11__:__
Percent__:__600975__:__GLAUCOMA 3, PRIMARY INFANTILE, B; GLC3B__:__GLAUCOMA, PRIMARY CONGENITAL, TYPE B;; GLC3, TYPE B__:__
Asterisk__:__600976__:__FAT TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 1; FAT1__:____:__
Number Sign__:__600977__:__CONE-ROD DYSTROPHY 5; CORD5__:____:__
Asterisk__:__600978__:__LYMPHOTOXIN-BETA; LTB__:__TUMOR NECROSIS FACTOR C; TNFC__:__
Asterisk__:__600979__:__LYMPHOTOXIN B RECEPTOR; LTBR__:__LYMPHOTOXIN-BETA RECEPTOR;; LT-BETA-R;; TUMOR NECROSIS FACTOR C RECEPTOR; TNFCR__:__
Asterisk__:__600980__:__DENTIN MATRIX ACIDIC PHOSPHOPROTEIN 1; DMP1__:____:__
Asterisk__:__600981__:__PHOSPHOGLUCOMUTASE 5; PGM5__:____:__
Asterisk__:__600982__:__MITOGEN-ACTIVATED KINASE KINASE KINASE 1; MAP3K1__:__MAP/ERK KINASE KINASE 1; MEKK1;; MAPKKK1;; MEK KINASE__:__
Asterisk__:__600983__:__NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, MEMBER 2; NR3C2__:__MINERALOCORTICOID RECEPTOR; MLR; MCR; MR;; ALDOSTERONE RECEPTOR__:__
Asterisk__:__600984__:__ACTIVATING TRANSCRIPTION FACTOR 6, BETA; ATF6B__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN-LIKE 1; CREBL1;; CREB-RELATED PROTEIN; CREBRP__:__
Asterisk__:__600985__:__TENASCIN XB; TNXB__:__TENASCIN X; TNX;; HEXABRACHION-LIKE; HXBL__:__TENASCIN XB, ISOFORM 1, INCLUDED; TNXB1, INCLUDED;; TENASCIN XB, ISOFORM 2, INCLUDED; TNXB2, INCLUDED
Asterisk__:__600986__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 46; TRIM46__:__GENE Y; GENEY;; TRIFIC__:__
Number Sign__:__600987__:__CLEFT PALATE, CARDIAC DEFECTS, AND MENTAL RETARDATION; CPCMR__:__CARDIAC MALFORMATION, CLEFT LIP/PALATE, MICROCEPHALY, AND DIGITAL ANOMALIES__:__
Asterisk__:__600988__:__MANNOSIDASE, ALPHA, CLASS 2A, MEMBER 2; MAN2A2__:__MANA2X__:__
NULL__:__600989__:__INFUNDIBULOPELVIC DYSGENESIS__:____:__
Caret__:__600990__:__MOVED TO 119580__:____:__
NULL__:__600991__:__HYDROCEPHALUS, SPRENGEL ANOMALY, AND COSTOVERTEBRAL DYSPLASIA__:____:__
Caret__:__600992__:__MOVED TO 206900__:____:__
Asterisk__:__600993__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 4; SMAD4__:__MADH4;; SMA- AND MAD-RELATED PROTEIN 4;; DELETED IN PANCREATIC CARCINOMA 4; DPC4__:__
Number Sign__:__600994__:__DEAFNESS, AUTOSOMAL DOMINANT 5; DFNA5__:____:__
Number Sign__:__600995__:__NEPHROTIC SYNDROME, TYPE 2; NPHS2__:__NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE; SRN1__:__
Number Sign__:__600996__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 2; ARVC2__:__
Asterisk__:__600997__:__EPHRIN RECEPTOR EphB2; EPHB2__:__ELK-RELATED TYROSINE KINASE; ERK;; DEVELOPMENTALLY REGULATED EPH-RELATED TYROSINE KINASE; DRT;; EPH TYROSINE KINASE 3; EPHT3;; HEK5__:__
Asterisk__:__600998__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, Q POLYPEPTIDE; GNAQ__:__G PROTEIN, ALPHA SUBUNIT, Gq CLASS;; G-ALPHA-q__:__
Asterisk__:__600999__:__MYC-ASSOCIATED ZINC FINGER PROTEIN; MAZ__:__ZF87;; PUR1, MOUSE, HOMOLOG OF__:__
Caret__:__601000__:__MOVED TO 109170__:____:__
Number Sign__:__601001__:__EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 1; EBSB1__:____:__
Asterisk__:__601002__:__GLUTATHIONE SYNTHETASE; GSS__:__GSHS__:__
Number Sign__:__601003__:__BRODY MYOPATHY__:____:__
NULL__:__601004__:__PORTAL VEIN, CAVERNOUS TRANSFORMATION OF__:____:__
Number Sign__:__601005__:__TIMOTHY SYNDROME; TS__:__LONG QT SYNDROME WITH SYNDACTYLY;; LONG QT SYNDROME 8; LQT8__:__
Caret__:__601006__:__MOVED TO 138890__:____:__
Asterisk__:__601007__:__LEPTIN RECEPTOR; LEPR__:__OBR__:__
Caret__:__601008__:__MOVED TO 148760__:____:__
Asterisk__:__601009__:__TIGHT JUNCTION PROTEIN 1; TJP1__:__ZONA OCCLUDENS 1; ZO1__:__
Asterisk__:__601010__:__TRANSCRIPTION FACTOR 15; TCF15__:__PARAXIS;; EC2__:__
Asterisk__:__601011__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, P/Q TYPE, ALPHA-1A SUBUNIT; CACNA1A__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 4; CACNL1A4;; CaV2.1__:__CACNA1A C-TERMINAL POLYPEPTIDE, INCLUDED;; ALPHA-1A C-TERMINAL POLYPEPTIDE, INCLUDED;; ALPHA-1ACT, INCLUDED
Asterisk__:__601012__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, N TYPE, ALPHA-1B SUBUNIT; CACNA1B__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 5; CACNL1A5;; CaV2.2__:__
Asterisk__:__601013__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-1E SUBUNIT; CACNA1E__:__CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 6; CACNL1A6 CaV2.3;; CALCIUM CHANNEL, R TYPE__:__
Asterisk__:__601014__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 1; DLG1__:__SYNAPSE-ASSOCIATED PROTEIN 97; SAP97__:__
Asterisk__:__601015__:__NPC2 GENE; NPC2__:__EPIDIDYMAL SECRETORY PROTEIN; HE1__:__
NULL__:__601016__:__MIDLINE MALFORMATIONS, MULTIPLE, WITH LIMB ABNORMALITIES AND HYPOPITUITARISM__:__DINCSOY SYNDROME__:__
Asterisk__:__601017__:__SYNTROPHIN, ALPHA-1; SNTA1__:__SNT1;; PRO-TGF-ALPHA CYTOPLASMIC DOMAIN-INTERACTING PROTEIN 1; TACIP1__:__
Caret__:__601018__:__MOVED TO 600027__:____:__
Asterisk__:__601019__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GLYCINE), MEMBER 9; SLC6A9__:__GLYCINE TRANSPORTER, TYPE 1; GLYT1__:__GLYCINE TRANSPORTER 1A, INCLUDED; GLYT1A, INCLUDED;; GLYCINE TRANSPORTER 1B, INCLUDED; GLYT1B, INCLUDED
Asterisk__:__601020__:__CD86 ANTIGEN; CD86__:__CD28 ANTIGEN LIGAND 2; CD28LG2;; B-LYMPHOCYTE ACTIVATION ANTIGEN B7-2; LAB7-2;; B72 ANTIGEN__:__
Asterisk__:__601021__:__NUCLEOPORIN, 98-KD; NUP98__:____:__NUP98-NUP96 PRECURSOR PROTEIN, INCLUDED;; NUCLEOPORIN, 96-KD, INCLUDED; NUP96, INCLUDED;; NUP98/NSD1 FUSION GENE, INCLUDED;; NUP98/NSD3 FUSION GENE, INCLUDED;; NUP98/PMX1 FUSION GENE, INCLUDED;; NUP98/HOXA9 FUSION GENE, INCLUDED;; NUP98/TOP1 FUSION GENE, INCLUDED;; NUP98/DDX10 FUSION GENE, INCLUDED;; NUP98/HOXD11 FUSION GENE, INCLUDED;; NUP98/HOXC13 FUSION GENE, INCLUDED;; NUP98/ADD3 FUSION GENE, INCLUDED;; NUP98/SETBP1 FUSION GENE, INCLUDED;; NUB98/PHF23 FUSION GENE, INCLUDED;; NUB98/RARG FUSION GENE, INCLUDED;; NUP98/CCDC28A FUSION GENE, INCLUDED;; NUP98/IQCG FUSION GENE, INCLUDED
Asterisk__:__601022__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR-LIKE 1; NFKBIL1__:__INHIBITOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS-LIKE; IKBL;; NUCLEAR FACTOR KAPPA-B INHIBITOR-LIKE__:__
Asterisk__:__601023__:__VALOSIN-CONTAINING PROTEIN; VCP__:__CDC48, YEAST, HOMOLOG OF;; p97__:__
Asterisk__:__601024__:__ADAPTOR-RELATED PROTEIN COMPLEX 2, MU-1 SUBUNIT; AP2M1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, MEDIUM 1; CLAPM1;; CLATHRIN ADAPTOR PROTEIN 50; AP50;; CLATHRIN ADAPTOR COMPLEX AP2, MU SUBUNIT;; MU-2__:__
Asterisk__:__601025__:__ADAPTOR-RELATED PROTEIN COMPLEX 2, BETA-1 SUBUNIT; AP2B1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, LARGE, BETA-1; CLAPB1;; CLATHRIN ADAPTOR COMPLEX AP2, BETA SUBUNIT;; AP2-BETA;; ADAPTIN, BETA-2__:__
Asterisk__:__601026__:__ADAPTOR-RELATED PROTEIN COMPLEX 2, ALPHA-1 SUBUNIT; AP2A1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, LARGE, ALPHA-1; CLAPA1;; CLATHRIN ADAPTOR COMPLEX AP2, ALPHA SUBUNIT;; AP2-ALPHA;; ADAPTIN, ALPHA__:__
NULL__:__601027__:__TIBIA, ABSENCE OR HYPOPLASIA OF, WITH POLYDACTYLY, RETROCEREBELLAR ARACHNOID CYST, AND OTHER ANOMALIES__:____:__
Asterisk__:__601028__:__CD47 ANTIGEN; CD47__:__SURFACE ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY 1D8; MER6;; INTEGRIN-ASSOCIATED PROTEIN; IAP;; CD47 GLYCOPROTEIN__:__
Asterisk__:__601029__:__MESODERM-SPECIFIC TRANSCRIPT, MOUSE, HOMOLOG OF; MEST__:__PATERNALLY EXPRESSED GENE 1; PEG1__:__
Asterisk__:__601030__:__RIBONUCLEASE, RNase A FAMILY, 4; RNASE4__:____:__
Asterisk__:__601031__:__RHOPHILIN 1; RHPN1__:__RHOPHILIN;; RHO GTPase-BINDING PROTEIN 1;; OUTER DENSE FIBER OF SPERM TAILS 5; ODF5;; PKN-RELATED RHO-BINDING PROTEIN__:__
Asterisk__:__601032__:__PROTEIN KINASE N1; PKN1__:__PROTEIN KINASE C-RELATED KINASE 1; PRK1;; SERINE/THREONINE PROTEIN KINASE N; PKN;; PKN-ALPHA;; PROTEIN KINASE C-LIKE 1; PRKCL1;; PAK1, RAT, HOMOLOG OF__:__
Asterisk__:__601033__:__LAMININ, ALPHA-5; LAMA5__:__KIAA0533;; KIAA1907__:__
Caret__:__601034__:__MOVED TO 155735__:____:__
Asterisk__:__601035__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1; HNRNPH1__:__HNRPH1;; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H__:__
Caret__:__601036__:__MOVED TO 300610__:____:__
Asterisk__:__601037__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F; HNRNPF__:__HNRPF__:__
Asterisk__:__601038__:__DEIODINASE, IODOTHYRONINE, TYPE III; DIO3__:__THYROXINE DEIODINASE, TYPE III; TXDI3;; IODOTHYRONINE DEIODINASE, PLACENTAL TYPE__:__
NULL__:__601039__:__ICHTHYOSIS-MENTAL RETARDATION SYNDROME WITH LARGE KERATOHYALIN GRANULES IN THE SKIN__:____:__
Asterisk__:__601040__:__SCAVENGER RECEPTOR CLASS B, MEMBER 1; SCARB1__:__CD36 ANTIGEN-LIKE 1; CD36L1;; CD36 AND LIMPII ANALOGOUS 1; CLA1;; SCAVENGER RECEPTOR, CLASS B, TYPE I; SRBI; SRB1__:__
Asterisk__:__601041__:__TRANSDUCIN-LIKE ENHANCER OF SPLIT 2; TLE2__:__ENHANCER OF SPLIT GROUCHO 2; ESG2__:__
Number Sign__:__601042__:__DYSTONIA 9; DYT9__:__CHOREOATHETOSIS/SPASTICITY, EPISODIC;; CSE CHOREOATHETOSIS, PAROXYSMAL, WITH EPISODIC ATAXIA;; CHOREOATHETOSIS, KINESIGENIC, WITH EPISODIC ATAXIA AND SPASTICITY__:__
Caret__:__601043__:__MOVED TO 600701__:____:__
Caret__:__601044__:__MOVED TO 600701__:____:__
Asterisk__:__601045__:__CATENIN, DELTA-1; CTNND1__:__CATENIN, DELTA; CTNND;; CADHERIN-ASSOCIATED SRC SUBSTRATE; CAS;; p120(CTN)__:__
Asterisk__:__601046__:__MATRIX METALLOPROTEINASE 12; MMP12__:__MACROPHAGE METALLOELASTASE; MME__:__
Asterisk__:__601047__:__CAVEOLIN 1; CAV1__:__CAVEOLAE PROTEIN, 22-KD; CAV__:__
Asterisk__:__601048__:__CAVEOLIN 2; CAV2__:__CAVEOLAE PROTEIN, 20-KD__:__
Caret__:__601049__:__MOVED TO 300119__:____:__
Caret__:__601050__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__601051__:__MESOTHELIN; MSLN__:__ANTIGEN RECOGNIZED BY MONOCLONAL ANTIBODY K1;; MEGAKARYOCYTE-POTENTIATING FACTOR; MPF;; SOLUBLE MPF/MESOTHELIN-RELATED PROTEIN; SMR__:__
Asterisk__:__601052__:__PEPTIDYL-PROLYL CIS/TRANS ISOMERASE, NIMA-INTERACTING, 1; PIN1__:__DODO, DROSOPHILA, HOMOLOG OF; DOD__:__
Asterisk__:__601053__:__PLEXIN B1; PLXNB1__:__PLEXIN 5; PLXN5;; TRANSMEMBRANE PROTEIN SEP; SEP__:__
Asterisk__:__601054__:__PLEXIN A2; PLXNA2__:__PLEXIN 2; PLXN2;; TRANSMEMBRANE PROTEIN OCT; OCT__:__
Asterisk__:__601055__:__PLEXIN A1; PLXNA1__:__PLEXIN 1; PLXN1;; TRANSMEMBRANE PROTEIN NOV; NOV__:__
Asterisk__:__601056__:__BCL2-RELATED PROTEIN A1; BCL2A1__:__BCL2-RELATED GENE BFL1; BFL1__:__
Asterisk__:__601057__:__PROGRAMMED CELL DEATH 6; PDCD6__:__APOPTOSIS-LINKED GENE 2; ALG2__:__
Asterisk__:__601058__:__H3 HISTONE, FAMILY 3B; H3F3B__:__H3.3B__:__
Caret__:__601059__:__MOVED TO 146920__:____:__
Asterisk__:__601060__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 2; ENPP2__:__PHOSPHODIESTERASE I/NUCLEOTIDE PYROPHOSPHATASE 2; PDNP2;; PDI-ALPHA;; AUTOTAXIN; ATX;; LYSOPHOSPHOLIPASE D__:__
Asterisk__:__601061__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE D2; SNRPD2__:____:__
Asterisk__:__601062__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE D3; SNRPD3__:____:__
Asterisk__:__601063__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE D1; SNRPD1__:____:__
Asterisk__:__601064__:__ZINC FINGER PROTEIN 36-LIKE 1; ZFP36L1__:__ZFP36-LIKE 1;; EGF-RESPONSE FACTOR 1; ERF1;; BUTYRATE RESPONSE FACTOR 1; BRF1;; B-CELL EARLY RESPONSE GENE, 36-KD; BERG36__:__
Asterisk__:__601065__:__ALANYL-tRNA SYNTHETASE; AARS__:__ALARS__:__
Asterisk__:__601066__:__OXIDASE, CYTOCHROME c, ASSEMBLY 1-LIKE; OXA1L__:__CYTOCHROME c OXIDASE ASSEMBLY 1-LIKE;; OXA1-LIKE GENE__:__
Number Sign__:__601067__:__USHER SYNDROME, TYPE ID; USH1D__:____:__USHER SYNDROME, TYPE ID/F, CDH23/PCDH15, DIGENIC, INCLUDED;; USH1D/F, CDH23/PCDH15, DIGENIC, INCLUDED
Number Sign__:__601068__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 1; FAME1__:__BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 1; BAFME1;; CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 1; FCMTE1__:__
Asterisk__:__601069__:__ZINC FINGER PROTEIN 239; ZNF239__:__ZINC FINGER PROTEIN MOK2; MOK2__:__
Asterisk__:__601070__:__INTERLEUKIN 15 RECEPTOR, ALPHA; IL15RA__:____:__
Number Sign__:__601071__:__DEAFNESS, AUTOSOMAL RECESSIVE 9; DFNB9__:__NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 9; NSRD9__:__AUDITORY NEUROPATHY, AUTOSOMAL RECESSIVE, 1, INCLUDED; AUNB1, INCLUDED;; AUDITORY NEUROPATHY, NONSYNDROMIC RECESSIVE, INCLUDED; NSRAN, INCLUDED
Number Sign__:__601072__:__DEAFNESS, AUTOSOMAL RECESSIVE 8; DFNB8__:__DEAFNESS, AUTOSOMAL RECESSIVE 10; DFNB10;; DEAFNESS, CHILDHOOD-ONSET NEUROSENSORY, AUTOSOMAL RECESSIVE 8; DFNB8;; NEUROSENSORY NONSYNDROMIC RECESSIVE DEAFNESS 8; NSRD8__:__
Caret__:__601073__:__MOVED TO 600737__:____:__
Asterisk__:__601074__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 1; CELF1__:__CUG TRIPLET REPEAT, RNA-BINDING PROTEIN 1; CUGBP1;; CUG-BINDING PROTEIN; CUGBP;; NUCLEAR POLYADENYLATED RNA-BINDING PROTEIN, 50-KD; NAB50;; BRUNO-LIKE 2; BRUNOL2__:__
NULL__:__601075__:__APLASIA CUTIS CONGENITA, HIGH MYOPIA, AND CONE-ROD DYSFUNCTION__:____:__
Percent__:__601076__:__MULLERIAN DUCT APLASIA, UNILATERAL RENAL AGENESIS, AND CERVICOTHORACIC SOMITE ANOMALIES; MURCS__:__MAYER-ROKITANSKY-KUSTER-HAUSER SYNDROME, TYPE II;; MRKH, TYPE II;; KLIPPEL-FEIL DEFORMITY, CONDUCTIVE DEAFNESS, AND ABSENT VAGINA__:__
Asterisk__:__601077__:__KERATIN 31, TYPE I; KRT31__:__K31;; KA25;; KERATIN, HAIR, ACIDIC, 1; KRTHA1;; KERATIN, HARD, TYPE I, 1; HA1__:__
Asterisk__:__601078__:__KERATIN 82, TYPE II; KRT82__:__K82;; KB22;; KERATIN, HAIR, BASIC, 2; KRTHB2;; KERATIN, HARD, TYPE II, 2; HB2__:__
Asterisk__:__601079__:__ZINC FINGER-, CCCH DOMAIN-, AND RNA-BINDING MOTIF-CONTAINING SERINE/ARGININE-RICH PROTEIN 1; ZRSR1__:__U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, SMALL SUBUNIT 1; U2AF1RS1__:__
Asterisk__:__601080__:__U2 SMALL NUCLEAR RNA AUXILIARY FACTOR 1-LIKE 4; U2AF1L4__:__U2AF1-LIKE 4;; U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, SMALL SUBUNIT 3; U2AF1RS3;; U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AUXILIARY FACTOR, 26-KD; U2AF26__:__
Asterisk__:__601081__:__ATP-BINDING CASSETTE, SUBFAMILY 3, MEMBER 2; ABCD2__:__ADRENOLEUKODYSTROPHY-LIKE 1; ALDL1;; ADRENOLEUKODYSTROPHY-RELATED; ALDR__:__
Asterisk__:__601082__:__UBIQUITIN-CONJUGATING ENZYME E2H; UBE2H__:__UBIQUITIN-CONJUGATING ENZYME UBC8, YEAST, HOMOLOG OF;; UBCH2;; GID COMPLEX, SUBUNIT 3; GID3;; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 3, S. CEREVISIAE, HOMOLOG OF__:__
NULL__:__601083__:__CD4/CD8 T-CELL RATIO__:____:__
Caret__:__601084__:__MOVED TO 606634__:____:__
Caret__:__601085__:__MOVED TO 245570__:____:__
Percent__:__601086__:__LATERALITY DEFECTS, AUTOSOMAL DOMINANT__:____:__
Caret__:__601087__:__MOVED TO 121210__:____:__
Number Sign__:__601088__:__AYME-GRIPP SYNDROME; AYGRP__:__CATARACTS, CONGENITAL, WITH SENSORINEURAL DEAFNESS, DOWN SYNDROME-LIKE FACIAL APPEARANCE, SHORT STATURE, AND MENTAL RETARDATION__:__
Asterisk__:__601089__:__FORKHEAD BOX F1; FOXF1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 5; FKHL5;; FORKHEAD-RELATED ACTIVATOR 1; FREAC1__:__
Asterisk__:__601090__:__FORKHEAD BOX C1; FOXC1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 7; FKHL7;; FORKHEAD-RELATED ACTIVATOR 3; FREAC3__:__
Asterisk__:__601091__:__FORKHEAD BOX D1; FOXD1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 8; FKHL8;; FORKHEAD-RELATED ACTIVATOR 4; FREAC4__:__
Asterisk__:__601092__:__FORKHEAD BOX D4; FOXD4__:__FORKHEAD-LIKE 9; FKHL9;; FKH-LIKE 9;; FORKHEAD-RELATED ACTIVATOR 5; FREAC5__:__
Asterisk__:__601093__:__FORKHEAD BOX I1; FOXI1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 10; FKHL10;; FKH10;; FORKHEAD-RELATED ACTIVATOR 6; FREAC6__:__
Asterisk__:__601094__:__FORKHEAD BOX E3; FOXE3__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 12; FKHL12;; FORKHEAD-RELATED ACTIVATOR 8; FREAC8__:__
NULL__:__601095__:__HARROD SYNDROME__:____:__
NULL__:__601096__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MICROMELIC__:__SEMD, MICROMELIC;; DWARFISM, MICROMELIC, WITH CONE EPIPHYSES, METAPHYSEAL DYSPLASIA, AND VERTEBRAL SEGMENTATION DEFECTS__:__
Asterisk__:__601097__:__PERIPHERAL MYELIN PROTEIN 22; PMP22__:__GROWTH ARREST-SPECIFIC 3; GAS3__:__
Number Sign__:__601098__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C__:__CMT, SLOW NERVE CONDUCTION TYPE C;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1C;; NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE IC; HMSN1C;; HMSN IC__:__
Asterisk__:__601099__:__SRC-LIKE ADAPTOR; SLA__:__SLAP__:__
Asterisk__:__601100__:__HEAT SHOCK 70-KD PROTEIN 13; HSPA13__:__STRESS 70 PROTEIN CHAPERONE, MICROSOME-ASSOCIATED, 60-KD; STCH__:__
Percent__:__601101__:__TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 3; HHT3__:____:__
Asterisk__:__601102__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4A, ISOFORM 2; EIF4A2__:__DDX2B__:__
Asterisk__:__601103__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 5; MFAP5__:__MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 2; MAGP2__:__
Number Sign__:__601104__:__SUPRANUCLEAR PALSY, PROGRESSIVE, 1; PSNP1__:__PSP;; STEELE-RICHARDSON-OLSZEWSKI SYNDROME__:__
Asterisk__:__601105__:__CATHEPSIN K; CTSK__:____:__
Caret__:__601106__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__601107__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 2; ABCC2__:__MULTISPECIFIC ORGANIC ANION TRANSPORTER, CANALICULAR; CMOAT;; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; MRP2__:__
Caret__:__601108__:__MOVED TO 300283__:____:__
Asterisk__:__601109__:__5-HYDROXYTRYPTAMINE RECEPTOR 6; HTR6__:__SEROTONIN 5-HT-6 RECEPTOR__:__
Number Sign__:__601110__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Id; CDG1D__:__CDG Id; CDGId;; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE IV, FORMERLY; CDGS4, FORMERLY;; CDGS, TYPE IV, FORMERLY__:__
Caret__:__601111__:__MOVED TO 600941__:____:__
Asterisk__:__601112__:__THIOREDOXIN REDUCTASE 1; TXNRD1__:__TXNR;; TR1__:__
Asterisk__:__601113__:__HEAT-SHOCK 70-KD PROTEIN 4; HSPA4__:__HSP70__:__
Asterisk__:__601114__:__MEMBRANE PROTEIN, PALMITOYLATED 3; MPP3__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 3, FORMERLY; DLG3, FORMERLY__:__
Asterisk__:__601115__:__GLUTAMATE RECEPTOR, METABOTROPIC, 3; GRM3__:__MGLUR3__:__
Asterisk__:__601116__:__GLUTAMATE RECEPTOR, METABOTROPIC, 8; GRM8__:__MGLUR8__:__
Asterisk__:__601117__:__THIMET OLIGOPEPTIDASE 1; THOP1__:__TOP__:__
Asterisk__:__601118__:__CALCIUM-MODULATING CYCLOPHILIN LIGAND; CAMLG__:__CAML__:__
Asterisk__:__601119__:__CASEINOLYTIC MITOCHONDRIAL MATRIX PEPTIDASE PROTEOLYTIC SUBUNIT; CLPP__:__ClpP, E. COLI, HOMOLOG OF; CLPP__:__
Asterisk__:__601120__:__CADHERIN 5; CDH5__:__CADHERIN, VASCULAR ENDOTHELIAL, 1;; CADHERIN, VASCULAR ENDOTHELIAL;; VE-CADHERIN__:__
Asterisk__:__601121__:__PLACENTAL GROWTH FACTOR; PGF__:__PLGF__:__
Asterisk__:__601122__:__5-HYDROXYTRYPTAMINE RECEPTOR 2B; HTR2B__:__SEROTONIN 5-HT-2B RECEPTOR__:__
Asterisk__:__601123__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 1; ST8SIA1__:__ALPHA-2,8-SIALYLTRANSFERASE I;; ST8SIA I;; SIALYLTRANSFERASE 8; SIAT8;; ALPHA-N-ACETYLNEURAMINATE: ALPHA-2,8-SIALYLTRANSFERASE;; GANGLIOSIDE GD3 SYNTHASE__:__
Asterisk__:__601124__:__SEMAPHORIN 3F; SEMA3F__:__SEMAPHORIN III/F;; SEMAPHORIN IV; SEMA4;; SEMAPHORIN K; SEMAK__:__
Asterisk__:__601125__:__HEXOKINASE 2; HK2__:____:__
Asterisk__:__601126__:__TATA ELEMENT MODULATORY FACTOR 1; TMF1__:____:__
NULL__:__601127__:__FALLOT COMPLEX WITH SEVERE MENTAL AND GROWTH RETARDATION__:____:__
Asterisk__:__601128__:__H3 HISTONE, FAMILY 3A; H3F3A__:__H3F3;; H3.3A__:__
Asterisk__:__601129__:__CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 8; CYP2C8__:____:__
Asterisk__:__601130__:__CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9__:____:__
Asterisk__:__601131__:__CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 18; CYP2C18__:____:__
Asterisk__:__601132__:__KINASE SUPPRESSOR OF RAS 1; KSR1__:__KSR__:__
Asterisk__:__601133__:__CYTOCHROME P450, SUBFAMILY IIG, POLYPEPTIDE 1; CYP2G1__:__CYTOCHROME P450, FAMILY II, OLFACTORY-SPECIFIC, 1__:__
Asterisk__:__601134__:__OLIGOSACCHARYLTRANSFERASE COMPLEX, CATALYTIC SUBUNIT STT3A; STT3A__:__STT3, S. CEREVISIAE, HOMOLOG OF, A;; INTEGRAL MEMBRANE PROTEIN 1; ITM1;; TRANSMEMBRANE CONSERVED GENE; TMC__:__
Asterisk__:__601135__:__GASTRULATION BRAIN HOMEOBOX 2; GBX2__:__GASTRULATION AND BRAIN-SPECIFIC 2__:__
NULL__:__601136__:__TRANSSUPPRESSOR OF EXPRESSION 2__:__TSE2;; ALBUMIN EXTINGUISHER__:__
Caret__:__601137__:__MOVED TO 601138__:____:__
NULL__:__601138__:__GUANYLATE CYCLASE 2E, PSEUDOGENE; GUCY2EP__:__GUCY2E;; GUANYLYL CYCLASE, MEMBRANE, TYPE E;; GC-E;; GUCY2D, MOUSE, HOMOLOG OF__:__
Asterisk__:__601139__:__ZINC FINGER PROTEIN 175; ZNF175__:__ZINC FINGER PROTEIN OTK18; OTK18__:__
Asterisk__:__601140__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 14B; PPP1R14B__:__PHOSPHOLIPASE C, BETA-3, NEIGHBORING GENE OF; PLCB3N;; PNG__:__
Asterisk__:__601141__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, BETA MEMBER 1; KCNAB1__:__KCNA1B;; KV-BETA-1__:__
Asterisk__:__601142__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, BETA MEMBER 2; KCNAB2__:__KCNA2B;; KV-BETA-2__:__
Asterisk__:__601143__:__DYNACTIN 1; DCTN1__:__p150(GLUED), DROSOPHILA, HOMOLOG OF__:__
Number Sign__:__601144__:__BRUGADA SYNDROME 1; BRGDA1__:__RIGHT BUNDLE BRANCH BLOCK, ST SEGMENT ELEVATION, AND SUDDEN DEATH SYNDROME;; SUDDEN UNEXPLAINED NOCTURNAL DEATH SYNDROME; SUNDS__:__CARDIAC CONDUCTION DEFECT, NONSPECIFIC, INCLUDED
Asterisk__:__601145__:__CYSTATIN B; CSTB__:__STEFIN B; STFB__:__
Asterisk__:__601146__:__GROWTH/DIFFERENTIATION FACTOR 5; GDF5__:__CARTILAGE-DERIVED MORPHOGENETIC PROTEIN 1; CDMP1;; LIPOPOLYSACCHARIDE-ASSOCIATED PROTEIN 4; LAP4;; LPS-ASSOCIATED PROTEIN 4;; BONE MORPHOGENETIC PROTEIN 14; BMP14__:__
Asterisk__:__601147__:__GROWTH/DIFFERENTIATION FACTOR 6; GDF6__:__CARTILAGE-DERIVED MORPHOGENETIC PROTEIN 2; CDMP2__:__
Asterisk__:__601148__:__SPERM MITOCHONDRIA-ASSOCIATED CYSTEINE-RICH PROTEIN; SMCP__:__MITOCHONDRIAL CAPSULE SELENOPROTEIN; MCSP; MCS__:__
Asterisk__:__601149__:__ISOCITRATE DEHYDROGENASE 3, ALPHA SUBUNIT; IDH3A__:__ISOCITRATE DEHYDROGENASE, NAD(+)-SPECIFIC, MITOCHONDRIAL, ALPHA SUBUNIT;; ICDM__:__
Asterisk__:__601150__:__DEAD/H BOX 11; DDX11__:__CHL1-RELATED HELICASE GENE 1; CHLR1;; KERATINOCYTE GROWTH FACTOR REGULATED GENE 2; KRG2__:__
Asterisk__:__601151__:__DEAD/H BOX 12; DDX12__:__CHL1-RELATED HELICASE GENE 2; CHLR2__:__
Number Sign__:__601152__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA; HMSN6A__:__HMSN VIA;; NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VI; HMSN6;; PERIPHERAL NEUROPATHY AND OPTIC ATROPHY;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A; CMT6A;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 6; CMT6__:__
Asterisk__:__601153__:__FRAGILE HISTIDINE TRIAD GENE; FHIT__:__AP3A HYDROLASE__:__FRAGILE SITE 3p14.2, INCLUDED; FRA3B, INCLUDED
Number Sign__:__601154__:__CARDIOMYOPATHY, DILATED, 1E; CMD1E__:__CARDIOMYOPATHY, DILATED, WITH CONDUCTION DISORDER AND ARRHYTHMIA;; CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT 2; CDCD2__:__
Asterisk__:__601155__:__MINOR HISTOCOMPATIBILITY ANTIGEN HA-1; HMHA1__:__HISTOCOMPATIBILITY (MINOR) HA-1;; HLA-HA1;; KIAA0223__:__
Asterisk__:__601156__:__CHEMOKINE, CC MOTIF, LIGAND 11; CCL11__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 11; SCYA11;; SMALL INDUCIBLE CYTOKINE A11;; EOTAXIN__:__
Asterisk__:__601157__:__DEFENSIN, ALPHA, 4; DEFA4__:__DEFENSIN 4, CORTICOSTATIN; DEF4;; CORTICOSTATIN HP4 PRECURSOR__:__
Asterisk__:__601158__:__MITOGEN-ACTIVATED PROTEIN KINASE 8; MAPK8__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 8; PRKM8;; C-JUN KINASE 1; JNK1;; STRESS-ACTIVATED PROTEIN KINASE JNK1; SAPK1__:__
Asterisk__:__601159__:__CHEMOKINE, CC MOTIF, RECEPTOR 1; CCR1__:__CMKBR1;; CKR1;; MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA/RANTES RECEPTOR;; HM145__:__
NULL__:__601160__:__LISSENCEPHALY TYPE III AND BONE DYSPLASIA__:____:__
NULL__:__601161__:__TRISOMY 18-LIKE SYNDROME__:____:__
Number Sign__:__601162__:__SPASTIC PARAPLEGIA 9A, AUTOSOMAL DOMINANT; SPG9A__:__CATARACTS WITH MOTOR NEURONOPATHY, SHORT STATURE, AND SKELETAL ABNORMALITIES;; SPASTIC PARAPARESIS WITH AMYOTROPHY, CATARACTS, AND GASTROESOPHAGEAL REFLUX__:__
Percent__:__601163__:__DIAPHRAGMATIC DEFECTS, LIMB DEFICIENCIES, AND OSSIFICATION DEFECTS OF SKULL__:__FROSTER SYNDROME__:__
Caret__:__601164__:__MOVED TO 241080__:____:__
NULL__:__601165__:__CLEFT LIP/PALATE WITH CHARACTERISTIC FACIES, INTESTINAL MALROTATION, AND LETHAL CONGENITAL HEART DISEASE__:____:__
Asterisk__:__601166__:__G PROTEIN-COUPLED RECEPTOR 15; GPR15__:____:__
Asterisk__:__601167__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 1; P2RY1__:__PURINOCEPTOR P2Y1; P2Y1__:__
Asterisk__:__601168__:__DIHYDROPYRIMIDINASE-LIKE 3; DPYSL3__:__UNC33-LIKE PHOSPHOPROTEIN; ULIP;; DIHYDROPYRIMIDINASE-RELATED PROTEIN 3; DRP3;; COLLAPSIN RESPONSE MEDIATOR PROTEIN 4; CRMP4__:__
Caret__:__601169__:__REMOVED FROM DATABASE__:____:__
NULL__:__601170__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH SEVERE CENTRAL NERVOUS SYSTEM ATROPHY AND ABSENCE OF LARGE MYELINATED FIBERS__:____:__
Caret__:__601171__:__MOVED TO 173321__:____:__
Asterisk__:__601172__:__CHONDROITIN SULFATE PROTEOGLYCAN 4; CSPG4__:__CHONDROITIN SULFATE PROTEOGLYCAN, MELANOMA-ASSOCIATED; MCSP; MCSPG;; MEL-CSPG;; MSK16;; CHONDROITIN SULFATE PROTEOGLYCAN NG2, RAT, HOMOLOG OF; NG2__:__
Caret__:__601173__:__MOVED TO 253600__:____:__
Caret__:__601174__:__MOVED TO 123280__:____:__
Asterisk__:__601175__:__ADP-RIBOSYLATION FACTOR-LIKE 2; ARL2__:____:__
Asterisk__:__601176__:__GLUTAMATE-CYSTEINE LIGASE, MODIFIER SUBUNIT; GCLM__:__GLUTAMATE-CYSTEINE LIGASE, REGULATORY; GLCLR;; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE, REGULATORY SUBUNIT__:__
Asterisk__:__601177__:__ADP-RIBOSYLATION FACTOR 4; ARF4__:__ADP-RIBOSYLATION FACTOR 2, FORMERLY; ARF2, FORMERLY__:__
Asterisk__:__601178__:__CELL CYCLE-ASSOCIATED PROTEIN 1; CAPRIN1__:__CYTOPLASMIC ACTIVATION- AND PROLIFERATION-ASSOCIATED PROTEIN 1;; CAPRIN 1;; MEMBRANE COMPONENT, CHROMOSOME 11, SURFACE MARKER 1; M11S1;; GPI-ANCHORED MEMBRANE PROTEIN 1; GPIAP1;; GPI-ANCHORED MEMBRANE PROTEIN, 137-KD; GRIP137;; p137GPI;; RNA GRANULE PROTEIN 105; RNG105__:__
Asterisk__:__601179__:__RAS-RELATED NUCLEAR PROTEIN; RAN__:____:__
Asterisk__:__601180__:__RAN-BINDING PROTEIN 1; RANBP1__:__HPAII TINY FRAGMENTS LOCUS 9A; HTF9A__:__
Asterisk__:__601181__:__RAN-BINDING PROTEIN 2; RANBP2__:__NUP358__:__
Asterisk__:__601182__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 2, S. CEREVISIAE, HOMOLOG OF; ORC2__:__ORC2-LIKE; ORC2L__:__
Asterisk__:__601183__:__CYSTEINE-RICH INTESTINAL PROTEIN 2; CRIP2__:__CYSTEINE-RICH PROTEIN 2; CRP2;; LIM DOMAIN PROTEIN ESP1/CRP2__:__
Asterisk__:__601184__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 3; DNAJC3__:__PROTEIN KINASE, INTERFERON-INDUCIBLE DOUBLE-STRANDED RNA-DEPENDENT, INHIBITOR OF; PRKRI;; PROTEIN KINASE INHIBITOR P58__:__
Asterisk__:__601185__:__STANNIOCALCIN 1; STC1__:__STANNIOCALCIN; STC__:__
Number Sign__:__601186__:__MICROPHTHALMIA, SYNDROMIC 9; MCOPS9__:__ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLE MALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM;; ANOPHTHALMIA/MICROPHTHALMIA AND PULMONARY HYPOPLASIA;; PULMONARY HYPOPLASIA-DIAPHRAGMATIC HERNIA-ANOPHTHALMIA-CARDIAC DEFECT; PDAC;; SPEAR SYNDROME;; MATTHEW-WOOD SYNDROME;; PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT; PMD__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 8, INCLUDED; MCOPCB8, INCLUDED
NULL__:__601187__:__GURRIERI SYNDROME__:____:__
NULL__:__601188__:__SUPPRESSION OF TUMORIGENICITY 12; ST12__:__PROSTATE ADENOCARCINOMA 1; PAC1__:__
Asterisk__:__601189__:__POLYMERASE II, RNA, SUBUNIT L; POLR2L__:__RPB10, S. CEREVISIAE, HOMOLOG OF;; RPB10-BETA, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 7.6-KD SUBUNIT__:__
Asterisk__:__601190__:__PHOSPHODIESTERASE 6H, cGMP-SPECIFIC, CONE, GAMMA; PDE6H__:____:__
Asterisk__:__601191__:__ENHANCER OF RUDIMENTARY, DROSOPHILA, HOMOLOG OF; ERH__:__DROER, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__601192__:__PHOSPHOLIPASE A2, GROUP V; PLA2G5__:____:__
Asterisk__:__601193__:__CYSTEINE-RICH SECRETORY PROTEIN 1; CRISP1__:__ACIDIC EPIDIDYMAL GLYCOPROTEIN-LIKE 1; AEGL1__:__
Asterisk__:__601194__:__TOLL-LIKE RECEPTOR 1; TLR1__:__TOLL/INTERLEUKIN 1 RECEPTOR-LIKE; TIL__:__
NULL__:__601195__:__IRON OVERLOAD IN AFRICA__:__AFRICAN IRON OVERLOAD;; BANTU SIDEROSIS__:__
Asterisk__:__601196__:__PR DOMAIN-CONTAINING PROTEIN 2; PRDM2__:__RETINOBLASTOMA PROTEIN-BINDING ZINC FINGER PROTEIN RIZ; RIZ__:__
Asterisk__:__601197__:__TUBBY, MOUSE, HOMOLOG OF; TUB__:____:__
Number Sign__:__601198__:__HYPOCALCEMIA, AUTOSOMAL DOMINANT 1; HYPOC1__:__HYPERCALCIURIC HYPOCALCEMIA;; HYPOCALCEMIA, FAMILIAL__:__HYPOCALCEMIA, AUTOSOMAL DOMINANT 1, WITH BARTTER SYNDROME, INCLUDED
Asterisk__:__601199__:__CALCIUM-SENSING RECEPTOR; CASR__:__PARATHYROID CA(2+)-SENSING RECEPTOR 1; PCAR1__:__
Number Sign__:__601200__:__PLEUROPULMONARY BLASTOMA; PPB__:__PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME; PPBFTDS__:__
Asterisk__:__601201__:__METHYLATION MODIFIER FOR CLASS I HLA__:__MEMO1__:__
Percent__:__601202__:__CATARACT 24; CTRCT24__:__CATARACT 24, ANTERIOR POLAR;; CATARACT, ANTERIOR POLAR, 2; CTAA2__:__
Asterisk__:__601203__:__INTERLEUKIN 1 RECEPTOR-LIKE 1; IL1RL1__:__GROWTH STIMULATION-EXPRESSED GENE, MOUSE, HOMOLOG OF;; ST2, MOUSE, HOMOLOG OF; ST2;; INTERLEUKIN 33 RECEPTOR; IL33R__:__
Asterisk__:__601204__:__PROSTAGLANDIN F2 RECEPTOR NEGATIVE REGULATOR; PTGFRN__:__FP REGULATORY PROTEIN; FPRP;; CD9 PARTNER 1; CD9P1__:__
Asterisk__:__601205__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 1; SIX1__:____:__
Asterisk__:__601206__:__POU DOMAIN, CLASS 2, ASSOCIATING FACTOR 1; POU2AF1__:__OCT-BINDING FACTOR 1; OBF1;; BOB1;; OCAB__:__
Asterisk__:__601207__:__DIACYLGLYCEROL KINASE, THETA, 110-KD; DGKQ__:__DIACYLGLYCEROL KINASE, DELTA, 110-KD, FORMERLY; DAGK4, FORMERLY;; DGK-DELTA, FORMERLY__:__
Percent__:__601208__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 11; IDDM11__:__INSULIN-DEPENDENT DIABETES MELLITUS 11__:__
Asterisk__:__601209__:__POLY(rC)-BINDING PROTEIN 1; PCBP1__:____:__
Asterisk__:__601210__:__POLY(rC)-BINDING PROTEIN 2; PCBP2__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN E2; HNRNPE2;; HNRPE2__:__
Asterisk__:__601211__:__ADHESION G PROTEIN-COUPLED RECEPTOR E5; ADGRE5__:__CD97 ANTIGEN; CD97__:__
Asterisk__:__601212__:__PROTEIN-TYROSINE KINASE 2, BETA; PTK2B__:__PROLINE-RICH TYROSINE KINASE 2; PYK2;; FOCAL ADHESION KINASE 2; FAK2;; CELL ADHESION KINASE, BETA; CAKB__:__
Asterisk__:__601213__:__RIBONUCLEASE 4 INHIBITOR; RNS4I__:__RNase L INHIBITOR;; ATP-BINDING CASSETTE, SUBFAMILY E, MEMBER 1; ABCE1__:__
Number Sign__:__601214__:__NAXOS DISEASE; NXD__:__CARDIOMYOPATHY, ARRHYTHMOGENIC RIGHT VENTRICULAR, WITH SKIN, HAIR, AND NAIL ABNORMALITIES;; MAL DE NAXOS;; KERATOSIS PALMOPLANTARIS WITH ARRHYTHMOGENIC CARDIOMYOPATHY;; WOOLLY HAIR, PALMOPLANTAR KERATODERMA, AND CARDIAC ABNORMALITIES;; PALMOPLANTAR KERATODERMA WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY AND WOOLLY HAIR__:__
Asterisk__:__601215__:__ATR GENE; ATR__:__ATAXIA-TELANGIECTASIA AND RAD3-RELATED;; FRAP-RELATED PROTEIN 1; FRP1__:__
Number Sign__:__601216__:__DENTAL ANOMALIES AND SHORT STATURE; DASS__:__VERLOES-BOURGUIGNON SYNDROME; VBS;; PLATYSPONDYLY WITH AMELOGENESIS IMPERFECTA;; TOOTH AGENESIS, SELECTIVE, 6, FORMERLY; STHAG6, FORMERLY__:__
NULL__:__601217__:__ALOPECIA-MENTAL RETARDATION SYNDROME WITH CONVULSIONS AND HYPERGONADOTROPIC HYPOGONADISM__:____:__
Asterisk__:__601218__:__ADENOSINE DEAMINASE, RNA-SPECIFIC, B1; ADARB1__:__ADENOSINE DEAMINASE, RNA-SPECIFIC, 2; ADAR2;; RNA-EDITING ENZYME 1, RAT, HOMOLOG OF; RED1;; RNA EDITASE 1__:__
Caret__:__601219__:__MOVED TO 182390__:____:__
NULL__:__601220__:__OSTEOPOROSIS AND OCULOCUTANEOUS HYPOPIGMENTATION SYNDROME; OOCH__:____:__
NULL__:__601221__:__TISSUE-SPECIFIC EXTINGUISHER 3__:__TSE3__:__
Caret__:__601222__:__MOVED TO 185900__:____:__
NULL__:__601223__:__NEURONAL INTESTINAL DYSPLASIA, TYPE B__:__NID B__:__
Number Sign__:__601224__:__POTOCKI-SHAFFER SYNDROME__:__PSS;; CHROMOSOME 11p11.2 DELETION SYNDROME;; PROXIMAL 11p DELETION SYNDROME; P11pDS;; DEFECT11 SYNDROME__:__
Asterisk__:__601225__:__DISHEVELLED 1-LIKE 1; DVL1L1__:__DISHEVELLED, DROSOPHILA, HOMOLOG-LIKE;; DSH__:__
Caret__:__601226__:__MOVED TO 601227__:____:__
Caret__:__601227__:__MOVED TO 157640__:____:__
Number Sign__:__601228__:__POLYPOSIS SYNDROME, HEREDITARY MIXED, 1; HMPS1__:__CHROMOSOME 15q13-q14 DUPLICATION SYNDROME, 40-KB;; COLORECTAL ADENOMA AND CARCINOMA 1; CRAC1__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 4, INCLUDED; CRCS4, INCLUDED;; COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 15, INCLUDED
Caret__:__601229__:__MOVED TO 151430__:____:__
NULL__:__601230__:__DERMATITIS HERPETIFORMIS, FAMILIAL__:__DH__:__
Asterisk__:__601231__:__MECHANISTIC TARGET OF RAPAMYCIN; MTOR__:__MAMMALIAN TARGET OF RAPAMYCIN;; FKBP12-RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN 1; FRAP1;; FK506-BINDING PROTEIN 12-RAPAMYCIN COMPLEX-ASSOCIATED PROTEIN 1;; FRAP;; FRAP2;; RAFT1__:__MTOR COMPLEX, INCLUDED; MTORC, INCLUDED;; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1, INCLUDED; MTORC1, INCLUDED;; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 2, INCLUDED; MTORC2, INCLUDED
Asterisk__:__601232__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, GAMMA; PIK3CG__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, GAMMA;; p110-GAMMA;; PI3K-GAMMA;; PIK3-GAMMA;; p120-PI3K__:__
Asterisk__:__601233__:__INHIBIN, BETA C; INHBC__:____:__
Asterisk__:__601234__:__NASCENT POLYPEPTIDE-ASSOCIATED COMPLEX, ALPHA POLYPEPTIDE; NACA__:____:__SKELETAL MUSCLE NACA, INCLUDED; SKNAC, INCLUDED
Asterisk__:__601235__:__DEAD/H BOX 10; DDX10__:____:__DDX10/NUP98 FUSION GENE, INCLUDED
Asterisk__:__601236__:__DISABLED, DROSOPHILA, HOMOLOG OF, 2; DAB2__:__DIFFERENTIALLY EXPRESSED IN OVARIAN CANCER 2; DOC2__:__
Asterisk__:__601237__:__RING FINGER PROTEIN 112; RNF112__:__ZINC FINGER PROTEIN 179; ZNF179;; BRAIN FINGER PROTEIN, MOUSE, HOMOLOG OF; BFP;; NEUROLASTIN__:__
Number Sign__:__601238__:__CEREBELLAR ATAXIA, CAYMAN TYPE; ATCAY__:____:__
Asterisk__:__601239__:__DYSTROBREVIN, ALPHA; DTNA__:__DYSTROBREVIN;; DYSTROPHIN-RELATED PROTEIN 3; DRP3;; D18S892E__:__
Asterisk__:__601240__:__GUANIDINOACETATE METHYLTRANSFERASE; GAMT__:____:__
Asterisk__:__601241__:__HISTONE DEACETYLASE 1; HDAC1__:__HD1;; REDUCED POTASSIUM DEPENDENCY 3, YEAST, HOMOLOG-LIKE 1; RPD3L1;; RPD3-LIKE 1__:__
Asterisk__:__601242__:__MICROTUBULE-ASSOCIATED PROTEIN 1, LIGHT CHAIN 3, ALPHA; MAP1LC3A__:__MICROTUBULE-ASSOCIATED PROTEINS 1A AND 1B, LIGHT CHAIN 3;; MAP1ALC3;; MAP1BLC3;; LC3A;; LC3__:__
Asterisk__:__601243__:__TOPOISOMERASE, DNA, III, ALPHA; TOP3A__:__TOPOISOMERASE, DNA, III; TOP3;; TOPO III-ALPHA__:__
Asterisk__:__601244__:__GUANYLATE CYCLASE 1, SOLUBLE, ALPHA-2; GUCY1A2__:__GUC1A2;; GUANYLYL CYCLASE, SOLUBLE, ALPHA-2;; GUANYLYL CYCLASE, NITRIC OXIDE-SENSITIVE, ALPHA-2 SUBUNIT;; NITRIC OXIDE-SENSITIVE GUANYLYL CYCLASE, ALPHA-2 SUBUNIT;; NOGC, ALPHA-2 SUBUNIT__:__
Asterisk__:__601245__:__CHROMATIN ASSEMBLY FACTOR I, SUBUNIT B; CHAF1B__:__CHROMATIN ASSEMBLY FACTOR I, p60 SUBUNIT; CAF1P60;; CAF1A__:__
Asterisk__:__601246__:__CHROMATIN ASSEMBLY FACTOR I, SUBUNIT A; CHAF1A__:__CHROMATIN ASSEMBLY FACTOR I, p150 SUBUNIT; CAF1P150;; CAF1B__:__
Asterisk__:__601247__:__SON OF SEVENLESS, DROSOPHILA, HOMOLOG 2; SOS2__:____:__
Asterisk__:__601248__:__BRIDGING INTEGRATOR 1; BIN1__:__AMPHIPHYSIN II; AMPH2;; BOX-DEPENDENT MYC-INTERACTING PROTEIN 1;; AMPHIPHYSIN-LIKE, FORMERLY; AMPHL, FORMERLY__:__
Asterisk__:__601249__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE-ASSOCIATED PROTEIN 1; PRPSAP1__:__PAP39__:__
Asterisk__:__601250__:__PEPTIDE METHIONINE SULFOXIDE REDUCTASE; MSRA__:____:__
Caret__:__601251__:__MOVED TO 601777__:____:__
Asterisk__:__601252__:__FICOLIN 1; FCN1__:__COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING LECTIN 1 P35-LIKE;; FICOLIN B, MOUSE, HOMOLOG OF; FCNB__:__
Asterisk__:__601253__:__CAVEOLIN 3; CAV3__:__M-CAVEOLIN__:__
Asterisk__:__601254__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6; MAP2K6__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 6; PRKMK6;; MKK6; MAPKK6;; MAPK/ERK KINASE 6; MEK6__:__
Asterisk__:__601255__:__KINESIN FAMILY MEMBER 1A; KIF1A__:__AXONAL TRANSPORTER OF SYNAPTIC VESICLES; ATSV;; UNC104, C. ELEGANS, HOMOLOG OF; UNC104;; KINESIN, HEAVY CHAIN, MEMBER 1A, MOUSE, HOMOLOG OF__:__
Caret__:__601256__:__MOVED TO 106165__:____:__
Asterisk__:__601257__:__DEAD/H BOX 1; DDX1__:____:__
Asterisk__:__601258__:__CYTOCHROME P450, SUBFAMILY IIJ, POLYPEPTIDE 2; CYP2J2__:__CYTOCHROME P450 ARACHIDONIC ACID EPOXYGENASE__:__
Asterisk__:__601259__:__AMELOBLASTIN ENAMEL MATRIX PROTEIN; AMBN__:____:__
Asterisk__:__601260__:__ZINC FINGER PROTEIN WITH KRAB AND SCAN DOMAINS 1; ZKSCAN1__:__ZINC FINGER PROTEIN 36; ZNF36;; ZINC FINGER PROTEIN, KRUPPEL TYPE, 18; KOX18;; ZINC FINGER PROTEIN 139, FORMERLY; ZNF139, FORMERLY__:__
Asterisk__:__601261__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 21; ZSCAN21__:__ZINC FINGER PROTEIN 38; ZNF38;; ZINC FINGER PROTEIN, KRUPPEL TYPE, 25; KOX25__:__
Asterisk__:__601262__:__ZINC FINGER PROTEIN 16; ZNF16__:__ZINC FINGER PROTEIN, KRUPPEL TYPE, 9; KOX9__:__
Asterisk__:__601263__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2; MAP2K2__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 2; PRKMK2;; MKK2; MAPKK2;; MAPK/ERK KINASE 2; MEK2__:__
Caret__:__601264__:__MOVED TO 601271__:____:__
Asterisk__:__601265__:__NODAL, MOUSE, HOMOLOG OF; NODAL__:____:__
Asterisk__:__601266__:__dUTP PYROPHOSPHATASE; DUT__:__DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE;; DEOXYURIDINE TRIPHOSPHATASE;; dUTPase__:__
Asterisk__:__601267__:__CHEMOKINE, CC MOTIF, RECEPTOR 2; CCR2__:__CMKBR2;; CKR2;; MONOCYTE CHEMOTACTIC PROTEIN 1 RECEPTOR;; MCP1 RECEPTOR__:__CCR2A, INCLUDED; CKR2A, INCLUDED;; CCR2B, INCLUDED; CKR2B, INCLUDED
Asterisk__:__601268__:__CHEMOKINE, CC MOTIF, RECEPTOR 3; CCR3__:__CMKBR3;; CKR3;; EOTAXIN RECEPTOR__:__
Asterisk__:__601269__:__COMPLEMENT COMPONENT C1q-BINDING PROTEIN; C1QBP__:__C1q GLOBULAR DOMAIN-BINDING PROTEIN;; GLOBULAR DOMAIN OF C1q, RECEPTOR FOR; GC1qR;; HYALURONIC ACID-BINDING PROTEIN 1; HABP1;; P32 SPLICING FACTOR SF2-ASSOCIATED PROTEIN__:__
Asterisk__:__601270__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 3; CYP4F3__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 3;; LEUKOTRIENE B4 OMEGA-HYDROXYLASE; LTB4H;; LTB4 OMEGA-HYDROXYLASE__:__
Asterisk__:__601271__:__GUANYLATE CYCLASE ACTIVATOR 2B; GUCA2B__:__UROGUANYLIN; UGN;; GUANYLATE CYCLASE C ACTIVATING PEPTIDE II;; GCAP II__:__
Asterisk__:__601272__:__SORTING NEXIN 1; SNX1__:____:__SORTING NEXIN 1A, INCLUDED; SNX1A, INCLUDED
Asterisk__:__601273__:__CLATHRIN, HEAVY POLYPEPTIDE-LIKE 1; CLTCL1__:__CLATHRIN, HEAVY POLYPEPTIDE D; CLTD;; CLH22;; CHC22__:__
Asterisk__:__601274__:__PROSTAGLANDIN REDUCTASE 1; PTGR1__:__LEUKOTRIENE B4 12-HYDROXYDEHYDROGENASE; LTB4DH__:__
Asterisk__:__601275__:__GLYCOPROTEIN M6A; GPM6A__:__NEURONAL MEMBRANE GLYCOPROTEIN M6A__:__
Asterisk__:__601276__:__ZINC FINGER PROTEIN 177; ZNF177__:__KRAB ZINC FINGER PROTEIN 177__:__
Number Sign__:__601277__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 4A; ARCI4A__:__ICHTHYOSIS CONGENITA IIB; ICR2B;; ICHTHYOSIS, LAMELLAR, 2, FORMERLY; LI2, FORMERLY__:__
Asterisk__:__601278__:__FSHD REGION GENE 1; FRG1__:____:__
Asterisk__:__601279__:__DIGEORGE SYNDROME CRITICAL REGION GENE 6; DGCR6__:____:__
Asterisk__:__601280__:__MAB21, C. ELEGANS, HOMOLOG-LIKE 1; MAB21L1__:__CAGR1__:__
Asterisk__:__601281__:__SEMAPHORIN 3B; SEMA3B__:__SEMAPHORIN A; SEMAA;; SEMAPHORIN V; SEMA5__:__
Asterisk__:__601282__:__PLECTIN; PLEC__:__PLEC1;; PCN; PLTN__:__
Number Sign__:__601283__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT, 1; NIDDM1__:__NONINSULIN-DEPENDENT DIABETES MELLITUS 1__:__
Asterisk__:__601284__:__ACTIVIN A RECEPTOR, TYPE II-LIKE 1; ACVRL1__:__ACTIVIN A RECEPTOR, TYPE II-LIKE KINASE 1; ACVRLK1;; ACTIVIN RECEPTOR-LIKE KINASE 1; ALK1__:__
Asterisk__:__601285__:__PROTEASOME 26S SUBUNIT SEM1; SEM1__:__DELETED IN SPLIT-HAND/SPLIT-FOOT 1 REGION; DSS1__:__
Caret__:__601286__:__MOVED TO 115700__:____:__
Number Sign__:__601287__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6; LGMDR6__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2F; LGMD2F__:__
Asterisk__:__601288__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, ZETA ISOFORM; YWHAZ__:__BRAIN PROTEIN 14-3-3, ZETA ISOFORM;; 14-3-3-ZETA__:__
Asterisk__:__601289__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, BETA ISOFORM; YWHAB__:__BRAIN PROTEIN 14-3-3, BETA ISOFORM;; 14-3-3-BETA__:__
Asterisk__:__601290__:__STRATIFIN; SFN__:__14-3-3-SIGMA__:__
Asterisk__:__601291__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 8; UGT8__:__UDP GLYCOSYLTRANSFERASE 8;; UDP-GALACTOSE CERAMIDE GALACTOSYLTRANSFERASE; CGT;; CEREBROSIDE SYNTHASE__:__
Asterisk__:__601292__:__SULFOTRANSFERASE FAMILY 1A, CYTOSOLIC, PHENOL-PREFERRING, MEMBER 2; SULT1A2__:__SULFOTRANSFERASE, PHENOL-PREFERRING 2; STP2;; PHENOL SULFOTRANSFERASE 2__:__
Asterisk__:__601293__:__RAS HOMOLOG ENRICHED IN BRAIN; RHEB__:__RAS HOMOLOG ENRICHED IN BRAIN 2, FORMERLY; RHEB2, FORMERLY__:__
Caret__:__601294__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__601295__:__SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID COTRANSPORTER FAMILY), MEMBER 2; SLC10A2__:__SODIUM/TAUROCHOLATE COTRANSPORTING POLYPEPTIDE, ILEAL; NTCP2;; ILEAL SODIUM/BILE SALT TRANSPORTER; ISBT;; APICAL SODIUM/BILE SALT TRANSPORTER; ASBT;; APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER__:__
Asterisk__:__601296__:__MUSCLE, SKELETAL, RECEPTOR TYROSINE KINASE; MUSK__:__RECEPTOR TYROSINE KINASE NSK2, MOUSE, HOMOLOG OF; NSK2__:__
Asterisk__:__601297__:__SRY-BOX 15; SOX15__:__SOX20;; SOX26;; SOX27__:__
Caret__:__601298__:__MOVED TO 102576__:____:__
Asterisk__:__601299__:__BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE IA; BMPR1A__:__ACTIVIN A RECEPTOR, TYPE II-LIKE KINASE 3; ACVRLK3;; ACTIVIN RECEPTOR-LIKE KINASE 3; ALK3__:__
Asterisk__:__601300__:__ACTIVIN A RECEPTOR, TYPE IB; ACVR1B__:__ACTIVIN A RECEPTOR, TYPE II-LIKE KINASE 4; ACVRLK4;; ACTIVIN RECEPTOR-LIKE KINASE 4; ALK4__:__
Asterisk__:__601301__:__PEPTIDYL-PROLYL ISOMERASE-LIKE 1; PPIL1__:__CYCLOPHILIN-RELATED GENE 1; CYPL1__:__
Asterisk__:__601302__:__PROTEIN PHOSPHATASE 3, REGULATORY SUBUNIT B, ALPHA; PPP3R1__:__CALCINEURIN B, TYPE 1; CNB1;; CNB__:__
Asterisk__:__601303__:__CYTOSKELETON-ASSOCIATED PROTEIN 1; CKAP1__:__CKAPI__:__
Asterisk__:__601304__:__SMALL NUCLEAR RIBONUCLEOPROTEIN (U4/U6.U5), SNU13 HOMOLOG; SNU13__:__NON-HISTONE CHROMOSOME PROTEIN 2, S. CEREVISIAE, HOMOLOG-LIKE 1; NHP2L1;; NHP2-LIKE PROTEIN 1;; U4/U6-15.5K PROTEIN;; 15.5K__:__
Asterisk__:__601305__:__5-HYDROXYTRYPTAMINE RECEPTOR 5A; HTR5A__:__SEROTONIN 5-HT-5A RECEPTOR__:__
Asterisk__:__601306__:__HEMATOPOIETIC CELL-SPECIFIC LYN SUBSTRATE 1; HCLS1__:__HS1__:__
Caret__:__601307__:__MOVED TO 600924__:____:__
Percent__:__601308__:__MYELOID TUMOR SUPPRESSOR__:__MYELOID LEUKEMIA-RELATED LOCUS; MLRL__:__
Asterisk__:__601309__:__PATCHED, DROSOPHILA, HOMOLOG OF, 1; PTCH1__:__PTCH;; PTC__:__
Asterisk__:__601310__:__CYTOCHROME P450, SUBFAMILY IVA, POLYPEPTIDE 11; CYP4A11__:__OMEGA-HYDROXYLASE, FATTY ACID;; CYP4AII__:__
Asterisk__:__601311__:__STEROL O-ACYLTRANSFERASE 2; SOAT2__:__ACYL-CoA:CHOLESTEROL ACYLTRANSFERASE 2; ACACT2;; ACAT2__:__
Caret__:__601312__:__MOVED TO 600408__:____:__
Asterisk__:__601313__:__POLYCYSTIN 1; PKD1__:__PKD1 GENE;; PBP__:__
Asterisk__:__601314__:__HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 1; HINT1__:__HINT;; PROTEIN KINASE C INHIBITOR 1; PRKCNH1;; PROTEIN KINASE C-INTERACTING PROTEIN 1; PKCI1__:__
NULL__:__601315__:__EPITHELIAL BASOLATERAL CHLORIDE CONDUCTANCE REGULATOR, RABBIT, HOMOLOG OF__:__EBCR__:__
Number Sign__:__601316__:__DEAFNESS, AUTOSOMAL DOMINANT 10; DFNA10__:____:__
Number Sign__:__601317__:__DEAFNESS, AUTOSOMAL DOMINANT 11; DFNA11__:____:__
Percent__:__601318__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 13; IDDM13__:__INSULIN-DEPENDENT DIABETES MELLITUS 13__:__
NULL__:__601319__:__ODONTOMICRONYCHIAL DYSPLASIA__:__ECTODERMAL DYSPLASIA, NAIL/TOOTH TYPE__:__
Caret__:__601320__:__MOVED TO 601984__:____:__
Number Sign__:__601321__:__NEUROFIBROMATOSIS-NOONAN SYNDROME; NFNS__:__NOONAN-NEUROFIBROMATOSIS SYNDROME;; NEUROFIBROMATOSIS WITH NOONAN PHENOTYPE__:__
NULL__:__601322__:__PORENCEPHALY, CEREBELLAR HYPOPLASIA, AND INTERNAL MALFORMATIONS__:____:__
Asterisk__:__601323__:__NUCLEOBINDIN 1; NUCB1__:__NUC__:__
Asterisk__:__601324__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; HNRNPD__:__HNRPD;; AU-RICH ELEMENT RNA-BINDING PROTEIN 1, 37-KD; AUF1;; ARE-BINDING PROTEIN AUF1, TYPE A; AUF1A__:__
Asterisk__:__601325__:__CONTACTIN 3; CNTN3__:__PLASMACYTOMA-ASSOCIATED NEURONAL GLYCOPROTEIN; PANG;; BIG1, RAT, HOMOLOG OF; BIG1__:__
Asterisk__:__601326__:__CLAUDIN 11; CLDN11__:__OLIGODENDROCYTE TRANSMEMBRANE PROTEIN; OTM;; OLIGODENDROCYTE-SPECIFIC PROTEIN; OSP__:__
Asterisk__:__601327__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE II, BETA SUBUNIT; SCN2B__:__SODIUM CHANNEL, NEURONAL TYPE II, BETA SUBUNIT;; SODIUM CHANNEL, VOLTAGE-GATED, BETA-2 SUBUNIT__:__
Asterisk__:__601328__:__SODIUM CHANNEL, NONVOLTAGE-GATED 1, DELTA SUBUNIT; SCNN1D__:__SODIUM CHANNEL, EPITHELIAL, DELTA SUBUNIT; SCNED__:__
Asterisk__:__601329__:__LIM DOMAIN KINASE 1; LIMK1__:__LIMK;; LIM KINASE__:__
Asterisk__:__601330__:__GUANYLATE CYCLASE 2C; GUCY2C__:__GUANYLYL CYCLASE 2C; GUC2C;; HEAT-STABLE ENTEROTOXIN RECEPTOR__:__
Number Sign__:__601331__:__RENAL DYSPLASIA, CYSTIC, SUSCEPTIBILITY TO; CYSRD__:____:__
Asterisk__:__601332__:__MOHAWK HOMEOBOX; MKX__:__IROQUOIS FAMILY-RELATED HOMEODOMAIN PROTEIN; IFRX;; IROQUOIS HOMEOBOX-LIKE 1; IRXL1__:__
Asterisk__:__601333__:__SUPPRESSOR OF TY 6, S. CEREVISIAE, HOMOLOG OF; SUPT6H__:__CHROMATIN STRUCTURE REGULATOR, YEAST, HOMOLOG OF; SPT6__:__
Asterisk__:__601334__:__KINESIN LIGHT CHAIN 3; KLC3__:__KINESIN LIGHT CHAIN 2-LIKE; KLC2L;; KNS2B__:__
Asterisk__:__601335__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; MAP2K4__:__SAPK/ERK KINASE 1; SERK1; SEK1;; PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 4; PRKMK4;; MKK4; MAPKK4;; MAPK/ERK KINASE 4; MEK4;; JNK-ACTIVATED KINASE 1; JNKK1__:__
Asterisk__:__601336__:__MANNOSYL-OLIGOSACCHARIDE GLYCOSIDASE; MOGS__:__GLUCOSIDASE I; GCS1__:__
Asterisk__:__601337__:__REGULATORY FACTOR X, 3; RFX3__:____:__
Number Sign__:__601338__:__CEREBELLAR ATAXIA, AREFLEXIA, PES CAVUS, OPTIC ATROPHY, AND SENSORINEURAL HEARING LOSS; CAPOS__:____:__
Caret__:__601339__:__MOVED TO 601112__:____:__
Asterisk__:__601340__:__MELANOMA INHIBITORY ACTIVITY PROTEIN; MIA__:__CARTILAGE-DERIVED RETINOIC ACID-SENSITIVE PROTEIN; CDRAP__:__
NULL__:__601341__:__ATROPHIA MACULOSA VARIOLIFORMIS CUTIS, FAMILIAL; AMVC__:__VARIOLIFORM MACULAR ATROPHY OF THE SKIN__:__
Asterisk__:__601342__:__CHROMOSOME SEGREGATION 1-LIKE; CSE1L__:__CELLULAR APOPTOSIS SUSCEPTIBILITY; CAS;; CHROMOSOME SEGREGATION GENE CSE1, YEAST, HOMOLOG OF;; CSE1, YEAST, HOMOLOG OF__:__
Caret__:__601343__:__MOVED TO 276821__:____:__
NULL__:__601344__:__SPINAL DYSPLASIA, ANHALT TYPE__:____:__
NULL__:__601345__:__ECTODERMAL DYSPLASIA WITH NATAL TEETH, TURNPENNY TYPE__:__ECTODERMAL DYSPLASIA, HAIR/TOOTH TYPE__:__
Percent__:__601346__:__MARTINEZ-FRIAS SYNDROME__:__PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA, AND GALLBLADDER APLASIA OR HYPOPLASIA, WITH OR WITHOUT TRACHEOESOPHAGEAL FISTULA__:__
NULL__:__601347__:__MYELODYSPLASIA, IMMUNODEFICIENCY, FACIAL DYSMORPHISM, SHORT STATURE, AND PSYCHOMOTOR DELAY__:____:__
NULL__:__601348__:__ECTRODACTYLY OF LOWER LIMBS, CONGENITAL HEART DEFECT, AND MICROGNATHIA__:____:__
Percent__:__601349__:__MICROPHTHALMIA, SYNDROMIC 8; MCOPS8__:__MICROCEPHALY, MICROPHTHALMIA, ECTRODACTYLY OF LOWER LIMBS, AND PROGNATHISM; MMEP__:__
NULL__:__601350__:__SHORT STATURE SYNDROME, BRUSSELS TYPE__:____:__
NULL__:__601351__:__GROWTH RETARDATION, DEAFNESS, FEMORAL EPIPHYSEAL DYSPLASIA, AND LACRIMAL DUCT OBSTRUCTION__:____:__
NULL__:__601352__:__MENTAL RETARDATION, MICROCEPHALY, EPILEPSY, AND COARSE FACE__:____:__
Percent__:__601353__:__BRACHYCEPHALY, DEAFNESS, CATARACT, MICROSTOMIA, AND MENTAL RETARDATION__:__FINE-LUBINSKY SYNDROME__:__
Caret__:__601354__:__MOVED TO 300166__:____:__
NULL__:__601355__:__MICROCEPHALY, CONGENITAL HEART DISEASE, UNILATERAL RENAL AGENESIS, AND HYPOSEGMENTED LUNGS__:____:__
Percent__:__601356__:__LETHAL SHORT-LIMB SKELETAL DYSPLASIA, AL GAZALI TYPE__:____:__
Percent__:__601357__:__BRACHIAL AMELIA, CLEFT LIP, AND HOLOPROSENCEPHALY; ACLH__:__BRACHIAL AMELIA, FOREBRAIN DEFECTS, AND FACIAL CLEFTS__:__
Number Sign__:__601358__:__NICOLAIDES-BARAITSER SYNDROME; NCBRS__:__SPARSE HAIR AND MENTAL RETARDATION;; NBS__:__
Caret__:__601359__:__MOVED TO 163200__:____:__
NULL__:__601360__:__AMELIA, AUTOSOMAL RECESSIVE__:____:__
Asterisk__:__601361__:__GROWTH/DIFFERENTIATION FACTOR 10; GDF10__:__BONE MORPHOGENETIC PROTEIN 3B; BMP3B__:__
Percent__:__601362__:__DIGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME COMPLEX 2__:__DGS2__:__
Percent__:__601363__:__WILMS TUMOR 4; WT4__:__FAMILIAL WILMS TUMOR 1; FWT1__:__
Asterisk__:__601364__:__CADHERIN 13; CDH13__:__H-CADHERIN; CDHH;; CADHERIN, HEART;; T-CADHERIN__:__
Asterisk__:__601365__:__DISHEVELLED 1; DVL1__:__DSH, DROSOPHILA, HOMOLOG OF, 1; DVL__:__
Asterisk__:__601366__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 2; SMAD2__:__MADH2;; SMA- AND MAD-RELATED PROTEIN 2 MAD, DROSOPHILA, HOMOLOG OF;; MADR2__:__
Number Sign__:__601367__:__STROKE, ISCHEMIC__:__CEREBROVASCULAR ACCIDENT;; CEREBRAL INFARCTION__:__
Asterisk__:__601368__:__DISHEVELLED 3; DVL3__:____:__
Number Sign__:__601369__:__DEAFNESS, AUTOSOMAL DOMINANT 9; DFNA9__:____:__
NULL__:__601370__:__HOLOPROSENCEPHALY, SEMILOBAR, WITH CRANIOSYNOSTOSIS__:__GENOA SYNDROME__:__
NULL__:__601371__:__CATARACT, AGE-RELATED NUCLEAR__:__NUCLEAR SCLEROSIS OF THE LENS__:__
NULL__:__601372__:__CHOREA, REMITTING, WITH NYSTAGMUS AND CATARACT__:____:__
Asterisk__:__601373__:__CHEMOKINE, CC MOTIF, RECEPTOR 5; CCR5__:__CC CHEMOKINE RECEPTOR 5; CCCKR5;; CMKBR5;; CKR5__:__
NULL__:__601374__:__APROSENCEPHALY AND CEREBELLAR DYSGENESIS__:____:__
NULL__:__601375__:__ECTODERMAL DYSPLASIA, HIDROTIC, CHRISTIANSON-FOURIE TYPE__:____:__
NULL__:__601376__:__CHONDRODYSPLASIA, LETHAL, WITH LONG BONE ANGULATION AND MIXED BONE DENSITY__:____:__
Caret__:__601377__:__MOVED TO 218340__:____:__
Caret__:__601378__:__MOVED TO 272430__:____:__
NULL__:__601379__:__HUNTER-MCALPINE CRANIOSYNOSTOSIS SYNDROME__:____:__
Asterisk__:__601380__:__EPHRIN A4; EFNA4__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 4; EPLG4;; LIGAND OF EPH-RELATED KINASE 4; LERK4;; EFL4__:__
Asterisk__:__601381__:__EPHRIN A3; EFNA3__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 3; EPLG3;; LIGAND OF EPH-RELATED KINASE 3; LERK3;; EFL2;; EHK1 LIGAND; EHK1L__:__
Number Sign__:__601382__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B1; CMT4B1__:__CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, WITH FOCALLY FOLDED MYELIN SHEATHS, AUTOSOMAL RECESSIVE, TYPE 4B1;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B1;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B; CMT4B__:__
Asterisk__:__601383__:__AQUAPORIN 6; AQP6__:__AQUAPORIN 2-LIKE, KIDNEY SPECIFIC; AQP2L__:__
Asterisk__:__601384__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS E; LY6E__:__RETINOIC ACID-INDUCED GENE E; RIGE;; THYMIC SHARED ANTIGEN 1; TSA1__:__
Asterisk__:__601385__:__TUMOR SUPPRESSOR CANDIDATE 3; TUSC3__:__PUTATIVE PROSTATE CANCER TUMOR SUPPRESSOR;; N33;; D8S1992__:__
Number Sign__:__601386__:__DEAFNESS, AUTOSOMAL RECESSIVE 12; DFNB12__:____:__
Asterisk__:__601387__:__TUMOR SUSCEPTIBILITY GENE 101; TSG101__:__VACUOLAR PROTEIN SORTING 23, YEAST, HOMOLOG OF; VPS23__:__
Number Sign__:__601388__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 12; IDDM12__:__INSULIN-DEPENDENT DIABETES MELLITUS 12__:__
NULL__:__601389__:__CERVICAL RIBS, SPRENGEL ANOMALY, ANAL ATRESIA, AND URETHRAL OBSTRUCTION__:____:__
Number Sign__:__601390__:__VAN MALDERGEM SYNDROME 1; VMLDS1__:__CEREBROFACIOARTICULAR SYNDROME__:__
Asterisk__:__601391__:__CHEMOKINE, CC MOTIF, LIGAND 13; CCL13__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 13; SCYA13;; NEW CC CHEMOKINE 1; NCC1;; MONOCYTE CHEMOTACTIC PROTEIN 4; MCP4__:__
Asterisk__:__601392__:__CHEMOKINE, CC MOTIF, LIGAND 14; CCL14__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 14; SCYA14;; NEW CC CHEMOKINE 2; NCC2;; HEMOFILTRATE CC CHEMOKINE 1; HCC1__:__
Asterisk__:__601393__:__CHEMOKINE, CC MOTIF, LIGAND 15; CCL15__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 15; SCYA15;; LEUKOTACTIN 1; LKN1;; NEW CC CHEMOKINE 3; NCC3;; HCC2;; MACROPHAGE INFLAMMATORY PROTEIN 5; MIP5__:__
Asterisk__:__601394__:__CHEMOKINE, CC MOTIF, LIGAND 16; CCL16__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 16; SCYA16;; NEW CC CHEMOKINE 4; NCC4;; LIVER-EXPRESSED CHEMOKINE; LEC;; HEMOFILTRATE CC CHEMOKINE 4; HCC4;; LYMPHOCYTE AND MONOCYTE CHEMOATTRACTANT; LMC__:__
Asterisk__:__601395__:__CHEMOKINE, CC MOTIF, LIGAND 3-LIKE 1; CCL3L1__:__LD78-BETA;; MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA-P;; MIP1-ALPHA-P; MIP1AP;; SMALL INDUCIBLE CYTOKINE A3-LIKE 1; SCYA3L1;; G0S19-2__:__
Asterisk__:__601396__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 8B; WNT8B__:____:__
Asterisk__:__601397__:__T BRACHYURY, MOUSE, HOMOLOG OF; T__:__TRANSCRIPTION FACTOR T; TFT__:__
Asterisk__:__601398__:__VASCULAR ENDOTHELIAL GROWTH FACTOR B; VEGFB__:__VASCULAR ENDOTHELIAL GROWTH FACTOR-RELATED FACTOR; VRF__:__
Number Sign__:__601399__:__PLATELET DISORDER, FAMILIAL, WITH ASSOCIATED MYELOID MALIGNANCY; FPDMM__:__PLATELET DISORDER, ASPIRIN-LIKE;; THROMBOCYTOPENIA, FAMILIAL, WITH PROPENSITY TO ACUTE MYELOGENOUS LEUKEMIA; FPD/AML__:__
Caret__:__601400__:__MOVED TO 275355__:____:__
Asterisk__:__601401__:__MYELOID LEUKEMIA FACTOR 2; MLF2__:__MYELODYSPLASIA-MYELOID LEUKEMIA FACTOR 2__:__
Asterisk__:__601402__:__MYELOID LEUKEMIA FACTOR 1; MLF1__:__MYELODYSPLASIA-MYELOID LEUKEMIA FACTOR 1__:__
Asterisk__:__601403__:__DEDICATOR OF CYTOKINESIS 1; DOCK1__:__DOWNSTREAM OF CRK; DOCK;; DOWNSTREAM OF CRK, 180-KD; DOCK180;; CED5, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__601404__:__G PROTEIN-COUPLED RECEPTOR 68; GPR68__:__OVARIAN CANCER G PROTEIN-COUPLED RECEPTOR 1; OGR1__:__
Asterisk__:__601405__:__CHYMOTRYPSIN C; CTRC__:__CALDECRIN; CLCR__:__
Asterisk__:__601406__:__B-CELL CLL/LYMPHOMA 7A; BCL7A__:__B-CELL CLL/LYMPHOMA 7; BCL7__:__
Percent__:__601407__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2; NIDDM2__:__NONINSULIN-DEPENDENT DIABETES MELLITUS 2__:__
Asterisk__:__601408__:__LYSINE ACETYLTRANSFERASE 6A; KAT6A__:__HISTONE ACETYLTRANSFERASE MYST3; MYST3;; ZINC FINGER PROTEIN 220; ZNF220;; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; MOZ__:__MOZ/CBP FUSION GENE, INCLUDED;; MOZ/TIF2 FUSION GENE, INCLUDED
Asterisk__:__601409__:__LYSINE ACETYLTRANSFERASE 5; KAT5__:__HIV-1 TAT-INTERACTING PROTEIN; HTATIP;; TAT-INTERACTING PROTEIN, 60-KD; TIP60;; ESA1, S. CEREVISIAE, HOMOLOG OF; ESA1__:__PLA2-INTERACTING PROTEIN, INCLUDED; PLIP, INCLUDED
Number Sign__:__601410__:__DIABETES MELLITUS, TRANSIENT NEONATAL, 1__:__TNDM1;; TNDM;; DMTN__:__
Asterisk__:__601411__:__SARCOGLYCAN, DELTA; SGCD__:____:__
Percent__:__601412__:__DEAFNESS, AUTOSOMAL DOMINANT 7; DFNA7__:____:__
Asterisk__:__601413__:__DEIODINASE, IODOTHYRONINE, TYPE II; DIO2__:__THYROXINE DEIODINASE, TYPE II; TXDI2;; D2__:__
Number Sign__:__601414__:__RETINITIS PIGMENTOSA 18; RP18__:____:__
Asterisk__:__601415__:__V-MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG-LIKE 2; MYBL2__:__MYB-RELATED GENE BMYB__:__
Asterisk__:__601416__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 7; SLC39A7__:__KE4, MOUSE, HOMOLOG OF; HKE4;; D6S2244E__:__
Asterisk__:__601417__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE VIII; HSD17B8__:__FabG-LIKE; FABGL;; FabG, E. COLI, HOMOLOG OF;; KE6, MOUSE, HOMOLOG OF;; HKE6;; D6S2245E;; 3-OXOACYL-ACYL CARRIER PROTEIN REDUCTASE, E. COLI, HOMOLOG OF__:__
Asterisk__:__601418__:__RIBOSOME BINDING PROTEIN 1; RRBP1__:__EXTRACELLULAR MATRIX GLYCOPROTEIN ES/130, CHICKEN, HOMOLOG OF; ES130__:__
Number Sign__:__601419__:__MYOPATHY, MYOFIBRILLAR, 1; MFM1__:__MYOPATHY, MYOFIBRILLAR, DESMIN-RELATED;; DESMINOPATHY, PRIMARY;; DESMIN-RELATED MYOPATHY; DRM;; MYOFIBRILLAR MYOPATHY WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;; DESMIN-RELATED MYOPATHY WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY;; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 7, FORMERLY; ARVD7, FORMERLY;; ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 7, FORMERLY; ARVC7, FORMERLY;; INCLUSION BODY MYOPATHY 1, AUTOSOMAL DOMINANT, FORMERLY; IBM1, FORMERLY;; CARDIOMYOPATHY, DILATED, 1F AND LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 1D, FORMERLY;; CMD1F AND LGMD1D, FORMERLY;; CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT AND MUSCULAR DYSTROPHY; CDCD3, FORMERLY;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2R, FORMERLY; LGMD2R, FORMERLY__:__
NULL__:__601420__:__MICROCEPHALY, CORPUS CALLOSUM DYSGENESIS, AND CLEFT LIP/PALATE__:____:__
Asterisk__:__601421__:__LYSYL-tRNA SYNTHETASE; KARS__:__KRS__:__
Asterisk__:__601422__:__LEUCINE ZIPPER PROTEIN 1; LUZP1__:__LUZP__:__
Asterisk__:__601423__:__THYMINE-DNA GLYCOSYLASE; TDG__:____:__
Asterisk__:__601424__:__3-OXOACID CoA TRANSFERASE 1; OXCT1__:__OXCT;; SUCCINYL-CoA:3-OXOACID-CoA TRANSFERASE; SCOT__:__
Asterisk__:__601425__:__TRANSCRIPTION ELONGATION FACTOR A, 1; TCEA1__:__TCEA;; TFIIS; TF2S;; SII__:__
Asterisk__:__601426__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP C, MEMBER 2; NR2C2__:__NUCLEAR HORMONE RECEPTOR TR4 TESTICULAR NUCLEAR RECEPTOR 4; TR4;; TAK1__:__
NULL__:__601427__:__ANTERIOR CHAMBER CLEAVAGE DISORDER, CEREBELLAR HYPOPLASIA, HYPOTHYROIDISM, AND TRACHEAL STENOSIS__:____:__
Asterisk__:__601428__:__RNA, U4ATAC SMALL NUCLEAR; RNU4ATAC__:__RNA, U4, SMALL NUCLEAR, AT-AC FORM; U4ATAC__:__
Asterisk__:__601429__:__RNA, U6ATAC SMALL NUCLEAR; RNU6ATAC__:__RNA, U6, SMALL NUCLEAR, AT-AC FORM; U6ATAC__:__
Asterisk__:__601430__:__UPF1, YEAST, HOMOLOG OF; UPF1__:__HUPF1;; REGULATOR OF NONSENSE TRANSCRIPTS 1; RENT1__:__
Asterisk__:__601431__:__TRANSFER RNA ALANINE 1; TRNAA1__:__tRNA ALANINE__:__
Asterisk__:__601432__:__TRANSFER RNA ARGININE 3; TRNAR3__:__tRNA ARGININE 3; TRR3__:__
Caret__:__601433__:__MOVED TO 180621__:____:__
Asterisk__:__601434__:__S-PHASE KINASE-ASSOCIATED PROTEIN 1; SKP1__:__S-PHASE KINASE-ASSOCIATED PROTEIN 1A; SKP1A;; CDK2/CYCLIN A-ASSOCIATED PROTEIN p19A;; ORGAN OF CORTI PROTEIN 2; OCP2;; TRANSCRIPTION ELONGATION FACTOR B, 1-LIKE; TCEB1L__:__
Asterisk__:__601435__:__S-PHASE KINASE-ASSOCIATED PROTEIN 1 PSEUDOGENE 2; SKP1P2__:__S-PHASE KINASE-ASSOCIATED PROTEIN 1B; SKP1B;; CDK2/CYCLIN A-ASSOCIATED PROTEIN p19B__:__
Asterisk__:__601436__:__S-PHASE KINASE-ASSOCIATED PROTEIN 2; SKP2__:__CDK2/CYCLIN A-ASSOCIATED PROTEIN p45;; F-BOX AND LEUCINE-RICH REPEAT PROTEIN 1; FBXL1; FBL1__:__
Asterisk__:__601437__:__Fc FRAGMENT OF IgG, RECEPTOR TRANSPORTER, ALPHA; FCGRT__:__IMMUNOGLOBULIN RECEPTOR, INTESTINAL, HEAVY CHAIN__:__
NULL__:__601438__:__RHIZOMELIC DYSPLASIA, PATTERSON-LOWRY TYPE__:____:__
Asterisk__:__601439__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 9; ABCC9__:__SULFONYLUREA RECEPTOR 2; SUR2__:__
Asterisk__:__601440__:__DIACYLGLYCEROL KINASE, EPSILON, 64-KD; DGKE__:__DGK-EPSILON__:__
Asterisk__:__601441__:__DIACYLGLYCEROL KINASE, ZETA, 104-KD: DGKZ__:__DGK-ZETA__:__
Asterisk__:__601442__:__COFILIN 1; CFL1__:__COFILIN, NONMUSCLE__:__
Asterisk__:__601443__:__COFILIN 2; CFL2__:__COFILIN, MUSCLE__:__
Asterisk__:__601444__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 1; BLOC1S1__:__BLOC1, SUBUNIT 1; BLOS1;; GCN5-LIKE 1; GCN5L1__:__
Asterisk__:__601445__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 9; NDUFB9__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT B22; UQOR22__:__
Caret__:__601446__:__MOVED TO 300707__:____:__
Asterisk__:__601447__:__UBIQUITIN-SPECIFIC PROTEASE 5; USP5__:__ISOPEPTIDASE T; ISOT__:__
Asterisk__:__601448__:__NUCLEAR PROTEIN, ATAXIA-TELANGIECTASIA LOCUS; NPAT__:__E14 GENE__:__
NULL__:__601449__:__DEAFNESS, PROGRESSIVE, WITH STAPES FIXATION__:____:__
NULL__:__601450__:__DISLOCATION OF HIP, CONGENITAL, WITH HYPEREXTENSIBILITY OF FINGERS AND FACIAL DYSMORPHISM__:__HIP, CONGENITAL DISLOCATION OF, WITH HYPEREXTENSIBILITY OF FINGERS AND FACIAL DYSMORPHISM__:__
Caret__:__601451__:__MOVED TO 225400__:____:__
Percent__:__601452__:__OCULOAURICULOFRONTONASAL SYNDROME; OAFNS__:__OCULOAURICULOFRONTONASAL DYSPLASIA__:__
NULL__:__601453__:__TRICHODENTAL DYSPLASIA__:____:__
Percent__:__601454__:__PSORIASIS 3, SUSCEPTIBILITY TO; PSORS3__:____:__
Number Sign__:__601455__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4D; CMT4D__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, LOM TYPE; HMSNL;; CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4D;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4D;; HMSN4D__:__
Asterisk__:__601456__:__MULTIMERIN 1; MMRN1__:__MMRN;; ENDOTHELIAL CELL MULTIMERIN; ECM__:__
Number Sign__:__601457__:__SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE__:__SCID, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE__:__
Percent__:__601458__:__INFLAMMATORY BOWEL DISEASE 2; IBD2__:____:__
Asterisk__:__601459__:__PREPRONOCICEPTIN; PNOC__:__PPNOC;; N/OFQ__:__NOCICEPTIN, INCLUDED;; NOCISTATIN, INCLUDED
Asterisk__:__601460__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 2A1; SLCO2A1__:__ORGANIC ANION TRANSPORTER 2A1; OATP2A1;; PROSTAGLANDIN TRANSPORTER; PGT;; SOLUTE CARRIER FAMILY 21 (PROSTAGLANDIN TRANSPORTER), MEMBER 2, FORMERLY; SLC21A2, FORMERLY__:__
Asterisk__:__601461__:__ATONAL, DROSOPHILA, HOMOLOG OF, 1; ATOH1__:__MATH1, MOUSE, HOMOLOG OF;; ATH1;; HATH1__:__
Number Sign__:__601462__:__MYASTHENIC SYNDROME, CONGENITAL, 1A, SLOW-CHANNEL; CMS1A__:__MYASTHENIC SYNDROME, CONGENITAL, TYPE IIa, FORMERLY; CMS2A, FORMERLY;; CMS IIa, FORMERLY__:__
Asterisk__:__601463__:__HYALURONAN SYNTHASE 1; HAS1__:____:__
Asterisk__:__601464__:__AF4/FMR2 FAMILY, MEMBER 3; AFF3__:__LYMPHOID NUCLEAR PROTEIN RELATED TO AF4; LAF4;; MLLT2-RELATED PROTEIN__:__FRAGILE SITE, FOLIC ACID TYPE, RARE, FRA(2)(q11.2), INCLUDED; FRA2A, INCLUDED;; FRAGILE SITE 2q11, INCLUDED;; LAF4/MLL FUSION GENE, INCLUDED
Asterisk__:__601465__:__DEOXYGUANOSINE KINASE; DGUOK__:__DEOXYGUANOSINE KINASE, MITOCHONDRIAL; DGK__:__
NULL__:__601466__:__PATENT DUCTUS VENOSUS; PDV__:__PORTOSYSTEMIC VENOUS SHUNT, CONGENITAL; PSVS__:__
Asterisk__:__601467__:__MITOTIC ARREST-DEFICIENT 2, S. CEREVISIAE, HOMOLOG-LIKE 1; MAD2L1__:__MITOTIC ARREST-DEFICIENT 2, S. CEREVISIAE, HOMOLOG OF;; MAD2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__601468__:__METHIONINE ADENOSYLTRANSFERASE II, ALPHA; MAT2A__:__MATA2;; MAT II, KIDNEY-SPECIFIC;; S-ADENOSYLMETHIONINE SYNTHETASE 2; SAMS2__:__
Asterisk__:__601469__:__PARATHYROID HORMONE 2 RECEPTOR; PTH2R__:__PARATHYROID HORMONE RECEPTOR 2; PTHR2__:__
Asterisk__:__601470__:__CHEMOKINE, CX3C MOTIF, RECEPTOR 1; CX3CR1__:__FRACTALKINE RECEPTOR CX3CR1;; G PROTEIN-COUPLED RECEPTOR 13; GPR13;; G PROTEIN-COUPLED RECEPTOR V28; V28__:__
Percent__:__601471__:__FACIAL PARESIS, HEREDITARY CONGENITAL, 1; HCFP1__:__FACIAL PALSY, CONGENITAL, UNILATERAL OR BILATERAL;; MOEBIUS SYNDROME 2, FORMERLY; MBS2, FORMERLY;; MOBIUS SYNDROME 2, FORMERLY__:__
Number Sign__:__601472__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D; CMT2D__:__CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2D;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2D__:__
Asterisk__:__601473__:__ZINC FINGER PROTEIN 75A; ZNF75A__:____:__
Caret__:__601474__:__MOVED TO 314997__:____:__
Asterisk__:__601475__:__PERIODIC TRYPTOPHAN PROTEIN 2, YEAST, HOMOLOG OF; PWP2__:__PWP2H__:__
Asterisk__:__601476__:__LYSOSOME-ASSOCIATED PROTEIN, TRANSMEMBRANE 5; LAPTM5__:__LYSOSOME-ASSOCIATED TRANSMEMBRANE PROTEIN 5;; LYSOSOME-ASSOCIATED MULTISPANNING MEMBRANE PROTEIN 5;; RETINOIC ACID-INDUCIBLE GENE E3; E3__:__
NULL__:__601477__:__RIBBING DISEASE__:__DIAPHYSEAL SCLEROSIS, MULTIPLE__:__
Asterisk__:__601478__:__MYOSIN IA; MYO1A__:____:__
Asterisk__:__601479__:__MYOSIN IE; MYO1E__:__MYOSIN IC, FORMERLY; MYO1C, FORMERLY__:__
Asterisk__:__601480__:__MYOSIN IF; MYO1F__:__MYOSIN ID, FORMERLY; MYO1D, FORMERLY__:__
Asterisk__:__601481__:__MYOSIN X; MYO10__:____:__
Asterisk__:__601482__:__DOWNREGULATOR OF TRANSCRIPTION 1, TBP-BINDING; DR1__:__TATA BOX-BINDING PROTEIN-ASSOCIATED PHOSPHOPROTEIN DR1;; NEGATIVE COFACTOR 2-BETA;; NC2-BETA__:__
Asterisk__:__601483__:__PATERNALLY EXPRESSED GENE 3; PEG3__:____:__ZINC FINGER GENE, IMPRINTED, 2, INCLUDED; ZIM2, INCLUDED
Asterisk__:__601484__:__SELENOPROTEIN P; SELENOP__:__SELP; SEPP;; SELENOPROTEIN P, PLASMA, 1; SEPP1__:__
Asterisk__:__601485__:__SYNTAXIN 1B; STX1B__:____:__
Asterisk__:__601486__:__DELETED IN AZOOSPERMIA-LIKE; DAZL__:__DAZLA;; DELETED IN AZOOSPERMIA HOMOLOG; DAZH;; SPGYLA__:__
Asterisk__:__601487__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA; PPARG__:____:__PPARG1, INCLUDED;; PPARG2, INCLUDED;; PPARG3, INCLUDED;; PAX8/PPARG FUSION GENE, INCLUDED
Asterisk__:__601488__:__NEUTROPHIL CYTOSOLIC FACTOR 4; NCF4__:__NCF, 40-KD;; p40-PHOX__:__
Asterisk__:__601489__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN, ACID-LABILE SUBUNIT; IGFALS__:__IGFBP, SOLUBLE;; ACID-LABILE SUBUNIT; ALS__:__
Asterisk__:__601490__:__NUCLEAR FACTOR ERYTHROID 2, p45 SUBUNIT; NFE2__:__p45__:__
Asterisk__:__601491__:__IMPRINTED IN PRADER-WILLI SYNDROME; IPW__:____:__
Number Sign__:__601492__:__MUCOPOLYSACCHARIDOSIS, TYPE IX; MPS9__:__MPS IX;; HYALURONIDASE DEFICIENCY__:__
Number Sign__:__601493__:__CARDIOMYOPATHY, DILATED, 1C, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION; CMD1C__:____:__LEFT VENTRICULAR NONCOMPACTION 3, INCLUDED; LVNC3, INCLUDED;; CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 24, INCLUDED; CMH24, INCLUDED
Number Sign__:__601494__:__CARDIOMYOPATHY, DILATED, 1D; CMD1D__:__LEFT VENTRICULAR NONCOMPACTION 6, INCLUDED; LVNC6, INCLUDED__:__
Number Sign__:__601495__:__AGAMMAGLOBULINEMIA 1, AUTOSOMAL RECESSIVE; AGM1__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO IGHM DEFECT__:__
Asterisk__:__601496__:__GDNF FAMILY RECEPTOR ALPHA-1; GFRA1__:__GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA; GDNFRA; GDNFR__:__
Asterisk__:__601497__:__BCL2-ASSOCIATED ATHANOGENE 1; BAG1__:__RECEPTOR-ASSOCIATED PROTEIN, 46-KD; RAP46__:__
Asterisk__:__601498__:__PEROXISOME BIOGENESIS FACTOR 6; PEX6__:__PEROXIN 6;; PEROXISOMAL ASSEMBLY FACTOR 2; PAF2;; PEROXISOMAL-TYPE ATPase 1; PXAAA1__:__
Percent__:__601499__:__AXENFELD-RIEGER SYNDROME, TYPE 2; RIEG2__:__RIEGER SYNDROME, TYPE 2__:__
Asterisk__:__601500__:__SMOOTHENED, DROSOPHILA, HOMOLOG OF; SMOH__:__SMO__:__
Asterisk__:__601501__:__VACUOLAR PROTEIN SORTING 35, YEAST, HOMOLOG OF; VPS35__:__MEM3, MOUSE, HOMOLOG OF; MEM3__:__
Asterisk__:__601502__:__Fc FRAGMENT OF IgG, HIGH AFFINITY Ib, RECEPTOR FOR; FCGR1B__:__IMMUNOGLOBULIN G Fc RECEPTOR IB; IGFRB;; CD64__:__
Asterisk__:__601503__:__Fc FRAGMENT OF IgG, HIGH AFFINITY Ic, RECEPTOR FOR; FCGR1C__:__IMMUNOGLOBULIN G Fc RECEPTOR IC; IGFRC;; CD64__:__
Asterisk__:__601504__:__SEC14-LIKE 1; SEC14L1__:__SEC14, S. CEREVISIAE, HOMOLOG OF, 1__:__
Asterisk__:__601505__:__ZINC FINGER PROTEIN 146; ZNF146__:__ONLY ZINC FINGERS; OZF__:__
Asterisk__:__601506__:__SEPTIN 2; SEPT2__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 5; NEDD5;; DIFF6__:__
Asterisk__:__601507__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, SIGMA-1 SUBUNIT; AP3S1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, SMALL 3, 22-KD; CLAPS3;; CLATHRIN ADAPTOR COMPLEX AP3, SIGMA-3A SUBUNIT__:__
Caret__:__601508__:__MOVED TO 168601__:____:__
Asterisk__:__601509__:__GAMMA-GLUTAMYL HYDROLASE; GGH__:____:__
Asterisk__:__601510__:__SREBP CLEAVAGE-ACTIVATING PROTEIN; SCAP__:____:__
Asterisk__:__601511__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5A; STAT5A__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5; STAT5;; MAMMARY GLAND FACTOR; MGF__:__
Asterisk__:__601512__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6; STAT6__:__STAT, INTERLEUKIN 4-INDUCED;; IL4-STAT__:__STAT6b, INCLUDED;; STAT6c, INCLUDED;; STAT6/NAB2 FUSION GENE, INCLUDED
Asterisk__:__601513__:__FIBROBLAST GROWTH FACTOR 12; FGF12__:__FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 1; FHF1__:__
Asterisk__:__601514__:__FIBROBLAST GROWTH FACTOR 11; FGF11__:__FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 3; FHF3__:__
Asterisk__:__601515__:__FIBROBLAST GROWTH FACTOR 14; FGF14__:__FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTOR 4; FHF4__:__
Asterisk__:__601516__:__SPLICING FACTOR 1; SF1__:__ZINC FINGER PROTEIN 162; ZNF162;; ZFM1;; D11S636__:__
Asterisk__:__601517__:__ATAXIN 2; ATXN2__:____:__
Number Sign__:__601518__:__PROSTATE CANCER, HEREDITARY, 1; HPC1__:__PRCA1__:__
Asterisk__:__601519__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT E; ATP5I__:__F1FO-ATP SYNTHASE, MURINE e SUBUNIT GENE; ATP5K__:__
Asterisk__:__601520__:__CHEMOKINE, CC MOTIF, LIGAND 17; CCL17__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 17; SCYA17;; THYMUS AND ACTIVATION-REGULATED CHEMOKINE; TARC__:__
Asterisk__:__601521__:__ENDOTHELIAL CELL-SPECIFIC MOLECULE 1; ESM1__:____:__
Asterisk__:__601522__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 7; GRB7__:____:__
Asterisk__:__601523__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 10; GRB10__:__GRB-IR;; MATERNALLY EXPRESSED GENE 1; MEG1__:__
Asterisk__:__601524__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 14; GRB14__:____:__
Asterisk__:__601525__:__CHITINASE 3-LIKE 1; CHI3L1__:__CARTILAGE GLYCOPROTEIN 39; GP39;; CHONDROCYTE PROTEIN YKL40__:__
Asterisk__:__601526__:__CHITINASE 3-LIKE 2; CHI3L2__:__CHONDROCYTE PROTEIN YKL39; YKL39;; CHONDROCYTE PROTEIN 39__:__
Asterisk__:__601527__:__ARISTALESS-LIKE HOMEOBOX 1; ALX1__:__CARTILAGE HOMEOPROTEIN 1; CART1__:__
Asterisk__:__601528__:__VASCULAR ENDOTHELIAL GROWTH FACTOR C; VEGFC__:__VASCULAR ENDOTHELIAL GROWTH FACTOR-RELATED PROTEIN; VRP__:__
Asterisk__:__601529__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP C, MEMBER 1; NR2C1__:__NUCLEAR HORMONE RECEPTOR TR2; TR2__:__
Asterisk__:__601530__:__SEQUESTOSOME 1; SQSTM1__:__UBIQUITIN-BINDING PROTEIN P62; P62__:__
Asterisk__:__601531__:__LEUKOTRIENE B4 RECEPTOR; LTB4R__:__LTB4R1;; CHEMOKINE RECEPTOR-LIKE 1; CMKRL1;; PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 7; P2RY7;; PURINOCEPTOR P2Y7; P2Y7;; LEUKOTRIENE B4 G PROTEIN-COUPLED RECEPTOR; BLTR;; BLT1;; G PROTEIN-COUPLED RECEPTOR 16; GPR16__:__
Asterisk__:__601532__:__CASPASE 6, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP6__:__APOPTOTIC CYSTEINE PROTEASE MCH2__:__
Asterisk__:__601533__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 2; ADAM2__:__FERTILIN, BETA; FTNB;; PH30__:__
Asterisk__:__601534__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 3; KCNJ3__:__INWARDLY RECTIFYING POTASSIUM CHANNEL KIR3.1;; GIRK1__:__
Asterisk__:__601535__:__EPHRIN A5; EFNA5__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 7; EPLG7;; LIGAND OF EPH-RELATED KINASE 7; LERK7;; RAGS;; EFL5__:__
Number Sign__:__601536__:__ATHABASKAN BRAINSTEM DYSGENESIS SYNDROME; ABDS__:__NAVAJO BRAINSTEM SYNDROME__:__BOSLEY-SALIH-ALORAINY SYNDROME, INCLUDED; BSAS, INCLUDED
Percent__:__601537__:__MICROCEPHALY, RETINITIS PIGMENTOSA, AND SUTURAL CATARACT__:____:__
Asterisk__:__601538__:__PROP PAIRED-LIKE HOMEOBOX 1; PROP1__:__PROPHET OF PIT1, PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR__:__
Number Sign__:__601539__:__PEROXISOME BIOGENESIS DISORDER 1B; PBD1B__:__PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILE REFSUM DISEASE);; PEROXISOME BIOGENESIS DISORDER (NALD/IRD);; ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL;; REFSUM DISEASE, INFANTILE;; INFANTILE PHYTANIC ACID STORAGE DISEASE__:__
Asterisk__:__601540__:__BROMODOMAIN-CONTAINING PROTEIN 2; BRD2__:__FEMALE STERILE HOMEOTIC-RELATED GENE 1, MOUSE, HOMOLOG OF; FSRG1;; RING3__:__
Asterisk__:__601541__:__BROMODOMAIN-CONTAINING PROTEIN 3; BRD3__:__RING3-LIKE GENE; RING3L;; OPEN READING FRAME X; ORFX__:__
Asterisk__:__601542__:__PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 2; PITX2__:__PITUITARY HOMEOBOX 2; PTX2;; RIEG BICOID-RELATED HOMEOBOX TRANSCRIPTION FACTOR 1; RIEG1;; RIEG;; SOLURSHIN;; ALL1-RESPONSIVE GENE 1; ARP1__:__
Number Sign__:__601543__:__DEAFNESS, AUTOSOMAL DOMINANT 12; DFNA12__:__DEAFNESS, AUTOSOMAL DOMINANT 8; DFNA8__:__
Number Sign__:__601544__:__DEAFNESS, AUTOSOMAL DOMINANT 3A; DFNA3A__:____:__
Asterisk__:__601545__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM 1B, ALPHA SUBUNIT; PAFAH1B1__:__LIS1 GENE; LIS1__:__
Asterisk__:__601546__:__PROSPERO-RELATED HOMEOBOX 1; PROX1__:__HOMEOBOX GENE PROX1__:__
Number Sign__:__601547__:__CATARACT 3, MULTIPLE TYPES; CTRCT3__:__CATARACT 3, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, CONGENITAL, CERULEAN TYPE, 2; CCA2__:__
Asterisk__:__601548__:__EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1; EFEMP1__:__FIBRILLIN-LIKE; FBNL;; FIBULIN 3; FBLN3;; S1-5__:__
Percent__:__601549__:__ALACRIMA, CONGENITAL, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__601550__:__BLOOD GROUP--SWANN SYSTEM; SW__:__SWANN BLOOD GROUP__:__
Number Sign__:__601551__:__BLOOD GROUP--FROESE__:__FR;; FROESE BLOOD GROUP ANTIGEN__:__
Number Sign__:__601552__:__FACIAL DYSMORPHISM, LENS DISLOCATION, ANTERIOR SEGMENT ABNORMALITIES, AND SPONTANEOUS FILTERING BLEBS; FDLAB__:__TRABOULSI SYNDROME;; ECTOPIA LENTIS, SPONTANEOUS FILTERING BLEBS, AND CRANIOFACIAL DYSMORPHISM__:__
Number Sign__:__601553__:__HYPOTRICHOSIS, CONGENITAL, WITH JUVENILE MACULAR DYSTROPHY; HJMD__:__HYPOTRICHOSIS WITH CONE-ROD DYSTROPHY__:__
Asterisk__:__601554__:__DYNEIN, LIGHT CHAIN, TCTEX TYPE, 1; DYNLT1__:__T COMPLEX-ASSOCIATED TESTIS-EXPRESSED 1-LIKE 1; TCTEL1;; TCTE1, MOUSE, HOMOLOG OF;; TCTEX1, MOUSE, HOMOLOG OF__:__
Asterisk__:__601555__:__RHO FAMILY GTPase 2; RND2__:__RAS HOMOLOG GENE FAMILY, MEMBER N; RHON;; ARHN;; GTP-BINDING PROTEIN RHO7; RHO7__:__
Asterisk__:__601556__:__ATAXIN 1; ATXN1__:____:__ATXN1, ALTERNATIVE READING FRAME, INCLUDED;; ALT-ATXN1, INCLUDED
Asterisk__:__601557__:__ACETYL-CoA CARBOXYLASE-BETA; ACACB__:__ACCB;; ACETYL-CoA CARBOXYLASE 2; ACC2__:__
Asterisk__:__601558__:__RNA-BINDING PROTEIN GENE WITH MULTIPLE SPLICING; RBPMS__:____:__
Number Sign__:__601559__:__STUVE-WIEDEMANN SYNDROME; STWS__:__SWS;; SCHWARTZ-JAMPEL SYNDROME, TYPE 2; SJS2;; SCHWARTZ-JAMPEL SYNDROME, NEONATAL;; STUVE-WIEDEMANN/SCHWARTZ-JAMPEL TYPE 2 SYNDROME__:__
NULL__:__601560__:__MULTIPLE EPIPHYSEAL DYSPLASIA WITH ROBIN PHENOTYPE__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH ROBIN PHENOTYPE__:__
NULL__:__601561__:__DYSSEGMENTAL DYSPLASIA WITH GLAUCOMA__:____:__
Asterisk__:__601562__:__DYNEIN, LIGHT CHAIN, LC8 TYPE, 1; DYNLL1__:__DYNEIN, CYTOPLASMIC, LIGHT CHAIN 1; DNCL1; DLC1;; PROTEIN INHIBITOR OF NEURONAL NOS; PIN;; LC8__:__
NULL__:__601563__:__HORNS IN SHEEP__:__HO__:__
Asterisk__:__601564__:__PROTEASE, SERINE, 2; PRSS2__:__TRYPSINOGEN 2; TRY2;; TRYPSINOGEN, ANIONIC__:__TRYPSIN 2, INCLUDED
Asterisk__:__601565__:__INTERFERON REGULATORY FACTOR 8; IRF8__:__INTERFERON CONSENSUS SEQUENCE-BINDING PROTEIN 1; ICSBP1; ICSBP__:__
Asterisk__:__601566__:__INHIBITOR OF GROWTH 1; ING1__:__p33ING1__:__
Asterisk__:__601567__:__LECTIN, MANNOSE-BINDING, 1; LMAN1__:__INTRACELLULAR MANNOSE SPECIFIC LECTIN; MR60;; ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT 53; ERGIC53__:__
Asterisk__:__601568__:__ADDUCIN 3; ADD3__:__ADDUCIN, GAMMA;; ADDUCIN-LIKE; ADDL__:__ADD3/NUP98 FUSION GENE, INCLUDED
Asterisk__:__601569__:__UBIQUITIN-CONJUGATING ENZYME E2G 1; UBE2G1__:__UBE2G;; UBC7, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__601570__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 7A; WNT7A__:____:__
Asterisk__:__601571__:__CAPPING PROTEIN, ALPHA-2; CAPZA2__:__CAP PROTEIN, ACTIN, ALPHA-2 SUBUNIT; CAPPA2__:__
Asterisk__:__601572__:__CAPPING PROTEIN, BETA; CAPZB__:__CAP PROTEIN, ACTIN, BETA; CAPPB__:__
Asterisk__:__601573__:__ENHANCER OF ZESTE, DROSOPHILA, HOMOLOG 2; EZH2__:__ENX1__:__
Asterisk__:__601574__:__TAF15 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 68-KD; TAF15__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2N; TAF2N;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 68-KD;; RNA-BINDING PROTEIN 56; RBP56__:__RBP56/NR4A3 FUSION GENE, INCLUDED
Asterisk__:__601575__:__FOS-LIKE ANTIGEN 2; FOSL2__:__FOS-RELATED ANTIGEN 2; FRA2__:__
Asterisk__:__601576__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, SIGMA; PTPRS__:__RPTP-SIGMA__:__
Asterisk__:__601577__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, C POLYPEPTIDE-ASSOCIATED PROTEIN; PTPRCAP__:__PTPRC-ASSOCIATED PROTEIN;; LYMPHOCYTE PHOSPHATASE-ASSOCIATED PHOSPHOPROTEIN; LPAP__:__
Asterisk__:__601578__:__CYCLIN G1; CCNG1__:__CYCLIN G; CCNG__:__
Asterisk__:__601579__:__ORNITHINE DECARBOXYLASE ANTIZYME 1; OAZ1__:__OAZ;; ANTIZYME 1__:__
Asterisk__:__601580__:__CAPPING PROTEIN, ALPHA-1; CAPZA1__:__CAP PROTEIN, ACTIN, ALPHA-1 SUBUNIT; CAPPA1__:__
Asterisk__:__601581__:__NEURONAL CELL ADHESION MOLECULE; NRCAM__:__KIAA0343__:__
Asterisk__:__601582__:__INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 145-KD; INPP5D__:__SH2-CONTAINING INOSITOL PHOSPHATASE; SHIP;; SHIP1__:__
Number Sign__:__601583__:__WILMS TUMOR 5; WT5__:__WILMS TUMOR, SUSCEPTIBILITY TO; WTSL__:__
Asterisk__:__601584__:__PROTEIN-TYROSINE PHOSPHATASE, TYPE 4A, 2; PTP4A2__:__PTP4A;; PTP(CAAX2);; OV1;; PHOSPHATASE OF REGENERATING LIVER 2; PRL2;; HH13;; HH7-2__:__
Asterisk__:__601585__:__PROTEIN-TYROSINE PHOSPHATASE, TYPE 4A, 1; PTP4A1__:__PHOSPHATASE OF REGENERATING LIVER 1; PRL1;; PTP(CAAX1)__:__
Asterisk__:__601586__:__PROSTAGLANDIN E RECEPTOR 4, EP4 SUBTYPE; PTGER4__:__EP4R__:__
Caret__:__601587__:__MOVED TO 300939__:____:__
Caret__:__601588__:__MOVED TO 152445__:____:__
Asterisk__:__601589__:__RAS p21 PROTEIN ACTIVATOR 2; RASA2__:__GTPase-ACTIVATING PROTEIN OF RAS; GAP1M__:__
Asterisk__:__601590__:__ENVOPLAKIN; EVPL__:____:__
Asterisk__:__601591__:__PROTEIN KINASE, cGMP-DEPENDENT, TYPE II; PRKG2__:__PRKGR2;; cGK, TYPE II;; cGKII__:__
Asterisk__:__601592__:__RECEPTOR-ASSOCIATED PROTEIN OF THE SYNAPSE, 43-KD; RAPSN__:__RAPSYN__:__
Asterisk__:__601593__:__BRCA1-ASSOCIATED RING DOMAIN 1; BARD1__:____:__
Asterisk__:__601594__:__JUMONJI, AT-RICH INTERACTIVE DOMAIN 2; JARID2__:__JUMONJI; JMJ__:__
Asterisk__:__601595__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 1; SMAD1__:__MAD, DROSOPHILA, HOMOLOG OF;; MADH1;; SMA- AND MAD-RELATED PROTEIN 1;; MADR1;; TGF-BETA SIGNALING PROTEIN 1; BSP1__:__
Number Sign__:__601596__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4C;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4C__:__
Asterisk__:__601597__:__B-CELL TRANSLOCATION GENE 2; BTG2__:__PHEOCHROMOCYTOMA CELL 3; PC3__:__
Asterisk__:__601598__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, DELTA; PTPRD__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, D;; PROTEIN-TYROSINE PHOSPHATASE-DELTA; PTPD__:__
Asterisk__:__601599__:__SARCOSPAN; SSPN__:__SPN1;; K-RAS ONCOGENE-ASSOCIATED GENE; KRAG;; KIRSTEN-RAS-ASSOCIATED GENE;; DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 25-KD;; DAGA5__:__
Asterisk__:__601600__:__ETS VARIANT GENE 5; ETV5__:__ETS-RELATED MOLECULE; ERM__:__
Asterisk__:__601601__:__TRANSCRIPTION FACTOR AP2-BETA; TFAP2B__:____:__
Asterisk__:__601602__:__TRANSCRIPTION FACTOR AP2-GAMMA; TFAP2C__:__ESTROGEN RECEPTOR FACTOR 1; ERF1__:__
Asterisk__:__601603__:__LYMPHOCYTE CYTOSOLIC PROTEIN 2; LCP2__:__SH2 DOMAIN-CONTAINING LEUKOCYTE PROTEIN, 76-KD; SLP76__:__
Asterisk__:__601604__:__INTERLEUKIN 12 RECEPTOR, BETA-1; IL12RB1__:__IL12RB;; CD212__:__
Caret__:__601605__:__MOVED TO 601448__:____:__
Number Sign__:__601606__:__TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1__:__MFT1;; EPITHELIOMA ADENOIDES CYSTICUM OF BROOKE; EAC;; EPITHELIOMA, HEREDITARY MULTIPLE BENIGN CYSTIC;; BROOKE-FORDYCE TRICHOEPITHELIOMAS__:__
Asterisk__:__601607__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY B, MEMBER 1; SMARCB1__:__SNF5, YEAST, HOMOLOG OF; SNF5;; INTEGRASE INTERACTOR 1; INI1;; MALIGNANT RHABDOID TUMOR SUPPRESSOR__:__
NULL__:__601608__:__SPASTIC PARAPLEGIA AND EVANS SYNDROME__:____:__
Asterisk__:__601609__:__3-HYDROXYACYL-CoA DEHYDROGENASE; HADH__:__HAD;; HADSC, FORMERLY;; HADHSC, FORMERLY;; SCHAD, FORMERLY__:__
Asterisk__:__601610__:__BUTYROPHILIN, SUBFAMILY 1, MEMBER A1; BTN1A1__:__BTN__:__
Asterisk__:__601611__:__SOLUTE CARRIER FAMILY 14 (UREA TRANSPORTER), MEMBER 2; SLC14A2__:__UREA TRANSPORTER, RENAL; UTR;; UREA TRANSPORTER 2; UT2;; UREA TRANSPORTER A, MOUSE, HOMOLOG OF; UTA__:__
Percent__:__601612__:__LUNG AGENESIS, CONGENITAL HEART DEFECTS, AND THUMB ANOMALIES SYNDROME; LACHT__:__MARDINI-NYHAN ASSOCIATION__:__
Asterisk__:__601613__:__CHEMOKINE, CXC MOTIF, RECEPTOR 5; CXCR5__:__BURKITT LYMPHOMA RECEPTOR 1; BLR1__:__
Asterisk__:__601614__:__NETRIN 1; NTN1__:__NETRIN 1, MOUSE, HOMOLOG OF;; NETRIN 1-LIKE; NTN1L__:__
Asterisk__:__601615__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 3; ABCA3__:__ATP-BINDING CASSETTE 3; ABC3;; ATP-BINDING CASSETTE TRANSPORTER 3;; ABC TRANSPORTER 3;; CED7, C. ELEGANS, HOMOLOG OF__:__
Percent__:__601616__:__IRIS PIGMENT EPITHELIUM ANOMALIES__:__RUFFLES AND CYSTS OF IRIS PIGMENT EPITHELIUM;; CYSTS OF IRIS PIGMENT EPITHELIUM__:__
Asterisk__:__601617__:__RETINOL DEHYDROGENASE 5; RDH5__:__RETINOL DEHYDROGENASE, 11-CIS;; RETINOL DEHYDROGENASE 1, FORMERLY; RDH1, FORMERLY__:__
Asterisk__:__601618__:__SRY-BOX 18; SOX18__:____:__
Asterisk__:__601619__:__RAL GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR; RALGDS__:____:__
Asterisk__:__601620__:__T-BOX 5; TBX5__:____:__
Asterisk__:__601621__:__T-BOX 3; TBX3__:____:__
Asterisk__:__601622__:__TWIST, DROSOPHILA, HOMOLOG OF, 1; TWIST1__:__TRANSCRIPTION FACTOR TWIST; TWIST__:__
Asterisk__:__601623__:__UBIQUITIN-PROTEIN LIGASE E3A; UBE3A__:__HUMAN PAPILLOMAVIRUS E6-ASSOCIATED PROTEIN; E6AP__:__
Asterisk__:__601624__:__FICOLIN 2; FCN2__:__L-FICOLIN; FCNL;; COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING LECTIN 2 P35;; OPSONIN P35__:__
Asterisk__:__601625__:__ADP-RIBOSYLTRANSFERASE 1; ART1__:__ART2, FORMERLY__:__
Number Sign__:__601626__:__LEUKEMIA, ACUTE MYELOID; AML__:__LEUKEMIA, ACUTE MYELOGENOUS__:__LEUKEMIA, ACUTE MYELOID, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__601627__:__SURVIVAL OF MOTOR NEURON 2; SMN2__:__SURVIVAL OF MOTOR NEURON, CENTROMERIC COPY; SMNC;; C-BCD541__:__
Caret__:__601628__:__MOVED TO 111730__:____:__
Asterisk__:__601629__:__PURKINJE CELL PROTEIN 4; PCP4__:__PEP19__:__
Caret__:__601630__:__MOVED TO 600274__:____:__
Number Sign__:__601631__:__ANTERIOR SEGMENT DYSGENESIS 3; ASGD3__:__IRIDOGONIODYSGENESIS, TYPE 1; IRID1;; IRIDOGONIODYSGENESIS ANOMALY, AUTOSOMAL DOMINANT; IGDA;; IRIS HYPOPLASIA WITH GLAUCOMA;; GLAUCOMA IRIDOGONIODYSPLASIA, FAMILIAL__:__
Asterisk__:__601632__:__POU DOMAIN, CLASS 4, TRANSCRIPTION FACTOR 1; POU4F1__:__POU-DOMAIN TRANSCRIPTION FACTOR BRN3A; BRN3A;; BRN3.0, MOUSE, HOMOLOG OF__:__
Asterisk__:__601633__:__N-ETHYLMALEIMIDE-SENSITIVE FACTOR; NSF__:____:__
Number Sign__:__601634__:__NEURAL TUBE DEFECTS, FOLATE-SENSITIVE; NTDFS__:__NTD, FOLATE-SENSITIVE__:__SPINA BIFIDA, FOLATE-SENSITIVE, INCLUDED
Caret__:__601635__:__MOVED TO 608317__:____:__
Asterisk__:__601636__:__HYALURONAN SYNTHASE 2; HAS2__:____:__
Asterisk__:__601637__:__CYTOCHROME P450, FAMILY 51, SUBFAMILY A, POLYPEPTIDE 1; CYP51A1__:__CYP51;; LANOSTEROL 14-ALPHA-DEMETHYLASE__:__
Asterisk__:__601638__:__ADP-RIBOSYLATION FACTOR-INTERACTING PROTEIN 2; ARFIP2__:__ARFAPTIN 2;; PARTNER OF RAC1; POR1__:__
Asterisk__:__601639__:__PROTEIN KINASE, cAMP-DEPENDENT, CATALYTIC, ALPHA; PRKACA__:__PROTEIN KINASE A, C-ALPHA SUBUNIT__:__PRKACA/DNAJB1 FUSION GENE, INCLUDED
Caret__:__601640__:__MOVED TO 601314__:____:__
Asterisk__:__601641__:__ACYL-CoA OXIDASE 2, BRANCHED-CHAIN; ACOX2__:__ACYL-CoA OXIDASE, BRANCHED-CHAIN, PEROXISOMAL;; BRANCHED-CHAIN ACYL-CoA OXIDASE; BRCACOX; BCOX__:__
Asterisk__:__601642__:__INTERLEUKIN 12 RECEPTOR, BETA-2; IL12RB2__:____:__
Asterisk__:__601643__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), ALPHA; PPP2R5A__:____:__
Asterisk__:__601644__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), BETA; PPP2R5B__:____:__
Asterisk__:__601645__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), GAMMA; PPP2R5C__:____:__
Asterisk__:__601646__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), DELTA; PPP2R5D__:____:__
Asterisk__:__601647__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), EPSILON; PPP2R5E__:____:__
Asterisk__:__601648__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 4; PSMD4__:__PROTEASE 26S, SUBUNIT 5A; S5A;; RPN10__:__
Caret__:__601649__:__MOVED TO 101400__:____:__
Number Sign__:__601650__:__PARAGANGLIOMAS 2; PGL2__:__GLOMUS TUMORS, FAMILIAL, 2__:__
Asterisk__:__601651__:__NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 4; NAP1L4__:__NUCLEOSOME ASSEMBLY PROTEIN 2-LIKE; NAP2L;; NAP2__:__
Asterisk__:__601652__:__MYOCILIN; MYOC__:__TRABECULAR MESHWORK-INDUCED GLUCOCORTICOID RESPONSE PROTEIN; TIGR__:__
Asterisk__:__601653__:__EYES ABSENT 1; EYA1__:__EYES ABSENT, DROSOPHILA, HOMOLOG OF, 1__:__
Asterisk__:__601654__:__EYES ABSENT 2; EYA2__:__EYES ABSENT, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__601655__:__EYES ABSENT 3; EYA3__:__EYES ABSENT, DROSOPHILA, HOMOLOG OF, 3__:__
Asterisk__:__601656__:__GATA-BINDING PROTEIN 6; GATA6__:____:__
Asterisk__:__601657__:__EPIPHYCAN; EPYC__:__DERMATAN SULFATE PROTEOGLYCAN 3; DSPG3__:__
Asterisk__:__601658__:__OTOCONIN 90; OC90__:____:__PLA2-LIKE, INCLUDED; PLA2L, INCLUDED
Asterisk__:__601659__:__GLUTAMINE AMIDOTRANSFERASE-LIKE CLASS 1 DOMAIN-CONTAINING PROTEIN 3A; GATD3A__:__ES1, ZEBRAFISH, HOMOLOG OF; ES1; HES1;; CHROMOSOME 21 OPEN READING FRAME 33; C21ORF33;; D21S2048E;; KNPI;; GT335__:__
Caret__:__601660__:__MOVED TO 601150__:____:__
Asterisk__:__601661__:__UBIQUITIN-CONJUGATING ENZYME E2I; UBE2I__:__UBIQUITIN-CONJUGATING ENZYME UBC9, YEAST, HOMOLOG OF; UBC9__:__
Asterisk__:__601662__:__ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALCAM__:__CD166__:__
Asterisk__:__601663__:__ESTROGEN RECEPTOR 2; ESR2__:__ESTROGEN RECEPTOR, BETA; ESRB;; ESR-BETA;; ER-BETA__:__
Asterisk__:__601664__:__SMALL NUCLEAR RIBONUCLEOPROTEIN, 200-KD; SNRNP200__:__ACTIVATING SIGNAL COINTEGRATOR I COMPLEX SUBUNIT 3-LIKE 1; ASCC3L1;; U5 snRNP-SPECIFIC PROTEIN, 200-KD;; BRR2, YEAST, HOMOLOG OF;; U5-200KD;; KIAA0788__:__
Number Sign__:__601665__:__OBESITY__:____:__LEANNESS, INCLUDED
Percent__:__601666__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 15; IDDM15__:__INSULIN-DEPENDENT DIABETES MELLITUS 15__:__
Asterisk__:__601667__:__ANGIOPOIETIN 1; ANGPT1__:__ANG1__:__
NULL__:__601668__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH ABNORMAL DENTITION; SEMDAD__:____:__
Caret__:__601669__:__MOVED TO 602229__:____:__
Asterisk__:__601670__:__D4, ZINC, AND DOUBLE PHD FINGERS FAMILY, MEMBER 1; DPF1__:__NEURO-D4, RAT, HOMOLOG OF; NEUD4;; BRG1-ASSOCIATED FACTOR, 45-KD, B; BAF45B__:__
Asterisk__:__601671__:__D4, ZINC, AND DOUBLE PHD FINGERS FAMILY, MEMBER 2; DPF2__:__REQUIEM, APOPTOSIS RESPONSE ZINC FINGER GENE; REQ;; UBI-D4/REQUIEM HOMOLOG; UBID4__:__
Asterisk__:__601672__:__D4, ZINC, AND DOUBLE PHD FINGERS FAMILY, MEMBER 3; DPF3__:__CER-D4, MOUSE, HOMOLOG OF; CERD4__:__
Asterisk__:__601673__:__EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA, HOMOLOG-LIKE 2; ELAVL2__:__HOMOLOG OF DROSOPHILA ELAV-LIKE NEURONAL PROTEIN; HELN1;; HU-ANTIGEN B; HUB__:__
Asterisk__:__601674__:__ENHANCER OF ZESTE, DROSOPHILA, HOMOLOG 1; EZH1__:____:__
Number Sign__:__601675__:__TRICHOTHIODYSTROPHY 1, PHOTOSENSITIVE; TTD1__:__TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP;; ICHTHYOSIFORM ERYTHRODERMA WITH HAIR ABNORMALITY AND MENTAL AND GROWTH RETARDATION;; TAY SYNDROME;; TRICHOTHIODYSTROPHY WITH CONGENITAL ICHTHYOSIS; ICHTHYOSIS, CONGENITAL, WITH TRICHOTHIODYSTROPHY;; PIBIDS SYNDROME__:__
Percent__:__601676__:__ACUTE INSULIN RESPONSE__:__AIR__:__
Asterisk__:__601677__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 5; NDUFA5__:__NADH-UBIQUINONE OXIDOREDUCTASE, SUBUNIT B13; UQOR13;; B13__:__
Number Sign__:__601678__:__BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1__:__HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1__:__
Asterisk__:__601679__:__GENERAL TRANSCRIPTION FACTOR II-I; GTF2I__:__BTK-ASSOCIATED PROTEIN, 135-KD; BAP135;; BRUTON TYROSINE KINASE-ASSOCIATED PROTEIN 135;; TFII-I__:__
Number Sign__:__601680__:__ARTHROGRYPOSIS, DISTAL, TYPE 2B; DA2B__:__ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE 2B;; SHELDON-HALL SYNDROME; SHS;; FREEMAN-SHELDON SYNDROME VARIANT; FSSV;; ARTHROGRYPOSIS MULTIPLEX CONGENITA, DISTAL, TYPE II, WITH CRANIOFACIAL ABNORMALITIES__:__
Asterisk__:__601681__:__PROTEASOME 26S SUBUNIT, ATPase, 5; PSMC5__:__THYROID HORMONE RECEPTOR INTERACTOR 1; TRIP1__:__
Percent__:__601682__:__GLAUCOMA 1, PRIMARY OPEN ANGLE, C; GLC1C__:____:__
Asterisk__:__601683__:__COQ7, S. CEREVISIAE, HOMOLOG OF; COQ7__:__CLK1, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__601684__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 1; RPS6KA1__:__RIBOSOMAL S6 KINASE 1; RSK1;; MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 1A; MAPKAPK1A;; MAPKAP KINASE 1A__:__
Asterisk__:__601685__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 2; RPS6KA2__:__RIBOSOMAL S6 KINASE 3; RSK3;; MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 1C; MAPKAPK1C;; MAPKAP KINASE 1C__:__
Asterisk__:__601686__:__TELOMERASE-ASSOCIATED PROTEIN 1; TEP1__:__TELOMERASE PROTEIN COMPONENT 1__:__
Asterisk__:__601687__:__KERATIN 12, TYPE I; KRT12__:__K12;; KA12;; CYTOKERATIN 12__:__
Asterisk__:__601688__:__15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; HPGD__:__15-HYDROXYPROSTAGLANDIN DEHYDROGENASE, TYPE I; PGDH1;; PGDH__:__
Asterisk__:__601689__:__TAF4B RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 105-KD; TAF4B__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR C2; TAF2C2;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 105-KD; TAFII105__:__
Asterisk__:__601690__:__PHOSPHOLIPASE A2, GROUP VII; PLA2G7__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE; PAFAH;; PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, PLASMA;; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;; LP-PLA2;; LDL-PLA2__:__
Asterisk__:__601691__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 4; ABCA4__:__ATP-BINDING CASSETTE TRANSPORTER, RETINA-SPECIFIC; ABCR;; ABC TRANSPORTER, RETINA-SPECIFIC;; PHOTORECEPTOR RIM PROTEIN; RMP__:__
Asterisk__:__601692__:__TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68-KD; TGFBI__:__BETA-IG-H3; BIGH3;; KERATOEPITHELIN__:__
Asterisk__:__601693__:__UNCOUPLING PROTEIN 2; UCP2__:____:__
Percent__:__601694__:__LEPTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; LEPQTL1__:__LSL__:__
Asterisk__:__601695__:__CASEIN, KAPPA; CSN3__:__CSN10;; CSNK;; KCA__:__
NULL__:__601696__:__NOVELTY SEEKING PERSONALITY TRAIT__:____:__RISK-TAKING BEHAVIOR, INCLUDED
Asterisk__:__601697__:__SERPIN FAMILY B, MEMBER 8; SERPINB8__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 8;; PROTEASE INHIBITOR 8; PI8;; CYTOPLASMIC ANTIPROTEINASE 2; CAP2__:__
Asterisk__:__601698__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, N, POLYPEPTIDE 2; PTPRN2__:__ISLET CELL ANTIGEN-RELATED PROTEIN-TYROSINE PHOSPHATASE;; IA2-BETA, MOUSE, HOMOLOG OF; IAR;; ICAAR;; PHOGRIN;; KIAA0387__:__
Asterisk__:__601699__:__PROSTAGLANDIN I2 SYNTHASE; PTGIS__:__PGIS;; PROSTACYCLIN SYNTHASE;; CYP8;; CYP8A1__:__
Percent__:__601700__:__SEBACEOUS GLAND HYPERPLASIA, FAMILIAL PRESENILE__:____:__
NULL__:__601701__:__ARTHROGRYPOSIS AND ECTODERMAL DYSPLASIA__:__TRICHOOCULODERMOVERTEBRAL SYNDROME;; TODV SYNDROME;; ALVES SYNDROME__:__
Asterisk__:__601702__:__RHO-ASSOCIATED COILED-COIL-CONTAINING PROTEIN KINASE 1; ROCK1__:__p160-ROCK;; RHO KINASE__:__
Asterisk__:__601703__:__VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASP__:____:__
Asterisk__:__601704__:__CHEMOKINE, CXC MOTIF, LIGAND 9; CXCL9__:__MONOKINE INDUCED BY GAMMA INTERFERON; MIG;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 9; SCYB9__:__
Number Sign__:__601705__:__T-CELL IMMUNODEFICIENCY, CONGENITAL ALOPECIA, AND NAIL DYSTROPHY__:____:__
NULL__:__601706__:__YEMENITE DEAF-BLIND HYPOPIGMENTATION SYNDROME__:____:__
Number Sign__:__601707__:__CURRY-JONES SYNDROME; CRJS__:__CRANIOFACIAL MALFORMATIONS, ASYMMETRIC, WITH POLYSYNDACTYLY AND ABNORMAL SKIN AND GUT DEVELOPMENT__:__
NULL__:__601708__:__SUPERIOR TRANSVERSE SCAPULAR LIGAMENT, CALCIFICATION OF, FAMILIAL__:____:__
Number Sign__:__601709__:__QUEBEC PLATELET DISORDER; QPD__:__BLEEDING DISORDER, PLATELET-TYPE, 5; BDPLT5;; FACTOR V QUEBEC__:__
Asterisk__:__601710__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 5; EIF5__:____:__
Asterisk__:__601711__:__TNF RECEPTOR-ASSOCIATED FACTOR 1; TRAF1__:__EPSTEIN-BARR VIRUS-INDUCED mRNA 6; EBI6__:__
Asterisk__:__601712__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 2; BIRC2__:__APOPTOSIS INHIBITOR 1; API1;; HIAP2;; CIAP1;; MAMMALIAN IAP HOMOLOG B; MIHB__:__
Asterisk__:__601713__:__GLIA MATURATION FACTOR, BETA; GMFB__:__GLIA MATURATION FACTOR; GMF__:__
Asterisk__:__601714__:__TEA DOMAIN FAMILY MEMBER 4; TEAD4__:__TRANSCRIPTION FACTOR 13-LIKE 1; TCF13L1;; TRANSCRIPTIONAL ENHANCER FACTOR 1-RELATED GENE; RTEF1;; TRANSCRIPTIONAL ENHANCER FACTOR 3; TEF3__:__
Caret__:__601715__:__MOVED TO 601582__:____:__
Asterisk__:__601716__:__STAUFEN, DROSOPHILA, HOMOLOG OF, 1; STAU1__:__STAU;; STAUFEN-LIKE__:__
Asterisk__:__601717__:__SYNTAXIN-BINDING PROTEIN 2; STXBP2__:__UNC18, C. ELEGANS, HOMOLOG OF, 2;; UNC18B;; MUNC18-2__:__
Number Sign__:__601718__:__RETINITIS PIGMENTOSA 19; RP19__:____:__
Asterisk__:__601719__:__T-BOX 4; TBX4__:____:__
Asterisk__:__601720__:__ANTIGENIC DETERMINANT OF RECOMBINATION PROTEIN A, MOUSE, HOMOLOG OF; KIN__:__ANTIGENIC DETERMINANT OF RECA, MOUSE, HOMOLOG OF;; KIN17;; BINDING TO CURVED DNA; BTCD__:__
Asterisk__:__601721__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 3; BIRC3__:__APOPTOSIS INHIBITOR 2; API2;; HIAP1;; CIAP2;; MAMMALIAN IAP HOMOLOG C; MIHC__:__API2/MALT1 FUSION GENE, INCLUDED
Caret__:__601722__:__MOVED TO 601712__:____:__
Asterisk__:__601723__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 5; FZD5__:__FRIZZLED 5__:__
Asterisk__:__601724__:__NEUROGENIC DIFFERENTIATION 1; NEUROD1__:__NEUROD;; BETA-CELL E-BOX TRANSACTIVATOR 2; BETA2__:__
Asterisk__:__601725__:__NEUROGENIC DIFFERENTIATION 2; NEUROD2__:____:__
Asterisk__:__601726__:__NEUROGENIN 1; NEUROG1__:__NGN1;; NEUROGENIC DIFFERENTIATION 3; NEUROD3__:__
Caret__:__601727__:__MOVED TO 601714__:____:__
Asterisk__:__601728__:__PHOSPHATASE AND TENSIN HOMOLOG; PTEN__:__PTEN1;; MUTATED IN MULTIPLE ADVANCED CANCERS 1; MMAC1;; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10__:__
Asterisk__:__601729__:__TEA DOMAIN FAMILY MEMBER 2; TEAD2__:__TRANSCRIPTIONAL ENHANCER FACTOR 4; TEF4__:__
Asterisk__:__601730__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS C PROTEIN; PIGC__:__GPI2, YEAST, HOMOLOG OF__:__
Asterisk__:__601731__:__5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE/IMP CYCLOHYDROLASE; ATIC__:__AICARFT/IMPCHASE;; AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE;; PURH__:__
Asterisk__:__601732__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY C, MEMBER 1; SMARCC1__:__MAMMALIAN CHROMATIN REMODELING COMPLEX, BRG1-ASSOCIATED FACTOR 155;; BRG1-ASSOCIATED FACTOR, 155-KD; BAF155;; CHROMATIN REMODELING COMPLEX BAF155 SUBUNIT;; SWI3, YEAST, HOMOLOG OF__:__
Asterisk__:__601733__:__GLUTATHIONE S-TRANSFERASE, MICROSOMAL, 2; MGST2__:__GST2__:__
Asterisk__:__601734__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY C, MEMBER 2; SMARCC2__:__MAMMALIAN CHROMATIN REMODELING COMPLEX, BRG1-ASSOCIATED FACTOR 170;; BRG1-ASSOCIATED FACTOR, 170-KD; BAF170;; CHROMATIN REMODELING COMPLEX BAF170 SUBUNIT;; SWI3, YEAST, HOMOLOG OF__:__
Asterisk__:__601735__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY D, MEMBER 1; SMARCD1__:__MAMMALIAN CHROMATIN REMODELING COMPLEX, BRG1-ASSOCIATED FACTOR 60A;; BRG1-ASSOCIATED FACTOR, 60-KD, A; BAF60A;; CHROMATIN REMODELING COMPLEX BAF60A SUBUNIT;; SWP73, YEAST, HOMOLOG OF__:__
Asterisk__:__601736__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY D, MEMBER 2; SMARCD2__:__MAMMALIAN CHROMATIN REMODELING COMPLEX, BRG1-ASSOCIATED FACTOR 60B;; BRG1-ASSOCIATED FACTOR, 60-KD, B; BAF60B;; CHROMATIN REMODELING COMPLEX BAF60B SUBUNIT;; SWP73, YEAST, HOMOLOG OF__:__
Asterisk__:__601737__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY D, MEMBER 3; SMARCD3__:__MAMMALIAN CHROMATIN REMODELING COMPLEX, BRG1-ASSOCIATED FACTOR 60C;; BRG1-ASSOCIATED FACTOR, 60-KD, C; BAF60C;; CHROMATIN REMODELING COMPLEX BAF60C SUBUNIT;; SWP73 YEAST, HOMOLOG OF__:__
Asterisk__:__601738__:__EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 1; EXTL1__:__EXOSTOSIN-LIKE 1;; MULTIPLE EXOSTOSES-LIKE 1;; EXTL__:__
Asterisk__:__601739__:__MEIS1, MOUSE, HOMOLOG OF, 1; MEIS1__:__MEIS1 HOMEOBOX PROTEIN__:__
Asterisk__:__601740__:__MEIS1, MOUSE, HOMOLOG OF, 2; MEIS2__:__MEIS1-RELATED GENE 1; MRG1__:__
Asterisk__:__601741__:__CULLIN 5; CUL5__:__VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING RECEPTOR 1; VACM1__:__
Asterisk__:__601742__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 28; TRIM28__:__KRAB-ASSOCIATED PROTEIN 1; KAP1;; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1-BETA; TIF1B__:__
Asterisk__:__601743__:__ONCOSTATIN M RECEPTOR; OSMR__:__ONCOSTATIN M-SPECIFIC RECEPTOR, BETA; OSMRB__:__
Number Sign__:__601744__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 1; SLEB1__:____:__SYSTEMIC LUPUS ERYTHEMATOSUS, RESISTANCE TO, 1, INCLUDED
Asterisk__:__601745__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 1; KCNK1__:__POTASSIUM CHANNEL, WEAKLY INWARD-RECTIFYING, WITH TWIN P DOMAINS, 1; TWIK1;; K2P1__:__
Asterisk__:__601746__:__HYPOXIA UP-REGULATED 1; HYOU1__:__OXYGEN-REGULATED PROTEIN, 150-KD; ORP150__:__
Asterisk__:__601747__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 23; TRIM23__:__ADP-RIBOSYLATION FACTOR DOMAIN PROTEIN 1; ARFD1; ARD1;; ARF DOMAIN PROTEIN 1__:__
Asterisk__:__601748__:__GENERAL TRANSCRIPTION FACTOR IIH, POLYPEPTIDE 2; GTF2H2__:__TRANSCRIPTION FACTOR IIH, 44-KD SUBUNIT__:__
Asterisk__:__601749__:__GLOMULIN; GLMN__:__FKBP-ASSOCIATED PROTEIN, 48-KD; FAP48;; FKBP-ASSOCIATED PROTEIN, 68-KD; FAP68__:__
Asterisk__:__601750__:__GENERAL TRANSCRIPTION FACTOR IIH, POLYPEPTIDE 3; GTF2H3__:__TRANSCRIPTION FACTOR IIH, 34-KD SUBUNIT;; TFB4__:__
Asterisk__:__601751__:__MELANIN-CONCENTRATING HORMONE RECEPTOR 1; MCHR1__:__G PROTEIN-COUPLED RECEPTOR 24; GPR24;; SLC1;; MCHR__:__
Asterisk__:__601752__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; ENTPD1__:__CD39 ANTIGEN; CD39;; VASCULAR ATP DIPHOSPHOHYDROLASE; ATPDase;; APYRASE__:__
Asterisk__:__601753__:__PEPTIDYL-PROLYL ISOMERASE D; PPID__:__CYCLOPHILIN D; CYPD;; CYCLOPHILIN 40; CYP40__:__
Asterisk__:__601754__:__UBIQUITIN FUSION DEGRADATION 1-LIKE; UFD1L__:____:__
Asterisk__:__601755__:__ESS2 SPLICING FACTOR, XENOPUS, HOMOLOG OF; ESS2__:__DIGEORGE SYNDROME CRITICAL REGION GENE DGSI; DGSI;; DIGEORGE SYNDROME CRITICAL REGION GENE 14; DGCR14;; ES2__:__
Asterisk__:__601756__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 3; GALNT3__:__GalNAc TRANSFERASE 3; GalNAcT3;; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 3__:__
Asterisk__:__601757__:__PEROXISOME BIOGENESIS FACTOR 7; PEX7__:__PEROXIN 7;; PEROXISOMAL PTS2 RECEPTOR__:__
Asterisk__:__601758__:__PEROXISOME BIOGENESIS FACTOR 12; PEX12__:__PEROXIN 12__:__
NULL__:__601759__:__PREAXIAL HALLUCAL POLYDACTYLY__:____:__
Asterisk__:__601760__:__GENERAL TRANSCRIPTION FACTOR IIH, POLYPEPTIDE 4; GTF2H4__:__TRANSCRIPTION FACTOR IIH, 52-KD SUBUNIT;; TFB2__:__
Asterisk__:__601761__:__CASPASE 7, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP7__:__MCH3__:__
Asterisk__:__601762__:__CASPASE 10, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP10__:__MCH4__:__CASPASE 10, ISOFORM B, INCLUDED; CASP10B, INCLUDED;; FADD-LIKE ICE 2, INCLUDED; FLICE2, INCLUDED
Asterisk__:__601763__:__CASPASE 8, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP8__:__MORT1-ASSOCIATED CED3 HOMOLOG; MACH;; FADD-HOMOLOGOUS ICE/CED3-LIKE PROTEASE;; FADD-LIKE ICE; FLICE;; MCH5__:__
Percent__:__601764__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 1; BFIS1__:__CONVULSIONS, BENIGN FAMILIAL INFANTILE, 1; BFIC1__:__
Caret__:__601765__:__MOVED TO 601542__:____:__
Asterisk__:__601766__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 9; FZD9__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 3; FZD3__:__
Asterisk__:__601767__:__HUNTINGTIN-INTERACTING PROTEIN 1; HIP1__:____:__HIP1/PDGFRB FUSION GENE, INCLUDED
Asterisk__:__601768__:__SH3 DOMAIN, GRB2-LIKE, 1; SH3GL1__:__SH3p8;; EXTRA ELEVEN-NINETEEN LEUKEMIA FUSION GENE; EEN;; EEN FUSION PARTNER OF MLL;; ENDOPHILIN 2;; ENDOPHILIN A2__:__EEN/MLL FUSION GENE, INCLUDED
Asterisk__:__601769__:__VITAMIN D RECEPTOR; VDR__:__1,25-DIHYDROXYVITAMIN D3 RECEPTOR;; VITAMIN D HORMONE RECEPTOR__:__
Asterisk__:__601770__:__NEUROPEPTIDE Y RECEPTOR Y6; NPY6R__:__PP2;; Y2B__:__
Asterisk__:__601771__:__CYTOCHROME P450, SUBFAMILY I, POLYPEPTIDE 1; CYP1B1__:__P4501B1__:__
Asterisk__:__601772__:__H2A HISTONE FAMILY, MEMBER X; H2AFX__:__H2AX HISTONE;; H2AX__:__
Asterisk__:__601773__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, N; PTPRN__:__ISLET CELL ANTIGEN 512; ICA512;; INSULINOMA-ASSOCIATED PROTEIN 2; IA2;; ISLET ANTIGEN 2__:__
Asterisk__:__601774__:__ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT5__:__N-ACETYLGLUCOSAMINYLTRANSFERASE V;; GNT-V;; GNT-VA__:__
NULL__:__601775__:__FOLATE LEVEL IN ERYTHROCYTES__:____:__
Number Sign__:__601776__:__EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1__:__EDSMC;; ADDUCTED THUMB, CLUBFOOT, AND PROGRESSIVE JOINT AND SKIN LAXITY SYNDROME;; EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY;; ADDUCTED THUMB-CLUBFOOT SYNDROME; ATCS;; DUNDAR SYNDROME;; ARTHROGRYPOSIS, DISTAL, WITH PECULIAR FACIES AND HYDRONEPHROSIS__:__
Number Sign__:__601777__:__CONE-ROD DYSTROPHY 6; CORD6__:__RETINAL CONE DYSTROPHY 2; RCD2__:__
Asterisk__:__601778__:__POLYMERASE, RNA, MITOCHONDRIAL; POLRMT__:__MTRNAP__:__POLYMERASE, RNA, NUCLEAR, SINGLE-POLYPEPTIDE, IV, INCLUDED; SPRNAPIV, INCLUDED
Caret__:__601779__:__MOVED TO 258450__:____:__
Number Sign__:__601780__:__CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6__:__CEROID LIPOFUSCINOSIS, NEURONAL, 6, VARIABLE AGE AT ONSET__:__NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, VARIANT, INCLUDED; vLINCL, INCLUDED
Caret__:__601781__:__MOVED TO 194554__:____:__
Asterisk__:__601782__:__TESTIS-SPECIFIC PROTEIN KINASE 1; TESK1__:____:__
Asterisk__:__601783__:__MICROTUBULE-ASSOCIATED PROTEIN 6; MAP6__:__MTAP6;; STABLE TUBULE-ONLY POLYPEPTIDE; STOP;; KIAA1878__:__
Asterisk__:__601784__:__CATION CHANNEL, AMILORIDE-SENSITIVE, NEURONAL, 1; ACCN1__:__ACID-SENSING ION CHANNEL 2; ASIC2;; BRAIN SODIUM CHANNEL 1; BNAC1;; BNC1;; SODIUM CHANNEL, NONVOLTAGE-GATED, NEURONAL, 1;; MAMMALIAN DEGENERIN; MDEG__:__
Asterisk__:__601785__:__PHOSPHOMANNOMUTASE 2; PMM2__:____:__
Asterisk__:__601786__:__PHOSPHOMANNOMUTASE 1; PMM1__:____:__
Asterisk__:__601787__:__TAF5 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 100-KD; TAF5__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2D; TAF2D;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 100-KD; TAFII100__:__
Asterisk__:__601788__:__MYOSTATIN; MSTN__:__GROWTH/DIFFERENTIATION FACTOR 8; GDF8__:__
Asterisk__:__601789__:__PEROXISOME BIOGENESIS FACTOR 13; PEX13__:__PEROXIN 13__:__
Asterisk__:__601790__:__PANCREATIC POLYPEPTIDE RECEPTOR 1; PPYR1__:__Y4;; NPY4R;; PP1__:__
Asterisk__:__601791__:__PEROXISOME BIOGENESIS FACTOR 14; PEX14__:__PEROXIN 14;; NFE2-ASSOCIATED POLYPEPTIDE 2; NAPP2__:__
Asterisk__:__601792__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 2; PPP1R2__:__PHOSPHATASE INHIBITOR 2; IPP2__:__
Caret__:__601793__:__MOVED TO 600724__:____:__
Percent__:__601794__:__COLOBOMA-OBESITY-HYPOGENITALISM-MENTAL RETARDATION SYNDROME__:____:__
Asterisk__:__601795__:__MITOGEN-ACTIVATED PROTEIN KINASE 3; MAPK3__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 3; PRKM3;; EXTRACELLULAR SIGNAL-REGULATED KINASE 1; ERK1;; p44ERK1;; p44MAPK__:__
Asterisk__:__601796__:__TAF4 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 135-KD; TAF4__:__TAF4A RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 135-KD; TAF4A;; TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR C1; TAF2C1;; TAF2C;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 130-KD; TAFII130;; TAFII135__:__
Asterisk__:__601797__:__ABSENT IN MELANOMA 1; AIM1__:____:__
Asterisk__:__601798__:__GLUCOSAMINE-6-PHOSPHATE DEAMINASE 1; GNPDA1__:__GNP1;; GNPI;; OSCILLIN, HAMSTER, HOMOLOG OF;; KIAA0060__:__
Asterisk__:__601799__:__PROTEASE INHIBITOR 9, OVALBUMIN TYPE; PI9__:__CYTOPLASMIC ANTIPROTEINASE 3; CAP3;; SERPIN FAMILY B, MEMBER 9; SERPINB9__:__
Number Sign__:__601800__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3__:__SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN;; SKIN/HAIR/EYE PIGMENTATION 3, FRECKLING;; SKIN/HAIR/EYE PIGMENTATION 3, BLUE/GREEN EYE COLOR;; EYE COLOR 1; EYCL1;; EYE COLOR, GREEN/BLUE; GEY__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8, INCLUDED
Asterisk__:__601801__:__TRANSCRIPTION FACTOR Sp2; SP2__:__SPECIFICITY PROTEIN 2__:__
Asterisk__:__601802__:__HOMEOBOX GENE EXPRESSED IN ES CELLS; HESX1__:__RATHKE POUCH HOMEOBOX; RPX__:__
Number Sign__:__601803__:__PALLISTER-KILLIAN SYNDROME; PKS__:__TETRASOMY 12p, MOSAIC;; ISOCHROMOSOME 12p SYNDROME__:__HEXASOMY 12p, MOSAIC, INCLUDED
Asterisk__:__601804__:__TRANSCRIPTION FACTOR Sp3; SP3__:____:__SP3/EWS FUSION GENE, INCLUDED
Asterisk__:__601805__:__G PROTEIN-COUPLED ESTROGEN RECEPTOR; GPER__:__G PROTEIN-COUPLED RECEPTOR 30; GPR30;; CHEMOKINE RECEPTOR-LIKE 2; CMKRL2__:__
Asterisk__:__601806__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 6; MCM6__:__MINICHROMOSOME MAINTENANCE, S. POMBE, HOMOLOG OF, 6__:__REGULATORY ELEMENT, CIS-ACTING, ENHANCER, 14 KB UPSTREAM OF LCT, INCLUDED;; LACTASE REGULATORY ELEMENT, INCLUDED
Asterisk__:__601807__:__MATRIX METALLOPROTEINASE 19; MMP19__:__MATRIX METALLOPROTEINASE 18, FORMERLY; MMP18, FORMERLY__:__
Number Sign__:__601808__:__CHROMOSOME 18q DELETION SYNDROME__:__CHROMOSOME 18q- SYNDROME;; 18q- SYNDROME__:__
NULL__:__601809__:__SPONDYLOSPINAL THORACIC DYSOSTOSIS__:____:__
Asterisk__:__601810__:__DNA REPLICATION HELICASE 2, YEAST, HOMOLOG OF; DNA2__:__DNA2-LIKE; DNA2L;; KIAA0083__:__
NULL__:__601811__:__PREMATURE AGING SYNDROME, OKAMOTO TYPE__:____:__
Number Sign__:__601812__:__PREMATURE AGING SYNDROME, PENTTINEN TYPE; PENTT__:____:__
Number Sign__:__601813__:__EXUDATIVE VITREORETINOPATHY 4; EVR4__:____:__
Asterisk__:__601814__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 2; FXYD2__:__SODIUM-POTASSIUM-ATPase, GAMMA-1 POLYPEPTIDE; ATP1G1__:__
Number Sign__:__601815__:__PHOSPHOGLYCERATE DEHYDROGENASE DEFICIENCY; PHGDHD__:__PHGDH DEFICIENCY__:__
Number Sign__:__601816__:__BILIRUBIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; BILIQTL1__:____:__
Asterisk__:__601817__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 3; NME3__:__NONMETASTATIC CELLS 3, PROTEIN EXPRESSED IN;; DR-NM23;; NONMETASTATIC PROTEIN 23, HOMOLOG OF; NM23H3__:__
Asterisk__:__601818__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 4; NME4__:__NONMETASTATIC CELLS 4, PROTEIN EXPRESSED IN;; NONMETASTATIC PROTEIN 23, HOMOLOG 4; NM23H4;; METASTASIS INHIBITION FACTOR NM23H4;; NUCLEOSIDE DIPHOSPHATE KINASE D; NDPKD__:__
Asterisk__:__601819__:__BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR; BPTF__:__FETAL ALZHEIMER ANTIGEN; FALZ;; FAC1;; NURF301, DROSOPHILA, HOMOLOG OF; NURF301;; BROMODOMAIN AND PHD DOMAIN TRANSCRIPTION FACTOR__:__
Number Sign__:__601820__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 2; HHF2__:__PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHHI;; HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT;; HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA;; HYPERINSULINISM, NEONATAL;; HYPERINSULINISM, CONGENITAL;; HYPERINSULINISM, FAMILIAL;; NESIDIOBLASTOSIS__:__
Asterisk__:__601821__:__RNA, Y1 SMALL CYTOPLASMIC; RNY1__:__RNA POLYMERASE III TRANSCRIPT 1; Y1__:__
Asterisk__:__601822__:__RNA, Y3 SMALL CYTOPLASMIC; RNY3__:__RNA POLYMERASE III TRANSCRIPT 3; Y3__:__
Asterisk__:__601823__:__RNA, Y4 SMALL CYTOPLASMIC; RNY4__:__RNA POLYMERASE III TRANSCRIPT 4; Y4__:__
Asterisk__:__601824__:__RNA, Y5 SMALL CYTOPLASMIC; RNY5__:__RNA POLYMERASE III TRANSCRIPT 5; Y5__:__
Asterisk__:__601825__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 7; NDUFS7__:__NADH-COENZYME Q REDUCTASE, 20-KD;; COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 20-KD SUBUNIT;; PSST__:__
Asterisk__:__601826__:__DIACYLGLYCEROL KINASE, DELTA, 130-KD; DGKD__:__KIAA0145;; DGK ISOZYME, 130-KD;; DGK-DELTA__:__
Caret__:__601827__:__MOVED TO 601659__:____:__
Asterisk__:__601828__:__NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; NR4A2__:__NUCLEAR RECEPTOR-RELATED 1; NURR1;; NUCLEAR RECEPTOR OF T CELLS; NOT;; TRANSCRIPTIONALLY INDUCIBLE NUCLEAR RECEPTOR; TINUR__:__
NULL__:__601829__:__ACROFACIAL DYSOSTOSIS, PALAGONIA TYPE__:____:__
Caret__:__601830__:__MOVED TO 601770__:____:__
Asterisk__:__601831__:__HISTONE GENE CLUSTER 2, H2B HISTONE FAMILY, MEMBER E; HIST2H2BE__:__HISTONE GENE CLUSTER 2, H2BE;; HIST2 CLUSTER, H2BE;; H2B HISTONE FAMILY, MEMBER Q; H2BFQ;; H2B/Q;; H2B.1__:__
Asterisk__:__601832__:__RIBOSOMAL PROTEIN L29; RPL29__:__HP/HS-INTERACTING PROTEIN; HIP;; HEPARIN/HEPARAN SULFATE-BINDING PROTEIN__:__
Asterisk__:__601833__:__ALLOGRAFT INFLAMMATORY FACTOR 1; AIF1__:__INTERFERON RESPONSE TRANSCRIPT 1; IRT1;; IBA1__:__
Asterisk__:__601834__:__CHEMOKINE, CC MOTIF, RECEPTOR 8; CCR8__:__CHEMOKINE, CC MOTIF, RECEPTOR-LIKE 2; CMKBRL2;; CHEMOKINE RECEPTOR-LIKE 1; CKRL1;; CMKBR8__:__
Asterisk__:__601835__:__CHEMOKINE, CC MOTIF, RECEPTOR 6; CCR6__:__CHEMOKINE RECEPTOR-LIKE 3; CKRL3;; G PROTEIN-COUPLED RECEPTOR 29; GPR29;; GPRCY4;; STRL22;; CMKBR6__:__
Asterisk__:__601836__:__KINESIN-ASSOCIATED PROTEIN 3; KIFAP3__:__KAP3;; smg GDS-ASSOCIATED PROTEIN; SMAP__:__
Asterisk__:__601837__:__LIGASE IV, DNA, ATP-DEPENDENT; LIG4__:__DNA LIGASE IV__:__
Asterisk__:__601838__:__INOSITOL 1,3,4-TRISPHOSPHATE 5/6-KINASE; ITPK1__:__ITRPK1__:__
Asterisk__:__601839__:__EPHRIN RECEPTOR EphB3; EPHB3__:__EPH-LIKE TYROSINE KINASE 2; ETK2;; HUMAN EMBRYO KINASE 2; HEK2;; TYRO6__:__
Caret__:__601840__:__MOVED TO 600286__:____:__
Asterisk__:__601841__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 5; SERPINA5__:__PROTEIN C INHIBITOR; PCI__:__
Caret__:__601842__:__MOVED TO 601543__:____:__
Asterisk__:__601843__:__SOLUTE CARRIER FAMILY 5 (SODIUM IODIDE SYMPORTER), MEMBER 5; SLC5A5__:__SODIUM-IODIDE SYMPORTER; NIS__:__
Asterisk__:__601844__:__PROTEIN KINASE, LYSINE-DEFICIENT 4; WNK4__:__PRKWNK4__:__
Asterisk__:__601845__:__GOOSECOID HOMEOBOX 2; GSC2__:__GOOSECOID-LIKE; GSCL__:__
Percent__:__601846__:__VACUOLAR NEUROMYOPATHY__:__MUSCULAR DYSTROPHY, AUTOSOMAL DOMINANT, WITH RIMMED VACUOLES; MDRV__:__
Number Sign__:__601847__:__CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 2; PFIC2__:____:__
Asterisk__:__601848__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20, S. CEREVISIAE, HOMOLOG OF; TOMM20__:__TOM20;; MAS20, S. CEREVISIAE, HOMOLOG OF; MAS20;; KIAA0016__:__
Caret__:__601849__:__MOVED TO 228930__:____:__
Caret__:__601850__:__MOVED TO 500004__:____:__
Asterisk__:__601851__:__CIRCADIAN LOCOMOTOR OUTPUT CYCLES KAPUT; CLOCK__:__CLOCK, MOUSE, HOMOLOG OF__:__
Asterisk__:__601852__:__INTERCELLULAR ADHESION MOLECULE 5; ICAM5__:__TELENCEPHALIN; TLCN; TLN__:__
Percent__:__601853__:__GOMEZ-LOPEZ-HERNANDEZ SYNDROME; GLHS__:__CEREBELLOTRIGEMINAL DERMAL DYSPLASIA CEREBELLO-TRIGEMINAL-DERMAL DYSPLASIA__:__
Asterisk__:__601854__:__DIACYLGLYCEROL KINASE, GAMMA, 90-KD; DGKG__:__DIACYLGLYCEROL KINASE, GAMMA; DAGK3;; DAGK, 90-KD;; DGK-GAMMA__:__
Asterisk__:__601855__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; ARHGEF1__:__GUANINE NUCLEOTIDE EXCHANGE FACTOR, 115-KD;; p115-RhoGEF;; LSC, MOUSE, HOMOLOG OF; LSC__:__
Asterisk__:__601856__:__ZINC FINGER PROTEIN 211; ZNF211__:____:__
Caret__:__601857__:__MOVED TO 601056__:____:__
Asterisk__:__601858__:__CALMEGIN; CLGN__:____:__
Number Sign__:__601859__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS__:__CANALE-SMITH SYNDROME;; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE I, AUTOSOMAL DOMINANT__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IA, INCLUDED; ALPS1A, INCLUDED;; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IB, INCLUDED; ALPS1B, INCLUDED;; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE I, AUTOSOMAL RECESSIVE, INCLUDED
Asterisk__:__601860__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE IV; HSD17B4__:__17-BETA-HSD IV;; D-3-HYDROXYACYL-CoA DEHYDRATASE/D-3-HYDROXYACYL-CoA DEHYDROGENASE BIFUNCTIONAL PROTEIN;; D-BIFUNCTIONAL PROTEIN, PEROXISOMAL;; DBP, PEROXISOMAL;; MULTIFUNCTIONAL PROTEIN 2; MFP2__:__
Asterisk__:__601861__:__REGULATORY FACTOR X-ASSOCIATED PROTEIN; RFXAP__:__RFX-ASSOCIATED PROTEIN__:__
Caret__:__601862__:__MOVED TO 104160__:____:__
Asterisk__:__601863__:__REGULATORY FACTOR X, 5; RFX5__:____:__
Caret__:__601864__:__MOVED TO 177060__:____:__
Asterisk__:__601865__:__PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2; PLOD2__:__LYSYL HYDROXYLASE 2; LH2;; LYSINE HYDROXYLASE 2;; TELOPEPTIDE LYSYL HYDROXYLASE; TLH__:__
Asterisk__:__601866__:__SEMAPHORIN 4D; SEMA4D__:__SEMAPHORIN J; SEMAJ;; LEUKOCYTE ACTIVATION ANTIGEN CD100; CD100;; COLLAPSIN 4; COLL4__:__
Asterisk__:__601867__:__ATPase, Na+/K+ TRANSPORTING, BETA-3 POLYPEPTIDE; ATP1B3__:__Na,K-ATPase BETA-3 POLYPEPTIDE__:__
Number Sign__:__601868__:__DEAFNESS, AUTOSOMAL DOMINANT 13; DFNA13__:____:__
Number Sign__:__601869__:__DEAFNESS, AUTOSOMAL RECESSIVE 15; DFNB15__:__DEAFNESS, AUTOSOMAL RECESSIVE 72; DFNB72;; DEAFNESS, AUTOSOMAL RECESSIVE 95; DFNB95__:__
Asterisk__:__601870__:__METHIONINE AMINOPEPTIDASE 2; METAP2__:__EUKARYOTIC INITIATION FACTOR 2-ASSOCIATED PROTEIN, 67-KD;; p67__:__
Asterisk__:__601871__:__CYSTEINE- AND GLYCINE-RICH PROTEIN 2; CSRP2__:__CYSTEINE-RICH PROTEIN 2; CRP2;; LIM DOMAIN ONLY, SMOOTH MUSCLE;; LIM DOMAIN ONLY 5; LMO5__:__
Asterisk__:__601872__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 2; SLC7A2__:__AMINO ACID TRANSPORTER, CATIONIC 2; ATRC2;; CATIONIC AMINO ACID TRANSPORTER 2; CAT2__:__
Asterisk__:__601873__:__BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE 1; B4GALNT1__:__BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE; GALGT;; GalNAcT;; GM2/GD2 SYNTHASE__:__
Asterisk__:__601874__:__ELONGATION FACTOR, RNA POLYMERASE II, 2; ELL2__:____:__
Caret__:__601875__:__MOVED TO 601630__:____:__
NULL__:__601876__:__SPERM-SPECIFIC ANTIGEN 1; SSFA1__:__FERTILIZATION ANTIGEN 1; FA1__:__
Asterisk__:__601877__:__LEFT-RIGHT DETERMINATION FACTOR 2; LEFTY2__:__ENDOMETRIAL BLEEDING-ASSOCIATED FACTOR; EBAF;; LEFT-RIGHT DETERMINATION, FACTOR A; LEFTA;; LEFTY A;; LEFTY2, MOUSE, HOMOLOG OF;; TRANSFORMING GROWTH FACTOR, BETA-4; TGFB4__:__
Asterisk__:__601878__:__KRUPPEL-LIKE FACTOR 10; KLF10__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCIBLE EARLY GROWTH RESPONSE; TIEG TGFB-INDUCIBLE EARLY GROWTH RESPONSE;; TGF-BETA-INDUCIBLE EARLY GENE;; ZINC FINGER TRANSCRIPTION FACTOR TIEG;; TRANSFORMING GROWTH FACTOR-BETA-INDUCIBLE EARLY GROWTH RESPONSE 1; TIEG1;; EARLY GROWTH RESPONSE-ALPHA__:__
Asterisk__:__601879__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 9; LGALS9__:__GALECTIN 9__:__ECALECTIN, INCLUDED
Asterisk__:__601880__:__CHEMOKINE, CX3C MOTIF, LIGAND 1; CX3CL1__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY D, MEMBER 1; SCYD1;; NEUROTACTIN; NTT; NTN;; FRACTALKINE__:__
Asterisk__:__601881__:__RETINA AND ANTERIOR NEURAL FOLD HOMEOBOX GENE; RAX__:__RX HOMEOBOX GENE; RX__:__
Asterisk__:__601882__:__DNA FRAGMENTATION FACTOR, 45-KD, ALPHA SUBUNIT; DFFA__:__DFF1;; DFF45;; INHIBITOR OF CASPASE-ACTIVATED DNase; ICAD__:__
Asterisk__:__601883__:__DNA FRAGMENTATION FACTOR, 40-KD, BETA SUBUNIT; DFFB__:__DFF2;; DFF40;; DEOXYRIBONUCLEASE III, CASPASE-ACTIVATED;; CASPASE-ACTIVATED DNase; CAD__:__
Number Sign__:__601884__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 1; BMND1__:____:__HIGH BONE MASS, INCLUDED; HBM, INCLUDED;; OSTEOPOROSIS, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__601885__:__CATARACT 14, MULTIPLE TYPES; CTRCT14__:__CATARACT, ZONULAR PULVERULENT 3; CZP3;; CAE3__:__
Asterisk__:__601886__:__ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG OF, 2; ASCL2__:__ACHAETE-SCUTE HOMOLOG 2; ASH2; HASH2__:__
Number Sign__:__601887__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5__:__MHS5__:__
Percent__:__601888__:__MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 6__:__MHS6__:__
Asterisk__:__601889__:__NEUROBEACHIN PSEUDOGENE 1; NBEAP1__:__B-CELL CLL/LYMPHOMA 8; BCL8;; B-CELL LEUKEMIA 8__:__
Asterisk__:__601890__:__PROTEIN-TYROSINE KINASE PTK7; PTK7__:__COLON CARCINOMA KINASE-4__:__
Asterisk__:__601891__:__CYSTATIN 6; CST6__:__CYSTATIN M;; CYSTATIN M/E__:__
Asterisk__:__601892__:__KARYOPHERIN ALPHA-3; KPNA3__:__IMPORTIN ALPHA-4__:__
Asterisk__:__601893__:__TRIPLE FUNCTIONAL DOMAIN; TRIO__:____:__
Number Sign__:__601894__:__GLOMERULOPATHY WITH FIBRONECTIN DEPOSITS 2; GFND2__:__GLOMERULAR NEPHRITIS, FAMILIAL, WITH FIBRONECTIN DEPOSITS;; FIBRONECTIN GLOMERULOPATHY__:__
Asterisk__:__601895__:__TNF RECEPTOR-ASSOCIATED FACTOR 2; TRAF2__:__TNF RECEPTOR-ASSOCIATED PROTEIN; TRAP__:__
Asterisk__:__601896__:__TNF RECEPTOR-ASSOCIATED FACTOR 3; TRAF3__:__CD40-BINDING PROTEIN; CD40BP;; LMP1-ASSOCIATED PROTEIN 1; LAP1;; CD40-ASSOCIATED PROTEIN 1; CAP1;; CD40 RECEPTOR-ASSOCIATED FACTOR 1; CRAF1__:__
Asterisk__:__601897__:__ZINC FINGER PROTEIN 148; ZNF148__:__ZINC-BINDING PROTEIN 89; ZBP89;; HT-BETA;; ZFP148__:__
Asterisk__:__601898__:__GROWTH HORMONE SECRETAGOGUE RECEPTOR; GHSR__:____:__
Asterisk__:__601899__:__SIGNAL-TRANSDUCING ADAPTOR MOLECULE 1; STAM__:__SIGNAL-TRANSDUCING ADAPTOR MOLECULE;; STAM1__:__
Asterisk__:__601900__:__INTERFERON REGULATORY FACTOR 4; IRF4__:__LYMPHOCYTE-SPECIFIC IRF; LSIRF;; MULTIPLE MYELOMA ONCOGENE 1; MUM1__:__
Asterisk__:__601901__:__SOLUTE CARRIER FAMILY 8 (SODIUM-CALCIUM EXCHANGER), MEMBER A2; SLC8A2__:__SODIUM-CALCIUM EXCHANGER 2; NCX2;; KIAA1087__:__
Asterisk__:__601902__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 1, S. CEREVISIAE, HOMOLOG OF; ORC1__:__ORC1-LIKE; ORC1L__:__
Asterisk__:__601903__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B17; UGT2B17__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B17;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B17__:__
Caret__:__601904__:__MOVED TO 300899__:____:__
Asterisk__:__601905__:__RAB GERANYLGERANYL TRANSFERASE, ALPHA SUBUNIT; RABGGTA__:____:__
Asterisk__:__601906__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 10B; WNT10B__:____:__
Asterisk__:__601907__:__NEOGENIN; NEO1__:__NGN__:__
Asterisk__:__601908__:__G PROTEIN-COUPLED RECEPTOR 20; GPR20__:____:__
Asterisk__:__601909__:__G PROTEIN-COUPLED RECEPTOR 21; GPR21__:____:__
Asterisk__:__601910__:__G PROTEIN-COUPLED RECEPTOR 22; GPR22__:____:__
Asterisk__:__601911__:__DISTAL-LESS HOMEOBOX 4; DLX4__:____:__DISTAL-LESS HOMEOBOX 7, INCLUDED; DLX7, INCLUDED;; BETA PROTEIN 1, INCLUDED; BP1, INCLUDED
Asterisk__:__601912__:__SMALL UBIQUITIN-LIKE MODIFIER 1; SUMO1__:__UBIQUITIN-LIKE 1; UBL1;; SMT3, YEAST, HOMOLOG 3; SMT3H3;; SMT3C;; SENTRIN;; PIC1__:__
Asterisk__:__601913__:__arsA ARSENITE TRANSPORTER, ATP-BINDING, E. COLI, HOMOLOG OF, 1; ASNA1__:__ARSA1;; TRANSMEMBRANE DOMAIN RECOGNITION COMPLEX, 40-KD; TRC40__:__
Asterisk__:__601914__:__PROLINE-ARGININE-RICH END LEUCINE-RICH REPEAT PROTEIN; PRELP__:____:__
Asterisk__:__601915__:__TISSUE INHIBITOR OF METALLOPROTEINASE 4; TIMP4__:____:__
Asterisk__:__601916__:__ARGININE-RICH PROTEIN MUTATED IN EARLY STAGE TUMORS; ARMET__:__ARGININE-RICH PROTEIN; ARP;; MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR; MANF__:__
Asterisk__:__601917__:__ALDEHYDE DEHYDROGENASE 3 FAMILY, MEMBER B2; ALDH3B2__:__ALDEHYDE DEHYDROGENASE 8; ALDH8;; ACETALDEHYDE DEHYDROGENASE 8__:__
Asterisk__:__601918__:__GROWTH/DIFFERENTIATION FACTOR 9; GDF9__:____:__
Asterisk__:__601919__:__COAGULATION FACTOR II RECEPTOR-LIKE 2; F2RL2__:__THROMBIN RECEPTOR-LIKE 2;; PROTEASE-ACTIVATED RECEPTOR 3; PAR3__:__
Asterisk__:__601920__:__JAGGED 1; JAG1__:__JAGL1__:__
Caret__:__601921__:__MOVED TO 156535__:____:__
Asterisk__:__601922__:__ANGIOPOIETIN 2; ANGPT2__:__ANG2__:__
Caret__:__601923__:__MOVED TO 601124__:____:__
Asterisk__:__601924__:__COATOMER PROTEIN COMPLEX, SUBUNIT ALPHA; COPA__:__ALPHA COAT PROTEIN__:__COATOMER PROTEIN COMPLEX, INCLUDED; COPI, INCLUDED
Asterisk__:__601925__:__RHO GDP-DISSOCIATION INHIBITOR ALPHA; ARHGDIA__:__RHOGDI;; GDP-DISSOCIATION INHIBITOR, APLYSIA RAS-RELATED 1; GDIA1__:__
Asterisk__:__601926__:__THYROID HORMONE-RESPONSIVE SPOT14, RAT, HOMOLOG OF; THRSP__:__S14__:__
Percent__:__601927__:__LYMPHEDEMA, CARDIAC SEPTAL DEFECTS, AND CHARACTERISTIC FACIES__:__IRONS-BIANCHI SYNDROME;; LYMPHEDEMA, ATRIAL SEPTAL DEFECT, AND CHARACTERISTIC FACIES__:__
Asterisk__:__601928__:__KERATIN 86, TYPE II; KRT86__:__K86;; KB26;; K2.11;; KERATIN, HAIR, BASIC, 6; KRTHB6;; KERATIN, HARD, TYPE II, 6; HB6__:__
Asterisk__:__601929__:__ATPase, Ca(2+)-TRANSPORTING, UBIQUITOUS; ATP2A3__:__SARCOPLASMIC RETICULUM Ca(2+)-ATPase 3; SERCA3__:__
Asterisk__:__601930__:__BASONUCLIN 1; BNC1__:__BNC__:__
Asterisk__:__601931__:__BCL2-LIKE 2; BCL2L2__:__BCLW__:__
Asterisk__:__601932__:__MUCIN 8, TRACHEOBRONCHIAL; MUC8__:____:__
Asterisk__:__601933__:__CRYPTOCHROME 1; CRY1__:__PHOTOLYASE 1; PHLL1__:__
Asterisk__:__601934__:__G PROTEIN PATHWAY SUPPRESSOR 1; GPS1__:__FUS6/COP11, ARABIDOPSIS, HOMOLOG OF;; COP9 SIGNALOSOME, SUBUNIT 1; COPS1; CSN1__:__
Asterisk__:__601935__:__G PROTEIN PATHWAY SUPPRESSOR 2; GPS2__:____:__
Asterisk__:__601936__:__PRKC, APOPTOSIS, WT1, REGULATOR; PAWR__:__PROSTATE APOPTOSIS RESPONSE PROTEIN 4; PAR4;; TRANSCRIPTIONAL REPRESSOR PAR4;; WT1-INTERACTING PROTEIN__:__
Asterisk__:__601937__:__NUCLEAR RECEPTOR COACTIVATOR 3; NCOA3__:__AMPLIFIED IN BREAST CANCER 1; AIB1;; ACTR;; THYROID HORMONE RECEPTOR ACTIVATOR MOLECULE 1; TRAM1;; STEROID RECEPTOR COACTIVATOR 3; SRC3;; RAC3__:__
Caret__:__601938__:__MOVED TO 600523__:____:__
Asterisk__:__601939__:__PROTEIN KINASE, SERINE/ARGININE-SPECIFIC, 1; SRPK1__:__PROTEIN KINASE, ARGININE/SERINE-RICH SPLICING FACTOR, 1;; SFRS PROTEIN KINASE 1__:__
Asterisk__:__601940__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 4; SRSF4__:__SERINE/ARGININE-RICH SPLICING FACTOR 4;; SPLICING FACTOR, ARGININE/SERINE-RICH, 4; SFRS4;; SPLICING FACTOR, ARGININE/SERINE-RICH, 75-KD; SRp75__:__
Percent__:__601941__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 6; IDDM6__:__INSULIN-DEPENDENT DIABETES MELLITUS 6__:__AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 5, INCLUDED; AITD5, INCLUDED
Number Sign__:__601942__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 10; IDDM10__:__INSULIN-DEPENDENT DIABETES MELLITUS 10__:__
Asterisk__:__601943__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 9; SRSF9__:__SERINE/ARGININE-RICH SPLICING FACTOR 9;; SPLICING FACTOR, ARGININE/SERINE-RICH, 9; SFRS9;; SPLICING FACTOR, ARGININE/SERINE-RICH, 30-KD, C; SRp30c__:__
Asterisk__:__601944__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 6; SRSF6__:__SERINE/ARGININE-RICH SPLICING FACTOR 6;; SPLICING FACTOR, ARGININE/SERINE-RICH, 6; SFRS6;; SPLICING FACTOR, ARGININE/SERINE-RICH, 55-KD; SRp55__:__
Asterisk__:__601945__:__SPLICING FACTOR, SUPPRESSOR-OF-WHITE-APRICOT FAMILY; SFSWAP__:__SPLICING FACTOR, ARGININE/SERINE-RICH, 8; SFRS8;; SUPPRESSOR-OF-WHITE-APRICOT, DROSOPHILA, HOMOLOG OF; SWAP__:__
Caret__:__601946__:__MOVED TO 601531__:____:__
Asterisk__:__601947__:__SRY-BOX 12; SOX12__:__SRY-BOX 22; SOX22__:__
Caret__:__601948__:__MOVED TO 601784__:____:__
Asterisk__:__601949__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA-4 SUBUNIT; CACNB4__:____:__
Asterisk__:__601950__:__ZINC FINGER PROTEIN, MULTITYPE 1; ZFPM1__:__FRIEND OF GATA1; FOG;; FOG1__:__
Asterisk__:__601951__:__CDC-LIKE KINASE 1; CLK1__:__CLK;; CDC28/CDC2-LIKE KINASE;; PROTEIN-TYROSINE KINASE STY; STY;; CLK/STY__:__
Number Sign__:__601952__:__KERATOSIS LINEARIS WITH ICHTHYOSIS CONGENITA AND SCLEROSING KERATODERMA; KLICK__:__KLICK SYNDROME__:__
Asterisk__:__601953__:__CYCLIN H; CCNH__:__CDK-ACTIVATING KINASE;; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE; CAK__:__
Number Sign__:__601954__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 7; LGMDR7__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2G; LGMD2G__:__
Asterisk__:__601955__:__CYCLIN-DEPENDENT KINASE 7; CDK7__:__CELL DIVISION PROTEIN KINASE 7;; MO15, XENOPUS, HOMOLOG OF;; SERINE/THREONINE PROTEIN KINASE 1; STK1;; KINASE SUBUNIT OF CAK; CAK1__:__
Asterisk__:__601956__:__GDNF FAMILY RECEPTOR ALPHA-2; GFRA2__:__GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR BETA; GDNFRB__:__
NULL__:__601957__:__ODONTOTRICHOUNGUAL-DIGITAL-PALMAR SYNDROME__:__OTUDP SYNDROME__:__
Asterisk__:__601958__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA-3 SUBUNIT; CACNB3__:__CALCIUM CHANNEL, L TYPE, BETA-3 POLYPEPTIDE; CACNLB3__:__
Asterisk__:__601959__:__NEVER IN MITOSIS GENE A-RELATED KINASE 4; NEK4__:__NIMA-RELATED KINASE 4; NRK2;; SERINE/THREONINE PROTEIN KINASE 2; STK2__:__
Asterisk__:__601960__:__CHEMOKINE, CC MOTIF, LIGAND 20; CCL20__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 20; SCYA20;; EXODUS 1;; MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA; MIP3A;; LARC__:__
Asterisk__:__601961__:__PROTEIN ARGININE METHYLTRANSFERASE 2; PRMT2__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN METHYLTRANSFERASE 1-LIKE 1; HRMT1L1;; HMT1-LIKE 1__:__
Asterisk__:__601962__:__TAP-BINDING PROTEIN; TAPBP__:__TAPASIN; TPSN; TPN__:__
Asterisk__:__601963__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 1; TTC1__:__TPR1__:__
Asterisk__:__601964__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 7; DNAJC7__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 2; TTC2;; TPR2;; DJ11__:__
Asterisk__:__601965__:__SPHINGOSINE-1-PHOSPHATE RECEPTOR 3; S1PR3__:__ENDOTHELIAL DIFFERENTIATION GENE 3; EDG3;; S1P RECEPTOR 3; S1P3__:__
Asterisk__:__601966__:__REGULATORY SOLUTE CARRIER PROTEIN, FAMILY 1, MEMBER 1; RSC1A1__:__RS1__:__
Asterisk__:__601967__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 7B; WNT7B__:____:__
Asterisk__:__601968__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 2B; WNT2B__:__XWNT2, XENOPUS, HOMOLOG OF;; WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 13, FORMERLY; WNT13, FORMERLY__:__
Asterisk__:__601969__:__DELETED IN MALIGNANT BRAIN TUMORS 1; DMBT1__:__SURFACTANT, PULMONARY-ASSOCIATED PROTEIN D-BINDING PROTEIN;; GLYCOPROTEIN 340;; GP340__:__
Asterisk__:__601970__:__VASOACTIVE INTESTINAL PEPTIDE RECEPTOR 2; VIPR2__:____:__
Caret__:__601971__:__MOVED TO 600825__:____:__
Asterisk__:__601972__:__RAR-RELATED ORPHAN RECEPTOR B; RORB__:__RAR-RELATED ORPHAN RECEPTOR BETA;; RZR-BETA; RZRB;; RETINOIC ACID-BINDING RECEPTOR BETA__:__
Asterisk__:__601973__:__RETINOIC ACID RECEPTOR RESPONDER 2; RARRES2__:__TAZAROTENE-INDUCED GENE 2; TIG2;; CHEMERIN__:__
Asterisk__:__601974__:__SPHINGOSINE-1-PHOSPHATE RECEPTOR 1; S1PR1__:__ENDOTHELIAL DIFFERENTIATION GENE 1;; EDG1 S1P RECEPTOR 1; S1P1__:__
Asterisk__:__601975__:__PLAKOPHILIN 1; PKP1__:____:__
NULL__:__601976__:__OTOFACIOOSSEOUS-GONADAL SYNDROME__:____:__
Number Sign__:__601977__:__THROMBOCYTHEMIA 2; THCYT2__:____:__
Asterisk__:__601978__:__SIGMA NONOPIOID INTRACELLULAR RECEPTOR 1; SIGMAR1__:__SIGMA RECEPTOR, TYPE 1;; SR31747A-BINDING PROTEIN; SRBP__:__
NULL__:__601979__:__HYPERZINCEMIA WITH FUNCTIONAL ZINC DEPLETION__:____:__
Asterisk__:__601980__:__LIPASE, GASTRIC; LIPF__:__GASTRIC TRIACYLGLYCEROL LIPASE__:__
Asterisk__:__601981__:__RIBONUCLEASE, RNase A FAMILY, 6; RNASE6__:__RNase k6__:__
Asterisk__:__601982__:__8-OXOGUANINE DNA GLYCOSYLASE; OGG1__:__8-HYDROXYGUANINE DNA GLYCOSYLASE__:__
Asterisk__:__601983__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 1; MAP4K1__:__HEMATOPOIETIC PROGENITOR KINASE 1; HPK1__:__
Asterisk__:__601984__:__NUCLEAR RECEPTOR COACTIVATOR 4; NCOA4__:__RET-ACTIVATING GENE ELE1; ELE1;; ANDROGEN RECEPTOR COACTIVATOR, 70-KD; ARA70__:__PTC3 CHIMERIC ONCOGENE, INCLUDED
Asterisk__:__601985__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 6; CCDC6__:__H4 GENE;; D10S170;; TRANSFORMING SEQUENCE, THYROID 1; TST1__:__PTC1 CHIMERIC ONCOGENE, INCLUDED;; H4/RET FUSION GENE, INCLUDED;; H4/PDGFRB FUSION GENE, INCLUDED
Caret__:__601986__:__MOVED TO 601698__:____:__
Asterisk__:__601987__:__CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B__:__CPT IB;; CPT I, MUSCLE;; MCCPT1; MCPT1;; KIAA1670__:__
Asterisk__:__601988__:__LIM DOMAIN KINASE 2; LIMK2__:____:__
Asterisk__:__601989__:__S100 CALCIUM-BINDING PROTEIN A13; S100A13__:____:__
Asterisk__:__601990__:__TUMOR PROTEIN p73; TP73__:__p53-RELATED PROTEIN p73; p73;; TRP73, MOUSE, HOMOLOG OF__:__
Asterisk__:__601991__:__NEUROONCOLOGIC VENTRAL ANTIGEN 2; NOVA2__:__ASTROCYTIC NOVA1-LIKE GENE; ANOVA__:__
Percent__:__601992__:__FRIEDREICH ATAXIA 2; FRDA2__:____:__
Asterisk__:__601993__:__NUCLEAR RECEPTOR COACTIVATOR 2; NCOA2__:__GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1; GRIP1;; TRANSCRIPTIONAL INTERMEDIARY FACTOR 2; TIF2;; p160 STEROID RECEPTOR COACTIVATOR 2; SRC2__:__TIF2/MOZ FUSION GENE, INCLUDED
Asterisk__:__601994__:__TRANSFER RNA ARGININE__:__TRR__:__
Asterisk__:__601995__:__TENASCIN R; TNR__:__RESTRICTIN__:__
Caret__:__601996__:__MOVED TO 602026__:____:__
Asterisk__:__601997__:__BH3-INTERACTING DOMAIN DEATH AGONIST; BID__:____:__
Asterisk__:__601998__:__ESTROGEN-RELATED RECEPTOR, ALPHA; ESRRA__:__ESTROGEN RECEPTOR-LIKE 1; ESRL1;; ESTROGEN-RELATED RECEPTOR 1; ERR1__:__
Asterisk__:__601999__:__LIM HOMEOBOX GENE 1; LHX1__:__LIM1__:__
Asterisk__:__602000__:__POLYMERASE I, RNA, SUBUNIT B; POLR1B__:__RPA2;; RPA135;; RPO1-2__:__
Asterisk__:__602001__:__NEUROPEPTIDE Y RECEPTOR Y5; NPY5R__:____:__
Asterisk__:__602002__:__ZYXIN; ZYX__:____:__
Asterisk__:__602003__:__LYMPHOID-RESTRICTED MEMBRANE PROTEIN; LRMP__:__LYMPHOID PROTEIN OF ENDOPLASMIC RETICULUM;; JAW1__:__
Asterisk__:__602004__:__PROTEIN-TYROSINE KINASE 6; PTK6__:__BREAST TUMOR KINASE; BRK;; PROTEIN-TYROSINE KINASE BRK__:__
Asterisk__:__602005__:__SORTILIN-RELATED RECEPTOR; SORL1__:__SORLA1;; SORLA;; LR11__:__
Asterisk__:__602006__:__MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 2; MAPKAPK2__:__MAPKAP KINASE 2; MK2__:__
Asterisk__:__602007__:__V-CRK AVIAN SARCOMA VIRUS CT10 ONCOGENE HOMOLOG-LIKE; CRKL__:__ONCOGENE CRKL__:__
Asterisk__:__602008__:__IMPORTIN 5; IPO5__:__RAN-BINDING PROTEIN 5; RANBP5;; KARYOPHERIN BETA-3; KPNB3;; IMPORTIN BETA-3__:__
Asterisk__:__602009__:__CYTOCHROME c OXIDASE, SUBUNIT 6A2; COX6A2__:__CYTOCHROME c OXIDASE, SUBUNIT VIa, POLYPEPTIDE 2__:__
Asterisk__:__602010__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 11; SRSF11__:__SERINE/ARGININE-RICH SPLICING FACTOR 11;; SPLICING FACTOR, ARGININE/SERINE-RICH, 11; SFRS11;; SPLICING FACTOR, ARGININE/SERINE-RICH, 54-KD__:__
Asterisk__:__602011__:__SUPPRESSOR OF TUMORIGENICITY 11; ST11__:__PANCREATIC ENDOCRINE TUMOR SUPPRESSOR 1; PETS1__:__
Asterisk__:__602012__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 2; ENTPD2__:__CD39-LIKE 1; CD39L1__:__
Asterisk__:__602013__:__POLYMERASE II, RNA, SUBUNIT G; POLR2G__:__RPB7, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__602014__:__HYPOMAGNESEMIA 1, INTESTINAL; HOMG1__:__HOMG;; HYPOMAGNESEMIA WITH SECONDARY HYPOCALCEMIA; HSH;; HYPOMAGNESEMIC TETANY;; HYPOMAGNESEMIA, INTESTINAL, WITH SECONDARY HYPOCALCEMIA__:__
Asterisk__:__602015__:__OUTER DENSE FIBER OF SPERM TAILS 2; ODF2__:__OUTER DENSE FIBER OF SPERM TAILS, 84-KD; ODF84__:__CENEXIN 1, INCLUDED;; CENEXIN 1 VARIANT 1, INCLUDED
Asterisk__:__602016__:__KRUPPEL-LIKE FACTOR 2; KLF2__:__LUNG KRUPPEL-LIKE ZINC FINGER TRANSCRIPTION FACTOR; LKLF__:__
Asterisk__:__602017__:__PROTEASOME SUBUNIT, BETA-TYPE, 1; PSMB1__:__PROTEASOMAL SUBUNIT C5; HC5;; PROTEASOME SUBUNIT BETA-6__:__
Asterisk__:__602018__:__NEURTURIN; NRTN__:__NTN__:__
Asterisk__:__602019__:__SQUALENE EPOXIDASE; SQLE__:____:__
Asterisk__:__602020__:__V-MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE FAMILY, PROTEIN G; MAFG__:____:__
Asterisk__:__602021__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 12A; PPP1R12A__:__MYOSIN PHOSPHATASE TARGET SUBUNIT 1; MYPT1;; MYOSIN PHOSPHATASE, MYOSIN-BINDING SUBUNIT__:__
Asterisk__:__602022__:__MAL-LIKE; MALL__:__BENE PROTEIN; BENE__:__
Asterisk__:__602023__:__CHLORIDE CHANNEL, KIDNEY, B; CLCNKB__:__CLCKB__:__
Asterisk__:__602024__:__CHLORIDE CHANNEL, KIDNEY, A; CLCNKA__:__CLCK1__:__
Number Sign__:__602025__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 9; BMIQ9__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__602026__:__PHYTANOYL-CoA HYDROXYLASE; PHYH__:__PAHX;; LNAP1, MOUSE, HOMOLOG OF__:__
Asterisk__:__602027__:__TELOMERIC REPEAT-BINDING FACTOR 2; TERF2__:__TRF2__:__
Caret__:__602028__:__MOVED TO 601900__:____:__
Caret__:__602029__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__602030__:__FUCOSYLTRANSFERASE 7; FUT7__:____:__
Asterisk__:__602031__:__PROTEIN GERANYLGERANYLTRANSFERASE TYPE I, BETA SUBUNIT; PGGT1B__:____:__
Number Sign__:__602032__:__ECTODERMAL DYSPLASIA 4, HAIR/NAIL TYPE; ECTD4__:__ECTODERMAL DYSPLASIA, 'PURE' HAIR/NAIL TYPE__:__
Asterisk__:__602033__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 1; EML1__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE; EMAPL;; EMAP__:__
Asterisk__:__602034__:__CORTICOTROPIN-RELEASING HORMONE RECEPTOR 2; CRHR2__:__CORTICOTROPIN-RELEASING FACTOR RECEPTOR 2; CRFR2;; CRF2 RECEPTOR__:__
Asterisk__:__602035__:__PROTEIN PHOSPHATASE 4, CATALYTIC SUBUNIT; PPP4C__:__SERINE/THREONINE PROTEIN PHOSPHATASE 4; PP4;; PROTEIN PHOSPHATASE X; PPX__:__
Caret__:__602036__:__MOVED TO 133200__:____:__
Asterisk__:__602037__:__RAS HOMOLOG GENE FAMILY, MEMBER H; RHOH__:__ARHH;; TRANSLOCATION THREE FOUR; TTF__:__
Asterisk__:__602038__:__DUAL-SPECIFICITY PHOSPHATASE 8; DUSP8__:__H1 PHOSPHATASE, VACCINIA VIRUS, HOMOLOG OF; HVH5;; M3/6, MOUSE, HOMOLOG OF__:__
Asterisk__:__602039__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT A; EIF3A__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, THETA; EIF3-THETA;; EIF3, p180 SUBUNIT;; EIF3, p170 SUBUNIT;; CYTOPLASMIC PROTEIN p167;; CENTROSOMIN B, MOUSE, HOMOLOG OF;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 10, FORMERLY; EIF3S10, FORMERLY__:__
Asterisk__:__602040__:__CELL ADHESION MOLECULE, NEURAL, 2; NCAM2__:____:__
Asterisk__:__602041__:__NK3 HOMEOBOX 1; NKX3-1__:__NKX3.1, MOUSE, HOMOLOG OF;; NK HOMEOBOX, FAMILY 3, MEMBER A; NKX3A;; BAPX2__:__
Asterisk__:__602042__:__G PROTEIN-COUPLED RECEPTOR 18; GPR18__:____:__
Asterisk__:__602043__:__G PROTEIN-COUPLED RECEPTOR 31; GPR31__:__12-(S)-HYDROXYEICOSATETRAENOIC ACID RECEPTOR;; 12-(S)-HETE RECEPTOR;; 12-HETER__:__
Asterisk__:__602044__:__UNCOUPLING PROTEIN 3; UCP3__:____:__
Asterisk__:__602045__:__RING FINGER PROTEIN 1; RING1__:__RING1A;; RNF1__:__
Asterisk__:__602046__:__PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 3; PDIA3__:__GLUCOSE-REGULATED PROTEIN, 58-KD; GRP58;; ERp57;; ER60__:__
Asterisk__:__602047__:__PHOSPHODIESTERASE 3B, cGMP-INHIBITED; PDE3B__:__cAMP PHOSPHODIESTERASE, ADIPOCYTE, cGMP-INHIBITED;; HcGIP1, RAT, HOMOLOG OF__:__
Asterisk__:__602048__:__RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1; RAC1__:__RHO FAMILY, SMALL GTP-BINDING PROTEIN RAC1;; CED10, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__602049__:__RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 2; RAC2__:__RHO FAMILY, SMALL GTP-BINDING PROTEIN RAC2__:__
Asterisk__:__602050__:__RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 3; RAC3__:__RHO FAMILY, SMALL GTP-BINDING PROTEIN RAC3__:__
Asterisk__:__602051__:__PEPTIDYL-PROLYL CIS/TRANS ISOMERASE, NIMA-INTERACTING, 1-LIKE; PIN1L__:____:__
Asterisk__:__602052__:__CYCLIN G-ASSOCIATED KINASE; GAK__:____:__
Asterisk__:__602053__:__KRUPPEL-LIKE FACTOR 6; KLF6__:__B CELL-DERIVED 1; BCD1;; PROTOONCOGENE BCD1;; TRANSCRIPTION FACTOR ZF9; ZF9;; CORE PROMOTER ELEMENT-BINDING PROTEIN; COPEB__:__
Asterisk__:__602054__:__T-BOX 1; TBX1__:____:__
Asterisk__:__602055__:__INSULIN-INDUCED GENE 1; INSIG1__:__CL6, RAT, HOMOLOG OF__:__
Asterisk__:__602056__:__DEFENSIN, BETA, 1; DEFB1__:____:__
Caret__:__602057__:__MOVED TO 300256__:____:__
Asterisk__:__602058__:__PROTEASE INHIBITOR 10; PI10__:__BOMAPIN;; SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 10; SERPINB10__:__
Asterisk__:__602059__:__IMMUNOGLOBULIN SUPERFAMILY CONTAINING LEUCINE-RICH REPEAT; ISLR__:____:__
Asterisk__:__602060__:__TRANSMEMBRANE PROTEASE, SERINE 2; TMPRSS2__:____:__TMPRSS2/ERG FUSION GENE, INCLUDED;; TMPRSS2/ETV1 FUSION GENE, INCLUDED
Asterisk__:__602061__:__EPIREGULIN; EREG__:____:__
Asterisk__:__602062__:__NERVE INJURY-INDUCED PROTEIN 1; NINJ1__:__NINJURIN__:__
Asterisk__:__602063__:__TRANSALDOLASE 1; TALDO1__:____:__
Asterisk__:__602064__:__MYOINOSITOL MONOPHOSPHATASE 1; IMPA1__:__IMPase;; IMPA;; IMP__:__
Asterisk__:__602065__:__ADENOSINE DEAMINASE, RNA-SPECIFIC, B2; ADARB2__:__ADENOSINE DEAMINASE, RNA-SPECIFIC, 3; ADAR3;; RNA-EDITING ENZYME 2, RAT, HOMOLOG OF; RED2__:__
Number Sign__:__602066__:__CONVULSIONS, FAMILIAL INFANTILE, WITH PAROXYSMAL CHOREOATHETOSIS; ICCA__:__INFANTILE CONVULSIONS AND PAROXYSMAL CHOREOATHETOSIS, FAMILIAL;; ICCA SYNDROME;; PAROXYSMAL KINESIGENIC DYSKINESIA WITH INFANTILE CONVULSIONS; PKD/IC__:__
Caret__:__602067__:__MOVED TO 601419__:____:__
NULL__:__602068__:__LEISHMANIASIS, TEGUMENTARY, SUSCEPTIBILITY TO__:____:__
Asterisk__:__602069__:__NEUROPILIN 1; NRP1__:__NPN1; NP1;; NRP;; VASCULAR ENDOTHELIAL GROWTH FACTOR-165 RECEPTOR; VEGF165R;; BLOOD DENDRITIC CELL ANTIGEN 4; BDCA4__:__
Asterisk__:__602070__:__NEUROPILIN 2; NRP2__:__NPN2;; VASCULAR ENDOTHELIAL GROWTH FACTOR-165 RECEPTOR 2; VEGF165R2__:__
Percent__:__602071__:__BROAD TERMINAL PHALANGES, FAMILIAL__:____:__
Asterisk__:__602072__:__CYTOCHROME c OXIDASE, SUBUNIT 6A1; COX6A1__:__CYTOCHROME c OXIDASE, SUBUNIT VIa, POLYPEPTIDE 1;; COX6A, LIVER; COX6AL__:__
Caret__:__602073__:__MOVED TO 601533__:____:__
Asterisk__:__602074__:__DEATH-ASSOCIATED PROTEIN 3; DAP3__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S29; MRPS29__:__
Asterisk__:__602075__:__SPECIAL AT-RICH SEQUENCE-BINDING PROTEIN 1; SATB1__:____:__
Asterisk__:__602076__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 1; TRPV1__:__VANILLOID RECEPTOR 1; VR1;; CAPSAICIN RECEPTOR__:__
Caret__:__602077__:__MOVED TO 604292__:____:__
Number Sign__:__602078__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 2; CFEOM2__:__FEOM2 LOCUS;; FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, AUTOSOMAL RECESSIVE__:__
Number Sign__:__602079__:__TRIMETHYLAMINURIA; TMAU__:__FISH-ODOR SYNDROME__:__
Number Sign__:__602080__:__PAGET DISEASE OF BONE 2, EARLY-ONSET; PDB2__:____:__
Number Sign__:__602081__:__SPEECH-LANGUAGE DISORDER 1; SPCH1__:__CHILDHOOD APRAXIA OF SPEECH; CAS;; DEVELOPMENTAL VERBAL DYSPRAXIA; DVD;; SPEECH AND LANGUAGE DISORDER WITH OROFACIAL DYSPRAXIA__:__
Number Sign__:__602082__:__CORNEAL DYSTROPHY, THIEL-BEHNKE TYPE; CDTB__:__THIEL-BEHNKE CORNEAL DYSTROPHY; TBCD;; CORNEAL DYSTROPHY OF BOWMAN LAYER, TYPE II; CDB2;; CORNEAL DYSTROPHY, HONEYCOMB-SHAPED__:__
Number Sign__:__602083__:__USHER SYNDROME, TYPE IF; USH1F__:____:__
Caret__:__602084__:__MOVED TO 601728__:____:__
Percent__:__602085__:__POLYDACTYLY, POSTAXIAL, TYPE A2; PAPA2__:__POSTAXIAL POLYDACTYLY, TYPE A2__:__
Percent__:__602086__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 3; ARVD3__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 3; ARVC3__:__
Percent__:__602087__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 4; ARVD4__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 4; ARVC4__:__
Number Sign__:__602088__:__NEPHRONOPHTHISIS 2; NPHP2__:__NPH2__:__
Number Sign__:__602089__:__HEMANGIOMA, CAPILLARY INFANTILE__:__HCI;; HEMANGIOMA, HEREDITARY CAPILLARY__:__
Asterisk__:__602090__:__LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 3; LTBP3__:__LTBP2, FORMERLY__:__
Asterisk__:__602091__:__LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 2; LTBP2__:__LTBP3, FORMERLY__:__
Number Sign__:__602092__:__DEAFNESS, AUTOSOMAL RECESSIVE 18A; DFNB18A__:__DEAFNESS, AUTOSOMAL RECESSIVE 18; DFNB18__:__
Number Sign__:__602093__:__CONE DYSTROPHY 3; COD3__:__RETINAL CONE DYSTROPHY__:__CONE-ROD DYSTROPHY 14, INCLUDED; CORD14, INCLUDED
Caret__:__602094__:__MOVED TO 151660__:____:__
Asterisk__:__602095__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 4; SLC30A4__:__ZINC TRANSPORTER 4; ZNT4__:__
Percent__:__602096__:__ALZHEIMER DISEASE 5__:__AD5;; ALZHEIMER DISEASE, FAMILIAL, 5__:__
Percent__:__602097__:__USHER SYNDROME, TYPE IE; USH1E__:____:__
Asterisk__:__602098__:__POLO-LIKE KINASE 1; PLK1__:__POLO-LIKE KINASE; PLK;; SERINE/THREONINE PROTEIN KINASE 13; STPK13__:__
Number Sign__:__602099__:__AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE; ALS5__:____:__
Asterisk__:__602100__:__PBX/KNOTTED 1 HOMEOBOX 1; PKNOX1__:__PBX-REGULATING PROTEIN 1; PREP1__:__
Asterisk__:__602101__:__CLAUDIN 5; CLDN5__:__TRANSMEMBRANE PROTEIN DELETED IN VELOCARDIOFACIAL SYNDROME; TMVCF__:__
Asterisk__:__602102__:__SUPPRESSOR OF TY 5, S. CEREVISIAE, HOMOLOG OF; SUPT5H__:__CHROMATIN STRUCTURE REGULATOR, YEAST, HOMOLOG OF; SPT5__:__
Asterisk__:__602103__:__TRANSMEMBRANE PROTEIN 1; TMEM1__:__EPILEPSY HOLOPROSENCEPHALY CANDIDATE 1; EHOC1__:__
Asterisk__:__602104__:__SH3 DOMAIN-BINDING PROTEIN 2; SH3BP2__:____:__
Asterisk__:__602105__:__MutS, E. COLI, HOMOLOG OF, 4; MSH4__:____:__
Asterisk__:__602106__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 15; KCNJ15__:__KIR4.2__:__
NULL__:__602107__:__NEUROPATHY, HEREDITARY THERMOSENSITIVE__:____:__
Asterisk__:__602108__:__MATRILIN 2; MATN2__:____:__
Asterisk__:__602109__:__MATRILIN 3; MATN3__:____:__
Asterisk__:__602110__:__SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 2; SLC29A2__:__EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; ENT2;; HYDROPHOBIC NUCLEOLAR PROTEIN, 36-KD; HNP36;; DELAYED-EARLY RESPONSE GENE 12; DER12__:__
Number Sign__:__602111__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MISSOURI TYPE__:__SEMD, MISSOURI TYPE__:__METAPHYSEAL ANADYSPLASIA 1, INCLUDED; MANDP1, INCLUDED
Asterisk__:__602112__:__METALLOPHOSPHOESTERASE DOMAIN-CONTAINING PROTEIN 1; MPPED1__:__CHROMOSOME 22 OPEN READING FRAME 1; C22ORF1;; ADULT BRAIN PROTEIN 239; 239AB__:__
Asterisk__:__602113__:__LYSINE-SPECIFIC METHYLTRANSFERASE 2D; KMT2D__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA 2; MLL2;; MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA 4; MLL4;; ALL1-RELATED GENE; ALR__:__
NULL__:__602114__:__NEPHROPATHY, PROGRESSIVE TUBULOINTERSTITIAL, WITH CHOLESTATIC LIVER DISEASE__:____:__
Asterisk__:__602115__:__FIBROBLAST GROWTH FACTOR 10; FGF10__:____:__
Asterisk__:__602116__:__YEATS DOMAIN-CONTAINING PROTEIN 4; YEATS4__:__GLIOMA-AMPLIFIED SEQUENCE 41; GAS41__:__
Asterisk__:__602117__:__NECDIN; NDN__:____:__
Asterisk__:__602118__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 1; CHD1__:____:__
Asterisk__:__602119__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 2; CHD2__:____:__
Asterisk__:__602120__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 3; CHD3__:__Mi2-ALPHA__:__
Asterisk__:__602121__:__DIAPHANOUS, DROSOPHILA, HOMOLOG OF, 1; DIAPH1__:__DIA1__:__
Asterisk__:__602122__:__SIGNAL RECOGNITION PARTICLE, 72-KD; SRP72__:____:__
Asterisk__:__602123__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II-GAMMA; CAMK2G__:__CaM KINASE II GAMMA SUBUNIT;; CAMKG__:__
Percent__:__602124__:__DYSTONIA 7, TORSION; DYT7__:__TORSION DYSTONIA, FOCAL ADULT-ONSET__:__CERVICAL DYSTONIA, PRIMARY, INCLUDED
Asterisk__:__602125__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX10; COX10__:__COX10, S. CEREVISIAE, HOMOLOG OF;; HEME A:FARNESYLTRANSFERASE__:__
Asterisk__:__602126__:__ZINC FINGER PROTEIN 161, MOUSE, HOMOLOG OF; ZFP161__:__ZF5, MOUSE, HOMOLOG OF__:__
Asterisk__:__602127__:__SMOOTHELIN; SMTN__:____:__
Asterisk__:__602128__:__GROWTH ARREST-SPECIFIC 2-LIKE 1; GAS2L1__:__GAS2-RELATED ON CHROMOSOME 22;; GAR22__:__
Asterisk__:__602129__:__MYOSIN IXB; MYO9B__:__MYOSIN, RAT, HOMOLOG OF; MYR5__:__
Asterisk__:__602130__:__MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 3; MAPKAPK3__:__MAPKAP3;; MAPKAP KINASE 3; MK3;; 3PK__:__
Asterisk__:__602131__:__PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER 2; PHLDA2__:__TUMOR-SUPPRESSING SUBCHROMOSOMAL TRANSFERABLE FRAGMENT CANDIDATE GENE 3; TSSC3;; TUMOR-SUPPRESSING STF cDNA 3;; IMPRINTED IN PLACENTA AND LIVER; IPL;; BECKWITH-WIEDEMANN REGION 1C; BWR1C__:__
Asterisk__:__602132__:__CUTANEOUS T-CELL LYMPHOMA-ASSOCIATED ANTIGEN 5; CTAGE5__:__MENINGIOMA-EXPRESSED ANTIGEN; MGEA;; MENINGIOMA-EXPRESSED ANTIGEN 6; MGEA6; MEA6__:__
Asterisk__:__602133__:__PHOSPHORIBOSYLFORMYLGLYCINAMIDINE SYNTHASE; PFAS__:__PHOSPHORIBOSYLFORMYLGLYCINAMIDE AMIDOTRANSFERASE; FGARAT__:__
Percent__:__602134__:__TREMOR, HEREDITARY ESSENTIAL, 2; ETM2__:____:__
Asterisk__:__602135__:__DYNEIN, AXONEMAL, LIGHT INTERMEDIATE POLYPEPTIDE 1; DNALI1__:__INNER DYNEIN ARM, CHLAMYDOMONAS, HOMOLOG OF;; p28__:__
Asterisk__:__602136__:__PEROXISOME BIOGENESIS FACTOR 1; PEX1__:__PEROXIN 1__:__
Asterisk__:__602137__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 2; NDUFA2__:__B8 PROTEIN__:__
Asterisk__:__602138__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 6; NDUFA6__:____:__
Asterisk__:__602139__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 7; NDUFA7__:____:__
Asterisk__:__602140__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 8; NDUFB8__:____:__
Asterisk__:__602141__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 8; NDUFS8__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 23-KD SUBUNIT;; TYKY__:__
Asterisk__:__602142__:__PHOSPHOLIPASE C, DELTA-1; PLCD1__:____:__
Asterisk__:__602143__:__TUMOR PROTEIN p53-BINDING PROTEIN 2; TP53BP2__:__53BP2;; APOPTOSIS-STIMULATING PROTEIN OF p53, 2; ASPP2__:__
Asterisk__:__602144__:__BROMODOMAIN, TESTIS-SPECIFIC; BRDT__:____:__
Asterisk__:__602145__:__PROLIFERATION-ASSOCIATED 2G4, 38-KD; PA2G4__:__ERBB3-BINDING PROTEIN 1; EBP1__:__
Asterisk__:__602146__:__LIM HOMEOBOX GENE 4; LHX4__:____:__LHX4/IGHG1 FUSION GENE, INCLUDED
Caret__:__602147__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__602148__:__SRY-BOX 1; SOX1__:__SRY-RELATED HMG-BOX GENE 1__:__
Asterisk__:__602149__:__PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 1; PITX1__:__PITUITARY HOMEOBOX 1; PTX1;; BACKFOOT, MOUSE, HOMOLOG OF; BFT;; PITUITARY OTX-RELATED FACTOR; POTX__:__
Asterisk__:__602150__:__SNAIL, DROSOPHILA, HOMOLOG OF, 2; SNAI2__:__SLUG, CHICKEN, HOMOLOG OF; SLUG;; NEURAL CREST TRANSCRIPTION FACTOR SLUG__:__
Asterisk__:__602151__:__DISHEVELLED 2; DVL2__:____:__
Number Sign__:__602152__:__RHYNS SYNDROME; RHYNS__:__RETINITIS PIGMENTOSA SYNDROME;; RETINITIS PIGMENTOSA, HYPOPITUITARISM, NEPHRONOPHTHISIS, AND MILD SKELETAL DYSPLASIA__:__
Asterisk__:__602153__:__KERATIN 81, TYPE II; KRT81__:__K81;; KB21;; K2.9;; KERATIN, HAIR, BASIC, 1; KRTHB1;; KERATIN, HARD, TYPE II, 1; HB1__:__
Asterisk__:__602154__:__NONCODING TRANSCRIPT IN T CELLS__:__NTT__:__
Asterisk__:__602155__:__UBX DOMAIN PROTEIN 8; UBXN8__:__REPRODUCTION/CHROMOSOME 8; REP8;; D8S2298E__:__
Caret__:__602156__:__MOVED TO 601134__:____:__
Asterisk__:__602157__:__NEUROONCOLOGIC VENTRAL ANTIGEN 1; NOVA1__:__VENTRAL NEURON-SPECIFIC PROTEIN 1;; Ri ANTIGEN__:__
Asterisk__:__602158__:__CHLORIDE CHANNEL, NUCLEOTIDE SENSITIVE, 1A; CLNS1A__:__CHLORIDE CONDUCTANCE REGULATOR, VOLUME SENSITIVE; ICln__:__
Asterisk__:__602159__:__CORONIN 2A; CORO2A__:__CORONIN-LIKE PROTEIN B; CLIPINB;; WD REPEAT-CONTAINING PROTEIN 2; WDR2;; IR10__:__
Asterisk__:__602160__:__TRANSCRIPTION FACTOR DP2; TFDP2__:__E2F DIMERIZATION PARTNER 2; DP2__:__
Asterisk__:__602161__:__PROTEASOME ACTIVATOR SUBUNIT 2; PSME2__:__PROTEASOME ACTIVATOR 28-BETA;; PA28-BETA; PA28B;; MCP ACTIVATOR, 31-KD SUBUNIT__:__
Asterisk__:__602162__:__SYNAPTONEMAL COMPLEX PROTEIN 1; SYCP1__:__SCP1__:__
Asterisk__:__602163__:__UBIQUITIN-CONJUGATING ENZYME E2E 2; UBE2E2__:____:__
Asterisk__:__602164__:__5-HYDROXYTRYPTAMINE RECEPTOR 4; HTR4__:__SEROTONIN 5-HT-4 RECEPTOR;; SEROTONIN 5-HT-4A RECEPTOR;; CARDIAC 5-HT4 RECEPTOR__:__
Asterisk__:__602165__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 27; TRIM27__:__RET FINGER PROTEIN; RFP__:__
Asterisk__:__602166__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, BETA-2 SUBUNIT; AP3B2__:__ADAPTOR-RELATED PROTEIN COMPLEX 3B, NEURON-SPECIFIC, BETA-3B;; AP3B, BETA-3B;; NEURONAL ADAPTIN-LIKE PROTEIN, BETA SUBUNIT; NAPTB__:__
Asterisk__:__602167__:__ESTROGEN-RELATED RECEPTOR, BETA; ESRRB__:__ESTROGEN RECEPTOR-LIKE 2; ESRL2;; ESTROGEN-RELATED RECEPTOR 2; ERR2__:__
Asterisk__:__602168__:__VACCINIA-RELATED KINASE 1; VRK1__:__VACCINIA VIRUS B1R-RELATED KINASE 1__:__
Asterisk__:__602169__:__VACCINIA-RELATED KINASE 2; VRK2__:__VACCINIA VIRUS B1R-RELATED KINASE 2__:__
Asterisk__:__602170__:__MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88; MYD88__:____:__
Asterisk__:__602171__:__GLYCOPROTEIN A33; GPA33__:__CELL SURFACE ANTIGEN A33; A33__:__
Asterisk__:__602172__:__CYTOCHROME P450, SUBFAMILY VIIIB, POLYPEPTIDE 1; CYP8B1__:__CYP12;; STEROL 12-ALPHA-HYDROXYLASE__:__
Asterisk__:__602173__:__SEC62, S. CEREVISIAE, HOMOLOG OF; SEC62__:__TRANSLOCATION PROTEIN 1, DROSOPHILA, HOMOLOG OF; TLOC1;; HTP1__:__
Asterisk__:__602174__:__G PROTEIN-COUPLED RECEPTOR 25; GPR25__:____:__
Asterisk__:__602175__:__PROTEASOME SUBUNIT, BETA-TYPE, 2; PSMB2__:__PROTEASOME SUBUNIT BETA-4__:__
Asterisk__:__602176__:__PROTEASOME SUBUNIT, BETA-TYPE, 3; PSMB3__:__PROTEASOME SUBUNIT BETA-3__:__
Asterisk__:__602177__:__PROTEASOME SUBUNIT, BETA-TYPE, 4; PSMB4__:__PROTEASOME SUBUNIT BETA-7__:__
Asterisk__:__602178__:__CHONDROADHERIN; CHAD__:____:__
Asterisk__:__602179__:__HEAT-SHOCK 27-KD PROTEIN 2; HSPB2__:____:__
Asterisk__:__602180__:__SIGNAL-INDUCED PROLIFERATION-ASSOCIATED GENE 1; SIPA1__:__SPA1__:__
Asterisk__:__602181__:__STAPHYLOCOCCAL NUCLEASE DOMAIN- AND TUDOR DOMAIN-CONTAINING PROTEIN 1; SND1__:__TUDOR-SN; TSN;; EBNA2 COACTIVATOR p100; p100__:__
Asterisk__:__602182__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 3; ENPP3__:__PHOSPHODIESTERASE I/NUCLEOTIDE PYROPHOSPHATASE 3; PDNP3__:__
Asterisk__:__602183__:__NK3 HOMEOBOX 2; NKX3-2__:__BAGPIPE HOMEOBOX, DROSOPHILA, HOMOLOG OF, 1; BAPX1;; NKX3.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__602184__:__NADH-UBIQUINONE OXIDOREDUCTASE FLAVOPROTEIN 3; NDUFV3__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 10-KD SUBUNIT__:__
Caret__:__602185__:__MOVED TO 600004__:____:__
Asterisk__:__602186__:__VGF, NERVE GROWTH FACTOR-INDUCIBLE; VGF__:____:__NEUROENDOCRINE REGULATORY PEPTIDE 1, INCLUDED; NERP1, INCLUDED;; NEUROENDOCRINE REGULATORY PEPTIDE 2, INCLUDED; NERP2, INCLUDED
Asterisk__:__602187__:__ZINC FINGER PROTEIN 195; ZNF195__:____:__
Asterisk__:__602188__:__EPHRIN RECEPTOR EphA4; EPHA4__:__HEK8;; SEK, MOUSE, HOMOLOG OF;; TYRO1__:__
Asterisk__:__602189__:__REGULATOR OF G PROTEIN SIGNALING 3; RGS3__:____:__
Asterisk__:__602190__:__EPHRIN RECEPTOR EphA7; EPHA7__:__HEK11__:__
Asterisk__:__602191__:__E74-LIKE FACTOR 3; ELF3__:__ETS DOMAIN TRANSCRIPTION FACTOR, SERINE BOX; ESX;; EPITHELIUM-SPECIFIC ETS FACTOR 1; ESE1__:__
Asterisk__:__602192__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 10; ADAM10__:__AD10;; KUZBANIAN, DROSOPHILA, HOMOLOG OF; KUZ__:__
Asterisk__:__602193__:__SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 1; SLC29A1__:__EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ENT1__:__
Asterisk__:__602194__:__HTRA SERINE PEPTIDASE 1; HTRA1__:__HtrA, E. COLI, HOMOLOG OF; HTRA;; PROTEASE, SERINE, 11; PRSS11__:__
Asterisk__:__602195__:__HEAT-SHOCK 27-KD PROTEIN 1; HSPB1__:__HEAT-SHOCK PROTEIN 27; HSP27__:__
Percent__:__602196__:__PIERRE ROBIN SEQUENCE WITH PECTUS EXCAVATUM AND RIB AND SCAPULAR ANOMALIES__:__SKELETAL DYSPLASIA RELATED TO CAMPOMELIC DYSPLASIA;; CAMPOMELIC DYSPLASIA, MILD__:__
NULL__:__602197__:__CEREBELLAR DEGENERATION-RELATED AUTOANTIGEN 3__:__CDR3__:__
Asterisk__:__602198__:__CDK2-ASSOCIATED PROTEIN 1; CDK2AP1__:__DELETED IN ORAL CANCER 1; DOC1__:__
Percent__:__602199__:__MEDIUM CHAIN 3-KETOACYL-CoA THIOLASE DEFICIENCY__:__MCKAT DEFICIENCY__:__
Percent__:__602200__:__VENTRICULOMEGALY WITH DEFECTS OF THE RADIUS AND KIDNEY__:____:__
Asterisk__:__602201__:__EXTRACELLULAR MATRIX PROTEIN 1; ECM1__:____:__
Asterisk__:__602202__:__DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE-PROTEIN GLYCOSYLTRANSFERASE; DDOST__:__OLIGOSACCHARYLTRANSFERASE; OST;; OLIGOSACCHARYLTRANSFERASE, 48-KD; OST48__:__
Asterisk__:__602203__:__SARCOLIPIN; SLN__:____:__
Asterisk__:__602204__:__BICAUDAL D, DROSOPHILA, HOMOLOG OF, 1; BICD1__:____:__
Caret__:__602205__:__MOVED TO 601805__:____:__
Asterisk__:__602206__:__RAS-ASSOCIATED PROTEIN RAB17; RAB17__:____:__
Asterisk__:__602207__:__RAS-ASSOCIATED PROTEIN RAB18; RAB18__:____:__
Asterisk__:__602208__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 10; KCNJ10__:__GLIAL INWARDLY RECTIFYING POTASSIUM CHANNEL Kir4.1__:__
Asterisk__:__602209__:__RAS-RESPONSIVE ELEMENT BINDING PROTEIN 1; RREB1__:____:__
Asterisk__:__602210__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT E; EIF3E__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, 48-KD; EIF3-p48;; ONCOGENE INT6; INT6;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 6, FORMERLY; EIF3S6, FORMERLY__:__MOUSE MAMMARY TUMOR VIRUS INTEGRATION SITE 6, INCLUDED
Asterisk__:__602211__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 17; FKHL17__:__FORKHEAD-RELATED ACTIVATOR 9; FREAC9__:__
Asterisk__:__602212__:__SIAH E3 UBIQUITIN PROTEIN LIGASE FAMILY, MEMBER 1; SIAH1__:__SEVEN IN ABSENTIA, DROSOPHILA, HOMOLOG OF, 1__:__
Asterisk__:__602213__:__SIAH E3 UBIQUITIN PROTEIN LIGASE FAMILY, MEMBER 2; SIAH2__:__SEVEN IN ABSENTIA, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__602214__:__CASEIN KINASE I, GAMMA-2; CSNK1G2__:____:__
Asterisk__:__602215__:__DEFENSIN, BETA, 4A; DEFB4A__:__HBD2;; DEFENSIN, BETA, 4, FORMERLY; DEFB4, FORMERLY;; DEFENSIN, BETA, 2, FORMERLY; DEFB2, FORMERLY__:__
Asterisk__:__602216__:__SERINE/THREONINE PROTEIN KINASE 11; STK11__:__LKB1__:__
Asterisk__:__602217__:__SYNDECAN-BINDING PROTEIN; SDCBP__:__SYNTENIN;; PRO-TGF-ALPHA CYTOPLASMIC DOMAIN-INTERACTING PROTEIN 18; TACIP18;; MELANOMA DIFFERENTIATION-ASSOCIATED GENE 9; MDA9__:__
Asterisk__:__602218__:__SAL-LIKE 1; SALL1__:__HSAL1__:__
Asterisk__:__602219__:__SAL-LIKE 2; SALL2__:__HSAL2__:__
Asterisk__:__602220__:__RAS-LIKE, FAMILY 10, MEMBER A; RASL10A__:__RAS-RELATED ON CHROMOSOME 22; RRP22__:__
Asterisk__:__602221__:__ZINC FINGER, MYM-TYPE 2; ZMYM2__:__ZINC FINGER PROTEIN 198; ZNF198;; REARRANGED IN ATYPICAL MYELOPROLIFERATIVE DISORDER; RAMP;; FUSED IN MYELOPROLIFERATIVE DISORDERS; FIM__:__ZNF198/FGFR1 FUSION GENE, INCLUDED
Caret__:__602222__:__MOVED TO 602022__:____:__
Asterisk__:__602223__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E-BINDING PROTEIN 1; EIF4EBP1__:__4EBP1__:__
Asterisk__:__602224__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E-BINDING PROTEIN 2; EIF4EBP2__:__4EBP2__:__
Asterisk__:__602225__:__CONE-ROD HOMEOBOX-CONTAINING GENE; CRX__:____:__
Asterisk__:__602226__:__CD180 MOLECULE; CD180__:__CD180 ANTIGEN;; LYMPHOCYTE ANTIGEN 64, RADIOPROTECTIVE, 105-KD; LY64;; RP105, MOUSE, HOMOLOG OF__:__
Asterisk__:__602227__:__CHEMOKINE, CC MOTIF, LIGAND 19; CCL19__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 19; SCYA19;; EBI1-LIGAND CHEMOKINE; ELC;; MACROPHAGE INFLAMMATORY PROTEIN 3-BETA; MIP3B;; EXODUS 3__:__
Asterisk__:__602228__:__TRANSCRIPTION FACTOR 7-LIKE 2; TCF7L2__:__T-CELL TRANSCRIPTION FACTOR 4, FORMERLY; TCF4, FORMERLY__:__TCF7L2/VTI1A FUSION GENE, INCLUDED
Asterisk__:__602229__:__SRY-BOX 10; SOX10__:__SRY-RELATED HMG-BOX GENE 10;; DOMINANT MEGACOLON, MOUSE, HOMOLOG OF; DOM__:__
Asterisk__:__602230__:__SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH PROTEIN; SH3BGR__:____:__
Asterisk__:__602231__:__SMALL UBIQUITIN-LIKE MODIFIER 3; SUMO3__:__SMT3, YEAST, HOMOLOG 1; SMT3H1;; SMT3A__:__
Asterisk__:__602232__:__POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 3; KCNQ3__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY Q, MEMBER 3__:__
Asterisk__:__602233__:__APOPTOTIC PROTEASE ACTIVATING FACTOR 1; APAF1__:____:__
Asterisk__:__602234__:__CASPASE 9, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP9__:__APOPTOTIC PROTEASE ACTIVATING FACTOR 3; APAF3__:__
Asterisk__:__602235__:__POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 2; KCNQ2__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY Q, MEMBER 2__:__
Caret__:__602236__:__MOVED TO 601880__:____:__
Caret__:__602237__:__MOVED TO 601470__:____:__
Asterisk__:__602238__:__EXOSOME COMPONENT 2; EXOSC2__:__RIBOSOMAL RNA-PROCESSING PROTEIN 4, S. CEREVISIAE, HOMOLOG OF; RRP4__:__
Asterisk__:__602239__:__CYTOCHROME P450, SUBFAMILY XXVIA, POLYPEPTIDE 1; CYP26A1__:__P450, RETINOIC ACID-INACTIVATING, 1; P450RAI1__:__
Asterisk__:__602240__:__ZINC FINGER PROTEIN 192; ZNF192__:____:__
Asterisk__:__602241__:__MITOCHONDRIAL INTERMEDIATE PEPTIDASE; MIPEP__:____:__
Asterisk__:__602242__:__ADAPTOR-RELATED PROTEIN COMPLEX 2, SIGMA-1 SUBUNIT; AP2S1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, SMALL 2, 17-KD; CLAPS2;; CLATHRIN ADAPTOR PROTEIN AP17; AP17;; CLATHRIN ADAPTOR COMPLEX AP2, SIGMA SUBUNIT__:__
Asterisk__:__602243__:__CD151 ANTIGEN; CD151__:__PLATELET-ENDOTHELIAL CELL TETRASPANIN ANTIGEN 3; PETA3;; SFA1;; RED BLOOD CELL ANTIGEN MER 2; MER2__:__
Asterisk__:__602244__:__DEOXYRIBONUCLEASE I-LIKE 3; DNASE1L3__:____:__
Asterisk__:__602245__:__GTP-BINDING PROTEIN 1; GTPBP1__:__GP1__:__
Asterisk__:__602246__:__ZINC FINGER PROTEIN 193; ZNF193__:____:__
Percent__:__602247__:__XANTHOMATOSIS, SUSCEPTIBILITY TO__:____:__
Percent__:__602248__:__MALIGNANT ATROPHIC PAPULOSIS__:__DEGOS DISEASE;; PAPULOSIS, MALIGNANT ATROPHIC__:__
NULL__:__602249__:__PROGEROID FACIAL APPEARANCE WITH HAND ANOMALIES__:____:__
Asterisk__:__602250__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9; TNFRSF9__:__INDUCED BY LYMPHOCYTE ACTIVATION; ILA;; CD137;; Ly63, MOUSE, HOMOLOG OF;; 4-1BB, MOUSE, HOMOLOG OF__:__
Asterisk__:__602251__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 10, YEAST, HOMOLOG OF; TIMM10__:__TIM10;; TIM10A__:__
NULL__:__602252__:__MITOCHONDRIAL INTERMEMBRANE SPACE PROTEIN TIM12, YEAST, HOMOLOG OF__:____:__
Asterisk__:__602253__:__KRUPPEL-LIKE FACTOR 4; KLF4__:__ENDOTHELIAL KRUPPEL-LIKE ZINC FINGER PROTEIN; EZF;; GUT-ENRICHED KRUPPEL-LIKE FACTOR; GKLF__:__
Asterisk__:__602254__:__SRR1 DOMAIN-CONTAINING PROTEIN; SRRD__:__HEPATOCELLULAR CARCINOMA COMPLICATING HEMOCHROMATOSIS;; HC/HCC__:__
Asterisk__:__602255__:__SERINE/THREONINE PROTEIN KINASE 25; STK25__:__STERILE 20/OXIDANT STRESS-RESPONSE KINASE 1; SOK1;; YEAST SPS1/STE20-RELATED KINASE 1; YSK1__:__
Asterisk__:__602256__:__PROTEIN PHOSPHATASE, EF-HAND CALCIUM-BINDING DOMAIN 2; PPEF2__:____:__
Asterisk__:__602257__:__SCAVENGER RECEPTOR CLASS B, MEMBER 2; SCARB2__:__CD36 ANTIGEN-LIKE 2; CD36L2;; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN II; LIMPII; LIMP2__:__
Caret__:__602258__:__MOVED TO 601040__:____:__
Asterisk__:__602259__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 3; TTC3__:__TETRATRICOPEPTIDE REPEAT DOMAIN IN THE DOWN SYNDROME REGION; TPRD;; DCRR1__:__
Asterisk__:__602260__:__PERIOD, DROSOPHILA, HOMOLOG OF; PER1__:__RIGUI;; PER__:__PER1/ETV6 FUSION GENE, INCLUDED
Asterisk__:__602261__:__MATRIX METALLOPROTEINASE 15; MMP15__:__MATRIX METALLOPROTEINASE 15, MEMBRANE-TYPE;; MEMBRANE-TYPE MATRIX METALLOPROTEINASE 2; MT2-MMP__:__
Asterisk__:__602262__:__MATRIX METALLOPROTEINASE 16; MMP16__:__MATRIX METALLOPROTEINASE 16, MEMBRANE-TYPE;; MEMBRANE-TYPE MATRIX METALLOPROTEINASE 3; MT3-MMP__:__
Caret__:__602263__:__MOVED TO 601807__:____:__
Asterisk__:__602264__:__SPARC/OSTEONECTIN, CWCV, AND KAZAL-LIKE DOMAINS PROTEOGLYCAN; SPOCK1__:__SPOCK;; TESTICAN__:__
Asterisk__:__602265__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 9; NEDD9__:__HUMAN ENHANCER OF FILAMENTATION 1; HEF1;; CRK-ASSOCIATED SUBSTRATE-RELATED PROTEIN; CASL__:__
Caret__:__602266__:__MOVED TO 300135__:____:__
Asterisk__:__602267__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 8; ADAM8__:__HUMAN LEUKOCYTE DIFFERENTIATION ANTIGEN; CD156__:__
Asterisk__:__602268__:__AMINE OXIDASE, COPPER-CONTAINING, 2; AOC2__:__RETINA-SPECIFIC AMINE OXIDASE; RAO__:__
Asterisk__:__602269__:__ARMADILLO REPEAT GENE DELETED IN VCFS; ARVCF__:____:__
Asterisk__:__602270__:__ANTIOXIDANT PROTEIN 1; ATOX1__:__ATX, YEAST, HOMOLOG OF, 1; HAH1__:__
Number Sign__:__602271__:__SPONDYLOMETAPHYSEAL DYSPLASIA, AXIAL; SMDAX__:__SMD, AXIAL;; AXIAL SMD__:__
Asterisk__:__602272__:__TRANSCRIPTION FACTOR 4; TCF4__:__IMMUNOGLOBULIN TRANSCRIPTION FACTOR 2; ITF2;; SEF2-1B;; SEF2;; E2-2__:__
Asterisk__:__602273__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 1; GALNT1__:__GalNAc TRANSFERASE 1; GalNAcT1__:__
Asterisk__:__602274__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 2; GALNT2__:__GalNAc TRANSFERASE 2; GalNAcT2__:__
Asterisk__:__602275__:__GUANYLATE CYCLASE ACTIVATOR 1B; GUCA1B__:__GUANYLATE CYCLASE-ACTIVATING PROTEIN, PHOTORECEPTOR 2; GCAP2;; GUANYLIN 2, RETINA; GUCA2__:__
Asterisk__:__602276__:__TRANSCRIPTIONAL ADAPTOR 2A; TADA2A__:__TRANSCRIPTIONAL ADAPTOR 2-LIKE; TADA2L;; ADA2, YEAST, HOMOLOG OF, ALPHA;; ADA2-ALPHA; ADA2A__:__
Asterisk__:__602277__:__ZINC FINGER PROTEIN 184; ZNF184__:____:__
Asterisk__:__602278__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 4; NEDD4__:__KIAA0093__:__
Asterisk__:__602279__:__POLYADENYLATE-BINDING PROTEIN, NUCLEAR, 1; PABPN1__:__POLYADENYLATE-BINDING PROTEIN 2; PABP2; PAB2;; POLY(A)-BINDING PROTEIN 2__:__
Asterisk__:__602280__:__TUBBY-LIKE PROTEIN 1; TULP1__:____:__
Asterisk__:__602281__:__MILK FAT GLOBULE-EGF FACTOR 8; MFGE8__:__LACTADHERIN;; SECRETED EGF REPEAT AND DISCOIDIN DOMAINS-CONTAINING PROTEIN 1; SED1__:__MEDIN, INCLUDED
Asterisk__:__602282__:__LYSOPHOSPHATIDIC ACID RECEPTOR 1; LPAR1__:__ENDOTHELIAL DIFFERENTIATION GENE 2; EDG2;; LYSOPHOSPHATIDIC ACID RECEPTOR EDG2;; LPA RECEPTOR EDG2;; LPA1;; VENTRICULAR ZONE GENE 1; VZG1__:__
Asterisk__:__602283__:__CHEMOKINE, CC MOTIF, LIGAND 8; CCL8__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 8; SCYA8;; MONOCYTE CHEMOTACTIC PROTEIN 2; MCP2__:__
Asterisk__:__602284__:__BONE MORPHOGENETIC PROTEIN 8B; BMP8B__:__BMP8;; OSTEOGENIC PROTEIN 2; OP2__:__
Asterisk__:__602285__:__MATRIX METALLOPROTEINASE 17; MMP17__:__MATRIX METALLOPROTEINASE 17, MEMBRANE-TYPE;; MEMBRANE-TYPE MATRIX METALLOPROTEINASE 4; MT4-MMP__:__
Asterisk__:__602286__:__STEROL C5-DESATURASE-LIKE; SC5DL__:__STEROL C5-DESATURASE; SC5D;; 3-BETA-HYDROXYSTEROID-DELTA-5-DESATURASE;; DELTA-5-DESATURASE;; LATHOSTEROL DEHYDROGENASE;; ERG3, CANDIDA GLABRATA, HOMOLOG OF__:__
Asterisk__:__602287__:__ENDOPLASMIC RETICULUM PROTEIN, 29-KD; ERP29__:__CHROMOSOME 12 OPEN READING FRAME 8; C12ORF8;; ERp29;; ERP28__:__
Asterisk__:__602288__:__RHOTEKIN; RTKN__:____:__
Asterisk__:__602289__:__DR1-ASSOCIATED PROTEIN 1; DRAP1__:__NEGATIVE COFACTOR 2-ALPHA;; NC2-ALPHA__:__
Asterisk__:__602290__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 32; TRIM32__:__TAT-INTERACTING PROTEIN, 72-KD;; HT2A;; BBS11 GENE; BBS11__:__
Asterisk__:__602291__:__FORKHEAD BOX J1; FOXJ1__:__FORKHEAD, DROSOPHILA, HOMOLOG OF, 13; FKHL13;; HFH4__:__
Asterisk__:__602292__:__ENOYL-CoA HYDRATASE, SHORT-CHAIN, 1, MITOCHONDRIAL; ECHS1__:__SHORT-CHAIN ENOYL-CoA HYDRATASE; SCEH__:__
Asterisk__:__602293__:__CALCIUM- AND INTEGRIN-BINDING PROTEIN 1; CIB1__:__CIB;; KINASE-INTERACTING PROTEIN 1; KIP1;; KIP;; CALMYRIN__:__
Asterisk__:__602294__:__FORKHEAD BOX A1; FOXA1__:__HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HNF3A__:__
Asterisk__:__602295__:__FORKHEAD BOX A3; FOXA3__:__HEPATOCYTE NUCLEAR FACTOR 3-GAMMA; HNF3G__:__
Asterisk__:__602296__:__ADAPTOR-RELATED PROTEIN COMPLEX 4, MU-1 SUBUNIT; AP4M1__:__MU-ADAPTIN-RELATED PROTEIN 2;; MU-ARP2__:__
Asterisk__:__602297__:__EPHRIN B3; EFNB3__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 8; EPLG8;; LIGAND OF EPH-RELATED KINASE 8; LERK8;; EFL6__:__
Asterisk__:__602298__:__RAS-ASSOCIATED PROTEIN RAB7; RAB7__:____:__
Caret__:__602299__:__MOVED TO 300284__:____:__
Asterisk__:__602300__:__GALACTOSE-3-O-SULFOTRANSFERASE 1; GAL3ST1__:__CEREBROSIDE SULFOTRANSFERASE; CST;; 3-PRIME-PHOSPHOADENYLYLSULFATE:GALACTOSYLCERAMIDE 3-PRIME-SULFOTRANSFERASE;; GalCer SULFOTRANSFERASE;; GALACTOSYLCERAMIDE 3-PRIME SULFOTRANSFERASE__:__
Asterisk__:__602301__:__LYSINE ACETYLTRANSFERASE 2A; KAT2A__:__GCN5;; GENERAL CONTROL OF AMINO ACID SYNTHESIS, YEAST, HOMOLOG-LIKE 2; GCN5L2__:__
Asterisk__:__602302__:__HAIRLESS, MOUSE, HOMOLOG OF; HR__:____:__
Asterisk__:__602303__:__LYSINE ACETYLTRANSFERASE 2B; KAT2B__:__CREBBP-ASSOCIATED FACTOR; CAF;; p300/CBP-ASSOCIATED FACTOR; PCAF;; P/CAF__:__
Asterisk__:__602304__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 2; NR1D2__:__REV-ERBA-ALPHA-RELATED RECEPTOR; RVR;; REV-ERBA-BETA;; REV-ERB-BETA;; BD73__:__
Caret__:__602305__:__MOVED TO 602162__:____:__
Asterisk__:__602306__:__RAL GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR-LIKE 2; RGL2__:__RAS-ASSOCIATED PROTEIN RAB2L; RAB2L__:__
Asterisk__:__602307__:__WW DOMAIN-CONTAINING PROTEIN 1; WWP1__:__WW DOMAIN-CONTAINING E3 UBIQUITIN PROTEIN LIGASE 1;; TGIF-INTERACTING UBIQUITIN LIGASE 1; TIUL1__:__
Asterisk__:__602308__:__WW DOMAIN-CONTAINING PROTEIN 2; WWP2__:__WW DOMAIN-CONTAINING E3 UBIQUITIN PROTEIN LIGASE 2__:__
Asterisk__:__602309__:__TUBBY-LIKE PROTEIN 2; TULP2__:____:__
Asterisk__:__602310__:__RNA-BINDING MOTIF PROTEIN, SINGLE STRAND-INTERACTING, 1; RBMS1__:__MYC SINGLE-STRAND BINDING PROTEIN; MSSP;; SCR2__:__
Asterisk__:__602311__:__AGOUTI-RELATED PROTEIN, MOUSE, HOMOLOG OF; AGRP__:__AGOUTI-RELATED TRANSCRIPT, MOUSE, HOMOLOG OF; AGRT; ART__:__
Caret__:__602312__:__MOVED TO 142711__:____:__
Asterisk__:__602313__:__OVO-LIKE 1; OVOL1__:__OVO, DROSOPHILA, HOMOLOG OF, 1__:__
Asterisk__:__602314__:__LADININ 1; LAD1__:__LINEAR IgA DISEASE ANTIGEN__:__
Asterisk__:__602315__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 3; MAP2K3__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 3; PRKMK3;; MKK3; MAPKK3;; MAPK/ERK KINASE 3; MEK3__:__
Asterisk__:__602316__:__PEROXIREDOXIN 6; PRDX6__:__PHOSPHOLIPASE A2, LYSOSOMAL__:__
Asterisk__:__602317__:__SH3 AND CYSTEINE-RICH DOMAINS 1; STAC1__:__STAC__:__
Asterisk__:__602318__:__TRANSCRIPTION TERMINATION FACTOR 1, MITOCHONDRIAL; MTERF1__:__MTERF__:__
Asterisk__:__602319__:__NEL-LIKE 1; NELL1__:____:__
Asterisk__:__602320__:__NEL-LIKE 2; NELL2__:____:__
Asterisk__:__602321__:__GLUTATHIONE S-TRANSFERASE, KAPPA-1; GSTK1__:__GLUTATHIONE S-TRANSFERASE K1;; GST13-13, RAT, HOMOLOG OF__:__
Asterisk__:__602322__:__TELOMERASE RNA COMPONENT; TERC__:__TELOMERASE RNA CANDIDATE 3; TRC3;; TR__:__
Asterisk__:__602323__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 12; KCNJ12__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, INHIBITOR 1; KCNJN1;; INWARDLY RECTIFYING POTASSIUM CHANNEL Kir2.2__:__
Asterisk__:__602324__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H3; HNRNPH3__:__HNRPH3;; 2H9__:__
Asterisk__:__602325__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4-GAMMA, 2; EIF4G2__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4G-LIKE 1;; p97;; DEATH-ASSOCIATED PROTEIN 5; DAP5__:__
Asterisk__:__602326__:__RIBOSOMAL PROTEIN L23A; RPL23A__:____:__
Asterisk__:__602327__:__PLECKSTRIN AND SEC7 DOMAINS-CONTAINING PROTEIN; PSD__:__TYL;; EXCHANGE FACTOR FOR ARF6; EFA6;; EFA6A__:__
Caret__:__602328__:__MOVED TO 300118__:____:__
Asterisk__:__602329__:__SUPPRESSOR OF LIN12-LIKE; SEL1L__:__SEL1-LIKE__:__
Asterisk__:__602330__:__ACTIN-BINDING LIM PROTEIN FAMILY, MEMBER 1; ABLIM1__:__ABLIM;; LIM ACTIN-BINDING PROTEIN 1; LIMAB1;; LIMATIN__:__
Asterisk__:__602331__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 5, S. CEREVISIAE, HOMOLOG OF; ORC5__:__ORC5-LIKE; ORC5L__:__
Asterisk__:__602332__:__NON-SMC CONDENSIN I COMPLEX SUBUNIT H; NCAPH__:__CONDENSIN I COMPLEX, NON-SMC SUBUNIT H;; CHROMOSOME-ASSOCIATED PROTEIN H; CAPH;; BARREN, DROSOPHILA, HOMOLOG OF, 1; BRRN1__:__
Asterisk__:__602333__:__EPITHELIAL MEMBRANE PROTEIN 1; EMP1__:__TUMOR-ASSOCIATED MEMBRANE PROTEIN; TMP__:__
Asterisk__:__602334__:__EPITHELIAL MEMBRANE PROTEIN 2; EMP2__:____:__
Asterisk__:__602335__:__EPITHELIAL MEMBRANE PROTEIN 3; EMP3__:____:__
Asterisk__:__602336__:__RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 1; ROR1__:__NEUROTROPHIC TYROSINE KINASE, RECEPTOR-RELATED 1; NTRKR1__:__
Asterisk__:__602337__:__RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 2; ROR2__:__NEUROTROPHIC TYROSINE KINASE, RECEPTOR-RELATED 2; NTRKR2__:__
Asterisk__:__602338__:__PRECURSOR mRNA-PROCESSING FACTOR 4, S. POMBE, HOMOLOG OF, B; PRPF4B__:__PRP4, YEAST, HOMOLOG OF__:__
Asterisk__:__602339__:__SOLUTE CARRIER FAMILY 15 (H+/PEPTIDE TRANSPORTER), MEMBER 2; SLC15A2__:__HYDROGEN ION/PEPTIDE COTRANSPORTER, KIDNEY; PEPT2__:__
NULL__:__602340__:__SENSORINEURAL HEARING LOSS, RETINAL PIGMENT EPITHELIUM LESIONS, DISCOLORED TEETH__:____:__
Asterisk__:__602341__:__FORKHEAD BOX M1; FOXM1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 16; FKHL16;; FORKHEAD BOX M1B TRANSCRIPTION FACTOR; FOXM1B;; HFH11;; TRIDENT__:__
Number Sign__:__602342__:__PIERPONT SYNDROME; PRPTS__:__PLANTAR LIPOMATOSIS, UNUSUAL FACIES, AND DEVELOPMENTAL DELAY__:__
Asterisk__:__602343__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 1; TRPC1__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 1;; TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 1; TRP1__:__
Asterisk__:__602344__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE 2; PAFAH2__:____:__
Asterisk__:__602345__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 3; TRPC3__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 3;; TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 3; TRP3__:__
Asterisk__:__602346__:__CONTACTIN-ASSOCIATED PROTEIN 1; CNTNAP1__:__CONTACTIN-ASSOCIATED PROTEIN; CASPR;; CONTACTIN-ASSOCIATED TRANSMEMBRANE RECEPTOR;; p190;; NEUREXIN IV; NRXN4;; PARANODIN;; NCP1__:__
Number Sign__:__602347__:__CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 3; PFIC3__:__MDR3 DEFICIENCY;; CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, WITH ELEVATED SERUM GAMMA-GLUTAMYLTRANSFERASE__:__
Asterisk__:__602348__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, POLYPEPTIDE 3; SNAPC3__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, 50-KD SUBUNIT; SNAP50;; PSE-BINDING TRANSCRIPTION FACTOR, BETA;; PTF-BETA__:__
Asterisk__:__602349__:__NETRIN 3; NTN3__:__NETRIN 2, CHICKEN, HOMOLOG-LIKE; NTN2L__:__
Asterisk__:__602350__:__NEUROGRANIN; NRGN__:__PROTEIN KINASE C SUBSTRATE RC3__:__
Asterisk__:__602351__:__CHEMOKINE-LIKE RECEPTOR 1; CMKLR1__:__CHEMR23;; CHEMERIN RECEPTOR; CHEMERINR__:__
Asterisk__:__602352__:__GONADOTROPIN-RELEASING HORMONE 2; GNRH2__:____:__
Asterisk__:__602353__:__TRANSFORMING GROWTH FACTOR, BETA-1-INDUCED 1; TGFB1I1__:__TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 55-KD;; ANDROGEN RECEPTOR COACTIVATOR; ARA55;; HIC5__:__
Asterisk__:__602354__:__LINKER FOR ACTIVATION OF T CELLS; LAT__:____:__
Asterisk__:__602355__:__TNF RECEPTOR-ASSOCIATED FACTOR 6; TRAF6__:____:__
Asterisk__:__602356__:__TNF RECEPTOR-ASSOCIATED FACTOR 5; TRAF5__:____:__
Asterisk__:__602357__:__WAS/WASL-INTERACTING PROTEIN FAMILY, MEMBER 1; WIPF1__:__WISKOTT-ALDRICH SYNDROME PROTEIN-INTERACTING PROTEIN; WASPIP;; WASP-INTERACTING PROTEIN; WIP__:__
Asterisk__:__602358__:__HYPOCRETIN; HCRT__:__OREXIN; OX;; PREPROOREXIN__:__OREXIN A, INCLUDED;; OREXIN B, INCLUDED;; HYPOCRETIN 1, INCLUDED; HCRT1, INCLUDED;; HYPOCRETIN 2, INCLUDED; HCRT2, INCLUDED
Asterisk__:__602359__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 1; FXYD1__:__PHOSPHOLEMMAN; PLM__:__
Asterisk__:__602360__:__L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM__:__AGAT__:__
Number Sign__:__602361__:__GRACILE BONE DYSPLASIA; GCLEB__:__SKELETAL DYSPLASIA, LETHAL, WITH GRACILE BONES;; OSTEOCRANIOSPLENIC SYNDROME;; OSTEOCRANIOSTENOSIS;; HABRODYSPLASIA__:__
Asterisk__:__602362__:__GTPase-ACTIVATING PROTEIN, RAN, 1; RANGAP1__:__RAN GTPase-ACTIVATING PROTEIN 1__:__
Caret__:__602363__:__MOVED TO 225500__:____:__
Asterisk__:__602364__:__CATHEPSIN W; CTSW__:____:__
Asterisk__:__602365__:__CATHEPSIN C; CTSC__:__DIPEPTIDYL PEPTIDASE I; DPPI__:__
Asterisk__:__602366__:__INTEGRIN-LINKED KINASE; ILK__:__p59__:__
Asterisk__:__602367__:__PENTRAXIN I, NEURONAL; NPTX1__:__NP1__:__
Asterisk__:__602368__:__GLUTAMATE RECEPTOR, IONOTROPIC, DELTA 2; GRID2__:____:__
Asterisk__:__602369__:__CYSTEINE-RICH, ANGIOGENIC INDUCER, 61; CYR61__:__CYSTEINE-RICH PROTEIN 61, MOUSE, HOMOLOG OF;; INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 10; IGFBP10;; CCN FAMILY, MEMBER 1; CCN1__:__
Asterisk__:__602370__:__GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED MOLECULE-LIKE PROTEIN; GML__:____:__
Asterisk__:__602371__:__ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 3; ACSL3__:__FATTY ACID CoA LIGASE, LONG CHAIN 3; FACL3;; ACYL-CoA SYNTHETASE 3; ACS3__:__
Asterisk__:__602372__:__ZONADHESIN; ZAN__:____:__
Asterisk__:__602373__:__CALPONIN 2; CNN2__:__CALPONIN, NEUTRAL, NON-SMOOTH MUSCLE;; CALPONIN H2, MOUSE, HOMOLOG OF__:__
Asterisk__:__602374__:__CALPONIN 3; CNN3__:__CALPONIN, ACIDIC__:__
Asterisk__:__602375__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L12; MRPL12__:__RIBOSOMAL PROTEIN, MITOCHONDRIAL, L12; RPML12;; L12 RIBOSOMAL PROTEIN, BACTERIA, HOMOLOG OF__:__
Asterisk__:__602376__:__INTERFERON-ALPHA, -BETA, AND -OMEGA RECEPTOR 2; IFNAR2__:____:__
Asterisk__:__602377__:__DYNAMIN 1; DNM1__:____:__
Asterisk__:__602378__:__DYNAMIN 2; DNM2__:__DYN2__:__
Caret__:__602379__:__MOVED TO 300141__:____:__
Asterisk__:__602380__:__UROPLAKIN 1B; UPK1B__:____:__
Asterisk__:__602381__:__NGFIA-BINDING PROTEIN 2; NAB2__:__EGR1-BINDING PROTEIN 2__:__NAB2/STAT6 FUSION GENE, INCLUDED
Asterisk__:__602382__:__PHOSPHOLIPASE D1, PHOSPHATIDYLCHOLINE-SPECIFIC; PLD1__:____:__
Asterisk__:__602383__:__OSTEOGLYCIN; OGN__:__OSTEOINDUCTIVE FACTOR; OIF;; MIMECAN__:__
Asterisk__:__602384__:__PHOSPHOLIPASE D2; PLD2__:____:__
Asterisk__:__602385__:__SULFOTRANSFERASE FAMILY 1C, MEMBER 2; SULT1C2__:__SULFOTRANSFERASE FAMILY 1C, MEMBER 1, FORMERLY; SULT1C1, FORMERLY;; SULFOTRANSFERASE 1C1, FORMERLY__:__
Asterisk__:__602386__:__ZINC FINGER PROTEIN 212; ZNF212__:__ZINC FINGER PROTEIN C2H2-150__:__
Asterisk__:__602387__:__RNA-BINDING MOTIF PROTEIN, SINGLE STRAND-INTERACTING, 2; RBMS2__:__SCR3__:__
Asterisk__:__602388__:__SYMPLEKIN; SYMPK__:__SPK__:__
Asterisk__:__602389__:__Tu TRANSLATION ELONGATION FACTOR, MITOCHONDRIAL; TUFM__:__MITOCHONDRIAL TRANSLATION ELONGATION FACTOR Tu;; EF-Tu, MITOCHONDRIAL;; EF-TuMT__:__
Number Sign__:__602390__:__HEMOCHROMATOSIS, TYPE 2A; HFE2A__:____:__HEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED;; HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED
Asterisk__:__602391__:__PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; PEMT__:__PEMPT__:__PEMT1, INCLUDED;; PEMT2, INCLUDED
Asterisk__:__602392__:__HYPOCRETIN RECEPTOR 1; HCRTR1__:__OREXIN 1 RECEPTOR; OX1R;; OREXIN A RECEPTOR__:__
Asterisk__:__602393__:__HYPOCRETIN RECEPTOR 2; HCRTR2__:__OREXIN 2 RECEPTOR; OX2R;; OREXIN A/OREXIN B RECEPTOR;; OREXIN RECEPTOR__:__
Asterisk__:__602394__:__NUCLEOLAR AND COILED-BODY PHOSPHOPROTEIN 1; NOLC1__:__NUCLEOLAR PROTEIN, 130-KD; p130;; NOPP140__:__
Asterisk__:__602395__:__GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE, MITOCHONDRIAL; GPAM__:__GPAT, MITOCHONDRIAL;; GPAT1__:__
Asterisk__:__602396__:__ANNEXIN A8; ANXA8__:__ANNEXIN VIII; ANX8__:__
Asterisk__:__602397__:__ATPase, CLASS I, TYPE 8B, MEMBER 1; ATP8B1__:__FIC GENE 1; FIC1__:__
Number Sign__:__602398__:__DESMOSTEROLOSIS__:____:__
Asterisk__:__602399__:__MITOGEN-ACTIVATED PROTEIN KINASE 12; MAPK12__:__STRESS-ACTIVATED PROTEIN KINASE 3; SAPK3;; EXTRACELLULAR SIGNAL-REGULATED KINASE 6; ERK6;; p38-GAMMA__:__
Number Sign__:__602400__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 11; ARCI11__:__ICHTHYOSIS WITH HYPOTRICHOSIS, AUTOSOMAL RECESSIVE; ARIH;; ICHTHYOSIS AND FOLLICULAR ATROPHODERMA WITH HYPOTRICHOSIS AND HYPOHIDROSIS; IFAH__:__
Percent__:__602401__:__ECTODERMAL DYSPLASIA 8, HAIR/TOOTH/NAIL TYPE; ECTD8__:____:__
Asterisk__:__602402__:__FORKHEAD BOX C2; FOXC2__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 14; FKHL14;; MESENCHYME FORKHEAD 1; MFH1__:__
Asterisk__:__602403__:__BLEOMYCIN HYDROLASE; BLMH__:__BMH__:__
Percent__:__602404__:__PARKINSON DISEASE 3, AUTOSOMAL DOMINANT; PARK3__:__PARKINSON DISEASE 3, AUTOSOMAL DOMINANT LEWY BODY__:__
Caret__:__602405__:__MOVED TO 600910__:____:__
Asterisk__:__602406__:__HEART- AND NEURAL CREST DERIVATIVES-EXPRESSED 1; HAND1__:__HLH TRANSCRIPTION FACTOR HAND1;; EHAND__:__
Asterisk__:__602407__:__HEART- AND NEURAL CREST DERIVATIVES-EXPRESSED 2; HAND2__:__HLH TRANSCRIPTION FACTOR HAND2;; DECIDUUM, HEART, AUTONOMIC NERVOUS SYSTEM, NEURAL CREST-DERIVED; DHAND2;; DHAND__:__
Asterisk__:__602408__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1; NR1D1__:__THYROID HORMONE RECEPTOR, ALPHA-1-LIKE; THRAL;; REV-ERBA-ALPHA;; REV-ERB-ALPHA;; ERBA-RELATED 1; EAR1__:__
Asterisk__:__602409__:__MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA, TRANSLOCATED TO, 10; MLLT10__:__ALL1-FUSED GENE FROM CHROMOSOME 10; AF10__:__AF10/MLL FUSION GENE, INCLUDED;; AF10/HEAB FUSION GENE, INCLUDED
Asterisk__:__602410__:__BROMODOMAIN- AND PHD FINGER-CONTAINING PROTEIN; BRPF1__:__BROMODOMAIN-CONTAINING PROTEIN, 140-KD; BR140;; PEREGRIN__:__
Asterisk__:__602411__:__EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 2; EXTL2__:__EXOSTOSIN-LIKE 2;; MULTIPLE EXOSTOSES-LIKE 2;; EXT-RELATED GENE 2; EXTR2__:__
Asterisk__:__602412__:__RIBOSOMAL PROTEIN S24; RPS24__:____:__
Asterisk__:__602413__:__SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT C, INTEGRAL MEMBRANE PROTEIN, 15-KD; SDHC__:__SUCCINATE DEHYDROGENASE 3, INTEGRAL MEMBRANE SUBUNIT; SDH3;; SUCCINATE DEHYDROGENASE CYTOCHROME b__:__
Asterisk__:__602414__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY A, MEMBER 1; APBA1__:__X11;; X11-ALPHA;; D9S411E;; MUNC18-1-INTERACTING PROTEIN 1; MINT1;; VERTEBRATE LIN10 HOMOLOG; LIN10__:__
Asterisk__:__602415__:__DYSTROBREVIN, BETA; DTNB__:____:__
Asterisk__:__602416__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, SIGMA-2 SUBUNIT; AP3S2__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, SMALL 4, 22-KD;; CLATHRIN ADAPTOR COMPLEX AP3, SIGMA-3B SUBUNIT__:__
Caret__:__602417__:__MOVED TO 602974__:____:__
NULL__:__602418__:__WEYERS ULNAR RAY/OLIGODACTYLY SYNDROME__:____:__
Asterisk__:__602419__:__EARLY GROWTH RESPONSE 3; EGR3__:____:__
Asterisk__:__602420__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 10; KCNA10__:____:__
Asterisk__:__602421__:__CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 7; ABCC7__:__
Asterisk__:__602422__:__STEM-LOOP BINDING PROTEIN; SLBP__:__HAIRPIN BINDING PROTEIN, HISTONE; HBP__:__
Asterisk__:__602423__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 3; NR1H3__:__LIVER X RECEPTOR, ALPHA;; LX RECEPTOR, ALPHA; LXRA__:__
Asterisk__:__602424__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR 1; DMRT1__:__DM-DOMAIN GENE EXPRESSED IN TESTIS; DMT1__:__
Asterisk__:__602425__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 4; MAP3K4__:__MAP/ERK KINASE KINASE 4; MEKK4;; MAP THREE KINASE 1; MTK1;; MAPKKK4;; SSK2/SSK22 MAP KINASE KINASE KINASE, YEAST, HOMOLOG OF;; KIAA0213__:__
Asterisk__:__602426__:__NUCLEAR VALOSIN-CONTAINING PROTEIN-LIKE; NVL__:__NUCLEAR VCP-LIKE__:__
Asterisk__:__602427__:__T-BOX 6; TBX6__:____:__
Asterisk__:__602428__:__HYALURONAN SYNTHASE 3; HAS3__:____:__
Percent__:__602429__:__GLAUCOMA 1, OPEN ANGLE, D; GLC1D__:__GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET__:__
Asterisk__:__602430__:__ROUNDABOUT, DROSOPHILA, HOMOLOG OF, 1; ROBO1__:__SAX3, C. ELEGANS, HOMOLOG OF, 1__:__DELETED IN U TWENTY TWENTY, INCLUDED; DUTT1, INCLUDED
Asterisk__:__602431__:__ROUNDABOUT, DROSOPHILA, HOMOLOG OF, 2; ROBO2__:__SAX3, C. ELEGANS, HOMOLOG OF, 2;; KIAA1568__:__
Asterisk__:__602432__:__OPTINEURIN; OPTN__:__14.7K-INTERACTING PROTEIN; FIP2;; HYPL;; TRANSCRIPTION FACTOR IIIA-INTERACTING PROTEIN;; TFIIIA-INTP;; NEMO-RELATED PROTEIN; NRP;; GLC1E GENE__:__
Number Sign__:__602433__:__AMYOTROPHIC LATERAL SCLEROSIS 4, JUVENILE; ALS4__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, WITH PYRAMIDAL FEATURES__:__
Asterisk__:__602434__:__ANCIENT UBIQUITOUS PROTEIN 1; AUP1__:____:__
Asterisk__:__602435__:__PEPTIDYL-PROLYL ISOMERASE E; PPIE__:__CYCLOPHILIN, 33-KD; CYP33;; CYCLOPHILIN E__:__
Asterisk__:__602436__:__MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I CHAIN-RELATED GENE B; MICB__:____:__
Asterisk__:__602437__:__GTP CYCLOHYDROLASE I FEEDBACK REGULATORY PROTEIN; GCHFR__:__GFRP__:__
Asterisk__:__602438__:__HEAT-SHOCK TRANSCRIPTION FACTOR 4; HSF4__:____:__
Caret__:__602439__:__MOVED TO 601626__:____:__
Percent__:__602440__:__AMYOTROPHY, MONOMELIC__:__HIRAYAMA DISEASE;; SPINAL MUSCULAR ATROPHY, JUVENILE, NONPROGRESSIVE__:__
Asterisk__:__602441__:__CYTOKINE-INDUCIBLE SH2-CONTAINING PROTEIN; CISH__:__CIS__:__
Asterisk__:__602442__:__INTERSECTIN 1; ITSN1__:__ITSN;; SH3 DOMAIN PROTEIN 1A; SH3D1A;; SRC HOMOLOGY 3 DOMAIN-CONTAINING PROTEIN;; SH3P17__:__
Asterisk__:__602443__:__X-PROLYL AMINOPEPTIDASE 1; XPNPEP1__:__X-PROLYL AMINOPEPTIDASE-LIKE; XPNPEPL;; AMINOPEPTIDASE P-LIKE;; AMINOPEPTIDASE P, SOLUBLE; SAMP;; AMINOPEPTIDASE P, CYTOSOLIC;; APP1__:__
Asterisk__:__602444__:__TRANSCRIPTION FACTOR 17; TCF17__:__KID1, RAT, HOMOLOG OF__:__
Asterisk__:__602445__:__SERINE PROTEASE INHIBITOR, CLADE I, MEMBER 1; SERPINI1__:__PROTEASE INHIBITOR 12; PI12;; NEUROSERPIN__:__
Asterisk__:__602446__:__GLYPICAN 5; GPC5__:____:__
Asterisk__:__602447__:__PARAOXONASE 2; PON2__:____:__
Asterisk__:__602448__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5; MAP3K5__:__MAP/ERK KINASE KINASE 5; MEKK5;; MAPKKK5;; APOPTOSIS SIGNAL-REGULATING KINASE 1; ASK1__:__
Asterisk__:__602449__:__A-KINASE ANCHOR PROTEIN 1; AKAP1__:__A-KINASE ANCHOR PROTEIN, 149-KD; AKAP149;; SPERMATID A-KINASE ANCHOR PROTEIN 84; SAKAP84__:__
Number Sign__:__602450__:__SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION__:__RS-SCID;; SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE, WITH SENSITIVITY TO IONIZING RADIATION__:__SEVERE COMBINED IMMUNODEFICIENCY, ATHABASKAN-TYPE, INCLUDED; SCIDA, INCLUDED;; ATHABASKAN SEVERE COMBINED IMMUNODEFICIENCY, INCLUDED;; SEVERE COMBINED IMMUNODEFICIENCY, PARTIAL, INCLUDED
Asterisk__:__602451__:__PYRIMIDINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 6; P2RY6__:__PURINOCEPTOR P2Y6; P2Y6__:__
Asterisk__:__602452__:__BUDDING UNINHIBITED BY BENZIMIDAZOLES 1, S. CEREVISIAE, HOMOLOG OF; BUB1__:__BUB1, S. CEREVISIAE, HOMOLOG OF;; MITOTIC CHECKPOINT GENE BUB1;; BUB1A__:__
Asterisk__:__602453__:__INTEGRIN, ALPHA-D; ITGAD__:__CD11D__:__
Asterisk__:__602454__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, U; PTPRU__:__PROTEIN-TYROSINE PHOSPHATASE J; PTPJ;; PANCREATIC CARCINOMA PHOSPHATASE 2; PCP2;; PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, PSI;; PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, LAMBDA, MOUSE, HOMOLOG OF__:__
Caret__:__602455__:__MOVED TO 605271__:____:__
Caret__:__602456__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__602457__:__FAS-ASSOCIATED VIA DEATH DOMAIN; FADD__:__FAS-ASSOCIATING PROTEIN WITH DEATH DOMAIN;; MORT1__:__
Asterisk__:__602458__:__SORTILIN; SORT1__:__NEUROTENSIN RECEPTOR 3; NTSR3; NT3;; NEUROTENSIN RECEPTOR, 100-KD__:__SORT1 TRANSCRIPTION FACTOR BINDING SITE 1, INCLUDED;; SORT1-TBS1, INCLUDED
Number Sign__:__602459__:__DEAFNESS, AUTOSOMAL DOMINANT 15; DFNA15__:____:__
Asterisk__:__602460__:__POU DOMAIN, CLASS 4, TRANSCRIPTION FACTOR 3; POU4F3__:__POU-DOMAIN TRANSCRIPTION FACTOR BRN3C; BRN3C;; BRN3.1, MOUSE, HOMOLOG OF__:__
Asterisk__:__602461__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR TYPE, SUBSTRATE 1; PTPNS1__:__SIGNAL REGULATORY PROTEIN, ALPHA TYPE, 1;; SIRP-ALPHA-1;; SIRPA;; SHP SUBSTRATE 1; SHPS1;; TYROSINE PHOSPHATASE SHP SUBSTRATE 1;; P84;; MYD1;; MACROPHAGE FUSION RECEPTOR, MFR__:__
Asterisk__:__602462__:__COLLAPSIN RESPONSE MEDIATOR PROTEIN 1; CRMP1__:__DIHYDROPYRIMIDINASE-LIKE 1; DPYSL1;; DIHYDROPYRIMIDINASE-RELATED PROTEIN 1; DRP1__:__
Asterisk__:__602463__:__DIHYDROPYRIMIDINASE-LIKE 2; DPYSL2__:__DIHYDROPYRIMIDINASE-RELATED PROTEIN 2; DRP2;; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CRMP2__:__
Asterisk__:__602464__:__TNF RECEPTOR-ASSOCIATED FACTOR 4; TRAF4__:__MALIGNANT 62; MLN62;; CYSTEINE-RICH DOMAIN ASSOCIATED WITH RING AND TRAF DOMAINS; CART1__:__
Asterisk__:__602465__:__SPROUTY, DROSOPHILA, HOMOLOG OF, 1; SPRY1__:____:__
Asterisk__:__602466__:__SPROUTY, DROSOPHILA, HOMOLOG OF, 2; SPRY2__:____:__
Caret__:__602467__:__MOVED TO 300531__:____:__
Asterisk__:__602468__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 9A; PPP1R9A__:__NEURABIN I; NRBI; NRB1;; KIAA1222__:__
Asterisk__:__602469__:__FOLATE RECEPTOR 3; FOLR3__:__FOLATE RECEPTOR, GAMMA__:__
Asterisk__:__602470__:__PROSTATE STEM CELL ANTIGEN; PSCA__:____:__
Number Sign__:__602471__:__SHORT STATURE, AUDITORY CANAL ATRESIA, MANDIBULAR HYPOPLASIA, AND SKELETAL ABNORMALITIES; SAMS__:____:__
NULL__:__602472__:__CREASES, INFRA-AURICULAR CUTANEOUS, WITH TALL STATURE AND ADVANCED BONE AGE__:____:__
Number Sign__:__602473__:__ENCEPHALOPATHY, ETHYLMALONIC; EE__:____:__
Asterisk__:__602474__:__PROTEIN KINASE, MEMBRANE-ASSOCIATED TYROSINE/THREONINE, 1; PKMYT1__:__CDC2-INHIBITORY KINASE, MEMBRANE-ASSOCIATED TYROSINE/THREONINE, 1; MYT1__:__
Percent__:__602475__:__OSSIFICATION OF THE POSTERIOR LONGITUDINAL LIGAMENT OF SPINE; OPLL__:____:__
Caret__:__602476__:__MOVED TO 121210__:____:__
Percent__:__602477__:__FEBRILE SEIZURES, FAMILIAL, 2; FEB2__:__CONVULSIONS, FAMILIAL FEBRILE, 2__:__
Asterisk__:__602478__:__tRNA ASPARTIC ACID METHYLTRANSFERASE 1; TRDMT1__:__DNA METHYLTRANSFERASE 2; DNMT2__:__
Asterisk__:__602479__:__POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 1; POU3F1__:__OCT6;; SCIP__:__
Asterisk__:__602480__:__POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 3; POU3F3__:__BRN1, MOUSE, HOMOLOG OF; BRN1__:__
Number Sign__:__602481__:__MIGRAINE, FAMILIAL HEMIPLEGIC, 2; FHM2__:__MHP2__:__MIGRAINE, FAMILIAL BASILAR, INCLUDED
Number Sign__:__602482__:__AXENFELD-RIEGER SYNDROME, TYPE 3; RIEG3__:__AXENFELD-RIEGER ANOMALY WITH CARDIAC DEFECTS AND/OR SENSORINEURAL HEARING LOSS;; ANTERIOR CHAMBER CLEAVAGE SYNDROME;; RIEGER SYNDROME, TYPE 3__:__
Number Sign__:__602483__:__AURICULOCONDYLAR SYNDROME 1; ARCND1__:__QUESTION MARK EARS SYNDROME__:__
NULL__:__602484__:__PELVIC HYPOPLASIA WITH LOWER-LIMB ARTHROGRYPOSIS__:____:__
Number Sign__:__602485__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3__:____:__
Asterisk__:__602486__:__PROCESSING OF PRECURSOR 1, S. CEREVISIAE, HOMOLOG OF; POP1__:____:__
Asterisk__:__602487__:__HEAT-RESPONSIVE PROTEIN 12; HRSP12__:__PERCHLORIC ACID-SOLUBLE PROTEIN, 14.5-KD; PSP;; p14.5;; UK114__:__
Asterisk__:__602488__:__CYTOHESIN 2; CYTH2__:__PLECKSTRIN HOMOLOGY, SEC7, AND COILED-COIL DOMAINS PROTEIN 2; PSCD2;; ARF NUCLEOTIDE-BINDING SITE OPENER; ARNO;; PSCD2L, FORMERLY__:__
Asterisk__:__602489__:__KH DOMAIN-CONTAINING, RNA-BINDING, SIGNAL TRANSDUCTION-ASSOCIATED PROTEIN 1; KHDRBS1__:__GAP-ASSOCIATED TYROSINE PHOSPHOPROTEIN, 62-KD;; SRC-ASSOCIATED PROTEIN IN MITOSIS, 68-KD; SAM68__:__
Asterisk__:__602490__:__NUCLEAR RECEPTOR-INTERACTING PROTEIN 1; NRIP1__:__RECEPTOR-INTERACTING PROTEIN 140; RIP140__:__
Number Sign__:__602491__:__HYPERLIPIDEMIA, COMBINED, 1__:__HYPLIP1;; HYPERLIPIDEMIA, FAMILIAL COMBINED, 1; FCHL1__:__
Asterisk__:__602492__:__PENTRAXIN 3, LONG; PTX3__:__PENTRAXIN 3__:__
Asterisk__:__602493__:__UV RADIATION RESISTANCE-ASSOCIATED GENE; UVRAG__:____:__
Asterisk__:__602494__:__CHEMOKINE, CC MOTIF, LIGAND 23; CCL23__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 23; SCYA23;; MYELOID PROGENITOR INHIBITORY FACTOR 1; MPIF1;; CK-BETA-8__:__
Asterisk__:__602495__:__CHEMOKINE, CC MOTIF, LIGAND 24; CCL24__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 24; SCYA24;; MYELOID PROGENITOR INHIBITORY FACTOR 2; MPIF2;; EOTAXIN 2__:__
Asterisk__:__602496__:__MERCAPTOPYRUVATE SULFURTRANSFERASE; MPST__:__MST__:__
NULL__:__602497__:__CHONDRODYSPLASIA PUNCTATA, BRACHYTELEPHALANGIC, AUTOSOMAL__:__BRACHYTELEPHALANGIC CHONDRODYSPLASIA PUNCTATA; BCDP__:__
Asterisk__:__602498__:__TRK-FUSED GENE; TFG__:____:__TRKT3 ONCOGENE, INCLUDED;; TFG/NTRK1 FUSION GENE, INCLUDED;; TFG/NR4A3 FUSION GENE, INCLUDED
Number Sign__:__602499__:__MACROPHTHALMIA, COLOBOMATOUS, WITH MICROCORNEA; MACOM__:____:__
Asterisk__:__602500__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY B, 1; GOLGB1__:__GIANTIN;; MACROGOLGIN;; GCP372__:__
Number Sign__:__602501__:__MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP__:__MACROCEPHALY-CAPILLARY MALFORMATION; MCM;; MEGALENCEPHALY-CAPILLARY MALFORMATION SYNDROME;; MACROCEPHALY-CUTIS MARMORATA TELANGIECTATICA CONGENITA; MCMTC;; MEGALENCEPHALY-CUTIS MARMORATA TELANGIECTATICA CONGENITA__:__
Asterisk__:__602502__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 1; GOLGA1__:__GOLGIN 97__:__
Asterisk__:__602503__:__FREQUENTLY REARRANGED IN ADVANCED T-CELL LYMPHOMAS; FRAT1__:____:__
Asterisk__:__602504__:__SHORT STATURE HOMEOBOX 2; SHOX2__:__SHOX HOMOLOGOUS GENE ON CHROMOSOME THREE; SHOT__:__
Asterisk__:__602505__:__PAXILLIN; PXN__:____:__
Caret__:__602506__:__MOVED TO 143055__:____:__
Asterisk__:__602507__:__ZINC FINGER PROTEIN 103, MOUSE, HOMOLOG OF; ZFP103__:__KF1__:__
Asterisk__:__602508__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM 1B, BETA SUBUNIT; PAFAH1B2__:____:__
Asterisk__:__602509__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 4; GOLGA4__:__TRANS-GOLGI p230;; GOLGIN 245__:__
Asterisk__:__602510__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, H; PTPRH__:____:__
NULL__:__602511__:__PSEUDOACROMEGALY WITH SEVERE INSULIN RESISTANCE__:____:__
Asterisk__:__602512__:__REGULATOR OF G PROTEIN SIGNALING 12; RGS12__:____:__
Asterisk__:__602513__:__REGULATOR OF G PROTEIN SIGNALING 14; RGS14__:____:__
Asterisk__:__602514__:__REGULATOR OF G PROTEIN SIGNALING 16; RGS16__:____:__
Asterisk__:__602515__:__PHOSPHOLIPASE D1, GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC; GPLD1__:__PHOSPHOLIPASE D, PHOSPHATIDYLINOSITOL-GLYCAN-SPECIFIC; PIGPLD;; GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE D; GPIPLD__:__
Asterisk__:__602516__:__REGULATOR OF G PROTEIN SIGNALING 4; RGS4__:____:__
Asterisk__:__602517__:__REGULATOR OF G PROTEIN SIGNALING 7; RGS7__:____:__
Asterisk__:__602518__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 4; LGALS4__:__GALECTIN 4; GAL4__:__
Asterisk__:__602519__:__UBIQUITIN-SPECIFIC PROTEASE 7; USP7__:__UBIQUITIN-SPECIFIC PROTEASE, HERPESVIRUS-ASSOCIATED;; HERPESVIRUS-ASSOCIATED UBIQUITIN-SPECIFIC PROTEASE; HAUSP;; VMW110-ASSOCIATED PROTEIN, 135-KD__:__
Asterisk__:__602520__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5; MAP2K5__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 5; PRKMK5;; MAPK/ERK KINASE 5; MEK5;; MAPKK5__:__
Asterisk__:__602521__:__MITOGEN-ACTIVATED PROTEIN KINASE 7; MAPK7__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 7; PRKM7;; EXTRACELLULAR SIGNAL-REGULATED KINASE 5; ERK5__:__
Number Sign__:__602522__:__BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A__:__BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND__:__SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED
Asterisk__:__602523__:__DOWN SYNDROME CELL ADHESION MOLECULE; DSCAM__:____:__
Asterisk__:__602524__:__PYRUVATE DEHYDROGENASE KINASE, ISOENZYME 1; PDK1__:____:__
Asterisk__:__602525__:__PYRUVATE DEHYDROGENASE KINASE, ISOENZYME 2; PDK2__:____:__
Caret__:__602526__:__MOVED TO 300906__:____:__
Asterisk__:__602527__:__PYRUVATE DEHYDROGENASE KINASE, ISOENZYME 4; PDK4__:____:__
Asterisk__:__602528__:__TUBULIN, ALPHA-3C; TUBA3C__:__TUBULIN, ALPHA-2; TUBA2__:__
Asterisk__:__602529__:__TUBULIN, ALPHA-1A; TUBA1A__:__TUBULIN, ALPHA, BRAIN-SPECIFIC;; B-ALPHA-1;; TUBA3__:__
Asterisk__:__602530__:__TUBULIN, ALPHA-1B; TUBA1B__:__TUBULIN, ALPHA, UBIQUITOUS;; K-ALPHA-1__:__
Number Sign__:__602531__:__GRANGE SYNDROME; GRNG__:__ARTERIAL OCCLUSIVE DISEASE, PROGRESSIVE, WITH HYPERTENSION, HEART DEFECTS, BONE FRAGILITY, AND BRACHYSYNDACTYLY;; GRANGE OCCLUSIVE ARTERIAL SYNDROME__:__
Asterisk__:__602532__:__SIX-TWELVE LEUKEMIA GENE__:__STL__:__
Asterisk__:__602533__:__ONCOGENE DJ1; DJ1__:__PARK7 GENE; PARK7__:__
Asterisk__:__602534__:__SYNAPTOSOMAL-ASSOCIATED PROTEIN, 23-KD; SNAP23__:__SNAP23A__:__SNAP23B, INCLUDED;; SNAP23C, INCLUDED;; SNAP23D, INCLUDED;; SNAP23E, INCLUDED
Number Sign__:__602535__:__MARSHALL-SMITH SYNDROME; MRSHSS__:____:__
Asterisk__:__602536__:__RAB3 GTPase-ACTIVATING PROTEIN, CATALYTIC SUBUNIT; RAB3GAP1__:__RAB3GAP;; RAB3GAP, 130-KD SUBUNIT;; RAB3GAP, CATALYTIC SUBUNIT;; p130;; WARBM1 GENE;; KIAA0066__:__
Asterisk__:__602537__:__CALPAIN 5; CAPN5__:__HTRA3__:__
Asterisk__:__602538__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 2; CELF2__:__CUG TRIPLET REPEAT, RNA-BINDING PROTEIN 2; CUGBP2;; RNA-BINDING PROTEIN ETR3; ETR3;; BRUNO-LIKE 3; BRUNOL3__:__
Asterisk__:__602539__:__MITOGEN-ACTIVATED KINASE KINASE KINASE 3; MAP3K3__:__MAP/ERK KINASE KINASE 3; MEKK3;; MAPKKK3__:__
Number Sign__:__602540__:__ICHTHYOSIS, HYSTRIX-LIKE, WITH DEAFNESS__:__HID SYNDROME__:__
Number Sign__:__602541__:__MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES__:__
Asterisk__:__602542__:__BASIC TRANSCRIPTION FACTOR 3; BTF3__:__NASCENT POLYPEPTIDE-ASSOCIATED COMPLEX, BETA POLYPEPTIDE; NACB;; BETA-NAC__:__BTF3A, INCLUDED;; BTF3B, INCLUDED
Asterisk__:__602543__:__BASIC TRANSCRIPTION FACTOR 3-LIKE 1; BTF3L1__:____:__
Asterisk__:__602544__:__PARKIN; PARK2__:__PRKN__:__FRAGILE SITE FRA6E, INCLUDED
Asterisk__:__602545__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, KAPPA; PTPRK__:____:__
Asterisk__:__602546__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 2; ST8SIA2__:__ALPHA-2,8-SIALYLTRANSFERASE II;; ST8SIA II;; SIALYLTRANSFERASE 8B; SIAT8B;; SIALYLTRANSFERASE X; STX__:__
Asterisk__:__602547__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 4; ST8SIA4__:__ALPHA-2,8-SIALYLTRANSFERASE IV;; ST8SIA IV;; POLYSIALYLTRANSFERASE; PST;; PST1__:__
Asterisk__:__602548__:__OPIOID RECEPTOR-LIKE 1; OPRL1__:__ORL1;; LC132 RECEPTOR, RAT, HOMOLOG OF;; NOCICEPTIN RECEPTOR; NOCIR;; NOCICEPTIN/ORPHANIN FQ (N/OFQ) PEPTIDE RECEPTOR; NOP__:__
Asterisk__:__602549__:__PROTEIN KINASE N2; PKN2__:__PROTEIN KINASE C-LIKE 2; PRKCL2;; PROTEIN-KINASE C-RELATED KINASE 2; PRK2;; PAK2, RAT, HOMOLOG OF__:__
Asterisk__:__602550__:__ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR-LIKE PROTEIN; ARNTL__:__BRAIN AND MUSCLE ARNT-LIKE PROTEIN 1; BMAL1;; TIC, MOUSE, HOMOLOG OF;; MEMBER OF PAS SUPERFAMILY 3; MOP3;; CYCLE, DROSOPHILA, HOMOLOG OF__:__
NULL__:__602551__:__JEJUNAL ATRESIA WITH RENAL ADYSPLASIA__:____:__
Asterisk__:__602552__:__NUCLEOPORIN, 88-KD; NUP88__:____:__
NULL__:__602553__:__ANAL ATRESIA, HYPOSPADIAS, AND PENOSCROTAL INVERSION__:____:__
NULL__:__602554__:__TORSION DYSTONIA WITH ONSET IN INFANCY__:____:__
NULL__:__602555__:__MICROCEPHALY, MACROTIA, AND MENTAL RETARDATION__:____:__
NULL__:__602556__:__FACIAL DYSMORPHISM, CLEFT PALATE, HEARING LOSS, AND CAMPTODACTYLY__:____:__
Number Sign__:__602557__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, SHOHAT TYPE; SEMDSH__:__SEMD, SHOHAT TYPE__:__
NULL__:__602558__:__CRANIOMICROMELIC SYNDROME__:____:__
Asterisk__:__602559__:__EXPORTIN 1; XPO1__:__REQUIRED FOR CHROMOSOME REGION MAINTENANCE; CRM1__:__
Asterisk__:__602560__:__TRACHEAL ANTIMICROBIAL PEPTIDE__:__TAP__:__
NULL__:__602561__:__BRACHYDACTYLY, INTRAVENTRICULAR SEPTAL DEFECT, AND DEAFNESS__:____:__
NULL__:__602562__:__MANDIBULOFACIAL DYSOSTOSIS WITH MACROBLEPHARON AND MACROSTOMIA__:__VERLOES-LESENFANTS SYNDROME;; MACROBLEPHARON, ECTROPION, HYPERTELORISM, AND MACROSTOMIA; MEHM__:__
Asterisk__:__602563__:__NK6, DROSOPHILA, HOMOLOG OF, 1; NKX6-1__:__NKX6.1;; NK HOMEOBOX, FAMILY 6, MEMBER A;; HOMEOBOX 6A, NK; NKX6A__:__
NULL__:__602564__:__EMPHYSEMA, CONGENITAL, WITH DEAFNESS, PENOSCROTAL WEB, AND MENTAL RETARDATION__:____:__
Asterisk__:__602565__:__CHEMOKINE, CC MOTIF, LIGAND 25; CCL25__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 25; SCYA25;; THYMUS-EXPRESSED CHEMOKINE; TECK__:__
Asterisk__:__602566__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 7; P2RX7__:__PURINOCEPTOR P2X7; P2X7__:__
Asterisk__:__602567__:__LIM AND SENESCENT CELL ANTIGEN-LIKE DOMAINS 1; LIMS1__:__PARTICULARLY INTERESTING NEW CYS-HIS PROTEIN; PINCH; PINCH1__:__
Asterisk__:__602568__:__METHIONINE SYNTHASE REDUCTASE; MTRR__:__MSR__:__
Asterisk__:__602569__:__SYNUCLEIN, BETA; SNCB__:____:__
Asterisk__:__602570__:__JAGGED 2; JAG2__:__SERRATE 2; SER2__:__
Asterisk__:__602571__:__RNA-BINDING MOTIF PROTEIN 4; RBM4__:__LARK, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__602572__:__ANNEXIN A11; ANXA11__:__ANNEXIN XI; ANX11;; AUTOANTIGEN, 56-KD__:__
Asterisk__:__602573__:__ANNEXIN A13; ANXA13__:__ANNEXIN XIII; ANX13;; ANNEXIN, INTESTINE-SPECIFIC; ISA__:__
Asterisk__:__602574__:__TECTORIN, ALPHA; TECTA__:____:__
Asterisk__:__602575__:__LIM HOMEOBOX TRANSCRIPTION FACTOR 1, BETA; LMX1B__:__LMX1.2__:__
Asterisk__:__602576__:__LUNATIC FRINGE; LFNG__:__FRINGE, DROSOPHILA, HOMOLOG OF, LUNATIC__:__
Asterisk__:__602577__:__MANIC FRINGE; MFNG__:__FRINGE, DROSOPHILA, HOMOLOG OF, MANIC__:__
Asterisk__:__602578__:__RADICAL FRINGE; RFNG__:__FRINGE, DROSOPHILA, HOMOLOG OF, RADICAL__:__
Number Sign__:__602579__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B__:__CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME__:__
Asterisk__:__602580__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 2; GOLGA2__:__GOLGIN 95;; GM130__:__
Asterisk__:__602581__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 3; GOLGA3__:__GOLGIN 160;; MEA2__:__
Asterisk__:__602582__:__DELTEX, DROSOPHILA, HOMOLOG OF, 1; DTX1__:____:__
Asterisk__:__602583__:__G PROTEIN-COUPLED RECEPTOR 37; GPR37__:__PARKIN-ASSOCIATED ENDOTHELIN RECEPTOR-LIKE RECEPTOR; PAELR__:__
Asterisk__:__602584__:__RETICULOCALBIN 2; RCN2__:__ENDOPLASMIC RETICULUM CALCIUM-BINDING PROTEIN, 55-KD; ERC55;; TCBP49__:__
Caret__:__602585__:__MOVED TO 164280__:____:__
Caret__:__602586__:__MOVED TO 602857__:____:__
Asterisk__:__602587__:__ACYL-CoA THIOESTERASE 7; ACOT7__:__ACYL-CoA THIOESTERASE, LONG-CHAIN, CYTOSOLIC;; ACYL-CoA THIOESTERASE ; ACT;; CTE-II;; ACYL-CoA THIOESTER HYDROLASE, LONG-CHAIN, 2;; ACYL-CoA HYDROLASE, LONG-CHAIN, BRAIN; BACH;; ACYL-CoA HYDROLASE, LONG-CHAIN, LIVER; LACH;; ACYL-CoA THIOESTERASE 2, FORMERLY__:__
Number Sign__:__602588__:__BRANCHIOOTIC SYNDROME 1; BOS1__:__BO SYNDROME 1;; BRANCHIOOTIC DYSPLASIA__:__ANTERIOR SEGMENT ANOMALIES WITH OR WITHOUT CATARACT, INCLUDED
Asterisk__:__602589__:__FUCOSYLTRANSFERASE 8; FUT8__:__ALPHA-1,6-FUCOSYLTRANSFERASE__:__
Asterisk__:__602590__:__p21 PROTEIN-ACTIVATED KINASE 1; PAK1__:__p21 CDC42/RAC1-ACTIVATED KINASE 1__:__
Asterisk__:__602591__:__KINESIN HEAVY CHAIN MEMBER 2A; KIF2A__:__KIF2__:__
Asterisk__:__602592__:__LYMPHOCYTE ANTIGEN CD5-LIKE; CD5L__:__SCAVENGER RECEPTOR CYSTEINE-RICH FAMILY, MEMBER SP-ALPHA;; SP-ALPHA;; APOPTOSIS INHIBITOR 6; API6;; APOPTOSIS INHIBITOR OF MACROPHAGES; AIM__:__
Asterisk__:__602593__:__CORNEODESMOSIN; CDSN__:__S GENE__:__
Percent__:__602594__:__RETINITIS PIGMENTOSA 22; RP22__:____:__
Asterisk__:__602595__:__GEM-ASSOCIATED PROTEIN 2; GEMIN2__:__SMN-INTERACTING PROTEIN 1; SIP1__:__
NULL__:__602596__:__PANCREATIC LYMPHOMA, FAMILIAL__:____:__
Asterisk__:__602597__:__B-CELL CLL/LYMPHOMA 9; BCL9__:__LEGLESS, DROSOPHILA, HOMOLOG OF; LGS__:__
Asterisk__:__602598__:__PROSTAGLANDIN D2 SYNTHASE, HEMATOPOIETIC; HPGDS__:__PGDS__:__
Caret__:__602599__:__MOVED TO 602631__:____:__
Asterisk__:__602600__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8; LRP8__:__APOLIPOPROTEIN E RECEPTOR 2; APOER2__:__
Asterisk__:__602601__:__LOW DENSITY LIPOPROTEIN, OXIDIZED, RECEPTOR 1; OLR1__:__LECTIN-LIKE OXIDIZED-LDL RECEPTOR 1; LOX1;; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1__:__
Asterisk__:__602602__:__SECRETED AND TRANSMEMBRANE 1; SECTM1__:__K12__:__
Asterisk__:__602603__:__MAGO NASHI, DROSOPHILA, HOMOLOG OF; MAGOH__:____:__
Caret__:__602604__:__MOVED TO 602323__:____:__
Caret__:__602605__:__MOVED TO 602221__:____:__
Asterisk__:__602606__:__CART PREPROPEPTIDE; CARTPT__:__COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT; CART__:__
Asterisk__:__602607__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 1; SLC22A1__:__ORGANIC CATION TRANSPORTER 1; OCT1__:__
Asterisk__:__602608__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 2; SLC22A2__:__ORGANIC CATION TRANSPORTER 2; OCT2__:__
Asterisk__:__602609__:__PHOSPHATIDYLINOSITOL 3-KINASE, CLASS 3; PIK3C3__:__VPS34, YEAST, HOMOLOG OF__:__
Asterisk__:__602610__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 4; PIK3R4__:__VPS15, YEAST, HOMOLOG OF;; p150__:__
NULL__:__602611__:__SPONDYLOEPIPHYSEAL DYSPLASIA WITH CORONAL CRANIOSYNOSTOSIS, CATARACTS, CLEFT PALATE, AND MENTAL RETARDATION__:____:__
NULL__:__602612__:__CAMPTODACTYLY, MYOPIA, AND FIBROSIS OF THE MEDIAL RECTUS MUSCLE OF EYE__:____:__
NULL__:__602613__:__SKELETAL DYSPLASIA AND PROGRESSIVE CENTRAL NERVOUS SYSTEM DEGENERATION, LETHAL__:____:__
Asterisk__:__602614__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7; MAP3K7__:__TRANSFORMING GROWTH FACTOR-BETA-ACTIVATED KINASE 1; TAK1;; TGF-BETA-ACTIVATED KINASE 1__:__TAK1a, INCLUDED;; TAK1b, INCLUDED;; TAK1c, INCLUDED;; TAK1d, INCLUDED
Asterisk__:__602615__:__TAK1-BINDING PROTEIN 1; TAB1__:__TGF-BETA-ACTIVATED KINASE 1/MAP3K7-BINDING PROTEIN 1;; TAK1/MAP3K7-BINDING PROTEIN 1;; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7-INTERACTING PROTEIN 1; MAP3K7IP1__:__
Asterisk__:__602616__:__ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT2__:__GlcNAc-T II;; GnT II; GnT2;; UDP-N-ACETYLGLUCOSAMINE:ALPHA-6-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE II__:__
Asterisk__:__602617__:__FORKHEAD BOX E1; FOXE1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 15; FKHL15;; THYROID TRANSCRIPTION FACTOR 2; TTF2;; TITF2__:__
Asterisk__:__602618__:__C-TERMINAL-BINDING PROTEIN 1; CTBP1__:____:__
Asterisk__:__602619__:__C-TERMINAL-BINDING PROTEIN 2; CTBP2__:____:__
Asterisk__:__602620__:__LEGUMAIN; LGMN__:__PROTEASE, CYSTEINE, 1; PRSC1;; ASPARAGINYL ENDOPEPTIDASE; AEP__:__
Asterisk__:__602621__:__COXSACKIEVIRUS AND ADENOVIRUS RECEPTOR; CXADR__:__CAR;; CVB3 BINDING PROTEIN;; COXSACKIEVIRUS B RECEPTOR__:__
Asterisk__:__602622__:__DEOXYRIBONUCLEASE I-LIKE 2; DNASE1L2__:____:__
Asterisk__:__602623__:__FK506-BINDING PROTEIN 5; FKBP5__:__FK506-BINDING PROTEIN, 51-KD; FKBP51;; FKBP54__:__
Caret__:__602624__:__MOVED TO 602570__:____:__
Asterisk__:__602625__:__MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAINS-CONTAINING, 1; MAGI1__:__MEMBRANE-ASSOCIATED GUANYLATE KINASE WITH INVERTED STRUCTURE 1; MAGI1;; MAGUK WITH INVERTED STRUCTURE 1;; BAI1-ASSOCIATED PROTEIN 1; BAP1; BAIAP1;; WW DOMAIN-CONTAINING PROTEIN 3; WWP3;; TRINUCLEOTIDE REPEAT-CONTAINING GENE 19; TNRC19__:__
Asterisk__:__602626__:__INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; IL1RAP__:__IL1RACP__:__
Asterisk__:__602627__:__CELL DIVISION CYCLE 6, S. CEREVISIAE, HOMOLOG OF; CDC6__:__CELL DIVISION CYCLE 18, S. POMBE, HOMOLOG-LIKE; CDC18L;; CELL CYCLE CONTROLLER CDC6__:__
Asterisk__:__602628__:__FORKHEAD BOX N3; FOXN3__:__CHECKPOINT SUPPRESSOR 1; CHES1__:__
Number Sign__:__602629__:__DYSTONIA 6, TORSION; DYT6__:__TORSION DYSTONIA, ADULT-ONSET, MIXED TYPE__:__
Asterisk__:__602630__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCED FACTOR; TGIF__:__TGFB-INDUCED FACTOR;; TG-INTERACTING FACTOR__:__
Asterisk__:__602631__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 18; SLC22A18__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 1-LIKE; SLC22A1L;; BECKWITH-WIEDEMANN SYNDROME CHROMOSOME REGION 1, CANDIDATE A; BWSCR1A;; BECKWITH-WIEDEMANN REGION 1A; BWR1A;; IMPRINTED POLYSPECIFIC MEMBRANE TRANSPORTER 1; IMPT1;; ORGANIC-CATION TRANSPORTER-LIKE 2; ORCTL2;; TUMOR-SUPPRESSING SUBCHROMOSOMAL TRANSFERABLE FRAGMENT CANDIDATE GENE 5; TSSC5__:__BECKWITH-WIEDEMANN SYNDROME CRITICAL REGION, INCLUDED
Asterisk__:__602632__:__PODOCALYXIN-LIKE; PODXL__:__PODOCALYXIN-LIKE PROTEIN; PCLP;; PODOCALYXIN; PC;; GP200__:__
Asterisk__:__602633__:__FOUR-AND-A-HALF LIM DOMAINS 2; FHL2__:__DOWNREGULATED IN RHABDOMYOSARCOMA LIM PROTEIN; DRAL;; SLIM3__:__
Asterisk__:__602634__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 9; DNAJB9__:__MICROVASCULAR ENDOTHELIAL DIFFERENTIATION GENE 1; MDG1;; ERDJ4__:__
Asterisk__:__602635__:__DEFORMED EPIDERMAL AUTOREGULATORY FACTOR 1 HOMOLOG; DEAF1__:__DEAF1, DROSOPHILA, HOMOLOG OF;; SUPPRESSIN; SPN;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 5; ZMYND5__:__
Asterisk__:__602636__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 8; PPP1R8__:__NUCLEAR INHIBITOR OF PROTEIN PHOSPHATASE 1; NIPP1;; ACTIVATOR OF RNA DECAY; ARD1;; RNase E, E. COLI, HOMOLOG OF__:__
Asterisk__:__602637__:__SECRETED PHOSPHOPROTEIN 2; SPP2__:__SECRETED PHOSPHOPROTEIN, 24-KD; SPP24__:__
Asterisk__:__602638__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 4; MCM4__:__MINICHROMOSOME MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, 4;; CELL DIVISION CYCLE 21, S. POMBE, HOMOLOG OF;; CDC21, S. POMBE, HOMOLOG OF__:__
Percent__:__602639__:__TOOTH AGENESIS, SELECTIVE, 2; STHAG2__:__HYPODONTIA/OLIGODONTIA 2; HYD2__:__
Asterisk__:__602640__:__N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE-LIKE 1; NAALADL1__:__ILEAL DIPEPTIDYLPEPTIDASE;; I100, RAT, HOMOLOG OF;; NAALADase L__:__
Asterisk__:__602641__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4A, ISOFORM 1; EIF4A1__:__DDX2A__:__
Asterisk__:__602642__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 11; TNFSF11__:__OSTEOPROTEGERIN LIGAND; OPGL;; RECEPTOR ACTIVATOR OF NF-KAPPA-B LIGAND; RANKL;; TNF-RELATED ACTIVATION-INDUCED CYTOKINE; TRANCE;; OSTEOCLAST DIFFERENTIATION FACTOR; ODF__:__
Asterisk__:__602643__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 11B; TNFRSF11B__:__OSTEOPROTEGERIN; OPG;; OSTEOCLASTOGENESIS INHIBITORY FACTOR; OCIF__:__
Asterisk__:__602644__:__TETRASPANIN 4; TSPAN4__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 7; TM4SF7;; TETRASPAN;; NOVEL ANTIGEN 2; NAG2__:__
Asterisk__:__602645__:__SEMAPHORIN 3C; SEMA3C__:__SEMAPHORIN E; SEMAE__:__
Asterisk__:__602646__:__G PROTEIN-COUPLED RECEPTOR 35; GPR35__:__CHEMOKINE, CXC MOTIF, RECEPTOR 8; CXCR8__:__
Asterisk__:__602647__:__NUCLEAR RNA EXPORT FACTOR 1; NXF1__:__TIP-ASSOCIATED PROTEIN; TAP;; MEX67, YEAST, HOMOLOG OF; MEX67__:__
Asterisk__:__602648__:__ATYPICAL CHEMOKINE RECEPTOR 2; ACKR2__:__CHEMOKINE-BINDING PROTEIN 2; CCBP2;; CMKBR9;; D6__:__
Asterisk__:__602649__:__COLD-INDUCIBLE RNA-BINDING PROTEIN; CIRBP__:__CIRP__:__
Asterisk__:__602650__:__SPECKLE-TYPE POZ PROTEIN; SPOP__:____:__
Asterisk__:__602651__:__NARDILYSIN; NRD1__:__N-ARGININE DIBASIC CONVERTASE;; NRD CONVERTASE__:__
Asterisk__:__602652__:__KALLIKREIN-RELATED PEPTIDASE 6; KLK6__:__KALLIKREIN 6;; PROTEASE, SERINE, 9; PRSS9;; PROTEASE M;; ZYME;; NEUROSIN__:__
Asterisk__:__602653__:__TECTORIN, BETA; TECTB__:____:__
Asterisk__:__602654__:__FERM, ARHGEF, AND PLECKSTRIN DOMAINS-CONTAINING PROTEIN 1; FARP1__:__CHONDROCYTE-DERIVED EZRIN-LIKE PROTEIN; CDEP__:__
Asterisk__:__602655__:__SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1, ADAPTOR PROTEIN; SLC4A1AP__:__KIDNEY ANION EXCHANGER ADAPTOR PROTEIN;; KANADAPTIN__:__
Asterisk__:__602656__:__ENDONUCLEASE III-LIKE 1; NTHL1__:__ENDONUCLEASE III, E. COLI, HOMOLOG OF; NTH1;; OCTS3__:__
Caret__:__602657__:__MOVED TO 300572__:____:__
Asterisk__:__602658__:__PHOSPHODIESTERASE 2A, cGMP-STIMULATED; PDE2A__:____:__
Asterisk__:__602659__:__MENAGE A TROIS 1; MNAT1__:__MAT1;; TFB3__:__
Asterisk__:__602660__:__TUBULIN, BETA-4B; TUBB4B__:__TUBULIN, BETA-2C; TUBB2C;; TUBULIN, BETA-2;; TUBULIN, BETA, CLASS IVB__:__
Asterisk__:__602661__:__TUBULIN, BETA-3; TUBB3__:__TUBB4;; TUBULIN, BETA, CLASS III__:__
Asterisk__:__602662__:__TUBULIN, BETA-4A; TUBB4A__:__TUBB4;; TUBULIN, BETA, CLASS IVA__:__
Asterisk__:__602663__:__PROLACTIN-RELEASING HORMONE; PRLH__:__PRH;; PROLACTIN-RELEASING PEPTIDE; PRRP__:__
Asterisk__:__602664__:__CASPASE 4, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP4__:__ICE AND CED3 HOMOLOG 2; ICH2;; CASPASE 11, MOUSE, HOMOLOG OF; CASP11__:__
Asterisk__:__602665__:__CASPASE 5, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP5__:____:__
Asterisk__:__602666__:__MYOSIN XVA; MYO15A__:__MYOSIN XV; MYO15__:__
Asterisk__:__602667__:__NIBRIN; NBN__:__p95 PROTEIN OF THE MRE11/RAD50 COMPLEX;; NBS1__:__
Number Sign__:__602668__:__MYOTONIC DYSTROPHY 2; DM2__:__DYSTROPHIA MYOTONICA 2;; PROXIMAL MYOTONIC MYOPATHY; PROMM;; MYOTONIC MYOPATHY, PROXIMAL;; RICKER SYNDROME__:__
Asterisk__:__602669__:__PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 3; PITX3__:__PITUITARY HOMEOBOX 3; PTX3__:__
Asterisk__:__602670__:__POLYMERASE, DNA, EPSILON-2; POLE2__:__DPE2__:__
Asterisk__:__602671__:__SOLUTE CARRIER FAMILY 37 (GLUCOSE-6-PHOSPHATE TRANSPORTER), MEMBER 4; SLC37A4__:__GLUCOSE-6-PHOSPHATE TRANSPORTER 1; G6PT1;; GLUCOSE-6-PHOSPHATE TRANSLOCASE;; G6P TRANSLOCASE__:__
Asterisk__:__602672__:__RAS-ASSOCIATED PROTEIN RAB13; RAB13__:____:__
Asterisk__:__602673__:__KALLIKREIN-RELATED PEPTIDASE 10; KLK10__:__KALLIKREIN 10;; PROTEASE, SERINE-LIKE, 1; PRSSL1__:__
Caret__:__602674__:__MOVED TO 601802__:____:__
Asterisk__:__602675__:__ARGINYL AMINOPEPTIDASE; RNPEP__:__AMINOPEPTIDASE B__:__
Asterisk__:__602676__:__PHOSPHODIESTERASE 6D, cGMP-SPECIFIC, ROD, DELTA; PDE6D__:__RETINAL ROD PHOTORECEPTOR cGMP PHOSPHODIESTERASE, DELTA SUBUNIT; PDED;; PDE-DELTA__:__
Asterisk__:__602677__:__RING FINGER PROTEIN 5; RNF5__:__RING5;; RMA1__:__
Asterisk__:__602678__:__MAP/MICROTUBULE AFFINITY-REGULATING KINASE 3; MARK3__:__MICROTUBULE-ASSOCIATED PROTEIN/MICROTUBULE AFFINITY-REGULATING KINASE 3;; CDC25C-ASSOCIATED PROTEIN KINASE 1; CTAK1;; PAR1, C. ELEGANS, HOMOLOG OF, A; PAR1A__:__
Asterisk__:__602679__:__PHOSPHATE CYTIDYLYLTRANSFERASE 2, ETHANOLAMINE; PCYT2__:__CYTIDYLYLTRANSFERASE, CTP-PHOSPHOETHANOLAMINE; ET;; ETHANOLAMINE-PHOSPHATE CYTIDYLYLTRANSFERASE__:__
Asterisk__:__602680__:__RHO GTPase-ACTIVATING PROTEIN 5; ARHGAP5__:__GTPase-ACTIVATING PROTEIN, RHO, 5; RHOGAP5__:__
Asterisk__:__602681__:__FORKHEAD BOX O3A; FOXO3A__:__FOXO3;; FORKHEAD IN RHABDOMYOSARCOMA-LIKE 1; FKHRL1;; FKHR-LIKE 1__:__
Asterisk__:__602682__:__ADHESION G PROTEIN-COUPLED RECEPTOR B1; ADGRB1__:__BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 1; BAI1;; ANGIOGENESIS INHIBITORY FACTOR, GLIOMA-DERIVED; GDAIF__:__
Asterisk__:__602683__:__ADHESION G PROTEIN-COUPLED RECEPTOR B2; ADGRB2__:__BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 2; BAI2__:__
Asterisk__:__602684__:__ADHESION G PROTEIN-COUPLED RECEPTOR B3; ADGRB3__:__BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 3; BAI3__:__
Percent__:__602685__:__MENTAL RETARDATION, SEVERE, WITH SPASTICITY AND PIGMENTARY TAPETORETINAL DEGENERATION__:__MRST__:__
Asterisk__:__602686__:__MITOTIC ARREST-DEFICIENT 1, YEAST, HOMOLOG-LIKE 1; MAD1L1__:__MITOTIC ARREST-DEFICIENT 1, YEAST, HOMOLOG OF;; MAD1, YEAST, HOMOLOG OF;; TAX-BINDING PROTEIN 181; TXBP181__:__
Caret__:__602687__:__MOVED TO 603072__:____:__
Asterisk__:__602688__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A/B; HNRNPAB__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE 1-BINDING PROTEIN 1;; APOBEC1-BINDING PROTEIN 1; ABBP1;; HNRPAB__:__
Asterisk__:__602689__:__FASCIN ACTIN-BUNDLING PROTEIN 1; FSCN1__:__FASCIN, SEA URCHIN, HOMOLOG OF, 1;; SINGED, DROSOPHILA, HOMOLOG OF; SNL;; ACTIN-BUNDLING PROTEIN, 55-KD;; p55__:__
Asterisk__:__602690__:__SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT D, INTEGRAL MEMBRANE PROTEIN; SDHD__:__SUCCINATE DEHYDROGENASE 4, INTEGRAL MEMBRANE PROTEIN; SDH4__:__
Asterisk__:__602691__:__NUCLEAR RECEPTOR COACTIVATOR 1; NCOA1__:__STEROID RECEPTOR COACTIVATOR 1; SRC1__:__
Asterisk__:__602692__:__GLIOMA PATHOGENESIS-RELATED PROTEIN 1; GLIPR1__:__GLIPR;; RELATED TO TESTIS-SPECIFIC, VESPID, AND PATHOGENESIS PROTEINS 1; RTVP1__:__
Asterisk__:__602693__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 3; MCM3__:__MINICHROMOSOME MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, 3;; REPLICATION LICENSING FACTOR, BETA SUBUNIT; RLFB;; P1 PROTEIN__:__
Asterisk__:__602694__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 4; NDUFS4__:__NADH-COENZYME Q REDUCTASE, 18-KD;; COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 18-KD SUBUNIT;; AQDQ__:__
Asterisk__:__602695__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 12; TNFSF12__:__TNF-RELATED WEAK INDUCER OF APOPTOSIS; TWEAK__:__TWEAK/APRIL SPLICED READ-THROUGH TRANSCRIPT, INCLUDED; TWEPRIL, INCLUDED
Asterisk__:__602696__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 5; MCM5__:__MINICHROMOSOME MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, 5;; CELL DIVISION CYCLE 46; CDC46__:__
Asterisk__:__602697__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 11; P2RY11__:____:__P2RY11/PPAN SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__602698__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC, CALCINEURIN-DEPENDENT 3; NFATC3__:__NFATX;; NFAT4__:__
Asterisk__:__602699__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, CYTOPLASMIC, CALCINEURIN-DEPENDENT 4; NFATC4__:__NFAT3__:__
Asterisk__:__602700__:__E1A-BINDING PROTEIN, 300-KD; EP300__:__p300__:__
Asterisk__:__602701__:__SARCOLEMMAL-ASSOCIATED PROTEIN; SLMAP__:__SLAP__:__
Asterisk__:__602702__:__PERILIPIN 3; PLIN3__:__MANNOSE 6-PHOSPHATE RECEPTOR-BINDING PROTEIN 1; M6PRBP1;; MPR-BINDING PROTEIN, 47-KD;; MPR TAIL-INTERACTING PROTEIN, 47-KD; TIP47__:__
Asterisk__:__602703__:__KATANIN, p80 SUBUNIT, B1; KATNB1__:____:__
Asterisk__:__602704__:__MOUSE DOUBLE MINUTE 4 HOMOLOG; MDM4__:__p53-BINDING PROTEIN MDM4;; MDMX;; HDMX__:__
Asterisk__:__602705__:__SYNAPSIN III; SYN3__:____:__
Asterisk__:__602706__:__PROTEASOME 26S SUBUNIT, ATPase, 1; PSMC1__:__PROTEASE 26S, SUBUNIT 4; S4__:__
Asterisk__:__602707__:__PROTEASOME 26S SUBUNIT, ATPase, 4; PSMC4__:__TAT-BINDING PROTEIN 7; TBP7;; PROTEASE 26S, SUBUNIT 6; S6__:__
Asterisk__:__602708__:__PROTEASOME 26S SUBUNIT, ATPase, 6; PSMC6__:____:__
Asterisk__:__602709__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY B, MEMBER 1; APBB1__:__FE65__:__
Asterisk__:__602710__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY B, MEMBER 2; APBB2__:__FE65-LIKE 1; FE65L1__:__
Asterisk__:__602711__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY B, MEMBER 3; APBB3__:__FE65-LIKE 2; FE65L2__:__
Asterisk__:__602712__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY A, MEMBER 2; APBA2__:__X11-LIKE; X11L;; MUNC18-1-INTERACTING PROTEIN 2; MINT2;; X11-BETA__:__
Asterisk__:__602713__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 9; ADAM9__:__MYELOMA CELL METALLOPROTEINASE; MCMP;; METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN 9; MDC9__:__
Asterisk__:__602714__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 12; ADAM12__:__MELTRIN-ALPHA, MOUSE, HOMOLOG OF; MLTN__:__
Asterisk__:__602715__:__LEIOMODIN 1; LMOD1__:__LEIOMODIN, SMOOTH MUSCLE; SMLMOD;; THYROID AND EYE MUSCLE AUTOANTIGEN, 64-KD;; THYROID-ASSOCIATED OPHTHALMOPATHY AUTOANTIGEN, 64-KD;; HASHIMOTO THYROIDITIS AUTOANTIGEN, 64-KD;; D1; 1D__:__
Asterisk__:__602716__:__NEPHRIN; NPHS1__:__NPHN;; RENAL GLOMERULUS-SPECIFIC CELL ADHESION RECEPTOR__:__
Asterisk__:__602717__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 2D; GRIN2D__:__N-METHYL-D-ASPARTATE RECEPTOR CHANNEL, SUBUNIT EPSILON-4; NMDAR2D__:__
Asterisk__:__602718__:__TRANSFORMER 2, DROSOPHILA, HOMOLOG OF, ALPHA; TRA2A__:____:__
Asterisk__:__602719__:__TRANSFORMER 2, DROSOPHILA, HOMOLOG OF, BETA; TRA2B__:__TRA2-BETA;; HTRA2-BETA-1;; SPLICING FACTOR, ARGININE/SERINE-RICH, 10; SFRS10__:__
Asterisk__:__602720__:__PARAOXONASE 3; PON3__:____:__
Asterisk__:__602721__:__DISRUPTED MEIOTIC cDNA 1, YEAST, HOMOLOG OF; DMC1__:__LIM15__:__
Number Sign__:__602722__:__RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE; RTADR__:__RTA, DISTAL, AUTOSOMAL RECESSIVE;; RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PRESERVED HEARING__:__RENAL TUBULAR ACIDOSIS, DISTAL, AUTOSOMAL RECESSIVE, WITH LATE-ONSET SENSORINEURAL HEARING LOSS, INCLUDED
Number Sign__:__602723__:__PSORIASIS 2; PSORS2__:____:__
Asterisk__:__602724__:__SEPTIN 5; SEPT5__:__PEANUT-LIKE 1; PNUTL1;; CELL DIVISION CYCLE-RELATED; CDCREL;; CDCREL1__:__PNUTL1/MLL FUSION GENE, INCLUDED
Asterisk__:__602725__:__INTERFERON-RELATED DEVELOPMENTAL REGULATOR 2; IFRD2__:__INTERFERON-RELATED PROTEIN__:__
Asterisk__:__602726__:__CHLORIDE CHANNEL 6; CLCN6__:__CLC6__:__
Asterisk__:__602727__:__CHLORIDE CHANNEL 7; CLCN7__:__CLC7__:__
Asterisk__:__602728__:__SCAVENGER RECEPTOR CLASS A, MEMBER 3; SCARA3__:__MACROPHAGE SCAVENGER RECEPTOR-LIKE 1; MSRL1;; CELLULAR STRESS RESPONSE; CSR__:__
Asterisk__:__602729__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR, PI; GABRP__:__GABA-A RECEPTOR, PI POLYPEPTIDE__:__
Asterisk__:__602730__:__ACTIVIN A RECEPTOR, TYPE IIB; ACVR2B__:__ACTRIIB__:__
Asterisk__:__602731__:__FYN-BINDING PROTEIN; FYB__:__ADHESION AND DEGRANULATION ADAPTOR PROTEIN; ADAP;; SLAP130;; p120/130__:__
Asterisk__:__602732__:__RHO GTPase-ACTIVATING PROTEIN 1; ARHGAP1__:__GTPase-ACTIVATING PROTEIN, RHO, 1;; RHOGAP1;; RHOGAP;; CDC42GAP__:__
Asterisk__:__602733__:__ALDEHYDE DEHYDROGENASE, FAMILY 9, SUBFAMILY A, MEMBER 1; ALDH9A1__:__ALDEHYDE DEHYDROGENASE 9; ALDH9;; E3__:__
Asterisk__:__602734__:__PLASTIN 1; PLS1__:__INTESTINE-SPECIFIC PLASTIN;; I-PLASTIN;; FIMBRIN__:__
Asterisk__:__602735__:__RETICULOCALBIN 1; RCN1__:____:__
Asterisk__:__602736__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT C, ISOFORM 3; ATP5G3__:__MITOCHONDRIAL ATP SYNTHASE, SUBUNIT C, ISOFORM 3;; MITOCHONDRIAL ATP SYNTHASE, SUBUNIT 9, ISOFORM 3__:__
Asterisk__:__602737__:__CHEMOKINE, CC MOTIF, LIGAND 21; CCL21__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 21; SCYA21;; SECONDARY LYMPHOID TISSUE CHEMOKINE; SLC;; EXODUS 2__:__
Asterisk__:__602738__:__KARYOPHERIN BETA-1; KPNB1__:__IMPORTIN BETA-1__:__
Asterisk__:__602739__:__PROTEIN KINASE, AMP-ACTIVATED, CATALYTIC, ALPHA-1; PRKAA1__:__AMP-ACTIVATED PROTEIN KINASE, CATALYTIC, ALPHA-1;; AMPK-ALPHA-1__:__
Asterisk__:__602740__:__PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, BETA-1; PRKAB1__:__AMP-ACTIVATED PROTEIN KINASE, NONCATALYTIC, BETA-1;; AMPK-BETA-1__:__
Asterisk__:__602741__:__PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, BETA-2; PRKAB2__:__AMP-ACTIVATED PROTEIN KINASE, NONCATALYTIC, BETA-2;; AMPK-BETA-2__:__
Asterisk__:__602742__:__PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-1; PRKAG1__:__AMP-ACTIVATED PROTEIN KINASE, NONCATALYTIC, GAMMA-1;; AMPK-GAMMA-1__:__
Asterisk__:__602743__:__PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-2; PRKAG2__:__AMP-ACTIVATED PROTEIN KINASE, NONCATALYTIC, GAMMA-2;; AMPK-GAMMA-2__:__
Asterisk__:__602744__:__GLYCERONEPHOSPHATE O-ACYLTRANSFERASE; GNPAT__:__DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE; DHAPAT; DAPAT;; ACYL-CoA:DIHYDROXYACETONEPHOSPHATE ACYLTRANSFERASE__:__
Asterisk__:__602745__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE I, BETA; PIP5K1B__:__MSS4, YEAST, HOMOLOG OF;; STM7__:__
Asterisk__:__602746__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14__:__HERPESVIRUS ENTRY MEDIATOR; HVEM;; HERPESVIRUS ENTRY MEDIATOR A; HVEA;; TR2__:__
Asterisk__:__602747__:__DUAL-SPECIFICITY PHOSPHATASE 4; DUSP4__:__MAP KINASE PHOSPHATASE 2; MKP2;; VH1 HOMOLOGOUS PHOSPHATASE 2; HVH2__:__
Asterisk__:__602748__:__DUAL-SPECIFICITY PHOSPHATASE 6; DUSP6__:__MAP KINASE PHOSPHATASE 3; MKP3;; PYST1__:__
Asterisk__:__602749__:__DUAL-SPECIFICITY PHOSPHATASE 7; DUSP7__:__MAP KINASE PHOSPHATASE X; MKPX;; PYST2__:__
Asterisk__:__602750__:__D-DOPACHROME TAUTOMERASE; DDT__:____:__
Asterisk__:__602751__:__BTB AND CNC HOMOLOGY 1; BACH1__:__BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1__:__
Asterisk__:__602752__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 8; RGPD8__:__RGP8;; RANBP2-ALPHA;; RANBP2-LIKE 1; RANBP2L1__:__
Asterisk__:__602753__:__ARISTALESS HOMEOBOX, DROSOPHILA, HOMOLOG OF; ARIX__:__PHOX2A__:__
Asterisk__:__602754__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, INTERMEDIATE/SMALL CONDUCTANCE, SUBFAMILY N, MEMBER 4; KCNN4__:__IK1;; SK4;; KCA4;; KCA3.1__:__
Asterisk__:__602755__:__CYCLIN B2; CCNB2__:____:__
Asterisk__:__602756__:__EPHRIN A2; EFNA2__:__EPH-RELATED RECEPTOR TYROSINE KINASE LIGAND 6; EPLG6;; LIGAND OF EPH-RELATED KINASE 6; LERK6__:__
Asterisk__:__602757__:__EPHRIN RECEPTOR EphB6; EPHB6__:__HUMAN KINASE-DEFECTIVE Eph-FAMILY RECEPTOR PROTEIN; HEP__:__
Asterisk__:__602758__:__PHOSPHATIDYLINOSITOL 4-KINASE, CATALYTIC, BETA; PIK4CB__:__PI4K-BETA; PI4KB;; PHOSPHATIDYLINOSITOL 4-KINASE, TYPE III, BETA;; PI4KIII-BETA;; PHOSPHATIDYLINOSITOL 4-KINASE, WORTMANNIN-SENSITIVE__:__
Percent__:__602759__:__PROSTATE CANCER, HEREDITARY, 8; HPC8__:__PREDISPOSING FOR PROSTATE CANCER; PCAP__:__
Asterisk__:__602760__:__KERATIN 32, TYPE I; KRT32__:__K32;; KA26;; KERATIN, HAIR, ACIDIC, 2; KRTHA2;; KERATIN, HARD, TYPE I, 2; HA2__:__
Asterisk__:__602761__:__KERATIN 33A, TYPE I; KRT33A__:__K33A;; KA27;; KERATIN, HAIR, ACIDIC, 3A; KRTHA3A;; KERATIN, HARD, TYPE I, 3I; HA3I__:__
Asterisk__:__602762__:__KERATIN 33B, TYPE I; KRT33B__:__K33B;; KA28;; KERATIN, HAIR, ACIDIC, 3B; KRTHA3B;; KERATIN, HARD, TYPE I, 3II; HA3II__:__
Asterisk__:__602763__:__KERATIN 34, TYPE I; KRT34__:__K34;; KA29;; KERATIN, HAIR, ACIDIC, 4; KRTHA4;; KERATIN, HARD, TYPE I, 4; HA4__:__
Asterisk__:__602764__:__KERATIN 35, TYPE I; KRT35__:__K35;; KA30;; KERATIN, HAIR, ACIDIC, 5; KRTHA5;; KERATIN, HARD, TYPE I, 5; HA5__:__
Asterisk__:__602765__:__KERATIN 83, TYPE II; KRT83__:__K83;; KB23;; K2.10;; KERATIN, HAIR, BASIC, 3; KRTHB3;; KERATIN, HARD, TYPE II, 3; HB3__:__
Asterisk__:__602766__:__KERATIN 84, TYPE II; KRT84__:__K84;; KB24;; KERATIN, HAIR, BASIC, 4; KRTHB4;; KERATIN, HARD, TYPE II, 4; HB4__:__
Asterisk__:__602767__:__KERATIN 85, TYPE II; KRT85__:__K85;; KB25;; K2.12;; KERATIN, HAIR, BASIC, 5; KRTHB5;; KERATIN, HARD, TYPE II, 5; HB5__:__
Asterisk__:__602768__:__DELTA-LIKE 3; DLL3__:__DELTA, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__602769__:__DNA METHYLTRANSFERASE 3A; DNMT3A__:____:__
Asterisk__:__602770__:__CHROMOBOX HOMOLOG 2, DROSOPHILA POLYCOMB CLASS; CBX2__:__M33, MOUSE, HOMOLOG OF__:__
Number Sign__:__602771__:__RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1__:__RIGID SPINE SYNDROME; RSS;; MYOPATHY, SEPN1-RELATED;; MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE, WITH EARLY SPINE RIGIDITY; MDRS1;; MULTICORE MYOPATHY, SEVERE CLASSIC FORM;; MINICORE MYOPATHY, SEVERE CLASSIC FORM;; MULTIMINICORE DISEASE, SEVERE CLASSIC FORM;; DESMIN-RELATED MYOPATHY WITH MALLORY BODIES;; MUSCULAR DYSTROPHY, CONGENITAL, EICHSFELD TYPE__:__
Number Sign__:__602772__:__RETINITIS PIGMENTOSA 25; RP25__:____:__
Asterisk__:__602773__:__DISRUPTED IN RENAL CARCINOMA 2; DIRC2__:____:__
Asterisk__:__602774__:__RAD51, S. CEREVISIAE, HOMOLOG OF, C; RAD51C__:____:__
Asterisk__:__602775__:__SUPPRESSOR OF CLEAR, C. ELEGANS, HOMOLOG OF; SHOC2__:__RAS-BINDING PROTEIN SUR8, C. ELEGANS, HOMOLOG OF; SUR8__:__
Asterisk__:__602776__:__REV3, S. CEREVISIAE, HOMOLOG OF; REV3L__:__REV3;; POLYMERASE, DNA, ZETA; POLZ__:__
Asterisk__:__602777__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, POLYPEPTIDE 4; SNAPC4__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, 190-KD SUBUNIT; SNAP190;; PSE-BINDING TRANSCRIPTION FACTOR, ALPHA;; PTF-ALPHA__:__
Asterisk__:__602778__:__NUCLEAR RECEPTOR SUBFAMILY 6, GROUP A, MEMBER 1; NR6A1__:__GERM CELL NUCLEAR FACTOR; GCNF;; RETINOID RECEPTOR-RELATED TESTIS-ASSOCIATED RECEPTOR; RTR__:__
Asterisk__:__602779__:__COAGULATION FACTOR II RECEPTOR-LIKE 3; F2RL3__:__THROMBIN RECEPTOR-LIKE 3;; PROTEASE-ACTIVATED RECEPTOR 4; PAR4__:__
Asterisk__:__602780__:__HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED POTASSIUM CHANNEL 1; HCN1__:__BRAIN CYCLIC-NUCLEOTIDE GATED 1; BCNG1;; POTASSIUM CHANNEL, VOLTAGE-GATED, BRAIN, 1__:__
Asterisk__:__602781__:__HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED POTASSIUM CHANNEL 2; HCN2__:__BRAIN CYCLIC-NUCLEOTIDE GATED 2; BCNG2;; POTASSIUM CHANNEL, VOLTAGE-GATED, BRAIN, 2__:__
Number Sign__:__602782__:__HISTIOCYTOSIS-LYMPHADENOPATHY PLUS SYNDROME__:__HISTIOCYTOSIS AND LYMPHADENOPATHY WITH OR WITHOUT CUTANEOUS, CARDIAC, AND/OR ENDOCRINE FEATURES, JOINT CONTRACTURES, AND/OR DEAFNESS;; HYPERPIGMENTATION, CUTANEOUS, WITH HYPERTRICHOSIS, HEPATOSPLENOMEGALY, HEART ANOMALIES, AND HYPOGONADISM WITH OR WITHOUT HEARING LOSS;; H SYNDROME;; PIGMENTED HYPERTRICHOSIS WITH INSULIN-DEPENDENT DIABETES MELLITUS; PHID;; HISTIOCYTOSIS WITH JOINT CONTRACTURES AND SENSORINEURAL DEAFNESS; HJCD;; FAISALABAD HISTIOCYTOSIS;; ROSAI-DORFMAN DISEASE, FAMILIAL;; SINUS HISTIOCYTOSIS AND MASSIVE LYMPHADENOPATHY; SHML__:__
Asterisk__:__602783__:__SPG7 GENE; SPG7__:__PARAPLEGIN; PGN;; CELL MATRIX ADHESION REGULATOR; CMAR;; CELL ADHESION REGULATOR; CAR__:__
Asterisk__:__602784__:__CORTISTATIN; CORT__:____:__
Asterisk__:__602785__:__H1 HISTONE FAMILY, MEMBER X; H1FX__:__H1X__:__
Asterisk__:__602786__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER E; HIST1H2AE__:__HISTONE GENE CLUSTER 1, H2AE;; HIST1 CLUSTER, H2AE;; H2A HISTONE FAMILY, MEMBER A; H2AFA;; H2A/A;; H2A.1__:__
Asterisk__:__602787__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER I; HIST1H2AI__:__HISTONE GENE CLUSTER 1, H2AI;; HIST1 CLUSTER, H2AI;; H2A HISTONE FAMILY, MEMBER C; H2AFC;; H2A/C__:__
Asterisk__:__602788__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER K; HIST1H2AK__:__HISTONE GENE CLUSTER 1, H2AK;; HIST1 CLUSTER, H2AK;; H2A HISTONE FAMILY, MEMBER D; H2AFD;; H2A/D;; HIST1H2AI, FORMERLY__:__
Caret__:__602789__:__MOVED TO 300163__:____:__
Asterisk__:__602790__:__FOUR-AND-A-HALF LIM DOMAINS 3; FHL3__:__SLIM2__:__
Asterisk__:__602791__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER J; HIST1H2AJ__:__HISTONE GENE CLUSTER 1, H2AJ;; HIST1 CLUSTER, H2AJ;; H2A HISTONE FAMILY, MEMBER E; H2AFE;; H2A/E;; HIST1H2AK, FORMERLY__:__
Asterisk__:__602792__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER D; HIST1H2AD__:__HISTONE GENE CLUSTER 1, H2AD;; HIST1 CLUSTER, H2AD;; H2A HISTONE FAMILY, MEMBER G; H2AFG;; H2A/G__:__
Asterisk__:__602793__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER L; HIST1H2AL__:__HISTONE GENE CLUSTER 1, H2AL;; HIST1 CLUSTER, H2AL;; H2A HISTONE FAMILY, MEMBER I; H2AFI;; H2A/I__:__
Asterisk__:__602794__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER C; HIST1H2AC__:__HISTONE GENE CLUSTER 1, H2AC;; HIST1 CLUSTER, H2AC;; H2A HISTONE FAMILY, MEMBER L; H2AFL;; H2A/L__:__
Asterisk__:__602795__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER B; HIST1H2AB__:__HISTONE GENE CLUSTER 1, H2AB;; HIST1 CLUSTER, H2AB;; H2A HISTONE FAMILY, MEMBER M; H2AFM;; H2A/M__:__
Asterisk__:__602796__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER M; HIST1H2AM__:__HISTONE GENE CLUSTER 1, H2AM;; HIST1 CLUSTER, H2AM;; H2A HISTONE FAMILY, MEMBER N; H2AFN;; H2A/N;; H2A.1__:__
Asterisk__:__602797__:__HISTONE GENE CLUSTER 2, H2A HISTONE FAMILY, MEMBER C; HIST2H2AC__:__HISTONE GENE CLUSTER 2, H2AC;; HIST2 CLUSTER, H2AC;; H2A HISTONE FAMILY, MEMBER Q; H2AFQ;; H2A/Q__:__
Asterisk__:__602798__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER G; HIST1H2BG__:__HISTONE GENE CLUSTER 1, H2BG;; HIST1 CLUSTER, H2BG;; H2B HISTONE FAMILY, MEMBER A; H2BFA;; H2B/A;; H2B.1A__:__
Asterisk__:__602799__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER D; HIST1H2BD__:__HISTONE GENE CLUSTER 1, H2BD;; HIST1 CLUSTER, H2BD;; H2B HISTONE FAMILY, MEMBER B; H2BFB;; H2B/B;; H2B.1B__:__
Asterisk__:__602800__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER L; HIST1H2BL__:__HISTONE GENE CLUSTER 1, H2BL;; HIST1 CLUSTER, H2BL;; H2B HISTONE FAMILY, MEMBER C; H2BFC;; H2B/C__:__
Asterisk__:__602801__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER N; HIST1H2BN__:__HISTONE GENE CLUSTER 1, H2BN;; HIST1 CLUSTER, H2BN;; H2B HISTONE FAMILY, MEMBER D; H2BFD;; H2B/D__:__
Asterisk__:__602802__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER M; HIST1H2BM__:__HISTONE GENE CLUSTER 1, H2BM;; HIST1 CLUSTER, H2BM;; H2B HISTONE FAMILY, MEMBER E; H2BFE;; H2B/E__:__
Asterisk__:__602803__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER B; HIST1H2BB__:__HISTONE GENE CLUSTER 1, H2BB;; HIST1 CLUSTER, H2BB;; H2B HISTONE FAMILY, MEMBER F; H2BFF;; H2B/F;; H2B.1__:__
Asterisk__:__602804__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER F; HIST1H2BF__:__HISTONE GENE CLUSTER 1, H2BF;; HIST1 CLUSTER, H2BF;; H2B HISTONE FAMILY, MEMBER G; H2BFG;; H2B/G__:__
Asterisk__:__602805__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER E; HIST1H2BE__:__HISTONE GENE CLUSTER 1, H2BE;; HIST1 CLUSTER, H2BE;; H2B HISTONE FAMILY, MEMBER H; H2BFH;; H2B/H__:__
Asterisk__:__602806__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER H; HIST1H2BH__:__HISTONE GENE CLUSTER 1, H2BH;; HIST1 CLUSTER, H2BH;; H2B HISTONE FAMILY, MEMBER J; H2BFJ;; H2B/J__:__
Asterisk__:__602807__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER I; HIST1H2BI__:__HISTONE GENE CLUSTER 1, H2BI;; HIST1 CLUSTER, H2BI;; H2B HISTONE FAMILY, MEMBER K; H2BFK;; H2B/K__:__
Asterisk__:__602808__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER O; HIST1H2BO__:__HISTONE GENE CLUSTER 1, H2BO;; HIST1 CLUSTER, H2BO;; H2B HISTONE FAMILY, MEMBER N; H2BFN;; H2B/N;; H2B.2__:__
Asterisk__:__602809__:__KINESIN FAMILY MEMBER 5B; KIF5B__:__KINESIN 1 HEAVY CHAIN; KNS1;; KINESIN, HEAVY CHAIN, UBIQUITOUS; UKHC;; KINH__:__
Asterisk__:__602810__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER A; HIST1H3A__:__HISTONE GENE CLUSTER 1, H3A;; HIST1 CLUSTER, H3A;; H3 HISTONE FAMILY, MEMBER A; H3FA;; H3/A__:__
Asterisk__:__602811__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER D; HIST1H3D__:__HISTONE GENE CLUSTER 1, H3D;; HIST1 CLUSTER, H3D;; H3 HISTONE FAMILY, MEMBER B; H3FB;; H3/B__:__
Asterisk__:__602812__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER C; HIST1H3C__:__HISTONE GENE CLUSTER 1, H3C;; HIST1 CLUSTER, H3C;; H3 HISTONE FAMILY, MEMBER C; H3FC;; H3/C__:__
Asterisk__:__602813__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER E; HIST1H3E__:__HISTONE GENE CLUSTER 1, H3E;; HIST1 CLUSTER, H3E;; H3 HISTONE FAMILY, MEMBER D; H3FD;; H3/D__:__
Asterisk__:__602814__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER I; HIST1H3I__:__HISTONE GENE CLUSTER 1, H3I;; HIST1 CLUSTER, H3I;; H3 HISTONE FAMILY, MEMBER F; H3FF;; H3/F__:__
Asterisk__:__602815__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER G; HIST1H3G__:__HISTONE GENE CLUSTER 1, H3G;; HIST1 CLUSTER, H3G;; H3 HISTONE FAMILY, MEMBER H; H3FH;; H3/H__:__
Asterisk__:__602816__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER F; HIST1H3F__:__HISTONE GENE CLUSTER 1, H3F;; HIST1 CLUSTER, H3F;; H3 HISTONE FAMILY, MEMBER I; H3FI;; H3/I__:__
Asterisk__:__602817__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER J; HIST1H3J__:__HISTONE GENE CLUSTER 1, H3J;; HIST1 CLUSTER, H3J;; H3 HISTONE FAMILY, MEMBER J; H3FJ;; H3/J__:__
Asterisk__:__602818__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER H; HIST1H3H__:__HISTONE GENE CLUSTER 1, H3H;; HIST1 CLUSTER, H3H;; H3 HISTONE FAMILY, MEMBER K; H3FK;; H3/K__:__
Asterisk__:__602819__:__HISTONE GENE CLUSTER 1, H3 HISTONE FAMILY, MEMBER B; HIST1H3B__:__HISTONE GENE CLUSTER 1, H3B;; HIST1 CLUSTER, H3B;; H3 HISTONE FAMILY, MEMBER L; H3FL;; H3/L__:__
Asterisk__:__602820__:__HISTONE GENE CLUSTER 3, H3 HISTONE; HIST3H3__:__HISTONE GENE CLUSTER 3, H3;; HIST3 CLUSTER, H3;; H3 HISTONE FAMILY, MEMBER T; H3FT; H3T;; H3.4__:__
Asterisk__:__602821__:__KINESIN FAMILY MEMBER 5A; KIF5A__:__KINESIN, HEAVY CHAIN, NEURON-SPECIFIC; NKHC__:__
Asterisk__:__602822__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER A; HIST1H4A__:__HISTONE GENE CLUSTER 1, H4A;; HIST1 CLUSTER, H4A;; H4 HISTONE FAMILY, MEMBER A; H4FA;; H4/A__:__
Asterisk__:__602823__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER D; HIST1H4D__:__HISTONE GENE CLUSTER 1, H4D;; HIST1 CLUSTER, H4D;; H4 HISTONE FAMILY, MEMBER B; H4FB;; H4/B__:__
Asterisk__:__602824__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER F; HIST1H4F__:__HISTONE GENE CLUSTER 1, H4F;; HIST1 CLUSTER, H4F;; H4 HISTONE FAMILY, MEMBER C; H4FC;; H4/C__:__
Asterisk__:__602825__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER K; HIST1H4K__:__HISTONE GENE CLUSTER 1, H4K;; HIST1 CLUSTER, H4K;; H4 HISTONE FAMILY, MEMBER D; H4FD;; H4/D__:__
Asterisk__:__602826__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER J; HIST1H4J__:__HISTONE GENE CLUSTER 1, H4J;; HIST1 CLUSTER, H4J;; H4 HISTONE FAMILY, MEMBER E; H4FE;; H4/E__:__
Asterisk__:__602827__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER C; HIST1H4C__:__HISTONE GENE CLUSTER 1, H4C;; HIST1 CLUSTER, H4C;; H4 HISTONE FAMILY, MEMBER G; H4FG;; H4/G__:__
Asterisk__:__602828__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER H; HIST1H4H__:__HISTONE GENE CLUSTER 1, H4H;; HIST1 CLUSTER, H4H;; H4 HISTONE FAMILY, MEMBER H; H4FH;; H4/H__:__
Asterisk__:__602829__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER B; HIST1H4B__:__HISTONE GENE CLUSTER 1, H4B;; HIST1 CLUSTER, H4B;; H4 HISTONE FAMILY, MEMBER I; H4FI;; H4/I__:__
Asterisk__:__602830__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER E; HIST1H4E__:__HISTONE GENE CLUSTER 1, H4E;; HIST1 CLUSTER, H4E;; H4 HISTONE FAMILY, MEMBER J; H4FJ; H4/J__:__
Asterisk__:__602831__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER L; HIST1H4L__:__HISTONE GENE CLUSTER 1, H4L;; HIST1 CLUSTER, H4L;; H4 HISTONE FAMILY, MEMBER K; H4FK;; H4/K__:__
Asterisk__:__602832__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER G; HIST1H4G__:__HISTONE GENE CLUSTER 1, H4G;; HIST1 CLUSTER, H4G;; H4 HISTONE FAMILY, MEMBER L; H4FL;; H4/L__:__
Asterisk__:__602833__:__HISTONE GENE CLUSTER 1, H4 HISTONE FAMILY, MEMBER I; HIST1H4I__:__HISTONE GENE CLUSTER 1, H4I;; HIST1 CLUSTER, H4I;; H4 HISTONE FAMILY, MEMBER M; H4FM; H4M__:__H4FM/BCL6 FUSION GENE, INCLUDED
Caret__:__602834__:__MOVED TO 600279__:____:__
Asterisk__:__602835__:__GROWTH ARREST-SPECIFIC 2; GAS2__:____:__
Asterisk__:__602836__:__PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 5; P2RX5__:__P2X5R; P2X5__:__
Asterisk__:__602837__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY A, MEMBER 1; DNAJA1__:__DJA1;; HEAT-SHOCK PROTEIN, DNAJ-LIKE 2; HDJ2; HSJ2; HSDJ;; HEAT-SHOCK 40-KD PROTEIN 4; HSPF4__:__
Asterisk__:__602838__:__PHOSPHATIDYLINOSITOL 3-KINASE, CLASS 2, BETA; PIK3C2B__:____:__
Asterisk__:__602839__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, DELTA; PIK3CD__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, DELTA;; p110-DELTA;; PI3K-DELTA;; PIK3-DELTA__:__
Asterisk__:__602840__:__CD70 ANTIGEN; CD70__:__CD27 LIGAND; CD27L;; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 7; TNFSF7__:__
Asterisk__:__602841__:__ALDEHYDE OXIDASE 1; AOX1__:____:__
Asterisk__:__602842__:__GEMININ; GMNN__:__GEM__:__
Asterisk__:__602843__:__RHO GDP-DISSOCIATION INHIBITOR BETA; ARHGDIB__:__GDP-DISSOCIATION INHIBITOR D4; GDID4; D4;; LYGDI__:__
Asterisk__:__602844__:__RHO GDP-DISSOCIATION INHIBITOR GAMMA; ARHGDIG__:__RHOGDI-GAMMA__:__
Asterisk__:__602845__:__KINESIN FAMILY MEMBER 3C; KIF3C__:____:__
Asterisk__:__602846__:__UBIQUITIN-CONJUGATING ENZYME E2K; UBE2K__:__HUNTINGTIN-INTERACTING PROTEIN 2; HIP2;; UBIQUITIN-CONJUGATING ENZYME E2-25K__:__
Asterisk__:__602847__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER C; HIST1H2BC__:__HISTONE GENE CLUSTER 1, H2BC;; HIST1 CLUSTER, H2BC;; H2B HISTONE FAMILY, MEMBER L; H2BFL;; H2B/L__:__
Asterisk__:__602848__:__BROMODOMAIN-CONTAINING PROTEIN 8; BRD8__:__SKELETAL MUSCLE ABUNDANT PROTEIN; SMAP;; THYROID HORMONE RECEPTOR-INTERACTING PROTEIN p120__:__
Number Sign__:__602849__:__MUENKE SYNDROME; MNKES__:__MUENKE NONSYNDROMIC CORONAL CRANIOSYNOSTOSIS__:__
Asterisk__:__602850__:__RING FINGER PROTEIN 4; RNF4__:____:__
Asterisk__:__602851__:__ADHESION G PROTEIN-COUPLED RECEPTOR V1; ADGRV1__:__G PROTEIN-COUPLED RECEPTOR 98; GPR98;; MONOGENIC AUDIOGENIC SEIZURE SUSCEPTIBILITY 1, MOUSE, HOMOLOG OF; MASS1;; VERY LARGE G PROTEIN-COUPLED RECEPTOR 1; VLGR1;; KIAA0686__:__
Asterisk__:__602852__:__NUDIX HYDROLASE 2; NUDT2__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 2;; NUDIX MOTIF 2;; AP4A HYDROLASE 1; APAH1__:__
Asterisk__:__602853__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, R; PTPRR__:__PC12 PROTEIN-TYROSINE PHOSPHATASE; PCPTP1__:__
Asterisk__:__602854__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 1; PSMA1__:__PROTEASOME SUBUNIT NU;; HC2;; PROS30__:__
Asterisk__:__602855__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 6; PSMA6__:__PROTEASOME SUBUNIT IOTA;; PROS27;; p27K__:__
Asterisk__:__602856__:__REGULATOR OF G PROTEIN SIGNALING 10; RGS10__:____:__
Asterisk__:__602857__:__CHIMERIN 2; CHN2__:__CHIMERIN, BETA-2;; GTPase-ACTIVATING PROTEIN, RHO, 3; ARHGAP3;; RHO GTPase-ACTIVATING PROTEIN 3; RHOGAP3__:__CHIMERIN, BETA, INCLUDED;; CHIMERIN, BETA-1, INCLUDED;; CHIMERIN, TESTIS-SPECIFIC, INCLUDED
Asterisk__:__602858__:__7-DEHYDROCHOLESTEROL REDUCTASE; DHCR7__:__STEROL DELTA-7-REDUCTASE__:__
Asterisk__:__602859__:__PEROXISOME BIOGENESIS FACTOR 10; PEX10__:__PEROXIN 10__:__
Asterisk__:__602860__:__BUDDING UNINHIBITED BY BENZIMIDAZOLES 1, S. CEREVISIAE, HOMOLOG OF, BETA; BUB1B__:__BUB1, S. CEREVISIAE, HOMOLOG OF, BETA;; MITOTIC CHECKPOINT GENE BUB1B;; BUBR1__:__
Asterisk__:__602861__:__PLAKOPHILIN 2; PKP2__:____:__
Asterisk__:__602862__:__UDP-N-ACETYLGLUCOSAMINE PYROPHOSPHORYLASE 1; UAP1__:__SPERM-ASSOCIATED ANTIGEN 2; SPAG2;; ANTIGEN X; AgX__:__
Asterisk__:__602863__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 9A; WNT9A__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 14; WNT14__:__
Asterisk__:__602864__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 9B; WNT9B__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 15; WNT15__:__
Asterisk__:__602865__:__BONE MORPHOGENETIC PROTEIN/RETINOIC ACID-INDUCIBLE NEURAL-SPECIFIC PROTEIN 1; BRINP1__:__DELETED IN BLADDER CANCER 1; DBC1;; DELETED IN BLADDER CANCER CHROMOSOME REGION CANDIDATE 1; DBCCR1__:__
Asterisk__:__602866__:__CATION CHANNEL, AMILORIDE-SENSITIVE, NEURONAL, 2; ACCN2__:__BRAIN SODIUM CHANNEL 2; BNAC2;; ACID-SENSING ION CHANNEL; ASIC;; ASIC1__:__
Asterisk__:__602867__:__INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7; IGFBP7__:__IGF-BINDING PROTEIN-RELATED PROTEIN 1; IGFBPRP1;; MAC25;; PROSTACYCLIN-STIMULATING FACTOR; PSF;; ANGIOMODULIN; AGM__:__
Asterisk__:__602868__:__CELL DIVISION CYCLE 5, S. POMBE, HOMOLOG OF; CDC5L__:__CDC5-LIKE__:__
Asterisk__:__602869__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U; HNRNPU__:__HNRPU;; SCAFFOLD ATTACHMENT FACTOR A; SAFA__:__
Asterisk__:__602870__:__INTERPHOTORECEPTOR MATRIX PROTEOGLYCAN 1; IMPG1__:__INTERPHOTORECEPTOR MATRIX PROTEOGLYCAN 150; IPM150__:__
Asterisk__:__602871__:__PERIPLAKIN; PPL__:____:__
Asterisk__:__602872__:__CHLORIDE INTRACELLULAR CHANNEL 1; CLIC1__:__NCC27__:__
Asterisk__:__602873__:__NEBULIN-RELATED ANCHORING PROTEIN; NRAP__:____:__
Asterisk__:__602874__:__UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE; UGCG__:__GLUCOSYLCERAMIDE SYNTHASE; GCS;; CERAMIDE GLUCOSYLTRANSFERASE__:__
Number Sign__:__602875__:__ACROMESOMELIC DYSPLASIA, MAROTEAUX TYPE; AMDM__:__ST. HELENA DYSPLASIA__:__
Asterisk__:__602876__:__OCCLUDIN; OCLN__:____:__
Asterisk__:__602877__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 7; PPP1R7__:__SDS22, S. POMBE, HOMOLOG OF__:__
Asterisk__:__602878__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 3; SLC30A3__:__ZINC TRANSPORTER 3; ZNT3__:__
Asterisk__:__602879__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 1; EPB41L1__:__NONERYTHROID PROTEIN 4.1, NEURON TYPE; 4.1N__:__
Asterisk__:__602880__:__GROWTH/DIFFERENTIATION FACTOR 1; GDF1__:____:__
Asterisk__:__602881__:__PHD FINGER PROTEIN 1; PHF1__:__POLYCOMBLIKE, DROSOPHILA, HOMOLOG OF, 1; PCL1;; PCL, DROSOPHILA, HOMOLOG OF, 1__:__
Asterisk__:__602882__:__LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2; LECT2__:____:__
Asterisk__:__602883__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1A2; SLCO1A2__:__ORGANIC ANION TRANSPORTER A; OATPA;; ORGANIC ANION TRANSPORTER 1A2; OATP1A2;; SOLUTE CARRIER FAMILY 21 (ORGANIC ANION TRANSPORTER), MEMBER 3, FORMERLY; SLC21A3, FORMERLY__:__
Asterisk__:__602884__:__GDP-MANNOSE 4,6-DEHYDRATASE; GMDS__:__GMD__:__
Asterisk__:__602885__:__MOTILIN RECEPTOR; MLNR__:__MOTILIN RECEPTOR 1; MTLR1;; G PROTEIN-COUPLED RECEPTOR 38; GPR38__:__
Asterisk__:__602886__:__G PROTEIN-COUPLED RECEPTOR 39; GPR39__:____:__
Asterisk__:__602887__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 4; DLG4__:__POSTSYNAPTIC DENSITY 95; PSD95;; SYNAPSE-ASSOCIATED PROTEIN 90; SAP90__:__
Asterisk__:__602888__:__BETAINE-HOMOCYSTEINE METHYLTRANSFERASE; BHMT__:____:__
Caret__:__602889__:__MOVED TO 601533__:____:__
Asterisk__:__602890__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 1; KLRB1__:__NKRP1A;; NKR;; CD161__:__
Asterisk__:__602891__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY C, MEMBER 2; KLRC2__:__NKG2C__:__
Asterisk__:__602892__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY C, MEMBER 3; KLRC3__:__NKG2E__:__
Asterisk__:__602893__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY C, MEMBER 4; KLRC4__:__NKG2F__:__
Asterisk__:__602894__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY D, MEMBER 1; KLRD1__:__CD94 ANTIGEN; CD94__:__
Asterisk__:__602895__:__SCAFFOLD ATTACHMENT FACTOR B; SAFB__:__SAFB1;; HSP27 ESTROGEN RESPONSE ELEMENT- AND TATA BOX-BINDING PROTEIN; HET__:__
Asterisk__:__602896__:__MITOGEN-ACTIVATED PROTEIN KINASE 9; MAPK9__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 9; PRKM9;; C-JUN KINASE 2; JNK2__:__
Asterisk__:__602897__:__MITOGEN-ACTIVATED PROTEIN KINASE 10; MAPK10__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 10; PRKM10;; C-JUN KINASE 3; JNK3__:__
Asterisk__:__602898__:__MITOGEN-ACTIVATED PROTEIN KINASE 11; MAPK11__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 11; PRKM11;; STRESS-ACTIVATED PROTEIN KINASE 2B; SAPK2B;; p38-BETA;; p38-2;; p38-BETA-2__:__
Asterisk__:__602899__:__MITOGEN-ACTIVATED PROTEIN KINASE 13; MAPK13__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 13; PRKM13;; STRESS-ACTIVATED PROTEIN KINASE 4; SAPK4;; p38-DELTA__:__
Asterisk__:__602900__:__DNA METHYLTRANSFERASE 3B; DNMT3B__:____:__
Asterisk__:__602901__:__TRANSPORTIN 1; TNPO1__:__TRANSPORTIN;; KARYOPHERIN BETA-2; KPNB2;; M9-INTERACTING PROTEIN; MIP1;; IMPORTIN BETA-2__:__
Asterisk__:__602902__:__KRUPPEL-LIKE FACTOR 9; KLF9__:__BASIC TRANSCRIPTION ELEMENT-BINDING PROTEIN 1; BTEB1;; BTEB__:__
Asterisk__:__602903__:__KRUPPEL-LIKE FACTOR 5; KLF5__:__BASIC TRANSCRIPTION ELEMENT-BINDING PROTEIN 2; BTEB2__:__
Asterisk__:__602904__:__MITOGEN-ACTIVATED PROTEIN KINASE 6; MAPK6__:__PROTEIN KINASE, MITOGEN-ACTIVATED, 6; PRKM6;; EXTRACELLULAR SIGNAL-REGULATED KINASE 3; ERK3;; p97MAPK__:__
Asterisk__:__602905__:__POTASSIUM CHANNEL, VOLTAGE-GATED, DELAYED-RECTIFIER, SUBFAMILY S, MEMBER 1; KCNS1__:__VOLTAGE-GATED POTASSIUM CHANNEL 9.1; KV9.1__:__
Asterisk__:__602906__:__POTASSIUM CHANNEL, VOLTAGE-GATED, DELAYED-RECTIFIER, SUBFAMILY S, MEMBER 2; KCNS2__:__VOLTAGE-GATED POTASSIUM CHANNEL 9.2; KV9.2__:__
Asterisk__:__602907__:__CENTRIN 3; CETN3__:__CDC31, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__602908__:__RETINOBLASTOMA-BINDING PROTEIN 9; RBBP9__:__B5T OVEREXPRESSED GENE; BOG;; RBBP10__:__
Asterisk__:__602909__:__CLAUDIN 4; CLDN4__:__CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTOR 1; CPETR1;; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTOR, HIGH AFFINITY;; ENTEROTOXIN OF CLOSTRIDIUM PERFRINGENS, RECEPTOR OF, 1;; CPER__:__
Asterisk__:__602910__:__CLAUDIN 3; CLDN3__:__CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTOR 2; CPETR2;; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTOR, LOW AFFINITY;; ENTEROTOXIN OF CLOSTRIDIUM PERFRINGENS, RECEPTOR OF, 2;; VENTRAL PROSTATE 1, RAT, HOMOLOG OF;; RVP1 ANDROGEN WITHDRAWAL APOPTOSIS PROTEIN, RAT, HOMOLOG OF__:__
Asterisk__:__602911__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-2 SUBUNIT; CACNG2__:__STARGAZIN, MOUSE, HOMOLOG OF;; TRANSMEMBRANE AMPA RECEPTOR REGULATORY PROTEIN, GAMMA-2;; TARP-GAMMA-2__:__
Asterisk__:__602912__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 6; EIF6__:__INTEGRIN, BETA-4, BINDING PROTEIN OF; ITGB4BP;; p27, BETA-4 INTEGRIN-BINDING PROTEIN; p27BBP;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3A; EIF3A__:__
Asterisk__:__602913__:__POLO-LIKE KINASE 3; PLK3__:__CYTOKINE-INDUCIBLE KINASE; CNK;; PROLIFERATION-RELATED KINASE; PRK__:__
Asterisk__:__602914__:__AQUAPORIN 9; AQP9__:____:__
Asterisk__:__602915__:__TRYPTOPHAN-RICH BASIC PROTEIN; WRB__:__CONGENITAL HEART DISEASE 5 GENE, FORMERLY; CHD5, FORMERLY__:__
Asterisk__:__602916__:__UBIQUITIN-CONJUGATING ENZYME E2E 1; UBE2E1__:__UBIQUITIN-CONJUGATING ENZYME UBCH6; UBCH6;; UBCM3__:__
Asterisk__:__602917__:__REGULATOR OF CALCINEURIN 1; RCAN1__:__DOWN SYNDROME CRITICAL REGION GENE 1; DSCR1;; MYOCYTE-ENRICHED CALCINEURIN-INTERACTING PROTEIN 1; MCIP1;; MODULATORY CALCINEURIN-INTERACTING PROTEIN 1;; CALCIPRESSIN 1; CSP1__:__
Asterisk__:__602918__:__PHENYLALANINE-tRNA SYNTHETASE, ALPHA SUBUNIT; FARSA__:__PHENYLALANINE-tRNA SYNTHETASE, CYTOPLASMIC, ALPHA SUBUNIT; FRSA;; PHENYLALANINE-tRNA SYNTHETASE-LIKE, ALPHA SUBUNIT; FARSLA;; PHERSA;; CML33__:__
Asterisk__:__602919__:__DOCKING PROTEIN 1; DOK1__:__DOCKING PROTEIN, 62-KD;; p62DOK;; DOWNSTREAM OF TYROSINE KINASE 1__:__
Asterisk__:__602920__:__LIM AND SH3 PROTEIN 1; LASP1__:__MLN50__:__LASP1/MLL FUSION GENE, INCLUDED
Asterisk__:__602921__:__PERSEPHIN; PSPN__:____:__
Caret__:__602922__:__MOVED TO 300825__:____:__
Asterisk__:__602923__:__RETINOBLASTOMA-BINDING PROTEIN 4; RBBP4__:__RBAP48__:__
Asterisk__:__602924__:__RHO FAMILY GTPase 3; RND3__:__RAS HOMOLOG GENE FAMILY, MEMBER E; RHOE;; ARHE__:__
Asterisk__:__602925__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, BETA; PIK3CB__:__PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, 110-KD, BETA;; p110-BETA;; PI3KCB;; PI3K-BETA;; PIK3-BETA__:__
Asterisk__:__602926__:__SYNTAXIN-BINDING PROTEIN 1; STXBP1__:__UNC18, C. ELEGANS, HOMOLOG OF, 1;; MUNC18-1__:__
Asterisk__:__602927__:__G PROTEIN-COUPLED RECEPTOR 19; GPR19__:____:__
Asterisk__:__602928__:__TROPOMODULIN 2; TMOD2__:__TROPOMODULIN, NEURON-SPECIFIC;; N-TROPOMODULIN; NTMOD__:__
Asterisk__:__602929__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 5A; VWA5A__:__LOSS OF HETEROZYGOSITY, CHROMOSOME 11, REGION 2, GENE A; LOH11CR2A;; BREAST CANCER SUPPRESSOR CANDIDATE 1; BCSC1__:__
Asterisk__:__602930__:__RNA EXONUCLEASE 4, S. CEREVISIAE, HOMOLOG OF; REXO4__:__REX4, S. CEREVISIAE, HOMOLOG OF; REX4;; PREVENTS MITOTIC CATASTROPHE 2, XENOPUS, HOMOLOG OF; XPMC2H__:__
Asterisk__:__602931__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 6; SMAD6__:__MADH6;; SMA- AND MAD-RELATED PROTEIN 6__:__
Asterisk__:__602932__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 7; SMAD7__:__MADH7;; SMA- AND MAD-RELATED PROTEIN 7__:__
Asterisk__:__602933__:__THYROID HORMONE RECEPTOR INTERACTOR 6; TRIP6__:__OPA-INTERACTING PROTEIN 1; OIP1__:__
Asterisk__:__602934__:__STROMAL CELL-DERIVED FACTOR 2; SDF2__:____:__
Asterisk__:__602935__:__FATTY ACID AMIDE HYDROLASE; FAAH__:____:__
Caret__:__602936__:__MOVED TO 300149__:____:__
Asterisk__:__602937__:__CBP/p300-INTERACTING TRANSACTIVATOR, WITH GLU/ASP-RICH C-TERMINAL DOMAIN, 2; CITED2__:__MELANOCYTE-SPECIFIC GENE 1-RELATED GENE 1; MRG1;; MSG1-RELATED GENE 1;; p35SRJ__:__
Asterisk__:__602938__:__BILE ACID CoA:AMINO ACID N-ACYLTRANSFERASE; BAAT__:__BACAT; BAT;; GLYCINE N-CHOLOYLTRANSFERASE__:__
Asterisk__:__602939__:__FORKHEAD BOX S1; FOXS1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 18; FKHL18;; FORKHEAD-RELATED ACTIVATOR 10; FREAC10__:__
Asterisk__:__602940__:__MARCKS-LIKE PROTEIN 1; MARCKSL1__:__MLP;; MARCKS-RELATED PROTEIN; MRP;; MAC-MARCKS;; F52__:__
Asterisk__:__602941__:__BREAST CANCER ANTIESTROGEN RESISTANCE 1; BCAR1__:__CRK-ASSOCIATED SUBSTRATE; CRKAS;; p130CAS;; CAS__:__
Asterisk__:__602942__:__ECOTROPIC VIRAL INTEGRATION SITE 5; EVI5__:__NEUROBLASTOMA STAGE 4S GENE; NB4S__:__
Asterisk__:__602943__:__RAR-RELATED ORPHAN RECEPTOR C; RORC__:__RAR-RELATED ORPHAN RECEPTOR GAMMA; RORG;; RZR-GAMMA; RZRG;; RETINOIC ACID-BINDING RECEPTOR GAMMA__:__
Asterisk__:__602944__:__E2F TRANSCRIPTION FACTOR 6; E2F6__:____:__
Asterisk__:__602945__:__TRANSCRIPTIONAL ADAPTOR 3; TADA3__:__TRANSCRIPTIONAL ADAPTOR 3-LIKE; TADA3L;; ADA3, YEAST, HOMOLOG OF; ADA3__:__
Asterisk__:__602946__:__TAF6-LIKE RNA POLYMERASE II; TAF6L__:__PCAF-ASSOCIATED FACTOR 65 ALPHA; PAF65A;; PCAF-ASSOCIATED FACTOR, 65-KD__:__
Asterisk__:__602947__:__SUPPRESSOR OF TY 3, S. CEREVISIAE, HOMOLOG OF; SUPT3H__:__SPT3__:__
Asterisk__:__602948__:__RAD51, S. CEREVISIAE, HOMOLOG OF, B; RAD51L1__:__S. CEREVISIAE RAD51-LIKE 1;; RAD51B;; REC2;; RAD51 HOMOLOG 2; R51H2__:__RAD51L1/HMGIC FUSION GENE, INCLUDED
Asterisk__:__602949__:__SIN3-ASSOCIATED POLYPEPTIDE, 18-KD; SAP18__:____:__
Asterisk__:__602950__:__PROTEIN ARGININE METHYLTRANSFERASE 1; PRMT1__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN METHYLTRANSFERASE 1-LIKE 2; HRMT1L2;; HMT1-LIKE 2;; INTERFERON RECEPTOR 1-BOUND PROTEIN 4; IR1B4__:__
Asterisk__:__602951__:__ZINC FINGER PROTEIN 37, MOUSE, HOMOLOG OF; ZFP37__:____:__
Asterisk__:__602952__:__NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 2; NSD2__:__WOLF-HIRSCHHORN SYNDROME CANDIDATE 1; WHSC1;; MULTIPLE MYELOMA SET DOMAIN; MMSET__:__
Asterisk__:__602953__:__HAIRY/ENHANCER OF SPLIT-RELATED WITH YRPW MOTIF 1; HEY1__:__HAIRY/ENHANCER OF SPLIT-RELATED REPRESSOR PROTEIN 2; HERP2;; HESR1__:__
Asterisk__:__602954__:__RAD51, S. CEREVISIAE, HOMOLOG OF, D; RAD51D__:__S. CEREVISIAE RAD51-LIKE 3; RAD51L3;; TRAD__:__
Asterisk__:__602955__:__TAF6 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 80-KD; TAF6__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2E; TAF2E;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 70- TO 85-KD;; TAFII80;; TAFII70;; TAFII85__:__
Asterisk__:__602956__:__FANCG GENE; FANCG__:__X-RAY REPAIR, COMPLEMENTING DEFECTIVE, IN CHINESE HAMSTER, 9; XRCC9__:__
Asterisk__:__602957__:__CHEMOKINE, CC MOTIF, LIGAND 22; CCL22__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 22; SCYA22;; MACROPHAGE-DERIVED CHEMOKINE; MDC__:__
Asterisk__:__602958__:__SERUM/GLUCOCORTICOID-REGULATED KINASE 1; SGK1__:__SGK__:__
Asterisk__:__602959__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, ALPHA-2; EEF1A2__:__ELONGATION FACTOR 1, ALPHA-2__:__
Caret__:__602960__:__MOVED TO 300506__:____:__
Asterisk__:__602961__:__UBIQUITIN-CONJUGATING ENZYME E2D 1; UBE2D1__:__UBC4/5, S. CEREVISIAE, HOMOLOG OF;; UBIQUITIN-CONJUGATING ENZYME UBCH5A; UBCH5A;; UBCH5__:__
Asterisk__:__602962__:__UBIQUITIN-CONJUGATING ENZYME E2D 2; UBE2D2__:__UBC4/5, S. CEREVISIAE, HOMOLOG OF;; UBIQUITIN-CONJUGATING ENZYME UBCH5B; UBCH5B;; UBC4__:__
Asterisk__:__602963__:__UBIQUITIN-CONJUGATING ENZYME E2D 3; UBE2D3__:__UBC4/5, S. CEREVISIAE, HOMOLOG OF;; UBIQUITIN-CONJUGATING ENZYME UBCH5C; UBCH5C__:__
Asterisk__:__602964__:__TRANSLIN-ASSOCIATED FACTOR X; TSNAX__:__TRAX__:__
Asterisk__:__602965__:__FATTY ACID-BINDING PROTEIN 7; FABP7__:__FATTY ACID-BINDING PROTEIN, BRAIN; FABPB;; BRAIN LIPID-BINDING PROTEIN; BLBP__:__
Percent__:__602966__:__OROFACIAL CLEFT 2; OFC2__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 2__:__
Asterisk__:__602967__:__ZINC FINGER PROTEIN 217; ZNF217__:____:__
Asterisk__:__602968__:__BREAST CARCINOMA AMPLIFIED SEQUENCE 1; BCAS1__:__NOVEL AMPLIFIED IN BREAST CANCER 1; NABC1__:__
Asterisk__:__602969__:__ESTROGEN-RELATED RECEPTOR, GAMMA; ESRRG__:__ESTROGEN-RELATED RECEPTOR 3; ERR3__:__
Asterisk__:__602970__:__KARYOPHERIN ALPHA-4; KPNA4__:__IMPORTIN ALPHA-3;; QIP1__:__
Asterisk__:__602971__:__TUBULIN-SPECIFIC CHAPERONE C; TBCC__:__COFACTOR C IN BETA-TUBULIN FOLDING; CFC__:__
Asterisk__:__602972__:__PHOSPHODIESTERASE 8A; PDE8A__:____:__
Asterisk__:__602973__:__PHOSPHODIESTERASE 9A; PDE9A__:__HOMO SAPIENS PHOSPHODIESTERASE 9A2; HSPDE9A2__:__
Asterisk__:__602974__:__AQUAPORIN 7; AQP7__:__AQUAPORIN 7-LIKE; AQP7L;; AQUAPORIN, ADIPOSE;; AQPAP__:__
Caret__:__602975__:__MOVED TO 608833__:____:__
Asterisk__:__602976__:__MAX-LIKE PROTEIN X; MLX__:__TRANSCRIPTION FACTOR-LIKE 4; TCFL4__:__
Asterisk__:__602977__:__GLYCOPROTEIN 2, ZYMOGEN GRANULE MEMBRANE; GP2__:__ZYMOGEN GRANULE MEMBRANE GLYCOPROTEIN 2__:__
Asterisk__:__602978__:__POLYHOMEOTIC-LIKE 1; PHC1__:__EARLY DEVELOPMENT REGULATOR 1; EDR1;; POLYHOMEOTIC, DROSOPHILA, HOMOLOG OF, 1;; HUMAN POLYHOMEOTIC HOMOLOG 1; HPH1;; RETINOIC ACID-ACTIVATED EARLY-28, MOUSE, HOMOLOG OF; RAE28__:__
Asterisk__:__602979__:__POLYHOMEOTIC-LIKE 2; PHC2__:__EARLY DEVELOPMENT REGULATOR 2; EDR2;; POLYHOMEOTIC, DROSOPHILA, HOMOLOG OF, 2;; HUMAN POLYHOMEOTIC HOMOLOG 2; HPH2__:__
Asterisk__:__602980__:__PROTEIN KINASE, SERINE/ARGININE-SPECIFIC, 2; SRPK2__:__PROTEIN KINASE, ARGININE/SERINE-RICH SPLICING FACTOR, 2;; SFRS PROTEIN KINASE 2__:__
Asterisk__:__602981__:__AE-BINDING PROTEIN 1; AEBP1__:__AORTIC CARBOXYPEPTIDASE-LIKE PROTEIN; ACLP__:__
Asterisk__:__602982__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, INTERMEDIATE/SMALL CONDUCTANCE, SUBFAMILY N, MEMBER 1; KCNN1__:__SK1__:__
Asterisk__:__602983__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, INTERMEDIATE/SMALL CONDUCTANCE, SUBFAMILY N, MEMBER 3; KCNN3__:__SK3;; SKCA3__:__
Asterisk__:__602984__:__MEDIATOR COMPLEX SUBUNIT 6; MED6__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 6, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II TRANSCRIPTIONAL REGULATION MEDIATOR__:__
Asterisk__:__602985__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 2; NDUFS2__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 49-KD SUBUNIT__:__
Asterisk__:__602986__:__DEVELOPMENTALLY REGULATED GTP-BINDING PROTEIN 2; DRG2__:____:__
Asterisk__:__602987__:__PHOSPHODIESTERASE 1C; PDE1C__:__HCAM3__:__
Asterisk__:__602988__:__PROTOCADHERIN 7; PCDH7__:__BRAIN-HEART PROTOCADHERIN; BHPCDH__:__
Asterisk__:__602989__:__CDC-LIKE KINASE 2; CLK2__:____:__
Asterisk__:__602990__:__CDC-LIKE KINASE 3; CLK3__:____:__
Asterisk__:__602991__:__NOGGIN, MOUSE, HOMOLOG OF; NOG__:____:__
Asterisk__:__602992__:__LEUKOCYTE-ASSOCIATED IMMUNOGLOBULIN-LIKE RECEPTOR 1; LAIR1__:____:__
Asterisk__:__602993__:__LEUKOCYTE-ASSOCIATED IMMUNOGLOBULIN-LIKE RECEPTOR 2; LAIR2__:__CD306__:__
NULL__:__602994__:__LEUKOREGULIN__:____:__
Asterisk__:__602995__:__UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 1; UBE2V1__:__UEV1; UEV1A;; CROC1__:__
Asterisk__:__602996__:__IMMEDIATE-EARLY RESPONSE 3; IER3__:__DIFFERENTIATION-DEPENDENT GENE 2; DIF2;; GLY96, MOUSE, HOMOLOG OF;; IMMEDIATE-EARLY RESPONSE GENE; IEX1;; PACAP-RESPONSIVE GENE 1; PRG1__:__
Asterisk__:__602997__:__CUBILIN; CUBN__:__INTRINSIC FACTOR-COBALAMIN RECEPTOR; IFCR__:__
Asterisk__:__602998__:__SYNUCLEIN, GAMMA; SNCG__:__BREAST CANCER-SPECIFIC GENE 1; BCSG1;; PERSYN__:__
Asterisk__:__602999__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 3C; PPP1R3C__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 5; PPP1R5__:__
Asterisk__:__603000__:__IMMATURE COLON CARCINOMA TRANSCRIPT 1; ICT1__:__DS1__:__
Asterisk__:__603001__:__UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 2; UBE2V2__:__UEV2;; 1-ALPHA,25-DIHYDROXYVITAMIN D3-INDUCIBLE TRANSCRIPT 1; DDVIT1;; ENTEROCYTE DIFFERENTIATION-PROMOTING FACTOR 1; EDPF1;; METHYL METHANESULFONATE SENSITIVE 2, S. CEREVISIAE, HOMOLOG OF; MMS2__:__
Asterisk__:__603002__:__TRANSPORTIN 2; TNPO2__:__TRN2;; KARYOPHERIN BETA-2B; KPNB2B__:__
Percent__:__603003__:__BILE DUCT CYSTS__:__CHOLEDOCHAL CYSTS;; CHOLEDOCHOCELE__:__
Asterisk__:__603004__:__GLIOBLASTOMA AMPLIFIED SEQUENCE; GBAS__:__4-NITROPHENYLPHOSPHATASE DOMAIN AND NONNEURONAL SNAP25-LIKE 2; NIPSNAP2;; NIPSNAP, C. ELEGANS, HOMOLOG OF, 2__:__
Asterisk__:__603005__:__3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE SYNTHASE 2; PAPSS2__:__PHOSPHOADENOSINE-PHOSPHOSULFATE SYNTHETASE 2;; PAPS SYNTHASE 2;; PAPS SYNTHETASE 2;; ATP SULFURYLASE/ADENOSINE 5-PRIME PHOSPHOSULFATE KINASE 2; ATPSK2;; ATP SULFURYLASE/APS KINASE 2; SK2__:__
Asterisk__:__603006__:__CADHERIN 4; CDH4__:__CADHERIN, RETINAL;; R-CADHERIN__:__
Asterisk__:__603007__:__CADHERIN 6; CDH6__:__CADHERIN, FETAL KIDNEY;; K-CADHERIN__:__
Asterisk__:__603008__:__CADHERIN 8; CDH8__:____:__
Asterisk__:__603009__:__DYSFERLIN; DYSF__:____:__
Percent__:__603010__:__DEAFNESS, AUTOSOMAL RECESSIVE 17; DFNB17__:____:__
Asterisk__:__603011__:__SMALL EDRK-RICH FACTOR 1A; SERF1A__:__SMALL EDRK-RICH FACTOR 1; SERF1;; SPINAL MUSCULAR ATROPHY-RELATED GENE H4F5; H4F5;; SMA MODIFIER 1; SMAM1__:__
Asterisk__:__603012__:__HEAT-SHOCK 70-KD PROTEIN 1B; HSPA1B__:__HEAT-SHOCK PROTEIN, 70-KD, 1B;; HSP70-1B;; HEAT-SHOCK PROTEIN, 70-KD, 2;; HSP70-2__:__
Percent__:__603013__:__SCHIZOPHRENIA 6; SCZD6__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 8p-RELATED__:__
Asterisk__:__603014__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7; MAP2K7__:__PROTEIN KINASE, MITOGEN-ACTIVATED, KINASE 7; PRKMK7;; MKK7; MAPKK7;; JNK-ACTIVATING KINASE 2; JNKK2__:__
Asterisk__:__603015__:__TRANSFORMATION/TRANSCRIPTION DOMAIN-ASSOCIATED PROTEIN; TRRAP__:__PAF400__:__
Asterisk__:__603016__:__CADHERIN 19; CDH19__:__CADHERIN 7, FORMERLY; CDH7, FORMERLY__:__
Asterisk__:__603017__:__CADHERIN 17; CDH17__:__CADHERIN, LIVER-INTESTINE;; LI-CADHERIN;; HUMAN PEPTIDE TRANSPORTER 1; HPT1;; CADHERIN 16, FORMERLY; CDH16, FORMERLY__:__
Asterisk__:__603018__:__BETA-3-GALACTOSYLTRANSFERASE 2; B3GALT2__:__UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 2;; BETA-3-GALT2__:__
Asterisk__:__603019__:__CADHERIN 18; CDH18__:__CADHERIN 14, FORMERLY; CDH14, FORMERLY__:__
Asterisk__:__603020__:__ATPase FAMILY GENE 3-LIKE 1; AFG3L1__:__AFG3, YEAST, HOMOLOG OF__:__
Asterisk__:__603021__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S12; MRPS12__:__RIBOSOMAL PROTEIN, MITOCHONDRIAL, S12; RPMS12;; RPSM12__:__
Asterisk__:__603022__:__E4F TRANSCRIPTION FACTOR 1; E4F1__:__TRANSCRIPTION FACTOR E4F; E4F;; p120 E4F__:__
Asterisk__:__603023__:__IKAROS FAMILY ZINC FINGER 1; IKZF1__:__ZINC FINGER PROTEIN, SUBFAMILY 1A, MEMBER 1; ZNFN1A1;; IKAROS; IK1;; LYF1__:__IKAROS/BCL6 FUSION GENE, INCLUDED
Asterisk__:__603024__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 1A; ARID1A__:__ARID-CONTAINING PROTEIN 1A;; SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY F, MEMBER 1; SMARCF1;; BRG1-ASSOCIATED FACTOR, 250-KD, A; BAF250A;; CHROMOSOME 1 OPEN READING FRAME 4; C1ORF4;; B120 GENE; B120;; p270__:__
Asterisk__:__603025__:__PHOSPHATIDYLINOSITOL-BINDING CLATHRIN ASSEMBLY PROTEIN; PICALM__:__CLATHRIN ASSEMBLY LYMPHOID-MYELOID LEUKEMIA GENE; CALM;; CLTH;; LAP, DROSOPHILA, HOMOLOG OF; LAP__:__PICALM/AF10 FUSION GENE, INCLUDED
Asterisk__:__603026__:__PLEOMORPHIC ADENOMA GENE 1; PLAG1__:____:__PLAG1/CTNNB1 FUSION GENE, INCLUDED;; PLAG1/TCEA1 FUSION GENE, INCLUDED;; PLAG1/CHCHD7 FUSION GENE, INCLUDED
Asterisk__:__603027__:__FRUCTOSE-1,6-BISPHOSPHATASE 2; FBP2__:__D-FRUCTOSE-1,6-BISPHOSPHATE 1-PHOSPHOHYDROLASE;; FRUCTOSE-1,6-BISPHOSPHATASE, MUSCLE__:__
Asterisk__:__603028__:__TOLL-LIKE RECEPTOR 2; TLR2__:__TOLL/INTERLEUKIN 1 RECEPTOR-LIKE 4; TIL4__:__
Asterisk__:__603029__:__TOLL-LIKE RECEPTOR 3; TLR3__:____:__
Asterisk__:__603030__:__TOLL-LIKE RECEPTOR 4; TLR4__:__TOLL, DROSOPHILA, HOMOLOG OF; TOLL__:__
Asterisk__:__603031__:__TOLL-LIKE RECEPTOR 5; TLR5__:__TOLL/INTERLEUKIN 1 RECEPTOR-LIKE 5; TIL3__:__
Asterisk__:__603032__:__STANNIN; SNN__:____:__
Asterisk__:__603033__:__COLLAGENIC TAIL OF ENDPLATE ACETYLCHOLINESTERASE; COLQ__:__ACETYLCHOLINESTERASE-ASSOCIATED COLLAGEN__:__
Number Sign__:__603034__:__MYASTHENIC SYNDROME, CONGENITAL, 5; CMS5__:__ENDPLATE ACETYLCHOLINESTERASE DEFICIENCY; EAD;; ENGEL CONGENITAL MYASTHENIC SYNDROME;; MYASTHENIC SYNDROME, CONGENITAL, ENGEL TYPE;; CONGENITAL MYASTHENIC SYNDROME TYPE Ic, FORMERLY; CMS1C, FORMERLY;; CMS Ic, FORMERLY__:__
Asterisk__:__603035__:__INTERLEUKIN 16; IL16__:__LYMPHOCYTE CHEMOATTRACTANT FACTOR; LCF__:__
Caret__:__603036__:__MOVED TO 601877__:____:__
Asterisk__:__603037__:__LEFT-RIGHT DETERMINATION FACTOR 1; LEFTY1__:__LEFT-RIGHT DETERMINATION, FACTOR B; LEFTY B;; LEFTY1, MOUSE, HOMOLOG OF;; LEFTB__:__
Asterisk__:__603038__:__SPERM-ASSOCIATED ANTIGEN 4; SPAG4__:____:__
Asterisk__:__603039__:__MAX-BINDING PROTEIN; MNT__:__ROX__:__
Percent__:__603040__:__TUMOR SUPPRESSOR GENE ON CHROMOSOME 11__:__TSG11;; NONSMALL CELL LUNG CANCER SUPPRESSOR__:__
Number Sign__:__603041__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1__:__MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, TYMP-RELATED;; MNGIE, TYMP-RELATED;; MYONEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME;; POLYNEUROPATHY, OPHTHALMOPLEGIA, LEUKOENCEPHALOPATHY, AND INTESTINAL PSEUDOOBSTRUCTION;; POLIP SYNDROME__:__
Asterisk__:__603042__:__SMALL UBIQUITIN-LIKE MODIFIER 2; SUMO2__:__SMT3, YEAST, HOMOLOG 2; SMT3H2;; SMT3B;; SENTRIN 2__:__
Asterisk__:__603043__:__NEUTRAL SPHINGOMYELINASE ACTIVATION-ASSOCIATED FACTOR; NSMAF__:__N-SMase ACTIVATION-ASSOCIATED FACTOR;; FACTOR ASSOCIATED WITH N-SMase ACTIVATION; FAN__:__
Asterisk__:__603044__:__PLEOMORPHIC ADENOMA GENE-LIKE 1; PLAGL1__:__ZAC TUMOR SUPPRESSOR GENE; ZAC;; ZAC1;; LOST ON TRANSFORMATION 1; LOT1__:__
Caret__:__603045__:__MOVED TO 603499__:____:__
Asterisk__:__603046__:__RING FINGER PROTEIN 139; RNF139__:__TRANSLOCATION IN RENAL CARCINOMA ON CHROMOSOME 8; TRC8;; HEREDITARY RENAL CANCER ASSOCIATED 1; HRCA1__:__
Percent__:__603047__:__ASTIGMATISM__:____:__
Asterisk__:__603048__:__GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR ATTACHMENT PROTEIN 1; GPAA1__:__GAA1__:__
Asterisk__:__603049__:__THIOREDOXIN-LIKE 1; TXNL1__:__THIOREDOXIN-LIKE; TXNL;; TXL__:__
Asterisk__:__603050__:__ABL INTERACTOR 1; ABI1__:__SPECTRIN SH3 DOMAIN-BINDING PROTEIN 1; SSH3BP1;; E3B1__:__ABI1/MLL FUSION GENE, INCLUDED
Asterisk__:__603051__:__ALKYLGLYCERONE-PHOSPHATE SYNTHASE; AGPS__:__ALKYLDIHYDROXYACETONEPHOSPHATE SYNTHASE; ADHAPS;; ALKYL-DHAP SYNTHASE__:__
Asterisk__:__603052__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 4; CPSF4__:__CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR, 30-KD; CPSF30;; NS1 EFFECTOR DOMAIN-BINDING PROTEIN 1; NEB1__:__
Asterisk__:__603053__:__HISTONE ACETYLTRANSFERASE 1; HAT1__:____:__
Asterisk__:__603054__:__GREMLIN 1 HOMOLOG, CYSTINE KNOT SUPERFAMILY; GREM1__:__GREMLIN;; CYSTINE KNOT SUPERFAMILY 1, BMP ANTAGONIST 1; CKTSF1B1__:__
Asterisk__:__603055__:__SKI-INTERACTING PROTEIN; SKIIP__:__SKIP;; BX42, DROSOPHILA, HOMOLOG OF;; SNW1__:__
Asterisk__:__603056__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 4, S. CEREVISIAE, HOMOLOG OF; ORC4__:__ORC4-LIKE; ORC4L__:__
Asterisk__:__603057__:__DACHSOUS, DROSOPHILA, HOMOLOG OF, 1; DCHS1__:__PROTOCADHERIN 16; PCDH16;; CADHERIN, FIBROBLAST, 1; FIB1;; CADHERIN 19, FORMERLY; CDH19, FORMERLY__:__
Asterisk__:__603058__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 4; PCDHGB4__:__CADHERIN, FIBROBLAST, 2; FIB2;; CADHERIN 20, FORMERLY; CDH20, FORMERLY__:__
Asterisk__:__603059__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 12; PCDHGA12__:__PCDH-GAMMA-A12;; CADHERIN, FIBROBLAST, 3; FIB3;; KIAA0588;; CADHERIN 21, FORMERLY; CDH21, FORMERLY__:__
Asterisk__:__603060__:__KINESIN FAMILY MEMBER 1C; KIF1C__:__LTXS1, MOUSE, HOMOLOG OF; LTXS1;; KIAA0706__:__
Asterisk__:__603061__:__ENDOSULFINE, ALPHA; ENSA__:____:__
Asterisk__:__603062__:__TRANS-GOLGI NETWORK PROTEIN 2; TGOLN2__:__TRANS-GOLGI NETWORK PROTEIN, 46-KD; TGN46;; TRANS-GOLGI NETWORK PROTEIN, 38-KD, RAT, HOMOLOG OF; TGN38__:__
Asterisk__:__603063__:__3-HYDROXYBUTYRATE DEHYDROGENASE 1; BDH1__:__3-HYDROXYBUTYRATE DEHYDROGENASE; BDH__:__
Asterisk__:__603064__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B11; UGT2B11__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B11;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER B11__:__
Asterisk__:__603065__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP I, MEMBER 2; NR1I2__:__PREGNANE X RECEPTOR; PXR;; STEROID AND XENOBIOTIC RECEPTOR; SXR;; PAR;; PAR1__:__PAR2, INCLUDED
Asterisk__:__603066__:__PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 3; PLOD3__:__LYSINE HYDROXYLASE 3; LH3;; LYSYL HYDROXYLASE 3__:__
Caret__:__603067__:__MOVED TO 602413__:____:__
Asterisk__:__603068__:__DUAL-SPECIFICITY PHOSPHATASE 2; DUSP2__:__PHOSPHATASE OF ACTIVATED CELLS 1; PAC1__:__
Asterisk__:__603069__:__DUAL-SPECIFICITY PHOSPHATASE 5; DUSP5__:__VH1-LIKE PHOSPHATASE 3; HVH3__:__
Asterisk__:__603070__:__RAD51-ASSOCIATED PROTEIN 1; RAD51AP1__:__PROTEIN INTERACTING WITH RAD51; PIR51__:__
Asterisk__:__603071__:__G PROTEIN-COUPLED RECEPTOR 17; GPR17__:____:__
Asterisk__:__603072__:__AURORA KINASE A; AURKA__:__SERINE/THREONINE PROTEIN KINASE 15; STK15;; STK6, MOUSE, HOMOLOG OF; STK6;; AURORA-RELATED KINASE 1; ARK1;; AURORA/IPL1-LIKE KINASE; AIK;; AURORA2;; BTAK__:__
Asterisk__:__603073__:__ZIC FAMILY, MEMBER 2; ZIC2__:__ZINC FINGER PROTEIN OF CEREBELLUM 2__:__
Asterisk__:__603074__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE, ISOFORM 1B, GAMMA SUBUNIT; PAFAH1B3__:____:__
Number Sign__:__603075__:__MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1__:__MACULOPATHY, AGE-RELATED, 1__:__
Asterisk__:__603076__:__ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 1; ABCG1__:__ATP-BINDING CASSETTE TRANSPORTER 8; ABC8;; ABC TRANSPORTER 8;; WHITE, DROSOPHILA, HOMOLOG OF__:__
Caret__:__603077__:__MOVED TO 300157__:____:__
Asterisk__:__603078__:__CHECKPOINT, S. POMBE, HOMOLOG OF, 1; CHEK1__:__CELL CYCLE CHECKPOINT KINASE; CHK1__:__
Asterisk__:__603079__:__CHROMOBOX HOMOLOG 4, DROSOPHILA POLYCOMB CLASS; CBX4__:__POLYCOMB, DROSOPHILA, HOMOLOG OF, 2; PC2__:__
Asterisk__:__603080__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, BETAINE/GABA), MEMBER 12; SLC6A12__:__BETAINE/GABA TRANSPORTER 1; BGT1;; GABA TRANSPORTER 2, MOUSE, HOMOLOG OF; GAT2__:__
Asterisk__:__603081__:__ADP-RIBOSYLARGININE HYDROLASE; ADPRH__:____:__
Caret__:__603082__:__MOVED TO 188855__:____:__
Asterisk__:__603083__:__HETEROGENEOUS NUCLEAR RIBOPROTEIN L; HNRNPL__:__HNRPL__:__
Asterisk__:__603084__:__ASPARTYL-tRNA SYNTHETASE; DARS__:__ASPRS__:__
Asterisk__:__603085__:__SOLUTE CARRIER FAMILY 31 (COPPER TRANSPORTER), MEMBER 1; SLC31A1__:__COPPER TRANSPORTER 1; COPT1; CTR1__:__
Asterisk__:__603086__:__ADP-RIBOSYLTRANSFERASE 3; ART3__:____:__
Caret__:__603087__:__MOVED TO 110600__:____:__
Asterisk__:__603088__:__SOLUTE CARRIER FAMILY 31 (COPPER TRANSPORTER), MEMBER 2; SLC31A2__:__COPPER TRANSPORTER 2; COPT2; CTR2__:__
Asterisk__:__603089__:__BRCA1-ASSOCIATED PROTEIN 1; BAP1__:____:__
Asterisk__:__603090__:__UBIQUITIN CARBOXYL-TERMINAL ESTERASE L3; UCHL3__:____:__
Asterisk__:__603091__:__UBIQUITIN-SPECIFIC PROTEASE 12; USP12__:__UBIQUITIN-HYDROLYZING ENZYME 1; UBH1__:__
Asterisk__:__603092__:__DUAL-SPECIFICITY PHOSPHATASE 11; DUSP11__:__PHOSPHATASE THAT INTERACTS WITH RNA/RNP COMPLEX 1; PIR1;; RNA/RNP COMPLEX-INTERACTING PHOSPHATASE__:__
Asterisk__:__603093__:__BETA-3-GALACTOSYLTRANSFERASE 1; B3GALT1__:__UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 1;; BETA-3-GALT1__:__
Asterisk__:__603094__:__BETA-1,3-N-ACETYLGALACTOSAMINYLTRANSFERASE 1; B3GALNT1__:__BETA-3-GalNAc-T1;; UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 3; B3GALT3;; BETA-3-GALACTOSYLTRANSFERASE 3;; BETA-3-GALT3;; GLOBOSIDE SYNTHASE;; GLOB;; GB4 SYNTHASE;; P ANTIGEN SYNTHASE__:__
Asterisk__:__603095__:__UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 4; B3GALT4__:__BETA-3-GALACTOSYLTRANSFERASE 4;; BETA-3-GALT4__:__
Caret__:__603096__:__MOVED TO 262300__:____:__
Asterisk__:__603097__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 42-KD, V1 SUBUNIT C, ISOFORM 1; ATP6V1C1__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT C; ATP6C;; VACUOLAR PROTON PUMP, 42-KD SUBUNIT;; V-ATPase, SUBUNIT C;; ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT D, FORMERLY; ATP6D, FORMERLY__:__
Percent__:__603098__:__DEAFNESS, AUTOSOMAL RECESSIVE 13; DFNB13__:____:__
Asterisk__:__603099__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 1; AGPAT1__:__LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE-ALPHA;; LPAAT-ALPHA__:__
Asterisk__:__603100__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 2; AGPAT2__:__LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE-BETA;; LPAAT-BETA__:__
Asterisk__:__603101__:__CARBOXYPEPTIDASE B2, PLASMA; CPB2__:__CARBOXYPEPTIDASE U; CPU;; THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR; TAFI__:__
Asterisk__:__603102__:__CARBOXYPEPTIDASE D; CPD__:__GLYCOPROTEIN, 180-KD; GP180__:__
Asterisk__:__603103__:__CARBOXYPEPTIDASE N, POLYPEPTIDE 1, 50-KD; CPN1__:__CARBOXYPEPTIDASE N, CATALYTIC SUBUNIT;; SERUM CARBOXYPEPTIDASE N; SCPN;; CARBOXYPEPTIDASE N, SERUM; CPN;; CARBOXYPEPTIDASE B, SERUM;; KININASE I;; ANAPHYLATOXIN INACTIVATOR__:__
Asterisk__:__603104__:__CARBOXYPEPTIDASE N, POLYPEPTIDE 2, 83-KD; CPN2__:__CARBOXYPEPTIDASE N, REGULATORY SUBUNIT__:__
Asterisk__:__603105__:__CARBOXYPEPTIDASE Z; CPZ__:____:__
Asterisk__:__603106__:__NEURONATIN; NNAT__:____:__
Asterisk__:__603107__:__TRANSCRIPTION FACTOR 20; TCF20__:__STROMELYSIN 1 PDGF-RESPONSIVE ELEMENT-BINDING PROTEIN; SPBP;; SPRE-BINDING PROTEIN; AR1__:__
Asterisk__:__603108__:__MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, MEMBER 1; MAPRE1__:__END-BINDING PROTEIN 1; EB1;; ADENOMATOUS POLYPOSIS COLI-BINDING PROTEIN EB1__:__
Asterisk__:__603109__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 3; SMAD3__:__MADH3;; SMA- AND MAD-RELATED PROTEIN 3__:__
Asterisk__:__603110__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 5; SMAD5__:__MADH5;; SMA- AND MAD-RELATED PROTEIN 5__:__
Asterisk__:__603111__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY E, MEMBER 1; SMARCE1__:__BRG1-ASSOCIATED FACTOR, 57-KD; BAF57__:__
Asterisk__:__603112__:__S100 CALCIUM-BINDING PROTEIN A12; S100A12__:__CALCIUM-BINDING PROTEIN IN AMNIOTIC FLUID; CAAF1;; CALGRANULIN-RELATED PROTEIN; CGRP;; CALGRANULIN C;; p6;; EXTRACELLULAR NEWLY IDENTIFIED RAGE-BINDING PROTEIN; ENRAGE__:__
Asterisk__:__603113__:__PROTEIN PHOSPHATASE 2, STRUCTURAL/REGULATORY SUBUNIT A, BETA; PPP2R1B__:__PP2AA-BETA__:__
Asterisk__:__603114__:__S100 CALCIUM-BINDING PROTEIN A11; S100A11__:__CALGIZZARIN;; S100C__:__
Asterisk__:__603115__:__DEAH BOX POLYPEPTIDE 9; DHX9__:__DEAD/H BOX 9; DDX9;; RNA HELICASE A;; NUCLEAR DNA HELICASE II; NDHII__:__
Percent__:__603116__:__CDAGS SYNDROME__:__CRANIOSYNOSTOSIS, ANAL ANOMALIES, AND POROKERATOSIS;; CAP SYNDROME__:__
NULL__:__603117__:__SPASTIC PARAPLEGIA, OPTIC ATROPHY, MICROCEPHALY, AND XY SEX REVERSAL__:____:__
Asterisk__:__603118__:__CADHERIN 16; CDH16__:__CADHERIN, KIDNEY;; KSP-CADHERIN__:__
NULL__:__603119__:__APRAXIA OF EYELID OPENING__:____:__
Asterisk__:__603120__:__QUIESCIN Q6 SULFHYDRYL OXIDASE 1; QSOX1__:__QUIESCIN Q6; QSCN6;; Q6__:__
Caret__:__603121__:__MOVED TO 300768__:____:__
Asterisk__:__603122__:__DEDICATOR OF CYTOKINESIS 2; DOCK2__:____:__
Asterisk__:__603123__:__DEDICATOR OF CYTOKINESIS 3; DOCK3__:____:__
Asterisk__:__603124__:__UBIQUITIN-CONJUGATING ENZYME E2G 2; UBE2G2__:__UBC7, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__603125__:__TYROSYLPROTEIN SULFOTRANSFERASE 1; TPST1__:____:__
Asterisk__:__603126__:__TYROSYLPROTEIN SULFOTRANSFERASE 2; TPST2__:____:__
Asterisk__:__603127__:__GROWTH ARREST-SPECIFIC 7; GAS7__:____:__
Asterisk__:__603128__:__SINGLE-MINDED, DROSOPHILA, HOMOLOG OF, 1; SIM1__:____:__
Asterisk__:__603129__:__LIM DOMAIN ONLY 4; LMO4__:____:__
Asterisk__:__603130__:__ATTRACTIN; ATRN__:__MAHOGANY, MOUSE, HOMOLOG OF; MGCA__:__
Asterisk__:__603131__:__PEPTIDASE, MITOCHONDRIAL PROCESSING, BETA; PMPCB__:__MITOCHONDRIAL PROCESSING PEPTIDASE-BETA; MPPB__:__
Asterisk__:__603132__:__ZINC FINGER PROTEIN 189; ZNF189__:____:__
NULL__:__603133__:__DISLOCATED ELBOWS, BOWED TIBIAS, SCOLIOSIS, DEAFNESS, CATARACT, MICROCEPHALY, AND MENTAL RETARDATION__:____:__
Asterisk__:__603134__:__CULLIN 1; CUL1__:____:__
Asterisk__:__603135__:__CULLIN 2; CUL2__:____:__
Asterisk__:__603136__:__CULLIN 3; CUL3__:____:__
Asterisk__:__603137__:__CULLIN 4A; CUL4A__:____:__
Caret__:__603138__:__MOVED TO 300304__:____:__
Asterisk__:__603139__:__RAD17, S. POMBE, HOMOLOG OF; RAD17__:__RAD24, S. CEREVISIAE, HOMOLOG OF;; RAD24, MOUSE, HOMOLOG OF__:__
Asterisk__:__603140__:__PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE, TYPE II, ALPHA; PIP4K2A__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE II, ALPHA; PIP5K2A;; PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE, ALPHA; PI5P4KA__:__
Asterisk__:__603141__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN-BINDING PROTEIN 1; PPFIBP1__:__PTPRF-INTERACTING PROTEIN-BINDING PROTEIN 1;; LIPRIN-BETA-1__:__
Asterisk__:__603142__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN-BINDING PROTEIN 2; PPFIBP2__:__PTPRF-INTERACTING PROTEIN-BINDING PROTEIN 2;; LIPRIN-BETA-2__:__
Asterisk__:__603143__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN ALPHA-2; PPFIA2__:__PTPRF-INTERACTING PROTEIN ALPHA-2;; LIPRIN-ALPHA-2__:__
Asterisk__:__603144__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN ALPHA 3; PPFIA3__:__PTPRF-INTERACTING PROTEIN ALPHA-3;; LIPRIN-ALPHA-3__:__
Asterisk__:__603145__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN ALPHA 4; PPFIA4__:__PTPRF-INTERACTING PROTEIN ALPHA-4;; LIPRIN-ALPHA-4__:__
Asterisk__:__603146__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 9; PSMD9__:__BRIDGE 1, RAT, HOMOLOG OF__:__
Number Sign__:__603147__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ic; CDG1C__:__CDG Ic; CDGIc;; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE I, WITH DEFICIENT GLYCOSYLATION OF DOLICHOL-LINKED OLIGOSACCHARIDE, FORMERLY;; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME, TYPE V, FORMERLY; CDGS5, FORMERLY__:__
Asterisk__:__603148__:__ACTIVATING TRANSCRIPTION FACTOR 3; ATF3__:____:__
Asterisk__:__603149__:__INTERLEUKIN 17A; IL17A__:__IL17;; CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED SERINE ESTERASE 8; CTLA8__:__
Asterisk__:__603150__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, DELTA SUBUNIT; ATP5F1D__:__ATP5D;; MITOCHONDRIAL ATP SYNTHASE, DELTA SUBUNIT__:__
Asterisk__:__603151__:__SEPTIN 7; SEPT7__:__CELL DIVISION CYCLE 10; CDC10__:__
Asterisk__:__603152__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT F6; ATP5J__:__MITOCHONDRIAL ATP SYNTHASE, SUBUNIT F6;; MITOCHONDRIAL ATP SYNTHASE, COUPLING FACTOR 6;; ATP5__:__
Asterisk__:__603153__:__RAD1, S. POMBE, HOMOLOG OF; RAD1__:____:__
Asterisk__:__603154__:__PININ; PNN__:__DRS__:__
Asterisk__:__603155__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 14; PTPN14__:__PHOSPHATASE WITH EZRIN DOMAIN; PEZ__:__
Asterisk__:__603156__:__BIPHENYL HYDROLASE-LIKE; BPHL__:__VALACYCLOVIRASE;; MUCIN-ASSOCIATED ANTIGEN; MCNAA;; BREAST EPITHELIAL MUCIN-ASSOCIATED ANTIGEN__:__
Asterisk__:__603157__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 2; PIK3R2__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT, 85-KD, BETA;; p85-BETA__:__PIK3R2/UPS8 FUSION GENE, INCLUDED
Asterisk__:__603158__:__UBIQUITIN-SPECIFIC PROTEASE 8; USP8__:__DEUBIQUITINATING ENZYME HUMORF8; HUMORF8__:__USP8/PIK3R2 FUSION GENE, INCLUDED
Asterisk__:__603159__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 3; LRP3__:____:__
Asterisk__:__603160__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 6; ENTPD6__:__CD39-LIKE 2; CD39L2__:__
Asterisk__:__603161__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 3; ENTPD3__:__CD39-LIKE 3; CD39L3__:__
Asterisk__:__603162__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 5; ENTPD5__:__CD39-LIKE 4; CD39L4__:__
Asterisk__:__603163__:__STIMULATOR OF CHONDROGENESIS 1; SCRG1__:__SCRAPIE-RESPONSIVE GENE 1__:__
Asterisk__:__603164__:__PEROXISOME BIOGENESIS FACTOR 3; PEX3__:__PEROXIN 3__:__
Percent__:__603165__:__DERMATITIS, ATOPIC__:__ATOD;; ECZEMA, ATOPIC__:__DERMATITIS, ATOPIC, 1, INCLUDED; ATOD1, INCLUDED
Asterisk__:__603166__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 2; MAP4K2__:__GERMINAL CENTER KINASE; GCK;; RAB8-INTERACTING PROTEIN, FORMERLY; RAB8IP, FORMERLY__:__
Asterisk__:__603167__:__BCL2-ASSOCIATED AGONIST OF CELL DEATH; BAD__:__BCL2 ANTAGONIST;; BCL2-BINDING PROTEIN; BCL2L8;; BCL2-BINDING COMPONENT 6__:__
Asterisk__:__603168__:__UNC51-LIKE KINASE 1; ULK1__:__UNC51, C. ELEGANS, HOMOLOG OF;; UNC51.1__:__
Asterisk__:__603169__:__CATHEPSIN Z; CTSZ__:____:__
Asterisk__:__603170__:__TEA DOMAIN FAMILY MEMBER 3; TEAD3__:__TRANSCRIPTIONAL ENHANCER FACTOR 5; TEF5;; TEA DOMAIN FAMILY MEMBER 5, FORMERLY; TEAD5, FORMERLY__:__
Asterisk__:__603171__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 8; NEDD8__:____:__
Asterisk__:__603172__:__UBIQUITIN-ACTIVATING ENZYME E1C; UBE1C__:__UBIQUITIN-ACTIVATING ENZYME 3, S. CEREVISIAE, HOMOLOG OF; UBA3__:__
Asterisk__:__603173__:__UBIQUITIN-CONJUGATING ENZYME E2M; UBE2M__:__UBIQUITIN-CONJUGATING ENZYME 12, S. CEREVISIAE, HOMOLOG OF; UBC12__:__
NULL__:__603174__:__HOMOCYSTEINEMIA__:__HYPERHOMOCYSTEINEMIA__:__
Percent__:__603175__:__SCHIZOPHRENIA 5; SCZD5__:__SCHIZOPHRENIA 5 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 6q-RELATED__:__
Percent__:__603176__:__SCHIZOPHRENIA 7; SCZD7__:__SCHIZOPHRENIA 7 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 13q-RELATED__:__
Asterisk__:__603177__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 8; VAMP8__:__ENDOBREVIN;; SYNAPTOBREVIN-LIKE, ENDOSOME-ASSOCIATED__:__
Asterisk__:__603178__:__ALDEHYDE DEHYDROGENASE 6 FAMILY, MEMBER A1; ALDH6A1__:__METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE; MMSDH__:__
Asterisk__:__603179__:__CARBONIC ANHYDRASE IX; CA9__:__CA IX;; MEMBRANE ANTIGEN MN; MN__:__
Asterisk__:__603180__:__EXPORTIN, tRNA; XPOT__:__EXPORTIN-T__:__
Asterisk__:__603181__:__INTERLEUKIN ENHANCER-BINDING FACTOR 2; ILF2__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, 45-KD; NF45__:__
Asterisk__:__603182__:__INTERLEUKIN ENHANCER-BINDING FACTOR 3; ILF3__:__NUCLEAR FACTOR OF ACTIVATED T CELLS, 90-KD; NF90;; DOUBLE-STRANDED RNA-BINDING PROTEIN, 76-KD; DRBP76;; M-PHASE PHOSPHOPROTEIN 4; MPP4; MPHOSPH4;; NUCLEAR FACTOR ASSOCIATED WITH DOUBLE-STRANDED RNA; NFAR__:__
Asterisk__:__603183__:__RETICULON 2; RTN2__:__NEUROENDOCRINE-SPECIFIC PROTEIN-LIKE 1; NSPL1__:__
Asterisk__:__603184__:__CYCLIN-DEPENDENT KINASE 8; CDK8__:__K35__:__
Asterisk__:__603185__:__NUCLEAR AUTOANTIGENIC SPERM PROTEIN; NASP__:__N1/N2, XENOPUS, HOMOLOG OF__:__
Asterisk__:__603186__:__DEATH-ASSOCIATED PROTEIN 6; DAXX__:__BING2__:__
Asterisk__:__603187__:__CENTRIN 1; CETN1__:__CEN1__:__
Percent__:__603188__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 8; BMIQ8__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__603189__:__SYNTAXIN 5; STX5__:__STX5A;; SED5__:__
Asterisk__:__603190__:__PROTEIN ARGININE N-METHYLTRANSFERASE 3; PRMT3__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN METHYLTRANSFERASE 1-LIKE 3; HRMT1L3;; HMT1-LIKE 3__:__
Asterisk__:__603191__:__CILIA AND FLAGELLA-ASSOCIATED PROTEIN 410; CFAP410__:__CHROMOSOME 21 OPEN READING FRAME 2; C21ORF2__:__
Asterisk__:__603192__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT C, ISOFORM 1; ATP5G1__:__MITOCHONDRIAL ATP SYNTHASE, SUBUNIT C, ISOFORM 1;; MITOCHONDRIAL ATP SYNTHASE, SUBUNIT 9, ISOFORM 1__:__
Asterisk__:__603193__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT C, ISOFORM 2; ATP5G2__:__MITOCHONDRIAL ATP SYNTHASE, SUBUNIT C, ISOFORM 2;; MITOCHONDRIAL ATP SYNTHASE, SUBUNIT 9, ISOFORM 2__:__
Number Sign__:__603194__:__MECKEL SYNDROME, TYPE 2; MKS2__:__MECKEL-GRUBER SYNDROME, TYPE 2__:__
Asterisk__:__603195__:__G PROTEIN-COUPLED RECEPTOR 32; GPR32__:____:__
Asterisk__:__603196__:__COCHLIN; COCH__:__COCH5B2;; COAGULATION FACTOR C HOMOLOGY__:__
Asterisk__:__603197__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 6; PNPLA6__:__NEUROPATHY TARGET ESTERASE; NTE;; NEUROTOXIC ESTERASE__:__
Asterisk__:__603198__:__CAVEOLAE-ASSOCIATED PROTEIN 1; CAVIN1__:__CAVIN;; RNA POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; PTRF__:__
Asterisk__:__603199__:__PALS1-ASSOCIATED TIGHT JUNCTION PROTEIN; PATJ__:__PATJ, CRUMBS CELL POLARITY COMPLEX COMPONENT;; INAD-LIKE; INADL;; INAD, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__603200__:__REGULATORY FACTOR X, ANKYRIN REPEAT-CONTAINING; RFXANK__:____:__
Asterisk__:__603201__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 11; ABCB11__:__BILE SALT EXPORT PUMP; BSEP;; SISTER OF P-GLYCOPROTEIN; SPGP__:__
Asterisk__:__603202__:__LACTASE; LCT__:__LAC;; LACTASE-PHLORIZIN HYDROLASE; LPH__:__
Asterisk__:__603203__:__CYCLIN G2; CCNG2__:____:__
Percent__:__603204__:__EPILEPSY, NOCTURNAL FRONTAL LOBE, 2; ENFL2__:____:__
Asterisk__:__603205__:__MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 1; MORC1__:__MICRORCHIDIA, MOUSE, HOMOLOG OF; MORC__:__
Percent__:__603206__:__SCHIZOPHRENIA 8; SCZD8__:__SCHIZOPHRENIA 8 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 18-RELATED__:__
Asterisk__:__603207__:__VTI1, S. CEREVISIAE, HOMOLOG OF, B; VTI1B__:__VTI1;; VTI1-LIKE; VTI1L__:__
Asterisk__:__603208__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 13; KCNJ13__:__INWARDLY RECTIFYING POTASSIUM CHANNEL Kir7.1__:__
NULL__:__603209__:__CYTIDINE MONOPHOSPHO-N-ACETYLNEURAMINIC ACID HYDROXYLASE, PSEUDOGENE; CMAHP__:__CMAH;; CMP-NeuAc HYDROXYLASE;; CMP-Neu5Ac HYDROXYLASE;; CMP-SIALIC ACID HYDROXYLASE; CSAH__:__
Asterisk__:__603210__:__JERKY, MOUSE, HOMOLOG OF; JRK__:__JH8__:__
Asterisk__:__603211__:__JERKY, MOUSE, HOMOLOG-LIKE; JRKL__:__HHMJG__:__
Asterisk__:__603212__:__BEADED FILAMENT STRUCTURAL PROTEIN 2; BFSP2__:__BEADED FILAMENT STRUCTURAL PROTEIN, 49-KD;; CYTOSKELETAL PROTEIN, 49-KD; CP49;; CYTOSKELETAL PROTEIN, 47-KD; CP47;; PHAKININ;; PHAKOSIN__:__
Asterisk__:__603213__:__KINESIN FAMILY MEMBER 22; KIF22__:__KINESIN-LIKE 4; KNSL4;; KINESIN-LIKE DNA-BINDING PROTEIN; KID;; ORIGIN OF PLASMID DNA REPLICATION-BINDING PROTEIN; OBP;; ORIP-BINDING PROTEIN__:__
Asterisk__:__603214__:__ATP-BINDING CASSETTE, SUBFAMILY D, MEMBER 4; ABCD4__:__PEROXISOMAL MEMBRANE PROTEIN 1-LIKE; PXMP1L;; P70R;; PMP69__:__
Asterisk__:__603215__:__N-ETHYLMALEIMIDE-SENSITIVE FACTOR ATTACHMENT PROTEIN, ALPHA; NAPA__:__SOLUBLE NSF-ATTACHMENT PROTEIN, ALPHA; SNAPA;; SNAP, ALPHA__:__
Asterisk__:__603216__:__N-ETHYLMALEIMIDE-SENSITIVE FACTOR ATTACHMENT PROTEIN, GAMMA; NAPG__:__SOLUBLE NSF-ATTACHMENT PROTEIN, GAMMA;; SNAP, GAMMA__:__
Asterisk__:__603217__:__SYNTAXIN 7; STX7__:____:__
Number Sign__:__603218__:__HUNTINGTON DISEASE-LIKE 1; HDL1__:__HUNTINGTON-LIKE NEURODEGENERATIVE DISORDER 1; HLN1;; HUNTINGTON-LIKE NEURODEGENERATIVE DISORDER, AUTOSOMAL DOMINANT;; PRION DISEASE, EARLY-ONSET, WITH PROMINENT PSYCHIATRIC FEATURES__:__
Asterisk__:__603219__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 2; KCNK2__:__TWIK-RELATED K+ CHANNEL; TREK;; TREK1__:__
Asterisk__:__603220__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 3; KCNK3__:__TWIK-RELATED ACID-SENSITIVE K+ CHANNEL; TASK;; TASK1__:__
Percent__:__603221__:__MYOPIA 3, AUTOSOMAL DOMINANT; MYP3__:____:__
Asterisk__:__603222__:__U22 HOST GENE__:__U22HG;; UHG__:__
Asterisk__:__603223__:__RNA, U22 SMALL NUCLEOLAR; RNU22__:__snoRNA, U22;; RNA Y__:__
Asterisk__:__603224__:__RNA, U25 SMALL NUCLEOLAR; RNU25__:__snoRNA, U25__:__
Asterisk__:__603225__:__RNA, U26 SMALL NUCLEOLAR; RNU26__:__snoRNA, U26__:__
Asterisk__:__603226__:__RNA, U27 SMALL NUCLEOLAR; RNU27__:__snoRNA, U27__:__
Asterisk__:__603227__:__RNA, U28 SMALL NUCLEOLAR; RNU28__:__snoRNA, U28__:__
Asterisk__:__603228__:__RNA, U29 SMALL NUCLEOLAR; RNU29__:__snoRNA, U29__:__
Asterisk__:__603229__:__RNA, U30 SMALL NUCLEOLAR; RNU30__:__snoRNA, U30__:__
Asterisk__:__603230__:__RNA, U31 SMALL NUCLEOLAR; RNU31__:__snoRNA, U31__:__
Asterisk__:__603231__:__ZINC FINGER PROTEIN 200; ZNF200__:____:__
Asterisk__:__603232__:__OLFACTORY RECEPTOR, FAMILY 1, SUBFAMILY F, MEMBER 1; OR1F1__:__OLFMF__:__
Number Sign__:__603233__:__PSEUDOHYPOPARATHYROIDISM, TYPE IB; PHP1B__:__PHP IB__:__
Asterisk__:__603234__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 6; ABCC6__:__ANTHRACYCLINE RESISTANCE-ASSOCIATED PROTEIN; ARA;; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 6; MRP6__:__
Asterisk__:__603235__:__SELENOPROTEIN W; SELENOW__:__SELW;; SELENOPROTEIN W, 1; SEPW1__:__
Asterisk__:__603236__:__MEVALONATE PYROPHOSPHATE DECARBOXYLASE; MVD__:__MPD__:__
Asterisk__:__603237__:__ERYTHROCYTE MEMBRANE PROTEIN 4.1-LIKE 2; EPB41L2__:__NONERYTHROID PROTEIN 4.1, GENERAL TYPE; 4.1G__:__
Asterisk__:__603238__:__RNA, U17D SMALL NUCLEOLAR; RNU17D__:__snoRNA, U17D__:__U17 HOST GENE, INCLUDED; U17HG, INCLUDED
Asterisk__:__603239__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 73B; SNORA73B__:__RNA, U17B SMALL NUCLEOLAR; RNU17B;; snoRNA, U17B__:__
Asterisk__:__603240__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 18, ANTISENSE; SLC22A18AS__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 1-LIKE-ANTISENSE; SLC22A1LS;; ORGANIC-CATION TRANSPORTER-LIKE 2-ANTISENSE; ORCTL2S;; ORCTL2-ANTISENSE;; BECKWITH-WIEDEMANN SYNDROME CHROMOSOME REGION 1, CANDIDATE B; BWSCR1B;; BECKWITH-WIEDEMANN REGION 1B; BWR1B__:__
Asterisk__:__603241__:__LIMBIC SYSTEM-ASSOCIATED MEMBRANE PROTEIN; LSAMP__:__LAMP;; IGLON3__:__
Asterisk__:__603242__:__C-TYPE LECTIN DOMAIN FAMILY 2, MEMBER B; CLEC2B__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 2; CLECSF2;; ACTIVATION-INDUCED C-TYPE LECTIN; AICL;; LECTIN, C-TYPE, ACTIVATION-INDUCED__:__
Asterisk__:__603243__:__AUTOCRINE MOTILITY FACTOR RECEPTOR; AMFR__:__GP78__:__
Asterisk__:__603244__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 1; HS3ST1__:__HEPARAN SULFATE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE 1;; 3OST;; 3OST1__:__
Asterisk__:__603245__:__NK2 HOMEOBOX 8; NKX2-8__:__NK2, DROSOPHILA, HOMOLOG OF, 8; NKX2.8;; NK2, DROSOPHILA, HOMOLOG OF, H; NKX2H;; NKX2-9, MOUSE, HOMOLOG OF__:__
Asterisk__:__603246__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 1; GTF3C1__:__TRANSCRIPTION FACTOR IIIC, ALPHA SUBUNIT;; TFIIIC-ALPHA;; TF3C-ALPHA;; TFIIIC, 220-KD SUBUNIT__:__
Asterisk__:__603247__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 2; SLC27A2__:__FATTY ACID TRANSPORT PROTEIN 2; FATP2;; FATTY ACID CoA LIGASE, VERY LONG CHAIN 1; FACVL1;; VERY LONG CHAIN ACYL-CoA SYNTHETASE; VLACS; VLCS;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 1; ACSVL1__:__
Asterisk__:__603248__:__BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE IB; BMPR1B__:__ACTIVIN RECEPTOR-LIKE KINASE 6; ALK6__:__
Asterisk__:__603249__:__NIPSNAP, C. ELEGANS, HOMOLOG OF, 1; NIPSNAP1__:__4-NITROPHENYLPHOSPHATASE DOMAIN AND NONNEURONAL SNAP25-LIKE 1__:__
Asterisk__:__603250__:__FORKHEAD BOX F2; FOXF2__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 6; FKHL6;; FORKHEAD-RELATED ACTIVATOR 2; FREAC2__:__
Asterisk__:__603251__:__CYCLIN-DEPENDENT KINASE 9; CDK9__:__PITALRE;; CTK1, YEAST, HOMOLOG OF; CTK1__:__
Asterisk__:__603252__:__FORKHEAD BOX L1; FOXL1__:__FORKHEAD, DROSOPHILA, HOMOLOG-LIKE 11; FKHL11;; FORKHEAD-RELATED ACTIVATOR 7; FREAC7;; FKH6__:__
Asterisk__:__603253__:__CYSTATIN 7; CST7__:__CYSTATIN F; CF;; CYSTATIN-LIKE METASTASIS-ASSOCIATED PROTEIN; CMAP;; LEUKOCYSTATIN__:__
Asterisk__:__603254__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4; SMARCA4__:__BRM/SWI2-RELATED GENE 1; BRG1;; SNF2-BETA__:__
Asterisk__:__603255__:__NUCLEAR TRANSCRIPTION FACTOR, X BOX-BINDING, 1; NFX1__:____:__
Asterisk__:__603256__:__LEUCINE-RICH REPEAT IN FLII-INTERACTING PROTEIN 1; LRRFIP1__:__TRANSCRIPTION FACTOR 9-LIKE;; GC-BINDING FACTOR 2; GCF2;; TAR RNA-INTERACTING PROTEIN; TRIP;; FLII LRR-ASSOCIATED PROTEIN 1; FLAP1__:__
Asterisk__:__603257__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 3; SMARCA3__:__HELICASE-LIKE TRANSCRIPTION FACTOR; HLTF;; HIP116;; SUCROSE NONFERMENTING, YEAST, HOMOLOG-LIKE 3; SNF2L3;; SNF2-LIKE 3__:__
Asterisk__:__603258__:__INHIBITOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS, KINASE OF, BETA; IKBKB__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, KINASE OF, BETA; NFKBIKB;; I-KAPPA-B KINASE-BETA;; IKK-BETA; IKKB;; I-KAPPA-B KINASE 2; IKK2__:__
Caret__:__603259__:__MOVED TO 191195__:____:__
Asterisk__:__603260__:__BarH-LIKE HOMEOBOX GENE 1; BARX1__:____:__
Asterisk__:__603261__:__PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE, TYPE II, BETA; PIP4K2B__:__PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE, BETA; PI5P4KB;; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE II, BETA; PIP5K2B__:__
Asterisk__:__603262__:__3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE SYNTHASE 1; PAPSS1__:__PHOSPHOADENOSINE-PHOSPHOSULFATE SYNTHETASE 1;; PAPS SYNTHASE 1;; PAPS SYNTHETASE 1;; ATP SULFURYLASE/ADENOSINE 5-PRIME PHOSPHOSULFATE KINASE 1; ATPSK1;; ATP SULFURYLASE/APS KINASE 1;; SK1__:__
Asterisk__:__603263__:__CARBONIC ANHYDRASE XII; CA12__:__CA XII__:__
Asterisk__:__603264__:__RHOMBOID-LIKE 1; RHBDL1__:__RHBDL;; DROSOPHILA RHOMBOID-LIKE;; RHOMBOID-RELATED PROTEIN; RRP__:__
Asterisk__:__603265__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3A; ARID3A__:__ARID-CONTAINING PROTEIN 3A;; DEAD RINGER, DROSOPHILA, HOMOLOG-LIKE 1; DRIL1__:__
Percent__:__603266__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 17; IDDM17__:__INSULIN-DEPENDENT DIABETES MELLITUS 17__:__
Asterisk__:__603267__:__SMALL OPTIC LOBES, DROSOPHILA, HOMOLOG OF; SOLH__:____:__
Asterisk__:__603268__:__N-DEACETYLASE/N-SULFOTRANSFERASE 2; NDST2__:__HEPARAN GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE 2;; HEPARAN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE 2;; HEPARAN N-SULFOTRANSFERASE 2__:__
Asterisk__:__603269__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 8; SRSF8__:__SERINE/ARGININE-RICH SPLICING FACTOR 8;; SPLICING FACTOR, ARGININE/SERINE-RICH, 2B; SFRS2B;; SPLICING FACTOR, ARGININE/SERINE-RICH, 46-KD; SRp46__:__
Asterisk__:__603270__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL FO COMPLEX, SUBUNIT B, ISOFORM 1; ATP5F1__:____:__
Asterisk__:__603271__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 21; PTPN21__:__PROTEIN-TYROSINE PHOSPHATASE D1; PTPD1__:__
Asterisk__:__603272__:__CONNECTOR ENHANCER OF KINASE SUPPRESSOR OF RAS 1; CNKSR1__:__CONNECTOR ENHANCER OF KSR 1;; CNK, DROSOPHILA, HOMOLOG OF;; CNK1__:__
Asterisk__:__603273__:__TUMOR PROTEIN p63; TP63__:__TUMOR PROTEIN p73-LIKE; TP73L;; p53-RELATED PROTEIN p63; p63;; KET__:__
Caret__:__603274__:__MOVED TO 602961__:____:__
Asterisk__:__603275__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE I, ALPHA; PIP5K1A__:____:__
Asterisk__:__603276__:__REGULATOR OF G PROTEIN SIGNALING 5; RGS5__:____:__
Asterisk__:__603277__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 4; CHD4__:__Mi2-BETA__:__
Number Sign__:__603278__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 1; FSGS1__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 1__:__
Asterisk__:__603279__:__EXPANDED REPEAT DOMAIN, CAG/CTG, 1; ERDA1__:____:__
Caret__:__603280__:__MOVED TO 157640__:____:__
Asterisk__:__603281__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE-LIKE; OASL__:__THYROID HORMONE RECEPTOR INTERACTOR 14; TRIP14;; p59OASL__:__
NULL__:__603282__:__ZINC FINGER PROTEIN 204; ZNF204__:____:__ZINC FINGER PROTEIN 204 PSEUDOGENE, INCLUDED;; ZNF204 PSEUDOGENE, INCLUDED
Asterisk__:__603283__:__TRIADIN; TRDN__:__TRISK__:__
Number Sign__:__603284__:__CEREBRAL CAVERNOUS MALFORMATIONS 2; CCM2__:____:__
Number Sign__:__603285__:__CEREBRAL CAVERNOUS MALFORMATIONS 3; CCM3__:____:__
Asterisk__:__603286__:__KISS1 METASTASIS SUPPRESSOR; KISS1__:__METASTIN;; KISSPEPTIN__:__
Asterisk__:__603287__:__PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE; PNPO__:__PYRIDOXAMINE-PHOSPHATE OXIDASE__:__
Asterisk__:__603288__:__KERATOCAN; KERA__:____:__
Asterisk__:__603289__:__DEATH-ASSOCIATED PROTEIN KINASE 3; DAPK3__:__ZIP KINASE; ZIPK__:__
Asterisk__:__603290__:__SH3 AND MULTIPLE ANKYRIN REPEAT DOMAINS 2; SHANK2__:__CORTACTIN-BINDING PROTEIN 1; CORTBP1__:__
Asterisk__:__603291__:__BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 1; BNIP1__:__NIP1__:__
Asterisk__:__603292__:__BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 2; BNIP2__:__NIP2__:__
Asterisk__:__603293__:__BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 3; BNIP3__:__NIP3__:__
Asterisk__:__603294__:__MINICHROMOSOME MAINTENANCE 3-ASSOCIATED PROTEIN; MCM3AP__:__MCM3-ASSOCIATED PROTEIN, 80-KD; MAP80;; GERMINAL CENTER-ASSOCIATED NUCLEAR PROTEIN; GANP__:__
Asterisk__:__603295__:__MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 9; SMAD9__:__MADH9;; SMA- AND MAD-RELATED PROTEIN 9;; SMAD8;; MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 6, FORMERLY; MADH6, FORMERLY__:__
Asterisk__:__603296__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MITOGEN-ACTIVATED PROTEIN KINASE AND MAMMALIAN TARGET OF RAPAMYCIN ACTIVATOR 3; LAMTOR3__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MAPK AND MTOR ACTIVATOR 3;; MEK PARTNER 1; MP1;; MAPBP;; MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1-INTERACTING PROTEIN 1, FORMERLY; MAP2K1IP1, FORMERLY__:__
Asterisk__:__603297__:__DYNEIN, CYTOPLASMIC 2, HEAVY CHAIN 1; DYNC2H1__:__DNCH2; DHC2;; DYNEIN HEAVY CHAIN, ISOTYPE 1B; DHC1B__:__
Asterisk__:__603298__:__PALMITOYL-PROTEIN THIOESTERASE 2; PPT2__:__G14__:__
Caret__:__603299__:__MOVED TO 603339__:____:__
Asterisk__:__603300__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 2; TNFAIP2__:__EXOCYST COMPLEX COMPONENT 3-LIKE 3; EXOC3L3__:__
Asterisk__:__603301__:__KRUPPEL-LIKE FACTOR 11; KLF11__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCIBLE EARLY GROWTH RESPONSE 2; TIEG2;; TGFB-INDUCIBLE EARLY GROWTH RESPONSE 2;; KRUPPEL-LIKE TRANSCRIPTION FACTOR 1; FKLF1; FKLF__:__
Asterisk__:__603302__:__ADENYLATE CYCLASE 9; ADCY9__:__ADENYLYL CYCLASE 9__:__
Asterisk__:__603303__:__TRF1-INTERACTING, ANKYRIN-RELATED ADP-RIBOSE POLYMERASE; TNKS__:__TANKYRASE 1__:__
Asterisk__:__603304__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 2; IRAK2__:____:__
Asterisk__:__603305__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 1; KCNH1__:__Kv10.1;; ETHER-A-GO-GO, DROSOPHILA, HOMOLOG OF; EAG__:__
Asterisk__:__603306__:__TRANSCRIPTION FACTOR 21; TCF21__:__EPICARDIN;; PODOCYTE-EXPRESSED 1; POD1;; CAPSULIN__:__
Asterisk__:__603307__:__BEADED FILAMENT STRUCTURAL PROTEIN 1; BFSP1__:__CYTOSKELETAL PROTEIN, 115-KD; CP115;; FILENSIN__:__
Asterisk__:__603308__:__CATHEPSIN L2; CTSL2__:__CATHEPSIN V; CTSV__:__
Asterisk__:__603309__:__CYCLIN-DEPENDENT KINASE 13; CDK13__:__CELL DIVISION CYCLE 2-LIKE 5; CDC2L5;; CELL DIVISION CONTROLLER, CHOLINESTERASE-RELATED; CHED__:__
Asterisk__:__603310__:__PHOSPHODIESTERASE 5A; PDE5A__:____:__
Asterisk__:__603311__:__CELL DIVISION CYCLE 7, S. CEREVISIAE, HOMOLOG-LIKE 1; CDC7L1__:__CDC7__:__
Asterisk__:__603312__:__BUTYROBETAINE-GAMMA,2-OXOGLUTARATE DIOXYGENASE 1; BBOX1__:__GAMMA-BUTYROBETAINE HYDROXYLASE; GAMMA-BBH__:__
Asterisk__:__603313__:__ALG10, S. CEREVISIAE, HOMOLOG OF; ALG10__:__POTASSIUM CHANNEL REGULATOR 1;; KCR1__:__
Asterisk__:__603314__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 5; SLC27A5__:__FATTY ACID TRANSPORT PROTEIN 5; FATP5;; VERY LONG CHAIN ACYL-CoA SYNTHETASE-RELATED PROTEIN; VLACSR;; VLCS HOMOLOG 2; VLCSH2;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 6; ACSVL6__:__
Asterisk__:__603315__:__FREQUENIN, DROSOPHILA, HOMOLOG OF; FREQ__:__NEURONAL CALCIUM SENSOR 1; NCS1__:__
Asterisk__:__603316__:__CYTIDINE 5-PRIME-MONOPHOSPHATE N-ACETYLNEURAMINIC ACID SYNTHETASE; CMAS__:__CMP-Neu5Ac SYNTHETASE__:__
Asterisk__:__603317__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, Q; PTPRQ__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, EXPRESSED BY GLOMERULAR MESANGIAL CELLS 1; PTPGMC1__:__
Caret__:__603318__:__MOVED TO 603345__:____:__
Asterisk__:__603319__:__ANNEXIN A9; ANXA9__:__ANNEXIN 31, FORMERLY; ANX31, FORMERLY__:__
Asterisk__:__603320__:__MATRIX METALLOPROTEINASE 23A; MMP23A__:__MATRIX METALLOPROTEINASE 21, FORMERLY; MMP21, FORMERLY__:__
Asterisk__:__603321__:__MATRIX METALLOPROTEINASE 23B; MMP23B__:__MATRIX METALLOPROTEINASE 22, FORMERLY; MMP22, FORMERLY__:__
Asterisk__:__603322__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 6; NDUFB6__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, B17 SUBUNIT; B17__:__
NULL__:__603323__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH CEREBELLAR ATROPHY__:____:__
Plus__:__603324__:__GAP JUNCTION PROTEIN, BETA-3; GJB3__:__GAP JUNCTION PROTEIN, 31-KD;; CONNEXIN 31; CX31__:__DEAFNESS, AUTOSOMAL RECESSIVE, INCLUDED;; DEAFNESS, AUTOSOMAL DOMINANT, WITH PERIPHERAL NEUROPATHY, INCLUDED
Asterisk__:__603325__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 9B; PPP1R9B__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 9; PPP1R9;; SPINOPHILIN; SPINO;; NEURABIN II__:__
Asterisk__:__603326__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 3D; PPP1R3D__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 6; PPP1R6__:__
Asterisk__:__603327__:__RAN-BINDING PROTEIN 3; RANBP3__:____:__
Asterisk__:__603328__:__MUSASHI, DROSOPHILA, HOMOLOG OF, 1; MSI1__:____:__
Caret__:__603329__:__MOVED TO 300931__:____:__
Asterisk__:__603330__:__DYNEIN, AXONEMAL, HEAVY CHAIN 9; DNAH9__:__DYNEIN, AXONEMAL, HEAVY CHAIN 17-LIKE; DNAH17L;; DYNEIN, AXONEMAL, LIGHT INTERMEDIATE CHAIN 1; DNEL1;; HL20__:__
Asterisk__:__603331__:__DYNEIN, CYTOPLASMIC 1, INTERMEDIATE CHAIN 2; DYNC1I2__:__DNCI2;; IC2__:__
Asterisk__:__603332__:__DYNEIN, AXONEMAL, HEAVY CHAIN 1; DNAH1__:__HL11;; DNAHC1;; HDHC7__:__
Asterisk__:__603333__:__DYNEIN, AXONEMAL, HEAVY CHAIN 2; DNAH2__:__DNAHC2__:__
Asterisk__:__603334__:__DYNEIN, AXONEMAL, HEAVY CHAIN 3; DNAH3__:__DNAHC3B__:__
Asterisk__:__603335__:__DYNEIN, AXONEMAL, HEAVY CHAIN 5; DNAH5__:__HL1__:__
Asterisk__:__603336__:__DYNEIN, AXONEMAL, HEAVY CHAIN 6; DNAH6__:__HL2;; KIAA1697__:__
Asterisk__:__603337__:__DYNEIN, AXONEMAL, HEAVY CHAIN 8; DNAH8__:__HDHC9__:__
Caret__:__603338__:__MOVED TO 603330__:____:__
Asterisk__:__603339__:__DYNEIN, AXONEMAL, HEAVY CHAIN 11; DNAH11__:__DNAHC11;; DPL11;; DYNEIN, HEAVY CHAIN BETA-LIKE; DNAHBL__:__
Asterisk__:__603340__:__DYNEIN, AXONEMAL, HEAVY CHAIN 12; DNAH12__:__DNAHC3;; HL19;; HDHC3;; DHC3__:__
Asterisk__:__603341__:__DYNEIN, AXONEMAL, HEAVY CHAIN 14; DNAH14__:__HL18__:__
Percent__:__603342__:__SCHIZOPHRENIA 2; SCZD2__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 11q-RELATED__:__
Asterisk__:__603343__:__RNA EXPORT 1, S. POMBE, HOMOLOG OF; RAE1__:__mRNA-BINDING PROTEIN, 41-KD; MRNP41__:__
Asterisk__:__603344__:__USO1 VESICLE DOCKING PROTEIN, S. CEREVISIAE, HOMOLOG OF; USO1__:__VESICLE DOCKING PROTEIN, 115-KD; p115;; TRANSCYTOSIS-ASSOCIATED PROTEIN; TAP;; TAP/p115__:__
Asterisk__:__603345__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 4; SLC4A4__:__SODIUM BICARBONATE COTRANSPORTER 1; NBC1;; SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 5, FORMERLY; SLC4A5, FORMERLY__:__SODIUM BICARBONATE COTRANSPORTER, KIDNEY, INCLUDED; KNBC, INCLUDED; KNBC1, INCLUDED;; SODIUM BICARBONATE COTRANSPORTER, PANCREAS, INCLUDED; PNBC, INCLUDED; PNBC1, INCLUDED;; SODIUM BICARBONATE COTRANSPORTER, HEART, INCLUDED; HHNBC, INCLUDED; HHNBC1, INCLUDED
Asterisk__:__603346__:__NEURONAL PAS DOMAIN PROTEIN 1; NPAS1__:__MEMBER OF PAS SUPERFAMILY 5; MOP5__:__
Asterisk__:__603347__:__NEURONAL PAS DOMAIN PROTEIN 2; NPAS2__:__MEMBER OF PAS SUPERFAMILY 4; MOP4__:__
Asterisk__:__603348__:__HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HIF1A__:__HIF1-ALPHA;; MEMBER OF PAS SUPERFAMILY 1; MOP1__:__
Asterisk__:__603349__:__ENDOTHELIAL PAS DOMAIN PROTEIN 1; EPAS1__:__MEMBER OF PAS SUPERFAMILY 2; MOP2;; HYPOXIA-INDUCIBLE FACTOR 2, ALPHA SUBUNIT;; HIF2-ALPHA; HIF2A__:__
Asterisk__:__603350__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE 2; OAS2__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE, 69-KD;; p69__:__
Asterisk__:__603351__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE 3; OAS3__:__2-PRIME,5-PRIME-OLIGOADENYLATE SYNTHETASE, 100-KD;; p100__:__
Asterisk__:__603352__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5; BIRC5__:__APOPTOSIS INHIBITOR 4; API4;; SURVIVIN__:__
Asterisk__:__603353__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 7; SLC4A7__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 6, FORMERLY; SLC4A6, FORMERLY__:__SODIUM BICARBONATE COTRANSPORTER 2, INCLUDED; NBC2, INCLUDED;; SODIUM BICARBONATE COTRANSPORTER 3, INCLUDED; NBC3, INCLUDED;; SODIUM BICARBONATE COTRANSPORTER 3, MUSCLE, INCLUDED; MNBC3, INCLUDED
Asterisk__:__603354__:__GASTRULATION BRAIN HOMEOBOX 1; GBX1__:____:__
Asterisk__:__603355__:__MEMBRANE-BOUND TRANSCRIPTION FACTOR PROTEASE, SITE 1; MBTPS1__:__SITE-1 PROTEASE; S1P__:__
Asterisk__:__603356__:__CD164 ANTIGEN; CD164__:__SIALOMUCIN CD164;; ENDOLYN__:__
Asterisk__:__603357__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 7; SERPINB7__:__MESANGIUM-PREDOMINANT GENE; MEGSIN__:__
Number Sign__:__603358__:__GRACILE SYNDROME__:__GROWTH RETARDATION, AMINO ACIDURIA, CHOLESTASIS, IRON OVERLOAD, LACTIC ACIDOSIS, AND EARLY DEATH;; FINNISH LETHAL NEONATAL METABOLIC SYNDROME; FLNMS;; LACTIC ACIDOSIS, FINNISH, WITH HEPATIC HEMOSIDEROSIS;; FELLMAN SYNDROME__:__
Asterisk__:__603359__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 8; NDUFA8__:____:__
Asterisk__:__603360__:__PEROXISOME BIOGENESIS FACTOR 16; PEX16__:__PEROXIN 16__:__
Asterisk__:__603361__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 6B; TNFRSF6B__:__DECOY RECEPTOR 3; DCR3;; TR6__:__
Asterisk__:__603362__:__SH3 DOMAIN, GRB2-LIKE, 3; SH3GL3__:__SH3p13;; ENDOPHILIN A3__:__
Asterisk__:__603363__:__CGG-BINDING PROTEIN 1; CGGBP1__:__CGG-BINDING PROTEIN, 20-KD;; p20CGGBP__:__
Asterisk__:__603364__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 3; SRSF3__:__SERINE/ARGININE-RICH SPLICING FACTOR 3;; SPLICING FACTOR, ARGININE/SERINE-RICH, 3; SFRS3;; SPLICING FACTOR, ARGININE/SERINE-RICH, 20-KD; SRp20__:__
Asterisk__:__603365__:__HIRA-INTERACTING PROTEIN 3; HIRIP3__:____:__
Asterisk__:__603366__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25__:__TNFR25;; APO3;; DEATH RECEPTOR 3; DR3;; LYMPHOCYTE-ASSOCIATED RECEPTOR OF DEATH; LARD;; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 12, FORMERLY; TNFRSF12, FORMERLY__:__
Caret__:__603367__:__MOVED TO 300255__:____:__
Asterisk__:__603368__:__CYCLIN-DEPENDENT KINASE 6; CDK6__:__PLSTIRE__:__CDK6/MLL FUSION GENE, INCLUDED
Asterisk__:__603369__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2C; CDKN2C__:__p18(INK4C)__:__
Asterisk__:__603370__:__UDP-GLUCOSE DEHYDROGENASE; UGDH__:__UDPGDH__:__
Asterisk__:__603371__:__GLE1, RNA EXPORT MEDIATOR; GLE1__:__GLE1, S. CEREVISIAE, HOMOLOG OF;; GLE1-LIKE PROTEIN; GLE1L__:__
Plus__:__603372__:__THYROID-STIMULATING HORMONE RECEPTOR; TSHR__:__THYROTROPIN RECEPTOR;; LGR3__:__THYROID ADENOMA, HYPERFUNCTIONING, INCLUDED;; THYROID CARCINOMA WITH THYROTOXICOSIS, INCLUDED
Number Sign__:__603373__:__HYPERTHYROIDISM, FAMILIAL GESTATIONAL__:____:__
Caret__:__603374__:__MOVED TO 300186__:____:__
Asterisk__:__603375__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 5; SMARCA5__:__SUCROSE NONFERMENTING, YEAST, HOMOLOG OF; SNF2H;; WCRF135__:__
NULL__:__603376__:__LONG CHAIN FATTY ACIDS, DEFECT IN TRANSPORT OF__:____:__
Asterisk__:__603377__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 5; SLC22A5__:__ORGANIC CATION TRANSPORTER 2; OCTN2__:__
Asterisk__:__603378__:__SIN3-ASSOCIATED POLYPEPTIDE, 30-KD; SAP30__:____:__
Asterisk__:__603379__:__IQ MOTIF-CONTAINING GTPase-ACTIVATING PROTEIN 1; IQGAP1__:__RASGAP-LIKE WITH IQ MOTIFS;; p195;; SAR1, S. POMBE, HOMOLOG OF; SAR1;; HUMORFA01__:__
Asterisk__:__603380__:__LIN7, C. ELEGANS, HOMOLOG OF, A; LIN7A__:__VERTEBRATE LIN7 HOMOLOG 1; VELI1;; MAMMALIAN LIN7 HOMOLOG 1; MALS1__:__
Asterisk__:__603381__:__FILAMIN B; FLNB__:__FILAMIN, BETA;; ACTIN-BINDING PROTEIN 276/278; ABP276/278__:__TRUNCATED ACTIN-BINDING PROTEIN, INCLUDED; TABP, INCLUDED;; ACTIN-BINDING PROTEIN, TRUNCATED, INCLUDED;; FILAMIN HOMOLOG 1, INCLUDED; FH1, INCLUDED
Asterisk__:__603382__:__MutS, E. COLI, HOMOLOG OF, 5; MSH5__:____:__
Number Sign__:__603383__:__GLAUCOMA 1, OPEN ANGLE, F; GLC1F__:__GLAUCOMA, PRIMARY OPEN ANGLE, ADULT-ONSET__:__
Asterisk__:__603384__:__SYNAPTIC RAS-GTPase-ACTIVATING PROTEIN 1; SYNGAP1__:__GTPase-ACTIVATING PROTEIN, RAS, SYNAPTIC, 135-KD, RAT, HOMOLOG OF;; RAS-GTPase-ACTIVATING PROTEIN, SYNAPTIC, 135-KD, RAT, HOMOLOG OF;; SYNAPTIC RAS-GTPase-ACTIVATING PROTEIN, 135-KD, RAT, HOMOLOG OF;; SYNGAP, p135, RAT, HOMOLOG OF; SYNGAP__:__
Asterisk__:__603385__:__NEDD8-ACTIVATING ENZYME E1, SUBUNIT 1; NAE1__:__AMYLOID BETA PRECURSOR PROTEIN-BINDING PROTEIN 1; APPBP1__:__
Percent__:__603386__:__THYROID CARCINOMA, NONMEDULLARY, WITH OR WITHOUT CELL OXYPHILIA__:__TCO;; TCO1__:__
Number Sign__:__603387__:__MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 1; MPPH1__:__MEGALENCEPHALY, POLYMICROGYRIA, MEGA CORPUS CALLOSUM SYNDROME; MPPH;; MEG-PMG-MEGACC SYNDROME;; MEGALENCEPHALY, MEGA CORPUS CALLOSUM, AND COMPLETE LACK OF MOTOR DEVELOPMENT__:__
Percent__:__603388__:__GRAVES DISEASE, SUSCEPTIBILITY TO, 2__:__GRD2__:__
NULL__:__603389__:__OSEBOLD SKELETAL DYSPLASIA/OSTEOLYSIS SYNDROME__:____:__
Asterisk__:__603390__:__PHOSPHODIESTERASE 8B; PDE8B__:____:__
Caret__:__603391__:__MOVED TO 139210__:____:__
Asterisk__:__603392__:__BCL2-INTERACTING KILLER; BIK__:__NBK__:__
NULL__:__603393__:__OSTEOSCLEROTIC CHONDRODYSPLASIA, LETHAL, WITH INTRACELLULAR INCLUSIONS__:____:__
NULL__:__603394__:__MICROCEPHALY, SEVERE, WITH SKELETAL ANOMALIES INCLUDING POSTERIOR RIB-GAP DEFECTS__:____:__
Asterisk__:__603395__:__SPERM-ASSOCIATED ANTIGEN 1; SPAG1__:____:__
NULL__:__603396__:__TONOKI SYNDROME__:____:__
Asterisk__:__603397__:__ZINC FINGER PROTEIN 282; ZNF282__:__HTLV-1 U5 REPRESSIVE ELEMENT-BINDING PROTEIN 1; HUB1__:__
Asterisk__:__603398__:__WNT1-INDUCIBLE SIGNALING PATHWAY PROTEIN 1; WISP1__:____:__
Asterisk__:__603399__:__WNT1-INDUCIBLE SIGNALING PATHWAY PROTEIN 2; WISP2__:__CCN FAMILY, MEMBER 5; CCN5__:__
Asterisk__:__603400__:__WNT1-INDUCIBLE SIGNALING PATHWAY PROTEIN 3; WISP3__:____:__
Asterisk__:__603401__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, BETA-1 SUBUNIT; AP3B1__:__ADAPTIN, BETA-3A; ADTB3A;; HPS2 GENE; HPS2;; PEARL, MOUSE, HOMOLOG OF; PE__:__
Asterisk__:__603402__:__ACYL-CoA OXIDASE 3, PRISTANOYL; ACOX3__:__ACYL-CoA OXIDASE, PRISTANOYL, PEROXISOMAL;; PRISTANOYL-CoA OXIDASE__:__
Asterisk__:__603403__:__DEAH BOX POLYPEPTIDE 15; DHX15__:__DEAD/H BOX 15; DDX15;; DEAH BOX PROTEIN 1; DBP1;; PRP43, S. CEREVISIAE, HOMOLOG OF;; RNA HELICASE 2; HRH2__:__
Asterisk__:__603404__:__ZINC FINGER PROTEIN 169; ZNF169__:____:__
Asterisk__:__603405__:__DEAH BOX POLYPEPTIDE 16; DHX16__:__DEAD/H BOX 16; DDX16;; DEAH-BOX PROTEIN 2; DBP2;; PRP8, S. POMBE, HOMOLOG OF;; MISSION IMPOSSIBLE, ZEBRAFISH, HOMOLOG OF; MIS;; KIAA0577__:__
Asterisk__:__603406__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 24; TRIM24__:__TRANSCRIPTIONAL INTERMEDIARY FACTOR 1; TIF1;; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1-ALPHA; TIF1A__:__PTC6 CHIMERIC ONCOGENE, INCLUDED
Asterisk__:__603407__:__POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 4; PABPC4__:__POLYADENYLATE-BINDING PROTEIN 4; PABP4;; POLY(A)-BINDING PROTEIN 4;; POLYADENYLATE-BINDING PROTEIN, INDUCIBLE; IPABP;; ACTIVATED-PLATELET PROTEIN 1; APP1__:__
Asterisk__:__603408__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 1; FZD1__:__FZ1__:__
Asterisk__:__603409__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 6; FZD6__:____:__
Asterisk__:__603410__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 7; FZD7__:__FZE3__:__
Asterisk__:__603411__:__EFFECTOR CELL PROTEASE RECEPTOR 1; EPR1__:____:__
Asterisk__:__603412__:__CDC42-BINDING PROTEIN KINASE, ALPHA; CDC42BPA__:__CDC42BP-ALPHA;; PROTEIN KINASE, SERINE/THREONINE, RELATED TO THE MYOTONIC DYSTROPHY PROTEIN KINASE;; PK428;; MYOTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE, ALPHA; MRCKA;; MRCK-ALPHA__:__
Asterisk__:__603413__:__TIA1 CYTOTOXIC GRANULE-ASSOCIATED RNA-BINDING PROTEIN-LIKE 1; TIAL1__:__TIA1-RELATED PROTEIN; TIAR;; T CLUSTER-BINDING PROTEIN; TCBP__:__
Asterisk__:__603414__:__TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 2; TM7SF2__:__ANG1__:__
Asterisk__:__603415__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT; SCN9A__:__NAV1.7;; NEUROENDOCRINE SODIUM CHANNEL; NENA;; PERIPHERAL SODIUM CHANNEL 1; PN1__:__
NULL__:__603416__:__RIBOSOMAL PROTEIN L21 PSEUDOGENE 1; RPL21P1__:____:__
Asterisk__:__603417__:__RAB-INTERACTING FACTOR; RABIF__:__RAS-SPECIFIC GUANINE-RELEASING FACTOR 3; RASGRF3;; MAMMALIAN SUPPRESSOR OF SEC4; MSS4__:__
Asterisk__:__603418__:__ALDO-KETO REDUCTASE FAMILY 7, MEMBER A2; AKR7A2__:__ALDO-KETO REDUCTASE 7; AKR7;; AFLATOXIN B1-ALDEHYDE REDUCTASE; AFAR__:__
Asterisk__:__603419__:__SMALL GLUTAMINE-RICH TETRATRICOPEPTIDE REPEAT-CONTAINING PROTEIN, ALPHA; SGTA__:__SMALL GLUTAMINE-RICH TETRATRICOPEPTIDE REPEAT-CONTAINING PROTEIN; SGT__:__
Asterisk__:__603420__:__CALUMENIN; CALU__:____:__
Asterisk__:__603421__:__TRANSMEMBRANE PROTEIN WITH EGF-LIKE AND 2 FOLLISTATIN-LIKE DOMAINS 1; TMEFF1__:__CHROMOSOME 9 OPEN READING FRAME 2; C9ORF2__:__
Asterisk__:__603422__:__PDZ AND LIM DOMAIN PROTEIN 4; PDLIM4__:__LIM DOMAIN PROTEIN RIL__:__
Asterisk__:__603423__:__PR DOMAIN-CONTAINING PROTEIN 1; PRDM1__:__B LYMPHOCYTE-INDUCED MATURATION PROTEIN 1; BLIMP1;; POSITIVE REGULATORY DOMAIN I-BINDING FACTOR 1; PRDIBF1__:__
Asterisk__:__603424__:__PROTEIN KINASE, INTERFERON-INDUCIBLE DOUBLE-STRANDED RNA-DEPENDENT ACTIVATOR; PRKRA__:__PROTEIN ACTIVATOR OF INTERFERON-INDUCED PROTEIN KINASE; PACT;; PKR PROTEIN ACTIVATOR;; RAX__:__
Asterisk__:__603425__:__ADP-RIBOSYLATION FACTOR-LIKE 1; ARL1__:____:__
Asterisk__:__603426__:__PERIOD, DROSOPHILA, HOMOLOG OF, 2; PER2__:____:__
Asterisk__:__603427__:__PERIOD, DROSOPHILA, HOMOLOG OF, 3; PER3__:____:__
Asterisk__:__603428__:__ZINC FINGER PROTEIN 207; ZNF207__:____:__
Asterisk__:__603429__:__ATP-BINDING CASSETTE, SUBFAMILY F, MEMBER 1; ABCF1__:__ATP-BINDING CASSETTE 50; ABC50__:__
Asterisk__:__603430__:__ZINC FINGER PROTEIN 202; ZNF202__:____:__
Asterisk__:__603431__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4H; EIF4H__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 1; WBSCR1;; WSCR1__:__
Asterisk__:__603432__:__CAP-GLY DOMAIN-CONTAINING LINKER PROTEIN 2; CLIP2__:__CYTOPLASMIC LINKER 2; CYLN2;; WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 4; WBSCR4; WSCR4;; CYTOPLASMIC LINKER PROTEIN 115; CLIP115__:__
Asterisk__:__603433__:__ZINC FINGER PROTEIN 143; ZNF143__:__SPH-BINDING FACTOR; SBF__:__
Asterisk__:__603434__:__PHOSPHOPROTEIN ENRICHED IN ASTROCYTES, 15-KD; PEA15__:__PHOSPHOPROTEIN ENRICHED IN DIABETES; PED;; MAMMARY TRANSFORMING GENE 1, MOUSE, HOMOLOG OF; HMAT1;; MAT1, MOUSE, HOMOLOG OF__:__
Asterisk__:__603435__:__GLUTATHIONE PEROXIDASE 5; GPX5__:__GLUTATHIONE PEROXIDASE, EPIDIDYMAL__:__
Asterisk__:__603436__:__ZINC FINGER PROTEIN 205; ZNF205__:__ZINC FINGER PROTEIN 210; ZNF210__:__
Asterisk__:__603437__:__COLD-SHOCK DOMAIN PROTEIN A; CSDA__:__DNA-BINDING PROTEIN A; DBPA__:__
NULL__:__603438__:__RADIOULNAR SYNOSTOSIS WITH MICROCEPHALY, SHORT STATURE, SCOLIOSIS, AND MENTAL RETARDATION__:__TSUKAHARA SYNDROME;; GIUFFRE-TSUKAHARA SYNDROME__:__
NULL__:__603439__:__EXPANSILE BONE LESIONS__:____:__
Asterisk__:__603440__:__CYCLIN-DEPENDENT KINASE 17; CDK17__:__PCTAIRE PROTEIN KINASE 2; PCTK2;; PCTAIRE2__:__
Asterisk__:__603441__:__CYCLIN-DEPENDENT KINASE-LIKE 1; CDKL1__:__KKIALRE;; p42__:__
Asterisk__:__603442__:__CYCLIN-DEPENDENT KINASE-LIKE 2; CDKL2__:__KKIAMRE;; p56__:__
Asterisk__:__603443__:__VACUOLAR PROTEIN SORTING 52, S. CEREVISIAE, HOMOLOG OF; VPS52__:__SUPPRESSOR OF ACTIN MUTATIONS 2, S. CEREVISIAE, HOMOLOG-LIKE; SACM2L__:__
Asterisk__:__603444__:__FAR UPSTREAM ELEMENT-BINDING PROTEIN 1; FUBP1__:__FAR UPSTREAM ELEMENT-BINDING PROTEIN; FUBP;; FUSE-BINDING PROTEIN; FBP__:__
Asterisk__:__603445__:__KH-TYPE SPLICING REGULATORY PROTEIN; KHSRP__:__KSRP;; FAR UPSTREAM ELEMENT-BINDING PROTEIN 2; FUBP2;; FUSE-BINDING PROTEIN 2; FBP2__:__
NULL__:__603446__:__OROACRAL SYNDROME, VERLOES-KOULISCHER TYPE__:____:__
Asterisk__:__603447__:__HARAKIRI; HRK__:__BCL2-INTERACTING PROTEIN;; DP5__:__
Asterisk__:__603448__:__DISABLED, DROSOPHILA, HOMOLOG OF, 1; DAB1__:____:__
Asterisk__:__603449__:__RUVB, E. COLI, HOMOLOG-LIKE 1; RUVBL1__:__NUCLEAR MATRIX PROTEIN 238; NMP238;; TATA BOX-BINDING PROTEIN-INTERACTING PROTEIN, 49-KD; TIP49;; TBP-INTERACTING PROTEIN, 49-KD;; PONTIN 52;; PONTIN;; ERYTHROCYTE CYTOSOLIC PROTEIN, 54-KD; ECP54__:__
Asterisk__:__603450__:__LIM DOMAIN-BINDING 2; LDB2__:__CARBOXYL-TERMINAL LIM DOMAIN PROTEIN 1; CLIM1__:__
Asterisk__:__603451__:__LIM DOMAIN-BINDING 1; LDB1__:__CARBOXYL-TERMINAL LIM DOMAIN PROTEIN 2; CLIM2;; NUCLEAR LIM DOMAIN INTERACTOR; NLI__:__
Caret__:__603452__:__MOVED TO 602712__:____:__
Asterisk__:__603453__:__RECEPTOR-INTERACTING SERINE/THREONINE KINASE 1; RIPK1__:__RECEPTOR-INTERACTING PROTEIN; RIP;; RIP1__:__
Asterisk__:__603454__:__CASP2 AND RIPK1 DOMAIN-CONTAINING ADAPTOR WITH DEATH DOMAIN; CRADD__:__CASPASE AND RIP ADAPTOR WITH DEATH DOMAIN;; RIP-ASSOCIATED ICH1/CED3-HOMOLOGOUS PROTEIN WITH DEATH DOMAIN; RAIDD__:__
Asterisk__:__603455__:__RECEPTOR-INTERACTING SERINE/THREONINE KINASE 2; RIPK2__:__CARD-CONTAINING ICE-ASSOCIATED KINASE; CARDIAK;; RECEPTOR-INTERACTING PROTEIN 2; RIP2;; RIP-LIKE INTERACTING CLARP KINASE; RICK__:__
Asterisk__:__603456__:__DPH2, S. CEREVISIAE, HOMOLOG OF; DPH2__:__DPH2-LIKE 2; DPH2L2__:__
Number Sign__:__603457__:__BOSMA ARHINIA MICROPHTHALMIA SYNDROME; BAMS__:__ARHINIA, CHOANAL ATRESIA, MICROPHTHALMIA, AND HYPOGONADOTROPIC HYPOGONADISM__:__
Asterisk__:__603458__:__EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA, HOMOLOG-LIKE 3; ELAVL3__:__HU-ANTIGEN C; HUC;; PARANEOPLASTIC LIMBIC ENCEPHALITIS ANTIGEN 21; PLE21__:__
Caret__:__603459__:__MOVED TO 160980__:____:__
Asterisk__:__603460__:__CYCLIN-DEPENDENT KINASE 5, REGULATORY SUBUNIT 1; CDK5R1__:__NEURONAL CDK5 ACTIVATOR; NCK5A;; CYCLIN-DEPENDENT KINASE 5, REGULATORY PARTNER, 35-KD; p35(NCK5A);; p35__:__p25, INCLUDED
Asterisk__:__603461__:__CELL DIVISION CYCLE 16, S. CEREVISIAE, HOMOLOG OF; CDC16__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 6; APC6__:__
Asterisk__:__603462__:__CELL DIVISION CYCLE 23; CDC23__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 8; APC8;; ANAPC8__:__
Caret__:__603463__:__MOVED TO 211380__:____:__
Asterisk__:__603464__:__CYCLIN-DEPENDENT KINASE 10; CDK10__:__PISSLRE__:__
Asterisk__:__603465__:__CELL DIVISION CYCLE 45; CDC45__:__CDC45, S. CEREVISIAE, HOMOLOG OF;; CDC45-LIKE; CDC45L;; CDC45L2__:__
Asterisk__:__603466__:__EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA, HOMOLOG-LIKE 1; ELAVL1__:__HU-ANTIGEN R; HuR__:__
Number Sign__:__603467__:__FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF__:____:__
Caret__:__603468__:__MOVED TO 227650__:____:__
Caret__:__603469__:__MOVED TO 603240__:____:__
Asterisk__:__603470__:__ARGININOSUCCINATE SYNTHETASE 1; ASS1__:__ASS__:__ARGININOSUCCINATE SYNTHETASE PSEUDOGENES, INCLUDED
Number Sign__:__603471__:__CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2__:__CITRIN DEFICIENCY__:__
NULL__:__603472__:__NEURONAL INTRANUCLEAR INCLUSION DISEASE__:__NIID__:__
Asterisk__:__603473__:__LARGE TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 1; LATS1__:____:__
Asterisk__:__603474__:__RIBOSOMAL PROTEIN S19; RPS19__:____:__
Asterisk__:__603475__:__CHORDIN; CHRD__:____:__
Asterisk__:__603476__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN-LIKE 2; CREBL2__:____:__
Asterisk__:__603477__:__BUD31, S. CEREVISIAE, HOMOLOG OF; BUD31__:__G10 MATERNAL TRANSCRIPT, XENOPUS, HOMOLOG OF__:__
Asterisk__:__603478__:__UBIQUITIN-SPECIFIC PROTEASE 1; USP1__:____:__
Asterisk__:__603479__:__EXTRACELLULAR MATRIX PROTEIN 2; ECM2__:____:__
Caret__:__603480__:__MOVED TO 300880__:____:__
Asterisk__:__603481__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 13; PSMD13__:__p40.5;; PROTEASE 26S, SUBUNIT 11; S11__:__
Asterisk__:__603482__:__BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN; BTRC__:__BETA-TRCP;; BTRCP; BTRCP1;; SLIMB, DROSOPHILA, HOMOLOG OF;; F-BOX AND WD40 DOMAIN PROTEIN 1A; FBXW1A; FBW1A;; FBXW1__:__
Asterisk__:__603483__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E-BINDING PROTEIN 3; EIF4EBP3__:__4EBP3__:__
Asterisk__:__603484__:__PROTEIN REGULATING CYTOKINESIS 1; PRC1__:____:__
Asterisk__:__603485__:__NITROGEN FIXATION GENE 1; NFS1__:__NITROGEN-FIXING BACTERIA S, HOMOLOG OF; NIFS;; CYSTEINE DESULFURASE;; ISCS__:__
Asterisk__:__603486__:__UBIQUITIN-SPECIFIC PROTEASE 4; USP4__:__UBIQUITIN-SPECIFIC PROTEASE; UNP__:__
Asterisk__:__603487__:__MYOSIN, SKELETAL MUSCLE, HEAVY CHAIN 13; MYH13__:__MYOSIN, HEAVY CHAIN, EXTRAOCULAR MUSCLE;; EO MYOSIN;; MYHC-EO__:__
Asterisk__:__603488__:__ANGIO-ASSOCIATED MIGRATORY CELL PROTEIN; AAMP__:____:__
Asterisk__:__603489__:__CARTILAGE INTERMEDIATE LAYER PROTEIN; CILP__:__CILP1__:__NUCLEOTIDE PYROPHOSPHOHYDROLASE, PORCINE, HOMOLOG OF, INCLUDED;; NTPPHase, PORCINE, HOMOLOG OF, INCLUDED
Asterisk__:__603490__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 4; WNT4__:____:__
Asterisk__:__603491__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 3; IGSF3__:____:__
Asterisk__:__603492__:__SLAM FAMILY, MEMBER 1; SLAMF1__:__SIGNALING LYMPHOCYTE ACTIVATION MOLECULE; SLAM;; CDW150;; CD150__:__
Asterisk__:__603493__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 5; KCNK5__:__TASK2__:__
Asterisk__:__603494__:__PREFOLDIN-LIKE CHAPERONE URI1; URI1__:__NNX3 PROTEIN; NNX3;; RNA POLYMERASE II, SUBUNIT 5-MEDIATING PROTEIN; RMP;; RPB5-MEDIATING PROTEIN;; UNCONVENTIONAL PREFOLDIN RPB5 INTERACTOR; URI__:__
Asterisk__:__603495__:__AURORA KINASE C; AURKC__:__SERINE/THREONINE PROTEIN KINASE 13; STK13;; AURORA/IPL1/EG2-2; AIE2;; AURORA/IPL1-LIKE KINASE 3; AIK3__:__
Asterisk__:__603496__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 2; DYRK2__:____:__
Asterisk__:__603497__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 3; DYRK3__:____:__
Asterisk__:__603498__:__SPHINGOMYELIN PHOSPHODIESTERASE 2, NEUTRAL MEMBRANE; SMPD2__:__SPHINGOMYELINASE, NEUTRAL, 1; NSMASE1__:__
Asterisk__:__603499__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 11A; TNFRSF11A__:__RECEPTOR ACTIVATOR OF NF-KAPPA-B; RANK;; OSTEOCLAST DIFFERENTIATION FACTOR RECEPTOR; ODFR;; PDB2 GENE;; TRANCER;; LOSS OF HETEROZYGOSITY, CHROMOSOME 18, REGION 1; LOH18CR1;; OSTEOSARCOMA TUMOR SUPPRESSOR; OSTS__:__
Asterisk__:__603500__:__TUMOR NECROSIS FACTOR RECEPTOR 1-ASSOCIATED DEATH DOMAIN PROTEIN; TRADD__:__TNFR1-ASSOCIATED DEATH DOMAIN PROTEIN__:__
Asterisk__:__603501__:__POLY(ADP-RIBOSE) GLYCOHYDROLASE; PARG__:____:__
Asterisk__:__603502__:__INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1; IFRD1__:__TETRADECANOYL PHORBOL ACETATE-INDUCED SEQUENCE 7; TIS7;; TPA-INDUCED SEQUENCE 7;; PC4__:__
Asterisk__:__603503__:__DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE 1, CATALYTIC SUBUNIT; DPM1__:__DOLICHOL-PHOSPHATE MANNOSYLTRANSFERASE 1;; DOLICHOL-PHOSPHATE-MANNOSE SYNTHASE 1;; MPD SYNTHASE; MPDS__:__
Asterisk__:__603504__:__CELL DIVISION CYCLE 14, S. CEREVISIAE, HOMOLOG A; CDC14A__:____:__
Asterisk__:__603505__:__CELL DIVISION CYCLE 14, S. CEREVISIAE, HOMOLOG B; CDC14B__:____:__
Asterisk__:__603506__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 5; LRP5__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 7; LRP7;; LR3__:__
Asterisk__:__603507__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6; LRP6__:____:__
Asterisk__:__603508__:__MYOMESIN 1; MYOM1__:__TITIN-ASSOCIATED PROTEIN, 185-KD;; TITIN-ASSOCIATED PROTEIN, 190-KD;; SKELEMIN__:__
Asterisk__:__603509__:__MYOMESIN 2; MYOM2__:__TITIN-ASSOCIATED PROTEIN, 165-KD;; M BAND PROTEIN__:__
Caret__:__603510__:__MOVED TO 300904__:____:__
Number Sign__:__603511__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 1; LGMDD1__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1E; LGMD1E;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1D, FORMERLY; LGMD1D, FORMERLY__:__
Asterisk__:__603512__:__RNA GUANYLYLTRANSFERASE AND 5-PRIME-PHOSPHATASE; RNGTT__:__HUMAN CAPPING ENZYME 1; HCE1;; CAPPING ENZYME 1, HUMAN;; CAP1A__:__
Number Sign__:__603513__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 1; CPSQ1__:____:__
Asterisk__:__603514__:__RNA GUANINE-7-METHYLTRANSFERASE; RNMT__:__MET__:__
Asterisk__:__603515__:__CHORIONIC SOMATOMAMMOTROPIN HORMONE-LIKE 1; CSHL1__:__CHORIONIC SOMATOMAMMOTROPIN-LIKE; CSL__:__
Number Sign__:__603516__:__SPINOCEREBELLAR ATAXIA 10; SCA10__:____:__
Asterisk__:__603517__:__B-CELL CLL/LYMPHOMA 10; BCL10__:__B-CELL LEUKEMIA/LYMPHOMA 10__:__
Asterisk__:__603518__:__TIA1 CYTOTOXIC GRANULE-ASSOCIATED RNA-BINDING PROTEIN; TIA1__:____:__
Asterisk__:__603519__:__SURVIVAL MOTOR NEURON DOMAIN-CONTAINING PROTEIN 1; SMNDC1__:__SURVIVAL OF MOTOR NEURON-RELATED PROTEIN; SMNR;; SMN-RELATED PROTEIN__:__
Asterisk__:__603520__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE B-DOUBLE PRIME; SNRPB2__:____:__
Asterisk__:__603521__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE A-PRIME; SNRPA1__:____:__
Asterisk__:__603522__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE C; SNRPC__:____:__
NULL__:__603523__:__CHYLOTHORAX, CONGENITAL__:__HYDROTHORAX, CONGENITAL__:__
Asterisk__:__603524__:__RCC1 DOMAIN- AND BTB DOMAIN-CONTAINING PROTEIN 2; RCBTB2__:__CHROMOSOME CONDENSATION 1-LIKE; CHC1L__:__
Asterisk__:__603525__:__NMYC INTERACTOR; NMI__:__NMYC AND STAT INTERACTOR__:__
Asterisk__:__603526__:__METASTASIS-ASSOCIATED GENE 1; MTA1__:____:__
Asterisk__:__603527__:__DPH1, S. CEREVISIAE, HOMOLOG OF; DPH1__:__DPH2-LIKE 1; DPH2L1;; OVARIAN CANCER-ASSOCIATED GENE 1; OVCA1__:__
Caret__:__603528__:__MOVED TO 194380__:____:__
NULL__:__603529__:__DYSERYTHROPOIESIS, CONGENITAL, WITH ULTRASTRUCTURALLY NORMAL ERYTHROBLAST HETEROCHROMATIN__:____:__
NULL__:__603530__:__LIGHT FIXATION SEIZURE SYNDROME__:__LFSS;; M SYNDROME__:__
Asterisk__:__603531__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, SIGMA-1 SUBUNIT; AP1S1__:__CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, SMALL 1; CLAPS1;; CLATHRIN ADAPTOR PROTEIN 19; AP19;; CLATHRIN ADAPTOR COMPLEX AP1, SIGMA-1A SUBUNIT__:__
Caret__:__603532__:__MOVED TO 300629__:____:__
Asterisk__:__603533__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, GAMMA-1 SUBUNIT; AP1G1__:__ADAPTIN, GAMMA; ADTG;; CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, LARGE, GAMMA-1; CLAPG1__:__
Asterisk__:__603534__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, GAMMA-2 SUBUNIT; AP1G2__:__ADAPTIN, GAMMA-2;; CLATHRIN-ASSOCIATED/ASSEMBLY/ADAPTOR PROTEIN, LARGE, GAMMA-2__:__
Asterisk__:__603535__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, MU-1 SUBUNIT; AP1M1__:__CLATHRIN ASSEMBLY PROTEIN COMPLEX AP1, MU SUBUNIT;; CLATHRIN ADAPTOR PROTEIN AP47; AP47;; MU-1A__:__
Asterisk__:__603536__:__FAR UPSTREAM ELEMENT-BINDING PROTEIN 3; FUBP3__:__FUSE-BINDING PROTEIN 3; FBP3__:__
Asterisk__:__603537__:__POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 4; KCNQ4__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY Q, MEMBER 4__:__
Asterisk__:__603538__:__KYNURENINE 3-MONOOXYGENASE; KMO__:__KYNURENINE 3-HYDROXYLASE__:__
Asterisk__:__603539__:__CATHEPSIN F; CTSF__:____:__
Asterisk__:__603540__:__GAMMA-AMINOBUTYRIC ACID B RECEPTOR 1; GABBR1__:__GABA-B RECEPTOR, R1 SUBUNIT; GABABR1__:__
Asterisk__:__603541__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE F; SNRPF__:____:__
Asterisk__:__603542__:__SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE G; SNRPG__:____:__
Number Sign__:__603543__:__LIMB-MAMMARY SYNDROME; LMS__:____:__
Asterisk__:__603544__:__CYCLIN K; CCNK__:__CYCK__:__
Caret__:__603545__:__MOVED TO 600791__:____:__
Number Sign__:__603546__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, TYPE 2; SEMDJL2__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, HALL TYPE;; SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH JOINT LAXITY, LEPTODACTYLIC TYPE;; SPONDYLOEPIMETAPHYSEAL DYSPLASIA WITH MULTIPLE DISLOCATIONS, HALL TYPE__:__
Asterisk__:__603547__:__METHYL-CpG-BINDING DOMAIN PROTEIN 2; MBD2__:__DEMETHYLASE; DMTase__:__
Asterisk__:__603548__:__CDP-DIACYLGLYCEROL SYNTHASE 1; CDS1__:__PHOSPHATIDATE CYTIDYLYLTRANSFERASE 1__:__
Asterisk__:__603549__:__CDP-DIACYLGLYCEROL SYNTHASE 2; CDS2__:__PHOSPHATIDATE CYTIDYLYLTRANSFERASE 2__:__
Asterisk__:__603550__:__EYES ABSENT 4; EYA4__:__EYES ABSENT, DROSOPHILA, HOMOLOG OF, 4__:__
Asterisk__:__603551__:__HYALURONOGLUCOSAMINIDASE 2; HYAL2__:__LUCA2;; HYALURONIDASE 2__:__
Number Sign__:__603552__:__HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 4; FHL4__:__HPLH4;; HLH4__:__
Number Sign__:__603553__:__HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2; FHL2__:__HPLH2;; HLH2__:__
Number Sign__:__603554__:__OMENN SYNDROME__:__RETICULOENDOTHELIOSIS, FAMILIAL, WITH EOSINOPHILIA;; SEVERE COMBINED IMMUNODEFICIENCY WITH HYPEREOSINOPHILIA__:__
Asterisk__:__603555__:__SUPPRESSOR OF TY 4, S. CEREVISIAE, HOMOLOG OF, 1; SUPT4H1__:__SUPT4H__:__
Caret__:__603556__:__MOVED TO 300171__:____:__
Asterisk__:__603557__:__MYOTUBULARIN-RELATED PROTEIN 2; MTMR2__:__KIAA1073__:__
Asterisk__:__603558__:__MYOTUBULARIN-RELATED PROTEIN 3; MTMR3__:__KIAA0371__:__
Asterisk__:__603559__:__MYOTUBULARIN-RELATED PROTEIN 4; MTMR4__:__KIAA0647__:__
Asterisk__:__603560__:__SET-BINDING FACTOR 1; SBF1__:__MYOTUBULARIN-RELATED PROTEIN 5; MTMR5__:__
Asterisk__:__603561__:__MYOTUBULARIN-RELATED PROTEIN 6; MTMR6__:____:__
Asterisk__:__603562__:__MYOTUBULARIN-RELATED PROTEIN 7; MTMR7__:____:__
Number Sign__:__603563__:__SPASTIC PARAPLEGIA 8, AUTOSOMAL DOMINANT; SPG8__:____:__
Asterisk__:__603564__:__DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE 2, REGULATORY SUBUNIT; DPM2__:__DOLICHOL-PHOSPHATE MANNOSYLTRANSFERASE 2;; DOLICHOL-PHOSPHATE MANNOSE SYNTHASE 2__:__
Asterisk__:__603565__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 4; GALNT4__:__GalNAc TRANSFERASE 4; GalNAcT4__:__
Asterisk__:__603566__:__PROTEIN INHIBITOR OF ACTIVATED STAT1; PIAS1__:__DEAD/H BOX-BINDING PROTEIN 1; DDXBP1;; GU-BINDING PROTEIN; GBP__:__
Asterisk__:__603567__:__PROTEIN INHIBITOR OF ACTIVATED STAT2; PIAS2__:__PROTEIN INHIBITOR OF ACTIVATED STAT X; PIASX;; MIZ1__:__PIASX-ALPHA, INCLUDED;; PIASX-BETA, INCLUDED
Asterisk__:__603568__:__RNA, U73 SMALL NUCLEOLAR; RNU73__:__snoRNA, U73__:__
NULL__:__603569__:__TRACHEOBRONCHIAL STENOSIS, CONGENITAL__:____:__
Plus__:__603570__:__VANIN 1; VNN1__:____:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 8, INCLUDED; HDLCQ8, INCLUDED
Asterisk__:__603571__:__VANIN 2; VNN2__:____:__
NULL__:__603572__:__MICROCEPHALY, FACIAL ABNORMALITIES, MICROMELIA, AND MENTAL RETARDATION__:____:__
Asterisk__:__603573__:__METHYL-CpG-BINDING DOMAIN PROTEIN 3; MBD3__:____:__
Asterisk__:__603574__:__METHYL-CpG-BINDING DOMAIN PROTEIN 4; MBD4__:__METHYL-CpG-BINDING ENDONUCLEASE; MED1__:__
Asterisk__:__603575__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 5; NME5__:__NONMETASTATIC CELLS 5, PROTEIN EXPRESSED IN;; NONMETASTATIC PROTEIN 23, HOMOLOG 5; NM23H5;; RADIAL SPOKE HEAD 23, CHLAMYDOMONAS, HOMOLOG OF; RSPH23__:__
Asterisk__:__603576__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 1; TRPM1__:__MELASTATIN 1; MLSN1__:__
Asterisk__:__603577__:__NUCLEOLAR PROTEIN 4; NOL4__:__NUCLEOLAR-LOCALIZED PROTEIN; NOLP__:__
Asterisk__:__603578__:__OVIDUCTAL GLYCOPROTEIN 1; OVGP1__:__OVIDUCTAL GLYCOPROTEIN, 120-KD__:__
Asterisk__:__603579__:__RIO KINASE 3; RIOK3__:__SUDD, ASPERGILLUS NIDULANS, HOMOLOG OF; SUDD__:__
Asterisk__:__603580__:__PROTOCADHERIN 8; PCDH8__:____:__
Asterisk__:__603581__:__PROTOCADHERIN 9; PCDH9__:____:__
Asterisk__:__603582__:__TOPOISOMERASE, DNA, III, BETA; TOP3B__:__TOPOISOMERASE III-BETA__:__
Asterisk__:__603583__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 2; DLG2__:__CHANNEL-ASSOCIATED PROTEIN OF SYNAPSES, 110-KD;; CHAPSYN-110__:__
Asterisk__:__603584__:__MAP KINASE-ACTIVATING DEATH DOMAIN; MADD__:__DIFFERENTIALLY EXPRESSED IN NORMAL AND NEOPLASTIC CELLS; DENN;; INSULINOMA-GLUCAGONOMA PROTEIN 20; IG20;; RAB3 GDP/GTP EXCHANGE PROTEIN; RAB3GEP;; KIAA0358__:__
Number Sign__:__603585__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIf; CDG2F__:__CDG IIf; CDGIIf__:__
Caret__:__603586__:__MOVED TO 603147__:____:__
NULL__:__603587__:__FOLLICULAR ATROPHODERMA, PERIORAL PIGMENTED, WITH MILIA AND EPIDERMOID CYSTS__:____:__
NULL__:__603588__:__PAROTITIS, JUVENILE RECURRENT__:____:__
NULL__:__603589__:__FACIAL DYSMORPHISM, SELECTIVE TOOTH AGENESIS, AND CHOROID CALCIFICATION__:____:__
Asterisk__:__603590__:__ACETYLGLUCOSAMINYLTRANSFERASE-LIKE PROTEIN; LARGE1__:__LARGE;; KIAA0609;; LIKE-GLYCOSYLTRANSFERASE__:__
Asterisk__:__603591__:__UBIQUITIN-SPECIFIC PROTEASE 13; USP13__:__ISOPEPTIDASE T3; ISOT3__:__
Number Sign__:__603592__:__XANTHINURIA, TYPE II; XAN2__:__XANTHINE DEHYDROGENASE AND ALDEHYDE OXIDASE, COMBINED DEFICIENCY OF__:__
Asterisk__:__603593__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 7; SLC7A7__:__y(+)L-TYPE AMINO ACID TRANSPORTER 1;; y(+)LAT1__:__
Asterisk__:__603594__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 4; TNFSF4__:__GLYCOPROTEIN, 34-KD; GP34;; OX40 ANTIGEN LIGAND; OX40L;; CD134 LIGAND; CD134L__:__
NULL__:__603595__:__CRANIOSYNOSTOSIS WITH ECTOPIA LENTIS__:____:__
Number Sign__:__603596__:__POLYDACTYLY__:____:__
Asterisk__:__603597__:__SUPPRESSOR OF CYTOKINE SIGNALING 1; SOCS1__:__STAT-INDUCED STAT INHIBITOR 1; SSI1;; CYTOKINE-INDUCIBLE SH2 PROTEIN 1; CIS1; CISH1;; JAK-BINDING PROTEIN; JAB;; TEC-INTERACTING PROTEIN 3; TIP3__:__
Asterisk__:__603598__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 10; TNFSF10__:__TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRAIL;; APO2 LIGAND; APO2L__:__
Asterisk__:__603599__:__CASP8- AND FADD-LIKE APOPTOSIS REGULATOR; CFLAR__:__FLICE INHIBITORY PROTEIN; FLIP;; INHIBITOR OF FLICE; I-FLICE;; CASPASE-EIGHT-RELATED PROTEIN; CASPER;; FADD-LIKE ANTIAPOPTOTIC MOLECULE 1; FLAME1;; CASPASE HOMOLOG; CASH;; CASPASE-LIKE APOPTOSIS REGULATORY PROTEIN; CLARP;; MACH-RELATED INDUCER OF TOXICITY; MRIT__:__
NULL__:__603600__:__OSTEOMA OF CRANIAL VAULT, FAMILIAL__:____:__
Asterisk__:__603601__:__PHOSPHATIDYLINOSITOL 3-KINASE, CLASS 2, ALPHA; PIK3C2A__:__C2-CONTAINING PHOSPHATIDYLINOSITOL KINASE; CPK__:__
Asterisk__:__603602__:__PHOSPHOLIPASE A2, GROUP IVC; PLA2G4C__:__PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-INDEPENDENT, GAMMA;; CPLA2-GAMMA__:__
Asterisk__:__603603__:__PHOSPHOLIPASE A2, GROUP X; PLA2G10__:__SECRETORY PHOSPHOLIPASE A2, GROUP X; SPLA2;; PHOSPHOLIPASE A2, SECRETORY, CALCIUM-DEPENDENT, GROUP X; GXSPLA2__:__
Asterisk__:__603604__:__PHOSPHOLIPASE A2, GROUP VI; PLA2G6__:__PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT; IPLA2;; PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 9; PNPLA9;; PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT, GROUP VI, A;; IPLA2-VIA__:__
Asterisk__:__603605__:__AMINOACYL-tRNA SYNTHETASE COMPLEX-INTERACTING MULTIFUNCTIONAL PROTEIN 1; AIMP1__:__ARS-INTERACTING MULTIFUNCTIONAL PROTEIN 1;; ENDOTHELIAL MONOCYTE-ACTIVATING POLYPEPTIDE 2; EMAP2; EMAPII;; SMALL INDUCIBLE CYTOKINE SUBFAMILY E, MEMBER 1, FORMERLY; SCYE1, FORMERLY__:__
Asterisk__:__603606__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 4; RPS6KA4__:__RIBOSOMAL S6 KINASE B; RSKB;; MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE 2; MSK2__:__
Asterisk__:__603607__:__RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 5; RPS6KA5__:__MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE 1; MSK1__:__
Asterisk__:__603608__:__CARBONYL REDUCTASE 3; CBR3__:____:__
Asterisk__:__603609__:__FUCOSE-1-PHOSPHATE GUANYLYLTRANSFERASE; FPGT__:__GDP-BETA-L-FUCOSE PYROPHOSPHORYLASE; GFPP__:__
Asterisk__:__603610__:__UNC5, C. ELEGANS, HOMOLOG OF, C; UNC5C__:__UNC5H3__:__
Asterisk__:__603611__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10A; TNFRSF10A__:__DEATH RECEPTOR 4; DR4;; TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 1; TRAILR1;; APO2__:__
Asterisk__:__603612__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10B; TNFRSF10B__:__DEATH RECEPTOR 5; DR5;; TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 2; TRAILR2;; KILLER/DR5;; TRICK2__:__
Asterisk__:__603613__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10C; TNFRSF10C__:__DECOY RECEPTOR 1; DCR1;; TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 3; TRAILR3;; TRAIL RECEPTOR WITHOUT AN INTRACELLULAR DOMAIN; TRID__:__
Asterisk__:__603614__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10D; TNFRSF10D__:__DECOY RECEPTOR 2; DCR2;; TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR 4; TRAILR4;; TRAIL RECEPTOR WITH A TRUNCATED DEATH DOMAIN; TRUNDD__:__
Asterisk__:__603615__:__RAD54, S. CEREVISIAE, HOMOLOG-LIKE; RAD54L__:__HR54;; HRAD54__:__
Asterisk__:__603616__:__RABAPTIN, RAB GTPase-BINDING EFFECTOR PROTEIN 1; RABEP1__:__RABAPTIN 5; RABPT5__:__RABEP1/PDGFRB FUSION GENE, INCLUDED
Asterisk__:__603617__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 1; SLC24A1__:__SODIUM/CALCIUM/POTASSIUM EXCHANGER 1; NCKX1__:__
Asterisk__:__603618__:__CELL DIVISION CYCLE 20, S. CEREVISIAE, HOMOLOG OF; CDC20__:__p55CDC__:__
Asterisk__:__603619__:__FIZZY-RELATED PROTEIN, DROSOPHILA, HOMOLOG OF, 1; FZR1__:__FZR, DROSOPHILA, HOMOLOG OF, 1;; CDH1/HCT1, S. CEREVISIAE, HOMOLOG OF; HCDH; HCDH1__:__
Asterisk__:__603620__:__PC4- AND SFRS1-INTERACTING PROTEIN 1; PSIP1__:__TRANSCRIPTIONAL COACTIVATOR p75; p75;; LENS EPITHELIUM-DERIVED GROWTH FACTOR; LEDGF__:__TRANSCRIPTIONAL COACTIVATOR p52, INCLUDED
Asterisk__:__603621__:__FORKHEAD BOX H1; FOXH1__:__FORKHEAD ACTIVIN SIGNAL TRANSDUCER 1, XENOPUS, HOMOLOG OF; FAST1;; TGF-BETA/ACTIVIN SIGNAL TRANSDUCER FAST1__:__
Number Sign__:__603622__:__DEAFNESS, AUTOSOMAL DOMINANT 17; DFNA17__:____:__COCHLEOSACCULAR DEGENERATION, INCLUDED
Asterisk__:__603623__:__TYROSYL-tRNA SYNTHETASE; YARS__:__TYRRS;; YTS;; YRS__:__
Asterisk__:__603624__:__RIBOSOMAL PROTEIN S2; RPS2__:____:__
Asterisk__:__603625__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS H; LY6H__:____:__
Asterisk__:__603626__:__PROTOCADHERIN 1; PCDH1__:__PC42__:__
Asterisk__:__603627__:__PROTOCADHERIN-GAMMA, SUBFAMILY C, MEMBER 3; PCDHGC3__:__PCDH-GAMMA-C3;; PC43;; PROTOCADHERIN 2, FORMERLY; PCDH2, FORMERLY__:__
Asterisk__:__603628__:__MUSCULIN; MSC__:__ACTIVATED B-CELL FACTOR 1; ABF1;; MYOGENIC REPRESSOR; MYOR__:__
Number Sign__:__603629__:__DEAFNESS, AUTOSOMAL RECESSIVE 21; DFNB21__:____:__
Asterisk__:__603630__:__RIBOSOMAL PROTEIN S5; RPS5__:____:__
Asterisk__:__603631__:__RIBOSOMAL PROTEIN S9; RPS9__:____:__
Asterisk__:__603632__:__RIBOSOMAL PROTEIN S10; RPS10__:____:__
Asterisk__:__603633__:__RIBOSOMAL PROTEIN S29; RPS29__:____:__
Asterisk__:__603634__:__RIBOSOMAL PROTEIN L5; RPL5__:____:__
Asterisk__:__603635__:__RNA, U21 SMALL NUCLEOLAR; RNU21__:__snoRNA, U21__:__
Asterisk__:__603636__:__RIBOSOMAL PROTEIN L21; RPL21__:____:__
Asterisk__:__603637__:__RIBOSOMAL PROTEIN L27a; RPL27A__:____:__
Asterisk__:__603638__:__RIBOSOMAL PROTEIN L28; RPL28__:____:__
Asterisk__:__603639__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 17; ADAM17__:__TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TACE__:__
Asterisk__:__603640__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 19; ADAM19__:__MELTRIN-BETA, MOUSE, HOMOLOG OF; MLTNB__:__
NULL__:__603641__:__NEUROENDOCRINE CARCINOMA OF SALIVARY GLANDS, SENSORINEURAL HEARING LOSS, AND ENAMEL HYPOPLASIA__:____:__
NULL__:__603642__:__ATRIAL SEPTAL DEFECT, SECUNDUM, WITH VARIOUS CARDIAC AND NONCARDIAC DEFECTS__:____:__
NULL__:__603643__:__SITUS INVERSUS TOTALIS WITH CYSTIC DYSPLASIA OF KIDNEYS AND PANCREAS__:____:__
Asterisk__:__603644__:__SCO1 CYTOCHROME c OXIDASE ASSEMBLY PROTEIN; SCO1__:__SCO1, S. CEREVISIAE, HOMOLOG OF;; CYTOCHROME OXIDASE-DEFICIENT 1, S. CEREVISIAE, HOMOLOG OF; SCOD1__:__
Asterisk__:__603645__:__GLUTAMYL-tRNA AMIDOTRANSFERASE, SUBUNIT B; GATB__:__GLUTAMYL-tRNA-GLN AMIDOTRANSFERASE, SUBUNIT B, MITOCHONDRIAL;; PET112, S. CEREVISIAE, HOMOLOG OF; PET112;; PET112-LIKE; PET112L__:__
Asterisk__:__603646__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX15; COX15__:__COX15, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__603647__:__BCS1, S. CEREVISIAE, HOMOLOG-LIKE; BCS1L__:____:__
Asterisk__:__603648__:__CYTOCHROME c OXIDASE COPPER CHAPERONE COX11; COX11__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX11;; COX11, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__603649__:__CONE-ROD DYSTROPHY 7; CORD7__:____:__
Asterisk__:__603650__:__BBS5 GENE; BBS5__:____:__
Asterisk__:__603651__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 4; TRPC4__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 4;; TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 4; TRP4;; TRPC4-ALPHA__:__TRPC4-BETA, INCLUDED
Asterisk__:__603652__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 6; TRPC6__:__TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 6; TRP6__:__
Caret__:__603653__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__603654__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 7; SLC16A7__:__MONOCARBOXYLATE TRANSPORTER 2; MCT2__:__
Caret__:__603655__:__MOVED TO 139391__:____:__
NULL__:__603656__:__EXOSTOSIS, DUPUYTREN SUBUNGUAL__:____:__
Asterisk__:__603657__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 3; VAMP3__:__CELLUBREVIN; CEB__:__
Asterisk__:__603658__:__RIBOSOMAL PROTEIN S7; RPS7__:____:__
Asterisk__:__603659__:__GLUCAGON-LIKE PEPTIDE 2 RECEPTOR; GLP2R__:____:__
Asterisk__:__603660__:__RIBOSOMAL PROTEIN S12; RPS12__:____:__
Asterisk__:__603661__:__RIBOSOMAL PROTEIN L17; RPL17__:____:__
Asterisk__:__603662__:__RIBOSOMAL PROTEIN L23; RPL23__:____:__
Percent__:__603663__:__MENTAL HEALTH WELLNESS 1__:__MHW1__:__
NULL__:__603664__:__MENTAL HEALTH WELLNESS 2__:__MHW2__:__
Asterisk__:__603665__:__STANNIOCALCIN 2; STC2__:__STANNIOCALCIN-RELATED PROTEIN; STCRP__:__
Asterisk__:__603666__:__SYNTAXIN 16; STX16__:__SYN16__:__
Asterisk__:__603667__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ARALAR), MEMBER 12; SLC25A12__:__ARALAR;; ASPARTATE-GLUTAMATE CARRIER ISOFORM 1, MITOCHONDRIAL; AGC1__:__
Asterisk__:__603668__:__SR-RELATED C-TERMINAL DOMAIN-ASSOCIATED FACTOR 11; SCAF11__:__SR-RELATED CTD-ASSOCIATED FACTOR 11;; SPLICING FACTOR, ARGININE/SERINE-RICH, 2-INTERACTING PROTEIN; SFRS2IP;; SFRS2-INTERACTING PROTEIN;; SC35-INTERACTING PROTEIN 1; SIP1;; CTD-ASSOCIATED SR PROTEIN 11; CASP11;; SR-RELATED PROTEIN, 129-KD; SRRP129__:__
NULL__:__603669__:__ECCRINE SYRINGOFIBROADENOMATOSIS WITH EYELID ABNORMALITIES__:____:__
NULL__:__603670__:__BLUE NEVI, FAMILIAL MULTIPLE__:____:__
Number Sign__:__603671__:__ACROMELIC FRONTONASAL DYSOSTOSIS; AFND__:____:__
Asterisk__:__603672__:__CORE-BINDING FACTOR, RUNT DOMAIN, ALPHA SUBUNIT 2, TRANSLOCATED TO, 2; CBFA2T2__:__MYELOID TRANSLOCATION GENE-RELATED PROTEIN 1; MTGR1;; ETO HOMOLOG ON CHROMOSOME 20; EHT;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 3; ZMYND3__:__
Asterisk__:__603673__:__PATCHED, DROSOPHILA, HOMOLOG OF, 2; PTCH2__:____:__
Asterisk__:__603674__:__RIBOSOMAL PROTEIN S15a; RPS15A__:____:__
Asterisk__:__603675__:__RIBOSOMAL PROTEIN S16; RPS16__:____:__
Caret__:__603676__:__MOVED TO 181350__:____:__
Asterisk__:__603677__:__MYELIN TRANSCRIPTION FACTOR 2; MYT2__:__CEREBRIN 50__:__
Percent__:__603678__:__DEAFNESS, AUTOSOMAL RECESSIVE 14; DFNB14__:____:__
Asterisk__:__603679__:__UBIQUITIN-CONJUGATING ENZYME E2N; UBE2N__:__UBIQUITIN-CONJUGATING ENZYME 13, S. CEREVISIAE, HOMOLOG OF; UBC13; UBCH13;; BENDLESS, DROSOPHILA, HOMOLOG OF; UBCHBEN__:__
Asterisk__:__603680__:__ATAXIN 8 OPPOSITE STRAND; ATXN8OS__:__SCA8 GENE; SCA8;; KLHL1AS__:__
Asterisk__:__603681__:__OTOFERLIN; OTOF__:____:__
Asterisk__:__603682__:__RIBOSOMAL PROTEIN S20; RPS20__:____:__
Asterisk__:__603683__:__RIBOSOMAL PROTEIN S23; RPS23__:____:__
Asterisk__:__603684__:__LIPASE, ENDOTHELIAL; LIPG__:__EL;; ENDOTHELIAL CELL-DERIVED LIPASE; EDL__:__
Asterisk__:__603685__:__RIBOSOMAL PROTEIN S28; RPS28__:____:__
Asterisk__:__603686__:__RIBOSOMAL PROTEIN L9; RPL9__:____:__
Asterisk__:__603687__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER A2; ALDH1A2__:__RETINALDEHYDE DEHYDROGENASE 2; RALDH2__:__
Number Sign__:__603688__:__PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY__:__PCBC;; CAPB__:__
Number Sign__:__603689__:__HEREDITARY MYOPATHY WITH EARLY RESPIRATORY FAILURE; HMERF__:__MYOPATHY, PROXIMAL, WITH EARLY RESPIRATORY MUSCLE INVOLVEMENT; MPRM;; EDSTROM MYOPATHY__:__
Asterisk__:__603690__:__SOLUTE CARRIER FAMILY 33 (ACETYL-CoA TRANSPORTER), MEMBER 1; SLC33A1__:__ACETYL-CoA TRANSPORTER; ACATN;; AT1__:__
Asterisk__:__603691__:__GALANIN RECEPTOR 2; GALR2__:__GALNR2__:__
Asterisk__:__603692__:__GALANIN RECEPTOR 3; GALR3__:____:__
Asterisk__:__603693__:__ZINC FINGER PROTEIN, MULTITYPE 2; ZFPM2__:__FRIEND OF GATA2; FOG2;; TRANSCRIPTION FACTOR GATA4, MODULATOR OF__:__FOG2/AML1 FUSION GENE, INCLUDED
Percent__:__603694__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT, 3__:__NIDDM3;; NONINSULIN-DEPENDENT DIABETES MELLITUS 3__:__
Asterisk__:__603695__:__GUANYLATE CYCLASE 1, SOLUBLE, BETA-2; GUCY1B2__:__GUANYLATE CYCLASE, SOLUBLE, BETA-2;; GCS-BETA-2__:__
Asterisk__:__603696__:__SEPTIN 4; SEPT4__:__SEP4;; PEANUT-LIKE 2; PNUTL2;; BRADEION;; APOPTOSIS-RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY; ARTS__:__
Asterisk__:__603697__:__ARACHIDONATE 15-LIPOXYGENASE, SECOND TYPE; ALOX15B__:__15-LIPOXYGENASE, RETICULOCYTE ARACHIDONATE, SECOND TYPE__:__
Asterisk__:__603698__:__GOLGI-SPECIFIC BREFELDIN-A RESISTANCE FACTOR 1; GBF1__:____:__
Asterisk__:__603699__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 11; WNT11__:____:__
Asterisk__:__603700__:__ARACHIDONATE 5-LIPOXYGENASE-ACTIVATING PROTEIN; ALOX5AP__:__FIVE-LIPOXYGENASE-ACTIVATING PROTEIN; FLAP;; 5-LIPOXYGENASE-ACTIVATING PROTEIN__:__
Asterisk__:__603701__:__RIBOSOMAL PROTEIN S26; RPS26__:____:__
Asterisk__:__603702__:__RIBOSOMAL PROTEIN S27; RPS27__:__METALLOPANSTIMULIN 1; MPS1__:__
Asterisk__:__603703__:__RIBOSOMAL PROTEIN L6; RPL6__:____:__
Asterisk__:__603704__:__RIBOSOMAL PROTEIN L26; RPL26__:____:__
Asterisk__:__603705__:__ANGIOPOIETIN 4; ANGPT4__:__ANG4__:__
Asterisk__:__603706__:__SEMAPHORIN 4F; SEMA4F__:__SEMAPHORIN W; SEMAW;; SEMAPHORIN M; SEMAM__:__
Asterisk__:__603707__:__MOLYBDENUM COFACTOR SYNTHESIS GENE 1; MOCS1__:____:__MOCS1A, INCLUDED;; MOCS1B, INCLUDED
Asterisk__:__603708__:__MOLYBDENUM COFACTOR SYNTHESIS GENE 2; MOCS2__:__MOLYBDOPTERIN SYNTHASE; MPTS;; MOCO1__:__
Asterisk__:__603709__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 22; ADAM22__:__METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN 2; MDC2__:__
Asterisk__:__603710__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 23; ADAM23__:__METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN 3; MDC3__:__
Asterisk__:__603711__:__CYTOCHROME P450, FAMILY 7, SUBFAMILY B, POLYPEPTIDE 1; CYP7B1__:__OXYSTEROL 7-ALPHA-HYDROXYLASE 1__:__
Asterisk__:__603712__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 20; ADAM20__:____:__
Asterisk__:__603713__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 21; ADAM21__:____:__
Asterisk__:__603714__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 3; SIX3__:____:__
Asterisk__:__603715__:__GLIAL CELLS MISSING, DROSOPHILA, HOMOLOG OF, 1; GCM1__:__GCMA__:__
Asterisk__:__603716__:__GLIAL CELLS MISSING, DROSOPHILA, HOMOLOG OF, 2; GCM2__:__GCMB__:__
Asterisk__:__603717__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 21-KD, V0 SUBUNIT C-PRIME, PRIME; ATP6V0B__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT F; ATP6F;; VACUOLAR PROTON PUMP, 21-KD SUBUNIT;; VMA16, S. CEREVISIAE, HOMOLOG OF; VMA16__:__
Asterisk__:__603718__:__CLAUDIN 1; CLDN1__:__SENESCENCE-ASSOCIATED EPITHELIAL MEMBRANE PROTEIN 1; SEMP1__:__
Asterisk__:__603719__:__BUDDING UNINHIBITED BY BENZIMIDAZOLES 3, S. CEREVISIAE, HOMOLOG OF; BUB3__:____:__
Number Sign__:__603720__:__DEAFNESS, AUTOSOMAL RECESSIVE 16; DFNB16__:____:__
Asterisk__:__603721__:__UBIQUITIN-CONJUGATING ENZYME E2L 3; UBE2L3__:__UBIQUITIN-CONJUGATING ENZYME UBCH7; UBCH7__:__
Asterisk__:__603722__:__INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, KINASE COMPLEX-ASSOCIATED PROTEIN; IKBKAP__:__IKK COMPLEX-ASSOCIATED PROTEIN; IKAP;; ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 1; ELP1;; ELP1, YEAST, HOMOLOG OF__:__
Caret__:__603723__:__MOVED TO 300248__:____:__
Caret__:__603724__:__MOVED TO 300827__:____:__
Asterisk__:__603725__:__FIBROBLAST GROWTH FACTOR 17; FGF17__:____:__
Asterisk__:__603726__:__FIBROBLAST GROWTH FACTOR 18; FGF18__:____:__
Asterisk__:__603727__:__GLUTAMINYL-tRNA SYNTHETASE; QARS__:__GLNRS__:__
Asterisk__:__603728__:__NUMB, DROSOPHILA, HOMOLOG OF; NUMB__:____:__
Asterisk__:__603729__:__SPHINGOSINE-1-PHOSPHATE LYASE 1; SGPL1__:__SPL__:__
Asterisk__:__603730__:__SPHINGOSINE KINASE 1; SPHK1__:____:__
Asterisk__:__603731__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 8; CNOT8__:__CAF1-LIKE FACTOR; CALIF;; PKG PROMOTER-DIRECTED OVERPRODUCTION 2, S. CEREVISIAE, HOMOLOG OF; POP2__:__
Asterisk__:__603732__:__CRYPTOCHROME 2; CRY2__:____:__
Asterisk__:__603733__:__SOLUTE CARRIER FAMILY 43 (L-TYPE AMINO ACID TRANSPORTER), MEMBER 1; SLC43A1__:__L-TYPE AMINO ACID TRANSPORTER 3; LAT3;; PROSTATE CANCER OVEREXPRESSED GENE 1; POV1__:__
Asterisk__:__603734__:__INTERFERON REGULATORY FACTOR 3; IRF3__:____:__
Asterisk__:__603735__:__AMINE OXIDASE, COPPER-CONTAINING, 3; AOC3__:__HUMAN PLACENTA AMINE OXIDASE; HPAO;; VASCULAR ADHESION PROTEIN 1; VAP1__:__
Number Sign__:__603736__:__OHDO SYNDROME, SBBYS VARIANT; SBBYSS__:__SAY-BARBER-BIESECKER-YOUNG-SIMPSON SYNDROME;; YOUNG-SIMPSON SYNDROME; YSS__:__
NULL__:__603737__:__OVARIAN GERM CELL CANCER__:____:__
Asterisk__:__603738__:__BASIC TRANSCRIPTION FACTOR 3-LIKE 2; BTF3L2__:____:__
Asterisk__:__603739__:__BASIC TRANSCRIPTION FACTOR 3-LIKE 3; BTF3L3__:____:__
NULL__:__603740__:__ACRODYSPLASIA WITH OSSIFICATION ABNORMALITIES, SHORT STATURE, AND FIBULAR HYPOPLASIA__:____:__
Asterisk__:__603741__:__ARACHIDONATE 12-LIPOXYGENASE, R TYPE; ALOX12B__:__12R-LIPOXYGENASE;; 12R-LOX;; 12-LIPOXYGENASE, R TYPE__:__
Asterisk__:__603742__:__SLIT, DROSOPHILA, HOMOLOG OF, 1; SLIT1__:__SLIT GUIDANCE LIGAND 1;; SLIL1;; MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 4; MEGF4__:__
Asterisk__:__603743__:__APOLIPOPROTEIN L-I; APOL1__:__APOL;; APOL-I__:__
NULL__:__603744__:__PAPILLARY THYROID MICROCARCINOMA__:____:__
Asterisk__:__603745__:__SLIT, DROSOPHILA, HOMOLOG OF, 3; SLIT3__:__SLIT GUIDANCE LIGAND 3;; SLIL2;; MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 5; MEGF5__:__
Asterisk__:__603746__:__SLIT, DROSOPHILA, HOMOLOG OF, 2; SLIT2__:__SLIT GUIDANCE LIGAND 2__:__
Asterisk__:__603747__:__TUMOR PROTEIN D52-LIKE 2; TPD52L2__:__D54__:__
Caret__:__603748__:__MOVED TO 300297__:____:__
Asterisk__:__603749__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 2; TRPM2__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; TRPC7;; LONG TRANSIENT RECEPTOR POTENTIAL CHANNEL 2; LTRPC2;; KNP3__:__
Asterisk__:__603750__:__AQUAPORIN 8; AQP8__:____:__
Asterisk__:__603751__:__SPHINGOSINE-1-PHOSPHATE RECEPTOR 4; S1PR4__:__ENDOTHELIAL DIFFERENTIATION GENE 6; EDG6;; S1P RECEPTOR 4; S1P4__:__
Asterisk__:__603752__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 4; SLC7A4__:__CATIONIC AMINO ACID TRANSPORTER 4; CAT4__:__
Asterisk__:__603753__:__UBIQUITINATION FACTOR E4A; UBE4A__:__UFD2, S. CEREVISIAE, HOMOLOG OF;; UBIQUITIN CONJUGATION FACTOR E4; E4__:__
Asterisk__:__603754__:__KINESIN FAMILY MEMBER 3B; KIF3B__:__KIAA0359__:__
Asterisk__:__603755__:__ZINC FINGER FYVE TYPE-CONTAINING PROTEIN 9; ZFYVE9__:__SMAD ANCHOR FOR RECEPTOR ACTIVATION; SARA;; MADH-INTERACTING PROTEIN; MADHIP;; RECEPTOR ACTIVATION ANCHOR__:__
Asterisk__:__603756__:__ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 2; ABCG2__:__ATP-BINDING CASSETTE TRANSPORTER, PLACENTA-SPECIFIC; ABCP;; BREAST CANCER RESISTANCE PROTEIN; BCRP;; MITOXANTRONE-RESISTANCE PROTEIN; MRX__:__
Asterisk__:__603757__:__CHEMOKINE, CC MOTIF, LIGAND 18; CCL18__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 18; SCYA18;; PULMONARY AND ACTIVATION-REGULATED CHEMOKINE; PARC;; ALTERNATIVE MACROPHAGE ACTIVATION-ASSOCIATED CC CHEMOKINE 1; AMAC1;; DENDRITIC CELL CHEMOKINE 1; DCCK1__:__
Asterisk__:__603758__:__GLUTATHIONE S-TRANSFERASE, ZETA-1; GSTZ1__:__GLUTATHIONE S-TRANSFERASE Z1;; MALEYLACETOACETATE ISOMERASE; MAAI__:__
Asterisk__:__603759__:__LIM HOMEOBOX GENE 2; LHX2__:__LIM HOX GENE 2; LH2__:__
Asterisk__:__603760__:__HYDROXYUREA-SENSITIVE 1, S. POMBE, HOMOLOG OF; HUS1__:____:__
Asterisk__:__603761__:__RAD9, S. POMBE, HOMOLOG OF, A; RAD9A__:__RAD9, S. POMBE, HOMOLOG OF; RAD9__:__
Asterisk__:__603762__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE-ASSOCIATED PROTEIN 2; PRPSAP2__:__PAP41__:__
Asterisk__:__603763__:__KINESIN FAMILY MEMBER C1; KIFC1__:__KINESIN-LIKE 2; KNSL2;; HSET__:__
Asterisk__:__603764__:__CYCLIN-DEPENDENT KINASE 5, REGULATORY SUBUNIT 2; CDK5R2__:__NEURONAL CDK5 ACTIVATOR ISOFORM; NCK5AI;; CYCLIN-DEPENDENT KINASE 5, REGULATORY PARTNER, 39-KD; p39;; p39(NCK5AI)__:__
Asterisk__:__603765__:__SYNTAXIN 10; STX10__:__SYN10__:__
Asterisk__:__603766__:__MITOCHONDRIAL TRANSLATIONAL INITIATION FACTOR 2; MTIF2__:____:__
Asterisk__:__603767__:__KALLIKREIN-RELATED PEPTIDASE 4; KLK4__:__KALLIKREIN 4;; PROTEASE, SERINE, 17; PRSS17;; PROSTASE; PSTS;; ENAMEL MATRIX SERINE PROTEINASE 1; EMSP1__:__
Asterisk__:__603768__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 12B; PPP1R12B__:__MYOSIN PHOSPHATASE TARGET SUBUNIT 2; MYPT2__:__
Asterisk__:__603769__:__T-CELL LYMPHOMA/LEUKEMIA 1B; TCL1B__:__TML1__:__
Asterisk__:__603770__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1B; PPM1B__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1B;; PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1, BETA ISOFORM;; PROTEIN PHOSPHATASE 2C, BETA ISOFORM, FORMERLY; PP2CB, FORMERLY__:__
Asterisk__:__603771__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 10; PPP1R10__:__PROTEIN PHOSPHATASE 1 NUCLEAR TARGETING SUBUNIT; PNUTS;; PP1 NUCLEAR TARGETING SUBUNIT__:__
Asterisk__:__603772__:__DYNEIN, CYTOPLASMIC 1, INTERMEDIATE CHAIN 1; DYNC1I1__:__DNCI1;; IC74__:__
Asterisk__:__603773__:__CYTOCHROME c OXIDASE, SUBUNIT 5A; COX5A__:__CYTOCHROME c OXIDASE, SUBUNIT Va__:__
Asterisk__:__603774__:__CYTOCHROME c OXIDASE, SUBUNIT 7C; COX7C__:__CYTOCHROME c OXIDASE, SUBUNIT VIIc__:__
Asterisk__:__603775__:__CYCLIN E2; CCNE2__:____:__
Number Sign__:__603776__:__HYPERCHOLESTEROLEMIA, AUTOSOMAL DOMINANT, 3; HCHOLA3__:__FH3__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; LDLCQ1, INCLUDED
Asterisk__:__603777__:__CERBERUS 1 HOMOLOG, CYSTINE KNOT SUPERFAMILY; CER1__:__CERBERUS, XENOPUS, HOMOLOG OF, 1__:__
Asterisk__:__603778__:__CHROMODOMAIN PROTEIN ON Y CHROMOSOME-LIKE; CDYL__:____:__
Asterisk__:__603779__:__SYNUCLEIN-ALPHA-INTERACTING PROTEIN; SNCAIP__:__SYNPHILIN 1__:__
Asterisk__:__603780__:__RECQ PROTEIN-LIKE 4; RECQL4__:__DNA HELICASE, RECQ-LIKE, TYPE 4; RECQ4__:__
Asterisk__:__603781__:__RECQ PROTEIN-LIKE 5; RECQL5__:__DNA HELICASE, RECQ-LIKE, TYPE 5; RECQ5__:__
Asterisk__:__603782__:__CHEMOKINE, CC MOTIF, LIGAND 4-LIKE 1; CCL4L1__:__CCL4L;; SMALL INDUCIBLE CYTOKINE A4-LIKE; SCYA4L;; LYMPHOCYTE ACTIVATION GENE 1; LAG1;; AT744.2__:__
Percent__:__603783__:__INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1__:__INTLQ1;; COGNITIVE ABILITY, GENERAL__:__SELF-PERCEIVED ABILITY, INCLUDED
Asterisk__:__603784__:__PITUITARY TUMOR-TRANSFORMING GENE 1 PROTEIN-INTERACTING PROTEIN; PTTG1IP__:__PTTG-BINDING FACTOR; PBF;; CHROMOSOME 21 OPEN READING FRAME 1; C21ORF1;; CHROMOSOME 21 OPEN READING FRAME 3; C21ORF3__:__
Asterisk__:__603785__:__MULTIPLE PDZ DOMAIN PROTEIN; MPDZ__:__MUPP1__:__
Number Sign__:__603786__:__STARGARDT DISEASE 4; STGD4__:____:__
Asterisk__:__603787__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY F, MEMBER 1; KCNF1__:__KH1__:__
Asterisk__:__603788__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY G, MEMBER 1; KCNG1__:__KH2__:__
Caret__:__603789__:__MOVED TO 300237__:____:__
Asterisk__:__603790__:__SOLUTE CARRIER FAMILY 23 (NUCLEOBASE TRANSPORTER), MEMBER 1; SLC23A1__:__SODIUM-DEPENDENT VITAMIN C TRANSPORTER 1; SVCT1;; YOLK SAC PERMEASE-LIKE MOLECULE 3; YSPL3__:__
Asterisk__:__603791__:__SOLUTE CARRIER FAMILY 23 (NUCLEOBASE TRANSPORTER), MEMBER 2; SLC23A2__:__SODIUM-DEPENDENT VITAMIN C TRANSPORTER 2; SVCT2;; YOLK SAC PERMEASE-LIKE MOLECULE 2; YSPL2;; KIAA0238__:__
Caret__:__603792__:__MOVED TO 300885__:____:__
Caret__:__603793__:__REMOVED FROM DATABASE__:____:__
NULL__:__603794__:__HYDROA VACCINIFORME, FAMILIAL__:____:__
Asterisk__:__603795__:__LIPOPOLYSACCHARIDE-INDUCED TUMOR NECROSIS FACTOR-ALPHA FACTOR; LITAF__:__LPS-INDUCED TNF-ALPHA FACTOR;; SMALL INTEGRAL MEMBRANE PROTEIN OF LYSOSOME/LATE ENDOSOME; SIMPLE__:__
Asterisk__:__603796__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2; KCNE2__:__MINIMUM POTASSIUM ION CHANNEL-RELATED PEPTIDE 1; MIRP1;; MINK-RELATED PEPTIDE 1__:__
Asterisk__:__603797__:__CARBOHYDRATE SULFOTRANSFERASE 1; CHST1__:__KERATAN SULFATE GAL-6-SULFOTRANSFERASE; KSGAL6ST__:__
Asterisk__:__603798__:__CARBOHYDRATE SULFOTRANSFERASE 2; CHST2__:__N-ACETYLGLUCOSAMINE-6-O-SULFOTRANSFERASE 1;; GlcNAc-6-O-SULFOTRANSFERASE;; GlcNAc6ST1;; GST2__:__
Asterisk__:__603799__:__CARBOHYDRATE SULFOTRANSFERASE 3; CHST3__:__CHONDROITIN 6-SULFOTRANSFERASE; C6ST;; C6ST1__:__
Asterisk__:__603800__:__MEDIATOR COMPLEX SUBUNIT 21; MED21__:__SUPPRESSOR OF RNA POLYMERASE B 7, S. CEREVISIAE, HOMOLOG OF; SURB7; SRB7__:__
Asterisk__:__603801__:__N-MYRISTOYLTRANSFERASE 2; NMT2__:____:__
Percent__:__603802__:__MICROCEPHALY WITH SIMPLIFIED GYRAL PATTERN__:____:__
Asterisk__:__603803__:__DACHSHUND, DROSOPHILA, HOMOLOG OF, 1; DACH1__:__DACH__:__
Asterisk__:__603804__:__NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 1; NEURL1__:__NEURALIZED-LIKE; NEURL;; NEUR1__:__
Asterisk__:__603805__:__TRANSGLUTAMINASE 5; TGM5__:__TRANSGLUTAMINASE X; TGX__:__
NULL__:__603806__:__URINARY TRACT INFECTIONS, RECURRENT, SUSCEPTIBILITY TO__:____:__
Caret__:__603807__:__MOVED TO 107250__:____:__
Asterisk__:__603808__:__MEDIATOR COMPLEX SUBUNIT 13; MED13__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 1; THRAP1;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 240-KD; TRAP240__:__
Asterisk__:__603809__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 3; THRAP3__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 150-KD; TRAP150__:__
Asterisk__:__603810__:__MEDIATOR COMPLEX SUBUNIT 17; MED17__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 17, S. CEREVISIAE, HOMOLOG OF;; COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 6; CRSP6;; CRSP, 77-KD SUBUNIT; CRSP77;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 80-KD SUBUNIT; TRAP80;; VITAMIN D RECEPTOR-INTERACTING PROTEIN, 80-KD; DRIP80__:__
Asterisk__:__603811__:__BARRIER-TO-AUTOINTEGRATION FACTOR 1; BANF1__:__BARRIER-TO-AUTOINTEGRATION FACTOR; BAF__:__
Asterisk__:__603812__:__DDB1- AND CUL4-ASSOCIATED FACTOR 5; DCAF5__:__WD REPEAT-CONTAINING PROTEIN 22; WDR22;; BREAKPOINT CLUSTER REGION PROTEIN 2; BCRP2;; D14S1461E__:__
Number Sign__:__603813__:__HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE; ARH__:__HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE, 1, FORMERLY; ARH1, FORMERLY;; FHCB1, FORMERLY;; HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE, 2, FORMERLY; ARH2, FORMERLY;; FHCB2, FORMERLY__:__
Asterisk__:__603814__:__RING-BOX 1; RBX1__:__REGULATOR OF CULLINS 1; ROC1__:__
Asterisk__:__603815__:__KINESIN FAMILY MEMBER 25; KIF25__:__KINESIN-LIKE 3; KNSL3__:__
Asterisk__:__603816__:__AXIS INHIBITOR 1; AXIN1__:__AXIN;; FUSED, MOUSE, HOMOLOG OF__:__
Asterisk__:__603817__:__DEVELOPMENT- AND DIFFERENTIATION-ENHANCING FACTOR 2; DDEF2__:__PYK C-TERMINUS ASSOCIATED PROTEIN; PAP;; KIAA0400__:__
Asterisk__:__603818__:__NEUREGULIN 2; NRG2__:__DIVERGENT OF NEUREGULIN 1; DON1;; NEURAL- AND THYMUS-DERIVED ACTIVATOR FOR THE ERBB KINASE; NTAK__:__
Asterisk__:__603819__:__STEROID RECEPTOR RNA ACTIVATOR 1; SRA1__:__SRA__:__
Asterisk__:__603820__:__FREE FATTY ACID RECEPTOR 1; FFAR1__:__G PROTEIN-COUPLED RECEPTOR 40; GPR40__:__
Asterisk__:__603821__:__FREE FATTY ACID RECEPTOR 3; FFAR3__:__G PROTEIN-COUPLED RECEPTOR 41; GPR41__:__
Asterisk__:__603822__:__G PROTEIN-COUPLED RECEPTOR 42; GPR42__:____:__
Asterisk__:__603823__:__FREE FATTY ACID RECEPTOR 2; FFAR2__:__G PROTEIN-COUPLED RECEPTOR 43; GPR43__:__
Asterisk__:__603824__:__UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE; GNE__:__GLCNE__:__
Asterisk__:__603825__:__HYPERMETHYLATED IN CANCER 1; HIC1__:____:__
Asterisk__:__603826__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 4; NR1H4__:__FARNESOID X-ACTIVATED RECEPTOR; FXR;; RETINOID X RECEPTOR-INTERACTING PROTEIN 14; RIP14;; RXR-INTERACTING PROTEIN 14;; BILE ACID RECEPTOR; BAR__:__
Asterisk__:__603827__:__BCL2-LIKE 11; BCL2L11__:__BCL2-INTERACTING PROTEIN BIM; BIM__:__
NULL__:__603828__:__BRITTLE BONE DISORDER__:____:__
Number Sign__:__603829__:__VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 1; VF1__:__VF;; IVF__:__VENTRICULAR FIBRILLATION DURING MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__603830__:__LONG QT SYNDROME 3; LQT3__:____:__LONG QT SYNDROME 3, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED;; LONG QT SYNDROME 2/3, DIGENIC, INCLUDED; LQT2/3, DIGENIC, INCLUDED;; LONG QT SYNDROME 3/6, DIGENIC, INCLUDED; LQT3/6, DIGENIC, INCLUDED
Asterisk__:__603831__:__PDZ DOMAIN-CONTAINING 1; PDZK1__:__PDZD1;; C-TERMINAL LINKING AND MODULATING PROTEIN; CLAMP;; CFTR-ASSOCIATED PROTEIN, 70-KD; CAP70__:__
Asterisk__:__603832__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 3; NDUFA3__:____:__
Asterisk__:__603833__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 4; NDUFA4__:__MLRQ__:__
Asterisk__:__603834__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 9; NDUFA9__:____:__
Asterisk__:__603835__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 10; NDUFA10__:____:__
Asterisk__:__603836__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA/BETA SUBCOMPLEX, 1; NDUFAB1__:__ACYL CARRIER PROTEIN, MITOCHONDRIAL; ACP__:__
Asterisk__:__603837__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 1; NDUFB1__:____:__
Asterisk__:__603838__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 2; NDUFB2__:____:__
Asterisk__:__603839__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 3; NDUFB3__:____:__
Asterisk__:__603840__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 4; NDUFB4__:____:__
Asterisk__:__603841__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 5; NDUFB5__:____:__
Asterisk__:__603842__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 7; NDUFB7__:__SQM1__:__
Asterisk__:__603843__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 BETA SUBCOMPLEX, 10; NDUFB10__:____:__
Asterisk__:__603844__:__NADH-UBIQUINONE OXIDOREDUCTASE 1, SUBUNIT C1; NDUFC1__:____:__
Asterisk__:__603845__:__NADH-UBIQUINONE OXIDOREDUCTASE 1, SUBUNIT C2; NDUFC2__:____:__
Asterisk__:__603846__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 3; NDUFS3__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 30-KD SUBUNIT__:__
Asterisk__:__603847__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 5; NDUFS5__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 15-KD SUBUNIT__:__
Asterisk__:__603848__:__NADH-UBIQUINONE OXIDOREDUCTASE Fe-S PROTEIN 6; NDUFS6__:__COMPLEX I, MITOCHONDRIAL RESPIRATORY CHAIN, 13-KD SUBUNIT__:__
Asterisk__:__603849__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP E, MEMBER 1; NR2E1__:__TAILLESS, DROSOPHILA, HOMOLOG OF; TLX__:__
Asterisk__:__603850__:__DYNAMIN 1-LIKE; DNM1L__:__DYNAMIN-LIKE PROTEIN 1; DLP1;; DYNAMIN-RELATED PROTEIN 1; DRP1;; S. CEREVISIAE DNM1/VPS1-LIKE PROTEIN; DVLP;; DYNAMIN FAMILY MEMBER, PROLINE-RICH C-TERMINAL DOMAIN-LESS; DYMPLE__:__
Asterisk__:__603851__:__PAIRED-LIKE HOMEOBOX 2B; PHOX2B__:__PAIRED MESODERM HOMEOBOX 2B; PMX2B;; NEUROBLASTOMA PAIRED-TYPE HOMEOBOX GENE; NBPHOX__:__
Asterisk__:__603852__:__TUMOR-SUPPRESSING SUBCHROMOSOMAL TRANSFERABLE FRAGMENT CANDIDATE GENE 4; TSSC4__:__TUMOR-SUPPRESSING STF cDNA 4__:__
Asterisk__:__603853__:__TETRASPANIN 32; TSPAN32__:__PAN-HEMATOPOIETIC EXPRESSION GENE; PHEMX;; TUMOR-SUPPRESSING SUBCHROMOSOMAL TRANSFERABLE FRAGMENT CANDIDATE GENE 6; TSSC6;; TUMOR-SUPPRESSING STF cDNA 6;; AML1-REGULATED TRANSMEMBRANE PROTEIN 1; ART1__:__
Asterisk__:__603854__:__RAN-BINDING PROTEIN 9; RANBP9__:__RANBPM__:__
Percent__:__603855__:__CYSTIC FIBROSIS, MODIFIER OF, 1; CFM1__:____:__MECONIUM ILEUS IN CYSTIC FIBROSIS, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__603856__:__MAKORIN 3; MKRN3__:__ZINC FINGER PROTEIN 127; ZNF127; ZFP127__:__
Asterisk__:__603857__:__MKRN3 ANTISENSE RNA; MKRN3AS__:__ZINC FINGER PROTEIN 127, ANTISENSE; ZNF127AS__:__
Caret__:__603858__:__MOVED TO 256370__:____:__
Asterisk__:__603859__:__SOLUTE CARRIER FAMILY 25 (CITRIN), MEMBER 13; SLC25A13__:__CITRIN__:__
Number Sign__:__603860__:__MEDULLARY CYSTIC KIDNEY DISEASE 2; MCKD2__:__MEDULLARY CYSTIC KIDNEY DISEASE 2, AUTOSOMAL DOMINANT; ADMCKD2__:__
Asterisk__:__603861__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ORNITHINE TRANSPORTER), MEMBER 15; SLC25A15__:__ORNITHINE TRANSPORTER, MITOCHONDRIAL, 1; ORNT1__:__
Asterisk__:__603862__:__CYCLIN T2; CCNT2__:____:__
Asterisk__:__603863__:__RING FINGER PROTEIN 7; RNF7__:__REGULATOR OF CULLINS 2; ROC2;; RBX2;; SENSITIVE TO APOPTOSIS GENE; SAG__:__
Asterisk__:__603864__:__COPPER CHAPERONE FOR SUPEROXIDE DISMUTASE; CCS__:____:__
Asterisk__:__603865__:__GLUTAMINE:FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE 2; GFPT2__:__GFAT2__:__
Asterisk__:__603866__:__PEROXISOME BIOGENESIS FACTOR 11A; PEX11A__:__PEX11-ALPHA__:__
Asterisk__:__603867__:__PEROXISOME BIOGENESIS FACTOR 11B; PEX11B__:__PEX11-BETA__:__
Asterisk__:__603868__:__RAS-ASSOCIATED PROTEIN RAB27A; RAB27A__:__RAB27;; RAS-RELATED GENE FROM MEGAKARYOCYTE; RAM__:__
Asterisk__:__603869__:__RAS-ASSOCIATED PROTEIN RAB27B; RAB27B__:____:__
Asterisk__:__603870__:__CORE-BINDING FACTOR, ALPHA SUBUNIT 2, TRANSLOCATED TO, 3; CBFA2T3__:__MTG8-RELATED GENE 2; MTGR2;; MYELOID TRANSLOCATION GENE ON CHROMOSOME 16; MTG16;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 4; ZMYND4;; ETO2__:__
Asterisk__:__603871__:__BY THE RIBOSOMAL PROTEIN S6 GENE, DROSOPHILA, HOMOLOG-LIKE; BYSL__:__BYSTIN;; ENP1__:__
Asterisk__:__603872__:__TROPHININ-ASSOCIATED PROTEIN; TROAP__:__TROPHININ-ASSISTING PROTEIN;; TASTIN__:__
Asterisk__:__603873__:__PHOSPHOLIPASE A2-ACTIVATING PROTEIN; PLAA__:__PLAP__:__
Asterisk__:__603874__:__ANGIOPOIETIN-LIKE 1; ANGPTL1__:__ANGIOPOIETIN 3, FORMERLY; ANGPT3, FORMERLY; ANG3, FORMERLY__:__
Asterisk__:__603875__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 8; TNFSF8__:__CD30 LIGAND; CD30L; CD30LG;; CD153__:__
Asterisk__:__603876__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 4; ADAMTS4__:__AGGRECANASE 1__:__
Asterisk__:__603877__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 3; SLC16A3__:__MONOCARBOXYLATE TRANSPORTER 4; MCT4__:__
Asterisk__:__603878__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 4; SLC16A4__:__MONOCARBOXYLATE TRANSPORTER 5; MCT5__:__
Asterisk__:__603879__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 5; SLC16A5__:__MONOCARBOXYLATE TRANSPORTER 6; MCT6__:__
Asterisk__:__603880__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 6; SLC16A6__:__MONOCARBOXYLATE TRANSPORTER 7; MCT7__:__
Asterisk__:__603881__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP I, MEMBER 3; NR1I3__:__CONSTITUTIVE ANDROSTANE RECEPTOR, BETA;; CAR-BETA;; CAR;; MB67__:__
Asterisk__:__603882__:__BCL2-ASSOCIATED ATHANOGENE 2; BAG2__:____:__
Asterisk__:__603883__:__BCL2-ASSOCIATED ATHANOGENE 3; BAG3__:____:__
Asterisk__:__603884__:__BCL2-ASSOCIATED ATHANOGENE 4; BAG4__:__SILENCER OF DEATH DOMAINS; SODD__:__
Asterisk__:__603885__:__BCL2-ASSOCIATED ATHANOGENE 5; BAG5__:____:__
Asterisk__:__603886__:__ARTEMIN; ARTN__:__NEUBLASTIN;; ENOVIN__:__
Asterisk__:__603887__:__TIMELESS, DROSOPHILA, HOMOLOG OF; TIMELESS__:__TIM; TIM1__:__
Asterisk__:__603888__:__POTASSIUM CHANNEL, VOLTAGE-GATED, DELAYED-RECTIFIER, SUBFAMILY S, MEMBER 3; KCNS3__:__VOLTAGE-GATED POTASSIUM CHANNEL 9.3; KV9.3__:__
Asterisk__:__603889__:__SIGNAL REGULATORY PROTEIN, BETA-1; SIRPB1__:____:__
Asterisk__:__603890__:__UBIQUITIN-CONJUGATING ENZYME E2L 6; UBE2L6__:__UBIQUITIN-CONJUGATING ENZYME UBCH8; UBCH8__:__
Asterisk__:__603891__:__FIBROBLAST GROWTH FACTOR 19; FGF19__:____:__
Asterisk__:__603892__:__ELONGATION FACTOR Tu GTP-BINDING DOMAIN-CONTAINING 2; EFTUD2__:__U5 snRNP-SPECIFIC PROTEIN, 116-KD;; U5-116KD;; KIAA0031__:__
Asterisk__:__603893__:__TRAF FAMILY MEMBER-ASSOCIATED NF-KAPPA-B ACTIVATOR; TANK__:__TRAF-INTERACTING PROTEIN; ITRAF__:__
Asterisk__:__603894__:__REGULATOR OF G PROTEIN SIGNALING 6; RGS6__:____:__
Asterisk__:__603895__:__REGULATOR OF G PROTEIN SIGNALING 11; RGS11__:____:__
Number Sign__:__603896__:__LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER; VWM__:__CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION; CACH;; VANISHING WHITE MATTER LEUKODYSTROPHY;; CREE LEUKOENCEPHALOPATHY; CLE__:__VANISHING WHITE MATTER LEUKODYSTROPHY WITH OVARIAN FAILURE, INCLUDED;; OVARIOLEUKODYSTROPHY, INCLUDED
Asterisk__:__603897__:__MATRILIN 4; MATN4__:____:__
Asterisk__:__603898__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 18; TNFSF18__:__AITR LIGAND; AITRL;; GITR LIGAND; GITRL__:__
Asterisk__:__603899__:__ZINC FINGER PROTEIN 85; ZNF85__:____:__
Asterisk__:__603900__:__ZINC FINGER PROTEIN 174; ZNF174__:____:__
Asterisk__:__603901__:__ZPR1 ZINC FINGER; ZPR1__:__ZINC FINGER PROTEIN 259; ZNF259__:__
Number Sign__:__603902__:__BETA-THALASSEMIA, DOMINANT INCLUSION BODY TYPE__:__DYSERYTHROPOIETIC ANEMIA, CONGENITAL, IRISH OR WEATHERALL TYPE__:__
Number Sign__:__603903__:__SICKLE CELL ANEMIA__:____:__
Asterisk__:__603904__:__INTEGRAL MEMBRANE PROTEIN 2B; ITM2B__:__BRI;; BRI2__:__
Asterisk__:__603905__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 18; TNFRSF18__:__ACTIVATION-INDUCIBLE TNFR FAMILY MEMBER; AITR;; GLUCOCORTICOID-INDUCED TNFR-RELATED GENE; GITR__:__
Asterisk__:__603906__:__CHLORIDE CHANNEL ACCESSORY 1; CLCA1__:__CHLORIDE CHANNEL, CALCIUM-ACTIVATED, 1;; CALCIUM-ACTIVATED CHLORIDE CHANNEL 1; CACC1;; GOB5__:__
Asterisk__:__603907__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 1; EIF2S1__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA;; EIF2-ALPHA__:__
Asterisk__:__603908__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 2; EIF2S2__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-BETA__:__
Number Sign__:__603909__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE II; ALPS2__:__
Asterisk__:__603910__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT J; EIF3J__:__EIF3-p35;; EIF3-ALPHA;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 1, FORMERLY; EIF3S1, FORMERLY__:__
Asterisk__:__603911__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT I; EIF3I__:__TGF-BETA RECEPTOR-INTERACTING PROTEIN 1; TRIP1;; EIF3-p36;; EIF3-BETA;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 2, FORMERLY; EIF3S2, FORMERLY__:__
Asterisk__:__603912__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT H; EIF3H__:__EIF3-p40;; EIF3-GAMMA;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 3, FORMERLY; EIF3S3, FORMERLY__:__
Asterisk__:__603913__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT G; EIF3G__:__EIF3-p42;; EIF3-p44;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 4, FORMERLY; EIF3S4, FORMERLY__:__
Asterisk__:__603914__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT F; EIF3F__:__EIF3-p47;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 5, FORMERLY; EIF3S5, FORMERLY__:__
Asterisk__:__603915__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT D; EIF3D__:__EIF3-p66;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 7, FORMERLY; EIF3S7, FORMERLY__:__
Asterisk__:__603916__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT C; EIF3C__:__EIF3-p110;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 8, FORMERLY; EIF3S8, FORMERLY__:__
Asterisk__:__603917__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT B; EIF3B__:__PROTEIN SYNTHESIS DEFECTIVE AT 36 DEGREES CELSIUS 1, S. CEREVISIAE, HOMOLOG OF; PRT1;; EIF3-p116;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 9, FORMERLY; EIF3S9, FORMERLY__:__
Percent__:__603918__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 1__:__HYT1__:__
Asterisk__:__603919__:__SERINE/THREONINE PROTEIN KINASE 10; STK10__:__LOK;; POLO-LIKE KINASE KINASE 1, XENOPUS, HOMOLOG OF; PLKK1;; AT1-46, RAT, HOMOLOG OF__:__
Asterisk__:__603920__:__CRYSTALLIN, ZETA-LIKE 1; CRYZL1__:__QUINONE OXIDOREDUCTASE-LIKE 1__:__
Asterisk__:__603921__:__SUCCINATE-CoA LIGASE, ADP-FORMING, BETA SUBUNIT; SUCLA2__:__ATP-SPECIFIC SUCCINYL-CoA SYNTHETASE, BETA SUBUNIT;; A-BETA__:__
Asterisk__:__603922__:__SUCCINATE-CoA LIGASE, GDP-FORMING, BETA SUBUNIT; SUCLG2__:__GTP-SPECIFIC SUCCINYL-CoA SYNTHETASE, BETA SUBUNIT;; G-BETA__:__
Caret__:__603923__:__MOVED TO 139260__:____:__
Asterisk__:__603924__:__HYALURONAN-BINDING PROTEIN 2; HABP2__:__HYALURONIC ACID-BINDING PROTEIN 2; HABP2;; HYALURONAN-BINDING PROTEIN, PLASMA; PHBP;; HEPATOCYTE GROWTH FACTOR ACTIVATOR-LIKE; HGFAL;; FACTOR VII-ACTIVATING PROTEASE; FSAP__:__
Asterisk__:__603925__:__SYNAPTOGYRIN 1; SYNGR1__:____:__
Asterisk__:__603926__:__SYNAPTOGYRIN 2; SYNGR2__:__CELLUGYRIN__:__
Asterisk__:__603927__:__SYNAPTOGYRIN 3; SYNGR3__:____:__
Asterisk__:__603928__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4B; EIF4B__:____:__
Asterisk__:__603929__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4-GAMMA, 3; EIF4G3__:__EIF4GII__:__
Asterisk__:__603930__:__GEPHYRIN; GPHN__:__GPH; GEPH;; KIAA1385__:__MLL/GPHN FUSION GENE, INCLUDED
Asterisk__:__603931__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 9-KD, V0 SUBUNIT E1; ATP6V0E1__:__ATP6V0E;; ATPase, H+ TRANSPORTING, LYSOSOMAL, SUBUNIT H; ATP6H__:__
Number Sign__:__603932__:__INTERVERTEBRAL DISC DISEASE; IDD__:____:__LUMBAR DISC DISEASE, INCLUDED; LDD, INCLUDED;; LUMBAR DISC HERNIATION, SUSCEPTIBILITY TO, INCLUDED;; LUMBAR DISC DEGENERATION, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__603933__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1__:__PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO;; NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, INCLUDED;; MICROVASCULAR COMPLICATIONS OF DIABETES, PROTECTION AGAINST, INCLUDED;; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED;; END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO, INCLUDED;; PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED;; NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED;; NEUROPATHY, DIABETIC, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__603934__:__COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1; CARM1__:__PROTEIN ARGININE N-METHYLTRANSFERASE 4; PRMT4__:__
Percent__:__603935__:__PSORIASIS 4, SUSCEPTIBILITY TO; PSORS4__:____:__
Asterisk__:__603936__:__GROWTH/DIFFERENTIATION FACTOR 11; GDF11__:__BONE MORPHOGENETIC PROTEIN 11; BMP11__:__
Asterisk__:__603937__:__RP1 GENE; RP1__:__OXYGEN-REGULATED PHOTORECEPTOR PROTEIN 1; ORP1__:__
Caret__:__603938__:__MOVED TO 300205__:____:__
Asterisk__:__603939__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 6; KCNK6__:__POTASSIUM CHANNEL, WEAKLY INWARD-RECTIFYING, WITH TWIN P DOMAINS, 2; TWIK2;; TWIK-ORIGINATED SIMILARITY SEQUENCE; TOSS__:__
Asterisk__:__603940__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 7; KCNK7__:____:__
Asterisk__:__603941__:__SOLUTE CARRIER FAMILY 19 (THIAMINE TRANSPORTER), MEMBER 2; SLC19A2__:__THIAMINE TRANSPORTER PROTEIN 1; THTR1; THT1__:__
Asterisk__:__603942__:__GLYCOGENIN 1; GYG1__:____:__
Asterisk__:__603943__:__CYSTEINE DIOXYGENASE; CDO__:__CYSTEINE DIOXYGENASE, TYPE I; CDO1;; L-CYSTEINE: OXYGEN OXIDOREDUCTASE__:__
Asterisk__:__603944__:__SYNTAXIN 6; STX6__:____:__
Asterisk__:__603945__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 5; EIF2B5__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, EPSILON;; EIF2B-EPSILON__:__
Asterisk__:__603946__:__HELICASE, LYMPHOID-SPECIFIC; HELLS__:__LSH;; SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 6; SMARCA6;; PROLIFERATION-ASSOCIATED SNF2-LIKE GENE; PASG__:__
Asterisk__:__603947__:__METASTASIS-ASSOCIATED PROTEIN 2; MTA2__:__METASTASIS-ASSOCIATED 1-LIKE 1; MTA1L1;; PID__:__
Asterisk__:__603948__:__NUCLEOPORIN, 153-KD; NUP153__:____:__
Asterisk__:__603949__:__RAB7-LIKE 1; RAB7L1__:____:__
Asterisk__:__603950__:__N-DEACETYLASE/N-SULFOTRANSFERASE 3; NDST3__:__HEPARAN GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE 3;; HEPARAN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE 3;; GlcNAc N-DEACETYLASE/N-SULFOTRANSFERASE, HEPARAN SULFATE/HEPARIN, 3__:__
Asterisk__:__603951__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, SUBFAMILY M, BETA MEMBER 1; KCNMB1__:__SLO-BETA__:__
Asterisk__:__603952__:__DEVELOPMENTALLY REGULATED GTP-BINDING PROTEIN 1; DRG1__:__DEVELOPMENTALLY REGULATED GTP-BINDING PROTEIN; DRG;; NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 3; NEDD3__:__
Asterisk__:__603953__:__POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 14; KCNJ14__:__KIR2.4__:__
Asterisk__:__603954__:__ZESTE-WHITE 10, DROSOPHILA, HOMOLOG OF; ZW10__:____:__
Asterisk__:__603955__:__FLAVIN-CONTAINING MONOOXYGENASE 2; FMO2__:__FMO, PULMONARY__:__
Number Sign__:__603956__:__CERVICAL CANCER__:____:__
Asterisk__:__603957__:__FLAVIN-CONTAINING MONOOXYGENASE 5; FMO5__:____:__
Asterisk__:__603958__:__REGULATORY FACTOR X, 4; RFX4__:____:__
Asterisk__:__603959__:__CLAUDIN 16; CLDN16__:__PARACELLIN 1; PCLN1__:__
Asterisk__:__603960__:__CALICIN; CCIN__:____:__
Asterisk__:__603961__:__SEMAPHORIN 3A; SEMA3A__:__SEMAPHORIN III;; SEMAPHORIN D; SEMAD;; COLLAPSIN 1; COLL1__:__
Asterisk__:__603962__:__RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 1; RASGRP1__:____:__
Asterisk__:__603963__:__INTEGRIN, ALPHA-9; ITGA9__:__ALPHA RELATED TO THE DEVELOPMENT OF LUNG CANCER;; ALPHA-RLC__:__
Percent__:__603964__:__DEAFNESS, AUTOSOMAL DOMINANT 16; DFNA16__:____:__
Number Sign__:__603965__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2; FSGS2__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 2__:__
Asterisk__:__603966__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER C3; AKR1C3__:__ALDO-KETO REDUCTASE B; HAKRB;; DIHYDRODIOL DEHYDROGENASE 3; DD3;; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE, TYPE II;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE V; HSD17B5__:__
Asterisk__:__603967__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE IV, ALPHA SUBUNIT; SCN4A__:__NAV1.4__:__
Asterisk__:__603968__:__POLYMERASE, DNA, ETA; POLH__:__RAD30, S. CEREVISIAE, HOMOLOG OF, A; RAD30A__:__
Asterisk__:__603969__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 13B; TNFSF13B__:__B-LYMPHOCYTE STIMULATOR; BLYS;; B CELL-ACTIVATING FACTOR; BAFF;; TNF- AND APOL-RELATED LEUKOCYTE EXPRESSED LIGAND 1; TALL1;; TNF HOMOLOG THAT ACTIVATES APOPTOSIS, NKFB, AND JNK; THANK__:__
Asterisk__:__603970__:__PARANEOPLASTIC MA ANTIGEN 2; PNMA2__:__PARANEOPLASTIC ANTIGEN MA2; MA2;; ONCONEURONAL ANTIGEN MA2;; MM2__:__
Asterisk__:__603971__:__ZINC FINGER PROTEIN 91; ZNF91__:____:__
Asterisk__:__603972__:__ZINC FINGER PROTEIN 43; ZNF43__:____:__
Asterisk__:__603973__:__ZINC FINGER PROTEIN 90; ZNF90__:____:__
Asterisk__:__603974__:__ZINC FINGER PROTEIN 92; ZNF92__:____:__
Asterisk__:__603975__:__ZINC FINGER PROTEIN 93; ZNF93__:____:__
Asterisk__:__603976__:__ZINC FINGER PROTEIN 94; ZNF94__:____:__
Asterisk__:__603977__:__ZINC FINGER PROTEIN 208; ZNF208__:__ZINC FINGER PROTEIN 95; ZNF95__:__
Asterisk__:__603978__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 12; ZSCAN12__:__ZINC FINGER PROTEIN 96; ZFP96; ZNF96;; KIAA0426__:__
Asterisk__:__603979__:__ZINC FINGER PROTEIN 97; ZNF97__:____:__
Asterisk__:__603980__:__ZINC FINGER PROTEIN 98; ZNF98__:____:__
Asterisk__:__603981__:__ZINC FINGER PROTEIN 99; ZNF99__:____:__
Asterisk__:__603982__:__ZINC FINGER PROTEIN 100; ZNF100__:____:__
Asterisk__:__603983__:__ZINC FINGER PROTEIN 101; ZNF101__:____:__
Asterisk__:__603984__:__ZINC FINGER PROTEIN 737; ZNF737__:__ZINC FINGER PROTEIN 102; ZNF102__:__
Asterisk__:__603985__:__ZINC FINGER PROTEIN 103; ZNF103__:____:__
Caret__:__603986__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__603987__:__ZINC FINGER PROTEIN 105; ZNF105__:____:__
Asterisk__:__603988__:__ZINC FINGER PROTEIN 106; ZNF106__:____:__
Asterisk__:__603989__:__ZINC FINGER PROTEIN 107; ZNF107__:__ZFD25;; ZINC FINGER PROTEIN 588, FORMERLY; ZNF588, FORMERLY__:__
Caret__:__603990__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__603991__:__ZINC FINGER PROTEIN 109; ZNF109__:____:__
Asterisk__:__603992__:__ZINC FINGER PROTEIN 110; ZNF110__:____:__
Asterisk__:__603993__:__ZINC FINGER PROTEIN 111; ZNF111__:____:__
Asterisk__:__603994__:__ZINC FINGER PROTEIN 112; ZNF112__:____:__
Asterisk__:__603995__:__ZINC FINGER PROTEIN 113; ZNF113__:____:__
Asterisk__:__603996__:__ZINC FINGER PROTEIN 114; ZNF114__:____:__
Asterisk__:__603997__:__ZINC FINGER PROTEIN 118; ZNF118__:____:__
Asterisk__:__603998__:__ZINC FINGER PROTEIN 119; ZNF119__:____:__
Asterisk__:__603999__:__ZINC FINGER PROTEIN 120; ZNF120__:____:__
Asterisk__:__604000__:__ZINC FINGER PROTEIN 122; ZNF122__:____:__
Asterisk__:__604001__:__A-KINASE ANCHOR PROTEIN 9; AKAP9__:__YOTIAO;; A-KINASE ANCHOR PROTEIN, 450-KD; AKAP450;; CENTROSOME- AND GOLGI-LOCALIZED PROTEIN KINASE N-ASSOCIATED PROTEIN; CGNAP__:__AKAP9/BRAF FUSION GENE, INCLUDED
Asterisk__:__604002__:__RHO-ASSOCIATED COILED-COIL-CONTAINING PROTEIN KINASE 2; ROCK2__:____:__
Asterisk__:__604003__:__CHLORIDE CHANNEL ACCESSORY 2; CLCA2__:__CHLORIDE CHANNEL, CALCIUM-ACTIVATED, 2;; CALCIUM-ACTIVATED CHLORIDE CHANNEL 3; CACC3__:__
Number Sign__:__604004__:__MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 1; MLC1__:__VACUOLATING MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS;; LVM;; VL;; LEUKOENCEPHALOPATHY WITH SWELLING AND CYSTS;; VAN DER KNAAP DISEASE__:__
Caret__:__604005__:__MOVED TO 157640__:____:__
Caret__:__604006__:__REMOVED FROM DATABASE__:____:__
Caret__:__604007__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__604008__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, ZETA-2; PTPRZ2__:____:__
Asterisk__:__604009__:__BAI1-ASSOCIATED PROTEIN 3; BAIAP3__:__BAP3__:__
Asterisk__:__604010__:__PARANEOPLASTIC MA ANTIGEN 1; PNMA1__:__PARANEOPLASTIC ANTIGEN MA1; MA1;; NEURON- AND TESTIS-SPECIFIC PROTEIN 1__:__
Plus__:__604011__:__UNC119, C. ELEGANS, HOMOLOG OF; UNC119__:__HUMAN RETINAL GENE 4; HRG4__:__CONE-ROD DYSTROPHY, INCLUDED
Asterisk__:__604012__:__RNA, U20 SMALL NUCLEOLAR; RNU20__:__snoRNA, U20__:__
Asterisk__:__604013__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 2; B4GALT2__:__BETA-1,4-GALACTOSYLTRANSFERASE 2;; BETA-4-GALT2__:__
Asterisk__:__604014__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 3; B4GALT3__:__BETA-1,4-GALACTOSYLTRANSFERASE 3;; BETA-4-GALT3__:__
Asterisk__:__604015__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 4; B4GALT4__:__BETA-1,4-GALACTOSYLTRANSFERASE 4__:__
Asterisk__:__604016__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 5; B4GALT5__:__BETA-1,4-GALACTOSYLTRANSFERASE 5__:__
Asterisk__:__604017__:__UDP-GAL:BETA-GlcNAc BETA-1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 6; B4GALT6__:__BETA-1,4-GALACTOSYLTRANSFERASE 6__:__
Asterisk__:__604018__:__NUMB, DROSOPHILA, HOMOLOG-LIKE; NUMBL__:__NUMB-RELATED GENE; NUMBR;; NUMBLIKE; NBL;; TRINUCLEOTIDE REPEAT-CONTAINING GENE 23; TNRC23__:__
Asterisk__:__604019__:__ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN WITH FG REPEATS 2; AGFG2__:__ARFGAP WITH FG REPEATS 2;; HIV-1 REV-BINDING PROTEIN-LIKE; HRBL;; REV/REX ACTIVATION DOMAIN-BINDING PROTEIN-RELATED; RABR__:__
Asterisk__:__604020__:__BASSOON, MOUSE, HOMOLOG OF; BSN__:__ZINC FINGER PROTEIN 231; ZNF231__:__
Caret__:__604021__:__MOVED TO 162662__:____:__
Caret__:__604022__:__MOVED TO 162662__:____:__
Caret__:__604023__:__MOVED TO 162662__:____:__
Asterisk__:__604024__:__SOLUTE CARRIER FAMILY 5 (SODIUM-DEPENDENT VITAMIN TRANSPORTER), MEMBER 6; SLC5A6__:__SODIUM-DEPENDENT MULTIVITAMIN TRANSPORTER; SMVT__:__
Asterisk__:__604025__:__AXIS INHIBITOR 2; AXIN2__:__CONDUCTIN, MOUSE, HOMOLOG OF__:__
Asterisk__:__604026__:__GOLGI SNAP RECEPTOR COMPLEX MEMBER 1; GOSR1__:__GOS28;; GOLGI SNARE, 28-KD; GS28__:__
Asterisk__:__604027__:__GOLGI SNAP RECEPTOR COMPLEX MEMBER 2; GOSR2__:__GOLGI SNARE, 27-KD; GS27;; MEMBRIN__:__
Asterisk__:__604028__:__SECRETION DEFICIENT 22, S. CEREVISIAE, HOMOLOG OF, C; SEC22C__:____:__
Asterisk__:__604029__:__SECRETION DEFICIENT 22, S. CEREVISIAE, HOMOLOG-LIKE 1; SEC22L1__:__SEC22B__:__
Asterisk__:__604030__:__PROTEASOME SUBUNIT, BETA-TYPE, 7; PSMB7__:__PROTEASOME SUBUNIT Z;; PROTEASOME SUBUNIT BETA-2__:__
Asterisk__:__604031__:__STEAROYL-CoA DESATURASE; SCD__:__SCD1;; DELTA-9-DESATURASE__:__
Asterisk__:__604032__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3; EIF2AK3__:__PANCREATIC EIF2-ALPHA KINASE; PEK;; PERK__:__
Asterisk__:__604033__:__ENDOPLASMIC RETICULUM-TO-NUCLEUS SIGNALING 1; ERN1__:__INOSITOL-REQUIRING ENZYME 1, S. CEREVISIAE, HOMOLOG OF; IRE1;; IRE1-ALPHA; IRE1A__:__
Asterisk__:__604034__:__ENDOPLASMIC RETICULUM-TO-NUCLEUS SIGNALING 2; ERN2__:__INOSITOL-REQUIRING ENZYME 1, S. CEREVISIAE, HOMOLOG OF, BETA; IRE1B;; IRE1-BETA__:__
Asterisk__:__604035__:__CYLICIN 2; CYLC2__:____:__
Asterisk__:__604036__:__CYCLIN A1; CCNA1__:____:__
Asterisk__:__604037__:__RAS-ASSOCIATED PROTEIN RAB5C; RAB5C__:__RAB-LIKE, FORMERLY; RABL, FORMERLY__:__
Asterisk__:__604038__:__HYALURONOGLUCOSAMINIDASE 3; HYAL3__:__HYALURONIDASE 3;; LUCA3__:__
Asterisk__:__604039__:__MENINGIOMA-EXPRESSED ANTIGEN 5; MGEA5__:__O-LINKED N-ACETYLGLUCOSAMINASE; OGA;; O-GlcNAcase;; NUCLEAR CYTOPLASMIC O-GlcNAcase AND ACETYLTRANSFERASE; NCOAT__:__
Asterisk__:__604040__:__RAD50, S. CEREVISIAE, HOMOLOG OF; RAD50__:____:__
Asterisk__:__604041__:__MANNOSE-P-DOLICHOL UTILIZATION DEFECT 1; MPDU1__:__SUPPRESSOR OF LEC15; SL15;; LEC35__:__
Asterisk__:__604042__:__INTEGRIN, ALPHA-10; ITGA10__:____:__
Asterisk__:__604043__:__NEVER IN MITOSIS GENE A-RELATED KINASE 2; NEK2__:__NIMA-RELATED KINASE 2__:__
Asterisk__:__604044__:__NEVER IN MITOSIS GENE A-RELATED KINASE 3; NEK3__:__NIMA-RELATED KINASE 3__:__
Asterisk__:__604045__:__PROTEIN ARGININE METHYLTRANSFERASE 5; PRMT5__:__SHK1 KINASE-BINDING PROTEIN 1, S. POMBE, HOMOLOG OF; SKB1;; ICLN-BINDING PROTEIN, 72-KD; IBP72;; JAK-BINDING PROTEIN 1; JBP1;; HISTONE SYNTHETIC LETHAL 7, S. CEREVISIAE, HOMOLOG OF; HSL7__:__
Asterisk__:__604046__:__OXIDATIVE STRESS-RESPONSIVE 1; OXSR1__:__OSR1__:__
Asterisk__:__604047__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION/URATE TRANSPORTER), MEMBER 13; SLC22A13__:__ORGANIC-CATION TRANSPORTER-LIKE 3; ORCTL3;; OCTL1__:__
Asterisk__:__604048__:__SOLUTE CARRIER FAMILY 22, MEMBER 14; SLC22A14__:__ORGANIC-CATION TRANSPORTER-LIKE 4; ORCTL4;; OCTL2__:__
Asterisk__:__604049__:__XYLULOKINASE, H. INFLUENZAE, HOMOLOG OF; XYLB__:____:__
Asterisk__:__604050__:__DELETED IN LUNG AND ESOPHAGEAL CANCER 1; DLEC1__:__DLC1__:__
Asterisk__:__604051__:__ENDO/EXONUCLEASE, ENDOG-LIKE; EXOG__:__ENDONUCLEASE G-LIKE 1; ENDOGL1;; ENGL__:__
Asterisk__:__604052__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 15; TNFSF15__:__TNF15;; TNF LIGAND-RELATED MOLECULE 1; TL1;; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VEGI__:__
Asterisk__:__604053__:__3-PRIME(2-PRIME),5-PRIME-BISPHOSPHATE NUCLEOTIDASE 1; BPNT1__:__BISPHOSPHATE 3-PRIME-NUCLEOTIDASE__:__
Asterisk__:__604054__:__ACETYL-CoA ACYLTRANSFERASE 1; ACAA1__:__ACETYL-CoA ACYLTRANSFERASE; ACAA;; PEROXISOMAL 3-OXOACYL-CoA THIOLASE; PTHIO; THIO;; 3-OXOACYL-CoA THIOLASE, PEROXISOMAL;; 3-KETOACYL-CoA THIOLASE, PEROXISOMAL; PTL__:__
Asterisk__:__604055__:__ISOPENTENYL-DIPHOSPHATE DELTA ISOMERASE 1; IDI1__:__ISOPENTENYL DIPHOSPHATE:DIMETHYLALLYL DIPHOSPHATE ISOMERASE;; IPP ISOMERASE__:__
Asterisk__:__604056__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 2; HS3ST2__:__HEPARAN SULFATE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE 2;; 3OST2__:__
Asterisk__:__604057__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 3A1; HS3ST3A1__:__HEPARAN SULFATE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE 3A1;; 3OST3A1__:__
Asterisk__:__604058__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 3B1; HS3ST3B1__:__HEPARAN SULFATE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE 3B1;; 3OST3B1__:__
Asterisk__:__604059__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 4; HS3ST4__:__HEPARAN SULFATE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE 4;; 3OST4__:__
Percent__:__604060__:__DEAFNESS, AUTOSOMAL RECESSIVE 20; DFNB20__:____:__
Asterisk__:__604061__:__SEPTIN 9; SEPT9__:__MLL SEPTIN-LIKE FUSION GENE; MSF;; MSF1;; PEANUT-LIKE 4; PNUTL4;; SINT1;; KIAA0991__:__
Asterisk__:__604062__:__MEDIATOR COMPLEX SUBUNIT 16; MED16__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 5; THRAP5;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 95-KD; TRAP95;; VITAMIN D RECEPTOR-INTERACTING PROTEIN, 92-KD; DRIP92__:__
Asterisk__:__604063__:__INTEGRIN, ALPHA-8; ITGA8__:____:__
Asterisk__:__604064__:__ACTIVATING TRANSCRIPTION FACTOR 4; ATF4__:__CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN 2; CREB2;; TAX-RESPONSIVE ENHANCER ELEMENT-BINDING PROTEIN 67; TAXREB67__:__
Asterisk__:__604065__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, T TYPE, ALPHA-1G SUBUNIT; CACNA1G__:____:__
Asterisk__:__604066__:__UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 5; B3GALT5__:__BETA-3-GALACTOSYLTRANSFERASE 5;; BETA-3-GALT5__:__
Asterisk__:__604067__:__REGULATOR OF G PROTEIN SIGNALING 9; RGS9__:____:__
Asterisk__:__604068__:__TUMOR PROTEIN D52; TPD52__:__D52__:__
Asterisk__:__604069__:__TUMOR PROTEIN D52-LIKE 1; TPD52L1__:__D53__:__
Asterisk__:__604070__:__DIACYLGLYCEROL KINASE, BETA, 90-KD; DGKB__:__DGK-BETA;; DGK, 90-KD;; KIAA0718__:__
Asterisk__:__604071__:__DIACYLGLYCEROL KINASE, ETA, 130-KD; DGKH__:__DGK-ETA__:__
Asterisk__:__604072__:__DIACYLGLYCEROL KINASE, IOTA, 130-KD; DGKI__:__DGK-IOTA__:__
Asterisk__:__604073__:__ZINC FINGER PROTEIN 131; ZNF131__:____:__
Asterisk__:__604074__:__ZINC FINGER PROTEIN 132; ZNF132__:____:__
Asterisk__:__604075__:__ZINC FINGER PROTEIN 133; ZNF133__:____:__
Asterisk__:__604076__:__ZINC FINGER PROTEIN 134; ZNF134__:____:__
Asterisk__:__604077__:__ZINC FINGER PROTEIN 135; ZNF135__:____:__
Asterisk__:__604078__:__ZINC FINGER PROTEIN 136; ZNF136__:____:__
Asterisk__:__604079__:__ZINC FINGER PROTEIN 137; ZNF137__:____:__
Asterisk__:__604080__:__ZINC FINGER PROTEIN 138; ZNF138__:____:__
Caret__:__604081__:__MOVED TO 601260__:____:__
Asterisk__:__604082__:__ZINC FINGER PROTEIN 140; ZNF140__:____:__
Asterisk__:__604083__:__ZINC FINGER PROTEIN 142; ZNF142__:____:__
Asterisk__:__604084__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 17; ZBTB17__:__ZINC FINGER PROTEIN 151; ZNF151;; MYC-INTERACTING ZINC FINGER PROTEIN 1; MIZ1__:__
Asterisk__:__604085__:__ZINC FINGER PROTEIN 154; ZNF154__:____:__
Asterisk__:__604086__:__ZINC FINGER PROTEIN 155; ZNF155__:____:__
Asterisk__:__604087__:__CYTOCHROME P450, FAMILY 46, SUBFAMILY A, POLYPEPTIDE 1; CYP46A1__:__CYTOCHROME P450, SUBFAMILY 46; CYP46;; CHOLESTEROL 24-HYDROXYLASE__:__
Asterisk__:__604088__:__PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 17; PP1R17__:__G-SUBSTRATE; GSBS;; CHROMOSOME 7 OPEN READING FRAME 16; C7ORF16__:__
Asterisk__:__604089__:__HEMATOPOIETIC CELL SIGNAL TRANSDUCER; HCST__:__DNAX-ACTIVATION PROTEIN 10; DAP10__:__
Asterisk__:__604090__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 5; DLG5__:__PLACENTA AND PROSTATE DLG; PDLG;; KIAA0583__:__
Number Sign__:__604091__:__HYPOALPHALIPOPROTEINEMIA, PRIMARY__:__HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC__:__
Asterisk__:__604092__:__TTK PROTEIN KINASE; TTK__:__MONOPOLAR SPINDLE 1-LIKE 1; MPS1L1;; MPS1, YEAST, HOMOLOG OF; MPS1;; PHOSPHOTYROSINE-PICKED THREONINE KINASE; PYT;; ESK, MOUSE, HOMOLOG OF; ESK__:__
Number Sign__:__604093__:__KERATOSIS PILARIS ATROPHICANS; KPA__:____:__
Asterisk__:__604094__:__MITOTIC ARREST-DEFICIENT 2, S. CEREVISIAE, HOMOLOG-LIKE 2; MAD2L2__:__MAD2B;; REV7, S. CEREVISIAE, HOMOLOG OF; REV7__:__
Asterisk__:__604095__:__ECTODYSPLASIN A RECEPTOR; EDAR__:__ECTODYSPLASIN 1, ANHIDROTIC RECEPTOR;; DOWNLESS, MOUSE, HOMOLOG OF; DL;; ECTODYSPLASIN A1 ISOFORM RECEPTOR;; EDA-A1 RECEPTOR;; EDA-A1R;; EDA1R__:__
Asterisk__:__604096__:__GLUTAMATE RECEPTOR, METABOTROPIC, 6; GRM6__:__MGLUR6__:__
Asterisk__:__604097__:__UROTENSIN II; UTS2__:____:__
Asterisk__:__604098__:__SUPPRESSOR OF G2 ALLELE OF SKP1, S. CEREVISIAE, HOMOLOG OF; SUGT1__:__SGT1__:__
Asterisk__:__604099__:__GLUTAMATE RECEPTOR, METABOTROPIC, 2; GRM2__:__MGLUR2__:__
Asterisk__:__604100__:__GLUTAMATE RECEPTOR, METABOTROPIC, 4; GRM4__:__MGLUR4__:__
Asterisk__:__604101__:__GLUTAMATE RECEPTOR, METABOTROPIC, 7; GRM7__:__MGLUR7__:__
Asterisk__:__604102__:__GLUTAMATE RECEPTOR, METABOTROPIC, 5; GRM5__:__MGLUR5__:__
Asterisk__:__604103__:__MYOTILIN; MYOT__:__MYO;; TITIN IMMUNOGLOBULIN DOMAIN PROTEIN; TTID__:__
Asterisk__:__604104__:__GLIA MATURATION FACTOR, GAMMA; GMFG__:__GMF-GAMMA__:__
Asterisk__:__604105__:__SYNAPTONEMAL COMPLEX PROTEIN 2; SYCP2__:__SCP2__:__
Asterisk__:__604106__:__G PROTEIN-COUPLED RECEPTOR 52; GPR52__:____:__
Asterisk__:__604107__:__G PROTEIN-COUPLED RECEPTOR 55; GPR55__:____:__
Asterisk__:__604108__:__MICROTUBULE-ASSOCIATED PROTEIN 7; MAP7__:__MICROTUBULE-ASSOCIATED PROTEIN, EPITHELIAL, 115-KD; EMAP115;; ENSCONSIN, DROSOPHILA, HOMOLOG OF; ENS__:__
Asterisk__:__604109__:__HUMAN ENDOGENOUS RETROVIRUS-H LONG TERMINAL REPEAT-ASSOCIATING 1; HHLA1__:__HERV-H LTR-ASSOCIATING 1__:__
Asterisk__:__604110__:__ADHESION G PROTEIN-COUPLED RECEPTOR G1; ADGRG1__:__G PROTEIN-COUPLED RECEPTOR 56; GPR56;; 7-TRANSMEMBRANE PROTEIN WITH NO EGF-LIKE N-TERMINAL DOMAINS 1; TM7XN1__:__
Asterisk__:__604111__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, BETA MEMBER 3; KCNAB3__:__KCNA3B;; KV-BETA-3__:__
Asterisk__:__604112__:__SCIELLIN; SCEL__:____:__
Asterisk__:__604113__:__INTERLEUKIN 18-BINDING PROTEIN; IL18BP__:__IL18BPa__:__IL18BPb, INCLUDED;; IL18BPc, INCLUDED
Asterisk__:__604114__:__PHOSPHOLIPASE C, BETA-2; PLCB2__:____:__
Asterisk__:__604115__:__KCNQ1-OVERLAPPING TRANSCRIPT 1; KCNQ1OT1__:__LONG QT INTRONIC TRANSCRIPT 1; LIT1__:__
Number Sign__:__604116__:__CONE-ROD DYSTROPHY 3; CORD3__:____:__
Number Sign__:__604117__:__VOHWINKEL SYNDROME, VARIANT FORM__:__VOHWINKEL SYNDROME WITH ICHTHYOSIS;; MUTILATING KERATODERMA WITH ICHTHYOSIS;; LORICRIN KERATODERMA__:__
Asterisk__:__604118__:__RAS PROTEIN ACTIVATOR-LIKE 1; RASAL1__:__RAS-GTPase-ACTIVATING PROTEIN-LIKE; RASAL;; RASGAP1-LIKE__:__
Asterisk__:__604119__:__SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 4; SLC12A4__:__POTASSIUM-CHLORIDE COTRANSPORTER 1; KCC1__:__
Caret__:__604120__:__MOVED TO 600894__:____:__
Number Sign__:__604121__:__CEREBELLAR ATAXIA, DEAFNESS, AND NARCOLEPSY, AUTOSOMAL DOMINANT; ADCADN__:____:__
Asterisk__:__604122__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS B PROTEIN; PIGB__:____:__
Asterisk__:__604123__:__RIBONUCLEASE H1; RNASEH1__:__H1RNA__:__
Asterisk__:__604124__:__RETINOBLASTOMA-BINDING PROTEIN 8; RBBP8__:__RETINOBLASTOMA-INTERACTING AND MYOSIN-LIKE; RIM;; CTBP-INTERACTING PROTEIN; CTIP__:__
Asterisk__:__604125__:__SULFOTRANSFERASE FAMILY 2B, MEMBER 1; SULT2B1__:____:__
Asterisk__:__604126__:__SUPERVILLIN; SVIL__:____:__
Asterisk__:__604127__:__T-BOX 15; TBX15__:____:__
Asterisk__:__604128__:__TRANSCRIPTION ELONGATION FACTOR A, 3; TCEA3__:____:__
Number Sign__:__604129__:__EPIDERMOLYSIS BULLOSA PRURIGINOSA__:__DYSTROPHIC EPIDERMOLYSIS BULLOSA PRURIGINOSA;; DEB, PRURIGINOSA__:__
Asterisk__:__604130__:__UNDIFFERENTIATED EMBRYONIC CELL TRANSCRIPTION FACTOR 1; UTF1__:____:__
Number Sign__:__604131__:__ALPHA-THALASSEMIA__:____:__
Caret__:__604132__:__MOVED TO 300601__:____:__
Caret__:__604133__:__MOVED TO 300288__:____:__
Asterisk__:__604134__:__A DISINTEGRIN-LIKE AND METALLOPROTEASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 13; ADAMTS13__:__VON WILLEBRAND FACTOR-CLEAVING PROTEASE; VWFCP__:__
Asterisk__:__604135__:__NUCLEAR FACTOR ERYTHROID 2-LIKE 3; NFE2L3__:__NFE2-RELATED FACTOR 3; NRF3__:__
Asterisk__:__604136__:__INTERLEUKIN 24; IL24__:__SUPPRESSION OF TUMORIGENICITY 16; ST16;; MELANOMA DIFFERENTIATION-ASSOCIATED GENE 7; MDA7__:__
Caret__:__604137__:__MOVED TO 192150__:____:__
Asterisk__:__604138__:__G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, MEMBER A; GPRC5A__:__RETINOIC ACID-INDUCED 3; RAI3;; RETINOIC ACID-INDUCIBLE GENE 1; RAIG1__:__
Asterisk__:__604139__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 2; DNAJB2__:__HEAT-SHOCK PROTEIN, DNAJ-LIKE 1; HSJ1;; HEAT-SHOCK 40-KD PROTEIN 3; HSPF3__:__
Asterisk__:__604140__:__DEATH INDUCER-OBLITERATOR 1; DIDO1__:__DEATH-ASSOCIATED TRANSCRIPTION FACTOR 1; DATF1;; DIO1;; KIAA0333__:__
Asterisk__:__604141__:__ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; ARFGEF1__:__ADP-RIBOSYLATION FACTOR-GUANINE NUCLEOTIDE EXCHANGE PROTEIN 1; ARFGEP1;; BREFELDIN A-INHIBITED GUANINE NUCLEOTIDE EXCHANGE PROTEIN 1; BIG1;; p200__:__
Asterisk__:__604142__:__TYRO PROTEIN TYROSINE KINASE-BINDING PROTEIN; TYROBP__:__DNAX-ACTIVATION PROTEIN 12; DAP12__:__
Asterisk__:__604143__:__EXTRA SPINDLE POLES-LIKE 1; ESPL1__:__ESP1;; SEPARIN;; SEPARASE__:__
Asterisk__:__604144__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 9; SLC7A9__:____:__
Number Sign__:__604145__:__CARDIOMYOPATHY, DILATED, 1G; CMD1G__:____:__
Asterisk__:__604146__:__SYNAPTOTAGMIN 7; SYT7__:__PROSTATE CANCER-ASSOCIATED PROTEIN 7; PCANAP7;; IPCA7__:__
Asterisk__:__604147__:__PITUITARY TUMOR-TRANSFORMING GENE 1; PTTG1__:__PTTG;; ESP1-ASSOCIATED PROTEIN 1; EAP1;; TUMOR-TRANSFORMING 1; TUTR1;; SECURIN__:__
Asterisk__:__604148__:__SOLUTE CARRIER FAMILY 13 (SODIUM-DEPENDENT DICARBOXYLATE TRANSPORTER), MEMBER 2; SLC13A2__:__SODIUM-DEPENDENT DICARBOXYLATE TRANSPORTER 1; NADC1__:__
Asterisk__:__604149__:__SARCOGLYCAN, EPSILON; SGCE__:____:__
Asterisk__:__604150__:__POLYMERASE II, RNA, SUBUNIT J; POLR2J__:__RPB11, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 13.3-KD SUBUNIT__:__
Asterisk__:__604151__:__UBIQUITIN-CONJUGATING ENZYME E2E 3; UBE2E3__:__UBIQUITIN-CONJUGATING ENZYME UBCH9; UBCH9;; UBCM2__:__
Asterisk__:__604152__:__ORNITHINE DECARBOXYLASE ANTIZYME 2; OAZ2__:__ANTIZYME 2__:__
Asterisk__:__604153__:__NEUROMEDIN U RECEPTOR 1; NMUR1__:__NMU1R;; G PROTEIN-COUPLED RECEPTOR 66; GPR66;; GROWTH HORMONE SECRETAGOGUE RECEPTOR FAMILY, MEMBER 3; FM3__:__
NULL__:__604154__:__ALZHEIMER DISEASE WITHOUT NEUROFIBRILLARY TANGLES__:____:__
Asterisk__:__604155__:__LanC-LIKE 1; LANCL1__:__LANTHIONINE-SYNTHETASE COMPONENT C-LIKE 1 G PROTEIN-COUPLED RECEPTOR;; G PROTEIN-COUPLED RECEPTOR 69A; GPR69A__:__
Asterisk__:__604156__:__SECRETED FRIZZLED-RELATED PROTEIN 1; SFRP1__:__FRIZZLED-RELATED PROTEIN; FRP;; SECRETED APOPTOSIS-RELATED PROTEIN 2; SARP2__:__
Asterisk__:__604157__:__SECRETED FRIZZLED-RELATED PROTEIN 2; SFRP2__:__SECRETED APOPTOSIS-RELATED PROTEIN 1; SARP1__:__
Asterisk__:__604158__:__SECRETED FRIZZLED-RELATED PROTEIN 5; SFRP5__:__SECRETED APOPTOSIS-RELATED PROTEIN 3; SARP3__:__
Asterisk__:__604159__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GLYCINE), MEMBER 5; SLC6A5__:__GLYCINE TRANSPORTER, TYPE 2; GLYT2__:__
Asterisk__:__604160__:__INTEGRIN, BETA-8; ITGB8__:____:__
Asterisk__:__604161__:__KISS1 RECEPTOR; KISS1R__:__G PROTEIN-COUPLED RECEPTOR 54;; GPR54 METASTIN RECEPTOR__:__
Caret__:__604162__:__MOVED TO 600816__:____:__
Asterisk__:__604163__:__RIBOSOMAL PROTEIN L3; RPL3__:____:__
Asterisk__:__604164__:__ONE CUT HOMEOBOX 1; ONECUT1__:__ONE CUT DOMAIN, FAMILY MEMBER 1;; HEPATOCYTE NUCLEAR FACTOR 6-ALPHA; HNF6A;; HEPATOCYTE NUCLEAR FACTOR 6; HNF6__:__
Asterisk__:__604165__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, OXOGLUTARATE CARRIER), MEMBER 11; SLC25A11__:__SOLUTE CARRIER FAMILY 20, MEMBER 4, FORMERLY; SLC20A4, FORMERLY;; OXOGLUTARATE CARRIER; OGC;; OXOGLUTARATE/MALATE CARRIER__:__
Asterisk__:__604166__:__RIBOSOMAL PROTEIN L7; RPL7__:____:__
Asterisk__:__604167__:__CCCTC-BINDING FACTOR; CTCF__:__TRANSCRIPTIONAL REPRESSOR CTCF__:__
Number Sign__:__604168__:__CONGENITAL CATARACTS, FACIAL DYSMORPHISM, AND NEUROPATHY; CCFDN__:__CATARACT, CONGENITAL, WITH FACIAL DYSMORPHISM AND NEUROPATHY__:__
Number Sign__:__604169__:__LEFT VENTRICULAR NONCOMPACTION 1; LVNC1__:__LEFT VENTRICULAR NONCOMPACTION 1 WITH OR WITHOUT CONGENITAL HEART DEFECTS__:__
Asterisk__:__604170__:__PHOSPHOLIPID SCRAMBLASE 1; PLSCR1__:__MM1 CELL-DERIVED TRANSPLANTABILITY-ASSOCIATED GENE 1b, MOUSE, HOMOLOG OF; MMTRA1B__:__
Asterisk__:__604171__:__ALY/REF EXPORT FACTOR; ALYREF__:__TRANSCRIPTIONAL COACTIVATOR ALY; ALY;; REF;; bZIP-ENHANCING FACTOR; BEF;; THO COMPLEX, SUBUNIT 4; THOC4__:__
NULL__:__604172__:__CARONTE__:__CAR__:__
Number Sign__:__604173__:__POIKILODERMA WITH NEUTROPENIA; PN__:__POIKILODERMA WITH NEUTROPENIA, CLERICUZIO-TYPE__:__
Asterisk__:__604174__:__RIBOSOMAL PROTEIN L15; RPL15__:____:__
Asterisk__:__604175__:__RIBOSOMAL PROTEIN L11; RPL11__:____:__
Asterisk__:__604176__:__SUPPRESSOR OF CYTOKINE SIGNALING 3; SOCS3__:__STAT-INDUCED STAT INHIBITOR 3; SSI3;; CYTOKINE-INDUCIBLE SH2 PROTEIN 3; CIS3__:__
Asterisk__:__604177__:__RIBOSOMAL PROTEIN L8; RPL8__:____:__
Asterisk__:__604178__:__RIBOSOMAL PROTEIN L18A; RPL18A__:____:__
Asterisk__:__604179__:__RIBOSOMAL PROTEIN L18; RPL18__:____:__
Asterisk__:__604180__:__RIBOSOMAL PROTEIN L24; RPL24__:____:__
Asterisk__:__604181__:__RIBOSOMAL PROTEIN L37; RPL37__:____:__
Asterisk__:__604182__:__RIBOSOMAL PROTEIN L38; RPL38__:____:__
NULL__:__604183__:__CHOLESTEATOMA, CONGENITAL__:____:__
Asterisk__:__604184__:__PUTATIVE NEURONAL CELL ADHESION MOLECULE; PUNC__:____:__
Percent__:__604185__:__FACIAL PARESIS, HEREDITARY CONGENITAL, 2; HCFP2__:__MOEBIUS SYNDROME 3, FORMERLY; MBS3, FORMERLY;; MOBIUS SYNDROME 3, FORMERLY__:__
Asterisk__:__604186__:__CHEMOKINE, CXC MOTIF, LIGAND 14; CXCL14__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 14; SCYB14;; BRAK__:__
Number Sign__:__604187__:__SPASTIC PARAPLEGIA 10, AUTOSOMAL DOMINANT; SPG10__:__SPASTIC PARAPLEGIA 10 WITH OR WITHOUT PERIPHERAL NEUROPATHY__:__
Asterisk__:__604188__:__SELENIUM-BINDING PROTEIN 1; SELENBP1__:__METHANETHIOL OXIDASE; MTO;; SELENIUM-BINDING PROTEIN, 56-KD; SP56__:__
Asterisk__:__604189__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 4; DNAJC4__:__HEAT-SHOCK 40-KD PROTEIN 2; HSPF2;; MCG18__:__
Asterisk__:__604190__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 4; SLC22A4__:__ORGANIC CATION TRANSPORTER 1; OCTN1__:__
Asterisk__:__604191__:__ZINC FINGER PROTEIN 263; ZNF263__:____:__
Caret__:__604192__:__MOVED TO 603247__:____:__
Asterisk__:__604193__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 3; SLC27A3__:__FATTY ACID TRANSPORT PROTEIN 3; FATP3;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 3; ACSVL3__:__
Asterisk__:__604194__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 4; SLC27A4__:__FATTY ACID TRANSPORT PROTEIN 4; FATP4;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 5; ACSVL5__:__
Caret__:__604195__:__MOVED TO 603314__:____:__
Asterisk__:__604196__:__SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 6; SLC27A6__:__FATTY ACID TRANSPORT PROTEIN 6; FATP6;; VERY LONG CHAIN ACYL-CoA SYNTHETASE HOMOLOG 1; VLCSH1;; VLCS HOMOLOG 1;; ACYL-CoA SYNTHETASE VERY LONG CHAIN FAMILY, MEMBER 2; ACSVL2__:__
Asterisk__:__604197__:__5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; MTHFS__:__5-FORMYLTETRAHYDROFOLATE CYCLOLIGASE__:__
Asterisk__:__604198__:__RAS-ASSOCIATED PROTEIN RAB11B; RAB11B__:____:__
Asterisk__:__604199__:__RAS-ASSOCIATED PROTEIN RAB35; RAB35__:____:__
Asterisk__:__604200__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 5; SIGLEC5__:__CD33 ANTIGEN-LIKE 2; CD33L2;; OB-BINDING PROTEIN 2; OBBP2__:__
Percent__:__604201__:__HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA MANSONI INFECTION__:__SM2__:__HEPATIC FIBROSIS, SEVERE, SUSCEPTIBILITY TO, DUE TO SCHISTOSOMA JAPONICUM INFECTION, INCLUDED
Asterisk__:__604202__:__SYNAPTOSOMAL-ASSOCIATED PROTEIN, 29-KD; SNAP29__:____:__
Asterisk__:__604203__:__SYNTAXIN 8; STX8__:____:__
Asterisk__:__604204__:__SYNTAXIN 17; STX17__:____:__
Asterisk__:__604205__:__COPINE I; CPNE1__:__CPN1__:__
Asterisk__:__604206__:__COPINE II; CPNE2__:__CPN2__:__
Asterisk__:__604207__:__COPINE III; CPNE3__:__CPN3__:__
Asterisk__:__604208__:__COPINE IV; CPNE4__:__CPN4__:__
Asterisk__:__604209__:__COPINE V; CPNE5__:__CPN5__:__
Asterisk__:__604210__:__CRUMBS, DROSOPHILA, HOMOLOG OF, 1; CRB1__:____:__
NULL__:__604211__:__HIRSCHSPRUNG DISEASE WITH HEART DEFECTS, LARYNGEAL ANOMALIES, AND PREAXIAL POLYDACTYLY__:____:__
Asterisk__:__604212__:__POLYADENYLATE-SPECIFIC RIBONUCLEASE; PARN__:__POLY(A)-SPECIFIC RIBONUCLEASE;; DEADENYLATING NUCLEASE; DAN__:__
Number Sign__:__604213__:__CHUDLEY-MCCULLOUGH SYNDROME; CMCS__:__DEAFNESS, SENSORINEURAL, WITH PARTIAL AGENESIS OF THE CORPUS CALLOSUM AND ARACHNOID CYSTS;; DEAFNESS, AUTOSOMAL RECESSIVE 82, FORMERLY; DFNB82, FORMERLY__:__
Asterisk__:__604214__:__KREV INTERACTION TRAPPED 1; KRIT1__:__CCM1 GENE; CCM1__:__
Asterisk__:__604215__:__INHIBITOR OF GROWTH 2; ING2__:__INHIBITOR OF GROWTH 1-LIKE; ING1L;; p33ING2__:__
Asterisk__:__604216__:__SOLUTE CARRIER FAMILY 17, MEMBER 4; SLC17A4__:__SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 4__:__
Asterisk__:__604217__:__SOLUTE CARRIER FAMILY 34 (SODIUM/PHOSPHATE COTRANSPORTER), MEMBER 2; SLC34A2__:__NaPi3B__:__
Number Sign__:__604218__:__ENCEPHALOPATHY, FAMILIAL, WITH NEUROSERPIN INCLUSION BODIES; FENIB__:__ENCEPHALOPATHY, FAMILIAL, WITH COLLINS BODIES__:__
Number Sign__:__604219__:__CATARACT 9, MULTIPLE TYPES; CTRCT9__:__CATARACT 9, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, AUTOSOMAL DOMINANT;; CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 1; CATC1__:__
Asterisk__:__604220__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 1A; ARPC1A__:__SOP2-LIKE; SOP2L__:__
Asterisk__:__604221__:__ACTIN-RELATED PROTEIN 2; ACTR2__:__ARP2__:__ARP2/3 COMPLEX, INCLUDED
Asterisk__:__604222__:__ACTIN-RELATED PROTEIN 3; ACTR3__:__ARP3__:__
Asterisk__:__604223__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 1B; ARPC1B__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, 41-KD SUBUNIT; ARC41;; p41-ARC;; p40-ARC__:__
Asterisk__:__604224__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 2; ARPC2__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, 34-KD SUBUNIT; ARC34;; p34-ARC__:__
Asterisk__:__604225__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 3; ARPC3__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, 21-KD SUBUNIT; ARC21;; p21-ARC__:__
Asterisk__:__604226__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 4; ARPC4__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, 20-KD SUBUNIT; ARC20;; p20-ARC__:__
Asterisk__:__604227__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 5; ARPC5__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX, 16-KD SUBUNIT; ARC16;; p16-ARC__:__
Caret__:__604228__:__MOVED TO 607624__:____:__
Number Sign__:__604229__:__ANTERIOR SEGMENT DYSGENESIS 5; ASGD5__:____:__
Asterisk__:__604230__:__ADENOSINE DEAMINASE, tRNA-SPECIFIC, 1; ADAT1__:__TAD1, S. CEREVISIAE, HOMOLOG OF; TAD1__:__
Asterisk__:__604231__:__PITUITARY TUMOR-TRANSFORMING GENE 2; PTTG2__:____:__
Number Sign__:__604232__:__LEBER CONGENITAL AMAUROSIS 3; LCA3__:____:__RETINITIS PIGMENTOSA, JUVENILE, SPATA7-RELATED, INCLUDED
Number Sign__:__604233__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 1; GEFSP1__:__GEFS+, TYPE 1; GEFS+1__:__
Asterisk__:__604234__:__INTEGRIN, BETA-LIKE 1; ITGBL1__:__TEN BETA-INTEGRIN EGF-LIKE REPEAT DOMAINS; TIED__:__
Asterisk__:__604235__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 8; SLC7A8__:__L-TYPE AMINO ACID TRANSPORTER 2; LAT2__:__
Caret__:__604236__:__MOVED TO 604233__:____:__
Asterisk__:__604237__:__CYTOKINE RECEPTOR-LIKE FACTOR 1; CRLF1__:__CLF1;; NR6__:__
Asterisk__:__604238__:__SNAIL, DROSOPHILA, HOMOLOG OF, 1; SNAI1__:____:__
Asterisk__:__604239__:__PHOSPHOSERINE PHOSPHATASE-LIKE; PSPHL__:__CO9__:__
Asterisk__:__604240__:__T-CELL LEUKEMIA, HOMEOBOX 2; TLX2__:__HOMEOBOX 11-LIKE 1; HOX11L1;; TLX2;; NCX;; ENX__:__
Asterisk__:__604241__:__CD2-ASSOCIATED PROTEIN; CD2AP__:__CAS LIGAND WITH MULTIPLE SH3 DOMAINS; CMS__:__
Asterisk__:__604242__:__RING FINGER PROTEIN 6; RNF6__:____:__
Caret__:__604243__:__MOVED TO 300594__:____:__
Caret__:__604244__:__MOVED TO 300595__:____:__
Caret__:__604245__:__MOVED TO 300596__:____:__
Caret__:__604246__:__MOVED TO 300597__:____:__
Caret__:__604247__:__MOVED TO 300598__:____:__
Caret__:__604248__:__MOVED TO 300599__:____:__
Asterisk__:__604249__:__RETICULON 3; RTN3__:__NEUROENDOCRINE-SPECIFIC PROTEIN-LIKE 2; NSPL2__:__
Number Sign__:__604250__:__HEMOCHROMATOSIS, TYPE 3; HFE3__:__HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2__:__
Asterisk__:__604251__:__CALCINEURIN-BINDING PROTEIN 1__:__CABIN1;; CAIN__:__
Asterisk__:__604252__:__BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 1; BACE1__:__BETA-SITE APP-CLEAVING ENZYME; BACE;; SECRETASE, BETA;; MEMAPSIN 2__:__
Asterisk__:__604253__:__CASEIN KINASE I, GAMMA-3; CSNK1G3__:____:__
Percent__:__604254__:__DYSLEXIA, SUSCEPTIBILITY TO, 3; DYX3__:____:__
Asterisk__:__604255__:__LADY BIRD LATE, DROSOPHILA, HOMOLOG OF, 1__:__LBX1;; LBX1H__:__
Asterisk__:__604256__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER E40; BHLHE40__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 2; BHLHB2;; DEC1;; STRA13, MOUSE, HOMOLOG OF;; ENHANCER OF SPLIT- AND HAIRY-RELATED PROTEIN 2, RAT, HOMOLOG OF; SHARP2__:__
NULL__:__604257__:__CAMERA-MARUGO-COHEN SYNDROME__:____:__
Asterisk__:__604258__:__DELETED IN LIVER CANCER 1; DLC1__:__RHO GTPase-ACTIVATING PROTEIN 7; ARHGAP7__:__
Asterisk__:__604259__:__PLEXIN C1; PLXNC1__:__VIRUS-ENCODED SEMAPHORIN PROTEIN RECEPTOR; VESPR__:__
Asterisk__:__604260__:__SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5B; STAT5B__:____:__STAT5B/RARA FUSION GENE, INCLUDED
Asterisk__:__604261__:__AUTOPHAGY 5, S. CEREVISIAE, HOMOLOG OF; ATG5__:__APG5, S. CEREVISIAE, HOMOLOG OF; APG5;; APG5-LIKE; APG5L;; APOPTOSIS-SPECIFIC PROTEIN; ASP__:__
Asterisk__:__604262__:__AMYLOID BETA A4 PRECURSOR PROTEIN-BINDING, FAMILY A, MEMBER 3; APBA3__:__X11-LIKE 2; X11L2;; MUNC18-1-INTERACTING PROTEIN 3, RAT, HOMOLOG OF;; MINT3, RAT, HOMOLOG OF__:__
Asterisk__:__604263__:__PRION GENE COMPLEX, DOWNSTREAM; PRND__:__DOWNSTREAM, PRION-LIKE; DPL;; DOPPEL__:__
Asterisk__:__604264__:__CADHERIN EGF LAG SEVEN-PASS G-TYPE RECEPTOR 3; CELSR3__:__EPIDERMAL GROWTH FACTOR-LIKE 1; EGFL1;; MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 2; MEGF2;; FLAMINGO, DROSOPHILA, HOMOLOG OF, 1; FMI1__:__
Asterisk__:__604265__:__CADHERIN EGF LAG SEVEN-PASS G-TYPE RECEPTOR 2; CELSR2__:__EPIDERMAL GROWTH FACTOR-LIKE 2; EGFL2;; MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 3; MEGF3__:__
Asterisk__:__604266__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 6; MEGF6__:__EPIDERMAL GROWTH FACTOR-LIKE 3, FORMERLY; EGFL3, FORMERLY__:__
Asterisk__:__604267__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 8; MEGF8__:__EPIDERMAL GROWTH FACTOR-LIKE 4, FORMERLY; EGFL4, FORMERLY__:__
Asterisk__:__604268__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 9; MEGF9__:__EPIDERMAL GROWTH FACTOR-LIKE 5, FORMERLY; EGFL5, FORMERLY__:__
Asterisk__:__604269__:__FAT TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 2; FAT2__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 1; MEGF1__:__
Asterisk__:__604270__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4; LRP4__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 7; MEGF7__:__
Number Sign__:__604271__:__GROWTH HORMONE INSENSITIVITY, PARTIAL; GHIP__:____:__INCREASED RESPONSIVENESS TO GROWTH HORMONE, INCLUDED
Asterisk__:__604272__:__SCO2 CYTOCHROME c OXIDASE ASSEMBLY PROTEIN; SCO2__:__SCO2, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__604273__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 1; MC5DN1__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATPAF2 TYPE__:__
Asterisk__:__604274__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 1; KLRA1__:__LY49, MOUSE, HOMOLOG OF;; LY49L__:__
Asterisk__:__604275__:__CATENIN, DELTA-2; CTNND2__:__NEURAL PLAKOPHILIN-RELATED ARMADILLO-REPEAT PROTEIN; NPRAP;; CATENIN, DELTA__:__
Asterisk__:__604276__:__PLAKOPHILIN 4; PKP4__:__p0071__:__
Asterisk__:__604277__:__SPASTIN; SPAST__:__SPG4 GENE; SPG4__:__
Number Sign__:__604278__:__RENAL TUBULAR ACIDOSIS, PROXIMAL, WITH OCULAR ABNORMALITIES AND MENTAL RETARDATION__:__RTA, PROXIMAL, AUTOSOMAL RECESSIVE__:__
Asterisk__:__604279__:__JUNCTION-MEDIATING AND REGULATORY PROTEIN; JMY__:__JMY__:__
Asterisk__:__604280__:__PLEXIN A4; PLXNA4__:____:__
Asterisk__:__604281__:__DBF4, S. CEREVISIAE, HOMOLOG OF; DBF4__:__DBF4A;; ACTIVATOR OF S-PHASE KINASE; ASK;; DUMBBELL FORMER 4, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__604282__:__PLEXIN D1; PLXND1__:____:__
Asterisk__:__604283__:__PROTEOGLYCAN 4; PRG4__:__MEGAKARYOCYTE-STIMULATING FACTOR; MSF;; CACP GENE; CACP;; SUPERFICIAL ZONE PROTEIN; SZP__:__HEMANGIOPOIETIN, INCLUDED; HAPO, INCLUDED;; LUBRICIN, INCLUDED
Caret__:__604284__:__MOVED TO 137920__:____:__
Asterisk__:__604285__:__ALANINE-GLYOXYLATE AMINOTRANSFERASE; AGXT__:__AGXT1;; AGT;; SERINE-PYRUVATE AMINOTRANSFERASE; SPT; SPAT__:__
Number Sign__:__604286__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 4; LGMDR4__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2E; LGMD2E__:__
NULL__:__604287__:__CARNEY TRIAD__:__GASTRIC LEIOMYOSARCOMA, PULMONARY CHONDROMA, AND EXTRAADRENAL PARAGANGLIOMA__:__
Percent__:__604288__:__CARDIOMYOPATHY, DILATED, 1H; CMD1H__:__CARDIOMYOPATHY, DILATED, WITH CONDUCTION DEFECT__:__
Asterisk__:__604289__:__RAD54, S. CEREVISIAE, HOMOLOG OF, B__:__RAD54B__:__
Number Sign__:__604290__:__ACERULOPLASMINEMIA__:____:__HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED
NULL__:__604291__:__ASCARIS LUMBRICOIDES INFECTION, SUSCEPTIBILITY TO__:__ASCARIASIS, SUSCEPTIBILITY TO__:__
Number Sign__:__604292__:__ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3; EEC3__:__EEC SYNDROME 3__:__
Asterisk__:__604293__:__PLEXIN B2; PLXNB2__:__MM1__:__
Asterisk__:__604294__:__VENTRAL ANTERIOR HOMEOBOX 1; VAX1__:____:__
Asterisk__:__604295__:__VENTRAL ANTERIOR HOMEOBOX 2; VAX2__:____:__
Asterisk__:__604296__:__GLYOXYLATE REDUCTASE/HYDROXYPYRUVATE REDUCTASE; GRHPR__:__GLXR__:__
Asterisk__:__604297__:__SYNAPTOJANIN 1; SYNJ1__:____:__
Asterisk__:__604298__:__SIGNAL TRANSDUCING ADAPTOR FAMILY MEMBER 1; STAP1__:__BCR DOWNSTREAM SIGNALING 1; BRDG1__:__
Asterisk__:__604299__:__ADAPTOR PROTEIN, PHOSPHOTYROSINE INTERACTION, PH DOMAIN, AND LEUCINE ZIPPER-CONTAINING PROTEIN 1; APPL1__:__ADAPTOR PROTEIN CONTAINING PH DOMAIN, PTB DOMAIN, AND LEUCINE ZIPPER MOTIF 1;; APPL;; DIP13-ALPHA;; AKT2 INTERACTOR__:__
Asterisk__:__604300__:__2-HYDROXYACYL-CoA LYASE 1; HACL1__:__2-HYDROXYPHYTANOYL-CoA LYASE;; 2-HPCL;; HPCL2__:__
Asterisk__:__604301__:__OCULOMEDIN; OCLM__:__TRABECULAR MESHWORK-INDUCIBLE STRETCH RESPONSE; TISR__:__
Number Sign__:__604302__:__RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE__:__SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS__:__
Asterisk__:__604303__:__ACTIN-LIKE 7A; ACTL7A__:____:__
Asterisk__:__604304__:__ACTIN-LIKE 7B; ACTL7B__:____:__
Asterisk__:__604305__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DQ BETA-1; HLA-DQB1__:____:__
Asterisk__:__604306__:__FAS APOPTOTIC INHIBITORY MOLECULE 2; FAIM2__:__LIFEGUARD; LFG;; NEUROMEMBRANE PROTEIN 35; NMP35__:__
Number Sign__:__604307__:__CATARACT 2, MULTIPLE TYPES; CTRCT2__:__CATARACT 2, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, COPPOCK-LIKE; CCL__:__
Number Sign__:__604308__:__MASS SYNDROME__:__MASS PHENOTYPE;; OVERLAP CONNECTIVE TISSUE DISEASE; OCTD__:__
Asterisk__:__604309__:__SOLUTE CARRIER FAMILY 13 (SODIUM-DEPENDENT DICARBOXYLATE TRANSPORTER), MEMBER 4; SLC13A4__:__SULFATE TRANSPORTER 1; SUT1__:__
Asterisk__:__604310__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 6; BLOC1S6__:__BLOC1, SUBUNIT 6; BLOS6;; PALLIDIN; PLDN;; PA;; PALLID, MOUSE, HOMOLOG OF;; HPS9 GENE; HPS9__:__
Asterisk__:__604311__:__MEDIATOR COMPLEX SUBUNIT 1; MED1__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-BINDING PROTEIN; PPARBP;; PPAR-BINDING PROTEIN; PBP;; COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 1; CRSP1;; CRSP, 200-KD SUBUNIT; CRSP200;; THYROID HORMONE RECEPTOR INTERACTOR 2; TRIP2;; TRAP220;; RECOGNIZED BY PAb1801 MONOCLONAL ANTIBODY; RB18A;; VITAMIN D RECEPTOR-INTERACTING PROTEIN, 230-KD; DRIP230;; VITAMIN D RECEPTOR-INTERACTING PROTEIN, 205-KD; DRIP205__:__
Asterisk__:__604312__:__CYSTATIN 3; CST3__:__CYSTATIN C;; GAMMA-TRACE__:__
Asterisk__:__604313__:__GALACTOKINASE 1; GALK1__:__GALK;; GK1__:__
Percent__:__604314__:__BLEPHAROPHIMOSIS WITH FACIAL AND GENITAL ANOMALIES AND MENTAL RETARDATION__:__BLEPHAROPHIMOSIS-MENTAL RETARDATION SYNDROME, VERLOES TYPE__:__
NULL__:__604315__:__ANEMIA, CONGENITAL HYPOPLASTIC, WITH MULTIPLE CONGENITAL ANOMALIES/MENTAL RETARDATION SYNDROME__:____:__
Percent__:__604316__:__PSORIASIS 5, SUSCEPTIBILITY TO; PSORS5__:____:__
Number Sign__:__604317__:__MICROCEPHALY 2, PRIMARY, AUTOSOMAL RECESSIVE, WITH OR WITHOUT CORTICAL MALFORMATIONS; MCPH2__:____:__
Asterisk__:__604318__:__GTF2I REPEAT DOMAIN-CONTAINING PROTEIN 1; GTF2IRD1__:__GENERAL TRANSCRIPTION FACTOR II-I REPEAT DOMAIN-CONTAINING PROTEIN 1;; GENERAL TRANSCRIPTION FACTOR III; GTF3;; MUSCLE TFII-I REPEAT DOMAIN-CONTAINING PROTEIN 1; MUSTRD1;; WBSCR11;; BINDING FACTOR FOR EARLY ENHANCER; BEN__:__
Asterisk__:__604319__:__TRF1-INTERACTING NUCLEAR FACTOR 2; TINF2__:__TIN2__:__
Number Sign__:__604320__:__SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 1; DSMA1__:__SPINAL MUSCULAR ATROPHY WITH RESPIRATORY DISTRESS 1; SMARD1;; NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VI; DHMN6;; HMN6;; HMN VI;; SEVERE INFANTILE AXONAL NEUROPATHY WITH RESPIRATORY FAILURE; SIANRF;; NEURONOPATHY, SEVERE INFANTILE AXONAL, WITH RESPIRATORY FAILURE;; SPINAL MUSCULAR ATROPHY, DIAPHRAGMATIC__:__
Number Sign__:__604321__:__MICROCEPHALY 4, PRIMARY, AUTOSOMAL RECESSIVE; MCPH4__:____:__
Asterisk__:__604322__:__SOLUTE CARRIER FAMILY 17 (ACIDIC SUGAR TRANSPORTER), MEMBER 5; SLC17A5__:__SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 5;; SIALIN__:__
Asterisk__:__604323__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 3; ABCC3__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; MRP3;; CANALICULAR MULTISPECIFIC ORGANIC ANION TRANSPORTER 2; CMOAT2__:__
NULL__:__604324__:__ACNE, ADULT__:____:__
Asterisk__:__604325__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B, BETA; PPP2R2B__:__PP2APR55-BETA;; PP2AB55-BETA;; PP2AB-BETA;; PR55-BETA;; B55-BETA__:__
Number Sign__:__604326__:__SPINOCEREBELLAR ATAXIA 12; SCA12__:____:__
Asterisk__:__604327__:__BETA-1,4-GALACTOSYLTRANSFERASE 7; B4GALT7__:__XYLOSYLPROTEIN 4-BETA-GALACTOSYLTRANSFERASE, POLYPEPTIDE 7;; XGPT1; XGALT1;; GALACTOSYLTRANSFERASE I__:__
Asterisk__:__604328__:__STRUCTURE-SPECIFIC RECOGNITION PROTEIN 1; SSRP1__:__CHROMATIN-SPECIFIC TRANSCRIPTION ELONGATION FACTOR, 80-KD SUBUNIT;; FACT, 80-KD SUBUNIT__:__
Percent__:__604329__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 2__:__HYT2__:__
Asterisk__:__604330__:__GRB2-RELATED ADAPTOR PROTEIN; GRAP__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2-RELATED ADAPTOR PROTEIN__:__
Asterisk__:__604331__:__INTEGRATOR COMPLEX SUBUNIT 6; INTS6__:__DEAD/H BOX 26; DDX26;; DELETED IN CANCER 1; DICE1;; INT6__:__
Asterisk__:__604332__:__CYSTEINE-RICH HYDROPHOBIC DOMAIN PROTEIN 2; CHIC2__:__BRX-LIKE GENE TRANSLOCATED IN LEUKEMIA; BTL__:__BTL/ETV6 FUSION GENE, INCLUDED
Asterisk__:__604333__:__WD40 REPEAT-CONTAINING PROTEIN CIAO1; CIAO1__:__WD REPEAT-CONTAINING PROTEIN 39; WDR39__:__
Asterisk__:__604334__:__UBIQUITIN-SPECIFIC PROTEASE 6; USP6__:__TRE2 ONCOGENE; TRE2__:__
NULL__:__604335__:__REFLEX SYMPATHETIC DYSTROPHY__:____:__
Asterisk__:__604336__:__TRANSMEMBRANE PHOSPHATASE WITH TENSIN HOMOLOGY; TPTE__:____:__
Asterisk__:__604337__:__CHLORIDE CHANNEL ACCESSORY 3, PSEUDOGENE; CLCA3P__:__CHLORIDE CHANNEL, CALCIUM-ACTIVATED, 3; CLCA3__:__
Caret__:__604338__:__REMOVED FROM DATABASE__:____:__
Caret__:__604339__:__REMOVED FROM DATABASE__:____:__
Caret__:__604340__:__REMOVED FROM DATABASE__:____:__
Caret__:__604341__:__REMOVED FROM DATABASE__:____:__
Caret__:__604342__:__REMOVED FROM DATABASE__:____:__
Caret__:__604343__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__604344__:__MANNOSIDASE, ALPHA, CLASS 1A, MEMBER 1; MAN1A1__:____:__
Asterisk__:__604345__:__MANNOSIDASE, ALPHA, CLASS 1A, MEMBER 2; MAN1A2__:____:__
Asterisk__:__604346__:__MANNOSIDASE, ALPHA, CLASS 1B, MEMBER 1; MAN1B1__:____:__
Asterisk__:__604347__:__ZINC FINGER RANBP2-TYPE DOMAIN-CONTAINING PROTEIN 2; ZRANB2__:__ZINC FINGER RAN-BINDING DOMAIN-CONTAINING PROTEIN 2;; ZINC FINGER PROTEIN 265; ZNF265;; ZINC FINGER, SPLICING; ZIS__:__
Number Sign__:__604348__:__ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 1; FASPS1__:____:__
Asterisk__:__604349__:__LAMININ, GAMMA-3; LAMC3__:____:__
Asterisk__:__604350__:__RAS-ASSOCIATED PROTEIN RAB3D; RAB3D__:__GLIOBLASTOMA OVEREXPRESSED; GOV__:__
Asterisk__:__604351__:__PHD FINGER PROTEIN 2; PHF2__:____:__
Number Sign__:__604352__:__FEBRILE SEIZURES, FAMILIAL, 4; FEB4__:__CONVULSIONS, FAMILIAL FEBRILE, 4__:__
Asterisk__:__604353__:__CYSTEINE- AND HISTIDINE-RICH DOMAIN-CONTAINING PROTEIN 1; CHORDC1__:__CHORD DOMAIN-CONTAINING PROTEIN 1; CHP1__:__
Asterisk__:__604354__:__NUCLEAR FMRP-INTERACTING PROTEIN 1; NUFIP1__:__NUCLEAR FMRP-INTERACTING PROTEIN; NUFIP__:__
Asterisk__:__604355__:__COATOMER PROTEIN COMPLEX, SUBUNIT GAMMA-2; COPG2__:__COAT PROTEIN, NONCLATHRIN, GAMMA-2__:__
Number Sign__:__604356__:__DUANE RETRACTION SYNDROME 2; DURS2__:____:__
Asterisk__:__604357__:__MAB21, C. ELEGANS, HOMOLOG-LIKE 2; MAB21L2__:____:__
Asterisk__:__604358__:__STROMAL ANTIGEN 1; STAG1__:__COHESIN SUBUNIT SA1__:__
Caret__:__604359__:__MOVED TO 300826__:____:__
Number Sign__:__604360__:__SPASTIC PARAPLEGIA 11, AUTOSOMAL RECESSIVE; SPG11__:__SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, WITH MENTAL IMPAIRMENT AND THIN CORPUS CALLOSUM;; SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, COMPLICATED, WITH THIN CORPUS CALLOSUM;; HSP-TCC__:__
Caret__:__604361__:__MOVED TO 600638__:____:__
Asterisk__:__604362__:__LIM DOMAIN ONLY 7; LMO7__:__F-BOX ONLY PROTEIN 20; FBXO20;; FBX20;; KIAA0858__:__
NULL__:__604363__:__MYOCLONIC EPILEPSY, CONGENITAL DEAFNESS, MACULAR DYSTROPHY, AND PSYCHIATRIC DISORDERS__:____:__
Number Sign__:__604364__:__EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 1; FFEVF1__:__EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI; FFEVF;; EPILEPSY, PARTIAL, WITH VARIABLE FOCI; FPEVF__:__
Asterisk__:__604365__:__PROMININ 1; PROM1__:__PROMININ, MOUSE, HOMOLOG-LIKE 1; PROML1;; AC133;; CD133 ANTIGEN; CD133__:__
Asterisk__:__604366__:__DYNEIN, AXONEMAL, INTERMEDIATE CHAIN 1; DNAI1__:____:__
Number Sign__:__604367__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 3; FPLD3__:__LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH PPARG MUTATIONS__:__
Asterisk__:__604368__:__GLYCOPROTEIN NMB; GPNMB__:__NMB__:__
Number Sign__:__604369__:__SALLA DISEASE; SD__:__SIALURIA, FINNISH TYPE__:__
Number Sign__:__604370__:__BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1__:____:__BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED;; OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1, INCLUDED
Asterisk__:__604371__:__HUMAN ENDOGENOUS RETROVIRUS-H LONG TERMINAL REPEAT-ASSOCIATING 2; HHLA2__:__HERV-H LTR-ASSOCIATING 2;; B7 HOMOLOG 5; B7H5;; B7 HOMOLOG 7; B7H7__:__
Asterisk__:__604372__:__HUMAN ENDOGENOUS RETROVIRUS-H LONG TERMINAL REPEAT-ASSOCIATING 3; HHLA3__:__HERV-H LTR-ASSOCIATING 3__:__
Plus__:__604373__:__CHECKPOINT KINASE 2, S. POMBE, HOMOLOG OF; CHEK2__:__CHK2;; RAD53, S. CEREVISIAE, HOMOLOG OF; RAD53;; CDS1, S. POMBE, HOMOLOG OF__:__BREAST AND COLORECTAL CANCER, SUSCEPTIBILITY TO, INCLUDED;; HBCC, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__604374__:__METALLOTHIONEIN-LIKE 5, TESTIS-SPECIFIC; MTL5__:__TESTIS-SPECIFIC METALLOTHIONEIN-LIKE PROTEIN; TESMIN__:__
Asterisk__:__604375__:__HUMAN GROWTH FACTOR-REGULATED TYROSINE KINASE SUBSTRATE; HGS__:__HEPATOCYTE GROWTH FACTOR-REGULATED TYROSINE KINASE SUBSTRATE; HRS;; HGF-REGULATED TYROSINE KINASE SUBSTRATE__:__
Asterisk__:__604376__:__MYELIN PROTEIN ZERO-LIKE 1; MPZL1__:__PROTEIN ZERO-RELATED; PZR__:__
Number Sign__:__604377__:__CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 1; CEMCOX1__:__CYTOCHROME c OXIDASE DEFICIENCY, FATAL INFANTILE, WITH CARDIOENCEPHALOMYOPATHY__:__
Asterisk__:__604378__:__BECLIN 1; BECN1__:____:__
Number Sign__:__604379__:__HYPOTRICHOSIS 7; HYPT7__:__HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 2; LAH2;; HYPOTRICHOSIS, AUTOSOMAL RECESSIVE; AH;; HYPOTRICHOSIS, TOTAL, MARI TYPE__:__WOOLLY HAIR, AUTOSOMAL RECESSIVE 2, WITH OR WITHOUT HYPOTRICHOSIS, INCLUDED; ARWH2, INCLUDED;; WH/HT, INCLUDED
NULL__:__604380__:__ULNAR RAY DYSGENESIS WITH POSTAXIAL POLYDACTYLY AND RENAL CYSTIC DYSPLASIA__:____:__
NULL__:__604381__:__PATENT DUCTUS ARTERIOSUS AND BICUSPID AORTIC VALVE WITH HAND ANOMALIES__:____:__
NULL__:__604382__:__LISSENCEPHALY, FAMILIAL, WITH CLEFT PALATE AND CEREBELLAR HYPOPLASIA__:____:__
Asterisk__:__604383__:__GROWTH FACTOR-INDEPENDENT 1B; GFI1B__:____:__
Asterisk__:__604384__:__ATPase, Ca(2+)-TRANSPORTING, TYPE 2C, MEMBER 1; ATP2C1__:__ATPase, Ca(2+)-SEQUESTERING;; SECRETORY PATHWAY Ca(2+) ATPase 1; SPCA1;; PMR1, RAT, HOMOLOG OF;; KIAA1347__:__
Asterisk__:__604385__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE XI, ALPHA SUBUNIT; SCN11A__:__NAV1.9__:__
Asterisk__:__604386__:__ZINC FINGER TRANSCRIPTION FACTOR TRPS1; TRPS1__:__TRPS1 GENE__:__
Number Sign__:__604387__:__NEPHRONOPHTHISIS 3; NPHP3__:__NPH3__:__
Asterisk__:__604388__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-4; GNG4__:____:__
Asterisk__:__604389__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-10; GNG10__:____:__
Asterisk__:__604390__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-11; GNG11__:____:__
Number Sign__:__604391__:__ATAXIA-TELANGIECTASIA-LIKE DISORDER 1; ATLD1__:__ATLD__:__
Asterisk__:__604392__:__ARYLHYDROCARBON-INTERACTING RECEPTOR PROTEIN-LIKE 1; AIPL1__:____:__
Number Sign__:__604393__:__LEBER CONGENITAL AMAUROSIS 4; LCA4__:____:__RETINITIS PIGMENTOSA, JUVENILE, AIPL1-RELATED, INCLUDED;; CONE-ROD DYSTROPHY, AIPL1-RELATED, INCLUDED
Asterisk__:__604394__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-12; GNA12__:____:__
Asterisk__:__604395__:__MutL, E. COLI, HOMOLOG OF, 3; MLH3__:____:__
Asterisk__:__604396__:__SET DOMAIN PROTEIN, BIFURCATED, 1; SETDB1__:__ERG-ASSOCIATED PROTEIN WITH SET DOMAIN; ESET;; KIAA0067__:__
Asterisk__:__604397__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-14; GNA14__:____:__
Asterisk__:__604398__:__SECRETOGLOBIN, FAMILY 2A, MEMBER 1; SCGB2A1__:__MAMMAGLOBIN 2; MGB2;; MAMMAGLOBIN B;; LACRYGLOBIN;; LIPOPHILIN C; LPNC__:__
Asterisk__:__604399__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 1B; PPP1R1B__:__DOPAMINE- AND cAMP-REGULATED PHOSPHOPROTEIN, 32-KD; DARPP32__:__
Number Sign__:__604400__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 5; ARVD5__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 5; ARVC5__:__
Percent__:__604401__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 6; ARVD6__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 6; ARVC6__:__
Asterisk__:__604402__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 5; ST3GAL5__:__SIALYLTRANSFERASE 9; SIAT9;; CMP-NeuAc:LACTOSYLCERAMIDE ALPHA-2,3-SIALYLTRANSFERASE;; ALPHA-2,3-SIALYLTRANSFERASE V; ST3GALV;; GM3 SYNTHASE;; SATI__:__
Number Sign__:__604403__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2; GEFSP2__:__GEFS+, TYPE 2; GEFS+2__:__FEBRILE SEIZURES, FAMILIAL, 3A, INCLUDED; FEB3A, INCLUDED
Asterisk__:__604404__:__GLYPICAN 6; GPC6__:____:__
Asterisk__:__604405__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 6; SIGLEC6__:__CD33 ANTIGEN-LIKE; CD33L;; CD33 ANTIGEN-LIKE 1; CD33L1;; OB-BINDING PROTEIN 1; OBBP1__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 6, MEMBRANE-BOUND, INCLUDED;; CD33 ANTIGEN-LIKE, MEMBRANE-BOUND, INCLUDED;; SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 6, SOLUBLE, INCLUDED;; CD33 ANTIGEN-LIKE, SOLUBLE, INCLUDED
Asterisk__:__604406__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-13; GNA13__:__G-ALPHA-13__:__
Asterisk__:__604407__:__LEUCINE ZIPPER/EF-HAND-CONTAINING TRANSMEMBRANE PROTEIN 1; LETM1__:____:__
Caret__:__604408__:__MOVED TO 600610__:____:__
Asterisk__:__604409__:__GLUCOCORTICOID MODULATORY ELEMENT-BINDING PROTEIN 1; GMEB1__:__PARVOVIRUS INITIATION FACTOR, p96 SUBUNIT__:__
Asterisk__:__604410__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 7; SIGLEC7__:__ADHESION INHIBITORY RECEPTOR MOLECULE 1; AIRM1;; p75__:__
Asterisk__:__604411__:__INNER CENTROMERE PROTEIN; INCENP__:____:__
Asterisk__:__604412__:__T-CELL LEUKEMIA/LYMPHOMA 6; TCL6__:__TCL1-NEIGHBORING GENE 1; TNG1;; TCL1-NEIGHBORING GENE 2; TNG2__:__
Caret__:__604413__:__MOVED TO 604412__:____:__
Asterisk__:__604414__:__POLYMERASE II, RNA, SUBUNIT F; POLR2F__:__RPB6, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 14.4-KD SUBUNIT__:__
Asterisk__:__604415__:__SIX-TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE; STEAP__:__STEAP1__:__
Number Sign__:__604416__:__PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE__:__PAPA SYNDROME; PAPAS;; FAMILIAL RECURRENT ARTHRITIS; FRA__:__
Asterisk__:__604417__:__AF4/FMR2 FAMILY, MEMBER 4; AFF4__:__ALL1-FUSED GENE FROM CHROMOSOME 5q31; AF5Q31__:__
Asterisk__:__604418__:__GAP JUNCTION PROTEIN, BETA-6; GJB6__:__CONNEXIN 30; CX30__:__
Asterisk__:__604419__:__POLYMERASE, DNA, THETA; POLQ__:____:__
Asterisk__:__604420__:__HEMATOPOIETICALLY EXPRESSED HOMEOBOX; HHEX__:__PRHX; PRH__:__
Asterisk__:__604421__:__PHOSDUCIN-LIKE; PDCL__:____:__
Asterisk__:__604422__:__PANCREATIC LIPASE-RELATED PROTEIN 1; PNLIPRP1__:__PLRP1__:__
Asterisk__:__604423__:__PANCREATIC LIPASE-RELATED PROTEIN 2; PNLIPRP2__:__PLRP2__:__
Asterisk__:__604424__:__HOMEODOMAIN-INTERACTING PROTEIN KINASE 3; HIPK3__:__PKY;; DYRK6;; FAS-INTERACTING SERINE/THREONINE PROTEIN KINASE; FIST__:__
Asterisk__:__604425__:__LIM HOMEOBOX GENE 8; LHX8__:__LHX7__:__
Asterisk__:__604426__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 2; CYP4F2__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 2;; LEUKOTRIENE B4 OMEGA-HYDROXYLASE, LIVER;; LTB4 OMEGA-HYDROXYLASE, LIVER__:__
Asterisk__:__604427__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE X, ALPHA SUBUNIT; SCN10A__:__NAV1.8;; PN3;; SENSORY NEURON-SPECIFIC SODIUM CHANNEL; SNS__:__
Caret__:__604428__:__MOVED TO 300935__:____:__
Asterisk__:__604429__:__PROLINE-RICH GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 2; PRRG2__:__PROLINE-RICH GLA PROTEIN 2; PRGP2__:__
Asterisk__:__604430__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-7; GNG7__:____:__
Percent__:__604431__:__POLYNEUROPATHY, LETHAL NEONATAL, AXONAL SENSORIMOTOR, AUTOSOMAL RECESSIVE__:____:__
Number Sign__:__604432__:__SPINOCEREBELLAR ATAXIA 11; SCA11__:____:__
Asterisk__:__604433__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 3; KCNE3__:__MINIMUM POTASSIUM ION CHANNEL-RELATED PEPTIDE 2; MIRP2;; MINK-RELATED PEPTIDE 2__:__
Asterisk__:__604434__:__KALLIKREIN-RELATED PEPTIDASE 11; KLK11__:__KALLIKREIN 11;; PROTEASE, SERINE, 20; PRSS20;; TRYPSIN-LIKE SERINE PROTEASE; TLSP__:__
Caret__:__604435__:__MOVED TO 164010__:____:__
Asterisk__:__604436__:__PROLINE SYNTHETASE COTRANSCRIBED, BACTERIA, HOMOLOG OF; PROSC__:____:__
Asterisk__:__604437__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 3; SLC38A3__:__TRANSPORT SYSTEM N, PROTEIN 1; SN1;; G17;; N-SYSTEM AMINO ACID TRANSPORTER 1; NAT1__:__
Asterisk__:__604438__:__KALLIKREIN-RELATED PEPTIDASE 7; KLK7__:__KALLIKREIN 7;; PROTEASE, SERINE, 6; PRSS6;; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; SCCE__:__
Asterisk__:__604439__:__GRB2-ASSOCIATED BINDING PROTEIN 1; GAB1__:____:__
Asterisk__:__604440__:__CELL DEATH-INDUCING DFFA-LIKE EFFECTOR A; CIDEA__:____:__
Asterisk__:__604441__:__CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B; CIDEB__:____:__
Caret__:__604442__:__MOVED TO 144700__:____:__
Asterisk__:__604443__:__ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 6; ACSL6__:__FATTY ACID CoA LIGASE, LONG CHAIN 6; FACL6;; LONG CHAIN ACYL-CoA SYNTHETASE 2; LACS2;; LONG CHAIN ACYL-CoA SYNTHETASE 5; LACS5;; ACYL-CoA SYNTHETASE 2; ACS2;; KIAA0837__:__ACS2/ETV6 FUSION GENE, INCLUDED
Asterisk__:__604444__:__BMP AND ACTIVIN MEMBRANE-BOUND INHIBITOR, XENOPUS, HOMOLOG OF; BAMBI__:__NEUROMEDIN A; NMA__:__
Asterisk__:__604445__:__PROTEASE INHIBITOR 13; PI13__:__SERINE PROTEASE INHIBITOR, CLADE B, MEMBER 13; SERPINB13;; HURPIN;; HEADPIN__:__
Asterisk__:__604446__:__PHOSPHOTRIESTERASE-RELATED PROTEIN; PTER__:____:__
Asterisk__:__604447__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-5; GNB5__:__GB5__:__
Asterisk__:__604448__:__CYTOHESIN 1-INTERACTING PROTEIN; CYTIP__:__CYTH1-INTERACTING PROTEIN;; PLECKSTRIN HOMOLOGY, SEC7, AND COILED-COIL DOMAINS PROTEIN-BINDING PROTEIN; PSCDBP;; CYTOHESIN-BINDING PROTEIN; HE;; CYTOHESIN BINDER AND REGULATOR; CYBR__:__
Asterisk__:__604449__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 11; PSMD11__:__PROTEASE 26S, SUBUNIT 9; S9;; p44.5__:__
Asterisk__:__604450__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 12; PSMD12__:__p55;; RPN5__:__
NULL__:__604451__:__BASAL CELL CARCINOMA, INFUNDIBULOCYSTIC__:__BASAL CELL CARCINOMA WITH FOLLICULAR DIFFERENTIATION__:__
Asterisk__:__604452__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 5; PSMD5__:__PROTEASE 26S, SUBUNIT 5B; S5B__:__
Asterisk__:__604453__:__NUCLEAR RECEPTOR SUBFAMILY 5, GROUP A, MEMBER 2; NR5A2__:__FETOPROTEIN TRANSCRIPTION FACTOR; FTF;; HUMAN B1-BINDING FACTOR; HB1F;; CYP7A PROMOTER-BINDING FACTOR; CPF;; LIVER RECEPTOR HOMOLOG 1; LRH1__:__
Number Sign__:__604454__:__WELANDER DISTAL MYOPATHY; WDM__:__MUSCULAR DYSTROPHY, DISTAL, LATE-ONSET, AUTOSOMAL DOMINANT;; MYOPATHY, DISTAL, SWEDISH__:__
Asterisk__:__604455__:__SARCOSINE DEHYDROGENASE; SARDH__:__SDH__:__
Asterisk__:__604456__:__INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 1; IFITM1__:__INTERFERON-INDUCED PROTEIN 17; IFI17;; LEU13;; CD225__:__
Asterisk__:__604457__:__NUCLEAR BODY PROTEIN SP110; SP110__:__SPECKLED, 110-KD;; INTRACELLULAR PATHOGEN RESISTANCE 1, MOUSE, HOMOLOG OF; IPR1__:__INTERFERON-INDUCED PROTEIN 41, INCLUDED; IFI41, INCLUDED;; INTERFERON-INDUCED PROTEIN 75, INCLUDED; IFI75, INCLUDED
Caret__:__604458__:__MOVED TO 604457__:____:__
Asterisk__:__604459__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 3; IRAK3__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE M; IRAKM__:__
Asterisk__:__604460__:__FAS-ASSOCIATED FACTOR 1; FAF1__:__HFAF1__:__
Asterisk__:__604461__:__HUMAN PAPILLOMAVIRUS TYPE 6A INTEGRATION SITE 1; HPV6AI1__:____:__
Asterisk__:__604462__:__SEMAPHORIN 4C; SEMA4C__:__SEMAPHORIN F; SEMAF;; KIAA1739__:__
Asterisk__:__604463__:__CD160 ANTIGEN; CD160__:__NATURAL KILLER CELL RECEPTOR BY55; BY55__:__
Asterisk__:__604464__:__INTERSECTIN 2; ITSN2__:__SH3 DOMAIN PROTEIN 1B; SH3D1B;; SWA;; KIAA1256__:__
Asterisk__:__604465__:__SH3 DOMAIN, GRB2-LIKE, 2; SH3GL2__:__SH3p4;; ENDOPHILIN 1;; ENDOPHILIN A1__:__
Asterisk__:__604466__:__METHYLTRANSFERASE-LIKE 1; METTL1__:____:__
Asterisk__:__604467__:__MONOCYTE-TO-MACROPHAGE DIFFERENTIATION-ASSOCIATED PROTEIN; MMD__:__MMD1;; PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 11; PAQR11__:__
Asterisk__:__604468__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 6; MAP3K6__:__MAPKKK6;; APOPTOSIS SIGNAL-REGULATING KINASE 2; ASK2__:__
Asterisk__:__604469__:__EXOCYST COMPLEX COMPONENT 5; EXOC5__:__SEC10, S. CEREVISIAE, HOMOLOG OF;; SEC10-LIKE 1; SEC10L1__:__
Asterisk__:__604470__:__CD2 ANTIGEN-BINDING PROTEIN 2; CD2BP2__:____:__
Asterisk__:__604471__:__SOLUTE CARRIER FAMILY 1 (GLUTAMATE TRANSPORTER), MEMBER 7; SLC1A7__:__EXCITATORY AMINO ACID TRANSPORTER 5; EAAT5;; GLUTAMATE TRANSPORTER, RETINA__:__
Asterisk__:__604472__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 13; TNFSF13__:__APRIL;; TNF- AND APOL-RELATED LEUKOCYTE EXPRESSED LIGAND 2; TALL2__:__
Asterisk__:__604473__:__GLUTAMATE RECEPTOR, METABOTROPIC, 1; GRM1__:__MGLUR1;; GRM1-ALPHA; GRM1A;; MGLUR1-ALPHA; MGLUR1A__:__
NULL__:__604474__:__HUMAN HERPESVIRUS TYPE 6, INTEGRATED__:____:__
Asterisk__:__604475__:__RETICULON 4; RTN4__:__NEURITE OUTGROWTH INHIBITOR; NOGO__:__NOGOA, INCLUDED;; NOGOB, INCLUDED;; NOGOC, INCLUDED;; NEURITE GROWTH INHIBITOR 220, INCLUDED; NI220, INCLUDED;; NI220/250, INCLUDED
Caret__:__604476__:__MOVED TO 604350__:____:__
Asterisk__:__604477__:__CHROMOBOX HOMOLOG 3; CBX3__:__HP1, DROSOPHILA, HOMOLOG OF, GAMMA;; HP1-GAMMA__:__
Asterisk__:__604478__:__CHROMOBOX HOMOLOG 5; CBX5__:__HP1, DROSOPHILA, HOMOLOG OF, ALPHA;; HP1-ALPHA;; HETEROCHROMATIN PROTEIN 1; HP1__:__
Asterisk__:__604479__:__SIRTUIN 1; SIRT1__:__SIR2, S. CEREVISIAE, HOMOLOG-LIKE 1; SIR2L1;; SIR2-ALPHA;; HST2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__604480__:__SIRTUIN 2; SIRT2__:__SIR2, S. CEREVISIAE, HOMOLOG-LIKE 2; SIR2L2;; SIR2L__:__
Asterisk__:__604481__:__SIRTUIN 3; SIRT3__:__SIR2, S. CEREVISIAE, HOMOLOG-LIKE 3; SIR2L3__:__
Asterisk__:__604482__:__SIRTUIN 4; SIRT4__:__SIR2-LIKE 4; SIR2L4__:__
Asterisk__:__604483__:__SIRTUIN 5; SIRT5__:__SIR2, S. CEREVISIAE, HOMOLOG-LIKE 5; SIR2L5__:__
Number Sign__:__604484__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, OKINAWA TYPE; HMSNO__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY, PROXIMAL TYPE, FORMERLY; HMSNP, FORMERLY__:__
Asterisk__:__604485__:__NUCLEAR RECEPTOR SUBFAMILY 2, GROUP E, MEMBER 3; NR2E3__:__PHOTORECEPTOR-SPECIFIC NUCLEAR RECEPTOR; PNR__:__
Asterisk__:__604486__:__PEPTIDYL-PROLYL CIS/TRANS ISOMERASE, MITOCHONDRIAL; PPIF__:__CYCLOPHILIN 3; CYP3;; CYCLOPHILIN F__:__
Asterisk__:__604487__:__OTOGELIN; OTOG__:__OTGN__:__
Asterisk__:__604488__:__TITIN-CAP; TCAP__:__TELETHONIN__:__
Asterisk__:__604489__:__ALPHA-METHYLACYL-CoA RACEMASE; AMACR__:____:__
Asterisk__:__604490__:__SACSIN; SACS__:____:__
Asterisk__:__604491__:__CAS-BR-M MURINE ECOTROPIC RETROVIRAL TRANSFORMING SEQUENCE B; CBLB__:____:__
Asterisk__:__604492__:__VOLTAGE-DEPENDENT ANION CHANNEL 1; VDAC1__:__PORIN;; OMP2, YEAST, HUMAN COMPLEMENT OF__:__
Asterisk__:__604493__:__GAP JUNCTION PROTEIN, BETA-5; GJB5__:__CONNEXIN 31.1; CX31.1__:__
Asterisk__:__604494__:__INTERLEUKIN 18 RECEPTOR 1; IL18R1__:__INTERLEUKIN 18 RECEPTOR, ALPHA CHAIN; IL18RA;; IL1 RECEPTOR-RELATED PROTEIN; IL1RRP__:__
Asterisk__:__604495__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, BETA; NFKBIB__:__INHIBITOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS, BETA;; I-KAPPA-B-BETA; IKBB;; THYROID HORMONE RECEPTOR INTERACTOR 9; TRIP9__:__
Asterisk__:__604496__:__NFKB INHIBITOR-INTERACTING RAS-LIKE PROTEIN 1; NKIRAS1__:__I-KAPPA-B-INTERACTING RAS-LIKE PROTEIN 1;; KAPPA-B-RAS1;; KBRAS1__:__
Asterisk__:__604497__:__NFKB INHIBITOR-INTERACTING RAS-LIKE PROTEIN 2; NKIRAS2__:__I-KAPPA-B-INTERACTING RAS-LIKE PROTEIN 2;; KAPPA-B-RAS2;; KBRAS2__:__
Number Sign__:__604498__:__AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL; CAMT__:____:__
Percent__:__604499__:__HYPERLIPIDEMIA, COMBINED, 2__:__HYPLIP2;; HYPERLIPIDEMIA, FAMILIAL COMBINED, 2; FCHL2__:__
Asterisk__:__604500__:__ZINC FINGER HIT DOMAIN-CONTAINING PROTEIN 3; ZNHIT3__:__HIT-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 3;; THYROID HORMONE RECEPTOR INTERACTOR 3; TRIP3__:__
Asterisk__:__604501__:__THYROID HORMONE RECEPTOR INTERACTOR 4; TRIP4__:__ACTIVATING SIGNAL COINTEGRATOR 1; ASC1__:__
Asterisk__:__604502__:__HIGH MOBILITY GROUP NUCLEOSOMAL BINDING PROTEIN 3; HMGN3__:__THYROID HORMONE RECEPTOR INTERACTOR 7; TRIP7__:__
Asterisk__:__604503__:__JUMONJI DOMAIN-CONTAINING PROTEIN 1C; JMJD1C__:__THYROID HORMONE RECEPTOR INTERACTOR 8; TRIP8;; KIAA1380__:__
Asterisk__:__604504__:__THYROID HORMONE RECEPTOR INTERACTOR 10; TRIP10__:__CDC42-INTERACTING PROTEIN 4; CIP4__:__
Asterisk__:__604505__:__THYROID HORMONE RECEPTOR INTERACTOR 11; TRIP11__:__TRIP, 230-KD; TRIP230;; CLONAL EVOLUTION-RELATED GENE ON CHROMOSOME 14; CEV14;; GOLGI-MICROTUBULE-ASSOCIATED PROTEIN, 210-KD; GMAP210__:__GOLGI-MICROTUBULE-ASSOCIATED PROTEIN, 200-KD, INCLUDED; GMAP200, INCLUDED;; CEV14/PDGFRB FUSION GENE, INCLUDED
Asterisk__:__604506__:__THYROID HORMONE RECEPTOR INTERACTOR 12; TRIP12__:__UBIQUITIN LIGASE FOR ARF; ULF__:__
Asterisk__:__604507__:__THYROID HORMONE RECEPTOR INTERACTOR 13; TRIP13__:__HUMAN PAPILLOMAVIRUS TYPE 16 E1 PROTEIN-BINDING PROTEIN; 16E1BP__:__
Asterisk__:__604508__:__COP9 SIGNALOSOME, SUBUNIT 2; COPS2__:__THYROID HORMONE RECEPTOR INTERACTOR 15; TRIP15;; SGN2;; ALIEN, DROSOPHILA, HOMOLOG OF;; CSN2__:__
Asterisk__:__604509__:__INTERLEUKIN 18 RECEPTOR ACCESSORY PROTEIN; IL18RAP__:__INTERLEUKIN 18 RECEPTOR, BETA CHAIN; IL18RB;; ACCESSORY PROTEIN-LIKE; ACPL__:__
Asterisk__:__604510__:__HYALURONOGLUCOSAMINIDASE 4; HYAL4__:____:__
Asterisk__:__604511__:__CHROMOBOX HOMOLOG 1; CBX1__:__CBX;; HP1, DROSOPHILA, HOMOLOG OF, BETA;; HP1-BETA__:__
Asterisk__:__604512__:__INTERLEUKIN 1 RECEPTOR-LIKE 2; IL1RL2__:__IL1RRP2;; INTERLEUKIN 36 RECEPTOR; IL36R IL36 RECEPTOR__:__
Asterisk__:__604513__:__CD84 ANTIGEN; CD84__:__SLAM FAMILY, MEMBER 5; SLAMF5__:__
Asterisk__:__604514__:__SH2 DOMAIN PROTEIN 2A; SH2D2A__:__T-CELL SH2 DOMAIN-CONTAINING ADAPTOR PROTEIN; TSAD__:__
Asterisk__:__604515__:__B-CELL LINKER PROTEIN; BLNK__:__SH2 DOMAIN-CONTAINING LEUKOCYTE PROTEIN, 65-KD; SLP65;; B CELL-SPECIFIC ADAPTOR PROTEIN; BASH__:__
Asterisk__:__604516__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 2; IGSF2__:__V7;; CD101__:__
Asterisk__:__604517__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, COACTIVATOR 1, ALPHA; PPARGC1A__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, COACTIVATOR 1; PPARGC1;; PPAR-GAMMA COACTIVATOR 1-ALPHA; PGC1A;; PGC1-ALPHA;; PPAR-GAMMA COACTIVATOR 1; PGC1__:__
Asterisk__:__604518__:__GRB2-RELATED ADAPTOR PROTEIN 2; GRAP2__:__GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2-RELATED ADAPTOR PROTEIN 2;; GRB2-RELATED PROTEIN WITH INSERT DOMAIN; GRID;; GADS__:__
Percent__:__604519__:__INFLAMMATORY BOWEL DISEASE 3; IBD3__:____:__
Asterisk__:__604520__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 14; TNFSF14__:__LIGHT;; HERPESVIRUS ENTRY MEDIATOR LIGAND; HVEML__:__
Asterisk__:__604521__:__3-HYDROXYANTHRANILATE 3,4-DIOXYGENASE; HAAO__:__3-HYDROXYANTHRANILIC ACID DIOXYGENASE;; 3-HAO__:__
Asterisk__:__604522__:__DEFENSIN, ALPHA, 3; DEFA3__:__DEF3;; HUMAN NEUTROPHIL PEPTIDE 3; HNP3__:__
Asterisk__:__604523__:__CADHERIN EGF LAG SEVEN-PASS G-TYPE RECEPTOR 1; CELSR1__:__FLAMINGO, DROSOPHILA, HOMOLOG OF, 2; FMI2__:__
Asterisk__:__604524__:__LYMPHOCYTE ANTIGEN 75; LY75__:__DEC205;; GP200-MR6;; CD205;; CLEC13B__:__
Asterisk__:__604525__:__HISTAMINE RECEPTOR H3; HRH3__:__G PROTEIN-COUPLED RECEPTOR 97; GPCR97__:__
Asterisk__:__604526__:__ISOCITRATE DEHYDROGENASE 3, BETA SUBUNIT; IDH3B__:__ISOCITRATE DEHYDROGENASE, NAD(+)-SPECIFIC, MITOCHONDRIAL, BETA SUBUNIT__:__
Asterisk__:__604527__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 3; KCNH3__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ETHER-A-GO-GO-RELATED SUBFAMILY, MEMBER 3;; BRAIN-SPECIFIC EAG-LIKE CHANNEL 1; BEC1__:__
Asterisk__:__604528__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 4; KCNH4__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ETHER-A-GO-GO-RELATED SUBFAMILY, MEMBER 4;; BRAIN-SPECIFIC EAG-LIKE CHANNEL 2; BEC2__:__
Asterisk__:__604529__:__ORTHOPEDIA, DROSOPHILA, HOMOLOG OF; OTP__:____:__
Asterisk__:__604530__:__NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NCR1__:__LYMPHOCYTE ANTIGEN 94, MOUSE, HOMOLOG OF; LY94;; ACTIVATING NATURAL KILLER RECEPTOR p46; NKp46__:__
Asterisk__:__604531__:__NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NCR2__:__LYMPHOCYTE ANTIGEN 95, MOUSE, HOMOLOG OF; LY95;; ACTIVATING NK RECEPTOR NKp44; NKp44__:__
Asterisk__:__604532__:__POLYCYSTIN 2-LIKE 1; PKD2L1__:__PKDL;; PKD2L;; POLYCYSTIN-L__:__
Asterisk__:__604533__:__INTERFERON-STIMULATED GENE, 20-KD; ISG20__:__HEM45__:__
Asterisk__:__604534__:__CD83 ANTIGEN; CD83__:__HB15;; BL11__:__
Asterisk__:__604535__:__KINESIN FAMILY MEMBER C3; KIFC3__:____:__
Number Sign__:__604536__:__ECTODERMAL DYSPLASIA/SKIN FRAGILITY SYNDROME__:__MCGRATH SYNDROME__:__
Number Sign__:__604537__:__LEBER CONGENITAL AMAUROSIS 5; LCA5__:____:__
Asterisk__:__604538__:__KINESIN FAMILY MEMBER 2C; KIF2C__:__KINESIN-LIKE 6; KNSL6;; MITOTIC CENTROMERE-ASSOCIATED KINESIN; MCAK__:__
Asterisk__:__604539__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 2; ADAMTS2__:__PROCOLLAGEN I N-PROTEINASE; NPI__:__
Asterisk__:__604540__:__KERATIN 36, TYPE I; KRT36__:__K36;; KA31;; KERATIN, HAIR, ACIDIC, 6; KRTHA6;; KERATIN, HARD, TYPE I, 6; HA6__:__
Asterisk__:__604541__:__KERATIN 37, TYPE I; KRT37__:__K37;; KA32;; KERATIN, HAIR, ACIDIC, 7; KRTHA7;; KERATIN, HARD, TYPE I, 7; HA7__:__
Asterisk__:__604542__:__KERATIN 38, TYPE I; KRT38__:__K38;; KA33;; KERATIN, HAIR, ACIDIC, 8; KRTHA8;; KERATIN, HARD, TYPE I, 8; HA8__:__
Asterisk__:__604543__:__LIM DOMAIN-CONTAINING PROTEIN 1; LIMD1__:____:__
Asterisk__:__604544__:__LEUCYL-tRNA SYNTHETASE 2; LARS2__:__LEUCYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL LEURS__:__
Asterisk__:__604545__:__KARYOPHERIN ALPHA-5; KPNA5__:__IMPORTIN ALPHA-6__:__
Asterisk__:__604546__:__TONSOKU-LIKE DNA REPAIR PROTEIN; TONSL__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR-LIKE 2; NFKBIL2;; I-KAPPA-B-RELATED; IKBR__:__
Percent__:__604547__:__VAN DER WOUDE SYNDROME 1, MODIFIER OF__:__VWSM__:__
Asterisk__:__604548__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, EPSILON; NFKBIE__:__INHIBITOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS, EPSILON; IKBE__:__
Caret__:__604549__:__MOVED TO 172471__:____:__
Asterisk__:__604550__:__DENSITY-REGULATED PROTEIN; DENR__:__DRP__:__
Asterisk__:__604551__:__CHOLESTEROL 25-HYDROXYLASE; CH25H__:____:__
Asterisk__:__604552__:__HEPATOCYTE GROWTH FACTOR ACTIVATOR; HGFAC__:__HGF ACTIVATOR; HGFA__:__
Asterisk__:__604553__:__HEAT-SHOCK FACTOR-BINDING PROTEIN 1; HSBP1__:____:__
Asterisk__:__604554__:__HEAT-SHOCK TRANSCRIPTION FACTOR 2-BINDING PROTEIN; HSF2BP__:____:__
Asterisk__:__604555__:__CADHERIN 10; CDH10__:__T2-CADHERIN__:__
Asterisk__:__604556__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1B; DYRK1B__:__MINIBRAIN-RELATED KINASE; MIRK__:__
Asterisk__:__604557__:__ZINC FINGER PROTEIN 423; ZNF423__:__ZINC FINGER PROTEIN 423, MOUSE, HOMOLOG OF; ZFP423;; OLF1/EBF-ASSOCIATED ZINC FINGER PROTEIN; OAZ;; KIAA0760__:__
Asterisk__:__604558__:__INDUCIBLE T-CELL COSTIMULATOR; ICOS__:__INDUCIBLE COSTIMULATOR;; ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE; AILIM__:__
Number Sign__:__604559__:__PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IB; PFHB1B__:__PFHBIB__:__
Caret__:__604560__:__MOVED TO 604453__:____:__
Asterisk__:__604561__:__ALPHA-1,3-MANNOSYL-GLYCOPROTEIN BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME B; MGAT4B__:__UDP-N-ACETYLGLUCOSAMINE:ALPHA-1,3-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME B;; GNT-IVB__:__
Asterisk__:__604562__:__APOPTOTIC CHROMATIN CONDENSATION INDUCER 1; ACIN1__:__APOPTOTIC CHROMATIN CONDENSATION INDUCER IN THE NUCLEUS; ACINUS__:__
Number Sign__:__604563__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2__:__CHARCOT-MARIE-TOOTH DISEASE, WITH FOCALLY FOLDED MYELIN SHEATHS, AUTOSOMAL RECESSIVE, TYPE 4B2;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B2__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2, WITH EARLY-ONSET GLAUCOMA, INCLUDED;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4B2, WITH EARLY-ONSET GLAUCOMA, INCLUDED
Asterisk__:__604564__:__GLUTATHIONE S-TRANSFERASE, MICROSOMAL, 3; MGST3__:____:__
Asterisk__:__604565__:__ALG5, S. CEREVISIAE, HOMOLOG OF; ALG5__:__DOLICHYL PHOSPHATE GLUCOSYLTRANSFERASE__:__
Asterisk__:__604566__:__ALG6, S. CEREVISIAE, HOMOLOG OF; ALG6__:____:__
Asterisk__:__604567__:__DOUBLE C2-LIKE DOMAIN-CONTAINING PROTEIN, ALPHA; DOC2A__:____:__
Asterisk__:__604568__:__DOUBLE C2-LIKE DOMAIN-CONTAINING PROTEIN, BETA; DOC2B__:____:__
Asterisk__:__604569__:__CONTACTIN-ASSOCIATED PROTEIN-LIKE 2; CNTNAP2__:__CONTACTIN-ASSOCIATED PROTEIN 2; CASPR2;; NEUREXIN IV, DROSOPHILA, HOMOLOG OF; NRXN4__:__
Asterisk__:__604570__:__SHROOM FAMILY MEMBER 3; SHROOM3__:__SHROOM, MOUSE, HOMOLOG OF; SHRM;; KIAA1481__:__
Number Sign__:__604571__:__BARE LYMPHOCYTE SYNDROME, TYPE I__:__BLS, TYPE I;; HLA CLASS I DEFICIENCY__:__
Asterisk__:__604572__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 1; DNAJB1__:__HEAT-SHOCK 40-KD PROTEIN 1; HSPF1;; HDJ1__:__DNAJB1/PRKACA FUSION GENE, INCLUDED
Asterisk__:__604573__:__CHROMOSOME 14 OPEN READING FRAME 2; C14ORF2__:__MP68, RAT, HOMOLOG OF; MP68__:__
Asterisk__:__604574__:__FERRIC CHELATE REDUCTASE 1-LIKE; FRRS1L__:__CHROMOSOME 9 OPEN READING FRAME 4; C9ORF4;; CG6__:__
Asterisk__:__604575__:__ZINC FINGER HIT DOMAIN-CONTAINING PROTEIN 2; ZNHIT2__:__HIT-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 2;; CHROMOSOME 11 OPEN READING FRAME 5; C11ORF5;; FON__:__
Asterisk__:__604576__:__ERGOSTEROL BIOSYNTHESIS 28 HOMOLOG; ERG28__:__CHROMOSOME 14 OPEN READING FRAME 1; C14ORF1__:__
Asterisk__:__604577__:__BLOOD VESSEL EPICARDIAL SUBSTANCE; BVES__:__HBVES;; POPEYE PROTEIN 1; POP1;; POPEYE DOMAIN-CONTAINING PROTEIN 1; POPDC1__:__
Asterisk__:__604578__:__ABSENT IN MELANOMA 2; AIM2__:____:__
Asterisk__:__604579__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 4; FZD4__:____:__
Asterisk__:__604580__:__FIBULIN 5; FBLN5__:__DEVELOPMENTAL ARTERIES AND NEURAL CREST EGF-LIKE; DANCE__:__
Asterisk__:__604581__:__ATPase FAMILY GENE 3-LIKE 2; AFG3L2__:____:__
Asterisk__:__604582__:__A-KINASE ANCHOR PROTEIN 2; AKAP2__:__AKAPKL;; KIAA0920__:__PARALEMMIN 2, INCLUDED; PALM2, INCLUDED;; PALM2-AKAP2 TRANSCRIPT, INCLUDED
Asterisk__:__604583__:__PROGRAMMED CELL DEATH 5; PDCD5__:__TF1 CELL APOPTOSIS-RELATED GENE 19; TFAR19__:__
Asterisk__:__604584__:__PLATELET-DERIVED GROWTH FACTOR RECEPTOR-LIKE; PDGFRL__:__PLATELET-DERIVED GROWTH FACTOR-BETA-LIKE TUMOR SUPPRESSOR; PRLTS;; PDGRL__:__
Asterisk__:__604585__:__NUCLEAR BODY PROTEIN SP100; SP100__:__NUCLEAR ANTIGEN SP100; SP100;; SPECKLED, 100-KD__:__SP100B, INCLUDED;; LYSP100B, INCLUDED;; SP100-HMG, INCLUDED
Asterisk__:__604586__:__SYNTAXIN-BINDING PROTEIN 5; STXBP5__:__TOMOSYN__:__
Asterisk__:__604587__:__CALCIUM BINDING AND COILED-COIL DOMAIN PROTEIN 2; CALCOCO2__:__NUCLEAR DOMAIN 10 PROTEIN 52; NDP52__:__
Asterisk__:__604588__:__NEVER IN MITOSIS GENE A-RELATED KINASE 1; NEK1__:__NIMA-RELATED KINASE 1;; KIAA1901__:__
Asterisk__:__604589__:__BROMODOMAIN-CONTAINING PROTEIN 1; BRD1__:__BR140-LIKE GENE; BRL;; BROMODOMAIN- AND PHD FINGER-CONTAINING PROTEIN 2; BRPF2__:__
Asterisk__:__604590__:__Fc FRAGMENT OF IgG, LOW AFFINITY IIb, RECEPTOR FOR; FCGR2B__:__CD32;; FC-GAMMA-RIIB__:__
Asterisk__:__604591__:__PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN 1; PEBP1__:__PBP;; RAF KINASE INHIBITOR PROTEIN; RKIP;; HIPPOCAMPAL CHOLINERGIC NEUROSTIMULATING PEPTIDE PRECURSOR PROTEIN;; HCNP PRECURSOR PROTEIN__:__
Asterisk__:__604592__:__T CELL IMMUNE REGULATOR 1; TCIRG1__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A3; ATP6V0A3;; VACUOLAR PROTON PUMP, ALPHA SUBUNIT 3__:__TIRC7, INCLUDED;; OC116, INCLUDED
Asterisk__:__604593__:__KINESIN FAMILY MEMBER 5C; KIF5C__:__KINESIN, HEAVY CHAIN, NEURON-SPECIFIC, 2; NKHC2__:__
Asterisk__:__604594__:__CYSTEINE-RICH PDZ DOMAIN-BINDING PROTEIN; CRIPT__:__CYSTEINE-RICH INTERACTOR OF PDZ3__:__
Percent__:__604595__:__CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1__:__CLQTL1;; CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 13;; CHOLESTEROL-LOWERING FACTOR; CLF__:__
Asterisk__:__604596__:__CMT1A DUPLICATED REGION TRANSCRIPT 1; CDRT1__:__CHROMOSOME 17 OPEN READING FRAME 1A; C17ORF1A;; C17ORF1__:__
Asterisk__:__604597__:__GLUTAMATE RECEPTOR-INTERACTING PROTEIN 1; GRIP1__:____:__
Asterisk__:__604598__:__OXIDATIVE STRESS-INDUCED GROWTH INHIBITOR FAMILY MEMBER 2; OSGIN2__:__CHROMOSOME 8 OPEN READING FRAME 1; C8ORF1__:__
Asterisk__:__604599__:__EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2; EHMT2__:__HLA-B-ASSOCIATED TRANSCRIPT 8; BAT8;; G9A;; NG36__:__
Asterisk__:__604600__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 5; TRPM5__:__LONG TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; LTRPC5;; MLSN1- AND TRP-RELATED GENE 1; MTR1__:__
Asterisk__:__604601__:__TRANSLATIONAL RELEASE FACTOR, MITOCHONDRIAL, 1; MTRF1__:____:__
Asterisk__:__604602__:__RIBOSOME-RECYCLING FACTOR, MITOCHONDRIAL; MRRF__:__RRF__:__
Asterisk__:__604603__:__FER-1, C. ELEGANS, HOMOLOG-LIKE 3; FER1L3__:__MYOFERLIN; MYOF__:__
Asterisk__:__604604__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 9; SLC30A9__:__CHROMOSOME 4 OPEN READING FRAME 1; C4ORF1;; HUEL__:__
Asterisk__:__604605__:__KALIRIN; KALRN__:____:__HUNTINGTIN-ASSOCIATED PROTEIN-INTERACTING PROTEIN, INCLUDED; HAPIP, INCLUDED;; DUO, INCLUDED;; SERINE/THREONINE PROTEIN KINASE WITH DBL HOMOLOGY AND PLECKSTRIN HOMOLOGY DOMAINS, INCLUDED; DUET, INCLUDED
Asterisk__:__604606__:__ODORANT-BINDING PROTEIN 2B; OBP2B__:____:__
Asterisk__:__604607__:__HOMEOBOX B13; HOXB13__:____:__
Caret__:__604608__:__MOVED TO 604609__:____:__
Asterisk__:__604609__:__MUCIN 12; MUC12__:__MUCIN 11; MUC11__:__
Asterisk__:__604610__:__RECQ PROTEIN-LIKE 3; RECQL3__:__DNA HELICASE, RECQ-LIKE, TYPE 2; RECQ2;; BLM GENE; BLM__:__
Asterisk__:__604611__:__RECQ PROTEIN-LIKE 2; RECQL2__:__DNA HELICASE, RECQ-LIKE, TYPE 3; RECQ3;; WRN GENE; WRN__:__
Asterisk__:__604612__:__NK2 HOMEOBOX 2; NKX2-2__:__NK2, DROSOPHILA, HOMOLOG OF, B; NKX2B;; NKX2.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__604613__:__T-BOX 18; TBX18__:____:__
Asterisk__:__604614__:__T-BOX 19; TBX19__:__T-BOX FACTOR, PITUITARY; TPIT__:__
Asterisk__:__604615__:__EOMESODERMIN, XENOPUS, HOMOLOG OF; EOMES__:__T-BOX, BRAIN, 2; TBR2__:__
Asterisk__:__604616__:__T-BOX, BRAIN, 1; TBR1__:____:__
Asterisk__:__604617__:__NEURAMINIDASE 3; NEU3__:__SIALIDASE 3; SIAL3;; SIALIDASE, MEMBRANE__:__
Asterisk__:__604618__:__NITRILASE 1; NIT1__:____:__
Asterisk__:__604619__:__LEUCINE-RICH GENE, GLIOMA-INACTIVATED, 1; LGI1__:__EPITEMPIN; EPTP__:__
Asterisk__:__604620__:__G PROTEIN-COUPLED RECEPTOR 65; GPR65__:__T-CELL DEATH-ASSOCIATED GENE 8; TDAG8__:__
Asterisk__:__604621__:__BETA-1,4-MANNOSYL-GLYCOPROTEIN BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT3__:__UDP-N-ACETYLGLUCOSAMINE:BETA-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE;; GNT-III__:__
Caret__:__604622__:__MOVED TO 606519__:____:__
Asterisk__:__604623__:__ALPHA-1,3-MANNOSYL-GLYCOPROTEIN BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME A; MGAT4A__:__UDP-N-ACETYLGLUCOSAMINE:ALPHA-1,3-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME A;; GNT-IVA;; N-ACETYLGLUCOSAMINE TRANSFERASE 4A__:__
Asterisk__:__604624__:__HEAT-SHOCK 27-KD PROTEIN 3; HSPB3__:__HEAT-SHOCK PROTEIN 27-LIKE PROTEIN; HSPL27__:__
Number Sign__:__604625__:__TOOTH AGENESIS, SELECTIVE, 3; STHAG3__:__HYPODONTIA/OLIGODONTIA 3__:__
Asterisk__:__604626__:__MALIC ENZYME 3; ME3__:__MALIC ENZYME, NADP(+)-DEPENDENT, MITOCHONDRIAL__:__
Asterisk__:__604627__:__INTERLEUKIN 17B; IL17B__:____:__
Asterisk__:__604628__:__INTERLEUKIN 17C; IL17C__:____:__
Asterisk__:__604629__:__MATRIX METALLOPROTEINASE 20; MMP20__:__ENAMELYSIN__:__
Asterisk__:__604630__:__NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; NR0B2__:__SMALL HETERODIMER PARTNER; SHP; SHP1__:__
Asterisk__:__604631__:__VESICLE AMINE TRANSPORT PROTEIN 1; VAT1__:____:__
Asterisk__:__604632__:__VAC14, S. CEREVISIAE, HOMOLOG OF; VAC14__:__ASSOCIATED REGULATOR OF PIKFYVE; ARPIKFYVE;; TAX1-BINDING PROTEIN 2; TAX1BP2;; TAX-REACTIVE PROTEIN X; TRX__:__
Asterisk__:__604633__:__EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 2; EFEMP2__:__FIBULIN 4; FBLN4__:__
Asterisk__:__604634__:__TRANSGELIN 2; TAGLN2__:____:__
Asterisk__:__604635__:__NEUREXOPHILIN 2; NXPH2__:__NPH2__:__
Asterisk__:__604636__:__NEUREXOPHILIN 3; NXPH3__:__NPH3__:__
Asterisk__:__604637__:__NEUREXOPHILIN 4; NXPH4__:__NPH4__:__
Asterisk__:__604638__:__ACTININ, ALPHA-4; ACTN4__:__ACTININ-4__:__
Asterisk__:__604639__:__NEUREXOPHILIN 1; NXPH1__:__NPH1__:__
Asterisk__:__604640__:__T-CELL LEUKEMIA HOMEOBOX 3; TLX3__:__HOMEOBOX 11-LIKE 2; HOX11L2;; RESPIRATORY NEURON HOMEOBOX, MOUSE, HOMOLOG OF; RNX__:__
Asterisk__:__604641__:__MITOGEN-ACTIVATED PROTEIN KINASE 8-INTERACTING PROTEIN 1; MAPK8IP1__:__JNK-INTERACTING PROTEIN 1; JIP1;; ISLET-BRAIN 1; IB1__:__
Asterisk__:__604642__:__CARBONIC ANHYDRASE X; CA10__:__CA X;; CARBONIC ANHYDRASE-RELATED PROTEIN X;; CARP X__:__
Asterisk__:__604643__:__NEUROPEPTIDE FF-AMIDE PEPTIDE; NPFF__:____:__NEUROPEPTIDE AF-AMIDE PEPTIDE, INCLUDED; NPAF, INCLUDED;; NEUROPEPTIDE FF- AND AF-AMIDE PEPTIDE PRECURSOR, INCLUDED;; FMRF-AMIDE-LIKE PEPTIDE PRECURSOR, INCLUDED; FMRFAL, INCLUDED
Asterisk__:__604644__:__CARBONIC ANHYDRASE XI; CA11__:__CARBONIC ANHYDRASE-RELATED PROTEIN 11;; CARP XI;; CARBONIC ANHYDRASE-RELATED PROTEIN 2; CARP2__:__
Asterisk__:__604645__:__PHOSPHODIESTERASE 7B, cAMP-SPECIFIC, HIGH AFFINITY; PDE7B__:____:__
Asterisk__:__604646__:__NUCLEOPORIN, 50-KD; NUP50__:__NPAP60, RAT, HOMOLOG OF; NPAP60L__:__
Asterisk__:__604647__:__CALCYON; CALY__:__DOPAMINE RECEPTOR D1-INTERACTING PROTEIN; DRD1IP__:__
Asterisk__:__604648__:__T-BOX 10; TBX10__:____:__
Asterisk__:__604649__:__TUBULIN-SPECIFIC CHAPERONE D; TBCD__:____:__
Asterisk__:__604650__:__INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 3; IFIT3__:__RETINOIC ACID-INDUCED GENE G; RIGG;; INTERFERON-INDUCED PROTEIN 60; IFI60;; IFIT4__:__
Asterisk__:__604651__:__GROWTH/DIFFERENTIATION FACTOR 7; GDF7__:__BONE MORPHOGENETIC PROTEIN 12; BMP12__:__
Asterisk__:__604652__:__TRANSCRIPTION FACTOR 7-LIKE 1; TCF7L1__:__TRANSCRIPTION FACTOR 3, FORMERLY; TCF3, FORMERLY__:__
Asterisk__:__604653__:__SOLUTE CARRIER FAMILY 40 (IRON-REGULATED TRANSPORTER), MEMBER 1; SLC40A1__:__FERROPORTIN 1; FPN1;; IRON-REGULATED TRANSPORTER 1; IREG1;; SOLUTE CARRIER FAMILY 11 (PROTON-COUPLED DIVALENT METAL ION TRANSPORTER), MEMBER 3, FORMERLY; SLC11A3, FORMERLY__:__
Asterisk__:__604654__:__5-HYDROXYTRYPTAMINE RECEPTOR 3B; HTR3B__:__SEROTONIN 5-HT-3B RECEPTOR__:__
Asterisk__:__604655__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14; MAP3K14__:__NF-KAPPA-B-INDUCING KINASE; NIK;; SERINE/THREONINE PROTEIN KINASE NIK;; HSNIK__:__
Asterisk__:__604656__:__FORMIN-LIKE 1; FMNL1__:__FORMIN-LIKE; FMNL;; CHROMOSOME 17 OPEN READING FRAME 1B; C17ORF1B;; C17ORF1__:__
Asterisk__:__604657__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 5; TM4SF5__:____:__
Asterisk__:__604658__:__TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 1; TM7SF1__:____:__TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 1, LONG, INCLUDED; TM7SF1L, INCLUDED;; TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 1, INTERMEDIATE, INCLUDED; TM7SF1I, INCLUDED;; TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 1, SHORT, INCLUDED; TM7SF1S, INCLUDED
Asterisk__:__604659__:__ENDOGENOUS RETROVIRAL FAMILY W, MEMBER 1; ERVW1__:__ENDOGENOUS RETROVIRAL FAMILY W, ENV-C7, MEMBER 1; ERVWE1;; HERV-W;; SYNCYTIN;; SYNCYTIN 1;; SYNCYTIN A, MOUSE, HOMOLOG OF__:__
Asterisk__:__604660__:__POTASSIUM CHANNEL-INTERACTING PROTEIN 1; KCNIP1__:__KCHIP1__:__
Asterisk__:__604661__:__POTASSIUM CHANNEL-INTERACTING PROTEIN 2; KCNIP2__:__KCHIP2__:__
Asterisk__:__604662__:__POTASSIUM CHANNEL-INTERACTING PROTEIN 3; KCNIP3__:__KCHIP3;; CALSENILIN; CSEN;; DRE-ANTAGONIST MODULATOR; DREAM__:__
Asterisk__:__604663__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 6; WNT6__:____:__
Asterisk__:__604664__:__INTERFERON-GAMMA-INDUCIBLE PROTEIN 30; IFI30__:__LYSOSOMAL THIOL REDUCTASE, GAMMA-INTERFERON-INDUCIBLE; GILT__:__
Asterisk__:__604665__:__COP9 SIGNALOSOME, SUBUNIT 3; COPS3__:__SGN3__:__
Asterisk__:__604666__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4; MAP4K4__:__HEMATOPOIETIC PROGENITOR KINASE/GERMINAL CENTER KINASE-LIKE KINASE; HGK;; NCK-INTERACTING KINASE; NIK__:__
Asterisk__:__604667__:__CALCIUM-DEPENDENT ACTIVATOR PROTEIN FOR SECRETION; CADPS__:__CAPS;; CADPS1;; KIAA1121__:__
Asterisk__:__604668__:__ZINC FINGER PROTEIN 264; ZNF264__:____:__
Asterisk__:__604669__:__POLYCYSTIN 2-LIKE 2; PKD2L2__:____:__
Asterisk__:__604670__:__POLYCYSTIN AND SEA URCHIN REJ HOMOLOG-LIKE; PKDREJ__:____:__
Asterisk__:__604671__:__JUMPING TRANSLOCATION BREAKPOINT; JTB__:____:__
Asterisk__:__604672__:__CD209 ANTIGEN; CD209__:__DENDRITIC CELL-SPECIFIC ICAM3-GRABBING NONINTEGRIN; DCSIGN;; HIV GP120-BINDING PROTEIN;; C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER L; CLEC4L__:__
Asterisk__:__604673__:__MURINE RETROVIRUS INTEGRATION SITE 1, HOMOLOG OF; MRVI1__:__INOSITOL 1,4,5-TRIPHOSPHATE-ASSOCIATED cGMP KINASE SUBSTRATE; IRAG;; IP3R-ASSOCIATED cGMP KINASE SUBSTRATE__:__
Asterisk__:__604674__:__HAIRY/ENHANCER OF SPLIT-RELATED WITH YRPW MOTIF 2; HEY2__:__CARDIOVASCULAR BASIC-LOOP-HELIX FACTOR, FORMERLY; CHF1, FORMERLY;; HAIRY/ENHANCER OF SPLIT-RELATED REPRESSOR PROTEIN 1; HERP1;; GRIDLOCK; GRL;; HAIRY-RELATED TRANSCRIPTION FACTOR 2; HRT2__:__
Asterisk__:__604675__:__PAIRED-RELATED HOMEOBOX GENE 2; PRRX2__:__PAIRED-LIKE HOMEOBOX GENE 2; PRX2__:__
Asterisk__:__604676__:__HLA COMPLEX P5 GENE; HCP5__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS I, GENE P5-1;; P5-1;; D6S2650E__:__
Asterisk__:__604677__:__COL4A3-BINDING PROTEIN; COL4A3BP__:__GOODPASTURE ANTIGEN-BINDING PROTEIN; GPBP__:__CERAMIDE TRANSPORTER, INCLUDED; CERT, INCLUDED
Asterisk__:__604678__:__TRANSMEMBRANE 9 SUPERFAMILY, MEMBER 2; TM9SF2__:__p76__:__
Asterisk__:__604679__:__POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 1; PABPC1__:__POLYADENYLATE-BINDING PROTEIN 1; PABP1; PAB1;; POLY(A)-BINDING PROTEIN 1;; POLY(A)-BINDING PROTEIN; PABP__:__
Asterisk__:__604680__:__POLYADENYLATE-BINDING PROTEIN, CYTOPLASMIC, 3; PABPC3__:__POLYADENYLATE-BINDING PROTEIN 3; PABP3;; POLY(A)-BINDING PROTEIN 3;; POLYADENYLATE-BINDING PROTEIN-LIKE 3; PABPL3__:__
Caret__:__604681__:__MOVED TO 604680__:____:__
Asterisk__:__604682__:__INTEGRIN, ALPHA-E; ITGAE__:__CD103 ANTIGEN;; HUMAN MUCOSAL LYMPHOCYTE ANTIGEN 1, ALPHA SUBUNIT__:__
Asterisk__:__604683__:__KINESIN FAMILY MEMBER 3A; KIF3A__:____:__
Asterisk__:__604684__:__MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA, TRANSLOCATED TO, 11; MLLT11__:__ALL1-FUSED GENE FROM CHROMOSOME 1q; AF1Q__:__
Asterisk__:__604685__:__HOMEOBOX A2; HOXA2__:____:__
Asterisk__:__604686__:__A-KINASE ANCHOR PROTEIN 13; AKAP13__:____:__LYMPHOID BLAST CRISIS ONCOGENE, INCLUDED; LBC, INCLUDED;; BREAST CANCER cDNA-ENCODED NUCLEAR RECEPTOR-BINDING AUXILIARY PROTEIN 1, INCLUDED; BRX1, INCLUDED; BRX, INCLUDED
Asterisk__:__604687__:__PROSTAGLANDIN D2 RECEPTOR; PTGDR__:__PROSTANOID DP RECEPTOR; DP;; DP1__:__
Asterisk__:__604688__:__A-KINASE ANCHOR PROTEIN 5; AKAP5__:__A-KINASE ANCHOR PROTEIN, 79-KD; AKAP79;; AKAP75, BOVINE, HOMOLOG OF;; AKAP150, MOUSE, HOMOLOG OF__:__
Asterisk__:__604689__:__A-KINASE ANCHOR PROTEIN 3; AKAP3__:__A-KINASE ANCHOR PROTEIN, 110-KD; AKAP110;; FIBROUS SHEATH PROTEIN, 95-KD; FSP95;; SPERM OOCYTE-BINDING PROTEIN 1; SOB1__:__
NULL__:__604690__:__GROWTH AND DEVELOPMENTAL RETARDATION, OCULAR PTOSIS, CARDIAC DEFECT, AND ANAL ATRESIA__:__ROCA SYNDROME;; ROCA-WEIDEMANN SYNDROME__:__
Asterisk__:__604691__:__A-KINASE ANCHOR PROTEIN 6; AKAP6__:__A-KINASE ANCHOR PROTEIN, 100-KD; AKAP100__:__
Asterisk__:__604692__:__A-KINASE ANCHOR PROTEIN 8; AKAP8__:__A-KINASE ANCHOR PROTEIN, 95-KD; AKAP95__:__
Asterisk__:__604693__:__A-KINASE ANCHOR PROTEIN 7; AKAP7__:__A-KINASE ANCHOR PROTEIN, 18-KD; AKAP18__:__
Asterisk__:__604694__:__A-KINASE ANCHOR PROTEIN 10; AKAP10__:__DUAL-SPECIFIC A KINASE-ANCHORING PROTEIN 2; DAKAP2__:__
Asterisk__:__604695__:__ADP-RIBOSYLATION FACTOR-LIKE 3; ARL3__:__ARFL3__:__
Asterisk__:__604696__:__A-KINASE ANCHOR PROTEIN 11; AKAP11__:__A-KINASE ANCHOR PROTEIN, 220-KD; AKAP220__:__
Asterisk__:__604697__:__CHEMOKINE, CC MOTIF, LIGAND 26; CCL26__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 26; SCYA26;; EOTAXIN 3__:__
Asterisk__:__604698__:__A-KINASE ANCHOR PROTEIN 12; AKAP12__:__A-KINASE ANCHOR PROTEIN, 250-KD; AKAP250;; GRAVIN__:__
Asterisk__:__604699__:__ADP-RIBOSYLATION FACTOR-RELATED PROTEIN 1; ARFRP1__:__ARP__:__
Asterisk__:__604700__:__TARGET OF MYB1, CHICKEN, HOMOLOG OF; TOM1__:____:__
Asterisk__:__604701__:__TOM1-LIKE 1; TOM1L1__:____:__
Asterisk__:__604702__:__HMG BOX DOMAIN-CONTAINING 4; HMGXB4__:__HIGH MOBILITY GROUP PROTEIN 2-LIKE 1; HMG2L1;; THC211630__:__
Caret__:__604703__:__MOVED TO 604702__:____:__
Asterisk__:__604704__:__BREAST CANCER ANTIESTROGEN RESISTANCE 3; BCAR3__:__SH2 DOMAIN-CONTAINING PROTEIN 3B; SH2D3B;; NOVEL SH2-CONTAINING PROTEIN 2; NSP2__:__
Asterisk__:__604705__:__MER TYROSINE KINASE PROTOONCOGENE; MERTK__:____:__
Caret__:__604706__:__MOVED TO 164015__:____:__
Asterisk__:__604707__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER B10; AKR1B10__:__ALDOSE REDUCTASE-LIKE 1; ARL1;; HUMAN SMALL INTESTINE REDUCTASE;; HSI REDUCTASE__:__
Asterisk__:__604708__:__NUCLEAR FACTOR OF ACTIVATED T CELLS 5; NFAT5__:__TONICITY-RESPONSIVE ENHANCER-BINDING PROTEIN; TONEBP;; NFAT-LIKE PROTEIN 1; NFATL1;; KIAA0827__:__
Asterisk__:__604709__:__T-CELL LYMPHOMA INVASION AND METASTASIS 2; TIAM2__:____:__
Asterisk__:__604710__:__LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 4; LTBP4__:____:__LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 4, SHORT, INCLUDED; LTBP4S, INCLUDED;; LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 4, LONG, INCLUDED; LTBP4L, INCLUDED
Asterisk__:__604711__:__UBIQUITIN-LIKE 3; UBL3__:____:__
Asterisk__:__604712__:__RIBONUCLEOTIDE REDUCTASE, M2 B; RRM2B__:__RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT 2-LIKE, p53-INDUCIBLE; P53R2;; p53-INDUCIBLE AND RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT 2-LIKE__:__
Asterisk__:__604713__:__C-TYPE LECTIN DOMAIN FAMILY 11, MEMBER A; CLEC11A__:__STEM CELL GROWTH FACTOR; SCGF;; LYMPHOCYTIC SECRETED LONG FORM OF C-TYPE LECTIN; LSLCL;; LECTIN, C-TYPE, LYMPHOCYTE-SECRETED LONG FORM__:__
Asterisk__:__604714__:__TSPY-LIKE 1; TSPYL1__:__TSPY-LIKE; TSPYL__:__
Number Sign__:__604715__:__ORTHOSTATIC INTOLERANCE__:__NEUROCIRCULATORY ASTHENIA;; MITRAL VALVE PROLAPSE SYNDROME;; IRRITABLE HEART;; SOLDIERS HEART__:__
Asterisk__:__604716__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER A1; UGT2A1__:__UDP GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER A1;; UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER A1__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER A2, INCLUDED; UGT2A2, INCLUDED
Number Sign__:__604717__:__DEAFNESS, AUTOSOMAL DOMINANT 20; DFNA20__:__DFNA26__:__
Asterisk__:__604718__:__TRANSCRIPTION TERMINATION FACTOR, RNA POLYMERASE II; TTF2__:____:__
Asterisk__:__604719__:__SERINE/THREONINE PROTEIN KINASE 16; STK16__:__PKL12, MOUSE, HOMOLOG OF;; TRANSFORMING GROWTH FACTOR-BETA-STIMULATED FACTOR 1; TSF1;; TGFB-STIMULATED FACTOR 1__:__
Asterisk__:__604720__:__TRANSFERRIN RECEPTOR 2; TFR2__:____:__
Asterisk__:__604721__:__SH2 DOMAIN-CONTAINING PROTEIN 3A; SH2D3A__:__NOVEL SH2-CONTAINING PROTEIN 1; NSP1__:__
Asterisk__:__604722__:__SH2 DOMAIN-CONTAINING PROTEIN 3C; SH2D3C__:__SH2 DOMAIN-CONTAINING PROTEIN 3;; NOVEL SH2-CONTAINING PROTEIN 3; NSP3;; SH2 DOMAIN-CONTAINING EPH RECEPTOR-BINDING PROTEIN 1; SHEP1;; CAS/HEF1-ASSOCIATED SIGNAL TRANSDUCER; CHAT__:__
Asterisk__:__604723__:__Ts TRANSLATION ELONGATION FACTOR, MITOCHONDRIAL; TSFM__:__MITOCHONDRIAL TRANSLATION ELONGATION FACTOR Ts;; EFTsMT__:__
Asterisk__:__604724__:__HEPARANASE; HPSE__:__HPSE1; HSE1;; HPA;; HPA1__:__
Asterisk__:__604725__:__UBIQUITIN-SPECIFIC PROTEASE 2; USP2__:__UBIQUITIN-SPECIFIC PROTEASE, 41-KD; UBP41__:__
Asterisk__:__604726__:__SERINE/THREONINE PROTEIN KINASE 17A; STK17A__:__DAP KINASE-RELATED APOPTOSIS-INDUCING PROTEIN KINASE 1; DRAK1__:__
Asterisk__:__604727__:__SERINE/THREONINE PROTEIN KINASE 17B; STK17B__:__DAP KINASE-RELATED APOPTOSIS-INDUCING PROTEIN KINASE 2; DRAK2__:__
Asterisk__:__604728__:__UBIQUITIN-SPECIFIC PROTEASE 3; USP3__:____:__
Asterisk__:__604729__:__UBIQUITIN-SPECIFIC PROTEASE 21; USP21__:__UBIQUITIN-SPECIFIC PROTEASE 23, FORMERLY; USP23, FORMERLY__:__
Asterisk__:__604730__:__TUBBY-LIKE PROTEIN 3; TULP3__:____:__
Asterisk__:__604731__:__UBIQUITIN-SPECIFIC PROTEASE 15; USP15__:____:__
Asterisk__:__604732__:__TRANSCRIPTION FACTOR EC; TFEC__:__TFECL__:__
Asterisk__:__604733__:__TRYPTOPHANYL-tRNA SYNTHETASE 2; WARS2__:__TRYPTOPHANYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL TRPRS__:__
Asterisk__:__604734__:__WD REPEAT-CONTAINING PROTEIN 1; WDR1__:__ACTIN-INTERACTING PROTEIN 1; AIP1__:__
Asterisk__:__604735__:__UBIQUITIN-SPECIFIC PROTEASE 16; USP16__:__UBPM__:__
Asterisk__:__604736__:__UBIQUITIN-SPECIFIC PROTEASE 25; USP25__:__UBIQUITIN-SPECIFIC PROTEASE ON CHROMOSOME 21; USP21__:__
Asterisk__:__604737__:__WD REPEAT-CONTAINING PROTEIN 3; WDR3__:____:__
Asterisk__:__604738__:__CHEMOKINE, CC MOTIF, RECEPTOR 9; CCR9__:__GPR-9-6__:__
Asterisk__:__604739__:__RNA BINDING MOTIF PROTEIN 39; RBM39__:__SPLICING FACTOR HCC1;; COACTIVATOR OF ACTIVATOR PROTEIN 1 AND ESTROGEN RECEPTORS; CAPER;; RNA-BINDING REGION-CONTAINING PROTEIN 2; RNPC2__:__HCC1.3, INCLUDED;; HCC1.4, INCLUDED
Asterisk__:__604740__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 1; SLC39A1__:__ZINC/IRON-REGULATED TRANSPORTER-LIKE; ZIRTL;; ZRT- AND IRT-LIKE PROTEIN 1; ZIP1__:__
Asterisk__:__604741__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER D1; AKR1D1__:__DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE;; STEROID 5-BETA-REDUCTASE; SRD5B1;; 5-BETA-REDUCTASE__:__
Asterisk__:__604742__:__DOUBLECORTIN-LIKE KINASE 1; DCLK1__:__DOUBLECORTIN- AND CALMODULIN KINASE-LIKE 1; DCAMKL1;; CAMK-LIKE CREB REGULATORY KINASE 1; CLICK1; CL1;; KIAA0369__:__
Asterisk__:__604743__:__DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; DDAH1__:____:__
Asterisk__:__604744__:__DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; DDAH2__:____:__
Asterisk__:__604745__:__TRANSCRIPTION FACTOR-LIKE 5; TCFL5__:____:__
Asterisk__:__604746__:__TESTIS-SPECIFIC PROTEIN KINASE 2; TESK2__:____:__
Asterisk__:__604747__:__SRY-BOX 14; SOX14__:__SRY-RELATED HMG-BOX GENE 14;; SOX28__:__
Asterisk__:__604748__:__SRY-BOX 13; SOX13__:__SRY-RELATED HMG-BOX GENE 12;; ISLET CELL ANTIBODY 12; ICA12__:__
Asterisk__:__604749__:__ZINC FINGER PROTEIN 93, MOUSE, HOMOLOG OF; ZFP93__:__ZINC FINGER PROTEIN 270; ZNF270;; HZF6__:__
Asterisk__:__604750__:__ZINC FINGER PROTEIN 234; ZNF234__:__ZINC FINGER PROTEIN 269; ZNF269;; HZF4__:__
Asterisk__:__604751__:__ZINC FINGER PROTEIN 266; ZNF266__:__HZF1__:__
Asterisk__:__604752__:__ZINC FINGER PROTEIN 267; ZNF267__:__HZF2__:__
Asterisk__:__604753__:__ZINC FINGER PROTEIN 268; ZNF268__:__HZF3__:__
Asterisk__:__604754__:__ZINC FINGER PROTEIN 271; ZNF271__:__HZF7;; EPSTEIN-BARR VIRUS-INDUCED ZINC FINGER PROTEIN; ZNFEB__:__
Asterisk__:__604755__:__ZINC FINGER PROTEIN 272; ZNF272__:__HZF8;; ZNF460__:__
Asterisk__:__604756__:__ZINC FINGER PROTEIN 273; ZNF273__:__HZF9__:__
Number Sign__:__604757__:__CRANIOSYNOSTOSIS 2; CRS2__:__CRANIOSYNOSTOSIS, BOSTON-TYPE; CSB__:__
Asterisk__:__604758__:__V-REL AVIAN RETICULOENDOTHELIOSIS VIRAL ONCOGENE HOMOLOG B; RELB__:__IREL__:__
Asterisk__:__604759__:__SYNAPTONEMAL COMPLEX PROTEIN 3; SYCP3__:__SCP3;; COR1__:__
Asterisk__:__604760__:__ZINC FINGER PROTEIN 236; ZNF236__:____:__ZNF236A, INCLUDED;; ZNF236B, INCLUDED
Asterisk__:__604761__:__ZINC FINGER AN1 DOMAIN-CONTAINING PROTEIN 5; ZFAND5__:__AN1-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 5;; ZINC FINGER PROTEIN 216; ZNF216__:__
Asterisk__:__604762__:__SWITCH-ASSOCIATED PROTEIN 70__:__SWAP70__:__
Asterisk__:__604763__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 12; ARHGEF12__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR, LEUKEMIA-ASSOCIATED;; LEUKEMIA-ASSOCIATED RHO GEF; LARG;; KIAA0382__:__LARG/MLL FUSION GENE, INCLUDED
Asterisk__:__604764__:__ZINC FINGER AND HOMEODOMAIN PROTEIN 1; ZHX1__:____:__
Number Sign__:__604765__:__CARDIOMYOPATHY, DILATED, 1I; CMD1I__:____:__
Asterisk__:__604766__:__PODOCIN; NPHS2__:__PDCN__:__
Asterisk__:__604767__:__DELETED IN ESOPHAGEAL CANCER 1; DEC1__:____:__
Asterisk__:__604768__:__ZINC FINGER PROTEIN 254; ZNF254__:__ZINC FINGER PROTEIN 91-LIKE; ZNF91L__:__
Asterisk__:__604769__:__PEROXIREDOXIN 3; PRDX3__:__PRX3;; ANTIOXIDANT PROTEIN 1; AOP1__:__
Asterisk__:__604770__:__ACETYL-CoA ACYLTRANSFERASE 2; ACAA2__:__3-OXOACYL-CoA THIOLASE, MITOCHONDRIAL__:__
NULL__:__604771__:__POLYCYSTIC BONE DISEASE__:__PCBD__:__
Number Sign__:__604772__:__VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY; CPVT1__:__VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC; VTSIP__:__
Asterisk__:__604773__:__ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8; ACAD8__:____:__
Asterisk__:__604774__:__ANGIOPOIETIN-LIKE 3; ANGPTL3__:__ANGIOPOIETIN 5; ANGPT5__:__
Asterisk__:__604775__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY A, MEMBER 1; TRPA1__:__ANKYRIN-LIKE PROTEIN WITH TRANSMEMBRANE DOMAINS 1; ANKTM1__:__
Asterisk__:__604776__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DR BETA-5; HLA-DRB5__:____:__
Number Sign__:__604777__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 5; ARCI5__:__ICHTHYOSIS, NONLAMELLAR AND NONERYTHRODERMIC, CONGENITAL, AUTOSOMAL RECESSIVE; NNCI;; ICHTHYOSIS CONGENITA III;; ICHTHYOSIS, LAMELLAR, 3, FORMERLY; LI3, FORMERLY__:__
Asterisk__:__604778__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 29; ADAM29__:____:__
Asterisk__:__604779__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 30; ADAM30__:____:__
Asterisk__:__604780__:__ABHYDROLASE DOMAIN-CONTAINING 5; ABHD5__:__COMPARATIVE GENE IDENTIFICATION 58; CGI58;; NCIE2 GENE; NCIE2__:__
Caret__:__604781__:__MOVED TO 604777__:____:__
Asterisk__:__604782__:__ASH2-LIKE; ASH2L__:__ASH2;; DROSOPHILA ASH2-LIKE;; DROSOPHILA ABSENT, SMALL, OR HOMEOTIC DISCS 2-LIKE;; ASH2L1;; ASH2L2__:__
Asterisk__:__604783__:__CLEFT LIP AND PALATE-ASSOCIATED TRANSMEMBRANE PROTEIN 1; CLPTM1__:____:__
Asterisk__:__604784__:__TRANSCRIPTION ELONGATION FACTOR A, 2; TCEA2__:____:__
Asterisk__:__604785__:__CATENIN, ALPHA-LIKE, 1; CTNNAL1__:__CATULIN, ALPHA__:__
Asterisk__:__604786__:__ADP-RIBOSYLATION FACTOR-LIKE 4A; ARL4A__:__ADP-RIBOSYLATION FACTOR-LIKE 4; ARL4__:__
Asterisk__:__604787__:__ADP-RIBOSYLATION FACTOR-LIKE 4C; ARL4C__:__ADP-RIBOSYLATION FACTOR-LIKE 7; ARL7__:__
Asterisk__:__604788__:__RUVB, E. COLI, HOMOLOG-LIKE 2; RUVBL2__:__TATA BOX-BINDING PROTEIN-INTERACTING PROTEIN, 48-KD; TIP48;; TBP-INTERACTING PROTEIN, 48-KD;; TIP49B;; REPTIN;; ERYTHROCYTE CYTOSOLIC PROTEIN, 51-KD; ECP51__:__
Asterisk__:__604789__:__INTEGRIN, ALPHA-11; ITGA11__:____:__
Asterisk__:__604790__:__TASTE RECEPTOR, TYPE 2, MEMBER 14; TAS2R14__:__T2R14;; TASTE RECEPTOR, FAMILY B, MEMBER 1; TRB1__:__
Asterisk__:__604791__:__TASTE RECEPTOR, TYPE 2, MEMBER 10; TAS2R10__:__T2R10;; TASTE RECEPTOR, FAMILY B, MEMBER 2; TRB2__:__
Asterisk__:__604792__:__TASTE RECEPTOR, TYPE 2, MEMBER 13; TAS2R13__:__T2R13;; TASTE RECEPTOR, FAMILY B, MEMBER 3; TRB3__:__
Asterisk__:__604793__:__TASTE RECEPTOR, TYPE 2, MEMBER 7; TAS2R7__:__T2R7;; TASTE RECEPTOR, FAMILY B, MEMBER 4; TRB4__:__
Asterisk__:__604794__:__TASTE RECEPTOR, TYPE 2, MEMBER 8; TAS2R8__:__T2R8;; TASTE RECEPTOR, FAMILY B, MEMBER 5; TRB5__:__
Asterisk__:__604795__:__TASTE RECEPTOR, TYPE 2, MEMBER 9; TAS2R9__:__T2R9;; TASTE RECEPTOR, FAMILY B, MEMBER 6; TRB6__:__
Asterisk__:__604796__:__TASTE RECEPTOR, TYPE 2, MEMBER 1; TAS2R1__:__T2R1;; TASTE RECEPTOR, FAMILY B, MEMBER 7; TRB7__:__
Asterisk__:__604797__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 2; APOBEC2__:__APOBEC1-LIKE__:__
Asterisk__:__604798__:__HOMER, DROSOPHILA, HOMOLOG OF, 1; HOMER1__:__HOMER__:__HOMER1A, INCLUDED;; HOMER1B, INCLUDED;; HOMER1C, INCLUDED
Asterisk__:__604799__:__HOMER, DROSOPHILA, HOMOLOG OF, 2; HOMER2__:____:__HOMER2A, INCLUDED;; HOMER2B, INCLUDED
Asterisk__:__604800__:__HOMER, DROSOPHILA, HOMOLOG OF, 3; HOMER3__:____:__
Percent__:__604801__:__MUSCULAR DYSTROPHY, CONGENITAL, 1B; MDC1B__:____:__
Percent__:__604802__:__HUNTINGTON DISEASE-LIKE 3; HDL3__:__HUNTINGTON DISEASE-LIKE NEURODEGENERATIVE DISORDER, AUTOSOMAL RECESSIVE__:__
Asterisk__:__604803__:__DOPEY FAMILY MEMBER 2; DOPEY2__:__PATTERNING DEFECTIVE 1, C. ELEGANS, HOMOLOG OF; PAD1;; CHROMOSOME 21 OPEN READING FRAME 5; C21ORF5__:__
Number Sign__:__604804__:__MICROCEPHALY 3, PRIMARY, AUTOSOMAL RECESSIVE; MCPH3__:____:__
Number Sign__:__604805__:__SPASTIC PARAPLEGIA 12, AUTOSOMAL DOMINANT; SPG12__:____:__
Asterisk__:__604806__:__FIBRONECTIN-LIKE DOMAIN-CONTAINING LEUCINE-RICH TRANSMEMBRANE PROTEIN 1; FLRT1__:____:__
Asterisk__:__604807__:__FIBRONECTIN-LIKE DOMAIN-CONTAINING LEUCINE-RICH TRANSMEMBRANE PROTEIN 2; FLRT2__:____:__
Asterisk__:__604808__:__FIBRONECTIN-LIKE DOMAIN-CONTAINING LEUCINE-RICH TRANSMEMBRANE PROTEIN 3; FLRT3__:____:__
Percent__:__604809__:__PANBRONCHIOLITIS, DIFFUSE__:__DPB;; PBLT__:__
Asterisk__:__604810__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 1; LILRA1__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 6; LIR6;; CD85I__:__
Asterisk__:__604811__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 1; LILRB1__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 1; LIR1;; IMMUNOGLOBULIN-LIKE TRANSCRIPT 2; ILT2;; MONOCYTE/MACROPHAGE IMMUNOGLOBULIN-LIKE RECEPTOR 7; MIR7;; CD85;; CD85J__:__
Asterisk__:__604812__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 2; LILRA2__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 7; LIR7;; IMMUNOGLOBULIN-LIKE TRANSCRIPT 1; ILT1;; CD85H__:__
Asterisk__:__604813__:__CYTOCHROME c OXIDASE COPPER CHAPERONE COX17; COX17__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX17;; COX17, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__604814__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 5; LILRB5__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 8; LIR8;; CD85C__:__
Asterisk__:__604815__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 2; LILRB2__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 2; LIR2;; IMMUNOGLOBULIN-LIKE TRANSCRIPT 4; ILT4;; MONOCYTE/MACROPHAGE IMMUNOGLOBULIN-LIKE RECEPTOR 10; MIR10;; CD85D__:__
Caret__:__604816__:__MOVED TO 604213__:____:__
Asterisk__:__604817__:__CARBOHYDRATE SULFOTRANSFERASE 5; CHST5__:__N-ACETYLGLUCOSAMINE-6-O-SULFOTRANSFERASE, INTESTINAL; IGlcNAc6ST;; GlcNAc-6-O-SULFOTRANSFERASE, INTESTINAL__:__
Asterisk__:__604818__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 3; LILRA3__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 4; LIR4;; IMMUNOGLOBULIN-LIKE TRANSCRIPT 6; ILT6;; HM43;; CD85E__:__
Asterisk__:__604819__:__POLY-U-BINDING SPLICING FACTOR, 60-KD; PUF60__:__FUSE-BINDING PROTEIN-INTERACTING REPRESSOR; FIR;; FBP-INTERACTING REPRESSOR;; SIAH-BINDING PROTEIN 1; SIAHBP1__:__
Asterisk__:__604820__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 3; LILRB3__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 3; LIR3;; IMMUNOGLOBULIN LEUKOCYTE TRANSCRIPT 5; ILT5;; HL9;; CD85A;; PAIRED IMMUNOGLOBULIN-LIKE RECEPTOR B; PIRB__:__
Asterisk__:__604821__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY B, MEMBER 4; LILRB4__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 5; LIR5;; IMMUNOGLOBULIN LEUKOCYTE TRANSCRIPT 3; ILT3;; HM18;; CD85K__:__
Asterisk__:__604822__:__CALPAIN 11; CAPN11__:____:__
Asterisk__:__604823__:__BarH-LIKE HOMEOBOX GENE 2; BARX2__:____:__
Asterisk__:__604824__:__KLOTHO; KL__:__ALPHA-KLOTHO__:__
Asterisk__:__604825__:__FASCICULATION AND ELONGATION PROTEIN ZETA 1; FEZ1__:__FASCICULATION AND ELONGATION PROTEIN ZYGIN I__:__
Asterisk__:__604826__:__FASCICULATION AND ELONGATION PROTEIN ZETA 2; FEZ2__:__FASCICULATION AND ELONGATION PROTEIN ZYGIN II__:__
Percent__:__604827__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 7; EIG7__:____:__MYOCLONIC EPILEPSY, JUVENILE, 2, INCLUDED; EJM2, INCLUDED
Asterisk__:__604828__:__CHEMOKINE, C MOTIF, LIGAND 2; XCL2__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY C, MEMBER 2; SCYC2;; SINGLE CYSTEINE MOTIF 1B; SCM1B__:__
Asterisk__:__604829__:__DOWN SYNDROME CRITICAL REGION GENE 4; DSCR4__:__DOWN SYNDROME CRITICAL REGION GENE B; DSCRB__:__
NULL__:__604830__:__MANDIBULOFACIAL DYSOSTOSIS SYNDROME, BAURU TYPE__:____:__
Asterisk__:__604831__:__EVC GENE; EVC__:__EVC1__:__
Asterisk__:__604832__:__CARBONIC ANHYDRASE XIV; CA14__:__CA XIV__:__
Asterisk__:__604833__:__CHEMOKINE, CC MOTIF, LIGAND 27; CCL27__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY A, MEMBER 27; SCYA27;; IL11RA-LOCUS CHEMOKINE; ILC;; CUTANEOUS T CELL-ATTRACTING CHEMOKINE; CTACK;; ESKINE__:__
Asterisk__:__604834__:__TANK-BINDING KINASE 1; TBK1__:__NF-KAPPA-B-ACTIVATING KINASE; NAK__:__
Asterisk__:__604835__:__DUAL-SPECIFICITY PHOSPHATASE 12; DUSP12__:__YVH1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__604836__:__CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4__:__CKR4;; CMKBR4__:__
Asterisk__:__604837__:__PROSTAGLANDIN D2 RECEPTOR 2; PTGDR2__:__G PROTEIN-COUPLED RECEPTOR 44; GPR44;; CRTH2__:__
Asterisk__:__604838__:__G PROTEIN-COUPLED RECEPTOR 45; GPR45__:____:__
Asterisk__:__604839__:__FK506-BINDING PROTEIN 6; FKBP6__:__FK506-BINDING PROTEIN, 36-KD__:__
Asterisk__:__604840__:__FK506-BINDING PROTEIN 8; FKBP8__:__FK506-BINDING PROTEIN, 38-KD; FKBP38__:__
Number Sign__:__604841__:__STICKLER SYNDROME, TYPE II; STL2__:__STICKLER SYNDROME, VITREOUS TYPE 2;; STICKLER SYNDROME, BEADED VITREOUS TYPE__:__
Asterisk__:__604842__:__SOLUTE CARRIER FAMILY 22 (EXTRANEURONAL MONOAMINE TRANSPORTER), MEMBER 3; SLC22A3__:__EXTRANEURONAL MONOAMINE TRANSPORTER; EMT;; ORGANIC CATION TRANSPORTER 3; OCT3__:__
Asterisk__:__604843__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B1; SLCO1B1__:__LIVER-SPECIFIC TRANSPORTER 1; LST1;; ORGANIC ANION TRANSPORTER 2; OATP2;; ORGANIC ANION TRANSPORTER C; OATPC;; ORGANIC ANION TRANSPORTER 1B1; OATP1B1;; SOLUTE CARRIER FAMILY 21 (ORGANIC ANION TRANSPORTER), MEMBER 6, FORMERLY; SLC21A6, FORMERLY__:__
Asterisk__:__604844__:__HEPARAN SULFATE 2-O-SULFOTRANSFERASE 1; HS2ST1__:____:__
Asterisk__:__604845__:__PROSTATE CANCER ANTIGEN 3; PCA3__:__PROSTATE-SPECIFIC GENE DD3; DD3__:__
Asterisk__:__604846__:__HEPARAN SULFATE 6-O-SULFOTRANSFERASE 1; HS6ST1__:__HS6ST__:__
Asterisk__:__604847__:__G PROTEIN-COUPLED RECEPTOR 26; GPR26__:____:__
Caret__:__604848__:__MOVED TO 604849__:____:__
Asterisk__:__604849__:__TRACE AMINE-ASSOCIATED RECEPTOR 2; TAAR2__:__G PROTEIN-COUPLED RECEPTOR 58; GPR58__:__
Asterisk__:__604850__:__COP9 SIGNALOSOME, SUBUNIT 5; COPS5__:__CSN5;; JUN ACTIVATION DOMAIN-BINDING PROTEIN; JAB1;; SGN5;; MOV34 FAMILY, 38-KD MEMBER__:__
Asterisk__:__604851__:__G-RICH RNA SEQUENCE-BINDING FACTOR 1; GRSF1__:____:__
Asterisk__:__604852__:__CHEMOKINE, CXC MOTIF, LIGAND 11; CXCL11__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 11; SCYB11;; INTERFERON-GAMMA-INDUCIBLE PROTEIN 9; IP9;; INTERFERON-INDUCIBLE T-CELL ALPHA CHEMOATTRACTANT; ITAC;; SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 9B; SCYB9B__:__
Asterisk__:__604853__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L28; MRPL28__:__MELANOMA-ASSOCIATED ANTIGEN RECOGNIZED BY T LYMPHOCYTES 1; MAAT1__:__
Asterisk__:__604854__:__INDOLETHYLAMINE N-METHYLTRANSFERASE; INMT__:____:__
NULL__:__604855__:__HYALURONAN METABOLISM, DEFECT IN__:____:__
NULL__:__604856__:__LANGERHANS CELL HISTIOCYTOSIS__:__LCH__:__
Asterisk__:__604857__:__SIGNAL RECOGNITION PARTICLE, 54-KD; SRP54__:____:__
Asterisk__:__604858__:__SIGNAL RECOGNITION PARTICLE, 68-KD; SRP68__:____:__
Asterisk__:__604859__:__LIM AND CYSTEINE-RICH DOMAINS 1; LMCD1__:____:__
Asterisk__:__604860__:__MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA TRANSLOCATION GENE 1; MALT1__:__MLT;; PARACASPASE__:__MALT1/API2 FUSION GENE, INCLUDED
Asterisk__:__604861__:__LARGE TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 2; LATS2__:____:__
Asterisk__:__604862__:__CD207 ANTIGEN; CD207__:__LECTIN, C-TYPE, LANGERHANS CELL-SPECIFIC;; LANGERIN;; C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER K; CLEC4K__:__
Asterisk__:__604863__:__LECITHIN RETINOL ACYLTRANSFERASE; LRAT__:____:__
Number Sign__:__604864__:__OSTEOARTHRITIS WITH MILD CHONDRODYSPLASIA; OSCDP__:__NAMAQUALAND HIP DYSPLASIA; NHD__:__
Asterisk__:__604865__:__KRUPPEL-LIKE FACTOR 7; KLF7__:__UBIQUITOUS KRUPPEL-LIKE FACTOR; UKLF__:__
Asterisk__:__604866__:__PLEOMORPHIC ADENOMA GENE-LIKE 2; PLAGL2__:____:__
Asterisk__:__604867__:__TASTE RECEPTOR, TYPE 2, MEMBER 16; TAS2R16__:__T2R16__:__
Asterisk__:__604868__:__TASTE RECEPTOR, TYPE 2, MEMBER 3; TAS2R3__:__T2R3__:__
Asterisk__:__604869__:__TASTE RECEPTOR, TYPE 2, MEMBER 4; TAS2R4__:__T2R4__:__
Asterisk__:__604870__:__MACROPHAGE RECEPTOR WITH COLLAGENOUS STRUCTURE; MARCO__:__SCAVENGER RECEPTOR CLASS A, MEMBER 2; SCARA2__:__
Asterisk__:__604871__:__MATRIX METALLOPROTEINASE 24; MMP24__:__MEMBRANE-TYPE MATRIX METALLOPROTEINASE 5; MT5-MMP__:__
Asterisk__:__604872__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 7; PCSK7__:__PC8;; PC7;; LYMPHOMA PROPROTEIN CONVERTASE; LPC__:__
Asterisk__:__604873__:__MYELIN PROTEIN ZERO-LIKE 2; MPZL2__:__EPITHELIAL V-LIKE ANTIGEN 1; EVA1;; EVA__:__
Asterisk__:__604874__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY G, MEMBER 1; KLRG1__:__MAST CELL FUNCTION-ASSOCIATED ANTIGEN, RAT, HOMOLOG OF; MAFA;; MAFA-LIKE; MAFAL__:__
Asterisk__:__604875__:__MYOSIN IXA; MYO9A__:____:__
Asterisk__:__604876__:__REGULATOR OF CALCINEURIN 2; RCAN2__:__THYROID HORMONE-RESPONSIVE GENE ZAKI4; ZAKI4;; DOWN SYNDROME CANDIDATE REGION 1-LIKE 1; DSCR1L1;; MYOCYTE-ENRICHED CALCINEURIN-INTERACTING PROTEIN 2; MCIP2;; CALCIPRESSIN 2; CSP2__:__
Asterisk__:__604877__:__V-MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE FAMILY, PROTEIN F; MAFF__:____:__
Asterisk__:__604878__:__SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 6; SLC12A6__:__POTASSIUM-CHLORIDE COTRANSPORTER 3; KCC3__:__POTASSIUM-CHLORIDE COTRANSPORTER 3, ISOFORM A, INCLUDED; KCC3A, INCLUDED;; POTASSIUM-CHLORIDE COTRANSPORTER 3, ISOFORM B, INCLUDED; KCC3B, INCLUDED
Asterisk__:__604879__:__SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 7; SLC12A7__:__POTASSIUM-CHLORIDE COTRANSPORTER 4; KCC4__:__
Caret__:__604880__:__MOVED TO 300609__:____:__
Asterisk__:__604881__:__RABPHILIN 3A-LIKE; RPH3AL__:__NOC2__:__
Asterisk__:__604882__:__NEUROGENIN 3; NEUROG3__:__NGN3;; ATOH5__:__
Asterisk__:__604883__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 2; GTF3C2__:__TRANSCRIPTION FACTOR IIIC, BETA SUBUNIT;; TFIIIC-BETA;; TFIIIC, 110-KD SUBUNIT__:__
Asterisk__:__604884__:__NEVER IN MITOSIS GENE A-RELATED KINASE 6; NEK6__:__NIMA-RELATED KINASE 6__:__
Asterisk__:__604885__:__MYB-BINDING PROTEIN 1A; MYBBP1A__:__P160__:__
Asterisk__:__604886__:__ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 8; EMC8__:__ER MEMBRANE PROTEIN COMPLEX, SUBUNIT 8;; COX4, NEIGHBOR OF; NOC4__:__
Asterisk__:__604887__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE 2; MTHFD2__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE/METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE, NAD(+)-DEPENDENT__:__
Asterisk__:__604888__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 3; GTF3C3__:__TRANSCRIPTION FACTOR IIIC, 102-KD SUBUNIT; TFIIIC102__:__
Asterisk__:__604889__:__NEUROBEACHIN; NBEA__:____:__FRAGILE SITE FRA13A, INCLUDED
Asterisk__:__604890__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 5; GTF3C5__:__TRANSCRIPTION FACTOR IIIC, 63-KD SUBUNIT; TFIIIC63__:__
Asterisk__:__604891__:__NCK-ASSOCIATED PROTEIN 1; NCKAP1__:__NAP1;; NCK-ASSOCIATED PROTEIN, 125-KD; NAP125__:__
Asterisk__:__604892__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 4; GTF3C4__:__TRANSCRIPTION FACTOR IIIC, 90-KD SUBUNIT; TFIIIC90__:__
Asterisk__:__604893__:__ANTISENSE IGF2R RNA, NONCODING; AIRN__:__ANTISENSE IGF2R RNA; AIR__:__
Asterisk__:__604894__:__ONE CUT HOMEOBOX 2; ONECUT2__:__ONE CUT DOMAIN, FAMILY MEMBER 2; OC2__:__
Asterisk__:__604895__:__T-BOX 21; TBX21__:__T-BOX EXPRESSED IN T CELLS; TBET__:__
Asterisk__:__604896__:__MKKS GENE; MKKS__:__MKS;; BBS6 GENE; BBS6__:__
Asterisk__:__604897__:__PREFOLDIN 1; PFDN1__:____:__
Asterisk__:__604898__:__PREFOLDIN 4; PFDN4__:__C1__:__
Asterisk__:__604899__:__PREFOLDIN 5; PFDN5__:__MM1__:__
Asterisk__:__604900__:__DIACYLGLYCEROL O-ACYLTRANSFERASE 1; DGAT1__:__DGAT;; ACYL-CoA:DIACYLGLYCEROL ACYLTRANSFERASE;; ARGP1__:__
Percent__:__604901__:__NORTH AMERICAN INDIAN CHILDHOOD CIRRHOSIS; NAIC__:____:__
Asterisk__:__604902__:__BRF1 SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR; BRF1__:__BRF1, S. CEREVISIAE, HOMOLOG OF;; BRF;; TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, RNA POLYMERASE III, SUBUNIT 2; TAF3B2;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE III, 90-KD;; GENERAL TRANSCRIPTION FACTOR 3B, 90-KD SUBUNIT;; GTF3B, 90-KD SUBUNIT;; TRANSCRIPTION FACTOR IIIB, 90-KD SUBUNIT; TFIIIB90;; TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 3C, FORMERLY; TAF3C, FORMERLY__:__
Asterisk__:__604903__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1A; TAF1A__:__TBP-ASSOCIATED FACTOR, RNA POLYMERASE I, 48-KD; TAFI48;; SL1, 48-KD SUBUNIT__:__
Asterisk__:__604904__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1B; TAF1B__:__TBP-ASSOCIATED FACTOR, RNA POLYMERASE I, 63-KD; TAFI63;; SL1, 63-KD SUBUNIT__:__
Asterisk__:__604905__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1C; TAF1C__:__TBP-ASSOCIATED FACTOR, RNA POLYMERASE I, 110-KD; TAFI110;; SL1, 110-KD SUBUNIT__:__
Number Sign__:__604906__:__SCHIZOPHRENIA 9; SCZD9__:__SCHIZOPHRENIA 9 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 1q42-RELATED__:__
Asterisk__:__604907__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 13B; TNFRSF13B__:__TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TACI__:__
Asterisk__:__604908__:__PROTEIN PHOSPHATASE 4, REGULATORY SUBUNIT 1; PPP4R1__:__PP4R1__:__
Asterisk__:__604909__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 2; CNOT2__:__NEGATIVE REGULATOR OF TRANSCRIPTION 2, S. CEREVISIAE, HOMOLOG OF; NOT2__:__
Asterisk__:__604910__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 3; CNOT3__:__NEGATIVE REGULATOR OF TRANSCRIPTION 3, S. CEREVISIAE, HOMOLOG OF; NOT3__:__
Asterisk__:__604911__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 4; CNOT4__:__NEGATIVE REGULATOR OF TRANSCRIPTION 4, S. CEREVISIAE, HOMOLOG OF; NOT4__:__
Asterisk__:__604912__:__TAF2 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 150-KD; TAF2__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2B; TAF2B;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 150-KD; TAFII150;; COFACTOR OF INITIATOR FUNCTION, 150-KD SUBUNIT; CIF150__:__
Asterisk__:__604913__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 7; CNOT7__:__CCR4-ASSOCIATED FACTOR 1; CAF1;; CARBON CATABOLITE REPRESSOR 4-ASSOCIATED FACTOR 1__:__
Asterisk__:__604914__:__JUMONJI DOMAIN-CONTAINING PROTEIN 6; JMJD6__:__PHOSPHATIDYLSERINE RECEPTOR; PSR__:__
Asterisk__:__604915__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 13; MAP3K13__:__LEUCINE ZIPPER-BEARING KINASE; LZK__:__
NULL__:__604916__:__HYDRONEPHROSIS, CONGENITAL, WITH CLEFT PALATE, CHARACTERISTIC FACIES, HYPOTONIA, AND MENTAL RETARDATION__:__OKAMOTO SYNDROME__:__
Asterisk__:__604917__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 1; CNOT1__:__NEGATIVE REGULATOR OF TRANSCRIPTION 1, S. CEREVISIAE, HOMOLOG OF; NOT1__:__
Asterisk__:__604918__:__PICCOLO, MOUSE, HOMOLOG OF; PCLO__:____:__
NULL__:__604919__:__BECKER NEVUS SYNDROME__:____:__
Caret__:__604920__:__MOVED TO 603218__:____:__
Asterisk__:__604921__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3; MAP4K3__:__MAPKKKK3;; GERMINAL CENTER KINASE-LIKE KINASE; GLK;; RAB8-INTERACTING PROTEIN-LIKE 1, FORMERLY; RAB8IPL1, FORMERLY__:__
NULL__:__604922__:__CORTICAL DEFECTS, WORMIAN BONES, AND DENTINOGENESIS IMPERFECTA__:____:__
Asterisk__:__604923__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 5; MAP4K5__:__MAPKKKK5__:__
Asterisk__:__604924__:__PHOSPHORYLATED ADAPTOR FOR RNA EXPORT; PHAX__:__RNA, U SMALL NUCLEAR, EXPORT ADAPTOR; RNUXA__:__
Asterisk__:__604925__:__RAB ACCEPTOR 1; RABAC1__:__PRENYLATED RAB ACCEPTOR 1; PRA1;; PRA1 DOMAIN FAMILY, MEMBER 1; PRAF1;; YIP3, YEAST, HOMOLOG OF__:__
Caret__:__604926__:__MOVED TO 300948__:____:__
Asterisk__:__604927__:__C-TERMINAL DOMAIN OF RNA POLYMERASE II SUBUNIT A, PHOSPHATASE OF, SUBUNIT 1; CTDP1__:__CTD OF POLR2A, PHOSPHATASE OF, SUBUNIT 1;; TRANSCRIPTION FACTOR IIF-ASSOCIATING CTD PHOSPHATASE 1; FCP1;; TFIIF-ASSOCIATING CTD PHOSPHATASE 1__:__TRANSCRIPTION FACTOR IIF-ASSOCIATING CTD PHOSPHATASE 1, ISOFORM A, INCLUDED; FCP1A, INCLUDED;; TRANSCRIPTION FACTOR IIF-ASSOCIATING CTD PHOSPHATASE 1, ISOFORM B, INCLUDED; FCP1B, INCLUDED
Number Sign__:__604928__:__WOLFRAM SYNDROME 2; WFS2__:____:__
Caret__:__604929__:__MOVED TO 181350__:____:__
Asterisk__:__604930__:__NCK ADAPTOR PROTEIN 2; NCK2__:__NONCATALYTIC REGION OF TYROSINE KINASE, BETA;; NCK-BETA;; GRB4__:__
Number Sign__:__604931__:__CORTISONE REDUCTASE DEFICIENCY 1; CORTRD1__:____:__
Asterisk__:__604932__:__PROTEIN KINASE, cAMP-DEPENDENT CATALYTIC, INHIBITOR GAMMA; PKIG__:____:__
Asterisk__:__604933__:__MutY, E. COLI, HOMOLOG OF; MUTYH__:__MYH__:__
Asterisk__:__604934__:__TUBULIN-SPECIFIC CHAPERONE E; TBCE__:__COFACTOR E__:__
Asterisk__:__604935__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR 2; DMRT2__:____:__
Asterisk__:__604936__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 1; KIR2DL1__:__NK-ASSOCIATED TRANSCRIPT 1; NKAT1;; CD158A__:__
Asterisk__:__604937__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 2; KIR2DL2__:__NK-ASSOCIATED TRANSCRIPT 6; NKAT6;; CD158B1__:__
Asterisk__:__604938__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 3; KIR2DL3__:__NK-ASSOCIATED TRANSCRIPT 2; NKAT2;; P58;; CD158B2__:__NK-ASSOCIATED TRANSCRIPT 2A, INCLUDED; NKAT2A, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 2B, INCLUDED; NKAT2B, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 2delIg2, INCLUDED; NKAT2delIg2, INCLUDED
Asterisk__:__604939__:__PHOSPHOLIPASE A2 RECEPTOR 1; PLA2R1__:__PHOSPHOLIPASE A2 RECEPTOR, 180-KD;; PLA2R__:__
Caret__:__604940__:__MOVED TO 601228__:____:__
Asterisk__:__604941__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B, ALPHA; PPP2R2A__:__PR55-ALPHA;; B55-ALPHA__:__
Asterisk__:__604942__:__SYNTAPHILIN; SNPH__:____:__
Asterisk__:__604943__:__SOLUTE CARRIER FAMILY 26, MEMBER 5; SLC26A5__:__PRESTIN; PRES__:__SLC26A5A, INCLUDED;; SLC26A5B, INCLUDED;; SLC26A5C, INCLUDED;; SLC26A5D, INCLUDED
Asterisk__:__604944__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, ALPHA; PPP2R3A__:____:__PR72, INCLUDED;; PR130, INCLUDED
Asterisk__:__604945__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 4; KIR2DL4__:__KIR103AS;; CD158D__:__
Asterisk__:__604946__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, LONG CYTOPLASMIC TAIL, 1; KIR3DL1__:__NK-ASSOCIATED TRANSCRIPT 3; NKAT3;; NKB1;; AMB11;; CD158E1__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, SHORT CYTOPLASMIC TAIL, 1, INCLUDED; KIR3DS1, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 10, INCLUDED; NKAT10, INCLUDED;; CD158E2, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 3delIg1, INCLUDED; NKAT3delIg1, INCLUDED
Asterisk__:__604947__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, LONG CYTOPLASMIC TAIL, 2; KIR3DL2__:__NK-ASSOCIATED TRANSCRIPT 4; NKAT4;; CD158K__:__NK-ASSOCIATED TRANSCRIPT 4A, INCLUDED; NKAT4A, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 4B, INCLUDED; NKAT4B, INCLUDED
Asterisk__:__604948__:__GROWTH ARREST- AND DNA DAMAGE-INDUCIBLE GENE GADD45, BETA; GADD45B__:__MYD118, MOUSE, HOMOLOG OF; MYD118__:__
Asterisk__:__604949__:__GROWTH ARREST- AND DNA DAMAGE-INDUCIBLE GENE GADD45, GAMMA; GADD45G__:__GADD-RELATED PROTEIN, 17-KD; GRP17;; OIG37, MOUSE, HOMOLOG OF__:__
Asterisk__:__604950__:__PUTATIVE HOMEODOMAIN TRANSCRIPTION FACTOR 1; PHTF1__:__PHTF__:__
Asterisk__:__604951__:__6-PHOSPHOGLUCONOLACTONASE; PGLS__:__6PGL__:__
Asterisk__:__604952__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 1; KIR2DS1__:__CD158H__:__
Asterisk__:__604953__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 2; KIR2DS2__:__NK-ASSOCIATED TRANSCRIPT 5; NKAT5;; CD158J__:__NK-ASSOCIATED TRANSCRIPT 5delIg1, INCLUDED; NKAT5delIg1, INCLUDED;; NK-ASSOCIATED TRANSCRIPT 5delIg1/Ig2, INCLUDED; NKAT5delIg1/Ig2, INCLUDED
Asterisk__:__604954__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 3; KIR2DS3__:__NK-ASSOCIATED TRANSCRIPT; NKAT7__:__
Asterisk__:__604955__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 4; KIR2DS4__:__NK-ASSOCIATED TRANSCRIPT 8; NKAT8;; KKA3;; CD158I__:__
Asterisk__:__604956__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 5; KIR2DS5__:__NK-ASSOCIATED TRANSCRIPT 9; NKAT9;; CD158G__:__
Caret__:__604957__:__MOVED TO 604946__:____:__
Asterisk__:__604958__:__ACTIN-LIKE 6A; ACTL6A__:__BRG1-ASSOCIATED FACTOR, 53-KD; BAF53;; BAF53A;; ACTIN-RELATED PROTEIN, BETA;; ARPN-BETA__:__
Asterisk__:__604959__:__PHORBOL-12-MYRISTATE-13-ACETATE-INDUCED PROTEIN 1; PMAIP1__:__PMA-INDUCED PROTEIN 1;; ATL-DERIVED PMA-RESPONSIVE GENE; APR;; NOXA__:__
Asterisk__:__604960__:__PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE IN NEURONS 2; PACSIN2__:____:__
Asterisk__:__604961__:__PHOSPHODIESTERASE 11A; PDE11A__:__PDE11A1__:__PDE11A2, INCLUDED;; PDE11A3, INCLUDED
Asterisk__:__604962__:__T-CELL RECEPTOR-ASSOCIATED TRANSMEMBRANE ADAPTOR 1; TRAT1__:__T-CELL ANTIGEN RECEPTOR-INTERACTING MOLECULE;; TCR-INTERACTING MOLECULE; TRIM__:__
Asterisk__:__604963__:__PEPTIDOGLYCAN RECOGNITION PROTEIN 1; PGLYRP1__:__PGLYRP; PGRP;; PGRP, SHORT; PGRPS__:__
Asterisk__:__604964__:__SHP2-INTERACTING TRANSMEMBRANE ADAPTOR PROTEIN 1; SIT1__:____:__
Asterisk__:__604965__:__SERINE/THREONINE PROTEIN KINASE 4; STK4__:__MAMMALIAN STERILE 20-LIKE 1; MST1;; KINASE RESPONSIVE TO STRESS 2; KRS2__:__
Number Sign__:__604966__:__PROTOCADHERIN-ALPHA GENE CLUSTER; PCDHA@__:__PCDH-ALPHA GENE CLUSTER; PCDHA__:__
Number Sign__:__604967__:__PROTOCADHERIN-BETA GENE CLUSTER; PCDHB@__:__PCDH-BETA GENE CLUSTER; PCDHB__:__
Number Sign__:__604968__:__PROTOCADHERIN-GAMMA GENE CLUSTER; PCDHG@__:__PCDH-GAMMA GENE CLUSTER; PCDHG__:__
Asterisk__:__604969__:__SRC KINASE-ASSOCIATED PHOSPHOPROTEIN 1; SKAP1__:__SRC FAMILY-ASSOCIATED PHOSPHOPROTEIN 1; SCAP1;; SRC KINASE-ASSOCIATED PHOSPHOPROTEIN, 55-KD; SKAP55__:__
Asterisk__:__604970__:__AURORA KINASE B; AURKB__:__SERINE/THREONINE PROTEIN KINASE 12; STK12;; AURORA-RELATED KINASE 2; ARK2;; AURORA/IPL1-LIKE KINASE 2; AIK2;; AIM1, RAT, HOMOLOG OF; AIM1__:__
Asterisk__:__604971__:__MYOD FAMILY INHIBITOR; MDFI__:____:__
Asterisk__:__604972__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 3, S. CEREVISIAE, HOMOLOG OF; ORC3__:__ORC3-LIKE; ORC3L;; LATHEO, DROSOPHILA, HOMOLOG OF; LAT__:__
Asterisk__:__604973__:__FICOLIN 3; FCN3__:__HAKATA ANTIGEN; HAKA1;; COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING LECTIN 3 P35__:__
Asterisk__:__604974__:__SRY-BOX 21; SOX21__:__SRY-RELATED HMG-BOX GENE 21;; SOX25__:__
Asterisk__:__604975__:__SRY-BOX 5; SOX5__:__SRY-RELATED HMG-BOX GENE 5__:__LONG SOX5, INCLUDED;; L-SOX5, INCLUDED
Plus__:__604976__:__PROTEIN KINASE, AMP-ACTIVATED, NONCATALYTIC, GAMMA-3; PRKAG3__:____:__GLYCOGEN CONTENT IN SKELETAL MUSCLE, INCREASED, INCLUDED
Asterisk__:__604977__:__SERINE/THREONINE PROTEIN KINASE 19; STK19__:__HLA-RP1__:__
Asterisk__:__604978__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 5; CPSF5__:__PRECURSOR mRNA CLEAVAGE FACTOR Im, 25-KD SUBUNIT; CFIM25__:__
Asterisk__:__604979__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 6; CPSF6__:__PRECURSOR mRNA CLEAVAGE FACTOR Im, 68-KD SUBUNIT; CFIM68__:__
Asterisk__:__604980__:__GTPase-ACTIVATING PROTEIN, RAC, 1; RACGAP1__:__RAC GTPase-ACTIVATING PROTEIN 1;; RAC GTPase-ACTIVATING PROTEIN, MALE GERM CELL; MGCRACGAP;; CYK4, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__604981__:__WW DOMAIN-CONTAINING BINDING PROTEIN 4; WBP4__:__FORMIN-BINDING PROTEIN 21; FBP21__:__
Asterisk__:__604982__:__HPS1 GENE; HPS1__:__PALE EAR, MOUSE, HOMOLOG OF__:__
Asterisk__:__604983__:__POLYMERASE, DNA, GAMMA-2; POLG2__:__POLG, ACCESSORY SUBUNIT;; POLG-BETA; POLGB__:__
Asterisk__:__604984__:__SERINE/THREONINE PROTEIN KINASE 24; STK24__:__MAMMALIAN STERILE 20-LIKE 3; MST3__:__MAMMALIAN STERILE 20-LIKE 3, ISOFORM B, INCLUDED; MST3B, INCLUDED
Asterisk__:__604985__:__SPECTRIN, BETA, NONERYTHROCYTIC, 2; SPTBN2__:__SPECTRIN, BETA-III;; GLUTAMATE TRANSPORTER EAAT4-ASSOCIATED PROTEIN 41; GTRAP41__:__
Asterisk__:__604986__:__BRCA1-ASSOCIATED PROTEIN; BRAP__:__BRAP2;; IMPEDES MITOGENIC SIGNAL PROPAGATION; IMP__:__
Asterisk__:__604987__:__C-TYPE LECTIN DOMAIN FAMILY 5, MEMBER A; CLEC5A__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 5; CLECSF5;; MYELOID DAP12-ASSOCIATING LECTIN 1; MDL1__:__
Asterisk__:__604988__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 2B1; SLCO2B1__:__ORGANIC ANION TRANSPORTER B; OATPB;; ORGANIC ANION TRANSPORTER 2B1; OATP2B1;; SOLUTE CARRIER FAMILY 21 (ORGANIC ANION TRANSPORTER), MEMBER 9, FORMERLY; SLC21A9, FORMERLY__:__
Asterisk__:__604989__:__SPONDIN 1; SPON1__:__F-SPONDIN, RAT, HOMOLOG OF;; KIAA0762__:__
Asterisk__:__604990__:__SOLUTE CARRIER FAMILY 9, MEMBER 3, REGULATOR 1; SLC9A3R1__:__SODIUM/HYDROGEN EXCHANGER REGULATORY FACTOR 1; NHERF1;; ERM-BINDING PHOSPHOPROTEIN, 50-KD; EBP50__:__
Asterisk__:__604991__:__PROSTATE ANDROGEN-REGULATED TRANSCRIPT 1; PART1__:____:__
Asterisk__:__604992__:__SARCALUMENIN; SRL__:____:__
Asterisk__:__604993__:__PRECURSOR mRNA-PROCESSING FACTOR 18, S. CEREVISIAE, HOMOLOG OF; PRPF18__:__PRP18__:__
Asterisk__:__604994__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 2; SIX2__:____:__
Asterisk__:__604995__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION TRANSPORTER), MEMBER 7; SLC22A7__:__ORGANIC ANION TRANSPORTER 2; OAT2__:__
Asterisk__:__604996__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 3; FXYD3__:__PHOSPHOLEMMAN-LIKE; PLML;; MAMMARY TUMOR, 8-KD; MAT8__:__
Asterisk__:__604997__:__DOCKING PROTEIN 2; DOK2__:__DOCKING PROTEIN, 56-KD;; p56DOK__:__
Asterisk__:__604998__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I; CAMK1__:__CAMKI__:__
Asterisk__:__604999__:__SH3 AND MULTIPLE ANKYRIN REPEAT DOMAINS 1; SHANK1__:__SOMATOSTATIN RECEPTOR-INTERACTING PROTEIN; SSTRIP__:__
Asterisk__:__605000__:__CORONIN 1A; CORO1A__:__CORONIN 1;; CORONIN-LIKE PROTEIN A; CLIPINA;; TRYPTOPHANE ASPARTATE-CONTAINING COAT PROTEIN; TACO__:__
Asterisk__:__605001__:__ANGIOPOIETIN-LIKE 2; ANGPTL2__:__ANGIOPOIETIN-RELATED PROTEIN 2; ARP2__:__
Asterisk__:__605002__:__CORONIN 2B; CORO2B__:__CORONIN-LIKE PROTEIN C; CLIPINC__:__
Asterisk__:__605003__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 6; SENP6__:__SUMO1-SPECIFIC PROTEASE 1; SUSP1; SSP1__:__SUSP1/TCBA1 FUSION GENE, INCLUDED
Asterisk__:__605004__:__GLYCOGEN SYNTHASE KINASE 3-BETA; GSK3B__:____:__
Asterisk__:__605005__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 7; GALNT7__:__GalNAc TRANSFERASE 7; GalNAcT7__:__
Asterisk__:__605006__:__FREQUENTLY REARRANGED IN ADVANCED T-CELL LYMPHOMAS 2; FRAT2__:____:__
Asterisk__:__605007__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 5; ADAMTS5__:__AGGRECANASE 2;; ADAMTS11, FORMERLY__:__
Asterisk__:__605008__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 6; ADAMTS6__:____:__
Asterisk__:__605009__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 7; ADAMTS7__:____:__
Asterisk__:__605010__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 5; SPINK5__:__LYMPHOEPITHELIAL KAZAL-TYPE-RELATED INHIBITOR; LEKTI__:__
Asterisk__:__605011__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 3; ADAMTS3__:____:__
Asterisk__:__605012__:__SUPPRESSOR OF TY 16, S. CEREVISIAE, HOMOLOG OF; SUPT16H__:__CHROMATIN-SPECIFIC TRANSCRIPTION ELONGATION FACTOR, 140-KD SUBUNIT;; FACT, 140-KD SUBUNIT;; SPT16, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__605013__:__MICROHYDRANENCEPHALY; MHAC__:__HYDRANENCEPHALY AND MICROCEPHALY__:__
Asterisk__:__605014__:__SYNTAXIN 11; STX11__:____:__
Asterisk__:__605015__:__ZINC FINGER PROTEIN 214; ZNF214__:____:__
Asterisk__:__605016__:__ZINC FINGER PROTEIN 215; ZNF215__:____:__
Asterisk__:__605017__:__PRE-B-LYMPHOCYTE GENE 3; VPREB3__:____:__
Asterisk__:__605018__:__CYLD GENE; CYLD__:__CYLD1;; KIAA0849__:__
Number Sign__:__605019__:__HYPOBETALIPOPROTEINEMIA, FAMILIAL, 2; FHBL2__:__HYPOLIPIDEMIA, FAMILIAL, COMBINED__:__
Asterisk__:__605020__:__VISUAL SYSTEM HOMEOBOX GENE 1, ZEBRAFISH, HOMOLOG OF; VSX1__:__RETINAL INNER NUCLEAR LAYER HOMEOBOX; RINX__:__
Number Sign__:__605021__:__MYOCLONIC EPILEPSY, FAMILIAL INFANTILE; FIME__:__EIM__:__
Asterisk__:__605022__:__p21 PROTEIN-ACTIVATED KINASE 2; PAK2__:__p21 CDC42/RAC1-ACTIVATED KINASE 1;; p21-ACTIVATED KINASE, 65-KD; PAK65__:__
Asterisk__:__605023__:__HYDROXYACID OXIDASE 1; HAO1__:__HAOX1;; GLYCOLATE OXIDASE 1; GOX1;; GOX__:__
Asterisk__:__605024__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 8; SLC4A8__:__KIAA0739;; KNBC3__:__
Asterisk__:__605025__:__INTEGRIN, ALPHA-3; ITGA3__:__CD49C;; VERY LATE ACTIVATION PROTEIN 3 RECEPTOR, ALPHA-3 SUBUNIT; VLA3;; GALACTOPROTEIN B3; GAPB3__:__
NULL__:__605026__:__DIABETES MELLITUS, CONGENITAL AUTOIMMUNE__:____:__
Number Sign__:__605027__:__LYMPHOMA, NON-HODGKIN, FAMILIAL__:__NON-HODGKIN LYMPHOMA; NHL__:__
NULL__:__605028__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL, MILD ELEVATION OF__:__LDLC, MILD ELEVATION OF__:__
Asterisk__:__605029__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY F, MEMBER 1; KLRF1__:__NKp80;; C-TYPE LECTIN DOMAIN FAMILY 5, MEMBER C; CLEC5C__:__
Asterisk__:__605030__:__SERINE/THREONINE PROTEIN KINASE 3; STK3__:__MAMMALIAN STERILE 20-LIKE 2; MST2;; KINASE RESPONSIVE TO STRESS 1; KRS1__:__
Asterisk__:__605031__:__POLO-LIKE KINASE 4; PLK4__:__SERINE/THREONINE PROTEIN KINASE 18; STK18;; SAK, MOUSE, HOMOLOG OF; SAK__:__
Asterisk__:__605032__:__COMPLEXIN 1; CPLX1__:__CPX1;; SYNAPHIN 2__:__
Asterisk__:__605033__:__COMPLEXIN 2; CPLX2__:__CPX2;; SYNAPHIN 1__:__
Asterisk__:__605034__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 23, YEAST, HOMOLOG OF; TIMM23__:__TIM23__:__
Asterisk__:__605035__:__WAS PROTEIN FAMILY, MEMBER 1; WASF1__:__WASP FAMILY, MEMBER 1;; WASP FAMILY, VERPROLIN HOMOLOGY DOMAIN-CONTAINING PROTEIN; WAVE;; WASP FAMILY, VERPROLIN HOMOLOGY DOMAIN-CONTAINING PROTEIN 1; WAVE1;; SCAR, DICTYOSTELIUM, HOMOLOG OF, 1; SCAR1__:__
Asterisk__:__605036__:__ZINC FINGER PROTEIN 219; ZNF219__:____:__
Asterisk__:__605037__:__KINESIN FAMILY MEMBER 17; KIF17__:__KIAA1405__:__
Asterisk__:__605038__:__POSTMEIOTIC SEGREGATION INCREASED 2-LIKE 1; PMS2L1__:__PMS3__:__
Number Sign__:__605039__:__BOHRING-OPITZ SYNDROME; BOPS__:__C-LIKE SYNDROME;; OPITZ TRIGONOCEPHALY-LIKE SYNDROME;; BOHRING SYNDROME__:__
NULL__:__605040__:__CLAVICULAR HYPOPLASIA, ZYGOMATIC ARCH HYPOPLASIA, AND MICROGNATHIA__:__CHZAM__:__
Number Sign__:__605041__:__BROOKE-SPIEGLER SYNDROME; BRSS__:__BSS;; SPIEGLER-BROOKE SYNDROME; SBS__:__
Asterisk__:__605042__:__MEDIATOR COMPLEX SUBUNIT 23; MED23__:__COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 3; CRSP3;; CRSP, 130-KD SUBUNIT; CRSP130;; DRIP130;; SUR2__:__
Asterisk__:__605043__:__MEDIATOR COMPLEX SUBUNIT 26; MED26__:__COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 7; CRSP7;; CRSP, 70-KD SUBUNIT; CRSP70__:__
Asterisk__:__605044__:__MEDIATOR COMPLEX SUBUNIT 27; MED27__:__TRAP/SMCC/PC2 SUBUNIT p37; TRAP37;; COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 8; CRSP8;; CRSP, 34-KD SUBUNIT; CRSP34__:__
Asterisk__:__605045__:__MEDIATOR COMPLEX SUBUNIT 7; MED7__:__COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 9; CRSP9;; CRSP, 33-KD SUBUNIT; CRSP33__:__
Asterisk__:__605046__:__UBIQUILIN 1; UBQLN1__:__DA41, RAT, HOMOLOG OF; DA41;; PLIC1, MOUSE, HOMOLOG OF; PLIC1;; UBQN, DROSOPHILA, HOMOLOG OF; UBQN__:__
Asterisk__:__605047__:__INTERFERON REGULATORY FACTOR 7; IRF7__:__IRF7A__:__IRF7B, INCLUDED;; IRF7C, INCLUDED;; IRF7H, INCLUDED
Asterisk__:__605048__:__INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, KINASE OF, EPSILON; IKBKE__:__I-KAPPA-B KINASE-EPSILON; IKKE;; IKK-EPSILON;; INDUCIBLE I-KAPPA-B KINASE; IKKI;; KIAA0151__:__
Asterisk__:__605049__:__TWISTED GASTRULATION HOMOLOG 1; TWSG1__:__TSG__:__
Caret__:__605050__:__MOVED TO 142750__:____:__
Asterisk__:__605051__:__CANNABINOID RECEPTOR 2; CNR2__:__CB2 RECEPTOR; CB2;; CX5__:__
Asterisk__:__605052__:__TAR RNA-BINDING PROTEIN 1; TARBP1__:__TRP185__:__
Asterisk__:__605053__:__TAR RNA-BINDING PROTEIN 2; TARBP2__:__TRBP;; LOQUACIOUS, DROSOPHILA, HOMOLOG OF; LOQS__:__
Asterisk__:__605054__:__SMALL EDRK-RICH FACTOR 2; SERF2__:__H4F5REL__:__
Percent__:__605055__:__ALZHEIMER DISEASE, FAMILIAL EARLY-ONSET, WITH COEXISTING AMYLOID AND PRION PATHOLOGY__:____:__
Asterisk__:__605056__:__WAS GENE-LIKE; WASL__:__N-WASP; NWASP__:__
Asterisk__:__605057__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 17, YEAST, HOMOLOG OF, A; TIMM17A__:__TIM17A;; TIM17__:__
Asterisk__:__605058__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 44, YEAST, HOMOLOG OF; TIMM44__:__TIM44__:__
Caret__:__605059__:__MOVED TO 123930__:____:__
Asterisk__:__605060__:__SEDOHEPTULOKINASE; SHPK__:__SHK;; CARBOHYDRATE KINASE-LIKE; CARKL__:__
Asterisk__:__605061__:__TERF2-INTERACTING PROTEIN; TERF2IP__:__TRF2-INTERACTING TELOMERIC PROTEIN;; RAP1, YEAST, HOMOLOG OF; RAP1__:__
Asterisk__:__605062__:__TASTE RECEPTOR, TYPE 2, MEMBER 5; TAS2R5__:__T2R5__:__
Asterisk__:__605063__:__STRESS-INDUCED PHOSPHOPROTEIN 1; STIP1__:__STI1, YEAST, HOMOLOG OF;; HSP70/HSP90-ORGANIZING PROTEIN; HOP__:__
Asterisk__:__605064__:__KINESIN FAMILY MEMBER 23; KIF23__:__KINESIN-LIKE 5; KNSL5;; MITOTIC KINESIN-LIKE 1; MKLP1;; ZEN4, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__605065__:__CELL DIVISION CYCLE 37, S. CEREVISIAE, HOMOLOG OF; CDC37__:____:__
Asterisk__:__605066__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, EPSILON ISOFORM; YWHAE__:__14-3-3 PROTEIN, EPSILON ISOFORM;; 14-3-3-EPSILON__:__
NULL__:__605067__:__TRICUSPID ATRESIA__:____:__
Asterisk__:__605068__:__WAS PROTEIN FAMILY, MEMBER 3; WASF3__:__WASP FAMILY, MEMBER 3;; WASP FAMILY, VERPROLIN HOMOLOGY DOMAIN-CONTAINING PROTEIN 3; WAVE3;; SCAR, DICTYOSTELIUM, HOMOLOG OF, 3; SCAR3__:__
Asterisk__:__605069__:__MITOGEN-ACTIVATED PROTEIN KINASE-INTERACTING SERINE/THREONINE KINASE 2; MKNK2__:__MAPK-INTERACTING KINASE 2; MNK2;; G PROTEIN-COUPLED RECEPTOR KINASE 7, FORMERLY; GPRK7, FORMERLY__:__MKNK2A, INCLUDED;; MKNK2B, INCLUDED
Asterisk__:__605070__:__EARLY ENDOSOME ANTIGEN 1; EEA1__:__EARLY ENDOSOME ANTIGEN, 162-KD__:__
Asterisk__:__605071__:__REGULATOR OF G PROTEIN SIGNALING 19; RGS19__:__G PROTEIN, ALPHA-INTERACTING PROTEIN; GAIP__:__
Asterisk__:__605072__:__GIPC PDZ DOMAIN-CONTAINING FAMILY, MEMBER 1; GIPC1__:__GAIP C-TERMINUS-INTERACTING PROTEIN 1;; GIPC;; RGS19-INTERACTING PROTEIN 1; RGS19IP1;; CHROMOSOME 19 OPEN READING FRAME 3; C19ORF3;; GLUT1 C-TERMINUS-BINDING PROTEIN; GLUT1CBP;; SYNECTIN__:__
Asterisk__:__605073__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 37; TRIM37__:__MULIBREY NANISM GENE; MUL;; KIAA0898__:__
Number Sign__:__605074__:__RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1__:____:__
Caret__:__605075__:__MOVED TO 605074__:____:__
Asterisk__:__605076__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, POLYPEPTIDE 2; SNAPC2__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, 45-KD SUBUNIT; SNAP45;; PSE-BINDING TRANSCRIPTION FACTOR, DELTA;; PTF-DELTA__:__
Asterisk__:__605077__:__DNMT1-ASSOCIATED PROTEIN 1; DNMAP1__:__DNA METHYLTRANSFERASE 1-ASSOCIATED PROTEIN 1; DMAP1__:__
Asterisk__:__605078__:__TAR DNA-BINDING PROTEIN; TARDBP__:__TAR DNA-BINDING PROTEIN, 43-KD; TDP43__:__
Asterisk__:__605079__:__SAL-LIKE 3; SALL3__:____:__
Asterisk__:__605080__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, BETA-3; CNGB3__:____:__
Asterisk__:__605081__:__CYTOHESIN 3; CYTH3__:__PLECKSTRIN HOMOLOGY, SEC7, AND COILED-COIL DOMAINS PROTEIN 3; PSCD3;; ARF NUCLEOTIDE-BINDING SITE OPENER 3; ARNO3;; GRP1, MOUSE, HOMOLOG OF; GRP1__:__
Asterisk__:__605082__:__RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; RASSF1__:__RASSF1A__:__
Asterisk__:__605083__:__FRIZZLED-RELATED PROTEIN; FRZB__:__FRIZZLED-RELATED PROTEIN 1; FRZB1;; SECRETED FRIZZLED-RELATED PROTEIN 3; SFRP3__:__
Asterisk__:__605084__:__MITOCHONDRIAL CALCIUM UPTAKE PROTEIN 1; MICU1__:__CALCIUM-BINDING ATOPY-RELATED AUTOANTIGEN 1; CBARA1__:__
Asterisk__:__605085__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TREM1__:____:__
Asterisk__:__605086__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TREM2__:____:__
Asterisk__:__605087__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS K PROTEIN; PIGK__:__GPI8, YEAST, HOMOLOG OF; GPI8__:__
Asterisk__:__605088__:__MAJOR VAULT PROTEIN, RAT, HOMOLOG OF; MVP__:__LUNG RESISTANCE-RELATED PROTEIN; LRP__:__
Asterisk__:__605089__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L40; MRPL40__:__NUCLEAR LOCALIZATION SIGNAL DELETED IN VELOCARDIOFACIAL SYNDROME; NLVCF;; MRPL22__:__
Asterisk__:__605090__:__RETINOIC ACID RECEPTOR RESPONDER 1; RARRES1__:__TAZAROTENE-INDUCED GENE 1; TIG1__:__
Asterisk__:__605091__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 2; FGD2__:__FGD1 FAMILY, MEMBER 2__:__
Asterisk__:__605092__:__RETINOIC ACID RECEPTOR RESPONDER 3; RARRES3__:__TAZAROTENE-INDUCED GENE 3; TIG3;; RETINOID-INDUCIBLE GENE 1; RIG1__:__
Asterisk__:__605093__:__SH2B ADAPTOR PROTEIN 3; SH2B3__:__LYMPHOCYTE ADAPTOR PROTEIN; LNK__:__
Asterisk__:__605094__:__SIX-TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 2; STEAP2__:__SIX-TRANSMEMBRANE PROTEIN OF PROSTATE 1; STAMP1;; PROSTATE CANCER-ASSOCIATED PROTEIN 1; PCANAP1;; IPCA1__:__
Asterisk__:__605095__:__PROSTATE CANCER-ASSOCIATED PROTEIN 2; PCANAP2__:__IPCA2__:__
Asterisk__:__605096__:__ANOCTAMIN 7; ANO7__:__TRANSMEMBRANE PROTEIN 16G; TMEM16G;; PROSTATE CANCER-ASSOCIATED PROTEIN 5; PCANAP5;; IPCA5;; DRESDEN TRANSMEMBRANE PROTEIN OF PROSTATE; DTMPP;; NOVEL GENE EXPRESSED IN PROSTATE; NGEP__:__
Asterisk__:__605097__:__SOLUTE CARRIER FAMILY 45, MEMBER 3; SLC45A3__:__PROSTATE CANCER-ASSOCIATED PROTEIN 6; PCANAP6;; PROSTEIN; PRST;; IPCA6__:__
Caret__:__605098__:__MOVED TO 604146__:____:__
Asterisk__:__605099__:__PROSTATE CANCER-ASSOCIATED PROTEIN 8; PCANAP8__:__IPCA8__:__
Asterisk__:__605100__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1D; PPM1D__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1D;; PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1, DELTA ISOFORM;; WILDTYPE p53-INDUCED PHOSPHATASE 1; WIP1__:__
Asterisk__:__605101__:__TAK1-BINDING PROTEIN 2; TAB2__:__TGF-BETA-ACTIVATED KINASE 1/MAP3K7-BINDING PROTEIN 2;; TAK1/MAP3K7-BINDING PROTEIN 2;; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7-INTERACTING PROTEIN 2; MAP3K7IP2;; KIAA0733__:__
Asterisk__:__605102__:__MANNAN-BINDING LECTIN SERINE PROTEASE 2; MASP2__:____:__MAP19, INCLUDED
Asterisk__:__605103__:__NEUROMEDIN U; NMU__:____:__
Asterisk__:__605104__:__RNA-BINDING PROTEIN FOX1, C. ELEGANS, HOMOLOG OF, 1; RBFOX1__:__ATAXIN 2-BINDING PROTEIN 1; A2BP1;; FOX1;; HRNBP1__:__
NULL__:__605105__:__EARLY RESPONSE TO NEURAL INDUCTION GENE__:__ERNI__:__
Asterisk__:__605106__:__LYSOPHOSPHATIDIC ACID RECEPTOR 3; LPAR3__:__ENDOTHELIAL DIFFERENTIATION GENE 7; EDG7;; LPA RECEPTOR EDG7;; LPA3__:__
Asterisk__:__605107__:__ENDOTHELIAL DIFFERENTIATION-RELATED FACTOR 1; EDF1__:____:__
Asterisk__:__605108__:__NEUROMEDIN U RECEPTOR 2; NMUR2__:__NMU2R;; GROWTH HORMONE SECRETAGOGUE RECEPTOR FAMILY, MEMBER 4; FM4__:__
Asterisk__:__605109__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 1; HERC1__:__P532__:__
Asterisk__:__605110__:__LYSOPHOSPHATIDIC ACID RECEPTOR 2; LPAR2__:__LPA2;; ENDOTHELIAL DIFFERENTIATION GENE 4; EDG4;; LYSOPHOSPHATIDIC ACID RECEPTOR EDG4;; LPA RECEPTOR EDG4__:__
Asterisk__:__605111__:__SPHINGOSINE-1-PHOSPHATE RECEPTOR 2; S1PR2__:__ENDOTHELIAL DIFFERENTIATION GENE 5; EDG5;; S1P RECEPTOR 2; S1P2__:__
Asterisk__:__605112__:__TROPOMODULIN 3; TMOD3__:__TROPOMODULIN, UBIQUITOUS; UTMOD__:__TMOD3/CYP19A1 FUSION GENE, INCLUDED
Asterisk__:__605113__:__ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE; AASS__:____:__
Asterisk__:__605114__:__SPO11, S. CEREVISIAE, HOMOLOG OF; SPO11__:__TOPOISOMERASE VI-A; TOPOVIA__:__
Number Sign__:__605115__:__HYPERTENSION, EARLY-ONSET, AUTOSOMAL DOMINANT, WITH SEVERE EXACERBATION IN PREGNANCY__:____:__
Asterisk__:__605116__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 9; CHRNA9__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-9 SUBUNIT__:__
Asterisk__:__605117__:__SUPPRESSOR OF CYTOKINE SIGNALING 2; SOCS2__:__STAT-INDUCED STAT INHIBITOR 2; SSI2; STATI2;; CYTOKINE-INDUCIBLE SH2 PROTEIN 2; CIS2__:__
Asterisk__:__605118__:__SUPPRESSOR OF CYTOKINE SIGNALING 6; SOCS6__:__STAT-INDUCED STAT INHIBITOR 4; SSI4; STAI4;; CYTOKINE-INDUCIBLE SH2 PROTEIN 4; CIS4;; SUPPRESSOR OF CYTOKINE SIGNALING 4, FORMERLY; SOCS4, FORMERLY__:__
Asterisk__:__605119__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1G; PPM1G__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1G;; PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1, GAMMA ISOFORM;; PROTEIN PHOSPHATASE 2C, GAMMA ISOFORM; PP2CG;; PP2C-GAMMA__:__
Asterisk__:__605120__:__GROWTH/DIFFERENTIATION FACTOR 2; GDF2__:__BONE MORPHOGENETIC PROTEIN 9; BMP9__:__
Asterisk__:__605121__:__RRN3, S. CEREVISIAE, HOMOLOG OF; RRN3__:__RNA POLYMERASE I TRANSCRIPTION FACTOR RRN3;; TRANSCRIPTION INITIATION FACTOR IA; TIFIA__:__
Asterisk__:__605122__:__SUV3-LIKE 1; SUPV3L1__:__S. CEREVISIAE SUPPRESSOR OF VAR1 3-LIKE 1__:__
Asterisk__:__605123__:__SERINE PROTEASE INHIBITOR, KUNITZ-TYPE, 1; SPINT1__:__HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR; HAI__:__
Asterisk__:__605124__:__SERINE PROTEASE INHIBITOR, KUNITZ-TYPE, 2; SPINT2__:__HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; HAI2;; BIKUNIN, PLACENTAL__:__
Asterisk__:__605125__:__GABA-A RECEPTOR-ASSOCIATED PROTEIN; GABARAP__:____:__
Asterisk__:__605126__:__FOUR-AND-A-HALF LIM DOMAINS 5; FHL5__:__ACTIVATOR OF CREM IN TESTIS; ACT__:__
Asterisk__:__605127__:__OPTICIN; OPTC__:____:__
Asterisk__:__605128__:__GUANYLATE CYCLASE ACTIVATOR 1C; GUCA1C__:__GUANYLATE CYCLASE-ACTIVATING PROTEIN, PHOTORECEPTOR 3; GCAP3__:__
Asterisk__:__605129__:__PROTEASOME ACTIVATOR SUBUNIT 3; PSME3__:__PROTEASOME ACTIVATOR 28-GAMMA; PA28G;; PA28-GAMMA;; REG-GAMMA;; KI ANTIGEN__:__
Number Sign__:__605130__:__WIEDEMANN-STEINER SYNDROME; WDSTS__:__HAIRY ELBOWS, SHORT STATURE, FACIAL DYSMORPHISM, AND DEVELOPMENTAL DELAY__:__
Asterisk__:__605131__:__WW DOMAIN-CONTAINING OXIDOREDUCTASE; WWOX__:__FRAGILE SITE FRA16D OXIDOREDUCTASE; FOR;; WOX1__:__FRAGILE SITE 16q23.2, INCLUDED; FRA16D, INCLUDED
Asterisk__:__605132__:__TRANSDUCIN-LIKE ENHANCER OF SPLIT 4; TLE4__:__ENHANCER OF SPLIT GROUCHO 4; ESG4;; GROUCHO-RELATED GENE 4; GRG4__:__
Asterisk__:__605133__:__NUCLEAR CAP-BINDING PROTEIN 2; NCBP2__:__NUCLEAR CAP-BINDING PROTEIN, 20-KD;; CAP-BINDING PROTEIN, 20-KD; CBP20;; NUCLEAR CAP-BINDING PROTEIN-INTERACTING PROTEIN 1; NIP1__:__
Asterisk__:__605134__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, CYTOPLASMIC, 1; PITPNC1__:__RETINAL DEGENERATION GENE B, DROSOPHILA, HOMOLOG OF, BETA; RDGBB__:__
Caret__:__605135__:__MOVED TO 172100__:____:__
Caret__:__605136__:__MOVED TO 604974__:____:__
Caret__:__605137__:__MOVED TO 601297__:____:__
Asterisk__:__605138__:__ORNITHINE DECARBOXYLASE ANTIZYME 3; OAZ3__:__ANTIZYME 3; AZ3__:__
Asterisk__:__605139__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 2; CCT2__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 2;; CCT-BETA; CCTB__:__
Asterisk__:__605140__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 7; CCT7__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 7;; CCT-ETA; CCTH__:__
Asterisk__:__605141__:__PRE-B-LYMPHOCYTE GENE 1; VPREB1__:__VPREB; IGVPB;; IMMUNOGLOBULIN IOTA POLYPEPTIDE CHAIN; IGI__:__
Asterisk__:__605142__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 4; CCT4__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 4;; CCT-DELTA; CCTD;; STIMULATOR OF TAR RNA-BINDING PROTEINS; SRB__:__
Asterisk__:__605143__:__ACTIN-RELATED PROTEIN 1A; ACTR1A__:__ARP1;; CENTRACTIN, ALPHA__:__
Asterisk__:__605144__:__ACTIN-RELATED PROTEIN 1B; ACTR1B__:__ARP1B;; CENTRACTIN, BETA;; CTRN2__:__
Asterisk__:__605145__:__ANK, MOUSE, HOMOLOG OF; ANKH__:__HANK__:__
Asterisk__:__605146__:__SPHINGOSINE-1-PHOSPHATE RECEPTOR 5; S1PR5__:__ENDOTHELIAL DIFFERENTIATION GENE 8; EDG8;; S1P RECEPTOR 5; S1P5__:__
Asterisk__:__605147__:__LEUKOCYTE CELL-DERIVED CHEMOTAXIN 1; LECT1__:__CHONDROMODULIN I; CHM1__:__CHONDROMODULIN I PRECURSOR, INCLUDED
Asterisk__:__605148__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 6; GALNT6__:__GalNAc TRANSFERASE 6; GalNAcT6__:__
Asterisk__:__605149__:__CHEMOKINE, CXC MOTIF, LIGAND 13; CXCL13__:__SMALL INDUCIBLE CYTOKINE SUBFAMILY B, MEMBER 13; SCYB13;; B CELL-ATTRACTING CHEMOKINE 1; BCA1;; B-LYMPHOCYTE CHEMOATTRACTANT; BLC__:__
Caret__:__605150__:__MOVED TO 601297__:____:__
Caret__:__605151__:__MOVED TO 604747__:____:__
Asterisk__:__605152__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 19; CCDC19__:__NASOPHARYNGEAL EPITHELIUM-SPECIFIC PROTEIN 1; NESG1__:__
Asterisk__:__605153__:__RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; RAMP1__:____:__
Asterisk__:__605154__:__RECEPTOR ACTIVITY-MODIFYING PROTEIN 2; RAMP2__:____:__
Asterisk__:__605155__:__RECEPTOR ACTIVITY-MODIFYING PROTEIN 3; RAMP3__:____:__
Caret__:__605156__:__MOVED TO 259600__:____:__
Asterisk__:__605157__:__p53-RESPONSIVE GENE 1__:__PRG1__:__
Asterisk__:__605158__:__PEROXIDASIN, DROSOPHILA, HOMOLOG OF; PXDN__:__PXN;; p53-RESPONSIVE GENE 2; PRG2;; VASCULAR PEROXIDASE 1; VPO1;; MELANOMA-ASSOCIATED GENE 50; MG50;; D2S448__:__
Asterisk__:__605159__:__APOPTOSIS-INDUCING FACTOR, MITOCHONDRIA-ASSOCIATED, 2; AIFM2__:__p53-RESPONSIVE GENE 3; PRG3__:__
Asterisk__:__605160__:__p53-RESPONSIVE GENE 4__:__PRG4;; FLJ36000__:__
Asterisk__:__605161__:__WAP 4-DISULFIDE CORE DOMAIN 5; WFDC5__:__p53-RESPONSIVE GENE 5; PRG5;; WHEY ACIDIC PROTEIN 1; WAP1__:__
Asterisk__:__605162__:__GROWTH ARREST- AND DNA DAMAGE-INDUCIBLE GADD45G-INTERACTING PROTEIN; GADD45GIP1__:__p53-RESPONSIVE GENE 6; PRG6;; CR6-INTERACTING FACTOR 1; CRIF1__:__
Asterisk__:__605163__:__CHEMOKINE, CXC MOTIF, RECEPTOR 6; CXCR6__:__G PROTEIN-COUPLED RECEPTOR STRL33; STRL33;; BONZO__:__
Asterisk__:__605164__:__HISTONE DEACETYLASE 2; HDAC2__:__YY1-ASSOCIATED FACTOR 1; YAF1__:__
Asterisk__:__605165__:__ZINC FINGER PROTEIN 278; ZNF278__:__POZ-, AT HOOK-, AND ZINC FINGER-CONTAINING PROTEIN; PATZ;; MAZ-RELATED FACTOR; MAZR;; ZINC FINGER SARCOMA GENE; ZSG__:__ZNF278/EWS FUSION GENE, INCLUDED;; ZNF278/UQCRH FUSION GENE, INCLUDED
Asterisk__:__605166__:__HISTONE DEACETYLASE 3; HDAC3__:____:__
Asterisk__:__605167__:__B MELANOMA ANTIGEN; BAGE__:__BAGE FAMILY, MEMBER 1; BAGE1__:__
Asterisk__:__605168__:__FATTY ACID-BINDING PROTEIN 5; FABP5__:__FATTY ACID-BINDING PROTEIN, PSORIASIS-ASSOCIATED; PAFABP;; FATTY ACID-BINDING PROTEIN, EPIDERMAL; EFABP__:__
Asterisk__:__605169__:__E74-LIKE FACTOR 5; ELF5__:__EPITHELIUM-SPECIFIC ETS FACTOR 2; ESE2__:__
Asterisk__:__605170__:__ETOPOSIDE-INDUCED 1.4 mRNA; EI24__:__EI24, MOUSE, HOMOLOG OF;; p53-INDUCED GENE 8; PIG8__:__
Asterisk__:__605171__:__TUMOR PROTEIN p53-INDUCIBLE PROTEIN 3; TP53I3__:__p53-INDUCED GENE 3; PIG3__:__
Asterisk__:__605172__:__PROSTAGLANDIN E SYNTHASE; PTGES__:__PGES;; PROSTAGLANDIN E SYNTHASE, MICROSOMAL; MPGES;; p53-INDUCED GENE 12; PIG12;; MGST1-LIKE 1; MGST1L1__:__
Asterisk__:__605173__:__ECTODERMAL-NEURAL CORTEX 1; ENC1__:__p53-INDUCED GENE 10; PIG10;; NUCLEAR RESTRICTED PROTEIN/BRAIN; NRPB__:__
Asterisk__:__605174__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 1; ADAMTS1__:__METH1__:__
Asterisk__:__605175__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 8; ADAMTS8__:__METH2__:__
Asterisk__:__605176__:__HYDROXYACID OXIDASE 2; HAO2__:__HAOX2;; HYDROXYACID OXIDASE, LONG-CHAIN__:__
Caret__:__605177__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__605178__:__GROWTH ARREST-SPECIFIC 8; GAS8__:__GROWTH ARREST-SPECIFIC 11, FORMERLY; GAS11, FORMERLY__:__
Asterisk__:__605179__:__GAS8 ANTISENSE RNA 1, NONCODING; GAS8AS1__:__CHROMOSOME 16 OPEN READING FRAME 3; C16ORF3__:__
Asterisk__:__605180__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 2; SLC38A2__:__AMINO ACID TRANSPORTER A2; ATA2;; SODIUM-DEPENDENT NEUTRAL AMINO ACID TRANSPORTER 2; SNAT2__:__
Asterisk__:__605181__:__TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 3; TM7SF3__:____:__
Asterisk__:__605182__:__RAS p21 PROTEIN ACTIVATOR 3; RASA3__:__GTPase-ACTIVATING PROTEIN 1 FAMILY, INOSITOL 1,3,4,5-TETRAKISPHOSPHATE-BINDING PROTEIN;; GAP1(IP4BP)__:__
Asterisk__:__605183__:__CALMODULIN-LIKE 5; CALML5__:__CALMODULIN-LIKE SKIN PROTEIN; CLSP__:__
Asterisk__:__605184__:__POLYADENYLATE-BINDING PROTEIN-INTERACTING PROTEIN 1; PAIP1__:__POLY(A)-BINDING PROTEIN-INTERACTING PROTEIN 1;; PABP-INTERACTING PROTEIN 1__:__
Asterisk__:__605185__:__DELTA-LIKE 4; DLL4__:____:__
Asterisk__:__605186__:__WNT INHIBITORY FACTOR 1; WIF1__:____:__
Asterisk__:__605187__:__G PROTEIN-COUPLED RECEPTOR 27; GPR27__:__SUPERCONSERVED RECEPTOR EXPRESSED IN BRAIN 1; SREB1__:__
Asterisk__:__605188__:__G PROTEIN-COUPLED RECEPTOR 85; GPR85__:__SUPERCONSERVED RECEPTOR EXPRESSED IN BRAIN 2; SREB2__:__
Asterisk__:__605189__:__DICKKOPF, XENOPUS, HOMOLOG OF, 1; DKK1__:____:__
Asterisk__:__605190__:__TRANSLOCATION-ASSOCIATING MEMBRANE PROTEIN 1; TRAM1__:____:__
Asterisk__:__605191__:__BTAF1 RNA POLYMERASE II, B-TFIID TRANSCRIPTION FACTOR-ASSOCIATED, 170-KD;  BTAF1__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, RNA POLYMERASE II, 170-KD;; TAFII170;; TAF172;; MOT1, YEAST, HOMOLOG OF__:__
Number Sign__:__605192__:__DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23__:____:__
Asterisk__:__605193__:__DIRAS FAMILY, GTP-BINDING RAS-LIKE PROTEIN 3; DIRAS3__:__DISTINCT SUBGROUP OF THE RAS FAMILY, MEMBER 3;; RAS HOMOLOG GENE FAMILY, MEMBER I; ARHI__:__
Asterisk__:__605194__:__CRYPTIC PROTEIN; CFC1__:__CRYPTIC, MOUSE, HOMOLOG OF;; CRYPTIC__:__
Asterisk__:__605195__:__MESODERM POSTERIOR BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR 2; MESP2__:__MESODERM POSTERIOR PROTEIN 2__:__
Asterisk__:__605196__:__COQ3, S. CEREVISIAE, HOMOLOG OF; COQ3__:__METHYLTRANSFERASE COQ3__:__
Asterisk__:__605197__:__KYNURENINASE; KYNU__:__L-KYNURENINE HYDROLASE__:__
Asterisk__:__605198__:__TERMINAL NUCLEOTIDYLTRANSFERASE 4A; TENT4A__:__POLY(A) POLYMERASE-ASSOCIATED DOMAIN-CONTAINING PROTEIN 7; PAPD7;; PAP-ASSOCIATED DOMAIN-CONTAINING PROTEIN 7;; POLYMERASE, DNA, SIGMA; POLS;; TOPOISOMERASE-RELATED FUNCTION PROTEIN 4-1;; TRF4, S. CEREVISIAE, HOMOLOG OF; TRF4__:__
Asterisk__:__605199__:__SPLICING FACTOR, PROLINE- AND GLUTAMINE-RICH; SFPQ__:__POLYPYRIMIDINE TRACT-BINDING PROTEIN-ASSOCIATED SPLICING FACTOR; PSF;; PTB-ASSOCIATED SPLICING FACTOR__:__SFPQ/TFE3 FUSION GENE, INCLUDED
Asterisk__:__605200__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 3; HERC3__:____:__
Percent__:__605201__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 14; HDLCQ14__:____:__
Asterisk__:__605202__:__N-ACETYLNEURAMINIC ACID PHOSPHATE SYNTHASE; NANS__:__SIALIC ACID SYNTHASE; SAS__:__
Caret__:__605203__:__MOVED TO 263650__:____:__
Asterisk__:__605204__:__TORSIN 1A; TOR1A__:__DYT1 GENE__:__
Asterisk__:__605205__:__ADENYLATE CYCLASE 10; ADCY10__:__SOLUBLE ADENYLYL CYCLASE; SAC;; ADENYLYL CYCLASE, SOLUBLE__:__
Asterisk__:__605206__:__HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED POTASSIUM CHANNEL 4; HCN4__:____:__
Asterisk__:__605207__:__CYTOCHROME P450, SUBFAMILY XXVIB, POLYPEPTIDE 1; CYP26B1__:__CYTOCHROME P450, SUBFAMILY XXVIA, POLYPEPTIDE 2; CYP26A2;; P450, RETINOIC ACID-INACTIVATING, 2; P450RAI2__:__
Asterisk__:__605208__:__SOLUTE CARRIER FAMILY 17 (VESICULAR GLUTAMATE COTRANSPORTER), MEMBER 7; SLC17A7__:__SOLUTE CARRIER FAMILY 17 (SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER), MEMBER 7;; SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER, BRAIN;; BRAIN SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER; BNPI;; VESICULAR GLUTAMATE TRANSPORTER 1; VGLUT1__:__
Asterisk__:__605209__:__CHECKPOINT PROTEIN WITH FHA AND RING FINGER DOMAINS; CHFR__:____:__
Asterisk__:__605210__:__DISRUPTED IN SCHIZOPHRENIA 1; DISC1__:____:__
Asterisk__:__605211__:__BARH-LIKE 1; BARHL1__:____:__
Asterisk__:__605212__:__BARH-LIKE 2; BARHL2__:____:__
Asterisk__:__605213__:__3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1; PDPK1__:__PDK1__:__
Asterisk__:__605214__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, SUBFAMILY M, BETA MEMBER 2; KCNMB2__:____:__
Asterisk__:__605215__:__SRC KINASE-ASSOCIATED PHOSPHOPROTEIN 2; SKAP2__:__SKAP55-RELATED PROTEIN; SKAP55R__:__
Asterisk__:__605216__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 4; ARHGEF4__:__APC-STIMULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR; ASEF;; ASEF1__:__
Asterisk__:__605217__:__SHC TRANSFORMING PROTEIN 2; SHC2__:__SHC PROTEIN B; SHCB;; SHC-LIKE PROTEIN SCK; SCK;; SHC ADAPTOR HOMOLOG, NEURONAL__:__
Number Sign__:__605218__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 2; SLEB2__:____:__
Asterisk__:__605219__:__DIRECT IAP-BINDING PROTEIN WITH LOW pI; DIABLO__:__SECOND MITOCHONDRIA-DERIVED ACTIVATOR OF CASPASE; SMAC__:__
Asterisk__:__605220__:__APOLIPOPROTEIN B RECEPTOR; APOBR__:__APOLIPOPROTEIN B48 RECEPTOR; APOB48R__:__
Asterisk__:__605221__:__SPLICING FACTOR, SERINE/ARGININE-RICH, 10; SRSF10__:__SERINE/ARGININE-RICH SPLICING FACTOR 10;; FUS-INTERACTING PROTEIN 1; FUSIP1;; TLS-ASSOCIATED PROTEIN WITH SERINE-ARGININE REPEATS; TASR;; SPLICING FACTOR, ARGININE/SERINE-RICH, 38-KD; SRp38;; SR REPRESSOR PROTEIN, 40-KD; SRRp40;; NEURAL-SALIENT SR-RICH PROTEIN; NSSR;; SPLICING FACTOR, ARGININE/SERINE-RICH, 13A; SFRS13A__:__TLS-ASSOCIATED PROTEIN WITH SERINE-ARGININE REPEATS, ISOFORM 1, INCLUDED; TASR1, INCLUDED;; TLS-ASSOCIATED PROTEIN WITH SERINE-ARGININE REPEATS, ISOFORM 2, INCLUDED; TASR2, INCLUDED
Asterisk__:__605222__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, SUBFAMILY M, BETA MEMBER 3; KCNMB3__:____:__
Asterisk__:__605223__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, SUBFAMILY M, BETA MEMBER 4; KCNMB4__:____:__
Asterisk__:__605224__:__RHODOPSIN HOMOLOG, RETINAL PIGMENT EPITHELIUM-DERIVED; RRH__:__RHODOPSIN HOMOLOG, RPE-DERIVED;; PEROPSIN__:__
Percent__:__605225__:__INFLAMMATORY BOWEL DISEASE 7; IBD7__:____:__
Asterisk__:__605226__:__RE REPEATS-ENCODING GENE; RERE__:__ARGININE-GLUTAMIC ACID REPEATS-ENCODING GENE;; ATROPHIN 1-ASSOCIATED PROTEIN;; ATROPHIN-RELATED PROTEIN;; ATROPHIN 2__:__
Asterisk__:__605227__:__REVERSION-INDUCING CYSTEINE-RICH PROTEIN WITH KAZAL MOTIFS; RECK__:__SUPPRESSOR OF TUMORIGENICITY 15; ST15__:__
Asterisk__:__605228__:__COREPRESSOR INTERACTING WITH RBPJ, 1; CIR1__:__CBF1-INTERACTING COREPRESSOR; CIR__:__
Percent__:__605229__:__SPASTIC PARAPLEGIA 14, AUTOSOMAL RECESSIVE; SPG14__:____:__
Asterisk__:__605230__:__TUMOR PROTEIN p53-BINDING PROTEIN 1; TP53BP1__:__53BP1__:__
Number Sign__:__605231__:__BARDET-BIEDL SYNDROME 6; BBS6__:____:__
Asterisk__:__605232__:__PROTEIN KINASE, LYSINE-DEFICIENT 1; WNK1__:__PROSTATE-DERIVED STERILE 20-LIKE KINASE; PSK;; PRKWNK1;; KDP;; KIAA0344__:__WNK1/HSN2 ISOFORM, INCLUDED
Percent__:__605233__:__DIANZANI AUTOIMMUNE LYMPHOPROLIFERATIVE DISEASE__:__DALD__:__
Asterisk__:__605234__:__VOMERONASAL 1 RECEPTOR 1; VN1R1__:__V1R-LIKE 1; V1RL1;; VOMERONASAL RECEPTOR 1;; V3R-RELATED GENE;; VNR19I1;; ZVNH1;; ZVNR1__:__
Asterisk__:__605235__:__NUCLEOLAR PROTEIN 3; NOL3__:__NOP__:__APOPTOSIS REPRESSOR WITH CARD DOMAIN, INCLUDED; ARC, INCLUDED;; NUCLEOLAR PROTEIN, 30-KD, INCLUDED; NOP30, INCLUDED;; MUSCLE-ENRICHED CYTOSOLIC PROTEIN, INCLUDED; MYP, INCLUDED
Asterisk__:__605236__:__CORIN, SERINE PEPTIDASE; CORIN__:__CRN;; TRANSMEMBRANE PROTEASE, SERINE 10; TMPRSS10;; ATC2;; PRO-ANP-CONVERTING ENZYME__:__
Asterisk__:__605237__:__XENOTROPIC AND POLYTROPIC RETROVIRUS RECEPTOR; XPR1__:__X RECEPTOR;; SYG1, YEAST, HOMOLOG OF; SYG1__:__
Asterisk__:__605238__:__HISTAMINE N-METHYLTRANSFERASE; HNMT__:____:__
Asterisk__:__605239__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A, ISOFORM 4; ATP6V0A4__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, NONCATALYTIC ACCESSORY PROTEIN 1B; ATP6N1B;; ATP6N2;; VACUOLAR PROTEIN PUMP, SUBUNIT 2; VPP2__:__
Asterisk__:__605240__:__CHEMOKINE, CC MOTIF, LIGAND 28; CCL28__:____:__
Asterisk__:__605241__:__LYMPHOCYTE ANTIGEN 86; LY86__:__MD1 PROTEIN; MD1__:__
Asterisk__:__605242__:__USH1C GENE; USH1C__:__HARMONIN;; PDZ DOMAIN-CONTAINING PROTEIN, 73-KD; PDZ73__:__
Asterisk__:__605243__:__LYMPHOCYTE ANTIGEN 96; LY96__:__MD2 PROTEIN; MD2__:__
Percent__:__605244__:__CARNEY COMPLEX, TYPE 2; CNC2__:__CARNEY MYXOMA-ENDOCRINE COMPLEX, TYPE 2__:__
Asterisk__:__605245__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 8; SLC2A8__:__GLUCOSE TRANSPORTER 8; GLUT8;; GLUCOSE TRANSPORTER X1__:__
Asterisk__:__605246__:__COMPLEMENT COMPONENT 3a RECEPTOR 1; C3AR1__:__C3AR__:__
Asterisk__:__605247__:__LEUCINE-RICH REPEATS- AND DEATH DOMAIN-CONTAINING PROTEIN; LRDD__:__p53-INDUCED PROTEIN WITH DEATH DOMAIN; PIDD__:__
Asterisk__:__605248__:__MUCOLIPIN 1; MCOLN1__:__ML4 GENE;; MUCOLIPIDIN;; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, MUCOLIPIN SUBFAMILY, MEMBER 1; TRPML1__:__
Caret__:__605249__:__MOVED TO 155100__:____:__
Asterisk__:__605250__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 4; ABCC4__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 4; MRP4;; MULTISPECIFIC ORGANIC ANION TRANSPORTER B; MOATB__:__
Asterisk__:__605251__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 5; ABCC5__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 5; MRP5;; MOATC__:__
Asterisk__:__605252__:__POLYMERASE, DNA, IOTA; POLI__:__RAD30, S. CEREVISIAE, HOMOLOG OF, B; RAD30B__:__
Number Sign__:__605253__:__NEUROPATHY, CONGENITAL HYPOMYELINATING, 1, AUTOSOMAL RECESSIVE; CHN1__:__NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMAL RECESSIVE;; HYPOMYELINATION, SEVERE CONGENITAL;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 4E; CMT4E;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4E__:__NEUROPATHY, CONGENITAL HYPOMYELINATING, 1, AUTOSOMAL DOMINANT, INCLUDED
Asterisk__:__605254__:__NICASTRIN; NCSTN__:__ANTERIOR PHARYNX DEFECTIVE 2, C. ELEGANS, HOMOLOG OF; APH2__:__
Asterisk__:__605255__:__ETS VARIANT GENE 7; ETV7__:__ETS TRANSCRIPTION FACTOR TEL2; TEL2;; TELB__:__
Asterisk__:__605256__:__RAD18, S. CEREVISIAE, HOMOLOG OF; RAD18__:____:__
Asterisk__:__605257__:__ACTIVATION-INDUCED CYTIDINE DEAMINASE; AICDA__:__AID__:__
Number Sign__:__605258__:__IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 2; HIGM2__:__HYPER-IgM SYNDROME 2__:__
Number Sign__:__605259__:__SPINOCEREBELLAR ATAXIA 13; SCA13__:____:__
Caret__:__605260__:__MOVED TO 145900__:____:__
Asterisk__:__605261__:__NADPH OXIDASE 4; NOX4__:__RENAL NADPH OXIDASE; RENOX__:__
Asterisk__:__605262__:__NMYC DOWNSTREAM-REGULATED GENE 1; NDRG1__:__PROTEIN REGULATED BY OXYGEN 1; PROXY1__:__
Asterisk__:__605263__:__SHC TRANSFORMING PROTEIN 3; SHC3__:__SHC-LIKE PROTEIN, NEURONAL; NSHC;; SHC PROTEIN C; SHCC;; RAI__:__
Asterisk__:__605264__:__SORBIN AND SH3-DOMAINS CONTAINING PROTEIN 1; SORBS1__:__SH3 DOMAIN PROTEIN 5; SH3D5;; CBL-ASSOCIATED PROTEIN; CAP;; SH3 DOMAIN-CONTAINING PROTEIN 12; SH3P12;; PONSIN;; SORB1__:__
Asterisk__:__605265__:__APOPTOSIS AND CASPASE ACTIVATION INHIBITOR; AVEN__:__CELL DEATH REGULATOR AVEN__:__
Asterisk__:__605266__:__JUNCTOPHILIN 1; JPH1__:__JP1__:__
Asterisk__:__605267__:__JUNCTOPHILIN 2; JPH2__:__JP2__:__
Asterisk__:__605268__:__JUNCTOPHILIN 3; JPH3__:__JP3__:__
Asterisk__:__605269__:__CORONIN 1C; CORO1C__:__CORONIN 3, MOUSE, HOMOLOG OF__:__
Asterisk__:__605270__:__N-SULFOGLUCOSAMINE SULFOHYDROLASE; SGSH__:__HEPARAN SULFATE SULFATASE; HSS;; SULFAMIDASE__:__
Asterisk__:__605271__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 10; SERPINA10__:__REGENERATION-ASSOCIATED SERPIN 1; RASP1;; PROTEIN Z-DEPENDENT PROTEASE INHIBITOR PRECURSOR; ZPI__:__
Asterisk__:__605272__:__NMYC DOWNSTREAM-REGULATED GENE 2; NDRG2__:__KIAA1248__:__
Asterisk__:__605273__:__NMYC DOWNSTREAM-REGULATED GENE 3; NDRG3__:____:__
NULL__:__605274__:__MESOMELIC DYSPLASIA, SAVARIRAYAN TYPE__:__MESOMELIC DYSPLASIA WITH ABSENT FIBULAS AND TRIANGULAR TIBIAS__:__
Number Sign__:__605275__:__NOONAN SYNDROME 2; NS2__:__NOONAN SYNDROME, AUTOSOMAL RECESSIVE__:__
Asterisk__:__605276__:__APOPTOSIS-ASSOCIATED TYROSINE KINASE; AATK__:__AATYK__:__
Asterisk__:__605277__:__GLUCOCORTICOID RECEPTOR DNA-BINDING FACTOR 1; GRLF1__:__p190A, RAT, HOMOLOG OF; p190A;; p190RHOGAP__:__
Asterisk__:__605278__:__CARBOXYLESTERASE 2; CES2__:____:__
Asterisk__:__605279__:__CARBOXYLESTERASE 3; CES3__:__ES31, MOUSE, HOMOLOG OF;; CES1D, MOUSE, HOMOLOG OF__:__
Number Sign__:__605280__:__SPASTIC PARAPLEGIA 13, AUTOSOMAL DOMINANT; SPG13__:____:__
Asterisk__:__605281__:__DEAD/H BOX 4; DDX4__:__VASA, DROSOPHILA, HOMOLOG OF; VASA__:__
Number Sign__:__605282__:__TEMTAMY PREAXIAL BRACHYDACTYLY SYNDROME; TPBS__:__PREAXIAL BRACHYDACTYLY SYNDROME, TEMTAMY TYPE__:__
Asterisk__:__605283__:__MAGE-LIKE 2; MAGEL2__:__NECDIN-LIKE 1; NDNL1__:__
Asterisk__:__605284__:__TSC1 GENE; TSC1__:__HAMARTIN__:__
Number Sign__:__605285__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, RUSSE TYPE; HMSNR__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4G; CMT4G;; CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4G;; HEREDITARY MOTOR AND SENSORY NEUROPATHY, RUSSE TYPE;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4G__:__
Asterisk__:__605286__:__CALPAIN 10; CAPN10__:____:__
Asterisk__:__605287__:__ARGINYL AMINOPEPTIDASE-LIKE 1; RNPEPL1__:__AMINOPEPTIDASE B-LIKE__:__
Caret__:__605288__:__MOVED TO 273300__:____:__
Number Sign__:__605289__:__SPLIT-HAND/FOOT MALFORMATION 4; SHFM4__:____:__
Asterisk__:__605290__:__OPA1 GENE; OPA1__:__KIAA0567;; DYNAMIN-LIKE 120-KD PROTEIN, MITOCHONDRIAL__:__
Caret__:__605291__:__MOVED TO 191720__:____:__
Asterisk__:__605292__:__5-PRIME-NUCLEOTIDASE, MITOCHONDRIAL; NT5M__:__DEOXYRIBONUCLEOTIDASE, MITOCHONDRIAL; DNT2__:__
Percent__:__605293__:__OPTIC ATROPHY 4; OPA4__:____:__
Asterisk__:__605294__:__CARBOHYDRATE SULFOTRANSFERASE 6; CHST6__:__CORNEAL N-ACETYLGLUCOSAMINE-6-SULFOTRANSFERASE;; CORNEAL GlcNAc-6-SULFOTRANSFERASE__:__
Asterisk__:__605295__:__FIDGETIN; FIGN__:____:__
Asterisk__:__605296__:__PROTEASOME ASSEMBLY CHAPERONE 1; PSMG1__:__PAC1;; DOWN SYNDROME CRITICAL REGION GENE 2; DSCR2;; CHROMOSOME 21 LEUCINE-RICH PROTEIN; C21LRP__:__
Asterisk__:__605297__:__TH1-LIKE; TH1L__:__TH1, DROSOPHILA, HOMOLOG OF; TH1__:__NEGATIVE ELONGATION FACTOR POLYPEPTIDE C, INCLUDED; NELFC, INCLUDED;; NEGATIVE ELONGATION FACTOR POLYPEPTIDE D, INCLUDED; NELFD, INCLUDED
Asterisk__:__605298__:__DOWN SYNDROME CRITICAL REGION GENE 3; DSCR3__:__DOWN SYNDROME CRITICAL REGION GENE A; DSCRA__:__
Asterisk__:__605299__:__NUCLEAR RECEPTOR COACTIVATOR 6; NCOA6__:__THYROID HORMONE RECEPTOR-BINDING PROTEIN; TRBP;; NUCLEAR RECEPTOR-ACTIVATING PROTEIN, 250-KB; RAP250;; NUCLEAR RECEPTOR COACTIVATOR RAP250; NRC;; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-INTERACTING PROTEIN; PRIP;; ACTIVATING SIGNAL COINTEGRATOR 2; ASC2;; AMPLIFIED IN BREAST CANCER 3; AIB3;; KIAA0181__:__
Asterisk__:__605300__:__SH2B ADAPTOR PROTEIN 2; SH2B2__:__ADAPTOR PROTEIN CONTAINING PH AND SH2 DOMAINS; APS__:__
Asterisk__:__605301__:__TRANSFORMING, ACIDIC, COILED-COIL-CONTAINING PROTEIN 1; TACC1__:____:__TACC1/FGFR1 FUSION GENE, INCLUDED
Asterisk__:__605302__:__TRANSFORMING, ACIDIC, COILED-COIL-CONTAINING PROTEIN 2; TACC2__:____:__
Asterisk__:__605303__:__TRANSFORMING, ACIDIC, COILED-COIL-CONTAINING PROTEIN 3; TACC3__:____:__TACC3/FGFR3 FUSION GENE, INCLUDED
Asterisk__:__605304__:__NEUROGLOBIN; NGB__:____:__
Asterisk__:__605305__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 5A; KIR2DL5A__:__CD158F;; KIR2DL5__:__
Asterisk__:__605306__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER A; CLEC4A__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 6; CLECSF6;; DENDRITIC CELL IMMUNORECEPTOR; DCIR;; LECTIN-LIKE IMMUNORECEPTOR; LLIR__:__
Asterisk__:__605307__:__ADRENOMEDULLIN RECEPTOR; ADMR__:__AMR__:__
Asterisk__:__605308__:__ZINC FINGER PROTEIN 346; ZNF346__:__DOUBLE-STRANDED RNA-BINDING ZINC FINGER PROTEIN;; JUST ANOTHER ZINC FINGER PROTEIN; JAZ__:__
Number Sign__:__605309__:__MACROCEPHALY/AUTISM SYNDROME__:____:__
Asterisk__:__605310__:__COILED-COIL ALPHA-HELICAL ROD PROTEIN 1; CCHCR1__:__ALPHA-HELIX COILED-COIL ROD HOMOLOG; HCR;; C6ORF18__:__
Caret__:__605311__:__MOVED TO 601776__:____:__
Asterisk__:__605312__:__GROWTH/DIFFERENTIATION FACTOR 15; GDF15__:__BONE MORPHOGENETIC PROTEIN, PLACENTA; PLAB;; PROSTATE-DERIVED FACTOR; PDF;; MACROPHAGE-INHIBITING CYTOKINE 1; MIC1__:__
Asterisk__:__605313__:__RNA-BINDING MOTIF PROTEIN 8A; RBM8A__:__RNA-BINDING MOTIF PROTEIN 8; RBM8;; Y14__:__
Asterisk__:__605314__:__HISTONE DEACETYLASE 4; HDAC4__:__HDACA__:__
Asterisk__:__605315__:__HISTONE DEACETYLASE 5; HDAC5__:____:__
Caret__:__605316__:__MOVED TO 601072__:____:__
Asterisk__:__605317__:__FORKHEAD BOX P2; FOXP2__:__TRINUCLEOTIDE REPEAT-CONTAINING GENE 10; TNRC10;; CAGH44__:__
Caret__:__605318__:__MOVED TO 600833__:____:__
Asterisk__:__605319__:__6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3; PFKFB3__:__PFKFB, PLACENTAL;; PFK2, INDUCIBLE; IPFK2__:__
Asterisk__:__605320__:__6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 4; PFKFB4__:__PFKFB, TESTIS__:__
NULL__:__605321__:__FRONTOOCULAR SYNDROME__:____:__
Asterisk__:__605322__:__WAP 4-DISULFIDE CORE DOMAIN 1; WFDC1__:__PROSTATE STROMAL PROTEIN, 20-KD, RAT, HOMOLOG OF; PS20__:__
Asterisk__:__605323__:__C-TERMINAL DOMAIN OF RNA POLYMERASE II POLYPEPTIDE A, SMALL PHOSPHATASE OF, 1; CTDSP1__:__CTD SMALL PHOSPHATASE 1;; SMALL CTD PHOSPHATASE 1; SCP1;; NUCLEAR LIM INTERACTOR-INTERACTING FACTOR; NLIIF__:__
Asterisk__:__605324__:__AMYLOID BETA PRECURSOR PROTEIN-BINDING PROTEIN 2; APPBP2__:__PROTEIN INTERACTING WITH APP TAIL 1; PAT1__:__
Asterisk__:__605325__:__CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 5; CYP3A5__:__P450PCN3__:__
Asterisk__:__605326__:__TAX1-BINDING PROTEIN 1; TAX1BP1__:__HUMAN T-CELL LEUKEMIA VIRUS TYPE 1-BINDING PROTEIN;; TXBP151;; TRAF6-INTERACTING PROTEIN; T6BP__:__
Asterisk__:__605327__:__NUCLEAR FACTOR, INTERLEUKIN 3-REGULATED; NFIL3__:__NFIL3A;; E4BP4__:__
Asterisk__:__605328__:__KRUPPEL-LIKE FACTOR 13; KLF13__:__RANTES FACTOR OF LATE-ACTIVATED T LYMPHOCYTES 1; RFLAT1;; FKLF2__:__
Caret__:__605329__:__MOVED TO 605205__:____:__
Asterisk__:__605330__:__INTERLEUKIN 22; IL22__:__INTERLEUKIN 10-RELATED T CELL-DERIVED INDUCIBLE FACTOR; ILTIF__:__
Asterisk__:__605331__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 3; EPB41L3__:__DIFFERENTIALLY EXPRESSED IN ADENOCARCINOMA OF THE LUNG; DAL1;; NONERYTHROID PROTEIN 4.1, BRAIN TYPE; 4.1B__:__
Asterisk__:__605332__:__KELCH-LIKE 1; KLHL1__:____:__
Asterisk__:__605333__:__PDS5, REGULATOR OF COHESION MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, B; PDS5B__:__ANDROGEN-INDUCED PROSTATE PROLIFERATIVE SHUTOFF-ASSOCIATED PROTEIN;; APRIN;; AS3__:__
Caret__:__605334__:__MOVED TO 300290__:____:__
Asterisk__:__605335__:__PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER 1; PHLDA1__:__T CELL DEATH-ASSOCIATED GENE 51; TDAG51__:__
Asterisk__:__605336__:__COMPLEMENT FACTOR H-RELATED 3; CFHR3__:__FACTOR H-RELATED GENE 3; FHR3;; H FACTOR-LIKE 4; HLF4;; CFHL3__:__
Asterisk__:__605337__:__COMPLEMENT FACTOR H-RELATED 4; CFHR4__:__FACTOR H-RELATED GENE 4; FHR4;; CFHL4__:__FHR-4A, INCLUDED;; FHR-4B, INCLUDED
Asterisk__:__605338__:__INTERNEXIN, ALPHA; INA__:__NEUROFILAMENT, 66-KD; NF66;; NEUROFILAMENT PROTEIN 5; NEF5__:__
Asterisk__:__605339__:__FMR1 AUTOSOMAL HOMOLOG 2; FXR2__:__FRAGILE X-RELATED PROTEIN 2; FXR2P;; FRAGILE X MENTAL RETARDATION, AUTOSOMAL HOMOLOG 2__:__
Asterisk__:__605340__:__CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 7; CYP3A7__:____:__
Asterisk__:__605341__:__PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, ALPHA; PILRA__:____:__
Asterisk__:__605342__:__PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, BETA; PILRB__:____:__
Asterisk__:__605343__:__FOLLISTATIN-LIKE 3; FSTL3__:__FOLLISTATIN-RELATED GENE; FLRG__:__
Asterisk__:__605344__:__NUCLEAR TRANSCRIPTION FACTOR Y, GAMMA; NFYC__:__TRANSCRIPTION FACTOR NF-Y, C SUBUNIT;; CCAAT-BINDING FACTOR, C SUBUNIT; CBFC__:__
Asterisk__:__605345__:__AlkB, E. COLI, HOMOLOG OF, 1; ALKBH1__:__ABH1;; ABH__:__
Caret__:__605346__:__MOVED TO 176730__:____:__
Asterisk__:__605347__:__PEPTIDYLARGININE DEIMINASE, TYPE IV; PADI4__:__PAD4;; PEPTIDYLARGININE DEIMINASE V; PADI5;; PROTEIN-ARGININE DEIMINASE; PAD__:__
Asterisk__:__605348__:__TRANSMEMBRANE PROTEIN 50A; TMEM50A__:__SMALL MEMBRANE PROTEIN 1; SMP1__:__
Asterisk__:__605349__:__NUCLEAR PRELAMIN A RECOGNITION FACTOR; NARF__:__IOP2__:__
Asterisk__:__605350__:__INTERLEUKIN 27 RECEPTOR, ALPHA; IL27RA__:__INTERLEUKIN 27 RECEPTOR; IL27R;; T-CELL CYTOKINE RECEPTOR; TCCR;; WSX1__:__
Asterisk__:__605351__:__FIBRINOGEN-LIKE 2; FGL2__:__FIBROLEUKIN__:__
Asterisk__:__605352__:__MALIGNANT FIBROUS HISTIOCYTOMA-AMPLIFIED SEQUENCE 1; MFHAS1__:__MALIGNANT FIBROUS HISTIOCYTOMA-AMPLIFIED SEQUENCES WITH LEUCINE-RICH TANDEM REPEATS 1; MASL1__:__
Asterisk__:__605353__:__GHRELIN; GHRL__:__GROWTH HORMONE SECRETAGOGUE RECEPTOR LIGAND;; MOTILIN-RELATED PEPTIDE__:__OBESTATIN, INCLUDED
Asterisk__:__605354__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 18; CARD18__:__CASPASE 1 INHIBITOR;; ICEBERG__:__
Number Sign__:__605355__:__NEMALINE MYOPATHY 5; NEM5__:__NEMALINE MYOPATHY, AMISH TYPE; ANM;; AMISH NEMALINE MYOPATHY__:__
Asterisk__:__605356__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, GAMMA ISOFORM; YWHAG__:__14-3-3-GAMMA__:__
Asterisk__:__605357__:__STONIN 1; STON1__:__STN1;; STONED B-LIKE FACTOR; SBLF__:__STONED B/TFIIA-ALPHA/BETA-LIKE FACTOR, INCLUDED; SALF, INCLUDED;; STON1/ALF SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__605358__:__GENERAL TRANSCRIPTION FACTOR IIA, 1-LIKE; GTF2A1L__:__TFIIA-ALPHA/BETA-LIKE FACTOR; ALF__:__
Asterisk__:__605359__:__PROLINE-RICH 4; PROL4__:__LACRIMAL PROLINE-RICH PROTEIN; LPRP__:__
Asterisk__:__605360__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 85B; CCDC85B__:__DELTA ANTIGEN-INTERACTING PROTEIN A; DIPA;; HEPATITIS DELTA ANTIGEN-INTERACTING PROTEIN A__:__
Number Sign__:__605361__:__SPINOCEREBELLAR ATAXIA 14; SCA14__:____:__
Number Sign__:__605362__:__CARDIOMYOPATHY, DILATED, 1J; CMD1J__:__CARDIOMYOPATHY, DILATED, WITH SENSORINEURAL HEARING LOSS, AUTOSOMAL DOMINANT__:__
Asterisk__:__605363__:__GLUTAMATE DECARBOXYLASE 1; GAD1__:__GAD;; GLUTAMATE DECARBOXYLASE, BRAIN, 67-KD; GAD67__:__
Percent__:__605364__:__PSORIASIS 6, SUSCEPTIBILITY TO; PSORS6__:____:__
Caret__:__605365__:__MOVED TO 114480__:____:__
Asterisk__:__605366__:__OLFACTOMEDIN 1; OLFM1__:__NOELIN 1;; NEUROBLASTOMA PROTEIN;; AMY__:__
Asterisk__:__605367__:__ELAC, E. COLI, HOMOLOG OF, 2; ELAC2__:__HPC2;; RIBONUCLEASE Z, LONG FORM;; RNase ZL__:__
Asterisk__:__605368__:__BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 3-LIKE; BNIP3L__:__NIX__:__
Asterisk__:__605369__:__TRANSMEMBRANE PROTEASE, SERINE 11D; TMPRSS11D__:__AIRWAY TRYPSIN-LIKE PROTEASE;; HAT__:__
Asterisk__:__605370__:__RHO GTPase-ACTIVATING PROTEIN 26; ARHGAP26__:__GTPase REGULATOR ASSOCIATED WITH FOCAL ADHESION KINASE; GRAF;; KIAA0621__:__GRAF/MLL FUSION GENE, INCLUDED
Asterisk__:__605371__:__ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; ARFGEF2__:__BREFELDIN A-INHIBITED GUANINE NUCLEOTIDE EXCHANGE PROTEIN 2; BIG2__:__
Asterisk__:__605372__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A3; HNRNPA3__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-LIKE;; HNRPA3;; FBRNP;; D10S102__:__
Number Sign__:__605373__:__PARAGANGLIOMAS 3; PGL3__:__GLOMUS TUMORS, FAMILIAL, 3__:__
Asterisk__:__605374__:__MYCN, OPPOSITE STRAND; MYCNOS__:__DNA-BINDING TRANSCRIPTIONAL ACTIVATOR NCYM; NYCM__:__
Number Sign__:__605375__:__EPILEPSY, NOCTURNAL FRONTAL LOBE, 3; ENFL3__:____:__
Number Sign__:__605376__:__HETEROTAXY, VISCERAL, 2, AUTOSOMAL; HTX2__:__HTX__:__
Asterisk__:__605377__:__DYSTROPHIA MYOTONICA PROTEIN KINASE; DMPK__:__DM KINASE; DMK;; DM PROTEIN KINASE;; MYOTONIN-PROTEIN KINASE__:__
Asterisk__:__605378__:__AAAS GENE; AAAS__:__ALADIN;; ADRACALIN__:__
Asterisk__:__605379__:__GIGAXONIN; GAN__:__GAN1__:__
Asterisk__:__605380__:__FIBROBLAST GROWTH FACTOR 23; FGF23__:____:__
Asterisk__:__605381__:__RHESUS BLOOD GROUP, C GLYCOPROTEIN; RHCG__:__RHESUS BLOOD GROUP-ASSOCIATED KIDNEY HOMOLOG;; RH-RELATED GLYCOPROTEIN RhGK; RHGK__:__
Caret__:__605382__:__MOVED TO 167320__:____:__
Asterisk__:__605383__:__INTERLEUKIN 21 RECEPTOR; IL21R__:____:__IL21R/BCL6 FUSION GENE, INCLUDED
Asterisk__:__605384__:__INTERLEUKIN 21; IL21__:____:__
Asterisk__:__605385__:__PRENYL PROTEIN PROTEASE RCE1; RCE1__:____:__
Asterisk__:__605386__:__MICRO RNA LET7A1; MIRLET7A1__:__MIRNLET7A1;; LET7, C. ELEGANS, HOMOLOG OF, A1;; miRNA LET7A1;; LET7A1;; LET7A1, SMALL TEMPORAL RNA;; LET7A1, stRNA__:__
Number Sign__:__605387__:__CATARACT 31, MULTIPLE TYPES; CTRCT31__:__CATARACT, POSTERIOR POLAR, 3; CTPP3; CPP3__:__
Percent__:__605388__:__CEREBRAL PALSY, ATAXIC, AUTOSOMAL RECESSIVE__:__ACP;; ATAXIC CEREBRAL PALSY__:__
Number Sign__:__605389__:__HYPOTRICHOSIS 1; HYPT1__:__HYPOTRICHOSIS SIMPLEX, GENERALIZED, HEREDITARY; HHS;; HTS__:__
Asterisk__:__605390__:__LEUPAXIN; LPXN__:____:__
Asterisk__:__605391__:__MULTIPLE INOSITOL POLYPHOSPHATE PHOSPHATASE 1; MINPP1__:__MIPP, RAT, HOMOLOG OF;; HIPER1, CHICKEN, HOMOLOG OF__:__
Asterisk__:__605392__:__FIBROBLAST GROWTH FACTOR RECEPTOR 1 ONCOGENE PARTNER; FGFR1OP__:__FGFR1 ONCOGENE PARTNER; FOP__:__FOP/FGFR1 FUSION GENE, INCLUDED
Asterisk__:__605393__:__LYSINE-SPECIFIC DEMETHYLASE 5B; KDM5B__:__JUMONJI, AT-RICH INTERACTIVE DOMAIN 1B; JARID1B;; PUTATIVE DNA/CHROMATIN-BINDING MOTIF 1;; PUT1;; PLU1;; RETINOBLASTOMA-BINDING PROTEIN 2, HOMOLOG 1A; RBBP2H1A__:__
Asterisk__:__605394__:__BTB AND CNC HOMOLOGY 2; BACH2__:__BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 2__:__
Asterisk__:__605395__:__TRANSMEMBRANE p24 TRAFFICKING PROTEIN 1; TMED1__:__TRANSMEMBRANE EMP24 TRANSPORT DOMAIN-CONTAINING PROTEIN 1;; INTERLEUKIN 1 RECEPTOR-LIKE 1 LIGAND; IL1RL1LG;; IL1RL1-BINDING PROTEIN__:__
Caret__:__605396__:__MOVED TO 604686__:____:__
Asterisk__:__605397__:__CD226 ANTIGEN; CD226__:__DNAX ACCESSORY MOLECULE 1; DNAM1__:__
Asterisk__:__605398__:__CHEMOKINE, CXC MOTIF, LIGAND 16; CXCL16__:__SRPSOX__:__
Asterisk__:__605399__:__NIDOGEN 2; NID2__:__OSTEONIDOGEN__:__
NULL__:__605400__:__FIBROMATOSIS, GINGIVAL, WITH HYPERTRICHOSIS AND MENTAL RETARDATION__:____:__
Asterisk__:__605401__:__IQ MOTIF-CONTAINING GTPase-ACTIVATING PROTEIN 2; IQGAP2__:____:__
Asterisk__:__605402__:__CD274 MOLECULE; CD274__:__PROGRAMMED CELL DEATH 1 LIGAND 1; PDCD1LG1;; PDCD1 LIGAND 1; PDCD1L1;; PROGRAMMED DEATH LIGAND 1; PDL1;; B7 HOMOLOG 1; B7H1__:__
Asterisk__:__605403__:__TOLL-LIKE RECEPTOR 6; TLR6__:____:__
Asterisk__:__605404__:__BCL2-RELATED OVARIAN KILLER; BOK__:__BCL2-LIKE 9; BCL2L9__:__
Asterisk__:__605405__:__USP6 N-TERMINAL-LIKE; USP6NL__:__RELATED TO THE N TERMINUS OF TRE; RNTRE__:__
Asterisk__:__605406__:__TRANSMEMBRANE p24 TRAFFICKING PROTEIN 10; TMED10__:__TRANSMEMBRANE EMP24 TRANSPORT DOMAIN-CONTAINING PROTEIN 10;; TRANSMEMBRANE TRAFFICKING PROTEIN, 21-KD; TMP21__:__
Number Sign__:__605407__:__SEGAWA SYNDROME, AUTOSOMAL RECESSIVE__:__PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY__:__
Caret__:__605408__:__MOVED TO 159900__:____:__
Asterisk__:__605409__:__TRANSCRIPTION ELONGATION REGULATOR 1; TCERG1__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 2S; TAF2S;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 150-KD;; TRANSCRIPTION FACTOR CA150; CA150__:__
Asterisk__:__605410__:__POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 2; KCND2__:__Kv4.2;; KIAA1044__:__
Asterisk__:__605411__:__POTASSIUM VOLTAGE-GATED CHANNEL, SHAL-RELATED SUBFAMILY, MEMBER 3; KCND3__:__Kv4.3;; KCND3S__:__KCND3L, INCLUDED
Asterisk__:__605412__:__RAB-LIKE 2A; RABL2A__:____:__
Asterisk__:__605413__:__RAB-LIKE 2B; RABL2B__:____:__
Asterisk__:__605414__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 7; ABCA7__:__ABCX;; SJOGREN SYNDROME ANTIGEN SS-N__:__
Asterisk__:__605415__:__DICKKOPF, XENOPUS, HOMOLOG OF, 2; DKK2__:____:__
Asterisk__:__605416__:__DICKKOPF, XENOPUS, HOMOLOG OF, 3; DKK3__:__REGULATED IN GLIOMA; RIG__:__
Asterisk__:__605417__:__DICKKOPF, XENOPUS, HOMOLOG OF, 4; DKK4__:____:__
Asterisk__:__605418__:__DICKKOPF-LIKE 1; DKKL1__:__SOGGY 1; SGY1;; SGY__:__
Percent__:__605419__:__SCHIZOPHRENIA 10; SCZD10__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 15q15-RELATED;; CATATONIA, PERIODIC__:__
Asterisk__:__605420__:__ARISTALESS-LIKE 4, MOUSE, HOMOLOG OF; ALX4__:____:__
Asterisk__:__605421__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 9; ADAMTS9__:____:__
Asterisk__:__605422__:__ZINC FINGER PROTEIN 350; ZNF350__:__ZINC FINGER AND BRCA1-INTERACTING PROTEIN WITH A KRAB DOMAIN 1; ZBRK1__:__
Asterisk__:__605423__:__DESERT HEDGEHOG; DHH__:____:__
Asterisk__:__605424__:__MASTERMIND-LIKE 1; MAML1__:__MASTERMIND, DROSOPHILA, HOMOLOG OF, 1; MAM1__:__
Asterisk__:__605425__:__GAP JUNCTION PROTEIN, BETA-4; GJB4__:__CONNEXIN 30.3; CX30.3__:__
Asterisk__:__605426__:__TUMOR PROTEIN p53-REGULATED APOPTOSIS-INDUCING PROTEIN 1; TP53AIP1__:__p53-REGULATED APOPTOSIS-INDUCING PROTEIN 1; P53AIP1__:__
Asterisk__:__605427__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 4; TRPV4__:__VANILLOID RECEPTOR-RELATED OSMOTICALLY ACTIVATED CHANNEL; VROAC;; OSM9-LIKE TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; OTRPC4;; TRANSIENT RECEPTOR POTENTIAL CHANNEL 12; TRP12;; TRANSIENT RECEPTOR POTENTIAL, DROSOPHILA, HOMOLOG OF, 12__:__
Number Sign__:__605428__:__DEAFNESS, AUTOSOMAL RECESSIVE 26; DFNB26__:____:__
Number Sign__:__605429__:__DEAFNESS, AUTOSOMAL RECESSIVE 26, MODIFIER OF; DFNB26M__:__DFNB26, MODIFIER OF;; DFNB26, SUPPRESSOR OF;; DEAFNESS, NONSYNDROMIC, MODIFIER OF, 1; DFNM1__:__
Asterisk__:__605430__:__SPERM-ASSOCIATED ANTIGEN 9; SPAG9__:__SUNDAY DRIVER, DROSOPHILA, HOMOLOG OF, 1; SYD1;; PROTEIN HIGHLY EXPRESSED IN TESTIS; PHET;; KIAA0516__:__
Asterisk__:__605431__:__MITOGEN-ACTIVATED PROTEIN KINASE 8-INTERACTING PROTEIN 3; MAPK8IP3__:__SUNDAY DRIVER, DROSOPHILA, HOMOLOG OF, 2; SYD2;; JNK/STRESS-ACTIVATED PROTEIN KINASE-ASSOCIATED PROTEIN 1; JSAP1;; JNK-INTERACTING PROTEIN 3; JIP3__:__
Number Sign__:__605432__:__RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA 1; RUSAT1__:__RUSAT;; THROMBOCYTOPENIA, CONGENITAL, WITH RADIOULNAR SYNOSTOSIS; CTRUS__:__
Asterisk__:__605433__:__KINESIN FAMILY MEMBER 13A; KIF13A__:____:__
Asterisk__:__605434__:__CLASPIN, XENOPUS, HOMOLOG OF; CLSPN__:____:__
Asterisk__:__605435__:__PROTEIN KINASE D1; PRKD1__:__PROTEIN KINASE C, MU; PRKCM;; PKC-MU;; PROTEIN KINASE D; PKD__:__
Asterisk__:__605436__:__SMALL NUCLEOLAR RNA, C/D BOX, 116-1; SNORD116-1__:__PRADER-WILLI CRITICAL REGION GENE 1; PWCR1;; RNA, HBII-85 SMALL NUCLEOLAR snoRNA, HBII-85__:__
Asterisk__:__605437__:__PROTEIN KINASE C, ETA; PRKCH__:__PKCL; PRKCL__:__
Asterisk__:__605438__:__DISCS LARGE-ASSOCIATED PROTEIN 2; DLGAP2__:__DAP2;; SAP90/PSD95-ASSOCIATED PROTEIN 2; SAPAP2__:__
Asterisk__:__605439__:__ETS HOMOLOGOUS FACTOR; EHF__:__EPITHELIUM-SPECIFIC ETS FACTOR 3; ESE3__:__
Asterisk__:__605440__:__UBIQUILIN 4; UBQLN4__:__ATAXIN-1 UBIQUITIN-LIKE INTERACTING PROTEIN; A1U;; CHROMOSOME 1 OPEN READING FRAME 6; C1ORF6;; CONNEXIN 43-INTERACTING PROTEIN, 75-KD; CIP75__:__
Asterisk__:__605441__:__ADIPOCYTE-, C1q-, AND COLLAGEN DOMAIN-CONTAINING; ADIPOQ__:__ADIPOSE MOST ABUNDANT GENE TRANSCRIPT 1; APM1;; GELATIN-BINDING PROTEIN, 28-KD; GBP28;; ADIPONECTIN; ADPN;; ACRP30;; ADIPOCYTE-SPECIFIC SECRETORY PROTEIN;; ACDC__:__
Asterisk__:__605442__:__WT1-ASSOCIATED PROTEIN; WTAP__:__KIAA0105__:__
Asterisk__:__605443__:__PROSTATE-SPECIFIC GENE PCGEM1; PCGEM1__:____:__
Asterisk__:__605444__:__RNA-BINDING MOTIF PROTEIN, X CHROMOSOME, LIKE 2; RBMXL2__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN G-T;; HNRNPGT;; HNRPGT__:__
Asterisk__:__605445__:__DISCS LARGE-ASSOCIATED PROTEIN 1; DLGAP1__:__DAP1;; GUANYLATE KINASE-ASSOCIATED PROTEIN; GKAP;; SAP90/PSD95-ASSOCIATED PROTEIN 1; SAPAP1__:__DISCS LARGE-ASSOCIATED PROTEIN 1, ALPHA ISOFORM, INCLUDED; DLGAP1A, INCLUDED; DAP1A, INCLUDED;; DISCS LARGE-ASSOCIATED PROTEIN 1, BETA ISOFORM, INCLUDED; DLGAP1B, INCLUDED; DAP1B, INCLUDED
Asterisk__:__605446__:__RETINITIS PIGMENTOSA GTPase REGULATOR-INTERACTING PROTEIN; RPGRIP1__:__RPGR-INTERACTING PROTEIN__:__
Asterisk__:__605447__:__CHROMOSOME 6 OPEN READING FRAME 48; C6ORF48__:__G8 PROTEIN; G8__:__
Asterisk__:__605448__:__RUN DOMAIN-CONTAINING PROTEIN 3A; RUNDC3A__:__RAP2-INTERACTING PROTEIN 8; RPIP8__:__
Asterisk__:__605449__:__GLUTATHIONE S-TRANSFERASE, ALPHA-3; GSTA3__:__GLUTATHIONE S-TRANSFERASE A3__:__
Asterisk__:__605450__:__GLUTATHIONE S-TRANSFERASE, ALPHA-4; GSTA4__:__GLUTATHIONE S-TRANSFERASE A4__:__
Asterisk__:__605451__:__p21 PROTEIN-ACTIVATED KINASE 4; PAK4__:__p21 CDC42/RAC1-ACTIVATED KINASE 4;; KIAA1142__:__
Asterisk__:__605452__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 6; ABCB6__:__MITOCHONDRIAL ABC PROTEIN 3; MTABC3__:__
Asterisk__:__605453__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 9; ABCB9__:____:__
Asterisk__:__605454__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 10; ABCB10__:__MITOCHONDRIAL ABC PROTEIN 2; MABC2; MTABC2__:__
Asterisk__:__605455__:__RAS-ASSOCIATED PROTEIN RAB26; RAB26__:____:__
Asterisk__:__605456__:__BET1 GOLGI VESICULAR MEMBRANE-TRAFFICKING PROTEIN; BET1__:__BET1, S. CEREVISIAE, HOMOLOG OF;; GOLGI VESICULAR MEMBRANE-TRAFFICKING PROTEIN p18__:__
Asterisk__:__605457__:__INTERLEUKIN 22 RECEPTOR, ALPHA-1; IL22RA1__:__IL22R1__:__
Asterisk__:__605458__:__INTERLEUKIN 17 RECEPTOR B; IL17RB__:__INTERLEUKIN 17B RECEPTOR; IL17BR;; INTERLEUKIN 17 RECEPTOR HOMOLOG 1; IL17RH1__:__
Asterisk__:__605459__:__ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 5; ABCG5__:__STEROLIN 1__:__
Asterisk__:__605460__:__ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 8; ABCG8__:__STEROLIN 2__:__
Asterisk__:__605461__:__INTERLEUKIN 17 RECEPTOR A; IL17RA__:__IL17R__:__
Percent__:__605462__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 1; BCC1__:____:__BASAL CELL CARCINOMA, NONSYNDROMIC, INCLUDED;; BASAL CELL CARCINOMA, MULTIPLE, INCLUDED
NULL__:__605463__:__RADIATION SENSITIVITY/CHROMOSOME INSTABILITY SYNDROME, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__605464__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 8; ABCB8__:__MITOCHONDRIAL ATP-BINDING CASSETTE 1; MABC1__:__
Asterisk__:__605465__:__ZINC FINGER PROTEIN 277; ZNF277__:____:__
Asterisk__:__605466__:__SIGNAL REGULATORY PROTEIN, GAMMA; SIRPG__:__SIRP-GAMMA;; SIGNAL REGULATORY PROTEIN, BETA-2; SIRPB2__:__
Asterisk__:__605467__:__ZINC FINGER PROTEIN 274; ZNF274__:____:__ZINC FINGER PROTEIN 274, ISOFORM A, INCLUDED; ZNF274A, INCLUDED;; ZINC FINGER PROTEIN 274, ISOFORM B, INCLUDED; ZNF274B, INCLUDED
Asterisk__:__605468__:__CDC42 EFFECTOR PROTEIN 4; CDC42EP4__:__CEP4;; BINDER OF RHO GTPases 4; BORG4__:__
Asterisk__:__605469__:__LYSINE-SPECIFIC DEMETHYLASE 4C; KDM4C__:__JUMONJI DOMAIN-CONTAINING PROTEIN 2C; JMJD2C;; GENE AMPLIFIED IN SQUAMOUS CELL CARCINOMA 1; GASC1;; KIAA0780__:__
Asterisk__:__605470__:__MATRIX METALLOPROTEINASE 26; MMP26__:__MATRILYSIN 2__:__
Asterisk__:__605471__:__ZINC FINGER FYVE TYPE-CONTAINING PROTEIN 1; ZFYVE1__:__ZINC FINGER PROTEIN, SUBFAMILY 2A, MEMBER 1; ZNFN2A1;; DOUBLE FYVE-CONTAINING PROTEIN 1; DFCP1;; TANDEM FYVE FINGERS 1; TAFF1__:__
Number Sign__:__605472__:__USHER SYNDROME, TYPE IIC; USH2C__:____:__USHER SYNDROME, TYPE IIC, GPR98/PDZD7, DIGENIC, INCLUDED;; USHER SYNDROME, TYPE IIB, FORMERLY, INCLUDED; USH2B, FORMERLY, INCLUDED
Asterisk__:__605473__:__UBIQUILIN 3; UBQLN3__:____:__
Asterisk__:__605474__:__TOLL-LIKE RECEPTOR 9; TLR9__:____:__
Asterisk__:__605475__:__BAI1-ASSOCIATED PROTEIN 2; BAIAP2__:__INSULIN RECEPTOR SUBSTRATE p53; IRSP53__:__
Asterisk__:__605476__:__ARF GTPase-ACTIVATING PROTEIN WITH GTPase DOMAIN, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAIN 2; AGAP2__:__CENTAURIN, GAMMA-1; CENTG1;; PHOSPHOINOSITIDE 3-KINASE ENHANCER;; PI3K ENHANCER; PIKE;; KIAA0167__:__
Asterisk__:__605477__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 7; ARHGEF7__:__PAK-INTERACTING EXCHANGE FACTOR, BETA; PIXB;; BETA-PIX;; COOL1;; KIAA0142__:__
Asterisk__:__605478__:__SINGLE IMMUNOGLOBULIN DOMAIN-CONTAINING IL1R-RELATED PROTEIN; SIGIRR__:__TOLL/IL1R 8; TIR8__:__
Number Sign__:__605479__:__CHOLESTASIS, BENIGN RECURRENT INTRAHEPATIC, 2; BRIC2__:____:__
Percent__:__605480__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 3; SLEB3__:____:__
Asterisk__:__605481__:__ABNORMAL SPINDLE-LIKE, MICROCEPHALY-ASSOCIATED; ASPM__:__ASP, DROSOPHILA, HOMOLOG OF;; MCPH5 GENE__:__
Asterisk__:__605482__:__GLUTATHIONE S-TRANSFERASE, OMEGA-1; GSTO1__:____:__
Asterisk__:__605483__:__DYNEIN, AXONEMAL, INTERMEDIATE CHAIN 2; DNAI2__:____:__
Asterisk__:__605484__:__Fc FRAGMENT OF IgA AND IgM, RECEPTOR FOR; FCAMR__:____:__
Asterisk__:__605485__:__VACUOLAR PROTEIN SORTING 41, YEAST, HOMOLOG OF; VPS41__:____:__
Caret__:__605486__:__MOVED TO 605313__:____:__
Asterisk__:__605487__:__CYCLIC AMP-REGULATED PHOSPHOPROTEIN, 19-KD; ARPP19__:__cAMP-REGULATED PHOSPHOPROTEIN, 19-KD__:__cAMP-REGULATED PHOSPHOPROTEIN, 16-KD, INCLUDED; ARPP16, INCLUDED
Asterisk__:__605488__:__CYCLIC AMP-REGULATED PHOSPHOPROTEIN, 21-KD; ARPP21__:__cAMP-REGULATED PHOSPHOPROTEIN, 21-KD;; REGULATOR OF CALMODULIN SIGNALING; RCS__:__
Asterisk__:__605489__:__INTRAFLAGELLAR TRANSPORT 81, CHLAMYDOMONAS, HOMOLOG OF; IFT81__:__CARNITINE DEFICIENCY-ASSOCIATED GENE EXPRESSED IN VENTRICLE 1; CDV1__:__CDV1-RELATED, INCLUDED; CDV1R, INCLUDED
Asterisk__:__605490__:__LON PEPTIDASE 1, MITOCHONDRIAL; LONP1__:__LON, E. COLI, HOMOLOG OF; LON;; PROTEASE, SERINE, 15; PRSS15__:__
Asterisk__:__605491__:__NEBULETTE; NEBL__:____:__LIM-NEBULETTE, INCLUDED
Asterisk__:__605492__:__LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 2; LRRN2__:__GLIOMA AMPLIFICATION ON CHROMOSOME 1; GAC1;; LEUCINE-RICH AND ANKYRIN REPEATS 1; LRANK1;; LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 5; LRRN5__:__
Asterisk__:__605493__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 3; TRIM3__:__RING FINGER PROTEIN 22; RNF22;; BRAIN-EXPRESSED RING FINGER; BERP__:__
Asterisk__:__605494__:__INTEGRIN, BETA-3, BINDING PROTEIN OF; ITGB3BP__:__ENDONEXIN, BETA-3__:__ENDONEXIN, BETA-3, LONG FORM, INCLUDED;; NUCLEAR RECEPTOR-INTERACTING FACTOR 3, INCLUDED; NRIF3, INCLUDED;; CENTROMERIC PROTEIN R, INCLUDED; CENPR, INCLUDED
Asterisk__:__605495__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B3; SLCO1B3__:__ORGANIC ANION TRANSPORTER 8; OATP8;; ORGANIC ANION TRANSPORTER 1B3; OATP1B3;; SOLUTE CARRIER FAMILY 21 (ORGANIC ANION TRANSPORTER), MEMBER 8, FORMERLY; SLC21A8, FORMERLY__:__
Asterisk__:__605496__:__CENTROSOMAL PROTEIN 1; CEP1__:__CEP110;; FAN__:__CEP1/FGFR1 FUSION GENE, INCLUDED
Asterisk__:__605497__:__CARTILAGE-ASSOCIATED PROTEIN; CRTAP__:__CASP;; LEPRECAN-LIKE 3; LEPREL3__:__
Asterisk__:__605498__:__M-PHASE PHOSPHOPROTEIN 1; MPHOSPH1__:__MPP1;; KINESIN-RELATED MOTOR INTERACTING WITH PIN1; KRMP1__:__
Asterisk__:__605499__:__ZW10 INTERACTOR, ANTISENSE; ZWINTAS__:__M-PHASE PHOSPHOPROTEIN 5; MPHOSPH5; MPP5__:__
Asterisk__:__605500__:__M-PHASE PHOSPHOPROTEIN 6; MPHOSPH6__:__MPP6__:__
Asterisk__:__605501__:__M-PHASE PHOSPHOPROTEIN 9; MPHOSPH9__:__MPP9__:__
Asterisk__:__605502__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 2; DNAJC2__:__ZUOTIN-RELATED FACTOR 1; ZRF1;; M-PHASE PHOSPHOPROTEIN 11; MPHOSPH11; MPP11__:__
Asterisk__:__605503__:__M-PHASE PHOSPHOPROTEIN 10; MPHOSPH10__:__MPP10__:__
Asterisk__:__605504__:__KALLIKREIN-RELATED PEPTIDASE 9; KLK9__:__KALLIKREIN 9;; KALLIKREIN-LIKE 3; KLKL3__:__
Asterisk__:__605505__:__KALLIKREIN-RELATED PEPTIDASE 13; KLK13__:__KALLIKREIN 13;; KALLIKREIN-LIKE 4; KLKL4__:__
Asterisk__:__605506__:__VACUOLAR PROTEIN SORTING 26, YEAST, HOMOLOG OF, A; VPS26A__:__VPS26;; HB58, MOUSE, HOMOLOG OF__:__
Asterisk__:__605507__:__INTERLEUKIN 36 RECEPTOR ANTAGONIST; IL36RN__:__INTERLEUKIN 1 FAMILY, MEMBER 5; IL1F5;; INTERLEUKIN 1 RECEPTOR ANTAGONIST HOMOLOG 1; IL1HY1;; FAMILY OF INTERLEUKIN 1-DELTA;; FIL1-DELTA;; IL1RP3__:__
Asterisk__:__605508__:__INTERLEUKIN 36, BETA; IL36B__:__INTERLEUKIN 1 FAMILY, MEMBER 8; IL1F8;; FAMILY OF INTERLEUKIN 1-ETA;; FIL1-ETA;; INTERLEUKIN 1 SUPERFAMILY E;; IL1H2__:__
Asterisk__:__605509__:__INTERLEUKIN 36, ALPHA; IL36A__:__INTERLEUKIN 1 FAMILY, MEMBER 6; IL1F6;; FAMILY OF INTERLEUKIN 1-EPSILON;; FIL1-EPSILON__:__
Asterisk__:__605510__:__INTERLEUKIN 37; IL37__:__INTERLEUKIN 1 FAMILY, MEMBER 7; IL1F7;; FAMILY OF INTERLEUKIN 1-ZETA;; FIL1-ZETA;; IL1H4;; IL1RP1__:__
Asterisk__:__605511__:__TRANSMEMBRANE PROTEASE, SERINE 3; TMPRSS3__:____:__
Asterisk__:__605512__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 4; ELOVL4__:____:__
Asterisk__:__605513__:__MELAN A; MLANA__:__MELANOMA ANTIGEN RECOGNIZED BY T CELLS 1; MART1__:__
Asterisk__:__605514__:__PROTOCADHERIN 15; PCDH15__:____:__
Asterisk__:__605515__:__FORKHEAD BOX P1; FOXP1__:__GLUTAMINE-RICH FACTOR 1; QRF1__:__
Asterisk__:__605516__:__CADHERIN 23; CDH23__:__OTOCADHERIN;; CADHERIN-RELATED FAMILY, MEMBER 23; CDHR23__:__
Asterisk__:__605517__:__BETA-1,4-GLUCURONYLTRANSFERASE 1; B4GAT1__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 1;B3GNT1;; i-BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE; iGNT__:__
Asterisk__:__605518__:__LIPIN 1; LPIN1__:__KIAA0188;; PHOSPHATIDIC ACID PHOSPHOHYDROLASE 1; PAP1;; PAH1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__605519__:__LIPIN 2; LPIN2__:____:__
Asterisk__:__605520__:__LIPIN 3; LPIN3__:____:__
Asterisk__:__605521__:__TATA BOX-BINDING PROTEIN-LIKE PROTEIN 1; TBPL1__:__TBP-LIKE PROTEIN 1;; TLP;; TBP-RELATED FACTOR 2; TRF2;; TBP-LIKE FACTOR; TLF__:__
Asterisk__:__605522__:__LIMB REGION 1, MOUSE, HOMOLOG OF; LMBR1__:__CHROMOSOME 7 OPEN READING FRAME 2; C7ORF2__:__ZPA REGULATORY SEQUENCE, INCLUDED; ZRS, INCLUDED
Asterisk__:__605523__:__TRANSDUCER OF ERBB2, 1; TOB1__:__TOB__:__
Caret__:__605524__:__MOVED TO 164874__:____:__
Asterisk__:__605525__:__CHROMATIN LICENSING AND DNA REPLICATION FACTOR 1; CDT1__:__DOUBLE PARKED, DROSOPHILA, HOMOLOG OF; DUP__:__
Percent__:__605526__:__ALZHEIMER DISEASE 6__:__AD6;; ALZHEIMER DISEASE 6, LATE-ONSET__:__PLASMA BETA-AMYLOID-42 LEVEL QUANTITATIVE TRAIT LOCUS, INCLUDED
Asterisk__:__605527__:__METHIONINE ADENOSYLTRANSFERASE II, BETA; MAT2B__:____:__
Asterisk__:__605528__:__NEURAMINIDASE 2; NEU2__:__SIALIDASE 2; SIAL2;; SIALIDASE, CYTOSOLIC__:__
Asterisk__:__605529__:__UPF2, YEAST, HOMOLOG OF; UPF2__:__REGULATOR OF NONSENSE TRANSCRIPTS 2; RENT2__:__
Asterisk__:__605530__:__UPF3, YEAST, HOMOLOG OF, A; UPF3A__:__REGULATOR OF NONSENSE TRANSCRIPTS 3A; RENT3A;; UPF3__:__
Caret__:__605531__:__MOVED TO 300298__:____:__
Asterisk__:__605532__:__SMAD-SPECIFIC E3 UBIQUITIN PROTEIN LIGASE 2; SMURF2__:__SMAD UBIQUITINATION REGULATORY FACTOR 2__:__
Asterisk__:__605533__:__NEUREGULIN 3; NRG3__:____:__
Asterisk__:__605534__:__HIGH MOBILITY GROUP PROTEIN 20A; HMG20A__:____:__
Asterisk__:__605535__:__HIGH MOBILITY GROUP PROTEIN 20B; HMG20B__:__BRCA2-ASSOCIATED FACTOR, 35-KD; BRAF35__:__
Asterisk__:__605536__:__RAB11 FAMILY-INTERACTING PROTEIN 5; RAB11FIP5__:__RAB11-INTERACTING PROTEIN; RIP11;; KIAA0857__:__
Asterisk__:__605537__:__ACTIVATING TRANSCRIPTION FACTOR 6; ATF6__:__ACTIVATING TRANSCRIPTION FACTOR 6, ALPHA; ATF6A__:__
Asterisk__:__605538__:__NEUROTENSIN RECEPTOR 2; NTSR2__:____:__
Asterisk__:__605539__:__KALLIKREIN-RELATED PEPTIDASE 12; KLK12__:__KALLIKREIN 12;; KALLIKREIN-LIKE 5; KLKL5__:__
Asterisk__:__605540__:__TERMINAL NUCLEOTIDYLTRANSFERASE 4B; TENT4B__:__POLY(A) POLYMERASE-ASSOCIATED DOMAIN-CONTAINING PROTEIN 5; PAPD5;; PAP-ASSOCIATED DOMAIN-CONTAINING PROTEIN 5;; TOPOISOMERASE-RELATED FUNCTION PROTEIN 4-2; TRF4-2;; TUTase 3; TUT3;; GLD4__:__
Asterisk__:__605541__:__VAV3 ONCOGENE; VAV3__:__ONCOGENE VAV3__:__
Asterisk__:__605542__:__INTERLEUKIN 36, GAMMA; IL36G__:__INTERLEUKIN 1 FAMILY, MEMBER 9; IL1F9;; INTERLEUKIN 1 HOMOLOG 1; IL1H1;; INTERLEUKIN 1-RELATED PROTEIN 2; IL1RP2__:__
Number Sign__:__605543__:__PARKINSON DISEASE 4, AUTOSOMAL DOMINANT; PARK4__:__PARKINSON DISEASE 4, AUTOSOMAL DOMINANT LEWY BODY__:__
Percent__:__605544__:__FIBROMATOSIS, GINGIVAL, 2; GINGF2__:__GGF2;; FIBROMATOSIS, GINGIVAL, HEREDITARY, 2; HGF2__:__
Asterisk__:__605545__:__CD163 ANTIGEN; CD163__:__HEMOGLOBIN SCAVENGER RECEPTOR__:__
Asterisk__:__605546__:__GLYCOPROTEIN VI, PLATELET; GP6__:__PLATELET GLYCOPROTEIN VI;; GP VI__:__
Asterisk__:__605547__:__FOLLISTATIN-LIKE 1; FSTL1__:__FOLLISTATIN-RELATED PROTEIN; FRP__:__MICRO RNA 198, INCLUDED; MIR198, INCLUDED;; miRNA198, INCLUDED
Asterisk__:__605548__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 15; ADAM15__:__METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN 15; MDC15;; METARGIDIN__:__
Percent__:__605549__:__CONE-ROD DYSTROPHY 8; CORD8__:____:__
Asterisk__:__605550__:__RAS PROTEIN, DEXAMETHASONE-INDUCED, 1; RASD1__:__DEXAMETHASONE-INDUCED RAS PROTEIN 1; DEXRAS1__:__
Asterisk__:__605551__:__NITRIC OXIDE SYNTHASE 1 (NEURONAL) ADAPTOR PROTEIN; NOS1AP__:__C-TERMINAL PDZ DOMAIN LIGAND OF NEURONAL NITRIC OXIDE SYNTHASE; CAPON__:__
Percent__:__605552__:__ABDOMINAL OBESITY-METABOLIC SYNDROME 1; AOMS1__:__METABOLIC SYNDROME X__:__ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 1, INCLUDED;; METABOLIC SYNDROME, PROTECTION AGAINST, INCLUDED
Asterisk__:__605553__:__POLY(A) POLYMERASE, ALPHA; PAPOLA__:__PAP__:__
Asterisk__:__605554__:__CD244 ANTIGEN; CD244__:__NATURAL KILLER CELL RECEPTOR 2B4; 2B4;; NATURAL KILLER CELL ACTIVATION-INDUCING LIGAND; NAIL;; SLAM FAMILY, MEMBER 4; SLAMF4__:__
Asterisk__:__605555__:__ARYL HYDROCARBON RECEPTOR-INTERACTING PROTEIN; AIP__:__HEPATITIS B VIRUS X-ASSOCIATED PROTEIN 2; XAP2;; ARA9__:__
Asterisk__:__605556__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE TRANSPORTER-LIKE), MEMBER 10; SLC4A10__:____:__
Asterisk__:__605557__:__PR DOMAIN-CONTAINING PROTEIN 16; PRDM16__:__MDS1/EVI1-LIKE GENE 1; MEL1__:__
Asterisk__:__605558__:__FIBROBLAST GROWTH FACTOR 20; FGF20__:____:__
Asterisk__:__605559__:__HOMEOBOX C11; HOXC11__:____:__
Asterisk__:__605560__:__HOMEOBOX C10; HOXC10__:____:__
Asterisk__:__605561__:__PLAKOPHILIN 3; PKP3__:____:__
Asterisk__:__605562__:__SECRETOGLOBIN, FAMILY 2A, MEMBER 2; SCGB2A2__:__MAMMAGLOBIN 1; MGB1__:__
Asterisk__:__605563__:__CALCIUM-BINDING PROTEIN 1; CABP1__:__CALBRAIN__:__
Asterisk__:__605564__:__CALCIUM- AND INTEGRIN-BINDING PROTEIN 2; CIB2__:__DNA-DEPENDENT PROTEIN KINASE-INTERACTING PROTEIN 2;; KINASE-INTERACTING PROTEIN 2; KIP2__:__
Asterisk__:__605565__:__RESISTIN; RETN__:__RSTN;; FOUND IN INFLAMMATORY ZONE 3; FIZZ3__:__
Asterisk__:__605566__:__RETICULON 4 RECEPTOR; RTN4R__:__NOGO RECEPTOR; NGR__:__
Asterisk__:__605567__:__SIVA APOPTOSIS-INDUCING FACTOR 1; SIVA1__:__CD27-BINDING PROTEIN; CD27BP__:__
Asterisk__:__605568__:__SMAD-SPECIFIC E3 UBIQUITIN PROTEIN LIGASE 1; SMURF1__:__SMAD UBIQUITINATION REGULATORY FACTOR 1__:__
Asterisk__:__605569__:__G PROTEIN-COUPLED RECEPTOR 83; GPR83__:__GIR, MOUSE, HOMOLOG OF; GIR;; G PROTEIN-COUPLED RECEPTOR 72; GPR72__:__
Asterisk__:__605570__:__RAS-ASSOCIATED PROTEIN RAB11A; RAB11A__:____:__
Asterisk__:__605571__:__PIWI-LIKE 1; PIWIL1__:__HIWI;; MIWI, MOUSE, HOMOLOG OF; MIWI__:__
Percent__:__605572__:__ABDOMINAL OBESITY-METABOLIC SYNDROME QUANTITATIVE TRAIT LOCUS 2__:__AOMS2__:__
Asterisk__:__605573__:__17-BETA HYDROXYSTEROID DEHYDROGENASE III; HSD17B3__:__17-BETA-HSD III;; ESTRADIOL 17-BETA-DEHYDROGENASE; EDH17B3;; TESTICULAR 17-BETA-HYDROXYSTEROID DEHYDROGENASE III__:__
Asterisk__:__605574__:__UBIQUITIN-CONJUGATING ENZYME E2C; UBE2C__:__UBIQUITIN-CONJUGATING ENZYME UBCH10; UBCH10__:__
Asterisk__:__605575__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 4; SMC4__:__CHROMOSOME-ASSOCIATED PROTEIN C; CAPC__:__
Asterisk__:__605576__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 2; SMC2__:__CHROMOSOME-ASSOCIATED PROTEIN E; CAPE__:__
Asterisk__:__605577__:__RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 2; RASGRP2__:__CALCIUM AND DIACYLGLYCEROL-REGULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR I;; CALDAG-GEFI;; CDC25-LIKE GENE; CDC25L__:__
Asterisk__:__605578__:__INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 2; IFITM2__:____:__
Asterisk__:__605579__:__INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 3; IFITM3__:____:__
Asterisk__:__605580__:__INTERLEUKIN 23-ALPHA; IL23A__:__INTERLEUKIN 23, p19 SUBUNIT;; p19;; SGRF__:__
Asterisk__:__605581__:__BETA-1,3-N-ACETYLGLUCOSYAMINYLTRANSFERASE 2; B3GNT2__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 1, FORMERLY; B3GNT1, FORMERLY;; B3GNT__:__
Percent__:__605582__:__CARDIOMYOPATHY, DILATED, 1K; CMD1K__:____:__
Number Sign__:__605583__:__DEAFNESS, AUTOSOMAL DOMINANT 25; DFNA25__:____:__
Asterisk__:__605584__:__DEAH BOX POLYPEPTIDE 38; DHX38__:__PRP16, S. CEREVISIAE, HOMOLOG OF; PRP16;; DDX38__:__
Asterisk__:__605585__:__CELL DIVISION CYCLE 40, S. CEREVISIAE, HOMOLOG OF; CDC40__:__PRP17, S. CEREVISIAE, HOMOLOG OF; PRP17__:__
Asterisk__:__605586__:__IMPORTIN 7; IPO7__:__RAN-BINDING PROTEIN 7; RANBP7__:__
Asterisk__:__605587__:__PROTEASE INHIBITOR 14; PI14__:__SERINE PROTEASE INHIBITOR, CLADE I, MEMBER 2; SERPINI2;; MYOEPITHELIUM-DERIVED SERINE PROTEASE INHIBITOR; MEPI;; PANCPIN__:__
Number Sign__:__605588__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B1; CMT2B1__:__CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2B1;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2B1;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B1__:__
Number Sign__:__605589__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B2; CMT2B2__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2B2;; CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2B2;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2B2;; ARCMT2B__:__
Asterisk__:__605590__:__SPLICING FACTOR 3B, SUBUNIT 1; SF3B1__:__SF3B, 155-KD SUBUNIT; SF3B155;; SPLICEOSOME-ASSOCIATED PROTEIN, 155-KD; SAP155__:__
Asterisk__:__605591__:__SPLICING FACTOR 3B, SUBUNIT 2; SF3B2__:__SF3B, 145-KD SUBUNIT; SF3B145;; SPLICEOSOME-ASSOCIATED PROTEIN, 145-KD; SAP145__:__
Asterisk__:__605592__:__SPLICING FACTOR 3B, SUBUNIT 3; SF3B3__:__SF3B, 130-KD SUBUNIT; SF3B130;; SPLICEOSOME-ASSOCIATED PROTEIN, 130-KD; SAP130__:__
Asterisk__:__605593__:__SPLICING FACTOR 3B, SUBUNIT 4; SF3B4__:__SF3B, 49-KD SUBUNIT; SF3B49;; SPLICEOSOME-ASSOCIATED PROTEIN, 49-KD; SAP49__:__
Number Sign__:__605594__:__DEAFNESS, AUTOSOMAL DOMINANT 39, WITH DENTINOGENESIS IMPERFECTA 1__:__DFNA39/DENTINOGENESIS IMPERFECTA 1 SYNDROME;; DFNA39/DGI1 SYNDROME;; DGI1/DFNA39 SYNDROME__:__
Asterisk__:__605595__:__SPLICING FACTOR 3A, SUBUNIT 1; SF3A1__:__SF3A, 120-KD SUBUNIT; SF3A120;; SPLICEOSOME-ASSOCIATED PROTEIN, 114-KD; SAP114;; PRP21, S. CEREVISIAE, HOMOLOG OF; PRP21__:__
Asterisk__:__605596__:__SPLICING FACTOR 3A, SUBUNIT 3; SF3A3__:__SF3A, 60-KD SUBUNIT; SF3A60;; SPLICEOSOME-ASSOCIATED PROTEIN, 61-KD; SAP61;; PRP9, S. CEREVISIAE, HOMOLOG OF; PRP9__:__
Asterisk__:__605597__:__FORKHEAD TRANSCRIPTION FACTOR FOXL2; FOXL2__:__PITUITARY FORKHEAD FACTOR, MOUSE, HOMOLOG OF; PFRK__:__
Percent__:__605598__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 18; IDDM18__:__INSULIN-DEPENDENT DIABETES MELLITUS 18__:__
Asterisk__:__605599__:__LYSOPHOSPHOLIPASE I; LYPLA1__:__ACYL PROTEIN THIOESTERASE 1; APT1__:__
Asterisk__:__605600__:__IMPORTIN 8; IPO8__:__IMP8;; RAN-BINDING PROTEIN 8; RANBP8__:__
Asterisk__:__605601__:__PROTEOGLYCAN 2; PRG2__:__EOSINOPHIL GRANULE MAJOR BASIC PROTEIN; MBP__:__
Asterisk__:__605602__:__MYOZENIN 2; MYOZ2__:__CALSARCIN 1__:__
Asterisk__:__605603__:__MYOZENIN 1; MYOZ1__:__CALSARCIN 2__:__
Asterisk__:__605604__:__POLYADENYLATE-BINDING PROTEIN-INTERACTING PROTEIN 2; PAIP2__:__POLY(A)-BINDING PROTEIN-INTERACTING PROTEIN 2;; PABP-INTERACTING PROTEIN 2;; PAIP2A__:__
Caret__:__605605__:__MOVED TO 605535__:____:__
Percent__:__605606__:__PSORIASIS 7, SUSCEPTIBILITY TO; PSORS7__:____:__
Asterisk__:__605607__:__CENTROMERIC PROTEIN H; CENPH__:____:__
Asterisk__:__605608__:__CLAUDIN 14; CLDN14__:____:__
Asterisk__:__605609__:__OXIDATION RESISTANCE 1; OXR1__:____:__
Asterisk__:__605610__:__POLYNUCLEOTIDE KINASE 3-PRIME PHOSPHATASE; PNKP__:__POLYNUCLEOTIDE KINASE; PNK;; DNA KINASE__:__
Asterisk__:__605611__:__SH3 DOMAIN-BINDING PROTEIN 4; SH3BP4__:__BOG25__:__
Asterisk__:__605612__:__SH3 DOMAIN-BINDING PROTEIN 5; SH3BP5__:__SAB__:__
Asterisk__:__605613__:__HUNTINGTIN-INTERACTING PROTEIN 1-RELATED PROTEIN; HIP1R__:__HUNTINGTIN-INTERACTING PROTEIN 12; HIP12;; HIP1-RELATED PROTEIN__:__
Asterisk__:__605614__:__GENERAL CONTROL OF AMINO ACID SYNTHESIS 1, YEAST, HOMOLOG-LIKE 1; GCN1L1__:____:__
Asterisk__:__605615__:__ARIADNE, DROSOPHILA, HOMOLOG OF, 2; ARIH2__:__ARI2;; TRIAD DOMAIN-CONTAINING PROTEIN 1; TRIAD1__:__
Asterisk__:__605616__:__SOLUTE CARRIER FAMILY 6 (PROLINE IMINO TRANSPORTER), MEMBER 20; SLC6A20__:__X TRANSPORTER PROTEIN 3; XT3__:__
Caret__:__605617__:__MOVED TO 220600__:____:__
NULL__:__605618__:__TETRALOGY OF FALLOT SYNDROME, AUTOSOMAL RECESSIVE__:____:__
Asterisk__:__605619__:__INTERLEUKIN 20; IL20__:____:__
Asterisk__:__605620__:__INTERLEUKIN 20 RECEPTOR, ALPHA; IL20RA__:__IL20R1__:__
Asterisk__:__605621__:__INTERLEUKIN 20 RECEPTOR, BETA; IL20RB__:__IL20R2;; DIRS1__:__
Asterisk__:__605622__:__PROTOCADHERIN 12; PCDH12__:__CADHERIN, VASCULAR ENDOTHELIAL, 2; VECAD2;; VE-CADHERIN 2__:__
Asterisk__:__605623__:__MUSKELIN 1; MKLN1__:__TWO-HYBRID-ASSOCIATED PROTEIN WITH RANBPM 2; TWA2__:__
Asterisk__:__605624__:__ARIADNE, DROSOPHILA, HOMOLOG OF, 1; ARIH1__:__HHARI;; UBCH7-BINDING PROTEIN; UBCH7BP__:__
Asterisk__:__605625__:__MYELOMA OVEREXPRESSED GENE; MYEOV__:____:__
Asterisk__:__605626__:__ENDOGENOUS RETROVIRUS GROUP K, MEMBER 6; ERVK-6__:____:__
Percent__:__605627__:__CEREBROOCULONASAL SYNDROME__:____:__
Asterisk__:__605628__:__HIV-1 TAT-INTERACTING PROTEIN 2, 30-KD; HTATIP2__:__TIP30;; CC3__:__
Asterisk__:__605629__:__CITRON RHO-INTERACTING SERINE/THREONINE KINASE; CIT__:__SERINE/THREONINE PROTEIN KINASE 21; STK21;; CITRON RHO-INTERACTING KINASE; CRIK;; RHO-INTERACTING SERINE/THREONINE KINASE__:__
Asterisk__:__605630__:__PHOSPHOLIPASE A2, GROUP IID; PLA2G2D__:__SECRETORY-TYPE PLA, STROMA-ASSOCIATED HOMOLOG; SPLASH__:__
Asterisk__:__605631__:__NAPSIN A; NAPSA__:__PRONAPSIN A;; NAPA;; NAP1__:__
Asterisk__:__605632__:__SOLUTE CARRIER FAMILY 35 (UDP-N-ACETYLGLUCOSAMINE TRANSPORTER), MEMBER 3; SLC35A3__:__UDP-N-ACETYLGLUCOSAMINE TRANSPORTER;; UDP-GlcNAc TRANSPORTER__:__
Asterisk__:__605633__:__MUCIN 3B, INTESTINAL; MUC3B__:____:__
Asterisk__:__605634__:__SOLUTE CARRIER FAMILY 35 (CMP-SIALIC ACID TRANSPORTER), MEMBER 1; SLC35A1__:__CYTIDINE MONOPHOSPHATE-SIALIC ACID TRANSPORTER; CST;; CMP-SIA TRANSPORTER__:__
Number Sign__:__605635__:__HYPERALDOSTERONISM, FAMILIAL, TYPE II; HALD2__:__FH II__:__
Asterisk__:__605636__:__MATERNALLY EXPRESSED GENE 3; MEG3__:__GENE TRAP LOCUS 2; GTL2__:__
Number Sign__:__605637__:__MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA__:__MYPOP;; MYOPATHY WITH CONGENITAL JOINT CONTRACTURES, OPHTHALMOPLEGIA, AND RIMMED VACUOLES;; INCLUSION BODY MYOPATHY 3, AUTOSOMAL DOMINANT, FORMERLY; IBM3, FORMERLY__:__
Asterisk__:__605638__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 6; BIRC6__:__APOLLON;; BRUCE, MOUSE, HOMOLOG OF; BRUCE;; KIAA1289__:__
Asterisk__:__605639__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 8; SIGLEC8__:__SIALOADHESIN FAMILY MEMBER 2; SAF2__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 8, LONG ISOFORM, INCLUDED; SIGLEC8L, INCLUDED
Asterisk__:__605640__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 9; SIGLEC9__:____:__
Asterisk__:__605641__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 6; SLC7A6__:__y(+)L-TYPE AMINO ACID TRANSPORTER 2;; y(+)LAT2__:__
Percent__:__605642__:__THYROID CARCINOMA, PAPILLARY, WITH PAPILLARY RENAL NEOPLASIA__:__PTCPRN;; PRN1__:__
Asterisk__:__605643__:__KALLIKREIN-RELATED PEPTIDASE 5; KLK5__:__KALLIKREIN 5;; STRATUM CORNEUM TRYPTIC ENZYME; SCTE;; KALLIKREIN-LIKE 2; KLKL2__:__
Asterisk__:__605644__:__KALLIKREIN-RELATED PEPTIDASE 8; KLK8__:__KALLIKREIN 8;; NEUROPSIN, MOUSE, HOMOLOG OF;; TUMOR-ASSOCIATED DIFFERENTIALLY EXPRESSED GENE 14; TADG14;; PROTEASE, SERINE, 19; PRSS19__:__NEUROPSIN, TYPE 1, INCLUDED;; NEUROPSIN, TYPE 2, INCLUDED
Asterisk__:__605645__:__RESISTIN-LIKE PROTEIN, BETA; RETNLB__:__RESISTIN-LIKE MOLECULE-BETA; RELMB;; FOUND IN INFLAMMATORY ZONE 2; FIZZ2__:__
Asterisk__:__605646__:__SOLUTE CARRIER FAMILY 26, MEMBER 4; SLC26A4__:__PENDRIN;; PDS GENE__:__
Asterisk__:__605647__:__F-BOX ONLY PROTEIN 6; FBXO6__:__FBX6;; F-BOX/G-DOMAIN PROTEIN 2; FBG2__:__
Asterisk__:__605648__:__F-BOX ONLY PROTEIN 7; FBXO7__:__FBX7;; FBX__:__
Asterisk__:__605649__:__F-BOX ONLY PROTEIN 8; FBXO8__:__FBX8;; F-BOX/SEC7 PROTEIN; FBS__:__
Asterisk__:__605650__:__POLYMERASE, DNA, KAPPA; POLK__:__DINB1;; POLQ__:__
Asterisk__:__605651__:__F-BOX AND WD40 DOMAIN PROTEIN 11; FBXW11__:__FBW11;; F-BOX AND WD40 DOMAIN PROTEIN 1B, FORMERLY; FBXW1B, FORMERLY;; FBW1B;; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN 2; BTRC2; BTRCP2__:__BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN 2, ISOFORM A, INCLUDED; BTRCP2A, INCLUDED;; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN 2, ISOFORM B, INCLUDED; BTRCP2B, INCLUDED;; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN 2, ISOFORM C, INCLUDED; BTRCP2C, INCLUDED
Asterisk__:__605652__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 2; FBXL2__:__FBL2__:__
Asterisk__:__605653__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 3; FBXL3__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 3A, FORMERLY; FBXL3A, FORMERLY;; FBL3A;; FBL3__:__
Asterisk__:__605654__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 4; FBXL4__:__FBL4__:__
Asterisk__:__605655__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 5; FBXL5__:__FBL5__:__
Asterisk__:__605656__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 7; FBXL7__:__FBL7;; KIAA0840__:__
Asterisk__:__605657__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 11; FBXL11__:__FBL11;; CXXC FINGER PROTEIN 8; CXXC8;; KIAA1004;; JMJC DOMAIN-CONTAINING HISTONE DEMETHYLASE 1; JHDM1A__:__
Asterisk__:__605658__:__INTERLEUKIN 25; IL25__:__INTERLEUKIN 17E; IL17E__:__
Asterisk__:__605659__:__C-TYPE LECTIN DOMAIN FAMILY 2, MEMBER D; CLEC2D__:__NATURAL KILLER CELL LECTIN-LIKE RECEPTOR;; LECTIN-LIKE TRANSCRIPT 1; LLT1__:__
Asterisk__:__605660__:__PREFOLDIN 6; PFDN6__:__KE2, MOUSE, HOMOLOG OF; HKE2__:__
Asterisk__:__605661__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 13; TRIM13__:__RET FINGER PROTEIN 2; RFP2;; LEU5__:__
Asterisk__:__605662__:__RAS-ASSOCIATED PROTEIN RAB36; RAB36__:____:__
Asterisk__:__605663__:__RADIAL SPOKE HEAD 14, CHLAMYDOMONAS, HOMOLOG OF; RSPH14__:__RHABDOID TUMOR DELETION REGION GENE 1; RTDR1__:__
Asterisk__:__605664__:__KINESIN FAMILY MEMBER 20A; KIF20A__:__RAB6-INTERACTING PROTEIN, KINESIN-LIKE; RAB6KIFL;; RABKINESIN 6__:__
Caret__:__605665__:__MOVED TO 600582__:____:__
Asterisk__:__605666__:__CYSTEINYL LEUKOTRIENE RECEPTOR 2; CYSLTR2__:__CYSLT2__:__
Asterisk__:__605667__:__RAL GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR-LIKE 1; RGL1__:__RALGDS-LIKE GENE; RGL__:__
Asterisk__:__605668__:__BETA-SITE AMYLOID BETA A4 PRECURSOR PROTEIN-CLEAVING ENZYME 2; BACE2__:__BETA-SITE APP-CLEAVING ENZYME 2;; ASPARTIC-LIKE PROTEASE, 56-KD; ALP56;; DOWN SYNDROME REGION ASPARTIC PROTEASE; DRAP__:__
Asterisk__:__605669__:__PROSTATE AND BREAST CANCER OVEREXPRESSED 1; PBOV1__:__UROC28;; UC28__:__
Number Sign__:__605670__:__LATE-ONSET RETINAL DEGENERATION; LORD__:__RETINAL DEGENERATION, LATE-ONSET, AUTOSOMAL DOMINANT__:__
Asterisk__:__605671__:__DMX-LIKE 1; DMXL1__:____:__
NULL__:__605672__:__CEREBELLAR ATAXIA AND HYPERGONADOTROPIC HYPOGONADISM__:____:__
Asterisk__:__605673__:__B-CELL TRANSLOCATION GENE 4; BTG4__:__PC3B__:__
Asterisk__:__605674__:__B-CELL TRANSLOCATION GENE 3; BTG3__:__ABUNDANT IN NEUROEPITHELIUM AREA; ANA;; TOB5__:__
Asterisk__:__605675__:__RING FINGER PROTEIN 14; RNF14__:__ANDROGEN RECEPTOR-ASSOCIATED PROTEIN 54; ARA54__:__
Number Sign__:__605676__:__CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR AND KERATODERMA; DCWHK__:__CARVAJAL SYNDROME;; PALMOPLANTAR KERATODERMA WITH LEFT VENTRICULAR CARDIOMYOPATHY AND WOOLLY HAIR__:__
Asterisk__:__605677__:__ACYL-CoA SYNTHETASE LONG CHAIN FAMILY, MEMBER 5; ACSL5__:__FATTY ACID CoA LIGASE, LONG CHAIN 5; FACL5;; ACYL-CoA SYNTHETASE 5; ACS5__:__
Asterisk__:__605678__:__MLX-INTERACTING PROTEIN-LIKE; MLXIPL__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 14; WBSCR14;; MONDO FAMILY, MEMBER B; MONDOB;; CARBOHYDRATE RESPONSE ELEMENT-BINDING PROTEIN, RAT, HOMOLOG OF; CHREBP__:__
Asterisk__:__605679__:__INTERLEUKIN 26; IL26__:__AK155__:__
Asterisk__:__605680__:__BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN, 1A; BAZ1A__:__WCRF180;; ACF1, DROSOPHILA, HOMOLOG OF; ACF1__:__
Asterisk__:__605681__:__BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN, 1B; BAZ1B__:__WILLIAMS SYNDROME TRANSCRIPTION FACTOR; WSTF;; WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 9; WBSCR9__:__
Asterisk__:__605682__:__BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN, 2A; BAZ2A__:____:__
Asterisk__:__605683__:__BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN, 2B; BAZ2B__:____:__
Asterisk__:__605684__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 34; TRIM34__:__RING FINGER PROTEIN 21; RNF21;; INTERFERON-RESPONSIVE FINGER PROTEIN 1; IFP1__:__
Caret__:__605685__:__MOVED TO 216550__:____:__
Asterisk__:__605686__:__CELL ADHESION MOLECULE 1; CADM1__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4; IGSF4;; IGSF4A;; TUMOR SUPPRESSOR IN LUNG CANCER 1; TSLC1;; BL2;; ST17;; SYNAPTIC CELL ADHESION MOLECULE; SYNCAM;; SYNCAM1;; NECTIN-LIKE PROTEIN 2; NECL2__:__
Asterisk__:__605687__:__INTERLEUKIN 19; IL19__:____:__
Asterisk__:__605688__:__COPINE VI; CPNE6__:__N-COPINE__:__
Asterisk__:__605689__:__COPINE VII; CPNE7__:____:__
Asterisk__:__605690__:__GLIOMA TUMOR SUPPRESSOR CANDIDATE REGION GENE 1; GLTSCR1__:____:__
Asterisk__:__605691__:__RIBOSOME BIOGENESIS FACTOR NOP53; NOP53__:__GLIOMA TUMOR SUPPRESSOR CANDIDATE REGION GENE 2; GLTSCR2;; PROTEIN INTERACTING WITH PTEN C TERMINUS 1; PICT1__:__
Asterisk__:__605692__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 7; TRPM7__:__LONG TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; LTRPC7;; TRANSIENT RECEPTOR POTENTIAL-PHOSPHOLIPASE C-INTERACTING KINASE; TRP-PLIK;; CHAK__:__TRPM7/CYP19A1 FUSION GENE, INCLUDED
Asterisk__:__605693__:__RAS-ASSOCIATED PROTEIN RAB30; RAB30__:____:__
Asterisk__:__605694__:__RAS-ASSOCIATED PROTEIN RAB31; RAB31__:____:__
Asterisk__:__605695__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 4; BLOC1S4__:__BLOC1, SUBUNIT 4; BLOS4;; CAPPUCCINO, MOUSE, HOMOLOG OF; CNO__:__
Asterisk__:__605696__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY G, MEMBER 2; KCNG2__:__Kv6.2__:__
Asterisk__:__605697__:__UL16-BINDING PROTEIN 1; ULBP1__:__RETINOIC ACID EARLY TRANSCRIPT 1I; RAET1I;; MULT1__:__
Asterisk__:__605698__:__UL16-BINDING PROTEIN 2; ULBP2__:__RETINOIC ACID EARLY TRANSCRIPT 1H; RAET1H__:__
Asterisk__:__605699__:__UL16-BINDING PROTEIN 3; ULBP3__:__RETINOIC ACID EARLY TRANSCRIPT 1N; RAET1N__:__
Asterisk__:__605700__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 39; TRIM39__:__TESTIS-ABUNDANT FINGER PROTEIN; TFP;; TRIM39, B30.2 DOMAIN-CONTAINING; TRIM39B;; RING FINGER PROTEIN 23, FORMERLY; RNF23, FORMERLY__:__TRIM39/RPP21 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED;; TRIM39, RPP21 DOMAIN-CONTAINING, INCLUDED; TRIM39R, INCLUDED
Asterisk__:__605701__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 10; TRIM10__:__RFB30;; HEMATOPOIETIC RING FINGER 1; HERF1;; RING FINGER PROTEIN 9, FORMERLY; RNF9, FORMERLY__:__
Asterisk__:__605702__:__LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1__:__LYVE1__:__
Asterisk__:__605703__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN-ASSOCIATED PROTEIN A; VAPA__:__VAMP-ASSOCIATED PROTEIN A;; VAMP-ASSOCIATED PROTEIN, 33-KD; VAP33__:__
Asterisk__:__605704__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN-ASSOCIATED PROTEIN B; VAPB__:__VAMP-ASSOCIATED PROTEIN B;; DVAP33A, DROSOPHILA, HOMOLOG OF__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN-ASSOCIATED PROTEIN C, INCLUDED; VAPC, INCLUDED;; VAMP-ASSOCIATED PROTEIN C, INCLUDED
Asterisk__:__605705__:__SALT-INDUCIBLE KINASE 1; SIK1__:__SNF1-LIKE KINASE; SNF1LK;; MSK, MOUSE, HOMOLOG OF__:__
Asterisk__:__605706__:__RECEPTOR-INTERACTING SERINE-THREONINE KINASE 4; RIPK4__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 3; ANKRD3;; PKC-DELTA-INTERACTING PROTEIN KINASE; DIK;; RIP4__:__
Caret__:__605707__:__MOVED TO 604985__:____:__
Asterisk__:__605708__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 11; ARHGEF11__:__PDZ-RHOGEF;; GLUTAMATE TRANSPORTER EAAT4-ASSOCIATED PROTEIN 48; GTRAP48;; KIAA0380__:__
Asterisk__:__605709__:__ADP-RIBOSYLATION-LIKE FACTOR 6-INTERACTING PROTEIN 5; ARL6IP5__:__PRA1 DOMAIN FAMILY, MEMBER 3; PRAF3;; GLUTAMATE TRANSPORTER EAAC1-ASSOCIATED PROTEIN;; GTRAP3-18;; JWA__:__
Asterisk__:__605710__:__GDNF FAMILY RECEPTOR ALPHA-3; GFRA3__:__GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA-3__:__
Number Sign__:__605711__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 1; MMDS1__:__MMDS__:__
Asterisk__:__605712__:__SERINE PALMITOYLTRANSFERASE, LONG-CHAIN BASE SUBUNIT 1; SPTLC1__:__SPT1;; LCB1__:__
Asterisk__:__605713__:__SERINE PALMITOYLTRANSFERASE, LONG-CHAIN BASE SUBUNIT 2; SPTLC2__:__SPT2;; LCB2A;; KIAA0526__:__
Number Sign__:__605714__:__CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED__:__AMYLOIDOSIS, CEREBROARTERIAL, APP-RELATED;; AMYLOIDOSIS, HEREDITARY, WITH CEREBRAL HEMORRHAGE, DUTCH VARIANT; HCHWAD;; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, DUTCH VARIANT;; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, IOWA VARIANT;; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, ITALIAN VARIANT;; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, FLEMISH VARIANT;; CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED, ARCTIC VARIANT__:__
Asterisk__:__605715__:__CD276 ANTIGEN; CD276__:__B7 HOMOLOG 3; B7H3__:__
Asterisk__:__605716__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 5; KCNH5__:____:__
Asterisk__:__605717__:__INDUCIBLE T-CELL COSTIMULATOR LIGAND; ICOSLG__:__ICOS LIGAND; ICOSL; LICOS;; B7 HOMOLOG 2; B7H2;; GL50;; B7-RELATED PROTEIN 1; B7RP1__:__
Asterisk__:__605718__:__MEDIATOR COMPLEX SUBUNIT 4; MED4__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 4, S. CEREVISIAE, HOMOLOG OF;; VITAMIN D RECEPTOR-INTERACTING PROTEIN, 36-KD; DRIP36;; MEDIATOR, 34-KD SUBUNIT, MOUSE, HOMOLOG OF;; HSPC126__:__
Asterisk__:__605719__:__LINKER FOR ACTIVATION OF T CELLS FAMILY, MEMBER 2; LAT2__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 5; WBSCR5;; LINKER FOR ACTIVATION OF B CELLS; LAB;; NON-T-CELL ACTIVATION LINKER; NTAL__:__
Asterisk__:__605720__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 4; KCNK4__:__TRAAK__:__
Asterisk__:__605721__:__JUNCTION ADHESION MOLECULE 1; JAM1__:__JUNCTION ADHESION MOLECULE, MOUSE, HOMOLOG OF; JAM;; JAM-A__:__
Asterisk__:__605722__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 16; KCNJ16__:__KIR5.1__:__
Asterisk__:__605723__:__PROGRAMMED CELL DEATH 1 LIGAND 2; PDCD1LG2__:__PDCD1 LIGAND 2; PDCD1L2;; PROGRAMMED DEATH LIGAND 2; PDL2;; B7DC__:__
Number Sign__:__605724__:__FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1__:__FAD1__:__
Asterisk__:__605725__:__PERIAXIN; PRX__:____:__
Number Sign__:__605726__:__SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 2; DSMA2__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, JERASH TYPE;; NEUROPATHY, DISTAL HEREDITARY MOTOR, JERASH TYPE; HMNJ;; SPINAL MUSCULAR ATROPHY, JERASH TYPE__:__
Percent__:__605727__:__OTOSCLEROSIS 2; OTSC2__:____:__
Percent__:__605728__:__CATARACT 25; CTRCT25__:__CATARACT, CENTRAL SACCULAR, WITH SUTURAL OPACITIES; CCSSO;; CATARACT, CENTRAL POUCH-LIKE, WITH SUTURAL OPACITIES__:__
Asterisk__:__605729__:__AT-HOOK TRANSCRIPTION FACTOR AKNA; AKNA__:____:__
Asterisk__:__605730__:__SPERM-ASSOCIATED ANTIGEN 6; SPAG6__:____:__
Asterisk__:__605731__:__SPERM-ASSOCIATED ANTIGEN 8; SPAG8__:__SPERM MEMBRANE PROTEIN 1; SMP1__:__
Asterisk__:__605732__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 21; TNFRSF21__:__DEATH RECEPTOR 6; DR6__:__
Asterisk__:__605733__:__PRELI DOMAIN-CONTAINING PROTEIN 1; PRELID1__:__PRELI;; PX19, CHICKEN, HOMOLOG OF; PX19__:__
Asterisk__:__605734__:__TRANSMEMBRANE PROTEIN WITH EGF-LIKE AND 2 FOLLISTATIN-LIKE DOMAINS 2; TMEFF2__:__TOMOREGULIN; TR;; HYPERPLASTIC POLYPOSIS GENE 1; HPP1__:__
Percent__:__605735__:__BLEEDING DISORDER, PLATELET-TYPE, 12; BDPLT12__:__PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE 1 DEFICIENCY, PLATELET;; PGHS1 DEFICIENCY;; PLATELET CYCLOOXYGENASE 1 DEFICIENCY;; PLATELET COX1 DEFICIENCY__:__
Asterisk__:__605736__:__UBIQUITIN-ASSOCIATED AND SH3 DOMAIN-CONTAINING PROTEIN A; UBASH3A__:__SUPPRESSOR OF T-CELL RECEPTOR SIGNALING 2; STS2;; CBL-INTERACTING PROTEIN 4; CLIP4;; TULA__:__
Asterisk__:__605737__:__BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7; BIRC7__:__INHIBITOR OF APOPTOSIS PROTEIN, MELANOMA; MLIAP;; INHIBITOR OF APOPTOSIS PROTEIN, KIDNEY; KIAP;; LIVIN__:__
Percent__:__605738__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 2; MCOPCB2__:__MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 2; MCOPCB2__:__
Asterisk__:__605739__:__KYPHOSCOLIOSIS PEPTIDASE; KY__:__KYPHOSCOLIOSIS, MOUSE, HOMOLOG OF__:__
Asterisk__:__605740__:__SCLEROSTIN; SOST__:____:__
Asterisk__:__605741__:__G PROTEIN-COUPLED RECEPTOR 183; GPR183__:__EPSTEIN-BARR VIRUS-INDUCED GENE 2; EBI2__:__
Asterisk__:__605742__:__TUBULIN, ALPHA-8; TUBA8__:__TUBULIN, ALPHA-LIKE 2; TUBAL2__:__
Asterisk__:__605743__:__HEDGEHOG ACYLTRANSFERASE; HHAT__:__MELANOMA ANTIGEN RECOGNIZED BY T CELLS 2; MART2;; SKINNY HEDGEHOG, DROSOPHILA, HOMOLOG OF; SKI1__:__
Asterisk__:__605744__:__EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 3; EXTL3__:__EXOSTOSIN-LIKE 3;; MULTIPLE EXOSTOSES-LIKE 3;; EXT-RELATED GENE 1; EXTR1;; REG PROTEIN RECEPTOR, RAT, HOMOLOG OF__:__
Asterisk__:__605745__:__CYTOCHROME b REDUCTASE 1; CYBRD1__:__DUODENAL CYTOCHROME b; DCYTB__:__
Percent__:__605746__:__ANISOMASTIA__:____:__
Asterisk__:__605747__:__LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTOR PROTEIN 1; LDLRAP1__:__LDLR ADAPTOR PROTEIN 1;; ARH GENE; ARH__:__
Asterisk__:__605748__:__BETA-CAROTENE OXYGENASE 1; BCO1__:__BETA-CAROTENE 15,15-PRIME-MONOOXYGENASE 1; BCMO1;; BETA-CAROTENE 15,15-PRIME-DIOXYGENASE; BCDO;; BETA-CAROTENE 15,15-PRIME OXYGENASE 1__:__
Percent__:__605749__:__CATARACT 26, MULTIPLE TYPES; CTRCT26__:__CATARACT, AUTOSOMAL RECESSIVE, EARLY-ONSET, PULVERULENT; CAAR__:__
Percent__:__605750__:__EXUDATIVE VITREORETINOPATHY 3; EVR3__:____:__
Number Sign__:__605751__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 2; BFIS2__:__CONVULSIONS, BENIGN FAMILIAL INFANTILE, 2; BFIC2__:__
Asterisk__:__605752__:__HID1 DOMAIN-CONTAINING PROTEIN 1; HID1__:__DOWNREGULATED IN MULTIPLE CANCERS 1; DMC1;; CHROMOSOME 17 OPEN READING FRAME 28; C17ORF28__:__
Asterisk__:__605753__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 2; SPINK2__:__ACROSIN-TRYPSIN INHIBITOR HUSI-II__:__
Asterisk__:__605754__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS Q PROTEIN; PIGQ__:____:__
Asterisk__:__605755__:__DOUBLECORTIN DOMAIN-CONTAINING PROTEIN 2; DCDC2__:__RU2;; RU2S__:__
NULL__:__605756__:__OVARIAN DYSGENESIS, HYPERGONADOTROPIC, WITH SHORT STATURE AND RECURRENT METABOLIC ACIDOSIS__:__GONADAL DYSGENESIS, HYPERGONADOTROPIC, XX TYPE, WITH SHORT STATURE AND RECURRENT METABOLIC ACIDOSIS__:__
Asterisk__:__605757__:__PELOTA, DROSOPHILA, HOMOLOG OF; PELO__:____:__
Asterisk__:__605758__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 1; ASB1__:____:__
Asterisk__:__605759__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 2; ASB2__:____:__
Asterisk__:__605760__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 3; ASB3__:____:__
Asterisk__:__605761__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 4; ASB4__:____:__
Asterisk__:__605762__:__RENAL TUMOR ANTIGEN; RAGE__:__MOK__:__
Asterisk__:__605763__:__SOLUTE CARRIER FAMILY 45, MEMBER 1; SLC45A1__:__DELETED IN NEUROBLASTOMA 5; DNB5__:__
Asterisk__:__605764__:__TYROSYL-DNA PHOSPHODIESTERASE 2; TDP2__:__TRAF- AND TNF RECEPTOR-ASSOCIATED PROTEIN; TTRAP__:__
Asterisk__:__605765__:__DELETED IN LYMPHOCYTIC LEUKEMIA, 1; DLEU1__:__LEU1;; B-CELL NEOPLASIA-ASSOCIATED GENE WITH MULTIPLE SPLICING; BCMS__:__
Asterisk__:__605766__:__DELETED IN LYMPHOCYTIC LEUKEMIA, 2; DLEU2__:__LEU2;; BCMSUN__:__
Asterisk__:__605767__:__PHOSPHOPROTEIN ASSOCIATED WITH GLYCOSPHINGOLIPID-ENRICHED MICRODOMAINS 1; PAG1__:__CSK-BINDING PROTEIN; CBP__:__
Asterisk__:__605768__:__DUAL ADAPTOR OF PHOSPHOTYROSINE AND 3-PHOSPHOINOSITIDES 1__:__DAPP1;; B-CELL ADAPTOR MOLECULE, 32-KD; BAM32__:__
Asterisk__:__605769__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 33; TRIM33__:__TRANSCRIPTIONAL INTERMEDIARY FACTOR 1-GAMMA; TIF1G;; TIF1-GAMMA;; RET-FUSED GENE 7; RFG7;; ECTODERMIN, XENOPUS, HOMOLOG OF; ECTO__:__PTC7 CHIMERIC ONCOGENE, INCLUDED
Asterisk__:__605770__:__ILVB-LIKE; ILVBL__:__ACETOLACTATE SYNTHASE, BACTERIAL, HOMOLOG OF; AHAS__:__
Asterisk__:__605771__:__COX7A2-LIKE PROTEIN; COX7A2L__:__CYTOCHROME C OXIDASE SUBUNIT 7A2-LIKE;; CYTOCHROME C OXIDASE SUBUNIT VIIA POLYPEPTIDE 2-LIKE;; COX7RP;; COX7AR;; EB1;; SUPERCOMPLEX ASSEMBLY FACTOR 1; SCAF1;; SILICA-INDUCED GENE 81; SIG81__:__
Asterisk__:__605772__:__ESTROGEN RECEPTOR-BINDING SITE-ASSOCIATED ANTIGEN, 9; EBAG9__:__RCAS1;; EB9__:__
Asterisk__:__605773__:__LEUKOTRIENE B4 RECEPTOR 2; LTB4R2__:__LEUKOTRIENE B4 G PROTEIN-COUPLED RECEPTOR 2; BLT2; BLTR2__:__
Asterisk__:__605774__:__KELCH-LIKE 2; KLHL2__:__MAYVEN__:__
Asterisk__:__605775__:__KELCH-LIKE 3; KLHL3__:____:__
Asterisk__:__605776__:__FIBRINOGEN-LIKE 1; FGL1__:__HEPATOCYTE-DERIVED FIBRINOGEN-RELATED PROTEIN 1; HFREP1;; HEPASSOCIN__:__
Asterisk__:__605777__:__SPHINGOMYELIN PHOSPHODIESTERASE 3, NEUTRAL MEMBRANE; SMPD3__:__SPHINGOMYELINASE, NEUTRAL, 2; NSMASE2__:__
Asterisk__:__605778__:__NIF3-LIKE 1; NIF3L1__:__ALS2 CHROMOSOME REGION GENE 1; ALS2CR1__:__
Percent__:__605779__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 7; NDNC7__:__ONYCHODYSPLASIA, ISOLATED CONGENITAL__:__
Asterisk__:__605780__:__PR DOMAIN-CONTAINING PROTEIN 4; PRDM4__:__PFM1__:__
Asterisk__:__605781__:__RAS HOMOLOG GENE FAMILY, MEMBER D; RHOD__:__ARHD;; RHO-RELATED PROTEIN HP1; RHOHP1__:__
Asterisk__:__605782__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 5A2; EIF5A2__:____:__
Asterisk__:__605783__:__BREAST CARCINOMA AMPLIFIED SEQUENCE 2; BCAS2__:__DAM1__:__
Asterisk__:__605784__:__TWEETY, DROSOPHILA, HOMOLOG OF, 1; TTYH1__:____:__
Asterisk__:__605785__:__TUBULIN, GAMMA-2; TUBG2__:____:__
Asterisk__:__605786__:__RNA-BINDING MOTIF PROTEIN, SINGLE STRAND-INTERACTING, 3; RBMS3__:____:__
Asterisk__:__605787__:__ANKYRIN REPEAT-CONTAINING PROTEIN, FAMILY A, MEMBER 2; ANKRA2__:__ANKRA;; RFXANK-LIKE PROTEIN__:__
Asterisk__:__605788__:__MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, MEMBER 3; MAPRE3__:__ADENOMATOUS POLYPOSIS COLI-BINDING PROTEIN EB3; EB3;; APC-BINDING PROTEIN RP3; RP3;; EB1 FAMILY, MEMBER 3; EBF3__:__
Asterisk__:__605789__:__MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, MEMBER 2; MAPRE2__:__ADENOMATOUS POLYPOSIS COLI-BINDING PROTEIN EB2; EB2;; APC-BINDING PROTEIN RP1; RP1__:__
Asterisk__:__605790__:__SERINE/THREONINE KINASE 31; STK31__:____:__
Asterisk__:__605791__:__TESTIS-EXPRESSED GENE 12; TEX12__:____:__
Asterisk__:__605792__:__TESTIS-EXPRESSED GENE 14; TEX14__:____:__
Asterisk__:__605793__:__RING FINGER PROTEIN 17; RNF17__:____:__
Asterisk__:__605794__:__MOV10-LIKE 1; MOV10L1__:__CARDIAC HELICASE ACTIVATED BY MEF2C PROTEIN; CHAMP__:__
Asterisk__:__605795__:__TESTIS-EXPRESSED GENE 15; TEX15__:____:__
Asterisk__:__605796__:__TUDOR DOMAIN-CONTAINING PROTEIN 1; TDRD1__:____:__
Asterisk__:__605797__:__ANKYRIN REPEAT, SAM, AND BASIC LEUCINE ZIPPER DOMAIN-CONTAINING 1; ASZ1__:__ANKYRIN-LIKE PROTEIN 1; ALP1;; ANKL1;; GERM CELL-SPECIFIC PROTEIN CONTAINING ANK, SAM, AND BASIC LEUCINE ZIPPER DOMAINS; GASZ;; C7ORF7__:__
Asterisk__:__605798__:__NEURAL PROLIFERATION, DIFFERENTIATION, AND CONTROL PROTEIN 1; NPDC1__:__CAB1, YEAST, HOMOLOG OF; CAB1__:__
Asterisk__:__605799__:__AMNIONLESS, MOUSE, HOMOLOG OF; AMN__:____:__
Asterisk__:__605800__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U-LIKE 1; HNRNPUL1__:__HNRPUL1;; ADENOVIRUS E1B 55-KD PROTEIN-ASSOCIATED PROTEIN 5;; E1B55-ASSOCIATED PROTEIN 5; E1BAP5__:__
Asterisk__:__605801__:__RALA-BINDING PROTEIN 1; RALBP1__:__RAL-INTERACTING PROTEIN, 76-KD; RLIP76;; RAL-INTERACTING PROTEIN 1; RIP1;; DINITROPHENYL S-GLUTATHIONE ATPase;; DNP-SG ATPase__:__
Asterisk__:__605802__:__ZINC FINGER E BOX-BINDING HOMEOBOX 2; ZEB2__:__ZINC FINGER HOMEOBOX 1B; ZFHX1B;; SMAD-INTERACTING PROTEIN 1; SMADIP1;; SIP1;; KIAA0569__:__
Number Sign__:__605803__:__DERMATITIS, ATOPIC, 2; ATOD2__:____:__
Percent__:__605804__:__DERMATITIS, ATOPIC, 3; ATOD3__:__DERMATITIS, ATOPIC, WITH ASTHMA__:__
Percent__:__605805__:__DERMATITIS, ATOPIC, 4; ATOD4__:____:__
Asterisk__:__605806__:__CADHERIN 7; CDH7__:____:__
Asterisk__:__605807__:__CADHERIN 20; CDH20__:____:__
NULL__:__605808__:__BIRDSHOT CHORIORETINOPATHY__:__BSCR__:__
Number Sign__:__605809__:__MYASTHENIC SYNDROME, CONGENITAL, 4A, SLOW-CHANNEL; CMS4A__:__CONGENITAL MYASTHENIC SYNDROME TYPE Ia1, FORMERLY; CMS1A1, FORMERLY;; CMS Ia1, FORMERLY__:__
Asterisk__:__605810__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S22; MRPS22__:__CHROMOSOME 3 OPEN READING FRAME 5; C3ORF5__:__
Asterisk__:__605811__:__NTF2-LIKE EXPORT FACTOR 1; NXT1__:__MTR2, YEAST, HOMOLOG OF; MTR2__:__
Asterisk__:__605812__:__DEAD/H BOX 19; DDX19__:__DBP5, YEAST, HOMOLOG OF; DBP5__:__
Asterisk__:__605813__:__NUCLEAR TRANSPORT FACTOR 2__:__NTF2;; PLACENTAL PROTEIN 15; PP15__:__
Number Sign__:__605814__:__CITRULLINEMIA, TYPE II, NEONATAL-ONSET__:__CITRULLINEMIA, TYPE II, NEONATAL-ONSET, WITH OR WITHOUT FAILURE TO THRIVE AND DYSLIPIDEMIA;; CHOLESTASIS, NEONATAL INTRAHEPATIC, CAUSED BY CITRIN DEFICIENCY; NICCD__:__
Asterisk__:__605815__:__NUCLEOPORIN, 62-KD; NUP62__:____:__
Asterisk__:__605816__:__EPSTEIN-BARR VIRUS-INDUCED GENE 3; EBI3__:__INTERLEUKIN 27, EBI3 SUBUNIT;; IL27, EBI3 SUBUNIT;; INTERLEUKIN 35, EBI3 SUBUNIT;; IL35, EBI3 SUBUNIT__:__
Asterisk__:__605817__:__RECEPTOR-INTERACTING SERINE/THREONINE KINASE 3; RIPK3__:__RECEPTOR-INTERACTING PROTEIN 3; RIP3__:__
Percent__:__605818__:__DEAFNESS, AUTOSOMAL RECESSIVE 27; DFNB27__:____:__
Asterisk__:__605819__:__PESCADILLO, ZEBRAFISH, HOMOLOG OF, 1; PES1__:__PES__:__
Number Sign__:__605820__:__NONAKA MYOPATHY; NM__:__NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY__:__
Asterisk__:__605821__:__ERYTHROID-ASSOCIATED FACTOR; ERAF__:__ERYTHROID DIFFERENTIATION-RELATED FACTOR; EDRF;; ALPHA-HEMOGLOBIN STABILIZING PROTEIN; AHSP__:__
Number Sign__:__605822__:__SPONDYLOOCULAR SYNDROME; SOS__:____:__
Asterisk__:__605823__:__POPEYE DOMAIN-CONTAINING PROTEIN 2; POPDC2__:__POPEYE PROTEIN 2; POP2__:__
Asterisk__:__605824__:__POPEYE DOMAIN-CONTAINING PROTEIN 3; POPDC3__:__POPEYE PROTEIN 3; POP3__:__
Asterisk__:__605825__:__HEME-BINDING PROTEIN 2; HEBP2__:__CHROMOSOME 6 OPEN READING FRAME 34; C6ORF34;; SOUL, CHICKEN, HOMOLOG OF; SOUL__:__
Asterisk__:__605826__:__HEME-BINDING PROTEIN 1; HEBP1__:__HBP; HEBP__:__FPRL2 LIGAND, INCLUDED; F2L, INCLUDED
Percent__:__605827__:__BASALOID FOLLICULAR HAMARTOMA SYNDROME, GENERALIZED, AUTOSOMAL DOMINANT; GBFHS__:____:__
Asterisk__:__605828__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 6; TMC6__:__EV1 GENE; EV1;; EVER1__:__
Asterisk__:__605829__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 8; TMC8__:__EV GENE 2; EV2;; EVER2__:__
Asterisk__:__605830__:__FIBROBLAST GROWTH FACTOR RECEPTOR-LIKE 1; FGFRL1__:____:__
Asterisk__:__605831__:__FIBROBLAST GROWTH FACTOR 22; FGF22__:____:__
Asterisk__:__605832__:__ACETYL-CoA SYNTHETASE SHORT CHAIN FAMILY, MEMBER 2; ACSS2__:__ACS;; ACETATE-CoA LIGASE;; ACYL-CoA SYNTHETASE 1; ACECS1__:__
Percent__:__605833__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 2; BMND2__:____:__
Asterisk__:__605834__:__TROPOMODULIN 4; TMOD4__:____:__
Asterisk__:__605835__:__TRANSMEMBRANE PROTEIN 2; TMEM2__:____:__
Asterisk__:__605836__:__UNC13, C. ELEGANS, HOMOLOG OF, B; UNC13B__:__UNC13;; MUNC13__:__
Asterisk__:__605837__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 2; HERC2__:____:__
NULL__:__605838__:__BABY RATTLE PELVIS DYSPLASIA__:____:__
Caret__:__605839__:__MOVED TO 150800__:____:__
Asterisk__:__605840__:__RING FINGER PROTEIN 111; RNF111__:__ARKADIA, MOUSE, HOMOLOG OF__:__
Percent__:__605841__:__NARCOLEPSY 2, SUSCEPTIBILITY TO; NRCLP2__:____:__
Asterisk__:__605842__:__TRANSDUCIN-BETA-LIKE 2; TBL2__:__WBSCR13__:__
Asterisk__:__605843__:__PEROXISOMAL TRANS-2-ENOYL-CoA REDUCTASE; PECR__:__TRANS-2-ENOYL-CoA REDUCTASE, PEROXISOMAL; TERP__:__
Percent__:__605844__:__DERMATITIS, ATOPIC, 5; ATOD5__:____:__
Percent__:__605845__:__DERMATITIS, ATOPIC, 6; ATOD6__:____:__
Asterisk__:__605846__:__B-CELL CLL/LYMPHOMA 7B; BCL7B__:____:__
Asterisk__:__605847__:__B-CELL CLL/LYMPHOMA 7C; BCL7C__:____:__
Asterisk__:__605848__:__CASPASE 14, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP14__:____:__
Asterisk__:__605849__:__DIMETHYLGLYCINE DEHYDROGENASE; DMGDH__:____:__
Number Sign__:__605850__:__DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD__:__DMGDH DEFICIENCY__:__
Asterisk__:__605851__:__ISOPRENYLCYSTEINE CARBOXYLMETHYLTRANSFERASE; ICMT__:__PRENYLCYSTEINE CARBOXYLMETHYLTRANSFERASE; PCCMT; PCMT__:__
Asterisk__:__605852__:__CYTOPLASMIC LINKER-ASSOCIATED PROTEIN 1; CLASP1__:__CLIP-ASSOCIATED PROTEIN 1__:__
Asterisk__:__605853__:__CYTOPLASMIC LINKER-ASSOCIATED PROTEIN 2; CLASP2__:__CLIP-ASSOCIATED PROTEIN 2__:__
Asterisk__:__605854__:__BCL2-BINDING COMPONENT 3; BBC3__:__p53-UPREGULATED MODULATOR OF APOPTOSIS; PUMA__:__
Asterisk__:__605855__:__ATPase, CLASS V, TYPE 10A; ATP10A__:__ATPase, CLASS V, TYPE 10C; ATP10C;; ATPVC__:__
Percent__:__605856__:__SHORT STATURE, MENTAL RETARDATION, CALLOSAL AGENESIS, HEMINASAL HYPOPLASIA, MICROPHTHALMIA, AND ATYPICAL CLEFTING__:____:__
Asterisk__:__605857__:__RAS HOMOLOG GENE FAMILY, MEMBER Q; RHOQ__:__RAS-LIKE PROTEIN TC10; TC10;; TC10-ALPHA;; ARHQ__:__
Asterisk__:__605858__:__SCRATCH, MOUSE, HOMOLOG OF; SCRT1__:__SCRT__:__
Asterisk__:__605859__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 32; ZBTB32__:__FANCONI ANEMIA ZINC FINGER PROTEIN; FAZF;; TESTIS ZINC FINGER PROTEIN; TZFP;; REPRESSOR OF GATA; ROG__:__
Asterisk__:__605860__:__RCAN FAMILY MEMBER 3; RCAN3__:__DOWN SYNDROME CRITICAL REGION GENE 1-LIKE 2; DSCR1L2;; MYOCYTE-ENRICHED CALCINEURIN-INTERACTING PROTEIN 3; MCIP3__:__
Asterisk__:__605861__:__CANOPY FGF SIGNALING REGULATOR 2; CNPY2__:__CANOPY 2, ZEBRAFISH, HOMOLOG OF;; TRANSMEMBRANE PROTEIN 4; TMEM4;; MIR-INTERACTING SAPOSIN-LIKE PROTEIN; MSAP__:__
Asterisk__:__605862__:__RIBITOL XYLOSYLTRANSFERASE 1; RXYLT1__:__TRANSMEMBRANE PROTEIN 5; TMEM5__:__
Asterisk__:__605863__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 3; B3GNT3__:__TRANSMEMBRANE PROTEIN 3; TMEM3__:__
Asterisk__:__605864__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 4; B3GNT4__:____:__
Asterisk__:__605865__:__TASTE RECEPTOR TYPE 1, MEMBER 3; TAS1R3__:__T1R3__:__
Asterisk__:__605866__:__ATPase, CLASS I, TYPE 8B, MEMBER 3; ATP8B3__:__ATPIK__:__
Asterisk__:__605867__:__ATPase, CLASS I, TYPE 8B, MEMBER 2; ATP8B2__:__ATPID__:__
Asterisk__:__605868__:__ATPase, CLASS VI, TYPE 11A; ATP11A__:__ATPIS;; ATPIH, MOUSE, HOMOLOG OF; ATPIH__:__
Asterisk__:__605869__:__ATPase, CLASS VI, TYPE 11B; ATP11B__:__ATPIR__:__
Asterisk__:__605870__:__ATPase, CLASS I, TYPE 8A, MEMBER 2; ATP8A2__:__ATPIB__:__
Caret__:__605871__:__MOVED TO 193090__:____:__
Asterisk__:__605872__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER M; CLEC4M__:__LIVER/LYMPH NODE-SPECIFIC ICAM3-GRABBING NONINTEGRIN; LSIGN;; CD209 ANTIGEN-LIKE; CD209L;; DCSIGN-RELATED PROTEIN; DCSIGNR__:__
Asterisk__:__605873__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 10; KCNK10__:__TWIK-RELATED K+ CHANNEL 2; TREK2__:__
Asterisk__:__605874__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 9; KCNK9__:__TWIK-RELATED ACID-SENSITIVE K+ CHANNEL 3; TASK3__:__
Asterisk__:__605875__:__WASP PROTEIN FAMILY, MEMBER 2; WASF2__:__WASP FAMILY, MEMBER 2;; WASP FAMILY, VERPROLIN HOMOLOGY DOMAIN-CONTAINING PROTEIN 2; WAVE2;; SCAR, DICTYOSTELIUM, HOMOLOG OF, 2; SCAR2__:__
Asterisk__:__605876__:__Fc RECEPTOR-LIKE PROTEIN 4; FCRL4__:__IMMUNOGLOBULIN SUPERFAMILY RECEPTOR TRANSLOCATION-ASSOCIATED GENE 1; IRTA1__:__
Asterisk__:__605877__:__Fc RECEPTOR-LIKE PROTEIN 5; FCRL5__:__IMMUNOGLOBULIN SUPERFAMILY RECEPTOR TRANSLOCATION-ASSOCIATED GENE 2; IRTA2;; BXMAS1__:__
Asterisk__:__605878__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 7A; ZBTB7A__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 7; ZBTB7;; HIV-1 INDUCER OF SHORT TRANSCRIPTS-BINDING FACTOR 1;; HIV-1 IST-BINDING FACTOR 1; FBI1;; LEUKEMIA/LYMPHOMA-RELATED FACTOR; LRF;; POKEMON__:__
Asterisk__:__605879__:__POTASSIUM CHANNEL, CALCIUM-ACTIVATED, INTERMEDIATE/SMALL CONDUCTANCE, SUBFAMILY N, MEMBER 2; KCNN2__:__SK2__:__
Asterisk__:__605880__:__LYSINE ACETYLTRANSFERASE 6B; KAT6B__:__HISTONE ACETYLTRANSFERASE MYST4; MYST4;; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN-RELATED FACTOR; MORF__:__MORF/CBF FUSION GENE, INCLUDED
Asterisk__:__605881__:__SOLUTE CARRIER FAMILY 35, MEMBER C1; SLC35C1__:__GDP-FUCOSE TRANSPORTER 1__:__
Asterisk__:__605882__:__BRCA1-INTERACTING PROTEIN 1; BRIP1__:__BRCA1-ASSOCIATED C-TERMINAL HELICASE 1; BACH1;; DELETIONS OF GUANINE-RICH DNA, C. ELEGANS, HOMOLOG OF;; DOG1, HOMOLOG OF;; FANCJ GENE; FANCJ__:__
Asterisk__:__605883__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 3; LAMP3__:__LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEIN, DENDRITIC CELL-SPECIFIC; DCLAMP__:__
Asterisk__:__605884__:__DYNEIN, AXONEMAL, HEAVY CHAIN 10; DNAH10__:____:__
Asterisk__:__605885__:__SEMAPHORIN 6A; SEMA6A__:____:__
Asterisk__:__605886__:__COMPLEMENT COMPONENT RECEPTOR 1-LIKE; CR1L__:__COMPLEMENT COMPONENT 3b/4b RECEPTOR-LIKE__:__
Caret__:__605887__:__MOVED TO 300357__:____:__
Asterisk__:__605888__:__EH DOMAIN-CONTAINING 1; EHD1__:____:__
Asterisk__:__605889__:__PDZ AND LIM DOMAIN PROTEIN 3; PDLIM3__:__ACTININ-ASSOCIATED LIM PROTEIN; ALP__:__
Asterisk__:__605890__:__EH DOMAIN-CONTAINING 2; EHD2__:____:__
Asterisk__:__605891__:__EH DOMAIN-CONTAINING 3; EHD3__:____:__
Asterisk__:__605892__:__EH DOMAIN-CONTAINING 4; EHD4__:____:__
Asterisk__:__605893__:__CDP-DIACYLGLYCEROL-INOSITOL 3-PHOSPHATIDYLTRANSFERASE; CDIPT__:__PHOSPHATIDYLINOSITOL SYNTHASE 1; PIS1__:__
Asterisk__:__605894__:__EP300-INTERACTING INHIBITOR OF DIFFERENTIATION 1; EID1__:__E1A-LIKE INHIBITOR OF DIFFERENTIATION 1;; CREBBP/EP300 INHIBITORY PROTEIN 1; CRI1;; CHROMOSOME 15 OPEN READING FRAME 3; C15ORF3__:__
Asterisk__:__605895__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E FAMILY, MEMBER 2; EIF4E2__:__EIF4E FAMILY, MEMBER 2;; EIF4E-LIKE 3; EIF4EL3;; EIF4E HOMOLOGOUS PROTEIN; 4EHP__:__
Asterisk__:__605896__:__ENDOTHELIN-CONVERTING ENZYME-LIKE 1; ECEL1__:__XCE__:__
Asterisk__:__605897__:__UDP-GLUCOSE:GLYCOPROTEIN GLUCOSYLTRANSFERASE 1; UGGT1__:__HUGT1__:__
Asterisk__:__605898__:__UDP-GLUCOSE:GLYCOPROTEIN GLUCOSYLTRANSFERASE 2; UGGT2__:__HUGT2__:__
Number Sign__:__605899__:__GLYCINE ENCEPHALOPATHY; GCE__:__HYPERGLYCINEMIA, NONKETOTIC; NKH__:__HYPERGLYCINEMIA, TRANSIENT NEONATAL, INCLUDED; TNH, INCLUDED
Asterisk__:__605900__:__PDZ AND LIM DOMAIN PROTEIN 1; PDLIM1__:__ELFIN;; CLP36, RAT, HOMOLOG OF; CLP36;; C-TERMINAL LIM DOMAIN PROTEIN 1; CLIM1__:__
Asterisk__:__605901__:__UROCORTIN III; UCN3__:__STRESSCOPIN; SCP__:__
Asterisk__:__605902__:__UROCORTIN II; UCN2__:__STRESSCOPIN-RELATED PEPTIDE;; SRP;; UROCORTIN-RELATED PEPTIDE; URP__:__
Asterisk__:__605903__:__PDZ AND LIM DOMAIN PROTEIN 7; PDLIM7__:__LIM DOMAIN PROTEIN ENIGMA; ENIGMA;; LIM MINERALIZATION PROTEIN 1; LMP1__:__
Asterisk__:__605904__:__PDZ AND LIM DOMAIN PROTEIN 5; PDLIM5__:__ENIGMA-LIKE LIM DOMAIN PROTEIN;; ENIGMA HOMOLOG; ENH__:__
Asterisk__:__605905__:__DCN1 DOMAIN-CONTAINING PROTEIN 1; DCUN1D1__:__RP42 HOMOLOG; RP42;; SQUAMOUS CELL CARCINOMA-RELATED ONCOGENE 1; SCCRO1__:__
Asterisk__:__605906__:__LIM DOMAIN-BINDING 3; LDB3__:__Z-BAND ALTERNATIVELY SPLICED PDZ MOTIF-CONTAINING PROTEIN; ZASP;; CYPHER, MOUSE, HOMOLOG OF; CYPHER;; KIAA0613__:__
Asterisk__:__605907__:__ALG1, YEAST, HOMOLOG OF; ALG1__:__ASPARAGINE-LINKED GLYCOSYLATION 1 HOMOLOG;; BETA-1,4 MANNOSYLTRANSFERASE;; HMAT1;; HMT1__:__
Asterisk__:__605908__:__MLC1 GENE; MLC1__:__KIAA0027__:__
Number Sign__:__605909__:__PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6__:__PARKINSON DISEASE 6, EARLY-ONSET; PARK6__:__PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO, INCLUDED;; PARKINSON DISEASE, AUTOSOMAL RECESSIVE EARLY-ONSET, DIGENIC, PINK1/DJ1, INCLUDED
Asterisk__:__605910__:__ANGIOPOIETIN-LIKE 4; ANGPTL4__:__PPARG ANGIOPOIETIN-RELATED PROTEIN; PGAR;; FASTING-INDUCED ADIPOSE FACTOR; FIAF;; HEPATIC FIBRINOGEN/ANGIOPOIETIN-RELATED PROTEIN; HFARP__:__
Number Sign__:__605911__:__3-HYDROXY-3-METHYLGLUTARYL-CoA SYNTHASE-2 DEFICIENCY; HMGCS2D__:__MITOCHONDRIAL HMG-CoA SYNTHASE DEFICIENCY;; HMGCS2 DEFICIENCY__:__
Asterisk__:__605912__:__MATRIX, EXTRACELLULAR, PHOSPHOGLYCOPROTEIN; MEPE__:__EXTRACELLULAR MATRIX PHOSPHOGLYCOPROTEIN, ASARM MOTIF-CONTAINING;; OSTEOBLAST/OSTEOCYTE FACTOR 45; OF45__:__
Percent__:__605913__:__BLEEDING DISORDER, EAST TEXAS TYPE__:__BDET__:__
Asterisk__:__605914__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 12A; TNFRSF12A__:__TYPE I TRANSMEMBRANE PROTEIN FN14; FN14;; TWEAK RECEPTOR; TWEAKR__:__
Asterisk__:__605915__:__TRANSDUCIN-BETA-LIKE 3; TBL3__:____:__
Asterisk__:__605916__:__SPECTRIN, BETA, NONERYTHROCYTIC, 5; SPTBN5__:__SPECTRIN, BETA-V; BSPECV__:__
Asterisk__:__605917__:__TPX2, XENOPUS, HOMOLOG OF; TPX2__:__CHROMOSOME 20 OPEN READING FRAME 1; C20ORF1;; p100__:__
Asterisk__:__605918__:__SPONDIN 2; SPON2__:__MINDIN;; M-SPONDIN__:__
Caret__:__605919__:__MOVED TO 300361__:____:__
Asterisk__:__605920__:__STAUFEN, DROSOPHILA, HOMOLOG OF, 2; STAU2__:____:__
Asterisk__:__605921__:__STROMAL INTERACTION MOLECULE 1; STIM1__:____:__
Asterisk__:__605922__:__MYOINOSITOL MONOPHOSPHATASE 2; IMPA2__:____:__
Asterisk__:__605923__:__SRY-BOX 8; SOX8__:____:__
Asterisk__:__605924__:__WD REPEAT-CONTAINING PROTEIN 4; WDR4__:____:__
Asterisk__:__605925__:__PERICENTRIN; PCNT__:__KENDRIN; KEN;; PERICENTRIN B;; PERICENTRIN 2, FORMERLY; PCNT2, FORMERLY__:__
Asterisk__:__605926__:__PROTEIN INTERACTING WITH C KINASE 1; PICK1__:__PICK;; PRKCA-BINDING PROTEIN; PRKCABP;; PROTEIN KINASE C-ALPHA-BINDING PROTEIN__:__
Asterisk__:__605927__:__MOUSE DOUBLE MINUTE 2 HOMOLOG, BINDING PROTEIN OF; MTBP__:__MDM2-BINDING PROTEIN__:__
Asterisk__:__605928__:__ADP-RIBOSYLATION FACTOR-INTERACTING PROTEIN 1; ARFIP1__:__ARFAPTIN 1__:__
Asterisk__:__605929__:__SORTING NEXIN 2; SNX2__:____:__
Asterisk__:__605930__:__SORTING NEXIN 3; SNX3__:____:__
Asterisk__:__605931__:__SORTING NEXIN 4; SNX4__:____:__
Asterisk__:__605932__:__BETAINE-HOMOCYSTEINE METHYLTRANSFERASE 2; BHMT2__:____:__
Asterisk__:__605933__:__TRANSMEMBRANE 7 SUPERFAMILY, MEMBER 4; TM7SF4__:__DENDRITIC CELL-SPECIFIC TRANSMEMBRANE PROTEIN; DCSTAMP;; INTERLEUKIN 4-INDUCED GENE; FIND;; IL4-INDUCED GENE__:__
Percent__:__605934__:__HOLOPROSENCEPHALY 6; HPE6__:____:__
NULL__:__605935__:__ARTHROPATHY, EROSIVE__:____:__
Asterisk__:__605936__:__BRIDGING INTEGRATOR 2; BIN2__:____:__
Asterisk__:__605937__:__SORTING NEXIN 5; SNX5__:____:__
Asterisk__:__605938__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS P PROTEIN; PIGP__:__DOWN SYNDROME CRITICAL REGION GENE 5; DSCR5__:__
Asterisk__:__605939__:__PHOSPHOLIPASE C, DELTA-4; PLCD4__:____:__
Asterisk__:__605940__:__BRAIN-ABUNDANT SIGNAL PROTEIN, MEMBRANE-ATTACHED, 1; BASP1__:__BRAIN ACID-SOLUBLE PROTEIN 1;; NAP22, RAT, HOMOLOG OF; NAP22;; CAP23, CHICKEN, HOMOLOG OF; CAP23__:__
Asterisk__:__605941__:__SQUAMOUS CELL CARCINOMA ANTIGEN RECOGNIZED BY T CELLS 1; SART1__:__HOMS1__:__
Asterisk__:__605942__:__DERMATAN SULFATE EPIMERASE; DSE__:__SQUAMOUS CELL CARCINOMA ANTIGEN RECOGNIZED BY T CELLS 2; SART2__:__
Asterisk__:__605943__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 1; GDE1__:__MEMBRANE INTERACTING PROTEIN OF RGS16; MIR16;; RGS16-INTERACTING MEMBRANE PROTEIN__:__
NULL__:__605944__:__LIVER FIBROCYSTIC DISEASE AND POLYDACTYLY__:____:__
NULL__:__605945__:__CRUMPLED HELICES AND SMALL MOUTH__:____:__
Percent__:__605946__:__METAPHYSEAL DYSPLASIA, BRAUN-TINSCHERT TYPE__:____:__
Asterisk__:__605947__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS L PROTEIN; PIGL__:____:__
Asterisk__:__605948__:__G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, MEMBER B; GPRC5B__:__RETINOIC ACID-INDUCIBLE GENE 2; RAIG2__:__
Asterisk__:__605949__:__G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, MEMBER C; GPRC5C__:__RETINOIC ACID-INDUCIBLE GENE 3; RAIG3__:__
Asterisk__:__605950__:__RAS-ASSOCIATED PROTEIN RAB33B; RAB33B__:____:__
Asterisk__:__605951__:__DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE 3; DPM3__:__DOLICHOL-PHOSPHATE MANNOSYLTRANSFERASE 3;; DOLICHOL-PHOSPHATE-MANNOSE SYNTHASE 3__:__
Asterisk__:__605952__:__SORTING NEXIN 9; SNX9__:__SH3 DOMAIN- AND PX DOMAIN-CONTAINING PROTEIN; SH3PX1__:__
Asterisk__:__605953__:__ARF GTPase-ACTIVATING PROTEIN WITH SH3 DOMAIN, ANKYRIN REPEAT, AND PH DOMAIN 1; ASAP1__:__ADP-RIBOSYLATION FACTOR-DIRECTED GTPase-ACTIVATING PROTEIN;; ARF GTPase-ACTIVATING PROTEIN 1;; DEVELOPMENT- AND DIFFERENTIATION-ENHANCING FACTOR 1; DDEF1__:__
Asterisk__:__605954__:__FETUIN B; FETUB__:____:__
Asterisk__:__605955__:__NK6, DROSOPHILA, HOMOLOG OF, 2; NKX6-2__:__HOMEOBOX 6B, NK;; NKX6B;; NK HOMEOBOX, FAMILY 6, MEMBER B;; NKX6.2, MOUSE, HOMOLOG OF__:__
Asterisk__:__605956__:__NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 2; NOD2__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 15; CARD15__:__
Caret__:__605957__:__MOVED TO 600965__:____:__
Asterisk__:__605958__:__TRAF-INTERACTING PROTEIN; TRAIP__:__TRIP;; RING FINGER PROTEIN 206; RNF206__:__
Asterisk__:__605959__:__HR44 ANTIGEN__:__HR44__:__
Asterisk__:__605960__:__EXOSOME COMPONENT 10; EXOSC10__:__POLYMYOSITIS/SCLERODERMA AUTOANTIGEN 2; PMSCL2;; POLYMYOSITIS/SCLERODERMA AUTOANTIGEN, 100-KD;; PMSCL AUTOANTIGEN, 100-KD__:__
Asterisk__:__605961__:__PLEIOTROPIC REGULATOR 1; PLRG1__:__PRL1, ARABIDOPSIS, HOMOLOG OF; PRL1__:__
Asterisk__:__605962__:__RAB9 EFFECTOR PROTEIN WITH KELCH MOTIFS; RABEPK__:__RAB9 EFFECTOR, 40-KD; p40__:__
Asterisk__:__605963__:__SORTING NEXIN 17; SNX17__:____:__
Asterisk__:__605964__:__SORTING NEXIN 15; SNX15__:____:__
Asterisk__:__605965__:__RAS AND RAB INTERACTOR 1; RIN1__:__RAS INHIBITOR 1__:__
Asterisk__:__605966__:__HEPATOCYTE NUCLEAR FACTOR 4-GAMMA; HNF4G__:__HNF4-GAMMA__:__
Percent__:__605967__:__ACROPECTORAL SYNDROME; ACRPS__:__ACRP SYNDROME;; DUNDAR ACROPECTORAL SYNDROME;; SYNDACTYLY, PREAXIAL POLYDACTYLY, AND STERNAL DEFORMITY__:__
Asterisk__:__605968__:__RET FINGER PROTEIN-LIKE 1; RFPL1__:__RFP-LIKE 1__:__
Asterisk__:__605969__:__RET FINGER PROTEIN-LIKE 2; RFPL2__:__RFP-LIKE 2__:__
Asterisk__:__605970__:__RET FINGER PROTEIN-LIKE 3; RFPL3__:__RFP-LIKE 3__:__
Asterisk__:__605971__:__RET FINGER PROTEIN-LIKE 3, ANTISENSE; RFPL3S__:__RFP-LIKE 3, ANTISENSE__:__
Asterisk__:__605972__:__RET FINGER PROTEIN-LIKE 1, ANTISENSE; RFPL1S__:__RFP-LIKE 1, ANTISENSE__:__
Asterisk__:__605973__:__DDB1- AND CUL4-ASSOCIATED FACTOR 7; DCAF7__:__AN11, PETUNIA, HOMOLOG OF; AN11__:__
Asterisk__:__605974__:__SLU7 SPLICING FACTOR, S. CEREVISIAE, HOMOLOG OF; SLU7__:____:__
Asterisk__:__605975__:__SERINE/ARGININE REPETITIVE MATRIX PROTEIN 1; SRRM1__:__SERINE/ARGININE-RICH SPLICING FACTOR-RELATED NUCLEAR MATRIX PROTEIN, 160-KD;; SR-RELATED NUCLEAR MATRIX PROTEIN, 160-KD; SRM160__:__
Asterisk__:__605976__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 6; ZBTB6__:__ZINC FINGER PROTEIN WITH INTERACTION DOMAIN; ZID__:__
Asterisk__:__605977__:__INNER MITOCHONDRIAL MEMBRANE PEPTIDASE, SUBUNIT 2, S. CEREVISIAE, HOMOLOG OF; IMMP2L__:__IMP2, S. CEREVISIAE, HOMOLOG OF; IMP2;; IMP2-LIKE__:__
Asterisk__:__605978__:__VACUOLAR PROTEIN SORTING 13, YEAST, HOMOLOG OF, A; VPS13A__:__CHAC GENE; CHAC;; CHOREIN;; KIAA0986__:__
Asterisk__:__605979__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, POLYPEPTIDE 5; SNAPC5__:__SMALL NUCLEAR RNA-ACTIVATING PROTEIN COMPLEX, 19-KD SUBUNIT; SNAP19__:__
Asterisk__:__605980__:__NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 1; NOD1__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 4; CARD4__:__
Asterisk__:__605981__:__UBIQUITIN-PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 1; UBR1__:____:__
Caret__:__605982__:__MOVED TO 194070__:____:__
Asterisk__:__605983__:__PROTEIN PHOSPHATASE 2, STRUCTURAL/REGULATORY SUBUNIT A, ALPHA; PPP2R1A__:__PROTEIN PHOSPHATASE 2, 65-KD REGULATORY SUBUNIT A, ALPHA;; PR65-ALPHA__:__
Asterisk__:__605984__:__EMBRYONIC ECTODERM DEVELOPMENT PROTEIN, MOUSE, HOMOLOG OF; EED__:__EED, MOUSE, HOMOLOG OF;; WD PROTEIN ASSOCIATING WITH INTEGRIN CYTOPLASMIC TAILS 1; WAIT1__:__
Caret__:__605985__:__MOVED TO 300408__:____:__
Asterisk__:__605986__:__SERINE/THREONINE KINASE RECEPTOR-ASSOCIATED PROTEIN; STRAP__:__UNR-INTERACTING PROTEIN; UNRIP;; MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATOR WITH WD REPEATS; MAWD;; MAPK ACTIVATOR WITH WD REPEATS__:__
Asterisk__:__605987__:__PROTEIN INHIBITOR OF ACTIVATED STAT3__:__PIAS3__:__
Asterisk__:__605988__:__DNA CROSS-LINK REPAIR PROTEIN 1C; DCLRE1C__:__ARTEMIS__:__
Asterisk__:__605989__:__PROTEIN INHIBITOR OF ACTIVATED STAT4; PIAS4__:__PROTEIN INHIBITOR OF ACTIVATED STAT Y; PIASY__:__
Number Sign__:__605990__:__NEPHROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO__:__UAN;; UROLITHIASIS, URIC ACID, SUSCEPTIBILITY TO__:__
Asterisk__:__605991__:__NEURONAL GUANINE NUCLEOTIDE EXCHANGE FACTOR; NGEF__:__GUANINE NUCLEOTIDE EXCHANGE FACTOR, NEURONAL;; EPH RECEPTOR-INTERACTING EXCHANGE PROTEIN;; EPHEXIN;; EPHEXIN 1__:__
Asterisk__:__605992__:__LIM HOMEOBOX PROTEIN 5; LHX5__:____:__
Asterisk__:__605993__:__PYRUVATE DEHYDROGENASE PHOSPHATASE CATALYTIC SUBUNIT 1; PDP1__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 2C; PPM2C;; PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 2, CATALYTIC SUBUNIT;; PYRUVATE DEHYDROGENASE PHOSPHATASE; PDP1;; PYRUVATE DEHYDROGENASE PHOSPHATASE, CATALYTIC SUBUNIT; PDPC__:__
Asterisk__:__605994__:__CYTOCHROME P450, FAMILY 39, SUBFAMILY A, POLYPEPTIDE 1; CYP39A1__:__OXYSTEROL 7-ALPHA-HYDROXYLASE 2__:__
Asterisk__:__605995__:__KINESIN FAMILY MEMBER 1B; KIF1B__:__KIAA0591__:__
Asterisk__:__605996__:__DOM3, C. ELEGANS, HOMOLOG OF, Z; DOM3Z__:__RAT1-INTERACTING PROTEIN 1, S. CEREVISIAE, HOMOLOG OF; RAI1__:__
Asterisk__:__605997__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B, GAMMA ISOFORM; PPP2R2C__:__PROTEIN PHOSPHATASE 2A, REGULATORY SUBUNIT B, GAMMA ISOFORM;; PR52;; B55-GAMMA__:__
Asterisk__:__605998__:__HCLS1-ASSOCIATED PROTEIN X1; HAX1__:____:__
Asterisk__:__605999__:__C-TYPE LECTIN DOMAIN FAMILY 10, MEMBER A; CLEC10A__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 14; CLECSF14;; MACROPHAGE GALACTOSE-TYPE C-TYPE LECTIN; MGL;; HML;; CD301__:__
Asterisk__:__606000__:__BUTYROPHILIN-LIKE PROTEIN 2; BTNL2__:__BUTYROPHILIN-LIKE PROTEIN, MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-ASSOCIATED;; BTL II__:__
Asterisk__:__606001__:__INTERLEUKIN 32; IL32__:__NATURAL KILLER CELL TRANSCRIPT 4; NK4__:__
Number Sign__:__606002__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 1; SCAR1__:__ATAXIA-OCULOMOTOR APRAXIA 2; AOA2;; ATAXIA-OCULAR APRAXIA 2__:__
Number Sign__:__606003__:__TRANSALDOLASE DEFICIENCY__:__EYAID SYNDROME;; TALDO DEFICIENCY__:__
Asterisk__:__606004__:__GOLGI-ASSOCIATED, GAMMA-ADAPTIN EAR-CONTAINING, ARF-BINDING PROTEIN 1; GGA1__:__ADP-RIBOSYLATION FACTOR-BINDING PROTEIN 1;; ARF-BINDING PROTEIN 1__:__
Asterisk__:__606005__:__GOLGI-ASSOCIATED, GAMMA-ADAPTIN EAR-CONTAINING, ARF-BINDING PROTEIN 2; GGA2__:__VHS DOMAIN- AND EAR DOMAIN-CONTAINING PROTEIN; VEAR;; ADP-RIBOSYLATION FACTOR-BINDING PROTEIN 2;; ARF-BINDING PROTEIN 2__:__
Asterisk__:__606006__:__GOLGI-ASSOCIATED, GAMMA-ADAPTIN EAR-CONTAINING, ARF-BINDING PROTEIN 3; GGA3__:__ADP-RIBOSYLATION FACTOR-BINDING PROTEIN 3;; ARF-BINDING PROTEIN 3;; KIAA0154__:__
Asterisk__:__606007__:__POLYMERASE III, RNA, SUBUNIT K; POLR3K__:__RNA POLYMERASE III, 12.3-KD SUBUNIT;; RPC11, S. CEREVISIAE, HOMOLOG OF; RPC11; C11__:__
Asterisk__:__606008__:__NATURAL KILLER CELL GROUP 7 SEQUENCE; NKG7__:__GCSF-INDUCED GENE 1; GIG1__:__
Asterisk__:__606009__:__DOUBLE HOMEOBOX PROTEIN 4; DUX4__:____:__D4Z4 MACROSATELLITE REPEAT, INCLUDED
Asterisk__:__606010__:__NUCLEAR RECEPTOR-BINDING PROTEIN 1; NRBP1__:____:__
Asterisk__:__606011__:__V-SET AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 2; VSIG2__:__CTX, XENOPUS, HOMOLOG-LIKE; CTXL;; CTH__:__
Percent__:__606012__:__DEAFNESS, AUTOSOMAL DOMINANT 18; DFNA18__:____:__
Asterisk__:__606013__:__F-BOX ONLY PROTEIN 5; FBXO5__:__FBX5;; EMI1, XENOPUS, HOMOLOG OF; EMI1__:__
Asterisk__:__606014__:__ARISTALESS-LIKE HOMEOBOX 3; ALX3__:____:__
Asterisk__:__606015__:__FAS APOPTOTIC INHIBITORY MOLECULE 3; FAIM3__:__TOSO;; Fc FRAGMENT OF IgM, RECEPTOR FOR; FCMR__:__
Asterisk__:__606016__:__KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; KEAP1__:____:__
Asterisk__:__606017__:__POLYMERASE II, RNA, SUBUNIT D; POLR2D__:__RPB4, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 16.3-KD SUBUNIT__:__
Asterisk__:__606018__:__EGF-LIKE REPEATS- AND DISCOIDIN I-LIKE DOMAINS-CONTAINING PROTEIN 3; EDIL3__:__DEVELOPMENTALLY REGULATED ENDOTHELIAL CELL LOCUS 1; DEL1__:__
Asterisk__:__606019__:__EXOSOME COMPONENT 8; EXOSC8__:__OPA-INTERACTING PROTEIN 2; OIP2;; RIBOSOMAL RNA-PROCESSING PROTEIN 43, S. CEREVISIAE, HOMOLOG OF; RRP43__:__
Asterisk__:__606020__:__OPA-INTERACTING PROTEIN 5; OIP5__:__MIS18 KINETOCHORE PROTEIN B: MIS18B;; MIS18, S. POMBE, HOMOLOG OF, B;; MIS18-BETA__:__
Asterisk__:__606021__:__PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA; PRAME__:__MAPE;; OPA-INTERACTING PROTEIN 4; OIP4__:__
Asterisk__:__606022__:__NUDIX HYDROLASE 9; NUDT9__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 9;; NUDIX MOTIF 9__:__
Asterisk__:__606023__:__POLYMERASE II, RNA, SUBUNIT H; POLR2H__:__RPB8, S. CEREVISIAE, HOMOLOG OF;; RNA POLYMERASE II, 17-KD SUBUNIT__:__
Caret__:__606024__:__MOVED TO 604753__:____:__
Asterisk__:__606025__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 20; ZBTB20__:__ZINC FINGER PROTEIN 288; ZNF288;; DENDRITIC-DERIVED BTB/POZ ZINC FINGER; DPZF;; HOF__:__
Asterisk__:__606026__:__WHS CANDIDATE 2 GENE; WHSC2__:__WOLF-HIRSCHHORN SYNDROME CANDIDATE 2;; NEGATIVE ELONGATION FACTOR POLYPEPTIDE A; NELFA__:__
Asterisk__:__606027__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 1; CPSF1__:__CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR, 160-KD SUBUNIT; CPSF160__:__
Asterisk__:__606028__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 2; CPSF2__:__CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR, 100-KD SUBUNIT; CPSF100__:__
Asterisk__:__606029__:__CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 3; CPSF3__:__CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR, 73-KD SUBUNIT; CPSF73__:__
Asterisk__:__606030__:__ENHANCER OF mRNA DECAPPING 4; EDC4__:__AUTOANTIGEN RCD8; RCD8;; GE1;; HUMAN ENHANCER OF DECAPPING, LARGE SUBUNIT; HEDLS__:__
Asterisk__:__606031__:__WD REPEAT-CONTAINING PROTEIN 6; WDR6__:____:__
Asterisk__:__606032__:__SERINE/ARGININE REPETITIVE MATRIX PROTEIN 2; SRRM2__:__SERINE/ARGININE-RICH SPLICING FACTOR-RELATED NUCLEAR MATRIX PROTEIN, 300-KD;; SR-RELATED NUCLEAR MATRIX PROTEIN, 300-KD; SRM300;; SRL300__:__
Asterisk__:__606033__:__POLYMERASE II, RNA, SUBUNIT K; POLR2K__:__RPB10-ALPHA, S. CEREVISIAE, HOMOLOG OF; RPB12;; RNA POLYMERASE II, 7-KD SUBUNIT__:__
Asterisk__:__606034__:__RIBONUCLEASE H2, SUBUNIT A; RNASEH2A__:__RIBONUCLEASE H2, LARGE SUBUNIT;; RIBONUCLEASE HI, LARGE SUBUNIT;; RNase HI, LARGE SUBUNIT__:__
Percent__:__606035__:__FASTING INSULIN LEVEL QUANTITATIVE TRAIT LOCUS 1; FIQTL1__:____:__
Asterisk__:__606036__:__ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR 2; ARNT2__:____:__
Asterisk__:__606037__:__CD96 ANTIGEN; CD96__:__T-CELL ACTIVATION ANTIGEN, INCREASED LATE EXPRESSION; TACTILE__:__
Asterisk__:__606038__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS G6D; LY6G6D__:__G6D;; MEGAKARYOCYTE-ENHANCED GENE TRANSCRIPT 1; MEGT1__:__
Asterisk__:__606039__:__HYDROXYCARBOXYLIC ACID RECEPTOR 3; HCAR3__:__HCA3;; G PROTEIN-COUPLED RECEPTOR 109B; GPR109B;; CHEMOKINE RECEPTOR HM74; HM74__:__
Asterisk__:__606040__:__WD REPEAT-CONTAINING PROTEIN 8; WDR8__:____:__
Asterisk__:__606041__:__SPARC-LIKE PROTEIN 1; SPARCL1__:__HIGH ENDOTHELIAL VENULE PROTEIN; HEVIN__:__
Asterisk__:__606042__:__MYONEURIN; MYNN__:____:__
Asterisk__:__606043__:__ZINC FINGER PROTEIN 331; ZNF331__:__ZINC FINGER PROTEIN 463; ZNF463;; REARRANGED IN THYROID ADENOMAS; RITA__:__
Asterisk__:__606044__:__SJOGREN SYNDROME/SCLERODERMA AUTOANTIGEN 1; SSSCA1__:__CENTROMERIC AUTOANTIGEN, 27-KD__:__
Asterisk__:__606045__:__INTRAFLAGELLAR TRANSPORT 122, CHLAMYDOMONAS, HOMOLOG OF; IFT122__:__WD REPEAT-CONTAINING PROTEIN 10; WDR10__:__
Asterisk__:__606046__:__SYNTAXIN 18; STX18__:____:__
Asterisk__:__606047__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 5; LILRA5__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR 9; LIR9;; IMMUNOGLOBULIN-LIKE TRANSCRIPT 11; ILT11;; CD85F__:__
Asterisk__:__606048__:__MEMBRANE-BOUND O-ACETYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 7; MBOAT7__:__LYSOPHOSPHATIDYLINOSITOL ACYLTRANSFERASE; LPIAT;; MEMBRANE-BOUND O-ACETYLTRANSFERASE 7;; LEUKOCYTE RECEPTOR CLUSTER GENE 4; LENG4;; BREAST AND BLADDER CANCER OVEREXPRESSED GENE 1; BB1__:__
Percent__:__606049__:__ACROMEGALOID FEATURES, OVERGROWTH, CLEFT PALATE, AND HERNIA__:__AOCH__:__
Asterisk__:__606050__:__UBIQUITIN D; UBD__:__DIUBIQUITIN;; FAT10__:__
Asterisk__:__606051__:__SECRETION-REGULATING GUANINE NUCLEOTIDE EXCHANGE FACTOR; SERGEF__:__DEAFNESS LOCUS-ASSOCIATED PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR; DELGEF__:__
Caret__:__606052__:__MOVED TO 607745__:____:__
Number Sign__:__606053__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH AUTISM AND SPEECH DELAY; IDDAS__:__PHRASE SPEECH DELAY, AUTISM-RELATED;; AUTISM-RELATED SPEECH DELAY;; AUTISM, SUSCEPTIBILITY TO, 5, FORMERLY; AUTS5, FORMERLY__:__
Number Sign__:__606054__:__PROPIONIC ACIDEMIA__:__PROPIONYL-CoA CARBOXYLASE DEFICIENCY;; PCC DEFICIENCY;; GLYCINEMIA, KETOTIC;; HYPERGLYCINEMIA WITH KETOACIDOSIS AND LEUKOPENIA;; KETOTIC HYPERGLYCINEMIA__:__
Asterisk__:__606055__:__PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; PCTP__:__START DOMAIN-CONTAINING PROTEIN 2; STARD2__:__
Number Sign__:__606056__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIb; CDG2B__:__CDG IIb; CDGIIb;; GLUCOSIDASE I DEFICIENCY__:__
Asterisk__:__606057__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; RAPGEF3__:__cAMP-REGULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR I;; cAMP-GEFI;; EXCHANGE PROTEIN ACTIVATED BY cAMP; EPAC;; EPAC1__:__
Asterisk__:__606058__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAPGEF4__:__cAMP-REGULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR II;; cAMP-GEFII;; EPAC2__:__
Asterisk__:__606059__:__PROTEIN KINASE, cAMP-DEPENDENT CATALYTIC, INHIBITOR ALPHA; PKIA__:____:__
Asterisk__:__606060__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 12; DNAJC12__:__J DOMAIN-CONTAINING PROTEIN 1; JDP1__:__
Asterisk__:__606061__:__T-BOX 20; TBX20__:____:__
Asterisk__:__606062__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 3; SMC3__:__CHONDROITIN SULFATE PROTEOGLYCAN 6; CSPG6;; BAMACAN; BAM;; HUMAN CHROMOSOME-ASSOCIATED POLYPEPTIDE; HCAP__:__
Asterisk__:__606063__:__EXONUCLEASE 1, S. CEREVISIAE, HOMOLOG OF; EXO1__:__HEX1__:__
Asterisk__:__606064__:__CD248 ANTIGEN; CD248__:__TUMOR ENDOTHELIAL MARKER 1; TEM1;; ENDOSIALIN__:__
Asterisk__:__606065__:__ATYPICAL CHEMOKINE RECEPTOR 4; ACKR4__:__CHEMOKINE, CC MOTIF, RECEPTOR-LIKE PROTEIN 1; CCRL1;; PPR1, BOVINE, HOMOLOG OF; PPR1__:__
Asterisk__:__606066__:__LIM HOMEOBOX GENE 9; LHX9__:____:__
Asterisk__:__606067__:__OTORAPLIN; OTOR__:____:__
Number Sign__:__606068__:__RETINITIS PIGMENTOSA 28; RP28__:____:__
Number Sign__:__606069__:__HEMOCHROMATOSIS, TYPE 4; HFE4__:__HEMOCHROMATOSIS, AUTOSOMAL DOMINANT;; HEMOCHROMATOSIS DUE TO DEFECT IN FERROPORTIN__:__
Number Sign__:__606070__:__AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21__:__MYOPATHY, DISTAL, 2, FORMERLY; MPD2, FORMERLY;; VOCAL CORD AND PHARYNGEAL DYSFUNCTION WITH DISTAL MYOPATHY, FORMERLY; VCPDM, FORMERLY__:__
Number Sign__:__606071__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY, TYPE IIC; HMSN2C__:__HMSN IIC;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2C; CMT2C;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2C__:__
Number Sign__:__606072__:__RIPPLING MUSCLE DISEASE 2; RMD2__:__RIPPLING MUSCLE DISEASE; RMD;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1C, FORMERLY; LGMD1C, FORMERLY__:__
Asterisk__:__606073__:__NADPH-DEPENDENT DIFLAVIN OXIDOREDUCTASE 1; NDOR1__:__NADPH-DEPENDENT FMN- AND FAD-CONTAINING OXIDOREDUCTASE;; NR1__:__
Asterisk__:__606074__:__GLOBOSIDE ALPHA-1,3-N-ACETYLGALACTOSAMINYLTRANSFERASE; GBGT1__:__FORSSMAN SYNTHETASE; FS__:__
Asterisk__:__606075__:__TWINKLE mtDNA HELICASE; TWNK__:__CHROMOSOME 10 OPEN READING FRAME 2; C10ORF2;; T7 GENE 4-LIKE PROTEIN WITH INTRAMITOCHONDRIAL NUCLEOID LOCALIZATION; TWINKLE;; p72__:__TWINKY, INCLUDED
Asterisk__:__606076__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 3; PIK3R3__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT, 55-KD, GAMMA;; p55-GAMMA__:__
Asterisk__:__606077__:__RNA-BINDING MOTIF PROTEIN 15; RBM15__:__OTT;; ONE-TWENTY TWO PROTEIN 1; OTT1__:__RBM15/MKL1 FUSION GENE, INCLUDED
Asterisk__:__606078__:__MEGAKARYOBLASTIC LEUKEMIA 1 GENE; MKL1__:__MAL;; MYOCARDIN-RELATED PROTEIN;; MRTFA__:__MKL1/RBM15 FUSION GENE, INCLUDED
Asterisk__:__606079__:__CD163 ANTIGEN-LIKE 1; CD163L1__:__CD163 ANTIGEN B; CD163B;; SCAVENGER RECEPTOR M160; M160__:__
Asterisk__:__606080__:__CHITINASE, ACIDIC; CHIA__:__ACIDIC MAMMALIAN CHITINASE; AMCase__:__
Asterisk__:__606081__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 70, YEAST, HOMOLOG OF, A; TOMM70A__:____:__
Percent__:__606082__:__GOITER, MULTINODULAR 3; MNG3__:____:__
Asterisk__:__606083__:__POLYBROMO 1, CHICKEN, HOMOLOG OF; PBRM1__:__PB1;; BRG1-ASSOCIATED FACTOR, 180-KD; BAF180__:__
Asterisk__:__606084__:__CDC42 EFFECTOR PROTEIN 1; CDC42EP1__:__CEP1;; BONE MARROW STROMAL/ENDOTHELIAL CELL PROTEIN, 55-KD; MSE55__:__
Asterisk__:__606085__:__TESTIS-DERIVED TRANSCRIPT; TES__:__TESTIN__:__
Asterisk__:__606086__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 5B; EIF5B__:__TRANSLATION INITIATION FACTOR IF2; IF2__:__
Asterisk__:__606087__:__DESMUSLIN; DMN__:____:__
Asterisk__:__606088__:__PHOSPHOLIPASE A2, GROUP IVB; PLA2G4B__:__PHOSPHOLIPASE A2, CYTOSOLIC, CALCIUM-DEPENDENT, BETA;; CPLA2-BETA__:__
Asterisk__:__606089__:__BRAIN CYTOPLASMIC RNA 1; BCYRN1__:__BC200 RNA; BC200;; BC200-ALPHA__:__
Asterisk__:__606090__:__CARNITINE OCTANOYLTRANSFERASE; CROT__:__COT__:__
Asterisk__:__606091__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 10; SIGLEC10__:____:__
Asterisk__:__606092__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 14; DNAJC14__:__DOPAMINE RECEPTOR-INTERACTING PROTEIN, 78-KD; DRIP78;; HEAT-SHOCK PROTEIN, DNAJ-LIKE 3; HDJ3__:__
Asterisk__:__606093__:__PEPTIDYL-PROLYL ISOMERASE G; PPIG__:__CYCLOPHILIN G__:__
Asterisk__:__606094__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 12; SIGLEC12__:__SIGLEC-LIKE PROTEIN 1; SIGLECL1;; SIGLEC-LIKE GENE; SLG;; S2V__:__
Asterisk__:__606095__:__PEPTIDYL-PROLYL ISOMERASE H; PPIH__:__CYCLOPHILIN H__:__
Asterisk__:__606096__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 12__:__LGALS12;; GALECTIN 12__:__
Asterisk__:__606097__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS N PROTEIN; PIGN__:____:__
Asterisk__:__606098__:__SORTING NEXIN 6; SNX6__:____:__
Asterisk__:__606099__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 8; LGALS8__:__GALECTIN 8;; PROSTATE CARCINOMA TUMOR ANTIGEN 1; PCTA1__:__
Asterisk__:__606100__:__ADHESION G PROTEIN-COUPLED RECEPTOR E2; ADGRE2__:__EGF-LIKE MODULE-CONTAINING, MUCIN-LIKE HORMONE RECEPTOR 2; EMR2__:__
Asterisk__:__606101__:__ADHESION G PROTEIN-COUPLED RECEPTOR E3; ADGRE3__:__EGF-LIKE MODULE-CONTAINING, MUCIN-LIKE HORMONE RECEPTOR 3; EMR3__:__
Asterisk__:__606102__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE I, GAMMA; PIP5K1C__:__PIP5K1-GAMMA__:__
Asterisk__:__606103__:__SESTRIN 1; SESN1__:__SEST1;; p53-ACTIVATED GENE 26;; PA26__:__
Caret__:__606104__:__MOVED TO 124000__:____:__
Asterisk__:__606105__:__SOLUTE CARRIER FAMILY 44, MEMBER 1; SLC44A1__:__CHOLINE TRANSPORTER-LIKE PROTEIN 1; CTL1;; CDW92__:__
Asterisk__:__606106__:__SOLUTE CARRIER FAMILY 44, MEMBER 2; SLC44A2__:__CHOLINE TRANSPORTER-LIKE PROTEIN 2; CTL2__:__
Asterisk__:__606107__:__SOLUTE CARRIER FAMILY 44, MEMBER 4; SLC44A4__:__CHOLINE TRANSPORTER-LIKE PROTEIN 4; CTL4;; THIAMINE PYROPHOSPHATE TRANSPORTER; TPPT;; TPP TRANSPORTER;; CHROMOSOME 6 OPEN READING FRAME 29; C6ORF29__:__
Asterisk__:__606108__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1A; PPM1A__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1A;; PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1, ALPHA ISOFORM;; PROTEIN PHOSPHATASE 2C, ALPHA ISOFORM; PP2CA;; PP2C-ALPHA__:__
Asterisk__:__606109__:__NUDC DOMAIN-CONTAINING PROTEIN 1; NUDCD1__:__IMMUNOGENIC TUMOR ANTIGEN CML66; CML66__:__
Asterisk__:__606110__:__LY6/NEUROTOXIN 1; LYNX1__:__SECRETED LY6/PLAUR DOMAIN-CONTAINING PROTEIN 2; SLURP2;; SECRETED LY6/UPAR-RELATED PROTEIN 2__:__
Asterisk__:__606111__:__MELANIN-CONCENTRATING HORMONE RECEPTOR 2; MCHR2__:__MCH2R;; MCH2;; SLT__:__
Asterisk__:__606112__:__RIBONUCLEASE P, 14-KD SUBUNIT; RPP14__:____:__
Asterisk__:__606113__:__PROCESSING OF PRECURSOR 7, S. CEREVISIAE, HOMOLOG OF; POP7__:__RIBONUCLEASE P, 20-KD SUBUNIT; RPP20__:__
Asterisk__:__606114__:__PROCESSING OF PRECURSOR 4, S. CEREVISIAE, HOMOLOG OF; POP4__:__RIBONUCLEASE P/MRP SUBUNIT, 29-KD SUBUNIT; RPP29;; RIBONUCLEASE P, 29-KD SUBUNIT__:__
Asterisk__:__606115__:__RIBONUCLEASE P/MRP, 30-KD SUBUNIT; RPP30__:__RIBONUCLEASE P, 30-KD SUBUNIT__:__
Asterisk__:__606116__:__RIBONUCLEASE P/MRP, 38-KD SUBUNIT; RPP38__:__RIBONUCLEASE P, 38-KD SUBUNIT__:__
Asterisk__:__606117__:__RIBONUCLEASE P, 40-KD SUBUNIT; RPP40__:____:__
Asterisk__:__606118__:__HPS3 GENE; HPS3__:__COCOA, MOUSE, HOMOLOG OF__:__
Asterisk__:__606119__:__SECRETED LY6/PLAUR DOMAIN-CONTAINING PROTEIN 1; SLURP1__:__SECRETED LY6/UPAR-RELATED PROTEIN 1;; ARS COMPONENT B;; ARS COMPONENT B-81/S PRECURSOR__:__
Caret__:__606120__:__MOVED TO 561010__:____:__
Asterisk__:__606121__:__CALCITONIN GENE-RELATED PEPTIDE RECEPTOR COMPONENT PROTEIN__:__CGRP RECEPTOR COMPONENT PROTEIN; CGRPRCP; RCP;; CGRPR COMPONENT PROTEIN__:__
Asterisk__:__606122__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 19; TNFRSF19__:__TOXICITY AND JNK INDUCER; TAJ;; TROY__:__
Asterisk__:__606123__:__RING FINGER PROTEIN 16; RNF16__:__TESTIS RING FINGER PROTEIN; TERF__:__
Asterisk__:__606124__:__RING FINGER PROTEIN 18; RNF18__:____:__
Asterisk__:__606125__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 8; TRIM8__:__RING FINGER PROTEIN 27; RNF27;; GLIOBLASTOMA-EXPRESSED RING FINGER PROTEIN; GERP__:__
Asterisk__:__606126__:__APOPTOSIS REGULATOR BCLG__:__BCLG__:__
Asterisk__:__606127__:__MYOCARDIN; MYOCD__:__MYCD__:__
Caret__:__606128__:__MOVED TO 606078__:____:__
Percent__:__606129__:__DIAMOND-BLACKFAN ANEMIA 2; DBA2__:____:__
Asterisk__:__606130__:__RING FINGER PROTEIN 26; RNF26__:____:__
Asterisk__:__606131__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 63; TRIM63__:__E3 UBIQUITIN PROTEIN LIGASE TRIM63;; RING FINGER PROTEIN 28; RNF28;; STRIATED MUSCLE RING ZINC FINGER PROTEIN; SMRZ;; MUSCLE-SPECIFIC RING FINGER PROTEIN 1; MURF1__:__
Asterisk__:__606132__:__CDC42 EFFECTOR PROTEIN 2; CDC42EP2__:__CEP2;; BINDER OF RHO GTPases 1; BORG1__:__
Asterisk__:__606133__:__CDC42 EFFECTOR PROTEIN 3; CDC42EP3__:__CEP3;; BINDER OF RHO GTPases 2; BORG2__:__
Asterisk__:__606134__:__REV1, S. CEREVISIAE, HOMOLOG OF; REV1L__:__REV1;; ALPHA-INTEGRIN-BINDING PROTEIN 80__:__
Asterisk__:__606135__:__KALLIKREIN-RELATED PEPTIDASE 14; KLK14__:__KALLIKREIN 14__:__
Asterisk__:__606136__:__RAS PROTEIN ACTIVATOR-LIKE 2; RASAL2__:__NGAP__:__
Asterisk__:__606137__:__CELL GROWTH REGULATOR WITH EF-HAND DOMAIN 1; CGREF1__:__CELL GROWTH REGULATORY GENE 11; CGR11__:__
Asterisk__:__606138__:__CELL GROWTH REGULATOR WITH RING FINGER DOMAIN 1; CGRRF1__:__CELL GROWTH REGULATORY GENE 19; CGR19__:__
Asterisk__:__606139__:__KRUPPEL-LIKE FACTOR 16; KLF16__:__BASIC TRANSCRIPTION ELEMENT-BINDING PROTEIN 4; BTEB4;; DOPAMINE RECEPTOR-REGULATING FACTOR; DRRF__:__
Asterisk__:__606140__:__EXPORTIN 7; XPO7__:__RAN-BINDING PROTEIN 16; RANBP16__:__
Asterisk__:__606141__:__RAN-BINDING PROTEIN 17; RANBP17__:____:__
Asterisk__:__606142__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 9; SLC2A9__:__GLUCOSE TRANSPORTER 9; GLUT9__:__
Asterisk__:__606143__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 3; FZD3__:____:__
Asterisk__:__606144__:__RAS-ASSOCIATED PROTEIN RAB23; RAB23__:____:__
Asterisk__:__606145__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 10; SLC2A10__:__GLUCOSE TRANSPORTER 10; GLUT10__:__
Asterisk__:__606146__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 8; FZD8__:____:__
Asterisk__:__606147__:__FRIZZLED, DROSOPHILA, HOMOLOG OF, 10; FZD10__:____:__
Asterisk__:__606148__:__FATTY ACID DESATURASE 1; FADS1__:____:__
Asterisk__:__606149__:__FATTY ACID DESATURASE 2; FADS2__:____:__
Asterisk__:__606150__:__FATTY ACID DESATURASE 3; FADS3__:____:__
Asterisk__:__606151__:__BBS2 GENE; BBS2__:____:__
Asterisk__:__606152__:__SOLUTE CARRIER FAMILY 19 (THIAMINE TRANSPORTER), MEMBER 3; SLC19A3__:__THIAMINE TRANSPORTER 2; THTR2__:__
Asterisk__:__606153__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F1 COMPLEX, EPSILON SUBUNIT; ATP5F1E__:__ATP5E__:__
Asterisk__:__606154__:__MUCIN 16; MUC16__:__OVARIAN CARCINOMA ANTIGEN CA125__:__
Caret__:__606155__:__MOVED TO 243310__:____:__
NULL__:__606156__:__SENER SYNDROME__:__FRONTONASAL DYSPLASIA AND DILATED VIRCHOW-ROBIN SPACES__:__
Asterisk__:__606157__:__PANTOTHENATE KINASE 2; PANK2__:____:__
Asterisk__:__606158__:__BSCL2 GENE; BSCL2__:__SEIPIN;; GNG3LG, MOUSE, HOMOLOG OF__:__
Number Sign__:__606159__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3__:__NEUROFERRITINOPATHY;; BASAL GANGLIA DISEASE, ADULT-ONSET__:__
Asterisk__:__606160__:__PANTOTHENATE KINASE 1; PANK1__:____:__
Asterisk__:__606161__:__PANTOTHENATE KINASE 3; PANK3__:____:__
Asterisk__:__606162__:__PANTOTHENATE KINASE 4; PANK4__:____:__
Caret__:__606163__:__MOVED TO 300829__:____:__
Number Sign__:__606164__:__DIAMOND-BLACKFAN ANEMIA 15 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA15__:____:__
Asterisk__:__606165__:__BOL-LIKE; BOLL__:__BOULE, DROSOPHILA, HOMOLOG OF; BOULE__:__
Caret__:__606166__:__MOVED TO 603100__:____:__
Asterisk__:__606167__:__G PROTEIN-COUPLED RECEPTOR 132; GPR132__:__G2 ACCUMULATION PROTEIN; G2A__:__
Asterisk__:__606168__:__DEAD/H BOX 20; DDX20__:__DP103;; GEMIN3__:__
Caret__:__606169__:__MOVED TO 277410__:____:__
Number Sign__:__606170__:__GENITOPATELLAR SYNDROME; GTPTS__:__ABSENT PATELLAE, SCROTAL HYPOPLASIA, RENAL ANOMALIES, FACIAL DYSMORPHISM, AND MENTAL RETARDATION__:__
Asterisk__:__606171__:__TRANSFER RNA SERINE 1; TRNAS1__:__tRNA SERINE 1; TRS1__:__
Asterisk__:__606172__:__TRANSFER RNA SERINE (TGA) 4-1; TRS-TGA4-1__:__TRANSFER RNA SERINE 3; TRNAS3;; tRNA SERINE 3; TRS3__:__
Asterisk__:__606173__:__GrpE, E. COLI, HOMOLOG OF, 1; GRPEL1__:__GrpE-LIKE 1;; HUMAN MITOCHONDRIAL GrpE PROTEIN; HMGE__:__
NULL__:__606174__:__BACULUM, CONGENITAL ABSENCE OF__:__OS PENIS, CONGENITAL ABSENCE OF__:__
NULL__:__606175__:__CARNITINE ACETYLTRANSFERASE DEFICIENCY__:____:__
Number Sign__:__606176__:__DIABETES MELLITUS, PERMANENT NEONATAL; PNDM__:__DIABETES MELLITUS, PERMANENT, OF INFANCY; PDMI__:__DIABETES MELLITUS, PERMANENT NEONATAL, WITH NEUROLOGIC FEATURES, INCLUDED;; DEVELOPMENTAL DELAY, EPILEPSY, AND NEONATAL DIABETES, INCLUDED; DEND, INCLUDED
NULL__:__606177__:__PARS PLANITIS__:____:__
Asterisk__:__606178__:__HEDGEHOG-INTERACTING PROTEIN; HHIP__:__HIP__:__
NULL__:__606179__:__ANEURYSMAL BONE CYSTS__:____:__
Asterisk__:__606180__:__EXOSOME COMPONENT 9; EXOSC9__:__POLYMYOSITIS/SCLERODERMA AUTOANTIGEN 1; PMSCL1;; POLYMYOSITIS/SCLERODERMA AUTOANTIGEN, 75-KD;; PMSCL AUTOANTIGEN, 75-KD__:__
Asterisk__:__606181__:__DEAD/H BOX 24; DDX24__:____:__
Asterisk__:__606182__:__TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 9; TNFSF9__:__4-1BB-L, MOUSE, HOMOLOG OF;; CD137 LIGAND; CD137L__:__
NULL__:__606183__:__LARYNGEAL ABDUCTOR PARALYSIS WITH CEREBELLAR ATAXIA AND MOTOR NEUROPATHY__:____:__
Asterisk__:__606184__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 12; ADAMTS12__:____:__
Asterisk__:__606185__:__TUMOR PROTEIN p53-INDUCIBLE NUCLEAR PROTEIN 1; TP53INP1__:__p53-DEPENDENT DAMAGE-INDUCIBLE NUCLEAR PROTEIN 1; P53DINP1__:__
Asterisk__:__606186__:__CALCYCLIN-BINDING PROTEIN; CACYBP__:__SIAH1-INTERACTING PROTEIN; SIP__:__
Percent__:__606187__:__ALZHEIMER DISEASE 7__:__ALZHEIMER DISEASE, FAMILIAL, 7;; AD7__:__
Asterisk__:__606188__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 28; ADAM28__:__METALLOPROTEINASE-LIKE, DISINTEGRIN-LIKE, AND CYSTEINE-RICH PROTEIN, LYMPHOCYTE-EXPRESSED; MDCL__:__
Asterisk__:__606189__:__CYSTEINE-RICH MOTOR NEURON PROTEIN 1; CRIM1__:____:__
NULL__:__606190__:__MENINGIOMA, RADIATION-INDUCED__:__MNRI__:__
Asterisk__:__606191__:__FORMIN-BINDING PROTEIN 1; FNBP1__:__FORMIN-BINDING PROTEIN 17; FBP17__:__FBP17/MLL FUSION GENE, INCLUDED
Asterisk__:__606192__:__BUTYROPHILIN-LIKE PROTEIN 3; BTNL3__:____:__
Asterisk__:__606193__:__SOLUTE CARRIER FAMILY 13 (SODIUM/SULFATE SYMPORTER), MEMBER 1; SLC13A1__:__SODIUM-INORGANIC SULFATE COTRANSPORTER 1; NASI1; NAS1__:__
Asterisk__:__606194__:__KERATIN 23, TYPE I; KRT23__:__K23;; KA23__:__
Asterisk__:__606195__:__IROQUOIS HOMEOBOX PROTEIN 5; IRX5__:__IRXB2__:__
Asterisk__:__606196__:__IROQUOIS HOMEOBOX PROTEIN 6; IRX6__:__IRXB3;; IROQUOIS HOMEOBOX PROTEIN 7, FORMERLY; IRX7, FORMERLY__:__
Asterisk__:__606197__:__IROQUOIS HOMEOBOX PROTEIN 1; IRX1__:__IRXA1__:__
Asterisk__:__606198__:__IROQUOIS HOMEOBOX PROTEIN 2; IRX2__:__IRXA2__:__
Asterisk__:__606199__:__IROQUOIS HOMEOBOX PROTEIN 4; IRX4__:__IRXA3__:__
Asterisk__:__606200__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER E41; BHLHE41__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 3; BHLHB3 DIFFERENTIALLY EXPRESSED IN CHONDROCYTES 2; DEC2;; ENHANCER OF SPLIT- AND HAIRY-RELATED PROTEIN 1, RAT, HOMOLOG OF; SHARP1__:__
Asterisk__:__606201__:__WOLFRAMIN ER TRANSMEMBRANE GLYCOPROTEIN; WFS1__:__WOLFRAMIN__:__
Asterisk__:__606202__:__SOLUTE CARRIER FAMILY 45, MEMBER 2; SLC45A2__:__MEMBRANE-ASSOCIATED TRANSPORTER PROTEIN; MATP;; MELANOMA ANTIGEN AIM1; AIM1__:__
Asterisk__:__606203__:__GRB2-ASSOCIATED BINDING PROTEIN 2; GAB2__:__KIAA0571__:__
Asterisk__:__606204__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS D; LY6D__:__E48 ANTIGEN; E48__:__
Asterisk__:__606205__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, L-PROLINE), MEMBER 7; SLC6A7__:__L-PROLINE TRANSPORTER, BRAIN-SPECIFIC; PROT__:__
Asterisk__:__606206__:__METALLOTHIONEIN 4; MT4__:__METALLOTHIONEIN IV; MTIV__:__
Asterisk__:__606207__:__SOLUTE CARRIER FAMILY 28 (SODIUM-COUPLED NUCLEOSIDE TRANSPORTER), MEMBER 1; SLC28A1__:__CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CNT1__:__
Asterisk__:__606208__:__SOLUTE CARRIER FAMILY 28 (SODIUM-COUPLED NUCLEOSIDE TRANSPORTER), MEMBER 2; SLC28A2__:__CONCENTRATIVE NUCLEOSIDE TRANSPORTER 2; CNT2;; SODIUM-DEPENDENT PURINE NUCLEOSIDE TRANSPORTER 1; SPNT1__:__
Asterisk__:__606209__:__YKT6, S. CEREVISIAE, HOMOLOG OF; YKT6__:____:__
Asterisk__:__606210__:__SELENOPROTEIN N; SELENON__:__SELN;; SEPN1__:__
Asterisk__:__606211__:__SIRTUIN 6; SIRT6__:__SIR2-LIKE 6; SIR2L6__:__
Asterisk__:__606212__:__SIRTUIN 7; SIRT7__:__SIR2, S.CEREVISIAE, HOMOLOG-LIKE 7; SIR2L7__:__
Asterisk__:__606213__:__SIGNAL SEQUENCE RECEPTOR, GAMMA; SSR3__:__TRANSLOCON-ASSOCIATED PROTEIN, GAMMA SUBUNIT; TRAPG__:__
Asterisk__:__606214__:__SPECTRIN, BETA, NONERYTHROCYTIC, 4; SPTBN4__:__SPECTRIN, BETA-IV; SPNB4;; QUIVERING, MOUSE, HOMOLOG OF; QV__:__
Percent__:__606215__:__ATRIOVENTRICULAR SEPTAL DEFECT; AVSD__:__ATRIOVENTRICULAR CANAL DEFECT; AVCD;; AVC DEFECT;; ENDOCARDIAL CUSHION DEFECT; ECD__:__ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 1, INCLUDED; AVSD1, INCLUDED
Asterisk__:__606216__:__METHIONINE SULFOXIDE REDUCTASE B1; MSRB1__:__SELENOPROTEIN X, 1; SEPX1;; SELX;; SELENOPROTEIN R; SELR__:__
Number Sign__:__606217__:__ATRIOVENTRICULAR SEPTAL DEFECT, SUSCEPTIBILITY TO, 2; AVSD2__:____:__ATRIOVENTRICULAR SEPTAL DEFECT, PARTIAL, WITH HETEROTAXY SYNDROME, INCLUDED
Asterisk__:__606218__:__SELENOPHOSPHATE SYNTHETASE 2; SEPHS2__:__SPS2__:__
Asterisk__:__606219__:__TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PROTEIN 1; TRAP1__:__TNFR-ASSOCIATED PROTEIN 1 HEAT-SHOCK PROTEIN, 75-KD; HSP75;; HSP90-LIKE PROTEIN; HSP90L__:__
NULL__:__606220__:__MENTAL RETARDATION, SHORT STATURE, FACIAL ANOMALIES, AND JOINT DISLOCATIONS__:____:__
Asterisk__:__606221__:__IKAROS FAMILY ZINC FINGER 3; IKZF3__:__ZINC FINGER PROTEIN, SUBFAMILY 1A, MEMBER 3; ZNFN1A3;; AIOLOS; AIO__:__
Asterisk__:__606222__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 6; IGSF6__:__DOWNREGULATED BY ACTIVATION GENE; DORA__:__
Asterisk__:__606223__:__PROTEASOME 26S SUBUNIT, NON-ATPASE, 2; PSMD2__:__PROTEASOME 26S, SUBUNIT 2; S2;; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PROTEIN 2; TRAP2;; TNFR-ASSOCIATED PROTEIN 2__:__
Asterisk__:__606224__:__5-PRIME-NUCLEOTIDASE, CYTOSOLIC IIIA; NT5C3A__:__NUCLEOTIDASE, 5-PRIME, CYTOSOLIC III; NT5C3;; URIDINE 5-PRIME MONOPHOSPHATE HYDROLASE 1; UMPH1;; PYRIMIDINE 5-PRIME-NUCLEOTIDASE 1; P5N1__:__
Asterisk__:__606225__:__TASTE RECEPTOR TYPE 1, MEMBER 1; TAS1R1__:__T1R1__:__
Asterisk__:__606226__:__TASTE RECEPTOR TYPE 1, MEMBER 2; TAS1R2__:__T1R2__:__
Asterisk__:__606227__:__MEMBRANE-TYPE FRIZZLED-RELATED PROTEIN; MFRP__:____:__
Asterisk__:__606228__:__ARGONAUTE 1, RISC CATALYTIC COMPONENT; AGO1__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2C, SUBUNIT 1; EIF2C1;; EIF2C;; GERP95__:__
Asterisk__:__606229__:__ARGONAUTE 2, RISC CATALYTIC COMPONENT; AGO2__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2C, SUBUNIT 2; EIF2C2__:__
Asterisk__:__606230__:__SH3 AND MULTIPLE ANKYRIN REPEAT DOMAINS 3; SHANK3__:__PROLINE-RICH SYNAPSE-ASSOCIATED PROTEIN 2; PSAP2;; PROSAP2;; KIAA1650__:__
Asterisk__:__606231__:__ADAPTOR PROTEIN, PHOSPHOTYROSINE INTERACTION, PH DOMAIN, AND LEUCINE ZIPPER-CONTAINING PROTEIN 2; APPL2__:__ADAPTOR PROTEIN CONTAINING PH DOMAIN, PTB DOMAIN, AND LEUCINE ZIPPER MOTIF 2;; DIP13-BETA;; FLJ10659__:__
Number Sign__:__606232__:__PHELAN-MCDERMID SYNDROME; PHMDS__:__CHROMOSOME 22q13.3 DELETION SYNDROME;; TELOMERIC 22q13 MONOSOMY SYNDROME__:__
Asterisk__:__606233__:__PROKINETICIN 1; PROK1__:__PK1; PRK1;; ENDOCRINE GLAND-DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; EG-VEGF__:__
Asterisk__:__606234__:__IKAROS FAMILY ZINC FINGER 2; IKZF2__:__ZINC FINGER PROTEIN, SUBFAMILY 1A, MEMBER 2; ZNF1A2;; HELIOS__:__
Asterisk__:__606235__:__THIOREDOXIN REDUCTASE 3; TXNRD3__:__TRXR3;; TR2__:__
Asterisk__:__606236__:__ALVEOLAR SOFT PART SARCOMA CHROMOSOME REGION, CANDIDATE 1; ASPSCR1__:__ASPL;; TETHER, CONTAINING UBX DOMAIN FOR GLUT4; TUG__:__ASPSCR1/TFE3 FUSION GENE, INCLUDED
Asterisk__:__606237__:__TRANSFORMING GROWTH FACTOR-BETA RECEPTOR-ASSOCIATED PROTEIN 1; TGFBRAP1__:__TGFBR-ASSOCIATED PROTEIN 1; TRAP1__:__
Asterisk__:__606238__:__IKAROS FAMILY ZINC FINGER 5; IKZF5__:__ZINC FINGER PROTEIN, SUBFAMILY 1A, MEMBER 5; ZNFN1A5;; PEGASUS__:__
Asterisk__:__606239__:__IKAROS FAMILY ZINC FINGER 4; IKZF4__:__ZINC FINGER PROTEIN, SUBFAMILY 1A, MEMBER 4; ZNFN1A4;; EOS;; KIAA1782__:__
Percent__:__606240__:__THYROID CANCER, NONMEDULLARY, 3; NMTC3__:__THYROID CANCER, NONMEDULLARY, 1, FORMERLY; NMTC1, FORMERLY__:__
Asterisk__:__606241__:__DICER, DROSOPHILA, HOMOLOG OF, 1; DICER1__:__DCR1;; HELICASE WITH RNASE MOTIF; HERNA;; HELICASE-MOI;; K12H4.8-LIKE;; KIAA0928__:__
Percent__:__606242__:__MENTAL RETARDATION, MICROCEPHALY, GROWTH RETARDATION, JOINT CONTRACTURES, AND FACIAL DYSMORPHISM__:__KONDOH SYNDROME__:__
Number Sign__:__606243__:__ALVEOLAR SOFT PART SARCOMA; ASPS__:____:__
Asterisk__:__606244__:__SIGNAL-TRANSDUCING ADAPTOR MOLECULE 2; STAM2__:____:__
Asterisk__:__606245__:__SUPPRESSOR OF ZESTE 12, DROSOPHILA, HOMOLOG OF; SUZ12__:__JOINED TO JAZF1; JJAZ1;; KIAA0160__:__JJAZ1/JAZF1 FUSION GENE, INCLUDED
Asterisk__:__606246__:__JUXTAPOSED WITH ANOTHER ZINC FINGER GENE 1; JAZF1__:__TAK1-INTERACTING PROTEIN 27; TIP27__:__JAZF1/JJAZ1 FUSION GENE, INCLUDED
Asterisk__:__606247__:__STAM-BINDING PROTEIN; STAMBP__:__ASSOCIATED MOLECULE WITH THE SH3 DOMAIN OF STAM; AMSH__:__
Asterisk__:__606248__:__QUINOLINATE PHOSPHORIBOSYLTRANSFERASE; QPRT__:__QPRTase__:__
Asterisk__:__606249__:__PROTEIN KINASE, LYSINE-DEFICIENT 2; WNK2__:__PRKWNK2;; KIAA1760__:__
Asterisk__:__606250__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 8; GALNT8__:__GalNAc TRANSFERASE 8; GalNAcT8__:__
Asterisk__:__606251__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 9; GALNT9__:__GalNAc TRANSFERASE 9; GalNAcT9__:__
Asterisk__:__606252__:__TIR DOMAIN-CONTAINING ADAPTOR PROTEIN; TIRAP__:__MYD88 ADAPTOR-LIKE; MAL__:__
Caret__:__606253__:__MOVED TO 191343__:____:__
Asterisk__:__606254__:__SELENOPROTEIN F; SELENOF__:__SELENOPROTEIN, 15-KD; SEP15__:__
Percent__:__606255__:__STATURE AS A QUANTITATIVE TRAIT__:____:__STATURE QUANTITATIVE TRAIT LOCUS 1, INCLUDED; STQTL1, INCLUDED
Percent__:__606256__:__STATURE QUANTITATIVE TRAIT LOCUS 2; STQTL2__:____:__
Percent__:__606257__:__STATURE QUANTITATIVE TRAIT LOCUS 3; STQTL3__:____:__
Percent__:__606258__:__STATURE QUANTITATIVE TRAIT LOCUS 4; STQTL4__:____:__
Asterisk__:__606259__:__BREAST CANCER METASTASIS SUPPRESSOR 1; BRMS1__:____:__
Asterisk__:__606260__:__MYOTUBULARIN-RELATED PROTEIN 9; MTMR9__:__MYOTUBULARIN-RELATED PROTEIN 8, FORMERLY; MTMR8, FORMERLY__:__
Asterisk__:__606261__:__NUDIX HYDROLASE 6; NUDT6__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 6;; NUDIX MOTIF 6;; FIBROBLAST GROWTH FACTOR 2, ANTISENSE; FGF2AS;; ASFGF2;; FIBROBLAST GROWTH FACTOR, BASIC, ANTISENSE;; GFG1;; GFG__:__
Caret__:__606262__:__MOVED TO 602080__:____:__
Percent__:__606263__:__PAGET DISEASE OF BONE 4; PDB4__:____:__
Asterisk__:__606264__:__C-TYPE LECTIN DOMAIN FAMILY 7, MEMBER A; CLEC7A__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 12; CLECSF12;; DECTIN 1;; DECTIN1;; BETA-GLUCAN RECEPTOR; BGR__:__
Asterisk__:__606265__:__E1A-BINDING PROTEIN, 400-KD; EP400__:__p400;; CAGH32;; KIAA1498;; KIAA1818;; DOMINO, DROSOPHILA, HOMOLOG OF;; TRINUCLEOTIDE REPEAT-CONTAINING GENE 12, FORMERLY; TNRC12, FORMERLY__:__
Asterisk__:__606266__:__BCL2-MODIFYING FACTOR; BMF__:____:__
Asterisk__:__606267__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 16; WNT16__:____:__
Asterisk__:__606268__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 10A; WNT10A__:____:__
Asterisk__:__606269__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 13C; TNFRSF13C__:__B CELL-ACTIVATING FACTOR RECEPTOR;; BAFF RECEPTOR; BAFFR__:__
Asterisk__:__606270__:__TOLL-LIKE RECEPTOR 10; TLR10__:____:__TLR11, INCLUDED
Asterisk__:__606271__:__DISRUPTED IN SCHIZOPHRENIA 2; DISC2__:____:__
Asterisk__:__606272__:__CYSTINOSIN; CTNS__:____:__
Asterisk__:__606273__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 3; EIF2B3__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, GAMMA;; EIF2B-GAMMA__:__
Asterisk__:__606274__:__CASEIN KINASE I, GAMMA-1; CSNK1G1__:____:__
Caret__:__606275__:__MOVED TO 601172__:____:__
Asterisk__:__606276__:__CARTILAGE ACIDIC PROTEIN 1; CRTAC1__:__CHONDROCYTE-EXPRESSED PROTEIN, 68-KD; CEP68;; LATERAL OLFACTORY TRACT USHER SUBSTANCE; LOTUS__:__
Asterisk__:__606277__:__TOLL-INTERACTING PROTEIN; TOLLIP__:____:__
Asterisk__:__606278__:__F-BOX AND WD40 DOMAIN PROTEIN 7; FBXW7__:__FBW7;; FBXW6; FBW6;; FBXO30; FBX30;; ARCHIPELAGO, DROSOPHILA, HOMOLOG OF; AGO;; CDC4, S. CEREVISIAE, HOMOLOG OF;; SEL10, C. ELEGANS, HOMOLOG OF; SEL10__:__
Asterisk__:__606279__:__ABI FAMILY MEMBER 3 BINDING PROTEIN; ABI3BP__:__TARGET OF NESH-SH3; TARSH__:__
Asterisk__:__606280__:__NON-SMC CONDENSIN I COMPLEX SUBUNIT G; NCAPG__:__CONDENSIN I COMPLEX, NON-SMC SUBUNIT G;; CHROMOSOME-ASSOCIATED PROTEIN G; CAPG__:__
Asterisk__:__606281__:__RAS-ASSOCIATED PROTEIN RAB38; RAB38__:____:__
Percent__:__606282__:__DEAFNESS, AUTOSOMAL DOMINANT 24; DFNA24__:____:__
Asterisk__:__606283__:__SORCS RECEPTOR 1; SORCS1__:____:__
Asterisk__:__606284__:__SORCS RECEPTOR 2; SORCS2__:__KIAA1329__:__
Asterisk__:__606285__:__SORCS RECEPTOR 3; SORCS3__:__KIAA1059__:__
Asterisk__:__606286__:__DEAD/H BOX 43; DDX43__:__HELICASE ANTIGEN; HAGE__:__
Caret__:__606287__:__MOVED TO 605743__:____:__
Asterisk__:__606288__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 1; PCDHGA1__:__PCDH-GAMMA-A1__:__
Asterisk__:__606289__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 2; PCDHGA2__:__PCDH-GAMMA-A2__:__
Asterisk__:__606290__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 3; PCDHGA3__:__PCDH-GAMMA-A3__:__
Asterisk__:__606291__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 4; PCDHGA4__:__PCDH-GAMMA-A4__:__
Asterisk__:__606292__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 5; PCDHGA5__:__PCDH-GAMMA-A5__:__
Asterisk__:__606293__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 6; PCDHGA6__:__PCDH-GAMMA-A6__:__
Asterisk__:__606294__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 7; PCDHGA7__:__PCDH-GAMMA-A7__:__
Asterisk__:__606295__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 8; PCDHGA8__:__PCDH-GAMMA-A8;; KIAA0327__:__
Asterisk__:__606296__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 9; PCDHGA9__:__PCDH-GAMMA-A9__:__
Asterisk__:__606297__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 10; PCDHGA10__:__PCDH-GAMMA-A10__:__
Asterisk__:__606298__:__PROTOCADHERIN-GAMMA, SUBFAMILY A, MEMBER 11; PCDHGA11__:__PCDH-GAMMA-A11__:__
Asterisk__:__606299__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 1; PCDHGB1__:__PCDH-GAMMA-B1__:__
Asterisk__:__606300__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 2; PCDHGB2__:__PCDH-GAMMA-B2__:__
Asterisk__:__606301__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 3; PCDHGB3__:__PCDH-GAMMA-B3__:__
Asterisk__:__606302__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 5; PCDHGB5__:__PCDH-GAMMA-B5__:__
Asterisk__:__606303__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 6; PCDHGB6__:__PCDH-GAMMA-B6__:__
Asterisk__:__606304__:__PROTOCADHERIN-GAMMA, SUBFAMILY B, MEMBER 7; PCDHGB7__:__PCDH-GAMMA-B7__:__
Asterisk__:__606305__:__PROTOCADHERIN-GAMMA, SUBFAMILY C, MEMBER 4; PCDHGC4__:__PCDH-GAMMA-C4__:__
Asterisk__:__606306__:__PROTOCADHERIN-GAMMA, SUBFAMILY C, MEMBER 5; PCDHGC5__:__PCDH-GAMMA-C5__:__
Asterisk__:__606307__:__PROTOCADHERIN-ALPHA 1; PCDHA1__:__PCDH-ALPHA-1__:__
Asterisk__:__606308__:__PROTOCADHERIN-ALPHA 2; PCDHA2__:__PCDH-ALPHA-2__:__
Asterisk__:__606309__:__PROTOCADHERIN-ALPHA 3; PCDHA3__:__PCDH-ALPHA-3__:__
Asterisk__:__606310__:__PROTOCADHERIN-ALPHA 4; PCDHA4__:__PCDH-ALPHA-4;; CADHERIN-RELATED NEURONAL RECEPTOR 1, MOUSE, HOMOLOG OF; CNR1__:__
Asterisk__:__606311__:__PROTOCADHERIN-ALPHA 5; PCDHA5__:__PCDH-ALPHA-5;; CADHERIN-RELATED NEURONAL RECEPTOR 6, MOUSE, HOMOLOG OF; CNR6__:__
Asterisk__:__606312__:__PROTOCADHERIN-ALPHA 6; PCDHA6__:__PCDH-ALPHA-6;; CADHERIN-RELATED NEURONAL RECEPTOR 2, MOUSE, HOMOLOG OF; CNR2__:__
Asterisk__:__606313__:__PROTOCADHERIN-ALPHA 7; PCDHA7__:__PCDH-ALPHA-7;; CADHERIN-RELATED NEURONAL RECEPTOR 4, MOUSE, HOMOLOG OF; CNR4__:__
Asterisk__:__606314__:__PROTOCADHERIN-ALPHA 8; PCDHA8__:__PCDH-ALPHA-8__:__
Asterisk__:__606315__:__PROTOCADHERIN-ALPHA 9; PCDHA9__:__PCDH-ALPHA-9;; KIAA0345__:__
Asterisk__:__606316__:__PROTOCADHERIN-ALPHA 10; PCDHA10__:__PCDH-ALPHA-10;; CADHERIN-RELATED NEURONAL RECEPTOR 8, MOUSE, HOMOLOG OF; CNR8__:__
Asterisk__:__606317__:__PROTOCADHERIN-ALPHA 11; PCDHA11__:__PCDH-ALPHA-11;; CADHERIN-RELATED NEURONAL RECEPTOR 7, MOUSE, HOMOLOG OF; CNR7__:__
Asterisk__:__606318__:__PROTOCADHERIN-ALPHA 12; PCDHA12__:__PCDH-ALPHA-12__:__
Asterisk__:__606319__:__PROTOCADHERIN-ALPHA 13; PCDHA13__:__PCDH-ALPHA-13;; CADHERIN-RELATED NEURONAL RECEPTOR 5, MOUSE, HOMOLOG OF; CNR5__:__
Asterisk__:__606320__:__PROTOCADHERIN-ALPHA, SUBFAMILY C, MEMBER 1; PCDHAC1__:__PCDH-ALPHA-C1__:__
Asterisk__:__606321__:__PROTOCADHERIN-ALPHA, SUBFAMILY C, MEMBER 2; PCDHAC2__:__PCDH-ALPHA-C2__:__
Asterisk__:__606322__:__CYTOPLASMIC FMRP-INTERACTING PROTEIN 1; CYFIP1__:__SPECIFICALLY RAC1-ASSOCIATED PROTEIN 1; SRA1;; KIAA0068__:__
Asterisk__:__606323__:__CYTOPLASMIC FMRP-INTERACTING PROTEIN 2; CYFIP2__:__p53-INDUCIBLE PROTEIN; PIR121__:__
Number Sign__:__606324__:__PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK7__:____:__
Percent__:__606325__:__HETEROTAXY, VISCERAL, 3, AUTOSOMAL; HTX3__:____:__
Asterisk__:__606326__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 6; SIX6__:____:__
Asterisk__:__606327__:__PROTOCADHERIN-BETA 1; PCDHB1__:__PCDH-BETA-1__:__
Asterisk__:__606328__:__PROTOCADHERIN-BETA 2; PCDHB2__:__PCDH-BETA-2__:__
Asterisk__:__606329__:__PROTOCADHERIN-BETA 3; PCDHB3__:__PCDH-BETA-3__:__
Asterisk__:__606330__:__PROTOCADHERIN-BETA 4; PCDHB4__:__PCDH-BETA-4__:__
Asterisk__:__606331__:__PROTOCADHERIN-BETA 5; PCDHB5__:__PCDH-BETA-5__:__
Asterisk__:__606332__:__PROTOCADHERIN-BETA 6; PCDHB6__:__PCDH-BETA-6__:__
Asterisk__:__606333__:__PROTOCADHERIN-BETA 7; PCDHB7__:__PCDH-BETA-7__:__
Asterisk__:__606334__:__PROTOCADHERIN-BETA 8; PCDHB8__:__PCDH-BETA-8__:__
Asterisk__:__606335__:__PROTOCADHERIN-BETA 9; PCDHB9__:__PCDH-BETA-9__:__
Asterisk__:__606336__:__PROTOCADHERIN-BETA 10; PCDHB10__:__PCDH-BETA-10__:__
Asterisk__:__606337__:__PROTOCADHERIN-BETA 11; PCDHB11__:__PCDH-BETA-11__:__
Asterisk__:__606338__:__PROTOCADHERIN-BETA 12; PCDHB12__:__PCDH-BETA-12__:__
Asterisk__:__606339__:__PROTOCADHERIN-BETA 13; PCDHB13__:__PCDH-BETA-13__:__
Asterisk__:__606340__:__PROTOCADHERIN-BETA 14; PCDHB14__:__PCDH-BETA-14__:__
Asterisk__:__606341__:__PROTOCADHERIN-BETA 15; PCDHB15__:__PCDH-BETA-15__:__
Asterisk__:__606342__:__SINE OCULIS HOMEOBOX, DROSOPHILA, HOMOLOG OF, 4; SIX4__:____:__
Asterisk__:__606343__:__POLYMERASE, DNA, LAMBDA; POLL__:____:__
Asterisk__:__606344__:__POLYMERASE, DNA, MU; POLM__:____:__
Asterisk__:__606345__:__PROTOCADHERIN-BETA 16; PCDHB16__:__PCDH-BETA-16;; PCDHB8A;; KIAA1621__:__
Number Sign__:__606346__:__DEAFNESS, AUTOSOMAL DOMINANT 22; DFNA22__:____:__DEAFNESS, AUTOSOMAL DOMINANT 22, WITH HYPERTROPHIC CARDIOMYOPATHY, INCLUDED
Asterisk__:__606347__:__PROLINE/SERINE/THREONINE PHOSPHATASE-INTERACTING PROTEIN 1; PSTPIP1__:__PSTPIP;; CD2 ANTIGEN-BINDING PROTEIN 1; CD2BP1__:__
Percent__:__606348__:__INFLAMMATORY BOWEL DISEASE 5; IBD5__:____:__
NULL__:__606349__:__GAMBLING, PATHOLOGIC__:____:__
Asterisk__:__606350__:__APRATAXIN; APTX__:__FLJ20157__:__
Asterisk__:__606351__:__ESPIN, MOUSE, HOMOLOG OF; ESPN__:____:__
Asterisk__:__606352__:__ALSIN__:__ALS2 GENE;; KIAA1563__:__
Number Sign__:__606353__:__PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ__:__PLS, JUVENILE__:__
Caret__:__606354__:__MOVED TO 605317__:____:__
Asterisk__:__606355__:__DEAD BOX POLYPEPTIDE 18; DDX18__:____:__
Asterisk__:__606356__:__TRANSMEMBRANE PROTEIN 123; TMEM123__:__PRO-ONCOSIS RECEPTOR INDUCING MEMBRANE INJURY; PORIMIN;; KERATINOCYTE-ASSOCIATED TRANSMEMBRANE PROTEIN 3; KCT3__:__
Asterisk__:__606357__:__DEAD/H BOX 21; DDX21__:____:__
Asterisk__:__606358__:__ANTERIOR GRADIENT 2, XENOPUS, HOMOLOG OF; AGR2__:__AG2__:__
Asterisk__:__606359__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 3A; WNT3A__:____:__
Asterisk__:__606360__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 8A; WNT8A__:____:__
Asterisk__:__606361__:__WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5B; WNT5B__:____:__
Asterisk__:__606362__:__ACID PHOSPHATASE, TESTICULAR; ACPT__:__TESTICULAR ACID PHOSPHATASE__:__
Asterisk__:__606363__:__ABI FAMILY MEMBER 3; ABI3__:__NESH PROTEIN; NESH__:__
Caret__:__606364__:__MOVED TO 606658__:____:__
Asterisk__:__606365__:__GLUTAMINASE 2; GLS2__:__GLUTAMINASE, LIVER;; GA__:__
Asterisk__:__606366__:__RAS HOMOLOG GENE FAMILY, MEMBER U; RHOU__:__WNT1-RESPONSIVE CDC42 HOMOLOG; WRCH1__:__
Number Sign__:__606367__:__IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMD41__:__INTERLEUKIN 2 RECEPTOR, ALPHA, DEFICIENCY OF;; IL2RA DEFICIENCY;; CD25 DEFICIENCY__:__
Asterisk__:__606368__:__APOLIPOPROTEIN A-V; APOA5__:__APOAV__:__
NULL__:__606369__:__MACROCEPHALY AND EPILEPTIC ENCEPHALOPATHY__:____:__
Asterisk__:__606370__:__THIAMINE PYROPHOSPHOKINASE; TPK1__:__THIAMINE KINASE__:__
Asterisk__:__606371__:__ACTIVATING TRANSCRIPTION FACTOR 7; ATF7__:__ATFA__:__
Asterisk__:__606372__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 10; CHRNA10__:__ACETYLCHOLINE RECEPTOR, NEURONAL NICOTINIC, ALPHA-10 SUBUNIT__:__
Asterisk__:__606373__:__FORMIN 2; FMN2__:____:__
Asterisk__:__606374__:__BETA-1,3-GLUCURONYLTRANSFERASE 3; B3GAT3__:__GLUCURONOSYLTRANSFERASE I; GLCATI__:__
Caret__:__606375__:__MOVED TO 151290__:____:__
Asterisk__:__606376__:__CARBOHYDRATE SULFOTRANSFERASE 10; CHST10__:__HNK1 SULFOTRANSFERASE; HNK1ST__:__
Asterisk__:__606377__:__DIMERIC DIHYDRODIOL DEHYDROGENASE; DHDH__:__HUM2DD__:__
Asterisk__:__606378__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 4; ST6GALNAC4__:__SIALYLTRANSFERASE 3C; SIAT3C;; NeuAc-ALPHA-2,3-Gal-BETA-1,3-GalNAc-ALPHA-2,6-SIALYLTRANSFERASE IV;; ST6GalNAc IV__:__
Asterisk__:__606379__:__G PROTEIN-COUPLED RECEPTOR 87; GPR87__:__GPR95__:__
Asterisk__:__606380__:__G PROTEIN-COUPLED RECEPTOR 86; GPR86__:__GPR94__:__
Asterisk__:__606381__:__SUCCINATE RECEPTOR 1; SUCNR1__:__G PROTEIN-COUPLED RECEPTOR 91; GPR91__:__
Asterisk__:__606382__:__MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAINS-CONTAINING, 2; MAGI2__:__ATROPHIN 1-INTERACTING PROTEIN 1; AIP1;; SYNAPTIC SCAFFOLDING MOLECULE; SSCAM;; KIAA0705__:__
Asterisk__:__606383__:__G PROTEIN-COUPLED RECEPTOR 84; GPR84__:____:__
Asterisk__:__606384__:__UBIQUITIN PROTEIN LIGASE NEDD4-LIKE; NEDD4L__:__NEDD4-2;; KIAA0439;; RSP5, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__606385__:__OLIGODENDROCYTE LINEAGE TRANSCRIPTION FACTOR 1; OLIG1__:____:__
Asterisk__:__606386__:__OLIGODENDROCYTE LINEAGE TRANSCRIPTION FACTOR 2; OLIG2__:__PROTEIN KINASE C BINDING PROTEIN 2; PRKCBP2;; BASIC HELIX-LOOP-HELIX PROTEIN, CLASS B, 1; BHLHB1__:__
Asterisk__:__606387__:__TOPOISOMERASE I, MITOCHONDRIAL; TOP1MT__:____:__
Asterisk__:__606388__:__THIOESTERASE SUPERFAMILY MEMBER 4; THEM4__:__C-TERMINAL MODULATOR PROTEIN; CTMP__:__
Asterisk__:__606389__:__CATION CHANNEL, SPERM-ASSOCIATED, 1; CATSPER1__:__CATSPER__:__
Caret__:__606390__:__MOVED TO 142560__:____:__
Number Sign__:__606391__:__MATURITY-ONSET DIABETES OF THE YOUNG; MODY__:__MASON-TYPE DIABETES__:__
Number Sign__:__606392__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 4; MODY4__:__MODY, TYPE 4__:__
Asterisk__:__606393__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN-LIKE PROTEIN DECYSIN 1; ADAMDEC1__:__ADAM-LIKE PROTEIN DECYSIN 1;; DECYSIN__:__
Number Sign__:__606394__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 6; MODY6__:__MODY, TYPE 6__:__
Asterisk__:__606395__:__PROLACTIN REGULATORY ELEMENT-BINDING PROTEIN; PREB__:____:__
Asterisk__:__606396__:__BRIDGING INTEGRATOR 3; BIN3__:____:__
Asterisk__:__606397__:__CLARIN 1; CLRN1__:__USH3A GENE; USH3A;; USH3__:__
Asterisk__:__606398__:__ACTIVATING TRANSCRIPTION FACTOR 5; ATF5__:__ATFX__:__
Asterisk__:__606399__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-2/DELTA SUBUNIT 3; CACNA2D3__:____:__
Asterisk__:__606400__:__CALPAIN 7; CAPN7__:__PALB, ASPERGILLUS NIDULANS, HOMOLOG OF; PALBH__:__
Asterisk__:__606401__:__CALPAIN 9; CAPN9__:__NCL4__:__
Asterisk__:__606402__:__GASTROKINE 1; GKN1__:__CA11 GENE;; BRICHOS DOMAIN-CONTAINING 1; BRICD1;; ANTRUM MUCOSA PROTEIN, 18-KD; AMP18;; FOVEOLIN; FOV__:__
Asterisk__:__606403__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-3 SUBUNIT; CACNG3__:____:__
Asterisk__:__606404__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-4 SUBUNIT; CACNG4__:____:__
Asterisk__:__606405__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-5 SUBUNIT; CACNG5__:____:__
Asterisk__:__606406__:__NUCLEAR PORE COMPLEX-INTERACTING PROTEIN; NPIP__:____:__
Number Sign__:__606407__:__HYPOTONIA-CYSTINURIA SYNDROME__:__CYSTINURIA WITH MITOCHONDRIAL DISEASE;; HOMOZYGOUS 2p16 DELETION SYNDROME, FORMERLY__:__HOMOZYGOUS 2p21 DELETION SYNDROME, INCLUDED
Number Sign__:__606408__:__EHLERS-DANLOS SYNDROME, CLASSIC-LIKE; EDSCLL__:__EHLERS-DANLOS SYNDROME DUE TO TENASCIN-X DEFICIENCY;; EDS DUE TO TNX DEFICIENCY;; TNX DEFICIENCY__:__
Asterisk__:__606409__:__ITCHY E3 UBIQUITIN PROTEIN LIGASE, MOUSE, HOMOLOG OF; ITCH__:__ATROPHIN 1-INTERACTING PROTEIN 4; AIP4;; NFE2-ASSOCIATED POLYPEPTIDE 1; NAPP1__:__
Asterisk__:__606410__:__ANTHRAX TOXIN RECEPTOR 1; ANTXR1__:__TUMOR ENDOTHELIAL MARKER 8; TEM8;; ANTHRAX TOXIN RECEPTOR; ATR__:__
Asterisk__:__606411__:__SOLUTE CARRIER FAMILY 13 (SODIUM-DEPENDENT DICARBOXYLATE TRANSPORTER), MEMBER 3; SLC13A3__:__SODIUM-DEPENDENT DICARBOXYLATE TRANSPORTER 3; NADC3__:__
Asterisk__:__606412__:__BSND GENE; BSND__:__BARTTIN__:__
Asterisk__:__606413__:__INSULIN-LIKE 5; INSL5__:____:__
Asterisk__:__606414__:__INSULIN-LIKE 6; INSL6__:__RELAXIN/INSULIN-LIKE FACTOR 1; RIF1__:__
Caret__:__606415__:__MOVED TO 114580__:____:__
Asterisk__:__606416__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 3; NLRP3__:__CIAS1 GENE; CIAS1;; CRYOPYRIN;; NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 3; NALP3;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 1; PYPAF1;; AII/AVP RECEPTOR-LIKE__:__
Asterisk__:__606417__:__WD REPEAT-CONTAINING PROTEIN 11; WDR11__:__WDR15;; KIAA1351;; BROMODOMAIN- AND WD REPEAT-CONTAINING PROTEIN 2, FORMERLY; BRWD2, FORMERLY__:__
Asterisk__:__606418__:__24-DEHYDROCHOLESTEROL REDUCTASE; DHCR24__:__KIAA0018;; SELECTIVE AD INDICATOR 1; SELADIN1;; DESMOSTEROL DELTA-24-REDUCTASE__:__
Asterisk__:__606419__:__PRECURSOR mRNA-PROCESSING FACTOR 31, S. CEREVISIAE, HOMOLOG OF; PRPF31__:__PRP31__:__
Asterisk__:__606420__:__ENGULFMENT AND CELL MOTILITY GENE 1; ELMO1__:__CED12, C. ELEGANS, HOMOLOG OF, 1__:__
Asterisk__:__606421__:__ENGULFMENT AND CELL MOTILITY GENE 2; ELMO2__:__CED12, C. ELEGANS, HOMOLOG OF, 2__:__
Asterisk__:__606422__:__ENGULFMENT AND CELL MOTILITY GENE 3; ELMO3__:__CED12, C. ELEGANS, HOMOLOG OF, 3__:__
Asterisk__:__606423__:__DISRUPTED IN RENAL CARCINOMA 1; DIRC1__:____:__
Asterisk__:__606424__:__EGL9, C. ELEGANS, HOMOLOG OF, 2; EGLN2__:__PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN 1; PHD1;; HYPOXIA-INDUCIBLE FACTOR PROLYL 4-HYDROXYLASE 1; HIFPH1; HIFP4H1;; HIF PROLYL 4-HYDROXYLASE 1__:__
Asterisk__:__606425__:__EGL9, C. ELEGANS, HOMOLOG OF, 1; EGLN1__:__PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN 2; PHD2;; HYPOXIA-INDUCIBLE FACTOR PROLYL 4-HYDROXYLASE 2; HPH2; HIFPH2; HIFP4H2;; HIF PROLYL 4-HYDROXYLASE 2;; CHROMOSOME 1 OPEN READING FRAME 12; C1ORF12;; SM20, RAT, HOMOLOG OF; SM20;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 6; ZMYND6__:__
Asterisk__:__606426__:__EGL9, C. ELEGANS, HOMOLOG OF, 3; EGLN3__:__PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN 3; PHD3;; HYPOXIA-INDUCIBLE FACTOR PROLYL 4-HYDROXYLASE 3; HIFPH3; HIFP4H3;; HIF PROLYL 4-HYDROXYLASE 3__:__
Asterisk__:__606427__:__ZINC FINGER PROTEIN 320; ZNF320__:____:__
Asterisk__:__606428__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A3; UGT1A3__:__UGT1C__:__
Asterisk__:__606429__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A4; UGT1A4__:__UGT1D__:__
Asterisk__:__606430__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A5; UGT1A5__:__UGT1E__:__
Asterisk__:__606431__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A6; UGT1A6__:__UGT1F;; GNT1__:__
Asterisk__:__606432__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A7; UGT1A7__:__UGT1G__:__
Asterisk__:__606433__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A8; UGT1A8__:__UGT1H__:__
Asterisk__:__606434__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A9; UGT1A9__:____:__
Asterisk__:__606435__:__UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A10; UGT1A10__:__UGT1J__:__
Asterisk__:__606436__:__SYNAPTOTAGMIN 12; SYT12__:__SYNAPTOTAGMIN-RELATED GENE 1, RAT, HOMOLOG OF; SRG1__:__
Caret__:__606437__:__MOVED TO 121200__:____:__
Number Sign__:__606438__:__HUNTINGTON DISEASE-LIKE 2; HDL2__:____:__
Asterisk__:__606439__:__ATLASTIN GTPase 1; ATL1__:__ATLASTIN;; SPG3A GENE; SPG3A__:__
Asterisk__:__606440__:__STEREOCILIN; STRC__:____:__
Asterisk__:__606441__:__HTRA SERINE PEPTIDASE 2; HTRA2__:__HTRA, E. COLI, HOMOLOG OF, 2;; PROTEASE, SERINE, 25; PRSS25;; OMI__:__
Asterisk__:__606442__:__ABL INTERACTOR 2; ABI2__:__ABL-INTERACTING PROTEIN 1; AIP1__:__
Asterisk__:__606443__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 3; CREB3__:__LUMAN;; BASIC LEUCINE ZIPPER PROTEIN; LZIP__:__
Asterisk__:__606444__:__CREB/ATF BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CREBZF__:__CREB/ATF bZIP TRANSCRIPTION FACTOR;; ZHANGFEI; ZF__:__
NULL__:__606445__:__PERSISTENT POLYCLONAL B-CELL LYMPHOCYTOSIS; PPBL__:____:__
Asterisk__:__606446__:__SLAM FAMILY, MEMBER 6; SLAMF6__:__NATURAL KILLER-, T-, AND B-CELL ANTIGEN;; NK-, T-, AND B-CELL ANTIGEN; NTBA;; LY108__:__
Asterisk__:__606447__:__RNA-BINDING PROTEIN S1; RNPS1__:____:__
Asterisk__:__606448__:__THIOREDOXIN REDUCTASE 2; TXNRD2__:__TRXR2;; THIOREDOXIN REDUCTASE, MITOCHONDRIAL;; TR-BETA;; TR3;; SELENOPROTEIN Z; SELZ__:__
Asterisk__:__606449__:__PROTEIN-TYROSINE PHOSPHATASE, TYPE 4A, 3; PTP4A3__:__PRL3__:__
Asterisk__:__606450__:__NEUROEPITHELIAL CELL TRANSFORMING GENE 1; NET1__:____:__
Percent__:__606451__:__DEAFNESS, AUTOSOMAL DOMINANT 30; DFNA30__:____:__
Asterisk__:__606452__:__WILDTYPE p53-INDUCED GENE__:__WIG1__:__
Asterisk__:__606453__:__LIPOPOLYSACCHARIDE-RESPONSIVE, BEIGE-LIKE ANCHOR PROTEIN; LRBA__:__LBA;; CELL DIVISION CYCLE 4-LIKE PROTEIN; CDC4L;; CDC4-LIKE PROTEIN__:__
Asterisk__:__606454__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 2; EIF2B2__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, BETA;; EIF2B-BETA__:__
Asterisk__:__606455__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 13B; PPP1R13B__:__APOPTOSIS-STIMULATING PROTEIN OF p53, 1; ASPP1;; KIAA0771__:__
Asterisk__:__606456__:__NUCLEOPHOSMIN/NUCLEOPLASMIN FAMILY, MEMBER 3; NPM3__:____:__
Asterisk__:__606457__:__INHIBITOR OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; IBTK__:____:__
Asterisk__:__606458__:__AXIN1 UPREGULATED; AXUD1__:____:__
Asterisk__:__606459__:__OPIOID GROWTH FACTOR RECEPTOR; OGFR__:____:__
Percent__:__606460__:__LONGEVITY 2__:__LGV2__:__
Asterisk__:__606461__:__TRIMETHYLGUANOSINE SYNTHASE, S. CEREVISIAE, HOMOLOG OF; TGS1__:__PRIP-INTERACTING PROTEIN WITH METHYLTRANSFERASE DOMAIN; PIMT;; NUCLEAR RECEPTOR COACTIVATOR 6; NCOA6IP__:__
Asterisk__:__606462__:__RAD21, S. POMBE, HOMOLOG OF; RAD21__:__NUCLEAR MATRIX PROTEIN 1; NXP1;; SISTER CHROMATID COHESION 1; SCC1;; HR21;; KIAA0078__:__
Asterisk__:__606463__:__GLUCOSIDASE, BETA, ACID; GBA__:__GBA1;; ACID BETA-GLUCOSIDASE;; BETA-GLUCOSIDASE, ACID;; BETA-GC;; GLUCOCEREBROSIDASE;; GLUCOSYLCERAMIDASE__:__GLUCOCEREBROSIDASE PSEUDOGENE, INCLUDED; GBAP, INCLUDED
Asterisk__:__606464__:__HEPCIDIN ANTIMICROBIAL PEPTIDE; HAMP__:__LIVER-EXPRESSED ANTIMICROBIAL PEPTIDE; LEAP1;; HEPCIDIN; HEPC__:__
Asterisk__:__606465__:__KRUPPEL-LIKE FACTOR 15; KLF15__:__KIDNEY-ENRICHED KRUPPEL-LIKE FACTOR; KKLF__:__
Asterisk__:__606466__:__PML-RARA TARGET GENE ENCODING AN ADAPTOR MOLECULE 1; PRAM1__:____:__
Asterisk__:__606467__:__ALDEHYDE DEHYDROGENASE 8 FAMILY, MEMBER A1; ALDH8A1__:__ALDH12__:__
Asterisk__:__606468__:__NUCLEOLAR PROTEIN FAMILY A, MEMBER 1; NOLA1__:__GAR1, S. CEREVISIAE, HOMOLOG OF; GAR1__:__
Asterisk__:__606469__:__RING FINGER PROTEIN 29; RNF29__:__MUSCLE-SPECIFIC RING FINGER PROTEIN 2; MURF2__:__
Asterisk__:__606470__:__NUCLEOLAR PROTEIN FAMILY A, MEMBER 2; NOLA2__:__NHP2, S. CEREVISIAE, HOMOLOG OF; NHP2__:__
Asterisk__:__606471__:__NUCLEOLAR PROTEIN FAMILY A, MEMBER 3; NOLA3__:__NOP10, S. CEREVISIAE, HOMOLOG OF; NOP10__:__
Asterisk__:__606472__:__SS18-LIKE GENE 1; SS18L1__:__KIAA0693;; CALCIUM-RESPONSIVE TRANSACTIVATOR; CREST__:__
Asterisk__:__606473__:__SS18-LIKE GENE 2; SS18L2__:____:__
Asterisk__:__606474__:__RING FINGER PROTEIN 30; RNF30__:__MUSCLE-SPECIFIC RING FINGER PROTEIN 3; MURF3__:__
Asterisk__:__606475__:__CD320 ANTIGEN; CD320__:__8D6 ANTIGEN; 8D6; 8D6A;; TRANSCOBALAMIN RECEPTOR; TCBLR__:__
Asterisk__:__606476__:__INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE C; ITPKC__:____:__
Asterisk__:__606477__:__SERINE RACEMASE; SRR__:____:__
Asterisk__:__606478__:__PROTECTION OF TELOMERES 1; POT1__:____:__
Asterisk__:__606479__:__NEUROLIGIN 2; NLGN2__:__NL2;; KIAA1366__:__
Asterisk__:__606480__:__ZINC METALLOPROTEINASE STE24; ZMPSTE24__:__STE24, S. CEREVISIAE, HOMOLOG OF;; FACE1__:__
Asterisk__:__606481__:__PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE, A; PIB5PA__:__PROLINE-RICH INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; PIPP;; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE__:__
Number Sign__:__606482__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B; CMTDIB__:__CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE B;; DI-CMTB;; CMTDI1__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2M, INCLUDED; CMT2M, INCLUDED;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2M, INCLUDED;; CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2M, INCLUDED;; CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA, INCLUDED;; CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE B, WITH NEUTROPENIA, INCLUDED
Percent__:__606483__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE A; CMTDIA__:__CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE A;; DI-CMTA__:__
Asterisk__:__606484__:__MYOTROPHIN; MTPN__:__V-1__:__
Asterisk__:__606485__:__POLYMERASE II, RNA, SUBUNIT M; POLR2M__:__GRINL1A COMPLEX LOCUS DOWNSTREAM GENE; GDOWN;; GCOM1 DOWNSTREAM GENE;; GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL D-ASPARTATE-LIKE 1A; GRINL1A__:__GRINL1A COMPLEX LOCUS DOWNSTREAM TRANSCRIPT 1, INCLUDED; GDOWN1, INCLUDED
Asterisk__:__606486__:__CHMP FAMILY, MEMBER 1B; CHMP1B__:__CHROMATIN-MODIFYING PROTEIN 1B;; CHARGED MULTIVESICULAR BODY PROTEIN 1B;; CHROMOSOME 18 OPEN READING FRAME 2; C18ORF2__:__
Asterisk__:__606487__:__HRAS-LIKE SUPPRESSOR; HRASLS__:____:__
Asterisk__:__606488__:__EXOSOME COMPONENT 7; EXOSC7__:__RIBOSOMAL RNA-PROCESSING PROTEIN 42, S. CEREVISIAE, HOMOLOG OF; RRP42;; KIAA0116__:__
Asterisk__:__606489__:__EXOSOME COMPONENT 3; EXOSC3__:__RIBOSOMAL RNA-PROCESSING PROTEIN 40, S. CEREVISIAE, HOMOLOG OF; RRP40__:__
Asterisk__:__606490__:__EXOSOME COMPONENT 6; EXOSC6__:__mRNA TRANSPORT REGULATOR 3, S. CEREVISIAE, HOMOLOG OF; MTR3__:__
Asterisk__:__606491__:__EXOSOME COMPONENT 4; EXOSC4__:__RIBOSOMAL RNA-PROCESSING PROTEIN 41, S. CEREVISIAE, HOMOLOG OF; RRP41__:__
Asterisk__:__606492__:__EXOSOME COMPONENT 5; EXOSC5__:__RIBOSOMAL RNA-PROCESSING PROTEIN 46, S. CEREVISIAE, HOMOLOG OF; RRP46__:__
Asterisk__:__606493__:__EXOSOME COMPONENT 1; EXOSC1__:__CSL4, S. CEREVISIAE, HOMOLOG OF; CSL4__:__
Asterisk__:__606494__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 3; ST3GAL3__:__SIALYLTRANSFERASE 6; SIAT6;; N-ACETYLLACTOSAMINIDE ALPHA-2,3-SIALYLTRANSFERASE;; ALPHA-2,3-SIALYLTRANSFERASE II; ST3GALII;; ST3N__:__
Asterisk__:__606495__:__MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4; MARK4__:__MAP/MICROTUBULE AFFINITY-REGULATING KINASE-LIKE 1; MARKL1;; KIAA1860__:__
Asterisk__:__606496__:__INTERLEUKIN 17F; IL17F__:__ML1__:__
Asterisk__:__606497__:__URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B28; UGT2B28__:____:__
Asterisk__:__606498__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 3; MS4A3__:__HEMATOPOIETIC CELL 4-TRANSMEMBRANE PROTEIN; HTM4;; CD20 ANTIGEN-LIKE; CD20L__:__
Asterisk__:__606499__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 5; MS4A5__:__TESTIS-EXPRESSED TRANSMEMBRANE 4; TETM4;; CD20 ANTIGEN-LIKE 2; CD20L2__:__
Asterisk__:__606500__:__SECRETOGLOBIN, FAMILY 3A, MEMBER 1; SCGB3A1__:__UTEROGLOBIN-RELATED PROTEIN 2; UGRP2;; HIN1__:__
Asterisk__:__606501__:__MYOTUBULARIN-RELATED PROTEIN 12; MTMR12__:__PHOSPHATIDYLINOSITOL 3-PHOSPHATE 3-PHOSPHATASE ADAPTOR SUBUNIT; 3PAP;; KIAA1682__:__
Asterisk__:__606502__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 7; MS4A7__:__CD20/FCER1B FAMILY MEMBER 4; CFFM4__:__
Asterisk__:__606503__:__SUPPRESSOR OF VARIEGATION 3-9, DROSOPHILA, HOMOLOG OF, 2; SUV39H2__:__SU(VAR)3-9, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__606504__:__CANCER SUSCEPTIBILITY CANDIDATE 3; CASC3__:__MLN51 GENE; MLN51;; BARENTSZ, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__606505__:__PIN2-INTERACTING PROTEIN 1; PINX1__:__TRF1-INTERACTING PROTEIN 1;; LPTS__:__
Caret__:__606506__:__MOVED TO 300927__:____:__
Caret__:__606507__:__MOVED TO 602488__:____:__
Asterisk__:__606508__:__Fc RECEPTOR-LIKE PROTEIN 1; FCRL1__:__FCRH1__:__
Asterisk__:__606509__:__Fc RECEPTOR-LIKE PROTEIN 2; FCRL2__:__FCRH2;; SH2 DOMAIN-CONTAINING PHOSPHATASE ANCHOR PROTEIN 1; SPAP1__:__SH2 DOMAIN-CONTAINING PHOSPHATASE ANCHOR PROTEIN 1A, INCLUDED; SPAP1A, INCLUDED;; SH2 DOMAIN-CONTAINING PHOSPHATASE ANCHOR PROTEIN 1B, INCLUDED; SPAP1B, INCLUDED;; SH2 DOMAIN-CONTAINING PHOSPHATASE ANCHOR PROTEIN 1C, INCLUDED; SPAP1C, INCLUDED
Asterisk__:__606510__:__Fc RECEPTOR-LIKE PROTEIN 3; FCRL3__:__FCRH3__:__
Asterisk__:__606511__:__MAP/MICROTUBULE AFFINITY-REGULATING KINASE 1; MARK1__:__MARK;; KIAA1477__:__
Asterisk__:__606512__:__PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE IN NEURONS 1; PACSIN1__:__KIAA1379__:__
Asterisk__:__606513__:__PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE IN NEURONS 3; PACSIN3__:____:__
Asterisk__:__606514__:__CYTOHESIN 4; CYTH4__:__CYT4;; PLECKSTRIN HOMOLOGY, SEC7, AND COILED-COIL DOMAINS PROTEIN 4; PSCD4;; DJ63G5.1__:__
Asterisk__:__606515__:__RNA, 7SK, SMALL NUCLEAR; RN7SK__:__snRNA, 7SK; 7SK__:__
Asterisk__:__606516__:__MUSCLEBLIND-LIKE SPLICING REGULATOR 1; MBNL1__:__MUSCLEBLIND-LIKE PROTEIN 1;; MUSCLEBLIND-LIKE PROTEIN; MBNL;; MUSCLEBLIND, DROSOPHILA, HOMOLOG OF;; KIAA0428;; CUG TRIPLET REPEAT EXPANSION DOUBLE-STRANDED RNA-BINDING PROTEIN; EXP__:__
Asterisk__:__606517__:__ARYLHYDROCARBON RECEPTOR REPRESSOR; AHRR__:__KIAA1234__:__
Asterisk__:__606518__:__HEPATITIS A VIRUS CELLULAR RECEPTOR 1; HAVCR1__:__HAVCR;; T-CELL IMMUNOGLOBULIN AND MUCIN DOMAINS-CONTAINING PROTEIN 1; TIM1;; KIDNEY INJURY MOLECULE 1; KIM1__:__
NULL__:__606519__:__PHACE ASSOCIATION__:__PHACES ASSOCIATION;; AORTIC ANEURYSM, GIANT CONGENITAL__:__
Asterisk__:__606520__:__MEGAKARYOCYTE AND PLATELET INHIBITORY RECEPTOR G6B; MPIG6B__:__G6B PROTEIN; G6B;; CHROMOSOME 6 OPEN READING FRAME 25; C6ORF25__:__
Asterisk__:__606521__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL THIAMINE PYROPHOSPHATE CARRIER), MEMBER 19; SLC25A19__:__MITOCHONDRIAL UNCOUPLING PROTEIN 1; MUP1;; MITOCHONDRIAL THIAMINE PYROPHOSPHATE CARRIER; TPC;; MITOCHONDRIAL DEOXYNUCLEOTIDE CARRIER, FORMERLY; DNC, FORMERLY__:__
Asterisk__:__606522__:__GROWTH/DIFFERENTIATION FACTOR 3; GDF3__:____:__
Asterisk__:__606523__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 1; SRGAP1__:__SLIT-ROBO GTPase-ACTIVATING PROTEIN, RHO, 1;; SLIT-ROBO GAP1;; KIAA1304;; ARHGAP13__:__
Asterisk__:__606524__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 2; SRGAP2__:__SRGAP2A;; SLIT-ROBO GTPase-ACTIVATING PROTEIN, RHO, 2;; SLIT-ROBO GAP 2;; KIAA0456;; FORMIN-BINDING PROTEIN 2; FNBP2__:__
Asterisk__:__606525__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 3; SRGAP3__:__SLIT-ROBO GAP 3;; MENTAL DISORDER-ASSOCIATED GAP PROTEIN; MEGAP;; WAVE-ASSOCIATED RAC GTPase-ACTIVATING PROTEIN; WRP;; KIAA0411;; ARHGAP14__:__SRGAP3/RAF1 FUSION GENE, INCLUDED
Asterisk__:__606526__:__MELANOPHILIN; MLPH__:__SYNAPTOTAGMIN-LIKE PROTEIN LACKING C2 DOMAINS A; SLAC2A__:__
NULL__:__606527__:__MEGARBANE SYNDROME__:____:__
Number Sign__:__606528__:__HOMOZYGOUS 11p15-p14 DELETION SYNDROME__:__HYPERINSULINISM, INFANTILE, WITH ENTEROPATHY AND DEAFNESS__:__
NULL__:__606529__:__CRANIOSYNOSTOSIS SYNDROME, AUTOSOMAL RECESSIVE__:____:__
Asterisk__:__606530__:__CYTOCHROME P450, SUBFAMILY XXVIIA, POLYPEPTIDE 1; CYP27A1__:__CYP27;; STEROL 27-HYDROXYLASE__:__
Asterisk__:__606531__:__SECRETOGLOBIN, FAMILY 3A, MEMBER 2; SCGB3A2__:__UTEROGLOBIN-RELATED PROTEIN 1; UGRP1__:__
Asterisk__:__606532__:__HORMONALLY UPREGULATED NEU-ASSOCIATED KINASE; HUNK__:____:__
Asterisk__:__606533__:__CHLORIDE INTRACELLULAR CHANNEL 3; CLIC3__:____:__
Asterisk__:__606534__:__CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 43; CYP3A43__:____:__
Asterisk__:__606535__:__MYC-BINDING PROTEIN; MYCBP__:__ASSOCIATE OF MYC; AMY1__:__
Asterisk__:__606536__:__CHLORIDE INTRACELLULAR CHANNEL 4; CLIC4__:__CHLORIDE INTRACELLULAR CHANNEL, MITOCHONDRIAL; MTCLIC__:__
Asterisk__:__606537__:__MYOSIN IB; MYO1B__:____:__
Asterisk__:__606538__:__MYOSIN IC; MYO1C__:__MYOSIN 2, RAT, HOMOLOG OF; MYR2;; NUCLEAR MYOSIN I; NMI__:__
Asterisk__:__606539__:__MYOSIN ID; MYO1D__:__KIAA0727__:__
Asterisk__:__606540__:__MYOSIN VB; MYO5B__:__KIAA1119__:__
Asterisk__:__606541__:__MYOSIN VIIB; MYO7B__:____:__
Asterisk__:__606542__:__HISTONE DEACETYLASE 7A; HDAC7A__:__HDAC7;; DKFZP586J0917__:__
Asterisk__:__606543__:__HISTONE DEACETYLASE 9; HDAC9__:__HISTONE DEACETYLASE 7B; HDAC7B;; MEF2-INTERACTING TRANSCRIPTION REPRESSOR PROTEIN; MITR;; KIAA0744__:__HISTONE DEACETYLASE 9A, INCLUDED; HDAC9A, INCLUDED
Asterisk__:__606544__:__MITOCHONDRIAL ELONGATION FACTOR G2; GFM2__:__ELONGATION FACTOR G2; EFG2;; RIBOSOME-RECYCLING FACTOR 2, MITOCHONDRIAL; MRRF2; RRF2__:__
Number Sign__:__606545__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3; ARCI3__:__COLLODION BABY, SELF-HEALING;; ICHTHYOSIS, LAMELLAR, 5, FORMERLY; LI5, FORMERLY__:__
Asterisk__:__606546__:__HYDATIDIFORM MOLE-ASSOCIATED AND IMPRINTED TRANSCRIPT; HYMAI__:____:__
Asterisk__:__606547__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4A; MS4A4A__:__MS4A4__:__
Asterisk__:__606548__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6A; MS4A6A__:__MS4A6__:__
Asterisk__:__606549__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 8B; MS4A8B__:____:__
Asterisk__:__606550__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 12__:__MS4A12__:__
Asterisk__:__606551__:__LEUCINE ZIPPER, PUTATIVE TUMOR SUPPRESSOR 1; LZTS1__:__F37;; FEZ1, FORMERLY__:__
Percent__:__606552__:__EPISODIC ATAXIA, TYPE 4; EA4__:__PERIODIC VESTIBULOCEREBELLAR ATAXIA; PATX;; ATAXIA, PERIODIC VESTIBULOCEREBELLAR__:__
Asterisk__:__606553__:__SOLUTE CARRIER FAMILY 9, MEMBER 3, REGULATOR 2; SLC9A3R2__:__SRY-INTERACTING PROTEIN 1; SIP1;; SODIUM/HYDROGEN EXCHANGER 3 KINASE A REGULATORY PROTEIN; E3KARP;; NHE3 KINASE A REGULATORY PROTEIN;; SODIUM/HYDROGEN EXCHANGER REGULATORY FACTOR 2; NHERF2;; NHE3 REGULATORY FACTOR 2; NHE3RF2__:__
Percent__:__606554__:__EPISODIC ATAXIA, TYPE 3; EA3__:__ATAXIA, EPISODIC, WITH VERTIGO AND TINNITUS__:__
Asterisk__:__606555__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 9; TRIM9__:__SNAP25-INTERACTING RING FINGER, RAT, HOMOLOG OF; SPRING;; KIAA0282__:__
Asterisk__:__606556__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 14; TRIM14__:__KIAA0129__:__
Asterisk__:__606557__:__B-CELL CLL/LYMPHOMA 11A; BCL11A__:__CTIP1, MOUSE, HOMOLOG OF; CTIP1;; EVI9, MOUSE, HOMOLOG OF; EVI9;; KIAA1809;; FLJ10173__:__
Asterisk__:__606558__:__B-CELL CLL/LYMPHOMA 11B; BCL11B__:__CTIP2, MOUSE, HOMOLOG OF; CTIP2;; RADIATION-INDUCED TUMOR SUPPRESSOR GENE 1; RIT1__:__
Asterisk__:__606559__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 22; TRIM22__:__STIMULATED TRANS-ACTING FACTOR, 50-KD; STAF50__:__
Asterisk__:__606560__:__SPERM-ASSOCIATED ANTIGEN 11; SPAG11__:__BIN1B, RAT, HOMOLOG OF;; HE2;; EP2__:__
Asterisk__:__606561__:__SOLUTE CARRIER FAMILY 36 (PROTON/AMINO ACID SYMPORTER), MEMBER 1; SLC36A1__:__LYSOSOMAL AMINO ACID TRANSPORTER 1; LYAAT1;; PROTON/AMINO ACID TRANSPORTER 1; PAT1__:__
Asterisk__:__606562__:__TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 1; TM6SF1__:____:__
Asterisk__:__606563__:__TRANSMEMBRANE 6 SUPERFAMILY, MEMBER 2; TM6SF2__:__KIAA1926__:__
Asterisk__:__606564__:__PROSTATE TRANSMEMBRANE PROTEIN, ANDROGEN-INDUCED; PMEPA1__:__TRANSMEMBRANE PROSTATE ANDROGEN-INDUCED RNA; TMEPAI__:__
Asterisk__:__606565__:__TRANSMEMBRANE PROTEASE, SERINE 4; TMPRSS4__:____:__
Asterisk__:__606566__:__MYOSIN LIGHT CHAIN KINASE 2; MYLK2__:__MYOSIN LIGHT POLYPEPTIDE KINASE, SKELETAL/CARDIAC;; MLCK, SKELETAL/CARDIAC__:__
Asterisk__:__606567__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 4; TM4SF4__:__INTESTINE AND LIVER TETRASPAN MEMBRANE PROTEIN; ILTMP__:__
Asterisk__:__606568__:__LEUCINE ZIPPER TRANSCRIPTION FACTOR-LIKE 1; LZTFL1__:__BBS17 GENE__:__
Asterisk__:__606569__:__SUPPRESSOR OF ACTIN MUTATIONS 1-LIKE; SACM1L__:__SUPPRESSOR OF ACTIN 1; SAC1;; KIAA0851__:__
Asterisk__:__606570__:__SECRETED FRIZZLED-RELATED PROTEIN 4; SFRP4__:__FRIZZLED-RELATED PROTEIN, HUMAN ENDOMETRIUM; FRPHE__:__
Asterisk__:__606571__:__LOW DENSITY LIPOPROTEIN RECEPTOR CLASS A DOMAIN-CONTAINING PROTEIN 4; LDLRAD4__:__LDLR CLASS A DOMAIN-CONTAINING PROTEIN 4;; CHROMOSOME 18 OPEN READING FRAME 1; C18ORF1__:__
Asterisk__:__606572__:__NADPH OXIDASE 5; NOX5__:____:__
Asterisk__:__606573__:__FYN-RELATED KINASE; FRK__:__RAK;; GTK, MOUSE, HOMOLOG OF; GTK__:__
Number Sign__:__606574__:__ALBINISM, OCULOCUTANEOUS, TYPE IV; OCA4__:__OCULOCUTANEOUS ALBINISM, TYPE IV__:__
Asterisk__:__606575__:__MEMBRANE PROTEIN, PALMITOYLATED 4; MPP4__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 6; DLG6__:__
Asterisk__:__606576__:__TAF3 RNA POLYMERASE II, TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR, 140-KD; TAF3__:__TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 140-KD; TAFII140__:__
Asterisk__:__606577__:__SRC-LIKE ADAPTOR 2; SLA2__:__SLAP2__:__
Asterisk__:__606578__:__AQUAPORIN 10; AQP10__:____:__
Number Sign__:__606579__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1; VAMAS1__:__VITILIGO; VTLG;; SYSTEMIC LUPUS ERYTHEMATOSUS, VITILIGO-RELATED; SLEV1__:__
Asterisk__:__606580__:__OPA3 GENE; OPA3__:____:__
Number Sign__:__606581__:__POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB__:__DRUG ADDICTION, SUSCEPTIBILITY TO__:__
Asterisk__:__606582__:__DELTA-LIKE 1; DLL1__:__DL1;; DELTA, DROSOPHILA, HOMOLOG OF, 1; DELTA1__:__
Asterisk__:__606583__:__PEROXIREDOXIN 5; PRDX5__:__ANTIOXIDANT ENZYME B166; AOEB166__:__
Asterisk__:__606584__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 23; PTPN23__:__HIS-DOMAIN PROTEIN-TYROSINE PHOSPHATASE; HDPTP;; KIAA1471__:__
Asterisk__:__606585__:__ENAMELIN; ENAM__:____:__
Asterisk__:__606586__:__RETINOIC ACID-INDUCED 14; RAI14__:__NOVEL RETINAL PIGMENT EPITHELIAL CELL GENE; NORPEG;; KIAA1334__:__
Asterisk__:__606587__:__PROTEIN-TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 18; PTPN18__:__BRAIN-DERIVED PHOSPHATASE; BDP1__:__
Asterisk__:__606588__:__DNA METHYLTRANSFERASE 3-LIKE PROTEIN; DNMT3L__:__DNA CYTOSINE-5-METHYLTRANSFERASE 3-LIKE PROTEIN__:__
Asterisk__:__606589__:__SORTING NEXIN 13; SNX13__:__RGS DOMAIN- AND PHOX DOMAIN-CONTAINING PROTEIN; RGS-PX1;; KIAA0713__:__
Asterisk__:__606590__:__NUCLEAR PROTEIN LOCALIZATION 4, S. CEREVISIAE, HOMOLOG OF; NPLOC4__:__NPL4, S. CEREVISIAE, HOMOLOG OF;; KIAA1499__:__
Asterisk__:__606591__:__MUS81, S. CEREVISIAE, HOMOLOG OF; MUS81__:__SLX3, YEAST, HOMOLOG OF; SLX3__:__
Asterisk__:__606592__:__VANIN 3; VNN3__:____:__
Number Sign__:__606593__:__LIG4 SYNDROME__:____:__
Asterisk__:__606594__:__SET DOMAIN-CONTAINING PROTEIN 7; SETD7__:__SET7;; SET9;; HISTONE H3-LYSINE 4-SPECIFIC METHYLTRANSFERASE;; H3-K4-HMTase;; KIAA1717__:__
Number Sign__:__606595__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2F; CMT2F__:__CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2F;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2F__:__
Asterisk__:__606596__:__FUKUTIN-RELATED PROTEIN; FKRP__:____:__
Asterisk__:__606597__:__PAIRED BOX GENE 3; PAX3__:__PAIRED DOMAIN GENE HuP2; HUP2__:__PAX3/FKHR FUSION GENE, INCLUDED
Asterisk__:__606598__:__GANGLIOSIDE-INDUCED DIFFERENTIATION-ASSOCIATED PROTEIN 1; GDAP1__:____:__
Asterisk__:__606599__:__THIOREDOXIN-INTERACTING PROTEIN; TXNIP__:__VITAMIN D3-UPREGULATED PROTEIN 1; VDUP1;; THIOREDOXIN-BINDING PROTEIN 2__:__
Asterisk__:__606600__:__RAS PROTEIN-SPECIFIC GUANINE NUCLEOTIDE-RELEASING FACTOR 1; RASGRF1__:__GUANINE NUCLEOTIDE-RELEASING FACTOR, 55-KD; GRF55__:__
Asterisk__:__606601__:__ENDOGENOUS RETROVIRAL SEQUENCE E, 1; ERVE1__:__HERVE1__:__
Asterisk__:__606602__:__BRAIN AND ACUTE LEUKEMIA GENE, CYTOPLASMIC; BAALC__:____:__
Asterisk__:__606603__:__EDAR-ASSOCIATED DEATH DOMAIN; EDARADD__:____:__
Asterisk__:__606604__:__F-BOX ONLY PROTEIN 32; FBXO32__:__MUSCLE ATROPHY F-BOX; MAFBX;; ATROPHY GENE 1; ATROGIN1;; FLJ32424__:__
Asterisk__:__606605__:__ATR-INTERACTING PROTEIN; ATRIP__:____:__
Caret__:__606606__:__MOVED TO 262700__:____:__
Asterisk__:__606607__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 7; PSMA7__:__XAPC7;; PROTEASOME SUBUNIT ALPHA-4__:__
Asterisk__:__606608__:__YES-ASSOCIATED PROTEIN 1, 65-KD; YAP1__:__YAP;; YAP65;; YORKIE, DROSOPHILA, HOMOLOG OF; YKI__:__YAP2, INCLUDED
Asterisk__:__606609__:__3-PRIME REPAIR EXONUCLEASE 1; TREX1__:__DNase III__:__
Asterisk__:__606610__:__NSFL1 COFACTOR; NSFL1C__:__p47__:__
Asterisk__:__606611__:__DEFENSIN, BETA, 103A; DEFB103A__:__DEFB103;; HBD3;; HBP3;; DEFENSIN, BETA, 3, FORMERLY; DEFB3, FORMERLY__:__
Number Sign__:__606612__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT MENTAL RETARDATION), TYPE B, 5; MDDGB5__:__MUSCULAR DYSTROPHY, CONGENITAL, 1C; MDC1C;; MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED__:__
Percent__:__606613__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1; HDLCQ1__:__HDLC1__:__
Asterisk__:__606614__:__RAS PROTEIN-SPECIFIC GUANINE NUCLEOTIDE-RELEASING FACTOR 2; RASGRF2__:____:__
Asterisk__:__606615__:__HYPOXIA-INDUCIBLE FACTOR 1-ALPHA INHIBITOR; HIF1AN__:__HIF1A INHIBITOR;; FACTOR-INHIBITING HIF1A; FIH1__:__
Percent__:__606616__:__DYSLEXIA, SUSCEPTIBILITY TO, 6; DYX6__:____:__
Caret__:__606617__:__MOVED TO 604169__:____:__
Asterisk__:__606618__:__DUAL-SPECIFICITY PHOSPHATASE 14; DUSP14__:__MAP KINASE PHOSPHATASE 6; MKP6__:__
Asterisk__:__606619__:__GLUCOSIDASE, BETA, ACID 3; GBA3__:__BETA-GLUCOSIDASE, CYTOSOLIC; CBGL1;; BETA-GLYCOSIDASE, CYTOSOLIC;; KLOTHO-RELATED PROTEIN; KLRP__:__
Asterisk__:__606620__:__SLAM FAMILY, MEMBER 8; SLAMF8__:__B-LYMPHOCYTE ACTIVATOR, MACROPHAGE-EXPRESSED; BLAME__:__
Asterisk__:__606621__:__INTRAFLAGELLAR TRANSPORT 57, CHLAMYDOMONAS, HOMOLOG OF; IFT57__:__ESTROGEN-RELATED RECEPTOR-BETA-LIKE 1; ESRRBL1;; HIP1 PROTEIN INTERACTOR; HIPPI__:__
Asterisk__:__606622__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A-LIKE PROTEIN 1; SMARCAL1__:__SMARCA-LIKE PROTEIN 1;; HepA-RELATED PROTEIN; HARP__:__
Asterisk__:__606623__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE VI; HSD17B6__:__3-ALPHA-HYDROXYSTEROID EPIMERASE; HSE;; RETINOL DEHYDROGENASE; RODH;; OXIDATIVE 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE__:__
Asterisk__:__606624__:__NEUROGENIN 2; NEUROG2__:__NGN2;; ATOH4__:__
Asterisk__:__606625__:__SLAM FAMILY, MEMBER 7; SLAMF7__:__CD2-LIKE RECEPTOR ACTIVATING CYTOTOXIC CELLS; CRACC;; CS1;; CD319__:__
Asterisk__:__606626__:__DISHEVELLED-ASSOCIATED ACTIVATOR OF MORPHOGENESIS 1; DAAM1__:__KIAA0666__:__
Asterisk__:__606627__:__DISHEVELLED-ASSOCIATED ACTIVATOR OF MORPHOGENESIS 2; DAAM2__:__KIAA0381__:__
Asterisk__:__606628__:__GLYCINE N-METHYLTRANSFERASE; GNMT__:____:__
Asterisk__:__606629__:__PROTEIN REGULATING SYNAPTIC MEMBRANE EXOCYTOSIS 1; RIMS1__:__RAB3A-INTERACTING MOLECULE 1; RIM1;; RIM;; KIAA0340__:__
Asterisk__:__606630__:__PROTEIN REGULATING SYNAPTIC MEMBRANE EXOCYTOSIS 2; RIMS2__:__RAB3A-INTERACTING MOLECULE 2; RIM2;; KIAA0751;; OBOE__:__
Percent__:__606631__:__CAMURATI-ENGELMANN DISEASE, TYPE 2__:__CAEND2__:__
NULL__:__606632__:__ODOR, MALE, WOMEN'S CHOICE OF__:____:__
Asterisk__:__606633__:__TRANSCRIPTION FACTOR Sp7; SP7__:__SPECIFICITY PROTEIN 7;; OSTERIX; OSX__:__
Asterisk__:__606634__:__DERMCIDIN; DCD__:__PROTEOLYSIS-INDUCING FACTOR; PIF;; DIFFUSIBLE SURVIVAL/EVASION PEPTIDE; DSEP;; SURVIVAL-PROMOTING PEPTIDE;; CANCER CACHECTIC FACTOR 1; CCF1__:__
Asterisk__:__606635__:__TRANSMEMBRANE PROTEASE, SERINE 15; TMPRSS15__:__PROTEASE, SERINE, 7; PRSS7;; ENTEROKINASE; ENTK;; PROENTEROKINASE__:__
Asterisk__:__606636__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 1; NLRP1__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 1; NALP1;; DEATH EFFECTOR FILAMENT-FORMING CED4-LIKE APOPTOSIS PROTEIN; DEFCAP;; KIAA0926;; CARD7;; NLRP1A, MOUSE, HOMOLOG OF; NLRP1A__:__DEFCAP-L, INCLUDED;; DEFCAP-S, INCLUDED
Asterisk__:__606637__:__PEPTIDE YY, 2; PYY2__:__SEMINALPLASMIN__:__
Asterisk__:__606638__:__PANCREATIC POLYPEPTIDE 2; PPY2__:____:__
Asterisk__:__606639__:__MITOCHONDRIAL ELONGATION FACTOR G1; GFM1__:__ELONGATION FACTOR G1; EFG; EFG1;; GFM__:__
Percent__:__606640__:__AMYOTROPHIC LATERAL SCLEROSIS 3; ALS3__:____:__
Percent__:__606641__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 1; BMIQ1__:__BODY MASS INDEX; BMI__:__
Caret__:__606642__:__MOVED TO 606641__:____:__
Percent__:__606643__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 2; BMIQ2__:____:__
Asterisk__:__606644__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 8; IGSF8__:__PROSTAGLANDIN REGULATORY-LIKE; PGRL;; CD81 PARTNER 3; CD81P3__:__
Asterisk__:__606645__:__CENTAURIN, DELTA-1; CENTD1__:__ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 2; ARAP2;; KIAA0580__:__
Asterisk__:__606646__:__CENTAURIN, DELTA-2; CENTD2__:__ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 1; ARAP1;; KIAA0782__:__
Asterisk__:__606647__:__CENTAURIN, DELTA-3; CENTD3__:__ARF-GAP, RHO-GAP, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 3; ARAP3__:__
Asterisk__:__606648__:__INTERLEUKIN 22 RECEPTOR, ALPHA-2; IL22RA2__:__INTERLEUKIN 22-BINDING PROTEIN; IL22BP__:__
Asterisk__:__606649__:__HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENHANCER-BINDING PROTEIN 3; HIVEP3__:__ZAS FAMILY, MEMBER 3; ZAS3;; KRC, MOUSE, HOMOLOG OF; KRC;; SCHNURRI, DROSOPHILA, HOMOLOG OF, 3; SHN3__:__
Asterisk__:__606650__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE 3A; GRIN3A__:__NR3A__:__
Asterisk__:__606651__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE 3B; GRIN3B__:__NR3B__:__
Asterisk__:__606652__:__HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HAVCR2__:__T-CELL IMMUNOGLOBULIN AND MUCIN DOMAINS-CONTAINING PROTEIN 3; TIM3__:__
Asterisk__:__606653__:__LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 6; LGR6__:____:__
Asterisk__:__606654__:__RELAXIN/INSULIN-LIKE FAMILY PEPTIDE RECEPTOR 1; RXFP1__:__LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 7; LGR7__:__
Asterisk__:__606655__:__RELAXIN/INSULIN-LIKE FAMILY PEPTIDE RECEPTOR 2; RXFP2__:__LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 8; LGR8;; GREAT;; GPR106__:__
Percent__:__606656__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 2; IBGC2__:____:__
Number Sign__:__606657__:__GLAUCOMA, NORMAL TENSION, SUSCEPTIBILITY TO__:__NTG;; GLAUCOMA, NORMAL PRESSURE, SUSCEPTIBILITY TO; NPG__:__
Number Sign__:__606658__:__SPINOCEREBELLAR ATAXIA 15; SCA15__:__SPINOCEREBELLAR ATAXIA 16, FORMERLY; SCA16, FORMERLY__:__
Asterisk__:__606659__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 8, YEAST, HOMOLOG OF, B; TIMM8B__:__TIM8B;; DEAFNESS/DYSTONIA PEPTIDE 2; DDP2__:__
Percent__:__606660__:__MELANOMA, UVEAL, SUSCEPTIBILITY TO, 1__:__UVM1__:__
Percent__:__606661__:__MELANOMA, UVEAL, SUSCEPTIBILITY TO, 2__:__UVM2__:__
Percent__:__606662__:__WAARDENBURG SYNDROME, TYPE 2C; WS2C__:__WAARDENBURG SYNDROME, TYPE IIC__:__
Asterisk__:__606663__:__LYSYL OXIDASE-LIKE 2; LOXL2__:____:__
Number Sign__:__606664__:__GLYCINE N-METHYLTRANSFERASE DEFICIENCY__:__GNMT DEFICIENCY__:__
Asterisk__:__606665__:__OPSIN 4; OPN4__:__MELANOPSIN__:__
Asterisk__:__606666__:__G PROTEIN-COUPLED RECEPTOR 48; GPR48__:__LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 4; LGR4__:__
Asterisk__:__606667__:__LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 5; LGR5__:__G PROTEIN-COUPLED RECEPTOR 49; GPR49__:__
Percent__:__606668__:__INFLAMMATORY BOWEL DISEASE 8; IBD8__:____:__
Asterisk__:__606669__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 5; FXYD5__:__DYSADHERIN__:__
Asterisk__:__606670__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 11; PPP1R11__:__PROTEIN PHOSPHATASE 1 INHIBITOR 3; IPP3;; TCTEX5, MOUSE, HOMOLOG OF; TCTEX5__:__
Asterisk__:__606671__:__NCK-INTERACTING PROTEIN WITH SH3 DOMAIN; NCKIPSD__:__ALL1-FUSED GENE FROM CHROMOSOME 3p21; AF3P21;; SH3 PROTEIN INTERACTING WITH NCK, 90-KD; SPIN90;; WASP-INTERACTING SH3 PROTEIN; WISH__:__
Asterisk__:__606672__:__GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE; GP1BA__:__GP Ib, ALPHA SUBUNIT;; PLATELET GLYCOPROTEIN Ib, ALPHA POLYPEPTIDE;; CD42B__:__GLYCOCALICIN, INCLUDED
Asterisk__:__606673__:__BETA-UREIDOPROPIONASE; UPB1__:__BUP1;; BETA-ALANINE SYNTHASE__:__
Percent__:__606674__:__INFLAMMATORY BOWEL DISEASE 6; IBD6__:____:__
Percent__:__606675__:__INFLAMMATORY BOWEL DISEASE 4; IBD4__:____:__
Asterisk__:__606676__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 2; TRPV2__:__VANILLOID RECEPTOR-LIKE PROTEIN 1; VRL1__:__
Asterisk__:__606677__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER C; CLEC4C__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 11; CLECSF11;; DENDRITIC CELL LECTIN; DLEC;; BLOOD DENDRITIC CELL ANTIGEN 2; BDCA2;; CLECSF7;; HECL;; CD303 ANTIGEN; CD303__:__
Asterisk__:__606678__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 8; TRPM8__:__TRPP8;; COLD-MENTHOL RECEPTOR 1; CMR1__:__
Asterisk__:__606679__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 5; TRPV5__:__EPITHELIAL CALCIUM CHANNEL 1; ECAC1;; CALCIUM TRANSPORTER 2; CAT2__:__
Asterisk__:__606680__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 6; TRPV6__:__EPITHELIAL CALCIUM CHANNEL 2; ECAC2;; CALCIUM TRANSPORTER 1; CAT1;; CALCIUM TRANSPORTER-LIKE PROTEIN; CATL__:__
Asterisk__:__606681__:__NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 1; NSD1__:__NUCLEAR RECEPTOR-BINDING Su-var, ENHANCER OF ZESTE, AND TRITHORAX DOMAIN PROTEIN 1;; SET DOMAIN PROTEIN 1;; ANDROGEN RECEPTOR-ASSOCIATED COREGULATOR 267; ARA267__:__NSD1/NUP98 FUSION GENE, INCLUDED
Asterisk__:__606682__:__HPS4 GENE; HPS4__:__LIGHT EAR, MOUSE, HOMOLOG OF; LE__:__
Asterisk__:__606683__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 6; FXYD6__:____:__
Asterisk__:__606684__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 7; FXYD7__:____:__
Number Sign__:__606685__:__CARDIOMYOPATHY, DILATED, 1L; CMD1L__:____:__
Asterisk__:__606686__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 1; EIF2B1__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, ALPHA;; EIF2B-ALPHA__:__
Asterisk__:__606687__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 4; EIF2B4__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, DELTA;; EIF2B-DELTA__:__
Number Sign__:__606688__:__SPONGIFORM ENCEPHALOPATHY WITH NEUROPSYCHIATRIC FEATURES__:____:__
Percent__:__606689__:__GLAUCOMA 1, OPEN ANGLE, B; GLC1B__:____:__
Number Sign__:__606690__:__LYMPHANGIOLEIOMYOMATOSIS; LAM__:__LYMPHANGIOMYOMATOSIS__:__
Asterisk__:__606691__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 19; CEACAM19__:__CARCINOEMBRYONIC ANTIGEN-LIKE 1; CEAL1__:__
Asterisk__:__606692__:__TNF RECEPTOR-ASSOCIATED FACTOR 7; TRAF7__:__RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 1; RFWD1__:__
Number Sign__:__606693__:__KUFOR-RAKEB SYNDROME; KRS__:__PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET; PARK9;; PALLIDOPYRAMIDAL DEGENERATION WITH SUPRANUCLEAR UPGAZE PARESIS AND DEMENTIA; KRPPD__:__
Asterisk__:__606694__:__NUCLEOPORIN, 155-KD; NUP155__:__KIAA0791__:__
Asterisk__:__606695__:__OPSIN 3; OPN3__:__PANOPSIN;; ENCEPHALOPSIN; ECPN__:__
Asterisk__:__606696__:__KATANIN, p60 SUBUNIT, A1; KATNA1__:____:__
Asterisk__:__606697__:__ZINC FINGER PROTEIN ZK1__:__ZK1__:__
Asterisk__:__606698__:__SRY-BOX 30__:__SOX30__:__
Asterisk__:__606699__:__HELICASE WITH ZINC FINGER DOMAIN; HELZ__:__KIAA0054;; HUMORF5__:__
Asterisk__:__606700__:__MIDNOLIN, MOUSE, HOMOLOG OF; MIDN__:____:__
Asterisk__:__606701__:__DORSAL ROOT GANGLIA HOMEOBOX; DRGX__:__DRG11, RAT, HOMOLOG OF; DRG11;; PRRXL1, MOUSE, HOMOLOG OF; PRRXL1__:__
Asterisk__:__606702__:__PKHD1 GENE; PKHD1__:__FIBROCYSTIN; FCYT;; POLYDUCTIN;; POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1 GENE__:__
Number Sign__:__606703__:__DYSKINESIA, FAMILIAL, WITH FACIAL MYOKYMIA; FDFM__:____:__
Asterisk__:__606704__:__G PROTEIN-COUPLED RECEPTOR 75; GPR75__:____:__
Number Sign__:__606705__:__DEAFNESS, AUTOSOMAL DOMINANT 36; DFNA36__:____:__
Asterisk__:__606706__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1; TMC1__:__TRANSMEMBRANE COCHLEAR-EXPRESSED GENE 1__:__
Asterisk__:__606707__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 2; TMC2__:__TRANSMEMBRANE COCHLEAR-EXPRESSED GENE 2__:__
Percent__:__606708__:__SPLIT-HAND/FOOT MALFORMATION 5; SHFM5__:____:__
Asterisk__:__606709__:__PROTEASE, SERINE, 12; PRSS12__:__NEUROTRYPSIN;; MOTOPSIN;; BRAIN-SPECIFIC SERINE PROTEASE 3; BSSP3__:__
Asterisk__:__606710__:__LIPOMA HMGIC FUSION PARTNER; LHFP__:____:__LHFP/HMGIC FUSION GENE, INCLUDED
Percent__:__606711__:__SPECIFIC LANGUAGE IMPAIRMENT 1; SLI1__:__SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 16__:__
Percent__:__606712__:__SPECIFIC LANGUAGE IMPAIRMENT 2; SLI2__:__SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 19__:__
Number Sign__:__606713__:__VAN DER WOUDE SYNDROME 2; VWS2__:____:__
Asterisk__:__606714__:__PROLINE-RICH NUCLEAR RECEPTOR COACTIVATOR 1; PNRC1__:__PROLINE-RICH PROTEIN 2; PROL2__:__
Asterisk__:__606715__:__CATION CHANNEL, AMILORIDE-SENSITIVE, NEURONAL, 4; ACCN4__:__ACID-SENSING ION CHANNEL 4; ASIC4;; BRAIN SODIUM CHANNEL 4; BNAC4__:__
Asterisk__:__606716__:__N-ACETYLTRANSFERASE 8; NAT8__:__TSC510;; CAMELLO, XENOPUS, HOMOLOG OF, 1; CML1__:__
Asterisk__:__606717__:__XIAP-ASSOCIATED FACTOR 1; XAF1__:____:__
Asterisk__:__606718__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 2; SLC26A2__:__DTD SULFATE TRANSPORTER; DTDST__:__
Number Sign__:__606719__:__MELANOMA-PANCREATIC CANCER SYNDROME__:__FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA-PANCREATIC CARCINOMA SYNDROME; FAMMMPC__:__
Asterisk__:__606720__:__ENDONUCLEASE, POLY(U)-SPECIFIC; ENDOU__:__PLACENTAL PROTEIN 11; PP11__:__
Number Sign__:__606721__:__PARTIAL LIPODYSTROPHY, CONGENITAL CATARACTS, AND NEURODEGENERATION SYNDROME; LCCNS__:__LIPODYSTROPHY, PARTIAL, WITH CONGENITAL CATARACTS AND NEURODEGENERATION__:__
Asterisk__:__606722__:__NEUROCALCIN, DELTA; NCALD__:____:__
Asterisk__:__606723__:__MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 5; MAPKAPK5__:__MAPKAP KINASE 5; MK5;; p38-REGULATED/ACTIVATED KINASE; PRAK__:__
Asterisk__:__606724__:__MITOGEN-ACTIVATED PROTEIN KINASE-INTERACTING SERINE/THREONINE KINASE 1; MKNK1__:__MAPK-INTERACTING KINASE 1; MNK1__:__
Asterisk__:__606725__:__CLN6 GENE; CLN6__:____:__
Asterisk__:__606726__:__SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 5; SLC12A5__:__POTASSIUM-CHLORIDE COTRANSPORTER 2; KCC2;; KIAA1176__:__
Asterisk__:__606727__:__NK2 HOMEOBOX 3; NKX2-3__:__NK2, DROSOPHILA, HOMOLOG OF, C; NKX2C;; NK2.3, MOUSE, HOMOLOG OF;; CARDIAC-SPECIFIC HOMEOBOX 3; CSX3__:__
Asterisk__:__606728__:__CAVEOLAE-ASSOCIATED PROTEIN 2; CAVIN2__:__SERUM DEPRIVATION RESPONSE PHOSPHATIDYLSERINE-BINDING PROTEIN; SDPR;; SDR__:__
Asterisk__:__606729__:__OXYSTEROL-BINDING PROTEIN 2; OSBP2__:__OSBP-RELATED PROTEIN 4; ORP4;; KIAA1664__:__
Asterisk__:__606730__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 1A; OSBPL1A__:__OSBP-RELATED PROTEIN 1; ORP1;; OSBPL1B__:__
Asterisk__:__606731__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 2; OSBPL2__:__OSBP-RELATED PROTEIN 2; ORP2;; KIAA0772__:__
Asterisk__:__606732__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 3; OSBPL3__:__OSBP-RELATED PROTEIN 3; ORP3;; KIAA0704__:__
Asterisk__:__606733__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 5; OSBPL5__:__OSBP-RELATED PROTEIN 5; ORP5;; KIAA1534;; OBPH1__:__
Asterisk__:__606734__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 6; OSBPL6__:__OSBP-RELATED PROTEIN 6; ORP6__:__
Asterisk__:__606735__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 7; OSBPL7__:__OSBP-RELATED PROTEIN 7; ORP7__:__
Asterisk__:__606736__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 8; OSBPL8__:__OSBP-RELATED PROTEIN 8; ORP8;; KIAA1451__:__
Asterisk__:__606737__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 9; OSBPL9__:__OSBP-RELATED PROTEIN 9; ORP9__:__
Asterisk__:__606738__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 10; OSBPL10__:__OSBP-RELATED PROTEIN 10; ORP10__:__
Asterisk__:__606739__:__OXYSTEROL-BINDING PROTEIN-LIKE PROTEIN 11; OSBPL11__:__OSBP-RELATED PROTEIN 11; ORP11__:__
Asterisk__:__606740__:__ZINC FINGER PROTEIN 180; ZNF180__:____:__
Asterisk__:__606741__:__ZINC FINGER PROTEIN 181; ZNF181__:____:__
Asterisk__:__606742__:__TOLLOID-LIKE 1; TLL1__:__TLL__:__
Asterisk__:__606743__:__TOLLOID-LIKE 2; TLL2__:__KIAA0932__:__
Number Sign__:__606744__:__SECKEL SYNDROME 2; SCKL2__:__SECKEL-TYPE DWARFISM 2;; MICROCEPHALIC PRIMORDIAL DWARFISM 2__:__
Asterisk__:__606745__:__PARTITIONING-DEFECTIVE PROTEIN 3, C. ELEGANS, HOMOLOG OF; PARD3__:__PAR3__:__
Asterisk__:__606746__:__CHROMOSOME 19 OPEN READING FRAME 10; C19ORF10__:__INTERLEUKIN 25; IL25;; STROMA-DERIVED GROWTH FACTOR 20; SF20__:__
Asterisk__:__606747__:__VASCULAR ENDOTHELIAL ZINC FINGER 1; VEZF1__:__ZINC FINGER PROTEIN 161; ZNF161__:__
Asterisk__:__606748__:__COACTOSIN-LIKE PROTEIN 1; COTL1__:__CLP__:__
Asterisk__:__606749__:__TUBULOINTERSTITIAL NEPHRITIS ANTIGEN; TINAG__:____:__TIN1, INCLUDED;; TIN2, INCLUDED
Asterisk__:__606750__:__Z-DNA BINDING PROTEIN 1; ZBP1__:__CHROMOSOME 20 OPEN READING FRAME 183; C20ORF183;; TUMOR STROMA AND ACTIVATED MACROPHAGE PROTEIN DLM1; DLM1;; DNA-DEPENDENT ACTIVATOR OF INTERFERON REGULATORY FACTORS; DAI__:__
Asterisk__:__606751__:__TRANSMEMBRANE PROTEASE, SERINE 5; TMPRSS5__:__SPINAL CORD-ENRICHED TRYPSIN-LIKE PROTEASE; SPINESIN__:__
NULL__:__606752__:__ACUTE HEMORRHAGIC LEUKOENCEPHALITIS__:__AHL__:__
Asterisk__:__606753__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 4; TTC4__:____:__
Asterisk__:__606754__:__SAM DOMAIN- AND HD DOMAIN-CONTAINING PROTEIN 1; SAMHD1__:__DENDRITIC CELL-DERIVED IFNG-INDUCED PROTEIN; DCIP__:__
Asterisk__:__606755__:__PEPTIDYLARGININE DEIMINASE, TYPE III; PADI3__:__PDI3__:__
Asterisk__:__606756__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE VII; HSD17B7__:____:__
Asterisk__:__606757__:__SOLUTE CARRIER FAMILY 4 (SODIUM BICARBONATE COTRANSPORTER), MEMBER 5; SLC4A5__:__SODIUM BICARBONATE COTRANSPORTER 4; NBC4__:__
Asterisk__:__606758__:__DUAL OXIDASE 1; DUOX1__:__THYROID OXIDASE 1; THOX1__:__
Asterisk__:__606759__:__DUAL OXIDASE 2; DUOX2__:__THYROID OXIDASE 2; THOX2__:__
Caret__:__606760__:__MOVED TO 603977__:____:__
Asterisk__:__606761__:__MALONYL-CoA DECARBOXYLASE; MLYCD__:__MCD__:__
Number Sign__:__606762__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6__:__HYPERINSULINISM-HYPERAMMONEMIA SYNDROME__:__
Number Sign__:__606763__:__CILIARY DYSKINESIA, PRIMARY, 2; CILD2__:__CILIARY DYSKINESIA, PRIMARY, 2, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__606764__:__GASTROINTESTINAL STROMAL TUMOR; GIST__:____:__
Asterisk__:__606765__:__THYROID PEROXIDASE; TPO__:__THYROPEROXIDASE__:__
Number Sign__:__606766__:__SPERMATOGENIC FAILURE 3; SPGF3__:____:__
Asterisk__:__606767__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY G, MEMBER 3; KCNG3__:__KV6.3;; KV10.1__:__
Number Sign__:__606768__:__MYOPATHY, DISTAL, WITH ANTERIOR TIBIAL ONSET; DMAT__:____:__
Asterisk__:__606769__:__HELICASE, POLQ-LIKE; HELQ__:__POLQ-LIKE HELICASE;; HEL308__:__
Percent__:__606770__:__ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 2; ADIPQTL2__:__CIRCULATING ADIPONECTIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 5; CAQ5__:__
Percent__:__606771__:__ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 3; ADIPQTL3__:__CIRCULATING ADIPONECTIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 14; CAQ14__:__
Percent__:__606772__:__MENTAL RETARDATION, OBESITY, MANDIBULAR PROGNATHISM, AND EYE AND SKIN ANOMALIES__:__MOMES SYNDROME__:__
NULL__:__606773__:__HEMIFACIAL MYOHYPERPLASIA; HMH__:____:__
Asterisk__:__606774__:__MYOINOSITOL OXYGENASE; MIOX__:__ALDEHYDE REDUCTASE-LIKE 6; ALDRL6;; ALDOSE REDUCTASE-LIKE 6;; ALDR6R__:__
Asterisk__:__606775__:__CHONDROITIN SULFATE PROTEOGLYCAN 5; CSPG5__:__NEUROGLYCAN C; NGC__:__
Asterisk__:__606776__:__TRANSGLUTAMINASE 7; TGM7__:__TRANSGLUTAMINASE Z__:__
Number Sign__:__606777__:__GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1__:__GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER__:__GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED
Asterisk__:__606778__:__SLINGSHOT, DROSOPHILA, HOMOLOG OF, 1; SSH1__:__KIAA1298__:__
Asterisk__:__606779__:__SLINGSHOT, DROSOPHILA, HOMOLOG OF, 2; SSH2__:__KIAA1725__:__
Asterisk__:__606780__:__SLINGSHOT, DROSOPHILA, HOMOLOG OF, 3; SSH3__:____:__
Asterisk__:__606781__:__TRANSKETOLASE; TKT__:__TKT1__:__
Asterisk__:__606782__:__C-TYPE LECTIN DOMAIN FAMILY 1, MEMBER A; CLEC1A__:__C-TYPE LECTIN-LIKE RECEPTOR 1; CLEC1;; MELANIN-SENSING C-TYPE LECTIN RECEPTOR; MELLEC__:__
Asterisk__:__606783__:__C-TYPE LECTIN DOMAIN FAMILY 1, MEMBER B; CLEC1B__:__C-TYPE LECTIN-LIKE RECEPTOR 2; CLEC2__:__
Asterisk__:__606784__:__GLYCOGEN SYNTHASE KINASE 3-ALPHA; GSK3A__:____:__
Number Sign__:__606785__:__CRIGLER-NAJJAR SYNDROME, TYPE II__:__HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2__:__
Asterisk__:__606786__:__CD300C ANTIGEN; CD300C__:__CMRF35 ANTIGEN; CMRF35;; CMRF35A;; CMRF35A1__:__
Percent__:__606787__:__PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 1__:__PAOD1__:__
Percent__:__606788__:__ANOREXIA NERVOSA, SUSCEPTIBILITY TO; ANON__:__AN__:__ANOREXIA NERVOSA, SUSCEPTIBILITY TO, 1, INCLUDED; ANON1, INCLUDED
Percent__:__606789__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 4; HBFQTL4__:____:__
Asterisk__:__606790__:__CD300A ANTIGEN; CD300A__:__CMRF35H ANTIGEN; CMRF35H;; CMRF35H9;; IRP60__:__
Asterisk__:__606791__:__TRANSMEMBRANE PHOSPHOINOSITIDE 3-PHOSPHATASE AND TENSIN HOMOLOG 2; TPTE2__:__TPTE AND PTEN HOMOLOGOUS INOSITOL LIPID PHOSPHATASE; TPIP__:__TPIP-ALPHA, INCLUDED;; TPIP-BETA, INCLUDED
Asterisk__:__606792__:__HISTAMINE RECEPTOR H4; HRH4__:__HH4R__:__
Asterisk__:__606793__:__AMINOPEPTIDASE, PUROMYCIN-SENSITIVE; NPEPPS__:__PSA;; METALLOPROTEASE MP100; MP100__:__
Asterisk__:__606794__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER), MEMBER 10; SLC25A10__:__DICARBOXYLATE ION CARRIER; DIC__:__
Asterisk__:__606795__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER), MEMBER 17; SLC25A17__:__PEROXISOMAL MEMBRANE PROTEIN, 34-KD; PMP34__:__
Asterisk__:__606796__:__SUPPRESSION OF TUMORIGENICITY 13; ST13__:__P48;; HSC70-INTERACTING PROTEIN; HIP__:__
Asterisk__:__606797__:__SUPPRESSION OF TUMORIGENICITY 14; ST14__:__MATRIPTASE;; EPITHIN;; MEMBRANE-TYPE SERINE PROTEASE 1; MTSP1__:__
Number Sign__:__606798__:__BLEPHAROSPASM, BENIGN ESSENTIAL, SUSCEPTIBILITY TO__:____:__
Percent__:__606799__:__STROKE, SUSCEPTIBILITY TO, 1__:__STRK1__:__
Asterisk__:__606800__:__GLUCOSIDASE, ALPHA, ACID; GAA__:__ACID ALPHA-GLUCOSIDASE;; ALPHA-GLUCOSIDASE, ACID;; ALPHA-1,4-GLUCOSIDASE;; ACID MALTASE__:__
Asterisk__:__606801__:__MACROPHAGE ERYTHROBLAST ATTACHER; MAEA__:__ERYTHROBLAST MACROPHAGE PROTEIN; EMP;; GID COMPLEX, SUBUNIT 9; GID9;; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 9, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__606802__:__SPIB TRANSCRIPTION FACTOR; SPIB__:____:__
Asterisk__:__606803__:__ACYL-CoA THIOESTERASE 11; ACOT11__:__THIOESTERASE, ADIPOSE-ASSOCIATED; THEA;; BROWN FAT-INDUCIBLE THIOESTERASE; BFIT;; KIAA0707__:__BFIT1, INCLUDED;; BFIT2, INCLUDED
Asterisk__:__606804__:__GOLGI MEMBRANE PROTEIN 1; GOLM1__:__GOLGI PHOSPHOPROTEIN 2; GOLPH2;; GOLGI PROTEIN, 73-KD; GP73__:__
Asterisk__:__606805__:__GOLGI INTEGRAL MEMBRANE PROTEIN 4; GOLIM4__:__GOLGI PHOSPHOPROTEIN 4; GOLPH4;; GOLGI PHOSPHOPROTEIN, 130-KD; GPP130__:__
Asterisk__:__606806__:__FORMIMINOTRANSFERASE CYCLODEAMINASE; FTCD__:____:__
Asterisk__:__606807__:__INTERLEUKIN 17 RECEPTOR D; IL17RD__:__SEF, ZEBRAFISH, HOMOLOG OF; SEF__:__
Asterisk__:__606808__:__MYOSIN IIIA; MYO3A__:____:__
Asterisk__:__606809__:__ACYL-CoA-BINDING DOMAIN-CONTAINING PROTEIN 3; ACBD3__:__GOLGI COMPLEX-ASSOCIATED PROTEIN 1; GOCAP1;; GOLGI PHOSPHOPROTEIN 1; GOLPH1;; GOLGI COMPLEX-ASSOCIATED PROTEIN, 60-KD; GCP60__:__
Asterisk__:__606810__:__PROLINE DEHYDROGENASE 1; PRODH__:__PRODH1;; PROLINE OXIDASE 1; POX__:__
Asterisk__:__606811__:__ALDEHYDE DEHYDROGENASE, FAMILY 4, SUBFAMILY A, MEMBER 1; ALDH4A1__:__ALDEHYDE DEHYDROGENASE 4; ALDH4;; PYRROLINE-5-CARBOXYLATE DEHYDROGENASE; P5CDH; P5CD__:__
Number Sign__:__606812__:__FUMARASE DEFICIENCY; FMRD__:__FUMARIC ACIDURIA__:__
Asterisk__:__606813__:__SOLUTE CARRIER FAMILY 2i (FACILITATED GLUCOSE TRANSPORTER), MEMBER 6; SLC2A6__:____:__
Asterisk__:__606814__:__PROTEOGLYCAN 3; PRG3__:__PREPRO-MAJOR BASIC PROTEIN HOMOLOG; MBPH__:__
Asterisk__:__606815__:__CBP/P300-INTERACTING TRANSACTIVATOR, WITH GLU/ASP-RICH CARBOXY TERMINAL DOMAIN, 4; CITED4__:__TRANSCRIPTIONAL COACTIVATOR 4__:__
Asterisk__:__606816__:__SID1 TRANSMEMBRANE FAMILY, MEMBER 1; SIDT1__:__SID1, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__606817__:__PRE-T-CELL RECEPTOR, ALPHA-CHAIN PRECURSOR; PTCRA__:__PT-ALPHA__:__
Asterisk__:__606818__:__DIPEPTIDYL PEPTIDASE III; DPP3__:____:__
Asterisk__:__606819__:__DIPEPTIDYL PEPTIDASE VIII; DPP8__:____:__
Asterisk__:__606820__:__GLUTAREDOXIN 2; GLRX2__:__GRX2__:__
Asterisk__:__606821__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 5; COG5__:__GOLGI TRANSPORT COMPLEX 1; GOLTC1;; GOLGI TRANSPORT COMPLEX, 90-KD SUBUNIT; GTC90__:__
Asterisk__:__606822__:__PROTEIN O-MANNOSE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE; POMGNT1__:____:__
Asterisk__:__606823__:__ADHESION G PROTEIN-COUPLED RECEPTOR A2; ADGRA2__:__G PROTEIN-COUPLED RECEPTOR 124; GPR124;; TUMOR ENDOTHELIAL MARKER 5; TEM5;; KIAA1531__:__
Number Sign__:__606824__:__GLUCOSE/GALACTOSE MALABSORPTION; GGM__:__MONOSACCHARIDE MALABSORPTION; GM__:__
Asterisk__:__606825__:__TENSIN 3; TNS3__:__TUMOR ENDOTHELIAL MARKER 6; TEM6__:__
Asterisk__:__606826__:__PLEXIN DOMAIN-CONTAINING PROTEIN 1; PLXDC1__:__TUMOR ENDOTHELIAL MARKER 7; TEM7__:__
Asterisk__:__606827__:__PLEXIN DOMAIN-CONTAINING PROTEIN 2; PLXDC2__:__TUMOR ENDOTHELIAL MARKER 7-RELATED PROTEIN; TEM7R__:__
Asterisk__:__606828__:__N-ACETYLGLUCOSAMINE KINASE; NAGK__:__GlcNAc KINASE; GNK__:__
Asterisk__:__606829__:__FRATAXIN; FXN__:__FRDA GENE;; X25__:__
Asterisk__:__606830__:__ATP/GTP-BINDING PROTEIN 1; AGTPBP1__:__NERVOUS SYSTEM NUCLEAR PROTEIN INDUCED BY AXOTOMY; NNA1;; KIAA1035;; CYTOSOLIC CARBOXYPEPTIDASE 1; CCP1__:__
Asterisk__:__606831__:__NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 4; NLRC4__:__NLR FAMILY, CARD-CONTAINING 4;; CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 12; CARD12;; CARD, LRR, AND NACHT DOMAIN-CONTAINING PROTEIN; CLAN;; ICE PROTEASE-ACTIVATING FACTOR; IPAF__:__
Asterisk__:__606832__:__ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1; ERAP1__:__ADIPOCYTE-DERIVED LEUCINE AMINOPEPTIDASE; ALAP;; AMINOPEPTIDASE REGULATOR OF TNFR1 SHEDDING 1; ARTS1;; PUROMYCIN-INSENSITIVE LEUCYL-SPECIFIC AMINOPEPTIDASE; PILSAP;; ENDOPLASMIC RETICULUM AMINOPEPTIDASE ASSOCIATED WITH ANTIGEN PROCESSING; ERAAP;; KIAA0525__:__
Asterisk__:__606833__:__LYSINE-SPECIFIC METHYLTRANSFERASE 2C; KMT2C__:__MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA 3; MLL3;; KIAA1506__:__
Asterisk__:__606834__:__LYSINE-SPECIFIC METHYLTRANSFERASE 2B; KMT2B__:__MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA 4; MLL4;; MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA 2; MLL2;; TRITHORAX, DROSOPHILA, HOMOLOG OF, 2; TRX2;; KIAA0304__:__
Number Sign__:__606835__:__DIGITAL ARTHROPATHY-BRACHYDACTYLY, FAMILIAL; FDAB__:____:__
Asterisk__:__606836__:__GLUCOSAMINYL (N-ACETYL) TRANSFERASE 3, MUCIN-TYPE; GCNT3__:__BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE 3__:__
Asterisk__:__606837__:__RB1-INDUCIBLE COILED-COIL 1; RB1CC1__:__CC1;; FAK FAMILY KINASE-INTERACTING PROTEIN, 200-KD; FIP200;; KIAA0203__:__
Asterisk__:__606838__:__PYD AND CARD DOMAIN-CONTAINING PROTEIN; PYCARD__:__APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN CONTAINING A CARD; ASC;; TARGET OF METHYLATION-INDUCED SILENCING 1; TMS__:__
Asterisk__:__606839__:__CADHERIN-RELATED FAMILY, MEMBER 5; CDHR5__:__MUCIN AND CADHERIN-LIKE; MUCDHL__:__
Percent__:__606840__:__PARASOMNIA, SLEEP BRUXISM TYPE; PSMNSB__:__FACIOMANDIBULAR MYOCLONUS, NOCTURNAL__:__PARASOMNIA, SLEEPTALKING TYPE, INCLUDED; PSMNST, INCLUDED
Asterisk__:__606841__:__DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN; DEDD__:__DEATH EFFECTOR DOMAIN-CONTAINING DNA-BINDING PROTEIN;; DEATH EFFECTOR DOMAIN-CONTAINING TESTICULAR PROTEIN; DEFT__:__
Percent__:__606842__:__CARDIONEUROMYOPATHY WITH HYALINE MASSES AND NEMALINE RODS__:____:__
Number Sign__:__606843__:__IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 3; HIGM3__:__HYPER-IgM SYNDROME 3__:__
Asterisk__:__606844__:__ALMS1 GENE; ALMS1__:__KIAA0328__:__
Asterisk__:__606845__:__GOLGI-ASSOCIATED PDZ AND COILED-COIL DOMAINS-CONTAINING PROTEIN; GOPC__:__PDZ PROTEIN INTERACTING SPECIFICALLY WITH TC10; PIST;; FUSED IN GLIOBLASTOMA; FIG;; CFTR-ASSOCIATED LIGAND; CAL__:__FIG/ROS1 FUSION GENE, INCLUDED
Asterisk__:__606846__:__SET AND MYND DOMAIN-CONTAINING PROTEIN 1; SMYD1__:__CD8B-OPPOSITE; BOP;; ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 18; ZMYND18__:__
Asterisk__:__606847__:__TCOF1 GENE; TCOF1__:__TREACLE__:__
Asterisk__:__606848__:__NEVER IN MITOSIS GENE A-RELATED KINASE 7; NEK7__:__NIMA-RELATED KINASE 7__:__
Asterisk__:__606849__:__UBIQUITIN-LIKE 5; UBL5__:__HUB1, S. CEREVISIAE, HOMOLOG OF; HUB1__:__
Asterisk__:__606850__:__MIPOL1 GENE; MIPOL1__:____:__
NULL__:__606851__:__CREE MENTAL RETARDATION SYNDROME__:____:__
Percent__:__606852__:__PARKINSON DISEASE 10; PARK10__:__PARKINSON DISEASE, AGE AT ONSET OF; AAOPD__:__
Asterisk__:__606853__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 13-KD, V1 SUBUNIT G, ISOFORM 2; ATP6V1G2__:__ATP6G2__:__
Number Sign__:__606854__:__POLYMICROGYRIA, BILATERAL FRONTOPARIETAL; BFPP__:__CEREBELLAR ATAXIA WITH NEURONAL MIGRATION DEFECT__:__
Asterisk__:__606855__:__RELAXIN 3; RLN3__:__H3;; RXN3__:__
Number Sign__:__606856__:__PANCREATIC CANCER, SUSCEPTIBILITY TO, 1__:__PNCA1__:__
Asterisk__:__606857__:__GLUTAMATE-CYSTEINE LIGASE, CATALYTIC SUBUNIT; GCLC__:__GLCLC;; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE, CATALYTIC SUBUNIT__:__
Caret__:__606858__:__MOVED TO 251200__:____:__
Caret__:__606859__:__MOVED TO 270700__:____:__
Asterisk__:__606860__:__COMPLEMENT COMPONENT 1 INHIBITOR; C1NH__:__C1I; C1INH;; SERPIN PEPTIDASE INHIBITOR, CLADE G, MEMBER 1; SERPING1__:__
Asterisk__:__606861__:__PROSTATE- AND TESTIS-EXPRESSED GENE; PATE__:____:__
Asterisk__:__606862__:__OSTEOCLAST-ASSOCIATED RECEPTOR; OSCAR__:____:__
Asterisk__:__606863__:__THYMOCYTE SELECTION-ASSOCIATED HIGH MOBILITY GROUP BOX; TOX__:__THYMUS HIGH MOBILITY GROUP BOX PROTEIN, MOUSE, HOMOLOG OF;; TOX1;; KIAA0808__:__
Number Sign__:__606864__:__PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA__:__CARNEY-STRATAKIS SYNDROME;; PARAGANGLIOMA AND GASTROINTESTINAL STROMAL TUMOR__:__
Asterisk__:__606865__:__FUCOSYLTRANSFERASE 9; FUT9__:____:__
Asterisk__:__606866__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L49; MRPL49__:__NEXT TO FAU; NOF; NOF1__:__
Asterisk__:__606867__:__GOLGI REASSEMBLY STACKING PROTEIN 1; GORASP1__:__GOLGI PHOSPHOPROTEIN 5; GOLPH5;; GOLGI REASSEMBLY AND STACKING PROTEIN, 65-KD; GRASP65;; GOLGI PERIPHERAL MEMBRANE PROTEIN P65; P65__:__
Asterisk__:__606868__:__HOMEODOMAIN-INTERACTING PROTEIN KINASE 2; HIPK2__:____:__
Asterisk__:__606869__:__HEXOSAMINIDASE A; HEXA__:__BETA-HEXOSAMINIDASE A__:__
Asterisk__:__606870__:__JUNCTIONAL ADHESION MOLECULE 2; JAM2__:__JAM, VASCULAR ENDOTHELIAL; VEJAM;; JAM-B__:__
Asterisk__:__606871__:__JUNCTIONAL ADHESION MOLECULE 3; JAM3__:__JAM-C__:__
Asterisk__:__606872__:__CAS-BR-M MURINE ECTOPIC RETROVIRAL TRANSFORMING SEQUENCE LIKE-1; CBLL1__:__HAKAI, MOUSE, HOMOLOG OF; HAKAI__:__
Asterisk__:__606873__:__HEXOSAMINIDASE B; HEXB__:____:__ENC1, ANTISENSE, INCLUDED; ENC1AS, INCLUDED
Percent__:__606874__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 6; HSCR6__:____:__
Percent__:__606875__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 7; HSCR7__:____:__
Asterisk__:__606876__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, BETA; PITPNB__:____:__
Asterisk__:__606877__:__ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER C; ANP32C__:__PP32R1__:__
Asterisk__:__606878__:__ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER D; ANP32D__:__PP32R2__:__
Asterisk__:__606879__:__PHOSPHOGLYCERATE DEHYDROGENASE; PHGDH__:__3-PHOSPHOGLYCERATE DEHYDROGENASE; 3PGDH__:__
Asterisk__:__606880__:__CASPASE 8-ASSOCIATED PROTEIN 2; CASP8AP2__:__FLICE-ASSOCIATED HUGE PROTEIN; FLASH;; KIAA1315__:__
Asterisk__:__606881__:__FORMIN HOMOLOGY-2 DOMAIN-CONTAINING PROTEIN 1; FHOD1__:__FH1/FH2 DOMAIN-CONTAINING PROTEIN; FHOS__:__
Asterisk__:__606882__:__ATPase, Cu(2+)-TRANSPORTING, BETA POLYPEPTIDE; ATP7B__:____:__
Asterisk__:__606883__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4; IRAK4__:__REN64__:__
Asterisk__:__606884__:__RNA-BINDING MOTIF PROTEIN 5; RBM5__:__LUCA15;; G15__:__
Asterisk__:__606885__:__ACYL-CoA DEHYDROGENASE, SHORT-CHAIN; ACADS__:__SHORT-CHAIN ACYL-CoA DEHYDROGENASE; SCAD;; ACYL-CoA DEHYDROGENASE, C-2 TO C-3 SHORT CHAIN__:__
Asterisk__:__606886__:__RNA-BINDING MOTIF PROTEIN 6; RBM6__:__DEF3__:__
Asterisk__:__606887__:__SULFITE OXIDASE; SUOX__:____:__
Asterisk__:__606888__:__CHOLINERGIC RECEPTOR, NEURONAL NICOTINIC, ALPHA POLYPEPTIDE 6; CHRNA6__:____:__
Number Sign__:__606889__:__ALZHEIMER DISEASE 4__:__AD4;; ALZHEIMER DISEASE, FAMILIAL, 4__:__
Asterisk__:__606890__:__GALACTOSYLCERAMIDASE; GALC__:__GALACTOCEREBROSIDASE__:__
Asterisk__:__606891__:__Fc RECEPTOR-LIKE PROTEIN A; FCRLA__:__Fc RECEPTOR HOMOLOG EXPRESSED IN B CELLS; FREB;; FCRX;; Fc RECEPTOR-LIKE PROTEIN; FCRL;; FCRL1__:__
Asterisk__:__606892__:__SYNTAXIN 12; STX12__:__STX13__:__
Number Sign__:__606893__:__VASCULAR MALFORMATION, PRIMARY INTRAOSSEOUS__:__VASCULAR MALFORMATION OSSEOUS; VMOS;; HEMANGIOMA, INTRAOSSEOUS__:__
NULL__:__606894__:__DUODENOJEJUNAL ATRESIA WITH VOLVULUS, ABSENT DORSAL MESENTERY, AND ABSENT SUPERIOR MESENTERIC ARTERY__:____:__
NULL__:__606895__:__SYMPHALANGISM, DISTAL, WITH MICRODONTIA, DENTAL PULP STONES, AND NARROWED ZYGOMATIC ARCH__:____:__
Percent__:__606896__:__DYSLEXIA, SUSCEPTIBILITY TO, 5; DYX5__:____:__
Asterisk__:__606897__:__LYSOSOMAL TRAFFICKING REGULATOR; LYST__:__CHS1 GENE; CHS1__:__
Asterisk__:__606898__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-6 SUBUNIT; CACNG6__:____:__
Asterisk__:__606899__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-7 SUBUNIT; CACNG7__:____:__
Asterisk__:__606900__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA-8 SUBUNIT; CACNG8__:____:__
Caret__:__606901__:__MOVED TO 604754__:____:__
Asterisk__:__606902__:__PYGOPUS, DROSOPHILA, HOMOLOG OF, 1__:__PYGO1__:__
Asterisk__:__606903__:__PYGOPUS, DROSOPHILA, HOMOLOG OF, 2__:__PYGO2__:__
Caret__:__606904__:__MOVED TO 254770__:____:__
Asterisk__:__606905__:__PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE-DEPENDENT RAC EXCHANGER 1; PREX1__:__KIAA1415__:__
Asterisk__:__606906__:__FTSJ, E. COLI, HOMOLOG OF, 2; FTSJ2__:__FJH1__:__
Asterisk__:__606907__:__APOLIPOPROTEIN M; APOM__:__NG20, MOUSE, HOMOLOG OF__:__
Asterisk__:__606908__:__ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN 2; ARFGAP2__:__ZINC FINGER PROTEIN 289, ID1-REGULATED, FORMERLY; ZNF289, FORMERLY__:__
Asterisk__:__606909__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 4; VAMP4__:____:__
Asterisk__:__606910__:__BCL2-LIKE 10; BCL2L10__:____:__
Asterisk__:__606911__:__SECRETORY CARRIER MEMBRANE PROTEIN 1; SCAMP1__:__SCAMP37, RAT, HOMOLOG OF__:__
Asterisk__:__606912__:__SECRETORY CARRIER MEMBRANE PROTEIN 2; SCAMP2__:____:__
Asterisk__:__606913__:__SECRETORY CARRIER MEMBRANE PROTEIN 3; SCAMP3__:__PROPIN1__:__
Asterisk__:__606914__:__PROTEIN KINASE, cAMP-DEPENDENT CATALYTIC, INHIBITOR BETA; PKIB__:____:__
Asterisk__:__606915__:__G PROTEIN-COUPLED RECEPTOR 63; GPR63__:__PSP24B__:__
Asterisk__:__606916__:__G PROTEIN-COUPLED RECEPTOR 61; GPR61__:__BIOGENIC AMINE RECEPTOR-LIKE GPCR; BALGR__:__
Asterisk__:__606917__:__G PROTEIN-COUPLED RECEPTOR 62; GPR62__:____:__
Asterisk__:__606918__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 5; GOLGA5__:__GOLGIN 84;; RET-FUSED GENE 5; RFG5__:__PTC5 CHIMERIC ONCOGENE, INCLUDED
Asterisk__:__606919__:__CERAMIDE SYNTHASE 1; CERS1__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 1; LASS1;; UPSTREAM OF GDF1; UOG1__:__
Asterisk__:__606920__:__CERAMIDE SYNTHASE 2; CERS2__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 2; LASS2__:__
Asterisk__:__606921__:__G PROTEIN-COUPLED RECEPTOR 78; GPR78__:____:__
Asterisk__:__606922__:__G PROTEIN-COUPLED RECEPTOR 80; GPR80__:__GPR99__:__
Asterisk__:__606923__:__HYDROXYCARBOXYLIC ACID RECEPTOR 1; HCAR1__:__HCA1;; G PROTEIN-COUPLED RECEPTOR 81; GPR81;; T-CELL ACTIVATION G PROTEIN-COUPLED RECEPTOR; TAGPCR__:__
Caret__:__606924__:__MOVED TO 300748__:____:__
Asterisk__:__606925__:__PYROGLUTAMYLATED RF-AMIDE PEPTIDE RECEPTOR; QRFPR__:__G PROTEIN-COUPLED RECEPTOR 103; GPR103;; SP9155;; AQ27__:__
Asterisk__:__606926__:__LYSOPHOSPHATIDIC ACID RECEPTOR 5; LPAR5__:__LPA5;; G PROTEIN-COUPLED RECEPTOR 92; GPR92;; GPR93__:__
Asterisk__:__606927__:__TRACE AMINE-ASSOCIATED RECEPTOR 8; TAAR8__:__TRACE AMINE RECEPTOR 5; TRAR5;; TA5;; G PROTEIN-COUPLED RECEPTOR 102; GPR102__:__
Percent__:__606928__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 3; BMND3__:__BONE MINERAL DENSITY, LOW, SUSCEPTIBILITY TO__:__
Asterisk__:__606929__:__THO COMPLEX, SUBUNIT 3; THOC3__:__TEX1, YEAST, HOMOLOG OF; TEX1__:__
Asterisk__:__606930__:__THO COMPLEX, SUBUNIT 1; THOC1__:__NUCLEAR MATRIX PROTEIN p84;; p84N5;; HPR1, YEAST, HOMOLOG OF; HPR1__:__
Caret__:__606931__:__MOVED TO 601501__:____:__
Asterisk__:__606932__:__VACUOLAR PROTEIN SORTING 29, YEAST, HOMOLOG OF; VPS29__:__RETROMER PROTEIN;; PEP11;; DC7;; DC15__:__
Asterisk__:__606933__:__TYROSINASE; TYR__:____:__
Asterisk__:__606934__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 1; NDUFAF1__:__NADH DEHYDROGENASE 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 1;; NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 1;; COMPLEX I INTERMEDIATE-ASSOCIATED PROTEIN 30; CIA30;; CGI65__:__
Asterisk__:__606935__:__RNA-BINDING MOTIF PROTEIN 17; RBM17__:__SPLICING FACTOR, 45-KD; SPF45__:__
Asterisk__:__606936__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 4; TRPM4__:____:__
Caret__:__606937__:__MOVED TO 251300__:____:__
Asterisk__:__606938__:__UROPORPHYRINOGEN III SYNTHASE; UROS__:__UROIIIS__:__
Asterisk__:__606939__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 56/58-KD, V1 SUBUNIT B, ISOFORM 2; ATP6V1B2__:__ATP6B2;; VACUOLAR PROTON PUMP B ISOFORM 2__:__
Asterisk__:__606940__:__ZINC FINGER HOMEOBOX 4; ZFHX4__:__ZFH4__:__
Asterisk__:__606941__:__ALG9, S. CEREVISIAE, HOMOLOG OF; ALG9__:__DISRUPTED IN BIPOLAR DISORDER 1; DIBD1__:__
Asterisk__:__606942__:__COATOMER PROTEIN COMPLEX, SUBUNIT EPSILON; COPE__:__EPSILON COAT PROTEIN__:__
Number Sign__:__606943__:__USHER SYNDROME, TYPE IG; USH1G__:____:__
Asterisk__:__606944__:__ERBB2 INTERACTING PROTEIN; ERBB2IP__:__DENSIN-180-LIKE PROTEIN; ERBIN__:__
Asterisk__:__606945__:__LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR__:____:__
Asterisk__:__606946__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 2; ANAPC2__:__APC2;; KIAA1406__:__
Asterisk__:__606947__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 4; ANAPC4__:__APC4__:__
Asterisk__:__606948__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 5; ANAPC5__:__APC5__:__
Asterisk__:__606949__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 7; ANAPC7__:__APC7__:__
Asterisk__:__606950__:__THYROTROPIN-RELEASING HORMONE-DEGRADING ECTOENZYME; TRHDE__:__TRH-DEGRADING ECTOENZYME__:__
Asterisk__:__606951__:__INTERFERON-INDUCED HELICASE C DOMAIN-CONTAINING PROTEIN 1; IFIH1__:__MELANOMA DIFFERENTIATION-ASSOCIATED GENE 5; MDA5__:__
Number Sign__:__606952__:__ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B__:__OCULOCUTANEOUS ALBINISM, TYPE IB;; ALBINISM, YELLOW MUTANT TYPE;; YELLOW ALBINISM__:__ALBINISM, OCULOCUTANEOUS, TYPE I, TEMPERATURE-SENSITIVE, INCLUDED;; OCA1-TS, INCLUDED
Asterisk__:__606953__:__UDP-GALACTOSE-4-EPIMERASE; GALE__:__GALACTOSE EPIMERASE__:__
Asterisk__:__606954__:__ZINC FINGER PROTEIN 253; ZNF253__:____:__
Caret__:__606955__:__MOVED TO 194555__:____:__
Asterisk__:__606956__:__ZINC FINGER PROTEIN 256; ZNF256__:____:__
Asterisk__:__606957__:__ZINC FINGER PROTEIN 257; ZNF257__:____:__
Asterisk__:__606958__:__MEMBRANE PROTEIN, PALMITOYLATED 5; MPP5__:__PROTEIN ASSOCIATED WITH LIN7 1, MOUSE, HOMOLOG OF; PALS1__:__
Asterisk__:__606959__:__MEMBRANE PROTEIN, PALMITOYLATED 6; MPP6__:__VELI-ASSOCIATED MAGUK 1; VAM1;; PROTEIN ASSOCIATED WITH LIN7 2, MOUSE, HOMOLOG OF; PALS2__:__
Percent__:__606960__:__INSULINOMA TUMOR SUPPRESSOR GENE LOCUS__:____:__
Asterisk__:__606961__:__WW DOMAIN-BINDING PROTEIN 1; WBP1__:____:__
Asterisk__:__606962__:__WW DOMAIN-BINDING PROTEIN 2; WBP2__:____:__
Percent__:__606963__:__PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; COPD__:____:__PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, SEVERE EARLY-ONSET, INCLUDED;; COPD, SEVERE EARLY-ONSET, INCLUDED;; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, RATE OF DECLINE OF LUNG FUNCTION IN, INCLUDED
Asterisk__:__606964__:__SERINE/THREONINE PROTEIN KINASE 38; STK38__:__NUCLEAR DBF2-RELATED PROTEIN; NDR;; NDR1__:__
Asterisk__:__606965__:__FAS-ACTIVATED SERINE/THREONINE KINASE; FASTK__:__FAST__:__
Number Sign__:__606966__:__NEPHRONOPHTHISIS 4; NPHP4__:__NEPHRONOPHTHISIS 4, JUVENILE__:__
Asterisk__:__606967__:__LECITHIN:CHOLESTEROL ACYLTRANSFERASE; LCAT__:____:__
Asterisk__:__606968__:__EUKARYOTIC ELONGATION FACTOR 2 KINASE; EEF2K__:__CALMODULIN-DEPENDENT PROTEIN KINASE III__:__
Asterisk__:__606969__:__GEM-ASSOCIATED PROTEIN 4; GEMIN4__:____:__
Caret__:__606970__:__MOVED TO 600669__:____:__
Caret__:__606971__:__MOVED TO 607631__:____:__
Percent__:__606972__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 2; EIG2__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 14__:__
Asterisk__:__606973__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 1; COG1__:__LOW DENSITY LIPOPROTEIN RECEPTOR DEFECT B-COMPLEMENTING PROTEIN; LDLB;; KIAA1381__:__
Asterisk__:__606974__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 2; COG2__:__LOW DENSITY LIPOPROTEIN RECEPTOR DEFECT C-COMPLEMENTING PROTEIN; LDLC__:__
Asterisk__:__606975__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 3; COG3__:__SEC34, S. CEREVISIAE, HOMOLOG OF; SEC34__:__
Asterisk__:__606976__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 4; COG4__:__COD1, S. CEREVISIAE, HOMOLOG OF; COD1__:__
Asterisk__:__606977__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 6; COG6__:__KIAA1134;; COD2, S. CEREVISIAE, HOMOLOG OF; COD2__:__
Asterisk__:__606978__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 7; COG7__:____:__
Asterisk__:__606979__:__COMPONENT OF OLIGOMERIC GOLGI COMPLEX 8; COG8__:__DOR1, S. CEREVISIAE, HOMOLOG OF; DOR1__:__
Asterisk__:__606980__:__COENZYME Q8A; COQ8A__:__COQ8, S. CEREVISIAE, HOMOLOG OF; COQ8;; AARF DOMAIN-CONTAINING KINASE 3; ADCK3;; CHAPERONE-ACTIVITY OF BC1 COMPLEX-LIKE; CABC1__:__
Asterisk__:__606981__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-2; GNG2__:__G PROTEIN GAMMA-2 SUBUNIT;; GUANINE NUCLEOTIDE-BINDING PROTEIN G(I)/G(O)__:__
Asterisk__:__606982__:__GERANYLGERANYL DIPHOSPHATE SYNTHASE 1; GGPS1__:__GGPPS; GGPPS1__:__
Asterisk__:__606983__:__DIACYLGLYCEROL O-ACYLTRANSFERASE 2; DGAT2__:__ACYL-CoA:DIACYLGLYCEROL ACYLTRANSFERASE 2__:__
Percent__:__606984__:__HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 2__:__FHHA2__:__
Asterisk__:__606985__:__ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 4; ELP4__:__ELONGATION PROTEIN 4, S. CEREVISIAE, HOMOLOG OF;; PAX6 NEIGHBOR GENE; PAX6NEB__:__CIS-REGULATORY ELEMENT SIMO, INCLUDED; SIMO, INCLUDED
Caret__:__606986__:__MOVED TO 600716__:____:__
Asterisk__:__606987__:__G PROTEIN-COUPLED RECEPTOR KINASE 7; GRK7__:__GPRK7__:__
Asterisk__:__606988__:__CALCINEURIN B HOMOLOGOUS PROTEIN__:__CHP;; CALCIUM-BINDING PROTEIN P22__:__
Asterisk__:__606989__:__MYELOPEROXIDASE; MPO__:____:__
Asterisk__:__606990__:__COATOMER PROTEIN COMPLEX, SUBUNIT BETA-2; COPB2__:__BETA-2 COAT PROTEIN;; BETA-PRIME COP__:__
Asterisk__:__606991__:__INOSITOL HEXAPHOSPHATE KINASE 1; IHPK1__:__IP6K1;; KIAA0263__:__
Asterisk__:__606992__:__INOSITOL HEXAPHOSPHATE KINASE 2; IHPK2__:__IP6K2__:__
Asterisk__:__606993__:__INOSITOL HEXAPHOSPHATE KINASE 3; IHPK3__:__INSP6K3; IP6K3__:__
Asterisk__:__606994__:__TYROSINE KINASE, NONRECEPTOR, 2; TNK2__:__ACTIVATED p21CDC42 KINASE; ACK; ACK1__:__
Percent__:__606995__:__SENIOR-LOKEN SYNDROME 3; SLSN3__:____:__
Number Sign__:__606996__:__SENIOR-LOKEN SYNDROME 4; SLSN4__:____:__
Asterisk__:__606997__:__C1D NUCLEAR RECEPTOR COREPRESSOR; C1D__:__NUCLEAR DNA-BINDING PROTEIN C1D;; SMALL UNIQUE NUCLEAR RECEPTOR COREPRESSOR; SUNCOR__:__
Asterisk__:__606998__:__FLOTILLIN 1; FLOT1__:____:__
Asterisk__:__606999__:__GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; GALT__:____:__GALT/IL11RA SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__607000__:__MEDIATOR COMPLEX SUBUNIT 24; MED24__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 4; THRAP4;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 100-KD; TRAP100;; KIAA0130__:__
Asterisk__:__607001__:__EUCHROMATIC HISTONE METHYLTRANSFERASE 1; EHMT1__:__EUHMTASE1;; G9A-LIKE PROTEIN; GLP__:__
Asterisk__:__607002__:__PROKINETICIN 2; PROK2__:__PK2;; BV8__:__
Asterisk__:__607003__:__THYMIC STROMAL LYMPHOPOIETIN; TSLP__:____:__
Percent__:__607004__:__BRACHYDACTYLY, TYPE A1, B; BDA1B__:____:__
Asterisk__:__607005__:__GEM-ASSOCIATED PROTEIN 5__:__GEMIN5__:__
Asterisk__:__607006__:__GEM-ASSOCIATED PROTEIN 6; GEMIN6__:____:__
Asterisk__:__607007__:__SNAP-ASSOCIATED PROTEIN; SNAPIN__:__SNARE-ASSOCIATED PROTEIN SNAPIN; SNAPAP;; BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 7; BLOC1S7;; BLOC1, SUBUNIT 7; BLOS7__:__
Asterisk__:__607008__:__ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN; ACADM__:__MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE; MCAD; MCADH__:__
Asterisk__:__607009__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 6; TRPM6__:__CHANNEL KINASE 2; CHAK2;; MELASTATIN-RELATED TRP CATION CHANNEL 6__:__
Asterisk__:__607010__:__DECAPPING ENZYME 1, S. CEREVISIAE, HOMOLOG OF, A; DCP1A__:__DCP1, S. CEREVISIAE, HOMOLOG OF, A;; SMAD4-INTERACTING TRANSCRIPTION FACTOR; SMIF__:__
Asterisk__:__607011__:__UBIQUITIN-SPECIFIC PROTEASE 17; USP17__:____:__
Asterisk__:__607012__:__B-DOUBLE PRIME 1, SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR IIIB; BDP1__:__TRANSCRIPTION FACTOR-LIKE NUCLEAR REGULATOR; TFNR;; KIAA1689__:__
Asterisk__:__607013__:__BRF2 SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR; BRF2__:__BRFU;; TRANSCRIPTION FACTOR IIB-RELATED FACTOR; TFIIIB50__:__
Number Sign__:__607014__:__HURLER SYNDROME__:__MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H__:__
Number Sign__:__607015__:__HURLER-SCHEIE SYNDROME__:__MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS__:__
Number Sign__:__607016__:__SCHEIE SYNDROME__:__MUCOPOLYSACCHARIDOSIS TYPE IS; MPS1-S;; MUCOPOLYSACCHARIDOSIS TYPE V, FORMERLY;; MPS V, FORMERLY; MPS5, FORMERLY__:__
Percent__:__607017__:__DEAFNESS, AUTOSOMAL DOMINANT 21; DFNA21__:____:__
Asterisk__:__607018__:__ADHESION G PROTEIN-COUPLED RECEPTOR L2; ADGRL2__:__LATROPHILIN 2; LPHN2;; LATROPHILIN HOMOLOG 1; LPHH1;; CALCIUM-INDEPENDENT ALPHA-LATROTOXIN RECEPTOR 2; CIRL2; CL2;; LECTOMEDIN 1;; KIAA0786__:__
Asterisk__:__607019__:__RAS ASSOCIATION DOMAIN FAMILY PROTEIN 3; RASSF3__:____:__
Asterisk__:__607020__:__RAS ASSOCIATION DOMAIN FAMILY PROTEIN 5; RASSF5__:__NORE1, MOUSE, HOMOLOG OF; NORE1__:__REGULATOR FOR CELL ADHESION AND POLARIZATION ENRICHED IN LYMPHOID TISSUE, INCLUDED; RAPL, INCLUDED
Asterisk__:__607021__:__SEZ6-LIKE PROTEIN; SEZ6L__:__SEZ6L1;; BRAIN-SPECIFIC RECEPTOR-LIKE PROTEIN B; BSRPB__:__
Asterisk__:__607022__:__CCCTC-BINDING FACTOR-LIKE PROTEIN; CTCFL__:__BROTHER OF THE REGULATOR OF IMPRINTED SITES; BORIS__:__
Asterisk__:__607023__:__POLO-LIKE KINASE 2; PLK2__:__SERUM-INDUCIBLE KINASE; SNK__:__
Asterisk__:__607024__:__DEBRANCHING ENZYME 1, S. CEREVISIAE, HOMOLOG OF; DBR1__:____:__
Asterisk__:__607025__:__MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; MELK__:__KIAA0175;; HPK38__:__
Asterisk__:__607026__:__NEURON NAVIGATOR 2; NAV2__:__RETINOIC ACID-INDUCIBLE GENE IN NEUROBLASTOMA 1; RAINB1;; PORE MEMBRANE- AND/OR FILAMENT-INTERACTING-LIKE PROTEIN 2; POMFIL2;; UNC53, C. ELEGANS, HOMOLOG OF, 2; UNC53H2;; KIAA1419__:__
Asterisk__:__607027__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 70-KD, VI SUBUNIT A; ATP6V1A__:__ATP6V1A1;; V-ATPase A SUBUNIT 1;; VACUOLAR PROTON PUMP, ALPHA SUBUNIT 1;; VA68__:__HO68, INCLUDED
Asterisk__:__607028__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 38-KD, V0 SUBUNIT D, ISOFORM 1; ATP6V0D1__:__VACUOLAR PROTON PUMP, V0 SUBUNIT D, ISOFORM 1;; V-ATPase, SUBUNIT D__:__
Asterisk__:__607029__:__VESICLE-ASSOCIATED MEMBRANE PROTEIN 5; VAMP5__:__MYOBREVIN__:__
Asterisk__:__607030__:__GRANCALCIN; GCA__:____:__
Asterisk__:__607031__:__LIPOIC ACID SYNTHASE; LIAS__:____:__
Asterisk__:__607032__:__SMG1, C. ELEGANS, HOMOLOG OF; SMG1__:__PI3-KINASE-RELATED KINASE SMG1;; LAMBDA/IOTA PROTEIN KINASE C-INTERACTING PROTEIN; LIP;; KIAA0421__:__
Asterisk__:__607033__:__TRANSCRIPTION FACTOR B1, MITOCHONDRIAL; TFB1M__:__MITOCHONDRIAL 12S rRNA DIMETHYLASE 1;; DIMETHYLADENOSINE TRANSFERASE 1, MITOCHONDRIAL;; CGI75;; mtTFB1__:__
Caret__:__607034__:__MOVED TO 135700__:____:__
Asterisk__:__607035__:__SUPPRESSOR OF FUSED, DROSOPHILA, HOMOLOG OF; SUFU__:__SUFUH__:__SUFUXL, INCLUDED
Asterisk__:__607036__:__ISOVALERYL-CoA DEHYDROGENASE; IVD__:____:__
Asterisk__:__607037__:__ENOYL-CoA HYDRATASE/3-HYDROXYACYL CoA DEHYDROGENASE; EHHADH__:__L-BIFUNCTIONAL PROTEIN, PEROXISOMAL; LBFP; LBP__:__
Asterisk__:__607038__:__OTOANCORIN; OTOA__:____:__
Number Sign__:__607039__:__DEAFNESS, AUTOSOMAL RECESSIVE 22; DFNB22__:____:__
Asterisk__:__607040__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 11; ABCC11__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 8; MRP8__:__
Asterisk__:__607041__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 12; ABCC12__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 9; MRP9__:__
Asterisk__:__607042__:__CLN3 GENE; CLN3__:__BATTENIN__:__
Asterisk__:__607043__:__TRAF3-INTERACTING PROTEIN 2; TRAF3IP2__:__CHROMOSOME 6 OPEN READING FRAME 5; C6ORF5;; NUCLEAR FACTOR KAPPA-B ACTIVATOR 1; ACT1;; CONNECTION TO I-KAPPA-B KINASE AND STRESS-ACTIVATED PROTEIN KINASE; CIKS;; CHROMOSOME 6 OPEN READING FRAME 4; C6ORF4;; CHROMOSOME 6 OPEN READING FRAME 6; C6ORF6__:__
NULL__:__607044__:__T-BOX 24__:__TBX24__:__
Asterisk__:__607045__:__RHABDOMYOSARCOMA 2-ASSOCIATED TRANSCRIPT; RMST__:__NONCODING RNA IN RHABDOMYOSARCOMA; NCRMS;; NONCODING RNA 54; NCRNA00054__:__
Asterisk__:__607046__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 22, YEAST, HOMOLOG OF; TOMM22__:__TOM22__:__
Asterisk__:__607047__:__ATAXIN 3; ATXN3__:__AT3;; MJD GENE; MJD1;; SCA3 GENE__:__
Asterisk__:__607048__:__START DOMAIN-CONTAINING PROTEIN 3; STARD3__:__METASTATIC LYMPH NODE 64; MLN64__:__
Asterisk__:__607049__:__START DOMAIN-CONTAINING PROTEIN 4; STARD4__:____:__
Asterisk__:__607050__:__START DOMAIN-CONTAINING PROTEIN 5; STARD5__:____:__
Asterisk__:__607051__:__START DOMAIN-CONTAINING PROTEIN 6; STARD6__:____:__
Asterisk__:__607052__:__TUMOR SUPPRESSOR CANDIDATE 2; TUSC2__:__FUS1__:__
Percent__:__607053__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2; HDLCQ2__:____:__
Asterisk__:__607054__:__PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY A, MEMBER 3; PHLDA3__:__TDAG51/IPL HOMOLOG 1; TIH1__:__
Asterisk__:__607055__:__TRANSCRIPTION FACTOR B2, MITOCHONDRIAL; TFB2M__:__MITOCHONDRIAL 12S rRNA DIMETHYLASE 2;; DIMETHYLADENOSINE TRANSFERASE 2, MITOCHONDRIAL;; mtTFB2__:__
Asterisk__:__607056__:__INTERPHOTORECEPTOR MATRIX PROTEOGLYCAN 2; IMPG2__:__SPACRCAN;; IPM200__:__
Asterisk__:__607057__:__UBIQUITIN-SPECIFIC PROTEASE 18; USP18__:__UBIQUITIN-SPECIFIC PROTEASE, 43-KD; UBP43;; INTERFERON-STIMULATED GENE, 43-KD; ISG43__:__
Asterisk__:__607058__:__GAP JUNCTION PROTEIN, DELTA-2; GJD2__:__GAP JUNCTION PROTEIN, 36-KD;; CONNEXIN 36; CX36;; GAP JUNCTION PROTEIN, ALPHA-9, FORMERLY; GJA9, FORMERLY__:__
Asterisk__:__607059__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 4; SLC39A4__:__ZIP4__:__
Number Sign__:__607060__:__PARKINSON DISEASE 8, AUTOSOMAL DOMINANT; PARK8__:____:__
Asterisk__:__607061__:__PROSTAGLANDIN E SYNTHASE 3; PTGES3__:__UNACTIVE PROGESTERONE RECEPTOR, 23-KD; P23;; PROSTAGLANDIN E SYNTHASE, CYTOSOLIC; CPGES__:__
Asterisk__:__607062__:__FK506-BINDING PROTEIN 7; FKBP7__:__FKBP23__:__
Asterisk__:__607063__:__FK506-BINDING PROTEIN 10; FKBP10__:__FKBP65__:__
Asterisk__:__607064__:__PROCOLLAGEN C-ENDOPEPTIDASE ENHANCER 2; PCOLCE2__:____:__
Asterisk__:__607065__:__GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE; QPCT__:__GLUTAMINYL CYCLASE; QC__:__
Asterisk__:__607066__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 3; TRPV3__:__VANILLOID RECEPTOR-LIKE PROTEIN 3; VRL3__:__
Asterisk__:__607067__:__SAITOHIN__:__STH__:__
Asterisk__:__607068__:__CYTOCHROME b561 DOMAIN-CONTAINING PROTEIN 2; CYB561D2__:__101F6__:__
Asterisk__:__607069__:__PL6 GENE__:__PL6__:__
Asterisk__:__607070__:__ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 10; ZMYND10__:__BLU__:__
Asterisk__:__607071__:__HYALURONOGLUCOSAMINIDASE 1; HYAL1__:__HYALURONIDASE 1__:__
Asterisk__:__607072__:__NPR2-LIKE PROTEIN, GATOR1 COMPLEX SUBUNIT; NPRL2__:__NPR2, S. CEREVISIAE, HOMOLOG OF; NPR2;; NPR2L;; TUMOR SUPPRESSOR CANDIDATE 4; TUSC4__:__
Asterisk__:__607073__:__FUS2 GENE__:__FUS2__:__
Asterisk__:__607074__:__PROTEIN KINASE D2; PRKD2__:__PKD2__:__
Asterisk__:__607075__:__PDGFA-ASSOCIATED PROTEIN 1; PDAP1__:__PAP1; PAP__:__
Asterisk__:__607076__:__PROTEASE INHIBITOR 15; PI15__:__P25TI__:__
Asterisk__:__607077__:__PROTEIN KINASE C, NU; PRKCN__:__PKC-NU__:__
Number Sign__:__607078__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 5; EDM5__:__MULTIPLE EPIPHYSEAL DYSPLASIA, MATN3-RELATED;; MICROEPIPHYSEAL DYSPLASIA, BILATERAL HEREDITARY; BHMED__:__
Asterisk__:__607079__:__RHESUS BLOOD GROUP, B GLYCOPROTEIN; RHBG__:____:__
Number Sign__:__607080__:__46,XY GONADAL DYSGENESIS, PARTIAL, WITH MINIFASCICULAR NEUROPATHY__:____:__
Asterisk__:__607081__:__TAP-BINDING PROTEIN-LIKE; TAPBPL__:__TAP-BINDING PROTEIN-RELATED PROTEIN; TAPBPR;; TAPBP-RELATED PROTEIN;; TAPASIN-RELATED PROTEIN__:__
Asterisk__:__607082__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-2/DELTA SUBUNIT 2; CACNA2D2__:__KIAA0558__:__
Asterisk__:__607083__:__NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 3; NSD3__:__WHSC1L1 GENE; WHSC1L1__:__NSD3/NUP98 FUSION GENE, INCLUDED
Number Sign__:__607084__:__DEAFNESS, AUTOSOMAL RECESSIVE 31; DFNB31__:__WHIRLER, MOUSE, HOMOLOG OF__:__
Percent__:__607085__:__MYASTHENIA GRAVIS WITH THYMUS HYPERPLASIA__:__MYAS1__:__
Percent__:__607086__:__AORTIC ANEURYSM, FAMILIAL THORACIC 1; AAT1__:__FAA1;; ANNULOAORTIC ECTASIA;; AORTIC DISSECTION, FAMILIAL;; AORTIC ANEURYSM, FAMILIAL THORACIC;; ANEURYSM, THORACIC AORTIC__:__ERDHEIM CYSTIC MEDIAL NECROSIS OF AORTA, INCLUDED
Percent__:__607087__:__AORTIC ANEURYSM, FAMILIAL THORACIC 2; AAT2__:__FAA2__:__
Percent__:__607088__:__SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 3; DSMA3__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IV; HMN4;; DHMN4;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IV;; HMN IV;; NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE III; HMN3;; DHMN3;; HMN III__:__
Asterisk__:__607089__:__CYCLIN D-TYPE-BINDING PROTEIN 1; CCNDBP1__:__GRAP2 CYCLIN-D-INTERACTING PROTEIN; GCIP__:__
Asterisk__:__607090__:__SYF2, S. CEREVISIAE, HOMOLOG OF; SYF2__:__GCIP-INTERACTING PROTEIN P29; P29__:__
Number Sign__:__607091__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D__:__CDG IId; CDGIId__:__
Asterisk__:__607092__:__SPHINGOSINE KINASE 2; SPHK2__:____:__
Asterisk__:__607093__:__5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; MTHFR__:____:__
Asterisk__:__607094__:__SUPPRESSOR OF CYTOKINE SIGNALING 5; SOCS5__:__CYTOKINE-INDUCIBLE SH2 PROTEIN 6; CIS6;; KIAA0671__:__
Number Sign__:__607095__:__ANAUXETIC DYSPLASIA 1; ANXD1__:__ANAUXETIC DYSPLASIA; ANXD;; SPONDYLOMETAEPIPHYSEAL DYSPLASIA, ANAUXETIC TYPE;; SPONDYLOEPIMETAPHYSEAL DYSPLASIA, ANAUXETIC TYPE;; SPONDYLOMETAEPIPHYSEAL DYSPLASIA, MENGER TYPE__:__
Asterisk__:__607096__:__SOLUTE CARRIER FAMILY 22 (URATE TRANSPORTER), MEMBER 12; SLC22A12__:__ORGANIC ANION TRANSPORTER 4-LIKE; OAT4L;; URATE TRANSPORTER 1; URAT1__:__
Asterisk__:__607097__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION/CATION TRANSPORTER), MEMBER 11__:__SLC22A11;; ORGANIC ANION TRANSPORTER 4; OAT4__:__
Asterisk__:__607098__:__ENOLASE ALPHA, LUNG-SPECIFIC; ENO1B__:__HUMAN LUNG ENOLASE; HLE1__:__
Asterisk__:__607099__:__MBD2-INTERACTING ZINC FINGER PROTEIN; MIZF__:____:__
Asterisk__:__607100__:__NEPHROCYSTIN 1; NPHP1__:__NPH1__:__
Number Sign__:__607101__:__DEAFNESS, AUTOSOMAL RECESSIVE 30; DFNB30__:____:__
Asterisk__:__607102__:__WT1 GENE; WT1__:____:__WT1/EWS FUSION GENE, INCLUDED
Asterisk__:__607103__:__ARGINYLTRANSFERASE 1; ATE1__:____:__
Asterisk__:__607104__:__TANKYRASE 1-BINDING PROTEIN 1; TNKS1BP1__:__TANKYRASE 1-BINDING PROTEIN, 182-KD;; TAB182;; KIAA1741__:__
Asterisk__:__607105__:__NADPH OXIDASE 3; NOX3__:__GP91-3__:__
Asterisk__:__607106__:__MINOR HISTOCOMPATIBILITY 13; HM13__:__HISTOCOMPATIBILITY 13;; SIGNAL PEPTIDE PEPTIDASE; SPP;; INTRAMEMBRANE PROTEASE 1; IMP1__:__
Percent__:__607107__:__NASOPHARYNGEAL CARCINOMA__:__NPCA;; NPC;; NASOPHARYNGEAL CANCER__:__NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 1, INCLUDED; NPCA1, INCLUDED
Asterisk__:__607108__:__PAIRED BOX GENE 6; PAX6__:____:__
Asterisk__:__607109__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3A; APOBEC3A__:__PHORBOLIN 1__:__
Asterisk__:__607110__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3B; APOBEC3B__:__PHORBOLIN 1-RELATED PROTEIN__:__
Asterisk__:__607111__:__SPARTIN; SPART__:__SPG20;; KIAA0610__:__
Asterisk__:__607112__:__F-BOX ONLY PROTEIN 2; FBXO2__:__FBX2;; FBG1;; NEURAL F-BOX PROTEIN, 42-KD, RAT, HOMOLOG OF; NFB42__:__
Asterisk__:__607113__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3G; APOBEC3G__:__PHORBOLIN-LIKE PROTEIN MDS019; MDS019;; CEM15;; dJ494G10.1;; FLJ12740;; bK150C2.7__:__
Asterisk__:__607114__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 33; ADAM33__:____:__
Number Sign__:__607115__:__CINCA SYNDROME; CINCA__:__CHRONIC NEUROLOGIC CUTANEOUS AND ARTICULAR SYNDROME;; MULTISYSTEM INFLAMMATORY DISEASE, NEONATAL-ONSET; NOMID;; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME 3; CAPS3__:__
Percent__:__607116__:__ALZHEIMER DISEASE 8__:__ALZHEIMER DISEASE, FAMILIAL, 8;; AD8__:__
Asterisk__:__607117__:__MCPH1 GENE; MCPH1__:__MICROCEPHALIN;; BRCT-REPEAT INHIBITOR OF TERT EXPRESSION 1; BRIT1__:__
Asterisk__:__607118__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L3; MRPL3__:__MRL3__:__
Asterisk__:__607119__:__DOUBLE RING FINGER PROTEIN__:__DORFIN__:__
Asterisk__:__607120__:__PHOSPHOLIPASE C, BETA-1; PLCB1__:__KIAA0581__:__PLCB1A, INCLUDED;; PLCB1B, INCLUDED
Caret__:__607121__:__MOVED TO 605569__:____:__
Asterisk__:__607122__:__PROKINETICIN RECEPTOR 1; PROKR1__:__PKR1;; G PROTEIN-COUPLED RECEPTOR 73; GPR73__:__
Asterisk__:__607123__:__PROKINETICIN RECEPTOR 2; PROKR2__:__PKR2;; G PROTEIN-COUPLED RECEPTOR 73-LIKE 1; GPR73L1__:__
Asterisk__:__607124__:__PHOSPHOLIPID PHOSPHATASE 1; PLPP1__:__PHOSPHATIDIC ACID PHOSPHATASE TYPE 2A; PPAP2A; PAP2A__:__
Asterisk__:__607125__:__PHOSPHOLIPID PHOSPHATASE 3; PLPP3__:__PHOSPHATIDIC ACID PHOSPHATASE TYPE 2B; PPAP2B; PAP2B__:__
Asterisk__:__607126__:__PHOSPHOLIPID PHOSPHATASE 2; PLPP2__:__PHOSPHATIDIC ACID PHOSPHATASE TYPE 2C; PPAP2C; PAP2C__:__
Asterisk__:__607127__:__ELKS/RAB6-INTERACTING/CAST FAMILY, MEMBER 1; ERC1__:__RAB6-INTERACTING PROTEIN 2; RAB6IP2;; ELKS GENE; ELKS;; KIAA1081__:__ELKS/RET FUSION GENE, INCLUDED
Asterisk__:__607128__:__TRF1-INTERACTING ANKYRIN-RELATED ADP-RIBOSE POLYMERASE 2; TNKS2__:__TANKYRASE 2; TANK2;; TNKL__:__
Asterisk__:__607129__:__MICROTUBULE-ASSOCIATED MONOOXYGENASE, CALPONIN AND LIM DOMAINS-CONTAINING, 1; MICAL1__:__MOLECULE INTERACTING WITH CASL; MICAL;; NEDD9-INTERACTING PROTEIN WITH CALPONIN HOMOLOGY AND LIM DOMAINS; NICAL__:__
Asterisk__:__607130__:__REGULATORY ASSOCIATED PROTEIN OF MTOR; RPTOR__:__RAPTOR;; KIAA1303__:__
Number Sign__:__607131__:__AL-GAZALI-BAKALINOVA SYNDROME; AGBK__:__MACROCEPHALY WITH MULTIPLE EPIPHYSEAL DYSPLASIA AND DISTINCTIVE FACIES; MMEDF__:__
NULL__:__607132__:__LARYNGEAL ATRESIA, ENCEPHALOCELE, AND LIMB DEFORMITIES__:__LEL__:__
Caret__:__607133__:__MOVED TO 601547__:____:__
Percent__:__607134__:__SPECIFIC LANGUAGE IMPAIRMENT 3; SLI3__:__SPECIFIC LANGUAGE IMPAIRMENT QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 13__:__
Percent__:__607135__:__CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS__:__CRCL__:__
Number Sign__:__607136__:__SPINOCEREBELLAR ATAXIA 17; SCA17__:__HUNTINGTON DISEASE-LIKE 4; HDL4__:__
Asterisk__:__607137__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D-LIKE PROTEIN; HNRNPDL__:__HNRPDL;; HNRPD-LIKE PROTEIN;; AU-RICH ELEMENT RNA-BINDING FACTOR;; JKTBP__:__
Asterisk__:__607138__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 4; CREB3L4__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 4; CREB4;; ANDROGEN-INDUCED BASIC LEUCINE ZIPPER PROTEIN; AIBZIP__:__
Asterisk__:__607139__:__FANCA GENE; FANCA__:__FACA; FAA__:__
Number Sign__:__607140__:__ANGIOID STREAKS__:____:__
Asterisk__:__607141__:__GLIOMA PATHOGENESIS-RELATED PROTEIN 2; GLIPR2__:__GOLGI-ASSOCIATED PR1 PROTEIN; GAPR1;; CHROMOSOME 9 OPEN READING FRAME 19; C9ORF19__:__
Caret__:__607142__:__MOVED TO 602617__:____:__
Number Sign__:__607143__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ig; CDG1G__:__CDG Ig; CDGIg__:__
Asterisk__:__607144__:__ALG12, S. CEREVISIAE, HOMOLOG OF; ALG12__:__ASPARAGINE-LINKED GLYCOSYLATION 12, HOMOLOG OF;; DOLICHYL-P-MANNOSE:MAN-7-GlcNAc-2-PP-DOLICHYL-ALPHA-6-MANNOSYLTRANSFERASE__:__
Asterisk__:__607145__:__DYSTROBREVIN-BINDING PROTEIN 1; DTNBP1__:__DYSBINDIN;; SANDY, MOUSE, HOMOLOG OF; SDY;; HPS7 GENE; HPS7;; BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 8; BLOC1S8;; BLOC1, SUBUNIT 8; BLOS8__:__
Asterisk__:__607146__:__PDZ DOMAIN-CONTAINING 3; PDZD3__:__INTESTINE- AND KIDNEY-ENRICHED PDZ PROTEIN; IKEPP__:__
Asterisk__:__607147__:__NECTIN 3; NECTIN3__:__POLIOVIRUS RECEPTOR-LIKE 3; PVRL3;; POLIOVIRUS RECEPTOR-RELATED 3; PVRR3; PRR3__:__
Caret__:__607148__:__MOVED TO 300417__:____:__
Asterisk__:__607149__:__RNA EXONUCLEASE 2, S. CEREVISIAE, HOMOLOG OF; REXO2__:__REX2, S. CEREVISIAE, HOMOLOG OF; REX2;; SMALL FRAGMENT NUCLEASE; SFN__:__
Asterisk__:__607150__:__FIFTH EWING SARCOMA VARIANT; FEV__:__PET1__:__FEV/EWS FUSION GENE, INCLUDED
Number Sign__:__607151__:__MOYAMOYA DISEASE 2; MYMY2__:____:__
Percent__:__607152__:__SPASTIC PARAPLEGIA 19, AUTOSOMAL DOMINANT; SPG19__:____:__
Asterisk__:__607153__:__INTEGRIN, BETA-1, BINDING PROTEIN OF, 1; ITGB1BP1__:__INTEGRIN CYTOPLASMIC DOMAIN-ASSOCIATED PROTEIN 1; ICAP1__:__ICAP1A, INCLUDED;; ICAP1B, INCLUDED
Number Sign__:__607154__:__ALLERGIC RHINITIS__:__ALRH__:__
Number Sign__:__607155__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED__:__
Asterisk__:__607156__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 6; ST3GAL6__:__ALPHA-2,3-SIALYLTRANSFERASE VI; ST3GALVI__:__
Asterisk__:__607157__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 11; SIGLEC11__:____:__
Asterisk__:__607158__:__VENT HOMEOBOX; VENTX__:__VENT-LIKE HOMEOBOX 2; VENTX2;; HPX42B__:__
Asterisk__:__607159__:__ZINC FINGER MIZ-DOMAIN CONTAINING 1; ZMIZ1__:__RETINOIC ACID-INDUCED GENE 17; RAI17;; KIAA1224;; ZIMP10__:__
Asterisk__:__607160__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 14-KD, V1 SUBUNIT F; ATP6V1F__:__VACUOLAR ATPase, 14-KD SUBUNIT__:__
NULL__:__607161__:__MULTIPLE CONGENITAL ANOMALIES SYNDROME WITH CLOVERLEAF SKULL__:____:__
Asterisk__:__607162__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 5; ST8SIA5__:__ALPHA-2,8-SIALYLTRANSFERASE V;; ST8SIA V;; SIALYLTRANSFERASE 8E; SIAT8E__:__
Asterisk__:__607163__:__LYSYL OXIDASE-LIKE 3; LOXL3__:____:__
Asterisk__:__607164__:__LADY BIRD-LIKE HOMEOBOX 2; LBX2__:__LADY BIRD LATE, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__607165__:__SERINE INCORPORATOR 3; SERINC3__:__TUMOR DIFFERENTIALLY EXPRESSED 1; TDE1;; TMS1__:__
Asterisk__:__607166__:__TESTIS-SPECIFIC PROTEIN 10; TSGA10__:____:__
Asterisk__:__607167__:__DYNEIN, LIGHT CHAIN, ROADBLOCK TYPE, 1; DYNLRB1__:__DYNEIN, CYTOPLASMIC, LIGHT CHAIN 2A; DNCL2A; DNLC2A__:__
Asterisk__:__607168__:__DYNEIN, LIGHT CHAIN, ROADBLOCK TYPE, 2; DYNLRB2__:__DYNEIN, LIGHT CHAIN 2B; DNLC2B__:__
Asterisk__:__607169__:__PROTEASE, SERINE, 16; PRSS16__:__THYMUS-SPECIFIC SERINE PROTEASE; TSSP__:__
Asterisk__:__607170__:__CYSTEINE-RICH PROTEIN WITH EGF-LIKE DOMAINS 1; CRELD1__:__CIRRIN__:__
Asterisk__:__607171__:__CYSTEINE-RICH PROTEIN WITH EGF-LIKE DOMAINS 2__:__CRELD2__:__
Asterisk__:__607172__:__SERINE/THREONINE KINASE 11-INTERACTING PROTEIN; STK11IP__:__LKB1-INTERACTING PROTEIN 1; LIP1;; KIAA1898__:__
Asterisk__:__607173__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 14; PSMD14__:__PAD1, YEAST, HOMOLOG OF;; 26S PROTEASOME-ASSOCIATED PAD1 HOMOLOG; POH1__:__
Number Sign__:__607174__:__MENINGIOMA, FAMILIAL, SUSCEPTIBILITY TO__:____:__
Asterisk__:__607175__:__DUAL-SPECIFICITY PHOSPHATASE 16; DUSP16__:__MAP KINASE PHOSPHATASE 7; MKP7;; KIAA1700__:__
Asterisk__:__607176__:__CALNEURON 1; CALN1__:____:__
Asterisk__:__607177__:__IMMEDIATE-EARLY RESPONSE GENE 5; IER5__:____:__
Asterisk__:__607178__:__PDZK1-INTERACTING PROTEIN 1; PDZK1IP1__:__MEMBRANE-ASSOCIATED PROTEIN 17; MAP17;; DD96__:__
Asterisk__:__607179__:__RNA-BINDING MOTIF PROTEIN 12; RBM12__:__KIAA0765__:__
Asterisk__:__607180__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 2; LRRC2__:____:__
Asterisk__:__607181__:__RECEPTOR-TRANSPORTING PROTEIN 3; RTP3__:__TRANSMEMBRANE PROTEIN 7; TMEM7__:__
Asterisk__:__607182__:__FYVE AND COILED-COIL DOMAIN CONTAINING 1; FYCO1__:____:__
Asterisk__:__607183__:__SEC24-RELATED GENE FAMILY, MEMBER A; SEC24A__:____:__
Asterisk__:__607184__:__SEC24-RELATED GENE FAMILY, MEMBER B; SEC24B__:____:__
Asterisk__:__607185__:__SEC24-RELATED GENE FAMILY, MEMBER C; SEC24C__:__KIAA0079__:__
Asterisk__:__607186__:__SEC24-RELATED GENE FAMILY, MEMBER D; SEC24D__:__KIAA0755__:__
Asterisk__:__607187__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 1; ST3GAL1__:__SIALYLTRANSFERASE 4A; SIAT4A;; ST3O__:__
Asterisk__:__607188__:__ST3 BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASE 2; ST3GAL2__:__SIALYLTRANSFERASE 4B; SIAT4B__:__
Asterisk__:__607189__:__REGULATOR OF G PROTEIN SIGNALING 8; RGS8__:____:__
Asterisk__:__607190__:__REGULATOR OF G PROTEIN SIGNALING 13; RGS13__:____:__
Asterisk__:__607191__:__REGULATOR OF G PROTEIN SIGNALING 17; RGS17__:__RGSZ2__:__
Asterisk__:__607192__:__REGULATOR OF G PROTEIN SIGNALING 18; RGS18__:____:__
Asterisk__:__607193__:__REGULATOR OF G PROTEIN SIGNALING 20; RGS20__:____:__RGSZ1 ISOFORM, INCLUDED;; RET-RGS ISOFORM, INCLUDED
Asterisk__:__607194__:__PANCREAS TRANSCRIPTION FACTOR 1, ALPHA SUBUNIT; PTF1A__:__PTF1-p48__:__
Caret__:__607195__:__MOVED TO 128230__:____:__
Number Sign__:__607196__:__MICROCEPHALY, AMISH TYPE; MCPHA__:__AMISH LETHAL MICROCEPHALY;; THIAMINE METABOLISM DYSFUNCTION SYNDROME 3 (MICROCEPHALY TYPE); THMD3__:__
NULL__:__607197__:__DEAFNESS, AUTOSOMAL RECESSIVE__:____:__
Asterisk__:__607198__:__TYROSYL-DNA PHOSPHODIESTERASE 1; TDP1__:____:__
Asterisk__:__607199__:__INTERFERON REGULATORY FACTOR 6; IRF6__:____:__
Number Sign__:__607200__:__THYROID DYSHORMONOGENESIS 6; TDH6__:__THYROID HORMONOGENESIS, GENETIC DEFECT IN, 6;; HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 6__:__
Asterisk__:__607201__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN R; HNRNPR__:__HNRPR__:__
Percent__:__607202__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 5; CELIAC5__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 5;; GSES__:__
Asterisk__:__607203__:__SALVADOR, DROSOPHILA, HOMOLOG OF; SAV1__:__SAV;; WW DOMAIN-CONTAINING PROTEIN, 45-KD; WW45__:__
Asterisk__:__607204__:__PUMILIO, DROSOPHILA, HOMOLOG OF, 1; PUM1__:__KIAA0099__:__
Asterisk__:__607205__:__PUMILIO, DROSOPHILA, HOMOLOG OF, 2; PUM2__:__KIAA0235__:__
Asterisk__:__607206__:__ARACHIDONATE LIPOXYGENASE 3; ALOXE3__:__LOX TYPE 3;; LIPOXYGENASE TYPE 3, EPIDERMAL__:__
Asterisk__:__607207__:__STIP1 HOMOLOGOUS AND U BOX-CONTAINING PROTEIN 1; STUB1__:__C TERMINUS OF HSC70-INTERACTING PROTEIN; CHIP__:__
Number Sign__:__607208__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 6; EIEE6__:__DRAVET SYNDROME;; SEVERE MYOCLONIC EPILEPSY OF INFANCY; SMEI__:__
Asterisk__:__607209__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 10; CARD10__:__CARD-MAGUK PROTEIN 3; CARMA3;; BCL10-INTERACTING MAGUK PROTEIN 1; BIMP1__:__
Asterisk__:__607210__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 11; CARD11__:__CARD-MAGUK PROTEIN 1; CARMA1;; BCL10-INTERACTING MAGUK PROTEIN 3; BIMP3__:__
Asterisk__:__607211__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 14; CARD14__:__CARD-MAGUK PROTEIN 2; CARMA2;; BCL10-INTERACTING MAGUK PROTEIN 2; BIMP2__:__
Asterisk__:__607212__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9; CARD9__:____:__
Asterisk__:__607213__:__ORIGIN RECOGNITION COMPLEX, SUBUNIT 6, S. CEREVISIAE, HOMOLOG OF; ORC6__:__ORC6-LIKE; ORC6L__:__
NULL__:__607214__:__ANONYCHIA, TOTAL, WITH MICROCEPHALY__:____:__
Asterisk__:__607215__:__NEPHROCYSTIN 4; NPHP4__:__KIAA0673;; NEPHRORETININ__:__
Asterisk__:__607216__:__SIDEKICK, DROSOPHILA, HOMOLOG OF, 1; SDK1__:____:__
Asterisk__:__607217__:__SIDEKICK, DROSOPHILA, HOMOLOG OF, 2; SDK2__:__KIAA1514__:__
Asterisk__:__607218__:__INTERFERON REGULATORY FACTOR 5; IRF5__:____:__
Asterisk__:__607219__:__CONTACTIN 5; CNTN5__:__NB2__:__
Asterisk__:__607220__:__CONTACTIN 6; CNTN6__:__NB3__:__
Percent__:__607221__:__EPILEPSY, PARTIAL, WITH PERICENTRAL SPIKES; PEPS__:__EPPS__:__
Asterisk__:__607222__:__F-BOX ONLY PROTEIN 18; FBXO18__:__F-BOX DNA HELICASE 1; FBH1__:__
Asterisk__:__607223__:__SPARC-RELATED MODULAR CALCIUM-BINDING PROTEIN 2; SMOC2__:__SECRETED MODULAR CALCIUM-BINDING PROTEIN 2;; SMOOTH MUSCLE-ASSOCIATED PROTEIN 2; SMAP2__:__
Asterisk__:__607224__:__ORAL CANCER OVEREXPRESSED GENE 1; ORAOV1__:__TUMOR AMPLIFIED AND OVEREXPRESSED SEQUENCE 1; TAOS1__:__
Number Sign__:__607225__:__SPASTIC PARALYSIS, INFANTILE-ONSET ASCENDING; IAHSP__:____:__
Asterisk__:__607226__:__HISTONE DEACETYLASE 11; HDAC11__:____:__
Asterisk__:__607227__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER X1; MRGPRX1__:__MRGX1__:__
Asterisk__:__607228__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER X2; MRGPRX2__:__MRGX2__:__
Asterisk__:__607229__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER X3; MRGPRX3__:__MRGX3__:__
Asterisk__:__607230__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER X4; MRGPRX4__:__MRGX4__:__
Asterisk__:__607231__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER D; MRGPRD__:__MRGD__:__
Asterisk__:__607232__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER E; MRGPRE__:__MRGE__:__
Asterisk__:__607233__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER F; MRGPRF__:__MRGF;; RAT THORACIC ARTERY PROTEIN, HOMOLOG OF; RTA__:__
Asterisk__:__607234__:__MAS-RELATED G PROTEIN-COUPLED RECEPTOR FAMILY, MEMBER G; MRGPRG__:__MRGG__:__
Asterisk__:__607235__:__MAS1 ONCOGENE-LIKE; MAS1L__:__MRG__:__
Number Sign__:__607236__:__HYPOPREBETALIPOPROTEINEMIA, ACANTHOCYTOSIS, RETINITIS PIGMENTOSA, AND PALLIDAL DEGENERATION__:__HARP SYNDROME__:__
Asterisk__:__607237__:__TRANSMEMBRANE INNER EAR-EXPRESSED GENE; TMIE__:____:__
Asterisk__:__607238__:__COMM DOMAIN-CONTAINING PROTEIN 1; COMMD1__:__COPPER METABOLISM MURR1 DOMAIN-CONTAINING PROTEIN 1;; COPPER METABOLISM GENE MURR1; MURR1__:__
Percent__:__607239__:__DEAFNESS, AUTOSOMAL RECESSIVE 33; DFNB33__:____:__
Asterisk__:__607240__:__SET DOMAIN-CONTAINING PROTEIN 8; SETD8__:__SET8;; PR/SET DOMAIN-CONTAINING PROTEIN 7; PR/SET7;; PR/SET07;; HISTONE H4-LYSINE 20-SPECIFIC METHYLTRANSFERASE__:__
Asterisk__:__607241__:__CHROMOSOME 4 OPEN READING FRAME 7; C4ORF7__:__FOLLICULAR DENDRITIC CELL SECRETED PEPTIDE; FDCSP__:__
Asterisk__:__607242__:__ADAPTOR-RELATED PROTEIN COMPLEX 2, ALPHA-2 SUBUNIT; AP2A2__:__KIAA0899__:__
Asterisk__:__607243__:__ADAPTOR-RELATED PROTEIN COMPLEX 4, SIGMA-1 SUBUNIT; AP4S1__:____:__
Asterisk__:__607244__:__ADAPTOR-RELATED PROTEIN COMPLEX 4, EPSILON-1 SUBUNIT; AP4E1__:____:__
Asterisk__:__607245__:__ADAPTOR-RELATED PROTEIN COMPLEX 4, BETA-1 SUBUNIT; AP4B1__:____:__
Asterisk__:__607246__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, DELTA-1 SUBUNIT; AP3D1__:__ADAPTIN, DELTA;; GARNET, DROSOPHILA, HOMOLOG OF;; MOCHA, MOUSE, HOMOLOG OF__:__
Asterisk__:__607247__:__CHONDROLECTIN; CHODL__:____:__
Percent__:__607248__:__GLIOMA SUSCEPTIBILITY 4; GLM4__:____:__
Asterisk__:__607249__:__CATION CHANNEL, SPERM-ASSOCIATED, 2; CATSPER2__:____:__
Number Sign__:__607250__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY; SCAN1__:____:__
Asterisk__:__607251__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 22, YEAST, HOMOLOG OF; TIMM22__:__TIM22__:__
Asterisk__:__607252__:__APOLIPOPROTEIN L-II; APOL2__:__APOL-II__:__
Asterisk__:__607253__:__APOLIPOPROTEIN L-III; APOL3__:__APOL-III__:__
Asterisk__:__607254__:__APOLIPOPROTEIN L-IV; APOL4__:__APOL-IV__:__
Asterisk__:__607255__:__APOLIPOPROTEIN L-V; APOL5__:__APOL-V__:__
Asterisk__:__607256__:__APOLIPOPROTEIN L-VI; APOL6__:__APOL-VI__:__
Asterisk__:__607257__:__SRY-BOX 6; SOX6__:____:__
Percent__:__607258__:__HYPERCALCIURIA, ABSORPTIVE, 1__:__HCA1__:__
Number Sign__:__607259__:__SPASTIC PARAPLEGIA 7, AUTOSOMAL RECESSIVE; SPG7__:____:__
Asterisk__:__607260__:__PLACENTAL PROTEIN 13-LIKE PROTEIN__:__PPL13__:__
Asterisk__:__607261__:__EVC2 GENE; EVC2__:__LIMBIN; LBN__:__
Asterisk__:__607262__:__EPSIN 1; EPN1__:__EPSIN__:__
Asterisk__:__607263__:__EPSIN 2; EPN2__:__KIAA1065__:__
Asterisk__:__607264__:__EPSIN 3; EPN3__:____:__
Asterisk__:__607265__:__CLATHRIN INTERACTOR 1; CLINT1__:__EPSIN 4; EPN4;; EPSIN-RELATED PROTEIN; EPNR;; ENTHOPROTIN;; KIAA0171__:__
Caret__:__607266__:__MOVED TO 608048__:____:__
Asterisk__:__607267__:__POLYMERASE, DNA, EPSILON-3; POLE3__:__POLYMERASE, DNA, EPSILON, 17-KD SUBUNIT;; CHROMATIN ACCESSIBILITY COMPLEX, 17-KD SUBUNIT; CHRAC17;; NFYB-LIKE PROTEIN 1; YBL1__:__
Asterisk__:__607268__:__CHROMATIN ACCESSIBILITY COMPLEX, SUBUNIT 1; CHRAC1__:__CHROMATIN ACCESSIBILITY COMPLEX, 15-KD SUBUNIT; CHRAC15;; NFYC-LIKE PROTEIN 1; YCL1__:__
Asterisk__:__607269__:__POLYMERASE, DNA, EPSILON-4; POLE4__:__POLYMERASE, DNA, EPSILON, 12-KD SUBUNIT__:__
Asterisk__:__607270__:__KIAA0442 GENE; KIAA0442__:__AUTISM SUSCEPTIBILITY CANDIDATE 2; AUTS2__:__
Number Sign__:__607271__:__CASPASE 8 DEFICIENCY__:__CEDS;; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIB; ALPS2B__:__
Asterisk__:__607272__:__NDC80, S. CEREVISIAE, HOMOLOG OF; NDC80__:__KINETOCHORE-ASSOCIATED PROTEIN 2; KNTC2;; HIGHLY EXPRESSED IN CANCER; HEC;; HEC1__:__
Asterisk__:__607273__:__FOLLICULIN; FLCN__:__FLCL;; BHD GENE; BHD__:__
Asterisk__:__607274__:__UBIQUITIN-SPECIFIC PROTEASE 14; USP14__:__tRNA-GUANINE TRANSGLYCOSYLASE, 60-KD SUBUNIT;; TGT, 60-KD SUBUNIT__:__
Asterisk__:__607275__:__HOP HOMEOBOX; HOPX__:__HOMEODOMAIN-ONLY PROTEIN; HOP__:__
Number Sign__:__607276__:__RESTING HEART RATE, VARIATION IN__:__RHR__:__
Number Sign__:__607277__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 1__:__ASRT1;; AS1__:__
Number Sign__:__607278__:__OSTEOFIBROUS DYSPLASIA, SUSCEPTIBILITY TO; OSFD__:__OFD;; TIBIA, BOWING OF, WITH PSEUDARTHROSIS AND PECTUS EXCAVATUM__:__
Percent__:__607279__:__SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITY TO, 1; SLEH1__:__SYSTEMIC LUPUS ERYTHEMATOSUS, HEMOLYTIC ANEMIA-RELATED__:__
Asterisk__:__607280__:__CONTACTIN 4; CNTN4__:__BIG2, RAT, HOMOLOG OF; BIG2__:__
Asterisk__:__607281__:__LSM1 PROTEIN; LSM1__:__CANCER-ASSOCIATED SM-LIKE PROTEIN; CASM__:__
Asterisk__:__607282__:__LSM2 PROTEIN; LSM2__:__CHROMOSOME 6 OPEN READING FRAME 28; C6ORF28__:__
Asterisk__:__607283__:__LSM3 PROTEIN; LSM3__:____:__
Asterisk__:__607284__:__LSM4 PROTEIN; LSM4__:____:__
Asterisk__:__607285__:__LSM5 PROTEIN; LSM5__:____:__
Asterisk__:__607286__:__LSM6 PROTEIN; LSM6__:____:__
Asterisk__:__607287__:__LSM7 PROTEIN; LSM7__:____:__
Asterisk__:__607288__:__LSM8 PROTEIN; LSM8__:____:__
Asterisk__:__607289__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 5; BLOC1S5__:__BLOC1, SUBUNIT 5; BLOS5;; MUTED, MOUSE, HOMOLOG OF; MUTED__:__
Asterisk__:__607290__:__SHISA FAMILY, MEMBER 5; SHISA5__:__SCOTIN__:__
Asterisk__:__607291__:__ADAPTOR-RELATED PROTEIN COMPLEX 1 GAMMA SUBUNIT-BINDING PROTEIN 1; AP1GBP1__:__AP1 GAMMA SUBUNIT-BINDING PROTEIN 1;; SYNERGIN, GAMMA; SYNG__:__
Asterisk__:__607292__:__SEMAPHORIN 4A; SEMA4A__:__SEMAPHORIN B; SEMAB; SEMB__:__
Asterisk__:__607293__:__CHLORIDE INTRACELLULAR CHANNEL 5; CLIC5__:____:__
Asterisk__:__607294__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCED FACTOR 2; TGIF2__:__TGFB-INDUCED FACTOR 2__:__
Asterisk__:__607295__:__MYOSIN XVIIIB; MYO18B__:____:__
Asterisk__:__607296__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 13-KD, V1 SUBUNIT G, ISOFORM 1; ATP6V1G1__:__ATP6G1__:__
Asterisk__:__607297__:__NERVE INJURY-INDUCED PROTEIN 2; NINJ2__:__NINJURIN 2__:__
Asterisk__:__607298__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-13; GNG13__:____:__
Asterisk__:__607299__:__DELTA- AND NOTCH-LIKE EPIDERMAL GROWTH FACTOR-RELATED RECEPTOR; DNER__:__DELTA- AND NOTCH-LIKE EGF-RELATED RECEPTOR__:__
Asterisk__:__607300__:__PRECURSOR mRNA-PROCESSING FACTOR 8, S. CEREVISIAE, HOMOLOG OF; PRPF8__:__PRP8;; PRPC8;; U5 snRNP-SPECIFIC PROTEIN, 220-KD__:__
Asterisk__:__607301__:__PRECURSOR mRNA-PROCESSING FACTOR 3, S. CEREVISIAE, HOMOLOG OF; PRPF3__:__PRP3;; HPRP3__:__
Caret__:__607302__:__MOVED TO 116960__:____:__
Asterisk__:__607303__:__MORTALITY FACTOR 4-LIKE PROTEIN 1; MORF4L1__:__MORF4-LIKE PROTEIN 1;; MORF-RELATED GENE 15; MRG15__:__
Percent__:__607304__:__CATARACT 27; CTRCT27__:__CATARACT 27, NUCLEAR PROGRESSIVE;; CCNP__:__
Asterisk__:__607305__:__MDS2 GENE__:__MDS2__:__MDS2/ETV6 FUSION GENE, INCLUDED
Asterisk__:__607306__:__STEROID 5-ALPHA-REDUCTASE 2; SRD5A2__:____:__
Asterisk__:__607307__:__FILAMIN A-INTERACTING PROTEIN 1; FILIP1__:__FILIP;; KIAA1275__:__
Percent__:__607308__:__MAMMOGRAPHIC DENSITY__:____:__
Asterisk__:__607309__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, MU-2 SUBUNIT; AP1M2__:__MU-1B__:__
Asterisk__:__607310__:__A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 7; ADAM7__:____:__
Asterisk__:__607311__:__PROGESTERONE RECEPTOR; PGR__:__PR;; NUCLEAR RECEPTOR SUBFAMILY 3, GROUP C, MEMBER 3; NR3C3__:__
Asterisk__:__607312__:__ZINC FINGER CCCH DOMAIN-CONTAINING ANTIVIRAL PROTEIN 1; ZC3HAV1__:__ZINC FINGER ANTIVIRAL PROTEIN; ZAP__:__
Number Sign__:__607313__:__GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS, 1; HGPPS1__:__HGPPS__:__OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, AND SCOLIOSIS, INCLUDED
Asterisk__:__607314__:__CALCIUM-BINDING PROTEIN 2; CABP2__:____:__
Asterisk__:__607315__:__CALCIUM-BINDING PROTEIN 5; CABP5__:__CALCIUM-BINDING PROTEIN 3; CABP3__:__
Caret__:__607316__:__MOVED TO 607315__:____:__
Number Sign__:__607317__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 4; SCAR4__:__SPINOCEREBELLAR ATAXIA WITH SACCADIC INTRUSIONS; SCASI;; SPINOCEREBELLAR ATAXIA 24, FORMERLY; SCA24, FORMERLY__:__
Asterisk__:__607318__:__LYSYL OXIDASE-LIKE 4; LOXL4__:__LOXC__:__
Asterisk__:__607319__:__SCM-LIKE PROTEIN WITH 4 MBT DOMAINS 1; SFMBT1__:__SFMBT;; RENAL UBIQUITOUS PROTEIN 1; RU1__:__
Asterisk__:__607320__:__RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 4; RASGRP4__:____:__
Asterisk__:__607321__:__ATPase, Na+/K+ TRANSPORTING, ALPHA-4 POLYPEPTIDE; ATP1A4__:__SODIUM-POTASSIUM-ATPase, ALPHA-4 POLYPEPTIDE;; Na,K-ATPase, ALPHA-D POLYPEPTIDE;; ATPase, Na+/K+ TRANSPORTING, ALPHA POLYPEPTIDE-LIKE 2; ATP1AL2__:__
Caret__:__607322__:__MOVED TO 143470__:____:__
Number Sign__:__607323__:__DUANE-RADIAL RAY SYNDROME; DRRS__:__OKIHIRO SYNDROME;; DUANE ANOMALY WITH RADIAL RAY ABNORMALITIES AND DEAFNESS;; DR SYNDROME;; ACRORENOOCULAR SYNDROME__:__
Percent__:__607324__:__POLYDACTYLY, POSTAXIAL, TYPE A3; PAPA3__:__POSTAXIAL POLYDACTYLY, TYPE A3__:__
Asterisk__:__607325__:__DEDICATOR OF CYTOKINESIS 9; DOCK9__:__ZIZIMIN 1; ZIZ1;; KIAA1058__:__
Number Sign__:__607326__:__SMITH-MCCORT DYSPLASIA 1; SMC1__:__SMC__:__
Asterisk__:__607327__:__MUSCLEBLIND-LIKE SPLICING REGULATOR 2; MBNL2__:__MUSCLEBLIND-LIKE PROTEIN 2;; MUSCLEBLIND-LIKE PROTEIN-LIKE; MBLL__:__
Asterisk__:__607328__:__HEXAMETHYLENE BIS ACETAMIDE-INDUCIBLE PROTEIN 1; HEXIM1__:__CARDIAC LINEAGE PROTEIN 1; CLP1;; HIS1;; MENAGE A QUATRE 1; MAQ1__:__
Percent__:__607329__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 3__:__HYT3__:__
Number Sign__:__607330__:__LATHOSTEROLOSIS__:__STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY__:__
Asterisk__:__607331__:__RP9 GENE; RP9__:__PIM1-ASSOCIATED PROTEIN, MOUSE, HOMOLOG OF; PAP1__:__
Asterisk__:__607332__:__CHROMOSOME 5 OPEN READING FRAME 13; C5ORF13__:__3.1 GENE;; P311;; PTZ17;; D4S114__:__
Asterisk__:__607333__:__STE20-RELATED KINASE ADAPTOR BETA; STRADB__:__ILP-INTERACTING PROTEIN; ILPIP;; ALS2 CHROMOSOME REGION GENE 2; ALS2CR2__:__
Asterisk__:__607334__:__TRAFFICKING PROTEIN, KINESIN-BINDING 2; TRAK2__:__GAMMA-AMINOBUTYRIC ACID RECEPTOR-INTERACTING FACTOR 1; GRIF1;; GABA-A RECEPTOR-INTERACTING FACTOR 1;; ALS2 CHROMOSOME REGION GENE 3; ALS2CR3;; OGT-INTERACTING PROTEIN, 98-KD; OIP98;; KIAA0549__:__
Asterisk__:__607335__:__BESTROPHIN 2; BEST2__:__VMD2-LIKE GENE 1; VMD2L1__:__
Asterisk__:__607336__:__BESTROPHIN 4; BEST4__:__VMD2-LIKE GENE 2; VMD2L2__:__
Asterisk__:__607337__:__BESTROPHIN 3; BEST3__:__VMD2-LIKE GENE 3; VMD2L3__:__
Asterisk__:__607338__:__LEPTIN RECEPTOR OVERLAPPING TRANSCRIPT-LIKE 1; LEPROTL1__:____:__
Percent__:__607339__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1__:__CHDS1__:__
Asterisk__:__607340__:__GAMMA-AMINOBUTYRIC ACID B RECEPTOR 2; GABBR2__:__G PROTEIN-COUPLED RECEPTOR 51; GPR51;; GABA-B RECEPTOR, R2 SUBUNIT; GABABR2__:__
Number Sign__:__607341__:__FOCAL CORTICAL DYSPLASIA, TYPE II; FCORD2__:__CORTICAL DYSPLASIA OF TAYLOR; CDT;; FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT;; FCD2__:__FOCAL CORTICAL DYSPLASIA, TYPE IIA, INCLUDED; FCORD2A, INCLUDED;; FCD IIA, INCLUDED;; CORTICAL DYSPLASIA OF TAYLOR WITHOUT BALLOON CELLS, INCLUDED;; CORTICAL DYSPLASIA OF TAYLOR, DYSPLASIA ONLY, INCLUDED; CDTD, INCLUDED;; FOCAL CORTICAL DYSPLASIA, TYPE IIB, INCLUDED; FCORD2B, INCLUDED;; FCD IIB, INCLUDED;; CORTICAL DYSPLASIA OF TAYLOR WITH BALLOON CELLS, INCLUDED; CDTBC, INCLUDED
Asterisk__:__607342__:__CYTOPLASMIC POLYADENYLATION ELEMENT-BINDING PROTEIN 1; CPEB1__:__CPEB__:__
Asterisk__:__607343__:__SAL-LIKE 4; SALL4__:__HSAL4__:__
Asterisk__:__607344__:__TUBULIN, DELTA-1; TUBD1__:__TUBD__:__
Asterisk__:__607345__:__TUBULIN, EPSILON-1; TUBE1__:__TUBULIN, EPSILON; TUBE__:__
Number Sign__:__607346__:__SPINOCEREBELLAR ATAXIA 19; SCA19__:__SPINOCEREBELLAR ATAXIA 22; SCA22__:__
Asterisk__:__607347__:__ALPHA KINASE 1; ALPK1__:__LYMPHOCYTE ALPHA KINASE; LAK;; KIAA1527__:__
Asterisk__:__607348__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 5; HES5__:____:__
Asterisk__:__607349__:__TALIN 2; TLN2__:__KIAA0320__:__
Asterisk__:__607350__:__KINESIN FAMILY MEMBER 13B; KIF13B__:__GUANYLATE KINASE-ASSOCIATED KINESIN; GAKIN;; KIAA0639__:__
Asterisk__:__607351__:__RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 1; RHOBTB1__:__KIAA0740__:__
Asterisk__:__607352__:__RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 2; RHOBTB2__:__DELETED IN BREAST CANCER 2; DBC2;; KIAA0717__:__
Asterisk__:__607353__:__RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 3; RHOBTB3__:__KIAA0878__:__
Percent__:__607354__:__SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 2; IS2__:____:__
Asterisk__:__607355__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2C, SUBUNIT 3; EIF2C3__:__ARGONAUTE 3; AGO3__:__
Asterisk__:__607356__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2C, SUBUNIT 4; EIF2C4__:__ARGONAUTE 4; AGO4;; KIAA1567__:__
Asterisk__:__607357__:__POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 5; KCNQ5__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY Q, MEMBER 5__:__
Asterisk__:__607358__:__AUTOIMMUNE REGULATOR; AIRE__:____:__
Asterisk__:__607359__:__CELL DIVISION CYCLE AND APOPTOSIS REGULATOR 2; CCAR2__:__DELETED IN BREAST CANCER 1; DBC1;; KIAA1967 GENE; KIAA1967__:__
Asterisk__:__607360__:__LACRITIN; LACRT__:____:__
Number Sign__:__607361__:__MECKEL SYNDROME, TYPE 3; MKS3__:__MECKEL-GRUBER SYNDROME, TYPE 3__:__
Asterisk__:__607362__:__RGM DOMAIN FAMILY, MEMBER A; RGMA__:__REPULSIVE GUIDANCE MOLECULE; RGM__:__
Asterisk__:__607363__:__KINETOCHORE-ASSOCIATED PROTEIN 1; KNTC1__:__ROUGH DEAL, DROSOPHILA, HOMOLOG OF; ROD;; KIAA0166__:__
Number Sign__:__607364__:__BARTTER SYNDROME, TYPE 3; BARTS3__:__BARTTER SYNDROME, CLASSIC__:__BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED
Asterisk__:__607365__:__LIPASE H; LIPH__:__MEMBRANE-ASSOCIATED PHOSPHATIDIC ACID-SELECTIVE PHOSPHOLIPASE A1; MPAPLA1;; PHOSPHOLIPASE A1, PHOSPHATIDIC ACID-SELECTIVE, MEMBRANE-ASSOCIATED;; LPD LIPASE-RELATED PROTEIN; LPDLR__:__
Asterisk__:__607366__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 12; KCNK12__:__TANDEM PORE DOMAIN HALOTHANE-INHIBITED POTASSIUM CHANNEL 2; THIK2__:__
Asterisk__:__607367__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13; KCNK13__:__TANDEM PORE DOMAIN HALOTHANE-INHIBITED POTASSIUM CHANNEL 1; THIK1__:__
Asterisk__:__607368__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 15; KCNK15__:__TWIK-RELATED ACID-SENSITIVE K+ CHANNEL 5; TASK5__:__
Asterisk__:__607369__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 16; KCNK16__:__TWIK-RELATED ALKALINE pH-ACTIVATED K+ CHANNEL 1; TALK1__:__
Asterisk__:__607370__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 17; KCNK17__:__TWIK-RELATED ACID-SENSITIVE K+ CHANNEL 4; TASK4;; TWIK-RELATED ALKALINE pH-ACTIVATED K+ CHANNEL 2; TALK2__:__
Number Sign__:__607371__:__DYSTONIA, JUVENILE-ONSET; DJO__:____:__
Asterisk__:__607372__:__MEDIATOR COMPLEX SUBUNIT 15; MED15__:__PC2 GLUTAMINE/Q-RICH-ASSOCIATED PROTEIN; PCQAP;; TPA-INDUCIBLE GENE 1; TIG1;; ACTIVATOR-RECRUITED COFACTOR, 105-KD; ARC105__:__
Percent__:__607373__:__AUTISM, SUSCEPTIBILITY TO, 8; AUTS8__:__AUTS2, FORMERLY__:__
Asterisk__:__607374__:__PRKR INHIBITOR, REPRESSOR OF; PRKRIR__:__PROTEIN KINASE, INTERFERON-INDUCIBLE DOUBLE-STRANDED RNA-DEPENDENT INHIBITOR, REPRESSOR OF;; REPRESSOR OF THE INHIBITOR OF PROTEIN KINASE, 52-KD; P52(RIPK);; P58 REPRESSOR;; PRKRI REPRESSOR;; THAP DOMAIN-CONTAINING PROTEIN 0; THAP0__:__
Asterisk__:__607375__:__DOT1-LIKE; DOT1L__:__DOT1, S. CEREVISIAE, HOMOLOG OF; DOT1;; HISTONE H3 METHYLTRANSFERASE DOT1-LIKE;; KIAA1814__:__
Asterisk__:__607376__:__DYNACTIN 2; DCTN2__:__DYNAMITIN;; DYNACTIN COMPLEX, 50-KD SUBUNIT; DCTN50__:__
Asterisk__:__607377__:__LENS EPITHELIAL PROTEIN; LENEP__:__LEP503, RAT, HOMOLOG OF; LEP503__:__
Asterisk__:__607378__:__SERPINE1 mRNA-BINDING PROTEIN 1; SERBP1__:__PAI1 RNA-BINDING PROTEIN 1;; PAIRBP1__:__
Asterisk__:__607379__:__NEUROFIBROMIN 2; NF2__:__MERLIN;; SCHWANNOMIN; SCH__:__
Asterisk__:__607380__:__TNF RECEPTOR-ASSOCIATED FACTOR 3-INTERACTING PROTEIN 1; TRAF3IP1__:__TRAF3-INTERACTING PROTEIN 1;; MICROTUBULE-INTERACTING PROTEIN ASSOCIATED WITH TRAF3; MIPT3;; INTRAFLAGELLAR TRANSPORT PROTEIN 54, CHLAMYDOMONAS, HOMOLOG OF; IFT54__:__
Asterisk__:__607381__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 50, YEAST, HOMOLOG OF; TIMM50__:__TIM50__:__
Asterisk__:__607382__:__CAP-GLY DOMAIN-CONTAINING LINKER PROTEIN 3; CLIP3__:__CYTOPLASMIC LINKER PROTEIN 170-RELATED PROTEIN, 59-KD; CLIPR59__:__
Asterisk__:__607383__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 13, YEAST, HOMOLOG OF; TIMM13__:__TIM13__:__
Asterisk__:__607384__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 9, YEAST, HOMOLOG OF; TIMM9__:__TIM9__:__
Asterisk__:__607385__:__UDP-N-ACETYLGLUCOSAMINE:ALPHA-1,3-D-MANNOSIDE BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE IV__:__GNT-IV-H__:__
Asterisk__:__607386__:__INTRAFLAGELLAR TRANSPORT 172, CHLAMYDOMONAS, HOMOLOG OF; IFT172__:__SELECTIVE LIM-BINDING FACTOR, RAT, HOMOLOG OF; SLB;; KIAA1179__:__
Asterisk__:__607387__:__DYNACTIN 3; DCTN3__:__DYNACTIN COMPLEX, 22-KD SUBUNIT; DCTN22__:__
Asterisk__:__607388__:__FRACTURE CALLUS 1, RAT, HOMOLOG OF; FXC1__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 10, YEAST, HOMOLOG OF, B; TIMM10B; TIM10B__:__
Asterisk__:__607389__:__SINGLE-STRANDED DNA-BINDING PROTEIN 2; SSBP2__:__SENSOR OF SINGLE-STRANDED DNA COMPLEX, SUBUNIT B2; SOSSB2;; SOSS COMPLEX, SUBUNIT B2__:__
Asterisk__:__607390__:__SINGLE-STRANDED DNA-BINDING PROTEIN 3; SSBP3__:____:__
Asterisk__:__607391__:__SINGLE-STRANDED DNA-BINDING PROTEIN 4; SSBP4__:____:__
Asterisk__:__607392__:__WW DOMAIN-CONTAINING TRANSCRIPTION REGULATOR 1; WWTR1__:__TRANSCRIPTIONAL COACTIVATOR WITH PDZ-BINDING MOTIF; TAZ__:__
Asterisk__:__607393__:__CELL DIVISION CYCLE PROTEIN 73, S. CEREVISIAE, HOMOLOG OF; CDC73__:__PARAFIBROMIN;; HYRAX, DROSOPHILA, HOMOLOG OF; HYX;; CHROMOSOME 1 OPEN READING FRAME 28; C1ORF28;; HRPT2__:__
Asterisk__:__607394__:__POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 3; POU2F3__:__OCTAMER-BINDING TRANSCRIPTION FACTOR 11; OCT11;; SKN1A__:__
NULL__:__607395__:__STREPTOCOCCUS, GROUP A, SEVERITY OF INFECTION BY__:____:__
Asterisk__:__607396__:__TRANSDUCER OF ERBB2, 2; TOB2__:__KIAA1663__:__
Asterisk__:__607397__:__MELANOCORTIN 2 RECEPTOR; MC2R__:__MC2 RECEPTOR;; ACTH RECEPTOR; ACTHR;; CORTICOTROPIN RECEPTOR__:__
Number Sign__:__607398__:__GLUCOCORTICOID DEFICIENCY 2; GCCD2__:__FAMILIAL GLUCOCORTICOID DEFICIENCY 2; FGD2__:__
Asterisk__:__607399__:__MUCOLIPIN 2; MCOLN2__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, MUCOLIPIN SUBFAMILY, MEMBER 2; TRPML2__:__
Asterisk__:__607400__:__MUCOLIPIN 3; MCOLN3__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, MUCOLIPIN SUBFAMILY, MEMBER 3; TRPML3__:__
Asterisk__:__607401__:__INTERFERON, LAMBDA-2; IFNL2__:__INTERLEUKIN 28A; IL28A__:__
Asterisk__:__607402__:__INTERFERON, LAMBDA-3; IFNL3__:__INTERLEUKIN 28B; IL28B__:__
Asterisk__:__607403__:__INTERFERON, LAMBDA-1; IFNL1__:__INTERLEUKIN 29; IL29__:__
Asterisk__:__607404__:__INTERFERON-LAMBDA RECEPTOR 1; IFNLR1__:__INTERLEUKIN 28 RECEPTOR, ALPHA; IL28RA__:__
Asterisk__:__607405__:__TRACE AMINE-ASSOCIATED RECEPTOR 5; TAAR5__:__PUTATIVE NEUROTRANSMITTER RECEPTOR; PNR__:__
Asterisk__:__607406__:__STARCH-BINDING DOMAIN-CONTAINING PROTEIN 1; STBD1__:__GENETHONIN 1;; GENEX3414__:__
Asterisk__:__607407__:__EARLY B-CELL FACTOR 3; EBF3__:__COLLIER/OLF1/EBF TRANSCRIPTION FACTOR 3; COE3__:__
Asterisk__:__607408__:__D-AMINO ACID OXIDASE ACTIVATOR; DAOA__:__G72__:__
Asterisk__:__607409__:__NEURITIN 1; NRN1__:__NEURITIN; NRN__:__
Asterisk__:__607410__:__DIENCEPHALON/MESENCEPHALON HOMEOBOX 1; DMBX1__:__ORTHODENTICLE, DROSOPHILA, HOMOLOG OF, 3; OTX3__:__
Percent__:__607411__:__PATENT DUCTUS ARTERIOSUS 1; PDA1__:__PDA__:__
Asterisk__:__607412__:__BPI FOLD-CONTAINING PROTEIN, FAMILY A, MEMBER 1; BPIFA1__:__PALATE, LUNG, AND NASAL EPITHELIUM CARCINOMA-ASSOCIATED PROTEIN; PLUNC;; SPLUNC1__:__
NULL__:__607413__:__ALZHEIMER DISEASE NEURONAL THREAD PROTEIN__:__AD7CNTP__:__
Asterisk__:__607414__:__FEZ FAMILY ZINC FINGER PROTEIN 2; FEZF2__:__ZINC FINGER PROTEIN 312; ZNF312;; FOREBRAIN EMBRYONIC ZINC FINGER-LIKE; FEZL;; TOO FEW, ZEBRAFISH, HOMOLOG OF; TOF__:__
Asterisk__:__607415__:__DAOA ANTISENSE RNA; DAOAAS__:__G30__:__
Asterisk__:__607416__:__CHL1, MOUSE, HOMOLOG OF; CHL1__:__CELL ADHESION MOLECULE L1-LIKE; CALL;; L1 CELL ADHESION MOLECULE 2; L1CAM2__:__
Number Sign__:__607417__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2; MRT2__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 2A; MRT2A__:__
Asterisk__:__607418__:__GRIP AND COILED-COIL DOMAINS-CONTAINING PROTEIN 1; GCC1__:__GOLGI COILED-COIL PROTEIN 1;; GCC PROTEIN, 88-KD; GCC88__:__
Asterisk__:__607419__:__GEM-ASSOCIATED PROTEIN 7; GEMIN7__:____:__
Asterisk__:__607420__:__GABA-A RECEPTOR-ASSOCIATED PROTEIN-LIKE PROTEIN 1; GABARAPL1__:__GABARAP-LIKE PROTEIN 1;; GLANDULAR EPITHELIAL CELL PROTEIN 1; GEC1;; APG8-LIKE; APG8L__:__
Asterisk__:__607421__:__NME/NM23 FAMILY MEMBER 8; NME8__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 3; TXNDC3;; SPERM-SPECIFIC THIOREDOXIN 2; SPTRX2__:__
Asterisk__:__607422__:__GLYCINE C-ACETYLTRANSFERASE; GCAT__:__2-AMINO-3-KETOBUTYRATE COENZYME A LIGASE; KBL__:__
Asterisk__:__607423__:__PROTEIN O-MANNOSYLTRANSFERASE 1; POMT1__:__ROTATED ABDOMEN, DROSOPHILA, HOMOLOG OF; RT__:__
Asterisk__:__607424__:__GLYCINE N-ACYLTRANSFERASE; GLYAT__:__GAT;; ACYL-CoA:GLYCINE N-ACYLTRANSFERASE; ACGNAT__:__
Asterisk__:__607425__:__GAP JUNCTION PROTEIN, DELTA-3; GJD3__:__GAP JUNCTION PROTEIN, ALPHA-11; GJA11;; GAP JUNCTION PROTEIN, 31.9-KD;; CONNEXIN 31.9; CX31.9;; GAP JUNCTION PROTEIN, CHI-1, FORMERLY; GJC1, FORMERLY__:__
Number Sign__:__607426__:__COENZYME Q10 DEFICIENCY, PRIMARY, 1; COQ10D1__:__CoQ10 DEFICIENCY, PRIMARY, 1;; UBIQUINONE DEFICIENCY 1;; COENZYME Q DEFICIENCY 1;; CoQ DEFICIENCY 1__:__
Asterisk__:__607427__:__ENOLASE SUPERFAMILY MEMBER 1; ENOSF1__:__THYMIDYLATE SYNTHASE, ANTISENSE; RTS__:__
Asterisk__:__607428__:__KIN OF IRRE-LIKE; KIRREL__:__NEPHRIN-LIKE 1; NEPH1__:__
Asterisk__:__607429__:__PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 1; PDSS1__:__DECAPRENYL DIPHOSPHATE SYNTHASE; DPS;; SOLANESYL DIPHOSPHATE SYNTHASE, MOUSE, HOMOLOG OF; SPS;; TRANS-PRENYLTRANSFERASE; TPT;; POLYPRENYL PYROPHOSPHATE SYNTHETASE;; COQ1, S. CEREVISIAE, HOMOLOG OF; COQ1__:__
Asterisk__:__607430__:__DAZ-ASSOCIATED PROTEIN 1; DAZAP1__:____:__
Asterisk__:__607431__:__DAZ-ASSOCIATED PROTEIN 2; DAZAP2__:__KIAA0058__:__
Number Sign__:__607432__:__LISSENCEPHALY 1; LIS1__:__LISSENCEPHALY SEQUENCE, ISOLATED; ILS;; LISSENCEPHALY, CLASSIC__:__SUBCORTICAL LAMINAR HETEROTOPIA, INCLUDED; SCLH, INCLUDED;; SUBCORTICAL BAND HETEROTOPIA, INCLUDED; SBH, INCLUDED
Asterisk__:__607433__:__TWINFILIN, DROSOPHILA, HOMOLOG OF, 2; TWF2__:__PROTEIN TYROSINE KINASE 9-LIKE; PTK9L;; A6-RELATED PROTEIN; A6RP__:__
Asterisk__:__607434__:__GTP-BINDING PROTEIN 2; GTPBP2__:____:__
Asterisk__:__607435__:__ERA G-PROTEIN-LIKE 1; ERAL1__:__ERAL1A__:__ERAL1B, INCLUDED
Asterisk__:__607436__:__POLY(A) POLYMERASE, BETA; PAPOLB__:__POLY(A) POLYMERASE, TESTIS-SPECIFIC; PAPT; TPAP__:__
Asterisk__:__607437__:__G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, MEMBER D; GPRC5D__:____:__
Caret__:__607438__:__MOVED TO 138210__:____:__
Asterisk__:__607439__:__PROTEIN O-MANNOSYLTRANSFERASE 2; POMT2__:____:__
Asterisk__:__607440__:__FUKUTIN; FKTN__:__FCMD GENE; FCMD__:__
Asterisk__:__607441__:__EPITHELIAL STROMAL INTERACTION 1; EPSTI1__:____:__
Asterisk__:__607442__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 4; EML4__:__ROPP120__:__EML4-ALK FUSION GENE, INCLUDED
Asterisk__:__607443__:__EPIDIDYMAL SPERM BINDING PROTEIN 1; ELSPBP1__:____:__
Asterisk__:__607444__:__SBDS GENE; SBDS__:____:__
Asterisk__:__607445__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E NUCLEAR IMPORT FACTOR 1; EIF4ENIF1__:__EIF4E-TRANSPORTER;; 4E-T__:__
Percent__:__607446__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 3; BMIQ3__:____:__
Number Sign__:__607447__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 4; BMIQ4__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__607448__:__G PROTEIN-COUPLED RECEPTOR 147; GPR147__:__NEUROPEPTIDE FF1; NPFF1__:__
Asterisk__:__607449__:__G PROTEIN-COUPLED RECEPTOR 74; GPR74__:__NEUROPEPTIDE FF2; NPFF2;; NEUROPEPTIDE G PROTEIN-COUPLED RECEPTOR; NPGPR__:__
Number Sign__:__607450__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 8; ARVD8__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 8; ARVC8__:__
Asterisk__:__607451__:__GLUCOCORTICOID MODULATORY ELEMENT-BINDING PROTEIN 2; GMEB2__:__PARVOVIRUS INITIATION FACTOR, p79 SUBUNIT;; KIAA1269__:__
Asterisk__:__607452__:__GABA-A RECEPTOR-ASSOCIATED PROTEIN-LIKE PROTEIN 2; GABARAPL2__:__GATE16, BOVINE, HOMOLOG OF; GATE16__:__
Number Sign__:__607453__:__DEAFNESS, AUTOSOMAL DOMINANT 44; DFNA44__:____:__
Number Sign__:__607454__:__SPINOCEREBELLAR ATAXIA 21; SCA21__:____:__
Asterisk__:__607455__:__ZINC FINGER AN1 DOMAIN-CONTAINING PROTEIN 3; ZFAND3__:__AN1-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 3;; TESTIS-EXPRESSED GENE 27; TEX27__:__
Asterisk__:__607456__:__UTP4, S. CEREVISIAE, HOMOLOG OF; UTP4__:__CIRHIN; CIRH1A;; TESTIS-EXPRESSED GENE 292; TEX292;; KIAA1988__:__
Number Sign__:__607457__:__GIL BLOOD GROUP__:____:__
Percent__:__607458__:__SPINOCEREBELLAR ATAXIA 18; SCA18__:__SENSORIMOTOR NEUROPATHY WITH ATAXIA, AUTOSOMAL DOMINANT; SMNA__:__
Number Sign__:__607459__:__SENSORY ATAXIC NEUROPATHY, DYSARTHRIA, AND OPHTHALMOPARESIS; SANDO__:__SENSORY ATAXIC NEUROPATHY WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE__:__SPINOCEREBELLAR ATAXIA WITH EPILEPSY, INCLUDED; SCAE, INCLUDED;; EPILEPSY, PROGRESSIVE MYOCLONIC, WITH SENSORY ATAXIC NEUROPATHY, INCLUDED;; EPILEPSY, PROGRESSIVE MYOCLONIC, 5, FORMERLY; EPM5, FORMERLY
Asterisk__:__607460__:__PHOSPHATIDYLSERINE-SPECIFIC PHOSPHOLIPASE A1-ALPHA; PLA1A__:__PHOSPHATIDYLSERINE-SPECIFIC PHOSPHOLIPASE A1; PSPLA1__:__
Asterisk__:__607461__:__DYMECLIN; DYM__:____:__
Asterisk__:__607462__:__ATROPHIN 1; ATN1__:__DRPLA GENE; DRPLA__:__
Asterisk__:__607463__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 13-LIKE; PPP1R13L__:__RELA-ASSOCIATED INHIBITOR; RAI;; INHIBITORY MEMBER OF THE ASPP FAMILY; IASPP;; NF-KAPPA-B-INTERACTING PROTEIN 1; NKIP1__:__
Number Sign__:__607464__:__THYROID CARCINOMA, HURTHLE CELL__:__HURTHLE CELL THYROID NEOPLASIA__:__
Asterisk__:__607465__:__CODANIN 1; CDAN1__:__DISCS LOST, DROSOPHILA, HOMOLOG OF; DLT__:__
Asterisk__:__607466__:__RAS-ASSOCIATED PROTEIN RAB2B; RAB2B__:____:__
Asterisk__:__607467__:__C-TYPE LECTIN-LIKE 1; CLECL1__:__DENDRITIC CELL-ASSOCIATED LECTIN 1; DCAL1__:__
Asterisk__:__607468__:__G PROTEIN-COUPLED RECEPTOR 88; GPR88__:__STRIATUM-SPECIFIC G PROTEIN-COUPLED RECEPTOR; STRG__:__
Asterisk__:__607469__:__N-ACYLETHANOLAMINE ACID AMIDASE; NAAA__:__N-ACYLSPHINGOSINE AMIDOHYDROLASE-LIKE PROTEIN; ASAHL;; ASAH-LIKE PROTEIN;; ACID CERAMIDASE-LIKE PROTEIN__:__
Asterisk__:__607470__:__BREAST CARCINOMA AMPLIFIED SEQUENCE 3; BCAS3__:____:__
Asterisk__:__607471__:__BREAST CARCINOMA AMPLIFIED SEQUENCE 4; BCAS4__:____:__
Asterisk__:__607472__:__MITOCHONDRIAL ESCAPE 1-LIKE 1; YME1L1__:__YME1L;; YME1, S. CEREVISIAE, HOMOLOG OF, 1;; PRESENILIN-ASSOCIATED METALLOPROTEASE; PAMP__:__
Number Sign__:__607473__:__VITAMIN K-DEPENDENT CLOTTING FACTORS, COMBINED DEFICIENCY OF, 2; VKCFD2__:____:__
Asterisk__:__607474__:__HOMOGENTISATE 1,2-DIOXYGENASE; HGD__:__HOMOGENTISIC ACID OXIDASE; HGO__:__
Number Sign__:__607475__:__BOTHNIA RETINAL DYSTROPHY__:__VASTERBOTTEN DYSTROPHY__:__
Number Sign__:__607476__:__NEWFOUNDLAND ROD-CONE DYSTROPHY; NFRCD__:____:__
Asterisk__:__607477__:__G2- AND S-PHASE EXPRESSED GENE 1; GTSE1__:____:__
Asterisk__:__607478__:__TRYPTOPHAN HYDROXYLASE 2; TPH2__:__TRYPTOPHAN HYDROXYLASE, NEURONAL; NTPH__:__
Asterisk__:__607479__:__APC, DOWNREGULATED BY, 1; APCDD1__:____:__
Caret__:__607480__:__MOVED TO 300424__:____:__
Asterisk__:__607481__:__MMAA GENE; MMAA__:____:__
Number Sign__:__607482__:__CARDIOMYOPATHY, DILATED, 1M; CMD1M__:____:__
Number Sign__:__607483__:__THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2__:__BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE__:__
Asterisk__:__607484__:__PARTITIONING-DEFECTIVE PROTEIN 6, C. ELEGANS, HOMOLOG OF, ALPHA; PARD6A__:__PAR6;; TAX-INTERACTING PROTEIN 40; TAX40__:__
Number Sign__:__607485__:__FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, GRN-RELATED__:__FTLD-TDP, GRN-RELATED;; FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, GRN-RELATED;; FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS; FTLDU;; FRONTOTEMPORAL DEMENTIA, UBIQUITIN-POSITIVE; FTDU;; DEMENTIA, HEREDITARY DYSPHASIC DISINHIBITION; HDDD__:__APHASIA, PRIMARY PROGRESSIVE, INCLUDED; PPA, INCLUDED
Number Sign__:__607486__:__KNOPS BLOOD GROUP SYSTEM; KN__:____:__
Number Sign__:__607487__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 25; CMH25__:____:__
Percent__:__607488__:__DYSTONIA 15, MYOCLONIC; DYT15__:____:__
Asterisk__:__607489__:__CULLIN 9; CUL9__:__p53-ASSOCIATED PARKIN-LIKE CYTOPLASMIC PROTEIN; PARC;; KIAA0708__:__
Asterisk__:__607490__:__LACTATE DEHYDROGENASE D; LDHD__:__D-LACTATE DEHYDROGENASE__:__
Asterisk__:__607491__:__PROTEIN O-FUCOSYLTRANSFERASE 1; POFUT1__:__OFUT1; OFUCT1;; KIAA0180__:__
Asterisk__:__607492__:__PHOSPHOFURIN ACIDIC CLUSTER SORTING PROTEIN 1; PACS1__:____:__
Asterisk__:__607493__:__INHIBITOR OF GROWTH 3; ING3__:__p47ING3__:__
Asterisk__:__607494__:__INOSITOL POLYPHOSPHATE-4-PHOSPHATASE, TYPE II, 105-KD; INPP4B__:____:__
Caret__:__607495__:__MOVED TO 607138__:____:__
Asterisk__:__607496__:__NITRIC OXIDE SYNTHASE TRAFFICKER; NOSTRIN__:__ENDOTHELIAL NITRIC OXIDE SYNTHASE TRAFFIC INDUCER;; ENOS TRAFFIC INDUCER__:__
Asterisk__:__607497__:__BETA-1,3-GLUCURONYLTRANSFERASE 2; B3GAT2__:__UDP-GLUCURONYLTRANSFERASE S;; GLUCURONOSYLTRANSFERASE S; GLCATS;; KIAA1963__:__
Percent__:__607498__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 3__:__MGR3__:__
Percent__:__607499__:__BULIMIA NERVOSA, SUSCEPTIBILITY TO; BULN__:__BN__:__BULIMIA NERVOSA, SUSCEPTIBILITY TO, 1, INCLUDED; BULN1, INCLUDED
Caret__:__607500__:__MOVED TO 146390__:____:__
Percent__:__607501__:__MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO, 4__:__MGR4;; MGOA__:__
Asterisk__:__607502__:__DISPATCHED, DROSOPHILA, HOMOLOG OF, 1; DISP1__:__DISPA__:__
Asterisk__:__607503__:__DISPATCHED, DROSOPHILA, HOMOLOG OF, 2; DISP2__:__DISPB;; KIAA1742__:__
NULL__:__607504__:__HEADACHE ASSOCIATED WITH SEXUAL ACTIVITY; HSA__:__BENIGN SEXUAL HEADACHE; BSH__:__
Asterisk__:__607505__:__PAS DOMAIN-CONTAINING SERINE/THREONINE KINASE; PASK__:__PAS KINASE;; PASKIN;; KIAA0135__:__
Asterisk__:__607506__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 14; ADAMTS14__:____:__
Number Sign__:__607507__:__PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO__:____:__PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO, 1, INCLUDED; PSORAS1, INCLUDED
Percent__:__607508__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 5__:__MGR5__:__
Asterisk__:__607509__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 15; ADAMTS15__:____:__
Asterisk__:__607510__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 16; ADAMTS16__:____:__
Asterisk__:__607511__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 17; ADAMTS17__:____:__
Asterisk__:__607512__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 18; ADAMTS18__:____:__
Asterisk__:__607513__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 19; ADAMTS19__:____:__
Number Sign__:__607514__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 10; BMIQ10__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__607515__:__PLACENTA-SPECIFIC GENE 8; PLAC8__:____:__
Percent__:__607516__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 6__:__MGR6__:__MIGRAINE, FAMILIAL HEMIPLEGIC, 4, INCLUDED; FHM4, INCLUDED
Asterisk__:__607517__:__LEUKOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR, SUBFAMILY A, MEMBER 4; LILRA4__:__IMMUNOGLOBULIN-LIKE TRANSCRIPT 7; ILT7__:__
Asterisk__:__607518__:__MONOCYTE AND PLASMACYTOID ACTIVATED MOLECULE__:__MAPA__:__
Asterisk__:__607519__:__POLY(ADP-RIBOSE) POLYMERASE 4; PARP4__:__ADP-RIBOSYLTRANSFERASE-LIKE 1; ADPRTL1;; VAULT POLY(ADP-RIBOSE) POLYMERASE; VPARP;; KIAA0177__:__
Asterisk__:__607520__:__ZYGOTE ARREST 1; ZAR1__:____:__
Asterisk__:__607521__:__HPS5 GENE; HPS5__:__RUBY-EYE 2, MOUSE, HOMOLOG OF; RU2;; KIAA1017;; ALPHA-INTEGRIN-BINDING PROTEIN 63; AIBP63__:__
Asterisk__:__607522__:__HPS6 GENE; HPS6__:__RUBY-EYE, MOUSE, HOMOLOG OF; RU__:__
Number Sign__:__607523__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 8; NDNC8__:__TOENAIL DYSTROPHY, ISOLATED__:__
Asterisk__:__607524__:__RING FINGER PROTEIN 39; RNF39__:__HZFW;; HZF;; LONG-TERM POTENTIATION-INDUCED RING FINGER PROTEIN; LIRF__:__
Asterisk__:__607525__:__ZINC RIBBON DOMAIN-CONTAINING PROTEIN 1; ZNRD1__:__TCTEX6, MOUSE, HOMOLOG OF; TCTEX6;; TEX6; HTEX6__:__
Asterisk__:__607526__:__RIBOSOMAL PROTEIN L27; RPL27__:____:__
Asterisk__:__607527__:__REGULATOR OF DIFFERENTIATION 1; ROD1__:____:__
Asterisk__:__607528__:__ROUNDABOUT, DROSOPHILA, HOMOLOG OF, 4; ROBO4__:__MAGIC ROUNDABOUT__:__
Asterisk__:__607529__:__SERYL-tRNA SYNTHETASE; SARS__:__SERS;; SERRS__:__
Asterisk__:__607530__:__HOMEOBOX A11, ANTISENSE; HOXA11AS__:__HOXA11S__:__
Asterisk__:__607531__:__KRUPPEL-LIKE FACTOR 12; KLF12__:__AP2 REPRESSOR; AP2REP__:__
Asterisk__:__607532__:__PROGESTERONE-INDUCED BLOCKING FACTOR 1; PIBF1__:__PIBF__:__
Asterisk__:__607533__:__DIS3 MITOTIC CONTROL, S. CEREVISIAE, HOMOLOG OF; DIS3__:__EXOSOME COMPONENT 11; EXOSC11;; RIBOSOMAL RNA-PROCESSING PROTEIN 44, S. CEREVISIAE, HOMOLOG OF; RRP44;; KIAA1008__:__
Asterisk__:__607534__:__YY1-ASSOCIATED FACTOR 2; YAF2__:____:__
Asterisk__:__607535__:__RING1- AND YY1-BINDING PROTEIN; RYBP__:__YY1- AND E4TF1/GABP-ASSOCIATED FACTOR 1; YEAF1__:__
Asterisk__:__607536__:__CREB-REGULATED TRANSCRIPTION COACTIVATOR 1; CRTC1__:__MUCOEPIDERMOID CARCINOMA-TRANSLOCATED 1; MECT1;; TRANSDUCER OF REGULATED cAMP RESPONSE ELEMENT-BINDING PROTEIN 1; TORC1;; TRANSDUCER OF REGULATED CREB 1;; KIAA0616;; FLJ14027__:__MECT1/MAML2 FUSION GENE, INCLUDED
Asterisk__:__607537__:__MASTERMIND-LIKE 2; MAML2__:__MASTERMIND, DROSOPHILA, HOMOLOG OF, 3; MAM3;; KIAA1819__:__MAML2/MECT1 FUSION GENE, INCLUDED;; MAML2/MLL FUSION GENE, INCLUDED
Asterisk__:__607538__:__NUDE NEURODEVELOPMENT PROTEIN 1-LIKE 1; NDEL1__:__NUDE-LIKE PROTEIN; NUDEL;; ENDOOLIGOPEPTIDASE A; EOPA__:__
Number Sign__:__607539__:__CAMPTOSYNPOLYDACTYLY, COMPLEX; CCSPD__:__CAMPTOPOLYDACTYLY, DISORGANIZATION TYPE__:__
NULL__:__607540__:__SECRETORY DIARRHEA, MYOPATHY, AND DEAFNESS__:____:__
Number Sign__:__607541__:__CORNEAL DYSTROPHY, AVELLINO TYPE; CDA__:__ACD;; AVELLINO CORNEAL DYSTROPHY;; COMBINED GRANULAR-LATTICE CORNEAL DYSTROPHY;; GRANULAR CORNEAL DYSTROPHY, TYPE II; CGD2__:__
Asterisk__:__607542__:__POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 1; KCNQ1__:__KVLQT1;; POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 9; KCNA9;; KCNA8__:__
NULL__:__607543__:__SPONDYLOMETAPHYSEAL DYSPLASIA WITH BOWED FOREARMS AND FACIAL DYSMORPHISM__:__SMD WITH BOWED FOREARMS AND FACIAL DYSMORPHISM__:__
Asterisk__:__607544__:__LEUCINE-RICH PPR MOTIF-CONTAINING PROTEIN; LRPPRC__:__LEUCINE-RICH PROTEIN, 130-KD; LRP130__:__
Asterisk__:__607545__:__METHYLSTEROL MONOOXYGENASE 1; MSMO1__:__STEROL C4-METHYLOXIDASE-LIKE; SC4MOL;; ERG25__:__
Asterisk__:__607546__:__CD200 RECEPTOR 1; CD200R1__:__CD200R;; MOX2 RECEPTOR; MOX2R;; OX2 RECEPTOR; OX2R__:__
Asterisk__:__607547__:__RIBOSOMAL PROTEIN L39-LIKE; RPL39L__:____:__
Asterisk__:__607548__:__RADIAL SPOKEHEAD-LIKE 1; RSHL1__:____:__
Asterisk__:__607549__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER D; POTED__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 21; ANKRD21;; PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE; POTE;; PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 21; POTE21__:__
Asterisk__:__607550__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 10; SLC16A10__:__T-TYPE AMINO ACID TRANSPORTER 1; TAT1__:__
Asterisk__:__607551__:__STROMAL CELL-DERIVED FACTOR 2-LIKE 1; SDF2L1__:__SDF2-LIKE 1__:__
Caret__:__607552__:__MOVED TO 255320__:____:__
Asterisk__:__607553__:__EPIPLAKIN 1; EPPK1__:____:__
Number Sign__:__607554__:__ATRIAL FIBRILLATION, FAMILIAL, 3; ATFB3__:____:__
Asterisk__:__607555__:__TORSIN 3A; TOR3A__:__ATP-DEPENDENT INTERFERON-RESPONSIVE PROTEIN; ADIR__:__
Asterisk__:__607556__:__TWIST, DROSOPHILA, HOMOLOG OF, 2; TWIST2__:__DERMIS-EXPRESSED PROTEIN 1, MOUSE, HOMOLOG OF; DERMO1__:__
Asterisk__:__607557__:__SOLUTE CARRIER FAMILY 17 (VESICULAR GLUTAMATE COTRANSPORTER), MEMBER 8; SLC17A8__:__SOLUTE CARRIER FAMILY 17 (SODIUM-DEPENDENT PHOSPHATE COTRANSPORTER), MEMBER 8;; VESICULAR GLUTAMATE TRANSPORTER 3; VGLUT3__:__
Asterisk__:__607558__:__SEC14-LIKE 2; SEC14L2__:__SEC14, S. CEREVISIAE, HOMOLOG OF, 2;; TOCOPHEROL-ASSOCIATED PROTEIN 1; TAP1;; TAP KIAA1186__:__
Asterisk__:__607559__:__MAHOGUNIN, RING FINGER 1; MGRN1__:__MAHOGANOID, MOUSE, HOMOLOG OF;; KIAA0544__:__
Asterisk__:__607560__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; ARHGEF2__:__GEFH1;; KIAA0651__:__
Caret__:__607561__:__MOVED TO 210720__:____:__
Asterisk__:__607562__:__INTERLEUKIN 23 RECEPTOR; IL23R__:____:__
Asterisk__:__607563__:__SOLUTE CARRIER FAMILY 17 (VESICULAR GLUTAMATE COTRANSPORTER), MEMBER 6; SLC17A6__:__SOLUTE CARRIER FAMILY 17 (SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER), MEMBER 6;; VESICULAR GLUTAMATE TRANSPORTER 2; VGLUT2;; DIFFERENTIATION-ASSOCIATED SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER; DNPI;; SODIUM-DEPENDENT INORGANIC PHOSPHATE COTRANSPORTER, DIFFERENTIATION-ASSOCIATED__:__
Asterisk__:__607564__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 6; TRIM6__:____:__
NULL__:__607565__:__SPASTIC PARAPLEGIA, ATAXIA, AND MENTAL RETARDATION__:__SPAR__:__
Asterisk__:__607566__:__EPM2A GENE; EPM2A__:__LAFORIN__:__EPM2A, ISOFORM A, INCLUDED;; EPM2A, ISOFORM B, INCLUDED
Asterisk__:__607567__:__OLFACTOMEDIN 3; OLFM3__:__OPTIMEDIN;; NOELIN 3; NOE3__:__
Asterisk__:__607568__:__MMAB GENE; MMAB__:__COB(I)ALAMIN ADENOSYLTRANSFERASE__:__
NULL__:__607569__:__MYOPATHY, DISTAL, WITH EARLY RESPIRATORY FAILURE, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__607570__:__DEAH BOX POLYPEPTIDE 40; DHX40__:__DDX40__:__
Asterisk__:__607571__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL OXODICARBOXYLATE CARRIER), MEMBER 21; SLC25A21__:__OXODICARBOXYLATE CARRIER; ODC__:__
Percent__:__607572__:__LEPROSY, SUSCEPTIBILITY TO, 2; LPRS2__:____:__
Asterisk__:__607573__:__MICROTUBULE-ASSOCIATED PROTEIN 1S; MAP1S__:__MAP8;; BPY2-INTERACTING PROTEIN 1; BPY2IP1;; VCY2-INTERACTING PROTEIN 1; VCY2IP1;; CHROMOSOME 19 OPEN READING FRAME 5; C19ORF5__:__
Asterisk__:__607574__:__ARYLSULFATASE A; ARSA__:__CEREBROSIDE-SULFATASE;; CEREBROSIDE 3-SULFATASE__:__
Asterisk__:__607575__:__CAT EYE SYNDROME CHROMOSOME REGION, CANDIDATE 1; CECR1__:__ADENOSINE DEAMINASE 2; ADA2__:__
Asterisk__:__607576__:__CAT EYE SYNDROME CHROMOSOME REGION, CANDIDATE 2; CECR2__:__KIAA1740__:__
Asterisk__:__607577__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 4; ENTPD4__:__LYSOSOMAL APYRASE-LIKE PROTEIN 1; LYSAL1;; URIDINE DIPHOSPHATASE, GOLGI LUMINAL;; UDPase, GOLGI LUMINAL;; GOLGI LUMINAL UDPase;; LAP70; LALP70;; KIAA0392__:__
NULL__:__607578__:__BREATH-HOLDING SPELLS__:__BHS__:__
Asterisk__:__607579__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION/CATION TRANSPORTER), MEMBER 9; SLC22A9__:__ORGANIC ANION TRANSPORTER 4; OAT4;; UST3__:__
Asterisk__:__607580__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION/CATION TRANSPORTER), MEMBER 10; SLC22A10__:__ORGANIC ANION TRANSPORTER 5; OAT5__:__
Asterisk__:__607581__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION TRANSPORTER), MEMBER 8; SLC22A8__:__ORGANIC ANION TRANSPORTER 3; OAT3__:__
Asterisk__:__607582__:__SOLUTE CARRIER FAMILY 22 (ORGANIC ANION TRANSPORTER), MEMBER 6; SLC22A6__:__ORGANIC ANION TRANSPORTER 1; OAT1;; PARA-AMINOHIPPURATE TRANSPORTER; PAHT;; PAH TRANSPORTER__:__
Asterisk__:__607583__:__PEROXISOME BIOGENESIS FACTOR 11G; PEX11G__:__PEX11-GAMMA__:__
Percent__:__607584__:__SPASTIC PARAPLEGIA 24, AUTOSOMAL RECESSIVE; SPG24__:____:__
Asterisk__:__607585__:__ATAXIA-TELANGIECTASIA MUTATED GENE; ATM__:____:__
Asterisk__:__607586__:__CALCIUM RESPONSE FACTOR; CARF__:__ALS2 CHROMOSOME REGION GENE 8; ALS2CR8__:__
Asterisk__:__607587__:__INTERLEUKIN 17D; IL17D__:____:__
Asterisk__:__607588__:__PEPTIDYL-PROLYL ISOMERASE-LIKE 2; PPIL2__:__CYCLOPHILIN, 60-KD; CYP60__:__
Asterisk__:__607589__:__SERUM/GLUCOCORTICOID-REGULATED KINASE 2; SGK2__:____:__
Asterisk__:__607590__:__BBS7 GENE; BBS7__:__FLJ10715__:__
Asterisk__:__607591__:__SERUM/GLUCOCORTICOID-REGULATED KINASE 3; SGK3__:__SERUM/GLUCOCORTICOID-REGULATED KINASE-LIKE PROTEIN; SGKL;; CYTOKINE-INDEPENDENT SURVIVAL KINASE; CISK__:__
Percent__:__607592__:__PROSTATE CANCER AGGRESSIVENESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 19__:__HPCQTL19__:__
Asterisk__:__607593__:__MEDIATOR OF DNA DAMAGE CHECKPOINT PROTEIN 1; MDC1__:__NUCLEAR FACTOR WITH BRCT DOMAINS PROTEIN 1; NFBD1;; KIAA0170__:__
Number Sign__:__607594__:__IMMUNODEFICIENCY, COMMON VARIABLE, 1; CVID1__:__ANTIBODY DEFICIENCY DUE TO ICOS DEFECT__:__IMMUNODEFICIENCY, COMMON VARIABLE, INCLUDED; CVID, INCLUDED
Number Sign__:__607595__:__BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; BSVD__:__BRAIN SMALL VESSEL DISEASE WITH HEMORRHAGE;; INFANTILE HEMIPARESIS;; RETINAL ARTERIOLAR TORTUOSITY, INFANTILE HEMIPARESIS, AND LEUKOENCEPHALOPATHY, AUTOSOMAL DOMINANT;; BRAIN SMALL VESSEL DISEASE WITH AXENFELD-RIEGER ANOMALY;; LEUKOENCEPHALOPATHY WITH AXENFELD-RIEGER ANOMALY__:__
Number Sign__:__607596__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 1A; PCH1A__:__PCH1;; PONTOCEREBELLAR HYPOPLASIA WITH INFANTILE SPINAL MUSCULAR ATROPHY;; PONTOCEREBELLAR HYPOPLASIA WITH ANTERIOR HORN CELL DISEASE__:__
NULL__:__607597__:__MICROPHTHALMIA WITH CYST, BILATERAL FACIAL CLEFTS, AND LIMB ANOMALIES__:____:__
Number Sign__:__607598__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 2; LCCS2__:__MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE A__:__
Asterisk__:__607599__:__RETINOL DEHYDROGENASE 10; RDH10__:____:__
Percent__:__607600__:__EPIDERMOLYSIS BULLOSA SIMPLEX SUPERFICIALIS; EBSS__:____:__
Asterisk__:__607601__:__TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 1; TICAM1__:__TIR DOMAIN-CONTAINING ADAPTOR INDUCING INTERFERON-BETA; TRIF__:__
Number Sign__:__607602__:__ICHTHYOSIS, CYCLIC, WITH EPIDERMOLYTIC HYPERKERATOSIS__:__CIEHK;; EPIDERMOLYTIC ICHTHYOSIS, ANNULAR; AEI__:__
Asterisk__:__607603__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY G, MEMBER 4; KCNG4__:__KV6.3;; KV6.4__:__
Asterisk__:__607604__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY V, MEMBER 2; KCNV2__:__KV8.2__:__
Asterisk__:__607605__:__GLUTATHIONE S-TRANSFERASE, ALPHA-5; GSTA5__:__GLUTATHIONE S-TRANSFERASE A5__:__
Asterisk__:__607606__:__KERATIN 9, TYPE I; KRT9__:__K9;; KA9__:__
Asterisk__:__607607__:__NUCLEOPORIN, 54-KD; NUP54__:____:__
Asterisk__:__607608__:__SPHINGOMYELIN PHOSPHODIESTERASE 1, ACID LYSOSOMAL; SMPD1__:__SPHINGOMYELINASE, ACID; ASM__:__
Asterisk__:__607609__:__PEPTIDYL-PROLYL ISOMERASE-LIKE 4; PPIL4__:____:__
Asterisk__:__607610__:__PHOSPHOLIPID SCRAMBLASE 2; PLSCR2__:____:__
Asterisk__:__607611__:__PHOSPHOLIPID SCRAMBLASE 3; PLSCR3__:____:__
Asterisk__:__607612__:__PHOSPHOLIPID SCRAMBLASE 4; PLSCR4__:____:__
Asterisk__:__607613__:__NUCLEOPORIN, 133-KD; NUP133__:____:__
Asterisk__:__607614__:__NUCLEOPORIN, 160-KD; NUP160__:__NUP120;; KIAA0197__:__
Asterisk__:__607615__:__NUCLEOPORIN, 58-KD; NUP58__:__NUCLEOPORIN-LIKE 1; NUPL1;; KIAA0410__:__
Number Sign__:__607616__:__NIEMANN-PICK DISEASE, TYPE B__:____:__NIEMANN-PICK DISEASE, TYPE E, INCLUDED;; NIEMANN-PICK DISEASE, TYPE F, INCLUDED;; NIEMANN-PICK DISEASE, INTERMEDIATE, WITH VISCERAL INVOLVEMENT AND RAPID PROGRESSION, INCLUDED
Asterisk__:__607617__:__NUCLEOPORIN, 107-KD; NUP107__:__NUP84, YEAST, HOMOLOG OF; NUP84__:__
Asterisk__:__607618__:__DEAD/H BOX 28; DDX28__:__MITOCHONDRIAL DEAD BOX POLYPEPTIDE 28; MDDX28__:__
Asterisk__:__607619__:__FERM DOMAIN-CONTAINING PROTEIN 3; FRMD3__:__NONERYTHROID PROTEIN 4.1, OVARY TYPE;; PROTEIN 4.1O;; EPB41LO__:__
Asterisk__:__607620__:__COLLECTIN 10; COLEC10__:__COLLECTIN, LIVER, 1; CLL1__:__
Asterisk__:__607621__:__COLLECTIN 12; COLEC12__:__SCAVENGER RECEPTOR WITH C-TYPE LECTIN DOMAIN; SRCL;; COLLECTIN, PLACENTA, 1; CLP1;; SCAVENGER RECEPTOR CLASS A, MEMBER 4; SCARA4__:__
Asterisk__:__607622__:__PHOSPHOMEVALONATE KINASE; PMVK__:__PMK;; PMKase__:__
Asterisk__:__607623__:__NPC1 GENE; NPC1__:____:__
Number Sign__:__607624__:__GRISCELLI SYNDROME, TYPE 2; GS2__:__GRISCELLI SYNDROME WITH HEMOPHAGOCYTIC SYNDROME;; PARTIAL ALBINISM AND IMMUNODEFICIENCY SYNDROME;; PAID SYNDROME__:__
Number Sign__:__607625__:__NIEMANN-PICK DISEASE, TYPE C2; NPC2__:____:__
Number Sign__:__607626__:__ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS; ILVASC__:__ICHTHYOSIS-SCLEROSING CHOLANGITIS SYNDROME;; NEONATAL ICHTHYOSIS-SCLEROSING CHOLANGITIS SYNDROME;; NISCH SYNDROME__:__
Asterisk__:__607627__:__BREAST CANCER- AND SALIVARY GLAND-EXPRESSED GENE__:__BASE__:__
Number Sign__:__607628__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 11; EIG11__:____:__EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 8, INCLUDED; EJM8, INCLUDED;; EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 2, INCLUDED; EJA2, INCLUDED
Asterisk__:__607629__:__ANTERIOR PHARYNX DEFECTIVE 1, C. ELEGANS, HOMOLOG OF, A; APH1A__:____:__
Asterisk__:__607630__:__ANTERIOR PHARYNX DEFECTIVE 1, C. ELEGANS, HOMOLOG OF, B; APH1B__:____:__
Number Sign__:__607631__:__EPILEPSY, JUVENILE ABSENCE, SUSCEPTIBILITY TO, 1; EJA1__:__JAE1__:__
Asterisk__:__607632__:__PRESENILIN ENHANCER 2, C. ELEGANS, HOMOLOG OF; PSENEN__:__PEN2__:__
Asterisk__:__607633__:__XANTHINE DEHYDROGENASE; XDH__:__XANTHINE OXIDOREDUCTASE; XOR;; XANTHINE OXIDASE; XO__:__
Number Sign__:__607634__:__OSTEOPETROSIS, AUTOSOMAL DOMINANT 1; OPTA1__:__OSTEOPETROSIS, AUTOSOMAL DOMINANT, TYPE I__:__
Asterisk__:__607635__:__CARBOXYPEPTIDASE A4; CPA4__:__CPA3__:__
Number Sign__:__607636__:__VAN BUCHEM DISEASE, TYPE 2__:__VBCH2__:__
Asterisk__:__607637__:__EMX2 OPPOSITE STRAND; EMX2OS__:__EMX2-ANTISENSE__:__
Asterisk__:__607638__:__DEOXYCYTIDYLATE DEAMINASE; DCTD__:____:__
Asterisk__:__607639__:__SCAVENGER RECEPTOR CYSTEINE-RICH FAMILY MEMBER WITH 4 DOMAINS; SSC4D__:__PROTEIN WITH 4 GROUP B SCAVENGER RECEPTOR CYSTEINE-RICH DOMAINS; SRCRB4D;; S4D-SRCRB__:__
Asterisk__:__607640__:__ATAXIN 7; ATXN7__:____:__
Number Sign__:__607641__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB; HMN7B__:__HMN VIIB;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VIIB;; DHMN7B;; NEUROPATHY, DISTAL HEREDITARY MOTOR, WITH VOCAL CORD PARALYSIS, TYPE VIIB;; LOWER MOTOR NEURON DISEASE, DYNACTIN TYPE__:__
Asterisk__:__607642__:__RETINOIC ACID-INDUCED GENE 1; RAI1__:__RETINOIC ACID-INDUCIBLE 1__:__
Asterisk__:__607643__:__FASCIN ACTIN-BUNDLING PROTEIN 2, RETINAL; FSCN2__:__FASCIN, SEA URCHIN, HOMOLOG OF, 2;; FASCIN, RETINAL; RFSN__:__
Percent__:__607644__:__CANDIDIASIS, FAMILIAL, 3; CANDF3__:__CANDIDIASIS, FAMILIAL CHRONIC NAIL, WITH ICAM1 DEFICIENCY; CANDN1;; FCNC__:__
Asterisk__:__607645__:__D4S234E GENE; D4S234E__:____:__
Asterisk__:__607646__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 7B; ZBTB7B__:__ZINC FINGER PROTEIN 67, MOUSE, HOMOLOG OF; ZFP67;; COLLAGEN KROX PROTEIN; CKROX;; T HELPER-INDUCING POZ/KRUPPEL-LIKE FACTOR; THPOK__:__
Asterisk__:__607647__:__PLASMALEMMA VESICLE-ASSOCIATED PROTEIN; PLVAP__:__PLASMALEMMA VESICLE PROTEIN 1; PV1__:__
Asterisk__:__607648__:__SERINE/THREONINE PROTEIN KINASE 39; STK39__:__STE20/SPS1-RELATED PROLINE- AND ALANINE-RICH KINASE; SPAK__:__
Asterisk__:__607649__:__OSTEOPETROSIS-ASSOCIATED TRANSMEMBRANE PROTEIN 1; OSTM1__:__GREY-LETHAL, MOUSE, HOMOLOG OF; GL__:__
Asterisk__:__607650__:__DEFENSIN, BETA, 118; DEFB118__:__CHROMOSOME 20 OPEN READING FRAME 63; C20ORF63;; EPIDIDYMIS-SPECIFIC CLONE 42; ESC42__:__
Asterisk__:__607651__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY B, MEMBER 1; PLEKHB1__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, RETINAL, 1; PHR1;; KPL1__:__
Asterisk__:__607652__:__SERINE/THREONINE PROTEIN KINASE 36; STK36__:__FUSED, DROSOPHILA, HOMOLOG OF; FU;; KIAA1278__:__
Asterisk__:__607653__:__RAS HOMOLOG GENE FAMILY, MEMBER J; RHOJ__:__ARHJ;; TC10-LIKE PROTEIN; TCL;; TC10-BETA__:__
Number Sign__:__607654__:__KERATOSIS PALMOPLANTARIS STRIATA III; PPKS3__:__STRIATE PALMOPLANTAR KERATODERMA III; SPPK3;; KERATODERMA, PALMOPLANTAR, STRIATE FORM III; KPPS3__:__
Number Sign__:__607655__:__SKIN FRAGILITY-WOOLLY HAIR SYNDROME; SFWHS__:____:__
Percent__:__607656__:__CURLY HAIR-ACRAL KERATODERMA-CARIES SYNDROME__:__CHACS__:__
Asterisk__:__607657__:__CYSTATHIONINE GAMMA-LYASE; CTH__:__CYSTATHIONASE__:__
Percent__:__607658__:__HYPOTRICHOSIS-OSTEOLYSIS-PERIODONTITIS-PALMOPLANTAR KERATODERMA SYNDROME__:__HOPP SYNDROME__:__
Asterisk__:__607659__:__ELL-ASSOCIATED FACTOR 2; EAF2__:____:__
Asterisk__:__607660__:__TESTIS-SPECIFIC SERINE/THREONINE KINASE 3; TSSK3__:__SERINE/THREONINE PROTEIN KINASE 22C; STK22C;; STK22D, MOUSE, HOMOLOG OF; STK22D__:__
Asterisk__:__607661__:__SPERM-ASSOCIATED ANTIGEN 10; SPAG10__:____:__
Asterisk__:__607662__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 2; SPATA2__:__KIAA0757__:__
Asterisk__:__607663__:__DEAD BOX POLYPEPTIDE 25; DDX25__:__GONADOTROPIN-REGULATED TESTICULAR RNA HELICASE; GRTH__:__
Asterisk__:__607664__:__N-ACETYLGLUCOSAMINE-6-SULFATASE; GNS__:__GLUCOSAMINE-6-SULFATASE; G6S__:__
NULL__:__607665__:__TUBULOINTERSTITIAL NEPHRITIS WITH UVEITIS; TINU__:____:__ACUTE TUBULOINTERSTITIAL NEPHRITIS, INCLUDED; ATIN, INCLUDED
Asterisk__:__607666__:__ANGIOPOIETIN-LIKE 5; ANGPTL5__:____:__
Asterisk__:__607667__:__CATENIN, ALPHA-3; CTNNA3__:__ALPHA-T-CATENIN;; VR22__:__
Asterisk__:__607668__:__ADP-RIBOSYLATION-LIKE FACTOR 6-INTERACTING PROTEIN 4; ARL6IP4__:____:__
Asterisk__:__607669__:__ADP-RIBOSYLATION-LIKE FACTOR 6-INTERACTING PROTEIN 1; ARL6IP1__:__ARL6IP;; KIAA0069__:__
Asterisk__:__607670__:__SERINE/THREONINE PROTEIN KINASE 33; STK33__:____:__
Percent__:__607671__:__DYSTONIA 13, TORSION, AUTOSOMAL DOMINANT; DYT13__:____:__
Asterisk__:__607672__:__CARDIOTROPHIN-LIKE CYTOKINE FACTOR 1; CLCF1__:__CLC;; B-CELL STIMULATORY FACTOR 3; BSF3__:__
Asterisk__:__607673__:__ENDOPLASMIC RETICULUM DEGRADATION-ENHANCING ALPHA-MANNOSIDASE-LIKE PROTEIN 1; EDEM1__:__EDEM;; KIAA0212__:__
Percent__:__607674__:__CATARACT, CONGENITAL, WITH MENTAL IMPAIRMENT AND DENTATE GYRUS ATROPHY__:____:__
Asterisk__:__607675__:__REST COREPRESSOR; RCOR__:__COREST;; KIAA0071__:__
Number Sign__:__607676__:__IRAK4 DEFICIENCY__:__IRAK4D__:__
Number Sign__:__607677__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2I__:__
Number Sign__:__607678__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D__:__HEREDITARY MOTOR AND SENSORY NEUROPATHY 1D;; HMSN ID;; HMSN1D;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1D__:__
Asterisk__:__607679__:__DEDICATOR OF CYTOKINESIS 4; DOCK4__:__KIAA0716__:__
Asterisk__:__607680__:__ZINC FINGER PROTEIN 363; ZNF363__:__p53-INDUCED PROTEIN, RING-H2 DOMAIN-CONTAINING; PIRH2;; ANDROGEN RECEPTOR N-TERMINAL DOMAIN-INTERACTING PROTEIN; ARNIP__:__
Number Sign__:__607681__:__EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2; ECA2__:____:__
Number Sign__:__607682__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 9; EIG9__:____:__EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 6, INCLUDED; EJM6, INCLUDED
Percent__:__607683__:__DEAFNESS, AUTOSOMAL DOMINANT 52; DFNA52__:__DEAFNESS, AUTOSOMAL DOMINANT 42; DFNA42__:__
Number Sign__:__607684__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E__:__
Number Sign__:__607685__:__HYPEREOSINOPHILIC SYNDROME, IDIOPATHIC; HES__:____:__
Asterisk__:__607686__:__FIP1-LIKE 1; FIP1L1__:____:__FIP1L1/PDGFRA FUSION GENE, INCLUDED
Percent__:__607687__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 3__:__HDLCQ3__:__
Number Sign__:__607688__:__PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK11__:____:__
Caret__:__607689__:__MOVED TO 246700__:____:__
Asterisk__:__607690__:__SAR1, S. CEREVISIAE, HOMOLOG B; SAR1B__:__SAR1A, S. CEREVISIAE, HOMOLOG 2; SARA2__:__
Asterisk__:__607691__:__SAR1, S. CEREVISIAE, HOMOLOG OF, A; SAR1A__:__SAR1A, S. CEREVISIAE, HOMOLOG OF, 1; SARA1__:__
Caret__:__607692__:__MOVED TO 248800 AND 246700__:____:__
Asterisk__:__607693__:__SELENOCYSTEINE INSERTION SEQUENCE-BINDING PROTEIN 2; SECISBP2__:__SECIS-BINDING PROTEIN 2; SBP2__:__
Number Sign__:__607694__:__LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD7__:__LEUKOENCEPHALOPATHY, HYPOMYELINATING, WITH ATAXIA AND DELAYED DENTITION;; ATAXIA, DELAYED DENTITION, AND HYPOMYELINATION; ADDH;; LEUKODYSTROPHY, HYPOMYELINATING, WITH HYPODONTIA AND HYPOGONADOTROPIC HYPOGONADISM;; 4H SYNDROME__:__
Asterisk__:__607695__:__EUKARYOTIC ELONGATION FACTOR, SELENOCYSTEINE-tRNA-SPECIFIC; EEFSEC__:__SELENOPROTEIN TRANSLATION FACTOR SELB; SELB;; EFSEC__:__
Asterisk__:__607696__:__USH1G GENE; USH1G__:__SCAFFOLD PROTEIN CONTAINING ANKYRIN REPEATS AND SAM DOMAIN; SANS__:__
Asterisk__:__607697__:__SET-BINDING FACTOR 2; SBF2__:__MYOTUBULARIN-RELATED 13; MTMR13;; KIAA1766__:__
Asterisk__:__607698__:__LIGAND-DEPENDENT NUCLEAR RECEPTOR COREPRESSOR; LCOR__:__MBLK1-RELATED PROTEIN 2; MLR2;; KIAA1795__:__CHROMOSOME 10 OPEN READING FRAME 12, INCLUDED; C10ORF12, INCLUDED;; PRC2-ASSOCIATED LCOR ISOFORM 1, INCLUDED; PALI1, INCLUDED
Asterisk__:__607699__:__RING FINGER PROTEIN 20; RNF20__:__BRE1, S. CEREVISIAE, HOMOLOG OF, A; BRE1A__:__
Asterisk__:__607700__:__RING FINGER PROTEIN 40; RNF40__:__BRE1, S. CEREVISIAE, HOMOLOG OF, B; BRE1B;; SYNTAXIN 1-INTERACTING RING FINGER PROTEIN; STARING;; RB1-BINDING PROTEIN, 95-KD; RBP95;; KIAA0661__:__
Asterisk__:__607701__:__KELCH-LIKE 41; KLHL41__:__KELCH REPEAT- AND BTB/POZ DOMAIN-CONTAINING PROTEIN 10; KBTBD10;; SARCOSIN__:__
Asterisk__:__607702__:__TRANSCRIPTIONAL AND IMMUNE RESPONSE REGULATOR; TCIM__:__CHROMOSOME 8 OPEN READING FRAME 4; C8ORF4;; THYROID CANCER 1; TC1__:__
Asterisk__:__607703__:__NUCLEOPORIN, 210-KD; NUP210__:__GP210;; KIAA0906__:__
Asterisk__:__607704__:__KN MOTIF- AND ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 1; KANK1__:__KIDNEY ANKYRIN REPEAT-CONTAINING PROTEIN; KANK;; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 15; ANKRD15;; KIAA0172__:__
Asterisk__:__607705__:__PROTEASOME ACTIVATOR SUBUNIT 4; PSME4__:__PROTEASOME ACTIVATOR, 200-KD; PA200;; KIAA0077__:__
Number Sign__:__607706__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE__:__CMT2 WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 4A, AXONAL FORM;; CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE__:__
Asterisk__:__607707__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II-BETA; CAMK2B__:____:__
Asterisk__:__607708__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II-DELTA; CAMK2D__:____:__
Asterisk__:__607709__:__TIGHT JUNCTION PROTEIN 2; TJP2__:__ZONA OCCLUDENS 2; ZO2__:__
Asterisk__:__607710__:__FAMILY WITH SEQUENCE SIMILARITY 189, MEMBER A2; FAM189A2__:__X123 GENE;; CHROMOSOME 9 OPEN READING FRAME 61; C9ORF61__:__
Asterisk__:__607711__:__DISCO-INTERACTING PROTEIN 2, DROSOPHILA, HOMOLOG OF, A; DIP2A__:__DIP2;; KIAA0184__:__
Asterisk__:__607712__:__HYPERMETHYLATED IN CANCER 2; HIC2__:__HIC1-RELATED GENE ON CHROMOSOME 22; HRG22;; KIAA1020__:__
Asterisk__:__607713__:__KILLER-SPECIFIC SECRETORY PROTEIN, 37-KD__:__KSP37__:__
Asterisk__:__607714__:__TNFAIP3-INTERACTING PROTEIN 1; TNIP1__:__NEF-ASSOCIATED FACTOR 1; NAF1;; A20-BINDING INHIBITOR OF NFKB 1; ABIN1;; KIAA0113__:__
Asterisk__:__607715__:__TSC22 DOMAIN FAMILY, MEMBER 1; TSC22D1__:__TSC22__:__
Asterisk__:__607716__:__SYNAPTOTAGMIN 13; SYT13__:__KIAA1427__:__
Asterisk__:__607717__:__TENSIN 2; TNS2__:__TENSIN-LIKE C1 DOMAIN-CONTAINING PHOSPHATASE; TENC1;; C1TEN;; KIAA1075__:__
Asterisk__:__607718__:__SYNAPTOTAGMIN 6; SYT6__:____:__
Asterisk__:__607719__:__SYNAPTOTAGMIN 8; SYT8__:____:__
Asterisk__:__607720__:__TRANSLIN-ASSOCIATED FACTOR X-INTERACTING PROTEIN 1; TSNAXIP1__:__TSNAX-INTERACTING PROTEIN 1;; TRAX-INTERACTING PROTEIN 1; TXI1__:__
Number Sign__:__607721__:__NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR 1; NSLH1__:__NSLH;; TOSTI SYNDROME__:__
Asterisk__:__607722__:__ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 2; EMC2__:__ER MEMBRANE PROTEIN COMPLEX, SUBUNIT 2;; KIAA0103__:__
Asterisk__:__607723__:__SAD1 AND UNC84 DOMAIN-CONTAINING PROTEIN 1; SUN1__:__SUN DOMAIN-CONTAINING PROTEIN 1;; UNC84, C. ELEGANS, HOMOLOG OF, A; UNC84A;; KIAA0810__:__
Asterisk__:__607724__:__CALCYPHOSINE 2; CAPS2__:____:__
Asterisk__:__607725__:__POLY(ADP-RIBOSE) POLYMERASE 2; PARP2__:__ADP-RIBOSYLTRANSFERASE-LIKE 2; ADPRTL2;; ADP-RIBOSYLTRANSFERASE 2; ADPRT2__:__
Asterisk__:__607726__:__POLY(ADP-RIBOSE) POLYMERASE 3; PARP3__:__ADP-RIBOSYLTRANSFERASE-LIKE 3; ADPRTL3__:__
Asterisk__:__607727__:__CULLIN-ASSOCIATED NEDDYLATION-DISSOCIATED PROTEIN 1; CAND1__:__TBP-INTERACTING PROTEIN, 120-KD, A;; TIP120A;; TIP120;; p120(CAND1);; KIAA0829__:__
Percent__:__607728__:__POROKERATOSIS 4, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK4__:__POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 2; DSAP2__:__
Asterisk__:__607729__:__DNA DAMAGE-INDUCIBLE TRANSCRIPT 4; DDIT4__:__REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1; REDD1;; HIF1-RESPONSIVE PROTEIN RTP801; RTP801__:__
Asterisk__:__607730__:__DNA DAMAGE-INDUCIBLE TRANSCRIPT 4-LIKE; DDIT4L__:__REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 2; REDD2__:__
Percent__:__607731__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2H; CMT2H__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, WITH PYRAMIDAL FEATURES, AUTOSOMAL RECESSIVE;; CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH PYRAMIDAL FEATURES, AUTOSOMAL RECESSIVE__:__
Asterisk__:__607732__:__STERILE ALPHA AND TIR MOTIFS-CONTAINING PROTEIN 1; SARM1__:__STERILE ALPHA AND HEAT/ARMADILLO MOTIFS-CONTAINING PROTEIN; SARM;; KIAA0524__:__
Asterisk__:__607733__:__SCRIBBLE, DROSOPHILA, HOMOLOG OF; SCRIB__:__SCRIBBLE 1; SCRB1;; CIRCLETAIL, MOUSE, HOMOLOG OF;; KIAA0147__:__
Number Sign__:__607734__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1F; CMT1F__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F__:__
Asterisk__:__607735__:__PROGESTERONE RECEPTOR MEMBRANE COMPONENT 2; PGRMC2__:____:__
Number Sign__:__607736__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2J; CMT2J__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2J;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 2, WITH HEARING LOSS AND PUPILLARY ABNORMALITIES__:__
Asterisk__:__607737__:__FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 1; FGFBP1__:__FGF-BINDING PROTEIN 1; FGFBP;; HEPARIN-BINDING GROWTH FACTOR-BINDING PROTEIN, 17-KD; HBP17;; HBGF-BINDING PROTEIN, 17-KD__:__
Asterisk__:__607738__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SHAB-RELATED SUBFAMILY, MEMBER 2; KCNB2__:__KV2.2__:__
Caret__:__607739__:__MOVED TO 604563__:____:__
Asterisk__:__607740__:__UBIQUITIN-SPECIFIC PROTEASE 32; USP32__:__NY-REN-60__:__
Asterisk__:__607741__:__TBC1 DOMAIN FAMILY, MEMBER 3; TBC1D3__:__TBC1D3A__:__
Asterisk__:__607742__:__KERATIN 24, TYPE I; KRT24__:__K24;; KA24;; FLJ20261__:__
Asterisk__:__607743__:__FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2; FRS2__:__FGFR SUBSTRATE 2;; FRS2-ALPHA; FRS2A;; SUC1-ASSOCIATED NEUROTROPHIC FACTOR TARGET 1; SNT1; SNT__:__
Asterisk__:__607744__:__FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 3; FRS3__:__FGFR SUBSTRATE 3;; FRS2-BETA; FRS2B;; SUC1-ASSOCIATED NEUROTROPHIC FACTOR TARGET 2; SNT2__:__
Number Sign__:__607745__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 3; BFIS3__:__CONVULSIONS, BENIGN FAMILIAL INFANTILE, 3; BFIC3;; SEIZURES, BENIGN FAMILIAL NEONATAL-INFANTILE; BFNIS__:__
Asterisk__:__607746__:__FERMITIN FAMILY, MEMBER 2; FERMT2__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY C, MEMBER 1; PLEKHC1;; MITOGEN-INDUCIBLE GENE 2; MIG2;; UNC112, C. ELEGANS, HOMOLOG OF; UNC112;; KINDLIN 2; KIND2__:__
Asterisk__:__607747__:__FILAMIN-BINDING LIM PROTEIN 1; FBLP1__:__MIG2- AND FILAMIN-INTERACTING PROTEIN; MIGFILIN__:__
Number Sign__:__607748__:__HYPERCHOLANEMIA, FAMILIAL; FHCA__:____:__
Asterisk__:__607749__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 3; CDCA3__:__TRIGGER OF MITOTIC ENTRY 1; TOME1__:__
Asterisk__:__607750__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3C; APOBEC3C__:__A3C__:__
Asterisk__:__607751__:__TASTE RECEPTOR, TYPE 2, MEMBER 38; TAS2R38__:__TRANSFORMING GROWTH FACTOR BETA-STIMULATED CLONE 22; TSC22;; PTC;; T2R61__:__
Asterisk__:__607752__:__CYCLIN O; CCNO__:__URACIL-DNA GLYCOSYLASE 2; UNG2; UDG2;; URACIL-DNA GLYCOSYLASE, CYCLIN-LIKE__:__
Asterisk__:__607753__:__SINGLE-STRAND-SELECTIVE MONOFUNCTIONAL URACIL-DNA GLYCOSYLASE 1__:__SMUG1__:__
Asterisk__:__607754__:__MAKORIN 1; MKRN1__:____:__
Asterisk__:__607755__:__MITOGEN-ACTIVATED PROTEIN KINASE 8-INTERACTING PROTEIN 2; MAPK8IP2__:__JNK-INTERACTING PROTEIN 2; JIP2;; ISLET-BRAIN 2; IB2__:__
Asterisk__:__607756__:__ALPHA-AMINOADIPATE SEMIALDEHYDE DEHYDROGENASE-PHOSPHOPANTETHEINYL TRANSFERASE; AASDHPPT__:__AASDPPT;; LYS5, S. CEREVISIAE, HOMOLOG OF;; CGI-80;; DKFZP566E2346__:__
Asterisk__:__607757__:__CHIBBY; CBY__:__HS508I15A;; C22ORF2__:__
Asterisk__:__607758__:__CATENIN, BETA-INTERACTING PROTEIN 1; CTNNBIP1__:__INHIBITOR OF BETA-CATENIN AND TCF4; ICAT__:__
Asterisk__:__607759__:__INTEGRIN, ALPHA-2B; ITGA2B__:__PLATELET GLYCOPROTEIN IIb; GP2B;; GP IIb;; PLATELET FIBRINOGEN RECEPTOR, ALPHA SUBUNIT;; CD41B__:__PLATELET-SPECIFIC ANTIGEN BAK, INCLUDED
Asterisk__:__607760__:__DNA TOPOISOMERASE II-BINDING PROTEIN 1; TOPBP1__:__KIAA0259__:__
Asterisk__:__607761__:__KIN OF IRRE-LIKE 3; KIRREL3__:__NEPHRIN-LIKE 2; NEPH2;; KIAA1867;; KIRRE, MOUSE, HOMOLOG OF__:__
Asterisk__:__607762__:__KIN OF IRRE-LIKE 2; KIRREL2__:__NEPHRIN-LIKE 3; NEPH3;; NEPHRIN-LIKE GENE 1; NLG1;; FILTRIN__:__
Asterisk__:__607763__:__CENTAURIN, BETA-1; CENTB1__:__KIAA0050;; ARF-GAP WITH COILED-COIL, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS 1; ACAP1__:__
Asterisk__:__607764__:__3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE; HSD3B7__:__C27-3-BETA-HSD__:__
Number Sign__:__607765__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1__:__3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY__:__
Asterisk__:__607766__:__CENTAURIN, BETA-2; CENTB2__:__KIAA0041;; ARF-GAP WITH COILED-COIL, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS 2; ACAP2__:__
Asterisk__:__607767__:__SESTRIN 2; SESN2__:__SEST2;; HYPOXIA-INDUCED GENE 95; HI95__:__
Asterisk__:__607768__:__SESTRIN 3; SESN3__:__SEST3__:__
Asterisk__:__607769__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 4; PLEKHA4__:__PHOSPHATIDYLINOSITOL 3-PHOSPHATE-BINDING PH DOMAIN PROTEIN 1; PEPP1__:__
Asterisk__:__607770__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 5; PLEKHA5__:__PHOSPHATIDYLINOSITOL 3-PHOSPHATE-BINDING PH DOMAIN PROTEIN 2; PEPP2;; KIAA1686__:__
Asterisk__:__607771__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 6; PLEKHA6__:__PHOSPHATIDYLINOSITOL 3-PHOSPHATE-BINDING PH DOMAIN PROTEIN 3; PEPP3;; KIAA0969__:__
Asterisk__:__607772__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 1; PLEKHA1__:__TANDEM PH DOMAIN-CONTAINING PROTEIN 1; TAPP1__:__
Asterisk__:__607773__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 2; PLEKHA2__:__TANDEM PH DOMAIN-CONTAINING PROTEIN 2; TAPP2__:__
Asterisk__:__607774__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 3; PLEKHA3__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE ADAPTOR PROTEIN 1; FAPP1__:__
Asterisk__:__607775__:__POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 4; KCNE4__:__MINIMUM POTASSIUM ION CHANNEL-RELATED PEPTIDE 3; MIRP3;; MINK-RELATED PEPTIDE 3__:__
Asterisk__:__607776__:__SIN3, YEAST, HOMOLOG OF, A; SIN3A__:____:__
Asterisk__:__607777__:__SIN3, YEAST, HOMOLOG OF, B; SIN3B__:__KIAA0700__:__
Number Sign__:__607778__:__ACROCAPITOFEMORAL DYSPLASIA; ACFD__:____:__
Asterisk__:__607779__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 7; PAQR7__:__MEMBRANE PROGESTIN RECEPTOR, ALPHA; MPRA;; PGLP, MOUSE, HOMOLOG OF; PGLP__:__
Asterisk__:__607780__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 8; PAQR8__:__CHROMOSOME 6 OPEN READING FRAME 33; C6ORF33;; LYSOSOMAL MEMBRANE PROTEIN, BRAIN-EXPRESSED, 1; LMPB1;; MEMBRANE PROGESTIN RECEPTOR, BETA; MPRB__:__
Asterisk__:__607781__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 5; PAQR5__:__MEMBRANE PROGESTIN RECEPTOR, GAMMA; MPRG__:__
Asterisk__:__607782__:__LUC7, S. CEREVISIAE, HOMOLOG OF; LUC7L__:__LUC7-LIKE__:__
Asterisk__:__607783__:__MESODERM DEVELOPMENT CANDIDATE GENE 2; MESDC2__:__MESODERM DEVELOPMENT GENE; MESD;; KIAA0081;; BOCA, DROSOPHILA, HOMOLOG OF; BOCA__:__MESDC2/SENP1 FUSION GENE, INCLUDED
Asterisk__:__607784__:__ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 4; ABCG4__:__WHITE, DROSOPHILA, HOMOLOG OF, 2; WHITE2__:__
Number Sign__:__607785__:__JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML__:__LEUKEMIA, JUVENILE MYELOMONOCYTIC__:__LEUKEMIA, CHRONIC MYELOMONOCYTIC, INCLUDED; CMML, INCLUDED
Asterisk__:__607786__:__PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 9; PCSK9__:__NEURAL APOPTOSIS-REGULATED CONVERTASE 1; NARC1__:__
Asterisk__:__607787__:__G PROTEIN-COUPLED RECEPTOR 180; GPR180__:__INTIMAL THICKNESS-RELATED RECEPTOR; ITR__:__
Asterisk__:__607788__:__MULTIPLE COAGULATION FACTOR DEFICIENCY PROTEIN 2; MCFD2__:____:__
Asterisk__:__607789__:__PHD FINGER PROTEIN 3; PHF3__:__KIAA0244__:__
Asterisk__:__607790__:__TET ONCOGENE FAMILY, MEMBER 1; TET1__:__METHYLCYTOSINE DIOXYGENASE TET1;; TET ONCOGENE 1;; CXXC FINGER PROTEIN 6; CXXC6;; LEUKEMIA-ASSOCIATED PROTEIN WITH A CXXC DOMAIN; LCX;; KIAA1676__:__
Number Sign__:__607791__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D; CMTDID__:__CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE D;; DI-CMTD__:__
Asterisk__:__607792__:__GERMINAL CENTER-ASSOCIATED, SIGNALING AND MOTILITY; GCSAM__:__GERMINAL CENTER-EXPRESSED TRANSCRIPT 2; GCET2;; HGAL__:__
Asterisk__:__607793__:__PETER PAN, DROSOPHILA, HOMOLOG OF; PPAN__:__SSF1, S. CEREVISIAE, HOMOLOG OF; SSF1__:__PPAN/P2RY11 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__607794__:__MEST INTRONIC TRANSCRIPT 1; MESTIT1__:____:__
Asterisk__:__607795__:__PRECURSOR mRNA-PROCESSING FACTOR 4, S. CEREVISIAE, HOMOLOG OF; PRPF4__:__PRP4;; HPRP4__:__
Asterisk__:__607796__:__PHD FINGER PROTEIN 11; PHF11__:__NY-REN-34__:__
Asterisk__:__607797__:__SMALL NUCLEAR RIBONUCLEOPROTEIN, 40-KD; SNRNP40__:__U5 snRNP-SPECIFIC PROTEIN, 40-KD;; SPLICING FACTOR, 38-KD; SPF38;; PRPF8-BINDING PROTEIN; PRPF8BP__:__
Asterisk__:__607798__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1-LIKE; TAF1L__:__TAF1 RNA POLYMERASE II-LIKE__:__
Asterisk__:__607799__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 17; ZDHHC17__:__HUNTINGTIN-INTERACTING PROTEIN 14; HIP14__:__
Asterisk__:__607800__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 12; ABCA12__:____:__
Caret__:__607801__:__MOVED TO 606072__:____:__
Asterisk__:__607802__:__CYCLIN M1; CNNM1__:__ANCIENT CONSERVED DOMAIN PROTEIN 1; ACDP1__:__
Asterisk__:__607803__:__CYCLIN M2; CNNM2__:__ANCIENT CONSERVED DOMAIN PROTEIN 2; ACDP2__:__
Asterisk__:__607804__:__CYCLIN M3; CNNM3__:__ANCIENT CONSERVED DOMAIN PROTEIN 3; ACDP3__:__
Asterisk__:__607805__:__CYCLIN M4; CNNM4__:__ANCIENT CONSERVED DOMAIN PROTEIN 4; ACDP4;; KIAA1592__:__
Asterisk__:__607806__:__OTOPETRIN 1; OTOP1__:____:__
Asterisk__:__607807__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 13; ABCA13__:____:__
Asterisk__:__607808__:__NK2 HOMEOBOX 4; NKX2-4__:__NK2, DROSOPHILA, HOMOLOG OF, D; NKX2D;; NKX2.4, MOUSE, HOMOLOG OF__:__
Asterisk__:__607809__:__ACETYL-CoA ACETYLTRANSFERASE 1; ACAT1__:__ACAT;; ACETOACETYL-CoA THIOLASE, MITOCHONDRIAL;; T2;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE; MAT__:__
Asterisk__:__607810__:__RADICAL S-ADENOSYL METHIONINE DOMAIN-CONTAINING PROTEIN 2; RSAD2__:__VIRUS INHIBITORY PROTEIN, ENDOPLASMIC RETICULUM-ASSOCIATED, INTERFERON-INDUCIBLE; VIPERIN__:__
Asterisk__:__607811__:__p21-ACTIVATED KINASE- AND PHOSPHOLIPASE C-INTERACTING PROTEIN 1; PAK1IP1__:__PAK- AND PLC-INTERACTING PROTEIN 1; PIP1;; PAK1-INTERACTING PROTEIN__:__
Number Sign__:__607812__:__CRANIOLENTICULOSUTURAL DYSPLASIA; CLSD__:__BOYADJIEV-JABS SYNDROME__:__
Asterisk__:__607813__:__PHOSPHOLIPID PHOSPHATASE-RELATED PROTEIN 4; PLPPR4__:__PLASTICITY-RELATED GENE 1;; LIPID PHOSPHATE PHOSPHATASE-RELATED 4; LPPR4;; LPR4;; PRG1;; KIAA0455__:__
Asterisk__:__607814__:__REGULATOR OF G PROTEIN SIGNALING 9-BINDING PROTEIN; RGS9BP__:__RGS9-BINDING PROTEIN;; RGS9 ANCHOR PROTEIN; R9AP__:__
Asterisk__:__607815__:__ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS-CONTAINING PROTEIN 1B; ANKS1B__:__E2A/PBX1-ACTIVATED GENE IN PRE-B CELLS 1; EB1__:__
Asterisk__:__607816__:__POLYCOMB GROUP RING FINGER PROTEIN 6; PCGF6__:__RING FINGER PROTEIN 134; RNF134;; MEL18- AND BMI1-LIKE RING FINGER PROTEIN; MBLR__:__
Asterisk__:__607817__:__VACUOLAR PROTEIN SORTING 13, YEAST, HOMOLOG OF, B; VPS13B__:__COH1 GENE; COH1;; KIAA0532__:__
Asterisk__:__607818__:__ZINC FINGER PROTEIN 365; ZNF365__:__SU48;; KIAA0844__:__TALANIN, INCLUDED; TALN, INCLUDED
Asterisk__:__607819__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 5; SLC30A5__:__ZINC TRANSPORTER 5; ZNT5;; ZNT1-LIKE 1; ZTL1__:__
Asterisk__:__607820__:__HOOK, DROSOPHILA, HOMOLOG OF, 1; HOOK1__:__HK1__:__
Number Sign__:__607821__:__DEAFNESS, AUTOSOMAL RECESSIVE 37; DFNB37__:____:__
Number Sign__:__607822__:__ALZHEIMER DISEASE 3; AD__:__ALZHEIMER DISEASE 3, EARLY-ONSET;; ALZHEIMER DISEASE, FAMILIAL, 3__:__ALZHEIMER DISEASE, FAMILIAL, 3, WITH SPASTIC PARAPARESIS AND UNUSUAL PLAQUES, INCLUDED;; ALZHEIMER DISEASE, FAMILIAL, 3, WITH SPASTIC PARAPARESIS AND APRAXIA, INCLUDED
Number Sign__:__607823__:__HYPOTRICHOSIS-LYMPHEDEMA-TELANGIECTASIA SYNDROME; HLTS__:____:__
Asterisk__:__607824__:__HOOK, DROSOPHILA, HOMOLOG OF, 2; HOOK2__:__HK2__:__
Asterisk__:__607825__:__HOOK, DROSOPHILA, HOMOLOG OF, 3; HOOK3__:__HK3__:__
Asterisk__:__607826__:__ADENOSYLHOMOCYSTEINASE-LIKE 2; AHCYL1__:__S-ADENOSYLHOMOCYSTEINE HYDROLASE-LIKE 1;; AHCY-LIKE 1;; DENDRITIC CELL-EXPRESSED AHCY-LIKE PROTEIN; DCAL;; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR 1-BINDING PROTEIN RELEASED WITH INOSITOL 1,4,5-TRISPHOSPHATE; IRBIT;; ITPR1-BINDING PROTEIN RELEASED WITH IP3__:__
Asterisk__:__607827__:__OTOPETRIN 2; OTOP2__:____:__
Asterisk__:__607828__:__OTOPETRIN 3; OTOP3__:____:__
Number Sign__:__607829__:__MITRAL VALVE PROLAPSE 2; MVP2__:__MITRAL VALVE PROLAPSE, MYXOMATOUS 2; MMVP2;; MYXOMATOUS MITRAL VALVE PROLAPSE 2__:__
Asterisk__:__607830__:__FRAS1 GENE; FRAS1__:__FRAS1;; KIAA1500__:__
Number Sign__:__607831__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2K; CMT2K__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2K;; CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2K__:__CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K, INCLUDED
Number Sign__:__607832__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 3, SUSCEPTIBILITY TO; FSGS3__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 3, SUSCEPTIBILITY TO__:__
Asterisk__:__607833__:__TACHYKININ 4; TAC4__:__PREPROTACHYKININ C; PPTC__:__HEMOKININ 1, INCLUDED; HK1, INCLUDED
Percent__:__607834__:__ANXIETY__:____:__HARM AVOIDANCE, INCLUDED
Asterisk__:__607835__:__SPLICING FACTOR 3B, 14-KD SUBUNIT__:__p14;; SF3B, 14-KD SUBUNIT; SF3B14;; SPLICEOSOME-ASSOCIATED PROTEIN, 14-KD; SAP14;; PRE-mRNA BRANCH SITE PROTEIN p14__:__
Number Sign__:__607836__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 1; AIS1__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 2; VAMAS2;; AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 1p-RELATED__:__
Asterisk__:__607837__:__CLN8 GENE; CLN8__:____:__
Asterisk__:__607838__:__N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE, GAMMA SUBUNIT; GNPTG__:__GNPTAG__:__
Asterisk__:__607839__:__GLYCOGEN BRANCHING ENZYME; GBE1__:__GBE;; 1,4-ALPHA-GLUCAN BRANCHING ENZYME;; AMYLO-(1,4 to 1,6) TRANSGLUCOSIDASE;; AMYLO-(1,4 to 1,6) TRANSGLYCOSYLASE__:__
Asterisk__:__607840__:__N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE, ALPHA/BETA SUBUNITS; GNPTAB__:__GNPTA;; MGC4170__:__
Percent__:__607841__:__DEAFNESS, AUTOSOMAL DOMINANT 48; DFNA48__:____:__
Number Sign__:__607842__:__AURAL ATRESIA, CONGENITAL; CAA__:__AURAL ATRESIA, CONGENITAL, WITH HYPOSMIA__:__
Asterisk__:__607843__:__PKHD1-LIKE 1; PKHD1L1__:__FIBROCYSTIN-L__:__
Asterisk__:__607844__:__LEM DOMAIN-CONTAINING PROTEIN 3; LEMD3__:__INTEGRAL INNER NUCLEAR MEMBRANE PROTEIN;; MAN ANTIGEN 1; MAN1__:__
Asterisk__:__607845__:__EXPORTIN 5; XPO5__:__KIAA1291__:__
Asterisk__:__607846__:__METHYLTRANSFERASE-LIKE 2; METTL2__:__METL, DROSOPHILA, HOMOLOG OF; METL__:__
Number Sign__:__607847__:__NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF ADULTS__:__NONIMMUNE CHRONIC IDIOPATHIC NEUTROPENIA OF ADULTS;; NI-CINA__:__
Asterisk__:__607848__:__RAB-INTERACTING LYSOSOMAL PROTEIN; RILP__:____:__
Asterisk__:__607849__:__RETINOL DEHYDROGENASE 11; RDH11__:__PROSTATE SHORT-CHAIN DEHYDROGENASE/REDUCTASE 1; PSDR1;; RETINAL REDUCTASE 1; RALR1__:__
Number Sign__:__607850__:__OSTEOARTHRITIS SUSCEPTIBILITY 3; OS3__:__OSTEOARTHRITIS OF KNEE/HIP__:__
Asterisk__:__607851__:__NAKED CUTICLE, DROSOPHILA, HOMOLOG OF, 1; NKD1__:____:__
Asterisk__:__607852__:__NAKED CUTICLE, DROSOPHILA, HOMOLOG OF, 2; NKD2__:____:__
Percent__:__607853__:__PANIC DISORDER 2__:__PAND2;; PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 9q-RELATED__:__
Asterisk__:__607854__:__BESTROPHIN 1; BEST1__:__VMD2 GENE;; TU15B__:__
Number Sign__:__607855__:__MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A__:__MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT__:__MUSCULAR DYSTROPHY, CONGENITAL, DUE TO PARTIAL LAMA2 DEFICIENCY, INCLUDED
Asterisk__:__607856__:__CINGULIN-LIKE 1; CGNL1__:__FLJ14957;; KIAA1749__:__CGNL1/CYP19A1 FUSION GENE, INCLUDED
Percent__:__607857__:__PSORIASIS 9, SUSCEPTIBILITY TO; PSORS9__:____:__
Asterisk__:__607858__:__PRESENILIN-ASSOCIATED RHOMBOID-LIKE PROTEIN; PARL__:____:__
NULL__:__607859__:__ANGIOMA, TUFTED__:__TUFTED ANGIOMA__:__
Asterisk__:__607860__:__YY1 ASSOCIATED PROTEIN 1; YY1AP1__:__YY1-ASSOCIATED PROTEIN; YAP;; HEPATOCELLULAR CARCINOMA-ASSOCIATED PROTEIN 2; HCCA2__:__
Asterisk__:__607861__:__DAPPER, ANTAGONIST OF BETA-CATENIN, 1; DACT1__:__DAPPER, XENOPUS, HOMOLOG OF, 1; DPR1;; DAPPER1;; FRODO__:__
Asterisk__:__607862__:__DIRAS FAMILY, GTP-BINDING RAS-LIKE PROTEIN 1; DIRAS1__:__DISTINCT SUBGROUP OF THE RAS FAMILY, MEMBER 1;; RAS-RELATED INHIBITOR OF CELL GROWTH; RIG__:__
Asterisk__:__607863__:__DIRAS FAMILY, GTP-BINDING RAS-LIKE PROTEIN 2; DIRAS2__:__DISTINCT SUBGROUP OF THE RAS FAMILY, MEMBER 2__:__
Number Sign__:__607864__:__CAUDAL DUPLICATION ANOMALY__:____:__
Asterisk__:__607865__:__SET DOMAIN PROTEIN, BIFURCATED, 2; SETDB2__:__CHRONIC LYMPHOCYTIC LEUKEMIA DELETION REGION GENE 8; CLLD8__:__
Asterisk__:__607866__:__SPRY DOMAIN-CONTAINING PROTEIN 7; SPRYD7__:__CHROMOSOME 13 OPEN READING FRAME 1; C13ORF1;; CHRONIC LYMPHOCYTIC LEUKEMIA DELETION REGION GENE 6; CLLD6__:__
Asterisk__:__607867__:__RCC1 DOMAIN- AND BTB DOMAIN-CONTAINING PROTEIN 1; RCBTB1__:__CHRONIC LYMPHOCYTIC LEUKEMIA DELETION REGION GENE 7; CLLD7;; GDP/GTP EXCHANGE FACTOR-LIKE PROTEIN; GLP__:__
Asterisk__:__607868__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 11; TRIM11__:____:__
Asterisk__:__607869__:__UNC5, C. ELEGANS, HOMOLOG OF, A; UNC5A__:__UNC5H1__:__
Asterisk__:__607870__:__UNC5, C. ELEGANS, HOMOLOG OF, B; UNC5B__:__UNC5H2__:__
Asterisk__:__607871__:__F-BOX ONLY PROTEIN 11; FBXO11__:__FBX11;; VITILIGO-ASSOCIATED PROTEIN 1; VIT1;; PROTEIN ARGININE METHYLTRANSFERASE 9; PRMT9__:__
Number Sign__:__607872__:__CHROMOSOME 1p36 DELETION SYNDROME__:__MONOSOMY 1p36 SYNDROME__:__
Asterisk__:__607873__:__SCAVENGER RECEPTOR CLASS F, MEMBER 1; SCARF1__:__SCAVENGER RECEPTOR EXPRESSED BY ENDOTHELIAL CELLS; SREC;; SREC1;; SREC I;; KIAA0149__:__
Asterisk__:__607874__:__ZINC FINGER PROTEIN 444; ZNF444__:__ENDOTHELIAL ZINC FINGER PROTEIN 2; EZF2__:__
Asterisk__:__607875__:__INOSITOL POLYPHOSPHATE-5-PHOSPHATASE K; INPP5K__:__SKELETAL MUSCLE- AND KIDNEY-ENRICHED INOSITOL PHOSPHATASE; SKIP__:__
Number Sign__:__607876__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 2; FAME2__:__BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 2; BAFME2;; CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 2; FCMTE2;; CORTICAL MYOCLONUS AND EPILEPSY, AUTOSOMAL DOMINANT; ADCME__:__
Asterisk__:__607877__:__OTOSPIRALIN__:__OTOSP__:__
Asterisk__:__607878__:__NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; NNT__:____:__
Asterisk__:__607879__:__EXOCYST COMPLEX COMPONENT 1; EXOC1__:__SEC3, S. CEREVISIAE, HOMOLOG OF; SEC3__:__
Asterisk__:__607880__:__EXOCYST COMPLEX COMPONENT 6B; EXOC6B__:__SEC15, S. CEREVISIAE, HOMOLOG OF, B; SEC15B;; KIAA0919__:__
Asterisk__:__607881__:__SIGNAL-TRANSDUCING ADAPTOR PROTEIN 2__:__STAP2;; BREAST TUMOR KINASE SUBSTRATE; BKS;; BRK SUBSTRATE__:__
Asterisk__:__607882__:__SOLUTE CARRIER FAMILY 52 (RIBOFLAVIN TRANSPORTER), MEMBER 2; SLC52A2__:__G PROTEIN-COUPLED RECEPTOR 172A; GPR172A;; G PROTEIN-COUPLED RECEPTOR 41; GPCR41;; PORCINE ENDOGENOUS RETROVIRUS, SUBGROUP A, RECEPTOR 1; PAR1;; PERV-A RECEPTOR 1;; RIBOFLAVIN TRANSPORTER 3; RFT3;; RFVT2;; FLJ11856__:__
Asterisk__:__607883__:__SOLUTE CARRIER FAMILY 52 (RIBOFLAVIN TRANSPORTER), MEMBER 1; SLC52A1__:__G PROTEIN-COUPLED RECEPTOR 172B; GPR172B;; G PROTEIN-COUPLED RECEPTOR 42; GPCR42;; PORCINE ENDOGENOUS RETROVIRUS, SUBGROUP A, RECEPTOR 2; PAR2;; PERV-A RECEPTOR 2;; RIBOFLAVIN TRANSPORTER 1; RFT1; RFVT1;; FLJ10060__:__
Asterisk__:__607884__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 1; CMTM1__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 1; CKLFSF1__:__
Asterisk__:__607885__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 2; CMTM2__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 2; CKLFSF2__:__
Asterisk__:__607886__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 3; CMTM3__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 3; CKLFSF3__:__
Asterisk__:__607887__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 4; CMTM4__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 4; CKLFSF4__:__
Asterisk__:__607888__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 5; CMTM5__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 5; CKLFSF5__:__
Asterisk__:__607889__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 6; CMTM6__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 6; CKLFSF6__:__
Asterisk__:__607890__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 7; CMTM7__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 7; CKLFSF7__:__
Asterisk__:__607891__:__CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 8; CMTM8__:__CHEMOKINE-LIKE FACTOR SUPERFAMILY, MEMBER 8; CKLFSF8__:__
Asterisk__:__607892__:__DESMOGLEIN 4; DSG4__:____:__
Percent__:__607893__:__OVARIAN CANCER, SUSCEPTIBILITY TO, 1; OVCAS1__:____:__
Asterisk__:__607894__:__POLYCYSTIN 1-LIKE 2; PKD1L2__:__PC1L2;; KIAA1879__:__
Asterisk__:__607895__:__POLYCYSTIN 1-LIKE 3; PKD1L3__:____:__
Asterisk__:__607896__:__OVARIAN CANCER-ASSOCIATED GENE 2__:__OVCA2__:__
Asterisk__:__607897__:__MUSASHI, DROSOPHILA, HOMOLOG OF, 2; MSI2__:____:__MSI2/HOXA9 FUSION GENE, INCLUDED
Asterisk__:__607898__:__TRIBBLES, DROSOPHILA, HOMOLOG OF, 3; TRIB3__:__TRB3;; NERVE GROWTH FACTOR-INDUCED PROTEIN KINASE; NIPK;; p65-INTERACTING INHIBITOR OF NFKB; SINK;; SKIP3;; CHROMOSOME 20 OPEN READING FRAME 97; C20ORF97__:__
Asterisk__:__607899__:__WT1 ANTISENSE RNA; WT1AS__:__WIT1 GENE__:__
Asterisk__:__607900__:__FERMITIN FAMILY, MEMBER 1; FERMT1__:__KINDLIN 1; KIND1;; KINDLERIN;; UNC112-RELATED PROTEIN 1; URP1;; CHROMOSOME 20 OPEN READING FRAME 42; C20ORF42__:__
Asterisk__:__607901__:__FERMITIN FAMILY, MEMBER 3; FERMT3__:__UNC112-RELATED PROTEIN 2; URP2;; KINDLIN 3; KIND3;; MIG2B__:__
Asterisk__:__607902__:__SNURPORTIN 1; SNUPN__:__RNA, U TRANSPORTER 1; RNUT1__:__
Number Sign__:__607903__:__HYPOTRICHOSIS 6; HYPT6__:__HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE 1; LAH1;; HYPOTRICHOSIS, LOCALIZED, AUTOSOMAL RECESSIVE; LAH;; HTL;; MONILETHRIX-LIKE HYPOTRICHOSIS__:__
Asterisk__:__607904__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, T TYPE, ALPHA-1H SUBUNIT; CACNA1H__:____:__
Asterisk__:__607905__:__ALG2, S. CEREVISIAE, HOMOLOG OF; ALG2__:____:__
Number Sign__:__607906__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ii; CDG1I__:__CDG Ii; CDGIi__:__
Number Sign__:__607907__:__DERMATOFIBROSARCOMA PROTUBERANS; DFSP__:__GIANT CELL FIBROBLASTOMA__:__
Asterisk__:__607908__:__LIM AND SENESCENT CELL ANTIGEN-LIKE DOMAINS 2; LIMS2__:__PARTICULARLY INTERESTING NEW CYS-HIS PROTEIN 2; PINCH2__:__
Asterisk__:__607909__:__ANTIZYME INHIBITOR 1; AZIN1__:__ORNITHINE DECARBOXYLASE ANTIZYME INHIBITOR; OAZIN__:__
Asterisk__:__607910__:__KINESIN FAMILY MEMBER 9; KIF9__:____:__
Asterisk__:__607911__:__EPM2A-INTERACTING PROTEIN 1; EPM2AIP1__:__LAFORIN-INTERACTING PROTEIN 1;; KIAA0766__:__
Asterisk__:__607912__:__SELENOPROTEIN T; SELENOT__:__SELT__:__
Asterisk__:__607913__:__GLUTATHIONE PEROXIDASE 6; GPX6__:____:__
Asterisk__:__607914__:__SELENOPROTEIN H; SELENOH__:__SELH__:__
Asterisk__:__607915__:__SELENOPROTEIN I; SELENOI__:__SELI__:__
Asterisk__:__607916__:__SELENOPROTEIN K; SELENOK__:__SELK;; HSPC030__:__
Asterisk__:__607917__:__SELENOPROTEIN O; SELENOO__:__SELO__:__
Asterisk__:__607918__:__SELENOPROTEIN S; SELENOS__:__SELS;; SEPS1;; VCP-INTERACTING MEMBRANE PROTEIN; VIMP;; AD-015__:__
Asterisk__:__607919__:__SELENOPROTEIN V; SELENOV__:__SELV__:__
Caret__:__607920__:__MOVED TO 159001__:____:__
Number Sign__:__607921__:__RETINITIS PIGMENTOSA 30; RP30__:____:__MACULAR DEGENERATION, INCLUDED
Asterisk__:__607922__:__ALPHA-1,4-GALACTOSYLTRANSFERASE; A4GALT__:__4-N-ACETYLGLUCOSAMINYLTRANSFERASE;; GB3 SYNTHASE;; P(k) ANTIGEN SYNTHASE;; CD77 SYNTHASE__:__
Asterisk__:__607923__:__SYNAPTOSOMAL-ASSOCIATED PROTEIN, 91-KD; SNAP91__:__ASSEMBLY PROTEIN, 180-KD; AP180;; KIAA0656__:__
Asterisk__:__607924__:__METASTASIS-ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MALAT1__:__ALPHA GENE;; PRO1073;; NONCODING NUCLEAR-ENRICHED ABUNDANT TRANSCRIPT 2; NEAT2;; NONCODING RNA 47; NCRNA00047__:__ALPHA/TFEB FUSION GENE, INCLUDED;; MALAT1-ASSOCIATED SMALL CYTOPLASMIC RNA, INCLUDED; MASCRNA, INCLUDED
Asterisk__:__607925__:__B- AND T-LYMPHOCYTE ATTENUATOR; BTLA__:__B- AND T-LYMPHOCYTE-ASSOCIATED PROTEIN__:__
Asterisk__:__607926__:__HOST CELL FACTOR C2; HCFC2__:__HCF2__:__
Asterisk__:__607927__:__ANKYRIN REPEATS- AND FYVE DOMAIN-CONTAINING PROTEIN 1; ANKFY1__:__ANKYRIN REPEATS HOOKED TO A ZINC FINGER MOTIF; ANKHZN;; KIAA1255__:__
Asterisk__:__607928__:__WHIRLIN; WHRN__:__CASK-INTERACTING PROTEIN, 98-KD; CIP98;; KIAA1526__:__
Asterisk__:__607929__:__CCM2 GENE; CCM2__:__MALCAVERNIN;; CHROMOSOME 7 OPEN READING FRAME 22; C7ORF22;; OSMOSENSING SCAFFOLD FOR MEKK3; OSM__:__
Asterisk__:__607930__:__CYTOKINE-LIKE PROTEIN 1; CYTL1__:__C17__:__
Asterisk__:__607931__:__ATAXIN 2-LIKE; ATXN2L__:____:__
Number Sign__:__607932__:__MICROPHTHALMIA, SYNDROMIC 6; MCOPS6__:__MICROPHTHALMIA AND PITUITARY ANOMALIES;; MICROPHTHALMIA WITH BRAIN AND DIGIT DEVELOPMENTAL ANOMALIES;; ANOPHTHALMIA, CLINICAL, WITH MICROGNATHIA, MALFORMED EARS, DIGITAL ANOMALIES, AND ABNORMAL EXTERNAL GENITALIA__:__
Asterisk__:__607933__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 11; SLC7A11__:__SYSTEM Xc(-) TRANSPORTER-RELATED PROTEIN; XCT__:__
Asterisk__:__607934__:__PEPTIDYLARGININE DEIMINASE, TYPE I; PADI1__:____:__
Asterisk__:__607935__:__PEPTIDYLARGININE DEIMINASE, TYPE II; PADI2__:____:__
Number Sign__:__607936__:__PEELING SKIN SYNDROME 4; PSS4__:__ICHTHYOSIS BULLOSA OF SIEMENS-LIKE;; ICHTHYOSIS, EXFOLIATIVE, AUTOSOMAL RECESSIVE; AREI__:__
Asterisk__:__607937__:__HOMEOBOX TRANSCRIPTION FACTOR NANOG; NANOG__:__FLJ12581__:__
Asterisk__:__607938__:__NEUROTRIMIN; NTM__:__HNT;; IGLON2__:__
Asterisk__:__607939__:__SULFATASE-MODIFYING FACTOR 1; SUMF1__:__C-ALPHA-FORMYLGLYCINE-GENERATING ENZYME; FGE;; FGLY-GENERATING ENZYME__:__
Asterisk__:__607940__:__SULFATASE-MODIFYING FACTOR 2; SUMF2__:____:__
Number Sign__:__607941__:__ATRIAL SEPTAL DEFECT 2; ASD2__:____:__
Asterisk__:__607942__:__PHOSPHOINOSITIDE 3-KINASE ADAPTOR PROTEIN 1; PIK3AP1__:__PIK3 ADAPTOR PROTEIN 1;; B-CELL ADAPTOR PROTEIN; BCAP;; FLJ35564__:__
Asterisk__:__607943__:__RAS p21 PROTEIN ACTIVATOR 4; RASA4__:__Ca(2+)-PROMOTED RAS INACTIVATOR; CAPRI;; GTPase-ACTIVATING PROTEIN-LIKE; GAPL;; CALCIUM-RAS PROMOTED INACTIVATOR;; KIAA0538__:__
Number Sign__:__607944__:__SPONDYLOENCHONDRODYSPLASIA WITH IMMUNE DYSREGULATION; SPENCDI__:__SPENCD;; COMBINED IMMUNODEFICIENCY WITH AUTOIMMUNITY AND SPONDYLOMETAPHYSEAL DYSPLASIA;; ROIFMAN IMMUNOSKELETAL SYNDROME__:__
Asterisk__:__607945__:__ADIPONECTIN RECEPTOR 1; ADIPOR1__:__CGI45;; PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 1; PAQR1__:__
Asterisk__:__607946__:__ADIPONECTIN RECEPTOR 2; ADIPOR2__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 2; PAQR2__:__
Asterisk__:__607947__:__POTASSIUM CHANNEL REGULATOR; KCNRG__:__DLTET__:__
Number Sign__:__607948__:__MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO__:____:__MYCOBACTERIUM TUBERCULOSIS, PROTECTION AGAINST, INCLUDED
Percent__:__607949__:__MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 1__:__MTBS1__:__
Asterisk__:__607950__:__TESTIS-SPECIFIC PROTEASE 50__:__TSP50__:__
Asterisk__:__607951__:__CENTROSOMAL PROTEIN, 57-KD; CEP57__:__PROLIFERATION-INDUCING GENE 8; PIG8;; TESTES-SPECIFIC PROTEIN 57; TSP57;; TRANSLOKIN;; KIAA0092__:__
Asterisk__:__607952__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), MEMBER 11; SLC6A11__:__GABA TRANSPORTER 3, RAT, HOMOLOG OF; GAT3;; GABA TRANSPORTER 4, MOUSE, HOMOLOG OF; GAT4__:__
Asterisk__:__607953__:__NEURONAL PROTEIN, 25-KD, RAT, HOMOLOG OF__:__NP25;; NEURONAL PROTEIN, 22-KD; NP22__:__
Asterisk__:__607954__:__RAN GUANINE NUCLEOTIDE RELEASE FACTOR__:__RANGNRF;; MOG1, S. CEREVISIAE, HOMOLOG OF; MOG1__:__
Asterisk__:__607955__:__STERILE ALPHA MOTIFS- AND SH3 DOMAIN-CONTAINING PROTEIN 1; SASH1__:__KIAA0790__:__
Asterisk__:__607956__:__MEDIATOR COMPLEX SUBUNIT 8; MED8__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 8, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__607957__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I-DELTA; CAMK1D__:__CAMK1-LIKE PROTEIN KINASE; CKLIK__:__
Asterisk__:__607958__:__SYNTAXIN-BINDING PROTEIN 6; STXBP6__:__AMISYN;; HSPC156__:__
Asterisk__:__607959__:__SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 10; SLC7A10__:__ASC1__:__
Asterisk__:__607960__:__DEAH BOX POLYPEPTIDE 32; DHX32__:__DDX32__:__
Asterisk__:__607961__:__SEMAPHORIN 7A; SEMA7A__:__SEMAPHORIN L; SEMAL;; SEMAPHORIN K1; SEMAK1;; CDW108__:__
Asterisk__:__607962__:__MICRO RNA 23A; MIR23A__:__miRNA23A;; MIRN23A__:__
Asterisk__:__607963__:__METHYL-CpG BINDING DOMAIN PROTEIN 3-LIKE 1; MBD3L1__:____:__
Asterisk__:__607964__:__METHYL-CpG BINDING DOMAIN PROTEIN 3-LIKE 2; MBD3L2__:____:__
Percent__:__607965__:__SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 1; SLEN1__:____:__
Percent__:__607966__:__SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 2; SLEN2__:____:__
Percent__:__607967__:__SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 3; SLEN3__:____:__
Asterisk__:__607968__:__PARATHYROID HORMONE-RESPONSIVE B1 GENE__:__PTH-RESPONSIVE B1 GENE; B1; PTHB1;; BBS9 GENE; BBS9__:__
Asterisk__:__607969__:__CDC-LIKE KINASE 4; CLK4__:____:__
Asterisk__:__607970__:__G PROTEIN-COUPLED RECEPTOR 135; GPR135__:____:__
Asterisk__:__607971__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 15; SLC6A15__:__TRANSPORTER V7-3, RAT, HOMOLOG OF;; V7-3;; SODIUM-COUPLED BRANCHED-CHAIN AMINO ACID TRANSPORTER 1; SBAT1__:__
Asterisk__:__607972__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 16; SLC6A16__:__NTT5__:__
Asterisk__:__607973__:__NEUROPILIN- AND TOLLOID-LIKE 1; NETO1__:__BRAIN-SPECIFIC TRANSMEMBRANE PROTEIN 1; BCTL1__:__
Asterisk__:__607974__:__NEUROPILIN- AND TOLLOID-LIKE 2; NETO2__:____:__
Asterisk__:__607975__:__OXIDATIVE STRESS-INDUCED GROWTH INHIBITOR 1; OSGIN1__:__PREGNANCY-INDUCED GROWTH INHIBITOR OKL38; OKL38__:__
Asterisk__:__607976__:__CYTOCHROME c OXIDASE, SUBUNIT 4I2; COX4I2__:__CYTOCHROME c OXIDASE, SUBUNIT IV, ISOFORM 2;; COX IV-2;; COX4-2__:__
Asterisk__:__607977__:__HEADCASE, DROSOPHILA, HOMOLOG OF; HECA__:__HDC__:__
Asterisk__:__607978__:__SAM DOMAIN, SH3 DOMAIN, AND NUCLEAR LOCALIZATION SIGNALS 1; SAMSN1__:__HEMATOPOIETIC ADAPTOR CONTAINING SH3 AND SAM DOMAINS 1; HACS1__:__
Asterisk__:__607979__:__SERINE HYDROLASE-LIKE; SERHL__:____:__
Asterisk__:__607980__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 7, YEAST, HOMOLOG OF; TOMM7__:__TOM7__:__
Asterisk__:__607981__:__NEGATIVE REGULATOR OF UBIQUITIN-LIKE PROTEINS 1; NUB1__:__NEDD8 ULTIMATE BUSTER 1;; NY-REN-18__:__
Asterisk__:__607982__:__SCY1-LIKE 1; SCYL1__:__SCY1, S. CEREVISIAE, HOMOLOG OF, 1;; N-TERMINAL KINASE-LIKE; NTKL__:__
Asterisk__:__607983__:__GOLGIN, RAB6-INTERACTING; GORAB__:__SCYL1-BINDING PROTEIN 1; SCYL1BP1;; NTKL-BINDING PROTEIN 1; NTKLBP1__:__
Asterisk__:__607984__:__SPROUTY, DROSOPHILA, HOMOLOG OF, 4; SPRY4__:____:__
Asterisk__:__607985__:__N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER ALPHA-N-ACETYLGLUCOSAMINIDASE; NAGPA__:__PHOSPHODIESTER GLYCOSIDE;; PHOSPHODIESTER ALPHA-GlcNAcase;; MANNOSE 6-PHOSPHATE-UNCOVERING ENZYME; UCE__:__
Asterisk__:__607986__:__S100 CALCIUM-BINDING PROTEIN A14; S100A14__:__BCMP84__:__
Asterisk__:__607987__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 10; DNAJC10__:__ENDOPLASMIC RETICULUM RESIDENT PROTEIN ERDJ5; ERDJ5;; J DOMAIN-CONTAINING PROTEIN DISULFIDE ISOMERASE-LIKE PROTEIN; JPDI;; J DOMAIN-CONTAINING PDI-LIKE PROTEIN__:__
Asterisk__:__607988__:__SPARC/OSTEONECTIN, CWCV, AND KAZAL-LIKE DOMAINS PROTEOGLYCAN 2; SPOCK2__:__TESTICAN 2;; KIAA0275__:__
Asterisk__:__607989__:__SPARC/OSTEONECTIN, CWCV, AND KAZAL-LIKE DOMAINS PROTEOGLYCAN 3; SPOCK3__:__TESTICAN 3__:__N-TES, INCLUDED
Asterisk__:__607990__:__UBIQUITIN-LIKE PROTEIN CONTAINING PHD AND RING FINGER DOMAINS 1; UHRF1__:__INVERTED CCAAT BOX-BINDING PROTEIN, 90-KD; ICBP90;; NUCLEAR PHOSPHOPROTEIN, 95-KD; NP95__:__
Asterisk__:__607991__:__SOLUTE CARRIER FAMILY 8 (SODIUM-CALCIUM EXCHANGER), MEMBER A3; SLC8A3__:__SODIUM-CALCIUM EXCHANGER 3; NCX3__:__
Asterisk__:__607992__:__SURP AND G-PATCH DOMAINS-CONTAINING PROTEIN 1; SUGP1__:__SPLICING FACTOR 4; SF4__:__
Asterisk__:__607993__:__SURP AND G-PATCH DOMAINS-CONTAINING PROTEIN 2; SUGP2__:__SPLICING FACTOR, ARGININE/SERINE-RICH, 14; SFRS14;; KIAA0365__:__
Asterisk__:__607994__:__5-PRIME,3-PRIME-EXORIBONUCLEASE 1; XRN1__:__STRAND EXCHANGE PROTEIN 1; SEP1__:__
Asterisk__:__607995__:__UNC93, C. ELEGANS, HOMOLOG OF, A; UNC93A__:____:__
Asterisk__:__607996__:__PREPRONEUROPEPTIDE B__:__PPNPB;; PREPRO-G PROTEIN-COUPLED RECEPTOR 7 LIGAND; PPL7;; PREPRO-GPCR7 LIGAND__:__NEUROPEPTIDE B, INCLUDED; NPB, INCLUDED;; G PROTEIN-COUPLED RECEPTOR 7 LIGAND, INCLUDED; L7, INCLUDED;; GPCR7 LIGAND, INCLUDED;; GPCR7 LIGAND WITH C-TERMINAL EXTENSION, INCLUDED; L7C, INCLUDED
Asterisk__:__607997__:__NEUROPEPTIDE W; NPW__:__G PROTEIN-COUPLED RECEPTOR 8 LIGAND; L8;; GPCR8 LIGAND__:__PREPRONEUROPEPTIDE W, INCLUDED; PPNPW, INCLUDED;; PREPRO-G PROTEIN-COUPLED RECEPTOR 8 LIGAND, INCLUDED; PPL8, INCLUDED;; PREPRO-GPCR8 LIGAND, INCLUDED;; GPCR8 LIGAND WITH C-TERMINAL EXTENSION, INCLUDED; L8C, INCLUDED
Asterisk__:__607998__:__TRIPEPTIDYL PEPTIDASE I; TPP1__:__TPP I;; CLN2 GENE; CLN2__:__
Asterisk__:__607999__:__ASH1-LIKE; ASH1L__:__ASH1, DROSOPHILA, HOMOLOG OF; ASH1;; LYSINE-SPECIFIC METHYLTRANSFERASE 2H; KMT2H;; KIAA1420__:__
Asterisk__:__608000__:__N-ALPHA-ACETYLTRANSFERASE 15, NatA AUXILIARY SUBUNIT; NAA15__:__NMDA RECEPTOR-REGULATED 1; NARG1;; NAT1, S. CEREVISIAE, HOMOLOG OF; NATH__:__
Asterisk__:__608001__:__MELANOMA INHIBITORY ACTIVITY PROTEIN 2; MIA2__:____:__
Asterisk__:__608002__:__NEPHROCYSTIN 3; NPHP3__:____:__
Asterisk__:__608003__:__HOMEODOMAIN-INTERACTING PROTEIN KINASE 1; HIPK1__:__KIAA0630__:__
Asterisk__:__608004__:__NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELLS INHIBITOR, ZETA; NFKBIZ__:__INTERLEUKIN 1-INDUCED NUCLEAR ANKYRIN REPEAT PROTEIN;; IL1-INDUCED NUCLEAR ANKYRIN REPEAT PROTEIN; INAP;; MOLECULE POSSESSING ANKYRIN REPEATS INDUCED BY LIPOPOLYSACCHARIDE; MAIL;; I-KAPPA-B-ZETA; IKBZ__:__
Asterisk__:__608005__:__SIL1, S. CEREVISIAE, HOMOLOG OF; SIL1__:__BIP-ASSOCIATED PROTEIN; BAP__:__
Asterisk__:__608006__:__LEIOMODIN 2; LMOD2__:__LEIOMODIN, CARDIAC; CLMOD__:__
Asterisk__:__608007__:__PLECKSTRIN 2; PLEK2__:____:__
Asterisk__:__608008__:__ANNEXIN A10; ANXA10__:____:__
Asterisk__:__608009__:__ADENYLATE KINASE 5; AK5__:____:__
Asterisk__:__608010__:__NPC1-LIKE 1; NPC1L1__:____:__
Asterisk__:__608011__:__GUANINE NUCLEOTIDE-BINDING PROTEIN-LIKE 3; GNL3__:__NUCLEOSTEMIN; NS;; E2-INDUCED GENE 3; E2IG3__:__
Asterisk__:__608012__:__PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 2; PDIA2__:__PROTEIN DISULFIDE ISOMERASE, PANCREATIC; PDIP__:__
Number Sign__:__608013__:__GAUCHER DISEASE, PERINATAL LETHAL__:__GAUCHER DISEASE, COLLODION TYPE__:__
Asterisk__:__608014__:__HEAT-SHOCK 22-KD PROTEIN 8; HSPB8__:__HSP22;; PROTEIN KINASE H11; H11;; E2-INDUCED GENE 1; E2IG1;; HEAT-SHOCK 27-KD PROTEIN 8__:__
Asterisk__:__608015__:__TSUKUSHIN; TSKU__:__TSUKUSHI, CHICKEN, HOMOLOG OF; TSK;; E2-INDUCED GENE 4; E2IG4__:__
Asterisk__:__608016__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 8; CHCHD8__:__E2-INDUCED GENE 2; E2IG2__:__
Asterisk__:__608017__:__FAMILY WITH SEQUENCE SIMILARITY 162, MEMBER A; FAM162A__:__CHROMOSOME 3 OPEN READING FRAME 28; C3ORF28;; E2-INDUCED GENE 5; E2IG5__:__
Asterisk__:__608018__:__PANCREASIN__:____:__
Asterisk__:__608019__:__TNFAIP3-INTERACTING PROTEIN 3; TNIP3__:__LISTERIA-INDUCED GENE; LIND;; FLJ21162__:__
Asterisk__:__608020__:__NUCLEOBINDIN 2; NUCB2__:__NEFA__:__
Asterisk__:__608021__:__WAP, FOLLISTATIN, IMMUNOGLOBULIN, KUNITZ, AND NTR DOMAINS-CONTAINING PROTEIN 1; WFIKKN1__:__WFIKKN;; GDF-ASSOCIATED SERUM PROTEIN 2; GASP2__:__
Number Sign__:__608022__:__DIAPHANOSPONDYLODYSOSTOSIS__:__VERTEBRAL OSSIFICATION, DEFECT IN, WITH NEPHROGENIC RESTS__:__
Asterisk__:__608023__:__DEAD/H BOX 56; DDX56__:__NUCLEOLAR HELICASE, 61-KD; NOH61__:__
Asterisk__:__608024__:__PEROXISOMAL D3,D2-ENOYL-CoA ISOMERASE; PECI__:__DIAZEPAM BINDING INHIBITOR-RELATED SEQUENCE 1; DRS1;; DBI-RELATED SEQUENCE 1__:__
Asterisk__:__608025__:__NEUROBLASTOMA-AMPLIFIED SEQUENCE; NBAS__:__NEUROBLASTOMA-AMPLIFIED GENE; NAG__:__
Percent__:__608026__:__HYPERTENSIVE NEPHROPATHY; HNP1__:____:__
Number Sign__:__608027__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 3; PCH3__:__CEREBELLAR ATROPHY WITH PROGRESSIVE MICROCEPHALY; CLAM;; PCH WITH OPTIC ATROPHY__:__
NULL__:__608028__:__THAI SYMPHALANGISM SYNDROME__:____:__
Percent__:__608029__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 6; SCAR6__:__CEREBELLAR ATAXIA, INFANTILE NONPROGRESSIVE, AUTOSOMAL RECESSIVE;; NORWEGIAN INFANTILE ONSET ATAXIA__:__
Number Sign__:__608030__:__AMYOTROPHIC LATERAL SCLEROSIS 6 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS6__:____:__
Percent__:__608031__:__AMYOTROPHIC LATERAL SCLEROSIS 7; ALS7__:____:__
Caret__:__608032__:__MOVED TO 127500__:____:__
Number Sign__:__608033__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 3; IIAE3__:__ENCEPHALOPATHY, ACUTE NECROTIZING, SUSCEPTIBILITY TO; ANE__:__
Asterisk__:__608034__:__ASPARTOACYLASE; ASPA__:__AMINOACYLASE 2; ACY2__:__
Percent__:__608035__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 4; CMM4__:____:__
Percent__:__608036__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT, 4__:__NIDDM4;; NONINSULIN-DEPENDENT DIABETES MELLITUS 4__:__
Asterisk__:__608037__:__CHONDROITIN POLYMERIZING FACTOR 2; CHPF2__:__CHONDROITIN SULFATE GLUCURONYLTRANSFERASE; CSGlcAT;; KIAA1402__:__
Asterisk__:__608038__:__p21 PROTEIN-ACTIVATED KINASE 7; PAK7__:__p21 CDC42/RAC1-ACTIVATED KINASE 7;; PAK5;; KIAA1264__:__
Asterisk__:__608039__:__NYD-SP16__:__FLJ35906__:__
Asterisk__:__608040__:__INTRAFLAGELLAR TRANSPORT 74, CHLAMYDOMONAS, HOMOLOG OF; IFT74__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 2; CCDC2;; CAPILLARY MORPHOGENESIS GENE 1; CMG1__:__
Asterisk__:__608041__:__ANTHRAX TOXIN RECEPTOR 2; ANTXR2__:__CAPILLARY MORPHOGENESIS GENE 2; CMG2__:__
Asterisk__:__608042__:__SYNAPTOTAGMIN-LIKE 1; SYTL1__:__SLP1;; C2 DOMAIN-CONTAINING PROTEIN JFC1; JFC1__:__
Asterisk__:__608043__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10; GALNT10__:__GalNAc TRANSFERASE 10; GalNAcT10__:__
Asterisk__:__608044__:__SOLUTE CARRIER FAMILY 5 (IODIDE TRANSPORTER), MEMBER 8; SLC5A8__:__APICAL IODIDE TRANSPORTER; AIT;; SODIUM-COUPLED MONOCARBOXYLATE TRANSPORTER; SMCT;; SMCT1__:__
Percent__:__608045__:__REPRESSOR OF TELOMERASE EXPRESSION 1__:__RTE1__:__
Asterisk__:__608046__:__SYNOVIAL APOPTOSIS INHIBITOR 1; SYVN1__:__SYNOVIOLIN;; HRD1, S. CEREVISIAE, HOMOLOG OF; HRD1;; KIAA1810__:__
Asterisk__:__608047__:__UBIQUITIN-PROTEIN LIGASE E3B; UBE3B__:____:__
Asterisk__:__608048__:__SNF2, LINKER HISTONE, PHD FINGER, RING FINGER, AND HELICASE DOMAINS-CONTAINING PROTEIN; SHPRH__:__RAD5, YEAST, HOMOLOG OF__:__
Percent__:__608049__:__AUTISM, SUSCEPTIBILITY TO, 3; AUTS3__:____:__
Asterisk__:__608050__:__TORSIN 1B; TOR1B__:__TORSIN B;; DQ1__:__
Number Sign__:__608051__:__MACULAR DYSTROPHY, RETINAL, 2; MCDR2__:____:__
Asterisk__:__608052__:__TORSIN 2A; TOR2A__:__TORSIN-RELATED PROTEIN 1; TORP1__:__PREPROSALUSIN, INCLUDED;; SALUSIN-ALPHA, INCLUDED;; SALUSIN-BETA, INCLUDED
Asterisk__:__608053__:__ELECTRON TRANSFER FLAVOPROTEIN, ALPHA POLYPEPTIDE; ETFA__:____:__
Asterisk__:__608054__:__CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 7; CYP2A7__:____:__
Asterisk__:__608055__:__CYTOCHROME P450, SUBFAMILY IIA, POLYPEPTIDE 13; CYP2A13__:____:__
Caret__:__608056__:__MOVED TO 151660__:____:__
Asterisk__:__608057__:__DEOXYRIBONUCLEASE II BETA; DNASE2B__:__DNase II-BETA;; DNASE2-LIKE ACID DNase; DLAD__:__
Asterisk__:__608058__:__GLUCOSE-6-PHOSPHATASE, CATALYTIC, 2; G6PC2__:__ISLET-SPECIFIC GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT-RELATED PROTEIN; IGRP;; ISLET-SPECIFIC G6CP-RELATED PROTEIN__:__
Asterisk__:__608059__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 7; HES7__:____:__
Asterisk__:__608060__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 4__:__HES4__:__
Asterisk__:__608061__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 40, YEAST, HOMOLOG OF; TOMM40__:__TOM40;; PEREC1__:__
Asterisk__:__608062__:__DOUBLECORTIN DOMAIN-CONTAINING PROTEIN 1; DCDC1__:____:__
NULL__:__608063__:__BILE AND PANCREATIC DUCTS, COMPLETE ABSENCE OF__:____:__
Asterisk__:__608064__:__KELCH-LIKE 5; KLHL5__:____:__
Asterisk__:__608065__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 4; SLC38A4__:__NEUTRAL AMINO ACID TRANSPORTER 3; NAT3;; N-SYSTEM AMINO ACID TRANSPORTER 3;; AMINO ACID TRANSPORTER A3; ATA3__:__
Asterisk__:__608066__:__SCAFFOLD ATTACHMENT FACTOR B2; SAFB2__:__KIAA0138__:__
Asterisk__:__608067__:__RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 2; RFWD2__:__CONSTITUTIVE PHOTOMORPHOGENESIS PROTEIN 1, ARABIDOPSIS, HOMOLOG OF; COP1__:__
Percent__:__608068__:__NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE__:__AFND;; SWEET SYNDROME; SS;; GOMM-BUTTON DISEASE__:__
Asterisk__:__608069__:__ERBB RECEPTOR FEEDBACK INHIBITOR 1; ERRFI1__:__MITOGEN-INDUCIBLE GENE 6; MIG6;; RECEPTOR-ASSOCIATED LATE TRANSDUCER; RALT;; GENE 33, RAT, HOMOLOG OF__:__
Asterisk__:__608070__:__HOMOCYSTEINE- AND ENDOPLASMIC RETICULUM STRESS-INDUCIBLE PROTEIN, UBIQUITIN-LIKE DOMAIN-CONTAINING, 1; HERPUD1__:__HOMOCYSTEINE-RESPONSIVE ENDOPLASMIC RETICULUM RESIDENT PROTEIN; HERP;; METHYL METHANESULFONATE-INDUCIBLE FRAGMENT 1; MIF1;; KIAA0025__:__
Asterisk__:__608071__:__F-BOX AND WD40 DOMAIN PROTEIN 4; FBXW4__:__FBW4; FBWD4;; DACTYLIN;; DACTYLAPLASIA, MOUSE, HOMOLOG OF;; DAC, MOUSE, HOMOLOG OF;; SHFM3 GENE, FORMERLY; SHFM3, FORMERLY__:__
Asterisk__:__608072__:__NHL REPEAT-CONTAINING PROTEIN 1; NHLRC1__:__EPM2B GENE; EPM2B;; MALIN__:__
Asterisk__:__608073__:__NUCLEOPHOSMIN/NUCLEOPLASMIN FAMILY, MEMBER 2; NPM2__:____:__
Asterisk__:__608074__:__PROGRAMMED CELL DEATH 6-INTERACTING PROTEIN; PDCD6IP__:__PDCD6-INTERACTING PROTEIN;; ALG2-INTERACTING PROTEIN 1; AIP1;; ALG2-INTERACTING PROTEIN X; ALIX;; KIAA1375__:__
Asterisk__:__608075__:__PHOSPHOLIPASE C, ZETA-1; PLCZ1__:____:__
Asterisk__:__608076__:__TYROSINE KINASE, NONRECEPTOR, 1; TNK1__:__CD38-NEGATIVE KINASE__:__
Asterisk__:__608077__:__PURINERGIC RECEPTOR P2X-LIKE 1; P2RXL1__:__P2RX-LIKE 1;; P2X, SKELETAL MUSCLE-EXPRESSED; P2XM;; PURINORECEPTOR P2X6; P2X6__:__
Percent__:__608078__:__SCHIZOPHRENIA 11__:__SCZD11;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 10q-RELATED__:__
Asterisk__:__608079__:__ELAC, E. COLI, HOMOLOG OF, 1; ELAC1__:__DELETED IN MA29 CELL LINE; D29;; RIBONUCLEASE Z, SHORT FORM;; RNase ZS__:__
Asterisk__:__608080__:__MAESTRO; MRO__:__GENE BESIDE THE MA29 DELETION; B29;; CHROMOSOME 18 OPEN READING FRAME 3; C18ORF3__:__
Asterisk__:__608081__:__SYNAPTOTAGMIN 15; SYT15__:____:__
Asterisk__:__608082__:__YIPPEE-LIKE 1; YPEL1__:____:__
Asterisk__:__608083__:__APOLIPOPROTEIN C-II; APOC2__:____:__
Asterisk__:__608084__:__GTPase, IMAP FAMILY, MEMBER 1; GIMAP1__:__IMMUNITY-ASSOCIATED PROTEIN 1; IMAP1__:__
Asterisk__:__608085__:__GTPase, IMAP FAMILY, MEMBER 2; GIMAP2__:__IMMUNITY-ASSOCIATED PROTEIN 2; IMAP2__:__
Asterisk__:__608086__:__GTPase, IMAP FAMILY, MEMBER 5; GIMAP5__:__IMMUNITY-ASSOCIATED NUCLEOTIDE 4-LIKE 1; IAN4L1;; IAN4-LIKE 1;; IMMUNITY-ASSOCIATED PROTEIN 3; IMAP3__:__
Asterisk__:__608087__:__GTPase, IMAP FAMILY, MEMBER 4; GIMAP4__:__IMMUNITY-ASSOCIATED PROTEIN 4; IMAP4;; IMMUNITY-ASSOCIATED NUCLEOTIDE 1; IAN1__:__
Percent__:__608088__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE I, WITH COUGH AND GASTROESOPHAGEAL REFLUX__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IB; HSAN1B;; NEUROPATHY, HEREDITARY SENSORY, TYPE IB; HSN1B__:__
Number Sign__:__608089__:__ENDOMETRIAL CANCER__:____:__
Asterisk__:__608090__:__MLX-INTERACTING PROTEIN; MLXIP__:__MONDO FAMILY, MEMBER A; MONDOA;; KIAA0867__:__
Number Sign__:__608091__:__JOUBERT SYNDROME 2; JBTS2__:__CEREBELLOOCULORENAL SYNDROME 2; CORS2__:__
Asterisk__:__608092__:__PALLADIN, MOUSE, HOMOLOG OF; PALLD__:__KIAA0992__:__
Number Sign__:__608093__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ij; CDG1J__:__CDG Ij; CDGIj__:__
Asterisk__:__608094__:__SOLUTE CARRIER FAMILY 37 (SUGAR-PHOSPHATE TRANSPORTER), MEMBER 1; SLC37A1__:__GLYCEROL-3-PHOSPHATE PERMEASE; G3PP__:__
Asterisk__:__608095__:__SODIUM CHANNEL MODIFIER 1; SCNM1__:__MGC3180__:__
Percent__:__608096__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 2; ETL2__:__FTLE__:__
Number Sign__:__608097__:__PERIVENTRICULAR HETEROTOPIA WITH MICROCEPHALY, AUTOSOMAL RECESSIVE; ARPHM__:__PERIVENTRICULAR NODULAR HETEROTOPIA 2; PVNH2;; HETEROTOPIA, PERIVENTRICULAR, AUTOSOMAL RECESSIVE__:__
Percent__:__608098__:__PERIVENTRICULAR NODULAR HETEROTOPIA 3; PVNH3__:__HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5p ANOMALIES__:__
Number Sign__:__608099__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D;; DUCHENNE-LIKE AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, TYPE 2; DMDA2;; ADHALINOPATHY, PRIMARY__:__
Asterisk__:__608100__:__NFU1, S. CEREVISIAE, HOMOLOG OF; NFU1__:__IRON-SULFUR CLUSTER SCAFFOLD PROTEIN NFU1;; HIRA-INTERACTING PROTEIN 5; HIRIP5__:__
Asterisk__:__608101__:__SPERMATID-SPECIFIC LINKER HISTONE H1-LIKE PROTEIN__:__HILS1__:__
Asterisk__:__608102__:__CLN5 GENE; CLN5__:____:__
Asterisk__:__608103__:__ALG8, S. CEREVISIAE, HOMOLOG OF; ALG8__:__DOLICHYL-P-GLUCOSE:Glc-1-Man-9-GlcNAc-2-PP-DOLICHYL-ALPHA-3-GLUCOSYLTRANSFERASE__:__
Number Sign__:__608104__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ih; CDG1H__:__CDG Ih; CDGIh__:__
Percent__:__608105__:__EPILEPSY, ROLANDIC, WITH PAROXYSMAL EXERCISE-INDUCED DYSTONIA AND WRITER'S CRAMP; EPRPDC__:__RE-PED-WC__:__
Number Sign__:__608106__:__IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 5; HIGM5__:__HYPER-IgM SYNDROME 5__:__
Asterisk__:__608107__:__FAMILIAL MEDITERRANEAN FEVER GENE; MEFV__:__PYRIN;; MARENOSTRIN__:__
Asterisk__:__608108__:__CRANIOFACIAL DEVELOPMENT PROTEIN 1; CFDP1__:__CRANIOFACIAL PROTEIN, 27-KD; CP27;; BUCENTAUR; BCNT__:__
Asterisk__:__608109__:__PSEUDOURIDINE SYNTHASE 1; PUS1__:____:__
Asterisk__:__608110__:__p21 PROTEIN-ACTIVATED KINASE 6; PAK6__:__p21 CDC42/RAC1-ACTIVATED KINASE 6__:__
Asterisk__:__608111__:__FANCL GENE; FANCL__:__PHD FINGER PROTEIN 9; PHF9;; FANCONI ANEMIA-ASSOCIATED POLYPEPTIDE, 43-KD; FAAP43__:__
Asterisk__:__608112__:__TRAFFICKING PROTEIN, KINESIN-BINDING 1; TRAK1__:__OGT-INTERACTING PROTEIN, 106-KD; OIP106;; KIAA1042;; MILTON, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__608113__:__SARCOGLYCAN, ZETA; SGCZ__:__ZSG1;; ZETA-SARCOGLYCAN__:__
Asterisk__:__608114__:__CENTAURIN, ALPHA-1; CENTA1__:__p42-IP4__:__
Number Sign__:__608115__:__OVARIAN HYPERSTIMULATION SYNDROME; OHSS__:__OVARIAN HYPERSTIMULATION SYNDROME, FAMILIAL GESTATIONAL SPONTANEOUS__:__
Asterisk__:__608116__:__HEDGEHOG ACYLTRANSFERASE-LIKE PROTEIN; HHATL__:__HHAT-LIKE PROTEIN;; MEMBRANE-BOUND O-ACETYLTRANSFERASE DOMAIN-CONTAINING 3; MBOAT3;; MEMBRANE-BOUND O-ACETYLTRANSFERASE 3;; CHROMOSOME 3 OPEN READING FRAME 3; C3ORF3;; KIAA1173__:__
Asterisk__:__608117__:__PHOSPHODIESTERASE 4D-INTERACTING PROTEIN; PDE4DIP__:__MYOMEGALIN, RAT, HOMOLOG OF;; MYOMEGALIN-LIKE PROTEIN; MMGL;; KIAA0454;; KIAA0477__:__
Number Sign__:__608118__:__ZINC DEFICIENCY, TRANSIENT NEONATAL; TNZD__:__ZINC DEFICIENCY, NEONATAL, DUE TO LOW BREAST MILK ZINC__:__ZINC IN BREAST MILK, REDUCED, INCLUDED
Asterisk__:__608119__:__HOMEODOMAIN LEUCINE ZIPPER-CONTAINING FACTOR__:__HOMEZ;; KIAA1443__:__
Asterisk__:__608120__:__PARVIN, ALPHA; PARVA__:____:__
Asterisk__:__608121__:__PARVIN, BETA; PARVB__:____:__
Asterisk__:__608122__:__PARVIN, GAMMA; PARVG__:____:__
Asterisk__:__608123__:__ACYL-CoA THIOESTERASE 8; ACOT8__:__PEROXISOMAL ACYL-CoA THIOESTERASE 1; PTE1__:__
Asterisk__:__608124__:__XYLOSYLTRANSFERASE 1; XYLT1__:__XT1;; UDP-D-XYLOSE:PROTEOGLYCAN CORE PROTEIN BETA-D-XYLOSYLTRANSFERASE 1__:__
Asterisk__:__608125__:__XYLOSYLTRANSFERASE 2; XYLT2__:__XT2;; UDP-D-XYLOSE:PROTEOGLYCAN CORE PROTEIN BETA-D-XYLOSYLTRANSFERASE 2__:__
Asterisk__:__608126__:__ACIDIC NUCLEOPLASMIC DNA-BINDING PROTEIN 1, XENOPUS, HOMOLOG OF__:__AND1__:__
Asterisk__:__608127__:__PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 4; PBX4__:____:__
Caret__:__608128__:__MOVED TO 604605__:____:__
Asterisk__:__608129__:__UBIQUITIN-ASSOCIATED DOMAIN-CONTAINING PROTEIN 1; UBAC1__:__UBA DOMAIN-CONTAINING PROTEIN 1;; GLIOBLASTOMA DIFFERENTIATION-RELATED PROTEIN 1; GBDR1;; KIP1 UBIQUITINATION-PROMOTING COMPLEX 2; KPC2__:__
Asterisk__:__608130__:__NUAK FAMILY, SNF1-LIKE KINASE, 1; NUAK1__:__AMPK-RELATED PROTEIN KINASE 5; ARK5;; KIAA0537__:__
Asterisk__:__608131__:__NUAK FAMILY, SNF1-LIKE KINASE, 2; NUAK2__:__SNF1/AMPK-RELATED PROTEIN KINASE; SNARK__:__
Asterisk__:__608132__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 8; TTC8__:__BBS8 GENE__:__
Number Sign__:__608133__:__RETINITIS PIGMENTOSA 7; RP7__:____:__RETINITIS PIGMENTOSA 7, DIGENIC, INCLUDED;; LEBER CONGENITAL AMAUROSIS 18, INCLUDED; LCA18, INCLUDED
Asterisk__:__608134__:__PARALEMMIN; PALM__:__KIAA0270__:__
Asterisk__:__608135__:__ASPORIN; ASPN__:__PERIODONTAL LIGAMENT-ASSOCIATED PROTEIN 1; PLAP1__:__
Asterisk__:__608136__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 10; ARHGEF10__:__KIAA0294__:__
Asterisk__:__608137__:__NMDA RECEPTOR SYNAPTONUCLEAR SIGNALING AND NEURONAL MIGRATION FACTOR; NSMF__:__NASAL EMBRYONIC LHRH FACTOR; NELF;; NASAL EMBRYONIC LUTEINIZING HORMONE-RELEASING HORMONE FACTOR__:__
Asterisk__:__608138__:__PROGRAMMED CELL DEATH 7; PDCD7__:____:__
Asterisk__:__608139__:__CENTROMERE PROTEIN V; CENPV__:__NUCLEAR PROTEIN p30__:__
Asterisk__:__608140__:__NUCLEOPORIN, 35-KD; NUP35__:__MITOTIC PHOSPHOPROTEIN 44; MP44;; NUP53, S. CEREVISIAE, HOMOLOG OF; NUP53__:__
Asterisk__:__608141__:__NUCLEOPORIN, 43-KD; NUP43__:__p42__:__
Asterisk__:__608142__:__HSC20, E. COLI, HOMOLOG OF__:__HSC20;; HSCB;; JAC1, S. CEREVISIAE, HOMOLOG OF; JAC1__:__
Asterisk__:__608143__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 6; AGPAT6__:__LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE-ZETA;; LPAAT-ZETA__:__
Asterisk__:__608144__:__SAM POINTED DOMAIN-CONTAINING ETS TRANSCRIPTION FACTOR; SPDEF__:__PROSTATE EPITHELIUM-SPECIFIC ETS TRANSCRIPTION FACTOR; PDEF__:__
Asterisk__:__608145__:__NONIMPRINTED GENE IN PRADER-WILLI SYNDROME/ANGELMAN SYNDROME CHROMOSOME REGION 1; NIPA1__:____:__
Asterisk__:__608146__:__NONIMPRINTED GENE IN PRADER-WILLI SYNDROME/ANGELMAN SYNDROME CHROMOSOME REGION 2; NIPA2__:____:__
Asterisk__:__608147__:__TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 5; TUBGCP5__:__TUBG COMPLEX-ASSOCIATED PROTEIN 5;; GAMMA-TUBULIN COMPLEX COMPONENT 5; GCP5;; KIAA1899__:__
Asterisk__:__608148__:__SPECIAL AT-RICH SEQUENCE-BINDING PROTEIN 2; SATB2__:__KIAA1034__:__
Number Sign__:__608149__:__KAGAMI-OGATA SYNDROME__:__UNIPARENTAL DISOMY, PATERNAL, CHROMOSOME 14__:__
Asterisk__:__608150__:__PERIPHILIN 1; PPHLN1__:____:__
Asterisk__:__608151__:__WD REPEAT-CONTAINING PROTEIN 19; WDR19__:__IFT144__:__
Asterisk__:__608152__:__PROSTAGLANDIN E SYNTHASE 2; PTGES2__:__PGES2;; GATE-BINDING FACTOR 1; GBF1__:__
Asterisk__:__608153__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 14A; PPP1R14A__:__PROTEIN KINASE C-POTENTIATED INHIBITOR OF PROTEIN PHOSPHATASE 1, 17-KD;; PKC-POTENTIATED INHIBITOR OF PP1, 17-KD; CPI17__:__
Percent__:__608154__:__LIPODYSTROPHY, GENERALIZED, WITH MENTAL RETARDATION, DEAFNESS, SHORT STATURE, AND SLENDER BONES__:____:__
Asterisk__:__608155__:__SYNAPTOPODIN; SYNPO__:__KIAA1029__:__
Number Sign__:__608156__:__NABLUS MASK-LIKE FACIAL SYNDROME; NMLFS__:__CHROMOSOME 8q22.1 DELETION SYNDROME__:__
Asterisk__:__608157__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ORNITHINE TRANSPORTER), MEMBER 2; SLC25A2__:__ORNITHINE TRANSPORTER, MITOCHONDRIAL, 2; ORNT2__:__
Percent__:__608158__:__CoQ-RESPONSIVE OXPHOS DEFICIENCY__:____:__
Asterisk__:__608159__:__PROTEASE, SERINE, 21; PRSS21__:__EOSINOPHIL SERINE PROTEASE 1; ESP1;; TESTISIN__:__
Asterisk__:__608160__:__SRY-BOX 9; SOX9__:__SRY-RELATED HMG-BOX GENE 9__:__XXSR, INCLUDED;; XYSR, INCLUDED;; TESTIS-SPECIFIC ENHANCER OF SOX9, INCLUDED; TES, INCLUDED;; TESTIS-SPECIFIC ENHANCER OF SOX9 CORE, INCLUDED; TESCO, INCLUDED;; REGULATORY ELEMENT, ENHANCER, 13, INCLUDED; ENH13, INCLUDED
Number Sign__:__608161__:__MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3__:__VITELLIFORM MACULAR DYSTROPHY, ADULT-ONSET; AVMD;; FOVEOMACULAR DYSTROPHY, ADULT-ONSET; AOFMD;; FOVEOMACULAR DYSTROPHY, ADULT-ONSET, WITH OR WITHOUT CHOROIDAL NEOVASCULARIZATION__:__
Asterisk__:__608162__:__V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1; VTCN1__:__B7 HOMOLOG 4; B7H4;; B7 SUPERFAMILY, MEMBER 1; B7S1;; B7X__:__
Asterisk__:__608163__:__EXOCYST COMPLEX COMPONENT 7; EXOC7__:__EXO70, S. CEREVISIAE, HOMOLOG OF; EXO70;; KIAA1067__:__
Asterisk__:__608164__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY V, MEMBER 1; KCNV1__:__KV8.1__:__
Asterisk__:__608165__:__PTB DOMAIN-CONTAINING ENGULFMENT ADAPTOR PROTEIN 1; GULP1__:__GULP;; CED6, C. ELEGANS, HOMOLOG OF__:__
Asterisk__:__608166__:__SEMAPHORIN 3E; SEMA3E__:__SEMAPHORIN H, MOUSE, HOMOLOG OF; SEMAH;; KIAA0331__:__
Asterisk__:__608167__:__POTASSIUM CHANNEL, SUBFAMILY T, MEMBER 1; KCNT1__:__KIAA1422;; SLACK__:__
Asterisk__:__608168__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 6; KCNH6__:__ETHER-A-GO-GO-RELATED GENE 2; ERG2; HERG2;; EAG-RELATED GENE 2;; KV11.2__:__
Asterisk__:__608169__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 7; KCNH7__:__ETHER-A-GO-GO-RELATED GENE 3; ERG3; HERG3;; EAG-RELATED GENE 3;; KV11.3__:__
Asterisk__:__608170__:__DEAD/H BOX 41; DDX41__:__ABSTRAKT, DROSOPHILA, HOMOLOG OF; ABS__:__
Asterisk__:__608171__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA-2/DELTA SUBUNIT 4; CACNA2D4__:____:__
Asterisk__:__608172__:__DEHYDRODOLICHYL DIPHOSPHATE SYNTHASE; DHDDS__:__DEDOL-PP SYNTHASE;; HDS;; CIS-ISOPRENYLTRANSFERASE; CIT__:__
Percent__:__608173__:__AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 1__:__AITD1__:__
Percent__:__608174__:__AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 2__:__AITD2__:__
Number Sign__:__608175__:__AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 3; AITD3__:____:__
Percent__:__608176__:__AUTOIMMUNE THYROID DISEASE, SUSCEPTIBILITY TO, 4__:__AITD4__:__
Asterisk__:__608177__:__EXOSTOSIN GLYCOSYLTRANSFERASE 1; EXT1__:__EXOSTOSIN 1;; EXT__:__
Asterisk__:__608178__:__LEUCINE ZIPPER PROTEIN 2; LUZP2__:____:__
Asterisk__:__608179__:__CAYTAXIN; ATCAY__:__BNIPH;; KIAA1872__:__
Number Sign__:__608180__:__SYNPOLYDACTYLY 2; SPD2__:__SYNPOLYDACTYLY, 3/3-PRIME/4, ASSOCIATED WITH METACARPAL AND METATARSAL SYNOSTOSES__:__
Asterisk__:__608181__:__ACIDIC CLUSTER PROTEIN, 33-KD; ACP33__:__MASPARDIN;; SPG21 GENE__:__
Asterisk__:__608182__:__POTASSIUM CHANNEL-INTERACTING PROTEIN 4__:__KCNIP4; KCHIP4;; CALSENILIN-LIKE PROTEIN; CALP__:__
Asterisk__:__608183__:__CHONDROITIN SULFATE SYNTHASE 1; CHSY1__:__CHONDROITIN SYNTHASE 1; CSS1;; CARBOHYDRATE SYNTHASE 1;; KIAA0990__:__
NULL__:__608184__:__IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 4; HIGM4__:__HYPER-IgM SYNDROME 4__:__
Asterisk__:__608185__:__EXOCYST COMPLEX COMPONENT 4; EXOC4__:__SEC8, S. CEREVISIAE, HOMOLOG OF; SEC8;; KIAA1699__:__
Asterisk__:__608186__:__EXOCYST COMPLEX COMPONENT 3; EXOC3__:__SEC6, S. CEREVISIAE, HOMOLOG OF; SEC6__:__
Asterisk__:__608187__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 8; MCM8__:____:__
Asterisk__:__608188__:__CARDIOLIPIN SYNTHASE 1; CRLS1__:__GCD10, S. CEREVISIAE, HOMOLOG OF; GCD10;; CHROMOSOME 20 OPEN READING FRAME 155; C20ORF155__:__
Number Sign__:__608189__:__TROPICAL CALCIFIC PANCREATITIS__:__TCP__:__
Asterisk__:__608190__:__N-ACETYLTRANSFERASE 8B; NAT8B__:__CAMELLO, XENOPUS, HOMOLOG OF, 2; CML2__:__
Asterisk__:__608191__:__RB-ASSOCIATED KRAB REPRESSOR__:__RBAK__:__
Asterisk__:__608192__:__SCY1-LIKE PROTEIN 3; SCYL3__:__SCY1, S. CEREVISIAE, HOMOLOG OF, 3;; PROTEIN ASSOCIATED WITH THE C-TERMINAL DOMAIN OF EZRIN; PACE1__:__
Asterisk__:__608193__:__REC8, S. POMBE, HOMOLOG OF; REC8L1__:__REC8__:__
Number Sign__:__608194__:__CONE-ROD DYSTROPHY 13; CORD13__:____:__
Asterisk__:__608195__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 1; LRRC1__:__LAP AND NO PDZ PROTEIN; LANO__:__
Asterisk__:__608196__:__WERNER HELICASE-INTERACTING PROTEIN 1; WRNIP1__:__WHIP__:__
Asterisk__:__608197__:__PEPTIDOGLYCAN RECOGNITION PROTEIN 3; PGLYRP3__:__PEPTIDOGLYCAN RECOGNITION PROTEIN, INTERMEDIATE, ALPHA;; PGRPI-ALPHA; PGRPIA__:__
Asterisk__:__608198__:__PEPTIDOGLYCAN RECOGNITION PROTEIN 4; PGLYRP4__:__PEPTIDOGLYCAN RECOGNITION PROTEIN, INTERMEDIATE, BETA;; PGRPI-BETA; PGRPIB__:__
Asterisk__:__608199__:__PEPTIDOGLYCAN RECOGNITION PROTEIN 2; PGLYRP2__:__PEPTIDOGLYCAN RECOGNITION PROTEIN, LONG; PGRPL__:__
Asterisk__:__608200__:__CDK5 REGULATORY SUBUNIT-ASSOCIATED PROTEIN 1; CDK5RAP1__:____:__
Asterisk__:__608201__:__CDK5 REGULATORY SUBUNIT-ASSOCIATED PROTEIN 2; CDK5RAP2__:__CENTROSOMAL PROTEIN, 215-KD; CEP215;; KIAA1633__:__
Asterisk__:__608202__:__CDK5 REGULATORY SUBUNIT-ASSOCIATED PROTEIN 3; CDK5RAP3__:__LXXLL/LEUCINE ZIPPER-CONTAINING ARF-BINDING PROTEIN; LZAP;; C53__:__
Number Sign__:__608203__:__NEUTROPHIL IMMUNODEFICIENCY SYNDROME__:____:__
Asterisk__:__608204__:__UNC93, C. ELEGANS, HOMOLOG OF, B1; UNC93B1__:____:__
Asterisk__:__608205__:__MITOCHONDRIAL TRANS-2-ENOYL-CoA REDUCTASE; MECR__:__TRANS-2-ENOYL-CoA REDUCTASE, MITOCHONDRIAL;; 2-ENOYL THIOESTER REDUCTASE;; NUCLEAR RECEPTOR-BINDING FACTOR 1; NRBF1__:__
Asterisk__:__608206__:__SH3 DOMAIN AND TETRATRICOPEPTIDE REPEAT DOMAIN 2; SH3TC2__:__KIAA1985__:__
Percent__:__608207__:__KALA-AZAR, SUSCEPTIBILITY TO, 1; KAZA1__:__LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 1__:__
Asterisk__:__608208__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 4; MARCH4__:__MARCH IV;; KIAA1399__:__
Asterisk__:__608209__:__DIPEPTIDYL PEPTIDASE X; DPP10__:__DIPEPTIDYL PEPTIDASE IV-RELATED PROTEIN 3; DPRP3;; KIAA1492__:__
Asterisk__:__608210__:__EXOSTOSIN GLYCOSYLTRANSFERASE 2; EXT2__:__EXOSTOSIN 2__:__
Asterisk__:__608211__:__KIDNEY-ASSOCIATED ANTIGEN 1; KAAG1__:__RU2, ANTISENSE; RU2AS__:__
Asterisk__:__608212__:__IMMUNITY-RELATED GTPase FAMILY, M; IRGM__:__LRG47, MOUSE, HOMOLOG OF; LRG47;; INTERFERON-INDUCIBLE PROTEIN 1, MOUSE, HOMOLOG OF; IFI1;; IRGM1__:__
Asterisk__:__608213__:__CELL CYCLE EXIT AND NEURONAL DIFFERENTIATION 1; CEND1__:__BM88 ANTIGEN; BM88__:__
Asterisk__:__608214__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE III, BETA SUBUNIT; SCN3B__:__SODIUM CHANNEL, BETA-3 SUBUNIT; SCNB3__:__
Asterisk__:__608215__:__LIM HOMEOBOX GENE 6; LHX6__:__LHX6.1__:__
Asterisk__:__608216__:__COMM DOMAIN-CONTAINING PROTEIN 5; COMMD5__:__COPPER METABOLISM MURR1 DOMAIN-CONTAINING PROTEIN 5;; HYPERTENSION-RELATED CALCIUM-REGULATED GENE; HCARG__:__
Percent__:__608217__:__SEIZURES, BENIGN FAMILIAL NEONATAL, 3; BFNS3__:__CONVULSIONS, BENIGN FAMILIAL NEONATAL, 3; BFNC3__:__
Asterisk__:__608218__:__KERATIN 20, TYPE I; KRT20__:__K20;; KA20;; CYTOKERATIN 20; CK20;; KERATIN 21, RAT, HOMOLOG OF; KRT21__:__
Percent__:__608219__:__DEAFNESS, AUTOSOMAL RECESSIVE 38; DFNB38__:____:__
Percent__:__608220__:__SPASTIC PARAPLEGIA 25, AUTOSOMAL RECESSIVE; SPG25__:__DISC HERNIATION WITH SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE__:__
Asterisk__:__608221__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE-LIKE; MASTL__:__FLJ14813;; GREATWALL; GWL__:__
Asterisk__:__608222__:__ADENYLOSUCCINATE LYASE; ADSL__:__ADENYLOSUCCINASE__:__
NULL__:__608223__:__ASPIRIN RESISTANCE__:__ASPIRIN, RESISTANCE TO ANTITHROMBOTIC EFFECT OF;; ASPIRIN, RESISTANCE TO CARDIOPROTECTIVE EFFECT OF__:__
Number Sign__:__608224__:__DEAFNESS, AUTOSOMAL DOMINANT 41; DFNA41__:____:__
Asterisk__:__608225__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 14; GALNT14__:__GalNAc TRANSFERASE 14; GalNAcT14__:__
Asterisk__:__608226__:__NANOS, DROSOPHILA, HOMOLOG OF, 1; NANOS1__:__NOS1__:__
NULL__:__608227__:__CRANIOFACIAL ABNORMALITIES, CATARACTS, CONGENITAL HEART DISEASE, SACRAL NEURAL TUBE DEFECTS, AND GROWTH AND DEVELOPMENTAL RETARDATION__:____:__
Asterisk__:__608228__:__NANOS, DROSOPHILA, HOMOLOG OF, 2; NANOS2__:__NOS2__:__
Asterisk__:__608229__:__NANOS, DROSOPHILA, HOMOLOG OF, 3; NANOS3__:__NOS3__:__
Asterisk__:__608230__:__CALCIUM CHANNEL, VOLTAGE-DEPENDENT, T TYPE, ALPHA-1I SUBUNIT; CACNA1I__:__KIAA1120__:__
Asterisk__:__608231__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 8; RASSF8__:__CHROMOSOME 12 OPEN READING FRAME 2; C12ORF2__:__
Number Sign__:__608232__:__LEUKEMIA, CHRONIC MYELOID; CML__:__LEUKEMIA, CHRONIC MYELOGENOUS__:__LEUKEMIA, CHRONIC MYELOID, ATYPICAL, INCLUDED; ACML, INCLUDED
Number Sign__:__608233__:__HERMANSKY-PUDLAK SYNDROME 2; HPS2__:____:__
Asterisk__:__608234__:__GALACTOSE-3-O-SULFOTRANSFERASE 3; GAL3ST3__:__GAL3ST2__:__
Asterisk__:__608235__:__GALACTOSE-3-O-SULFOTRANSFERASE 4; GAL3ST4__:____:__
Number Sign__:__608236__:__SLOWED NERVE CONDUCTION VELOCITY, AUTOSOMAL DOMINANT; SNCV__:____:__
Asterisk__:__608237__:__GALACTOSE-3-O-SULFOTRANSFERASE 2; GAL3ST2__:__GLYCOPROTEIN BETA-GALACTOSE 3-PRIME-SULFOTRANSFERASE; GP3ST__:__
Asterisk__:__608238__:__SIGNAL PEPTIDE PEPTIDASE-LIKE 2A; SPPL2A__:__SPP-LIKE 2A;; INTRAMEMBRANE PROTEASE 3; IMP3__:__
Asterisk__:__608239__:__SIGNAL PEPTIDE PEPTIDASE-LIKE 2B__:__SPP-LIKE 2B; SPPL2B;; INTRAMEMBRANE PROTEASE 4; IMP4;; KIAA1532__:__
Asterisk__:__608240__:__SIGNAL PEPTIDE PEPTIDASE-LIKE 3__:__SPP-LIKE 3; SPPL3;; INTRAMEMBRANE PROTEASE 2; IMP2__:__
Asterisk__:__608241__:__SMAD NUCLEAR INTERACTING PROTEIN 1; SNIP1__:____:__
Asterisk__:__608242__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 5; HERC5__:__CYCLIN E-BINDING PROTEIN 1; CEB1__:__
Asterisk__:__608243__:__NONSTRUCTURAL MAINTENANCE OF CHROMOSOMES ELEMENT 3 HOMOLOG; NSMCE3__:__NSE3;; NECDIN-LIKE GENE 2; NDNL2;; MELANOMA ANTIGEN, FAMILY G, 1; MAGEG1__:__
Percent__:__608244__:__OTOSCLEROSIS 3; OTSC3__:____:__
Asterisk__:__608245__:__KERATIN 71, TYPE II; KRT71__:__K71;; KB34;; KERATIN 6, INNER ROOT SHEATH, 1; KRT6IRS1;; K6IRS1__:__
Asterisk__:__608246__:__KERATIN 72, TYPE II; KRT72__:__K72;; KB35;; KERATIN 6, INNER ROOT SHEATH, 2; KRT6IRS2;; K6IRS2__:__
Asterisk__:__608247__:__KERATIN 73, TYPE II; KRT73__:__K73;; KB36;; KERATIN 6, INNER ROOT SHEATH, 3; KRT6IRS3;; K6IRS3__:__
Asterisk__:__608248__:__KERATIN 74, TYPE II; KRT74__:__K74;; KB37;; KERATIN 6, INNER ROOT SHEATH, 4; KRT6IRS4;; K6IRS4__:__
Asterisk__:__608249__:__CYCLIN B1 INTERACTING PROTEIN 1; CCNB1IP1__:__HUMAN ENHANCER OF INVASION 10; HEI10;; CHROMOSOME 14 OPEN READING FRAME 18; C14ORF18__:__HEI10/HMGIC FUSION GENE, INCLUDED
Asterisk__:__608250__:__SDS3, YEAST, HOMOLOG OF__:__SDS3;; SIN3A-ASSOCIATED PROTEIN, 45-KD; SAP45__:__
Percent__:__608251__:__PHOBIA, SPECIFIC__:__PHOBIA, SIMPLE__:__
Asterisk__:__608252__:__ACTIN FILAMENT-ASSOCIATED PROTEIN 1; AFAP1__:__AFAP;; AFAP, 110-KD; AFAP110__:__
Asterisk__:__608253__:__TESTIS-SPECIFIC KINASE SUBSTRATE__:__TSKS__:__
Asterisk__:__608254__:__PAX TRANSCRIPTION ACTIVATION DOMAIN-INTERACTING PROTEIN 1; PAXIP1__:__PAXIP1L;; PAX TRANSACTIVATION DOMAIN-INTERACTING PROTEIN; PTIP__:__
Asterisk__:__608255__:__TRAF3-INTERACTING PROTEIN 3; TRAF3IP3__:__TRAF3-INTERACTING JNK-ACTIVATING MODULATOR; T3JAM__:__
Asterisk__:__608256__:__SODIUM CHANNEL, VOLTAGE-GATED, TYPE IV, BETA SUBUNIT; SCN4B__:____:__
NULL__:__608257__:__MANDIBULOFACIAL DYSOSTOSIS WITH PTOSIS, AUTOSOMAL DOMINANT__:____:__
Asterisk__:__608258__:__DIPEPTIDYL PEPTIDASE IX; DPP9__:__DIPEPTIDYL PEPTIDASE IV-RELATED PROTEIN 2; DPRP2__:__
Asterisk__:__608259__:__INSULIN-LIKE GROWTH FACTOR 2 mRNA-BINDING PROTEIN 3; IGF2BP3__:__IGF2 mRNA-BINDING PROTEIN 3; IMP3;; KH DOMAIN CONTAINING PROTEIN OVEREXPRESSED IN CANCER; KOC1;; VICKZ3__:__
Asterisk__:__608260__:__POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 8; KCNH8__:__ETHER-A-GO-GO-LIKE POTASSIUM CHANNEL 1; ELK1;; EAG-LIKE POTASSIUM CHANNEL 1__:__
Asterisk__:__608261__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 2; SENP2__:__SUMO-SPECIFIC PROTEASE 2;; SMT3-SPECIFIC ISOPEPTIDASE 2, MOUSE, HOMOLOG OF; SMT3IP2;; AXAM2, RAT, HOMOLOG OF; AXAM2;; KIAA1331__:__
Asterisk__:__608262__:__DISRUPTED IN RENAL CARCINOMA 3; DIRC3__:____:__DIRC3/HSPBAP1 FUSION GENE, INCLUDED
Asterisk__:__608263__:__HEAT-SHOCK 27-KD PROTEIN-ASSOCIATED PROTEIN 1; HSPBAP1__:__HSPB-ASSOCIATED PROTEIN 1;; PASS1, RAT, HOMOLOG OF; PASS1__:__HSPBAP1/DIRC3 FUSION GENE, INCLUDED
Percent__:__608264__:__DEAFNESS, AUTOSOMAL RECESSIVE 40; DFNB40__:____:__
Number Sign__:__608265__:__DEAFNESS, AUTOSOMAL RECESSIVE 39; DFNB39__:____:__
Number Sign__:__608266__:__PARATHYROID CARCINOMA__:__PRTC__:__
Asterisk__:__608267__:__RAS-RELATED GTP-BINDING PROTEIN C; RRAGC__:__RAGC__:__
Asterisk__:__608268__:__RAS-RELATED GTP-BINDING PROTEIN D; RRAGD__:__RAGD__:__
Asterisk__:__608269__:__SOLUTE CARRIER FAMILY 28 (SODIUM-COUPLED NUCLEOSIDE TRANSPORTER), MEMBER 3; SLC28A3__:__CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; CNT3__:__
Asterisk__:__608270__:__THREONINE ASPARTASE 1; TASP1__:__TASPASE 1;; CHROMOSOME 20 OPEN READING FRAME 13; C20ORF13__:__
Asterisk__:__608271__:__MICROTUBULE-ACTIN CROSS-LINKING FACTOR 1; MACF1__:__MACROPHIN 1;; TRABECULIN-ALPHA;; ACTIN CROSS-LINKING FACTOR 7; ACF7;; KIAA1251__:__
Asterisk__:__608272__:__NEURAMINIDASE 1; NEU1__:__SIALIDASE 1; SIAL1;; SIALIDASE, LYSOSOMAL__:__
Asterisk__:__608273__:__INTERLEUKIN 27; IL27__:__INTERLEUKIN 27, 28-KD SUBUNIT;; IL27p28;; INTERLEUKIN 30; IL30__:__
Asterisk__:__608274__:__PROTEIN ARGININE N-METHYLTRANSFERASE 6; PRMT6__:____:__
Asterisk__:__608275__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 15; SLC22A15__:__FLY-LIKE PUTATIVE TRANSPORTER 1; FLIPT1__:__
Asterisk__:__608276__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 16; SLC22A16__:__FLY-LIKE PUTATIVE TRANSPORTER 2; FLIPT2;; CARNITINE TRANSPORTER 2; CT2__:__
Asterisk__:__608277__:__CARBOHYDRATE SULFOTRANSFERASE 15; CHST15__:__B-CELL RAG-ASSOCIATED GENE; BRAG;; N-ACETYLGALACTOSAMINE 4-SULFATE 6-O-SULFOTRANSFERASE;; GalNAc4S-6ST;; KIAA0598__:__
NULL__:__608278__:__GROWTH FAILURE, MICROCEPHALY, MENTAL RETARDATION, CATARACTS, LARGE JOINT CONTRACTURES, OSTEOPOROSIS, CORTICAL DYSPLASIA, AND CEREBELLAR ATROPHY__:____:__
NULL__:__608279__:__CRANIOSYNOSTOSIS WITH OCULAR ABNORMALITIES AND HALLUCAL DEFECTS__:____:__
Asterisk__:__608280__:__GROWTH ARREST-SPECIFIC 5; GAS5__:____:__
NULL__:__608281__:__SCIMITAR ANOMALY, MULTIPLE CARDIAC MALFORMATIONS, AND CRANIOFACIAL AND CENTRAL NERVOUS SYSTEM ABNORMALITIES__:__ANOMALOUS PULMONARY VENOUS RETURN, MULTIPLE CARDIAC MALFORMATIONS, AND CRANIOFACIAL AND CENTRAL NERVOUS SYSTEM ABNORMALITIES__:__
Asterisk__:__608282__:__TRACE AMINE-ASSOCIATED RECEPTOR 9; TAAR9__:__TRACE AMINE RECEPTOR 3; TRAR3;; TAR3; TA3__:__
Asterisk__:__608283__:__KINESIN FAMILY MEMBER 21A; KIF21A__:__KIAA1708__:__
Asterisk__:__608284__:__INTRAMEMBRANE PROTEASE 5__:__IMP5__:__
Asterisk__:__608285__:__NAD SYNTHETASE 1; NADSYN1__:____:__
Asterisk__:__608286__:__PROTOCADHERIN 10; PCDH10__:__KIAA1400__:__
Asterisk__:__608287__:__PROTOCADHERIN 18; PCDH18__:__KIAA1562__:__
Asterisk__:__608288__:__INSULIN-LIKE GROWTH FACTOR 2 mRNA-BINDING PROTEIN 1; IGF2BP1__:__IGF2 mRNA-BINDING PROTEIN 1; IMP1;; CODING REGION DETERMINANT-BINDING PROTEIN, MOUSE, HOMOLOG OF; CRDBP;; ZIPCODE-BINDING PROTEIN 1; ZBP1__:__
Asterisk__:__608289__:__INSULIN-LIKE GROWTH FACTOR 2 mRNA-BINDING PROTEIN 2; IGF2BP2__:__IGF2 mRNA-BINDING PROTEIN 2; IMP2__:__
Percent__:__608290__:__LELIS SYNDROME__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH ACANTHOSIS NIGRICANS__:__
Asterisk__:__608291__:__TUBULIN-TYROSINE LIGASE; TTL__:____:__
Asterisk__:__608292__:__STOMATIN-LIKE PROTEIN 2; STOML2__:__SLP2;; PARAPROTEIN TARGET 7; PARATARG7;; PARATARG 7__:__
Asterisk__:__608293__:__RHO GTPase-ACTIVATING PROTEIN 17; ARHGAP17__:__RHOGAP INTERACTING WITH CIP4 HOMOLOGS 1; RICH1;; NADRIN, RAT, HOMOLOG OF__:__
Asterisk__:__608294__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 6; NME6__:__NONMETASTATIC CELLS 6, PROTEIN EXPRESSED IN;; NM23H6__:__
Asterisk__:__608295__:__FAMILY WITH SEQUENCE SIMILARITY 107, MEMBER A; FAM107A__:__DOWNREGULATED IN RENAL CELL CARCINOMA 1; DRR1;; TU3A PROTEIN; TU3A__:__
Asterisk__:__608296__:__FIBROBLAST GROWTH FACTOR, ACIDIC, INTRACELLULAR BINDING PROTEIN; FIBP__:____:__
Caret__:__608297__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__608298__:__URB, MOUSE, HOMOLOG OF__:__URB;; STEROID-SENSITIVE GENE 1, RAT, HOMOLOG OF; SSG1__:__
Asterisk__:__608299__:__RING FINGER PROTEIN 34; RNF34__:__RING FINGER HOMOLOGOUS TO IAP TYPE; RFI__:__
Asterisk__:__608300__:__N-ACETYLGLUTAMATE SYNTHASE; NAGS__:____:__
Asterisk__:__608301__:__LEUCINE-RICH GENE, GLIOMA-INACTIVATED, 2; LGI2__:__KIAA1916__:__
Asterisk__:__608302__:__LEUCINE-RICH GENE, GLIOMA-INACTIVATED, 3; LGI3__:____:__
Asterisk__:__608303__:__LEUCINE-RICH GENE, GLIOMA-INACTIVATED, 4; LGI4__:____:__
Asterisk__:__608304__:__CANCER/TESTIS ANTIGEN 3; CTAG3__:__CANCER-ASSOCIATED GENE 1; CAGE1__:__
Asterisk__:__608305__:__SOLUTE CARRIER FAMILY 13 (SODIUM-DEPENDENT CITRATE TRANSPORTER), MEMBER 5; SLC13A5__:__SODIUM-COUPLED CITRATE TRANSPORTER; NACT__:__
Asterisk__:__608306__:__TRANSCRIPTION FACTOR Sp8; SP8__:__BUTTONHEAD, DROSOPHILA, HOMOLOG OF; BTD__:__
Plus__:__608307__:__CARBAMOYL PHOSPHATE SYNTHETASE I; CPS1__:____:__VENOOCCLUSIVE DISEASE AFTER BONE MARROW TRANSPLANTATION, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__608308__:__ANKYRIN REPEAT AND BTB/POZ DOMAIN CONTAINING 1; ABTB1__:__BPOZ__:__
Asterisk__:__608309__:__PTEN-INDUCED PUTATIVE KINASE 1; PINK1__:____:__
Asterisk__:__608310__:__ARGININOSUCCINATE LYASE; ASL__:__ARGININOSUCCINASE__:__
Asterisk__:__608311__:__GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL D-ASPARTATE-LIKE 1B; GRINL1B__:____:__
Asterisk__:__608312__:__TWIST NEIGHBOR; TWISTNB__:____:__
Asterisk__:__608313__:__ARGINASE 1; ARG1__:__ARGINASE, LIVER__:__
Asterisk__:__608314__:__SEPTIN 3; SEPT3__:__SEP3__:__
Asterisk__:__608315__:__ELL-ASSOCIATED FACTOR 1; EAF1__:____:__
Percent__:__608316__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 2__:__CHDS2__:__
Asterisk__:__608317__:__GRAINYHEAD-LIKE 3; GRHL3__:__GRAINYHEAD, DROSOPHILA, HOMOLOG OF, 3;; SISTER OF MAMMALIAN GRAINYHEAD;; SISTER OF MGR; SOM;; TRANSCRIPTION FACTOR CP2-LIKE 4; TFCP2L4;; CURLY TAIL, MOUSE, HOMOLOG OF__:__
Percent__:__608318__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 4__:__CHDS4__:__
Caret__:__608319__:__MOVED TO 605097__:____:__
Number Sign__:__608320__:__CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1__:__CORONARY ARTERY DISEASE WITH MYOCARDIAL INFARCTION__:__
Asterisk__:__608321__:__TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 2; TICAM2__:__TOLL/INTERLEUKIN-1 RECEPTOR DOMAIN-CONTAINING PROTEIN; TIRP;; TRIF-RELATED ADAPTOR MOLECULE; TRAM__:__
Asterisk__:__608322__:__KINESIN FAMILY MEMBER 21B; KIF21B__:__KIAA0449__:__
Number Sign__:__608323__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC__:__CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE C;; DI-CMTC__:__
Asterisk__:__608324__:__SMALL INTEGRAL MEMBRANE PROTEIN 3; SMIM3__:__NGF-INDUCED DIFFERENTIATION CLONE 67; NID67__:__
Asterisk__:__608325__:__PHD FINGER PROTEIN 21A; PHF21A__:__BRAF35/HDAC COMPLEX, 80-KD SUBUNIT; BHC80;; KIAA1696__:__
Asterisk__:__608326__:__STOMATIN-LIKE PROTEIN 1; STOML1__:__SLP1;; STOMATIN-RELATED PROTEIN; STORP__:__
Asterisk__:__608327__:__STOMATIN-LIKE PROTEIN 3; STOML3__:__STOMATIN-RELATED OLFACTORY PROTEIN; SRO__:__
Number Sign__:__608328__:__WEILL-MARCHESANI SYNDROME 2; WMS2__:__WEILL-MARCHESANI SYNDROME, AUTOSOMAL DOMINANT;; SPHEROPHAKIA-BRACHYMORPHIA SYNDROME;; MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL;; GLAUCOMA-LENS ECTOPIA-MICROSPHEROPHAKIA-STIFFNESS-SHORTNESS SYNDROME; GEMSS__:__
Asterisk__:__608329__:__MYELIN REGULATORY FACTOR; MYRF__:__MRF;; CHROMOSOME 11 OPEN READING FRAME 9; C11ORF9;; KIAA0954__:__
Asterisk__:__608330__:__PRECURSOR mRNA-PROCESSING FACTOR 19, S. CEREVISIAE, HOMOLOG OF; PRPF19__:__PRP19;; PSO4, S. CEREVISIAE, HOMOLOG OF; PSO4;; NUCLEAR MATRIX PROTEIN 200; NMP200__:__
Asterisk__:__608331__:__SOLUTE CARRIER FAMILY 36 (PROTON/AMINO ACID SYMPORTER), MEMBER 2; SLC36A2__:__PROTON/AMINO ACID TRANSPORTER 2; PAT2;; TRAMDORIN 1__:__
Asterisk__:__608332__:__SOLUTE CARRIER FAMILY 36 (PROTON/AMINO ACID SYMPORTER), MEMBER 3; SLC36A3__:__PROTON/AMINO ACID TRANSPORTER 3; PAT3__:__
Asterisk__:__608333__:__DOCKING PROTEIN 4; DOK4__:__DOWNSTREAM OF TYROSINE KINASE 4__:__
Asterisk__:__608334__:__DOCKING PROTEIN 5; DOK5__:__DOWNSTREAM OF TYROSINE KINASE 5__:__
Asterisk__:__608335__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY O, MEMBER 1; PLEKHO1__:__CK2-INTERACTING PROTEIN 1; CKIP1;; CASEIN KINASE II-INTERACTING PROTEIN 1__:__
Asterisk__:__608336__:__TRANSMEMBRANE DOMAIN PROTEIN REGULATED IN ADIPOCYTES, 40-KD__:__TPRA40__:__
Asterisk__:__608337__:__OTU DOMAIN-CONTAINING UBIQUITIN ALDEHYDE-BINDING PROTEIN 1; OTUB1__:__OTU DOMAIN-CONTAINING UBAL-BINDING PROTEIN 1;; OTUBAIN 1; OTU1; OTB1__:__
Asterisk__:__608338__:__OTU DOMAIN-CONTAINING UBIQUITIN ALDEHYDE-BINDING PROTEIN 2; OTUB2__:__OTU DOMAIN-CONTAINING UBAL-BINDING PROTEIN 2;; OTUBAIN 2; OTU2; OTB2;; CHROMOSOME 14 OPEN READING FRAME 137; C14ORF137__:__
Asterisk__:__608339__:__SYNTAXIN-BINDING PROTEIN 3; STXBP3__:__UNC18, C. ELEGANS, HOMOLOG OF, 3;; MUNC18-3;; MUNC18C;; PLATELET SEC1 PROTEIN; PSP__:__
Number Sign__:__608340__:__CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA__:__CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE A;; RI-CMTA__:__
Asterisk__:__608341__:__CYTOCHROME b5 REDUCTASE 1; CYB5R1__:__B5R.1;; NAD(P)H:QUINONE OXIDOREDUCTASE TYPE 3, POLYPEPTIDE A2; NQO3A2__:__
Asterisk__:__608342__:__CYTOCHROME b5 REDUCTASE 2; CYB5R2__:__B5R.2__:__
Asterisk__:__608343__:__CYTOCHROME b5 REDUCTASE 4; CYB5R4__:__NADPH CYTOCHROME b5 OXIDOREDUCTASE; NCB5OR__:__
Asterisk__:__608344__:__HEAT-SHOCK 27-KD PROTEIN 9__:__HSPB9__:__
Percent__:__608345__:__NYSTAGMUS 3, CONGENITAL, AUTOSOMAL DOMINANT; NYS3__:____:__
Caret__:__608346__:__MOVED TO 236670__:____:__
Asterisk__:__608347__:__DICARBONYL/L-XYLULOSE REDUCTASE; DCXR__:__CARBONYL REDUCTASE 2;; DICARBONYL REDUCTASE;; DIACETYL REDUCTASE;; L-XYLULOSE REDUCTASE;; P34H__:__
Asterisk__:__608348__:__BRANCHED-CHAIN KETO ACID DEHYDROGENASE E1, ALPHA POLYPEPTIDE; BCKDHA__:__BCKD, E1-ALPHA SUBUNIT; BCKDE1A__:__
Asterisk__:__608349__:__HEMATOPOIETIC SH2 DOMAIN-CONTAINING PROTEIN; HSH2D__:__HSH2;; ALX__:__
Asterisk__:__608350__:__ENDOMUCIN; EMCN__:__ENDOMUCIN 2; EMCN2__:__
Asterisk__:__608351__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 11; IGSF11__:__BRAIN- AND TESTIS-SPECIFIC IMMUNOGLOBULIN SUPERFAMILY PROTEIN; BTIGSF__:__
Asterisk__:__608352__:__ACROSIN-BINDING PROTEIN; ACRBP__:__PROACROSIN-BINDING PROTEIN SP32 PRECURSOR; SP32;; OY-TES-1__:__
Asterisk__:__608353__:__ANTIZYME INHIBITOR 2; AZIN2__:__ORNITHINE DECARBOXYLASE-LIKE PROTEIN;; ODC-LIKE PROTEIN; ODC1L;; KIAA1945__:__
Number Sign__:__608354__:__CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION 1; CMAVM1__:__CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION; CMAVM__:__
Caret__:__608355__:__MOVED TO 608354__:____:__
Asterisk__:__608356__:__OUTER DENSE FIBER OF SPERM TAILS 3; ODF3__:__SHIPPO1__:__
Asterisk__:__608357__:__SULFOTRANSFERASE FAMILY 1C, MEMBER 4; SULT1C4__:__SULFOTRANSFERASE FAMILY 1C, MEMBER 2, FORMERLY; SULT1C2, FORMERLY__:__
Number Sign__:__608358__:__MYOPATHY, MYOSIN STORAGE, AUTOSOMAL DOMINANT; MSMA__:__MYOPATHY, HYALINE BODY, AUTOSOMAL DOMINANT;; MYOPATHY WITH LYSIS OF TYPE I MYOFIBRILS__:__
Asterisk__:__608359__:__SULFOTRANSFERASE FAMILY 4A, MEMBER 1; SULT4A1__:__BRAIN SULFOTRANSFERASE-LIKE PROTEIN 1; BRSTL1__:__
Asterisk__:__608360__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8A; LRRC8A__:__LRRC8;; SWELL1;; KIAA1437__:__
Number Sign__:__608361__:__SPONDYLOEPIPHYSEAL DYSPLASIA, KIMBERLEY TYPE; SEDK__:____:__
Asterisk__:__608362__:__STATHMIN-LIKE 3; STMN3__:__SCG10-LIKE PROTEIN; SCLIP__:__
Number Sign__:__608363__:__CHROMOSOME 22q11.2 DUPLICATION SYNDROME__:__CHROMOSOME 22q11.2 MICRODUPLICATION SYNDROME__:__
Asterisk__:__608364__:__LIM DOMAIN AND ACTIN-BINDING PROTEIN 1; LIMA1__:__EPITHELIAL PROTEIN LOST IN NEOPLASM; EPLIN;; STEROL REGULATORY ELEMENT-BINDING PROTEIN 3; SREBP3__:__
Asterisk__:__608365__:__T-COMPLEX PROTEIN 10-LIKE; TCP10L__:____:__
Asterisk__:__608366__:__KIAA1199 GENE; KIAA1199__:____:__
Percent__:__608367__:__MYOPIA 17, AUTOSOMAL DOMINANT; MYP17__:__MYOPIA 4, FORMERLY; MYP4, FORMERLY__:__
Asterisk__:__608368__:__RAD9, S. POMBE, HOMOLOG OF, B; RAD9B__:____:__
Asterisk__:__608369__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 13; GALNT13__:__GalNAc TRANSFERASE 13; GalNAcT13;; KIAA1918__:__
Asterisk__:__608370__:__STEAROYL-CoA DESATURASE 5; SCD5__:__ACYL-CoA DESATURASE 4; ACOD4__:__
Percent__:__608371__:__OROFACIAL CLEFT 4; OFC4__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 4__:__
Percent__:__608372__:__DEAFNESS, AUTOSOMAL DOMINANT 49; DFNA49__:____:__
Asterisk__:__608373__:__SYNAPTOGYRIN 4; SYNGR4__:____:__
Asterisk__:__608374__:__HEMOJUVELIN; HJV__:__HFE2__:__
Asterisk__:__608375__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 6; DNAJC6__:__DJC6;; AUXILIN, BOVINE, HOMOLOG OF;; KIAA0473__:__
Asterisk__:__608376__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 12; DNAJB12__:__DJ10;; FLJ20027__:__
Asterisk__:__608377__:__ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN 1; ARFGAP1__:____:__
Asterisk__:__608378__:__NUCLEAR EXPORT MEDIATOR FACTOR; NEMF__:__SEROLOGICALLY DEFINED COLON CANCER ANTIGEN 1; SDCCAG1;; NY-CO-1__:__
Asterisk__:__608379__:__CHEMOKINE, CC MOTIF, RECEPTOR-LIKE PROTEIN 2; CCRL2__:__HCR;; CRAM;; ATYPICAL CHEMOKINE RECEPTOR 5; ACKR5__:__
Number Sign__:__608380__:__RETINITIS PIGMENTOSA 26; RP26__:____:__
Asterisk__:__608381__:__CERAMIDE KINASE-LIKE; CERKL__:____:__
Asterisk__:__608382__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY A, MEMBER 3; DNAJA3__:__TID56, DROSOPHILA, HOMOLOG OF, 1; TID1__:__
Asterisk__:__608383__:__DIHYDROPYRIMIDINASE-LIKE 5; DPYSL5__:__COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; CRMP5;; CRMP3-ASSOCIATED MOLECULE; CRAM;; ULIP6__:__
Asterisk__:__608384__:__GASDERMIN C; GSDMC__:__MELANOMA-DERIVED LEUCINE ZIPPER-CONTAINING EXTRANUCLEAR FACTOR; MLZE__:__
Asterisk__:__608385__:__TENSIN 4; TNS4__:__C-TERMINAL TENSIN-LIKE PROTEIN; CTEN__:__
Asterisk__:__608386__:__TUBEROINFUNDIBULAR PEPTIDE OF 39 AMINO ACIDS__:__TIP39__:__
Asterisk__:__608387__:__ZINC FINGER PROTEIN 213; ZNF213__:__CR53__:__
Asterisk__:__608388__:__EVOLUTIONARILY-CONSERVED SIGNALING INTERMEDIATE IN TOLL PATHWAY; ECSIT__:__SITPEC__:__
Number Sign__:__608389__:__BRANCHIOOTIC SYNDROME 3; BOS3__:__BO SYNDROME 3__:__
Number Sign__:__608390__:__MYOTONIA, POTASSIUM-AGGRAVATED__:__MYOTONIA FLUCTUANS;; MYOTONIA PERMANENS;; SODIUM CHANNEL MUSCLE DISEASE;; MYOTONIA CONGENITA, ACETAZOLAMIDE-RESPONSIVE;; MYOTONIA CONGENITA, ATYPICAL__:__LARYNGOSPASM, SEVERE NEONATAL EPISODIC, INCLUDED; SNEL, INCLUDED
Percent__:__608391__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 2; AIS2__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 3; VAMAS3;; AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 7-RELATED__:__
Percent__:__608392__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 3; AIS3__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 4; VAMAS4;; AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 8-RELATED__:__
Number Sign__:__608393__:__MICROCEPHALY 6, PRIMARY, AUTOSOMAL RECESSIVE; MCPH6__:____:__
Percent__:__608394__:__DEAFNESS, AUTOSOMAL DOMINANT 43; DFNA43__:____:__
Caret__:__608395__:__MOVED TO 610217__:____:__
Asterisk__:__608396__:__SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN EXCHANGER), MEMBER 9; SLC9A9__:__SODIUM/HYDROGEN EXCHANGER 9; NHE9__:__
Asterisk__:__608397__:__CUB AND SUSHI MULTIPLE DOMAINS 1; CSMD1__:__KIAA1890__:__
Asterisk__:__608398__:__CUB AND SUSHI MULTIPLE DOMAINS 2; CSMD2__:__KIAA1884__:__
Asterisk__:__608399__:__CUB AND SUSHI MULTIPLE DOMAINS 3; CSMD3__:__KIAA1894__:__
Asterisk__:__608400__:__USH2A GENE; USH2A__:__USHERIN;; USH2; US2__:__
Asterisk__:__608401__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 4E; MS4A4E__:____:__
Asterisk__:__608402__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 6E; MS4A6E__:____:__
Asterisk__:__608403__:__MEMBRANE-SPANNING 4-DOMAINS, SUBFAMILY A, MEMBER 10; MS4A10__:____:__
Number Sign__:__608404__:__PLATELET GLYCOPROTEIN IV DEFICIENCY__:__BLEEDING DISORDER, PLATELET-TYPE, 10; BDPLT10;; CD36 DEFICIENCY__:__
Asterisk__:__608405__:__1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; ACCS__:__ACC SYNTHASE; ACS;; PHACS__:__
NULL__:__608406__:__VATER-LIKE DEFECTS WITH PULMONARY HYPERTENSION, LARYNGEAL WEBS, AND GROWTH DEFICIENCY__:____:__
Asterisk__:__608407__:__DIHYDROPYRIMIDINASE-LIKE 4; DPYSL4__:__COLLAPSIN RESPONSE MEDIATOR PROTEIN 3; CRMP3;; UNC33-LIKE PHOSPHOPROTEIN 4; ULIP4__:__
Asterisk__:__608408__:__DEVELOPMENTAL PLURIPOTENCY-ASSOCIATED GENE 3; DPPA3__:__STELLA, MOUSE, HOMOLOG OF;; PRIMORDIAL GERM CELL PROTEIN 7; PGC7__:__
Asterisk__:__608409__:__NORMAL MUCOSA OF ESOPHAGUS-SPECIFIC GENE 1__:__NMES1__:__
Percent__:__608410__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 7; BMIQ7__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__608411__:__EXPORTIN 6; XPO6__:__EXP6;; KIAA0370__:__
Asterisk__:__608412__:__GC-RICH PROMOTER-BINDING PROTEIN 1; GPBP1__:__GPBP;; VASCULAR WALL-LINKED PROTEIN;; VASCULIN__:__
Asterisk__:__608413__:__UBIQUITIN-PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 5; UBR5__:__E3 UBIQUITIN PROTEIN LIGASE, HECT DOMAIN-CONTAINING, 1; EDD1; EDD;; PROGESTIN-INDUCED PROTEIN;; HYPERPLASTIC DISCS, DROSOPHILA, HOMOLOG OF; HYD;; KIAA0896__:__
Asterisk__:__608414__:__PHOSPHOLIPASE C, EPSILON-1; PLCE1__:__PLCE;; KIAA1516__:__
Number Sign__:__608415__:__PROLONGED ELECTRORETINAL RESPONSE SUPPRESSION; PERRS__:__BRADYOPSIA__:__
Asterisk__:__608416__:__MATRIX METALLOPROTEINASE 21; MMP21__:____:__
Asterisk__:__608417__:__MATRIX METALLOPROTEINASE 28; MMP28__:__EPILYSIN__:__
Asterisk__:__608418__:__SEPTIN 8; SEPT8__:__KIAA0202__:__
Asterisk__:__608419__:__METHYLMALONYL-CoA EPIMERASE; MCEE__:__METHYLMALONYL-CoA RACEMASE__:__
Asterisk__:__608420__:__PANNEXIN 1; PANX1__:__PX1__:__
Asterisk__:__608421__:__PANNEXIN 2; PANX2__:__PX2__:__
Asterisk__:__608422__:__PANNEXIN 3; PANX3__:__PX3__:__
Number Sign__:__608423__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 2; LGMDD2__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1F; LGMD1F__:__
Asterisk__:__608424__:__MUCIN 17; MUC17__:____:__
Asterisk__:__608425__:__FRUCTOSAMINE 3-KINASE__:__FN3K__:__
Asterisk__:__608426__:__MAKORIN 2; MKRN2__:____:__
Asterisk__:__608427__:__PARKIN COREGULATED GENE; PACRG__:____:__
Asterisk__:__608428__:__CYTOCHROME P450, SUBFAMILY XXVIC, POLYPEPTIDE 1; CYP26C1__:____:__
Asterisk__:__608429__:__CARBOHYDRATE SULFOTRANSFERASE 14; CHST14__:__DERMATAN-4-SULFOTRANSFERASE 1; D4ST1;; N-ACETYLGALACTOSAMINE 4-0 SULFOTRANSFERASE__:__
Asterisk__:__608430__:__TRPC4-ASSOCIATED PROTEIN; TRPC4AP__:__TRANSIENT RECEPTOR POTENTIAL CHANNEL 4-ASSOCIATED PROTEIN;; TUMOR NECROSIS FACTOR RECEPTOR 1-ASSOCIATED UBIQUITOUS SCAFFOLDING AND SIGNALING PROTEIN;; TNFR1-ASSOCIATED UBIQUITOUS SCAFFOLDING AND SIGNALING PROTEIN; TRUSS__:__
Asterisk__:__608431__:__GTPase-ACTIVATING PROTEIN SH3 DOMAIN-BINDING PROTEIN 1; G3BP1__:__RAS-GTPase-ACTIVATING PROTEIN SH3 DOMAIN-BINDING PROTEIN;; GAP SH3 DOMAIN-BINDING PROTEIN; G3BP;; HUMAN DNA HELICASE VIII;; HDH-VIII__:__
NULL__:__608432__:__CRANIOSYNOSTOSIS, CALCIFICATION OF BASAL GANGLIA, AND FACIAL DYSMORPHISM__:____:__
Asterisk__:__608433__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 18; ZBTB18__:__ZINC FINGER PROTEIN 238; ZNF238;; REPRESSOR PROTEIN, 58-KD; RP58;; C2H2-171__:__
Asterisk__:__608434__:__G PROTEIN-COUPLED RECEPTOR KINASE-INTERACTING PROTEIN 1; GIT1__:__GRK-INTERACTING PROTEIN 1__:__
Asterisk__:__608435__:__MUSCLE RAS VIRAL ONCOGENE HOMOLOG; MRAS__:__RELATED RAS VIRAL ONCOGENE HOMOLOG 3; RRAS3__:__
Asterisk__:__608436__:__SULFOTRANSFERASE FAMILY 1B, MEMBER 1; SULT1B1__:__SULFOTRANSFERASE 1B2; ST1B2__:__
Percent__:__608437__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 4; SLEB4__:____:__
Asterisk__:__608438__:__TOUSLED-LIKE KINASE 1; TLK1__:__KIAA0137;; PROTEIN KINASE, UBIQUITOUS-BETA; PKU-BETA__:__
Asterisk__:__608439__:__TOUSLED-LIKE KINASE 2; TLK2__:__PROTEIN KINASE, UBIQUITOUS-ALPHA; PKU-ALPHA__:__
Asterisk__:__608440__:__LACTAMASE, BETA; LACTB__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L56; MRPL56__:__
Asterisk__:__608441__:__SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 1; SYNE1__:__SYNAPTIC NUCLEAR ENVELOPE PROTEIN 1;; NUCLEAR ENVELOPE SPECTRIN REPEAT PROTEIN 1;; NESPRIN 1;; KIAA0796;; KIAA1756;; KIAA1262__:__CPG2 ISOFORM, INCLUDED; CPG2, INCLUDED;; CPG2B ISOFORM, INCLUDED; CPG2B, INCLUDED
Asterisk__:__608442__:__SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 2; SYNE2__:__SYNAPTIC NUCLEAR ENVELOPE PROTEIN 2;; NUCLEAR ENVELOPE SPECTRIN REPEAT PROTEIN 2;; NESPRIN 2;; NUCLEUS AND ACTIN CONNECTING ELEMENT; NUANCE;; KIAA1011__:__
Number Sign__:__608443__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 3; MRT3__:____:__
Asterisk__:__608444__:__LYSINE-SPECIFIC METHYLTRANSFERASE 2E; KMT2E__:__MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA 5; MLL5__:__
Percent__:__608445__:__SPEECH-SOUND DISORDER__:__SSD__:__
Number Sign__:__608446__:__MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO__:____:__MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 1, INCLUDED; MCI1, INCLUDED;; MYOCARDIAL INFARCTION, PROTECTION AGAINST, INCLUDED
Percent__:__608447__:__CAROTID INTIMAL MEDIAL THICKNESS 2__:__CIMT2;; CAROTID INTIMAL MEDIAL THICKNESS QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 12__:__
Percent__:__608448__:__INFLAMMATORY BOWEL DISEASE 9; IBD9__:____:__
Asterisk__:__608449__:__POLYPYRIMIDINE TRACT-BINDING PROTEIN 2; PTBP2__:__NEURONAL POLYPYRIMIDINE TRACT-BINDING PROTEIN; NPTB__:__
Asterisk__:__608450__:__B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA-EXPRESSED GENE; BLACE__:____:__
Asterisk__:__608451__:__ETHE1 GENE; ETHE1__:__HEPATOMA SUBTRACTED CLONE ONE; HSCO;; D83198__:__
Asterisk__:__608452__:__PLATELET-DERIVED GROWTH FACTOR C; PDGFC__:__FALLOTEIN__:__
Asterisk__:__608453__:__CAS-BR-M MURINE ECOTROPIC RETROVIRAL TRANSFORMING SEQUENCE C; CBLC__:__CBL3__:__
Caret__:__608454__:__MOVED TO 267750__:____:__
Asterisk__:__608455__:__GLYCOGEN PHOSPHORYLASE, MUSCLE; PYGM__:__MYOPHOSPHORYLASE__:__
Number Sign__:__608456__:__FAMILIAL ADENOMATOUS POLYPOSIS 2; FAP2__:__COLORECTAL ADENOMATOUS POLYPOSIS, AUTOSOMAL RECESSIVE;; ADENOMAS, MULTIPLE COLORECTAL, AUTOSOMAL RECESSIVE__:__
Asterisk__:__608457__:__CHROMOBOX HOMOLOG 7; CBX7__:____:__
Asterisk__:__608458__:__NEUROCHONDRIN; NCDN__:__NORBIN;; KIAA0607__:__
Asterisk__:__608459__:__CYCLIN-DEPENDENT KINASE-LIKE 3; CDKL3__:__NKIAMRE__:__
Asterisk__:__608460__:__ZINC FINGER PROTEIN 276; ZFP276__:____:__
Asterisk__:__608461__:__COLLAGEN, TYPE XXVII, ALPHA-1; COL27A1__:__KIAA1870__:__
Percent__:__608462__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 8; HSCR8__:____:__
Asterisk__:__608463__:__APOPTOSIS-ANTAGONIZING TRANSCRIPTION FACTOR; AATF__:__CHE1__:__
Asterisk__:__608464__:__ANGIOGENIC FACTOR WITH G-PATCH AND FHA DOMAINS 1; AGGF1__:__VG5Q GENE;; FLJ10283__:__
Asterisk__:__608465__:__SENATAXIN; SETX__:____:__
Asterisk__:__608466__:__ACTIVATOR OF HEAT-SHOCK 90-KD PROTEIN ATPase 1; AHSA1__:__AHA1__:__
Asterisk__:__608467__:__STONIN 2; STON2__:__STN2;; STONED B, DROSOPHILA, HOMOLOG OF; STNB__:__
Asterisk__:__608468__:__CARBON CATABOLITE REPRESSION 4-LIKE; CCRN4L__:__CCR4L;; CCR4, S. CEREVISIAE, HOMOLOG OF; CCR4;; NOCTURNIN, XENOPUS, HOMOLOG OF; NOC__:__
Asterisk__:__608469__:__DEAD/H BOX 17; DDX17__:__RNA HELICASE, 70-KD; RH70;; p72__:__
Number Sign__:__608470__:__CORNEAL DYSTROPHY, REIS-BUCKLERS TYPE; CDRB__:__REIS-BUCKLERS CORNEAL DYSTROPHY; RBCD;; CORNEAL DYSTROPHY OF BOWMAN LAYER, TYPE I; CDB1;; CORNEAL DYSTROPHY, GEOGRAPHIC;; GRANULAR CORNEAL DYSTROPHY, TYPE III__:__
Number Sign__:__608471__:__CORNEAL DYSTROPHY, LATTICE TYPE IIIA; CDL3A__:__LATTICE CORNEAL DYSTROPHY, TYPE IIIA__:__
Asterisk__:__608472__:__ST6 BETA-GALACTOSAMIDE ALPHA-2,6-SIALYLTRANSFERASE 2; ST6GAL2__:__ST6GALII;; KIAA1877__:__
Asterisk__:__608473__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 1; ANAPC1__:__APC1__:__
Percent__:__608474__:__MYOPIA 5, AUTOSOMAL DOMINANT; MYP5__:____:__
Asterisk__:__608475__:__3-HYDROXYISOBUTYRATE DEHYDROGENASE; HIBADH__:____:__
Asterisk__:__608476__:__TBK1-BINDING PROTEIN 1; TBKBP1__:__PROSAPIP2;; KIAA0775__:__
Asterisk__:__608477__:__ALDO-KETO REDUCTASE FAMILY 7, MEMBER A3; AKR7A3__:__AFLATOXIN B1-ALDEHYDE REDUCTASE 2; AFAR2__:__
Asterisk__:__608478__:__ALDO-KETO REDUCTASE FAMILY 7, MEMBER A4__:__AKR7A4;; AFLATOXIN B1-ALDEHYDE REDUCTASE 3; AFAR3__:__
Asterisk__:__608479__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 7; SLC26A7__:____:__
Asterisk__:__608480__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 8; SLC26A8__:__TESTIS ANION TRANSPORTER 1; TAT1__:__
Asterisk__:__608481__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 9; SLC26A9__:____:__
Asterisk__:__608482__:__MATRIX METALLOPROTEINASE 25; MMP25__:__MEMBRANE-TYPE MATRIX METALLOPROTEINASE 6;; MT6-MMP;; LEUKOLYSIN;; MMP20A__:__
Asterisk__:__608483__:__AKT-INTERACTING PROTEIN; AKTIP__:__FUSED TOES, MOUSE, HOMOLOG OF; FTS;; FT1__:__
NULL__:__608484__:__CONGENITAL CORNEAL OPACITIES, CORNEA GUTTATA, AND CORECTOPIA__:__CORNEAL OPACITIES, CONGENITAL, WITH CORNEA GUTTATA AND CORECTOPIA__:__
Asterisk__:__608485__:__TRANSLOCATION-ASSOCIATED MEMBRANE PROTEIN 2; TRAM2__:__KIAA0057__:__
Asterisk__:__608486__:__METASTASIS SUPPRESSOR 1; MTSS1__:__MIM;; KIAA0429__:__
Asterisk__:__608487__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 5; TRIM5__:__RNF88__:__
Asterisk__:__608488__:__SPARC-RELATED MODULAR CALCIUM-BINDING 1; SMOC1__:__SECRETED MODULAR CALCIUM-BINDING PROTEIN 1__:__
Asterisk__:__608489__:__STROMAL ANTIGEN 3; STAG3__:__STROMALIN 3;; COHESIN SUBUNIT SA3__:__
Asterisk__:__608490__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 1; SLC38A1__:__AMINO ACID TRANSPORTER SYSTEM A, MEMBER 1; ATA1;; N-SYSTEM AMINO ACID TRANSPORTER 2; NAT2__:__
Asterisk__:__608491__:__CYCLIN D-BINDING MYB-LIKE TRANSCRIPTION FACTOR 1; DMTF1__:__DMP1__:__
Asterisk__:__608492__:__OLFACTORY RECEPTOR, FAMILY 5, SUBFAMILY F, MEMBER 1; OR5F1__:__OR11-10__:__
Asterisk__:__608493__:__OLFACTORY RECEPTOR, FAMILY 10, SUBFAMILY A, MEMBER 1; OR10A1__:__OR11-403__:__
Asterisk__:__608494__:__OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY D, MEMBER 2; OR2D2__:__OR11-610__:__
Asterisk__:__608495__:__OLFACTORY RECEPTOR, FAMILY 6, SUBFAMILY A, MEMBER 2; OR6A2__:__OR6A1;; OR11-55__:__
Asterisk__:__608496__:__OLFACTORY RECEPTOR, FAMILY 5, SUBFAMILY I, MEMBER 1; OR5I1__:__OLF1__:__
Asterisk__:__608497__:__OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY F, MEMBER 1; OR2F1__:__OLF3__:__
Asterisk__:__608498__:__ZONA PELLUCIDA-BINDING PROTEIN; ZPBP__:__ZPBP1;; SP38__:__
Asterisk__:__608499__:__ZONA PELLUCIDA-BINDING PROTEIN 2; ZPBP2__:__ZONA PELLUCIDA BINDING PROTEIN-LIKE; ZPBPL__:__
Asterisk__:__608500__:__PRICKLE, DROSOPHILA, HOMOLOG OF, 1; PRICKLE1__:__PK1;; PRICKLE-LIKE 1;; REST-INTERACTING LIM DOMAIN PROTEIN; RILP__:__
Asterisk__:__608501__:__PRICKLE, DROSOPHILA, HOMOLOG OF, 2; PRICKLE2__:__PRICKLE-LIKE 2__:__
Asterisk__:__608502__:__POLY(rC)-BINDING PROTEIN 3; PCBP3__:__ALPHA-CP3__:__
Asterisk__:__608503__:__POLY(rC)-BINDING PROTEIN 4; PCBP4__:__ALPHA-CP4;; MCG10__:__
Asterisk__:__608504__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 15; ARHGEF15__:__EPHEXIN 5; E5;; KIAA0915__:__
Caret__:__608505__:__MOVED TO 225750__:____:__
Asterisk__:__608506__:__MITOFUSIN 1; MFN1__:____:__
Asterisk__:__608507__:__MITOFUSIN 2; MFN2__:__KIAA0214__:__
Asterisk__:__608508__:__CYTOCHROME b(-245), ALPHA SUBUNIT; CYBA__:__CYTOCHROME b(558), ALPHA SUBUNIT;; p22-PHOX;; CYTOCHROME b LIGHT CHAIN__:__
NULL__:__608509__:__ALOPECIA UNIVERSALIS CONGENITA, XY GONADAL DYSGENESIS, AND LARYNGOMALACIA__:____:__
Asterisk__:__608510__:__SH2 DOMAIN-CONTAINING 1B; SH2D1B__:__EWS/FLI1-ACTIVATED TRANSCRIPT 2; EAT2__:__
Asterisk__:__608511__:__PHYTANOYL-CoA HYDROXYLASE-INTERACTING PROTEIN; PHYHIP__:__PAHX-ASSOCIATED PROTEIN 1; PAHXAP1;; KIAA0273__:__
Asterisk__:__608512__:__NEUTROPHIL CYTOSOLIC FACTOR 1; NCF1__:__NOXO2;; p47-PHOX__:__
Asterisk__:__608513__:__RIBONUCLEASE P, RNA COMPONENT H1; RPPH1__:__H1 RNA; H1RNA__:__
Asterisk__:__608514__:__ANDROGEN-INDUCED GENE 1; AIG1__:____:__
Asterisk__:__608515__:__NEUTROPHIL CYTOSOLIC FACTOR 2; NCF2__:__p67-PHOX;; NOXA2__:__
Number Sign__:__608516__:__MAJOR DEPRESSIVE DISORDER; MDD__:__UNIPOLAR DEPRESSION__:__SEASONAL AFFECTIVE DISORDER, INCLUDED; SAD, INCLUDED
Asterisk__:__608517__:__MYOPALLADIN; MYPN__:____:__
NULL__:__608518__:__OROFACIODIGITAL SYNDROME VII; OFD7__:__OFDS VII;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE VII;; WHELAN SYNDROME__:__
Asterisk__:__608519__:__F-BOX ONLY PROTEIN 16; FBXO16__:__FBX16__:__
Percent__:__608520__:__MAJOR DEPRESSIVE DISORDER 1__:__MDD1;; UNIPOLAR DEPRESSION 1__:__
Asterisk__:__608521__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MITOGEN-ACTIVATED PROTEIN KINASE AND MAMMALIAN TARGET OF RAPAMYCIN ACTIVATOR 5; LAMTOR5__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MAPK AND MTOR ACTIVATOR 5;; HEPATITIS B VIRUS X PROTEIN-INTERACTING PROTEIN; HBXIP;; HBX-INTERACTING PROTEIN; XIP__:__
Asterisk__:__608522__:__HEPATITIS B VIRUS X-ASSOCIATED PROTEIN; HBXAP__:__REMODELING AND SPACING FACTOR 1; RSF1__:__
Asterisk__:__608523__:__DIO3, OPPOSITE STRAND; DIO3OS__:____:__
Asterisk__:__608524__:__INHIBITOR OF GROWTH 4; ING4__:____:__
Asterisk__:__608525__:__INHIBITOR OF GROWTH 5; ING5__:____:__
Percent__:__608526__:__PERIODONTITIS, AGGRESSIVE, 2__:____:__
Asterisk__:__608527__:__NEURAMINIDASE 4; NEU4__:____:__
Asterisk__:__608528__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS U PROTEIN; PIGU__:__CELL DIVISION CYCLE 91, S. CEREVISIAE, HOMOLOG-LIKE 1; CDC91L1__:__
Asterisk__:__608529__:__FIBRILLIN 3; FBN3__:__KIAA1776__:__
Asterisk__:__608530__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 1; BTBD1__:____:__
Asterisk__:__608531__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 2; BTBD2__:____:__
Asterisk__:__608532__:__NON-SMC CONDENSIN II COMPLEX SUBUNIT G2; NCAPG2__:__CONDENSIN II COMPLEX, NON-SMC SUBUNIT G2;; CHROMOSOME-ASSOCIATED PROTEIN G2; CAPG2;; MORE THAN BLOOD, MOUSE, HOMOLOG OF; MTB__:__
Asterisk__:__608533__:__F-BOX ONLY PROTEIN 38; FBXO38__:__FBX38;; MODULATOR OF KLF7 ACTIVITY, MOUSE, HOMOLOG OF; MOKA__:__
Asterisk__:__608534__:__ACTIN-RELATED PROTEIN M1__:__ARPM1__:__
Asterisk__:__608535__:__ACTIN-RELATED PROTEIN T2; ACTRT2__:__ARPT2;; ACTIN-RELATED PROTEIN M2; ARPM2__:__
Asterisk__:__608536__:__GTP-BINDING PROTEIN 3; GTPBP3__:__MSS1, S. CEREVISIAE, HOMOLOG OF; MSS1__:__
Asterisk__:__608537__:__VHL GENE; VHL__:____:__
Asterisk__:__608538__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 5B; ARID5B__:__ARID-CONTAINING PROTEIN 5B;; MODULATOR RECOGNITION FACTOR 2; MRF2;; DESRT, MOUSE, HOMOLOG OF; DESRT__:__
Asterisk__:__608539__:__GLIS FAMILY ZINC FINGER PROTEIN 2; GLIS2__:__GLI-SIMILAR PROTEIN 2__:__
Number Sign__:__608540__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ik; CDG1K__:__CDG Ik; CDGIk__:__
Asterisk__:__608541__:__RHO GTPase INVOLVED IN BETA-CATENIN, N-CADHERIN, AND NMDA RECEPTOR SIGNALING__:__RICS;; GTPase INTERACTING WITH TRKA; GRIT;; p200RHOGAP;; p250GAP;; KIAA0712__:__PX-RICS ISOFORM, INCLUDED; PXRICS, INCLUDED
Percent__:__608542__:__ANEURYSM, INTRACRANIAL BERRY, 2; ANIB2__:____:__
Percent__:__608543__:__SCHIZOPHRENIA 12__:__SCZD12;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 1p-RELATED__:__
Asterisk__:__608544__:__HISTONE DEACETYLASE 10; HDAC10__:____:__
Percent__:__608545__:__LARSEN-LIKE SYNDROME__:__LRSL__:__
Asterisk__:__608546__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4A, ISOFORM 3; EIF4A3__:__DEAD/H BOX 48; DDX48;; NUK34;; NUCLEAR MATRIX PROTEIN 265; NMP265;; KIAA0111__:__
Asterisk__:__608547__:__VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1; VKORC1__:__VKOR;; FLJ00289__:__
Asterisk__:__608548__:__HEMICENTIN; HMCN1__:__FIBULIN 6; FBLN6;; FIBL6__:__
Asterisk__:__608549__:__VACUOLAR PROTEIN SORTING 11, YEAST, HOMOLOG OF; VPS11__:____:__
Asterisk__:__608550__:__VACUOLAR PROTEIN SORTING 16, YEAST, HOMOLOG OF; VPS16__:____:__
Asterisk__:__608551__:__VACUOLAR PROTEIN SORTING 18, YEAST, HOMOLOG OF; VPS18__:__KIAA1475__:__
Asterisk__:__608552__:__VACUOLAR PROTEIN SORTING 33, YEAST, HOMOLOG OF, B; VPS33B__:____:__
Number Sign__:__608553__:__LEBER CONGENITAL AMAUROSIS 9; LCA9__:____:__
Asterisk__:__608554__:__NEURONAL PAS DOMAIN PROTEIN 4; NPAS4__:__HLH-PAS TRANSCRIPTION FACTOR NXF; NXF__:__
Asterisk__:__608555__:__METAXIN 2; MTX2__:____:__
Number Sign__:__608556__:__LEGIONNAIRE DISEASE, SUSCEPTIBILITY TO__:____:__
Percent__:__608557__:__MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO, 2__:__MCI2__:__
Percent__:__608558__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 5; BMIQ5__:____:__
Percent__:__608559__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 6; BMIQ6__:____:__
Asterisk__:__608560__:__STABILIN 1; STAB1__:__MS-1 ANTIGEN;; FASCICLIN EGF-LIKE, LAMININ-TYPE EGF-LIKE, AND LINK DOMAIN-CONTAINING SCAVENGER RECEPTOR 1; FEEL1;; KIAA0246__:__
Asterisk__:__608561__:__STABILIN 2; STAB2__:__HEPATIC HYALURONAN CLEARANCE RECEPTOR;; FASCICLIN EGF-LIKE, LAMININ-TYPE EGF-LIKE, AND LINK DOMAIN-CONTAINING SCAVENGER RECEPTOR 2; FEEL2__:__
Percent__:__608562__:__POLYDACTYLY, POSTAXIAL, TYPE A4__:__PAPA4;; POSTAXIAL POLYDACTYLY, TYPE A4__:__
Caret__:__608563__:__MOVED TO 204650__:____:__
Asterisk__:__608564__:__G PROTEIN-COUPLED RECEPTOR KINASE-INTERACTING PROTEIN 2; GIT2__:__GRK-INTERACTING PROTEIN 2;; COOL-INTERACTING TYROSINE-PHOSPHORYLATED PROTEIN 2; CAT2;; KIAA0148__:__
Number Sign__:__608565__:__DEAFNESS, AUTOSOMAL RECESSIVE 35; DFNB35__:____:__
Asterisk__:__608566__:__MUCIN 15, TRANSMEMBRANE; MUC15__:__PASIII;; PAS3;; GLYCOPROTEIN C;; GLYCOPROTEIN 4;; COMPONENT II__:__
Number Sign__:__608567__:__SICK SINUS SYNDROME 1; SSS1__:__SINUS RHYTHM, CONGENITAL ABSENCE OF;; SINUS NODE DISEASE, FAMILIAL, AUTOSOMAL RECESSIVE;; SICK SINUS SYNDROME, CONGENITAL;; SINUS BRADYCARDIA SYNDROME, FAMILIAL__:__
Asterisk__:__608568__:__MYOSIN, HEAVY CHAIN 14, NONMUSCLE; MYH14__:__NONMUSCLE MYOSIN HEAVY CHAIN IIC;; NMHC IIC;; KIAA2034__:__
Number Sign__:__608569__:__CARDIOMYOPATHY, DILATED, 1O; CMD1O__:__CARDIOMYOPATHY, DILATED, WITH VENTRICULAR TACHYCARDIA__:__
Asterisk__:__608570__:__AHNAK NUCLEOPROTEIN 2; AHNAK2__:__CHROMOSOME 14 OPEN READING FRAME 78; C14ORF78;; KIAA2019__:__
NULL__:__608571__:__ULNAR/FIBULAR RAY DEFECT AND BRACHYDACTYLY__:____:__
Number Sign__:__608572__:__BURN-MCKEOWN SYNDROME; BMKS__:__OCULOOTOFACIAL DYSPLASIA; OOFD__:__
Caret__:__608573__:__MOVED TO 605096__:____:__
Asterisk__:__608574__:__EMSY GENE; EMSY__:__CHROMOSOME 11 OPEN READING FRAME 30; C11ORF30__:__
Asterisk__:__608575__:__RETINOL DEHYDROGENASE 8; RDH8__:__RETINOL DEHYDROGENASE, ALL-TRANS;; RETINOL DEHYDROGENASE, PHOTORECEPTOR; PRRDH__:__
Asterisk__:__608576__:__GRAINYHEAD-LIKE 2; GRHL2__:__GRAINYHEAD, DROSOPHILA, HOMOLOG OF, 2;; BROTHER OF GRAINYHEAD; BOM;; TRANSCRIPTION FACTOR CP2-LIKE 3; TFCP2L3__:__
Asterisk__:__608577__:__CHURCHILL DOMAIN-CONTAINING 1; CHURC1__:__CHURCHILL; CHCH;; CHROMOSOME 14 OPEN READING FRAME 52; C14ORF52__:__
Caret__:__608578__:__MOVED TO 243310__:____:__
Number Sign__:__608579__:__SEVERE CUTANEOUS ADVERSE REACTION, SUSCEPTIBILITY TO__:____:__TOXIC EPIDERMAL NECROLYSIS, SUSCEPTIBILITY TO, INCLUDED;; STEVENS-JOHNSON SYNDROME, SUSCEPTIBILITY TO, INCLUDED;; HYPERSENSITIVITY SYNDROME, CARBAMAZEPINE-INDUCED, SUSCEPTIBILITY TO, INCLUDED
NULL__:__608580__:__MYOSIN, HEAVY CHAIN 16, SKELETAL MUSCLE, PSEUDOGENE; MYH16__:____:__
Asterisk__:__608581__:__RP1-LIKE PROTEIN 1; RP1L1__:____:__
Asterisk__:__608582__:__EPIDERMAL GROWTH FACTOR-LIKE 7; EGFL7__:__VASCULAR ENDOTHELIAL STATIN;; VE-STATIN__:__
Percent__:__608583__:__ATRIAL FIBRILLATION, FAMILIAL, 1; ATFB1__:__ATRIAL FIBRILLATION, AUTOSOMAL DOMINANT__:__
Number Sign__:__608584__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 2__:__ASRT2__:__
Percent__:__608585__:__BRACHIAL PALSY, FAMILIAL CONGENITAL__:____:__
Percent__:__608586__:__KERATOCONUS 3; KTCN3__:____:__
Asterisk__:__608587__:__LGP1, MOUSE, HOMOLOG OF__:__LGP1;; D11LGP1__:__
Asterisk__:__608588__:__DEXH BOX POLYPEPTIDE 58; DHX58__:__LGP2, MOUSE, HOMOLOG OF; LGP2;; D11LGP2__:__
Asterisk__:__608589__:__SLAM FAMILY, MEMBER 9; SLAMF9__:__CD2 FAMILY, MEMBER 10; CD2F10__:__
Caret__:__608590__:__MOVED TO 608358__:____:__
Caret__:__608591__:__MOVED TO 614436__:____:__
Asterisk__:__608592__:__CTD SMALL PHOSPHATASE-LIKE; CTDSPL__:__CTDSP-LIKE;; SMALL CTD PHOSPHATASE 3; SCP3;; HYA22;; RBSP3__:__
Asterisk__:__608593__:__COMPLEMENT FACTOR H-RELATED 5; CFHR5__:__FACTOR H-RELATED GENE 5; FHR5;; CFHL5__:__
Number Sign__:__608594__:__LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 1; CGL1__:__BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 1; BSCL1;; LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 1;; BRUNZELL SYNDROME, AGPAT2-RELATED__:__
Asterisk__:__608595__:__NEUROPEPTIDE S RECEPTOR 1; NPSR1__:__G PROTEIN-COUPLED RECEPTOR 154; GPR154;; G PROTEIN-COUPLED RECEPTOR FOR ASTHMA SUSCEPTIBILITY; GPRA;; VASOPRESSIN RECEPTOR-RELATED RECEPTOR 1; VRR1;; PGR14__:__
Asterisk__:__608596__:__ASTHMA-ASSOCIATED ALTERNATIVELY SPLICED GENE 1__:__AAA1__:__
Asterisk__:__608597__:__NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 2; NEURL2__:__NEURALIZED-LIKE 2;; OZZ__:__
Asterisk__:__608598__:__CANCER SUSCEPTIBILITY CANDIDATE 2; CASC2__:____:__
Asterisk__:__608599__:__RAB11 FAMILY-INTERACTING PROTEIN 2; RAB11FIP2__:__KIAA0941__:__
Percent__:__608600__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 1; FPLD1__:__LIPODYSTROPHY, FAMILIAL PARTIAL, KOBBERLING TYPE__:__
Asterisk__:__608601__:__FIBROSIN 1; FBS1__:____:__
Asterisk__:__608602__:__NUCLEAR BODY PROTEIN SP140; SP140__:__SPECKLED, 140-KD;; LYMPHOID-RESTRICTED SP100 HOMOLOG; LYSP100__:__
Asterisk__:__608603__:__GLIOMEDIN; GLDN__:__CANCER-RELATED GENE, LIVER, 2; CRGL2__:__
Asterisk__:__608604__:__RETINOL-BINDING PROTEIN 7; RBP7__:__CELLULAR RETINOL-BINDING PROTEIN 4; CRBP4;; CRBPIV__:__
Asterisk__:__608605__:__OLIGOSACCHARYLTRANSFERASE COMPLEX, CATALYTIC SUBUNIT STT3B; STT3B__:__STT3, S. CEREVISIAE, HOMOLOG OF, B;; SOURCE OF IMMUNODOMINANT MAJOR HISTOCOMPATIBILITY COMPLEX-ASSOCIATED PEPTIDES;; SOURCE OF IMMUNODOMINANT MHC-ASSOCIATED PEPTIDES; SIMP__:__
Asterisk__:__608606__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER A15; BHLHA15__:__BASIC HELIX-LOOP-HELIX PROTEIN MIST1; MIST1__:__
Asterisk__:__608607__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 12; NBPF12__:__CHROMOSOME 1 AMPLIFIED SEQUENCE 1; COAS1;; KIAA1245__:__
Asterisk__:__608608__:__PEPTIDYL-PROLYL ISOMERASE A-LIKE PROTEIN 4E; PPIAL4E__:__PPIA-LIKE PROTEIN 4E;; CYCLOPHILIN A-LIKE PROTEIN 4E;; CHROMOSOME 1 AMPLIFIED SEQUENCE 2;; COAS2__:__
Asterisk__:__608609__:__CHROMOSOME 1 OPEN READING FRAME 152; C1ORF152__:__CHROMOSOME 1 AMPLIFIED SEQUENCE 3; COAS3__:__
Asterisk__:__608610__:__PROGRAMMED CELL DEATH 4; PDCD4__:__NEOPLASTIC TRANSFORMATION INHIBITOR__:__
Number Sign__:__608611__:__RIBOSE 5-PHOSPHATE ISOMERASE DEFICIENCY__:____:__
Number Sign__:__608612__:__MANDIBULOACRAL DYSPLASIA WITH TYPE B LIPODYSTROPHY; MADB__:__LIPODYSTROPHY, TYPE B, ASSOCIATED WITH MANDIBULOACRAL DYSPLASIA__:__
Asterisk__:__608613__:__TRANSCRIPTION FACTOR Sp6; SP6__:__KRUPPEL-LIKE FACTOR 14; KLF14;; EPIPROFIN; EPFN__:__
Asterisk__:__608614__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY V, POLYPEPTIDE 2; CYP4V2__:____:__
Number Sign__:__608615__:__OLIGODONTIA-COLORECTAL CANCER SYNDROME; ODCRCS__:__TOOTH AGENESIS-COLORECTAL CANCER SYNDROME__:__
Asterisk__:__608616__:__OBSCURIN; OBSCN__:__KIAA1556;; KIAA1639__:__OBSCURIN-RHOGEF, INCLUDED;; OBSCURIN-MLCK, INCLUDED
Asterisk__:__608617__:__FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER B; FAM3B__:____:__
Asterisk__:__608618__:__FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER C; FAM3C__:____:__
Asterisk__:__608619__:__FAMILY WITH SEQUENCE SIMILARITY 3, MEMBER D; FAM3D__:____:__
Caret__:__608620__:__MOVED TO 605232__:____:__
Asterisk__:__608621__:__SPERM AUTOANTIGENIC PROTEIN 17; SPA17__:__SP17__:__
Number Sign__:__608622__:__HYPERTENSION, DIASTOLIC, RESISTANCE TO__:____:__
Caret__:__608623__:__MOVED TO 276300__:____:__
NULL__:__608624__:__MIDFACE HYPOPLASIA, OBESITY, DEVELOPMENTAL DELAY, AND NEONATAL HYPOTONIA__:____:__
Asterisk__:__608625__:__PEPTIDYL-tRNA HYDROLASE 2; PTRH2__:__BCL2 INHIBITOR OF TRANSCRIPTION 1; BIT1__:__
Asterisk__:__608626__:__STE20-RELATED KINASE ADAPTOR ALPHA; STRADA__:__STE20-RELATED ADAPTOR PROTEIN; STRAD;; LYK5__:__
Number Sign__:__608627__:__AMYOTROPHIC LATERAL SCLEROSIS 8; ALS8__:____:__
Asterisk__:__608628__:__TRANSDUCIN-BETA-LIKE 1 RECEPTOR 1; TBL1XR1__:__TBL1X RECEPTOR 1;; TBL1-RELATED PROTEIN 1; TBLR1;; IRA1, MOUSE, HOMOLOG OF; IRA1;; C21__:__
Number Sign__:__608629__:__JOUBERT SYNDROME 3; JBTS3__:____:__
Asterisk__:__608630__:__ROUNDABOUT, DROSOPHILA, HOMOLOG OF, 3; ROBO3__:__RB-INHIBITING GENE 1; RBIG1; RIG1__:__
Percent__:__608631__:__ASPERGER SYNDROME, SUSCEPTIBILITY TO, 2; ASPG2__:____:__
Asterisk__:__608632__:__MICRO RNA 196A1; MIR196A1__:__miRNA196A1;; MIRN196A1__:__
Asterisk__:__608633__:__CASPASE 12, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP12__:__CASP12P1__:__
Number Sign__:__608634__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; HMN2B__:__HMN IIB;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIB; DHMN2B__:__
Asterisk__:__608635__:__ARFGAP WITH DUAL PLECKSTRIN HOMOLOGY DOMAINS 2; ADAP2__:__CENTAURIN, ALPHA-2; CENTA2__:__
Number Sign__:__608636__:__CHROMOSOME 15q11-q13 DUPLICATION SYNDROME__:__DUPLICATION 15q11-q13 SYNDROME__:__AUTISM, SUSCEPTIBILITY TO, 4, INCLUDED; AUTS4, INCLUDED;; CHROMOSOME 15q11.2 DUPLICATION SYNDROME, INCLUDED
Caret__:__608637__:__MOVED TO 143095__:____:__
Percent__:__608638__:__ASPERGER SYNDROME, SUSCEPTIBILITY TO, 1; ASPG1__:____:__
Asterisk__:__608639__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 8; PLEKHA8__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE ADAPTOR PROTEIN 2; FAPP2__:__
Asterisk__:__608640__:__ZINC FINGER PROTEIN 461; ZNF461__:__GONADOTROPIN-INDUCIBLE TRANSCRIPTION REPRESSOR 1, RAT, HOMOLOG OF;; GIOT1, RAT, HOMOLOG OF; GIOT1__:__
Number Sign__:__608641__:__DEAFNESS, AUTOSOMAL DOMINANT 28; DFNA28__:____:__
Asterisk__:__608642__:__ZINC-BINDING ALCOHOL DEHYDROGENASE DOMAIN-CONTAINING PROTEIN 1; ZADH1__:____:__
Number Sign__:__608643__:__AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY__:__AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY__:__
Number Sign__:__608644__:__CILIARY DYSKINESIA, PRIMARY, 3; CILD3__:__CILIARY DYSKINESIA, PRIMARY, 3, WITH OR WITHOUT SITUS INVERSUS__:__
Percent__:__608645__:__DEAFNESS, AUTOSOMAL DOMINANT 31; DFNA31__:____:__
Percent__:__608646__:__CILIARY DYSKINESIA, PRIMARY, 4; CILD4__:__CILIARY DYSKINESIA, PRIMARY, 4, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__608647__:__CILIARY DYSKINESIA, PRIMARY, 5; CILD5__:__CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS__:__
Asterisk__:__608648__:__SEC63, S. CEREVISIAE, HOMOLOG OF; SEC63__:____:__
Number Sign__:__608649__:__ICHTHYOSIS PREMATURITY SYNDROME; IPS__:__ICHTHYOSIS CONGENITA IV__:__
Asterisk__:__608650__:__UNC51-LIKE KINASE 2; ULK2__:__KIAA0623;; UNC51.2__:__
Asterisk__:__608651__:__ARF GTPase-ACTIVATING PROTEIN WITH GTPase DOMAIN, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAIN 1; AGAP1__:__CENTAURIN, GAMMA-2; CENTG2;; KIAA1099__:__HUMAN-ACCELERATED CONSERVED NONCODING SEQUENCE 1, INCLUDED; HACNS1, INCLUDED
Percent__:__608652__:__DEAFNESS, AUTOSOMAL DOMINANT 47; DFNA47__:____:__
Number Sign__:__608653__:__DEAFNESS, AUTOSOMAL RECESSIVE 32, WITH OR WITHOUT IMMOTILE SPERM; DFNB32__:__HEARING IMPAIRMENT INFERTILE MALE SYNDROME; HIIMS;; DEAFNESS, AUTOSOMAL RECESSIVE 105, FORMERLY; DFNB105, FORMERLY__:__
Number Sign__:__608654__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE V; HSAN5__:__HSAN V;; INSENSITIVITY TO PAIN, CONGENITAL__:__
Asterisk__:__608655__:__GAP JUNCTION PROTEIN, GAMMA-1; GJC1__:__GAP JUNCTION PROTEIN, ALPHA-7; GJA7;; GAP JUNCTION PROTEIN, 45-KD;; CONNEXIN 45; CX45__:__
Percent__:__608656__:__PROSTATE CANCER, HEREDITARY, 3__:__HPC3__:__
Asterisk__:__608657__:__JUN DIMERIZATION PROTEIN 2; JDP2__:____:__
Percent__:__608658__:__PROSTATE CANCER, HEREDITARY, 4__:__HPC4;; PROSTATE CANCER, HEREDITARY, ON CHROMOSOME 7__:__
Asterisk__:__608659__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 8; SENP8__:__NEDD8-SPECIFIC PROTEASE 1; NEDP1;; DENEDDYLASE 1; DEN1__:__
Asterisk__:__608660__:__INSULIN-INDUCED GENE 2; INSIG2__:____:__
Asterisk__:__608661__:__PODOCAN; PODN__:____:__
Asterisk__:__608662__:__ANOCTAMIN 5; ANO5__:__TRANSMEMBRANE PROTEIN 16E; TMEM16E;; GDD1 GENE; GDD1__:__
Asterisk__:__608663__:__ANOCTAMIN 6; ANO6__:__TRANSMEMBRANE PROTEIN 16F; TMEM16F__:__
Caret__:__608664__:__MOVED TO 210600__:____:__
Asterisk__:__608665__:__PSMC3-INTERACTING PROTEIN; PSMC3IP__:__TBP1-INTERACTING PROTEIN; TBPIP;; GT198;; HOP2, S. CEREVISIAE, HOMOLOG OF; HOP2__:__
Asterisk__:__608666__:__PEROXISOME BIOGENESIS FACTOR 26; PEX26__:__PEROXIN 26__:__
Asterisk__:__608667__:__NIPPED-B-LIKE; NIPBL__:__NIPPED-B, DROSOPHILA, HOMOLOG OF;; DELANGIN;; SISTER CHROMATID COHESION 2, S. CEREVISIAE, HOMOLOG OF; SCC2__:__
Asterisk__:__608668__:__ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 11; ZMYND11__:__BS69__:__BONE MORPHOGENETIC PROTEIN RECEPTOR-ASSOCIATED MOLECULE 1, INCLUDED; BRAM1, INCLUDED
Asterisk__:__608669__:__BASONUCLIN 2; BNC2__:____:__
NULL__:__608670__:__ROBIN SEQUENCE WITH DISTINCTIVE FACIAL APPEARANCE AND BRACHYDACTYLY__:____:__
Asterisk__:__608671__:__DAZ-INTERACTING ZINC FINGER PROTEIN 1; DZIP1__:__DAZ-INTERACTING PROTEIN 1;; DZIP;; KIAA0996__:__
Asterisk__:__608672__:__DAZ-INTERACTING ZINC FINGER PROTEIN 3; DZIP3__:__DAZ-INTERACTING PROTEIN 3;; KIAA0675__:__
Number Sign__:__608673__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2L; CMT2L__:__CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2L;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2L__:__
Asterisk__:__608674__:__SH3 DOMAIN PROTEIN 19__:__SH3D19;; EEN-BINDING PROTEIN; EBP__:__SH3D19/RUNX1 FUSION GENE, INCLUDED
Asterisk__:__608675__:__FUCOKINASE; FUK__:__L-FUCOSE KINASE__:__
Asterisk__:__608676__:__TAXILIN, ALPHA; TXLNA__:__TXLN;; INTERLEUKIN 14; IL14__:__
Asterisk__:__608677__:__MINDBOMB, DROSOPHILA, HOMOLOG OF, 1; MIB1__:__MIB;; DAPK-INTERACTING PROTEIN 1; DIP1;; KIAA1323__:__
Asterisk__:__608678__:__INTERLEUKIN 33; IL33__:__NUCLEAR FACTOR FROM HIGH ENDOTHELIAL VENULES; NFHEV;; IL1F11;; CHROMOSOME 9 OPEN READING FRAME 26; C9ORF26__:__
Asterisk__:__608679__:__TP53-REGULATING KINASE; TP53RK__:__p53-RELATED PROTEIN KINASE; PRPK__:__
Asterisk__:__608680__:__TP53RK-BINDING PROTEIN; TPRKB__:__PRPK-BINDING PROTEIN;; CGI-121__:__
Number Sign__:__608681__:__SPONDYLOCOSTAL DYSOSTOSIS 2, AUTOSOMAL RECESSIVE; SCDO2__:____:__
Asterisk__:__608682__:__ADRENOMEDULLIN 2; ADM2__:__AM2;; INTERMEDIN__:__
Asterisk__:__608683__:__CYSTATIN 8; CST8__:__CYSTATIN-RELATED PROTEIN, EPIDIDYMIS-SPECIFIC; CRES__:__
Asterisk__:__608684__:__NINEIN; NIN__:__GSK3B-INTERACTING PROTEIN;; KIAA1565__:__
Asterisk__:__608685__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 1B; SMC1B__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 1-LIKE 2; SMC1L2;; SMC1-BETA__:__
Asterisk__:__608686__:__RAB3A-INTERACTING PROTEIN; RAB3IP__:__RABIN8;; RABIN3, RAT, HOMOLOG OF; RABIN3__:__
Number Sign__:__608687__:__SPINOCEREBELLAR ATAXIA 20; SCA20__:__CHROMOSOME 11q12 DUPLICATION SYNDROME, 260-KB;; SPINOCEREBELLAR ATAXIA WITH DYSPHONIA;; SPINOCEREBELLAR ATAXIA WITH SPASMODIC COUGH__:__
Number Sign__:__608688__:__AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY__:__ATIC DEFICIENCY;; AICA-RIBOSURIA DUE TO ATIC DEFICIENCY__:__
Asterisk__:__608689__:__MESODERM POSTERIOR BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR 1; MESP1__:__MESODERM POSTERIOR PROTEIN 1__:__
Asterisk__:__608690__:__SSX2-INTERACTING PROTEIN; SSX2IP__:__AFADIN DIL DOMAIN-INTERACTING PROTEIN; ADIP;; KIAA0923__:__
Percent__:__608691__:__MAJOR DEPRESSIVE DISORDER 2__:__MDD2;; UNIPOLAR DEPRESSION 2__:__
Asterisk__:__608692__:__BASIC LEUCINE ZIPPER NUCLEAR FACTOR 1; BLZF1__:__JEM1;; GOLGIN 45__:__
Asterisk__:__608693__:__GOLGI REASSEMBLY STACKING PROTEIN 2; GORASP2__:__GOLGI REASSEMBLY STACKING PROTEIN, 55-KD; GRASP55__:__
Asterisk__:__608694__:__ZINC FINGER PROTEIN 622; ZNF622__:__ZPR9__:__
Percent__:__608695__:__GLAUCOMA 1, OPEN ANGLE, J; GLC1J__:__GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 2; JOAG2__:__
Percent__:__608696__:__GLAUCOMA 1, OPEN ANGLE, K; GLC1K__:__GLAUCOMA, PRIMARY OPEN ANGLE, JUVENILE-ONSET, 3; JOAG3__:__
Asterisk__:__608697__:__FACTOR IN GERMLINE ALPHA, MOUSE, HOMOLOG OF; FIGLA__:__FOLLICULOGENESIS-SPECIFIC BASIC HELIX-LOOP-HELIX__:__
Asterisk__:__608698__:__DISCOIDIN, CUB, AND LCCL DOMAIN-CONTAINING PROTEIN 2; DCBLD2__:__ENDOTHELIAL AND SMOOTH MUSCLE CELL-DERIVED NEUROPILIN-LIKE PROTEIN; ESDN__:__
Asterisk__:__608699__:__BONE MORPHOGENETIC PROTEIN-BINDING ENDOTHELIAL REGULATOR PROTEIN; BMPER__:__BMP-BINDING ENDOTHELIAL CELL PRECURSOR-DERIVED REGULATOR;; CROSSVEINLESS 2, DROSOPHILA, HOMOLOG OF; CV2__:__
Asterisk__:__608700__:__NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 1; NMNAT1__:__NMNAT;; PYRIDINE NUCLEOTIDE ADENYLYLTRANSFERASE 1; PNAT1__:__
Asterisk__:__608701__:__NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 2; NMNAT2__:__PYRIDINE NUCLEOTIDE ADENYLYLTRANSFERASE 2; PNAT2;; KIAA0479__:__
Asterisk__:__608702__:__NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 3; NMNAT3__:__PYRIDINE NUCLEOTIDE ADENYLYLTRANSFERASE 3; PNAT3__:__
Percent__:__608703__:__SPINOCEREBELLAR ATAXIA 25; SCA25__:____:__
Asterisk__:__608704__:__NICOTINAMIDE RIBOSIDE KINASE 1; NMRK1__:__NRK1;; CHROMOSOME 9 OPEN READING FRAME 95; C9ORF95__:__
Asterisk__:__608705__:__INTEGRIN, BETA-1, BINDING PROTEIN OF, 3; ITGB1BP3__:__MUSCLE INTEGRIN-BINDING PROTEIN; MIBP__:__NICOTINAMIDE RIBOSIDE KINASE 2, INCLUDED; NRK2, INCLUDED
Asterisk__:__608706__:__DYNEIN, AXONEMAL, ASSEMBLY FACTOR 4; DNAAF4__:__DYX1C1 GENE; DYX1C1;; DYXC1;; EKN1__:__
Asterisk__:__608707__:__CELL ADHESION MOLECULE-RELATED/DOWNREGULATED BY ONCOGENES; CDON__:__CDO__:__
Asterisk__:__608708__:__BROTHER OF CDON; BOC__:__BROTHER OF CDO__:__
Number Sign__:__608709__:__LIPODYSTROPHY, PARTIAL, ACQUIRED, SUSCEPTIBILITY TO; APLD__:__APLD, SUSCEPTIBILITY TO;; BARRAQUER-SIMONS SYNDROME;; LIPODYSTROPHY, CEPHALOTHORACIC TYPE;; LIPODYSTROPHY, PARTIAL, PROGRESSIVE__:__
Percent__:__608710__:__GRANULOMATOSIS WITH POLYANGIITIS; GPA__:__WEGENER GRANULOMATOSIS, FORMERLY; WG, FORMERLY__:__
Asterisk__:__608711__:__CTD SMALL PHOSPHATASE 2; CTDSP2__:__SMALL CTD PHOSPHATASE 2; SCP2;; CONSERVED GENE AMPLIFIED IN OSTEOSARCOMA 4; OS4__:__
Asterisk__:__608712__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, T; PTPRT__:__RPTP-RHO;; KIAA0283__:__
Asterisk__:__608713__:__CYTOCHROME P450, SUBFAMILY IIR, POLYPEPTIDE 1; CYP2R1__:____:__
Asterisk__:__608714__:__SYNTROPHIN, GAMMA-1; SNTG1__:__SYN4__:__
Asterisk__:__608715__:__SYNTROPHIN, GAMMA-2; SNTG2__:__SYN5__:__
Number Sign__:__608716__:__MICROCEPHALY 5, PRIMARY, AUTOSOMAL RECESSIVE; MCPH5__:____:__
Asterisk__:__608717__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 13; LGALS13__:__GALECTIN 13; GAL13;; PLACENTAL PROTEIN 13; PP13__:__
Asterisk__:__608718__:__KERATIN-ASSOCIATED PROTEIN 13-1; KRTAP13-1__:__KAP13.1__:__
Asterisk__:__608719__:__TR4-ASSOCIATED PROTEIN, 16-KD__:__TRA16__:__
NULL__:__608720__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, ADULT-ONSET, WITH ANOSMIA__:____:__
Asterisk__:__608721__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II INHIBITOR 2; CAMK2N2__:__CAMKII INHIBITORY PROTEIN; CAMKIIN;; CAMKIIN-BETA__:__
Asterisk__:__608722__:__CAPPING PROTEIN, ALPHA-3; CAPZA3__:__CAP PROTEIN, ACTIN, ALPHA-3 SUBUNIT; CAPPA3;; CP-ALPHA-3__:__
Asterisk__:__608723__:__PHOSPHATASE AND ACTIN REGULATOR 1; PHACTR1__:__KIAA1733__:__
Asterisk__:__608724__:__PHOSPHATASE AND ACTIN REGULATOR 2; PHACTR2__:__KIAA0680__:__
Asterisk__:__608725__:__PHOSPHATASE AND ACTIN REGULATOR 3; PHACTR3__:__SCAFFOLD-ASSOCIATED PROTEIN PHOSPHATASE 1-INHIBITING PROTEIN; SCAPININ__:__
Asterisk__:__608726__:__PHOSPHATASE AND ACTIN REGULATOR 4; PHACTR4__:____:__
Asterisk__:__608727__:__DE-ETIOLATED 1, ARABIDOPSIS, HOMOLOG OF; DET1__:____:__
Number Sign__:__608728__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, MATRILIN-3 RELATED__:__SEMD, MATN3-RELATED__:__
Asterisk__:__608729__:__ANGIOTENSIN II RECEPTOR-ASSOCIATED PROTEIN; AGTRAP__:__ATRAP__:__
Asterisk__:__608730__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 5; SLC39A5__:____:__
Asterisk__:__608731__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 6; SLC39A6__:__LIV1__:__
Asterisk__:__608732__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 8; SLC39A8__:__BIGM103;; ZIP8__:__
Asterisk__:__608733__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 10; SLC39A10__:__KIAA1265__:__
Asterisk__:__608734__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 12; SLC39A12__:__ZRT- AND IRT-LIKE PROTEIN 12; ZIP12__:__
Asterisk__:__608735__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 13; SLC39A13__:__ZIP13;; LZT-HS9__:__
Asterisk__:__608736__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 14; SLC39A14__:__ZIP14;; KIAA0062__:__
Asterisk__:__608737__:__RAB11 FAMILY-INTERACTING PROTEIN 1; RAB11FIP1__:____:__RAB-COUPLING PROTEIN, INCLUDED; RCP, INCLUDED
Asterisk__:__608738__:__RAB11 FAMILY-INTERACTING PROTEIN 3; RAB11FIP3__:__EF-HANDS-CONTAINING RAB-INTERACTING PROTEIN; EFERIN;; KIAA0665__:__
Asterisk__:__608739__:__EXORIBONUCLEASE 1; ERI1__:__HISTONE mRNA 3-PRIME END-SPECIFIC EXORIBONUCLEASE; HEXO__:__
Asterisk__:__608740__:__NFAT ACTIVATING PROTEIN WITH ITAM MOTIF 1; NFAM1__:__NFAT ACTIVATION MOLECULE 1;; CALCINEURIN- AND NFAT-ACTIVATING ITAM-CONTAINING PROTEIN; CNAIP__:__
Asterisk__:__608741__:__SYNAPTOTAGMIN 11; SYT11__:__KIAA0080__:__
Percent__:__608742__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 4__:__HYT4__:__
Asterisk__:__608743__:__JP45, MOUSE, HOMOLOG OF__:__JP45__:__
Asterisk__:__608744__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PHOSPHATE CARRIER), MEMBER 24; SLC25A24__:__SHORT CALCIUM-BINDING MITOCHONDRIAL CARRIER 1; SCAMC1__:__
Asterisk__:__608745__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PHOSPHATE CARRIER), MEMBER 25; SLC25A25__:__SHORT CALCIUM-BINDING MITOCHONDRIAL CARRIER 2; SCAMC2;; MITOCHONDRIAL CALCIUM-DEPENDENT SOLUTE CARRIER; MCSC;; KIAA1896__:__
Asterisk__:__608746__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PHOSPHATE CARRIER), MEMBER 23; SLC25A23__:__SHORT CALCIUM-BINDING MITOCHONDRIAL CARRIER 3; SCAMC3__:__
Number Sign__:__608747__:__INSULIN-LIKE GROWTH FACTOR I DEFICIENCY__:__IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION__:__
Asterisk__:__608748__:__BONE MORPHOGENETIC PROTEIN 10; BMP10__:____:__
Asterisk__:__608749__:__BROMODOMAIN-CONTAINING PROTEIN 4; BRD4__:__MITOTIC CHROMOSOME-ASSOCIATED PROTEIN; MCAP; CAP;; HUNK1__:__BRD4/NUT FUSION GENE, INCLUDED
Asterisk__:__608750__:__ALG3, S. CEREVISIAE, HOMOLOG OF; ALG3__:__NOT56-LIKE PROTEIN; NOT56L__:__
Number Sign__:__608751__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 8; CMH8__:__CARDIOMYOPATHY, HYPERTROPHIC, MID-LEFT VENTRICULAR CHAMBER TYPE, 1__:__
Asterisk__:__608752__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 5; C1QTNF5__:__CTRP5__:__
Asterisk__:__608753__:__tRNA SPLICING ENDONUCLEASE 2, S. CEREVISIAE, HOMOLOG OF; TSEN2__:__SEN2, YEAST, HOMOLOG OF; SEN2__:__
Asterisk__:__608754__:__tRNA SPLICING ENDONUCLEASE 34, S. CEREVISIAE, HOMOLOG OF; TSEN34__:__LEUKOCYTE RECEPTOR CLUSTER GENE 5; LENG5;; SEN34, YEAST, HOMOLOG OF; SEN34__:__
Asterisk__:__608755__:__tRNA SPLICING ENDONUCLEASE 54, S. CEREVISIAE, HOMOLOG OF; TSEN54__:__SEN54, YEAST, HOMOLOG OF; SEN54__:__
Asterisk__:__608756__:__tRNA SPLICING ENDONUCLEASE 15, S. CEREVISIAE, HOMOLOG OF; TSEN15__:__SEN15, YEAST, HOMOLOG OF; SEN15;; CHROMOSOME 1 OPEN READING FRAME 19; C1ORF19__:__
Asterisk__:__608757__:__CLEAVAGE AND POLYADENYLATION FACTOR I SUBUNIT 1, YEAST, HOMOLOG OF; CLP1__:__CLP1, YEAST, HOMOLOG OF; HEAB__:__HEAB/AF10 FUSION GENE, INCLUDED
Number Sign__:__608758__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 10; CMH10__:__CARDIOMYOPATHY, HYPERTROPHIC, MID-LEFT VENTRICULAR CHAMBER TYPE, 2__:__
Asterisk__:__608759__:__CYTOGLOBIN; CYGB__:__HISTOGLOBIN; HGB;; STELLATE CELL ACTIVATION-ASSOCIATED PROTEIN; STAP__:__
Asterisk__:__608760__:__AUTOPHAGY 7, S. CEREVISIAE, HOMOLOG OF; ATG7__:__APG7, S. CEREVISIAE, HOMOLOG OF, APG7;; APG7-LIKE; APG7L;; GSA7__:__
Asterisk__:__608761__:__SOLUTE CARRIER FAMILY 5 (CHOLINE TRANSPORTER), MEMBER 7; SLC5A7__:__CHOLINE TRANSPORTER; CHT; CHT1__:__
Percent__:__608762__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 3; EIG3__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 9__:__
NULL__:__608763__:__EHLERS-DANLOS SYNDROME, BEASLEY-COHEN TYPE__:__EHLERS-DANLOS SYNDROME WITH MENTAL RETARDATION, DEAFNESS, AND CATARACT__:__
Asterisk__:__608764__:__NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NAMPT__:__PRE-B-CELL COLONY-ENHANCING FACTOR 1; PBEF1;; PBEF;; VISFATIN; VF__:__
Percent__:__608765__:__SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3; IS3__:____:__
Asterisk__:__608766__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1B; LRP1B__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN DELETED IN TUMORS; LRPDIT__:__
Asterisk__:__608767__:__FEM1, C. ELEGANS, HOMOLOG OF, C; FEM1C__:__KIAA1785__:__
Number Sign__:__608768__:__SPINOCEREBELLAR ATAXIA 8; SCA8__:____:__
Asterisk__:__608769__:__PYRUVATE DEHYDROGENASE COMPLEX, COMPONENT X; PDHX__:__PDX1;; PYRUVATE DEHYDROGENASE COMPLEX, E3-BINDING PROTEIN SUBUNIT; E3BP;; PYRUVATE DEHYDROGENASE COMPLEX, LIPOYL-CONTAINING COMPONENT X__:__
Asterisk__:__608770__:__DIHYDROLIPOAMIDE S-ACETYLTRANSFERASE; DLAT__:__PYRUVATE DEHYDROGENASE COMPLEX, E2 SUBUNIT; PDCE2;; M2 ANTIGEN COMPLEX, 70-KD SUBUNIT__:__
Asterisk__:__608771__:__MEDIATOR COMPLEX SUBUNIT 13-LIKE; MED13L__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 2; THRAP2;; PROTEIN SIMILAR TO TRAP240; PROSIT240;; TRAP240-LIKE PROTEIN; TRAP240L;; KIAA1025__:__
Asterisk__:__608772__:__INVASION INHIBITORY PROTEIN, 45-KD__:__IIP45__:__
Asterisk__:__608773__:__TUBULIN POLYMERIZATION-PROMOTING PROTEIN; TPPP__:__p25;; p24__:__
Asterisk__:__608774__:__ANKYRIN REPEAT- AND KINASE DOMAIN-CONTAINING PROTEIN 1; ANKK1__:____:__
Asterisk__:__608775__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 1; HAUS1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 5; CCDC5;; HUMAN ENHANCER OF INVASION CLUSTER; HEIC__:__
Number Sign__:__608776__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Il; CDG1L__:__CDG Il; CDGIl__:__
Asterisk__:__608777__:__PERIOSTIN; POSTN__:__PN;; OSTEOBLAST-SPECIFIC FACTOR 2; OSF2__:__
Asterisk__:__608778__:__KELCH-LIKE 10; KLHL10__:____:__
Number Sign__:__608779__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIe; CDG2E__:__CDG IIe; CDGIIe__:__
Asterisk__:__608780__:__GENERAL TRANSCRIPTION FACTOR IIH, POLYPEPTIDE 5; GTF2H5__:__TFIIH BASAL TRANSCRIPTION FACTOR COMPLEX, TTDA SUBUNIT; TTDA;; TFB5;; TRANSCRIPTION FACTOR IIH, 8-KD SUBUNIT;; CHROMOSOME 6 OPEN READING FRAME 175; C6ORF175__:__
Percent__:__608781__:__ASPERGER SYNDROME, SUSCEPTIBILITY TO, 3; ASPG3__:____:__
Number Sign__:__608782__:__PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY; PDHPD__:__LACTIC ACIDEMIA WITH PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY__:__
Asterisk__:__608783__:__SET AND MYND DOMAIN-CONTAINING PROTEIN 3; SMYD3__:____:__
Asterisk__:__608784__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 8; ZDHHC8__:__ZNF378;; KIAA1292__:__
Asterisk__:__608785__:__HTRA SERINE PEPTIDASE 3; HTRA3__:__HTRA, E. COLI, HOMOLOG OF, 3;; PREGNANCY-RELATED SERINE PROTEASE, MOUSE, HOMOLOG OF; PRSP__:__
Asterisk__:__608786__:__PYRUVATE CARBOXYLASE; PC__:____:__
Percent__:__608787__:__OTOSCLEROSIS 5; OTSC5__:____:__
Asterisk__:__608788__:__SUPPRESSOR OF CYTOKINE SIGNALING 7; SOCS7__:__NCK-ASSOCIATED PROTEIN 4; NAP4;; NCK-, ASH-, AND PLCG-BINDING PROTEIN 4__:__
Asterisk__:__608789__:__NCK-ASSOCIATED PROTEIN 5; NCKAP5__:__NAP5__:__
Asterisk__:__608790__:__TRANSCRIPTIONAL ADAPTOR 2B; TADA2B__:__ADA2, YEAST, HOMOLOG OF, BETA; ADA2B;; ADA2-BETA__:__
Asterisk__:__608791__:__NUCLEOREDOXIN-LIKE PROTEIN 1; NXNL1__:__ROD-DERIVED CONE VIABILITY FACTOR; RDCVF;; THIOREDOXIN-LIKE 6, MOUSE, HOMOLOG OF; TXNL6;; LOC115861__:__
Asterisk__:__608792__:__GIPC PDZ DOMAIN-CONTAINING FAMILY, MEMBER 3; GIPC3__:__GAIP C-TERMINUS-INTERACTING PROTEIN 3__:__
Asterisk__:__608793__:__SPERM ANTIGEN WITH CALPONIN HOMOLOGY AND COILED-COIL DOMAINS 1; SPECC1__:__HCMOGT1;; NSP__:__HCMOGT1/PDGFRB FUSION GENE, INCLUDED
Asterisk__:__608794__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, MEMBRANE-ASSOCIATED, 1; PITPNM1__:__DRES9;; PYK2 N-TERMINAL DOMAIN-INTERACTING RECEPTOR 2; NIR2;; RETINAL DEGENERATION GENE B, DROSOPHILA, HOMOLOG OF, ALPHA; RDGBA__:__
Asterisk__:__608795__:__PHOSPHOLIPASE C, DELTA-3; PLCD3__:____:__
Percent__:__608796__:__MOYAMOYA DISEASE 3; MYMY3__:____:__
Asterisk__:__608797__:__MEI1, MOUSE, HOMOLOG OF; MEI1__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 38; SPATA38__:__
Asterisk__:__608798__:__GASDERMIN E; GSDME__:__DFNA5 GENE; DFNA5;; INVERSELY CORRELATED WITH ESTROGEN RECEPTOR EXPRESSION 1; ICERE1__:__
Number Sign__:__608799__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E__:__CDG Ie; CDGIe__:__
Number Sign__:__608800__:__SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT__:____:__
Asterisk__:__608801__:__GLUTARYL-CoA DEHYDROGENASE; GCDH__:____:__
Asterisk__:__608802__:__L3MBT-LIKE; L3MBTL__:__L3MBTL1;; L3MBT, DROSOPHILA, HOMOLOG OF, 1;; KIAA0681__:__
Asterisk__:__608803__:__GAP JUNCTION PROTEIN, GAMMA-2; GJC2__:__GAP JUNCTION PROTEIN, ALPHA 12; GJA12;; GAP JUNCTION PROTEIN, 47-KD;; CONNEXIN 47; CX47;; CONNEXIN 46.6; CX46.6__:__
Number Sign__:__608804__:__LEUKODYSTROPHY, HYPOMYELINATING, 2; HLD2__:__PELIZAEUS-MERZBACHER-LIKE DISEASE, 1; PMLD1__:__
Number Sign__:__608805__:__AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 1; ANFH1__:__FEMORAL HEAD, AVASCULAR NECROSIS OF; ANFH;; FEMORAL HEAD, ASEPTIC NECROSIS OF;; ISCHEMIC NECROSIS OF FEMORAL HEAD;; OSTEONECROSIS OF FEMORAL HEAD__:__
Asterisk__:__608806__:__N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE-LIKE 2__:__NAALADL2__:__
Number Sign__:__608807__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 10; LGMDR10__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2J; LGMD2J__:__
Number Sign__:__608808__:__TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1__:__D-TGA__:__
NULL__:__608809__:__LEUKOENCEPHALOPATHY, ARTHRITIS, COLITIS, AND HYPOGAMMAGLOBULINEMA; LACH__:____:__
Number Sign__:__608810__:__MYOPATHY, MYOFIBRILLAR, 2; MFM2__:__MYOPATHY, MYOFIBRILLAR, ALPHA-B CRYSTALLIN-RELATED;; MYOPATHY, DESMIN-RELATED, ASSOCIATED WITH MUTATION IN THE CRYAB GENE;; ALPHA-B CRYSTALLINOPATHY;; MYOPATHY, MYOFIBRILLAR, WITH OR WITHOUT CATARACT AND/OR CARDIOMYOPATHY__:__
NULL__:__608811__:__METAPHYSEAL UNDERMODELING, SPONDYLAR DYSPLASIA, AND OVERGROWTH__:____:__
Number Sign__:__608812__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 1; CRCS1__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 9;; COLORECTAL ADENOMA AND CANCER, SUSCEPTIBILITY TO__:__
Asterisk__:__608813__:__DER1-LIKE DOMAIN FAMILY, MEMBER 1; DERL1__:__DEGRADATION IN ENDOPLASMIC RETICULUM 1, YEAST, HOMOLOG OF; DER1;; DERLIN 1__:__
NULL__:__608814__:__LATERAL SEMICIRCULAR CANAL MALFORMATION, FAMILIAL, WITH EXTERNAL AND MIDDLE EAR ABNORMALITIES__:____:__
Asterisk__:__608815__:__EF-HAND DOMAIN (C-TERMINAL)-CONTAINING PROTEIN 1; EFHC1__:__EF-HAND DOMAIN-CONTAINING PROTEIN 1;; MYOCLONIN 1__:__
Percent__:__608816__:__MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 3; EJM3__:____:__
Asterisk__:__608817__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 4C; LRRC4C__:__NETRIN-G1 LIGAND; NGL1;; KIAA1580__:__
Asterisk__:__608818__:__NETRIN G1; NTNG1__:__LAMINET 1; LMNT1;; KIAA0976__:__
Asterisk__:__608819__:__KERATIN-ASSOCIATED PROTEIN 1-1; KRTAP1-1__:__KAP1.1__:__KAP1.1A, INCLUDED;; KAP1.1B, INCLUDED;; KAP1.6, INCLUDED;; KAP1.7, INCLUDED;; B2A, INCLUDED
Asterisk__:__608820__:__KERATIN-ASSOCIATED PROTEIN 1-3; KRTAP1-3__:__KAP1.3__:__KAP1.2, INCLUDED;; KAP18.A, INCLUDED;; KAP18.B, INCLUDED;; KAP1.9, INCLUDED;; B2B, INCLUDED
Asterisk__:__608821__:__KERATIN-ASSOCIATED PROTEIN 1-4; KRTAP1-4__:__KAP1.4__:__
Asterisk__:__608822__:__KERATIN-ASSOCIATED PROTEIN 1-5; KRTAP1-5__:__KAP1.5__:__
Asterisk__:__608823__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 1; CGB1__:____:__
Asterisk__:__608824__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 2; CGB2__:____:__
Asterisk__:__608825__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 5; CGB5__:____:__
Asterisk__:__608826__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 7; CGB7__:____:__CGB6, INCLUDED
Asterisk__:__608827__:__CHORIONIC GONADOTROPIN, BETA POLYPEPTIDE 8; CGB8__:____:__
Asterisk__:__608828__:__RIBONUCLEASE III, NUCLEAR; RNASEN__:__DROSHA, DROSOPHILA, HOMOLOG OF; DROSHA;; RNASE3L;; RN3__:__
Asterisk__:__608829__:__SMALL UBIQUITIN-LIKE MODIFIER 4; SUMO4__:____:__
Asterisk__:__608830__:__RETINOL DEHYDROGENASE 12; RDH12__:__RETINOL DEHYDROGENASE, ALL-TRANS AND 9-CIS__:__
Percent__:__608831__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2; RLS2__:____:__
Asterisk__:__608832__:__GREMLIN 2 HOMOLOG, CYSTINE KNOT SUPERFAMILY; GREM2__:__PROTEIN RELATED TO DAN AND CERBERUS; PRDC__:__
Asterisk__:__608833__:__REGULATOR OF TELOMERE ELONGATION HELICASE 1; RTEL1__:__NOVEL HELICASE-LIKE PROTEIN; NHL;; REGULATOR OF TELOMERE LENGTH; RTEL;; TELOMERE LENGTH REGULATOR;; KIAA1088;; CHROMOSOME 20 OPEN READING FRAME 41; C20ORF41__:__
Asterisk__:__608834__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 2; CREB3L2__:__BBF2H7__:__CREB3L2/FUS FUSION GENE, INCLUDED
Asterisk__:__608835__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 13; ABCC13__:____:__
Number Sign__:__608836__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL__:__CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, NEONATAL;; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, ANTENATAL;; CPT II DEFICIENCY, LETHAL NEONATAL;; CPT2 DEFICIENCY, LETHAL NEONATAL__:__
Number Sign__:__608837__:__CARNEY COMPLEX VARIANT__:____:__
Asterisk__:__608838__:__VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1-LIKE 1; VKORC1L1__:____:__
Asterisk__:__608839__:__CALPAIN 12; CAPN12__:____:__
Number Sign__:__608840__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6; MDDGB6__:__MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED;; MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D; MDC1D__:__
Asterisk__:__608841__:__COMPLEMENT COMPONENT 3- AND PREGNANCY ZONE PROTEIN-LIKE ALPHA-2-MACROGLOBULIN DOMAIN-CONTAINING PROTEIN 8; CPAMD8__:__C3- AND PZP-LIKE A2M DOMAIN-CONTAINING PROTEIN 8;; KIAA1283__:__
Asterisk__:__608842__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 1; CHCHD1__:____:__
Asterisk__:__608843__:__VASORIN__:____:__
Asterisk__:__608844__:__ENDONUCLEASE VIII-LIKE 1; NEIL1__:__NEI1;; FPG1__:__
Asterisk__:__608845__:__ADP-RIBOSYLATION FACTOR-LIKE 6; ARL6__:__ARF-LIKE 6;; BBS3 GENE__:__
Asterisk__:__608846__:__CARNITINE PALMITOYLTRANSFERASE IC; CPT1C__:__CARNITINE PALMITOYLTRANSFERASE-I RELATED C;; CARNITINE PALMITOYLTRANSFERASE I, BRAIN__:__
Asterisk__:__608847__:__FERRITIN, MITOCHONDRIAL; FTMT__:__MITOCHONDRIAL FERRITIN; MTF__:__
Asterisk__:__608848__:__FORMIN-BINDING PROTEIN 1-LIKE; FNBP1L__:__TRANSDUCER OF CDC42-DEPENDENT ACTIN ASSEMBLY 1; TOCA1;; CHROMOSOME 1 OPEN READING FRAME 39; C1ORF39__:__
Asterisk__:__608849__:__U2AF HOMOLOGY MOTIF KINASE 1; UHMK1__:__KINASE-INTERACTING STATHMIN; KIS__:__
Percent__:__608850__:__MACULAR DYSTROPHY, RETINAL, 3; MCDR3__:____:__
Asterisk__:__608851__:__5-PRIME,3-PRIME-EXORIBONUCLEASE 2; XRN2__:__DHM1-LIKE PROTEIN__:__
Percent__:__608852__:__PULMONARY FUNCTION__:__PLF;; LUNG FUNCTION, ACCELERATED RATE OF DECLINE IN, SMOKING-RELATED__:__
Asterisk__:__608853__:__BH3-LIKE MOTIF-CONTAINING CELL DEATH INDUCER; BLID__:__BREAST CANCER CELL 2; BRCC2__:__
Asterisk__:__608854__:__OXIDORED-NITRO DOMAIN-CONTAINING PROTEIN 1__:__NOR1__:__
Asterisk__:__608855__:__TWEETY, DROSOPHILA, HOMOLOG OF, 2; TTYH2__:____:__
Asterisk__:__608856__:__CUTANEOUS T-CELL LYMPHOMA-ASSOCIATED ANTIGEN 1; CTAGE1__:____:__CUTANEOUS T-CELL LYMPHOMA-ASSOCIATED ANTIGEN 2, INCLUDED; CTAGE2, INCLUDED
Asterisk__:__608857__:__CUTANEOUS T-CELL LYMPHOMA-ASSOCIATED ANTIGEN 3; CTAGE3__:____:__
Asterisk__:__608858__:__FIBROBLAST GROWTH FACTOR RECEPTOR 1 ONCOGENE PARTNER 2; FGFR1OP2__:____:__FGFR1OP2/FGFR1 FUSION GENE, INCLUDED
Asterisk__:__608859__:__CD109 ANTIGEN; CD109__:____:__PLATELET-SPECIFIC ANTIGEN SYSTEM GOV, INCLUDED
Asterisk__:__608860__:__ASTACIN-LIKE METALLOENDOPEPTIDASE; ASTL__:__OVASTACIN__:__
Asterisk__:__608861__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 50/57-KD, V1 SUBUNIT H; ATP6V1H__:__NEF-BINDING PROTEIN 1; NBP1;; VMA13, S. CEREVISIAE, HOMOLOG OF; VMA13__:__
Asterisk__:__608862__:__NAD(P)HX EPIMERASE; NAXE__:__APOLIPOPROTEIN A-I-BINDING PROTEIN; APOA1BP;; APOA-I-BINDING PROTEIN; AIBP;; APOA1-BINDING PROTEIN__:__
Asterisk__:__608863__:__PODOPLANIN; PDPN__:__T1-ALPHA GENE; T1A;; T1A2;; GLYCOPROTEIN, 36-KD; GP36;; OTS8;; AGGRUS__:__
Number Sign__:__608864__:__OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 6__:__
Asterisk__:__608865__:__URB1 RIBOSOME BIOGENESIS 1, S. CEREVISIAE, HOMOLOG OF; URB1__:__NPA1, YEAST, HOMOLOG OF; NPA1;; CHROMOSOME 21 OPEN READING FRAME 108; C21ORF108;; KIAA0539__:__
Asterisk__:__608866__:__FRAGILE SITE, FOLIC ACID-TYPE, RARE, FRA(10)(q23.3), CANDIDATE GENE 1; FRA10AC1__:__FRA10A, CANDIDATE GENE 1;; CHROMOSOME 10 OPEN READING FRAME 4; C10ORF4__:__FRAGILE SITE, FOLIC ACID-TYPE, RARE, FRA(10)(q23.3), INCLUDED; FRA10A, INCLUDED;; FRAGILE SITE 10q23.3, INCLUDED
Asterisk__:__608867__:__DUAL-SPECIFICITY PHOSPHATASE 10; DUSP10__:__MAP KINASE PHOSPHATASE 5; MKP5__:__
Asterisk__:__608868__:__LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 1; LRIG1__:__LIG1__:__
Asterisk__:__608869__:__LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 2; LRIG2__:__LIG2;; KIAA0806__:__
Asterisk__:__608870__:__LEUCINE-RICH REPEATS- AND IMMUNOGLOBULIN-LIKE DOMAINS-CONTAINING PROTEIN 3; LRIG3__:__LIG3__:__
Asterisk__:__608871__:__NIPSNAP, C. ELEGANS, HOMOLOG OF, 3A; NIPSNAP3A__:__NIPSNAP4;; TARGET FOR SALMONELLA SECRETED PROTEIN C; TASSC__:__
Asterisk__:__608872__:__NIPSNAP, C. ELEGANS, HOMOLOG OF, 3B; NIPSNAP3B__:__NIPSNAP3__:__
Asterisk__:__608873__:__SEMAPHORIN 6B; SEMA6B__:____:__
Number Sign__:__608874__:__OROFACIAL CLEFT 5; OFC5__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 5__:__
Percent__:__608875__:__GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 14__:__GEVQ1__:__
Asterisk__:__608876__:__PCF11, YEAST, HOMOLOG OF__:__PCF11;; KIAA0824__:__
Asterisk__:__608877__:__VACUOLAR PROTEIN SORTING 13, YEAST, HOMOLOG OF, D; VPS13D__:____:__
Percent__:__608878__:__GENE EXPRESSION, VARIATION IN, QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 20__:__GEVQ2__:__
Asterisk__:__608879__:__VACUOLAR PROTEIN SORTING 13, YEAST, HOMOLOG OF, C; VPS13C__:__KIAA1421__:__
Asterisk__:__608880__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 16; ZFYVE16__:__ENDOSOME-ASSOCIATED FYVE DOMAIN PROTEIN; ENDOFIN;; KIAA0305__:__
Asterisk__:__608881__:__MICROTUBULE-ASSOCIATED MONOOXYGENASE, CALPONIN AND LIM DOMAINS-CONTAINING, 2; MICAL2__:__FLAVOPROTEIN OXIDOREDUCTASE MICAL2;; KIAA0750__:__
Asterisk__:__608882__:__MICROTUBULE-ASSOCIATED MONOOXYGENASE, CALPONIN AND LIM DOMAINS-CONTAINING, 3; MICAL3__:__FLAVOPROTEIN OXIDOREDUCTASE MICAL3;; KIAA1364__:__
Caret__:__608883__:__MOVED TO 137030__:____:__
Asterisk__:__608884__:__RAL GTPase-ACTIVATING PROTEIN, ALPHA SUBUNIT 1; RALGAPA1__:__TUBERIN-LIKE PROTEIN 1; TULIP1;; GAP-RELATED INTERACTING PROTEIN TO E12; GRIPE;; KIAA0884;; GTPase-ACTIVATING RAP/RAN-GAP DOMAIN-LIKE 1; GARNL1__:__
Number Sign__:__608885__:__STOMATIN-DEFICIENT CRYOHYDROCYTOSIS WITH NEUROLOGIC DEFECTS; SDCHCN__:__GLUT1 DEFICIENCY SYNDROME WITH PSEUDOHYPERKALEMIA AND HEMOLYSIS;; CRYOHYDROCYTOSIS, STOMATIN-DEFICIENT, WITH MENTAL RETARDATION, SEIZURES, CATARACTS, AND MASSIVE HEPATOSPLENOMEGALY__:__
Asterisk__:__608886__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, COACTIVATOR 1, BETA; PPARGC1B__:__PPAR-GAMMA COACTIVATOR 1-BETA; PGC1B;; PGC1-BETA;; PGC1-RELATED ESTROGEN RECEPTOR COACTIVATOR; PERC;; ESTROGEN RECEPTOR-RELATED RECEPTOR LIGAND 1; ERRL1__:__
Asterisk__:__608887__:__PURINE-RICH ELEMENT-BINDING PROTEIN B; PURB__:__PUR-BETA__:__
Asterisk__:__608888__:__DEVELOPMENTALLY REGULATED RNA-BINDING PROTEIN 1__:__DRB1__:__
Asterisk__:__608889__:__AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE; ACMSD__:____:__
Number Sign__:__608890__:__WAARDENBURG SYNDROME, TYPE 2D; WS2D__:__WAARDENBURG SYNDROME, TYPE IID__:__
Asterisk__:__608891__:__ODD-SKIPPED-RELATED 1; OSR1__:__ODD-SKIPPED, DROSOPHILA, HOMOLOG OF; ODD__:__
Asterisk__:__608892__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 7; CHD7__:__KIAA1416__:__
Asterisk__:__608893__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 19; SLC6A19__:__SYSTEM B(0) NEUTRAL AMINO ACID TRANSPORTER 1__:__
Asterisk__:__608894__:__ABELSON HELPER INTEGRATION SITE 1; AHI1__:__JOUBERIN__:__
Number Sign__:__608895__:__NEUROPATHY, HEREDITARY, WITH OR WITHOUT AGE-RELATED MACULAR DEGENERATION; HNARMD__:____:__MACULAR DEGENERATION, AGE-RELATED, 3, INCLUDED; ARMD3, INCLUDED
Asterisk__:__608896__:__SARCOGLYCAN, GAMMA; SGCG__:__DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 35-KD__:__
Asterisk__:__608897__:__UNC13, C. ELEGANS, HOMOLOG OF, D; UNC13D__:__MUNC13-4__:__
Number Sign__:__608898__:__HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 3; FHL3__:__HPLH3;; HLH3__:__
Asterisk__:__608899__:__GTF2I REPEAT DOMAIN-CONTAINING PROTEIN 2, ALPHA__:__GTF2IRD2A;; GTF2IRD2__:__
Asterisk__:__608900__:__GTF2I REPEAT DOMAIN-CONTAINING PROTEIN 2, BETA__:__GTF2IRD2B__:__
Number Sign__:__608901__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 5__:__CHDS5;; CORONARY ARTERY DISEASE, EARLY-ONSET__:__
Number Sign__:__608902__:__DRUG METABOLISM, POOR, CYP2D6-RELATED__:____:__DRUG METABOLISM, ULTRARAPID, CYP2D6-RELATED, INCLUDED;; DEBRISOQUINE, POOR METABOLISM OF, INCLUDED;; DEBRISOQUINE, ULTRARAPID METABOLISM OF, INCLUDED;; SPARTEINE, POOR METABOLISM OF, INCLUDED;; NORTRIPTYLINE, POOR METABOLISM OF, INCLUDED;; CODEINE, ULTRARAPID METABOLISM OF, INCLUDED
Percent__:__608903__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 1__:__ADHD1__:__
Percent__:__608904__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 2__:__ADHD2__:__
Percent__:__608905__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 3__:__ADHD3__:__
Percent__:__608906__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 4__:__ADHD4__:__
Number Sign__:__608907__:__ALZHEIMER DISEASE 9, SUSCEPTIBILITY TO; AD9__:__ALZHEIMER DISEASE 9, LATE-ONSET__:__
Number Sign__:__608908__:__MYOPIA 6; MYP6__:____:__
Asterisk__:__608909__:__ADP-RIBOSYLATION FACTOR-LIKE 5B; ARL5B__:__ADP-RIBOSYLATION FACTOR-LIKE 8; ARL8__:__
Asterisk__:__608910__:__CUTANEOUS T-CELL LYMPHOMA-ASSOCIATED ANTIGEN 4; CTAGE4__:____:__
Percent__:__608911__:__CHOANAL ATRESIA, POSTERIOR; PCA__:____:__
Asterisk__:__608912__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER B; POTEB__:__PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 15; POTE15__:__
Asterisk__:__608913__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER H; POTEH__:__PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 22; POTE22;; ACTIN, BETA-LIKE, 1; ACTBL1__:__
Asterisk__:__608914__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER E; POTEE__:__PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 1; POTE2;; POTE2-GAMMA__:__
Asterisk__:__608915__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER A; POTEA__:__PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 8; POTE8__:__
Asterisk__:__608916__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER G; POTEG__:__PROSTATE-, OVARY-, TESTIS-, AND PLACENTA-EXPRESSED GENE ON CHROMOSOME 14; POTE14__:__
Asterisk__:__608917__:__ATP SYNTHASE, MITOCHONDRIAL F1 COMPLEX, ASSEMBLY FACTOR 1; ATPAF1__:__ATP11, S. CEREVISIAE, HOMOLOG OF; ATP11__:__
Asterisk__:__608918__:__ATP SYNTHASE, MITOCHONDRIAL F1 COMPLEX, ASSEMBLY FACTOR 2; ATPAF2__:__ATP12, S. CEREVISIAE, HOMOLOG OF; ATP12__:__
Asterisk__:__608919__:__TWEETY, DROSOPHILA, HOMOLOG OF, 3; TTYH3__:__KIAA1691__:__
Asterisk__:__608920__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, MEMBRANE-ASSOCIATED, 2; PITPNM2__:__PYK2 N-TERMINAL DOMAIN-INTERACTING RECEPTOR 3; NIR3;; KIAA1457__:__
Asterisk__:__608921__:__PHOSPHATIDYLINOSITOL TRANSFER PROTEIN, MEMBRANE-ASSOCIATED, 3; PITPNM3__:__PYK2 N-TERMINAL DOMAIN-INTERACTING RECEPTOR 1; NIR1;; ATYPICAL CHEMOKINE RECEPTOR 6; ACKR6__:__
Asterisk__:__608922__:__ADP-RIBOSYLATION FACTOR-LIKE 13B; ARL13B__:__ARL2-LIKE PROTEIN 1; ARL2L1__:__
Asterisk__:__608923__:__TRACE AMINE-ASSOCIATED RECEPTOR 6; TAAR6__:__TRACE AMINE RECEPTOR 4; TRAR4__:__
Asterisk__:__608924__:__FORKHEAD BOX P4; FOXP4__:____:__
Asterisk__:__608925__:__MULTIMERIN 2; MMRN2__:__ENDOGLYX1__:__
Asterisk__:__608926__:__EMI DOMAIN-CONTAINING PROTEIN 1; EMID1__:__EMU1__:__
Asterisk__:__608927__:__EMI DOMAIN-CONTAINING PROTEIN 2; EMID2__:__EMU2;; COLLAGEN, TYPE XXVI, ALPHA-1; COL26A1__:__
Asterisk__:__608928__:__ELASTIN MICROFIBRIL INTERFACER 2; EMILIN2__:____:__
Asterisk__:__608929__:__ELASTIN MICROFIBRIL INTERFACER 3; EMILIN3__:____:__
Number Sign__:__608930__:__MYASTHENIC SYNDROME, CONGENITAL, 1B, FAST-CHANNEL; CMS1B__:____:__
Number Sign__:__608931__:__MYASTHENIC SYNDROME, CONGENITAL, 4C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS4C__:__MYASTHENIC SYNDROME, CONGENITAL, TYPE Id; CMS1D, FORMERLY;; CMS Id, FORMERLY;; MYASTHENIA, FAMILIAL INFANTILE, 1, FORMERLY; FIM1, FORMERLY__:__
Percent__:__608932__:__KERATOCONUS 2; KTCN2__:____:__
Asterisk__:__608933__:__ENDONUCLEASE VIII-LIKE 2; NEIL2__:__NEI2__:__
Asterisk__:__608934__:__ENDONUCLEASE VIII-LIKE 3; NEIL3__:__NEI3;; FGP2__:__
Percent__:__608935__:__LUNG CANCER SUSCEPTIBILITY 1; LNCR1__:____:__
Asterisk__:__608936__:__PROLINE-RICH LACRIMAL PROTEIN 1; PROL1__:__PRL1;; BASIC PROLINE-RICH LACRIMAL PROTEIN; BPLP__:__OPIORPHIN, INCLUDED
Asterisk__:__608937__:__SH2B ADAPTOR PROTEIN 1; SH2B1__:__SH2B, MOUSE, HOMOLOG OF; SH2B;; KIAA1299__:__
Asterisk__:__608938__:__RIBOSOMAL PROTEIN S6 KINASE, 70-KD, 1; RPS6KB1__:__S6K1;; p70 S6 KINASE, ALPHA;; p70(S6K)-ALPHA;; p70-ALPHA__:__
Asterisk__:__608939__:__RIBOSOMAL PROTEIN S6 KINASE, 70-KD, 2; RPS6KB2__:__S6K2;; p70 S6 KINASE, BETA;; p70(S6K)-BETA;; p70-BETA__:__
Number Sign__:__608940__:__SPONDYLOMETAPHYSEAL DYSPLASIA WITH CONE-ROD DYSTROPHY; SMDCRD__:____:__
Asterisk__:__608941__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-3; GNG3__:____:__
Asterisk__:__608942__:__DYNEIN, LIGHT CHAIN, LC8 TYPE, 2; DYNLL2__:__DYNEIN LIGHT CHAIN 2; DLC2__:__
Asterisk__:__608943__:__CYTOKINE-INDUCED APOPTOSIS INHIBITOR 1; CIAPIN1__:__ANAMORSIN__:__
Asterisk__:__608944__:__FRAS1-RELATED EXTRACELLULAR MATRIX PROTEIN 1; FREM1__:__CHROMOSOME 9 OPEN READING FRAME 154; C9ORF154__:__
Asterisk__:__608945__:__FRAS1-RELATED EXTRACELLULAR MATRIX PROTEIN 2; FREM2__:____:__
Asterisk__:__608946__:__FRAS1-RELATED EXTRACELLULAR MATRIX PROTEIN 3__:__FREM3__:__
Asterisk__:__608947__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 13; KCTD13__:__POLYMERASE DELTA-INTERACTING PROTEIN 1; PDIP1; POLDIP1;; TNFAIP1-LIKE;; FKSG86__:__
Asterisk__:__608948__:__ZIC FAMILY, MEMBER 4; ZIC4__:__ZINC FINGER PROTEIN OF CEREBELLUM 4__:__
Asterisk__:__608949__:__GLYCOLIPID TRANSFER PROTEIN; GLTP__:____:__
Asterisk__:__608950__:__MAGI2 INTRONIC TRANSCRIPT; MAGI2IT__:__PLATELET RECEPTOR FOR TYPE III COLLAGEN, 47-KD; PR47;; PLATELET MEMBRANE PROTEIN, 47-KD__:__
Asterisk__:__608951__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 6; CNOT6__:__CCR4, S. CEREVISIAE, HOMOLOG OF; CCR4;; KIAA1194__:__
Asterisk__:__608952__:__REPLICATION TIMING REGULATORY FACTOR 1; RIF1__:__RAP1-INTERACTING FACTOR 1, YEAST, HOMOLOG OF__:__
Asterisk__:__608953__:__TEKTIN 2; TEKT2__:__TEKTIN, TESTICULAR;; TEKTIN-T;; TEKTIN B1; TEKTB1__:__
Asterisk__:__608954__:__MON1, S. CEREVISIAE, HOMOLOG OF, B; MON1B__:__HSV-1 STIMULATION-RELATED GENE 1; HSRG1;; KIAA0872__:__
Asterisk__:__608955__:__TUBULIN TYROSINE LIGASE-LIKE FAMILY, MEMBER 1; TTLL1__:__KIAA0173__:__
Asterisk__:__608956__:__SOLUTE CARRIER FAMILY 46, MEMBER 2; SLC46A2__:__THYMIC STROMAL COTRANSPORTER; TSCOT__:__
Number Sign__:__608957__:__CD8 DEFICIENCY, FAMILIAL__:____:__
Asterisk__:__608958__:__ADENOSINE DEAMINASE; ADA__:__ADENOSINE AMINOHYDROLASE__:__
Asterisk__:__608959__:__DPH3, S. CEREVISIAE, HOMOLOG OF; DPH3__:__KTI11, S. CEREVISIAE, HOMOLOG OF; KTI11;; ZINC FINGER, CSL DOMAIN-CONTAINING 2; ZCSL2;; DEAFNESS LOCUS PUTATIVE GUANINE NUCLEOTIDE EXCHANGE FACTOR-INTERACTING PROTEIN 1; DELGIP1;; DELGEF-INTERACTING PROTEIN 1;; DESR1__:__
Asterisk__:__608960__:__ADP-RIBOSYLATION FACTOR-LIKE 5A; ARL5A__:__ADP-RIBOSYLATION FACTOR-LIKE 5; ARL5__:__
Asterisk__:__608961__:__TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 3; TRPM3__:__MELASTATIN 2; MLSN2;; LONG TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; LTRPC3;; KIAA1616__:__
Asterisk__:__608962__:__RHOMBOID-LIKE 2; RHBDL2__:____:__
Asterisk__:__608963__:__NUCLEAR PROTEIN IN TESTIS__:__NUT__:__NUT/BRD4 FUSION GENE, INCLUDED
Asterisk__:__608964__:__TATA BOX-BINDING PROTEIN-LIKE PROTEIN 2; TBPL2__:__TPB-RELATED FACTOR 3; TRF3__:__
Asterisk__:__608965__:__CALCIUM-BINDING PROTEIN 4; CABP4__:____:__
Asterisk__:__608966__:__DAPPER, ANTAGONIST OF BETA-CATENIN, 2; DACT2__:__DAPPER, XENOPUS, HOMOLOG OF, 2; DPR2;; DAPPER2__:__
Caret__:__608967__:__MOVED TO 609192__:____:__
Asterisk__:__608968__:__V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE FAMILY, PROTEIN B; MAFB__:__KRML, MOUSE, HOMOLOG OF; KRML__:__
Asterisk__:__608969__:__UTP14, S. CEREVISIAE, HOMOLOG OF, B__:__UTP14B;; KIAA0266__:__
Number Sign__:__608970__:__MACULAR DYSTROPHY, PATTERNED, 2; MDPT2__:__MACULAR DYSTROPHY, BUTTERFLY-SHAPED PIGMENTARY, 2__:__
Number Sign__:__608971__:__SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE__:__SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE__:__
Asterisk__:__608972__:__CREB-REGULATED TRANSCRIPTION COACTIVATOR 2; CRTC2__:__TRANSDUCER OF REGULATED cAMP RESPONSE ELEMENT-BINDING PROTEIN 2; TORC2;; TRANSDUCER OF REGULATED CREB 2__:__
Asterisk__:__608973__:__SALT-INDUCIBLE KINASE 2; SIK2__:__SALT-INDUCIBLE SERINE/THREONINE KINASE 2;; SNF1-LIKE KINASE 2; SNF1LK2;; KIAA0781__:__
Asterisk__:__608974__:__COMPLEMENT COMPONENT C1r-LIKE PROTEIN; C1RL__:__C1r-LIKE SERINE PROTEASE ANALOG; CLSPA;; C1r-LIKE PROTEIN; C1RLP__:__
Asterisk__:__608975__:__PARTITIONING-DEFECTIVE PROTEIN 6, C. ELEGANS, HOMOLOG OF, BETA; PARD6B__:__PAR6-BETA__:__
Asterisk__:__608976__:__PARTITIONING-DEFECTIVE PROTEIN 6, C. ELEGANS, HOMOLOG OF, GAMMA; PARD6G__:__PAR6-GAMMA__:__
Asterisk__:__608977__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 19; DNAJC19__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 14, YEAST, HOMOLOG OF; TIM14__:__
Number Sign__:__608978__:__MEACHAM SYNDROME__:____:__
Asterisk__:__608979__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1M; PPM1M__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1M;; PROTEIN PHOSPHATASE 2C, ETA ISOFORM; PP2CE;; PP2C-ETA__:__
Number Sign__:__608980__:__BIFID NOSE WITH OR WITHOUT ANORECTAL AND RENAL ANOMALIES; BNAR__:____:__
Asterisk__:__608981__:__ACTIVIN A RECEPTOR, TYPE IC; ACVR1C__:__ACTIVIN RECEPTOR-LIKE KINASE 7; ALK7__:__
Percent__:__608982__:__STATURE QUANTITATIVE TRAIT LOCUS 5; STQTL5__:____:__
Caret__:__608983__:__MOVED TO 115700__:____:__
Number Sign__:__608984__:__ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1__:__ADSA__:__
Asterisk__:__608985__:__RING FINGER PROTEIN 2; RNF2__:__RING2;; RING1B;; HUNTINGTIN-INTERACTING PROTEIN 2-INTERACTING PROTEIN 3; HIPI3;; HIP2-INTERACTING PROTEIN 3;; DING;; BAP1__:__
Asterisk__:__608986__:__CREB-REGULATED TRANSCRIPTION COACTIVATOR 3; CRTC3__:__TRANSDUCER OF REGULATED cAMP RESPONSE ELEMENT-BINDING PROTEIN 3; TORC3;; TRANSDUCER OF REGULATED CREB 3__:__
Asterisk__:__608987__:__PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, ISOFORM 3; P4HA3__:__PROLYL 4-HYDROXYLASE, ALPHA-3 SUBUNIT__:__
Percent__:__608988__:__ATRIAL FIBRILLATION, FAMILIAL, 2; ATFB2__:____:__
Asterisk__:__608989__:__RETINAL DEHYDROGENASE, EPIDERMAL, 2__:__RDHE2;; EPIDERMAL RETINAL DEHYDROGENASE 2__:__
Asterisk__:__608990__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 10; ADAMTS10__:____:__
Asterisk__:__608991__:__MASTERMIND-LIKE 3; MAML3__:__MASTERMIND, DROSOPHILA, HOMOLOG OF, 2; MAM2;; KIAA1816__:__
Asterisk__:__608992__:__B-CELL LYMPHOMA 6B; BCL6B__:__BCL6-ASSOCIATED ZINC FINGER PROTEIN; BAZF__:__
Asterisk__:__608993__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3F; APOBEC3F__:____:__
Asterisk__:__608994__:__ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS-CONTAINING PROTEIN 1A; ANKS1A__:__ODIN;; KIAA0229__:__
Percent__:__608995__:__DYSLEXIA, SUSCEPTIBILITY TO, 8; DYX8__:____:__
Number Sign__:__608996__:__PREMATURE OVARIAN FAILURE 3; POF3__:____:__
Caret__:__608997__:__MOVED TO 300512__:____:__
Asterisk__:__608998__:__EARP COMPLEX AND GARP COMPLEX INTERACTING PROTEIN 1; EIPR1__:__TUMOR-SUPPRESSING SUBTRANSFERABLE FRAGMENT CANDIDATE GENE 1; TSSC1;; TUMOR-SUPPRESSING STF cDNA 1__:__
Asterisk__:__608999__:__TUMOR-SUPPRESSING SUBTRANSFERABLE FRAGMENT CANDIDATE GENE 2; TSSC2__:__TUMOR-SUPPRESSING STF cDNA 2__:__
Asterisk__:__609000__:__MONOOXYGENASE, DBH-LIKE, 1; MOXD1__:__MONOOXYGENASE X; MOX__:__
Asterisk__:__609001__:__PHOSPHATIDYLINOSITOL 3-KINASE, CLASS 2, GAMMA; PIK3C2G__:____:__
Asterisk__:__609002__:__TEKTIN 1; TEKT1__:____:__
Asterisk__:__609003__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 11; TTC11__:__FIS1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__609004__:__B-CELL CLL/LYMPHOMA 9-LIKE; BCL9L__:__BCL9-2__:__
Asterisk__:__609005__:__WD REPEAT-CONTAINING PROTEIN 17; WDR17__:____:__
Number Sign__:__609006__:__DEAFNESS, AUTOSOMAL RECESSIVE 36, WITH OR WITHOUT VESTIBULAR INVOLVEMENT; DFNB36__:____:__DEAFNESS, AUTOSOMAL DOMINANT, WITHOUT VESTIBULAR INVOLVEMENT, INCLUDED
Asterisk__:__609007__:__LEUCINE-RICH REPEAT KINASE 2; LRRK2__:__DARDARIN__:__
NULL__:__609008__:__MARFANOID HABITUS WITH SITUS INVERSUS__:____:__
Asterisk__:__609009__:__TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN, THETA ISOFORM; YWHAQ__:__14-3-3 PROTEIN, T-CELL;; 14-3-3-THETA;; 14-3-3-TAU;; HS1__:__
Asterisk__:__609010__:__3-METHYLCROTONYL-CoA CARBOXYLASE 1; MCCC1__:__3-METHYLCROTONYL-CoA CARBOXYLASE, ALPHA; MCCA;; 3-METHYLCROTONYL-CoA CARBOXYLASE, BIOTIN-CONTAINING SUBUNIT__:__
Asterisk__:__609011__:__VASOHIBIN 1; VASH1__:__KIAA1036__:__
Asterisk__:__609012__:__WD REPEAT-CONTAINING PROTEIN 5; WDR5__:__BMP2-INDUCED GENE, 3-KB; BIG3__:__
Asterisk__:__609013__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 4C1; SLCO4C1__:__ORGANIC ANION TRANSPORTER 4C1; OATP4C1__:__
Asterisk__:__609014__:__3-METHYLCROTONYL-CoA CARBOXYLASE 2; MCCC2__:__3-METHYLCROTONYL-CoA CARBOXYLASE, BETA; MCCB;; 3-METHYLCROTONYL-CoA CARBOXYLASE, NON-BIOTIN-CONTAINING SUBUNIT__:__
Number Sign__:__609015__:__MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFICIENCY; MTPD__:__TRIFUNCTIONAL PROTEIN DEFICIENCY__:__TRIFUNCTIONAL PROTEIN DEFICIENCY WITH MYOPATHY AND NEUROPATHY, INCLUDED
Number Sign__:__609016__:__LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY__:__LCHAD DEFICIENCY__:__
Asterisk__:__609017__:__ERYTHROBLAST MEMBRANE-ASSOCIATED PROTEIN; ERMAP__:__ERYTHROID MEMBRANE-ASSOCIATED PROTEIN;; ERYTHROCYTE MEMBRANE-ASSOCIATED PROTEIN__:__
Asterisk__:__609018__:__HOLOCARBOXYLASE SYNTHETASE; HLCS__:__HCS__:__
Asterisk__:__609019__:__BIOTINIDASE; BTD__:____:__
Asterisk__:__609020__:__FOLATE HYDROLASE 1B; FOLH1B__:__PROSTATE-SPECIFIC MEMBRANE ANTIGEN-LIKE; PSMAL;; PSMA-LIKE;; GLUTAMATE CARBOXYPEPTIDASE III; GCP3__:__
Percent__:__609021__:__PERIPHERAL CONE DYSTROPHY__:____:__
Asterisk__:__609022__:__RAPAMYCIN-INSENSITIVE COMPANION OF MTOR; RICTOR__:__AVO3, S. CEREVISIAE, HOMOLOG OF; AVO3;; KIAA1999__:__
Asterisk__:__609023__:__MYOFIBRILLOGENESIS REGULATOR 1__:__MR1;; PNKD;; TRANSACTIVATED BY HEPATITIS C VIRUS CORE PROTEIN 2; TAHCCP2;; BRAIN PROTEIN 17, MOUSE, HOMOLOG OF; BRP17;; KIAA1184__:__
Asterisk__:__609024__:__KDEL ENDOPLASMIC RETICULUM PROTEIN RETENTION RECEPTOR 2; KDELR2__:__ERD2-LIKE PROTEIN 1; ELP1;; ERD2.2__:__
Asterisk__:__609025__:__KERATIN 75, TYPE II; KRT75__:__K75;; KB18;; KERATIN 6, HAIR FOLLICLE; K6HF__:__
Percent__:__609026__:__CATARACT 28; CTRCT28__:__CATARACT, AGE-RELATED CORTICAL, 1; ARCC1__:__
Number Sign__:__609027__:__BLOOD GROUP, INDIAN SYSTEM; IN__:__INDIAN BLOOD GROUP SYSTEM; IN__:__
Asterisk__:__609028__:__TRAF-INTERACTING PROTEIN WITH FORKHEAD-ASSOCIATED DOMAIN; TIFA__:__TIFAA;; TRAF-INTERACTING PROTEIN WITH FHA DOMAIN;; TRAF2-BINDING PROTEIN; T2BP__:__
Number Sign__:__609029__:__EMANUEL SYNDROME__:__SUPERNUMERARY DER(22)t(11;22) SYNDROME__:__
Asterisk__:__609030__:__DIGEORGE SYNDROME CRITICAL REGION GENE 8; DGCR8__:____:__
Asterisk__:__609031__:__SERINE PROTEASE INHIBITOR-LIKE PROTEIN WITH KUNITZ AND WAP DOMAINS 1; SPINLW1__:__EPIDIDYMAL PROTEASE INHIBITOR; EPPIN;; WAP7__:__
Asterisk__:__609032__:__FSHD REGION GENE 2; FRG2__:__FSHD GENE 2__:__
Number Sign__:__609033__:__POSTERIOR COLUMN ATAXIA WITH RETINITIS PIGMENTOSA; AXPC1__:__PCARP__:__
Asterisk__:__609034__:__HAIRY/ENHANCER OF SPLIT-RELATED WITH YRPW MOTIF-LIKE PROTEIN; HEYL__:__HEY-LIKE PROTEIN__:__
Asterisk__:__609035__:__RAS ASSOCIATION AND PLECKSTRIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 1; RAPH1__:__LAMELLIPODIN; LPD;; KIAA1681__:__
Asterisk__:__609036__:__APBB1-INTERACTING PROTEIN; APBB1IP__:__RAP1-INTERACTING ADAPTOR MOLECULE; RIAM;; RETINOIC ACID-RESPONSIVE PROLINE-RICH PROTEIN 1; RARP1__:__
NULL__:__609037__:__MENTAL RETARDATION WITH OPTIC ATROPHY, FACIAL DYSMORPHISM, MICROCEPHALY, AND SHORT STATURE__:____:__
Asterisk__:__609038__:__RHO FAMILY GTPase 1; RND1__:__RHO6__:__
Percent__:__609039__:__NARCOLEPSY 3; NRCLP3__:____:__
Number Sign__:__609040__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 9; ARVC9__:__
Percent__:__609041__:__SPASTIC PARAPLEGIA 27, AUTOSOMAL RECESSIVE; SPG27__:____:__
Asterisk__:__609042__:__OPSIN 5; OPN5__:__NEUROPSIN;; G PROTEIN-COUPLED RECEPTOR 136; GPR136;; PGR12__:__
Asterisk__:__609043__:__RELAXIN/INSULIN-LIKE FAMILY PEPTIDE RECEPTOR 4; RXFP4__:__RELAXIN 3 RECEPTOR 2; RLN3R2;; RLN3 RECEPTOR 2;; G PROTEIN-COUPLED RECEPTOR 100; GPR100;; G PROTEIN-COUPLED RECEPTOR 142; GPCR142__:__
Asterisk__:__609044__:__FREE FATTY ACID RECEPTOR 4; FFAR4__:__G PROTEIN-COUPLED RECEPTOR 120; GPR120;; PGR4__:__
Asterisk__:__609045__:__G PROTEIN-COUPLED RECEPTOR 141; GPR141__:__PGR13__:__
Asterisk__:__609046__:__G PROTEIN-COUPLED RECEPTOR 142; GPR142__:__PGR2__:__
NULL__:__609047__:__SKELETAL DYSPLASIA, RHIZOMELIC, WITH RETINITIS PIGMENTOSA__:____:__
Number Sign__:__609048__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 3; CMM3__:____:__
Number Sign__:__609049__:__PIERSON SYNDROME__:__MICROCORIA-CONGENITAL NEPHROTIC SYNDROME__:__
Asterisk__:__609050__:__METASTASIS-ASSOCIATED GENE 3; MTA3__:__KIAA1266__:__
Asterisk__:__609051__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 8; CARD8__:__TUMOR-UPREGULATED CARD-CONTAINING ANTAGONIST OF CASP9; TUCAN;; CARD INHIBITOR OF NFKB-ACTIVATING LIGANDS; CARDINAL;; NDPP1;; KIAA0955__:__
Percent__:__609052__:__SPONDYLOMETAPHYSEAL DYSPLASIA, TYPE A4__:____:__
Number Sign__:__609053__:__FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI__:____:__
Number Sign__:__609054__:__FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ__:____:__
Percent__:__609055__:__CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9__:____:__
Number Sign__:__609056__:__SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS__:__AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME__:__
Number Sign__:__609057__:__NEPHROPATHY WITH PRETIBIAL EPIDERMOLYSIS BULLOSA AND DEAFNESS__:____:__
Asterisk__:__609058__:__METHYLMALONYL-CoA MUTASE; MUT__:__MCM;; METHYLMALONYL-CoA ISOMERASE__:__
Asterisk__:__609059__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 2; PNPLA2__:__ADIPOSE TRIGLYCERIDE LIPASE; ATGL;; DESNUTRIN;; TRANSPORT-SECRETION PROTEIN 2; TTS2;; TTS2.2;; PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT, ZETA;; IPLA2-ZETA__:__
Number Sign__:__609060__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1__:__HEPATOENCEPHALOPATHY, EARLY FATAL PROGRESSIVE__:__
Asterisk__:__609061__:__ENABLED, DROSOPHILA, HOMOLOG OF; ENAH__:__ENA;; MAMMALIAN ENABLED; MENA;; NDPP1__:__
Asterisk__:__609062__:__POU DOMAIN, CLASS 6, TRANSCRIPTION FACTOR 2; POU6F2__:__RETINA-DERIVED POU-DOMAIN FACTOR 1; RPF1__:__
Asterisk__:__609063__:__THIOREDOXIN 2; TXN2__:__TRX2;; THIOREDOXIN, MITOCHONDRIAL; MTRX__:__
Asterisk__:__609064__:__CARNOSINE DIPEPTIDASE 1; CNDP1__:__CARNOSINASE 1; CN1;; CARNOSINASE, SERUM__:__
Caret__:__609065__:__MOVED TO 605714__:____:__
Asterisk__:__609066__:__AJUBA, MOUSE, HOMOLOG OF; JUB__:____:__
Asterisk__:__609067__:__SCLERAXIS, MOUSE, HOMOLOG OF, A; SCXA__:__SCLERAXIS; SCX__:__
Asterisk__:__609068__:__DAN DOMAIN FAMILY, MEMBER 5; DAND5__:__CERBERUS, XENOPUS, HOMOLOG OF, 2; CER2;; CERBERUS-LIKE 2; CRL2; CERL2;; DANTE;; COCO__:__
Number Sign__:__609069__:__PANCREATIC AND CEREBELLAR AGENESIS; PACA__:__DIABETES MELLITUS, PERMANENT NEONATAL, WITH CEREBELLAR AGENESIS__:__
Number Sign__:__609070__:__HEMOGLOBIN, HIGH ALTITUDE ADAPTATION; HALAH__:__HEMOGLOBIN, HIGH OXYGEN SATURATION OF__:__
Asterisk__:__609071__:__F-BOX AND WD40 DOMAIN PROTEIN 2; FBXW2__:__FBW2; FWD2__:__
Asterisk__:__609072__:__F-BOX AND WD40 DOMAIN PROTEIN 5; FBXW5__:__FBW5__:__
Asterisk__:__609073__:__F-BOX AND WD40 DOMAIN PROTEIN 8; FBXW8__:__FBW8;; FBXW6; FBW6;; FBXO29; FBX29__:__
Asterisk__:__609074__:__F-BOX AND WD40 DOMAIN PROTEIN 9; FBXW9__:__FBW9__:__
Asterisk__:__609075__:__F-BOX AND WD40 DOMAIN PROTEIN 12; FBXW12__:__FBW12;; FBXO35;; FBXO12__:__
Asterisk__:__609076__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 6; FBXL6__:__FBL6;; FBL6A__:__
Asterisk__:__609077__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 8; FBXL8__:__FBL8__:__
Asterisk__:__609078__:__LYSINE-SPECIFIC DEMETHYLASE 2B; KDM2B__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 10; FBXL10;; FBL10;; CXXC FINGER PROTEIN 2; CXXC2;; JUMONJI C DOMAIN-CONTAINING HISTONE DEMETHYLASE 1B; JHDM1B__:__
Asterisk__:__609079__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 12; FBXL12__:__FBL12__:__
Asterisk__:__609080__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 13; FBXL13__:__FBL13__:__
Asterisk__:__609081__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 14; FBXL14__:__FBL14__:__
Asterisk__:__609082__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 16; FBXL16__:__FBL16;; CHROMOSOME 16 OPEN READING FRAME 22; C16ORF22__:__
Asterisk__:__609083__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 17; FBXL17__:__FBL17;; FBXO13; FBX13__:__
Asterisk__:__609084__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 18; FBXL18__:__FBL18__:__
Asterisk__:__609085__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 19; FBXL19__:__FBL19__:__
Asterisk__:__609086__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 20; FBXL20__:__FBL20;; FBL2;; SCRAPPER; SCR__:__
Asterisk__:__609087__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 21; FBXL21__:__FBL21;; FBXL3B; FBL3B__:__
Asterisk__:__609088__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 22; FBXL22__:__FBL22__:__
Asterisk__:__609089__:__F-BOX ONLY PROTEIN 3; FBXO3__:__FBX3;; FBA__:__
Asterisk__:__609090__:__F-BOX ONLY PROTEIN 4; FBXO4__:__FBX4__:__
Asterisk__:__609091__:__F-BOX ONLY PROTEIN 9; FBXO9__:__FBX9;; NY-REN-57__:__
Asterisk__:__609092__:__F-BOX ONLY PROTEIN 10; FBXO10__:__FBX10;; PROTEIN ARGININE METHYLTRANSFERASE 11; PRMT11__:__
Asterisk__:__609093__:__F-BOX ONLY PROTEIN 15; FBXO15__:__FBX15__:__
Asterisk__:__609094__:__F-BOX ONLY PROTEIN 17; FBXO17__:__FBX17;; FBXO26; FBX26;; FBG4__:__
Asterisk__:__609095__:__F-BOX ONLY PROTEIN 21; FBXO21__:__FBX21;; KIAA0875__:__
Asterisk__:__609096__:__F-BOX ONLY PROTEIN 22; FBXO22__:__FBX22__:__
Asterisk__:__609097__:__F-BOX ONLY PROTEIN 24; FBXO24__:__FBX24__:__
Asterisk__:__609098__:__F-BOX ONLY PROTEIN 25; FBXO25__:__FBX25__:__
Asterisk__:__609099__:__F-BOX ONLY PROTEIN 27; FBXO27__:__FBX27;; FBG5__:__
Asterisk__:__609100__:__F-BOX ONLY PROTEIN 28; FBXO28__:__FBX28;; KIAA0483__:__
Asterisk__:__609101__:__F-BOX ONLY PROTEIN 30; FBXO30__:__FBX30__:__
Asterisk__:__609102__:__F-BOX ONLY PROTEIN 31; FBXO31__:__FBX31;; FBXO14; FBX14__:__
Asterisk__:__609103__:__F-BOX ONLY PROTEIN 33; FBXO33__:__FBX33__:__
Asterisk__:__609104__:__F-BOX ONLY PROTEIN 34; FBXO34__:__FBX34__:__
Asterisk__:__609105__:__F-BOX ONLY PROTEIN 36; FBXO36__:__FBX36__:__
Asterisk__:__609106__:__F-BOX ONLY PROTEIN 39; FBXO39__:__FBX39__:__
Asterisk__:__609107__:__F-BOX ONLY PROTEIN 40; FBXO40__:__FBX40;; KIAA1195__:__
Asterisk__:__609108__:__F-BOX ONLY PROTEIN 41; FBXO41__:__FBX41;; KIAA1940__:__
Asterisk__:__609109__:__F-BOX ONLY PROTEIN 42; FBXO42__:__FBX42;; KIAA1332;; JUST 1 F-BOX- AND KELCH DOMAIN-CONTAINING PROTEIN; JFK__:__
Asterisk__:__609110__:__F-BOX ONLY PROTEIN 43; FBXO43__:__FBX43;; ENDOGENOUS MEIOTIC INHIBITOR 2, XENOPUS, HOMOLOG OF; EMI2;; ERP1, XENOPUS, HOMOLOG OF; ERP1__:__
Asterisk__:__609111__:__F-BOX ONLY PROTEIN 44; FBXO44__:__FBX44;; FBX6A;; FBG3__:__
Asterisk__:__609112__:__F-BOX ONLY PROTEIN 45; FBXO45__:__FBX45__:__
Percent__:__609113__:__TELOMERE LENGTH, MEAN LEUKOCYTE; LTL__:__TELM__:__
Asterisk__:__609114__:__DESTRIN; DSTN__:__ACTIN DEPOLYMERIZING FACTOR; ADF__:__
Number Sign__:__609115__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 3; LGMDD3__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1G; LGMD1G__:__
Percent__:__609116__:__RESPIRATORY RHYTHMICITY IN SLEEP__:__RRIS__:__
Asterisk__:__609117__:__F-BOX ONLY PROTEIN 46; FBXO46__:__FBX46__:__
Asterisk__:__609118__:__PROGRAMMED CELL DEATH 10; PDCD10__:__CCM3 GENE;; TFAR15__:__
Asterisk__:__609119__:__THAP DOMAIN-CONTAINING PROTEIN 11; THAP11__:__RONIN__:__
Asterisk__:__609120__:__CATION CHANNEL, SPERM-ASSOCIATED, 3; CATSPER3__:____:__
Asterisk__:__609121__:__CATION CHANNEL, SPERM-ASSOCIATED, 4; CATSPER4__:____:__
Percent__:__609122__:__ANEURYSM, INTRACRANIAL BERRY, 3; ANIB3__:____:__
Asterisk__:__609123__:__ATPase, CLASS I, TYPE 8B, MEMBER 4; ATP8B4__:__KIAA1939__:__
Asterisk__:__609124__:__ZINC FINGER PROTEIN 385A; ZNF385A__:__ZINC FINGER PROTEIN 385; ZNF385;; RETINAL ZINC FINGER PROTEIN; RZF;; HEMATOPOIETIC ZINC FINGER PROTEIN; HZF__:__
Asterisk__:__609125__:__MOTILE SPERM DOMAIN-CONTAINING PROTEIN 3; MOSPD3__:____:__
Asterisk__:__609126__:__ATPase, CLASS II, TYPE 9A; ATP9A__:__ATPase IIA; ATPIIA;; KIAA0611__:__
Caret__:__609127__:__MOVED TO 300516__:____:__
Percent__:__609128__:__ARTHROGRYPOSIS, DISTAL, TYPE 4; DA4__:__ARTHROGRYPOSIS WITH SEVERE SCOLIOSIS;; ARTHROGRYPOSIS, DISTAL, TYPE IID; DAIID__:__
Number Sign__:__609129__:__AUDITORY NEUROPATHY, AUTOSOMAL DOMINANT, 1; AUNA1__:__AUDITORY NEUROPATHY, NONSYNDROMIC DOMINANT; NSDAN__:__
Asterisk__:__609130__:__APOPTOSIS-INDUCING, TAF9-LIKE DOMAIN 1; APITD1__:__CENTROMERIC PROTEIN S; CENPS;; FANCM-INTERACTING HISTONE-FOLD PROTEIN 1; MHF1__:__
Asterisk__:__609131__:__CLAUDIN 7; CLDN7__:____:__
Asterisk__:__609132__:__LYSINE-SPECIFIC DEMETHYLASE 1A; KDM1A__:__LYSINE-SPECIFIC DEMETHYLASE 1; LSD1;; AMINE OXIDASE, FLAVIN-CONTAINING, 2; AOF2;; BRAF35/HDAC COMPLEX, 110-KD SUBUNIT; BHC110;; KIAA0601__:__
Asterisk__:__609133__:__FLT3-INTERACTING ZINC FINGER PROTEIN 1; FIZ1__:__FLJ14768__:__
Asterisk__:__609134__:__UBIQUITIN-PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 2; UBR2__:__CHROMOSOME 6 OPEN READING FRAME 133; C6ORF133;; KIAA0349__:__
Number Sign__:__609135__:__APLASTIC ANEMIA__:____:__APLASTIC ANEMIA, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__609136__:__PERIPHERAL DEMYELINATING NEUROPATHY, CENTRAL DYSMYELINATION, WAARDENBURG SYNDROME, AND HIRSCHSPRUNG DISEASE; PCWH__:__WAARDENBURG-SHAH SYNDROME, NEUROLOGIC VARIANT__:__
Asterisk__:__609137__:__RECEPTOR-TRANSPORTING PROTEIN 1; RTP1__:____:__
Asterisk__:__609138__:__RECEPTOR-TRANSPORTING PROTEIN 2; RTP2__:____:__
Asterisk__:__609139__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 1; REEP1__:__CHROMOSOME 2 OPEN READING FRAME 23; C2ORF23__:__
Number Sign__:__609140__:__CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 2; PPCD2__:____:__
Number Sign__:__609141__:__CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 3; PPCD3__:____:__
Asterisk__:__609142__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 3; CEACAM3__:__CGM1;; CD66D__:__
Caret__:__609143__:__MOVED TO 607278__:____:__
Asterisk__:__609144__:__FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 1; FLVCR1__:__FLVCR__:__
Asterisk__:__609145__:__NEUROFASCIN; NFASC__:__KIAA0756__:__
Asterisk__:__609146__:__RIC8, C. ELEGANS, HOMOLOG OF, A; RIC8A__:__SYNEMBRYN, C. ELEGANS, HOMOLOG OF, A__:__
Asterisk__:__609147__:__RIC8, C. ELEGANS, HOMOLOG OF, B; RIC8B__:__SYNEMBRYN, C. ELEGANS, HOMOLOG OF, B__:__
Number Sign__:__609148__:__MALARIA, MILD, SUSCEPTIBILITY TO__:__MALS__:__
Asterisk__:__609149__:__SOLUTE CARRIER FAMILY 29 (MONOAMINE TRANSPORTER), MEMBER 4; SLC29A4__:__PLASMA MEMBRANE MONOAMINE TRANSPORTER; PMAT;; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; ENT4__:__
Asterisk__:__609150__:__CXXC FINGER PROTEIN 1; CXXC1__:__CpG-BINDING PROTEIN; CGBP;; PROTEIN CONTAINING CXXC DOMAIN 1; PCCX1__:__
Asterisk__:__609151__:__UBX DOMAIN PROTEIN 11; UBXN11__:__SOCIUS; SOC__:__
Number Sign__:__609152__:__HYPERTHYROIDISM, NONAUTOIMMUNE__:__HYPERTHYROIDISM, CONGENITAL NONAUTOIMMUNE;; HYPERTHYROIDISM, NONAUTOIMMUNE, AUTOSOMAL DOMINANT;; TOXIC THYROID HYPERPLASIA, AUTOSOMAL DOMINANT__:__
Number Sign__:__609153__:__PSEUDOHYPERKALEMIA, FAMILIAL, 2, DUE TO RED CELL LEAK; PSHK2__:__PSEUDOHYPERKALEMIA LILLE;; PSEUDOHYPERKALEMIA FALKIRK;; PSEUDOHYPERKALEMIA CHISWICK;; PSEUDOHYPERKALEMIA CARDIFF;; PSEUDOHYPERKALEMIA EAST LONDON;; CRYOHYDROCYTOSIS, MILD__:__
Asterisk__:__609154__:__ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG OF, 3; ASCL3__:__HUMAN ACHAETE-SCUTE HOMOLOG 3; HASH3;; SGN1__:__
Asterisk__:__609155__:__ACHAETE-SCUTE COMPLEX, DROSOPHILA, HOMOLOG OF, 4; ASCL4__:__HUMAN ACHAETE-SCUTE HOMOLOG 4; HASH4__:__
Asterisk__:__609156__:__NICALIN, ZEBRAFISH, HOMOLOG OF; NCLN__:____:__
Asterisk__:__609157__:__NODAL MODULATOR 1; NOMO1__:__PM5, TELOMERIC COPY__:__
Asterisk__:__609158__:__NODAL MODULATOR 2; NOMO2__:__PM5, CENTROMERIC COPY__:__
Asterisk__:__609159__:__NODAL MODULATOR 3; NOMO3__:__PM5, MIDDLE COPY__:__
Caret__:__609160__:__MOVED TO 601419__:____:__
Number Sign__:__609161__:__STRIATAL DEGENERATION, AUTOSOMAL DOMINANT 1; ADSD1__:____:__
Number Sign__:__609162__:__CZECH DYSPLASIA__:__CZECH DYSPLASIA, METATARSAL TYPE;; PSEUDORHEUMATOID DYSPLASIA, PROGRESSIVE, WITH HYPOPLASTIC TOES;; SPONDYLOEPIPHYSEAL DYSPLASIA WITH PRECOCIOUS OSTEOARTHRITIS__:__
Asterisk__:__609163__:__HYDROXYCARBOXYLIC ACID RECEPTOR 2; HCAR2__:__HCA2;; G PROTEIN-COUPLED RECEPTOR 109A; GPR109A;; NIACIN RECEPTOR 1; NIACR1;; HM74A;; HM74B;; PROTEIN UPREGULATED IN MACROPHAGES BY IFNG, MOUSE, HOMOLOG OF; PUMAG__:__
Percent__:__609164__:__UMBILICUS, FAMILIAL FLAT__:__FLAT UMBILICUS, AUTOSOMAL DOMINANT__:__
Number Sign__:__609165__:__ERYTHRODERMA, ICHTHYOSIFORM, CONGENITAL RETICULAR; CRIE__:__ICHTHYOSIS WITH CONFETTI; IWC;; ICHTHYOSIS VARIEGATA__:__ERYTHROKERATODERMA, RETICULAR, INCLUDED;; AARAU DISEASE, INCLUDED
Percent__:__609166__:__BRANCHIOGENIC-DEAFNESS SYNDROME__:____:__
Caret__:__609167__:__MOVED TO 604379__:____:__
Asterisk__:__609168__:__SHUGOSHIN-LIKE 1; SGOL1__:__SGO; SGO1__:__
Asterisk__:__609169__:__GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, SPERMATOGENIC; GAPDHS__:__GAPDS;; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, TESTIS-SPECIFIC;; GAPD2__:__
Asterisk__:__609170__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 4; TXNDC4__:__ENDOPLASMIC RETICULUM RESIDENT PROTEIN, 44-KD; ERp44;; KIAA0573__:__
Asterisk__:__609171__:__CDC42 EFFECTOR PROTEIN 5; CDC42EP5__:__CEP5;; BINDER OF RHO GTPases 3; BORG3__:__
Asterisk__:__609172__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 16A; PPP1R16A__:__MYOSIN PHOSPHATASE TARGET SUBUNIT 3; MYPT3__:__
Asterisk__:__609173__:__KINETOCHORE SCAFFOLD 1; KNL1__:__CASC5 GENE; CASC5;; ALL1-FUSED GENE FROM CHROMOSOME 15q14; AF15Q14;; KIAA1570;; D40__:__AF15Q14/ALL1 FUSION GENE, INCLUDED
Asterisk__:__609174__:__NSL1, MIS12 KINETOCHORE COMPLEX COMPONENT; NSL1__:__DC8;; CHROMOSOME 1 OPEN READING FRAME 48; C1ORF48__:__
Asterisk__:__609175__:__DSN1, MIS12 KINETOCHORE COMPLEX COMPONENT; DSN1__:__DSN1, S. CEREVISIAE, HOMOLOG OF;; CHROMOSOME 20 OPEN READING FRAME 172; C20ORF172__:__
Asterisk__:__609176__:__POLYAMINE-MODULATED FACTOR 1; PMF1__:____:__
Asterisk__:__609177__:__ZW10 INTERACTOR; ZWINT__:__ZWINT1__:__
Asterisk__:__609178__:__MIS12, S. POMBE, HOMOLOG OF; MIS12__:____:__
Percent__:__609179__:__MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 7__:__MGR7__:__
Number Sign__:__609180__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE If; CDG1F__:__CDG If; CDGIf__:__
Asterisk__:__609181__:__DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 4; DYRK4__:____:__
Asterisk__:__609182__:__SOLUTE CARRIER FAMILY 35, MEMBER D2; SLC35D2__:__FRINGE CONNECTION, DROSOPHILA, HOMOLOG OF, 1; HFRC1;; SQV7-LIKE PROTEIN; SQV7L;; UGTREL8__:__
Asterisk__:__609183__:__AURORA KINASE A-INTERACTING PROTEIN__:__AURKA-INTERACTING PROTEIN; AIP__:__
Asterisk__:__609184__:__KINESIN FAMILY MEMBER 4B; KIF4B__:____:__
Asterisk__:__609185__:__ZINC FINGER AND HOMEODOMAIN PROTEIN 2; ZHX2__:__ALPHA-FETOPROTEIN REGULATOR 1, MOUSE, HOMOLOG OF; AFR1;; AFP REGULATOR 1, MOUSE, HOMOLOG OF;; REGULATOR OF AFP, MOUSE, HOMOLOG OF; RAF;; KIAA0854__:__
Asterisk__:__609186__:__D-2-HYDROXYGLUTARATE DEHYDROGENASE; D2HGDH__:__D2HGD__:__
Asterisk__:__609187__:__SUCCINYL-CoA:GLUTARATE-CoA TRANSFERASE; SUGCT__:__CHROMOSOME 7 OPEN READING FRAME 10; C7ORF10__:__
Asterisk__:__609188__:__M-PHASE-SPECIFIC PLK1-INTERACTING PROTEIN; MPLKIP__:__CHROMOSOME 7 OPEN READING FRAME 11; C7ORF11;; TTDN1 GENE; TTDN1__:__
Asterisk__:__609189__:__ANTI-SILENCING FUNCTION 1, S. CEREVISIAE, HOMOLOG OF, A; ASF1A__:__CCG1-INTERACTING FACTOR A; CIA__:__
Asterisk__:__609190__:__ANTI-SILENCING FUNCTION 1, S. CEREVISIAE, HOMOLOG OF, B; ASF1B__:____:__
Asterisk__:__609191__:__PROTEIN KINASE A-INTERACTING PROTEIN 1; AKIP1__:__PKA-INTERACTING PROTEIN 1;; BREAST CANCER-ASSOCIATED GENE 3; BCA3;; CHROMOSOME 11 OPEN READING FRAME 17; C11ORF17__:__
Number Sign__:__609192__:__LOEYS-DIETZ SYNDROME 1; LDS1__:__FURLONG SYNDROME;; LOEYS-DIETZ AORTIC ANEURYSM SYNDROME;; AORTIC ANEURYSM, FAMILIAL THORACIC 5; AAT5__:__
Asterisk__:__609193__:__PEPTIDYL-PROLYL ISOMERASE-LIKE 5; PPIL5__:__LEUCINE-RICH REPEAT PROTEIN 1; LRR1__:__
Asterisk__:__609194__:__CDK5 AND ABL ENZYME SUBSTRATE 1; CABLES1__:__CABLES;; INTERACTOR WITH CDK3 1;; IK3-1__:__
Number Sign__:__609195__:__SPASTIC PARAPLEGIA 26, AUTOSOMAL RECESSIVE; SPG26__:____:__
Asterisk__:__609196__:__MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN; MRAP__:__FAT TISSUE-SPECIFIC LOW MOLECULAR WEIGHT PROTEIN; FALP;; CHROMOSOME 21 OPEN READING FRAME 61; C21ORF61__:__
Percent__:__609197__:__GLUCOCORTICOID DEFICIENCY 3; GCCD3__:__FAMILIAL GLUCOCORTICOID DEFICIENCY 3; FGD3;; GLUCOCORTICOID DEFICIENCY 2, FORMERLY; GCCD2, FORMERLY__:__
Asterisk__:__609198__:__ADAMTS-LIKE PROTEIN 1; ADAMTSL1__:__PUNCTIN;; PUNCTIN 1__:__
Asterisk__:__609199__:__ADAMTS-LIKE PROTEIN 3; ADAMTSL3__:__PUNCTIN 2;; KIAA1233__:__
Number Sign__:__609200__:__MYOPATHY, MYOFIBRILLAR, 3; MFM3__:__MYOTILINOPATHY;; MYOPATHY, MYOFIBRILLAR, MYOTILIN-RELATED;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1, FORMERLY; LGMD1, FORMERLY;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A, FORMERLY; LGMD1A, FORMERLY__:__
Asterisk__:__609201__:__UBIQUITIN-ASSOCIATED AND SH3 DOMAIN-CONTAINING PROTEIN B; UBASH3B__:__SUPPRESSOR OF T-CELL RECEPTOR SIGNALING 1; STS1;; p70;; T-CELL UBIQUITIN LIGAND 2; TULA2;; KIAA1959__:__
Asterisk__:__609202__:__SECRETAGOGIN; SCGN__:____:__
Asterisk__:__609203__:__CLAUDIN 23; CLDN23__:____:__
Asterisk__:__609204__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S16: MRPS16__:____:__
Asterisk__:__609205__:__DAB2-INTERACTING PROTEIN; DAB2IP__:__ASK1-INTERACTING PROTEIN; AIP1;; KIAA1743__:__
Asterisk__:__609206__:__EUKARYOTIC TRANSLATION ELONGATION FACTOR 1, EPSILON-1; EEF1E1__:__ELONGATION FACTOR p18;; AMINOACYL-tRNA SYNTHETASE-INTERACTING MULTIFUNCTIONAL PROTEIN 3; AIMP3__:__
Asterisk__:__609207__:__MELANOREGULIN; MREG__:__DILUTE SUPPRESSOR, MOUSE, HOMOLOG OF;; DSU, MOUSE, HOMOLOG OF; DSU__:__
Asterisk__:__609208__:__KAZAL-TYPE PROTEASE INHIBITOR DOMAIN-CONTAINING PROTEIN 1; KAZALD1__:__BONE- AND ODONTOBLAST-EXPRESSED GENE 1; BONO1;; IGFBP-RELATED PROTEIN 10; IGFBPRP10__:__
Asterisk__:__609209__:__INFLUENZA VIRUS NS1A PROTEIN-BINDING PROTEIN; IVNS1ABP__:__NS1-BINDING PROTEIN; NS1BP;; NCX DOWNSTREAM GENE 1; ND1;; KIAA0850__:__
Asterisk__:__609210__:__CLAUDIN 18; CLDN18__:____:__
Asterisk__:__609211__:__MYOSIN, LIGHT CHAIN 12B, REGULATORY; MYL12B__:__MYOSIN REGULATORY LIGHT CHAIN 2; MRLC2__:__
Asterisk__:__609212__:__ASPARAGINASE-LIKE PROTEIN 1; ASRGL1__:__ALP__:__
Asterisk__:__609213__:__SEC61 TRANSLOCON, ALPHA-1 SUBUNIT; SEC61A1__:__SEC61 COMPLEX, ALPHA-1 SUBUNIT;; SEC61A;; SEC61, S. CEREVISIAE, HOMOLOG OF; SEC61__:__
Asterisk__:__609214__:__SEC61 TRANSLOCON, BETA SUBUNIT; SEC61B__:__SEC61 COMPLEX, BETA SUBUNIT__:__
Asterisk__:__609215__:__SEC61 TRANSLOCON, GAMMA SUBUNIT; SEC61G__:__SEC61 COMPLEX, GAMMA SUBUNIT__:__
Asterisk__:__609216__:__SPIRE, DROSOPHILA, HOMOLOG OF, 1; SPIRE1__:__SPIR1;; KIAA1135__:__
Asterisk__:__609217__:__SPIRE, DROSOPHILA, HOMOLOG OF, 2; SPIRE2__:__SPIR2;; KIAA1832__:__
Number Sign__:__609218__:__FOVEAL HYPOPLASIA 2; FVH2__:__FOVEAL HYPOPLASIA 2 WITH OR WITHOUT OPTIC NERVE MISROUTING AND/OR ANTERIOR SEGMENT DYSGENESIS;; FOVEAL HYPOPLASIA 2 WITH OPTIC NERVE DECUSSATION DEFECTS AND ANTERIOR SEGMENT DYSGENESIS WITHOUT ALBINISM; FHONDA__:__
Asterisk__:__609219__:__NUDIX HYDROLASE 14; NUDT14__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 14;; NUDIX MOTIF 14;; URIDINE DIPHOSPHATE GLUCOSE PYROPHOSPHATASE; UGPP;; UDPG PYROPHOSPHATASE;; UGPPase__:__
Number Sign__:__609220__:__BRUCK SYNDROME 2; BRKS2__:__OSTEOGENESIS IMPERFECTA WITH CONGENITAL JOINT CONTRACTURES__:__
Asterisk__:__609221__:__N-ACETYLTRANSFERASE 10; NAT10__:__N-ACETYLTRANSFERASE-LIKE PROTEIN; ALP;; KRE33, YEAST, HOMOLOG OF;; RIBOSOMAL RNA CYTIDINE ACETYLTRANSFERASE 1; RRA1;; KIAA1709__:__
Percent__:__609222__:__DANDY-WALKER MALFORMATION WITH OCCIPITAL CEPHALOCELE, AUTOSOMAL DOMINANT; ADDWOC__:____:__
Percent__:__609223__:__SPONDYLOEPIPHYSEAL DYSPLASIA TARDA, AUTOSOMAL RECESSIVE, LEROY-SPRANGER TYPE__:____:__
Asterisk__:__609224__:__WD40 REPEAT PROTEIN INTERACTING WITH PHOSPHOINOSITIDES 1; WIPI1__:__WIPI, 49-KD; WIPI49__:__
Asterisk__:__609225__:__WD40 REPEAT PROTEIN INTERACTING WITH PHOSPHOINOSITIDES 2; WIPI2__:____:__
Asterisk__:__609226__:__WD REPEAT-CONTAINING PROTEIN 45B; WDR45B__:__WD REPEAT-CONTAINING PROTEIN 45-LIKE; WDR45L;; WD40 REPEAT PROTEIN INTERACTING WITH PHOSPHOINOSITIDES 3; WIPI3__:__
Number Sign__:__609227__:__GRISCELLI SYNDROME, TYPE 3; GS3__:____:__
Asterisk__:__609228__:__NUDIX HYDROLASE 3; NUDT3__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 3;; NUDIX MOTIF 3;; DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE; DIPP;; DIPP1__:__
Asterisk__:__609229__:__NUDIX HYDROLASE 4; NUDT4__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 4;; NUDIX MOTIF 4;; DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE 2; DIPP2;; KIAA0487__:__
Asterisk__:__609230__:__NUDIX HYDROLASE 5; NUDT5__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 5;; NUDIX MOTIF 5;; YSA1, S. CEREVISIAE, HOMOLOG OF; YSA1; YSA1H__:__
Asterisk__:__609231__:__NUDIX HYDROLASE 7; NUDT7__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 7;; NUDIX MOTIF 7__:__
Asterisk__:__609232__:__NUDIX HYDROLASE 12; NUDT12__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 12;; NUDIX MOTIF 12__:__
Asterisk__:__609233__:__NUDIX HYDROLASE 13; NUDT13__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 13;; NUDIX MOTIF 13__:__
Asterisk__:__609234__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2A; EIF2A__:____:__
Asterisk__:__609235__:__BR SERINE/THREONINE KINASE 1; BRSK1__:__KIAA1811__:__
Asterisk__:__609236__:__BR SERINE/THREONINE KINASE 2; BRSK2__:__SAD1, C. ELEGANS, HOMOLOG OF; SAD1;; PEN11B__:__
Asterisk__:__609237__:__IQ MOTIF-CONTAINING PROTEIN B1; IQCB1__:__NEPHROCYSTIN 5; NPHP5;; p53- AND DNA DAMAGE-REGULATED IQ MOTIF PROTEIN; PIQ;; KIAA0036__:__
Asterisk__:__609238__:__RAB GTPase-ACTIVATING PROTEIN 1-LIKE; RABGAP1L__:__TBC1 DOMAIN FAMILY, MEMBER 18; TBC1D18;; KIAA0471__:__
Asterisk__:__609239__:__LYSOPHOSPHATIDIC ACID RECEPTOR 6; LPAR6__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 5; P2RY5;; P2RY5__:__
Asterisk__:__609240__:__GERM CELL-SPECIFIC GENE 2; GSG2__:__HAPLOID GERM CELL-SPECIFIC NUCLEAR PROTEIN KINASE; HASPIN__:__
Number Sign__:__609241__:__SCHINDLER DISEASE, TYPE I__:__NEUROAXONAL DYSTROPHY, SCHINDLER TYPE;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE I;; NAGA DEFICIENCY, TYPE I__:__ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE III, INCLUDED;; NAGA DEFICIENCY, TYPE III, INCLUDED;; SCHINDLER DISEASE, TYPE III, INCLUDED
Number Sign__:__609242__:__KANZAKI DISEASE__:__ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET;; NAGA DEFICIENCY, TYPE II;; SCHINDLER DISEASE, TYPE II__:__
Asterisk__:__609243__:__RETINOIC ACID EARLY TRANSCRIPT 1E; RAET1E__:__LYMPHOCYTE EFFECTOR CELL TOXICITY-ACTIVATING LIGAND; LETAL;; UL16-BINDING PROTEIN 4; ULBP4__:__
Asterisk__:__609244__:__RETINOIC ACID EARLY TRANSCRIPT 1G; RAET1G__:____:__
Asterisk__:__609245__:__G PROTEIN SIGNALING MODULATOR 2; GPSM2__:__LEU-GLY-ASN REPEAT-ENRICHED PROTEIN; LGN;; TRANSDUCIN-BINDING PARTNER, ROD-SPECIFIC;; PINS, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__609246__:__PYRIDOXAL PHOSPHATASE; PDXP__:__PLP PHOSPHATASE;; CHRONOPHIN; CIN__:__PDXP/SH3BP1 FUSION GENE, INCLUDED
Asterisk__:__609247__:__RING FINGER PROTEIN 13; RNF13__:____:__
Asterisk__:__609248__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 4; HERC4__:__KIAA1593__:__
Asterisk__:__609249__:__HECT DOMAIN AND RCC1-LIKE DOMAIN 6; HERC6__:____:__
NULL__:__609250__:__HYPOTRICHOSIS, PROGRESSIVE PATTERNED SCALP, WITH WIRY HAIR, ONYCHOLYSIS, AND CLEFT LIP/PALATE__:__MARIE UNNA-LIKE SCALP HYPOTRICHOSIS__:__
Asterisk__:__609251__:__Fc RECEPTOR-LIKE PROTEIN B; FCRLB__:__Fc RECEPTOR-LIKE PROTEIN 2; FCRL2;; Fc RECEPTOR HOMOLOG EXPRESSED IN B CELLS 2; FREB2;; FCRY__:__
Asterisk__:__609252__:__LIPASE I; LIPI__:__LPD LIPASE; LPDL;; PRED5__:__
Percent__:__609253__:__FEBRILE SEIZURES, FAMILIAL, 6; FEB6__:__CONVULSIONS, FAMILIAL FEBRILE, 6__:__
Number Sign__:__609254__:__SENIOR-LOKEN SYNDROME 5; SLSN5__:____:__
Percent__:__609255__:__FEBRILE SEIZURES, FAMILIAL, 5; FEB5__:__CONVULSIONS, FAMILIAL FEBRILE, 5__:__
Percent__:__609256__:__MYOPIA 7; MYP7__:____:__
Percent__:__609257__:__MYOPIA 8; MYP8__:____:__
Percent__:__609258__:__MYOPIA 9; MYP9__:____:__
Percent__:__609259__:__MYOPIA 10; MYP10__:____:__
Number Sign__:__609260__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2A2A; CMT2A2A__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2;; CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2A2;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2A2;; HEREDITARY MOTOR AND SENSORY NEUROPATHY IIA2; HMSN2A2;; HMSN IIA2__:__
Percent__:__609261__:__STUTTERING, FAMILIAL PERSISTENT, 2; STUT2__:____:__
Asterisk__:__609262__:__CEREBLON; CRBN__:____:__
Asterisk__:__609263__:__SEH1-LIKE PROTEIN; SEH1L__:__SEH1, YEAST, HOMOLOG OF; SEH1;; SEC13-LIKE PROTEIN; SEC13L__:__
Asterisk__:__609264__:__NUCLEOPORIN, 37-KD; NUP37__:__p37__:__
Number Sign__:__609265__:__LI-FRAUMENI SYNDROME 2; LFS2__:____:__
Caret__:__609266__:__MOVED TO 151623__:____:__
Asterisk__:__609267__:__MELANOMA ANTIGEN, FAMILY F, 1; MAGEF1__:____:__
Asterisk__:__609268__:__SPLICING REGULATORY PROTEIN, GLUTAMINE/LYSINE-RICH, 1; SREK1__:__SPLICING FACTOR, ARGININE/SERINE-RICH, 12; SFRS12;; SR-RELATED PROTEIN, 86-KD; SRRp86;; SRRp508__:__
Asterisk__:__609269__:__KIAA0319 GENE; KIAA0319__:____:__
Number Sign__:__609270__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 7; SCAR7__:____:__
Percent__:__609271__:__KERATOCONUS 4; KTCN4__:____:__
Asterisk__:__609272__:__TRYPTASE, DELTA-1; TPSD1__:__TRYPTASE, DELTA;; MAST CELL PROTEASE 7-LIKE;; MCP7-LIKE__:__
Number Sign__:__609273__:__NEMALINE MYOPATHY 6; NEM6__:____:__
Asterisk__:__609274__:__NASCENT POLYPEPTIDE-ASSOCIATED COMPLEX, ALPHA POLYPEPTIDE, 2__:____:__
Asterisk__:__609275__:__RAB3 GTPase-ACTIVATING PROTEIN, NONCATALYTIC SUBUNIT; RAB3GAP2__:__RAB3GAP, 150-KD SUBUNIT; RAB3GAP150;; p150;; KIAA0839__:__
Asterisk__:__609276__:__NON-SMC CONDENSIN II COMPLEX SUBUNIT D3; NCAPD3__:__CONDENSIN II COMPLEX, NON-SMC SUBUNIT D3;; CHROMOSOME-ASSOCIATED PROTEIN D3; CAPD3;; KIAA0056__:__
Asterisk__:__609277__:__MOLYBDENUM COFACTOR SYNTHESIS 3; MOCS3__:____:__
Asterisk__:__609278__:__IZUMO SPERM-EGG FUSION PROTEIN 1; IZUMO1__:__SPERM-SPECIFIC PROTEIN IZUMO;; MGC34799__:__
Asterisk__:__609279__:__CENTROMERIC PROTEIN J; CENPJ__:__CENTROSOMAL P4.1-ASSOCIATED PROTEIN; CPAP__:__
Asterisk__:__609280__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 4; EIF2AK4__:__GENERAL CONTROL NONDEREPRESSIBLE 2; GCN2;; KIAA1338__:__
Asterisk__:__609281__:__MOB1-LIKE PROTEIN 1B; MOBKL1B__:__MATS, DROSOPHILA, HOMOLOG OF, 1; MATS1__:__
Asterisk__:__609282__:__MOB1-LIKE PROTEIN 1A; MOBKL1A__:__MATS, DROSOPHILA, HOMOLOG OF, 2; MATS2__:__
Number Sign__:__609283__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2__:__
Number Sign__:__609284__:__NEMALINE MYOPATHY 1; NEM1__:____:__CAP MYOPATHY 1, INCLUDED; CAPM1, INCLUDED
Number Sign__:__609285__:__NEMALINE MYOPATHY 4; NEM4__:____:__CAP MYOPATHY 2, INCLUDED; CAPM2, INCLUDED
Number Sign__:__609286__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3__:__
Asterisk__:__609287__:__SH3 DOMAIN, GRB2-LIKE, ENDOPHILIN B1; SH3GLB1__:__ENDOPHILIN B1;; BAX-INTERACTING FACTOR 1; BIF1;; KIAA0491__:__
Asterisk__:__609288__:__SH3 DOMAIN, GRB2-LIKE, ENDOPHILIN B2; SH3GLB2__:__ENDOPHILIN B2;; KIAA1848__:__
Percent__:__609289__:__SYNCOPE, FAMILIAL VASOVAGAL; VVS__:__SYNCOPE, FAMILIAL NEUROCARDIOGENIC__:__
Asterisk__:__609290__:__ADENYLATE KINASE 3; AK3__:__ADENYLATE KINASE 3-LIKE 1, FORMERLY; AK3L1, FORMERLY__:__
Asterisk__:__609291__:__SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 1; SPRED1__:____:__
Asterisk__:__609292__:__SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 2; SPRED2__:____:__
Asterisk__:__609293__:__SPROUTY-RELATED EVH1 DOMAIN-CONTAINING PROTEIN 3; SPRED3__:____:__
Asterisk__:__609294__:__SEMAPHORIN 6C; SEMA6C__:__KIAA1869__:__
Asterisk__:__609295__:__SEMAPHORIN 6D; SEMA6D__:__KIAA1479__:__
Percent__:__609296__:__B-CELL IMMUNODEFICIENCY, DISTAL LIMB ANOMALIES, AND UROGENITAL MALFORMATIONS__:__BILU SYNDROME;; HOFFMAN SYNDROME__:__
Asterisk__:__609297__:__SEMAPHORIN 5A; SEMA5A__:__SEMAPHORIN F; SEMAF; SEMF__:__
Asterisk__:__609298__:__SEMAPHORIN 5B; SEMA5B__:__SEMAPHORIN G; SEMAG; SEMG;; KIAA1445__:__
Percent__:__609299__:__PROSTATE CANCER, HEREDITARY, 5; HPC5__:____:__
Asterisk__:__609300__:__CYTOCHROME P450, FAMILY 17, SUBFAMILY A, POLYPEPTIDE 1; CYP17A1__:__STEROID 17-ALPHA-MONOOXYGENASE;; CYTOCHROME P450, SUBFAMILY XVII;; CYP17;; P450C17;; S17AH;; STEROID 17-HYDROXYLASE/17,20-LYASE__:__
Asterisk__:__609301__:__p53 EFFECTOR RELATED TO PMP22; PERP__:__THW__:__
Asterisk__:__609302__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, GLUTAMATE), MEMBER 22; SLC25A22__:__GLUTAMATE CARRIER 1; GC1__:__
Asterisk__:__609303__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, GLUTAMATE), MEMBER 18; SLC25A18__:__GLUTAMATE CARRIER 2; GC2__:__
Number Sign__:__609304__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 3; EIEE3__:____:__
Asterisk__:__609305__:__LATEXIN; LXN__:__ENDOGENOUS CARBOXYPEPTIDASE INHIBITOR; ECI;; TISSUE CARBOXYPEPTIDASE INHIBITOR; TCI__:__
Number Sign__:__609306__:__SPINOCEREBELLAR ATAXIA 26; SCA26__:____:__
Number Sign__:__609307__:__SPINOCEREBELLAR ATAXIA 27; SCA27__:__CEREBELLAR ATAXIA, AUTOSOMAL DOMINANT, FGF14-RELATED__:__
Number Sign__:__609308__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 11; LGMDR11;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2K; LGMD2K__:__
Asterisk__:__609309__:__MutS, E. COLI, HOMOLOG OF, 2; MSH2__:____:__
Number Sign__:__609310__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 2; HNPCC2__:__COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 2; FCC2;; COCA2__:__
Number Sign__:__609311__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4H; CMT4H__:__CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4H;; CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4H;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 4H__:__
Asterisk__:__609312__:__DOPAMINE BETA-HYDROXYLASE, PLASMA; DBH__:__DOPAMINE BETA-MONOOXYGENASE__:__
Number Sign__:__609313__:__MENTAL RETARDATION, ENTEROPATHY, DEAFNESS, PERIPHERAL NEUROPATHY, ICHTHYOSIS, AND KERATODERMA; MEDNIK__:__ERYTHROKERATODERMIA VARIABILIS 3; EKV3;; ERYTHROKERATODERMIA VARIABILIS, KAMOURASKA TYPE__:__
Asterisk__:__609314__:__RADIAL SPOKE HEAD 1, CHLAMYDOMONAS, HOMOLOG OF; RSPH1__:__TSA2;; MALE MEIOTIC METAPHASE CHROMOSOME-ASSOCIATED ACIDIC PROTEIN; MEICHROACIDIN;; TESTIS-SPECIFIC PROTEIN 2; TSGA2__:__
Asterisk__:__609315__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 7; TRIM7__:__GLYCOGEN-INTERACTING PROTEIN; GNIP__:__
Asterisk__:__609316__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 31; TRIM31__:__HCGI__:__
Asterisk__:__609317__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 36; TRIM36__:__RBCC728__:__
Asterisk__:__609318__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 45; TRIM45__:____:__
Percent__:__609319__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HCHGQ1__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 6__:__
Percent__:__609320__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 2; HCHGQ2__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 9__:__
Asterisk__:__609321__:__SAS6 CENTRIOLAR ASSEMBLY PROTEIN; SASS6__:__SAS6, C. ELEGANS, HOMOLOG OF; SAS6__:__
Number Sign__:__609322__:__RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1__:__BRAIN TUMOR, POSTERIOR FOSSA, OF INFANCY, FAMILIAL__:__MALIGNANT RHABDOID TUMOR, SOMATIC, INCLUDED;; RHABDOID TUMOR, INCLUDED; RDT, INCLUDED;; TERATOID TUMOR, ATYPICAL, INCLUDED;; AT/RT, INCLUDED
Asterisk__:__609323__:__OLIGODENDROCYTE LINEAGE TRANSCRIPTION FACTOR 3; OLIG3__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 7; BHLHB7__:__
Percent__:__609324__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH SEVERE PROXIMAL FEMORAL DYSPLASIA__:____:__
Percent__:__609325__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH MINIEPIPHYSES__:____:__
Asterisk__:__609326__:__MICRO RNA 1-1; MIR1-1__:__miRNA1-1;; MIRN1-1__:__
Asterisk__:__609327__:__MICRO RNA 124-1; MIR124-1__:__miRNA124-1;; MIRN124-1;; miRNA124A1;; MIR124A1;; MIRN124A1__:__
Asterisk__:__609328__:__URIDINE/CYTIDINE KINASE 1; UCK1__:____:__
Asterisk__:__609329__:__URIDINE/CYTIDINE KINASE 2; UCK2__:__TSA903__:__
Asterisk__:__609330__:__ONCOPROTEIN-INDUCED TRANSCRIPT 3, MOUSE, HOMOLOG OF; OIT3__:__LIVER-SPECIFIC ZONA PELLUCIDA DOMAIN-CONTAINING PROTEIN; LZP__:__
Asterisk__:__609331__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER E23; BHLHE23__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 4; BHLHB4__:__
Asterisk__:__609332__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 7A; TTC7A__:__TTC7;; KIAA1140__:__
Asterisk__:__609333__:__TRACE AMINE-ASSOCIATED RECEPTOR 1; TAAR1__:__TAR1; TA1__:__
Number Sign__:__609334__:__CHROMOSOME 18 PERICENTRIC INVERSION__:____:__
Asterisk__:__609335__:__ODORANT RESPONSE ABNORMAL 4, C. ELEGANS, HOMOLOG OF; ODR4__:__ODR4 GPCR LOCALIZATION FACTOR HOMOLOG;; CHROMOSOME 1 OPEN READING FRAME 27; C1ORF27__:__
Asterisk__:__609336__:__ANGIOPOIETIN-LIKE 6; ANGPTL6__:__ANGIOPOIETIN-RELATED GROWTH FACTOR; AGF__:__
Asterisk__:__609337__:__MICRO RNA 155; MIR155__:__miRNA155;; MIRN155__:__BIC TRANSCRIPT, INCLUDED; BIC, INCLUDED
Number Sign__:__609338__:__CAROTID INTIMAL MEDIAL THICKNESS 1__:__CIMT1;; INTIMAL MEDIAL THICKNESS OF INTERNAL CAROTID ARTERY__:__
Caret__:__609339__:__MOVED TO 265000__:____:__
Number Sign__:__609340__:__SPASTIC PARAPLEGIA 28, AUTOSOMAL RECESSIVE; SPG28__:____:__
Asterisk__:__609341__:__TRYPTASE, GAMMA-1; TPSG1__:__TRYPTASE, GAMMA;; TRANSMEMBRANE TRYPTASE; TMT__:__
Asterisk__:__609342__:__GASTRIC INTRINSIC FACTOR; GIF__:__IF__:__
Asterisk__:__609343__:__PROTEASE, SERINE, 22; PRSS22__:__TRYPTASE, EPSILON__:__
Asterisk__:__609344__:__KIELIN/CHORDIN-LIKE PROTEIN__:__KCP;; KIELIN-LIKE PROTEIN__:__
NULL__:__609345__:__CEREBRORENODIGITAL SYNDROME WITH LIMB MALFORMATIONS AND TRIRADIATE ACETABULA__:____:__
Asterisk__:__609346__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 6; REEP6__:__DELETED IN POLYPOSIS 1-LIKE 1; DP1L1;; TB2-LIKE 1; TB2L1;; CHROMOSOME 19 OPEN READING FRAME 32; C19ORF32__:__
Asterisk__:__609347__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 2; REEP2__:__SGC32445;; CHROMOSOME 5 OPEN READING FRAME 19; C5ORF19__:__
Asterisk__:__609348__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 3; REEP3__:__CHROMOSOME 10 OPEN READING FRAME 74; C10ORF74__:__
Asterisk__:__609349__:__RECEPTOR EXPRESSION-ENHANCING PROTEIN 4; REEP4__:__CHROMOSOME 8 OPEN READING FRAME 20; C8ORF20__:__
Asterisk__:__609350__:__RECEPTOR-TRANSPORTING PROTEIN 4; RTP4__:____:__
Asterisk__:__609351__:__ADP-RIBOSYLATION FACTOR-LIKE 11; ARL11__:__ADP-RIBOSYLATION FACTOR-LIKE TUMOR SUPPRESSOR 1; ARLTS1__:__
Number Sign__:__609352__:__EPIDERMOLYSIS BULLOSA SIMPLEX WITH MIGRATORY CIRCINATE ERYTHEMA__:____:__
Asterisk__:__609353__:__ESTABLISHMENT OF COHESION 1, S. CEREVISIAE, HOMOLOG OF, 2; ESCO2__:__ECO1, S. CEREVISIAE, HOMOLOG OF, 2;; CTF7, S. CEREVISIAE, HOMOLOG OF, 2;; ESO1, S. POMBE, HOMOLOG OF, 2;; ESTABLISHMENT FACTOR ORTHOLOG 2; EFO2__:__
Percent__:__609354__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 5; BMND5__:____:__
Asterisk__:__609355__:__MICRO RNA 32; MIR32__:__miRNA32;; MIRN32__:__
Asterisk__:__609356__:__NUCLEAR FMRP-INTERACTING PROTEIN 2; NUFIP2__:__FMRP-INTERACTING PROTEIN, 82-KD;; 82-FIP;; KIAA1321;; PROLIFERATION-INDUCING GENE 1; PIG1__:__
Asterisk__:__609357__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 10; MCM10__:__MINICHROMOSOME MAINTENANCE 10, S. CEREVISIAE, HOMOLOG OF;; DNA43__:__
Asterisk__:__609358__:__ETS VARIANT GENE 2; ETV2__:__ETS-RELATED PROTEIN 71, MOUSE, HOMOLOG OF; ER71; ETSRP71__:__
Asterisk__:__609359__:__HS1-BINDING PROTEIN 3; HS1BP3__:__FLJ14249__:__
Asterisk__:__609360__:__RENALASE; RNLS__:__CHROMOSOME 10 OPEN READING FRAME 59; C10ORF59__:__
Asterisk__:__609361__:__MOB FAMILY, MEMBER 4; MOB4__:__PHOCEIN;; MOB1-LIKE PROTEIN 3; MOBKL3;; MOB1;; MOB3;; PREIMPLANTATION PROTEIN 3, MOUSE, HOMOLOG OF; PREI3__:__
Asterisk__:__609362__:__LYSOPHOSPHOLIPASE 3; LYPLA3__:__LCAT-LIKE LYSOPHOSPHOLIPASE; LLPL;; ACYLCERAMIDE SYNTHASE; ACS;; LYSOSOMAL PHOSPHOLIPASE A2; LPLA2__:__
NULL__:__609363__:__COLLOID CYSTS OF THIRD VENTRICLE__:__NEUROEPITHELIAL CYSTS OF THIRD VENTRICLE__:__
Asterisk__:__609364__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 2; NLRP2__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 2; NALP2;; PYRIN DOMAIN- AND NACHT DOMAIN-CONTAINING PROTEIN 1; PAN1;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 2; PYPAF2__:__
Asterisk__:__609365__:__GUANINE NUCLEOTIDE-BINDING PROTEIN-LIKE 2; GNL2__:__NGP1__:__
Asterisk__:__609366__:__SH2 DOMAIN-BINDING PROTEIN 1; SH2BP1__:__TETRATRICOPEPTIDE-CONTAINING SH2-BINDING PHOSPHOPROTEIN, 150-KD;; p150(TSP);; CTR9, S. CEREVISIAE, HOMOLOG OF;; KIAA0155__:__
Asterisk__:__609367__:__KIAA1279 GENE; KIAA1279__:__KINESIN-BINDING PROTEIN; KBP__:__
Asterisk__:__609368__:__ATLASTIN GTPase 2; ATL2__:__ADP-RIBOSYLATION-LIKE FACTOR 6-INTERACTING PROTEIN 2; ARL6IP2;; ARL6-INTERACTING PROTEIN 2__:__
Asterisk__:__609369__:__ATLASTIN GTPase 3; ATL3__:____:__
Asterisk__:__609370__:__SERINE/THREONINE KINASE 35; STK35__:__CLP36-INTERACTING KINASE; CLIK1__:__
Asterisk__:__609371__:__CHROMOSOME 5 OPEN READING FRAME 5; C5ORF5__:____:__
Asterisk__:__609372__:__FAMILY WITH SEQUENCE SIMILARITY 53, MEMBER C; FAM53C__:__CHROMOSOME 5 OPEN READING FRAME 6; C5ORF6__:__
Asterisk__:__609373__:__LYSINE-SPECIFIC DEMETHYLASE 3B; KDM3B__:__K-SPECIFIC DEMETHYLASE 3B;; CHROMOSOME 5 OPEN READING FRAME 7; C5ORF7;; KIAA1082;; JUMONJI DOMAIN-CONTAINING PROTEIN 1B, FORMERLY; JMJD1B, FORMERLY__:__
Asterisk__:__609374__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 5; CDCA5__:__SORORIN__:__
Asterisk__:__609375__:__LIN9, C. ELEGANS, HOMOLOG OF; LIN9__:____:__
Percent__:__609376__:__CATARACT 35; CTRCT35__:__CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 1; CATCN1__:__
Asterisk__:__609377__:__ACD, MOUSE, HOMOLOG OF; ACD__:__POT1- AND TIN2-ORGANIZING PROTEIN; PTOP;; POT1-INTERACTING PROTEIN 1; PIP1;; TIN2-INTERACTING PROTEIN 1; TINT1;; TELOMERE PROTEIN TPP1__:__
Percent__:__609378__:__AUTISM, SUSCEPTIBILITY TO, 6; AUTS6__:____:__
Asterisk__:__609379__:__LIPOCALIN 6; LCN6__:____:__
Asterisk__:__609380__:__LEISHMANOLYSIN-LIKE; LMLN__:__INVADOLYSIN, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__609381__:__SYNTAXIN-BINDING PROTEIN 5-LIKE; STXBP5L__:__LETHAL GIANT LARVAE, DROSOPHILA, HOMOLOG OF, 4; LLGL4__:__
Asterisk__:__609382__:__IMMEDIATE-EARLY RESPONSE 3-INTERACTING PROTEIN 1; IER3IP1__:____:__
Asterisk__:__609383__:__NIPA-LIKE DOMAIN-CONTAINING 4; NIPAL4__:__ICHTHYIN; ICHYN__:__
Percent__:__609384__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 3C; CFEOM3C__:__FEOM4 LOCUS__:__
Asterisk__:__609385__:__DEAD END, ZEBRAFISH, HOMOLOG OF, 1; DND1__:____:__
Asterisk__:__609386__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 5; SMC5__:__SMC5-LIKE 1; SMC5L1;; KIAA0594__:__
Asterisk__:__609387__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES 6; SMC6__:__SMC6-LIKE 1; SMC6L1__:__
Asterisk__:__609388__:__METHYLTRANSFERASE-LIKE 9; METTL9__:__DORA REVERSE STRAND; DREV__:__
Asterisk__:__609389__:__INOSITOL POLYPHOSPHATE 5-PHOSPHATASE F; INPP5F__:__SAC DOMAIN-CONTAINING INOSITOL PHOSPHATASE 2; SAC2;; KIAA0966__:__
Asterisk__:__609390__:__FIG4, S. CEREVISIAE, HOMOLOG OF; FIG4__:__SAC DOMAIN-CONTAINING INOSITOL PHOSPHATASE 3; SAC3;; KIAA0274__:__
Asterisk__:__609391__:__TRANSCRIPTION FACTOR Sp5; SP5__:__SPECIFICITY PROTEIN 5__:__
Asterisk__:__609392__:__KRUPPEL-LIKE FACTOR 3; KLF3__:__BASIC KRUPPEL-LIKE FACTOR; BKLF__:__
Asterisk__:__609393__:__KRUPPEL-LIKE FACTOR 14; KLF14__:__BASIC TRANSCRIPTION ELEMENT-BINDING PROTEIN 5; BTEB5__:__
Asterisk__:__609394__:__SPC24, NDC80 KINETOCHORE COMPLEX COMPONENT; SPC24__:__SPINDLE POLE BODY COMPONENT 24, S. CEREVISIAE, HOMOLOG OF; SPBC24 SPC24, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__609395__:__SPC25, NDC80 KINETOCHORE COMPLEX COMPONENT; SPC25__:__SPINDLE POLE BODY COMPONENT 25, S. CEREVISIAE, HOMOLOG OF; SPBC25;; SPC25, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__609396__:__PH DOMAIN AND LEUCINE-RICH REPEAT PROTEIN PHOSPHATASE 1; PHLPP1__:__PHLPP;; SUPRACHIASMATIC NUCLEUS CIRCADIAN OSCILLATORY PROTEIN; SCOP;; KIAA0606__:__
Asterisk__:__609397__:__STORKHEAD BOX 1; STOX1__:____:__
Asterisk__:__609398__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 34-KD, V1 SUBUNIT D; ATP6V1D__:__ATP6M__:__
Asterisk__:__609399__:__SPERM EQUATORIAL SEGMENT PROTEIN 1; SPESP1__:____:__
Percent__:__609400__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 4; AIS4__:__VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 5; VAMAS5;; AUTOIMMUNE DISEASE SUSCEPTIBILITY LOCUS, CHROMOSOME 4-RELATED__:__
Asterisk__:__609401__:__HEPARAN SULFATE 6-O-SULFOTRANSFERASE 3; HS6ST3__:____:__
Percent__:__609402__:__PREECLAMPSIA/ECLAMPSIA 2; PEE2__:____:__
Percent__:__609403__:__PREECLAMPSIA/ECLAMPSIA 3; PEE3__:____:__
Number Sign__:__609404__:__PREECLAMPSIA/ECLAMPSIA 4; PEE4__:____:__
Asterisk__:__609405__:__RHO GTPase-ACTIVATING PROTEIN 8; ARHGAP8__:__GTPase-ACTIVATING PROTEIN, RHO, 8;; BCH DOMAIN-CONTAINING, PROLINE-RICH, AND CDC42GAP-LIKE PROTEIN 1; BPGAP1__:__
Asterisk__:__609406__:__PROLINE-RICH PROTEIN 5; PRR5__:__PP610;; PROTEIN OBSERVED WITH RICTOR 1; PROTOR1__:__
Asterisk__:__609407__:__HEPARAN SULFATE (GLUCOSAMINE) 3-O-SULFOTRANSFERASE 5; HS3ST5__:__3OST5__:__
Percent__:__609408__:__HOLOPROSENCEPHALY 8; HPE8__:____:__
Asterisk__:__609409__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A0; HNRNPA0__:__HNRPA0__:__
Asterisk__:__609410__:__SYNAPTOJANIN 2; SYNJ2__:__KIAA0348__:__
Asterisk__:__609411__:__SYNAPTOJANIN 2-BINDING PROTEIN; SYNJ2BP__:__SYNJ2-BINDING PROTEIN;; OUTER MEMBRANE PROTEIN, 25-KD; OMP25;; ACTIVIN RECEPTOR-INTERACTING PROTEIN 2; ARIP2__:__
Asterisk__:__609412__:__EXCISION REPAIR CROSS-COMPLEMENTING, GROUP 8; ERCC8__:__CSA GENE;; CKN1 GENE__:__
Asterisk__:__609413__:__EXCISION REPAIR CROSS-COMPLEMENTING, GROUP 6; ERCC6__:__RAD26, S. CEREVISIAE, HOMOLOG OF;; CSB GENE__:__PIGGYBAC TRANSPOSABLE ELEMENT-DERIVED 3, INCLUDED; PGBD3, INCLUDED;; CSB/PGBD3 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED;; CSB/PGBD3 PROTEIN, INCLUDED;; ERCC6/PGBD3 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED;; ERCC6/PGBD3 PROTEIN, INCLUDED
Asterisk__:__609414__:__PHOSPHOINOSITIDE KINASE, FYVE FINGER-CONTAINING; PIKFYVE__:__PHOSPHATIDYLINOSITOL 3-PHOSPHATE 5-KINASE, TYPE III; PIP5K3;; FAB1, S. CEREVISIAE, HOMOLOG OF; FAB1;; KIAA0981__:__
Asterisk__:__609415__:__MICRO RNA 17 HOST GENE; MIR17HG__:__MIR17 HOST GENE;; MIR17-92 CLUSTER HOST GENE;; MICRO RNA HOST GENE 1; MIRHG1; MIHG1; MIRH1;; ONCOMIR1 HOST GENE;; CHROMOSOME 13 OPEN READING FRAME 25; C13ORF25__:__MIR17-92 CLUSTER, INCLUDED;; ONCOMIR1, INCLUDED
Asterisk__:__609416__:__MICRO RNA 17; MIR17__:__miRNA17;; MIRN17;; MIR17-5p;; MICRO RNA 91; MIR91;; miRNA91;; MIRN91__:__MICRO RNA 17*, INCLUDED; MIR17*, INCLUDED;; MIR17-3p, INCLUDED
Asterisk__:__609417__:__MICRO RNA 18A; MIR18A__:__miRNA18A;; MIRN18A__:__
Asterisk__:__609418__:__MICRO RNA 19A; MIR19A__:__miRNA19A;; MIRN19A__:__
Asterisk__:__609419__:__MICRO RNA 19B1; MIR19B1__:__miRNA19B1;; MIRN19B1__:__
Asterisk__:__609420__:__MICRO RNA 20A; MIR20A__:__miRNA20A;; MIRN20A__:__
Caret__:__609421__:__MOVED TO 609416__:____:__
Asterisk__:__609422__:__MICRO RNA 92A1; MIR92A1__:__miRNA92A1;; MIRN92A1;; MIR92-1;; MIRN92-1;; miRNA92-1__:__
Number Sign__:__609423__:__HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO__:__HIV-1, SUSCEPTIBILITY TO__:__HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, RESISTANCE TO, INCLUDED;; HIV-1, RESISTANCE TO, INCLUDED;; ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO, INCLUDED;; AIDS, PROGRESSION TO, INCLUDED
Asterisk__:__609424__:__RING FINGER AND CCCH-TYPE ZINC FINGER DOMAINS-CONTAINING 1; RC3H1__:__ROQUIN;; KIAA2025__:__
Number Sign__:__609425__:__CHROMOSOME 3q29 DELETION SYNDROME__:__MICRODELETION 3q29 SYNDROME__:__
Asterisk__:__609426__:__MISSHAPEN/NIK-RELATED KINASE 1; MINK1__:__MINK;; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 6; MAP4K6__:__
Asterisk__:__609427__:__LHFP-LIKE PROTEIN 5; LHFPL5__:__TETRASPAN MEMBRANE PROTEIN OF HAIR CELL STEREOCILIA; TMHS__:__
Percent__:__609428__:__TUKEL SYNDROME__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, WITH ULNAR HAND ANOMALIES;; CFEOM-U;; FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 4; CFEOM4__:__
Asterisk__:__609429__:__FORKHEAD BOX N4; FOXN4__:____:__
Asterisk__:__609430__:__NEURONAL PAS DOMAIN PROTEIN 3; NPAS3__:__MEMBER OF PAS SUPERFAMILY 6; MOP6__:__
Asterisk__:__609431__:__MAP3K12-BINDING INHIBITORY PROTEIN; MBIP__:__MUK-BINDING INHIBITORY PROTEIN__:__
Number Sign__:__609432__:__SYNDACTYLY, MESOAXIAL SYNOSTOTIC, WITH PHALANGEAL REDUCTION; MSSD__:__SYNDACTYLY, MALIK-PERCIN TYPE;; SYNDACTYLY, TYPE IX__:__
Asterisk__:__609433__:__UBIQUITIN INTERACTION MOTIF-CONTAINING PROTEIN 1; UIMC1__:__RECEPTOR-ASSOCIATED PROTEIN, 80-KD; RAP80__:__
Asterisk__:__609434__:__LUC7, S. CEREVISIAE, HOMOLOG OF, 3; LUC7L3__:__LUC7-LIKE 3;; CISPLATIN RESISTANCE-ASSOCIATED OVEREXPRESSED PROTEIN; CROP;; LUC7A__:__
Asterisk__:__609435__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 13; NDUFA13__:__GENE ASSOCIATED WITH RETINOID- AND INTERFERON-INDUCED MORTALITY 19; GRIM19__:__
Asterisk__:__609436__:__FIBROBLAST GROWTH FACTOR 21; FGF21__:____:__
Asterisk__:__609437__:__SERINE/THREONINE PROTEIN KINASE 40; STK40__:__SINK-HOMOLOGOUS INHIBITORY KINASE; SHIK__:__
NULL__:__609438__:__MENTAL RETARDATION, KERATOCONUS, FEBRILE SEIZURES, AND SINOATRIAL BLOCK__:____:__
Number Sign__:__609439__:__DEAFNESS, AUTOSOMAL RECESSIVE 48; DFNB48__:____:__
Asterisk__:__609440__:__UTP11-LIKE PROTEIN; UTP11L__:__CGI94__:__
Number Sign__:__609441__:__ACROMESOMELIC DYSPLASIA, DEMIRHAN TYPE; AMDD__:__CHONDRODYSPLASIA, ACROMESOMELIC, WITH OR WITHOUT GENITAL ANOMALIES__:__
NULL__:__609442__:__VALPROATE EMBRYOPATHY, SUSCEPTIBILITY TO__:__FETAL VALPROATE SYNDROME; FVS__:__
Asterisk__:__609443__:__CHYMOTRYPSIN-LIKE ELASTASE FAMILY, MEMBER 2A; CELA2A__:__ELASTASE 2A; ELA2A;; PANCREATIC ELASTASE 2A__:__
Asterisk__:__609444__:__CHYMOTRYPSIN-LIKE ELASTASE FAMILY, MEMBER 2B; CELA2B__:__ELASTASE 2B; ELA2B;; PANCREATIC ELASTASE 2B__:__
Asterisk__:__609445__:__RELAXIN/INSULIN-LIKE FAMILY PEPTIDE RECEPTOR 3; RXFP3__:__RELAXIN 3 RECEPTOR 1; RLN3R1;; RLN3 RECEPTOR 1;; SOMATOSTATIN- AND ANGIOTENSIN-LIKE PEPTIDE RECEPTOR; SALPR;; G PROTEIN-COUPLED RECEPTOR 135; GPCR135__:__
Number Sign__:__609446__:__PAROXYSMAL NONKINESIGENIC DYSKINESIA, 3, WITH OR WITHOUT GENERALIZED EPILEPSY; PNKD3__:__GENERALIZED EPILEPSY AND PAROXYSMAL DYSKINESIA; GEPD__:__
Asterisk__:__609447__:__MARGINAL ZONE B AND B1 CELL-SPECIFIC PROTEIN; MZB1__:__PROAPOPTOTIC CASPASE ADAPTOR PROTEIN; PACAP;; MGC29506__:__
Asterisk__:__609448__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 12; TXNDC12__:__THIOREDOXIN-LIKE PROTEIN p19; TLP19;; ENDOPLASMIC RETICULUM PROTEIN, 18-KD; ERP18;; ANTERIOR GRADIENT 1, XENOPUS, HOMOLOG OF; AGR1__:__
Asterisk__:__609449__:__NUDE NEURODEVELOPMENT PROTEIN 1; NDE1__:__NUDE, A. NIDULANS, HOMOLOG OF, 1;; NUDE;; HOM-TES-87__:__
Asterisk__:__609450__:__MAX DIMERIZATION PROTEIN 3; MXD3__:__MAD3__:__
Asterisk__:__609451__:__ZINC FINGER PROTEIN 90, MOUSE, HOMOLOG OF; ZFP90__:__NK10;; KIAA1954__:__FOXP3-INTERACTING KRAB DOMAIN-CONTAINING PROTEIN, INCLUDED; FIK, INCLUDED
Number Sign__:__609452__:__MYOPATHY, MYOFIBRILLAR, 4; MFM4__:____:__
Asterisk__:__609453__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 7; GOLGA7__:__GOLGI COMPLEX-ASSOCIATED PROTEIN, 16-KD; GCP16__:__
Percent__:__609454__:__SUPRANUCLEAR PALSY, PROGRESSIVE, 2; PSNP2__:____:__
Asterisk__:__609455__:__PROLINE-, GLUTAMIC ACID-, AND LEUCINE-RICH PROTEIN 1; PELP1__:__MNAR__:__
Percent__:__609456__:__MUSCULAR DYSTROPHY, CONGENITAL, MEROSIN-POSITIVE__:____:__
Asterisk__:__609457__:__HISTIDINE AMMONIA-LYASE; HAL__:__HISTIDASE__:__
Asterisk__:__609458__:__MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1__:__MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN__:__
Asterisk__:__609459__:__DIGEORGE SYNDROME CRITICAL REGION GENE 6-LIKE; DGCR6L__:____:__
Number Sign__:__609460__:__GOLDBERG-SHPRINTZEN SYNDROME; GOSHS__:__GOLDBERG-SHPRINTZEN MEGACOLON SYNDROME__:__
Asterisk__:__609461__:__TRIBBLES, DROSOPHILA, HOMOLOG OF, 1; TRIB1__:__TRB1;; SKIP1;; C8FW__:__
Asterisk__:__609462__:__TRIBBLES, DROSOPHILA, HOMOLOG OF, 2; TRIB2__:__TRB2;; C5FW;; GS3955__:__
Asterisk__:__609463__:__MKL/MYOCARDIN-LIKE 2; MKL2__:__MYOCARDIN-RELATED TRANSCRIPTION FACTOR B, MOUSE, HOMOLOG OF; MRTFB__:__MKL2/C11ORF95 FUSION GENE, INCLUDED
Caret__:__609464__:__MOVED TO 186580__:____:__
NULL__:__609465__:__AL-GAZALI SYNDROME__:____:__
NULL__:__609466__:__CLEFT PALATE, MIDFACIAL HYPOPLASIA, TRIANGULAR FACIES, AND SENSORINEURAL HEARING LOSS__:____:__
Asterisk__:__609467__:__CHEMOKINE, CC MOTIF, LIGAND 3-LIKE 2; CCL3L2__:__LD78-GAMMA;; G0S19-3;; G0S19-GAMMA__:__
Asterisk__:__609468__:__CHEMOKINE, CC MOTIF, LIGAND 3-LIKE 3; CCL3L3__:____:__
Percent__:__609469__:__NEPHROPATHY, PROGRESSIVE, WITH DEAFNESS__:__NEDE;; ALPORT/FOCAL SEGMENTAL GLOMERULOSCLEROSIS-LIKE SYNDROME__:__
Percent__:__609470__:__LEFT VENTRICULAR NONCOMPACTION 2; LVNC2__:____:__
Asterisk__:__609471__:__GLUCOSIDASE, BETA, ACID 2; GBA2__:__BETA-GLUCOSIDASE, BILE ACID;; BILE ACID BETA-GLUCOSIDASE;; KIAA1605;; GLUCOSYLCERAMIDASE, NONLYSOSOMAL__:__
Asterisk__:__609472__:__CYCLIC NUCLEOTIDE-GATED CHANNEL, ALPHA-4; CNGA4__:____:__
Asterisk__:__609473__:__CINGULIN, XENOPUS, HOMOLOG OF; CGN__:__KIAA1319__:__
Asterisk__:__609474__:__NEURONAL PENTRAXIN RECEPTOR; NPTXR__:__NPR__:__
Asterisk__:__609475__:__A-KINASE ANCHOR PROTEIN 8-LIKE PROTEIN; AKAP8L__:__AKAP8-LIKE PROTEIN;; HOMOLOGOUS TO AKAP95; HA95;; NEIGHBOR OF AKAP95; NAKAP95; NAKAP;; HELICASE A-BINDING PROTEIN, 95-KD; HAP95__:__
Asterisk__:__609476__:__NEMO-LIKE KINASE; NLK__:____:__
Asterisk__:__609477__:__SINGLE-PASS MEMBRANE PROTEIN WITH COILED-COIL DOMAINS 4; SMCO4__:__CHROMOSOME 11 OPEN READING FRAME 75; C11ORF75;; FN5, PUFFERFISH, HOMOLOG OF; FN5__:__
Asterisk__:__609478__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 3; ST8SIA3__:__ALPHA-2,8-SIALYLTRANSFERASE III;; ST8SIA III__:__
Asterisk__:__609479__:__LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE; ZAK__:__MLK-LIKE MITOGEN-ACTIVATED PROTEIN TRIPLE KINASE; MLTK;; MLK-RELATED KINASE; MRK__:__
Caret__:__609480__:__MOVED TO 194521__:____:__
Asterisk__:__609481__:__ISL2 TRANSCRIPTION FACTOR, LIM/HOMEODOMAIN; ISL2__:__ISLET 2__:__
Asterisk__:__609482__:__ANTERIOR GRADIENT 3, XENOPUS, HOMOLOG OF; AGR3__:__BREAST CANCER MEMBRANE PROTEIN 11; BCMP11__:__
Asterisk__:__609483__:__FAMILY WITH SEQUENCE SIMILARITY 84, MEMBER B; FAM84B__:__BREAST CANCER MEMBRANE PROTEIN 101; BCMP101__:__
Asterisk__:__609484__:__LY6/PLAUR DOMAIN-CONTAINING PROTEIN 3; LYPD3__:__GPI-ANCHORED METASTASIS-ASSOCIATED PROTEIN C4.4A;; C4.4A__:__
Asterisk__:__609485__:__MODULATOR OF APOPTOSIS 1; MOAP1__:__MAP1;; PARANEOPLASTIC MA ANTIGEN FAMILY, MEMBER 4; PNMA4;; PARANEOPLASTIC ANTIGEN-LIKE PROTEIN 4__:__
Asterisk__:__609486__:__E2F-ASSOCIATED PHOSPHOPROTEIN; EAPP__:__CHROMOSOME 14 OPEN READING FRAME 11; C14ORF11__:__
Asterisk__:__609487__:__MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2; MAP3K2__:__MAP/ERK KINASE KINASE 2; MEKK2__:__
Asterisk__:__609488__:__CANCER/TESTIS ANTIGEN KM-HN-1__:__MGC33607__:__
Asterisk__:__609489__:__MANNOSIDASE, BETA A, LYSOSOMAL; MANBA__:__MANB1;; MANNANASE;; MANNASE__:__
Asterisk__:__609490__:__INHIBITORY CASPASE RECRUITMENT DOMAIN PROTEIN__:__INCA__:__
Asterisk__:__609491__:__G PROTEIN SIGNALING MODULATOR 1; GPSM1__:__ACTIVATOR OF G PROTEIN SIGNALING 3; AGS3__:__
Asterisk__:__609492__:__RAS ASSOCIATION DOMAIN FAMILY PROTEIN 2; RASSF2__:__RASFADIN;; KIAA0168__:__
Asterisk__:__609493__:__SLC2A4 REGULATOR; SLC2A4RG__:__GLUT4 ENHANCER FACTOR; GEF;; HD GENE REGULATORY REGION-BINDING PROTEIN 1; HDBP1__:__
Asterisk__:__609494__:__ZINC FINGER PROTEIN 395; ZNF395__:__PAPILLOMAVIRUS-BINDING FACTOR; PBF;; HD GENE REGULATORY REGION-BINDING PROTEIN 2; HDBP2__:__
Asterisk__:__609495__:__GAMETOGENETIN-BINDING PROTEIN 1; GGNBP1__:____:__
Caret__:__609496__:__MOVED TO 609814__:____:__
Asterisk__:__609497__:__ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2; ERAP2__:__LEUKOCYTE-DERIVED ARGININE AMINOPEPTIDASE; LRAP__:__
Asterisk__:__609498__:__F-BOX ONLY PROTEIN 47__:__FBXO47__:__
Asterisk__:__609499__:__MCF2-LIKE PROTEIN; MCF2L__:__OST;; KIAA0362__:__
Percent__:__609500__:__MYOPATHY, AUTOPHAGIC VACUOLAR, INFANTILE-ONSET__:____:__
Asterisk__:__609501__:__TUDOR AND KH DOMAINS-CONTAINING PROTEIN; TDRKH__:____:__
Asterisk__:__609502__:__CADHERIN-RELATED FAMILY, MEMBER 1; CDHR1__:__PROTOCADHERIN 21; PCDH21;; PHOTORECEPTOR CADHERIN; PRCAD__:__
Asterisk__:__609503__:__TESTICULAR HAPLOID EXPRESSED GENE, MOUSE, HOMOLOG OF; THEG__:____:__
Asterisk__:__609504__:__MICROSPHERULE PROTEIN 1; MCRS1__:__p78__:__MICROSPHERULE PROTEIN, 58-KD, INCLUDED; MSP58, INCLUDED;; MICROSPHERULE PROTEIN 2, INCLUDED; MCRS2, INCLUDED
Asterisk__:__609505__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 16; TRIM16__:__ESTROGEN-RESPONSIVE B-BOX PROTEIN; EBBP__:__
Asterisk__:__609506__:__CYTOCHROME P450, SUBFAMILY XXVIIB, POLYPEPTIDE 1; CYP27B1__:__25-HYDROXYVITAMIN D3-1-ALPHA-HYDROXYLASE;; 1-ALPHA-HYDROXYLASE;; P450C1-ALPHA__:__
Asterisk__:__609507__:__TOPOISOMERASE I-BINDING ARGININE/SERINE-RICH PROTEIN; TOPORS__:__p53-BINDING PROTEIN 3; P53BP3;; LUN__:__
Number Sign__:__609508__:__STICKLER SYNDROME, TYPE I, NONSYNDROMIC OCULAR__:__STICKLER SYNDROME, TYPE I, PREDOMINANTLY OCULAR;; STICKLER SYNDROME, ATYPICAL__:__RHEGMATOGENOUS RETINAL DETACHMENT, AUTOSOMAL DOMINANT, INCLUDED; DRRD, INCLUDED
Asterisk__:__609509__:__INTERLEUKIN 31; IL31__:____:__
Asterisk__:__609510__:__INTERLEUKIN 31 RECEPTOR A; IL31RA__:__GP130-LIKE MONOCYTE RECEPTOR; GLMR;; GP130-LIKE RECEPTOR; GPL__:__
Asterisk__:__609511__:__RABENOSYN, RAB EFFECTOR; RBSN__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 20; ZFYVE20;; RABENOSYN 5__:__
Asterisk__:__609512__:__CHMP FAMILY, MEMBER 2B; CHMP2B__:__CHROMATIN-MODIFYING PROTEIN 2B;; CHARGED MULTIVESICULAR BODY PROTEIN 2B;; VACUOLAR PROTEIN SORTING 2, YEAST, HOMOLOG OF, B; VPS2B__:__
Asterisk__:__609513__:__NEUROPEPTIDE S__:__NPS__:__
Asterisk__:__609514__:__TAUBE NUSS, MOUSE, HOMOLOG OF; TBN__:__TBP-ASSOCIATED FACTOR 8; TAF8;; TBP-ASSOCIATED FACTOR, RNA POLYMERASE II, 43-KD; TAFII43__:__
NULL__:__609515__:__IRIDOGONIODYSGENESIS AND SKELETAL ANOMALIES__:____:__
Asterisk__:__609516__:__ZINC FINGER PROTEIN 382; ZNF382__:__KRAB/ZINC FINGER SUPPRESSOR PROTEIN 1, RAT, HOMOLOG OF; KS1__:__
Asterisk__:__609517__:__TGFB1-INDUCED ANTIAPOPTOTIC FACTOR 1; TIAF1__:__MYOSIN CONTAINING PDZ DOMAIN; MYSPDZ;; MOLECULE ASSOCIATED WITH JAK3 N TERMINUS; MAJN;; KIAA0216__:__
Asterisk__:__609518__:__THAP DOMAIN-CONTAINING PROTEIN 7; THAP7__:____:__
Asterisk__:__609519__:__TCF3 FUSION PARTNER; TFPT__:__FB1;; AMIDA, RAT, HOMOLOG OF__:__TFPT/E2A FUSION GENE, INCLUDED
Asterisk__:__609520__:__THAP DOMAIN-CONTAINING PROTEIN 1; THAP1__:____:__
Asterisk__:__609521__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 1; SLC30A1__:__ZINC TRANSPORTER 1; ZNT1__:__
Asterisk__:__609522__:__ELONGIN A2; ELOA2__:__TRANSCRIPTION ELONGATION FACTOR B, POLYPEPTIDE 3B; TCEB3B__:__
Asterisk__:__609523__:__ALDEHYDE DEHYDROGENASE, FAMILY 3, SUBFAMILY A, MEMBER 2; ALDH3A2__:__FATTY ALDEHYDE DEHYDROGENASE; FALDH;; ALDEHYDE DEHYDROGENASE 10; ALDH10__:__
Number Sign__:__609524__:__MYOPATHY, MYOFIBRILLAR, 5; MFM5__:__MYOPATHY, MYOFIBRILLAR, FILAMIN C-RELATED;; FILAMINOPATHY, AUTOSOMAL DOMINANT__:__
Asterisk__:__609525__:__TENSION-INDUCED/INHIBITED PROTEIN__:__TIP;; FLJ13984__:__
Asterisk__:__609526__:__PLECKSTRIN HOMOLOGY DOMAIN- AND RhoGEF DOMAIN-CONTAINING PROTEIN G4; PLEKHG4__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY G, MEMBER 4;; PURATROPHIN 1;; PURKINJE CELL ATROPHY-ASSOCIATED PROTEIN 1__:__
Asterisk__:__609527__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 5; RAPGEF5__:__GUANINE NUCLEOTIDE EXCHANGE FACTOR FOR RAP1; GFR;; MRAS-REGULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR; MRGEF;; KIAA0277__:__
Number Sign__:__609528__:__CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMA SYNDROME__:__CEDNIK SYNDROME__:__
Number Sign__:__609529__:__IMMUNOGLOBULIN A DEFICIENCY 2; IGAD2__:__IMMUNOGLOBULIN A, SELECTIVE DEFICIENCY OF, TACI-RELATED;; IgA, SELECTIVE DEFICIENCY OF, TACI-RELATED__:__
Asterisk__:__609530__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; RAPGEF2__:__NEURAL RAP GUANINE NUCLEOTIDE EXCHANGE PROTEIN; NRAPGEP;; RAS-ASSOCIATING GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAGEF;; PDZ DOMAIN-CONTAINING GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; PDZGEF1;; KIAA0313__:__
Asterisk__:__609531__:__RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 3; RASGRP3__:__GRP3;; KIAA0846__:__
Number Sign__:__609532__:__HEPATITIS C VIRUS, SUSCEPTIBILITY TO__:__HCV, SUSCEPTIBILITY TO__:__HEPATITIS C VIRUS, RESISTANCE TO, INCLUDED;; HCV, RESISTANCE TO, INCLUDED;; HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF, INCLUDED
Number Sign__:__609533__:__DEAFNESS, AUTOSOMAL RECESSIVE 23; DFNB23__:____:__
Asterisk__:__609534__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 5; ATAD5__:__CHROMOSOME 17 OPEN READING FRAME 41; C17ORF41;; FRAG1;; ENHANCED LEVEL OF GENOMIC INSTABILITY 1; ELG1;; FLJ12735__:__
Number Sign__:__609535__:__DRUG METABOLISM, POOR, CYP2C19-RELATED__:____:__MEPHENYTOIN, POOR METABOLISM OF, INCLUDED;; OMEPRAZOLE, POOR METABOLISM OF, INCLUDED;; PROGUANIL, POOR METABOLISM OF, INCLUDED;; CLOPIDOGREL, POOR METABOLISM OF, INCLUDED
Number Sign__:__609536__:__COMPLEMENT COMPONENT 5 DEFICIENCY; C5D__:__C5 DEFICIENCY__:__
NULL__:__609537__:__LIPOMYELOMENINGOCELE__:____:__
Asterisk__:__609538__:__PROTEIN-TYROSINE PHOSPHATASE, MITOCHONDRIAL, 1; PTPMT1__:__PTEN-LIKE PHOSPHATASE; PLIP;; PHOSPHOINOSITIDE LIPID PHOSPHATASE__:__
Asterisk__:__609539__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 2; ARID2__:__ARID-CONTAINING PROTEIN 2;; BRG1-ASSOCIATED FACTOR, 200-KD; BAF200;; KIAA1557__:__
Asterisk__:__609540__:__WD REPEAT-CONTAINING PROTEIN 61; WDR61__:__SKI8, YEAST, HOMOLOG OF; SKI8__:__
Number Sign__:__609541__:__SPASTIC PARAPLEGIA, OPTIC ATROPHY, AND NEUROPATHY; SPOAN__:____:__
Asterisk__:__609542__:__ATPase, CLASS I, TYPE 8A, MEMBER 1; ATP8A1__:__ATPase II__:__
Asterisk__:__609543__:__BEYLA GENE__:__BEYLA;; LOC497634__:__
Asterisk__:__609544__:__CENTRIOLAR COILED-COIL PROTEIN, 110-KD; CCP110__:__CENTROSOMAL PROTEIN, 110-KD; CP110;; KIAA0419__:__
NULL__:__609545__:__OMPHALOCELE, DIAPHRAGMATIC HERNIA, AND RADIAL RAY DEFECTS__:__GERSHONI-BARUCH SYNDROME__:__
Asterisk__:__609546__:__UBIQUITIN-SPECIFIC PROTEASE 29; USP29__:__HOM-TES-84/86__:__
Caret__:__609547__:__MOVED TO 131200__:____:__
Asterisk__:__609548__:__LMAN1-LIKE PROTEIN; LMAN1L__:__ERGIC53-LIKE PROTEIN; ERGL__:__
Number Sign__:__609549__:__NANOPHTHALMOS 2; NNO2__:__NANOPHTHALMIA 2;; NANOPHTHALMOS, AUTOSOMAL RECESSIVE__:__
Asterisk__:__609550__:__ZINC FINGER PROTEIN 330; ZNF330__:__NUCLEOLAR CYSTEINE-RICH PROTEIN;; NUCLEOLAR AUTOANTIGEN, 36-KD; NOA36__:__
Asterisk__:__609551__:__LECTIN, MANNOSE-BINDING, 2; LMAN2__:__VIP36;; GP36B__:__
Asterisk__:__609552__:__LMAN2-LIKE PROTEIN; LMAN2L__:__VIP36-LIKE PROTEIN; VIPL__:__
Asterisk__:__609553__:__RETBINDIN__:__RTBDN__:__
Asterisk__:__609554__:__INTEGRAL MEMBRANE PROTEIN 2C; ITM2C__:__BRI3__:__
Asterisk__:__609555__:__CARBOXYPEPTIDASE X, M14 FAMILY, MEMBER 1; CPXM1__:__CPXM;; CPX1__:__
Asterisk__:__609556__:__ATPase, TYPE 13A4; ATP13A4__:____:__
Asterisk__:__609557__:__PROLYL ENDOPEPTIDASE-LIKE; PREPL__:__KIAA0436__:__
Percent__:__609558__:__PROSTATE CANCER, HEREDITARY, 6__:__HPC6__:__
Asterisk__:__609559__:__CALMODULIN LYSINE N-METHYLTRANSFERASE; CAMKMT__:__CHROMOSOME 2 OPEN READING FRAME 34; C2ORF34__:__
Number Sign__:__609560__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2__:__MITOCHONDRIAL DNA DEPLETION MYOPATHY, TK2-RELATED__:__
Asterisk__:__609561__:__CARBOXYPEPTIDASE A5; CPA5__:____:__
Asterisk__:__609562__:__CARBOXYPEPTIDASE A6; CPA6__:__CPAH__:__
Asterisk__:__609563__:__CARBOXYPEPTIDASE O; CPO__:____:__
Asterisk__:__609564__:__POLY(ADP-RIBOSE) POLYMERASE 10; PARP10__:____:__
Asterisk__:__609565__:__MAST CELL-EXPRESSED MEMBRANE PROTEIN 1__:__MCEMP1__:__
Percent__:__609566__:__PARIETAL FORAMINA 3; PFM3__:____:__
Asterisk__:__609567__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3; PNPLA3__:__ADIPONUTRIN; ADPN;; PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT, EPSILON;; IPLA2-EPSILON__:__
Asterisk__:__609568__:__RHO GTPase-ACTIVATING PROTEIN 20; ARHGAP20__:__GTPase-ACTIVATING PROTEIN, RHO, 20;; RA AND RHOGAP DOMAINS-CONTAINING PROTEIN; RARHOGAP;; KIAA1391__:__
Caret__:__609569__:__MOVED TO 132100__:____:__
Percent__:__609570__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 8__:__MGR8__:__
Asterisk__:__609571__:__ZINC FINGER PROTEIN 699; ZNF699__:__HANGOVER, DROSOPHILA, HOMOLOG OF; HANG;; FLJ38144__:__
Percent__:__609572__:__PHOTOPAROXYSMAL RESPONSE 2; PPR2__:__PHOTOPAROXYSMAL RESPONSE WITH OR WITHOUT IDIOPATHIC GENERALIZED EPILEPSY__:__
Percent__:__609573__:__PHOTOPAROXYSMAL RESPONSE 3; PPR3__:__PHOTOPAROXYSMAL RESPONSE WITH OR WITHOUT MYOCLONIC EPILEPSY__:__
Asterisk__:__609574__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE XII; HSD17B12__:__17-BETA-HSD XII;; 3-KETOACYL-CoA REDUCTASE; KAR__:__
Asterisk__:__609575__:__ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN; ACADVL__:__VLCAD__:__
Asterisk__:__609576__:__ACYL-CoA DEHYDROGENASE, LONG-CHAIN; ACADL__:__LCAD__:__
Asterisk__:__609577__:__CULLIN 7; CUL7__:__KIAA0076__:__
Percent__:__609578__:__CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 2; RCM2__:____:__
Number Sign__:__609579__:__SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION__:____:__
Asterisk__:__609580__:__NINEIN-LIKE PROTEIN; NINL__:__NLP;; KIAA0980__:__
Caret__:__609581__:__MOVED TO 130720__:____:__
Asterisk__:__609582__:__MICRO RNA 122A; MIR122A__:__miRNA122A;; miRNA122;; MIRN122A;; MIR122__:__
Number Sign__:__609583__:__JOUBERT SYNDROME 4; JBTS4__:____:__
Asterisk__:__609584__:__L-2-HYDROXYGLUTARATE DEHYDROGENASE; L2HGDH__:__DURANIN;; CHROMOSOME 14 OPEN READING FRAME 160; C14ORF160__:__
Asterisk__:__609585__:__COMPLEXIN 3; CPLX3__:__CPX III__:__
Asterisk__:__609586__:__COMPLEXIN 4; CPLX4__:__CPX IV__:__
Asterisk__:__609587__:__REGULATOR OF CHROMOSOME CONDENSATION 2; RCC2__:__TD60;; KIAA1470__:__
Asterisk__:__609588__:__GLUTAREDOXIN 5; GLRX5__:__GRX5;; CHROMOSOME 14 OPEN READING FRAME 87; C14ORF87;; PRO1238;; FLB4739__:__
Asterisk__:__609589__:__MITOCHONDRIAL TUMOR SUPPRESSOR GENE 1; MTUS1__:__MTSG1;; ANGIOTENSIN II RECEPTOR 2-INTERACTING PROTEIN; ATIP;; AGTR2-INTERACTING PROTEIN;; KIAA1288__:__
Asterisk__:__609590__:__QUAKING, MOUSE, HOMOLOG OF; QKI__:__QK1;; QK__:__
Asterisk__:__609591__:__RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 1; RIT1__:__RAS-LIKE PROTEIN EXPRESSED IN MANY TISSUES; RIT;; ROC1__:__
Asterisk__:__609592__:__RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 2; RIT2__:__RAS-LIKE PROTEIN EXPRESSED IN NEURONS; RIN;; ROC2__:__
Asterisk__:__609593__:__CAPPING PROTEIN REGULATOR AND MYOSIN 1 LINKER 1; CARMIL1__:__CARMIL, DICTYOSTELIUM, HOMOLOG OF; CARMIL;; LEUCINE-RICH REPEAT-CONTAINING PROTEIN 16A; LRRC16A;; LRRC16__:__
Asterisk__:__609594__:__VENTRICULAR ZONE-EXPRESSED PH DOMAIN-CONTAINING PROTEIN, ZEBRAFISH, HOMOLOG OF, 1; VEPH1__:__MELTED, DROSOPHILA, HOMOLOG OF; MELT;; KIAA1692__:__
Asterisk__:__609595__:__R-SPONDIN FAMILY, MEMBER 1; RSPO1__:__ROOF PLATE-SPECIFIC SPONDIN, MOUSE, HOMOLOG OF;; R-SPONDIN; RSPO;; CRISTIN3;; FLJ40906__:__
Asterisk__:__609596__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT K; EIF3K__:__EIF3-p28;; PLAC24;; EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT 12, FORMERLY; EIF3S12, FORMERLY__:__
Number Sign__:__609597__:__PARIETAL FORAMINA 2; PFM2__:____:__
Asterisk__:__609598__:__ZINC FINGER AND HOMEODOMAIN PROTEIN 3; ZHX3__:__KIAA0395__:__
Asterisk__:__609599__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 1; ANKRD1__:__CARDIAC ANKYRIN REPEAT PROTEIN; CARP;; C193__:__
Asterisk__:__609600__:__ZINC FINGER PROTEIN 396; ZNF396__:____:__
Asterisk__:__609601__:__ZINC FINGER PROTEIN 397; ZNF397__:____:__
Asterisk__:__609602__:__ZINC FINGER PROTEIN 393; ZNF393__:__KRUPPEL-LIKE FACTOR 17; KLF17__:__
Asterisk__:__609603__:__CRYSTALLIN, GAMMA-N; CRYGN__:____:__
Asterisk__:__609604__:__MICROTUBULE-ASSOCIATED PROTEIN 1, LIGHT CHAIN 3, BETA; MAP1LC3B__:__LC3B__:__
Asterisk__:__609605__:__MICROTUBULE-ASSOCIATED PROTEIN 1, LIGHT CHAIN 3, GAMMA; MAP1LC3C__:__LC3C__:__
Asterisk__:__609606__:__AUTOPHAGY 3, S. CEREVISIAE, HOMOLOG OF; ATG3__:__APG3, S. CEREVISIAE, HOMOLOG OF; APG3;; APG3-LIKE; APG3L__:__
Asterisk__:__609607__:__NECTIN 4; NECTIN4__:__POLIOVIRUS RECEPTOR-LIKE 4; PVRL4;; POLIOVIRUS RECEPTOR-RELATED 4; PRR4__:__
Asterisk__:__609608__:__AUTOPHAGY 12, S. CEREVISIAE, HOMOLOG OF; ATG12__:__APG12, S. CEREVISIAE, HOMOLOG OF; APG12;; AGP12-LIKE; APG12L;; FBR93__:__
Caret__:__609609__:__MOVED TO 231530__:____:__
Asterisk__:__609610__:__TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 4; TUBGCP4__:__GAMMA-TUBULIN COMPLEX COMPONENT 4; GCP4__:__
Asterisk__:__609611__:__ACIDIC LEUCINE-RICH NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER E; ANP32E__:__LEUCINE-RICH ACIDIC NUCLEAR PROTEIN-LIKE; LANPL__:__
NULL__:__609612__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, WITH SYNERGISTIC DIVERGENCE__:__CONGENITAL FIBROSIS SYNDROME WITH SYNERGISTIC DIVERGENCE;; EXTERNAL OPHTHALMOPLEGIA WITH SYNERGISTIC DIVERGENCE__:__EXTERNAL OPHTHALMOPLEGIA, SYNERGISTIC DIVERGENCE, JAW WINKING, AND OCULOCUTANEOUS HYPOPIGMENTATION, INCLUDED
Asterisk__:__609613__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY M, MEMBER 2; PLEKHM2__:__SIFA- AND KINESIN-INTERACTING PROTEIN; SKIP;; KIAA0842__:__
Asterisk__:__609614__:__RNA EXONUCLEASE 1, S. CEREVISIAE, HOMOLOG OF; REXO1__:__REX1, S. CEREVISIAE, HOMOLOG OF; REX1;; ELONGIN A-BINDING PROTEIN 1; ELOABP1;; TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 3-BINDING PROTEIN 1; TCEB3BP1;; KIAA1138__:__
Asterisk__:__609615__:__QUEUINE tRNA-RIBOSYLTRANSFERASE 1; QTRT1__:__tRNA-GUANINE TRANSGLYCOSYLASE; TGT;; TGT, 43-KD SUBUNIT;; TGT, CATALYTIC SUBUNIT__:__
NULL__:__609616__:__SPONDYLOMEGAEPIPHYSEAL DYSPLASIA WITH UPPER LIMB MESOMELIA, PUNCTATE CALCIFICATIONS, AND DEAFNESS__:____:__
Asterisk__:__609617__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 2; SLC30A2__:__ZINC TRANSPORTER 2; ZNT2__:__
Asterisk__:__609618__:__NONCODING REPRESSOR OF NFAT; NRON__:____:__
Asterisk__:__609619__:__GOLGIN A8 FAMILY, MEMBER B; GOLGA8B__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 8B__:__
Number Sign__:__609620__:__SHORT QT SYNDROME 1; SQT1__:____:__
Number Sign__:__609621__:__SHORT QT SYNDROME 2; SQT2__:____:__
Number Sign__:__609622__:__SHORT QT SYNDROME 3; SQT3__:____:__
Asterisk__:__609623__:__RAS-INTERACTING PROTEIN 1; RASIP1__:__RAIN__:__
Asterisk__:__609624__:__MITOCHONDRIAL COILED-COIL DOMAIN 1; MCCD1__:____:__
Number Sign__:__609625__:__CHROMOSOME 10q26 DELETION SYNDROME__:__TERMINAL CHROMOSOME 10q26 DELETION SYNDROME__:__
Asterisk__:__609626__:__MAM DOMAIN-CONTAINING GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR 1; MDGA1__:__MAM DOMAIN-CONTAINING PROTEIN 3; MAMDC3;; GLYCOSYLPHOSPHATIDYLINOSITOL-MAM; GPIM__:__
Asterisk__:__609627__:__TASTE RECEPTOR, TYPE 2, MEMBER 50; TAS2R50__:__T2R50;; TAS2R51; T2R51__:__
Number Sign__:__609628__:__MAJEED SYNDROME; MJDS__:__CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS, CONGENITAL DYSERYTHROPOIETIC ANEMIA, AND NEUTROPHILIC DERMATOSIS__:__
Percent__:__609629__:__VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT__:__ENTERIC NEUROPATHY, FAMILIAL;; PSEUDOOBSTRUCTION, CHRONIC INTESTINAL, NEUROPATHIC;; PSEUDOOBSTRUCTION, IDIOPATHIC INTESTINAL__:__
Percent__:__609630__:__LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 1__:__CLLS1__:__
Asterisk__:__609631__:__DEAD BOX POLYPEPTIDE 58; DDX58__:__DEAD/H BOX 58;; RETINOIC ACID-INDUCIBLE GENE I; RIGI__:__
Asterisk__:__609632__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN-CONTAINING PROTEIN 5; GDPD5__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 2; GDE2;; PP1665__:__
Percent__:__609633__:__MAJOR AFFECTIVE DISORDER 3; MAFD3__:__BIPOLAR AFFECTIVE DISORDER, EARLY-ONSET; BPEO__:__
Number Sign__:__609634__:__MIGRAINE, FAMILIAL HEMIPLEGIC, 3; FHM3__:____:__
Asterisk__:__609635__:__TRANSCRIPTION FACTOR 23; TCF23__:__OUT__:__
Percent__:__609636__:__ALZHEIMER DISEASE 10__:__ALZHEIMER DISEASE, FAMILIAL, 10;; AD10__:__
Number Sign__:__609637__:__HOLOPROSENCEPHALY 5; HPE5__:____:__
Number Sign__:__609638__:__EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA__:__LETHAL ACANTHOLYTIC EPIDERMOLYSIS BULLOSA; LAEB__:__
Asterisk__:__609639__:__HEMOGLOBIN MU__:__HBM__:__
Number Sign__:__609640__:__FRIAS SYNDROME__:__CHROMOSOME 14q22 DELETION SYNDROME;; GROWTH DEFICIENCY, FACIAL ANOMALIES, AND BRACHYDACTYLY__:__
Asterisk__:__609641__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 3, SUBUNIT M; EIF3M__:__PCI DOMAIN-CONTAINING PROTEIN 1; PCID1;; HUMAN FETAL LUNG PROTEIN B5; HFLB5; B5;; DENDRITIC CELL PROTEIN GA17; GA17__:__
Asterisk__:__609642__:__T-CELL ANTIGEN RECEPTOR, GAMMA SUBUNIT, ALTERNATE READING FRAME PROTEIN__:__TCRG ALTERNATE READING FRAME PROTEIN; TARP__:__
Percent__:__609643__:__NGUYEN SYNDROME__:__MCA/MR WITH HYPOCHOLESTEROLEMIA DUE TO FAMILIAL HYPOBETALIPOPROTEINEMIA__:__
Asterisk__:__609644__:__FANCM GENE; FANCM__:__FANCONI ANEMIA-ASSOCIATED POLYPEPTIDE, 250-KD; FAAP250;; KIAA1596__:__
Asterisk__:__609645__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 4; NLRP4__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 4; NALP4;; PYRIN DOMAIN- AND NACHT DOMAIN-CONTAINING PROTEIN 2; PAN2;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 4; PYPAF4__:__
Number Sign__:__609646__:__DEAFNESS, AUTOSOMAL RECESSIVE 42; DFNB42__:____:__
Percent__:__609647__:__DEAFNESS, AUTOSOMAL RECESSIVE 46; DFNB46__:____:__
Asterisk__:__609648__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 12; NLRP12__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 12; NALP12;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 7; PYPAF7;; REGULATED BY NITRIC OXIDE; RNO;; MONARCH 1__:__
Percent__:__609649__:__TRICHILEMMAL CYST 1; TRICY1__:__TRICHOLEMMAL CYST;; PILAR CYST__:__
Asterisk__:__609650__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 6; NLRP6__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 6; NALP6;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 5; PYPAF5__:__
Asterisk__:__609651__:__GLYCOPROTEIN HORMONE, ALPHA-2; GPHA2__:__GPA2; A2__:__
Asterisk__:__609652__:__GLYCOPROTEIN HORMONE, BETA-5; GPHB5__:__GPB5; B5__:__
Asterisk__:__609653__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 2; NDUFAF2__:__NADH DEHYDROGENASE 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 2;; NDUFA12-LIKE; NDUFA12L;; MYC-INDUCED MITOCHONDRIAL PROTEIN;; MIMITIN; MMTN;; B17.2-LIKE;; B17.2L__:__
NULL__:__609654__:__SHORT STATURE AND FACIOAURICULOTHORACIC MALFORMATIONS__:____:__
NULL__:__609655__:__TALO-PATELLO-SCAPHOID OSTEOLYSIS, SYNOVITIS, AND SHORT FOURTH METACARPALS__:____:__
Percent__:__609656__:__BONE SIZE QUANTITATIVE TRAIT LOCUS 1__:__BSZQTL1__:__
Percent__:__609657__:__BONE SIZE QUANTITATIVE TRAIT LOCUS 2__:__BSZQTL2__:__
Asterisk__:__609658__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 5; NLRP5__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 5; NALP5;; MATER, MOUSE, HOMOLOG OF; MATER__:__
Asterisk__:__609659__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 8; NLRP8__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 8; NALP8;; PYRIN DOMAIN- AND NACHT DOMAIN-CONTAINING PROTEIN 4; PAN4;; NOD16__:__
Asterisk__:__609660__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 13; NLRP13__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 13; NALP13;; NOD14__:__
Asterisk__:__609661__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 7; NLRP7__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 7; NALP7;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 3; PYPAF3;; NOD12__:__
Asterisk__:__609662__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 10; NLRP10__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 10; NALP10;; PYNOD;; NOD8__:__
Asterisk__:__609663__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 9; NLRP9__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 9; NALP9;; NOD6__:__
Asterisk__:__609664__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 11; NLRP11__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 11; NALP11;; PYRIN DOMAIN-CONTAINING APAF1-LIKE PROTEIN 7; PYPAF7;; NOD17__:__
Asterisk__:__609665__:__NLR FAMILY, PYRIN DOMAIN-CONTAINING 14; NLRP14__:__NACHT DOMAIN-, LEUCINE-RICH REPEAT-, AND PYD-CONTAINING PROTEIN 14; NALP14;; NOD5__:__
Asterisk__:__609666__:__TWO-PORE SEGMENT CHANNEL 1; TPCN1__:__TWO-PORE CHANNEL 1; TPC1;; KIAA1169__:__
Asterisk__:__609667__:__T-CELL ACTIVATION GTPase-ACTIVATING PROTEIN; TAGAP__:____:__
Asterisk__:__609668__:__PTC7 PROTEIN PHOSPHATASE, S. CEREVISIAE, HOMOLOG OF; PPTC7__:__T-CELL ACTIVATION PROTEIN PHOSPHATASE 2C; TAPP2C__:__
Asterisk__:__609669__:__WD REPEAT-CONTAINING PROTEIN 36; WDR36__:__T-CELL ACTIVATION WD REPEAT-CONTAINING PROTEIN; TAWDRP;; UTP21, S. CEREVISIAE, HOMOLOG OF; UTP21__:__
Percent__:__609670__:__MIGRAINE WITH AURA, SUSCEPTIBILITY TO, 9__:__MGR9__:__
Asterisk__:__609671__:__SIX-TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 3; STEAP3__:__TUMOR SUPPRESSOR-ACTIVATED PATHWAY 6; TSAP6__:__
Asterisk__:__609672__:__EXOCYST COMPLEX COMPONENT 6; EXOC6__:__SEC15-LIKE 1; SEC15L1;; SEC15L;; SEC15, S. CEREVISIAE, HOMOLOG OF; SEC15__:__
Asterisk__:__609673__:__PLATELET-DERIVED GROWTH FACTOR D; PDGFD__:__SPINAL CORD-DERIVED GROWTH FACTOR B; SCDGFB;; IRIS-EXPRESSED GROWTH FACTOR; IEGF__:__
Asterisk__:__609674__:__ESTABLISHMENT OF COHESION 1, S. CEREVISIAE, HOMOLOG OF, 1; ESCO1__:__ECO1, S. CEREVISIAE, HOMOLOG OF, 1;; CTF7, S. CEREVISIAE, HOMOLOG OF, 1;; ESO1, S. POMBE, HOMOLOG OF, 1;; ESTABLISHMENT FACTOR ORTHOLOG 1; EFO1;; KIAA1911__:__
Asterisk__:__609675__:__SCLEROSTIN DOMAIN-CONTAINING PROTEIN 1; SOSTDC1__:__ECTODERMAL BMP INHIBITOR;; ECTODIN;; UTERINE SENSITIZATION-ASSOCIATED GENE 1; USAG1;; WISE__:__
Asterisk__:__609676__:__MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MAVS__:__VIRUS-INDUCED SIGNALING ADAPTOR; VISA;; IFNB PROMOTER STIMULATOR 1; IPS1;; CARD ADAPTOR INDUCING IFNB; CARDIF;; KIAA1271__:__
Asterisk__:__609677__:__OSTEOSARCOMA-AMPLIFIED GENE 9; OS9__:__AMPLIFIED IN OSTEOSARCOMA 9;; ENDOPLASMIC RETICULUM LECTIN OS9__:__
Asterisk__:__609678__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 1; SLITRK1__:__KIAA1910__:__
Asterisk__:__609679__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 3; SLITRK3__:__KIAA0848__:__
Asterisk__:__609680__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 5; SLITRK5__:__KIAA0918__:__
Asterisk__:__609681__:__SLIT- AND NTRK-LIKE FAMILY, MEMBER 6; SLITRK6__:____:__
Asterisk__:__609682__:__DNA CROSS-LINK REPAIR PROTEIN 1A; DCLRE1A__:__SNM1, S. CEREVISIAE, HOMOLOG OF; SNM1;; SNM1, S. CEREVISIAE, HOMOLOG OF, A; SNM1A;; KIAA0086__:__
Asterisk__:__609683__:__DNA CROSS-LINK REPAIR PROTEIN 1B; DCLRE1B__:__SNM1, S. CEREVISIAE, HOMOLOG OF, B; SNM1B;; APOLLO__:__
Asterisk__:__609684__:__MAL PROTEOLIPID PROTEIN 2; MAL2__:____:__
Asterisk__:__609685__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 7-LIKE; CDCA7L__:__CDCA7-LIKE;; R1;; JPO2__:__
Asterisk__:__609686__:__CITRATE LYASE BETA-LIKE; CLYBL__:__CITRATE LYASE, BETA SUBUNIT; CLB__:__
Asterisk__:__609687__:__MICRO RNA 196A2; MIR196A2__:__miRNA196A2;; MIRN196A2__:__
Asterisk__:__609688__:__MICRO RNA 196B; MIR196B__:__miRNA196B;; MIRN196B__:__
Asterisk__:__609689__:__CENTROSOMAL PROTEIN, 250-KD; CEP250__:__CENTROSOMAL PROTEIN 2; CEP2;; CENTROSOMAL NEK2-ASSOCIATED PROTEIN 1; CNAP1__:__
Asterisk__:__609690__:__PHENYLALANINE-tRNA SYNTHETASE, BETA SUBUNIT; FARSB__:__PHENYLALANINE-tRNA SYNTHETASE, CYTOPLASMIC, BETA SUBUNIT; FRSB;; PHENYLALANINE-tRNA SYNTHETASE-LIKE, BETA SUBUNIT; FARSLB;; PHERSB__:__
Asterisk__:__609691__:__FORMIN HOMOLOGY-2 DOMAIN-CONTAINING PROTEIN 3; FHOD3__:__FH1/FH2 DOMAIN-CONTAINING PROTEIN 2; FHOS2;; KIAA1695__:__
Asterisk__:__609692__:__WAS/WASL-INTERACTING PROTEIN FAMILY, MEMBER 2; WIPF2__:__WASP-INTERACTING PROTEIN-RELATED PROTEIN; WIRE;; WIP-RELATED PROTEIN;; WIP- AND CR16-HOMOLOGOUS PROTEIN; WICH__:__
Asterisk__:__609693__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 7; VWA7__:__CHROMOSOME 6 OPEN READING FRAME 27; C6ORF27;; G7C__:__
Asterisk__:__609694__:__GEM-INTERACTING PROTEIN; GMIP__:____:__
Asterisk__:__609695__:__4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; HPD__:__4-HYDROXYPHENYLPYRUVIC ACID OXIDASE__:__
Asterisk__:__609696__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 4B; ARID4B__:__ARID-CONTAINING PROTEIN 4B;; SIN3A-ASSOCIATED PROTEIN, 180-KD; SAP180;; RETINOBLASTOMA-BINDING PROTEIN 1-LIKE PROTEIN 1; RBP1L1;; RBBP1-LIKE PROTEIN 1; RBBP1L1;; BREAST CANCER-ASSOCIATED ANTIGEN 1; BRCAA1__:__
Asterisk__:__609697__:__SIN3A-ASSOCIATED PROTEIN, 130-KD; SAP130__:____:__
Number Sign__:__609698__:__THYROID HORMONE METABOLISM, ABNORMAL__:____:__
Asterisk__:__609699__:__MONOGLYCERIDE LIPASE; MGLL__:__MGL;; MONOACYLGLYCEROL LIPASE; MAGL;; HUK5__:__
Asterisk__:__609700__:__RAB GUANINE NUCLEOTIDE EXCHANGE FACTOR 1; RABGEF1__:__RABAPTIN 5-ASSOCIATED EXCHANGE FACTOR FOR RAB5; RABEX5__:__
Asterisk__:__609701__:__N-ACETYLGLUCOSAMINIDASE, ALPHA-; NAGLU__:__N-ACETYL-ALPHA-D-GLUCOSAMINIDASE;; N-ACETYL-ALPHA-GLUCOSAMINIDASE__:__
Asterisk__:__609702__:__PROTEASOME ASSEMBLY CHAPERONE 2; PSMG2__:__PAC2;; TNFSF5-INDUCED PROTEIN 1; TNFSF5IP1;; HEPATOCELLULAR CARCINOMA-ASSOCIATED PROTEIN 3; HCCA3;; CD40 LIGAND-ACTIVATED SPECIFIC TRANSCRIPT 3; CLAST3__:__
Asterisk__:__609703__:__MICRO RNA 15A; MIR15A__:__miRNA15A;; MIRN15A__:__
Asterisk__:__609704__:__MICRO RNA 16-1; MIR16-1__:__miRNA16-1;; MIRN16-1__:__
Asterisk__:__609705__:__MICRO RNA 24-1; MIR24-1__:__miRNA24-1;; MIRN24-1__:__MICRO RNA 189, INCLUDED; miRNA189, INCLUDED; MIR189, INCLUDED
Number Sign__:__609706__:__DEAFNESS, AUTOSOMAL RECESSIVE 53; DFNB53__:____:__
Asterisk__:__609707__:__DIHYDROURIDINE SYNTHASE 2-LIKE; DUS2L__:__DIHYDROURIDINE SYNTHASE 2, S. CEREVISIAE, HOMOLOG OF; DUS2__:__
Plus__:__609708__:__LIPOPROTEIN LIPASE; LPL__:____:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 11, INCLUDED; HDLCQ11, INCLUDED
Asterisk__:__609709__:__GLYCOSYLTRANSFERASE-LIKE 1B; GYLTL1B__:__LIKE-GLYCOSYLTRANSFERASE 2;; LARGE2__:__
Asterisk__:__609710__:__DENDRITIC CELL-ASSOCIATED NUCLEAR PROTEIN 1; DCANP1__:__DCNP1;; CHROMOSOME 5 OPEN READING FRAME 20; C5ORF20__:__
Asterisk__:__609711__:__UBIQUINOL-CYTOCHROME c REDUCTASE, 6.4-KD SUBUNIT; UQCR__:____:__
Asterisk__:__609712__:__PYRUVATE KINASE, LIVER AND RED BLOOD CELL; PKLR__:__PKRL;; PYRUVATE KINASE, LIVER TYPE; PKL;; PYRUVATE KINASE, RED CELL TYPE; PKR;; PYRUVATE KINASE 1; PK1__:__
Asterisk__:__609713__:__HYDROXYUREA-SENSITIVE 1, S. POMBE, HOMOLOG OF, B; HUS1B__:____:__
Asterisk__:__609714__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 1; TREML1__:__TREM-LIKE PROTEIN 1;; TREM-LIKE TRANSCRIPT 1; TLT1__:__
Asterisk__:__609715__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 2; TREML2__:__TREM-LIKE PROTEIN 2;; TREM-LIKE TRANSCRIPT 2; TLT2__:__
Asterisk__:__609716__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 3; TREML3__:__TREM-LIKE PROTEIN 3;; TREM-LIKE TRANSCRIPT 3; TLT3__:__
Asterisk__:__609717__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 4; PCAT4__:__GENE DIFFERENTIALLY EXPRESSED IN PROSTATE; GDEP__:__
Asterisk__:__609718__:__LHFP-LIKE PROTEIN 2; LHFPL2__:__KIAA0206__:__
Asterisk__:__609719__:__LHFP-LIKE PROTEIN 3; LHFPL3__:__LHFPL TETRASPAN SUBFAMILY, MEMBER 3__:__
Asterisk__:__609720__:__CRUMBS, DROSOPHILA, HOMOLOG OF, 2; CRB2__:____:__
Asterisk__:__609721__:__POLYCYSTIN 1-LIKE 1; PKD1L1__:____:__
Asterisk__:__609722__:__PDZ AND LIM DOMAIN PROTEIN 2; PDLIM2__:__MYSTIQUE;; STAT-INTERACTING LIM PROTEIN; SLIM__:__
Asterisk__:__609723__:__YIPPEE-LIKE 2; YPEL2__:____:__
Asterisk__:__609724__:__YIPPEE-LIKE 3; YPEL3__:____:__
Asterisk__:__609725__:__YIPPEE-LIKE 4; YPEL4__:____:__
Asterisk__:__609726__:__YIPPEE-LIKE 5; YPEL5__:____:__
Percent__:__609727__:__SPASTIC PARAPLEGIA 29, AUTOSOMAL DOMINANT; SPG29__:____:__
Asterisk__:__609728__:__METHIONYL-tRNA SYNTHETASE 2; MARS2__:__METHIONINE tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL METRS__:__
Asterisk__:__609729__:__PDZ DOMAIN-CONTAINING RING FINGER PROTEIN 3; PDZRN3__:__KIAA1095__:__
Asterisk__:__609730__:__PDZ DOMAIN-CONTAINING RING FINGER PROTEIN 4; PDZRN4__:____:__
Asterisk__:__609731__:__CYSTATIN 11; CST11__:__CST8L__:__
Asterisk__:__609732__:__LIGAND OF NUMB PROTEIN X1; LNX1__:__LIGAND OF NUMB PROTEIN X; LNX;; PDZ DOMAIN-CONTAINING RING FINGER PROTEIN 2; PDZRN2__:__
Asterisk__:__609733__:__LIGAND OF NUMB PROTEIN X2; LNX2__:__PDZ DOMAIN-CONTAINING RING FINGER PROTEIN 1; PDZRN1__:__
Number Sign__:__609734__:__OBESITY, EARLY-ONSET, WITH ADRENAL INSUFFICIENCY AND RED HAIR; OBAIRH__:__PROOPIOMELANOCORTIN DEFICIENCY__:__
Asterisk__:__609735__:__RING FINGER AND FYVE-LIKE DOMAIN CONTAINING 1; RFFL__:__RIFIFYLIN__:__
Asterisk__:__609736__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 88A; CCDC88A__:__HOOK RELATED PROTEIN 1; HKRP1;; GIRDERS OF ACTIN FILAMENT; GIRDIN;; AKT PHOSPHORYLATION ENHANCER; APE;; G-ALPHA-INTERACTING VESICLE-ASSOCIATED PROTEIN; GIV;; KIAA1212__:__
Asterisk__:__609737__:__CRUMBS, DROSOPHILA, HOMOLOG OF, 3; CRB3__:____:__
Asterisk__:__609738__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 9; IGSF9__:__KIAA1355__:__
Asterisk__:__609739__:__IMMUNOGLOBULIN-LIKE DOMAIN-CONTAINING RECEPTOR 1; ILDR1__:____:__
Asterisk__:__609740__:__PHD FINGER PROTEIN 19; PHF19__:____:__
Number Sign__:__609741__:__CATARACT 22, MULTIPLE TYPES; CTRCT22__:__CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 2; CATCN2__:__
Asterisk__:__609742__:__INTERLEUKIN 4-INDUCED GENE 1; IL4I1__:__IL4-INDUCED GENE 1;; FIG1__:__
Asterisk__:__609743__:__CELL ADHESION MOLECULE 3; CADM3__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4B; IGSF4B;; TSLC1-LIKE GENE 1; TSLL1;; NECTIN-LIKE PROTEIN 1; NECL1;; SYNAPTIC CELL ADHESION MOLECULE 3; SYNCAM3__:__
Asterisk__:__609744__:__CELL ADHESION MOLECULE 4; CADM4__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4C; IGSF4C;; TSLC1-LIKE GENE 2; TSLL2;; NECTIN-LIKE PROTEIN 4; NECL4;; SYNAPTIC CELL ADHESION MOLECULE 4; SYNCAM4__:__
Percent__:__609745__:__GLAUCOMA 1, OPEN ANGLE, I; GLC1I__:____:__
Asterisk__:__609746__:__RHO GTPase-ACTIVATING PROTEIN 10; ARHGAP10__:__GTPase-ACTIVATING PROTEIN, RHO, 10;; PSGAP;; GTPase REGULATOR ASSOCIATED WITH FOCAL ADHESION KINASE 2; GRAF2__:__
Asterisk__:__609747__:__ACTIN-BINDING RHO-ACTIVATING PROTEIN; ABRA__:__STRIATED MUSCLE ACTIVATOR OF RHO SIGNALING; STARS__:__
Asterisk__:__609748__:__UBIQUITIN-LIKE 7; UBL7__:____:__
Asterisk__:__609749__:__UDP-GLUCURONATE DECARBOXYLASE 1; UXS1__:__UGD__:__
Percent__:__609750__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 4; EIG4__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 10__:__
Asterisk__:__609751__:__ACYL-CoA OXIDASE 1, PALMITOYL; ACOX1__:__ACYL-CoA OXIDASE, PALMITOYL, PEROXISOMAL;; ACYL-CoA OXIDASE; ACOX;; PALMITOYL-CoA OXIDASE;; ACYL-CoA OXIDASE, STRAIGHT-CHAIN; SCOX__:__
Asterisk__:__609752__:__NUCLEAR RECEPTOR COACTIVATOR 7; NCOA7__:__ERAP140__:__
Number Sign__:__609753__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 4; CELIAC4__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 4__:__
Percent__:__609754__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 2; CELIAC2__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 2__:__
Number Sign__:__609755__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 3; CELIAC3__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 3__:__
Asterisk__:__609756__:__CHRNA7/FAM7A FUSION GENE; CHRFAM7A__:____:__
Number Sign__:__609757__:__WILLIAMS-BEUREN REGION DUPLICATION SYNDROME__:__WBS DUPLICATION SYNDROME;; CHROMOSOME 7q11.23 DUPLICATION SYNDROME;; SOMERVILLE-VAN DER AA SYNDROME__:__WBS TRIPLICATION SYNDROME, INCLUDED;; CHROMOSOME 7q11.23 TRIPLICATION SYNDROME, INCLUDED
Asterisk__:__609758__:__Na+/K+ TRANSPORTING ATPase-INTERACTING 2; NKAIN2__:__Na+/K+ TRANSPORTING ATPase-INTERACTING PROTEIN 2; NKAIP2;; SODIUM/POTASSIUM TRANSPORTING ATPase-INTERACTING PROTEIN 2;; T-CELL LYMPHOMA BREAKPOINT-ASSOCIATED TARGET 1; TCBA1__:__TCBA1/SUSP1 FUSION GENE, INCLUDED
Asterisk__:__609759__:__PR DOMAIN-CONTAINING PROTEIN 7; PRDM7__:____:__
Asterisk__:__609760__:__PR DOMAIN-CONTAINING PROTEIN 9; PRDM9__:__MEISETZ, MOUSE, HOMOLOG OF; MEISETZ__:__
Asterisk__:__609761__:__TRIO- AND F-ACTIN-BINDING PROTEIN; TRIOBP__:__TRIO- AND FILAMENTOUS-ACTIN-BINDING PROTEIN;; TRIO-ASSOCIATED REPEAT ON ACTIN; TARA;; KIAA1662__:__
Asterisk__:__609762__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 3; BLOC1S3__:__BLOC1, SUBUNIT 3; BLOS3;; REDUCED PIGMENTATION, MOUSE, HOMOLOG OF; RP;; HPS8 GENE; HPS8__:__
Asterisk__:__609763__:__PHOSPHATIDYLINOSITOL 4-KINASE, TYPE 2, ALPHA; PI4K2A__:__PHOSPHATIDYLINOSITOL 4-KINASE, TYPE II;; PI4KII;; PI4KII-ALPHA__:__
Asterisk__:__609764__:__LYSINE-SPECIFIC DEMETHYLASE 4A; KDM4A__:__JUMONJI DOMAIN-CONTAINING PROTEIN 2A; JMJD2A;; JHDM3A;; KIAA0677__:__
Asterisk__:__609765__:__LYSINE-SPECIFIC DEMETHYLASE 4B; KDM4B__:__JUMONJI DOMAIN-CONTAINING PROTEIN 2B; JMJD2B;; KIAA0876__:__
Asterisk__:__609766__:__LYSINE-SPECIFIC DEMETHYLASE 4D; KDM4D__:__LYSINE DEMETHYLASE 4D;; JUMONJI DOMAIN-CONTAINING PROTEIN 2D; JMJD2D__:__
Asterisk__:__609767__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER), MEMBER 28; SLC25A28__:__MITOFERRIN 2; MFRN2;; MRS3/4;; NPD016;; MRS4L__:__
Asterisk__:__609768__:__BIOGENESIS OF LYSOSOME-RELATED ORGANELLES COMPLEX 1, SUBUNIT 2; BLOC1S2__:__BLOC1, SUBUNIT 2; BLOS2__:__
Asterisk__:__609769__:__SHORT CHAIN DEHYDROGENASE/REDUCTASE FAMILY 9C, MEMBER 7; SDR9C7__:__ORPHAN SHORT-CHAIN DEHYDROGENASE/REDUCTASE; SDRO__:__
Asterisk__:__609770__:__ADHESION MOLECULE, INTERACTS WITH CXADR ANTIGEN 1; AMICA1__:__JUNCTIONAL ADHESION MOLECULE-LIKE; JAML__:__
Asterisk__:__609771__:__UBINUCLEIN 1; UBN1__:____:__
Asterisk__:__609772__:__CORTACTIN-BINDING PROTEIN 2; CTTNBP2__:__CORTBP2;; KIAA1758__:__
Asterisk__:__609773__:__EP300-INTERACTING INHIBITOR OF DIFFERENTIATION 2; EID2__:__E1A-LIKE INHIBITOR OF DIFFERENTIATION 2;; CREBBP/EP300 INHIBITORY PROTEIN 2; CRI2__:__
Asterisk__:__609774__:__APOPTOSIS INHIBITOR 5; API5__:__ANTIAPOPTOSIS CLONE 11; AAC11__:__
Asterisk__:__609775__:__YIP1 DOMAIN FAMILY, MEMBER 3; YIPF3__:__KILLER LINEAGE PROTEIN 1; KLIP1__:__
Asterisk__:__609776__:__PROLINE-RICH ACIDIC PROTEIN 1; PRAP1__:____:__
Asterisk__:__609777__:__CARDIOMYOPATHY-ASSOCIATED PROTEIN 1; CMYA1__:__XIN__:__
Asterisk__:__609778__:__CARDIOMYOPATHY-ASSOCIATED PROTEIN 3; CMYA3__:__XIN REPEAT PROTEIN 2; XIRP2;; MYOMAXIN__:__
Asterisk__:__609779__:__NEVER IN MITOSIS GENE A-RELATED KINASE 11; NEK11__:__NIMA-RELATED KINASE 11__:__
Asterisk__:__609780__:__CARBOXYPEPTIDASE, VITELLOGENIC-LIKE; CPVL__:__HVLP__:__
Caret__:__609781__:__MOVED TO 100070__:____:__
Percent__:__609782__:__AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 2; AAA2__:____:__
Asterisk__:__609783__:__INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 5; ITIH5__:____:__
Asterisk__:__609784__:__UPSTREAM BINDING PROTEIN 1; UBP1__:____:__LBP1A, INCLUDED;; LBP1B, INCLUDED
Asterisk__:__609785__:__TRANSCRIPTION FACTOR CP2-LIKE 1; TFCP2L1__:__CP2-RELATED TRANSCRIPTIONAL REPRESSOR 1; CRTR1;; LBP9__:__
Asterisk__:__609786__:__GRAINYHEAD-LIKE 1; GRHL1__:__GRAINYHEAD, DROSOPHILA, HOMOLOG OF, 1;; MAMMALIAN GRAINYHEAD; MGR;; LBP32__:__
Asterisk__:__609787__:__UBIQUITIN-ASSOCIATED PROTEIN 1; UBAP1__:__UBAP__:__
Asterisk__:__609788__:__X-RAY RADIATION RESISTANCE-ASSOCIATED 1; XRRA1__:____:__
Asterisk__:__609789__:__AQUAPORIN 12A; AQP12A__:__AQP12;; AQPX2__:__
Percent__:__609790__:__ALZHEIMER DISEASE 11__:__ALZHEIMER DISEASE, FAMILIAL, 11;; AD11__:__
Asterisk__:__609791__:__LEUCINE-RICH REPEAT- AND Ig DOMAIN-CONTAINING NOGO RECEPTOR-INTERACTING PROTEIN 1; LINGO1__:__LEUCINE-RICH REPEAT NEURONAL PROTEIN 1; LERN1;; LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 6A; LRRN6A__:__
Asterisk__:__609792__:__LEUCINE-RICH REPEAT- AND Ig DOMAIN-CONTAINING NOGO RECEPTOR-INTERACTING PROTEIN 3; LINGO3__:__LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 6B; LRRN6B;; LEUCINE-RICH REPEAT NEURONAL PROTEIN 2; LERN2__:__
Asterisk__:__609793__:__LEUCINE-RICH REPEAT- AND Ig DOMAIN-CONTAINING NOGO RECEPTOR-INTERACTING PROTEIN 2; LINGO2__:__LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 6C; LRRN6C;; LEUCINE-RICH REPEAT NEURONAL PROTEIN 3; LERN3__:__
Asterisk__:__609794__:__LEUCINE-RICH REPEAT- AND Ig DOMAIN-CONTAINING NOGO RECEPTOR-INTERACTING PROTEIN 4; LINGO4__:__LEUCINE-RICH REPEAT PROTEIN, NEURONAL, 6D; LRRN6D__:__
Asterisk__:__609795__:__PYROGLUTAMYLATED RF-AMIDE PEPTIDE PRECURSOR PROTEIN; QRFP__:__QRFP PRECURSOR PROTEIN;; NEUROPEPTIDE RF-AMIDE PEPTIDE PRECURSOR;; P518 PRECURSOR PROTEIN__:__NEUROPEPTIDE RF-AMIDE PEPTIDE, INCLUDED;; P518, INCLUDED;; RF-AMIDE PEPTIDE, 26-AMINO ACID, INCLUDED; 26RFA, INCLUDED;; PYROGLUTAMYLATED RF-AMIDE PEPTIDE, INCLUDED; QRFP, INCLUDED
Number Sign__:__609796__:__PEELING SKIN SYNDROME 2; PSS2__:__ACRAL PEELING SKIN SYNDROME; APSS;; PEELING SKIN SYNDROME, ACRAL TYPE__:__
Asterisk__:__609797__:__BICAUDAL D, DROSOPHILA, HOMOLOG OF, 2; BICD2__:__KIAA0699__:__
Asterisk__:__609798__:__NEVER IN MITOSIS GENE A-RELATED KINASE 9; NEK9__:__NIMA-RELATED KINASE 9;; NERCC1__:__
Asterisk__:__609799__:__NEVER IN MITOSIS GENE A-RELATED KINASE 8; NEK8__:__NIMA-RELATED KINASE 8;; JCK, MOUSE, HOMOLOG OF;; NEPHROCYSTIN 9; NPHP9__:__
Percent__:__609800__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 4; GEFSP4__:__GEFS+, TYPE 4; GEFS+4__:__
Asterisk__:__609801__:__CD300E ANTIGEN; CD300E__:__CD300 ANTIGEN-LIKE FAMILY, MEMBER E; CD300LE;; IMMUNE RECEPTOR EXPRESSED BY MYELOID CELLS 2; IREM2;; CLM2__:__
Asterisk__:__609802__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 5; SLC24A5__:__SODIUM/CALCIUM/POTASSIUM EXCHANGER 5; NCKX5;; JSX__:__
Asterisk__:__609803__:__ANKYRIN AND ARMADILLO REPEATS-CONTAINING PROTEIN; ANKAR__:__FLJ25415__:__
Asterisk__:__609804__:__WD REPEAT-CONTAINING PROTEIN 16; WDR16__:__WD40 REPEAT-CONTAINING PROTEIN UPREGULATED IN HEPATOCELLULAR CARCINOMA; WDRPUH__:__
Asterisk__:__609805__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 19; SPATA19__:__SPERGEN 1__:__
Asterisk__:__609806__:__HYDROXYMETHYLBILANE SYNTHASE; HMBS__:__PORPHOBILINOGEN DEAMINASE; PBGD;; PRE-UROPORPHYRINOGEN SYNTHASE;; UROPORPHYRINOGEN I SYNTHASE;; UROPORPHYRINOGEN I SYNTHETASE__:__
Asterisk__:__609807__:__CD300 ANTIGEN-LIKE FAMILY, MEMBER F; CD300LF__:__CD300F;; IMMUNOGLOBULIN SUPERFAMILY, MEMBER 13; IGSF13;; IMMUNE RECEPTOR EXPRESSED ON MYELOID CELLS 1; IREM1;; CLM1__:__
NULL__:__609808__:__HAMARTOMA, PRECALCANEAL CONGENITAL FIBROLIPOMATOUS__:__PCFH__:__
Asterisk__:__609809__:__LCK-INTERACTING TRANSMEMBRANE ADAPTOR 1; LIME1__:__LIME__:__
Asterisk__:__609810__:__PATERNALLY EXPRESSED GENE 10; PEG10__:__KIAA1051;; EMBRYONAL CARCINOMA DIFFERENTIATION-REGULATED GENE; EDR__:__
Asterisk__:__609811__:__CYTOCHROME C OXIDASE, SUBUNIT 7B2; COX7B2__:__CYTOCHROME C OXIDASE, SUBUNIT VIIb2__:__
Number Sign__:__609812__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 8, WITH EXOCRINE DYSFUNCTION; MODY8__:__DIABETES AND PANCREATIC EXOCRINE DYSFUNCTION; DPED;; DIABETES-PANCREATIC EXOCRINE DYSFUNCTION SYNDROME__:__
Number Sign__:__609813__:__SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE; SCDO3__:____:__
Number Sign__:__609814__:__COMPLEMENT FACTOR H DEFICIENCY; CFHD__:__FACTOR H DEFICIENCY;; CFH DEFICIENCY__:__
Percent__:__609815__:__ZYGODACTYLY 1__:__ZD1__:__
Asterisk__:__609816__:__NEUROBEACHIN-LIKE 1; NBEAL1__:__ALS2 CHROMOSOME REGION GENE 17; ALS2CR17__:__
Percent__:__609817__:__VASCULITIS, LYMPHOCYTIC, CUTANEOUS SMALL VESSEL__:____:__
Asterisk__:__609818__:__UBIQUITIN-SPECIFIC PROTEIN 10; USP10__:__KIAA0190__:__
Asterisk__:__609819__:__PROSTATE, RECTUM, AND COLON GENE 1; PRAC1__:__SMALL NUCLEAR PROTEIN PRAC__:__
Number Sign__:__609820__:__ERYTHROCYTOSIS, FAMILIAL, 3; ECYT3__:____:__
Number Sign__:__609821__:__BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8__:__BLEEDING DISORDER DUE TO P2RY12 DEFECT__:__
Percent__:__609822__:__STATURE QUANTITATIVE TRAIT LOCUS 7; STQTL7__:____:__
Number Sign__:__609823__:__DEAFNESS, AUTOSOMAL RECESSIVE 28; DFNB28__:____:__
Asterisk__:__609824__:__HORMA DOMAIN-CONTAINING 1; HORMAD1__:__NOHMA__:__
Asterisk__:__609825__:__COQ2, S. CEREVISIAE, HOMOLOG OF; COQ2__:__PARAHYDROXYBENZOATE-POLYPRENYLTRANSFERASE, MITOCHONDRIAL__:__
Asterisk__:__609826__:__SOLUTE CARRIER FAMILY 34 (SODIUM/PHOSPHATE COTRANSPORTER), MEMBER 3; SLC34A3__:__SODIUM/INORGANIC PHOSPHATE COTRANSPORTER, TYPE IIC; NPTIIC__:__
Asterisk__:__609827__:__PELLINO, DROSOPHILA, HOMOLOG OF, 3; PELI3__:____:__
Asterisk__:__609828__:__FIBRONECTIN TYPE III AND SPRY DOMAINS-CONTAINING PROTEIN 1; FSD1__:__GLFND__:__
Asterisk__:__609829__:__FSD1 N-TERMINUS-LIKE PROTEIN; FSD1NL__:__FSD1-LIKE PROTEIN; FSD1L;; MID1-RELATED PROTEIN 1; MIR1;; COILED-COIL DOMAIN-CONTAINING PROTEIN 10; CCDC10__:__
Caret__:__609830__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__609831__:__MMACHC GENE; MMACHC__:____:__
Asterisk__:__609832__:__SOLUTE CARRIER FAMILY 47, MEMBER 1; SLC47A1__:__MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MATE1__:__
Asterisk__:__609833__:__SOLUTE CARRIER FAMILY 47, MEMBER 2; SLC47A2__:__MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MATE2;; MATE2K__:__
Asterisk__:__609834__:__SET AND MARINER TRANSPOSASE DOMAINS-CONTAINING PROTEIN; SETMAR__:__METNASE__:__
Asterisk__:__609835__:__MYCBP-ASSOCIATED PROTEIN; MYCBPAP__:__AMY1-ASSOCIATING PROTEIN 1; AMAP1__:__
Asterisk__:__609836__:__PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE 2; PCBD2__:__DIMERIZATION COFACTOR OF HEPATOCYTE NUCLEAR FACTOR 1-ALPHA 2; DCOH2;; DIMERIZATION COFACTOR OF HEPATOCYTE NUCLEAR FACTOR 1 FROM MUSCLE; DCOHM__:__
Asterisk__:__609837__:__SMALL NUCLEOLAR RNA, C/D BOX, 115-1; SNORD115-1__:__RNA, HBII-52 SMALL NUCLEOLAR;; snoRNA, HBII-52;; MBII-52, MOUSE, HOMOLOG OF__:__
Asterisk__:__609838__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 2; SLC24A2__:__SODIUM/POTASSIUM/CALCIUM EXCHANGER 2; NCKX2;; RETINAL CONE SODIUM/POTASSIUM/CALCIUM EXCHANGER__:__
Asterisk__:__609839__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 3; SLC24A3__:__SODIUM/POTASSIUM/CALCIUM EXCHANGER 3; NCKX3__:__
Asterisk__:__609840__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 4; SLC24A4__:__SODIUM/POTASSIUM/CALCIUM EXCHANGER 4; NCKX4__:__
Asterisk__:__609841__:__SOLUTE CARRIER FAMILY 8 (SODIUM/LITHIUM/CALCIUM EXCHANGER), MEMBER B1; SLC8B1__:__SOLUTE CARRIER FAMILY 24 (SODIUM/POTASSIUM/CALCIUM EXCHANGER), MEMBER 6; SLC24A6;; SODIUM/POTASSIUM/CALCIUM EXCHANGER 6; NCKX6;; NCLX__:__
Asterisk__:__609842__:__ENHANCER OF mRNA DECAPPING 3, S. CEREVISIAE, HOMOLOG OF; EDC3__:__YJEF DOMAIN-CONTAINING PROTEIN; YJDC__:__
Asterisk__:__609843__:__DECAPPING ENZYME 1, S. CEREVISIAE, HOMOLOG OF, B; DCP1B__:__DCP1, S. CEREVISIAE, HOMOLOG OF, B__:__
Asterisk__:__609844__:__DECAPPING ENZYME 2, S. CEREVISIAE, HOMOLOG OF; DCP2__:__DCP2, S. CEREVISIAE, HOMOLOG OF;; NUDIX HYDROLASE 20; NUDT20__:__
Asterisk__:__609845__:__SUCRASE-ISOMALTASE; SI__:____:__
Asterisk__:__609846__:__REGENERATING ISLET-DERIVED FAMILY, MEMBER 4; REG4__:__REG IV__:__
Asterisk__:__609847__:__NOTUM, DROSOPHILA, HOMOLOG OF; NOTUM__:____:__
Asterisk__:__609848__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 11; KCTD11__:__GENE INDUCED BY RETINOIC ACID, EGF, AND NGF; REN__:__
Asterisk__:__609849__:__CORONIN 1B; CORO1B__:__CORONIN 2__:__
Asterisk__:__609850__:__TBC1 DOMAIN FAMILY, MEMBER 1; TBC1D1__:__KIAA1108__:__
Asterisk__:__609851__:__INOSITOL POLYPHOSPHATE MULTIKINASE; IPMK__:__INOSITOL 1,3,4,5-TETRAKISPHOSPHATE 5-KINASE__:__
Asterisk__:__609852__:__MIX1 HOMEOBOX-LIKE PROTEIN 1; MIXL1__:__MIXL;; MIX__:__
Asterisk__:__609853__:__PHOSPHOPANTOTHENOYLCYSTEINE SYNTHETASE; PPCS__:____:__
Asterisk__:__609854__:__PHOSPHOPANTOTHENOYLCYSTEINE DECARBOXYLASE; PPCDC__:____:__
Asterisk__:__609855__:__COENZYME A SYNTHASE; COASY__:__PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE/DEPHOSPHOCOENZYME A KINASE;; PPAT/DPCK__:__
Asterisk__:__609856__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 16; SPATA16__:__NYD-SP12__:__
Asterisk__:__609857__:__DYSTROPHIA MYOTONICA WD REPEAT-CONTAINING PROTEIN; DMWD__:__DMRN9, MOUSE, HOMOLOG OF; DMRN9__:__
Asterisk__:__609858__:__ETHANOLAMINE KINASE 1; ETNK1__:__EKI1__:__
Asterisk__:__609859__:__ETHANOLAMINE KINASE 2; ETNK2__:__EKI2__:__
Asterisk__:__609860__:__DAD1-RELATED GENE__:__DADR__:__
Asterisk__:__609861__:__I-KAPPA-B KINASE-INTERACTING PROTEIN; IKBIP__:__IKIP;; IKK-INTERACTING PROTEIN__:__
Asterisk__:__609862__:__TRANSMEMBRANE PROTEASE, SERINE 6; TMPRSS6__:__MATRIPTASE 2__:__
Asterisk__:__609863__:__TECTONIC FAMILY, MEMBER 1; TCTN1__:__TECTONIC 1; TECT1;; TECTONIC__:__
Asterisk__:__609864__:__TRANSMEMBRANE PROTEIN 55A; TMEM55A__:__PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 4-PHOSPHATASE, TYPE II__:__
Asterisk__:__609865__:__TRANSMEMBRANE PROTEIN 55B; TMEM55B__:__PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 4-PHOSPHATASE, TYPE I__:__
Asterisk__:__609866__:__START DOMAIN-CONTAINING PROTEIN 13; STARD13__:__DELETED IN LIVER CANCER 2; DLC2__:__
Asterisk__:__609867__:__UBIQUITIN-LIKE DOMAIN-CONTAINING CTD PHOSPHATASE 1; UBLCP1__:____:__
Asterisk__:__609868__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 7; SPATA7__:__HSD3__:__
Asterisk__:__609869__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 12; SPATA12__:__SRG5__:__
Asterisk__:__609870__:__RHO GTPase-ACTIVATING PROTEIN 21; ARHGAP21__:__GTPase-ACTIVATING PROTEIN, RHO, 21;; KIAA1424;; RHO GTPase-ACTIVATING PROTEIN 10, FORMERLY; ARHGAP10, FORMERLY__:__
Asterisk__:__609871__:__TBC1 DOMAIN FAMILY, MEMBER 2; TBC1D2__:__PARIS1__:__
Asterisk__:__609872__:__WAP 4-DISULFIDE CORE DOMAIN 12; WFDC12__:__WHEY ACIDIC PROTEIN 2; WAP2;; SINGLE WAP MOTIF PROTEIN 2; SWAM2__:__
Asterisk__:__609873__:__INTELECTIN 1; ITLN1__:__INTL;; LACTOFERRIN RECEPTOR; LFR;; HL1__:__
Asterisk__:__609874__:__INTELECTIN 2; ITLN2__:__HL2__:__
Asterisk__:__609875__:__ATONAL, DROSOPHILA, HOMOLOG OF, 7; ATOH7__:____:__REGULATORY ELEMENT, CIS-ACTING, ENHANCER, 21.7 KB UPSTREAM OF ATOH7, INCLUDED; RECE-ATOH7, INCLUDED
Percent__:__609876__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 6; BMND6__:____:__
Asterisk__:__609877__:__CRYSTALLIN, LAMBDA-1; CRYL1__:____:__
Asterisk__:__609878__:__MEDIATOR COMPLEX SUBUNIT 9; MED9__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 9, S. CEREVISIAE, HOMOLOG OF;; MED25;; FLJ10193__:__
Asterisk__:__609879__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 4; SPATA4__:__TESTIS- AND SPERMATOGENESIS CELL-RELATED PROTEIN 2; TSARG2__:__
Asterisk__:__609880__:__LYSINE ACETYLTRANSFERASE 7; KAT7__:__HISTONE ACETYLTRANSFERASE MYST2; MYST2;; HISTONE ACETYLTRANSFERASE BINDING TO ORC1; HBO1__:__
Asterisk__:__609881__:__RNA POLYMERASE II POLYPEPTIDE J-RELATED GENE__:__POLR2J2;; RPB11, S. CEREVISIAE, HOMOLOG OF, B__:__
Asterisk__:__609882__:__METAL-REGULATORY TRANSCRIPTION FACTOR 2; MTF2__:__METAL RESPONSE ELEMENT-BINDING TRANSCRIPTION FACTOR 2;; PCL2;; M96__:__
Asterisk__:__609883__:__MKS1 GENE; MKS1__:__BBS13 GENE; BBS13;; FLJ20345__:__
Asterisk__:__609884__:__TRANSMEMBRANE PROTEIN 67; TMEM67__:__MKS3 GENE;; MECKELIN__:__
Asterisk__:__609885__:__ELONGATION FACTOR, RNA POLYMERASE II, 3; ELL3__:____:__
Number Sign__:__609886__:__GLOMERULOCYSTIC KIDNEY DISEASE WITH HYPERURICEMIA AND ISOSTHENURIA__:____:__
Number Sign__:__609887__:__GLAUCOMA 1, OPEN ANGLE, G; GLC1G__:____:__
Percent__:__609888__:__LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1__:__LEPROSY, PAUCIBACILLARY TYPE, SUSCEPTIBILITY TO, 1__:__
Number Sign__:__609889__:__ALPHA/BETA T-CELL LYMPHOPENIA WITH GAMMA/DELTA T-CELL EXPANSION, SEVERE CYTOMEGALOVIRUS INFECTION, AND AUTOIMMUNITY__:____:__
Asterisk__:__609890__:__UBIQUITIN PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 4; UBR4__:__RETINOBLASTOMA-ASSOCIATED FACTOR 600; RBAF600;; KIAA1307;; p600__:__
Asterisk__:__609891__:__RIPPLY TRANSCRIPTIONAL REPRESSOR 2; RIPPLY2__:__CHROMOSOME 6 OPEN READING FRAME 59; C6ORF59__:__
Asterisk__:__609892__:__DOWN SYNDROME CRITICAL REGION GENE 6; DSCR6__:__RIPPLY3__:__
Percent__:__609893__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3__:__RESISTANCE TO THYROTROPIN; RTSH;; THYROTROPIN RESISTANCE__:__
Asterisk__:__609894__:__UNC13, C. ELEGANS, HOMOLOG OF, A; UNC13A__:__MUNC13-1;; KIAA1032__:__
Asterisk__:__609895__:__CASTOR ZINC FINGER PROTEIN 1; CASZ1__:__SURVIVAL-RELATED GENE; SRG__:__
Asterisk__:__609896__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 4E FAMILY, MEMBER 3; EIF4E3__:__EIF4E FAMILY, MEMBER 3__:__
Asterisk__:__609897__:__EPIDERMAL GROWTH FACTOR-LIKE 8; EGFL8__:____:__
Asterisk__:__609898__:__KRINGLE DOMAIN-CONTAINING TRANSMEMBRANE PROTEIN 1; KREMEN1__:__KRM1;; KREMEN__:__
Asterisk__:__609899__:__KRINGLE DOMAIN-CONTAINING TRANSMEMBRANE PROTEIN 2; KREMEN2__:__KRM2__:__
Asterisk__:__609900__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3D; APOBEC3D__:____:__
Asterisk__:__609901__:__ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS-CONTAINING PROTEIN 4B; ANKS4B__:__HARMONIN-INTERACTING, ANKYRIN REPEAT-CONTAINING PROTEIN; HARP;; FLJ38819__:__
Caret__:__609902__:__MOVED TO 603317__:____:__
Percent__:__609903__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 5; SLEB5__:____:__
Asterisk__:__609904__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER A; HIST1H2BA__:__HISTONE GENE CLUSTER 1, H2BA;; HIST1 CLUSTER, H2BA;; H2B HISTONE FAMILY, MEMBER U; H2BFU;; TESTIS-SPECIFIC HISTONE H2B; TSH2B__:__
Asterisk__:__609905__:__MYOSIN LIGHT CHAIN 9, REGULATORY; MYL9__:__MLC2__:__
Asterisk__:__609906__:__EMBRYONAL FYN-ASSOCIATED SUBSTRATE; EFS__:__SRC-INTERACTING PROTEIN; SIN__:__
Asterisk__:__609907__:__SEMAPHORIN 3D; SEMA3D__:____:__
Asterisk__:__609908__:__APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 4; APOBEC4__:____:__
Number Sign__:__609909__:__CARDIOMYOPATHY, DILATED, 1P; CMD1P__:____:__
Asterisk__:__609910__:__MYCBP-ASSOCIATED TESTIS-EXPRESSED PROTEIN 1; MAATS1__:__AMY1-ASSOCIATED PROTEIN EXPRESSED IN TESTIS 1; AAT1;; CHROMOSOME 3 OPEN READING FRAME 15; C3ORF15__:__
Asterisk__:__609911__:__HEPATOCELLULAR CARCINOMA-DOWNREGULATED MITOCHONDRIAL CARRIER PROTEIN__:__HDMCP;; CHROMOSOME 14 OPEN READING FRAME 68; C14ORF68__:__
Asterisk__:__609912__:__LYSINE ACETYLTRANSFERASE 8; KAT8__:__HISTONE ACETYLTRANSFERASE MYST1; MYST1;; MOF, DROSOPHILA, HOMOLOG OF; MOF__:__
Percent__:__609913__:__RETINITIS PIGMENTOSA 32; RP32__:____:__
Asterisk__:__609914__:__AQUAPORIN 11; AQP11__:__AQPX1__:__
Percent__:__609915__:__CARDIOMYOPATHY, DILATED, 1Q; CMD1Q__:____:__
Asterisk__:__609916__:__5-AZACYTIDINE-INDUCED GENE 2, MOUSE, HOMOLOG OF; AZI2__:__AZI2, MOUSE, HOMOLOG OF; AZ2;; NAK-ASSOCIATED PROTEIN 1; NAP1;; TILP__:__
Asterisk__:__609917__:__PRION PROTEIN-INTERACTING PROTEIN; PRNPIP__:__PRION INTERACTOR 1; PINT1__:__
Percent__:__609918__:__GALLBLADDER DISEASE 2; GBD2__:____:__
Percent__:__609919__:__GALLBLADDER DISEASE 3; GBD3__:____:__
Asterisk__:__609920__:__CADHERIN 22; CDH22__:__CADHERIN, PITUITARY AND BRAIN;; PB-CADHERIN__:__
Asterisk__:__609921__:__LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 10; LRP10__:__LRP9__:__
Asterisk__:__609922__:__EH DOMAIN-BINDING PROTEIN 1; EHBP1__:__KIAA0903__:__
Number Sign__:__609923__:__RETINITIS PIGMENTOSA 31; RP31__:____:__
Number Sign__:__609924__:__AMINOACYLASE 1 DEFICIENCY; ACY1D__:____:__
Asterisk__:__609925__:__DIPEPTIDASE 2; DPEP2__:__MEMBRANE-BOUND DIPEPTIDASE 2; MBD2__:__
Asterisk__:__609926__:__DIPEPTIDASE 3; DPEP3__:__MEMBRANE-BOUND DIPEPTIDASE 3; MBD3__:__
Asterisk__:__609927__:__VACUOLAR PROTEIN SORTING 37, YEAST, HOMOLOG OF, A; VPS37A__:__HEPATOCELLULAR CARCINOMA-RELATED PROTEIN 1; HCRP1__:__
Asterisk__:__609928__:__MYOSIN, HEAVY CHAIN 7B, CARDIAC MUSCLE, BETA; MYH7B__:__MYOSIN HEAVY CHAIN 14; MYH14;; KIAA1512__:__
Asterisk__:__609929__:__MYOSIN, HEAVY CHAIN 15; MYH15__:____:__
Asterisk__:__609930__:__MYOSIN, LIGHT CHAIN 6B, ALKALI, SMOOTH MUSCLE AND NONMUSCLE, SLOW; MYL6B__:__MYOSIN, LIGHT CHAIN 1, SLOW, A; MLC1SA__:__
Asterisk__:__609931__:__MYOSIN LIGHT CHAIN 6, ALKALI, SMOOTH MUSCLE AND NONMUSCLE; MYL6__:____:__
Asterisk__:__609932__:__SPERM ACROSOME-ASSOCIATED PROTEIN 4; SPACA4__:__SPERM ACROSOMAL MEMBRANE PROTEIN 14; SAMP14__:__
Asterisk__:__609933__:__REGENERATING ISLET-DERIVED 3-GAMMA; REG3G__:__REG III;; PAP IB__:__
Asterisk__:__609934__:__EARLY B-CELL FACTOR 2; EBF2__:____:__
Asterisk__:__609935__:__EARLY B-CELL FACTOR 4; EBF4__:__KIAA1442__:__
Asterisk__:__609936__:__SPINDLIN 1; SPIN1__:__SPINDLIN; SPIN__:__
Asterisk__:__609937__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 7; CDCA7__:__JPO1__:__
Asterisk__:__609938__:__CELL ADHESION MOLECULE 2; CADM2__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 4D; IGSF4D;; SYNAPTIC CELL ADHESION MOLECULE 2; SYNCAM2;; NECTIN-LIKE PROTEIN 3; NECL3__:__
Percent__:__609939__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 6; SLEB6__:____:__
Caret__:__609940__:__MOVED TO 112250__:____:__
Percent__:__609941__:__DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51__:____:__
Number Sign__:__609942__:__NOONAN SYNDROME 3; NS3__:____:__
NULL__:__609943__:__HYPERTRICHOSIS, HYPERKERATOSIS, MENTAL RETARDATION, AND DISTINCTIVE FACIAL FEATURES__:____:__
NULL__:__609944__:__ECTODERMAL DYSPLASIA, SENSORINEURAL HEARING LOSS, AND DISTINCTIVE FACIAL FEATURES__:____:__
NULL__:__609945__:__BRACHYPHALANGY, POLYDACTYLY, AND TIBIAL APLASIA/HYPOPLASIA__:____:__
Percent__:__609946__:__DEAFNESS, AUTOSOMAL RECESSIVE 47; DFNB47__:____:__
Asterisk__:__609947__:__KIAA0391 GENE; KIAA0391__:__MITOCHONDRIAL RIBONUCLEASE P PROTEIN 3; MRPP3__:__
Asterisk__:__609948__:__RING FINGER PROTEIN 216; RNF216__:__TRIAD DOMAIN-CONTAINING PROTEIN 3; TRIAD3;; ZINC FINGER PROTEIN INHIBITING NFKB; ZIN__:__
Asterisk__:__609949__:__COMPLEMENT COMPONENT 5a RECEPTOR 2; C5AR2__:__G PROTEIN-COUPLED RECEPTOR 77; GPR77;; C5L2__:__
Asterisk__:__609950__:__RAVER1, MOUSE, HOMOLOG OF__:__RAVER1;; KIAA1978__:__
Asterisk__:__609951__:__ZINC FINGER PROTEIN 384; ZNF384__:__CAS-INTERACTING ZINC FINGER PROTEIN; CIZ;; CAGH1;; NUCLEAR MATRIX PROTEIN 4; NMP4__:__
Percent__:__609952__:__DEAFNESS, AUTOSOMAL RECESSIVE 55; DFNB55__:____:__
Asterisk__:__609953__:__RAVER2, MOUSE, HOMOLOG OF__:__RAVER2;; KIAA1579__:__
Percent__:__609954__:__ASPERGER SYNDROME, SUSCEPTIBILITY TO, 4; ASPG4__:____:__
Percent__:__609955__:__FIBROMATOSIS, GINGIVAL, 3; GINGF3__:__GGF3;; FIBROMATOSIS, GINGIVAL, HEREDITARY, 3; HGF3__:__
Asterisk__:__609956__:__RAS-ASSOCIATED PROTEIN RAB37; RAB37__:____:__
Asterisk__:__609957__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1J; PPM1J__:__PROTEIN PHOSPHATASE, MAGNESIUM-DEPENDENT, 1J;; PROTEIN PHOSPHATASE 2C, ZETA ISOFORM; PP2CZ;; PPP2CZ__:__
Percent__:__609958__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 3__:__ASRT3__:__
Asterisk__:__609959__:__MYELOID-ASSOCIATED DIFFERENTIATION MARKER; MYADM__:____:__
Asterisk__:__609960__:__KIAA0020 GENE; KIAA0020__:__MINOR HISTOCOMPATIBILITY ANTIGEN HA-8;; HLA-HA8__:__
Asterisk__:__609961__:__MINOR HISTOCOMPATIBILITY ANTIGEN HB-1__:__HLA-HB1__:__
Asterisk__:__609962__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER E; CLEC4E__:__MACROPHAGE-INDUCIBLE C-TYPE LECTIN; MINCLE__:__
Asterisk__:__609963__:__CHONDROITIN SULFATE SYNTHASE 3; CHSY3__:__CSS3;; CARBOHYDRATE SYNTHASE 2__:__
Asterisk__:__609964__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER D; CLEC4D__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 8; CLECSF8;; CLEC6;; MACROPHAGE C-TYPE LECTIN; MCL;; DECTIN 3__:__
Percent__:__609965__:__DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53__:____:__
Asterisk__:__609966__:__GAMETOGENETIN, MOUSE, HOMOLOG OF; GGN__:____:__
Asterisk__:__609967__:__B-CELL NOVEL PROTEIN 1__:__BCNP1__:__
Number Sign__:__609968__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5; HHF5__:____:__
Asterisk__:__609969__:__SUPRABASIN__:__SBSN__:__
Asterisk__:__609970__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 2; HES2__:____:__
Asterisk__:__609971__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 3; HES3__:____:__
Asterisk__:__609972__:__ACYL-CoA THIOESTERASE 2; ACOT2__:__PEROXISOMAL LONG-CHAIN ACYL-CoA THIOESTERASE; PTE2;; MTE1;; PTE1A, MOUSE, HOMOLOG OF__:__
Asterisk__:__609973__:__HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED POTASSIUM CHANNEL 3; HCN3__:__KIAA1535__:__
Asterisk__:__609974__:__CADHERIN 9; CDH9__:__T1-CADHERIN__:__
Number Sign__:__609975__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 4; HHF4__:____:__
Asterisk__:__609976__:__HYPOXIA-INDUCIBLE FACTOR 3, ALPHA SUBUNIT; HIF3A__:__HIF3-ALPHA;; INHIBITORY PAS DOMAIN PROTEIN; IPAS__:__
Asterisk__:__609977__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 8; CDCA8__:__DASRA B;; BOREALIN__:__
Asterisk__:__609978__:__CALCIUM-DEPENDENT ACTIVATOR PROTEIN FOR SECRETION 2; CADPS2__:__KIAA1591__:__
Asterisk__:__609979__:__VESTIGIAL-LIKE 2; VGLL2__:__VGL2;; VESTIGIAL- AND TONDU-RELATED PROTEIN 1; VITO1__:__
Asterisk__:__609980__:__VESTIGIAL-LIKE 3; VGLL3__:__VGL3__:__
Number Sign__:__609981__:__IMMUNODEFICIENCY 54; IMD54__:__NATURAL KILLER CELL AND GLUCOCORTICOID DEFICIENCY WITH DNA REPAIR DEFECT; NKGCD;; NATURAL KILLER CELL DEFICIENCY, FAMILIAL ISOLATED; NKCD__:__
Asterisk__:__609982__:__VACUOLAR PROTEIN SORTING 4, YEAST, HOMOLOG OF, A; VPS4A__:__VPS4__:__
Asterisk__:__609983__:__VACUOLAR PROTEIN SORTING 4, S. CEREVISIAE, HOMOLOG OF, B; VPS4B__:__SKD1, MOUSE, HOMOLOG OF; SKD1__:__
Asterisk__:__609984__:__ZWILCH, DROSOPHILA, HOMOLOG OF; ZWILCH__:____:__
Percent__:__609985__:__PANIC DISORDER 3__:__PAND3;; PANIC DISORDER SUSCEPTIBILITY LOCUS, CHROMOSOME 4q-RELATED__:__
Asterisk__:__609986__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 6; CARD6__:____:__CARD-CONTAINING INHIBITOR OF NOD1- AND CARDIAK-INDUCED NFKB ACTIVATION 1, INCLUDED; CINCIN1, INCLUDED
Asterisk__:__609987__:__STIMULATED BY RETINOIC ACID 8; STRA8__:____:__
Asterisk__:__609988__:__PYROPHOSPHATASE, INORGANIC, 2; PPA2__:____:__
Percent__:__609989__:__METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES, NORMAL HAIR, AND NORMAL HANDS__:__CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES WITHOUT ALOPECIA OR BRACHYDACTYLY__:__
Percent__:__609990__:__TRICHOSCYPHODYSPLASIA__:__METAPHYSEAL CHONDRODYSPLASIA WITH CONE-SHAPED EPIPHYSES AND ALOPECIA;; METAPHYSEAL CHONDRODYSPLASIA WITH ECTODERMAL DYSPLASIA;; CUPPED METAPHYSES AND CONE-SHAPED EPIPHYSES WITH ALOPECIA__:__
Asterisk__:__609991__:__FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 1; FNDC1__:__ACTIVATOR OF G PROTEIN SIGNALING 8; AGS8;; KIAA1866__:__
Asterisk__:__609992__:__PROCESSING OF PRECURSOR 5, S. CEREVISIAE, HOMOLOG OF; POP5__:__HSPC004__:__
Percent__:__609993__:__OSTEOSCLEROSIS WITH ICHTHYOSIS AND PREMATURE OVARIAN FAILURE__:__SCLEROSING DYSPLASIA OF BONE WITH ICHTHYOSIS AND PREMATURE OVARIAN FAILURE__:__
Percent__:__609994__:__MYOPIA 11, AUTOSOMAL DOMINANT; MYP11__:____:__
Percent__:__609995__:__MYOPIA 12, AUTOSOMAL DOMINANT; MYP12__:____:__
Asterisk__:__609996__:__COLLAGEN, TYPE XXVIII, ALPHA-1; COL28A1__:____:__
Asterisk__:__609997__:__HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 2; HINT2__:____:__
Asterisk__:__609998__:__HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 3; HINT3__:____:__
Asterisk__:__609999__:__SYNAPSE DIFFERENTIATION-INDUCED GENE 1-LIKE; SYNDIG1L__:__TRANSMEMBRANE PROTEIN 90A; TMEM90A;; CAUDATE- AND PUTAMEN-ENRICHED GENE; CAPUCIN__:__
Asterisk__:__610000__:__CENTROSOMAL PROTEIN, 55-KD; CEP55__:____:__
NULL__:__610001__:__ARTHROGRYPOSIS MULTIPLEX WITH DEAFNESS, INGUINAL HERNIAS, AND EARLY DEATH__:____:__
Asterisk__:__610002__:__COLLAGEN, TYPE XXI, ALPHA-1; COL21A1__:____:__
Number Sign__:__610003__:__CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY VARIANT__:__NORTHERN EPILEPSY;; EPILEPSY, PROGRESSIVE, WITH MENTAL RETARDATION; EPMR__:__
Asterisk__:__610004__:__COLLAGEN, TYPE XXV, ALPHA-1; COL25A1__:__COLLAGEN-LIKE ALZHEIMER AMYLOID PLAQUE COMPONENT PRECURSOR;; CLAC PRECURSOR; CLACP__:__COLLAGEN-LIKE ALZHEIMER AMYLOID PLAQUE COMPONENT, INCLUDED; CLAC, INCLUDED
Asterisk__:__610005__:__TRAF2- AND NCK-INTERACTING KINASE; TNIK__:__KIAA0551__:__
Number Sign__:__610006__:__2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY__:__2-METHYLBUTYRYL GLYCINURIA;; SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD__:__
Asterisk__:__610007__:__LIMB REGION 1 HOMOLOG-LIKE; LMBR1L__:__LIPOCALIN-INTERACTING MEMBRANE RECEPTOR; LIMR;; KIAA1174__:__
Asterisk__:__610008__:__ARYLSULFATASE G; ARSG__:__KIAA1001__:__
Asterisk__:__610009__:__ARYLSULFATASE I; ARSI__:____:__
Asterisk__:__610010__:__ARYLSULFATASE J; ARSJ__:____:__
Asterisk__:__610011__:__ARYLSULFATASE K; ARSK__:____:__
Asterisk__:__610012__:__SULFATASE 1; SULF1__:__KIAA1077__:__
Asterisk__:__610013__:__SULFATASE 2; SULF2__:__KIAA1247__:__
Asterisk__:__610014__:__TM2 DOMAIN-CONTAINING PROTEIN 3; TM2D3__:__BBP-LIKE PROTEIN 2; BLP2__:__
Number Sign__:__610015__:__GLUTAMINE DEFICIENCY, CONGENITAL__:__GLUTAMINE SYNTHASE DEFICIENCY, CONGENITAL SYSTEMIC__:__
Asterisk__:__610016__:__MICRO RNA 132; MIR132__:__miRNA132;; MIRN132;; MIR132-3p__:__MICRO RNA 132*, INCLUDED; MIR132*, INCLUDED;; MICRO RNA 132-5p, INCLUDED; MIR132-5p, INCLUDED
Number Sign__:__610017__:__MULTIPLE SYNOSTOSES SYNDROME 2; SYNS2__:____:__
Asterisk__:__610018__:__SOLO GENE__:__SOLO;; FLJ10357__:__
Number Sign__:__610019__:__CATARACT 18; CTRCT18__:__CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 2; CATC2__:__
Asterisk__:__610020__:__TBC1 DOMAIN FAMILY, MEMBER 10A; TBC1D10A__:__EPI64__:__
Number Sign__:__610021__:__HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 7; HHF7__:__HYPERINSULINEMIC HYPOGLYCEMIA, EXERCISE-INDUCED__:__
Asterisk__:__610022__:__MYOSIN VC; MYO5C__:____:__
NULL__:__610023__:__BRACHYDACTYLY, COLOBOMA, AND ANTERIOR SEGMENT DYSGENESIS__:____:__
Number Sign__:__610024__:__RETINAL CONE DYSTROPHY 3A; RCD3A__:__CONE DYSTROPHY WITH NIGHT BLINDNESS AND SUPERNORMAL ROD RESPONSES, PDE6H-RELATED__:__ACHROMATOPSIA 6, INCLUDED; ACHM6, INCLUDED
Asterisk__:__610025__:__COLLAGEN, TYPE XXIV, ALPHA-1; COL24A1__:____:__
Asterisk__:__610026__:__COLLAGEN, TYPE XXII, ALPHA-1; COL22A1__:____:__
Asterisk__:__610027__:__VACUOLAR PROTEIN SORTING 26, YEAST, HOMOLOG OF, B; VPS26B__:____:__
Asterisk__:__610028__:__POLY(ADP-RIBOSE) POLYMERASE 14; PARP14__:__KIAA1268;; B-AGGRESSIVE LYMPHOMA 2; BAL2;; COLLABORATOR OF STAT6; COAST6__:__
Asterisk__:__610029__:__VOLTAGE-DEPENDENT ANION CHANNEL 3; VDAC3__:____:__
Asterisk__:__610030__:__VOLTAGE-DEPENDENT ANION CHANNEL 4; VDAC4__:____:__
Number Sign__:__610031__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 7; CDCBM7__:__POLYMICROGYRIA, SYMMETRIC OR ASYMMETRIC; PMGYSA__:__
Asterisk__:__610032__:__TRANSPORTIN 3; TNPO3__:__TRANSPORTIN-SR; TRNSR__:__
Asterisk__:__610033__:__PENTA-EF-HAND DOMAIN-CONTAINING PROTEIN 1; PEF1__:__PEFLIN__:__
Asterisk__:__610034__:__VACUOLAR PROTEIN SORTING 33, YEAST, HOMOLOG OF, A; VPS33A__:____:__
Asterisk__:__610035__:__VACUOLAR PROTEIN SORTING 45, YEAST, HOMOLOG OF; VPS45__:__VACUOLAR PROTEIN SORTING 45, YEAST, HOMOLOG OF, A; VPS45A__:__
Asterisk__:__610036__:__CLAUDIN 19; CLDN19__:____:__
Asterisk__:__610037__:__VACUOLAR PROTEIN SORTING 37, YEAST, HOMOLOG OF, B; VPS37B__:____:__
Asterisk__:__610038__:__VACUOLAR PROTEIN SORTING 37, YEAST, HOMOLOG OF, C; VPS37C__:____:__
Asterisk__:__610039__:__VACUOLAR PROTEIN SORTING 37, YEAST, HOMOLOG OF, D; VPS37D__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 24; WBSCR24__:__
Asterisk__:__610040__:__MYOSIN IIIB; MYO3B__:____:__
Asterisk__:__610041__:__NEDD4 FAMILY-INTERACTING PROTEIN 2; NDFIP2__:__NEDD4 WW DOMAIN-BINDING PROTEIN 5A; N4WBP5A;; KIAA1165__:__
Number Sign__:__610042__:__PITT-HOPKINS-LIKE SYNDROME 1; PTHSL1__:__CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME; CDFES__:__
Asterisk__:__610043__:__COLLAGEN, TYPE XXIII, ALPHA-1; COL23A1__:____:__
Asterisk__:__610044__:__POTASSIUM CHANNEL, SUBFAMILY T, MEMBER 2; KCNT2__:__SLICK__:__
Asterisk__:__610045__:__ALDEHYDE DEHYDROGENASE 5 FAMILY, MEMBER A1; ALDH5A1__:__SUCCINIC SEMIALDEHYDE DEHYDROGENASE, NAD(+)-DEPENDENT; SSADH__:__
Asterisk__:__610046__:__LAEVERIN; LVRN__:__FLJ90650;; CHL2 ANTIGEN;; AMINOPEPTIDASE Q; APQ;; TRANSMEMBRANE AMINOPEPTIDASE Q; TAQPEP__:__
Asterisk__:__610047__:__CANOPY FGF SIGNALING REGULATOR 4; CNPY4__:__CANOPY 4, ZEBRAFISH, HOMOLOG OF;; PROTEIN ASSOCIATED WITH TLR4; PRAT4B;; MGC40499__:__
Number Sign__:__610048__:__CORNEAL DYSTROPHY, CONGENITAL STROMAL; CSCD__:__CONGENITAL STROMAL CORNEAL DYSTROPHY__:__
Asterisk__:__610049__:__SAP DOMAIN-CONTAINING RIBONUCLEOPROTEIN; SARNP__:__CYTOKINE-INDUCED PROTEIN, 29-KD; CIP29;; HEPATOCELLULAR CARCINOMA 1; HCC1;; HSPC316__:__CIP29/MLL FUSION GENE, INCLUDED
Asterisk__:__610050__:__TRANSMEMBRANE PROTEASE, SERINE 13; TMPRSS13__:__MOSAIC SERINE PROTEASE LONG; MSPL__:__MOSAIC SERINE PROTEASE SHORT, INCLUDED; MSPS, INCLUDED
Asterisk__:__610051__:__CHMP FAMILY, MEMBER 4A; CHMP4A__:__CHROMATIN-MODIFYING PROTEIN 4A;; CHARGED MULTIVESICULAR BODY PROTEIN 4A;; CHMP4;; SNF7, YEAST, HOMOLOG OF, 1;; SNF7-1;; HSPC134__:__
Asterisk__:__610052__:__VACUOLAR PROTEIN SORTING 24, YEAST, HOMOLOG OF; VPS24__:__CHMP FAMILY, MEMBER 3; CHMP3;; CHARGED MULTIVESICULAR BODY PROTEIN 3;; CHROMATIN-MODIFYING PROTEIN 3;; NEUROENDOCRINE DIFFERENTIATION FACTOR; NEDF__:__
Asterisk__:__610053__:__TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 6; TUBGCP6__:__GCP6;; KIAA1669__:__
Asterisk__:__610054__:__H2A HISTONE FAMILY, MEMBER Y; H2AFY__:__MACRO H2A;; MACRO H2A1;; MH2A1__:__
Asterisk__:__610055__:__COILED-COIL AND C2 DOMAINS-CONTAINING PROTEIN 1A; CC2D1A__:____:__
Asterisk__:__610056__:__SPERM-ASSOCIATED ANTIGEN 7; SPAG7__:____:__
Asterisk__:__610057__:__TRANS-2,3-ENOYL-CoA REDUCTASE; TECR__:__GLYCOPROTEIN, SYNAPTIC, 2; GPSN2;; TER;; SC2__:__
Asterisk__:__610058__:__TUBULIN-SPECIFIC CHAPERONE A; TBCA__:__CHAPERONIN COFACTOR A__:__
Asterisk__:__610059__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L33; MRPL33__:____:__
Asterisk__:__610060__:__POLYMERASE I, RNA, SUBUNIT C; POLR1C__:__RPA39;; RPA40;; RPAC1;; RPA5__:__
Asterisk__:__610061__:__DYNEIN, AXONEMAL, HEAVY CHAIN 7; DNAH7__:__KIAA0944__:__
Asterisk__:__610062__:__DYNEIN, AXONEMAL, LIGHT CHAIN 1; DNAL1__:__CHROMOSOME 14 OPEN READING FRAME 168; C14ORF168__:__
Asterisk__:__610063__:__DYNEIN, AXONEMAL, HEAVY CHAIN 17; DNAH17__:__DNEL2__:__
Percent__:__610064__:__OPIOID DEPENDENCE, SUSCEPTIBILITY TO, 1__:__ODS1__:__
Percent__:__610065__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 7; SLEB7__:____:__
Percent__:__610066__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 8; SLEB8__:____:__
Asterisk__:__610067__:__MYOSIN XVIIIA; MYO18A__:__SURFACTANT PROTEIN A RECEPTOR, 210-KD; SPR210__:__MYO18A/PDGFRB FUSION GENE, INCLUDED
Asterisk__:__610068__:__SOLUTE CARRIER FAMILY 26 (ANION TRANSPORTER), MEMBER 6: SLC26A6__:____:__
Number Sign__:__610069__:__POLYPOSIS SYNDROME, HEREDITARY MIXED, 2; HMPS2__:____:__
Asterisk__:__610070__:__ASTER-ASSOCIATED PROTEIN__:__ASAP__:__
Percent__:__610071__:__HYPERPARATHYROIDISM 3; HRPT3__:____:__
Asterisk__:__610072__:__ERMIN; ERMN__:__JUXTANODIN; JN;; KIAA1189__:__
Asterisk__:__610073__:__ORM1-LIKE PROTEIN 1; ORMDL1__:____:__
Asterisk__:__610074__:__ORM1-LIKE PROTEIN 2; ORMDL2__:____:__
Asterisk__:__610075__:__ORM1-LIKE PROTEIN 3; ORMDL3__:____:__
Asterisk__:__610076__:__CYCLIN-DEPENDENT KINASE 20; CDK20__:__CELL CYCLE-RELATED KINASE; CCRK;; CYCLIN-DEPENDENT PROTEIN KINASE H; CDCH;; p42__:__
Asterisk__:__610077__:__REGULATOR OF CELL CYCLE; RGCC__:__RESPONSE GENE TO COMPLEMENT 32; RGC32;; CHROMOSOME 13 OPEN READING FRAME 15; C13ORF15__:__
Asterisk__:__610078__:__MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 3; MORC3__:__NUCLEAR MATRIX PROTEIN 2; NXP2__:__
Asterisk__:__610079__:__SIALIC ACID ACETYLESTERASE; SIAE__:____:__SIALIC ACID ACETYLESTERASE, LYSOSOMAL, INCLUDED; LSE, INCLUDED;; SIALIC ACID ACETYLESTERASE, CYTOSOLIC, INCLUDED; CSE, INCLUDED
Asterisk__:__610080__:__TM2 DOMAIN-CONTAINING PROTEIN 1; TM2D1__:__BETA-AMYLOID PEPTIDE-BINDING PROTEIN; BBP__:__
Asterisk__:__610081__:__TM2 DOMAIN-CONTAINING PROTEIN 2; TM2D2__:__BBP-LIKE PROTEIN 1; BLP1__:__
Asterisk__:__610082__:__MYOSIN REGULATORY LIGHT CHAIN-INTERACTING PROTEIN; MYLIP__:__MIR;; INDUCIBLE DEGRADER OF THE LOW DENSITY LIPOPROTEIN RECEPTOR; IDOL__:__
Asterisk__:__610083__:__TENEURIN TRANSMEMBRANE PROTEIN 3; TENM3__:__ODZ, DROSOPHILA, HOMOLOG OF, 3; ODZ3;; TENASCIN M3; TNM3;; KIAA1455__:__
Asterisk__:__610084__:__TENEURIN TRANSMEMBRANE PROTEIN 4; TENM4__:__ODZ, DROSOPHILA, HOMOLOG OF, 4; ODZ4;; TENASCIN M4; TNM4;; DOC4;; KIAA1302__:__
Asterisk__:__610085__:__FAMILY WITH SEQUENCE SIMILARITY 167, MEMBER A; FAM167A__:__CHROMOSOME 8 OPEN READING FRAME 13; C8ORF13__:__
Asterisk__:__610086__:__PROTEIN ARGININE METHYLTRANSFERASE 8; PRMT8__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN METHYLTRANSFERASE 1-LIKE 3; HRMT1L3;; HRMT1L4__:__
Asterisk__:__610087__:__PROTEIN ARGININE N-METHYLTRANSFERASE 7; PRMT7__:__KIAA1933__:__
Asterisk__:__610088__:__OLFACTOMEDIN-LIKE 3; OLFML3__:__OLFACTOMEDIN, 44-KD; OLF44__:__
Asterisk__:__610089__:__RAD50-INTERACTING PROTEIN 1; RINT1__:____:__
Number Sign__:__610090__:__PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD__:__PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED__:__
Asterisk__:__610091__:__WD REPEAT- AND SOCS BOX-CONTAINING PROTEIN 1; WSB1__:__SOCS BOX AND WB REPEATS IN PROTEIN 1; SWIP1__:__
Number Sign__:__610092__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 3; MCOPCB3__:__MICROPHTHALMIA, COLOBOMATOUS, ISOLATED 3__:__MICROPHTHALMIA, CATARACTS, AND IRIS ABNORMALITIES, INCLUDED
Number Sign__:__610093__:__MICROPHTHALMIA, ISOLATED 2; MCOP2__:__ANOPHTHALMIA, CLINICAL, ISOLATED__:__
Asterisk__:__610094__:__DEF6, MOUSE, HOMOLOG OF; DEF6__:__IRF4-BINDING PROTEIN; IBP;; SWAP70-LIKE ADAPTOR OF T CELLS; SLAT__:__
Asterisk__:__610095__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, LONG CYTOPLASMIC TAIL, 3; KIR3DL3__:__KIRC1;; KIR3DL7;; KIR44;; CD158Z__:__
Asterisk__:__610096__:__T-CELL IMMUNOGLOBULIN AND MUCIN DOMAINS-CONTAINING PROTEIN 4; TIMD4__:__TIM4;; SMUCKLER__:__
Asterisk__:__610097__:__OUTER DENSE FIBER OF SPERM TAILS 4; ODF4__:__OPPO1__:__
Asterisk__:__610098__:__MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 9; MCM9__:__MINICHROMOSOME MAINTENANCE DEFICIENT DOMAIN CONTAINING 1; MCMDC1__:__
Percent__:__610099__:__MYOPATHY, DISTAL, 3; MPD3__:____:__
Number Sign__:__610100__:__GIANT AXONAL NEUROPATHY 2, AUTOSOMAL DOMINANT; GAN2__:____:__
Asterisk__:__610101__:__CUTC COPPER TRANSPORTER, E. COLI, HOMOLOG OF; CUTC__:__COPPER TRANSPORTER PROTEIN CUTC__:__
Number Sign__:__610102__:__COMPLEMENT COMPONENT 7 DEFICIENCY; C7D__:__C7 DEFICIENCY__:__
Asterisk__:__610103__:__S100 CALCIUM-BINDING PROTEIN, ZETA; S100Z__:____:__
Asterisk__:__610104__:__MICRO RNA 125B1; MIR125B1__:__miRNA125B1;; MIRN125B1__:__
Asterisk__:__610105__:__MICRO RNA 125B2; MIR125B2__:__MIRN125B2;; miRNA125B2__:__
Asterisk__:__610106__:__DREBRIN-LIKE; DBNL__:__HPK1-INTERACTING PROTEIN, 55-KD; HIP55__:__
Asterisk__:__610107__:__O-SIALOGLYCOPROTEIN ENDOPEPTIDASE; OSGEP__:__KAE1;; TSC3;; FLJ20411__:__
Asterisk__:__610108__:__ANOCTAMIN 1, CALCIUM-ACTIVATED CHLORIDE CHANNEL; ANO1__:__TRANSMEMBRANE PROTEIN 16A; TMEM16A__:__
Asterisk__:__610109__:__ANOCTAMIN 2; ANO2__:__TRANSMEMBRANE PROTEIN 16B; TMEM16B;; CHROMOSOME 12 OPEN READING FRAME 3; C12ORF3__:__
Asterisk__:__610110__:__ANOCTAMIN 3; ANO3__:__TRANSMEMBRANE PROTEIN 16C; TMEM16C;; CHROMOSOME 11 OPEN READING FRAME 25; C11ORF25__:__
Asterisk__:__610111__:__ANOCTAMIN 4; ANO4__:__TRANSMEMBRANE PROTEIN 16D; TMEM16D;; FLJ34272__:__
Asterisk__:__610112__:__C-MAF-INDUCING PROTEIN__:__CMIP;; KIAA1694__:__C-MAF-INDUCING PROTEIN, TRUNCATED, INCLUDED; TCMIP, INCLUDED
Asterisk__:__610113__:__ADAMTS-LIKE 4; ADAMTSL4__:__THROMBOSPONDIN REPEAT-CONTAINING 1; TSRC1__:__
Percent__:__610114__:__STATURE QUANTITATIVE TRAIT LOCUS 8; STQTL8__:____:__
Asterisk__:__610115__:__TRANSMEMBRANE PROTEIN 48; TMEM48__:__NDC1, S. CEREVISIAE, HOMOLOG OF; NDC1__:__
Asterisk__:__610116__:__PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 14; P2RY14__:__G PROTEIN-COUPLED RECEPTOR 105; GPR105;; KIAA0001__:__
Asterisk__:__610117__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 11; SLC26A11__:____:__
Asterisk__:__610118__:__G PROTEIN-COUPLED RECEPTOR 33; GPR33__:____:__
Asterisk__:__610119__:__TENEURIN TRANSMEMBRANE PROTEIN 2; TENM2__:__ODZ, DROSOPHILA, HOMOLOG OF, 2; ODZ2;; TENASCIN M2; TNM2;; KIAA1127__:__
Asterisk__:__610120__:__TETRASPANIN 33; TSPAN33__:__PENUMBRA; PEN__:__
Asterisk__:__610121__:__5-HYDROXYTRYPTAMINE RECEPTOR 3C; HTR3C__:__SEROTONIN 5-HT-3C RECEPTOR__:__
Asterisk__:__610122__:__5-HYDROXYTRYPTAMINE RECEPTOR 3D; HTR3D__:__SEROTONIN 5-HT-3D RECEPTOR__:__
Asterisk__:__610123__:__5-HYDROXYTRYPTAMINE RECEPTOR 3E; HTR3E__:__SEROTONIN 5-HT-3E RECEPTOR__:__
Asterisk__:__610124__:__CARBOHYDRATE SULFOTRANSFERASE 13; CHST13__:__CHONDROITIN 4-SULFOTRANSFERASE 3; C4ST3__:__
Number Sign__:__610125__:__MICROPHTHALMIA, SYNDROMIC 5; MCOPS5__:____:__RETINAL DYSTROPHY, EARLY-ONSET, WITH OR WITHOUT PITUITARY DYSFUNCTION, INCLUDED
Caret__:__610126__:__MOVED TO 607932__:____:__
Number Sign__:__610127__:__CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10__:__CEROID LIPOFUSCINOSIS, NEURONAL, CATHEPSIN D-DEFICIENT;; NEURONAL CEROID LIPOFUSCINOSIS DUE TO CATHEPSIN D DEFICIENCY__:__NEURONAL CEROID LIPOFUSCINOSIS, CONGENITAL, INCLUDED
Asterisk__:__610128__:__CARBOHYDRATE SULFOTRANSFERASE 11; CHST11__:__CHONDROITIN 4-SULFOTRANSFERASE 1; C4ST1;; C4ST__:__
Asterisk__:__610129__:__CARBOHYDRATE SULFOTRANSFERASE 12; CHST12__:__CHONDROITIN 4-SULFOTRANSFERASE 2; C4ST2__:__
Asterisk__:__610130__:__SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 1; SLC26A1__:__SULFATE ANION TRANSPORTER 1; SAT1__:__
Number Sign__:__610131__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4__:__
Asterisk__:__610132__:__VANG-LIKE 1; VANGL1__:__VAN GOGH, DROSOPHILA, HOMOLOG OF, 1;; STRABISMUS, DROSOPHILA, HOMOLOG OF, 2; STB2; STBM2__:__
Asterisk__:__610133__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 3; ST6GALNAC3__:__ST6GALNAC III;; SIALYLTRANSFERASE 7C; SIAT7C__:__
Asterisk__:__610134__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 5; ST6GALNAC5__:__ST6GalNAc V;; SIALYLTRANSFERASE 7E; SIAT7E__:__
Asterisk__:__610135__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 6; ST6GALNAC6__:__ST6GalNAc VI;; SIALYLTRANSFERASE 7F; SIAT7F__:__
NULL__:__610136__:__DEVRIENDT SYNDROME__:____:__
Asterisk__:__610137__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 2; ST6GALNAC2__:__ST6GalNAc II;; SIALYLTRANSFERASE 7B; SIAT7B;; SIALYLTRANSFERASE-LIKE 1; SAITL1__:__
Asterisk__:__610138__:__ST6 ALPHA-N-ACETYL-NEURAMINYL-2,3-BETA-GALACTOSYL-1,3-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE 1; ST6GALNAC1__:__ST6GalNAc I;; STYI;; SIALYLTRANSFERASE 7A; SIAT7A__:__
Asterisk__:__610139__:__ST8 ALPHA-N-ACETYL-NEURAMINIDE ALPHA-2,8-SIALYLTRANSFERASE 6; ST8SIA6__:__ALPHA-2,8-SIALYLTRANSFERASE VI;; ST8SIA VI;; SIALYLTRANSFERASE 8F; SIAT8F__:__
Number Sign__:__610140__:__HEART-HAND SYNDROME, SLOVENIAN TYPE__:____:__
Percent__:__610141__:__QT INTERVAL, VARIATION IN__:____:__
Asterisk__:__610142__:__CENTROSOMAL PROTEIN, 290-KD; CEP290__:__ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY 3H11; 3H11AG;; KIAA0373;; NEPHROCYSTIN 6; NPHP6;; BBS14 GENE; BBS14__:__
Percent__:__610143__:__DEAFNESS, AUTOSOMAL RECESSIVE 62; DFNB62__:____:__
Asterisk__:__610144__:__TBC1 DOMAIN FAMILY, MEMBER 3B; TBC1D3B__:__PROSTATE CANCER GENE 17; PRC17__:__
Asterisk__:__610145__:__ENDOTHELIN-CONVERTING ENZYME 2; ECE2__:__KIAA0604__:__
Asterisk__:__610146__:__INSULIN-LIKE GROWTH FACTOR II, ANTISENSE; IGF2AS__:__IGF2, ANTISENSE;; PEG8__:__
Asterisk__:__610147__:__G PROTEIN-COUPLED BILE ACID RECEPTOR 1; GPBAR1__:__BG37;; TGR5__:__
Asterisk__:__610148__:__BBS10 GENE; BBS10__:__CHROMOSOME 12 OPEN READING FRAME 58; C12ORF58;; FLJ23560__:__
Number Sign__:__610149__:__MACULAR DEGENERATION, AGE-RELATED, 7; ARMD7__:____:__MACULAR DEGENERATION, AGE-RELATED, NEOVASCULAR TYPE, SUSCEPTIBILITY TO, INCLUDED;; MACULAR DEGENERATION, AGE-RELATED, WET TYPE, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__610150__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 5; CCT5__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 5;; CCT-EPSILON; CCTE;; KIAA0098__:__
Asterisk__:__610151__:__METHIONYL AMINOPEPTIDASE 1; METAP1__:__KIAA0094__:__
Asterisk__:__610152__:__CENTROMERIC PROTEIN M; CENPM__:__PROLIFERATION-ASSOCIATED NUCLEAR ELEMENT 1; PANE1__:__
Number Sign__:__610153__:__DEAFNESS, AUTOSOMAL RECESSIVE 49; DFNB49__:____:__
Number Sign__:__610154__:__DEAFNESS, AUTOSOMAL RECESSIVE 44; DFNB44__:____:__
Percent__:__610155__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 19; IDDM19__:____:__
Number Sign__:__610156__:__MENTAL RETARDATION, TRUNCAL OBESITY, RETINAL DYSTROPHY, AND MICROPENIS SYNDROME; MORMS__:__MORM SYNDROME__:__
NULL__:__610157__:__HEAT-SHOCK RNA 1__:__HSR1__:__
Percent__:__610158__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 2; FECD2__:__FCD1 LOCUS;; CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Asterisk__:__610159__:__ZINC FINGER PROTEIN 366; ZNF366__:__DENDRITIC CELL-SPECIFIC TRANSCRIPT; DCSCRIPT__:__
Asterisk__:__610160__:__ZINC FINGER PROTEIN 367; ZNF367__:__ZINC FINGER PROTEIN OF FETAL LIVER ERYTHROID CELLS 29; ZFF29__:__
Asterisk__:__610161__:__TRANSCRIPTION FACTOR AP2-DELTA; TFAP2D__:__TFAP2BL1__:__
Asterisk__:__610162__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 28B; CCDC28B__:__MGC1203__:__
Number Sign__:__610163__:__IMMUNODEFICIENCY 25; IMD25__:__IMMUNODEFICIENCY DUE TO DEFECT IN CD3-ZETA__:__
Asterisk__:__610164__:__MICRO RNA 134; MIRN134__:____:__
Asterisk__:__610165__:__GLYCOSYLTRANSFERASE-LIKE DOMAIN-CONTAINING PROTEIN 1; GTDC1__:____:__
Asterisk__:__610166__:__IQ MOTIF- AND SEC7 DOMAIN-CONTAINING PROTEIN 1; IQSEC1__:__ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE PROTEIN, 100-KD; ARFGEP100;; LONER, DROSOPHILA, HOMOLOG OF;; KIAA0763__:__
Asterisk__:__610167__:__PHOSPHOHISTIDINE PHOSPHATASE 1; PHPT1__:__SEX-REGULATED PROTEIN JANUS-A__:__
Number Sign__:__610168__:__LOEYS-DIETZ SYNDROME 2; LDS2__:__AORTIC ANEURYSM, FAMILIAL THORACIC 3; AAT3;; MARFAN SYNDROME, TYPE II, FORMERLY__:__
Asterisk__:__610169__:__INO80 COMPLEX SUBUNIT; INO80__:__INO80 COMPLEX, CATALYTIC SUBUNIT;; INO80 COMPLEX, SUBUNIT A; INO80A;; INO80 COMPLEX HOMOLOG 1; INOC1;; INO80, S. CEREVISIAE, HOMOLOG OF__:__
Percent__:__610170__:__KYPHOSCOLIOSIS 1; KYPSC1__:____:__
Asterisk__:__610171__:__CALMODULIN-LIKE 6; CALML6__:__CALGLANDULIN-LIKE PROTEIN; CAGLP__:__
Asterisk__:__610172__:__SPERM FLAGELLAR PROTEIN 2; SPEF2__:__KPL2 GENE; KPL2;; KIAA1770;; FLJ23577__:__
Asterisk__:__610173__:__MICRO RNA 10A; MIR10A__:__miRNA10A;; MIRN10A__:__
Asterisk__:__610174__:__UBIQUITIN DOMAIN-CONTAINING PROTEIN 2; UBTD2__:__DENDRITIC CELL UBIQUITIN-LIKE PROTEIN; DCUBP;; MGC30022__:__
Asterisk__:__610175__:__MICRO RNA 130A; MIR130A__:__miRNA130A;; MIRN130A__:__
Asterisk__:__610176__:__SECRETOGLOBIN, FAMILY 1C, MEMBER 1; SCGB1C1__:__RYD5, RAT, HOMOLOG OF; RYD5__:__
Asterisk__:__610177__:__APOPTOSIS-ENHANCING NUCLEASE; AEN__:__INTERFERON-STIMULATED EXONUCLEASE GENE 20-KD-LIKE 1; ISG20L1__:__
Asterisk__:__610178__:__KIAA0586 GENE; KIAA0586__:__TALPID 3, CHICKEN, HOMOLOG OF; TALPID3__:__
Asterisk__:__610179__:__PHOSPHOLIPASE B1; PLB1__:__PLB;; FLJ30866__:__
Asterisk__:__610180__:__OSTEOCLAST-STIMULATING FACTOR 1; OSTF1__:__OSF;; SH3P2__:__
Number Sign__:__610181__:__AICARDI-GOUTIERES SYNDROME 2; AGS2__:____:__
Asterisk__:__610182__:__PALMDELPHIN; PALMD__:__PARALEMMIN-LIKE; PALML__:__
Asterisk__:__610183__:__ZINC FINGER AN1 DOMAIN-CONTAINING PROTEIN 6; ZFAND6__:__AN1-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 6;; PROTEIN ASSOCIATED WITH PRK1; AWP1;; ZINC FINGER A20 DOMAIN-CONTAINING PROTEIN 3; ZA20D3;; A20-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 3__:__
Asterisk__:__610184__:__MONOACYLGLYCEROL O-ACYLTRANSFERASE 3; MOGAT3__:__ACYL-CoA:MONOACYLGLYCEROL ACYLTRANSFERASE 3;; MGAT3__:__
Number Sign__:__610185__:__CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 2; CAMRQ2__:__CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDAL LOCOMOTION 2__:__
Asterisk__:__610186__:__UBIQUITIN-SPECIFIC PEPTIDASE 17-LIKE FAMILY MEMBER 2; USP17L2__:__DEUBIQUITINATING ENZYME 3; DUB3__:__
Number Sign__:__610187__:__DIAPHRAGMATIC HERNIA 3; DIH3__:____:__
Number Sign__:__610188__:__JOUBERT SYNDROME 5; JBTS5__:____:__
Number Sign__:__610189__:__SENIOR-LOKEN SYNDROME 6; SLSN6__:____:__
Asterisk__:__610190__:__CARBOHYDRATE SULFOTRANSFERASE 8; CHST8__:__N-ACETYLGALACTOSAMINE-4-O-SULFOTRANSFERASE 1;; GalNAc4 SULFOTRANSFERASE 1; GalNAc4ST1;; GalNAc4ST__:__
Asterisk__:__610191__:__CARBOHYDRATE SULFOTRANSFERASE 9; CHST9__:__N-ACETYLGALACTOSAMINE-4-O-SULFOTRANSFERASE 2;; GalNAc4 SULFOTRANSFERASE 2; GalNAc4ST2__:__
Asterisk__:__610192__:__GLIS FAMILY ZINC FINGER PROTEIN 3; GLIS3__:__GLI-SIMILAR PROTEIN 3;; ZINC FINGER PROTEIN 515; ZNF515__:__
Number Sign__:__610193__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 10; ARVC10__:__
Asterisk__:__610194__:__BETA-1,3-N-ACETYLGALACTOSAMINYLTRANSFERASE 2; B3GALNT2__:__UDP-GalNAc:BETA-GLcNAc-BETA-1,3-GALACTOSAMINYLTRANSFERASE, POLYPEPTIDE 2;; B3GalNAc-T2;; MGC39558__:__
Asterisk__:__610195__:__PROSTATE TUMOR OVEREXPRESSED GENE 1; PTOV1__:__ACTIVATOR INTERACTION DOMAIN-CONTAINING PROTEIN 2; ACID2__:__
Asterisk__:__610196__:__ELMO/CED12 DOMAIN-CONTAINING PROTEIN 2; ELMOD2__:____:__
Asterisk__:__610197__:__MEDIATOR COMPLEX SUBUNIT 25; MED25__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 25, S. CEREVISIAE, HOMOLOG OF;; PROSTATE TUMOR OVEREXPRESSED GENE 2; PTOV2;; p78;; ACTIVATOR-RECRUITED COFACTOR, 92-KD; ARC92;; ACTIVATOR INTERACTION DOMAIN-CONTAINING PROTEIN 1; ACID1__:__
Number Sign__:__610198__:__3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5__:__CARDIOMYOPATHY, DILATED, WITH ATAXIA; DCMA;; MGA, TYPE V; MGA5__:__
Number Sign__:__610199__:__DIABETES MELLITUS, NEONATAL, WITH CONGENITAL HYPOTHYROIDISM; NDH__:__NDH SYNDROME__:__
Asterisk__:__610200__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L13; MRPL13__:__RIBOSOMAL PROTEIN, MITOCHONDRIAL, L13; RPML13;; L13A__:__
Asterisk__:__610201__:__CENTROSOMAL PROTEIN, 162-KD; CEP162__:__KIAA1009;; QN1__:__
Number Sign__:__610202__:__CATARACT 21, MULTIPLE TYPES; CTRCT21__:__CATARACT 21, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, CONGENITAL, CERULEAN TYPE, 4; CCA4;; CATARACT, PULVERULENT, JUVENILE-ONSET__:__
Asterisk__:__610203__:__CYSTEINE-RICH INHIBITOR OF PAK1; CRIPAK__:__FLJ34443__:__
Number Sign__:__610204__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 5; PCH5__:__OLIVOPONTOCEREBELLAR HYPOPLASIA, FETAL-ONSET__:__
Number Sign__:__610205__:__ALAGILLE SYNDROME 2; ALGS2__:____:__
Asterisk__:__610206__:__SOLUTE CARRIER FAMILY 4 (SODIUM BORATE COTRANSPORTER), MEMBER 11; SLC4A11__:__BICARBONATE TRANSPORTER-RELATED PROTEIN 1; BTR1;; SODIUM-COUPLED BORATE COTRANSPORTER 1; NABC1__:__
Asterisk__:__610207__:__SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 9; SLC4A9__:__ANION EXCHANGE PROTEIN 4; AE4__:__
Percent__:__610208__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 10__:__MGR10;; MIGRAINE WITH PULSATION__:__
Percent__:__610209__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 11__:__MGR11__:__
Asterisk__:__610210__:__MAF1, S. CEREVISIAE, HOMOLOG OF; MAF1__:____:__
Asterisk__:__610211__:__SRA STEM LOOP-INTERACTING RNA-BINDING PROTEIN; SLIRP__:__CHROMOSOME 14 OPEN READING FRAME 156; C14ORF156__:__
Number Sign__:__610212__:__DEAFNESS, AUTOSOMAL RECESSIVE 66; DFNB66__:____:__
Percent__:__610213__:__ANEURYSM, INTRACRANIAL BERRY, 4; ANIB4__:____:__
Asterisk__:__610214__:__ENDOPLASMIC RETICULUM DEGRADATION-ENHANCING ALPHA-MANNOSIDASE-LIKE PROTEIN 3; EDEM3__:__CHROMOSOME 1 OPEN READING FRAME 22; C1ORF22__:__
Asterisk__:__610215__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 25; ARHGEF25__:__RAC- AND CDC42-SPECIFIC GUANINE NUCLEOTIDE EXCHANGE FACTOR;; GUANINE NUCLEOTIDE EXCHANGE FACTOR GEFT; GEFT;; p63RHOGEF__:__
Asterisk__:__610216__:__ANOCTAMIN 8; ANO8__:__TRANSMEMBRANE PROTEIN 16H; TMEM16H;; KIAA1623__:__
Number Sign__:__610217__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2B; NBIA2B__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION, PLA2G6-RELATED;; NEUROAXONAL DYSTROPHY, ATYPICAL__:__KARAK SYNDROME, INCLUDED
Asterisk__:__610218__:__SAP30-BINDING PROTEIN; SAP30BP__:__HUMAN TRANSCRIPTION REGULATOR PROTEIN; HTRP;; HCNGP;; HTRG__:__
Asterisk__:__610219__:__DFNB59 GENE__:__PEJVAKIN; PJVK__:__
Number Sign__:__610220__:__DEAFNESS, AUTOSOMAL RECESSIVE 59; DFNB59__:____:__
Asterisk__:__610221__:__AKT1 SUBSTRATE 1, PROLINE-RICH; AKT1S1__:__PROLINE-RICH AKT SUBSTRATE, 40-KD; PRAS40;; MGC2865__:__
Asterisk__:__610222__:__RAS AND RAB INTERACTOR 2; RIN2__:__RAB5-INTERACTING PROTEIN 2;; RAS INHIBITOR JC265__:__
Asterisk__:__610223__:__RAS AND RAB INTERACTOR 3; RIN3__:__RAB5-INTERACTING PROTEIN 3;; FLJ22439__:__
Asterisk__:__610224__:__SPERMATOGENESIS- AND OOGENESIS-SPECIFIC BASIC HELIX-LOOP-HELIX PROTEIN 1; SOHLH1__:__NEWBORN OVARY HELIX-LOOP-HELIX PROTEIN; NOHLH;; TEB2__:__
Asterisk__:__610225__:__RIBOSOMAL PROTEIN S19 BINDING PROTEIN 1; RPS19BP1__:__S19BP;; ACTIVE REGULATOR OF SIRT1; AROS;; MGC52010__:__
Asterisk__:__610226__:__ZINC FINGER PROTEIN 750; ZNF750__:__FLJ13841__:__
Number Sign__:__610227__:__SEBORRHEA-LIKE DERMATITIS WITH PSORIASIFORM ELEMENTS__:____:__
Asterisk__:__610228__:__CALPAIN 13; CAPN13__:__FLJ23523__:__
Asterisk__:__610229__:__CALPAIN 14; CAPN14__:____:__
Asterisk__:__610230__:__tRNA 5-METHYLAMINOMETHYL-2-THIOURIDYLATE METHYLTRANSFERASE; TRMU__:__TRNT1;; MTO2, S. CEREVISIAE, HOMOLOG OF; MTO2__:__
Asterisk__:__610231__:__POLYCOMB GROUP RING FINGER PROTEIN 1; PCGF1__:__MGC10882;; NERVOUS SYSTEM POLYCOMB 1; NSPC1;; LETHAL(3)73AH, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__610232__:__ATPase, TYPE 13A3; ATP13A3__:__ATPase FAMILY HOMOLOG UPREGULATED IN SENESCENCE CELLS; AFURS1__:__
Caret__:__610233__:__MOVED TO 211900__:____:__
Percent__:__610234__:__SYNPOLYDACTYLY 3; SPD3__:____:__
Asterisk__:__610235__:__MITOCHONDRIAL PROTEIN, 18-KD__:__MTP18;; HSPC242__:__
Asterisk__:__610236__:__LUNAPARK; LNPK__:__LNP1; LNP;; KIAA1715__:__
Asterisk__:__610237__:__MEDIATOR COMPLEX SUBUNIT 30; MED30__:__THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN, 25-KD; TRAP25;; THYROID HORMONE RECEPTOR-ASSOCIATED PROTEIN 6; THRAP6__:__
Asterisk__:__610238__:__SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 11; SLC5A11__:__KST1, RABBIT, HOMOLOG OF; KST1;; SODIUM/GLUCOSE TRANSPORTER 6; SGLT6;; SODIUM MYOINOSITOL COTRANSPORTER 2; SMIT2__:__
Percent__:__610239__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4__:__HDLCQ4__:__
Asterisk__:__610240__:__LHFP-LIKE PROTEIN 4; LHFPL4__:____:__
Asterisk__:__610241__:__RING FINGER PROTEIN 32; RNF32__:____:__
Asterisk__:__610242__:__CHROMOSOME 7 OPEN READING FRAME 13; C7ORF13__:____:__
Asterisk__:__610243__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 27; ZFYVE27__:__PROTRUDIN__:__
Number Sign__:__610244__:__SPASTIC PARAPLEGIA 33, AUTOSOMAL DOMINANT; SPG33__:____:__
Number Sign__:__610245__:__SPINOCEREBELLAR ATAXIA 23; SCA23__:____:__
Number Sign__:__610246__:__SPINOCEREBELLAR ATAXIA 28; SCA28__:____:__
Percent__:__610247__:__ESOPHAGITIS, EOSINOPHILIC, 1; EOE1__:__ESOPHAGITIS, EOSINOPHILIC; EE__:__
Percent__:__610248__:__DEAFNESS, AUTOSOMAL RECESSIVE 65; DFNB65__:____:__
Asterisk__:__610249__:__PROTEIN O-FUCOSYLTRANSFERASE 2; POFUT2__:__CHROMOSOME 21 OPEN READING FRAME 80; C21ORF80;; KIAA0958__:__
Number Sign__:__610250__:__SPASTIC PARAPLEGIA 31, AUTOSOMAL DOMINANT; SPG31__:____:__
Number Sign__:__610251__:__ALCOHOL SENSITIVITY, ACUTE__:____:__HANGOVER, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__610252__:__MICRO RNA 1-2; MIR1-2__:__miRNA1-2;; MIRN1-2__:__
Number Sign__:__610253__:__KLEEFSTRA SYNDROME 1; KLEFS1__:__CHROMOSOME 9q34.3 DELETION SYNDROME;; 9q- SYNDROME;; 9q SUBTELOMERIC DELETION SYNDROME__:__
Asterisk__:__610254__:__MICRO RNA 133A1; MIR133A1__:__miRNA133A1;; MIRN133A1__:__
Asterisk__:__610255__:__MICRO RNA 133A2; MIR133A2__:__miRNA133A2;; MIRN133A2__:__
Number Sign__:__610256__:__ANTERIOR SEGMENT DYSGENESIS 2; ASGD2__:__APHAKIA, CONGENITAL PRIMARY; CPAK;; CPA__:__
Asterisk__:__610257__:__SEC31, YEAST, HOMOLOG OF, A; SEC31A__:__SEC31-LIKE 1; SEC31L1;; KIAA0905__:__
Asterisk__:__610258__:__SEC31, YEAST, HOMOLOG OF, B; SEC31B__:__SEC31-LIKE 2; SEC31L2__:__
Asterisk__:__610259__:__LONG INTERGENIC NONCODING RNA 163; LINC00163__:__NONCODING RNA 163; NCRNA00163;; NARCOLEPSY CANDIDATE REGION GENE 1A; NLC1A__:__
Percent__:__610260__:__PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 2; IHPS2__:____:__
Percent__:__610261__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 5__:__HYT5;; HYPERTENSION, ESSENTIAL, BODY MASS-RELATED__:__
Percent__:__610262__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 6__:__HYT6;; HYPERTENSION, ESSENTIAL, KIDNEY FUNCTION-RELATED__:__
Asterisk__:__610263__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 13; DNAJB13__:__TESTIS SPERMATOGENESIS APOPTOSIS-RELATED PROTEIN 6; TSARG6__:__
Asterisk__:__610264__:__TESTIS-PROSTATE-PLACENTA-EXPRESSED PROTEIN; TEPP__:____:__
Number Sign__:__610265__:__DEAFNESS, AUTOSOMAL RECESSIVE 67; DFNB67__:____:__
Asterisk__:__610266__:__TAO KINASE 1; TAOK1__:__TAO1;; MARK KINASE; MARKK;; PROSTATE-DERIVED STERILE 20-LIKE KINASE 2; PSK2;; KIAA1361__:__
Asterisk__:__610267__:__METHIONINE AMINOPEPTIDASE 1D; METAP1D__:__METHIONYL AMINOPEPTIDASE 1D; MAP1D__:__
Asterisk__:__610268__:__MONOACYLGLYCEROL O-ACYLTRANSFERASE 1; MOGAT1__:__ACYL-CoA:MONOACYLGLYCEROL ACYLTRANSFERASE 1;; MGAT1;; DIACYLGLYCEROL O-ACYLTRANSFERASE 2 LIKE-1; DGAT2L1__:__
Caret__:__610269__:__MOVED TO 607499 AND 606788__:____:__
Asterisk__:__610270__:__MONOACYLGLYCEROL O-ACYLTRANSFERASE 2; MOGAT2__:__ACYL-CoA:MONOACYLGLYCEROL ACYLTRANSFERASE 2;; MGAT2__:__
Asterisk__:__610271__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS S PROTEIN; PIGS__:____:__
Asterisk__:__610272__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS T PROTEIN; PIGT__:__NEURONAL DEVELOPMENT-ASSOCIATED PROTEIN; NDAP__:__
Asterisk__:__610273__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS M PROTEIN; PIGM__:__PIGM MANNOSYLTRANSFERASE__:__
Asterisk__:__610274__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS V PROTEIN; PIGV__:____:__
Asterisk__:__610275__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS W PROTEIN; PIGW__:____:__
Asterisk__:__610276__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS X PROTEIN; PIGX__:____:__
Asterisk__:__610277__:__ORAI CALCIUM RELEASE-ACTIVATED CALCIUM MODULATOR 1; ORAI1__:__CALCIUM RELEASE-ACTIVATED CALCIUM MODULATOR 1; CRACM1;; TRANSMEMBRANE PROTEIN 142A; TMEM142A__:__
Asterisk__:__610278__:__PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1__:__PEAR1__:__
Percent__:__610279__:__PACHYGYRIA, FRONTOTEMPORAL__:____:__
Asterisk__:__610280__:__OSTEOCRIN; OSTN__:__MUSCLIN__:__
Asterisk__:__610281__:__ZINC FINGER PROTEIN 62; ZFP62__:____:__
Number Sign__:__610282__:__RETINITIS PIGMENTOSA 35; RP35__:____:__
Number Sign__:__610283__:__CONE-ROD DYSTROPHY 10; CORD10__:____:__
Asterisk__:__610284__:__LIPOYLTRANSFERASE 1; LIPT1__:____:__
Asterisk__:__610285__:__DOWNSTREAM OF TYROSINE KINASE 7; DOK7__:__CHROMOSOME 4 OPEN READING FRAME 25; C4ORF25__:__
Asterisk__:__610286__:__LEUCINE CARBOXYL METHYLTRANSFERASE 1; LCMT1__:____:__
Asterisk__:__610287__:__F-BOX AND LEUCINE-RICH REPEAT PROTEIN 15; FBXL15__:__JETLAG, DROSOPHILA, HOMOLOG OF; JET;; F-BOX ONLY PROTEIN 37__:__
Asterisk__:__610288__:__GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 6; GOLGA6__:__GOLGIN LINKED TO PML; GLP__:__
Asterisk__:__610289__:__3-OXOACID CoA TRANSFERASE 2; OXCT2__:__SCOT-T;; FLJ00030__:__
Asterisk__:__610290__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 12; GALNT12__:__GalNAc TRANSFERASE 12; GalNAcT12__:__
Asterisk__:__610291__:__SYNAPTIC VESICLE GLYCOPROTEIN 2C; SV2C__:____:__
Asterisk__:__610292__:__B-CELL SCAFFOLD PROTEIN WITH ANKYRIN REPEATS 1; BANK1__:__FLJ20706;; BANK__:__
Number Sign__:__610293__:__GLYCOSYLPHOSPHATIDYLINOSITOL DEFICIENCY; GPID__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 1; GPIBD1__:__
Percent__:__610294__:__INTELLIGENCE QUANTITATIVE TRAIT LOCUS 2__:__INTLQ2__:__
Percent__:__610295__:__INTELLIGENCE QUANTITATIVE TRAIT LOCUS 3__:__INTLQ3__:__
Asterisk__:__610296__:__NUDC DOMAIN-CONTAINING PROTEIN 3; NUDCD3__:__KIAA1068;; NUDC-LIKE PROTEIN; NUDCL__:__
Number Sign__:__610297__:__PARKINSON DISEASE 13, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK13__:____:__
Asterisk__:__610298__:__PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY B, MEMBER 2; PHLDB2__:__LL5-BETA__:__
Asterisk__:__610299__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 17; SLC6A17__:__NTT4__:__
Asterisk__:__610300__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER), MEMBER 18; SLC6A18__:__XTRP2__:__
Asterisk__:__610301__:__TRANSMEMBRANE PROTEIN 57; TMEM57__:__MACOILIN;; FLJ10747__:__
Asterisk__:__610302__:__ENDOPLASMIC RETICULUM DEGRADATION-ENHANCING ALPHA-MANNOSIDASE-LIKE PROTEIN 2; EDEM2__:____:__
Asterisk__:__610303__:__V-MAF AVIAN MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE HOMOLOG A; MAFA__:__RIPE3B1__:__
Asterisk__:__610304__:__DER1-LIKE DOMAIN FAMILY, MEMBER 2; DERL2__:__F-LANa;; DERLIN 2__:__
Asterisk__:__610305__:__DER1-LIKE DOMAIN FAMILY, MEMBER 3; DERL3__:__DERLIN 3__:__
Asterisk__:__610306__:__NEPHRONECTIN; NPNT__:__PREOSTEOBLAST EGF-LIKE REPEAT PROTEIN WITH MAM DOMAIN; POEM__:__
Asterisk__:__610307__:__CERAMIDE KINASE; CERK__:__KIAA1646__:__
Asterisk__:__610308__:__BETA-3-GLUCOSYLTRANSFERASE; B3GLCT__:__UDP-GAL:BETA-GlcNAc BETA-1,3-GALACTOSYLTRANSFERASE-LIKE; B3GALTL;; BETA-3-GLYCOSYLTRANSFERASE-LIKE; B3GTL;; BETA-1,3-GLUCOSYLTRANSFERASE__:__
Asterisk__:__610309__:__UBIQUITIN-CONJUGATING ENZYME E2S; UBE2S__:__EPF5;; E2EPF__:__
Asterisk__:__610310__:__LOC152586 GENE__:__LOC152586__:__
Asterisk__:__610311__:__MEDIATOR COMPLEX SUBUNIT 28; MED28__:__MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION, SUBUNIT 28, S. CEREVISIAE, HOMOLOG OF;; ENDOTHELIAL-DERIVED GENE 1; EG1;; MERLIN- AND GRB2-INTERACTING CYTOSKELETAL PROTEIN;; MAGICIN__:__
Asterisk__:__610312__:__PIWI-LIKE 2: PIWIL2__:__MILI, MOUSE, HOMOLOG OF; MILI__:__
Number Sign__:__610313__:__CRISPONI/COLD-INDUCED SWEATING SYNDROME 2; CISS2__:____:__
Asterisk__:__610314__:__PIWI-LIKE 3: PIWIL3__:____:__
Asterisk__:__610315__:__PIWI-LIKE 4; PIWIL4__:__HIWI2;; MIWI2, MOUSE, HOMOLOG OF; MIWI2__:__
Asterisk__:__610316__:__POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE 1; PNPT1__:__OLD35;; PNPase__:__
Asterisk__:__610317__:__CORDON-BLEU, MOUSE, HOMOLOG OF; COBL__:__KIAA0633__:__
Asterisk__:__610318__:__COBL-LIKE PROTEIN 1: COBLL1__:__COBL-RELATED PROTEIN 1; COBLR1;; KIAA0977__:__
NULL__:__610319__:__RHIZOMELIC DYSPLASIA, SCOLIOSIS, AND RETINITIS PIGMENTOSA__:____:__
Percent__:__610320__:__MYOPIA 14; MYP14__:____:__
Percent__:__610321__:__PROSTATE CANCER, HEREDITARY, 7; HPC7__:__PROSTATE CANCER AGGRESSIVENESS__:__
Asterisk__:__610322__:__TRANSCRIPTIONAL REGULATING FACTOR 1; TRERF1__:__TRANSCRIPTIONAL REGULATING PROTEIN, 132-KD; TREP132__:__
Asterisk__:__610323__:__METADHERIN; MTDH__:__METASTASIS ADHESION PROTEIN;; LYRIC;; ASTROCYTE ELEVATED GENE 1; AEG1__:__
Asterisk__:__610324__:__3-OXOACYL-ACP SYNTHASE, MITOCHONDRIAL; OXSM__:__BETA-KETOACYL SYNTHASE, MITOCHONDRIAL; KS__:__
Asterisk__:__610325__:__NUCLEAR DISTRIBUTION GENE C, A. NIDULANS, HOMOLOG OF; NUDC__:____:__
Asterisk__:__610326__:__RIBONUCLEASE H2, SUBUNIT B; RNASEH2B__:__DLEU8;; FLJ11712__:__
Asterisk__:__610327__:__RUN AND FYVE DOMAINS-CONTAINING PROTEIN 1; RUFY1__:____:__
Asterisk__:__610328__:__RUN AND FYVE DOMAINS-CONTAINING PROTEIN 2; RUFY2__:__KIAA1537__:__
Number Sign__:__610329__:__AICARDI-GOUTIERES SYNDROME 3; AGS3__:____:__
Asterisk__:__610330__:__RIBONUCLEASE H2, SUBUNIT C; RNASEH2C__:__AYP1;; FLJ20974__:__
Asterisk__:__610331__:__HAIRY/ENHANCER OF SPLIT, DROSOPHILA, HOMOLOG OF, 6; HES6__:____:__
Caret__:__610332__:__MOVED TO 608572__:____:__
Number Sign__:__610333__:__AICARDI-GOUTIERES SYNDROME 4; AGS4__:____:__
Asterisk__:__610334__:__HEPATOCELLULAR CARCINOMA-ASSOCIATED ANTIGEN 112__:__HCA112;; GS188__:__
Asterisk__:__610335__:__PHD FINGER PROTEIN 20; PHF20__:__GLIOMA-EXPRESSED ANTIGEN 2; GLEA2;; HEPATOCELLULAR CARCINOMA-ASSOCIATED ANTIGEN 58; HCA58__:__
Asterisk__:__610336__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 4C; C2CD4C__:__NUCLEAR-LOCALIZED FACTOR 3; NLF3;; KIAA1957__:__
Asterisk__:__610337__:__UPREGULATOR OF CELL PROLIFERATION; URGCP__:__HEPATITIS B VIRUS-ENCODED X ANTIGEN-UPREGULATED GENE 4;; HBX ANTIGEN-UPREGULATED GENE 4;; URG4__:__
NULL__:__610338__:__RIGHT PULMONARY ARTERY, ANOMALOUS ORIGIN OF, FAMILIAL__:__RIGHT PULMONARY ARTERY, ANOMALOUS ORIGIN OF, WITH VENTRICULAR SEPTAL DEFECT, PATENT FORAMEN OVALE, AND PATENT DUCTUS ARTERIOSUS;; ARPA, FAMILIAL__:__
Asterisk__:__610339__:__PROLYL 3-HYDROXYLASE 1; P3H1__:__LEUCINE- AND PROLINE-ENRICHED PROTEOGLYCAN 1; LEPRE1;; LEPRECAN;; GROWTH SUPPRESSOR 1; GROS1__:__
Asterisk__:__610340__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 4B; EPB41L4B__:__EXPRESSED IN HIGHLY METASTATIC CELLS 2; EHM2__:__
Asterisk__:__610341__:__PROLYL 3-HYDROXYLASE 2; P3H2__:__LEPRECAN-LIKE 1; LEPREL1__:__
Asterisk__:__610342__:__PROLYL 3-HYDROXYLASE 3; P3H3__:__LEPRECAN-LIKE 2; LEPREL2__:__
Asterisk__:__610343__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 4A; C2CD4A__:__NUCLEAR-LOCALIZED FACTOR 1; NLF1__:__
Asterisk__:__610344__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 4B; C2CD4B__:__NUCLEAR-LOCALIZED FACTOR 2; NLF2__:__
Asterisk__:__610345__:__ACYLGLYCEROL KINASE; AGK__:__MULTISUBSTRATE LIPID KINASE; MULK__:__
Asterisk__:__610346__:__CDC37-LIKE 1; CDC37L1__:__CELL DIVISION CYCLE 37, S. CEREVISIAE, HOMOLOG-LIKE 1; CDC37L1;; HSP90-ASSOCIATING RELATIVE OF CDC37; HARC;; FLJ20639__:__
Asterisk__:__610347__:__REGULATION OF NUCLEAR PRE-mRNA DOMAIN-CONTAINING PROTEIN 1A; RPRD1A__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2B-RELATED PROTEIN;; CDKN2B-RELATED PROTEIN;; P15(INK4B)-RELATED PROTEIN;; P15RS;; FLJ10656__:__
Asterisk__:__610348__:__FAMILY WITH SEQUENCE SIMILARITY 178, MEMBER A; FAM178A__:__CHROMOSOME 10 OPEN READING FRAME 6; C10ORF6__:__
Asterisk__:__610349__:__MEF2-ACTIVATING SAP TRANSCRIPTIONAL REGULATOR; MAMSTR__:__MASTR__:__
Asterisk__:__610350__:__LINES, DROSOPHILA, HOMOLOG OF; LINS__:__LINES, DROSOPHILA, HOMOLOG OF, 1; LINS1;; WINS1;; FLJ10583__:__
Asterisk__:__610351__:__PROTEIN PHOSPHATASE 4, REGULATORY SUBUNIT 3, ALPHA; PPP4R3A__:__PP4R3-ALPHA; PP4R3A;; SUPPRESSOR OF MEK1, DICTYOSTELIUM, HOMOLOG OF, 1; SMEK1;; MEK1 SUPPRESSOR 1;; KIAA2010__:__
Asterisk__:__610352__:__PROTEIN PHOSPHATASE 4, REGULATORY SUBUNIT 3, BETA; PPP4R3B__:__PP4R3-BETA; PP4R3B;; SUPPRESSOR OF MEK1, DICTYOSTELIUM, HOMOLOG OF, 2; SMEK2;; MEK1 SUPPRESSOR 2;; KIAA1387__:__
Number Sign__:__610353__:__EPILEPSY, NOCTURNAL FRONTAL LOBE, 4; ENFL4__:__EPILEPSY, FAMILIAL, WITH NOCTURNAL WANDERING AND ICTAL FEAR__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 6, INCLUDED; BFIS6, INCLUDED;; CONVULSIONS, BENIGN FAMILIAL INFANTILE, 6, INCLUDED; BFIC6, INCLUDED
Asterisk__:__610354__:__CONNEXIN 43-INTERACTING PROTEIN, 150-KD__:__CIP150;; RIC1, S. CEREVISIAE, HOMOLOG OF; RIC1;; KIAA1432__:__
Asterisk__:__610355__:__PARTNER AND LOCALIZER OF BRCA2; PALB2__:__FANCN GENE; FANCN__:__
Number Sign__:__610356__:__RETINAL CONE DYSTROPHY 3B; RCD3B__:__CONE DYSTROPHY WITH SUPERNORMAL ROD RESPONSES; CDSRR;; CONE DYSTROPHY WITH NIGHT BLINDNESS AND SUPERNORMAL ROD RESPONSES, KCNV2-RELATED__:__
Number Sign__:__610357__:__SPASTIC PARAPLEGIA 30, AUTOSOMAL RECESSIVE; SPG30__:____:__
Asterisk__:__610358__:__SIGNAL PEPTIDASE COMPLEX, SUBUNIT 1, S. CEREVISIAE, HOMOLOG OF; SPCS1__:__SIGNAL PEPTIDASE, 12-KD SUBUNIT; SPC12__:__
Number Sign__:__610359__:__RETINITIS PIGMENTOSA 33; RP33__:____:__
Asterisk__:__610360__:__MUCIN 20, CELL SURFACE-ASSOCIATED; MUC20__:____:__
Percent__:__610361__:__OROFACIAL CLEFT 9; OFC9__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 9__:__
Asterisk__:__610362__:__RETINA AND ANTERIOR NEURAL FOLD HOMEOBOX 2; RAX2__:__RETINA AND ANTERIOR NEURAL FOLD HOMEOBOX-LIKE 1; RAXL1;; Q50-TYPE RETINAL HOMEOBOX; QRX__:__
Asterisk__:__610363__:__PEPTIDYLARGININE DEIMINASE, TYPE VI; PADI6__:____:__
Asterisk__:__610364__:__TRANSMEMBRANE BAX INHIBITOR MOTIF-CONTAINING PROTEIN 1; TMBIM1__:__RESPONSIVE TO CENTRIFUGAL FORCE AND SHEAR STRESS 1; RECS1__:__
Asterisk__:__610365__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 1; C1QTNF1__:__G PROTEIN-COUPLED RECEPTOR-INTERACTING PROTEIN; GIP__:__
Asterisk__:__610366__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, MU-1 SUBUNIT; AP3M1__:__CLATHRIN ADAPTOR COMPLEX AP3, MU-3A SUBUNIT__:__
Asterisk__:__610367__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 11; SLC2A11__:__GLUCOSE TRANSPORTER 11; GLUT11__:__
Asterisk__:__610368__:__LEUCINE-RICH REPEATS AND CALPONIN HOMOLOGY DOMAIN-CONTAINING 1; LRCH1__:__KIAA1016__:__
Asterisk__:__610369__:__HEAT-SHOCK 70-KD PROTEIN 14; HSPA14__:__HSP70-LIKE 1; HSP70L1__:__
Number Sign__:__610370__:__DIARRHEA 4, MALABSORPTIVE, CONGENITAL; DIAR4__:__ENTERIC ANENDOCRINOSIS__:__
Asterisk__:__610371__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 7; SLC2A7__:__GLUCOSE TRANSPORTER 7; GLUT7__:__
Asterisk__:__610372__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 12; SLC2A12__:__GLUCOSE TRANSPORTER 12; GLUT12__:__
Asterisk__:__610373__:__DEAD/H BOX 50; DDX50__:__RH-II/GU-BETA; GUB__:__
Number Sign__:__610374__:__DIABETES MELLITUS, TRANSIENT NEONATAL, 2__:__TNDM2__:__
Asterisk__:__610375__:__CAPRIN FAMILY, MEMBER 2; CAPRIN2__:__CYTOPLASMIC ACTIVATION- AND PROLIFERATION-ASSOCIATED PROTEIN 2;; CAPRIN 2;; EEG1;; RNA GRANULE PROTEIN 140; RNG140;; C1q DOMAIN-CONTAINING PROTEIN 1; C1QDC1;; KIAA1873__:__
Asterisk__:__610376__:__ATYPICAL CHEMOKINE RECEPTOR 3; ACKR3__:__CHEMOKINE, CXC MOTIF, RECEPTOR 7; CXCR7;; CHEMOKINE ORPHAN RECEPTOR 1; CMKOR1;; G PROTEIN-COUPLED RECEPTOR 159; GPR159;; RDC1__:__
Number Sign__:__610377__:__MEVALONIC ACIDURIA; MEVA__:____:__
Asterisk__:__610378__:__GLIS FAMILY ZINC FINGER PROTEIN 1; GLIS1__:__GLI-SIMILAR PROTEIN 1__:__
Number Sign__:__610379__:__WEST NILE VIRUS, SUSCEPTIBILITY TO__:__WNV, SUSCEPTIBILITY TO__:__
Caret__:__610380__:__MOVED TO 610168__:____:__
Number Sign__:__610381__:__CONE-ROD DYSTROPHY 11; CORD11__:____:__
Percent__:__610382__:__PROSOPAGNOSIA, HEREDITARY__:__FACE BLINDNESS;; PROSOPAGNOSIA, DEVELOPMENTAL;; PROSOPAGNOSIA, CONGENITAL__:__
Asterisk__:__610383__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 9; RASSF9__:__PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE C-TERMINAL INTERACTOR;; PAMCI;; PAM C-TERMINAL INTERACTOR PROTEIN 1; PCIP1__:__
Asterisk__:__610384__:__HECT, C2, AND WW DOMAINS-CONTAINING E3 UBIQUITIN-PROTEIN LIGASE 1; HECW1__:__NEDD4-LIKE UBIQUITIN-PROTEIN LIGASE 1; NEDL1;; KIAA0322__:__
Asterisk__:__610385__:__LR8 PROTEIN; LR8__:____:__
Asterisk__:__610386__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 7; BTBD7__:__FUP1__:__
Asterisk__:__610387__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL IRON CARRIER), MEMBER 37; SLC25A37__:__MITOFERRIN; MFRN;; MFRN1__:__
Asterisk__:__610388__:__RRAD- AND GEM-LIKE GTPase 1; REM1__:__RAS (RAD AND GEM)-LIKE GTP-BINDING PROTEIN 1;; GTPase-REGULATING ENDOTHELIAL CELL-SPROUTING PROTEIN; GES__:__
Asterisk__:__610389__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MAPK AND MTOR ACTIVATOR 2; LAMTOR2__:__MAPBP-INTERACTING PROTEIN; MAPBPIP;; p14__:__
Asterisk__:__610390__:__MACROPHAGE EXPRESSED GENE 1__:__MPEG1;; MPG1__:__
Asterisk__:__610391__:__PHOSPHOLIPID PHOSPHATASE-RELATED PROTEIN 3; PLPPR3__:__PLASTICITY-RELATED GENE 2;; LIPID PHOSPHATE PHOSPHATASE-RELATED 3; LPPR3;; LPR3;; PRG2__:__
Asterisk__:__610392__:__MYC-BINDING PROTEIN 2; MYCBP2__:__PROTEIN ASSOCIATED WITH MYC; PAM;; KIAA0916__:__
Asterisk__:__610393__:__GON4-LIKE PROTEIN; GON4L__:__KIAA1606__:__
Asterisk__:__610394__:__GLIPR1-LIKE PROTEIN 2; GLIPR1L2__:____:__
Asterisk__:__610395__:__GLIPR1-LIKE PROTEIN 1; GLIPR1L1__:____:__
Asterisk__:__610396__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 6A; TRAPPC6A__:__TRAPP COMPLEX, SUBUNIT 6A__:__
Asterisk__:__610397__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 6B; TRAPPC6B__:__TRAPP COMPLEX, SUBUNIT 6B;; TPC6__:__
Asterisk__:__610398__:__SAP30-LIKE PROTEIN; SAP30L__:____:__
Asterisk__:__610399__:__TRANSMEMBRANE PROTEASE, SERINE 11E; TMPRSS11E__:__DESC1__:__
Asterisk__:__610400__:__MACRO DOMAIN-CONTAINING 1; MACROD1__:__LRP16 PROTEIN; LRP16__:__
Asterisk__:__610401__:__NETRIN 4; NTN4__:__BETA-NETRIN__:__
Caret__:__610402__:__MOVED TO 609122 AND 300870__:____:__
Asterisk__:__610403__:__CULLIN-ASSOCIATED NEDDYLATION-DISSOCIATED 2; CAND2__:__TBP-INTERACTING PROTEIN B; TIP120B;; KIAA0667__:__
Asterisk__:__610404__:__RECQ-MEDIATED GENOME INSTABILITY 1; RMI1__:__RECQ-MEDIATED GENOME INSTABILITY 1, S. CEREVISIAE, HOMOLOG OF;; BLM-ASSOCIATED PROTEIN, 75-KD; BLAP75;; CHROMOSOME 9 OPEN READING FRAME 76; C9ORF76__:__
Asterisk__:__610405__:__CHONDROITIN POLYMERIZING FACTOR; CHPF__:__CHONDROITIN SULFATE SYNTHASE 2; CSS2__:__
Asterisk__:__610406__:__TRANSFER RNA ARGININE 1; TRNAR1__:__tRNA ARGININE 1; TRR1__:__
Asterisk__:__610407__:__TRANSFER RNA GLYCINE 2; TRNAG2__:__tRNA GLYCINE 2; TRG2__:__
Asterisk__:__610408__:__SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 3; SLC15A3__:__PEPTIDE/HISTIDINE TRANSPORTER 2; PHT2__:__
Asterisk__:__610409__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 8; SLC16A8__:__MONOCARBOXYLATE TRANSPORTER 3; MCT3__:__
Asterisk__:__610410__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 1; DHRS1__:__SDR FAMILY, MEMBER 1__:__
Asterisk__:__610411__:__IMPORTIN 13; IPO13__:__IMP13;; KIAA0724;; RAN-BINDING PROTEIN 13; RANBP13;; KARYOPHERIN 13 KAP13__:__
Asterisk__:__610412__:__SERINE PALMITOYLTRANSFERASE, SMALL SUBUNIT, B; SPTSSB__:__SMALL SUBUNIT OF SERINE PALMITOYLTRANSFERASE B; SSSPTB;; ADMP, MOUSE, HOMOLOG OF; ADMP;; CHROMOSOME 3 OPEN READING FRAME 57; C3ORF57__:__
Asterisk__:__610413__:__INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-LIKE 1; IGFBPL1__:__IGFBP-RELATED PROTEIN 4; IGFBPRP4__:__
Asterisk__:__610414__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 15; NBPF15__:__MGC8902__:__
Asterisk__:__610415__:__SYNTAXIN-BINDING PROTEIN 4; STXBP4__:__STX4-INTERACTING PROTEIN; SYNIP__:__
Asterisk__:__610416__:__SCAN DOMAIN-CONTAINING 1; SCAND1__:__RAZ1;; SDP1__:__
Asterisk__:__610417__:__SCAN DOMAIN-CONTAINING 2; SCAND2__:____:__
Asterisk__:__610418__:__WD REPEAT- AND FYVE DOMAIN-CONTAINING PROTEIN 2; WDFY2__:____:__
Number Sign__:__610419__:__DEAFNESS, AUTOSOMAL RECESSIVE 68; DFNB68__:____:__
Percent__:__610420__:__PREAURICULAR TAG, ISOLATED, AUTOSOMAL DOMINANT, 1__:____:__
Asterisk__:__610421__:__KH DOMAIN-CONTAINING, RNA-BINDING, SIGNAL TRANSDUCTION-ASSOCIATED PROTEIN 3; KHDRBS3__:__TSTAR;; ETOILE;; SALP;; SLM2__:__
Percent__:__610422__:__ALOPECIA-MENTAL RETARDATION SYNDROME 2; APMR2__:____:__
Asterisk__:__610423__:__PHOSPHOFURIN ACIDIC CLUSTER SORTING PROTEIN 2; PACS2__:__KIAA0602__:__
Number Sign__:__610424__:__HEPATITIS B VIRUS, SUSCEPTIBILITY TO__:__HBV, SUSCEPTIBILITY TO__:__HEPATITIS B VIRUS, RESISTANCE TO, INCLUDED;; HBV, RESISTANCE TO, INCLUDED
Number Sign__:__610425__:__CATARACT 23, MULTIPLE TYPES; CTRCT23__:__CATARACT 23, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA__:__
Caret__:__610426__:__MOVED TO 610425__:____:__
Number Sign__:__610427__:__CONE-ROD SYNAPTIC DISORDER, CONGENITAL NONPROGRESSIVE; CRSD__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2B, FORMERLY; CSNB2B, FORMERLY;; NIGHT BLINDNESS, CONGENITAL STATIONARY, INCOMPLETE, AUTOSOMAL RECESSIVE, FORMERLY__:__
Asterisk__:__610428__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX18; COX18__:__COX18, S. CEREVISIAE, HOMOLOG OF;; MITOCHONDRIAL COX18__:__
Asterisk__:__610429__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX19; COX19__:__COX19, S. CEREVISIAE, HOMOLOG OF__:__
Percent__:__610430__:__MACROGLOBULINEMIA, WALDENSTROM, SUSCEPTIBILITY TO, 2; WM2__:____:__
Asterisk__:__610431__:__RING FINGER PROTEIN 167; RNF167__:__RING105__:__
Asterisk__:__610432__:__RING FINGER PROTEIN 125; RNF125__:__T-CELL RING PROTEIN IDENTIFIED IN ACTIVATION SCREEN; TRAC1__:__
Asterisk__:__610433__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS G5B; LY6G5B__:__G5B__:__
Asterisk__:__610434__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS G5C; LY6G5C__:__G5C__:__
Asterisk__:__610435__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS G6C; LY6G6C__:__G6C__:__
Asterisk__:__610436__:__ROTATIN; RTTN__:____:__
Asterisk__:__610437__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS G6E; LY6G6E__:__G6E__:__
Percent__:__610438__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 3; RLS3__:____:__
Percent__:__610439__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 4; RLS4__:____:__
Asterisk__:__610440__:__SMALL G PROTEIN SIGNALING MODULATOR 3; SGSM3__:__RUN AND TBC1 DOMAINS-CONTAINING PROTEIN 3; RUTBC3;; MERLIN-ASSOCIATED PROTEIN; MAP;; MERLIN-BINDING PROTEIN;; RUSC3__:__
Percent__:__610441__:__TESTICULAR MICROLITHIASIS__:____:__
Number Sign__:__610442__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, GENEVIEVE TYPE; SEMDG__:__SEMD, GENEVIEVE TYPE;; NANS DEFICIENCY__:__
Number Sign__:__610443__:__KOOLEN-DE VRIES SYNDROME; KDVS__:__CHROMOSOME 17q21.31 DELETION SYNDROME;; MICRODELETION 17q21.31 SYNDROME__:__
Number Sign__:__610444__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 3; CSNBAD3__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, NOUGARET TYPE__:__
Number Sign__:__610445__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, AUTOSOMAL DOMINANT 1; CSNBAD1__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, RHODOPSIN-RELATED__:__
Number Sign__:__610446__:__BURULI ULCER, SUSCEPTIBILITY TO__:__MYCOBACTERIUM ULCERANS, SUSCEPTIBILITY TO__:__
Asterisk__:__610447__:__SHADOW OF PRION PROTEIN; SPRN__:__SHADOO;; SHO__:__
Number Sign__:__610448__:__CHILBLAIN LUPUS 1; CHBL1__:____:__
Asterisk__:__610449__:__MITOCHONDRIAL CARRIER HOMOLOG 1; MTCH1__:__PRESENILIN-ASSOCIATED PROTEIN; PSAP__:__
Asterisk__:__610450__:__LY6/PLAUR DOMAIN-CONTAINING PROTEIN 1; LYPD1__:__PUTATIVE HELA TUMOR SUPPRESSOR; PHTS__:__
Asterisk__:__610451__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 35; LRRC35__:__E-LIKE PROTEIN; EL__:__
Percent__:__610452__:__MUTAGEN SENSITIVITY__:____:__
Asterisk__:__610453__:__HEPARAN-ALPHA-GLUCOSAMINIDE N-ACETYLTRANSFERASE; HGSNAT__:__TRANSMEMBRANE PROTEIN 76; TMEM76__:__
Asterisk__:__610454__:__LEUCINE ZIPPER, PUTATIVE TUMOR SUPPRESSOR 2; LZTS2__:__KIAA1813;; LAPSER1__:__
Number Sign__:__610455__:__TUMORAL CALCINOSIS, NORMOPHOSPHATEMIC, FAMILIAL; NFTC__:__CALCINOSIS, TUMORAL, WITH NORMOPHOSPHATEMIA__:__
Asterisk__:__610456__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 9; SAMD9__:____:__
Asterisk__:__610457__:__SPHINGOMYELIN PHOSPHODIESTERASE 4, NEUTRAL MEMBRANE; SMPD4__:__SPHINGOMYELINASE, NEUTRAL, 3; NSMASE3;; KIAA1418__:__
Asterisk__:__610458__:__LEUCINE ZIPPER AND CTNNBIP1 DOMAINS-CONTAINING PROTEIN; LZIC__:____:__
Asterisk__:__610459__:__PROLINE-RICH PROTEIN 13; PRR13__:__TAXOL RESISTANCE GENE 1; TXR1__:__
Number Sign__:__610460__:__THIOPURINES, POOR METABOLISM OF, 1; THPM1__:__THIOPURINE S-METHYLTRANSFERASE DEFICIENCY; TPMTD;; TPMT DEFICIENCY__:__
Asterisk__:__610461__:__RETICULON 4 RECEPTOR-LIKE 1; RTN4RL1__:__NOGO-66 RECEPTOR HOMOLOG 2; NGRH2;; NOGO-66 RECEPTOR-RELATED PROTEIN 3; NGR3__:__
Asterisk__:__610462__:__RETICULON 4 RECEPTOR-LIKE 2; RTN4RL2__:__NOGO-66 RECEPTOR HOMOLOG 1; NGRH1;; NOGO-66 RECEPTOR-RELATED PROTEIN 2; NGR2__:__
Asterisk__:__610463__:__NUCLEAR UNDECAPRENYL PYROPHOSPHATE SYNTHASE 1, S. CEREVISIAE, HOMOLOG OF; NUS1__:__NOGOB RECEPTOR; NGBR;; CHROMOSOME 6 OPEN READING FRAME 68; C6ORF68__:__
Asterisk__:__610464__:__G PROTEIN-COUPLED RECEPTOR 156; GPR156__:__GABABL__:__
Asterisk__:__610465__:__ACYL-CoA SYNTHETASE FAMILY, MEMBER 2; ACSF2__:__FLJ20920__:__
Asterisk__:__610466__:__LIMB EXPRESSION 1, MOUSE, HOMOLOG OF; LIX1__:____:__
Asterisk__:__610467__:__3-HYDROXYACYL-CoA DEHYDRATASE 1; HACD1__:__PROTEIN TYROSINE PHOSPHATASE-LIKE (PROLINE INSTEAD OF CATALYTIC ARGININE), MEMBER A; PTPLA__:__
Asterisk__:__610468__:__INTERFERON-INDUCED PROTEIN 44; IFI44__:__INTERFERON-INDUCED, HEPATITIS C-ASSOCIATED MICROTUBULE AGGREGATE PROTEIN, 44 kD;; p44__:__
Asterisk__:__610469__:__ADAPTOR-RELATED PROTEIN COMPLEX 3, MU-2 SUBUNIT; AP3M2__:__CLATHRIN ADAPTOR COMPLEX AP3, MU-3B SUBUNIT;; CLA20__:__
Asterisk__:__610470__:__TRANSFER RNA PHOSPHOTRANSFERASE 1; TRPT1__:__tRNA PHOSPHOTRANSFERASE 1__:__
Asterisk__:__610471__:__VASOHIBIN 2; VASH2__:____:__
Asterisk__:__610472__:__ACYLTRANSFERASE-LIKE 2; AYTL2__:__LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE; LPCAT;; LPC ACYLTRANSFERASE 1; LPCAT1__:__
Asterisk__:__610473__:__LYSOPHOSPHATIDYLGLYCEROL ACYLTRANSFERASE 1; LPGAT1__:____:__
Number Sign__:__610474__:__CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME; CATSHLS__:__CATSHL SYNDROME__:__
Number Sign__:__610475__:__PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2__:__PIGMENTED MICRONODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2;; CUSHING SYNDROME, ADRENAL, DUE TO PPNAD2__:__
Number Sign__:__610476__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 11; ARVC11__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11, AND MILD PALMOPLANTAR KERATODERMA WITH OR WITHOUT WOOLLY HAIR, INCLUDED
Asterisk__:__610477__:__TRANSMEMBRANE PROTEASE, SERINE 9; TMPRSS9__:__POLYSERASE 1__:__
Number Sign__:__610478__:__RETINAL CONE DYSTROPHY 4; RCD4__:____:__
Asterisk__:__610479__:__SERUM RESPONSE FACTOR BINDING PROTEIN 1; SRFBP1__:__SRF-DEPENDENT TRANSCRIPTION REGULATION-ASSOCIATED PROTEIN;; p49/STRAP;; p49__:__
Asterisk__:__610480__:__LEM DOMAIN-CONTAINING PROTEIN 1; LEMD1__:____:__
Asterisk__:__610481__:__SH2 DOMAIN-CONTAINING PROTEIN D; SHD__:____:__
Asterisk__:__610482__:__SH2 DOMAIN-CONTAINING PROTEIN E; SHE__:____:__
Percent__:__610483__:__AGAMMAGLOBULINEMIA, MICROCEPHALY, AND SEVERE DERMATITIS__:____:__
Asterisk__:__610484__:__PROLINE-RICH SYNAPSE-ASSOCIATED PROTEIN-INTERACTING PROTEIN 1__:__PROSAP-INTERACTING PROTEIN 1; PROSAPIP1;; KIAA0552__:__
Asterisk__:__610485__:__LOSS OF HETEROZYGOSITY, CHROMOSOME 3, REGION 2, GENE A; LOH3CR2A__:__ESTROGEN RECEPTOR REPRESSOR, 10-KD; ERR10;; NAG7__:__
Asterisk__:__610486__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 4; LRRC4__:____:__
Asterisk__:__610487__:__KH DOMAIN-CONTAINING, RNA-BINDING, SIGNAL TRANSDUCTION-ASSOCIATED PROTEIN 2; KHDRBS2__:__SLM1__:__
Asterisk__:__610488__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 9; TTC9__:__KIAA0227__:__
Number Sign__:__610489__:__PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1__:__PIGMENTED MICRONODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1;; CUSHING SYNDROME, ADRENAL, DUE TO PPNAD1;; ADRENOCORTICAL NODULAR DYSPLASIA, PRIMARY__:__
Asterisk__:__610490__:__PURPLE ACID PHOSPHATASE, LONG FORM__:__PAPL;; FLJ16165__:__
Asterisk__:__610491__:__SLAIN MOTIF FAMILY, MEMBER 1; SLAIN1__:____:__
Asterisk__:__610492__:__SLAIN MOTIF FAMILY, MEMBER 2; SLAIN2__:__KIAA1458__:__
Asterisk__:__610493__:__DIX DOMAIN-CONTAINING PROTEIN 1; DIXDC1__:__COILED-COIL DIX1; CCD1;; KIAA1735__:__
Asterisk__:__610494__:__DDB1- AND CUL4-ASSOCIATED FACTOR 6; DCAF6__:__IQ MOTIF- AND WD REPEATS-CONTAINING 1; IQWD1;; NUCLEAR RECEPTOR INTERACTION PROTEIN; NRIP;; HOM-TES-88/94/95__:__
Asterisk__:__610495__:__HOM-TES-103 GENE__:____:__
Asterisk__:__610496__:__RHO GTPase-ACTIVATING PROTEIN 29; ARHGAP29__:__PTPL1-ASSOCIATED RHOGAP1; PARG1__:__
Asterisk__:__610497__:__BRAIN AND REPRODUCTIVE ORGAN-EXPRESSED PROTEIN; BRE__:__BRCC4;; BRCC45__:__
Number Sign__:__610498__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2__:__CORPUS CALLOSUM, AGENESIS OF, WITH DYSMORPHISM AND FATAL LACTIC ACIDOSIS__:__
Asterisk__:__610499__:__RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR 6; RAPGEF6__:__RAS-ASSOCIATING GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; RAGEF2;; PDZ DOMAIN-CONTAINING GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; PDZGEF2__:__
Asterisk__:__610500__:__ANKYRIN REPEAT AND KH DOMAIN-CONTAINING PROTEIN 1; ANKHD1__:__MULTIPLE ANKYRIN REPEATS, SINGLE KH-DOMAIN, DROSOPHILA, HOMOLOG OF; MASK;; KIAA1085__:__MASK-BP3, INCLUDED;; VPR-BINDING ANKYRIN REPEAT PROTEIN, INCLUDED; VBARP, INCLUDED
Asterisk__:__610501__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 1; NBPF1__:__KIAA1693__:__
Asterisk__:__610502__:__RETICULON 4-INTERACTING PROTEIN 1; RTN4IP1__:__NOGO-INTERACTING MITOCHONDRIAL PROTEIN; NIMP__:__
Asterisk__:__610503__:__CELL DEATH-INDUCING p53 TARGET 1; CDIP1__:__CHROMOSOME 16 OPEN READING FRAME 5; C16ORF5__:__
Number Sign__:__610504__:__PRETERM PREMATURE RUPTURE OF THE MEMBRANES; PPROM__:____:__
Number Sign__:__610505__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3__:__ENCEPHALOMYOPATHY, RESPIRATORY FAILURE, AND LACTIC ACIDOSIS;; CONCENTRIC CARDIOMYOPATHY, HYPOTONIA, AND LACTIC ACIDOSIS__:__
Asterisk__:__610506__:__PAF1 RNA POLYMERASE II-ASSOCIATED FACTOR, S. CEREVISIAE, HOMOLOG OF; PAF1__:__PANCREATIC DIFFERENTIATION PROTEIN 2; PD2__:__
Asterisk__:__610507__:__LEO1 RNA POLYMERASE II ASSOCIATED FACTOR, S. CEREVISIAE, HOMOLOG OF; LEO1__:__REPLICATIVE SENESCENCE DOWNREGULATED LEO1-LIKE; RDL__:__
Number Sign__:__610508__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 7; MODY7__:____:__
Asterisk__:__610509__:__RESISTANCE TO INHIBITORS OF CHOLINESTERASE 3, C. ELEGANS, HOMOLOG OF; RIC3__:____:__
Asterisk__:__610510__:__AURORA BOREALIS; BORA__:__CHROMOSOME 13 OPEN READING FRAME 34; C13ORF34__:__
Asterisk__:__610511__:__SEC23, S. CEREVISIAE, HOMOLOG OF, A; SEC23A__:____:__
Asterisk__:__610512__:__SEC23, S. CEREVISIAE, HOMOLOG OF, B; SEC23B__:____:__
Asterisk__:__610513__:__ATPase, TYPE 13A2; ATP13A2__:____:__
Asterisk__:__610514__:__PHD FINGER PROTEIN 17; PHF17__:__GENE FOR APOPTOSIS AND DIFFERENTIATION IN EPITHELIA; JADE1;; KIAA1807__:__
Asterisk__:__610515__:__PHD FINGER PROTEIN 15; PHF15__:__JADE2;; KIAA0239__:__
Asterisk__:__610516__:__GLYCERATE KINASE; GLYCTK__:__GLYCTK1__:__GLYCTK2, INCLUDED
Asterisk__:__610517__:__CONTACTIN-ASSOCIATED PROTEIN-LIKE 3; CNTNAP3__:__CONTACTIN-ASSOCIATED PROTEIN 3; CASPR3;; KIAA1714__:__
Asterisk__:__610518__:__CONTACTIN-ASSOCIATED PROTEIN-LIKE 4; CNTNAP4__:__CONTACTIN-ASSOCIATED PROTEIN 4; CASPR4;; KIAA1763__:__
Asterisk__:__610519__:__CONTACTIN-ASSOCIATED PROTEIN-LIKE 5; CNTNAP5__:__CONTACTIN-ASSOCIATED PROTEIN 5; CASPR5__:__
Asterisk__:__610520__:__CD300 ANTIGEN-LIKE FAMILY, MEMBER G; CD300LG__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 4; TREM4;; CLM9;; NEPMUCIN__:__
Asterisk__:__610521__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 12; KCTD12__:__PREDOMINANTLY FETAL-EXPRESSED T1 DOMAIN; PFET1;; PFETIN;; KIAA1778;; CHROMOSOME 13 OPEN READING FRAME 2; C13ORF2__:__
Asterisk__:__610522__:__COORDINATED EXPRESSION TO IRXA2__:__CEI__:__
Asterisk__:__610523__:__CENTROSOMAL PROTEIN, 41-KD; CEP41__:__TESTIS-SPECIFIC PROTEIN A14 TESTIS-SPECIFIC PROTEIN 14, FORMERLY; TSGA14, FORMERLY__:__
Asterisk__:__610524__:__ENDOGENOUS RETROVIRUS GROUP FRD, MEMBER 1; ERVFRD1__:__HUMAN ENDOGENOUS RETROVIRUS FRD ENVELOPE PROTEIN;; HERV-FRD ENV PROTEIN;; SYNCYTIN 2;; SYNCYTIN B, MOUSE, HOMOLOG OF__:__
Asterisk__:__610525__:__5-PRIME-NUCLEOTIDASE, CYTOSOLIC, IA; NT5C1A__:__NUCLEOTIDASE, 5-PRIME, CYTOSOLIC, IA;; CYTOSOLIC 5-PRIME NUCLEOTIDASE IA; CNIA; CN1A;; CYTOSOLIC 5-PRIME NUCLEOTIDASE I; CNI; CN1__:__
Asterisk__:__610526__:__5-PRIME-NUCLEOTIDASE, CYTOSOLIC, IB; NT5C1B__:__NUCLEOTIDASE, 5-PRIME, CYTOSOLIC, IB;; CYTOSOLIC 5-PRIME NUCLEOTIDASE IB; CNIB; CN1B;; AUTOIMMUNE INFERTILITY-RELATED PROTEIN; AIRP__:__
Asterisk__:__610527__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 1; TXNDC1__:__TRANSMEMBRANE TRX-RELATED PROTEIN; TMX__:__
Asterisk__:__610528__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 8; CHD8__:__AXIS DUPLICATION INHIBITOR; DUPLIN;; KIAA1564__:__
Asterisk__:__610529__:__TUMOR SUPPRESSOR CANDIDATE 1; TUSC1__:__TSG9__:__
Asterisk__:__610530__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 41; TRIM41__:____:__
Asterisk__:__610531__:__FAMILY WITH SEQUENCE SIMILARITY 126, MEMBER A; FAM126A__:__DOWNREGULATED BY CTNNB1, PROTEIN A; DRCTNNB1A;; HYCCIN__:__
Number Sign__:__610532__:__LEUKODYSTROPHY, HYPOMYELINATING, 5; HLD5__:__HYPOMYELINATION AND CONGENITAL CATARACT: HCC__:__
Asterisk__:__610533__:__WW, C2, AND COILED-COIL DOMAIN-CONTAINING 1; WWC1__:__KIDNEY AND BRAIN EXPRESSED PROTEIN; KIBRA;; KIAA0869__:__
Asterisk__:__610534__:__DECAPPING ENZYME, SCAVENGER; DCPS__:__HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 5; HINT5;; DCS1, C. ELEGANS, HOMOLOG OF; DCS1__:__
Percent__:__610535__:__GLAUCOMA 1, OPEN ANGLE, M; GLC1M__:____:__
Number Sign__:__610536__:__MANDIBULOFACIAL DYSOSTOSIS, GUION-ALMEIDA TYPE; MFDGA__:__MANDIBULOFACIAL DYSOSTOSIS WITH MICROCEPHALY; MFDM;; GROWTH AND MENTAL RETARDATION, MANDIBULOFACIAL DYSOSTOSIS, MICROCEPHALY, AND CLEFT PALATE__:__
Asterisk__:__610537__:__DIPEPTIDYL PEPTIDASE VII; DPP7__:__QUIESCENT CELL PROLINE DIPEPTIDASE; QPP__:__
Asterisk__:__610538__:__UBIQUITIN-CONJUGATING ENZYME E2T; UBE2T__:__HSPC150__:__
Number Sign__:__610539__:__GAUCHER DISEASE, ATYPICAL, DUE TO SAPOSIN C DEFICIENCY__:____:__
Asterisk__:__610540__:__GNAS COMPLEX LOCUS, ANTISENSE TRANSCRIPT 1; GNASAS1__:__GNASAS;; SANG;; GNAS1, ANTISENSE; GNAS1AS;; NESP, ANTISENSE; NESPAS__:__
Asterisk__:__610541__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 3B; PPP1R3B__:__PROTEIN PHOSPHATASE 1, GLYCOGEN-TARGETING SUBUNIT, LIVER; GL;; PP1G, HEPATIC__:__
Number Sign__:__610542__:__MYASTHENIC SYNDROME, CONGENITAL, 12; CMS12__:__MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 1; CMSTA1__:__
Number Sign__:__610543__:__CHROMOSOME 16p13.3 DELETION SYNDROME, PROXIMAL__:__RUBINSTEIN-TAYBI DELETION SYNDROME;; RSTS DELETION SYNDROME__:__
Asterisk__:__610544__:__IGF-LIKE FAMILY MEMBER 1; IGFL1__:____:__
Asterisk__:__610545__:__IGF-LIKE FAMILY MEMBER 2; IGFL2__:____:__
Asterisk__:__610546__:__IGF-LIKE FAMILY MEMBER 3; IGFL3__:____:__
Asterisk__:__610547__:__IGF-LIKE FAMILY MEMBER 4; IGFL4__:____:__
Asterisk__:__610548__:__AQUARIUS, MOUSE, HOMOLOG OF; AQR__:__INTRON-BINDING PROTEIN, 160-KD; IBP160;; KIAA0560__:__
Number Sign__:__610549__:__DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS__:__INSULIN RECEPTOR, DEFECT IN, WITH INSULIN-RESISTANT DIABETES MELLITUS AND ACANTHOSIS NIGRICANS;; DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS, TYPE A;; IRAN, TYPE A__:__
Asterisk__:__610550__:__METHIONINE ADENOSYLTRANSFERASE I, ALPHA; MAT1A__:__MATA1;; S-ADENOSYLMETHIONINE SYNTHETASE 1; SAMS1;; SAMS, LIVER-SPECIFIC__:__
Number Sign__:__610551__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 1; IIAE1__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 1__:__
Asterisk__:__610552__:__UBIQUITIN-LIKE MODIFIER ACTIVATING ENZYME 5; UBA5__:__UBIQUITIN-ACTIVATING ENZYME E1 DOMAIN-CONTAINING 1; UBE1DC1__:__
Asterisk__:__610553__:__UBIQUITIN-FOLD MODIFIER 1; UFM1__:____:__
Asterisk__:__610554__:__UBIQUITIN-FOLD MODIFIER-CONJUGATING ENZYME 1; UFC1__:__UFM1-CONJUGATING ENZYME 1__:__
Asterisk__:__610555__:__CORE 1 SYNTHASE, GLYCOPROTEIN-N-ACETYLGALACTOSAMINE 3-BETA-GALACTOSYLTRANSFERASE, 1; C1GALT1__:__CORE 1 BETA-3-GAL-T;; T SYNTHASE__:__
Asterisk__:__610556__:__HIGHLY ACCELERATED REGION GENE 1A; HAR1A__:__HAR1F__:__
Asterisk__:__610557__:__HIGHLY ACCELERATED REGION GENE 1B; HAR1B__:__HAR1R__:__
Asterisk__:__610558__:__MITOGEN-ACTIVATED PROTEIN KINASE-ASSOCIATED PROTEIN 1; MAPKAP1__:__SAPK-INTERACTING PROTEIN 1; SIN1;; MEKK2-INTERACTING PROTEIN 1; MIP1;; JC310__:__
Asterisk__:__610559__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 4; RASSF4__:__AD037__:__
Asterisk__:__610560__:__PROTEASE, SERINE, 36; PRSS36__:__POLYSERASE 2;; POLYSERINE PROTEASE 2__:__
Asterisk__:__610561__:__PROTEASE, SERINE, 53; PRSS53__:__POLYSERASE 3; POL3S__:__
Asterisk__:__610562__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12A; ZC3H12A__:__MCP1-INDUCED PROTEIN; MCPIP;; MCPIP1;; REGNASE 1__:__
Asterisk__:__610563__:__KARYOPHERIN ALPHA-6; KPNA6__:__IMPORTIN ALPHA-7__:__
Asterisk__:__610564__:__PRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 2; PDSS2__:__DECAPRENYL DIPHOSPHATE SYNTHASE, SUBUNIT 2;; D-LESS POLYPRENYL PYROPHOSPHATE SYNTHASE 1; DLP1;; CHROMOSOME 6 OPEN READING FRAME 210; C6ORF210__:__
Asterisk__:__610565__:__DYNEIN, AXONEMAL, LIGHT CHAIN 4; DNAL4__:__DNALC4, MOUSE, HOMOLOG OF__:__
Asterisk__:__610566__:__MICRO RNA 146A; MIR146A__:__miRNA146A;; MIRN146A__:__
Asterisk__:__610567__:__MICRO RNA 146B; MIR146B__:__miRNA146B;; MIRN146B__:__
Asterisk__:__610568__:__ZINC FINGER PROTEIN 687; ZNF687__:__KIAA1441__:__ZNF687/RUNX1 FUSION GENE, INCLUDED
Asterisk__:__610569__:__UBIQUITIN-SPECIFIC PROTEASE 24; USP24__:__KIAA1057__:__
Asterisk__:__610570__:__UBIQUITIN-SPECIFIC PROTEASE 40; USP40__:____:__
Asterisk__:__610571__:__FK506-BINDING PROTEIN 11; FKBP11__:__FK506-BINDING PROTEIN, 19-KD; FKBP19__:__
Asterisk__:__610572__:__MARVEL DOMAIN-CONTAINING PROTEIN 2; MARVELD2__:__MARVD2;; TRICELLULIN; TRIC__:__
Asterisk__:__610573__:__R-SPONDIN FAMILY, MEMBER 4; RSPO4__:__CRISTIN4__:__
Asterisk__:__610574__:__R-SPONDIN FAMILY, MEMBER 3; RSPO3__:__PWTSR;; CRISTIN1__:__
Asterisk__:__610575__:__R-SPONDIN FAMILY, MEMBER 2; RSPO2__:__CRISTIN2__:__
Asterisk__:__610576__:__RHO GTPase-ACTIVATING PROTEIN 9; ARHGAP9__:____:__
Asterisk__:__610577__:__RHO GTPase-ACTIVATING PROTEIN 12; ARHGAP12__:____:__
Asterisk__:__610578__:__RHO GTPase-ACTIVATING PROTEIN 15; ARHGAP15__:__BM046__:__
Asterisk__:__610579__:__RCSD DOMAIN-CONTAINING PROTEIN 1; RCSD1__:__CAPZ-INTERACTING PROTEIN; CAPZIP__:__
Asterisk__:__610580__:__ONCOGENE PIM3; PIM3__:__SERINE/THREONINE PROTEIN KINASE PIM3__:__
Asterisk__:__610581__:__COATOMER PROTEIN COMPLEX, SUBUNIT GAMMA-2, INTRONIC TRANSCRIPT 1; COPG2IT1__:__COPG2 INTRONIC TRANSCRIPT 1; CIT1__:__
Number Sign__:__610582__:__DIABETES MELLITUS, TRANSIENT NEONATAL, 3__:__TNDM3__:__DIABETES MELLITUS, TYPE II, AUTOSOMAL DOMINANT, INCLUDED
Asterisk__:__610583__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 6; ANKRD6__:__KIAA0957;; DIVERSIN__:__
Asterisk__:__610584__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 67; TRIM67__:__TRIM9-LIKE; TNL__:__
Asterisk__:__610585__:__RHO GTPase-ACTIVATING PROTEIN 22; ARHGAP22__:____:__
Asterisk__:__610586__:__RHO GTPase-ACTIVATING PROTEIN 24; ARHGAP24__:__RAC1- AND CDC42-SPECIFIC GTPase-ACTIVATING PROTEIN, 72-KD; RCGAP72;; p73RHOGAP;; FILAMIN A-ASSOCIATED RHOGAP; FILGAP__:__
Asterisk__:__610587__:__RHO GTPase-ACTIVATING PROTEIN 25; ARHGAP25__:__KIAA0053__:__
Asterisk__:__610588__:__DENDRIN; DDN__:__KIAA0749__:__
Asterisk__:__610589__:__RHO GTPase-ACTIVATING PROTEIN 11A; ARHGAP11A__:__KIAA0013__:__
Asterisk__:__610590__:__RHO GTPase-ACTIVATING PROTEIN 23; ARHGAP23__:__KIAA1501__:__
Asterisk__:__610591__:__RHO GTPase-ACTIVATING PROTEIN 27; ARHGAP27__:__CIN85-ASSOCIATED MULTIDOMAIN-CONTAINING RhoGAP1; CAMGAP1__:__
Asterisk__:__610592__:__RHO GTPase-ACTIVATING PROTEIN 28; ARHGAP28__:__KIAA1314__:__
Asterisk__:__610593__:__MAP6 DOMAIN-CONTAINING PROTEIN 1; MAP6D1__:__STOP-LIKE PROTEIN, 21-KD; SL21__:__
Asterisk__:__610594__:__FOLLICULIN-INTERACTING PROTEIN 1; FNIP1__:__KIAA1961__:__
Asterisk__:__610595__:__FLAVIN ADENINE DINUCLEOTIDE SYNTHETASE, S. CEREVISIAE, HOMOLOG OF; FLAD1__:__FAD1, S. CEREVISIAE, HOMOLOG OF;; FAD SYNTHETASE; FADS;; FMN ADENYLYLTRANSFERASE__:__
Asterisk__:__610596__:__BLOCK OF PROLIFERATION 1; BOP1__:__KIAA0124__:__
Asterisk__:__610597__:__GLUTAMATE-RICH WD REPEAT-CONTAINING PROTEIN 1; GRWD1__:__GRWD;; KIAA1942__:__
Asterisk__:__610598__:__PRCD, DOG, HOMOLOG OF; PRCD__:____:__
Number Sign__:__610599__:__RETINITIS PIGMENTOSA 36; RP36__:____:__
Number Sign__:__610600__:__CORTICOSTERONE METHYLOXIDASE TYPE II DEFICIENCY__:__CMO II DEFICIENCY;; ALDOSTERONE DEFICIENCY II;; HYPERRENINEMIC HYPOALDOSTERONISM, FAMILIAL, 1; FHHA1B;; ALDOSTERONE DEFICIENCY DUE TO DEFICIENCY OF STEROID 18-OXIDASE;; STEROID 18-OXIDASE DEFICIENCY;; 18-OXIDASE DEFICIENCY__:__
Asterisk__:__610601__:__KALLIKREIN-RELATED PEPTIDASE 15; KLK15__:__KALLIKREIN 15;; ACO PROTEASE;; PROSTINOGEN__:__PROSTIN, INCLUDED
Asterisk__:__610602__:__AlkB, E. COLI, HOMOLOG OF, 2; ALKBH2__:__ABH2__:__
Asterisk__:__610603__:__AlkB, E. COLI, HOMOLOG OF, 3; ALKBH3__:__PROSTATE CANCER ANTIGEN 1; PCA1;; DEPC1;; ABH3__:__
Asterisk__:__610604__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, PSEUDOGENE 1; KIR3DP1__:__CD158C;; KIRX;; KIR48;; KIR2DS6__:__
Asterisk__:__610605__:__CYTOPLASMIC POLYADENYLATION ELEMENT-BINDING PROTEIN 2; CPEB2__:____:__
Asterisk__:__610606__:__CYTOPLASMIC POLYADENYLATION ELEMENT-BINDING PROTEIN 3; CPEB3__:__KIAA0940__:__CPEB3 RIBOZYME, INCLUDED
Asterisk__:__610607__:__CYTOPLASMIC POLYADENYLATION ELEMENT-BINDING PROTEIN 4; CPEB4__:__CPE-BINDING PROTEIN 4;; KIAA1673__:__
Asterisk__:__610608__:__GINS COMPLEX SUBUNIT 1; GINS1__:__PSF1, S. CEREVISIAE, HOMOLOG OF; PSF1;; KIAA0186__:__GINS COMPLEX, INCLUDED
Asterisk__:__610609__:__GINS COMPLEX SUBUNIT 2; GINS2__:__PSF2, S. CEREVISIAE, HOMOLOG OF; PSF2__:__
Asterisk__:__610610__:__GINS COMPLEX SUBUNIT 3; GINS3__:__PSF3, S. CEREVISIAE, HOMOLOG OF; PSF3__:__
Asterisk__:__610611__:__GINS COMPLEX SUBUNIT 4; GINS4__:__SLD5, S. CEREVISIAE, HOMOLOG OF; SLD5__:__
Number Sign__:__610612__:__LEBER CONGENITAL AMAUROSIS 12; LCA12__:____:__
Asterisk__:__610613__:__CYTOCHROME P450, SUBFAMILY XIB, POLYPEPTIDE 1; CYP11B1__:__STEROID 11-BETA-HYDROXYLASE;; P450C11__:__
Asterisk__:__610614__:__TRANSFORMING GROWTH FACTOR-BETA REGULATOR 1; TBRG1__:__TGFB REGULATOR 1;; NUCLEAR INTERACTOR OF ARF AND MDM2; NIAM__:__
Asterisk__:__610615__:__RAB-LIKE PROTEIN 6; RABL6__:__PARTNER OF ARF; PARF;; CHROMOSOME 9 OPEN READING FRAME 86; C9ORF86__:__
Asterisk__:__610616__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 12; ANKRD12__:__ANKYRIN REPEAT-CONTAINING COFACTOR 2; ANCO2;; KIAA0874__:__
Asterisk__:__610617__:__DENTICLELESS, DROSOPHILA, HOMOLOG OF; DTL__:__RETINOIC ACID-REGULATED NUCLEAR MATRIX-ASSOCIATED PROTEIN; RAMP;; DDB1- AND CUL4-ASSOCIATED FACTOR 2; DCAF2;; CDT2, S. POMBE, HOMOLOG OF; CDT2;; L2DTL__:__
Number Sign__:__610618__:__ANGIOEDEMA, HEREDITARY, TYPE III; HAE3__:__HAE III;; ESTROGEN-RELATED HAE;; ESTROGEN-SENSITIVE HAE;; ANGIONEUROTIC EDEMA, HEREDITARY, WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION;; HAE WITH NORMAL C1 INHIBITOR CONCENTRATION AND FUNCTION;; HEREDITARY ANGIOEDEMA WITH NORMAL C1 INHIBITOR ACTIVITY__:__
Asterisk__:__610619__:__COAGULATION FACTOR XII; F12__:__HAGEMAN FACTOR__:__
Asterisk__:__610620__:__ADP-RIBOSYLHYDROLASE-LIKE 1; ADPRHL1__:__ADP-RIBOSYLHYDROLASE 2; ARH2__:__
Asterisk__:__610621__:__INTURNED, DROSOPHILA, HOMOLOG OF; INTU__:__KIAA1284;; PDZ DOMAIN-CONTAINING 6; PDZK6__:__
Asterisk__:__610622__:__FUZZY, DROSOPHILA, HOMOLOG OF; FUZ__:____:__
Number Sign__:__610623__:__CATARACT 11, MULTIPLE TYPES; CTRCT11__:__CATARACT, POSTERIOR POLAR, 4; CTPP4;; CPP4__:__CATARACT 11 WITH MICROPHTHALMIA AND NEURODEVELOPMENTAL ABNORMALITIES, INCLUDED
Asterisk__:__610624__:__ADP-RIBOSYLHYDROLASE-LIKE 2; ADPRHL2__:__ADP-RIBOSYLHYDROLASE 3; ARH3__:__
Asterisk__:__610625__:__ADP-RIBOSYLTRANSFERASE 5; ART5__:____:__
Asterisk__:__610626__:__PHOSPHOLIPID PHOSPHATASE 5; PLPP5__:__PPAP2 DOMAIN-CONTAINING PROTEIN 1B; PPAPDC1B;; HTPAP__:__
Asterisk__:__610627__:__ALPHA-2-MACROGLOBULIN-LIKE 1; A2ML1__:____:__
Number Sign__:__610628__:__HYPOGONADOTROPIC HYPOGONADISM 4 WITH OR WITHOUT ANOSMIA; HH4__:____:__
Number Sign__:__610629__:__DIAMOND-BLACKFAN ANEMIA 3; DBA3__:____:__
Asterisk__:__610630__:__PROTEIN TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 20A; PTPN20A__:__PTPN20, CENTROMERIC COPY__:__
Asterisk__:__610631__:__PROTEIN TYROSINE PHOSPHATASE, NONRECEPTOR-TYPE, 20B; PTPN20B__:__PTPN20, TELOMERIC COPY__:__
Asterisk__:__610632__:__MITOCHONDRIAL CALCIUM UPTAKE PROTEIN 2; MICU2__:__EF-HAND DOMAIN FAMILY, MEMBER A1; EFHA1__:__
Asterisk__:__610633__:__MITOCHONDRIAL CALCIUM UPTAKE PROTEIN 3; MICU3__:__EF-HAND DOMAIN FAMILY, MEMBER A2; EFHA2__:__
Caret__:__610634__:__MOVED TO 115650__:____:__
Asterisk__:__610635__:__COLLAGEN TRIPLE-HELIX REPEAT-CONTAINING PROTEIN 1; CTHRC1__:____:__
Asterisk__:__610636__:__MICRO RNA 27B; MIR27B__:__miRNA27B;; MIRN27B__:__
Asterisk__:__610637__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 5; MARCH5__:__MARCH V__:__
Asterisk__:__610638__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 5; IGSF5__:__JUNCTIONAL ADHESION MOLECULE 4; JAM4__:__
Asterisk__:__610639__:__GRID2-INTERACTING PROTEIN 1; GRID2IP1__:__DELPHILIN__:__
Asterisk__:__610640__:__YTH N6-METHYLADENOSINE RNA-BINDING PROTEIN 2; YTHDF2__:__YTH DOMAIN FAMILY, MEMBER 2__:__YTHDF2/RUNX1 FUSION GENE, INCLUDED
Asterisk__:__610641__:__TERMINAL URIDYLYL TRANSFERASE 1, U6 snRNA-SPECIFIC; TUT1__:__U6-TUTase;; POLY(A) POLYMERASE-ASSOCIATED DOMAIN-CONTAINING PROTEIN 2; PAPD2;; PAP-ASSOCIATED DOMAIN-CONTAINING PROTEIN 2;; NUCLEAR SPECKLE-TARGETED PIPK1A-REGULATED POLY(A) POLYMERASE; STAR-PAP__:__
Asterisk__:__610642__:__ENDOPLASMIC RETICULUM PROTEIN, 27-KD; ERP27__:__ERp27;; CHROMOSOME 12 OPEN READING FRAME 46; C12ORF46__:__
Asterisk__:__610643__:__CELL PROLIFERATION-REGULATING INHIBITOR OF PROTEIN PHOSPHATASE 2A; CIP2A__:__KIAA1524 GENE; KIAA1524;; AUTOANTIGEN, 90-KD;; p90;; CANCEROUS INHIBITOR OF PP2A__:__KIAA1524/MLL FUSION GENE, INCLUDED
Number Sign__:__610644__:__PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND 46,XX SEX REVERSAL__:____:__PALMOPLANTAR HYPERKERATOSIS AND TRUE HERMAPHRODITISM, INCLUDED
Asterisk__:__610645__:__CALCIUM- AND INTEGRIN-BINDING PROTEIN 3; CIB3__:__KINASE-INTERACTING PROTEIN 3; KIP3__:__
Asterisk__:__610646__:__CALCIUM- AND INTEGRIN-BINDING PROTEIN 4; CIB4__:__KINASE-INTERACTING PROTEIN 4; KIP4__:__
Asterisk__:__610647__:__N-ACETYLTRANSFERASE 8-LIKE; NAT8L__:__NAT8-LIKE;; ASPARTATE N-ACETYLTRANSFERASE;; CAMELL0, XENOPUS, HOMOLOG OF, 3; CML3__:__
Asterisk__:__610648__:__CUT-LIKE HOMEOBOX 2; CUX2__:__CUT, DROSOPHILA, HOMOLOG OF, 2;; CUT-LIKE 2; CUTL2;; CDP2;; KIAA0293__:__
Percent__:__610649__:__BONE SIZE QUANTITATIVE TRAIT LOCUS 3__:__BSZQTL3__:__
Asterisk__:__610650__:__ADHESION-REGULATING MOLECULE 1; ADRM1__:__ARM1;; RPN13, S. CEREVISIAE, HOMOLOG OF; RPN13__:__
Number Sign__:__610651__:__XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB__:__XP, GROUP B; XPBC__:__XERODERMA PIGMENTOSUM B/COCKAYNE SYNDROME, INCLUDED;; XPB/CS, INCLUDED
Asterisk__:__610652__:__PHOSPHODIESTERASE 10A; PDE10A__:____:__
Asterisk__:__610653__:__RIBOSOMAL RNA-PROCESSING 1, S. CEREVISIAE, HOMOLOG OF; RRP1__:__NUCLEOLAR PROTEIN, 52-KD; NOP52;; NOVEL NUCLEAR PROTEIN 1; NNP1__:__
Asterisk__:__610654__:__RIBOSOMAL RNA-PROCESSING PROTEIN 1, S. CEREVISIAE, HOMOLOG OF, B; RRP1B__:__KIAA0179 GENE; KIAA0179;; NNP1-LIKE; NNP1L__:__
Percent__:__610655__:__TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 4; HHT4__:____:__
Asterisk__:__610656__:__CYSTEINE CONJUGATE BETA-LYASE 2; CCBL2__:__KYNURENINE AMINOTRANSFERASE III; KAT3__:__
Asterisk__:__610657__:__WASH COMPLEX, SUBUNIT 5; WASHC5__:__KIAA0196 GENE; KIAA0196;; STRUMPELLIN__:__
Asterisk__:__610658__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 29; TRIM29__:__ATAXIA-TELANGIECTASIA GROUP D-ASSOCIATED PROTEIN; ATDC__:__
Asterisk__:__610659__:__GLUTAMATE RECEPTOR, IONOTROPIC, DELTA 1; GRID1__:__KIAA1220__:__
Asterisk__:__610660__:__GLYOXYLATE REDUCTASE 1 HOMOLOG; GLYR1__:__NUCLEAR PROTEIN, 60-KD; NP60;; CYTOKINE-LIKE NUCLEAR FACTOR N-PAC__:__
Asterisk__:__610661__:__N-GLYCANASE 1; NGLY1__:__PEPTIDE-N-GLYCANASE 1, S. CEREVISIAE, HOMOLOG OF; PNG1__:__
Asterisk__:__610662__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS Y PROTEIN; PIGY__:____:__PIGY UPSTREAM READING FRAME, INCLUDED; PYURF, INCLUDED;; PreY, INCLUDED
Asterisk__:__610663__:__SET AND MYND DOMAIN-CONTAINING PROTEIN 2; SMYD2__:____:__
Asterisk__:__610664__:__BREAST CANCER-OVEREXPRESSED GENE 1__:__BCOX1;; KIAA0100__:__
Asterisk__:__610665__:__Fc FRAGMENT OF IgG, LOW AFFINITY IIIb, RECEPTOR FOR; FCGR3B__:__IMMUNOGLOBULIN G Fc RECEPTOR III-1;; FCRIII-1;; CD16B__:__NEUTROPHIL ANTIGEN NA, INCLUDED;; NEUTROPHIL-SPECIFIC ANTIGEN NA1, INCLUDED;; NEUTROPHIL-SPECIFIC ANTIGEN NA2, INCLUDED;; NEUTROPHIL-SPECIFIC ANTIGEN NC1, INCLUDED
Asterisk__:__610666__:__NEURENSIN 2; NRSN2__:____:__
Asterisk__:__610667__:__UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L5; UCHL5__:__UCH37__:__
Asterisk__:__610668__:__INSCUTEABLE, DROSOPHILA, HOMOLOG OF; INSC__:____:__
Asterisk__:__610669__:__TNFAIP3-INTERACTING PROTEIN 2; TNIP2__:__A20-BINDING INHIBITOR OF NFKB 2; ABIN2;; FLIP1__:__
Asterisk__:__610670__:__CYTOCHROME P450, FAMILY 2, SUBFAMILY U, POLYPEPTIDE 1; CYP2U1__:____:__
Asterisk__:__610671__:__ZINC FINGER PROTEIN 628; ZNF628__:__ZEC__:__
Asterisk__:__610672__:__NUCLEUS ACCUMBENS-ASSOCIATED PROTEIN 1, BEN AND BTB/POZ DOMAINS-CONTAINING; NACC1__:__NAC1;; BTB/POZ DOMAIN-CONTAINING PROTEIN 14B; BTBD14B__:__
Asterisk__:__610673__:__NUCLEAR APOPTOSIS-INDUCING FACTOR 1; NAIF1__:__CHROMOSOME 9 OPEN READING FRAME 90; C9ORF90__:__
Asterisk__:__610674__:__SPERM FLAGELLAR PROTEIN 1; SPEF1__:__CHROMOSOME 20 OPEN READING FRAME 28; C20ORF28;; CALPONIN-HOMOLOGY AND MICROTUBULE-ASSOCIATED PROTEIN; CLAMP__:__
Asterisk__:__610675__:__UNCONVENTIONAL SNARE IN THE ER 1, S. CEREVISIAE, HOMOLOG OF; USE1__:__HEMATOPOIETIC STEM/PROGENITOR CELL PROTEIN MDS032; MDS032;; p31__:__
Percent__:__610676__:__AUTISM, SUSCEPTIBILITY TO, 7; AUTS7__:____:__
Asterisk__:__610677__:__LSM14A PROTEIN; LSM14A__:__RNA-ASSOCIATED PROTEIN 55; RAP55__:__
Number Sign__:__610678__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 4; COXPD4__:____:__
Asterisk__:__610679__:__CYCLIN-DEPENDENT KINASE 14; CDK14__:__PFTAIRE PROTEIN KINASE 1; PFTK1;; PFTAIRE1;; KIAA0834__:__
NULL__:__610680__:__HOLOPROSENCEPHALY, RECURRENT INFECTIONS, AND MONOCYTOSIS__:____:__
Asterisk__:__610681__:__PHOSPHOFRUCTOKINASE, MUSCLE TYPE; PFKM__:__PFK1;; PFK, MUSCLE TYPE__:__
Number Sign__:__610682__:__OSTEOGENESIS IMPERFECTA, TYPE VII; OI7__:__OI, TYPE VII;; OSTEOGENESIS IMPERFECTA, TYPE IIB, FORMERLY; OI2B, FORMERLY__:__
Asterisk__:__610683__:__BBS12 GENE; BBS12__:__FLJ35630;; C4ORF24__:__
Asterisk__:__610684__:__C-TERMINAL DOMAIN NUCLEAR ENVELOPE PHOSPHATASE 1; CTDNEP1__:__CTD NUCLEAR ENVELOPE PHOSPHATASE 1;; DULLARD, XENOPUS, HOMOLOG OF; DULLARD;; NEM1, S. CEREVISIAE, HOMOLOG OF__:__
Percent__:__610685__:__SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 2; SHFLD2__:____:__
Asterisk__:__610686__:__UBX DOMAIN PROTEIN 2B; UBXN2B__:__LOC137886 GENE;; p37__:__
Number Sign__:__610687__:__NEMALINE MYOPATHY 7; NEM7__:____:__
Number Sign__:__610688__:__JOUBERT SYNDROME 6; JBTS6__:____:__
Asterisk__:__610689__:__DIPLA1, ANTISENSE__:__DIPAS__:__
Asterisk__:__610690__:__3-HYDROXYISOBUTYRYL-CoA HYDROLASE; HIBCH__:__BETA-HYDROXYISOBUTYRYL-COENZYME A HYDROLASE;; HIBYL-CoA-H__:__
Asterisk__:__610691__:__PRUNE, DROSOPHILA, HOMOLOG OF, 2; PRUNE2__:__BCH MOTIF-CONTAINING MOLECULE AT THE C-TERMINAL REGION 1; BMCC1;; KIAA0367__:__
Asterisk__:__610692__:__HEAT-SHOCK 27-KD PROTEIN 7; HSPB7__:__CARDIOVASCULAR HEAT-SHOCK PROTEIN; CVHSP__:__
Asterisk__:__610693__:__HYLS1 GENE; HYLS1__:__FLJ32915__:__
Asterisk__:__610694__:__PYROGLUTAMYL PEPTIDASE I; PGPEP1__:__PGP; PGP I;; PYRROLIDONE-CARBOXYLATE PEPTIDASE; PCP;; 5-OXOPROLYL PEPTIDASE__:__
Asterisk__:__610695__:__HEAT-SHOCK 27-KD PROTEIN 6; HSPB6__:__HEAT-SHOCK PROTEIN, 20-KD; HSP20__:__
Asterisk__:__610696__:__PCNA-ASSOCIATED FACTOR, 15-KD__:__PAF;; p15(PAF);; OVEREXPRESSED IN ANAPLASTIC THYROID CARCINOMA 1; OEATC1;; KIAA0101__:__
Asterisk__:__610697__:__PDZ DOMAIN-CONTAINING 2; PDZD2__:__PLAKOPHILIN-RELATED ARMADILLO REPEAT PROTEIN-INTERACTING PDZ PROTEIN; PAPIN;; PIN1;; ACTIVATED IN PROSTATE CANCER; AIPC;; KIAA0300__:__
Number Sign__:__610698__:__MACULAR DEGENERATION, AGE-RELATED, 4; ARMD4__:____:__
Asterisk__:__610699__:__ZINC FINGER AN1 DOMAIN-CONTAINING PROTEIN 2A; ZFAND2A__:__AN1-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 2A;; ARSENITE-INDUCIBLE RNA-ASSOCIATED PROTEIN; AIRAP__:__
Asterisk__:__610700__:__HTRA SERINE PEPTIDASE 4; HTRA4__:____:__
Asterisk__:__610701__:__HEAT-SHOCK 70-KD PROTEIN 12A; HSPA12A__:__KIAA0417__:__
Asterisk__:__610702__:__HEAT-SHOCK 70-KD PROTEIN 12B; HSPA12B__:____:__
Asterisk__:__610703__:__HEAT-SHOCK 105/110-KD PROTEIN 1; HSPH1__:__HEAT-SHOCK PROTEIN, 105-KD; HSP105;; HEAT-SHOCK PROTEIN, 110-KD; HSP110;; KIAA0201__:__
Asterisk__:__610704__:__PROHIBITIN 2; PHB2__:__REPRESSOR OF ESTROGEN RECEPTOR ACTIVITY; REA__:__
Asterisk__:__610705__:__CD300 ANTIGEN-LIKE FAMILY, MEMBER B; CD300LB__:__CD300B;; CLM7;; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 5; TREM5;; IMMUNE RECEPTOR EXPRESSED BY MYELOID CELLS 3; IREM3;; LEUKOCYTE MONOIMMUNOGLOBULIN-LIKE RECEPTOR 5; LMIR5__:__
Number Sign__:__610706__:__DEAFNESS, CONGENITAL, WITH INNER EAR AGENESIS, MICROTIA, AND MICRODONTIA__:__DEAFNESS, CONGENITAL, WITH LABYRINTHINE APLASIA, MICROTIA, AND MICRODONTIA;; DEAFNESS WITH LAMM__:__
Percent__:__610707__:__PSORIASIS 8, SUSCEPTIBILITY TO; PSORS8__:____:__
Number Sign__:__610708__:__OPTIC ATROPHY 5; OPA5__:____:__
Asterisk__:__610709__:__TESTIS-SPECIFIC SERINE/THREONINE KINASE 1; TSSK1__:__STK22A, MOUSE, HOMOLOG OF;; SERINE/THREONINE PROTEIN KINASE 22D; STK22D__:__
Asterisk__:__610710__:__TESTIS-SPECIFIC SERINE/THREONINE KINASE 2; TSSK2__:__SERINE/THREONINE PROTEIN KINASE 22B; STK22B__:__
Asterisk__:__610711__:__TESTIS-SPECIFIC SERINE/THREONINE KINASE 4; TSSK4__:__TSSK5__:__
Asterisk__:__610712__:__TESTIS-SPECIFIC SERINE/THREONINE KINASE 6; TSSK6__:__SMALL SERINE/THREONINE PROTEIN KINASE; SSTK;; TSSK4__:__
Number Sign__:__610713__:__BRACHYDACTYLY-SYNDACTYLY SYNDROME; BDSD__:____:__BRACHYDACTYLY-SYNDACTYLY-OLIGODACTYLY SYNDROME, INCLUDED; BDSDO, INCLUDED
Asterisk__:__610714__:__PROTEIN KINASE N3; PKN3__:__PKN-BETA__:__
Asterisk__:__610715__:__HEMOGEN; HEMGN__:__ERYTHROID DIFFERENTIATION-ASSOCIATED GENE; EDAG__:__
Asterisk__:__610716__:__TIMELESS-INTERACTING PROTEIN; TIPIN__:____:__
Number Sign__:__610717__:__NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM__:__NEUTRAL LIPID STORAGE DISEASE WITHOUT ICHTHYOSIS__:__
Asterisk__:__610718__:__MICRO RNA 195; MIR195__:__miRNA195;; MIRN195__:__
Asterisk__:__610719__:__MICRO RNA 199A1; MIR199A1__:__miRNA199A1;; MIRN199A1__:__
Asterisk__:__610720__:__MICRO RNA 199A2; MIR199A2__:__miRNA199A2;; MIRN199A2__:__
Asterisk__:__610721__:__MICRO RNA 214; MIR214__:__miRNA214;; MIRN214__:__
Caret__:__610722__:__MOVED TO 607962__:____:__
Asterisk__:__610723__:__MICRO RNA 23B; MIR23B__:__miRNA23B;; MIRN23B__:__
Asterisk__:__610724__:__MICRO RNA 24-2; MIR24-2__:__miRNA24-2;; MIRN24-2__:__
Number Sign__:__610725__:__NEPHROTIC SYNDROME, TYPE 3; NPHS3__:__NEPHROTIC SYNDROME, EARLY-ONSET, TYPE 3__:__
Asterisk__:__610726__:__TRUB PSEUDOURIDINE SYNTHASE, E. COLI, HOMOLOG OF, 1; TRUB1__:__PUS4__:__
Asterisk__:__610727__:__TRUB PSEUDOURIDINE SYNTHASE, E. COLI, HOMOLOG OF, 2; TRUB2__:____:__
Asterisk__:__610728__:__SPHINGOMYELIN PHOSPHODIESTERASE, ACID-LIKE, 3A; SMPDL3A__:__ACID SPHINGOMYELINASE-LIKE PHOSPHODIESTERASE 3A; ASML3A__:__
Asterisk__:__610729__:__WD REPEAT-CONTAINING PROTEIN 92; WDR92__:__LOC116143;; MONAD PROTEIN__:__
Asterisk__:__610730__:__CHAPERONIN-CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 6B; CCT6B__:__CHAPERONIN-CONTAINING TCP1, SUBUNIT 6B;; CCT-ZETA 2; CCTZ2__:__
Asterisk__:__610731__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 7; ANKRD7__:____:__
Asterisk__:__610732__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 12; TTC12__:__TPARM__:__
Number Sign__:__610733__:__NOONAN SYNDROME 4; NS4__:____:__
Asterisk__:__610734__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 2; ANKRD2__:__ANKYRIN REPEAT PROTEIN WITH PEST MOTIF AND PROLINE-RICH REGION; ARPP__:__
Asterisk__:__610735__:__MYOZENIN 3; MYOZ3__:__CALSARCIN 3;; FATZ-RELATED PROTEIN 3; FRP3__:__
Asterisk__:__610736__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 23; ANKRD23__:__DIABETES-RELATED ANKYRIN REPEAT PROTEIN; DARP__:__
Asterisk__:__610737__:__KINASE SUPPRESSOR OF RAS 2; KSR2__:____:__
Number Sign__:__610738__:__NEUTROPENIA, SEVERE CONGENITAL, 3, AUTOSOMAL RECESSIVE; SCN3__:__KOSTMANN DISEASE;; AGRANULOCYTOSIS, INFANTILE__:__
Asterisk__:__610739__:__TRINUCLEOTIDE REPEAT-CONTAINING GENE 6A; TNRC6A__:__GLYCINE/TRYPTOPHAN REPEAT PROTEIN, 182-KD; GW182;; KIAA1460__:__
Asterisk__:__610740__:__TRINUCLEOTIDE REPEAT-CONTAINING GENE 6B; TNRC6B__:__KIAA1093__:__
Asterisk__:__610741__:__TRINUCLEOTIDE REPEAT-CONTAINING GENE 6C; TNRC6C__:__KIAA1582__:__
Asterisk__:__610742__:__MOLONEY LEUKEMIA VIRUS 10, MOUSE, HOMOLOG OF; MOV10__:__KIAA1631__:__
Number Sign__:__610743__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 8; SCAR8__:__ATAXIA, RECESSIVE, OF BEAUCE;; CEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, TYPE 1; ARCA1__:__
Percent__:__610744__:__IRIS PATTERN__:____:__
Asterisk__:__610745__:__STIMULATED BY RETINOIC ACID 6; STRA6__:____:__
Asterisk__:__610746__:__DOLICHOL KINASE; DOLK__:__DOLICHOL KINASE 1; DK1;; SEC59, YEAST, HOMOLOG OF; SEC59;; KIAA1094;; TRANSMEMBRANE PROTEIN 15, FORMERLY; TMEM15, FORMERLY__:__
Asterisk__:__610747__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 4A; SAMD4A__:__SMAUG, DROSOPHILA, HOMOLOG OF, 1; SMAUG1;; KIAA1053__:__
Asterisk__:__610748__:__UBIQUITIN-SPECIFIC PROTEASE 28; USP28__:__KIAA1515__:__
Asterisk__:__610749__:__KELCH-LIKE 31; KLHL31__:__KLHL__:__
Asterisk__:__610750__:__ZINC FINGER CCHC DOMAIN- AND RNA-BINDING MOTIF-CONTAINING PROTEIN 1; ZCRB1__:__MADP1;; U11/U12 snRNP, 31-KD SUBUNIT__:__
Asterisk__:__610751__:__PHOSPHORIBOSYL TRANSFERASE DOMAIN-CONTAINING PROTEIN 1; PRTFDC1__:____:__
Asterisk__:__610752__:__URONYL 2-SULFOTRANSFERASE; UST__:__URONOSYL 2-O-SULFOTRANSFERASE; 2OST__:__
Percent__:__610753__:__ALOPECIA AREATA 2; AA2__:____:__
Asterisk__:__610754__:__WINGS APART-LIKE PROTEIN, DROSOPHILA, HOMOLOG OF; WAPL__:__KIAA0261;; WAPAL;; FRIEND OF EBNA2; FOE__:__
Number Sign__:__610755__:__MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV; MEN4__:____:__
Number Sign__:__610756__:__CEREBROOCULOFACIOSKELETAL SYNDROME 2; COFS2__:____:__
Asterisk__:__610757__:__CHEMOKINE, CC MOTIF, LIGAND 4-LIKE 2; CCL4L2__:____:__
Number Sign__:__610758__:__CEREBROOCULOFACIOSKELETAL SYNDROME 4; COFS4__:____:__
Number Sign__:__610759__:__CORNELIA DE LANGE SYNDROME 3; CDLS3__:____:__
Percent__:__610760__:__CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 2__:__CLQTL2__:__
Percent__:__610761__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5__:__HDLCQ5__:__
Number Sign__:__610762__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6; HDLCQ6__:____:__
Asterisk__:__610763__:__N-ACETYLNEURAMINIC ACID PHOSPHATASE; NANP__:__Neu5Ac-9-PHOSPHATE PHOSPHATASE HALOACID DEHALOGENASE-LIKE HYDROLASE DOMAIN-CONTAINING PROTEIN-4; HDHD4__:__
Asterisk__:__610764__:__BENZODIAZAPINE RECEPTOR (PERIPHERAL)-ASSOCIATED PROTEIN 1; BZRAP1__:__PERIPHERAL BENZODIAZAPINE RECEPTOR-ASSOCIATED PROTEIN 1; PRAX1;; RIMS-BINDING PROTEIN 1; RIMBP1;; KIAA0612__:__
Caret__:__610765__:__MOVED TO 602400__:____:__
Asterisk__:__610766__:__MEIOSIS-SPECIFIC NUCLEAR STRUCTURAL PROTEIN 1; MNS1__:__FLJ11222__:__
Asterisk__:__610767__:__AUTOPHAGY 16-LIKE 1; ATG16L1__:__APG16-LIKE; APG16L__:__
Number Sign__:__610768__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M__:__CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY__:__
Asterisk__:__610769__:__NUCLEOLAR COMPLEX-ASSOCIATED PROTEIN 3, S. CEREVISIAE, HOMOLOG OF; NOC3L__:__FACTOR FOR ADIPOCYTE DIFFERENTIATION 24; FAD24__:__
Asterisk__:__610770__:__NUCLEOLAR COMPLEX-ASSOCIATED PROTEIN 2, S. CEREVISIAE, HOMOLOG OF; NOC2L__:__NOVEL INHAT REPRESSOR; NIR__:__
Asterisk__:__610771__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 5; CHD5__:____:__
Asterisk__:__610772__:__NK6 HOMEOBOX 3; NKX6-3__:__NK6, DROSOPHILA, HOMOLOG OF, 3;; NKX6.3__:__
Number Sign__:__610773__:__MITOCHONDRIAL PHOSPHATE CARRIER DEFICIENCY__:__MPCD__:__
Asterisk__:__610774__:__CANOPY FGF SIGNALING REGULATOR 3; CNPY3__:__CANOPY 3, ZEBRAFISH, HOMOLOG OF;; TRINUCLEOTIDE REPEAT-CONTAINING GENE 5; TNRC5;; PROTEIN ASSOCIATED WITH TOLL-LIKE RECEPTOR 4, A; PRAT4A;; PROTEIN ASSOCIATED WITH TLR4, A;; EXPANDED REPEAT DOMAIN, CAG/CTG, 5; ERDA5__:__
Asterisk__:__610775__:__TP53-INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR; TIGAR__:__CHROMOSOME 12 OPEN READING FRAME 5; C12ORF5__:__
Asterisk__:__610776__:__DAMAGE-REGULATED AUTOPHAGY MODULATOR 1; DRAM1__:__DRAM__:__
Asterisk__:__610777__:__NEUROGUIDIN; NGDN__:__NGD__:__
Asterisk__:__610778__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-1-LIKE; GNB1L__:__WD REPEAT-CONTAINING PROTEIN 14; WDR14__:__
Asterisk__:__610779__:__NUCLEOTIDE-BINDING PROTEIN 2; NUBP2__:__CYTOSOLIC Fe-S CLUSTER DEFICIENT 1, S. CEREVISIAE, HOMOLOG OF; CFD1__:__
Asterisk__:__610780__:__LARGE SUBUNIT GTPase 1, S. CEREVISIAE, HOMOLOG OF; LSG1__:____:__
Asterisk__:__610781__:__GUANOSINE MONOPHOSPHATE REDUCTASE 2; GMPR2__:__GMP REDUCTASE 2__:__
Asterisk__:__610782__:__MICRO RNA 29A; MIR29A__:__miRNA29A;; MIRN29A__:__
Asterisk__:__610783__:__MICRO RNA 29B1; MIR29B1__:__miRNA29B1;; MIRN29B1__:__
Asterisk__:__610784__:__MICRO RNA 29C; MIR29C__:__miRNA29C;; MIRN29C__:__
Asterisk__:__610785__:__PDLIM1-INTERACTING KINASE 1-LIKE; PDIK1L__:____:__
Asterisk__:__610786__:__SRC KINASE SIGNALING INHIBITOR 1; SRCIN1__:__SNAP25-INTERACTING PROTEIN; SNIP;; KIAA1684__:__
Asterisk__:__610787__:__PRAC2 SMALL NUCLEAR PROTEIN; PRAC2__:__PROSTATE, RECTUM, AND COLON GENE 2;; HOMEOBOX B CLUSTER ANTISENSE RNA 5; HOXBAS5__:__
Asterisk__:__610788__:__SOLUTE CARRIER FAMILY 35 (3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE TRANSPORTER), MEMBER B2; SLC35B2__:__3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE TRANSPORTER 1; PAPST1;; PAPS TRANSPORTER 1;; SLALOM, DROSOPHILA, HOMOLOG OF; SLL__:__
Asterisk__:__610789__:__p53 AND DNA DAMAGE-REGULATED 1; PDRG1__:__PDRG;; CHROMOSOME 20 OPEN READING FRAME 126; C20ORF126__:__
Asterisk__:__610790__:__SOLUTE CARRIER FAMILY 35, MEMBER B1; SLC35B1__:__UDP-GALACTOSE TRANSPORTER-RELATED 1; UGTREL1__:__
Asterisk__:__610791__:__SOLUTE CARRIER FAMILY 43 (L-TYPE AMINO ACID TRANSPORTER), MEMBER 2; SLC43A2__:__L-TYPE AMINO ACID TRANSPORTER 4; LAT4__:__
Asterisk__:__610792__:__SOLUTE CARRIER FAMILY 22, MEMBER 25; SLC22A25__:__ORGANIC ANION TRANSPORTER UST6; UST6__:__
Asterisk__:__610793__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, KIDNEY), MEMBER 30; SLC25A30__:__KIDNEY MITOCHONDRIAL CARRIER PROTEIN 1; KMCP1__:__
Asterisk__:__610794__:__ZINC FINGER PROTEIN 323; ZNF323__:____:__
Asterisk__:__610795__:__SORBIN AND SH3 DOMAINS-CONTAINING PROTEIN 3; SORBS3__:__SH3 DOMAIN-CONTAINING ADAPTOR MOLECULE 1; SCAM1;; SH3D4__:__VINEXIN-ALPHA, INCLUDED;; VINEXIN-BETA, INCLUDED
Asterisk__:__610796__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ADENINE NUCLEOTIDE TRANSLOCATOR), MEMBER 31; SLC25A31__:__ADENINE NUCLEOTIDE TRANSLOCATOR 4; ANT4;; ADP/ATP CARRIER 4; AAC4__:__
NULL__:__610797__:__EPIPHYSEAL DYSPLASIA, BAUMANN TYPE__:____:__
Number Sign__:__610798__:__IMMUNODEFICIENCY DUE TO DEFECT IN MAPBP-INTERACTING PROTEIN__:____:__
Number Sign__:__610799__:__INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 1; IPD1__:____:__INVASIVE PNEUMOCOCCAL DISEASE, PROTECTION AGAINST, INCLUDED
Asterisk__:__610800__:__AUTOPHAGY 10, S. CEREVISIAE, HOMOLOG OF; ATG10__:__APG10, S. CEREVISIAE, HOMOLOG OF; APG10__:__
Asterisk__:__610801__:__SOLUTE CARRIER FAMILY 41, MEMBER 1; SLC41A1__:____:__
Asterisk__:__610802__:__SOLUTE CARRIER FAMILY 41, MEMBER 2; SLC41A2__:____:__
Asterisk__:__610803__:__SOLUTE CARRIER FAMILY 41, MEMBER 3; SLC41A3__:____:__
Asterisk__:__610804__:__SOLUTE CARRIER FAMILY 35 (UDP-GLUCURONIC ACID/UDP-N-ACETYLGALACTOSAMINE DUAL TRANSPORTER), MEMBER D1; SLC35D1__:__UDP-GALACTOSE TRANSPORTER-RELATED 7; UGTREL7;; KIAA0260__:__
Number Sign__:__610805__:__CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 1; CAKUT1__:__RENAL HYPODYSPLASIA, NONSYNDROMIC, 1; RHDNS1__:__
Asterisk__:__610806__:__TBC1 DOMAIN FAMILY, MEMBER 3C; TBC1D3C__:____:__
Asterisk__:__610807__:__TBC1 DOMAIN FAMILY, MEMBER 3D; TBC1D3D__:____:__
Asterisk__:__610808__:__TBC1 DOMAIN FAMILY, MEMBER 3E; TBC1D3E__:____:__
Asterisk__:__610809__:__TBC1 DOMAIN FAMILY, MEMBER 3F; TBC1D3F__:____:__
Asterisk__:__610810__:__TBC1 DOMAIN FAMILY, MEMBER 3G; TBC1D3G__:____:__
Asterisk__:__610811__:__TBC1 DOMAIN FAMILY, MEMBER 3H; TBC1D3H__:____:__
Asterisk__:__610812__:__HYDROCEPHALUS-INDUCING, MOUSE, HOMOLOG OF; HYDIN__:__HYDIN1__:__
Asterisk__:__610813__:__HYDROCEPHALUS-INDUCING, MOUSE, HOMOLOG OF, 2; HYDIN2__:__HYDIN, MOUSE, HOMOLOG OF, 2;; KIAA1864__:__
Caret__:__610814__:__MOVED TO 601186__:____:__
Asterisk__:__610815__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, FOLATE), MEMBER 32; SLC25A32__:__MITOCHONDRIAL FOLATE TRANSPORTER; MFT__:__
Asterisk__:__610816__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PYRIMIDINE NUCLEOTIDE TRANSPORTER), MEMBER 33; SLC25A33__:__BONE MARROW STROMAL CELL MITOCHONDRIAL CARRIER PROTEIN; BMSCMCP;; PYRIMIDINE NUCLEOTIDE CARRIER 1; PNC1__:__
Asterisk__:__610817__:__SOLUTE CARRIER FAMILY 25, MEMBER 34; SLC25A34__:____:__
Asterisk__:__610818__:__SOLUTE CARRIER FAMILY 25, MEMBER 35; SLC25A35__:____:__
Asterisk__:__610819__:__SOLUTE CARRIER FAMILY 25, MEMBER 38; SLC25A38__:____:__
Asterisk__:__610820__:__SOLUTE CARRIER FAMILY 25, MEMBER 39; SLC25A39__:__CGI69__:__
Asterisk__:__610821__:__SOLUTE CARRIER FAMILY 25, MEMBER 40; SLC25A40__:____:__
Asterisk__:__610822__:__SOLUTE CARRIER FAMILY 25, MEMBER 41; SLC25A41__:____:__
Asterisk__:__610823__:__SOLUTE CARRIER FAMILY 25, MEMBER 42; SLC25A42__:____:__
Asterisk__:__610824__:__SOLUTE CARRIER FAMILY 25, MEMBER 44; SLC25A44__:____:__
Asterisk__:__610825__:__SOLUTE CARRIER FAMILY 25, MEMBER 45; SLC25A45__:____:__
Asterisk__:__610826__:__SOLUTE CARRIER FAMILY 25, MEMBER 46; SLC25A46__:____:__
Asterisk__:__610827__:__ZINC FINGER PROTEIN 335; ZNF335__:__NRC-INTERACTING FACTOR; NIF1__:__NIF2, INCLUDED
Number Sign__:__610828__:__HOLOPROSENCEPHALY 7; HPE7__:____:__
Number Sign__:__610829__:__HOLOPROSENCEPHALY 9; HPE9__:__PITUITARY ANOMALIES WITH HOLOPROSENCEPHALY-LIKE FEATURES;; HOLOPROSENCEPHALY WITH MICROPHTHALMIA AND FIRST BRANCHIAL ARCH ANOMALIES__:__
NULL__:__610830__:__POLYOSTEOLYSIS-HYPEROSTOSIS SYNDROME__:____:__
Asterisk__:__610831__:__TBC1 DOMAIN FAMILY, MEMBER 10C; TBC1D10C__:__CARABIN__:__
Number Sign__:__610832__:__FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN__:____:__
Asterisk__:__610833__:__N-ACETYLTRANSFERASE 5; NAT5__:__NAT3, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__610834__:__N-ACETYLTRANSFERASE 13; NAT13__:__NAT5, S. CEREVISIAE, HOMOLOG OF;; SAN, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__610835__:__NMDA RECEPTOR-REGULATED 2; NARG2__:____:__
Percent__:__610836__:__AUTISM, SUSCEPTIBILITY TO, 11; AUTS11__:____:__
Asterisk__:__610837__:__BCL2-LIKE 12; BCL2L12__:____:__
Percent__:__610838__:__AUTISM, SUSCEPTIBILITY TO, 12; AUTS12__:____:__
Percent__:__610839__:__OSTEOARTHRITIS SUSCEPTIBILITY 4; OS4__:__OSTEOARTHRITIS, GENERALIZED, WITHOUT DYSPLASIA; GOA1__:__
Percent__:__610840__:__MITRAL VALVE PROLAPSE 3; MVP3__:__MITRAL VALVE PROLAPSE, MYXOMATOUS 3; MMVP3;; MYXOMATOUS MITRAL VALVE PROLAPSE 3__:__
Asterisk__:__610841__:__STROMAL INTERACTION MOLECULE 2; STIM2__:__KIAA1482__:__
Number Sign__:__610842__:__PSEUDOXANTHOMA ELASTICUM-LIKE DISORDER WITH MULTIPLE COAGULATION FACTOR DEFICIENCY__:__PXE-LIKE DISORDER WITH MULTIPLE COAGULATION FACTOR DEFICIENCY__:__
Asterisk__:__610843__:__UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX, 7.2-KD SUBUNIT__:__UCRC;; CYTOCHROME C1-ASSOCIATED PROTEIN__:__
Asterisk__:__610844__:__SPG11 GENE; SPG11__:__SPATACSIN;; KIAA1840;; FLJ21439__:__
Asterisk__:__610845__:__SOLUTE CARRIER FAMILY 35 (3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE TRANSPORTER), MEMBER B3; SLC35B3__:__3-PRIME-PHOSPHOADENOSINE 5-PRIME-PHOSPHOSULFATE TRANSPORTER; PAPST2;; PAPS TRANSPORTER 2__:__
Asterisk__:__610846__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 10; LRRC10__:__HEART-RESTRICTED LEUCINE-RICH REPEAT PROTEIN; HRLRRP__:__
Asterisk__:__610847__:__ZINC FINGER PROTEIN 322A; ZNF322A__:__ZINC FINGER PROTEIN 489; ZNF489;; ZNF322__:__
Asterisk__:__610848__:__RAB15 EFFECTOR PROTEIN; REP15__:____:__
Asterisk__:__610849__:__TUBULIN TYROSINE LIGASE-LIKE FAMILY, MEMBER 6; TTLL6__:____:__
Asterisk__:__610850__:__XPA-BINDING PROTEIN 2; XAB2__:____:__
Asterisk__:__610851__:__CHROMOSOME 4 OPEN READING FRAME 16; C4ORF16__:__GAMMA-1 ADAPTIN BREFELDIN-A RESISTANCE PROTEIN; GBAR;; 2C18__:__
Number Sign__:__610852__:__CILIARY DYSKINESIA, PRIMARY, 6; CILD6__:____:__
Asterisk__:__610853__:__AT HOOK-CONTAINING TRANSCRIPTION FACTOR 1; AHCTF1__:__EMBRYONIC LARGE MOLECULE DERIVED FROM YOLK SAC; ELYS__:__
Caret__:__610854__:__MOVED TO 610682__:____:__
Asterisk__:__610855__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 26; ANKRD26__:__KIAA1074__:__
Asterisk__:__610856__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 30A; ANKRD30A__:__BREAST CANCER ANTIGEN NY-BR-1__:__
Asterisk__:__610857__:__SMALL BREAST EPITHELIAL MUCIN__:__SBEM__:__
Asterisk__:__610858__:__RNA TRANSCRIPTION, TRANSLATION, AND TRANSPORT FACTOR; RTRAF__:__CHROMOSOME 14 OPEN READING FRAME 166; C14ORF166;; CGI99;; CLE__:__
Asterisk__:__610859__:__CAPPING PROTEIN REGULATOR AND MYOSIN 1 LINKER 2; CARMIL2__:__RGD-, LEUCINE-RICH REPEAT-, TROPOMODULIN DOMAIN-, AND PROLINE-RICH DOMAIN-CONTAINING PROTEIN; RLTPR__:__
Asterisk__:__610860__:__AMYLO-1,6-GLUCOSIDASE, 4-ALPHA-GLUCANOTRANSFERASE; AGL__:__GLYCOGEN DEBRANCHER ENZYME; GDE__:__
Asterisk__:__610861__:__SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 3; SYNE3__:__NUCLEAR ENVELOPE SPECTRIN REPEAT PROTEIN 3; NESP3;; NESPRIN 3;; CHROMOSOME 14 OPEN READING FRAME 49; C14ORF49__:__
Asterisk__:__610862__:__DELTA(4)-DESATURASE, SPHINGOLIPID, 2; DEGS2__:__DEGENERATIVE SPERMATOCYTE, DROSOPHILA, HOMOLOG OF, 2;; DES2, MOUSE, HOMOLOG OF;; SPHINGOLIPID DELTA-4-DESATURASE/C4-HYDROXYLASE__:__
Asterisk__:__610863__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, BETA-4; GNB4__:__G PROTEIN, BETA-4 SUBUNIT; G BETA-4__:__
Asterisk__:__610864__:__LQK1 PROTEIN__:__LQK1__:__
Asterisk__:__610865__:__FELINE LEUKEMIA VIRUS SUBGROUP C RECEPTOR 2; FLVCR2__:__FLVCR-LIKE ON CHROMOSOME 14q; FLVCRL14q;; CALCIUM CHELATE TRANSPORTER; CCT;; CHROMOSOME 14 OPEN READING FRAME 58; C14ORF58__:__
Asterisk__:__610866__:__URIDINE/CYTIDINE KINASE-LIKE 1; UCKL1__:__URKL1;; UCK1-LIKE; UCK1L__:__
Asterisk__:__610867__:__LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN 1: LRRTM1__:____:__
Asterisk__:__610868__:__LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN 2; LRRTM2__:__KIAA0416__:__
Asterisk__:__610869__:__LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN 3; LRRTM3__:____:__
Asterisk__:__610870__:__LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN 4; LRRTM4__:____:__
NULL__:__610871__:__SAKODA COMPLEX__:__SPHENOETHMOIDAL ENCEPHALOMENINGOCELE, AGENESIS OF THE CORPUS CALLOSUM, AND CLEFT LIP/PALATE__:__SAKODA SPECTRUM, INCLUDED
Asterisk__:__610872__:__IBR DOMAIN-CONTAINING PROTEIN 3; IBRDC3__:__NATURAL KILLER LYTIC-ASSOCIATED MOLECULE; NKLAM__:__
Percent__:__610873__:__MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 1; MENAQ1__:____:__
Asterisk__:__610874__:__SPERMATOGENESIS AND CENTRIOLE-ASSOCIATED 1; SPATC1__:__SPERIOLIN__:__
Asterisk__:__610875__:__SAPS DOMAIN FAMILY, MEMBER 1; SAPS1__:__PROTEIN PHOSPHATASE 6, REGULATORY SUBUNIT 1; PP6R1;; KIAA1115__:__
Asterisk__:__610876__:__HECT DOMAIN- AND ANKYRIN REPEAT-CONTAINING E3 UBIQUITIN PROTEIN LIGASE 1; HACE1__:__KIAA1320__:__
Asterisk__:__610877__:__SAPS DOMAIN FAMILY, MEMBER 2; SAPS2__:__PROTEIN PHOSPHATASE 6, REGULATORY SUBUNIT 2; PP6R2;; KIAA0685__:__
Number Sign__:__610878__:__VESICOURETERAL REFLUX 2; VUR2__:____:__
Asterisk__:__610879__:__SAPS DOMAIN FAMILY, MEMBER 3; SAPS3__:__PROTEIN PHOSPHATASE 6, REGULATORY SUBUNIT 3; PP6R3;; CHROMOSOME 11 OPEN READING FRAME 23; C11ORF23;; KIAA1558__:__
Asterisk__:__610880__:__CHROMOSOME 11 OPEN READING FRAME 24; C11ORF24__:____:__
Asterisk__:__610881__:__LYSINE-SPECIFIC METHYLTRANSFERASE 5B; KMT5B__:__SUPPRESSOR OF VARIEGATION 4-20, DROSOPHILA, HOMOLOG OF, 1; SUV420H1;; SU(VAR)4-20, DROSOPHILA, HOMOLOG OF, 1;; CGI85__:__
Asterisk__:__610882__:__SJOGREN SYNDROME NUCLEAR AUTOANTIGEN 1; SSNA1__:__NUCLEAR AUTOANTIGEN, 14-KD; NA14__:__
Number Sign__:__610883__:__POTOCKI-LUPSKI SYNDROME; PTLS__:__CHROMOSOME 17p11.2 DUPLICATION SYNDROME__:__
Asterisk__:__610884__:__CHROMOSOME 19 OPEN READING FRAME 40; C19ORF40__:__FANCONI ANEMIA-ASSOCIATED PROTEIN, 24-KD; FAAP24__:__
Asterisk__:__610885__:__ESSENTIAL MEIOTIC ENDONUCLEASE 1, S. POMBE, HOMOLOG OF, 1; EME1__:__EME1, S. POMBE, HOMOLOG OF, 1__:__
Asterisk__:__610886__:__ESSENTIAL MEIOTIC ENDONUCLEASE 1, S. POMBE, HOMOLOG OF, 2; EME2__:__EME1, S. POMBE, HOMOLOG OF, 2__:__
Asterisk__:__610887__:__POLYMERASE, DNA, NU; POLN__:__DNA POLYMERASE N;; POL4P__:__
Asterisk__:__610888__:__GASTRIC CANCER-RELATED GENE 224__:__GCRG224__:__
Asterisk__:__610889__:__IMPORTIN 11; IPO11__:__RAN-BINDING PROTEIN 11; RANBP11__:__SYNLEURIN, INCLUDED; SLRN, INCLUDED
Asterisk__:__610890__:__REGULATOR OF G PROTEIN SIGNALING 7-BINDING PROTEIN; RGS7BP__:__R7-BINDING PROTEIN; R7BP__:__
Asterisk__:__610891__:__FAMILY WITH SEQUENCE SIMILARITY 102, MEMBER A; FAM102A__:__EARLY ESTROGEN-INDUCED GENE 1; EEIG1__:__
Asterisk__:__610892__:__SYNAPTOTAGMIN 14-LIKE PROTEIN; SYT14L__:__SYTDEP;; CHR415SYT__:__
Asterisk__:__610893__:__CHMP FAMILY, MEMBER 2A; CHMP2A__:__CHROMATIN-MODIFYING PROTEIN 2A;; CHARGED MULTIVESICULAR BODY PROTEIN 2A;; VACUOLAR PROTEIN SORTING 2, YEAST, HOMOLOG OF, A; VPS2A;; VPS2;; BC2__:__
Asterisk__:__610894__:__NEUREGULIN 4; NRG4__:__HEREGULIN 4; HRG4__:__
Asterisk__:__610895__:__WAP, FOLLISTATIN, IMMUNOGLOBULIN, KUNITZ, AND NTR DOMAINS-CONTAINING PROTEIN 2; WFIKKN2__:__WFIKKN RELATED-PROTEIN; WFIKKNRP;; GDF-ASSOCIATED SERUM PROTEIN 1; GASP1__:__
Number Sign__:__610896__:__BRANCHIOOTORENAL SYNDROME 2; BOR2__:____:__
Asterisk__:__610897__:__CHMP FAMILY, MEMBER 4B; CHMP4B__:__CHROMATIN-MODIFYING PROTEIN 4B;; CHARGED MULTIVESICULAR BODY PROTEIN 4B;; SNF7, YEAST, HOMOLOG OF, 2;; SNF7-2__:__
Percent__:__610898__:__SUPRANUCLEAR PALSY, PROGRESSIVE, 3; PSNP3__:____:__
Asterisk__:__610899__:__CHMP FAMILY, MEMBER 4C; CHMP4C__:__CHROMATIN-MODIFYING PROTEIN 4C;; CHARGED MULTIVESICULAR BODY PROTEIN 4C;; SNF7, YEAST, HOMOLOG OF, 3;; SNF7-3__:__
Asterisk__:__610900__:__CHMP FAMILY, MEMBER 5; CHMP5__:__CHROMATIN-MODIFYING PROTEIN 5;; CHARGED MULTIVESICULAR BODY PROTEIN 5;; HSPC177__:__
Asterisk__:__610901__:__CHMP FAMILY, MEMBER 6; CHMP6__:__CHROMATIN-MODIFYING PROTEIN 6;; CHARGED MULTIVESICULAR BODY PROTEIN 6;; VPS20, YEAST, HOMOLOG OF; VPS20__:__
Asterisk__:__610902__:__CHROMOSOME 6 OPEN READING FRAME 55; C6ORF55__:__SKD1-BINDING PROTEIN 1; SBP1;; LYST-INTERACTING PROTEIN 5; LIP5;; VTA1, YEAST, HOMOLOG OF; VTA1;; DOPAMINE-RESPONSIVE GENE 1; DRG1__:__
Asterisk__:__610903__:__VACUOLAR PROTEIN SORTING 36, S. CEREVISIAE, HOMOLOG OF; VPS36__:__ELL-ASSOCIATED PROTEIN, 45-KD; EAP45__:__
Asterisk__:__610904__:__SNF8, S. CEREVISIAE, HOMOLOG OF; SNF8__:__VACUOLAR PROTEIN SORTING 22, S. CEREVISIAE, HOMOLOG OF; VPS22;; ELL-ASSOCIATED PROTEIN, 30-KD; EAP30__:__
Caret__:__610905__:__MOVED TO 225750__:____:__
Percent__:__610906__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 4__:__ASRT4;; ASTHMA AND ALLERGIC RHINITIS, SUSCEPTIBILITY TO__:__
Asterisk__:__610907__:__VACUOLAR PROTEIN SORTING 25, S. CEREVISIAE, HOMOLOG OF; VPS25__:__ELL-ASSOCIATED PROTEIN, 20-KD; EAP20__:__
Percent__:__610908__:__AUTISM, SUSCEPTIBILITY TO, 13; AUTS13__:____:__
Asterisk__:__610909__:__MINICHROMOSOME MAINTENANCE COMPLEX-BINDING PROTEIN; MCMBP__:__CHROMOSOME 10 OPEN READING FRAME 119; C10ORF119__:__
Percent__:__610910__:__PULMONARY ALVEOLAR PROTEINOSIS, ACQUIRED__:__PAP, ACQUIRED;; PULMONARY ALVEOLAR LIPOPROTEINOSIS, ACQUIRED;; PULMONARY ALVEOLAR PROTEINOSIS, AUTOIMMUNE__:__
Asterisk__:__610911__:__RHO GTPase-ACTIVATING PROTEIN 31; ARHGAP31__:__CDC42 GTPase-ACTIVATING PROTEIN; CDGAP;; KIAA1204__:__
Asterisk__:__610912__:__AMELOTIN; AMTN__:____:__
Number Sign__:__610913__:__SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 2; SMDP2__:__INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN C DEFICIENCY;; DESQUAMATIVE INTERSTITIAL PNEUMONITIS DUE TO SURFACTANT PROTEIN C DEFICIENCY;; PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 2__:__
Asterisk__:__610914__:__ECTO-NOX DISULFIDE-THIOL EXCHANGER 1; ENOX1__:__CNOX__:__
Number Sign__:__610915__:__OSTEOGENESIS IMPERFECTA, TYPE VIII; OI8__:__OI, TYPE VIII__:__
Asterisk__:__610916__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 2; NSUN2__:__NOL1/NOP2/SUN DOMAIN FAMILY, MEMBER 2;; TRM4, S. CEREVISIAE, HOMOLOG OF; TRM4;; SUBSTRATE OF AIM1/AURORA KINASE B; SAKI;; MYC-INDUCED SUN DOMAIN-CONTAINING PROTEIN; MISU__:__
Asterisk__:__610917__:__RAS-ASSOCIATED PROTEIN 34; RAB34__:__RAH, MOUSE, HOMOLOG OF; RAH__:__
Asterisk__:__610918__:__SELENOPROTEIN M; SELENOM__:__SELM;; SEPM__:__
Asterisk__:__610919__:__GTP-BINDING PROTEIN 5; GTPBP5__:__OBGH1__:__
Asterisk__:__610920__:__GTP-BINDING PROTEIN 10; GTPBP10__:__OBGH2__:__
Number Sign__:__610921__:__SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 3; SMDP3__:__PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 3;; INTERSTITIAL LUNG DISEASE DUE TO ABCA3 DEFICIENCY__:__
Asterisk__:__610922__:__NUCLEAR PORE ASSOCIATED PROTEIN 1; NPAP1__:__CHROMOSOME 15 OPEN READING FRAME 2; C15ORF2__:__
Asterisk__:__610923__:__SOLUTE CARRIER FAMILY 35 (UDP-XYLOSE/UDP-N-ACETYLGLUCOSAMINE TRANSPORTER), MEMBER B4; SLC35B4__:____:__
Asterisk__:__610924__:__RANBP-TYPE AND C3HC4-TYPE ZINC FINGER-CONTAINING 1; RBCK1__:__RBCC PROTEIN INTERACTING WITH PKC 1;; HEME-OXIDIZED IRP2 UBIQUITIN LIGASE 1; HOIL1;; HOIL1L;; HEPATITIS B VIRUS X-ASSOCIATED PROTEIN 3; XAP3__:__
Asterisk__:__610925__:__INTERLEUKIN 17 RECEPTOR C; IL17RC__:__INTERLEUKIN 17 RECEPTOR-LIKE PROTEIN; IL17RL__:__
Percent__:__610926__:__TOOTH AGENESIS, SELECTIVE, 5; STHAG5__:__HYPODONTIA/OLIGODONTIA 5;; HE-ZHAO DEFICIENCY__:__
Number Sign__:__610927__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 9; SLEB9__:____:__
Asterisk__:__610928__:__SRY-BOX 17; SOX17__:__SRY-RELATED HMG-BOX GENE 17__:__
Asterisk__:__610929__:__ORAI CALCIUM RELEASE-ACTIVATED CALCIUM MODULATOR 2; ORAI2__:__TRANSMEMBRANE PROTEIN 142B; TMEM142B;; CHROMOSOME 7 OPEN READING FRAME 19; C7ORF19__:__
Asterisk__:__610930__:__ORAI CALCIUM RELEASE-ACTIVATED CALCIUM MODULATOR 3; ORAI3__:__TRANSMEMBRANE PROTEIN 142C; TMEM142C__:__
Asterisk__:__610931__:__ZINC FINGER GENE IN AUTOIMMUNE THYROID DISEASE 1; ZFAT1__:__ZINC FINGER PROTEIN 406; ZNF406__:__
Asterisk__:__610932__:__TWINFILIN, DROSOPHILA, HOMOLOG OF, 1; TWF1__:__PROTEIN TYROSINE KINASE 9; PTK9;; A6 PROTEIN TYROSINE KINASE__:__
Asterisk__:__610933__:__LEUCINE-RICH REPEAT- AND STERILE ALPHA MOTIF-CONTAINING 1; LRSAM1__:__TSG101-ASSOCIATED LIGASE; TAL;; RING ZINC FINGER AND LEUCINE-RICH REPEAT-CONTAINING PROTEIN; RIFLE__:__
Asterisk__:__610934__:__NEWBORN OVARY HOMEOBOX, MOUSE, HOMOLOG OF; NOBOX__:____:__
Asterisk__:__610935__:__LIGAND-GATED ION CHANNEL, ZINC-ACTIVATED, 1; LGICZ1__:__Zn(2+)-ACTIVATED CHANNEL; ZAC;; L2__:__
Asterisk__:__610936__:__PHOSPHOSERINE AMINOTRANSFERASE 1; PSAT1__:__PSAT;; ENDOMETRIAL PROGESTERONE-INDUCED PROTEIN; EPIP__:__
Asterisk__:__610937__:__RPGRIP1-LIKE; RPGRIP1L__:__NEPHROCYSTIN 8; NPHP8;; KIAA1005__:__
Number Sign__:__610938__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 7; CHDS7__:____:__
Asterisk__:__610939__:__MICRO RNA 192; MIR192__:__miRNA192;; MIRN192__:__
Asterisk__:__610940__:__MICRO RNA 194-1; MIR194-1__:__miRNA194-1;; MIRN194-1__:__
Asterisk__:__610941__:__MICRO RNA 194-2; MIR194-2__:__miRNA194-2;; MIRN194-2__:__
Asterisk__:__610942__:__MICRO RNA 204; MIR204__:__miRNA204;; MIRN204__:__
Asterisk__:__610943__:__MICRO RNA 215; MIR215__:__miRNA215;; MIRN215__:__
Asterisk__:__610944__:__MICRO RNA 216; MIR216__:__miRNA216;; MIRN216__:__
Asterisk__:__610945__:__MICRO RNA 296; MIR296__:__miRNA296;; MIRN296__:__
Asterisk__:__610946__:__MICRO RNA 133B; MIR133B__:__miRNA133B;; MIRN133B__:__
Number Sign__:__610947__:__CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT 2; ADCAD2__:____:__
Percent__:__610948__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 7__:__HYT7__:__
Asterisk__:__610949__:__SYNAPTOTAGMIN 14; SYT14__:____:__
Asterisk__:__610950__:__SYNAPTOTAGMIN 16; SYT16__:__SYNAPTOTAGMIN 14-RELATED PROTEIN; STREP14__:__
Number Sign__:__610951__:__CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7__:____:__
Asterisk__:__610952__:__CROOKED NECK PRE-mRNA SPLICING FACTOR-LIKE 1; CRNKL1__:__CROOKED NECK, DROSOPHILA, HOMOLOG OF; CRN__:__
Asterisk__:__610953__:__PIF1, S. CEREVISIAE, HOMOLOG OF; PIF1__:__PIF__:__
Number Sign__:__610954__:__PITT-HOPKINS SYNDROME; PTHS__:__ENCEPHALOPATHY, SEVERE EPILEPTIC, WITH AUTONOMIC DYSFUNCTION;; MENTAL RETARDATION, SYNDROMAL, WITH INTERMITTENT HYPERVENTILATION__:__
Asterisk__:__610955__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 3; TRAPPC3__:__BET3, YEAST, HOMOLOG OF; BET3__:__
Asterisk__:__610956__:__ASPARTYL-tRNA SYNTHETASE 2; DARS2__:__ASPARTYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MT-ASPRS__:__
Asterisk__:__610957__:__TYROSYL-tRNA SYNTHETASE 2; YARS2__:__TYROSYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MT-TYRRS__:__
Asterisk__:__610958__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 9; AGPAT9__:__GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 3; GPAT3;; GPAT, ENDOPLASMIC RETICULUM-ASSOCIATED;; LUNG CANCER METASTASIS-ASSOCIATED GENE 1; MAG1;; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, THETA;; LPAAT-THETA__:__
Asterisk__:__610959__:__MICRO RNA 376A1; MIR376A1__:__miRNA376A1;; MIRN376A1__:__
Asterisk__:__610960__:__MICRO RNA 376A2; MIR376A2__:__miRNA376A2;; MIRN376A2__:__
Asterisk__:__610961__:__MICRO RNA 376B; MIR376B__:__miRNA376B;; MIRN376B; MIR376B__:__
Asterisk__:__610962__:__SMG5, C. ELEGANS, HOMOLOG OF; SMG5__:__EVER SHORTER TELOMERES 1, S. CEREVISIAE, HOMOLOG OF, B; EST1B;; KIAA1089__:__
Asterisk__:__610963__:__SMG6, C. ELEGANS, HOMOLOG OF; SMG6__:__EVER SHORTER TELOMERES 1, S. CEREVISIAE, HOMOLOG OF, A; EST1A;; KIAA0732__:__
Asterisk__:__610964__:__SMG7, C. ELEGANS, HOMOLOG OF; SMG7__:__EVER SHORTER TELOMERES 1, S. CEREVISIAE, HOMOLOG OF, C; EST1C;; KIAA0250__:__
Number Sign__:__610965__:__XFE PROGEROID SYNDROME; XFEPS__:__XPF-ERCC1 PROGEROID SYNDROME__:__
Asterisk__:__610966__:__FAT MASS- AND OBESITY-ASSOCIATED GENE; FTO__:__FATSO, MOUSE, HOMOLOG OF__:__
Number Sign__:__610967__:__OSTEOGENESIS IMPERFECTA, TYPE V; OI5__:__OI, TYPE V__:__
Number Sign__:__610968__:__OSTEOGENESIS IMPERFECTA, TYPE XI; OI11__:__OI, TYPE XI__:__
Asterisk__:__610969__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 1; TRAPPC1__:__BET5, S. CEREVISIAE, HOMOLOG OF;; MELANOMA UBIQUITOUS MUTATED 2; MUM2__:__
Asterisk__:__610970__:__TRAFFICKING PROTEIN PARTICLE COMPLEX 2-LIKE; TRAPPC2L__:____:__
Asterisk__:__610971__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 4; TRAPPC4__:__SYNBINDIN__:__
Asterisk__:__610972__:__ADHERENS JUNCTION-ASSOCIATED PROTEIN 1; AJAP1__:__SHREW1__:__
Asterisk__:__610973__:__MEMBRANE PROTEIN, PALMITOYLATED 7; MPP7__:____:__
Asterisk__:__610974__:__ZINC FINGER PROTEIN 521; ZNF521__:__EARLY HEMATOPOIETIC ZINC FINGER; EHZF;; EVI3, MOUSE, HOMOLOG OF__:__
Asterisk__:__610975__:__SKIN-, EMBRYO-, BRAIN-, AND OOCYTE-SPECIFIC HOMEOBOX__:__SEBOX;; OG9__:__
Asterisk__:__610976__:__APOLIPOPROTEIN B mRNA EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3H; APOBEC3H__:__APOBEC-RELATED PROTEIN 10; ARP10__:__
Asterisk__:__610977__:__TETRACYCLINE TRANSPORTER-LIKE PROTEIN__:__TETRAN;; TPO1, S. CEREVISIAE, HOMOLOG OF; TPO1__:__
Number Sign__:__610978__:__CHOREOATHETOSIS AND CONGENITAL HYPOTHYROIDISM WITH OR WITHOUT PULMONARY DYSFUNCTION; CAHTP__:__BRAIN-LUNG-THYROID SYNDROME__:__
Asterisk__:__610979__:__DIPHOSPHOINOSITOL PENTAKISPHOSPHATE KINASE 1; PPIP5K1__:__HISTIDINE ACID PHOSPHATASE DOMAIN-CONTAINING PROTEIN 2A; HISPPD2A;; INOSITOL PYROPHOSPHATE SYNTHASE 1; IPS1;; IP6 KINASE: IP6K;; VIP1;; KIAA0377__:__
Asterisk__:__610980__:__KCNQ1 DOWNSTREAM NEIGHBOR; KCNQ1DN__:____:__
Asterisk__:__610981__:__WWBP2 N-TERMINAL-LIKE PROTEIN; WBP2NL__:__POSTACROSOMAL SHEATH WW DOMAIN-BINDING PROTEIN; PAWP__:__
Asterisk__:__610982__:__INVERTED FORMIN 2; INF2__:__FORMIN, INVERTED, 2;; CHROMOSOME 14 OPEN READING FRAME 173; C14ORF173__:__
Asterisk__:__610983__:__MICRO RNA 376C; MIR376C__:__miRNA376C;; MIRN376C;; MICRO RNA 368; MIR368; MIRN368;; miRNA368__:__
Number Sign__:__610984__:__COMPLEMENT FACTOR I DEFICIENCY; CFID__:__COMPLEMENT COMPONENT 3 INACTIVATOR DEFICIENCY;; C3 INACTIVATOR DEFICIENCY__:__
Asterisk__:__610985__:__UBIQUITIN E2 VARIANT AND LACTATE/MALATE DEHYDROGENASE DOMAINS-CONTAINING PROTEIN; UEVLD__:__UEV2 AND LDH DOMAINS-CONTAINING PROTEIN;; UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 3; UEV3;; ATTP__:__
Asterisk__:__610986__:__LEUCINE-RICH REPEAT KINASE 1; LRRK1__:____:__
Asterisk__:__610987__:__N-ACYLSPHINGOSINE AMIDOHYDROLASE 2C; ASAH2C__:__NONLYSOSOMAL CERAMIDASE C;; CERAMIDASE, NONLYSOSOMAL, C;; ASAH2-LIKE; ASAH2L__:__
Number Sign__:__610988__:__LEPROSY, SUSCEPTIBILITY TO, 4; LPRS4__:____:__LEPROSY, EARLY-ONSET, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__610989__:__LEMUR TYROSINE KINASE 2; LMTK2__:__KINASE/PHOSPHATASE INHIBITOR 2; KPI2;; BRAIN-ENRICHED KINASE; BREK;; KIAA1079__:__
Asterisk__:__610990__:__PROTEIN PHOSPHATASE 1 REGULATORY SUBUNIT 18; PPP1R18__:__KIAA1949 GENE; KIAA1949;; PROTEIN PHOSPHATASE 1 F-ACTIN CYTOSKELETON-TARGETING SUBUNIT;; PHOSTENSIN__:__
Asterisk__:__610991__:__OBSCURIN-LIKE 1; OBSL1__:__KIAA0657__:__
Number Sign__:__610992__:__PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY; PSATD__:__PSAT DEFICIENCY__:__
Asterisk__:__610993__:__UBIQUITIN-SPECIFIC PROTEASE 44; USP44__:____:__
Asterisk__:__610994__:__TRANSMEMBRANE PROTEIN 189; TMEM189__:__KUA__:__KUA/UEV1 SPLICED READ-THROUGH TRANSCRIPT, INCLUDED
Asterisk__:__610995__:__PRENYLCYSTEINE OXIDASE 1; PCYOX1__:__PRENYLCYSTEINE LYASE; PCL1;; KIAA0908__:__
Asterisk__:__610996__:__D-TYROSYL-tRNA DEACYLASE 1, S. CEREVISIAE, HOMOLOG OF; DTD1__:__CHROMOSOME 20 OPEN READING FRAME 88; C20ORF88__:__
Number Sign__:__610997__:__PROSTATE CANCER, HEREDITARY, 9; HPC9__:____:__
Asterisk__:__610998__:__METEORIN; METRN__:____:__
Asterisk__:__610999__:__ENHANCER OF POLYCOMB, DROSOPHILA, HOMOLOG OF, 1; EPC1__:____:__
Asterisk__:__611000__:__ENHANCER OF POLYCOMB, DROSOPHILA, HOMOLOG OF, 2; EPC2__:__EPC-LIKE__:__
Asterisk__:__611001__:__MYST/ESA1-ASSOCIATED FACTOR 6; MEAF6__:__EAF6, S. CEREVISIAE, HOMOLOG OF; EAF6;; CHROMOSOME 1 OPEN READING FRAME 149; C1ORF149__:__
Asterisk__:__611002__:__TRANSMEMBRANE PROTEIN 204; TMEM204__:__CLAUDIN-LIKE PROTEIN, 24-KD; CLP24;; CHROMOSOME 16 OPEN READING FRAME 30; C16ORF30__:__
Percent__:__611003__:__SMOKING AS A QUANTITATIVE TRAIT LOCUS 1; SQTL1__:____:__
Percent__:__611004__:__SMOKING AS A QUANTITATIVE TRAIT LOCUS 2; SQTL2__:____:__
Asterisk__:__611005__:__MEX3, C. ELEGANS, HOMOLOG OF, C; MEX3C__:__RING FINGER- AND KH DOMAIN-CONTAINING PROTEIN 2; RKHD2__:__
Asterisk__:__611006__:__IRON-SULFUR CLUSTER ASSEMBLY 1, S. CEREVISIAE, HOMOLOG OF; ISCA1__:__HESB-LIKE DOMAIN-CONTAINING 2; HBLD2;; HISCA__:__
Asterisk__:__611007__:__MEX3, C. ELEGANS, HOMOLOG OF, A; MEX3A__:____:__
Asterisk__:__611008__:__MEX3, C. ELEGANS, HOMOLOG OF, B; MEX3B__:__RING FINGER- AND KH DOMAIN-CONTAINING PROTEIN 3; RKHD3__:__
Asterisk__:__611009__:__MEX3, C. ELEGANS, HOMOLOG OF, D; MEX3D__:__RING FINGER- AND KH DOMAIN-CONTAINING PROTEIN 1; RKHD1;; TINO;; KIAA2031__:__
Percent__:__611010__:__FIBROMATOSIS, GINGIVAL, 4; GINGF4__:__GGF4;; FIBROMATOSIS, GINGIVAL, HEREDITARY, 4; HGF4__:__
Asterisk__:__611011__:__TRANSMEMBRANE PROTEIN 259; TMEM259__:__CHROMOSOME 19 OPEN READING FRAME 6; C19ORF6;; MEMBRALIN__:__
Asterisk__:__611012__:__REGULATOR OF G PROTEIN SIGNALING-LIKE 1; RGSL1__:____:__
Asterisk__:__611013__:__REGULATOR OF G PROTEIN SIGNALING-LIKE 2; RGSL2__:____:__
Percent__:__611014__:__HYPERTENSION, ESSENTIAL, SUSCEPTIBILITY TO, 8; HYT8__:____:__
Percent__:__611015__:__AUTISM, SUSCEPTIBILITY TO, 9; AUTS9__:____:__
Percent__:__611016__:__AUTISM, SUSCEPTIBILITY TO, 10; AUTS10__:____:__
Asterisk__:__611017__:__TRYPSIN DOMAIN-CONTAINING PROTEIN 1; TYSND1__:____:__
Asterisk__:__611018__:__POLYADENYLATE-BINDING PROTEIN-INTERACTING PROTEIN 2B; PAIP2B__:__POLY(A)-BINDING PROTEIN-INTERACTING PROTEIN 2B;; PABP-INTERACTING PROTEIN 2B__:__
Asterisk__:__611019__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 9-KD, V0 SUBUNIT E2; ATP6V0E2__:____:__
Asterisk__:__611020__:__MICRO RNA 21; MIR21__:__miRNA21;; MIRN21__:__
Asterisk__:__611021__:__NMD3, S. CEREVISIAE, HOMOLOG OF; NMD3__:____:__
Number Sign__:__611022__:__DEAFNESS, AUTOSOMAL RECESSIVE 24; DFNB24__:____:__
Asterisk__:__611023__:__tRNA METHYLTRANSFERASE 5, S. CEREVISIAE, HOMOLOG OF; TRMT5__:__TRM5;; KIAA1393__:__
Asterisk__:__611024__:__ZINC FINGER PROTEIN 667; ZNF667__:__MIPU1, RAT, HOMOLOG OF; MIPU1__:__
Asterisk__:__611025__:__ENKURIN, TRPC CHANNEL-INTERACTING PROTEIN; ENKUR__:__ENKURIN, MOUSE, HOMOLOG OF;; CHROMOSOME 10 OPEN READING FRAME 63; C10ORF63__:__
Asterisk__:__611026__:__FATTY ACID 2-HYDROXYLASE; FA2H__:__FATTY ACID ALPHA-HYDROXYLASE; FAAH;; FATTY ACID HYDROXYLASE DOMAIN-CONTAINING PROTEIN 1; FAXDC1;; FAH1, S. CEREVISIAE, HOMOLOG OF; FAH1;; SCS7, S. CEREVISIAE, HOMOLOG OF; SCS7__:__
Asterisk__:__611027__:__SHC SH2 DOMAIN-BINDING PROTEIN 1; SHCBP1__:__PROTEIN EXPRESSED IN ACTIVATED LYMPHOCYTES; PAL__:__
Asterisk__:__611028__:__TRANSMEMBRANE PROTEIN 30A; TMEM30A__:__CDC50, S. CEREVISIAE, HOMOLOG OF, A; CDC50A__:__
Asterisk__:__611029__:__TRANSMEMBRANE PROTEIN 30B; TMEM30B__:__CDC50, S. CEREVISIAE, HOMOLOG OF, B; CDC50B__:__
Asterisk__:__611030__:__TRANSMEMBRANE PROTEIN 30C; TMEM30C__:__CDC50, S. CEREVISIAE, HOMOLOG OF, C; CDC50C__:__
Percent__:__611031__:__EPISODIC KINESIGENIC DYSKINESIA 2; EKD2__:__DYSTONIA 19; DYT19__:__
Asterisk__:__611032__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 17; SPATA17__:__MSRG11__:__
Asterisk__:__611033__:__CHROMOSOME 11 OPEN READING FRAME 21; C11ORF21__:____:__
Asterisk__:__611034__:__SOLUTE CARRIER FAMILY 17 (ORGANIC ANION TRANSPORTER), MEMBER 3; SLC17A3__:__SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 3;; NPT4__:__
Asterisk__:__611035__:__APRATAXIN- AND PNKP-LIKE FACTOR; APLF__:__APRATAXIN- AND PNK-LIKE FACTOR;; CHROMOSOME 2 OPEN READING FRAME 13; C2ORF13__:__
Asterisk__:__611036__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 13; SLC2A13__:__PROTON (H+) MYOINOSITOL SYMPORTER; HMIT__:__
Asterisk__:__611037__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PHOSPHATE CARRIER), MEMBER 26; SLC25A26__:__S-ADENOSYLMETHIONINE CARRIER PROTEIN; SAMC__:__
Number Sign__:__611038__:__MICROPHTHALMIA, ISOLATED 3; MCOP3__:____:__
Asterisk__:__611039__:__SOLUTE CARRIER FAMILY 2 (FACILITATED GLUCOSE TRANSPORTER), MEMBER 14; SLC2A14__:__GLUCOSE TRANSPORTER 14; GLUT14__:__
Number Sign__:__611040__:__MICROPHTHALMIA, ISOLATED 5; MCOP5__:__MICROPHTHALMIA, POSTERIOR, WITH RETINITIS PIGMENTOSA, FOVEOSCHISIS, AND OPTIC DISC DRUSEN__:__
Asterisk__:__611041__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 47; TRIM47__:__GENE OVEREXPRESSED IN ASTROCYTOMA; GOA__:__
Asterisk__:__611042__:__LATE CORNIFIED ENVELOPE-LIKE PROLINE-RICH 1; LELP1__:____:__
Asterisk__:__611043__:__LIN28, C. ELEGANS, HOMOLOG OF, A; LIN28A__:__LIN28;; ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 1; ZCCHC1__:__
Asterisk__:__611044__:__LIN28, C. ELEGANS, HOMOLOG OF, B; LIN28B__:____:__
Asterisk__:__611045__:__GLUCOSE-6-PHOSPHATASE, CATALYTIC, 3; G6PC3__:__UBIQUITOUS GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT-RELATED PROTEIN; UGRP;; GLUCOSE-6-PHOSPHATASE, BETA;; G6Pase-BETA__:__
Percent__:__611046__:__MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 2__:__MTBS2__:__
Asterisk__:__611047__:__RETINOIC ACID EARLY TRANSCRIPT 1L; RAET1L__:____:__
Asterisk__:__611048__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 15A; PPP1R15A__:__GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE GENE 34; GADD34__:__
Asterisk__:__611049__:__SOLUTE CARRIER FAMILY 17, MEMBER 2; SLC17A2__:__SOLUTE CARRIER FAMILY 17 (SODIUM PHOSPHATE COTRANSPORTER), MEMBER 2;; NPT3__:__
Asterisk__:__611050__:__LEUCINE ZIPPER PROTEIN 6; LUZP6__:__MYELOPROLIFERATIVE DISEASE-ASSOCIATED ANTIGEN, 6-KD; MPD6__:__
Asterisk__:__611051__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 50; CCDC50__:__YMER;; CHROMOSOME 3 OPEN READING FRAME 6; C3ORF6__:__
Asterisk__:__611052__:__SET DOMAIN-CONTAINING PROTEIN 1A; SETD1A__:__SET1A;; SET1;; LYSINE-SPECIFIC METHYLTRANSFERASE 2F; KMT2F;; KIAA0339__:__
Asterisk__:__611053__:__RUN DOMAIN AND SH3 DOMAIN-CONTAINING PROTEIN 2; RUSC2__:__KIAA0375;; IPORIN__:__
Asterisk__:__611054__:__PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F POLYPEPTIDE-INTERACTING PROTEIN ALPHA-1; PPFIA1__:__LAR-INTERACTING PROTEIN 1; LIP1;; LIPRIN-ALPHA-1__:__
Asterisk__:__611055__:__SET DOMAIN-CONTAINING PROTEIN 1B; SETD1B__:__SET1B;; LYSINE-SPECIFIC METHYLTRANSFERASE 2G; KMT2G;; KIAA1076__:__
Asterisk__:__611056__:__SELENOCYSTEINE LYASE; SCLY__:__SCL__:__
Caret__:__611057__:__MOVED TO 603989__:____:__
Asterisk__:__611058__:__PEROXISOME BIOGENESIS FACTOR 5-LIKE; PEX5L__:__PEX5-RELATED PROTEIN; PEX5R;; PXR2B;; TRIP8B__:__
Asterisk__:__611059__:__WD REPEAT-CONTAINING PROTEIN 82; WDR82__:__TRANSMEMBRANE PROTEIN 113; TMEM113__:__
Asterisk__:__611060__:__SET-BINDING PROTEIN 1; SETBP1__:__SEB;; KIAA0437__:__SETBP1/NUP98 FUSION GENE, INCLUDED
Asterisk__:__611061__:__FAMILY WITH SEQUENCE SIMILARITY 20, MEMBER C; FAM20C__:__DENTIN MATRIX PROTEIN 4; DMP4__:__
Asterisk__:__611062__:__FAMILY WITH SEQUENCE SIMILARITY 20, MEMBER A; FAM20A__:____:__
Asterisk__:__611063__:__FAMILY WITH SEQUENCE SIMILARITY 20, MEMBER B; FAM20B__:__KIAA0475__:__
Number Sign__:__611064__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 5__:__ASRT5__:__
Asterisk__:__611065__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1K; PPM1K__:__PROTEIN PHOSPHATASE, PP2C DOMAIN-CONTAINING, 1K;; PROTEIN PHOSPHATASE 2C, MITOCHONDRIAL; PP2CM;; PP2C-TYPE MITOCHONDRIAL PHOSPHATASE; PTMP;; BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE PHOSPHATASE; BDP__:__
Asterisk__:__611066__:__PH DOMAIN AND LEUCINE-RICH REPEAT PROTEIN PHOSPHATASE-LIKE; PHLPPL__:__PHLPP-LIKE;; PHLPP2__:__
Number Sign__:__611067__:__SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 4; DSMA4__:____:__
Asterisk__:__611068__:__SMALL NUCLEOLAR RNA, C/D BOX, 43; SNORD43__:__RNA, U43 SMALL NUCLEOLAR; RNU43;; snoRNA, U43__:__
Asterisk__:__611069__:__RNA, U86 SMALL NUCLEOLAR__:__RNU86;; snoRNA, U86__:__
Asterisk__:__611070__:__SMALL NUCLEOLAR RNA, C/D BOX, 83A; SNORD83A__:__RNA, U83A SMALL NUCLEOLAR; RNU83A;; snoRNA, U83A__:__
Asterisk__:__611071__:__SMALL NUCLEOLAR RNA, C/D BOX, 83B; SNORD83B__:__RNA, U83B SMALL NUCLEOLAR; RNU83B;; snoRNA, U83B__:__
Asterisk__:__611072__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 24; DNAJC24__:__DPH4, S. CEREVISIAE, HOMOLOG OF; DPH4__:__
Percent__:__611073__:__ALZHEIMER DISEASE 12__:__AD12;; ALZHEIMER DISEASE, FAMILIAL, 12__:__
Asterisk__:__611074__:__BRAIN-SPECIFIC HOMEOBOX, MOUSE, HOMOLOG OF; BSX__:__BSX1__:__
Asterisk__:__611075__:__DPH5, S. CEREVISIAE, HOMOLOG OF; DPH5__:__HSPC143__:__
Asterisk__:__611076__:__5-PRIME-NUCLEOTIDASE DOMAIN-CONTAINING PROTEIN 3; NT5DC3__:__TU12B1TY;; GRP94-NEIGHBORING NUCLEOTIDASE; GNN__:__
Asterisk__:__611077__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 4; CHCHD4__:__MIA40, S. CEREVISIAE, HOMOLOG OF; MIA40__:__
Asterisk__:__611078__:__COBALAMIN SYNTHETASE W DOMAIN-CONTAINING PROTEIN 1; CBWD1__:__COBW DOMAIN-CONTAINING PROTEIN 1__:__
Asterisk__:__611079__:__COBALAMIN SYNTHETASE W DOMAIN-CONTAINING PROTEIN 2; CBWD2__:__COBW DOMAIN-CONTAINING PROTEIN 2__:__
Asterisk__:__611080__:__COBALAMIN SYNTHETASE W DOMAIN-CONTAINING PROTEIN 3; CBWD3__:__COBW DOMAIN-CONTAINING PROTEIN 3__:__
Number Sign__:__611081__:__INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 10; IBD10__:____:__
Asterisk__:__611082__:__MIAT GENE; MIAT__:__C22ORF35__:__
Asterisk__:__611083__:__ALCOHOL DEHYDROGENASE, IRON-CONTAINING, 1; ADHFE1__:__HYDROXYACID-OXOACID TRANSHYDROGENASE; HOT;; ALCOHOL DEHYDROGENASE 8; ADH8__:__
Asterisk__:__611084__:__FORKHEAD BOX D4-LIKE 1; FOXD4L1__:__FOXD4-LIKE 1__:__
Asterisk__:__611085__:__FORKHEAD BOX D4-LIKE 4; FOXD4L4__:__FOXD4B;; FORKHEAD BOX D4-LIKE 2; FOXD4L2;; FOXD4-LIKE 2__:__
Asterisk__:__611086__:__FORKHEAD BOX D4-LIKE 3; FOXD4L3__:__FOXD4-LIKE 3__:__
Number Sign__:__611087__:__POLYHYDRAMNIOS, MEGALENCEPHALY, AND SYMPTOMATIC EPILEPSY; PMSE__:__PMSE SYNDROME__:__
Asterisk__:__611088__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 65; CCDC65__:__NYD-SP28__:__
Asterisk__:__611089__:__MYOTUBULARIN-RELATED PROTEIN 14; MTMR14__:__CHROMOSOME 3 OPEN READING FRAME 29; C3ORF29;; EGG-DERIVED TYROSINE PHOSPHATASE, DROSOPHILA, HOMOLOG OF;; HJUMPY__:__
Number Sign__:__611090__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 12; MRT12__:____:__
Number Sign__:__611091__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 5; MRT5__:____:__
Number Sign__:__611092__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 6; MRT6__:____:__
Number Sign__:__611093__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 22; MRT22__:__
Caret__:__611094__:__MOVED TO 614300__:____:__
Percent__:__611095__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 9; MRT9__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 26; MRT26__:__
Percent__:__611096__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 20; MRT20__:__
Percent__:__611097__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 11; MRT11__:____:__
Asterisk__:__611098__:__SIX-TRANSMEMBRANE EPITHELIAL ANTIGEN OF PROSTATE 4; STEAP4__:__SIX-TRANSMEMBRANE PROTEIN OF PROSTATE 2; STAMP2;; TUMOR NECROSIS-ALPHA-INDUCED ADIPOSE-RELATED PROTEIN; TIARP__:__
Asterisk__:__611099__:__PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 6; PDIA6__:__P5;; ENDOPLASMIC RETICULUM PROTEIN 5; ERP5__:__
Percent__:__611100__:__PROSTATE CANCER, HEREDITARY, 10; HPC10__:____:__
Asterisk__:__611101__:__PLECKSTRIN HOMOLOGY DOMAIN- AND RhoGEF DOMAIN-CONTAINING PROTEIN G5; PLEKHG5__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY G, MEMBER 5;; KIAA0720__:__
Number Sign__:__611102__:__DEAFNESS-INFERTILITY SYNDROME; DIS__:__DEAFNESS, SENSORINEURAL, AND MALE INFERTILITY;; CHROMOSOME 15q15.3 DELETION SYNDROME__:__
Asterisk__:__611103__:__ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9; ACAD9__:____:__
Asterisk__:__611104__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 4; FGD4__:__FGD1-RELATED F-ACTIN-BINDING PROTEIN; FRABIN__:__
Number Sign__:__611105__:__LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL__:__MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY__:__
Asterisk__:__611106__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12D; ZC3H12D__:__p34;; C6ORF95;; MCPIP4__:__
Percent__:__611107__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 4; MRT4__:____:__
Asterisk__:__611108__:__VON WILLEBRAND FACTOR C DOMAIN-CONTAINING PROTEIN 2; VWC2__:__BRAIN-SPECIFIC CHORDIN-LIKE PROTEIN; BRORIN__:__
Percent__:__611109__:__CINNAMON ODOR, PLEASANTNESS OF__:__CINN__:__
Asterisk__:__611110__:__MAP3K7 C-TERMINAL-LIKE PROTEIN; MAP3K7CL__:__TAK1-LIKE; TAK1L;; CHROMOSOME 21 OPEN READING FRAME 7; C21ORF7__:__
Asterisk__:__611111__:__DEVELOPMENTAL PLURIPOTENCY-ASSOCIATED GENE 5; DPPA5__:__EMBRYONAL STEM CELL-SPECIFIC GENE 1; ESG1__:__
Asterisk__:__611112__:__DAPPER, ANTAGONIST OF BETA-CATENIN, 3; DACT3__:__DAPPER, XENOPUS, HOMOLOG OF, 3__:__
Asterisk__:__611113__:__CEMENTUM PROTEIN 1; CEMP1__:__CEMENTUM PROTEIN 23; CP23__:__
Asterisk__:__611114__:__MICRO RNA 150; MIR150__:__miRNA150;; MIRN150__:__
Asterisk__:__611115__:__VON WILLEBRAND FACTOR C AND EGF DOMAIN-CONTAINING PROTEIN; VWCE__:__VWC1;; URG11__:__
Asterisk__:__611116__:__MICRO RNA 208A; MIR208A__:__miRNA208A;; MIRN208A;; MIR208;; miRNA208;; MIRN208__:__
Asterisk__:__611117__:__PROTEIN PHOSPHATASE METHYLESTERASE 1; PPME1__:__PME1__:__
Asterisk__:__611118__:__NUCLEAR PRELAMIN A RECOGNITION FACTOR-LIKE; NARFL__:__IRON-ONLY HYDROGENASE-LIKE PROTEIN 1; IOP1__:__
Asterisk__:__611119__:__KELCH-LIKE 7; KLHL7__:____:__
Asterisk__:__611120__:__SERINE PALMITOYLTRANSFERASE, LONG-CHAIN BASE SUBUNIT 3; SPTLC3__:__SPTLC2L;; LCB2B__:__
Asterisk__:__611121__:__CALMIN; CLMN__:__CALPONIN-LINE TRANSMEMBRANE DOMAIN PROTEIN;; KIAA1188__:__
Asterisk__:__611122__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 28; ANKRD28__:__PHOSPHATASE INTERACTOR TARGETING K PROTEIN; PITK;; KIAA0379__:__
Asterisk__:__611123__:__EPHRIN RECEPTOR EphA10; EPHA10__:____:__
Asterisk__:__611124__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 8; MFSD8__:__MGC33302__:__
Asterisk__:__611125__:__DERMATAN SULFATE EPIMERASE-LIKE; DSEL__:__CHROMOSOME 18 OPEN READING FRAME 4; C18ORF4;; NCAG1__:__
Number Sign__:__611126__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 20; MC1DN20__:__MITOCHONDRIAL COMPLEX I DEFICIENCY DUE TO ACAD9 DEFICIENCY;; ACYL-CoA DEHYDROGENASE 9 DEFICIENCY;; ACAD9 DEFICIENCY__:__
Asterisk__:__611127__:__UBIQUITIN-LIKE 4B; UBL4B__:____:__
Asterisk__:__611128__:__MAM DOMAIN-CONTAINING GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR 2; MDGA2__:__MAM DOMAIN-CONTAINING PROTEIN 1; MAMDC1__:__
Asterisk__:__611129__:__WW DOMAIN-BINDING PROTEIN 1-LIKE; WBP1L__:__CHROMOSOME 10 OPEN READING FRAME 26; C10ORF26;; OPAL1__:__
Asterisk__:__611130__:__CHMP FAMILY, MEMBER 7; CHMP7__:__CHARGED MULTIVESICULAR BODY PROTEIN 7;; CHROMATIN-MODIFYING PROTEIN 7__:__
Number Sign__:__611131__:__RETINITIS PIGMENTOSA 37; RP37__:____:__
Asterisk__:__611132__:__RIBOKINASE; RBKS__:____:__
Asterisk__:__611133__:__SMALL NUCLEOLAR RNA, C/D BOX, 82; SNORD82__:__RNA, U82 SMALL NUCLEOLAR; RNU82;; snoRNA, U82__:__
Number Sign__:__611134__:__MECKEL SYNDROME, TYPE 4; MKS4__:__MECKEL-GRUBER SYNDROME, TYPE 4__:__MECKEL-LIKE CEREBRORENODIGITAL SYNDROME, INCLUDED
Asterisk__:__611135__:__KLOTHO, BETA; KLB__:__BETA-KLOTHO; BKL__:__
Number Sign__:__611136__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 13; EIG13__:____:__EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 5, INCLUDED; EJM5, INCLUDED;; EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 4, INCLUDED; ECA4, INCLUDED
Asterisk__:__611137__:__PROTEASOME SUBUNIT, BETA-TYPE, 11; PSMB11__:__PROTEASOME SUBUNIT, BETA-5 FAMILY, THYMUS-SPECIFIC;; PROTEASOME SUBUNIT BETA-5T__:__
Asterisk__:__611138__:__SPERMATID PERINUCLEAR RNA-BINDING PROTEIN; STRBP__:__SPNR;; p74, RAT, HOMOLOG OF__:__
Percent__:__611139__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 8; CHDS8__:____:__
Asterisk__:__611140__:__TELOMERE MAINTENANCE 2, S. CEREVISIAE, HOMOLOG OF; TELO2__:__TEL2, S. CEREVISIAE, HOMOLOG OF; TEL2;; CLK2, C. ELEGANS, HOMOLOG OF; CLK2;; KIAA0683;; HCLK2__:__
Asterisk__:__611141__:__MINDBOMB, DROSOPHILA, HOMOLOG OF, 2; MIB2__:__SKELETROPHIN__:__
Asterisk__:__611142__:__CYTOSKELETON-ASSOCIATED PROTEIN 5; CKAP5__:__COLONIC AND HEPATIC TUMOR OVEREXPRESSED GENE; CHTOG;; MINI SPINDLES, DROSOPHILA, HOMOLOG OF; MSPS;; KIAA0097__:__
Asterisk__:__611143__:__FAMILY WITH SEQUENCE SIMILARITY 175, MEMBER A; FAM175A__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 98; CCDC98;; ABRAXAS; ABRA1__:__
Asterisk__:__611144__:__FAMILY WITH SEQUENCE SIMILARITY 175, MEMBER B; FAM175B__:__ABRAXAS BROTHER 1; ABRO1;; KIAA0157__:__
Asterisk__:__611145__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 8; SLC30A8__:__ZINC TRANSPORTER 8; ZNT8__:__
Asterisk__:__611146__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 10; SLC30A10__:__ZINC TRANSPORTER 10; ZNT10__:__
Percent__:__611147__:__PAROXYSMAL NONKINESIGENIC DYSKINESIA 2; PNKD2__:__DYSTONIA 20; DYT20__:__
Asterisk__:__611148__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 6; SLC30A6__:__ZINC TRANSPORTER 6; ZNT6__:__
Asterisk__:__611149__:__SOLUTE CARRIER FAMILY 30 (ZINC TRANSPORTER), MEMBER 7; SLC30A7__:__ZINC TRANSPORTER 7; ZNT7__:__
Asterisk__:__611150__:__ATAXIN 10; ATXN10__:__E46-LIKE; E46L__:__
Asterisk__:__611151__:__tRNA METHYLTRANSFERASE 2, S. CEREVISIAE, HOMOLOG OF, A; TRMT2A__:__HPAII TINY FRAGMENTS LOCUS 9C; HTF9C__:__
Percent__:__611152__:__ALZHEIMER DISEASE 13; AD13__:____:__
Asterisk__:__611153__:__XPA GENE; XPA__:__XPA COMPLEMENTING GENE; XPAC__:__
Percent__:__611154__:__ALZHEIMER DISEASE 14; AD14__:____:__
Percent__:__611155__:__ALZHEIMER DISEASE 15; AD15__:____:__
Asterisk__:__611156__:__ENDOPLASMIC RETICULUM METALLOPEPTIDASE 1; ERMP1__:__FXNA, RAT, HOMOLOG OF;; KIAA1815__:__
Asterisk__:__611157__:__MRG/MORF4L-BINDING PROTEIN; MRGBP__:__CHROMOSOME 20 OPEN READING FRAME 20; C20ORF20__:__
Asterisk__:__611158__:__KERATIN 77, TYPE II; KRT77__:__K77;; KB39;; KERATIN 1B; K1B__:__
Asterisk__:__611159__:__KERATIN 78, TYPE II; KRT78__:__K78;; KB40;; KERATIN 5B; K5B__:__
Asterisk__:__611160__:__KERATIN 79, TYPE II; KRT79__:__K79;; KB38;; KERATIN 6-LIKE; K6L; KRT6L__:__
Asterisk__:__611161__:__KERATIN 80, TYPE II; KRT80__:__K80;; KERATIN B20; KB20__:__
Number Sign__:__611162__:__MALARIA, SUSCEPTIBILITY TO__:____:__MALARIA, RESISTANCE TO, INCLUDED;; MALARIA, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; MALARIA, SEVERE, RESISTANCE TO, INCLUDED;; MALARIA, CEREBRAL, SUSCEPTIBILITY TO, INCLUDED;; MALARIA, CEREBRAL, RESISTANCE TO, INCLUDED
Asterisk__:__611163__:__TOX HIGH MOBILITY GROUP BOX FAMILY MEMBER 2; TOX2__:__GRANULOSA CELL HMG-BOX PROTEIN 1; GCX1;; CHROMOSOME 20 OPEN READING FRAME 100; C20ORF100__:__
Asterisk__:__611164__:__ARGININE-FIFTY HOMEOBOX; ARGFX__:____:__
Asterisk__:__611165__:__DIVERGENT-PAIRED RELATED HOMEOBOX; DPRX__:____:__
Asterisk__:__611166__:__TETRAPEPTIDE REPEAT HOMEOBOX 1; TPRX1__:____:__
Asterisk__:__611167__:__TETRAPEPTIDE REPEAT HOMEOBOX-LIKE; TPRXL__:____:__
Asterisk__:__611168__:__DOUBLE HOMEOBOX A; DUXA__:____:__
Asterisk__:__611169__:__CATION CHANNEL, SPERM-ASSOCIATED, AUXILIARY SUBUNIT BETA; CATSPERB__:__CATSPER-BETA;; CHROMOSOME 14 OPEN READING FRAME 161; C14ORF161__:__
Asterisk__:__611170__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 9-LIKE; SAMD9L__:____:__
Asterisk__:__611171__:__SHOOTIN1; SHTN1__:__KIAA1598__:__
Asterisk__:__611172__:__MICRO RNA 34A; MIR34A__:__miRNA34A;; MIRN34A__:__
Asterisk__:__611173__:__MICRO RNA 375; MIR375__:__miRNA375;; MIRN375__:__
Number Sign__:__611174__:__HAMAMY SYNDROME; HMMS__:__HYPERTELORISM, SEVERE, WITH MIDFACE PROMINENCE, MYOPIA, MENTAL RETARDATION, AND BONE FRAGILITY__:__
Asterisk__:__611175__:__OBG-LIKE ATPase 1; OLA1__:__GTP-BINDING PROTEIN 9; GTPBP9__:__
Asterisk__:__611176__:__JNK/MAPK8-ASSOCIATED MEMBRANE PROTEIN; JKAMP__:__JNK1-ASSOCIATED MEMBRANE PROTEIN; JAMP;; CHROMOSOME 14 OPEN READING FRAME 100; C14ORF100__:__
Asterisk__:__611177__:__INTRAFLAGELLAR TRANSPORT 80, CHLAMYDOMONAS, HOMOLOG OF; IFT80__:__KIAA1374;; WD REPEAT-CONTAINING PROTEIN 56; WDR56__:__
Asterisk__:__611178__:__GALANIN-LIKE PEPTIDE; GALP__:____:__GALANIN-LIKE PEPTIDE PRECURSOR PROTEIN, INCLUDED;; GALP PRECURSOR PROTEIN, INCLUDED;; ALARIN, INCLUDED
Asterisk__:__611179__:__SHROOM FAMILY MEMBER 1; SHROOM1__:__APXL2;; KIAA1960__:__
Asterisk__:__611180__:__COFACTOR OF BRCA1; COBRA1__:__NEGATIVE ELONGATION FACTOR POLYPEPTIDE B; NELFB;; KIAA1182__:__
Asterisk__:__611181__:__ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 10; ACAD10__:____:__
Number Sign__:__611182__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIh; CDG2H__:__CDG IIh; CDGIIh__:__
Asterisk__:__611183__:__BRICK1, SCAR/WAVE ACTIN-NUCLEATING COMPLEX SUBUNIT; BRK1__:__BRICK1;; CHROMOSOME 3 OPEN READING FRAME 10; C3ORF10;; HSPC300__:__
Asterisk__:__611184__:__PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 1; PIEZO1__:__FAMILY WITH SEQUENCE SIMILARITY 38, MEMBER A; FAM38A;; MEMBRANE PROTEIN INDUCED BY BETA-AMYLOID TREATMENT; MIB__:__
Percent__:__611185__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 6; RLS6__:__PERIODIC LIMB MOVEMENTS IN SLEEP__:__
Asterisk__:__611186__:__MICRO RNA 9-1; MIR9-1__:__MIRN9-1;; miRNA9-1__:__
Asterisk__:__611187__:__MICRO RNA 9-2; MIR9-2__:__MIRN9-2;; miRNA9-2__:__
Asterisk__:__611188__:__MICRO RNA 9-3; MIR9-3__:__MIRN9-3;; miRNA9-3__:__
Asterisk__:__611189__:__MICRO RNA 197; MIR197__:__miRNA197;; MIRN197__:__
Asterisk__:__611190__:__MICRO RNA 346; MIR346__:__miRNA346;; MIRN346__:__
Asterisk__:__611191__:__MICRO RNA 125A; MIR125A__:__MIRN125A;; miRNA125A__:__
Asterisk__:__611192__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 11; ANKRD11__:__ANKYRIN REPEAT-CONTAINING COFACTOR 1; ANCO1;; NASOPHARYNGEAL CARCINOMA SUSCEPTIBILITY PROTEIN;; T13;; LZ16__:__
Asterisk__:__611193__:__RIBOSOMAL RNA-PROCESSING 15, S. CEREVISIAE, HOMOLOG OF; RRP15__:____:__
Asterisk__:__611194__:__RUN AND FYVE DOMAINS-CONTAINING PROTEIN 3; RUFY3__:__SINGLE AXON-RELATED 1; SINGAR1;; RAP2-INTERACTING PROTEIN X; RIPX__:__
Asterisk__:__611195__:__JANUS KINASE AND MICROTUBULE-INTERACTING PROTEIN 1; JAKMIP1__:__JAMIP1;; MULTIPLE ALPHA HELICES AND RNA-LINKER PROTEIN; MARLIN1__:__
Asterisk__:__611196__:__ZINC FINGER MIZ-DOMAIN CONTAINING 2; ZMIZ2__:__KIAA1886;; ZIMP7__:__
Asterisk__:__611197__:__JANUS KINASE AND MICROTUBULE-INTERACTING PROTEIN 2; JAKMIP2__:__JAMIP2;; NEUROENDOCRINE LONG COILED-COIL PROTEIN 1; NECC1;; KIAA0555__:__
Asterisk__:__611198__:__JANUS KINASE AND MICROTUBULE-INTERACTING PROTEIN 3; JAKMIP3__:__NEUROENDOCRINE LONG COILED-COIL PROTEIN 2; NECC2;; CHROMOSOME 10 OPEN READING FRAME 39; C10ORF39;; JAMIP3__:__
Asterisk__:__611199__:__DNTT-INTERACTING PROTEIN 2; DNTTIP2__:__ESTROGEN RECEPTOR-BINDING PROTEIN; ERBP;; FCF2, S. CEREVISIAE, HOMOLOG OF; FCF2__:__
Asterisk__:__611200__:__TUDOR DOMAIN-CONTAINING PROTEIN 6; TDRD6__:____:__
Asterisk__:__611201__:__KELCH-LIKE 9; KLHL9__:__KIAA1354__:__
Asterisk__:__611202__:__N-ACYLSPHINGOSINE AMIDOHYDROLASE 2; ASAH2__:__CERAMIDASE, NONLYSOSOMAL;; NONLYSOSOMAL CERAMIDASE__:__
Asterisk__:__611203__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 5; DNAJC5__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 5, ALPHA; DNAJC5A;; CYSTEINE STRING PROTEIN; CSP;; CSP-ALPHA__:__
Asterisk__:__611204__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 88C; CCDC88C__:__HOOK-RELATED PROTEIN 2; HKRP2;; DAPLE;; KIAA1509__:__
Asterisk__:__611205__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 88B; CCDC88B__:__HOOK-RELATED PROTEIN 3; HKRP3;; GPR78-INTERACTING PROTEIN INDUCED BY ENDOPLASMIC RETICULUM STRESS; GIPIE__:__
Asterisk__:__611206__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 9; DNAJC9__:__J DOMAIN OF DNAJ-LIKE PROTEIN 1; JDD1;; KIAA0974__:__
Asterisk__:__611207__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 1; DNAJC1__:__HTJ1__:__
Asterisk__:__611208__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L-LIKE; HNRNPLL__:__HNRPLL;; STROMAL RNA-REGULATING FACTOR; SRRF__:__
Number Sign__:__611209__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G__:__CDG IIg; CDGIIg;; CDGII/COG1 CEREBROCOSTOMANDIBULAR-LIKE SYNDROME__:__
Asterisk__:__611210__:__PDZ-BINDING KINASE; PBK__:__LYMPHOKINE-ACTIVATED KILLER T CELL-ORIGINATED PROTEIN KINASE; TOPK__:__
Asterisk__:__611211__:__RECEPTOR EXPRESSED IN LYMPHOID TISSUES; RELT__:__TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 19-LIKE; TNFRSF19L__:__
Asterisk__:__611212__:__RELT-LIKE 1; RELL1__:____:__
Asterisk__:__611213__:__RELT-LIKE 2; RELL2__:____:__
Asterisk__:__611214__:__TSR1, 20S rRNA ACCUMULATION, S. CEREVISIAE, HOMOLOG OF; TSR1__:__KIAA1401__:__
Asterisk__:__611215__:__PRADER-WILLI REGION NONCODING RNA 1; PWRN1__:____:__
Asterisk__:__611216__:__UBX DOMAIN PROTEIN 4; UBXN4__:__UBX DOMAIN-CONTAINING PROTEIN 2; UBXD2;; KIAA2042;; ERASIN__:__
Asterisk__:__611217__:__PRADER-WILLI REGION NONCODING RNA 2; PWRN2__:____:__
Asterisk__:__611218__:__GASDERMIN A; GSDMA__:__GASDERMIN 1; GSDM1;; GSDM__:__
Asterisk__:__611219__:__UNC45, C. ELEGANS, HOMOLOG OF, A; UNC45A__:__SMOOTH MUSCLE CELL-ASSOCIATED PROTEIN 1; SMAP1;; GCUNC45__:__
Asterisk__:__611220__:__UNC45, C. ELEGANS, HOMOLOG OF, B; UNC45B__:__SMUNC45__:__
Asterisk__:__611221__:__GASDERMIN B; GSDMB__:__GASDERMIN-LIKE; GSDML__:__
Percent__:__611222__:__MICROPHTHALMIA, SYNDROMIC 10; MCOPS10__:__MICROPHTHALMIA AND BRAIN ATROPHY; MOBA__:__
Asterisk__:__611223__:__V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3; AKT3__:__PROTEIN KINASE B, GAMMA; PKBG;; PKB-GAMMA__:__MAGI3/AKT3 FUSION GENE, INCLUDED
Asterisk__:__611224__:__SUCCINATE-CoA LIGASE, ALPHA SUBUNIT; SUCLG1__:__SUCCINATE-CoA LIGASE, GDP-FORMING, ALPHA SUBUNIT;; SUCCINATE-CoA LIGASE, ADP-FORMING, ALPHA SUBUNIT; SUCLA1;; G-ALPHA__:__
Number Sign__:__611225__:__SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE; SPG18__:__INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES; IDMDC__:__
Asterisk__:__611226__:__ARMADILLO REPEAT-CONTAINING PROTEIN 3; ARMC3__:__KU-CT-1__:__
Asterisk__:__611227__:__HYDROGEN VOLTAGE-GATED CHANNEL 1; HVCN1__:__HV1;; VOLTAGE SENSOR DOMAIN-ONLY PROTEIN; VSOP__:__
Number Sign__:__611228__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J__:__CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4J__:__
Asterisk__:__611229__:__ENDOPLASMIC RETICULUM LECTIN 1; ERLEC1__:__ERLECTIN;; CHROMOSOME 2 OPEN READING FRAME 30; C2ORF30__:__
Asterisk__:__611230__:__NON-SMC CONDENSIN II COMPLEX SUBUNIT H2; NCAPH2__:__CONDENSIN II COMPLEX, NON-SMC SUBUNIT H2;; CHROMOSOME-ASSOCIATED PROTEIN H2; CAPH2;; KLEISIN, BETA__:__
Asterisk__:__611231__:__CLAUDIN 8; CLDN8__:____:__
Asterisk__:__611232__:__CLAUDIN 12; CLDN12__:____:__
Asterisk__:__611233__:__ARGININE-RICH PROTEIN MUTATED IN EARLY STAGE TUMORS-LIKE 1; ARMETL1__:__CONSERVED DOPAMINE NEUROTROPHIC FACTOR; CDNF__:__
Asterisk__:__611234__:__FAMILY WITH SEQUENCE SIMILARITY 84, MEMBER A; FAM84A__:__NEUROLOGIC/SENSORY 1; NSE1__:__
Asterisk__:__611235__:__TRANSMEMBRANE PROTEIN 38A; TMEM38A__:__TRIMERIC INTRACELLULAR CATION CHANNEL TYPE A; TRICA;; MITSUGUMIN 33__:__
Asterisk__:__611236__:__TRANSMEMBRANE PROTEIN 38B; TMEM38B__:__TRIMERIC INTRACELLULAR CATION CHANNEL TYPE B; TRICB__:__
Asterisk__:__611237__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 9; BTBD9__:__KIAA1880__:__
Asterisk__:__611238__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 7; CHCHD7__:____:__CHCHD7/PLAG1 FUSION GENE, INCLUDED
Asterisk__:__611239__:__G PROTEIN-REGULATED INDUCER OF NEURITE OUTGROWTH 1; GPRIN1__:__GRIN1;; KIAA1893__:__
Asterisk__:__611240__:__G PROTEIN-REGULATED INDUCER OF NEURITE OUTGROWTH 2; GPRIN2__:__GRIN2;; KIAA0514__:__
Asterisk__:__611241__:__G PROTEIN-REGULATED INDUCER OF NEURITE OUTGROWTH 3; GPRIN3__:__GRIN3__:__
Percent__:__611242__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 5; RLS5__:____:__
Asterisk__:__611243__:__tRNA-WYBUTOSINE-SYNTHESIZING PROTEIN 1, S. CEREVISIAE, HOMOLOG OF; TYW1__:__tRNA-YW-SYNTHESIZING PROTEIN 1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__611244__:__tRNA METHYLTRANSFERASE 12, S. CEREVISIAE, HOMOLOG OF; TRMT12__:__TRM12;; tRNA-WYBUTOSINE-SYNTHESIZING PROTEIN 2, S. CEREVISIAE, HOMOLOG OF; TYW2;; tRNA-YW-SYNTHESIZING PROTEIN 2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__611245__:__tRNA-WYBUTOSINE-SYNTHESIZING PROTEIN 3, S. CEREVISIAE, HOMOLOG OF; TYW3__:__tRNA-YW-SYNTHESIZING PROTEIN 3, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__611246__:__LEUCINE CARBOXYL METHYLTRANSFERASE 2; LCMT2__:__tRNA-WYBUTOSINE-SYNTHESIZING PROTEIN 4, S. CEREVISIAE, HOMOLOG OF; TYW4;; tRNA-YW-SYNTHESIZING PROTEIN 4, S. CEREVISIAE, HOMOLOG OF;; KIAA0547__:__
Percent__:__611247__:__MAJOR AFFECTIVE DISORDER 4; MAFD4__:__BIPOLAR AFFECTIVE DISORDER; BPAD__:__
Asterisk__:__611248__:__KELCH DOMAIN-CONTAINING PROTEIN 3; KLHDC3__:__PEAS__:__
Asterisk__:__611249__:__MICRO RNA LET7B; MIRLET7B__:__LET7, C. ELEGANS, HOMOLOG OF, B; LET7B;; miRNA LET7B;; MIRNLET7B__:__
Asterisk__:__611250__:__MICRO RNA LET7E; MIRLET7E__:__LET7, C. ELEGANS, HOMOLOG OF, E; LET7E;; miRNA LET7E;; MIRNLET7E__:__
Asterisk__:__611251__:__PATCHED DOMAIN-CONTAINING PROTEIN 2; PTCHD2__:__DISPATCHED, DROSOPHILA, HOMOLOG OF, 3; DISP3;; KIAA1337__:__
Percent__:__611252__:__SPASTIC PARAPLEGIA 32, AUTOSOMAL RECESSIVE; SPG32__:____:__
Asterisk__:__611253__:__KINESIN FAMILY MEMBER 27; KIF27__:____:__
Asterisk__:__611254__:__KINESIN FAMILY MEMBER 7; KIF7__:____:__
Asterisk__:__611255__:__NADPH OXIDASE ACTIVATOR 1; NOXA1__:__NOX ACTIVATOR 1;; p51-NOX__:__
Asterisk__:__611256__:__NADPH OXIDASE ORGANIZER 1; NOXO1__:__p41-NOX__:__
Asterisk__:__611257__:__TRANSMEMBRANE PROTEIN 132D; TMEM132D__:__KIAA1944;; MATURE OLIGODENDROCYTE TRANSMEMBRANE PROTEIN; MOLT__:__
Asterisk__:__611258__:__TUDOR DOMAIN-CONTAINING PROTEIN 7; TDRD7__:__KIAA1529;; PCTAIRE2-BINDING PROTEIN;; TUDOR REPEAT ASSOCIATOR WITH PCTAIRE2; TRAP__:__
Asterisk__:__611259__:__CDK5 REGULATORY SUBUNIT-ASSOCIATED PROTEIN 1-LIKE 1; CDKAL1__:____:__
Asterisk__:__611260__:__THREONINE SYNTHASE-LIKE 1; THNSL1__:__TSH1__:__
Asterisk__:__611261__:__THREONINE SYNTHASE-LIKE 2; THNSL2__:__THS2__:__
Asterisk__:__611262__:__DEOXYHYPUSINE HYDROXYLASE; DOHH__:__DEOXYHYPUSINE MONOOXYGENASE;; DEOXYHYPUSINE DIOXYGENASE;; HEAT-LIKE REPEAT-CONTAINING PROTEIN 1; HLRC1__:__
Number Sign__:__611263__:__SHORT-RIB THORACIC DYSPLASIA 2 WITH OR WITHOUT POLYDACTYLY; SRTD2__:__ASPHYXIATING THORACIC DYSTROPHY 2; ATD2__:__
Asterisk__:__611264__:__CENTROMERIC PROTEIN W; CENPW__:__CHROMOSOME 6 OPEN READING FRAME 173; C6ORF173;; CANCER-UPREGULATED GENE 2; CUG2__:__
Asterisk__:__611265__:__PEROXISOMAL PROLIFERATOR-ACTIVATED RECEPTOR ALPHA-INTERACTING COFACTOR COMPLEX, 285-KD SUBUNIT__:__KIAA1769;; PRIC COMPLEX, 285-KD SUBUNIT; PRIC285;; PPAR-GAMMA DNA-BINDING DOMAIN-INTERACTING PROTEIN 1; PDIP1;; PDIP1-ALPHA;; PDIP1-BETA__:__
Asterisk__:__611266__:__POTE ANKYRIN DOMAIN FAMILY, MEMBER K, PSEUDOGENE; POTEKP__:__ACTIN, KAPPA ACTIN-LIKE PROTEIN;; FKSG30__:__
Asterisk__:__611267__:__OLFACTORY RECEPTOR, FAMILY 51, SUBFAMILY E, MEMBER 1; OR51E1__:__DGPCR;; PROSTATE-SPECIFIC G PROTEIN-COUPLED RECEPTOR 2; PSGR2__:__
Asterisk__:__611268__:__OLFACTORY RECEPTOR, FAMILY 51, SUBFAMILY E, MEMBER 2; OR51E2__:__PROSTATE-SPECIFIC G PROTEIN-COUPLED RECEPTOR; PSGR__:__
Asterisk__:__611269__:__NUCLEOLAR PROTEIN WITH MIF4G DOMAIN 1; NOM1__:__CHROMOSOME 7 OPEN READING FRAME 3; C7ORF3__:__
Asterisk__:__611270__:__N-ETHYLMALEIMIDE-SENSITIVE FACTOR ATTACHMENT PROTEIN, BETA; NAPB__:__SOLUBLE NSF-ATTACHMENT PROTEIN, BETA; SNAPB;; SNAP, BETA__:__
Asterisk__:__611271__:__KINESIN FAMILY MEMBER 18A; KIF18A__:__MARROW STROMAL KIF18A; MS-KIF18A__:__
Asterisk__:__611272__:__ZINC FINGER PROTEIN WITH KRAB AND SCAN DOMAINS 5; ZKSCAN5__:__ZINC FINGER PROTEIN 95; ZFP95;; KIAA1015__:__
Asterisk__:__611273__:__LBX1 COREPRESSOR 1, MOUSE, HOMOLOG OF; LBXCOR1__:__CORL1__:__
Percent__:__611274__:__GLAUCOMA 1, OPEN ANGLE, N; GLC1N__:____:__
Asterisk__:__611275__:__BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 2-LIKE; BNIPL__:__BNIP2-SIMILAR; BNIPS;; BNIPL1;; BNIPL2__:__
Percent__:__611276__:__GLAUCOMA 1, OPEN ANGLE, H; GLC1H__:____:__
Number Sign__:__611277__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 3; GEFSP3__:__GEFS+, TYPE 3; GEFS+3__:__FEBRILE SEIZURES, FAMILIAL, 8, INCLUDED; FEB8, INCLUDED
Asterisk__:__611278__:__KINESIN FAMILY MEMBER 12; KIF12__:____:__
Asterisk__:__611279__:__KINESIN FAMILY MEMBER 14; KIF14__:__KIAA0042__:__
Asterisk__:__611280__:__KELCH DOMAIN-CONTAINING PROTEIN 2; KLHDC2__:__HOST CELL FACTOR-LIKE PROTEIN 1; HCLP1__:__
Asterisk__:__611281__:__KELCH DOMAIN-CONTAINING PROTEIN 1; KLHDC1__:____:__
Asterisk__:__611282__:__DYNAMIN-BINDING PROTEIN; DNMBP__:__TUBA;; KIAA1010__:__
Number Sign__:__611283__:__ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY__:__IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY__:__
Percent__:__611284__:__DYSTONIA, FOCAL, TASK-SPECIFIC; FTSD__:____:__MUSICIAN'S DYSTONIA, INCLUDED
Asterisk__:__611285__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 5; KCTD5__:____:__
Asterisk__:__611286__:__RNA TERMINAL PHOSPHATE CYCLASE DOMAIN-CONTAINING PROTEIN 1; RTCD1__:__RTC DOMAIN-CONTAINING PROTEIN 1;; RNA 3-PRIME-TERMINAL PHOSPHATE CYCLASE: RPC__:__
Asterisk__:__611287__:__CORNICHON, DROSOPHILA, HOMOLOG OF, 1; CNIH1__:__CNIH;; T-CELL GROWTH-ASSOCIATED MOLECULE 77; TGAM77__:__
Asterisk__:__611288__:__CORNICHON, DROSOPHILA, HOMOLOG OF, 2; CNIH2__:__CNI-LIKE; CNIL__:__
Asterisk__:__611289__:__LEUCINE-RICH ALPHA-2-GLYCOPROTEIN 1; LRG1__:__LRG__:__
Asterisk__:__611290__:__NONHOMOLOGOUS END-JOINING FACTOR 1; NHEJ1__:__XRCC4-LIKE FACTOR; XLF;; CERNUNNOS;; NEJ1, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__611291__:__SEVERE COMBINED IMMUNODEFICIENCY WITH MICROCEPHALY, GROWTH RETARDATION, AND SENSITIVITY TO IONIZING RADIATION__:__SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE, WITH MICROCEPHALY, GROWTH RETARDATION, AND SENSITIVITY TO IONIZING RADIATION;; NHEJ1 SYNDROME__:__SEVERE COMBINED IMMUNODEFICIENCY WITH SENSITIVITY TO IONIZING RADIATION DUE TO NHEJ1 DEFICIENCY, INCLUDED;; SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-POSITIVE, AND SENSITIVITY TO IONIZING RADIATION DUE TO NHEJ1 DEFICIENCY, INCLUDED
Asterisk__:__611292__:__CLAVESIN 1; CLVS1__:__CLATHRIN VESICLE-ASSOCIATED SEC14 PROTEIN 1;; RETINALDEHYDE-BINDING PROTEIN 1-LIKE 1; RLBP1L1;; CELLULAR RETINALDEHYDE-BINDING PROTEIN-LIKE; CRALBPL__:__
Asterisk__:__611293__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 86; CCDC86__:__CYTOKINE-INDUCED PROTEIN WITH COILED-COIL DOMAIN; CYCLON__:__
Asterisk__:__611294__:__ONE CUT HOMEOBOX 3; ONECUT3__:__ONE CUT DOMAIN, FAMILY MEMBER 3; OC3__:__
Asterisk__:__611295__:__KELCH-LIKE 24; KLHL24__:__KAINATE RECEPTOR-INTERACTING PROTEIN FOR GLUR6; KRIP6__:__
Asterisk__:__611296__:__ANNEXIN A2 RECEPTOR; ANXA2R__:__CHROMOSOME 5 OPEN READING FRAME 39; C5ORF39;; ANNEXIN II RECEPTOR;; AXIIR__:__
Asterisk__:__611297__:__ODD-SKIPPED-RELATED 2; OSR2__:____:__
Asterisk__:__611298__:__KIAA1324__:__ESTROGEN-INDUCED GENE 121; EIG121__:__
Asterisk__:__611299__:__G2/M PHASE-SPECIFIC E3 UBIQUITIN LIGASE; G2E3__:__KIAA1333__:__
Asterisk__:__611300__:__La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 6; LARP6__:__ACHERON; ACHN__:__
Asterisk__:__611301__:__CHROMOSOME 17 OPEN READING FRAME 70; C17ORF70__:__FANCONI ANEMIA-ASSOCIATED PROTEIN, 100-KD SUBUNIT; FAAP100__:__
Number Sign__:__611302__:__SPASTIC ATAXIA 2, AUTOSOMAL RECESSIVE; SPAX2__:____:__
Asterisk__:__611303__:__C-TYPE LECTIN DOMAIN FAMILY 16, MEMBER A; CLEC16A__:__KIAA0350__:__
Asterisk__:__611304__:__TRANSMEMBRANE PROTEIN 159; TMEM159__:__PROMETHIN__:__
Asterisk__:__611305__:__ACTIN-BINDING LIM PROTEIN FAMILY, MEMBER 3; ABLIM3__:__KIAA0843__:__
Asterisk__:__611306__:__SCAVENGER RECEPTOR CLASS A, MEMBER 5; SCARA5__:____:__
Number Sign__:__611307__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L__:__
Percent__:__611308__:__PERSISTENT HYPERPLASTIC PRIMARY VITREOUS, AUTOSOMAL DOMINANT; PHPVAD__:____:__
Asterisk__:__611309__:__CHROMOSOME 10 OPEN READING FRAME 10; C10ORF10__:__DECIDUAL PROTEIN INDUCED BY PROGESTERONE; DEPP;; FASTING-INDUCED GENE; FIG__:__
Asterisk__:__611310__:__PHOSPHOSERYL-tRNA KINASE; PSTK__:__CHROMOSOME 10 OPEN READING FRAME; C10ORF89__:__
Caret__:__611311__:__MOVED TO 221900__:____:__
Asterisk__:__611312__:__CORNULIN; CRNN__:__CHROMOSOME 1 OPEN READING FRAME 10; C1ORF10;; PDRC1__:__
Asterisk__:__611313__:__ARMS2 GENE; ARMS2__:__LOC387715__:__
Asterisk__:__611314__:__HIGH MOBILITY GROUP NUCLEOSOMAL BINDING PROTEIN 2 PSEUDOGENE 46; HMGN2P46__:__HMGN2 PSEUDOGENE 46;; CHROMOSOME 15 OPEN READING FRAME 21; C15ORF21;; DPCA2__:__
Asterisk__:__611315__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 20; ZSCAN20__:__ZINC FINGER PROTEIN 31; ZNF31;; KOX29__:__
Asterisk__:__611316__:__SOLUTE CARRIER FAMILY 12 (SODIUM/POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 8; SLC12A8__:____:__
Asterisk__:__611317__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 5; PIK3R5__:__p101__:__
Asterisk__:__611318__:__MEDIATOR COMPLEX SUBUNIT 12-LIKE; MED12L__:__NO OPPOSITE-PAIRED REPEAT; NOPAR;; KIAA1635__:__
Asterisk__:__611319__:__INTERFERON-ALPHA-INDUCIBLE PROTEIN 27-LIKE 2; IFI27L2__:__INTERFERON-STIMULATED GENE 12B; ISG12B;; FAMILY WITH SEQUENCE SIMILARITY 14, MEMBER A; FAM14A__:__
Asterisk__:__611320__:__FAMILY WITH SEQUENCE SIMILARITY 14, MEMBER B; FAM14B__:__INTERFERON-STIMULATED GENE 12C; ISG12C__:__
Asterisk__:__611321__:__CALSYNTENIN 1; CLSTN1__:__ALCADEIN, ALPHA;; ALC-ALPHA;; KIAA0911__:__
Asterisk__:__611322__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY A, MEMBER 2; DNAJA2__:__DJ3;; CELL CYCLE PROGRESSION RESTORATION 3; CPR3__:__
Asterisk__:__611323__:__CALSYNTENIN 2; CLSTN2__:__ALCADEIN, GAMMA;; ALC-GAMMA__:__
Asterisk__:__611324__:__CALSYNTENIN 3; CLSTN3__:__ALCADEIN, BETA;; ALC-BETA;; KIAA0726__:__
Asterisk__:__611325__:__TRANSFORMING GROWTH FACTOR-BETA REGULATOR 4; TBRG4__:__FAST KINASE DOMAIN-CONTAINING PROTEIN 4; FASTKD4;; KIAA0948;; CELL CYCLE PROGRESSION RESTORATION 2; CPR2__:__
Asterisk__:__611326__:__CELL CYCLE PROGRESSION 1; CCPG1__:__KIAA1254;; CELL CYCLE PROGRESSION RESTORATION 8; CPR8__:__
Asterisk__:__611327__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 4; DNAJB4__:__HUMAN LIVER DNAJ-LIKE; HLJ1__:__
Asterisk__:__611328__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 5; DNAJB5__:__KIAA1045;; HEAT SHOCK COGNATE 40; HSC40__:__
Asterisk__:__611329__:__SMALL CAJAL BODY-SPECIFIC RNA 18; SCARNA18__:__snoRNA, U109__:__
Asterisk__:__611330__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 12; SNORA12__:__snoRNA, U108__:__
Asterisk__:__611331__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 74B; SNORA74B__:__snoRNA, U19-2__:__
Asterisk__:__611332__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 6; DNAJB6__:__MRJ;; DJ4__:__
Asterisk__:__611333__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 3B; SNORA3B__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 45; SNORA45;; snoRNA, ACA3-2__:__
Asterisk__:__611334__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 81; SNORA81__:__snoRNA, HBI-61__:__
Asterisk__:__611335__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 5C; SNORA5C__:__snoRNA, HBI-80__:__
Asterisk__:__611336__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 7; DNAJB7__:__DJ5;; HSC3__:__
Asterisk__:__611337__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 8; DNAJB8__:__DJ6__:__
Asterisk__:__611338__:__AUTOPHAGY 4, S. CEREVISIAE, HOMOLOG OF, B; ATG4B__:__APG4, S. CEREVISIAE, HOMOLOG OF, B; APG4B;; AUTOPHAGIN 1;; AUTL1;; KIAA0943__:__
Asterisk__:__611339__:__AUTOPHAGY 4, S. CEREVISIAE, HOMOLOG OF, C; ATG4C__:__APG4, S. CEREVISIAE, HOMOLOG OF, C; APG4C;; AUTOPHAGIN 3;; AUTL3__:__
Asterisk__:__611340__:__AUTOPHAGY 4, S. CEREVISIAE, HOMOLOG OF, D; ATG4D__:__APG4, S. CEREVISIAE, HOMOLOG OF, D; APG4D;; AUTOPHAGIN 4;; AUTL4__:__
Asterisk__:__611341__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 11; DNAJB11__:__HUMAN ENDOPLASMIC RETICULUM-ASSOCIATED DNAJ; HEDJ;; DJ9;; APOBEC1-BINDING PROTEIN 2; ABBP2__:__
Asterisk__:__611342__:__CHROMOSOME 9 OPEN READING FRAME 64; C9ORF64__:____:__
Asterisk__:__611343__:__CHROMOSOME 9 OPEN READING FRAME 103; C9ORF103__:____:__
Asterisk__:__611344__:__RAS AND EF-HAND DOMAINS-CONTAINING PROTEIN; RASEF__:____:__
Asterisk__:__611345__:__INTEGRATOR COMPLEX SUBUNIT 1; INTS1__:__INT1;; KIAA1440__:__
Asterisk__:__611346__:__INTEGRATOR COMPLEX SUBUNIT 2; INTS2__:__INT2;; KIAA1287__:__
Asterisk__:__611347__:__INTEGRATOR COMPLEX SUBUNIT 3; INTS3__:__INT3;; SENSOR OF SINGLE-STRANDED DNA COMPLEX, SUBUNIT A; SOSSA;; SOSS COMPLEX, SUBUNIT A__:__
Asterisk__:__611348__:__INTEGRATOR COMPLEX SUBUNIT 4; INTS4__:__INT4__:__
Asterisk__:__611349__:__INTEGRATOR COMPLEX SUBUNIT 5; INTS5__:__INT5;; KIAA1698__:__
Asterisk__:__611350__:__INTEGRATOR COMPLEX SUBUNIT 7; INTS7__:__INT7__:__
Asterisk__:__611351__:__INTEGRATOR COMPLEX SUBUNIT 8; INTS8__:__INT8__:__
Asterisk__:__611352__:__INTEGRATOR COMPLEX SUBUNIT 9; INTS9__:__INT9;; RELATED TO CPSF SUBUNITS, 74-KD PROTEIN; RC74__:__
Asterisk__:__611353__:__INTEGRATOR COMPLEX SUBUNIT 10; INTS10__:__INT10__:__
Asterisk__:__611354__:__CLEAVAGE AND POLYADENYLATION-SPECIFIC FACTOR 3-LIKE; CPSF3L__:__INTEGRATOR COMPLEX SUBUNIT 11; INTS11;; RELATED TO CPSF SUBUNITS, 68-KD PROTEIN; RC68__:__
Asterisk__:__611355__:__INTEGRATOR COMPLEX SUBUNIT 12; INTS12__:__INT12__:__
Asterisk__:__611356__:__G KINASE-ANCHORING PROTEIN 1; GKAP1__:__cGMP-DEPENDENT PROTEIN KINASE-ANCHORING PROTEIN, 42-KD; GKAP42__:__
Asterisk__:__611357__:__TERMINAL NUCLEOTIDYLTRANSFERASE 5A; TENT5A__:__FAMILY WITH SEQUENCE SIMILARITY 46, MEMBER A; FAM46A;; CHROMOSOME 6 OPEN READING FRAME 37; C6ORF37__:__
Asterisk__:__611358__:__RING FINGER PROTEIN 135; RNF135__:__RIPLET__:__
Asterisk__:__611359__:__ACTIVATING MOLECULE IN BECLIN 1-REGULATED AUTOPHAGY; AMBRA1__:__DDB1- AND CUL4-ASSOCIATED FACTOR 3; DCAF3;; KIAA1736__:__
Asterisk__:__611360__:__FANCI GENE; FANCI__:__KIAA1794__:__
Asterisk__:__611361__:__UBIQUITIN-ACTIVATING ENZYME E1-LIKE 2; UBE1L2__:__UBIQUITIN-ACTIVATING ENZYME 6; UBA6__:__
Asterisk__:__611362__:__UBIQUITIN-CONJUGATING ENZYME E2Z; UBE2Z__:__UBA6-SPECIFIC E2; USE1__:__
Number Sign__:__611363__:__ATRIAL SEPTAL DEFECT 4; ASD4__:____:__
Percent__:__611364__:__MYOCLONIC EPILEPSY, JUVENILE, SUSCEPTIBILITY TO, 4; EJM4__:____:__
Asterisk__:__611365__:__TRANSMEMBRANE PROTEIN 183B; TMEM183B__:__C1ORF37DUP__:__
Asterisk__:__611366__:__CHROMOSOME 12 OPEN READING FRAME 10; C12ORF10__:__MELANOCYTE PROLIFERATING GENE 1, MOUSE, HOMOLOG OF; MYG1__:__
Asterisk__:__611367__:__ASPARTYL AMINOPEPTIDASE; DNPEP__:__ASPEP; DAP__:__
Asterisk__:__611368__:__MAELSTROM, DROSOPHILA, HOMOLOG OF; MAEL__:____:__
Number Sign__:__611369__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 3; LCCS3__:__MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE B__:__
Asterisk__:__611370__:__FGGY CARBOHYDRATE KINASE DOMAIN-CONTAINING PROTEIN; FGGY__:__FLJ10986__:__
Asterisk__:__611371__:__ZINC FINGER PROTEIN 653; ZNF653__:__ZIP67__:__
Asterisk__:__611372__:__SMALL ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN 1; SMAP1__:__SMALL ARFGAP 1;; STROMAL MEMBRANE-ASSOCIATED PROTEIN 1__:__
Asterisk__:__611373__:__LIVER-EXPRESSED ANTIMICROBIAL PEPTIDE 2; LEAP2__:____:__
Asterisk__:__611374__:__MICRO RNA 34B; MIR34B__:__miRNA34B;; MIRN34B__:__
Asterisk__:__611375__:__MICRO RNA 34C; MIR34C__:__miRNA34C;; MIRN34C__:__
Number Sign__:__611376__:__MUNGAN SYNDROME; MGS__:__VISCERAL NEUROMYOPATHY, FAMILIAL, WITH PSEUDOOBSTRUCTION, MEGADUODENUM, BARRETT ESOPHAGUS, AND CARDIAC ABNORMALITIES;; PSEUDOOBSTRUCTION, CHRONIC IDIOPATHIC INTESTINAL, WITH BARRETT ESOPHAGUS AND CARDIAC ABNORMALITIES__:__
Number Sign__:__611377__:__BRACHYDACTYLY, TYPE B2; BDB2__:____:__
Number Sign__:__611378__:__MACULAR DEGENERATION, AGE-RELATED, 9; ARMD9__:____:__
Asterisk__:__611379__:__DISCO-INTERACTING PROTEIN 2, DROSOPHILA, HOMOLOG OF, B; DIP2B__:__KIAA1463__:__
Asterisk__:__611380__:__DISCO-INTERACTING PROTEIN 2, DROSOPHILA, HOMOLOG OF, C; DIP2C__:__KIAA0934__:__
Percent__:__611381__:__KALA-AZAR, SUSCEPTIBILITY TO, 2; KAZA2__:__LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 2__:__
Percent__:__611382__:__KALA-AZAR, SUSCEPTIBILITY TO, 3; KAZA3__:__LEISHMANIASIS, VISCERAL, SUSCEPTIBILITY TO, 3__:__
Number Sign__:__611383__:__USHER SYNDROME, TYPE IID; USH2D__:____:__
Percent__:__611384__:__PLASMODIUM FALCIPARUM FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1__:__PFFE1;; MALARIA FEVER EPISODES QUANTITATIVE TRAIT LOCUS 1__:__
Caret__:__611385__:__MOVED TO 176846__:____:__
Asterisk__:__611386__:__ACTIVITY-DEPENDENT NEUROPROTECTOR HOMEOBOX; ADNP__:__ADNP1;; KIAA0784__:__
Asterisk__:__611387__:__CXC CHEMOKINE LIGAND 17; CXCL17__:__VEGF COREGULATED CHEMOKINE 1; VCC1;; DENDRITIC CELL AND MONOCYTE CHEMOKINE-LIKE PROTEIN; DMC__:__
Asterisk__:__611388__:__DEOXYNUCLEOTIDYLTRANSFERASE, TERMINAL, INTERACTING PROTEIN 1; DNTTIP1__:__TDT-INTERACTING FACTOR; TDIF1;; CHROMOSOME 20 OPEN READING FRAME 167; C20ORF167__:__
Asterisk__:__611389__:__PRICKLE, DROSOPHILA, HOMOLOG OF, 4; PRICKLE4__:__PRICKLE-LIKE 4;; CHROMOSOME 6, OPEN READING FRAME 49; C6ORF49;; OVEREXPRESSED BREAST TUMOR PROTEIN; OEBT; OBTP__:__
Number Sign__:__611390__:__SPASTIC ATAXIA 3, AUTOSOMAL RECESSIVE; SPAX3__:__AUTOSOMAL RECESSIVE SPASTIC ATAXIA WITH LEUKOENCEPHALOPATHY; ARSAL__:__
Number Sign__:__611391__:__CATARACT 33, MULTIPLE TYPES; CTRCT33__:____:__
Asterisk__:__611392__:__2-AMINOETHANETHIOL DIOXYGENASE; ADO__:__CHROMOSOME 10 OPEN READING FRAME 22; C10ORF22;; CYSTEAMINE DIOXYGENASE__:__
Asterisk__:__611393__:__FAMILY WITH SEQUENCE SIMILARITY 110, MEMBER A; FAM110A__:__CHROMOSOME 20 OPEN READING FRAME 55; C20ORF55__:__
Asterisk__:__611394__:__FAMILY WITH SEQUENCE SIMILARITY 110, MEMBER B; FAM110B__:__CHROMOSOME 8 OPEN READING FRAME 72; C8ORF72__:__
Asterisk__:__611395__:__FAMILY WITH SEQUENCE SIMILARITY 110, MEMBER C; FAM110C__:____:__
Asterisk__:__611396__:__ADIPOGENIN; ADIG__:__SMALL ADIPOCYTE FACTOR 1; SMAF1__:__
Asterisk__:__611397__:__TETRATRICOPEPTIDE REPEAT-, ANKYRIN REPEAT-, AND COILED-COIL-CONTAINING PROTEIN 1; TANC1__:__TPR DOMAIN-, ANKYRIN REPEAT-, AND COILED-COIL-CONTAINING PROTEIN; TANC;; KIAA1728__:__
Asterisk__:__611398__:__GROWTH ARREST-SPECIFIC 2-LIKE 2; GAS2L2__:__GAS2-RELATED PROTEIN;; GAS2-RELATED ON CHROMOSOME 17; GAR17__:__
Asterisk__:__611399__:__SODIUM CHANNEL AND CLATHRIN LINKER 1; SCLT1__:__CLATHRIN-ASSOCIATED PROTEIN 1A; CAP1A__:__
Asterisk__:__611400__:__HOX TRANSCRIPT ANTISENSE RNA, NONCODING; HOTAIR__:__HOX ANTISENSE INTERGENIC RNA;; LONG INTERGENIC NONCODING RNA HOTAIR;; lincRNA HOTAIR__:__
Asterisk__:__611401__:__CHROMOSOME 6 OPEN READING FRAME 15; C6ORF15__:__SIMIAN TASTE BUD-SPECIFIC GENE; STG__:__
Asterisk__:__611402__:__DOCKING PROTEIN 6; DOK6__:____:__
Percent__:__611403__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 6__:__ASRT6__:__
Asterisk__:__611404__:__CHROMOSOME 6 OPEN READING FRAME 21; C6ORF21__:__G6F PROTEIN__:__
Asterisk__:__611405__:__RNA TERMINAL PHOSPHATE CYCLASE-LIKE 1; RCL1__:__RPCL1;; RNAC__:__
Asterisk__:__611406__:__DYNEIN, CYTOPLASMIC 1, LIGHT INTERMEDIATE CHAIN 2; DYNC1LI2__:__LIC2__:__
Number Sign__:__611407__:__CARDIOMYOPATHY, DILATED, 1W; CMD1W__:____:__
Asterisk__:__611408__:__LCA5 GENE; LCA5__:__LEBERCILIN;; CHROMOSOME 6 OPEN READING FRAME 152; C6ORF152__:__
Asterisk__:__611409__:__OCA2 MELANOSOMAL TRANSMEMBRANE PROTEIN; OCA2__:__OCA2 GENE;; PINK-EYED DILUTION; PED;; P GENE__:__
Asterisk__:__611410__:__FAMILY WITH SEQUENCE SIMILARITY 65, MEMBER B; FAM65B__:__CHROMOSOME 6 OPEN READING FRAME 32; C6ORF32;; KIAA0386;; PL48__:__
Asterisk__:__611411__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1, ALPHA; CAMKK1__:__CAMKK-ALPHA; CAMKKA__:__
Asterisk__:__611412__:__N-ACETYLNEURAMINATE PYRUVATE LYASE; NPL__:__CHROMOSOME 1 OPEN READING FRAME 13; C1ORF13;; DIHYDRODIPICOLINATE SYNTHASE;; C112__:__
Asterisk__:__611413__:__DISCS LARGE-ASSOCIATED PROTEIN 3; DLGAP3__:__SAP90/PSD95-ASSOCIATED PROTEIN 3; SAPAP3__:__
Asterisk__:__611414__:__CALRETICULIN 3; CALR3__:__CALRETICULIN 2; CRT2__:__
Asterisk__:__611415__:__POLYMERASE (DNA-DIRECTED), DELTA 3, ACCESSORY SUBUNIT; POLD3__:__KIAA0039;; P66__:__
Asterisk__:__611416__:__TOX HIGH MOBILITY GROUP BOX FAMILY MEMBER 3; TOX3__:__TRINUCLEOTIDE REPEAT-CONTAINING 9; TNRC9;; CAGF9__:__
Asterisk__:__611417__:__SMALL G PROTEIN SIGNALING MODULATOR 1; SGSM1__:__KIAA1941__:__
Asterisk__:__611418__:__SMALL G PROTEIN SIGNALING MODULATOR 2; SGSM2__:__KIAA0397__:__
Asterisk__:__611419__:__CHROMOSOME 6 OPEN READING FRAME 1; C6ORF1__:__LBH__:__
Asterisk__:__611420__:__CDKN1A-INTERACTING ZINC FINGER PROTEIN 1; CIZ1__:__CIP1-INTERACTING ZINC FINGER PROTEIN;; ZINC FINGER PROTEIN 356; ZNF356;; LSFR1;; NP94__:__
Asterisk__:__611421__:__SNF2-RELATED CBP ACTIVATOR PROTEIN; SRCAP__:__SWR1, S. CEREVISIAE, HOMOLOG OF; SWR1;; KIAA0309__:__
Asterisk__:__611422__:__MEIOTIC NUCLEAR DIVISION 1, S. CEREVISIAE, HOMOLOG OF; MND1__:____:__
Asterisk__:__611423__:__CENTROSOMAL PROTEIN, 135-KD; CEP135__:__KIAA0635__:__
Asterisk__:__611424__:__ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 19; ZMYND19__:__MCHR1-INTERACTING ZINC FINGER PROTEIN; MIZIP__:__
Asterisk__:__611425__:__CENTROSOMAL BRCA2-INTERACTING PROTEIN; CNTROB__:__CENTROBIN;; LYST-INTERACTING PROTEIN LIP8; LIP8__:__
NULL__:__611426__:__TENTED EYEBROWS__:____:__
Asterisk__:__611427__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE 1-LIKE, NADP(+)-DEPENDENT; MTHFD1L__:__MITOCHONDRIAL C1-TETRAHYDROFOLATE SYNTHASE; MTC1THFS__:__
Asterisk__:__611428__:__DOWNSTREAM NEIGHBOR OF SON; DONSON__:__CHROMOSOME 21 OPEN READING FRAME 60; C21ORF60;; B17__:__
Asterisk__:__611429__:__CHROMOSOME 3 OPEN READING FRAME 35; C3ORF35__:__AP20 REGION PROTEIN 1; APRG1__:__
Asterisk__:__611430__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 21A; TTC21A__:__STRESS-INDUCIBLE PROTEIN 2; STI2__:__
Number Sign__:__611431__:__LEGIUS SYNDROME__:__NEUROFIBROMATOSIS TYPE 1-LIKE SYNDROME; NFLS__:__
Asterisk__:__611432__:__DEDICATOR OF CYTOKINESIS 8; DOCK8__:____:__
Asterisk__:__611433__:__SERINE/THREONINE/TYROSINE KINASE 1; STYK1__:__NOVEL ONCOGENE WITH KINASE DOMAIN; NOK__:__
Asterisk__:__611434__:__CYTOKINE-DEPENDENT HEMATOPOIETIC CELL LINKER; CLNK__:__MAST CELL IMMUNORECEPTOR SIGNAL TRANSDUCER; MIST__:__
Asterisk__:__611435__:__DOCKING PROTEIN 3; DOK3__:__DOK-LIKE PROTEIN; DOKL__:__
Asterisk__:__611436__:__CARBONIC ANHYDRASE XIII; CA13__:____:__
Asterisk__:__611437__:__DUAL-SPECIFICITY PHOSPHATASE 19; DUSP19__:__SAPK PATHWAY-REGULATING PHOSPHATASE 1; SKRP1;; DUSP17;; LMWDSP3__:__
Asterisk__:__611438__:__TAXILIN, BETA; TXLNB__:____:__
Asterisk__:__611439__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 22; ZBTB22__:__BING1__:__
Asterisk__:__611440__:__WD REPEAT-CONTAINING PROTEIN 46; WDR46__:__BING4__:__
Asterisk__:__611441__:__DOUBLE HOMEOBOX PROTEIN 1; DUX1__:____:__
Asterisk__:__611442__:__DOUBLE HOMEOBOX PROTEIN 2; DUX2__:____:__
Asterisk__:__611443__:__DOUBLE HOMEOBOX PROTEIN 3; DUX3__:____:__
Asterisk__:__611444__:__DOUBLE HOMEOBOX PROTEIN 5; DUX5__:____:__
Asterisk__:__611445__:__DYNAMIN 3; DNM3__:__KIAA0820__:__
Asterisk__:__611446__:__DUAL-SPECIFICITY PHOSPHATASE 18; DUSP18__:__LMWDSP20__:__
Asterisk__:__611447__:__Y BOX-BINDING PROTEIN 2; YBX2__:__MSY2;; CSDA3;; CONTRIN;; DNA-BINDING PROTEIN C; DBPC__:__
Asterisk__:__611448__:__BMS1, RIBOSOME ASSEMBLY PROTEIN, S. CEREVISIAE, HOMOLOG OF; BMS1__:__RIBOSOME BIOGENESIS PROTEIN BMS1;; BMS1-LIKE; BMS1L;; KIAA0187__:__
Asterisk__:__611449__:__EXPORTIN 4; XPO4__:__EXP4;; KIAA1721__:__
Asterisk__:__611450__:__PXK DOMAIN-CONTAINING SERINE/THREONINE KINASE; PXK__:__MODULATOR OF Na,K-ATPase; MONAKA__:__
Number Sign__:__611451__:__DEAFNESS, AUTOSOMAL RECESSIVE 63; DFNB63__:____:__
Caret__:__611452__:__MOVED TO 278150__:____:__
Asterisk__:__611453__:__DYSBINDIN DOMAIN-CONTAINING 2; DBNDD2__:__SCF APOPTOSIS RESPONSE PROTEIN 1;; HSMNP1__:__
Caret__:__611454__:__MOVED TO 105550__:____:__
Asterisk__:__611455__:__KINOCILIN; KNCN__:__KINO;; L5__:__
Percent__:__611456__:__TREMOR, HEREDITARY ESSENTIAL, 3; ETM3__:____:__
Asterisk__:__611457__:__FORKHEAD BOX O6__:__FOXO6__:__
Asterisk__:__611458__:__GALACTOSIDASE, BETA-1; GLB1__:__BETA-GALACTOSIDASE-1__:__ELASTIN-BINDING PROTEIN, INCLUDED; EBP, INCLUDED;; S-GAL, INCLUDED;; ELASTIN RECEPTOR 1, INCLUDED
Asterisk__:__611459__:__SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID COTRANSPORTER FAMILY), MEMBER 7; SLC10A7__:____:__
Asterisk__:__611460__:__TUMOR PROTEIN p63-REGULATED PROTEIN 1-LIKE; TPRG1L__:__TPRG1-LIKE;; FAMILY WITH SEQUENCE SIMILARITY 79, MEMBER A; FAM79A;; MOVER__:__
Asterisk__:__611461__:__SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 17; SLC22A17__:__NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALCIN RECEPTOR; NGALR;; BRAIN-TYPE ORGANIC ION TRANSPORTER; BOCT; BOIT__:__NGALR2, INCLUDED;; NGALR3, INCLUDED
Asterisk__:__611462__:__PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 6; PIK3R6__:__CHROMOSOME 17 OPEN READING FRAME 38; C17ORF38;; PHOSPHOINOSITIDE 3-KINASE-GAMMA ADAPTOR PROTEIN, 87-KD;; p87-PIKAP__:__
Asterisk__:__611463__:__SPERMIDINE/SPERMINE N(1)-ACETYLTRANSFERASE 2; SAT2__:__SSAT2;; THIALYSINE N-EPSILON-ACETYLTRANSFERASE__:__
Asterisk__:__611464__:__MON1, S. CEREVISIAE, HOMOLOG OF, A; MON1A__:__SAND1__:__
Number Sign__:__611465__:__GALLBLADDER DISEASE 4; GBD4__:____:__
Asterisk__:__611466__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY M, MEMBER 1; PLEKHM1__:__ADAPTOR PROTEIN, 162-KD; AP162;; KIAA0356__:__
Asterisk__:__611467__:__GUANYLATE-BINDING PROTEIN 5: GBP5__:__GUANYLATE-BINDING PROTEIN 5, MOUSE, HOMOLOG OF__:__
Asterisk__:__611468__:__BDNF ANTISENSE RNA; BDNFAS__:__BRAIN-DERIVED NEUROTROPHIC FACTOR, OPPOSITE STRAND; BDNFOS;; ANTI-BDNF__:__
Percent__:__611469__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 2; CRCS2__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 8q24__:__
Asterisk__:__611470__:__GLUTAMATE-AMMONIA LIGASE (GLUTAMINE SYNTHETASE) DOMAIN-CONTAINING 1; GLULD1__:__LENGSIN; LGS__:__
Asterisk__:__611471__:__ACID PHOSPHATASE 6, LYSOPHOSPHATIDE; ACP6__:__LYSOPHOSPHATIDIC ACID-SPECIFIC PHOSPHATASE; LPAP;; ACID PHOSPHATASE-LIKE 1; ACPL1__:__
Asterisk__:__611472__:__METHYL-CpG-BINDING DOMAIN PROTEIN 5; MBD5__:__KIAA1461__:__
Asterisk__:__611473__:__EMBRYONIC STEM CELL-RELATED PROTEIN__:__HESRG__:__
Asterisk__:__611474__:__HRAS-LIKE SUPPRESSOR FAMILY, MEMBER 5; HRASLS5__:__LECITHIN-RETINOL ACYLTRANSFERASE-LIKE PROTEIN 1; RLP1;; H-REV107-LIKE PROTEIN 5; HRLP5__:__
Asterisk__:__611475__:__RNA POLYMERASE II-ASSOCIATED PROTEIN 1; RPAP1__:__KIAA1403__:__
Asterisk__:__611476__:__RNA POLYMERASE II-ASSOCIATED PROTEIN 2; RPAP2__:__CHROMOSOME 1 OPEN READING FRAME 82; C1ORF82__:__
Asterisk__:__611477__:__RNA POLYMERASE II-ASSOCIATED PROTEIN 3; RPAP3__:____:__
Asterisk__:__611478__:__METHYLPHOSPHATE CAPPING ENZYME; MEPCE__:__BICOID-INTERACTING 3, DROSOPHILA, HOMOLOG OF; BCDIN3__:__
Asterisk__:__611479__:__XPA-BINDING PROTEIN 1; XAB1__:__MBD2-INTERACTING PROTEIN; MBDIN__:__
Asterisk__:__611480__:__PIH1 DOMAIN-CONTAINING PROTEIN 1; PIH1D1__:__NOP17, S. CEREVISIAE, HOMOLOG OF; NOP17__:__
Asterisk__:__611481__:__UFM1-SPECIFIC PEPTIDASE 1; UFSP1__:__UFM1-SPECIFIC PROTEASE 1__:__
Asterisk__:__611482__:__UFM1-SPECIFIC PEPTIDASE 2; UFSP2__:__UFM1-SPECIFIC PROTEASE 2;; CHROMOSOME 4 OPEN READING FRAME 20; C4ORF20__:__
Asterisk__:__611483__:__YIP1 DOMAIN FAMILY, MEMBER 5; YIPF5__:__SMOOTH MUSCLE CELL-ASSOCIATED PROTEIN 5; SMAP5;; YIP1A__:__
Asterisk__:__611484__:__YIP1-INTERACTING FACTOR, S. CEREVISIAE, HOMOLOG OF, A; YIF1A__:__YIF1__:__
Asterisk__:__611485__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 12; CYP4F12__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 12__:__
Asterisk__:__611486__:__SYNAPTONEMAL COMPLEX CENTRAL ELEMENT PROTEIN 1; SYCE1__:____:__
Asterisk__:__611487__:__SYNAPTONEMAL COMPLEX CENTRAL ELEMENT PROTEIN 2; SYCE2__:__CENTRAL ELEMENT SYNAPTONEMAL COMPLEX 1; CESC1__:__
Percent__:__611488__:__MACULAR DEGENERATION, AGE-RELATED, 10; ARMD10__:____:__
Number Sign__:__611489__:__CORTICOSTEROID-BINDING GLOBULIN DEFICIENCY__:__CBG DEFICIENCY;; TRANSCORTIN DEFICIENCY__:__CORTICOSTEROID-BINDING GLOBULIN, ELEVATED, INCLUDED
Number Sign__:__611490__:__OSTEOPETROSIS,  AUTOSOMAL RECESSIVE 4; OPTB4__:__OSTEOPETROSIS, INFANTILE MALIGNANT 2__:__
Asterisk__:__611491__:__RAS ASSOCIATION AND DILUTE DOMAINS PROTEIN; RADIL__:__RAP GTPase INTERACTOR;; KIAA1849__:__
Asterisk__:__611492__:__CARBONIC ANHYDRASE II; CA2__:__CA II;; CARBONIC ANHYDRASE B;; CARBONIC ANHYDRASE C, FORMERLY__:__
Number Sign__:__611493__:__ATRIAL FIBRILLATION, FAMILIAL, 4; ATFB4__:____:__
Percent__:__611494__:__ATRIAL FIBRILLATION, FAMILIAL, 5; ATFB5__:____:__
Asterisk__:__611495__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 22; CYP4F22__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 22__:__
Asterisk__:__611496__:__GATA-BINDING PROTEIN 5; GATA5__:____:__
Number Sign__:__611497__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 6; OPTB6__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE, INTERMEDIATE FORM__:__
Number Sign__:__611498__:__NEPHRONOPHTHISIS 7; NPHP7__:____:__
Asterisk__:__611499__:__BETA-GLUCURONIDASE; GUSB__:____:__
Asterisk__:__611500__:__MICRO RNA 219-1; MIR219-1__:__miRNA219-1;; MIRN219-1__:__
Asterisk__:__611501__:__CALMODULIN-BINDING TRANSCRIPTION ACTIVATOR 1; CAMTA1__:__KIAA0833__:__
Asterisk__:__611502__:__CENTROMERIC PROTEIN K; CENPK__:__SOLT__:__
Asterisk__:__611503__:__CENTROMERIC PROTEIN L; CENPL__:____:__
Asterisk__:__611504__:__CENTROMERIC PROTEIN O; CENPO__:____:__
Asterisk__:__611505__:__CENTROMERIC PROTEIN P; CENPP__:____:__
Asterisk__:__611506__:__CENTROMERIC PROTEIN Q; CENPQ__:____:__
Asterisk__:__611507__:__CDGSH IRON SULFUR DOMAIN PROTEIN 2; CISD2__:__MITONEET-RELATED 1; MINER1;; ZINC FINGER PROTEIN ZCD2; ZCD2;; ENDOPLASMIC RETICULUM INTERMEMBRANE SMALL PROTEIN; ERIS;; NUTRIENT DEPRIVATION AUTOPHAGY FACTOR 1; NAF1__:__
Asterisk__:__611508__:__CALMODULIN-BINDING TRANSCRIPTION ACTIVATOR 2; CAMTA2__:__KIAA0909__:__
Asterisk__:__611509__:__CENTROMERIC PROTEIN N; CENPN__:____:__
Asterisk__:__611510__:__CENTROMERIC PROTEIN T; CENPT__:____:__
Asterisk__:__611511__:__MLF1-INTERACTING PROTEIN; MLF1IP__:__CENTROMERIC PROTEIN U; CENPU;; CENP50__:__
Asterisk__:__611512__:__LYSINE-SPECIFIC DEMETHYLASE 3A; KDM3A__:__K-SPECIFIC DEMETHYLASE 3A;; JMJC DOMAIN-CONTAINING HISTONE DEMETHYLASE 2A; JHDM2A;; TESTIS-SPECIFIC GENE A; TSGA;; KIAA0742;; JUMONJI DOMAIN-CONTAINING PROTEIN 1A, FORMERLY; JMJD1A, FORMERLY__:__
Asterisk__:__611513__:__NEUROGENIC DIFFERENTIATION 6; NEUROD6__:__ATOH2;; MATH2__:__
Asterisk__:__611514__:__WNTLESS, DROSOPHILA, HOMOLOG OF; WLS__:__G PROTEIN-COUPLED RECEPTOR 177; GPR177;; EVENNESS INTERRUPTED, DROSOPHILA, HOMOLOG OF; EVI__:__
Percent__:__611515__:__FEBRILE SEIZURES, FAMILIAL, 7; FEB7__:__FEBRILE CONVULSIONS, FAMILIAL, 7; FEB7__:__
Asterisk__:__611516__:__NICOLIN 1; NICN1__:____:__
Asterisk__:__611517__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 11; CYP4F11__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 11__:__
Asterisk__:__611518__:__DEDICATOR OF CYTOKINESIS 10; DOCK10__:__KIAA0694;; ZIZIMIN 3; ZIZ3__:__
Asterisk__:__611519__:__POLYMERASE DELTA-INTERACTING PROTEIN 2; POLDIP2__:__PDIP38__:__
Asterisk__:__611520__:__POLYMERASE DELTA-INTERACTING PROTEIN 3; POLDIP3__:__S6K1 ALY/REF-LIKE TARGET; SKAR;; PDIP46__:__
Number Sign__:__611521__:__IMMUNODEFICIENCY 35; IMD35__:__TYROSINE KINASE 2 DEFICIENCY;; TYK2 DEFICIENCY;; HYPER-IgE SYNDROME WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE;; HIES WITH ATYPICAL MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE__:__
Percent__:__611522__:__INTRAOCULAR PRESSURE QUANTITATIVE TRAIT LOCUS; IOPQTL__:__GLAUCOMA, SUSCEPTIBILITY TO__:__
Number Sign__:__611523__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 6; PCH6__:__ENCEPHALOPATHY, FATAL INFANTILE, WITH MITOCHONDRIAL RESPIRATORY CHAIN DEFECTS__:__
Asterisk__:__611524__:__ARGINYL-tRNA SYNTHETASE 2; RARS2__:__ARGINYL-tRNA SYNTHETASE, MITOCHONDRIAL;; RARSL__:__
Asterisk__:__611525__:__POLYMERASE (DNA-DIRECTED), DELTA 4; POLD4__:__CDM1, S. POMBE, HOMOLOG OF;; DNA POLYMERASE, DELTA 4, SMALLEST SUBUNIT; POLDS;; P12__:__
Asterisk__:__611526__:__NOP14, S. CEREVISIAE, HOMOLOG OF; NOP14__:__NUCLEOLAR PROTEIN 14; NOL14;; RES4-25__:__
Asterisk__:__611527__:__Na+/H+ EXCHANGER DOMAIN-CONTAINING PROTEIN 1; NHEDC1__:__SODIUM/HYDROGEN EXCHANGER DOMAIN-CONTAINING PROTEIN 1;; Na+/H+ EXCHANGER PROTEIN__:__
Number Sign__:__611528__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; ARVD12__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 12; ARVC12__:__
Asterisk__:__611529__:__CYTOCHROME P450, FAMILY 2, SUBFAMILY S, POLYPEPTIDE 1; CYP2S1__:__CYTOCHROME P450, SUBFAMILY IIS, POLYPEPTIDE 1__:__
Asterisk__:__611530__:__NEUROLYSIN; NLN__:__KIAA1226;; NEUROTENSIN ENDOPEPTIDASE;; ANGIOTENSIN-BINDING PROTEIN; AGTBP__:__
Asterisk__:__611531__:__ESSENTIAL FOR MITOTIC GROWTH 1, S. CEREVISIAE, HOMOLOG OF; EMG1__:__NUCLEOLAR ESSENTIAL PROTEIN 1; NEP1;; C2F__:__
Asterisk__:__611532__:__NUCLEOLAR PROTEIN 6; NOL6__:__NUCLEOLAR RNA-ASSOCIATED PROTEIN; NRAP;; UTP22, S. CEREVISIAE, HOMOLOG OF; UTP22__:__
Asterisk__:__611533__:__NUCLEOLAR PROTEIN 7; NOL7__:__NUCLEOLAR PROTEIN, 27-KD;; RETINOIC ACID REPRESSIBLE PROTEIN__:__
Asterisk__:__611534__:__NUCLEOLAR PROTEIN 8; NOL8__:__NOP132__:__
Percent__:__611535__:__MAJOR AFFECTIVE DISORDER 5; MAFD5__:__BIPOLAR AFFECTIVE DISORDER; BPAD__:__
Percent__:__611536__:__MAJOR AFFECTIVE DISORDER 6; MAFD6__:__BIPOLAR AFFECTIVE DISORDER; BPAD__:__
Asterisk__:__611537__:__CATENIN, BETA-LIKE, 1; CTNNBL1__:__NUCLEAR-ASSOCIATED PROTEIN; NAP__:__NYD-SP19, INCLUDED
Asterisk__:__611538__:__OLFACTORY RECEPTOR, FAMILY 7, SUBFAMILY D, MEMBER 4; OR7D4__:__OLFACTORY RECEPTOR OR19-7;; ODORANT RECEPTOR FAMILY SUBFAMILY D, MEMBER 4RT;; OR19-B__:__
Asterisk__:__611539__:__FORKHEAD BOX D3; FOXD3__:__HFH2;; GENESIS, MOUSE, HOMOLOG OF__:__
Asterisk__:__611540__:__SH3-DOMAIN GRB2-LIKE (ENDOPHILIN)-INTERACTING PROTEIN 1; SGIP1__:____:__
Asterisk__:__611541__:__SORTING NEXIN 27; SNX27__:__METHAMPHETAMINE-RESPONSIVE TRANSCRIPT 1; MRT1__:__
Asterisk__:__611542__:__ARYLSULFATASE B; ARSB__:____:__
Number Sign__:__611543__:__CAVITARY OPTIC DISC ANOMALIES; CODA__:____:__
Number Sign__:__611544__:__CATARACT 17, MULTIPLE TYPES; CTRCT17__:__CATARACT 17, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, CONGENITAL NUCLEAR, AUTOSOMAL RECESSIVE 3; CATCN3__:__
Asterisk__:__611545__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY F, POLYPEPTIDE 8; CYP4F8__:__CYTOCHROME P450, SUBFAMILY IVF, POLYPEPTIDE 8__:__
Asterisk__:__611546__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 6; ELOVL6__:__LONG-CHAIN FATTY-ACYL ELONGASE; LCE;; FATTY ACYL-CoA ELONGASE; FACE__:__
Percent__:__611547__:__STATURE QUANTITATIVE TRAIT LOCUS 9; STQTL9__:____:__
Number Sign__:__611548__:__PREMATURE OVARIAN FAILURE 5; POF5__:____:__
Asterisk__:__611549__:__SODIUM LEAK CHANNEL, NONSELECTIVE; NALCN__:____:__
Asterisk__:__611550__:__NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NCR3__:__1C7;; ACTIVATING NATURAL KILLER RECEPTOR p30; NKp30;; CD337 ANTIGEN; CD337__:__
Asterisk__:__611551__:__FIBULIN 7; FBLN7__:__TM14, MOUSE, HOMOLOG OF__:__
Asterisk__:__611552__:__NICOTINATE PHOSPHORIBOSYLTRANSFERASE DOMAIN-CONTAINING 1; NAPRT1__:__NICOTINIC ACID PHOSPHORIBOSYLTRANSFERASE__:__
Number Sign__:__611553__:__NOONAN SYNDROME 5; NS5__:____:__
Number Sign__:__611554__:__LEOPARD SYNDROME 2; LPRD2__:____:__
NULL__:__611555__:__RENAL TUBULAR ACIDOSIS, DISTAL, WITH NEPHROCALCINOSIS, SHORT STATURE, MENTAL RETARDATION, AND DISTINCTIVE FACIES__:____:__
Number Sign__:__611556__:__GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B__:__GSD 0b;; MUSCLE GLYCOGEN STORAGE DISEASE 0;; MUSCLE GLYCOGEN SYNTHASE DEFICIENCY__:__
Asterisk__:__611557__:__UROPLAKIN 1A; UPK1A__:__UPIA__:__
Asterisk__:__611558__:__UROPLAKIN 2; UPK2__:__UP2;; UPII__:__
Asterisk__:__611559__:__UROPLAKIN 3A; UPK3A__:__UROPLAKIN 3; UPK3;; UPIII;; UPIIIA__:__
Number Sign__:__611560__:__JOUBERT SYNDROME 7; JBTS7__:____:__
Number Sign__:__611561__:__MECKEL SYNDROME, TYPE 5; MKS5__:____:__
Asterisk__:__611562__:__SEPTIN 12; SEPT12__:____:__
Asterisk__:__611563__:__SEPTIN 13; SEPT13__:____:__
Asterisk__:__611564__:__BTG3-ASSOCIATED NUCLEAR PROTEIN; BANP__:__SCAFFOLD/MATRIX-ASSOCIATED REGION 1; SMAR1__:__
Asterisk__:__611565__:__KIAA1109 GENE; KIAA1109__:__TWEEK, DROSOPHILA, HOMOLOG OF; TWEEK__:__
Asterisk__:__611566__:__PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE 1-LIKE 1; PRPS1L1__:__PRPS1-LIKE 1;; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE 3; PRPS3__:__
Asterisk__:__611567__:__MACRO DOMAIN-CONTAINING 2; MACROD2__:__CHROMOSOME 20 OPEN READING FRAME 133; C20ORF133__:__
Asterisk__:__611568__:__SYNTABULIN; SYBU__:__GOLGI-LOCALIZED SYNTAPHILIN-RELATED PROTEIN; GOLSYN;; KIAA1472__:__GOLSYN A, INCLUDED;; GOLSYN B, INCLUDED;; GOLSYN C, INCLUDED
Asterisk__:__611569__:__CYTOSKELETON-ASSOCIATED PROTEIN 2; CKAP2__:__TUMOR- AND MICROTUBULE-ASSOCIATED PROTEIN; TMAP;; LB1__:__
Asterisk__:__611570__:__FRUCTOSE-1,6-BISPHOSPHATASE 1; FBP1__:__FRUCTOSE-1,6-BISPHOSPHATASE, LIVER;; FRUCTOSE-1,6-DIPHOSPHATASE__:__
Percent__:__611571__:__OTOSCLEROSIS 4; OTSC4__:____:__
Percent__:__611572__:__OTOSCLEROSIS 7; OTSC7__:____:__
Asterisk__:__611573__:__SPHINGOMYELIN SYNTHASE 1; SGMS1__:__SMS1;; TRANSMEMBRANE PROTEIN 23; TMEM23;; MEDULLA OBLONGATA-DERIVED PROTEIN; MOB__:__
Asterisk__:__611574__:__SPHINGOMYELIN SYNTHASE 2; SGMS2__:__SMS2__:__
Asterisk__:__611575__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 8; SAMD8__:__SPHINGOMYELIN SYNTHASE-RELATED; SMSR__:__
Asterisk__:__611576__:__MICRO RNA 10B; MIR10B__:__miRNA10B;; MIRN10B__:__
Asterisk__:__611577__:__LYSINE-SPECIFIC DEMETHYLASE 6B; KDM6B__:__JUMONJI DOMAIN-CONTAINING PROTEIN 3; JMJD3;; KIAA0346__:__
Asterisk__:__611578__:__FERRIC CHELATE REDUCTASE 1; FRRS1__:__STROMAL CELL-DERIVED RECEPTOR 2, MOUSE, HOMOLOG OF; SDR2__:__
Asterisk__:__611579__:__TRANSMEMBRANE PROTEIN 114; TMEM114__:____:__
Asterisk__:__611580__:__EPIDIDYMAL PROTEIN 3A; EDDM3A__:__HUMAN EPIDIDYMIS-SPECIFIC PROTEIN 3, ALPHA; HE3A;; FAMILY WITH SEQUENCE SIMILARITY 12, MEMBER A; FAM12A__:__
Caret__:__611581__:__MOVED TO 601067__:____:__
Asterisk__:__611582__:__FAMILY WITH SEQUENCE SIMILARITY 12, MEMBER B; FAM12B__:__HUMAN EPIDIDYMIS-SPECIFIC 3, BETA; HE3B__:__
Asterisk__:__611583__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 5A; ARID5A__:__ARID-CONTAINING PROTEIN 5A;; MODULATOR RECOGNITION FACTOR 1; MRF1__:__
Number Sign__:__611584__:__WAARDENBURG SYNDROME, TYPE 2E; WS2E__:__HYPOGONADOTROPIC HYPOGONADISM WITH ANOSMIA AND DEAFNESS, WITH OR WITHOUT HYPOPIGMENTATION;; WAARDENBURG SYNDROME, TYPE 2E, WITH OR WITHOUT NEUROLOGIC INVOLVEMENT;; WS2E, WITH OR WITHOUT NEUROLOGIC INVOLVEMENT;; WAARDENBURG SYNDROME, TYPE IIE__:__
Asterisk__:__611585__:__TESCALCIN, MOUSE, HOMOLOG OF; TESC__:__TSC__:__
Asterisk__:__611586__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 1; C1QL1__:__C1q-RELATED FACTOR; CRF;; C1QRF__:__
Asterisk__:__611587__:__RHO GTPase-ACTIVATING PROTEIN 19; ARHGAP19__:__GTPase-ACTIVATING PROTEIN, RHO, 19__:__
Number Sign__:__611588__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 4; MDDGC4__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 13; LGMDR13;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2M; LGMD2M__:__
Asterisk__:__611589__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 5; PNPLA5__:__GS2-LIKE PROTEIN; GS2L__:__
Number Sign__:__611590__:__RENAL TUBULAR ACIDOSIS, DISTAL, WITH HEMOLYTIC ANEMIA__:__RTA, DISTAL, AUTOSOMAL RECESSIVE, WITH HEMOLYTIC ANEMIA__:__RENAL TUBULAR ACIDOSIS, DISTAL, WITH NORMAL RED CELL MORPHOLOGY, INCLUDED
Asterisk__:__611591__:__PRO-PLATELET BASIC PROTEIN PSEUDOGENE 2; PPBPP2__:__PRO-PLATELET BASIC PROTEIN-LIKE 2; PPBPL2;; DNA-BINDING PROTEIN AMPLIFYING EXPRESSION OF SURFACTANT PROTEIN B__:__
Asterisk__:__611592__:__PHENYLALANYL-tRNA SYNTHETASE 2, MITOCHONDRIAL; FARS2__:__FARS1;; MITOCHONDRIAL PHERS__:__
Asterisk__:__611593__:__SUBMAXILLARY GLAND ANDROGEN-REGULATED PROTEIN 3, MOUSE, HOMOLOG OF, B; SMR3B__:__SUBMAXILLARY GLAND ANDROGEN-REGULATED PROTEIN 1, MOUSE, HOMOLOG OF, B; SMR1B;; PROLINE-RICH PROTEIN 3; PRL3;; PBII__:__P-B PEPTIDE, INCLUDED
Asterisk__:__611594__:__UBIQUITIN-SPECIFIC PROTEASE 39; USP39__:__snRNP ASSEMBLY DEFECTIVE 1, S. CEREVISIAE, HOMOLOG OF; SAD1__:__
Asterisk__:__611595__:__THIOREDOXIN-LIKE 4A; TXNL4A__:__DIM1, S. POMBE, HOMOLOG OF; DIM1;; U5 snRNP-SPECIFIC PROTEIN, 15-KD;; U5-15KD__:__
Asterisk__:__611596__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 4; DHRS4__:__SDR FAMILY, MEMBER 4;; NADPH-DEPENDENT RETINOL DEHYDROGENASE/REDUCTASE; NRDR__:__
Number Sign__:__611597__:__CATARACT 12, MULTIPLE TYPES; CTRCT12__:____:__
Percent__:__611598__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 6; CELIAC6__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 6__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 5, INCLUDED; AIS5, INCLUDED
Asterisk__:__611599__:__MICRO RNA 206; MIR206__:__miRNA206;; MIRN206__:__
Asterisk__:__611600__:__PROTEIN REGULATING SYNAPTIC MEMBRANE EXOCYTOSIS 3; RIMS3__:__RIM3-GAMMA;; NIM3;; KIAA0237__:__
Asterisk__:__611601__:__PROTEIN REGULATING SYNAPTIC MEMBRANE EXOCYTOSIS 4; RIMS4__:__RIM4-GAMMA__:__
Asterisk__:__611602__:__RIMS-BINDING PROTEIN 2; RIMBP2__:__KIAA0318__:__
Number Sign__:__611603__:__LISSENCEPHALY 3; LIS3__:____:__
Asterisk__:__611604__:__ENDOPLASMIC RETICULUM LIPID RAFT-ASSOCIATED PROTEIN 1; ERLIN1__:__KEO4__:__
Asterisk__:__611605__:__ENDOPLASMIC RETICULUM LIPID RAFT-ASSOCIATED PROTEIN 2; ERLIN2__:__SPFH DOMAIN-CONTAINING PROTEIN 2; SPFH2;; CHROMOSOME 8 OPEN READING FRAME 2; C8ORF2__:__
Asterisk__:__611606__:__MICRO RNA 96; MIR96__:__miRNA96;; MIRN96__:__
Asterisk__:__611607__:__MICRO RNA 182; MIR182__:__miRNA182;; MIRN182__:__
Asterisk__:__611608__:__MICRO RNA 183; MIR183__:__miRNA183;; MIRN183__:__
Asterisk__:__611609__:__SIPA1-LIKE PROTEIN 2; SIPA1L2__:__KIAA1389__:__
Asterisk__:__611610__:__PHOSPHOGLUCOMUTASE 2-LIKE 1; PGM2L1__:____:__
Asterisk__:__611611__:__S-PHASE CYCLIN A-ASSOCIATED PROTEIN IN THE ENDOPLASMIC RETICULUM; SCAPER__:__KIAA1454;; ZINC FINGER PROTEIN 291; ZNF291__:__
Asterisk__:__611612__:__THIAMINE TRIPHOSPHATASE; THTPA__:__THTPase__:__
Asterisk__:__611613__:__KDEL MOTIF-CONTAINING 1; KDELC1__:__ENDOPLASMIC RETICULUM RESIDENT PROTEIN 58; EP58__:__
Asterisk__:__611614__:__UTP3, S. CEREVISIAE, HOMOLOG OF; UTP3__:__CHARGED AMINO ACID-RICH LEUCINE ZIPPER 1; CRL1; CRLZ1__:__
Number Sign__:__611615__:__CARDIOMYOPATHY, DILATED, 1X; CMD1X__:__CARDIOMYOPATHY, DILATED, WITH MILD OR NO PROXIMAL MUSCLE WEAKNESS__:__
Asterisk__:__611616__:__NAD KINASE; NADK__:____:__
Asterisk__:__611617__:__EF-HAND DOMAIN FAMILY, MEMBER D1; EFHD1__:____:__
Caret__:__611618__:__MOVED TO 248370__:____:__
Asterisk__:__611619__:__MICRO RNA 877; MIR877__:__miRNA877;; MIRN877__:__
Asterisk__:__611620__:__MICRO RNA 1224; MIR1224__:__miRNA1224;; MIRN1224__:__
Asterisk__:__611621__:__MICRO RNA 1225; MIR1225__:__miRNA1225;; MIRN1225__:__
Asterisk__:__611622__:__IQ MOTIF-CONTAINING PROTEIN J; IQCJ__:____:__IQCJ/SCHIP1 FUSION GENE, INCLUDED
Asterisk__:__611623__:__NECAP ENDOCYTOSIS-ASSOCIATED PROTEIN 1; NECAP1__:__ADAPTIN EAR-BINDING COAT-ASSOCIATED PROTEIN 1__:__
Asterisk__:__611624__:__NECAP ENDOCYTOSIS-ASSOCIATED PROTEIN 2; NECAP2__:__ADAPTIN EAR-BINDING COAT-ASSOCIATED PROTEIN 2__:__
Asterisk__:__611625__:__GID COMPLEX, SUBUNIT 8; GID8__:__GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 8, S. CEREVISIAE, HOMOLOG OF;; CHROMOSOME 20 OPEN READING FRAME 11; C20ORF11;; TWO-HYBRID-ASSOCIATED PROTEIN WITH RANBPM 1; TWA1__:__
Asterisk__:__611626__:__M-PHASE PHOSPHOPROTEIN 8; MPHOSPH8__:__MPP8;; TWO-HYBRID-ASSOCIATED PROTEIN WITH RANBPM 3; TWA3__:__
Asterisk__:__611627__:__FAMILY WITH SEQUENCE SIMILARITY 57, MEMBER A; FAM57A__:__CT120__:__
Asterisk__:__611628__:__NEURON NAVIGATOR 1; NAV1__:__PORE MEMBRANE- AND/OR FILAMENT-INTERACTING-LIKE PROTEIN 3; POMFIL3;; KIAA1151__:__
Asterisk__:__611629__:__NEURON NAVIGATOR 3; NAV3__:__PORE MEMBRANE- AND/OR FILAMENT-INTERACTING-LIKE PROTEIN 1; POMFIL1;; KIAA0938__:__
Percent__:__611630__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 3; ETL3__:__EPILEPSY, FAMILIAL MESIAL TEMPORAL LOBE; FMTLE__:__
Percent__:__611631__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 4; ETL4__:__EPILEPSY, OCCIPITOTEMPORAL LOBE, AND MIGRAINE WITH AURA; EPOLM__:__
Asterisk__:__611632__:__UbiA PRENYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 1; UBIAD1__:__TRANSITIONAL EPITHELIAL RESPONSE PROTEIN 1; TERE1__:__
Asterisk__:__611633__:__RTF1, S. CEREVISIAE, HOMOLOG OF; RTF1__:__KIAA0252__:__
Percent__:__611634__:__FEBRILE SEIZURES, FAMILIAL, 9; FEB9__:__FEBRILE CONVULSIONS, FAMILIAL, 9; FEB9__:__
Asterisk__:__611635__:__NEUROGENIC DIFFERENTIATION 4; NEUROD4__:__MATH3__:__
Asterisk__:__611636__:__N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE 2; NAALAD2__:__NAALADase II__:__
Percent__:__611637__:__PRIMARY LATERAL SCLEROSIS, ADULT, 1; PLSA1__:__PLS, ADULT; PLSA__:__
Number Sign__:__611638__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 5; MCOPCB5__:____:__
Asterisk__:__611639__:__ZINC FINGER GATA-LIKE PROTEIN 1; ZGLP1__:__GATA-LIKE PROTEIN 1; GLP1__:__
Asterisk__:__611640__:__FIBRONECTIN TYPE III AND ANKYRIN REPEAT DOMAINS 1; FANK1__:____:__
Asterisk__:__611641__:__CANCER SUSCEPTIBILITY GENE HEPN1; HEPN1__:____:__
Asterisk__:__611642__:__HEPATOCYTE CELL ADHESION MOLECULE; HEPACAM__:__GLIAL CELL ADHESION MOLECULE; GLIALCAM;; HEPATOCYTE AND GLIAL CELL ADHESION MOLECULE__:__
Asterisk__:__611643__:__ZINC FINGER PROTEIN WITH KRAB AND SCAN DOMAINS 4; ZKSCAN4__:__ZINC FINGER PROTEIN 307; ZNF307__:__
Percent__:__611644__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 9; HSCR9__:____:__
Asterisk__:__611645__:__CXXC FINGER PROTEIN 4; CXXC4__:__DVL1-BINDING PROTEIN;; INHIBITOR OF DVL/AXIN COMPLEX; IDAX__:__
Asterisk__:__611646__:__SPHK1-INTERACTING PROTEIN; SPHKAP__:__SPHK1 INTERACTOR, AKAP DOMAIN-CONTAINING;; SKIP;; KIAA1678__:__
Asterisk__:__611647__:__ARV1, S. CEREVISIAE, HOMOLOG OF; ARV1__:____:__
Asterisk__:__611648__:__HISTIDINE ACID PHOSPHATASE DOMAIN-CONTAINING PROTEIN 1; HISPPD1__:__DIPHOSPHOINOSITOL PENTAKISPHOSPHATE KINASE 2; PPIP5K2;; VIP2;; KIAA0433__:__
Asterisk__:__611649__:__MINDY LYSINE-48 DEUBIQUITINASE 3; MINDY3__:__CARD-CONTAINING PROTEIN; CARP;; CHROMOSOME 10 OPEN READING FRAME 97; C10ORF97;; FAMILY WITH SEQUENCE SIMILARITY 188, MEMBER A; FAM188A__:__
NULL__:__611650__:__PERIPAPILLARY ATROPHY, BETA TYPE; PPAB__:__BETA-PPA;; PERIPAPILLARY CHORIORETINAL ATROPHY, BETA TYPE__:__
Asterisk__:__611651__:__PHOSPHOLIPASE A2, GROUP III; PLA2G3__:__PHOSPHOLIPASE A2, SECRETED, GROUP III;; GIII-SPLA2;; SPLA2-III__:__
Asterisk__:__611652__:__PHOSPHOLIPASE A2, GROUP XIIA; PLA2G12A__:__PHOSPHOLIPASE A2, SECRETED, GROUP XII;; SPLA2-GXII;; GXII;; ROSSY__:__
Asterisk__:__611653__:__PHOSPHOLIPASE A2, GROUP XIIB; PLA2G12B__:__PHOSPHOLIPASE A2, SECRETED, GROUP XIIB;; SPLA2-GXIIB;; GXIIB__:__
Asterisk__:__611654__:__CENTROSOME SPINDLE POLE-ASSOCIATED PROTEIN 1; CSPP1__:__CSPP__:__CSPP1-S, INCLUDED;; CSPP1-L, INCLUDED
Asterisk__:__611655__:__POST-GPI ATTACHMENT TO PROTEINS 1; PGAP1__:__GPI DEACYLASE__:__
Asterisk__:__611656__:__SUPPRESSOR OF IKBKE 1; SIKE1__:__SUPPRESSOR OF IKK-EPSILON; SIKE__:__
Asterisk__:__611657__:__SPRY DOMAIN- AND SOCS BOX-CONTAINING 1; SPSB1__:__SPRY DOMAIN-CONTAINING SOCS BOX PROTEIN 1; SSB1__:__
Asterisk__:__611658__:__SPRY DOMAIN- AND SOCS BOX-CONTAINING 2; SPSB2__:__SPRY DOMAIN-CONTAINING SOCS BOX PROTEIN 2; SSB2__:__
Asterisk__:__611659__:__SPRY DOMAIN- AND SOCS BOX-CONTAINING 3; SPSB3__:__SPRY DOMAIN-CONTAINING SOCS BOX PROTEIN 3; SSB3__:__
Asterisk__:__611660__:__SPRY DOMAIN- AND SOCS BOX-CONTAINING 4; SPSB4__:__SPRY DOMAIN-CONTAINING SOCS BOX PROTEIN 4; SSB4__:__
Asterisk__:__611661__:__DBF4, S. CEREVISIAE, HOMOLOG OF, B; DBF4B__:__DBF4-RELATED FACTOR 1; DRF1;; ASK-LIKE 1; ASKL1__:__
Asterisk__:__611662__:__EOSINOPHIL GRANULE ONTOGENY__:__EGO__:__
Asterisk__:__611663__:__TBC1 DOMAIN FAMILY, MEMBER 20; TBC1D20__:__CHROMOSOME 20 OPEN READING FRAME 140; C20ORF140__:__
Number Sign__:__611664__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 7; SHEP7__:__SKIN/HAIR/EYE PIGMENTATION 7, BLOND/BROWN HAIR;; SKIN/HAIR/EYE PIGMENTATION 7, DARK/LIGHT SKIN__:__
Asterisk__:__611665__:__DEAD/H BOX 54; DDX54__:__DEAD BOX RNA HELICASE, 97-KD; DP97__:__
Asterisk__:__611666__:__PHOSPHOLIPID PHOSPHATASE 6; PLPP6__:__PPAP2 DOMAIN-CONTAINING PROTEIN 2; PPAPDC2__:__
Asterisk__:__611667__:__SPERMATOGENESIS-ASSOCIATED SERINE-RICH PROTEIN 2; SPATS2__:__SPATA10;; SERINE-RICH SPERMATOCYTES AND ROUND SPERMATID PROTEIN, 59-KD; P59SCR;; SCR59__:__
Asterisk__:__611668__:__CORONIN 7; CORO7__:__POLARITY-OSMOTIC DEFECTIVE 1, DROSOPHILA, HOMOLOG OF; POD1;; CRN7__:__
Asterisk__:__611669__:__tRNA METHYLTRANSFERASE 1, S. CEREVISIAE, HOMOLOG OF; TRMT1__:__TRM1;; N2,N2-DIMETHYLGUANOSINE-26 tRNA METHYLTRANSFERASE;; tRNA(m(2,2)G26)DIMETHYLTRANSFERASE__:__
Asterisk__:__611670__:__INOSITOL-3-PHOSPHATE SYNTHASE 1; ISYNA1__:__MYOINOSITOL 1-PHOSPHATE SYNTHASE A1;; IPS__:__
Asterisk__:__611671__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS Z PROTEIN; PIGZ__:__SMP3, S. CEREVISIAE, HOMOLOG OF; SMP3__:__
Asterisk__:__611672__:__SOLUTE CARRIER FAMILY 46 (FOLATE TRANSPORTER), MEMBER 1; SLC46A1__:__HEME CARRIER PROTEIN 1; HCP1;; PROTON-COUPLED FOLATE TRANSPORTER; PCFT__:__
Asterisk__:__611673__:__tRNA METHYLTRANSFERASE 1-LIKE; TRMT1L__:__TRM1-LIKE; TRM1L;; CHROMOSOME 1 OPEN READING FRAME 25; C1ORF25__:__
Asterisk__:__611674__:__X KELL BLOOD GROUP PRECURSOR-RELATED FAMILY, MEMBER 3; XKR3__:__XTES;; XRG3__:__
Asterisk__:__611675__:__KIAA0513 GENE; KIAA0513__:____:__
Asterisk__:__611676__:__PHOSDUCIN-LIKE 2; PDCL2__:____:__
Asterisk__:__611677__:__OLFACTORY RECEPTOR, FAMILY 13, SUBFAMILY G, MEMBER 1; OR13G1__:__OR1-37__:__
Asterisk__:__611678__:__PHOSDUCIN-LIKE 3; PDCL3__:__VIRAL IAP-ASSOCIATED FACTOR; VIAF;; PHLP2A__:__
Asterisk__:__611679__:__F-BOX AND WD40 DOMAIN PROTEIN 10; FBXW10__:____:__
Asterisk__:__611680__:__SPECIFICALLY ANDROGEN-REGULATED GENE__:__SARG;; CHROMOSOME 1 OPEN READING FRAME 116; C1ORF116__:__
Asterisk__:__611681__:__A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 20; ADAMTS20__:____:__
Asterisk__:__611682__:__LIPOPROTEIN(a)-LIKE 2; LPAL2__:__LP(a)-LIKE 2;; LPA-LIKE 2;; APOLIPOPROTEIN(a)-RELATED GENE C; APOARGC__:__
Asterisk__:__611683__:__FRUCTOSAMINE 3-KINASE-RELATED PROTEIN__:__FN3K-RELATED PROTEIN; FN3KRP__:__
Asterisk__:__611684__:__SQUAMOUS CELL CARCINOMA ANTIGEN RECOGNIZED BY T CELLS 3; SART3__:__TAT-INTERACTING PROTEIN, 110-KD: TIP110;; p110;; KIAA0156__:__
Asterisk__:__611685__:__RING FINGER PROTEIN 8; RNF8__:__KIAA0646__:__
Asterisk__:__611686__:__CAS1 DOMAIN-CONTAINING PROTEIN 1; CASD1__:__CHROMOSOME 7 OPEN READING FRAME 12; C7ORF12__:__
Asterisk__:__611687__:__KHDC3-LIKE PROTEIN, SUBCORTICAL MATERNAL COMPLEX MEMBER; KHDC3L__:__CHROMOSOME 6 OPEN READING FRAME 221; C6ORF221;; EMBRYONIC STEM CELL-ASSOCIATED TRANSCRIPT 1; ECAT1__:__
Asterisk__:__611688__:__KH HOMOLOGY DOMAIN-CONTAINING PROTEIN 1; KHDC1__:____:__
Asterisk__:__611689__:__OOCYTE-EXPRESSED PROTEIN, DOG, HOMOLOG OF; OOEP__:__KH HOMOLOGY DOMAIN-CONTAINING PROTEIN 2; KHDC2;; FLOPED, MOUSE, HOMOLOG OF; FLOPED__:__
Asterisk__:__611690__:__PROLINE-RICH GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 4; PRRG4__:__PROLINE-RICH GLA PROTEIN 4; PRGP4;; TRANSMEMBRANE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN 4; TMG4__:__
Asterisk__:__611691__:__SUSHI, VON WILLEBRAND FACTOR TYPE A, EGF, AND PENTRAXIN DOMAINS-CONTAINING 1; SVEP1__:__POLYDOM;; SELECTIN-LIKE OSTEOBLAST-DERIVED PROTEIN; SELOB__:__
Asterisk__:__611692__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 34; ZBTB34__:__KIAA1993__:__
Asterisk__:__611693__:__COXSACKIEVIRUS- AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; CLMP__:__CXADR-LIKE MEMBRANE PROTEIN;; ADIPOCYTE-SPECIFIC ADHESION MOLECULE; ASAM;; ADIPOCYTE ADHESION MOLECULE; ACAM__:__
Percent__:__611694__:__DYSTONIA WITH CEREBELLAR ATROPHY; DYTCA__:____:__
Asterisk__:__611695__:__TAU TUBULIN KINASE 2; TTBK2__:____:__
Asterisk__:__611696__:__SOLUTE CARRIER FAMILY 22, MEMBER 20; SLC22A20__:__ORGANIC ANION TRANSPORTER 6; OAT6__:__
Asterisk__:__611697__:__CHROMOSOME 6 OPEN READING FRAME 85; C6ORF85__:__SOLUTE CARRIER FAMILY 22, MEMBER 23; SLC22A23__:__
Asterisk__:__611698__:__SOLUTE CARRIER FAMILY 22, MEMBER 24; SLC22A24__:____:__
Asterisk__:__611699__:__SV2-RELATED PROTEIN; SVOP__:____:__
Asterisk__:__611700__:__SV2-RELATED PROTEIN-LIKE; SVOPL__:____:__
Asterisk__:__611701__:__SPINSTER, DROSOPHILA, HOMOLOG OF, 3; SPNS3__:____:__
NULL__:__611702__:__SPONDYLOMETAPHYSEAL DYSPLASIA, EAST AFRICAN TYPE__:____:__
Asterisk__:__611703__:__ZINC FINGER PROTEIN 436; ZNF436__:__KIAA1710__:__
Asterisk__:__611704__:__TRANSMEMBRANE PROTEASE, SERINE 11A; TMPRSS11A__:__ESOPHAGEAL CANCER-RELATED GENE 1; ECRG1__:__
Number Sign__:__611705__:__SALIH MYOPATHY; SALMY__:__MYOPATHY, EARLY-ONSET, WITH FATAL CARDIOMYOPATHY; EOMFC__:__
Percent__:__611706__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 12; MGR12__:____:__
Asterisk__:__611707__:__MYELIN PROTEIN ZERO-LIKE 3; MPZL3__:____:__
Asterisk__:__611708__:__MICRO RNA 431; MIR431__:__miRNA431;; MIRN431__:__
Asterisk__:__611709__:__MICRO RNA 127; MIR127__:__miRNA127;; MIRN127__:__
Asterisk__:__611710__:__MICRO RNA 136; MIR136__:__miRNA136;; MIRN136__:__
Asterisk__:__611711__:__MICRO RNA 433; MIR433__:__miRNA433;; MIRN433__:__
Asterisk__:__611712__:__HOMEODOMAIN-INTERACTING PROTEIN KINASE 4; HIPK4__:____:__
Asterisk__:__611713__:__TCTEX1 DOMAIN-CONTAINING PROTEIN 4; TCTEX1D4__:__TCTEX2-BETA__:__
Asterisk__:__611714__:__GTPase-ACTIVATING PROTEIN AND VPS9 DOMAINS 1; GAPVD1__:__RAB5-ACTIVATING PROTEIN 6; RAP6;; RAB5 EXCHANGE FACTOR; GAPEX5;; KIAA1521__:__
Asterisk__:__611715__:__STEROID 5-ALPHA-REDUCTASE 3; SRD5A3__:__STEROID 5-ALPHA-REDUCTASE 2-LIKE 1; SRD5A2L1;; SRD5A2L;; POLYPRENOL REDUCTASE__:__
Asterisk__:__611716__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A2; ATP6V0A2__:__A2V-ATPase__:__
Percent__:__611717__:__SPONDYLOEPIPHYSEAL DYSPLASIA-BRACHYDACTYLY AND DISTINCTIVE SPEECH__:__SED-BDS;; FANTASY ISLAND SYNDROME;; TATOO DYSPLASIA__:__
Number Sign__:__611718__:__HYPOMAGNESEMIA 4, RENAL; HOMG4__:__HYPOMAGNESEMIA, RENAL, NORMOCALCIURIC__:__
Number Sign__:__611719__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5__:____:__
Asterisk__:__611720__:__INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN LIKE; IRF2BPL__:__CHROMOSOME 14 OPEN READING FRAME 4; C14ORF4;; ENHANCED AT PUBERTY 1; EAP1__:__
Number Sign__:__611721__:__COMBINED SAPOSIN DEFICIENCY__:__PROSAPOSIN DEFICIENCY; PSAPD;; COMBINED SAP DEFICIENCY__:__
Number Sign__:__611722__:__KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY__:__SAPOSIN A DEFICIENCY__:__
Asterisk__:__611723__:__CHROMOSOME 21 OPEN READING FRAME 24; C21ORF24__:____:__
Number Sign__:__611724__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 8; SHEP8__:__SKIN/HAIR/EYE PIGMENTATION 8, BROWN HAIR;; SKIN/HAIR/EYE PIGMENTATION 8, FAIR SKIN;; SKIN/HAIR/EYE PIGMENTATION 8, BLUE/LIGHT EYE COLOR;; SKIN/HAIR/EYE PIGMENTATION 8, FRECKLING/SUNBURN__:__
Asterisk__:__611725__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 7; KCTD7__:____:__
Number Sign__:__611726__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULAR INCLUSIONS; EPM3__:__CEROID LIPOFUSCINOSIS, NEURONAL, 14; CLN14__:__
Asterisk__:__611727__:__CHROMOSOME 1 OPEN READING FRAME 76; C1ORF76__:__NEUROBLASTOMA-DERIVED SECRETORY PROTEIN; NDSP__:__
Asterisk__:__611728__:__PROLINE-RICH PROTEIN 5-LIKE; PRR5L__:__PROTEIN OBSERVED WITH RICTOR 2; PROTOR2;; FLJ14213__:__
Asterisk__:__611729__:__KINESIN LIGHT CHAIN 2; KLC2__:____:__
Asterisk__:__611730__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 5; EPB41L5__:__KIAA1548__:__
Asterisk__:__611731__:__APC GENE; APC__:__DELETED IN POLYPOSIS 2.5; DP2.5__:__
Asterisk__:__611732__:__MEMBRANE-BOUND O-ACETYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 1; MBOAT1__:__MEMBRANE-BOUND O-ACETYLTRANSFERASE 1;; LYSOPHOSPHATIDYLETHANOLAMINE ACYLTRANSFERASE 1; LPEAT1__:__
NULL__:__611733__:__DAUWERSE-PETERS SYNDROME__:__SHORT STATURE, FACIAL DYSMORPHISM, SEVERE BRACHYDACTYLY, AND SYNDACTYLY__:__
Asterisk__:__611734__:__WD REPEAT-CONTAINING PROTEIN 77; WDR77__:__METHYLOSOME PROTEIN, 50-KD; MEP50;; ANDROGEN RECEPTOR-ASSOCIATED PROTEIN, 44-KD; p44__:__
Asterisk__:__611735__:__CUB DOMAIN-CONTAINING PROTEIN 1; CDCP1__:__SIMA135;; CD318 ANTIGEN; CD318__:__
Asterisk__:__611736__:__GREB1 PROTEIN__:__GREB1;; KIAA0575__:__
Asterisk__:__611737__:__SEPTIN 10; SEPT10__:__SEPT1-LIKE__:__
Percent__:__611738__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 7; BMND7__:____:__
Percent__:__611739__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 8; BMND8__:__OSTEOPOROSIS, SUSCEPTIBILITY TO__:__
Asterisk__:__611740__:__BETA-CAROTENE OXYGENASE 2; BCO2__:__BETA-CAROTENE DIOXYGENASE 2; BCDO2;; BETA-DIOX-II;; BETA-CAROTENE 9-PRIME,10-PRIME MONOOXYGENASE;; BETA-CAROTENE 9-PRIME,10-PRIME OXYGENASE__:__
Asterisk__:__611741__:__CATION CHANNEL, AMILORIDE-SENSITIVE, NEURONAL 3; ACCN3__:__ACID-SENSING ION CHANNEL 3; ASIC3;; TESTIS SODIUM CHANNEL 1; TNAC1;; DORSAL ROOT ACID-SENSING ION CHANNEL; DRASIC__:__
Number Sign__:__611742__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 9; SHEP9__:__SKIN/HAIR/EYE PIGMENTATION 9, DARK/LIGHT HAIR;; SKIN/HAIR/EYE PIGMENTATION 9, BROWN/NONBROWN EYES;; SKIN/HAIR/EYE PIGMENTATION 9, RED/NONRED HAIR;; SKIN/HAIR/EYE PIGMENTATION 9, FRECKLING/SUNBURN__:__
Asterisk__:__611743__:__PLECKSTRIN HOMOLOGY DOMAIN- AND RhoGEF DOMAIN-CONTAINING PROTEIN G6; PLEKHG6__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY G, MEMBER 6;; MYOSIN-INTERACTING GUANINE NUCLEOTIDE EXCHANGE FACTOR; MYOGEF__:__
Asterisk__:__611744__:__OTU DOMAIN-CONTAINING PROTEIN 4; OTUD4__:__HIV-1 INTEGRATION 1; HIN1;; KIAA1046__:__
Asterisk__:__611745__:__VCP/p47 COMPLEX-INTERACTING PROTEIN 1;   VCPIP1__:__VCP/p47 COMPLEX-INTERACTING PROTEIN, 135-KD; VCIP135;; KIAA1850__:__
Asterisk__:__611746__:__SIGNAL PEPTIDE-, CUB DOMAIN-, AND EGF-LIKE DOMAINS-CONTAINING PROTEIN 1; SCUBE1__:____:__
Asterisk__:__611747__:__SIGNAL PEPTIDE-, CUB DOMAIN-, AND EGF-LIKE DOMAINS-CONTAINING PROTEIN 2; SCUBE2__:____:__
Asterisk__:__611748__:__OTU DOMAIN-CONTAINING PROTEIN 7B; OTUD7B__:__CELLULAR ZINC FINGER ANTI-NFKB;; CEZANNE__:__
Asterisk__:__611749__:__ZINC FINGER RANBP2-TYPE DOMAIN-CONTAINING PROTEIN 1; ZRANB1__:__ZINC FINGER RAN-BINDING DOMAIN-CONTAINING PROTEIN 1;; TRAF-BINDING DOMAIN-CONTAINING PROTEIN; TRABID__:__
Asterisk__:__611750__:__SYNCOILIN 1; SYNC1__:__SYNCOILIN__:__
Asterisk__:__611751__:__THUMP DOMAIN-CONTAINING PROTEIN 2; THUMPD2__:__CHROMOSOME 2 OPEN READING FRAME 8; C2ORF8;; SAM-DEPENDENT METHYLTRANSFERASE__:__
Asterisk__:__611752__:__CHROMOSOME 2 OPEN READING FRAME 40; C2ORF40__:__ESOPHAGEAL CANCER-RELATED GENE 4; ECRG4__:__
Asterisk__:__611753__:__VACUOLE MEMBRANE PROTEIN 1; VMP1__:__TRANSMEMBRANE PROTEIN 49; TMEM49__:__
Asterisk__:__611754__:__ALPHA-AMINOADIPATE AMINOTRANSFERASE; AADAT__:__KYNURENINE AMINOTRANSFERASE II; KAT2__:__
Number Sign__:__611755__:__LEBER CONGENITAL AMAUROSIS 10; LCA10__:____:__
Asterisk__:__611756__:__RHOPHILIN ASSOCIATED TAIL PROTEIN 1-LIKE; ROPN1L__:__ROPN1-LIKE PROTEIN;; AKAP-ASSOCIATED SPERM PROTEIN; ASP;; RADIAL SPOKE HEAD 11, CHLAMYDOMONAS, HOMOLOG OF; RSPH11__:__
Asterisk__:__611757__:__RHOPHILIN-ASSOCIATED TAIL PROTEIN 1; ROPN1__:__ROPPORIN;; OUTER DENSE FIBER OF SPERM TAILS 6; ODF6__:__
Asterisk__:__611758__:__OTU DOMAIN-CONTAINING PROTEIN 3; OTUD3__:__KIAA0459__:__
Asterisk__:__611759__:__STARD3 N-TERMINAL-LIKE; STARD3NL__:__MLN64 N-TERMINAL DOMAIN HOMOLOG; MENTHO__:__
Asterisk__:__611760__:__PROTOCADHERIN 17; PCDH17__:__PROTOCADHERIN 68; PCDH68__:__
Asterisk__:__611761__:__LIPASE MATURATION FACTOR 1; LMF1__:__TRANSMEMBRANE PROTEIN 112; TMEM112__:__
Number Sign__:__611762__:__FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 2; FCAS2__:____:__
Asterisk__:__611763__:__LIMB BUD AND HEART DEVELOPMENT, MOUSE, HOMOLOG OF; LBH__:____:__
Asterisk__:__611764__:__CORNIFELIN; CNFN__:____:__
Asterisk__:__611765__:__ASPARTIC PEPTIDASE, RETROVIRAL-LIKE 1; ASPRV1__:__SKIN ASPARTIC PROTEASE; SASP;; SASPase;; TPA-INDUCIBLE ASPARTIC PROTEINASE; TAPS;; MUNO__:__
Asterisk__:__611766__:__MITOCHONDRIAL METHIONYL-tRNA FORMYLTRANSFERASE; MTFMT__:____:__
Asterisk__:__611767__:__MICRO RNA 126; MIR126__:__miRNA126;; MIRN126__:__MICRO RNA 126*, INCLUDED; MIR126*, INCLUDED;; MICRO RNA 123, INCLUDED; MIR123, INCLUDED
Asterisk__:__611768__:__MICRO RNA 335; MIR335__:__miRNA335;; MIRN335__:__
Asterisk__:__611769__:__MICRO RNA 128-2; MIR128-2__:__miRNA128-2;; MIRN128-2;; MIR128B__:__
Asterisk__:__611770__:__NK2, DROSOPHILA, HOMOLOG OF, 6; NKX2-6__:__CARDIAC-SPECIFIC HOMEOBOX 2; CSX2__:__
Number Sign__:__611771__:__LIPOPROTEIN GLOMERULOPATHY; LPG__:____:__
Asterisk__:__611772__:__NUF2, S. CEREVISIAE, HOMOLOG OF; NUF2__:__NUF2R;; CELL DIVISION CYCLE-ASSOCIATED PROTEIN 1; CDCA1__:__
Number Sign__:__611773__:__ANGIOPATHY, HEREDITARY, WITH NEPHROPATHY, ANEURYSMS, AND MUSCLE CRAMPS; HANAC__:____:__
Asterisk__:__611774__:__MICRO RNA 128-1; MIR128-1__:__miRNA128-1;; MIRN128-1;; MIR128A__:__
Number Sign__:__611775__:__KAWASAKI DISEASE__:__KD;; MUCOCUTANEOUS LYMPH NODE SYNDROME;; INFANTILE POLYARTERITIS__:__
Asterisk__:__611776__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 4; NDUFAF4__:__NADH DEHYDROGENASE 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 4;; HORMONE-REGULATED PROLIFERATION-ASSOCIATED PROTEIN, 20-KD; HRPAP20;; CHROMOSOME 6 OPEN READING FRAME 66; C6ORF66__:__
Number Sign__:__611777__:__BRUGADA SYNDROME 2; BRGDA2__:____:__
Asterisk__:__611778__:__GLYCEROL-3-PHOSPHATE DEHYDROGENASE 1-LIKE; GPD1L__:__KIAA0089__:__
Asterisk__:__611779__:__FIBROUS SHEATH CABYR-BINDING PROTEIN; FSCB__:__CHROMOSOME 14 OPEN READING FRAME 155; C14ORF155__:__
Asterisk__:__611780__:__PHD AND RING FINGER DOMAIN-CONTAINING PROTEIN 1; PHRF1__:__KIAA1542__:__
Asterisk__:__611781__:__PR DOMAIN-CONTAINING PROTEIN 14; PRDM14__:__PFM11__:__
Asterisk__:__611782__:__DOWN SYNDROME CELL ADHESION MOLECULE-LIKE 1; DSCAML1__:__DSCAM-LIKE 1;; KIAA1132__:__
Number Sign__:__611783__:__ERYTHROCYTOSIS, FAMILIAL, 4; ECYT4__:____:__
Asterisk__:__611784__:__GENERAL TRANSCRIPTION FACTOR 3C, POLYPEPTIDE 6; GTF3C6__:__TRANSCRIPTION FACTOR IIIC, 35-KD SUBUNIT; TFIIIC35;; C6ORF51__:__
Asterisk__:__611785__:__ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 5; ABCB5__:____:__
Asterisk__:__611786__:__MEDIATOR OF CELL MOTILITY 1; MEMO1__:__MEMO;; CHROMOSOME 2 OPEN READING FRAME 4; C2ORF4__:__
Asterisk__:__611787__:__CYTIDINE MONOPHOSPHATE (UMP-CMP) KINASE 2, MITOCHONDRIAL; CMPK2__:__CYTIDYLATE KINASE 2;; URIDINE MONOPHOSPHATE/CYTIDINE MONOPHOSPHATE 2;; UMP/CMP KINASE 2;; UMP/CMPK2__:__
Number Sign__:__611788__:__AORTIC ANEURYSM, FAMILIAL THORACIC 6; AAT6__:__FAMILIAL THORACIC AORTIC ANEURYSM WITH LIVEDO RETICULARIS AND IRIS FLOCCULI__:__
Asterisk__:__611789__:__NA+/H+ EXCHANGER DOMAIN-CONTAINING PROTEIN 2; NHEDC2__:__SODIUM/HYDROGEN EXCHANGER DOMAIN-CONTAINING PROTEIN 2;; SODIUM HYDROGEN ANTIPORTER 2; NHA2__:__
Asterisk__:__611790__:__MYOSIN VIIA- AND RAB-INTERACTING PROTEIN; MYRIP__:__SYNAPTOTAGMIN-LIKE PROTEIN LACKING C2 DOMAINS C; SLAC2C__:__
Asterisk__:__611791__:__PATCHED DOMAIN-CONTAINING PROTEIN 3; PTCHD3__:____:__
Asterisk__:__611792__:__ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 4; ZCCHC4__:____:__
Asterisk__:__611793__:__LSM12, S. CEREVISIAE, HOMOLOG OF; LSM12__:____:__
Asterisk__:__611794__:__MICRO RNA 369; MIR369__:__miRNA369;; MIRN369;; MIR369-3p; MIR369-3__:__MICRO RNA 369-5p, INCLUDED; MIR369-5p, INCLUDED
Asterisk__:__611795__:__MICRO RNA 145; MIR145__:__miRNA145;; MIRN145__:__
Asterisk__:__611796__:__SECRETOGRANIN III; SCG3__:____:__
Asterisk__:__611797__:__UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX CHAPERONE 1; UQCC1__:__UQCC;; CBP3, S. CEREVISIAE, HOMOLOG OF; CBP3;; BASIC FIBROBLAST GROWTH FACTOR-REPRESSED ZIC-BINDING PROTEIN; BFZB;; BFGF-REPRESSED ZIC-BINDING PROTEIN;; CHROMOSOME 20 OPEN READING FRAME 44; C20ORF44__:__
Asterisk__:__611798__:__EFR3, S. CEREVISIAE, HOMOLOG OF, A; EFR3A__:__KIAA0143__:__
Asterisk__:__611799__:__LIGAND-DEPENDENT NUCLEAR RECEPTOR COREPRESSOR-LIKE PROTEIN; LCORL__:__LCOR-LIKE PROTEIN;; MBLK1-RELATED PROTEIN 1; MLR1__:__PRC2-ASSOCIATED LCOR ISOFORM 2, INCLUDED; PALI2, INCLUDED
Asterisk__:__611800__:__THYROID ADENOMA-ASSOCIATED GENE; THADA__:__KIAA1767__:__
Asterisk__:__611801__:__POST-GPI ATTACHMENT TO PROTEINS 3; PGAP3__:__PER1-LIKE DOMAIN-CONTAINING PROTEIN 1; PERLD1;; GENE COAMPLIFIED WITH ERBB2; CAB2;; MGC9753__:__
Asterisk__:__611802__:__MIGRATION AND INVASION ENHANCER 1; MIEN1__:__CHROMOSOME 17 OPEN READING FRAME 37; C17ORF37;; REDOX PROTEIN, 12-KD; RDX12;; C35__:__
Asterisk__:__611803__:__INTEGRIN-ALPHA FG-GAP REPEAT-CONTAINING PROTEIN 1; ITFG1__:__T-CELL IMMUNOMODULATORY PROTEIN; TIP__:__
Number Sign__:__611804__:__ELLIPTOCYTOSIS 1; EL1__:__ELLIPTOCYTOSIS, RHESUS-LINKED TYPE;; PROTEIN 4.1 OF ERYTHROCYTE MEMBRANE, DEFECT OF;; 4.1-MINUS TRAIT;; 4.1- TRAIT__:__
Asterisk__:__611805__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 5; ELOVL5__:__HELO1__:__
Asterisk__:__611806__:__ARSENIC (+3 OXIDATION STATE) METHYLTRANSFERASE; AS3MT__:__S-ADENOSYL-L-METHIONINE:ARSENIC(III) METHYLTRANSFERASE;; CYT19__:__
Asterisk__:__611807__:__TIP41-LIKE PROTEIN; TIPRL__:__TIP41, S. CEREVISIAE, HOMOLOG OF; TIP41;; PROTEIN PHOSPHATASE 2A-INTERACTING PROTEIN; TIP__:__
NULL__:__611808__:__TREMOR, HEREDITARY ESSENTIAL, AND IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS; ETINPH__:____:__
Number Sign__:__611809__:__BESTROPHINOPATHY, AUTOSOMAL RECESSIVE; ARB__:____:__
Asterisk__:__611810__:__USH1C-BINDING PROTEIN 1; USHBP1__:__MUTATED IN COLON CANCER 2; MCC2__:__
Asterisk__:__611811__:__ZINC FINGER PROTEIN 333; ZNF333__:__KIAA1806__:__
Number Sign__:__611812__:__46,XX SEX REVERSAL WITH DYSGENESIS OF KIDNEYS, ADRENALS, AND LUNGS; SERKAL__:__SERKAL SYNDROME__:__
Asterisk__:__611813__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 1; ELOVL1__:__SSC1, MOUSE, HOMOLOG OF__:__
Asterisk__:__611814__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 2; ELOVL2__:__SSC2, MOUSE, HOMOLOG OF__:__
Asterisk__:__611815__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 3; ELOVL3__:__CIG30, MOUSE, HOMOLOG OF__:__
Number Sign__:__611816__:__TEMPLE-BARAITSER SYNDROME; TMBTS__:__MENTAL RETARDATION, SEVERE, AND ABSENT NAILS OF HALLUX AND POLLEX__:__
Asterisk__:__611817__:__KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY K, MEMBER 1; KLRK1__:__NKG2D__:__
Number Sign__:__611818__:__LONG QT SYNDROME 9; LQT9__:__LONG QT SYNDROME 9, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED;; LONG QT SYNDROME 2/9, DIGENIC, INCLUDED; LQT2/9, DIGENIC, INCLUDED__:__
Number Sign__:__611819__:__LONG QT SYNDROME 10; LQT10__:____:__ATRIAL FIBRILLATION, FAMILIAL, 17, INCLUDED; ATFB17, INCLUDED
Number Sign__:__611820__:__LONG QT SYNDROME 11; LQT11__:____:__
Asterisk__:__611821__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L1; MRPL1__:____:__
Asterisk__:__611822__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L2; MRPL2__:____:__
Asterisk__:__611823__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L4; MRPL4__:____:__
Asterisk__:__611824__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L9; MRPL9__:____:__
Asterisk__:__611825__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L10; MRPL10__:__MRPL8__:__
Asterisk__:__611826__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L11; MRPL11__:____:__
Asterisk__:__611827__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L14; MRPL14__:__MRPL32__:__
Asterisk__:__611828__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L15; MRPL15__:____:__
Asterisk__:__611829__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L16; MRPL16__:____:__
Asterisk__:__611830__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L17; MRPL17__:____:__
Asterisk__:__611831__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L18; MRPL18__:____:__
Asterisk__:__611832__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L19; MRPL19__:__MRPL15;; KIAA0104__:__
Asterisk__:__611833__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L20; MRPL20__:____:__
Asterisk__:__611834__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L21; MRPL21__:____:__
Asterisk__:__611835__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L22; MRPL22__:__MRPL25__:__
Asterisk__:__611836__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L24; MRPL24__:____:__
Asterisk__:__611837__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L27; MRPL27__:____:__
Asterisk__:__611838__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L30; MRPL30__:__MRPL28__:__
Asterisk__:__611839__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L32; MRPL32__:____:__
Asterisk__:__611840__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L34; MRPL34__:____:__
Asterisk__:__611841__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L35; MRPL35__:____:__
Asterisk__:__611842__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L36; MRPL36__:____:__
Asterisk__:__611843__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L37; MRPL37__:____:__
Asterisk__:__611844__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L38; MRPL38__:____:__
Asterisk__:__611845__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L39; MRPL39__:__MRPL5__:__
Asterisk__:__611846__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L41; MRPL41__:__MRPL27__:__
Asterisk__:__611847__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L42; MRPL42__:__MRPL31;; MRPS32__:__
Asterisk__:__611848__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L43; MRPL43__:____:__
Asterisk__:__611849__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L44; MRPL44__:____:__
Asterisk__:__611850__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L45; MRPL45__:____:__
Asterisk__:__611851__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L46; MRPL46__:____:__
Asterisk__:__611852__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L47; MRPL47__:____:__
Asterisk__:__611853__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L48; MRPL48__:____:__
Asterisk__:__611854__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L50; MRPL50__:____:__
Asterisk__:__611855__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L51; MRPL51__:__MRP64__:__
Asterisk__:__611856__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L52; MRPL52__:____:__
Asterisk__:__611857__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L53; MRPL53__:____:__
Asterisk__:__611858__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L54; MRPL54__:____:__
Asterisk__:__611859__:__MITOCHONDRIAL RIBOSOMAL PROTEIN L55; MRPL55__:____:__
Caret__:__611860__:__MOVED TO 210720__:____:__
Asterisk__:__611861__:__ADP-DEPENDENT GLUCOKINASE; ADPGK__:__ADP-GK__:__
Number Sign__:__611862__:__WHITE BLOOD CELL COUNT QUANTITATIVE TRAIT LOCUS 1; WBCQ1__:____:__
Percent__:__611863__:__MICROTIA WITH NASOLACRIMAL DUCT IMPERFORATION AND EYE COLOBOMA__:____:__
Asterisk__:__611864__:__ARMADILLO REPEAT-CONTAINING 10; ARMC10__:__SPLICING VARIANT INVOLVED IN HEPATOCARCINOGENESIS; SVH__:__
Asterisk__:__611865__:__L3MBT-LIKE 2; L3MBTL2__:__L3MBT, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__611866__:__RETINOL-BINDING PROTEIN 5; RBP5__:__CELLULAR RETINOL-BINDING PROTEIN 3; CRBP3;; CRBPIII__:__
Number Sign__:__611867__:__CHROMOSOME 22q11.2 DELETION SYNDROME, DISTAL__:__DISTAL CHROMOSOME 22q11.2 DELETION SYNDROME__:__
Number Sign__:__611868__:__PROSTATE CANCER, HEREDITARY, 12; HPC12__:____:__
Asterisk__:__611869__:__RABAPTIN, RAB GTPase-BINDING EFFECTOR PROTEIN 2; RABEP2__:__RABAPTIN 5-BETA__:__
Asterisk__:__611870__:__CENTLEIN; CNTLN__:__CHROMOSOME 9 OPEN READING FRAME 39; C9ORF39;; CHROMOSOME 9 OPEN READING FRAME 101; C9ORF101__:__
Asterisk__:__611871__:__FAMILY WITH SEQUENCE SIMILARITY 82, MEMBER B; FAM82B__:__REGULATOR OF MICROTUBULE DYNAMICS 1; RMD1__:__
Asterisk__:__611872__:__FAMILY WITH SEQUENCE SIMILARITY 82, MEMBER A1; FAM82A1__:__REGULATOR OF MICROTUBULE DYNAMICS 2; RMD2;; FAMILY WITH SEQUENCE SIMILARITY 82, MEMBER A, FORMERLY; FAM82A, FORMERLY__:__
Asterisk__:__611873__:__FAMILY WITH SEQUENCE SIMILARITY 82, MEMBER A2; FAM82A2__:__REGULATOR OF MICROTUBULE DYNAMICS 3; RMD3;; PROTEIN TYROSINE PHOSPHATASE-INTERACTING PROTEIN 51: PTPIP51 FAMILY WITH SEQUENCE SIMILARITY 82, MEMBER C, FORMERLY; FAM82C, FORMERLY__:__
Asterisk__:__611874__:__NEURON-DERIVED NEUROTROPHIC FACTOR; NENF__:__NEUDESIN;; CELL IMMORTALIZATION-RELATED PROTEIN 2; CIR2__:__
Number Sign__:__611875__:__BRUGADA SYNDROME 3; BRGDA3__:____:__
Number Sign__:__611876__:__BRUGADA SYNDROME 4; BRGDA4__:____:__
Asterisk__:__611877__:__BAI1-ASSOCIATED PROTEIN 2-LIKE 1; BAIAP2L1__:__INSULIN RECEPTOR TYROSINE KINASE SUBSTRATE; IRTKS__:__
Number Sign__:__611878__:__CARDIOMYOPATHY, DILATED, 1Y; CMD1Y__:____:__LEFT VENTRICULAR NONCOMPACTION 9, INCLUDED; LVNC9, INCLUDED
Number Sign__:__611879__:__CARDIOMYOPATHY, DILATED, 1Z; CMD1Z__:____:__
Number Sign__:__611880__:__CARDIOMYOPATHY, DILATED, 2A; CMD2A__:__CARDIOMYOPATHY, DILATED, AUTOSOMAL RECESSIVE;; CARDIOMYOPATHY, CONGESTIVE, AUTOSOMAL RECESSIVE__:__
Number Sign__:__611881__:__GLYCOGEN STORAGE DISEASE XII; GSD12__:__GSD XII;; ALDOLASE A DEFICIENCY;; ALDOA DEFICIENCY;; ALDOLASE DEFICIENCY, RED CELL;; RED CELL ALDOLASE DEFICIENCY__:__
Asterisk__:__611882__:__PROLINE-RICH NUCLEAR RECEPTOR COACTIVATOR 2; PNRC2__:____:__
Asterisk__:__611883__:__BRCA2- AND CDKN1A-INTERACTING PROTEIN; BCCIP__:__p21- AND CDK-ASSOCIATED PROTEIN 1; TOK1__:__
Number Sign__:__611884__:__CILIARY DYSKINESIA, PRIMARY, 7; CILD7__:__CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__611885__:__SHANK-ASSOCIATED RH DOMAIN INTERACTOR; SHARPIN__:__SHANK-INTERACTING PROTEIN-LIKE 1; SIPL1__:__
NULL__:__611886__:__MESOMELIC DYSPLASIA, CAMERA TYPE__:____:__
Asterisk__:__611887__:__UROPLAKIN 3B; UPK3B__:__UPIIIB;; P35__:__
Asterisk__:__611888__:__ETS2 REPRESSOR FACTOR; ERF__:__PE2__:__
Asterisk__:__611889__:__S100P-BINDING PROTEIN; S100PBP__:__S100PBPR__:__
Number Sign__:__611890__:__LETHAL ARTHROGRYPOSIS WITH ANTERIOR HORN CELL DISEASE; LAAHD__:____:__
Percent__:__611891__:__AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 3; AAA3__:____:__
Percent__:__611892__:__ANEURYSM, INTRACRANIAL BERRY, 6; ANIB6__:____:__
Asterisk__:__611893__:__PLECKSTRIN HOMOLOGY DOMAIN- AND RhoGEF DOMAIN-CONTAINING PROTEIN G2; PLEKHG2__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY G, MEMBER 2;; CLG__:__
Asterisk__:__611894__:__MICRO RNA 140; MIR140__:__miRNA140;; MIRN140__:__
Number Sign__:__611895__:__AMYOTROPHIC LATERAL SCLEROSIS 9; ALS9__:____:__
Asterisk__:__611896__:__RETROTRANSPOSON-LIKE GENE 1; RTL1__:__PATERNALLY EXPRESSED GENE 11; PEG11__:__
Percent__:__611897__:__NANOPHTHALMOS 3; NNO3__:__NANOPHTHALMIA 3__:__
Asterisk__:__611898__:__ENDO-BETA-N-ACETYLGLUCOSAMINIDASE; ENGASE__:__FLJ21865__:__
Asterisk__:__611899__:__MICRO RNA 203; MIR203__:__miRNA203;; MIRN203__:__
Asterisk__:__611900__:__METALLOPHOSPHOESTERASE 1; MPPE1__:__PGAP5__:__
Asterisk__:__611901__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 1; VWA1__:__VA DOMAIN-CONTAINING PROTEIN 1;; VON WILLEBRAND FACTOR A DOMAIN-RELATED PROTEIN; WARP__:__
Asterisk__:__611902__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 136; CCDC136__:__NAG6;; KIAA1793__:__
Asterisk__:__611903__:__ZINC FINGER PROTEIN 649; ZNF649__:____:__
Asterisk__:__611904__:__PLACENTA-EXPRESSED TRANSCRIPT 1, MOUSE, HOMOLOG OF; PLET1__:__CHROMOSOME 11 OPEN READING FRAME 34; C11ORF34__:__
Asterisk__:__611905__:__FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 4; FNDC4__:__FRCP1__:__
Asterisk__:__611906__:__FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 5; FNDC5__:__FRCP2__:__IRISIN, INCLUDED
Percent__:__611907__:__EPISODIC ATAXIA, TYPE 7; EA7__:____:__
Asterisk__:__611908__:__RFT1, S. CEREVISIAE, HOMOLOG OF; RFT1__:____:__
Asterisk__:__611909__:__FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 3B; FNDC3B__:__FACTOR FOR ADIPOCYTE DIFFERENTIATION 104; FAD104__:__
Asterisk__:__611910__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 12; SLC16A12__:__MONOCARBOXYLATE TRANSPORTER 12; MCT12__:__
Asterisk__:__611911__:__IRON-SULFUR CLUSTER SCAFFOLD, E. COLI, HOMOLOG OF; ISCU__:____:__
Asterisk__:__611912__:__NUCLEAR CASEIN KINASE AND CYCLIN-DEPENDENT KINASE SUBSTRATE 1; NUCKS1__:__NUCKS__:__
Number Sign__:__611913__:__CHROMOSOME 16p11.2 DELETION SYNDROME, 593-KB__:____:__AUTISM, SUSCEPTIBILITY TO, 14A, INCLUDED; AUTS14A, INCLUDED
Asterisk__:__611914__:__TSC22 DOMAIN FAMILY, MEMBER 4; TSC22D4__:__TSC22 HOMOLOGOUS GENE 1; THG1;; TSC22-LIKE__:__
Asterisk__:__611915__:__VESICULAR, OVEREXPRESSED IN CANCER, PROSURVIVAL PROTEIN 1; VOPP1__:__EGFR-COAMPLIFIED AND OVEREXPRESSED PROTEIN; ECOP;; GLIOBLASTOMA-AMPLIFIED SECRETED PROTEIN; GASP__:__
Asterisk__:__611916__:__COLLAGEN, TYPE VI, ALPHA-5; COL6A5__:__COLLAGEN, TYPE XXIX, ALPHA-1; COL29A1__:__
Asterisk__:__611917__:__LYSINE-SPECIFIC DEMETHYLASE 8; KDM8__:__LYSINE DEMETHYLASE 8;; JUMONJI DOMAIN-CONTAINING PROTEIN 5; JMJD5__:__
Caret__:__611918__:__MOVED TO 601869__:____:__
Asterisk__:__611919__:__RIBOSOMAL OXYGENASE 1; RIOX1__:__MYC-ASSOCIATED PROTEIN WITH JMJC DOMAIN; MAPJD;; NUCLEOLAR PROTEIN, 66-KD; NO66;; CHROMOSOME 14 OPEN READING FRAME 169; C14ORF169__:__
Percent__:__611920__:__C-REACTIVE PROTEIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; CRPQTL1__:____:__
Asterisk__:__611921__:__GAP JUNCTION PROTEIN, BETA-7; GJB7__:__CONNEXIN 25; CX25__:__
Asterisk__:__611922__:__GAP JUNCTION PROTEIN, DELTA-4; GJD4__:__CONNEXIN 40.1; CX40.1__:__
Asterisk__:__611923__:__GAP JUNCTION PROTEIN, ALPHA-9; GJA9__:__CONNEXIN 59; CX59__:__
Asterisk__:__611924__:__GAP JUNCTION PROTEIN, ALPHA-10; GJA10__:__CONNEXIN 62; CX62__:__
Asterisk__:__611925__:__GAP JUNCTION PROTEIN, GAMMA-3; GJC3__:__CONNEXIN 30.2; CX30.2;; CONNEXIN 31.3; CX31.3;; CONNEXIN 29; CX29;; GAP JUNCTION PROTEIN, EPSILON-1, FORMERLY; GJE1, FORMERLY__:__
Percent__:__611926__:__IMMUNODEFICIENCY, OVARIAN DYSGENESIS, AND PULMONARY FIBROSIS__:____:__
Asterisk__:__611927__:__FAMILY WITH SEQUENCE SIMILARITY 83, MEMBER H; FAM83H__:____:__
Number Sign__:__611928__:__PROSTATE CANCER, HEREDITARY, 13; HPC13__:____:__
Percent__:__611929__:__CAMPTODACTYLY SYNDROME, GUADALAJARA, TYPE III__:____:__
Asterisk__:__611930__:__INTERFERON-STIMULATED EXONUCLEASE GENE 20-KD-LIKE 2; ISG20L2__:____:__
Asterisk__:__611931__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1L; PPM1L__:__PROTEIN PHOSPHATASE 1-LIKE;; PPM1-LIKE;; PROTEIN PHOSPHATASE 2C, EPSILON ISOFORM; PP2CE;; PP2C-EPSILON__:__
Asterisk__:__611932__:__CDGSH IRON SULFUR DOMAIN PROTEIN 1; CISD1__:__MITOCHONDRIAL ASN-GLU-GLU-THR (NEET); MITONEET__:__
Asterisk__:__611933__:__CDGSH IRON SULFUR DOMAIN PROTEIN 3; CISD3__:__MITONEET-RELATED 2; MINER2__:__
Percent__:__611934__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 5; EIG5__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, LOCUS ON CHROMOSOME 10__:__
Asterisk__:__611935__:__MMADHC GENE; MMADHC__:__CHROMOSOME 2 OPEN READING FRAME 25; C2ORF25__:__
Number Sign__:__611936__:__CHROMOSOME 3q29 DUPLICATION SYNDROME__:__MICRODUPLICATION 3q29 SYNDROME__:__
Asterisk__:__611937__:__IMMUNOGLOBULIN HEAVY CHAIN DIVERSITY GENE 3-3; IGHD3-3__:__IGHD33;; DXP4__:__
Number Sign__:__611938__:__VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2__:__VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC; VTSIP__:__
Asterisk__:__611939__:__IMMUNOGLOBULIN HEAVY CHAIN VARIABLE GENE 3-23; IGHV3-23__:__IGHV323;; V3-23;; VH26;; DP47__:__
Asterisk__:__611940__:__MEMBRANE-BOUND O-ACETYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 4; MBOAT4__:__GHRELIN O-ACETYLTRANSFERASE; GOAT__:__
Asterisk__:__611941__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 2; ATAD2__:__AAA NUCLEAR COREGULATOR, CANCER-ASSOCIATED; ANCCA__:__
Number Sign__:__611942__:__EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 6; ECA6__:____:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 6, INCLUDED; EIG6, INCLUDED
Number Sign__:__611943__:__RIDDLE SYNDROME__:__RADIOSENSITIVITY, IMMUNODEFICIENCY, DYSMORPHIC FEATURES, AND LEARNING DIFFICULTIES__:__
Percent__:__611944__:__LYMPHATIC MALFORMATION 2; LMPHM2__:__LYMPHEDEMA, HEREDITARY, IB, FORMERLY; LMPH1B, FORMERLY__:__
Percent__:__611945__:__SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37__:____:__
Asterisk__:__611946__:__UBX DOMAIN PROTEIN 6; UBXN6__:__UBX DOMAIN-CONTAINING GENE 1; UBXD1__:__
Asterisk__:__611947__:__NLR FAMILY MEMBER X1; NLRX1__:__NOD9;; CLR11.3__:__
Caret__:__611948__:__MOVED TO 267750__:____:__
Asterisk__:__611949__:__MEMBRANE-BOUND O-ACYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 2; MBOAT2__:__MEMBRANE-BOUND O-ACYLTRANSFERASE 2;; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 4; LPCAT4__:__
Asterisk__:__611950__:__LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 3; LPCAT3__:__MEMBRANE-BOUND O-ACYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 5; MBOAT5;; MEMBRANE-BOUND O-ACYLTRANSFERASE 5;; NESSY, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__611951__:__B9 DOMAIN-CONTAINING PROTEIN 2; B9D2__:__STUMPY, MOUSE, HOMOLOG OF;; MKS1-RELATED PROTEIN 2; MKSR2__:__
Asterisk__:__611952__:__VACUOLAR PROTEIN SORTING 28, YEAST, HOMOLOG OF; VPS28__:____:__
Number Sign__:__611953__:__MACULAR DEGENERATION, AGE-RELATED, 11; ARMD11__:____:__
Asterisk__:__611954__:__MICRO RNA 373; MIR373__:__miRNA373;; MIRN373__:__
Percent__:__611955__:__PROSTATE CANCER, HEREDITARY, 11; HPC11__:____:__
Asterisk__:__611956__:__CHROMOSOME 3 OPEN READING FRAME 52; C3ORF52__:__TPA-INDUCED TRANSMEMBRANE PROTEIN; TTMP__:__
Asterisk__:__611957__:__MICRO RNA 378; MIRN378__:__miRNA378;; MIR378__:__
Percent__:__611958__:__PROSTATE CANCER, HEREDITARY, 14; HPC14__:____:__
Percent__:__611959__:__PROSTATE CANCER, HEREDITARY, 15; HPC15__:____:__
Number Sign__:__611960__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 7; ASRT7__:____:__
NULL__:__611961__:__STEVENSON-CAREY SYNDROME__:____:__
Percent__:__611962__:__HUNTER-MACDONALD SYNDROME__:____:__
Asterisk__:__611963__:__ACYL-CoA THIOESTERASE 7-LIKE__:__LOC344967__:__
Asterisk__:__611964__:__CYTOCHROME b5, TYPE B (OUTER MITOCHONDRIAL MEMBRANE); CYB5B__:__OUTER MITOCHONDRIAL MEMBRANE CYTOCHROME b5; OMB5;; CYPB5M;; CYTB5, TYPE 2__:__
Asterisk__:__611965__:__THO COMPLEX, SUBUNIT 7; THOC7__:__NIF3L1-BINDING PROTEIN 1; NIF3L1BP1;; FSAP24__:__
Asterisk__:__611966__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 9; TRAPPC9__:__NIK- AND IKBKB-BINDING PROTEIN; NIBP;; KIAA1882__:__
Asterisk__:__611967__:__KELCH-LIKE 8; KLHL8__:__KIAA1378__:__
Asterisk__:__611968__:__CLEAVAGE STIMULATION FACTOR, 3-PRIME PRE-RNA, SUBUNIT 2, 64-KD, TAU VARIANT; CSTF2T__:__CSTF2, TAU VARIANT;; CSTF64, TAU VARIANT;; TAU-CSTF64;; KIAA0689__:__
Asterisk__:__611969__:__HCCA2 GENE; HCCA2__:____:__
Asterisk__:__611970__:__NUCLEOLAR PROTEIN INTERACTING WITH THE FHA DOMAIN OF MKI67; NIFK__:__MKI67-INTERACTING NUCLEOLAR PHOSPHOPROTEIN; MKI67IP;; NOPP34__:__
Asterisk__:__611971__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S2; MRPS2__:____:__
Asterisk__:__611972__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S5; MRPS5__:____:__
Asterisk__:__611973__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S6; MRPS6__:____:__
Asterisk__:__611974__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S7; MRPS7__:____:__
Asterisk__:__611975__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S9; MRPS9__:____:__
Asterisk__:__611976__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S10; MRPS10__:____:__
Asterisk__:__611977__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S11; MRPS11__:____:__
Asterisk__:__611978__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S14; MRPS14__:____:__
Asterisk__:__611979__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S15; MRPS15__:____:__
Asterisk__:__611980__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S17; MRPS17__:____:__
Asterisk__:__611981__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S18A; MRPS18A__:__MRPS18-3__:__
Asterisk__:__611982__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S18B; MRPS18B__:__MRPS18-2__:__
Asterisk__:__611983__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S18C; MRPS18C__:__MRPS18-1__:__
Asterisk__:__611984__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S21; MRPS21__:____:__
Asterisk__:__611985__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S23; MRPS23__:____:__
Asterisk__:__611986__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S24; MRPS24__:____:__
Asterisk__:__611987__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S25; MRPS25__:____:__
Asterisk__:__611988__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S26; MRPS26__:__MRPS13__:__
Asterisk__:__611989__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S27; MRPS27__:__KIAA0264__:__
Asterisk__:__611990__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S28; MRPS28__:__MRPS35__:__
Asterisk__:__611991__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S30; MRPS30__:____:__
Asterisk__:__611992__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S31; MRPS31__:__IMOGEN 38__:__
Asterisk__:__611993__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S33; MRPS33__:____:__
Asterisk__:__611994__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S34; MRPS34__:__MRPS12__:__
Asterisk__:__611995__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S35; MRPS35__:__MRPS28__:__
Asterisk__:__611996__:__MITOCHONDRIAL RIBOSOMAL PROTEIN S36; MRPS36__:____:__
Asterisk__:__611997__:__MITOCHONDRIAL RIBOSOMAL PROTEIN 63; MRP63__:____:__
Asterisk__:__611998__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3__:__CREBH__:__
Asterisk__:__611999__:__RAB11 FAMILY-INTERACTING PROTEIN 4; RAB11FIP4__:__KIAA1821__:__
Asterisk__:__612000__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 66; TRIM66__:__TRANSCRIPTIONAL INTERMEDIARY FACTOR 1-DELTA; TIF1D;; TIF1-DELTA;; KIAA0298__:__
Number Sign__:__612001__:__CHROMOSOME 15q13.3 DELETION SYNDROME__:__CHROMOSOME 15q13.3 MICRODELETION SYNDROME__:__
Asterisk__:__612002__:__DEP DOMAIN-CONTAINING PROTEIN 1; DEPDC1__:__FLJ20354__:__
Asterisk__:__612003__:__GRB10-INTERACTING GYF PROTEIN 2; GIGYF2__:__KIAA0642__:__
Number Sign__:__612004__:__THROMBOCYTOPENIA 4; THC4__:__THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 4__:__
Percent__:__612005__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 7; CELIAC7__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 7__:__
Percent__:__612006__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 8; CELIAC8__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 8__:__
Percent__:__612007__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 9; CELIAC9__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 9__:__
Percent__:__612008__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 10; CELIAC10__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 10__:__
Percent__:__612009__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 11; CELIAC11__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 11__:__
Percent__:__612010__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 12; CELIAC12__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 12__:__
Percent__:__612011__:__CELIAC DISEASE, SUSCEPTIBILITY TO, 13; CELIAC13__:__GLUTEN-SENSITIVE ENTEROPATHY, SUSCEPTIBILITY TO, 13__:__
Asterisk__:__612012__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 26; ZFYVE26__:__KIAA0321;; SPASTIZIN;; SPG15 GENE; SPG15__:__
Asterisk__:__612013__:__COILED-COIL AND C2 DOMAINS-CONTAINING PROTEIN 2A; CC2D2A__:__KIAA1345__:__
Asterisk__:__612014__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 21B; TTC21B__:__TETRATRICOPEPTIDE REPEAT-CONTAINING HEDGEHOG MODULATOR 1; THM1__:__
Number Sign__:__612015__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE In; CDG1N__:__CDG In; CDGIn__:__
Number Sign__:__612016__:__COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9__:__
Percent__:__612017__:__PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 3; IHPS3__:____:__
Number Sign__:__612018__:__CATARACT 47; CTRCT47__:__CATARACT, JUVENILE, WITH MICROCORNEA;; CATARACT, JUVENILE, WITH MICROCORNEA AND GLUCOSURIA, FORMERLY; CJMG, FORMERLY__:__
Asterisk__:__612019__:__INTESTINE-SPECIFIC HOMEOBOX; ISX__:__RAX-LIKE HOMEOBOX; RAXLX__:__
Number Sign__:__612020__:__SPASTIC PARAPLEGIA 39, AUTOSOMAL RECESSIVE; SPG39__:__NTE-RELATED MOTOR NEURON DISORDER; NTEMND__:__
Asterisk__:__612021__:__OTU DOMAIN-CONTAINING PROTEIN 6B; OTUD6B__:__DUBA5__:__
Asterisk__:__612022__:__OTU DOMAIN-CONTAINING PROTEIN 1; OTUD1__:__DUBA7__:__
Asterisk__:__612023__:__YOD1 OTU DEUBIQUITINATING ENZYME 1, S. CEREVISIAE, HOMOLOG OF; YOD1__:__OTU DOMAIN-CONTAINING PROTEIN 2; OTUD2;; DUBA8__:__
Asterisk__:__612024__:__OTU DOMAIN-CONTAINING PROTEIN 7A; OTUD7A__:__OTUD7;; CHROMOSOME 16 OPEN READING FRAME 15; C16ORF15;; CEZANNE2__:__
Asterisk__:__612025__:__IODOTYROSINE DEIODINASE; IYD__:__IODOTYROSINE DEHALOGENASE 1; DEHAL1__:__
Asterisk__:__612026__:__La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 7; LARP7__:__PTEFB INTERACTION PROTEIN FOR 7SK STABILITY; PIP7S__:__
Asterisk__:__612027__:__GRP1-ASSOCIATED SCAFFOLD PROTEIN; GRASP__:__TAMALIN__:__
Asterisk__:__612028__:__FAT STORAGE-INDUCING TRANSMEMBRANE PROTEIN 1; FITM1__:__FAT-INDUCING TRANSCRIPT 1; FIT1__:__
Asterisk__:__612029__:__FAT STORAGE-INDUCING TRANSMEMBRANE PROTEIN 2; FITM2__:__FAT-INDUCING TRANSCRIPT 2; FIT2;; CHROMOSOME 20 OPEN READING FRAME 142; C20ORF142__:__
Percent__:__612030__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 9; CHDS9__:____:__
Asterisk__:__612031__:__INHIBIN, BETA E; INHBE__:____:__ACTIVIN BETA-E, INCLUDED
Asterisk__:__612032__:__DPY30, C. ELEGANS, HOMOLOG OF: DPY30__:____:__
Asterisk__:__612033__:__PAXIP1-ASSOCIATED GLUTAMATE-RICH PROTEIN 1; PAGR1__:__PTIP-ASSOCIATED 1 PROTEIN; PA1;; CHROMOSOME 16 OPEN READING FRAME 53; C16ORF53__:__
Asterisk__:__612034__:__APC2 GENE; APC2__:__APC-LIKE; APCL__:__
Asterisk__:__612035__:__ALANYL-tRNA SYNTHETASE 2; AARS2__:__ALANYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MT-ALARS;; KIAA1270__:__
Asterisk__:__612036__:__PROLYL-tRNA SYNTHETASE 2; PARS2__:__PROLYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MT-PRORS__:__
Asterisk__:__612037__:__MITOCHONDRIAL UBIQUITIN LIGASE ACTIVATOR OF NFKB 1; MUL1__:__MULAN;; CHROMOSOME 1 OPEN READING FRAME 166; C1ORF166__:__
Asterisk__:__612038__:__TRANSMEMBRANE p24 TRAFFICKING PROTEIN 4; TMED4__:__TRANSMEMBRANE EMP24 PROTEIN TRANSPORT DOMAIN-CONTAINING PROTEIN 4__:__
Asterisk__:__612039__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 7; AGPAT7__:__ACYLTRANSFERASE-LIKE 3; AYTL3__:__
Asterisk__:__612040__:__LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 2; LPCAT2__:__ACYLTRANSFERASE-LIKE 1; AYTL1__:__
Asterisk__:__612041__:__RING FINGER PROTEIN 212; RNF212__:__ZHP3, C. ELEGANS, HOMOLOG OF; ZHP3;; ZIP3-RELATED PROTEIN__:__
Number Sign__:__612042__:__RECOMBINATION RATE QUANTITATIVE TRAIT LOCUS 1; RRQTL1__:____:__
Asterisk__:__612043__:__MICRO RNA 371A; MIR371A__:__miRNA371A;; miRNA371;; MIRN371__:__
Asterisk__:__612044__:__MICRO RNA 372; MIRN372__:__miRNA372;; MIR372__:__
Asterisk__:__612045__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 3; C1QTNF3__:__CTRP3;; COLLAGENOUS REPEAT-CONTAINING SEQUENCE, 26-KD PROTEIN; CORS26__:__
Asterisk__:__612046__:__E2F TRANSCRIPTION FACTOR 7; E2F7__:____:__
Asterisk__:__612047__:__E2F TRANSCRIPTION FACTOR 8; E2F8__:____:__
Asterisk__:__612048__:__TRANSMEMBRANE PROTEIN 43; TMEM43__:__LUMA__:__
Asterisk__:__612049__:__MYC-INDUCED NUCLEAR ANTIGEN; MINA__:__MYC-INDUCED NUCLEAR ANTIGEN, 53-KD; MINA53;; MINERAL DUST-INDUCED GENE; MDIG__:__
Asterisk__:__612050__:__NEDD4 FAMILY-INTERACTING PROTEIN 1; NDFIP1__:__NEDD4 WW DOMAIN-BINDING PROTEIN 5; N4WBP5__:__
Asterisk__:__612051__:__BRAIN-EXPRESSED, ASSOCIATED WITH NEDD4; BEAN__:____:__
Number Sign__:__612052__:__SMOKING AS A QUANTITATIVE TRAIT LOCUS 3; SQTL3__:__NICOTINE DEPENDENCE, SUSCEPTIBILITY TO__:__LUNG CANCER SUSCEPTIBILITY 2, INCLUDED; LNCR2, INCLUDED
Asterisk__:__612053__:__ZINC FINGER PROTEIN 36-LIKE 2; ZFP36L2__:__ZFP36-LIKE 2;; EGF RESPONSE FACTOR 2; ERF2;; TIS11D, MOUSE, HOMOLOG OF; TIS11D__:__
Asterisk__:__612054__:__REQUIRED FOR CELL DIFFERENTIATION 1, S. POMBE, HOMOLOG OF; RQCD1__:__RCD1;; CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 9; CNOT9__:__
Asterisk__:__612055__:__RIBOSOMAL PROTEIN S27-LIKE; RPS27L__:__RPS27-LIKE__:__
Asterisk__:__612056__:__GOLGI TO ER TRAFFIC PROTEIN 4, S. CEREVISIAE, HOMOLOG OF; GET4__:__CHROMOSOME 7 OPEN READING FRAME 20; C7ORF20;; CONSERVED EDGE-EXPRESSED PROTEIN; CEE;; TRANSMEMBRANE DOMAIN RECOGNITION COMPLEX, 35-KD;; TRC35__:__
Asterisk__:__612057__:__SUPPRESSOR APC DOMAIN-CONTAINING PROTEIN 2; SAPCD2__:__CHROMOSOME 9 OPEN READING FRAME 140; C9ORF140;; p42.3__:__
Asterisk__:__612058__:__SORTING AND ASSEMBLY MACHINERY COMPONENT 50, S. CEREVISIAE, HOMOLOG OF; SAMM50__:__SAM50__:__
Asterisk__:__612059__:__La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 1; LARP1__:__La-RELATED PROTEIN; LARP;; KIAA0731__:__
Asterisk__:__612060__:__ZINC FINGER AND RING FINGER PROTEIN 1; ZNRF1__:__NERVE INJURY GENE 283; NIN283__:__
Asterisk__:__612061__:__ZINC FINGER AND RING FINGER PROTEIN 2; ZNRF2__:____:__
Asterisk__:__612062__:__ZINC FINGER AND RING FINGER PROTEIN 3; ZNRF3__:__KIAA1133__:__
Asterisk__:__612063__:__ZINC FINGER AND RING FINGER PROTEIN 4; ZNRF4__:__SPERMATID-SPECIFIC RING ZINC FINGER PROTEIN; SPERIZIN__:__
Asterisk__:__612064__:__GRB10-INTERACTING GYF PROTEIN 1; GIGYF1__:____:__
Asterisk__:__612065__:__POLY(ADP-RIBOSE) POLYMERASE 9; PARP9__:__B-AGGRESSIVE LYMPHOMA 1; BAL1;; BAL__:__
Asterisk__:__612066__:__POLY(ADP-RIBOSE) POLYMERASE 15; PARP15__:__B-AGGRESSIVE LYMPHOMA 3; BAL3__:__
Number Sign__:__612067__:__DYSTONIA 16; DYT16__:____:__
Asterisk__:__612068__:__PHOSPHOINOSITIDE-INTERACTING REGULATOR OF TRANSIENT RECEPTOR POTENTIAL CHANNELS; PIRT__:__PHOSPHOINOSITIDE-INTERACTING REGULATOR OF TRP__:__
Number Sign__:__612069__:__AMYOTROPHIC LATERAL SCLEROSIS 10 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS10__:____:__FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP43 INCLUSIONS, TARDBP-RELATED, INCLUDED;; FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, TARDBP-RELATED, INCLUDED;; FTLD-TDP, TARDBP-RELATED, INCLUDED
Asterisk__:__612070__:__MICRO RNA 144; MIRN144__:__miRNA144;; MIR144__:__
Asterisk__:__612071__:__MICRO RNA 451; MIRN451__:__miRNA451;; MIR451__:__
Asterisk__:__612072__:__MIF4G DOMAIN-CONTAINING PROTEIN; MIF4GD__:__SLBP-INTERACTING PROTEIN 1; SLIP1__:__
Number Sign__:__612073__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5__:__MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED__:__
Asterisk__:__612074__:__RNA-BINDING MOTIF PROTEIN 28; RBM28__:____:__
Number Sign__:__612075__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY); MTDPS8A__:__MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENAL TUBULOPATHY, AUTOSOMAL RECESSIVE__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 8B (MNGIE TYPE), INCLUDED; MTDPS8B, INCLUDED;; MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, RRM2B-RELATED, INCLUDED;; MNGIE, RRM2B-RELATED, INCLUDED
Number Sign__:__612076__:__HYPOURICEMIA, RENAL, 2; RHUC2__:____:__URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 2, INCLUDED; UAQTL2, INCLUDED;; GOUT SUSCEPTIBILITY 2, INCLUDED; GOUT2, INCLUDED
Asterisk__:__612077__:__MICRO RNA 22; MIR22__:__miRNA22;; MIRN22__:__
Asterisk__:__612078__:__ZINC FINGER PROTEIN 469; ZNF469__:__KIAA1858__:__
Number Sign__:__612079__:__ALOPECIA, NEUROLOGIC DEFECTS, AND ENDOCRINOPATHY SYNDROME; ANES__:__ANE SYNDROME__:__
Asterisk__:__612080__:__UBIQUINOL-CYTOCHROME c REDUCTASE, COMPLEX III SUBUNIT VII, 9.5-KD; UQCRQ__:__QPC__:__
Asterisk__:__612081__:__INTERLEUKIN 34; IL34__:__CHROMOSOME 16 OPEN READING FRAME 77; C16ORF77__:__
Asterisk__:__612082__:__CAPICUA, DROSOPHILA, HOMOLOG OF; CIC__:__KIAA0306__:__
Percent__:__612083__:__MUSCLE STRENGTH QUANTITATIVE TRAIT LOCUS 1__:__MUSTQTL1__:__
Asterisk__:__612084__:__ORGANIC SOLUTE TRANSPORTER, ALPHA__:__OST-ALPHA; OSTA__:__
Asterisk__:__612085__:__ORGANIC SOLUTE TRANSPORTER, BETA__:__OST-BETA; OSTB__:__
Asterisk__:__612086__:__MINOR HISTOCOMPATIBILITY ANTIGEN, SERPIN DOMAIN-CONTAINING; HMSD__:____:__
Asterisk__:__612087__:__C-TYPE LECTIN DOMAIN FAMILY 2, MEMBER A; CLEC2A__:__PROLIFERATION-INDUCED LYMPHOCYTE-ASSOCIATED RECEPTOR; PILAR__:__
Asterisk__:__612088__:__C-TYPE LECTIN DOMAIN FAMILY 12, MEMBER A; CLEC12A__:__MYELOID INHIBITORY C-TYPE LECTIN-LIKE RECEPTOR; MICL__:__
Percent__:__612089__:__HYPOPHOSPHATEMIC RICKETS AND HYPERPARATHYROIDISM__:____:__
Asterisk__:__612090__:__MICRO RNA 200A; MIR200A__:__miRNA200A;; MIRN200A__:__
Asterisk__:__612091__:__MICRO RNA 200B; MIRN200B__:__miRNA200B;; MIR200B__:__
Asterisk__:__612092__:__MICRO RNA 200C; MIR200C__:__miRNA200C;; MIRN200C__:__
Asterisk__:__612093__:__MICRO RNA 141; MIR141__:__miRNA141;; MIRN141__:__
Asterisk__:__612094__:__MICRO RNA 429; MIRN429__:__miRNA429;; MIR429__:__
Number Sign__:__612095__:__RETINITIS PIGMENTOSA 41; RP41__:__RETINAL DEGENERATION, AUTOSOMAL RECESSIVE, PROMININ-RELATED__:__
Percent__:__612096__:__OTOSCLEROSIS 8; OTSC8__:____:__
Percent__:__612097__:__DEAFNESS, UNILATERAL, WITH DELAYED ENDOLYMPHATIC HYDROPS__:____:__
Number Sign__:__612098__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 11; CMH11__:____:__
Percent__:__612099__:__TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 2__:__MFT2__:__
Number Sign__:__612100__:__AUTISM, SUSCEPTIBILITY TO, 15; AUTS15__:____:__
Asterisk__:__612101__:__PHOSPHATIDYLINOSITOL 4-KINASE, TYPE 2, BETA; PI4K2B__:__PHOSPHATIDYLINOSITOL 4-KINASE, TYPE II, BETA;; PI4KII-BETA__:__
Asterisk__:__612102__:__MICRO RNA LET7G; MIRNLET7G__:__LET7, C. ELEGANS, HOMOLOG OF, G; LET7G;; miRNA LET7G;; MIRLET7G__:__
Asterisk__:__612103__:__OLIGONUCLEOTIDE/OLIGOSACCHARIDE-BINDING FOLD-CONTAINING PROTEIN 2A; OBFC2A__:__SINGLE-STRANDED DNA-BINDING PROTEIN 2; SSB2__:__
Asterisk__:__612104__:__OLIGONUCLEOTIDE/OLIGOSACCHARIDE-BINDING FOLD-CONTAINING PROTEIN 2B; OBFC2B__:__SINGLE-STRANDED DNA-BINDING PROTEIN 1; SSB1__:__
Asterisk__:__612105__:__KILLIN; KLLN__:____:__
Asterisk__:__612106__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 40; ZBTB40__:__KIAA0478__:__
Asterisk__:__612107__:__SOLUTE CARRIER FAMILY 17 (VESICULAR NUCLEOTIDE TRANSPORTER), MEMBER 9; SLC17A9__:__CHROMOSOME 20 OPEN READING FRAME 59; C20ORF59__:__
Percent__:__612108__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 1; FGQTL1__:____:__
Number Sign__:__612109__:__OCULOAURICULAR SYNDROME; OCACS__:__MICROPHTHALMIA, MICROCORNEA, ANTERIOR SEGMENT DYSGENESIS, CATARACT, OCULAR COLOBOMA, RETINAL PIGMENT EPITHELIUM ABNORMALITIES, ROD-CONE DYSTROPHY, AND ANOMALIES OF THE EXTERNAL EAR;; SCHORDERET-MUNIER-FRANCESCHETTI SYNDROME__:__
Percent__:__612110__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 9; BMND9__:____:__
Asterisk__:__612111__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 8; TNFAIP8__:__SCC-S2;; OXI-ALPHA__:__
Asterisk__:__612112__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 8-LIKE 2; TNFAIP8L2__:__TNFAIP8-LIKE 2; TIPE2__:__
Percent__:__612113__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 10; BMND10__:____:__
Percent__:__612114__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 11; BMND11__:____:__
Asterisk__:__612115__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; ARHGEF3__:__XPLN__:__
Asterisk__:__612116__:__UBIQUITIN-SPECIFIC PROTEASE 22; USP22__:__KIAA1063__:__
Asterisk__:__612117__:__MICRO RNA 143; MIR143__:__miRNA143;; MIRN143__:__
Asterisk__:__612118__:__IQ MOTIF- AND SEC7 DOMAIN-CONTAINING PROTEIN 3; IQSEC3__:__KIAA1110__:__
Number Sign__:__612119__:__TREHALASE DEFICIENCY__:__TREHALOSE INTOLERANCE__:__
Asterisk__:__612120__:__CELL DEATH-INDUCING DFFA-LIKE EFFECTOR C; CIDEC__:__CELL DEATH ACTIVATOR CIDE3;; FAT-SPECIFIC PROTEIN 27; FSP27__:__
Asterisk__:__612121__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 1; PNPLA1__:____:__
Asterisk__:__612122__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 7; PNPLA7__:__NTE-LIKE 1; NTEL1__:__
Asterisk__:__612123__:__PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 8; PNPLA8__:__PNPLA-GAMMA;; PHOSPHOLIPASE A2, CALCIUM-INDEPENDENT, INTRACELLULAR MEMBRANE-ASSOCIATED, GAMMA; IPLA2-GAMMA;; IPLA2-2__:__
Number Sign__:__612124__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 12; CMH12__:____:__
Asterisk__:__612125__:__SERTA DOMAIN-CONTAINING PROTEIN 3; SERTAD3__:__RPA-BINDING TRANSACTIVATOR 1; RBT1__:__
Number Sign__:__612126__:__GLUT1 DEFICIENCY SYNDROME 2; GLUT1DS2__:__PAROXYSMAL EXERCISE-INDUCED DYSKINESIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA;; PED WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA;; PAROXYSMAL EXERTION-INDUCED DYSTONIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA;; DYSTONIA 18; DYT18__:__
Asterisk__:__612127__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE XIII; HSD17B13__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE 9; SCDR9__:__
Asterisk__:__612128__:__RAS-LIKE, FAMILY 10, MEMBER B; RASL10B__:__RAS-RELATED PROTEIN 17; RRP17__:__
Asterisk__:__612129__:__INDOLEAMINE 2,3-DIOXYGENASE 2; IDO2__:__INDOLEAMINE 2,3-DIOXYGENASE-LIKE 1; INDOL1;; INDOLEAMINE-PYRROLE 2,3-DIOXYGENASE-LIKE 1__:__
Asterisk__:__612130__:__GENE AMPLIFIED IN ESOPHAGEAL CANCER 1; GAEC1__:____:__
Asterisk__:__612131__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 9; DHRS9__:__SDR FAMILY, MEMBER 9;; RETINOL DEHYDROGENASE, TRACHEOBRONCHIAL EPITHELIAL CELL-SPECIFIC; RDHTBE;; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE;; 3-ALPHA-HSD;; RDHL__:__
Number Sign__:__612132__:__ECTODERMAL DYSPLASIA AND IMMUNODEFICIENCY 2; EDAID2__:__ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNODEFICIENCY 2;; ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNODEFICIENCY 2;; ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH T-CELL IMMUNODEFICIENCY, AUTOSOMAL DOMINANT__:__
Asterisk__:__612133__:__TRANSCRIPTION FACTOR NFE4; NFE4__:__ERYTHROID-SPECIFIC FACTOR p22-NFE4;; GAMMA-GLOBIN GENE ACTIVATOR;; FETAL GLOBIN ACTIVATOR NFE4__:__p14-NFE4, INCLUDED
Asterisk__:__612134__:__GLUCURONIC ACID EPIMERASE; GLCE__:__D-GLUCURONYL C5-EPIMERASE;; C5-EPIMERASE;; HEPARIN/HEPARAN SULFATE GLUCURONIC ACID C5-EPIMERASE;; HEPARAN SULFATE D-GLUCURONYL C5-EPIMERASE; HSEPI;; KIAA0836__:__
Asterisk__:__612135__:__CALCIUM-BINDING TYROSINE PHOSPHORYLATION-REGULATED PROTEIN; CABYR__:__FIBROUSHEATHIN 2; FSP2__:__
Asterisk__:__612136__:__ENOYL COENZYME A HYDRATASE DOMAIN-CONTAINING PROTEIN 1; ECHDC1__:____:__
Asterisk__:__612137__:__RING FINGER PROTEIN 146; RNF146__:__DACTYLIDIN;; IDUNA__:__
Number Sign__:__612138__:__EPIDERMOLYSIS BULLOSA SIMPLEX WITH PYLORIC ATRESIA; EBSPA__:__EBS WITH PYLORIC ATRESIA__:__
Asterisk__:__612139__:__PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE-DEPENDENT RAC EXCHANGER 2; PREX2__:__DEP DOMAIN-CONTAINING PROTEIN 2; DEPDC2__:__
Asterisk__:__612140__:__SEPTIN 14; SEPT14__:____:__SEPT14/EGFR FUSION GENE, INCLUDED
Asterisk__:__612141__:__ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1-LIKE 4A; EPB41L4A__:__EPB41L4;; NBL4__:__
Asterisk__:__612142__:__MICRO RNA LET7A2; MIRLET7A2__:__LET7, C. ELEGANS, HOMOLOG OF, A2; LET7A2;; miRNA LET7A2;; MIRNLET7A2__:__
Asterisk__:__612143__:__MICRO RNA LET7A3; MIRNLET7A3__:__LET7, C. ELEGANS, HOMOLOG OF, A3; LET7A3;; miRNA LET7A3;; MIRLET7A3__:__
Asterisk__:__612144__:__MICRO RNA LET7C; MIRLET7C__:__LET7, C. ELEGANS, HOMOLOG OF, C; LET7C;; miRNA LET7C;; MIRNLET7C__:__
Asterisk__:__612145__:__MICRO RNA LET7D; MIRNLET7D__:__LET7, C. ELEGANS, HOMOLOG OF, D; LET7D;; miRNA LET7D;; MIRLET7D__:__
Asterisk__:__612146__:__MICRO RNA LET7F1; MIRLET7F1__:__LET7, C. ELEGANS, HOMOLOG OF, F1; LET7F1;; miRNA LET7F1;; MIRNLET7F1__:__
Asterisk__:__612147__:__MYOSIN LIGHT CHAIN KINASE 3; MYLK3__:__MLCK, CARDIAC__:__
Asterisk__:__612148__:__MICRO RNA LET7I; MIRNLET7I__:__LET7, C. ELEGANS, HOMOLOG OF, I; LET7I;; miRNA LET7I;; MIRLET7I__:__
Asterisk__:__612149__:__RNA-BINDING PROTEIN FOX1, C. ELEGANS, HOMOLOG OF, 2; RBFOX2__:__FOX1, C. ELEGANS, HOMOLOG OF, 2; FOX2;; RNA-BINDING MOTIF PROTEIN 9; RBM9;; REPRESSOR OF TAMOXIFEN TRANSCRIPTIONAL ACTIVITY; RTA__:__
Asterisk__:__612150__:__MICRO RNA 25; MIR25__:__miRNA25;; MIRN25__:__
Asterisk__:__612151__:__MICRO RNA 26A1; MIR26A1__:__miRNA26A1;; MIRN26A1;; MIR26A__:__
Asterisk__:__612152__:__MICRO RNA 26B; MIR26B__:__miRNA26B;; MIRN26B__:__
Asterisk__:__612153__:__MICRO RNA 27A; MIR27A__:__miRNA27A;; MIRN27A;; MIR27__:__
Asterisk__:__612154__:__MICRO RNA 28; MIR28__:__miRNA28;; MIRN28__:__
Asterisk__:__612155__:__MICRO RNA 31; MIR31__:__miRNA31;; MIRN31__:__
Asterisk__:__612156__:__MICRO RNA 33A; MIR33A__:__MIRN33A;; miRNA33A;; MIR33__:__
Asterisk__:__612157__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 1; SENP1__:____:__SENP1/MESDC2 FUSION GENE, INCLUDED
Number Sign__:__612158__:__CARDIOMYOPATHY, DILATED, 1AA, WITH OR WITHOUT LEFT VENTRICULAR NONCOMPACTION; CMD1AA__:____:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 23, WITH OR WITHOUT VENTRICULAR NONCOMPACTION, INCLUDED; CMH23, INCLUDED
Asterisk__:__612159__:__RABPHILIN 3A; RPH3A__:__KIAA0985__:__
Number Sign__:__612160__:__HISTIOCYTOMA, ANGIOMATOID FIBROUS__:____:__
Percent__:__612161__:__ANEURYSM, INTRACRANIAL BERRY, 7; ANIB7__:____:__
Percent__:__612162__:__ANEURYSM, INTRACRANIAL BERRY, 8; ANIB8__:____:__
Asterisk__:__612163__:__TWO-PORE SEGMENT CHANNEL 2; TPCN2__:__TWO-PORE CHANNEL 2; TPC2__:__
Number Sign__:__612164__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4; EIEE4__:____:__
Percent__:__612165__:__RETINITIS PIGMENTOSA 29; RP29__:____:__
Asterisk__:__612166__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 2; SLC39A2__:__ZRT- AND IRT-LIKE PROTEIN 2; ZIP2__:__
Asterisk__:__612167__:__WD REPEAT-CONTAINING PROTEIN 48; WDR48__:__p80;; KIAA1449;; USP1-ASSOCIATED FACTOR 1; UAF1__:__
Asterisk__:__612168__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 3; SLC39A3__:__ZRT- AND IRT-LIKE PROTEIN 3; ZIP3__:__
Asterisk__:__612169__:__Fc FRAGMENT OF IgG, LOW AFFINITY IIc, RECEPTOR FOR; FCGR2C__:__Fc-GAMMA-RIIC;; FcRIIC;; CD32C__:__
Asterisk__:__612170__:__MUCIN 19, OLIGOMERIC; MUC19__:____:__
Asterisk__:__612171__:__REPRIMO; RPRM__:____:__
Asterisk__:__612172__:__DEAD BOX POLYPEPTIDE 23; DDX23__:__PRP28, S. CEREVISIAE, HOMOLOG OF; PRP28;; U5 snRNP-SPECIFIC PROTEIN, 100-KD;; U5-100KD__:__
Asterisk__:__612173__:__SPERM-ASSOCIATED ANTIGEN 16; SPAG16__:__PF20__:__
Asterisk__:__612174__:__CALCIUM-BINDING PROTEIN 39; CAB39__:__MO25-ALPHA__:__
Asterisk__:__612175__:__CALCIUM-BINDING PROTEIN 39-LIKE PROTEIN; CAB39L__:__CAB39-LIKE PROTEIN;; MO25-BETA__:__
Asterisk__:__612176__:__MYB-LIKE, SWIRM, AND MPN DOMAINS-CONTAINING PROTEIN 1; MYSM1__:__HISTONE H2A DEUBIQUITINASE; 2ADUB;; KIAA1915__:__
Asterisk__:__612177__:__RNA, 7SL, CYTOPLASMIC 1; RN7SL1__:__7SL;; 7L1A__:__
Asterisk__:__612178__:__HEN1 METHYLTRANSFERASE, ARABIDOPSIS, HOMOLOG OF; HENMT1__:__HEN1;; CHROMOSOME 1 OPEN READING FRAME 59; C1ORF59__:__
Asterisk__:__612179__:__RNA, 7SL, CYTOPLASMIC 2; RN7SL2__:__7L1C;; 7L30.1__:__
Asterisk__:__612180__:__RNA, 7SL, CYTOPLASMIC 3; RN7SL3__:__7L30.2__:__
Asterisk__:__612181__:__MUCIN 13, CELL SURFACE-ASSOCIATED; MUC13__:____:__
Asterisk__:__612182__:__N-ACETYLTRANSFERASE 2; NAT2__:__ARYLAMIDE ACETYLASE 2; AAC2__:__
Asterisk__:__612183__:__G PROTEIN-COUPLED RECEPTOR 176; GPR176__:____:__
Asterisk__:__612184__:__CASK-INTERACTING PROTEIN 1; CASKIN1__:__KIAA1306__:__
Asterisk__:__612185__:__CASK-INTERACTING PROTEIN 2; CASKIN2__:__KIAA1139__:__
Asterisk__:__612186__:__DMX-LIKE 2; DMXL2__:__RABCONNECTIN 3; RC3;; KIAA0856__:__
Asterisk__:__612187__:__HEME-RESPONSIVE GENE 1__:__HRG1__:__
Asterisk__:__612188__:__VACUOLAR PROTEIN SORTING 39, YEAST, HOMOLOG OF; VPS39__:__VAM6, YEAST, HOMOLOG OF; VAM6;; TRAP1-LIKE PROTEIN; TLP;; KIAA0770__:__
Asterisk__:__612189__:__PHENAZINE BIOSYNTHESIS-LIKE PROTEIN DOMAIN-CONTAINING PROTEIN; PBLD__:__MAWD-BINDING PROTEIN; MAWBP;; MAWDBP__:__
Asterisk__:__612190__:__MTOR-ASSOCIATED PROTEIN LST8; MLST8__:__G-BETA-LIKE PROTEIN; GBL;; G PROTEIN BETA SUBUNIT-LIKE PROTEIN;; LST8, S. CEREVISIAE, HOMOLOG OF; LST8;; WAT1, S. POMBE, HOMOLOG OF; WAT1;; POP3, S. POMBE, HOMOLOG OF; POP3__:__
Asterisk__:__612191__:__MICROSEMINOPROTEIN, PROSTATE-ASSOCIATED; MSMP__:__PC3 PROSTATE CANCER CELL-SECRETED MICROPROTEIN; PSMP__:__
Asterisk__:__612192__:__ZINC FINGER PROTEIN 57, MOUSE, HOMOLOG OF; ZFP57__:____:__
Asterisk__:__612193__:__CARDIOMYOPATHY-ASSOCIATED PROTEIN 5; CMYA5__:__MYOSPRYN;; TRIPARTITE MOTIF-CONTAINING PROTEIN 76; TRIM76__:__
Asterisk__:__612194__:__RAS-RELATED GTP-BINDING PROTEIN A; RRAGA__:__RAGA;; FIP1__:__
Asterisk__:__612195__:__ABHYDROLASE DOMAIN-CONTAINING 1; ABHD1__:__LUNG ALPHA/BETA HYDROLASE 1; LABH1__:__
Asterisk__:__612196__:__ABHYDROLASE DOMAIN-CONTAINING 2; ABHD2__:__LUNG ALPHA/BETA HYDROLASE 2; LABH2__:__
Asterisk__:__612197__:__ABHYDROLASE DOMAIN-CONTAINING 3; ABHD3__:__LUNG ALPHA/BETA HYDROLASE 3; LABH3__:__
Percent__:__612198__:__DIASTASIS RECTI AND WEAKNESS OF THE LINEA ALBA__:____:__
Number Sign__:__612199__:__CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS 1; CRMCC1__:__CRMCC;; COATS PLUS SYNDROME__:__
Asterisk__:__612200__:__CHROMOSOME 3 OPEN READING FRAME 58; C3ORF58__:__DELETED IN AUTISM 1; DIA1__:__
Number Sign__:__612201__:__ATRIAL FIBRILLATION, FAMILIAL, 6; ATFB6__:____:__
Asterisk__:__612202__:__SRY-BOX 7; SOX7__:____:__
Asterisk__:__612203__:__NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 5; NAP1L5__:__DOWNREGULATED IN LIVER MALIGNANCY; DRLM__:__
Asterisk__:__612204__:__AUTOPHAGY 9, S. CEREVISIAE, HOMOLOG OF, A; ATG9A__:__APG9-LIKE 1; APG9L1__:__
Asterisk__:__612205__:__AUTOPHAGY 9, S. CEREVISIAE, HOMOLOG OF, B; ATG9B__:__ENDOTHELIAL NITRIC OXIDE SYNTHASE 3 ANTISENSE; NOS3AS;; APG9-LIKE 2; APG9L2__:__SONE, INCLUDED
Asterisk__:__612206__:__FOUR-JOINTED BOX, DROSOPHILA, HOMOLOG OF, 1; FJX1__:____:__
Asterisk__:__612207__:__GOLGI PHOSPHOPROTEIN 3; GOLPH3__:__GOLGI-ASSOCIATED PROTEIN, 34-KD; GPP34;; MITOCHONDRIAL DNA ABSENCE-SENSITIVE FACTOR; MIDAS__:__
Asterisk__:__612208__:__GOLGI PHOSPHOPROTEIN 3-LIKE; GOLPH3L__:__GPP34-RELATED; GPP34R__:__
Asterisk__:__612209__:__MESOGENIN 1; MSGN1__:____:__
Asterisk__:__612210__:__HIGHLY UPREGULATED IN LIVER CANCER; HULC__:____:__
Asterisk__:__612211__:__TUMOR SUPPRESSOR CANDIDATE 5; TUSC5__:__LOST1__:__
Asterisk__:__612212__:__PLASMINOGEN-LIKE A; PLGLA__:__PLASMINOGEN-RELATED GENE A; PRGA__:__
Asterisk__:__612213__:__SEMINAL PLASMA PROTEIN, BOVINE, HOMOLOG OF, 1; BSPH1__:__BSP, BOVINE, HOMOLOG OF, 1;; BINDER OF SPERM PROTEIN, BOVINE, HOMOLOG OF, 1;; BOVINE SEMINAL PLASMA PROTEIN-LIKE 1__:__
Asterisk__:__612214__:__RAL GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR-LIKE 4; RGL4__:__RALGDS-RELATED, RABBIT, HOMOLOG OF; RGR__:__
Asterisk__:__612215__:__SMALL NUCLEOLAR RNA HOST GENE 6; SNHG6__:__U87 HOST GENE; U87HG__:__
Asterisk__:__612216__:__SMALL NUCLEOLAR RNA, C/D BOX, 87; SNORD87__:__U87__:__
Asterisk__:__612217__:__CHROMOSOME 6 OPEN READING FRAME 106; C6ORF106__:____:__
Asterisk__:__612218__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 38; ZBTB38__:____:__
Number Sign__:__612219__:__EWING SARCOMA; ES__:____:__NEUROEPITHELIOMA, PERIPHERAL, INCLUDED; PNE, INCLUDED;; ASKIN TUMOR, INCLUDED
Asterisk__:__612220__:__BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE 3; B4GALNT3__:__B4GalNAcT3__:__
Percent__:__612221__:__STATURE QUANTITATIVE TRAIT LOCUS 10; STQTL10__:____:__
Asterisk__:__612222__:__GALACTOSAMINE-6-SULFATE SULFATASE; GALNS__:__N-ACETYLGALACTOSAMINE-SULFATE SULFATASE__:__
Percent__:__612223__:__STATURE QUANTITATIVE TRAIT LOCUS 11; STQTL11__:____:__
Percent__:__612224__:__STATURE QUANTITATIVE TRAIT LOCUS 12; STQTL12__:____:__
Number Sign__:__612225__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 9; MODY9__:____:__
Percent__:__612226__:__STATURE QUANTITATIVE TRAIT LOCUS 13; STQTL13__:____:__
Number Sign__:__612227__:__DIABETES MELLITUS, KETOSIS-PRONE; KPD__:____:__
Percent__:__612228__:__STATURE QUANTITATIVE TRAIT LOCUS 14; STQTL14__:____:__
Number Sign__:__612229__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 3; CRCS3__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 18__:__
Percent__:__612230__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 5; CRCS5__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 10__:__
Percent__:__612231__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 6; CRCS6__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 8q23__:__
Percent__:__612232__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 7; CRCS7__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 11__:__
Number Sign__:__612233__:__LEUKODYSTROPHY, HYPOMYELINATING, 4; HLD4__:__MITOCHONDRIAL HSP60 CHAPERONOPATHY;; MITCHAP60 DISEASE__:__
Asterisk__:__612234__:__CALCIUM HOMEOSTASIS MODULATOR 1; CALHM1__:__FAMILY WITH SEQUENCE SIMILARITY 26, MEMBER C; FAM26C__:__
Asterisk__:__612235__:__CALCIUM HOMEOSTASIS MODULATOR 2; CALHM2__:__FAMILY WITH SEQUENCE SIMILARITY 26, MEMBER B; FAM26B__:__
Asterisk__:__612236__:__ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT PROTEIN 2; ERGIC2__:__CDA14;; PTX1__:__
Number Sign__:__612237__:__CHONDROSARCOMA, EXTRASKELETAL MYXOID__:__EMC__:__
Percent__:__612238__:__SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 4; IS4__:____:__
Percent__:__612239__:__SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 5; IS5__:____:__
Number Sign__:__612240__:__ATRIAL FIBRILLATION, FAMILIAL, 7; ATFB7__:____:__
Percent__:__612241__:__INFLAMMATORY BOWEL DISEASE 12; IBD12__:____:__
Number Sign__:__612242__:__CHROMOSOME 10q22.3-q23.2 DELETION SYNDROME__:____:__JUVENILE POLYPOSIS OF INFANCY, INCLUDED;; JUVENILE POLYPOSIS, INFANTILE, INCLUDED
Asterisk__:__612243__:__ADHESION G PROTEIN-COUPLED RECEPTOR G6; ADGRG6__:__G PROTEIN-COUPLED RECEPTOR 126; GPR126;; VASCULAR-INDUCIBLE G PROTEIN-COUPLED RECEPTOR; VIGR__:__
Number Sign__:__612244__:__INFLAMMATORY BOWEL DISEASE 13; IBD13__:____:__
Number Sign__:__612245__:__INFLAMMATORY BOWEL DISEASE 14; IBD14__:____:__
Asterisk__:__612246__:__CD302 ANTIGEN; CD302__:__DEC205-ASSOCIATED C-TYPE LECTIN 1; DCL1;; KIAA0022__:__
Number Sign__:__612247__:__CROUZON SYNDROME WITH ACANTHOSIS NIGRICANS; CAN__:__CROUZONODERMOSKELETAL SYNDROME__:__
Asterisk__:__612248__:__ZINC FINGER PROTEIN 627; ZNF627__:____:__
Asterisk__:__612249__:__THROMBOSPONDIN TYPE-1 DOMAIN-CONTAINING PROTEIN 7A; THSD7A__:__KIAA0960__:__
Asterisk__:__612250__:__G PROTEIN-COUPLED RECEPTOR 161: GPR161__:____:__
Number Sign__:__612251__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 10; SLEB10__:____:__
Asterisk__:__612252__:__C-TYPE LECTIN DOMAIN FAMILY 9, MEMBER A; CLEC9A__:__DENDRITIC CELL NATURAL KILLER LECTIN GROUP RECEPTOR 1; DNGR1__:__
Number Sign__:__612253__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 11; SLEB11__:____:__
Percent__:__612254__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 12; SLEB12__:____:__
Percent__:__612255__:__INFLAMMATORY BOWEL DISEASE 15; IBD15__:____:__
Asterisk__:__612256__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE 1; MAST1__:__SYNTROPHIN-ASSOCIATED SERINE/THREONINE KINASE; SAST;; KIAA0973__:__
Asterisk__:__612257__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE 2; MAST2__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE, 205-KD; MAST205;; KIAA0807__:__
Asterisk__:__612258__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE 3; MAST3__:__KIAA0561__:__
Percent__:__612259__:__INFLAMMATORY BOWEL DISEASE 16; IBD16__:____:__
Number Sign__:__612260__:__MYD88 DEFICIENCY; MYD88D__:__PYOGENIC BACTERIAL INFECTIONS, RECURRENT, DUE TO MYD88 DEFICIENCY;; RECURRENT PYOGENIC BACTERIAL INFECTIONS DUE TO MYD88 DEFICIENCY__:__
Number Sign__:__612261__:__INFLAMMATORY BOWEL DISEASE 17; IBD17__:____:__
Percent__:__612262__:__INFLAMMATORY BOWEL DISEASE 18; IBD18__:____:__
Percent__:__612263__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 7; CMM7__:____:__
Asterisk__:__612264__:__MANNOSE RECEPTOR, C-TYPE, 2; MRC2__:__ENDO180;; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN; UPARAP;; UPAR-ASSOCIATED PROTEIN;; CD280;; KIAA0709__:__
Asterisk__:__612265__:__FAMILY WITH SEQUENCE SIMILARITY 120, MEMBER A; FAM120A__:__OXIDATIVE STRESS-ASSOCIATED SRC ACTIVATOR; OSSA;; CHROMOSOME 9 OPEN READING FRAME 10; C9ORF10;; KIAA0183__:__
Asterisk__:__612266__:__FAMILY WITH SEQUENCE SIMILARITY 120, MEMBER B; FAM120B__:__PPARG CONSTITUTIVE COACTIVATOR 1; PGCC1;; CONSTITUTIVE COACTIVATOR OF PPARG; CCPG;; KIAA1838__:__
Number Sign__:__612267__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 10; SHEP10__:__SKIN/HAIR/EYE PIGMENTATION 10, BLOND/BROWN HAIR__:__
Asterisk__:__612268__:__TUBULIN TYROSINE LIGASE-LIKE FAMILY, MEMBER 5; TTLL5__:__SRC1- AND TIF2-ASSOCIATED BINDING PROTEIN; STAMP;; KIAA0998__:__
Number Sign__:__612269__:__EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 5; ECA5__:____:__
Asterisk__:__612270__:__CELL DIVISION CYCLE-ASSOCIATED PROTEIN 4; CDCA4__:__HEMATOPOIETIC PROGENITOR PROTEIN; HEPP__:__
Number Sign__:__612271__:__SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11__:__MELANESIAN BLOND HAIR;; SKIN/HAIR/EYE PIGMENTATION 11, BLUE/NONBLUE EYES__:__
Caret__:__612272__:__MOVED TO 608644__:____:__
Caret__:__612273__:__MOVED TO 611884__:____:__
Percent__:__612274__:__CILIARY DYSKINESIA, PRIMARY, 8; CILD8__:__CILIARY DYSKINESIA, PRIMARY, 8, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__612275__:__GAMETOGENETIN-BINDING PROTEIN 2; GGNBP2__:__DIOXIN-INDUCIBLE FACTOR 3; DIF3;; LARYNGEAL CARCINOMA RELATED-GENE 1; LCRG1;; LZK1__:__
Asterisk__:__612276__:__YRDC DOMAIN-CONTAINING PROTEIN; YRDC__:__YRDC, E. COLI, HOMOLOG OF;; ISCHEMIA/REPERFUSION-INDUCIBLE PROTEIN; IRIP__:__
Asterisk__:__612277__:__ADAMTS-LIKE PROTEIN 2; ADAMTSL2__:__KIAA0605__:__
Number Sign__:__612278__:__INFLAMMATORY BOWEL DISEASE (CROHN DISEASE) 19; IBD19__:____:__
Percent__:__612279__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 6; GEFSP6__:__GEFS+, TYPE 6; GEFS+6__:__
Asterisk__:__612280__:__FUCOSIDASE, ALPHA-L, 1; FUCA1__:__ALPHA-L-FUCOSIDASE 1;; FUCOSIDASE, ALPHA-L, TISSUE; FUCA__:__
Number Sign__:__612281__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 6; ARCI6__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE, NIPAL4-RELATED__:__
Asterisk__:__612282__:__ZINC FINGER PROTEIN 804A; ZNF804A__:__CHROMOSOME 2 OPEN READING FRAME 10; C2ORF10__:__
Asterisk__:__612283__:__PROTEIN C; PROC__:__PC__:__
Number Sign__:__612284__:__MECKEL SYNDROME, TYPE 6; MKS6__:____:__
Number Sign__:__612285__:__JOUBERT SYNDROME 9; JBTS9__:____:__JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED
Number Sign__:__612286__:__NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 1; NPHLOP1__:____:__
Number Sign__:__612287__:__NEPHROLITHIASIS/OSTEOPOROSIS, HYPOPHOSPHATEMIC, 2; NPHLOP2__:____:__
Percent__:__612288__:__INFLAMMATORY BOWEL DISEASE 20; IBD20__:____:__
Number Sign__:__612289__:__FONTAINE PROGEROID SYNDROME; FPS__:__GORLIN-CHAUDHRY-MOSS SYNDROME; GCMS;; PROGEROID SYNDROME, CONGENITAL, PETTY TYPE;; CRANIOFACIAL DYSOSTOSIS, HYPERTRICHOSIS, HYPOPLASIA OF LABIA MAJORA, DENTAL AND EYE ANOMALIES, PATENT DUCTUS ARTERIOSUS, AND NORMAL INTELLIGENCE__:__
Number Sign__:__612290__:__MICROTIA, HEARING IMPAIRMENT, AND CLEFT PALATE__:____:__MICROTIA WITH OR WITHOUT HEARING IMPAIRMENT, INCLUDED
Number Sign__:__612291__:__JOUBERT SYNDROME 8; JBTS8__:____:__
Number Sign__:__612292__:__BIRK-BAREL SYNDROME__:__BIRK-BAREL MENTAL RETARDATION DYSMORPHISM SYNDROME;; MENTAL RETARDATION WITH HYPOTONIA AND FACIAL DYSMORPHISM__:__
Percent__:__612293__:__POROKERATOSIS 5, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK5__:__POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 3; DSAP3__:__
Asterisk__:__612294__:__DEP DOMAIN-CONTAINING PROTEIN 7; DEPDC7__:__TR2__:__
Asterisk__:__612295__:__ADP RIBOSYLATION FACTOR-LIKE GTPase 14 EFFECTOR PROTEIN; ARL14EP__:__ADP-RIBOSYLATION FACTOR 7 EFFECTOR PROTEIN; ARF7EP;; CHROMOSOME 11 OPEN READING FRAME 46; C11ORF46__:__
Asterisk__:__612296__:__LOC283267 GENE__:__LOC283267__:__
Asterisk__:__612297__:__CHROMOSOME 11 OPEN READING FRAME 41; C11ORF41__:__G2__:__
Asterisk__:__612298__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 44; TRIM44__:__MC7__:__
Asterisk__:__612299__:__COMM DOMAIN-CONTAINING PROTEIN 9; COMMD9__:__COPPER METABOLISM MURR1 DOMAIN-CONTAINING PROTEIN 9__:__
Number Sign__:__612300__:__HEMOLYTIC ANEMIA, CD59-MEDIATED, WITH OR WITHOUT IMMUNE-MEDIATED POLYNEUROPATHY; HACD59__:__CD59 DEFICIENCY__:__
Number Sign__:__612301__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7__:__OSTEOPETROSIS, OSTEOCLAST-POOR, WITH HYPOGAMMAGLOBULINEMIA__:__
Asterisk__:__612302__:__ADHESION G PROTEIN-COUPLED RECEPTOR A1; ADGRA1__:__G PROTEIN-COUPLED RECEPTOR 123; GPR123;; KIAA1828__:__
Asterisk__:__612303__:__ADHESION G PROTEIN-COUPLED RECEPTOR A3; ADGRA3__:__G PROTEIN-COUPLED RECEPTOR 125; GPR125__:__
Number Sign__:__612304__:__THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; THPH4__:__PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE;; PROC DEFICIENCY, AUTOSOMAL RECESSIVE__:__
Asterisk__:__612305__:__ADHESION G PROTEIN-COUPLED RECEPTOR E4, PSEUDOGENE; ADGRE4P__:__EMR4, MOUSE, HOMOLOG OF; EMR4;; G PROTEIN-COUPLED RECEPTOR 127; GPR127;; FIRE__:__
Percent__:__612306__:__THYROID-STIMULATING HORMONE LEVEL QUANTITATIVE TRAIT LOCUS 1; TSHQTL1__:__THYROTROPIN QUANTITATIVE TRAIT LOCUS 1__:__
Asterisk__:__612307__:__ADHESION G PROTEIN-COUPLED RECEPTOR G7; ADGRG7__:__G PROTEIN-COUPLED RECEPTOR 128; GPR128__:__
Asterisk__:__612308__:__ZINC FINGER AND BTB DOMAIN-CONTAINING 4; ZBTB4__:__KIAA1538__:__
Asterisk__:__612309__:__COAGULATION FACTOR V; F5__:__PROTEIN C COFACTOR; PCCF;; ACTIVATED PROTEIN C COFACTOR;; APC COFACTOR;; LABILE FACTOR__:__FACTOR V LEIDEN, INCLUDED
Number Sign__:__612310__:__PREMATURE OVARIAN FAILURE 6; POF6__:____:__
Percent__:__612311__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 5__:__ADHD5;; MOTOR TIMING QUANTITATIVE TRAIT LOCUS__:__
Percent__:__612312__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 6__:__ADHD6;; DIGIT SPAN QUANTITATIVE TRAIT LOCUS__:__
Number Sign__:__612313__:__GLASS SYNDROME; GLASS__:__CHROMOSOME 2q32-q33 DELETION SYNDROME__:__
Asterisk__:__612314__:__GLUTATHIONE S-TRANSFERASE, OMEGA-2; GSTO2__:____:__
Asterisk__:__612315__:__KERATIN 6C, TYPE II; KRT6C__:__K6C;; KB12;; KERATIN 6E; KRT6E; K6E;; KERATIN 6H; K6H__:__
Asterisk__:__612316__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 3A; ATAD3A__:____:__
Asterisk__:__612317__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 3B; ATAD3B__:__TOB3;; AAA-TOB3;; KIAA1273__:__
Number Sign__:__612318__:__PSEUDOFOLLICULITIS BARBAE__:__PFB;; PILI INCARNATI;; INGROWN HAIRS__:__
Number Sign__:__612319__:__SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35__:__FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA__:__
Asterisk__:__612320__:__CUB DOMAIN-CONTAINING PROTEIN 2; CDCP2__:____:__
Asterisk__:__612321__:__DOUBLECORTIN DOMAIN-CONTAINING PROTEIN 5; DCDC5__:__KIAA1493__:__
Asterisk__:__612322__:__FAST KINASE DOMAINS 2; FASTKD2__:__FAST KINASE DOMAIN-CONTAINING PROTEIN 2;; KIAA0971__:__
Asterisk__:__612323__:__INNER MITOCHONDRIAL MEMBRANE PEPTIDASE, SUBUNIT 1, S. CEREVISIAE, HOMOLOG OF; IMMP1L__:__IMP1, S. CEREVISIAE, HOMOLOG OF; IMP1;; IMP1-LIKE__:__
Asterisk__:__612324__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 34; CCDC34__:__NY-REN-41__:__
Asterisk__:__612325__:__INTESTINAL CELL KINASE; ICK__:__MAK-RELATED KINASE; MRK;; KIAA0936__:__
Asterisk__:__612326__:__TRANSCRIPTION FACTOR 25; TCF25__:__NUCLEAR LOCALIZED PROTEIN 1; NULP1;; KIAA1049__:__
Asterisk__:__612327__:__MANNOSIDASE, ENDO-ALPHA; MANEA__:__ENDO-ALPHA-1,2-MANNOSIDASE;; ENDOMANNOSIDASE;; ENDO__:__
Asterisk__:__612328__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 73: CCDC73__:__NY-SAR-79__:__
Asterisk__:__612329__:__MICRO RNA 30A; MIR30A__:__miRNA30A;; MIRN30A__:__
Asterisk__:__612330__:__MICRO RNA 610; MIRN610__:__miRNA610;; MIR610__:__
Asterisk__:__612331__:__LIN7, C. ELEGANS, HOMOLOG OF, B; LIN7B__:__VERTEBRATE LIN7 HOMOLOG 2; VELI2;; MAMMALIAN LIN7 HOMOLOG 2; MALS2__:__
Asterisk__:__612332__:__LIN7, C. ELEGANS, HOMOLOG OF, C; LIN7C__:__VERTEBRATE LIN7 HOMOLOG 3; VELI3;; MAMMALIAN LIN7 HOMOLOG 3; MALS3__:__
Asterisk__:__612333__:__PROGRAMMED CELL DEATH 11; PDCD11__:__APOPTOSIS-LINKED GENE 4; ALG4;; NF-KAPPA-B-BINDING PROTEIN; NFBP;; KIAA0185__:__
Asterisk__:__612334__:__N-ACYL PHOSPHATIDYLETHANOLAMINE-HYDROLYZING PHOSPHOLIPASE D; NAPEPLD__:__N-ACYL PHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE D__:__
Percent__:__612335__:__SPASTIC PARAPLEGIA 38, AUTOSOMAL DOMINANT; SPG38__:____:__
Number Sign__:__612336__:__THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL DOMINANT; THPH5__:____:__
Number Sign__:__612337__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 22; MRD22__:____:__CHROMOSOME 1q43-q44 DELETION SYNDROME, INCLUDED;; CHROMOSOME 1qter DELETION SYNDROME, INCLUDED
Asterisk__:__612338__:__GAMMA-GLUTAMYLTRANSFERASE, LIGHT CHAIN 1; GGTLC1__:__GGT, TYPE II-M;; GGTL6;; GGTLA4__:__
Asterisk__:__612339__:__GAMMA-GLUTAMYLTRANSFERASE, LIGHT CHAIN 2; GGTLC2__:__GGT, TYPE III;; GGTL4__:__
Asterisk__:__612340__:__GAMMA-GLUTAMYLTRANSFERASE, LIGHT CHAIN 3; GGTLC3__:____:__
Asterisk__:__612341__:__GAMMA-GLUTAMYLTRANSFERASE 6; GGT6__:____:__
Asterisk__:__612342__:__GAMMA-GLUTAMYLTRANSFERASE 7; GGT7__:__GGTL3;; GGTL5;; GGT4__:__
Percent__:__612343__:__MUSICAL APTITUDE QUANTITATIVE TRAIT LOCUS__:____:__
Asterisk__:__612344__:__ZINC FINGER PROTEIN 385B; ZNF385B__:__ZINC FINGER PROTEIN 533; ZNF533__:__
Number Sign__:__612345__:__CHROMOSOME 2q31.2 DELETION SYNDROME__:____:__
Asterisk__:__612346__:__GAMMA-GLUTAMYLTRANSFERASE 1; GGT1__:__GGT__:__
Number Sign__:__612347__:__JERVELL AND LANGE-NIELSEN SYNDROME 2; JLNS2__:____:__
Percent__:__612348__:__THROMBOPHILIA, FAMILIAL, DUE TO DECREASED RELEASE OF TISSUE PLASMINOGEN ACTIVATOR; THPH9__:____:__HYPERFIBRINOLYSIS, FAMILIAL, DUE TO INCREASED RELEASE OF TISSUE PLASMINOGEN ACTIVATOR, INCLUDED
Asterisk__:__612349__:__PHENYLALANINE HYDROXYLASE; PAH__:____:__
Number Sign__:__612350__:__EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 3; EDSSPD3__:__SPONDYLOCHEIRODYSPLASIA, EHLERS-DANLOS SYNDROME-LIKE; SCD-EDS__:__
Asterisk__:__612351__:__FORKHEAD BOX I3; FOXI3__:____:__
Asterisk__:__612352__:__STAM-BINDING PROTEIN-LIKE 1; STAMBPL1__:__AMSH-LIKE PROTEIN; AMSHLP;; AMSH-FAMILY PROTEIN; AMSHFP;; KIAA1373__:__
Percent__:__612353__:__POROKERATOSIS 6, MULTIPLE TYPES; POROK6__:__POROKERATOSIS 6, DISSEMINATED SUPERFICIAL;; POROKERATOSIS, DISSEMINATED SUPERFICIAL ACTINIC, 4; DSAP4__:__
Percent__:__612354__:__INFLAMMATORY BOWEL DISEASE 21; IBD21__:____:__
Asterisk__:__612355__:__MICAL C TERMINUS-LIKE PROTEIN; MICALCL__:__ERK2-BINDING TESTICULAR PROTEIN 1; EBITEIN1__:__
Number Sign__:__612356__:__HEPARIN COFACTOR II DEFICIENCY__:__THROMBOPHILIA DUE TO HEPARIN COFACTOR II DEFICIENCY; THPH10;; HCF II DEFICIENCY;; HCF2 DEFICIENCY__:__
Percent__:__612357__:__MAJOR AFFECTIVE DISORDER 8; MAFD8__:__BIPOLAR AFFECTIVE DISORDER__:__
Asterisk__:__612358__:__KININOGEN 1; KNG1__:__KININOGEN; KNG__:__HIGH MOLECULAR WEIGHT KININOGEN, INCLUDED; HMWK, INCLUDED; HK, INCLUDED;; LOW MOLECULAR WEIGHT KININOGEN, INCLUDED; LMWK, INCLUDED; LK, INCLUDED;; BRADYKININ, INCLUDED; BK, INCLUDED;; FITZGERALD FACTOR, INCLUDED;; FLAUJEAC FACTOR, INCLUDED;; WILLIAMS FACTOR, INCLUDED
Caret__:__612359__:__MOVED TO 158350__:____:__
Asterisk__:__612360__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 5; NDUFAF5__:__CHROMOSOME 20 OPEN READING FRAME 7; C20ORF7__:__
Percent__:__612361__:__SCHIZOPHRENIA 14__:__SCZD14;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 2q32-RELATED__:__
Number Sign__:__612362__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 12; BMIQ12__:__OBESITY, SUSCEPTIBILITY TO__:__
Percent__:__612363__:__ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1__:__ALTQTL1__:__
Percent__:__612364__:__ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2__:__ALTQTL2__:__
Percent__:__612365__:__GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1__:__GGTQTL1__:__
Percent__:__612366__:__GAMMA GLUTAMYLTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2__:__GGTQTL2__:__
Percent__:__612367__:__ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 2__:__ALPQTL2__:__
Percent__:__612368__:__ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 3__:__ALPQTL3__:__
Percent__:__612369__:__ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 4__:__ALPQTL4__:__
Number Sign__:__612370__:__HYPOGONADOTROPIC HYPOGONADISM 5 WITH OR WITHOUT ANOSMIA; HH5__:____:__
Number Sign__:__612371__:__MAJOR AFFECTIVE DISORDER 7; MAFD7__:__BIPOLAR AFFECTIVE DISORDER__:__
Percent__:__612372__:__MAJOR AFFECTIVE DISORDER 9; MAFD9__:__BIPOLAR AFFECTIVE DISORDER__:__
Asterisk__:__612373__:__SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 3: SLC29A3__:__EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 3; ENT3__:__
Asterisk__:__612374__:__TRANSMEMBRANE PROTEIN 173; TMEM173__:__STIMULATOR OF INTERFERON GENES; STING;; MPYS;; MEDIATOR OF IRF3 ACTIVATION; MITA;; ENDOPLASMIC RETICULUM INTERFERON STIMULATOR; ERIS__:__
Asterisk__:__612375__:__AXIN INTERACTOR, DORSALIZATION-ASSOCIATED; AIDA__:__AXIN-INTERACTING PROTEIN AND DORSALIZATION ANTAGONIST__:__
Number Sign__:__612376__:__ACUTE PROMYELOCYTIC LEUKEMIA; APL__:__LEUKEMIA, ACUTE PROMYELOCYTIC__:__
Asterisk__:__612377__:__COMM DOMAIN-CONTAINING PROTEIN 6; COMMD6__:__COPPER METABOLISM MURR1 DOMAIN-CONTAINING PROTEIN 6__:__
Percent__:__612378__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 13; SLEB13__:____:__
Number Sign__:__612379__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iq; CDG1Q__:__COLOBOMA, OCULAR, WITH ICHTHYOSIS, BRAIN MALFORMATIONS, AND ENDOCRINE ABNORMALITIES;; CDG Iq; CDGIq__:__
Percent__:__612380__:__INFLAMMATORY BOWEL DISEASE 22; IBD22__:____:__
Percent__:__612381__:__INFLAMMATORY BOWEL DISEASE 23; IBD23__:____:__
Asterisk__:__612382__:__MEDIATOR COMPLEX SUBUNIT 10; MED10__:__NUT2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__612383__:__MEDIATOR COMPLEX SUBUNIT 11; MED11__:__HSPC296__:__
Asterisk__:__612384__:__MEDIATOR COMPLEX SUBUNIT 18; MED18__:__TRAP/MEDIATOR COMPLEX SUBUNIT p28b; P28B__:__
Asterisk__:__612385__:__MEDIATOR COMPLEX SUBUNIT 19; MED19__:__LUNG CANCER METASTASIS-RELATED PROTEIN 1; LCMR1;; DT2P1G7__:__
Asterisk__:__612386__:__FERROCHELATASE; FECH__:__HEME SYNTHASE;; HEME SYNTHETASE;; IRON CHELATASE__:__
Number Sign__:__612387__:__SARCOIDOSIS, SUSCEPTIBILITY TO, 2; SS2__:____:__
Percent__:__612388__:__SARCOIDOSIS, SUSCEPTIBILITY TO, 3; SS3__:____:__
Number Sign__:__612389__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2B; PCH2B__:____:__
Number Sign__:__612390__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2C; PCH2C__:____:__
Caret__:__612391__:__MOVED TO 602782__:____:__
Asterisk__:__612392__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 6; NDUFAF6__:__CHROMOSOME 8 OPEN READING FRAME 38; C8ORF38__:__
Asterisk__:__612393__:__WAS PROTEIN HOMOLOG ASSOCIATED WITH ACTIN, GOLGI MEMBRANES, AND MICROTUBULES; WHAMM__:__WASP HOMOLOG-ASSOCIATED PROTEIN WITH ACTIN, MEMBRANES, AND MICROTUBULES;; WAS PROTEIN HOMOLOGY REGION 2 DOMAIN-CONTAINING PROTEIN 1; WHDC1;; WH2 DOMAIN-CONTAINING PROTEIN 1;; KIAA1971__:__
Number Sign__:__612394__:__BONE FRAGILITY WITH CONTRACTURES, ARTERIAL RUPTURE, AND DEAFNESS__:__LYSYL HYDROXYLASE 3 DEFICIENCY;; LH3 DEFICIENCY__:__
Asterisk__:__612395__:__CHOLINE KINASE, BETA; CHKB__:__CKB;; CHOLINE KINASE-LIKE PROTEIN; CHKL;; CHOLINE/ETHANOLAMINE KINASE, BETA; CKEKB;; ETHANOLAMINE KINASE, BETA; EKB__:__
NULL__:__612396__:__ALLANTOICASE; ALLC__:____:__
Asterisk__:__612397__:__COLLAGEN, TYPE VI, ALPHA-4, PSEUDOGENE 1; COL6A4P1__:__DUAL INTRACELLULAR VON WILLEBRAND FACTOR DOMAIN A-CONTAINING PROTEIN; DVWA;; DIVA;; LOC344875__:__
Asterisk__:__612398__:__RAB-ASSOCIATED PROTEIN RAB21; RAB21__:__KIAA0118__:__
Asterisk__:__612399__:__TRANSDUCIN-LIKE ENHANCER OF SPLIT 6; TLE6__:__GROUCHO-RELATED GENE 6; GRG6__:__
Number Sign__:__612400__:__OSTEOARTHRITIS SUSCEPTIBILITY 5; OS5__:__OSTEOARTHRITIS OF HIP__:__
Percent__:__612401__:__OSTEOARTHRITIS SUSCEPTIBILITY 6; OS6__:__OSTEOARTHRITIS OF KNEE__:__
Asterisk__:__612402__:__ALS2 C-TERMINAL-LIKE PROTEIN; ALS2CL__:____:__
Asterisk__:__612403__:__RAS-LIKE, FAMILY 11, MEMBER A; RASL11A__:____:__
Asterisk__:__612404__:__RAS-LIKE, FAMILY 11, MEMBER B; RASL11B__:____:__
Asterisk__:__612405__:__ADP-RIBOSYLATION FACTOR-LIKE 9; ARL9__:____:__
Percent__:__612406__:__DYSTONIA 17, TORSION, AUTOSOMAL RECESSIVE; DYT17__:____:__
Asterisk__:__612407__:__REGULATOR OF G PROTEIN SIGNALING 21; RGS21__:____:__
Asterisk__:__612408__:__PARASPECKLE COMPONENT 1; PSPC1__:__PARASPECKLE PROTEIN 1; PSP1__:__
Asterisk__:__612409__:__RNA-BINDING MOTIF PROTEIN 14; RBM14__:__PARASPECKLE PROTEIN 2; PSP2;; COACTIVATOR ACTIVATOR; COAA;; SYT-INTERACTING PROTEIN; SIP__:__
Percent__:__612410__:__PSORIASIS 10, SUSCEPTIBILITY TO; PSORS10__:____:__
Asterisk__:__612411__:__FAT TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 4; FAT4__:__FATJ__:__
Asterisk__:__612412__:__SPERMATOGENESIS AND CENTRIOLE-ASSOCIATED PROTEIN 1-LIKE; SPATC1L__:__CHROMOSOME 21 OPEN READING FRAME 56; C21ORF56__:__
Asterisk__:__612413__:__RNA-BINDING MOTIF PROTEIN 7; RBM7__:____:__
Asterisk__:__612414__:__LEUCINE-RICH TRANSMEMBRANE O-METHYLTRANSFERASE; LRTOMT__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 51; LRRC51;; CATECHOL-O-METHYL-TRANSFERASE-2; COMT2__:__LEUCINE-RICH TRANSMEMBRANE O-METHYLTRANSFERASE 1, INCLUDED; LRTOMT1, INCLUDED;; LEUCINE-RICH TRANSMEMBRANE O-METHYLTRANSFERASE 2, INCLUDED; LRTOMT2, INCLUDED
Asterisk__:__612415__:__RAS-ASSOCIATED PROTEIN 24; RAB24__:____:__
Number Sign__:__612416__:__FACTOR XI DEFICIENCY__:__F11 DEFICIENCY;; PLASMA THROMBOPLASTIN ANTECEDENT DEFICIENCY;; PTA DEFICIENCY;; ROSENTHAL SYNDROME__:__
Percent__:__612417__:__NARCOLEPSY 4, SUSCEPTIBILITY TO; NRCLP4__:____:__
Asterisk__:__612418__:__TRANSMEMBRANE PROTEIN 70; TMEM70__:____:__
Asterisk__:__612419__:__CARTILAGE INTERMEDIATE LAYER PROTEIN 2; CILP2__:____:__
Asterisk__:__612420__:__ACTIN FILAMENT-ASSOCIATED PROTEIN 1-LIKE PROTEIN 2; AFAP1L2__:__AFAP1-LIKE PROTEIN 2;; XB130;; KIAA1914__:__
Percent__:__612421__:__ALOPECIA, ANDROGENETIC, 3; AGA3__:____:__
Number Sign__:__612422__:__CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 3; RCM3__:____:__
Number Sign__:__612423__:__PREKALLIKREIN DEFICIENCY__:__PKK DEFICIENCY;; FLETCHER FACTOR DEFICIENCY__:__
Asterisk__:__612424__:__EYES SHUT, DROSOPHILA, HOMOLOG OF; EYS__:__SPACEMAKER; SPAM__:__
Asterisk__:__612425__:__SHUGOSHIN-LIKE 2; SGOL2__:__SHUGOSHIN 2; SGO2;; TRIPIN__:__
Asterisk__:__612426__:__RECQ-MEDIATED GENOME INSTABILITY 2; RMI2__:__CHROMOSOME 16 OPEN READING FRAME 75; C16ORF75;; BLM-ASSOCIATED PROTEIN, 18-KD; BLAP18__:__
Asterisk__:__612427__:__RNA-BINDING MOTIF PROTEIN 25; RBM25__:__ARG/GLU/ASP-RICH PROTEIN, 120-KD; RED120__:__
Asterisk__:__612428__:__RNA-BINDING MOTIF PROTEIN 38; RBM38__:__RNPC1__:__
Asterisk__:__612429__:__ZINC FINGER PROTEIN 300; ZNF300__:____:__
Asterisk__:__612430__:__RNA-BINDING MOTIF PROTEIN 22; RBM22__:____:__
Percent__:__612431__:__DEAFNESS, AUTOSOMAL DOMINANT 27; DFNA27__:____:__
Asterisk__:__612432__:__WAS/WASL-INTERACTING PROTEIN FAMILY, MEMBER 3; WIPF3__:__CR16__:__
Percent__:__612433__:__DEAFNESS, AUTOSOMAL RECESSIVE 45; DFNB45__:____:__
Asterisk__:__612434__:__CYSTEINE-RICH SECRETORY PROTEIN, LCCL DOMAIN-CONTAINING, 2; CRISPLD2__:____:__
Asterisk__:__612435__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 3A1; SLCO3A1__:__ORGANIC ANION TRANSPORTER D; OATPD;; ORGANIC ANION TRANSPORTER 3A1; OATP3A1__:__
Asterisk__:__612436__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 4A1; SLCO4A1__:__ORGANIC ANION TRANSPORTER E; OATPE;; ORGANIC ANION TRANSPORTER 4A1; OATP4A1__:__
Number Sign__:__612437__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 1B; EPM1B__:____:__
Number Sign__:__612438__:__LEUKODYSTROPHY, HYPOMYELINATING, 6; HLD6__:__LEUKODYSTROPHY, HYPOMYELINATING, WITH ATROPHY OF THE BASAL GANGLIA AND CEREBELLUM; HABC__:__
Asterisk__:__612439__:__ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN 3; ARFGAP3__:____:__
Caret__:__612440__:__MOVED TO 607694__:____:__
Asterisk__:__612441__:__ALPHA-1,6-MANNOSYL-GLYCOPROTEIN BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, ISOZYME B; MGAT5B__:__UDP-N-ACETYLGLUCOSAMINE:ALPHA-1,6-D-MANNOSIDE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE;; GNT-VB;; GNT-IX__:__
Asterisk__:__612442__:__SECRETION DEFICIENT 22, S. CEREVISIAE, HOMOLOG OF, A; SEC22A__:__SEC22L2__:__
Caret__:__612443__:__MOVED TO 612319__:____:__
Number Sign__:__612444__:__CILIARY DYSKINESIA, PRIMARY, 9; CILD9__:__CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS__:__
NULL__:__612445__:__SCOLIOSIS, ARACHNODACTYLY, AND BLINDNESS__:____:__
Number Sign__:__612446__:__COMPLEMENT COMPONENT 6 DEFICIENCY; C6D__:__C6 DEFICIENCY__:__COMPLEMENT COMPONENT 6 DEFICIENCY, SUBTOTAL, INCLUDED;; C6 DEFICIENCY, SUBTOTAL, INCLUDED
Number Sign__:__612447__:__SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION__:____:__
Percent__:__612448__:__AGE-RELATED HEARING IMPAIRMENT 1; ARHI1__:__PRESBYCUSIS 1__:__
Asterisk__:__612449__:__GEN1, DROSOPHILA, HOMOLOG OF; GEN1__:____:__
Asterisk__:__612450__:__HBS1-LIKE PROTEIN; HBS1L__:__HBS1, S. CEREVISIAE, HOMOLOG OF;; ERF3-SIMILAR PROTEIN; ERFS;; KIAA1038__:__
Asterisk__:__612451__:__RING FINGER PROTEIN 114; RNF114__:__ZINC FINGER PROTEIN 313; ZNF313__:__
Asterisk__:__612452__:__KAT8 REGULATORY NSL COMPLEX, SUBUNIT 1; KANSL1__:__MSL1V1;; KIAA1267__:__
Asterisk__:__612453__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 10; MEGF10__:__KIAA1780__:__
Asterisk__:__612454__:__MULTIPLE EPIDERMAL GROWTH FACTOR-LIKE DOMAINS 11; MEGF11__:__KIAA1781__:__
Asterisk__:__612455__:__SOLUTE CARRIER FAMILY 5 (SODIUM/GLUCOSE COTRANSPORTER), MEMBER 12; SLC5A12__:__SODIUM-COUPLED MONOCARBOXYLATE TRANSPORTER 2; SMCT2__:__
Asterisk__:__612456__:__APOLIPOPROTEIN L DOMAIN-CONTAINING 1; APOLD1__:__VASCULAR EARLY RESPONSE GENE; VERGE__:__
Asterisk__:__612457__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3B; ARID3B__:__ARID-CONTAINING PROTEIN 3B;; DEAD RINGER, DROSOPHILA, HOMOLOG-LIKE 2; DRIL2;; BDP;; DEAD RINGER, DROSOPHILA, HOMOLOG OF, 2__:__
Asterisk__:__612458__:__ACTIN-LIKE 6B; ACTL6B__:__ACTIN-RELATED PROTEIN, ALPHA;; ARPN-ALPHA;; BAF53B__:__
Percent__:__612459__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 13; BMIQ13__:____:__
Number Sign__:__612460__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 14; BMIQ14__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__612461__:__ACTIVITY-REGULATED CYTOSKELETON-ASSOCIATED PROTEIN; ARC__:__KIAA0278__:__
Number Sign__:__612462__:__PSEUDOHYPOPARATHYROIDISM, TYPE IC; PHP1C__:__PHP IC__:__
Number Sign__:__612463__:__PSEUDOPSEUDOHYPOPARATHYROIDISM; PPHP__:__ALBRIGHT HEREDITARY OSTEODYSTROPHY WITHOUT MULTIPLE HORMONE RESISTANCE__:__
Asterisk__:__612464__:__ARRESTIN DOMAIN-CONTAINING 3; ARRDC3__:__THIOREDOXIN-BINDING PROTEIN-2-LIKE INDUCIBLE MEMBRANE; TLIMP;; KIAA1376__:__
Asterisk__:__612465__:__TBC1 DOMAIN FAMILY, MEMBER 4; TBC1D4__:__AKT SUBSTRATE, 160-KD; AS160;; KIAA0603__:__
Asterisk__:__612466__:__GUANYLATE-BINDING PROTEIN 4; GBP4__:__GUANYLATE-BINDING PROTEIN 3, MOUSE, HOMOLOG OF__:__
Asterisk__:__612467__:__GUANYLATE-BINDING PROTEIN 6; GBP6__:__GUANYLATE-BINDING PROTEIN 4, MOUSE, HOMOLOG OF; GBP4__:__
Asterisk__:__612468__:__GUANYLATE-BINDING PROTEIN 7; GBP7__:__GUANYLATE-BINDING PROTEIN 7, MOUSE, HOMOLOG OF__:__
Number Sign__:__612469__:__WILMS TUMOR, ANIRIDIA, GENITOURINARY ANOMALIES, MENTAL RETARDATION, AND OBESITY SYNDROME; WAGRO__:__WAGRO SYNDROME;; WAGR SYNDROME WITH OBESITY;; CHROMOSOME 11p13-p12 DELETION SYNDROME__:__
Asterisk__:__612470__:__BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 3; BATF3__:__SMALL NUCLEAR FACTOR ISOLATED FROM T CELLS, 21-KD;; p21(SNFT)__:__
Asterisk__:__612471__:__ALANINE-GLYOXYLATE AMINOTRANSFERASE 2; AGXT2__:__AGT2;; BETA-ALANINE PYRUVATE AMINOTRANSFERASE;; BETA-ALAAT II__:__
Asterisk__:__612472__:__METHYLTRANSFERASE-LIKE 3; METTL3__:__MT-A70;; IME4, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__612473__:__PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN 4__:__PEBP4;; COUSIN OF RKIP 1; CORK1__:__
Number Sign__:__612474__:__CHROMOSOME 1q21.1 DELETION SYNDROME, 1.35-MB__:____:__
Number Sign__:__612475__:__CHROMOSOME 1q21.1 DUPLICATION SYNDROME__:____:__
Asterisk__:__612476__:__BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE; BATF__:__B-CELL ACTIVATING TRANSCRIPTION FACTOR;; BATF1;; SFA2__:__
Asterisk__:__612477__:__IQ MOTIF-CONTAINING PROTEIN G; IQCG__:____:__IQCG/NUP98 FUSION GENE, INCLUDED
Asterisk__:__612478__:__N-TERMINAL EF-HAND CALCIUM-BINDING PROTEIN 3; NECAB3__:__EFCBP3;; NEK2-INTERACTING PROTEIN 1; NIP1;; AMYLOID BETA PRECURSOR PROTEIN-BINDING, FAMILY A, MEMBER 2; APBA2BP;; X11L-BINDING PROTEIN 51; XB51;; SYNAPTOTAGMIN-INTERACTING PROTEIN 3; STIP3;; SYNAPTOTAGMIN-INTERACTING PROTEIN 2; SYTIP2__:__
Caret__:__612479__:__MOVED TO 603075 AND 603029__:____:__
Asterisk__:__612480__:__TCDD-INDUCIBLE POLY(ADP-RIBOSE) POLYMERASE; TIPARP__:____:__
Asterisk__:__612481__:__POLY(ADP-RIBOSE) POLYMERASE FAMILY, MEMBER 12; PARP12__:__ZC3HDC1;; FLJ22693__:__
Asterisk__:__612482__:__RING FINGER PROTEIN 43; RNF43__:__RNF124__:__
Asterisk__:__612483__:__FAT TUMOR SUPPRESSOR, DROSOPHILA, HOMOLOG OF, 3; FAT3__:____:__
Asterisk__:__612484__:__RIBONUCLEASE, RNase A FAMILY, 7; RNASE7__:____:__
Asterisk__:__612485__:__RIBONUCLEASE, RNase A FAMILY, 8; RNASE8__:__RNASE8, PLACENTAL__:__
Asterisk__:__612486__:__DACHSOUS, DROSOPHILA, HOMOLOG OF, 2; DCHS2__:____:__CADHERIN J, INCLUDED; CDHJ, INCLUDED;; PROTOCADHERIN J, INCLUDED; PCDHJ, INCLUDED
Asterisk__:__612487__:__RING FINGER PROTEIN 31; RNF31__:__ZINC, IN-BETWEEN-RING FINGER, AND UBIQUITIN-ASSOCIATED DOMAINS; ZIBRA;; HOIL1-INTERACTING PROTEIN; HOIP__:__
Asterisk__:__612488__:__RING FINGER PROTEIN 38; RNF38__:____:__
Asterisk__:__612489__:__RING FINGER PROTEIN 24; RNF24__:__GOLIATH-LIKE PROTEIN (C3CH4 TYPE); G1L__:__
Asterisk__:__612490__:__RING FINGER PROTEIN 181; RNF181__:____:__
Asterisk__:__612491__:__APAF1-INTERACTING PROTEIN; APIP__:__CGI29;; MMRP19__:__
Asterisk__:__612492__:__UBIQUITIN-SPECIFIC PROTEASE 30; USP30__:____:__
Asterisk__:__612493__:__CANOPY FGF SIGNALING REGULATOR 1; CNPY1__:__CANOPY 1, ZEBRAFISH, HOMOLOG OF__:__
Asterisk__:__612494__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 10-LIKE PROTEIN; ARHGEF10L__:__GRINCHGEF;; KIAA1626__:__
Asterisk__:__612495__:__UBIQUITIN-CONJUGATING ENZYME E2C-BINDING PROTEIN; UBE2CBP__:__H10BH__:__
Asterisk__:__612496__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 19; ARHGEF19__:__WEAKLY SIMILAR TO RHOGEF5; WGEF__:__
Asterisk__:__612497__:__TRANSFORMING GROWTH FACTOR-BETA-INDUCIBLE NUCLEAR PROTEIN 1__:__TGFB-INDUCIBLE NUCLEAR PROTEIN 1; TINP1;; NSA2, S. CEREVISIAE, HOMOLOG OF; NSA2;; HUMAN SEQUENCE SIMILAR TO YEAST 29; HUSSY29__:__
Asterisk__:__612498__:__ADENYLOSUCCINATE SYNTHASE-LIKE 1; ADSSL1__:____:__
Asterisk__:__612499__:__DIMETHYLADENOSINE TRANSFERASE 1-LIKE; DIMT1L__:__DIM1, S. CEREVISIAE, HOMOLOG OF; DIM1;; HUMAN SEQUENCE SIMILAR TO YEAST 5; HUSSY5__:__
Asterisk__:__612500__:__DEAD BOX POLYPEPTIDE 52; DDX52__:__ROK1, S. CEREVISIAE, HOMOLOG OF; ROK1;; HUMAN SEQUENCE SIMILAR TO YEAST 19; HUSSY19__:__
Asterisk__:__612501__:__UBIQUITIN-CONJUGATING ENZYME E2Q 2; UBE2Q2__:__LOC92912__:__
Asterisk__:__612502__:__COLLECTIN 11; COLEC11__:__COLLECTIN, KIDNEY, 1; CLK1__:__
Asterisk__:__612503__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 5; ABCA5__:__KIAA1888__:__
Asterisk__:__612504__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 6; ABCA6__:____:__
Asterisk__:__612505__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 8; ABCA8__:__KIAA0822__:__
Asterisk__:__612506__:__UBIQUITIN-CONJUGATING ENZYME E2R 2; UBE2R2__:__UBIQUITIN-CONJUGATING ENZYME UBC3B; UBC3B__:__
Asterisk__:__612507__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 9; ABCA9__:____:__
Asterisk__:__612508__:__ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 10; ABCA10__:____:__
Asterisk__:__612509__:__ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 10; ABCC10__:__MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 7; MRP7__:__
Asterisk__:__612510__:__ATP-BINDING CASSETTE, SUBFAMILY F, MEMBER 2; ABCF2__:__HUMAN SEQUENCE SIMILAR TO YEAST 18; HUSSY18__:__
Asterisk__:__612511__:__MICRO RNA 101-1; MIRN101-1__:__miRNA101-1;; MIR101-1__:__
Asterisk__:__612512__:__MICRO RNA 101-2; MIRN101-2__:__miRNA101-2;; MIR101-2__:__
Number Sign__:__612513__:__CHROMOSOME 2p16.1-p15 DELETION SYNDROME__:____:__
Percent__:__612514__:__SPECIFIC LANGUAGE IMPAIRMENT 4; SLI4__:____:__
Asterisk__:__612515__:__DDB1- AND CUL4-ASSOCIATED FACTOR 17; DCAF17__:__CHROMOSOME 2 OPEN READING FRAME 37; C2ORF37__:__
Asterisk__:__612516__:__UVEAL AUTOANTIGEN WITH COILED-COIL DOMAINS AND ANKYRIN REPEATS; UACA__:__NUCLING__:__
Asterisk__:__612517__:__DYNEIN, AXONEMAL, ASSEMBLY FACTOR 2; DNAAF2__:__KINTOUN, MEDAKA, HOMOLOG OF; KTU;; CHROMOSOME 14 OPEN READING FRAME 104; C14ORF104__:__
Number Sign__:__612518__:__CILIARY DYSKINESIA, PRIMARY, 10; CILD10__:__CILIARY DYSKINESIA, PRIMARY, 10, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__612519__:__SOLUTE CARRIER FAMILY 35, MEMBER D3; SLC35D3__:____:__
Number Sign__:__612520__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 20; IDDM20__:____:__
Percent__:__612521__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 21; IDDM21__:____:__
Number Sign__:__612522__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 22; IDDM22__:____:__
Asterisk__:__612523__:__IQ MOTIF-CONTAINING PROTEIN H: IQCH__:__NYD-SP5__:__
Asterisk__:__612524__:__RIBONUCLEASE P/MRP, 21-KD SUBUNIT; RPP21__:____:__
Percent__:__612525__:__PYLORIC STENOSIS, INFANTILE HYPERTROPHIC, 5; IHPS5__:____:__
Number Sign__:__612526__:__LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 3; CGL3__:__BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 3; BSCL3;; LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 3__:__
Number Sign__:__612527__:__DIAMOND-BLACKFAN ANEMIA 4; DBA4__:____:__
Number Sign__:__612528__:__DIAMOND-BLACKFAN ANEMIA 5; DBA5__:____:__
Number Sign__:__612529__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA2; AI2A2__:__AMELOGENESIS IMPERFECTA, PIGMENTED HYPOMATURATION TYPE, 2__:__
Number Sign__:__612530__:__CHROMOSOME 1q41-q42 DELETION SYNDROME__:__HOLOPROSENCEPHALY 10, INCLUDED; HPE10, INCLUDED__:__
Asterisk__:__612531__:__THAP DOMAIN-CONTAINING PROTEIN 2; THAP2__:____:__
Asterisk__:__612532__:__THAP DOMAIN-CONTAINING PROTEIN 3; THAP3__:____:__
Asterisk__:__612533__:__THAP DOMAIN-CONTAINING PROTEIN 4; THAP4__:____:__
Asterisk__:__612534__:__THAP DOMAIN-CONTAINING PROTEIN 5; THAP5__:____:__
Asterisk__:__612535__:__THAP DOMAIN-CONTAINING PROTEIN 6; THAP6__:____:__
Asterisk__:__612536__:__THAP DOMAIN-CONTAINING PROTEIN 8; THAP8__:____:__
Asterisk__:__612537__:__THAP DOMAIN-CONTAINING PROTEIN 9; THAP9__:____:__
Asterisk__:__612538__:__THAP DOMAIN-CONTAINING PROTEIN 10; THAP10__:____:__
Number Sign__:__612539__:__SPASTIC PARAPLEGIA 42, AUTOSOMAL DOMINANT; SPG42__:____:__
Number Sign__:__612540__:__MYOPATHY, CONGENITAL, COMPTON-NORTH; MYPCN__:____:__
Number Sign__:__612541__:__NEUTROPENIA, SEVERE CONGENITAL, 4, AUTOSOMAL RECESSIVE; SCN4__:____:__DURSUN SYNDROME, INCLUDED;; PULMONARY ARTERIAL HYPERTENSION, LEUKOPENIA, AND ATRIAL SEPTAL DEFECT, INCLUDED
Number Sign__:__612542__:__VITAMIN B12 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B12QTL1__:____:__
Asterisk__:__612543__:__UBIQUITIN-SPECIFIC PROTEASE 36; USP36__:__KIAA1453__:__
Asterisk__:__612544__:__ACTIN-BINDING LIM PROTEIN FAMILY, MEMBER 2; ABLIM2__:__KIAA1808__:__
Asterisk__:__612545__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 26; WBSCR26__:____:__
Asterisk__:__612546__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 27; WBSCR27__:____:__
Asterisk__:__612547__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 28; WBSCR28__:____:__
Asterisk__:__612548__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 50; TRIM50__:__TRIM50A__:__
Asterisk__:__612549__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 73; TRIM73__:__TRIM50B__:__
Asterisk__:__612550__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 74; TRIM74__:__TRIM50C__:__
Number Sign__:__612551__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 4, SUSCEPTIBILITY TO; FSGS4__:__END-STAGE RENAL DISEASE, NONDIABETIC, SUSCEPTIBILITY TO, INCLUDED__:__
Asterisk__:__612552__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 4; ZBED4__:__BED-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 4;; KIAA0637__:__
Asterisk__:__612553__:__MICRO RNA 370; MIR370__:__miRNA370;; MIRN370__:__
Percent__:__612554__:__MYOPIA 16, AUTOSOMAL DOMINANT; MYP16__:____:__
Number Sign__:__612555__:__BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2__:____:__BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED;; OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2, INCLUDED
Number Sign__:__612556__:__ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1; ADIPQTL1__:____:__ADIPONECTIN DEFICIENCY, INCLUDED;; HYPOADIPONECTINEMIA, INCLUDED
Percent__:__612557__:__LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 3__:__CLLS3__:__
Percent__:__612558__:__LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 4__:__CLLS4__:__
Percent__:__612559__:__LEUKEMIA, CHRONIC LYMPHOCYTIC, SUSCEPTIBILITY TO, 5__:__CLLS5__:__
Number Sign__:__612560__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 12; BMND12__:____:__
Number Sign__:__612561__:__DIAMOND-BLACKFAN ANEMIA 6; DBA6__:__AASE-SMITH SYNDROME II__:__
Number Sign__:__612562__:__DIAMOND-BLACKFAN ANEMIA 7; DBA7__:____:__
Number Sign__:__612563__:__DIAMOND-BLACKFAN ANEMIA 8; DBA8__:____:__
Asterisk__:__612564__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 9; TXNDC9__:__PHOSDUCIN-LIKE PROTEIN 3; PHLP3__:__
Asterisk__:__612565__:__RAS-ASSOCIATED PROTEIN RAB1B; RAB1B__:____:__
Percent__:__612566__:__INFLAMMATORY BOWEL DISEASE 24; IBD24__:____:__
Number Sign__:__612567__:__INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25__:__INFLAMMATORY BOWEL DISEASE, EARLY-ONSET, AUTOSOMAL RECESSIVE__:__
Asterisk__:__612568__:__SPIC TRANSCRIPTION FACTOR; SPIC__:____:__
Asterisk__:__612569__:__CELL DIVISION CYCLE AND APOPTOSIS REGULATOR 1; CCAR1__:__CELL CYCLE AND APOPTOSIS REGULATORY PROTEIN 1; CARP1__:__
Asterisk__:__612570__:__FIBRILLIN 2; FBN2__:____:__
Percent__:__612571__:__LUNG CANCER SUSCEPTIBILITY 3; LNCR3__:__ADENOCARCINOMA OF LUNG, SUSCEPTIBILITY TO__:__
Number Sign__:__612572__:__RETINITIS PIGMENTOSA 46; RP46__:__RETINITIS PIGMENTOSA, AUTOSOMAL RECESSIVE, IDH3B-RELATED__:__
Percent__:__612573__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 1; MPVQTL1__:____:__
Percent__:__612574__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 2; MPVQTL2__:__PLATELET COUNT QUANTITATIVE TRAIT LOCUS 1__:__
Percent__:__612575__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 3; MPVQTL3__:____:__
Number Sign__:__612576__:__CHROMOSOME 17p13.3, TELOMERIC, DUPLICATION SYNDROME__:__SPLIT-HAND/FOOT MALFORMATION WITH LONG BONE DEFICIENCY 3; SHFLD3__:__
Number Sign__:__612577__:__AMYOTROPHIC LATERAL SCLEROSIS 11; ALS11__:____:__
Percent__:__612578__:__STATURE QUANTITATIVE TRAIT LOCUS 15; STQTL15__:____:__
Percent__:__612579__:__STATURE QUANTITATIVE TRAIT LOCUS 16; STQTL16__:____:__
Number Sign__:__612580__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 3; MRD3__:____:__
Percent__:__612581__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 4; MRD4__:____:__
Number Sign__:__612582__:__CHROMOSOME 6pter-p24 DELETION SYNDROME__:____:__
Asterisk__:__612583__:__SPINSTER, DROSOPHILA, HOMOLOG OF, 1; SPNS1__:__SPIN1__:__
Asterisk__:__612584__:__SPINSTER, DROSOPHILA, HOMOLOG OF, 2; SPNS2__:____:__
Asterisk__:__612585__:__CLPTM1-LIKE PROTEIN; CLPTM1L__:__CISPLATIN RESISTANCE-RELATED PROTEIN 9; CRR9__:__
Percent__:__612586__:__ANEURYSM, INTRACRANIAL BERRY, 9; ANIB9__:____:__
Percent__:__612587__:__ANEURYSM, INTRACRANIAL BERRY, 10; ANIB10__:____:__
Asterisk__:__612588__:__BCL2-ASSOCIATED TRANSCRIPTION FACTOR 1; BCLAF1__:__BTF;; KIAA0164__:__
Percent__:__612589__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 8; CRCS8__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 14q__:__
Percent__:__612590__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 9; CRCS9__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 16q__:__
Number Sign__:__612591__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 10; CRCS10__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 19q__:__
Percent__:__612592__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 11; CRCS11__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 20p__:__
Percent__:__612593__:__LUNG CANCER SUSCEPTIBILITY 4; LNCR4__:____:__
Percent__:__612594__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 2; MS2__:____:__
Percent__:__612595__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 3; MS3__:____:__
Percent__:__612596__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 4; MS4__:____:__
Asterisk__:__612597__:__CYTOTOXIC AND REGULATORY T-CELL MOLECULE; CRTAM__:__CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED T-CELL-ASSOCIATED MOLECULE__:__
Asterisk__:__612598__:__RING FINGER PROTEIN 11; RNF11__:____:__
Percent__:__612599__:__PSORIASIS 11, SUSCEPTIBILITY TO; PSORS11__:____:__
Asterisk__:__612600__:__RNA METHYLTRANSFERASE-LIKE 1; RNMTL1__:__HC90__:__
Asterisk__:__612601__:__RET FINGER PROTEIN-LIKE 4A; RFPL4A__:__RNF210__:__
Asterisk__:__612602__:__RNA-BINDING MOTIF PROTEIN 15B; RBM15B__:__ONE TWENTY TWO PROTEIN 3; OTT3;; HUMAGCGB__:__
Asterisk__:__612603__:__LATE CORNIFIED ENVELOPE PROTEIN 1A; LCE1A__:__LATE ENVELOPE PROTEIN 1; LEP1__:__LATE CORNIFIED ENVELOPE GENE CLUSTER, INCLUDED;; LCE GENE CLUSTER, INCLUDED
Asterisk__:__612604__:__LATE CORNIFIED ENVELOPE PROTEIN 1B; LCE1B__:__LATE ENVELOPE PROTEIN 2; LEP2__:__
Asterisk__:__612605__:__LATE CORNIFIED ENVELOPE 1C; LCE1C__:__LATE ENVELOPE PROTEIN 3; LEP3__:__
Asterisk__:__612606__:__LATE CORNIFIED ENVELOPE PROTEIN 1D; LCE1D__:__LATE ENVELOPE PROTEIN 4; LEP4__:__
Asterisk__:__612607__:__LATE CORNIFIED ENVELOPE PROTEIN 1E; LCE1E__:__LATE ENVELOPE PROTEIN 5; LEP5__:__
Asterisk__:__612608__:__LATE CORNIFIED ENVELOPE PROTEIN 1F; LCE1F__:__LATE ENVELOPE PROTEIN 6; LEP6__:__
Asterisk__:__612609__:__LATE CORNIFIED ENVELOPE PROTEIN 2A; LCE2A__:__LATE ENVELOPE PROTEIN 9; LEP9__:__
Asterisk__:__612610__:__LATE CORNIFIED ENVELOPE PROTEIN 2B; LCE2B__:__LATE ENVELOPE PROTEIN 10; LEP10;; XP5__:__
Asterisk__:__612611__:__LATE CORNIFIED ENVELOPE PROTEIN 2C; LCE2C__:__LATE ENVELOPE PROTEIN 11; LEP11__:__
Asterisk__:__612612__:__LATE CORNIFIED ENVELOPE PROTEIN 2D; LCE2D__:__LATE ENVELOPE PROTEIN 12; LEP12__:__
Asterisk__:__612613__:__LATE CORNIFIED ENVELOPE PROTEIN 3A; LCE3A__:__LATE ENVELOPE PROTEIN 13; LEP13__:__
Asterisk__:__612614__:__LATE CORNIFIED ENVELOPE PROTEIN 3B; LCE3B__:__LATE ENVELOPE PROTEIN 14; LEP14__:__
Asterisk__:__612615__:__LATE CORNIFIED ENVELOPE PROTEIN 3C; LCE3C__:__LATE ENVELOPE PROTEIN 15; LEP15__:__
Asterisk__:__612616__:__LATE CORNIFIED ENVELOPE PROTEIN 3D; LCE3D__:__LATE ENVELOPE PROTEIN 16; LEP16__:__
Asterisk__:__612617__:__LATE CORNIFIED ENVELOPE PROTEIN 3E; LCE3E__:__LATE ENVELOPE PROTEIN 17; LEP17__:__
Asterisk__:__612618__:__LATE CORNIFIED ENVELOPE PROTEIN 4A; LCE4A__:__LATE ENVELOPE PROTEIN 8; LEP8__:__
Asterisk__:__612619__:__LATE CORNIFIED ENVELOPE PROTEIN 5A; LCE5A__:__LATE ENVELOPE PROTEIN 18; LEP18__:__
Asterisk__:__612620__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 6; RASSF6__:____:__
Number Sign__:__612621__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 5; MRD5__:____:__
Percent__:__612622__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 23; IDDM23__:____:__
Number Sign__:__612623__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 2; MVCD2__:__PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO;; END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO__:__
Number Sign__:__612624__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3__:__NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO;; END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO__:__
Asterisk__:__612625__:__LMBR1 DOMAIN-CONTAINING PROTEIN 1: LMBRD1__:__LMBD1;; NES-INTERACTING PROTEIN; NESI__:__
Number Sign__:__612626__:__CHROMOSOME 15q26-qter DELETION SYNDROME__:__DRAYER SYNDROME__:__
Percent__:__612627__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 4; BFIS4__:__CONVULSIONS, BENIGN FAMILIAL INFANTILE, 4; BFIC4__:__
Number Sign__:__612628__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 4; MVCD4__:__NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO__:__
Percent__:__612629__:__ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 4; ADIPQTL4__:____:__
Number Sign__:__612630__:__HAIR MORPHOLOGY 1; HRM1__:__HAIR THICKNESS, VARIATION IN__:__
Number Sign__:__612631__:__ADENYLATE KINASE DEFICIENCY, HEMOLYTIC ANEMIA DUE TO__:____:__
Percent__:__612632__:__USHER SYNDROME, TYPE IH; USH1H__:____:__
Number Sign__:__612633__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 5; MVCD5__:__RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO__:__
Number Sign__:__612634__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 6; MVCD6__:__NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO__:__
Number Sign__:__612635__:__MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 7; MVCD7__:__PROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO;; NONPROLIFERATIVE RETINOPATHY, DIABETIC, SUSCEPTIBILITY TO;; NEPHROPATHY, DIABETIC, SUSCEPTIBILITY TO__:__
Asterisk__:__612636__:__UNC80, C. ELEGANS, HOMOLOG OF; UNC80__:__CHROMOSOME 2 OPEN READING FRAME 21; C2ORF21;; KIAA1843__:__
Percent__:__612637__:__FEBRILE SEIZURES, FAMILIAL, 10; FEB10__:__CONVULSIONS, FAMILIAL FEBRILE, 10__:__
Asterisk__:__612638__:__NADH DEHYDROGENASE 1 ALPHA SUBCOMPLEX, 11; NDUFA11__:____:__
Percent__:__612639__:__INFLAMMATORY BOWEL DISEASE 26; IBD26__:____:__
Asterisk__:__612640__:__THYMUS, BRAIN, AND TESTES ASSOCIATED; TBATA__:__CHROMOSOME 10 OPEN READING FRAME 27; C10ORF27__:__
Asterisk__:__612641__:__ANKYRIN 1; ANK1__:__ANKYRIN, ERYTHROID__:__ANKYRIN-R, INCLUDED; ANK, INCLUDED;; ANKYRIN 1 MUSCLE-SPECIFIC ISOFORM, INCLUDED
Percent__:__612642__:__DEAFNESS, AUTOSOMAL DOMINANT 59; DFNA59__:____:__
Number Sign__:__612643__:__DEAFNESS, AUTOSOMAL DOMINANT 3B; DFNA3B__:____:__
Number Sign__:__612644__:__DEAFNESS, AUTOSOMAL DOMINANT 2B; DFNA2B__:____:__
Number Sign__:__612645__:__DEAFNESS, AUTOSOMAL RECESSIVE 1B; DFNB1B__:____:__
Asterisk__:__612646__:__METASTASIS-ASSOCIATED GENE IN COLON CANCER 1; MACC1__:____:__
Asterisk__:__612647__:__RADIAL SPOKE HEAD 4, CHLAMYDOMONAS, HOMOLOG OF, A; RSPH4A__:____:__
Asterisk__:__612648__:__RADIAL SPOKE HEAD 9, CHLAMYDOMONAS, HOMOLOG OF; RSPH9__:____:__
Number Sign__:__612649__:__CILIARY DYSKINESIA, PRIMARY, 11; CILD11__:__CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS__:__
Number Sign__:__612650__:__CILIARY DYSKINESIA, PRIMARY, 12; CILD12__:__CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS__:__
Number Sign__:__612651__:__ENDOCRINE-CEREBROOSTEODYSPLASIA; ECO__:____:__
Caret__:__612652__:__MOVED TO 219150__:____:__
Number Sign__:__612653__:__SPHEROCYTOSIS, TYPE 4; SPH4__:__SPHEROCYTOSIS, HEREDITARY, 4; HS4__:__
Asterisk__:__612654__:__TRICHOPLEIN; TCHP__:__TRICHOPLEIN, KERATIN FILAMENT-BINDING;; MITOSTATIN__:__
Asterisk__:__612655__:__TBC1 DOMAIN FAMILY, MEMBER 7; TBC1D7__:__CELL MIGRATION-INDUCING PROTEIN 23;; PIG51;; TBC7__:__
Number Sign__:__612656__:__EPISODIC ATAXIA, TYPE 6; EA6__:____:__
Number Sign__:__612657__:__CONE-ROD DYSTROPHY 12; CORD12__:____:__
Asterisk__:__612658__:__TIGHT JUNCTION-ASSOCIATED PROTEIN 1; TJAP1__:__PROTEIN INCORPORATED LATER INTO TIGHT JUNCTIONS; PILT;; TIGHT JUNCTION PROTEIN 4; TJP4__:__
Asterisk__:__612659__:__REGULATORY FACTOR X, 6; RFX6__:__RFXDC1__:__
Asterisk__:__612660__:__REGULATORY FACTOR X, 7; RFX7__:__RFXDC2__:__
Asterisk__:__612661__:__WD REPEAT-CONTAINING PROTEIN ANTISENSE TO TP53; WRAP53__:__TELOMERASE CAJAL BODY PROTEIN 1; TCAB1;; WD REPEAT-CONTAINING PROTEIN 79; WDR79__:__
Asterisk__:__612662__:__TBC1 DOMAIN FAMILY, MEMBER 15; TBC1D15__:____:__
Asterisk__:__612663__:__TRAF-INTERACTING PROTEIN WITH FORKHEAD-ASSOCIATED DOMAIN, FAMILY MEMBER B; TIFAB__:__TIFA-RELATED PROTEIN__:__
Asterisk__:__612664__:__RAS-LIKE AND ESTROGEN-REGULATED GROWTH INHIBITOR; RERG__:____:__
Asterisk__:__612665__:__TESTIS-EXPRESSED GENE 101; TEX101__:__SPERMATOGENESIS-RELATED GENE; SGRG;; SCLERODERMA-ASSOCIATED AUTOANTIGEN;; TESTIS-SPECIFIC 101 REACTIVE PROTEIN; TES101RP__:__
Asterisk__:__612666__:__DUAL SERINE/THREONINE AND TYROSINE PROTEIN KINASE; DSTYK__:__RECEPTOR-INTERACTING SERINE/THREONINE KINASE 5; RIPK5;; KIAA0472;; RECEPTOR-INTERACTING PROTEIN 5; RIP5;; DUSTY PROTEIN KINASE; DUSTYPK__:__
Asterisk__:__612667__:__HOLLIDAY JUNCTION RECOGNITION PROTEIN; HJURP__:____:__
Asterisk__:__612668__:__TASTE RECEPTOR, TYPE 2, MEMBER 43; TAS2R43__:__T2R52__:__
Asterisk__:__612669__:__TASTE RECEPTOR, TYPE 2, MEMBER 31; TAS2R31__:__T2R53;; TASTE RECEPTOR, TYPE 2, MEMBER 44, FORMERLY; TAS2R44, FORMERLY__:__
Caret__:__612670__:__MOVED TO 138900__:____:__
Number Sign__:__612671__:__URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 4; UAQTL4__:__GOUT SUSCEPTIBILITY 4; GOUT4__:__
Asterisk__:__612672__:__RAS-ASSOCIATED PROTEIN RAB10; RAB10__:____:__
Asterisk__:__612673__:__RAS-ASSOCIATED PROTEIN RAB14; RAB14__:____:__
Number Sign__:__612674__:__POLYNEUROPATHY, HEARING LOSS, ATAXIA, RETINITIS PIGMENTOSA, AND CATARACT; PHARC__:____:__
Asterisk__:__612675__:__SMALL CAJAL BODY-SPECIFIC RNA 15; SCARNA15__:__ACA45__:__
Asterisk__:__612676__:__QUINOID DIHYDROPTERIDINE REDUCTASE; QDPR__:__DIHYDROPTERIDINE REDUCTASE; DHPR__:__
Asterisk__:__612677__:__PYRIN AND HIN DOMAIN FAMILY, MEMBER 1; PYHIN1__:__INTERFERON-INDUCIBLE PROTEIN X; IFIX__:__
Asterisk__:__612678__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 3; CELF3__:__TRINUCLEOTIDE REPEAT-CONTAINING GENE 4; TNRC4;; BRUNO-LIKE 1; BRUNOL1;; CUGBP- AND ETR3-LIKE FACTOR 3__:__
Asterisk__:__612679__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 4; CELF4__:__CUGBP- AND ETR3-LIKE FACTOR 4;; BRUNO-LIKE 4; BRUNOL4__:__
Asterisk__:__612680__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 5; CELF5__:__BRUNO-LIKE 5; BRUNOL5;; CUGBP- AND ETR3-LIKE FACTOR 5__:__
Asterisk__:__612681__:__CUGBP- AND ELAV-LIKE FAMILY, MEMBER 6; CELF6__:__BRUNO-LIKE 6; BRUNOL6;; CUGBP- AND ETR3-LIKE FACTOR 6__:__
Asterisk__:__612682__:__DORSAL REPULSIVE AXON GUIDANCE PROTEIN__:__DRAXIN;; CHROMOSOME 1 OPEN READING FRAME 187; C1ORF187;; NEUCRIN__:__
Asterisk__:__612683__:__TEKTIN 3; TEKT3__:__TESTICULAR MICROTUBULES-RELATED PROTEIN__:__
Asterisk__:__612684__:__ISTHMIN 2, ZEBRAFISH, HOMOLOG OF; ISM2__:__THROMBOSPONDIN TYPE 1 DOMAIN-CONTAINING PROTEIN 3; THSD3;; THROMBOSPONDIN- AND AMOP-CONTAINING ISTHMIN-LIKE 1; TAIL1__:__
Asterisk__:__612685__:__CALMODULIN-REGULATED SPECTRIN-ASSOCIATED PROTEIN 3; CAMSAP3__:__KIAA1543 GENE; KIAA1543;; NEZHA__:__
Asterisk__:__612686__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY A, MEMBER 7; PLEKHA7__:____:__
Asterisk__:__612687__:__RGM DOMAIN FAMILY, MEMBER B; RGMB__:__DRAGON;; REPULSIVE GUIDANCE MOLECULE B__:__
Asterisk__:__612688__:__RING FINGER PROTEIN 168; RNF168__:____:__
Asterisk__:__612689__:__TIGHT JUNCTION PROTEIN 3; TJP3__:__ZONA OCCLUDENS 3; ZO3__:__
Number Sign__:__612690__:__SPHEROCYTOSIS, TYPE 5; SPH5__:__SPHEROCYTOSIS, HEREDITARY, 5; HS5__:__
Number Sign__:__612691__:__POLYMICROGYRIA, BILATERAL TEMPOROOCCIPITAL; BTOP__:____:__
Number Sign__:__612692__:__AGAMMAGLOBULINEMIA 6, AUTOSOMAL RECESSIVE; AGM6__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO CD79B DEFECT__:__
Asterisk__:__612693__:__UBIQUITIN-RELATED MODIFIER 1, S. CEREVISIAE, HOMOLOG OF; URM1__:____:__
Asterisk__:__612694__:__CYTOSOLIC THIOURIDYLASE, SUBUNIT 1; CTU1__:__ATP-BINDING DOMAIN PROTEIN 3; ATPBD3__:__
Asterisk__:__612695__:__VAULT RNA 1-1; VTRNA1-1__:__HVG1;; VAULT RNA COMPONENT 1; VAULTRC1__:__
Asterisk__:__612696__:__VAULT RNA 1-2; VTRNA1-2__:__HVG2;; VAULT RNA COMPONENT 2; VAULTRC2__:__
Asterisk__:__612697__:__VAULT RNA 1-3; VTRNA1-3__:__HVG3;; VAULT RNA COMPONENT 3; VAULTRC3__:__
Asterisk__:__612698__:__MICRO RNA 187; MIR187__:__MIRN187;; miRNA187__:__
Asterisk__:__612699__:__RIMS-BINDING PROTEIN 3; RIMBP3__:__RIMBP3A;; RIMBP3.1;; KIAA1666__:__
Asterisk__:__612700__:__RIMS-BINDING PROTEIN 3B; RIMBP3B__:__RIMBP3.2__:__
Asterisk__:__612701__:__RIMS-BINDING PROTEIN 3C; RIMBP3C__:__RIMBP3.3__:__
Number Sign__:__612702__:__HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA; HH6__:____:__
Number Sign__:__612703__:__MICROCEPHALY 7, PRIMARY, AUTOSOMAL RECESSIVE; MCPH7__:____:__
Asterisk__:__612704__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 1; RGPD1__:__RGP1__:__
Asterisk__:__612705__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 2; RGPD2__:__RGP2__:__
Asterisk__:__612706__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 3; RGPD3__:__RGP3__:__
Asterisk__:__612707__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 4; RGPD4__:__RGP4__:__
Asterisk__:__612708__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 5; RGPD5__:__RGP5;; BS63__:__
Asterisk__:__612709__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 6; RGPD6__:__RGP6__:__
Asterisk__:__612710__:__RANBP2-LIKE AND GRIP DOMAIN-CONTAINING PROTEIN 7; RGPD7__:__RGP7__:__
Asterisk__:__612711__:__GRIP AND COILED-COIL DOMAIN-CONTAINING PROTEIN 2; GCC2__:__GCC PROTEIN, 185-KD; GCC185;; KIAA0336__:__
Number Sign__:__612712__:__LEBER CONGENITAL AMAUROSIS 13; LCA13__:____:__RETINITIS PIGMENTOSA 53, INCLUDED; RP53, INCLUDED
Number Sign__:__612713__:__KAHRIZI SYNDROME; KHRZ__:__MENTAL RETARDATION, CATARACT, COLOBOMA, AND KYPHOSIS, AUTOSOMAL RECESSIVE__:__
Number Sign__:__612714__:__EXOCRINE PANCREATIC INSUFFICIENCY, DYSERYTHROPOIETIC ANEMIA, AND CALVARIAL HYPEROSTOSIS__:____:__
Percent__:__612715__:__DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 2; DUH2__:____:__
Number Sign__:__612716__:__DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY__:__SEPIAPTERIN REDUCTASE DEFICIENCY; SRD;; SPR DEFICIENCY__:__
Percent__:__612717__:__MYOPIA 15, AUTOSOMAL DOMINANT; MYP15__:____:__
Number Sign__:__612718__:__CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3__:__ARGININE:GLYCINE AMIDINOTRANSFERASE DEFICIENCY;; AGAT DEFICIENCY;; GATM DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO AGAT DEFICIENCY__:__
Asterisk__:__612719__:__6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE; PTS__:__PTPS__:__
Asterisk__:__612720__:__DEAH BOX POLYPEPTIDE 29; DHX29__:____:__
Asterisk__:__612721__:__REGULATED ENDOCRINE-SPECIFIC PROTEIN 18__:__RESP18__:__
Asterisk__:__612722__:__ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 3; ELP3__:__ELONGATION PROTEIN 3, S. CEREVISIAE, HOMOLOG OF;; KAT9__:__
Asterisk__:__612723__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY H, MEMBER 2; PLEKHH2__:____:__
Asterisk__:__612724__:__ALDOLASE B, FRUCTOSE-BISPHOSPHATE; ALDOB__:__FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE B;; ALDOLASE B; ALDB;; ALDOLASE 2; ALDO2__:__
Asterisk__:__612725__:__PROTEIN PHOSPHATASE 6, CATALYTIC SUBUNIT; PPP6C__:____:__
Percent__:__612726__:__HARDIKAR SYNDROME__:____:__
Percent__:__612727__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 13; BMND13__:____:__
Percent__:__612728__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 14; BMND14__:____:__
Percent__:__612729__:__LEAN BODY MASS QUANTITATIVE TRAIT LOCUS 1; LBMQTL1__:____:__
Asterisk__:__612730__:__SOLUTE CARRIER FAMILY 9 (SODIUM/HYDROGEN EXCHANGER), MEMBER 8; SLC9A8__:__SODIUM/HYDROGEN EXCHANGER 8; NHE8;; KIAA0939__:__
Percent__:__612731__:__FACIOCARDIOMELIC SYNDROME__:____:__
Asterisk__:__612732__:__COPROPORPHYRINOGEN OXIDASE; CPOX__:__CPO;; CPX__:__
Asterisk__:__612733__:__THO COMPLEX, SUBUNIT 5; THOC5__:__FMS-INTERACTING PROTEIN; FMIP;; PK1.3;; FSAP79__:__
Asterisk__:__612734__:__TLX1 DIVERGENT GENE__:__TD1__:__
Asterisk__:__612735__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DR BETA-3; HLA-DRB3__:__HLA-DR52__:__
Number Sign__:__612736__:__CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2__:__GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY__:__
Percent__:__612737__:__STATURE QUANTITATIVE TRAIT LOCUS 17; STQTL17__:____:__
Asterisk__:__612738__:__SOLUTE CARRIER FAMILY 9, MEMBER 10; SLC9A10__:__SPERM-SPECIFIC SODIUM PROTON EXCHANGER__:__
Asterisk__:__612739__:__SPERM ACROSOME-ASSOCIATED PROTEIN 1; SPACA1__:__SPERM ACROSOME MEMBRANE-ASSOCIATED PROTEIN 32; SAMP32__:__
Number Sign__:__612740__:__PORPHYRIA, ACUTE HEPATIC__:__DELTA-AMINOLEVULINATE DEHYDRATASE DEFICIENCY;; ALAD DEFICIENCY;; PORPHYRIA, ALAD;; PORPHOBILINOGEN SYNTHASE DEFICIENCY;; DOSS PORPHYRIA__:__LEAD POISONING, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__612741__:__SNAIL, DROSOPHILA, HOMOLOG OF, 3; SNAI3__:__SNAIL3;; SMUC;; ZFP293__:__
Asterisk__:__612742__:__MICRO RNA 181A1; MIR181A1__:__miRNA181A1;; MIRN181A1;; MIR213__:__
Asterisk__:__612743__:__MICRO RNA 181A2; MIR181A2__:__miRNA181A2;; MIRN181A2__:__
Asterisk__:__612744__:__MICRO RNA 181B1; MIR181B1__:__miRNA181B1;; MIRN181B1__:__
Asterisk__:__612745__:__MICRO RNA 181B2; MIR181B2__:__miRNA181B2;; MIRN181B2__:__
Asterisk__:__612746__:__MICRO RNA 181C; MIR181C__:__miRNA181C;; MIRN181C__:__
Asterisk__:__612747__:__TUFTELIN-INTERACTING PROTEIN 11; TFIP11__:__TUFTELIN-INTERACTING PROTEIN, 39-KD; TIP39;; NTR1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__612748__:__LYSOZYME-LIKE 2; LYZL2__:__LYSOZYME 2__:__
Asterisk__:__612749__:__SPERM ACROSOME-ASSOCIATED PROTEIN 3; SPACA3__:__LYSOZYME-LIKE 3; LYZL3;; SPERM LYSOZYME-LIKE PROTEIN 1; SLLP1;; LYC3;; ALLP17__:__
Asterisk__:__612750__:__LYSOZYME-LIKE 4; LYZL4__:____:__
Asterisk__:__612751__:__LYSOZYME-LIKE 6; LYZL6__:____:__
Asterisk__:__612752__:__CXXC FINGER PROTEIN 5; CXXC5__:__RETINOID-INDUCIBLE NUCLEAR FACTOR; RINF__:__
Asterisk__:__612753__:__COLLAGEN AND CALCIUM-BINDING EGF DOMAIN-CONTAINING PROTEIN 1; CCBE1__:__KIAA1983__:__
Asterisk__:__612754__:__GLUTAREDOXIN 3; GLRX3__:__GRX3;; PROTEIN KINASE C-INTERACTING COUSIN OF THIOREDOXIN; PICOT__:__
Asterisk__:__612755__:__MITOCHONDRIAL DISTRIBUTION AND MORPHOLOGY 20, YEAST, HOMOLOG OF__:__MDM20;; CHROMOSOME 12 OPEN READING FRAME 30; C12ORF30__:__
Asterisk__:__612756__:__TESTICULAR CELL ADHESION MOLECULE 1; TCAM1__:____:__
Asterisk__:__612757__:__GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN 1; GPIHBP1__:____:__
Asterisk__:__612758__:__TRANSMEMBRANE ANTERIOR POSTERIOR TRANSFORMATION 1; TAPT1__:__CYTOMEGALOVIRUS gH FUSION RECEPTOR; CMVFR__:__
Percent__:__612759__:__SYNESTHESIA__:__SYNSTH__:__
Asterisk__:__612760__:__SNF-RELATED KINASE; SNRK__:__SNF1-RELATED KINASE;; KIAA0096__:__
Asterisk__:__612761__:__SWI/SNF-RELATED, MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, DEAD/H BOX-CONTAINING, 1; SMARCAD1__:__KIAA1122;; ENHANCER TRAP LOCUS 1, MOUSE, HOMOLOG OF; ETL1;; HUMAN HELICASE 1; HEL1__:__
Asterisk__:__612762__:__SUPPRESSOR OF TY 7-LIKE; SUPT7L__:__SUPPRESSOR OF TY 7, S. CEREVISIAE, HOMOLOG OF, 7; SUPT7H;; SPTF-ASSOCIATED FACTOR 65-GAMMA; STAF65-GAMMA;; STAGA COMPLEX, 65-KD, GAMMA SUBUNIT;; SPT7L;; KIAA0764__:__
Asterisk__:__612763__:__TRANSCRIPTIONAL ADAPTOR 1-LIKE; TADA1L__:__HFI1/ADA1, YEAST, HOMOLOG OF;; SPT3-ASSOCIATED FACTOR 42; STAF42__:__
Asterisk__:__612764__:__ISY1 SPLICING FACTOR, S. CEREVISIAE, HOMOLOG OF; ISY1__:__KIAA1160__:__
Asterisk__:__612765__:__SFI1, YEAST, HOMOLOG OF; SFI1__:__SPINDLE ASSEMBLY-ASSOCIATED PROTEIN SFI1;; KIAA0542__:__
Asterisk__:__612766__:__BRISC AND BRCA1 A COMPLEX, MEMBER 1; BABAM1__:__CHROMOSOME 19 OPEN READING FRAME 62; C19ORF62;; MEDIATOR OF RAP80 INTERACTIONS AND TARGETING, 40-KD; MERIT40;; NEW COMPONENT OF BRCA1 A COMPLEX 1; NBA1__:__
Asterisk__:__612767__:__DEAH BOX POLYPEPTIDE 36; DHX36__:__G4 RESOLVASE 1; G4R1;; RNA HELICASE ASSOCIATED WITH AU-RICH ELEMENTS; RHAU;; KIAA1488__:__
Asterisk__:__612768__:__FOLLICULIN-INTERACTING PROTEIN 2; FNIP2__:__FNIP1-LIKE PROTEIN; FNIPL;; METHYLGUANINE-INDUCED APOPTOSIS 1; MAPO1;; KIAA1450__:__
Asterisk__:__612769__:__NONCODING NUCLEAR-ENRICHED ABUNDANT TRANSCRIPT 1; NEAT1__:__NONCODING RNA 84; NCRNA00084__:__TROPHOBLAST-DERIVED NONCODING RNA, INCLUDED; TNCRNA, INCLUDED
Asterisk__:__612770__:__PHOSPHATIDYLSERINE DECARBOXYLASE; PISD__:__PSD;; PSSC__:__
Asterisk__:__612771__:__DUAL OXIDASE MATURATION FACTOR 1; DUOXA1__:____:__
Asterisk__:__612772__:__DUAL OXIDASE MATURATION FACTOR 2; DUOXA2__:____:__
Asterisk__:__612773__:__BASAL CELL ADHESION MOLECULE; BCAM__:__B-CELL ADHESION MOLECULE;; CD239;; MSK19__:__
Asterisk__:__612774__:__TASTE RECEPTOR, TYPE 2, MEMBER 46; TAS2R46__:__T2R46;; T2R54__:__
Number Sign__:__612775__:__CONE-ROD DYSTROPHY 9; CORD9__:____:__
Percent__:__612776__:__HYPOGLOSSIA WITH SITUS INVERSUS__:____:__HYPOGLOSSIA, ISOLATED, INCLUDED
NULL__:__612777__:__HYPOTONIA, SEIZURES, AND PRECOCIOUS PUBERTY__:____:__
Asterisk__:__612778__:__SET DOMAIN-CONTAINING PROTEIN 2; SETD2__:__SET2;; HUNTINGTIN-INTERACTING PROTEIN B; HYPB;; HUNTINGTIN-BINDING PROTEIN, 231-KD; HBP231;; KIAA1732__:__
Asterisk__:__612779__:__DIHYDROPYRIMIDINE DEHYDROGENASE; DPYD__:__DPD__:__
Number Sign__:__612780__:__SEIZURES, SENSORINEURAL DEAFNESS, ATAXIA, MENTAL RETARDATION, AND ELECTROLYTE IMBALANCE; SESAMES__:__SESAME SYNDROME;; EPILEPSY, ATAXIA, SENSORINEURAL DEAFNESS, AND TUBULOPATHY;; EAST SYNDROME__:__
Number Sign__:__612781__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB; IGHD1B__:__IGHD IB__:__
Number Sign__:__612782__:__IMMUNODEFICIENCY 9; IMD9__:__IMMUNE DYSFUNCTION WITH T-CELL INACTIVATION DUE TO CALCIUM ENTRY DEFECT 1__:__
Number Sign__:__612783__:__IMMUNODEFICIENCY 10; IMD10__:__IMMUNE DYSFUNCTION WITH T-CELL INACTIVATION DUE TO CALCIUM ENTRY DEFECT 2;; STIM1 DEFICIENCY__:__
Asterisk__:__612784__:__HUNTINGTIN-INTERACTING PROTEIN K__:__HUNTINGTIN YEAST 2-HYBRID PROTEIN K; HYPK__:__
NULL__:__612785__:__MEGARBANE-JALKH SYNDROME__:__DEVELOPMENTAL DELAY, DYSMORPHIC FEATURES, NEONATAL SPONTANEOUS FRACTURES, WRINKLED SKIN, AND HEPATIC FAILURE__:__
Asterisk__:__612786__:__CYCLIN Y; CCNY__:__CYCLIN-FOLD PROTEIN 1; CFP1;; CYCLIN X; CCNX;; CHROMOSOME 10 OPEN READING FRAME 9; C10ORF9__:__
Asterisk__:__612787__:__PSEUDOURIDYLATE SYNTHASE 10; PUS10__:__PSEUDOURIDINE SYNTHASE 10;; DOWNSTREAM OF BID; DOBI__:__
Asterisk__:__612788__:__FORKHEAD BOX Q1; FOXQ1__:__HFH1__:__
Percent__:__612789__:__DEAFNESS, AUTOSOMAL RECESSIVE 71; DFNB71__:____:__
Asterisk__:__612790__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 28; ARHGEF28__:__RGNEF, MOUSE, HOMOLOG OF;; GUANINE NUCLEOTIDE EXCHANGE FACTOR, 190-KD;; p190RHOGEF;; KIAA1998;; RHO-INTERACTING PROTEIN 2; RIP2;; RhoGEF__:__
Asterisk__:__612791__:__ZINC FINGER PROTEIN WITH KRAB AND SCAN DOMAINS 3; ZKSCAN3__:__ZINC FINGER PROTEIN 306; ZNF306__:__
Asterisk__:__612792__:__PHOSPHATIDYLSERINE SYNTHASE 1; PTDSS1__:__PSS1;; KIAA0024__:__
Asterisk__:__612793__:__PHOSPHATIDYLSERINE SYNTHASE 2; PTDSS2__:__PSS2__:__
Number Sign__:__612794__:__ATRIAL SEPTAL DEFECT 5; ASD5__:____:__
Percent__:__612795__:__POLYUNSATURATED FATTY ACIDS PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; PUFAQTL1__:____:__
Percent__:__612796__:__INFLAMMATORY BOWEL DISEASE 27; IBD27__:____:__
Number Sign__:__612797__:__HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 12; HDLCQ12__:____:__
Number Sign__:__612798__:__QUESTION MARK EARS, ISOLATED; QME__:__EARS, PROMINENT AND CONSTRICTED;; COSMAN DEFORMITY OF THE AURICLE;; AURICULAR CLEFT, CONGENITAL__:__
Asterisk__:__612799__:__GLUTAMYL-tRNA SYNTHETASE 2; EARS2__:__GLUTAMYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL GLURS;; KIAA1970__:__
Asterisk__:__612800__:__CYSTEINYL-tRNA SYNTHETASE 2; CARS2__:__CYSTEINYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL CYSRS__:__
Asterisk__:__612801__:__ISOLEUCYL-tRNA SYNTHETASE 2; IARS2__:__ISOLEUCYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL ILERS__:__
Asterisk__:__612802__:__VALYL-tRNA SYNTHETASE 2; VARS2__:__VALYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL VALRS;; KIAA1885__:__
Asterisk__:__612803__:__ASPARAGINYL-tRNA SYNTHETASE 2; NARS2__:__ASPARAGINYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL ASNRS__:__
Asterisk__:__612804__:__SERYL-tRNA SYNTHETASE 2; SARS2__:__SERYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL SERRS__:__
Asterisk__:__612805__:__THREONYL-tRNA SYNTHETASE 2; TARS2__:__THREONYL-tRNA SYNTHETASE, MITOCHONDRIAL;; MITOCHONDRIAL THRRS__:__
Asterisk__:__612806__:__G PROTEIN-COUPLED RECEPTOR 89B; GPR89B__:__GOLGI pH REGULATOR; GPHR;; GPR89, TELOMERIC COPY__:__
Asterisk__:__612807__:__LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 1; LRFN1__:__SYNAPTIC ADHESION-LIKE MOLECULE 2; SALM2;; KIAA1484__:__
Asterisk__:__612808__:__LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 2; LRFN2__:__SYNAPTIC ADHESION-LIKE MOLECULE 1; SALM1;; KIAA1246__:__
Asterisk__:__612809__:__LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 3; LRFN3__:__SYNAPTIC ADHESION-LIKE MOLECULE 4; SALM4__:__
Asterisk__:__612810__:__LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 4; LRFN4__:__SYNAPTIC ADHESION-LIKE MOLECULE 3; SALM3__:__
Asterisk__:__612811__:__LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 5; LRFN5__:__SYNAPTIC ADHESION-LIKE MOLECULE 5; SALM5__:__
Asterisk__:__612812__:__PROFILIN 3; PFN3__:____:__
Number Sign__:__612813__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, AGGRECAN TYPE; SEMDAG__:__SEMD, AGGRECAN TYPE__:__
Asterisk__:__612814__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 18; SPATA18__:__SPERMATID-EXPRESSED GENE 1; SPETEX1__:__
Asterisk__:__612815__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 13; ZDHHC13__:__HIP14-LIKE; HIP14L__:__
Asterisk__:__612816__:__UTP18, S. CEREVISIAE, HOMOLOG OF; UTP18__:____:__
Asterisk__:__612817__:__KRR1, YEAST, HOMOLOG OF; KRR1__:____:__
Asterisk__:__612818__:__NUCLEOLAR AND SPINDLE-ASSOCIATED PROTEIN 1; NUSAP1__:__NUCLEOLAR PROTEIN ANKT; ANKT;; NUSAP__:__
Asterisk__:__612819__:__NUCLEOLAR COMPLEX-ASSOCIATED PROTEIN 4, S. CEREVISIAE, HOMOLOG OF; NOC4L__:__NOC4__:__
Asterisk__:__612820__:__NEUROPLASTIN; NPTN__:__STROMAL CELL-DERIVED FACTOR RECEPTOR 1; SDFR1__:__GLYCOPROTEIN, 55-KD, INCLUDED; GP55, INCLUDED;; NEUROPLASTIN 55, INCLUDED; NP55, INCLUDED;; GLYCOPROTEIN, 65-KD, INCLUDED; GP65, INCLUDED;; NEUROPLASTIN 65, INCLUDED; NP65, INCLUDED
Asterisk__:__612821__:__G PROTEIN-COUPLED RECEPTOR 89A; GPR89A__:__GPR89, CENTROMERIC COPY__:__
Asterisk__:__612822__:__UTP20, S. CEREVISIAE, HOMOLOG OF; UTP20__:__DOWNREGULATED IN METASTASIS; DRIM__:__
Asterisk__:__612823__:__TATA BOX-BINDING PROTEIN-ASSOCIATED FACTOR 1D; TAF1D__:__TBP-ASSOCIATED FACTOR, RNA POLYMERASE I, 41-kD; TAFI41;; JOSEPHIN DOMAIN-CONTAINING 3; JOSD3__:__
Asterisk__:__612824__:__SEC14-LIKE 3; SEC14L3__:__SEC14, S. CEREVISIAE, HOMOLOG OF, 3;; TOCOPHEROL-ASSOCIATED PROTEIN 2; TAP2__:__
Asterisk__:__612825__:__SEC14-LIKE 4; SEC14L4__:__SEC14, S. CEREVISIAE, HOMOLOG OF, 4;; TOCOPHEROL-ASSOCIATED PROTEIN 3; TAP3__:__
Asterisk__:__612826__:__SPHINGOSINE-1-PHOSPHATE PHOSPHATASE 1; SGPP1__:__SPP1;; SPPASE1__:__
Asterisk__:__612827__:__SPHINGOSINE-1-PHOSPHATE PHOSPHATASE 2; SGPP2__:__SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE 2; SPP2__:__
Asterisk__:__612828__:__CCAAT/ENHANCER-BINDING PROTEIN, ZETA; CEBPZ__:__CBF;; NUCLEOLAR COMPLEX-ASSOCIATED PROTEIN 1, S. CEREVISIAE, HOMOLOG OF; NOC1__:__
Asterisk__:__612829__:__RAS-ASSOCIATED PROTEIN RAB3C; RAB3C__:____:__
Asterisk__:__612830__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 3; DHRS3__:__SDR FAMILY, MEMBER 3;; RETSDR1__:__
Asterisk__:__612831__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE XI; HSD17B11__:__17-BETA-HSDXI;; RETSDR2;; PAN1B__:__
Asterisk__:__612832__:__17-BETA-HYDROXYSTEROID DEHYDROGENASE XIV; HSD17B14__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 10; DHRS10;; SDR FAMILY, MEMBER 10;; RETSDR3__:__
Asterisk__:__612833__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 7; DHRS7__:__SDR FAMILY, MEMBER 7;; RETSDR4__:__
Asterisk__:__612834__:__PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY B, MEMBER 1; PHLDB1__:__LL5A;; KIAA0638__:__
Asterisk__:__612835__:__PHOSPHOLIPASE C, ETA-1; PLCH1__:__PHOSPHOLIPASE C LIKE-3; PLCL3;; KIAA1069__:__
Asterisk__:__612836__:__PHOSPHOLIPASE C, ETA-2; PLCH2__:__PHOSPHOLIPASE C LIKE-4; PLCL4__:__
Asterisk__:__612837__:__COENZYME 9; COQ9__:__COQ9, S. CEREVISIAE, HOMOLOG OF;; CHROMOSOME 16 OPEN READING FRAME 49; C16ORF49__:__
Number Sign__:__612838__:__BRUGADA SYNDROME 5; BRGDA5__:____:__CARDIAC CONDUCTION DEFECT, NONSPECIFIC, INCLUDED
Asterisk__:__612839__:__TET ONCOGENE FAMILY, MEMBER 2; TET2__:__KIAA1546__:__
Number Sign__:__612840__:__LEUKOCYTE ADHESION DEFICIENCY, TYPE III; LAD3__:__LEUKOCYTE ADHESION DEFICIENCY 3;; LEUKOCYTE ADHESION DEFICIENCY 1 VARIANT; LAD1V;; INTEGRIN ACTIVATION DEFICIENCY DISEASE; IADD__:__
Percent__:__612841__:__HYPOTRICHOSIS 5; HYPT5__:__MARIE UNNA HEREDITARY HYPOTRICHOSIS 2; MUHH2__:__
Asterisk__:__612842__:__RASD FAMILY, MEMBER 2; RASD2__:__RAS HOMOLOG ENRICHED IN STRIATUM; RHES;; TUMOR ENDOTHELIAL MARKER 2; TEM2__:__
Percent__:__612843__:__KERATOSIS FOLLICULARIS SPINULOSA DECALVANS, AUTOSOMAL DOMINANT; KFSD__:____:__
Asterisk__:__612844__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 3; SENP3__:__SUMO-SPECIFIC PROTEASE 3__:__
Asterisk__:__612845__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 5; SENP5__:__SUMO-SPECIFIC PROTEASE 5__:__
Asterisk__:__612846__:__SENTRIN-SPECIFIC PROTEASE FAMILY, MEMBER 7; SENP7__:__SUMO-SPECIFIC PROTEASE 7;; KIAA1707__:__
Number Sign__:__612847__:__BRACHYOLMIA TYPE 4 WITH MILD EPIPHYSEAL AND METAPHYSEAL CHANGES; BCYM4__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, PAKISTANI TYPE;; SEMD, PAKISTANI TYPE;; SPONDYLODYSPLASIA AND PREMATURE PUBARCHE__:__
Asterisk__:__612848__:__SUCCINATE DEHYDROGENASE COMPLEX ASSEMBLY FACTOR 1; SDHAF1__:____:__
Asterisk__:__612849__:__UBIQUITIN-SPECIFIC PEPTIDASE 46; USP46__:____:__
Asterisk__:__612850__:__TUBULIN, BETA-2B; TUBB2B__:__TUBULIN, BETA, CLASS IIB__:__
Percent__:__612851__:__NARCOLEPSY 5, SUSCEPTIBILITY TO; NRCLP5__:____:__
Number Sign__:__612852__:__OSTEOMYELITIS, STERILE MULTIFOCAL, WITH PERIOSTITIS AND PUSTULOSIS; OMPP__:__INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY; DIRA__:__
Percent__:__612853__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7; RLS7__:____:__
Asterisk__:__612854__:__SEC16, S. CEREVISIAE, HOMOLOG OF, A; SEC16A__:__SEC16L;; p250;; KIAA0310__:__
Asterisk__:__612855__:__SEC16, S. CEREVISIAE, HOMOLOG OF, B; SEC16B__:__LEUCINE ZIPPER TRANSCRIPTION REGULATOR 2; LZTR2;; REGUCALCIN GENE PROMOTER REGION-RELATED PROTEIN; RGPR;; SEC16S__:__
Asterisk__:__612856__:__ASTROTACTIN 2; ASTN2__:__KIAA0634__:__
Asterisk__:__612857__:__PLACENTA-SPECIFIC GENE 9; PLAC9__:____:__
Percent__:__612858__:__OROFACIAL CLEFT 12; OFC12__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 12__:__
Asterisk__:__612859__:__T-CELL IMMUNORECEPTOR WITH IMMUNOGLOBULIN AND ITIM DOMAINS; TIGIT__:____:__
Asterisk__:__612860__:__QUIESCIN Q6 SULFHYDRYL OXIDASE 2; QSOX2__:__SULFHYDRYL OXIDASE, NEUROBLASTOMA-DERIVED; SOXN__:__
Asterisk__:__612861__:__NOP16, S. CEREVISIAE, HOMOLOG OF; NOP16__:__HSPC111;; HBV PRE-S2 TRANSREGULATED PROTEIN 3__:__
Percent__:__612862__:__PULMONARY HYPERTENSION, CHRONIC THROMBOEMBOLIC, WITHOUT DEEP VEIN THROMBOSIS, SUSCEPTIBILITY TO__:__CTEPH, DVT-NEGATIVE, SUSCEPTIBILITY TO__:__
Number Sign__:__612863__:__CHROMOSOME 6q24-q25 DELETION SYNDROME__:____:__
Asterisk__:__612864__:__PHOSPHOLIPASE A2, GROUP IVD; PLA2G4D__:__PHOSPHOLIPASE A2 DELTA, CYTOSOLIC;; CPLA2-DELTA__:__
Asterisk__:__612865__:__PHOSPHATIDYLINOSITOL 4-PHOSPHATE-5-KINASE-LIKE 1; PIP5KL1__:__PHOSPHATIDYLINOSITOL PHOSPHATE KINASE HOMOLOG; PIPKH__:__
Asterisk__:__612866__:__ALG14, S. CEREVISIAE, HOMOLOG OF; ALG14__:__ASPARAGINE-LINKED GLYCOSYLATION 14, S. CEREVISIAE, HOMOLOG OF__:__
NULL__:__612867__:__CORNEAL DYSTROPHY, SUBEPITHELIAL MUCINOUS; SMCD__:__SUBEPITHELIAL MUCINOUS CORNEAL DYSTROPHY__:__
Number Sign__:__612868__:__CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD__:__CHROMOSOME 12q21.33 DELETION SYNDROME;; POSTERIOR AMORPHOUS CORNEAL DYSTROPHY__:__
Asterisk__:__612869__:__ATTRACTIN-LIKE 1; ATRNL1__:__KIAA0534;; ALP__:__
Asterisk__:__612870__:__PLECKSTRIN HOMOLOGY DOMAIN-INTERACTING PROTEIN; PHIP__:__DDB1- AND CUL4-ASSOCIATED FACTOR 14; DCAF14__:__
Asterisk__:__612871__:__Na+/K+ TRANSPORTING ATPase-INTERACTING 1; NKAIN1__:____:__
Asterisk__:__612872__:__Na+/K+ TRANSPORTING ATPase-INTERACTING 3; NKAIN3__:____:__
Asterisk__:__612873__:__Na+/K+ TRANSPORTING ATPase-INTERACTING 4; NKAIN4__:____:__
Number Sign__:__612874__:__ERYTHROCYTE AMP DEAMINASE DEFICIENCY__:____:__
NULL__:__612875__:__GONADOTROPIN-RELEASING HORMONE RECEPTOR 2; GNRHR2__:____:__
Percent__:__612876__:__SPINOCEREBELLAR ATAXIA 9; SCA9__:____:__
Number Sign__:__612877__:__CARDIOMYOPATHY, DILATED, 1BB; CMD1BB__:____:__
Asterisk__:__612878__:__EXOPHILIN 5; EXPH5__:__SYNAPTOTAGMIN-LIKE PROTEIN LACKING C2 DOMAINS B; SLAC2B;; KIAA0624__:__
Asterisk__:__612879__:__MAM DOMAIN-CONTAINING PROTEIN 2; MAMDC2__:____:__
Asterisk__:__612880__:__SYNAPTOTAGMIN-LIKE 2; SYTL2__:__SYNAPTOTAGMIN-LIKE PROTEIN 2; SLP2;; SLP2A;; EXOPHILIN 4; EXO4;; KIAA1597__:__
Number Sign__:__612881__:__CHROMOSOME 5q14.3 DELETION SYNDROME, DISTAL__:__HETEROTOPIA, PERIVENTRICULAR, ASSOCIATED WITH CHROMOSOME 5q DELETION;; PERIVENTRICULAR NODULAR HETEROTOPIA 5; PVNH5__:__
Percent__:__612882__:__MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENAQ2__:____:__
Percent__:__612883__:__MENARCHE, AGE AT, QUANTITATIVE TRAIT LOCUS 3; MENAQ3__:____:__
Percent__:__612884__:__MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 2; MENOQ2__:____:__
Number Sign__:__612885__:__PREMATURE OVARIAN FAILURE 10; POF10__:____:__MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 3, INCLUDED; MENOQ3, INCLUDED
Percent__:__612886__:__MENOPAUSE, NATURAL, AGE AT, QUANTITATIVE TRAIT LOCUS 4; MENOQ4__:____:__
Asterisk__:__612887__:__SEPTIN 11; SEPT11__:____:__
Asterisk__:__612888__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8B; LRRC8B__:__T-CELL ACTIVATION LEUCINE REPEAT-RICH PROTEIN; TALRRP;; KIAA0231__:__
Asterisk__:__612889__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8C; LRRC8C__:__FACTOR FOR ADIPOCYTE DIFFERENTIATION 158; FAD158;; AD158__:__
Asterisk__:__612890__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8D; LRRC8D__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 5; LRRC5__:__
Asterisk__:__612891__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 8E; LRRC8E__:____:__
Percent__:__612892__:__STATURE QUANTITATIVE TRAIT LOCUS 18; STQTL18__:____:__
Percent__:__612893__:__STATURE QUANTITATIVE TRAIT LOCUS 19; STQTL19__:____:__
Percent__:__612894__:__STATURE QUANTITATIVE TRAIT LOCUS 20; STQTL20__:____:__
Asterisk__:__612895__:__NUCLEOREDOXIN; NXN__:____:__
Asterisk__:__612896__:__RAD52 MOTIF-CONTAINING PROTEIN 1; RDM1__:____:__
Asterisk__:__612897__:__SEPTIN 1; SEPT1__:__DIFF6__:__
Asterisk__:__612898__:__COENZYME Q4, S. CEREVISIAE, HOMOLOG OF; COQ4__:____:__
Number Sign__:__612899__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 8; EIG8__:____:__
Number Sign__:__612900__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 2; CPSQ2__:____:__
Asterisk__:__612901__:__TUBULIN, BETA-1; TUBB1__:__TUBULIN, BETA, CLASS VI__:__
Asterisk__:__612902__:__LIPOCALIN 8; LCN8__:____:__
Asterisk__:__612903__:__LIPOCALIN 9; LCN9__:____:__
Asterisk__:__612904__:__LIPOCALIN 10; LCN10__:____:__
Asterisk__:__612905__:__LIPOCALIN 12; LCN12__:____:__
Asterisk__:__612906__:__RAS-ASSOCIATED PROTEIN RAB32; RAB32__:____:__
Asterisk__:__612907__:__tRNA NUCLEOTIDYLTRANSFERASE, CCA-ADDING, 1; TRNT1__:__MITOCHONDRIAL CCA-ADDING tRNA NUCLEOTIDYLTRANSFERASE;; CCA-ADDING tRNA NUCLEOTIDYLTRANSFERASE, MITOCHONDRIAL__:__
Number Sign__:__612908__:__KERATOSIS PALMOPLANTARIS STRIATA II; PPKS2__:__KERATODERMA, PALMOPLANTAR, STRIATE FORM II; KPPS2;; STRIATE PALMOPLANTAR KERATODERMA II; SPPK2__:__
Asterisk__:__612909__:__RAS-ASSOCIATED PROTEIN RAB6C; RAB6C__:__WTH3__:__
Asterisk__:__612910__:__PHD FINGER PROTEIN 23; PHF23__:____:__PHF23/NUP98 FUSION GENE, INCLUDED
Asterisk__:__612911__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 3; NDUFAF3__:__NADH DEHYDROGENASE 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 3__:__
Asterisk__:__612912__:__TRANSMEMBRANE PROTEIN 97; TMEM97__:__MAC30__:__
Percent__:__612913__:__OROFACIODIGITAL SYNDROME XI; OFD11__:__OFDS XI;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE XI;; ORAL-FACIAL-DIGITAL SYNDROME WITH SKELETAL ANOMALIES;; GABRIELLI SYNDROME__:__
Asterisk__:__612914__:__MEDIATOR COMPLEX SUBUNIT 29; MED29__:__INTERSEX, DROSOPHILA, HOMOLOG OF;; INTERSEX-LIKE; IXL__:__
Asterisk__:__612915__:__MEDIATOR COMPLEX SUBUNIT 20; MED20__:__TRF-PROXIMAL, DROSOPHILA, HOMOLOG OF; TRFP__:__
NULL__:__612916__:__ZECHI-CEIDE SYNDROME__:__OCCIPITAL ATRETIC CEPHALOCELE, UNUSUAL FACIES, AND LARGE FEET__:__
NULL__:__612917__:__GIACHETI SYNDROME__:__MARFANOID HABITUS AND SPECIFIC LANGUAGE AND LEARNING DISABILITIES__:__
Number Sign__:__612918__:__CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI__:__CLOVE SYNDROME;; CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, EPIDERMAL NEVI, AND SKELETAL/SPINAL ABNORMALITIES;; CLOVES SYNDROME__:__
Asterisk__:__612919__:__LanC-LIKE 2; LANCL2__:__TESTIS-SPECIFIC ADRIAMYCIN SENSITIVITY PROTEIN; TASP__:__
Asterisk__:__612920__:__THROMBOSPONDIN-TYPE LAMININ G DOMAIN AND EAR REPEATS; TSPEAR__:__CHROMOSOME 21 OPEN READING FRAME 29; C21ORF29__:__
Number Sign__:__612921__:__THREE M SYNDROME 2; 3M2__:__3M SYNDROME 2__:__
Number Sign__:__612922__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2; AHUS2__:__AHUS, SUSCEPTIBILITY TO, 2__:__
Number Sign__:__612923__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3; AHUS3__:__AHUS, SUSCEPTIBILITY TO, 3__:__
Number Sign__:__612924__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4; AHUS4__:__AHUS, SUSCEPTIBILITY TO, 4__:__
Number Sign__:__612925__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5; AHUS5__:__AHUS, SUSCEPTIBILITY TO, 5__:__
Number Sign__:__612926__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6; AHUS6__:__AHUS, SUSCEPTIBILITY TO, 6__:__
Asterisk__:__612927__:__AVL9, S. CEREVISIAE, HOMOLOG OF; AVL9__:__KIAA0241__:__
Asterisk__:__612928__:__ISOCHORISMATASE DOMAIN-CONTAINING 2; ISOC2__:____:__
Percent__:__612929__:__MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO, 3__:__MTBS3__:__
Asterisk__:__612930__:__PHOSPHOTYROSINE INTERACTION DOMAIN-CONTAINING 1; PID1__:__NYGGF4__:__
Asterisk__:__612931__:__PHOSPHOGLYCERATE MUTASE 2; PGAM2__:__PHOSPHOGLYCERATE MUTASE, MUSCLE; PGAMM__:__
Number Sign__:__612932__:__GLYCOGEN STORAGE DISEASE XIII; GSD13__:__GSD XIII;; ENOLASE 3 DEFICIENCY;; ENOLASE-BETA DEFICIENCY__:__
Number Sign__:__612933__:__GLYCOGEN STORAGE DISEASE XI; GSD11__:__GSD XI;; LACTATE DEHYDROGENASE A DEFICIENCY__:__
Caret__:__612934__:__MOVED TO 614921__:____:__
Asterisk__:__612935__:__MYOSIN PHOSPHATASE RHO-INTERACTING PROTEIN; MPRIP__:__MRIP;; KIAA0864;; p116 RHO-INTERACTING PROTEIN; p116RIP;; RIP3__:__
Number Sign__:__612936__:__SPASTIC PARAPLEGIA 50, AUTOSOMAL RECESSIVE; SPG50__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3, FORMERLY; CPSQ3, FORMERLY__:__
Number Sign__:__612937__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DPM3-RELATED;; CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O;; CDG Io; CDGIo;; CDG1(DPM3)__:__
Number Sign__:__612938__:__GROWTH RETARDATION, DEVELOPMENTAL DELAY, AND FACIAL DYSMORPHISM; GDFD__:____:__
Asterisk__:__612939__:__HEAT-SHOCK 70-KD PROTEIN-BINDING PROTEIN 1; HSPBP1__:__HSPA-BINDING PROTEIN 1;; HSP70-BINDING PROTEIN 1__:__
Number Sign__:__612940__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB; ARCL2B__:__CUTIS LAXA WITH PROGEROID FEATURES__:__
Asterisk__:__612941__:__PRECURSOR mRNA-PROCESSING FACTOR 40, S. CEREVISIAE, HOMOLOG OF, A; PRPF40A__:__PRPF40, S. CEREVISIAE, HOMOLOG OF, A;; HUNTINGTIN-INTERACTING PROTEIN A; HYPA;; FORMIN-BINDING PROTEIN 3; FNBP3;; FBP11, MOUSE, HOMOLOG OF; FBP11__:__
Asterisk__:__612942__:__RAS-ASSOCIATED PROTEIN RAB25; RAB25__:__RAB11C__:__
Number Sign__:__612943__:__RETINITIS PIGMENTOSA 42; RP42__:____:__
Asterisk__:__612944__:__RIBONUCLEASE T2; RNASET2__:__RNASE6PL__:__
Asterisk__:__612945__:__RAS-ASSOCIATED PROTEIN RAB4B; RAB4B__:____:__
Percent__:__612946__:__HADZISELIMOVIC SYNDROME__:__MICROCEPHALY-FACIOCARDIOSKELETAL SYNDROME__:__
NULL__:__612947__:__MICROCEPHALY, GROWTH RETARDATION, CATARACT, HEARING LOSS, AND UNUSUAL APPEARANCE__:____:__
NULL__:__612948__:__STARGARDT MACULAR DEGENERATION, ABSENT OR HYPOPLASTIC CORPUS CALLOSUM, MENTAL RETARDATION, AND DYSMORPHIC FEATURES__:____:__
Number Sign__:__612949__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39; EIEE39__:__HYPOMYELINATION, GLOBAL CEREBRAL;; ASPARTATE-GLUTAMATE CARRIER 1 DEFICIENCY;; AGC1 DEFICIENCY__:__
Percent__:__612950__:__PSORIASIS 12, SUSCEPTIBILITY TO; PSORS12__:____:__
Number Sign__:__612951__:__LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY__:____:__
Number Sign__:__612952__:__AICARDI-GOUTIERES SYNDROME 5; AGS5__:____:__
Number Sign__:__612953__:__PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14__:__DYSTONIA-PARKINSONISM, ADULT-ONSET__:__
Number Sign__:__612954__:__MYOPATHY, MYOFIBRILLAR, 6; MFM6__:____:__
Number Sign__:__612955__:__LONG QT SYNDROME 12; LQT12__:____:__
Number Sign__:__612956__:__VENTRICULAR FIBRILLATION, PAROXYSMAL FAMILIAL, 2; VF2__:____:__
Percent__:__612957__:__VITAMIN B6 PLASMA LEVEL QUANTITATIVE TRAIT LOCUS 1; B6QTL1__:____:__
Asterisk__:__612958__:__TRANSLATIONAL ACTIVATOR OF MITOCHONDRIALLY ENCODED CYTOCHROME c OXIDASE SUBUNIT I; TACO1__:__TRANSLATIONAL ACTIVATOR OF COX I;; TRANSLATIONAL ACTIVATOR OF MTCO1;; COILED-COIL DOMAIN-CONTAINING PROTEIN 44; CCDC44__:__
Asterisk__:__612959__:__EPITHELIAL SPLICING REGULATORY PROTEIN 1; ESRP1__:__RNA-BINDING MOTIF PROTEIN 35A; RBM35A__:__
Asterisk__:__612960__:__EPITHELIAL SPLICING REGULATORY PROTEIN 2; ESRP2__:__RNA-BINDING MOTIF PROTEIN 35B; RBM35B__:__
Number Sign__:__612961__:__MULTIPLE SYNOSTOSES SYNDROME 3; SYNS3__:____:__
Asterisk__:__612962__:__DYNACTIN 5; DCTN5__:__p25__:__
Asterisk__:__612963__:__DYNACTIN 6; DCTN6__:__WS3;; p27__:__
Number Sign__:__612964__:__PREMATURE OVARIAN FAILURE 7; POF7__:____:__ADRENAL INSUFFICIENCY, NR5A1-RELATED, INCLUDED
Number Sign__:__612965__:__46,XY SEX REVERSAL 3; SRXY3__:__46,XY SEX REVERSAL, PARTIAL OR COMPLETE, NR5A1-RELATED;; 46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, WITH OR WITHOUT ADRENAL FAILURE;; SEX REVERSAL, XY, WITH OR WITHOUT ADRENAL FAILURE;; DISORDER OF SEX DEVELOPMENT, 46,XY, NR5A1-RELATED__:__
Asterisk__:__612966__:__RAS-ASSOCIATED PROTEIN RAB22A; RAB22A__:____:__
Percent__:__612967__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 15; BMIQ15__:____:__
Number Sign__:__612968__:__CATARACT 34, MULTIPLE TYPES; CTRCT34__:__CATARACT 34, MULTIPLE TYPES, WITH OR WITHOUT MICROCORNEA;; CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 3; CATC3__:__
Asterisk__:__612969__:__TIGGER TRANSPOSABLE ELEMENT-DERIVED GENE 7; TIGD7__:__SANCHO__:__
NULL__:__612970__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 17, PSEUDOGENE; NBPF17P__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 23, PSEUDOGENE; NBPF23P; NBPF23__:__
Asterisk__:__612971__:__PDZ DOMAIN-CONTAINING 7; PDZD7__:____:__
Asterisk__:__612972__:__TIGGER TRANSPOSABLE ELEMENT-DERIVED GENE 1; TIGD1__:____:__
Asterisk__:__612973__:__TIGGER TRANSPOSABLE ELEMENT-DERIVED GENE 2; TIGD2__:____:__
Asterisk__:__612974__:__DEP DOMAIN-CONTAINING PROTEIN 6; DEPDC6__:__DEP DOMAIN-CONTAINING MTOR-INTERACTING PROTEIN; DEPTOR__:__
Number Sign__:__612975__:__SHORT SLEEPER__:__SHORT SLEEP PHENOTYPE__:__
Percent__:__612976__:__AGE-RELATED HEARING IMPAIRMENT 2; ARHI2__:__PRESBYCUSIS 2__:__
Asterisk__:__612977__:__DCN1 DOMAIN-CONTAINING PROTEIN 4; DCUN1D4__:__KIAA0276__:__
Asterisk__:__612978__:__PRECEREBELLIN 3; CBLN3__:____:__
Asterisk__:__612979__:__SYS1 GOLGI-LOCALIZED INTEGRAL MEMBRANE PROTEIN, S. CEREVISIAE, HOMOLOG OF; SYS1__:____:__
Asterisk__:__612980__:__IMP3, S. CEREVISIAE, HOMOLOG OF; IMP3__:__MITOCHONDRIAL RIBOSOMAL SUBUNIT COMPONENT; MRPS4;; BRMS2__:__
Asterisk__:__612981__:__IMP4, S. CEREVISIAE, HOMOLOG OF; IMP4__:__BXDC4__:__
Asterisk__:__612982__:__MICRO RNA 210; MIR210__:__miRNA210;; MIRN210__:__
Asterisk__:__612983__:__MICRO RNA 106B; MIR106B__:__miRNA106B;; MIRN106B__:__
Asterisk__:__612984__:__MICRO RNA 93; MIR93__:__miRNA93;; MIRN93__:__
Asterisk__:__612985__:__IROQUOIS HOMEOBOX PROTEIN 3; IRX3__:__IRXB1__:__
Asterisk__:__612986__:__EP300-INTERACTING INHIBITOR OF DIFFERENTIATION 3; EID3__:__E1A-LIKE INHIBITOR OF DIFFERENTIATION 3;; NON-SMC ELEMENT 4, S. CEREVISIAE, HOMOLOG OF, B; NSMCE4B;; NSE4B__:__
Asterisk__:__612987__:__NON-SMC ELEMENT 4, S. CEREVISIAE, HOMOLOG OF, A; NSMCE4A__:__NONSTRUCTURAL MAINTENANCE OF CHROMOSOMES ELEMENT 4 HOMOLOG A;; NSE4 HOMOLOG A, SMC5-SMC6 COMPLEX COMPONENT; NSE4A;; C10ORF86__:__
Asterisk__:__612988__:__TRANSMEMBRANE PROTEIN 126A; TMEM126A__:____:__
Number Sign__:__612989__:__OPTIC ATROPHY 7 WITH OR WITHOUT AUDITORY NEUROPATHY; OPA7__:____:__
Asterisk__:__612990__:__ADDITIONAL SEX COMBS-LIKE 1; ASXL1__:__KIAA0978__:__
Asterisk__:__612991__:__ADDITIONAL SEX COMBS-LIKE 2; ASXL2__:__KIAA1685__:__
Asterisk__:__612992__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 3; NBPF3__:____:__
Asterisk__:__612993__:__FILAMIN A-INTERACTING PROTEIN 1-LIKE; FILIP1L__:____:__
Asterisk__:__612994__:__RAS-ASSOCIATED PROTEIN 28; RAB28__:____:__
Asterisk__:__612995__:__TRANSFER RNA VALINE (CAC) 1-2; TRV-CAC1-2__:__TRANSFER RNA VALINE 2; TRNAV2;; tRNA VALINE 2; TRV2__:__
Asterisk__:__612996__:__TRANSFER RNA LYSINE (CTT) 2-4; TRK-CTT2-4__:__TRANSFER RNA LYSINE 2; TRNAK2;; tRNA LYSINE 2; TRK2__:__
Number Sign__:__612997__:__SPERMATOGENIC FAILURE 7; SPGF7__:__MALE INFERTILITY, NONSYNDROMIC, AUTOSOMAL RECESSIVE; MIAR__:__
Number Sign__:__612998__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 4, AUTOSOMAL DOMINANT; EDMD4__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES__:__
Number Sign__:__612999__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 5, AUTOSOMAL DOMINANT; EDMD5__:____:__
Number Sign__:__613000__:__PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 1; FNEPPK1__:__PPKFNE;; FOCAL NONEPIDERMOLYTIC PALMOPLANTAR KERATODERMA;; KERATODERMA, FOCAL NONEPIDERMOLYTIC PALMOPLANTAR__:__
Number Sign__:__613001__:__ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS; ECCL__:____:__
Number Sign__:__613002__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 2; IIAE2__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 2__:__
Number Sign__:__613003__:__ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7__:__ADHD7__:__
Asterisk__:__613004__:__HUNTINGTIN; HTT__:__IT15;; HD GENE__:__
NULL__:__613005__:__SANTOS SYNDROME__:__FIBULAR AGENESIS/HYPOPLASIA, OLIGODACTYLOUS CLUBFEET, AND ANONYCHIA/NAIL HYPOPLASIA SYNDROME__:__
Percent__:__613006__:__DIABETES MELLITUS, INSULIN-DEPENDENT, 24; IDDM24__:____:__
Percent__:__613007__:__BILIARY CIRRHOSIS, PRIMARY, 2; PBC2__:____:__
Percent__:__613008__:__BILIARY CIRRHOSIS, PRIMARY, 3; PBC3__:____:__
Asterisk__:__613009__:__O-PHOSPHOSERINE tRNA-SELENOCYSTEINE tRNA SYNTHASE; SEPSECS__:__SOLUBLE LIVER ANTIGEN; SLA;; LIVER PANCREAS ANTIGEN; LP__:__
Asterisk__:__613010__:__RIBOFLAVIN KINASE; RFK__:__FLAVOKINASE__:__
Number Sign__:__613011__:__LYMPHOPROLIFERATIVE SYNDROME 1; LPFS1__:____:__
Asterisk__:__613012__:__UROCANASE DOMAIN-CONTAINING PROTEIN 1; UROC1__:__UROCANASE__:__
Number Sign__:__613013__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 2; NBLST2__:____:__NEUROBLASTOMA WITH HIRSCHSPRUNG DISEASE, INCLUDED
Number Sign__:__613014__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 3; NBLST3__:____:__
Percent__:__613015__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 4; NBLST4__:____:__
Percent__:__613016__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 5; NBLST5__:____:__
Percent__:__613017__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 6; NBLST6__:____:__
Asterisk__:__613018__:__TYROSINE AMINOTRANSFERASE; TAT__:__TAT, SOLUBLE__:__
Asterisk__:__613019__:__SUCCINATE DEHYDROGENASE COMPLEX ASSEMBLY FACTOR 2; SDHAF2__:__SUCCINATE DEHYDROGENASE 5; SDH5__:__
Caret__:__613020__:__MOVED TO 116600__:____:__
Number Sign__:__613021__:__BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2__:__CYSTIC FIBROSIS-LIKE SYNDROME__:__
Asterisk__:__613022__:__OXOGLUTARATE DEHYDROGENASE; OGDH__:__ALPHA-KETOGLUTARATE DEHYDROGENASE; AKGDH;; E1K__:__
Asterisk__:__613023__:__CENTROSOMAL PROTEIN, 170-KD; CEP170__:__KIAA0470__:__
Percent__:__613024__:__FOLLICULAR LYMPHOMA, SUSCEPTIBILITY TO, 1; FL1__:____:__
Percent__:__613025__:__SCHIZOPHRENIA 13; SCZD13__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 15q13-q14-RELATED__:__
Number Sign__:__613026__:__CHROMOSOME 19q13.11 DELETION SYNDROME, DISTAL__:____:__
Number Sign__:__613027__:__GLYCOGEN STORAGE DISEASE IXc; GSD9C__:__GSD IXc__:__
Number Sign__:__613028__:__GLIOMA SUSCEPTIBILITY 2; GLM2__:____:__
Number Sign__:__613029__:__GLIOMA SUSCEPTIBILITY 3; GLM3__:____:__
Percent__:__613030__:__GLIOMA SUSCEPTIBILITY 5; GLM5__:____:__
Percent__:__613031__:__GLIOMA SUSCEPTIBILITY 6; GLM6__:____:__
Percent__:__613032__:__GLIOMA SUSCEPTIBILITY 7; GLM7__:____:__
Percent__:__613033__:__GLIOMA SUSCEPTIBILITY 8; GLM8__:____:__
Caret__:__613034__:__MOVED TO 612541__:____:__
Percent__:__613035__:__HEARING LOSS, NOISE-INDUCED, SUSCEPTIBILITY TO; NIHL__:____:__
Asterisk__:__613036__:__PEPTIDASE, MITOCHONDRIAL PROCESSING, ALPHA; PMPCA__:__MITOCHONDRIAL PROCESSING PEPTIDASE-ALPHA;; KIAA0123__:__
Asterisk__:__613037__:__INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 72-KD; INPP5E__:____:__
Number Sign__:__613038__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 1; CPHD1__:____:__
Asterisk__:__613039__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 1-LIKE; CHD1L__:__AMPLIFIED IN LIVER CANCER 1; ALC1__:__
Asterisk__:__613040__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 26; CCDC26__:__RETINOIC ACID MODULATOR; RAM__:__
Asterisk__:__613041__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A1; FAM90A1__:____:__
Asterisk__:__613042__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A3; FAM90A3__:__FAM90A COPY 2__:__
Asterisk__:__613043__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A5; FAM90A5__:__FAM90A COPY 5__:__
Asterisk__:__613044__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A7; FAM90A7__:__FAM90A COPY 8__:__
Asterisk__:__613045__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A8; FAM90A8__:__FAM90A COPY 15__:__
Asterisk__:__613046__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A9; FAM90A9__:__FAM90A COPY 18__:__
Asterisk__:__613047__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A10; FAM90A10__:__FAM90A COPY 19__:__
Asterisk__:__613048__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A12; FAM90A12__:__FAM90A COPY 22__:__
Asterisk__:__613049__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A13; FAM90A13__:__FAM90A COPY 4__:__
Asterisk__:__613050__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A14; FAM90A14__:__FAM90A COPY 12__:__
Asterisk__:__613051__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A15; FAM90A15__:__FAM90A COPY 1__:__
Asterisk__:__613052__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A18; FAM90A18__:__FAM90A COPY 13__:__
Asterisk__:__613053__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A19; FAM90A19__:__FAM90A COPY 17__:__
Asterisk__:__613054__:__FAMILY WITH SEQUENCE SIMILARITY 90, MEMBER A20; FAM90A20__:__FAM90A COPY 6__:__
Percent__:__613055__:__ATRIAL FIBRILLATION, FAMILIAL, 8; ATFB8__:____:__
Asterisk__:__613056__:__LUC7, S. CEREVISIAE, HOMOLOG OF, 2; LUC7L2__:__LUC7-LIKE 2__:__
Asterisk__:__613057__:__MICRO RNA 26A2; MIR26A2__:__miRNA26A2;; MIRN26A2__:__
Percent__:__613058__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 2; BCC2__:____:__
Percent__:__613059__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 3; BCC3__:____:__
Number Sign__:__613060__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 10; EIG10__:____:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5, SUSCEPTIBILITY TO, INCLUDED; GEFS5, INCLUDED;; GEFS+, TYPE 5, SUSCEPTIBILITY TO, INCLUDED;; GEFS+5, SUSCEPTIBILITY TO, INCLUDED;; GEFSP5, SUSCEPTIBILITY TO, INCLUDED;; EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 7, INCLUDED; EJM7, INCLUDED
Percent__:__613061__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 4; BCC4__:____:__
Percent__:__613062__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 5; BCC5__:____:__
Percent__:__613063__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 6; BCC6__:____:__
Percent__:__613064__:__DERMATITIS, ATOPIC, 7; ATOD7__:____:__
Percent__:__613065__:__LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL__:____:__LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 1, INCLUDED;; ALL1, INCLUDED;; LEUKEMIA, ACUTE LYMPHOCYTIC, SUSCEPTIBILITY TO, 1, INCLUDED;; LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, INCLUDED;; LEUKEMIA, T-CELL ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, INCLUDED;; LEUKEMIA, ACUTE LYMPHOBLASTIC, B-HYPERDIPLOID, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__613066__:__PBX/KNOTTED 1 HOMEOBOX 2; PKNOX2__:__PBX-REGULATING PROTEIN 2; PREP2__:__
Percent__:__613067__:__LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 2; ALL2__:__LEUKEMIA, ACUTE LYMPHOCYTIC, SUSCEPTIBILITY TO, 2__:__
Number Sign__:__613068__:__NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY__:____:__
Asterisk__:__613069__:__PHD FINGER PROTEIN 10; PHF10__:__BRG1-ASSOCIATED FACTOR, 45-KD, A; BAF45A__:__
Number Sign__:__613070__:__LIVER FAILURE, INFANTILE, TRANSIENT; LFIT__:____:__
Number Sign__:__613071__:__BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 3; BESC3__:__CYSTIC FIBROSIS-LIKE SYNDROME__:__
Asterisk__:__613072__:__LIPOXYGENASE HOMOLOGY DOMAIN-CONTAINING 1; LOXHD1__:____:__
Number Sign__:__613073__:__METAPHYSEAL ANADYSPLASIA 2; MANDP2__:____:__
Number Sign__:__613074__:__DEAFNESS, AUTOSOMAL DOMINANT 50; DFNA50__:____:__
Number Sign__:__613075__:__MACS SYNDROME__:__MACROCEPHALY, ALOPECIA, CUTIS LAXA, AND SCOLIOSIS;; TALL FOREHEAD, SPARSE HAIR, SKIN HYPEREXTENSIBILITY, AND SCOLIOSIS__:__
Number Sign__:__613076__:__MYOPATHY, MITOCHONDRIAL PROGRESSIVE, WITH CONGENITAL CATARACT, HEARING LOSS, AND DEVELOPMENTAL DELAY__:__MYOPATHY WITH CATARACT AND COMBINED RESPIRATORY CHAIN DEFICIENCY;; MITOCHONDRIAL COMPLEX DEFICIENCY, COMBINED__:__
Number Sign__:__613077__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5__:__
Number Sign__:__613078__:__NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD__:__NBS-LIKE DISORDER;; RAD50 DEFICIENCY;; MICROCEPHALY AND SPONTANEOUS CHROMOSOME INSTABILITY WITHOUT IMMUNODEFICIENCY__:__
Number Sign__:__613079__:__DEAFNESS, AUTOSOMAL RECESSIVE 77; DFNB77__:____:__
Number Sign__:__613080__:__46,XY SEX REVERSAL 5; SRXY5__:__46,XY SEX REVERSAL, CBX2-RELATED;; 46,XY GONADAL DYSGENESIS, COMPLETE, CBX2-RELATED;; SEX REVERSAL, XY, CBX2-RELATED;; DISORDER OF SEX DEVELOPMENT, 46,XY, CBX2-RELATED__:__
Asterisk__:__613081__:__LYSINE-SPECIFIC DEMETHYLASE 1B; KDM1B__:__LYSINE-SPECIFIC DEMETHYLASE 2; LSD2;; AMINE OXIDASE, FLAVIN-CONTAINING, 1; AOF1__:__
Asterisk__:__613082__:__ATPase, Ca(2+)-TRANSPORTING, TYPE 2C, MEMBER 2; ATP2C2__:__SECRETORY PATHWAY Ca(2+) ATPase 2; SPCA2;; KIAA0703__:__
Asterisk__:__613083__:__LISTERIN E3 UBIQUITIN PROTEIN LIGASE 1; LTN1__:__LISTERIN, MOUSE, HOMOLOG OF;; RING FINGER PROTEIN 160; RNF160;; KIAA0714__:__
Asterisk__:__613084__:__MYELIN TRANSCRIPTION FACTOR 1-LIKE; MYT1L__:__KIAA1106__:__
Percent__:__613085__:__GLAUCOMA 3, PRIMARY CONGENITAL, C; GLC3C__:____:__
Number Sign__:__613086__:__GLAUCOMA 3, PRIMARY CONGENITAL, D; GLC3D__:____:__
Number Sign__:__613087__:__ATRIAL SEPTAL DEFECT 6; ASD6__:____:__
Percent__:__613088__:__PELVIC ORGAN PROLAPSE, SUSCEPTIBILITY TO, 2__:__PVOP2__:__
Number Sign__:__613089__:__CAPILLARY MALFORMATION OF THE LOWER LIP, LYMPHATIC MALFORMATION OF FACE AND NECK, ASYMMETRY OF FACE AND LIMBS, AND PARTIAL/GENERALIZED OVERGROWTH__:__CLAPO;; LOPEZ-GUTIERREZ SYNDROME__:__
Number Sign__:__613090__:__BARTTER SYNDROME, TYPE 4B, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4B__:____:__
Number Sign__:__613091__:__SHORT-RIB THORACIC DYSPLASIA 3 WITH OR WITHOUT POLYDACTYLY; SRTD3__:__ASPHYXIATING THORACIC DYSTROPHY 3; ATD3;; SHORT RIB-POLYDACTYLY SYNDROME, TYPE I; SRPS1;; SALDINO-NOONAN SYNDROME;; POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE I;; SHORT RIB-POLYDACTYLY SYNDROME, TYPE III; SRPS3;; VERMA-NAUMOFF SYNDROME;; POLYDACTYLY WITH NEONATAL CHONDRODYSTROPHY, TYPE III;; SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIB; SRPS2B__:__
Number Sign__:__613092__:__HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 2; HNFJ2__:__EARLY-ONSET HYPERURICEMIA, ANEMIA, AND PROGRESSIVE KIDNEY FAILURE__:__
Number Sign__:__613093__:__CONE DYSTROPHY 4; COD4__:____:__ACHROMATOPSIA 5, INCLUDED; ACHM5, INCLUDED
Number Sign__:__613094__:__MICROPHTHALMIA, ISOLATED 4; MCOP4__:____:__
Number Sign__:__613095__:__POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD2__:__POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II; APKD2__:__
Percent__:__613096__:__SPASTIC PARAPLEGIA 36, AUTOSOMAL DOMINANT; SPG36__:____:__
Caret__:__613097__:__MOVED TO 601216__:____:__
Number Sign__:__613098__:__INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFIC__:____:__
Number Sign__:__613099__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 5; CMM5__:____:__
Number Sign__:__613100__:__GLAUCOMA 1, OPEN ANGLE, O; GLC1O__:____:__
Number Sign__:__613101__:__HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 5; FHL5__:____:__
Number Sign__:__613102__:__HYPOTRICHOSIS AND RECURRENT SKIN VESICLES__:____:__
Asterisk__:__613103__:__SERINE/ARGININE REPETITIVE MATRIX PROTEIN 4; SRRM4__:__NEURAL-SPECIFIC SR-RELATED PROTEIN, 100-KD; NSR100;; KIAA1853__:__
Asterisk__:__613104__:__CALCIUM CHANNEL FLOWER-DOMAIN CONTAINING PROTEIN 1; CACFD1__:__FLOWER, DROSOPHILA, HOMOLOG OF; FLOWER;; CHROMOSOME 9 OPEN READING FRAME 7; C9ORF7__:__
Number Sign__:__613105__:__CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2__:__MACULAR DYSTROPHY, PROGRESSIVE__:__
Percent__:__613106__:__VERTIGO, BENIGN RECURRENT, 2; BRV2__:____:__
Number Sign__:__613107__:__NEUTROPENIA, SEVERE CONGENITAL, 2, AUTOSOMAL DOMINANT; SCN2__:____:__
Number Sign__:__613108__:__CANDIDIASIS, FAMILIAL, 4; CANDF4__:__CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS__:__
Asterisk__:__613109__:__GM2 ACTIVATOR; GM2A__:____:__
Asterisk__:__613110__:__BLADDER CANCER-ASSOCIATED PROTEIN; BLCAP__:__BLADDER CANCER-ASSOCIATED, 10-KD; BC10__:__
Asterisk__:__613111__:__CATHEPSIN A; CTSA__:__CATHA;; BETA-GALACTOSIDASE PROTECTIVE PROTEIN; PPGB;; PROTECTIVE PROTEIN/CATHEPSIN A; PPCA;; CARBOXYPEPTIDASE L;; BETA-GALACTOSIDASE 2; GLB2__:__
Number Sign__:__613112__:__MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, TUBB1-RELATED__:____:__
Asterisk__:__613113__:__NEUROFIBROMIN 1; NF1__:__NEUROFIBROMIN__:__
Asterisk__:__613114__:__FAMILY WITH SEQUENCE SIMILARITY 134, MEMBER B; FAM134B__:__JK1__:__
Number Sign__:__613115__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IIB; HSAN2B__:____:__
Number Sign__:__613116__:__THROMBOPHILIA DUE TO HISTIDINE-RICH GLYCOPROTEIN DEFICIENCY; THPH11__:____:__THROMBOPHILIA DUE TO ELEVATED HISTIDINE-RICH GLYCOPROTEIN, INCLUDED
Asterisk__:__613117__:__SMALL NUCLEOLAR RNA, C/D BOX, 50A; SNORD50A__:__RNA, U50 SMALL NUCLEOLAR; RNU50;; snoRNA, U50__:__
Number Sign__:__613118__:__ANTITHROMBIN III DEFICIENCY; AT3D__:__THROMBOPHILIA DUE TO ANTITHROMBIN III DEFICIENCY; THPH7__:__
Number Sign__:__613119__:__BRUGADA SYNDROME 6; BRGDA6__:____:__
Number Sign__:__613120__:__BRUGADA SYNDROME 7; BRGDA7__:____:__ATRIAL FIBRILLATION, FAMILIAL, 16, INCLUDED; ATFB16, INCLUDED
Asterisk__:__613121__:__NEXILIN F-ACTIN-BINDING PROTEIN; NEXN__:__NEXILIN, RAT, HOMOLOG OF;; NEXILIN-LIKE PROTEIN; NELIN__:__
Number Sign__:__613122__:__CARDIOMYOPATHY, DILATED, 1CC; CMD1CC__:____:__
Number Sign__:__613123__:__BRUGADA SYNDROME 8; BRGDA8__:____:__
NULL__:__613124__:__HYDROPS FETALIS, NONIMMUNE, WITH GRACILE BONES AND DYSMORPHIC FEATURES__:____:__
Asterisk__:__613125__:__NUCLEAR RECEPTOR-INTERACTING PROTEIN 3; NRIP3__:____:__
Asterisk__:__613126__:__PROLINE/SERINE-RICH COILED-COIL PROTEIN 1; PSRC1__:__DDA3, MOUSE, HOMOLOG OF; DDA3__:__
Asterisk__:__613127__:__CHORDIN-LIKE 2; CHRDL2__:__CHL2;; BREAST TUMOR NOVEL FACTOR 1; BNF1__:__
Asterisk__:__613128__:__STN1, CST COMPLEX SUBUNIT; STN1__:__STN1, S. POMBE, HOMOLOG OF; STN1 ALPHA ACCESSORY FACTOR, 44-KD SUBUNIT; AAF44;; OLIGONUCLEOTIDE/OLIGOSACCHARIDE-BINDING FOLD-CONTAINING PROTEIN 1; OBFC1__:__
Asterisk__:__613129__:__CONSERVED TELOMERE MAINTENANCE COMPONENT 1; CTC1__:__ALPHA ACCESSORY FACTOR, 132-KD SUBUNIT; AAF132;; CHROMOSOME 17 OPEN READING FRAME 68; C17ORF68__:__
Asterisk__:__613130__:__TEN1, CST COMPLEX SUBUNIT; TEN1__:__TEN1, S. POMBE, HOMOLOG OF;; CHROMOSOME 17 OPEN READING FRAME 106; C17ORF106__:__
Asterisk__:__613131__:__MICRO RNA 449A; MIR449A__:__miRNA449A;; MIRN449A__:__
Asterisk__:__613132__:__MICRO RNA 449B; MIR449B__:__miRNA449B;; MIRN449B__:__
Asterisk__:__613133__:__TETRASPANIN 2; TSPAN2__:__NEW EST TETRASPAN 3; NET3__:__
Asterisk__:__613134__:__TETRASPANIN 3; TSPAN3__:____:__
Number Sign__:__613135__:__PARKINSONISM-DYSTONIA, INFANTILE, 1; PKDYS1__:__PKDYS;; DOPAMINE TRANSPORTER DEFICIENCY SYNDROME; DTDS__:__
Asterisk__:__613136__:__TETRASPANIN 5; TSPAN5__:__NEW EST TETRASPAN 4; NET4__:__
Asterisk__:__613137__:__TETRASPANIN 9; TSPAN9__:__NEW EST TETRASPAN 5; NET5__:__
Asterisk__:__613138__:__TETRASPANIN 12; TSPAN12__:__NEW EST TETRASPAN 2; NET2__:__
Asterisk__:__613139__:__TETRASPANIN 13; TSPAN13__:__NEW EST TETRASPAN 6; NET6__:__
Asterisk__:__613140__:__TETRASPANIN 15; TSPAN15__:__NEW EST TETRASPAN 7; NET7__:__
Asterisk__:__613141__:__DELTEX, DROSOPHILA, HOMOLOG OF, 2; DTX2__:__KIAA1528__:__
Asterisk__:__613142__:__DELTEX, DROSOPHILA, HOMOLOG OF, 3; DTX3__:____:__
Asterisk__:__613143__:__DTX3-LIKE; DTX3L__:__B LYMPHOMA- AND BAL-ASSOCIATED PROTEIN; BBAP__:__
Percent__:__613144__:__CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, 3; CACD3__:__CHOROIDAL DYSTROPHY, CENTRAL AREOLAR, WITH OR WITHOUT DRUSEN__:__
Percent__:__613145__:__SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 14; SLEB14__:____:__
Asterisk__:__613146__:__MICRO RNA 184; MIR184__:__miRNA184;; MIRN184__:__MICRO RNA 184*, INCLUDED; MIR184*, INCLUDED
Asterisk__:__613147__:__MICRO RNA 205; MIR205__:__miRNA205;; MIRN205__:__
Number Sign__:__613148__:__INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28__:__INFLAMMATORY BOWEL DISEASE, EARLY-ONSET, AUTOSOMAL RECESSIVE__:__
Asterisk__:__613149__:__CDKN2B ANTISENSE RNA; CDKN2BAS__:__ANTISENSE NONCODING RNA IN THE INK4 LOCUS; ANRIL__:__
Number Sign__:__613150__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED__:__
Number Sign__:__613151__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 3; MDDGB3__:__MUSCULAR DYSTROPHY, CONGENITAL, POMGNT1-RELATED__:__
Number Sign__:__613152__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITHOUT MENTAL RETARDATION), TYPE B, 4; MDDGB4__:__MUSCULAR DYSTROPHY, CONGENITAL, FKTN-RELATED__:__
Number Sign__:__613153__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED__:__
Number Sign__:__613154__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, LARGE-RELATED__:__
Number Sign__:__613155__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 1; MDDGB1__:__MUSCULAR DYSTROPHY, CONGENITAL, POMT1-RELATED__:__
Number Sign__:__613156__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 2; MDDGB2__:__MUSCULAR DYSTROPHY, CONGENITAL, POMT2-RELATED__:__
Number Sign__:__613157__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 15; LGMDR15;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2O; LGMD2O;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMGNT1-RELATED__:__
Number Sign__:__613158__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 2; MDDGC2__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 14; LGMDR14;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2N; LGMD2N;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMT2-RELATED__:__
Number Sign__:__613159__:__NEPHRONOPHTHISIS-LIKE NEPHROPATHY 1; NPHPL1__:____:__
Asterisk__:__613160__:__VON WILLEBRAND FACTOR; VWF__:__FACTOR VIII-VON WILLEBRAND FACTOR; F8VWF__:__
Number Sign__:__613161__:__BETA-UREIDOPROPIONASE DEFICIENCY; UPB1D__:____:__
Number Sign__:__613162__:__SPASTIC PARAPLEGIA 45, AUTOSOMAL RECESSIVE; SPG45__:____:__
Number Sign__:__613163__:__GABA-TRANSAMINASE DEFICIENCY__:____:__
Percent__:__613164__:__PARKINSON DISEASE 16; PARK16__:____:__
Asterisk__:__613165__:__CALCIUM-ACTIVATED NUCLEOTIDASE 1; CANT1__:__SOLUBLE CALCIUM-ACTIVATED NUCLEOTIDASE 1; SCAN1__:__
Asterisk__:__613166__:__DOUBLECORTIN-LIKE KINASE 2; DCLK2__:__DCK2;; CAMK-LIKE CREB REGULATORY KINASE 2; CLICK2; CL2__:__
Asterisk__:__613167__:__DOUBLECORTIN-LIKE KINASE 3; DCLK3__:__DCK3;; CLICK-RELATED PROTEIN; CLR__:__
Asterisk__:__613168__:__SERPIN PEPTIDASE INHIBITOR, CLADE F, MEMBER 2; SERPINF2__:__ALPHA-2-PLASMIN INHIBITOR; PLI;; ALPHA-2-ANTIPLASMIN; AAP__:__
Asterisk__:__613169__:__KELCH DOMAIN-CONTAINING PROTEIN 8B; KLHDC8B__:____:__
Asterisk__:__613170__:__TETRASPANIN 1; TSPAN1__:__NEW EST TETRASPAN 1; NET1__:__
Asterisk__:__613171__:__RNA-BINDING MOTIF PROTEIN 20; RBM20__:____:__
Number Sign__:__613172__:__CARDIOMYOPATHY, DILATED, 1DD; CMD1DD__:____:__
Asterisk__:__613173__:__NEURONAL GROWTH REGULATOR 1; NEGR1__:__KINDRED OF IgLON: KILON__:__
Number Sign__:__613174__:__CHROMOSOME 5p13 DUPLICATION SYNDROME__:____:__
Asterisk__:__613175__:__SMG8 NONSENSE MEDIATED mRNA DECAY FACTOR; SMG8__:__CHROMOSOME 17 OPEN READING FRAME 71; C17ORF71__:__
Asterisk__:__613176__:__SMG9 NONSENSE-MEDIATED mRNA DECAY FACTOR; SMG9__:__CHROMOSOME 19 OPEN READING FRAME 61; C19ORF61__:__
Number Sign__:__613177__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IC; ARCL1C__:__CUTIS LAXA WITH SEVERE PULMONARY, GASTROINTESTINAL, AND URINARY ABNORMALITIES;; URBAN-RIFKIN-DAVIS SYNDROME; URDS__:__
Asterisk__:__613178__:__KIAA0427 GENE; KIAA0427__:__CBP80/CBP20-DEPENDENT TRANSLATION INITIATION FACTOR; CTIF__:__
Number Sign__:__613179__:__PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY__:__NUCLEOSIDE PHOSPHORYLASE DEFICIENCY__:__
Number Sign__:__613180__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 8; CDCBM8__:__POLYMICROGYRIA WITH OPTIC NERVE HYPOPLASIA__:__
Asterisk__:__613181__:__BolA, E. COLI, HOMOLOG OF, 1; BOLA1__:____:__
Asterisk__:__613182__:__BolA, E. COLI, HOMOLOG OF, 2; BOLA2__:____:__
Asterisk__:__613183__:__BolA, E. COLI, HOMOLOG OF, 3; BOLA3__:____:__
Asterisk__:__613184__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 68; TRIM68__:__SS56;; GC109__:__
Asterisk__:__613185__:__MICRO RNA 95; MIR95__:__miRNA95;; MIRN95__:__
Asterisk__:__613186__:__MICRO RNA 100; MIR100__:__miRNA100;; MIRN100__:__
Asterisk__:__613187__:__MICRO RNA 103-1; MIR103-1__:__miRNA103-1;; MIRN103-1__:__
Asterisk__:__613188__:__MICRO RNA 103-2; MIR103-2__:__miRNA103-2;; MIRN103-2__:__
Asterisk__:__613189__:__MICRO RNA 107; MIR107__:__miRNA107;; MIRN107__:__
Asterisk__:__613190__:__DYNEIN, AXONEMAL, ASSEMBLY FACTOR 1; DNAAF1__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 50; LRRC50;; ODA7, CHLAMYDOMONAS, HOMOLOG OF; ODA7__:__
Asterisk__:__613191__:__DUAL-SPECIFICITY PHOSPHATASE 13; DUSP13__:____:__TESTIS- AND SKELETAL MUSCLE-SPECIFIC DUAL-SPECIFICITY PHOSPHATASE, INCLUDED; TMDP, INCLUDED;; MUSCLE-RESTRICTED DUAL-SPECIFICITY PHOSPHATASE, INCLUDED; MDSP, INCLUDED
Number Sign__:__613192__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 13; MRT13__:____:__
Number Sign__:__613193__:__CILIARY DYSKINESIA, PRIMARY, 13; CILD13__:__CILIARY DYSKINESIA, PRIMARY, 13, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__613194__:__RETINITIS PIGMENTOSA 50; RP50__:____:__RETINITIS PIGMENTOSA, CONCENTRIC, INCLUDED
Number Sign__:__613195__:__WEILL-MARCHESANI SYNDROME 4; WMS4__:__WEILL-MARCHESANI-LIKE SYNDROME; WMSL__:__
Asterisk__:__613196__:__EWING TUMOR-ASSOCIATED ANTIGEN 1; ETAA1__:__ETAA16__:__
Asterisk__:__613197__:__TRAF-TYPE ZINC FINGER DOMAIN-CONTAINING 1; TRAFD1__:__FLN29__:__
Asterisk__:__613198__:__SUPPRESSOR OF VARIEGATION 4-20, DROSOPHILA, HOMOLOG OF, 2; SUV420H2__:____:__
Asterisk__:__613199__:__TAO KINASE 2; TAOK2__:__TAO2;; KIAA0881;; PROSTATE-DERIVED STE20-LIKE KINASE; PSK;; PSK1;; PSK1-ALPHA;; PSK1-BETA__:__
Asterisk__:__613200__:__PDS5, REGULATOR OF COHESION MAINTENANCE, S. CEREVISIAE, HOMOLOG OF, A; PDS5A__:__KIAA0648;; SCC112__:__
Asterisk__:__613201__:__CHROMOSOME TRANSMISSION FIDELITY FACTOR 18, S. CEREVISIAE, HOMOLOG OF; CHTF18__:__CHL12, YEAST, HOMOLOG OF; CHL12;; CTF18__:__
Asterisk__:__613202__:__CHROMOSOME TRANSMISSION FIDELITY FACTOR 8, S. CEREVISIAE, HOMOLOG OF; CHTF8__:__CTF8__:__
Asterisk__:__613203__:__DEFECTIVE IN SISTER CHROMATID COHESION 1, S. CEREVISIAE, HOMOLOG OF; DSCC1__:__DCC1__:__
Number Sign__:__613204__:__MUSCULAR DYSTROPHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY__:__MYOPATHY, CONGENITAL, DUE TO INTEGRIN ALPHA-7 DEFICIENCY__:__
Number Sign__:__613205__:__MUSCULAR DYSTROPHY, CONGENITAL, LMNA-RELATED__:__MDCL__:__
Number Sign__:__613206__:__SPASTIC PARAPLEGIA 44, AUTOSOMAL RECESSIVE; SPG44__:____:__
Percent__:__613207__:__ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 8; ASRT8__:____:__RHINOCONJUNCTIVITIS, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__613208__:__XPC GENE; XPC__:__XPCC GENE;; RAD4, YEAST, HOMOLOG OF; RAD4__:__
Asterisk__:__613209__:__TRANSMEMBRANE PROTEIN 181; TMEM181__:__G PROTEIN-COUPLED RECEPTOR 178; GPR178;; KIAA1423__:__
Asterisk__:__613210__:__WD REPEAT-CONTAINING PROTEIN 85; WDR85__:____:__
Number Sign__:__613211__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA3; AI2A3__:____:__
Asterisk__:__613212__:__ALANYL-tRNA SYNTHETASE DOMAIN-CONTAINING 1; AARSD1__:____:__
Asterisk__:__613213__:__CYTOCHROME b5 REDUCTASE 3; CYB5R3__:__B5R;; NADH-DIAPHORASE 1; DIA1__:__
Asterisk__:__613214__:__WD REPEAT-CONTAINING PROTEIN 72; WDR72__:____:__
Number Sign__:__613215__:__CHROMOSOME 17p13.3, CENTROMERIC, DUPLICATION SYNDROME__:____:__
Number Sign__:__613216__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C__:__CSNB, COMPLETE, AUTOSOMAL RECESSIVE__:__
Number Sign__:__613217__:__DIARRHEA 5, WITH TUFTING ENTEROPATHY, CONGENITAL; DIAR5__:__ENTEROPATHY, CONGENITAL TUFTING; CTE;; INTESTINAL EPITHELIAL CELL DYSPLASIA__:__
Asterisk__:__613218__:__CYTOCHROME b5, TYPE A (MICROSOMAL); CYB5A__:__CYTOCHROME b5; CYB5;; MICROSOMAL CYTOCHROME b5; MCB5__:__
Percent__:__613219__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2; FGQTL2__:____:__BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 1, INCLUDED; BWQTL1, INCLUDED
Asterisk__:__613220__:__TRANSMEMBRANE PROTEIN 18; TMEM18__:____:__
Asterisk__:__613221__:__MITOCHONDRIAL CARRIER HOMOLOG 2; MTCH2__:__MET-INDUCED MITOCHONDRIAL PROTEIN; MIMP__:__
Asterisk__:__613222__:__GLUCOSAMINE-6-PHOSPHATE DEAMINASE 2; GNPDA2__:__GNP2__:__
Number Sign__:__613223__:__LEPROSY, SUSCEPTIBILITY TO, 5; LPRS5__:____:__LEPROSY, PROTECTION AGAINST, INCLUDED
Number Sign__:__613224__:__NOONAN SYNDROME 6; NS6__:____:__
Number Sign__:__613225__:__FACTOR XIII, A SUBUNIT, DEFICIENCY OF__:____:__
Asterisk__:__613226__:__ZINC FINGER PROTEIN 296; ZNF296__:__ZFP296;; ZNF342__:__
Number Sign__:__613227__:__CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 3; CAMRQ3__:__CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDAL LOCOMOTION 3__:__
Asterisk__:__613228__:__ASPARTYLGLUCOSAMINIDASE; AGA__:__GLYCOSYLASPARAGINASE__:__
Number Sign__:__613229__:__TRICHOTILLOMANIA; TTM__:____:__
Asterisk__:__613230__:__PEPTIDASE D; PEPD__:__PROLIDASE;; IMIDODIPEPTIDASE__:__
Asterisk__:__613231__:__KINESIN FAMILY MEMBER 26A; KIF26A__:__KIAA1236__:__
Asterisk__:__613232__:__RNA-BINDING MOTIF PROTEIN 42; RBM42__:____:__
Percent__:__613233__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 3; FGQTL3__:____:__
Asterisk__:__613234__:__NEUTRAL CHOLESTEROL ESTER HYDROLASE 1; NCEH1__:__NCEH;; KIAA1363__:__
Number Sign__:__613235__:__FACTOR XIII, B SUBUNIT, DEFICIENCY OF__:____:__
Asterisk__:__613236__:__POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 18; KCNJ18__:__KIR2.6__:__
Number Sign__:__613237__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 5; FSGS5__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 5__:__
Percent__:__613238__:__SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 3; SPDA3__:____:__
Number Sign__:__613239__:__THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 2; TTPP2__:____:__
Asterisk__:__613240__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 1C; PPP1R1C__:__PROTEIN PHOSPHATASE 1 INHIBITOR 5; IPP5__:__
NULL__:__613241__:__PSEUDOPILI ANNULATI__:____:__
Asterisk__:__613242__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 14C; PPP1R14C__:__KINASE-ENHANCED PROTEIN PHOSPHATASE 1 INHIBITOR; KEPI__:__
Number Sign__:__613243__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 13; CMH13__:____:__
Number Sign__:__613244__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 8; HNPCC8__:____:__
Asterisk__:__613245__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 12C; PPP1R12C__:__MYOSIN-BINDING SUBUNIT, 85-KD; MBS85__:__
Asterisk__:__613246__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 1A; PPP1R1A__:__PROTEIN PHOSPHATASE 1 INHIBITOR 1; IPP1;; INHIBITOR 1; I1__:__
Asterisk__:__613247__:__PERILIPIN 4; PLIN4__:__S3-12;; KIAA1881__:__
Asterisk__:__613248__:__PERILIPIN 5; PLIN5__:__LIPID STORAGE DROPLET PROTEIN 5; LSDP5__:__
Asterisk__:__613249__:__ENDOGENOUS BORNA-LIKE N ELEMENT-CONTAINING PROTEIN 1; EBLN1__:____:__
Asterisk__:__613250__:__ENDOGENOUS BORNA-LIKE N ELEMENT-CONTAINING PROTEIN 2; EBLN2__:____:__
Number Sign__:__613251__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 14; CMH14__:____:__
Number Sign__:__613252__:__CARDIOMYOPATHY, DILATED, 1EE; CMD1EE__:____:__
Caret__:__613253__:__MOVED TO 603046__:____:__
Number Sign__:__613254__:__TUBEROUS SCLEROSIS 2; TSC2__:____:__TSC2 ANGIOMYOLIPOMAS, RENAL, MODIFIER OF, INCLUDED
Number Sign__:__613255__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 15; CMH15__:____:__
Asterisk__:__613256__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 14D; PPP1R14D__:__GUT AND BRAIN PHOSPHATASE INHIBITOR 1; GBPI1__:__
Asterisk__:__613257__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 15B; PPP1R15B__:__CREP__:__
Asterisk__:__613258__:__CHROMOSOME 18 OPEN READING FRAME 54; C18ORF54__:__LAS2, MOUSE, HOMOLOG OF; LAS2__:__
Asterisk__:__613259__:__REPETIN; RPTN__:____:__
Asterisk__:__613260__:__KERATINOCYTE PROLINE-RICH PROTEIN; KPRP__:____:__
Asterisk__:__613261__:__PROTOGENIN, CHICKEN, HOMOLOG OF; PRTG__:____:__
Asterisk__:__613262__:__RIBOSOMAL PROTEIN L24 DOMAIN-CONTAINING PROTEIN 1; RSL24D1__:__RPL24 DOMAIN-CONTAINING PROTEIN 1;; RLP24, YEAST, HOMOLOG OF; RLP24__:__
Asterisk__:__613263__:__SMALL NUCLEOLAR RNA HOST GENE 5; SNHG5__:__U50 HOST GENE; U50HG__:__
Asterisk__:__613264__:__SMALL NUCLEOLAR RNA, C/D BOX; SNORD50B__:__snoRNA, U50-PRIME__:__
Number Sign__:__613265__:__WAARDENBURG SYNDROME, TYPE 4B; WS4B__:__WAARDENBURG SYNDROME, TYPE 4B, WITH HIRSCHSPRUNG DISEASE;; WAARDENBURG SYNDROME, TYPE IVB__:__
Number Sign__:__613266__:__WAARDENBURG SYNDROME, TYPE 4C; WS4C__:__WAARDENBURG SYNDROME WITH HIRSCHSPRUNG DISEASE, TYPE 4C;; WAARDENBURG SYNDROME, TYPE IVC__:__
Number Sign__:__613267__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 3; FECD3__:__FCD2 LOCUS;; CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Number Sign__:__613268__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 4; FECD4__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Percent__:__613269__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 5; FECD5__:__FCD3 LOCUS;; CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Number Sign__:__613270__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 6; FECD6__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Percent__:__613271__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 7; FECD7__:__FCD4 LOCUS;; CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, LATE-ONSET__:__
Asterisk__:__613272__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 3; KCTD3__:__NY-REN-45__:__
Asterisk__:__613273__:__INST3- AND NABP-INTERACTING PROTEIN; INIP__:__CHROMOSOME 9 OPEN READING FRAME 80; C9ORF80;; SENSOR OF SINGLE-STRANDED DNA COMPLEX, SUBUNIT C; SOSSC;; SOSS COMPLEX, SUBUNIT C__:__
Asterisk__:__613274__:__MOLYBDENUM COFACTOR SULFURASE; MOCOS__:__MCS;; HMCS__:__
Asterisk__:__613275__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 16B; PPP1R16B__:__TRANSFORMING GROWTH FACTOR-BETA-INHIBITED MEMBRANE-ASSOCIATED PROTEIN; TIMAP;; TGFB-INHIBITED MEMBRANE-ASSOCIATED PROTEIN;; KIAA0823__:__
Asterisk__:__613276__:__U6 SMALL NUCLEAR RNA BIOGENESIS PHOSPHODIESTERASE 1; USB1__:__U6 snRNA BIOGENESIS PHOSPHODIESTERASE 1;; CHROMOSOME 16 OPEN READING FRAME 57; C16ORF57__:__
Asterisk__:__613277__:__TRANSMEMBRANE PROTEIN 216; TMEM216__:____:__
Asterisk__:__613278__:__SLX4, S. CEREVISIAE, HOMOLOG OF; SLX4__:__STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT SLX4;; BTB/POZ DOMAIN-CONTAINING PROTEIN 12; BTBD12;; MUS312, DROSOPHILA, HOMOLOG OF; MUS312;; KIAA1784;; KIAA1987__:__
Asterisk__:__613279__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 14: ZC3H14__:__SUPPRESSOR OF TAU 2, C. ELEGANS, HOMOLOG OF; SUT2;; NY-REN-37__:__
Number Sign__:__613280__:__HYPERMANGANESEMIA WITH DYSTONIA 1; HMNDYT1__:__HYPERMANGANESEMIA WITH DYSTONIA, POLYCYTHEMIA, AND CIRRHOSIS; HMDPC__:__
Asterisk__:__613281__:__SORTING NEXIN 20; SNX20__:__SELECTIN LIGAND INTERACTOR CYTOPLASMIC 1; SLIC1__:__
Percent__:__613282__:__FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 1; NAFLD1__:____:__LIVER DISEASE, ALCOHOLIC, SUSCEPTIBILITY TO, 1, INCLUDED
Asterisk__:__613283__:__GLUTAREDOXIN, CYSTEINE-RICH, 1; GRXCR1__:____:__
Percent__:__613284__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 3; HCHGQ3__:__HEMATOCRIT/HEMOGLOBIN QUANTITATIVE TRAIT LOCUS ON CHROMOSOME 22__:__
Number Sign__:__613285__:__DEAFNESS, AUTOSOMAL RECESSIVE 25; DFNB25__:____:__
Number Sign__:__613286__:__CARDIOMYOPATHY, DILATED, 1FF; CMD1FF__:____:__
Number Sign__:__613287__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N__:__CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2N;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2N__:__
Asterisk__:__613288__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 72; TRIM72__:__MITSUGUMIN, 53-KD; MG53__:__
Asterisk__:__613289__:__ATAXIN 8; ATXN8__:____:__
Percent__:__613290__:__HEARING LOSS, CISPLATIN-INDUCED, SUSCEPTIBILITY TO; CIHL__:____:__
Number Sign__:__613291__:__BILE ACID MALABSORPTION, PRIMARY; PBAM__:____:__
Asterisk__:__613292__:__DENN/MADD DOMAIN-CONTAINING PROTEIN 1B; DENND1B__:__CONNECDENN 2;; FAMILY WITH SEQUENCE SIMILARITY 31, MEMBER B; FAM31B;; CHROMOSOME 1 OPEN READING FRAME 18; C1ORF18__:__
Asterisk__:__613293__:__SH3 AND PX DOMAINS-CONTAINING PROTEIN 2B; SH3PXD2B__:__TYROSINE KINASE SUBSTRATE WITH 4 SH3 DOMAINS; TKS4;; KIAA1295__:__
Asterisk__:__613294__:__SUMO1-ACTIVATING ENZYME, SUBUNIT 1; SAE1__:__SUA1;; ACTIVATOR OF SUMO1, S. CEREVISIAE, HOMOLOG OF; AOS1__:__
Asterisk__:__613295__:__UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 2; UBA2__:__UBA2, S. CEREVISIAE, HOMOLOG OF;; SUMO1-ACTIVATING ENZYME, SUBUNIT 2; SAE2__:__
Asterisk__:__613296__:__LYSOSOME-ASSOCIATED PROTEIN, TRANSMEMBRANE 4, BETA; LAPTM4B__:__LYSOSOME-ASSOCIATED TRANSMEMBRANE PROTEIN 4, BETA__:__
Asterisk__:__613297__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 6; MARCH6__:__MARCH VI;; TEB4;; DOA10, S. CEREVISIAE, HOMOLOG OF; DOA10;; KIAA0597__:__
Asterisk__:__613298__:__TOPBP1-INTERACTING CHECKPOINT AND REPLICATION REGULATOR; TICRR__:__CHROMOSOME 15 OPEN READING FRAME 42; C15ORF42;; TRESLIN;; SLD3, YEAST, HOMOLOG OF__:__
Asterisk__:__613299__:__FAMILY WITH SEQUENCE SIMILARITY 13, MEMBER A; FAM13A__:__FAM13A1;; KIAA0914__:__
Asterisk__:__613300__:__FAM13A OPPOSITE STRAND; FAM13AOS__:__FAM13A1OS__:__
Asterisk__:__613301__:__FEZ FAMILY ZINC FINGER PROTEIN 1; FEZF1__:__FOREBRAIN EMBRYONIC ZINC FINGER; FEZ;; ZINC FINGER PROTEIN 312B; ZNF312B__:__
Asterisk__:__613302__:__AlkB, E. COLI, HOMOLOG OF, 4; ALKBH4__:__ABH4__:__
Asterisk__:__613303__:__AlkB, E. COLI, HOMOLOG OF, 5; ALKBH5__:__ABH5__:__
Asterisk__:__613304__:__AlkB, E. COLI, HOMOLOG OF, 6; ALKBH6__:__ABH6__:__
Asterisk__:__613305__:__AlkB, E. COLI, HOMOLOG OF, 7; ALKBH7__:__ABH7__:__
Asterisk__:__613306__:__AlkB, E. COLI, HOMOLOG OF, 8; ALKBH8__:__ABH8__:__
Number Sign__:__613307__:__DEAFNESS, AUTOSOMAL RECESSIVE 79; DFNB79__:____:__
Number Sign__:__613308__:__DIAMOND-BLACKFAN ANEMIA 9; DBA9__:____:__
Number Sign__:__613309__:__DIAMOND-BLACKFAN ANEMIA 10; DBA10__:____:__
Number Sign__:__613310__:__EXUDATIVE VITREORETINOPATHY 5; EVR5__:____:__
Asterisk__:__613311__:__LYR MOTIF-CONTAINING PROTEIN 4; LYRM4__:__ISD11, S. CEREVISIAE, HOMOLOG OF; ISD11;; CHROMOSOME 6 OPEN READING FRAME 149; C6ORF149__:__
Number Sign__:__613312__:__HYPOPHOSPHATEMIC RICKETS, AUTOSOMAL RECESSIVE, 2; ARHR2__:____:__
Number Sign__:__613313__:__HEMOCHROMATOSIS, TYPE 2B; HFE2B__:____:__
Asterisk__:__613314__:__RIBOSOMAL PROTEIN L37A; RPL37A__:____:__
Asterisk__:__613315__:__RIBOSOMAL PROTEIN L41; RPL41__:__HG12__:__
Asterisk__:__613316__:__WD REPEAT- AND FYVE DOMAIN-CONTAINING PROTEIN 4; WDFY4__:__KIAA1607__:__
Asterisk__:__613317__:__DDB1- AND CUL4-ASSOCIATED FACTOR 11; DCAF11__:__WD REPEAT-CONTAINING PROTEIN 23; WDR23__:__
Percent__:__613318__:__MIYOSHI MUSCULAR DYSTROPHY 2; MMD2__:__MIYOSHI MYOPATHY 2__:__
Number Sign__:__613319__:__MIYOSHI MUSCULAR DYSTROPHY 3; MMD3__:__MIYOSHI MYOPATHY 3__:__
Number Sign__:__613320__:__SPONDYLOMETAPHYSEAL DYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE; SMDMDM__:__CHONDRODYSPLASIA, MEGARBANE-DAGHER-MELKI TYPE__:__
Asterisk__:__613321__:__GLUCOSIDE XYLOSYLTRANSFERASE 1; GXYLT1__:__GLYCOSYLTRANSFERASE 8 DOMAIN-CONTAINING PROTEIN 3; GLT8D3__:__
Asterisk__:__613322__:__GLUCOSIDE XYLOSYLTRANSFERASE 2; GXYLT2__:__GLYCOSYLTRANSFERASE 8 DOMAIN-CONTAINING PROTEIN 4; GLT8D4__:__
Asterisk__:__613323__:__FERM AND PDZ DOMAINS-CONTAINING PROTEIN 2; FRMPD2__:____:__
Asterisk__:__613324__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 13; SPATA13__:__APC-STIMULATED GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; ASEF2__:__
Number Sign__:__613325__:__RHABDOID TUMOR PREDISPOSITION SYNDROME 2; RTPS2__:____:__
Asterisk__:__613326__:__DIHYDROPYRIMIDINASE; DPYS__:__5,6-DIHYDROPYRIMIDINE AMIDOHYDROLASE; DHP__:__
Number Sign__:__613327__:__LIPODYSTROPHY, CONGENITAL GENERALIZED, TYPE 4; CGL4__:__BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY, TYPE 4, WITH MUSCULAR DYSTROPHY;; LIPODYSTROPHY, BERARDINELLI-SEIP CONGENITAL, TYPE 4, WITH MUSCULAR DYSTROPHY__:__
NULL__:__613328__:__ROIFMAN-CHITAYAT SYNDROME__:__COMBINED IMMUNODEFICIENCY, FACIAL DYSMORPHISM, OPTIC NERVE ATROPHY, SKELETAL ANOMALIES, AND DEVELOPMENTAL DELAY__:__
Number Sign__:__613329__:__PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY__:__HYPERFIBRINOLYSIS DUE TO PAI1 DEFICIENCY__:__
Number Sign__:__613330__:__SPONDYLO-MEGAEPIPHYSEAL-METAPHYSEAL DYSPLASIA; SMMD__:____:__
Asterisk__:__613331__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 1; MARCH1__:__MARCH I__:__
Asterisk__:__613332__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 2; MARCH2__:__MARCH II__:__
Asterisk__:__613333__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 3; MARCH3__:__MARCH III__:__
Asterisk__:__613334__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 7; MARCH7__:__MARCH VII__:__
Asterisk__:__613335__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 8; MARCH8__:__MARCH VIII;; MIR__:__
Asterisk__:__613336__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 9; MARCH9__:__MARCH IX__:__
Asterisk__:__613337__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 10; MARCH10__:__MARCH X__:__
Asterisk__:__613338__:__MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 11; MARCH11__:__MARCH XI__:__
Percent__:__613339__:__EPILEPSY, HOT WATER, 1; HWE1__:__BATHING EPILEPSY;; WATER IMMERSION EPILEPSY__:__
Percent__:__613340__:__EPILEPSY, HOT WATER, 2; HWE2__:____:__
Number Sign__:__613341__:__LEBER CONGENITAL AMAUROSIS 14; LCA14__:____:__RETINAL DYSTROPHY, EARLY-ONSET SEVERE, LRAT-RELATED, INCLUDED;; RETINITIS PIGMENTOSA, JUVENILE, LRAT-RELATED, INCLUDED
NULL__:__613342__:__MSELENI JOINT DISEASE__:____:__
Percent__:__613343__:__HANDIGODU JOINT DISEASE__:__HJD;; SPONDYLOEPIMETAPHYSEAL DYSPLASIA, HANDIGODU TYPE__:__
Asterisk__:__613344__:__KIAA1549 GENE; KIAA1549__:____:__KIAA1549/BRAF FUSION GENE, INCLUDED
Number Sign__:__613345__:__HYPOKALEMIC PERIODIC PARALYSIS, TYPE 2; HOKPP2__:____:__
Asterisk__:__613346__:__SHISA FAMILY, MEMBER 9; SHISA9__:__CYSTINE-KNOT AMPA RECEPTOR-MODULATING PROTEIN, 44-KD; CKAMP44__:__
Number Sign__:__613347__:__PANCREATIC CANCER, SUSCEPTIBILITY TO, 2__:__PNCA2__:__
Number Sign__:__613348__:__PANCREATIC CANCER, SUSCEPTIBILITY TO, 3__:__PNCA3__:__
Asterisk__:__613349__:__ORNITHINE AMINOTRANSFERASE; OAT__:__ORNITHINE KETO ACID AMINOTRANSFERASE; OKT;; ORNITHINE DELTA-AMINOTRANSFERASE__:__
Asterisk__:__613350__:__SOLUTE CARRIER FAMILY 52 (RIBOFLAVIN TRANSPORTER), MEMBER 3; SLC52A3__:__RIBOFLAVIN TRANSPORTER 2; RFT2;; RFVT3;; CHROMOSOME 20 OPEN READING FRAME 54; C20ORF54__:__
Asterisk__:__613351__:__RHO GTPase-ACTIVATING PROTEIN 18; ARHGAP18__:____:__
Asterisk__:__613352__:__ARGININE/SERINE-RICH COILED-COIL PROTEIN 1; RSRC1__:__SR-RELATED PROTEIN, 53-KD; SRRP53__:__
Number Sign__:__613353__:__MONONEUROPATHY OF THE MEDIAN NERVE, MILD; MNMN__:__CARPAL TUNNEL SYNDROME, SUSCEPTIBILITY TO__:__
Asterisk__:__613354__:__TAPERIN; TPRN__:__CHROMOSOME 9 OPEN READING FRAME 75; C9ORF75__:__
Number Sign__:__613355__:__CHROMOSOME 17q23.1-q23.2 DELETION SYNDROME__:____:__
Asterisk__:__613356__:__TLR4 INTERACTOR WITH LEUCINE-RICH REPEATS; TRIL__:__KIAA0644__:__
Asterisk__:__613357__:__FIBRINOGEN C DOMAIN-CONTAINING PROTEIN 1; FIBCD1__:____:__
Asterisk__:__613358__:__ALDEHYDE DEHYDROGENASE 16 FAMILY, MEMBER A1; ALDH16A1__:____:__
Asterisk__:__613359__:__LY6/PLAUR DOMAIN-CONTAINING PROTEIN 6; LYPD6__:____:__
Asterisk__:__613360__:__DAMAGE-REGULATED AUTOPHAGY MODULATOR 2; DRAM2__:__TRANSMEMBRANE PROTEIN 77; TMEM77__:__
Asterisk__:__613361__:__SOLUTE CARRIER FAMILY 18, MEMBER B1; SLC18B1__:__CHROMOSOME 6 OPEN READING FRAME 192; C6ORF192__:__
Asterisk__:__613362__:__CDK2-INTERACTING PROTEIN; CINP__:____:__
Asterisk__:__613363__:__WD REPEAT-CONTAINING PROTEIN 34; WDR34__:____:__
Percent__:__613364__:__SPASTIC PARAPLEGIA 41, AUTOSOMAL DOMINANT; SPG41__:____:__
Asterisk__:__613365__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 6A1; SLCO6A1__:__GONAD-SPECIFIC TRANSPORTER; GST__:__
Asterisk__:__613366__:__SOLUTE CARRIER FAMILY 10 (SODIUM/BILE ACID COTRANSPORTER FAMILY), MEMBER 6; SLC10A6__:__SODIUM-DEPENDENT ORGANIC ANION TRANSPORTER; SOAT__:__
Asterisk__:__613367__:__LIN54, C. ELEGANS, HOMOLOG OF; LIN54__:____:__
Asterisk__:__613368__:__CARNOSINE SYNTHASE 1; CARNS1__:__ATP-GRASP DOMAIN-CONTAINING PROTEIN 1; ATPGD1;; KIAA1394__:__
Asterisk__:__613369__:__DEAD BOX HELICASE 42; DDX42__:__DEAD BOX POLYPEPTIDE 42;; RNA HELICASE-LIKE PROTEIN; RHELP;; SPLICING FACTOR 3B, 125-KD SUBUNIT; SF3B125__:__
Number Sign__:__613370__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 10; MODY10__:____:__
Percent__:__613371__:__SPINOCEREBELLAR ATAXIA 30; SCA30__:____:__
Asterisk__:__613372__:__UFM1-SPECIFIC LIGASE 1; UFL1__:__NOVEL LZAP-BINDING PROTEIN; NLBP;; KIAA0776;; RCAD__:__
Asterisk__:__613373__:__YEATS DOMAIN-CONTAINING PROTEIN 2; YEATS2__:__KIAA1197__:__
Asterisk__:__613374__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 101; CCDC101__:__STAF36__:__
Number Sign__:__613375__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; MODY11__:____:__
Number Sign__:__613376__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; HMN2C__:__HMN IIC;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IIC; DHMN2C__:__
Asterisk__:__613377__:__SH3 DOMAIN-CONTAINING RING FINGER PROTEIN 2; SH3RF2__:__HEART PROTEIN PHOSPHATASE 1-BINDING PROTEIN; HEPP1__:__
Asterisk__:__613378__:__AIG2-LIKE DOMAIN-CONTAINING PROTEIN 1; A2LD1__:__GAMMA-GLUTAMYLAMINE CYCLOTRANSFERASE; GGACT__:__
Asterisk__:__613379__:__CARBOXYMETHYLENEBUTENOLIDASE-LIKE PROTEIN; CMBL__:__CARBOXYMETHYLENEBUTENOLIDASE, PSEUDOMONAS, HOMOLOG OF__:__
Asterisk__:__613380__:__H6 FAMILY HOMEOBOX 3; HMX3__:__NKX5.1__:__
Asterisk__:__613381__:__CYSTATHIONINE BETA-SYNTHASE; CBS__:____:__
Number Sign__:__613382__:__BRACHYDACTYLY, TYPE E2; BDE2__:____:__
Asterisk__:__613383__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 54; ANKRD54__:__LYN-INTERACTING ANKYRIN REPEAT PROTEIN; LIAR__:__
Asterisk__:__613384__:__CYCLIN L1; CCNL1__:__ACTIVITY- AND NEUROTRANSMITTER-INDUCED GENE 6A; ANIA6A__:__
Number Sign__:__613385__:__AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM; ADMFD__:____:__
Asterisk__:__613386__:__PROTEASOME MATURATION PROTEIN; POMP__:__UMP1, YEAST, HOMOLOG OF; UMP1;; PROTEASSEMBLIN__:__
Percent__:__613387__:__FATTY LIVER DISEASE, NONALCOHOLIC, SUSCEPTIBILITY TO, 2; NAFLD2__:____:__
Number Sign__:__613388__:__FANCONI RENOTUBULAR SYNDROME 2; FRTS2__:____:__
Asterisk__:__613389__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1C1; SLCO1C1__:__ORGANIC ANION TRANSPORTER F; OATPF;; ORGANIC ANION TRANSPORTER POLYPEPTIDE 14; OATP14;; SOLUTE CARRIER FAMILY 21 (ORGANIC ANION TRANSPORTER), MEMBER 14; SLC21A14__:__
Number Sign__:__613390__:__FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO__:____:__
Number Sign__:__613391__:__DEAFNESS, AUTOSOMAL RECESSIVE 84A; DFNB84A__:__DEAFNESS, AUTOSOMAL RECESSIVE 84; DFNB84;; DEAFNESS, AUTOSOMAL RECESSIVE 84A, WITH VESTIBULAR DYSFUNCTION__:__
Percent__:__613392__:__DEAFNESS, AUTOSOMAL RECESSIVE 85; DFNB85__:____:__
Number Sign__:__613393__:__BIRBECK GRANULE DEFICIENCY__:__BIRBECK GRANULES, ABSENCE OF__:__
Asterisk__:__613394__:__MICRO RNA 138-1; MIR138-1__:__miRNA138-1;; MIRN138-1__:__
Asterisk__:__613395__:__MICRO RNA 138-2; MIR138-2__:__miRNA138-2;; MIRN138-2__:__
Asterisk__:__613396__:__DOWN SYNDROME CRITICAL REGION GENE 8; DSCR8__:__MALIGNANT MELANOMA-ASSOCIATED PROTEIN 1; MMA1__:__
Asterisk__:__613397__:__ADVILLIN; AVIL__:____:__
Number Sign__:__613398__:__WARSAW BREAKAGE SYNDROME; WABS__:____:__
Number Sign__:__613399__:__BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3__:____:__BREAST CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED;; OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3, INCLUDED
Asterisk__:__613400__:__ACIREDUCTONE DIOXYGENASE 1; ADI1__:__SUBMERGENCE-INDUCED PROTEIN-LIKE; SIPL;; MT1-MMP CYTOPLASMIC TAIL-BINDING PROTEIN 1; MTCBP1__:__
Asterisk__:__613401__:__VPS33B-INTERACTING PROTEIN, APICAL-BASOLATERAL POLARITY REGULATOR, SPE39 HOMOLOG; VIPAS39__:__VPS33B-INTERACTING PROTEIN, APICAL-BASOLATERAL POLARITY REGULATOR; VIPAR;; SPE39, C. ELEGANS, HOMOLOG OF; SPE39;; CHROMOSOME 14 OPEN READING FRAME 133; C14ORF133__:__
Number Sign__:__613402__:__MICROCEPHALY, SEIZURES, AND DEVELOPMENTAL DELAY; MCSZ__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 10; EIEE10__:__
Asterisk__:__613403__:__TRANSMEMBRANE PROTEIN 127; TMEM127__:____:__
Number Sign__:__613404__:__ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS 2; ARCS2__:____:__
Asterisk__:__613405__:__MICRO RNA 2861; MIR2861__:__miRNA 2861;; MIRN2861__:__
Number Sign__:__613406__:__WITTEVEEN-KOLK SYNDROME; WITKOS__:____:__CHROMOSOME 15q24 DELETION SYNDROME, INCLUDED;; CHROMOSOME 15q24 DUPLICATION SYNDROME, INCLUDED
Percent__:__613407__:__LEPROSY, SUSCEPTIBILITY TO, 6; LPRS6__:____:__
Asterisk__:__613408__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 122; CCDC122__:____:__
Asterisk__:__613409__:__LACCASE (MULTICOPPER REDUCTASE) DOMAIN-CONTAINING PROTEIN 1; LACC1__:__CHROMOSOME 13 OPEN READING FRAME 31; C13ORF31__:__
Number Sign__:__613410__:__AUTISM, SUSCEPTIBILITY TO, 16; AUTS16__:__AUTISM WITH OR WITHOUT SEIZURES__:__
Number Sign__:__613411__:__OGUCHI DISEASE 2__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, OGUCHI TYPE 2; CSNBO2__:__
Percent__:__613412__:__ESOPHAGITIS, EOSINOPHILIC, 2; EOE2__:____:__
Asterisk__:__613413__:__TRANSMEMBRANE PROTEIN 106B; TMEM106B__:____:__
Asterisk__:__613414__:__INTERLEUKIN 17 RECEPTOR E-LIKE; IL17REL__:____:__
Asterisk__:__613415__:__CREATINE KINASE, MITOCHONDRIAL 1A; CKMT1A__:__CREATINE KINASE, MITOCHONDRIAL 1, TELOMERIC COPY;; CKMT1, TELOMERIC COPY__:__
Asterisk__:__613416__:__SCINDERIN; SCIN__:__ADSEVERIN;; KIAA1905__:__
Asterisk__:__613417__:__FAMILY WITH SEQUENCE SIMILARITY 48, MEMBER A; FAM48A__:__p38-INTERACTING PROTEIN; P38IP;; CHROMOSOME 13 OPEN READING FRAME 19; C13ORF19__:__
Number Sign__:__613418__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 15; BMND15__:__OSTEOPOROSIS, SUSCEPTIBILITY TO;; METAPHYSEAL FRACTURE, SUSCEPTIBILITY TO;; COMPRESSION FRACTURE, SUSCEPTIBILITY TO__:__
Asterisk__:__613419__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 4; ZSCAN4__:__ZINC FINGER PROTEIN 494; ZNF494__:__
Asterisk__:__613420__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1__:____:__
Asterisk__:__613421__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 10; KCTD10__:____:__
Asterisk__:__613422__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 2; KCTD2__:__KIAA0176__:__
Asterisk__:__613423__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 16; KCTD16__:__KIAA1317__:__
Number Sign__:__613424__:__CARDIOMYOPATHY, DILATED, 1R; CMD1R__:____:__LEFT VENTRICULAR NONCOMPACTION 4, INCLUDED; LVNC4, INCLUDED
Asterisk__:__613425__:__CHROMOSOME 2 OPEN READING FRAME 71; C2ORF71__:____:__
Number Sign__:__613426__:__CARDIOMYOPATHY, DILATED, 1S; CMD1S__:____:__LEFT VENTRICULAR NONCOMPACTION 5, INCLUDED; LVNC5, INCLUDED
Asterisk__:__613427__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 16; ANAPC16__:__METABOLIC SYNDROME-ASSOCIATED GENE; MSAG;; CHROMOSOME 10 OPEN READING FRAME 104; C10ORF104__:__
Number Sign__:__613428__:__RETINITIS PIGMENTOSA 54; RP54__:____:__
Asterisk__:__613429__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 2; HAUS2__:__CENTROSOMAL PROTEIN, 27-KD: CEP27__:__
Asterisk__:__613430__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 3; HAUS3__:__DIM GAMMA-TUBULIN 3, DROSOPHILA, HOMOLOG OF; DGT3;; CHROMOSOME 4 OPEN READING FRAME 15; C4ORF15__:__
Asterisk__:__613431__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 4; HAUS4__:__CHROMOSOME 14 OPEN READING FRAME 94; C14ORF94__:__
Asterisk__:__613432__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 5; HAUS5__:__DIM GAMMA-TUBULIN 5, DROSOPHILA, HOMOLOG OF; DGT5;; KIAA0841__:__
Asterisk__:__613433__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 6; HAUS6__:__DIM GAMMA-TUBULIN 6, DROSOPHILA, HOMOLOG OF; DGT6;; FAMILY WITH SEQUENCE SIMILARITY 29, MEMBER A; FAM29A__:__
Asterisk__:__613434__:__HAUS AUGMIN-LIKE COMPLEX, SUBUNIT 8; HAUS8__:__DIM GAMMA-TUBULIN 4, DROSOPHILA, HOMOLOG OF; DGT4;; HEC1-INTERACTING AND CENTROSOME-ASSOCIATED PROTEIN 1; HICE1__:__
Number Sign__:__613435__:__AMYOTROPHIC LATERAL SCLEROSIS 12; ALS12__:____:__
Number Sign__:__613436__:__AUTISM, SUSCEPTIBILITY TO, 17; AUTS17__:____:__
Asterisk__:__613437__:__FCH DOMAIN ONLY PROTEIN 1; FCHO1__:____:__
Asterisk__:__613438__:__FCH DOMAIN ONLY PROTEIN 2; FCHO2__:____:__
Asterisk__:__613439__:__CONSORTIN; CNST__:____:__
Percent__:__613440__:__STATURE QUANTITATIVE TRAIT LOCUS 21; STQTL21__:____:__
Asterisk__:__613441__:__TRANSCOBALAMIN II; TCN2__:__TC II;; VITAMIN B12-BINDING PROTEIN 2__:__
Asterisk__:__613442__:__PENTRAXIN 4, LONG; PTX4__:____:__
Number Sign__:__613443__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 20; MRD20__:__MENTAL RETARDATION, STEREOTYPIC MOVEMENTS, EPILEPSY, AND/OR CEREBRAL MALFORMATIONS__:__CHROMOSOME 5q14.3 DELETION SYNDROME, PROXIMAL, INCLUDED
Number Sign__:__613444__:__CHROMOSOME 16p11.2 DELETION SYNDROME, 220-KB__:____:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 16, INCLUDED; BMIQ16, INCLUDED;; OBESITY, SUSCEPTIBILITY TO, INCLUDED
Caret__:__613445__:__MOVED TO 600642__:____:__
Asterisk__:__613446__:__CENTROSOMAL PROTEIN, 120-KD; CEP120__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 100; CCDC100__:__
Asterisk__:__613447__:__SPINDLE- AND CENTRIOLE-ASSOCIATED PROTEIN 1; SPICE1__:__SPINDLE AND CENTRIOLE PROTEIN; SPICE;; COILED-COIL DOMAIN-CONTAINING PROTEIN 52, FORMERLY; CCDC52, FORMERLY__:__
Asterisk__:__613448__:__MITOTIC SPINDLE ORGANIZING PROTEIN 1; MZT1__:__MITOTIC SPINDLE-ORGANIZING PROTEIN ASSOCIATED WITH A RING OF GAMMA-TUBULIN 1; MOZART1;; CHROMOSOME 13 OPEN READING FRAME 37; C13ORF37__:__
Asterisk__:__613449__:__FAMILY WITH SEQUENCE SIMILARITY 128, MEMBER A; FAM128A__:__MITOTIC SPINDLE-ORGANIZING PROTEIN ASSOCIATED WITH A RING OF GAMMA-TUBULIN 2A; MOZART2A__:__
Asterisk__:__613450__:__FAMILY WITH SEQUENCE SIMILARITY 128, MEMBER B; FAM128B__:__MITOTIC SPINDLE-ORGANIZING PROTEIN ASSOCIATED WITH A RING OF GAMMA-TUBULIN 2B; MOZART2B__:__
Number Sign__:__613451__:__FRONTONASAL DYSPLASIA 2; FND2__:____:__
Asterisk__:__613452__:__CATION CHANNEL, SPERM-ASSOCIATED, AUXILIARY SUBUNIT GAMMA; CATSPERG__:____:__
Number Sign__:__613453__:__DEAFNESS, AUTOSOMAL RECESSIVE 91; DFNB91__:____:__
Number Sign__:__613454__:__RETT SYNDROME, CONGENITAL VARIANT__:____:__
Asterisk__:__613455__:__MELANOMA INHIBITORY ACTIVITY FAMILY, MEMBER 3; MIA3__:__TRANSPORT AND GOLGI ORGANIZATION GENE 1; TANGO1;; TANGO;; KIAA0268__:__
Number Sign__:__613456__:__FRONTONASAL DYSPLASIA 3; FND3__:____:__
Number Sign__:__613457__:__CHROMOSOME 14q11-q22 DELETION SYNDROME__:____:__
Number Sign__:__613458__:__CHROMOSOME 16p13.3 DUPLICATION SYNDROME__:____:__
Percent__:__613459__:__BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 2; BWQTL2__:____:__
Percent__:__613460__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 6; FGQTL6__:____:__BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 3, INCLUDED; BWQTL3, INCLUDED;; PLASMA GLUCOSE, 2-HOUR, QUANTITATIVE TRAIT LOCUS 1, INCLUDED; PGQTL1, INCLUDED
Asterisk__:__613461__:__LEPTIN RECEPTOR OVERLAPPING TRANSCRIPT; LEPROT__:__LEPTIN RECEPTOR GENE-RELATED PROTEIN; OBRGRP__:__
Percent__:__613462__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 4; FGQTL4__:____:__
Number Sign__:__613463__:__FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 5; FGQTL5__:____:__
Number Sign__:__613464__:__RETINITIS PIGMENTOSA 51; RP51__:____:__
Asterisk__:__613465__:__NME/NM23 NUCLEOSIDE DIPHOSPHATE KINASE 7; NME7__:__NONMETASTATIC CELLS 7, PROTEIN EXPRESSED IN;; NM23H7;; NUCLEOSIDE DIPHOSPHATE KINASE 7__:__
Asterisk__:__613466__:__PREFOLDIN 2; PFDN2__:____:__
Asterisk__:__613467__:__ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 6; ZCCHC6__:__TERMINAL URIDYLTRANSFERASE 7; TUT7;; KIAA1711__:__
Asterisk__:__613468__:__N-ACYLSPHINGOSINE AMIDOHYDROLASE 1; ASAH1__:__ASAH;; N-ACYLSPHINGOSINE DEACYLASE;; ACID CERAMIDASE; AC;; ACID CDase;; ACDase__:__
Asterisk__:__613469__:__HEPARANASE 2; HPSE2__:__HPA2__:__
Number Sign__:__613470__:__HEMOLYTIC ANEMIA, NONSPHEROCYTIC, DUE TO GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY__:____:__
Number Sign__:__613471__:__REYNOLDS SYNDROME__:__PRIMARY BILIARY CIRRHOSIS, SCLERODERMA, RAYNAUD DISEASE, AND TELANGIECTASIA__:__
Asterisk__:__613472__:__UNC51-LIKE KINASE 3; ULK3__:____:__
Asterisk__:__613473__:__WD REPEAT-CONTAINING PROTEIN 7; WDR7__:__TGF-BETA RESISTANCE-ASSOCIATED GENE; TRAG;; RABCONNECTIN 3, BETA;; KIAA0541__:__
Asterisk__:__613474__:__ZINC FINGER AN1 DOMAIN-CONTAINING PROTEIN 2B; ZFAND2B__:__AN1-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 2B;; ARSENITE-INDUCIBLE RNA-ASSOCIATED PROTEIN-LIKE PROTEIN; AIRAPL;; AIRAP-LIKE PROTEIN__:__
Asterisk__:__613475__:__RIBOSOMAL RNA-PROCESSING FACTOR, 36-KD, S. CEREVISIAE, HOMOLOG OF; RRP36__:__CHROMOSOME 6 OPEN READING FRAME 153; C6ORF153__:__
Asterisk__:__613476__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 6; MFSD6__:__MACROPHAGE MHC RECEPTOR 2; MMR2__:__
Number Sign__:__613477__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 5; EIEE5__:____:__
Asterisk__:__613478__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 106; CCDC106__:____:__
Asterisk__:__613479__:__5-AZACYTIDINE-INDUCED GENE 1, MOUSE, HOMOLOG OF; AZI1__:__AZ1, MOUSE, HOMOLOG OF; AZ1;; KIAA1118__:__
Number Sign__:__613480__:__LYMPHATIC MALFORMATION 3; LMPHM3__:__LYMPHEDEMA, HEREDITARY, IC, FORMERLY; LMPH1C, FORMERLY__:__
Asterisk__:__613481__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 62: CCDC62__:__ESTROGEN RECEPTOR-ASSOCIATED PROTEIN, 75-KD; ERAP75__:__
Asterisk__:__613482__:__CYCLIN L2; CCNL2__:____:__
Asterisk__:__613483__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER E22; BHLHE22__:__BASIC HELIX-LOOP-HELIX DOMAIN-CONTAINING PROTEIN, CLASS B, 5; BHLHB5;; BETA3__:__
Asterisk__:__613484__:__SPEN, DROSOPHILA, HOMOLOG OF; SPEN__:__MSX2-INTERACTING NUCLEAR TARGET; MINT;; SMART/HDAC1-ASSOCIATED REPRESSOR PROTEIN; SHARP;; KIAA0929__:__
Number Sign__:__613485__:__LONG QT SYNDROME 13; LQT13__:____:__
Asterisk__:__613486__:__MICRO RNA 33B; MIR33B__:__miRNA33B;; MIRN33B__:__
Asterisk__:__613487__:__MICRO RNA 212; MIR212__:__miRNA212;; MIRN212;; MIR212-3p__:__MICRO RNA 212*, INCLUDED; MIR212*, INCLUDED;; MICRO RNA 212-5p, INCLUDED; MIR212-5p, INCLUDED
Number Sign__:__613488__:__MYXOID LIPOSARCOMA__:____:__
Number Sign__:__613489__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIj; CDG2J__:__CDG IIj; CDGIIj__:__
Number Sign__:__613490__:__ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD__:____:__
Asterisk__:__613491__:__ALKALINE CERAMIDASE 1; ACER1__:__ALKALINE CDase 1;; ALKCDase1__:__
Asterisk__:__613492__:__ALKALINE CERAMIDASE 2; ACER2__:__ALKALINE CDase 2;; ALKCDase2__:__
Number Sign__:__613493__:__IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3__:__ANTIBODY DEFICIENCY DUE TO CD19 DEFECT__:__
Number Sign__:__613494__:__IMMUNODEFICIENCY, COMMON VARIABLE, 4; CVID4__:__ANTIBODY DEFICIENCY DUE TO BAFFR DEFECT__:__
Number Sign__:__613495__:__IMMUNODEFICIENCY, COMMON VARIABLE, 5; CVID5__:__ANTIBODY DEFICIENCY DUE TO CD20 DEFECT__:__
Number Sign__:__613496__:__IMMUNODEFICIENCY, COMMON VARIABLE, 6; CVID6__:__ANTIBODY DEFICIENCY DUE TO CD81 DEFECT__:__
Asterisk__:__613497__:__LIPASE A, LYSOSOMAL ACID; LIPA__:__LYSOSOMAL ACID LIPASE; LAL;; CHOLESTEROL ESTER HYDROLASE__:__
Percent__:__613498__:__SEX HORMONE-BINDING GLOBULIN CIRCULATING LEVEL QUANTITATIVE TRAIT LOCUS; SXGQTL1__:__TESTOSTERONE CIRCULATING LEVEL QUANTITATIVE TRAIT LOCUS, DUE TO SEX HORMONE-BINDING GLOBULIN__:__
Asterisk__:__613499__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER A; HIST1H2AA__:__HISTONE GENE CLUSTER 1, H2AA;; HIST1 CLUSTER, H2AA;; H2A HISTONE FAMILY, MEMBER R; H2AFR;; H2A/R__:__
Number Sign__:__613500__:__AGAMMAGLOBULINEMIA 2, AUTOSOMAL RECESSIVE; AGM2__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO IGLL1 DEFECT__:__
Number Sign__:__613501__:__AGAMMAGLOBULINEMIA 3, AUTOSOMAL RECESSIVE; AGM3__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO CD79A DEFECT__:__
Number Sign__:__613502__:__AGAMMAGLOBULINEMIA 4, AUTOSOMAL RECESSIVE; AGM4__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO BLNK DEFECT__:__
Asterisk__:__613503__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DQ ALPHA-2; HLA-DQA2__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DX ALPHA; HLA-DXA;; DX-ALPHA__:__
Asterisk__:__613504__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 21; ZFYVE21__:__ZINC FINGER PROTEIN 21; ZF21__:__
Asterisk__:__613505__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 26; LRRC26__:__CYTOKERATIN-ASSOCIATED PROTEIN IN CANCER; CAPC__:__
Number Sign__:__613506__:__AGAMMAGLOBULINEMIA 5, AUTOSOMAL DOMINANT; AGM5__:__AGAMMAGLOBULINEMIA, AUTOSOMAL DOMINANT, DUE TO LRRC8A DEFECT__:__
Number Sign__:__613507__:__GLYCOGEN STORAGE DISEASE XV; GSD15__:__GSD XV;; GLYCOGENIN DEFICIENCY;; GYG1 DEFICIENCY__:__
Number Sign__:__613508__:__SODIUM SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1; SSQTL1__:____:__HYPONATREMIA, INCLUDED
Number Sign__:__613509__:__CHROMOSOME 4q21 DELETION SYNDROME__:____:__
Asterisk__:__613510__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MITOGEN-ACTIVATED PROTEIN KINASE AND MAMMALIAN TARGET OF RAPAMYCIN ACTIVATOR 1; LAMTOR1__:__LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MAPK AND MTOR ACTIVATOR 1;; p27(Kip1)-RELEASING FACTOR FROM RHOA; p27RF-Rho;; PROTEIN ASSOCIATED WITH DETERGENT-RESISTANT MEMBRANES AND ENDOSOMES; PDRO;; CHROMOSOME 11 OPEN READING FRAME 59; C11ORF59__:__
Asterisk__:__613511__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 9; SPINK9__:__LYMPHOEPITHELIAL KAZAL-TYPE-RELATED INHIBITOR 2; LEKTI2__:__
Asterisk__:__613512__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 6; ZBED6__:__BED-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 6__:__
Asterisk__:__613513__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 11A; ZC3H11A__:__KIAA0663__:__
Asterisk__:__613514__:__ZONA PELLUCIDA GLYCOPROTEIN 4; ZP4__:__ZONA PELLUCIDA B PROTEIN; ZPB__:__
Asterisk__:__613515__:__AUTOPHAGY 14, S. CEREVISIAE, HOMOLOG OF; ATG14__:__YEAST ATG14-LIKE; ATG14L;; KIAA0831;; BECN1-INTERACTING PROTEIN;; BECN1-ASSOCIATED AUTOPHAGY-RELATED KEY REGULATOR; BARKOR__:__
Asterisk__:__613516__:__RUN DOMAIN- AND CYSTEINE-RICH DOMAIN-CONTAINING BECLIN-1-INTERACTING PROTEIN; RUBCN__:__KIAA0226 GENE; KIAA0226;; RUBICON;; RUNDATAXIN; RDTX__:__
Number Sign__:__613517__:__MICROPHTHALMIA, ISOLATED 6; MCOP6__:__MICROPHTHALMIA, POSTERIOR NONSYNDROMIC__:__
Percent__:__613518__:__DERMATITIS, ATOPIC, 8; ATOD8__:__DERMATITIS, ATOPIC, SEVERITY OF__:__
Percent__:__613519__:__DERMATITIS, ATOPIC, 9; ATOD9__:____:__
Asterisk__:__613520__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 6; FGD6__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 24; ZFYVE24__:__
Asterisk__:__613521__:__UROPORPHYRINOGEN DECARBOXYLASE; UROD__:____:__
Asterisk__:__613522__:__OPSIN 1, SHORT-WAVE-SENSITIVE; OPN1SW__:__BLUE CONE PIGMENT; BCP__:__
Number Sign__:__613523__:__CHROMOSOME 8p11 MYELOPROLIFERATIVE SYNDROME__:__STEM CELL LEUKEMIA/LYMPHOMA; SCLL__:__
Asterisk__:__613524__:__SEROLOGICALLY DEFINED COLON CANCER ANTIGEN 8; SDCCAG8__:__CENTROSOMAL COLON CANCER AUTOANTIGEN PROTEIN; CCCAP;; NY-CO-8;; SLSN7 GENE;; NPHP10 GENE;; BBS16 GENE__:__
Asterisk__:__613525__:__SEEK1 GENE__:__SEEK1;; PSORIASIS SUSCEPTIBILITY 1 CANDIDATE GENE 1; PSORS1C1;; PSORS1 CANDIDATE GENE 1;; CHROMOSOME 6 OPEN READING FRAME 16; C6ORF16__:__
Asterisk__:__613526__:__SPR1 GENE__:__SPR1;; PSORIASIS SUSCEPTIBILITY 1 CANDIDATE GENE 2; PSORS1C2;; PSORS1 CANDIDATE GENE 2;; CHROMOSOME 6 OPEN READING FRAME 17; C6ORF17__:__
Asterisk__:__613527__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 27; DNAJC27__:__RAB AND DNAJ DOMAIN-CONTAINING PROTEIN; RBJ__:__
Asterisk__:__613528__:__SYNAPTOTAGMIN 9; SYT9__:____:__
Asterisk__:__613529__:__CENTROSOMAL PROTEIN, 152-KD; CEP152__:__KIAA0912__:__
Percent__:__613530__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1H; LGMD1H__:____:__
Asterisk__:__613531__:__PHOSPHATASE AND TENSIN HOMOLOG PSEUDOGENE; PTENP1__:____:__
Asterisk__:__613532__:__RAS-ASSOCIATED PROTEIN RAB8B; RAB8B__:____:__
Number Sign__:__613533__:__CHROMOSOME 17q21.31 DUPLICATION SYNDROME__:____:__
Asterisk__:__613534__:__FANCD2/FANCI-ASSOCIATED NUCLEASE 1; FAN1__:__MYOTUBULARIN-RELATED PROTEIN 15; MTMR15;; KIAA1018__:__
Asterisk__:__613535__:__KIAA0319-LIKE; KIAA0319L__:__KIAA1837;; ADENO-ASSOCIATED VIRUS RECEPTOR; AAVR__:__
Asterisk__:__613536__:__LEUCINE-, GLUTAMATE-, AND LYSINE-RICH PROTEIN 1; LEKR1__:____:__
Asterisk__:__613537__:__NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5__:__NLR FAMILY, CARD-CONTAINING 5__:__
Asterisk__:__613538__:__FEM1, C. ELEGANS, HOMOLOG OF, A; FEM1A__:____:__
Asterisk__:__613539__:__FEM1, C. ELEGANS, HOMOLOG OF, B; FEM1B__:__FEM1-LIKE PROTEIN IN APOPTOTIC PATHWAY, ALPHA;; F1A-ALPHA;; KIAA0396__:__
Asterisk__:__613540__:__SERINE PALMITOYLTRANSFERASE, SMALL SUBUNIT, A; SPTSSA__:__SMALL SUBUNIT OF SERINE PALMITOYLTRANSFERASE A; SSSPTA;; CHROMOSOME 14 OPEN READING FRAME 147; C14ORF147__:__
Asterisk__:__613541__:__CHROMOSOME 12 OPEN READING FRAME 65; C12ORF65__:____:__
Asterisk__:__613542__:__MITOCHONDRIAL TRANSLATIONAL RELEASE FACTOR 1-LIKE; MTRF1L__:__MTRF1A;; HUMAN MITOCHONDRIAL RELEASE FACTOR 1-LIKE; HMRF1L__:__
Asterisk__:__613543__:__SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 5A1; SLCO5A1__:__ORGANIC ANION TRANSPORTER POLYPEPTIDE-RELATED PROTEIN 4; OATPRP4;; SOLUTE CARRIER FAMILY 21, MEMBER 15; SLC21A15;; ORGANIC ANION TRANSPORTER POLYPEPTIDE J; OATPJ;; OATP5A1__:__
Number Sign__:__613544__:__CHROMOSOME 6q11-q14 DELETION SYNDROME__:____:__CHROMOSOME 6q13-q14 DELETION SYNDROME, INCLUDED
Percent__:__613545__:__MACROSTOMIA, ISOLATED__:__LATERAL CLEFT, ISOLATED;; COMMISSURAL CLEFT, ISOLATED;; TRANSVERSE CLEFT, ISOLATED__:__
Number Sign__:__613546__:__AROMATASE DEFICIENCY__:__PSEUDOHERMAPHRODITISM, FEMALE, DUE TO PLACENTAL AROMATASE DEFICIENCY__:__
Percent__:__613547__:__STATURE QUANTITATIVE TRAIT LOCUS 22; STQTL22__:____:__
Percent__:__613548__:__STATURE QUANTITATIVE TRAIT LOCUS 23; STQTL23__:____:__
Percent__:__613549__:__STATURE QUANTITATIVE TRAIT LOCUS 24; STQTL24__:____:__
Number Sign__:__613550__:__NEPHRONOPHTHISIS 11; NPHP11__:____:__
Number Sign__:__613551__:__AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 6; AIS6__:____:__
Asterisk__:__613552__:__GAMMA-SECRETASE-ACTIVATING PROTEIN; GSAP__:__PIGEON, DROSOPHILA, HOMOLOG OF; PION__:__
Asterisk__:__613553__:__X-PROLYL AMINOPEPTIDASE 3; XPNPEP3__:__AMINOPEPTIDASE P3; APP3__:__
Number Sign__:__613554__:__VON WILLEBRAND DISEASE, TYPE 2; VWD2__:__VON WILLEBRAND DISEASE, TYPE II;; VWD, TYPE 2__:__VON WILLEBRAND DISEASE, TYPE 2A, INCLUDED; VWD2A, INCLUDED;; VON WILLEBRAND DISEASE, TYPE 2B, INCLUDED; VWD2B, INCLUDED;; VON WILLEBRAND DISEASE, TYPE 2M, INCLUDED; VWD2M, INCLUDED;; VON WILLEBRAND DISEASE, TYPE 2N, INCLUDED; VWD2N, INCLUDED
Asterisk__:__613555__:__TET ONCOGENE FAMILY, MEMBER 3; TET3__:__KIAA0401__:__
Asterisk__:__613556__:__MICRO RNA 659; MIR659__:__miRNA659;; MIRN659__:__
Caret__:__613557__:__MOVED TO 604213__:____:__
Number Sign__:__613558__:__DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51__:__CHROMOSOME 9q21.11 DUPLICATION SYNDROME__:__
Number Sign__:__613559__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7__:____:__
Asterisk__:__613560__:__N-TERMINAL X-PRO-LYS N-METHYLTRANSFERASE 1; NTMT1__:__METHYLTRANSFERASE-LIKE 11A; METTL11A;; N-TERMINAL RCC1 METHYLTRANSFERASE; NRMT;; RCC1 METHYLTRANSFERASE, N-TERMINAL;; C9ORF32__:__
Number Sign__:__613561__:__MYOPATHY, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA 2; MLASA2__:____:__
Asterisk__:__613562__:__Fc RECEPTOR-LIKE PROTEIN 6; FCRL6__:__FCRH6__:__
Number Sign__:__613563__:__NOONAN SYNDROME-LIKE DISORDER WITH OR WITHOUT JUVENILE MYELOMONOCYTIC LEUKEMIA; NSLL__:__CBL SYNDROME;; CBL MUTATION-ASSOCIATED SYNDROME__:__
Number Sign__:__613564__:__CHROMOSOME 2p12-p11.2 DELETION SYNDROME__:____:__
Asterisk__:__613565__:__UBIQUITINATION FACTOR E4B; UBE4B__:__UFD2, S. CEREVISIAE, HOMOLOG OF, A; UFD2A;; KIAA0684__:__
Number Sign__:__613566__:__FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 6; HBFQTL6__:__HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, KLF1-RELATED__:__
Asterisk__:__613567__:__ZINC FINGER, MYM-TYPE 6; ZMYM6__:__ZINC FINGER PROTEIN 258; ZNF258;; ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 7; ZBED7;; BUSTER2;; KIAA1353__:__
Asterisk__:__613568__:__ZINC FINGER, MYM-TYPE 4; ZMYM4__:__ZINC FINGER PROTEIN 262; ZNF262;; KIAA0425__:__CELL DEATH-INHIBITING RNA, INCLUDED; CDIR, INCLUDED
Asterisk__:__613569__:__SAD1 AND UNC84 DOMAIN-CONTAINING PROTEIN 2; SUN2__:__SUN DOMAIN-CONTAINING PROTEIN 2;; UNC84, C. ELEGANS, HOMOLOG OF, B; UNC84B;; KIAA0668__:__
Asterisk__:__613570__:__LIPID DROPLET ASSOCIATED HYDROLASE; LDAH__:__CHROMOSOME 2 OPEN READING FRAME 43; C2ORF43__:__
Number Sign__:__613571__:__DISORDERED STEROIDOGENESIS DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY__:__ADRENAL HYPERPLASIA, CONGENITAL, DUE TO CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY;; DISORDERED STEROIDOGENESIS DUE TO POR DEFICIENCY__:__
Asterisk__:__613572__:__G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 6, MEMBER A; GPRC6A__:____:__
Number Sign__:__613573__:__ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 1; EDSS1__:____:__
Asterisk__:__613574__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 39B; TTC39B__:____:__
Number Sign__:__613575__:__RETINITIS PIGMENTOSA 55; RP55__:____:__
Percent__:__613576__:__ECTODERMAL DYSPLASIA-SYNDACTYLY SYNDROME 2; EDSS2__:____:__
Asterisk__:__613577__:__TBC1 DOMAIN FAMILY, MEMBER 24; TBC1D24__:__KIAA1171__:__
Asterisk__:__613578__:__PROTEASE, SERINE, 3; PRSS3__:__TRYPSINOGEN 3; TRY3;; MESOTRYPSINOGEN;; T9__:__TRYPSIN 3, INCLUDED;; MESOTRYPSIN, INCLUDED;; TRYPSINOGEN 4, INCLUDED; TRY4, INCLUDED;; TRYPSIN 4, INCLUDED
Asterisk__:__613579__:__C-TYPE LECTIN DOMAIN FAMILY 6, MEMBER A; CLEC6A__:__DECTIN 2;; CLEC4N, MOUSE, HOMOLOG OF__:__
Asterisk__:__613580__:__WD REPEAT-CONTAINING PLANAR CELL POLARITY EFFECTOR; WDPCP__:__CHROMOSOME 2 OPEN READING FRAME 86; C2ORF86;; FRITZ, DROSOPHILA, HOMOLOG OF;; BBS15 GENE; BBS15__:__
Number Sign__:__613581__:__RETINITIS PIGMENTOSA 56; RP56__:____:__
Number Sign__:__613582__:__RETINITIS PIGMENTOSA 57; RP57__:____:__
Asterisk__:__613583__:__WD REPEAT-CONTAINING PROTEIN 62; WDR62__:__C19ORF14__:__
Asterisk__:__613584__:__ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER L2; ALDH1L2__:__10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE, MITOCHONDRIAL;; MITOCHONDRIAL 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE__:__
Asterisk__:__613585__:__TRANSMEMBRANE PROTEIN 147; TMEM147__:____:__
Asterisk__:__613586__:__NIN1/RPN12-BINDING PROTEIN 1, S. CEREVISIAE, HOMOLOG OF; NOB1__:____:__
Number Sign__:__613587__:__OCCULT MACULAR DYSTROPHY; OCMD__:__OMD__:__
Asterisk__:__613588__:__C-TYPE LECTIN DOMAIN FAMILY 3, MEMBER A; CLEC3A__:__LECTIN, C-TYPE, SUPERFAMILY MEMBER 1; CLECSF1__:__
Number Sign__:__613589__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6; LDLCQ6__:____:__
Asterisk__:__613590__:__BUTYROPHILIN, SUBFAMILY 2, MEMBER A1; BTN2A1__:__BT2.1;; BTF1__:__
Asterisk__:__613591__:__BUTYROPHILIN, SUBFAMILY 2, MEMBER A2; BTN2A2__:__BTF2;; BT2.2__:__
Asterisk__:__613592__:__BUTYROPHILIN, SUBFAMILY 2, MEMBER A3; BTN2A3__:____:__
Asterisk__:__613593__:__BUTYROPHILIN, SUBFAMILY 3, MEMBER A1; BTN3A1__:__BT3.1;; BTF5;; CD277__:__
Asterisk__:__613594__:__BUTYROPHILIN, SUBFAMILY 3, MEMBER A2; BTN3A2__:__BT3.2;; BTF4__:__
Asterisk__:__613595__:__BUTYROPHILIN, SUBFAMILY 3, MEMBER A3; BTN3A3__:__BTF3__:__
Asterisk__:__613596__:__FAMILY WITH SEQUENCE SIMILARITY 161, MEMBER A; FAM161A__:____:__
Asterisk__:__613597__:__4-HYDROXY-2-OXOGLUTARATE ALDOLASE 1; HOGA1__:__DIHYDRODIPICOLINATE SYNTHASE-LIKE, MITOCHONDRIAL; DHDPSL__:__
Asterisk__:__613598__:__ZINC FINGER PROTEIN 513; ZNF513__:____:__
Asterisk__:__613599__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12; ABHD12__:____:__
NULL__:__613600__:__TORSADE DE POINTES, SHORT-COUPLED VARIANT__:____:__
NULL__:__613601__:__EARLY REPOLARIZATION ASSOCIATED WITH VENTRICULAR FIBRILLATION__:__EARLY REPOLARIZATION SYNDROME__:__
Asterisk__:__613602__:__WD REPEAT-CONTAINING PROTEIN 35; WDR35__:__NAOFEN;; INTRAFLAGELLAR TRANSPORT 121, CHLAMYDOMONAS, HOMOLOG OF; IFT121;; KIAA1336__:__
Number Sign__:__613603__:__CHROMOSOME 4q32.1-q32.2 TRIPLICATION SYNDROME__:____:__
Number Sign__:__613604__:__CHROMOSOME 16p12.2-p11.2 DELETION SYNDROME, 7.1- TO 8.7-MB__:____:__
Asterisk__:__613605__:__BBS PROTEIN COMPLEX-INTERACTING PROTEIN 1; BBIP1__:__BBSOME-INTERACTING PROTEIN 1;; BBS PROTEIN COMPLEX-INTERACTING PROTEIN, 10-KD; BBIP10;; BBS18 GENE;; NONCODING RNA 81, FORMERLY; NCRNA00081, FORMERLY__:__
Percent__:__613606__:__FORSYTHE-WAKELING SYNDROME; FWS__:__MICROCEPHALY AND GROWTH RETARDATION WITH CHILDHOOD-ONSET NEPHROTIC SYNDROME AND THROMBOCYTOPENIA__:__
Asterisk__:__613607__:__THYMOCYTE SELECTION-ASSOCIATED PROTEIN; THEMIS__:__THYMOCYTE-EXPRESSED MOLECULE INVOLVED IN SELECTION;; THYMOCYTE SELECTION-ASSOCIATED PROTEIN FAMILY, MEMBER 1; THEMIS1;; GRB2-ASSOCIATED PROTEIN; GASP;; SIGNALING PHOSPHOPROTEIN SPECIFIC FOR T CELLS; SPOT;; CHROMOSOME 6 OPEN READING FRAME 190; C6ORF190__:__
Percent__:__613608__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 3; FAME3__:__CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 3; FCMTE3__:__
Asterisk__:__613609__:__HFE GENE; HFE__:__HLAH__:__
Number Sign__:__613610__:__CRANIOECTODERMAL DYSPLASIA 2; CED2__:____:__
Number Sign__:__613611__:__CHOANAL ATRESIA AND LYMPHEDEMA; CATLPH__:____:__
Number Sign__:__613612__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi; CDG2I__:__CDG IIi; CDGIIi__:__
Asterisk__:__613613__:__MICRO RNA 208B; MIR208B__:__miRNA208B;; MIRN208B__:__
Asterisk__:__613614__:__MICRO RNA 499; MIR499__:__miRNA499;; MIRN499__:__
Number Sign__:__613615__:__SENIOR-LOKEN SYNDROME 7; SLSN7__:____:__
Number Sign__:__613616__:__HYPEROXALURIA, PRIMARY, TYPE III; HP3__:____:__
Number Sign__:__613617__:__RETINITIS PIGMENTOSA 58; RP58__:____:__
Number Sign__:__613618__:__CHROMOSOME 17q23.1-q23.2 DUPLICATION SYNDROME__:____:__
Asterisk__:__613619__:__SCAVENGER RECEPTOR CLASS F, MEMBER 2; SCARF2__:__SCAVENGER RECEPTOR EXPRESSED BY ENDOTHELIAL CELLS 2; SREC2;; SREC II__:__
Asterisk__:__613620__:__TBC1 DOMAIN FAMILY, MEMBER 10B; TBC1D10B__:__RAB27AGAP-BETA__:__
Asterisk__:__613621__:__NUCLEOTIDE-BINDING PROTEIN-LIKE PROTEIN; NUBPL__:__IRON-SULFUR PROTEIN REQUIRED FOR NADH DEHYDROGENASE; IND1__:__
Asterisk__:__613622__:__FAD-DEPENDENT OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 1; FOXRED1__:____:__
NULL__:__613623__:__AGENESIS OF THE CORPUS CALLOSUM AND CONGENITAL LYMPHEDEMA__:____:__
Asterisk__:__613624__:__ZINC FINGER PROTEIN 592; ZNF592__:__KIAA0211__:__
Number Sign__:__613625__:__FACTOR V AND FACTOR VIII, COMBINED DEFICIENCY OF, 2; F5F8D2__:____:__
Caret__:__613626__:__MOVED TO 255500__:____:__
NULL__:__613627__:__BRACHYDACTYLY, TYPE A1, WITH SHORT STATURE, SCOLIOSIS, MICROCEPHALY, PTOSIS, HEARING LOSS, AND MENTAL RETARDATION__:__TSUKAHARA SYNDROME__:__
Percent__:__613628__:__ODONTOID HYPOPLASIA__:____:__
Asterisk__:__613629__:__PIEZO-TYPE MECHANOSENSITIVE ION CHANNEL COMPONENT 2; PIEZO2__:__FAMILY WITH SEQUENCE SIMILARITY 38, MEMBER B; FAM38B__:__
Number Sign__:__613630__:__COCOON SYNDROME__:__FETAL ENCASEMENT SYNDROME__:__
Asterisk__:__613631__:__WASH COMPLEX, SUBUNIT 2C; WASHC2C__:__FAMILY WITH SEQUENCE SIMILARITY 21, MEMBER C; FAM21C;; VACCINIA VIRUS PENETRATION FACTOR; VPEF;; KIAA0592__:__
Asterisk__:__613632__:__WASH COMPLEX, SUBUNIT 1; WASHC1__:__WAS PROTEIN FAMILY HOMOLOG 1; WASH1;; WASH__:__
Asterisk__:__613633__:__DENN/MADD DOMAIN-CONTAINING PROTEIN 1A; DENND1A__:__CONNECDENN;; CONNECDENN 1;; KIAA1608__:__
Asterisk__:__613634__:__DENN/MADD DOMAIN-CONTAINING PROTEIN 1C; DENND1C__:__CONNECDENN 3__:__
Asterisk__:__613635__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 1; EIF2AK1__:__HEME-REGULATED INHIBITOR; HRI__:__
Percent__:__613636__:__TUBERCULIN SKIN TEST REACTIVITY, ABSENCE OF__:__TST REACTIVITY, ABSENCE OF;; TST1__:__
Percent__:__613637__:__TUBERCULIN SKIN TEST REACTIVITY QUANTITATIVE TRAIT LOCUS__:__TST REACTIVITY QUANTITATIVE TRAIT LOCUS;; TST2__:__
Number Sign__:__613638__:__CHROMOSOME 19p13.13 DELETION SYNDROME__:____:__CHROMOSOME 19p13.13 DUPLICATION SYNDROME, INCLUDED
Asterisk__:__613639__:__ADHESION G PROTEIN-COUPLED RECEPTOR D1; ADGRD1__:__G PROTEIN-COUPLED RECEPTOR 133; GPR133;; PGR25__:__
Number Sign__:__613640__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE IC; HSAN1C__:__HSAN IC;; NEUROPATHY, HEREDITARY SENSORY, TYPE IC; HSN1C;; HSN IC__:__
Number Sign__:__613641__:__CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB__:__CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE B; RI-CMTB__:__
Number Sign__:__613642__:__CARDIOMYOPATHY, DILATED, 1GG; CMD1GG__:____:__
Number Sign__:__613643__:__PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK5__:____:__
Asterisk__:__613644__:__ACTIVATING TRANSCRIPTION FACTOR 7-INTERACTING PROTEIN; ATF7IP__:__ATF7-INTERACTING PROTEIN;; ATFA MODULATOR, MOUSE, HOMOLOG OF; AM;; MBD1-CONTAINING CHROMATIN-ASSOCIATED FACTOR; MCAF;; MCAF1__:__
Asterisk__:__613645__:__ACTIVATING TRANSCRIPTION FACTOR 7-INTERACTING PROTEIN 2; ATF7IP2__:__ATF7-INTERACTING PROTEIN 2;; MBD1-CONTAINING CHROMATIN-ASSOCIATED FACTOR 2; MCAF2__:__
Number Sign__:__613646__:__METHYLMALONIC ACIDURIA, TRANSIENT, DUE TO TRANSCOBALAMIN RECEPTOR DEFECT__:__METHYLMALONIC ACIDEMIA, TCblR TYPE__:__
Number Sign__:__613647__:__SPASTIC PARAPLEGIA 48, AUTOSOMAL RECESSIVE; SPG48__:____:__
Asterisk__:__613648__:__MATERNALLY EXPRESSED GENE 8; MEG8__:____:__
Asterisk__:__613649__:__SMALL NUCLEOLAR RNA, C/D BOX, 112; SNORD112__:__snoRNA 14q(0)__:__
Asterisk__:__613650__:__SMALL NUCLEOLAR RNA, C/D BOX, 113-1; SNORD113-1__:__snoRNA 14q(I-1)__:__
Asterisk__:__613651__:__SMALL NUCLEOLAR RNA, C/D BOX, 114-1; SNORD114-1__:__snoRNA 14q(II-1)__:__
Number Sign__:__613652__:__C1q DEFICIENCY; C1QD__:____:__
Asterisk__:__613653__:__ADAPTOR-RELATED PROTEIN COMPLEX 5, ZETA-1 SUBUNIT; AP5Z1__:__KIAA0415;; SPG48 GENE__:__
Asterisk__:__613654__:__MICRO RNA 380; MIR380__:__miRNA380;; MIRN380;; MIR380-3p__:__MICRO RNA 380*, INCLUDED; MIR380*, INCLUDED;; MIR380-5p, INCLUDED
Asterisk__:__613655__:__POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 18; KCNK18__:__TWIK-RELATED SPINAL CORD K+ CHANNEL; TRESK;; TWIK-RELATED INDIVIDUAL K+ CHANNEL; TRIK__:__
Number Sign__:__613656__:__MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 13; MGR13__:____:__
Number Sign__:__613657__:__D-2-HYDROXYGLUTARIC ACIDURIA 2; D2HGA2__:____:__
Percent__:__613658__:__RAJAB SYNDROME__:__DEVELOPMENTAL DELAY, SMALL STATURE, MICROCEPHALY, AND BRAIN CALCIFICATIONS__:__
Number Sign__:__613659__:__GASTRIC CANCER__:____:__GASTRIC CANCER, INTESTINAL, INCLUDED
Number Sign__:__613660__:__CONE-ROD DYSTROPHY 15; CORD15__:____:__RETINITIS PIGMENTOSA 65, INCLUDED; RP65, INCLUDED
Number Sign__:__613661__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip; CDG1P__:____:__
Number Sign__:__613662__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 4B (MNGIE TYPE); MTDPS4B__:__MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOPATHY SYNDROME, POLG-RELATED;; MNGIE, POLG-RELATED__:__
Asterisk__:__613663__:__SHQ1, S. CEREVISIAE, HOMOLOG OF; SHQ1__:____:__
Asterisk__:__613664__:__SMOOTHELIN-LIKE 1; SMTNL1__:__CALPONIN HOMOLOGY-ASSOCIATED SMOOTH MUSCLE PROTEIN; CHASM__:__
Asterisk__:__613665__:__ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1__:__DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES; DARC;; DUFFY CHEMOKINE RECEPTOR;; FY GLYCOPROTEIN;; GLYCOPROTEIN D; GPD__:__
Asterisk__:__613666__:__ALG11, S. CEREVISIAE, HOMOLOG OF; ALG11__:__ASPARAGINE-LINKED GLYCOSYLATION 11, S. CEREVISIAE, HOMOLOG OF;; KIAA0266__:__
Asterisk__:__613667__:__SINE OCULIS-BINDING PROTEIN, DROSOPHILA, HOMOLOG OF; SOBP__:__JACKSON CIRCLER PROTEIN 1, MOUSE, HOMOLOG OF; JXC1__:__
Number Sign__:__613668__:__MICROCEPHALY, POSTNATAL PROGRESSIVE, WITH SEIZURES AND BRAIN ATROPHY__:____:__
Asterisk__:__613669__:__MITOCHONDRIAL POLY(A) POLYMERASE; MTPAP__:__POLY(A) POLYMERASE, MITOCHONDRIAL;; POLY(A) POLYMERASE-ASSOCIATED DOMAIN-CONTAINING PROTEIN 1; PAPD1;; PAP-ASSOCIATED DOMAIN-CONTAINING PROTEIN 1__:__
Number Sign__:__613670__:__MENTAL RETARDATION WITH LANGUAGE IMPAIRMENT AND WITH OR WITHOUT AUTISTIC FEATURES__:____:__
Number Sign__:__613671__:__MENTAL RETARDATION, ANTERIOR MAXILLARY PROTRUSION, AND STRABISMUS; MRAMS__:____:__
Number Sign__:__613672__:__SPASTIC ATAXIA 4, AUTOSOMAL RECESSIVE; SPAX4__:____:__
Number Sign__:__613673__:__ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IV; CDAN4__:__CDA, TYPE IV__:__
Number Sign__:__613674__:__VESICOURETERAL REFLUX 3; VUR3__:____:__
Number Sign__:__613675__:__CHROMOSOME 17q11.2 DELETION SYNDROME, 1.4-MB__:__NEUROFIBROMATOSIS 1 MICRODELETION SYNDROME;; NF1 MICRODELETION SYNDROME;; VAN ASPEREN SYNDROME__:__NF1 MICRODUPLICATION SYNDROME, INCLUDED
Number Sign__:__613676__:__SECKEL SYNDROME 4; SCKL4__:____:__
Number Sign__:__613677__:__HYPERALDOSTERONISM, FAMILIAL, TYPE III; HALD3__:__FH III__:__
Percent__:__613678__:__BRACHYOLMIA TYPE 2; BCYM2__:__BRACHYOLMIA, MAROTEAUX TYPE__:__
Number Sign__:__613679__:__PROTHROMBIN DEFICIENCY, CONGENITAL__:__HYPOPROTHROMBINEMIA__:__DYSPROTHROMBINEMIA, INCLUDED
Number Sign__:__613680__:__BEAULIEU-BOYCOTT-INNES SYNDROME; BBIS__:__MICROCEPHALY, MENTAL RETARDATION, AND DISTINCTIVE FACIES, WITH CARDIAC AND GENITOURINARY MALFORMATIONS__:__
Number Sign__:__613681__:__CHROMOSOME 2q31.1 DUPLICATION SYNDROME__:__MESOMELIC DYSPLASIA, 2q31.1 DUPLICATION-RELATED__:__
Asterisk__:__613682__:__MICRO RNA 130B; MIR130B__:__miRNA130B;; MIRN130B__:__
Asterisk__:__613683__:__SOLUTE CARRIER FAMILY 50 (SUGAR TRANSPORTER), MEMBER 1; SLC50A1__:__RAG1-ACTIVATING PROTEIN 1; RAG1AP1;; SUGAR EFFLUX TRANSPORTER 1; SWEET1__:__
Number Sign__:__613684__:__RUBINSTEIN-TAYBI SYNDROME 2; RSTS2__:____:__
Percent__:__613685__:__DEAFNESS, AUTOSOMAL RECESSIVE 83; DFNB83__:____:__
Number Sign__:__613686__:__SPONDYLOCOSTAL DYSOSTOSIS 4, AUTOSOMAL RECESSIVE; SCDO4__:____:__
Asterisk__:__613687__:__PARP1-BINDING PROTEIN; PARPBP__:__ANTISENSE RNA OVERLAPPING MCH; AROM;; CHROMOSOME 12 OPEN READING FRAME 48; C12ORF48__:__
Number Sign__:__613688__:__LONG QT SYNDROME 2; LQT2__:____:__LONG QT SYNDROME 2, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED;; LONG QT SYNDROME 1/2, DIGENIC, INCLUDED; LQT1/2, DIGENIC, INCLUDED;; LONG QT SYNDROME 2/3, DIGENIC, INCLUDED; LQT2/3, DIGENIC, INCLUDED;; LONG QT SYNDROME 2/5, DIGENIC, INCLUDED; LQT2/5, DIGENIC, INCLUDED;; LONG QT SYNDROME 2/9, DIGENIC, INCLUDED; LQT2/9, DIGENIC, INCLUDED
Percent__:__613689__:__MAMMARY-DIGITAL-NAIL SYNDROME; MDNS__:____:__
Number Sign__:__613690__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 7; CMH7__:____:__
Asterisk__:__613691__:__GRAM DOMAIN-CONTAINING PROTEIN 4; GRAMD4__:__DEATH-INDUCING PROTEIN; DIP;; KIAA0767__:__
Asterisk__:__613692__:__ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 11; ZCCHC11__:__KIAA0191;; TERMINAL URIDYLTRANSFERASE 4; TUT4__:__
Number Sign__:__613693__:__LONG QT SYNDROME 6; LQT6__:____:__LONG QT SYNDROME 6, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED;; LONG QT SYNDROME 3/6, DIGENIC, INCLUDED; LQT3/6, DIGENIC, INCLUDED
Number Sign__:__613694__:__CARDIOMYOPATHY, DILATED, 1U; CMD1U__:____:__
Number Sign__:__613695__:__LONG QT SYNDROME 5; LQT5__:____:__LONG QT SYNDROME 5, ACQUIRED, SUSCEPTIBILITY TO, INCLUDED;; LONG QT SYNDROME 2/5, DIGENIC, INCLUDED; LQT2/5, DIGENIC, INCLUDED
Asterisk__:__613696__:__UPSTREAM BINDING TRANSCRIPTION FACTOR (RNA POLYMERASE I)-LIKE 1; UBTFL1__:__HMG-BOX PROTEIN, PREIMPLANTATION STAGE-SPECIFIC; HMGPI;; UBTF-LIKE 1__:__
Number Sign__:__613697__:__CARDIOMYOPATHY, DILATED, 1V; CMD1V__:____:__
Asterisk__:__613698__:__SOLUTE CARRIER FAMILY 25 (CARNITINE/ACYLCARNITINE TRANSLOCASE), MEMBER 20; SLC25A20__:__CARNITINE-ACYLCARNITINE TRANSLOCASE; CACT;; CARNITINE-ACYLCARNITINE CARRIER; CAC__:__
Asterisk__:__613699__:__GLYCOSYLTRANSFERASE 6 DOMAIN-CONTAINING 1; GLT6D1__:__GT6M7;; GLTDC1__:__
Number Sign__:__613700__:__SUPERNUMERARY DER(22)t(8;22) SYNDROME__:____:__
Asterisk__:__613701__:__MICRO RNA 328; MIR328__:__miRNA328;; MIRN328__:__
Number Sign__:__613702__:__KLIPPEL-FEIL SYNDROME 3, AUTOSOMAL DOMINANT; KFS3__:____:__
Number Sign__:__613703__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 6; MCOPCB6__:____:__
Number Sign__:__613704__:__MICROPHTHALMIA, ISOLATED 7; MCOP7__:____:__
Number Sign__:__613705__:__OROFACIAL CLEFT 10; OFC10__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 10__:__
Number Sign__:__613706__:__NOONAN SYNDROME 7; NS7__:____:__
Number Sign__:__613707__:__LEOPARD SYNDROME 3; LPRD3__:____:__
Number Sign__:__613708__:__NEUROPATHY, HEREDITARY SENSORY, TYPE ID; HSN1D__:____:__
Asterisk__:__613709__:__EUKARYOTIC TRANSLATION INITIATION FACTOR 2D; EIF2D__:__HEPATOCELLULAR CARCINOMA-ASSOCIATED ANTIGEN 56; HCA56;; LIGATIN, FORMERLY; LGTN, FORMERLY__:__
Number Sign__:__613710__:__THIAMINE METABOLISM DYSFUNCTION SYNDROME 4 (BILATERAL STRIATAL DEGENERATION AND PROGRESSIVE POLYNEUROPATHY TYPE); THMD4__:__BILATERAL STRIATAL DEGENERATION AND PROGRESSIVE POLYNEUROPATHY;; STRIATAL NECROSIS, BILATERAL, AND PROGRESSIVE POLYNEUROPATHY__:__
Number Sign__:__613711__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 3; HSCR3__:____:__
Number Sign__:__613712__:__HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 4; HSCR4__:____:__
Asterisk__:__613713__:__PCI DOMAIN-CONTAINING PROTEIN 2; PCID2__:____:__
Asterisk__:__613714__:__B7 HOMOLOG 6__:__B7H6__:__
Asterisk__:__613715__:__POLYMERASE I, RNA, SUBUNIT D; POLR1D__:__RNA POLYMERASE A, 16-KD, MOUSE, HOMOLOG OF; RPA16;; RPAC2__:__
Asterisk__:__613716__:__MICRO RNA 661; MIR661__:__miRNA661;; MIRN661__:__
Number Sign__:__613717__:__TREACHER COLLINS SYNDROME 2; TCS2__:____:__
Number Sign__:__613718__:__DEAFNESS, AUTOSOMAL RECESSIVE 74; DFNB74__:____:__
Asterisk__:__613719__:__METHIONINE SULFOXIDE REDUCTASE B3; MSRB3__:____:__
Number Sign__:__613720__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 7; EIEE7__:____:__
Number Sign__:__613721__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 11; EIEE11__:____:__
Number Sign__:__613722__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 12; EIEE12__:____:__
Number Sign__:__613723__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 17; LGMDR17__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Q; LGMD2Q__:__
Number Sign__:__613724__:__LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN__:__STEROL CARRIER PROTEIN 2 DEFICIENCY__:__
Asterisk__:__613725__:__SOLUTE CARRIER FAMILY 25, MEMBER 17; SLC25A27__:__UNCOUPLING PROTEIN 4; UCP4__:__
Asterisk__:__613726__:__ANOCTAMIN 10; ANO10__:__TRANSMEMBRANE PROTEIN 16K; TMEM16K__:__
Asterisk__:__613727__:__KELCH REPEAT- AND BTB/POZ DOMAIN-CONTAINING PROTEIN 13; KBTBD13__:____:__
Number Sign__:__613728__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 10; SCAR10__:____:__
Number Sign__:__613729__:__CHROMOSOME 7q11.23 DELETION SYNDROME, DISTAL, 1.2-MB__:__DISTAL CHROMOSOME 7q11.23 DELETION SYNDROME__:__
Number Sign__:__613730__:__HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION, AND CATARACTS; HDBSCC__:____:__
Number Sign__:__613731__:__RETINITIS PIGMENTOSA 4; RP4__:__RETINITIS PIGMENTOSA, RHODOPSIN-RELATED__:__
Caret__:__613732__:__MOVED TO 256040__:____:__
Asterisk__:__613733__:__MEN1 GENE; MEN1__:__MENIN__:__
Asterisk__:__613734__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 115; CCDC115__:__COILED-COIL PROTEIN 1; CCP1__:__
Number Sign__:__613735__:__BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS; BRMUTD__:____:__CHROMOSOME 1p32-p31 DELETION SYNDROME, INCLUDED
Number Sign__:__613736__:__ACNE INVERSA, FAMILIAL, 2, WITH OR WITHOUT DOWLING-DEGOS DISEASE; ACNINV2__:____:__
Number Sign__:__613737__:__ACNE INVERSA, FAMILIAL, 3; ACNINV3__:____:__
Asterisk__:__613738__:__ALKYLGLYCEROL MONOOXYGENASE; AGMO__:__GLYCERYL-ETHER MONOOXYGENASE;; TRANSMEMBRANE PROTEIN 195: TMEM195__:__
Asterisk__:__613739__:__THYMOCYTE NUCLEAR PROTEIN 1; THYN1__:__HEMATOPOIETIC STEM/PROGENITOR CELL-EXPRESSED GENE 144; HSPC144;; THY28, CHICKEN, HOMOLOG OF; THY28__:__
Caret__:__613740__:__MOVED TO 115200__:____:__
Asterisk__:__613741__:__GLYCOGEN PHOSPHORYLASE, LIVER; PYGL__:__LGP__:__
Asterisk__:__613742__:__GLUCOSE-6-PHOSPHATASE, CATALYTIC; G6PC__:__GLUCOSE-6-PHOSPHATASE, CATALYTIC, 1; G6PC1;; G6PT, FORMERLY__:__
Number Sign__:__613743__:__ADRENAL INSUFFICIENCY, CONGENITAL, WITH 46,XY SEX REVERSAL, PARTIAL OR COMPLETE__:__P450scc DEFICIENCY__:__
Number Sign__:__613744__:__SPASTIC PARAPLEGIA 51, AUTOSOMAL RECESSIVE; SPG51__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 4, FORMERLY; CPSQ4, FORMERLY__:__
Asterisk__:__613745__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 10; ANAPC10__:__APC10;; DOC1, S. CEREVISIAE, HOMOLOG OF; DOC1__:__
Asterisk__:__613746__:__BREAST CANCER ANTIESTROGEN RESISTANCE 4; BCAR4__:____:__
Asterisk__:__613747__:__KINESIN FAMILY MEMBER 24; KIF24__:____:__
Asterisk__:__613748__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 3; CHCHD3__:__MITOCHONDRIAL INNER MEMBRANE ORGANIZING SYSTEM PROTEIN 3; MINOS3 MICOS PROTEIN 3;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 19-KD SUBUNIT; MIC19;; MICOS COMPLEX, 19-KD SUBUNIT__:__
Asterisk__:__613749__:__ZINC FINGER PROTEIN 260; ZNF260__:__ZFP260;; PHENYLEPHRINE RESPONSE ELEMENT COMPLEX 1, RAT, HOMOLOG OF; PEX1__:__
Number Sign__:__613750__:__RETINITIS PIGMENTOSA 27; RP27__:____:__RETINAL DEGENERATION, AUTOSOMAL RECESSIVE, CLUMPED PIGMENT TYPE, INCLUDED
Number Sign__:__613751__:__HETEROTAXY, VISCERAL, 4, AUTOSOMAL; HTX4__:____:__
Number Sign__:__613752__:__HYPERMETHIONINEMIA WITH S-ADENOSYLHOMOCYSTEINE HYDROLASE DEFICIENCY__:____:__
Asterisk__:__613753__:__MICRO RNA 211; MIR211__:__miRNA211;; MIRN211__:__
Asterisk__:__613754__:__RING FINGER PROTEIN 187; RNF187__:__RING DOMAIN AP1 COACTIVATOR 1; RACO1__:__
Asterisk__:__613755__:__MICRO RNA 326; MIR326__:__miRNA326;; MIRN326__:__
Number Sign__:__613756__:__RETINITIS PIGMENTOSA 49; RP49__:____:__
Number Sign__:__613757__:__MACULAR DEGENERATION, AGE-RELATED, 6; ARMD6__:____:__
Number Sign__:__613758__:__RETINITIS PIGMENTOSA 47; RP47__:____:__
Number Sign__:__613759__:__INFECTIONS, RECURRENT, WITH ENCEPHALOPATHY, HEPATIC DYSFUNCTION, AND CARDIOVASCULAR MALFORMATIONS__:__FADD DEFICIENCY__:__
Asterisk__:__613760__:__SOLUTE CARRIER FAMILY 36, MEMBER 4; SLC36A4__:__PROTON/AMINO ACID TRANSPORTER 4; PAT4__:__
Number Sign__:__613761__:__MACULAR DEGENERATION, AGE-RELATED, 5; ARMD5__:____:__
Number Sign__:__613762__:__46,XY SEX REVERSAL 6; SRXY6__:__46,XY SEX REVERSAL, PARTIAL OR COMPLETE, MAP3K1-RELATED;; 46,XY GONADAL DYSGENESIS, PARTIAL OR COMPLETE, MAP3K1-RELATED__:__
Number Sign__:__613763__:__CATARACT 16, MULTIPLE TYPES; CTRCT16__:__CATARACT, POSTERIOR POLAR, 2; CTPP2;; CATARACT, CONGENITAL LAMELLAR__:__
Asterisk__:__613764__:__SECRETORY CARRIER MEMBRANE PROTEIN 4; SCAMP4__:____:__
Number Sign__:__613765__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 9; CMH9__:____:__
Asterisk__:__613766__:__SECRETORY CARRIER MEMBRANE PROTEIN 5; SCAMP5__:____:__
Number Sign__:__613767__:__RETINITIS PIGMENTOSA 45; RP45__:____:__
Asterisk__:__613768__:__RING FINGER PROTEIN 213; RNF213__:__ALK LYMPHOMA OLIGOMERIZATION PARTNER ON CHROMOSOME 17; ALO17;; KIAA1618__:__RNF213/ALK FUSION GENE, INCLUDED
Number Sign__:__613769__:__RETINITIS PIGMENTOSA 44; RP44__:____:__
Asterisk__:__613770__:__PLACENTA-SPECIFIC GENE 4; PLAC4__:____:__
Asterisk__:__613771__:__TRANSMEMBRANE PROTEIN 205; TMEM205__:____:__
Asterisk__:__613772__:__KELCH-LIKE 14; KLHL14__:__PROTEIN INTERACTOR OF TORSIN A; PRINTOR;; KIAA1384__:__
Asterisk__:__613773__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 9B; IGSF9B__:__KIAA1030__:__
Asterisk__:__613774__:__CALMODULIN-REGULATED SPECTRIN-ASSOCIATED PROTEIN 1; CAMSAP1__:____:__
Asterisk__:__613775__:__CALMODULIN-REGULATED SPECTRIN-ASSOCIATED PROTEIN 2; CAMSAP2__:__CALMODULIN-REGULATED SPECTRIN-ASSOCIATED PROTEIN 1-LIKE 1; CAMSAP1L1;; CAMSAP1-LIKE 1;; KIAA1078__:__
Number Sign__:__613776__:__CHROMOSOME 17p13.1 DELETION SYNDROME__:____:__
Asterisk__:__613777__:__FAD-DEPENDENT OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 2; FOXRED2__:__ENDOPLASMIC RETICULUM FLAVOPROTEIN ASSOCIATED WITH DEGRADATION; ERFAD__:__
Number Sign__:__613778__:__MACULAR DEGENERATION, AGE-RELATED, 8; ARMD8__:____:__
Number Sign__:__613779__:__COMPLEMENT COMPONENT 3 DEFICIENCY, AUTOSOMAL RECESSIVE; C3D__:__C3 DEFICIENCY, AUTOSOMAL RECESSIVE__:__
Number Sign__:__613780__:__AORTIC ANEURYSM, FAMILIAL THORACIC 7; AAT7__:__AORTIC DISSECTION, FAMILIAL, WITH OR WITHOUT AORTIC ANEURYSM__:__
Asterisk__:__613781__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 125; CCDC125__:__KENAE__:__
Asterisk__:__613782__:__METHIONINE SULFOXIDE REDUCTASE B2; MSRB2__:__CBS1__:__
Number Sign__:__613783__:__COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD__:__C1s DEFICIENCY__:__
Number Sign__:__613784__:__MACULAR DEGENERATION, AGE-RELATED, 12; ARMD12__:____:__
Asterisk__:__613785__:__COMPLEMENT COMPONENT 1, r SUBCOMPONENT; C1R__:__COMPLEMENT COMPONENT C1r__:__
Asterisk__:__613786__:__MICRO RNA 148A; MIR148A__:__miRNA148A;; MIRN148A__:__
Asterisk__:__613787__:__MICRO RNA 148B; MIR148B__:__miRNA148B;; MIRN148B__:__
Asterisk__:__613788__:__MICRO RNA 152; MIR152__:__miRNA152;; MIRN152__:__
Number Sign__:__613789__:__COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE II; C8D2__:__C8 DEFICIENCY, TYPE II;; COMPLEMENT COMPONENT 8B DEFICIENCY;; C8 BETA DEFICIENCY;; C8B DEFICIENCY__:__
Number Sign__:__613790__:__COMPLEMENT COMPONENT 8 DEFICIENCY, TYPE I; C8D1__:__C8 DEFICIENCY, TYPE I;; C8 ALPHA-GAMMA DEFICIENCY;; C8AG DEFICIENCY__:__
Number Sign__:__613791__:__MASP2 DEFICIENCY__:__LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 2; LCAPD2__:__
Number Sign__:__613792__:__CHROMOSOME 3pter-p25 DELETION SYNDROME__:__3p- SYNDROME__:__
Number Sign__:__613793__:__BLOOD GROUP, CROMER SYSTEM; CROM__:__CROMER BLOOD GROUP SYSTEM__:__
Number Sign__:__613794__:__RETINITIS PIGMENTOSA 20; RP20__:____:__
Number Sign__:__613795__:__LOEYS-DIETZ SYNDROME 3; LDS3__:__ANEURYSMS-OSTEOARTHRITIS SYNDROME;; LOEYS-DIETZ SYNDROME WITH OSTEOARTHRITIS;; LOEYS-DIETZ SYNDROME, TYPE 1C, FORMERLY; LDS1C, FORMERLY__:__
Number Sign__:__613796__:__IMMUNODEFICIENCY 31B; IMD31B__:__IMMUNODEFICIENCY 31B, MYCOBACTERIAL AND VIRAL INFECTIONS, AUTOSOMAL RECESSIVE;; STAT1 DEFICIENCY, AUTOSOMAL RECESSIVE__:__
Asterisk__:__613797__:__PROTEASE, SERINE, 33; PRSS33__:__EOS__:__
Asterisk__:__613798__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 39; CCDC39__:____:__
Asterisk__:__613799__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 40; CCDC40__:__KIAA1640__:__
Number Sign__:__613800__:__MEIER-GORLIN SYNDROME 2; MGORS2__:____:__
Number Sign__:__613801__:__RETINITIS PIGMENTOSA 40; RP40__:____:__
Asterisk__:__613802__:__MALECTIN; MLEC__:__KIAA0152__:__
Number Sign__:__613803__:__MEIER-GORLIN SYNDROME 3; MGORS3__:____:__
Number Sign__:__613804__:__MEIER-GORLIN SYNDROME 4; MGORS4__:____:__
Number Sign__:__613805__:__MEIER-GORLIN SYNDROME 5; MGORS5__:____:__
Percent__:__613806__:__CHOLANGITIS, PRIMARY SCLEROSING; PSC__:____:__
Number Sign__:__613807__:__CILIARY DYSKINESIA, PRIMARY, 14; CILD14__:__CILIARY DYSKINESIA, PRIMARY, 14, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__613808__:__CILIARY DYSKINESIA, PRIMARY, 15; CILD15__:__CILIARY DYSKINESIA, PRIMARY, 15, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__613809__:__RETINITIS PIGMENTOSA 39; RP39__:____:__
Number Sign__:__613810__:__RETINITIS PIGMENTOSA 43; RP43__:____:__
Number Sign__:__613811__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2D; PCH2D__:__CEREBELLOCEREBRAL ATROPHY, PROGRESSIVE; PCCA__:__
Number Sign__:__613812__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 3; CBAS3__:____:__
Asterisk__:__613813__:__MOUSE DOUBLE MINUTE 1 HOMOLOG; MDM1__:____:__
Asterisk__:__613814__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 19; TTC19__:____:__
Asterisk__:__613815__:__CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2__:__CYTOCHROME P450, SUBFAMILY XXIA, POLYPEPTIDE 2;; CYTOCHROME P450, SUBFAMILY XXI; CYP21;; STEROID CYTOCHROME P450 21-HYDROXYLASE; P450C21;; 21-HYDROXYLASE B; CYP21B;; CA21H__:__CYTOCHROME P450, SUBFAMILY XXIA, POLYPEPTIDE 1 PSEUDOGENE, INCLUDED; CYP21A1P, INCLUDED;; CYP21P, INCLUDED; CYP21A, INCLUDED
Asterisk__:__613816__:__UBIQUITIN PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 7; UBR7__:____:__
Asterisk__:__613817__:__SPERMATOGENESIS-ASSOCIATED SERINE-RICH PROTEIN 2-LIKE; SPATS2L__:__SPATS2-LIKE;; STRESS GRANULE AND NUCLEOLAR PROTEIN; SGNP__:__
Number Sign__:__613818__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 9; MDDGC9__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 16; LGMDR16;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2P; LGMD2P;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DAG1-RELATED__:__
Number Sign__:__613819__:__SHORT-RIB THORACIC DYSPLASIA 4 WITH OR WITHOUT POLYDACTYLY; SRTD4__:__ASPHYXIATING THORACIC DYSTROPHY 4; ATD4__:__
Number Sign__:__613820__:__NEPHRONOPHTHISIS 12; NPHP12__:____:__JOUBERT SYNDROME 11, INCLUDED; JBTS11, INCLUDED
Asterisk__:__613821__:__PROTEIN PHOSPHATASE 3, REGULATORY SUBUNIT B, BETA; PPP3R2__:__PROTEIN PHOSPHATASE 2B, REGULATORY SUBUNIT BETA-2;; PPP3R1-LIKE: PPP3RL;; CALCINEURIN B-LIKE PROTEIN; CBLP__:__
Asterisk__:__613822__:__PROTEIN PHOSPHATASE 4, REGULATORY SUBUNIT 2; PPP4R2__:__PP4R2__:__
Number Sign__:__613823__:__SECKEL SYNDROME 5; SCKL5__:____:__
Number Sign__:__613824__:__NEPHRONOPHTHISIS 9; NPHP9__:____:__
Number Sign__:__613825__:__COMPLEMENT COMPONENT 9 DEFICIENCY; C9D__:__C9 DEFICIENCY__:__
Number Sign__:__613826__:__LEBER CONGENITAL AMAUROSIS 6; LCA6__:____:__
Number Sign__:__613827__:__RETINITIS PIGMENTOSA 48; RP48__:____:__
Percent__:__613828__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 8; GEFSP8__:__GEFS+, TYPE 8; GEFS+8__:__
Number Sign__:__613829__:__LEBER CONGENITAL AMAUROSIS 7; LCA7__:____:__
Number Sign__:__613830__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1D; CSNB1D__:__CSNB, COMPLETE, AUTOSOMAL RECESSIVE__:__
Asterisk__:__613831__:__UBIQUITIN PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 3; UBR3__:____:__
Caret__:__613832__:__MOVED TO {607459}__:____:__
Asterisk__:__613833__:__KAT8 REGULATORY NSL COMPLEX SUBUNIT 1-LIKE PROTEIN; KANSL1L__:__KANSL1-LIKE PROTEIN;; CHROMOSOME 2 OPEN READING FRAME 67; C2ORF67;; MSL1V2__:__
Number Sign__:__613834__:__MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME__:__MYDRIASIS, CONGENITAL, WITH PATENT DUCTUS ARTERIOSUS, THORACIC AORTIC ANEURYSM, AND VASCULOPATHY__:__
Number Sign__:__613835__:__LEBER CONGENITAL AMAUROSIS 8; LCA8__:____:__
Percent__:__613836__:__ADIPONECTIN, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 5; ADIPQTL5__:____:__
Number Sign__:__613837__:__LEBER CONGENITAL AMAUROSIS 11; LCA11__:____:__
Number Sign__:__613838__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 16; CMH16__:____:__
Number Sign__:__613839__:__MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY__:__DHFR DEFICIENCY__:__
Asterisk__:__613840__:__ZINC FINGER PROTEIN 304; ZNF304__:____:__
Asterisk__:__613841__:__UBINUCLEIN 2; UBN2__:____:__
Asterisk__:__613842__:__GDNF-INDUCIBLE ZINC FINGER PROTEIN 1; GZF1__:__ZINC FINGER PROTEIN 336; ZNF336__:__
Number Sign__:__613843__:__LEBER CONGENITAL AMAUROSIS 15; LCA15__:____:__RETINITIS PIGMENTOSA, JUVENILE, TULP1-RELATED, INCLUDED
Asterisk__:__613844__:__UBIQUINOL-CYTOCHROME C REDUCTASE HINGE PROTEIN; UQCRH__:__HINGE PROTEIN, MITOCHONDRIAL__:__UQCRH/EWS FUSION GENE, INCLUDED;; UQCRH/ZSG FUSION GENE, INCLUDED
Number Sign__:__613845__:__HYPERURICEMIA, PULMONARY HYPERTENSION, RENAL FAILURE, AND ALKALOSIS SYNDROME; HUPRAS__:__HUPRA SYNDROME__:__
Asterisk__:__613846__:__TECTONIC FAMILY, MEMBER 2; TCTN2__:__TECTONIC 2; TECT2__:__
Asterisk__:__613847__:__TECTONIC FAMILY, MEMBER 3; TCTN3__:__TECTONIC 3; TECT3;; CHROMOSOME 10 OPEN READING FRAME 61; C10ORF61__:__
Number Sign__:__613848__:__OSTEOGENESIS IMPERFECTA, TYPE X; OI10__:__OI, TYPE X__:__
Number Sign__:__613849__:__OSTEOGENESIS IMPERFECTA, TYPE XII; OI12__:__OI, TYPE XII__:__
Number Sign__:__613850__:__INOSINE TRIPHOSPHATASE DEFICIENCY__:__INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE DEFICIENCY__:__
Asterisk__:__613851__:__PROLINE-RICH MEMBRANE ANCHOR 1; PRIMA1__:__PRIMA__:__
Number Sign__:__613852__:__FUCOSYLTRANSFERASE 6 DEFICIENCY__:____:__
Caret__:__613853__:__MOVED TO 605376__:____:__
Number Sign__:__613854__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 6; CHTD6__:__TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 3, FORMERLY; DTGA3, FORMERLY__:__
Number Sign__:__613855__:__EPISODIC ATAXIA, TYPE 5; EA5__:____:__
Number Sign__:__613856__:__ACHROMATOPSIA 4; ACHM4__:____:__
Percent__:__613857__:__OROFACIAL CLEFT 13; OFC13__:____:__
Asterisk__:__613858__:__PROTEASE, SERINE, 56; PRSS56__:____:__
Asterisk__:__613859__:__UROMODULIN-LIKE 1; UMODL1__:____:__
Number Sign__:__613860__:__FICOLIN 3 DEFICIENCY__:__FCN3 DEFICIENCY;; LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 3; LCAPD3__:__
Number Sign__:__613861__:__RETINITIS PIGMENTOSA 59; RP59__:____:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ibb, INCLUDED; CDG1BB, INCLUDED
Number Sign__:__613862__:__RETINITIS PIGMENTOSA 38; RP38__:__ROD-CONE DYSTROPHY, CHILDHOOD-ONSET__:__
Number Sign__:__613863__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7; GEFSP7__:__GEFS+, TYPE 7; GEFS+7__:__FEBRILE SEIZURES, FAMILIAL, 3B, INCLUDED; FEB3B, INCLUDED
Asterisk__:__613864__:__ZINC FINGER PROTEIN 317; ZNF317__:__KIAA1588__:__
Number Sign__:__613865__:__DEAFNESS, AUTOSOMAL RECESSIVE 61; DFNB61__:____:__
Asterisk__:__613866__:__HRAS-LIKE SUPPRESSOR 2; HRASLS2__:____:__
Asterisk__:__613867__:__PHOSPHOLIPASE A2, GROUP XVI; PLA2G16__:__HRAS-LIKE SUPPRESSOR 3; HRASLS3; HRSL3;; HREV107;; HREV107-1__:__
Asterisk__:__613868__:__SOLUTE CARRIER FAMILY 14 (UREA TRANSPORTER), MEMBER 1; SLC14A1__:__UREA TRANSPORTER, ERYTHROCYTE; UTE;; UT11;; UTB, MOUSE, HOMOLOG OF; UTB__:__
Number Sign__:__613869__:__MYOPATHY, MYOFIBRILLAR, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED__:__MFM, FATAL INFANTILE HYPERTONIC, ALPHA-B CRYSTALLIN-RELATED__:__
Number Sign__:__613870__:__HIRSCHSPRUNG DISEASE, CARDIAC DEFECTS, AND AUTONOMIC DYSFUNCTION; HCAD__:____:__
Asterisk__:__613871__:__FUMARYLACETOACETATE HYDROLASE; FAH__:__FUMARYLACETOACETASE__:__
Asterisk__:__613872__:__COAGULATION FACTOR X; F10__:____:__
Number Sign__:__613873__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 17; CMH17__:____:__
Number Sign__:__613874__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 18; CMH18__:____:__
Caret__:__613875__:__MOVED TO 192600__:____:__
Number Sign__:__613876__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 20; CMH20__:____:__
Number Sign__:__613877__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 4; FPLD4__:__LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH PLIN1 MUTATIONS__:__
Asterisk__:__613878__:__COAGULATION FACTOR VII; F7__:__FACTOR VII__:__
Asterisk__:__613879__:__THYROTROPIN-RELEASING HORMONE; TRH__:____:__
Asterisk__:__613880__:__BROMO-ADJACENT HOMOLOGY DOMAIN-CONTAINING PROTEIN 1; BAHD1__:__BAH DOMAIN-CONTAINING PROTEIN 1;; KIAA0945__:__
Number Sign__:__613881__:__CARDIOMYOPATHY, DILATED, 1HH; CMD1HH__:____:__
Number Sign__:__613882__:__HYPOMAGNESEMIA 6, RENAL; HOMG6__:____:__
Asterisk__:__613883__:__KELL BLOOD GROUP METALLOENDOPEPTIDASE; KEL__:__KELL BLOOD GROUP GLYCOPROTEIN;; KELL BLOOD GROUP ANTIGEN__:__
Number Sign__:__613884__:__CHROMOSOME 13q14 DELETION SYNDROME__:__CHROMOSOME 13q DELETION SYNDROME__:__
Number Sign__:__613885__:__MECKEL SYNDROME, TYPE 8; MKS8__:____:__
Number Sign__:__613886__:__OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY; OBHD__:____:__
Number Sign__:__613887__:__CATARACT 36; CTRCT36__:__CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 4; CATC4__:__
Asterisk__:__613888__:__RAS HOMOLOG GENE FAMILY, MEMBER T1; RHOT1__:__MITOCHONDRIAL RHO 1; MIRO1;; ARHT1__:__
Asterisk__:__613889__:__RAS HOMOLOG GENE FAMILY, MEMBER T2; RHOT2__:__MITOCHONDRIAL RHO 2; MIRO2;; ARHT2__:__
Asterisk__:__613890__:__3-BETA-HYDROXYSTEROID DEHYDROGENASE 2; HSD3B2__:__3-BETA-HYDROXYSTEROID DEHYDROGENASE/DELTA-ISOMERASE, TYPE II;; 3-BETA-HSD, ADRENAL AND GONADAL TYPE__:__
Asterisk__:__613891__:__URIDINE MONOPHOSPHATE SYNTHETASE; UMPS__:__OROTATE PHOSPHORIBOSYLTRANSFERASE; OPRT;; OROTIDYLIC DECARBOXYLASE; ODC__:__
Asterisk__:__613892__:__DPY19-LIKE 1; DPY19L1__:__KIAA0877__:__
Asterisk__:__613893__:__DPY19-LIKE 2; DPY19L2__:____:__
Asterisk__:__613894__:__DPY19-LIKE 3; DPY19L3__:____:__
Asterisk__:__613895__:__DPY19-LIKE 4; DPY19L4__:____:__
Asterisk__:__613896__:__BISPHOSPHOGLYCERATE MUTASE; BPGM__:__2,3-BISPHOSPHOGLYCERATE PHOSPHATASE;; 2,3-BPG PHOSPHATASE;; 2,3-DIPHOSPHOGLYCERATE MUTASE; DPGM__:__
Asterisk__:__613897__:__FANCF GENE; FANCF__:____:__
Asterisk__:__613898__:__3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE; HMGCL__:__HMG-CoA LYASE;; HL__:__
Asterisk__:__613899__:__FANCC GENE; FANCC__:__FAC; FACC__:__
Asterisk__:__613900__:__TRANSGLUTAMINASE 6; TGM6__:__TG6;; TRANSGLUTAMINASE Y; TGY__:__
Asterisk__:__613901__:__RNA 2-PRIME,3-PRIME CYCLIC PHOSPHATE AND 5-PRIME-OH LIGASE; RTCB__:__CHROMOSOME 22 OPEN READING FRAME 28; C22ORF28;; HEMATOPOIETIC STEM/PROGENITOR CELL-EXPRESSED GENE 117; HSPC117__:__
Asterisk__:__613902__:__ZINC FINGER PROTEIN 503; ZNF503__:__NOCA-LIKE ZINC FINGER PROTEIN 1; NOLZ1;; NLZ2;; ZINC FINGER ELBOW-RELATED PROLINE DOMAIN PROTEIN 2; ZEPPO2; ZPO2__:__
Asterisk__:__613903__:__ZINC FINGER PROTEIN 540; ZNF540__:____:__
Asterisk__:__613904__:__ZINC FINGER PROTEIN 569; ZNF569__:____:__
Asterisk__:__613905__:__ZINC FINGER PROTEIN 606; ZNF606__:__ZNF328;; KIAA1852__:__
Asterisk__:__613906__:__ZINC FINGER PROTEIN 641; ZNF641__:____:__
Asterisk__:__613907__:__ZINC FINGER PROTEIN 652; ZNF652__:__KIAA0924__:__
Number Sign__:__613908__:__SPINOCEREBELLAR ATAXIA 35; SCA35__:____:__
Percent__:__613909__:__SPINOCEREBELLAR ATAXIA 32; SCA32__:____:__
Asterisk__:__613910__:__ZINC FINGER PROTEIN 480; ZNF480__:____:__
Asterisk__:__613911__:__ZINC FINGER PROTEIN 496; ZNF496__:__NSD1-INTERACTING ZINC FINGER PROTEIN 1; NIZP1;; ZFP496__:__
Number Sign__:__613912__:__COMPLEMENT FACTOR D DEFICIENCY; CFDD__:__FACTOR D DEFICIENCY__:__
Percent__:__613913__:__LIPODYSTROPHY, PARTIAL, ACQUIRED, WITH LOW COMPLEMENT COMPONENT C3, WITH OR WITHOUT GLOMERULONEPHRITIS; APLDC3__:__LIPODYSTROPHY, PARTIAL, ACQUIRED, ASSOCIATED WITH C3 NEPHRITIC FACTOR__:__
Asterisk__:__613914__:__ZINC FINGER PROTEIN 746; ZNF746__:__PARKIN-INTERACTING SUBSTRATE; PARIS__:__
Asterisk__:__613915__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 42: ZBTB42__:__ZNF925__:__
Number Sign__:__613916__:__DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89__:____:__
Asterisk__:__613917__:__MUCIN 22; MUC22__:__PANBRONCHIOLITIS-RELATED MUCIN-LIKE 1; PBMUCL1__:__
Asterisk__:__613918__:__HLA COMPLEX GROUP 22; HCG22__:__PANBRONCHIOLITIS-RELATED MUCIN-LIKE 2; PBMUCL2__:__
Asterisk__:__613919__:__KINESIN FAMILY MEMBER 6; KIF6__:____:__
Asterisk__:__613920__:__CYTOCHROME C OXIDASE ASSEMBLY FACTOR 5; COA5__:__CHROMOSOME 2 OPEN READING FRAME 64; C2ORF64;; PET191, S. CEREVISIAE, HOMOLOG OF; PET191__:__
Asterisk__:__613921__:__LIPASE FAMILY, MEMBER J; LIPJ__:__LIPASE-LIKE ABHYDROLASE DOMAIN-CONTAINING PROTEIN 1; LIPL1__:__
Asterisk__:__613922__:__LIPASE FAMILY, MEMBER K; LIPK__:__LIPASE-LIKE ABHYDROLASE DOMAIN-CONTAINING PROTEIN 2; LIPL2__:__
Asterisk__:__613923__:__LIPASE FAMILY, MEMBER M; LIPM__:__LIPASE-LIKE ABHYDROLASE DOMAIN-CONTAINING PROTEIN 3; LIPL3__:__
Asterisk__:__613924__:__LIPASE FAMILY, MEMBER N; LIPN__:__LIPASE-LIKE ABHYDROLASE DOMAIN-CONTAINING PROTEIN 4; LIPL4__:__
Number Sign__:__613925__:__MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2A; MLC2A__:____:__
Number Sign__:__613926__:__MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS 2B, REMITTING, WITH OR WITHOUT MENTAL RETARDATION; MLC2B__:____:__
Asterisk__:__613927__:__COMPLEMENT COMPONENT 2; C2__:____:__
Asterisk__:__613928__:__DIFFUSE PANBRONCHIOLITIS CRITICAL REGION GENE 1; DPCR1__:__CHROMOSOME 6 OPEN READING FRAME 37; C6ORF37__:__
Asterisk__:__613929__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 4; SPINK4__:__PEC60__:__
Percent__:__613930__:__ALOPECIA-MENTAL RETARDATION SYNDROME 3; APMR3__:____:__
Asterisk__:__613931__:__TARGET OF EGR1; TOE1__:____:__
Asterisk__:__613932__:__TNNI3-INTERACTING KINASE; TNNI3K__:__CARDIAC TROPONIN I-INTERACTING KINASE__:__
Percent__:__613933__:__ACETYL-CoA CARBOXYLASE DEFICIENCY; ACACAD__:__ACACA DEFICIENCY;; ACC1 DEFICIENCY__:__
Asterisk__:__613934__:__TRANSMEMBRANE PROTEIN 25; TMEM25__:____:__
Asterisk__:__613935__:__TRANSMEMBRANE PROTEIN 74; TMEM74__:____:__
Asterisk__:__613936__:__TRANSMEMBRANE PROTEIN 102; TMEM102__:__COMMON BETA CHAIN-ASSOCIATED PROTEIN; CBAP__:__
Asterisk__:__613937__:__TRANSMEMBRANE PROTEIN 184C; TMEM184C__:__TRANSMEMBRANE PROTEIN 34; TMEM34__:__
Percent__:__613938__:__PARASOMNIA, SLEEPWALKING TYPE; PSMNSW__:____:__PARASOMNIA, SLEEP TERRORS TYPE, INCLUDED; PSMNST, INCLUDED
Asterisk__:__613939__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 20; SPATA20__:__SPERM-SPECIFIC PROTEIN 411; SSP411__:__
Asterisk__:__613940__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 5; SPATA5__:__SPERMATOGENESIS-ASSOCIATED FACTOR; SPAF__:__
Asterisk__:__613941__:__SERINE PROTEASE INHIBITOR, KUNITZ-TYPE, 3; SPINT3__:____:__
Asterisk__:__613942__:__SAD1 AND UNC84 DOMAIN-CONTAINING PROTEIN 5; SUN5__:__SUN DOMAIN-CONTAINING PROTEIN 5;; TESTIS- AND SPERMATOGENESIS-RELATED GENE 4; TSARG4;; SPERM-ASSOCIATED ANTIGEN 4-LIKE PROTEIN; SPAG4L;; SPAG4-LIKE PROTEIN__:__
Number Sign__:__613943__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 8; ARCI8__:__LAMELLAR ICHTHYOSIS, LATE-ONSET;; ICHTHYOSIS, LAMELLAR, 4, FORMERLY; LI4, FORMERLY__:__
Percent__:__613944__:__IgA NEPHROPATHY, SUSCEPTIBILITY TO, 2; IGAN2__:____:__
Asterisk__:__613945__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 5, BETA; DNAJC5B__:__CYSTEINE STRING PROTEIN, BETA;; CSP-BETA__:__
Asterisk__:__613946__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 5, GAMMA; DNAJC5G__:__CYSTEINE STRING PROTEIN, GAMMA;; CSP-GAMMA__:__
Asterisk__:__613947__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 6; SPATA6__:__SPERMATOGENESIS-RELATED FACTOR 1, RAT, HOMOLOG OF; SRF1;; HASH, RAT, HOMOLOG OF; HASH__:__
Asterisk__:__613948__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 8; SPATA8__:__SPERMATOGENESIS-RELATED GENE 8; SRG8__:__
Number Sign__:__613949__:__OKT4 EPITOPE DEFICIENCY__:__T4 EPITOPE DEFICIENCY__:__
Number Sign__:__613950__:__SCHIZOPHRENIA 15; SCZD15__:__SCHIZOPHRENIA 15 WITH OR WITHOUT AN AFFECTIVE DISORDER;; SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 22q13-RELATED__:__
Number Sign__:__613951__:__FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP__:____:__
Asterisk__:__613952__:__TERMINAL NUCLEOTIDYLTRANSFERASE 5C; TENT5C__:__FAMILY WITH SEQUENCE SIMILARITY 46, MEMBER C; FAM46C__:__
Number Sign__:__613953__:__IMMUNODEFICIENCY 51; IMD51__:__CANDIDIASIS, FAMILIAL, 5, FORMERLY; CANDF5, FORMERLY__:__
Number Sign__:__613954__:__AMYOTROPHIC LATERAL SCLEROSIS 14 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS14__:____:__
Number Sign__:__613955__:__AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 2; PLCA2__:____:__
Number Sign__:__613956__:__CANDIDIASIS, FAMILIAL, 6; CANDF6__:__CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT__:__
Number Sign__:__613957__:__SPERMATOGENIC FAILURE 8; SPGF8__:____:__
Number Sign__:__613958__:__SPERMATOGENIC FAILURE 9; SPGF9__:__GLOBOZOOSPERMIA, COMPLETE;; GLOBOZOOSPERMIA, TOTAL__:__
Number Sign__:__613959__:__SCHIZOPHRENIA 16; SCZD16__:__SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 7q36.3-RELATED;; CHROMOSOME 7q36.3 DUPLICATION SYNDROME, 362-KB__:__
Number Sign__:__613960__:__GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, CYTOCHROME b-POSITIVE, TYPE III; CDG3__:__CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE III;; GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF4 DEFICIENCY__:__
Asterisk__:__613961__:__TASTE RECEPTOR, TYPE 2, MEMBER 19; TAS2R19__:__T2R19;; T2R48__:__
Asterisk__:__613962__:__TASTE RECEPTOR, TYPE 2, MEMBER 20; TAS2R20__:__T2R56__:__
Asterisk__:__613963__:__TASTE RECEPTOR, TYPE 2, MEMBER 30; TAS2R30__:__T2R30;; T2R47__:__
Asterisk__:__613964__:__TASTE RECEPTOR, TYPE 2, MEMBER 40; TAS2R40__:__T2R40__:__
Asterisk__:__613965__:__TASTE RECEPTOR, TYPE 2, MEMBER 41; TAS2R41__:__T2R59__:__
Asterisk__:__613966__:__TASTE RECEPTOR, TYPE 2, MEMBER 42; TAS2R42__:__T2R42;; T2R55__:__
Asterisk__:__613967__:__TASTE RECEPTOR, TYPE 2, MEMBER 45; TAS2R45__:__T2R45__:__
Asterisk__:__613968__:__TASTE RECEPTOR, TYPE 2, MEMBER 60; TAS2R60__:__T2R60__:__
Percent__:__613969__:__MYOPIA 19, AUTOSOMAL DOMINANT; MYP19__:____:__
Number Sign__:__613970__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 6, WITH OR WITHOUT SEIZURES; MRD6__:____:__
Caret__:__613971__:__MOVED TO 245570__:____:__
Number Sign__:__613972__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 6; CMM6__:____:__
Asterisk__:__613973__:__CYCLIC GMP-AMP SYNTHASE; CGAS__:__MAB21 DOMAIN-CONTAINING PROTEIN 1; MB21D1;; CHROMOSOME 6 OPEN READING FRAME 150; C6ORF150__:__
Asterisk__:__613974__:__DEAD BOX POLYPEPTIDE 60; DDX60__:____:__
Asterisk__:__613975__:__INTERFERON-INDUCED PROTEIN 44-LIKE; IFI44L__:__IFI44-LIKE__:__
Asterisk__:__613976__:__FANCE GENE; FANCE__:____:__
Number Sign__:__613977__:__CYANOSIS, TRANSIENT NEONATAL; TNCY__:____:__
Number Sign__:__613978__:__HEMOGLOBIN H DISEASE; HBH__:__ALPHA-THALASSEMIA, HEMOGLOBIN H TYPE;; HEMOGLOBIN H DISEASE, DELETIONAL__:__HEMOGLOBIN H DISEASE, NONDELETIONAL, INCLUDED
Asterisk__:__613979__:__PRECURSOR mRNA-PROCESSING FACTOR 6, S. CEREVISIAE, HOMOLOG OF; PRPF6__:__PRP6;; ANDROGEN RECEPTOR N-TERMINAL DOMAIN-TRANSACTIVATING PROTEIN 1; ANT1;; TOM;; CHROMOSOME 20 OPEN READING FRAME 14; C20ORF14__:__
Number Sign__:__613980__:__ATRIAL FIBRILLATION, FAMILIAL, 9; ATFB9__:____:__
Number Sign__:__613981__:__HYPOTRICHOSIS 3; HYPT3__:__HYPOTRICHOSIS SIMPLEX OF THE SCALP 2; HTSS2__:__
Number Sign__:__613982__:__OSTEOGENESIS IMPERFECTA, TYPE VI; OI6__:____:__
Number Sign__:__613983__:__RETINITIS PIGMENTOSA 60; RP60__:____:__
Asterisk__:__613984__:__FANCD2 GENE; FANCD2__:____:__
Number Sign__:__613985__:__BETA-THALASSEMIA__:____:__
Number Sign__:__613986__:__PITUITARY HORMONE DEFICIENCY, COMBINED, 6; CPHD6__:____:__
Number Sign__:__613987__:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 2; DKCB2__:____:__
Number Sign__:__613988__:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 3; DKCB3__:____:__
Number Sign__:__613989__:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 2; DKCA2__:____:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 4, INCLUDED; DKCB4, INCLUDED
Number Sign__:__613990__:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 3; DKCA3__:____:__
Asterisk__:__613991__:__CDC42-BINDING PROTEIN KINASE, GAMMA; CDC42BPG__:__MYOTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE, GAMMA; MRCKG;; MRCK-GAMMA__:__
Asterisk__:__613992__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B, DELTA; PPP2R2D__:__B55-DELTA;; B-DELTA__:__
Asterisk__:__613993__:__MYOSIN, LIGHT CHAIN 7, REGULATORY; MYL7__:__MYOSIN LIGHT CHAIN 2, ATRIAL; MYL2A;; MLC2A;; MYLC2A__:__
Asterisk__:__613994__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 4; NBPF4__:____:__
Asterisk__:__613995__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 5; NBPF5__:____:__
Asterisk__:__613996__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 6; NBPF6__:____:__
Asterisk__:__613997__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 7; NBPF7__:____:__
Asterisk__:__613998__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 8; NBPF8__:____:__
Asterisk__:__613999__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 9; NBPF9__:____:__
Asterisk__:__614000__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 10; NBPF10__:____:__
Asterisk__:__614001__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 11; NBPF11__:____:__
Caret__:__614002__:__MOVED TO 608607__:____:__
Asterisk__:__614003__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 14; NBPF14__:____:__
Caret__:__614004__:__MOVED TO 610414__:____:__
Asterisk__:__614005__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 16; NBPF16__:____:__
Asterisk__:__614006__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 19; NBPF19__:____:__
Asterisk__:__614007__:__NEUROBLASTOMA BREAKPOINT FAMILY, MEMBER 20; NBPF20__:____:__
Number Sign__:__614008__:__NESTOR-GUILLERMO PROGERIA SYNDROME; NGPS__:__PROGERIA SYNDROME, CHILDHOOD-ONSET, WITH OSTEOLYSIS; PSCOO__:__
Number Sign__:__614009__:__BLEEDING DISORDER, PLATELET-TYPE, 13, SUSCEPTIBILITY TO; BDPLT13__:__BLEEDING DISORDER, SUSCEPTIBILITY TO, DUE TO DEFECTIVE PLATELET THROMBOXANE A2 RECEPTOR__:__
Asterisk__:__614010__:__INOSITOL MONOPHOSPHATASE DOMAIN-CONTAINING PROTEIN 1; IMPAD1__:__MYOINOSITOL MONOPHOSPHATASE A3; IMPA3;; GOLGI 3-PRIME PHOSPHOADENOSINE 5-PRIME PHOSPHATE 3-PRIME PHOSPHATASE; GPAPP;; LITHIUM-INHIBITED PHOSPHOMONOESTERASE__:__
Asterisk__:__614011__:__ENDOGENOUS RETROVIRUS GROUP K, MEMBER 4; ERVK-4__:__HUMAN ENDOGENOUS RETROVIRUS K I;; HERV-KI__:__
Asterisk__:__614012__:__ENDOGENOUS RETROVIRUS GROUP K, MEMBER 5; ERVK-5__:__HUMAN ENDOGENOUS RETROVIRUS K II;; HERV-KII__:__
Asterisk__:__614013__:__ENDOGENOUS RETROVIRUS GROUP K, MEMBER 7; ERVK-7__:__HUMAN ENDOGENOUS RETROVIRUS K III;; HERV-KIII;; HERV-K102__:__
Asterisk__:__614014__:__RIBONUCLEASE, RNase A FAMILY, 9; RNASE9__:____:__
Asterisk__:__614015__:__DIACYLGLYCEROL LIPASE, ALPHA; DAGLA__:__DAGL-ALPHA;; DGL-ALPHA;; DGLA;; KIAA0659__:__
Asterisk__:__614016__:__DIACYLGLYCEROL LIPASE, BETA; DAGLB__:__DAGL-BETA;; DGL-BETA;; DGLB__:__
Number Sign__:__614017__:__CILIARY DYSKINESIA, PRIMARY, 16; CILD16__:__CILIARY DYSKINESIA, PRIMARY, 16, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__614018__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 6; EPM6__:____:__
Number Sign__:__614019__:__LISSENCEPHALY 4; LIS4__:__LISSENCEPHALY 4 WITH MICROCEPHALY__:__
Number Sign__:__614020__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 14; MRT14__:____:__
Number Sign__:__614021__:__VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 3; CPVT3__:____:__
Number Sign__:__614022__:__ATRIAL FIBRILLATION, FAMILIAL, 10; ATFB10__:____:__
Number Sign__:__614023__:__PHOSPHOSERINE PHOSPHATASE DEFICIENCY; PSPHD__:____:__
Number Sign__:__614024__:__PROTEIN Z DEFICIENCY__:____:__
Number Sign__:__614025__:__HEPATIC LIPASE DEFICIENCY__:__LIPC DEFICIENCY;; HL DEFICIENCY__:__
Asterisk__:__614026__:__KINESIN FAMILY MEMBER 26B; KIF26B__:____:__
Asterisk__:__614027__:__INSULINOMA-ASSOCIATED 2; INSM2__:__INSULINOMA-ASSOCIATED GENE 6; IA6__:__
Number Sign__:__614028__:__APOLIPOPROTEIN C-III DEFICIENCY__:__HYPERALPHALIPOPROTEINEMIA 2; HALP2__:__
Asterisk__:__614029__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER A; SPDYA__:__SPEEDY, XENOPUS, HOMOLOG OF, A; SPDYA;; SPY1;; RAPID INDUCER OF G2/M PROGRESSION IN OOCYTES, XENOPUS, HOMOLOG OF, A;; RINGO A__:__
Asterisk__:__614030__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER C; SPDYC__:__SPEEDY, XENOPUS, HOMOLOG OF, C;; RAPID INDUCER OF G2/M PROGRESSION IN OOCYTES, XENOPUS, HOMOLOG OF, C;; RINGO C;; SPEEDY B4__:__
Asterisk__:__614031__:__RAN-BINDING PROTEIN 10; RANBP10__:__KIAA1464__:__
Asterisk__:__614032__:__TOX HIGH MOBILITY GROUP BOX FAMILY MEMBER 4; TOX4__:__LANGERHANS CELL PROTEIN 1; LCP1;; KIAA0737__:__
NULL__:__614033__:__HYDROXYACYL GLUTATHIONE HYDROLASE DEFICIENCY__:__GLYOXALASE II DEFICIENCY__:__
Number Sign__:__614034__:__HEME OXYGENASE 1 DEFICIENCY; HMOX1D__:____:__
Number Sign__:__614035__:__DEAFNESS, AUTOSOMAL RECESSIVE 29; DFNB29__:____:__
NULL__:__614036__:__ALPHA-2-MACROGLOBULIN DEFICIENCY; A2MD__:____:__
NULL__:__614037__:__LEUKOTRIENE C4 SYNTHASE DEFICIENCY__:__LTC4 SYNTHASE DEFICIENCY__:__
Number Sign__:__614038__:__LYMPHEDEMA, PRIMARY, WITH MYELODYSPLASIA__:__EMBERGER SYNDROME__:__
Number Sign__:__614039__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 1; CDCBM1__:____:__
Asterisk__:__614040__:__ZINC FINGER PROTEIN 467; ZNF467__:__EZI, MOUSE, HOMOLOG OF; EZI;; ZFP467__:__
Asterisk__:__614041__:__RB1 GENE; RB1__:__p105-Rb__:__
Number Sign__:__614042__:__MOYAMOYA DISEASE 5; MYMY5__:____:__
Asterisk__:__614043__:__LEUCINE-RICH REPEAT IN FLII-INTERACTING PROTEIN 2; LRRFIP2__:____:__
NULL__:__614044__:__TRYPSINOGEN DEFICIENCY__:____:__
Asterisk__:__614045__:__FAMILY WITH SEQUENCE SIMILARITY 129, MEMBER B; FAM129B__:__MELANOMA INVASION BY ERK; MINERVA__:__
Asterisk__:__614046__:__ARGININE- AND GLUTAMATE-RICH PROTEIN 1; ARGLU1__:____:__
Asterisk__:__614047__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE 2-LIKE, NADP(+)-DEPENDENT; MTHFD2L__:__MTHFD2-LIKE__:__
Asterisk__:__614048__:__KIAA1324-LIKE; KIAA1324L__:__EIG121-LIKE; EIG121L__:__
Number Sign__:__614049__:__ATRIAL FIBRILLATION, FAMILIAL, 11; ATFB11__:____:__
Number Sign__:__614050__:__ATRIAL FIBRILLATION, FAMILIAL, 12; ATFB12__:____:__
Caret__:__614051__:__MOVED TO 212066__:____:__
Number Sign__:__614052__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 2; MC5DN2__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, TMEM70 TYPE;; ENCEPHALOCARDIOMYOPATHY, MITOCHONDRIAL, NEONATAL, DUE TO ATP SYNTHASE DEFICIENCY__:__
Number Sign__:__614053__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 3; MC5DN3__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATP5E TYPE__:__
Asterisk__:__614054__:__RIBOSOMAL MODIFICATION PROTEIN RimK-LIKE FAMILY, MEMBER B; RIMKLB__:__N-ACETYLASPARTYL-GLUTAMATE SYNTHETASE; NAAGS;; NAAG SYNTHETASE;; KIAA1238__:__
NULL__:__614055__:__ACETYL-CoA ACETYLTRANSFERASE-2 DEFICIENCY; ACAT2D__:__ACAT2 DEFICIENCY__:__
Asterisk__:__614056__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 26; PPP1R26__:__KIAA0649 GENE; KIAA0649;; DRIM-INTERACTING PROTEIN__:__
Asterisk__:__614057__:__MICRO RNA 409; MIR409__:__miRNA409;; MIRN409;; MIR409-5p__:__MICRO RNA 409-3p, INCLUDED; MIR409-3p, INCLUDED
Asterisk__:__614058__:__KETOHEXOKINASE; KHK__:__FRUCTOKINASE, HEPATIC__:__
Asterisk__:__614059__:__MICRO RNA 338; MIR338__:__miRNA338;; MIRN338__:__
Asterisk__:__614060__:__HOXA DISTAL TRANSCRIPT ANTISENSE RNA; HOTTIP__:__HOXA TRANSCRIPT AT THE DISTAL TIP;; NONCODING RNA 213; NCRNA00213__:__
Asterisk__:__614061__:__OLFACTOMEDIN 4; OLFM4__:__GCSF-STIMULATED CLONE 1; GC1;; GW112__:__
Asterisk__:__614062__:__CDC42-BINDING PROTEIN KINASE, BETA; CDC42BPB__:__CDC42BP-BETA;; MYOTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE, BETA; MRCKB;; MRCK-BETA__:__
Number Sign__:__614063__:__N-ACETYLASPARTATE DEFICIENCY; NACED__:__NAA DEFICIENCY;; HYPOACETYLASPARTIA__:__
Asterisk__:__614064__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 24; ZBTB24__:__POZ-, AT HOOK-, AND ZINC FINGER-CONTAINING PROTEIN 2; PATZ2;; ZINC FINGER PROTEIN 450; ZNF450;; KIAA0441__:__
Number Sign__:__614065__:__MYOPATHY, DISTAL, 4; MPD4__:__WILLIAMS DISTAL MYOPATHY__:__
Number Sign__:__614066__:__SPASTIC PARAPLEGIA 47, AUTOSOMAL RECESSIVE; SPG47__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 5, FORMERLY; CPSQ5, FORMERLY__:__
Number Sign__:__614067__:__SPASTIC PARAPLEGIA 52, AUTOSOMAL RECESSIVE; SPG52__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 6, FORMERLY; CPSQ6, FORMERLY__:__
Asterisk__:__614068__:__INTRAFLAGELLAR TRANSPORT 43, CHLAMYDOMONAS, HOMOLOG OF; IFT43__:__CHROMOSOME 14 OPEN READING FRAME 179; C14ORF179__:__
Number Sign__:__614069__:__IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 2; ICF2__:____:__
Number Sign__:__614070__:__PSORIASIS 13, SUSCEPTIBILITY TO; PSORS13__:____:__
Asterisk__:__614071__:__MYOCARDIAL ZONULA ADHERENS PROTEIN; MYZAP__:__MYOCARDIUM-ENRICHED ZO1-ASSOCIATED PROTEIN; MYOZAP;; GRINL1A COMPLEX LOCUS UPSTREAM GENE; GUP;; GUP1__:__GRINL1A COMPLEX LOCUS, INCLUDED; GCOM1, INCLUDED;; GRINL1A COMPLEX TRANSCRIPTION UNIT, INCLUDED;; MYZAP-POLR2M LOCUS, INCLUDED;; GRINL1A COMPLEX LOCUS COMBINED TRANSCRIPT 1, INCLUDED; GCOM1, INCLUDED
Number Sign__:__614072__:__HERMANSKY-PUDLAK SYNDROME 3; HPS3__:____:__
Number Sign__:__614073__:__HERMANSKY-PUDLAK SYNDROME 4; HPS4__:____:__
Number Sign__:__614074__:__HERMANSKY-PUDLAK SYNDROME 5; HPS5__:____:__
Number Sign__:__614075__:__HERMANSKY-PUDLAK SYNDROME 6; HPS6__:____:__
Number Sign__:__614076__:__HERMANSKY-PUDLAK SYNDROME 7; HPS7__:____:__
Number Sign__:__614077__:__HERMANSKY-PUDLAK SYNDROME 8; HPS8__:____:__
Number Sign__:__614078__:__CHONDRODYSPLASIA WITH JOINT DISLOCATIONS, GPAPP TYPE__:__GPAPP DEFICIENCY__:__
Number Sign__:__614079__:__ASPERGILLOSIS, SUSCEPTIBILITY TO__:____:__
Number Sign__:__614080__:__MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3__:__
Number Sign__:__614081__:__ANHAPTOGLOBINEMIA; AHP__:__AHAPTOGLOBINEMIA__:__HYPOHAPTOGLOBINEMIA, INCLUDED
Number Sign__:__614082__:__FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG__:____:__
Number Sign__:__614083__:__FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL__:____:__
Asterisk__:__614084__:__WEE1, S. POMBE, HOMOLOG OF, 2; WEE2__:__WEE1B__:__
Asterisk__:__614085__:__RAD9-, RAD1-, AND HUS1-INTERACTING NUCLEAR ORPHAN 1; RHNO1__:__RHINO;; CHROMOSOME 12 OPEN READING FRAME 32; C12ORF32__:__
Asterisk__:__614086__:__MULTICILIATE DIFFERENTIATION AND DNA SYNTHESIS-ASSOCIATED CELL CYCLE PROTEIN; MCIDAS__:__IDAS;; MULTICILIN; MCI__:__
Caret__:__614087__:__MOVED TO 227650 AND 609644__:____:__
Asterisk__:__614088__:__INTRACELLULAR ADHESION MOLECULE 4; ICAM4__:__CD242 ANTIGEN; CD242;; LW GENE; LW__:__
Number Sign__:__614089__:__ATRIAL SEPTAL DEFECT 3; ASD3__:____:__
Number Sign__:__614090__:__SICK SINUS SYNDROME 3, SUSCEPTIBILITY TO; SSS3__:____:__
Number Sign__:__614091__:__SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY; SRTD7__:__SHORT RIB-POLYDACTYLY SYNDROME, TYPE V; SRPS5__:__SHORT-RIB THORACIC DYSPLASIA 7/20 WITH POLYDACTYLY, DIGENIC, INCLUDED; SRTD7/20, INCLUDED
Asterisk__:__614092__:__RAB-INTERACTING LYSOSOMAL PROTEIN-LIKE 1; RILPL1__:__RILP-LIKE PROTEIN 1; RLP1;; GAPDH COMPETITOR OF SIAH PROTEIN ENHANCES LIFE; GOSPEL__:__
Asterisk__:__614093__:__RAB-INTERACTING LYSOSOMAL PROTEIN-LIKE 2; RILPL2__:__RILP-LIKE PROTEIN 2; RLP2__:__
Asterisk__:__614094__:__MARVEL DOMAIN-CONTAINING PROTEIN 3; MARVELD3__:____:__
Asterisk__:__614095__:__PHOSPHOENOLPYRUVATE CARBOXYKINASE 2, MITOCHONDRIAL; PCK2__:__PEPCK2__:__
Number Sign__:__614096__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 8; COXPD8__:__CARDIOMYOPATHY, HYPERTROPHIC MITOCHONDRIAL, FATAL INFANTILE__:__
Number Sign__:__614097__:__ACATALASEMIA__:__ACATALASIA;; CATALASE DEFICIENCY__:__
Number Sign__:__614098__:__KEPPEN-LUBINSKY SYNDROME; KPLBS__:____:__
Number Sign__:__614099__:__CRANIOECTODERMAL DYSPLASIA 3; CED3__:____:__
Percent__:__614100__:__CUTIS LAXA, NEONATAL, WITH MARFANOID PHENOTYPE__:__CUTIS LAXA-MARFANOID SYNDROME__:__
Percent__:__614101__:__PLASMA FIBRONECTIN DEFICIENCY__:____:__
Number Sign__:__614102__:__IMMUNOGLOBULIN KAPPA LIGHT CHAIN DEFICIENCY; IGKCD__:__KAPPA CHAIN DEFICIENCY__:__
Percent__:__614103__:__LIPEDEMA__:____:__
Number Sign__:__614104__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 7; MRD7__:____:__
Number Sign__:__614105__:__METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; MMSDHD__:__MMSDH DEFICIENCY__:__
Asterisk__:__614106__:__MUSCULAR LMNA-INTERACTING PROTEIN; MLIP__:__CHROMOSOME 6 OPEN READING FRAME 142; C6ORF142__:__
Asterisk__:__614107__:__KARYOPHERIN ALPHA-7; KPNA7__:__IMPORTIN ALPHA-8__:__
Asterisk__:__614108__:__BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 2; BPIFB2__:__BACTERICIDAL PERMEABILITY-INCREASING PROTEIN-LIKE 1; BPIL1;; BPI-LIKE 1;; RYSR__:__
Asterisk__:__614109__:__BPI FOLD-CONTAINING PROTEIN, FAMILY C; BPIFC__:__BACTERICIDAL PERMEABILITY-INCREASING PROTEIN-LIKE 2; BPIL2;; BPI-LIKE 2__:__
Asterisk__:__614110__:__BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 6; BPIFB6__:__BACTERICIDAL PERMEABILITY-INCREASING PROTEIN-LIKE 3; BPIL3__:__
Number Sign__:__614111__:__PYRUVATE DEHYDROGENASE E1-BETA DEFICIENCY; PDHBD__:____:__
Asterisk__:__614112__:__MICRO RNA 320A; MIR320A__:__miRNA320A;; MIRN320A__:__
Number Sign__:__614113__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 2; MRD2__:____:__
Number Sign__:__614114__:__MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 2; MVA2__:____:__
Number Sign__:__614115__:__CORTICAL MALFORMATIONS, OCCIPITAL; OCCM__:____:__
Number Sign__:__614116__:__NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E__:__HSN IE;; NEUROPATHY, HEREDITARY SENSORY, WITH HEARING LOSS AND DEMENTIA__:__
Asterisk__:__614117__:__EXOCYST COMPLEX COMPONENT 3-LIKE 1; EXOC3L1__:__EXOC3L__:__
Asterisk__:__614118__:__TEASHIRT ZINC FINGER HOMEOBOX 2; TSHZ2__:____:__
Asterisk__:__614119__:__TEASHIRT ZINC FINGER HOMEOBOX 3; TSHZ3__:__KIAA1474__:__
Number Sign__:__614120__:__HYDROLETHALUS SYNDROME 2; HLS2__:____:__
Asterisk__:__614121__:__TERMINAL NUCLEOTIDYLTRANSFERASE 2; TENT2__:__POLY(A) POLYMERASE-ASSOCIATED DOMAIN-CONTAINING PROTEIN 4; PAPD4;; TERMINAL URIDYLTRANSFERASE 2; TUT2;; GLD2__:__
Number Sign__:__614122__:__CHITOTRIOSIDASE DEFICIENCY; CHITD__:____:__
Asterisk__:__614123__:__TRANSMEMBRANE AND COILED-COIL DOMAINS PROTEIN 1; TMCO1__:____:__
Asterisk__:__614124__:__GLYCEROPHOSPHOCHOLINE PHOSPHODIESTERASE GDE1, S. CEREVISIAE, HOMOLOG OF; GPCPD1__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 5; GDE5;; KIAA1434;; ENDOMETRIAL DIFFERENTIATION 3; ED13__:__
Asterisk__:__614125__:__DEVELOPMENTAL PLURIPOTENCY-ASSOCIATED GENE 4; DPPA4__:__EMBRYONIC STEM CELL-ASSOCIATED TRANSCRIPT 15-1;; ECAT15-1__:__
Asterisk__:__614126__:__MOLYBDENUM COFACTOR SULFURASE C-TERMINAL DOMAIN-CONTAINING PROTEIN 1; MOSC1__:__MOCO SULFURASE C-TERMINAL DOMAIN-CONTAINING PROTEIN 1;; MOSC DOMAIN-CONTAINING PROTEIN 1;; MITOCHONDRIAL AMIDOXIME-REDUCING COMPONENT 1; MARC1__:__
Asterisk__:__614127__:__MOLYBDENUM COFACTOR SULFURASE C-TERMINAL DOMAIN-CONTAINING PROTEIN 2; MOSC2__:__MOCO SULFURASE C-TERMINAL DOMAIN-CONTAINING PROTEIN 2;; MOSC DOMAIN-CONTAINING PROTEIN 2;; MITOCHONDRIAL AMIDOXIME-REDUCING COMPONENT 2; MARC2__:__
Number Sign__:__614128__:__LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD__:____:__
Number Sign__:__614129__:__PERRAULT SYNDROME 3; PRLTS3__:__DEAFNESS, AUTOSOMAL RECESSIVE 81, FORMERLY; DFNB81, FORMERLY__:__
Asterisk__:__614130__:__ADENOSINE DEAMINASE DOMAIN-CONTAINING PROTEIN 1, TESTIS-SPECIFIC; ADAD1__:__TESTIS NUCLEAR RNA-BINDING PROTEIN; TENR__:__
Number Sign__:__614131__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 6; FSGS6__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 6__:__
Caret__:__614132__:__MOVED TO 213980__:____:__
Asterisk__:__614133__:__HEPACAM FAMILY MEMBER 2; HEPACAM2__:__MITOTIC KINETICS REGULATOR; MIKI__:__
Number Sign__:__614134__:__STICKLER SYNDROME, TYPE IV; STL4__:____:__
Number Sign__:__614135__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 6; EDM6__:____:__
Asterisk__:__614136__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 8; TRAPPC8__:__KIAA1012__:__
Asterisk__:__614137__:__BET3, S. CEREVISIAE, HOMOLOG-LIKE; BET3L__:__TRAFFICKING PROTEIN PARTICLE COMPLEX 3-LIKE; TRAPPC3L__:__
Asterisk__:__614138__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 11; TRAPPC11__:__CHROMOSOME 4 OPEN READING FRAME 41; C4ORF41__:__
Asterisk__:__614139__:__TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 12; TRAPPC12__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 15; TTC15__:__
Asterisk__:__614140__:__SPERM ANTIGEN WITH CALPONIN HOMOLOGY AND COILED-COIL DOMAINS 1-LIKE; SPECC1L__:__SPECC1-LIKE;; NY-REN-22;; KIAA0376__:__
Asterisk__:__614141__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 2; TRIM2__:__KIAA0517__:__
Asterisk__:__614142__:__CUE DOMAIN-CONTAINING PROTEIN 2; CUEDC2__:____:__
Asterisk__:__614143__:__IGF-LIKE FAMILY RECEPTOR 1; IGFLR1__:__TRANSMEMBRANE PROTEIN 149; TMEM149__:__
Asterisk__:__614144__:__B9 DOMAIN-CONTAINING PROTEIN 1; B9D1__:__MKS1-RELATED PROTEIN 1; MKSR1__:__
Asterisk__:__614145__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 8; CCDC8__:____:__
Asterisk__:__614146__:__CHROMOSOME 20 OPEN READING FRAME 194; C20ORF194__:____:__
Asterisk__:__614147__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 8; C1QTNF8__:__CTRP8__:__
Asterisk__:__614148__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 9B; C1QTNF9B__:__CTRP9B__:__
Percent__:__614149__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 9; NDNC9__:__ANONYCHIA-ONYCHOLYSIS, ISOLATED;; ONYCHODYSTROPHY;; NAIL DYSPLASIA__:__
Asterisk__:__614150__:__PROTEIN KINASE DOMAIN-CONTAINING PROTEIN, CYTOPLASMIC, MOUSE, HOMOLOG OF; PKDCC__:__VERTEBRATE LONESOME KINASE; VLK;; SGK493__:__
Asterisk__:__614151__:__RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 3; RFWD3__:____:__
Number Sign__:__614152__:__DEAFNESS, AUTOSOMAL DOMINANT 64; DFNA64__:____:__
Number Sign__:__614153__:__SPINOCEREBELLAR ATAXIA 36; SCA36__:____:__
Asterisk__:__614154__:__NOP56, S. CEREVISIAE, HOMOLOG OF; NOP56__:____:__
Asterisk__:__614155__:__MICRO RNA 1292; MIR1292__:__miRNA1292;; MIRN1292__:__
Number Sign__:__614156__:__HYPERBILIVERDINEMIA; HBLVD__:__GREEN JAUNDICE__:__
Number Sign__:__614157__:__NAIL DISORDER, NONSYNDROMIC CONGENITAL, 10; NDNC10__:__CLAW-SHAPED NAILS;; ONYCHAUXIS, HYPONYCHIA, AND ONYCHOLYSIS__:__
NULL__:__614158__:__BLEEDING DISORDER, PLATELET-TYPE, 14; BDPLT14__:__THROMBOXANE SYNTHETASE DEFICIENCY__:__
Asterisk__:__614159__:__ZINC FINGER PROTEIN 644; ZNF644__:____:__
Number Sign__:__614160__:__MUSCLE HYPERTROPHY; MSLHP__:____:__
Asterisk__:__614161__:__PR DOMAIN-CONTAINING PROTEIN 5; PRDM5__:__PFM2__:__
Number Sign__:__614162__:__IMMUNODEFICIENCY 31C; IMD31C__:__CANDIDIASIS, FAMILIAL, 7; CANDF7;; CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL DOMINANT__:__
Number Sign__:__614163__:__DELAYED SLEEP PHASE DISORDER, SUSCEPTIBILITY TO; DSPD__:____:__
Percent__:__614164__:__GLUTATHIONE PEROXIDASE DEFICIENCY; GPXD__:____:__
Number Sign__:__614165__:__PARAGANGLIOMAS 5; PGL5__:____:__
Percent__:__614166__:__MYOPIA 20, AUTOSOMAL DOMINANT; MYP20__:____:__
Number Sign__:__614167__:__MYOPIA 21, AUTOSOMAL DOMINANT; MYP21__:____:__
Asterisk__:__614168__:__PHOSPHOENOLPYRUVATE CARBOXYKINASE 1, SOLUBLE; PCK1__:__PEPCK1;; PEPCK, CYTOSOLIC; PEPCKC__:__
Asterisk__:__614169__:__NEUROBEACHIN-LIKE 2; NBEAL2__:__KIAA0540__:__
Number Sign__:__614170__:__BRITTLE CORNEA SYNDROME 2; BCS2__:____:__
Number Sign__:__614171__:__HERMANSKY-PUDLAK SYNDROME 9; HPS9__:____:__
Number Sign__:__614172__:__IMMUNODEFICIENCY 21; IMD21__:__DENDRITIC CELL, MONOCYTE, B LYMPHOCYTE, AND NATURAL KILLER LYMPHOCYTE DEFICIENCY; DCML;; MONOCYTOPENIA AND MYCOBACTERIAL INFECTION SYNDROME; MONOMAC;; MONOCYTOPENIA WITH SUSCEPTIBILITY TO MYCOBACTERIAL, FUNGAL, AND PAPILLOMAVIRUS INFECTIONS AND MYELODYSPLASIA;; COMBINED IMMUNODEFICIENCY WITH SUSCEPTIBILITY TO MYCOBACTERIAL, VIRAL, AND FUNGAL INFECTIONS;; GATA2 DEFICIENCY__:__
Number Sign__:__614173__:__JOUBERT SYNDROME 13; JBTS13__:____:__
Asterisk__:__614174__:__MEIOSIS-EXPRESSED GENE 1, MOUSE, HOMOLOG OF; MEIG1__:____:__
Number Sign__:__614175__:__MECKEL SYNDROME, TYPE 10; MKS10__:____:__JOUBERT SYNDROME 34, INCLUDED; JBTS34, INCLUDED
Asterisk__:__614176__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 28; ZFYVE28__:__LST2, C. ELEGANS, ORTHOLOG OF; LST2;; KIAA1643__:__
Asterisk__:__614177__:__EF-HAND CALCIUM-BINDING DOMAIN-CONTAINING PROTEIN 4A; EFCAB4A__:__CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL REGULATOR 2B; CRACR2B__:__
Asterisk__:__614178__:__EF-HAND CALCIUM-BINDING DOMAIN-CONTAINING PROTEIN 4B; EFCAB4B__:__CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL REGULATOR 2A; CRACR2A__:__
Asterisk__:__614179__:__IMMUNOGLOBULIN SUPERFAMILY CONTAINING LEUCINE-RICH REPEAT 2; ISLR2__:__LEUCINE-RICH REPEAT DOMAIN- AND IMMUNOGLOBULIN DOMAIN-CONTAINING AXON EXTENSION PROTEIN; LINX;; KIAA1465__:__
Number Sign__:__614180__:__RETINITIS PIGMENTOSA 61; RP61__:____:__
Number Sign__:__614181__:__RETINITIS PIGMENTOSA 62; RP62__:____:__
Asterisk__:__614182__:__HEART OF GLASS, ZEBRAFISH, HOMOLOG OF, 1; HEG1__:__KIAA1237__:__
Asterisk__:__614183__:__DIS3 MITOTIC CONTROL, S. CEREVISIAE, HOMOLOG-LIKE; DIS3L__:__DIS3-LIKE EXONUCLEASE 1; DIS3L1;; KIAA1955__:__
Asterisk__:__614184__:__DIS3 MITOTIC CONTROL, S. CEREVISIAE, HOMOLOG-LIKE 2; DIS3L2__:____:__
Number Sign__:__614185__:__GELEOPHYSIC DYSPLASIA 2; GPHYSD2__:____:__
Number Sign__:__614186__:__LEBER CONGENITAL AMAUROSIS 16; LCA16__:____:__
Percent__:__614187__:__HYPERTELORISM, PREAURICULAR SINUS, PUNCTAL PITS, AND DEAFNESS; HPPD__:____:__
Number Sign__:__614188__:__CRANIOSYNOSTOSIS AND DENTAL ANOMALIES; CRSDA__:__KREIBORG-PAKISTANI SYNDROME__:__
Asterisk__:__614189__:__GOLGIN A7 FAMILY, MEMBER B; GOLGA7B__:__CHROMOSOME 10 OPEN READING FRAME 132; C10ORF132__:__
Number Sign__:__614190__:__PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 3; PPNAD3__:__CUSHING SYNDROME, ADRENAL, DUE TO PPNAD3__:__
Asterisk__:__614191__:__DEP DOMAIN-CONTAINING PROTEIN 5; DEPDC5__:__KIAA0645__:__
Number Sign__:__614192__:__MACROCEPHALY, MACROSOMIA, AND FACIAL DYSMORPHISM SYNDROME; MMFD__:____:__
Number Sign__:__614193__:__TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; TFQTL2__:____:__
Asterisk__:__614194__:__DEDICATOR OF CYTOKINESIS 6; DOCK6__:__KIAA1395__:__
Number Sign__:__614195__:__CRANIOFACIAL ANOMALIES AND ANTERIOR SEGMENT DYSGENESIS SYNDROME; CAASDS__:____:__
Number Sign__:__614196__:__NEPHROTIC SYNDROME, TYPE 6; NPHS6__:____:__
Asterisk__:__614197__:__MITOCHONDRIAL CALCIUM UNIPORTER; MCU__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 109A; CCDC109A__:__
Number Sign__:__614198__:__MYASTHENIC SYNDROME, CONGENITAL, 16; CMS16__:__MYASTHENIC SYNDROME, CONGENITAL, ACETAZOLAMIDE-RESPONSIVE__:__
Number Sign__:__614199__:__NEPHROTIC SYNDROME, TYPE 5, WITH OR WITHOUT OCULAR ABNORMALITIES; NPHS5__:____:__
Percent__:__614200__:__BLEEDING DISORDER, PLATELET-TYPE, 9; BDPLT9__:__GLYCOPROTEIN Ia DEFICIENCY;; GP Ia DEFICIENCY;; COLLAGEN PLATELET RECEPTOR DEFICIENCY__:__
Number Sign__:__614201__:__BLEEDING DISORDER, PLATELET-TYPE, 11; BDPLT11__:__GLYCOPROTEIN VI DEFICIENCY;; GP VI DEFICIENCY__:__
Number Sign__:__614202__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15__:____:__
Number Sign__:__614203__:__PARKINSON DISEASE 17; PARK17__:____:__
Number Sign__:__614204__:__PSORIASIS 14, PUSTULAR; PSORS14__:__INTERLEUKIN 36 RECEPTOR ANTAGONIST DEFICIENCY; DITRA;; GENERALIZED PUSTULAR PSORIASIS; GPP;; PSORP;; ACRODERMATITIS CONTINUA OF HALLOPEAU;; PALMOPLANTAR PUSTULOSIS__:__
Number Sign__:__614205__:__THREE M SYNDROME 3; 3M3__:__3M SYNDROME 3__:__
Asterisk__:__614206__:__CHROMATIN TARGET OF PRMT1; CHTOP__:__CHROMOSOME 1 OPEN READING FRAME 77; C1OORF77;; SMALL PROTEIN RICH IN ARGININE AND GLYCINE; SRAG;; FRIEND OF PRMT1; FOP__:__
Number Sign__:__614207__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 3; HPMRS3__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 17; MRT17;; MENTAL RETARDATION, AUTOSOMAL RECESSIVE 21; MRT21;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 8; GPIBD8__:__
Percent__:__614208__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 16; MRT16__:____:__
Number Sign__:__614209__:__MECKEL SYNDROME, TYPE 9; MKS9__:____:__
Percent__:__614210__:__LUNG CANCER SUSCEPTIBILITY 5; LNCR5__:____:__
Percent__:__614211__:__DEAFNESS, AUTOSOMAL DOMINANT 33; DFNA33__:____:__
Number Sign__:__614212__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 4; IIAE4__:____:__
Number Sign__:__614213__:__NEUROPATHY, HEREDITARY SENSORY, TYPE IIC; HSN2C__:____:__
Asterisk__:__614214__:__KELCH-LIKE 6; KLHL6__:__FLJ00029__:__
Asterisk__:__614215__:__ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 1; ASCC1__:__ASC1 COMPLEX, 50-KD SUBUNIT;; p50__:__
Asterisk__:__614216__:__ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 2; ASCC2__:__ASC1 COMPLEX, 100-KD SUBUNIT;; p100__:__
Asterisk__:__614217__:__ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX, SUBUNIT 3; ASCC3__:__ASC1 COMPLEX SUBUNIT, 200-KD SUBUNIT;; p200__:__
Asterisk__:__614218__:__WD REPEAT-CONTAINING PROTEIN 81; WDR81__:__SORF2, C. ELEGANS, HOMOLOG OF; SORF2__:__
Number Sign__:__614219__:__ADAMS-OLIVER SYNDROME 2; AOS2__:____:__
Percent__:__614220__:__BILIARY CIRRHOSIS, PRIMARY, 4; PBC4__:____:__
Percent__:__614221__:__BILIARY CIRRHOSIS, PRIMARY, 5; PBC5__:____:__
Number Sign__:__614222__:__WARBURG MICRO SYNDROME 3; WARBM3__:__MICRO SYNDROME 3__:__
Percent__:__614223__:__NARCOLEPSY 6, SUSCEPTIBILITY TO; NRCLP6__:____:__
Number Sign__:__614224__:__RETINAL ARTERIAL MACROANEURYSM WITH SUPRAVALVULAR PULMONIC STENOSIS; RAMSVPS__:____:__
Number Sign__:__614225__:__WARBURG MICRO SYNDROME 2; WARBM2__:__MICRO SYNDROME 2__:__
Number Sign__:__614226__:__HOLOPROSENCEPHALY 11; HPE11__:____:__
Percent__:__614227__:__HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 3; HNFJ3__:____:__
Number Sign__:__614228__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O__:__CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2O;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2O__:__
Number Sign__:__614229__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 11; SCAR11__:____:__
Number Sign__:__614230__:__CHROMOSOME 8q21.11 DELETION SYNDROME__:____:__
Number Sign__:__614231__:__MICROCEPHALY, EPILEPSY, AND DIABETES SYNDROME; MEDS__:____:__
Asterisk__:__614232__:__11-BETA-HYDROXYSTEROID DEHYDROGENASE, TYPE II; HSD11B2__:__11-BETA-HSD;; HSD11, KIDNEY AND PLACENTAL TYPE; HSD11K;; HSD11, TYPE II__:__
Percent__:__614233__:__HYPERPIGMENTATION, FAMILIAL PROGRESSIVE, 1; FPH1__:__FPH__:__
Asterisk__:__614234__:__PITCHFORK, MOUSE, HOMOLOG OF; PIFO__:__CHROMOSOME 1 OPEN READING FRAME 88; C1ORF88__:__
Asterisk__:__614235__:__PDZ DOMAIN-CONTAINING PROTEIN 8; PDZD8__:____:__
Asterisk__:__614236__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 7; SLC38A7__:__SODIUM-COUPLED NEUTRAL AMINO ACID TRANSPORTER 7; SNAT7__:__
Percent__:__614237__:__HYPOTRICHOSIS 9; HYPT9__:____:__
Percent__:__614238__:__HYPOTRICHOSIS 10; HYPT10__:____:__
Asterisk__:__614239__:__FAMILY WITH SEQUENCE SIMILARITY 109, MEMBER A; FAM109A__:__SESQUIPEDALIAN, DROSOPHILA, HOMOLOG OF, 1; SES1;; INOSITOL POLYPHOSPHATE PHOSPHATASE-INTERACTING PROTEIN, 27-KD, A; IPIP27A__:__
Asterisk__:__614240__:__FAMILY WITH SEQUENCE SIMILARITY 109, MEMBER B; FAM109B__:__SESQUIPEDALIAN, DROSOPHILA, HOMOLOG OF, 2; SES2;; INOSITOL POLYPHOSPHATE PHOSPHATASE-INTERACTING PROTEIN, 27-KD, B; IPIP27B__:__
Asterisk__:__614241__:__LYSOCARDIOLIPIN ACYLTRANSFERASE 1; LCLAT1__:__ACYL-CoA:LYSOCARDIOLIPIN ACYLTRANSFERASE 1; ALCAT1;; 1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 8; AGPAT8__:__
Asterisk__:__614242__:__SOLUTE CARRIER FAMILY 16 (MONOCARBOXYLIC ACID TRANSPORTER), MEMBER 9; SLC16A9__:__MONOCARBOXYLATE TRANSPORTER 9; MCT9__:__
Asterisk__:__614243__:__5-OXOPROLINASE (ATP-HYDROLYZING); OPLAH__:__5-OXO-L-PROLINASE__:__
Asterisk__:__614244__:__PYRIDOXAL-DEPENDENT DECARBOXYLASE DOMAIN-CONTAINING PROTEIN 1; PDXDC1__:__KIAA0251__:__
Asterisk__:__614245__:__ACYL-CoA SYNTHETASE FAMILY, MEMBER 3; ACSF3__:____:__
Asterisk__:__614246__:__N-ALPHA-ACETYLTRANSFERASE 60, NatF CATALYTIC SUBUNIT; NAA60__:__NAT15__:__
Asterisk__:__614247__:__MICRO RNA 519D; MIR519D__:__miRNA519D;; MIRN519D__:__
Asterisk__:__614248__:__PSEUDOPODIUM-ENRICHED ATYPICAL KINASE 1__:__PEAK1;; SGK269;; NKF3 KINASE FAMILY MEMBER;; KIAA2002__:__
Number Sign__:__614249__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 18; MRT18__:____:__
Number Sign__:__614250__:__NARCOLEPSY 7; NRCLP7__:____:__
Number Sign__:__614251__:__PARKINSON DISEASE 18, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO; PARK18__:____:__
Percent__:__614252__:__ANEURYSM, INTRACRANIAL BERRY, 11; ANIB11__:____:__
Caret__:__614253__:__MOVED TO 204690__:____:__
Number Sign__:__614254__:__NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT HYPERKINETIC MOVEMENTS AND SEIZURES, AUTOSOMAL DOMINANT; NDHMSD__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 8, FORMERLY; MRD8, FORMERLY__:__
Number Sign__:__614255__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 9; MRD9__:____:__
Number Sign__:__614256__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 10; MRD10__:____:__
Number Sign__:__614257__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 11; MRD11__:____:__
Asterisk__:__614258__:__POLYMERASE III, RNA, SUBUNIT A; POLR3A__:__RNA POLYMERASE III, SUBUNIT C1; RPC1;; RNA POLYMERASE III, 155-KD SUBUNIT;; RPC155__:__
Asterisk__:__614259__:__WD REPEAT-CONTAINING PROTEIN 65; WDR65__:____:__
Asterisk__:__614260__:__CHROMOSOME 9 OPEN READING FRAME 72; C9ORF72__:____:__
Number Sign__:__614261__:__MICROCEPHALY-CAPILLARY MALFORMATION SYNDROME; MICCAP__:____:__
Number Sign__:__614262__:__ARTHROGRYPOSIS, PERTHES DISEASE, AND UPWARD GAZE PALSY; APUG__:____:__
Asterisk__:__614263__:__BACE1 ANTISENSE RNA: BACE1AS__:____:__
Asterisk__:__614264__:__RHO GTPase-ACTIVATING PROTEIN 30; ARHGAP30__:____:__
Number Sign__:__614265__:__COMBINED MALONIC AND METHYLMALONIC ACIDURIA; CMAMMA__:____:__
Number Sign__:__614266__:__BARRETT ESOPHAGUS__:__BARRETT METAPLASIA__:__ADENOCARCINOMA OF ESOPHAGUS, INCLUDED
Asterisk__:__614267__:__ACYL-CoA THIOESTERASE 6; ACOT6__:____:__
Asterisk__:__614268__:__ADHESION G PROTEIN-COUPLED RECEPTOR F4; ADGRF4__:__G PROTEIN-COUPLED RECEPTOR 115; GPR115__:__
Asterisk__:__614269__:__G PROTEIN-COUPLED RECEPTOR 153; GPR153__:____:__
Asterisk__:__614270__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 65; CFAP65__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 108; CCDC108__:__
Asterisk__:__614271__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 137; CCDC137__:____:__
Asterisk__:__614272__:__FAST KINASE DOMAINS 5; FASTKD5__:__FAST KINASE DOMAIN-CONTAINING PROTEIN 5__:__
Asterisk__:__614273__:__OLFACTORY RECEPTOR, FAMILY 4, SUBFAMILY C, MEMBER 46; OR4C46__:____:__
Asterisk__:__614274__:__STRAWBERRY NOTCH, DROSOPHILA, HOMOLOG OF, 1; SBNO1__:____:__
Asterisk__:__614275__:__ZINC FINGER PROTEIN 565; ZNF565__:____:__
Asterisk__:__614276__:__PHOSPHOLIPASE C-LIKE 2; PLCL2__:__PHOSPHOLIPASE C-RELATED CATALYTICALLY INACTIVE PROTEIN 2; PRIP2;; KIAA1092__:__
Asterisk__:__614277__:__UBIQUITIN-CONJUGATING ENZYME 2W; UBE2W__:__UBC16, ARABIDOPSIS, HOMOLOG OF; UBC16__:__
Number Sign__:__614278__:__PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE DEFICIENCY; PAFAD__:____:__
Number Sign__:__614279__:__46,XY SEX REVERSAL 8; SRXY8__:__MALE PSEUDOHERMAPHRODITISM DUE TO DEFICIENCY OF TESTICULAR 17,20-DESMOLASE; TDD__:__
Percent__:__614280__:__EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 9; EJM9__:____:__
Asterisk__:__614281__:__ENDOTHELIAL CELL ADHESION MOLECULE; ESAM__:__ENDOTHELIAL CELL-SELECTIVE ADHESION MOLECULE__:__
Asterisk__:__614282__:__STROMAL CELL-DERIVED FACTOR 4; SDF4__:__CALCIUM-BINDING PROTEIN, 45-KD; CAB45__:__
Asterisk__:__614283__:__GLUCOCORTICOID-INDUCED TRANSCRIPT 1; GLCCI1__:__THYMOCYTE/SPERMATOCYTE SELECTION 1; TSSN1__:__
Number Sign__:__614284__:__STICKLER SYNDROME, TYPE V; STL5__:____:__
Asterisk__:__614285__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 9; C1QTNF9__:__CTRP9;; C1QTNF9A__:__
Number Sign__:__614286__:__MYELODYSPLASTIC SYNDROME; MDS__:__MYELODYSPLASTIC SYNDROME, SUSCEPTIBILITY TO, INCLUDED__:__
Asterisk__:__614287__:__OFC1 CANDIDATE GENE 1; OFCC1__:__MRDS1__:__
Asterisk__:__614288__:__ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 11; ACAD11__:____:__
Asterisk__:__614289__:__SUPPRESSOR OF LIN12-LIKE 2; SEL1L2__:__SEL1L-LIKE__:__
Number Sign__:__614290__:__TETRASOMY 18p__:__ISOCHROMOSOME 18p SYNDROME__:__
Number Sign__:__614291__:__BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 4; BROVCA4__:____:__
Number Sign__:__614292__:__MYOPIA, HIGH, WITH CATARACT AND VITREORETINAL DEGENERATION; MCVD__:____:__
Number Sign__:__614293__:__HYDATIDIFORM MOLE, RECURRENT, 2; HYDM2__:__HYDATIDIFORM MOLE, COMPLETE__:__
Number Sign__:__614294__:__CHROMOSOME 15q25 DELETION SYNDROME__:____:__
Asterisk__:__614295__:__BICAUDAL C, DROSOPHILA, HOMOLOG OF, 1; BICC1__:__BICC__:__
Number Sign__:__614296__:__WOLFRAM-LIKE SYNDROME, AUTOSOMAL DOMINANT; WFSL__:__HEARING LOSS, PROGRESSIVE, WITH OPTIC ATROPHY AND/OR IMPAIRED GLUCOSE REGULATION__:__
Asterisk__:__614297__:__CHROMOSOME 19 OPEN READING FRAME 12; C19ORF12__:____:__
Number Sign__:__614298__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 4; NBIA4__:__MITOCHONDRIAL PROTEIN-ASSOCIATED NEURODEGENERATION; MPAN__:__
Number Sign__:__614299__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 2 WITH HYPERGLYCINEMIA; MMDS2__:____:__
Number Sign__:__614300__:__HYPERMETHIONINEMIA DUE TO ADENOSINE KINASE DEFICIENCY__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 8, FORMERLY; MRT8, FORMERLY__:__
Asterisk__:__614301__:__ATAXIN 1-LIKE; ATXN1L__:__BROTHER OF ATAXIN 1; BOAT; BOAT1;; BROTHER OF ATXN1__:__
Number Sign__:__614302__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 7, AUTOSOMAL DOMINANT; EDMD7__:____:__
Number Sign__:__614303__:__EDICT SYNDROME; EDICT__:__ENDOTHELIAL DYSTROPHY, IRIS HYPOPLASIA, CONGENITAL CATARACT, AND STROMAL THINNING SYNDROME;; KERATOCONUS WITH CATARACT; KTCNCT;; KERATOCONUS, FAMILIAL, WITH EARLY-ONSET ANTERIOR POLAR CATARACT__:__
Asterisk__:__614304__:__MICRO RNA 137; MIR137__:__miRNA137;; MIRN137__:__
Number Sign__:__614305__:__SCLEROSTEOSIS 2; SOST2__:____:__
Number Sign__:__614306__:__COGNITIVE IMPAIRMENT WITH OR WITHOUT CEREBELLAR ATAXIA; CIAT__:____:__
Number Sign__:__614307__:__ALPHA-METHYLACYL-CoA RACEMASE DEFICIENCY; AMACRD__:__AMACR DEFICIENCY__:__
Asterisk__:__614308__:__FORMIMINOTRANSFERASE CYCLODEAMINASE N-TERMINAL-LIKE PROTEIN 1; FTCDNL1__:__FORMIMINOTRANSFERASE N-TERMINAL SUBDOMAIN-CONTAINING GENE; FONG__:__
Asterisk__:__614309__:__tRNA METHYLTRANSFERASE 44, S. CEREVISIAE, HOMOLOG OF; TRMT44__:__METHYLTRANSFERASE-LIKE 19; METTL19__:__
Asterisk__:__614310__:__CENTROSOMAL PROTEIN, 70-KD; CEP70__:____:__
Asterisk__:__614311__:__SYNAPSE DIFFERENTIATION-INDUCED GENE 1; SYNDIG1__:__TRANSMEMBRANE PROTEIN 90B; TMEM90B__:__
Asterisk__:__614312__:__ZINC FINGER MYND-CONTAINING PROTEIN 15; ZMYND15__:____:__
Asterisk__:__614313__:__ACYL-CoA THIOESTERASE 1; ACOT1__:____:__
Asterisk__:__614314__:__ACYL-CoA THIOESTERASE 4; ACOT4__:____:__
Asterisk__:__614315__:__ACYL-CoA THIOESTERASE 12; ACOT12__:__CYTOSOLIC ACETYL-CoA HYDROLASE; CACH__:__
Asterisk__:__614316__:__VTI1, S. CEREVISIAE, HOMOLOG OF, A; VTI1A__:__VTI1RP2__:__VTI1A/TCF7L2 FUSION GENE, INCLUDED
Percent__:__614317__:__VESICOURETERAL REFLUX 4; VUR4__:____:__
Percent__:__614318__:__VESICOURETERAL REFLUX 5; VUR5__:____:__
Percent__:__614319__:__VESICOURETERAL REFLUX 6; VUR6__:____:__
Number Sign__:__614320__:__PANCREATIC CANCER, SUSCEPTIBILITY TO, 4; PNCA4__:____:__
Number Sign__:__614321__:__MYOPATHY, DISTAL, TATEYAMA TYPE; MPDT__:____:__
Number Sign__:__614322__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 12; SCAR12__:__SPINOCEREBELLAR ATAXIA WITH MENTAL RETARDATION AND EPILEPSY__:__
Percent__:__614323__:__NEVOID HYPERMELANOSIS, LINEAR AND WHORLED; LWNH__:____:__HYPERPIGMENTATION, PROGRESSIVE CRIBRIFORM AND ZOSTERIFORM, INCLUDED; PCZH, INCLUDED
Number Sign__:__614324__:__OVARIAN DYSGENESIS 3; ODG3__:____:__
Number Sign__:__614325__:__PITT-HOPKINS-LIKE SYNDROME 2; PTHSL2__:____:__
Number Sign__:__614326__:__FEINGOLD SYNDROME 2; FGLDS2__:__BRACHYDACTYLY WITH SHORT STATURE AND MICROCEPHALY__:__
Number Sign__:__614327__:__TUMOR PREDISPOSITION SYNDROME; TPDS__:____:__
Number Sign__:__614328__:__INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 1; NISBD1__:____:__
Percent__:__614329__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 31; MRT31__:____:__
Asterisk__:__614330__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 2; C1QL2__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 10; C1QTNF10;; CTRP10__:__
Number Sign__:__614331__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6; HNPCC6__:__COLON CANCER, HEREDITARY NONPOLYPOSIS, TYPE 6__:__
Number Sign__:__614332__:__CHROMOSOME 2p16.3 DELETION SYNDROME__:____:__SCHIZOPHRENIA 17, INCLUDED; SCZD17, INCLUDED
Percent__:__614333__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 29; MRT29__:____:__
Asterisk__:__614334__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 13; DNAJC13__:__RECEPTOR-MEDIATED ENDOCYTOSIS 8, C. ELEGANS, HOMOLOG OF; RME8;; KIAA0678__:__
Number Sign__:__614335__:__ARTHROGRYPOSIS, DISTAL, TYPE 1B; DA1B__:____:__
Asterisk__:__614336__:__PRESEQUENCE TRANSLOCASE-ASSOCIATED MOTOR 16, S. CEREVISIAE, HOMOLOG OF; PAM16__:__MITOCHONDRIA-ASSOCIATED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR SIGNALING MOLECULE; MAGMAS__:__
Number Sign__:__614337__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 4; HNPCC4__:____:__
Number Sign__:__614338__:__PANCREATIC LIPASE DEFICIENCY; PNLIPD__:__LIPASE, CONGENITAL ABSENCE OF PANCREATIC;; PL DEFICIENCY__:__PANCREATIC COLIPASE DEFICIENCY, INCLUDED;; COLIPASE, CONGENITAL ABSENCE OF PANCREATIC, INCLUDED;; LIPASE AND COLIPASE, DEFICIENCY OF, INCLUDED;; LIPASE AND COLIPASE, CONGENITAL ABSENCE OF PANCREATIC, INCLUDED
Caret__:__614339__:__MOVED TO 607596__:____:__
Number Sign__:__614340__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 27; MRT27__:____:__
Percent__:__614341__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 33; MRT33__:____:__
Percent__:__614342__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 30; MRT30__:____:__
Percent__:__614343__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 19; MRT19__:____:__
Percent__:__614344__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 23; MRT23__:____:__
Percent__:__614345__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 24; MRT24__:____:__
Percent__:__614346__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 25; MRT25__:____:__
Percent__:__614347__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 28; MRT28__:____:__
Asterisk__:__614348__:__CHROMOSOME 6 OPEN READING FRAME 105; C6ORF105__:__ANDROGEN-DEPENDENT TFPI-REGULATING PROTEIN; ADTRP__:__
Asterisk__:__614349__:__ZINC FINGER PROTEIN 638; ZNF638__:__NUCLEAR PROTEIN, 220-KD; NP220__:__
Number Sign__:__614350__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 5; HNPCC5__:____:__
Asterisk__:__614351__:__NUCLEOPORIN, 93-KD; NUP93__:__NIC96, S. CEREVISIAE, HOMOLOG OF; NIC96;; KIAA0095__:__
Asterisk__:__614352__:__NUCLEOPORIN, 205-KD; NUP205__:__CHROMOSOME 7 OPEN READING FRAMER 14; C7ORF14;; KIAA0225__:__
Asterisk__:__614353__:__HAS2 ANTISENSE RNA 1; HAS2AS1__:__HYALURONAN SYNTHASE 2, ANTISENSE; HASNT__:__
Asterisk__:__614354__:__PRO2268 GENE__:____:__
Asterisk__:__614355__:__ACYL-CoA SYNTHETASE SHORT CHAIN FAMILY, MEMBER 1; ACSS1__:__ACYL-CoA SYNTHETASE 1; ACECS1__:__
Asterisk__:__614356__:__ACYL-CoA SYNTHETASE SHORT CHAIN FAMILY, MEMBER 3; ACSS3__:____:__
Asterisk__:__614357__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 1; ACSM1__:__MEDIUM CHAIN ACYL-CoA SYNTHETASE 1; MACS1__:__
Asterisk__:__614358__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 2A; ACSM2A__:____:__
Asterisk__:__614359__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 2B; ACSM2B__:__XENOBIOTIC/MEDIUM CHAIN FATTY ACID-CoA LIGASE A; HXMA__:__
Asterisk__:__614360__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 4; ACSM4__:____:__
Asterisk__:__614361__:__ACYL-CoA SYNTHETASE MEDIUM CHAIN FAMILY, MEMBER 5; ACSM5__:____:__
Asterisk__:__614362__:__ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 1; ACSBG1__:__BUBBLEGUM, DROSOPHILA, HOMOLOG OF; BG;; BG1;; LIPIDOSIN;; KIAA0631__:__
Asterisk__:__614363__:__ACYL-CoA SYNTHETASE, BUBBLEGUM FAMILY, MEMBER 2; ACSBG2__:__BUBBLEGUM-RELATED PROTEIN; BGR__:__
Asterisk__:__614364__:__ACETOACETYL-CoA SYNTHETASE; AACS__:__ACYL-CoA SYNTHETASE FAMILY, MEMBER 1; ACSF1__:__
Asterisk__:__614365__:__AMINOADIPATE-SEMIALDEHYDE DEHYDROGENASE; AASDH__:__ACYL-CoA SYNTHETASE FAMILY, MEMBER 4; ACSF4__:__
Asterisk__:__614366__:__POLYMERASE III, RNA, SUBUNIT B; POLR3B__:__RPC2;; C128, S. CEREVISIAE, HOMOLOG OF; C128__:__
Asterisk__:__614367__:__ADAPTOR-RELATED PROTEIN COMPLEX 5, BETA-1 SUBUNIT; AP5B1__:__ADAPTOR-RELATED PROTEIN COMPLEX 5, BETA SUBUNIT;; BETA-5;; DKFZp761E198__:__
Asterisk__:__614368__:__ADAPTOR-RELATED PROTEIN COMPLEX 5, MU-1 SUBUNIT; AP5M1__:__MU-2/AP1M2 DOMAIN-CONTAINING DEATH-INDUCING PROTEIN; MUDENG;; MUD;; CHROMOSOME 14 OPEN READING FRAME 108; C14ORF108;; ADAPTOR-RELATED PROTEIN COMPLEX 5, MU SUBUNIT;; MU-5__:__
Number Sign__:__614369__:__PERIPHERAL NEUROPATHY, MYOPATHY, HOARSENESS, AND HEARING LOSS; PNMHH__:____:__
Number Sign__:__614370__:__SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 5; SMDP5__:__PULMONARY ALVEOLAR PROTEINOSIS 5;; PAP DUE TO CSF2RB DEFICIENCY;; CSF2RB DEFICIENCY__:__
Number Sign__:__614371__:__DENGUE VIRUS, SUSCEPTIBILITY TO__:____:__DENGUE FEVER, SUSCEPTIBILITY TO, INCLUDED;; DENGUE FEVER, PROTECTION AGAINST, INCLUDED;; DENGUE HEMORRHAGIC FEVER, SUSCEPTIBILITY TO, INCLUDED;; DENGUE SHOCK SYNDROME, SUSCEPTIBILITY TO, INCLUDED
Number Sign__:__614372__:__MANNOSE-BINDING LECTIN DEFICIENCY; MBLD__:__LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 1; LCAPD1;; MBL DEFICIENCY;; MANNOSE-BINDING PROTEIN DEFICIENCY;; MBP DEFICIENCY;; MBL2 DEFICIENCY__:__
Number Sign__:__614373__:__AMYOTROPHIC LATERAL SCLEROSIS 16, JUVENILE; ALS16__:____:__
Number Sign__:__614374__:__BLOOD GROUP, CHIDO/RODGERS SYSTEM__:__CHIDO/RODGERS BLOOD GROUP SYSTEM__:__
Percent__:__614375__:__AORTIC ANEURYSM, FAMILIAL ABDOMINAL, 4; AAA4__:____:__
Number Sign__:__614376__:__SHORT-RIB THORACIC DYSPLASIA 5 WITH OR WITHOUT POLYDACTYLY; SRTD5__:__ASPHYXIATING THORACIC DYSTROPHY 5; ATD5__:__
Number Sign__:__614377__:__NEPHRONOPHTHISIS 13; NPHP13__:____:__
Number Sign__:__614378__:__CRANIOECTODERMAL DYSPLASIA 4; CED4__:____:__
Number Sign__:__614379__:__COMPLEMENT COMPONENT 4B DEFICIENCY; C4BD__:__C4B DEFICIENCY__:__
Number Sign__:__614380__:__COMPLEMENT COMPONENT 4A DEFICIENCY; C4AD__:__C4A DEFICIENCY__:__
Number Sign__:__614381__:__LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD8__:____:__
Number Sign__:__614382__:__BACTEREMIA, SUSCEPTIBILITY TO, 1; BACTS1__:____:__BACTEREMIA, RESISTANCE TO, INCLUDED
Number Sign__:__614383__:__BACTEREMIA, SUSCEPTIBILITY TO, 2; BACTS2__:____:__
Asterisk__:__614384__:__MICRO RNA 492; MIR492__:__miRNA492__:__
Number Sign__:__614385__:__COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS, TYPE 7; HNPCC7__:____:__
Asterisk__:__614386__:__PROLINE-RICH TRANSMEMBRANE PROTEIN 2; PRRT2__:____:__
Asterisk__:__614387__:__ZINC FINGER PROTEIN 526; ZNF526__:__KIAA1951__:__
Number Sign__:__614388__:__ENCEPHALOPATHY DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMAL FISSION 1; EMPF1__:__EMPF__:__
Number Sign__:__614389__:__PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 1; RPRGL1__:__RPRGL;; RPL;; ABORTION, SPONTANEOUS, RECURRENT;; FETAL LOSS, RECURRENT, SUSCEPTIBILITY TO;; MISCARRIAGE, RECURRENT;; EMBRYONIC LOSS, RECURRENT;; STILLBIRTH, RECURRENT__:__
Number Sign__:__614390__:__PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 2; RPRGL2__:____:__
Number Sign__:__614391__:__PREGNANCY LOSS, RECURRENT, SUSCEPTIBILITY TO, 3; RPRGL3__:____:__
Asterisk__:__614392__:__TUDOR DOMAIN-CONTAINING PROTEIN 3; TDRD3__:____:__
Asterisk__:__614393__:__O-ACYL-ADP-RIBOSE DEACYLASE 1; OARD1__:__CHROMOSOME 6 OPEN READING FRAME 130; C6ORF130__:__
Asterisk__:__614394__:__INTRAFLAGELLAR TRANSPORT 20, CHLAMYDOMONAS, HOMOLOG OF: IFT20__:____:__
Number Sign__:__614395__:__GRAFT-VERSUS-HOST DISEASE, SUSCEPTIBILITY TO; GVHDS__:____:__GRAFT-VERSUS-HOST DISEASE, RESISTANCE TO, INCLUDED
Asterisk__:__614396__:__G-PATCH DOMAIN-CONTAINING PROTEIN 8; GPATCH8__:__KIAA0553__:__
Asterisk__:__614397__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 2A; MFSD2A__:____:__
Asterisk__:__614398__:__KIAA1462 GENE; KIAA1462__:__JUNCTIONAL PROTEIN ASSOCIATED WITH CORONARY ARTERY DISEASE; JCAD__:__
Number Sign__:__614399__:__MYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET; EMARDD__:____:__MYOPATHY, AREFLEXIA, RESPIRATORY DISTRESS, AND DYSPHAGIA, EARLY-ONSET, MILD VARIANT, INCLUDED
Number Sign__:__614400__:__GLUCOCORTICOID THERAPY, RESPONSE TO; GCTR__:____:__
Number Sign__:__614401__:__ACCELERATED TUMOR FORMATION, SUSCEPTIBILITY TO; ACTFS__:____:__
Number Sign__:__614402__:__MICROPHTHALMIA, SYNDROMIC 11; MCOPS11__:____:__
Asterisk__:__614403__:__RHOMBOID 5, DROSOPHILA, HOMOLOG OF, 1; RHBDF1__:__INACTIVE RHOMBOID PROTEIN 1; IRHOM1;; DIST1__:__
Asterisk__:__614404__:__RHOMBOID 5, DROSOPHILA, HOMOLOG OF, 2; RHBDF2__:__INACTIVE RHOMBOID PROTEIN 2; IRHOM2__:__
Asterisk__:__614405__:__DEAH BOX POLYPEPTIDE 33; DHX33__:____:__
Asterisk__:__614406__:__SLP ADAPTOR- AND CSK-INTERACTING MEMBRANE PROTEIN; SCIMP__:__SLP65/SLP76- AND CSK-INTERACTING MEMBRANE PROTEIN;; CHROMOSOME 17 OPEN READING FRAME 87; C17ORF87__:__
Percent__:__614407__:__MICROCEPHALY, CEREBELLAR HYPOPLASIA, AND CARDIAC CONDUCTION DEFECT SYNDROME; MCHCCD__:__ZAKI-GLEESON SYNDROME__:__
Number Sign__:__614408__:__MYOPATHY, CENTRONUCLEAR, 3; CNM3__:____:__
Number Sign__:__614409__:__SPASTIC PARAPLEGIA 46, AUTOSOMAL RECESSIVE; SPG46__:____:__
Asterisk__:__614410__:__ACTIN FILAMENT-ASSOCIATED PROTEIN 1-LIKE 1; AFAP1L1__:____:__
Number Sign__:__614411__:__GLYCEROL QUANTITATIVE TRAIT LOCUS; GLYCQTL__:__GLYCEROL RELEASE DURING EXERCISE, DEFECTIVE__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 17, INCLUDED; BMIQ17, INCLUDED
Asterisk__:__614412__:__TESTIS- AND OVARY-SPECIFIC PAZ DOMAIN-CONTAINING PROTEIN 1; TOPAZ1__:__CHROMOSOME 3 OPEN READING FRAME 77; C3ORF77__:__
Asterisk__:__614413__:__AMINOACYLASE 3; ACY3__:__ASPARTOACYLASE 3;; HEPATITIS C VIRUS CORE-BINDING PROTEIN 1; HCBP1;; HCV CORE-BINDING PROTEIN 1__:__
Percent__:__614414__:__DEAFNESS, AUTOSOMAL RECESSIVE 96; DFNB96__:____:__
Number Sign__:__614415__:__CHILBLAIN LUPUS 2; CHBL2__:____:__
Number Sign__:__614416__:__RADIOHUMERAL FUSIONS WITH OTHER SKELETAL AND CRANIOFACIAL ANOMALIES; RHFCA__:____:__
Number Sign__:__614417__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 5; ETL5__:____:__
Number Sign__:__614418__:__FEBRILE SEIZURES, FAMILIAL, 11; FEB11__:__CONVULSIONS, FAMILIAL FEBRILE, 11__:__
Number Sign__:__614419__:__ASPARTATE AMINOTRANSFERASE, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS 1__:__ASTQTL1__:__
Number Sign__:__614420__:__SYSTEMIC LUPUS ERYTHEMATOSUS 16; SLEB16__:____:__
Caret__:__614421__:__MOVED TO 277590__:____:__
Percent__:__614422__:__CATARACT 37; CTRCT37__:__CATARACT, CONGENITAL, CERULEAN TYPE, 5; CCA5__:__
Asterisk__:__614423__:__TRANSMEMBRANE PROTEIN 237; TMEM237__:__ALS2 CHROMOSOME REGION GENE 4; ALS2CR4__:__
Number Sign__:__614424__:__JOUBERT SYNDROME 14; JBTS14__:____:__
Asterisk__:__614425__:__TELO2-INTERACTING PROTEIN 1; TTI1__:__KIAA0406__:__
Asterisk__:__614426__:__TELO2-INTERACTING PROTEIN 2; TTI2__:__CHROMOSOME 8 OPEN READING FRAME 41; C8ORF41__:__
Asterisk__:__614427__:__TEASHIRT ZINC FINGER HOMEOBOX 1; TSHZ1__:__TSH1;; NY-CO-33__:__
Asterisk__:__614428__:__TRANSCRIPTION FACTOR AP2-EPSILON; TFAP2E__:__AP2-EPSILON__:__
Number Sign__:__614429__:__VENTRICULAR SEPTAL DEFECT 1; VSD1__:____:__
Number Sign__:__614430__:__ATRIOVENTRICULAR SEPTAL DEFECT 4; AVSD4__:____:__
Number Sign__:__614431__:__VENTRICULAR SEPTAL DEFECT 2; VSD2__:____:__
Number Sign__:__614432__:__VENTRICULAR SEPTAL DEFECT 3; VSD3__:____:__
Number Sign__:__614433__:__ATRIAL SEPTAL DEFECT 8; ASD8__:____:__
Number Sign__:__614434__:__CUTIS LAXA, AUTOSOMAL DOMINANT 2; ADCL2__:____:__
Number Sign__:__614435__:__HYPOPLASTIC LEFT HEART SYNDROME 2; HLHS2__:____:__
Number Sign__:__614436__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2P;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2G, FORMERLY; CMT2G, FORMERLY__:__
Number Sign__:__614437__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IB; ARCL1B__:____:__
Number Sign__:__614438__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIIB; ARCL3B__:__DE BARSY SYNDROME B__:__
Asterisk__:__614439__:__ADP-RIBOSYLATION FACTOR-LIKE 14; ARL14__:__ADP-RIBOSYLATION FACTOR 7; ARF7__:__
Asterisk__:__614440__:__PLECKSTRIN AND SEC7 DOMAINS-CONTAINING PROTEIN 3; PSD3__:__HCA67;; EFA6R__:__
Number Sign__:__614441__:__HYPERTROPHIC OSTEOARTHROPATHY, PRIMARY, AUTOSOMAL RECESSIVE, 2; PHOAR2__:__PACHYDERMOPERIOSTOSIS, AUTOSOMAL RECESSIVE;; PDP, AUTOSOMAL RECESSIVE__:__
Asterisk__:__614442__:__PLECKSTRIN AND SEC7 DOMAINS-CONTAINING PROTEIN 4; PSD4__:__EXCHANGE FACTOR FOR ARF6, B; EFA6B;; TELOMERIC OF INTERLEUKIN 1 CLUSTER; TIC__:__
Asterisk__:__614443__:__EBNA1-BINDING PROTEIN 2; EBNA1BP2__:__EBP2__:__
Asterisk__:__614444__:__RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR WITH PH DOMAIN AND SH3 DOMAIN-BINDING MOTIF 1; RALGPS1__:__RAL GEF WITH PH DOMAIN AND SH3 DOMAIN-BINDING MOTIF;; RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR 2; RALGEF2;; KIAA0351__:__
Asterisk__:__614445__:__DEVELOPMENTAL PLURIPOTENCY-ASSOCIATED GENE 2; DPPA2__:__PLURIPOTENT EMBRYONIC STEM CELL-RELATED GENE 1; PESCRG1;; EMBRYONIC STEM CELL-ASSOCIATED TRANSCRIPT 15-2;; ECAT15-2__:__
Asterisk__:__614446__:__ATPase, CLASS II, TYPE 9B; ATP9B__:____:__
Asterisk__:__614447__:__G0/G1 SWITCH GENE 2; G0S2__:____:__
Asterisk__:__614448__:__GEMININ COILED-COIL DOMAIN-CONTAINING PROTEIN; GMNC__:__GEMC1__:__
Asterisk__:__614449__:__PROTOCADHERIN 20; PCDH20__:__PROTOCADHERIN 13; PCDH13__:__
Number Sign__:__614450__:__HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 6; CHNG6__:____:__
Asterisk__:__614451__:__ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 7; ELOVL7__:__ELOVL FATTY ACID ELONGASE 7__:__
Asterisk__:__614452__:__ATPASE FAMILY, AAA DOMAIN-CONTAINING, MEMBER 1; ATAD1__:__THORASE__:__
Asterisk__:__614453__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 7; LRRC7__:__DENSIN;; DENSIN 180;; KIAA1365__:__
Asterisk__:__614454__:__UBIQUITIN PROTEIN LIGASE E3C; UBE3C__:__HECTH2;; KIAA0010;; KIAA10__:__
Number Sign__:__614455__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE__:__CHARCOT-MARIE-TOOTH NEUROPATHY WITH FOCAL SEGMENTAL GLOMERULONEPHRITIS__:__
Number Sign__:__614456__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 8; CMM8__:__MELANOMA AND RENAL CELL CARCINOMA, SUSCEPTIBILITY TO__:__
Number Sign__:__614457__:__ICHTHYOSIS, SPASTIC QUADRIPLEGIA, AND MENTAL RETARDATION; ISQMR__:____:__
Number Sign__:__614458__:__THIAMINE METABOLISM DYSFUNCTION SYNDROME 5 (EPISODIC ENCEPHALOPATHY TYPE); THMD5__:__ENCEPHALOPATHY, EPISODIC, DUE TO THIAMINE PYROPHOSPHOKINASE DEFICIENCY__:__
Asterisk__:__614459__:__TRANSMEMBRANE PROTEIN 138; TMEM138__:____:__
Asterisk__:__614460__:__UBIQUITIN-SPECIFIC PROTEASE 47; USP47__:____:__
Asterisk__:__614461__:__UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX ASSEMBLY FACTOR 2; UQCC2__:__CHROMOSOME 6 OPEN READING FRAME 125; C6ORF125;; M19__:__
Number Sign__:__614462__:__HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS__:__PYRUVATE DEHYDROGENASE LIPOIC ACID SYNTHETASE DEFICIENCY; PDHLD__:__
Asterisk__:__614463__:__NMYC DOWNSTREAM-REGULATED GENE 4; NDRG4__:__SMOOTH MUSCLE-ASSOCIATED PROTEIN 8; SMAP8;; KIAA1180__:__
Number Sign__:__614464__:__JOUBERT SYNDROME 15; JBTS15__:____:__JOUBERT SYNDROME 9/15, DIGENIC, INCLUDED;; JOUBERT SYNDROME 12/15, DIGENIC, INCLUDED
Number Sign__:__614465__:__JOUBERT SYNDROME 16; JBTS16__:____:__
Number Sign__:__614466__:__CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 6; CHDS6__:____:__
Caret__:__614467__:__MOVED TO 212350__:____:__
Number Sign__:__614468__:__FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3__:__ANTIBODY DEFICIENCY AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED; PLAID;; FAMILIAL ATYPICAL COLD URTICARIA; FACU__:__
Asterisk__:__614469__:__SERRATE RNA EFFECTOR MOLECULE, ARABIDOPSIS, HOMOLOG OF; SRRT__:__ARSENITE RESISTANCE PROTEIN 2; ARS2__:__
Number Sign__:__614470__:__RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER; RALD__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IV; ALPS4__:__
Asterisk__:__614471__:__UBIQUITIN-SPECIFIC PROTEASE 19; USP19__:__KIAA0891__:__
Asterisk__:__614472__:__RING FINGER PROTEIN 123; RNF123__:__KIP1 UBIQUITINATION-PROMOTING COMPLEX 1; KPC1__:__
Number Sign__:__614473__:__ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 2; GACI2__:____:__
Number Sign__:__614474__:__ATRIOVENTRICULAR SEPTAL DEFECT 5; AVSD5__:____:__
Number Sign__:__614475__:__ATRIAL SEPTAL DEFECT 9; ASD9__:____:__
Asterisk__:__614476__:__THROMBOSPONDIN TYPE-1 DOMAIN-CONTAINING PROTEIN 4; THSD4__:__ADAMTS-LIKE PROTEIN 6; ADAMTSL6__:__
Asterisk__:__614477__:__CHROMOSOME 8 OPEN READING FRAME 37; C8ORF37__:____:__
Asterisk__:__614478__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX14; COX14__:__COX14, S. CEREVISIAE, HOMOLOG OF;; CHROMOSOME 12 OPEN READING FRAME 62; C12ORF62__:__
Asterisk__:__614479__:__MALONYL CoA:ACP ACYLTRANSFERASE, MITOCHONDRIAL; MCAT__:__MITOCHONDRIAL MALONYLTRANSFERASE;; MT, MITOCHONDRIAL__:__
Number Sign__:__614480__:__HYPERTRIGLYCERIDEMIA, TRANSIENT INFANTILE; HTGTI__:____:__
Asterisk__:__614481__:__ATXN7 ANTISENSE RNA 1; ATXN7AS1__:__SCA7 ANTISENSE NONCODING TRANSCRIPT 1; SCAANT1__:__
Number Sign__:__614482__:__CONGENITAL CATARACTS, HEARING LOSS, AND NEURODEGENERATION; CCHLND__:____:__
Number Sign__:__614483__:__PORENCEPHALY 2; POREN2__:____:__
Asterisk__:__614484__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 13; ANAPC13__:__APC13;; SWM1, S. CEREVISIAE, HOMOLOG OF; SWM1__:__
Number Sign__:__614485__:__TRIGONOCEPHALY 2; TRIGNO2__:__CRANIOSYNOSTOSIS, METOPIC__:__
Number Sign__:__614486__:__THROMBOPHILIA DUE TO THROMBOMODULIN DEFECT; THPH12__:____:__
Number Sign__:__614487__:__SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5__:____:__
Asterisk__:__614488__:__MICRO RNA 1258; MIR1258__:__miRNA1258__:__
Asterisk__:__614489__:__MICRO RNA 616; MIR616__:__miRNA616__:__
Number Sign__:__614490__:__BLOOD GROUP, JUNIOR SYSTEM; JR__:____:__
Number Sign__:__614491__:__PSEUDOHYPOALDOSTERONISM, TYPE IIB; PHA2B__:____:__
Number Sign__:__614492__:__PSEUDOHYPOALDOSTERONISM, TYPE IIC; PHA2C__:____:__
Number Sign__:__614493__:__WISKOTT-ALDRICH SYNDROME 2; WAS2__:__WIPF1 DEFICIENCY__:__
Percent__:__614494__:__RETINITIS PIGMENTOSA 63; RP63__:____:__
Number Sign__:__614495__:__PSEUDOHYPOALDOSTERONISM, TYPE IID; PHA2D__:__FAMILIAL HYPERKALEMIC HYPERTENSION; FHHT__:__
Number Sign__:__614496__:__PSEUDOHYPOALDOSTERONISM, TYPE IIE; PHA2E__:____:__
Number Sign__:__614497__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 7; MCOPCB7__:____:__
Number Sign__:__614498__:__RIGIDITY AND MULTIFOCAL SEIZURE SYNDROME, LETHAL NEONATAL; RMFSL__:____:__
Number Sign__:__614499__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 34, WITH VARIANT LISSENCEPHALY; MRT34__:____:__
Number Sign__:__614500__:__CONE-ROD DYSTROPHY 16; CORD16__:__RETINAL DYSTROPHY WITH EARLY MACULAR INVOLVEMENT__:__RETINITIS PIGMENTOSA 64, INCLUDED; RP64, INCLUDED
Number Sign__:__614501__:__PSYCHOMOTOR RETARDATION, EPILEPSY, AND CRANIOFACIAL DYSMORPHISM; PMRED__:____:__
Asterisk__:__614502__:__CHROMOSOME 9 OPEN READING FRAME 116; C9ORF116__:__p53-INDUCED EXPRESSION IN RB-NULL CELLS 1; PIERCE1__:__
Asterisk__:__614503__:__KELCH DOMAIN-CONTAINING PROTEIN 8A; KLHDC8A__:__SUBSTITUTE FOR DELTA-EGFR EXPRESSION 1;; S-DELTA-E1__:__
Number Sign__:__614504__:__USHER SYNDROME, TYPE IIIB; USH3B__:____:__
Asterisk__:__614505__:__FK506-BINDING PROTEIN 14; FKBP14__:____:__
Asterisk__:__614506__:__BRCA1-ASSOCIATED ATM ACTIVATOR 1; BRAT1__:__BAAT1;; CHROMOSOME 7 OPEN READING FRAME 27; C7ORF27__:__
Number Sign__:__614507__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R__:____:__
Number Sign__:__614508__:__MIRROR MOVEMENTS 2; MRMV2__:____:__
Asterisk__:__614509__:__MICRO RNA 99A; MIR99A__:__miRNA99A__:__
Asterisk__:__614510__:__MICRO RNA 99B; MIR99B__:__miRNA99B__:__
Asterisk__:__614511__:__MYOD FAMILY INHIBITOR DOMAIN-CONTAINING PROTEIN; MDFIC__:__IMFA DOMAIN-CONTAINING PROTEIN; HIC__:__
Asterisk__:__614512__:__TORSIN A-INTERACTING PROTEIN 1; TOR1AIP1__:__LAMIN-ASSOCIATED PROTEIN 1; LAP1;; LAP1B__:__
Asterisk__:__614513__:__TORSIN A-INTERACTING PROTEIN 2; TOR1AIP2__:__LUMINAL DOMAIN LIKE LAP1; LULL1__:__
Number Sign__:__614514__:__THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL RECESSIVE; THPH6__:____:__
Asterisk__:__614515__:__G PROTEIN-COUPLED RECEPTOR 179; GPR179__:__GPR158-LIKE; GPR158L;; GPR158L1__:__
Asterisk__:__614516__:__DOLICHYL PYROPHOSPHATE PHOSPHATASE 1; DOLPP1__:__LSFR2, PUFFERFISH, HOMOLOG OF; LSFR2__:__
Asterisk__:__614517__:__ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR-LIKE PROTEIN 2; ARNTL2__:__BRAIN AND MUSCLE ARNT-LIKE PROTEIN 2; BMAL2;; CYCLE-LIKE FACTOR; CLIF__:__
Asterisk__:__614518__:__GATA ZINC FINGER DOMAIN-CONTAINING PROTEIN 1; GATAD1__:__OCULAR DEVELOPMENT-ASSOCIATED GENE; ODAG__:__
Number Sign__:__614519__:__HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO; ICH__:__STROKE, HEMORRHAGIC, SUSCEPTIBILITY TO__:__
NULL__:__614520__:__ENCEPHALOMYOPATHY, MITOCHONDRIAL, DUE TO VOLTAGE-DEPENDENT ANION CHANNEL DEFICIENCY__:____:__
Number Sign__:__614521__:__THROMBOCYTHEMIA 3; THCYT3__:__THROMBOCYTOSIS 3__:__
Asterisk__:__614522__:__KELCH-LIKE 12; KLHL12__:__DKIR__:__
Asterisk__:__614523__:__MICRO RNA 489; MIR489__:__miRNA489__:__
Number Sign__:__614524__:__FIBROCHONDROGENESIS 2; FBCG2__:____:__
Asterisk__:__614525__:__NFATC2-INTERACTING PROTEIN; NFATC2IP__:__NFAT-INTERACTING PROTEIN, 45-KD; NIP45__:__
Number Sign__:__614526__:__CHROMOSOME 17q12 DUPLICATION SYNDROME__:____:__
Number Sign__:__614527__:__CHROMOSOME 17q12 DELETION SYNDROME__:____:__
Asterisk__:__614528__:__HIF1A ANTISENSE RNA 1; HIF1AAS1__:__ANTISENSE HIF1-ALPHA, 5-PRIME;; AHIF1A, 5-PRIME__:__
Asterisk__:__614529__:__HIF1A ANTISENSE RNA 2; HIF1AAS2__:__ANTISENSE HIF1-ALPHA; AHIF;; ANTISENSE HIF1-ALPHA, 3-PRIME;; AHIFIA, 3-PRIME__:__
Asterisk__:__614530__:__NADH-UBIQUINONE OXIDOREDUCTASE 1 ALPHA SUBCOMPLEX, 12; NDUFA12__:__B17.2__:__
Asterisk__:__614531__:__RASGEF DOMAIN FAMILY, MEMBER 1A; RASGEF1A__:____:__
Asterisk__:__614532__:__RASGEF DOMAIN FAMILY, MEMBER 1B; RASGEF1B__:__GPI-GAMMA-4; GPIG4__:__
Asterisk__:__614533__:__CELL DIVISION CYCLE 26, S. CEREVISIAE, HOMOLOG OF; CDC26__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 12; ANAPC12; APC12__:__
Asterisk__:__614534__:__ANAPHASE-PROMOTING COMPLEX SUBUNIT 11; ANAPC11__:__APC11__:__
Asterisk__:__614535__:__ZINC FINGER SWIM DOMAIN-CONTAINING PROTEIN 7; ZSWIM7__:__SWIM-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 7;; SWIM DOMAIN-CONTAINING SRS2-INTERACTING PROTEIN 1; SWS1__:__
Asterisk__:__614536__:__SWIM-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 7-ASSOCIATED PROTEIN 1; SWSAP1__:__SWS1-ASSOCIATED PROTEIN 1;; ZSWIM7-ASSOCIATED PROTEIN 1; ZSWIM7AP1;; CHROMOSOME 19 OPEN READING FRAME 39; C19ORF39__:__
Asterisk__:__614537__:__LEUCINE-RICH MELANOCYTE DIFFERENTIATION-ASSOCIATED PROTEIN; LRMDA__:__CHROMOSOME 10 OPEN READING FRAME 11; C10ORF11__:__
Asterisk__:__614538__:__MICRO RNA 570; MIR570__:__miRNA570__:__
Asterisk__:__614539__:__HELICASE, DNA, B; HELB__:__DNA HELICASE B;; HDHB__:__
Caret__:__614540__:__MOVED TO 213600__:____:__
Number Sign__:__614541__:__CHROMOSOME 16q22 DELETION SYNDROME__:____:__
Asterisk__:__614542__:__FAMILY WITH SEQUENCE SIMILARITY 69, MEMBER A; FAM69A__:____:__
Asterisk__:__614543__:__FAMILY WITH SEQUENCE SIMILARITY 69, MEMBER B; FAM69B__:____:__
Asterisk__:__614544__:__FAMILY WITH SEQUENCE SIMILARITY 69, MEMBER C; FAM69C__:____:__
Asterisk__:__614545__:__ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 10; EMC10__:__ER MEMBRANE PROTEIN COMPLEX, SUBUNIT 10;; CHROMOSOME 19 OPEN READING FRAME 63; C19ORF63__:__HEMATOPOIETIC SIGNAL PEPTIDE-CONTAINING SECRETED PROTEIN 1, INCLUDED; HSS1, INCLUDED;; HEMATOPOIETIC SIGNAL PEPTIDE- AND MEMBRANE DOMAIN-CONTAINING PROTEIN 1, INCLUDED; HSM1, INCLUDED
Number Sign__:__614546__:__EFAVIRENZ, POOR METABOLISM OF__:____:__EFAVIRENZ CENTRAL NERVOUS SYSTEM TOXICITY, SUSCEPTIBILITY TO, INCLUDED
Asterisk__:__614547__:__FAMILY WITH SEQUENCE SIMILARITY 103, MEMBER A1; FAM103A1__:__RNMT-ACTIVATING MINIPROTEIN; RAM__:__
Asterisk__:__614548__:__SERINE INCORPORATOR 1; SERINC1__:__TMS2;; KIAA1253__:__
Asterisk__:__614549__:__SERINE INCORPORATOR 2; SERINC2__:__TUMOR DIFFERENTIALLY EXPRESSED GENE 2; TDE2__:__
Asterisk__:__614550__:__SERINE INCORPORATOR 4; SERINC4__:____:__
Asterisk__:__614551__:__SERINE INCORPORATOR 5; SERINC5__:__CHROMOSOME 5 OPEN READING FRAME 12; C5ORF12;; TPO1__:__
Asterisk__:__614552__:__XYLOSIDE XYLOSYLTRANSFERASE 1; XXYLT1__:__CHROMOSOME 3 OPEN READING FRAME 21; C3ORF21__:__
Asterisk__:__614553__:__N6 ADENINE-SPECIFIC DNA METHYLTRANSFERASE 1, PUTATIVE; N6AMT1__:____:__
Asterisk__:__614554__:__FAMILY WITH SEQUENCE SIMILARITY 32, MEMBER A; FAM32A__:__OVARIAN TUMOR-ASSOCIATED GENE 12; OTAG12__:__
Asterisk__:__614555__:__FERM DOMAIN-CONTAINING PROTEIN 6; FRMD6__:__WILLIN;; CHROMOSOME 14 OPEN READING FRAME 31; C14ORF31__:__
Asterisk__:__614556__:__AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 1B; ARID1B__:__ARID-CONTAINING PROTEIN 1B;; BAF-ASSOCIATED FACTOR, 250-KD, B; BAF250B;; ELD/OSA1;; KIAA1235__:__
Number Sign__:__614557__:__EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 2; EDSKSCL2__:__EHLERS-DANLOS SYNDROME WITH PROGRESSIVE KYPHOSCOLIOSIS, MYOPATHY, AND HEARING LOSS; EDSKMH__:__
Number Sign__:__614558__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 13; EIEE13__:____:__
Number Sign__:__614559__:__INFANTILE CEREBELLAR-RETINAL DEGENERATION; ICRD__:____:__
Asterisk__:__614560__:__MAU2 CHROMATID COHESION FACTOR, C. ELEGANS, HOMOLOG OF; MAU2__:__SISTER CHROMATID COHESION 4, S. CEREVISIAE, HOMOLOG OF; SCC4;; KIAA0892__:__
Number Sign__:__614561__:__LEUKOENCEPHALOPATHY, BRAIN CALCIFICATIONS, AND CYSTS; LCC__:__LABRUNE SYNDROME__:__
Caret__:__614562__:__MOVED TO 135900__:____:__
Number Sign__:__614563__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 13; MRD13__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 13, WITH NEURONAL MIGRATION DEFECTS__:__
Number Sign__:__614564__:__CUTANEOUS TELANGIECTASIA AND CANCER SYNDROME, FAMILIAL; FCTCS__:__TELANGIECTASIA, CUTANEOUS, AND CANCER SYNDROME, FAMILIAL__:__
Number Sign__:__614565__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1E; CSNB1E__:__CSNB, COMPLETE, AUTOSOMAL RECESSIVE__:__
Asterisk__:__614566__:__DYNEIN, AXONEMAL, ASSEMBLY FACTOR 3; DNAAF3__:__PF22, CHLAMYDOMONAS, HOMOLOG OF; PF22;; DYNEIN ASSEMBLY BLOCKED 1, CHLAMYDOMONAS, HOMOLOG OF; DAB1__:__
Asterisk__:__614567__:__DIAPHANOUS, DROSOPHILA, HOMOLOG OF, 3; DIAPH3__:__DIA2;; DIAPHANOUS-RELATED FORMIN 3; DRF3__:__
Asterisk__:__614568__:__UNC13, C. ELEGANS, HOMOLOG OF, C; UNC13C__:__MUNC13-3__:__
Percent__:__614569__:__MULTIPLE ENCHONDROMATOSIS, MAFFUCCI TYPE__:__MAFFUCCI SYNDROME__:__
Asterisk__:__614570__:__KINESIN FAMILY MEMBER 18B; KIF18B__:____:__
Asterisk__:__614571__:__CILIOGENESIS AND PLANAR POLARITY EFFECTOR 1; CPLANE1__:__CHROMOSOME 5 OPEN READING FRAME 42; C5ORF42__:__
Asterisk__:__614572__:__ZINC FINGER PROTEIN 42; ZFP42__:__REDUCED EXPRESSION GENE 1; REX1__:__
Asterisk__:__614573__:__G PROTEIN-COUPLED RECEPTOR 158; GPR158__:__KIAA1136__:__
Asterisk__:__614574__:__ROGDI, DROSOPHILA, HOMOLOG OF; ROGDI__:____:__
Percent__:__614575__:__CEREBELLAR ATAXIA, NEUROPATHY, AND VESTIBULAR AREFLEXIA SYNDROME; CANVAS__:____:__
Number Sign__:__614576__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIl; CDG2L__:__CDG IIl; CDGIIl__:__
Asterisk__:__614577__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 3; PAQR3__:__RAF KINASE TRAPPING TO GOLGI; RKTG__:__
Asterisk__:__614578__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 4; PAQR4__:____:__
Asterisk__:__614579__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 6; PAQR6__:____:__
Asterisk__:__614580__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 9; PAQR9__:____:__
Asterisk__:__614581__:__MONOCYTE-TO-MACROPHAGE DIFFERENTIATION-ASSOCIATED PROTEIN 2; MMD2__:__PROGESTIN AND ADIPOQ RECEPTOR FAMILY, MEMBER 10; PAQR10__:__
Number Sign__:__614582__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 9; COXPD9__:____:__
Number Sign__:__614583__:__BARAITSER-WINTER SYNDROME 2; BRWS2__:____:__
Asterisk__:__614584__:__PROLYL 4-HYDROXYLASE, TRANSMEMBRANE; P4HTM__:__PROLINE HYDROXYLASE 4; PH4__:__
Asterisk__:__614585__:__FERREDOXIN 1-LIKE PROTEIN; FDX1L__:__FDX1-LIKE PROTEIN;; FERREDOXIN 2; FDX2__:__
Asterisk__:__614586__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 5; ZDHHC5__:__DHHC5;; ZINC FINGER PROTEIN 375; ZNF375;; KIAA1748__:__
Asterisk__:__614587__:__ChaC, E. COLI, HOMOLOG OF, 1; CHAC1__:__CATION TRANSPORT REGULATOR-LIKE PROTEIN 1__:__
Percent__:__614588__:__DYSTONIA 21; DYT21__:____:__
Asterisk__:__614589__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 37; TTC37__:__KIAA0372__:__
Percent__:__614590__:__PODOCONIOSIS, SUSCEPTIBILITY TO; PDCOS__:__NONFILARIAL ELEPHANTIASIS OF LOWER LEGS, SUSCEPTIBILITY TO;; ENDEMIC NONFILARIAL ELEPHANTIASIS, SUSCEPTIBILITY TO;; LYMPHOSTATIC VERRUCOSIS, SUSCEPTIBILITY TO__:__
Asterisk__:__614591__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 16; CEACAM16__:__CEA-LIKE 2; CEAL2__:__
Number Sign__:__614592__:__BENT BONE DYSPLASIA SYNDROME; BBDS__:____:__
Asterisk__:__614593__:__MEIOSIS REGULATOR AND mRNA STABILITY FACTOR 1; MARF1__:__KIAA0430;; LIMKAIN B1; LKAP;; MEIOSIS ARREST FEMALE 1__:__
Number Sign__:__614594__:__PALMOPLANTAR KERATODERMA, MUTILATING, WITH PERIORIFICIAL KERATOTIC PLAQUES__:__OLMSTED SYNDROME; OLMS__:__
Number Sign__:__614595__:__PREECLAMPSIA/ECLAMPSIA 5; PEE5__:____:__
Asterisk__:__614596__:__MICRO RNA 302A; MIR302A__:__miRNA302A__:__
Asterisk__:__614597__:__MICRO RNA 302B; MIR302B__:__miRNA302B__:__
Asterisk__:__614598__:__MICRO RNA 302C; MIR302C__:__miRNA302C__:__
Asterisk__:__614599__:__MICRO RNA 302D; MIR302D__:__miRNA302D__:__
Asterisk__:__614600__:__MICRO RNA 367; MIR367__:__miRNA367__:__
Asterisk__:__614601__:__ZINC FINGER PROTEIN 326; ZNF326__:__ZINC FINGER PROTEIN INTERACTING WITH NUCLEAR MESSENGER RIBONUCLEOPROTEINS AND DBC1; ZIRD__:__
Number Sign__:__614602__:__TRICHOHEPATOENTERIC SYNDROME 2; THES2__:____:__
Asterisk__:__614603__:__DDHD DOMAIN-CONTAINING PROTEIN 1; DDHD1__:__PHOSPHATIDIC ACID-PREFERRING PHOSPHOLIPASE A1; PAPLA1;; KIAA1705__:__
Asterisk__:__614604__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 7; ZDHHC7__:__DHHC7__:__
Asterisk__:__614605__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 21; ZDHHC21__:__DHHC21__:__
Asterisk__:__614606__:__FOCADHESIN; FOCAD__:__KIAA1797__:__
Number Sign__:__614607__:__COFFIN-SIRIS SYNDROME 2; CSS2__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 14; MRD14__:__CHROMOSOME 1p36.11 DUPLICATION SYNDROME, INCLUDED
Number Sign__:__614608__:__COFFIN-SIRIS SYNDROME 3; CSS3__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 15; MRD15__:__
Number Sign__:__614609__:__COFFIN-SIRIS SYNDROME 4; CSS4__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 16; MRD16__:__
Asterisk__:__614610__:__KN MOTIF- AND ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 2; KANK2__:__SRC-INTERACTING PROTEIN; SIP;; ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 25; ANKRD25;; KIAA1518__:__
Asterisk__:__614611__:__KN MOTIF- AND ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 3; KANK3__:____:__
Asterisk__:__614612__:__KN MOTIF- AND ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 4; KANK4__:____:__
Number Sign__:__614613__:__ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2__:____:__
Number Sign__:__614614__:__DEAFNESS, AUTOSOMAL DOMINANT 4B; DFNA4B__:____:__
Number Sign__:__614615__:__JOUBERT SYNDROME 17; JBTS17__:____:__
Number Sign__:__614616__:__DIARRHEA 6; DIAR6__:____:__
Number Sign__:__614617__:__DEAFNESS, AUTOSOMAL RECESSIVE 86; DFNB86__:____:__
Number Sign__:__614618__:__HYPEREKPLEXIA 3; HKPX3__:____:__
Number Sign__:__614619__:__HYPEREKPLEXIA 2; HKPX2__:____:__
Asterisk__:__614620__:__INTRAFLAGELLAR TRANSPORT 140, CHLAMYDOMONAS, HOMOLOG OF; IFT140__:__KIAA0590__:__
Number Sign__:__614621__:__UV-SENSITIVE SYNDROME 2; UVSS2__:____:__
Percent__:__614622__:__KERATOCONUS 5; KTCN5__:____:__
Percent__:__614623__:__KERATOCONUS 6; KTCN6__:____:__
Asterisk__:__614624__:__MITOCHONDRIAL ASSEMBLY OF RIBOSOMAL LARGE SUBUNIT 1; MALSU1__:__CHROMOSOME 7 OPEN READING FRAME 30; C7ORF30__:__
Asterisk__:__614625__:__DIFFERENTIATION-ANTAGONIZING NONCODING RNA; DANCR__:__ANTI-DIFFERENTIATION NONCODING RNA; ANCR;; KIAA0114__:__
Asterisk__:__614626__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 26; SNORA26__:__snoRNA, HBI-6;; MBI-6, MOUSE, HOMOLOG OF__:__
Asterisk__:__614627__:__MICRO RNA 4449; MIR4449__:__miRNA4449__:__
Percent__:__614628__:__KERATOCONUS 8; KTCN8__:____:__
Percent__:__614629__:__KERATOCONUS 7; KTCN7__:____:__
Asterisk__:__614630__:__ANDROGLOBIN; ADGB__:____:__
Asterisk__:__614631__:__ISOPRENOID SYNTHASE DOMAIN-CONTAINING PROTEIN; ISPD__:____:__
Asterisk__:__614632__:__UV-STIMULATED SCAFFOLD PROTEIN A; UVSSA__:__KIAA1530__:__
Asterisk__:__614633__:__VACUOLAR PROTEIN SORTING 54, S. CEREVISIAE, HOMOLOG OF; VPS54__:__VPS54-LIKE; VPS54L;; WOBBLER, MOUSE, HOMOLOG OF; WR;; SLP8__:__
Asterisk__:__614634__:__CENTROSOMAL PROTEIN 126; CEP126__:__KIAA1377__:__
Asterisk__:__614635__:__LONG INTERGENIC NONCODING RNA 538; LINC00538__:__YIYA__:__
Asterisk__:__614636__:__MYOSIN IH; MYO1H__:____:__
Asterisk__:__614637__:__DESUMOYLATING ISOPEPTIDASE 1; DESI1__:__PPPDE PEPTIDASE DOMAIN-CONTAINING PROTEIN 2; PPPDE2__:__
Asterisk__:__614638__:__DESUMOYLATING ISOPEPTIDASE 2; DESI2__:__PPPDE PEPTIDASE DOMAIN-CONTAINING PROTEIN 1; PPPDE1__:__
Asterisk__:__614639__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 46; ZBTB46__:__BTB-ZINC FINGER PROTEIN EXPRESSED IN EFFECTOR LYMPHOCYTES; BZEL__:__
Number Sign__:__614640__:__UV-SENSITIVE SYNDROME 3; UVSS3__:____:__
Asterisk__:__614641__:__LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 5; LAMP5__:__BRAIN- AND DENDRITIC CELL-ASSOCIATED LAMP; BADLAMP__:__
Asterisk__:__614642__:__START DOMAIN-CONTAINING PROTEIN 9; STARD9__:__KIAA1300__:__
Number Sign__:__614643__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, ISPD-RELATED__:__
Percent__:__614644__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 4; MPVQTL4__:____:__
Percent__:__614645__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 5; MPVQTL5__:____:__
Percent__:__614646__:__MEAN PLATELET VOLUME QUANTITATIVE TRAIT LOCUS 6; MPVQTL6__:____:__
Asterisk__:__614647__:__COQ6, S. CEREVISIAE, HOMOLOG OF; COQ6__:__COENZYME Q10 MONOOXYGENASE 6;; CGI10__:__
Asterisk__:__614648__:__RALY-LIKE PROTEIN; RALYL__:____:__
Asterisk__:__614649__:__RING FINGER PROTEIN 170; RNF170__:____:__
Number Sign__:__614650__:__COENZYME Q10 DEFICIENCY, PRIMARY, 6; COQ10D6__:____:__
Number Sign__:__614651__:__COENZYME Q10 DEFICIENCY, PRIMARY, 2; COQ10D2__:____:__
Number Sign__:__614652__:__COENZYME Q10 DEFICIENCY, PRIMARY, 3; COQ10D3__:____:__
Number Sign__:__614653__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VI; HSAN6__:__HSAN VI__:__
Number Sign__:__614654__:__COENZYME Q10 DEFICIENCY, PRIMARY, 5; COQ10D5__:____:__
Percent__:__614655__:__STUTTERING, FAMILIAL PERSISTENT, 3; STUT3__:____:__
Asterisk__:__614656__:__PALADIN1; PALD1__:__PALADIN, MOUSE, HOMOLOG OF; PALD;; KIAA1274__:__
Asterisk__:__614657__:__ANGIOMOTIN-LIKE 1; AMOTL1__:__JUNCTION-ENRICHED AND -ASSOCIATED PROTEIN; JEAP__:__
Asterisk__:__614658__:__ANGIOMOTIN-LIKE 2; AMOTL2__:__KIAA0989__:__
Asterisk__:__614659__:__FAMILY WITH SEQUENCE SIMILARITY 123, MEMBER A; FAM123A__:__APC MEMBRANE RECRUITMENT PROTEIN 2; AMER2__:__
Asterisk__:__614660__:__PROTEIN ASSOCIATED WITH TOPOISOMERASE II, S. CEREVISIAE, HOMOLOG OF, 1; PATL1__:__PAT1-LIKE 1;; PAT1B__:__
Asterisk__:__614661__:__PROTEIN ASSOCIATED WITH TOPOISOMERASE II, S. CEREVISIAE, HOMOLOG OF, 2; PATL2__:__PAT1-LIKE 2;; PAT1A__:__
Number Sign__:__614662__:__CORTISONE REDUCTASE DEFICIENCY 2; CORTRD2__:____:__
Asterisk__:__614663__:__HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN ASSOCIATED WITH LETHAL YELLOW, MOUSE, HOMOLOG OF; RALY__:__RALY, MOUSE, HOMOLOG OF;; RNA-BINDING PROTEIN RALY, AUTOANTIGENIC;; p542__:__
Asterisk__:__614664__:__TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 4; TREML4__:__TREM-LIKE TRANSCRIPT 4; TLT4__:__
Number Sign__:__614665__:__MECONIUM ILEUS__:____:__
Asterisk__:__614666__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 78; CCDC78__:__CHROMOSOME 16 OPEN READING FRAME 25; C16ORF25__:__
Asterisk__:__614667__:__MITOCHONDRIAL TRANSLATION OPTIMIZATION 1, S. CEREVISIAE, HOMOLOG OF; MTO1__:____:__
Percent__:__614668__:__STUTTERING, FAMILIAL PERSISTENT, 4; STUT4__:____:__
Number Sign__:__614669__:__AURICULOCONDYLAR SYNDROME 2; ARCND2__:____:__
Percent__:__614670__:__PERIPARTUM CARDIOMYOPATHY, SUSCEPTIBILITY TO__:__PPCM, SUSCEPTIBILITY TO__:__
Number Sign__:__614671__:__CHROMOSOME 16p11.2 DUPLICATION SYNDROME__:____:__AUTISM, SUSCEPTIBILITY TO, 14B, INCLUDED; AUTS14B, INCLUDED
Number Sign__:__614672__:__CARDIOMYOPATHY, DILATED, 2B; CMD2B__:____:__
Number Sign__:__614673__:__MICROCEPHALY 8, PRIMARY, AUTOSOMAL RECESSIVE; MCPH8__:____:__
Number Sign__:__614674__:__PERIODIC FEVER, MENSTRUAL CYCLE-DEPENDENT__:____:__
Number Sign__:__614675__:__BONE MARROW FAILURE SYNDROME 1; BMFS1__:____:__
Percent__:__614676__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 21; CMH21__:____:__
Asterisk__:__614677__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 103; CCDC103__:__SCHMALHANS, ZEBRAFISH, HOMOLOG OF; SMH;; PR46B, CHLAMYDOMONAS, HOMOLOG OF; PR46B__:__
Number Sign__:__614678__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 1B; PCH1B__:____:__
Number Sign__:__614679__:__CILIARY DYSKINESIA, PRIMARY, 17; CILD17__:__CILIARY DYSKINESIA, PRIMARY, 17, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__614680__:__INFLUENZA, SEVERE, SUSCEPTIBILITY TO__:____:__
Asterisk__:__614681__:__AMINOGLYCOSIDE PHOSPHOTRANSFERASE DOMAIN-CONTAINING PROTEIN 1; AGPHD1__:____:__
Asterisk__:__614682__:__ALANINE-GLYOXYLATE AMINOTRANSFERASE 2-LIKE 1; AGXT2L1__:____:__
Asterisk__:__614683__:__5-PHOSPHOHYDROXY-L-LYSINE PHOSPHO-LYASE; PHYKPL__:__ALANINE-GLYOXYLATE AMINOTRANSFERASE 2-LIKE 2; AGXT2L2__:__
Percent__:__614684__:__HYPERTELORISM AND OTHER FACIAL DYSMORPHISM, BRACHYDACTYLY, GENITAL ABNORMALITIES, MENTAL RETARDATION, AND RECURRENT INFLAMMATORY EPISODES__:____:__
Asterisk__:__614685__:__ZINC FINGER PROTEIN 597; ZNF597__:____:__
Asterisk__:__614686__:__FAMILY WITH SEQUENCE SIMILARITY 50, MEMBER B; FAM50B__:__XAP5-LIKE PROTEIN; X5L__:__FAMILY WITH SEQUENCE SIMILARITY 50, MEMBER B, ANTISENSE TRANSCRIPT, INCLUDED; FAM50BAS, INCLUDED
NULL__:__614687__:__ALAR CLEFT, ISOLATED__:____:__
NULL__:__614688__:__PONTINE TEGMENTAL CAP DYSPLASIA; PTCD__:____:__
Number Sign__:__614689__:__SOLUBLE INTERLEUKIN-6 RECEPTOR, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS__:__SOLUBLE IL6R, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS__:__
Asterisk__:__614690__:__CHROMOSOME 4 OPEN READING FRAME 48; C4ORF48__:____:__
Number Sign__:__614691__:__CATARACT 38; CTRCT38__:__CATARACT, AUTOSOMAL RECESSIVE CONGENITAL 5; CATC5__:__
Percent__:__614692__:__MEMBRANOUS NEPHROPATHY, SUSCEPTIBILITY TO; MBNP__:____:__
Asterisk__:__614693__:__ATM INTERACTOR; ATMIN__:__ATM SUBSTRATE CHK2-INTERACTING ZINC FINGER PROTEIN; ASCIZ;; KIAA0431__:__
Asterisk__:__614694__:__REGULATION OF NUCLEAR PRE-mRNA DOMAIN-CONTAINING PROTEIN 1B; RPRD1B__:__CELL CYCLE-RELATED AND EXPRESSION-ELEVATED PROTEIN IN TUMOR; CREPT__:__
Asterisk__:__614695__:__REGULATION OF NUCLEAR PRE-mRNA DOMAIN-CONTAINING 2; RPRD2__:____:__
Number Sign__:__614696__:__AMYOTROPHIC LATERAL SCLEROSIS 17; ALS17__:__AMYOTROPHIC LATERAL SCLEROSIS, CHMP2B-RELATED__:__
Asterisk__:__614697__:__KATANIN, p60 SUBUNIT, A-LIKE PROTEIN 2; KATNAL2__:__KATNA-LIKE 2__:__
Asterisk__:__614698__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR COX20; COX20__:__COX20, S. CEREVISIAE, HOMOLOG OF;; COX2 CHAPERONE COX20;; FAMILY WITH SEQUENCE SIMILARITY 36, MEMBER A; FAM36A__:__
Number Sign__:__614699__:__IMMUNODEFICIENCY, COMMON VARIABLE, 7; CVID7__:____:__
Number Sign__:__614700__:__IMMUNODEFICIENCY, COMMON VARIABLE, 8, WITH AUTOIMMUNITY; CVID8__:____:__
Number Sign__:__614701__:__CORNELIA DE LANGE SYNDROME 4; CDLS4__:____:__
Number Sign__:__614702__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 10; COXPD10__:__CARDIOMYOPATHY, INFANTILE HYPERTROPHIC MITOCHONDRIAL, AND LACTIC ACIDOSIS__:__
Asterisk__:__614703__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 2B; SRGAP2B__:____:__
Asterisk__:__614704__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 2C; SRGAP2C__:____:__
Asterisk__:__614705__:__SLIT-ROBO RHO GTPase-ACTIVATING PROTEIN 2D; SRGAP2D__:____:__
Number Sign__:__614706__:__CEROID LIPOFUSCINOSIS, NEURONAL, 11; CLN11__:____:__
Number Sign__:__614707__:__BROWN-VIALETTO-VAN LAERE SYNDROME 2; BVVLS2__:____:__
Asterisk__:__614708__:__SIGNAL PEPTIDE-, CUB DOMAIN-, AND EGF-LIKE DOMAINS-CONTAINING PROTEIN 3; SCUBE3__:____:__
Asterisk__:__614709__:__LYR MOTIF-CONTAINING PROTEIN 1; LYRM1__:____:__
Asterisk__:__614710__:__FAMILY WITH SEQUENCE SIMILARITY 72, MEMBER A; FAM72A__:__LATENT MEMBRANE PROTEIN 1-INDUCED PROTEIN; LMPIP;; LMP1-INDUCED PROTEIN;; UGENE__:__
Asterisk__:__614711__:__FAMILY WITH SEQUENCE SIMILARITY 72, MEMBER B; FAM72B__:____:__
Asterisk__:__614712__:__FAMILY WITH SEQUENCE SIMILARITY 72, MEMBER D; FAM72D__:____:__
Asterisk__:__614713__:__RAS ASSOCIATION DOMAIN FAMILY, MEMBER 10; RASSF10__:____:__
Number Sign__:__614714__:__POROKERATOSIS 7, MULTIPLE TYPES; POROK7__:____:__
Asterisk__:__614715__:__TRANSMEMBRANE AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 2; TMIGD2__:__IMMUNOGLOBULIN AND PROLINE-RICH RECEPTOR 1; IGPR1;; CD28 HOMOLOG; CD28H__:__
Asterisk__:__614716__:__CAPPING PROTEIN REGULATOR AND MYOSIN 1 LINKER 3; CARMIL3__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 16B; LRRC16B__:__
Asterisk__:__614717__:__ANAPHASE-PROMOTING COMPLEX, SUBUNIT 15; ANAPC15__:__APC15__:__
Asterisk__:__614718__:__KINETOCHORE-LOCALIZED ASTRIN/SPAG5-BINDING PROTEIN; KNSTRN__:__SMALL KINETOCHORE-ASSOCIATED PROTEIN; SKAP;; CHROMOSOME 15 OPEN READING FRAME 23; C15ORF23__:__
Asterisk__:__614719__:__POTASSIUM CHANNEL MODULATORY FACTOR 1; KCMF1__:__DIFFERENTIALLY EXPRESSED IN BRANCHING TUBULOGENESIS 91; DEBT91;; BASIC FIBROBLAST GROWTH FACTOR-INDUCED GENE IN GASTRIC CANCER; FIGC__:__
Asterisk__:__614720__:__CYCLIN-DEPENDENT KINASE 19; CDK19__:__KIAA1028__:__
Asterisk__:__614721__:__TSPY-LIKE 5; TSPYL5__:__KIAA1750__:__
Asterisk__:__614722__:__MICRO RNA 3120; MIR3120__:__miRNA3120;; MIR3120-5p__:__MICRO RNA 3120-3p, INCLUDED; MIR3120-3p, INCLUDED
Number Sign__:__614723__:__ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD__:__APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA__:__
Asterisk__:__614724__:__CENTROSOMAL PROTEIN, 63-KD; CEP63__:____:__
Asterisk__:__614725__:__SERINE ACTIVE SITE-CONTAINING PROTEIN 1; SERAC1__:____:__
Asterisk__:__614726__:__TRANSMEMBRANE PROTEIN 165; TMEM165__:__FT27__:__
Number Sign__:__614727__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIk; CDG2K__:__CDG IIk; CDGIIk__:__
Number Sign__:__614728__:__SECKEL SYNDROME 6; SCKL6__:____:__
Asterisk__:__614729__:__COP9 SIGNALOSOME, SUBUNIT 6; COPS6__:__CSN6;; MOV34 FAMILY, 34-KD MEMBER__:__
Asterisk__:__614730__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS O PROTEIN; PIGO__:____:__
Number Sign__:__614731__:__PROSTATE CANCER, HEREDITARY, 2; HPC2__:____:__
Number Sign__:__614732__:__INTRAUTERINE GROWTH RETARDATION, METAPHYSEAL DYSPLASIA, ADRENAL HYPOPLASIA CONGENITA, AND GENITAL ANOMALIES__:__IMAGE SYNDROME__:__
Asterisk__:__614733__:__MICRO RNA 193A; MIR193A__:__miRNA193A__:__
Asterisk__:__614734__:__MICRO RNA 193B; MIR193B__:__miRNA193B__:__
Asterisk__:__614735__:__MICRO RNA 365A; MIR365A__:__MIR365-1;; MIR365;; miRNA365A__:__
Number Sign__:__614736__:__GLUCOCORTICOID DEFICIENCY 4 WITH OR WITHOUT MINERALOCORTICOID DEFICIENCY; GCCD4__:____:__
Asterisk__:__614737__:__BRAIN PROTEIN 44; BRP44__:__MITOCHONDRIAL PYRUVATE CARRIER 2; MPC2;; PYRUVATE CARRIER, MITOCHONDRIAL, 2__:__
Asterisk__:__614738__:__BRAIN PROTEIN 44-LIKE; BRP44L__:__MITOCHONDRIAL PYRUVATE CARRIER 1; MPC1;; PYRUVATE CARRIER, MITOCHONDRIAL, 1__:__
Number Sign__:__614739__:__3-METHYLGLUTACONIC ACIDURIA WITH DEAFNESS, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME; MEGDEL__:__3-METHYLGLUTACONIC ACIDURIA WITH DYSTONIA-DEAFNESS, HEPATOPATHY, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME; MEGDHEL;; 3-METHYLGLUTACONIC ACIDURIA, TYPE VI; MGCA6__:__
Number Sign__:__614740__:__BASAL CELL CARCINOMA, SUSCEPTIBILITY TO, 7; BCC7__:____:__
Number Sign__:__614741__:__MITOCHONDRIAL PYRUVATE CARRIER DEFICIENCY; MPYCD__:____:__
Number Sign__:__614742__:__PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 1; PFBMFT1__:____:__
Number Sign__:__614743__:__PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 2; PFBMFT2__:____:__
Number Sign__:__614744__:__FACIAL PARESIS, HEREDITARY CONGENITAL, 3; HCFP3__:____:__
Number Sign__:__614745__:__BLOOD GROUP, JOHN MILTON HAGEN SYSTEM; JMH__:__JOHN MILTON HAGEN BLOOD GROUP SYSTEM;; JMH BLOOD GROUP SYSTEM__:__
Percent__:__614746__:__URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 5; UAQTL5__:____:__
Percent__:__614747__:__URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 6; UAQTL6__:____:__
Number Sign__:__614748__:__INTERSTITIAL LUNG DISEASE, NEPHROTIC SYNDROME, AND EPIDERMOLYSIS BULLOSA, CONGENITAL; ILNEB__:____:__
Number Sign__:__614749__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 2; HPMRS2__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 6; GPIBD6__:__
Number Sign__:__614750__:__MYASTHENIC SYNDROME, CONGENITAL, 13; CMS13__:__MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 2; CMSTA2__:__
Number Sign__:__614751__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; HMN5B__:__HMN VB;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VB; DHMN5B;; DHMN VB;; SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VB; DSMAVB__:__
Number Sign__:__614752__:__INTERLEUKIN 6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS__:__IL6, SERUM LEVEL OF, QUANTITATIVE TRAIT LOCUS__:__
Number Sign__:__614753__:__SOTOS SYNDROME 2; SOTOS2__:__MALAN SYNDROME__:__
Asterisk__:__614754__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR 3; DMRT3__:__DMRTA3__:__
Asterisk__:__614755__:__MICRO RNA 520H; MIR520H__:__miRNA520H__:__
Number Sign__:__614756__:__CEREBELLAR ATAXIA, NONPROGRESSIVE, WITH MENTAL RETARDATION; CANPMR__:____:__
Asterisk__:__614757__:__INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 5; IFITM5__:__BONE-RESTRICTED IFITM-LIKE PROTEIN 5; BRIL;; FRAGILIS 4, MOUSE, HOMOLOG OF__:__
Asterisk__:__614758__:__DYNACTIN 4; DCTN4__:__DYN4;; DYNACTIN, 62-KD SUBUNIT;; p62__:__
Asterisk__:__614759__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 11; CCDC11__:____:__
Asterisk__:__614760__:__PQ LOOP REPEAT-CONTAINING PROTEIN 2; PQLC2__:____:__
Asterisk__:__614761__:__GLYCINE N-ACYLTRANSFERASE-LIKE 1; GLYATL1__:____:__
Asterisk__:__614762__:__GLYCINE N-ACYLTRANSFERASE-LIKE 2; GLYATL2__:____:__
Asterisk__:__614763__:__GLYCINE N-ACYLTRANSFERASE-LIKE 3; GLYATL3__:____:__
Asterisk__:__614764__:__KATANIN, p60 SUBUNIT, A-LIKE 1; KATNAL1__:____:__
Asterisk__:__614765__:__STRIATIN, CALMODULIN-BINDING PROTEIN; STRN__:____:__
Asterisk__:__614766__:__STRIATIN, CALMODULIN-BINDING PROTEIN 3; STRN3__:__S/G2 NUCLEAR ANTIGEN; SG2NA__:__
Asterisk__:__614767__:__STRIATIN, CALMODULIN-BINDING PROTEIN 4; STRN4__:__ZINEDIN; ZIN__:__
Asterisk__:__614768__:__TRANSMEMBRANE PROTEIN 66; TMEM66__:__SOCE-ASSOCIATED REGULATORY FACTOR; SARAF__:__
Asterisk__:__614769__:__CYTOCHROME C OXIDASE ASSEMBLY FACTOR 1, S. CEREVISIAE, HOMOLOG OF; COA1__:__CHROMOSOME 7 OPEN READING FRAME 44; C7ORF44;; MITOCHONDRIAL TRANSLATION REGULATION ASSEMBLY INTERMEDIATE OF CYTOCHROME c OXIDASE 15; MITRAC15__:__
Asterisk__:__614770__:__PET100, S. CEREVISIAE, HOMOLOG OF; PET100__:__CHROMOSOME 19 OPEN READING FRAME 79; C19ORF79__:__
Asterisk__:__614771__:__PET117, S. CEREVISIAE, HOMOLOG OF; PET117__:____:__
Asterisk__:__614772__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR 6; COA6__:__CHROMOSOME 1 OPEN READING FRAME 31; C1ORF31__:__
Asterisk__:__614773__:__MSS51 MITOCHONDRIAL TRANSLATIONAL ACTIVATOR, S. CEREVISIAE, HOMOLOG OF; MSS51__:__ZINC FINGER MYND DOMAIN-CONTAINING 17; ZMYND17__:__
Asterisk__:__614774__:__PENTATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 1; PTCD1__:__KIAA0632__:__
Asterisk__:__614775__:__CYTOCHROME C OXIDASE ASSEMBLY FACTOR 3; COA3__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 56; CCDC56;; MITOCHONDRIAL TRANSLATION REGULATION ASSEMBLY INTERMEDIATE OF CYTOCHROME c OXIDASE 12; MITRAC12__:__
Asterisk__:__614776__:__SIK FAMILY KINASE 3; SIK3__:__SALT-INDUCIBLE KINASE 3;; KIAA0999__:__
Asterisk__:__614777__:__MMS19 NUCLEOTIDE EXCISION REPAIR, S. CEREVISIAE, HOMOLOG OF; MMS19__:__MMS19-LIKE PROTEIN; MMS19L__:__
Asterisk__:__614778__:__FAMILY WITH SEQUENCE SIMILARITY 96, MEMBER B; FAM96B__:__MSS19-INTERACTING PROTEIN OF 18 KD; MIP18__:__
Number Sign__:__614779__:__HETEROTAXY, VISCERAL, 6, AUTOSOMAL; HTX6__:____:__
Asterisk__:__614780__:__SORTING NEXIN 10; SNX10__:____:__
Asterisk__:__614781__:__TECTONIN BETA-PROPELLER REPEAT-CONTAINING 1; TECPR1__:__KIAA1358__:__
Number Sign__:__614782__:__TREMOR, HEREDITARY ESSENTIAL, 4; ETM4__:____:__
Asterisk__:__614783__:__POC1 CENTRIOLAR PROTEIN, CHLAMYDOMONAS, HOMOLOG OF, A; POC1A__:__PIX2;; PROTEOME OF CENTRIOLE 1A__:__
Asterisk__:__614784__:__POC1 CENTRIOLAR PROTEIN, CHLAMYDOMONAS, HOMOLOG OF, B; POC1B__:__PIX1;; PROTEOME OF THE CENTRIOLE 1B__:__
Asterisk__:__614785__:__MITOCHONDRIAL FISSION FACTOR; MFF__:__CHROMOSOME 2 OPEN READING FRAME 33; C2ORF33__:__
Asterisk__:__614786__:__TRANSMEMBRANE PROTEIN 207; TMEM207__:____:__
Asterisk__:__614787__:__POGO TRANSPOSABLE ELEMENT WITH ZNF DOMAIN; POGZ__:__KIAA0461__:__
Asterisk__:__614788__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 5; FGD5__:____:__
Asterisk__:__614789__:__EGF DOMAIN-SPECIFIC O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE; EOGT__:__EOGT1;; CHROMOSOME 3 OPEN READING FRAME 64; C3ORF64__:__
Asterisk__:__614790__:__WT1-INTERACTING PROTEIN; WTIP__:____:__
Asterisk__:__614791__:__MICRO RNA 199B; MIR199B__:__miRNA199B;; MIRN199B__:__
Asterisk__:__614792__:__TRANSMEMBRANE AND UBIQUITIN-LIKE DOMAIN-CONTAINING PROTEIN 1; TMUB1__:__DENDRITIC CELL-DERIVED UBIQUITIN-LIKE PROTEIN; DULP;; SB144;; CHROMOSOME 7 OPEN READING FRAME 21; C7ORF21__:__
Asterisk__:__614793__:__MIXED-LINEAGE KINASE 4__:__MLK4;; KIAA1804__:__
Asterisk__:__614794__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 3; AGPAT3__:__1-ACYL-sn-GLYCEROL 3-PHOSPHATE ACYLTRANSFERASE 3;; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, GAMMA;; LPAAT-GAMMA;; LPAAT3__:__
Asterisk__:__614795__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 4; AGPAT4__:__1-ACYL-sn-GLYCEROL 3-PHOSPHATE ACYLTRANSFERASE 4;; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, DELTA;; LPAAT-DELTA__:__
Asterisk__:__614796__:__1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 5; AGPAT5__:__1-ACYL-sn-GLYCEROL 3-PHOSPHATE ACYLTRANSFERASE 5;; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE, EPSILON;; LPAAT-EPSILON__:__
Asterisk__:__614797__:__PELLINO, DROSOPHILA, HOMOLOG OF, 1; PELI1__:____:__
Asterisk__:__614798__:__PELLINO, DROSOPHILA, HOMOLOG OF, 2; PELI2__:____:__
Asterisk__:__614799__:__CHROMOSOME 1 OPEN READING FRAME 109; C1ORF109__:____:__
Number Sign__:__614800__:__SHORT STATURE, OPTIC NERVE ATROPHY, AND PELGER-HUET ANOMALY; SOPH__:__SOPH SYNDROME__:__
Asterisk__:__614801__:__MALE-SPECIFIC LETHAL 1, DROSOPHILA, HOMOLOG OF; MSL1__:____:__
Asterisk__:__614802__:__MALE-SPECIFIC LETHAL 2, DROSOPHILA, HOMOLOG OF; MSL2__:__KIAA1585__:__
Asterisk__:__614803__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR A1; DMRTA1__:__DMRT4__:__
Asterisk__:__614804__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR A2; DMRTA2__:____:__
Asterisk__:__614805__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR B1; DMRTB1__:____:__
Asterisk__:__614806__:__DOUBLESEX- AND MAB3-RELATED TRANSCRIPTION FACTOR C2; DMRTC2__:____:__
Number Sign__:__614807__:__MYOPATHY, CENTRONUCLEAR, 4; CNM4__:____:__
Number Sign__:__614808__:__AMYOTROPHIC LATERAL SCLEROSIS 18; ALS18__:____:__
Number Sign__:__614809__:__CFHR5 DEFICIENCY__:____:__
Number Sign__:__614810__:__MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5__:____:__
Asterisk__:__614811__:__L-3-HYDROXYPROLINE DEHYDRATASE, TRANS; L3HYPDH__:__TRANS-3-HYDROXYL-L-PROLINE DEHYDRATASE;; CHROMOSOME 14 OPEN READING FRAME 149; C14ORF149__:__
Asterisk__:__614812__:__NUCLEAR PROTEIN, TRANSCRIPTIONAL REGULATOR, 1; NUPR1__:__CANDIDATE OF METASTASIS 1; COM1;; p8__:__
Number Sign__:__614813__:__SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS; SOFT__:__SOFT SYNDROME__:__
Number Sign__:__614814__:__ADAMS-OLIVER SYNDROME 3; AOS3__:____:__
Number Sign__:__614815__:__JOUBERT SYNDROME 18; JBTS18__:____:__
Number Sign__:__614816__:__LOEYS-DIETZ SYNDROME 4; LDS4__:__ANEURYSM, AORTIC AND CEREBRAL, WITH ARTERIAL TORTUOSITY AND SKELETAL MANIFESTATIONS__:__
Number Sign__:__614817__:__INTERSTITIAL NEPHRITIS, KARYOMEGALIC; KMIN__:____:__
Asterisk__:__614818__:__FURRY, DROSOPHILA, HOMOLOG OF; FRY__:__CHROMOSOME 13 OPEN READING FRAME 14; C13ORF14__:__
Number Sign__:__614819__:__WEILL-MARCHESANI SYNDROME 3; WMS3__:____:__
Number Sign__:__614820__:__ALTERNATING HEMIPLEGIA OF CHILDHOOD 2; AHC2__:____:__
Asterisk__:__614821__:__PTCSC3 GENE; PTCSC3__:____:__
Number Sign__:__614822__:__SPERMATOGENIC FAILURE 10; SPGF10__:__SPERMATOGENIC FAILURE WITH DEFECTIVE SPERM ANNULUS__:__
Number Sign__:__614823__:__AORTIC VALVE DISEASE 2; AOVD2__:__BICUSPID AORTIC VALVE;; AORTIC VALVE STENOSIS__:__
Asterisk__:__614824__:__ADAPTOR-RELATED PROTEIN COMPLEX 5, SIGMA-1 SUBUNIT; AP5S1__:__CHROMOSOME 20 OPEN READING FRAME 29; C20ORF29;; SIGMA 5__:__
Asterisk__:__614825__:__RALBP1-ASSOCIATED EPS DOMAIN-CONTAINING PROTEIN 1; REPS1__:____:__
Percent__:__614826__:__NYSTAGMUS 7, CONGENITAL, AUTOSOMAL DOMINANT; NYS7__:____:__
Asterisk__:__614827__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 11; DNAJC11__:____:__
Asterisk__:__614828__:__PROTEIN O-MANNOSE BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE 2; POMGNT2__:__GLYCOSYLTRANSFERASE-LIKE DOMAIN-CONTAINING PROTEIN 2; GTDC2;; CHROMOSOME 3 OPEN READING FRAME 39; C3ORF39;; AGO61__:__
Asterisk__:__614829__:__ODONTOGENESIS-ASSOCIATED PHOSPHOPROTEIN; ODAPH__:__CHROMOSOME 4 OPEN READING FRAME 26; C4ORF26__:__
Number Sign__:__614830__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GTDC2-RELATED__:__
Number Sign__:__614831__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 13; SCAR13__:____:__
Number Sign__:__614832__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA4; AI2A4__:____:__
Number Sign__:__614833__:__MICROCEPHALY, SHORT STATURE, AND POLYMICROGYRIA WITH OR WITHOUT SEIZURES; MSSP__:__POLYMICROGYRIA WITH SEIZURES; PMGYS__:__
Percent__:__614834__:__THYROTOXIC PERIODIC PARALYSIS, SUSCEPTIBILITY TO, 3; TTPP3__:____:__
Asterisk__:__614835__:__ACTIN, BETA-LIKE, 2; ACTBL2__:____:__
Percent__:__614836__:__HUMAN HERPESVIRUS 8, SUSCEPTIBILITY TO; HHV8S__:__HHV-8, SUSCEPTIBILITY TO__:__
Number Sign__:__614837__:__HYPOGONADOTROPIC HYPOGONADISM 8 WITH OR WITHOUT ANOSMIA; HH8__:____:__
Number Sign__:__614838__:__HYPOGONADOTROPIC HYPOGONADISM 9 WITH OR WITHOUT ANOSMIA; HH9__:____:__
Number Sign__:__614839__:__HYPOGONADOTROPIC HYPOGONADISM 10 WITH OR WITHOUT ANOSMIA; HH10__:____:__
Number Sign__:__614840__:__HYPOGONADOTROPIC HYPOGONADISM 11 WITH OR WITHOUT ANOSMIA; HH11__:____:__
Number Sign__:__614841__:__HYPOGONADOTROPIC HYPOGONADISM 12 WITH OR WITHOUT ANOSMIA; HH12__:__EUNUCHOIDISM, FAMILIAL HYPOGONADOTROPIC;; GONADOTROPIN DEFICIENCY, FAMILIAL IDIOPATHIC; FIGD__:__
Number Sign__:__614842__:__HYPOGONADOTROPIC HYPOGONADISM 13 WITH OR WITHOUT ANOSMIA; HH13__:____:__
Asterisk__:__614843__:__ODONTOGENIC AMELOBLAST-ASSOCIATED PROTEIN; ODAM__:__APIN__:__
Number Sign__:__614844__:__NEPHRONOPHTHISIS 14; NPHP14__:____:__JOUBERT SYNDROME 19, INCLUDED; JBTS19, INCLUDED
Number Sign__:__614845__:__NEPHRONOPHTHISIS 15; NPHP15__:____:__
Number Sign__:__614846__:__TETRASOMY 15q26__:__LEVY-SHANSKE SYNDROME__:__
Number Sign__:__614847__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 12; EIG12__:____:__
Asterisk__:__614848__:__CENTROSOMAL PROTEIN, 164-KD; CEP164__:__KIAA1052__:__
Number Sign__:__614849__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 5; IIAE5__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 3__:__
Number Sign__:__614850__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 6; IIAE6__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 4__:__
Number Sign__:__614851__:__SECKEL SYNDROME 7; SCKL7__:____:__
Number Sign__:__614852__:__MICROCEPHALY 9, PRIMARY, AUTOSOMAL RECESSIVE; MCPH9__:____:__
Asterisk__:__614853__:__CYTOKINE RECEPTOR-LIKE FACTOR 3; CRLF3__:__CYTOKINE RECEPTOR-RELATED PROTEIN 4; CYTOR4;; CYTOKINE RECEPTOR-LIKE MOLECULE 9; CRLM9;; CREME9__:__
Asterisk__:__614854__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 59; LRRC59__:__p34__:__
Asterisk__:__614855__:__TBC1 DOMAIN FAMILY, MEMBER 14; TBC1D14__:__KIAA1322__:__
Number Sign__:__614856__:__OSTEOGENESIS IMPERFECTA, TYPE XIII; OI13__:__OI, TYPE XIII__:__
Number Sign__:__614857__:__METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblJ TYPE; MAHCJ__:____:__
Number Sign__:__614858__:__HYPOGONADOTROPIC HYPOGONADISM 14 WITH OR WITHOUT ANOSMIA; HH14__:____:__
Number Sign__:__614859__:__PEROXISOME BIOGENESIS DISORDER 3A (ZELLWEGER); PBD3A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 3, INCLUDED; CG3, INCLUDED
Number Sign__:__614860__:__DYSTONIA 23; DYT23__:____:__
Number Sign__:__614861__:__DEAFNESS, AUTOSOMAL RECESSIVE 98; DFNB98__:____:__
Number Sign__:__614862__:__PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 4, INCLUDED; CG4, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 6, INCLUDED; CG6, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP C, INCLUDED; CGC, INCLUDED
Number Sign__:__614863__:__PEROXISOME BIOGENESIS DISORDER 4B; PBD4B__:____:__
Asterisk__:__614864__:__DYNEIN AXONEMAL ASSEMBLY FACTOR 5; DNAAF5__:__HEAT REPEAT-CONTAINING PROTEIN 2; HEATR2__:__
Asterisk__:__614865__:__D4Z4 BINDING ELEMENT TRANSCRIPT, NONCODING; DBET__:__DBE TRANSCRIPT, NONCODING__:__
Number Sign__:__614866__:__PEROXISOME BIOGENESIS DISORDER 5A (ZELLWEGER); PBD5A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 5, INCLUDED; CG5, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 10, INCLUDED; CG10, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP F, INCLUDED; CGF, INCLUDED
Number Sign__:__614867__:__PEROXISOME BIOGENESIS DISORDER 5B; PBD5B__:____:__
Number Sign__:__614868__:__T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AND AUTOIMMUNITY WITH OR WITHOUT CARDIAC MALFORMATIONS; TIIAC__:__STK4 DEFICIENCY;; MST1 DEFICIENCY__:__
Number Sign__:__614869__:__USHER SYNDROME, TYPE IJ; USH1J__:____:__
Number Sign__:__614870__:__PEROXISOME BIOGENESIS DISORDER 6A (ZELLWEGER); PBD6A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 7, INCLUDED; CG7, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP B, INCLUDED; CGB, INCLUDED
Number Sign__:__614871__:__PEROXISOME BIOGENESIS DISORDER 6B; PBD6B__:____:__
Number Sign__:__614872__:__PEROXISOME BIOGENESIS DISORDER 7A (ZELLWEGER); PBD7A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 8, INCLUDED; CG8, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP A, INCLUDED; CGA, INCLUDED
Number Sign__:__614873__:__PEROXISOME BIOGENESIS DISORDER 7B; PBD7B__:____:__
Number Sign__:__614874__:__CILIARY DYSKINESIA, PRIMARY, 18; CILD18__:__CILIARY DYSKINESIA, PRIMARY, 18, WITH OR WITHOUT SITUS INVERSUS__:__
Percent__:__614875__:__METAPHYSEAL ENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA__:__SPONDYLOENCHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA;; METAPHYSEAL ENCHONDRODYSPLASIA WITH 2-HYDROXYGLUTARIC ACIDURIA;; METAPHYSEAL CHONDROMATOSIS WITH D-2-HYDROXYGLUTARIC ACIDURIA__:__
Number Sign__:__614876__:__PEROXISOME BIOGENESIS DISORDER 8A (ZELLWEGER); PBD8A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 9, INCLUDED; CG9, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP D, INCLUDED; CGD, INCLUDED
Number Sign__:__614877__:__PEROXISOME BIOGENESIS DISORDER 8B; PBD8B__:____:__
Number Sign__:__614878__:__AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED; APLAID__:____:__
Number Sign__:__614879__:__PEROXISOME BIOGENESIS DISORDER 9B; PBD9B__:__REFSUM DISEASE, ADULT, 2;; PEROXISOME BIOGENESIS DISORDER, PEX7-RELATED, ATYPICAL__:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 11, INCLUDED; CG11, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP R, INCLUDED; CGR, INCLUDED
Number Sign__:__614880__:__HYPOGONADOTROPIC HYPOGONADISM 15 WITH OR WITHOUT ANOSMIA; HH15__:____:__
Number Sign__:__614881__:__SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL RECESSIVE, 5; DSMA5__:____:__
Number Sign__:__614882__:__PEROXISOME BIOGENESIS DISORDER 10A (ZELLWEGER); PBD10A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 12, INCLUDED; CG12, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP G, INCLUDED; CGG, INCLUDED
Number Sign__:__614883__:__PEROXISOME BIOGENESIS DISORDER 11A (ZELLWEGER); PBD11A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 13, INCLUDED; CG13, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP H, INCLUDED; CGH, INCLUDED
Asterisk__:__614884__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 3B; VWA3B__:__VWA DOMAIN-CONTAINING PROTEIN 3B__:__
Number Sign__:__614885__:__PEROXISOME BIOGENESIS DISORDER 11B; PBD11B__:____:__
Number Sign__:__614886__:__PEROXISOME BIOGENESIS DISORDER 12A (ZELLWEGER); PBD12A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP 14, INCLUDED;; CG14, INCLUDED;; PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP J, INCLUDED;; CGJ, INCLUDED
Number Sign__:__614887__:__PEROXISOME BIOGENESIS DISORDER 13A (ZELLWEGER); PBD13A__:____:__PEROXISOME BIOGENESIS DISORDER, COMPLEMENTATION GROUP K, INCLUDED; CGK, INCLUDED
Asterisk__:__614888__:__ALPHA- AND GAMMA-ADAPTIN-BINDING PROTEIN; AAGAB__:__p34__:__
Number Sign__:__614889__:__IMMUNODEFICIENCY 28; IMD28__:__IMMUNODEFICIENCY 28, MYCOBACTERIOSIS;; IFNGR2 DEFICIENCY__:__
Number Sign__:__614890__:__IMMUNODEFICIENCY 29; IMD29__:__IL12B DEFICIENCY__:__
Number Sign__:__614891__:__IMMUNODEFICIENCY 30; IMD30__:__IL12RB1 DEFICIENCY__:__
Number Sign__:__614892__:__IMMUNODEFICIENCY 31A; IMD31A__:__IMMUNODEFICIENCY 31A, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT;; STAT1 DEFICIENCY, AUTOSOMAL DOMINANT__:__
Number Sign__:__614893__:__IMMUNODEFICIENCY 32A; IMD32A__:__IMMUNODEFICIENCY 32A, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT;; IRF8 DEFICIENCY, AUTOSOMAL DOMINANT;; CD11C-POSITIVE/CD1C-POSITIVE DENDRITIC CELL DEFICIENCY, AUTOSOMAL DOMINANT__:__
Caret__:__614894__:__MOVED TO 226990__:____:__
Number Sign__:__614895__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 4F; CMT4F__:____:__
Number Sign__:__614896__:__SINOATRIAL NODE DYSFUNCTION AND DEAFNESS; SANDD__:____:__
Number Sign__:__614897__:__HYPOGONADOTROPIC HYPOGONADISM 16 WITH OR WITHOUT ANOSMIA; HH16__:____:__
Number Sign__:__614898__:__SPASTIC PARAPLEGIA 53, AUTOSOMAL RECESSIVE; SPG53__:____:__
Number Sign__:__614899__:__DEAFNESS, AUTOSOMAL RECESSIVE 93; DFNB93__:____:__
Number Sign__:__614900__:__DIAMOND-BLACKFAN ANEMIA 11; DBA11__:____:__
Asterisk__:__614901__:__BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE KINASE; BCKDK__:__BCKDH KINASE; BDK;; BCKD KINASE__:__
Asterisk__:__614902__:__RHO GTPase-ACTIVATING PROTEIN 33; ARHGAP33__:__TC10/CDC42 GTPase-ACTIVATING PROTEIN; TCGAP__:__
Asterisk__:__614903__:__SORTING NEXIN 16; SNX16__:____:__
Asterisk__:__614904__:__SORTING NEXIN 7; SNX7__:____:__
Asterisk__:__614905__:__SORTING NEXIN 8; SNX8__:____:__
Asterisk__:__614906__:__SORTING NEXIN 11; SNX11__:____:__
Asterisk__:__614907__:__PRECURSOR mRNA-PROCESSING FACTOR 39, S. CEREVISIAE, HOMOLOG OF; PRPF39__:____:__
Asterisk__:__614908__:__HEAT SHOCK PROTEIN NUCLEAR IMPORT FACTOR HIKESHI; HIKESHI__:__CHROMOSOME 11 OPEN READING FRAME 73; C11ORF73__:__
Asterisk__:__614909__:__TRANSMEMBRANE PROTEIN 174; TMEM174__:____:__
Asterisk__:__614910__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 6; C1QTNF6__:__CTRP6__:__
Asterisk__:__614911__:__C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 4; C1QTNF4__:__CTRP4__:__
Asterisk__:__614912__:__TRAB DOMAIN-CONTAINING PROTEIN 2A; TRABD2A__:__TIKI1__:__
Asterisk__:__614913__:__TRAB DOMAIN-CONTAINING PROTEIN 2B; TRABD2B__:__TIKI2__:__
Asterisk__:__614914__:__MICRO RNA 298; MIR298__:__miRNA298__:__
Number Sign__:__614915__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 4; LCCS4__:____:__
Number Sign__:__614916__:__VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 4; CPVT4__:____:__
Asterisk__:__614917__:__REQUIRED FOR MEIOTIC NUCLEAR DIVISION 1, S. CEREVISIAE, HOMOLOG OF; RMND1__:____:__
Asterisk__:__614918__:__PENTATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 3; PTCD3__:____:__
Asterisk__:__614919__:__NITRIC OXIDE-ASSOCIATED PROTEIN 1; NOA1__:__CHROMOSOME 4 OPEN READING FRAME 14; C4ORF14__:__
Number Sign__:__614920__:__PEROXISOME BIOGENESIS DISORDER 14B; PEX14B__:____:__
Number Sign__:__614921__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T__:__CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV__:__
Number Sign__:__614922__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 11; COXPD11__:__ENCEPHALONEUROMYOPATHY, INFANTILE, DUE TO MITOCHONDRIAL TRANSLATION DEFECT__:__
Number Sign__:__614923__:__BRANCHED-CHAIN KETO ACID DEHYDROGENASE KINASE DEFICIENCY; BCKDKD__:__BCKDK DEFICIENCY__:__
Number Sign__:__614924__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 12; COXPD12__:__LEUKOENCEPHALOPATHY WITH THALAMUS AND BRAINSTEM INVOLVEMENT AND HIGH LACTATE; LTBL__:__
Asterisk__:__614925__:__OTOGELIN-LIKE PROTEIN; OTOGL__:__CHROMOSOME 12 OPEN READING FRAME 64; C12ORF64__:__
Number Sign__:__614926__:__PERRAULT SYNDROME 2; PRLTS2__:____:__
Percent__:__614927__:__ECTODERMAL DYSPLASIA 5, HAIR/NAIL TYPE; ECTD5__:____:__
Percent__:__614928__:__ECTODERMAL DYSPLASIA 6, HAIR/NAIL TYPE; ECTD6__:____:__
Number Sign__:__614929__:__ECTODERMAL DYSPLASIA 7, HAIR/NAIL TYPE; ECTD7__:____:__
Asterisk__:__614930__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 6; LRRC6__:__LEUCINE-RICH TESTIS PROTEIN; LRTP__:__
Number Sign__:__614931__:__ECTODERMAL DYSPLASIA 9, HAIR/NAIL TYPE; ECTD9__:____:__
Number Sign__:__614932__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13__:____:__
Asterisk__:__614933__:__LONG INTERGENIC NONCODING RNA, MUSCLE DIFFERENTIATION 1; LINCMD1__:____:__
Number Sign__:__614934__:__DEAFNESS, AUTOSOMAL RECESSIVE 70; DFNB70__:____:__
Number Sign__:__614935__:__CILIARY DYSKINESIA, PRIMARY, 19; CILD19__:__CILIARY DYSKINESIA, PRIMARY, 19, WITH OR WITHOUT SITUS INVERSUS__:__
Percent__:__614936__:__PALMOPLANTAR KERATODERMA, PUNCTATE TYPE IB; PPKP1B__:____:__
Number Sign__:__614937__:__MYOCLONUS, FAMILIAL CORTICAL; FCM__:____:__
Asterisk__:__614938__:__VAULT RNA 2-1; VTRNA2-1__:__VTRNA2;; NONCODING RNA 886; NC886;; PRECURSOR MICRO RNA 886;; PRE-MIR886;; CORD BLOOD LYMPHOCYTE-DERIVED NONCODING RNA 3; CBL3__:__
Asterisk__:__614939__:__PHOSPHOGLYCERATE MUTASE FAMILY, MEMBER 5; PGAM5__:____:__
Number Sign__:__614940__:__ECTODERMAL DYSPLASIA 11A, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL DOMINANT; ECTD11A__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC, AUTOSOMAL DOMINANT; HED__:__
Number Sign__:__614941__:__ECTODERMAL DYSPLASIA 11B, HYPOHIDROTIC/HAIR/TOOTH TYPE, AUTOSOMAL RECESSIVE; ECTD11B__:__ECTODERMAL DYSPLASIA, HYPOHIDROTIC; HED;; ECTODERMAL DYSPLASIA, ANHIDROTIC; EDA__:__
Asterisk__:__614942__:__PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE 1; PGS1__:__PGP SYNTHASE__:__
Asterisk__:__614943__:__TP53-REGULATED INHIBITOR OF APOPTOSIS 1; TRIAP1__:__p53-INDUCIBLE CELL SURVIVAL FACTOR; P53CSV;; HSPC132__:__
Number Sign__:__614944__:__DEAFNESS, AUTOSOMAL RECESSIVE 84B; DFNB84B__:____:__
Number Sign__:__614945__:__DEAFNESS, AUTOSOMAL RECESSIVE 18B; DFNB18B__:____:__
Number Sign__:__614946__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 14; COXPD14__:____:__
Number Sign__:__614947__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 15; COXPD15__:____:__
Asterisk__:__614948__:__TRANSLOCATOR ASSEMBLY AND MAINTENANCE, MITOCHONDRIAL, S. CEREVISIAE, HOMOLOG OF; TAMM41__:__TAM41;; CHROMOSOME 3 OPEN READING FRAME 31; C3ORF31__:__
Asterisk__:__614949__:__TRANSMEMBRANE PROTEIN 231; TMEM231__:____:__
Asterisk__:__614950__:__TRANSMEMBRANE PROTEIN 17; TMEM17__:____:__
Asterisk__:__614951__:__HEAT REPEAT-CONTAINING PROTEIN 3; HEATR3__:__SYNCHRONIZED IMPORT PROTEIN 1; SYO1;; SYMPORTIN__:__
Asterisk__:__614952__:__SCHLAFEN FAMILY, MEMBER 5; SLFN5__:____:__
Asterisk__:__614953__:__SCHLAFEN FAMILY, MEMBER 11; SLFN11__:____:__
Percent__:__614954__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 3; CHTD3__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, WITH CARDIAC RHYTHM AND CONDUCTION DISTURBANCES__:__
Asterisk__:__614955__:__SCHLAFEN FAMILY, MEMBER 12; SLFN12__:____:__
Asterisk__:__614956__:__SCHLAFEN FAMILY, MEMBER 12-LIKE; SLFN12L__:__SLFN12-LIKE__:__
Asterisk__:__614957__:__SCHLAFEN FAMILY, MEMBER 13; SLFN13__:____:__
Asterisk__:__614958__:__SCHLAFEN FAMILY, MEMBER 14; SLFN14__:____:__
Number Sign__:__614959__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 14; EIEE14__:____:__
Asterisk__:__614960__:__PHOSPHOLIPASE D FAMILY, MEMBER 6; PLD6__:__MITOCHONDRIAL PHOSPHOLIPASE; MITOPLD;; ZUCCHINI, DROSOPHILA, HOMOLOG OF; ZUC__:__
Number Sign__:__614961__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 8; PCH8__:____:__
Number Sign__:__614962__:__LEPTIN DEFICIENCY OR DYSFUNCTION; LEPD__:__OBESITY, MORBID, NONSYNDROMIC 1__:__
Number Sign__:__614963__:__LEPTIN RECEPTOR DEFICIENCY__:__OBESITY, MORBID, NONSYNDROMIC 2__:__
Asterisk__:__614964__:__EXTRACELLULAR LEUCINE-RICH REPEAT AND FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 1; ELFN1__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 28; PPP1R28__:__
Asterisk__:__614965__:__SECERNIN 1; SCRN1__:__SES1;; KIAA0193__:__
Asterisk__:__614966__:__SECERNIN 2; SCRN2__:__SES2__:__
Asterisk__:__614967__:__SECERNIN 3; SCRN3__:__SES3__:__
Asterisk__:__614968__:__SH2 DOMAIN-CONTAINING PROTEIN 4A; SH2D4A__:__SH2A;; PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 38; PPP1R38__:__
Number Sign__:__614969__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 7; PCH7__:____:__
Number Sign__:__614970__:__JOUBERT SYNDROME 20; JBTS20__:____:__
Asterisk__:__614971__:__TAURINE-UPREGULATED GENE 1, NONCODING; TUG1__:____:__
Number Sign__:__614972__:__CHOLESTASIS, INTRAHEPATIC, OF PREGNANCY 3; ICP3__:____:__
Percent__:__614973__:__FOCAL FACIAL DERMAL DYSPLASIA 2, BRAUER-SETLEIS TYPE; FFDD2__:__BRAUER-SETLEIS SYNDROME__:__
Number Sign__:__614974__:__FOCAL FACIAL DERMAL DYSPLASIA 4; FFDD4__:____:__
Asterisk__:__614975__:__FOXF1 ADJACENT NONCODING DEVELOPMENTAL REGULATORY RNA; FENDRR__:__FOXF1 ANTISENSE RNA 1, NONCODING; FOXF1AS1;; FOXF1 LONG INTERGENIC NONCODING RNA;; lincFOXF1;; lncFOXF1;; TCONS_00024240__:__
Number Sign__:__614976__:__CARPENTER SYNDROME 2; CRPT2__:____:__
Asterisk__:__614977__:__LONG INTERGENIC NONCODING RNA 1081; LINC01081__:__LONG NONCODING RNA TCONS_00024764;; lncRNA TCONS_00024764;; TCONS_00024764__:__
Asterisk__:__614978__:__LONG INTERGENIC NONCODING RNA 1082; LINC01082__:__LONG NONCODING RNA TCONS_00024492;; lncRNA TCONS_00024492;; TCONS_00024492__:__
Percent__:__614979__:__SPLENOMEGALY, CYTOPENIA, AND VISION LOSS__:____:__
Number Sign__:__614980__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 2; CHTD2__:____:__
Asterisk__:__614981__:__ATPase INHIBITORY FACTOR 1; ATPIF1__:__IF1__:__
Asterisk__:__614982__:__STRUCTURAL MAINTENANCE OF CHROMOSOMES FLEXIBLE HINGE DOMAIN-CONTAINING PROTEIN 1; SMCHD1__:__SMC HINGE DOMAIN-CONTAINING PROTEIN 1;; KIAA0650__:__
Asterisk__:__614983__:__BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE 2; BATF2__:__SUPPRESSOR OF ACTIVATOR PROTEIN 1, REGULATED BY INTERFERON; SARI;; SUPPRESSOR OF AP1, REGULATED BY IFN__:__
Asterisk__:__614984__:__DEHYDROGENASE E1 AND TRANSKETOLASE DOMAINS-CONTAINING PROTEIN 1; DHTKD1__:__KIAA1630__:__
Asterisk__:__614985__:__HELLP SYNDROME-ASSOCIATED LONG NONCODING RNA; HELLPAR__:__lncRNA HELLP; lncHELLP;; HELLP SYNDROME-ASSOCIATED LONG INTERGENIC NONCODING RNA;; lincRNA HELLP; lincHELLP__:__
Asterisk__:__614986__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II INHIBITOR 1; CAMK2N1__:__CAMKII INHIBITORY PROTEIN, ALPHA;; CAMKIIN-ALPHA__:__
Asterisk__:__614987__:__EPS8-LIKE PROTEIN 1; EPS8L1__:__EPS8-RELATED PROTEIN 1; EPS8R1__:__
Asterisk__:__614988__:__EPS8-LIKE PROTEIN 2; EPS8L2__:__EPS8-RELATED PROTEIN 2; EPS8R2__:__
Asterisk__:__614989__:__EPS8-LIKE PROTEIN 3; EPS8L3__:__EPS8-RELATED PROTEIN 3; EPS8R3__:__
Percent__:__614990__:__USHER SYNDROME, TYPE IK; USH1K__:____:__
Asterisk__:__614991__:__UBIQUITIN CARBOXYL-TERMINAL ESTERASE L1, ANTISENSE; UCH1LAS__:__UCH1L, ANTISENSE__:__
Asterisk__:__614992__:__LONG INTERGENIC NONCODING RNA 237; LINC00237__:__lincRNA 237__:__
Asterisk__:__614993__:__CAM KINASE-LIKE VESICLE-ASSOCIATED; CAMKV__:__1G5__:__
Asterisk__:__614994__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IG; CAMK1G__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I-GAMMA;; CAMKI-GAMMA;; CAMK-LIKE CREB KINASE III; CLICK3__:__
Asterisk__:__614995__:__INTERLEUKIN 17 RECEPTOR E; IL17RE__:____:__
Asterisk__:__614996__:__MYELINATING SCHWANN CELL ELEMENT; MSE__:____:__
Asterisk__:__614997__:__GATA ZINC FINGER DOMAIN-CONTAINING PROTEIN 2A; GATAD2A__:__p66-ALPHA__:__
Asterisk__:__614998__:__GATA ZINC FINGER DOMAIN-CONTAINING PROTEIN 2B; GATAD2B__:__p66;; p68;; p66-BETA;; KIAA1150__:__
Asterisk__:__614999__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY X, POLYPEPTIDE 1; CYP4X1__:__CYPIVX1__:__
Asterisk__:__615000__:__TECTONIN BETA-PROPELLER REPEAT-CONTAINING PROTEIN 2; TECPR2__:__KIAA0329__:__
Asterisk__:__615001__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12C; ZC3H12C__:__MCP1-INDUCED PROTEIN 3; MCPIP3__:__
Asterisk__:__615002__:__CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2, BETA; CAMKK2__:__CAMKK-BETA; CAMKKB;; KIAA0787__:__
Asterisk__:__615003__:__DDHD DOMAIN-CONTAINING PROTEIN 2; DDHD2__:__KIAA0725__:__
Asterisk__:__615004__:__LEUCINE-RICH REPEAT, IMMUNOGLOBULIN-LIKE, AND TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 3; LRIT3__:__FIGLER4__:__
Number Sign__:__615005__:__EPILEPSY, NOCTURNAL FRONTAL LOBE, 5; ENFL5__:____:__
Number Sign__:__615006__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 15; EIEE15__:____:__
Number Sign__:__615007__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 4; IBGC4__:____:__
Number Sign__:__615008__:__NEPHROTIC SYNDROME, TYPE 7; NPHS7__:__NEPHROTIC SYNDROME, TYPE 7, WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS__:__HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 7, INCLUDED; AHUS7, INCLUDED;; AHUS, SUSCEPTIBILITY TO, 7, INCLUDED
Number Sign__:__615009__:__SCHUURS-HOEIJMAKERS SYNDROME; SHMS__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 17; MRD17__:__
Number Sign__:__615010__:__AICARDI-GOUTIERES SYNDROME 6; AGS6__:____:__
Number Sign__:__615011__:__PHOSPHOHYDROXYLYSINURIA; PHLU__:____:__
Asterisk__:__615012__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER G; HIST1H2AG__:__HISTONE GENE CLUSTER 1, H2AG;; HIST1 CLUSTER, H2AG;; H2A HISTONE FAMILY, MEMBER P; H2AFP;; H2A/P__:__
Asterisk__:__615013__:__HISTONE GENE CLUSTER 1, H2A HISTONE FAMILY, MEMBER H; HIST1H2AH__:__HISTONE GENE CLUSTER 1, H2AH;; HIST1 CLUSTER, H2AH;; H2A/S__:__
Asterisk__:__615014__:__HISTONE GENE CLUSTER 2, H2A HISTONE FAMILY, MEMBER B; HIST2H2AB__:__HISTONE GENE CLUSTER 2, H2AB;; HIST2 CLUSTER, H2AB__:__
Asterisk__:__615015__:__HISTONE GENE CLUSTER 3, H2A HISTONE; HIST3H2A__:__HISTONE GENE CLUSTER 3, H2A;; HIST3 CLUSTER, H2A__:__
Asterisk__:__615016__:__OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY J, MEMBER 3; OR2J3__:____:__
Asterisk__:__615017__:__MICRO RNA 139; MIR139__:__miRNA139;; MIR139-5p__:__MICRO RNA 139-3p, INCLUDED; MIR139-3p, INCLUDED
Asterisk__:__615019__:__ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 5; ELP5__:__DERMAL PAPILLA-DERIVED PROTEIN 6; DERP6;; CHROMOSOME 17 OPEN READING FRAME 81; C17ORF81__:__
Asterisk__:__615020__:__ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 6; ELP6__:__TRANSMEMBRANE PROTEIN 103; TMEM103;; CHROMOSOME 3 OPEN READING FRAME 75; C3ORF75__:__
Number Sign__:__615021__:__BLOOD GROUP, GLOBOSIDE SYSTEM; GLOB__:____:__
Percent__:__615022__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 7; ARCI7__:____:__
Number Sign__:__615023__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 9; ARCI9__:____:__
Number Sign__:__615024__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 10; ARCI10__:____:__
Number Sign__:__615025__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Q;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Q__:__
Number Sign__:__615026__:__RIBOFLAVIN DEFICIENCY; RBFVD__:____:__
Asterisk__:__615027__:__SIN3-HDAC COMPLEX ASSOCIATED FACTOR; SINHCAF__:__FAMILY WITH SEQUENCE SIMILARITY 60, MEMBER A; FAM60A__:__
Number Sign__:__615028__:__EPIDERMOLYSIS BULLOSA, NONSPECIFIC, AUTOSOMAL RECESSIVE; EBNS__:____:__
Asterisk__:__615029__:__PRECEREBELLIN 4; CBLN4__:____:__
Number Sign__:__615030__:__SPASTIC PARAPLEGIA 56, AUTOSOMAL RECESSIVE; SPG56__:____:__
Number Sign__:__615031__:__SPASTIC PARAPLEGIA 49, AUTOSOMAL RECESSIVE; SPG49__:____:__
Number Sign__:__615032__:__AUTISM, SUSCEPTIBILITY TO, 18; AUTS18__:____:__
Number Sign__:__615033__:__SPASTIC PARAPLEGIA 54, AUTOSOMAL RECESSIVE; SPG54__:____:__
Number Sign__:__615034__:__DYSTONIA 24; DYT24__:____:__
Number Sign__:__615035__:__SPASTIC PARAPLEGIA 55, AUTOSOMAL RECESSIVE; SPG55__:____:__
Asterisk__:__615036__:__MICRO RNA 410; MIR410__:__miRNA410__:__
Asterisk__:__615037__:__MICRO RNA 487B; MIR487B__:__miRNA487B__:__
Asterisk__:__615038__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 114: CCDC114__:____:__
Asterisk__:__615039__:__N-DEACETYLASE/N-SULFOTRANSFERASE 4; NDST4__:__HEPARAN GLUCOSAMINYL N-DEACETYLASE/N-SULFOTRANSFERASE 4;; HEPARAN SULFATE N-DEACETYLASE/N-SULFOTRANSFERASE 4__:__
Number Sign__:__615040__:__EPISODIC PAIN SYNDROME, FAMILIAL, 1; FEPS1__:____:__
Number Sign__:__615041__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, TMEM5-RELATED__:__
Number Sign__:__615042__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U__:__CDG Iu; CDGIu__:__
Number Sign__:__615043__:__SPASTIC PARAPLEGIA 43, AUTOSOMAL RECESSIVE; SPG43__:____:__
Asterisk__:__615044__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER J; HIST1H2BJ__:__HISTONE GENE CLUSTER 1, H2BJ;; HIST1 CLUSTER, H2BJ__:__
Asterisk__:__615045__:__HISTONE GENE CLUSTER 1, H2B HISTONE FAMILY, MEMBER K; HIST1H2BK__:__HISTONE GENE CLUSTER 1, H2BK;; HIST1 CLUSTER, H2BK__:__
Asterisk__:__615046__:__HISTONE GENE CLUSTER 3, H2B HISTONE FAMILY, MEMBER B; HIST3H2BB__:__HISTONE GENE CLUSTER 3, H2BB;; HIST3 CLUSTER, H2BB__:__
Asterisk__:__615047__:__TETRATRICOPEPTIDE REPEAT-, ANKYRIN REPEAT-, AND COILED-COIL-CONTAINING PROTEIN 2; TANC2__:__KIAA1636__:__
Number Sign__:__615048__:__SPINAL MUSCULAR ATROPHY, JOKELA TYPE; SMAJ__:____:__
Asterisk__:__615049__:__WW DOMAIN-CONTAINING ADAPTOR WITH COILED-COIL REGION; WAC__:__KIAA1844__:__
Asterisk__:__615050__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 5; ASB5__:____:__
Asterisk__:__615051__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 6; ASB6__:____:__
Asterisk__:__615052__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 7; ASB7__:____:__
Asterisk__:__615053__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 8; ASB8__:____:__
Asterisk__:__615054__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 10; ASB10__:____:__
Asterisk__:__615055__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 13; ASB13__:____:__
Asterisk__:__615056__:__ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 16; ASB16__:____:__
Caret__:__615057__:__MOVED TO 244450__:____:__
Number Sign__:__615058__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1F; CSNB1F__:____:__
Number Sign__:__615059__:__HYPOTRICHOSIS 11; HYPT11__:____:__
Asterisk__:__615060__:__SECRETOGLOBIN, FAMILY 1D, MEMBER 1; SCGB1D1__:__LIPOPHILIN A; LPNA__:__
Asterisk__:__615061__:__SECRETOGLOBIN, FAMILY 1D, MEMBER 2; SCGB1D2__:__LIPOPHILIN B; LPNB__:__
Asterisk__:__615062__:__SECRETOGLOBIN, FAMILY 1D, MEMBER 4; SCGB1D4__:__INTERFERON-GAMMA-INDUCIBLE SECRETOGLOBIN; IIS__:__
Asterisk__:__615063__:__SECRETOGLOBIN, FAMILY 2B, MEMBER 2; SCGB2B2__:____:__
Asterisk__:__615064__:__SOLUTE CARRIER FAMILY 25 (CARNITINE/ACYLCARNITINE TRANSLOCASE), MEMBER 29; SLC25A29__:__CARNITINE-ACYLCARNITINE TRANSLOCASE-LIKE; CACL;; MITOCHONDRIAL ORNITHINE TRANSPORTER 3; ORNT3__:__
Number Sign__:__615065__:__ARTHROGRYPOSIS, DISTAL, TYPE 5D; DA5D__:____:__
Number Sign__:__615066__:__OSTEOGENESIS IMPERFECTA, TYPE XIV; OI14__:__OI, TYPE XIV__:__
Number Sign__:__615067__:__CILIARY DYSKINESIA, PRIMARY, 20; CILD20__:__CILIARY DYSKINESIA, PRIMARY, 20, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__615068__:__ECTOPIC P-GRANULES AUTOPHAGY PROTEIN 5, C. ELEGANS, HOMOLOG OF; EPG5__:__KIAA1632;; HEEW1__:__
Asterisk__:__615069__:__HISTONE GENE CLUSTER 4, H4 HISTONE; HIST4H4__:__HISTONE GENE CLUSTER 4, H4;; HIST4 CLUSTER, H4;; H4/P__:__
Asterisk__:__615070__:__MICRO RNA 590; MIR590__:__miRNA590;; MIRN590__:__
Number Sign__:__615071__:__ALAZAMI SYNDROME; ALAZS__:__FACIAL DYSMORPHISM, INTELLECTUAL DISABILITY, AND PRIMORDIAL DWARFISM__:__
Number Sign__:__615072__:__BRACHYDACTYLY, TYPE A1, C; BDA1C__:____:__
Number Sign__:__615073__:__DYSTONIA 25; DYT25__:____:__
Number Sign__:__615074__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 18; MRD18__:____:__
Number Sign__:__615075__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 19; MRD19__:____:__
Asterisk__:__615076__:__MITOCHONDRIAL GENOME MAINTENANCE EXONUCLEASE 1; MGME1__:__CHROMOSOME 20 OPEN READING FRAME 72; C20ORF72__:__
Asterisk__:__615077__:__TBC1 DOMAIN FAMILY, MEMBER 30; TBC1D30__:__KIAA0984__:__
Asterisk__:__615078__:__GOLGI TRANSPORT 1B; GOLT1B__:__GOT1B;; GERM CELL TUMOR 2; GCT2__:__
Asterisk__:__615079__:__ASUNDER, SPERMATOGENESIS REGULATOR; ASUN__:__ASUNDER, DROSOPHILA, HOMOLOG OF;; MAT89BB, DROSOPHILA, HOMOLOG OF; MAT89BB;; GERM CELL TUMOR 1; GCT1__:__
Percent__:__615080__:__ALZHEIMER DISEASE 17; AD17__:__ALZHEIMER DISEASE 17, LATE-ONSET__:__
Number Sign__:__615081__:__SPERMATOGENIC FAILURE 11; SPGF11__:____:__
Number Sign__:__615082__:__C3HEX, ABILITY TO SMELL__:____:__
Number Sign__:__615083__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, 12; CRCS12__:__COLORECTAL CANCER, SUSCEPTIBILITY TO, ON CHROMOSOME 12q24__:__
Number Sign__:__615084__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 11; MTDPS11__:____:__
Number Sign__:__615085__:__OSTEOPETROSIS, AUTOSOMAL RECESSIVE 8; OPTB8__:____:__
Asterisk__:__615086__:__HARBINGER TRANSPOSASE-DERIVED GENE 1; HARBI1__:____:__
Caret__:__615087__:__MOVED TO 613091__:____:__
Asterisk__:__615088__:__AUTOPHAGY 13, S. CEREVISIAE, HOMOLOG OF; ATG13__:__KIAA0652;; PARAPROTEIN TARGET 8; PARATARG8;; PARATARG 8__:__
Asterisk__:__615089__:__AUTOPHAGY-RELATED PROTEIN 101; ATG101__:__CHROMOSOME 12 OPEN READING FRAME 44; C12ORF44__:__
Asterisk__:__615090__:__INTERFERON, LAMBDA-4; IFNL4__:____:__
Number Sign__:__615091__:__AUTISM, SUSCEPTIBILITY TO, 19; AUTS19__:____:__
Number Sign__:__615092__:__LEFT VENTRICULAR NONCOMPACTION 7; LVNC7__:____:__
Asterisk__:__615093__:__LYMPHOCYTE ANTIGEN 6 COMPLEX, LOCUS K; LY6K__:____:__
Asterisk__:__615094__:__PROSPERO-RELATED HOMEOBOX 2; PROX2__:____:__
Number Sign__:__615095__:__MICROCEPHALY 10, PRIMARY, AUTOSOMAL RECESSIVE; MCPH10__:____:__
Asterisk__:__615096__:__MICRO RNA 217; MIR217__:__miRNA217__:__
Asterisk__:__615097__:__SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), MEMBER 13; SLC6A13__:__GABA TRANSPORTER 2; GAT2;; GABA TRANSPORTER 3, MOUSE, HOMOLOG OF; GAT3__:__
Asterisk__:__615098__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 28; TTC28__:__TPRBK;; KIAA1043__:__
Asterisk__:__615099__:__ERYTHROFERRONE; ERFE__:__FAMILY WITH SEQUENCE SIMILARITY 132, MEMBER B; FAM132B;; C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 15; CIQTNF15; CTRP15;; MYONECTIN__:__
Asterisk__:__615100__:__CTTNBP2 N TERMINUS-LIKE PROTEIN; CTTNBP2NL__:____:__
Asterisk__:__615101__:__TUBULIN, BETA-2A; TUBB2A__:__TUBULIN, BETA, CLASS IIA__:__
Percent__:__615102__:__TYSHCHENKO SYNDROME__:____:__
Asterisk__:__615103__:__TUBULIN, BETA-6; TUBB6__:__TUBULIN, BETA, CLASS V__:__
Asterisk__:__615104__:__NCK-ASSOCIATED PROTEIN 5-LIKE; NCKAP5L__:__NCKAP5-LIKE;; KIAA1602__:__
Asterisk__:__615105__:__METHYLTHIORIBOSE-1-PHOSPHATE ISOMERASE, S. CEREVISIAE, HOMOLOG OF; MRI1__:__MEDIATOR OF RHOA-DEPENDENT INVASION; MRDI__:__
Caret__:__615106__:__MOVED TO 158350__:____:__
Number Sign__:__615107__:__COWDEN SYNDROME 4; CWS4__:____:__
Number Sign__:__615108__:__COWDEN SYNDROME 5; CWS5__:____:__
Number Sign__:__615109__:__COWDEN SYNDROME 6; CWS6__:____:__
Asterisk__:__615110__:__WD REPEAT-CONTAINING PROTEIN 53; WDR53__:____:__
Asterisk__:__615111__:__DENN/MADD DOMAIN-CONTAINING PROTEIN 2D; DENND2D__:____:__
Number Sign__:__615112__:__UROFACIAL SYNDROME 2; UFS2__:____:__
Number Sign__:__615113__:__MICROPHTHALMIA, ISOLATED 8; MCOP8__:____:__
Asterisk__:__615114__:__ZINC FINGER PROTEIN 516; ZNF516__:__KIAA0222__:__
Asterisk__:__615115__:__ADDITIONAL SEX COMBS-LIKE 3; ASXL3__:__KIAA1713__:__
Asterisk__:__615116__:__SPERMATID MATURATION PROTEIN 1; SPEM1__:__CHROMOSOME 17 OPEN READING FRAME 83; C17ORF83__:__
Asterisk__:__615117__:__CHROMOSOME 2 OPEN READING FRAME 88; C2ORF88__:__SMALL MEMBRANE PROTEIN KINASE A-ANCHORING PROTEIN; SMAKAP__:__
Caret__:__615118__:__MOVED TO 269300__:____:__
Number Sign__:__615119__:__CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 2; CEMCOX2__:____:__
Number Sign__:__615120__:__MYASTHENIC SYNDROME, CONGENITAL, 8; CMS8__:__MYASTHENIC SYNDROME, CONGENITAL, WITH PRE- AND POSTSYNAPTIC DEFECTS; CMSPPD;; MYASTHENIC SYNDROME, CONGENITAL, DUE TO AGRIN DEFICIENCY__:__
Percent__:__615121__:__STOMATIN-LIKE PROTEIN-2, HYPERPHOSPHORYLATION OF__:__HYPERPHOSPHORYLATED PARATARG-7__:__
Number Sign__:__615122__:__LYMPHOPROLIFERATIVE SYNDROME 2; LPFS2__:__CD27 DEFICIENCY__:__
Asterisk__:__615123__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 13A; ANKRD13A__:____:__
Asterisk__:__615124__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 13B; ANKRD13B__:____:__
Asterisk__:__615125__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 13C; ANKRD13C__:____:__
Asterisk__:__615126__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 13D; ANKRD13D__:____:__
Percent__:__615127__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 4; FAME4__:__CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 4; FCMTE4__:__
Asterisk__:__615128__:__STIMULATED BY RETINOIC ACID 13; STRA13__:__CENTROMERIC PROTEIN X; CENPX;; FANCONI ANEMIA-ASSOCIATED POLYPEPTIDE, 10-KD; FAAP10;; FANCM-INTERACTING HISTONE-FOLD PROTEIN 2; MHF2;; RETINOIC ACID-INDUCIBLE GENE D9; D9__:__
Asterisk__:__615129__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 5; GALNT5__:__GalNAc TRANSFERASE 5; GalNAcT5__:__
Asterisk__:__615130__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 11; GALNT11__:__GalNAc TRANSFERASE 11; GalNAcT11__:__
Asterisk__:__615131__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 15; GALNT15__:__GalNAc TRANSFERASE 15; GalNAcT15__:__
Asterisk__:__615132__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 16; GALNT16__:__GalNAc TRANSFERASE 16; GalNAcT16;; GalNAc TRANSFERASE-LIKE 1; GALNTL1;; KIAA1130__:__
Asterisk__:__615133__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE-LIKE 5; GALNTL5__:__GalNAc TRANSFERASE 19; GalNAcT19__:__
Number Sign__:__615134__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9__:____:__
Number Sign__:__615135__:__MAPLE SYRUP URINE DISEASE, MILD VARIANT; MSUDMV__:____:__
Asterisk__:__615136__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 18; GALNT18__:__GalNAc TRANSFERASE 18; GalNAcT18;; GalNAc TRANSFERASE-LIKE 4; GALNTL4__:__
Asterisk__:__615137__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 17; WBSCR17__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE-LIKE 3; GALNTL3;; GalNAc TRANSFERASE 17; GalNAcT17__:__
Asterisk__:__615138__:__UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE-LIKE 6; GALNTL6__:__GalNAc TRANSFERASE 20; GalNAcT20__:__
Number Sign__:__615139__:__FACIAL DYSMORPHISM, IMMUNODEFICIENCY, LIVEDO, AND SHORT STATURE; FILS__:____:__
Asterisk__:__615140__:__CHROMOSOME 12 OPEN READING FRAME 57; C12ORF57__:__C10__:__
Caret__:__615141__:__MOVED TO 177700__:____:__
Asterisk__:__615142__:__KINESIN FAMILY MEMBER 2B; KIF2B__:____:__
Asterisk__:__615143__:__UBIQUITIN-SPECIFIC PROTEASE 20; USP20__:__VHL-INTERACTING DEUBIQUITINATING ENZYME 2; VDU2;; KIAA1003__:__
Asterisk__:__615144__:__PROTEASE, SERINE, 55; PRSS55__:__TESTIS SERINE PROTEASE 1; TSP1__:__
Number Sign__:__615145__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 9; MCOPCB9__:____:__
Asterisk__:__615146__:__UBIQUITIN-SPECIFIC PROTEASE 33; USP33__:__VHL-INTERACTING DEUBIQUITINATING ENZYME 1; VDU1;; KIAA1097__:__
Number Sign__:__615147__:__RETINAL DYSTROPHY, IRIS COLOBOMA, AND COMEDOGENIC ACNE SYNDROME; RDCCAS__:____:__
Asterisk__:__615148__:__MICRO RNA 551A; MIR551A__:__miRNA155A__:__
Asterisk__:__615149__:__MICRO RNA 495; MIR495__:__miRNA495__:__
Asterisk__:__615150__:__MICRO RNA 191; MIR191__:__miRNA191__:__
Asterisk__:__615151__:__MICRO RNA 30C-1; MIR30C1__:__miNA30C1__:__
Asterisk__:__615152__:__KELCH DOMAIN-CONTAINING PROTEIN 10; KLHDC10__:__SCRUIN-LIKE AT THE MIDLINE, DROSOPHILA, HOMOLOG OF;; SLIM, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__615153__:__MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN; MLKL__:____:__
Asterisk__:__615154__:__DPY30 DOMAIN-CONTAINING PROTEIN 1; DYDC1__:____:__
Number Sign__:__615155__:__STEEL SYNDROME; STLS__:__DISLOCATED HIPS AND RADIAL HEADS, CARPAL COALITION, SCOLIOSIS, AND SHORT STATURE__:__
Number Sign__:__615156__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6__:__
Number Sign__:__615157__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 2; MC3DN2__:____:__
Number Sign__:__615158__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 3; MC3DN3__:____:__
Number Sign__:__615159__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 4; MC3DN4__:____:__
Number Sign__:__615160__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 5; MC3DN5__:____:__
Asterisk__:__615161__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DQ BETA-2; HLA-DQB2__:__MAJOR HISTOCOMPATIBILITY COMPLEX, CLASS II, DX BETA; HLA-DXB;; DX-BETA__:__
Percent__:__615162__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 35; MRT35__:____:__
Percent__:__615163__:__CONE-ROD DYSTROPHY 17; CORD17__:____:__
Asterisk__:__615164__:__AKIRIN 1; AKIRIN1__:____:__
Asterisk__:__615165__:__AKIRIN 2; AKIRIN2__:____:__
Asterisk__:__615166__:__COX ASSEMBLY MITOCHONDRIAL PROTEIN 1, S. CEREVISIAE, HOMOLOG OF; CMC1__:__MITOCHONDRIAL METALLOCHAPERONE-LIKE PROTEIN;; C3ORF68__:__
Asterisk__:__615167__:__LEUCINE-RICH REPEATS- AND WD REPEAT DOMAIN-CONTAINING PROTEIN 1; LRWD1__:__ORIGIN RECOGNITION COMPLEX-ASSOCIATED PROTEIN; ORCA;; ORC-ASSOCIATED PROTEIN;; CENTROMERE PROTEIN 33__:__
Asterisk__:__615168__:__ARCHAELYSIN FAMILY METALLOPEPTIDASE 1; AMZ1__:__ARCHAEMETZINCIN 1;; KIAA1950__:__
Asterisk__:__615169__:__ARCHAELYSIN FAMILY METALLOPEPTIDASE 2; AMZ2__:__ARCHAEMETZINCIN 2__:__
Percent__:__615170__:__WAHAB SYNDROME__:__CAMPTODACTYLY, CLINODACTYLY, SYNDACTYLY, AND BIFID TOE SYNDROME__:__
Asterisk__:__615171__:__LOC100134040 GENE__:__LOC100134040__:__
Asterisk__:__615172__:__RING FINGER PROTEIN, TRANSMEMBRANE 1; RNFT1__:____:__
Asterisk__:__615173__:__LONG INTERGENIC NONCODING RNA, REGULATOR OF REPROGRAMMING; LINC-ROR__:__lincRNA ROR; lincROR__:__
NULL__:__615174__:__L-THREONINE DEHYDROGENASE, PSEUDOGENE; TDH__:____:__
Asterisk__:__615175__:__FAMILY WITH SEQUENCE SIMILARITY 57, MEMBER B; FAM57B__:____:__
Asterisk__:__615176__:__NPTN INTRONIC TRANSCRIPT 1, NONCODING; NPTNIT1__:__LONG NONCODING RNA, LOW EXPRESSION IN TUMOR;; lncRNA LET__:__
Asterisk__:__615177__:__RING FINGER PROTEIN 126; RNF126__:____:__
Asterisk__:__615178__:__KXDL MOTIF-CONTAINING PROTEIN 1; KXD1__:__CHROMOSOME 19 OPEN READING FRAME 50; C19ORF50__:__
Number Sign__:__615179__:__ALBINISM, OCULOCUTANEOUS, TYPE VII; OCA7__:____:__
Asterisk__:__615180__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 21, YEAST, HOMOLOG OF; TIMM21__:__TIM21__:__
Number Sign__:__615181__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GALNT2-RELATED__:__
Number Sign__:__615182__:__COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD__:____:__
Asterisk__:__615183__:__CHROMOSOME 1 OPEN READING FRAME 86; C1ORF86__:__FANCONI ANEMIA-ASSOCIATED PROTEIN, 20-KD; FAAP20__:__
Number Sign__:__615184__:__CARDIOMYOPATHY, DILATED, 1II; CMD1II__:____:__
Number Sign__:__615185__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF__:____:__
Asterisk__:__615186__:__CWC22 SPLICEOSOME-ASSOCIATED PROTEIN, S. CEREVISIAE, HOMOLOG OF; CWC22__:__KIAA1604;; NUCAMPHOLIN, DROSOPHILA, HOMOLOG OF; NCM__:__
Asterisk__:__615187__:__POST-GPI ATTACHMENT TO PROTEINS 2; PGAP2__:__FGF RECEPTOR-ACTIVATING PROTEIN 1; FRAG1__:__
Number Sign__:__615188__:__CATARACT 39, MULTIPLE TYPES; CTRCT39__:____:__
Asterisk__:__615189__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 55; ANKRD55__:____:__
Number Sign__:__615190__:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 5; DKCB5__:____:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 4, INCLUDED; DKCA4, INCLUDED
Number Sign__:__615191__:__LISSENCEPHALY 5; LIS5__:____:__
Percent__:__615192__:__BIRTH WEIGHT QUANTITATIVE TRAIT LOCUS 4; BWQTL4__:____:__
Number Sign__:__615193__:__BLEEDING DISORDER, PLATELET-TYPE, 15; BDPLT15__:__MACROTHROMBOCYTOPENIA, AUTOSOMAL DOMINANT, ACTN1-RELATED__:__
Asterisk__:__615194__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 2; DHRS2__:__SDR FAMILY, MEMBER 2;; HEP27__:__
Asterisk__:__615195__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 4-LIKE 1; DHRS4L1__:__DHRS4-LIKE 1__:__
Asterisk__:__615196__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 4-LIKE 2; DHRS4L2__:__DHRS4-LIKE 2;; DHRS4P1__:__
Percent__:__615197__:__RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 8; RLS8__:____:__
Percent__:__615198__:__OSTEOSCLEROTIC METAPHYSEAL DYSPLASIA; OSMD__:____:__
Asterisk__:__615199__:__SOLUTE CARRIER FAMILY 35, MEMBER G5; SLC35G5__:__ACYL-MALONYL-CONDENSING ENZYME; AMAC;; ACYL-MALONYL-CONDENSING ENZYME 1-LIKE 2; AMAC1L2__:__
Asterisk__:__615200__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 1; PLEKHF1__:__LYSOSOME-ASSOCIATED APOPTOSIS-INDUCING PROTEIN CONTAINING PH AND FYVE DOMAINS; LAPF;; PH AND FYVE DOMAINS-CONTAINING PROTEIN 1; PHAFIN1;; PHAFIN 1__:__
Asterisk__:__615201__:__MICRO RNA 1909; MIR1909__:__miRNA1909__:__
Asterisk__:__615202__:__MICRO RNA 1915; MIR1915__:__miRNA1915__:__
Asterisk__:__615203__:__RHOMBOID DOMAIN-CONTAINING PROTEIN 2; RHBDD2__:____:__
Asterisk__:__615204__:__UPREGULATED DURING SKELETAL MUSCLE GROWTH 5, MOUSE, HOMOLOG OF; USMG5__:__DIABETES-ASSOCIATED PROTEIN IN INSULIN-SENSITIVE TISSUES; DAPIT__:__
Asterisk__:__615205__:__SERINE PROTEASE INHIBITOR, KAZAL-TYPE, 13; SPINK13__:____:__
Number Sign__:__615206__:__IMMUNODEFICIENCY 11; IMD11A__:__IMMUNODEFICIENCY 11; IMD11;; CARD11 IMMUNODEFICIENCY__:__
Number Sign__:__615207__:__IMMUNODEFICIENCY 56; IMD56__:__IL21R IMMUNODEFICIENCY__:__
Asterisk__:__615208__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY F, MEMBER 2; PLEKHF2__:__ENDOPLASMIC RETICULUM-ASSOCIATED APOPTOSIS-INVOLVED PROTEIN CONTAINING PH AND FYVE DOMAINS; EAPF;; PH AND FYVE DOMAINS-CONTAINING PROTEIN 2; PHAFIN2;; PHAFIN 2__:__
Asterisk__:__615209__:__MICRO RNA 149; MIR149__:__miRNA149;; MIR149-5p__:__MICRO RNA 149*, INCLUDED; MIR149*, INCLUDED;; MICRO RNA 149-3p, INCLUDED; MIR149-3p, INCLUDED
Asterisk__:__615210__:__PEST-CONTAINING NUCLEAR PROTEIN; PCNP__:____:__
Asterisk__:__615211__:__UBIQUITIN-LIKE PROTEIN CONTAINING PHD AND RING FINGER DOMAINS 2, E3 UBIQUITIN PROTEIN LIGASE; UHRF2__:__NP95/ICBP90-LIKE RING FINGER PROTEIN; NIRF__:__
Asterisk__:__615212__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 38; LRRC38__:__BK CHANNEL, AUXILIARY GAMMA SUBUNIT 4__:__
Asterisk__:__615213__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 55; LRRC55__:__BK CHANNEL, AUXILIARY GAMMA SUBUNIT 3__:__
Number Sign__:__615214__:__AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7__:__AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO PIK3R1 DEFECT__:__
Asterisk__:__615215__:__POTASSIUM CHANNEL, SUBFAMILY U, MEMBER 1; KCNU1__:__SLOWPOKE, DROSOPHILA, HOMOLOG OF, 3; SLO3__:__
Asterisk__:__615216__:__KINESIN FAMILY MEMBER C2; KIFC2__:____:__
Number Sign__:__615217__:__ATAXIA-OCULOMOTOR APRAXIA 3; AOA3__:____:__
Asterisk__:__615218__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 52; LRRC52__:__BK CHANNEL, AUXILIARY GAMMA SUBUNIT 2__:__
Number Sign__:__615219__:__HYDROCEPHALUS, CONGENITAL, 2, WITH OR WITHOUT BRAIN OR EYE ANOMALIES; HYC2__:__HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 2, FORMERLY__:__
Number Sign__:__615220__:__OSTEOGENESIS IMPERFECTA, TYPE XV; OI15__:__OI, TYPE XV__:__
Number Sign__:__615221__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 16; BMND16__:__OSTEOPOROSIS, EARLY-ONSET, SUSCEPTIBILITY TO__:__
Number Sign__:__615222__:__SMITH-MCCORT DYSPLASIA 2; SMC2__:____:__
Asterisk__:__615223__:__INTERFERON, EPSILON; IFNE__:__IFNE1;; INTERFERON, TAU-1; IFNT1__:__
Number Sign__:__615224__:__ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 2; FASPS2__:____:__
Number Sign__:__615225__:__PALMOPLANTAR CARCINOMA, MULTIPLE SELF-HEALING; MSPC__:__CORNEAL INTRAEPITHELIAL DYSKERATOSIS AND ECTODERMAL DYSPLASIA, FORMERLY; CIDED, FORMERLY__:__
Number Sign__:__615226__:__POLYDACTYLY, POSTAXIAL, TYPE A6; PAPA6__:____:__
Asterisk__:__615227__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 3; C1QL3__:__C1q/TNF-RELATED PROTEIN 13; CTRP13;; K100__:__
Number Sign__:__615228__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 4; MC5DN4__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATP5A1 TYPE__:__
Asterisk__:__615229__:__COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 4; C1QL4__:__C1q/TNF-RELATED PROTEIN 11; CTRP11__:__
Asterisk__:__615230__:__LONG INTERGENIC NONCODING RNA 1080; LINC01080__:__lncRNA TCONS_00021856;; LONG INTERGENIC NONCODING RNA TCONS_00021856;; lincRNA TCONS_00021856;; TCONS_00021856__:__
Asterisk__:__615231__:__RING FINGER AND CCCH-TYPE ZINC FINGER DOMAINS-CONTAINING PROTEIN 2; RC3H2__:__ROQUIN 2;; MEMBRANE-ASSOCIATED NUCLEIC ACID-BINDING PROTEIN; MNAB__:__
Number Sign__:__615232__:__SCHIZOPHRENIA 18; SCZD18__:__SCHIZOPHRENIA 18 WITH OR WITHOUT AN AFFECTIVE DISORDER__:__
Number Sign__:__615233__:__RETINITIS PIGMENTOSA 66; RP66__:____:__
Number Sign__:__615234__:__ANEMIA, HYPOCHROMIC MICROCYTIC, WITH IRON OVERLOAD 2; AHMIO2__:____:__
Number Sign__:__615235__:__CARDIOMYOPATHY, DILATED, 1JJ; CMD1JJ__:____:__
NULL__:__615236__:__WOODS SYNDROME__:____:__
Number Sign__:__615237__:__CONGENITAL SHORT BOWEL SYNDROME; CSBS__:____:__
Number Sign__:__615238__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 5; FPLD5__:__LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH CIDEC MUTATIONS__:__
Asterisk__:__615239__:__MICRO RNA 7-1; MIR7-1__:__miRNA7-1;; MIR7__:__
Asterisk__:__615240__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 15; KCTD15__:____:__
Asterisk__:__615241__:__TERMINAL DIFFERENTIATION-INDUCED NONCODING RNA; TINCR__:__TISSUE DIFFERENTIATION-INDUCING NONCODING RNA__:__
Asterisk__:__615242__:__SMALL INTEGRAL MEMBRANE PROTEIN 1; SMIM1__:____:__
Asterisk__:__615243__:__DEFENSIN, BETA, 114; DEFB114__:__DEFENSIN, BETA, 14; DEFB14__:__
Number Sign__:__615244__:__NEPHROTIC SYNDROME, TYPE 8; NPHS8__:____:__
Asterisk__:__615245__:__MICRO RNA 671; MIR671__:__miRNA671__:__
Asterisk__:__615246__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 2; ZBED2__:____:__
Asterisk__:__615247__:__PROTEIN-O-MANNOSE KINASE; POMK__:__PROTEIN KINASE-LIKE PROTEIN SGK196;; SUGEN KINASE 196; SGK196__:__
Number Sign__:__615248__:__CARDIOMYOPATHY, DILATED, 1KK; CMD1KK__:____:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 22, INCLUDED; CMH22, INCLUDED;; CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 4, INCLUDED; RCM4, INCLUDED
Number Sign__:__615249__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMK-RELATED__:__
Asterisk__:__615250__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 3; ZBED3__:____:__
Asterisk__:__615251__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 5; ZBED5__:__BUSTER1__:__
Asterisk__:__615252__:__ZBED6 C TERMINUS-LIKE PROTEIN; ZBED6CL__:__CHROMOSOME 7 OPEN READING FRAME 29; C7ORF29__:__
Asterisk__:__615253__:__CHROMOSOME 5 OPEN READING FRAME 54; C5ORF54__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 8; ZBED8;; BUSTER3__:__
Asterisk__:__615254__:__SCAN DOMAIN-CONTAINING PROTEIN 3; SCAND3__:__ZINC FINGER BED DOMAIN-CONTAINING PROTEIN 9; ZBED9;; BUSTER4;; KIAA1925__:__
Asterisk__:__615255__:__METHYLTRANSFERASE-LIKE 18; METTL18__:__CHROMOSOME 1 OPEN READING FRAME 156; C1ORF156__:__
Asterisk__:__615256__:__ELECTRON TRANSFER FLAVOPROTEIN BETA-SUBUNIT LYSINE METHYLTRANSFERASE; ETFBKMT__:__METHYLTRANSFERASE-LIKE 20; METTL20;; ETF-BETA LYSINE METHYLTRANSFERASE;; CHROMOSOME 12 OPEN READING FRAME 72; C12ORF72__:__
Asterisk__:__615257__:__METHYLTRANSFERASE-LIKE 21A; METTL21A__:__FAMILY WITH SEQUENCE SIMILARITY 119, MEMBER A; FAM119A__:__
Asterisk__:__615258__:__EEF1A LYSINE METHYLTRANSFERASE 3; EEF1AKMT3__:__METHYLTRANSFERASE-LIKE 21B; METTL21B;; FAMILY WITH SEQUENCE SIMILARITY 119, MEMBER B; FAM119B__:__
Asterisk__:__615259__:__METHYLTRANSFERASE-LIKE 21C; METTL21C__:__CHROMOSOME 13 OPEN READING FRAME 39; C13ORF39__:__
Asterisk__:__615260__:__VALOSIN-CONTAINING PROTEIN LYSINE METHYLTRANSFERASE; VCPKMT__:__METHYLTRANSFERASE-LIKE 21D; METTL21D;; CHROMOSOME 14 OPEN READING FRAME 138; C14ORF138__:__
Asterisk__:__615261__:__METHYLTRANSFERASE-LIKE 22; METTL22__:__CHROMOSOME 16 OPEN READING FRAME 68; C16ORF68__:__
Asterisk__:__615262__:__METHYLTRANSFERASE-LIKE 23; METTL23__:__CHROMOSOME 17 OPEN READING FRAME 95; C17ORF95__:__
Asterisk__:__615263__:__EUKARYOTIC ELONGATION FACTOR 2 LYSINE METHYLTRANSFERASE; EEF2KMT__:__EEF2 LYSINE METHYLTRANSFERASE;; FAMILY WITH SEQUENCE SIMILARITY 86, MEMBER A; FAM86A__:__
Number Sign__:__615264__:__BLOOD GROUP, VEL SYSTEM; VEL__:____:__VEL-NULL PHENOTYPE, INCLUDED
Asterisk__:__615265__:__FORMIN-BINDING PROTEIN 4; FNBP4__:__FBP30;; KIAA1014__:__
Number Sign__:__615266__:__HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA; HH17__:____:__
Number Sign__:__615267__:__HYPOGONADOTROPIC HYPOGONADISM 18 WITH OR WITHOUT ANOSMIA; HH18__:____:__
Number Sign__:__615268__:__CEREBELLAR ATAXIA, MENTAL RETARDATION, AND DYSEQUILIBRIUM SYNDROME 4; CAMRQ4__:__CEREBELLAR ATAXIA AND MENTAL RETARDATION WITH OR WITHOUT QUADRUPEDAL LOCOMOTION 4__:__
Number Sign__:__615269__:__HYPOGONADOTROPIC HYPOGONADISM 19 WITH OR WITHOUT ANOSMIA; HH19__:____:__
Number Sign__:__615270__:__HYPOGONADOTROPIC HYPOGONADISM 20 WITH OR WITHOUT ANOSMIA; HH20__:____:__
Number Sign__:__615271__:__HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA; HH21__:____:__
Number Sign__:__615272__:__FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ__:____:__
Number Sign__:__615273__:__CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iv, FORMERLY; CDG1V, FORMERLY__:__
Number Sign__:__615274__:__CATARACT 15, MULTIPLE TYPES; CTRCT15__:____:__
Asterisk__:__615275__:__ACONITATE DECARBOXYLASE 1; ACOD1__:__IMMUNORESPONSIVE GENE 1, MOUSE, HOMOLOG OF; IRG1__:__
Asterisk__:__615276__:__CERAMIDE SYNTHASE 3; CERS3__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 3; LASS3__:__
Number Sign__:__615277__:__CATARACT 19, MULTIPLE TYPES; CTRCT19__:____:__
Number Sign__:__615278__:__CARDIOFACIOCUTANEOUS SYNDROME 2; CFC2__:____:__
Number Sign__:__615279__:__CARDIOFACIOCUTANEOUS SYNDROME 3; CFC3__:____:__
Number Sign__:__615280__:__CARDIOFACIOCUTANEOUS SYNDROME 4; CFC4__:____:__
Number Sign__:__615281__:__HYPOMYELINATION WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LEG SPASTICITY; HBSL__:__ASPARTYL-tRNA SYNTHETASE DEFICIENCY__:__
Number Sign__:__615282__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 2; CDCBM2__:____:__
Asterisk__:__615283__:__EXOCYST COMPLEX COMPONENT 8; EXOC8__:__EXOCYST COMPLEX, 84-KD SUBUNIT; EXO84;; SEC84, S. CEREVISIAE, HOMOLOG OF; SEC84__:__
Number Sign__:__615284__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B3; CMT4B3__:____:__
Number Sign__:__615285__:__NEUTROPENIA, SEVERE CONGENITAL, 5, AUTOSOMAL RECESSIVE; SCN5__:____:__
Number Sign__:__615286__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 36; MRT36__:____:__
Number Sign__:__615287__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GNT1-RELATED__:__
Asterisk__:__615288__:__DYNEIN REGULATORY COMPLEX, SUBUNIT 1, CHLAMYDOMONAS, HOMOLOG OF; DRC1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 164; CCDC164;; CHROMOSOME 2 OPEN READING FRAME 39; C2ORF39__:__
Asterisk__:__615289__:__MITOTIC SPINDLE-POSITIONING PROTEIN; MISP__:__MITOTIC INTERACTOR AND SUBSTRATE OF PLK1;; CHROMOSOME 19 OPEN READING FRAME 21; C19ORF21__:__
Number Sign__:__615290__:__SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2, AUTOSOMAL DOMINANT; SMALED2__:____:__
Asterisk__:__615291__:__BETA-1,3-GALACTOSYLTRANSFERASE 6; B3GALT6__:__UDP-GAL:BETA-GAL BETA-1,3-GALACTOSYLTRANSFERASE, POLYPEPTIDE 6;; GALACTOSYLTRANSFERASE II; GALTII;; BETA-3-GALT6__:__
Asterisk__:__615292__:__FAMILY WITH SEQUENCE SIMILARITY 111, MEMBER A; FAM111A__:__KIAA1895__:__
Number Sign__:__615293__:__MYOFIBROMATOSIS, INFANTILE, 2; IMF2__:____:__
Number Sign__:__615294__:__CILIARY DYSKINESIA, PRIMARY, 21; CILD21__:__CILIARY DYSKINESIA, PRIMARY, 21, WITHOUT SITUS INVERSUS__:__
Asterisk__:__615295__:__UBIQUITIN-SPECIFIC PROTEASE 34; USP34__:__KIAA0570__:__
Asterisk__:__615296__:__INTERLEUKIN 1 FAMILY, MEMBER 10; IL1F10__:__INTERLEUKIN 38; IL38;; INTERLEUKIN 1 RECEPTOR ANTAGONIST HOMOLOG 2; IL1HY2;; FAMILY OF INTERLEUKIN 1-THETA;; FIL1-THETA__:__
Number Sign__:__615297__:__ADAMS-OLIVER SYNDROME 4; AOS4__:____:__
Number Sign__:__615298__:__SYMPHALANGISM, PROXIMAL, 1B; SYM1B__:____:__
Asterisk__:__615299__:__NUCLEOREDOXIN-LIKE PROTEIN 2; NXNL2__:__ROD-DERIVED CONE VIABILITY FACTOR 2; RDCVF2__:__
Number Sign__:__615300__:__PERRAULT SYNDROME 4; PRLTS4__:____:__
Asterisk__:__615301__:__TRANSMEMBRANE PROTEIN 214; TMEM214__:____:__
Asterisk__:__615302__:__ADENOSINE DEAMINASE, tRNA-SPECIFIC, 3; ADAT3__:__TAD3, S. CEREVISIAE, HOMOLOG OF; TAD3__:__
Asterisk__:__615303__:__TRANSFER RNA GLYCINE 3; TRNAG3__:____:__
Asterisk__:__615304__:__TRANSFER RNA VALINE 32; TRNAV32__:____:__
Asterisk__:__615305__:__TRANSFER RNA ARGININE 2; TRNAR2__:____:__
Asterisk__:__615306__:__TRANSFER RNA VALINE 21; TRNAV21__:____:__
Asterisk__:__615307__:__TRANSFER RNA VALINE 12; TRNAV12__:____:__
Asterisk__:__615308__:__TRANSFER RNA VALINE 17; TRNAV17__:____:__
Asterisk__:__615309__:__TRANSFER RNA THREONINE 15; TRNAT15__:____:__
Asterisk__:__615310__:__TRANSFER RNA VALINE (AAC) 1-1; TRV-AAC1-1__:__TRANSFER RNA VALINE 24; TRNAV24__:__
Number Sign__:__615311__:__BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 17; BMND17__:__BONE MINERAL DENSITY, LOW, SUSCEPTIBILITY TO__:__
Percent__:__615312__:__ALBINISM, OCULOCUTANEOUS, TYPE V; OCA5__:____:__
Asterisk__:__615313__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 7; B3GNT7__:____:__
Number Sign__:__615314__:__CRANIOSYNOSTOSIS 3; CRS3__:____:__
Asterisk__:__615315__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 6; B3GNT6__:____:__
Asterisk__:__615316__:__IBA57, S. CEREVISIAE, HOMOLOG OF; IBA57__:__CHROMOSOME 1 OPEN READING FRAME 69; C1ORF69__:__
Asterisk__:__615317__:__IRON-SULFUR CLUSTER ASSEMBLY 2, S. CEREVISIAE, HOMOLOG OF; ISCA2__:____:__
Asterisk__:__615318__:__TRANSMEMBRANE PROTEIN 14C; TMEM14C__:____:__
Asterisk__:__615319__:__IMPACT RWD DOMAIN PROTEIN; IMPACT__:__IMPRINTED AND ANCIENT GENE, MOUSE, HOMOLOG OF;; RWD DOMAIN-CONTAINING PROTEIN 5; RWDD5__:__
Asterisk__:__615320__:__GDP-MANNOSE PYROPHOSPHORYLASE B; GMPPB__:__GDP-MANNOSE PYROPHOSPHORYLASE, BETA SUBUNIT;; GMPP-BETA__:__
Asterisk__:__615321__:__CHLORIDE INTRACELLULAR CHANNEL 6; CLIC6__:__CLIC1-LIKE; CLIC1L;; PARCHORIN, RABBIT, HOMOLOG OF__:__
Asterisk__:__615322__:__NEGATIVE REGULATOR OF REACTIVE OXYGEN SPECIES; NRROS__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 33; LRRC33__:__
Asterisk__:__615323__:__JOSEPHIN DOMAIN-CONTAINING PROTEIN 1; JOSD1__:__KIAA0063__:__
Asterisk__:__615324__:__JOSEPHIN DOMAIN-CONTAINING PROTEIN 2; JOSD2__:____:__
Caret__:__615325__:__MOVED TO 601419__:____:__
Asterisk__:__615326__:__INTERFERON, KAPPA; IFNK__:____:__
Number Sign__:__615327__:__DOWLING-DEGOS DISEASE 2; DDD2__:____:__
Number Sign__:__615328__:__SHAHEEN SYNDROME; SHNS__:____:__
Asterisk__:__615329__:__EXOCYST COMPLEX COMPONENT 2; EXOC2__:__SEC5-LIKE 1; SEC5L1;; SEC5__:__
Number Sign__:__615330__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 3; MMDS3__:____:__
Asterisk__:__615331__:__INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 1; IRF2BP1__:__IRF2-BINDING PROTEIN 1__:__
Asterisk__:__615332__:__INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 2; IRF2BP2__:__IRF2-BINDING PROTEIN 2__:__
Asterisk__:__615333__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 5; B3GNT5__:__LACTOTRIAOSYLCERAMIDE SYNTHASE;; LC3 SYNTHASE__:__
Asterisk__:__615334__:__CERAMIDE SYNTHASE 4; CERS4__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 4; LASS4;; TRAM HOMOLOG 1; TRH1__:__
Asterisk__:__615335__:__CERAMIDE SYNTHASE 5; CERS5__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 5; LASS5;; TRAM HOMOLOG 4; TRH4__:__
Asterisk__:__615336__:__CERAMIDE SYNTHASE 6; CERS6__:__LAG1, S. CEREVISIAE, HOMOLOG OF, 6; LASS6__:__
Asterisk__:__615337__:__BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE-LIKE 1; B3GNTL1__:____:__
Number Sign__:__615338__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 16; EIEE16__:____:__
Asterisk__:__615339__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 15; DNAJC15__:__METHYLATION-CONTROLLED J PROTEIN; MCJ__:__
Asterisk__:__615340__:__KELCH-LIKE 40: KLHL40__:__SARCOSYNAPSIN; SYRP;; KELCH REPEAT- AND BTB/POZ DOMAIN-CONTAINING PROTEIN 5; KBTBD5__:__
Asterisk__:__615341__:__CYTOCHROME P450, FAMILY 4, SUBFAMILY A, POLYPEPTIDE 22; CYP4A22__:____:__
Number Sign__:__615342__:__PULMONARY HYPERTENSION, PRIMARY, 2; PPH2__:____:__
Number Sign__:__615343__:__PULMONARY HYPERTENSION, PRIMARY, 3; PPH3__:____:__
Number Sign__:__615344__:__PULMONARY HYPERTENSION, PRIMARY, 4; PPH4__:____:__
Asterisk__:__615345__:__MYOMAKER; MYMK__:__TRANSMEMBRANE PROTEIN 8C; TMEM8C__:__
Number Sign__:__615346__:__PRECOCIOUS PUBERTY, CENTRAL, 2; CPPB2__:____:__
Asterisk__:__615347__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 2B; ATAD2B__:__KIAA1240__:__
Number Sign__:__615348__:__NEMALINE MYOPATHY 8; NEM8__:____:__
Number Sign__:__615349__:__EHLERS-DANLOS SYNDROME, SPONDYLODYSPLASTIC TYPE, 2; EDSSPD2__:__EHLERS-DANLOS SYNDROME, PROGEROID TYPE, 2, FORMERLY; EDSP2, FORMERLY__:__
Number Sign__:__615350__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 14; MDDGA14__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GMPPB-RELATED__:__
Number Sign__:__615351__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 14; MDDGB14__:__MUSCULAR DYSTROPHY, CONGENITAL, GMPPB-RELATED__:__
Number Sign__:__615352__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 14; MDDGC14__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 19; LGMDR19;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2T; LGMD2T;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, GMPPB-RELATED__:__
Asterisk__:__615353__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 28A; CCDC28A__:__CHROMOSOME 6 OPEN READING FRAME 80; C6ORF80__:__CCDC28A/NUP98 FUSION GENE, INCLUDED
Asterisk__:__615354__:__LIGAND-DEPENDENT NUCLEAR RECEPTOR-INTERACTING FACTOR 1; LRIF1__:__RECEPTOR-INTERACTING FACTOR 1; RIF1__:__
Number Sign__:__615355__:__NOONAN SYNDROME 8; NS8__:____:__
Number Sign__:__615356__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18; LGMDR18__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2S; LGMD2S__:__
Asterisk__:__615357__:__BETA-1,3-GALACTOSYLTRANSFERASE 8; B3GNT8__:__BGALT15;; BETA-1,3-GALACTOSYLTRANSFERASE 7, FORMERLY; B3GALT7, FORMERLY__:__
Asterisk__:__615358__:__ADENYLATE KINASE 9; AK9__:____:__
Asterisk__:__615359__:__MISSING OOCYTE/MEIOSIS REGULATOR, DROSOPHILA, HOMOLOG OF; MIOS__:____:__
Number Sign__:__615360__:__LEBER CONGENITAL AMAUROSIS 17; LCA17__:____:__
Number Sign__:__615361__:__HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2__:____:__
Number Sign__:__615362__:__CEROID LIPOFUSCINOSIS, NEURONAL, 13; CLN13__:__CEROID LIPOFUSCINOSIS, NEURONAL, 13, KUFS TYPE__:__
Number Sign__:__615363__:__ESTROGEN RESISTANCE; ESTRR__:__ESTROGEN INSENSITIVITY__:__
Asterisk__:__615364__:__ADENYLATE KINASE 7; AK7__:____:__
Asterisk__:__615365__:__ADENYLATE KINASE 8; AK8__:____:__
Asterisk__:__615366__:__NUCLEOLAR PROTEIN 11; NOL11__:____:__
Asterisk__:__615367__:__N-TERMINAL ASPARAGINE AMIDASE; NTAN1__:__N-TERMINAL ASPARAGINE AMIDOHYDROLASE__:__
Number Sign__:__615368__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 5; LCCS5__:__MYOPATHY, CENTRONUCLEAR, LETHAL, AUTOSOMAL RECESSIVE__:__
Number Sign__:__615369__:__EPILEPTIC ENCEPHALOPATHY, CHILDHOOD-ONSET; EEOC__:____:__
Asterisk__:__615370__:__ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS-CONTAINING PROTEIN 6; ANKS6__:__PKDR1;; SAMCYSTIN__:__
Number Sign__:__615371__:__PULMONARY HYPERTENSION, NEONATAL, SUSCEPTIBILITY TO; PHN__:____:__
Asterisk__:__615372__:__MICRO RNA 1260B; MIR1260B__:__miRNA1260B;; MIRN1260B__:__
Number Sign__:__615373__:__LEFT VENTRICULAR NONCOMPACTION 8; LVNC8__:____:__CARDIOMYOPATHY, DILATED, 1LL, INCLUDED; CMD1LL, INCLUDED
Number Sign__:__615374__:__CONE-ROD DYSTROPHY 18; CORD18__:____:__
Asterisk__:__615375__:__INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 1-BINDING PROTEIN 1; IRAK1BP1__:__IRAK1-BINDING PROTEIN 1;; SIGNALING MOLECULE THAT ASSOCIATES WITH PELLE-LIKE KINASE; SIMPL__:__
Number Sign__:__615376__:__CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC__:__CHARCOT-MARIE-TOOTH NEUROPATHY, RECESSIVE INTERMEDIATE C; RI-CMTC__:__
Number Sign__:__615377__:__ATRIAL FIBRILLATION, FAMILIAL, 13; ATFB13__:____:__
Number Sign__:__615378__:__ATRIAL FIBRILLATION, FAMILIAL, 14; ATFB14__:____:__
Asterisk__:__615379__:__MICRO RNA 650; MIR650__:__miRNA650__:__
Asterisk__:__615380__:__APOPTOSIS-RESISTANT E3 UBIQUITIN PROTEIN LIGASE 1; AREL1__:__KIAA0317__:__
Number Sign__:__615381__:__MANDIBULAR HYPOPLASIA, DEAFNESS, PROGEROID FEATURES, AND LIPODYSTROPHY SYNDROME; MDPL__:____:__
Number Sign__:__615382__:__NEPHRONOPHTHISIS 16; NPHP16__:____:__
Asterisk__:__615383__:__FIDGETIN-LIKE PROTEIN 1; FIGNL1__:____:__
Asterisk__:__615384__:__SCAFFOLDING PROTEIN INVOLVED IN DNA REPAIR; SPIDR__:__KIAA0146__:__
Asterisk__:__615385__:__MICRO RNA 485; MIR485__:__miRNA485__:__
Number Sign__:__615386__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 14; SCAR14__:__CEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, SPECTRIN-ASSOCIATED, 1; SPARCA1__:__
Number Sign__:__615387__:__T-CELL RECEPTOR-ALPHA/BETA DEFICIENCY__:__TCR-ALPHA/BETA DEFICIENCY;; IMMUNODEFICIENCY 7; IMD7__:__
Asterisk__:__615388__:__ADENOSINE DEAMINASE, tRNA-SPECIFIC, 2; ADAT2__:__TAD2, S. CEREVISIAE, HOMOLOG OF; TAD2__:__
Asterisk__:__615389__:__ISOPENTENYL-DIPHOSPHATE DELTA ISOMERASE 2; IDI2__:__IPPI2__:__
Percent__:__615390__:__VESICOURETERAL REFLUX 7; VUR7__:____:__
Asterisk__:__615391__:__IDI2 ANTISENSE RNA 1, NONCODING; IDI2AS1__:____:__
Asterisk__:__615392__:__SCM-LIKE PROTEIN WITH 4 MBT DOMAINS 2; SFMBT2__:__KIAA1617__:__
Asterisk__:__615393__:__MITOCHONDRIAL TRANSCRIPTION TERMINATION FACTOR 4; MTERF4__:__MTERF DOMAIN-CONTAINING PROTEIN 2; MTERFD2__:__
Asterisk__:__615394__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 4; NSUN4__:__NOP2/SUN DOMAIN FAMILY, MEMBER 4__:__
Number Sign__:__615395__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16__:____:__
Number Sign__:__615396__:__LEFT VENTRICULAR NONCOMPACTION 10; LVNC10__:____:__CARDIOMYOPATHY, DILATED, 1MM, INCLUDED; CMD1MM, INCLUDED
Number Sign__:__615397__:__MECKEL SYNDROME, TYPE 11; MKS11__:____:__
Number Sign__:__615398__:__MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7__:__
Number Sign__:__615399__:__PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2; PNH2__:____:__
Number Sign__:__615400__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 5; FAME5__:__CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 5; FCMTE5__:__
Number Sign__:__615401__:__IMMUNODEFICIENCY 8; IMD8__:____:__
Number Sign__:__615402__:__DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 3; DUH3__:____:__
Asterisk__:__615403__:__THO COMPLEX, SUBUNIT 6; THOC6__:__FUNCTIONAL SPLICEOSOME-ASSOCIATED PROTEIN, 35-KD; FSAP35__:__
Asterisk__:__615404__:__TRANSMEMBRANE 4 L6 FAMILY, MEMBER 20; TM4SF20__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 20__:__
Asterisk__:__615405__:__GUANINE NUCLEOTIDE-BINDING PROTEIN, GAMMA-12; GNG12__:____:__
Asterisk__:__615406__:__GNG12 ANTISENSE RNA 1, NONCODING; GNG12AS1__:__LONG NONCODING RNA GNG12AS1;; lncRNA GNG12AS1__:__
Asterisk__:__615407__:__ADP RIBOSYLATION FACTOR-LIKE 2-BINDING PROTEIN; ARL2BP__:__ARL2-BINDING PROTEIN;; BINDER OF ARL2; BART__:__
Asterisk__:__615408__:__ARMADILLO REPEAT-CONTAINING PROTEIN 4; ARMC4__:____:__
Asterisk__:__615409__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 33; SPATA33__:__CHROMOSOME 16 OPEN READING FRAME 55; C16ORF55__:__
Asterisk__:__615410__:__MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN 2; MRAP2__:__MC2R ACCESSORY PROTEIN 2;; CHROMOSOME 6 OPEN READING FRAME 117; C6ORF117__:__
Number Sign__:__615411__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 3; CDCBM3__:____:__
Number Sign__:__615412__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 4; CDCBM4__:____:__
Number Sign__:__615413__:__SPERMATOGENIC FAILURE 12; SPGF12__:____:__
Number Sign__:__615414__:__MICROCEPHALY 11, PRIMARY, AUTOSOMAL RECESSIVE; MCPH11__:____:__
Number Sign__:__615415__:__RENAL-HEPATIC-PANCREATIC DYSPLASIA 2; RHPD2__:____:__
Asterisk__:__615416__:__BASIC HELIX-LOOP-HELIX FAMILY, MEMBER A9; BHLHA9__:__BASIC HELIX-LOOP-HELIX FACTOR, CLASS F, 42; BHLHF42;; FINGERIN__:__
Asterisk__:__615417__:__BET1-LIKE PROTEIN; BET1L__:__GOLGI SNARE, 15-KD; GS15__:__
Number Sign__:__615418__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 12B (CARDIOMYOPATHIC TYPE), AUTOSOMAL RECESSIVE; MTDPS12B__:____:__
Number Sign__:__615419__:__HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 1; IHPRF1__:__IHPRF__:__
Number Sign__:__615420__:__MYOPIA 22, AUTOSOMAL DOMINANT; MYP22__:____:__
Asterisk__:__615421__:__COILED-COIL DOMAIN CONTAINING 111; CCDC111__:____:__
Number Sign__:__615422__:__INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 2; IBMPFD2__:__MULTISYSTEM PROTEINOPATHY 2; MSP2__:__
Asterisk__:__615423__:__tRNA METHYLTRANSFERASE 10, S. CEREVISIAE, HOMOLOG OF, C; TRMT10C__:__RNA (GUANINE-9-)METHYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 1; RG9MTD1;; MITOCHONDRIAL RIBONUCLEASE P PROTEIN 1; MRPP1__:__
Number Sign__:__615424__:__INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA 3; IBMPFD3__:__MULTISYSTEM PROTEINOPATHY 3; MSP3__:__
Number Sign__:__615425__:__EPIDERMOLYSIS BULLOSA SIMPLEX, AUTOSOMAL RECESSIVE 2; EBSB2__:____:__
Number Sign__:__615426__:__AMYOTROPHIC LATERAL SCLEROSIS 20; ALS20__:____:__
Asterisk__:__615427__:__ELMO/CED12 DOMAIN-CONTAINING PROTEIN 3; ELMOD3__:__RNA-BINDING MOTIF- AND ELMO DOMAIN-CONTAINING PROTEIN 1; RBED1__:__
Asterisk__:__615428__:__DEAD BOX POLYPEPTIDE 47; DDX47__:____:__
Number Sign__:__615429__:__DEAFNESS, AUTOSOMAL RECESSIVE 88; DFNB88__:____:__
Asterisk__:__615430__:__TRANSMEMBRANE PROTEIN 241; TMEM241__:__CHROMOSOME 18 OPEN READING FRAME 45; C18ORF45__:__
Number Sign__:__615431__:__MYOPIA 23, AUTOSOMAL RECESSIVE; MYP23__:____:__
Number Sign__:__615432__:__SPECIFIC LANGUAGE IMPAIRMENT 5; SLI5__:____:__
Number Sign__:__615433__:__CHROMOSOME 3q13.31 DELETION SYNDROME__:____:__
Number Sign__:__615434__:__RETINITIS PIGMENTOSA 82 WITH OR WITHOUT SITUS INVERSUS; RP82__:____:__
Asterisk__:__615435__:__ENDOPLASMIC RETICULUM OXIDOREDUCTIN 1-LIKE; ERO1L__:__ERO1-LIKE, ALPHA; ERO1LA;; ERO1, S. CEREVISIAE, HOMOLOG OF, ALPHA;; ERO1-ALPHA__:__
Number Sign__:__615436__:__AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8__:____:__
Asterisk__:__615437__:__ENDOPLASMIC RETICULUM OXIDOREDUCTIN 1-LIKE, BETA; ERO1LB__:__ERO1-LIKE, BETA;; ERO1, S. CEREVISIAE, HOMOLOG OF, BETA;; ERO1-BETA__:__
Number Sign__:__615438__:__INFANTILE LIVER FAILURE SYNDROME 1; ILFS1__:____:__
Number Sign__:__615439__:__MACULAR DEGENERATION, AGE-RELATED, 13; ARMD13__:____:__
Number Sign__:__615440__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17__:____:__
Number Sign__:__615441__:__VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 5, WITH OR WITHOUT MUSCLE WEAKNESS; CPVT5__:____:__
Asterisk__:__615442__:__T-CELL RECEPTOR ALPHA CHAIN VARIABLE GENE CLUSTER; TRAV@__:____:__
Asterisk__:__615443__:__T-CELL RECEPTOR ALPHA CHAIN JOINING GENE CLUSTER; TRAJ@__:____:__
Number Sign__:__615444__:__CILIARY DYSKINESIA, PRIMARY, 22; CILD22__:__CILIARY DYSKINESIA, PRIMARY, 22, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__615445__:__T-CELL RECEPTOR BETA CHAIN CONSTANT REGION 2; TRBC2__:____:__
Asterisk__:__615446__:__T-CELL RECEPTOR BETA CHAIN VARIABLE GENE CLUSTER; TRBV@__:____:__
Asterisk__:__615447__:__T-CELL RECEPTOR BETA CHAIN DIVERSITY GENE 1; TRBD1__:____:__
Asterisk__:__615448__:__T-CELL RECEPTOR BETA CHAIN DIVERSITY GENE 2; TRBD2__:____:__
Asterisk__:__615449__:__T-CELL RECEPTOR BETA CHAIN JOINING GENE CLUSTER; TRBJ@__:____:__
Asterisk__:__615450__:__T-CELL RECEPTOR GAMMA CHAIN CONSTANT REGION 2; TRGC2__:____:__
Number Sign__:__615451__:__CILIARY DYSKINESIA, PRIMARY, 23; CILD23__:__CILIARY DYSKINESIA, PRIMARY, 23, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__615452__:__PROSTATE CANCER-ASSOCIATED NONCODING RNA 1; PRNCR1__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 8; PCAT8;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 4; CARLO3;; lncRNA CARLO3__:__
Number Sign__:__615453__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 6; MC3DN6__:____:__
Asterisk__:__615454__:__T-CELL RECEPTOR GAMMA CHAIN VARIABLE GENE CLUSTER; TRGV@__:____:__
Asterisk__:__615455__:__T-CELL RECEPTOR GAMMA CHAIN JOINING GENE CLUSTER; TRGJ@__:____:__
Asterisk__:__615456__:__ELMO/CED12 DOMAIN-CONTAINING PROTEIN 1; ELMOD1__:____:__
Number Sign__:__615457__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 18; BMIQ18__:__OBESITY, SUSCEPTIBILITY TO__:__
Number Sign__:__615458__:__MICROCORNEA, MYOPIC CHORIORETINAL ATROPHY, AND TELECANTHUS; MMCAT__:____:__
Asterisk__:__615459__:__T-CELL RECEPTOR DELTA CHAIN VARIABLE GENE CLUSTER; TRDV@__:____:__
Asterisk__:__615460__:__T-CELL RECEPTOR DELTA CHAIN DIVERSITY GENE CLUSTER; TRDD@__:____:__
Asterisk__:__615461__:__T-CELL RECEPTOR DELTA CHAIN JOINING GENE CLUSTER; TRDJ@__:____:__
Asterisk__:__615462__:__WD REPEAT-CONTAINING PROTEIN 60; WDR60__:____:__
Asterisk__:__615463__:__SEIZURE THRESHOLD 2, MOUSE, HOMOLOG OF; SZT2__:__KIAA0467__:__
Asterisk__:__615464__:__DEAD BOX POLYPEPTIDE 59; DDX59__:____:__
Number Sign__:__615465__:__HARTSFIELD SYNDROME; HRTFDS__:__HOLOPROSENCEPHALY, ECTRODACTYLY, AND BILATERAL CLEFT LIP/PALATE__:__
Asterisk__:__615466__:__MESODERM DEVELOPMENT CANDIDATE 1; MESDC1__:____:__
Asterisk__:__615467__:__GLYCOLIPID TRANSFER PROTEIN DOMAIN-CONTAINING PROTEIN 1; GLTPD1__:__GLTP DOMAIN-CONTAINING PROTEIN 1;; CERAMIDE-1-PHOSPHATE TRANSFER PROTEIN; CPTP__:__
Number Sign__:__615468__:__IMMUNODEFICIENCY 12; IMD12__:____:__
Asterisk__:__615469__:__MICRO RNA 574; MIR574__:__miRNA574;; MIR574-5p__:__MICRO RNA 574-3p, INCLUDED; MIR574-3p, INCLUDED
Asterisk__:__615470__:__CENTROSOMAL PROTEIN, 89-KD; CEP89__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 123; CCDC123;; CENTROSOMAL PROTEIN 123; CEP123;; FLJ14640__:__
Number Sign__:__615471__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 13 (ENCEPHALOMYOPATHIC TYPE); MTDPS13__:____:__
Asterisk__:__615472__:__COATOMER PROTEIN COMPLEX, SUBUNIT ZETA-1; COPZ1__:__COPZ__:__
Number Sign__:__615473__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 17; EIEE17__:____:__
Number Sign__:__615474__:__PRIMARY ALDOSTERONISM, SEIZURES, AND NEUROLOGIC ABNORMALITIES; PASNA__:____:__
Asterisk__:__615475__:__DEAH BOX POLYPEPTIDE 34; DHX34__:__KIAA0134__:__
Number Sign__:__615476__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 18; EIEE18__:____:__
Asterisk__:__615477__:__NEURONAL TYROSINE-PHOSPHORYLATED PHOSPHOINOSITIDE 3-KINASE ADAPTOR 1; NYAP1__:____:__
Asterisk__:__615478__:__NEURONAL TYROSINE-PHOSPHORYLATED PHOSPHOINOSITIDE 3-KINASE ADAPTOR 2; NYAP2__:__KIAA1486__:__
Asterisk__:__615479__:__MYOSIN XVI; MYO16__:__NEURONAL TYROSINE-PHOSPHORYLATED PHOSPHOINOSITIDE 3-KINASE ADAPTOR 3; NYAP3;; KIAA0865;; MYR8__:__
Asterisk__:__615480__:__BLADDER CANCER-ASSOCIATED TRANSCRIPT 1, NONCODING; BLACAT1__:__LONG INTERGENIC NONCODING RNA 912; LINCOO912;; UPREGULATED IN BLADDER CANCER 1, LONG INTERGENIC NONCODING RNA;; lincUBC1;; lincRNA UBC1__:__
Number Sign__:__615481__:__CILIARY DYSKINESIA, PRIMARY, 24; CILD24__:__CILIARY DYSKINESIA, PRIMARY, 24, WITHOUT SITUS INVERSUS__:__
Number Sign__:__615482__:__CILIARY DYSKINESIA, PRIMARY, 25; CILD25__:__CILIARY DYSKINESIA, PRIMARY, 25, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__615483__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 5; IBGC5__:____:__
Asterisk__:__615484__:__PENTATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 2; PTCD2__:____:__
Number Sign__:__615485__:__BAINBRIDGE-ROPERS SYNDROME; BRPS__:____:__
Number Sign__:__615486__:__INTERSTITIAL LUNG AND LIVER DISEASE; ILLD__:__PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND;; INFANTILE LIVER FAILURE SYNDROME 2, FORMERLY; ILFS2, FORMERLY__:__
Asterisk__:__615487__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 2C; SNORA2C__:__SMALL NUCLEOLAR RNA, H/ACA BOX, 34; SNORA34;; ACA34__:__MICRO RNA 1291, INCLUDED; MIR1291, INCLUDED;; miRNA1291, INCLUDED
Asterisk__:__615488__:__KAT8 REGULATORY NSL COMPLEX, SUBUNIT 2; KANSL2__:__NONSPECIFIC LETHAL 2, DROSOPHILA, HOMOLOG OF; NSL2;; CHROMOSOME 12 OPEN READING FRAME 41; C12ORF41__:__
Number Sign__:__615489__:__MACULAR DEGENERATION, AGE-RELATED, 14; ARMD14__:____:__MACULAR DEGENERATION, AGE-RELATED, REDUCED RISK OF, INCLUDED
Number Sign__:__615490__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2R;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2R__:__
Number Sign__:__615491__:__SPASTIC PARAPLEGIA 79, AUTOSOMAL RECESSIVE; SPG79__:__NEURODEGENERATION WITH OPTIC ATROPHY, CHILDHOOD-ONSET; NDGOA__:__
Asterisk__:__615492__:__LONG INTERGENIC NONCODING RNA COX2__:__lincRNA COX2;; LONG NONCODING RNA COX2;; lncRNA COX2__:__
Number Sign__:__615493__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 37; MRT37__:____:__
Asterisk__:__615494__:__CHROMOSOME 21 OPEN READING FRAME 59; C21ORF59__:____:__
Asterisk__:__615495__:__GDP-MANNOSE PYROPHOSPHORYLASE A; GMPPA__:__GDP-MANNOSE PYROPHOSPHORYLASE, ALPHA SUBUNIT;; GMPP-ALPHA__:__
Asterisk__:__615496__:__ATP/GTP-BINDING PROTEIN-LIKE 1; AGBL1__:__CYTOSOLIC CARBOXYPEPTIDASE 4; CCP4__:__
Asterisk__:__615497__:__MITOCHONDRIAL ELONGATION FACTOR 1; MIEF1__:__SMCR7-LIKE PROTEIN; SMCR7L;; MITOCHONDRIAL DYNAMICS PROTEIN, 51-KD; MID51__:__
Asterisk__:__615498__:__MITOCHONDRIAL ELONGATION FACTOR 2; MIEF2__:__SMITH-MAGENIS SYNDROME CHROMOSOME REGION, CANDIDATE GENE 7; SMCR7;; MITOCHONDRIAL DYNAMICS PROTEIN, 49-KD; MID49__:__
Asterisk__:__615499__:__PYRUVATE DEHYDROGENASE PHOSPHATASE CATALYTIC SUBUNIT 2; PDP2__:__KIAA1348__:__
Number Sign__:__615500__:__CILIARY DYSKINESIA, PRIMARY, 26; CILD26__:__CILIARY DYSKINESIA, PRIMARY, 26, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__615501__:__MOLYBDENUM COFACTOR DEFICIENCY, COMPLEMENTATION GROUP C; MOCODC__:____:__
Number Sign__:__615502__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 21; MRD21__:____:__
Number Sign__:__615503__:__SHORT-RIB THORACIC DYSPLASIA 8 WITH OR WITHOUT POLYDACTYLY; SRTD8__:__SHORT RIB-POLYDACTYLY SYNDROME, TYPE VI; SRPS6__:__
Number Sign__:__615504__:__CILIARY DYSKINESIA, PRIMARY, 27; CILD27__:__CILIARY DYSKINESIA, PRIMARY, 27, WITHOUT SITUS INVERSUS__:__
Number Sign__:__615505__:__CILIARY DYSKINESIA, PRIMARY, 28; CILD28__:__CILIARY DYSKINESIA, PRIMARY, 28, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__615506__:__TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5__:____:__
Asterisk__:__615507__:__NISCHARIN; NISCH__:__IMIDAZOLINE RECEPTOR ANTISERA-SELECTED; IRAS;; KIAA0975__:__
Number Sign__:__615508__:__ERYTHRODERMA, CONGENITAL, WITH PALMOPLANTAR KERATODERMA, HYPOTRICHOSIS, AND HYPER-IgE; EPKHE__:__SEVERE DERMATITIS, MULTIPLE ALLERGIES, AND METABOLIC WASTING SYNDROME;; SAM SYNDROME__:__
Asterisk__:__615509__:__MICRO RNA 675; MIR675__:__miRNA675__:__
Number Sign__:__615510__:__ALACRIMA, ACHALASIA, AND MENTAL RETARDATION SYNDROME; AAMR__:____:__
Number Sign__:__615511__:__MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD__:__ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO__:__
Number Sign__:__615512__:__TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; TPID__:____:__
Number Sign__:__615513__:__IMMUNODEFICIENCY 14; IMD14__:__ACTIVATED PI3K-DELTA SYNDROME; APDS;; p110-DELTA-ACTIVATING MUTATION CAUSING SENESCENT T CELLS, LYMPHADENOPATHY, AND IMMUNODEFICIENCY; PASLI__:__
Asterisk__:__615514__:__CYCLIN-DEPENDENT KINASE 12; CDK12__:__CDC2-RELATED KINASE WITH AN ARGININE/SERINE-RICH DOMAIN; CRKRS;; CDC2-RELATED PROTEIN KINASE 7; CRK7;; KIAA0904__:__
Number Sign__:__615515__:__AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19__:____:__
Number Sign__:__615516__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 38; MRT38__:____:__
Number Sign__:__615517__:__HEMOCHROMATOSIS, TYPE 5; HFE5__:__IRON OVERLOAD, AUTOSOMAL DOMINANT__:__
Number Sign__:__615518__:__IMMUNODEFICIENCY 13; IMD13__:__IDIOPATHIC CD4 LYMPHOPENIA; ICL__:__
Asterisk__:__615519__:__TOM1-LIKE 2; TOM1L2__:____:__
Asterisk__:__615520__:__MICRO RNA 297; MIR297__:__miRNA297__:__
Asterisk__:__615521__:__SH3 AND CYSTEINE-RICH DOMAINS 3; STAC3__:____:__
Number Sign__:__615522__:__COLE DISEASE; COLED__:__GUTTATE HYPOPIGMENTATION AND PUNCTATE PALMOPLANTAR KERATODERMA WITH OR WITHOUT ECTOPIC CALCIFICATION__:__
Number Sign__:__615523__:__CORNEAL DYSTROPHY, FUCHS ENDOTHELIAL, 8; FECD8__:____:__
Number Sign__:__615524__:__MICROPHTHALMIA, SYNDROMIC 12; MCOPS12__:__MICROPHTHALMIA WITH OR WITHOUT PULMONARY HYPOPLASIA, DIAPHRAGMATIC HERNIA, AND/OR CARDIAC DEFECTS__:__
Asterisk__:__615525__:__COATOMER PROTEIN COMPLEX, SUBUNIT GAMMA-1; COPG1__:__COP, GAMMA-1__:__
Asterisk__:__615526__:__COATOMER PROTEIN COMPLEX, SUBUNIT ZETA-2; COPZ2__:__COP, ZETA-2__:__
Number Sign__:__615527__:__CANDIDIASIS, FAMILIAL, 8; CANDF8__:__CANDIDIASIS, FAMILIAL CHRONIC MUCOCUTANEOUS, AUTOSOMAL RECESSIVE__:__
Number Sign__:__615528__:__PARKINSON DISEASE 19A, JUVENILE-ONSET; PARK19A__:__PARK19, FORMERLY__:__PARKINSON DISEASE 19B, EARLY-ONSET, INCLUDED; PARK19B, INCLUDED
Number Sign__:__615529__:__CRANIOSYNOSTOSIS 5, SUSCEPTIBILITY TO; CRS5__:____:__
Number Sign__:__615530__:__PARKINSON DISEASE 20, EARLY-ONSET; PARK20__:____:__
Asterisk__:__615531__:__TRANSMEMBRANE PROTEIN 79; TMEM79__:__MATTRIN, MOUSE, HOMOLOG OF; MATT__:__
Asterisk__:__615532__:__ENDOPLASMIC RETICULUM MEMBRANE-ASSOCIATED RNA DEGRADATION PROTEIN; ERMARD__:__CHROMOSOME 6 OPEN READING FRAME 70; C6ORF70__:__
Asterisk__:__615533__:__TRANSMEMBRANE PROTEIN 126B; TMEM126B__:____:__
Asterisk__:__615534__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE DOMAIN-CONTAINING PROTEIN 1; TIMMDC1__:__TIMM DOMAIN CONTAINING-PROTEIN 1;; CHROMOSOME 3 OPEN READING FRAME 1; C3ORF1__:__
Asterisk__:__615535__:__SPECTRIN REPEAT-CONTAINING NUCLEAR ENVELOPE PROTEIN 4; SYNE4__:__NUCLEAR ENVELOPE SPECTRIN REPEAT PROTEIN 4; NESP4;; NESPRIN 4;; CHROMOSOME 19 OPEN READING FRAME 46; C19ORF46__:__
Asterisk__:__615536__:__CHROMOSOME 2 OPEN READING FRAME 80; C2ORF80__:__GONAD DEVELOPMENT-ASSOCIATED GENE 1; GONDA1__:__
Number Sign__:__615537__:__RETICULATE ACROPIGMENTATION OF KITAMURA; RAK__:__ACROPIGMENTATIO RETICULARIS;; RETICULATE PIGMENTATION OF KITAMURA; RPK;; KITAMURA RETICULATE ACROPIGMENTATION__:__
Number Sign__:__615538__:__CHROMOSOME 22q13 DUPLICATION SYNDROME__:____:__
Number Sign__:__615539__:__EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 2; EDSMC2__:____:__
Number Sign__:__615540__:__DEAFNESS, AUTOSOMAL RECESSIVE 76; DFNB76__:____:__
Number Sign__:__615541__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 39; MRT39__:____:__
Number Sign__:__615542__:__TESTICULAR ANOMALIES WITH OR WITHOUT CONGENITAL HEART DISEASE; TACHD__:____:__
Asterisk__:__615543__:__ACTIN-RELATED PROTEIN 2/3 COMPLEX INHIBITOR; ARPIN__:__CHROMOSOME 15 OPEN READING FRAME 38; C15ORF38__:__
Number Sign__:__615544__:__PERIVENTRICULAR NODULAR HETEROTOPIA 6; PVNH6__:____:__
Number Sign__:__615545__:__LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 3; ALL3__:____:__
Number Sign__:__615546__:__VAN MALDERGEM SYNDROME 2; VMLDS2__:____:__
Number Sign__:__615547__:__SCHAAF-YANG SYNDROME; SHFYNG__:__PRADER-WILLI-LIKE SYNDROME; PWLS__:__
Number Sign__:__615548__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VII; HSAN7__:__HSAN VII;; INSENSITIVITY TO PAIN, CONGENITAL, WITH GASTROINTESTINAL DYSFUNCTION AND HYPERHIDROSIS__:__
Asterisk__:__615549__:__ARMADILLO REPEAT-CONTAINING PROTEIN 5; ARMC5__:____:__
Number Sign__:__615550__:__DIAMOND-BLACKFAN ANEMIA 12; DBA12__:____:__
Number Sign__:__615551__:__EPISODIC PAIN SYNDROME, FAMILIAL, 2; FEPS2__:____:__
Number Sign__:__615552__:__EPISODIC PAIN SYNDROME, FAMILIAL, 3; FEPS3__:____:__
Number Sign__:__615553__:__ARTHROGRYPOSIS, MENTAL RETARDATION, AND SEIZURES; AMRS__:____:__
Number Sign__:__615554__:__MULTIPLE FIBROADENOMAS OF THE BREAST; MFAB__:____:__
Number Sign__:__615555__:__HYPERPROLACTINEMIA; HPRL__:____:__
Asterisk__:__615556__:__ALPHA-TUBULIN ACETYLTRANSFERASE 1; ATAT1__:__TUBULIN, ALPHA, ACETYLTRANSFERASE 1;; ALPHA-TAT1;; MEC17, C. ELEGANS, HOMOLOG OF; MEC17;; CHROMOSOME 6 OPEN READING FRAME 134; C6ORF134__:__
Number Sign__:__615557__:__MELIOIDOSIS, SUSCEPTIBILITY TO__:____:__MELIOIDOSIS, RESISTANCE TO, INCLUDED
Number Sign__:__615558__:__HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1__:__HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC__:__
Number Sign__:__615559__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3__:__IMMUNODEFICIENCY, COMMON VARIABLE, 9, FORMERLY; CVID9, FORMERLY__:__
Number Sign__:__615560__:__OTOFACIOCERVICAL SYNDROME 2; OTFCS2__:__OFC2__:__
Number Sign__:__615561__:__COMPLEMENT FACTOR B DEFICIENCY; CFBD__:____:__
Asterisk__:__615562__:__SPERM-ASSOCIATED ANTIGEN 5; SPAG5__:__MITOTIC SPINDLE-ASSOCIATED PROTEIN, 126-KD; MAP126;; ASTRIN__:__
Asterisk__:__615563__:__NUCLEAR RECEPTOR-BINDING PROTEIN 2; NRBP2__:____:__
Asterisk__:__615564__:__SIDEROFLEXIN 4; SFXN4__:____:__
Number Sign__:__615565__:__RETINITIS PIGMENTOSA 67; RP67__:____:__
Asterisk__:__615566__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 3; BTBD3__:__KIAA0952__:__
Asterisk__:__615567__:__COENZYME Q8B; COQ8B__:__AARF DOMAIN-CONTAINING KINASE 4; ADCK4__:__
Asterisk__:__615568__:__SWI/SNF COMPLEX ANTAGONIST ASSOCIATED WITH PROSTATE CANCER 1, NONCODING; SCHLAP1__:__SECOND CHROMOSOME LOCUS ASSOCIATED WITH PROSTATE 1;; PROSTATE CANCER-ASSOCIATED TRANSCRIPT 114; PCAT114;; LONG INTERGENIC NONCODING RNA 913; LINC00913;; lincRNA 913__:__
Asterisk__:__615569__:__SIDEROFLEXIN 1; SFXN1__:____:__
Asterisk__:__615570__:__SIDEROFLEXIN 2; SFXN2__:____:__
Asterisk__:__615571__:__SIDEROFLEXIN 3; SFXN3__:____:__
Asterisk__:__615572__:__SIDEROFLEXIN 5; SFXN5__:____:__
Number Sign__:__615573__:__NEPHROTIC SYNDROME, TYPE 9; NPHS9__:____:__
Number Sign__:__615574__:__ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD__:__ASNS DEFICIENCY__:__
Number Sign__:__615575__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; HMN2D__:__HMN IID;; NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IID; DHMN2D;; SPINAL MUSCULAR ATROPHY, DISTAL, AUTOSOMAL DOMINANT, CALF-PREDOMINANT__:__
Asterisk__:__615576__:__MICRO RNA 185; MIR185__:__miRNA185;; MIR185-5p__:__MICRO RNA 185*, INCLUDED; MIR185*, INCLUDED;; MIR185-3p, INCLUDED
Number Sign__:__615577__:__IMMUNODEFICIENCY, COMMON VARIABLE, 10; CVID10__:__IMMUNODEFICIENCY, COMMON VARIABLE, WITH CENTRAL ADRENAL INSUFFICIENCY;; DEFICIT IN ANTERIOR PITUITARY FUNCTION AND VARIABLE IMMUNODEFICIENCY; DAVID__:__
Number Sign__:__615578__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 18; COXPD18__:____:__
Asterisk__:__615579__:__ATAXIN 7-LIKE 3B; ATXN7L3B__:____:__
Asterisk__:__615580__:__ZINC FINGER PROTEIN 528; ZNF528__:__KIAA1827__:__
Asterisk__:__615581__:__DOUBLE HOMEOBOX 4-LIKE 9; DUX4L9__:__DUX4C__:__
Number Sign__:__615582__:__LOEYS-DIETZ SYNDROME 5; LDS5__:__RIENHOFF SYNDROME; RNHF__:__
Number Sign__:__615583__:__VERHEIJ SYNDROME; VRJS__:__CHROMOSOME 8q24.3 DELETION SYNDROME__:__
Asterisk__:__615584__:__FAMILY WITH SEQUENCE SIMILARITY 111, MEMBER B; FAM111B__:____:__
Asterisk__:__615585__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 8; SLC38A8__:____:__
Asterisk__:__615586__:__CENTROSOMAL PROTEIN, 19-KD; CEP19__:__CHROMOSOME 3 OPEN READING FRAME 34; C3ORF34__:__
Asterisk__:__615587__:__NUCLEOPORIN, 188-KD; NUP188__:__KIAA1069__:__
Asterisk__:__615588__:__SINGLE-PASS MEMBRANE PROTEIN WITH ASPARTATE-RICH TAIL 1; SMDT1__:__ESSENTIAL MCU REGULATOR; EMRE;; CHROMOSOME 22 OPEN READING FRAME 32; C22ORF32__:__
Percent__:__615589__:__OTOSCLEROSIS 10; OTSC10__:____:__
Number Sign__:__615590__:__ALZHEIMER DISEASE 18; AD18__:__ALZHEIMER DISEASE 18, LATE-ONSET__:__
Number Sign__:__615591__:__MACULAR DEGENERATION, AGE-RELATED, 15; ARMD15__:____:__
Number Sign__:__615592__:__IMMUNODEFICIENCY 15B; IMD15B__:____:__
Number Sign__:__615593__:__IMMUNODEFICIENCY 16; IMD16__:__OX40 DEFICIENCY__:__
Asterisk__:__615594__:__APELIN RECEPTOR EARLY ENDOGENOUS LIGAND; APELA__:__ELABELA;; ELA;; TODDLER;; LOC100506013__:__
Number Sign__:__615595__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 19; COXPD19__:____:__
Number Sign__:__615596__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iw; CDG1W__:__CDG Iw; CDGIw__:__
Number Sign__:__615597__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ix; CDG1X__:__CDG Ix; CDGIx__:__
Number Sign__:__615598__:__PALMOPLANTAR KERATODERMA, NAGASHIMA TYPE; PPKN__:____:__
Number Sign__:__615599__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 40; MRT40__:____:__
Asterisk__:__615600__:__ZINC FINGER PROTEIN 582; ZNF582__:____:__
Asterisk__:__615601__:__GLUTAMATE DECARBOXYLASE-LIKE 1; GADL1__:____:__
Number Sign__:__615602__:__MEMORY QUANTITATIVE TRAIT LOCUS; MEMRYQTL__:____:__
Asterisk__:__615603__:__CALCINEURIN-LIKE PHOSPHOESTERASE DOMAIN-CONTAINING PROTEIN 1; CPPED1__:____:__
Number Sign__:__615604__:__L-FERRITIN DEFICIENCY; LFTD__:____:__
Number Sign__:__615605__:__FANCONI RENOTUBULAR SYNDROME 3; FRTS3__:____:__
Asterisk__:__615606__:__BUTYROPHILIN-LIKE PROTEIN 8; BTNL8__:__BTN9.2__:__
Number Sign__:__615607__:__IMMUNODEFICIENCY 17; IMD17__:__CD3-GAMMA DEFICIENCY;; SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE__:__
Asterisk__:__615608__:__V-SET IMMUNOREGULATORY RECEPTOR; VSIR__:__CHROMOSOME 10 OPEN READING FRAME 54; C10ORF54;; DEATH DOMAIN 1-ALPHA;; DD1-ALPHA;; B7H5__:__
Asterisk__:__615609__:__SIAH E3 UBIQUITIN PROTEIN LIGASE FAMILY, MEMBER 3; SIAH3__:__SEVEN IN ABSENTIA, DROSOPHILA, HOMOLOG OF, 3__:__
Asterisk__:__615610__:__CADHERIN-RELATED FAMILY, MEMBER 3; CDHR3__:____:__
Asterisk__:__615611__:__CASEINOLYTIC MITOCHONDRIAL MATRIX PEPTIDASE CHAPERONE SUBUNIT; CLPX__:__ClpX, E. COLI, HOMOLOG OF__:__
Percent__:__615612__:__DEVELOPMENTAL DYSPLASIA OF THE HIP 2; DDH2__:____:__
Asterisk__:__615613__:__HEPATOCELLULAR CARCINOMA-ASSOCIATED TRANSCRIPT 5; HCCAT5__:__HEPATOMA-ASSOCIATED GENE; HTA__:__
Asterisk__:__615614__:__MMS22-LIKE PROTEIN; MMS22L__:__CHROMOSOME 6 OPEN READING FRAME 167; C6ORF167__:__
Number Sign__:__615615__:__IMMUNODEFICIENCY 18; IMD18__:__CD3-EPSILON DEFICIENCY__:__IMMUNODEFICIENCY 18, SEVERE COMBINED IMMUNODEFICIENCY VARIANT, INCLUDED;; IMMUNODEFICIENCY 18, SCID VARIANT, INCLUDED
Number Sign__:__615616__:__ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 13; ARVD13__:__ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 13; ARVC13__:__
Number Sign__:__615617__:__IMMUNODEFICIENCY 19; IMD19__:__CD3-DELTA DEFICIENCY;; SEVERE COMBINED IMMUNODEFICIENCY, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE;; SCID, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE__:__
Asterisk__:__615618__:__PROTEIN O-GLUCOSYLTRANSFERASE 1; POGLUT1__:__CAP10-LIKE PROTEIN, 46-KD; CLP46;; KTEL MOTIF-CONTAINING PROTEIN 1; KTELC1;; RUMI, DROSOPHILA, HOMOLOG OF; RUMI;; CHROMOSOME 3 OPEN READING FRAME 9; C3ORF9__:__
NULL__:__615619__:__CHOLANGIOCARCINOMA, SUSCEPTIBILITY TO__:__CHLC, SUSCEPTIBILITY TO__:__
Asterisk__:__615620__:__KAPTIN; KPTN__:__ACTIN-ASSOCIATED PROTEIN 2E4; 2E4__:__
Asterisk__:__615622__:__TNF- AND HNRNPL-RELATED IMMUNOREGULATORY LONG NONCODING RNA; THRIL__:__TNF- AND HNRNPL-RELATED IMMUNOREGULATORY lncRNA;; LONG INTERGENIC NONCODING RNA 1992; LINC1992;; lincRNA 1992;; BRI3BP ANTISENSE RNA 1; BRI3BPAS1;; TCONS_00020260__:__
Asterisk__:__615623__:__CYTOCHROME C OXIDASE ASSEMBLY FACTOR 7; COA7__:__RESPIRATORY CHAIN ASSEMBLY PROTEIN 1; RESA1;; SEL1 REPEAT-CONTAINING PROTEIN 1; SELRC1;; CHROMOSOME 1 OPEN READING FRAME 163; C1ORF163__:__
Asterisk__:__615624__:__COLORECTAL NEOPLASIA DIFFERENTIALLY EXPRESSED GENE, NONCODING; CRNDE__:____:__
Number Sign__:__615625__:__SPASTIC PARAPLEGIA 72, AUTOSOMAL RECESSIVE; SPG72__:____:__SPASTIC PARAPLEGIA 72, AUTOSOMAL DOMINANT, INCLUDED
Asterisk__:__615626__:__CHROMOSOME 15 OPEN READING FRAME 41; C15ORF41__:____:__
Asterisk__:__615627__:__BRI3-BINDING PROTEIN; BRI3BP__:____:__
Asterisk__:__615628__:__BRAIN PROTEIN I3; BRI3__:____:__
Number Sign__:__615629__:__DEAFNESS, AUTOSOMAL DOMINANT 56; DFNA56__:____:__
Number Sign__:__615630__:__SHORT-RIB THORACIC DYSPLASIA 10 WITH OR WITHOUT POLYDACTYLY; SRTD10__:____:__
Number Sign__:__615631__:__ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ib; CDAN1B__:__CDA, TYPE Ib__:__
Number Sign__:__615632__:__NEUROPATHY, HEREDITARY SENSORY, TYPE IF; HSN1F__:__HSN IF__:__
Number Sign__:__615633__:__SHORT-RIB THORACIC DYSPLASIA 11 WITH OR WITHOUT POLYDACTYLY; SRTD11__:____:__
Asterisk__:__615634__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 6; CHCHD6__:__COILED-COIL-HELIX CRISTAE MORPHOLOGY PROTEIN 1; CHCM1;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 25-KD SUBUNIT; MIC25;; MICOS COMPLEX, 25-KD SUBUNIT__:__
Asterisk__:__615635__:__ZINC FINGER RNA-BINDING PROTEIN; ZFR__:____:__
Number Sign__:__615636__:__JOUBERT SYNDROME 21; JBTS21__:____:__
Number Sign__:__615637__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 41; MRT41__:____:__
Asterisk__:__615638__:__NON-SMC CONDENSIN I COMPLEX SUBUNIT D2; NCAPD2__:__CHROMOSOME CONDENSATION-RELATED SMC-ASSOCIATED PROTEIN 1; CNAP1;; KIAA0159__:__
Asterisk__:__615639__:__SMALL CAJAL BODY-SPECIFIC RNA 10; SCARNA10__:__snoRNA, U85__:__
Asterisk__:__615640__:__SMALL CAJAL BODY-SPECIFIC RNA 5; SCARNA5__:__snoRNA, U87__:__
Asterisk__:__615641__:__SMALL CAJAL BODY-SPECIFIC RNA 6; SCARNA6__:__snoRNA, U88__:__
Asterisk__:__615642__:__SMALL CAJAL BODY-SPECIFIC RNA 12; SCARNA12__:__snoRNA, U89__:__
Number Sign__:__615643__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 6; NBIA6__:____:__
Asterisk__:__615644__:__SMALL CAJAL BODY-SPECIFIC RNA 7; SCARNA7__:__snoRNA, U90__:__
Asterisk__:__615645__:__SMALL CAJAL BODY-SPECIFIC RNA 17; SCARNA17__:__snoRNA, U91__:__
Asterisk__:__615646__:__SMALL CAJAL BODY-SPECIFIC RNA 8; SCARNA8__:__snoRNA, U92__:__
Asterisk__:__615647__:__TESTIS-EXPRESSED GENE 19; TEX19__:____:__
Asterisk__:__615648__:__NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 3; NLRC3__:__NLR FAMILY, CARD-CONTAINING 3;; CATERPILLER 16.2;; CLR16.2__:__
Percent__:__615649__:__DEAFNESS, AUTOSOMAL DOMINANT 54; DFNA54__:____:__
Asterisk__:__615650__:__REGULATOR OF G PROTEIN SIGNALING 22; RGS22__:____:__
Number Sign__:__615651__:__LEUKOENCEPHALOPATHY WITH ATAXIA; LKPAT__:____:__
Asterisk__:__615652__:__ACYL-CoA THIOESTERASE 13; ACOT13__:__THIOESTERASE SUPERFAMILY MEMBER 2; THEM2__:__
Asterisk__:__615653__:__THIOESTERASE SUPERFAMILY MEMBER 5; THEM5__:__ACYL-CoA THIOESTERASE 15; ACOT15__:__
Percent__:__615654__:__DEAFNESS, AUTOSOMAL DOMINANT 58; DFNA58__:____:__
Asterisk__:__615655__:__ZINC FINGER RANBP2-TYPE DOMAIN-CONTAINING PROTEIN 3; ZRANB3__:__ZINC FINGER RAN-BINDING DOMAIN-CONTAINING PROTEIN 3__:__
Number Sign__:__615656__:__CHROMOSOME 15q11.2 DELETION SYNDROME__:____:__
Asterisk__:__615657__:__MICRO RNA 142; MIR142__:__miRNA142;; MIR142-5p__:__MICRO RNA 142-3p, INCLUDED; MIR142-3p, INCLUDED
Number Sign__:__615658__:__SPASTIC PARAPLEGIA 57, AUTOSOMAL RECESSIVE; SPG57__:____:__
Asterisk__:__615659__:__TRANSMEMBRANE PROTEIN 131; TMEM131__:__KIAA0257;; CC28__:__
Asterisk__:__615660__:__RIBOSOMAL PROTEIN L10A; RPL10A__:__CSA19__:__
Asterisk__:__615661__:__PROGRAMMED CELL DEATH 2-LIKE PROTEIN; PDCD2L__:__PDCD2-LIKE PROTEIN;; MGC13096__:__
Asterisk__:__615662__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 12; SERPINB12__:____:__
Number Sign__:__615663__:__WARBURG MICRO SYNDROME 4; WARBM4__:____:__
Asterisk__:__615664__:__THYMOCYTE-EXPRESSED POSITIVE SELECTION-ASSOCIATED PROTEIN 1; TESPA1__:__KIAA0748__:__
Number Sign__:__615665__:__JOUBERT SYNDROME 22; JBTS22__:____:__
Asterisk__:__615666__:__KIAA1456 GENE; KIAA1456__:__tRNA METHYLTRANSFERASE 9-LIKE; TRM9L__:__
Asterisk__:__615667__:__ERCC6-LIKE 2; ERCC6L2__:__RAD26-LIKE; RAD26L__:__HELICASE MUTATED IN BONE MARROW FAILURE, INCLUDED; HEBO, INCLUDED
Number Sign__:__615668__:__CHROMOSOME 5q12 DELETION SYNDROME__:____:__
Asterisk__:__615669__:__EMBIGIN; EMB__:__GP70__:__
Number Sign__:__615670__:__SCHWANNOMATOSIS 2; SWNTS2__:____:__
Asterisk__:__615671__:__SET DOMAIN-CONTAINING PROTEIN 3; SETD3__:____:__
Asterisk__:__615672__:__MICRO RNA 497; MIR497__:__miRNA497;; MIRN497__:__
Number Sign__:__615673__:__MYOPATHY WITH EXTRAPYRAMIDAL SIGNS; MPXPS__:____:__
Percent__:__615674__:__DOWLING-DEGOS DISEASE 3; DDD3__:____:__
Asterisk__:__615675__:__MICRO RNA 301A; MIR301A__:__miRNA301A;; MIR301__:__
Asterisk__:__615676__:__TESTIS DEVELOPMENT-RELATED GENE 1, NONCODING; TDRG1__:__LONG INTERGENIC NONCODING RNA 532; LINC00532;; lincRNA 532__:__
Asterisk__:__615677__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 9; SERPINA9__:__GERMINAL CENTER B-CELL-EXPRESSED TRANSCRIPT 1; GCET1;; CENTERIN__:__
Asterisk__:__615678__:__SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH PROTEIN-LIKE PROTEIN 2; SH3BGRL2__:__SH3BGR-LIKE PROTEIN 2__:__
Asterisk__:__615679__:__SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH PROTEIN-LIKE PROTEIN 3; SH3BGRL3__:__SH3BGR-LIKE PROTEIN 3;; TNF INHIBITORY PROTEIN B1; TIPB1__:__
Asterisk__:__615680__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 16; CARD16__:__CASPASE RECRUITMENT DOMAIN-ONLY PROTEIN; COP; COP1;; CARD-ONLY PROTEIN;; PSEUDO-INTERLEUKIN 1-BETA-CONVERTING ENZYME;; PSEUDO-IL1B-CONVERTING ENZYME;; PSEUDO-ICE__:__
Number Sign__:__615681__:__SPASTIC PARAPLEGIA 62, AUTOSOMAL RECESSIVE; SPG62__:____:__
Asterisk__:__615682__:__SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 11; SERPINB11__:____:__
Number Sign__:__615683__:__SPASTIC PARAPLEGIA 64, AUTOSOMAL RECESSIVE; SPG64__:____:__
Asterisk__:__615684__:__HFM1, ATP-DEPENDENT DNA HELICASE, S. CEREVISIAE, HOMOLOG OF; HFM1__:__HELICASE FAMILY MEMBER 1;; MER3, S. CEREVISIAE, HOMOLOG OF; MER3__:__
Number Sign__:__615685__:__SPASTIC PARAPLEGIA 61, AUTOSOMAL RECESSIVE; SPG61__:____:__
Number Sign__:__615686__:__SPASTIC PARAPLEGIA 63, AUTOSOMAL RECESSIVE; SPG63__:____:__
Asterisk__:__615687__:__BECLIN 2; BECN2__:__BECLIN 1-LIKE PROTEIN 1; BECN1L1__:__
Number Sign__:__615688__:__POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN__:__ADA2 DEFICIENCY__:__
Asterisk__:__615689__:__ADHESION MOLECULE WITH Ig-LIKE DOMAIN 1; AMIGO1__:__AMPHOTERIN-INDUCED GENE AND OPEN READING FRAME; AMIGO;; ALIVIN 2; ALI2;; KIAA1163__:__
Asterisk__:__615690__:__ADHESION MOLECULE WITH Ig-LIKE DOMAIN 2; AMIGO2__:__AMPHOTERIN-INDUCED GENE AND OPEN READING FRAME 2; AMIGO2;; ALIVIN 1; ALI1__:__
Asterisk__:__615691__:__ADHESION MOLECULE WITH Ig-LIKE DOMAIN 3; AMIGO3__:__AMPHOTERIN-INDUCED GENE AND OPEN READING FRAME 3; AMIGO3;; ALIVIN 3; ALI3__:__
Asterisk__:__615692__:__CHITINASE DOMAIN-CONTAINING PROTEIN 1; CHID1__:__STABILIN 1-INTERACTING CHITINASE-LIKE PROTEIN; SICLP__:__
Asterisk__:__615693__:__COLCA1 GENE; COLCA1__:__COLORECTAL CANCER-ASSOCIATED GENE 1__:__
Asterisk__:__615694__:__COLCA2 GENE; COLCA2__:__COLORECTAL CANCER-ASSOCIATED GENE 2__:__
Asterisk__:__615695__:__HEXAMETHYLENE BIS ACETAMIDE-INDUCIBLE PROTEIN 2; HEXIM2__:____:__
Number Sign__:__615696__:__DOWLING-DEGOS DISEASE 4; DDD4__:____:__
Percent__:__615697__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 6; ETL6__:____:__
Asterisk__:__615698__:__PHOSPHOLIPASE D FAMILY, MEMBER 3; PLD3__:__HUK4__:__
Asterisk__:__615699__:__CHROMOSOME 11 OPEN READING FRAME 95; C11ORF95__:____:__C11ORF95/MKL2 FUSION GENE, INCLUDED;; C11ORF95/RELA FUSION GENE, INCLUDED
Asterisk__:__615700__:__PYRIN DOMAIN-CONTAINING PROTEIN 1; PYDC1__:__PAAD DOMAIN-ONLY PROTEIN 1; POP1;; PYRIN DOMAIN-ONLY PROTEIN 1;; PYC1;; ASC2__:__
Asterisk__:__615701__:__PYRIN DOMAIN-CONTAINING PROTEIN 2; PYDC2__:__PYRIN DOMAIN-ONLY PROTEIN 2; POP2__:__
Asterisk__:__615702__:__OLFACTORY RECEPTOR, FAMILY 5, SUBFAMILY AN, MEMBER 1; OR5AN1__:__OR11-244__:__
Number Sign__:__615703__:__MORBID OBESITY AND SPERMATOGENIC FAILURE; MOSPGF__:____:__
Number Sign__:__615704__:__POIKILODERMA, HEREDITARY FIBROSING, WITH TENDON CONTRACTURES, MYOPATHY, AND PULMONARY FIBROSIS; POIKTMP__:__POIKILODERMA, HEREDITARY SCLEROSING, WITH TENDON AND PULMONARY INVOLVEMENT__:__
Number Sign__:__615705__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 15; SCAR15__:__SALIH ATAXIA__:__
Number Sign__:__615706__:__AURICULOCONDYLAR SYNDROME 3; ARCND3__:____:__
Number Sign__:__615707__:__IMMUNODEFICIENCY 20; IMD20__:____:__
Asterisk__:__615708__:__ZINC FINGER PROTEIN 451; ZNF451__:__COACTIVATOR FOR STEROID RECEPTORS; COASTER__:__
Number Sign__:__615709__:__SACRAL AGENESIS WITH VERTEBRAL ANOMALIES; SAVA__:____:__
Number Sign__:__615710__:__MITCHELL-RILEY SYNDROME; MTCHRS__:__DIABETES, NEONATAL, WITH PANCREATIC HYPOPLASIA, INTESTINAL ATRESIA, AND GALLBLADDER APLASIA OR HYPOPLASIA__:__
NULL__:__615711__:__ALZHEIMER DISEASE 19; AD19__:__ALZHEIMER DISEASE 19, LATE-ONSET__:__
Asterisk__:__615712__:__OTU DEUBIQUITINASE WITH LINEAR LINKAGE SPECIFICITY; OTULIN__:__FAMILY WITH SEQUENCE SIMILARITY 105, MEMBER B; FAM105B;; GUMBY, MOUSE, HOMOLOG OF; GUM__:__
Asterisk__:__615713__:__ZINC FINGER MYND DOMAIN-CONTAINING PROTEIN 8; ZMYND8__:__PROTEIN KINASE C-BINDING PROTEIN 1; PRKCBP1;; RACK7__:__
Asterisk__:__615714__:__ZNRD1 ANTISENSE RNA 1; ZNRD1AS1__:__TCTEX4, MOUSE, HOMOLOG OF; TCTEX4;; TEX4; HTEX4__:__
Number Sign__:__615715__:__BONE MARROW FAILURE SYNDROME 2; BMFS2__:____:__
Number Sign__:__615716__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 4; HPMRS4__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 10; GPIBD10__:__
Asterisk__:__615717__:__BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 3; BPIFB3__:__RYA3__:__
Asterisk__:__615718__:__BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 4; BPIFB4__:__RY2G5__:__
Asterisk__:__615719__:__TCL1 UPSTREAM NEURAL DIFFERENTIATION-ASSOCIATED RNA; TUNAR__:__TCL1 UPSTREAM NEURON-ASSOCIATED RNA; TUNA;; LONG INTERGENIC NONCODING RNA 617; LINC00617;; lincRNA TUNAR__:__
Asterisk__:__615720__:__SOLUTE CARRIER FAMILY 7, MEMBER 14; SLC7A14__:__KIAA1613__:__
Number Sign__:__615721__:__RENAL HYPODYSPLASIA/APLASIA 2; RHDA2__:____:__
Number Sign__:__615722__:__BOSCH-BOONSTRA-SCHAAF OPTIC ATROPHY SYNDROME; BBSOAS__:____:__
Number Sign__:__615723__:__PREMATURE OVARIAN FAILURE 8; POF8__:____:__
Number Sign__:__615724__:__PREMATURE OVARIAN FAILURE 9; POF9__:____:__
Number Sign__:__615725__:__RETINITIS PIGMENTOSA 68; RP68__:____:__
Number Sign__:__615726__:__PACHYONYCHIA CONGENITA 3; PC3__:____:__
Asterisk__:__615727__:__KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, LONG CYTOPLASMIC TAIL, 5B; KIR2DL5B__:____:__
Number Sign__:__615728__:__PACHYONYCHIA CONGENITA 4; PC4__:____:__
Asterisk__:__615729__:__STRAWBERRY NOTCH, DROSOPHILA, HOMOLOG OF, 2; SBNO2__:__KIAA0963__:__
Asterisk__:__615730__:__DEDICATOR OF CYTOKINESIS 7; DOCK7__:__KIAA1771__:__
Number Sign__:__615731__:__NEMALINE MYOPATHY 9; NEM9__:____:__
Asterisk__:__615732__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 5; NSUN5__:__NOP2/SUN DOMAIN FAMILY, MEMBER 5;; WILLIAMS-BEUREN SYNDROME CRITICAL REGION 20; WBSCR20;; WBSCR20A__:__
Asterisk__:__615733__:__rRNA METHYLTRANSFERASE AND RIBOSOME MATURATION FACTOR BUD23; BUD23__:__METASTASIS-RELATED METHYLTRANSFERASE 1; MERM1;; WILLIAMS-BEUREN SYNDROME CRITICAL REGION 22; WBSCR22__:__
Asterisk__:__615734__:__WD REPEAT-CONTAINING PROTEIN 47; WDR47__:__NEURONAL ENRICHED MAP-INTERACTING PROTEIN; NEMITIN;; KIAA0893__:__
Number Sign__:__615735__:__PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL OR DIFFUSE; PPKNEFD__:____:__
Asterisk__:__615736__:__ENDOTHELIAL CELL SURFACE-EXPRESSED CHEMOTAXIS AND APOPTOSIS REGULATOR; ECSCR__:__ENDOTHELIAL CELL-SPECIFIC MOLECULE 2; ECSM2;; APOPTOSIS REGULATOR THROUGH MODULATING IAP EXPRESSION; ARIA__:__
Asterisk__:__615737__:__FOLATE RECEPTOR 4; FOLR4__:__FOLATE RECEPTOR, DELTA;; FR-DELTA;; FOLBP3, MOUSE, HOMOLOG OF;; JUNO__:__
Asterisk__:__615738__:__VACUOLAR PROTEIN SORTING 51, S. CEREVISIAE, HOMOLOG OF; VPS51__:__ANOTHER NEW GENE 2; ANG2__:__
Asterisk__:__615739__:__POU DOMAIN, CLASS 5, TRANSCRIPTION FACTOR 1B; POU5F1B__:__POU CLASS 5 HOMEOBOX 1B;; POU5F1P1;; OCT4PG1__:__
Asterisk__:__615740__:__TBC1 DOMAIN FAMILY, MEMBER 5; TBC1D5__:__KIAA0210__:__
Asterisk__:__615741__:__KIAA0141 GENE; KIAA0141__:__DEATH LIGAND SIGNAL ENHANCER; DELE__:__
Asterisk__:__615742__:__RGP1 RETROGRADE GOLGI TRANSPORT, S. CEREVISIAE, HOMOLOG OF; RGP1__:__KIAA0258__:__
Asterisk__:__615743__:__SET DOMAIN-CONTAINING PROTEIN 5; SETD5__:__KIAA1757__:__
Number Sign__:__615744__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 19; EIEE19__:____:__
Number Sign__:__615745__:__ATRIAL STANDSTILL 2; ATRST2__:__ATRIAL DILATION AND STANDSTILL;; CARDIOMYOPATHY, ATRIAL DILATED, WITH ATRIAL STANDSTILL__:__
Asterisk__:__615746__:__ZXD FAMILY ZINC FINGER PROTEIN C; ZXDC__:____:__
Asterisk__:__615747__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 8; CEACAM8__:__CD66B;; CGM6__:__
Asterisk__:__615748__:__WASH COMPLEX, SUBUNIT 4; WASHC4__:__KIAA1033 GENE; KIAA1033;; WASH COMPLEX, SUBUNIT 7;; STRUMPELLIN AND WASH-INTERACTING PROTEIN; SWIP__:__
Number Sign__:__615749__:__ECULIZUMAB, POOR RESPONSE TO__:____:__
Number Sign__:__615750__:__MOYAMOYA DISEASE 6 WITH OR WITHOUT ACHALASIA; MYMY6__:____:__
Number Sign__:__615751__:__CARBONIC ANHYDRASE VA DEFICIENCY, HYPERAMMONEMIA DUE TO; CA5AD__:____:__
Number Sign__:__615752__:__POLYMICROGYRIA, BILATERAL PERISYLVIAN, AUTOSOMAL RECESSIVE; BPPR__:__PMGR__:__
Asterisk__:__615753__:__POM121 TRANSMEMBRANE NUCLEOPORIN; POM121__:__POM121A;; KIAA0618__:__
Asterisk__:__615754__:__POM121 TRANSMEMBRANE NUCLEOPORIN C; POM121C__:__POM121-2__:__
Asterisk__:__615755__:__FORKHEAD BOX R1; FOXR1__:__FORKHEAD BOX N5; FOXN5__:__
Asterisk__:__615756__:__SELENOCYSTEINE INSERTION SEQUENCE-BINDING PROTEIN 2-LIKE; SECISBP2L__:__SECIS-BINDING PROTEIN 2-LIKE; SBP2L;; KIAA0256__:__
Asterisk__:__615757__:__KIZUNA CENTROSOMAL PROTEIN; KIZ__:__KIZUNA;; CHROMOSOME 20 OPEN READING FRAME 19; C20ORF19__:__
Number Sign__:__615758__:__IMMUNODEFICIENCY 22; IMD22__:____:__
Asterisk__:__615759__:__KINASE D-INTERACTING SUBSTRATE, 220-KD; KIDINS220__:__ANKYRIN REPEAT-RICH MEMBRANE-SPANNING PROTEIN; ARMS__:__
Number Sign__:__615760__:__MICROCEPHALY, PROGRESSIVE, WITH SEIZURES AND CEREBRAL AND CEREBELLAR ATROPHY; MSCCA__:____:__
Number Sign__:__615761__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 23; MRD23__:____:__
Asterisk__:__615762__:__GLUTAREDOXIN, CYSTEINE-RICH, 2; GRXCR2__:____:__
Number Sign__:__615763__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 5; CDCBM5__:____:__
Asterisk__:__615764__:__LONG STRESS-INDUCED NONCODING TRANSCRIPT 5; LSINCT5__:____:__
Asterisk__:__615765__:__SOLUTE CARRIER FAMILY 16, MEMBER 11; SLC16A11__:__MONOCARBOXYLATE TRANSPORTER 11; MCT11__:__
Asterisk__:__615766__:__MICROTUBULE CROSSLINKING FACTOR 1; MTCL1__:__KIAA0802__:__
Number Sign__:__615767__:__IMMUNODEFICIENCY, COMMON VARIABLE, 11; CVID11__:__IL21 DEFICIENCY__:__
Number Sign__:__615768__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 16; SCAR16__:____:__
Asterisk__:__615769__:__FAMILY WITH SEQUENCE SIMILARITY 169, MEMBER A; FAM169A__:__SOLUBLE LAMINA-ASSOCIATED PROTEIN, 75-KD; SLAP75;; KIAA0888__:__
Number Sign__:__615770__:__ATRIAL FIBRILLATION, FAMILIAL, 15; ATFB15__:____:__
Number Sign__:__615771__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 6; CDCBM6__:____:__
Asterisk__:__615772__:__LONG NONCODING RNA, DENDRITIC CELL__:__lncRNA DC;; lncDC;; LOC615638__:__
Asterisk__:__615773__:__ACN9, S. CEREVISIAE, HOMOLOG OF; ACN9__:____:__
Number Sign__:__615774__:__OOCYTE MATURATION DEFECT 1; OOMD1__:__OOMD__:__
Asterisk__:__615775__:__SYNAPTONEMAL COMPLEX CENTRAL ELEMENT PROTEIN 3; SYCE3__:____:__
Asterisk__:__615776__:__CILIARY ROOTLET COILED-COIL PROTEIN; CROCC__:__ROOTLETIN;; KIAA0445__:__
Number Sign__:__615777__:__DESBUQUOIS DYSPLASIA 2; DBQD2__:____:__
Asterisk__:__615778__:__CLAUDIN 15; CLDN15__:____:__
Number Sign__:__615779__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 4; CHTD4__:____:__
Number Sign__:__615780__:__RETINITIS PIGMENTOSA 69; RP69__:____:__
Asterisk__:__615781__:__ADAPTOR-RELATED PROTEIN COMPLEX 1, SIGMA-3 SUBUNIT; AP1S3__:__ADAPTOR PROTEIN COMPLEX 1, SIGMA-1C SUBUNIT__:__
Asterisk__:__615782__:__CIRCADIAN-ASSOCIATED REPRESSOR OF TRANSCRIPTION; CIART__:__COMPUTATIONALLY HIGHLIGHTED REPRESSOR OF NETWORK OSCILLATOR; CHRONO;; GENE MODEL 129; GM129__:__
Asterisk__:__615783__:__N-ACETYLTRANSFERASE 16; NAT16__:____:__
Asterisk__:__615784__:__GLUTATHIONE PEROXIDASE 7; GPX7__:__NONSELENOCYSTEINE-CONTAINING PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; NPGPX__:__
Number Sign__:__615785__:__WHITE SPONGE NEVUS 2; WSN2__:____:__
Asterisk__:__615786__:__NACC FAMILY, MEMBER 2, BEN AND BTB/POZ DOMAINS-CONTAINING; NACC2__:__REPRESSOR WITH BTB DOMAIN AND BEN DOMAIN; RBB__:__
Asterisk__:__615787__:__NAD KINASE 2, MITOCHONDRIAL; NADK2__:__CHROMOSOME 5 OPEN READING FRAME 33; C5ORF33__:__
Asterisk__:__615788__:__NEDD4-BINDING PROTEIN 2-LIKE 2; N4BP2L2__:__PHOSPHONOFORMATE IMMUNO-ASSOCIATED PROTEIN 5; PFAAP5__:__
Number Sign__:__615789__:__SHORT STATURE WITH MICROCEPHALY AND DISTINCTIVE FACIES__:____:__
Asterisk__:__615790__:__AT-HOOK DNA-BINDING MOTIF-CONTAINING PROTEIN 1; AHDC1__:____:__
Asterisk__:__615791__:__NUDIX HYDROLASE 18; NUDT18__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 18;; NUDIX MOTIF 18;; MutT HOMOLOG 3; MTH3__:__
Asterisk__:__615792__:__NUDIX HYDROLASE 15; NUDT15__:__NUCLEOSIDE DIPHOSPHATE-LINKED MOIETY X MOTIF 15;; NUDIX MOTIF 15;; MutT HOMOLOG 2; MTH2__:__
Asterisk__:__615793__:__ISTHMIN 1, ANGIOGENESIS INHIBITOR; ISM1__:__ISTHMIN; ISM__:__
Asterisk__:__615794__:__FIBRONECTIN TYPE III DOMAIN-CONTAINING PROTEIN 3A;; FNDC3A__:__KIAA0970;; HUMAN GENE EXPRESSED IN ODONTOBLASTS; HUGO__:__
Asterisk__:__615795__:__FIBROUS SHEATH-INTERACTING PROTEIN 1; FSIP1__:__HSD10__:__
Asterisk__:__615796__:__FIBROUS SHEATH-INTERACTING PROTEIN 2; FSIP2__:____:__
Asterisk__:__615797__:__HLA COMPLEX GROUP 9, NONCODING; HCG9__:__HCGIX;; HCGIX4__:__
Asterisk__:__615798__:__CLAUDIN 6; CLDN6__:____:__
Asterisk__:__615799__:__CLAUDIN 9; CLDN9__:____:__
Asterisk__:__615800__:__FASCIN ACTIN-BUNDLING PROTEIN 3, TESTICULAR; FSCN3__:__FASCIN, TESTIS__:__
Asterisk__:__615801__:__HLA COMPLEX GROUP 8; HCG8__:__HCGVIII__:__
Number Sign__:__615802__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 42; MRT42__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 9; GPIBD9__:__
Number Sign__:__615803__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 10; PCH10__:____:__
Asterisk__:__615804__:__UREIDOIMIDAZOLINE (2-OXO-4-HYDROXY-4-CARBOXY-5-) DECARBOXYLASE; URAD__:__OHCU DECARBOXYLASE__:__
Asterisk__:__615805__:__URATE (HYDROXYISO-) HYDROLASE, PSEUDOGENE; URAHP__:__HYDROXYISOURATE HYDROLASE; URAH__:__
Asterisk__:__615806__:__SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 4; SLC15A4__:__PEPTIDE/HISTIDINE TRANSPORTER 1; PHT1;; PEPTIDE TRANSPORTER 4; PTR4__:__
Number Sign__:__615807__:__SECKEL SYNDROME 8; SCKL8__:____:__
Asterisk__:__615808__:__TRANSLATION MACHINERY-ASSOCIATED 7, S. CEREVISIAE, HOMOLOG OF; TMA7__:__HSPC016__:__
Number Sign__:__615809__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 9; PCH9__:____:__
Asterisk__:__615810__:__CHROMOSOME 11 OPEN READING FRAME 54; C11ORF54__:__PTD012__:__
Asterisk__:__615811__:__PEPTIDYL-PROLYL ISOMERASE-LIKE 3; PPIL3__:____:__
Number Sign__:__615812__:__ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3__:__CENTRAL OBESITY, TYPE 2 DIABETES, HYPERTENSION, AND EARLY-ONSET CORONARY ARTERY DISEASE__:__
Asterisk__:__615813__:__FAMILY WITH SEQUENCE SIMILARITY 193, MEMBER B; FAM193B__:__IRIZIO;; KIAA1931__:__
Asterisk__:__615814__:__SERINE/THREONINE/TYROSINE-INTERACTING PROTEIN; STYX__:____:__
Asterisk__:__615815__:__SMOOTH MUSCLE- AND ENDOTHELIAL CELL-ENRICHED MIGRATION/DIFFERENTIATION-ASSOCIATED LONG NONCODING RNA; SENCR__:__LONG NONCODING RNA 9; lncRNA9__:__
Number Sign__:__615816__:__IMMUNODEFICIENCY 23; IMD23__:__IMMUNODEFICIENCY WITH HYPER IgE AND COGNITIVE IMPAIRMENT;; IMMUNODEFICIENCY-VASCULITIS-MYOCLONUS SYNDROME; IVMS__:__
Number Sign__:__615817__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 43; MRT43__:____:__
Asterisk__:__615818__:__RIBOSOMAL RNA PROCESSING PROTEIN 8, METHYLTRANSFERASE, S. CEREVISIAE, HOMOLOG OF; RRP8__:__NUCLEOMETHYLIN; NML;; KIAA0409__:__
Asterisk__:__615819__:__SULFOTRANSFERASE FAMILY 1A, CYTOSOLIC, PHENOL-PREFERRING, MEMBER 4; SULT1A4__:____:__
Asterisk__:__615820__:__DDB1- AND CUL4-ASSOCIATED FACTOR 8; DCAF8__:__WD REPEAT-CONTAINING PROTEIN 42A; WDR42A__:__
Number Sign__:__615821__:__CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR, KERATODERMA, AND TOOTH AGENESIS; DCWHKTA__:____:__
Asterisk__:__615822__:__SLX1 STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT, S. CEREVISIAE, HOMOLOG OF, A; SLX1A__:__GIY-YIG DOMAIN CONTAINING PROTEIN 1; GIYD1__:__
Asterisk__:__615823__:__SLX1 STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT, S. CEREVISIAE, HOMOLOG OF, B; SLX1B__:__GIY-YIG DOMAIN CONTAINING PROTEIN 2; GIYD2__:__
Number Sign__:__615824__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 7; MC3DN7__:____:__
Asterisk__:__615825__:__SUSHI DOMAIN-CONTAINING PROTEIN 2; SUSD2__:____:__
Asterisk__:__615826__:__SPERM-TAIL PG-RICH REPEAT-CONTAINING PROTEIN 1; STPG1__:__O(6)-METHYLGUANINE-INDUCED APOPTOSIS 2; MAPO2;; CHROMOSOME 1 OPEN READING FRAME 201; C1ORF201__:__
Asterisk__:__615827__:__SUSHI DOMAIN-CONTAINING PROTEIN 4; SUSD4__:____:__
Number Sign__:__615828__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 24; MRD24__:____:__
Number Sign__:__615829__:__XIA-GIBBS SYNDROME__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 25; MRD25__:__
Number Sign__:__615830__:__PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4__:__CUSHING SYNDROME, ADRENAL, DUE TO PPNAD4;; CHROMOSOME 19p13 DUPLICATION SYNDROME__:__ACTH-INDEPENDENT ADRENAL CUSHING SYNDROME, SOMATIC, INCLUDED
Asterisk__:__615831__:__LYR MOTIF-CONTAINING PROTEIN 7; LYRM7__:__MZM1-LIKE; MZM1L__:__
Asterisk__:__615832__:__UBIQUITIN-CONJUGATING ENZYME E2Q FAMILY-LIKE PROTEIN 1; UBE2QL1__:____:__
Number Sign__:__615833__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 21; EIEE21__:____:__
Number Sign__:__615834__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 26; MRD26__:____:__
Number Sign__:__615835__:__CHROMOSOME 16 INVERSION, 0.45-MB__:____:__
Asterisk__:__615836__:__SERINE/THREONINE PROTEIN KINASE 38-LIKE PROTEIN; STK38L__:__STK38-LIKE PROTEIN;; NUCLEAR DBF2-RELATED PROTEIN 2; NDR2;; KIAA0965__:__
Number Sign__:__615837__:__DEAFNESS, AUTOSOMAL RECESSIVE 101; DFNB101__:____:__
Number Sign__:__615838__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 8; MC3DN8__:____:__
Asterisk__:__615839__:__2,4-DIENOYL-CoA REDUCTASE 2, PEROXISOMAL; DECR2__:__PDCR__:__
Asterisk__:__615840__:__dCTP PYROPHOSPHATASE 1; DCTPP1__:__DEOXYCYTIDINE TRIPHOSPHATASE 1__:__
Number Sign__:__615841__:__SPERMATOGENIC FAILURE 13; SPGF13__:____:__
Number Sign__:__615842__:__SPERMATOGENIC FAILURE 14; SPGF14__:____:__
Asterisk__:__615843__:__DELTA(4)-DESATURASE, SPHINGOLIPID, 1; DEGS1__:__DIHYDROCERAMIDE DESATURASE 1; DES1;; MEMBRANE LIPID DESATURASE; MLD__:__
Asterisk__:__615844__:__DIHYDROXYACETONE KINASE 2, S. CEREVISIAE, HOMOLOG OF; DAK__:__DHA KINASE/FMN CYCLASE__:__
Asterisk__:__615845__:__MICRO RNA 190A; MIR190A__:____:__
Number Sign__:__615846__:__AICARDI-GOUTIERES SYNDROME 7; AGS7__:____:__
Asterisk__:__615847__:__CENTROSOMAL PROTEIN, 83-KD; CEP83__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 41; CCDC41;; RENAL CARCINOMA ANTIGEN NY-REN-58__:__
Number Sign__:__615848__:__MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 10; CMM10__:____:__
Number Sign__:__615849__:__CULLER-JONES SYNDROME; CJS__:__PALLISTER-HALL SYNDROME 2, FORMERLY; PHS2, FORMERLY__:__
Asterisk__:__615850__:__VACUOLAR PROTEIN SORTING 53, S. CEREVISIAE, HOMOLOG OF; VPS53__:__HCCS1__:__
Number Sign__:__615851__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2E; PCH2E__:____:__
Asterisk__:__615852__:__RAS-ASSOCIATED PROTEIN RAB6B; RAB6B__:____:__
Asterisk__:__615853__:__POLYAMINE OXIDASE; PAOX__:__PAO__:__
Asterisk__:__615854__:__SPERMINE OXIDASE; SMOX__:__SMO;; CHROMOSOME 20 OPEN READING FRAME 16; C20ORF16;; POLYAMINE OXIDASE 1; PAO1;; PAOH__:__
Asterisk__:__615855__:__TRANSMEMBRANE AND TETRATRICOPEPTIDE REPEAT DOMAINS-CONTAINING PROTEIN 1; TMTC1__:____:__
Asterisk__:__615856__:__TRANSMEMBRANE AND TETRATRICOPEPTIDE REPEAT DOMAINS-CONTAINING PROTEIN 2; TMTC2__:____:__
Asterisk__:__615857__:__2-OXOGLUTARATE- AND IRON-DEPENDENT OXYGENASE DOMAIN-CONTAINING PROTEIN 1; OGFOD1__:____:__
Asterisk__:__615858__:__ROUND SPERMATID BASIC PROTEIN 1; RSBN1__:__ROSBIN__:__
Number Sign__:__615859__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 23; EIEE23__:____:__
Number Sign__:__615860__:__CONE-ROD DYSTROPHY 19; CORD19__:____:__
Number Sign__:__615861__:__NEPHROTIC SYNDROME, TYPE 10; NPHS10__:____:__
Number Sign__:__615862__:__NEPHRONOPHTHISIS 18; NPHP18__:____:__
Number Sign__:__615863__:__DIARRHEA 7, PROTEIN-LOSING ENTEROPATHY TYPE; DIAR7__:____:__
Asterisk__:__615864__:__CENTROSOMAL PROTEIN, 97-KD; CEP97__:____:__
Asterisk__:__615865__:__NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 4; NEURL4__:__KIAA1787__:__
Number Sign__:__615866__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 27; MRD27__:____:__
Asterisk__:__615867__:__TBC1 DOMAIN FAMILY, MEMBER 32; TBC1D32__:__BROAD-MINDED, MOUSE, HOMOLOG OF; BROMI__:__
Asterisk__:__615868__:__SERINE PEPTIDASE INHIBITOR, KAZAL-TYPE, 6; SPINK6__:____:__
Asterisk__:__615869__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 8-LIKE 1; TNFAIP8L1__:__TNFAIP8-LIKE 1; TIPE1;; OXI-BETA__:__
Asterisk__:__615870__:__INTRAFLAGELLAR TRANSPORT 27, CHLAMYDOMONAS, HOMOLOG OF; IFT27__:__RAB-LIKE PROTEIN 4; RABL4;; BBS19 GENE__:__
Number Sign__:__615871__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 24; EIEE24__:____:__
Number Sign__:__615872__:__CILIARY DYSKINESIA, PRIMARY, 29; CILD29__:__CILIARY DYSKINESIA, PRIMARY, 29, WITHOUT SITUS INVERSUS__:__
Number Sign__:__615873__:__HELSMOORTEL-VAN DER AA SYNDROME; HVDAS__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 28; MRD28__:__
Asterisk__:__615874__:__RIBOSOMAL L1 DOMAIN-CONTAINING PROTEIN 1; RSL1D1__:__CELLULAR SENESCENCE-INHIBITED GENE; CSIG;; PBK1__:__
Asterisk__:__615875__:__RWD DOMAIN-CONTAINING PROTEIN 3; RWDD3__:__RWD-CONTAINING SUMOYLATION ENHANCER; RSUME__:__
Asterisk__:__615876__:__RADIAL SPOKE HEAD 3, CHLAMYDOMONAS, HOMOLOG OF; RSPH3__:__RADIAL SPOKEHEAD-LIKE 2; RSHL2;; RADIAL SPOKE PROTEIN 3; RSP3__:__
Number Sign__:__615877__:__MICROPHTHALMIA/COLOBOMA AND SKELETAL DYSPLASIA SYNDROME; MCSKS__:__MICROPHTHALMIA OR COLOBOMA WITH OR WITHOUT RHIZOMELIC SKELETAL DYSPLASIA;; MICROPHTHALMIA, SYNDROMIC 14; MCOPS14__:__
Number Sign__:__615878__:__CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 4; PFIC4__:____:__
Number Sign__:__615879__:__TATTON-BROWN-RAHMAN SYNDROME; TBRS__:____:__
Asterisk__:__615880__:__RHO GTPase-ACTIVATING PROTEIN 39; ARHGAP39__:__VILSE;; KIAA1688__:__
Number Sign__:__615881__:__PLASMA TRIGLYCERIDE LEVEL QUANTITATIVE TRAIT LOCUS; TGQTL__:____:__
Asterisk__:__615882__:__RAB GTPase-ACTIVATING PROTEIN 1; RABGAP1__:__GTPase-ACTIVATING PROTEIN, CENTROSOME-ASSOCIATED; GAPCENA;; TBC1 DOMAIN FAMILY, MEMBER 11; TBC1D11__:__
Number Sign__:__615883__:__MYOPATHY, TUBULAR AGGREGATE, 2; TAM2__:____:__
Asterisk__:__615884__:__ADIPOCYTE PLASMA MEMBRANE-ASSOCIATED PROTEIN; APMAP__:__CHROMOSOME 20 OPEN READING FRAME 3; C20ORF3;; BSCV__:__
Number Sign__:__615885__:__HYPOTRICHOSIS 12; HYPT12__:____:__
Asterisk__:__615886__:__FAMILY WITH SEQUENCE SIMILARITY 83, MEMBER G; FAM83G__:__PROTEIN ASSOCIATED WITH SMAD1; PAWS1__:__
Number Sign__:__615887__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA5; AI2A5__:____:__
Number Sign__:__615888__:__BLEEDING DISORDER, PLATELET-TYPE, 18; BDPLT18__:____:__
Number Sign__:__615889__:__LEUKOENCEPHALOPATHY, PROGRESSIVE, WITH OVARIAN FAILURE; LKENP__:____:__
Asterisk__:__615890__:__DYNEIN, CYTOPLASMIC 1, LIGHT INTERMEDIATE CHAIN 1; DYNC1LI1__:__LIGHT INTERMEDIATE CHAIN 1; LIC1;; DYNEIN LIGHT CHAIN A__:__
Asterisk__:__615891__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 8, OPPOSITE STRAND; ZBTB8OS__:__ARCHEASE; ARCH__:__
Percent__:__615892__:__OROFACIAL CLEFT 14; OFC14__:____:__
Asterisk__:__615893__:__NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 1B; NEURL1B__:__NEURALIZED 2; NEUR2__:__
Asterisk__:__615894__:__ZINC FINGER PROTEIN 407; ZNF407__:____:__
Number Sign__:__615895__:__POLYGLUCOSAN BODY MYOPATHY 1 WITH OR WITHOUT IMMUNODEFICIENCY; PGBM1__:__POLYGLUCOSAN BODY MYOPATHY, EARLY-ONSET, WITH OR WITHOUT IMMUNODEFICIENCY; PBMEI__:__
Number Sign__:__615896__:__HYPOTRICHOSIS 13; HYPT13__:__HYPOTRICHOSIS WITH WOOLLY HAIR__:__
Number Sign__:__615897__:__IMMUNODEFICIENCY 24; IMD24__:____:__
Asterisk__:__615898__:__NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 7; NDUFAF7__:__MITOCHONDRIAL DYSFUNCTION PROTEIN A, DICTYOSTELIUM, HOMOLOG OF; MIDA__:__
Asterisk__:__615899__:__OLFACTOMEDIN-LIKE 2A; OLFML2A__:____:__
Asterisk__:__615900__:__AATP/GTP-BINDING PROTEIN-LIKE 5; AGBL5__:__CYTOSOLIC CARBOXYPEPTIDASE 5; CCP5__:__
Asterisk__:__615901__:__NONSPECIFIC CYTOTOXIC CELL RECEPTOR PROTEIN 1, ZEBRAFISH, HOMOLOG OF; NCCRP1__:__F-BOX ONLY PROTEIN 50; FBXO50__:__
Asterisk__:__615902__:__PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, GAMMA; PPP2R3C__:__G5PR__:__
Asterisk__:__615903__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 10; CHCHD10__:____:__
Asterisk__:__615904__:__PEROXIDASIN, DROSOPHILA, HOMOLOG-LIKE; PXDNL__:__POLYSOMAL RIBONUCLEASE 1, XENOPUS, HOMOLOG OF; PMR1;; VASCULAR PEROXIDASE 2; VPO2__:__
Number Sign__:__615905__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 25; EIEE25__:____:__
Asterisk__:__615906__:__RING FINGER PROTEIN 219; RNF219__:__CHROMOSOME 13 OPEN READING FRAME 7; C13ORF7__:__
Number Sign__:__615907__:__LYMPHATIC MALFORMATION 4; LMPHM4__:__LYMPHEDEMA, HEREDITARY, ID, FORMERLY; LMPH1D, FORMERLY__:__
Asterisk__:__615908__:__MICRO RNA 520C; MIR520C__:__miRNA520C__:__
Number Sign__:__615909__:__DIAMOND-BLACKFAN ANEMIA 13; DBA13__:____:__
Asterisk__:__615910__:__NAD(P)HX DEHYDRATASE; NAXD__:__CARBOHYDRATE KINASE DOMAIN-CONTAINING PROTEIN; CARKD;; (S)-NADPH-HYDRATE DEHYDRATASE, ATP-DEPENDENT__:__
Number Sign__:__615911__:__FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 2; FTDALS2__:____:__
Asterisk__:__615912__:__GLUTATHIONE S-TRANSFERASE C-TERMINAL DOMAIN-CONTAINING PROTEIN; GSTCD__:____:__
Asterisk__:__615913__:__PEPTIDASE M20 DOMAIN-CONTAINING PROTEIN 2; PM20D2__:__AMINOACYLASE 1-LIKE 2; ACY1L2__:__
Asterisk__:__615914__:__CYCLIN-DEPENDENT KINASE INHIBITOR 2A-INTERACTING PROTEIN; CDKN2AIP__:__CDKN2A-INTERACTING PROTEIN;; COLLABORATOR OF ARF; CARF__:__
Asterisk__:__615915__:__ZONA PELLUCIDA-LIKE DOMAIN-CONTAINING PROTEIN 1; ZPLD1__:____:__
Number Sign__:__615916__:__CARDIOMYOPATHY, DILATED, 1NN; CMD1NN__:____:__
Number Sign__:__615917__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 20; COXPD20__:____:__
Number Sign__:__615918__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 21; COXPD21__:____:__
Number Sign__:__615919__:__ATAXIA-TELANGIECTASIA-LIKE DISORDER 2; ATLD2__:____:__
Asterisk__:__615920__:__PROLINE-RICH PROTEIN 11; PRR11__:____:__
Asterisk__:__615921__:__PPARGC1- AND ESRR-INDUCED REGULATOR, MUSCLE, 1; PERM1__:__PGC1- AND ERR-INDUCED REGULATOR IN MUSCLE 1;; CHROMOSOME 1 OPEN READING FRAME 170; C1ORF170__:__
Number Sign__:__615922__:__RETINITIS PIGMENTOSA 70; RP70__:____:__
Number Sign__:__615923__:__EPIPHYSEAL CHONDRODYSPLASIA, MIURA TYPE; ECDM__:____:__
Number Sign__:__615924__:__ENCEPHALOPATHY, PROGRESSIVE, WITH OR WITHOUT LIPODYSTROPHY; PELD__:____:__
Number Sign__:__615925__:__GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL; GHDP__:____:__
Number Sign__:__615926__:__WEBB-DATTANI SYNDROME; WEDAS__:__HYPOTHALAMO-PITUITARY-FRONTOTEMPORAL HYPOPLASIA WITH VISUAL AND RENAL ANOMALIES__:__
Asterisk__:__615927__:__FAMILY WITH SEQUENCE SIMILARITY 101, MEMBER A; FAM101A__:__CFM2__:__
Asterisk__:__615928__:__FAMILY WITH SEQUENCE SIMILARITY 101, MEMBER B; FAM101B__:__CFM1__:__
Asterisk__:__615929__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 17; ANKRD17__:__GTAR__:__
Asterisk__:__615930__:__COLORECTAL ADENOCARCINOMA HYPERMETHYLATED GENE, NONCODING; CAHM__:__LONG INTERGENIC NONCODING RNA 468; LINC00468__:__
Asterisk__:__615931__:__PROLINE-RICH PROTEIN 16; PRR16__:__LARGEN__:__
Asterisk__:__615932__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 20; KCTD20__:____:__
Asterisk__:__615933__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 10; BTBD10__:____:__
Number Sign__:__615934__:__STING-ASSOCIATED VASCULOPATHY, INFANTILE-ONSET; SAVI__:____:__
Number Sign__:__615935__:__PANCREATIC AGENESIS 2; PAGEN2__:__PANCREATIC HYPOPLASIA, CONGENITAL 2__:__
Asterisk__:__615936__:__RHO GTPase-ACTIVATING PROTEIN 42; ARHGAP42__:__GRAF3__:__
Number Sign__:__615937__:__MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 2; MPPH2__:____:__
Number Sign__:__615938__:__MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME 3; MPPH3__:____:__
Asterisk__:__615939__:__PROTEIN TYROSINE PHOSPHATASE-LIKE (PROLINE INSTEAD OF CATALYTIC ARGININE), MEMBER B; PTPLB__:__3-HYDROXYACYL-CoA DEHYDRATASE 2; HACD2;; VERY LONG CHAIN-3-HYDROXYACYL-CoA DEHYDRATASE 2__:__
Asterisk__:__615940__:__PROTEIN TYROSINE PHOSPHATASE-LIKE A DOMAIN-CONTAINING PROTEIN 1; PTPLAD1__:__BUTYRATE-INDUCED PROTEIN 1; BIND1;; 3-HYDROXYACYL-CoA DEHYDRATASE 3; HACD3;; VERY LONG CHAIN-3-HYDROXYACYL-CoA DEHYDRATASE 3__:__
Asterisk__:__615941__:__PROTEIN TYROSINE PHOSPHATASE-LIKE A DOMAIN-CONTAINING PROTEIN 2; PTPLAD2__:__3-HYDROXYACYL-CoA DEHYDRATASE 4; HACD4;; VERY LONG CHAIN-3-HYDROXYACYL-CoA DEHYDRATASE 4__:__
Number Sign__:__615942__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 44; MRT44__:____:__
Asterisk__:__615943__:__MEMBRANE-ASSOCIATED GUANYLATE KINASE, WW AND PDZ DOMAINS-CONTAINING, 3; MAGI3__:__MEMBRANE-ASSOCIATED GUANYLATE KINASE WITH INVERTED STRUCTURE 3; MAGI3;; KIAA1634__:__
Asterisk__:__615944__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 3; C2CD3__:____:__
Number Sign__:__615945__:__SPINOCEREBELLAR ATAXIA 37; SCA37__:____:__
Number Sign__:__615946__:__MYOPIA 24, AUTOSOMAL DOMINANT; MYP24__:____:__
Number Sign__:__615947__:__HYPERLIPOPROTEINEMIA, TYPE ID__:____:__
Number Sign__:__615948__:__OROFACIODIGITAL SYNDROME XIV; OFD14__:____:__
Asterisk__:__615949__:__TRANSMEMBRANE PROTEIN 98; TMEM98__:____:__
Asterisk__:__615950__:__SPEG COMPLEX LOCUS; SPEG__:____:__AORTIC PREFERENTIALLY EXPRESSED PROTEIN 1, INCLUDED; APEG1, INCLUDED;; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN, ALPHA, INCLUDED;; SPEG-ALPHA, INCLUDED;; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN, BETA, INCLUDED;; SPEG-BETA, INCLUDED;; BRAIN PREFERENTIALLY EXPRESSED PROTEIN, INCLUDED; BPEG, INCLUDED
Asterisk__:__615951__:__ZINC FINGER SWIM DOMAIN-CONTAINING PROTEIN 6; ZSWIM6__:__KIAA1577__:__
Number Sign__:__615952__:__AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1; ADMIO1__:____:__
Number Sign__:__615953__:__KALLIKREIN, DECREASED URINARY ACTIVITY OF__:____:__
Number Sign__:__615954__:__ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2__:__PRIMARY MACRONODULAR ADRENAL HYPERPLASIA__:__
Asterisk__:__615955__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 183; CCDC183__:__KIAA1984__:__
Asterisk__:__615956__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 151; CCDC151__:____:__
Number Sign__:__615957__:__SPINOCEREBELLAR ATAXIA 38; SCA38__:____:__
Asterisk__:__615958__:__SLX4-INTERACTING PROTEIN; SLX4IP__:__CHROMOSOME 20 OPEN READING FRAME 94; C20ORF94__:__
Number Sign__:__615959__:__MYOPATHY, CENTRONUCLEAR, 5; CNM5__:____:__
Number Sign__:__615960__:__PORETTI-BOLTSHAUSER SYNDROME; PTBHS__:____:__
Number Sign__:__615961__:__ACID-LABILE SUBUNIT DEFICIENCY; ACLSD__:____:__
Number Sign__:__615962__:__GLUCOCORTICOID RESISTANCE, GENERALIZED; GCCR__:__GLUCOCORTICOID RECEPTOR DEFICIENCY;; GCCR DEFICIENCY;; GCR DEFICIENCY;; GRL DEFICIENCY;; CORTISOL RESISTANCE FROM GLUCOCORTICOID RECEPTOR DEFECT__:__
Number Sign__:__615963__:__VESICOURETERAL REFLUX 8; VUR8__:____:__
Asterisk__:__615964__:__MIR99A-LET7C CLUSTER HOST GENE, NONCODING; MIR99AHG__:__MEGAKARYOCYTIC ONCOGENIC NONCODING RNA; MONC;; LONG INTERGENIC NONCODING RNA 478; LINC00478;; lincRNA 478__:__
Asterisk__:__615965__:__MIR100-LET7A2 CLUSTER HOST GENE, NONCODING; MIR100HG__:__ADIPOGENESIS-DOWNREGULATED TRANSCRIPT 1; AGD1;; LONG NONCODING RNA, NEURONAL, 2;; lncRNA-N2__:__
Number Sign__:__615966__:__IMMUNODEFICIENCY 26 WITH OR WITHOUT NEUROLOGIC ABNORMALITIES; IMD26__:____:__
Asterisk__:__615967__:__CYTOCHROME P450, FAMILY 2, SUBFAMILY W, POLYPEPTIDE 1; CYP2W1__:____:__
Asterisk__:__615968__:__MYCN UPSTREAM TRANSCRIPT, NONCODING; MYCNUT__:__LONG NONCODING RNA UPSTREAM OF MYCN;; lncUSMYCN__:__
Number Sign__:__615969__:__ALPHA-FETOPROTEIN DEFICIENCY; AFPD__:____:__
Number Sign__:__615970__:__ALPHA-FETOPROTEIN, HEREDITARY PERSISTENCE OF; HPAFP__:____:__
Caret__:__615971__:__REMOVED FROM DATABASE__:____:__
Number Sign__:__615972__:__NANOPHTHALMOS 4; NNO4__:__NANOPHTHALMIA 4__:__
Number Sign__:__615973__:__CONE-ROD DYSTROPHY 20; CORD20__:____:__
Number Sign__:__615974__:__DEAFNESS, AUTOSOMAL RECESSIVE 102; DFNB102__:____:__
Asterisk__:__615975__:__TRANSMEMBRANE PROTEIN 129; TMEM129__:____:__
Asterisk__:__615976__:__FOXC1 UPSTREAM TRANSCRIPT, NONCODING; FOXCUT__:__LONG INTERGENIC NONCODING RNA 1379; LINC01379;; TCONS_00011636__:__
Asterisk__:__615977__:__MICRO RNA 339; MIR339__:__miRNA339;; MIR339-5p__:__
Number Sign__:__615978__:__IMMUNODEFICIENCY 27B; IMD27B__:__IMMUNODEFICIENCY 27B, MYCOBACTERIOSIS, AUTOSOMAL DOMINANT;; IFNGR1 DEFICIENCY, AUTOSOMAL DOMINANT__:__
Number Sign__:__615979__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 45; MRT45__:____:__
Number Sign__:__615980__:__LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 6; FPLD6__:__LIPODYSTROPHY, FAMILIAL PARTIAL, ASSOCIATED WITH LIPE MUTATIONS__:__
Number Sign__:__615981__:__BARDET-BIEDL SYNDROME 2; BBS2__:____:__
Number Sign__:__615982__:__BARDET-BIEDL SYNDROME 4; BBS4__:____:__
Number Sign__:__615983__:__BARDET-BIEDL SYNDROME 5; BBS5__:____:__
Number Sign__:__615984__:__BARDET-BIEDL SYNDROME 7; BBS7__:____:__
Number Sign__:__615985__:__BARDET-BIEDL SYNDROME 8; BBS8__:____:__
Number Sign__:__615986__:__BARDET-BIEDL SYNDROME 9; BBS9__:____:__
Number Sign__:__615987__:__BARDET-BIEDL SYNDROME 10; BBS10__:____:__
Number Sign__:__615988__:__BARDET-BIEDL SYNDROME 11; BBS11__:____:__
Number Sign__:__615989__:__BARDET-BIEDL SYNDROME 12; BBS12__:____:__
Number Sign__:__615990__:__BARDET-BIEDL SYNDROME 13; BBS13__:____:__
Number Sign__:__615991__:__BARDET-BIEDL SYNDROME 14; BBS14__:____:__
Number Sign__:__615992__:__BARDET-BIEDL SYNDROME 15; BBS15__:____:__
Number Sign__:__615993__:__BARDET-BIEDL SYNDROME 16; BBS16__:____:__
Number Sign__:__615994__:__BARDET-BIEDL SYNDROME 17; BBS17__:____:__
Number Sign__:__615995__:__BARDET-BIEDL SYNDROME 18; BBS18__:____:__
Number Sign__:__615996__:__BARDET-BIEDL SYNDROME 19; BBS19__:____:__
Asterisk__:__615997__:__DEFENSIN, BETA, 119; DEFB119__:__DEFENSIN, BETA, 19; DEFB19__:__DEFENSIN, BETA, 120, INCLUDED; DEFB120, INCLUDED;; DEFENSIN, BETA, 20, INCLUDED; DEFB20, INCLUDED
Asterisk__:__615998__:__RING FINGER PROTEIN 10; RNF10__:__KIAA0262__:__
Number Sign__:__615999__:__HYPERTHYROXINEMIA, FAMILIAL DYSALBUMINEMIC; FDAH__:__FDH;; EUTHYROID HYPERTHYROXINEMIA 1__:__
Number Sign__:__616000__:__ANALBUMINEMIA; ANALBA__:____:__
Number Sign__:__616001__:__BREASTS AND/OR NIPPLES, APLASIA OR HYPOPLASIA OF, 2; BNAH2__:____:__
Number Sign__:__616002__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7; FSGS7__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 7__:__
Asterisk__:__616003__:__APOPTOGENIC PROTEIN 1, MITOCHONDRIAL; APOPT1__:__APOPTOGENIC PROTEIN; APOP__:__
Number Sign__:__616004__:__DYSFIBRINOGENEMIA, CONGENITAL__:____:__HYPODYSFIBRINOGENEMIA, CONGENITAL, INCLUDED
Number Sign__:__616005__:__IMMUNODEFICIENCY 36; IMD36__:____:__
Number Sign__:__616006__:__HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 2; HKLLS2__:____:__
Number Sign__:__616007__:__CATARACTS, GROWTH HORMONE DEFICIENCY, SENSORY NEUROPATHY, SENSORINEURAL HEARING LOSS, AND SKELETAL DYSPLASIA; CAGSSS__:____:__
Asterisk__:__616008__:__COP9 SIGNALOSOME, SUBUNIT 4; COPS4__:__CSN4__:__
Asterisk__:__616009__:__COP9 SIGNALOSOME, SUBUNIT 7A; COPS7A__:__CSN7__:__
Asterisk__:__616010__:__COP9 SIGNALOSOME, SUBUNIT 7B; COPS7B__:____:__
Asterisk__:__616011__:__COP9 SIGNALOSOME, SUBUNIT 8; COPS8__:__CSN8__:__
Asterisk__:__616012__:__JAGUNAL, DROSOPHILA, HOMOLOG OF, 1; JAGN1__:____:__
Asterisk__:__616013__:__tRNA METHYLTRANSFERASE 10, S. CEREVISIAE, HOMOLOG OF, A; TRMT10A__:__RNA (GUANINE-9-)METHYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 2; RG9MTD2__:__
Asterisk__:__616014__:__RING FINGER PROTEIN 25; RNF25__:__RING FINGER PROTEIN AO7; AO7__:__
Asterisk__:__616015__:__RING FINGER PROTEIN 180; RNF180__:__RING FINGER PROTEIN IN NEURAL STEM CELLS; RINES__:__
Asterisk__:__616016__:__PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1H; PPM1H__:__KIAA1157__:__
Asterisk__:__616017__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 69; TRIM69__:__TESTIS-SPECIFIC RING FINGER PROTEIN; TRIF;; RING FINGER PROTEIN 36; RNF36__:__
Caret__:__616018__:__REMOVED FROM DATABASE__:____:__
Asterisk__:__616019__:__REST COREPRESSOR 2; RCOR2__:____:__
Asterisk__:__616020__:__CYSTEINE/TYROSINE-RICH PROTEIN 1; CYYR1__:____:__
Asterisk__:__616021__:__CYYR1 ANTISENSE RNA 1; CYYR1AS1__:____:__
Number Sign__:__616022__:__NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6__:____:__
Asterisk__:__616023__:__SR-RELATED C-TERMINAL DOMAIN-ASSOCIATED FACTOR 4; SCAF4__:__SR-RELATED CTD-ASSOCIATED FACTOR 4;; PRE-mRNA SPLICING SR PROTEIN RA4;; KIAA1172__:__
Asterisk__:__616024__:__SR-RELATED C-TERMINAL DOMAIN-ASSOCIATED FACTOR 8; SCAF8__:__SR-RELATED CTD-ASSOCIATED FACTOR 8;; PRE-mRNA-SPLICING SR PROTEIN RA8;; KIAA1116__:__
Number Sign__:__616025__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 11; GPIBD11__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 5; HPMRS5__:__
Number Sign__:__616026__:__FANCONI RENOTUBULAR SYNDROME 4 WITH MATURITY-ONSET DIABETES OF THE YOUNG; FRTS4__:__FRTS4 WITH MODY__:__
Asterisk__:__616027__:__ACTIN-BINDING PROTEIN ANILLIN; ANLN__:____:__
Number Sign__:__616028__:__ADAMS-OLIVER SYNDROME 5; AOS5__:____:__
Number Sign__:__616029__:__ECTODERMAL DYSPLASIA/SHORT STATURE SYNDROME; ECTDS__:____:__
Number Sign__:__616030__:__HYPOGONADOTROPIC HYPOGONADISM 22 WITH OR WITHOUT ANOSMIA; HH22__:____:__
Asterisk__:__616031__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 141; CCDC141__:__COILED-COIL PROTEIN ASSOCIATED WITH MYOSIN II AND DISC1; CAMDI__:__
Number Sign__:__616032__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 8; FSGS8__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 8__:__
Number Sign__:__616033__:__MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 1; MSSGM1__:__MSSGM__:__
Number Sign__:__616034__:__2,4-DIENOYL-CoA REDUCTASE DEFICIENCY; DECRD__:____:__
Asterisk__:__616035__:__FORKHEAD BOX J3; FOXJ3__:__KIAA1041__:__
Asterisk__:__616036__:__MICRO RNA 494; MIR494__:__miRNA494__:__
Number Sign__:__616037__:__CILIARY DYSKINESIA, PRIMARY, 30; CILD30__:__CILIARY DYSKINESIA, PRIMARY, 30, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__616038__:__NEU-LAXOVA SYNDROME 2; NLS2__:____:__
Number Sign__:__616039__:__CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID__:____:__
Number Sign__:__616040__:__MYASTHENIC SYNDROME, CONGENITAL, 7, PRESYNAPTIC; CMS7__:__MYASTHENIC SYNDROME, PRESYNAPTIC, CONGENITAL, WITH OR WITHOUT MOTOR NEUROPATHY; MYSPC__:__
Asterisk__:__616041__:__THIOSULFATE SULFURTRANSFERASE (RHODANESE)-LIKE DOMAIN-CONTAINING PROTEIN 1; TSTD1__:__KAT__:__
Number Sign__:__616042__:__DEAFNESS, AUTOSOMAL RECESSIVE 103; DFNB103__:____:__
Asterisk__:__616043__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 1, NONCODING; PCAT1__:____:__
Number Sign__:__616044__:__DEAFNESS, AUTOSOMAL DOMINANT 65; DFNA65__:____:__
Number Sign__:__616045__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 22; COXPD22__:____:__
Asterisk__:__616046__:__PROLINE/SERINE/THREONINE PHOSPHATASE-INTERACTING PROTEIN 2; PSTPIP2__:__MACROPHAGE ACTIN-ASSOCIATED TYROSINE-PHOSPHORYLATED PROTEIN; MAYP__:__
Asterisk__:__616047__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 97; CFAP97__:__HEMINGWAY, DROSOPHILA, HOMOLOG OF; HMW;; KIAA1430__:__
Asterisk__:__616048__:__ALU-MEDIATED CDKN1A/p21 TRANSCRIPTIONAL REGULATOR, NONCODING; APTR__:__LONG NONCODING RNA APTR;; lncRNA APTR__:__
Asterisk__:__616049__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 34, YEAST, HOMOLOG OF; TOMM34__:__TOM34__:__
Number Sign__:__616050__:__AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS; AIFEC__:____:__
Number Sign__:__616051__:__MICROCEPHALY 13, PRIMARY, AUTOSOMAL RECESSIVE; MCPH13__:____:__
Number Sign__:__616052__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 7; MDDGC7__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 20; LGMDR20;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2U; LGMD2U__:__
Number Sign__:__616053__:__SPINOCEREBELLAR ATAXIA 40; SCA40__:____:__
Asterisk__:__616054__:__ELONGATOR ACETYLTRANSFERASE COMPLEX, SUBUNIT 2; ELP2__:__STAT-INTERACTING PROTEIN 1; STATIP1__:__
Percent__:__616055__:__EPISODIC ATAXIA, TYPE 8; EA8__:____:__
Number Sign__:__616056__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 26; EIEE26__:____:__
Asterisk__:__616057__:__TUMOR SUPPRESSOR CANDIDATE 7, NONCODING; TUSC7__:__LONG NONCODING RNA LOC285194;; lncRNA LOC285194;; LSAMP ANTISENSE RNA 3; LSAMPAS3__:__
Asterisk__:__616058__:__TCF21 ANTISENSE RNA INDUCING PROMOTER DEMETHYLATION; TARID__:____:__
Number Sign__:__616059__:__MIRROR MOVEMENTS 3; MRMV3__:____:__
Number Sign__:__616060__:__BLOOD GROUP, DOMBROCK SYSTEM; DO__:__DOMBROCK BLOOD GROUP SYSTEM__:__
Asterisk__:__616061__:__MAX DIMERIZATION PROTEIN MGA; MGA__:__KIAA0518__:__
Asterisk__:__616062__:__ANKYRIN REPEAT- AND LEM DOMAIN-CONTAINING PROTEIN 2; ANKLE2__:__LEM DOMAIN-CONTAINING PROTEIN 4; LEM4;; KIAA0692__:__
Number Sign__:__616063__:__POROKERATOSIS 8, DISSEMINATED SUPERFICIAL ACTINIC TYPE; POROK8__:____:__
Asterisk__:__616064__:__TUBULOINTERSTITIAL NEPHRITIS ANTIGEN-LIKE PROTEIN 1; TINAGL1__:__TINAG-LIKE PROTEIN 1;; TINAG-RELATED PROTEIN; TINAGRP__:__
Asterisk__:__616065__:__PILR-ALPHA-ASSOCIATED NEURAL PROTEIN; PIANP__:__PILRA-ASSOCIATED NEURAL PROTEIN; PANP;; LIVER ENDOTHELIAL DIFFERENTIATION-ASSOCIATED PROTEIN, 1; LEDA1__:__
Asterisk__:__616066__:__SPERMATOGENESIS- AND OOGENESIS-SPECIFIC BASIC HELIX-LOOP-HELIX PROTEIN 2; SOHLH2__:____:__
Number Sign__:__616067__:__46,XY SEX REVERSAL 9; SRXY9__:__46,XY SEX REVERSAL, ZFPM2-RELATED__:__
Asterisk__:__616068__:__HOXA CLUSTER ANTISENSE RNA 2; HOXAAS2__:__LONG INTERGENIC NONCODING RNA HOXAAS2;; lincRNA HOXAAS2__:__
Number Sign__:__616069__:__INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2; NISBD2__:____:__
Asterisk__:__616070__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 113; CCDC113__:____:__
Asterisk__:__616071__:__CHROMOSOME 7 OPEN READING FRAME 31; C7ORF31__:____:__
Asterisk__:__616072__:__HETEROCHROMATIN PROTEIN 1-BINDING PROTEIN 3; HP1BP3__:__HP1-BINDING PROTEIN 74; HP1BP74__:__
Asterisk__:__616073__:__DEP DOMAIN-CONTAINING PROTEIN 1B; DEPDC1B__:____:__
Asterisk__:__616074__:__CHEMOKINE-LIKE FACTOR; CKLF__:__HSPC224__:__
Asterisk__:__616075__:__DEFENSIN, BETA, 121; DEFB121__:__DEFENSIN, BETA, 21; DEFB21__:__
Asterisk__:__616076__:__DEFENSIN, BETA, 123; DEFB123__:__DEFENSIN, BETA, 23; DEFB23__:__
Asterisk__:__616077__:__DEFENSIN, BETA, 122, PSEUDOGENE; DEFB122__:__DEFB122P;; DEFENSIN, BETA, 22; DEFB22;; DEFB22P__:__
Number Sign__:__616078__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 29; MRD29__:____:__
Number Sign__:__616079__:__RETINAL DYSTROPHY WITH INNER RETINAL DYSFUNCTION AND GANGLION CELL ABNORMALITIES; RDGCA__:____:__
Number Sign__:__616080__:__MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE; MCPH12__:____:__
Number Sign__:__616081__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 1C; PCH1C__:__HYPOMYELINATION WITH SPINAL MUSCULAR ATROPHY AND CEREBELLAR HYPOPLASIA__:__
Asterisk__:__616082__:__CHROMOSOME 12 OPEN READING FRAME 4; C12ORF4__:____:__
Number Sign__:__616083__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 30; MRD30__:____:__
Number Sign__:__616084__:__SIDEROBLASTIC ANEMIA WITH B-CELL IMMUNODEFICIENCY, PERIODIC FEVERS, AND DEVELOPMENTAL DELAY; SIFD__:____:__
Asterisk__:__616085__:__ZINC FINGER PROTEIN 37A; ZNF37A__:__KOX21;; ZNF37__:__
Asterisk__:__616086__:__SprT-LIKE N-TERMINAL DOMAIN PROTEIN; SPRTN__:__SprT-LIKE DOMAIN AT N TERMINUS;; SPARTAN;; DNA DAMAGE-TARGETING VCP ADAPTOR C1ORF124; DVC1;; CHROMOSOME 1 OPEN READING FRAME 124; C1ORF124__:__
Number Sign__:__616087__:__DIABETES MELLITUS, NONINSULIN-DEPENDENT, 5; NIDDM5__:____:__
Asterisk__:__616088__:__CHROMOSOME 1 OPEN READING FRAME 186; C1ORF186__:__REGULATOR OF HUMAN ERYTHROID CELL EXPANSION; RHEX__:__
Number Sign__:__616089__:__BLOOD GROUP, GERBICH SYSTEM; GE__:__GERBICH BLOOD GROUP SYSTEM__:__
Asterisk__:__616090__:__MICRO RNA 802; MIR802__:__miRNA802__:__
Asterisk__:__616091__:__METHYLTRANSFERASE-LIKE 17; METTL17__:__METHYLTRANSFERASE 11 DOMAIN-CONTAINING PROTEIN 1; METT11D1__:__
Asterisk__:__616092__:__FOCALLY AMPLIFIED LONG NONCODING RNA IN EPITHELIAL CANCER; FALEC__:__FOCALLY AMPLIFIED lncRNA ON CHROMOSOME 1; FAL1__:__
Number Sign__:__616093__:__BLOOD GROUP, ABO SYSTEM__:__ABO BLOOD GROUP SYSTEM__:__
Number Sign__:__616094__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 12; MDDGC12__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMK-RELATED__:__
Number Sign__:__616095__:__MONOCARBOXYLATE TRANSPORTER 1 DEFICIENCY; MCT1D__:____:__
Asterisk__:__616096__:__MYOSIN HEAVY CHAIN-ASSOCIATED RNA TRANSCRIPT, NONCODING; MHRT__:__LONG NONCODING RNA MHRT;; lncRNA MHRT;; MYHEART__:__
Asterisk__:__616097__:__UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX ASSEMBLY FACTOR 3; UQCC3__:__CHROMOSOME 11 OPEN READING FRAME 83; C11ORF83__:__
Number Sign__:__616098__:__IMMUNODEFICIENCY 37; IMD37__:____:__
Number Sign__:__616099__:__PALMOPLANTAR KERATODERMA AND WOOLLY HAIR; PPKWH__:____:__
Number Sign__:__616100__:__AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE V; ALPS5__:__CTLA4 HAPLOINSUFFICIENCY WITH AUTOIMMUNE INFILTRATION; CHAI__:__
Asterisk__:__616101__:__TRANSMEMBRANE PROTEIN 240; TMEM240__:__CHROMOSOME 1 OPEN READING FRAME 70; C1ORF70__:__
Asterisk__:__616102__:__THIOREDOXIN-RELATED TRANSMEMBRANE PROTEIN 3; TMX3__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 10; TXNDC10;; KIAA1830__:__
Asterisk__:__616103__:__LEUCINE-RICH REPEAT, IMMUNOGLOBULIN-LIKE, AND TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 1; LRIT1__:__PAL__:__
Asterisk__:__616104__:__RBPJ-LIKE PROTEIN; RBPJL__:__RBPL;; SUHL__:__
Asterisk__:__616105__:__SORTING NEXIN 14; SNX14__:____:__
Number Sign__:__616106__:__PSORIASIS 15, PUSTULAR, SUSCEPTIBILITY TO; PSORS15__:____:__
Asterisk__:__616107__:__FATTY ACYL CoA REDUCTASE 1; FAR1__:__MALE STERILITY DOMAIN-CONTAINING PROTEIN 2; MLSTD2__:__
Number Sign__:__616108__:__RETINAL DYSTROPHY, JUVENILE CATARACTS, AND SHORT STATURE SYNDROME; RDJCSS__:____:__
Asterisk__:__616109__:__CHROMOSOME 11 OPEN READING FRAME 80; C11ORF80__:__TOPOISOMERASE VI-B LIKE; TOPOVIBL;; TOPOVIB;; TOP6BL__:__FRAGILE SITE, FOLIC ACID TYPE, RARE, FRA(11)(q13.3), INCLUDED; FRA11A, INCLUDED
Asterisk__:__616110__:__DELTEX, DROSOPHILA, HOMOLOG OF, 4; DTX4__:__RING FINGER PROTEIN 155; RNF155;; KIAA0937__:__
Number Sign__:__616111__:__MITOCHONDRIAL COMPLEX III DEFICIENCY, NUCLEAR TYPE 9; MC3DN9__:____:__
Asterisk__:__616112__:__LEIOMODIN 3; LMOD3__:____:__
Number Sign__:__616113__:__POLYENDOCRINE-POLYNEUROPATHY SYNDROME; PEPNS__:____:__
Asterisk__:__616114__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 6; CHD6__:__CHD5;; RIGB__:__
Number Sign__:__616115__:__FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4__:____:__
Number Sign__:__616116__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 46; MRT46__:____:__
Number Sign__:__616117__:__CARDIAC CONDUCTION DISEASE WITH OR WITHOUT DILATED CARDIOMYOPATHY; CCDD__:____:__
Number Sign__:__616118__:__MACULAR DEGENERATION, EARLY-ONSET; EOMD__:____:__
Asterisk__:__616119__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 126; CFAP126__:__FLATTOP; FLTP__:__
Asterisk__:__616120__:__CWF19-LIKE PROTEIN 1; CWF19L1__:__C19L1__:__
NULL__:__616121__:__GTPase, VERY LARGE INTERFERON-INDUCIBLE, PSEUDOGENE 1; GVINP1__:__VERY LARGE INDUCIBLE GTPase 1; VLIG1__:__
Asterisk__:__616122__:__FAMILY WITH SEQUENCE SIMILARITY 86, MEMBER B1; FAM86B1__:____:__
Asterisk__:__616123__:__FAMILY WITH SEQUENCE SIMILARITY 86, MEMBER B2; FAM86B2__:____:__
Asterisk__:__616124__:__FAMILY WITH SEQUENCE SIMILARITY 86, MEMBER C1; FAM86C1__:__FAM86C__:__
Asterisk__:__616125__:__PROTEIN ARGININE METHYLTRANSFERASE 9; PRMT9__:__PRMT10__:__
Number Sign__:__616126__:__IMMUNODEFICIENCY 38 WITH BASAL GANGLIA CALCIFICATION; IMD38__:__IMMUNODEFICIENCY 38, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE;; ISG15 DEFICIENCY, AUTOSOMAL RECESSIVE__:__
Number Sign__:__616127__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 17; SCAR17__:____:__
Asterisk__:__616128__:__FAMILY WITH SEQUENCE SIMILARITY 89, MEMBER B; FAM89B__:__MAMMARY TUMOR VIRUS RECEPTOR, MOUSE, HOMOLOG OF; MTVR;; LEUCINE REPEAT ADAPTOR PROTEIN, 25-KD; LRAP25__:__
Asterisk__:__616129__:__LEUCINE-RICH ADAPTOR PROTEIN 1; LURAP1__:__LEUCINE REPEAT ADAPTOR PROTEIN, 35-KD, A; LRAP35A__:__
Asterisk__:__616130__:__LEUCINE-RICH ADAPTOR PROTEIN 1-LIKE; LURAP1L__:__LURAP1-LIKE;; LEUCINE REPEAT ADAPTOR PROTEIN, 35-KD, B; LRAP35B__:__
Asterisk__:__616131__:__GASTRIC CANCER-ASSOCIATED TRANSCRIPT 2, NONCODING; GACAT2__:__MTCL1 ANTISENSE RNA 1; MTCL1AS1;; LONG INTERGENIC NONCODING RNA 717;; lincRNA717__:__
Asterisk__:__616132__:__GASTRIC CANCER-ASSOCIATED TRANSCRIPT 3, NONCODING; GACAT3__:__LONG NONCODING RNA AC130170;; lncRNA AC130710;; LINC01458__:__
Asterisk__:__616133__:__MPV17-LIKE PROTEIN 2; MPV17L2__:____:__
Asterisk__:__616134__:__H3 HISTONE, FAMILY 3C; H3F3C__:__H3.5__:__
Asterisk__:__616135__:__INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 5; IFIT5__:__RETINOIC ACID- AND INTERFERON-INDUCED PROTEIN, 58-KD; RI58;; INTERFERON-STIMULATED PROTEIN, 58-KD; ISG58__:__
Asterisk__:__616136__:__RING FINGER PROTEIN 220; RNF220__:____:__
Asterisk__:__616137__:__MICRO RNA 873; MIR873__:__miRNA873__:__
Number Sign__:__616138__:__PERRAULT SYNDROME 5; PRLTS5__:____:__
Number Sign__:__616139__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 27; EIEE27__:____:__
Number Sign__:__616140__:__LEUKODYSTROPHY, HYPOMYELINATING, 9; HLD9__:____:__
Asterisk__:__616141__:__H2A HISTONE FAMILY, MEMBER Y2; H2AFY2__:__MACRO H2A2__:__
Asterisk__:__616142__:__FAMILY WITH SEQUENCE SIMILARITY 98, MEMBER B; FAM98B__:____:__
Asterisk__:__616143__:__LYSOPHOSPHOLIPASE II; LYPLA2__:__ACYL PROTEIN THIOESTERASE 2; APT2__:__
Asterisk__:__616144__:__WD REPEAT-CONTAINING PROTEIN 73; WDR73__:__HSPC264__:__
Number Sign__:__616145__:__CATEL-MANZKE SYNDROME; CATMANS__:__HYPERPHALANGY-CLINODACTYLY OF INDEX FINGER WITH PIERRE ROBIN SYNDROME;; PIERRE ROBIN SYNDROME WITH HYPERPHALANGY AND CLINODACTYLY;; INDEX FINGER ANOMALY WITH PIERRE ROBIN SYNDROME;; PALATODIGITAL SYNDROME, CATEL-MANZKE TYPE;; MICROGNATHIA DIGITAL SYNDROME__:__
Asterisk__:__616146__:__TDP-GLUCOSE 4,6-DEHYDRATASE; TGDS__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 2E, MEMBER 1; SDR2E1;; GROWTH-INHIBITING PROTEIN 21__:__
Asterisk__:__616147__:__CYCLIN-DEPENDENT KINASE 15; CDK15__:__PFTAIRE PROTEIN KINASE 2; PFTAIRE2;; ALS2 CHROMOSOME REGION GENE 7; ALS2CR7__:__
Asterisk__:__616148__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 59; TRIM59__:__RING FINGER PROTEIN 104; RNF104;; MOUSE RING FINGER 1, HOMOLOG OF; MRF1__:__IFT80-LONG, INCLUDED; IFT80L, INCLUDED
Asterisk__:__616149__:__SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, PYRIMIDINE NUCLEOTIDE TRANSPORTER), MEMBER 36; SLC25A36__:__PYRIMIDINE NUCLEOTIDE CARRIER 2; PNC2__:__
Asterisk__:__616150__:__SOLUTE CARRIER FAMILY 25, MEMBER 48; SLC25A48__:____:__
Number Sign__:__616151__:__MACULAR DYSTROPHY, VITELLIFORM, 4; VMD4__:____:__
Number Sign__:__616152__:__MACULAR DYSTROPHY, VITELLIFORM, 5; VMD5__:____:__
Asterisk__:__616153__:__SOLUTE CARRIER FAMILY 25, MEMBER 52; SLC25A52__:__MITOCHONDRIAL CARRIER TRIPLE REPEAT 2; MCART2__:__
Number Sign__:__616154__:__PEROXISOMAL FATTY ACYL-CoA REDUCTASE 1 DISORDER; PFCRD__:____:__
Number Sign__:__616155__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2S;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2S__:__
Asterisk__:__616156__:__FATTY ACYL CoA REDUCTASE 2; FAR2__:__MALE STERILITY DOMAIN-CONTAINING PROTEIN 1; MLSTD1__:__
Asterisk__:__616157__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 13; DHRS13__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 7C, MEMBER 5; SDR7C5__:__
Number Sign__:__616158__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 31; MRD31__:____:__
Asterisk__:__616159__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 11; DHRS11__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 24C, MEMBER 1; SDR24C1__:__
Asterisk__:__616160__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 7B; DHRS7B__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 32C, MEMBER 1; SDR32C1__:__
Asterisk__:__616161__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 7C; DHRS7C__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 32C, MEMBER 2; SDR32C2__:__
Asterisk__:__616162__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 39U, MEMBER 1; SDR39U1__:____:__
Asterisk__:__616163__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY, MEMBER 12; DHRS12__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 40C, MEMBER 1; SDR40C1__:__
Asterisk__:__616164__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 42E, MEMBER 1; SDR42E1__:____:__
Number Sign__:__616165__:__NEMALINE MYOPATHY 10; NEM10__:____:__
Number Sign__:__616166__:__AORTIC ANEURYSM, FAMILIAL THORACIC 9; AAT9__:__AORTIC ANEURYSM, THORACIC, WITH OR WITHOUT AORTIC DISSECTION__:__
Asterisk__:__616167__:__DCN1 DOMAIN-CONTAINING PROTEIN 3; DCUN1D3__:__SQUAMOUS CELL CARCINOMA-RELATED ONCOGENE 3; SCCRO3__:__
Asterisk__:__616168__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 6, YEAST, HOMOLOG OF; TOMM6__:__TOM6__:__
Asterisk__:__616169__:__TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 5, YEAST, HOMOLOG OF; TOMM5__:__TOM5__:__
Number Sign__:__616170__:__MACULAR DYSTROPHY WITH CENTRAL CONE INVOLVEMENT; CCMD__:____:__
Number Sign__:__616171__:__MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 2; MCCRP2__:____:__
Number Sign__:__616172__:__GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 9; GEFSP9__:__GEFS+, TYPE 9; GEFS+9__:__
Asterisk__:__616173__:__NUCLEAR SPECKLE SPLICING REGULATORY PROTEIN 1; NSRP1__:__NUCLEAR SPECKLE-RELATED PROTEIN, 70-KD; NSRP70;; COILED-COIL DOMAIN-CONTAINING PROTEIN 55; CCDC55__:__
Asterisk__:__616174__:__CYTOSKELETON-ASSOCIATED PROTEIN 2-LIKE; CKAP2L__:__RADIAL FIBER AND MITOTIC SPINDLE PROTEIN; RADMIS__:__
Asterisk__:__616175__:__UBIQUITIN-CONJUGATING ENZYME E2J 1; UBE2J1__:__UBC6E__:__
Number Sign__:__616176__:__BLEEDING DISORDER, PLATELET-TYPE, 19; BDPLT19__:____:__
Asterisk__:__616177__:__DDRGK DOMAIN-CONTAINING PROTEIN 1; DDRGK1__:__DASHURIN;; UFM1-BINDING PROTEIN CONTAINING A PCI DOMAIN 1; UFBP1;; CHROMOSOME 20 OPEN READING FRAME 116; C20ORF116__:__
Asterisk__:__616178__:__TRANSMEMBRANE PROTEIN 132E; TMEM132E__:____:__
Asterisk__:__616179__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 16; TXNDC16__:__KIAA1344;; ERp90__:__
Asterisk__:__616180__:__GOLGIN A8 FAMILY, MEMBER A; GOLGA8A__:__KIAA0855__:__
Asterisk__:__616181__:__ZINC FINGER PROTEIN 713; ZNF713__:____:__FRAGILE SITE, FOLIC ACID TYPE, RARE, FRA(7)(p11.2), INCLUDED; FRA7A, INCLUDED
Percent__:__616182__:__CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO__:__MONGE DISEASE__:__
Asterisk__:__616183__:__TRANSMEMBRANE PROTEIN 107; TMEM107__:__SCHLEI, MOUSE, HOMOLOG OF__:__
Asterisk__:__616184__:__CLUSTERED MITOCHONDRIA, D. DISCOIDEUM, HOMOLOG OF; CLUH__:__cluA, D. DISCOIDEUM, HOMOLOG OF;; CLU1, S. CEREVISIAE, HOMOLOG OF; CLU1;; KIAA0664__:__
Number Sign__:__616185__:__OVARIAN DYSGENESIS 4; ODG4__:____:__
Asterisk__:__616186__:__H19/IGF2-IMPRINTING CONTROL REGION__:__ICR1;; H19 ICR__:__
Number Sign__:__616187__:__EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7__:____:__
Number Sign__:__616188__:__RETINAL DYSTROPHY AND OBESITY; RDOB__:____:__
Asterisk__:__616189__:__CAP METHYLTRANSFERASE 1; CMTR1__:__METHYLTRANSFERASE 1; MTR1;; INTERFERON-STIMULATED GENE 95; ISG95;; FtsJ METHYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 2; FTSJD2;; KIAA0082__:__
Asterisk__:__616190__:__CAP METHYLTRANSFERASE 2; CMTR2__:__METHYLTRANSFERASE 2; MTR2;; FtsJ METHYLTRANSFERASE DOMAIN-CONTAINING PROTEIN 1; FTSJD1__:__
Asterisk__:__616191__:__DISCS LARGE-ASSOCIATED PROTEIN 4; DLGAP4__:__SAP90/PSD95-ASSOCIATED PROTEIN 4; SAPAP4;; KIAA0964__:__DLGAP4 NONCODING RNAS, INCLUDED;; DLGAP ncRNAS, INCLUDED
Number Sign__:__616192__:__ATAXIA, COMBINED CEREBELLAR AND PERIPHERAL, WITH HEARING LOSS AND DIABETES MELLITUS; ACPHD__:____:__
Number Sign__:__616193__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 47; MRT47__:____:__
Asterisk__:__616194__:__UTP15, U3 SMALL NUCLEOLAR RIBONUCLEOPROTEIN, S. CEREVISIAE, HOMOLOG OF; UTP15__:__U3 SMALL NUCLEOLAR RNA-ASSOCIATED PROTEIN 15__:__
Asterisk__:__616195__:__WD REPEAT-CONTAINING PROTEIN 43; WDR43__:__UTP5;; KIAA0007__:__
Asterisk__:__616196__:__DDB1- AND CUL4-ASSOCIATED FACTOR 13; DCAF13__:__WD REPEAT- AND SOF1 DOMAIN-CONTAINING PROTEIN 1; WDSOF1__:__
Asterisk__:__616197__:__NUCLEOLAR PROTEIN 10; NOL10__:__POLYGLUTAMINE-BINDING PROTEIN 5; PQBP5__:__
Number Sign__:__616198__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 23; COXPD23__:____:__
Number Sign__:__616199__:__POLYGLUCOSAN BODY MYOPATHY 2; PGBM2__:____:__
Number Sign__:__616200__:__RUIJS-AALFS SYNDROME; RJALS__:____:__
Number Sign__:__616201__:__CHRONIC ATRIAL AND INTESTINAL DYSRHYTHMIA; CAID__:____:__
Number Sign__:__616202__:__CEREBELLOFACIODENTAL SYNDROME; CFDS__:__CEREBELLAR-FACIAL-DENTAL SYNDROME__:__
Asterisk__:__616203__:__SOLUTE CARRIER FAMILY 38, MEMBER 9; SLC38A9__:__UPREGULATED IN LUNG CANCER 11; URLC11__:__
Number Sign__:__616204__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 18; SCAR18__:____:__
Asterisk__:__616205__:__MICRO RNA 648; MIR648__:__miRNA648__:__
Asterisk__:__616206__:__NEUROBLASTOMA-ASSOCIATED TRANSCRIPT 1, NONCODING; NBAT1__:__LONG NONCODING RNA NBAT1;; lncRNA NBAT1;; CANCER SUSCEPTIBILITY CANDIDATE 14; CASC14__:__
Asterisk__:__616207__:__NEGATIVE REGULATOR OF ANTIVIRAL RESPONSE, NONCODING; NRAV__:__LONG NONCODING RNA NRAV;; lncRNA NRAV;; DYNLL1 ANTISENSE RNA 1; DYNLL1AS1__:__
Number Sign__:__616208__:__AMYOTROPHIC LATERAL SCLEROSIS 22 WITH OR WITHOUT FRONTOTEMPORAL DEMENTIA; ALS22__:____:__
Number Sign__:__616209__:__MYOPATHY, ISOLATED MITOCHONDRIAL, AUTOSOMAL DOMINANT; IMMD__:____:__
Asterisk__:__616210__:__CHROMOSOME 4 OPEN READING FRAME 46; C4ORF46__:__RENAL CANCER DIFFERENTIATION GENE 1; RCDG1__:__
Number Sign__:__616211__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 28; EIEE28__:____:__
Number Sign__:__616212__:__LISSENCEPHALY 6 WITH MICROCEPHALY; LIS6__:____:__
Asterisk__:__616213__:__ZINC FINGER PROTEIN 292; ZNF292__:__ZFP292;; ZN16;; KIAA0530__:__
Number Sign__:__616214__:__HYPERPROINSULINEMIA__:____:__
Asterisk__:__616215__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 1; CREB3L1__:__OLD ASTROCYTE SPECIFICALLY INDUCED SUBSTANCE; OASIS__:__
Number Sign__:__616216__:__THROMBOCYTOPENIA 5; THC5__:__THROMBOCYTOPENIA 5 WITH INCREASED SUSCEPTIBILITY TO MALIGNANCY;; THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 5__:__
Number Sign__:__616217__:__NEPHRONOPHTHISIS 19; NPHP19__:____:__
Asterisk__:__616218__:__TBC1 DOMAIN FAMILY, MEMBER 13; TBC1D13__:____:__
Number Sign__:__616219__:__FIBROSIS OF EXTRAOCULAR MUSCLES, CONGENITAL, 5; CFEOM5__:____:__
Number Sign__:__616220__:__FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9; FSGS9__:__GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, 9__:__
Number Sign__:__616221__:__AMELOGENESIS IMPERFECTA, TYPE IH; AI1H__:____:__
Number Sign__:__616222__:__TEMPLE SYNDROME__:__UNIPARENTAL DISOMY, MATERNAL, CHROMOSOME 14__:__
Asterisk__:__616223__:__CHROMOSOME 19 OPEN READING FRAME 80; C19ORF80__:__ANGIOPOIETIN-LIKE PROTEIN 8; ANGPTL8;; LIPASE INHIBITION PROTEIN; LIPASIN__:__
Number Sign__:__616224__:__MYASTHENIC SYNDROME, CONGENITAL, 22; CMS22__:__PREPL DEFICIENCY__:__
Asterisk__:__616225__:__AUTOPHAGY 2, S. CEREVISIAE, HOMOLOG OF, A; ATG2A__:__KIAA0404__:__
Asterisk__:__616226__:__AUTOPHAGY 2, S. CEREVISIAE, HOMOLOG OF, B; ATG2B__:____:__
Number Sign__:__616227__:__MYASTHENIC SYNDROME, CONGENITAL, 15; CMS15__:__MYASTHENIC SYNDROME, CONGENITAL, WITHOUT TUBULAR AGGREGATES; CMSWTA__:__
Number Sign__:__616228__:__MYASTHENIC SYNDROME, CONGENITAL, 14; CMS14__:__MYASTHENIC SYNDROME, CONGENITAL, WITH TUBULAR AGGREGATES 3; CMSTA3__:__
Number Sign__:__616229__:__OSTEOGENESIS IMPERFECTA, TYPE XVI; OI16__:__OI, TYPE XVI__:__CHROMOSOME 11p11.2 DELETION SYNDROME, 91.3-KB, INCLUDED
Number Sign__:__616230__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8__:____:__
Number Sign__:__616231__:__MYOPATHY, VACUOLAR, WITH CASQ1 AGGREGATES; VMCQA__:____:__
Asterisk__:__616232__:__MEIOTIC KINETOCHORE FACTOR; MEIKIN__:__MEIOSIS-SPECIFIC KINETOCHORE PROTEIN__:__
Caret__:__616233__:__MOVED TO 614881__:____:__
Asterisk__:__616234__:__WD REPEAT- AND COILED-COIL-CONTAINING PROTEIN; WDCP__:__CHROMOSOME 2 OPEN READING FRAME 44; C2ORF44__:__
Asterisk__:__616235__:__KATANIN, p80 SUBUNIT, B-LIKE 1; KATNBL1__:__KATNB1-LIKE PROTEIN 1;; CHROMOSOME 15 OPEN READING FRAME 29; C15ORF29__:__
Asterisk__:__616236__:__CHONDROADHERIN-LIKE; CHADL__:____:__
Asterisk__:__616237__:__KINASE NONCATALYTIC C-LOBE DOMAIN-CONTAINING PROTEIN 1; KNDC1__:__KIND-CONTAINING PROTEIN 1;; VERY KIND PROTEIN; VKIND;; RASGEF DOMAIN-CONTAINING FAMILY, MEMBER 2; RASGEF2;; KIAA1768__:__
Asterisk__:__616238__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 49; ZBTB49__:__ZINC FINGER PROTEIN 509; ZNF509__:__
Number Sign__:__616239__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 24; COXPD24__:____:__
Asterisk__:__616240__:__OLIGODENDROCYTE MATURATION-ASSOCIATED LONG INTERGENIC NONCODING RNA; OLMALINC__:__LONG INTERGENIC NONCODING RNA 263; LINC00263;; lincRNA OLMALINC__:__OLMALINC ANTISENSE RNA, INCLUDED; OLMALINCAS, INCLUDED
Asterisk__:__616241__:__METEORIN-LIKE PROTEIN; METRNL__:__SUBFATIN__:__
Asterisk__:__616242__:__TRANSMEMBRANE AND COILED-COIL DOMAIN FAMILY, MEMBER 1; TMCC1__:__KIAA0779__:__
Asterisk__:__616243__:__KIAA0922 GENE; KIAA0922__:__TRANSMEMBRANE PROTEIN 131-LIKE; TMEM131L__:__
Asterisk__:__616244__:__COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING PROTEIN 2; CHCHD2__:____:__
Asterisk__:__616245__:__ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 4; EMC4__:__ER MEMBRANE PROTEIN COMPLEX, SUBUNIT 4;; TRANSMEMBRANE PROTEIN 85; TMEM85;; PROLIFERATION-INDUCING GENE 17; PIG17__:__
Asterisk__:__616246__:__MYOREGULIN; MRLN__:__MLN;; LINC00948__:__
Number Sign__:__616247__:__LONG QT SYNDROME 14; LQT14__:____:__
Number Sign__:__616248__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 6; LCCS6__:____:__
Number Sign__:__616249__:__LONG QT SYNDROME 15; LQT15__:____:__
Asterisk__:__616250__:__NACHT DOMAIN- AND WD REPEAT-CONTAINING PROTEIN 1; NWD1__:____:__
Asterisk__:__616251__:__TRPM8 CHANNEL-ASSOCIATED FACTOR 1; TCAF1__:__FAMILY WITH SEQUENCE SIMILARITY 115, MEMBER A; FAM115A;; KIAA0738__:__
Asterisk__:__616252__:__TRPM8 CHANNEL-ASSOCIATED FACTOR 2; TCAF2__:__FAMILY WITH SEQUENCE SIMILARITY 115, MEMBER C; FAM115C;; FAMILY WITH SEQUENCE SIMILARITY 139, MEMBER A; FAM139A__:__
Asterisk__:__616253__:__GS HOMEOBOX 2; GSX2__:__GENETIC-SCREENED HOMEOBOX 2; GSH2__:__
Asterisk__:__616254__:__CASEINOLYTIC PEPTIDASE B; CLPB__:__ClpB, E. COLI, HOMOLOG OF;; SUPPRESSOR OF POTASSIUM TRANSPORT DEFECT 3; SKD3__:__
Number Sign__:__616255__:__SHORT STATURE WITH NONSPECIFIC SKELETAL ABNORMALITIES; SNSK__:____:__
Asterisk__:__616256__:__C-TYPE LECTIN DOMAIN FAMILY 4, MEMBER G; CLEC4G__:__LIVER AND LYMPH NODE SINUSOIDAL ENDOTHELIAL CELL C-TYPE LECTIN; LSECTIN__:__
Asterisk__:__616257__:__FK506-BINDING PROTEIN 9; FKBP9__:__FK506-BINDING PROTEIN, 60-KD; FKBP60;; FK506-BINDING PROTEIN, 63-KD; FKBP63__:__
Number Sign__:__616258__:__MECKEL SYNDROME 12; MKS12__:____:__
Asterisk__:__616259__:__SMALL NUCLEOLAR RNA HOST GENE 14; SNHG14__:__LARGE NONCODING ANTISENSE TRANSCRIPT, MOUSE, HOMOLOG OF; LNCAT;; UBE3A ANTISENSE TRANSCRIPT; UBE3AAS; UBE3AATS__:__
Number Sign__:__616260__:__TENORIO SYNDROME; TNORS__:__OVERGROWTH, MACROCEPHALY, AND INTELLECTUAL DISABILITY SYNDROME__:__
Asterisk__:__616261__:__PSEUDOURIDYLATE SYNTHASE 7, PUTATIVE; PUS7__:__KIAA1897__:__
Asterisk__:__616262__:__KELCH-LIKE 21; KLHL21__:__KIAA0469__:__
Number Sign__:__616263__:__NEUROLOGIC, ENDOCRINE, AND PANCREATIC DISEASE, MULTISYSTEM, INFANTILE-ONSET; IMNEPD__:____:__
Asterisk__:__616264__:__MAF TRANSCRIPTIONAL REGULATOR RNA, NONCODING; MAFTRR__:__LONG INTERGENIC NONCODING RNA MAF4;; lincRNA MAF4;; lincMAF4__:__
Number Sign__:__616265__:__PEELING SKIN SYNDROME 3; PSS3__:____:__
Number Sign__:__616266__:__CONGENITAL CONTRACTURES OF THE LIMBS AND FACE, HYPOTONIA, AND DEVELOPMENTAL DELAY; CLIFAHDD__:____:__
Number Sign__:__616267__:__ATAXIA-OCULOMOTOR APRAXIA 4; AOA4__:____:__
Number Sign__:__616268__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 32; MRD32__:____:__
Number Sign__:__616269__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 48; MRT48__:____:__
Number Sign__:__616270__:__AMELOGENESIS IMPERFECTA, TYPE IF; AI1F__:__AMELOGENESIS IMPERFECTA, HYPOPLASTIC TYPE IF; AI1F__:__
Number Sign__:__616271__:__3-METHYLGLUTACONIC ACIDURIA WITH CATARACTS, NEUROLOGIC INVOLVEMENT, AND NEUTROPENIA; MEGCANN__:__3-METHYLGLUTACONIC ACIDURIA, TYPE VII; MGCA7__:__
Asterisk__:__616272__:__MICRO RNA 520G; MIR520G__:__miRNA520G__:__
Asterisk__:__616273__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 29, NONCODING; PCAT29__:__LONG NONCODING RNA PCAT29;; lncRNA PCAT29__:__
Asterisk__:__616274__:__MICRO RNA 4276; MIR4276__:__miRNA4276__:__
Asterisk__:__616275__:__FAMILY WITH SEQUENCE SIMILARITY 136, MEMBER A; FAM136A__:____:__
Number Sign__:__616276__:__COENZYME Q10 DEFICIENCY, PRIMARY, 7; COQ10D7__:____:__
Number Sign__:__616277__:__MITOCHONDRIAL SHORT-CHAIN ENOYL-CoA HYDRATASE 1 DEFICIENCY; ECHS1D__:____:__
Number Sign__:__616278__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 5; CBAS5__:____:__
Number Sign__:__616279__:__CATARACT 43; CTRCT43__:____:__
Number Sign__:__616280__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2U; CMT2U__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2U;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2U__:__
Number Sign__:__616281__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 49; MRT49__:____:__
Number Sign__:__616282__:__SPASTIC PARAPLEGIA 73, AUTOSOMAL DOMINANT; SPG73__:____:__
Asterisk__:__616283__:__PSEUDOURIDYLATE SYNTHASE 3; PUS3__:____:__
Asterisk__:__616284__:__FILAGGRIN FAMILY MEMBER 2; FLG2__:__FILAGGRIN 2;; IFAPSORIASIN; IFPS__:__
Asterisk__:__616285__:__FORMIN-LIKE 2; FMNL2__:__KIAA1902__:__
Number Sign__:__616286__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 7; LCCS7__:____:__
Number Sign__:__616287__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 8; LCCS8__:____:__
Asterisk__:__616288__:__FORMIN-LIKE 3; FMNL3__:__FRL2__:__
Number Sign__:__616289__:__OPTIC ATROPHY 9; OPA9__:____:__
Asterisk__:__616290__:__ZINC FINGER PROTEIN 658; ZNF658__:____:__
Number Sign__:__616291__:__LICHTENSTEIN-KNORR SYNDROME; LIKNS__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 19; SCAR19__:__
Asterisk__:__616292__:__STABILIZER OF AXONEMAL MICROTUBULES 1; SAXO1__:__FAMILY WITH SEQUENCE SIMILARITY 154, MEMBER A; FAM154A__:__
Asterisk__:__616293__:__HORNERIN; HRNR__:____:__
Number Sign__:__616294__:__COLE-CARPENTER SYNDROME 2; CLCRP2__:____:__
Number Sign__:__616295__:__PEELING SKIN WITH LEUKONYCHIA, ACRAL PUNCTATE KERATOSES, CHEILITIS, AND KNUCKLE PADS; PLACK__:____:__
Asterisk__:__616296__:__MULTIPLE C2 DOMAINS-CONTAINING TRANSMEMBRANE PROTEIN 1; MCTP1__:____:__
Asterisk__:__616297__:__MULTIPLE C2 DOMAINS-CONTAINING TRANSMEMBRANE PROTEIN 2; MCTP2__:____:__
Number Sign__:__616298__:__SINGLETON-MERTEN SYNDROME 2; SGMRT2__:____:__
Number Sign__:__616299__:__LIPOYLTRANSFERASE 1 DEFICIENCY; LIPT1D__:____:__
Number Sign__:__616300__:__SHORT-RIB THORACIC DYSPLASIA 13 WITH OR WITHOUT POLYDACTYLY; SRTD13__:____:__
Asterisk__:__616301__:__CD300 ANTIGEN-LIKE FAMILY, MEMBER D; CD300LD__:__CD300D__:__
Asterisk__:__616302__:__FORKHEAD BOX K1; FOXK1__:__MYOCYTE NUCLEAR FACTOR; MNF__:__
Asterisk__:__616303__:__WD REPEAT-CONTAINING PROTEIN 91; WDR91__:__SORF1, C. ELEGANS, HOMOLOG OF; SORF1__:__
Number Sign__:__616304__:__MYASTHENIC SYNDROME, CONGENITAL, 17; CMS17__:____:__
Asterisk__:__616305__:__FERM DOMAIN-CONTAINING PROTEIN 4A; FRMD4A__:__KIAA1294__:__
Asterisk__:__616306__:__FIBRINOGEN SILENCER-BINDING PROTEIN; FSBP__:____:__
Number Sign__:__616307__:__SENIOR-LOKEN SYNDROME 8; SLSN8__:____:__
Asterisk__:__616308__:__BETA-GLOBIN LOCUS TRANSCRIPT 3, NONCODING; BGLT3__:__LONG NONCODING RNA BGL3;; lncRNA BGL3;; LINC01083__:__
Asterisk__:__616309__:__FERM DOMAIN-CONTAINING PROTEIN 5; FRMD5__:____:__
Asterisk__:__616310__:__RHO GTPase-ACTIVATING PROTEIN 11B; ARHGAP11B__:__FAMILY WITH SEQUENCE SIMILARITY 7, MEMBER B1; FAM7B1__:__
Number Sign__:__616311__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 33; MRD33__:____:__
Asterisk__:__616312__:__LEM DOMAIN-CONTAINING PROTEIN 2; LEMD2__:__NUCLEAR ENVELOPE TRANSMEMBRANE PROTEIN 25; NET25;; LEM2__:__
Number Sign__:__616313__:__MYASTHENIC SYNDROME, CONGENITAL, 2A, SLOW-CHANNEL; CMS2A__:____:__
Number Sign__:__616314__:__MYASTHENIC SYNDROME, CONGENITAL, 2C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS2C__:____:__
Asterisk__:__616315__:__PARALOG OF XRCC4 AND XLF; PAXX__:__CHROMOSOME 9 OPEN READING FRAME 142; C9ORF142;; XRCC4-LIKE SMALL PROTEIN; XLS__:__
Asterisk__:__616316__:__FAMILY WITH SEQUENCE SIMILARITY 168, MEMBER A; FAM168A__:__TONGUE CANCER CHEMOTHERAPY RESISTANCE-ASSOCIATED PROTEIN 1; TCRP1;; KIAA0280__:__
Asterisk__:__616317__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN-CONTAINING PROTEIN 1; GDPD1__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 4; GDE4__:__
Asterisk__:__616318__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN-CONTAINING PROTEIN 3; GDPD3__:__GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE 7; GDE7__:__
Asterisk__:__616319__:__RING FINGER PROTEIN 138; RNF138__:__NEMO-LIKE KINASE-ASSOCIATED RING FINGER PROTEIN; NARF;; NLK-ASSOCIATED RING FINGER PROTEIN__:__
Asterisk__:__616320__:__FUMARYLACETOACETATE HYDROLASE DOMAIN-CONTAINING PROTEIN 1; FAHD1__:__FAH DOMAIN-CONTAINING PROTEIN 1;; FLJ36880__:__
Number Sign__:__616321__:__MYASTHENIC SYNDROME, CONGENITAL, 3A, SLOW-CHANNEL; CMS3A__:____:__
Number Sign__:__616322__:__MYASTHENIC SYNDROME, CONGENITAL, 3B, FAST-CHANNEL; CMS3B__:____:__
Number Sign__:__616323__:__MYASTHENIC SYNDROME, CONGENITAL, 3C, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS3C__:____:__
Number Sign__:__616324__:__MYASTHENIC SYNDROME, CONGENITAL, 4B, FAST-CHANNEL; CMS4B__:____:__
Number Sign__:__616325__:__MYASTHENIC SYNDROME, CONGENITAL, 9, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS9__:____:__
Number Sign__:__616326__:__MYASTHENIC SYNDROME, CONGENITAL, 11, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR DEFICIENCY; CMS11__:__MYASTHENIC SYNDROME, CONGENITAL, Ie, FORMERLY; CMS1E, FORMERLY;; CMS Ie, FORMERLY__:__
Asterisk__:__616327__:__CHROMOSOME ALIGNMENT-MAINTAINING PHOSPHOPROTEIN 1; CHAMP1__:__CAMP; CHAMP;; ZINC FINGER PROTEIN 828; ZNF828;; CHROMOSOME 13 OPEN READING FRAME 8; C13ORF8;; KIAA1802__:__
Asterisk__:__616328__:__LONG INTERGENIC NONCODING RNA PINKY__:__lincRNA PINKY; PNKY__:__
Number Sign__:__616329__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13__:__MODY, TYPE 13__:__
Number Sign__:__616330__:__MYASTHENIC SYNDROME, CONGENITAL, 18; CMS18__:__MYASTHENIC SYNDROME, CONGENITAL, 18, WITH INTELLECTUAL DISABILITY AND ATAXIA__:__
Number Sign__:__616331__:__ROBINOW SYNDROME, AUTOSOMAL DOMINANT 2; DRS2__:____:__
Asterisk__:__616332__:__ACIDIC RESIDUE METHYLTRANSFERASE 1; ARMT1__:__CHROMOSOME 6 OPEN READING FRAME 211; C6ORF211__:__
Asterisk__:__616333__:__WNT SIGNALING PATHWAY ACTIVATING NONCODING RNA; WSPAR__:__LONG NONCODING RNA WSPAR;; lncRNA WSPAR;; lncTCF7__:__
Asterisk__:__616334__:__TRANSMEMBRANE PROTEIN 100; TMEM100__:____:__
Number Sign__:__616335__:__MICROCEPHALY AND CHORIORETINOPATHY, AUTOSOMAL RECESSIVE, 3; MCCRP3__:____:__
Asterisk__:__616336__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER B15; AKR1B15__:__AKR1B10-LIKE; AKR1B10L;; AKR1R1B7__:__
Asterisk__:__616337__:__SUPPRESSOR OF CYTOKINE SIGNALING 4; SOCS4__:__SUPPRESSOR OF CYTOKINE SIGNALING 7; SOCS7__:__
Asterisk__:__616338__:__SOX2 OVERLAPPING TRANSCRIPT, NONCODING; SOX2OT__:__NONCODING RNA 43; NCRNA00043__:__
Number Sign__:__616339__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 29; EIEE29__:____:__
Number Sign__:__616340__:__DEAFNESS, AUTOSOMAL DOMINANT 67; DFNA67__:____:__
Number Sign__:__616341__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 30; EIEE30__:____:__
Number Sign__:__616342__:__LISSENCEPHALY 7 WITH CEREBELLAR HYPOPLASIA; LIS7__:____:__
Asterisk__:__616343__:__TUMOR PROTEIN p53 PATHWAY COREPRESSOR 1, NONCODING; TP53COR1__:__LONG INTERGENIC NONCODING RNA TP53COR1;; lincRNA TP53COR1;; lincRNA-p21__:__
Asterisk__:__616344__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 23-LIKE; TTC23L__:__TTC23-LIKE__:__
Number Sign__:__616345__:__IMMUNODEFICIENCY 39; IMD39__:____:__
Number Sign__:__616346__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 31; EIEE31__:____:__
Asterisk__:__616347__:__PR DOMAIN-CONTAINING PROTEIN 11; PRDM11__:__PFM8__:__
Asterisk__:__616348__:__ZINC FINGER PROTEIN 695; ZNF695__:__SBZF3__:__
Asterisk__:__616349__:__SORBIN AND SH3 DOMAINS-CONTAINING PROTEIN 2; SORBS2__:__ARG-BINDING PROTEIN 2; ARGBP2;; KIAA0777__:__
Asterisk__:__616350__:__PROMOTER OF MAT2A ANTISENSE RADIATION-INDUCED CIRCULATING LONG NONCODING RNA; PARTICL__:__LONG NONCODING RNA PARTICL;; lncRNA PARTICL;; PARTICLE__:__
Number Sign__:__616351__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 34; MRD34__:____:__
Asterisk__:__616352__:__ACYL-CoA-BINDING DOMAIN-CONTAINING PROTEIN 6; ACBD6__:____:__
Number Sign__:__616353__:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 6; DKCB6__:____:__
Number Sign__:__616354__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 20; SCAR20__:____:__
Number Sign__:__616355__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 35; MRD35__:____:__
Asterisk__:__616356__:__MICRO RNA 31 HOST GENE, NONCODING; MIR31HG__:__MIR31 HOST GENE;; LONG NONCODING RNA MIR31HG;; lncRNA MIR31HG;; LOC554202__:__
Number Sign__:__616357__:__DEAFNESS, AUTOSOMAL DOMINANT 40; DFNA40__:____:__
Asterisk__:__616358__:__MICRO RNA 379; MIR379__:__miRNA379__:__
Asterisk__:__616359__:__COQ5, S. CEREVISIAE, HOMOLOG OF; COQ5__:____:__
Asterisk__:__616360__:__TRANSMEMBRANE PROTEIN 135; TMEM135__:__PEROXISOMAL MEMBRANE PROTEIN 52; PMP52__:__
Percent__:__616361__:__PARKINSON DISEASE 21; PARK21__:____:__
Number Sign__:__616362__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 36; MRD36__:____:__
Asterisk__:__616363__:__SMALL PROLINE-RICH PROTEIN 4; SPRR4__:____:__
Number Sign__:__616364__:__WHITE-SUTTON SYNDROME; WHSUS__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 37; MRD37__:__
Asterisk__:__616365__:__SCY1-LIKE PROTEIN 2; SCYL2__:__SCY1, S. CEREVISIAE, HOMOLOG OF, 2;; COATED VESICLE-ASSOCIATED KINASE, 104-KD; CVAK104;; KIAA1360__:__
Number Sign__:__616366__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 32; EIEE32__:____:__
Number Sign__:__616367__:__MANDIBULOFACIAL DYSOSTOSIS WITH ALOPECIA; MFDA__:____:__
Number Sign__:__616368__:__CHOPS SYNDROME; CHOPS__:__COGNITIVE IMPAIRMENT, COARSE FACIES, HEART DEFECTS, OBESITY, PULMONARY INVOLVEMENT, SHORT STATURE, AND SKELETAL DYSPLASIA__:__
Caret__:__616369__:__MOVED TO 243605__:____:__
Number Sign__:__616370__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 4; MMDS4__:____:__
Number Sign__:__616371__:__PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 4; PFBMFT4__:____:__
Asterisk__:__616372__:__DDB1- AND CUL4-ASSOCIATED FACTOR 4; DCAF4__:__WD REPEAT-CONTAINING PROTEIN 21; WDR21;; WDR21A__:__
Number Sign__:__616373__:__PULMONARY FIBROSIS AND/OR BONE MARROW FAILURE, TELOMERE-RELATED, 3; PFBMFT3__:____:__
Asterisk__:__616374__:__BEN DOMAIN-CONTAINING PROTEIN 3; BEND3__:__KIAA1553__:__
Asterisk__:__616375__:__UNKEMPT FAMILY ZINC FINGER PROTEIN; UNK__:__UNKEMPT;; ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 5; ZC3HDC5; ZC3H5;; KIAA1753__:__
Asterisk__:__616376__:__MICRO RNA 656; MIR656__:__miRNA656__:__
Asterisk__:__616377__:__PROLINE DEHYDROGENASE (OXIDASE) 2; PRODH2__:__HYDROXYPROLINE OXIDASE;; HYDROXYPROLINE DEHYDROGENASE; HYPDH__:__
Asterisk__:__616378__:__UBX DOMAIN PROTEIN 1; UBXN1__:__SAPK SUBSTRATE PROTEIN 1; SAKS1__:__
Asterisk__:__616379__:__UBX DOMAIN PROTEIN 7; UBXN7__:__KIAA0794__:__
Asterisk__:__616380__:__LAMININ, BETA-4; LAMB4__:____:__
Asterisk__:__616381__:__ZINC FINGER CCHC DOMAIN-CONTAINING PROTEIN 8; ZCCHC8__:____:__
Asterisk__:__616382__:__URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER A3; UGT2A3__:__UDP GLUCURONOSYLTRANSFERASE 2 FAMILY, MEMBER A3__:__
Asterisk__:__616383__:__URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 3 FAMILY, MEMBER A1; UGT3A1__:__UDP GLUCURONOSYLTRANSFERASE 3 FAMILY, MEMBER A1__:__
Asterisk__:__616384__:__URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 3 FAMILY, MEMBER A2; UGT3A2__:__UDP GLUCURONOSYLTRANSFERASE 3 FAMILY, MEMBER A2__:__
Asterisk__:__616385__:__LONG INTERGENIC NONCODING RNA 1018; LINC01018__:__lincRNA 1018;; SRHC__:__
Asterisk__:__616386__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 17; KCTD17__:____:__
Asterisk__:__616387__:__DOWNREGULATED RNA IN ANDROGEN-INDEPENDENT CELLS, NONCODING; DRAIC__:__LONG NONCODING RNA DRAIC;; lncRNA DRAIC__:__
Asterisk__:__616388__:__UBIQUITIN DOMAIN-CONTAINING PROTEIN 1; UBTD1__:____:__
Number Sign__:__616389__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1G; CSNB1G__:____:__
Number Sign__:__616390__:__TRICHOTHIODYSTROPHY 2, PHOTOSENSITIVE; TTD2__:____:__
Asterisk__:__616391__:__RAN-BINDING PROTEIN 3-LIKE; RANBP3L__:__RANBP3-LIKE__:__
NULL__:__616392__:__SKINT1-LIKE PSEUDOGENE; SKINTL__:__SKINT1L;; SKINTP__:__
Number Sign__:__616393__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 38; MRD38__:__PSYCHOMOTOR RETARDATION, EPILEPSY, AND LANGUAGE DISABILITY SYNDROME; PRELDS__:__
Number Sign__:__616394__:__RETINITIS PIGMENTOSA 71; RP71__:____:__
Number Sign__:__616395__:__TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE; TTD3__:__TRICHOTHIODYSTROPHY, COMPLEMENTATION GROUP A; TTDA__:__
Asterisk__:__616396__:__SEX COMB ON MIDLEG, DROSOPHILA, HOMOLOG OF, 1; SCMH1__:____:__
Asterisk__:__616397__:__PEROXISOMAL MEMBRANE PROTEIN 4; PXMP4__:__PEROXISOMAL MEMBRANE PROTEIN, 24-KD; PMP24__:__
Number Sign__:__616398__:__DYSTONIA 26, MYOCLONIC; DYT26__:____:__
Number Sign__:__616399__:__BRUGADA SYNDROME 9; BRGDA9__:____:__
Number Sign__:__616400__:__PALMOPLANTAR KERATODERMA, NONEPIDERMOLYTIC, FOCAL 2; FNEPPK2__:____:__
Asterisk__:__616401__:__SPINDLE APPARATUS COILED-COIL PROTEIN 1; SPDL1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 99; CCDC99;; SPINDLY, DROSOPHILA, HOMOLOG OF__:__
Number Sign__:__616402__:__MICROCEPHALY 14, PRIMARY, AUTOSOMAL RECESSIVE; MCPH14__:____:__
Asterisk__:__616403__:__TP53 TARGET GENE 1; TP53TG1__:____:__
Asterisk__:__616404__:__POLYMERASE I, RNA, SUBUNIT A; POLR1A__:__RNA POLYMERASE I, 194-KD SUBUNIT; RPA194__:__
Asterisk__:__616405__:__ADAPTOR PROTEIN 2-ASSOCIATED KINASE 1; AAK1__:__AP2-ASSOCIATED KINASE 1;; KIAA1048__:__
Asterisk__:__616406__:__PYRROLINE-5-CARBOXYLATE REDUCTASE 2; PYCR2__:____:__
Percent__:__616407__:__BROWN SYNDROME; BRWNS__:____:__
Asterisk__:__616408__:__PYRROLINE-5-CARBOXYLATE REDUCTASE-LIKE; PYCRL__:__PYRROLINE-5-CARBOXYLATE REDUCTASE 3; PYCR3__:__
Number Sign__:__616409__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 33; EIEE33__:____:__
Number Sign__:__616410__:__SPINOCEREBELLAR ATAXIA 41; SCA41__:____:__
Number Sign__:__616411__:__DYSTONIA 27; DYT27__:____:__
Asterisk__:__616412__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 5; TXNDC5__:__ENDOPLASMIC RETICULUM PROTEIN, 46-KD; ERP46;; ENDOTHELIAL PROTEIN DISULFIDE ISOMERASE; ENDOPDI;; HEPATOCELLULAR CARCINOMA 2; HCC2__:__
Number Sign__:__616413__:__BASAL GANGLIA CALCIFICATION, IDIOPATHIC, 6; IBGC6__:____:__
Number Sign__:__616414__:__AUTOIMMUNE INTERSTITIAL LUNG, JOINT, AND KIDNEY DISEASE; AILJK__:____:__
Number Sign__:__616415__:__FAMILIAL ADENOMATOUS POLYPOSIS 3; FAP3__:____:__
Asterisk__:__616416__:__ADHESION G PROTEIN-COUPLED RECEPTOR L1; ADGRL1__:__LATROPHILIN 1; LPHN1;; CALCIUM-INDEPENDENT ALPHA-LATROTOXIN RECEPTOR 1; CIRL1; CL1;; LECTOMEDIN 2; LEC2;; KIAA0821__:__
Asterisk__:__616417__:__ADHESION G PROTEIN-COUPLED RECEPTOR L3; ADGRL3__:__LATROPHILIN 3; LPHN3;; CALCIUM-INDEPENDENT ALPHA-LATROTOXIN RECEPTOR 3; CIRL3; CL3;; LECTOMEDIN 3; LEC3;; KIAA0768__:__
Number Sign__:__616418__:__HYPOMAGNESEMIA, SEIZURES, AND MENTAL RETARDATION; HOMGSMR__:____:__
Asterisk__:__616419__:__ADHESION G PROTEIN-COUPLED RECEPTOR L4; ADGRL4__:__EGF-, TM7-, AND LATROPHILIN-RELATED PROTEIN; ETL;; EGF, LATROPHILIN, AND 7 TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 1; ELTD1__:__
Number Sign__:__616420__:__LEUKODYSTROPHY, HYPOMYELINATING, 10; HLD10__:____:__
Number Sign__:__616421__:__MYOCLONIC-ATONIC EPILEPSY; MAE__:____:__
Asterisk__:__616422__:__TRANSCRIPTION ELONGATION FACTOR, MITOCHONDRIAL; TEFM__:__CHROMOSOME 17 OPEN READING FRAME 42; C17ORF42__:__
Asterisk__:__616423__:__DEAH BOX POLYPEPTIDE 30; DHX30__:__DDX30;; RETINA COREPRESSOR; RETCOR;; KIAA0890__:__
Asterisk__:__616424__:__SET DOMAIN-CONTAINING PROTEIN 6; SETD6__:____:__
Number Sign__:__616425__:__46,XY SEX REVERSAL 10; SRXY10__:__CHROMOSOME 17q24 DELETION SYNDROME__:__
Asterisk__:__616426__:__CENTROSOMAL PROTEIN, 192-KD; CEP192__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 62; PPP1R62;; KIAA1569__:__
Asterisk__:__616427__:__A-KINASE ANCHOR INHIBITOR 1; AKAIN1__:__CHROMOSOME 18 OPEN READING FRAME 42; C18ORF42__:__
Number Sign__:__616428__:__MICROPHTHALMIA, ISOLATED, WITH COLOBOMA 10; MCOPCB10__:____:__
Asterisk__:__616429__:__SUSHI DOMAIN-CONTAINING PROTEIN 3; SUSD3__:____:__
Number Sign__:__616430__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 25; COXPD25__:____:__
Asterisk__:__616431__:__GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 2, MITOCHONDRIAL; GPAT2__:____:__
Asterisk__:__616432__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 18; ARHGEF18__:__RHO-SPECIFIC GUANINE NUCLEOTIDE EXCHANGE FACTOR, 114-KD; p114RHOGEF;; KIAA0521__:__
Number Sign__:__616433__:__IMMUNODEFICIENCY 40; IMD40__:____:__
Asterisk__:__616434__:__INCREASED SODIUM TOLERANCE 1, YEAST, HOMOLOG OF; IST1__:__KIAA0174__:__
Number Sign__:__616435__:__FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT__:____:__
Number Sign__:__616436__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 7; ETL7__:____:__
Number Sign__:__616437__:__FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3__:____:__
Asterisk__:__616438__:__TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 8-LIKE 3; TNFAIP8L3__:__TNFAIP8-LIKE 3; TIPE3__:__
Number Sign__:__616439__:__FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 4; FTDALS4__:____:__
Asterisk__:__616440__:__SOLUTE CARRIER FAMILY 32 (GABA VESICULAR TRANSPORTER), MEMBER 1; SLC32A1__:__VESICULAR GABA TRANSPORTER; VGAT;; VESICULAR INHIBITORY AMINO ACID TRANSPORTER; VIAAT__:__
Asterisk__:__616441__:__OVO-LIKE 2; OVOL2__:__OVO, DROSOPHILA, HOMOLOG OF, 2;; ZINC FINGER PROTEIN 339; ZNF339__:__
Asterisk__:__616442__:__OVO-LIKE 3; OVOL3__:__OVO, DROSOPHILA, HOMOLOG OF, 3__:__
Asterisk__:__616443__:__ZINC FINGER, MYM-TYPE 5; ZMYM5__:__ZINC FINGER PROTEIN 237; ZNF237;; ZINC FINGER PROTEIN 198-LIKE 1; ZNF198L1__:__
Asterisk__:__616444__:__RNA-BINDING MOTIF PROTEIN 19; RBM19__:__KIAA0682__:__
Number Sign__:__616445__:__CANDIDIASIS, FAMILIAL, 9; CANDF9__:____:__
Asterisk__:__616446__:__CHROMOSOME 1 OPEN READING FRAME 177; C1ORF177__:____:__
Asterisk__:__616447__:__KIAA1429 GENE; KIAA1429__:__VIRILIZER__:__
Asterisk__:__616448__:__RAS-ASSOCIATED PROTEIN RAB12; RAB12__:____:__
Number Sign__:__616449__:__BASEL-VANAGAITE-SMIRIN-YOSEF SYNDROME; BVSYS__:____:__
Asterisk__:__616450__:__EF-HAND DOMAIN FAMILY, MEMBER D2; EFHD2__:__SWIPROSIN 1; SWS1__:__
Number Sign__:__616451__:__SPASTIC PARAPLEGIA 74, AUTOSOMAL RECESSIVE; SPG74__:____:__
Number Sign__:__616452__:__B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY; BENTA__:____:__
Asterisk__:__616453__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 13; ZC3H13__:__KIAA0853__:__
Asterisk__:__616454__:__ZINC FINGER PROTEIN 408; ZNF408__:____:__
Number Sign__:__616455__:__ZIMMERMANN-LABAND SYNDROME 2; ZLS2__:____:__
Asterisk__:__616456__:__INO80 COMPLEX, SUBUNIT B; INO80B__:__PAP1-ASSOCIATED PROTEIN 1; PAPA1;; HMGA1-LIKE PROTEIN 4; HMGA1L4__:__
Number Sign__:__616457__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 50; EIEE50__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iz, FORMERLY; CDG1Z, FORMERLY__:__
Asterisk__:__616458__:__PR DOMAIN-CONTAINING PROTEIN 12; PRDM12__:__POSITIVE REGULATORY DOMAIN ZINC FINGER PROTEIN 12__:__
Number Sign__:__616459__:__AL-RAQAD SYNDROME; ARS__:____:__
Number Sign__:__616460__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 50; MRT50__:____:__
Number Sign__:__616461__:__EPILEPSY, FAMILIAL TEMPORAL LOBE, 8; ETL8__:____:__
Number Sign__:__616462__:__ACROFACIAL DYSOSTOSIS, CINCINNATI TYPE; AFDCIN__:____:__
Asterisk__:__616463__:__ZINC FINGER PROTEIN 232; ZNF232__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 11; ZSCAN11__:__
Asterisk__:__616464__:__ECDYSONELESS, DROSOPHILA, HOMOLOG OF; ECD__:__SUPPRESSOR OF GCR2; SGT1__:__
Asterisk__:__616465__:__VPS50, EARP/GARPII COMPLEX SUBUNIT; VPS50__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 132; CCDC132;; SYNDETIN;; KIAA1861__:__
Asterisk__:__616466__:__UNC5, C. ELEGANS, HOMOLOG OF, D; UNC5D__:__UNC5H4__:__
Asterisk__:__616467__:__DELETED IN PRIMARY CILIARY DYSKINESIA, MOUSE, HOMOLOG OF; DPCD__:____:__
Number Sign__:__616468__:__EXUDATIVE VITREORETINOPATHY 6; EVR6__:____:__
Number Sign__:__616469__:__RETINITIS PIGMENTOSA 72; RP72__:____:__
Number Sign__:__616470__:__ULLRICH CONGENITAL MUSCULAR DYSTROPHY 2; UCMD2__:____:__
Number Sign__:__616471__:__BETHLEM MYOPATHY 2; BTHLM2__:__EHLERS-DANLOS SYNDROME, MYOPATHIC TYPE; EDSMYP;; EDS, MYOPATHIC TYPE__:__
Asterisk__:__616472__:__UBIQUITIN-ASSOCIATED PROTEIN 2-LIKE; UBAP2L__:__NICE4;; KIAA0144__:__
Asterisk__:__616473__:__MICRO RNA 558; MIR558__:__miRNA558__:__
Asterisk__:__616474__:__ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 26; ZSCAN26__:__SREZBP__:__
Asterisk__:__616475__:__CENTROSOMAL PROTEIN, 72-KD; CEP72__:__KIAA1519__:__
Asterisk__:__616476__:__ATP/GTP-BINDING PROTEIN-LIKE 4; AGBL4__:__CYTOSOLIC CARBOXYPEPTIDASE 6; CCP6__:__
Asterisk__:__616477__:__NUCLEAR RECEPTOR-BINDING FACTOR 2; NRBF2__:__COMODULATOR OF PPAR AND RXR; COPR__:__
Asterisk__:__616478__:__LEUCINE-RICH REPEATS- AND GUANYLATE KINASE DOMAIN-CONTAINING PROTEIN; LRGUK__:____:__
Number Sign__:__616479__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2__:__
Asterisk__:__616480__:__KIAA1328 GENE; KIAA1328__:__HINDERIN__:__
Number Sign__:__616481__:__CILIARY DYSKINESIA, PRIMARY, 32; CILD32__:__CILIARY DYSKINESIA, PRIMARY, 32, WITHOUT SITUS INVERSUS__:__
Number Sign__:__616482__:__ACHONDROPLASIA, SEVERE, WITH DEVELOPMENTAL DELAY AND ACANTHOSIS NIGRICANS; SADDAN__:__SADDAN DYSPLASIA__:__
Number Sign__:__616483__:__INFANTILE LIVER FAILURE SYNDROME 2; ILFS2__:____:__
Asterisk__:__616484__:__TAX1-BINDING PROTEIN 3; TAX1BP3__:__TAX INTERACTION PROTEIN 1; TIP1__:__
Asterisk__:__616485__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 21; ZBTB21__:__ZINC FINGER PROTEIN 295; ZNF295;; KIAA1227__:__
Number Sign__:__616486__:__MICROCEPHALY 15, PRIMARY, AUTOSOMAL RECESSIVE; MCPH15__:____:__
Number Sign__:__616487__:__EPIDERMOLYSIS BULLOSA SIMPLEX WITH NAIL DYSTROPHY; EBSND__:____:__
Number Sign__:__616488__:__NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, TYPE VIII; HSAN8__:__HSAN VIII__:__
Number Sign__:__616489__:__GROWTH RESTRICTION, SEVERE, WITH DISTINCTIVE FACIES; GRDF__:____:__
Number Sign__:__616490__:__JOUBERT SYNDROME 23; JBTS23__:____:__
Number Sign__:__616491__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2V; CMT2V__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2V;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2V__:__
Asterisk__:__616492__:__EWING SARCOMA-ASSOCIATED TRANSCRIPT 1, NONCODING; EWSAT1__:__LONG INTERGENIC NONCODING RNA 277; LINC00277__:__
Asterisk__:__616493__:__FAMILY WITH SEQUENCE SIMILARITY 208, MEMBER A; FAM208A__:__RB1-ASSOCIATED PROTEIN, 140-KD; RAP140;; TRANSGENE ACTIVATION SUPPRESSOR PROTEIN; TASOR;; CHROMOSOME 3 OPEN READING FRAME 63; C3ORF63;; KIAA1105__:__
Number Sign__:__616494__:__LEUKODYSTROPHY, HYPOMYELINATING, 11; HLD11__:____:__
Asterisk__:__616495__:__ADP-RIBOSYLATION FACTOR-LIKE 6-INTERACTING PROTEIN 6; ARL6IP6__:__ARL6-INTERACTING PROTEIN 6; AIP6__:__
Asterisk__:__616496__:__NUCLEAR ENVELOPE INTEGRAL MEMBRANE PROTEIN 1; NEMP1__:__TRANSMEMBRANE PROTEIN 194A; TMEM194A__:__
Asterisk__:__616497__:__NUCLEAR ENVELOPE INTEGRAL MEMBRANE PROTEIN 2; NEMP2__:__TRANSMEMBRANE PROTEIN 194B; TMEM194B__:__
Asterisk__:__616498__:__FAMILY WITH SEQUENCE SIMILARITY 134, MEMBER C; FAM134C__:____:__
Asterisk__:__616499__:__TRANSMEMBRANE PROTEIN 203; TMEM203__:____:__
Number Sign__:__616500__:__CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 3; CEMCOX3__:____:__
Number Sign__:__616501__:__CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE DEFICIENCY 4; CEMCOX4__:____:__
Number Sign__:__616502__:__CONE-ROD DYSTROPHY 21; CORD21__:__RETINAL DYSTROPHY WITH EARLY MACULAR INVOLVEMENT__:__
Number Sign__:__616503__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 9; LCCS9__:____:__
Asterisk__:__616504__:__METHYLTRANSFERASE-LIKE 14; METTL14__:__KIAA1627__:__
Number Sign__:__616505__:__NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB; HMSN6B__:__HMSN VIB;; CHARCOT-MARIE-TOOTH DISEASE, TYPE 6B; CMT6B__:__
Asterisk__:__616506__:__NEURON-DERIVED NEUROTROPHIC FACTOR; NDNF__:__CHROMOSOME 4 OPEN READING FRAME 31; C4ORF31;; EPIDERMACAN;; NORD, DROSOPHILA, HOMOLOG OF; NORD__:__
Number Sign__:__616507__:__OSTEOGENESIS IMPERFECTA, TYPE XVII; OI17__:____:__
Asterisk__:__616508__:__SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 11; SLC39A11__:__ZRT- AND IRT-LIKE PROTEIN 11; ZIP11;; CHROMOSOME 17 OPEN READING FRAME 26; C17ORF26__:__
Number Sign__:__616509__:__CATARACT 44; CTRCT44__:__CATARACT 44 AND HYPOTRICHOSIS__:__
Asterisk__:__616510__:__GLUCOSAMINE-PHOSPHATE N-ACETYLTRANSFERASE 1; GNPNAT1__:__GLUCOSAMINE-6-PHOSPHATE N-ACETYLTRANSFERASE 1; GNA1__:__
Number Sign__:__616511__:__MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 14; MODY14__:____:__
Asterisk__:__616512__:__RING FINGER PROTEIN 152; RNF152__:____:__
Asterisk__:__616513__:__La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 4B; LARP4B__:__La-RELATED PROTEIN 4B;; La RIBONUCLEOPROTEIN DOMAIN FAMILY, MEMBER 5; LARP5;; La-RELATED PROTEIN 5;; KIAA0217__:__
Asterisk__:__616514__:__FAMILY WITH SEQUENCE SIMILARITY 195, MEMBER B; FAM195B__:__MAPK-REGULATED COREPRESSOR-INTERACTING PROTEIN 1; MCRIP1__:__
Number Sign__:__616515__:__DEAFNESS, AUTOSOMAL RECESSIVE 104; DFNB104__:____:__
Number Sign__:__616516__:__EMERY-DREIFUSS MUSCULAR DYSTROPHY 3, AUTOSOMAL RECESSIVE; EDMD3__:____:__
Number Sign__:__616517__:__ACHROMATOPSIA 7; ACHM7__:____:__
Asterisk__:__616518__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 6; SLC38A6__:__SODIUM-COUPLED AMINO ACID TRANSPORTER 6; SNAT6__:__
Asterisk__:__616519__:__PHOSPHODIESTERASE 12; PDE12__:__PDE, 2-PRIME__:__
Asterisk__:__616520__:__ADENOSYLHOMOCYSTEINASE-LIKE 2; AHCYL2__:__S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE 3;; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR 1-BINDING PROTEIN RELEASED WITH INOSITOL 1,4,5-TRISPHOSPHATE 2; IRBIT2;; ITPR1-BINDING PROTEIN RELEASED WITH IP3 2;; IRBIT, LONG;; KIAA0828__:__
Number Sign__:__616521__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 39; MRD39__:____:__CHROMOSOME 2p25.3 DELETION SYNDROME, INCLUDED;; CHROMOSOME 2p25.3 DUPLICATION SYNDROME, INCLUDED
Asterisk__:__616522__:__DCN1 DOMAIN-CONTAINING PROTEIN 5; DCUN1D5__:__SQUAMOUS CELL CARCINOMA-RELATED ONCOGENE 5; SCCRO5__:__
Asterisk__:__616523__:__MICROFIBRILLAR-ASSOCIATED PROTEIN 3-LIKE; MFAP3L__:__KIAA0626__:__
Asterisk__:__616524__:__TRANSMEMBRANE PROTEIN 139; TMEM139__:____:__
Asterisk__:__616525__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 10; SLC38A10__:____:__
Asterisk__:__616526__:__SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 11; SLC38A11__:____:__
Asterisk__:__616527__:__SWI5-DEPENDENT HOMOLOGOUS RECOMBINATION REPAIR PROTEIN 1; SFR1__:__SFR1, S. POMBE, HOMOLOG OF;; MEIOSIS PROTEIN 5, S. CEREVISIAE, HOMOLOG OF; MEI5;; CHROMOSOME 10 OPEN READING FRAME 78; C10ORF78__:__
Asterisk__:__616528__:__SWI5 HOMOLOGOUS RECOMBINATION REPAIR PROTEIN; SWI5__:__SWI5, S. POMBE, HOMOLOG OF;; SAE3, S. CEREVISIAE, HOMOLOG OF; SAE3;; CHROMOSOME 9 OPEN READING FRAME 119; C9ORF119__:__
Asterisk__:__616529__:__YTH N6-METHYLADENOSINE RNA-BINDING PROTEIN 1; YTHDF1__:__YTH DOMAIN FAMILY, MEMBER 1__:__
Asterisk__:__616530__:__YTH DOMAIN-CONTAINING PROTEIN 2; YTHDC2__:__CYCLOSPORIN A-ASSOCIATED HELICASE-LIKE PROTEIN; CAHL__:__
Number Sign__:__616531__:__POLYMICROGYRIA, PERISYLVIAN, WITH CEREBELLAR HYPOPLASIA AND ARTHROGRYPOSIS; PMGYCHA__:____:__
Number Sign__:__616532__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 7; IIAE7__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 5__:__
Asterisk__:__616533__:__DEAD BOX POLYPEPTIDE 31; DDX31__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 25; PPP1R25__:__
Number Sign__:__616534__:__THYROID CANCER, NONMEDULLARY, 4; NMTC4__:____:__
Number Sign__:__616535__:__THYROID CANCER, NONMEDULLARY, 5; NMTC5__:____:__
Asterisk__:__616536__:__CYSTATIN 9-LIKE; CST9L__:__TESTATIN__:__
Asterisk__:__616537__:__V-SET AND TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 2-LIKE; VSTM2L__:__VSTM2-LIKE;; CHROMOSOME 20 OPEN READING FRAME 102; C20ORF102__:__
Number Sign__:__616538__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9__:__WALKER-WARBURG SYNDROME OR MUSCLE-EYE BRAIN DISEASE, DAG1-RELATED__:__
Number Sign__:__616539__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 26; COXPD26__:____:__
Number Sign__:__616540__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 9; EPM9__:____:__
Number Sign__:__616541__:__SHORT STATURE, MICROCEPHALY, AND ENDOCRINE DYSFUNCTION; SSMED__:____:__
Asterisk__:__616542__:__GS HOMEOBOX 1; GSX1__:__GENOMIC-SCREENED HOMEOBOX 1; GSH1__:__
Asterisk__:__616543__:__CYSTATIN 9; CST9__:__CYSTATIN-LIKE MOLECULE; CLM__:__
Number Sign__:__616544__:__RETINITIS PIGMENTOSA 73; RP73__:____:__
Asterisk__:__616545__:__PRELI DOMAIN-CONTAINING PROTEIN 3A; PRELID3A__:__PRELI;; SLOWMO, DROSOPHILA, HOMOLOG OF, 1; SLMO1;; CHROMOSOME 18 OPEN READING FRAME 43; C18ORF43__:__
Number Sign__:__616546__:__SHORT-RIB THORACIC DYSPLASIA 14 WITH POLYDACTYLY; SRTD14__:____:__
Asterisk__:__616547__:__LYSOZYME G-LIKE 2; LYG2__:__LYSG2__:__
Asterisk__:__616548__:__LYSOPHOSPHOLIPASE-LIKE 1; LYPLAL1__:____:__
Number Sign__:__616549__:__KLIPPEL-FEIL SYNDROME 4, AUTOSOMAL RECESSIVE, WITH NEMALINE MYOPATHY AND FACIAL DYSMORPHISM; KFS4__:____:__
Asterisk__:__616550__:__TRANSMEMBRANE PROTEIN 120A; TMEM120A__:__TRANSMEMBRANE PROTEIN INDUCED BY TUMOR NECROSIS FACTOR-ALPHA; TMPIT;; NUCLEAR ENVELOPE TRANSMEMBRANE PROTEIN 29; NET29__:__
Asterisk__:__616551__:__TRANSMEMBRANE PROTEIN 120B; TMEM120B__:____:__
Asterisk__:__616552__:__CARNOSINE N-METHYLTRANSFERASE 1; CARNMT1__:__CHROMOSOME 9 OPEN READING FRAME 41; C9ORF41;; UPF0586__:__
Number Sign__:__616553__:__DYSKERATOSIS CONGENITA, AUTOSOMAL DOMINANT 6; DKCA6__:____:__DYSKERATOSIS CONGENITA, AUTOSOMAL RECESSIVE 7, INCLUDED; DKCB7, INCLUDED
Asterisk__:__616554__:__SPERM-ASSOCIATED ANTIGEN 17; SPAG17__:__PF6, CHLAMYDOMONAS, HOMOLOG OF; PF6__:__
Asterisk__:__616555__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 37A; LRRC37A__:____:__
Asterisk__:__616556__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 37A2; LRRC37A2__:____:__
Asterisk__:__616557__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 37A3; LRRC37A3__:____:__
Asterisk__:__616558__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 37B; LRRC37B__:____:__
Number Sign__:__616559__:__NOONAN SYNDROME 9; NS9__:____:__
Asterisk__:__616560__:__CD300H ANTIGEN__:__CD300H;; CD300C-LIKE MOLECULE__:__
Asterisk__:__616561__:__RAS PROTEIN ACTIVATOR-LIKE 3; RASAL3__:____:__
Number Sign__:__616562__:__RETINITIS PIGMENTOSA 74; RP74__:____:__
Asterisk__:__616563__:__STE20-LIKE PROTEIN KINASE; SLK__:__LONG STE20-LIKE PROTEIN KINASE; LOSK;; KIAA0204__:__
Number Sign__:__616564__:__NOONAN SYNDROME 10; NS10__:____:__
Asterisk__:__616565__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 30B; ANKRD30B__:__BREAST CANCER ANTIGEN NY-BR-1.1__:__
Number Sign__:__616566__:__SPONDYLOCOSTAL DYSOSTOSIS 6, AUTOSOMAL RECESSIVE; SCDO6__:____:__
Asterisk__:__616567__:__DEATH-ASSOCIATED PROTEIN KINASE 2; DAPK2__:__DAP KINASE-RELATED PROTEIN 1; DRP1__:__
Number Sign__:__616568__:__GLIOMA SUSCEPTIBILITY 9; GLM9__:____:__
Asterisk__:__616569__:__CYSTEINE SULFINIC ACID DECARBOXYLASE; CSAD__:__CSD;; P-SELECTIN CYTOPLASMIC TAIL-ASSOCIATED PROTEIN; PCAP__:__
Number Sign__:__616570__:__CEREBROOCULOFACIOSKELETAL SYNDROME 3; COFS3__:____:__
Asterisk__:__616571__:__C-TYPE LECTIN DOMAIN FAMILY 18, MEMBER A; CLEC18A__:____:__
Asterisk__:__616572__:__C-TYPE LECTIN DOMAIN FAMILY 18, MEMBER B; CLEC18B__:____:__
Asterisk__:__616573__:__C-TYPE LECTIN DOMAIN FAMILY 18, MEMBER C; CLEC18C__:____:__
Asterisk__:__616574__:__MITOCHONDRIAL INNER MEMBRANE ORGANIZING SYSTEM PROTEIN 1; MINOS1__:__MICOS PROTEIN 1;; MIO10, YEAST, HOMOLOG OF; MIO10;; MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 10-KD SUBUNIT; MIC10;; MICOS COMPLEX, 10-KD SUBUNIT;; CHROMOSOME 1 OPEN READING FRAME 51; C1ORF51__:__
Asterisk__:__616575__:__LEUKOCYTE RECEPTOR CLUSTER GENE 8; LENG8__:__KIAA1932__:__
Number Sign__:__616576__:__IMMUNODEFICIENCY, COMMON VARIABLE, 12; CVID12__:__NFKB1 DEFICIENCY__:__
Number Sign__:__616577__:__EPILEPSY, HEARING LOSS, AND MENTAL RETARDATION SYNDROME; EHLMRS__:____:__
Asterisk__:__616578__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 1; ZBTB1__:____:__
Number Sign__:__616579__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 40; MRD40__:____:__
Number Sign__:__616580__:__AU-KLINE SYNDROME; AUKS__:____:__
Asterisk__:__616581__:__LYSINE-SPECIFIC DEMETHYLASE 4E; KDM4E__:__JUMONJI DOMAIN-CONTAINING PROTEIN 2E; JMJD2E__:__
Asterisk__:__616582__:__LIPOLYSIS-STIMULATED LIPOPROTEIN RECEPTOR; LSR__:__IMMUNOGLOBULIN-LIKE DOMAIN-CONTAINING RECEPTOR 3; ILDR3__:__
Number Sign__:__616583__:__SPONDYLOEPIPHYSEAL DYSPLASIA, STANESCU TYPE; SEDSTN__:__SED, STANESCU TYPE__:__
Asterisk__:__616584__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 31, SUBFAMILY A, MEMBER 7; SPATA31A7__:__ACROSOME-EXPRESSED PROTEIN 1; AEP1;; FAMILY WITH SEQUENCE SIMILARITY 75, MEMBER A7; FAM75A7;; CHROMOSOME 9 OPEN READING FRAME 36; C9ORF36;; VAD1.3__:__
Asterisk__:__616585__:__RING FINGER- AND SPRY DOMAIN-CONTAINING PROTEIN 1; RSPRY1__:__KIAA1972__:__
Number Sign__:__616586__:__SPASTIC PARAPLEGIA 9B, AUTOSOMAL RECESSIVE; SPG9B__:____:__
Asterisk__:__616587__:__FAMILY WITH SEQUENCE SIMILARITY 118, MEMBER B; FAM118B__:____:__
Asterisk__:__616588__:__DIHYDROFOLATE REDUCTASE-LIKE 1; DHFRL1__:__DIHYDROFOLATE REDUCTASE PSEUDOGENE 4, FORMERLY; DHFRP4, FORMERLY__:__
Number Sign__:__616589__:__ADAMS-OLIVER SYNDROME 6; AOS6__:____:__
Asterisk__:__616590__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 5; ZBTB5__:__KIAA0354__:__
Asterisk__:__616591__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 7C; ZBTB7C__:__AFFECTED BY PAPILLOMAVIRUS DNA INTEGRATION IN ME180 CELLS; APM1__:__
Number Sign__:__616592__:__KOSAKI OVERGROWTH SYNDROME; KOGS__:__SKELETAL OVERGROWTH WITH FACIAL DYSMORPHISM, HYPERELASTIC SKIN, WHITE MATTER LESIONS, AND NEUROLOGIC DETERIORATION__:__
Asterisk__:__616593__:__FAMILY WITH SEQUENCE SIMILARITY 132, MEMBER A; FAM132A__:__C1q DOMAIN-CONTAINING PROTEIN 2; C1QDC2;; C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 12; CTRP12; C1QTNF12;; ADIPOSE-DERIVED INSULIN-SENSITIZING FACTOR;; ADIPOLIN__:__
Asterisk__:__616594__:__ARF GTPase-ACTIVATING PROTEIN WITH SH3 DOMAIN, ANKYRIN REPEAT, AND PH DOMAIN 3; ASAP3__:__UPREGULATED IN LIVER CANCER 1; UPLC1;; CENTAURIN, BETA-6; CENTB6;; DEVELOPMENT- AND DIFFERENTIATION-ENHANCING FACTOR-LIKE 1; DDEFL1;; ARF GTPase-ACTIVATING PROTEIN WITH COILED-COIL, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAINS 4; ACAP4__:__
Asterisk__:__616595__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 2; ZBTB2__:__ZINC FINGER PROTEIN 437; ZNF437;; KIAA1483__:__
Asterisk__:__616596__:__ADP-RIBOSYLATION FACTOR-LIKE 8B; ARL8B__:__SMALL G PROTEIN INDISPENSABLE FOR EQUAL CHROMOSOME SEGREGATION 1; GIE1__:__
Asterisk__:__616597__:__ADP-RIBOSYLATION FACTOR-LIKE 8A; ARL8A__:__SMALL G PROTEIN INDISPENSABLE FOR EQUAL CHROMOSOME SEGREGATION 2; GIE2__:__
Asterisk__:__616598__:__BLOC1-RELATED COMPLEX, SUBUNIT 5; BORCS5__:__BORC, SUBUNIT 5;; LOSS OF HETEROZYGOSITY, CHROMOSOME 12, REGION 1; LOH12CR1;; MYRISTOYLATED LYSOSOMAL PROTEIN; MYRLYSIN__:__
Asterisk__:__616599__:__BLOC1-RELATED COMPLEX, SUBUNIT 6; BORCS6__:__BORC, SUBUNIT 6;; CHROMOSOME 17 OPEN READING FRAME 59; C17ORF59;; LYSOSOME-DISPERSING PROTEIN; LYSPERSIN__:__
Asterisk__:__616600__:__BLOC1-RELATED COMPLEX, SUBUNIT 7; BORCS7__:__BORC, SUBUNIT 7;; CHROMOSOME 10 OPEN READING FRAME 32; C10ORF32;; DIASKEDIN__:__
Asterisk__:__616601__:__BLOC1-RELATED COMPLEX, SUBUNIT 8; BORCS8__:__BORC, SUBUNIT 8;; MEF2B NEIGHBOR GENE; MEF2BNB__:__
Number Sign__:__616602__:__CRANIOSYNOSTOSIS 6; CRS6__:____:__
Number Sign__:__616603__:__CUTIS LAXA, AUTOSOMAL DOMINANT 3; ADCL3__:____:__
Number Sign__:__616604__:__CHROMOSOME 14q32 DUPLICATION SYNDROME, 700-KB__:__MYELOPROLIFERATIVE NEOPLASMS, FAMILIAL, SUSCEPTIBILITY TO__:__
Asterisk__:__616605__:__GSK3B-INTERACTING PROTEIN; GSKIP__:__CHROMOSOME 14 OPEN READING FRAME 129; C14ORF129__:__
Number Sign__:__616606__:__RING CHROMOSOME 14 SYNDROME__:____:__
Asterisk__:__616607__:__KELCH REPEAT- AND BTB/POZ DOMAIN-CONTAINING PROTEIN 8; KBTBD8__:__T-CELL ACTIVATION KELCH REPEAT PROTEIN; TAKRP;; KIAA1842__:__
Asterisk__:__616608__:__CHROMOSOME 5 OPEN READING FRAME 30; C5ORF30__:____:__
Asterisk__:__616609__:__TRANSMEMBRANE PROTEIN 65; TMEM65__:____:__
Asterisk__:__616610__:__CANCER SUSCEPTIBILITY CANDIDATE 15, NONCODING; CASC15__:__LONG INTERGENIC NONCODING RNA 340: LINC00340;; lincRNA 340__:__
Asterisk__:__616611__:__LONG INTERGENIC NONCODING RNA 461; LINC00461__:__lincRNA 461;; VISUAL CORTEX-EXPRESSED GENE; VISC__:__
Asterisk__:__616612__:__COLLAGEN, TYPE VI, ALPHA-4, PSEUDOGENE 2; COL6A4P2__:____:__
Asterisk__:__616613__:__COLLAGEN, TYPE VI, ALPHA-6; COL6A6__:____:__
Asterisk__:__616614__:__HISTONE PARYLATION FACTOR 1; HPF1__:__CHROMOSOME 4 OPEN READING FRAME 27; C4ORF27__:__
Asterisk__:__616615__:__CHONDROITIN SULFATE N-ACETYLGALACTOSAMINYLTRANSFERASE 1; CSGALNACT1__:____:__
Asterisk__:__616616__:__CHONDROITIN SULFATE N-ACETYLGALACTOSAMINYLTRANSFERASE 2; CSGALNACT2__:____:__
Number Sign__:__616617__:__HEIMLER SYNDROME 2; HMLR2__:__PEROXISOME BIOGENESIS DISORDER 4C; PBD4C__:__
Asterisk__:__616618__:__ACYL-CoA-BINDING DOMAIN-CONTAINING PROTEIN 5; ACBD5__:__KIAA1996__:__
Asterisk__:__616619__:__DPPA2 UPSTREAM-BINDING RNA, NONCODING; DUBR__:__DPPA2 UPSTREAM-BINDING MUSCLE LONG NONCODING RNA; DUM;; LONG INTERGENIC NONCODING RNA 883; LINC0883;; lincRNA 883__:__
Asterisk__:__616620__:__WD REPEAT-CONTAINING PROTEIN 12; WDR12__:____:__
Asterisk__:__616621__:__DEAD BOX POLYPEPTIDE 27; DDX27__:__DEAD/H BOX POLYPEPTIDE 27;; RNA HELICASE-LIKE PROTEIN; RHLP__:__
Number Sign__:__616622__:__IMMUNODEFICIENCY 42; IMD42__:____:__
Asterisk__:__616623__:__FAMILY WITH SEQUENCE SIMILARITY 30, MEMBER A; FAM30A__:__KIAA0125;; CHROMOSOME 14 OPEN READING FRAME 110; C14ORF110__:__
Asterisk__:__616624__:__NUCLEAR CAP-BINDING PROTEIN 3; NCBP3__:__CHROMOSOME 17 OPEN READING FRAME 85; C17ORF85__:__
Number Sign__:__616625__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2W; CMT2W__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2W;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2W__:__
Asterisk__:__616626__:__CEREBRAL ENDOTHELIAL CELL ADHESION MOLECULE; CERCAM__:__CEECAM;; GLYCOSYLTRANSFERASE 25 FAMILY, MEMBER 3__:__
Asterisk__:__616627__:__PODOCALYXIN-LIKE 2; PODXL2__:__ENDOGLYCAN; EG__:__
Asterisk__:__616628__:__FAMILY WITH SEQUENCE SIMILARITY 220, MEMBER A; FAM220A__:__STAT3-INTERACTING PROTEIN AS A REPRESSOR; SIPAR;; ACROSOMAL PROTEIN 1; ACPIN1;; CHROMOSOME 7 OPEN READING FRAME 70; C7ORF70__:__SALIVARY GLAND-SPECIFIC PROTEIN 1, INCLUDED; SAGSIN1, INCLUDED
Number Sign__:__616629__:__SENIOR-LOKEN SYNDROME 9; SLSN9__:____:__
Asterisk__:__616630__:__NEURENSIN 1; NRSN1__:__VESICULAR MEMBRANE PROTEIN; VMP__:__
Number Sign__:__616631__:__POROKERATOSIS 9, MULTIPLE TYPES; POROK9__:____:__
Number Sign__:__616632__:__SEIZURES, CORTICAL BLINDNESS, AND MICROCEPHALY SYNDROME; SCBMS__:____:__
Asterisk__:__616633__:__PROLINE-RICH PROTEIN 12; PRR12__:__KIAA1205__:__
Asterisk__:__616634__:__SUSHI, NIDOGEN, AND EGF-LIKE DOMAINS PROTEIN 1; SNED1__:__STROMAL NIDOGEN EXTRACELLULAR MATRIX PROTEIN; SNEP__:__
Asterisk__:__616635__:__CYSTEINE- AND HISTIDINE-RICH PROTEIN 1; CYHR1__:__CHRP;; KIAA0496__:__
Number Sign__:__616636__:__IMMUNODEFICIENCY 44; IMD44__:____:__
Asterisk__:__616637__:__TBC1 DOMAIN FAMILY, MEMBER 16; TBC1D16__:____:__
Number Sign__:__616638__:__SMITH-KINGSMORE SYNDROME; SKS__:__MACROCEPHALY-INTELLECTUAL DISABILITY-NEURODEVELOPMENTAL DISORDER-SMALL THORAX SYNDROME;; MINDS SYNDROME;; MACROCEPHALY, SEIZURES, MENTAL RETARDATION, UMBILICAL HERNIA, AND FACIAL DYSMORPHISM__:__
Asterisk__:__616639__:__PR DOMAIN-CONTAINING PROTEIN 8; PRDM8__:____:__
Number Sign__:__616640__:__EPILEPSY, PROGRESSIVE MYOCLONIC, 10; EPM10__:____:__
Asterisk__:__616641__:__RING FINGER PROTEIN 141; RNF141__:__ZINC FINGER PROTEIN 230; ZNF230;; ZFP2__:__
Asterisk__:__616642__:__C6ORF89 GENE; C6ORF89__:__BOMBESIN RECEPTOR-ACTIVATED PROTEIN; BRAP;; AMFION__:__
Asterisk__:__616643__:__HEPATOMA-DERIVED GROWTH FACTOR-RELATED PROTEIN 3__:__HRP3;; HDGFRP3__:__
Asterisk__:__616644__:__CUB AND ZONA PELLUCIDA-LIKE DOMAINS 1; CUZD1__:__ESTROGEN-REGULATED GENE; ERG1;; INTEGRAL MEMBRANE-ASSOCIATED PROTEIN 1; ITMAP1__:__
Number Sign__:__616645__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 34; EIEE34__:____:__
Asterisk__:__616646__:__KERATIN 25, TYPE I; KRT25__:__K25; KRT25A; K25A;; KERATIN 25, INNER ROOT SHEATH, 1; KRT25IRS1; K25IRS1;; KA38;; K10C;; IRSA1__:__
Number Sign__:__616647__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 35; EIEE35__:____:__
Percent__:__616648__:__OPTIC ATROPHY 8; OPA8__:____:__
Number Sign__:__616649__:__SPHEROCYTOSIS, TYPE 2; SPH2__:__SPHEROCYTOSIS, HEREDITARY, 2; HS2__:__
Asterisk__:__616650__:__KIAA0556 GENE; KIAA0556__:__KATANIN-INTERACTING PROTEIN; KATNIP__:__
Number Sign__:__616651__:__ROIFMAN SYNDROME; RFMN__:__SPONDYLOEPIPHYSEAL DYSPLASIA, RETINAL DYSTROPHY, AND ANTIBODY DEFICIENCY__:__
Number Sign__:__616652__:__YUAN-HAREL-LUPSKI SYNDROME; YUHAL__:____:__
Asterisk__:__616653__:__PNN-INTERACTING SERINE/ARGININE-RICH PROTEIN; PNISR__:__SERINE/ARGININE-RICH SPLICING REGULATORY PROTEIN, 130-KD; SRRP130;; SPLICING FACTOR, ARGININE/SERINE-RICH, 18; SFRS18__:__
Number Sign__:__616654__:__JOUBERT SYNDROME 24; JBTS24__:____:__
Asterisk__:__616655__:__SIPA1-LIKE PROTEIN 3; SIPA1L3__:__SPAL3;; SPAR3;; KIAA0545__:__
Asterisk__:__616656__:__COMM DOMAIN-CONTAINING PROTEIN 8; COMMD8__:__COPPER METABOLISM MURR1 DOMAIN-CONTAINING PROTEIN 8__:__
Number Sign__:__616657__:__SPASTIC TETRAPLEGIA, THIN CORPUS CALLOSUM, AND PROGRESSIVE MICROCEPHALY; SPATCCM__:____:__
Asterisk__:__616658__:__CHROMOSOME 19 OPEN READING FRAME 70; C19ORF70__:__MITOCHONDRIAL CONTACT SITE AND CRISTAE ORGANIZING SYSTEM, 13-KD SUBUNIT; MIC13;; MICOS COMPLEX, 13-KD SUBUNIT;; QIL1__:__
Asterisk__:__616659__:__TBC1 DOMAIN FAMILY, MEMBER 17; TBC1D17__:____:__
Asterisk__:__616660__:__TRANSMEMBRANE PROTEIN 175: TMEM175__:____:__
Asterisk__:__616661__:__MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 2; MORC2__:__ZINC FINGER CW DOMAIN PROTEIN 3: ZCW3;; ZINC FINGER CW DOMAIN- AND COILED-COIL DOMAIN-CONTAINING PROTEIN 1; ZCWCC1;; MICRORCHIDIA, MOUSE, HOMOLOG OF, 2;; KIAA0852__:__
Asterisk__:__616662__:__THUMP DOMAIN-CONTAINING PROTEIN 1; THUMPD1__:__TAN1, YEAST, HOMOLOG OF__:__
Asterisk__:__616663__:__SMALL NUCLEOLAR RNA, C/D BOX, 118; SNORD118__:__snoRNA, U8__:__
Asterisk__:__616664__:__SMALL NUCLEOLAR RNA, C/D BOX, 13; SNORD13__:__snoRNA, U13__:__
Asterisk__:__616665__:__SYNAPTOPHYSIN-LIKE 1; SYPL1__:__SYPL;; PANTOPHYSIN__:__
Asterisk__:__616666__:__SEIZURE-RELATED 6, MOUSE, HOMOLOG OF; SEZ6__:__BRAIN-SPECIFIC RECEPTOR-LIKE PROTEIN C; BSRPC__:__
Asterisk__:__616667__:__SEZ6-LIKE PROTEIN 2; SEZ6L2__:__BRAIN-SPECIFIC RECEPTOR-LIKE PROTEIN A; BSRPA__:__
Number Sign__:__616668__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2X; CMT2X__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2X;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2X__:__
Number Sign__:__616669__:__IMMUNODEFICIENCY 45; IMD45__:____:__
Asterisk__:__616670__:__EXTENDED SYNAPTOTAGMIN-LIKE PROTEIN 1; ESYT1__:__EXTENDED SYNAPTOTAGMIN 1;; MEMBRANE-BOUND C2 DOMAIN-CONTAINING PROTEIN; MBC2;; FAMILY WITH SEQUENCE SIMILARITY 62, MEMBER A; FAM62A__:__
Asterisk__:__616671__:__KERATIN 76, TYPE II; KRT76__:__K76;; K2P; KRT2P;; CYTOKERATIN 2P; CK2P;; KB9__:__
Number Sign__:__616672__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 27; COXPD27__:____:__
Asterisk__:__616673__:__SPINDLE- AND KINETOCHORE-ASSOCIATED COMPLEX, SUBUNIT 1; SKA1__:__SPINDLE- AND KINETOCHORE-ASSOCIATED PROTEIN 1;; CHROMOSOME 18 OPEN READING FRAME 24; C18ORF24__:__
Asterisk__:__616674__:__SPINDLE- AND KINETOCHORE-ASSOCIATED COMPLEX, SUBUNIT 2; SKA2__:__SPINDLE- AND KINETOCHORE-ASSOCIATED PROTEIN 2;; FAMILY WITH SEQUENCE SIMILARITY 33, MEMBER A; FAM33A__:__
Asterisk__:__616675__:__KERATIN 26, TYPE I; KRT26__:__K26;; KA39;; K10D;; KERATIN 25B; KRT25B; K25B;; KERATIN 25, INNER ROOT SHEATH, 2; KRT25IRS2; K25IRS2;; CYTOKERATIN 26; CK26__:__
Asterisk__:__616676__:__KERATIN 27, TYPE I; KRT27__:__K27;; KRT25C; K25C;; KA40;; K10B;; KERATIN 25, INNER ROOT SHEATH, 3; KRT25IRS3; K25IRS3;; IRSA3.1;; CYTOKERATIN 27; CK27__:__
Asterisk__:__616677__:__KERATIN 28, TYPE I; KRT28__:__K28;; KRT25D; K25D;; KA41;; KERATIN 25, INNER ROOT SHEATH, 4; KRT25IRS4; K25IRS4;; IRS1A2;; CYTOKERATIN 28; CK28__:__
Asterisk__:__616678__:__KERATIN 39, TYPE I; KRT39__:__K39;; KA35;; CYTOKERATIN 39; CK39__:__
Asterisk__:__616679__:__KERATIN 40, TYPE I; KRT40__:__K40;; KA36;; CYTOKERATIN 40; CK40__:__
Number Sign__:__616680__:__SPASTIC PARAPLEGIA 75, AUTOSOMAL RECESSIVE; SPG75__:____:__
Number Sign__:__616681__:__MICROCEPHALY 16, PRIMARY, AUTOSOMAL RECESSIVE; MCPH16__:____:__
Number Sign__:__616682__:__SEIZURES, SCOLIOSIS, AND MACROCEPHALY SYNDROME; SSMS__:____:__
Number Sign__:__616683__:__LEUKODYSTROPHY, HYPOMYELINATING, 12; HLD12__:____:__
Number Sign__:__616684__:__CHARCOT-MARIE-TOOTH DISEASE, TYPE 4K; CMT4K__:__CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4K;; CHARCOT-MARIE-TOOTH NEUROPATHY, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4K__:__
Number Sign__:__616685__:__EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 14; EIG14__:____:__
Asterisk__:__616686__:__SYNAPTOTAGMIN-BINDING CYTOPLASMIC RNA-INTERACTING PROTEIN; SYNCRIP__:__NS1-ASSOCIATED PROTEIN 1; NSAP1;; GLYCINE-, ARGININE-, AND TYROSINE-RICH RNA-BINDING PROTEIN; GRYRBP;; HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN Q; HNRNPQ__:__
Number Sign__:__616687__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Y; CMT2Y__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Y;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Y__:__
Number Sign__:__616688__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Z; CMT2Z__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2Z;; CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2Z__:__
Number Sign__:__616689__:__DEHYDRATED HEREDITARY STOMATOCYTOSIS 2; DHS2__:__XEROCYTOSIS GARDOS;; DESICCYTOSIS GARDOS__:__
Asterisk__:__616690__:__CENTROSOMAL PROTEIN, 104-KD; CEP104__:__GLYCINE-, GLUTAMATE-, AND THIENYLCYCLOHEXYLPIPERIDINE-BINDING PROTEIN; GLYBP;; FAP256, CHLAMYDOMONAS, HOMOLOG OF;; KIAA0562__:__
Asterisk__:__616691__:__EXTENDED SYNAPTOTAGMIN-LIKE PROTEIN 2; ESYT2__:__EXTENDED SYNAPTOTAGMIN 2;; FAMILY WITH SEQUENCE SIMILARITY 62, MEMBER B; FAM62B__:__
Asterisk__:__616692__:__EXTENDED SYNAPTOTAGMIN-LIKE PROTEIN 3; ESYT3__:__EXTENDED SYNAPTOTAGMIN 3;; FAMILY WITH SEQUENCE SIMILARITY 62, MEMBER C; FAM62C__:__
Asterisk__:__616693__:__ACID-SENSING ION CHANNEL FAMILY MEMBER 5; ASIC5__:__HUMAN INTESTINE SODIUM CHANNEL; HINAC__:__
Asterisk__:__616694__:__KIAA0368 GENE; KIAA0368__:__ECM29, YEAST, HOMOLOG OF; ECM29__:__
Asterisk__:__616695__:__SERINE/THREONINE/TYROSINE-INTERACTING PROTEIN-LIKE 1; STYXL1__:__STYX-LIKE 1;; MAP KINASE PHOSPHATASE-LIKE STYX DOMAIN PROTEIN; MKSTYX;; DUAL-SPECIFICITY PHOSPHATASE 24; DUSP24__:__
Asterisk__:__616696__:__KIAA0040 GENE; KIAA0040__:____:__
Number Sign__:__616697__:__DEAFNESS, AUTOSOMAL DOMINANT 69; DFNA69__:__DEAFNESS, CONGENITAL, UNILATERAL OR ASYMMETRIC; DCUA__:__
Asterisk__:__616698__:__ZINC FINGER PROTEIN 593; ZNF593__:__ZINC FINGER PROTEIN T86; ZT86__:__
Asterisk__:__616699__:__COMM DOMAIN-CONTAINING PROTEIN 2; COMMD2__:____:__
Asterisk__:__616700__:__COMM DOMAIN-CONTAINING PROTEIN 3; COMMD3__:____:__
Asterisk__:__616701__:__COMM DOMAIN-CONTAINING PROTEIN 4; COMMD4__:____:__
Asterisk__:__616702__:__ZINC FINGER PROTEIN 589; ZNF589__:__STEM CELL ZINC FINGER PROTEIN 1; SZF1__:__
Asterisk__:__616703__:__COMM DOMAIN-CONTAINING PROTEIN 7; COMMD7__:____:__
Asterisk__:__616704__:__COMM DOMAIN-CONTAINING PROTEIN 10; COMMD10__:____:__
Number Sign__:__616705__:__DEAFNESS, AUTOSOMAL RECESSIVE 97; DFNB97__:____:__
Asterisk__:__616706__:__POLY(ADP-RIBOSE) POLYMERASE FAMILY, MEMBER 11; PARP11__:__ARTD11__:__
Number Sign__:__616707__:__DEAFNESS, AUTOSOMAL DOMINANT 68; DFNA68__:____:__
Number Sign__:__616708__:__DESANTO-SHINAWI SYNDROME; DESSH__:__DEVELOPMENTAL DELAY, BEHAVIORAL ABNORMALITIES, FACIAL DYSMORPHISM, AND OCULAR ABNORMALITIES__:__CHROMOSOME 10p12-p11 DELETION SYNDROME, INCLUDED
Asterisk__:__616709__:__ALPHA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; A4GNT__:____:__
Number Sign__:__616710__:__PARKINSON DISEASE 22, AUTOSOMAL DOMINANT; PARK22__:____:__
Asterisk__:__616711__:__TAO KINASE 3; TAOK3__:__JNK/SAPK-INHIBITORY KINASE; JIK;; DENDRITIC CELL-DERIVED PROTEIN KINASE; DPK__:__
Asterisk__:__616712__:__START DOMAIN-CONTAINING PROTEIN 7; STARD7__:__GESTATIONAL TROPHOBLASTIC TUMOR PROTEIN 1; GTT1__:__
Asterisk__:__616713__:__PIPECOLIC ACID OXIDASE; PIPOX__:____:__
Asterisk__:__616714__:__HMG-BOX TRANSCRIPTION FACTOR 1; HBP1__:____:__
Asterisk__:__616715__:__THIOREDOXIN-RELATED TRANSMEMBRANE PROTEIN 2; TMX2__:____:__
Number Sign__:__616716__:__RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 5; RCDP5__:____:__
Asterisk__:__616717__:__TESTIS-EXPRESSED GENE 10; TEX10__:____:__
Asterisk__:__616718__:__NEURITE OUTGROWTH-ASSOCIATED PROTEIN; NGRN__:__NEUGRIN__:__
Number Sign__:__616719__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21; SCAR21__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21, WITH HEPATOPATHY__:__
Number Sign__:__616720__:__MYASTHENIC SYNDROME, CONGENITAL, 19; CMS19__:____:__
Number Sign__:__616721__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIn; CDG2N__:__CDG IIn; CDGIIn__:__
Number Sign__:__616722__:__RETINAL DYSTROPHY AND IRIS COLOBOMA WITH OR WITHOUT CONGENITAL CATARACT; RDICC__:____:__
Number Sign__:__616723__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, FADEN-ALKURAYA TYPE; SEMDFA__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, PROGRESSIVE, WITH SHORT STATURE, FACIAL DYSMORPHISM, SHORT FOURTH METATARSALS, AND MENTAL RETARDATION, WITH OR WITHOUT CRANIOSYNOSTOSIS__:__
Number Sign__:__616724__:__TOOTH AGENESIS, SELECTIVE, 7; STHAG7__:____:__
Asterisk__:__616725__:__DEAD BOX POLYPEPTIDE 60-LIKE; DDX60L__:____:__
Number Sign__:__616726__:__CILIARY DYSKINESIA, PRIMARY, 33; CILD33__:__CILIARY DYSKINESIA, PRIMARY, 33, WITHOUT SITUS INVERSUS__:__
Asterisk__:__616727__:__PHD FINGER PROTEIN 21B; PHF21B__:__PHF4;; BHC80L__:__
Number Sign__:__616728__:__CLEFT PALATE, PSYCHOMOTOR RETARDATION, AND DISTINCTIVE FACIAL FEATURES; CPRF__:____:__
Asterisk__:__616729__:__OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY W, MEMBER 3; OR2W3__:____:__
Number Sign__:__616730__:__NEPHROTIC SYNDROME, TYPE 11; NPHS11__:____:__
Asterisk__:__616731__:__NEVER IN MITOSIS GENE A-RELATED KINASE 5; NEK5__:__NIMA-RELATED KINASE 5__:__
Number Sign__:__616732__:__OPTIC ATROPHY 10 WITH OR WITHOUT ATAXIA, MENTAL RETARDATION, AND SEIZURES; OPA10__:____:__
Number Sign__:__616733__:__COENZYME Q10 DEFICIENCY, PRIMARY, 8; COQ10D8__:____:__
Number Sign__:__616734__:__SKIN CREASES, CONGENITAL SYMMETRIC CIRCUMFERENTIAL, 2; CSCSC2__:____:__
Asterisk__:__616735__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 174: CCDC174__:__HEMATOPOIETIC STEM/PROGENITOR CELL-EXPRESSED GENE 212; HSPC212__:__
Number Sign__:__616736__:__TREMOR, HEREDITARY ESSENTIAL, 5; ETM5__:____:__
Number Sign__:__616737__:__TAKENOUCHI-KOSAKI SYNDROME; TKS__:__MACROTHROMBOCYTOPENIA AND MENTAL RETARDATION SYNDROME__:__
Number Sign__:__616738__:__RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA 2; RUSAT2__:____:__
Number Sign__:__616739__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 51; MRT51__:____:__
Number Sign__:__616740__:__IMMUNODEFICIENCY 46; IMD46__:____:__
Asterisk__:__616741__:__PR DOMAIN-CONTAINING PROTEIN 13; PRDM13__:__PR DOMAIN ZINC FINGER PROTEIN 13__:__
Asterisk__:__616742__:__NOP58, S. CEREVISIAE, HOMOLOG OF; NOP58__:__NOP58 RIBONUCLEOPROTEIN;; NOP5, S. CEREVISIAE, HOMOLOG OF; NOP5__:__
Asterisk__:__616743__:__RAL GUANINE NUCLEOTIDE DISSOCIATION STIMULATOR-LIKE 3; RGL3__:____:__
Number Sign__:__616744__:__AUTOINFLAMMATORY SYNDROME, FAMILIAL, BEHCET-LIKE; AISBL__:____:__
Asterisk__:__616745__:__BIORIENTATION OF CHROMOSOMES IN CELL DIVISION 1; BOD1__:__BIORIENTATION DEFECTIVE 1;; FAMILY WITH SEQUENCE SIMILARITY 44, MEMBER B; FAM44B__:__
Asterisk__:__616746__:__BOD1-LIKE PROTEIN 1; BOD1L1__:__BOD1L;; FAMILY WITH SEQUENCE SIMILARITY 4, MEMBER A; FAM44A__:__
Asterisk__:__616747__:__CHOLINE PHOSPHOTRANSFERASE 1; CHPT1__:__CPT; CPT1__:__
Asterisk__:__616748__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 8; ENTPD8__:__ENTPDase 8__:__
Number Sign__:__616749__:__HETEROTAXY, VISCERAL, 7, AUTOSOMAL; HTX7__:____:__
Asterisk__:__616750__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 16; ZDHHC16__:__ABL-PHILIN 2; APH2__:__
Asterisk__:__616751__:__CHOLINE/ETHANOLAMINE PHOSPHOTRANSFERASE 1; CEPT1__:____:__
Asterisk__:__616752__:__HYPOTHALAMUS GOLGI APPARATUS-EXPRESSED PROTEIN, 19-KD__:__HMP19;; NEURON-SPECIFIC GENE 2; NSG2__:__
Asterisk__:__616753__:__ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 7; ENTPD7__:__LYSOSOMAL APYRASE-LIKE PROTEIN 1; LALP1__:__
Number Sign__:__616754__:__BOMBAY PHENOTYPE__:____:__PARA-BOMBAY PHENOTYPE, INCLUDED;; REUNION VARIANT, INCLUDED;; BOMBAY PHENOTYPE, DIGENIC, INCLUDED
Asterisk__:__616755__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 62; TRIM62__:__DUCTAL EPITHELIUM-ASSOCIATED RING PROTEIN, CHROMOSOME 1; DEAR1__:__
Number Sign__:__616756__:__SPASTIC PARAPLEGIA AND PSYCHOMOTOR RETARDATION WITH OR WITHOUT SEIZURES; SPPRS__:____:__
Asterisk__:__616757__:__TRANSMEMBRANE PROTEIN 150A; TMEM150A__:__TRANSMEMBRANE PROTEIN 150; TMEM150;; TENTONIN 1; TTN1;; TM6P1__:__
Asterisk__:__616758__:__KERATINOCYTE DIFFERENTIATION FACTOR 1; KDF1__:__CHROMOSOME 1 OPEN READING FRAME 172; C1ORF172__:__
Asterisk__:__616759__:__NITRIC OXIDE SYNTHASE-INTERACTING PROTEIN; NOSIP__:____:__
Number Sign__:__616760__:__WOOLLY HAIR, AUTOSOMAL RECESSIVE 3; ARWH3__:__WOOLLY HAIR, AUTOSOMAL RECESSIVE 3, WITH HYPOTRICHOSIS__:__
Asterisk__:__616761__:__SUSHI DOMAIN-CONTAINING PROTEIN 6; SUSD6__:__DRUG-ACTIVATED GENE OVEREXPRESSED; DRAGO;; KIAA0247__:__
Asterisk__:__616762__:__CENTRIOLE-, CILIA-, AND SPINDLE-ASSOCIATED PROTEIN; CCSAP__:__CENTRIOLE- AND SPINDLE-ASSOCIATED PROTEIN; CSAP;; CHROMOSOME 10 OPEN READING FRAME 96; C1ORF96__:__
Number Sign__:__616763__:__LEUKODYSTROPHY AND ACQUIRED MICROCEPHALY WITH OR WITHOUT DYSTONIA; LDAMD__:____:__
Asterisk__:__616764__:__SOLUTE CARRIER FAMILY 46, MEMBER 3; SLC46A3__:____:__
Asterisk__:__616765__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 11; SAMD11__:__MAJOR RETINAL SAM DOMAIN PROTEIN; MR-S__:__
Asterisk__:__616766__:__THIOREDOXIN-RELATED TRANSMEMBRANE PROTEIN 4; TMX4__:____:__
Asterisk__:__616767__:__CALPAIN, SMALL SUBUNIT 2; CAPNS2__:__CALCIUM-DEPENDENT PROTEASE SMALL SUBUNIT 2; CSS2__:__
Asterisk__:__616768__:__TUBULIN, BETA-8; TUBB8__:__TUBULIN, BETA, CLASS VIII__:__
Asterisk__:__616769__:__NITRILASE FAMILY MEMBER 2; NIT2__:____:__
Asterisk__:__616770__:__MICRO RNA 218-1; MIR218-1__:__miRNA218-1__:__
Asterisk__:__616771__:__MICRO RNA 218-2; MIR218-2__:__miRNA218-2__:__
Asterisk__:__616772__:__MANNOSIDASE, ALPHA, CLASS 1C, MEMBER 1; MAN1C1__:____:__
Asterisk__:__616773__:__FAMILY WITH SEQUENCE SIMILARITY 73, MEMBER A; FAM73A__:__MIGA, DROSOPHILA, HOMOLOG OF, 1; MIGA1;; MITOGUARDIN 1__:__
Asterisk__:__616774__:__FAMILY WITH SEQUENCE SIMILARITY 73, MEMBER B; FAM73B__:__MIGA, DROSOPHILA, HOMOLOG OF, 2; MIGA2;; MITOGUARDIN 2__:__
Asterisk__:__616775__:__ZINC FINGER PROTEIN 683; ZNF683__:__HOMOLOG OF BLIMP1 IN T CELLS; HOBIT__:__
Asterisk__:__616776__:__DUAL-SPECIFICITY PHOSPHATASE 15; DUSP15__:__VH1-RELATED FAMILY, MEMBER Y; VHY__:__
Number Sign__:__616777__:__SECKEL SYNDROME 9; SCKL9__:____:__
Asterisk__:__616778__:__DUAL-SPECIFICITY PHOSPHATASE 22; DUSP22__:__LOW MOLECULAR WEIGHT DUAL-SPECIFICITY PHOSPHATASE 2; LMWDSP2;; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE X; MKPX;; VHR-RELATED MKPX; VHX;; JNK PATHWAY-ASSOCIATED PHOSPHATASE; JKAP;; JNK STIMULATORY PHOSPHATASE 1; JSP1__:__
Number Sign__:__616779__:__CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY, TYPE 2; CADASIL2__:____:__
Number Sign__:__616780__:__OOCYTE MATURATION DEFECT 2; OOMD2__:____:__
Number Sign__:__616781__:__JOUBERT SYNDROME 25; JBTS25__:____:__
Asterisk__:__616782__:__GLUCOSAMINYL (N-ACETYL) TRANSFERASE 4, CORE 2; GCNT4__:__BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE 4, CORE 2__:__
Asterisk__:__616783__:__UBX DOMAIN PROTEIN 10; UBXN10__:____:__
Number Sign__:__616784__:__JOUBERT SYNDROME 26; JBTS26__:____:__
Asterisk__:__616785__:__PUTATIVE HOMEODOMAIN TRANSCRIPTION FACTOR 2; PHTF2__:____:__
Asterisk__:__616786__:__MITOGEN-ACTIVATED PROTEIN KINASE-BINDING PROTEIN 1; MAPKBP1__:__JNK-BINDING PROTEIN 1; JNKBP1__:__
Asterisk__:__616787__:__CLUSTERIN-ASSOCIATED PROTEIN 1; CLUAP1__:__FLAGELLAR-ASSOCIATED PROTEIN 22, CHLAMYDOMONAS, HOMOLOG OF; FAP22;; DYF3, C. ELEGANS, HOMOLOG OF;; QILIN;; KIAA0643__:__
Number Sign__:__616788__:__OROFACIAL CLEFT 15; OFC15__:____:__
Number Sign__:__616789__:__MENTAL RETARDATION AND DISTINCTIVE FACIAL FEATURES WITH OR WITHOUT CARDIAC DEFECTS; MRFACD__:____:__
Asterisk__:__616790__:__PROTEIN PHOSPHATASE 4, REGULATORY SUBUNIT 4; PPP4R4__:__PP4R4;; KIAA1622__:__
Asterisk__:__616791__:__PIGGYBAC TRANSPOSABLE ELEMENT-DERIVED GENE 5; PGBD5__:__PIGGYBAC DOMAIN-RELATED PROTEIN 5__:__
Percent__:__616792__:__NEUROBLASTOMA, SUSCEPTIBILITY TO, 7; NBLST7__:____:__
Asterisk__:__616793__:__PHOSPHOLIPASE A2, GROUP IIF; PLA2G2F__:__PHOSPHOLIPASE A2, SECRETED, GROUP IIF;; SPLA2 IIF__:__
Number Sign__:__616794__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 28; COXPD28__:____:__
Number Sign__:__616795__:__SPINOCEREBELLAR ATAXIA 42; SCA42__:____:__
Asterisk__:__616796__:__RETINOL DEHYDROGENASE 14; RDH14__:__SHORT-CHAIN DEHYDROGENASE/REDUCTASE FAMILY 7C, MEMBER 4; SDR7C4;; PANCREAS PROTEIN 2; PAN2__:__
Asterisk__:__616797__:__EFR3, S. CEREVISIAE, HOMOLOG OF, B; EFR3B__:__KIAA0953__:__
Asterisk__:__616798__:__ZINC FINGER PROTEIN 28; ZFP28__:____:__
Asterisk__:__616799__:__SYNAPTONEMAL COMPLEX PROTEIN 2-LIKE; SYCP2L__:__SYCP2-LIKE;; CHROMOSOME 6 OPEN READING FRAME 177; C6ORF177__:__
Asterisk__:__616800__:__LOXL1 ANTISENSE RNA 1, NONCODING; LOXL1AS1__:__LONG NONCODING RNA LOXL1AS1;; lncRNA LOXL1AS1__:__
Number Sign__:__616801__:__HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 2; IHPRF2__:____:__
Asterisk__:__616802__:__T CELL-INTERACTING ACTIVATING RECEPTOR ON MYELOID CELLS 1; TARM1__:____:__
Number Sign__:__616803__:__LAMB-SHAFFER SYNDROME; LAMSHF__:____:__
Asterisk__:__616804__:__V-SET AND TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 1; VSTM1__:__SIGNAL INHIBITORY RECEPTOR ON LEUKOCYTES 1; SIRL1__:__
Asterisk__:__616805__:__MYC TARGET IN MYELOID CELLS 1; MYCT1__:__MYC TARGET PROTEIN 1;; MYC TARGET FROM LARYNGEAL CANCER CELLS; MTLC__:__
Number Sign__:__616806__:__WILMS TUMOR 6; WT6__:__WILMS TUMOR, SUSCEPTIBILITY TO__:__
Asterisk__:__616807__:__FAS-BINDING FACTOR 1; FBF1__:__ALBATROSS; ALB__:__
Asterisk__:__616808__:__CHROMOSOME 19 OPEN READING FRAME 66; C19ORF66__:__REPRESSOR FOR YIELD OF DENGUE VIRUS; RYDEN__:__
Number Sign__:__616809__:__HYPERPHOSPHATASIA WITH MENTAL RETARDATION SYNDROME 6; HPMRS6__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 12; GPIBD12__:__
Asterisk__:__616810__:__IMMUNOGLOBULIN SUPERFAMILY, DCC SUBCLASS, MEMBER 4; IGDCC4__:__NEIGHBOR OF PUNC E11; NOPE;; KIAA1628__:__
Number Sign__:__616811__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 29; COXPD29__:____:__
Number Sign__:__616812__:__CARDIAC ARRHYTHMIA WITH INCREASED SERUM CREATINE KINASE; CARICK__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2X; LGMD2X__:__
Asterisk__:__616813__:__ARF GTPase-ACTIVATING PROTEIN WITH GTPase DOMAIN, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAIN 3; AGAP3__:__CENTAURIN, GAMMA-3; CENTG3__:__CRAM-ASSOCIATED GTPase, INCLUDED; CRAG, INCLUDED
Number Sign__:__616814__:__PREIMPLANTATION EMBRYONIC LETHALITY 1; PREMBL1__:__PREMBL__:__
Asterisk__:__616815__:__TRANSMEMBRANE PROTEIN 199; TMEM199__:__VMA12, S. CEREVISIAE, HOMOLOG OF; VMA12;; VPH2, S. CEREVISIAE, HOMOLOG OF; VPH2;; CHROMOSOME 17 OPEN READING FRAME 32; C17ORF32__:__
Number Sign__:__616816__:__HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION; IHPMR__:____:__
Number Sign__:__616817__:__MICROCEPHALY, SHORT STATURE, AND IMPAIRED GLUCOSE METABOLISM 2; MSSGM2__:____:__
Number Sign__:__616818__:__IgA NEPHROPATHY, SUSCEPTIBILITY TO, 3; IGAN3__:____:__
Number Sign__:__616819__:__CORPUS CALLOSUM, AGENESIS OF, WITH FACIAL ANOMALIES AND CEREBELLAR ATAXIA; CCAFCA__:__BIRK-FLUSSER SYNDROME__:__
Asterisk__:__616820__:__METHENYLTETRAHYDROFOLATE SYNTHETASE DOMAIN-CONTAINING PROTEIN; MTHFSD__:__MTHFS DOMAIN-CONTAINING PROTEIN__:__
Asterisk__:__616821__:__THROMBOSPONDIN TYPE 1 DOMAIN-CONTAINING PROTEIN 1; THSD1__:__TRANSMEMBRANE MOLECULE WITH THROMBOSPONDIN MODULE; TMTSP__:__
Asterisk__:__616822__:__MON2, S. CEREVISIAE, HOMOLOG OF; MON2__:__MON2, REGULATOR OF ENDOSOME-TO-GOLGI TRAFFICKING;; KIAA1040__:__
Asterisk__:__616823__:__DOPEY FAMILY MEMBER 1; DOPEY1__:__DOP1;; KIAA1117__:__
Asterisk__:__616824__:__TMF1-REGULATED NUCLEAR PROTEIN 1; TRNP1__:__TMF-REGULATED NUCLEAR PROTEIN; TRNP__:__
Asterisk__:__616825__:__NUCLEAR RECEPTOR COACTIVATOR 5; NCOA5__:__COACTIVATOR INDEPENDENT OF AF2; CIA__:__
Asterisk__:__616826__:__EPS15-LIKE PROTEIN 1; EPS15L1__:__EPS15-RELATED PROTEIN; EPS15R__:__
Number Sign__:__616827__:__MUSCULAR DYSTROPHY, AUTOSOMAL RECESSIVE, WITH CARDIOMYOPATHY AND TRIANGULAR TONGUE; MDRCMTT__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2W; LGMD2W__:__
Number Sign__:__616828__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIo; CDG2O__:__CDG IIo; CDGIIo__:__
Number Sign__:__616829__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIp; CDG2P__:__CDG IIp; CDGIIp__:__
Asterisk__:__616830__:__TRANSPORT AND GOLGI ORGANIZATION 2, DROSOPHILA, HOMOLOG OF; TANGO2__:__CHROMOSOME 22 OPEN READING FRAME 25; C22ORF25__:__
Number Sign__:__616831__:__LUSCAN-LUMISH SYNDROME; LLS__:____:__
Asterisk__:__616832__:__MYOMESIN 3; MYOM3__:____:__
Number Sign__:__616833__:__PAGET DISEASE OF BONE 6; PDB6__:____:__
Number Sign__:__616834__:__MICROCEPHALY, CONGENITAL CATARACT, AND PSORIASIFORM DERMATITIS; MCCPD__:__SC4MOL DEFICIENCY__:__
Number Sign__:__616835__:__MEIER-GORLIN SYNDROME 6; MGORS6__:____:__
Asterisk__:__616836__:__G-PATCH DOMAIN-CONTAINING PROTEIN 2; GPATCH2__:__GPATC2__:__
Asterisk__:__616837__:__HUMAN PLURIPOTENCY-ASSOCIATED TRANSCRIPT 5, NONCODING__:__HPAT5;; LONG INTERGENIC NONCODING RNA HPAT5;; lincRNA HPAT5__:__
Asterisk__:__616838__:__C-TYPE LECTIN DOMAIN FAMILY 17, MEMBER A; CLEC17A__:__PROLECTIN__:__
Number Sign__:__616839__:__EXERCISE INTOLERANCE, RIBOFLAVIN-RESPONSIVE; RREI__:____:__
Number Sign__:__616840__:__PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK23__:____:__
Asterisk__:__616841__:__ZINC FINGER PROTEIN 468; ZNF468__:____:__
Asterisk__:__616842__:__DNase1 HYPERSENSITIVITY, CHROMOSOME 6, SITE 1; DHS6S1__:____:__
Number Sign__:__616843__:__LYMPHATIC MALFORMATION 6; LMPHM6__:__GENERALIZED LYMPHATIC DYSPLASIA OF FOTIOU;; LYMPHEDEMA, HEREDITARY, III, FORMERLY; LMPH3, FORMERLY__:__
Asterisk__:__616844__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 17; DNAJC17__:____:__
Asterisk__:__616845__:__C-TYPE LECTIN DOMAIN FAMILY 14, MEMBER A; CLEC14A__:____:__
Asterisk__:__616846__:__ENDOPLASMIC RETICULUM MEMBRANE PROTEIN COMPLEX, SUBUNIT 1; EMC1__:__ER MEMBRANE PROTEIN COMPLEX, SUBUNIT 1;; KIAA0090__:__
Asterisk__:__616847__:__ZINC FINGER PROTEIN 543; ZNF543__:____:__
Asterisk__:__616848__:__MESODERM INDUCTION-EARLY RESPONSE PROTEIN 1; MIER1__:__MIER1 TRANSCRIPTIONAL REGULATOR;; KIAA1610__:__
Number Sign__:__616849__:__BRACHYDACTYLY, TYPE A1, D; BDA1D__:____:__
Asterisk__:__616850__:__WD REPEAT-CONTAINING PROTEIN 83; WDR83__:__MITOGEN-ACTIVATED PROTEIN KINASE ORGANIZER 1; MORG1;; MAPK ORGANIZER 1__:__
Number Sign__:__616851__:__CATARACT 45; CTRCT45__:____:__
Number Sign__:__616852__:__MYOPATHY, SCAPULOHUMEROPERONEAL; SHPM__:____:__
Asterisk__:__616853__:__FAMILY WITH SEQUENCE SIMILARITY 72, MEMBER C: FAM72C__:____:__
Number Sign__:__616854__:__EVEN-PLUS SYNDROME; EVPLS__:__EPIPHYSEAL AND VERTEBRAL DYSPLASIA, MICROTIA, AND FLAT NOSE, PLUS ASSOCIATED MALFORMATIONS__:__
Asterisk__:__616855__:__CYTOCHROME c OXIDASE, SUBUNIT 8C; COX8C__:__CYTOCHROME c OXIDASE, SUBUNIT VIIIc;; COX VIII-3;; COX8-3__:__
Asterisk__:__616856__:__BROMODOMAIN- AND PHD FINGER-CONTAINING PROTEIN 3; BRPF3__:__KIAA1286__:__
Asterisk__:__616857__:__CHLORIDE CHANNEL ACCESSORY 4; CLCA4__:__CHLORIDE CHANNEL, CALCIUM-ACTIVATED, 4;; CALCIUM-ACTIVATED CHLORIDE CHANNEL 2; CACC2__:__
Number Sign__:__616858__:__COWDEN SYNDROME 7; CWS7__:____:__
Number Sign__:__616859__:__SPASTICITY, CHILDHOOD-ONSET, WITH HYPERGLYCINEMIA; SPAHGC__:____:__
Number Sign__:__616860__:__ANEMIA, SIDEROBLASTIC, 3, PYRIDOXINE-REFRACTORY; SIDBA3__:____:__
Asterisk__:__616861__:__SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTER), MEMBER 9; SLC12A9__:__CATION-CHLORIDE COTRANSPORTER-INTERACTING PROTEIN 1; CIP1;; CATION-CHLORIDE COTRANSPORTER 6; CCC6;; POTASSIUM-CHLORIDE TRANSPORTER 9__:__
Asterisk__:__616862__:__RIBOSOMAL PROTEIN L34; RPL34__:__60S RIBOSOMAL PROTEIN 34__:__
Number Sign__:__616863__:__CHROMOSOME 16p13.2 DELETION SYNDROME__:____:__
Asterisk__:__616864__:__HEXOSAMINIDASE (GLYCOSYL HYDROLASE FAMILY 20, CATALYTIC DOMAIN)-CONTAINING PROTEIN; HEXDC__:__HEXOSAMINIDASE D__:__
Asterisk__:__616865__:__POLY(A) POLYMERASE, GAMMA; PAPOLG__:__PAP-GAMMA;; SIGNAL RECOGNITION PARTICLE RNA-ADENYLATING ENZYME;; SRP RNA-ADENYLATING ENZYME;; NEO-PAP__:__
Number Sign__:__616866__:__SPINAL MUSCULAR ATROPHY WITH CONGENITAL BONE FRACTURES 1; SMABF1__:____:__
Number Sign__:__616867__:__SPINAL MUSCULAR ATROPHY WITH CONGENITAL BONE FRACTURES 2; SMABF2__:____:__
Number Sign__:__616868__:__DIARRHEA 8, SECRETORY SODIUM, CONGENITAL; DIAR8__:__DIARRHEA, CONGENITAL SODIUM; CSD__:__
Asterisk__:__616869__:__C-TERMINAL DOMAIN NUCLEAR ENVELOPE PHOSPHATASE 1 REGULATORY SUBUNIT 1; CNEP1R1__:__CTDNEP1 REGULATORY SUBUNIT 1;; NEP1R1;; TRANSMEMBRANE PROTEIN 188; TMEM188;; SPO7, S. CEREVISIAE, HOMOLOG OF;; CHROMOSOME 16 OPEN READING FRAME 69; C16ORF69__:__ENDOPLASMIC RETICULUM ADAPTOR PROTEIN, INCLUDED; ERADP, INCLUDED
Asterisk__:__616870__:__TRANSMEMBRANE PROTEIN 14A; TMEM14A__:____:__
Number Sign__:__616871__:__MYELOPROLIFERATIVE/LYMPHOPROLIFERATIVE NEOPLASMS, FAMILIAL (MULTIPLE TYPES), SUSCEPTIBILITY TO; MPLPF__:____:__
Asterisk__:__616872__:__TRANSMEMBRANE 9 SUPERFAMILY, MEMBER 3; TM9SF3__:__SM11044-BINDING PROTEIN; SMBP__:__
Number Sign__:__616873__:__IMMUNODEFICIENCY, COMMON VARIABLE, 13; CVID13__:____:__
Asterisk__:__616874__:__TRANSMEMBRANE BAX INHIBITOR MOTIF-CONTAINING PROTEIN 4; TMBIM4__:__GOLGI-ASSOCIATED ANTIAPOPTOTIC PROTEIN; GAAP__:__
Number Sign__:__616875__:__CEREBELLAR ATROPHY, VISUAL IMPAIRMENT, AND PSYCHOMOTOR RETARDATION; CAVIPMR__:____:__
Asterisk__:__616876__:__TRANSMEMBRANE p24 TRAFFICKING PROTEIN 5; TMED5__:__TRANSMEMBRANE EMP24 PROTEIN TRANSPORT DOMAIN-CONTAINING PROTEIN 5;; p24, GAMMA-2;; p28__:__
Asterisk__:__616877__:__TRANSMEMBRANE PROTEIN 9; TMEM9__:__TMEM9A;; DERMAL PAPILLA-DERIVED PROTEIN 4; DERM4__:__
Number Sign__:__616878__:__METABOLIC ENCEPHALOMYOPATHIC CRISES, RECURRENT, WITH RHABDOMYOLYSIS, CARDIAC ARRHYTHMIAS, AND NEURODEGENERATION; MECRCN__:____:__
Asterisk__:__616879__:__TBC1 DOMAIN FAMILY, MEMBER 22A; TBC1D22A__:__CHROMOSOME 22 OPEN READING FRAME 4; C22ORF4__:__
Asterisk__:__616880__:__TBC1 DOMAIN FAMILY, MEMBER 22B; TBC1D22B__:__CHROMOSOME 6 OPEN READING FRAME 197; C6ORF197__:__
Number Sign__:__616881__:__LEUKODYSTROPHY, HYPOMYELINATING, 13; HLD13__:____:__
Number Sign__:__616882__:__ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 3; FASPS3__:____:__
Asterisk__:__616883__:__SIGNAL RECOGNITION PARTICLE RECEPTOR, BETA SUBUNIT; SRPRB__:__SRP RECEPTOR, BETA SUBUNIT;; APMCF1__:__
Asterisk__:__616884__:__UNC79, C. ELEGANS, HOMOLOG OF; UNC79__:____:__
Asterisk__:__616885__:__CALCIUM-REGULATED HEAT-STABLE PROTEIN 1; CARHSP1__:__CALCIUM-REGULATED HEAT-STABLE PROTEIN, 24-KD; CRHSP24;; COLD-SHOCK DOMAIN-CONTAINING PROTEIN C1; CSDC1__:__
Asterisk__:__616886__:__GSE1 COILED-COIL PROTEIN; GSE1__:__KIAA0182__:__
Number Sign__:__616887__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 52; MRT52__:____:__
Asterisk__:__616888__:__TRANSMEMBRANE PROTEIN 8B; TMEM8B__:__NASOPHARYNGEAL CANCER-RELATED GENE 6; NGX6;; NAG5__:__
Asterisk__:__616889__:__CENTROSOMAL PROTEIN, 68-KD; CEP68__:__KIAA0582__:__
Number Sign__:__616890__:__SPLIT-FOOT MALFORMATION WITH MESOAXIAL POLYDACTYLY; SFMMP__:____:__
Asterisk__:__616891__:__DWARF OPEN READING FRAME__:__DWORF;; LOC100507537__:__
Number Sign__:__616892__:__NEPHROTIC SYNDROME, TYPE 12; NPHS12__:____:__
Number Sign__:__616893__:__NEPHROTIC SYNDROME, TYPE 13; NPHS13__:____:__
Number Sign__:__616894__:__ROBINOW SYNDROME, AUTOSOMAL DOMINANT 3; DRS3__:____:__
Asterisk__:__616895__:__SURVIVAL-ASSOCIATED MITOCHONDRIAL MELANOMA-SPECIFIC ONCOGENIC NONCODING RNA; SAMMSON__:__LONG INTERGENIC NONCODING RNA 1212; LINC01212;; lincRNA 1212__:__
Number Sign__:__616896__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14__:____:__
Number Sign__:__616897__:__OSTEOCHONDRODYSPLASIA, COMPLEX LETHAL, SYMOENS-BARNES-GISTELINCK TYPE; OCLSBG__:____:__
Number Sign__:__616898__:__CHROMOSOME 15q14 DELETION SYNDROME__:____:__
Asterisk__:__616899__:__TBC1 DOMAIN-CONTAINING KINASE; TBCK__:____:__
Number Sign__:__616900__:__HYPOTONIA, INFANTILE, WITH PSYCHOMOTOR RETARDATION AND CHARACTERISTIC FACIES 3; IHPRF3__:____:__
Number Sign__:__616901__:__DEVELOPMENTAL DELAY WITH SHORT STATURE, DYSMORPHIC FEATURES, AND SPARSE HAIR; DEDSSH__:__LOUCKS-INNES SYNDROME__:__
Number Sign__:__616902__:__CHROMOSOME 11p13 DELETION SYNDROME, DISTAL__:____:__
Number Sign__:__616903__:__THIOPURINES, POOR METABOLISM OF, 2; THPM2__:__NUDT15 DEFICIENCY__:__
Asterisk__:__616904__:__DEDICATOR OF CYTOKINESIS 5; DOCK5__:____:__
Asterisk__:__616905__:__MORF4 FAMILY-ASSOCIATED PROTEIN 1; MRFAP1__:__PROTEIN ASSOCIATED WITH MRG, 14-KD; PAM14;; PGR1__:__
Asterisk__:__616906__:__CANCER SUSCEPTIBILITY CANDIDATE 1; CASC1__:__LUNG ADENOMA SUSCEPTIBILITY GENE 1; LAS1;; PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 54; PPP1R54__:__
Number Sign__:__616907__:__SPASTIC PARAPLEGIA 76, AUTOSOMAL RECESSIVE; SPG76__:____:__
Asterisk__:__616908__:__PATCHED DOMAIN-CONTAINING PROTEIN 4; PTCHD4__:__PATCHED PROTEIN, p53-REGULATED; PTCH53;; CHROMOSOME 6 OPEN READING FRAME 138; C6ORF138__:__
Asterisk__:__616909__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 68; CCDC68__:__SE57-1__:__
Number Sign__:__616910__:__IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 3; ICF3__:____:__
Number Sign__:__616911__:__IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4; ICF4__:____:__
Asterisk__:__616912__:__ENAH/VASP-LIKE PROTEIN; EVL__:____:__
Number Sign__:__616913__:__BLEEDING DISORDER, PLATELET-TYPE, 20; BDPLT20__:____:__
Number Sign__:__616914__:__MARFAN LIPODYSTROPHY SYNDROME; MFLS__:__MARFANOID-PROGEROID SYNDROME;; MARFAN-PROGEROID-LIPODYSTROPHY SYNDROME__:__
Asterisk__:__616915__:__ZEB1 ANTISENSE RNA 1, NONCODING; ZEB1AS1__:__LONG NONCODING RNA ZEB1AS1;; lncRNA ZEB1AS1__:__
Asterisk__:__616916__:__SMALL ADP-RIBOSYLATION FACTOR GTPase-ACTIVATING PROTEIN 2; SMAP2__:__SMALL ARFGAP 2;; SMAP1-LIKE; SMAP1L__:__
Number Sign__:__616917__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 53; MRT53__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 13; GPIBD13__:__
Asterisk__:__616918__:__PHOSPHATIDYLINOSITOL GLYCAN ANCHOR BIOSYNTHESIS CLASS G PROTEIN; PIGG__:__GPI7, S. CEREVISIAE, HOMOLOG OF; GPI7__:__
Asterisk__:__616919__:__FERM AND PDZ DOMAINS-CONTAINING PROTEIN 1; FRMPD1__:__FERM DOMAIN-CONTAINING PROTEIN 2; FRMD2;; KIAA0967__:__
Number Sign__:__616920__:__HEART AND BRAIN MALFORMATION SYNDROME; HBMS__:____:__
Number Sign__:__616921__:__DYSKINESIA, LIMB AND OROFACIAL, INFANTILE-ONSET; IOLOD__:____:__
Number Sign__:__616922__:__STRIATAL DEGENERATION, AUTOSOMAL DOMINANT 2; ADSD2__:____:__
Asterisk__:__616923__:__RING FINGER PROTEIN 207; RNF207__:__CHROMOSOME 1 OPEN READING FRAME 188; C1ORF188__:__
Number Sign__:__616924__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2CC; CMT2CC__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2CC__:__
Asterisk__:__616925__:__DDHRS4 ANTISENSE RNA 1, NONCODING; DHRS4AS1__:__LONG NONCODING RNA DHRS4AS1;; lncRNA DHRS4AS1;; AS1DHRS4;; CHROMOSOME 14 OPEN READING FRAME 167; C14ORF67__:__
Asterisk__:__616926__:__FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 4; FXYD4__:__CHANNEL-INDUCING FACTOR; CHIF__:__
Asterisk__:__616927__:__EXOCYST COMPLEX COMPONENT 3-LIKE 2; EXOC3L2__:__EXOC3-LIKE 2;; HEPATITIS B VIRUS X ANTIGEN-TRANSACTIVATED GENE 7;; HBV X-TRANSACTIVATED PROTEIN 7; XTP7__:__
Asterisk__:__616928__:__TRANSMEMBRANE PROTEIN 45A; TMEM45A__:__DERMAL PAPILLA-DERIVED PROTEIN 7; DERP7;; DNA POLYMERASE-TRANSACTIVATED PROTEIN 4; DNAPTP4__:__
Asterisk__:__616929__:__TRANSCRIPTION TERMINATION FACTOR 2, MITOCHONDRIAL; MTERF2__:__MTERF-LIKE; MTERFL;; MTERFD3__:__
Asterisk__:__616930__:__TRANSCRIPTION TERMINATION FACTOR 3, MITOCHONDRIAL; MTERF3__:__MTERFD1__:__
Asterisk__:__616931__:__FUCOSYLTRANSFERASE 10; FUT10__:__FUCTX__:__
Asterisk__:__616932__:__FUCOSYLTRANSFERASE 11; FUT11__:__FUCTXI__:__
Asterisk__:__616933__:__FORTY-TWO-THREE DOMAIN-CONTAINING PROTEIN 1; FYTTD1__:__UAP56-INTERACTING FACTOR; UIF__:__
Asterisk__:__616934__:__MEIOSIS-SPECIFIC PROTEIN WITH COILED-COIL DOMAIN; MEIOC__:__CHROMOSOME 17 OPEN READING FRAME 104; C17ORF104__:__
Asterisk__:__616935__:__FAS-ASSOCIATED FACTOR FAMILY, MEMBER 2; FAF2__:__FAF FAMILY, MEMBER 2;; EXPRESSED IN T CELLS AND EOSINOPHILS IN ATOPIC DERMATITIS; ETEA;; UBX DOMAIN-CONTAINING PROTEIN 8; UBXD8;; KIAA0887__:__
Asterisk__:__616936__:__CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 9; CHD9__:__CHROMATIN-RELATED MESENCHYMAL MODULATOR; CREMM;; PPARA-INTERACTING COFACTOR COMPLEX COMPONENT, 320-KD; PRIC320;; PRIC COMPLEX, 320-KD COMPONENT;; KIAA0308__:__
Number Sign__:__616937__:__THROMBOCYTOPENIA 6; THC6__:__THROMBOCYTOPENIA, AUTOSOMAL DOMINANT, 6__:__
Number Sign__:__616938__:__COFFIN-SIRIS SYNDROME 5; CSS5__:____:__
Number Sign__:__616939__:__CHOREA, CHILDHOOD-ONSET, WITH PSYCHOMOTOR RETARDATION; COCPMR__:____:__
Asterisk__:__616940__:__EXONUCLEASE 3-PRIME-TO-5-PRIME DOMAIN-CONTAINING PROTEIN 2; EXD2__:__EXDL2__:__
Number Sign__:__616941__:__AGAMMAGLOBULINEMIA 8, AUTOSOMAL DOMINANT; AGM8__:__AGAMMAGLOBULINEMIA, AUTOSOMAL DOMINANT, DUE TO TCF3 DEFECT__:__
Asterisk__:__616942__:__PROTEIN DISULFIDE ISOMERASE, FAMILY A, MEMBER 5; PDIA5__:__PROTEIN DISULFIDE ISOMERASE-RELATED PROTEIN; PDIR__:__
Number Sign__:__616943__:__TRICHOTHIODYSTROPHY 6, NONPHOTOSENSITIVE; TTD6__:____:__
Number Sign__:__616944__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 41; MRD41__:____:__
Asterisk__:__616945__:__CLAVESIN 2; CLVS2__:__CLATHRIN VESICLE-ASSOCIATED SEC14 PROTEIN 2__:__
Number Sign__:__616946__:__PREMATURE OVARIAN FAILURE 11; POF11__:____:__
Number Sign__:__616947__:__PREMATURE OVARIAN FAILURE 12; POF12__:____:__
Number Sign__:__616948__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 22; SCAR22__:____:__
Number Sign__:__616949__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 23; SCAR23__:____:__
Number Sign__:__616950__:__SPERMATOGENIC FAILURE 15; SPGF15__:____:__
Asterisk__:__616951__:__METASTASIS SUPPRESSOR 1-LIKE PROTEIN; MTSS1L__:__ACTIN-BUNDLING PROTEIN WITH BAIAP2 HOMOLOGY 1; ABBA1;; ABBA__:__
Asterisk__:__616952__:__MITOCHONDRIAL CALCIUM UNIPORTER REGULATOR 1; MCUR1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 90A; CCDC90A;; FMP32, S. CEREVISIAE, HOMOLOG OF; FMP32__:__
Asterisk__:__616953__:__CutA, E. COLI, HOMOLOG OF; CUTA__:__DIVALENT CATION TOLERANCE PROTEIN CUTA;; ACETYLCHOLINESTERASE-ASSOCIATED PROTEIN; ACHAP;; CHROMOSOME 6 OPEN READING FRAME 82; C6ORF82__:__
Number Sign__:__616954__:__YOU-HOOVER-FONG SYNDROME; YHFS__:____:__
Asterisk__:__616955__:__RRAD- AND GEM-LIKE GTPase 2; REM2__:__RAD- AND GEM-LIKE GTP-BINDING PROTEIN 2;; REM-, RAD-, AND GEM-RELATED PROTEIN 2__:__
Asterisk__:__616956__:__TUBULIN POLYMERIZATION-PROMOTING PROTEIN FAMILY, MEMBER 2; TPPP2__:__TPPP FAMILY, MEMBER 2;; p18__:__
Asterisk__:__616957__:__TUBULIN POLYMERIZATION-PROMOTING PROTEIN FAMILY, MEMBER 3; TPPP3__:__TPPP FAMILY, MEMBER 3;; p20__:__
Caret__:__616958__:__MOVED TO 608653__:____:__
Number Sign__:__616959__:__RETINITIS PIGMENTOSA AND ERYTHROCYTIC MICROCYTOSIS; RPEM__:____:__
Asterisk__:__616960__:__GTPase, IMAP FAMILY, MEMBER 6; GIMAP6__:__GTPase, IMMUNITY-ASSOCIATED PROTEIN FAMILY, MEMBER 6__:__
Asterisk__:__616961__:__GTPase, IMAP FAMILY, MEMBER 7; GIMAP7__:__GTPase, IMMUNITY-ASSOCIATED PROTEIN FAMILY, MEMBER 7__:__
Asterisk__:__616962__:__GTPase, IMAP FAMILY, MEMBER 8; GIMAP8__:__GTPase, IMMUNITY-ASSOCIATED PROTEIN FAMILY, MEMBER 8__:__
Number Sign__:__616963__:__HYPERCALCEMIA, INFANTILE, 2; HCINF2__:____:__
Caret__:__616964__:__MOVED TO 615225__:____:__
Asterisk__:__616965__:__ADHESION G PROTEIN-COUPLED RECEPTOR G5; ADGRG5__:__G PROTEIN-COUPLED RECEPTOR 114; GPR114__:__
Asterisk__:__616966__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 6; ABHD6__:__ALPHA/BETA-HYDROLASE DOMAIN-CONTAINING PROTEIN 6__:__
Asterisk__:__616967__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 17; TXNDC17__:__THIOREDOXIN-RELATED PROTEIN, 14-KD; TRP14;; THIOREDOXIN-LIKE PROTEIN 5; TXNL5__:__
Number Sign__:__616968__:__DEAFNESS, AUTOSOMAL DOMINANT 70; DFNA70__:____:__
Number Sign__:__616969__:__DEAFNESS, AUTOSOMAL DOMINANT 66; DFNA66__:____:__
Asterisk__:__616970__:__MARVEL DOMAIN-CONTAINING PROTEIN 1; MARVELD1__:__MRVLDC1; MARVD1__:__
Asterisk__:__616971__:__ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT PROTEIN 3; ERGIC3__:__ERGIC AND GOLGI PROTEIN 3;; ENDOPLASMIC RETICULUM-ASSOCIATED PROTEIN, 43-KD; ERP43 BREAST CANCER ANTIGEN NY-BR-84;; CHROMOSOME 20 OPEN READING FRAME 47; C20ORF47__:__
Asterisk__:__616972__:__MICRO RNA 490; MIR490__:__miRNA490__:__
Number Sign__:__616973__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 42; MRD42__:____:__
Number Sign__:__616974__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 30; COXPD30__:____:__
Number Sign__:__616975__:__NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT ANOMALIES OF THE BRAIN, EYE, OR HEART; NEDBEH__:____:__
Asterisk__:__616976__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 40; TRIM40__:__RING FINGER PROTEIN 35; RNF35__:__
Number Sign__:__616977__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 43; MRD43__:____:__
Asterisk__:__616978__:__COILED COIL-HELIX-COILED COIL-HELIX DOMAIN-CONTAINING PROTEIN 5; CHCHD5__:__MITOCHONDRIAL INTERMEMBRANE SPACE CYSTEINE MOTIF PROTEIN, 14-KD; MIC14__:__
Asterisk__:__616979__:__DEATH DOMAIN-CONTAINING PROTEIN 1; DTHD1__:____:__
Asterisk__:__616980__:__CELL CYCLE REGULATOR OF NONHOMOLOGOUS END JOINING; CYREN__:__CHROMOSOME 7 OPEN READING FRAME 49; C7ORF49;; MODULATOR OF RETROVIRUS INFECTION; MRI__:__
Number Sign__:__616981__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 37; EIEE37__:____:__
Asterisk__:__616982__:__PR DOMAIN-CONTAINING PROTEIN 6; PRDM6__:__PR DOMAIN-CONTAINING PROTEIN IN SMOOTH MUSCLE; PRISM__:__
Asterisk__:__616983__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 6; ENPP6__:__NPP6;; GLYCEROPHOSPHOCHOLINE CHOLINEPHOSPHODIESTERASE;; CHOLINE-SPECIFIC GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE__:__
Asterisk__:__616984__:__NEUROPEPTIDE VF PRECURSOR; NPVF__:__RF-AMIDE-RELATED PEPTIDE PRECURSOR; RFRP;; CHROMOSOME 7 OPEN READING FAME 9; C7ORF9__:__
Asterisk__:__616985__:__MTRNR2-LIKE 1; MTRNR2L1__:__HUMANIN-LIKE 1; HN1__:__
Asterisk__:__616986__:__LONG INTERGENIC NONCODING RNA AC011288.2__:__lincRNA AC011288.2;; LOC105375159__:__
Asterisk__:__616987__:__CHROMOSOME 6 OPEN READING FRAME 120; C6ORF120__:____:__
Asterisk__:__616988__:__CHRONIC LYMPHOCYTIC LEUKEMIA UPREGULATED GENE 1; CLLU1__:____:__
Asterisk__:__616989__:__CHRONIC LYMPHOCYTIC LEUKEMIA UPREGULATED 1, OPPOSITE STRAND; CLLU1OS__:____:__
Asterisk__:__616990__:__CLUSTERIN-LIKE PROTEIN 1; CLUL1__:____:__
Asterisk__:__616991__:__MUCIN 21, CELL SURFACE-ASSOCIATED; MUC21__:__EPIGLYCANIN;; CHROMOSOME 6 OPEN READING FRAME 205; C6ORF205__:__
Asterisk__:__616992__:__CHROMOSOME 8 OPEN READING FRAME 17; C8ORF17__:__MOLT-4 SEQUENCE TAG 1; MOST1__:__
Asterisk__:__616993__:__TRANSMEMBRANE PROTEIN 243; TMEM243__:__CHROMOSOME 7 OPEN READING FRAME 23; C7ORF23;; MDR1- AND MITOCHONDRIAL TAXOL RESISTANCE-ASSOCIATED GENE; MMTRAG;; MGC4175__:__
Asterisk__:__616995__:__CLOCK-INTERACTING PACEMAKER; CIPC__:__KIAA1737__:__
Asterisk__:__616996__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 56; TRIM56__:____:__
Asterisk__:__616997__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 7; ENPP7__:__ALKALINE SPHINGOMYELINASE; ALK-SMase__:__
Asterisk__:__616998__:__LLP, APLYSIA, HOMOLOG OF; LLPH__:__LONG-TERM SYNAPTIC FACILITATION PROTEIN LLPH__:__
Asterisk__:__616999__:__RNA-BINDING PROTEIN FOX1, C. ELEGANS, HOMOLOG OF, 3; RBFOX3__:__FOX3;; NEURONAL NUCLEI ANTIGEN; NEUN;; HEXARIBONUCLEOTIDE-BINDING PROTEIN 3; HRNBP3__:__
Asterisk__:__617000__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 4; ENPP4__:__NPP4;; KIAA0879__:__
Asterisk__:__617001__:__ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 5; ENPP5__:__NPP5__:__
Asterisk__:__617002__:__BICD FAMILY-LIKE CARGO ADAPTOR 1; BICDL1__:__BICAUDAL D-RELATED PROTEIN 1; BICDR1;; COILED-COIL DOMAIN-CONTAINING PROTEIN 64; CCDC64;; CCDC64A__:__
Asterisk__:__617003__:__BICD FAMILY-LIKE CARGO ADAPTOR 2; BICDL2__:__BICAUDAL D-RELATED PROTEIN 2; BICDR2;; COILED-COIL DOMAIN-CONTAINING PROTEIN 64B; CCDC64B__:__
Number Sign__:__617004__:__POLYCYSTIC LIVER DISEASE 2 WITH OR WITHOUT KIDNEY CYSTS; PCLD2__:____:__
Asterisk__:__617005__:__CLAUDIN 17; CLDN17__:____:__
Number Sign__:__617006__:__AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 2; ADMIO2__:____:__
Asterisk__:__617007__:__TRIPARTITE MOTIF-CONTAINING PROTEIN 35; TRIM35__:__MACROPHAGE-DERIVED APOPTOSIS-INDUCING RBCC PROTEIN; MAIR;; HEMOPOIETIC LINEAGE SWITCH 5; HLS5;; KIAA1098__:__
Number Sign__:__617008__:__CEREBRAL PALSY, SPASTIC QUADRIPLEGIC, 3; CPSQ3__:____:__
Asterisk__:__617009__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 53; ANKRD53__:____:__
Asterisk__:__617010__:__UNC51-LIKE KINASE 4; ULK4__:__SERINE/THREONINE PROTEIN KINASE ULK4;; FAM7C1__:__
Number Sign__:__617011__:__MACROCEPHALY, DYSMORPHIC FACIES, AND PSYCHOMOTOR RETARDATION; MDFPMR__:____:__
Asterisk__:__617012__:__POLIOVIRUS RECEPTOR-RELATED IMMUNOGLOBULIN DOMAIN-CONTAINING PROTEIN; PVRIG__:__CD112 RECEPTOR; CD112R;; CHROMOSOME 7 OPEN READING FROME 15; C7ORF15__:__
Number Sign__:__617013__:__HYPERMANGANESEMIA WITH DYSTONIA 2; HMNDYT2__:____:__
Number Sign__:__617014__:__NEUTROPENIA, SEVERE CONGENITAL, 7, AUTOSOMAL RECESSIVE; SCN7__:____:__
Asterisk__:__617015__:__PHOSPHOLIPASE C, PHOSPHATIDYLINOSITOL-SPECIFIC, X DOMAIN-CONTAINING PROTEIN 2; PLCXD2__:__PIPLC X DOMAIN-CONTAINING PROTEIN 2__:__
Asterisk__:__617016__:__PHOSPHOLIPASE C, PHOSPHATIDYLINOSITOL-SPECIFIC, X DOMAIN-CONTAINING PROTEIN 3; PLCXD3__:__PIPLC X DOMAIN-CONTAINING PROTEIN 3__:__
Number Sign__:__617017__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2T;; CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2T__:__
Number Sign__:__617018__:__SPINOCEREBELLAR ATAXIA 43; SCA43__:____:__
Asterisk__:__617019__:__TRANSMEMBRANE PROTEIN 230; TMEM230__:__CHROMOSOME 20 OPEN READING FRAME 30; C20ORF30__:__
Number Sign__:__617020__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 38; EIEE38__:____:__
Number Sign__:__617021__:__HYDROPS, LACTIC ACIDOSIS, AND SIDEROBLASTIC ANEMIA; HLASA__:____:__
Number Sign__:__617022__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 10; LCCS10__:____:__
Number Sign__:__617023__:__RETINITIS PIGMENTOSA 75; RP75__:____:__
Number Sign__:__617024__:__NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1H; CSNB1H__:____:__
Number Sign__:__617025__:__NEVUS COMEDONICUS; NC__:____:__
Number Sign__:__617026__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 2F; PCH2F__:____:__
Number Sign__:__617027__:__HYPERALDOSTERONISM, FAMILIAL, TYPE IV; HALD4__:__FH IV;; ALDOSTERONISM, PRIMARY, AND HYPERTENSION__:__
Number Sign__:__617028__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 54; MRT54__:____:__
Asterisk__:__617029__:__SEMAPHORIN 4B; SEMA4B__:____:__
Number Sign__:__617030__:__MYOPATHY, DISTAL, 5; MPD5__:____:__
Asterisk__:__617031__:__PRECURSOR mRNA-PROCESSING FACTOR 38, S. CEREVISIAE, HOMOLOG OF, A; PRPF38A__:__PRP38A;; PRP38__:__
Asterisk__:__617032__:__PROTEIN-GLUCOSYLGALACTOSYLHYDROXYLYSINE GLUCOSIDASE; PGGHG__:__ACID TREHALASE-LIKE PROTEIN 1; ATHL1__:__
Asterisk__:__617033__:__GATS PROTEIN-LIKE 2; GATSL2__:__CELLULAR ARGININE SENSOR FOR MTORC1 PROTEIN 2; CASTOR2__:__
Asterisk__:__617034__:__GATS PROTEIN-LIKE 3; GATSL3__:__CELLULAR ARGININE SENSOR FOR MTORC1 PROTEIN 1; CASTOR1__:__
Number Sign__:__617035__:__PATENT DUCTUS ARTERIOSUS 2; PDA2__:____:__
Asterisk__:__617036__:__ALKALINE CERAMIDASE 3; ACER3__:__ALKALINE PHYTOCERAMIDASE; APHC;; PHYTOCERAMIDASE, ALKALINE; PHCA__:__
Asterisk__:__617037__:__NONCODING RNA ACTIVATED BY DNA DAMAGE; NORAD__:__LONG NONCODING RNA NORAD;; lncRNA NORAD;; LONG INTERGENIC NONCODING RNA 657; LINC00657;; lincRNA 657__:__
Asterisk__:__617038__:__LONG INTERGENIC NONCODING RNA 1370; LINC01370__:__lincRNA 1370;; HUMAN ISLET LONG NONCODING RNA 25; HILNC25__:__
Number Sign__:__617039__:__PATENT DUCTUS ARTERIOSUS 3; PDA3__:____:__
Asterisk__:__617040__:__MICRO RNA 1231; MIR1231__:__miRNA1231__:__
Number Sign__:__617041__:__DUANE RETRACTION SYNDROME 3 WITH OR WITHOUT DEAFNESS; DURS3__:____:__
Asterisk__:__617042__:__GASDERMIN D; GSDMD__:__GASDERMIN DOMAIN-CONTAINING PROTEIN 1; GSDMDC1;; DFNA5-LIKE; DFNA5L__:__
Asterisk__:__617043__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 17; ARHGEF17__:__RHOGEF17;; RHO-SPECIFIC GUANINE NUCLEOTIDE EXCHANGE FACTOR, 164-KD; p164RHOGEF;; TUMOR ENDOTHELIAL MARKER 4; TEM4;; KIAA0337__:__
Number Sign__:__617044__:__SHORT STATURE, DEVELOPMENTAL DELAY, AND CONGENITAL HEART DEFECTS; SDDHD__:____:__
Asterisk__:__617045__:__ZINC FINGER PROTEIN 703; ZNF703__:__ZFP703;; ZINC FINGER ELBOW-RELATED PROLINE DOMAIN PROTEIN 1; ZEPPO1; ZPO1;; NOCA-LIKE ZINC FINGER 1; NLZ1__:__
Number Sign__:__617046__:__SPASTIC PARAPLEGIA 77, AUTOSOMAL RECESSIVE; SPG77__:____:__
Number Sign__:__617047__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 26; CMH26__:____:__CARDIOMYOPATHY, FAMILIAL RESTRICTIVE, 5, INCLUDED; RCM5, INCLUDED
Asterisk__:__617048__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 21; DNAJC21__:__DNAJ HOMOLOGY SUBFAMILY A, MEMBER 5; DNAJA5__:__
Number Sign__:__617049__:__CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 5; PFIC5__:____:__
Number Sign__:__617050__:__HERMANSKY-PUDLAK SYNDROME 10; HPS10__:____:__
Number Sign__:__617051__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 55; MRT55__:____:__
Number Sign__:__617052__:__BONE MARROW FAILURE SYNDROME 3; BMFS3__:____:__
Number Sign__:__617053__:__MIRAGE SYNDROME; MIRAGE__:__MYELODYSPLASIA, INFECTION, RESTRICTION OF GROWTH, ADRENAL HYPOPLASIA, GENITAL PHENOTYPES, AND ENTEROPATHY__:__
Number Sign__:__617054__:__STRIATONIGRAL DEGENERATION, CHILDHOOD-ONSET; SNDC__:__LENK-PLOSKI SYNDROME__:__
Number Sign__:__617055__:__CRISPONI/COLD-INDUCED SWEATING SYNDROME 3; CISS3__:____:__
Number Sign__:__617056__:__HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 4; HNFJ4__:____:__
Asterisk__:__617057__:__CYTOSOLIC THIOURIDYLASE, SUBUNIT 2; CTU2__:__CHROMOSOME 16 OPEN READING FRAME 84; C16ORF84;; UPF0432;; NCS2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__617058__:__TSR3, AMINOCARBOXYPROPYL TRANSFERASE RIBOSOME MATURATION FACTOR; TSR3__:__ACP TRANSFERASE TSR3__:__
Asterisk__:__617059__:__ZINC FINGER DBF DOMAIN-CONTAINING PROTEIN 2; ZDBF2__:__DBF-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 2;; KIAA1571__:__LONG ISOFORM OF ZDBF2, INCLUDED; LIZ, INCLUDED
Asterisk__:__617060__:__LACTASE-LIKE PROTEIN; LCTL__:__KLOTHO, GAMMA; KLG;; GAMMA-KLOTHO;; KLOTHO LACTASE-PHLORIZIN HYDROLASE-RELATED PROTEIN; KLPH__:__
Number Sign__:__617061__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 44; MRD44__:____:__
Number Sign__:__617062__:__OKUR-CHUNG NEURODEVELOPMENTAL SYNDROME; OCNDS__:____:__
Number Sign__:__617063__:__MEIER-GORLIN SYNDROME 7; MGORS7__:____:__
Asterisk__:__617064__:__GUF1 GTPase, S. CEREVISIAE, HOMOLOG OF; GUF1__:__ELONGATION FACTOR 4, E. COLI, HOMOLOG OF; EF4__:__
Number Sign__:__617065__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 40; EIEE40__:____:__
Number Sign__:__617066__:__MUSCULAR DYSTROPHY, CONGENITAL, DAVIGNON-CHAUVEAU TYPE; MDCDC__:____:__
Asterisk__:__617067__:__LY6/PLAUR DOMAIN-CONTAINING PROTEIN 8; LYPD8__:____:__
Number Sign__:__617068__:__PORTAL HYPERTENSION, NONCIRRHOTIC; NCPH__:____:__
Number Sign__:__617069__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3__:__
Number Sign__:__617070__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4__:__
Asterisk__:__617071__:__LONG NONCODING RNA 13__:__lncRNA 13; LNC13__:__
Number Sign__:__617072__:__MYOPATHY, AUTOSOMAL RECESSIVE, WITH RIGID SPINE AND DISTAL JOINT CONTRACTURES; MRRSDC__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Y; LGMD2Y__:__
Number Sign__:__617073__:__TOOTH AGENESIS, SELECTIVE, 8; STHAG8__:____:__
Asterisk__:__617074__:__SMITH-MAGENIS SYNDROME CHROMOSOME REGION, CANDIDATE GENE 8; SMCR8__:____:__
Number Sign__:__617075__:__NASOPHARYNGEAL CARCINOMA, SUSCEPTIBILITY TO, 3; NPCA3__:____:__
Asterisk__:__617076__:__FK506-BINDING PROTEIN-LIKE; FKBPL__:__DOWNREGULATED BY IONIZING RADIATION 1; DIR1;; WAF1/CIP1-STABILIZING PROTEIN, 39-KD; WISP39__:__
Asterisk__:__617077__:__ZINC FINGER PROTEIN 618; ZNF618__:__NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWNREGULATED 10; NEDD10;; KIAA1952__:__
Asterisk__:__617078__:__DEATH EFFECTOR DOMAIN-CONTAINING PROTEIN 2; DEDD2__:__FADD-LIKE ANTIAPOPTOTIC MOLECULE 3; FLAME3__:__
Asterisk__:__617079__:__LONG INTERGENIC NONCODING RNA 673; LINC00673__:__lincRNA 673;; HUMAN ISLET LONG NONCODING RNA 75; HILNC75;; SRA-LIKE NONCODING RNA; SLNCR;; LUCAIR1__:__
Number Sign__:__617080__:__SEIZURES, BENIGN FAMILIAL INFANTILE, 5; BFIS5__:__CONVULSIONS, BENIGN FAMILIAL INFANTILE, 5; BFIC5__:__
Asterisk__:__617081__:__OMA1 ZINC METALLOPEPTIDASE; OMA1__:__OVERLAPPING ACTIVITY WITH M-AAA PROTEASE;; METALLOPROTEASE-RELATED PROTEIN 1; MPRP1__:__
Number Sign__:__617082__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iaa; CDG1AA__:____:__
Asterisk__:__617083__:__DYNEIN, CYTOPLASMIC 2, LIGHT INTERMEDIATE CHAIN 1; DYNC2LI1__:__DYNEIN 2, LIGHT INTERMEDIATE CHAIN; D2LIC;; LIGHT INTERMEDIATE CHAIN 3; LIC3__:__
Asterisk__:__617084__:__TRANSMEMBRANE PROTEIN 59; TMEM59__:__LIVER MEMBRANE PROTEIN;; DENDRITIC CELL FACTOR 1; DCF1__:__
Asterisk__:__617085__:__FIN BUD INITIATION FACTOR, ZEBRAFISH, HOMOLOG OF; FIBIN__:____:__
Number Sign__:__617086__:__ENCEPHALOPATHY DUE TO DEFECTIVE MITOCHONDRIAL AND PEROXISOMAL FISSION 2; EMPF2__:____:__
Number Sign__:__617087__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL RECESSIVE, TYPE 2A2B; CMT2A2B__:____:__
Number Sign__:__617088__:__SHORT-RIB THORACIC DYSPLASIA 15 WITH POLYDACTYLY; SRTD15__:____:__
Asterisk__:__617089__:__NUCLEOLUS AND NEURAL PROGENITOR PROTEIN; NEPRO__:__CHROMOSOME 3 OPEN READING FRAME 17; C3ORF17__:__
Number Sign__:__617090__:__MICROCEPHALY 17, PRIMARY, AUTOSOMAL RECESSIVE; MCPH17__:____:__
Number Sign__:__617091__:__CILIARY DYSKINESIA, PRIMARY, 34; CILD34__:__CILIARY DYSKINESIA, PRIMARY, 34, WITHOUT SITUS INVERSUS__:__
Number Sign__:__617092__:__CILIARY DYSKINESIA, PRIMARY, 35; CILD35__:__CILIARY DYSKINESIA, PRIMARY, 35, WITH OR WITHOUT SITUS INVERSUS__:__
Number Sign__:__617093__:__GROWTH RETARDATION, INTELLECTUAL DEVELOPMENTAL DISORDER, HYPOTONIA, AND HEPATOPATHY; GRIDHH__:____:__
Asterisk__:__617094__:__INTRAFLAGELLAR TRANSPORT 52, CHLAMYDOMONAS, HOMOLOG OF; IFT52__:____:__
Asterisk__:__617095__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 25; TTC25__:____:__
Asterisk__:__617096__:__TRANSMEMBRANE PROTEIN 59-LIKE; TMEM59L__:__BRAIN-SPECIFIC MEMBRANE-ANCHORED PROTEIN; BSMAP__:__
Asterisk__:__617097__:__LONG INTERGENIC NONCODING RNA 1194; LINC01194__:__lincRNA 1194;; TUMOR ANTIGEN GENE; TAG__:__
Asterisk__:__617098__:__RIBONUCLEASE K; RNASEK__:__RNase KAPPA;; RNase K__:__
Number Sign__:__617099__:__AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME; AIPDS__:__OTULIN-RELATED AUTOINFLAMMATORY SYNDROME; ORAS;; OTULIPENIA__:__
Number Sign__:__617100__:__FAMILIAL ADENOMATOUS POLYPOSIS 4; FAP4__:____:__
Number Sign__:__617101__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH PERSISTENCE OF FETAL HEMOGLOBIN__:__DIAS-LOGAN SYNDROME;; INTELLECTUAL DEVELOPMENTAL DISORDER WITH HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN__:__
Number Sign__:__617102__:__SHORT-RIB THORACIC DYSPLASIA 16 WITH OR WITHOUT POLYDACTYLY; SRTD16__:____:__
Asterisk__:__617103__:__ZINC FINGER PROTEIN 668; ZNF668__:____:__
Asterisk__:__617104__:__PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE, TYPE II, GAMMA; PIP4K2C__:__PIP4K2-GAMMA;; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE, TYPE II, GAMMA; PIP5K2C__:__
Number Sign__:__617105__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 41; EIEE41__:____:__
Number Sign__:__617106__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 42; EIEE42__:____:__
Number Sign__:__617107__:__THAUVIN-ROBINET-FAIVRE SYNDROME; TROFAS__:____:__
Number Sign__:__617108__:__SESSILE SERRATED POLYPOSIS CANCER SYNDROME; SSPCS__:____:__
Asterisk__:__617109__:__CREB3 RECRUITMENT FACTOR; CREBRF__:__LUMAN RECRUITMENT FACTOR; LRF;; CHROMOSOME 5 OPEN READING FRAME 41; C5ORF41__:__
Asterisk__:__617110__:__CENTROSOMAL PROTEIN, 78-KD; CEP78__:____:__
Number Sign__:__617111__:__MACULAR DYSTROPHY, PATTERNED, 3; MDPT3__:__MARTINIQUE CRINKLED RETINAL PIGMENT EPITHELIOPATHY__:__
Asterisk__:__617112__:__KIAA0753 GENE; KIAA0753__:__OFD1- AND FOPNL-INTERACTING PROTEIN; OFIP;; MOONRAKER__:__
Number Sign__:__617113__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 43; EIEE43__:____:__
Number Sign__:__617114__:__MYOPATHY, MYOFIBRILLAR, 7; MFM7__:____:__
Number Sign__:__617115__:__PEELING SKIN SYNDROME 5; PSS5__:____:__
Number Sign__:__617116__:__EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 2; FFEVF2__:____:__
Asterisk__:__617117__:__LONG INTERGENIC NONCODING RNA 663; LINC00663__:__lincRNA 663__:__
Number Sign__:__617118__:__EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 3; FFEVF3__:____:__
Number Sign__:__617119__:__BARDET-BIEDL SYNDROME 20; BBS20__:____:__
Number Sign__:__617120__:__JOUBERT SYNDROME 27; JBTS27__:____:__
Number Sign__:__617121__:__JOUBERT SYNDROME 28; JBTS28__:____:__
Asterisk__:__617122__:__C1QTNF9B ANTISENSE RNA 1; C1QTNF9BAS1__:__PROSTATE COLLAGEN TRIPLE-HELIX PROTEIN; PCOTH__:__
Number Sign__:__617123__:__RETINITIS PIGMENTOSA 76; RP76__:____:__
Asterisk__:__617124__:__PEPTIDASE M20 DOMAIN-CONTAINING PROTEIN 1; PM20D1__:____:__
Number Sign__:__617125__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 56; MRT56__:____:__
Number Sign__:__617126__:__ALAZAMI-YUAN SYNDROME; ALYUS__:____:__
Number Sign__:__617127__:__OROFACIODIGITAL SYNDROME XV; OFD15__:__OFDS XV;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE XV__:__
Asterisk__:__617128__:__INHIBITORY SYNAPTIC FACTOR 1; INSYN1__:__CHROMOSOME 15 OPEN READING FRAME 59; C15ORF59;; INHIBITORY SYNAPTIC PROTEIN 1__:__
Asterisk__:__617129__:__FAMILY WITH SEQUENCE SIMILARITY 196, MEMBER A; FAM196A__:__CHROMOSOME 10 OPEN READING FRAME 141; C10ORF141;; INHIBITORY SYNAPTIC PROTEIN 2; INSYN2__:__
Asterisk__:__617130__:__MEMBRANE-ANCHORED JUNCTION PROTEIN; MAJIN__:__CHROMOSOME 11 OPEN READING FRAME 85; C11ORF85__:__
Asterisk__:__617131__:__TELOMERE REPEAT-BINDING BOUQUET FORMATION PROTEIN 2; TERB2__:__CHROMOSOME 15 OPEN READING FRAME 43; C15ORF43__:__
Number Sign__:__617132__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 44; EIEE44__:____:__
Number Sign__:__617133__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 24; SCAR24__:____:__
Asterisk__:__617134__:__TRANSMEMBRANE AND COILED-COIL DOMAINS PROTEIN 3; TMCO3__:__CHROMOSOME 13 OPEN READING FRAME 11; C13ORF11__:__
Asterisk__:__617135__:__L3MBT-LIKE 4; L3MBTL4__:____:__
Asterisk__:__617136__:__LONG NONCODING RNA HIPSTR__:__HETEROGENOUSLY EXPRESSED FROM THE INTRONIC PLUS STRAND OF THE TFAP2A LOCUS RNA; HIPSTR;; lncRNA HIPSTR__:__
Number Sign__:__617137__:__FRONTOMETAPHYSEAL DYSPLASIA 2; FMD2__:____:__
Asterisk__:__617138__:__SKI FAMILY TRANSCRIPTIONAL COREPRESSOR 2; SKOR2__:__FUNCTIONAL SMAD-SUPPRESSING ELEMENT ON CHROMOSOME 18; FUSSEL18;; CORL2__:__
Asterisk__:__617139__:__LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 7B; LGALS7B__:____:__
Number Sign__:__617140__:__ZTTK SYNDROME; ZTTKS__:__ZHU-TOKITA-TAKENOUCHI-KIM SYNDROME;; ZTTK MULTIPLE CONGENITAL ANOMALIES-MENTAL RETARDATION SYNDROME__:__
Number Sign__:__617141__:__ANIRIDIA 2; AN2__:____:__
Number Sign__:__617142__:__ANIRIDIA 3; AN3__:____:__
Number Sign__:__617143__:__MYASTHENIC SYNDROME, CONGENITAL, 20, PRESYNAPTIC; CMS20__:____:__
Asterisk__:__617144__:__MICRO RNA 4435-2 HOST GENE, NONCODING; MIR4435-2HG__:__MIR4435-2 HOST GENE;; miRNA4435-2 HOST GENE;; LONG NONCODING RNA MORRBID;; lncRNA MORRBID;; MYELOID RNA REGULATOR OF BIM-INDUCED DEATH__:__
Number Sign__:__617145__:__NEURODEGENERATION WITH ATAXIA, DYSTONIA, AND GAZE PALSY, CHILDHOOD-ONSET; NADGP__:____:__
Number Sign__:__617146__:__ARTHROGRYPOSIS, DISTAL, WITH IMPAIRED PROPRIOCEPTION AND TOUCH; DAIPT__:____:__
Asterisk__:__617147__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 14; CCDC14__:____:__
Asterisk__:__617148__:__DEUTEROSOME ASSEMBLY PROTEIN 1; DEUP1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 67; CCDC67__:__
Asterisk__:__617149__:__FGFR1OP N-TERMINAL DOMAIN-LIKE PROTEIN; FOPNL__:__FOP-RELATED PROTEIN, 20-KD; FOR20;; CHROMOSOME 16 OPEN READING FRAME 63; C16ORF63__:__
Asterisk__:__617150__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 3; ZDHHC3__:__DHHC3;; GOLGI-SPECIFIC DHHC ZINC FINGER PROTEIN; GODZ__:__
Asterisk__:__617151__:__SULFOTRANSFERASE FAMILY 1C, MEMBER 3; SULT1C3__:____:__
Asterisk__:__617152__:__SULFOTRANSFERASE FAMILY 6B, MEMBER 1; SULT6B1__:____:__
Number Sign__:__617153__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 45; EIEE45__:____:__
Asterisk__:__617154__:__MRN COMPLEX-INTERACTING PROTEIN; MRNIP__:__CHROMOSOME 5 OPEN READING FRAME 45; C5ORF45__:__
Asterisk__:__617155__:__SUPPRESSION OF TUMORIGENICITY 18; ST18__:__ZINC FINGER PROTEIN 387; ZNF387;; KIAA0535__:__
Number Sign__:__617156__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 15 (HEPATOCEREBRAL TYPE); MTDPS15__:____:__
Number Sign__:__617157__:__SHORT STATURE, BRACHYDACTYLY, INTELLECTUAL DEVELOPMENTAL DISABILITY, AND SEIZURES; SBIDDS__:____:__
Number Sign__:__617158__:__MYOPATHY, DISTAL, WITH RIMMED VACUOLES; DMRV__:____:__
Number Sign__:__617159__:__SIFRIM-HITZ-WEISS SYNDROME; SIHIWES__:__SIFRIM-HITZ-WEISS MULTIPLE CONGENITAL ANOMALIES-MENTAL RETARDATION SYNDROME__:__
Asterisk__:__617160__:__PROMININ 2; PROM2__:__PROMININ-LIKE PROTEIN 2; PROML2__:__
Asterisk__:__617161__:__GSG1-LIKE PROTEIN; GSG1L__:____:__
Number Sign__:__617162__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 46; EIEE46__:____:__
Asterisk__:__617163__:__RING FINGER PROTEIN 186; RNF186__:____:__
Number Sign__:__617164__:__SHORT STATURE, RHIZOMELIC, WITH MICROCEPHALY, MICROGNATHIA, AND DEVELOPMENTAL DELAY; SRMMD__:____:__
Asterisk__:__617165__:__FAMILY WITH SEQUENCE SIMILARITY 213, MEMBER A; FAM213A__:__PEROXIREDOXIN ACTIVATED IN MCSF-STIMULATED MONOCYTES; PAMM;; CHROMOSOME 10 OPEN READING FRAME 58__:__
Number Sign__:__617166__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 47; EIEE47__:____:__
Asterisk__:__617167__:__SOLUTE CARRIER FAMILY 35, MEMBER G1; SLC35G1__:__PARTNER OF STIM1; POST;; TRANSMEMBRANE PROTEIN 20; TMEM20;; CHROMOSOME 10 OPEN READING FRAME 60; C10ORF60__:__
Number Sign__:__617168__:__AORTIC ANEURYSM, FAMILIAL THORACIC 10; AAT10__:__AORTIC ANEURYSM, THORACIC, WITH OR WITHOUT AORTIC DISSECTION__:__
Number Sign__:__617169__:__SOTOS SYNDROME 3; SOTOS3__:____:__
Asterisk__:__617170__:__CWC27 SPLICEOSOME-ASSOCIATED PROTEIN, S. CEREVISIAE, HOMOLOG OF; CWC27__:__SEROLOGICALLY DEFINED COLON CANCER ANTIGEN 10: SDCCAG10;; NY-CO-10__:__
Number Sign__:__617171__:__DYSKINESIA, SEIZURES, AND INTELLECTUAL DEVELOPMENTAL DISORDER; DYSEIDD__:____:__
Asterisk__:__617172__:__GLUTATHIONE PEROXIDASE 8; GPX8__:____:__
Number Sign__:__617173__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH CARDIAC ARRHYTHMIA; IDDCA__:____:__
Number Sign__:__617174__:__EHLERS-DANLOS SYNDROME, PERIODONTAL TYPE, 2; EDSPD2__:____:__
Number Sign__:__617175__:__RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES; RDEOA__:____:__
Asterisk__:__617176__:__MICRO RNA 4271; MIR4271__:__miRNA4271__:__
Asterisk__:__617177__:__MYOSIN LIGHT CHAIN 10; MYL10__:__PRECURSOR LYMPHOCYTE-SPECIFIC REGULATORY LIGHT CHAIN; PLRLC__:__
Asterisk__:__617178__:__RING FINGER PROTEIN 166; RNF166__:____:__
Asterisk__:__617179__:__PROMOTER OF CDKN1A ANTISENSE DNA DAMAGE-ACTIVATED RNA; PANDAR__:__PANDA__:__
Number Sign__:__617180__:__CHITAYAT SYNDROME; CHYTS__:____:__
Asterisk__:__617181__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 4; TMC4__:____:__
Number Sign__:__617182__:__LANGUAGE DELAY AND ATTENTION DEFICIT-HYPERACTIVITY DISORDER/COGNITIVE IMPAIRMENT WITH OR WITHOUT CARDIAC ARRHYTHMIA; LADCI__:____:__
Number Sign__:__617183__:__HAREL-YOON SYNDROME; HAYOS__:____:__
Number Sign__:__617184__:__MITOCHONDRIAL DNA DEPLETION SYNDROME 12A (CARDIOMYOPATHIC TYPE), AUTOSOMAL DOMINANT; MTDPS12A__:____:__
Asterisk__:__617185__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 7; NSUN7__:__NOL1/NOP2/SUN DOMAIN FAMILY, MEMBER 7__:__
Number Sign__:__617186__:__ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN EDEMA AND/OR LEUKOENCEPHALOPATHY; PEBEL__:____:__
Number Sign__:__617187__:__SPERMATOGENIC FAILURE 16; SPGF16__:__ACEPHALIC SPERMATOZOA SYNDROME__:__
Number Sign__:__617188__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 57; MRT57__:____:__
Asterisk__:__617189__:__TRANSMEMBRANE PROTEIN 110; TMEM110__:__STIM-ACTIVATING ENHANCER; STIMATE__:__
Number Sign__:__617190__:__SHASHI-PENA SYNDROME; SHAPNS__:____:__
Asterisk__:__617191__:__p38-INHIBITED CUTANEOUS SQUAMOUS CELL CARCINOMA-ASSOCIATED LONG INTERGENIC NONCODING RNA; PICSAR__:__lincRNA PICSAR;; LONG INTERGENIC NONCODING RNA 162; LINC00162;; NARCOLEPSY CANDIDATE REGION GENE 1C; NLC1C__:__
Asterisk__:__617192__:__ENDONUCLEASE/EXONUCLEASE/PHOSPHATASE FAMILY DOMAIN-CONTAINING PROTEIN 1; EEPD1__:__KIAA1706__:__
Number Sign__:__617193__:__ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN ATROPHY AND THIN CORPUS CALLOSUM; PEBAT__:____:__
Number Sign__:__617194__:__LETHAL CONGENITAL CONTRACTURE SYNDROME 11; LCCS11__:____:__
Asterisk__:__617195__:__MUSCULOSKELETAL EMBRYONIC NUCLEAR PROTEIN 1; MUSTN1__:__MUSCULOSKELETAL TEMPORALLY ACTIVATED NOVEL GENE; MUSTANG__:__
Asterisk__:__617196__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 3; TMC3__:____:__
Asterisk__:__617197__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 5; TMC5__:____:__
Asterisk__:__617198__:__TRANSMEMBRANE CHANNEL-LIKE PROTEIN 7; TMC7__:____:__
Asterisk__:__617199__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 6; NSUN6__:__NOL1/NOP2/SUN DOMAIN FAMILY, MEMBER 6__:__
Asterisk__:__617200__:__OLIGODENDROCYTIC MYELIN PARANODAL AND INNER LOOP PROTEIN; OPALIN__:__TRANSMEMBRANE PROTEIN 10; TMEM10;; HTMP10; TMP10__:__
Number Sign__:__617201__:__PERIVENTRICULAR NODULAR HETEROTOPIA 7; PVNH7__:____:__
Asterisk__:__617202__:__FORKHEAD BOX I2; FOXI2__:____:__
Asterisk__:__617203__:__TRANSMEMBRANE PROTEIN 87B; TMEM87B__:____:__
Asterisk__:__617204__:__VIMENTIN-TYPE INTERMEDIATE FILAMENT-ASSOCIATED COILED-COIL PROTEIN; VMAC__:____:__
Number Sign__:__617205__:__HETEROTAXY, VISCERAL, 8, AUTOSOMAL; HTX8__:____:__
Asterisk__:__617206__:__NEURALIZED E3 UBIQUITIN PROTEIN LIGASE 3; NEURL3__:__LUNG-INDUCIBLE NEURALIZED-RELATED C3HC4 RING DOMAIN PROTEIN; LINCR__:__
Number Sign__:__617207__:__ENCEPHALOPATHY, PROGRESSIVE, WITH AMYOTROPHY AND OPTIC ATROPHY; PEAMO__:____:__
Asterisk__:__617208__:__MAM DOMAIN-CONTAINING PROTEIN 4; MAMDC4__:____:__
Asterisk__:__617209__:__GLUTAMINYL-tRNA SYNTHASE (GLUTAMINE-HYDROLYZING)-LIKE PROTEIN 1; QRSL1__:__GLUTAMYL-tRNA AMIDOTRANSFERASE, SUBUNIT A; GATA;; GLUTAMYL-tRNA-GLN AMIDOTRANSFERASE, SUBUNIT A, MITOCHONDRIAL__:__
Asterisk__:__617210__:__GLUTAMYL-tRNA AMIDOTRANSFERASE, SUBUNIT C; GATC__:__GLUTAMYL-tRNA-GLN AMIDOTRANSFERASE, SUBUNIT C, MITOCHONDRIAL__:__
Asterisk__:__617211__:__DERMOKINE; DMKN__:____:__
Asterisk__:__617212__:__KERATINOCYTE DIFFERENTIATION-ASSOCIATED PROTEIN; KRTDAP__:__KDAP__:__
Number Sign__:__617213__:__SEDOHEPTULOKINASE DEFICIENCY; SHPKD__:____:__
Number Sign__:__617214__:__SPERMATOGENIC FAILURE 17; SPGF17__:__MALE INFERTILITY DUE TO OOCYTE ACTIVATION FAILURE__:__
Asterisk__:__617215__:__CHROMOSOME 17 OPEN READING FRAME 49; C17ORF49__:__BPTF-ASSOCIATED PROTEIN, 18-KD; BAP18__:__
Asterisk__:__617216__:__ZINC FINGER PROTEIN 420; ZNF420__:__ATM- AND p53-ASSOCIATED KZNF PROTEIN; APAK__:__
Number Sign__:__617217__:__AMELOGENESIS IMPERFECTA, HYPOMATURATION TYPE, IIA6; AI2A6__:____:__
Asterisk__:__617218__:__TRANSMEMBRANE AND TETRATRICOPEPTIDE REPEAT DOMAINS-CONTAINING PROTEIN 3; TMTC3__:__SMILE__:__
Number Sign__:__617219__:__CHROMOSOME 19q13.11 DELETION SYNDROME, PROXIMAL__:____:__
Asterisk__:__617220__:__PYRIDINE NUCLEOTIDE-DISULFIDE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 1; PYROXD1__:__PNDR DOMAIN-CONTAINING PROTEIN 1__:__
Asterisk__:__617221__:__HEXOKINASE DOMAIN-CONTAINING PROTEIN 1; HKDC1__:____:__
Number Sign__:__617222__:__SUDDEN CARDIAC FAILURE, INFANTILE; SCFI__:____:__
Number Sign__:__617223__:__SUDDEN CARDIAC FAILURE, ALCOHOL-INDUCED; SCFAI__:____:__
Asterisk__:__617224__:__GROWTH ARREST-SPECIFIC 2-LIKE 3; GAS2L3__:__GAS2-LIKE 3; G2L3__:__
Number Sign__:__617225__:__SPASTIC PARAPLEGIA 78, AUTOSOMAL RECESSIVE; SPG78__:____:__
Asterisk__:__617226__:__MITOGEN-ACTIVATED PROTEIN KINASE 1-INTERACTING PROTEIN 1-LIKE PROTEIN; MAPK1IP1L__:__MAPK1IP1-LIKE PROTEIN;; MAPK1IP1, MOUSE, HOMOLOG OF;; MAPK-INTERACTING AND SPINDLE-STABILIZING PROTEIN, MOUSE, HOMOLOG OF; MISS;; MISS, MOUSE, HOMOLOG OF__:__
Asterisk__:__617227__:__ATPase FAMILY, AAA DOMAIN-CONTAINING, MEMBER 3C; ATAD3C__:____:__
Number Sign__:__617228__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 31; COXPD31__:____:__
Asterisk__:__617229__:__FAMILY WITH SEQUENCE SIMILARITY 53, MEMBER A; FAM53A__:__DORSAL NEURAL TUBE NUCLEAR PROTEIN; DNTNP__:__
Asterisk__:__617230__:__ZINC FINGER PROTEIN 1, MOUSE, HOMOLOG OF; ZFP1__:__ZINC FINGER PROTEIN 475; ZNF475__:__
Asterisk__:__617231__:__PHOSPHOLYSINE PHOSPHOHISTIDINE INORGANIC PYROPHOSPHATE PHOSPHATASE; LHPP__:____:__
Number Sign__:__617232__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 21; LGMDR21__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2Z; LGMD2Z__:__
Asterisk__:__617233__:__WD REPEAT-CONTAINING PROTEIN 70; WDR70__:____:__
Number Sign__:__617234__:__PREIMPLANTATION EMBRYONIC LETHALITY 2; PREMBL2__:____:__
Number Sign__:__617235__:__MYOCLONUS, INTRACTABLE, NEONATAL; NEIMY__:____:__
Number Sign__:__617236__:__CONE-ROD DYSTROPHY AND HEARING LOSS; CRDHL__:____:__
Number Sign__:__617237__:__IMMUNODEFICIENCY 49; IMD49__:__SEVERE COMBINED IMMUNODEFICIENCY, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE, WITH INTELLECTUAL DISABILITY, SPASTICITY, AND CRANIOFACIAL ABNORMALITIES;; SCID, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE, WITH INTELLECTUAL DISABILITY, SPASTICITY, AND CRANIOFACIAL ABNORMALITIES__:__
Number Sign__:__617238__:__MYOPIA 25, AUTOSOMAL DOMINANT; MYP25__:____:__
Number Sign__:__617239__:__MYASTHENIC SYNDROME, CONGENITAL, 21, PRESYNAPTIC; CMS21__:____:__
Asterisk__:__617240__:__HAND2 ANTISENSE RNA 1, NONCODING; HAND2AS1__:__UPPERHAND; UPH;; DIFFERENTIALLY EXPRESSED IN NEUROBLASTOMA; DEIN__:__
Number Sign__:__617241__:__LUNG DISEASE, IMMUNODEFICIENCY, AND CHROMOSOME BREAKAGE SYNDROME; LICS__:____:__
Asterisk__:__617242__:__TRANS-2,3-ENOYL-CoA REDUCTASE-LIKE PROTEIN; TECRL__:__TECR-LIKE PROTEIN;; TER-LIKE PROTEIN; TERL;; STEROID 5-ALPHA-REDUCTASE 2-LIKE 2; SRD5A2L2;; GPSN2-LIKE; GPSN2L__:__
Number Sign__:__617243__:__FANCONI ANEMIA, COMPLEMENTATION GROUP V; FANCV__:____:__
Number Sign__:__617244__:__FANCONI ANEMIA, COMPLEMENTATION GROUP R; FANCR__:____:__
Asterisk__:__617245__:__HECT, C2, AND WW DOMAINS-CONTAINING E3 UBIQUITIN-PROTEIN LIGASE 2; HECW2__:__NEDD4-LIKE E3 UBIQUITIN-PROTEIN LIGASE 2; NEDL2;; KIAA1301__:__
Asterisk__:__617246__:__NON-SMC ELEMENT 2, S. CEREVISIAE, HOMOLOG OF; NSMCE2__:__NSE2;; MMS21, S. CEREVISIAE, HOMOLOG OF; MMS21;; SMC5/SMC6 COMPLEX SUMO LIGASE NSMCE2__:__
Number Sign__:__617247__:__FANCONI ANEMIA, COMPLEMENTATION GROUP U; FANCU__:____:__
Number Sign__:__617248__:__3-METHYLGLUTACONIC ACIDURIA, TYPE VIII; MGCA8__:____:__
Asterisk__:__617249__:__FAMILY WITH SEQUENCE SIMILARITY 122, MEMBER A; FAM122A__:__CHROMOSOME 9 OPEN READING FRAME 42; C9ORF42__:__
Asterisk__:__617250__:__ELKS/RAB6-INTERACTING/CAST FAMILY, MEMBER 2; ERC2__:__CYTOMATRIX PROTEIN, 110-KD;; CAZ-ASSOCIATED STRUCTURAL PROTEIN; CAST;; CAST1;; KIAA0378__:__
Number Sign__:__617251__:__UNCOMBABLE HAIR SYNDROME 2; UHS2__:____:__
Number Sign__:__617252__:__UNCOMBABLE HAIR SYNDROME 3; UHS3__:____:__
Number Sign__:__617253__:__SECKEL SYNDROME 10; SCKL10__:____:__
Asterisk__:__617254__:__LAMIN TAIL DOMAIN-CONTAINING PROTEIN 1; LMNTD1__:__INTERMEDIATE FILAMENT TAIL DOMAIN-CONTAINING PROTEIN 1; IFLTD1;; LAMIN A-RELATED SEQUENCE 1; LMNARS1;; PAS1 CANDIDATE 1, MOUSE, HOMOLOG OF; PAS1C1__:__
Number Sign__:__617255__:__LISSENCEPHALY 8; LIS8__:____:__
Asterisk__:__617256__:__SOLUTE CARRIER FAMILY 7, MEMBER 13; SLC7A13__:__SODIUM-INDEPENDENT ASPARTATE/GLUTAMATE TRANSPORTER 1; AGT1;; X AMINO ACID TRANSPORTER 2; XAT2__:__
Asterisk__:__617257__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 46; SPATA46__:____:__
Number Sign__:__617258__:__MYOPATHY, MYOFIBRILLAR, 8; MFM8__:____:__
Asterisk__:__617259__:__DDB1- AND CUL4-ASSOCIATED FACTOR 1; DCAF1__:__VPR-INTERACTING PROTEIN; RIP;; VPR-BINDING PROTEIN; VPRBP;; KIAA0800__:__
Number Sign__:__617260__:__GLOBAL DEVELOPMENTAL DELAY, ABSENT OR HYPOPLASTIC CORPUS CALLOSUM, AND DYSMORPHIC FACIES; GDACCF__:____:__
Asterisk__:__617261__:__TRANSMEMBRANE PROTEIN 261; TMEM261__:__DISTAL MEMBRANE ARM ASSEMBLY COMPONENT 1; DMAC1;; CHROMOSOME 9 OPEN READING FRAME 123; C9ORF123__:__
Asterisk__:__617262__:__ATP5S-LIKE PROTEIN; ATP5SL__:____:__
Asterisk__:__617263__:__NON-SMC ELEMENT 1, S. CEREVISIAE, HOMOLOG OF; NSMCE1__:__NSE1;; SMC5-SMC6 COMPLEX COMPONENT NSE1__:__
Asterisk__:__617264__:__SR-RELATED C-TERMINAL DOMAIN-ASSOCIATED FACTOR 1; SCAF1__:__SR-RELATED CTD-ASSOCIATED FACTOR 1;; SERINE- AND ARGININE-RICH PRE-mRNA SPLICING FACTOR SRA1__:__
Asterisk__:__617265__:__POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 9; KCTD9__:__BTB/POZ DOMAIN-CONTAINING PROTEIN 27; BTBD27__:__
Asterisk__:__617266__:__KIAA0825 GENE; KIAA0825__:____:__
Asterisk__:__617267__:__MATRIX AAA PEPTIDASE-INTERACTING PROTEIN 1; MAIP1__:__CHROMOSOME 2 OPEN READING FAME 47; C2ORF47__:__
Number Sign__:__617268__:__NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, SEIZURES, AND ABSENT LANGUAGE; NDHSAL__:____:__
Asterisk__:__617269__:__SOCS2 ANTISENSE RNA 1, NONCODING; SOCS2AS1__:__LONG NONCODING RNA SOCS2AS1;; lncRNA SOCS2AS1__:__
Number Sign__:__617270__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 58; MRT58__:____:__
Number Sign__:__617271__:__NEPHRONOPHTHISIS 20; NPHP20__:____:__
Number Sign__:__617272__:__GLAUCOMA 3, PRIMARY CONGENITAL, E; GLC3E__:____:__
Asterisk__:__617273__:__FAMILY WITH SEQUENCE SIMILARITY 92, MEMBER A; FAM92A__:__FAM92A1__:__
Asterisk__:__617274__:__FAMILY WITH SEQUENCE SIMILARITY 92, MEMBER B; FAM92B__:____:__
Number Sign__:__617275__:__TOOTH AGENESIS, SELECTIVE, 9; STHAG9__:____:__
Number Sign__:__617276__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 48; EIEE48__:____:__
Asterisk__:__617277__:__DYNEIN HEAVY CHAIN DOMAIN 1; DNHD1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 35;; FLJ00251__:__
Asterisk__:__617278__:__DENN DOMAIN-CONTAINING PROTEIN 5A; DENND5A__:__RAB6-INTERACTING PROTEIN 1; RAB6IP1;; KIAA1091__:__
Asterisk__:__617279__:__DENN DOMAIN-CONTAINING PROTEIN 5B; DENND5B__:__RAB6IP-LIKE PROTEIN__:__
Number Sign__:__617280__:__ATRIAL FIBRILLATION, FAMILIAL, 18; ATFB18__:____:__
Number Sign__:__617281__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 49; EIEE49__:____:__
Number Sign__:__617282__:__DYSTONIA, CHILDHOOD-ONSET, WITH OPTIC ATROPHY AND BASAL GANGLIA ABNORMALITIES; DYTOABG__:__DYSTONIA 29, CHILDHOOD-ONSET; DYT29__:__
Asterisk__:__617283__:__YTH DOMAIN-CONTAINING PROTEIN 1; YTHDC1__:__YT521;; YT521B;; KIAA1966__:__
Number Sign__:__617284__:__DYSTONIA 28, CHILDHOOD-ONSET; DYT28__:____:__
Asterisk__:__617285__:__HIGH MOBILITY GROUP BOX 4; HMGB4__:__HIGH MOBILITY GROUP PROTEIN B4;; HMG2-LIKE__:__
Asterisk__:__617286__:__PITX2 ADJACENT NONCODING RNA; PANCR__:__LONG NONCODING RNA PANCR;; lncRNA PANCR__:__
Asterisk__:__617287__:__PHOSPHOLIPID PHOSPHATASE-RELATED PROTEIN 5; PLPPR5__:__PLASTICITY-RELATED GENE 5; PRG5;; LIPID PHOSPHATE PHOSPHATASE-RELATED 5; LPPR5;; PHOSPHATIDIC ACID PHOSPHATASE 2D; PAP2D;; PHOSPHATIDIC ACID PHOSPHATASE TYPE 2; PAP2__:__
Asterisk__:__617288__:__SERINE PEPTIDASE INHIBITOR, KAZAL-TYPE, 7; SPINK7__:__ESOPHAGUS CANCER-RELATED GENE 2; ECRG2__:__
Asterisk__:__617289__:__FAMILY WITH SEQUENCE SIMILARITY 53, MEMBER B; FAM53B__:__SIMPLET, MEDAKA, HOMOLOG OF;; KIAA0140__:__
Number Sign__:__617290__:__EPILEPSY, EARLY-ONSET, VITAMIN B6-DEPENDENT; EPVB6D__:____:__
Asterisk__:__617291__:__TRANSMEMBRANE PROTEIN 150B; TMEM150B__:__DAMAGE-REGULATED AUTOPHAGY MODULATOR 3; DRAM3;; TENTONIN 2; TTN2;; TMEM224__:__
Asterisk__:__617292__:__TRANSMEMBRANE PROTEIN 150C; TMEM150C__:__TENTONIN 3; TTN3__:__
Asterisk__:__617293__:__MATRIX REMODELING-ASSOCIATED PROTEIN 8; MXRA8__:__LIMITRIN;; ADIPOCYTE-SPECIFIC PROTEIN 3; ASP3__:__
Number Sign__:__617294__:__EPIDERMOLYSIS BULLOSA SIMPLEX, GENERALIZED, WITH SCARRING AND HAIR LOSS; EBSSH__:____:__
Asterisk__:__617295__:__RUN DOMAIN-CONTAINING PROTEIN 3B; RUNDC3B__:__RAP2-INTERACTING PROTEIN 9; RPIP9__:__
Number Sign__:__617296__:__SPASTIC PARAPLEGIA, INTELLECTUAL DISABILITY, NYSTAGMUS, AND OBESITY; SINO__:____:__
Number Sign__:__617297__:__AMELOGENESIS IMPERFECTA, TYPE IJ; AI1J__:____:__
Asterisk__:__617298__:__APOPTOSIS-INDUCING FACTOR, MITOCHONDRIA-ASSOCIATED, 3; AIFM3__:__APOPTOSIS-INDUCING FACTOR-LIKE; AIFL__:__
Asterisk__:__617299__:__RPA-INTERACTING PROTEIN; RPAIN__:__RAP-INTERACTING PROTEIN; RIP__:__
Number Sign__:__617300__:__LYMPHATIC MALFORMATION 7; LMPHM7__:__CENTRAL CONDUCTION LYMPHATIC ANOMALY;; HYDROPS FETALIS, NONIMMUNE, AND/OR ATRIAL SEPTAL DEFECT; HFASD__:__
Number Sign__:__617301__:__GLYCINE ENCEPHALOPATHY WITH NORMAL SERUM GLYCINE__:____:__
Number Sign__:__617302__:__OPTIC ATROPHY 11; OPA11__:____:__
Number Sign__:__617303__:__MUCOPOLYSACCHARIDOSIS-PLUS SYNDROME; MPSPS__:____:__
Number Sign__:__617304__:__RETINITIS PIGMENTOSA 77; RP77__:____:__
Asterisk__:__617305__:__FAMILY WITH SEQUENCE SIMILARITY 26, MEMBER F; FAM26F__:__IRF3-DEPENDENT NATURAL KILLER CELL-ACTIVATING MOLECULE; INAM__:__
Number Sign__:__617306__:__COLOBOMA, OSTEOPETROSIS, MICROPHTHALMIA, MACROCEPHALY, ALBINISM, AND DEAFNESS; COMMAD__:____:__
Asterisk__:__617307__:__CHROMOSOME 14 OPEN READING FRAME 39; C14ORF39__:__SIX6 OPPOSITE STRAND TRANSCRIPT 1; SIX6OS1__:__
Number Sign__:__617308__:__BILE ACID SYNTHESIS DEFECT, CONGENITAL, 6; CBAS6__:____:__
Asterisk__:__617309__:__IMMUNOGLOBULIN-LIKE AND FIBRONECTIN TYPE III DOMAINS-CONTAINING PROTEIN 1; IGFN1__:__EEF1A2-BINDING PROTEIN 1; EEF1A2BP1__:__
Asterisk__:__617310__:__ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS-CONTAINING PROTEIN 3; ANKS3__:____:__
Asterisk__:__617311__:__ZYMOGEN GRANULE PROTEIN, 16-KD; ZG16__:__ZG16A;; JACALIN-LIKE LECTIN DOMAIN-CONTAINING PROTEIN 1; JCLN1__:__
Asterisk__:__617312__:__FAMILY WITH SEQUENCE SIMILARITY 160, MEMBER B1; FAM160B1__:__KIAA1600__:__
Asterisk__:__617313__:__SH2 DOMAIN-CONTAINING ADAPTOR PROTEIN F; SHF__:____:__
Asterisk__:__617314__:__SH3 DOMAIN- AND SYLF DOMAIN-CONTAINING PROTEIN 1; SH3YL1__:__SH3 DOMAIN-CONTAINING YSC84-LIKE PROTEIN 1__:__
Number Sign__:__617315__:__ANTERIOR SEGMENT DYSGENESIS 6; ASGD6__:____:__
Asterisk__:__617316__:__TP53 TARGET GENE 5; TP53TG5__:____:__
Asterisk__:__617317__:__ZINC FINGER PROTEIN 30, MOUSE, HOMOLOG OF; ZFP30__:__ZINC FINGER PROTEIN 745; ZNF745;; KIAA0961__:__
Asterisk__:__617318__:__RUN DOMAIN- AND SH3 DOMAIN-CONTAINING PROTEIN 1; RUSC1__:__NEW MOLECULE CONTAINING SH3 DOMAIN AT THE C TERMINUS; NESCA__:__
Number Sign__:__617319__:__ANTERIOR SEGMENT DYSGENESIS 8; ASGD8__:____:__
Number Sign__:__617320__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 12; ARCI12__:____:__
Number Sign__:__617321__:__YAO SYNDROME; YAOS__:____:__
Asterisk__:__617322__:__SH3KBP1-BINDING PROTEIN 1; SHKBP1__:__SETA-BINDING PROTEIN 1; SB1__:__
Number Sign__:__617323__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 59; MRT59__:____:__
Asterisk__:__617324__:__SHISA FAMILY, MEMBER 2; SHISA2__:__CHROMOSOME 13 OPEN READING FRAME 13; C13ORF13;; TRANSMEMBRANE PROTEIN 46; TMEM46__:__
Asterisk__:__617325__:__SHISA FAMILY, MEMBER 3; SHISA3__:____:__
Asterisk__:__617326__:__SHISA FAMILY, MEMBER 4; SHISA4__:__CHROMOSOME 1 OPEN READING FRAME 40; C1ORF40;; TRANSMEMBRANE PROTEIN 58; TMEM58__:__
Asterisk__:__617327__:__SHISA FAMILY, MEMBER 6; SHISA6__:____:__
Asterisk__:__617328__:__SHISA FAMILY, MEMBER 7; SHISA7__:____:__
Asterisk__:__617329__:__SHISA FAMILY, MEMBER 8; SHISA8__:____:__
Number Sign__:__617330__:__HYPOTONIA, ATAXIA, AND DELAYED DEVELOPMENT SYNDROME; HADDS__:____:__
Asterisk__:__617331__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 4B; MFSD4B__:__SODIUM-DEPENDENT GLUCOSE TRANSPORTER 1; NAGLT1;; KIAA1919__:__
Asterisk__:__617332__:__TELOMERE REPEAT-BINDING BOUQUET FORMATION PROTEIN 1; TERB1__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 79; CCDC79__:__
Number Sign__:__617333__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND PTOSIS; IDDDFP__:____:__
Asterisk__:__617334__:__ZINC FINGER DHHC-TYPE CONTAINING 23; ZDHHC23__:__NEURONAL NITRIC OXIDE SYNTHASE-INTERACTING DHHC DOMAIN-CONTAINING PROTEIN WITH DENDRITIC mRNA; NIDD__:__
Asterisk__:__617335__:__EMOPAMIL-BINDING PROTEIN-LIKE; EBPL__:____:__
Number Sign__:__617336__:__NEMALINE MYOPATHY 11, AUTOSOMAL RECESSIVE; NEM11__:____:__
Number Sign__:__617337__:__ECTODERMAL DYSPLASIA 12, HYPOHIDROTIC/HAIR/TOOTH/NAIL TYPE; ECTD12__:____:__
Asterisk__:__617338__:__NUDIX HYDROLASE 16-LIKE 1; NUDT16L1__:__SYNDESMOS; SDOS;; TUDOR-INTERACTING REPAIR REGULATOR; TIRR__:__
Number Sign__:__617339__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 51; EIEE51__:____:__
Asterisk__:__617340__:__URIDINE PHOSPHORYLASE 2; UPP2__:__UPase2__:__
Number Sign__:__617341__:__CEREBRORETINAL MICROANGIOPATHY WITH CALCIFICATIONS AND CYSTS 2; CRMCC2__:____:__
Asterisk__:__617342__:__PEPTIDYL-tRNA HYDROLASE DOMAIN-CONTAINING 1; PTRHD1__:__CHROMOSOME 2 OPEN READING FRAME 79; C2ORF79__:__
Number Sign__:__617343__:__HYPERPARATHYROIDISM 4; HRPT4__:____:__
Asterisk__:__617344__:__PEAK1-RELATED KINASE-ACTIVATING PSEUDOKINASE 1; PRAG1__:__PRAGMA OF RND2; PRAGMIN;; NOTCH ACTIVATION COMPLEX KINASE; NACK__:__
Asterisk__:__617345__:__ATP/GTP-BINDING PROTEIN-LIKE 2; AGBL2__:__CYTOSOLIC CARBOXYPEPTIDASE 2; CCP2__:__
Asterisk__:__617346__:__ATP/GTP-BINDING PROTEIN-LIKE 3; AGBL3__:__CYTOSOLIC CARBOXYPEPTIDASE 3; CCP3__:__
Number Sign__:__617347__:__HYPERLIPOPROTEINEMIA, TYPE III__:__APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA__:__CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED
Asterisk__:__617348__:__CARBOXYPEPTIDASE X, M14 FAMILY, MEMBER 2; CPXM2__:__CPX2__:__
Number Sign__:__617349__:__AORTIC ANEURYSM, FAMILIAL THORACIC 11, SUSCEPTIBILITY TO; AAT11__:____:__
Number Sign__:__617350__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 52; EIEE52__:____:__
Asterisk__:__617351__:__IMMUNOGLOBULIN SUPERFAMILY, MEMBER 10; IGSF10__:____:__
Number Sign__:__617352__:__MULCHANDANI-BHOJ-CONLIN SYNDROME; MBCS__:__UNIPARENTAL DISOMY, MATERNAL, CHROMOSOME 20__:__
Asterisk__:__617353__:__TCTEX1 DOMAIN-CONTAINING PROTEIN 2; TCTEX1D2__:____:__
Asterisk__:__617354__:__CHROMOBOX HOMOLOG 8; CBX8__:__POLYCOMB 3; PC3__:__
Asterisk__:__617355__:__EP300-INTERACTING INHIBITOR OF DIFFERENTIATION 2B; EID2B__:____:__
Asterisk__:__617356__:__SUBCOMMISSURAL ORGAN SPONDIN; SSPO__:__SCO-SPONDIN__:__
Asterisk__:__617357__:__ZINC FINGER PROTEIN 222; ZNF222__:____:__
Asterisk__:__617358__:__SYNDECAN-BINDING PROTEIN 2; SDCBP2__:__SIMILAR TO TACIP18; SITAC;; SYNTENIN-2; ST2;; SITAC18__:__
Asterisk__:__617359__:__STORKHEAD BOX 2; STOX2__:__KIAA1392__:__
Number Sign__:__617360__:__CONGENITAL HEART DEFECTS, DYSMORPHIC FACIAL FEATURES, AND INTELLECTUAL DEVELOPMENTAL DISORDER; CHDFIDD__:____:__
Asterisk__:__617361__:__TRANSMEMBRANE PROTEIN 108; TMEM108__:__RETROLINKIN; RTLN;; KIAA1690__:__
Asterisk__:__617362__:__DEAH BOX POLYPEPTIDE 37; DHX37__:__DEAD/DEAH BOX 37;; KIAA1517__:__
Asterisk__:__617363__:__TRANSMEMBRANE PROTEIN 132A; TMEM132A__:__GRP78-BINDING PROTEIN; GBP;; KIAA1583__:__
Number Sign__:__617364__:__CONGENITAL HEART DEFECTS AND ECTODERMAL DYSPLASIA; CHDED__:____:__
Asterisk__:__617365__:__AAR2 SPLICING FACTOR, S. CEREVISIAE, HOMOLOG OF; AAR2__:__CHROMOSOME 20 OPEN READING FRAME 4; C20ORF4__:__
Asterisk__:__617366__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 91; CCDC91__:__p56__:__
Asterisk__:__617367__:__KIAA1217 GENE; KIAA1217__:__SICKLE TAIL, MOUSE, HOMOLOG OF; SKT__:__
Asterisk__:__617368__:__SH3 DOMAIN-BINDING PROTEIN 1; SH3BP1__:__RHO GTPase-ACTIVATING PROTEIN 43; ARHGAP43;; 3BP1__:__BARGIN, INCLUDED; BGIN, INCLUDED;; SH3BP1/PDXP FUSION GENE, INCLUDED
Asterisk__:__617369__:__HYALURONAN-BINDING PROTEIN 4; HABP4__:__INTRACELLULAR HYALURONAN-BINDING PROTEIN 4; IHABP4;; KI1-INTERACTING 57-KD INTRACELLULAR ANTIGEN;; KI1/57__:__
Number Sign__:__617370__:__PEROXISOME BIOGENESIS DISORDER 10B; PBD10B__:____:__
Asterisk__:__617371__:__ZINC FINGER PROTEIN 462; ZNF462__:__KIAA1803__:__
Asterisk__:__617372__:__SHC TRANSFORMING PROTEIN 4; SHC4__:__SHC ADAPTOR PROTEIN 4;; RAI-LIKE PROTEIN; RALP;; SHC PROTEIN D; SHCD;; SH2 DOMAIN PROTEIN C4__:__
Asterisk__:__617373__:__PROLINE-RICH COILED-COIL PROTEIN 2C; PRRC2C__:__KIAA1096__:__
Asterisk__:__617374__:__INHIBITOR OF CDK, CYCLIN A1-INTERACTING PROTEIN 1; INCA1__:__HSD45__:__
Asterisk__:__617375__:__KELCH DOMAIN-CONTAINING PROTEIN 9; KLHDC9__:__KELCH/ANKYRIN REPEAT-CONTAINING CYCLIN A1-INTERACTING PROTEIN; KARCA1__:__
Asterisk__:__617376__:__PROLINE-RICH CYCLIN A1-INTERACTING PROTEIN; PROCA1__:____:__
Asterisk__:__617377__:__SYNAPSE DEFECTIVE RHO GTPase, C. ELEGANS, HOMOLOG OF, 1; SYDE1__:__SYD1__:__
Asterisk__:__617378__:__MYOSIN LIGHT CHAIN, PHOSPHORYLATABLE, FAST SKELETAL MUSCLE; MYLPF__:__MYOSIN LIGHT CHAIN 2B; MLC2B;; MYOSIN REGULATORY LIGHT CHAIN 2, SKELETAL MUSCLE ISOFORM; MRLC2;; MYOSIN LIGHT CHAIN 11, REGULATORY; MYL11;; HSRLC__:__
Asterisk__:__617379__:__MYOSIN XIX; MYO19__:__MYOSIN HEAD DOMAIN-CONTAINING PROTEIN 1; MYOHD1__:__
Asterisk__:__617380__:__TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 29; TIMM29__:__TIM29;; CHROMOSOME 19 OPEN READING FRAME 52; C19ORF52__:__
Asterisk__:__617381__:__NUDIX HYDROLASE 16; NUDT16__:__NUDIX MOTIF 16__:__
Asterisk__:__617382__:__START DOMAIN-CONTAINING PROTEIN 10; STARD10__:__NY-CO-28__:__
Number Sign__:__617383__:__AVASCULAR NECROSIS OF FEMORAL HEAD, PRIMARY, 2; ANFH2__:____:__
Number Sign__:__617384__:__HYPERPHENYLALANINEMIA, MILD, NON-BH4-DEFICIENT; HPANBH4__:____:__
Asterisk__:__617385__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 31-KD, V1 SUBUNIT E, ISOFORM 1; ATP6V1E2__:__VACUOLAR-TYPE PROTON-TRANSLOCATING ATPase SUBUNIT E1; ATP6E1; E1__:__
NULL__:__617386__:__NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 5, PSEUDOGENE; NR1H5P__:__FARNESOID X-ACTIVATED RECEPTOR, BETA, PSEUDOGENE; FXRB__:__
Asterisk__:__617387__:__GLUTAMINE-RICH PROTEIN 1; QRICH1__:____:__
Number Sign__:__617388__:__AUTOINFLAMMATION WITH ARTHRITIS AND DYSKERATOSIS; AIADK__:____:__
Number Sign__:__617389__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 53; EIEE53__:____:__
Asterisk__:__617390__:__KIAA1958 GENE; KIAA1958__:____:__
Number Sign__:__617391__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 54; EIEE54__:____:__
Number Sign__:__617392__:__ECTODERMAL DYSPLASIA 13, HAIR/TOOTH TYPE; ECTD13__:____:__
Number Sign__:__617393__:__NEURODEVELOPMENTAL DISORDER WITH EPILEPSY, CATARACTS, FEEDING DIFFICULTIES, AND DELAYED BRAIN MYELINATION; NECFM__:____:__
Number Sign__:__617394__:__SCLEROSING CHOLANGITIS, NEONATAL; NSC__:____:__
Number Sign__:__617395__:__CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIq; CDG2Q__:__CDG IIq; CDGIIq__:__
Number Sign__:__617396__:__ANAUXETIC DYSPLASIA 2; ANXD2__:____:__
Number Sign__:__617397__:__PSEUDO-TORCH SYNDROME 2; PTORCH2__:____:__
Asterisk__:__617398__:__FK506-BINDING PROTEIN 15; FKBP15__:__FK506-BINDING PROTEIN, 133-KD; FKBP133;; KIAA0674;; WASP- AND FKBP-LIKE PROTEIN; WAFL__:__
Asterisk__:__617399__:__PEROXISOMAL MEMBRANE PROTEIN 2; PXMP2__:__PEROXISOMAL MEMBRANE PROTEIN, 22-KD; PMP22__:__
Asterisk__:__617400__:__EPOXIDE HYDROLASE 3; EPHX3__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 9; ABHD9;; EH3__:__
Asterisk__:__617401__:__EPOXIDE HYDROLASE 4; EPHX4__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 7; ABHD7;; EPOXIDE HYDROLASE-RELATED PROTEIN; EPHXRP;; EH4__:__
Number Sign__:__617402__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC; ARCL2C__:____:__
Number Sign__:__617403__:__CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID; ARCL2D__:____:__
Number Sign__:__617404__:__MUSCULAR DYSTROPHY, CONGENITAL, WITH CATARACTS AND INTELLECTUAL DISABILITY; MDCCAID__:____:__
Number Sign__:__617405__:__SHORT-RIB THORACIC DYSPLASIA 17 WITH OR WITHOUT POLYDACTYLY; SRTD17__:____:__
Number Sign__:__617406__:__BARDET-BIEDL SYNDROME 21; BBS21__:____:__
Asterisk__:__617407__:__POLYCOMB GROUP RING FINGER PROTEIN 5; PCGF5__:____:__
Number Sign__:__617408__:__DIAMOND-BLACKFAN ANEMIA 16; DBA16__:____:__
Number Sign__:__617409__:__DIAMOND-BLACKFAN ANEMIA 17; DBA17__:____:__
Asterisk__:__617410__:__ZINC FINGER PROTEIN 419; ZNF419__:____:__
Asterisk__:__617411__:__ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE FACTOR 3; ARFGEF3__:__BREFELDIN A-INHIBITED GUANINE NUCLEOTIDE EXCHANGE PROTEIN 3; BIG3;; KIAA1244__:__
Number Sign__:__617412__:__BRACHYCEPHALY, TRICHOMEGALY, AND DEVELOPMENTAL DELAY; BTDD__:__MACINNES SYNDROME; MCINS__:__
Asterisk__:__617413__:__PRUNE EXOPOLYPHOSPHATASE 1; PRUNE1__:__PRUNE, DROSOPHILA, HOMOLOG OF; PRUNE;; DROSOPHILA-RELATED EXPRESSED SEQUENCE 17; DRES17__:__
Asterisk__:__617414__:__RIBOSOMAL PROTEIN L14; RPL14__:__60S RIBOSOMAL PROTEIN 14__:__
Asterisk__:__617415__:__RIBOSOMAL PROTEIN L31; RPL31__:__60S RIBOSOMAL PROTEIN 31__:__
Asterisk__:__617416__:__RIBOSOMAL PROTEIN L3-LIKE; RPL3L__:__60S RIBOSOMAL PROTEIN L3-LIKE__:__
Asterisk__:__617417__:__RIBOSOMAL PROTEIN L7-LIKE 1; RPL7L1__:__60S RIBOSOMAL PROTEIN L7-LIKE 1__:__
Asterisk__:__617418__:__WD REPEAT-CONTAINING PROTEIN 59; WDR59__:__KIAA1923__:__
Asterisk__:__617419__:__PROLYL 3-HYDROXYLASE 4; P3H4__:__SYNAPTONEMAL COMPLEX PROTEIN 65; SC65;; LEPRECAN-LIKE 4; LEPREL4__:__
Asterisk__:__617420__:__CHROMOSOME 12 OPEN READING FRAME 66; C12ORF66__:____:__
Asterisk__:__617421__:__INTEGRIN-ALPHA FG-GAP REPEAT-CONTAINING PROTEIN 2; ITFG2__:__FG-GAP REPEAT-CONTAINING PROTEIN 1; FGGAP1__:__
Asterisk__:__617422__:__ACTIVITY-DEPENDENT NEUROPROTECTOR HOMEOBOX 2; ADNP2__:__ADNP HOMEOBOX 2;; KIAA0863__:__
Asterisk__:__617423__:__PROLINE-RICH PROTEIN 14; PRR14__:____:__
Asterisk__:__617424__:__WD REPEAT-CONTAINING PROTEIN 26; WDR26__:__GID COMPLEX, SUBUNIT 7; GID7;; GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 7, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__617425__:__IMMUNOSKELETAL DYSPLASIA WITH NEURODEVELOPMENTAL ABNORMALITIES; ISDNA__:____:__
Asterisk__:__617426__:__CYSTEINE-RICH C-TERMINAL 1; CRCT1__:__NICE1;; CHROMOSOME 1 OPEN READING FRAME 42; C1ORF42__:__
Asterisk__:__617427__:__S100 CALCIUM-BINDING PROTEIN A7A; S100A7A__:__S100 CALCIUM-BINDING PROTEIN A15; S100A15;; S100 CALCIUM-BINDING PROTEIN A7-LIKE 1; S100A7L1;; NICE2__:__
Asterisk__:__617428__:__CHROMOSOME 1 OPEN READING FRAME 43; C1ORF43__:__HEPATITIS C VIRUS NS5A-TRANSACTIVATED PROTEIN 4; NS5ATP4;; NICE3;; HSPC012__:__
Asterisk__:__617429__:__UBIQUITIN-CONJUGATING ENZYME E2Q FAMILY MEMBER 1; UBE2Q1__:__GALACTOSYL TRANSFERASE-ASSOCIATED PROTEIN; GTAP;; NICE5__:__
Asterisk__:__617430__:__ADHESION G PROTEIN-COUPLED RECEPTOR F1; ADGRF1__:__G PROTEIN-COUPLED RECEPTOR 110; GPR110__:__
Asterisk__:__617431__:__UBIQUITIN-SPECIFIC PEPTIDASE 53; USP53__:__KIAA1350__:__
Number Sign__:__617432__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 60; MRT60__:____:__
Number Sign__:__617433__:__RETINITIS PIGMENTOSA 78; RP78__:____:__
Asterisk__:__617434__:__LONG NONCODING RNA HOST2__:__HOST2__:__
Number Sign__:__617435__:__LOPES-MACIEL-RODAN SYNDROME; LOMARS__:____:__
Asterisk__:__617436__:__GON7, S. CEREVISIAE, HOMOLOG OF; GON7__:__CHROMOSOME 14 OPEN READING FRAME 142; C14ORF142__:__
Asterisk__:__617437__:__S100 CALCIUM-BINDING PROTEIN A16; S100A16__:__AGING-ASSOCIATED GENE 13; AAG13__:__
Asterisk__:__617438__:__CHROMOBOX HOMOLOG 6; CBX6__:____:__
Number Sign__:__617439__:__CRANIOSYNOSTOSIS 7; CRS7__:__CRANIOSYNOSTOSIS 7, DIGENIC;; CRS7, DIGENIC__:__
Asterisk__:__617440__:__PAPILLARY THYROID CARCINOMA SUSCEPTIBILITY CANDIDATE 1 GENE; PTCSC1__:__NONCODING RNA 197; NCRNA00197__:__
Number Sign__:__617441__:__THROMBOCYTOPENIA, ANEMIA, AND MYELOFIBROSIS; THAMY__:____:__
Number Sign__:__617442__:__PREMATURE OVARIAN FAILURE 13; POF13__:____:__
Number Sign__:__617443__:__BLEEDING DISORDER, PLATELET-TYPE, 21; BDPLT21__:____:__
Asterisk__:__617444__:__ZINC FINGER PROTEIN 479; ZNF479__:__KR19__:__
Asterisk__:__617445__:__UBIQUITIN-SPECIFIC PEPTIDASE 48; USP48__:__UBIQUITIN-SPECIFIC PROTEASE 48;; UBIQUITIN-SPECIFIC PEPTIDASE 31, FORMERLY; USP31, FORMERLY;; UBIQUITIN-SPECIFIC PROTEASE 31, FORMERLY__:__
Asterisk__:__617446__:__ChaC, E. COLI, HOMOLOG OF, 2; CHAC2__:__CATION TRANSPORT REGULATOR-LIKE PROTEIN 2__:__
Asterisk__:__617447__:__PABP-DEPENDENT POLY(A) NUCLEASE 2; PAN2__:__PAN2 POLY(A)-SPECIFIC RIBONUCLEASE SUBUNIT;; UBIQUITIN-SPECIFIC PROTEASE 52: USP52;; KIAA0710__:__
Asterisk__:__617448__:__PABP-DEPENDENT POLY(A) NUCLEASE 3; PAN3__:__PAN3 POLY(A)-SPECIFIC RIBONUCLEASE SUBUNIT__:__
Asterisk__:__617449__:__TRANSMEMBRANE PROTEIN 260; TMEM260__:__CHROMOSOME 14 OPEN READING FRAME 101; C14ORF101__:__
Number Sign__:__617450__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH GASTROINTESTINAL DIFFICULTIES AND HIGH PAIN THRESHOLD; IDDGIP__:____:__
Asterisk__:__617451__:__ALDO-KETO REDUCTASE FAMILY 1, MEMBER E2; AKR1E2__:__HUMAN TESTIS-SPECIFIC PROTEIN; HTSP;; TESTIS ALDO-KETO REDUCTASE; TAKR__:__
Number Sign__:__617452__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES, SEIZURES, AND DISTAL LIMB ANOMALIES; IDDFSDA__:____:__
Asterisk__:__617453__:__TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 26; TTC26__:__INTRAFLAGELLAR TRANSPORT 56, CHLAMYDOMONAS, HOMOLOG OF; IFT56__:__
Asterisk__:__617454__:__POLYMERASE III, RNA, SUBUNIT C; POLR3C__:__RNA POLYMERASE III, 62-KD SUBUNIT; RPC62;; RNA POLYMERASE III, SUBUNIT C3; RPC3;; DNA-DIRECTED RNA POLYMERASE III, SUBUNIT C__:__
Asterisk__:__617455__:__POLYMERASE III, RNA, SUBUNIT F; POLR3F__:__RNA POLYMERASE III, 39-KD SUBUNIT; RPC39;; RNA POLYMERASE III, SUBUNIT C6; RPC6;; DNA-DIRECTED RNA POLYMERASE III, SUBUNIT F__:__
Asterisk__:__617456__:__POLYMERASE III, RNA, SUBUNIT G; POLR3G__:__RNA POLYMERASE III, 32-KD SUBUNIT; RPC32;; RNA POLYMERASE III, 32-KD SUBUNIT, ALPHA;; RPC32-ALPHA;; RNA POLYMERASE III, SUBUNIT C7; RPC7;; DNA-DIRECTED RNA POLYMERASE III, SUBUNIT G__:__
Asterisk__:__617457__:__POLYMERASE III, RNA, SUBUNIT G-LIKE; POLR3GL__:__RNA POLYMERASE III, 32-KD SUBUNIT, BETA;; RPC32-BETA;; RNA POLYMERASE III, SUBUNIT C7-LIKE__:__
Asterisk__:__617458__:__PRKR-INTERACTING PROTEIN 1, IL11-INDUCIBLE; PRKRIP1__:__C114__:__
Asterisk__:__617459__:__TRANSMEMBRANE AND COILED-COIL DOMAIN FAMILY, MEMBER 3; TMCC3__:____:__
Number Sign__:__617460__:__RETINITIS PIGMENTOSA 79; RP79__:____:__
Asterisk__:__617461__:__YBEY METALLOPEPTIDASE; YBEY__:__YbeY, E. COLI, HOMOLOG OF;; CHROMOSOME 21 OPEN READING FRAME 57; C21ORF57__:__
Asterisk__:__617462__:__PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA, COACTIVATOR-RELATED PROTEIN 1; PPRC1__:__PGC1-RELATED COACTIVATOR; PRC;; KIAA0595__:__
Asterisk__:__617463__:__UNKEMPT FAMILY-LIKE ZINC FINGER; UNKL__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 5-LIKE; ZC3HDC5L; ZC3H5L;; CHROMOSOME 16 OPEN READING FRAME 28; C16ORF28__:__
Asterisk__:__617464__:__UNC5 FAMILY C-TERMINAL-LIKE PROTEIN; UNC5CL__:__ZU5 AND DEATH DOMAINS-CONTAINING PROTEIN; ZUD__:__
Asterisk__:__617465__:__SMALL INTEGRAL MEMBRANE PROTEIN 20; SMIM20__:__MITOCHONDRIAL TRANSLATION REGULATION ASSEMBLY INTERMEDIATE OF CYTOCHROME c OXIDASE 7; MITRAC7;; CHROMOSOME 4 OPEN READING FRAME 52; C4ORF52__:__
Number Sign__:__617466__:__TOWNES-BROCKS SYNDROME 2; TBS2__:____:__
Asterisk__:__617467__:__FERM DOMAIN-CONTAINING PROTEIN 4B; FRMD4B__:__GRP1-SIGNALING PARTNER 1; GRSP1;; KIAA1013__:__
Number Sign__:__617468__:__ARTHROGRYPOSIS MULTIPLEX CONGENITA, NEUROGENIC, WITH MYELIN DEFECT; AMCNMY__:____:__
Asterisk__:__617469__:__AFG1-LIKE ATPase; AFG1L__:__ATPase FAMILY GENE 1, S. CEREVISIAE, HOMOLOG OF; AFG1;; LACTATION-ELEVATED GENE 1; LACE1__:__
Asterisk__:__617470__:__UBIQUITIN-SPECIFIC PEPTIDASE-LIKE 1; USPL1__:__USP-LIKE 1__:__
Asterisk__:__617471__:__SERPIN PEPTIDASE INHIBITOR, CLADE A, MEMBER 12; SERPINA12__:__VISCERAL ADIPOSE-SPECIFIC SERPIN; VASPIN__:__
Asterisk__:__617472__:__TENASCIN N; TNN__:____:__
Asterisk__:__617473__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT G; ATP5L__:__ATP5JG__:__
Asterisk__:__617474__:__ZINC FINGER PROTEIN 609; ZNF609__:__KIAA0295__:__
Number Sign__:__617475__:__SPECIFIC GRANULE DEFICIENCY 2; SGD2__:____:__
Asterisk__:__617476__:__CNKSR FAMILY, MEMBER 3; CNKSR3__:__CONNECTOR ENHANCER OF KSR 3;; CNK, DROSOPHILA, HOMOLOG OF, 3; CNK3__:__INTERACTION PROTEIN FOR CYTOHESIN EXCHANGE FACTORS 1, INCLUDED; IPCEF1, INCLUDED; IPCEF, INCLUDED;; PIP3E, INCLUDED
Asterisk__:__617477__:__ZINC FINGER PROTEIN 324; ZNF324__:__ZF5128__:__
Number Sign__:__617478__:__STRUCTURAL HEART DEFECTS AND RENAL ANOMALIES SYNDROME; SHDRA__:____:__
Asterisk__:__617479__:__SSU2, C. ELEGANS, HOMOLOG OF; SSUH2__:__SSU2;; CHROMOSOME 3 OPEN READING FRAME 32; C3ORF32;; FLS485__:__
Number Sign__:__617480__:__46,XX SEX REVERSAL 4; SRXX4__:__46,XX SEX REVERSAL, SRY-NEGATIVE__:__
Number Sign__:__617481__:__NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, HYPOTONIA, AND VARIABLE BRAIN ANOMALIES; NMIHBA__:____:__
Asterisk__:__617482__:__TP53 TARGET GENE 3; TP53TG3__:____:__
Asterisk__:__617483__:__CORNICHON FAMILY AMPA RECEPTOR AUXILIARY PROTEIN 4; CNIH4__:__CORNICHON, DROSOPHILA, HOMOLOG OF, 4; CNIH2__:__
Asterisk__:__617484__:__GAMETOCYTE-SPECIFIC FACTOR 1; GTSF1__:__FAMILY WITH SEQUENCE SIMILARITY 112, MEMBER B; FAM112B__:__
Asterisk__:__617485__:__WD REPEAT- AND FYVE DOMAIN-CONTAINING PROTEIN 3; WDFY3__:__AUTOPHAGY-LINKED FYVE PROTEIN; ALFY;; BLUE CHEESE, DROSOPHILA, HOMOLOG OF; BCHS__:__
Asterisk__:__617486__:__G-PATCH DOMAIN-CONTAINING PROTEIN 3; GPATCH3__:____:__
Asterisk__:__617487__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 14; DNAJB14__:____:__
Asterisk__:__617488__:__RNA PSEUDOURIDYLATE SYNTHASE DOMAIN-CONTAINING PROTEIN 4; RPUSD4__:____:__
Asterisk__:__617489__:__LONG INTERGENIC NONCODING RNA 305; LINC00305__:__lincRNA 305__:__
Asterisk__:__617490__:__CATION CHANNEL, SPERM-ASSOCIATED, AUXILIARY SUBUNIT DELTA; CATSPERD__:__TRANSMEMBRANE PROTEIN 146; TMEM146__:__
Asterisk__:__617491__:__NOP2/SUN RNA METHYLTRANSFERASE FAMILY, MEMBER 3; NSUN3__:__NOL1/NOP2/SUN DOMAIN FAMILY, MEMBER 3__:__
Asterisk__:__617492__:__OLFACTOMEDIN 2; OLFM2__:__NOELIN 2; NOE2__:__
Number Sign__:__617493__:__NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENTS; NEDIM__:____:__
Asterisk__:__617494__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 2; EML2__:__EMAP-LIKE 2;; EMAP-RELATED PROTEIN 2; EMAP2;; EMAP-LIKE PROTEIN, 70-KD; ELP70__:__
Asterisk__:__617495__:__FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A1, CC MOTIF CHEMOKINE-LIKE; FAM19A1__:__TAFA1__:__
Asterisk__:__617496__:__FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A2, CC MOTIF CHEMOKINE-LIKE; FAM19A2__:__TAFA2__:__
Asterisk__:__617497__:__FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A3, CC MOTIF CHEMOKINE-LIKE; FAM19A3__:__TAFA3__:__
Asterisk__:__617498__:__FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A4, CC MOTIF CHEMOKINE-LIKE; FAM19A4__:__TAFA4__:__
Asterisk__:__617499__:__FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5, CC MOTIF CHEMOKINE-LIKE; FAM19A5__:__TAFA5__:__
Asterisk__:__617500__:__UROTHELIAL CANCER-ASSOCIATED GENE 1; UCA1__:__LONG INTERGENIC NONCODING RNA 178; LINC00178;; CUDR__:__
Asterisk__:__617501__:__LYSINE ACETYLTRANSFERASE 14; KAT14__:__CRP2-BINDING PARTNER; CRP2BP; CSRP2BP;; ADA2A-CONTAINING COMPLEX SUBUNIT 2; ATAC2__:__
Asterisk__:__617502__:__WD REPEAT-CONTAINING PROTEIN 41; WDR41__:____:__
Asterisk__:__617503__:__DENN DOMAIN-CONTAINING PROTEIN 3; DENND3__:__DENN/MADD DOMAIN-CONTAINING PROTEIN 3;; KIAA0870__:__
Asterisk__:__617504__:__SIPA1-LIKE PROTEIN 1; SIPA1L1__:__E6-TARGETED PROTEIN 1; E6TP1;; KIAA0440__:__
Asterisk__:__617505__:__TRANSLOCATION-ASSOCIATED MEMBRANE PROTEIN 1-LIKE 1; TRAM1L1__:____:__
Number Sign__:__617506__:__NOONAN SYNDROME-LIKE DISORDER WITH LOOSE ANAGEN HAIR 2; NSLH2__:____:__
Number Sign__:__617507__:__PEHO-LIKE SYNDROME; PEHOL__:__PROGRESSIVE ENCEPHALOPATHY WITH EDEMA, HYPSARRHYTHMIA, AND OPTIC ATROPHY-LIKE SYNDROME__:__
Asterisk__:__617508__:__ZINC FINGER PROTEIN 598; ZNF598__:____:__
Asterisk__:__617509__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 8; VWA8__:__KIAA0564__:__
Asterisk__:__617510__:__CATION CHANNEL, SPERM-ASSOCIATED, AUXILIARY SUBUNIT EPSILON; CATSPERE__:__CHROMOSOME 1 OPEN READING FRAME 101; C1ORF101__:__
Asterisk__:__617511__:__CATION CHANNEL, SPERM-ASSOCIATED, AUXILIARY SUBUNIT ZETA; CATSPERZ__:__TESTIS-EXPRESSED GENE 40; TEX40__:__
Asterisk__:__617512__:__ZINC FINGER PROTEIN 318; ZNF318__:__TESTICULAR ZINC FINGER; TZF;; ZFP318__:__
Asterisk__:__617513__:__OXOGLUTARATE DEHYDROGENASE-LIKE PROTEIN; OGDHL__:__KIAA1290__:__
Number Sign__:__617514__:__IMMUNODEFICIENCY 52; IMD52__:____:__
Asterisk__:__617515__:__RHOMBOID DOMAIN-CONTAINING 1; RHBDD1__:__RHOMBOID-RELATED PROTEIN 4; RRP4;; RHOMBOID-LIKE PROTEIN 4; RHBDL4__:__
Number Sign__:__617516__:__STANKIEWICZ-ISIDOR SYNDROME; STISS__:____:__
Asterisk__:__617517__:__RIBOSOMAL PROTEIN S6 KINASE C1; RPS6KC1__:__RIBOSOMAL PROTEIN S6 KINASE-LIKE PROTEIN WITH 2 PSK DOMAINS, 118-KD; RPK118__:__
Asterisk__:__617518__:__BSD DOMAIN-CONTAINING PROTEIN 1; BSDC1__:____:__
Number Sign__:__617519__:__NEURODEVELOPMENTAL DISORDER WITH HYPOTONIA, NEUROPATHY, AND DEAFNESS; NEDHND__:__MYOPATHY, CONGENITAL, WITH NEUROPATHY AND DEAFNESS; CMND__:__
Number Sign__:__617520__:__MICROCEPHALY 18, PRIMARY, AUTOSOMAL DOMINANT; MCPH18__:____:__
Asterisk__:__617521__:__YIP1 DOMAIN FAMILY, MEMBER 1; YIPF1__:____:__
Asterisk__:__617522__:__YIP1 DOMAIN FAMILY, MEMBER 2; YIPF2__:____:__
Number Sign__:__617523__:__NEURODEVELOPMENTAL DISORDER WITH MIDBRAIN AND HINDBRAIN MALFORMATIONS; NEDMHM__:____:__
Number Sign__:__617524__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 2; EKVP2__:____:__
Number Sign__:__617525__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 3; EKVP3__:____:__
Number Sign__:__617526__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 4; EKVP4__:____:__
Number Sign__:__617527__:__NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN ANOMALIES; NDMSBA__:____:__
Asterisk__:__617528__:__PROTEASOME ASSEMBLY CHAPERONE 3; PSMG3__:__PAC3__:__
Asterisk__:__617529__:__FAST KINASE DOMAINS 1; FASTKD1__:__FAST KINASE DOMAIN-CONTAINING PROTEIN 1;; KIAA1800__:__
Asterisk__:__617530__:__FAST KINASE DOMAINS 3; FASTKD3__:__FAST KINASE DOMAIN-CONTAINING PROTEIN 3__:__
Asterisk__:__617531__:__COLLAGEN BETA(1-O)GALACTOSYLTRANSFERASE 1; COLGALT1__:__GLYCOSYLTRANSFERASE 25 FAMILY, MEMBER 1; GLT25D1;; HYDROXYLYSINE GALACTOSYLTRANSFERASE 1__:__
Number Sign__:__617532__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH NEUROPSYCHIATRIC FEATURES; IDDNPF__:____:__
Asterisk__:__617533__:__COLLAGEN BETA(1-O)GALACTOSYLTRANSFERASE 2; COLGALT2__:__GLYCOSYLTRANSFERASE 25 FAMILY, MEMBER 2; GLT25D2;; HYDROXYLYSINE GALACTOSYLTRANSFERASE 2;; KIAA0584__:__
Asterisk__:__617534__:__YIP1 DOMAIN FAMILY, MEMBER 4; YIPF4__:____:__
Asterisk__:__617535__:__FAS APOPTOTIC INHIBITORY MOLECULE; FAIM__:__FAIM1__:__
Asterisk__:__617536__:__BAI1-ASSOCIATED PROTEIN 2-LIKE 2; BAIAP2L2__:__PLANAR INTESTINE- AND KIDNEY-SPECIFIC BAR DOMAIN PROTEIN; PINKBAR__:__
Number Sign__:__617537__:__RAHMAN SYNDROME; RMNS__:____:__
Asterisk__:__617538__:__ELONGATION FACTOR-LIKE GTPase 1; EFL1__:__RIBOSOME ASSEMBLY 1 HOMOLOG; RIA1;; ELONGATION FACTOR Tu GTP-BINDING DOMAIN-CONTAINING 1; EFTUD1;; FAM42A__:__
Asterisk__:__617539__:__CHLORIDE CHANNEL CLIC-LIKE 1; CLCC1__:__MID1-RELATED CHLORIDE CHANNEL 1; MCLC__:__
Number Sign__:__617540__:__PITUITARY ADENOMA 5, MULTIPLE TYPES; PITA5__:____:__
Asterisk__:__617541__:__ANKYRIN REPEAT- AND ZINC FINGER DOMAIN-CONTAINING 1; ANKZF1__:__ZINC FINGER PROTEIN 744; ZNF744__:__
Number Sign__:__617542__:__GAZE PALSY, FAMILIAL HORIZONTAL, WITH PROGRESSIVE SCOLIOSIS, 2; HGPPS2__:____:__
Asterisk__:__617543__:__POLYCOMB GROUP RING FINGER PROTEIN 3; PCGF3__:__RING FINGER PROTEIN 3; RNF3;; RNF3A__:__
Asterisk__:__617544__:__LONG INTERGENIC NONCODING RNA 672; LINC00672__:__lincRNA 672__:__
Asterisk__:__617545__:__MINICHROMOSOME MAINTENANCE DOMAIN-CONTAINING PROTEIN 2; MCMDC2__:__MCM DOMAIN-CONTAINING PROTEIN 2;; CHROMOSOME 8 OPEN READING FRAME 45; C8ORF45__:__
Asterisk__:__617546__:__HELT BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTOR; HELT__:__HEY-LIKE TRANSCRIPTION FACTOR;; HES-LIKE TRANSCRIPTION FACTOR; HESLIKE; HESL;; MEGANE BASIC HELIX-LOOP-HELIX FACTOR; MGN__:__
Number Sign__:__617547__:__RETINAL DYSTROPHY WITH OR WITHOUT MACULAR STAPHYLOMA; RDMS__:____:__
Asterisk__:__617548__:__WAP 4-DISULFIDE CORE DOMAIN 2; WFDC2__:__HUMAN EPIDIDYMIS PROTEIN 4; HE4;; WAP5__:__
Asterisk__:__617549__:__TUMOR PROTEIN p53-INDUCIBLE NUCLEAR PROTEIN 2; TP53INP2__:__TP53-INDUCIBLE PROTEIN U; PIGU;; DIABETES- AND OBESITY-REGULATED GENE; DOR;; CHROMOSOME 20 OPEN READING FRAME 110; C20ORF110__:__
Asterisk__:__617550__:__PROTEASOME ASSEMBLY CHAPERONE 4; PSMG4__:__PAC4;; CHROMOSOME 6 OPEN READING FRAME 86; C6ORF86__:__
Asterisk__:__617551__:__SID1 TRANSMEMBRANE FAMILY, MEMBER 2; SIDT2__:____:__
Asterisk__:__617552__:__RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 26; ARHGEF26__:__SH3 DOMAIN-CONTAINING GUANINE NUCLEOTIDE EXCHANGE FACTOR; SGEF__:__
Asterisk__:__617553__:__Fc FRAGMENT OF IgG-BINDING PROTEIN; FCGBP__:__FC-GAMMA-BP__:__
Asterisk__:__617554__:__FYVE, RhoGEF, AND PH DOMAIN-CONTAINING PROTEIN 3; FGD3__:__ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 5; ZFYVE5__:__
Asterisk__:__617555__:__FCH AND DOUBLE SH3 DOMAINS PROTEIN 1; FCHSD1__:__NERVOUS WRECK, DROSOPHILA, HOMOLOG OF, 2; NWK2__:__
Asterisk__:__617556__:__FCH AND DOUBLE SH3 DOMAINS PROTEIN 2; FCHSD2__:__NERVOUS WRECK, DROSOPHILA, HOMOLOG OF; NWK;; KIAA0769__:__
Number Sign__:__617557__:__GABRIELE-DE VRIES SYNDROME; GADEVS__:____:__
Asterisk__:__617558__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 43; CFAP43__:__WD REPEAT-CONTAINING PROTEIN 96; WDR96;; CHROMOSOME 10 OPEN READING FRAME 79; C10ORF79__:__
Asterisk__:__617559__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 44; CFAP44__:__WD REPEAT-CONTAINING PROTEIN 52; WDR52__:__
Number Sign__:__617560__:__SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY; SPAX8__:____:__
Number Sign__:__617561__:__COHEN-GIBSON SYNDROME; COGIS__:____:__
Number Sign__:__617562__:__MECKEL SYNDROME 13; MKS13__:____:__JOUBERT SYNDROME 29, INCLUDED; JBTS29, INCLUDED
Number Sign__:__617563__:__OROFACIODIGITAL SYNDROME XVI; OFD16__:__OFDS XVI;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVI__:__
Number Sign__:__617564__:__MEIER-GORLIN SYNDROME 8; MGORS8__:____:__
Number Sign__:__617565__:__PERRAULT SYNDROME 6; PRLTS6__:____:__
Asterisk__:__617566__:__ZINC FINGER PROTEIN 568; ZNF568__:__ZFP568__:__
Asterisk__:__617567__:__TUMOR PROTEIN D52-LIKE 3; TPD52L3__:__D55__:__
Asterisk__:__617568__:__UPSTREAM TRANSCRIPTION FACTOR FAMILY, MEMBER 3; USF3__:____:__
Asterisk__:__617569__:__KINESIN FAMILY, MEMBER 15; KIF15__:__KINESIN-LIKE PROTEIN 2; KLP2;; KINESIN-LIKE 7; KNSL7;; NY-BR-62__:__
Asterisk__:__617570__:__DAZ-INTERACTING ZINC FINGER PROTEIN 1-LIKE; DZIP1L__:__DZIP1-LIKE;; DAZ-INTERACTING ZINC FINGER PROTEIN 2; DZIP2__:__
Number Sign__:__617571__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 14; ARCI14__:____:__
Number Sign__:__617572__:__EXUDATIVE VITREORETINOPATHY 7; EVR7__:____:__
Asterisk__:__617573__:__C-TYPE LECTIN DOMAIN FAMILY 12, MEMBER B; CLEC12B__:__MACROPHAGE ANTIGEN H__:__
Number Sign__:__617574__:__ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 13; ARCI13__:____:__
Number Sign__:__617575__:__NEPHROTIC SYNDROME, TYPE 14; NPHS14__:____:__
Number Sign__:__617576__:__SPERMATOGENIC FAILURE 18; SPGF18__:____:__
Number Sign__:__617577__:__CILIARY DYSKINESIA, PRIMARY, 37; CILD37__:__CILIARY DYSKINESIA, PRIMARY, 37, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__617578__:__FER3, DROSOPHILA, HOMOLOG OF; FERD3L__:__NEURONAL TWIST; NTWIST;; NEPHEW OF ATONAL 3; NATO3;; BASIC HELIX-LOOP-HELIX FAMILY, MEMBER A31; BHLHA31;; PANCREAS-SPECIFIC TRANSCRIPTION FACTOR B; PTFB__:__
Asterisk__:__617579__:__CLAUDIN 10; CLDN10__:__OLIGODENDROCYTE-SPECIFIC PROTEIN-LIKE; OSPL;; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTOR-LIKE 3; CPETRL3__:__
Asterisk__:__617580__:__TETRASPANIN 16; TSPAN16__:__TRANSMEMBRANE 4 SUPERFAMILY, MEMBER 16; TM4SF16;; TM4B__:__
Asterisk__:__617581__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 2; C2CD2__:__TRANSMEMBRANE PROTEIN 24-LIKE; TMEM24L;; CHROMOSOME 21 OPEN READING FRAME 25; C21ORF25;; CHROMOSOME 21 OPEN READING FRAME 258; C21ORF258__:__
Asterisk__:__617582__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 2-LIKE; C2CD2L__:__C2CD2-LIKE;; TRANSMEMBRANE PROTEIN 24; TMEM24__:__
Asterisk__:__617583__:__SULFIREDOXIN 1; SRXN1__:__SRX;; SRX1__:__
Number Sign__:__617584__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 25; SCAR25__:____:__
Number Sign__:__617585__:__IMMUNODEFICIENCY 53; IMD53__:____:__
Asterisk__:__617586__:__FERM, ARHGEF, AND PLECKSTRIN DOMAINS-CONTAINING PROTEIN 2; FARP2__:__FGD1-RELATED CDC42 GUANINE NUCLEOTIDE EXCHANGE FACTOR; FRG;; PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY C, MEMBER 3; PLEKHC3;; FERM DOMAIN-INCLUDING RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; FIR;; KIAA0793__:__
Asterisk__:__617587__:__SMALL PROLINE-RICH PROTEIN 2D; SPRR2D__:____:__
Asterisk__:__617588__:__SMALL PROLINE-RICH PROTEIN 2E; SPRR2E__:____:__
Asterisk__:__617589__:__SMALL PROLINE-RICH PROTEIN 2F; SPRR2F__:____:__
Asterisk__:__617590__:__SMALL PROLINE-RICH PROTEIN 2G; SPRR2G__:____:__
Number Sign__:__617591__:__PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 3; PRAAS3__:____:__PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 3, DIGENIC, INCLUDED
Number Sign__:__617592__:__SPERMATOGENIC FAILURE 19; SPGF19__:____:__
Number Sign__:__617593__:__SPERMATOGENIC FAILURE 20; SPGF20__:____:__
Asterisk__:__617594__:__JHY, MOUSE, HOMOLOG OF; JHY__:__CHROMOSOME 11 OPEN READING FRAME 63; C11ORF63__:__
Number Sign__:__617595__:__BIRK-LANDAU-PEREZ SYNDROME; BILAPES__:____:__
Number Sign__:__617596__:__MALEYLACETOACETATE ISOMERASE DEFICIENCY; MAAID__:__MAAI DEFICIENCY;; HYPERSUCCINYLACETONEMIA, MILD; MHSA;; BENIGN HYPERSUCCINYLACETONEMIA; BHSA__:__
Asterisk__:__617597__:__RETINOL SATURASE; RETSAT__:____:__
Number Sign__:__617598__:__MOSAIC VARIEGATED ANEUPLOIDY SYNDROME 3; MVA3__:____:__
Number Sign__:__617599__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 55; EIEE55__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 14; GPIBD14__:__
Number Sign__:__617600__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 45; MRD45__:____:__
Number Sign__:__617601__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 46; MRD46__:____:__
Number Sign__:__617602__:__CONGENITAL HEART DEFECTS AND SKELETAL MALFORMATIONS SYNDROME; CHDSKM__:____:__
Asterisk__:__617603__:__RNA-BINDING MOTIF PROTEIN 24; RBM24__:__RNA-BINDING REGION-CONTAINING PROTEIN 6; RNPC6__:__
Number Sign__:__617604__:__MICROCEPHALY, SHORT STATURE, AND LIMB ABNORMALITIES; MISSLA__:____:__
Number Sign__:__617605__:__DEAFNESS, AUTOSOMAL DOMINANT 71; DFNA71__:____:__
Number Sign__:__617606__:__DEAFNESS, AUTOSOMAL DOMINANT 72; DFNA72__:____:__
Number Sign__:__617607__:__AMELOGENESIS IMPERFECTA, TYPE IIIB; AI3B__:____:__
Asterisk__:__617608__:__ALPHA KINASE 3; ALPK3__:__MYOCYTE INDUCTION/DIFFERENTIATION ORIGINATOR; MIDORI;; MUSCLE ALPHA KINASE; MAK;; KIAA1330__:__
Number Sign__:__617609__:__NEPHROTIC SYNDROME, TYPE 15; NPHS15__:____:__
Number Sign__:__617610__:__POLYCYSTIC KIDNEY DISEASE 5; PKD5__:____:__
Asterisk__:__617611__:__PICALM-INTERACTING MITOTIC REGULATOR; PIMREG__:__REGULATOR OF CHROMOSOME SEGREGATION 1; RCS1;; FAMILY WITH SEQUENCE SIMILARITY 64, MEMBER A; FAM64A__:__
Asterisk__:__617612__:__ARMADILLO REPEAT-CONTAINING PROTEIN 9; ARMC9__:__KIAA1868__:__
Number Sign__:__617613__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 5; MMDS5__:____:__
Asterisk__:__617614__:__SPOUT DOMAIN-CONTAINING METHYLTRANSFERASE 1; SPOUT1__:__CENTROMERE PROTEIN 32; CENP32;; CHROMOSOME 9 OPEN READING FRAME 114; C9ORF114__:__
Asterisk__:__617615__:__TRANSMEMBRANE PROTEIN 258; TMEM258__:__CHROMOSOME 11 OPEN READING FRAME 10; C11ORF10__:__
Number Sign__:__617616__:__SKRABAN-DEARDORFF SYNDROME; SKDEAS__:__INTELLECTUAL DISABILITY WITH SEIZURES, ABNORMAL GAIT, AND DISTINCTIVE FACIAL FEATURES__:__
Asterisk__:__617617__:__SPRY4 INTRONIC TRANSCRIPT 1, NONCODING; SPRY4IT1__:__LONG NONCODING RNA SPRY4IT1;; lncRNA SPRY4IT1;; SPRIGHTLY__:__
Asterisk__:__617618__:__TOG ARRAY REGULATOR OF AXONEMAL MICROTUBULES 1; TOGARAM1__:__FAMILY WITH SEQUENCE SIMILARITY 179, MEMBER B; FAM179B;; CRESCERIN 1;; KIAA0423__:__
Asterisk__:__617619__:__MISATO 1, MITOCHONDRIAL DISTRIBUTION AND MORPHOLOGY REGULATOR; MSTO1__:__MISATO, DROSOPHILA, HOMOLOG OF__:__
Asterisk__:__617620__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 3; LRRC3__:__CHROMOSOME 21 OPEN READING FRAME 102; C21ORF102;; CHROMOSOME 21 OPEN READING FRAME 30; C21ORF30__:__
Asterisk__:__617621__:__PAX3- AND PAX7-BINDING PROTEIN 1; PAXBP1__:__PAX3/7BP;; GC-RICH SEQUENCE DNA-BINDING FACTOR 1; GCFC1;; GCFC;; CHROMOSOME 21 OPEN READING FRAME 66; C21ORF66__:__
Number Sign__:__617622__:__JOUBERT SYNDROME 30; JBTS30__:____:__
Asterisk__:__617623__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER E1; SPDYE1__:__SPDYE;; SPEEDY B2-LIKE 2; SPDYB2L2;; RAPID INDUCER OF G2/M PROGRESSION IN OOCYTES 1; RINGO1;; WBSCR19__:__
Asterisk__:__617624__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER E2; SPDYE2__:__SPEEDY B2-LIKE 1; SPDYB2L1__:__
Asterisk__:__617625__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER E3; SPDYE3__:__SPEEDY B2; SPDYB2__:__
Number Sign__:__617626__:__FIBROMATOSIS, GINGIVAL, 5; GINGF5__:__GGF5;; FIBROMATOSIS, GINGIVAL, HEREDITARY, 5; HGF5__:__
Asterisk__:__617627__:__SMALL REGULATORY POLYPEPTIDE OF AMINO ACID RESPONSE; SPAAR__:__SPAR;; LONG INTERGENIC NONCODING RNA 961; LINC00961;; lincRNA 961__:__
Asterisk__:__617628__:__SPEEDY/RINGO CELL CYCLE REGULATOR FAMILY, MEMBER E4; SPDYE4__:__SPEEDY B1__:__
Number Sign__:__617629__:__SCHIZOPHRENIA 19; SCZD19__:__SCHIZOPHRENIA 19 WITH OR WITHOUT AN AFFECTIVE DISORDER__:__
Asterisk__:__617630__:__G PROTEIN-COUPLED RECEPTOR 37-LIKE 1; GPR37L1__:__ENDOTHELIN TYPE B RECEPTOR-LIKE PROTEIN 2; ETBRLP2__:__
Asterisk__:__617631__:__IQ DOMAIN-CONTAINING PROTEIN E; IQCE__:__KIAA1023__:__
Asterisk__:__617632__:__EF-HAND CALCIUM-BINDING DOMAIN-CONTAINING PROTEIN 7; EFCAB7__:__KIAA1799__:__
Number Sign__:__617633__:__SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 26; SCAR26__:____:__
Asterisk__:__617634__:__COILED-COIL GLUTAMATE-RICH PROTEIN 2; CCER2__:____:__
Number Sign__:__617635__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 47; MRD47__:____:__
Asterisk__:__617636__:__GPR1 ANTISENSE RNA; GPR1AS__:__G PROTEIN-COUPLED RECEPTOR 1, ANTISENSE RNA__:__
Number Sign__:__617637__:__DEAFNESS, AUTOSOMAL RECESSIVE 106; DFNB106__:____:__
Number Sign__:__617638__:__IMMUNODEFICIENCY 11B WITH ATOPIC DERMATITIS; IMD11B__:__ATOPIC DERMATITIS, ELEVATED IgE, AND EOSINOPHILIA__:__
Number Sign__:__617639__:__DEAFNESS, AUTOSOMAL RECESSIVE 107; DFNB107__:____:__
Asterisk__:__617640__:__SUPPRESSOR OF TUMORIGENICITY 7-LIKE PROTEIN; ST7L__:__ST7-RELATED PROTEIN; ST7R__:__
Number Sign__:__617641__:__CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT SYNDROME WITH OR WITHOUT HEARING LOSS, ABNORMAL EARS, OR DEVELOPMENTAL DELAY; CAKUTHED__:____:__
Number Sign__:__617642__:__POLYDACTYLY, POSTAXIAL, TYPE A7; PAPA7__:____:__
Number Sign__:__617643__:__CEREBELLAR ATROPHY, DEVELOPMENTAL DELAY, AND SEIZURES; CADEDS__:____:__
Number Sign__:__617644__:__SPERMATOGENIC FAILURE 21; SPGF21__:____:__
Asterisk__:__617645__:__KELCH REPEAT- AND BTB/POZ DOMAIN-CONTAINING PROTEIN 4; KBTBD4__:__HEMATOPOIETIC STEM/PROGENITOR CELL-EXPRESSED GENE 252; HSPC252;; BKLHD4__:__
Asterisk__:__617646__:__BAH DOMAIN- AND COILED-COIL DOMAIN-CONTAINING PROTEIN 1; BAHCC1__:__BROMO ADJACENT HOMOLOGY DOMAIN-CONTAINING PROTEIN 2; BAHD2;; KIAA1447__:__
Asterisk__:__617647__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 18, NONCODING; PCAT18__:__LONG INTERGENIC NONCODING RNA 1092; LINC01092;; lincRNA 1092__:__
Asterisk__:__617648__:__BMP2-INDUCIBLE KINASE; BMP2K__:__BIKE__:__
Asterisk__:__617649__:__UBIQUITIN-CONJUGATING ENZYME E2O; UBE2O__:__UBIQUITIN-CONJUGATING ENZYME E2, 230-KD; UBE2-230K;; KIAA1734__:__
Asterisk__:__617650__:__PTGS2 ANTISENSE NFKB1 COMPLEX-MEDIATED EXPRESSION REGULATOR RNA, NONCODING; PACERR__:__LONG NONCODING RNA PACERR;; lnRNA PACERR;; p50-ASSOCIATED COX2 EXTRAGENIC RNA; PACER;; PTGS2 ANTISENSE RNA 1; PTGS2AS1__:__
Asterisk__:__617651__:__EQTN, MOB3B, IFNK, AND C9ORF72 ENHANCER RNA I, NONCODING__:__EMICERI; EMICER1;; LONG NONCODING RNA EMICERI;; lncRNA EMICERI__:__
Asterisk__:__617652__:__MOB KINASE ACTIVATOR 3B; MOB3B__:__MOB1 DOMAIN-CONTAINING PROTEIN; MOB1D;; MOB KINASE ACTIVATOR-LIKE 2B; MOBKL2B;; CHROMOSOME 9 OPEN READING FRAME 35; C9ORF35__:__
Asterisk__:__617653__:__EQUATORIN; EQTN__:__ACROSOME FORMATION-ASSOCIATED FACTOR; AFAF;; SPERM ACROSOME-ASSOCIATED PROTEIN 8; SPACA8;; CHROMOSOME 9 OPEN READING FRAME 11; C9ORF11__:__
Number Sign__:__617654__:__DEAFNESS, AUTOSOMAL RECESSIVE 108; DFNB108__:____:__
Asterisk__:__617655__:__PECANEX,  DROSOPHILA, HOMOLOG OF, 1; PCNX1__:__KIAA0805;; KIAA0995__:__
Asterisk__:__617656__:__PECANEX, DROSOPHILA, HOMOLOG OF, 2; PCNX2__:__KIAA0435__:__
Asterisk__:__617657__:__PECANEX, DROSOPHILA, HOMOLOG OF, 3; PCNX3__:____:__
Asterisk__:__617658__:__SULFIDE QUINONE OXIDOREDUCTASE; SQOR__:__SULFIDE DEHYDROGENASE-LIKE; SQRDL;; SQR__:__
Asterisk__:__617659__:__LIPOYL(OCTANOYL) TRANSFERASE 2; LIPT2__:____:__
Number Sign__:__617660__:__VERTEBRAL, CARDIAC, RENAL, AND LIMB DEFECTS SYNDROME 1; VCRL1__:__CONGENITAL NAD DEFICIENCY DISORDER 1;; 3-HYDROXYANTHRANILIC ACIDEMIA__:__
Number Sign__:__617661__:__VERTEBRAL, CARDIAC, RENAL, AND LIMB DEFECTS SYNDROME 2; VCRL2__:__CONGENITAL NAD DEFICIENCY DISORDER 2;; KYNURENINASE DEFICIENCY, COMPLETE__:__
Number Sign__:__617662__:__JOINT LAXITY, SHORT STATURE, AND MYOPIA; JLSM__:____:__
Number Sign__:__617663__:__DEAFNESS, AUTOSOMAL DOMINANT 73; DFNA73__:____:__
Number Sign__:__617664__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 32; COXPD32__:____:__
Number Sign__:__617665__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 56; EIEE56__:____:__
Number Sign__:__617666__:__FRASER SYNDROME 2; FRASRS2__:____:__
Number Sign__:__617667__:__FRASER SYNDROME 3; FRASRS3__:____:__
Number Sign__:__617668__:__ENCEPHALOPATHY, NEONATAL SEVERE, WITH LACTIC ACIDOSIS AND BRAIN ABNORMALITIES; NELABA__:__LIPOYLTRANSFERASE 2 DEFICIENCY; LIPT2D__:__
Number Sign__:__617669__:__ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN ATROPHY AND SPASTICITY; PEBAS__:____:__
Asterisk__:__617670__:__MEIOSIS-SPECIFIC PROTEIN WITH OB DOMAINS; MEIOB__:____:__
Number Sign__:__617671__:__HELIX SYNDROME; HELIX__:__HYPOHIDROSIS, ELECTROLYTE IMBALANCE, LACRIMAL GLAND DYSFUNCTION, ICHTHYOSIS, AND XEROSTOMIA__:__
Number Sign__:__617672__:__NEURODEGENERATION, CHILDHOOD-ONSET, WITH BRAIN ATROPHY; CONDBA__:____:__
Asterisk__:__617673__:__SPERMATOGENESIS-ASSOCIATED PROTEIN 22; SPATA22__:____:__
Asterisk__:__617674__:__STRESS-ASSOCIATED ENDOPLASMIC RETICULUM PROTEIN 1; SERP1__:__RIBOSOME-ASSOCIATED MEMBRANE PROTEIN 4; RAMP4__:__
Number Sign__:__617675__:__MYOPATHY, MITOCHONDRIAL, AND ATAXIA; MMYAT__:____:__
Asterisk__:__617676__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 3; PSMD3__:__PROTEASE 26S, SUBUNIT 3; S3;; p58;; RPN3__:__
Asterisk__:__617677__:__ZO2-ASSOCIATED SPECKLE PROTEIN__:__ZASP__:__
Asterisk__:__617678__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 2, NONCODING; PCAT2__:__PCA2;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 4; CARLO4;; lncRNA CARLO4__:__
Asterisk__:__617679__:__KELCH-LIKE 20; KLHL20__:__KELCH-LIKE ECT2-INTERACTING PROTEIN; KLEIP;; KELCH-LIKE PROTEIN X; KLHLX__:__
Asterisk__:__617680__:__SSU72, S. CEREVISIAE, HOMOLOG OF; SSU72__:__RNA POLYMERASE II CTD PHOSPHATASE SSU72__:__
Number Sign__:__617681__:__BLEPHAROCHEILODONTIC SYNDROME 2; BCDS2__:____:__
Number Sign__:__617682__:__PILAROWSKI-BJORNSSON SYNDROME; PILBOS__:__DEVELOPMENTAL DELAY AND SPEECH APRAXIA WITH OR WITHOUT SEIZURES__:__
Asterisk__:__617683__:__EGF-LIKE, FIBRONECTIN TYPE III, AND LAMININ G DOMAINS-CONTAINING PROTEIN; EGFLAM__:__PIKACHURIN; PIKA;; AGRIN-LIKE PROTEIN; AGRNL; AGRINL__:__
Asterisk__:__617684__:__Ly1 ANTIBODY-REACTIVE PROTEIN, MOUSE, HOMOLOG OF; LYAR__:____:__
Asterisk__:__617685__:__CADHERIN 26; CDH26__:____:__
Number Sign__:__617686__:__PITUITARY ADENOMA 3, MULTIPLE TYPES; PITA3__:____:__
Asterisk__:__617687__:__TBC1 DOMAIN FAMILY, MEMBER 23; TBC1D23__:____:__
Asterisk__:__617688__:__PROSTATE ANDROGEN-REGULATED MUCIN-LIKE PROTEIN 1; PARM1__:__PROSTATIC ANDROGEN-REPRESSED MESSAGE 1;; CASTRATION-INDUCED PROSTATIC APOPTOSIS-RELATED PROTEIN 1; CIPAR1__:__
Asterisk__:__617689__:__COLD-SHOCK DOMAIN-CONTAINING PROTEIN C2; CSDC2__:__PIPPIN__:__
Number Sign__:__617690__:__OVARIAN DYSGENESIS 5; ODG5__:____:__
Number Sign__:__617691__:__SPINOCEREBELLAR ATAXIA 44; SCA44__:____:__
Asterisk__:__617692__:__PR DOMAIN-CONTAINING PROTEIN 15; PRDM15__:__PR/SET DOMAIN PROTEIN 15;; ZINC FINGER PROTEIN 298; ZNF298__:__
Asterisk__:__617693__:__VITRIN; VIT__:__VIT1__:__
Number Sign__:__617694__:__AL KAISSI SYNDROME; ALKAS__:__GROWTH RETARDATION, SPINE MALFORMATION, DYSMORPHIC FACIES, AND DEVELOPMENTAL DELAY__:__
Number Sign__:__617695__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 11; PCH11__:____:__
Asterisk__:__617696__:__LONG INTERGENIC NONCODING RNA 1488; LINC01488__:__lincRNA 1488;; CCND1 UPSTREAM INTERGENIC DNA REPAIR 1, NONCODING; CUPID1;; BREAST CANCER-ASSOCIATED TRANSCRIPT 8; BRCAT8__:__
Asterisk__:__617697__:__CCND1 UPSTREAM INTERGENIC DNA REPAIR 2, NONCODING__:__LONG INTERGENIC NONCODING RNA CUPID2; CUPID2;; lincRNA CUPID2__:__
Number Sign__:__617698__:__3-METHYLGLUTACONIC ACIDURIA, TYPE IX; MGCA9__:____:__
Asterisk__:__617699__:__GID COMPLEX, SUBUNIT 4; GID4__:__GLUCOSE-INDUCED DEGRADATION-DEFICIENT PROTEIN 4, S. CEREVISIAE, HOMOLOG OF;; VACUOLAR IMPORT AND DEGRADATION PROTEIN 24; VID24;; CHROMOSOME 17 OPEN READING FRAME 39; C17ORF39__:__
Asterisk__:__617700__:__UBIQUITIN-CONJUGATING ENZYME E2F; UBE2F__:__NEDD8-CONJUGATING ENZYME 2; NCE2__:__
Asterisk__:__617701__:__CANCER SUSCEPTIBILITY CANDIDATE 8, NONCODING; CASC8__:__LONG INTERGENIC NONCODING RNA 860; LINC00860;; lincRNA 860;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 1; CARLO1__:__
Asterisk__:__617702__:__CANCER SUSCEPTIBILITY CANDIDATE 21, NONCODING; CASC21__:__LONG INTERGENIC NONCODING RNA 1244; LINC01244;; lincRNA 1244;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 2; CARLO2__:__
Asterisk__:__617703__:__CANCER SUSCEPTIBILITY CANDIDATE 19, NONCODING; CASC19__:__LONG INTERGENIC NONCODING RNA 1245; LINC01245;; lincRNA 1245;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 6; CARLO6__:__
Asterisk__:__617704__:__CANCER SUSCEPTIBILITY CANDIDATE 11, NONCODING; CASC11__:__LONG INTERGENIC NONCODING RNA 990; LINC00990;; lincRNA 990;; CANCER-ASSOCIATED REGION LONG NONCODING RNA 7; CARLO7__:__
Asterisk__:__617705__:__COLON CANCER-ASSOCIATED TRANSCRIPT 1, NONCODING; CCAT1__:__CANCER-ASSOCIATED REGION LONG NONCODING RNA 5; CARLO5;; lncRNA CARLO5__:__
Number Sign__:__617706__:__SPERMATOGENIC FAILURE 22; SPGF22__:____:__
Number Sign__:__617707__:__SPERMATOGENIC FAILURE 23; SPGF23__:____:__
Asterisk__:__617708__:__CELL DIVISION CYCLE 123; CDC123__:__D123__:__
Number Sign__:__617709__:__NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, ATAXIA, AND SEIZURES; NEDMAS__:____:__
Number Sign__:__617710__:__NEURODEVELOPMENTAL DISORDER, MITOCHONDRIAL, WITH ABNORMAL MOVEMENTS AND LACTIC ACIDOSIS, WITH OR WITHOUT SEIZURES; NEMMLAS__:____:__
Number Sign__:__617711__:__EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 1; IECEE1__:____:__
Number Sign__:__617712__:__OOCYTE MATURATION DEFECT 3; OOMD3__:____:__
Number Sign__:__617713__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 33; COXPD33__:____:__
Asterisk__:__617714__:__CAVEOLAE-ASSOCIATED PROTEIN 4; CAVIN4__:__MUSCLE-RESTRICTED COILED-COIL PROTEIN; MURC__:__
Asterisk__:__617715__:__MAM AND LDL RECEPTOR CLASS A DOMAIN-CONTAINING PROTEIN 1; MALRD1__:__CHROMOSOME 10 OPEN READING FRAME 112; C10ORF112;; DIET1__:__
Asterisk__:__617716__:__RHO GTPase-ACTIVATING PROTEIN 44; ARHGAP44__:__RHOGAP INTERACTING WITH CIP4 HOMOLOGS 2; RICH2;; RHO-TYPE GTPase-ACTIVATING PROTEIN 2;; KIAA0672__:__
Number Sign__:__617717__:__AUDITORY NEUROPATHY AND OPTIC ATROPHY; ANOA__:____:__
Number Sign__:__617718__:__PLATELET ABNORMALITIES WITH EOSINOPHILIA AND IMMUNE-MEDIATED INFLAMMATORY DISEASE; PLTEID__:____:__
Number Sign__:__617719__:__EPIPHYSEAL DYSPLASIA, MULTIPLE, 7; EDM7__:____:__
Asterisk__:__617720__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 42; PPP1R42__:__TESTIS LEUCINE-RICH REPEAT PROTEIN; TLRR;; LEUCINE-RICH REPEAT-CONTAINING PROTEIN 67; LRRC67__:__
Number Sign__:__617721__:__NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX; HMN9__:__NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IX; DHMN9__:__
Asterisk__:__617722__:__THIOREDOXIN-LIKE 4B; TXNL4B__:__DIM1-LIKE PROTEIN; DLP;; DIM2__:__
Asterisk__:__617723__:__RIBOSOMAL RNA-PROCESSING PROTEIN 12, S. CEREVISIAE, HOMOLOG OF; RRP12__:__KIAA0690__:__
Asterisk__:__617724__:__TSC22 DOMAIN FAMILY, MEMBER 2; TSC22D2__:__KIAA0669__:__
Asterisk__:__617725__:__FUCOSE MUTAROTASE; FUOM__:__FUCM;; FucU, E. COLI, HOMOLOG OF; FUCU__:__
Asterisk__:__617726__:__CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 19; CARD19__:__BCL10-INTERACTING CARD PROTEIN; BINCARD;; CHROMOSOME 9 OPEN READING FRAME 89; C9ORF89__:__
Asterisk__:__617727__:__TRANSMEMBRANE 9 SUPERFAMILY, MEMBER 4; TM9SF4__:__KIAA0255;; PHG1A, DICTYOSTELIUM, HOMOLOG OF__:__
Asterisk__:__617728__:__CENTROSOMAL PROTEIN, 295-KD; CEP295__:__KIAA1731__:__
Number Sign__:__617729__:__GALLOWAY-MOWAT SYNDROME 3; GAMOS3__:____:__
Number Sign__:__617730__:__GALLOWAY-MOWAT SYNDROME 4; GAMOS4__:____:__
Number Sign__:__617731__:__GALLOWAY-MOWAT SYNDROME 5; GAMOS5__:____:__
Number Sign__:__617732__:__FACIAL PALSY, CONGENITAL, WITH PTOSIS AND VELOPHARYNGEAL DYSFUNCTION; FPVEPD__:____:__
Asterisk__:__617733__:__ZINC FINGER PROTEIN 518A; ZNF518A__:__KIAA0335__:__
Asterisk__:__617734__:__ZINC FINGER PROTEIN 518B; ZNF518B__:__KIAA1729__:__
Asterisk__:__617735__:__CHROMOSOME 10 OPEN READING FRAME 90; C10ORF90__:__FRAGILE SITE-ASSOCIATED TUMOR SUPPRESSOR; FATS__:__
Asterisk__:__617736__:__MORN REPEAT-CONTAINING PROTEIN 4; MORN4__:__MEMBRANE OCCUPATION AND RECOGNITION NEXUS PROTEIN 4;; RETINOPHILIN, DROSOPHILA, HOMOLOG OF; RTP;; UNDERTAKER, DROSOPHILA, HOMOLOG OF; UTA__:__
Asterisk__:__617737__:__SPHINGOMYELIN PHOSPHODIESTERASE, ACID-LIKE, 3B; SMPDL3B__:__ACID SPHINGOMYELINASE-LIKE PHOSPHODIESTERASE 3B; ASML3B;; ASMLPD__:__
Asterisk__:__617738__:__KELCH REPEAT- AND BTB DOMAIN-CONTAINING PROTEIN 6; KBTBD6__:____:__
Asterisk__:__617739__:__KELCH REPEAT- AND BTB DOMAIN-CONTAINING PROTEIN 7; KBTBD7__:____:__
Asterisk__:__617740__:__V-SET AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 10-LIKE; VSIG10L__:__VSIG10-LIKE PROTEIN__:__
Asterisk__:__617741__:__WD REPEAT-CONTAINING PROTEIN 20; WDR20__:____:__
Asterisk__:__617742__:__KAT8 REGULATORY NSL COMPLEX, SUBUNIT 3; KANSL3__:__NONSPECIFIC LETHAL 3 HOMOLOG; NSL3;; KIAA1310__:__
Number Sign__:__617743__:__OOCYTE MATURATION DEFECT 4; OOMD4__:____:__
Number Sign__:__617744__:__IMMUNODEFICIENCY, DEVELOPMENTAL DELAY, AND HYPOHOMOCYSTEINEMIA; IMDDHH__:____:__
Asterisk__:__617745__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 12; MFSD12__:__PP3501__:__
Number Sign__:__617746__:__SWEENEY-COX SYNDROME; SWCOS__:____:__
Asterisk__:__617747__:__NUCLEAR BODY PROTEIN SP140-LIKE; SP140L__:____:__
Asterisk__:__617748__:__TUDOR DOMAIN-CONTAINING PROTEIN 5; TDRD5__:__TUDOR3__:__
Number Sign__:__617749__:__ACTN3 DEFICIENCY__:__ALPHA-ACTININ-3 DEFICIENCY__:__SPRINTING PERFORMANCE, INCLUDED
Asterisk__:__617750__:__LIM AND CALPONIN HOMOLOGY DOMAINS-CONTAINING PROTEIN 1; LIMCH1__:__LIMCH1A;; LMO7B__:__
Number Sign__:__617751__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 48; MRD48__:____:__
Number Sign__:__617752__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 49; MRD49__:____:__
Asterisk__:__617753__:__RIO KINASE 1; RIOK1__:__RIO1__:__
Asterisk__:__617754__:__RIO KINASE 2; RIOK2__:__RIO2__:__
Number Sign__:__617755__:__NEURODEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND DISTAL LIMB ANOMALIES; NEDDFL__:____:__
Number Sign__:__617756__:__ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 5; EKVP5__:____:__
Number Sign__:__617757__:__JOUBERT SYNDROME 32; JBTS32__:____:__
Asterisk__:__617758__:__ZINC FINGER PROTEIN 692; ZNF692__:__ZFP692;; AICAR-RESPONSIVE ELEMENT-BINDING PROTEIN; AREBP__:__
Asterisk__:__617759__:__RNA PSEUDOURIDYLATE SYNTHASE DOMAIN-CONTAINING PROTEIN 3; RPUSD3__:____:__
Number Sign__:__617760__:__MYOPATHY, CENTRONUCLEAR, 6, WITH FIBER-TYPE DISPROPORTION; CNM6__:____:__
Number Sign__:__617761__:__JOUBERT SYNDROME 31; JBTS31__:____:__
Number Sign__:__617762__:__LEUKODYSTROPHY, PROGRESSIVE, EARLY CHILDHOOD-ONSET; PLDECO__:____:__
Number Sign__:__617763__:__SHORT STATURE, HEARING LOSS, RETINITIS PIGMENTOSA, AND DISTINCTIVE FACIES; SHRF__:____:__
Asterisk__:__617764__:__ZYG11-RELATED CELL CYCLE REGULATOR; ZER1__:__ZER1, C. ELEGANS, HOMOLOG OF;; ZYG11B-LIKE PROTEIN; ZYG11BL;; ZYG;; CHROMOSOME 9 OPEN READING FRAME 60; C9ORF60__:__
Number Sign__:__617765__:__IMMUNODEFICIENCY, COMMON VARIABLE, 14; CVID14__:____:__
Asterisk__:__617766__:__FAMILY WITH SEQUENCE SIMILARITY 192, MEMBER A; FAM192A__:__NEFA-INTERACTING NUCLEAR PROTEIN 30; NIP30;; CHROMOSOME 16 OPEN READING FRAME 94; C16ORF94__:__
Number Sign__:__617767__:__JOUBERT SYNDROME 33; JBTS33__:____:__
Number Sign__:__617768__:__KLEEFSTRA SYNDROME 2; KLEFS2__:____:__
Number Sign__:__617769__:__SPINOCEREBELLAR ATAXIA 45; SCA45__:____:__
Number Sign__:__617770__:__SPINOCEREBELLAR ATAXIA 46; SCA46__:__SPINOCEREBELLAR ATAXIA, 46, AUTOSOMAL DOMINANT, WITH SENSORY AXONAL NEUROPATHY__:__
Number Sign__:__617771__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 57; EIEE57__:____:__
Number Sign__:__617772__:__DEAFNESS, AUTOSOMAL DOMINANT 34, WITH OR WITHOUT INFLAMMATION; DFNA34__:____:__
Number Sign__:__617773__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 61; MRT61__:__ALWADEI SYNDROME__:__
Asterisk__:__617774__:__LON PEPTIDASE 2, PEROXISOMAL; LONP2__:__PEROXISOMAL LON PROTEASE; PLON;; LON PROTEASE 2;; PSLON__:__
Asterisk__:__617775__:__CHROMOSOME 10 OPEN READING FRAME 99; C10ORF99__:__COLON-DERIVED SUSD2-BINDING FACTOR; CSBF;; ANTIMICROBIAL PEPTIDE OF 57 AMINO ACIDS; AP57__:__
Asterisk__:__617776__:__BAGE FAMILY, MEMBER 2; BAGE2__:__B MELANOMA ANTIGEN 2__:__
Asterisk__:__617777__:__BAGE FAMILY, MEMBER 3; BAGE3__:__B MELANOMA ANTIGEN 3__:__
Asterisk__:__617778__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 15; TXNDC15__:__CHROMOSOME 5 OPEN READING FAME 14; C5ORF14;; BUNKER GEAR, DROSOPHILA, HOMOLOG OF; BUG__:__
Asterisk__:__617779__:__TRANSMEMBRANE PROTEIN 256; TMEM256__:__CHROMOSOME 17 OPEN READING FRAME 61; C17ORF61__:__
Number Sign__:__617780__:__COMBINED IMMUNODEFICIENCY AND MEGALOBLASTIC ANEMIA WITH OR WITHOUT HYPERHOMOCYSTEINEMIA; CIMAH__:__METHYLENETETRAHYDROFOLATE DEHYDROGENASE 1 DEFICIENCY__:__
Number Sign__:__617781__:__RETINITIS PIGMENTOSA 80; RP80__:____:__
Asterisk__:__617782__:__GREB1-LIKE PROTEIN; GREB1L__:__CHROMOSOME 18 OPEN READING FRAME 6; C18ORF6;; KIAA1772__:__
Number Sign__:__617783__:__NEPHROTIC SYNDROME, TYPE 16; NPHS16__:____:__
Number Sign__:__617784__:__FANCONI ANEMIA, COMPLEMENTATION GROUP W; FANCW__:____:__
Asterisk__:__617785__:__PAPILIN, PROTEOGLYCAN-LIKE SULFATED GLYCOPROTEIN; PAPLN__:__PAPILIN, DROSOPHILA, HOMOLOG OF; PPN__:__
Asterisk__:__617786__:__CHAPERONIN CONTAINING T-COMPLEX POLYPEPTIDE 1, SUBUNIT 8; CCT8__:__CHAPERONIN CONTAINING TCP1, SUBUNIT 8;; CCT-THETA; CCTQ;; KIAA0002__:__
Number Sign__:__617787__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 50; MRD50__:____:__
Number Sign__:__617788__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 51; MRD51__:____:__
Asterisk__:__617789__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 8; TXNDC8__:__SPERM-SPECIFIC THIOREDOXIN 3; SPTRX3__:__
Asterisk__:__617790__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 2; TXNDC2__:__SPERM-SPECIFIC THIOREDOXIN 1; SPTRX; SPTRX1__:__
Asterisk__:__617791__:__LEUCINE-RICH REPEAT- AND COILED-COIL DOMAIN-CONTAINING CENTROSOMAL PROTEIN 1; LRRCC1__:__CENTROSOMAL LEUCINE-RICH REPEAT- AND COILED-COIL DOMAIN-CONTAINING PROTEIN; CLERK;; KIAA1764__:__
Asterisk__:__617792__:__THIOREDOXIN DOMAIN-CONTAINING PROTEIN 11; TXNDC11__:__EF-HAND-BINDING PROTEIN 1; EFP1__:__
Asterisk__:__617793__:__EEF1A LYSINE METHYLTRANSFERASE 1; EEF1AKMT1__:__N6 ADENINE-SPECIFIC DNA METHYLTRANSFERASE 2; N6AMT2__:__
Asterisk__:__617794__:__EEF1A LYSINE METHYLTRANSFERASE 2; EEF1AKMT2__:__METHYLTRANSFERASE-LIKE 10; METTL10__:__
Asterisk__:__617795__:__ELONGIN BC- AND POLYCOMB REPRESSIVE COMPLEX 2-ASSOCIATED PROTEIN; EPOP__:__CHROMOSOME 17 OPEN READING FRAME 96; C17ORF96__:__
Number Sign__:__617796__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 52; MRD52__:____:__
Asterisk__:__617797__:__SRC-RELATED KINASE LACKING C-TERMINAL REGULATORY TYROSINE AND N-TERMINAL MYRISTYLATION SITES; SRMS__:__SRM;; CHROMOSOME 20 OPEN READING FRAME 148; C20ORF148__:__
Number Sign__:__617798__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 53; MRD53__:____:__
Number Sign__:__617799__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 54; MRD54__:____:__
Number Sign__:__617800__:__MICROCEPHALY 19, PRIMARY, AUTOSOMAL RECESSIVE; MCPH19__:____:__
Asterisk__:__617801__:__CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1; CAP1__:__ADENYLYL CYCLASE-ASSOCIATED PROTEIN 1;; CAP__:__
Number Sign__:__617802__:__NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, SEIZURES, AND CORTICAL ATROPHY; NDMSCA__:____:__
Asterisk__:__617803__:__TRANSMEMBRANE PROTEIN 26; TMEM26__:____:__
Number Sign__:__617804__:__NEURODEVELOPMENTAL DISORDER WITH SEVERE MOTOR IMPAIRMENT AND ABSENT LANGUAGE; NEDMIAL__:____:__
Number Sign__:__617805__:__RENAL HYPODYSPLASIA/APLASIA 3; RHDA3__:____:__
Asterisk__:__617806__:__TRANSMEMBRANE PROTEIN 86B; TMEM86B__:__LYSOPLASMALOGENASE__:__
Number Sign__:__617807__:__NEURODEVELOPMENTAL DISORDER WITH ATAXIC GAIT, ABSENT SPEECH, AND DECREASED CORTICAL WHITE MATTER; NDAGSCW__:____:__
Number Sign__:__617808__:__COFFIN-SIRIS SYNDROME 6; CSS6__:____:__
Number Sign__:__617809__:__GELEOPHYSIC DYSPLASIA 3; GPHYSD3__:____:__
Number Sign__:__617810__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 15; GPIBD15__:__DEVELOPMENTAL DELAY, EPILEPSY, CEREBELLAR ATROPHY, AND OSTEOPENIA__:__
Asterisk__:__617811__:__DNA REPLICATION REGULATOR AND SPLICEOSOMAL FACTOR SMU1; SMU1__:__BRAIN-ENRICHED WD-REPEAT PROTEIN; BWD__:__
Asterisk__:__617812__:__SOLUTE CARRIER FAMILY 35, MEMBER G2; SLC35G2__:__TRANSMEMBRANE PROTEIN 22; TMEM22__:__
Asterisk__:__617813__:__TRANSMEMBRANE PROTEIN 88; TMEM88__:____:__
Asterisk__:__617814__:__TRANSMEMBRANE PROTEIN 95; TMEM95__:____:__
Asterisk__:__617815__:__POLYMERASE III, RNA, SUBUNIT E; POLR3E__:__SXL INTERACTOR; SIN;; KIAA1452__:__
Number Sign__:__617816__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 16; GPIBD16__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 62; MRT62__:__
Asterisk__:__617817__:__TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 2; TUBGCP2__:__GAMMA-TUBULIN COMPLEX PROTEIN 2; GCP2;; GAMMA RING COMPLEX PROTEIN, 103-KD; GRIP103;; SPC97, S. POMBE, HOMOLOG OF; SPC97;; ALP4, S. CEREVISIAE, HOMOLOG OF; ALP4__:__
Asterisk__:__617818__:__TUBULIN-GAMMA COMPLEX-ASSOCIATED PROTEIN 3; TUBGCP3__:__GAMMA-TUBULIN COMPLEX PROTEIN 3; GCP3;; GAMMA RING COMPLEX PROTEIN, 104-KD; GRIP104;; SPC98, S. POMBE, HOMOLOG OF; SPC98;; ALP6, S. CEREVISIAE, HOMOLOG OF; ALP6__:__
Asterisk__:__617819__:__RAL GUANINE NUCLEOTIDE EXCHANGE FACTOR WITH PH DOMAIN AND SH3 DOMAIN-BINDING MOTIF 2; RALGPS2__:__RAL GEF WITH PH DOMAIN AND SH3-BINDING MOTIF 2;; FLJ10244__:__
Number Sign__:__617820__:__NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT HYPERKINETIC MOVEMENTS AND SEIZURES, AUTOSOMAL RECESSIVE; NDHMSR__:____:__
Number Sign__:__617821__:__EHLERS-DANLOS SYNDROME, ARTHROCHALASIA TYPE, 2; EDSARTH2__:__EHLERS-DANLOS SYNDROME, TYPE VIIB, AUTOSOMAL DOMINANT; EDS7B;; EDS VIIB__:__
Number Sign__:__617822__:__ALKURAYA-KUCINSKAS SYNDROME; ALKKUCS__:____:__
Asterisk__:__617823__:__PWWP DOMAIN-CONTAINING PROTEIN 2A; PWWP2A__:____:__
Asterisk__:__617824__:__BROMODOMAIN AND WD REPEAT DOMAIN-CONTAINING PROTEIN 1; BRWD1__:__WD REPEAT-CONTAINING PROTEIN 9; WRD9;; CHROMOSOME 21 OPEN READING FRAME 107; C21ORF107__:__
Number Sign__:__617825__:__GLUCOCORTICOID DEFICIENCY 5; GCCD5__:____:__
Asterisk__:__617826__:__UNC50, INNER NUCLEAR MEMBRANE RNA-BINDING PROTEIN; UNC50__:__UNC50, C. ELEGANS, HOMOLOG OF;; UNCL;; GEA1-6 MEMBRANE-ASSOCIATED HIGH-COPY SUPPRESSOR 1, S. CEREVISIAE, HOMOLOG OF; GMH1__:__
Number Sign__:__617827__:__IMMUNODEFICIENCY 55; IMD55__:____:__
Asterisk__:__617828__:__ZINC FINGER HOMEOBOX 2; ZFHX2__:__ZFH2;; ZINC FINGER HOMEOBOX 5; ZFH5;; ZINC FINGER PROTEIN 409; ZNF409;; KIAA1056;; KIAA1762__:__
Number Sign__:__617829__:__EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 2; IECEE2__:____:__
Number Sign__:__617830__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 58; EIEE58__:____:__
Number Sign__:__617831__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 55, WITH SEIZURES; MRD55__:____:__
Asterisk__:__617832__:__SENTAN, CILIA APICAL STRUCTURAL PROTEIN; SNTN__:__S100A-LIKE PROTEIN; S100AL;; S100A1L__:__
Asterisk__:__617833__:__ZFHX2 ANTISENSE RNA 1, NONCODING; ZFHX2AS1__:__ZFH5 ANTISENSE RNA__:__
Asterisk__:__617834__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY J, MEMBER 1; PLEKHJ1__:__GUANINE NUCLEOTIDE-RELEASING PROTEIN X; GNRPX__:__
Asterisk__:__617835__:__PYRUVATE DEHYDROGENASE PHOSPHATASE REGULATORY SUBUNIT; PDPR__:__KIAA1990__:__
Number Sign__:__617836__:__DEVELOPMENTAL DELAY AND SEIZURES WITH OR WITHOUT MOVEMENT ABNORMALITIES; DEDSM__:____:__
Asterisk__:__617837__:__GDNF FAMILY RECEPTOR ALPHA-LIKE PROTEIN; GFRAL__:__GRAL__:__
Asterisk__:__617838__:__FAMILY WITH SEQUENCE SIMILARITY 234, MEMBER B; FAM234B__:__KIAA1467__:__
Number Sign__:__617839__:__AMYOTROPHIC LATERAL SCLEROSIS 23; ALS23__:____:__
Asterisk__:__617840__:__tRNA ISOPENTENYLTRANSFERASE 1; TRIT1__:__ISOPENTENYLTRANSFERASE; IPT__:__
Asterisk__:__617841__:__PROTEASOME SUBUNIT, ALPHA-TYPE, 8; PSMA8__:__PSMA7-LIKE; PSMA7L__:__
Asterisk__:__617842__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 1; PSMD1__:__p112__:__
Asterisk__:__617843__:__RWD DOMAIN-CONTAINING PROTEIN 2B; RWDD2B__:__CHROMOSOME 21 OPEN READING FRAME 6; C21ORF6__:__
Asterisk__:__617844__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 8; PSMD8__:__p31__:__
Asterisk__:__617845__:__MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 2B; MFSD2B__:____:__
Asterisk__:__617846__:__PHD FINGER PROTEIN 5A; PHF5A__:__SPLICING FACTOR 3B, SUBUNIT 7; SF3B7;; SF3B, 14-KD SUBUNIT, B; SF3B14B__:__
Asterisk__:__617847__:__SPLICING FACTOR 3B, SUBUNIT 5; SF3B5__:__SF3B, 10-KD SUBUNIT; SF3B10__:__
Asterisk__:__617848__:__DEAD BOX HELICASE 46; DDX46__:__DEAD BOX PROTEIN 46;; PRP5, S. CEREVISIAE, HOMOLOG OF; PRP5;; KIAA0801__:__
Asterisk__:__617849__:__U2 SMALL NUCLEAR RIBONUCLEOPROTEIN-ASSOCIATED SURP DOMAIN-CONTAINING PROTEIN; U2SURP__:__U2 snRNP-ASSOCIATED SURP DOMAIN-CONTAINING PROTEIN;; SER/ARG-RICH DOMAIN PROTEIN, 140-KD; SR140;; KIAA0332__:__
Asterisk__:__617850__:__SERTA DOMAIN-CONTAINING PROTEIN 1; SERTAD1__:__TRANSCRIPTIONAL REGULATOR INTERACTING WITH PHD-BROMODOMAIN 1; TRIPBR1;; SEI1;; p34(SEI1)__:__
Asterisk__:__617851__:__SERTA DOMAIN-CONTAINING PROTEIN 2; SERTAD2__:__TRANSCRIPTIONAL REGULATOR INTERACTING WITH PHD-BROMODOMAIN 2; TRIPBR2;; KIAA0127__:__
Asterisk__:__617852__:__SEC23-INTERACTING PROTEIN; SEC23IP__:__p125__:__
Asterisk__:__617853__:__SMALL VASOHIBIN-BINDING PROTEIN; SVBP__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 23; CCDC23__:__
Number Sign__:__617854__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 56; MRD56__:____:__
Asterisk__:__617855__:__BASE METHYLTRANSFERASE OF 25S rRNA 2, S. CEREVISIAE, HOMOLOG OF; BMT2__:__S-ADENOSYLMETHIONINE SENSOR UPSTREAM OF MTORC1; SAMTOR;; CHROMOSOME 7 OPEN READING FRAME 60; C7ORF60__:__
Asterisk__:__617856__:__THYMOCYTE SELECTION-ASSOCIATED PROTEIN FAMILY, MEMBER 2; THEMIS2__:__CHROMOSOME 1 OPEN READING FRAME 38; C1ORF38;; INDUCED BY CONTACT WITH BASEMENT MEMBRANE 1; ICB1__:__
Asterisk__:__617857__:__PROTEASOME 26S SUBUNIT, NON-ATPase, 6; PSMD6__:__PROTEASOME 26S, SUBUNIT 10, 44-KD;; p44S10;; KIAA0107__:__
Asterisk__:__617858__:__PROTEASOME INHIBITOR SUBUNIT 1; PSMF1__:__PROTEASOME INHIBITOR, 31-KD; PI31__:__
Asterisk__:__617859__:__DISCS LARGE-ASSOCIATED PROTEIN 5; DLGAP5__:__DISCS LARGE, DROSOPHILA, HOMOLOG OF, 7; DLG7;; HEPATOMA-UPREGULATED PROTEIN; HURP;; KIAA0008__:__
Asterisk__:__617860__:__SURFACTANT-ASSOCIATED PROTEIN 3; SFTA3__:__SURFACTANT PROTEIN H; SPH__:__
Asterisk__:__617861__:__MYB-RELATED TRANSCRIPTION FACTOR, PARTNER OF PROFILIN; MYPOP__:__PARTNER OF PROFILIN, 42-KD;; p42(POP)__:__
Number Sign__:__617862__:__NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, EPILEPSY, AND BRAIN ATROPHY; NEDMEBA__:____:__
Number Sign__:__617864__:__NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT SEIZURES AND GAIT ABNORMALITIES; NEDSGA__:____:__
Number Sign__:__617865__:__NEURODEVELOPMENTAL DISORDER WITH MOVEMENT ABNORMALITIES, ABNORMAL GAIT, AND AUTISTIC FEATURES; NEDMAGA__:____:__
Number Sign__:__617866__:__SHORT-RIB THORACIC DYSPLASIA 18 WITH POLYDACTYLY; SRTD18__:____:__
Asterisk__:__617867__:__TUMOR PROTEIN p53-INDUCIBLE PROTEIN 11; TP53I11__:__p53-INDUCIBLE GENE 11; PIG11__:__
Asterisk__:__617868__:__NUCLEAR ASSEMBLY FACTOR 1 RIBONUCLEOPROTEIN; NAF1__:__NAF1, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__617869__:__NK1 HOMEOBOX 1; NKX1-1__:__SAX2__:__
Asterisk__:__617870__:__CENTROSOMAL PROTEIN 350; CEP350__:__CENTROSOME-ASSOCIATED PROTEIN, 350-KD; CAP350;; KIAA0480__:__
Number Sign__:__617871__:__RETINITIS PIGMENTOSA 81; RP81__:____:__
Number Sign__:__617872__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 34; COXPD34__:____:__
Number Sign__:__617873__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 35; COXPD35__:____:__
Number Sign__:__617874__:__POLYCYSTIC LIVER DISEASE 3 WITH OR WITHOUT KIDNEY CYSTS; PCLD3__:____:__
Number Sign__:__617875__:__POLYCYSTIC LIVER DISEASE 4 WITH OR WITHOUT KIDNEY CYSTS; PCLD4__:____:__
Asterisk__:__617876__:__RNA, U7 SMALL NUCLEAR, 1; RNU7-1__:__RNU7;; U7.1__:__
Number Sign__:__617877__:__SHORT STATURE, FACIAL DYSMORPHISM, AND SKELETAL ANOMALIES WITH OR WITHOUT CARDIAC ANOMALIES; SSFSC__:____:__
Asterisk__:__617878__:__TUBULIN, ALPHA-3D; TUBA3D__:__H2-ALPHA__:__
Number Sign__:__617879__:__LEBER CONGENITAL AMAUROSIS WITH EARLY-ONSET DEAFNESS; LCAEOD__:____:__
Asterisk__:__617880__:__POC5 CENTRIOLAR PROTEIN; POC5__:__PROTEOME OF CENTRIOLE 5, CHLAMYDOMONAS, HOMOLOG OF;; CHROMOSOME 5 OPEN READING FRAME 37; C5ORF37__:__
Asterisk__:__617881__:__CHROMOSOME 4 OPEN READING FRAME 54; C4ORF54__:__LOC285556;; FOPV GENE__:__
Number Sign__:__617882__:__CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE G; CMTDIG__:____:__
Number Sign__:__617883__:__FANCONI ANEMIA, COMPLEMENTATION GROUP S; FANCS__:____:__
Asterisk__:__617884__:__HEPATOMA-DERIVED GROWTH FACTOR-LIKE PROTEIN 2; HDGFL2__:__HDGF-LIKE PROTEIN 2;; HDGF-RELATED PROTEIN 2; HRP2; HDGFRP2__:__
Number Sign__:__617885__:__BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 19; BMIQ19__:__OBESITY, SUSCEPTIBILITY TO__:__
Asterisk__:__617886__:__ZINC FINGER PROTEIN 512B; ZNF512B__:__GAM;; KIAA1196__:__
Asterisk__:__617887__:__AGMATINASE; AGMAT__:__AGMATINE UREOHYDROLASE; AUH__:__
Asterisk__:__617888__:__ZINC FINGER PROTEIN 580; ZNF580__:____:__
Asterisk__:__617889__:__PYRIDINE NUCLEOTIDE-DISULPHIDE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 2; PYROXD2__:__CHROMOSOME 10 OPEN READING FRAME 33; C10ORF33;; YUEF__:__
Asterisk__:__617890__:__ZINC FINGER PROTEIN 664; ZNF664__:__ZINC FINGER, ORGAN OF CORTI, 1; ZFOC1__:__
Asterisk__:__617891__:__ZINC FINGER PROTEIN 655; ZNF655__:__VAV1-INTERACTING KRUPPEL-LIKE PROTEIN; VIK__:__
Number Sign__:__617892__:__AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 24; ALS24__:____:__
Asterisk__:__617893__:__RIBOSOMAL PROTEIN L36; RPL36__:____:__
Asterisk__:__617894__:__TRANSMEMBRANE PROTEIN 50B; TMEM50B__:__CHROMOSOME 21 OPEN READING FRAME 4; C21ORF4__:__
Number Sign__:__617895__:__SHORT-RIB THORACIC DYSPLASIA 19 WITH OR WITHOUT POLYDACTYLY; SRTD19__:____:__
Asterisk__:__617896__:__ZIC FAMILY, MEMBER 5; ZIC5__:__ZINC FINGER PROTEIN OF CEREBELLUM 5;; ODD PAIRED-RELATED PROTEIN; OPR;; OPA-RELATED PROTEIN__:__
Asterisk__:__617897__:__CITRATE SYNTHASE LYSINE METHYLTRANSFERASE; CSKMT__:__METHYLTRANSFERASE-LIKE 12; METTL12__:__
Number Sign__:__617898__:__MULTIPLE SYNOSTOSES SYNDROME 4; SYNS4__:____:__
Number Sign__:__617899__:__LEUKODYSTROPHY, HYPOMYELINATING, 14; HLD14__:____:__
Number Sign__:__617900__:__ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED (HERPES-SPECIFIC), SUSCEPTIBILITY TO, 8; IIAE8__:__HERPES SIMPLEX ENCEPHALITIS, SUSCEPTIBILITY TO, 6__:__
Asterisk__:__617901__:__DEXAMETHASONE-INDUCED GENE; DEXI__:__MYLE__:__
Asterisk__:__617902__:__GALECTIN-LIKE PROTEIN; LGALSL__:__GALECTIN-RELATED PROTEIN; GRP;; HSPC159__:__
Number Sign__:__617903__:__NEURODEVELOPMENTAL DISORDER WITH POOR LANGUAGE AND LOSS OF HAND SKILLS; NDPLHS__:____:__
Number Sign__:__617904__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 59; EIEE59__:____:__
Asterisk__:__617905__:__HYPOXIA-INDUCIBLE LIPID DROPLET-ASSOCIATED PROTEIN; HILPDA__:__HYPOXIA-INDUCIBLE PROTEIN 2; HIG2__:__
Asterisk__:__617906__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 20; CFAP20__:__BASAL BODY UPREGULATED GENE 22; BUG22;; CHROMOSOME 16 OPEN READING FRAME 80; C16ORF80;; FUNCTIONAL SPLICEOSOME-ASSOCIATED PROTEIN 23; FSAP23__:__
Number Sign__:__617907__:__ERYTHROCYTOSIS, FAMILIAL, 5; ECYT5__:____:__
Asterisk__:__617908__:__ZINC FINGER PROTEIN 473; ZNF473__:__ZINC FINGER PROTEIN, 100-KD; ZFP100;; KIAA1141__:__
Asterisk__:__617909__:__LSM10, U7 SMALL NUCLEAR RNA-ASSOCIATED PROTEIN; LSM10__:____:__
Asterisk__:__617910__:__LSM11, U7 SMALL NUCLEAR RNA-ASSOCIATED PROTEIN; LSM11__:____:__
Number Sign__:__617911__:__DIAMOND-BLACKFAN ANEMIA-LIKE; DBAL__:____:__
Number Sign__:__617912__:__CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 5; CHTD5__:____:__
Number Sign__:__617913__:__NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, CATARACTS, AND RENAL ABNORMALITIES; NEDMCR__:____:__
Number Sign__:__617914__:__MICROCEPHALY 20, PRIMARY, AUTOSOMAL RECESSIVE; MCPH20__:____:__
Number Sign__:__617915__:__HYPOTONIA, ATAXIA, DEVELOPMENTAL DELAY, AND TOOTH ENAMEL DEFECT SYNDROME; HADDTS__:____:__
Number Sign__:__617916__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 7; NBIA7__:____:__
Number Sign__:__617917__:__NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 8; NBIA8__:____:__
Asterisk__:__617918__:__STRIATIN-INTERACTING PROTEIN 1; STRIP1__:__FAR11, S. CEREVISIAE, HOMOLOG OF, A; FAR11A;; FAMILY WITH SEQUENCE SIMILARITY 40, MEMBER A; FAM40A__:__
Asterisk__:__617919__:__STRIATIN-INTERACTING PROTEIN 2; STRIP2__:__FAR11, S. CEREVISIAE, HOMOLOG OF, B; FAR11B;; FAMILY WITH SEQUENCE SIMILARITY 40, MEMBER B; FAM40B__:__
Number Sign__:__617920__:__AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3; PLCA3__:__AMYLOIDOSIS CUTIS DYSCHROMICA; ACD__:__
Number Sign__:__617921__:__AMYOTROPHIC LATERAL SCLEROSIS, SUSCEPTIBILITY TO, 25; ALS25__:____:__
Asterisk__:__617922__:__GLYCOPHORIN A; GYPA__:__GPA;; GLYCOPHORIN, ALPHA__:__
Asterisk__:__617923__:__GLYCOPHORIN B; GYPB__:__GPB;; GLYCOPHORIN, DELTA__:__
Number Sign__:__617924__:__EPILEPSY, JUVENILE MYOCLONIC, SUSCEPTIBILITY TO, 10; EJM10__:____:__
Number Sign__:__617925__:__SHORT-RIB THORACIC DYSPLASIA 20 WITH POLYDACTYLY; SRTD20__:____:__
Number Sign__:__617926__:__OROFACIODIGITAL SYNDROME XVII; OFD17__:__OFDS XVII;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVII__:__
Number Sign__:__617927__:__OROFACIODIGITAL SYNDROME XVIII; OFD18__:__OFDS XVIII;; ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVIII__:__
Number Sign__:__617928__:__KERATOCONUS 9; KTCN9__:____:__
Number Sign__:__617929__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 60; EIEE60__:____:__
Number Sign__:__617930__:__CHROMOSOME 1p35 DELETION SYNDROME__:____:__
Number Sign__:__617931__:__SPINOCEREBELLAR ATAXIA 47; SCA47__:____:__
Asterisk__:__617932__:__RHOPHILIN 2; RHPN2__:__RHO GTPase-BINDING PROTEIN 2__:__
Number Sign__:__617933__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 61; EIEE61__:____:__
Asterisk__:__617934__:__AE-BINDING PROTEIN 2; AEBP2__:__ADIPOCYTE ENHANCER-BINDING PROTEIN 2;; ZINC FINGER PROTEIN AEBP2__:__
Number Sign__:__617935__:__EPILEPSY, FAMILIAL FOCAL, WITH VARIABLE FOCI 4; FFEVF4__:____:__
Number Sign__:__617936__:__BUTYRYLCHOLINESTERASE DEFICIENCY; BCHED__:__ACHOLINESTERASEMIA;; PSEUDOCHOLINESTERASE DEFICIENCY__:__SUXAMETHONIUM SENSITIVITY, INCLUDED;; APNEA, POSTANESTHETIC, INCLUDED;; BUTYRYLCHOLINESTERASE DEFICIENCY, FLUORIDE-RESISTANT, JAPANESE TYPE, INCLUDED;; HYPOCHOLINESTERASEMIA, FLUORIDE-RESISTANT, JAPANESE TYPE, INCLUDED
Asterisk__:__617937__:__RNA-BINDING MOTIF PROTEIN 11; RBM11__:____:__
Number Sign__:__617938__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 62; EIEE62__:____:__
Asterisk__:__617939__:__ZINC FINGER PROTEIN 69; ZFP69__:__ZINC FINGER PROTEIN 642; ZNF642__:__
Asterisk__:__617940__:__PLECKSTRIN HOMOLOGY DOMAIN- AND RhoGEF DOMAIN-CONTAINING PROTEIN G3; PLEKHG3__:__PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY G, MEMBER 3;; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 43; ARHGEF43;; KIAA0599__:__
Number Sign__:__617941__:__SHWACHMAN-DIAMOND SYNDROME 2; SDS2__:____:__
Asterisk__:__617942__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17A; ABHD17A__:__ALPHA/BETA HYDROLASE DOMAIN-CONTAINING PROTEIN 17A;; CHROMOSOME 19 OPEN READING FRAME 27;; FAMILY WITH SEQUENCE SIMILARITY 108, MEMBER A1; FAM108A1__:__
Asterisk__:__617943__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17B; ABHD17B__:__ALPHA/BETA HYDROLASE DOMAIN-CONTAINING PROTEIN 17B;; CHROMOSOME 9 OPEN READING FRAME 77;; FAMILY WITH SEQUENCE SIMILARITY 108, MEMBER B1; FAM108B1__:__
Asterisk__:__617944__:__ABHYDROLASE DOMAIN-CONTAINING PROTEIN 17C; ABHD17C__:__ALPHA/BETA HYDROLASE DOMAIN-CONTAINING PROTEIN 17C;; FAMILY WITH SEQUENCE SIMILARITY 108, MEMBER C1; FAM108C1__:__
Asterisk__:__617945__:__KIAA1107 GENE; KIAA1107__:__AP2-INTERACTING CLATHRIN-ENDOCYTOSIS PROTEIN; APACHE__:__
Asterisk__:__617946__:__ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT PROTEIN 1; ERGIC1__:__ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT PROTEIN, 32-KD; ERGIC32;; KIAA1181__:__
Asterisk__:__617947__:__WD REPEAT-CONTAINING PROTEIN 74; WDR74__:____:__
Number Sign__:__617948__:__ELLIPTOCYTOSIS 3; EL3__:____:__ANEMIA, PERINATAL HEMOLYTIC, FATAL OR NEAR-FATAL, INCLUDED
Asterisk__:__617949__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 69; CFAP69__:__CHROMOSOME 7 OPEN READING FRAME 63; C7ORF63__:__
Number Sign__:__617950__:__COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 36; COXPD36__:____:__
Number Sign__:__617951__:__LEUKODYSTROPHY, HYPOMYELINATING, 15; HLD15__:____:__
Number Sign__:__617952__:__OSTEOGENESIS IMPERFECTA, TYPE XVIII; OI18__:____:__
NULL__:__617953__:__HYPERTHYROXINEMIA, EUTHYROID, CAUSED BY GENERALIZED 5-PRIME-DEIODINASE DEFICIENCY__:__HYPERTHYROXINEMIA, EUTHYROID, DUE TO DECREASED PERIPHERAL CONVERSION OF T4__:__
Number Sign__:__617954__:__MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 6; MMDS6__:____:__
Percent__:__617955__:__PHENYTOIN TOXICITY__:__ARENE OXIDE DETOXIFICATION DEFECT;; DIPHENYLHYDANTOIN, DEFECT IN HYDROXYLATION OF__:__FETAL HYDANTOIN SYNDROME, INCLUDED; FHS, INCLUDED
Number Sign__:__617956__:__BETA-GLUCOPYRANOSIDE TASTING__:____:__
Asterisk__:__617957__:__LEUCINE RICH REPEATS- AND IQ MOTIF-CONTAINING PROTEIN 3; LRRIQ3__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 44; LRRC44__:__
Asterisk__:__617958__:__INTERACTOR OF LITTLE ELONGATION COMPLEX ELL SUBUNIT 1; ICE1__:__KIAA0947__:__
Number Sign__:__617959__:__SPERMATOGENIC FAILURE 24; SPGF24__:____:__
Number Sign__:__617960__:__SPERMATOGENIC FAILURE 25; SPGF25__:____:__
Number Sign__:__617961__:__SPERMATOGENIC FAILURE 26; SPGF26__:____:__
Asterisk__:__617962__:__ZINC FINGER PROTEIN 827; ZNF827__:____:__
Asterisk__:__617963__:__TUDOR DOMAIN-CONTAINING PROTEIN 9; TDRD9__:__CHROMOSOME 14 OPEN READING FRAME 75; C14ORF75;; HOMELESS, DROSOPHILA, HOMOLOG OF; HLS;; SPINDLE E, DROSOPHILA, HOMOLOG OF; SPNE__:__
Number Sign__:__617964__:__LEUKODYSTROPHY, HYPOMYELINATING, 16; HLD16__:____:__
Number Sign__:__617965__:__SPERMATOGENIC FAILURE 27; SPGF27__:____:__
Number Sign__:__617966__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 7; LDLCQ7__:____:__EZETIMIBE, RESPONSE TO, INCLUDED
Number Sign__:__617967__:__HYDROCEPHALUS, CONGENITAL, 3, WITH BRAIN ANOMALIES; HYC3__:__HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 3, FORMERLY__:__
Asterisk__:__617968__:__WD REPEAT-CONTAINING PROTEIN 63; WDR63__:____:__
Asterisk__:__617969__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 63; CCDC63__:__OUTER ROW DYNEIN ASSEMBLY 5, CHLAMYDOMONAS, HOMOLOG OF; ODA5__:__
Number Sign__:__617970__:__RH-NULL, AMORPH TYPE; RHNA__:____:__
Number Sign__:__617971__:__METHEMOGLOBINEMIA, BETA TYPE__:____:__
Asterisk__:__617972__:__ZINC FINGER DHHC DOMAIN-CONTAINING PROTEIN 20; ZDHHC20__:__DHHC20__:__
Number Sign__:__617973__:__METHEMOGLOBINEMIA, ALPHA TYPE__:____:__
Number Sign__:__617974__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, DI ROCCO TYPE; SEMDDR__:____:__
Asterisk__:__617975__:__FAMILY WITH SEQUENCE SIMILARITY 210, MEMBER A; FAM210A__:__CHROMOSOME 18 OPEN READING FRAME 19; C18ORF19__:__
Number Sign__:__617976__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 63; EIEE63__:____:__
Number Sign__:__617977__:__NEURODEVELOPMENTAL DISORDER WITH SPASTIC QUADRIPLEGIA AND BRAIN ABNORMALITIES WITH OR WITHOUT SEIZURES; NEDSBAS__:__ELHATTAB-ALKURAYA SYNDROME__:__
Asterisk__:__617978__:__FAMILY WITH SEQUENCE SIMILARITY 49, MEMBER B; FAM49B__:____:__
Asterisk__:__617979__:__LONG NONCODING RNA NEAR ACOD1__:__lncRNA-ACOD1;; LOC105370268__:__
Number Sign__:__617980__:__ERYTHROCYTOSIS, FAMILIAL, 6; ECYT6__:__ERYTHROCYTOSIS, BETA-GLOBIN TYPE;; POLYCYTHEMIA, BETA-GLOBIN TYPE__:__
Number Sign__:__617981__:__ERYTHROCYTOSIS, FAMILIAL, 7; ECYT7__:__ERYTHROCYTOSIS, ALPHA-GLOBIN TYPE;; POLYCYTHEMIA, ALPHA-GLOBIN TYPE__:__
Number Sign__:__617982__:__VERVERI-BRADY SYNDROME; VERBRAS__:____:__
Number Sign__:__617983__:__MICROCEPHALY 21, PRIMARY, AUTOSOMAL RECESSIVE; MCPH21__:____:__
Number Sign__:__617984__:__MICROCEPHALY 22, PRIMARY, AUTOSOMAL RECESSIVE; MCPH22__:____:__
Number Sign__:__617985__:__MICROCEPHALY 23, PRIMARY, AUTOSOMAL RECESSIVE; MCPH23__:____:__
Asterisk__:__617986__:__LOW DENSITY LIPOPROTEIN RECEPTOR CLASS A DOMAIN-CONTAINING PROTEIN 3; LDLRAD3__:__LDLR CLASS A DOMAIN-CONTAINING PROTEIN 3; LRAD3__:__
Asterisk__:__617987__:__EEF1A LYSINE AND N-TERMINAL METHYLTRANSFERASE; EEF1AKNMT__:__METHYLTRANSFERASE-LIKE 13; METTL13;; FEAT;; KIAA0859__:__
Number Sign__:__617988__:__JABERI-ELAHI SYNDROME; JABELS__:____:__
Asterisk__:__617989__:__N-ALPHA-ACETYLTRANSFERASE 30, NatC CATALYTIC SUBUNIT; NAA30__:__N-ACETYLTRANSFERASE 12, GCN5-RELATED; NAT12;; MAK3, S. CEREVISIAE, HOMOLOG OF; MAK3;; CHROMOSOME 14 OPEN READING FRAME 35; C14ORF35__:__
Asterisk__:__617990__:__N-ALPHA-ACETYLTRANSFERASE 38, NatC AUXILIARY SUBUNIT; NAA38__:__LSM DOMAIN-CONTAINING PROTEIN 1; LSMD1;; MAK31, S. CEREVISIAE, HOMOLOG OF; MAK31__:__
Number Sign__:__617991__:__DEVELOPMENTAL DELAY, INTELLECTUAL DISABILITY, OBESITY, AND DYSMORPHIC FEATURES; DIDOD__:____:__
Number Sign__:__617992__:__DEAFNESS, CONGENITAL HEART DEFECTS, AND POSTERIOR EMBRYOTOXON; DCHE__:____:__
Number Sign__:__617993__:__TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 2; HFTC2__:____:__
Number Sign__:__617994__:__TUMORAL CALCINOSIS, HYPERPHOSPHATEMIC, FAMILIAL, 3; HFTC3__:____:__
Number Sign__:__617995__:__IMPDH2 ENZYME ACTIVITY, VARIATION IN; IMPDH2V__:____:__
Number Sign__:__617996__:__OOCYTE MATURATION DEFECT 5; OOMD5__:____:__
Asterisk__:__617997__:__RCC1 DOMAIN-CONTAINING PROTEIN 1; RCCD1__:____:__
Asterisk__:__617998__:__GRB2-ASSOCIATED REGULATOR OF MAPK1, SUBTYPE 1; GAREM1__:__GRB2-ASSOCIATED REGULATOR OF ERK/MAPK; GAREM__:__
Asterisk__:__617999__:__GRB2-ASSOCIATED REGULATOR OF MAPK1, SUBTYPE 2; GAREM2__:__GRB2-ASSOCIATED REGULATOR OF ERK/MAPK 2__:__
Number Sign__:__618000__:__EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 2; EDSCLL2__:____:__
Asterisk__:__618001__:__RAB11 EFFECTOR CONTAINING LIS1 HOMOLOGY DOMAIN, COILED-COIL DOMAINS, AND HEAT REPEATS; RELCH__:__KIAA1468__:__
Asterisk__:__618002__:__MICROTUBULE-ASSOCIATED SERINE/THREONINE KINASE 4; MAST4__:____:__
Number Sign__:__618003__:__DEAFNESS, AUTOSOMAL RECESSIVE 57; DFNB57__:____:__
Number Sign__:__618004__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 64; EIEE64__:____:__
Number Sign__:__618005__:__CONGENITAL DISORDER OF GLYCOSYLATION WITH DEFECTIVE FUCOSYLATION; CDGF__:____:__
Number Sign__:__618006__:__LEUKODYSTROPHY, HYPOMYELINATING, 17; HLD17__:____:__
Number Sign__:__618007__:__NEURODEVELOPMENTAL DISORDER WITH BRAIN, LIVER, AND LUNG ABNORMALITIES; NEDBLLA__:____:__
Number Sign__:__618008__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 65; EIEE65__:____:__
Number Sign__:__618010__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 17; GPIBD17__:____:__
Number Sign__:__618011__:__HYPEREKPLEXIA 4; HKPX4__:____:__
Number Sign__:__618012__:__EPILEPTIC ENCEPHALOPATHY, INFANTILE OR EARLY CHILDHOOD, 3; IECEE3__:____:__
Number Sign__:__618013__:__DEAFNESS, AUTOSOMAL RECESSIVE 109; DFNB109__:____:__
Number Sign__:__618014__:__PREMATURE OVARIAN FAILURE 14; POF14__:____:__
Number Sign__:__618015__:__PROTOPORPHYRIA, ERYTHROPOIETIC, 2; EPP2__:____:__
Asterisk__:__618016__:__RNA-BINDING REGION-CONTAINING PROTEIN 3; RNPC3__:__U11/U12 SMALL NUCLEAR RIBONUCLEOPROTEIN, 65-KD PROTEIN;; U11/U12 snRNP, 65-KD PROTEIN; SNRNP65;; KIAA1839__:__
Asterisk__:__618017__:__ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 16; ANKRD16__:____:__
Number Sign__:__618018__:__DRUG METABOLISM, ALTERED, CYP2C8-RELATED__:____:__
Number Sign__:__618019__:__PELGER-HUET ANOMALY WITH MILD SKELETAL ANOMALIES; PHASK__:__REGRESSIVE SPONDYLOMETAPHYSEAL DYSPLASIA__:__
Asterisk__:__618020__:__KELCH-LIKE 22; KLHL22__:____:__
Number Sign__:__618021__:__TETRAAMELIA SYNDROME 2; TETAMS2__:__TETRAAMELIA SYNDROME 2 WITH PULMONARY AGENESIS__:__
Number Sign__:__618022__:__HUMEROFEMORAL HYPOPLASIA WITH RADIOTIBIAL RAY DEFICIENCY; HHRRD__:__HFHRTRD__:__
Asterisk__:__618023__:__NOTCH2 N-TERMINAL-LIKE PROTEIN A; NOTCH2NLA__:__NOTCH2NL;; N2N__:__
Asterisk__:__618024__:__NOTCH2 N-TERMINAL-LIKE PROTEIN B; NOTCH2NLB__:____:__
Asterisk__:__618025__:__NOTCH2 N-TERMINAL-LIKE PROTEIN C; NOTCH2NLC__:____:__
NULL__:__618026__:__NOTCH2 N-TERMINAL-LIKE-RELATED, PSEUDOGENE; NOTCH2NLR__:____:__
Number Sign__:__618027__:__COFFIN-SIRIS SYNDROME 7; CSS7__:____:__
Asterisk__:__618028__:__SHIELD COMPLEX, SUBUNIT 1; SHLD1__:__RINN1/REV7-INTERACTING NOVEL NONHOMOLOGOUS END-JOINING REGULATOR 3; RINN3;; CHROMOSOME 20 OPEN READING FRAME 196; C20ORF196__:__
Asterisk__:__618029__:__SHIELD COMPLEX, SUBUNIT 2; SHLD2__:__RINN1/REV7-INTERACTING NOVEL NONHOMOLOGOUS END-JOINING REGULATOR 2; RINN2;; FAMILY WITH SEQUENCE SIMILARITY 35, MEMBER A; FAM35A__:__
Asterisk__:__618030__:__SHIELD COMPLEX, SUBUNIT 3; SHLD3__:__REV7-INTERACTING NOVEL NONHOMOLOGOUS END-JOINING REGULATOR 1; RINN1__:__
Number Sign__:__618031__:__CORNEAL DYSTROPHY, POSTERIOR POLYMORPHOUS, 4; PPCD4__:____:__
Asterisk__:__618032__:__ZINC FINGER PROTEIN 768; ZNF768__:____:__
Asterisk__:__618033__:__ZINC FINGER PROTEIN 689; ZNF689__:__TRANSCRIPTION-INVOLVED PROTEIN UPREGULATED IN HEPATOCELLULAR CARCINOMA 1; TIPUH1__:__
Asterisk__:__618034__:__SOLUTE CARRIER FAMILY 43, MEMBER 3; SLC43A3__:__EMBRYONIC EPITHELIA GENE 1; EEG1;; EQUILIBRATIVE NUCLEOBASE TRANSPORTER 1; ENBT1__:__
Asterisk__:__618035__:__TBC1 DOMAIN FAMILY, MEMBER 9; TBC1D9__:__TBC1D9A;; KIAA0882__:__
Number Sign__:__618036__:__CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2DD; CMT2DD__:__CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2DD__:__
Asterisk__:__618037__:__ZINC FINGER PROTEIN 536; ZNF536__:__KIAA0390__:__
Asterisk__:__618038__:__CHROMOSOME 9 OPEN READING FRAME 84; C9ORF84__:__SHORTAGE IN CHIASMATA 1, ARABIDOPSIS, HOMOLOG OF; SHOC1;; ZIP2, S. CEREVISIAE, HOMOLOG OF__:__
Asterisk__:__618039__:__TBC1 DOMAIN FAMILY, MEMBER 9B; TBC1D9B__:__KIAA0676__:__
Asterisk__:__618040__:__DIGEORGE SYNDROME CRITICAL REGION GENE 5; DGCR5__:__LONG INTERGENIC NONCODING RNA 37; LINC00037__:__
Asterisk__:__618041__:__PURINE-RICH ELEMENT-BINDING PROTEIN G; PURG__:____:__PURGA, INCLUDED;; PURGB, INCLUDED
Percent__:__618042__:__PULMONARY ALVEOLAR PROTEINOSIS WITH HYPOGAMMAGLOBULINEMIA; PAPHG__:____:__
Asterisk__:__618043__:__POU DOMAIN, CLASS 6, TRANSCRIPTION FACTOR 1; POU6F1__:__POU CLASS 6 HOMEOBOX 1;; TCF-BETA-1; TCFB1;; BRN5;; MPOU__:__
Asterisk__:__618044__:__C2 CALCIUM-DEPENDENT DOMAIN-CONTAINING PROTEIN 5; C2CD5__:__C2 DOMAIN-CONTAINING PHOSPHOPROTEIN, 138-KD; CDP138;; KIAA0528__:__
Asterisk__:__618045__:__DNA DAMAGE-INDUCED APOPTOSIS SUPPRESSOR; DDIAS__:__NITRIC OXIDE-INDUCIBLE GENE; NOXIN;; CHROMOSOME 11 OPEN READING FRAME 82; C11ORF82__:__
Asterisk__:__618046__:__OLFACTORY RECEPTOR, FAMILY 1, SUBFAMILY A, MEMBER 1; OR1A1__:__OR17-7__:__
Asterisk__:__618047__:__OLFACTORY RECEPTOR, FAMILY 1, SUBFAMILY A, MEMBER 2; OR1A2__:__OR17-6__:__
Number Sign__:__618048__:__PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 2; PRAAS2__:____:__
Number Sign__:__618049__:__PARKINSONISM-DYSTONIA, INFANTILE, 2; PKDYS2__:____:__
Number Sign__:__618050__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 57; MRD57__:____:__
Asterisk__:__618051__:__INNATE IMMUNITY ACTIVATOR; INAVA__:__CHROMOSOME 1 OPEN READING FRAME 106; C1ORF106__:__
Number Sign__:__618052__:__CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC 27; CMH27__:____:__
Asterisk__:__618053__:__ANDROGEN RECEPTOR-REGULATED LONG NONCODING RNA 1; ARLNC1__:__AR-REGULATED lncRNA 1;; LONG INTERGENIC NONCODING RNA 2170; LINC02170__:__
Asterisk__:__618054__:__KIAA1024 GENE; KIAA1024__:__MAJOR INTRINSICALLY DISORDERED NOTCH2-BINDING RECEPTOR 1; MINAR1__:__
Asterisk__:__618055__:__CELLULAR REPRESSOR OF E1A-STIMULATED GENES 1; CREG1__:__CREG__:__
Number Sign__:__618056__:__NEURODEVELOPMENTAL DISORDER WITH CEREBELLAR ATROPHY AND WITH OR WITHOUT SEIZURES; NEDCAS__:____:__
Number Sign__:__618057__:__DRUG METABOLISM, ALTERED, CES1-RELATED__:____:__CARBOXYLESTERASE 1 DEFICIENCY, INCLUDED;; MONOCYTE ESTERASE DEFICIENCY, INCLUDED
Asterisk__:__618058__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 300; CFAP300__:__CHROMOSOME 11 OPEN READING FRAME 70; C11ORF70__:__
Asterisk__:__618059__:__WD REPEAT-CONTAINING PROTEIN 25; WDR25__:____:__
Number Sign__:__618060__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH OR WITHOUT EPILEPSY OR CEREBELLAR ATAXIA; IDDECA__:____:__
Number Sign__:__618061__:__POLYCYSTIC KIDNEY DISEASE 6 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD6__:____:__
Asterisk__:__618062__:__CYSTEINE-RICH SECRETORY PROTEIN 3; CRISP3__:__SPECIFIC GRANULE PROTEIN, 28-KD; SGP28__:__
Number Sign__:__618063__:__CILIARY DYSKINESIA, PRIMARY, 38; CILD38__:__CILIARY DYSKINESIA, PRIMARY, 38, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__618064__:__CYTOCHROME c OXIDASE ASSEMBLY FACTOR 16; COX16__:__COX16, S. CEREVISIAE, HOMOLOG OF__:__
Number Sign__:__618065__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 1D; PCH1D__:____:__
Asterisk__:__618066__:__HOMEOBOX B CLUSTER ANTISENSE RNA 1, NONCODING; HOXBAS1__:__HOXB CLUSTER ANTISENSE RNA 1;; LONG NONCODING RNA HOXBAS1;; lncRNA HOXBAS1;; HOXB3 OPPOSITE STRAND, MOUSE, HOMOLOG OF; HOXB3OS__:__
Number Sign__:__618067__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 66; EIEE66__:____:__
Asterisk__:__618068__:__SPERMATOGENIC LEUCINE ZIPPER PROTEIN 1; SPZ1__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 148; PPP1R148__:__
Asterisk__:__618069__:__CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 6-LIKE; CNOT6L__:__CNOT6-LIKE;; CCR4, S. CEREVISIAE, HOMOLOG OF, B; CCR4B__:__
Asterisk__:__618070__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 42-KD, V1 SUBUNIT C, ISOFORM 2; ATP6V1C2__:____:__
Asterisk__:__618071__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 13-KD, V1 SUBUNIT G, ISOFORM 3; ATP6V1G3__:____:__
Asterisk__:__618072__:__ATPase, H+ TRANSPORTING, LYSOSOMAL, 38-KD, V0 SUBUNIT D, ISOFORM 2; ATP6V0D2__:____:__
Asterisk__:__618073__:__STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 12; SAMD12__:__SAM DOMAIN-CONTAINING PROTEIN 12__:__
Number Sign__:__618074__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 6; FAME6__:__BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 6; BAFME6;; CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 6; FCMTE6__:__
Number Sign__:__618075__:__EPILEPSY, FAMILIAL ADULT MYOCLONIC, 7; FAME7__:__BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY 7; BAFME7;; CORTICAL MYOCLONIC TREMOR WITH EPILEPSY, FAMILIAL, 7; FCMTE7__:__
Number Sign__:__618076__:__NEURODEVELOPMENTAL DISORDER WITH SPASTICITY AND POOR GROWTH; NEDSG__:____:__
Number Sign__:__618077__:__INFLAMMATORY BOWEL DISEASE 29; IBD29__:____:__
Number Sign__:__618078__:__OVARIAN DYSGENESIS 6; ODG6__:____:__
Number Sign__:__618079__:__LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 8; LDLCQ8__:____:__
Asterisk__:__618080__:__WD REPEAT-AND FYVE DOMAIN-CONTAINING PROTEIN 1; WDFY1__:__FYVE DOMAIN-CONTAINING PROTEIN LOCALIZED TO ENDOSOMES 1; FENS1__:__
Asterisk__:__618081__:__IMMUNOGLOBULIN-LIKE DOMAIN-CONTAINING RECEPTOR 2; ILDR2__:____:__
Asterisk__:__618082__:__WD REPEAT-CONTAINING PROTEIN 33; WDR33__:__WD REPEAT-CONTAINING PROTEIN, 146-KD; WDC146__:__
Asterisk__:__618083__:__WW-BINDING PROTEIN 11; WBP11__:__NPW38-BINDING PROTEIN; NPWBP;; SPLICING FACTOR THAT INTERACTS WITH PQBP1 AND PP1; SIPP1__:__
Number Sign__:__618084__:__PEELING SKIN SYNDROME 6; PSS6__:____:__
Asterisk__:__618085__:__POLYAMINE-MODULATED FACTOR 1-BINDING PROTEIN 1; PMFBP1__:__PMF1-BINDING PROTEIN 1;; SPERM TAIL-ASSOCIATED PROTEIN; STAP__:__
Number Sign__:__618086__:__SPERMATOGENIC FAILURE 28; SPGF28__:____:__
Number Sign__:__618087__:__SPINOCEREBELLAR ATAXIA 42, EARLY-ONSET, SEVERE, WITH NEURODEVELOPMENTAL DEFICITS; SCA42ND__:____:__
Number Sign__:__618088__:__NEURODEVELOPMENTAL DISORDER WITH REGRESSION, ABNORMAL MOVEMENTS, LOSS OF SPEECH, AND SEIZURES; NEDAMSS__:____:__
Number Sign__:__618089__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND BEHAVIORAL ABNORMALITIES; IDDFBA__:____:__
Number Sign__:__618090__:__NEURODEVELOPMENTAL DISORDER WITH EPILEPSY AND HYPOPLASIA OF THE CORPUS CALLOSUM; NEDEHCC__:____:__
Number Sign__:__618091__:__SPERMATOGENIC FAILURE 29; SPGF29__:____:__
Number Sign__:__618092__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH SPEECH DELAY, DYSMORPHIC FACIES, AND T-CELL ABNORMALITIES; IDDSFTA__:____:__
Number Sign__:__618093__:__SPINOCEREBELLAR ATAXIA 48; SCA48__:____:__
Number Sign__:__618094__:__DEAFNESS, AUTOSOMAL RECESSIVE 110; DFNB110__:____:__
Number Sign__:__618095__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 63; MRT63__:____:__
Number Sign__:__618096__:__PREMATURE OVARIAN FAILURE 15; POF15__:____:__
Number Sign__:__618097__:__MICROCEPHALY, GROWTH RESTRICTION, AND INCREASED SISTER CHROMATID EXCHANGE 2; MGRISCE2__:____:__
Number Sign__:__618098__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5__:__PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5__:__
Asterisk__:__618099__:__MITOCHONDRIAL RIBOSOMAL RNA METHYLTRANSFERASE 1; MRM1__:____:__
Asterisk__:__618100__:__MPV17-LIKE PROTEIN; MPV17L__:____:__
Asterisk__:__618101__:__MATRIX METALLOPROTEINASE 27; MMP27__:____:__
Asterisk__:__618102__:__SUMO-INTERACTING MOTIFS-CONTAINING PROTEIN 1; SIMC1__:__PLATFORM ELEMENT FOR INHIBITION OF AUTOLYTIC DEGRADATION; PLEIAD__:__
Number Sign__:__618103__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 64; MRT64__:____:__
Asterisk__:__618104__:__MEMBRANE METALLOENDOPEPTIDASE-LIKE 1; MMEL1__:__NEPRILYSIN II; NEPII;; NEPRILYSIN 2; NEP2;; NEPRILYSIN-LIKE 1; NL1;; SOLUBLE SECRETED ENDOPEPTIDASE; SEP__:__
Asterisk__:__618105__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 15; SIGLEC15__:____:__
Number Sign__:__618106__:__MENTAL RETARDATION, AUTOSOMAL DOMINANT 58; MRD58__:____:__
Number Sign__:__618107__:__OSTEOPETROSIS, AUTOSOMAL DOMINANT 3; OPTA3__:____:__
Number Sign__:__618108__:__IMMUNODEFICIENCY 57; IMD57__:____:__
Number Sign__:__618109__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 65; MRT65__:____:__
Number Sign__:__618110__:__SPERMATOGENIC FAILURE 30; SPGF30__:____:__
Asterisk__:__618111__:__ZINC FINGER PROTEIN 64; ZFP64__:__ZINC FINGER PROTEIN 338; ZNF338__:__
Number Sign__:__618112__:__SPERMATOGENIC FAILURE 31; SPGF31__:____:__
Number Sign__:__618113__:__ENCEPHALITIS/ENCEPHALOPATHY, MILD, WITH REVERSIBLE MYELIN VACUOLIZATION; MMERV__:__ENCEPHALITIS/ENCEPHALOPATHY, MILD, WITH REVERSIBLE SPLENIAL LESION; MERS__:__
Number Sign__:__618114__:__LIDDLE SYNDROME 2; LIDLS2__:____:__
Number Sign__:__618115__:__SPERMATOGENIC FAILURE 32; SPGF32__:____:__
Number Sign__:__618116__:__BONE MARROW FAILURE SYNDROME 4; BMFS4__:____:__
Number Sign__:__618117__:__OVARIAN DYSGENESIS 7; ODG7__:____:__
Asterisk__:__618118__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 3; EML3__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN 3; EMAP3;; ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN, 95-KD; EMAP95__:__
Asterisk__:__618119__:__ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 5; EML5__:____:__
Number Sign__:__618120__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, NUCLEAR TYPE 5; MC5DN5__:__MITOCHONDRIAL COMPLEX V (ATP SYNTHASE) DEFICIENCY, ATP5F1D TYPE__:__
Asterisk__:__618121__:__ATP SYNTHASE, PERIPHERAL STALK, SUBUNIT D; ATP5PD__:__ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT D; ATP5H__:__
Asterisk__:__618122__:__MTR4 EXOSOME RNA HELICASE; MTREX__:__MTR4, S. CEREVISIAE, HOMOLOG OF; MTR4;; SUPERKILLER VIRALICIDIC ACTIVITY 2-LIKE 2; SKIV2L2;; SKI2, S. CEREVISIAE, HOMOLOG OF, 2;; KIAA0052__:__
Number Sign__:__618123__:__POLYDACTYLY, POSTAXIAL, TYPE A8; PAPA8__:____:__
Number Sign__:__618124__:__PERIPHERAL NEUROPATHY, AUTOSOMAL RECESSIVE, WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT; PNRIID__:____:__
Asterisk__:__618125__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 155; CCDC155__:__KASH DOMAIN-CONTAINING PROTEIN 5; KASH5__:__
Number Sign__:__618126__:__LIDDLE SYNDROME 3; LIDLS3__:____:__
Asterisk__:__618127__:__CYTOCHROME C OXIDASE, SUBUNIT 6B2; COX6B2__:__CYTOCHROME C OXIDASE, SUBUNIT VIb, POLYPEPTIDE 2;; CYTOCHROME C OXIDASE, SUBUNIT VIb, TESTIS-SPECIFIC;; CANCER/TESTIS ANTIGEN 59; CT59__:__
Asterisk__:__618128__:__GANGLIOSIDE-INDUCED DIFFERENTIATION-ASSOCIATED PROTEIN 2; GDAP2__:____:__
Number Sign__:__618129__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 4; LGMDD4__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1I; LGMD1I__:__
Asterisk__:__618130__:__N-TERMINAL EF-HAND CALCIUM-BINDING PROTEIN 2; NECAB2__:__NEURAL CALCIUM-BINDING PROTEIN 2__:__
Number Sign__:__618131__:__IMMUNODEFICIENCY 58; IMD58__:____:__
Asterisk__:__618132__:__SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 14; SIGLEC14__:____:__
Asterisk__:__618133__:__NEUREXOPHILIN AND PC-ESTERASE DOMAIN FAMILY, MEMBER 4; NXPE4__:__CHROMOSOME 11 OPEN READING FRAME 33; C11ORF33;; FLJ20127__:__
Asterisk__:__618134__:__UROTENSIN 2B; UTS2B__:__UROTENSIN II-RELATED PEPTIDE; URP__:__
Number Sign__:__618135__:__MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 8; MDDGC8__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 24; LGMDR24;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, POMGNT2-RELATED__:__
Asterisk__:__618136__:__MAD2L1-BINDING PROTEIN; MAD2L1BP__:__p31(COMET);; CAUGHT BY MAD2; CMT2__:__
Asterisk__:__618137__:__MIS18 KINETOCHORE PROTEIN A: MIS18A__:__MIS18, S. POMBE, HOMOLOG OF, A;; MIS18-ALPHA__:__
Number Sign__:__618138__:__MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 23; LGMDR23__:____:__
Asterisk__:__618139__:__MIS18-BINDING PROTEIN 1; MIS18BP1__:__CHROMOSOME 14 OPEN READING FRAME 106; C14ORF106__:__
Number Sign__:__618140__:__DEAFNESS, AUTOSOMAL DOMINANT 74; DFNA74__:____:__
Number Sign__:__618141__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 67; EIEE67__:____:__
Number Sign__:__618142__:__MICROCEPHALY, FACIAL DYSMORPHISM, RENAL AGENESIS, AND AMBIGUOUS GENITALIA SYNDROME; MFRG__:____:__
Number Sign__:__618143__:__GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 18; GPIBD18__:____:__
Number Sign__:__618144__:__USHER SYNDROME, TYPE IV; USH4__:____:__
Number Sign__:__618145__:__DEAFNESS, AUTOSOMAL RECESSIVE 111; DFNB111__:____:__
Asterisk__:__618146__:__WD REPEAT-CONTAINING PROTEIN 66; WDR66__:__CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 251; CFAP251__:__
Number Sign__:__618147__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH HYPERTELORISM AND DISTINCTIVE FACIES; IDDHDF__:____:__CHROMOSOME 14q32 DELETION SYNDROME, INCLUDED
Number Sign__:__618148__:__EXTRAORAL HALITOSIS DUE TO METHANETHIOL OXIDASE DEFICIENCY; EHMTO__:__METHANETHIOL OXIDASE DEFICIENCY;; MTO DEFICIENCY;; EXTRAORAL HALITOSIS WITH DIMETHYLSULFOXIDURIA__:__
Number Sign__:__618149__:__OROFACIAL CLEFT 8; OFC8__:__CLEFT LIP WITH OR WITHOUT CLEFT PALATE, NONSYNDROMIC, 8__:__
Number Sign__:__618150__:__SAUL-WILSON SYNDROME; SWILS__:__MICROCEPHALIC OSTEODYSPLASTIC DYSPLASIA__:__
Asterisk__:__618151__:__TESTIS-EXPRESSED BASIC PROTEIN 1; TSBP1__:__TESTIS SPERM-BINDING PROTEIN; TSBP;; CHROMOSOME 6 OPEN READING FRAME 10; C6ORF10__:__
Number Sign__:__618152__:__SPERMATOGENIC FAILURE 33; SPGF33__:____:__
Number Sign__:__618153__:__SPERMATOGENIC FAILURE 34; SPGF34__:____:__
Number Sign__:__618154__:__HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 3; HKLLS3__:____:__
Number Sign__:__618155__:__OPHTHALMOPLEGIA, EXTERNAL, WITH RIB AND VERTEBRAL ANOMALIES; EORVA__:____:__
Number Sign__:__618156__:__SQUALENE SYNTHASE DEFICIENCY; SQSD__:__NEURODEVELOPMENTAL DISORDER WITH LOW CHOLESTEROL AND ABNORMAL URINE ORGANIC ACIDS__:__
Number Sign__:__618157__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IV; IGHD4__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IB, FORMERLY; IGHD1B, FORMERLY;; DWARFISM OF SINDH__:__
Number Sign__:__618158__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH MACROCEPHALY, SEIZURES, AND SPEECH DELAY; IDDMSSD__:____:__
Asterisk__:__618159__:__PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 21; PPP1R21__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 128; CCDC128;; KLRAQ MOTIF-CONTAINING PROTEIN 1; KLRAQ1__:__
Number Sign__:__618160__:__ISOLATED GROWTH HORMONE DEFICIENCY, TYPE V; IGHD5__:____:__
Number Sign__:__618161__:__JOUBERT SYNDROME 35; JBTS35__:____:__
Number Sign__:__618162__:__SPONDYLOEPIMETAPHYSEAL DYSPLASIA, KRAKOW TYPE; SEMDK__:__IMMUNOOSSEOUS DYSPLASIA, KRAKOW TYPE__:__
Asterisk__:__618163__:__TRANSMEMBRANE PROTEIN 94; TMEM94__:__KIAA0195__:__
Number Sign__:__618164__:__CARDIAC, FACIAL, AND DIGITAL ANOMALIES WITH DEVELOPMENTAL DELAY; CAFDADD__:____:__
Number Sign__:__618165__:__BONE MARROW FAILURE SYNDROME 5; BMFS5__:____:__
Asterisk__:__618166__:__CYCLIN N-TERMINAL DOMAIN-CONTAINING PROTEIN 1; CNTD1__:__CROSSOVER SITE-ASSOCIATED PROTEIN 1; COSA1__:__
Number Sign__:__618167__:__OSTEOCHONDRODYSPLASIA, BRACHYDACTYLY, AND OVERLAPPING MALFORMED DIGITS; OCBMD__:____:__
Number Sign__:__618168__:__DIARRHEA 9; DIAR9__:____:__
Asterisk__:__618169__:__POU3F3-ADJACENT NONCODING TRANSCRIPT 1; PANTR1__:__LONG INTERGENIC NONCODING RNA POU3F3;; lincRNA-POU3F3;; lincRNA 1158; LINC01158__:__
Number Sign__:__618170__:__NEURODEGENERATION, CHILDHOOD-ONSET, STRESS-INDUCED, WITH VARIABLE ATAXIA AND SEIZURES; CONDSIAS__:____:__
Asterisk__:__618171__:__KINESIN FAMILY MEMBER 16B; KIF16B__:____:__
Asterisk__:__618172__:__LONG NONCODING RNA UPREGULATOR OF ANTIVIRAL RESPONSE INTERFERON SIGNALING; LUARIS__:__LONG NONCODING RNA 32;; lncRNA32__:__
Number Sign__:__618173__:__RETINITIS PIGMENTOSA 83; RP83__:____:__
Number Sign__:__618174__:__CORTICAL DYSPLASIA, COMPLEX, WITH OTHER BRAIN MALFORMATIONS 9; CDCBM9__:____:__
Number Sign__:__618176__:__NEPHROTIC SYNDROME, TYPE 17; NPHS17__:____:__
Number Sign__:__618177__:__NEPHROTIC SYNDROME, TYPE 18; NPHS18__:____:__
Number Sign__:__618178__:__NEPHROTIC SYNDROME, TYPE 19; NPHS19__:____:__
Number Sign__:__618179__:__MICROCEPHALY 24, PRIMARY, AUTOSOMAL RECESSIVE; MCPH24__:____:__
Number Sign__:__618180__:__ECTODERMAL DYSPLASIA 14, HAIR/TOOTH TYPE WITH OR WITHOUT HYPOHIDROSIS; ECTD14__:____:__
Asterisk__:__618181__:__ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 11; ZBTB11__:__CKII-ALPHA INTERACTOR 1, DROSOPHILA, HOMOLOG OF;; CKII-ALPHA-I1, DROSOPHILA, HOMOLOG OF__:__
Number Sign__:__618182__:__ORTHOSTATIC HYPOTENSION 2; ORTHYP2__:____:__
Number Sign__:__618183__:__DIARRHEA 10, PROTEIN-LOSING ENTEROPATHY TYPE; DIAR10__:____:__
Number Sign__:__618184__:__NEUROPATHY, CONGENITAL HYPOMYELINATING, 2; CHN2__:____:__
Number Sign__:__618185__:__PERIVENTRICULAR NODULAR HETEROTOPIA 8; PVNH8__:____:__
Number Sign__:__618186__:__NEUROPATHY, CONGENITAL HYPOMYELINATING, 3; CHN3__:____:__
Number Sign__:__618187__:__OVARIAN DYSGENESIS 8; ODG8__:____:__
Number Sign__:__618188__:__HYPERPARATHYROIDISM, TRANSIENT NEONATAL; HRPTTN__:____:__
Number Sign__:__618189__:__CARDIOMYOPATHY, DILATED, 2C; CMD2C__:____:__
Asterisk__:__618190__:__LUNG CANCER-ASSOCIATED TRANSCRIPT 1, NONCODING; LUCAT1__:__SMOKE- AND CANCER-ASSOCIATED LONG NONCODING RNA 1; SCAL1;; SMOKE- AND CANCER-ASSOCIATED lncRNA 1__:__
Asterisk__:__618191__:__CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 21; CEACAM21__:____:__
Asterisk__:__618192__:__PROSTATE CANCER-ASSOCIATED TRANSCRIPT 19, NONCODING; PCAT19__:__LONG INTERGENIC NONCODING RNA 1190; LINC01190;; lincRNA 1190__:__
Number Sign__:__618193__:__POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY 2; PLOSL2__:____:__
Asterisk__:__618194__:__SCAVENGER RECEPTOR CYSTEINE-RICH FAMILY MEMBER WITH 5 DOMAINS; SSC5D__:__SSCR FAMILY MEMBER WITH 5 DOMAINS;; SOLUBLE SCAVENGER WITH 5 DOMAINS__:__
Number Sign__:__618195__:__INTELLECTUAL DEVELOPMENTAL DISORDER AND RETINITIS PIGMENTOSA; IDDRP__:____:__
Number Sign__:__618196__:__CAPILLARY MALFORMATION-ARTERIOVENOUS MALFORMATION 2; CMAVM2__:____:__
Number Sign__:__618197__:__MYASTHENIC SYNDROME, CONGENITAL, 23, PRESYNAPTIC; CMS23__:____:__
Number Sign__:__618198__:__MYASTHENIC SYNDROME, CONGENITAL, 24, PRESYNAPTIC; CMS24__:____:__
Asterisk__:__618199__:__APOBEC1 COMPLEMENTATION FACTOR; A1CF__:__ACF;; APOBEC1-STIMULATING PROTEIN; ASP__:__
Asterisk__:__618200__:__MIDASIN AAA ATPase 1; MDN1__:__MIDASIN 1;; MIDAS-CONTAINING PROTEIN 1__:__
Number Sign__:__618201__:__EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 68; EIEE68__:____:__
Asterisk__:__618202__:__DNAJ/HSP40 HOMOLOG, SUBFAMILY C, MEMBER 30; DNAJC30__:__WILLIAMS-BEUREN SYNDROME CHROMOSOME REGION 18; WBSCR18__:__
Asterisk__:__618203__:__TRANSMEMBRANE AND TETRATRICOPEPTIDE REPEAT DOMAINS-CONTAINING PROTEIN 4; TMTC4__:____:__
Number Sign__:__618204__:__IMMUNODEFICIENCY 15A; IMD15A__:____:__
Number Sign__:__618205__:__SNIJDERS BLOK-CAMPEAU SYNDROME; SNIBCPS__:__INTELLECTUAL DEVELOPMENTAL DISORDER WITH MACROCEPHALY, SPEECH DELAY, AND DYSMORPHIC FACIES; IDDMSF__:__
Asterisk__:__618206__:__ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 7B; ZC3H7B__:__ROTAVIRUS X PROTEIN ASSOCIATED WITH NSP3 1; ROXAN1;; ROXAN;; KIAA1031__:__
Asterisk__:__618207__:__SEC1 FAMILY DOMAIN-CONTAINING PROTEIN 1; SCFD1__:__SLY1, S. CEREVISIAE, HOMOLOG OF; SLY1;; RA410__:__
Asterisk__:__618208__:__LONG INTERGENIC NONCODING RNA 1159; LINC01159__:__lincRNA 1159;; LINC-BRN1B__:__
Asterisk__:__618209__:__HOXD ANTISENSE GROWTH-ASSOCIATED LONG NONCODING RNA; HAGLR__:__LONG INTERGENIC NONCODING RNA HAGLR;; lincRNA HAGLR;; MDGT__:__
Asterisk__:__618210__:__LIPID RAFT LINKING PROTEIN 1; RFTN1__:__RAFTLIN;; KIAA0084__:__
Asterisk__:__618211__:__PITRILYSIN METALLOPEPTIDASE 1; PITRM1__:__METALLOENDOPROTEASE 1; MP1;; PRESEQUENCE PROTEASE; PREP__:__
Asterisk__:__618212__:__LONG INTERGENIC NONCODING RNA, p53-INDUCED TRANSCRIPT; LINC-PINT__:__lincRNA PINT;; p53-INDUCED TRANSCRIPT; PINT__:__
Number Sign__:__618213__:__INFLAMMATORY BOWEL DISEASE, IMMUNODEFICIENCY, AND ENCEPHALOPATHY; IBDIMDE__:____:__
Asterisk__:__618214__:__LONG INTERGENIC NONCODING RNA 1157; LINC01157__:__lincRNA 1157;; LINC-ENC1__:__
Asterisk__:__618215__:__LIPID RAFT LINKING PROTEIN 2; RFTN2__:____:__
Asterisk__:__618216__:__MIRLET7B HOST GENE, NONCODING; MIRLET7BHG__:__LONG INTERGENIC NONCODING RNA MIRLET7BHG;; lincRNA MIRLET7BHG;; LONG INTERGENIC NONCODING RNA PPARA; LINC-PPARA__:__
Asterisk__:__618217__:__EGFR LONG NONCODING DOWNSTREAM RNA; ELDR__:__LONG INTERGENIC NONCODING RNA ELDR;; lincRNA ELDR;; LONG INTERGENIC NONCODING RNA 1156; LINC01156;; FABL__:__
Number Sign__:__618218__:__BAKER-GORDON SYNDROME; BAGOS__:__NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENT AND ABNORMAL ELECTROENCEPHALOGRAM; NEDIMAE__:__
Number Sign__:__618219__:__POLYDACTYLY, POSTAXIAL, TYPE A9; PAPA9__:____:__
Number Sign__:__618220__:__RETINITIS PIGMENTOSA 84; RP84__:____:__
Number Sign__:__618221__:__MENTAL RETARDATION, AUTOSOMAL RECESSIVE 66; MRT66__:____:__
Number Sign__:__618222__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 2; MC1DN2__:____:__
Number Sign__:__618223__:__VERTEBRAL ANOMALIES AND VARIABLE ENDOCRINE AND T-CELL DYSFUNCTION; VETD__:____:__
Number Sign__:__618224__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 3; MC1DN3__:____:__
Number Sign__:__618225__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 4; MC1DN4__:____:__
Number Sign__:__618226__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 5; MC1DN5__:____:__
Asterisk__:__618227__:__LEUCINE-RICH REPEAT-CONTAINING PROTEIN 56; LRRC56__:____:__
Number Sign__:__618228__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 6; MC1DN6__:____:__
Number Sign__:__618229__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 7; MC1DN7__:____:__
Number Sign__:__618230__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 8; MC1DN8__:____:__
Number Sign__:__618231__:__EPIDERMODYSPLASIA VERRUCIFORMIS 2; EV2__:____:__
Number Sign__:__618232__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 9; MC1DN9__:____:__
Number Sign__:__618233__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 10; MC1DN10__:____:__
Number Sign__:__618234__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 11; MC1DN11__:____:__
Number Sign__:__618235__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 13; MC1DN13__:____:__
Number Sign__:__618236__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 14; MC1DN14__:____:__
Number Sign__:__618237__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 15; MC1DN15__:____:__
Number Sign__:__618238__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 16; MC1DN16__:____:__
Number Sign__:__618239__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 17; MC1DN17__:____:__
Number Sign__:__618240__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 18; MC1DN18__:____:__
Number Sign__:__618241__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 19; MC1DN19__:____:__
Number Sign__:__618242__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 21; MC1DN21__:____:__
Number Sign__:__618243__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 22; MC1DN22__:____:__
Number Sign__:__618244__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 23; MC1DN23__:____:__
Number Sign__:__618245__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 24; MC1DN24__:____:__
Number Sign__:__618246__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 25; MC1DN25__:____:__
Number Sign__:__618247__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 26; MC1DN26__:____:__
Number Sign__:__618248__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 27; MC1DN27__:____:__
Number Sign__:__618249__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 28; MC1DN28__:____:__
Number Sign__:__618250__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 29; MC1DN29__:____:__
Number Sign__:__618251__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 31; MC1DN31__:____:__
Number Sign__:__618252__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 32; MC1DN32__:____:__
Number Sign__:__618253__:__MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 33; MC1DN33__:____:__
Number Sign__:__618254__:__CILIARY DYSKINESIA, PRIMARY, 39; CILD39__:__CILIARY DYSKINESIA, PRIMARY, 39, WITH OR WITHOUT SITUS INVERSUS__:__
Asterisk__:__618255__:__MYOGENESIS-REGULATING GLYCOSIDASE; MYORG__:__NUCLEAR ENVELOPE TRANSMEMBRANE PROTEIN 37; NET37;; KIAA1161__:__
NULL__:__618256__:__BIPARENTAL MITOCHONDRIAL DNA TRANSMISSION__:____:__
Number Sign__:__618257__:__DEAFNESS, AUTOSOMAL RECESSIVE 112; DFNB112__:____:__
Asterisk__:__618258__:__SEC11, YEAST, HOMOLOG OF, A; SEC11A__:__SIGNAL PEPTIDASE COMPLEX, 18-KD SUBUNIT; SPC18__:__
Asterisk__:__618259__:__LONG INTERGENIC NONCODING RNA 1565; LINC01565__:__lincRNA 1565;; GR6__:__GR6/EVI1 FUSION GENE, INCLUDED
Asterisk__:__618260__:__COILED-COIL DOMAIN-CONTAINING PROTEIN 47; CCDC47__:__CALUMIN__:__
Number Sign__:__618261__:__LYMPHOPROLIFERATIVE SYNDROME 3; LPFS3__:__CD70 DEFICIENCY__:__
Asterisk__:__618262__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN 5; CREB5__:__cAMP RESPONSE ELEMENT-BINDING PROTEIN A; CREBPA__:__
Asterisk__:__618263__:__CALCIUM HOMEOSTASIS MODULATOR 3; CALHM3__:____:__
Number Sign__:__618264__:__MIRROR MOVEMENTS 4; MRMV4__:____:__
Number Sign__:__618265__:__ARTHROGRYPOSIS, CLEFT PALATE, CRANIOSYNOSTOSIS, AND IMPAIRED INTELLECTUAL DEVELOPMENT; ACCIID__:____:__
Number Sign__:__618266__:__PONTOCEREBELLAR HYPOPLASIA, TYPE 12; PCH12__:____:__
Number Sign__:__618267__:__EPIDERMODYSPLASIA VERRUCIFORMIS 3; EV3__:____:__
Number Sign__:__618268__:__TRICHOHEPATONEURODEVELOPMENTAL SYNDROME; THNS__:____:__
Asterisk__:__618269__:__ZINC FINGER PROTEIN 341; ZNF341__:____:__
Number Sign__:__618270__:__CONGENITAL ANOMALIES OF KIDNEY AND URINARY TRACT 3; CAKUT3__:____:__
Asterisk__:__618271__:__SEC61 TRANSLOCON, ALPHA-2 SUBUNIT; SEC61A2__:__SEC61 COMPLEX, ALPHA-2 SUBUNIT__:__
Number Sign__:__618272__:__GLOBAL DEVELOPMENTAL DELAY, LUNG CYSTS, OVERGROWTH, AND WILMS TUMOR; GLOW__:__GLOW SYNDROME__:__
Number Sign__:__618273__:__MEGA-CORPUS-CALLOSUM SYNDROME WITH CEREBELLAR HYPOPLASIA AND CORTICAL MALFORMATIONS; MCCCHCM__:____:__
Asterisk__:__618274__:__PEPTIDYLPROLYL ISOMERASE DOMAIN- AND WD40 REPEAT-CONTAINING PROTEIN 1; PPWD1__:____:__
Number Sign__:__618275__:__HYPOTRICHOSIS 14; HYPT14__:____:__
Number Sign__:__618276__:__NEURODEGENERATION, CHILDHOOD-ONSET, WITH CEREBELLAR ATROPHY; CONDCA__:____:__
Number Sign__:__618280__:__CARDIAC-UROGENITAL SYNDROME; CUGS__:____:__
Asterisk__:__618281__:__VON WILLEBRAND FACTOR A DOMAIN-CONTAINING PROTEIN 2; VWA2__:__AMACO;; COLON CANCER-SECRETED PROTEIN 2; CCSP2__:__